Australian Government Department of Health

Medicare Benefits Schedule Book Operating from 1 March 2019

Title: Medicare Benefits Schedule Book

ISBN: 978-1-76007-376-3 Publications Number: 12289

Copyright

© 2019 Commonwealth of Australia as represented by the Department of Health.

This work is copyright. You may copy, print, download, display and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation:

- (a) do not use the copy or reproduction for any commercial purpose; and
- (b) retain this copyright notice and all disclaimer notices as part of that copy or reproduction.

Apart from rights as permitted by the Copyright Act 1968 (Cth) or allowed by this copyright notice, all other rights are reserved, including (but not limited to) all commercial rights.

Requests and inquiries concerning reproduction and other rights to use are to be sent to the Communication Branch, Department of Health, GPO Box 9848, Canberra ACT 2601, or via e-mail to corporatecomms@health.gov.au

At the time of printing, the relevant legislation giving authority for the changes included in this edition of the book may still be subject to the approval of Executive Council and the usual Parliamentary scrutiny. This book is not a legal document, and, in cases of discrepancy, the legislation will be the source document for payment of Medicare benefits.

The latest Medicare Benefits Schedule information is available from MBS Online at

http://www.health.gov.au/mbsonline

TABLE OF CONTENTS

MMARY OF CHANGES FROM 01/03/2019	
NERAL EXPLANATORY NOTES	
GENERAL EXPLANATORY NOTES	13
TEGORY 1: PROFESSIONAL ATTENDANCES	
SUMMARY OF CHANGES FROM 01/03/2019	
PROFESSIONAL ATTENDANCES NOTES	
Group A1. General Practitioner Attendances To Which No Other Item Applies	
Group A2. Other Non-Referred Attendances To Which No Other Item Applies	
Subgroup 1. Other Medical Practitioner Attendances	
Group A3. Specialist Attendances To Which No Other Item Applies	
Group A4. Consultant Physician Attendances To Which No Other Item Applies	
Group A5. Prolonged Attendances To Which No Other Item Applies	
Group A6. Group TherapyGroup A7. Acupuncture and Non-Specialist Practitioner Items	202
Subgroup 1. Acupuncture	
Subgroup 2. Non-Specialist Practitioner attendances to which no other item applies	
Subgroup 3. Non-Specialist Practitioner prolonged attendances to which no other item applies	
Subgroup 4. Non-Specialist Practitioner group therapy	
Subgroup 5. Non-Specialist Practitioner health assessments	
Subgroup 6. Non-Specialist Practitioner management plans, team care arrangements and multidisciplinary	
plans and case conferences	
Subgroup 7. Non-Specialist Practitioner domiciliary and residential medication management review	
Subgroup 8. Non-Specialist Practitioner attendances associated with Practice Incentive Program payments	
Subgroup 9. Non-Specialist Practitioner mental health care	
Subgroup 10. Non-Specialist Practitioner after-hours attendances to which no other item applies	
Subgroup 11. Non-Specialist Practitioner pregnancy support counselling	
Subgroup 12. Non-Specialist Practitioner video conferencing consultation	
Group A8. Consultant Psychiatrist Attendances To Which No Other Item Applies	
Group A9. Contact Lenses - Attendances	
Group A10. Optometrical Services	
Subgroup 1. General	
Subgroup 2. Telehealth Attendance	
Subgroup 1. Urgent Attendance - After Hours	
Subgroup 2. Urgent Attendance Unsociable After Hours	
Group A12. Consultant Occupational Physician Attendances To Which No Other Item Applies	
Group A13. Public Health Physician Attendances To Which No Other Item Applies	
Group A14. Health Assessments	
Group A15. GP Management Plans, Team Care Arrangements, Multidisciplinary Care Plans	255
Subgroup 1. GP Management Plans, Team Care Arrangements And Multidisciplinary Care Plans	255
Subgroup 2. Case Conferences	
Group A17. Domiciliary And Residential Management Reviews	260
Group A18. General Practitioner Attendance Associated With Pip Incentive Payments	
Subgroup 1. Taking Of A Cervical Smear From An Unscreened Or Significantly Underscreened Person	
Subgroup 2. Completion Of A Cycle Of Care For Patients With Established Diabetes Mellitus	
Subgroup 3. Completion Of The Asthma Cycle Of Care	268
Group A19. Other Non-Referred Attendances Associated With Pip Incentive Payments To Which No Other Iter	
Applies	
Subgroup 1. Taking Of A Cervical Smear From An Unscreened Or Significantly Underscreened Person	
Subgroup 2. Completion Of An Annual Cycle Of Care For Patients With Established Diabetes Mellitus	
Subgroup 3. Completion Of The Asthma Cycle Of Care	
Group A20. GP Mental Health Treatment	
Subgroup 2. Focussed Psychological Strategies	
Group A21. Medical Practitioner (Emergency Physician) Attendances To Which No Other Item Applies	
Subgroup 1. ConsultationsSubgroup 1. Consultations	
Subgroup 2. Prolonged Professional Attendances To Which No Other Group Applies	
Group A22. General Practitioner After-Hours Attendances To Which No Other Item Applies	
Group A23. Other Non-Referred After-Hours Attendances To Which No Other Item Applies	
Group A24. Pain And Palliative Medicine	

Subgroup 1. Pain Medicine Attendances	
Subgroup 2. Pain Medicine Case Conferences	
Subgroup 3. Palliative Medicine Attendances	
Subgroup 4. Palliative Medicine Case Conferences	
Group A26. Neurosurgery Attendances To Which No Other Item Applies	294
Group A27. Pregnancy Support Counselling	296
Group A28. Geriatric Medicine	296
Group A29. Early Intervention Services For Children With Autism, Pervasive Developmental Disorder Or Di	,
Oncome A 2 O A Maratina I Deportition on A 1 of the A 2	
Group A30. Medical Practitioner (Including A General Practitioner, Specialist Or Consultant Physician) Tele	
Attendances	
Subgroup 1. Telehealth Attendance At Consulting Rooms, Home Visits Or Other Institutions	
Subgroup 2. Telehealth Attendance At A Residential Aged Care Facility	207
Subgroup 4. Non-referred Telehealth Consultations To Which No Other Item Applies	
Group A31. Addiction Medicine	
Subgroup 1. Addiction Medicine Attendances	
Subgroup 2. Group Therapy	
Subgroup 3. Addiction Medicine Case Conferences	312
Group A32. Sexual Health Medicine	
Subgroup 1. Sexual Health Medicine Attendances	
Subgroup 2. Home Visits	
Subgroup 3. Sexual Health Medicine Case Conferences	
Group A33. Transcatheter Aortic Valve Implantation Case Conference	
Group A34. Health Care Homes	
Group A35. Services For Patients in Residential Aged Care Facilities	
Subgroup 1. Flag Fall Amount For Residential Aged Care Facilities	
Subgroup 2. General Practitioner Non-Referred Attendance At A Residential Aged Care Facility	
Subgroup 3. Other Medical Practitioner Non-Referred Attendance At A Residential Aged Care Facility	310
Subgroup 4. Non-Specialist Practitioner Non-Referred Attendance At A Residential Aged Care Facility	
INDEXINDEX	
CATEGORY 2: DIAGNOSTIC PROCEDURES AND INVESTIGATIONS	
SUMMARY OF CHANGES FROM 01/03/2019	
DIAGNOSTIC PROCEDURES AND INVESTIGATIONS NOTES	
Group D1. Miscellaneous Diagnostic Procedures And Investigations	
Subgroup 1. Neurology	
Subgroup 2. Ophthalmology	
Subgroup 3. Otolaryngology	
Subgroup 4. Respiratory	
Subgroup 5. Vascular	
Subgroup 6. Cardiovascular	
Subgroup 7. Gastroenterology & Colorectal	
Subgroup 8. Genito/Urinary Physiological Investigations	
Subgroup 9. Allergy Testing	
Subgroup 10. Other Diagnostic Procedures And Investigations	
Group D2. Nuclear Medicine (Non-Imaging)	
INDEX.	
CATEGORY 3: THERAPEUTIC PROCEDURES	
SUMMARY OF CHANGES FROM 01/03/2019	
THERAPEUTIC PROCEDURES NOTES	
Group T1. Miscellaneous Therapeutic Procedures	
Subgroup 1. Hyperbaric Oxygen Therapy	
Subgroup 2. Dialysis	
Subgroup 3. Assisted Reproductive Services	
Subgroup 4. Paediatric & Neonatal	
Subgroup 5. Cardiovascular	
Subgroup 6. Gastroenterology	
Subgroup 8. Haematology	
Subgroup 9. Procedures Associated With Intensive Care And Cardiopulmonary Support	
Subgroup 10. Management And Procedures Undertaken In An Intensive Care Unit	
Subgroup 11. Chemotherapeutic Procedures	
Subgroup 12. Dermatology	
- I ∨	

Subgroup 13. Other Therapeutic Procedures	454
Group T2. Radiation Oncology	
Subgroup 1. Superficial	
Subgroup 2. Orthovoltage	
Subgroup 3. Megavoltage	
Subgroup 4. Brachytherapy	
Subgroup 5. Computerised Planning	
Subgroup 6. Stereotactic Radiosurgery	
Subgroup 7. Radiation Oncology Treatment Verification	
Subgroup 8. Brachytherapy Planning And Verification	469
Subgroup 10. Targetted Intraoperative Radiotherapy	460
Group T3. Therapeutic Nuclear Medicine	
Group T4. Obstetrics	
Group T6. Anaesthetics	
Subgroup 1. Anaesthesia Consultations	
Group T7. Regional Or Field Nerve Blocks	
Group T8. Surgical Operations	
Subgroup 1. General	
Subgroup 2. Colorectal	
Subgroup 3. Vascular	
Subgroup 4. Gynaecological	
Subgroup 5. Urological	
Subgroup 6. Cardio-Thoracic	
Subgroup 7. Neurosurgical	
Subgroup 8. Ear, Nose And Throat	623
Subgroup 9. Ophthalmology	634
Subgroup 10. Operations For Osteomyelitis	
Subgroup 11. Paediatric	
Subgroup 12. Amputations	652
Subgroup 13. Plastic And Reconstructive Surgery	653
Subgroup 14. Hand Surgery	682
Subgroup 15. Orthopaedic	688
Subgroup 16. Radiofrequency And Microwave Tissue Ablation	729
Subgroup 17. Spinal Surgery	730
Group T9. Assistance At Operations	
Group T10. Relative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For Anaesthe	
Performed In Association With An Eligible Service	738
Subgroup 1. Head	
Subgroup 2. Neck	
Subgroup 3. Thorax	
Subgroup 4. Intrathoracic	
Subgroup 5. Spine And Spinal Cord	
Subgroup 6. Upper Abdomen	
Subgroup 7. Lower Abdomen	
Subgroup 8. Perineum	
Subgroup 9. Pelvis (Except Hip)	754
Subgroup 10. Upper Leg (Except Knee)	
Subgroup 11. Knee And Popliteal Area	755 757
Subgroup 12. Lower Leg (Below Knee)	750
Subgroup 13. Shoulder And Axilla	
Subgroup 14. Upper Arm And Elbow	
Subgroup 15. Forearm Wrist And Hand	
Subgroup 16. Anaesthesia For Burns	/64
Subgroup 17. Anaesthesia For Radiological Or Other Diagnostic Or Therapeutic Procedures	
Subgroup 18. Miscellaneous	768
Subgroup 19. Therapeutic And Diagnostic Services	
Subgroup 20. Administration Of Anaesthesia In Connection With A Dental Service	
Subgroup 21. Anaesthesia/Perfusion Time Units	
Subgroup 22. Anaesthesia/Perfusion Modifying Units - Physical Status	
Subgroup 23. Anaesthesia/Perfusion Modifying Units - Other	
Subgroup 24. Anaesthesia After Hours Emergency Modifier	
Subgroup 25. Perfusion After Hours Emergency Modifier	785

Subgroup 26. Assistance At Anaesthesia	
Group T11. Botulinum Toxin Injections	
INDEX	791
CATEGORY 4: ORAL AND MAXILLOFACIAL SERVICES	
SUMMARY OF CHANGES FROM 01/03/2019	824
ORAL AND MAXILLOFACIAL SERVICES NOTES	825
Group O1. Consultations	830
Group O2. Assistance At Operation	
Group O3. General Surgery	
Group O4. Plastic & Reconstructive	
Group O5. Preprosthetic	
Group O6. Neurosurgical	
Group O7. Ear, Nose & Throat	
Group O8. Temporomandibular Joint	
Group O9. Treatment Of Fractures	
Group O11. Regional Or Field Nerve Blocks	
INDEX	
CATEGORY 5: DIAGNOSTIC IMAGING SERVICES	852
SUMMARY OF CHANGES FROM 01/03/2019	853
DIAGNOSTIC IMAGING SERVICES NOTES	
Group I1. Ultrasound	
Subgroup 1. General	
Subgroup 2. Cardiac	
Subgroup 3. Vascular	
Subgroup 4. Urological	
Subgroup 5. Obstetric And Gynaecological	
Subgroup 6. Musculoskeletal	
Group I2. Computed Tomography	
Subgroup 1. Head	
Subgroup 2. Neck	
Subgroup 3. Spine	
Subgroup 4. Chest and upper abdomen	
Subgroup 5. Upper abdomen only	
Subgroup 6. Upper abdomen and pelvis	
Subgroup 7. Extremities	
Subgroup 8. Chest, abdomen, pelvis and neck	
Subgroup 9. Brain, chest and upper abdomen	966
Subgroup 10. Pelvimetry	
Subgroup 11. Interventional techniques	
Subgroup 12. Spiral angiography	967
Subgroup 13. Cone beam computed tomography	
Group I3. Diagnostic Radiology	970
Subgroup 1. Radiographic Examination Of Extremities	
Subgroup 2. Radiographic Examination Of Shoulder Or Pelvis	972
Subgroup 3. Radiographic Examination Of Head	
Subgroup 4. Radiographic Examination Of Spine	
Subgroup 5. Bone Age Study And Skeletal Surveys	978
Subgroup 6. Radiographic Examination Of Thoracic Region	979
Subgroup 7. Radiographic Examination Of Urinary Tract	980
Subgroup 8. Radiographic Examination Of Alimentary Tract And Biliary System	
Subgroup 9. Radiographic Examination For Localisation Of Foreign Bodies	984
Subgroup 10. Radiographic Examination Of Breasts	
Subgroup 12. Radiographic Examination With Opaque Or Contrast Media	
Subgroup 13. Angiography	
Subgroup 15. Fluoroscopic Examination	
Subgroup 16. Preparation For Radiological Procedure	
Subgroup 17. Interventional Techniques	
Group I4. Nuclear Medicine Imaging	
Subgroup 1. Nuclear medicine - non PET	
Subgroup 2. PET	
Group I5. Magnetic Resonance Imaging	
Subgroup 1. Scan Of Head - For Specified Conditions	
Subgroup 1. Sour Of Fical - For Openied Conditions	1012

Subgroup 3. Scan Of Head And Neck Vessels - For Specified Conditions	013
Subgroup 4. Scan Of Head And Cervical Spine - For Specified Conditions.	
	016
Subgroup 5. Scan Of Head And Cervical Spine - For Specified Conditions	017
Subgroup 6. Scan Of Spine - One Region Or Two Contiguous Regions - For Specified Conditions	018
Subgroup 7. Scan Of Spine - One Region Or Two Contiguous Regions - For Specified Conditions	019
Subgroup 8. Scan Of Spine - Three Contiguous Regions Or Two Non-Contiguous Regions - For Specified	
Conditions	021
Subgroup 9. Scan Of Spine - Three Contiguous Regions Or Two Non-Contiguous Regions - For Specified	021
Conditions	021
Subgroup 10. Scan Of Cervical Spine And Brachial Plexus - For Specified Conditions	
Subgroup 11. Scan Of Musculoskeletal System - For Specified Conditions	
Subgroup 12. Scan Of Musculoskeletal System - For Specified Conditions	
Subgroup 13. Scan Of Musculoskeletal System - For Specified Conditions	
Subgroup 14. Scan Of Cardiovascular System - For Specified Conditions	
Subgroup 15. Magnetic Resonance Angiography - Scan Of Cardiovascular System - For Specified Condition	
1	032
Subgroup 16. Magnetic Resonance Angiography - For Specified Conditions - Person Under The Age Of 16	
Years1	
Subgroup 17. Magnetic Resonance Imaging - For Specified Conditions - Person Under The Age Of 16 Years	s
1	
Subgroup 18. Magnetic Resonance Imaging - For Specified Conditions - Person Under The Age Of 16 Years	s
Subgroup 19. Scan Of Body - For Specified Conditions 1	
Subgroup 20. Scan Of Pelvis And Upper Abdomen - For Specified Conditions	
Subgroup 21. Scan Of Body - For Specified Conditions	
Subgroup 22. Modifying Items	
Subgroup 32. Magnetic Resonance Imaging - Pip Breast Implant	
Subgroup 33. Magnetic Resonance Imaging - For Specified Conditions - Person Under The Age Of 16yrs. 1	
Subgroup 34. Magnetic Resonance Imaging - For Specified Conditions	051
Group I6. Management Of Bulk-Billed Services	
INDEX	
CATEGORY 6: PATHOLOGY SERVICES1	062
SUMMARY OF CHANGES FROM 01/03/20191	063
SUMMARY OF CHANGES FROM 01/03/2019	063 064
SUMMARY OF CHANGES FROM 01/03/20191	063 064
SUMMARY OF CHANGES FROM 01/03/2019	063 064 120
SUMMARY OF CHANGES FROM 01/03/2019	063 064 120 125
SUMMARY OF CHANGES FROM 01/03/2019 1 PATHOLOGY SERVICES NOTES 1 Group P1. Haematology 1 Group P2. Chemical 1 Group P3. Microbiology 1	063 064 120 125 141
SUMMARY OF CHANGES FROM 01/03/2019 1 PATHOLOGY SERVICES NOTES 1 Group P1. Haematology 1 Group P2. Chemical 1 Group P3. Microbiology 1 Group P4. Immunology 1	.063 .064 .120 .125 .141 .151
SUMMARY OF CHANGES FROM 01/03/2019 1 PATHOLOGY SERVICES NOTES 1 Group P1. Haematology 1 Group P2. Chemical 1 Group P3. Microbiology 1 Group P4. Immunology 1 Group P5. Tissue Pathology 1	063 064 120 125 141 151 158
SUMMARY OF CHANGES FROM 01/03/2019 1 PATHOLOGY SERVICES NOTES 1 Group P1. Haematology 1 Group P2. Chemical 1 Group P3. Microbiology 1 Group P4. Immunology 1 Group P5. Tissue Pathology 1 Group P6. Cytology 1	063 064 120 125 141 151 158 162
SUMMARY OF CHANGES FROM 01/03/2019 1 PATHOLOGY SERVICES NOTES 1 Group P1. Haematology 1 Group P2. Chemical 1 Group P3. Microbiology 1 Group P4. Immunology 1 Group P5. Tissue Pathology 1 Group P6. Cytology 1 Group P7. Genetics 1	063 064 120 125 141 151 158 162
SUMMARY OF CHANGES FROM 01/03/2019 1 PATHOLOGY SERVICES NOTES 1 Group P1. Haematology 1 Group P2. Chemical 1 Group P3. Microbiology 1 Group P4. Immunology 1 Group P5. Tissue Pathology 1 Group P6. Cytology 1 Group P7. Genetics 1 Group P8. Infertility And Pregnancy Tests 1	063 064 120 125 141 151 158 162 166 174
SUMMARY OF CHANGES FROM 01/03/2019 1 PATHOLOGY SERVICES NOTES 1 Group P1. Haematology 1 Group P2. Chemical 1 Group P3. Microbiology 1 Group P4. Immunology 1 Group P5. Tissue Pathology 1 Group P6. Cytology 1 Group P7. Genetics 1 Group P8. Infertility And Pregnancy Tests 1 Group P9. Simple Basic Pathology Tests 1	063 064 120 125 141 151 158 162 166 174
SUMMARY OF CHANGES FROM 01/03/2019 1 PATHOLOGY SERVICES NOTES 1 Group P1. Haematology 1 Group P2. Chemical 1 Group P3. Microbiology 1 Group P4. Immunology 1 Group P5. Tissue Pathology 1 Group P6. Cytology 1 Group P7. Genetics 1 Group P8. Infertility And Pregnancy Tests 1 Group P9. Simple Basic Pathology Tests 1 Group P10. Patient Episode Initiation 1	063 064 120 125 141 151 158 162 166 174 175
SUMMARY OF CHANGES FROM 01/03/2019 1 PATHOLOGY SERVICES NOTES 1 Group P1. Haematology 1 Group P2. Chemical 1 Group P3. Microbiology 1 Group P4. Immunology 1 Group P5. Tissue Pathology 1 Group P6. Cytology 1 Group P7. Genetics 1 Group P8. Infertility And Pregnancy Tests 1 Group P9. Simple Basic Pathology Tests 1 Group P10. Patient Episode Initiation 1 Group P11. Specimen Referred 1	063 064 120 125 141 151 158 162 166 174 175 177
SUMMARY OF CHANGES FROM 01/03/2019 1 PATHOLOGY SERVICES NOTES 1 Group P1. Haematology 1 Group P2. Chemical 1 Group P3. Microbiology 1 Group P4. Immunology 1 Group P5. Tissue Pathology 1 Group P6. Cytology 1 Group P7. Genetics 1 Group P8. Infertility And Pregnancy Tests 1 Group P9. Simple Basic Pathology Tests 1 Group P10. Patient Episode Initiation 1 Group P11. Specimen Referred 1 Group P12. Management Of Bulk-Billed Services 1	063 064 120 125 141 151 158 162 166 174 175 177
SUMMARY OF CHANGES FROM 01/03/2019 1 PATHOLOGY SERVICES NOTES 1 Group P1. Haematology 1 Group P2. Chemical 1 Group P3. Microbiology 1 Group P4. Immunology 1 Group P5. Tissue Pathology 1 Group P6. Cytology 1 Group P7. Genetics 1 Group P8. Infertility And Pregnancy Tests 1 Group P9. Simple Basic Pathology Tests 1 Group P10. Patient Episode Initiation 1 Group P11. Specimen Referred 1 Group P12. Management Of Bulk-Billed Services 1 Group P13. Bulk-Billing Incentive 1	063 064 120 125 141 151 158 162 166 174 175 177 179 181
SUMMARY OF CHANGES FROM 01/03/2019	063 064 120 125 141 151 158 162 166 174 175 177 179 181 183
SUMMARY OF CHANGES FROM 01/03/2019.	063 064 120 125 141 151 158 162 166 174 175 177 179 181 183 196
SUMMARY OF CHANGES FROM 01/03/2019 1 PATHOLOGY SERVICES NOTES 1 Group P1. Haematology 1 Group P2. Chemical 1 Group P3. Microbiology 1 Group P4. Immunology 1 Group P5. Tissue Pathology 1 Group P6. Cytology 1 Group P7. Genetics 1 Group P8. Infertility And Pregnancy Tests 1 Group P9. Simple Basic Pathology Tests 1 Group P10. Patient Episode Initiation 1 Group P11. Specimen Referred 1 Group P12. Management Of Bulk-Billed Services 1 Group P13. Bulk-Billing Incentive 1 INDEX. 1 CATEGORY 7: CLEFT LIP AND CLEFT PALATE SERVICES 1 SUMMARY OF CHANGES FROM 01/03/2019 1	063 064 120 125 141 151 158 162 166 174 175 177 179 181 183 196
SUMMARY OF CHANGES FROM 01/03/2019 1 PATHOLOGY SERVICES NOTES 1 Group P1. Haematology 1 Group P2. Chemical 1 Group P3. Microbiology 1 Group P4. Immunology 1 Group P5. Tissue Pathology 1 Group P6. Cytology 1 Group P7. Genetics 1 Group P7. Genetics 1 Group P8. Infertility And Pregnancy Tests 1 Group P9. Simple Basic Pathology Tests 1 Group P9. Simple Basic Pathology Tests 1 Group P10. Patient Episode Initiation 1 Group P11. Specimen Referred 1 Group P12. Management Of Bulk-Billed Services 1 Group P13. Bulk-Billing Incentive 1 INDEX. 1 CATEGORY 7: CLEFT LIP AND CLEFT PALATE SERVICES 1 SUMMARY OF CHANGES FROM 01/03/2019 1 CLEFT LIP AND CLEFT PALATE SERVICES NOTES 1	063 064 120 125 141 151 158 162 166 174 175 177 179 181 183 196 197
SUMMARY OF CHANGES FROM 01/03/2019 1 PATHOLOGY SERVICES NOTES 1 Group P1. Haematology 1 Group P2. Chemical 1 Group P3. Microbiology 1 Group P4. Immunology 1 Group P5. Tissue Pathology 1 Group P6. Cytology 1 Group P7. Genetics 1 Group P8. Infertility And Pregnancy Tests 1 Group P9. Simple Basic Pathology Tests 1 Group P9. Simple Basic Pathology Tests 1 Group P10. Patient Episode Initiation 1 Group P11. Specimen Referred 1 Group P12. Management Of Bulk-Billed Services 1 Group P13. Bulk-Billing Incentive 1 INDEX 1 CATEGORY 7: CLEFT LIP AND CLEFT PALATE SERVICES 1 SUMMARY OF CHANGES FROM 01/03/2019 1 CLEFT LIP AND CLEFT PALATE SERVICES NOTES 1 Group C1. Orthodontic Services 1	063 064 120 125 141 151 158 162 166 174 175 177 179 181 183 196 197 198 209
SUMMARY OF CHANGES FROM 01/03/2019 1 PATHOLOGY SERVICES NOTES 1 Group P1. Haematology 1 Group P2. Chemical 1 Group P3. Microbiology 1 Group P4. Immunology 1 Group P5. Tissue Pathology 1 Group P6. Cytology 1 Group P6. Cytology 1 Group P7. Genetics 1 Group P7. Genetics 1 Group P8. Infertility And Pregnancy Tests 1 Group P9. Simple Basic Pathology Tests 1 Group P10. Patient Episode Initiation 1 Group P11. Specimen Referred 1 Group P12. Management Of Bulk-Billed Services 1 Group P13. Bulk-Billing Incentive 1 INDEX 1 CATEGORY 7: CLEFT LIP AND CLEFT PALATE SERVICES 1 CLEFT LIP AND CLEFT PALATE SERVICES 1 CLEFT LIP AND CLEFT PALATE SERVICES 1 CROUP C1. Orthodontic Services 1 Group C2. Oral And Maxillofacial Services 1 Group C3. Oral And Maxillofacial Services 1 Group C4. Oral And Maxillofacia	063 064 120 125 141 151 158 162 166 174 175 177 179 181 183 196 197 198 209 211
SUMMARY OF CHANGES FROM 01/03/2019 1 PATHOLOGY SERVICES NOTES 1 Group P1. Haematology 1 Group P2. Chemical 1 Group P3. Microbiology 1 Group P4. Immunology 1 Group P5. Tissue Pathology 1 Group P6. Cytology 1 Group P7. Genetics 1 Group P8. Infertility And Pregnancy Tests 1 Group P9. Simple Basic Pathology Tests 1 Group P9. Simple Basic Pathology Tests 1 Group P10. Patient Episode Initiation 1 Group P11. Specimen Referred 1 Group P12. Management Of Bulk-Billed Services 1 Group P13. Bulk-Billing Incentive 1 INDEX 1 CATEGORY 7: CLEFT LIP AND CLEFT PALATE SERVICES 1 SUMMARY OF CHANGES FROM 01/03/2019 1 CLEFT LIP AND CLEFT PALATE SERVICES NOTES 1 Group C1. Orthodontic Services 1	063 064 120 125 141 151 158 162 166 174 175 177 179 181 183 196 197 198 209 211
SUMMARY OF CHANGES FROM 01/03/2019 1 PATHOLOGY SERVICES NOTES 1 Group P1. Haematology 1 Group P2. Chemical 1 Group P3. Microbiology 1 Group P4. Immunology 1 Group P5. Tissue Pathology 1 Group P6. Cytology 1 Group P6. Cytology 1 Group P7. Genetics 1 Group P7. Genetics 1 Group P8. Infertility And Pregnancy Tests 1 Group P9. Simple Basic Pathology Tests 1 Group P10. Patient Episode Initiation 1 Group P11. Specimen Referred 1 Group P12. Management Of Bulk-Billed Services 1 Group P13. Bulk-Billing Incentive 1 INDEX 1 CATEGORY 7: CLEFT LIP AND CLEFT PALATE SERVICES 1 CLEFT LIP AND CLEFT PALATE SERVICES 1 CLEFT LIP AND CLEFT PALATE SERVICES 1 CROUP C1. Orthodontic Services 1 Group C2. Oral And Maxillofacial Services 1 Group C3. Oral And Maxillofacial Services 1 Group C4. Oral And Maxillofacia	063 064 120 125 141 151 158 162 166 174 175 177 179 181 183 196 197 198 209 211 215
SUMMARY OF CHANGES FROM 01/03/2019	063 064 120 125 141 151 158 162 166 174 175 177 179 181 183 196 197 198 209 211 215 217
SUMMARY OF CHANGES FROM 01/03/2019	063 064 120 125 141 151 158 162 166 174 175 177 181 183 196 197 198 209 211 215 217
SUMMARY OF CHANGES FROM 01/03/2019	063 064 120 125 141 151 158 162 166 174 175 179 181 183 196 197 219 211 215 217
SUMMARY OF CHANGES FROM 01/03/2019	063 064 120 125 141 151 158 162 166 174 175 179 181 183 196 197 211 215 217 218
SUMMARY OF CHANGES FROM 01/03/2019	063 064 120 125 141 151 158 162 166 174 175 179 181 183 196 197 211 215 217 218 229 281 284

Group M8. Pregnancy Support Counselling	1306
Group M9. Allied Health Group Services	1308
Group M10. Autism, Pervasive Developmental Disorder And Disability Services	
Group M11. Allied Health Services For Indigenous Australians Who Have Had A Health Check	
Group M12. Services Provided By A Practice Nurse Or Aboriginal And Torres Strait Islander Health P	
On Behalf Of A Medical Practitioner	
Subgroup 1. Telehealth Support Service On Behalf Of A Medical Practitioner	
Subgroup 2. Telehealth Support Service On Behalf Of A Medical Practitioner At A Residential Age	
Facility	
Subgroup 3. Services Provided By A Practice Nurse Or Aboriginal And Torres Strait Islander Healt	th Practitioner
On Behalf Of A Medical Practitioner	1329
Group M13. Midwifery Services	1330
Subgroup 1. MBS Items For Participating Midwives	1330
Subgroup 2. Telehealth Attendances	
Group M14. Nurse Practitioners	1334
Subgroup 1. Nurse Practitioners	1334
Subgroup 2. Telehealth Attendance	1336
Subgroup 3. Telehealth Attendance At A Residential Aged Care Facility	
Group M15. Diagnostic Audiology Services	1338
INDEX	1344

GUIDE TO SUMMARY OF CHANGES INCLUDED IN THIS EDITION

Services for patients in Residential Aged Care Facilities

The Government will increase the Medicare Benefits Schedule fees for general practitioners (GPs) and medical practitioners attending a residential aged care facility to help ensure that GPs and medical practitioners have appropriate incentives to provide care in aged care facilities.

Currently, the Medicare benefit is calculated from the type of service provided and the number of patients seen at a residential aged care facility. This arrangement, known as a 'ready reckoner', calculates the total benefit based on a nominal amount plus a modifier. The modifier must be divided or multiplied (6 or fewer patients is divided, 7 or more patients is multiplied) by the number of patients seen by the doctor at the residential aged care facility.

From 1 March 2019, this arrangement will be changed for the most commonly claimed GPs and medical practitioner services in residential aged care facilities. The existing ready reckoner attendance items (20, 35, 43, 51, 92, 93, 95, 96, 183, 188, 202 and 212) will be replaced with 12 new attendance items in group A35. These items have the same requirements as the deleted attendance items, but have a nominal fee amount, like attendance items in consulting rooms. The new attendance items can be claimed for each patient attended during a residential aged care facility visit.

A new single callout fee recognises the important role of GPs and medical practitioners in supporting the health and care of patients in residential aged care facilities. The call out fee is \$55 for GPs (item 90001) and \$40 (item 90002) for medical practitioners working in general practice. This amount is intended to reflect the costs doctors incur when providing professional services in residential aged care facilities. The call out fee is only payable once per visit to a residential aged care facility.

Medicare Benefits Schedule – Telehealth services for people living in flood-affected communities in Queensland

Eight new, time-limited MBS telehealth consultation items allow GPs and non-specialist medical practitioners to provide general attendance services by videoconference to patients living in flood-affected Local Government Areas in Queensland.

The new items replicate the clinical requirements and fee/rebate structures of the current Level A to D items provided in consulting rooms by both sets of practitioners.

Eligibility for the new items is based on patient location only.

The new items are time-limited and will end on 30 June 2019.

The affected Local Government Areas are:

- Burdekin
- Burke
- Charters Towers
- Cloncurry
- Cook
- Doomadgee
- Douglas
- Flinders
- McKinlay
- Palm Island
- Richmond
- Townsville
- Winton
- Wujal Wujal.

Amendment to 73343 - Addition of Venetoclax

This change amends MBS Item 73343 to determine eligibility for venetoclax on the Pharmaceutical Benefits Scheme.

Correct fee on MBS online from \$1,435.30 to \$1,435.50

The fee for item 51011 on MBS online does not match the fee outlined in the Health Insurance (General Medical Services Tables) Regulations 2018, or the fee administered by the Department of Human Services. This change will align MBS Online with the legislation.

SUMMARY OF CHANGES FROM 01/03/2019

The 01/03/2019 changes to the MBS are summarised below and are identified in the Schedule pages by one or more of the following words appearing above the item number:

(a) new item(b) amended description(c) fee amended(d) item number changed(e) EMSN changed						New Amend Fee Renum EMSN						
Delet 20	ed Items	43	51	92	93	95	96	183	188	202	212	
New 899	Items 901	905	906	2095	2144	2180	2193	90001	90002	90020	90035	90043

90188

90202

90212

New Group Under Category 1

90093

90092

A35 – Services For Patients in Residential Aged Care Facilities

90095

Amended Item

73343

90051

Amended Fee effective 8 March 2019

51011

New Subgroups Under A35

- 1 Flag Fall Amount For Residential Aged Care Facilities
- 2 General Practitioner Non-Referred Attendance At A Residntial Aged Care Facility

90096

90183

- 3 Other Medical Practitioner Non-Referred Attendance At A Residential Aged Care Facility
- 4 Non-Specialist Practitioner Non-Referred Attence At A Residential Aged Care acility

New Notes

AN.7.28 AN.30.2 AN.35.1 AN.35.2

Amended Notes

GN.2.8 GN.12.30 AN.0.9 AN.0.11 AN.0.15 AN.7.1 TN.7.4

Ceased Note

AN.0.17

GENERAL EXPLANATORY NOTES

GENERAL EXPLANATORY NOTES

GN.1.1 The Medicare Benefits Schedule - Introduction Schedules of Services

Each professional service contained in the Schedule has been allocated a unique item number. Located with the item number and description for each service is the Schedule fee and Medicare benefit, together with a reference to an explanatory note relating to the item (if applicable).

If the service attracts an anaesthetic, the word (Anaes.) appears following the description. Where an operation qualifies for the payment of benefits for an assistant, the relevant items are identified by the inclusion of the word (Assist.) in the item description. Medicare benefits are not payable for surgical assistance associated with procedures which have not been so identified.

Higher rates of benefits are provided for consultations by a recognised consultant physician where the patient has been referred by another medical practitioner or an approved dental practitioner (oral surgeons).

Differential fees and benefits also apply to services listed in Category 5 (Diagnostic Imaging Services). The conditions relating to these services are set out in Category 5.

Explanatory Notes

Explanatory notes relating to the Medicare benefit arrangements and notes that have general application to services are located at the beginning of the schedule, while notes relating to specific items are located at the beginning of each Category. While there may be a reference following the description of an item to specific notes relating to that item, there may also be general notes relating to each Group of items.

GN.1.2 Medicare - an outline

The Medicare Program ('Medicare') provides access to medical and hospital services for all Australian residents and certain categories of visitors to Australia. The Department of Human Services administers Medicare and the payment of Medicare benefits. The major elements of Medicare are contained in the Health Insurance Act 1973, as amended, and include the following:

- a. Free treatment for public patients in public hospitals.
- b. The payment of 'benefits', or rebates, for professional services listed in the Medicare Benefits Schedule (MBS). In general, the Medicare benefit is 85% of the Schedule fee, otherwise the benefits are
 - i. 100% of the Schedule fee for services provided by a general practitioner to non-referred, non-admitted patients;
 - ii. 100% of the Schedule fee for services provided on behalf of a general practitioner by a practice nurse or Aboriginal and Torres Strait Islander health practitioner;
 - iii. 75% of the Schedule fee for professional services rendered to a patient as part of an episode of hospital treatment (other than public patients);
 - iv. 75% of the Schedule fee for professional services rendered as part of a privately insured episode of hospital-substitute treatment.

Medicare benefits are claimable only for 'clinically relevant' services rendered by an appropriate health practitioner. A 'clinically relevant' service is one which is generally accepted by the relevant profession as necessary for the appropriate treatment of the patient.

When a service is not clinically relevant, the fee and payment arrangements are a private matter between the practitioner and the patient.

Services listed in the MBS must be rendered according to the provisions of the relevant Commonwealth, State and Territory laws. For example, medical practitioners must ensure that the medicines and medical devices they use have been supplied to them in strict accordance with the provisions of the Therapeutic Goods Act 1989.

Where a Medicare benefit has been inappropriately paid, the Department of Human Services may request its return from the practitioner concerned.

GN.1.3 Medicare benefits and billing practices

Key information on Medicare benefits and billing practices

The *Health Insurance Act 1973* stipulates that Medicare benefits are payable for professional services. A professional service is a clinically relevant service which is listed in the MBS. A medical service is clinically relevant if it is generally accepted in the medical profession as necessary for the appropriate treatment of the patient.

Medical practitioners are free to set their fees for their professional service. However, the amount specified in the patient's account must be the amount charged for the service specified. The fee may not include a cost of goods or services which are not part of the MBS service specified on the account.

Billing practices contrary to the Act

A *non-clinically relevant service* must not be included in the charge for a Medicare item. The non-clinically relevant service must be separately listed on the account and not billed to Medicare.

Goods supplied for the patient's home use (such as wheelchairs, oxygen tanks, continence pads) must not be included in the consultation charge. Medicare benefits are limited to services which the medical practitioner provides at the time of the consultation - any other services must be separately listed on the account and must not be billed to Medicare.

Charging part of all of an episode of hospital treatment or a hospital substitute treatment to a non-admitted consultation is prohibited. This would constitute a false or misleading statement on behalf of the medical practitioner and no Medicare benefits would be payable.

An account may not be re-issued to include charges and out-of-pocket expenses excluded in the original account. The account can only be reissued to correct a genuine error.

Potential consequence of improperly issuing an account

The potential consequences for improperly issuing an account are

- (a) No Medicare benefits will be paid for the service;
- (b) The medical practitioner who issued the account, or authorised its issue, may face charges under sections 128A or 128B of the *Health Insurance Act 1973*.
- (c) Medicare benefits paid as a result of a false or misleading statement will be recoverable from the doctor under section 129AC of the *Health Insurance Act 1973*.

Providers should be aware that the Department of Human Services is legally obliged to investigate doctors suspected of making false or misleading statements, and may refer them for prosecution if the evidence indicates fraudulent charging to Medicare. If Medicare benefits have been paid inappropriately or incorrectly, the Department of Human Services will take recovery action.

The Department of Human Services (DHS) has developed a <u>Health Practitioner Guideline for responding to a request to substantiate that a patient attended a service</u>. There is also a <u>Health Practitioner Guideline for substantiating that a specific treatment was performed</u>. These guidelines are located on the DHS website.

GN.2.4 Provider eligibility for Medicare

To be eligible to provide medical service which will attract Medicare benefits, or to provide services for or on behalf of another practitioner, practitioners must meet one of the following criteria:

- (a) be a recognised specialist, consultant physician or general practitioner; or
- (b) be in an approved placement under section 3GA of the Health Insurance Act 1973; or
- (c) be a temporary resident doctor with an exemption under section 19AB of the *Health Insurance Act 1973*, and working in accord with that exemption.

Any practitioner who does not satisfy the requirements outlined above may still practice medicine but their services will not be eligible for Medicare benefits.

NOTE: New Zealand citizens entering Australia do so under a special temporary entry visa and are regarded as temporary resident doctors.

NOTE: It is an offence under Section 19CC of the *Health Insurance Act 1973* to provide a service without first informing a patient where a Medicare benefit is not payable for that service (i.e. the service is not listed in the MBS).

Non-medical practitioners

To be eligible to provide services which will attract Medicare benefits under MBS items 10950-10977 and MBS items 80000-88000 and 82100-82140 and 82200-82215, allied health professionals, dentists, and dental specialists, participating midwives and participating nurse practitioners must be

- (a) registered according to State or Territory law or, absent such law, be members of a professional association with uniform national registration requirements; and
- (b) registered with the Department of Human Services to provide these services.

GN.2.5 Provider Numbers

Practitioners eligible to have Medicare benefits payable for their services and/or who for Medicare purposes wish to raise referrals for specialist services and requests for pathology or diagnostic imaging services, may apply *in writing* to the Department of Human Services for a Medicare provider number for the locations where these services/referrals/requests will be provided. The form may be downloaded from the Department of Human Services website.

For Medicare purposes, an account/receipt issued by a practitioner must include the practitioner's name and *either* the provider number for the location where the service was provided *or* the address where the services were provided.

Medicare provider number information is released in accord with the secrecy provisions of the *Health Insurance Act* 1973 (section 130) to authorized external organizations including private health insurers, the Department of Veterans' Affairs and the Department of Health.

When a practitioner ceases to practice at a given location they must inform Medicare promptly. Failure to do so can lead to the misdirection of Medicare cheques and Medicare information.

Practitioners at practices participating in the Practice Incentives Program (PIP) should use a provider number linked to that practice. Under PIP, only services rendered by a practitioner whose provider number is linked to the PIP will be considered for PIP payments.

GN.2.6 Locum tenens

Where a locum tenens will be in a practice for more than two weeks *or* in a practice for less than two weeks but on a regular basis, the locum should apply for a provider number for the relevant location. If the locum will be in a practice for less than two weeks and will not be returning there, they should contact the Department of Human Services (provider liaison - 132 150) to discuss their options (for example, use one of the locum's other provider numbers).

A locum must use the provider number allocated to the location if

- (a) they are an approved general practice or specialist trainee with a provider number issued for an approved training placement; or
- (b) they are associated with an approved rural placement under Section 3GA of the Health Insurance Act 1973; or
- (c) they have access to Medicare benefits as a result of the issue of an exemption under section 19AB of the *Health Insurance Act 1973* (i.e. they have access to Medicare benefits at specific practice locations); or
- (d) they will be at a practice which is participating in the Practice Incentives Program; or
- (e) they are associated with a placement on the MedicarePlus for Other Medical Practitioners (OMPs) program, the After Hours OMPs program, the Rural OMPs program or Outer Metropolitan OMPs program.

GN.2.7 Overseas trained doctor

Ten year moratorium

Section 19AB of the Health Insurance Act 1973 states that services provided by overseas trained doctors (including New Zealand trained doctors) and former overseas medical students trained in Australia, will not attract Medicare benefits for 10 years from either

- a. their date of registration as a medical practitioner for the purposes of the Health Insurance Act 1973; or
- b. their date of permanent residency (the reference date will vary from case to case).

Exclusions - Practitioners who before 1 January 1997 had

- a. registered with a State or Territory medical board and retained a continuing right to remain in Australia; or
- b. lodged a valid application with the Australian Medical Council (AMC) to undertake examinations whose successful completion would normally entitle the candidate to become a medical practitioner.

The Minister of Health and Ageing may grant an overseas trained doctor (OTD) or occupational trainee (OT) an exemption to the requirements of the ten year moratorium, with or without conditions. When applying for a Medicare provider number, the OTD or OT must

- a. demonstrate that they need a provider number and that their employer supports their request; and
- b. provide the following documentation:
 - i. Australian medical registration papers; and
 - ii. a copy of their personal details in their passport and all Australian visas and entry stamps; and
 - iii. a letter from the employer stating why the person requires a Medicare provider number and/or prescriber number is required; and
 - iv. a copy of the employment contract.

GN.2.8 Contact details for the Department of Human Services Changes to Provider Contact Details

It is important that you contact the Department of Human Services promptly of any changes to your preferred contact details. Your preferred mailing address is used to contact you about Medicare provider matters. We require requests for changes to your preferred contact details to be made by the provider in writing to the Department of Human Services at:

Medicare

GPO Box 9822

in your capital city

or

By email: medicare.prov@medicareaustralia.gov.au

You may also be able to update some provider details through HPOS http://www.medicareaustralia.gov.au/hpos/index.jsp

MBS Interpretations

The day-to-day administration and payment of benefits under the Medicare arrangements is the responsibility of the Department of Human Services. Inquiries concerning matters of interpretation of MBS items should be directed to the Department of Health at Email: askmbs@health.gov.au

or by phone on 132 150

GN.3.9 Patient eligibility for Medicare

An "eligible person" is a person who resides permanently in Australia. This includes New Zealand citizens and holders of permanent residence visas. Applicants for permanent residence may also be eligible persons, depending on circumstances. Eligible persons must enrol with Medicare before they can receive Medicare benefits.

Medicare covers services provided only in Australia. It does not refund treatment or evacuation expenses overseas.

GN.3.10 Medicare cards

The green Medicare card is for people permanently in Australia. Cards may be issued for individuals or families.

The **blue** Medicare card bearing the words "INTERIM CARD" is for people who have applied for permanent residence.

Visitors from countries with which Australia has a Reciprocal Health Care Agreement receive a card bearing the words "RECIPROCAL HEALTH CARE"

GN.3.11 Visitors to Australia and temporary residents

Visitors and temporary residents in Australia are not eligible for Medicare and should therefore have adequate private health insurance.

GN.3.12 Reciprocal Health Care Agreements

Australia has Reciprocal Health Care Agreements with New Zealand, Ireland, the United Kingdom, the Netherlands, Sweden, Finland, Norway, Italy, Malta, Belgium and Slovenia.

Visitors from these countries are entitled to medically necessary treatment while they are in Australia, comprising public hospital care (as public patients), Medicare benefits and drugs under the Pharmaceutical Benefits Scheme (PBS). Visitors must enroll with the Department of Human Services to receive benefits. A passport is sufficient for public hospital care and PBS drugs.

Exceptions:

- · Visitors from Ireland and New Zealand are entitled to public hospital care and PBS drugs, and should present their passports before treatment as they are not issued with Medicare cards.
- · Visitors from Italy and Malta are covered for a period of six months only.

The Agreements do not cover treatment as a private patient in a public or private hospital. People visiting Australia for the purpose of receiving treatment are not covered.

GN.4.13 General Practice

Some MBS items may only be used by general practitioners. For MBS purposes a general practitioner is a medical practitioner who is

- (a) vocationally registered under section 3F of the *Health Insurance Act 1973* (see General Explanatory Note below); or
- (b) a Fellow of the Royal Australian College of General Practitioners (FRACGP), who participates in, and meets the requirements for the RACGP Quality Assurance and Continuing Medical Education Program; or
- (c) a Fellow of the Australian College of Rural and Remote Medicine (FACRRM) who participates in, and meets the requirements for the ACRRM Quality Assurance and Continuing Medical Education Program; or
- (d) is undertaking an approved general practice placement in a training program for *either* the award of FRACGP *or* a training program recognised by the RACGP being of an equivalent standard; or
- (e) is undertaking an approved general practice placement in a training program for *either* the award of FACRRM *or* a training program recognised by ACRRM as being of an equivalent standard.

A medical practitioner seeking recognition as an FRACGP should apply to the Department of Human Services, having completed an application form available from the Department of Human Services's website. A general practice trainee should apply to General Practice Education and Training Limited (GPET) for a general practitioner trainee placement. GPET will advise the Department of Human Services when a placement is approved. General practitioner trainees need to apply for a provider number using the appropriate provider number application form available on the Department of Human Services's website.

Vocational recognition of general practitioners

The only qualifications leading to vocational recognition are FRACGP and FACRRM. The criteria for recognition as a GP are:

- (a) certification by the RACGP that the practitioner
- · is a Fellow of the RACGP; and
- · practice is, or will be within 28 days, predominantly in general practice; and
- · has met the minimum requirements of the RACGP for taking part in continuing medical education and quality assurance programs.
- (b) certification by the General Practice Recognition Eligibility Committee (GPREC) that the practitioner
- · is a Fellow of the RACGP; and
- · practice is, or will be within 28, predominantly in general practice; and
- · has met minimum requirements of the RACGP for taking part in continuing medical education and quality assurance programs.
- (c) certification by ACRRM that the practitioner
- · is a Fellow of ACRRM; and
- · has met the minimum requirements of the ACRRM for taking part in continuing medical education and quality assurance programs.

In assessing whether a practitioner's medical practice is predominantly in general practice, the practitioner must have at least 50% of clinical time and services claimed against Medicare. Regard will also be given as to whether the

practitioner provides a comprehensive primary medical service, including treating a wide range of patients and conditions using a variety of accepted medical skills and techniques, providing services away from the practitioner's surgery on request, for example, home visits and making appropriate provision for the practitioner's patients to have access to after hours medical care.

Further information on eligibility for recognition should be directed to:

OI&CPD Program Administrator, RACGP

Tel: 1800 472 247 Email at: qicpd@racgp.org.au

Secretary, General Practice Recognition Eligibility Committee:

Email at gprec@health.gov.au

Executive Assistant, ACRRM:

Tel: (07) 3105 8200 Email at acrrm@acrrm.org.au

How to apply for vocational recognition

Medical practitioners seeking vocational recognition should apply to the Department of Human Services using the approved Application Form available on the Department of Human Services website: www.humanservices.gov.au. Applicants should forward their applications, as appropriate, to

The Secretariat
The General Practice Recognition Eligibility Committee
National Registration and Accreditation Scheme Policy Section
MDP 152
Department of Health
GPO Box 9848
CANBERRA ACT 2601
email address: gprec@health.gov.au

The Secretariat
The General Practice Recognition Appeal Committee
National Registration and Accreditation Scheme Policy Section
MDP 152
Department of Health
GPO Box 9848
CANBERRA ACT 2601
email address: gprac@health.gov.au

The relevant body will forward the application together with its certification of eligibility to the Department of Human Services CEO for processing.

Continued vocational recognition is dependent upon:

(a) the practitioner's practice continuing to be predominantly in general practice (for medical practitioners in the Register only); and

(b) the practitioner continuing to meet minimum requirements for participation in continuing professional development programs approved by the RACGP or the ACRRM.

Further information on continuing medical education and quality assurance requirements should be directed to the RACGP or the ACRRM depending on the college through which the practitioner is pursuing, or is intending to pursue, continuing medical education.

Medical practitioners refused certification by the RACGP, the ACRRM or GPREC may appeal in writing to The Secretariat, General Practice Recognition Appeal Committee (GPRAC), National Registration and Accreditation Scheme Policy Section, MDP 152, Department of Health, GPO Box 9848, Canberra, ACT, 2601.

Removal of vocational recognition status

A medical practitioner may at any time request the Department of Human Services to remove their name from the Vocational Register of General Practitioners.

Vocational recognition status can also be revoked if the RACGP, the ACRRM or GPREC certifies to the Department of Human Services that it is no longer satisfied that the practitioner should remain vocationally recognised. Appeals of the decision to revoke vocational recognition may be made in writing to GPRAC, at the above address.

A practitioner whose name has been removed from the register, or whose determination has been revoked for any reason must make a formal application to re-register, or for a new determination.

GN.5.14 Recognition as a Specialist or Consultant Physician

A medical practitioner who:

- · is registered as a specialist under State or Territory law; or
- · holds a fellowship of a specified specialist College and has obtained, after successfully completing an appropriate course of study, a relevant qualification from a relevant College

and has formally applied and paid the prescribed fee, may be recognised by the Minister as a specialist or consultant physician for the purposes of the *Health Insurance Act 1973*.

A relevant specialist College may also give the Department of Human Services' Chief Executive Officer a written notice stating that a medical practitioner meets the criteria for recognition.

A medical practitioner who is training for a fellowship of a specified specialist College and is undertaking training placements in a private hospital or in general practice, may provide services which attract Medicare rebates. Specialist trainees should consult the information available at the Department of Human Services' Medicare website.

Once the practitioner is recognised as a specialist or consultant physician for the purposes of the *Health Insurance Act 1973*, Medicare benefits will be payable at the appropriate higher rate for services rendered in the relevant speciality, provided the patient has been appropriately referred to them.

Further information about applying for recognition is available at the <u>Department of Human Services' Medicare</u> website.

The Department of Human Services (DHS) has developed an <u>Health Practitioner Guideline to substantiate that a valid referral existed (specialist or consultant physician)</u> which is located on the DHS website.

GN.5.15 Emergency Medicine

A practitioner will be acting as an emergency medicine specialist when treating a patient within 30 minutes of the patient's presentation, and that patient is

- (a) at risk of serious morbidity or mortality requiring urgent assessment and resuscitation; or
- (b) suffering from suspected acute organ or system failure; or
- (c) suffering from an illness or injury where the viability or function of a body part or organ is acutely threatened; or
- (d) suffering from a drug overdose, toxic substance or toxin effect; or
- (e) experiencing severe psychiatric disturbance whereby the health of the patient or other people is at immediate risk; or
- (f) suffering acute severe pain where the viability or function of a body part or organ is suspected to be acutely threatened; or
- (g) suffering acute significant haemorrhage requiring urgent assessment and treatment; and
- (h) treated in, or via, a bona fide emergency department in a hospital.

Benefits are not payable where such services are rendered in the accident and emergency departments or outpatient departments of public hospitals.

GN.6.16 Referral Of Patients To Specialists Or Consultant Physicians

For certain services provided by specialists and consultant physicians, the Medicare benefit payable is dependent on acceptable evidence that the service has been provided following referral from another practitioner.

A reference to a referral in this Section does not refer to written requests made for pathology services or diagnostic imaging services.

What is a Referral?

A "referral" is a request to a specialist or a consultant physician for investigation, opinion, treatment and/or management of a condition or problem of a patient or for the performance of a specific examination(s) or test(s).

Subject to the exceptions in the paragraph below, for a valid "referral" to take place

- (i) the referring practitioner must have undertaken a professional attendance with the patient and turned his or her mind to the patient's need for referral and have communicated relevant information about the patient to the specialist or consultant physician (this need not mean an attendance on the occasion of the referral):
- (ii) the instrument of referral must be in writing as a letter or note to a specialist or to a consultant physician and must be signed and dated by the referring practitioner; and
- (iii) the specialist or consultant physician to whom the patient is referred must have received the instrument of referral on or prior to the occasion of the professional service to which the referral relates.

The exceptions to the requirements in paragraph above are that

- (a) sub-paragraphs (i), (ii) and (iii) do not apply to
- a pre-anaesthesia consultation by a specialist anaesthetist (items 16710-17625);
- (b) sub-paragraphs (ii) and (iii) do not apply to
- a referral generated during an episode of hospital treatment, for a service provided or arranged by that hospital, where the hospital records provide evidence of a referral (including the referring practitioner's signature); or

- an emergency where the referring practitioner or the specialist or the consultant physician was of the opinion that the service be rendered as quickly as possible; and
- (c) sub-paragraph (iii) does not apply to instances where a written referral was completed by a referring practitioner but was lost, stolen or destroyed.

Examination by Specialist Anaesthetists

A referral is not required in the case of pre-anaesthesia consultation items 17610-17625. However, for benefits to be payable at the specialist rate for consultations, other than pre-anaesthesia consultations by specialist anaesthetists (items 17640 -17655) a referral is required.

Who can Refer?

The general practitioner is regarded as the primary source of referrals. Cross-referrals between specialists and/or consultant physicians should usually occur in consultation with the patient's general practitioner.

Referrals by Dentists or Optometrists or Participating Midwives or Participating Nurse Practitioners

For Medicare benefit purposes, a referral may be made to

- (i) a recognised specialist:
- (a) by a registered dental practitioner, where the referral arises from a dental service; or
- (b) by a registered optometrist where the specialist is an ophthalmologist; or
- (c) by a participating midwife where the specialist is an obstetrician or a paediatrician, as clinical needs dictate. A referral given by a participating midwife is valid until 12 months after the first service given in accordance with the referral and for I pregnancy only or
- (d) by a participating nurse practitioner to specialists and consultant physicians. A referral given by a participating nurse practitioner is valid until 12 months after the first service given in accordance with the referral.
- (ii) a consultant physician, by an approved dental practitioner (oral surgeon), where the referral arises out of a dental service.

In any other circumstances (i.e. a referral to a consultant physician by a dentist, other than an approved oral surgeon, or an optometrist, or a referral by an optometrist to a specialist other than a specialist ophthalmologist), it is <u>not</u> a valid referral. Any resulting consultant physician or specialist attendances will attract Medicare benefits at unreferred rates.

Registered dentists and registered optometrists may refer themselves to specialists in accordance with the criteria above, and Medicare benefits are payable at the levels which apply to their referred patients.

Billing

Routine Referrals

In addition to providing the usual information required to be shown on accounts, receipts or assignment forms, specialists and consultant physicians must provide the following details (unless there are special circumstances as indicated in paragraph below):-

- name and either practice address or provider number of the referring practitioner;
- date of referral; and
- period of referral (when other than for 12 months) expressed in months, eg "3", "6" or "18" months, or "indefinitely" should be shown.

Special Circumstances

(i) Lost, stolen or destroyed referrals.

If a referral has been made but the letter or note of referral has been lost, stolen or destroyed, benefits will be payable at the referred rate if the account, receipt or the assignment form shows the name of the referring medical practitioner, the practice address or provider number of the referring practitioner (if either of these are known to the consultant physician or specialist) and the words 'Lost referral'. This provision only applies to the initial attendance. For subsequent attendances to attract Medicare benefits at the referred rate a duplicate or replacement letter of referral must be obtained by the specialist or the consultant physician.

(ii) Emergencies

If the referral occurred in an emergency, benefit will be payable at the referred rate if the account, receipt or assignment form is endorsed 'Emergency referral'. This provision only applies to the initial attendance. For subsequent attendances to attract Medicare benefits at the referred rate the specialist/consultant physician must obtain a letter of referral.

(iii) Hospital referrals.

Private Patients - Where a referral is generated during an episode of hospital treatment for a service provided or arranged by that hospital, benefits will be payable at the referred rate if the account, receipt or assignment form is endorsed 'Referral within (name of hospital)' and the patient's hospital records show evidence of the referral (including the referring practitioner's signature). However, in other instances where a medical practitioner within a hospital is involved in referring a patient (e.g. to a specialist or a consultant physician in private rooms) the normal referral arrangements apply, including the requirement for a referral letter or note and its retention by the specialist or the consultant physician billing for the service.

Public Hospital Patients

State and Territory Governments are responsible for the provision of public hospital services to eligible persons in accordance with the National Healthcare Agreement.

Bulk Billing

Bulk billing assignment forms should show the same information as detailed above. However, faster processing of the claim will be facilitated where the provider number (rather than the practice address) of the referring practitioner is shown.

Period for which Referral is Valid

The referral is valid for the period specified in the referral which is taken to commence on the date of the specialist's or consultant physician's first service covered by that referral.

Specialist Referrals

Where a referral originates from a specialist or a consultant physician, the referral is valid for 3 months, except where the referred patient is an admitted patient. For admitted patients, the referral is valid for 3 months or the duration of the admission whichever is the longer.

As it is expected that the patient's general practitioner will be kept informed of the patient's progress, a referral from a specialist or a consultant physician must include the name of the patient's general practitioners and/or practice. Where a patient is unable or unwilling to nominate a general practitioner or practice this must be stated in the referral.

Referrals by other Practitioners

Where the referral originates from a practitioner other than those listed in *Specialist Referrals*, the referral is valid for a period of 12 months, unless the referring practitioner indicates that the referral is for a period more or less than 12 months (eg. 3, 6 or 18 months or valid indefinitely). Referrals for longer than 12 months should only be used where the patient's clinical condition requires continuing care and management of a specialist or a consultant physician for a specific condition or specific conditions.

Definition of a Single Course of Treatment

A single course of treatment involves an initial attendance by a specialist or consultant physician and the continuing management/treatment up to the stage where the patient is referred back to the care of the referring practitioner. It also includes any subsequent review of the patient's condition by the specialist or the consultant physician that may be necessary. Such a review may be initiated by either the referring practitioner or the specialist/consultant physician.

The presentation of an unrelated illness, requiring the referral of the patient to the specialist's or the consultant physician's care would initiate a new course of treatment in which case a new referral would be required.

The receipt by a specialist or consultant physician of a new referral following the expiration of a previous referral for the same condition(s) does not necessarily indicate the commencement of a new course of treatment involving the itemisation of an initial consultation. In the continuing management/treatment situation the new referral is to facilitate the payment of benefits at the specialist or the consultant physician referred rates rather than the unreferred rates.

However, where the referring practitioner:-

- (a) deems it necessary for the patient's condition to be reviewed; and
- (b) the patient is seen by the specialist or the consultant physician outside the currency of the last referral; and
- (c) the patient was last seen by the specialist or the consultant physician more than 9 months earlier

the attendance following the new referral initiates a new course of treatment for which Medicare benefit would be payable at the initial consultation rates.

Retention of Referral Letters

The prima facie evidence that a valid referral exists is the provision of the referral particulars on the specialist's or the consultant physician's account.

A specialist or a consultant physician is required to retain the instrument of referral (and a hospital is required to retain the patient's hospital records which show evidence of a referral) for 2 years from the date the service was rendered.

A specialist or a consultant physician is required, if requested by the Department of Human Services CEO, to produce to a medical practitioner who is an employee of the Department of Human Services, the instrument of referral within seven days after the request is received. Where the referral originates in an emergency situation or in a hospital, the specialist or consultant physician is required to produce such information as is in his or her possession or control relating to whether the patient was so treated.

Attendance for Issuing of a Referral

Medicare benefit is attracted for an attendance on a patient even where the attendance is solely for the purpose of issuing a referral letter or note. However, if a medical practitioner issues a referral without an attendance on the patient, no benefit is payable for any charge raised for issuing the referral.

Locum-tenens Arrangements

It should be noted that where a non-specialist medical practitioner acts as a locum-tenens for a specialist or consultant physician, or where a specialist acts as a locum-tenens for a consultant physician, Medicare benefit is only payable at the level appropriate for the particular locum-tenens, eg, general practitioner level for a general practitioner locum-tenens and specialist level for a referred service rendered by a specialist locum tenens.

Medicare benefits are not payable where a practitioner is not eligible to provide services attracting Medicare benefits acts as a locum-tenens for any practitioner who is eligible to provide services attracting Medicare benefits.

Fresh referrals are not required for locum-tenens acting according to accepted medical practice for the principal of a practice ie referrals to the latter are accepted as applying to the former and benefit is not payable at the initial attendance rate for an attendance by a locum-tenens if the principal has already performed an initial attendance in respect of the particular instrument of referral.

Self Referral

Medical practitioners may refer themselves to consultant physicians and specialists and Medicare benefits are payable at referred rates.

GN.7.17 Billing procedures

The Department of Human Services website contains information on Medicare billing and claiming options. Please visit the <u>Department of Human Services</u> website for further information.

Bulk billing

Under the *Health Insurance Act 1973*, a bulk billing facility for professional services is available to all persons in Australia who are eligible for a benefit under the Medicare program. If a practitioner bulk bills for a service the practitioner undertakes to accept the relevant Medicare benefit as full payment for the service. Additional charges for that service cannot be raised. This includes but is not limited to:

- any consumables that would be reasonably necessary to perform the service, including bandages and/or dressings;
- record keeping fees;
- a booking fee to be paid before each service, or;
- an annual administration or registration fee.

Where the patient is bulk billed, an additional charge can **only** be raised against the patient by the practitioner where the patient is provided with a vaccine or vaccines from the practitioner's own supply held on the practitioner's premises. This exemption only applies to general practitioners and other non-specialist practitioners in association with attendance items **3** to **96**, **179** to **212**, **733** to **789** and **5000** to **5267** (inclusive) and only relates to vaccines that are not available to the patient free of charge through Commonwealth or State funding arrangements or available through the Pharmaceutical Benefits Scheme. The additional charge must only be to cover the supply of the vaccine.

Where a practitioner provides a number of services (excluding operations) on the one occasion, they can choose to bulk bill some or all of those services and privately charge a fee for the other service (or services), in excess of the Medicare rebate. The privately charged fee can only be charged in relation to said service (or services). Where two or more operations are provided on the one occasion, all services must be either bulk billed or privately charged.

It should be noted that, where a service is not bulk billed, a practitioner may privately raise an additional charge against a patient, such as for a consumable. An additional charge can also be raised where a practitioner does not bulk bill a patient but instead charges a fee that is equal to the rebate for the Medicare service. For example, where a general practitioner provides a professional service to which item 23 relates the practitioner could, in place of bulk billing the patient, charge the rebate for the service and then also raise an additional charge (such as for a consumable).

GN.8.18 Provision for review of individual health professionals

The Professional Services Review (PSR) reviews and investigates service provision by health practitioners to determine if they have engaged in inappropriate practice when rendering or initiating Medicare services, or when prescribing or dispensing under the PBS.

Section 82 of the *Health Insurance Act 1973* defines inappropriate practice as conduct that is such that a PSR Committee could reasonably conclude that it would be unacceptable to the general body of the members of the profession in which the practitioner was practicing when they rendered or initiated the services under review. It is also an offence under Section 82 for a person or officer of a body corporate to knowingly, recklessly or negligently cause or permit a practitioner employed by the person to engage in such conduct.

The Department of Human Services monitors health practitioners' claiming patterns. Where the Department of Human Services detects an anomaly, it may request the Director of PSR to review the practitioner's service provision. On receiving the request, the Director must decide whether to a conduct a review and in which manner the review will be conducted. The Director is authorized to require that documents and information be provided.

Following a review, the Director must:

decide to take no further action; or

enter into an agreement with the person under review (which must then be ratified by an independent Determining Authority); or

refer the matter to a PSR Committee.

A PSR Committee normally comprises three medically qualified members, two of whom must be members of the same profession as the practitioner under review. However, up to two additional Committee members may be appointed to provide wider range of clinical expertise.

The Committee is authorized to:

investigate any aspect of the provision of the referred services, and without being limited by the reasons given in the review request or by a Director's report following the review;

hold hearings and require the person under review to attend and give evidence;

require the production of documents (including clinical notes).

The methods available to a PSR Committee to investigate and quantify inappropriate practice are specified in legislation:

(a) Patterns of Services - The Health Insurance (Professional Services Review) Regulations 1999 specify that when a general practitioner or other medical practitioner reaches or exceeds 80 or more attendances on each of 20 or more days in a 12-month period, they are deemed to have practiced inappropriately.

A professional attendance means a service of a kind mentioned in group A1, A2, A5, A6, A7, A9, A11, A13, A14, A15, A16, A17, A18, A19, A20, A21, A22 or A23 of Part 3 of the General Medical Services Table.

If the practitioner can satisfy the PSR Committee that their pattern of service was as a result of exceptional circumstances, the quantum of inappropriate practice is reduce accordingly. Exceptional circumstances include, but are not limited to, those set out in the *Regulations*. These include:

an unusual occurrence;

the absence of other medical services for the practitioner's patients (having regard to the practice location); and the characteristics of the patients.

- **Sampling** A PSR Committee may use statistically valid methods to sample the clinical or practice records.
- **Generic findings** If a PSR Committee cannot use patterns of service or sampling (for example, there are insufficient medical records), it can make a 'generic' finding of inappropriate practice.

Additional Information

A PSR Committee may not make a finding of inappropriate practice unless it has given the person under review notice of its intention to review them, the reasons for its findings, and an opportunity to respond. In reaching their decision, a PSR Committee is required to consider whether or not the practitioner has kept adequate and contemporaneous patient records (See general explanatory note G15.1 for more information on adequate and contemporaneous patient records).

The practitioner under review is permitted to make submissions to the PSR Committee before key decisions or a final report is made.

If a PSR Committee finds that the person under review has engaged in inappropriate practice, the findings will be reported to the Determining Authority to decide what action should be taken:

- (i) a reprimand;
- (ii) counselling;
- (iii) repayment of Medicare benefits; and/or
- (iv) complete or partial disqualification from Medicare benefit arrangements for up to three years.

Further information is available from the PSR website - www.psr.gov.au

GN.8.19 Medicare Participation Review Committee

The Medicare Participation Review Committee determines what administrative action should be taken against a practitioner who:

- (a) has been successfully prosecuted for relevant criminal offences;
- (b) has breached an Approved Pathology Practitioner undertaking;
- (c) has engaged in prohibited diagnostic imaging practices; or
- (d) has been found to have engaged in inappropriate practice under the Professional Services Review scheme and has received Final Determinations on two (or more) occasions.

The Committee can take no further action, counsel or reprimand the practitioner, or determine that the practitioner be disqualified from Medicare for a particular period or in relation to particular services for up to five years.

Medicare benefits are not payable in respect of services rendered by a practitioner who has been fully disqualified, or partly disqualified in relation to relevant services under the *Health Insurance Act 1973* (Section 19B applies).

GN.8.20 Referral of professional issues to regulatory and other bodies

The Health Insurance Act 1973 provides for the following referral, to an appropriate regulatory body:

- i. a significant threat to a person's life or health, when caused or is being caused or is likely to be caused by the conduct of the practitioner under review; or
- ii. a statement of concerns of non-compliance by a practitioner with 'professional standards'.

GN.8.21 Comprehensive Management Framework for the MBS

The Government announced the Comprehensive Management Framework for the MBS in the 2011-12 Budget to improve MBS management and governance into the future. As part of this framework, the Medical Services Advisory Committee (MSAC) Terms of Reference and membership have been expanded to provide the Government with independent expert advice on all new proposed services to be funded through the MBS, as well as on all proposed amendments to existing MBS items. Processes developed under the previously funded MBS Quality Framework are now being integrated with MSAC processes under the Comprehensive Management Framework for the MBS.

GN.8.22 Medical Services Advisory Committee

The Medical Services Advisory Committee (MSAC) advises the Minister on the strength of evidence relating to the safety, effectiveness and cost effectiveness of new and emerging medical services and technologies and under what circumstances public funding, including listing on the MBS, should be supported.

MSAC members are appointed by the Minister and include specialist practitioners, general practitioners, health economists, a health consumer representative, health planning and administration experts and epidemiologists.

For more information on the MSAC refer to their website - www.msac.gov.au or email on msac.secretariat@health.gov.au or by phoning the MSAC secretariat on (02) 6289 7550.

GN.8.23 Pathology Services Table Committee

This Pathology Services Table Committee comprises six representatives from the interested professions and six from the Australian Government. Its primary role is to advise the Minister on the need for changes to the structure and content of the Pathology Services Table (except new medical services and technologies) including the level of fees.

GN.9.25 Penalties and Liabilities

Penalties of up to \$10,000 or imprisonment for up to five years, or both, may be imposed on any person who makes a statement (oral or written) or who issues or presents a document that is false or misleading in a material particular and which is capable of being used with a claim for benefits. In addition, any practitioner who is found guilty of such offences by a court shall be subject to examination by a Medicare Participation Review Committee and may be counselled or reprimanded or may have services wholly or partially disqualified from the Medicare benefit arrangements.

A penalty of up to \$1,000 or imprisonment for up to three months, or both, may be imposed on any person who obtains a patient's signature on a direct-billing form without the obligatory details having been entered on the form before the person signs, or who fails to cause a patient to be given a copy of the completed form.

GN.10.26 Schedule fees and Medicare benefits

Medicare benefits are based on fees determined for each medical service. The fee is referred to in these notes as the "Schedule fee". The fee for any item listed in the MBS is that which is regarded as being reasonable on average for that service having regard to usual and reasonable variations in the time involved in performing the service on different occasions and to reasonable ranges of complexity and technical difficulty encountered.

Schedule fees are usually adjusted on an annual basis except for Pathology, Diagnostic Imaging and certain other items.

The Schedule fee and Medicare benefit levels for the medical services contained in the MBS are located with the item descriptions. Where appropriate, the calculated benefit has been rounded to the nearest higher 5 cents. However, in no circumstances will the Medicare benefit payable exceed the fee actually charged.

There are presently three levels of Medicare benefit payable:

a. 75% of the Schedule fee:

- i. for professional services rendered to a patient as part of an episode of hospital treatment (other than public patients). Medical practitioners must indicate on their accounts if a medical service is rendered in these circumstances by placing an asterisk '*' or the letter 'H' directly after an item number where used; or a description of the professional service and an indication the service was rendered as an episode of hospital treatment (for example, 'in hospital', 'admitted' or 'in patient');
- for professional services rendered as part of an episode of hospital-substitute treatment, and the patient who receives the treatment chooses to receive a benefit from a private health insurer. Medical practitioners must indicate on their accounts if a medical service is rendered in these circumstances by placing the words 'hospital-substitute treatment' directly after an item number where used; or a description of the professional service, preceded by the words 'hospital-substitute treatment'
- b. 100% of the Schedule fee for non-referred attendances by general practitioners to non-admitted patients and services provided by a practice nurse or Aboriginal and Torres Strait Islander health practitioner on behalf of a general practitioner.
- c. 85% of the Schedule fee, or the Schedule fee less \$83.40 (indexed annually in November), whichever is the greater, for all other professional services.

Public hospital services are to be provided free of charge to eligible persons who choose to be treated as public patients in accordance with the National Healthcare Agreement.

A medical service rendered to a patient on the day of admission to, or day of discharge from hospital, but prior to admission or subsequent to discharge, will attract benefits at the 85% or 100% level, not 75%. This also applies to a pathology service rendered to a patient prior to admission. Attendances on patients at a hospital (other than patients covered by paragraph (i) above) attract benefits at the 85% level.

The 75% benefit level applies even though a portion of the service (eg. aftercare) may be rendered outside the hospital. With regard to obstetric items, benefits would be attracted at the 75% level where the confinement takes place in hospital.

Pathology tests performed after discharge from hospital on bodily specimens taken during hospitalisation also attract the 75% level of benefits.

It should be noted that private health insurers can cover the "patient gap" (that is, the difference between the Medicare rebate and the Schedule fee) for services attracting benefits at the 75% level. Patient's may insure with private health insurers for the gap between the 75% Medicare benefits and the Schedule fee or for amounts in excess of the Schedule fee where the doctor has an arrangement with their health insurer.

GN.10.27 Medicare safety nets

The Medicare Safety Nets provide families and singles with an additional rebate for out-of-hospital Medicare services, once annual thresholds are reached. There are two safety nets: the original Medicare safety net and the extended Medicare safety net.

Original Medicare Safety Net:

Under the original Medicare safety net, the Medicare benefit for out-of-hospital services is increased to 100% of the Schedule Fee (up from 85%) once an annual threshold in gap costs is reached. Gap costs refer to the difference between the Medicare benefit (85%) and the Schedule Fee. The threshold from 1 January 2019 is \$470.00. This threshold applies to all Medicare-eligible singles and families.

Extended Medicare Safety Net:

Under the extended Medicare safety net (EMSN), once an annual threshold in out-of-pocket costs for out-of-hospital Medicare services is reached, Medicare will pay for 80% of any future out-of-pocket costs for out-of-hospital Medicare services for the remainder of the calendar year. However, where the item has an EMSN benefit cap, there is a maximum limit on the EMSN benefit that will be paid for that item. Further explanation about EMSN benefit

caps is provided below. Out-of-pocket costs refer to the difference between the Medicare benefit and the fee charged by the practitioner.

In 2019, the threshold for singles and families that hold Commonwealth concession card, families that received Family Tax Benefit Part (A) (FTB(A)) and families that qualify for notional FTB (A) is \$680.70. The threshold for all other singles and families in 2019 is \$2,133.00.

The thresholds for both safety nets are usually indexed on 1 January each year.

Individuals are automatically registered with the Department of Human Services for the safety nets; however couples and families are required to register in order to be recognised as a family for the purposes on the safety nets. In most cases, registered families have their expenses combined to reach the safety net thresholds. This may help to qualify for safety net benefits more quickly. Registration forms can be obtained from the Department of Human Services offices, or completed online at http://www.humanservices.gov.au/customer/services/medicare/medicare-safety-net.

EMSN Benefit Caps:

The EMSN benefit cap is the maximum EMSN benefit payable for that item and is paid in addition to the standard Medicare rebate. Where there is an EMSN benefit cap in place for the item, the amount of the EMSN cap is displayed in the item descriptor.

Once the EMSN threshold is reached, each time the item is claimed the patient is eligible to receive up to the EMSN benefit cap. As with the safety nets, the EMSN benefit cap only applies to out-of-hospital services.

Where the item has an EMSN benefit cap, the EMSN benefit is calculated as 80% of the out-of-pocket cost for the service. If the calculated EMSN benefit is less than the EMSN benefit cap; then calculated EMSN rebate is paid. If the calculated EMSN benefit is greater than the EMSN benefit cap; the EMSN benefit cap is paid.

For example: Item A has a Schedule fee of \$100, the out-of-hospital benefit is \$85 (85% of the Schedule fee). The EMSN benefit cap is \$30. Assuming that the patient has reached the EMSN threshold:

o If the fee charged by the doctor for Item A is \$125, the standard Medicare rebate is \$85, with an out-of-pocket cost of \$40. The EMSN benefit is calculated as $40 \times 80\% = 32$. However, as the EMSN benefit cap is \$30, only \$30 will be paid.

o If the fee charged by the doctor for Item A is \$110, the standard Medicare rebate is \$85, with an out-of-pocket cost of \$25. The EMSN benefit is calculated as $25 \times 80\% = 20$. As this is less than the EMSN benefit cap, the full 20 is paid.

GN.11.28 Services not listed in the MBS

Benefits are not generally payable for services not listed in the MBS. However, there are some procedural services which are not specifically listed because they are regarded as forming part of a consultation or else attract benefits on an attendance basis. For example, intramuscular injections, aspiration needle biopsy, treatment of sebhorreic keratoses and less than 10 solar keratoses by ablative techniques and closed reduction of the toe (other than the great toe).

Enquiries about services not listed or on matters of interpretation should be directed to the Department of Human Services on 132 150.

GN.11.29 Ministerial Determinations

Section 3C of the *Health Insurance Act 1973* empowers the Minister to determine an item and Schedule fee (for the purposes of the Medicare benefits arrangements) for a service not included in the health insurance legislation. This provision may be used to facilitate payment of benefits for new developed procedures or techniques where close monitoring is desirable. Services which have received section 3C approval are located in their relevant Groups in the MBS with the notation "(Ministerial Determination)".

GN.12.30 Professional services

Professional services which attract Medicare benefits include medical services rendered by or "on behalf of" a medical practitioner. The latter include services where a part of the service is performed by a technician employed by or, in accordance with accepted medical practice, acting under the supervision of the medical practitioner.

The following medical services will attract benefits only if they have been personally performed by a medical practitioner on not more than one patient on the one occasion (i.e. two or more patients cannot be attended simultaneously, although patients may be seen consecutively), unless a group session is involved (i.e. Items 170-172). The requirement of "personal performance" is met whether or not assistance is provided, according to accepted medical standards:-

- (a) Category 1 (Professional Attendances) items except 170-172, 342-346, 820-880, 6029-6042, 6064-6075;
- (b) Each of the following items in Group D1 (Miscellaneous Diagnostic):- 11012, 11015, 11018, 11021, 11304, 11600, 11627, 11701, 11712, 11722, 11724, 11728, 11921, 12000, 12003;
- (c) All Group T1 (Miscellaneous Therapeutic) items (except 13020, 13025, 13200-13206, 13212-13221, 13703, 13706, 13709, 13750-13760, 13915-13948, 14050, 14053, 14218, 14221 and 14245);
- (d) Item 15600 in Group T2 (Radiation Oncology);
- (e) All Group T3 (Therapeutic Nuclear Medicine) items;
- (f) All Group T4 (Obstetrics) items (except 16400 and 16514);
- (g) All Group T6 (Anaesthetics) items;
- (h) All Group T7 (Regional or Field Nerve Block) items;
- (i) All Group T8 (Operations) items;
- (j) All Group T9 (Assistance at Operations) items;
- (k) All Group T10 (Relative Value Guide for Anaesthetics) items.

For the group psychotherapy and family group therapy services covered by Items 170, 171, 172, 342, 344 and 346, benefits are payable only if the services have been conducted personally by the medical practitioner.

Medicare benefits are not payable for these group items or any of the items listed in (a) - (k) above when the service is rendered by a medical practitioner employed by the proprietor of a hospital (not being a private hospital), except where the practitioner is exercising their right of private practice, or is performing a medical service outside the hospital. For example, benefits are not paid when a hospital intern or registrar performs a service at the request of a staff specialist or visiting medical officer.

Medicare benefits are only payable for items 12306 - 12322 (Bone Densitometry) when the service is performed by a specialist or consultant physician in the practice of his or her specialty where the patient is referred by another medical practitioner.

GN.12.31 Services rendered on behalf of medical practitioners

Medical services in Categories 2 and 3 not included in GN.12.30 and Category 5 (Diagnostic Imaging) services continue to attract Medicare benefits if the service is rendered by:-

- (a) the medical practitioner in whose name the service is being claimed;
- (b) a person, other than a medical practitioner, who is employed by a medical practitioner or, in accordance with accepted medical practice, acts under the supervision of a medical practitioner.

See Category 6 Notes for Guidance for arrangements relating to Pathology services.

So that a service rendered by an employee or under the supervision of a medical practitioner may attract a Medicare rebate, the service must be billed in the name of the practitioner who must accept full responsibility for the service. All practitioners should ensure they maintain adequate and contemporaneous records. All elements of the service must be performed in accordance with accepted medical practice.

Supervision from outside of Australia is not acceptable.

While the supervising medical practitioner need not be present for the entire service, they must have a direct involvement in at least part of the service. Although the supervision requirements will vary according to the service in question, they will, as a general rule, be satisfied where the medical practitioner has:-

- (a) established consistent quality assurance procedures for the data acquisition; and
- (b) personally analysed the data and written the report.

Benefits are not payable for these services when a medical practitioner refers patients to self-employed medical or paramedical personnel, such as radiographers and audiologists, who either bill the patient or the practitioner requesting the service.

GN.12.32 Medicare benefits and vaccinations

Where a medical practitioner administers an injection for immunisation purposes on his or her own patient, Medicare benefits for that service would be payable on a consultation basis, that is, for the attendance at which the injection is given. However, the cost of the vaccine itself does not attract a Medicare rebate. The Medicare benefits arrangements cover only the professional component of the medical practitioner's service. There are some circumstances where a Medicare benefit is not payable when a medical practitioner administers an injection for immunisation purposes – please refer to example 3 below for further details.

Example 1

A patient presents to a GP to receive the influenza vaccination. The patient is not in the cohort of patients which is covered for the influenza vaccine under the NIP.

After taking a short patient history, the GP administers the vaccine to the patient. The GP has met the requirements of a level A consultation and claims item 3. The GP can bulk bill the patient for the cost of the MBS service and can charge a separate amount for the cost of the vaccine, which is not covered under the NIP.

If a patient presented to a GP to receive a vaccine and to enquire about a medical condition, the GP may claim the appropriate item (such as item 23).

Example 2

A patient presents to a GP to receive the influenza vaccination. The patient is in the cohort of patients which is covered for the influenza vaccine under the NIP.

After taking a short patient history, the GP administers the vaccine to the patient. The GP has met the requirements of a level A consultation and claims item 3. The GP can bulk bill the patient but does not need to charge a separate amount for the cost of the vaccine, which is covered under the NIP.

If a patient presented to a GP to receive a vaccine and to enquire about a medical condition, the GP may claim the appropriate item (such as item 23).

Example 3

A GP is employed by a State or Territory community health centre to administer vaccines and provides no additional medical services.

A Medicare benefit is not payable as the GP is providing the service under an arrangement with the State or Territory, which is prohibited under subsection 19(2) of the Health Insurance Act 1973. The service is also prohibited on the basis that it is a mass immunisation which is prohibited under subsection 19(4).

A mass immunisation is a program to inoculate people that is funded by the Commonwealth or State Government, or through an international or private organisation.

GN.13.33 Services which do not attract Medicare benefits Services not attracting benefits

- (a) telephone consultations;
- (b) issue of repeat prescriptions when the patient does not attend the surgery in person;
- (c) group attendances (unless otherwise specified in the item, such as items 170, 171, 172, 342, 344 and 346);
- (d) non-therapeutic cosmetic surgery;
- (e) euthanasia and any service directly related to the procedure. However, services rendered for counselling/assessment about euthanasia will attract benefits.

Medicare benefits are not payable where the medical expenses for the service

- (a) are paid/payable to a public hospital;
- (b) are for a compensable injury or illness for which the patient's insurer or compensation agency has accepted liability. (Please note that if the medical expenses relate to a compensable injury/illness for which the insurer/compensation agency is disputing liability, then Medicare benefits are payable until the liability is accepted.);
- (c) are for a medical examination for the purposes of life insurance, superannuation, a provident account scheme, or admission to membership of a friendly society;
- (d) are incurred in mass immunisation (see General Explanatory Note 12.3 for further explanation).

Unless the Minister otherwise directs

Medicare benefits are not payable where:

- (a) the service is rendered by or on behalf of, or under an arrangement with the Australian Government, a State or Territory, a local government body or an authority established under Commonwealth, State or Territory law;
- (b) the medical expenses are incurred by the employer of the person to whom the service is rendered;
- (c) the person to whom the service is rendered is employed in an industrial undertaking and that service is rendered for the purposes related to the operation of the undertaking; or
- (d) the service is a health screening service.
- (e) the service is a pre-employment screening service

Current regulations preclude the payment of Medicare benefits for professional services rendered in relation to or in association with:

- (a) chelation therapy (that is, the intravenous administration of ethylenediamine tetra-acetic acid or any of its salts) other than for the treatment of heavy-metal poisoning;
- (b) the injection of human chorionic gonadotrophin in the management of obesity;

- (c) the use of hyperbaric oxygen therapy in the treatment of multiple sclerosis;
- (d) the removal of tattoos;
- (e) the transplantation of a thoracic or abdominal organ, other than a kidney, or of a part of an organ of that kind; or the transplantation of a kidney in conjunction with the transplantation of a thoracic or other abdominal organ, or part of an organ of that kind;
- (f) the removal from a cadaver of kidneys for transplantation;
- (g) the administration of microwave (UHF radio wave) cancer therapy, including the intravenous injection of drugs used in the therapy.

Pain pumps for post-operative pain management

The cannulation and/or catheterisation of surgical sites associated with pain pumps for post-operative pain management cannot be billed under any MBS item.

The filling or re-filling of drug reservoirs of ambulatory pain pumps for post-operative pain management cannot be billed under any MBS items.

Non Medicare Services

No MBS item applies to a service mentioned in the item if the service is provided to a patient at the same time as, or in connection with, an injection of blood or a blood product that is autologous.

No MBS item applies to a service mentioned in the item if the service is provided to a patient at the same time as, or in connection with, the harvesting, storage, in vitro processing or injection of non-haematopoietic stem cells.

An item in the range 1 to 10943 does not apply to the service described in that item if the service is provided at the same time as, or in connection with, any of the services specified below:

- (a) endoluminal gastroplication, for the treatment of gastro-oesophageal reflux disease;
- (b) gamma knife surgery;
- (c) intradiscal electro thermal arthroplasty;
- (d) intravascular ultrasound (except where used in conjunction with intravascular brachytherapy);
- (e) intro-articular viscosupplementation, for the treatment of osteoarthritis of the knee;
- (f) low intensity ultrasound treatment, for the acceleration of bone fracture healing, using a bone growth stimulator;
- (g) lung volume reduction surgery, for advanced emphysema;
- (h) photodynamic therapy, for skin and mucosal cancer;
- (i) placement of artificial bowel sphincters, in the management of faecal incontinence;
- (j) selective internal radiation therapy for any condition other than hepatic metastases that are secondary to colorectal cancer;
- (k) specific mass measurement of bone alkaline phosphatase;
- (1) transmyocardial laser revascularisation;
- (m) vertebral axial decompression therapy, for chronic back pain.

- (n) autologous chondrocyte implantation and matrix-induced autologous chondrocyte implantation.
- (o) vertebroplasty

Health Screening Services

Unless the Minister otherwise directs Medicare benefits are not payable for health screening services. A health screening service is defined as a medical examination or test that is not reasonably required for the management of the medical condition of the patient. Services covered by this proscription include such items as:

- (a) multiphasic health screening;
- (b) mammography screening (except as provided for in Items 59300/59303);
- (c) testing of fitness to undergo physical training program, vocational activities or weight reduction programs;
- (d) compulsory examinations and tests to obtain a flying, commercial driving or other licence;
- (e) entrance to schools and other educational facilities;
- (f) for the purposes of legal proceedings;
- (g) compulsory examinations for admission to aged persons' accommodation and pathology services associated with clinical ecology.

The Minister has directed that Medicare benefits be paid for the following categories of health screening:

- (a) a medical examination or test on a symptomless patient by that patient's own medical practitioner in the course of normal medical practice, to ensure the patient receives any medical advice or treatment necessary to maintain their state of health. Benefits would be payable for the attendance and tests which are considered reasonably necessary according to patients individual circumstances (such as age, physical condition, past personal and family history). For example, a cervical screening test in a person (see General Explanatory note 12.3 for more information), blood lipid estimation where a person has a family history of lipid disorder. However, such routine check-up should not necessarily be accompanied by an extensive battery of diagnostic investigations;
- (b) a pathology service requested by the National Heart Foundation of Australia, Risk Evaluation Service;
- (c) age or health related medical examinations to obtain or renew a licence to drive a private motor vehicle;
- (d) a medical examination of, and/or blood collection from persons occupationally exposed to sexual transmission of disease, in line with conditions determined by the relevant State or Territory health authority, (one examination or collection per person per week). Benefits are not paid for pathology tests resulting from the examination or collection;
- (e) a medical examination for a person as a prerequisite of that person becoming eligible to foster a child or children;
- (f) a medical examination being a requisite for Social Security benefits or allowances;
- (g) a medical or optometrical examination provided to a person who is an unemployed person (as defined by the Social Security Act 1991), as the request of a prospective employer.

The National Policy for the National Cervical Screening Program (NCSP) is as follows:

- (a) Cervical screening should be undertaken every five years in asymptomatic persons, using a primary human papillomavirus (HPV) test with partial genotyping and reflex liquid based cytology (LBC) triage;
- (b) Persons who have ever been sexually active should commence cervical screening at 25 years of age;

- (c) Persons aged 25 years or older and less than 70 years will receive invitations and reminders to participate in the program;
- (d) Persons will be invited to exit the program by having a HPV test between 70 years or older and less than 75 years of age and may cease cervical screening if their test result is low risk;
- (e) Persons 75 years of age or older who have either never had a cervical screening test or have not had one in the previous five years, may request a cervical screening test and can be screened;
- (f) All persons, both HPV vaccinated and unvaccinated, are included in the program;
- (g) Self collection of a sample for testing is available for persons who are aged 30 years and over and has never participated in the NCSP; or is overdue for cervical screening by two years or longer.
- Self collection must be facilitated and requested by a healthcare professional who also routinely offers cervical screening services;
- The self collection device and the HPV test, when used together, must meet the requirements of the National Pathology Accreditation Advisory Council (NPAAC) Requirements for Laboratories Reporting Tests for the NCSP; and
- (h) Persons with intermediate and higher risk screening test results should be followed up in accordance with the cervical screening pathway and the NCSP: Guidelines for the management of screen detected abnormalities, screening women in specific populations and investigation of women with abnormal vaginal bleeding (2016 Guidelines) endorsed by the Royal Australian College of General Practitioners, the Royal Australian and New Zealand College of Obstetricians and Gynaecologists, the Royal College of Pathologists of Australasia, the Australian Society of Gynaecologic Oncologists and the Australian Society for Colposcopy and Cervical Pathology.
- Note 1: As separate items exist for routine screening, screening in specific population and investigation of persons with abnormal vaginal bleeding, treating practitioners are asked to clearly identify on the request form, if the sample is collected as part of routine screening or for another purpose (see paragraph PP.16.11 of Pathology Services Explanatory Notes in Category 6).
- Note 2: Where reflex cytology is performed following the detection of HPV in routine screening, the HPV test and the LBC test results must be issued as a combined report with the overall risk rating.
- Note 3: See items 2501 to 2509, and 2600 to 2616 in Group A18 and A19 of Category 1 Professional Attendances and the associated explanatory notes for these items in Category 1 Professional Attendances.

Services rendered to a doctor's dependants, practice partner, or practice partner's dependants

Medicare benefits are not paid for professional services rendered by a medical practitioner to dependants or partners or a partner's dependants.

A 'dependant' person is a spouse or a child. The following provides definitions of these dependant persons:

- (a) a spouse, in relation to a dependant person means:
- a. a person who is legally married to, and is not living, on a permanent basis, separately and apart from, that person; and
- b. a de facto spouse of that person.
- (b) a child, in relation to a dependant person means:
- a. a child under the age of 16 years who is in the custody, care and control of the person or the spouse of the person; and

b. a person who:

- (i) has attained the age of 16 years who is in the custody, care and control of the person of the spouse of the person; or
- (ii) is receiving full time education at a school, college or university; and
- (iii) is not being paid a disability support pension under the Social Security Act 1991; and
- (iv) is wholly or substantially dependent on the person or on the spouse of the person.

GN.14.34 Principles of interpretation of the MBS

Each professional service listed in the MBS is a complete medical service. Where a listed service is also a component of a more comprehensive service covered by another item, the benefit for the latter service will cover the former.

Where a service is rendered partly by one medical practitioner and partly by another, only the one amount of benefit is payable. For example, where a radiographic examination is started by one medical practitioner and finalised by another.

GN.14.35 Services attracting benefits on an attendance basis

Some services are not listed in the MBS because they are regarded as forming part of a consultation or they attract benefits on an attendance basis.

GN.14.36 Consultation and procedures rendered at the one attendance

Where, during a single attendance, a consultation (under Category 1 of the MBS) and another medical service (under any other Category of the Schedule) occur, benefits are payable subject to certain exceptions, for both the consultation and the other service. Benefits are not payable for the consultation in addition to an item rendered on the same occasion where the item is qualified by words such as "each attendance", "attendance at which", "including associated attendances/consultations", and all items in Group T6 and T9. In the case of radiotherapy treatment (Group T2 of Category 3) benefits are payable for both the radiotherapy and an initial referred consultation.

Where the level of benefit for an attendance depends upon the consultation time (for example, in psychiatry), the time spent in carrying out a procedure which is covered by another item in the MBS, may not be included in the consultation time

A consultation fee may only be charged if a consultation occurs; that is, it is not expected that consultation fee will be charged on every occasion a procedure is performed.

GN.14.37 Aggregate items

The MBS includes a number of items which apply only in conjunction with another specified service listed in the MBS. These items provide for the application of a fixed loading or factor to the fee and benefit for the service with which they are rendered.

When these particular procedures are rendered in conjunction, the legislation provides for the procedures to be regarded as one service and for a single patient gap to apply. The Schedule fee for the service will be ascertained in accordance with the particular rules shown in the relevant items.

GN.14.38 Residential aged care facility

A residential aged care facility is defined in the *Aged Care Act 1997*; the definition includes facilities formerly known as nursing homes and hostels.

GN.15.39 Practitioners should maintain adequate and contemporaneous records

All practitioners who provide, or initiate, a service for which a Medicare benefit is payable, should ensure they maintain **adequate** and **contemporaneous** records.

Note: 'Practitioner' is defined in Section 81 of the *Health Insurance Act 1973* and includes: medical practitioners, dentists, optometrists, chiropractors, physiotherapists, podiatrists and osteopaths.

Since 1 November 1999 PSR Committees determining issues of inappropriate practice have been obliged to consider if the practitioner kept adequate and contemporaneous records. It will be up to the peer judgement of the PSR Committee to decide if a practitioner's records meet the prescribed standards.

The standards which determine if a record is adequate and contemporaneous are prescribed in the *Health Insurance* (*Professional Services Review*) Regulations 1999.

To be *adequate*, the patient or clinical record needs to:

clearly identify the name of the patient; and

contain a separate entry for each attendance by the patient for a service and the date on which the service was rendered or initiated; and

each entry needs to provide clinical information adequate to explain the type of service rendered or initiated; and

each entry needs to be sufficiently comprehensible that another practitioner, relying on the record, can effectively undertake the patient's ongoing care.

To be *contemporaneous*, the patient or clinical record should be completed at the time that the service was rendered or initiated or as soon as practicable afterwards. Records for hospital patients are usually kept by the hospital and the practitioner could rely on these records to document in-patient care.

The Department of Human Services (DHS) has developed an <u>Health Practitioner Guideline to substantiate that a specific treatment was performed</u> which is located on the DHS website.

CATEGORY 1: PROFESSIONAL ATTENDANCES

SUMMARY OF CHANGES FROM 01/03/2019

The 01/03/2019 changes to the MBS are summarised below and are identified in the Schedule pages by one or more of the following words appearing above the item number:

(a) new item(b) amended description(c) fee amended(d) item number changed(e) EMSN changed			New Amend Fee Renum EMSN									
Delete 20	od Items 35	43	51	92	93	95	96	183	188	202	212	
New It 899 90051	901 90092	905 90093	906 90095	2095 90096	2144 90183	2180 90188	2193 90202	90001 90212	90002	90020	90035	90043

New Group Under Category 1

A35 – Services For Patients in Residential Aged Care Facilities

New Subgroups Under A35

- 1 Flag Fall Amount For Residential Aged Care Facilities
- 2 General Practitioner Non-Referred Attendance At A Residntial Aged Care Facility
- 3 Other Medical Practitioner Non-Referred Attendance At A Residential Aged Care Facility
- 4 Non-Specialist Practitioner Non-Referred Attence At A Residential Aged Care acility

New Notes

AN.7.28 AN.30.2 AN.35.1 AN.35.2

Amended Note

AN.0.9 AN.0.11 AN.0.15 AN.7.1

Ceased Note

AN.0.17

Services for patients in Residential Aged Care Facilities

The Government will increase the Medicare Benefits Schedule fees for general practitioners (GPs) and medical practitioners attending a residential aged care facility to help ensure that GPs and medical practitioners have appropriate incentives to provide care in aged care facilities.

Currently, the Medicare benefit is calculated from the type of service provided and the number of patients seen at a residential aged care facility. This arrangement, known as a 'ready reckoner', calculates the total benefit based on a nominal amount plus a modifier. The modifier must be divided or multiplied (6 or fewer patients is divided, 7 or more patients is multiplied) by the number of patients seen by the doctor at the residential aged care facility.

From 1 March 2019, this arrangement will be changed for the most commonly claimed GPs and medical practitioner services in residential aged care facilities. The existing ready reckoner attendance items (20, 35, 43, 51, 92, 93, 95, 96, 183, 188, 202 and 212) will be replaced with 12 new attendance items in group A35. These items have the same requirements as the deleted attendance items, but have a nominal fee amount, like attendance items in consulting rooms. The new attendance items can be claimed for each patient attended during a residential aged care facility visit.

A new single callout fee recognises the important role of GPs and medical practitioners in supporting the health and care of patients in residential aged care facilities. The call out fee is \$55 for GPs (item 90001) and \$40 (item 90002) for medical practitioners working in general practice. This amount is intended to reflect the costs doctors incur when providing professional services in residential aged care facilities. The call out fee is only payable once per visit to a residential aged care facility.

Medicare Benefits Schedule – Telehealth services for people living in flood-affected communities in Queensland

Eight new, time-limited MBS telehealth consultation items allow GPs and non-specialist medical practitioners to provide general attendance services by videoconference to patients living in flood-affected Local Government Areas in Queensland.

The new items replicate the clinical requirements and fee/rebate structures of the current Level A to D items provided in consulting rooms by both sets of practitioners.

Eligibility for the new items is based on patient location only.

The new items are time-limited and will end on 30 June 2019.

The affected Local Government Areas are:

- Burdekin
- Burke
- Charters Towers
- Cloncurry
- Cook
- Doomadgee
- Douglas
- Flinders
- McKinlay
- Palm Island
- Richmond
- Townsville
- Winton
- Wujal Wujal.

PROFESSIONAL ATTENDANCES NOTES

AN.0.1 Personal Attendance by Practitioner

The personal attendance of the medical practitioner upon the patient is necessary, before a "consultation" may be regarded as a professional attendance. In itemising a consultation covered by an item which refers to a period of time, only that time during which a patient is receiving active attention should be counted. Periods such as when a patient is resting between blood pressure readings, waiting for pupils to dilate after the instillation of a mydriatic, or receiving short wave therapy etc., should not be included in the time of the consultation. Similarly, the time taken by a doctor to travel to a patient's home should not be taken into consideration in the determination of the length of the consultation. While the doctor is free to charge a fee for "travel time" when patients are seen away from the surgery, benefits are payable only in respect of the time a patient is receiving active attention.

AN.0.2 Benefits For Services

All Australian residents and certain categories of visitors to Australia can claim Medicare benefits for services by optometrists. The *Health Insurance Act 1973* contains legislation covering the major elements of the Medicare program.

Responsibility for regulating the Medicare program lies with the Australian Government through the Department of Health. The Department of Human Services is responsible for consideration of applications and for the day to day operation of Medicare and the payment of benefits. Contact details of the Department of Health and the Department of Human Services are located at the end of these Notes.

AN.0.3 Professional Attendances

Professional attendances by medical practitioners cover consultations during which the practitioner: evaluates the patient's health-related issue or issues, using certain health screening services if applicable; formulates a management plan in relation to one or more health-related issues for the patient; provides advice to the patient and/or relatives (if authorised by the patient); provides appropriate preventive health care; and records the clinical detail of the service(s) provided to the patient. (See the General Explanatory Notes for more information on health screening services.)

AN.0.4 Provider Numbers

To ensure that benefits are paid only for services provided by optometrists registered with the Optometry Board of Australia, each optometrist providing services for which a Medicare benefit is payable requires an individual provider number.

Provider numbers will be issued only to registered optometrists. Corporations, other business entities and individuals who are not registered optometrists will not be issued with provider numbers.

Provider numbers are allocated to enable claims for Medicare benefits to be processed. The number may be up to eight characters. The second last character identifies the practice location, the last being a check character.

Optometrists can obtain a provider number from the Department of Human Services. A separate provider number is issued for each location at which an optometrist practises and has current registration. Provider numbers for additional practice locations may also be obtained from the Department of Human Services following confirmation of registration. Optometrists cannot use another optometrist's provider number.

Locum Tenens

An optometrist who has signed an Undertaking and is to provide services at a practice location as a locum for more than two weeks or will return to the practice on a regular basis for short periods should apply for a provider number for that location.

If the locum is to provide services at a practice for less than two weeks, the locum can use their own provider number or can obtain an additional provider number for that location.

Normally, Medicare benefits are payable for services rendered by an optometrist only when the optometrist has completed an Undertaking. However, benefits may be claimed for services provided by an optometrist who has not signed the Undertaking if the optometrist has provided them on behalf of an optometrist who has signed the Undertaking.

To ensure benefits are payable when a locum practises in these circumstances, the locum optometrist should:

- · Check that they will be providing optometry services on behalf of a participating optometrist i.e. their employer has a current Undertaking.
- · Complete the Schedule which is available on the Department of Human Services' website http://www.humanservices.gov.au/, before commencing the locum arrangement of the name and address of the participating optometrist on whose behalf they will be providing services.

Locums can direct Medicare payments to a third party, for example the principal of the practice, by either arranging a pay group link and/or by nominating the principal as the payee provider on bulk-bill stationery.

AN.0.5 Services not Attracting Medicare Benefits

Telephone consultations, letters of advice by medical practitioners, the issue of repeat prescriptions when the patient is not in attendance, post mortem examinations, the issue of death certificates, cremation certificates, counselling of relatives (Note - items 348, 350 and 352 are not counselling services), group attendances (other than group attendances covered by items 170, 171, 172, 342, 344 and 346) such as group counselling, health education, weight reduction or fitness classes do not qualify for benefit.

Although Medicare benefits are not payable for the issue of a death certificate, an attendance on a patient at which it is determined that life is extinct can be claimed under the appropriate attendance item. The outcome of the attendance may be that a death certificate is issued, however, Medicare benefits are only payable for the attendance component of the service.

AN.0.6 Patient Eligibility

An "eligible person" is a person who resides permanently in Australia. This includes New Zealand citizens and holders of permanent residence visas. Applicants for permanent residence may also be eligible persons, depending on circumstances. Eligible persons must enrol with Medicare before they can receive Medicare benefits.

Medicare covers services provided only in Australia. It does not refund treatment or evacuation expenses overseas.

Medicare Cards

The green Medicare card is for people permanently in Australia. Cards may be issued for individuals or families.

The *blue* Medicare card bearing the words "INTERIM CARD" is for people who have applied for permanent residence.

Visitors from countries with which Australia has a Reciprocal Health Care Agreement (RHCA) receive a card bearing the words "RECIPROCAL HEALTH CARE".

Visitors to Australia and temporary residents

Visitors and temporary residents in Australia are generally not eligible for Medicare and should therefore have adequate private health insurance.

Reciprocal Health Care Agreements

Australia has RHCA with New Zealand, Ireland, the United Kingdom, the Netherlands, Sweden, Finland, Norway, Italy, Belgium Slovenia and Malta.

Visitors from these countries are entitled to medical treatment while they are in Australia, comprising public hospital care (as public patients), Medicare benefits for out of hospital services and drugs under the Pharmaceutical Benefits Scheme (PBS). Visitors must enrol with the Department of Human Services to receive benefits. A passport is sufficient for public hospital care and PBS drugs.

Exceptions:

- · Visitors from Ireland and New Zealand are entitled to public hospital care and PBS drugs only, and should present their passports before treatment as they are not issued with Medicare cards.
- · Visitors from Italy and Malta are covered for a period of six months only.

The RHCAs do not cover treatment as a private patient in a public or private hospital. People visiting Australia for the purpose of receiving treatment are not covered. Visitors from New Zealand and the Republic of Ireland are NOT entitled to optometric treatment under a RHCA.

AN.0.7 Multiple Attendances on the Same Day

Payment of benefit may be made for each of several attendances on a patient on the same day by the same medical practitioner provided the subsequent attendances are not a continuation of the initial or earlier attendances.

However, there should be a reasonable lapse of time between such attendances before they can be regarded as separate attendances.

Where two or more attendances are made on the one day by the same medical practitioner the time of each attendance should be stated on the account (eg 10.30 am and 3.15 pm) in order to assist in the assessment of benefits.

In some circumstances a subsequent attendance on the same day does in fact constitute a continuation of an earlier attendance. For example, a preliminary eye examination may be concluded with the instillation of a mydriatic and then an hour or so later eye refraction is undertaken. These sessions are regarded as being one attendance for benefit purposes. Further examples are the case of skin sensitivity testing, and the situation where a patient is issued a prescription for a vaccine and subsequently returns to the surgery for the injection.

AN.0.8 Benefits For Optometrists

What services are covered?

The *Health Insurance Act 1973* stipulates that Medicare benefits are payable for professional services. The professional services coming within the scope of the optometric benefit arrangements are those clinically relevant services ordinarily rendered by the optometrist in relation to a consultation on ocular or vision problems or related procedures. *The Health Insurance Act 1973* defines a 'clinically relevant service' as a service rendered by an optometrist that is generally accepted in the optometrical profession as being necessary for the appropriate treatment of the patient to whom it is rendered.

From 1 January 2015, optometrists will be free to set their own fees for their professional service. However, the amount specified in the patient's account must be the amount charged for the service specified. The fee may not include a cost of goods or services which are not part of the MBS service specified on the account. A non-clinically relevant service must not be included in the charge for a Medicare item. The non-clinically relevant service must be separately listed on the account and not billed to Medicare. Where it is necessary for the optometrist to seek patient information from the Department of Human Services in order to determine appropriate itemisation of accounts, receipts or bulk-billed claims, the optometrist must ensure that:

- (a) the patient is advised of the need to seek the information and the reason the information is required;
- (b) the patient's informed consent to the release of information has been obtained; and
- (c) the patient's records verify the patient's consent to the release of information.

Benefits may only be claimed when:

- (a) a service has been performed and a clinical record of the service has been made;
- (b) a significant consultation or examination procedure has been carried out;
- (c) the service has been performed at premises to which the Undertaking relates;
- (d) the service has involved the personal attendance of both the patient and the optometrist; and
- (e) the service is "clinically relevant" (as defined in the *Health Insurance Act 1973*).

Where Medicare benefits are not payable

Medicare benefits may <u>not</u> be claimed for attendances for:

- (a) delivery, dispensing, adjustment or repairs of visual aids;
- (b) filling of prescriptions written by other practitioners.

Benefits are <u>not</u> payable for optometric services associated with:

- (a) cosmetic surgery;
- (b) refractive surgery;
- (c) tests for fitness to undertake sporting, leisure or vocational activities;
- (d) compulsory examinations or tests to obtain any commercial licence (e.g. flying or driving);
- (e) entrance to schools or other educational facilities;
- (f) compulsory examinations for admissions to aged care facilities;
- (g) vision screening.

Medicare benefits are <u>not</u> payable for services in the following circumstances:

- (a) where the expenses for the service are paid or payable to a recognised (public) hospital;
- (b) an attendance on behalf of teaching institutions on patients of supervised students of optometry;
- (c) where the service is not "clinically relevant" (as defined in the *Health Insurance Act 1973*).

Unless the Minister otherwise directs, a benefit is not payable in respect of an optometric service where:

- (a) the service has been rendered by or on behalf of, or under an arrangement with, the Commonwealth, a State or a local governing body or an authority established by a law of the Commonwealth, a law of a State or a law of an internal Territory; or
- (b) the service was rendered in one or more of the following circumstances -
- (i) the employer arranges or requests the consultation
- (ii) the results are provided to the employer by the optometrist
- (iii) the employer requires that the employee have their eyes examined
- (iv) the account for the consultation is sent to the employer

(v) the consultation takes place at the patient's workplace or in a mobile consulting room at the patient's workplace.

Services rendered to an optometrist's dependants, employer or practice partner or dependants

A condition of the participating arrangement is that the optometrist agrees not to submit an account or a claim for services rendered to any dependants of the optometrist, to his or her employer or practice partner or any dependants of that employer or partner.

A 'dependant' person is a spouse or a child. The following provides definitions of these dependant persons:

a *spouse*, in relation to a dependant person means:

- (a) a person who is legally married to, and is not living, on a permanent basis, separately and apart from, that person; and
- (b) a de facto spouse of that person.

a *child*, in relation to a dependant person means:

- (a) a child under the age of 16 years who is in the custody, care and control of the person or the spouse of the person; and
- (b) a person who:
- (i) has attained the age of 16 years who is in the custody, care and control of the person of the spouse of the person; or
- (ii) is receiving full time education at a school, college or university; and
- (iii) is not being paid a disability support pension under the Social Security Act 1991; and
- (iv) is wholly or substantially dependent on the person or on the spouse of the person.

AN.0.9 Attendances by General Practitioners (Items 3-4, 23-24, 36-37, 44, 47, 193, 195, 197, 199, 585, 594, 599, 2095, 2144, 2180, 2193, 2497-2559, 5000-5067 and 90020-90051)
Attendances by General Practitioners (Items 3-4, 23-24, 36-37, 44, 47, 193, 195, 197, 199, 585, 594, 599, 2497-2559, 5000-5067 and 90020-90051)

Items 3-4, 23-24, 36-37, 44, 47, 193, 195, 197, 199, 585, 594, 599, 2095, 2144, 2180, 2193, 2497-2559, 5000-5067 and 90020-90051 relate to attendances rendered by medical practitioners who are:

- listed on the Vocational Register of General Practitioners maintained by the Department of Human Services; or
- holders of the Fellowship of the Royal Australian College of General Practitioners (FRACGP) who participate in, and meet the requirements of the RACGP for continuing medical education and quality assurance as defined in the RACGP Quality Assurance and Continuing Medical Education program; or
- holders of the Fellowship of the Australian College of Rural and Remote Medicine (FACRRM) who participate in, and meet the requirements of the Australian College of Rural and Remote Medicine (ACRRM) for continuing medical education and quality assurance as defined in ACRRM's Professional Development Program; or
- undertaking an approved placement in general practice as part of a training program for general practice leading to the award of the FRACGP or training recognised by the RACGP as being of an equivalent standard; or

- undertaking an approved placement in general practice as part of a training program for general practice leading to the award of the FACRRM or training recognised by ACRRM as being of an equivalent standard.

To assist general practitioners in selecting the appropriate item number for Medicare benefit purposes the following notes in respect of the various levels are given.

LEVEL A

A Level A item will be used for obvious and straightforward cases and this should be reflected in the practitioner's records. In this context, the practitioner should undertake the necessary examination of the affected part if required, and note the action taken.

LEVEL B

A Level B item will be used for a consultation lasting less than 20 minutes for cases that are not obvious or straightforward in relation to one or more health related issues. The medical practitioner may undertake all or some of the tasks set out in the item descriptor as clinically relevant, and this should be reflected in the practitioner's record. In the item descriptor singular also means plural and vice versa.

LEVEL C

A Level C item will be used for a consultation lasting at least 20 minutes for cases in relation to one or more health related issues. The medical practitioner may undertake all or some of the tasks set out in the item descriptor as clinically relevant, and this should be reflected in the practitioner's record. In the item descriptor singular also means plural and vice versa.

LEVEL D

A Level D item will be used for a consultation lasting at least 40 minutes for cases in relation to one or more health related issues. The medical practitioner may undertake all or some of the tasks set out in the item descriptor as clinically relevant, and this should be reflected in the practitioner's record. In the item descriptor singular also means plural and vice versa.

Creating and Updating a Personally Controlled Electronic Health Record (PCEHR)

The time spent by a medical practitioner on the following activities may be counted towards the total consultation time:

- · Reviewing a patient's clinical history, in the patient's file and/or the PCEHR, and preparing or updating a Shared Health Summary where it involves the exercise of clinical judgement about what aspects of the clinical history are relevant to inform ongoing management of the patient's care by other providers; or
- · Preparing an Event Summary for the episode of care.

Preparing or updating a Shared Health Summary and preparing an Event Summary are clinically relevant activities. When either of these activities are undertaken with any form of patient history taking and/or the other clinically relevant activities that can form part of a consultation, the item that can be billed is the one with the time period that matches the total consultation time

MBS rebates are not available for creating or updating a Shared Health Summary as a stand alone service.

Counselling or Advice to Patients or Relatives

For items 23-24, 36-37, 44, 47 and 5020 to 5067 'implementation of a management plan' includes counselling services.

Items 3-4, 23-24, 36-37, 44, 47, 193, 195, 197, 199, 585, 594, 599, 2497-2559, 5000-5067 and 90020-90051 include advice to patients and/or relatives during the course of an attendance. The advising of relatives at a later time does not extend the time of attendance.

Recording Clinical Notes

In relation to the time taken in recording appropriate details of the service, only clinical details recorded at the time of the attendance count towards the time of consultation. It does not include information added at a later time, such as reports of investigations.

Other Services at the Time of Attendance

Where, during the course of a single attendance by a general practitioner, both a consultation and another medical service are rendered, Medicare benefits are generally payable for both the consultation and the other service. Exceptions are in respect of medical services which form part of the normal consultative process, or services which include a component for the associated consultation (see the General Explanatory Notes for further information on the interpretation of the Schedule).

The Department of Human Services (DHS) has developed an <u>Health Practitioner Guideline for responding to a request to substantiate that a patient attended a service</u> which is located on the DHS website.

AN.0.10 Schedule Fees and Medicare Benefits

Medicare benefits are based on fees determined for each optometrical service. The services provided by participating optometrists which attract benefits are set out in the *Health Insurance (General Medical Services Table) Regulations* (as amended).

If the fee is greater than the Medicare benefit, optometrists participating in the scheme are to inform the patient of the Medicare benefit payable for the item, at the time of the consultation and that the additional fee will not attract benefits.

Medicare benefits are payable at 85% of the Schedule fee for services rendered.

Medicare Safety Nets

The Medicare safety net provides families and singles with an additional rebate for out-of-hospital Medicare services, once annual thresholds are reached. There are two safety nets: the original Medicare safety net and the extended Medicare safety net (EMSN).

Under the original Medicare safety net, the Medicare benefit for out-of-hospital services is increased to 100% of the Schedule Fee (up from 85%) once an annual threshold in gap costs is reached. Gap costs refer to the difference between the Medicare benefit (85%) and the Schedule Fee.

Under the EMSN, once an annual threshold in out-of-pocket costs for out-of-hospital Medicare services is reached, Medicare will pay for 80% of any future out-of-pocket costs for out-of-hospital Medicare services for the remainder of the calendar year. However, where the item has an EMSN benefit cap, there is a maximum limit on the EMSN benefit that will be paid for that item. Further explanation about EMSN benefit caps is provided at www.mbsonline.gov.au.

The thresholds for the Medicare safety nets are indexed on 1 January each year.

Individuals are automatically registered with the Department of Human Services for the safety nets, however couples and families are required to register in order to be recognised as a family for the purposes of the safety nets. In most cases, registered families have their expenses combined to reach the safety net thresholds. This may help to qualify for safety net benefits more quickly. Registration forms can be obtained from the Department of Human Services offices, or completed at www.humanservices.gov.au. If you have already registered it is important to ensure your details are up to date.

Further information on the Medicare safety nets is available at http://www.humanservices.gov.au/customer/services/medicare/medicare-safety-net.

Limiting rule for patient claims

Where a fee charged for a service is less than the Medicare benefit, the benefit will be reduced to the amount of the fee actually charged. In no case will the benefit payable exceed the fee charged.

Multiple attendances

Payment of benefit may be made for several attendances on a patient on the same day by the same optometrist provided that the subsequent attendances are not a continuation of the initial or earlier attendances. However, there should be a reasonable lapse of time between the services before they can be regarded as separate attendances.

Where two or more attendances are made on the one day by the same optometrist the time of each attendance should be stated on the account (e.g. 10.30 am and 3.15 pm) in order to assist in the payment of benefits. Times do not need to be specified where a perimetry item is performed in association with a consultation item.

In some circumstances a subsequent consultation on the same day may be judged to be a continuation of an earlier attendance and a second benefit is not payable. For example, a preliminary eye examination may be concluded with the instillation of mydriatic or cycloplegic drops and some time later additional examination procedures are undertaken. These sessions are regarded as being one attendance for benefit purposes.

Release of prescription

Where a spectacle prescription is prepared for the patient, it becomes the property of the patient, who is free to have the spectacles dispensed by any person of the patient's choice. The optometrist will ensure that the patient is made aware that he or she is entitled to a copy of the spectacle prescription.

Contact lens prescriptions are excluded from the above provision, although the prescription remains the property of the patient and should be available to the patient at the completion of the prescription and fitting process.

Reminder notices

The optometrist will ensure that any notice sent to a patient suggesting re-examination is sent solely on the basis of the clinical needs of the patient.

Aftercare period following surgery

Medicare schedule items that apply to surgery include all professional attendances necessary for the post-operative treatment of the patient, other than attendances provided by vocationally or non-vocationally trained general practitioners. The aftercare period includes all post-operative treatment, when provided by a medical specialist, consultant physician or optometrist. The amount and duration of the aftercare may vary but includes all attendances until recovery from the operation. Attendances unrelated to the operation provided by a vocationally or non-vocationally registered general practitioner in the aftercare period can also attract Medicare benefits. Attendances provided by an optometrist in the aftercare period do not attract a Medicare benefit.

The rebate for cataract surgery includes payment for aftercare attendances so payment for aftercare services provided by an optometrist on behalf of a surgeon should be arranged with the surgeon. The optometrist should not charge the patient. In the case of cataract surgery, the first visit following surgery for which the optometrist can charge a rebatable fee is generally the attendance at which a prescription for spectacles or contact lenses is written.

Medicare benefits are not available for refractive surgery, consultations in preparation for the surgery or consultations in the aftercare period. Charges for attendances by optometrists may be made directly to the patient or to the surgeon depending on the arrangements made prior to surgery. Accounts and the receipt issued to the patient should clearly indicate the fee is non-rebatable.

Single Course of Attention

A reference to a single course of attention means:

- (a) In the case of items 10905 to 10918, and old item 10900 a course of attention by one or more optometrists in relation to a specific episode of optometric care.
- (b) In relation to items 10921 to 10930 a course of attention, including all associated attendances, by one or more optometrists for the purpose of prescribing and fitting of contact lenses. This includes those after-care visits necessary to ensure the satisfactory performance of the lenses.

Referred comprehensive initial consultations (item 10905) - Read in conjunction with 08 Referrals

For the purposes of item 10905, the referring optometrist, having considered the patient's need for the referred consultation, is required to provide a written referral, dated and signed, and setting out the patient's condition and the reason for the referral.

Benefits will be paid at the level of item 10905 providing the referral is received before the provision of the service, and providing the account, receipt or bulk-billing form contains the name and provider number of the referring optometrist. Referrals from medical practitioners do not attract benefits under item 10905.

The optometrist claiming the item 10905 service is obliged to retain the written referral for a period of twenty-four months.

Referrals must be at "arms length". That is to say, no commercial arrangements or connections should exist between the optometrists.

Second comprehensive initial consultation, within 36 months for a patient who is less than 65 years of age and once every 12 months for a patient who is at least 65 years of age, of a previous comprehensive consultation (item 10907)

A patient can receive a comprehensive initial consultation by another optometrist within 36 months if the patient is less than 65 years of age, and once every 12 months if the patient is at least 65 years of age, if the patient has attended another optometrist for an attendance to which item 10905, 10907, 10910, 10911, 10912, 10913, 10914 or 10915 applies, or old item 10900 applied.

Comprehensive initial consultations (items 10910 and 10911)

There are two new MBS items for comprehensive initial consultation that have been introduced. Item 10910 has been introduced for a professional attendance of more than 15 minutes for a patient who is less than 65 years of age. This item is payable once only within a 36 month period, and if the patient has not received a service in this timeframe to which item 10905, 10907, 10910, 10912, 10913, 10914 or 10915 applies, or old item 10900 applied.

Item 10911 has been introduced for a professional attendance of more than 15 minutes for a patient who is at least 65 years of age. This item is payable once only within a 12 month period, and if the patient has not received a service in this timeframe to which item 10905, 10907, 10910, 10911, 10912, 10913, 10914 or 10915 applies, or old item 10900 applied.

However, a benefit is payable under item 10912, 10913, 10914 or 10915 where the patient has an ocular condition which necessitates a further course of attention being started within 36 months for a patient who is less than 65 years of age (item 10910) and within 12 months for a patient who is at least 65 years of age (item 10911) of the previous initial consultation. The conditions which qualify for a further course of attention are contained in the descriptions of these items.

Where an attendance would have been covered by item 10905, 10907, 10910, 10911, 10912, 10913, 10914, or 10915 but is of 15 minutes duration or less, item 10916 (Short consultation) applies.

Significant change in visual function requiring comprehensive re-evaluation (item 10912)

Significant changes in visual function which justify the charging of item 10912 could include documented changes of:

- · vision or visual acuity of 2 lines (0.2 logMAR) or more (corrected or uncorrected)
- · visual fields or previously undetected field loss
- · binocular vision
- · contrast sensitivity or previously undetected contrast sensitivity loss.

New signs or symptoms requiring comprehensive re-evaluation (item 10913)

When charging item 10913 the optometrist should document the new signs or symptoms suffered by the patient on the patient's record card.

Progressive disorder requiring comprehensive re-evaluation (item 10914)

When charging item 10914, the optometrist should document the nature of the progressive disorder suffered by the patient on the patient's record card. Progressive disorders may include conditions such as maculopathy (including age related maculopathy) cataract, corneal dystrophies, glaucoma etc.

Examination of the eyes of a patient with diabetes mellitus (item 10915)

Where an examination of the eyes, with the instillation of a mydriatic, of a patient with diabetes mellitus is being conducted, where possible this item should be billed rather than item 10914 to assist in identifying whether such patients are receiving appropriate eye care.

Second or subsequent consultations (item 10918)

Each consultation, apart from the initial consultation, in a single course of attention, other than a course of attention involving the fitting and prescription of contact lenses, is covered by item 10918.

Contact lens consultations (items 10921 to 10930)

In the case of contact lens consultations, benefit is payable only where the patient is one of the prescribed classes of patient entitled to benefit for contact lens consultations as described in items 10921 to 10929.

For claims under items 10921,10922,10923,10925 and 10930, eligibility is based on the patient's distance spectacle prescription, determining the spherical equivalent by adding to the spherical prescription, half the cylindrical correction.

Medicare benefits are not payable for item 10929 in circumstances where a patient wants contact lenses for:

- (a) reasons of appearance (because they do not want to wear spectacles);
- (b) sporting purposes;
- (c) work purposes; or
- (d) psychological reasons (because they cannot cope with spectacles).

All attendances subsequent to the initial consultation in a course of attention involving the prescription and fitting of contact lenses are collectively regarded as a single service under items 10921 to 10930, as appropriate. The date of service is deemed to be the date on which the contact lenses are delivered to the patient. In some cases, where the patient decides not to proceed with contact lenses, no Medicare fee is payable because the patient has not taken delivery of the lenses. In such instances, the patient may be charged a non-rebatable (private) fee for a 'part' service.

Any visits related to the prescribing and fitting of lenses are regarded to be covered by the relevant item in the range 10921 to 10930. The bulk item includes those aftercare visits necessary to ensure the satisfactory performance of the lenses. This interpretation is unaltered by the frequency of aftercare visits associated with various lens types including extended wear lenses.

Consultations during the aftercare period that are unrelated to the prescription and fitting of contact lenses or that are not part of normal aftercare may be billed under other appropriate items (not items 10921 to 10930).

For patients not eligible for Medicare rebates for contact lens care, fees charged for contact lens consultations are a matter between the practitioner and the patient. Any account for consultations involving the fitting and prescription of contact lenses issued to a patient who does not fall into the specified categories should be prepared in such a way that it cannot be used to obtain benefits. No Medicare item should be attached to any service that does not attract benefits and the optometrist should annotate the account with wording such as "Medicare benefits not payable".

Where an optometrist wishes to apportion the total fee to show the appropriate optometric consultation benefit and the balance of the fee, he or she should ensure that the balance is described in such a way (e.g. balance of account) that it cannot be mistaken as being a separate consultation. In particular no Medicare item number should be shown against the balance.

When a patient receives a course of attention involving the prescription and fitting of contact lenses an account should not be issued (or an assignment form completed) until the date on which the patient takes delivery of the lenses.

Benefit under items 10921 to 10929 is payable once only in any period of 36 consecutive months except where circumstances are met under item 10930 within a 36 month period.

Domiciliary visits (items 10931 - 10933)

Where patients are unable to travel to an optometrist's practice for treatment, and where the request for treatment is initiated by the patient, a domiciliary visit may be conducted, which involves the optometrist travelling to the patient's place of residence, and transporting the necessary equipment. Where possible, it is preferable that the patient travel to the practice so that the full range of equipment is available for the examination of the patient.

Benefits are payable under items 10931 - 10933 to provide some financial assistance in the form of a loading to the optometrist, in recompense for travel costs and packing and unpacking of equipment. The loading is in addition to the consultation item. For the purposes of the loading, acceptable places of residence for domiciliary visits are:

- the patient's home;
- a residential aged care facility as defined by the *Aged Care Act 1997*; or
- an institution which means a place (other than a residential aged care facility or hospital) at which residential accommodation and/or day care is made available to any of the following categories: disadvantaged children, juvenile offenders, aged persons, chronically ill psychiatric patients, homeless persons, unemployed persons, persons suffering from alcoholism, persons addicted to drugs, or physically or intellectually disabled persons.

Visits to a hospital at the patient's request are not covered by the loading and instead, an extra fee in addition to the Schedule fee can be charged, providing the service is not bulk-billed. Medicare benefits are not payable in respect of the private charge.

Items 10931 - 10933 may be used whether or not the optometrist chooses to bulk-bill but it is important that if the consultation is bulk-billed the loading is also, and no private charge can then be levied. If the consultation is not bulk-billed, the loading should also not be bulk-billed and a private charge may be levied. The usual requirement that the patient must have requested the domiciliary visit applies.

The choice of appropriate item in the range 10931 - 10933 depends on how many patients are seen at the one location. Benefits are payable under item 10931 where the optometrist travels to see one patient at a single location.

Item 10931 can be billed in addition to the consultation item. If the optometrist goes on to see another single patient **at a different location**, that patient can also be billed an item 10931 plus the consultation. However, if two patients are visited at a single location on the same occasion, each of the two patients should be billed item 10932 as well as the consultation item applying to each patient. Similarly, if three patients are visited at a single location on the same occasion, each of the three patients should be billed item 10933 as well as the consultation item applying to each patient.

Where more than three patients are seen at the same location, additional benefits for domiciliary visits are not payable for the fourth, fifth etc patients. On such occasions, the first three patients should be billed item 10933 as well as the appropriate consultation item, and all subsequent patients may only be billed the appropriate consultation item. Where multiple patients are seen at one location on one occasion, there is no provision for patients to be 'grouped' into twos and threes for billing purposes.

Where a private charge is levied for a domiciliary visit, bulk-billing is precluded. Medicare benefits are not payable in respect of the private charge and the patient should be informed of this. Private charges should be shown separately on accounts issued by optometrists and must not be included in the fees for the service. Domiciliary visit loading items cannot be claimed in conjunction with brief initial consultation item 10916, or with computerised perimetry items 10940 or 10941.

Computerised Perimetry Services (items 10940 and 10941)

Benefit under items 10940 and 10941 is payable where full quantitative computerised perimetry (automated absolute static threshold but not including multifocal multichannel objective perimetry) has been performed by an optometrist on both eyes (item 10940) or one eye (item 10941) where indicated by the presence of relevant ocular disease or suspected pathology of the visual pathways or brain. Item 10940 for bilateral procedures cannot be claimed for patients who are totally blind in one eye. In this instance, item 10941 for unilateral procedures should be claimed, where appropriate.

These items can be billed either in association with comprehensive consultation items 10905, 10907, 10910, 10911, 10912, 10913, 10914, or 10915, or independently, but they cannot be billed with items 10916, 10918, 10931, 10932 or 10933. An assessment and report is required and, where referral to an ophthalmologist for further treatment is required, the printed results of the perimetry should be provided to the ophthalmologist to discourage repetition of perimetry unless clinically necessary. If Medicare benefits are to be claimed, a maximum of two perimetry services in any twelve month period may be provided.

Low Vision Assessment (item 10942)

A benefit is payable under item 10942 where one or more of the tests outlined in the item description are carried out on a patient who has already been established during a comprehensive consultation as having low vision, as specifically defined in the item. This item is not intended for patients expected to undergo cataract surgery in the near future who may temporarily meet the criteria for having low vision.

Item 10942 may be claimed on the same day as either a comprehensive initial consultation (items 10905 - 10915) or a subsequent consultation (item 10918), but only where the additional low vision testing has been carried out on an eligible patient. Item 10942 is not intended to be claimed with a brief initial consultation (item 10916), or with any of the contact lens items (items 10921-10930).

Children's vision assessment (item 10943)

Children aged 0 to 2 years, and 15 years and over, are not eligible for item 10943 and may be treated under appropriate attendance items.

A benefit is payable under item 10943 where one or more of the assessment and testing procedures outlined in the item description are carried out on a patient aged 3 - 14 years inclusive, and where a finding of significant binocular or accommodative dysfunction is the outcome of the consultation and assessment/testing. The conditions to be assessed under this item are primarily amblyopia and strabismus, but dysfunctions relating to vergences are also covered, providing well established and evidence based optometry practice is observed.

A benefit is not payable under item 10943 for the assessment of learning difficulties or learning disabilities.

Item 10943 may be claimed on the same day as either a comprehensive consultation (items 10905 - 10915) or a subsequent consultation (item 10918), but only where the additional assessment/testing has been carried out on an eligible child. Item 10943 is not intended to be claimed with a brief initial consultation (item 10916), or with any of the contact lens items (items 10921-10930).

Removal of an embedded corneal foreign body (item 10944)

Item 10944 has been introduced for the complete removal of an embedded corneal foreign body that is sub-epithelial or intra-epithelial and the removal of rust rings from the cornea.

The removal of an embedded foreign body should be performed using a hypodermic needle, foreign body gouge or similar surgical instrument, with magnification provided by a slit lamp biomicroscope, loupe or similar device.

The optometrist should document the nature of the embedded foreign body (sub-epithelial or intra-epithelial), method of removal and the magnification. Similarly, with rust ring removal, the optometrist should document the method of removal and the magnification.

Where complexity of the procedure is beyond the skill of the optometrist, or if other complications are present (e.g. globe perforation, penetration >25%, or patient unable to hold still due to pathological anxiety, nystagmus, or tremor etc, without some form of systemic medication), the patient should be referred to an ophthalmologist.

This item cannot be billed on the same occasion as items 10905, 10907, 10910, 10911, 10912, 10913, 10914, 10915, 10916 or 10918. If the embedded foreign body or rust ring has not been completely removed, benefits are only payable under item 10916.

AN.0.11 Professional Attendances at an Institution (Items 4, 24, 37, 47, 58, 59, 60, 65, 5003, 5023, 5043, 5063, 5220, 5223, 5227 and 5228)

For the purposes of these items an "institution" means a place (not being a hospital or residential aged care facility) at which residential accommodation or day care or both such accommodation and such care is made available to:-

- (a) disadvantaged children;
- (b) juvenile offenders:
- (c) aged persons;
- (d) chronically ill psychiatric patients;
- (e) homeless persons;
- (f) unemployed persons;
- (g) persons suffering from alcoholism;
- (h) persons addicted to drugs; or
- (i) physically or intellectually disabled persons.

To facilitate assessment of the correct Medicare rebate in respect of a number of patients attended on the one occasion at one of the above locations, it is important that the total number of patients seen be recorded on each individual account, receipt or assignment form. For example, where ten patients were visited (for a brief consultation) in the one facility on the one occasion, each account, receipt or assignment form would show "Item 4 - 1 of 10 patients" for a general practitioner.

The number of patients seen should not include attendances which do not attract a Medicare rebate (e.g. public inpatients, attendances for normal after-care), or where a Medicare rebate is payable under an item other than these derived fee items (e.g. health assessments, care planning, emergency after-hours attendance - first patient).

AN.0.12 Billing Procedures

There are three ways benefits may be paid for optometric services:

- (a) the claimant may pay the optometrist's account in full and then claim benefits from the Department of Human Services office by submitting the account and the receipt;
- (b) the claimant may submit the unpaid account to the Department of Human Services who will then send a cheque in favour of the optometrist, to the claimant; or
- (c) the optometrist may bill Medicare instead of the patient for the consultation. This is known as bulk billing. If an optometrist direct-bills, they undertake to accept the relevant Medicare benefit as full payment for the consultation. Additional charges for that service (irrespective of the purpose or title of the charge) cannot be raised against the patient.

Claiming of benefits

The patient, upon receipt of an optometrist's account, has two options open for paying the account and receiving benefits.

Paid accounts

If the account has been paid in full a claimant can claim Medicare benefits in a number of ways:

- Electronically if the claimant's doctor offers this service and the claimant has completed and lodged a Bank account details collection form with Medicare.
- Online through Medicare Online Services.
- At the claimant's local Department of Human Services Service Centre.
- By mail by sending a completed Medicare claim form with the original accounts and/or receipts to:

Department of Human Services

GPO Box 9822

In the claimant's capital city

• Over the phone by calling 132 011 and giving the claim details and then sending the accounts and/or receipts to:

Telephone Claiming

Department of Human Services

GPO Box 9847

In the claimant's capital city

Practitioners seeking information regarding registration to allow EFT payments and other E-Business transactions, can do so by viewing the Health Professionals section at the Department of Human Services at www.humanservices.gov.au.

Unpaid accounts

Where the patient has not paid the account in full, the unpaid account may be presented to the Department of Human Services with a completed Medicare claim form. In this case the Department of Human Services will forward to the claimant a benefit cheque made payable to the optometrist.

It is the patient's responsibility to forward the cheque to the optometrist and make arrangements for payment of the balance of the account, if any. "Pay optometrist" cheques involving Medicare benefits must (by law), not be sent direct to optometrists, or to the claimant at an optometrist's address (even if requested by the claimant to do so). "Pay optometrist" cheques are required to be forwarded to the claimant's last known address as recorded with the Department of Human Services.

When issuing a receipt to a patient for an account that is being paid wholly or in part by a Medicare "pay optometrist" cheque the optometrist should indicate on the receipt that a "Medicare cheque for \$..... was involved in the payment of the account". The receipt should also include any money paid by the claimant or patient.

Itemised accounts

When an optometrist bills a patient for a service, the patient should be issued with a correctly itemised account and receipt to enable the patient to claim Medicare benefits. Where both a consultation and another service, for example computerised perimetry occur, these may be itemised on the same account.

Medicare benefits are only payable in respect of optometric services where it is recorded on the account setting out the fee for the service or on the receipt for the fee in respect of each service to each patient, the following information:

- (a) patient's name;
- (b) date on which the service(s) was rendered;
- (c) a description of the service(s) (e.g. "initial consultation," "subsequent consultation" or "contact lens consultation" and/or "computerised perimetry" in those cases where it is performed);
- (d) Medicare Benefits Schedule item number(s);
- (e) the name and practice address or name and provider number of the optometrist who actually rendered the service(s). Where the optometrist has more than one practice location, the provider number used should be that which is applicable to the practice location where the service(s) was given;
- (f) the fee charged for the service(s); and
- (g) the time each service began if the optometrist attended the patient on more than one occasion on the same day and on each occasion rendered a professional service relating to an optometric item, except where a perimetry item is performed in association with a consultation item, where times do not need to be specified.

The optometrist billing for the service bears responsibility for the accuracy and completeness of the information included on accounts, receipts and assignment of benefits forms even where such information has been recorded by an employee of the optometrist.

Payment of benefits could be delayed or disallowed if the account does not clearly identify the service as one which qualifies for Medicare benefits or that the practitioner is a registered optometrist practising at the address where the service was rendered. It is important to ensure that an appropriate description of the service, the item number and the optometrist's provider number are included on accounts, receipts and assignment of benefit forms.

Details of any charges made other than for services, e.g. a dispensing charge, a charge for a domiciliary visit, should be shown separately either on the same account or on a separate account.

Patients must be eligible to receive Medicare benefits and must also meet the clinical requirements outlined in the relevant item descriptors.

Duplicate accounts

Only one original itemised account per service should be issued, except in circumstances where both a consultation and computerised perimetry occur, in which case these may be itemised on the same original account. Duplicates of accounts or receipts should be clearly marked "duplicate" and should be issued only where the original has been lost. Duplicates should not be issued as a routine system for "accounts rendered".

Assignment of benefit (bulk billed) arrangements

Under the *Health Insurance Act 1973* an Assignment of Benefit (bulk-billing) facility for professional services is available to all persons in Australia who are eligible for benefit under the Medicare program. This facility is NOT confined to pensioners or people in special need.

If an optometrist bulk-bills, they undertake to accept the relevant Medicare benefit as full payment for the service. Additional charges for that service (irrespective of the purpose or title of the charge) cannot be raised against the patient. Under these arrangements:

- the patient's Medicare number must be quoted on all bulk-bill assignment of benefit forms for that patient;
- · the assignment of benefit forms provided are loose leaf to enable the patient details to be imprinted from the Medicare Card:
- the forms include information required by Regulations under Section 19(6) of the Health Insurance Act 1973; and
- · the optometrist must cause the particulars relating to the professional service to be set out on the assignment of benefit form, before the patient signs the form and cause the patient to receive a copy of the form as soon as practicable after the patient signs it.

Where a patient is unable to sign the assignment of benefit form, the signature of the patient's parent, guardian or other responsible person (other than the optometrist, optometrist's staff, hospital proprietor, hospital staff, residential aged care facility proprietor or residential aged care facility staff)) is acceptable.

Where the signature space is either left blank or another person signs on the patient's behalf, the form **must** include:

- the notation "Patient unable to sign" and
- in the section headed 'Practitioner's Use', an explanation should be given as to why the patient was unable to sign (e.g. unconscious, injured hand etc.) and this note should be signed or initialled by the optometrist. If in the opinion of the optometrist the reason is of such a "sensitive" nature that revealing it would constitute an unacceptable breach of patient confidentiality or unduly embarrass or distress the recipient of the patient's copy of the assignment of benefits form, a concessional reason "due to medical condition" to signify that such a situation exists may be substituted for the actual reason. However, this should not be used routinely and in most cases it is expected that the reason given will be more specific.

Use of Medicare cards in bulk-billing

Where a patient presents without a Medicare card and indicates that they have been issued with a card but does not know the details, the optometrist may contact the Department of Human Services on 132 150 to obtain the number.

It is important for the optometrist to check the eligibility of their patients for Medicare benefits by reference to the card, as entitlement is limited to the "valid to" date shown on the bottom of the card. Additionally the card will show if a person is enrolled through a Reciprocal Health Care Agreement.

Assignment of benefit forms

Only the approved assignment of benefit forms available from the Department of Human Services website, www.humanservices.gov.au, can be used to bulk-bill patients for optometric services and no other form can be used without its approval.

(a) Form DB2-OP

This form is designed for the use of optical scanning equipment and is used to assign benefits for optometrical services. It is loose leaf to enable imprinting of patient details from the Medicare card and comprises a throw away cover sheet (after imprinting), a Medicare copy, a Practitioner copy and a Patient copy.

(b) Form DB4

This is a continuous stationery version of Form DB2 and has been designed for use on most office accounting machines.

The Claim for Assigned Benefits (Form DB1N, DB1H)

Optometrists who accept assigned benefits must claim from the Department of Human Services using either Claim for Assigned Benefits form DB1N or DB1H. The DB1N form should be used where services are rendered to persons for treatment provided out of hospital or day hospital treatment. The DB1H form should be used where services are rendered to persons while hospital treatment is provided in a hospital or day hospital facility (other than public patients). Both forms have been designed to enable benefit for a claim to be directed to an optometrist other than the one who rendered the services. The facility is intended for use in situations such as where a short term locum is acting on behalf of the principal optometrist and setting the locum up with a provider number and pay-group link for the principal optometrist's practice is impractical. Optometrists should note that this facility cannot be used to generate payments to or through a person who does not have a provider number.

Each claim form must be accompanied by the assignment of benefit forms to which the claim relates.

Time limits applicable to lodgement of bulk bill claims for benefits

A time limit of two years applies to the lodgement of claims with the Department of Human Services under the bulk billed (assignment of benefits) arrangements. This means that Medicare benefits are not payable for any service where the service was rendered more than two years earlier than the date the claim was lodged with the Department of Human Services.

Provision exists whereby in certain circumstances (e.g. hardship cases), the Minister may waive the time limits. Special forms for this purpose are available, if required, from the <u>Department of Human Services website</u> at <u>www.humanservices.gov.au</u> or the processing centre to which bulk-bill claims are directed.

AN.0.13 Attendances at a Hospital (Items 4, 24, 37, 47, 58, 59, 60, 65)

These items refer to attendances on patients admitted to a hospital. Where medical practitioners have made arrangements with a local hospital to routinely use out-patient facilities to see their private patients, items for services provided in consulting rooms would apply.

AN.0.14 Referrals (Read in Connection with the Relevant Paragraphs at O.6) General

Optometrists are required to refer a patient for medical attention when it becomes apparent to them that the patient's condition is such that it would be more appropriate for treatment to be undertaken by a medical practitioner.

Optometrists may refer patients directly to specialist ophthalmologists with the patient being able to claim benefits for the ophthalmologist's services at the referred specialist rate.

Optometrists may refer patients directly to another optometrist, based on the clinical needs of the patient.

A referral letter or note must have been issued by the optometrist for all such services provided by specialist ophthalmologists or optometrists in order for patients to be eligible for Medicare benefits at the referred rate. Unless such a letter or note has been provided, benefits will be paid at the non-referred attendance rate, which has a lower rebate..

Medicare benefits at the referred rate are not paid for patients referred by optometrists to consultant physicians or to specialists other than ophthalmologists. See relevant paragraph regarding emergency situations.

What is a referral?

For the purposes of the optometric arrangements, a "referral" is a request to a specialist ophthalmologist or another optometrist for investigation, opinion, treatment and/or management of a condition or problem of a patient or for the performance of a specific examination(s) or test(s).

Subject to the exceptions in the paragraph below, for a valid "referral" to take place:

- (a) the referring optometrist must have turned his or her mind to the patient's need for referral and communicate relevant information about the patient to the specialist ophthalmologist or optometrist to whom the patient is referred (but this does not necessarily mean an attendance on the occasion of the referral);
- (b) the instrument of referral must be in writing by way of a letter or note and must be signed and dated by the referring optometrist; and
- (c) the practitioner to whom the patient is referred must have received the instrument of referral on or prior to the occasion of the professional service to which the referral relates.

The exceptions to the requirements in the above paragraph are that:

- (a) sub-paragraphs (b) and (c) do not apply to an emergency situation where the specialist ophthalmologist was of the opinion that the service be rendered as quickly as possible (see paragraph below on emergency situations); and
- (b) sub-paragraph (c) does not apply to instances where a written referral was completed by a referring optometrist but was lost, stolen or destroyed.

Period for which referral is valid

A referral from an optometrist to an ophthalmologist is valid for twelve months unless the optometrist specifies on the referral that the referral is for a different period (e.g. three, six or eighteen months or valid indefinitely).

The referral applies for the period specified in the referral from the date that the ophthalmologist provides the first service to the patient. If there is no period specified in the referral then the referral is valid for twelve months from the date of the first service provided by the ophthalmologist.

Referrals for longer than twelve months should be made only when the patient's clinical condition requires continuing care and management.

An optometrist may write a new referral when a patient presents with a condition unrelated to the condition for which the previous referral to an ophthalmologist was written. In these circumstances Medicare benefits for the consultation with the ophthalmologist would be payable at initial consultation rates.

A new course of treatment for which Medicare benefits would be payable at the initial consultation rates will also be paid where the referring optometrist:

- (a) deems it necessary for the patient's condition to be reviewed; and
- (b) the patient is seen by the ophthalmologist outside the currency of the previous referral; and

(c) the patient was last seen by the specialist ophthalmologist more than nine months earlier than the attendance following a new referral.

Self referral

Optometrists may refer themselves to specialist ophthalmologists or other optometrists and Medicare benefits are payable at referred rates.

Lost, stolen or destroyed referrals

If a referral has been made but the letter or note of referral has been lost, stolen or destroyed, benefits will be payable at the referred rate if the account, receipt or the assignment form shows the name of the referring practitioner, the practice address or provider number of the referring practitioner (if either of these are known to the consultant physician or specialist) and the words 'Lost referral'. This provision only applies to the initial attendance. For subsequent attendances to attract Medicare benefits at the referred rate, a duplicate or replacement letter of referral must be obtained by the specialist or the consultant physician.

Emergency situations

Medicare benefits are payable even though there is no written referral in an emergency situation (as defined in the *Health Insurance Regulations 2018*). The specialist or the consultant physician should be of the opinion that the service must be rendered as quickly as possible and endorses the account, receipt or assignment form as an "Emergency referral".

A referral must be obtained from a medical practitioner or, in the case of a specialist ophthalmologist, a medical practitioner or an optometrist if attendances subsequent to the emergency attendance are to attract Medicare benefits at the referred rate.

AN.0.15 Residential Aged Care Facility Attendances (Items 5010, 5028, 5049, 5067, 5260, 5263, 5265, 5267)

These items refer to attendances on patients in residential aged care facilities.

Where a medical practitioner attends a patient in a self-contained unit, within a residential aged care facility complex, the attendance attracts benefits under the appropriate home visit item.

Where a patient living in a self-contained unit attends a medical practitioner at consulting rooms situated within the precincts of the residential aged care facility, or at free standing consulting rooms within the residential aged care facility complex, the appropriate surgery consultation item applies.

If a patient who is accommodated in the residential aged care facility visits a medical practitioner at consulting rooms situated within the residential aged care facility complex, whether free standing or situated within the residential aged care facility precincts, benefits would be attracted under the appropriate residential aged care facility attendance item.

To facilitate assessment of the correct Medicare rebate in respect of a number of patients attended on the one occasion at one of the above locations, it is important that the total number of patients seen be recorded on each individual account, receipt or assignment form. For example, where two patients were visited (for a brief consultation) in the one facility on the one occasion, each account, receipt or assignment form would show "Item 5010 - 1 of 2 patients" for a general practitioner.

The number of patients seen should not include attendances which do not attract a Medicare rebate (e.g. public inpatients, attendances for normal after-care), or where a Medicare rebate is payable under an item other than these derived fee items (e.g. health assessments, care planning, emergency after-hours attendance - first patient).

AN.0.16 Provision for Review of the Schedule Optometric Benefits Consultative Committee (OBCC)

The OBCC is an advisory committee established in 1990 by arrangement between the Minister and Optometry Australia.

The OBCC's functions are:

- (a) to discuss the appropriateness of existing Medicare Benefits Schedule items for the purposes of considering whether an approach to the Medical Services Advisory Committee may be needed;
- (b) to undertake reviews of particular services and to report on the appropriateness of the existing structure of the Schedule, having regard to current optometric practice;
- (c) to consider and advise on the appropriateness of the participating optometrists' arrangements and the Common Form of Undertaking (as specified in the *Health Insurance Act 1973* and related legislation) and the administrative rules and interpretations which determine the payment of benefits for optometric services or the level of benefits:
- (d) to investigate specific matters associated with the participating optometrists' arrangements and to advise on desirable changes.

The OBCC comprises two representatives from the Department of Health, two representatives from the Department of Human Services, and three representatives from Optometry Australia.

AN.0.18 Provision for Review of Practitioner Behaviour Professional Services Review (PSR) Scheme

The Professional Services Review (PSR) Scheme is a scheme for reviewing and investigating the provision of services by a health practitioner to determine whether the practitioner has engaged in inappropriate practice in the rendering or initiating of Medicare services or in prescribing under the Pharmaceutical Benefits Scheme (PBS). 'Practitioner' is defined in Section 81 of the *Health Insurance Act 1973* and includes: medical practitioners, dentists, optometrists, chiropractors, midwives, nurse practitioners, physiotherapists, podiatrists and osteopaths.

Section 82 of the *Health Insurance Act 1973* defines inappropriate practice as conduct that is such that a PSR Committee could reasonably conclude that it would be unacceptable to the general body of the members of the profession in which the practitioner was practising when he or she rendered or initiated the services. It is also an offence under Section 82 for a person who is an officer of a body corporate to knowingly, recklessly or negligently cause or permit a practitioner employed by the person to engage in such conduct.

The Department of Human Services monitors health practitioners' claiming patterns. Where an anomaly is detected, for which a satisfactory explanation cannot be provided, the Department of Human Services can request that the Director of PSR review the provision of services by the practitioner. On receiving the request, the Director must decide whether to conduct a review and in which manner the review will be conducted. The Director is authorised to require that documents and information be provided.

Following a review, the Director must:

- (a) decide to take no further action; or
- (b) enter into an agreement with the person under review (which must then be ratified by an independent Determining Authority); or
- (c) refer the matter to a PSR Committee.

A PSR Committee consists of the Chairperson and two other panel members who must be members of the same profession as the practitioner under review. However, up to two additional Committee members may be appointed to provide a wider range of clinical expertise.

The Committee is authorised to:

- (a) investigate any aspect of the provision of the referred services, and without being limited by the reasons given in the review request or by a Director's report following the review;
- (b) hold hearings and require the person under review to attend and give evidence; and
- (c) require the production of documents (including clinical notes).

A PSR Committee may not make a finding of inappropriate practice unless it has given the person under review notice of its intention to review them, the reasons for its findings, and an opportunity to respond. In reaching their decision, a PSR Committee is required to consider whether or not the practitioner has kept adequate and contemporaneous patient records. It will be up to the peer judgement of the PSR Committee to decide if a practitioner's records meet the prescribed standards.

The standards which determine if a record is adequate and contemporaneous are prescribed in the *Health Insurance* (*Professional Services Review*) Regulations 1999.

To be *adequate*, the patient or clinical record needs to:

clearly identify the name of the patient; and

contain a separate entry for each attendance by the patient for a service and the date on which the service was rendered or initiated; and

each entry needs to provide clinical information adequate to explain the type of service rendered or initiated; and

each entry needs to be sufficiently comprehensible that another practitioner, relying on the record, can effectively undertake the patient's ongoing care.

To be *contemporaneous*, the patient or clinical record should be completed at the time that the service was rendered or initiated or as soon as practicable afterwards. Records for hospital patients are usually kept by the hospital and the practitioner could rely on these records to document in-patient care.

The practitioner under review is permitted to make submissions to the PSR Committee before key decisions or a final report is made.

If a PSR Committee finds that the person under review has engaged in inappropriate practice, the findings will be reported to the Determining Authority to decide what action should be taken:

- (i) a reprimand;
- (ii) counselling;
- (iii) repayment of Medicare benefits; and/or
- (iv) complete or partial disqualification from Medicare benefit arrangements for up to three years.

Further information on the Professional Services Review is available at www.psr.gov.au and information on Medicare compliance is available at http://www.humanservices.gov.au/health-professionals/subjects/compliance?utm id=9.

Penalties

Penalties of up to \$10,000 or imprisonment for up to five years, or both may be imposed on any person who makes a statement (either orally or in writing) or who issues or presents a document that is false or misleading in a material particular and which is capable of being used with a claim for benefits. In addition, any practitioner who is found guilty of such offences shall be subject to examination by a Medicare Participation Review Committee (MPRC) and may be counselled or reprimanded or may have services wholly or partially disqualified from the Medicare benefit arrangements.

A penalty of up to \$1,000 or imprisonment for up to three months, or both, may be imposed on any person who obtains a patient's signature on an assignment of benefit form without necessary details having been entered on the form before the patient signs or who fails to cause a patient to be given a copy of the completed form.

Medicare Participation Review Committee (MPRC)

The Medicare Participation Review Committee determines what administrative action should be taken against a practitioner who:

- (a) has been successfully prosecuted for relevant criminal offences; or
- (b) has been found to have engaged in inappropriate practice under the Professional Services Review scheme.

The Committee can take no further action, counsel or reprimand the practitioner, or determine that the practitioner be disqualified from Medicare for a particular period or in relation to particular services for up to five years.

Medicare benefits are not payable in respect of services rendered by a practitioner who has been fully disqualified, or partly disqualified in relation to relevant services under the *Health Insurance Act 1973* (Section 19B applies).

AN.0.19 After-Hours Attendances (Items 585, 588, 591, 594, 599, 600, 5000, 5003, 5010, 5020, 5023, 5028, 5040, 5043, 5049, 5060, 5063, 5067, 5200, 5203, 5207, 5208, 5220, 5223, 5227, 5228, 5260, 5263, 5265 and 5267)

After-Hours Attendances (Items 585, 588, 591, 594, 599, 600, 5000, 5003, 5010, 5020, 5023, 5028, 5040, 5049, 5060, 5063, 5067, 5200, 5203, 5207, 5208, 5220, 5223, 5227, 5228, 5260, 5263, 5265 and 5267)

Guidelines for the <u>After Hours Other Medical Practitioners (AHOMPs) Program</u> are available on the Department of Health's website.

After-hours attendance items may be claimed as follows:

Items 585, 588, 591, 594, 599, 600 apply only to a professional attendance that is provided:

- on a public holiday;
- on a Sunday;
- before 8am, or after 12 noon on a Saturday;
- before 8am, or after 6pm on any day other than a Saturday, Sunday or public holiday.

Items 5000, 5020, 5040, 5060, 5200, 5203, 5207 and 5208 apply only to a professional attendance that is provided:

- on a public holiday;
- on a Sunday;
- before 8am, or after 1 pm on a Saturday;
- before 8am, or after 8pm on any day other than a Saturday, Sunday or public holiday.

Items 5003, 5010, 5023, 5028, 5043, 5049, 5063, 5067, 5220, 5223, 5227, 5228, 5260, 5263, 5265 and 5267 apply to a professional attendance that is provided:

- on a public holiday;
- on a Sunday;
- before 8am, or after 12 noon on a Saturday;
- before 8am, or after 6pm on any day other than a Saturday, Sunday or public holiday.

Urgent After-Hours Attendances (Items 585 - 600)

Items 585, 588, 591, 594, 599 and 600 can be used for urgent after-hours services.

Urgent After-Hours Attendances (Items 585, 588, 591, and 594) allow for urgent attendances (other than an attendance between 11pm and 7am) in an after-hours period.

Urgent After-Hours Attendances during Unsociable Hours (Items 599 and 600) allow for urgent attendances between 11pm and 7am in an after-hours period.

The attendance for all these items must be requested by the patient or a responsible person during the same unbroken urgent after-hours period in which the medical service is provided. The medical practitioner must first determine that the patient requires urgent medical assessment.

In considering the need for an urgent assessment of a patient's condition, the practitioner may rely on information conveyed by the patient or patient's carer, other health professionals or emergency services personnel. A record of the assessment must be completed and included in the patient's medical record.

The MBS urgent after-hours items may be used when, on the information available to the medical practitioner, the patient's condition requires urgent medical assessment during the after-hours period to prevent deterioration or potential deterioration in their health. Specifically the patient's assessment:

- cannot be delayed until the next in-hours period; and
- the medical practitioner must attend the patient at the patient's location or reopen the practice rooms.

Appendix B of the Approved Medical Deputising Service (AMDS) Program Guidelines offers a useful protocol to determine whether prospective after-hours patients should be seen by a deputising medical practitioner or see their regular medical practitioner. The AMDS Program Guidelines are available at http://www.health.gov.au/internet/main/publishing.nsf/Content/approved-medical-deputising-service

If the attendance is undertaken at consulting rooms, it is necessary for the practitioner to return to and specially open the consulting rooms for the attendance.

MBS Item 585 is available to medical practitioners who are:

- listed on the Vocational Register of General Practitioners maintained by the Department of Human Services or;
- holders of the Fellowship of the Royal Australian College of General Practitioners (FRACGP) who participate in, and meet the requirements of the RACGP for continuing medical education and quality assurance as defined in the RACGP Quality Assurance and Continuing Medical Education Program; or
- holders of the Fellowship of the Australian College of Rural and Remote Medicine (FACRRM) who participate in, and meet the requirements of the Australian College of Rural and Remote Medicine (ACRRM) for continuing medical education and quality assurance as defined in ACRRM's Professional Development Program; or

- undertaking an approved placement in general practice as part of a training program for general practice leading to the award of the FRACGP or training recognised by the RACGP as being of an equivalent standard; or
- undertaking an approved placement in general practice as part of a training program for general practice leading to the award of the FACRRM or training recognised by ACRRM as being of an equivalent standard.

NOTE: MBS incentives continue to be available through the After-Hours Other Medical Practitioners (AHOMPs) Program to non-vocationally recognised medical practitioners who perform after-hours attendances. MBS item 585 will be available to AHOMPs Program participants if they perform an urgent after-hours attendance as part of their employment with a full-time general practice.

AHOMPs will not extend access to item 585 to non-vocationally recognised medical practitioners who work with an after-hours only practice or a medical deputising service (including an AMDS).

MBS Item 588 is available to non-vocationally recognised medical practitioners who are providing services (as a contractor, employee, member or otherwise) for a general practice or clinic or as part of medical deputising arrangements in Modified Monash Model Areas 2 to 7.

A locator map to identify a medical practice's Modified Monash Model Area location is available at the DoctorConnect website at http://www.doctorconnect.gov.au/internet/otd/publishing.nsf/Content/locator

MBS item 591 is available to non-vocationally recognised medical practitioners who perform attendances for afterhours clinics or as part of deputising arrangements in Modified Monash Model Area 1.

If more than one patient is seen on the same occasion (that is, the second and any further services are consequential to the first service) using either MBS items 585, 588 or 591, **MBS item 594** must be used in respect of the second and subsequent services to patients attended on the same occasion.

Medical practitioners who routinely provide services to patients in the after-hours periods at consulting rooms, or who provide the services (as a contractor, employee, member or otherwise) for a general practice or clinic that routinely provides services to patients in after-hours periods at consulting rooms, will not be able to bill urgent after-hours items 585, 588, 591, 594, 599 and 600.

A *routine service* means a regular or habitual provision of services to patients. This does not include *ad hoc* services provided after-hours in consulting rooms by a medical practitioner (excluding consultant physicians and specialists) working in a general practice or a clinic while participating in an on-call roster.

There is no change to the types of providers who can render services under the *Urgent After-Hours Attendances during Unsociable Hours items* (MBS items 599 and 600). Attendances using these items must be booked during the same unbroken urgent after-hours period.

MBS item 599 continues to be available to medical practitioners who are:

- listed on the Vocational Register of General Practitioners maintained by the Department of Human Services or;
- holders of the Fellowship of the Royal Australian College of General Practitioners (FRACGP) who participate in, and meet the requirements of the RACGP for continuing medical education and quality assurance as defined in the RACGP Quality Assurance and Continuing Medical Education Program; or
- holders of the Fellowship of the Australian College of Rural and Remote Medicine (FACRRM) who participate in, and meet the requirements of the Australian College of Rural and Remote Medicine (ACRRM) for continuing medical education and quality assurance as defined in ACRRM's Professional Development Program; or
- undertaking an approved placement in general practice as part of a training program for general practice leading to the award of the FRACGP or training recognised by the RACGP as being of an equivalent standard; or

- undertaking an approved placement in general practice as part of a training program for general practice leading to the award of the FACRRM or training recognised by ACRRM as being of an equivalent standard non-vocationally recognised medical practitioners through the AHOMPs Program; or
- non-vocationally recognised medical practitioners participating in the AHOMPs Program.

MBS item 600 continues to be available to non-vocationally recognised medical practitioners.

Non-Urgent After-Hours Attendances (5000 - 5067 and 5200 - 5267)

Non-Urgent After-Hours Attendances in Consulting Rooms (Items 5000, 5020, 5040, 5060, 5200, 5203, 5207 and 5208) are to be used for non-urgent consultations at consulting rooms initiated either on a public holiday, on a Sunday, or before 8am and after 1pm on a Saturday, or before 8am and after 8pm on any other day.

Non-Urgent After-Hours Attendances at a Place Other than Consulting Rooms (Other than a Hospital or Residential Aged Care Facility) (items 5003, 5023, 5043, 5063, 5220, 5223, 5227 and 5228) and Non-Urgent After-Hours Attendances in a Residential Aged Care Facility (Items 5010, 5028, 5049, 5067, 5260, 5263, 5265 and 5267) are to be used for non-urgent attendances on 1 or more patients on 1 occasion on a public holiday, on a Sunday, or before 8am and after 12 noon on a Saturday, or before 8am and after 6pm on any other day.

	Applicable Time	Items		
Attendance Period	Monday to Friday	Saturday*	Sunday and/or public holiday	
Urgent after-hours attendance	Between 7am - 8am and 6pm - 11pm	Between 7am - 8am and 12 noon - 11pm	Between 7am - 11pm	585, 588, 591, 594
Urgent after-hours in unsociable hours	Between 11pm - 7am	Between 11pm - 7am	Between 11pm - 7am	599, 600
Non-urgent After hours In consulting rooms	Before 8am or after 8pm	Before 8am or after 1pm	24 hours	5000, 5020, 5040, 5060 5200, 5203, 5207, 5208
Non-urgent after-hours at a place other than consulting rooms (other than a hospital or Residential Aged Care Facility)	Before 8am or after 6pm	Before 8am or after 12 noon	24 hours	5003, 5023,5043, 5063, 5220, 5223, 5227, 5228
Non-urgent after-hours in a Residential Aged Care Facility	Before 8am or after 6pm	Before 8am or after 12 noon	24 hours	5010, 5028, 5049, 5067 5260, 5263, 5265, 5267

^{*}with the exception of public holidays which fall on a Saturday

AN.0.20 Visiting Optometrists Scheme (VOS)

Special arrangements exist under the provisions of Section 129A of the Health Insurance Act 1973 to ensure that people in rural and remote locations have access to optometry services. Optometrists are encouraged to provide outreach services to national priority locations, particularly remote and very remote locations, Aboriginal and Torres Strait Islander communities and rural locations with an identified need for optometry services.

Under these arrangements, financial assistance may be provided to cover costs associated with delivering outreach services, including travel, accommodation and meals and facility fees.

Funding agreements are currently in place with optometrists for the delivery of services until 30 June 2015. Enquiries can be directed to vos@health.gov.au.

AN.0.21 Minor Attendance by a Consultant Physician (Items 119, 120, 131)

A minor consultation is regarded as being a consultation in which the assessment of the patient does not require the physical examination of the patient and does not involve a substantial alteration to the patient's treatment. Examples of consultations which could be regarded as being 'minor consultations' are listed below (this is by no means an exhaustive list):-

- hospital visits where a physical examination does not result, or where only a limited examination is performed;
- hospital visits where a significant alteration to the therapy or overall management plan does not ensue;
- brief consultations or hospital visits not involving subsequent discussions regarding patient's progress with a specialist colleague or the referring practitioner.

AN.0.22 Telehealth Patient-end Support Services by Optometrists

These notes provide information on the telehealth MBS attendance items for optometrists to provide clinical support to their patients, when clinically relevant, during video consultations with ophthalmologists under items 10945, 10946, 10947 and 10948 in Group A10.

Telehealth patient-end support services can only be claimed where:

- a Medicare eligible specialist service is claimed;
- the service is rendered in Australia; and
- this is necessary for the provision of the specialist service.

A video consultation will involve a single optometrist attending to the patient, with the possible participation of another medical practitioner, a participating nurse practitioner, a participating midwife, practice nurse, Aboriginal and Torres Strait Islander health practitioner or Aboriginal health worker at the patient end. The above time-tiered items provide for patient-end support services in various settings, including consulting rooms, other than consulting rooms, eligible residential aged care services and Aboriginal Medical Services.

Clinical indications

The ophthalmologist must be satisfied that it is clinically appropriate to provide a video consultation to a patient. The decision to provide clinically relevant support to the patient is the responsibility of the ophthalmologist.

Telehealth specialist services can be provided to patients when there is no patient-end support service provided.

Collaborative Consultation

The optometrist who provides assistance to the patient where this is necessary for the provision of the specialist service, may seek assistance from a health professional (e.g. a medical practitioner, practice nurse, Aboriginal or Torres Strait Islander health practitioner or Aboriginal health worker) but only one item is billable for the patient-end support service. The optometrist must be present during part or all of the consultation in order to bill an appropriate time-tiered MBS item. Any time spent by another health professional called to assist with the consultation may not be counted against the overall time taken to complete the video consultation.

Restrictions

The MBS telehealth attendance items are not payable for services to an admitted hospital patient (this includes Hospital in the Home patients). Benefits are not payable for telephone or email consultations. In order to fulfil the

item descriptor there must be a visual and audio link between the patient and the ophthalmologist. If the ophthalmologist is unable to establish both a video and audio link with the patient, a MBS rebate for a telehealth attendance is not payable.

Eligible Geographical Areas

Geographic eligibility for telehealth services funded under Medicare are determined according to the Australian Standard Geographical Classification Remoteness Area (ASGC-RA) classifications. Telehealth Eligible Areas are areas that are outside a Major City (RA1) according to ASGC-RA (RA2 - 5). Patients and providers are able to check their eligibility by following the links on the MBS Online website (www.mbsonline.gov.au/telehealth).

There is a requirement for the patient and specialist to be located a minimum of 15km apart at the time of the consultation. Minimum distance between specialist and patient video consultations are measured by the most direct (ie least distance) route by road. The patient or the specialist is not permitted to travel to an area outside the minimum 15 km distance in order to claim a video conference. This rule will not apply to specialist video consultations with patients who are a care recipient in an eligible residential care service; or at an eligible Aboriginal Medical Service or Aboriginal Community Controlled Health Service for which a direction, made under subsection 19(2) of the *Health Insurance Act 1973*, as these patients are able to receive telehealth services anywhere in Australia.

Telehealth Eligible Service Areas are defined at:

http://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/connectinghealthservices-eligible-geo.

Record Keeping

Telehealth optometrists must keep contemporaneous notes of the consultation including documenting that the service was performed by video conference, the date, time and the people who participated.

Only clinical details recorded at the time of the attendance count towards the time of the consultation. It does not include information added at a later time, such as reports of investigations.

Multiple attendances on the same day

In some situations a patient may receive a telehealth consultation and a face-to-face consultation by the same or different practitioner on the same day.

Medicare benefits may be paid for more than one video consultation on a patient on the same day by the same practitioner, provided the second (and any following) video consultations are not a continuation of the initial or earlier video consultations. Practitioners will need to provide the times of each consultation on the patient's account or bulk billing voucher.

Also, if a patient has an initial consultation via telehealth, they cannot also claim an initial face-to-face consultation as part of the same course of treatment.

Aftercare Rule

Video consultations are subject to the same aftercare rules as face-to-face consultations.

Referrals

The referral procedure for a video consultation is the same as for conventional face-to-face consultations.

Technical requirements

In order to fulfil the item descriptor there must be a visual and audio link between the patient and the ophthalmologist. If the ophthalmologist is unable to establish both a video and audio link with the patient, a MBS rebate for a specialist video consultation is not payable.

Individual clinicians must be confident that the technology used is able to satisfy the item descriptor and that software and hardware used to deliver a videoconference meets the applicable laws for security and privacy.

Duration of attendance

The optometrist attending at the patient end of the video consultation does not need to be present for the entire consultation, only as long as is clinically relevant - this can be established in consultation with the ophthalmologist. The MBS fee payable for the supporting optometrist will be determined by the total time spent assisting the patient. This time does not need to be continuous.

AN.0.23 Referred Patient Consultant Physician Treatment and Management Plan (Items 132 and 133)

Patients with at least two morbidities which can include complex congenital, development and behavioural disorders are eligible for these services when referred by their referring practitioner.

Item 132 should include the development of options for discussion with the patient, and family members, if present, including the exploration of treatment modalities and the development of a comprehensive consultant physician treatment and management plan, with discussion of recommendations for services by other health providers as appropriate.

Item 133 is available in instances where a review of the consultant physician treatment and management plan provided under item 132 is required, up to a maximum of two claims for this item in a 12 month period. Should further reviews of the consultant physician treatment and management plan be required, the appropriate item for such service/s is 116.

Where a patient with a GP health assessment, GP management plan (GPMP) or Team Care Arrangements (TCA's) is referred to a consultant physician for further assessment, it is intended that the consultant physician treatment and management plan should augment the GPMP or TCA's for that patient.

Preparation of the consultant physician treatment and management plan should be in consultation with the patient. If appropriate, a written copy of the consultant physician treatment and management plan should be provided to the patient. A written copy of the consultant physician treatment and management plan should be provided to the referring medical practitioner, usually within two weeks of the consultant physician consultation. In more serious cases, more prompt provision of the plan and verbal communication with the referring medical practitioner may be appropriate. A guide to the content of such consultant physician treatment and management plans which are to be provided under this item is included within this Schedule.

(Note: This information is provided as a guide only and each case should be addressed according to a patient's individual needs.)

REFERRED PATIENT CONSULTANT PHYSICIAN TREATMENT AND MANAGEMENT PLAN

- The following content outline is indicative of what would normally be sent back to the referring practitioner.
- The consultant physician treatment and management plan should address the specific questions and issues raised by the referring practitioner.

History

The consultant physician treatment and management plan should encompass a comprehensive patient history which addresses all aspects of the patient's health, including psychosocial history, past clinically relevant medical history, any relevant pathology results if performed and a review of medication and interactions. There should be a particular focus on the presenting symptoms and current difficulties, including precipitating and ongoing conditions. The results of relevant assessments by other health professionals, including GPs and/or specialists, including relevant care plans or health assessments performed by GPs under the Enhanced Primary Care and Chronic Disease Management should also be noted.

Examination

A comprehensive medical examination means a full multi-system or detailed single organ system assessment. The clinically relevant findings of the examination should be recorded in the management plan.

Diagnosis

This should be based on information obtained from the history and medical examination of the patient. The list of diagnoses and/or problems should form the basis of any actions to be taken as a result of the comprehensive assessment. In some cases, the diagnosis may differ from that stated by the referring practitioner, and an explanation of why the diagnosis differs should be included. The report should also provide a risk assessment, management options and decisions.

Management plan

Treatment options/Treatment plan

The consultant physician treatment and management plan should include a planned follow-up of issues and/or conditions, including an outline of the recommended intervention activities and treatment options. Consideration should also be given to recommendations for allied health professional services, where appropriate.

Medication recommendations

Provide recommendations for immediate management, including the alternatives or options. This should include doses, expected response times, adverse effects and interactions, and a warning of any contra-indicated therapies.

Social measures

Identify issues which may have triggered or are contributing to the problem in the family, workplace or other social environment which need to be addressed, including suggestions for addressing them.

Other non medication measures

This may include other options such as life style changes including exercise and diet, any rehabilitation recommendations and discussion of any relevant referrals to other health providers.

Indications for review

It is anticipated that the majority of patients will be able to be managed effectively by the referring practitioner using the consultant physician treatment and management plan. If there are particular concerns about the indications or possible need for further review, these should be noted in the consultant physician treatment and management plan.

Longer term management

Provide a longer term consultant physician treatment and management plan, listing alternative measures that might be taken in the future if the clinical situation changes. This might be articulated as anticipated response times, adverse effects and interactions with the consultant physician treatment and management plan options recommended under the consultant physician treatment and management plan.

The Department of Human Services (DHS) has developed an <u>Health Practitioner Guideline to substantiate that a valid referral existed (specialist or consultant physician)</u> which is located on the DHS website.

AN.0.24 Referred patient assessment, diagnosis and treatment and management plan for autism or any other pervasive developmental disorder (items 135 and 289)

These items are for consultant paediatricians (item 135) or psychiatrists (item 289), on referral from a medical practitioner, to provide early diagnosis and treatment of autism or any other pervasive development disorder (PDD)

for children aged under 13 years. The items are for assessment, diagnosis and the creation of a treatment and management plan, and are claimable only once per patient per lifetime.

When item 135 or item 289 is in place, a consultant paediatrician or psychiatrist can refer a child with autism or other PDD to eligible allied health professionals for treatment services.

A child can access either the allied health services for autism/other PDD (using item 135 or 289) or for disability (using item 137 or 139), but not both.

If a child sees a consultant paediatrician or psychiatrist other than the one who put the treatment and management plan in place, the consultant paediatrician or psychiatrist who is seen subsequently can refer the child for any remaining allied health treatment services that are available to the child.

Children with an existing treatment and management plan created under item 135 or 289 can be reviewed under attendance items for consultant psychiatrists and paediatricians.

Where the patient presents with another morbidity in addition to autism or other PDD, item 132 can also be used for development of a treatment and management plan. However, the use of this item will not provide access to Medicare rebateable allied health services for treatment of autism or any other PDD.

Items 135 or 289 also provide a referral pathway for access to services provided through Childhood Autism Advisors by the Department of Families, Housing, Community Services and Indigenous Affairs (FaHCSIA). For further information on assistance available through FaHCSIA, phone 1800 778 581 or email ASD.Support@fahcsia.gov.au. TTY users - phone 1800 555 677 then ask for the 1800 toll-free number you wish to contact.

Referral requirements

Items 135 (paediatrician) or 289 (psychiatrist) are for diagnosis and treatment of autism or any other PDD where clinically appropriate, including referral to allied health treatment services.

A course of treatment for the allied health treatment services consists of the number of allied health services stated on the child's referral, up to a maximum of 10 services. This enables the referring practitioner to consider a report from the allied health professional(s) about the services provided to the child, and the need for further treatment.

Within the maximum service allocation of twenty treatment services, the allied health professional(s) can provide one or more courses of treatment. Patients will require a separate referral for each allied health professional they are referred to and they will also need new referrals for each new course of treatment.

In addition to referrals to allied health treatment services, a consultant paediatrician or psychiatrist can refer a child to an eligible allied health provider to assist with diagnosis of the child or for the purpose of contributing to the child's pervasive developmental disorder (PDD). Referrals for these allied health assessment services can be made by a consultant paediatrician or psychiatrist as an outcome of the service provided under one of items 110-131 or 296-370 inclusive.

Referrals are only valid when prerequisite MBS services have been provided. If the referring service has not yet been claimed, the Department of Human Services (DHS) will not be aware of the child's eligibility and Medicare benefits cannot be paid. Providers can call DHS on 132 150 to confirm whether a relevant MBS service has been claimed and/or the number of allied health services already claimed by the child.

Referring medical practitioners are not required to use a specific form to refer patients for the allied health services that are available through the *Helping Children with Autism* program. The referral may be a letter or note to an eligible allied health professional signed and dated by the referring practitioner.

Allied health assistance with diagnosis/assessment and treatment

Helping Children with Autism Program - Allied Health Items

MBS items for allied health assessment and treatment of autism/PDD	Allied health provider				
Assistance with diagnosis / contribution to a treatment plan*					
82000	Psychologist				
82005	Speech pathologist				
82010	Occupational therapist				
82030	Audiologist, optometrist, orthoptist, physiotherapist				
Treatment services**					
82015	Psychologist				
82020	Speech pathologist				
82025	Occupational therapist				
82035	Audiologist, optometrist, orthoptist, physiotherapist				

^{*} Prerequisite MBS items: 110-131 (paediatrician) or items 296-370 (psychiatrist).

Assessment services

Assessment services are available for an allied health provider to assist the referring practitioner with diagnosis or for contributing to a child's treatment and management plan. These services can be accessed by children aged under 13 years.

Medicare rebates are available for up to four allied health services in total per eligible child.

An allied health professional can provide these services when:

- the child has previously been provided with any MBS service covering items 110-131 inclusive by a consultant paediatrician; or
- the child has previously been provided with any MBS service covering items 296-370 (excluding item 359) inclusive by a consultant psychiatrist.

The four allied health assessment services may consist of any combination of items 82000, 82005, 82010 and 82030.

It is the responsibility of the referring practitioner to allocate these services in keeping with the child's individual treatment needs and to refer the child to appropriate allied health professional(s) accordingly.

Treatment services

Treatment services can be accessed when a child with autism or other PDD is aged under 15 years and has had a treatment and management plan put in place for them before their 13th birthday.

Medicare rebates are available for up to twenty allied health treatment services in total per eligible child.

An eligible allied health professional can provide these services when:

- the child has previously been provided with a treatment plan (item 135) by a consultant paediatrician; or
- the child has previously been provided with a treatment plan (item 289) by a consultant psychiatrist.

^{**} Prerequisite MBS items: 135 (paediatrician) or 289 (psychiatrist).

The twenty treatment services may consist of any combination of items 82015, 82020, 82025 or 82035.

It is the responsibility of the referring practitioner to allocate these services in keeping with the child's individual treatment needs and to refer the child to appropriate allied health professional(s) accordingly.

Existing patients or patients with an existing diagnosis

Where a specific plan has not been created previously for the treatment and management of autism or any other PDD, a new plan can be developed by the treating practitioner under item 135 or 289 where it is clinically appropriate to treat the patient under such a plan.

Children with an existing treatment and management plan created under item 135 or 289 can be reviewed under attendance items for consultant psychiatrists and paediatricians.

AN.0.25 Patient Assessment, Diagnosis and Treatment and Management Plan for a Child with Disability (Items 137 and 139)

Items 137 and 139 are for specialists and consultant physicians (137) or for general practitioners (139) to provide early diagnosis and treatment of children with any of the following conditions:

(a) sight impairment that results in vision of less than or equal to 6/18 vision or equivalent field loss in the better eye, with

correction.

- (b) hearing impairment that results in:
- (i) a hearing loss of 40 decibels or greater in the better ear, across 4 frequencies; or
- (ii) permanent conductive hearing loss and auditory neuropathy.
- (c) deafblindness
- (d) cerebral palsy
- (e) Down syndrome
- (f) Fragile X syndrome
- (g) Prader-Willi syndrome
- (h) Williams syndrome
- (i) Angelman syndrome
- (j) Kabuki syndrome
- (k) Smith-Magenis syndrome
- (l) CHARGE syndrome
- (m) Cri du Chat syndrome
- (n) Cornelia de Lange syndrome
- (o) microcephaly if a child has:
- (i) a head circumference less than the third percentile for age and sex; and

(ii) a functional level at or below 2 standard deviations below the mean for age on a standard developmental test, or an IQ score of less than 70 on a standardised test of intelligence.

(p) Rett's disorder

"Standard developmental test" refers to the Bayley Scales of Infant Development or the Griffiths Mental Development Scales; "standardised test of intelligence" refers to the Wechsler Intelligence Scale for Children (WISC) or the Wechsler Preschool and Primary Scale of Intelligence (WPPSI). It is up to the clinical judgement of the diagnosing practitioner if other tests are appropriate to be used.

Items 137 and 139 are for assessment, diagnosis and the creation of a treatment and management plan, and are claimable only once per patient per lifetime.

AN.0.26 Geriatrician Referred Patient Assessment and Management Plan (Items 141-147)

Items 141 -147 apply only to services provided by a consultant physician or specialist in the specialty of Geriatric Medicine who has completed the additional requirements of the Royal Australasian College of Physicians for recognition in the subspecialty of geriatric medicine.

Referral for Items 141-147 should be through the general practitioner for the comprehensive assessment and management of frail older patients, older than 65, with complex, often interacting medical, physical and psychosocial problems who are at significant risk of poor health outcomes. In the event that a specialist of another discipline wishes to refer a patient for this item, the referral should take place through the GP.

A comprehensive assessment of an older person should as a minimum cover:

- · current active medical problems
- · past medical history;
- · medication review;
- · immunisation status;
- · advance care planning arrangements;
- · current and previous physical function including personal, domestic and community activities of daily living;
- · psychological function including cognition and mood; and
- · social function including living arrangements, financial arrangements, community services, social support and carer issues.

Note: Guidance on all aspects of conducting a comprehensive assessment on an older person is available on the Australian and New Zealand Society for Geriatric Medicine website at www.anzsgm.org.

Some of the information collection component of the assessment may be rendered by a nurse or other assistant in accordance with accepted medical practice, acting under the supervision of the geriatrician. The remaining components of the assessment and development of the management plan must include a personal attendance by the geriatrician.

A prioritised list of diagnoses/problems should be developed based on information provided by the history and examination, and any additional information provided by other means, including an interview of a person other than the patient.

The management plan should be explained and if necessary provided in written form to the patient or where appropriate, their family or carer(s).

A written report of the assessment including the management plan should be provided to the general practitioner within a maximum of 2 weeks of the assessment. More prompt verbal communication may be appropriate.

The Patient Assessment and Management plans must be kept for 2 years after the date of service.

Items 143 and 147 are available in instances where the GP initiates a review of the management plan provided under items 141 and 145, usually where the current plan is not achieving the anticipated outcome. It is expected that when a management plan is reviewed, any modification necessary will be made.

Items 143 and 147 can be claimed once in a 12 month period. However, if there has been a significant change in the patient's clinical condition or care circumstances necessitating another review, an additional item 143 or 147 can be claimed. In these circumstances, the patient's invoice or Medicare voucher should be annotated to briefly indicate the reason why the additional review was required (e.g. annotated as clinically indicated, exceptional circumstances, significant change etc).

AN.0.27 Prolonged Attendance in Treatment of a Critical Condition (Items 160 164)

The conditions to be met before services covered by items 160-164 attract benefits are:-

- (i) the patient must be in imminent danger of death;
- (ii) if the personal attendance is not continuous, the occasion on which the service is provided is taken to be the total time of the attendance; and
- (iii) if personal attendance on a single patient is provided by 1 or more general practitioners, specialists or consultant physicians concurrently, each general practitioner, specialist or consultant physician may claim an attendance fee.

AN.0.28 Family Group Therapy (Items 170, 171, 172)

These items refer to family group therapy supervised by general practitioner, specialist or consultant physician (other than consultant psychiatrists). To be used, these items require that a formal intervention with a specific therapeutic outcome, such as improved family function and/or communication, is undertaken. Other types of group attendances do not attract benefits. It should be noted that only one fee applies in respect of each group of patients.

AN.0.29 Acupuncture (Item 173, 193, 195, 197 and 199)

The service of "acupuncture" must be performed by a medical practitioner and itemised under item 173, 193, 195, 197 or 199 to attract benefits. These items cover not only the performance of the acupuncture but include any consultation on the same occasion and any other attendance on the same day for the condition for which acupuncture was given.

Items 193, 195, 197 and 199 may only be performed by a general practitioner, (see Note 4 of 'Medicare Benefit Arrangements' for a definition) if the Medicare Australia CEO has received a written notice from the Royal Australian College of General Practitioners (RACGP) stating that the person meets the skills requirements for providing services to which the items apply.

Other items in Category 1 of the Schedule should not be itemised for professional attendances when the service "acupuncture" is provided.

For the purpose of payment of Medicare benefits "acupuncture" is interpreted as including treatment by means other than the use of acupuncture needles where the same effect is achieved without puncture, eg by application of ultrasound, laser beams, pressure or moxibustion, etc.

For more information on the content-based item structure used in this Group, see A.5 in the explanatory notes.

AN.0.30 Consultant Psychiatrist - Initial consultations for NEW PATIENTS (Items 296 to 299 and 361) Referred Patient Assessment and Management Plan (Items 291, 293 and 359) and referral to Allied Mental Health Professionals

Referral for items 291, 293 and 359 should be through the general practitioner or participating nurse practitioner for the management of patients with mental illness. In the event that a specialist of another discipline wishes to refer a patient for this item the referral should take place through the GP or participating nurse practitioner.

In order to facilitate ongoing patient focussed management, an outcome tool will be utilised during the assessment and review stage of treatment, where clinically appropriate. The choice of outcome tools to be used is at the clinical discretion of the practitioner, however the following outcome tools are recommended:

- Kessler Psychological Distress Scale (K10)
- Short Form Health Survey (SF12)
- Health of the Nation Outcome Scales (HoNOS)

Preparation of the management plan should be in consultation with the patient. If appropriate, a written copy of the management plan should be provided to the patient. A written copy of the management plan should be provided to the general practitioner within a maximum of two weeks of the assessment. It should be noted that two weeks is the outer limit and in more serious cases more prompt provision of the plan and verbal communication with the GP or participating nurse practitioner may be appropriate. A guide to the content of the report which should be provided to the GP or participating nurse practitioner under this item is included within this Schedule.

It is expected that item 291 will be a single attendance. However, there may be particular circumstances where a patient has been referred by a GP or participating nurse practitioner for an assessment and management plan, but it is not possible for the consultant psychiatrist to determine in the initial consultation whether the patient is suitable for management under such a plan. In these cases, where clinically appropriate, items 296, 297, 299 or 361 (for a new patient) or 300-308 (for continuing patients) may be used, and item 291 may be used subsequently, in those circumstances where the consultant psychiatrist undertakes a consultation (in accordance with the item requirements) prior to the consultation for providing the referring practitioner with an assessment and management plan. It is not intended that items 296, 297, 299, 361 or 300-308 will generally or routinely be used in conjunction with, or prior to, item 291.

Items 293 and 359 are available in instances where the GP or participating nurse practitioner initiates a review of the plan provided under item 291, usually where the current plan is not achieving the anticipated outcome. It is expected that when a plan is reviewed, any modifications necessary will be made.

The Royal Australian and New Zealand College of Psychiatrists (RANZCP) Referred Patient Assessment and Management Plan Guidelines

Note: This information is provided as a guide only and each case should be addressed according to a patient's individual needs. An electronic version of the Guidelines is available on the RANZCP website at www.ranzcp.org

REFERRED PATIENT ASSESSMENT AND MANAGEMENT PLAN

Preliminary

- The following content outline is indicative of what would usually be sent back to GPs or participating nurse practitioner.
- The Management plan should address the specific questions and issues raised by the GP or participating nurse practitioner
- In most cases the patient is usually well known by the GP or participating nurse practitioner

History and Examination

This should focus on the presenting symptoms and current difficulties, including precipitating and ongoing stresses; and only briefly mention any relevant aspects of the patient's family history, developmental history, personality features, past psychiatric history and past medical history.

It should contain a comprehensive relevant Mental Status Examination and any relevant pathology results if performed.

It should summarise any psychological tests that were performed as part of the assessment.

Diagnosis

A diagnosis should be made either using ICD 10 or DSM IV classification. In some cases the diagnosis may differ from that stated by the GP or participating nurse practitioner, and an explanation of why the diagnosis differs should be included.

Psychiatric formulation

A brief integrated psychiatric formulation focussing on the biological, psychological and physical factors. Any precipitant and maintaining factors should be identified including relevant personality factors. Protective factors should also be noted. Issues of risk to the patient or others should be highlighted.

Management plan

- 1. *Education* Include a list of any handout material available to help people understand the nature of the problem. This includes recommending the relevant RANZCP consumer and carer clinical practice guidelines.
- 2. *Medication recommendations* Give recommendations for immediate management including the alternatives or options. This should include doses, expected response times, adverse effects and interactions, and a warning of any contra-indicated therapies.
- 3. *Psychotherapy* Recommendations should be given on the most appropriate mode of psychotherapy required, such as supportive psychotherapy, cognitive and behavioural psychotherapy, family or relationship therapy or intensive explorative psychotherapy. This should include recommendations on who should provide this therapy.
- 4. *Social measures* Identify issues which may have triggered or are contributing to the maintenance of the problem in the family, workplace or other social environment which need to be addressed, including suggestions for addressing them.
- 5. *Other non medication measures* This may include other options such as life style changes including exercise and diet, any rehabilitation recommendations, discussion of any complementary medicines, reading recommendations, relationship with other support services or agencies etc.
- 6. *Indications for re-referral* It is anticipated that the majority of patients will be able to be managed effectively by the GP or participating nurse practitioner using the plan. If there are particular concerns about the possible need for further review, these should be noted.
- 7. **Longer term management -** Provide a longer term management plan listing alternative measures that might be taken in the future if the clinical situation changes. This might be articulated as a relapse signature and relapse drill, and should include drug doses and other indicated interventions, expected response times, adverse effects and interactions.

Initial Consultation for a NEW PATIENT (item 296 in rooms, item 297 at hospital, item 299 for home visits and 361 for telepsychiatry)

The rationale for items 296 - 299 and 361 is to improve access to psychiatric services by encouraging an increase in the number of new patients seen by each psychiatrist, while acknowledging that ongoing care of patients with severe

mental illness is integral to the role of the psychiatrist. Referral for items 296 - 299 and 361 may be from a participating nurse practitioner, medical practitioner practising in general practice, a specialist or another consultant physician.

It is intended that either item 296, 297, 299 or 361 will apply once only for each new patient on the first occasion that the patient is seen by a consultant psychiatrist, **unless** the patient is referred by a medical practitioner practising in general practice or participating nurse practitioner for an assessment and management plan, in which case the consultant psychiatrist, if he or she agrees that the patient is suitable for management in a general practice setting, will use item 291 where an assessment and management plan is provided to the referring practitioner.

There may be particular circumstances where a patient has been referred by a GP or participating nurse practitioner to a consultant psychiatrist for an assessment and management plan, but it is not possible for the consultant psychiatrist to determine in the initial consultation whether the patient is suitable for management under such a plan. In these cases, where clinically appropriate, item 296, 297, 299 or 361(for a new patient) or 300-308 (for continuing patients) may be used and item 291 may be used subsequently, in those circumstances where the consultant psychiatrist undertakes a consultation (in accordance with the item requirements) and provides the referring practitioner with an assessment and management plan. It is not generally intended that item 296, 297, 299 or 361 will be used in conjunction with, or prior to, item 291.

Use of items 296 - 299 and 361 by one consultant psychiatrist does not preclude them being used by another consultant psychiatrist for the same patient.

Items 300 - 308 are available for consultations in consulting rooms other than those provided under item 296, and items 291, 293 and 359. Similarly time tiered items remain available for hospital, home visits and telepsychiatry. These would cover a new course of treatment for patients who have already been seen by the consultant psychiatrist in the preceding 24 months as well as subsequent consultations for all patients.

Referral to Allied Mental Health Professionals (for new and continuing patients)

To increase the clinical treatment options available to psychiatrists and paediatricians for which a Medicare benefit is payable, patients with an assessed mental disorder (dementia, delirium, tobacco use disorder and mental retardation are not regarded as mental disorders for the purposes of these items) may be referred, to an allied mental health professional for a total of ten individual allied mental health services in a calendar year. The ten services may consist of: psychological therapy services (items 80000 to 80015) - provided by eligible clinical psychologists; and/or focussed psychological strategies - allied mental health services (items 80100 to 80115; 80125 to 80140; 80150 to 80165) - provided by eligible psychologists, occupational therapists and social workers.

Referrals from psychiatrists and paediatricians to an allied mental health professional must be made from eligible Medicare services. For specialist psychiatrists and paediatricians these services include any of the specialist attendance items 104 through 109. For consultant physician psychiatrists the relevant eligible Medicare services cover any of the consultant psychiatrist items 293 through 370; while for consultant physician paediatricians the eligible services are consultant physician attendance items 110 through 133.

Within the maximum service allocation of ten services, the allied mental health professional can provide one or more courses of treatment. For the purposes of these services, a course of treatment will consist of the number of services stated in the patient's referral (up to a maximum of six in any one referral). These services should be provided, as required, for an initial course of treatment (a maximum of six services but may be less depending on the referral and patient need) to a maximum of ten services per calendar year.

While such referrals are likely to occur for new patients seen under items 296 - 299 and 361, they are also available for patients at any point in treatment (from items 293 to 370), as clinically required, under the same arrangements and limitations as outlined above. The referral may be in the form of a letter or note to an eligible allied health professional signed and dated by the referring practitioner.

Patients will also be eligible to claim up to ten services within a calendar year for group therapy services involving 6-10 patients to which items 80020 (psychological therapy - clinical psychologist), 80120 (focussed psychological strategies - psychologist), 80145 (focussed psychological strategies - occupational therapist) and 80170 (focussed

psychological strategies - social worker) apply. These group services are separate from the individual services and do not count towards the ten individual services per calendar year maximum associated with those items.

AN.0.31 Psychiatric Attendances (Item 319)

Medicare benefits are attracted under Item 319 only where patients are diagnosed as suffering from:

- severe personality disorder (predominantly from cluster B groupings), or in persons under 18 years of age a severe disruption of personality development; or
- anorexia nervosa; or
- bulimia nervosa; or
- dysthymic disorder; or
- substance-related disorder; or
- somatoform disorder; or
- a pervasive developmental disorder (including autism and Asperger's disorder)

according to the relevant criteria set out in the Diagnostic and Statistical Manual of the American Psychiatric Association - Fourth Edition (DSM-IV).

It is not sufficient for the patient's illness to fall within the diagnostic criteria. It must be evident that a significant level of impairment exists which interferes with the patient's quality of life. For persons 18 years and over, the level of impairment must be within the range 1 to 50 of the Global Assessment of Functioning (GAF) Scale contained in the DSM-IV (ie the patient is displaying at least "serious" symptoms). The GAF score, incorporating the parameters which have led to the score, should be recorded at the time of commencement of the current course of treatment. Once a patient is identified as meeting the criteria of item 319, he/she continues to be eligible under that item for the duration of the current course of treatment (provided that attendances under **items 300 to 308 and 319** do not exceed 160 in a calendar year). Where a patient commences a new course of treatment, the GAF score in relation to item 319 is the patient's score as assessed during the new course of treatment.

In addition to the above diagnostic criteria and level of functional impairment, it is also expected that other appropriate psychiatric treatment has been used for a suitable period and the patient has shown little or no response to such treatment. It is expected that such treatment would include, but not be limited to: shorter term psychotherapy; less frequent but long term psychotherapy; pharmacological therapy; cognitive behaviour therapy.

It is the responsibility of the psychiatrist to ensure that the patient meets these criteria. the Department of Human Services will be closely monitoring the use of item 319.

When a patient who meets the criteria defined in item 319 attends a psychiatrist on more than 160 occasions in a calendar year, such attendances would be covered by items 310 to 318.

The Royal Australian and New Zealand College of Psychiatrists (RANZCP) has undertaken to establish an appropriate mechanism to enable use of item 319 by suitably trained psychiatrists. In the interim it is expected that psychiatrists whose usual practice includes long term intensive treatment of patients whose diagnoses meet the criteria defined in the item will be using item 319.

On the basis of advice from the RANZCP it is expected that it would be generally inappropriate in normal clinical practice for psychiatric treatment performed out of hospital to extend beyond 220 sessions in a calendar year. In this regard, the Department of Human Services will be monitoring providers' practice patterns with a view to the referral of possible cases of inappropriate practice to the Director of Professional Services Review.

AN.0.32 Interview of Person other than a Patient by Consultant Psychiatrist (Items 348, 350, 352)

Items 348 and 350 refer to investigative interviews of a patient's relatives or close associates to determine whether the particular problem with which the patient presented was focused in the patient or in the interaction between the patient and the person being interviewed. These items do not cover counselling of family or friends of the patient. The term "in the course of initial diagnostic evaluation of the patient" should normally be interpreted as extending for up to one month from the date of the initial consultation. There is no strict limit to the number of interviews or persons interviewed in that period. These items should not be used for interviews concerned with the continuing management of the patient.

Item 352 refers to investigative interviews of a patient's relatives or close associates to focus on a particular clinically relevant problem arising in the continuing management of the patient. This item does not cover counselling of family or friends of the patient. The payment of Medicare benefits under this item is limited to four in any twelve month period.

Benefits are payable for Item 348, 350 or 352 and for a consultation with a patient (items 300 - 328) on the same day provided that separate attendances are involved.

For Medicare benefit purposes, charges relating to services covered by items 348, 350 and 352 should be raised against the patient rather than against the person interviewed.

AN.0.33 Consultant Occupational Physician Attendances (Items 385 to 388)

Attendances by consultant occupational physicians will attract Medicare benefits only where the attendance relates to one or more of the following:

- (i) evaluation and assessment of a patient's rehabilitation requirements where the patient presents with an accepted medical condition(s) which may be affected by his/her working environment or employability; or
- (ii) management of accepted medical condition(s) which may affect a patient's capacity for continued employment or return to employment following a <u>non-compensable</u> accident, injury or ill-health; or
- (iii) evaluation and opinion and/or management of a patient's medical condition(s) where causation may be related to acute or chronic exposures from scientifically accepted environmental hazards or toxins.

AN.0.34 Contact Lenses (Items 10801-10809)

Benefits are paid for consultations concerned with the prescription and fitting of contact lenses only if patients fall into specified categories (ie patients with certain conditions). The classes of patients eligible for benefits for contact lens consultations are described in items 10801 to 10809.

Benefits are not payable for item 10809 in circumstances where patients want contact lenses only for:

- (a) reasons of appearance (because they do not want to wear spectacles);
- (b) sporting purposes;
- (c) work purposes; or
- (d) psychological reasons (because they cannot cope with spectacles).

Benefits are payable for an initial referred consultation rendered in association with the fitting and prescribing of the lenses. Subsequent follow-up attendances attract benefits on a consultation basis.

AN.0.35 Refitting of Contact Lenses (Item 10816)

This item covers the refitting of contact lenses where this becomes necessary within the thirty-six month time limit where the patient requires a change in contact lens material or basic lens parameters, other than simple power change, because of a structure or functional change in the eye or an allergic response.

AN.0.36 Health Assessments (Items 701, 703, 705, 707)

There are four time-based health assessment items, consisting of brief, standard, long and prolonged consultations.

Brief Health Assessment (MBS Item 701)

A brief health assessment is used to undertake simple health assessments. The health assessment should take no more than 30 minutes to complete.

Standard Health Assessment (MBS Item 703)

A standard health assessment is used for straightforward assessments where the patient does not present with complex health issues but may require more attention than can be provided in a brief assessment. The assessment lasts more than 30 minutes but takes less than 45 minutes.

Long Health Assessment (MBS Item 705)

A long health assessment is used for an extensive assessment, where the patient has a range of health issues that require more in-depth consideration, and longer-term strategies for managing the patient's health may be necessary. The assessment lasts at least 45 minutes but less than 60 minutes.

Prolonged Health Assessment (MBS Item 707)

A prolonged health assessment is used for a complex assessment of a patient with significant, long-term health needs that need to be managed through a comprehensive preventive health care plan. The assessment takes 60 minutes or more to complete.

General practitioners may select one of the MBS health assessment items to provide a health assessment service to a member of any of the target groups listed in the table below. The health assessment item that is selected will depend on the time taken to complete the health assessment service. This is determined by the complexity of the patient's presentation and the specific requirements that have been established for each target group eligible for health assessments.

MBS Items 701, 703, 705 and 707 may be used to undertake a health assessment for the following target groups:

Target Group	Frequency of Service
A type 2 diabetes risk evaluation for people aged 40-49 years (inclusive) with a high risk of developing type 2 diabetes as determined by the Australian Type 2 Diabetes Risk Assessment Tool	Once every three years to an eligible patient
A health assessment for people aged 45-49 years (inclusive) who are at risk of developing chronic disease	Once only to an eligible patient
A health assessment for people aged 75 years and older	Provided annually to an eligible patient
A comprehensive medical assessment for permanent residents of residential aged care facilities	Provided annually to an eligible patient
A health assessment for people with an intellectual disability	Provided annually to an eligible patient
A health assessment for refugees and other humanitarian entrants	Once only to an eligible patient
A health assessment for former serving members of the Australian Defence Force	Once only to an eligible patient

A health assessment means the assessment of a patient's health and physical, psychological and social function and consideration of whether preventive health care and education should be offered to the patient, to improve that patient's health and physical, psychological and social function.

Health assessments are not available to people who are in-patients of a hospital or care recipients in a residential aged care facility (with the exception of a comprehensive medical assessment provided to a permanent resident of a residential aged care facility).

Before a health assessment is commenced, the patient (and/or his or her parent(s), carer or representative, as appropriate) must be given an explanation of the health assessment process and its likely benefits. The patient must be asked whether he or she consents to the health assessment being performed. In cases where the patient is not capable of giving consent, consent must be given by his or her parent(s), carer or representative. Consent to the health assessment must be noted in the patient's records.

A health assessment must include the following elements:

- a. information collection, including taking a patient history and undertaking or arranging examinations and investigations as required;
- b. making an overall assessment of the patient;
- c. recommending appropriate interventions;
- d. providing advice and information to the patient;
- e. keeping a record of the health assessment, and offering the patient a written report about the health assessment, with recommendations about matters covered by the health assessment; and
- f. offering the patient's carer (if any, and if the general practitioner considers it appropriate and the patient agrees) a copy of the report or extracts of the report relevant to the carer.

A health assessment may only be claimed by a general practitioner.

A health assessment should generally be undertaken by the patient's 'usual doctor'. For the purpose of the health assessment items, 'usual doctor' means the general practitioner, or a general practitioner working in the medical practice, which has provided the majority of primary health care to the patient over the previous twelve months and/or will be providing the majority of care to the patient over the next twelve months.

A health assessment should not take the form of a health screening service.

A copy of the Health Assessment must be retained for a period of 2 years after the date of service.

MBS health assessment items 701, 703, 705, 707 must be provided by a general practitioner personally attending upon a patient. Suitably qualified health professionals, such as practice nurses or Aboriginal and Torres Strait Islander health practitioners, employed and/or otherwise engaged by a general practice or health service, may assist general practitioners in performing health assessments. Such assistance must be provided in accordance with accepted medical practice and under the supervision of the general practitioner. This may include activities associated with:

- information collection; and
- providing patients with information about recommended interventions at the direction of the general practitioner.

The general practitioner should be satisfied that the assisting health professional has the necessary skills, expertise and training to collect the information required for the health assessment.

General practitioners should not conduct a separate consultation for another health-related issue in conjunction with a health assessment unless it is clinically necessary (ie. the patient has an acute problem that needs to be managed separately from the assessment). The only exception is the comprehensive medical assessment, where, if this health assessment is undertaken during the course of a consultation for another purpose, the health assessment item and the relevant item for the other consultation may both be claimed.

Items 701, 703, 705 and 707 do not apply for services that are provided by any other Commonwealth or State funded services. However, where an exemption under subsection 19(2) of the *Health Insurance Act 1973* has been granted to an Aboriginal Community Controlled Health Service or State/Territory Government health clinic, items 701, 703, 705 and 707 can be claimed for services provided by general practitioners salaried by or contracted to, the Service or health clinic. All other requirements of the items must be met.

Item 10990 or 10991 (bulk billing incentives) can be claimed in conjunction with any health assessment, provided the conditions of item 10990 and 10991 are satisfied.

AN.0.37 Health Assessment provided as a type 2 diabetes risk evaluation for people aged 40-49 years with a high risk of developing type 2 diabetes as determined by the Australian Type 2 Diabetes Risk Assessment Tool

Items 701, 703, 705 and 707 may be used to undertake a type 2 diabetes risk evaluation for people aged 40-49 years (inclusive) with a high risk of developing type 2 diabetes, as determined by the Australian Type 2 Diabetes Risk Assessment Tool.

The aim of this health assessment is to review the factors underlying the 'high risk' score identified by the Australian Type 2 Diabetes Risk Assessment Tool to instigate early interventions, such as lifestyle modification programs, to assist with the prevention of type 2 diabetes.

The Australian Type 2 Diabetes Risk Assessment Tool has been developed to provide a basis for both health professionals and health consumers to assess the risk of type 2 diabetes. It consists of a short list of questions which, when completed, provides a guide to a patient's current level of risk of developing type 2 diabetes. The item scores and risk rating calculations in the tool have been developed using demographic, lifestyle, anthropometric and biomedical data from the 2000 Australian Diabetes, Obesity and Lifestyle baseline survey and the AusDiab 2005 follow-up study.

The Australian Type 2 Diabetes Risk Assessment Tool can be obtained from the Department's prevention of diabetes web page.

Clinical risk factors that the general practitioner must consider when providing this health assessment include:

- (a) lifestyle, such as smoking, physical inactivity and poor nutrition;
- (b) biomedical risk factors, such as high blood pressure, impaired glucose metabolism and excess weight;
- (c) any relevant recent diagnostic test results; and
- (d) a family history of chronic disease.

The health assessment must include the following:

- (a) evaluating a patient's high risk score, as determined by the Australian Type 2 Diabetes Risk Assessment Tool which has been completed by the patient within a period of 3 months prior to undertaking the health assessment;
- (b) updating the patient's history and undertaking physical examinations and clinical investigations in accordance with relevant guidelines;
- (c) making an overall assessment of the patient's risk factors and of the results of relevant examinations and investigations;
- (d) initiating interventions, if appropriate, including referral to a lifestyle modification program and follow-up relating to the management of any risk factors identified (further information is available at the Department's prevention of diabetes web page.); and

(e) providing the patient with advice and information (such as the Lifescript resources produced by the Department of Health), including strategies to achieve lifestyle and behaviour changes if appropriate (further information is available at the Department's Lifescript web page).

The completion of the Australian Type 2 Diabetes Risk Assessment Tool is mandatory for patient access to this health assessment. The tool can be completed either by the patient or with the assistance of a health professional or practice staff. Patients with a 'high' score result are eligible for the health assessment, and subsequent referral to the subsidised lifestyle modification programs if appropriate (further information is available at <a href="https://doi.org/10.1001/journal

A health assessment for a type 2 diabetes risk evaluation for people aged 40-49 years with a high risk of developing type 2 diabetes as determined by the Australian Type 2 Diabetes Risk Assessment Tool may only be claimed once every three years by an eligible patient.

AN.0.38 Health Assessment provided for people aged 45-49 years who are at risk of developing chronic disease

Items 701, 703, 705 and 707 may be used to undertake a health assessment for people aged 45-49 years (inclusive) who are at risk of developing chronic disease.

For the purposes of this health assessment, a patient is at risk of developing a chronic disease if, in the clinical judgement of the attending general practitioner, a specific risk factor for chronic disease is identified.

Risk factors that the general practitioner can consider include, but are not limited to:

- (a) lifestyle risk factors, such as smoking, physical inactivity, poor nutrition or alcohol use;
- (b) biomedical risk factors, such as high cholesterol, high blood pressure, impaired glucose metabolism or excess weight; or
- (c) family history of a chronic disease.

A chronic disease or condition is one that has been or is likely to be present for at least six months, including but not limited to asthma, cancer, cardiovascular illness, diabetes mellitus, mental health conditions, arthritis and musculoskeletal conditions.

If, after receiving this health assessment, a patient is identified as having a high risk of type 2 diabetes as determined by the Australian Type 2 Diabetes Risk Assessment Tool, the general practitioner may refer that person to a subsidised lifestyle modification program, along with other possible strategies to improve the health status of the patient (further information is available at http://www.health.gov.au/preventionoftype2diabetes).

The Australian Type 2 Diabetes Risk Assessment Tool can be obtained from http://www.health.gov.au/preventionoftype2diabetes

A health assessment for people aged 45-49 years who are at risk of developing chronic disease may only be claimed once by an eligible patient.

AN.0.39 Health Assessment provided for people aged 75 years and older

Items 701, 703, 705 and 707 may be used to undertake a health assessment for people aged 75 years and older.

A health assessment for people aged 75 years and older is an assessment of a patient's health and physical, psychological and social function for the purpose of initiating preventive health care and/or medical interventions as appropriate.

This health assessment must include:

(a) measurement of the patient's blood pressure, pulse rate and rhythm;

- (b) an assessment of the patient's medication;
- (c) an assessment of the patient's continence;
- (d) an assessment of the patient's immunisation status for influenza, tetanus and pneumococcus;
- (e) an assessment of the patient's physical function, including the patient's activities of daily living, and whether or not the patient has had a fall in the last 3 months;
- (f) an assessment of the patient's psychological function, including the patient's cognition and mood; and
- (g) an assessment of the patient's social function, including the availability and adequacy of paid and unpaid help, and whether the patient is responsible for caring for another person.
- (h) A health assessment for people aged 75 years and older may be claimed once every twelve months by an eligible patient.

AN.0.40 Health Assessment provided as a comprehensive medical assessment for residents of residential aged care facilities

Items 701, 703, 705 and 707 may be used to undertake a comprehensive medical assessment of a resident of a residential aged care facility

This health assessment requires assessment of the resident's health and physical and psychological function, and must include:

- (a) making a written summary of the comprehensive medical assessment;
- (b) developing a list of diagnoses and medical problems based on the medical history and examination;
- (c) providing a copy of the summary to the residential aged care facility; and
- (d) offering the resident a copy of the summary.

A residential aged care facility is a facility in which residential care services, as defined in the *Aged Care Act 1997*, are provided. This includes facilities that were formerly known as nursing homes and hostels. A person is a resident of a residential aged care facility if the person has been admitted as a permanent resident of that facility.

This health assessment is available to new residents on admission into a residential aged care facility. It is recommended that new residents should receive the health assessment as soon as possible after admission, preferably within six weeks following admission into a residential aged care facility.

A health assessment for the purpose of a comprehensive medical assessment of a resident of a residential aged care facility may be claimed by an eligible patient:

- (a) on admission to a residential aged care facility, provided that a comprehensive medical assessment has not already been provided in another residential aged care facility within the previous 12 months; and
- (b) at 12 month intervals thereafter.

AN.0.41 Health Assessment provided for people with an intellectual disability

Items 701, 703, 705 and 707 may be used to undertake a health assessment for people with an intellectual disability.

A person is considered to have an intellectual disability if they have significantly sub-average general intellectual functioning (two standard deviations below the average intelligence quotient [IQ]) and would benefit from assistance with daily living activities. Where general practitioners wish to confirm intellectual disability and a patient's need for assistance with activities of daily living, they may seek verification from a paediatrician registered

to practice in Australia or from a government-provided or funded disability service that has assessed the patient's intellectual function.

The health assessment provides a structured clinical framework for general practitioners to comprehensively assess the physical, psychological and social function of patients with an intellectual disability and to identify any medical intervention and preventive health care required. The health assessment must include the following items as relevant to the patient or his or her representative:

- (a) Check dental health (including dentition);
- (b) Conduct aural examination (arrange formal audiometry if audiometry has not been conducted within 5 years);
- (c) Assess ocular health (arrange review by an ophthalmologist or optometrist if a comprehensive eye examination has not been conducted within 5 years);
- (d) Assess nutritional status (including weight and height measurements) and a review of growth and development;
- (e) Assess bowel and bladder function (particularly for incontinence or chronic constipation);
- (f) Assess medications (including non-prescription medicines taken by the patient, prescriptions from other doctors, medications prescribed but not taken, interactions, side effects and review of indications);
- Advise carers of the common side effects and interactions.
- Consider the need for a formal medication review.
- (g) Check immunisation status, including influenza, tetanus, hepatitis A and B, Measles, Mumps and Rubella (MMR) and pneumococcal vaccinations;
- (h) Check exercise opportunities (with the aim of moderate exercise for at least 30 minutes per day);
- (i) Check whether the support provided for activities of daily living adequately and appropriately meets the patient's needs, and consider formal review if required;
- (j) Consider the need for breast examination, mammography, cervical screening, testicular examination, lipid measurement and prostate assessment as for the general population;
- (k) Check for dysphagia and gastro-oesophageal disease (especially for patients with cerebral palsy), and arrange for investigation or treatment as required;
- (l) Assess risk factors for osteoporosis (including diet, exercise, Vitamin D deficiency, hormonal status, family history, medication fracture history) and arrange for investigation or treatment as required;
- (m) For patients diagnosed with epilepsy, review of seizure control (including anticonvulsant drugs) and consider referral to a neurologist at appropriate intervals;
- (n) Check for thyroid disease at least every two years (or yearly for patients with Down syndrome);
- (o) For patients without a definitive aetiological diagnosis, consider referral to a genetic clinic every 5 years;
- (p) Assess or review treatment for co-morbid mental health issues;
- (q) Consider timing of puberty and management of sexual development, sexual activity and reproductive health; and
- (r) Consider whether there are any signs of physical, psychological or sexual abuse.

A health assessment for people with an intellectual disability may be claimed once every twelve months by an eligible patient.

AN.0.42 Health Assessment provided for refugees and other humanitarian entrants

Items 701, 703, 705 and 707 may be used to undertake a health assessment for refugees and other humanitarian entrants.

The purpose of this health assessment is to introduce new refugees and other humanitarian entrants to the Australian primary health care system, as soon as possible after their arrival in Australia (within twelve months of arrival).

The health assessment applies to humanitarian entrants who are resident in Australia with access to Medicare services. This includes Refugees, Special Humanitarian Program and Protection Program entrants with the following visas:

Offshore Refugee Category including:

- (a) 200 Refugee
- (b) 201 In Country Special Humanitarian
- (c) 203 Emergency rescue
- (d) 204 Women at Risk
- (e) Offshore Special Humanitarian Program
- (f) 202 Global Special Humanitarian

Offshore - Temporary Humanitarian Visas (THV) including:

- (g) Subclass 695 (Return Pending)
- (h) Subclass 070 (Removal Pending Bridging)

Onshore Protection Program including:

- (i) 866 Permanent Protection Visa (PPV)
- (i) 785 Temporary Protection Visa (TPV)

Patients should be asked to provide proof of their visa status and date of arrival in Australia. Alternatively, general practitioners may telephone the Department of Human Services on 132011, with the patient present, to check eligibility.

The general practitioner and patient can use the service of a translator by accessing the Commonwealth Government's Translating and Interpreting Service (TIS) and the Doctors Priority Line. To be eligible for the feefree TIS and Doctors Priority Line, the medical examiner must be in a private practice and provide a Medicare service to patients who do not speak English and are permanent residents.

A health assessment for refugees and other humanitarian entrants may only be claimed once by an eligible patient.

AN.0.43 Health Assessment for Aboriginal and Torres Strait Islander People (MBS Item 715)

This health assessment is available to all people of Aboriginal and Torres Strait Islander descent and should be used for health assessments for the following age categories:

- · An Aboriginal or Torres Strait Islander child who is less than 15 years.
- · An Aboriginal or Torres Strait Islander person who is aged between 15 years and 54 years.
- · An Aboriginal or Torres Strait Islander older person who is aged 55 years and over.

A health assessment means the assessment of a patient's health and physical, psychological and social function and consideration of whether preventive health care and education should be offered to the patient, to improve that patient's health and physical, psychological and social function.

MBS item 715 must include the following elements:

- (a) information collection, including taking a patient history and undertaking examinations and investigations as required;
- (b) making an overall assessment of the patient;
- (c) recommending appropriate interventions;
- (d) providing advice and information to the patient; and
- (e) keeping a record of the health assessment, and offering the patient, and/or patient's carer, a written report about the health assessment with recommendations about matters covered by the health assessment; and
- (f) offering the patient's carer (if any, and if the general practitioner considers it appropriate and the patient agrees) a copy of the report or extracts of the report relevant to the carer.

If, after receiving this health assessment, a patient who is aged fifteen years and over but under the age of 55 years, is identified as having a high risk of developing type 2 diabetes as determined by the Australian Type 2 Diabetes Risk Assessment Tool, the general practitioner may refer that person to a subsidised lifestyle modification program, along with other possible strategies to improve the health status of the patient.

The Australian Type 2 Diabetes Risk Assessment Tool can be obtained from http://www.health.gov.au/preventionoftype2diabetes

A health assessment may only be claimed by a general practitioner.

A health assessment should generally be undertaken by the patient's 'usual doctor'. For the purpose of the health assessment, "usual doctor" means the general practitioner, or a general practitioner working in the medical practice, which has provided the majority of primary health care to the patient over the previous twelve months and/or will be providing the majority of care to the patient over the next twelve months.

The Health Assessment for Aboriginal and Torres Strait Islander People is not available to people who are inpatients of a hospital or care recipients in a residential aged care facility.

A health assessment should not take the form of a health screening service (see General Explanatory Notes G.13.1).

MBS health assessment item 715 must be provided by a general practitioner personally attending upon a patient. Suitably qualified health professionals, such as practice nurses, Aboriginal health workers or Aboriginal and Torres Strait Islander health practitioners employed and/or otherwise engaged by a general practice or health service, may assist general practitioners in performing this health assessment. Such assistance must be provided in accordance with accepted medical practice and under the supervision of the general practitioner. This may include activities associated with:

- information collection: and
- providing patients with information about recommended interventions at the direction of the general practitioner.

The general practitioner should be satisfied that the assisting health professional has the necessary skills, expertise and training to collect the information required for the health assessment.

General practitioners should not conduct a separate consultation in conjunction with a health assessment unless it is clinically necessary (ie. the patient has an acute problem that needs to be managed separately from the assessment).

Item 715 does not apply for services that are provided by any other Commonwealth or State funded services. However, where an exemption under subsection 19(2) of the *Health Insurance Act 1973* has been granted to an Aboriginal Community Controlled Health Service or State/Territory Government health clinic, item 715 can be claimed for services provided by general practitioners salaried by or contracted to, the Service or health clinic. All requirements of the item must be met.

Item 10990 or 10991 (bulk billing incentives) can be claimed in conjunction with any health assessment provided to an Aboriginal and Torres Strait Islander person, provided the conditions of item 10990 and 10991 are satisfied.

The Health Assessment for Aboriginal and Torres Strait Islander People may be provided once every 9 months.

AN.0.44 A Health Assessment for an Aboriginal and Torres Strait Islander child (less than 15 years of age)

An Aboriginal and Torres Strait Islander child health assessment must include:

- a. a personal attendance by a general practitioner;
- b. taking the patient's medical history, including the following:
 - i. mother's pregnancy history;
 - ii. birth and neo-natal history:
 - iii. breastfeeding history;
 - iv. weaning, food access and dietary history;
 - v. physical activity;
 - vi. previous presentations, hospital admissions and medication usage;
 - vii. relevant family medical history;
 - viii. immunisation status;
 - ix. vision and hearing (including neonatal hearing screening);
 - x. development (including achievement of age appropriate milestones);
 - xi. family relationships, social circumstances and whether the person is cared for by another person;
 - xii. exposure to environmental factors (including tobacco smoke);
 - xiii. environmental and living conditions;
 - xiv. educational progress;
 - xv. stressful life events;
 - xvi. mood (including incidence of depression and risk of self-harm);
 - xvii. substance use:
 - xviii. sexual and reproductive health; and
 - xix. dental hygiene (including access to dental services).
- c. examination of the patient, including the following:
 - i. measurement of height and weight to calculate body mass index and position on the growth curve;
 - ii. newborn baby check (if not previously completed);
 - iii. vision (including red reflex in a newborn):
 - iv. ear examination (including otoscopy);
 - v. oral examination (including gums and dentition);
 - vi. trachoma check, if indicated;
 - vii. skin examination, if indicated;
 - viii. respiratory examination, if indicated;
 - ix. cardiac auscultation, if indicated;
 - x. development assessment, if indicated, to determine whether age appropriate milestones have been achieved:
 - xi. assessment of parent and child interaction, if indicated; and
 - xii. other examinations in accordance with national or regional guidelines or specific regional needs, or as indicated by a previous child health assessment.
- d. undertaking or arranging any required investigation, considering the need for the following tests, in particular:
 - i. haemoglobin testing for those at a high risk of anaemia; and
 - ii. audiometry, if required, especially for those of school age

- e. assessing the patient using the information gained in the child health check; and
- f. making or arranging any necessary interventions and referrals, and documenting a simple strategy for the good health of the patient.

AN.0.45 A health assessment for an Aboriginal and Torres Strait Islander adult (aged between 15 years and 54 years)

An Aboriginal and Torres Strait Islander adult health assessment must include:

- a. a personal attendance by a general practitioner;
- b. taking the patient's medical history, including the following:
 - i. current health problems and risk factors;
 - ii. relevant family medical history;
 - iii. medication usage (including medication obtained without prescription or from other doctors);
 - iv. immunisation status, by reference to the appropriate current age and sex immunisation schedule;
 - v. sexual and reproductive health;
 - vi. physical activity, nutrition and alcohol, tobacco or other substance use;
 - vii. hearing loss;
 - viii. mood(including incidence of depression and risk of self-harm); and
 - ix. family relationships and whether the patient is a carer, or is cared for by another person;
 - x. vision
- c. examination of the patient, including the following:
 - i. measurement of the patient's blood pressure, pulse rate and rhythm;
 - ii. measurement of height and weight to calculate body mass index and, if indicated, measurement of waist circumference for central obesity:
 - iii. oral examination (including gums and dentition);
 - iv. ear and hearing examination (including otoscopy and, if indicated, a whisper test); and
 - v. urinalysis (by dipstick) for proteinurea;
 - vi. eye examination; and
- d. undertaking or arranging any required investigation, considering the need for the following tests, in particular, (in accordance with national or regional guidelines or specific regional needs):
 - i. fasting blood sugar and lipids (by laboratory based test on venous sample) or, if necessary, random blood glucose levels;
 - ii. cervical screening;
 - iii. examination for sexually transmitted infection (by urine or endocervical swab for chlamydia and gonorrhoea, especially for those aged from 15 to 35 years); and
 - iv. mammography, if eligible (by scheduling appointments with visiting services or facilitating direct referral).
- e. assessing the patient using the information gained in the adult health assessment; and
- f. making or arranging any necessary interventions and referrals, and documenting a simple strategy for the good health of the patient.

An Aboriginal and Torres Strait Islander Older Person's health assessment must also include:

- a. keeping a record of the health assessment; and
- b. offering the patient a written report on the health assessment, with recommendations on matters covered by the health assessment;

AN.0.46 A health assessment for an Aboriginal and Torres Strait Islander older person (aged 55 years and over)

An Aboriginal and Torres Strait Islander Older Person's health assessment must include:

- a. a personal attendance by the general practitioner;
- b. measurement of the patient's blood pressure, pulse rate and rhythm;
- c. an assessment of the patient's medication;
- d. an assessment of the patient's continence;

- e. an assessment of the patient's immunisation status for influenza, tetanus and pneumococcus;
- f. an assessment of the patient's physical functions, including the patient's activities of daily living and whether or not the patient has had a fall in the last 3months;
- g. an assessment of the patient's psychological function, including the patient's cognition and mood;
- h. an assessment of the patient's social function, including:
 - i. the availability and adequacy of paid, and unpaid, help;
 - ii. whether the patient is responsible for caring for another person;
- i. an eye examination

An Aboriginal and Torres Strait Islander Older Person's health assessment must also include:

- a. keeping a record of the health assessment; and
- b. offering the patient a written report on the health assessment, with
- c. recommendations on matters covered by the health assessment; and
- d. offering the patient's carer (if any, and if the practitioner considers it appropriate and the patient agrees) a copy of the report or extracts of the report relevant to the carer.

AN.0.47 Chronic Disease Management Items (Items 721 to 732)

Description	Item No	Minimum claiming period*
Preparation of a GP Management Plan (GPMP)	721	12 months
Coordination of Team Care Arrangements (TCAs)	723	12 months
Contribution to a Multidisciplinary Care Plan, or to a Review of a Multidisciplinary Care Plan, for a patient who is not a care recipient in a residential aged care facility	729	3 months
Contribution to a Multidisciplinary Care Plan, or to a review of a multidisciplinary care plan, for a resident in an aged care facility	731	3 months
Review of a GP Management Plan or Coordination of a Review of Team Care Arrangements	732	3 months

^{*} CDM services may be provided more frequently in the exceptional circumstances defined below.

Exceptional circumstances exist for a patient if there has been a significant change in the patient's clinical condition or care requirements that necessitates the performance of the service for the patient.

Regulatory requirements

Items 721, 723, 729, 731 and 732 provide rebates to manage chronic or terminal medical conditions by preparing, coordinating, reviewing or contributing to chronic disease management (CDM) plans. They apply for a patient who suffers from at least one medical condition that has been present (or is likely to be present) for at least six months or is terminal.

Restriction of Co-claiming of Chronic Disease and General Consultation Items

Co-claiming of consultation items 3, 4, 23, 24, 36, 37, 44, 47, 52, 53, 54, 57, 58, 59, 60, 65, 585, 588, 591, 594, 599, 600, 5000, 5003, 5020, 5023, 5040, 5043, 5060, 5063, 5200, 5203, 5207, 5208, 5220, 5223, 5227 and 5228 with chronic disease management items 721, 723, or 732 is not permitted for the same patient, on the same day.

Patient eligibility

In addition to the eligibility requirements listed in the individual CDM item descriptors, the General Medical Services Table (GMST) mandates the following eligibility criteria:

CDM items 721, 723 and 732

These are:

- · available to:
 - i. patients in the community; and
 - ii. private in-patients of a hospital (including private in-patients who are residents of aged care facilities) being discharged from hospital.
- · not available to:
 - i. public in-patients of a hospital; or
 - ii. care recipients in a residential aged care facility.

CDM item 729

This is:

- · available to:
 - i. patients in the community;
 - ii. both private and public in-patients being discharged from hospital.
- · not available to care recipients in a residential aged care facility.

CDM item 731

This item is available to care recipients in a residential aged care facility only.

Item 721

A comprehensive written plan must be prepared describing:

- a. the patient's health care needs, health problems and relevant conditions;
- b. management goals with which the patient agrees;
- c. actions to be taken by the patient;
- d. treatment and services the patient is likely to need;
- e. arrangements for providing this treatment and these services; and
- f. arrangements to review the plan by a date specified in the plan.

In preparing the plan, the provider must:

- a. explain to the patient and the patient's carer (if any, and if the practitioner considers it appropriate and the patient agrees) the steps involved in preparing the plan; and
- b. record the plan; and
- c. record the patient's agreement to the preparation of the plan; and
- d. offer a copy of the plan to the patient and the patient's carer (if any, and if the practitioner considers it appropriate and the patient agrees); and
- e. add a copy of the plan to the patient's medical records.

A copy of the written plan must be retained for 2 years.

Item 723

When coordinating the development of Team Care Arrangements (TCAs), the general practitioner must:

- a. consult with at least two collaborating providers, each of whom will provide a different kind of treatment or service to the patient, and one of whom may be another medical practitioner, when making arrangements for the multidisciplinary care of the patient; and
- b. prepare a document that describes:
 - i. treatment and service goals for the patient;
 - ii. treatment and services that collaborating providers will provide to the patient; and
 - iii. actions to be taken by the patient;
 - iv. arrangements to review (i), (ii) and (iii) by a date specified in the document; and
- c. explain the steps involved in the development of the arrangements to the patient and the patient's carer (if any, and if the practitioner considers it appropriate and the patient agrees);
- d. discuss with the patient the collaborating providers who will contribute to the development of the TCAs and provide treatment and services to the patient under those arrangements; and
- e. record the patient's agreement to the development of TCAs;
- f. give copies of the relevant parts of the document to the collaborating providers;
- g. offer a copy of the document to the patient and the patient's carer (if any, and if the practitioner considers it appropriate and the patient agrees); and
- h. add a copy of the document to the patient's medical records.

The document described above must be retained for 2 years.

One of the minimum two service providers collaborating with the GP can be another medical practitioner. The patient's informal or family carer can be included in the collaborative process but does not count towards the minimum of three collaborating providers.

Item 729

A multidisciplinary care plan means a written plan that:

- a. is prepared for a patient by:
 - i. a general practitioner in consultation with two other collaborating providers, each of whom provides a different kind of treatment or service to the patient, and one of whom may be another medical practitioner; or
 - ii. a collaborating provider (other than a general practitioner) in consultation with at least two other collaborating providers, each of whom provides a different kind of treatment or services to the patient; and
- b. describes, at least, treatment and services to be provided to the patient by the collaborating providers.

When contributing to a multidisciplinary care plan or to a review of the care plan, the general practitioner must:

- a. prepare part of the plan or amendments to the plan and add a copy to the patient's medical records; or
- b. give advice to a person who prepares or reviews the plan and record in writing, on the patient's medical records, any advice provided to such a person.

A copy of the written plan must be retained for 2 years.

Item 731

A multidisciplinary care plan in a Residential Aged Care Facility (RACF) means a written plan that:

- a. is prepared for a patient by a collaborating provider (other than a general practitioner, e.g. a RACF), in consultation with at least two other collaborating providers, each of whom provides a different kind of treatment or services to the patient; and
- b. describes, at least, treatment and services to be provided to the patient by the collaborating providers.

When contributing to a multidisciplinary care plan or to a review of the care plan, the general practitioner must:

- a. prepare part of the plan or amendments to the plan and add a copy to the patient's medical records; or
- b. give advice to a person who prepares or reviews the plan and record in writing, on the patient's medical records, any advice provided to such a person.

Item 731 can also be used for contribution to a multidisciplinary care plan prepared for a resident by another provider before the resident is discharged from a hospital or an approved day-hospital facility, or to a review of such a plan prepared by another provider (not being a service associated with a service to which items 735 to 758 apply).

Item 732

An "associated general practitioner" is a general practitioner who, if not engaged in the same general practice as the general practitioner mentioned in that item, performs the service mentioned in the item at the request of the patient (or the patient's guardian).

When reviewing a GP Management Plan, the general practitioner must:

- a. explain to the patient and the patient's carer (if any, and if the general practitioner considers it appropriate and the patient agrees) the steps involved in the review;
- b. record the patient's agreement to the review of the plan;
- c. review all the matters set out in the relevant plan;
- d. make any required amendments to the patient's plan;
- e. offer a copy of the amended document to the patient and the patient's carer (if any, and if the general practitioner considers it appropriate and the patient agrees);
- f. add a copy of the amended document to the patient's records; and
- g. provide for further review of the amended plan by a date specified in the plan.

When coordinating a review of Team Care Arrangements, a multidisciplinary community care plan or a multidisciplinary discharge care plan, the general practitioner must:

- a. explain the steps involved in the review to the patient and the patient's carer (if any, and if the general practitioner considers it appropriate and the patient agrees);
- b. record the patient's agreement to the review of the TCAs or plan;
- c. consult with at least two health or care providers (each of whom provides a service or treatment to the patient that is different from each other and different from the service or treatment provided by the general practitioner who is coordinating the TCAs or plan) to review all the matters set out in the relevant plan;
- d. make any required amendments to the patient's plan;
- e. offer a copy of the amended document to the patient and the patient's carer (if any, and if the general practitioner considers it appropriate and the patient agrees);
- f. provide for further review of the amended plan by a date specified in the plan;
- g. give copies of the relevant parts of the amended plan to the collaborating providers; and
- h. add a copy of the amended document to the patient's records.

A copy of the amended plan must be retained for 2 years.

Item 732 can also be used to COORDINATE A REVIEW OF a Multidisciplinary Community Care Plan (former item 720) or to COORDINATE REVIEW OF A Discharge Care Plan (former item 722), where these services were coordinated or prepared by that general practitioner (or an associated general practitioner), and not being a service associated with a service to which items 735-758 apply.

Claiming of benefits

Each service to which item 732 applies (i.e. Review of a GP Management Plan and Review of Team Care Arrangements) may be claimed once in a three-month period, except where there are exceptional circumstances arising from a significant change in the patient's clinical condition or care circumstances that necessitates earlier performance of the service for the patient.

Where a service is provided in exceptional circumstances, the patient's invoice or Medicare voucher should be annotated to indicate the reason why the service was required earlier than the minimum time interval for the relevant item. Payment can then be made.

Item 732 can be claimed twice on the same day providing an item 732 for reviewing a GP Management Plan and another 732 for reviewing Team Care Arrangements (TCAs) are both delivered on the same day as per the MBS item descriptors and explanatory notes.

Medicare requirements when item 732 is claimed twice on the same day

If a GPMP and TCAs are both reviewed on the same date and item 732 is to be claimed twice on the same day, both electronic claims and manual claims need to indicate they were rendered at different times:

Non electronic Medicare claiming of items 732 on the same date

The time that each item 732 commenced should be indicated next to each item

Electronic Medicare claiming of item 732 on the same date

Medicare Easyclaim: use the 'ItemOverrideCde" set to 'AP', which flags the item as *not duplicate services Medicare Online/ECLIPSE*: set the 'DuplicateServiceOverrideIND' to 'Y', which flags the item as *not duplicate*

Items 721, 723 and 732

The GP Management Plan items (721 and 732) and the Team Care Arrangement items (723 and 732) can not be claimed by general practitioners when they are a recognised specialist in the specialty of palliative medicine and treating a referred palliative care patient under items 3005-3093. The referring practitioner is able to provide the CDM services.

Additional information

Advice on the items and further guidance are available at: www.health.gov.au/mbsprimarycareitems

Items 721-732 should generally be undertaken by the patient's **usual general practitioner**. The patient's "usual GP" means the GP, or a GP working in the medical practice, who has provided the majority of care to the patient over the previous twelve months and/or will be providing the majority of GP services to the patient over the next twelve months. The term "usual GP" would not generally apply to a practice that provides only one specific CDM service.

A practice nurse, Aboriginal and Torres Strait Islander health practitioner, Aboriginal health worker or other health professional may assist a GP with items 721, 723, and 732 (e.g. in patient assessment, identification of patient needs and making arrangements for services). However, the GP must meet all regulatory requirements, review and confirm all assessments and see the patient.

Patients being managed under the chronic disease management items may be eligible for:

- · individual allied health services (items 10950 to 10970); and/or
- · group allied health services (items 81100 to 81125).

More information on eligibility requirements can be found in the explanatory note for individual allied health services and group allied health services.

Further information is also available for providers from the Department of Human Services provider inquiry line on 132 150.

The Department of Human Services (DHS) has developed two guidelines, the <u>Health Practitioner Guideline to</u> substantiate the preparation of a valid GP Management Plan (for medical practitioners) and the <u>Health Practitioner Guideline to substantiate the coordination of the development of Team Care Arrangements (for medical practitioners)</u> which are both located on the DHS website.

AN.0.48 Medicare Dental Items For Patients With Chronic Conditions And Complex Care Needs - Services Provided By A Dental Practitioner On Referral From A GP [Items 85011-87777] Closure of Medicare Dental Items 85011-87777

The Medicare Chronic Disease Dental Scheme closed on 30 November 2012. No Medicare benefits will be payable for any dental services provided under Medicare dental items 85011-87777 provided after this date. The cost of any future dental services will need to be met by the patient.

Further details regarding the closure are available at www.health.gov.au/dental.

AN.0.49 Multidisciplinary Case Conferences by General Practitioners - (Items 735 to 758)

Items 735 to 758 provide rebates for general practitioners to organise and coordinate, or participate in, multidisciplinary case conferences for patients in the community or patients being discharged into the community from hospital or people living in residential aged care facilities.

REGULATORY REQUIREMENTS

To organise and coordinate case conference items 735, 739 and 743, the provider must:

- (a) explain to the patient the nature of a multidisciplinary case conference, and ask the patient for their agreement to the conference taking place; and
- (b) record the patient's agreement to the conference; and
- (c) record the day on which the conference was held, and the times at which the conference started and ended; and
- (d) record the names of the participants; and
- (e) offer the patient and the patient's carer (if any, and if the practitioner considers it appropriate and the patient agrees) a summary of the conference and provide this summary to other team members; and
- (f) discuss the outcomes of the conference with the patient and the patient's carer (if any, and if the practitioner considers it appropriate and the patient agrees); and
- (g) record all matters discussed and identified by the case conferencing team and put a copy of that record in the patient's medical records.

To participate in multidisciplinary case conference items 747, 750 and 758, the provider must:

- (a) explain to the patient the nature of a multidisciplinary case conference, and ask the patient whether they agree to the general practitioner's participation in the conference; and
- (b) record the patient's agreement to the general practitioner's participation; and
- (c) record the day on which the conference was held, and the times at which the conference started and ended; and
- (d) record the names of the participants; and
- (e) record all matters discussed and identified by the case conferencing team and put a copy of that record in the patient's medical records.

ADDITIONAL INFORMATION

Usual general practitioner

Items 735-758 should generally be undertaken by the patient's usual general practitioner. This is a general practitioner, or a general practitioner working in the medical practice, that has provided the majority of services to

the patient over the previous 12 months and/or will be providing the majority of services to the patient over the coming 12 months.

Multidisciplinary case conference team members

Examples of persons who, for the purposes of care planning and case conferencing may be included in a multidisciplinary care team are allied health professionals such as, but not limited to: Aboriginal health care workers; asthma educators; audiologists; dental therapists; dentists; diabetes educators; dietitians; mental health workers; occupational therapists; optometrists; orthoptists; orthotists or prosthetists; pharmacists; physiotherapists; podiatrists; psychologists; registered nurses; social workers; speech pathologists.

A team may also include home and community service providers, or care organisers, such as: education providers; "meals on wheels" providers; personal care workers (workers who are paid to provide care services); probation officers.

The patient's informal or family carer may be included as a formal member of the team in addition to the minimum of three health or care providers. The patient and the informal or family carer do not count towards the minimum of three.

Discharge case conference

Organisation and coordination of a multidisciplinary discharge case conference (items 735, 739 and 743) may be provided for private in-patients being discharged into the community from hospital.

Further sources of information

Advice on the items and further guidance are available at: www.health.gov.au/mbsprimarycareitems

Further information is also available for providers from the Department of Human Services provider inquiry line on 132 150.

AN.0.50 Public Health Medicine - (Items 410 to 417)

Attendances by public health physicians will attract Medicare benefits under the new items only where the attendance relates to one or more of the following: -

- (i) management of a patient's vaccination requirements for accepted immunisation programs; or
- (ii) prevention or management of sexually transmitted disease; or
- (iii) prevention or management of disease due to environmental hazards or poisons; or
- (iv) prevention or management of exotic diseases; or
- (v) prevention or management of infection during outbreaks of infectious disease.

For more information on the content-based item structure used in this Group, see A.5 in the explanatory notes.

AN.0.51 Case Conferences by Consultant Physician - (Items 820 to 838, 6029 to 6034 and 6064 to 6075)

Items 820, 822, 823, 825, 826, 828, 6029, 6031, 6032, 6034, 6064, 6065, 6067, 6068, 6035, 6037, 6038, 6042, 6071, 6072, 6074 and 6075 apply to a community case conference (including a case conference conducted in a residential aged care facility) organised to discuss one patient in detail and applies only to a service in relation to a patient who suffers from at least one medical condition that has been (or is likely to be) present for at least 6 months, or that is terminal, and has complex needs requiring care from a multidisciplinary team. Items 820, 822, 823, 825, 826 and 828 do not apply to an in-patient of a hospital.

For items 830, 832, 834, 835, 837 and 838, a discharge case conference is a case conference carried out in relation to a patient before the patient is discharged from a hospital. Items 830, 832, 834, 835, 837 and 838 are payable not more than once for each hospital admission.

The purpose of a case conference is to establish and coordinate the management of the care needs of the patient.

A case conference is a process by which a multidisciplinary team carries out the following activities:

- -discusses a patient's history;
- -identifies the patient's multidisciplinary care needs;
- identifies outcomes to be achieved by members of the case conference team giving care and service to the patient;
- -identifies tasks that need to be undertaken to achieve these outcomes, and allocating those tasks to members of the case conference team; and
- -assesses whether previously identified outcomes (if any) have been achieved.

For the purposes of items 820, 822, 823, 830, 832, 834, 6029, 6031, 6032, 6034, 6064, 6065, 6067 and 6068 (that is, where a consultant physician organises a case conference) a multidisciplinary team requires the involvement of a minimum of four formal care providers from different disciplines. The consultant physician is counted toward the minimum of four. Although they may attend the case conference, neither the patient nor his or her informal carer, or any other medical practitioner (except where the medical practitioner is the patient's usual General Practitioner) can be counted toward the minimum of four.

For the purposes of items 825, 826, 828, 835, 837, 838, 6035, 6037, 6038, 6042, 6071, 6072, 6074 and 6075 (that is, where a consultant physician participates in a case conference) a multidisciplinary team requires the involvement of a minimum of three formal care providers from different disciplines. The consultant physician is counted toward the minimum of three. Although they may attend the case conference, neither the patient nor his or her informal carer, or any other medical practitioner (except where the medical practitioner is the patient's usual General Practitioner) can be counted toward the minimum of three.

For the purposes of items 820, 822, 823, 830, 832, 834, 6029, 6031, 6032, 6034, 6064, 6065, 6067 and 6068 (that is, where a consultant physician organises a case conference), and items 825, 826, 828, 835, 837, 838, 6035, 6037, 6038, 6042, 6071, 6072, 6074 and 6075 (that is, where a consultant physician participates in a case conference) "formal care providers" includes:

- -the patient's usual General Practitioner;
- -allied health professionals, being: registered nurse, physiotherapist, occupational therapist, podiatrist, speech pathologist, pharmacist; dietician; psychologist; orthoptist; orthotist and prosthetist, optometrist; audiologist, social worker, Aboriginal and Torres Strait Islander health practitioner, Aboriginal health worker, mental health worker, asthma educator, diabetes educator, dental therapist, dentist; and
- -community service providers being: personal care worker, home and community care service provider, meals on wheels provider, education provider and probation officer.

Organisation of a case conference

For items 820, 822, 823, 830, 832, 834, 6029, 6031, 6032, 6034, 6064, 6065, 6067 and 6068, organise and coordinate a community case conference means undertaking the following activities in relation to a case conference:

- (a) explaining to the patient or the patient's agent the nature of a case conference, and asking the patient or the patient's agent whether he or she agrees to the case conference taking place; and
- (b) recording the patient's or agent's agreement to the case conference; and

- (c)recording the day on which the conference was held, and the times at which the conference started and ended; and
- (d)recording the names of the participants; and
- (e)putting a copy of that record in the patient's medical records; and
- (f) giving the patient or the patient's agent, and each other member of the team a summary of the conference; and
- (h)giving a copy of the summary of the conference to the patient's usual general practitioner; and
- (i) discussing the outcomes of the patient or the patient's agent.

Organisation of a discharge case conference (items 830, 832 and 834), may be provided for private in-patients only, and must be organised by the medical practitioner who is providing in-patient care.

Participation in a case conference

For items 825, 826, 828, 835, 837, 838, 6035, 6037, 6038, 6042, 6071, 6072, 6074, 6075. participation in a case conference must be at the request of the person who organises and coordinates the case conference and includes undertaking the following activities when participating in a case conference:

- (a)recording the day on which the conference was held, and the times at which the conference started and ended; and
- (b) recording the matters mentioned in **Organisation of a case conference**in so far as they relate to the medical practitioner's participation in the case conference, and putting a copy of that record in the patient's medical records.

See Health Insurance (General Medical Services Table) Regulation, Division 2.21.

General requirements

The case conference must be arranged in advance, within a time frame that allows for all the participants to attend. The minimum of three care providers for participating in a case conference or four care providers for organising a case conference must be present for the whole of the case conference. All participants must be in communication with each other throughout the conference, either face to face, by telephone or by video link, or a combination of these.

A record of the case conference which contains: a list of the participants; the times the conference commenced and concluded; a description of the problems, goals and strategies; and a summary of the outcomes must be kept in the patient's record. The notes and summary of outcomes must be provided to all participants and to the patient's usual general practitioner.

Prior informed consent must be obtained from the patient, or the patient's agent. In obtaining informed consent the consultant physician should:

- -Inform the patient that his or her medical history, diagnosis and care preferences will be discussed with other case conference participants;
- Provide an opportunity for the patient to specify what medical and personal information he or she wants to be conveyed to, or withheld from, the other care providers;
- -Inform the patient that he or she will incur a charge for the service for which a Medicare rebate will be payable.

Medicare benefits are only payable in respect of the service provided by the coordinating consultant physician or the participating consultant physician. Benefits are not payable for another medical practitioner organising a case

conference or for participation by other medical practitioners at a case conference, except where a medical practitioner organises or participates in a case conference in accordance with Items 734 to 779.

The benefit is not claimable (and an account should not be rendered) until all components of these items have been provided. See point G.7.1 of the General Explanatory Notes for further details on billing procedures.

It is expected that a patient would not normally require more than 5 case conferences in a 12 month period.

This item does not preclude the claiming of a consultation on the same day if other clinically relevant services are provided.

AN.0.52 Medication Management Reviews - (Items 900 and 903) Item 900 - Domiciliary Medication Management Review

A Domiciliary Medication Management Review (DMMR) (Item 900), also known as Home Medicines Review, is intended to maximise an individual patient's benefit from their medication regimen, and prevent medication-related problems through a team approach, involving the patient's GP and preferred community pharmacy or accredited pharmacist.

Patient eligibility

The item is available to people living in the community who meet the criteria for a DMMR.

The item is not available for in-patients of a hospital, or care recipients in residential aged care facilities.

DMMRs are targeted at patients who are likely to benefit from such a review: patients for whom quality use of medicines may be an issue or; patients who are at risk of medication misadventure because of factors such as their co-morbidities, age or social circumstances, the characteristics of their medicines, the complexity of their medication treatment regimen, or a lack of knowledge and skills to use medicines to their best effect.

DMMR's are targeted at patients who are:

- · currently taking five or more regular medications;
- · taking more than 12 doses of medication per day;
- · have had significant changes made to medication treatment regimen in the last three months;
- taking medication with a narrow therapeutic index or medications requiring therapeutic monitoring;
- · experiencing symptoms suggestive of an adverse drug reaction;
- · displaying sub-optimal response to treatment with medicines;
- · suspected of non-compliance or inability to manage medication related therapeutic devices;
- · having difficulty managing their own medicines because of literacy or language difficulties, dexterity problems or impaired sight, confusion/dementia or other cognitive difficulties;
- · attending a number of different doctors, both general practitioners and specialists; and/or
- · recently discharged from a facility / hospital (in the last four weeks).

In referring a patient for a DMMR, general practitioners should note that only patients meeting the following criteria will have the pharmacist portion funded through a Community Pharmacy Agreement program:

· Is a Medicare and/or Department of Veterans' Affairs (DVA) cardholder or a person who is eligible for a Medicare card;

- · Is subject to a chronic condition and/or complex medication regimen; and
- · Is failing to respond to treatment in the expected manner.

If the patient does not meet these criteria, the general practitioner can still issue a referral under this item. However, the remainder of the service will be on a "user pays" basis as determined by the accredited pharmacist.

REGULATORY REQUIREMENTS

In conducting a DMMR, a general practitioner must, with the patient's consent:

- (a) assess a patient is subject to a chronic medical condition and/or complex medication regimen but their therapeutic goals are not being met; and
- (b) following that assessment, refer the patient to a community pharmacy or an accredited pharmacist for a DMMR and provide the relevant clinical information required for the review; and
- (c) discuss with the reviewing pharmacist the result of that review including suggested medication management strategies; and
- (d) develop a written medication management plan following discussion with the patient; and
- (e) provide the written medication management plan to a community pharmacy chosen by the patient.

For any particular patient - applicable not more than once in each 12 month period, except if there has been a significant change in the patient's condition or medication regimen requiring a new DMMR.

Claiming

A DMMR includes all DMMR-related services provided by the general practitioner from the time the patient is identified as potentially needing a medication management review to the preparation of a draft medication management plan, and discussion and agreement with the patient.

The benefit is not claimable until all the components of the item have been rendered.

Benefits for a DMMR service under item 900 are payable only once in each 12 month period, except where there has been a significant change in the patient's condition or medication regimen requiring a new DMMR (e.g. diagnosis of a new condition or recent discharge from hospital involving significant changes in medication). In such cases the patient's invoice or Medicare voucher should be annotated to indicate that the DMMR service was required to be provided within 12 months of another DMMR service.

Provision of a subsequent DMMR must not be made solely by reaching an anniversary date, and the service is not intended to be undertaken on an ongoing review cycle.

If the DMMR is initiated during the course of a consultation undertaken for another purpose, this consultation may also be claimed separately.

If the consultation at which the medication management review is initiated is only for the purposes of initiating the review, only item 900 may be claimed.

If the general practitioner determines that a DMMR is not necessary, item 900 does not apply. In this case, normal consultation items should be used.

Where a DMMR cannot be completed due to circumstances beyond the control of the general practitioner (e.g. because the patient decides to not proceed further with the DMMR, or because of a change in the circumstances of the patient), the relevant MBS attendance items should be used.

FURTHER GUIDANCE

A DMMR should generally be undertaken by the patient's usual general practitioner. This is the general practitioner, or a general practitioner working in the medical practice, that has provided the majority of services to the patient over the previous 12 months and/or will be providing the majority of services to the patient over the coming 12 months.

The potential need for a DMMR may be identified either by the general practitioner in the process of a consultation or by receipt of advice from the patient, a carer or another health professional including a pharmacist.

The process of referral to a community pharmacy or an accredited pharmacist includes:

- · Obtaining consent from the patient, consistent with normal clinical practice, for a pharmacist to undertake the medication management review and for a charge to be incurred for the service for which a Medicare rebate is payable. The patient must be clearly informed of the purpose and possible outcomes of the DMMR, the process involved (including that the pharmacist will visit the patient at home, unless exceptional circumstances apply or they are an Aboriginal or Torres Strait Islander patient), what information will be provided to the pharmacist as part of the DMMR, and any additional costs that may be incurred; and
- · Provision to the patient's preferred community pharmacy or accredited pharmacist, of relevant clinical information, by the general practitioner for each individual patient, covering the patient's diagnosis, relevant test results and medication history, and current prescribed medications.
- · A DMMR referral form is available for this purpose. If this form is not used, the general practitioner must provide patient details and relevant clinical information to the patient's preferred community pharmacy or accredited pharmacist.

The discussion of the review findings and report including suggested medication management strategies with the reviewing pharmacist includes:

- · Receiving a written report from the reviewing pharmacist; and
- \cdot Discussing the relevant findings and suggested management strategies with the pharmacist (either by phone or face to face); and
- · Developing a summary of the relevant review findings as part of the draft medication management plan.

Development of a written medication management plan following discussion with the patient includes:

- · Developing a draft medication management plan and discussing this with the patient; and
- · Once agreed, offering a copy of the written medication management plan to the patient and providing a copy to the community pharmacy or accredited pharmacist.

The agreed plan should identify the medication management goals and the proposed medication regimen for the patient.

Item 903 - Residential Medication Management Review

A Residential Medication Management Review (RMMR) is a collaborative service available to permanent residents of a Residential Aged Care facility (RACF) who are likely to benefit from such a review. This includes residents for whom quality use of medicines may be an issue or residents who are at risk of medication misadventure because of a significant change in their condition or medication regimen.

Patient eligibility

RMMRs are available to:

new residents on admission into a RACF; and

existing residents on an 'as required' basis, where in the opinion of the resident's general practitioner, it is required because of a significant change in medical condition or medication regimen.

RMMRs are not available to people receiving respite care in a RACF. Domiciliary Medicines Reviews are available to these people when they are living in the community setting.

REGULATORY REQUIREMENTS

When conducting a RMMR, a GP must:

- (a) discuss the proposed review with the resident and seek the resident's consent to the review; and
- (b) collaborate with the reviewing pharmacist about the pharmacist's involvement in the review; and
- (c) provide input from the resident's most recent comprehensive medical assessment or, if such an assessment has not been undertaken, provide relevant clinical information for the review and for the resident's records; and
- (d) If recommended changes to the resident's medication management arise out of the review, participate in a post-review discussion (either face-to-face or by telephone) with the pharmacist to discuss the outcomes of the review including:
- (i) the findings; and
- (ii) medication management strategies; and
- (iii) means to ensure that the strategies are implemented and reviewed, including any issues for implementation and follow-up; and
- (iv) develop or revise the resident's medication management plan after discussion with the reviewing pharmacist; and
- (v) finalise the plan after discussion with the resident.

A general practitioner's involvement in a residential medication management review also includes:

- (a) offering a copy of the medication management plan to the resident (or the resident's carer or representative if appropriate); and
- (b) providing copies of the plan for the resident's records and for the nursing staff of the residential aged care facility; and
- (c) discussing the plan with nursing staff if necessary.

A post-review discussion is not required if:

- (a) there are no recommended changes to the resident's medication management arising out of the review; or
- (b) any changes are minor in nature and do not require immediate discussion; or
- (c) the pharmacist and general practitioner agree that issues arising out of the review should be considered in a case conference.

A RMMR comprises all activities to be undertaken by the general practitioner from the time the resident is identified as potentially needing a medication management review up to the development of a written medication management plan for the resident.

Claiming

A maximum of one RMMR rebate is payable for each resident in any 12 month period, except where there has been a significant change in the resident's medical condition or medication regimen requiring a new RMMR.

Benefits are payable when all the activities of a RMMR have been completed. A RMMR service covers the consultation at which the results of the medication management review are discussed and the medication management plan agreed with the resident:

- · any immediate action required to be done at the time of completing the RMMR, based on and as a direct result of information gathered in the RMMR, should be treated as part of the RMMR item;
- · any subsequent follow up should be treated as a separate consultation item;
- · an additional consultation in conjunction with completing the RMMR should not be undertaken unless it is clinically indicated that a problem must be treated immediately.

In some cases a RMMR may not be able to be completed due to circumstances beyond the control of the general practitioner (e.g. because the resident decides not to proceed with the RMMR or because of a change in the circumstances of the resident). In these cases the relevant MBS attendance item should be used in relation to any consultation undertaken with the resident.

If the consultation at which the RMMR is initiated, including discussion with resident and obtaining consent for the RMMR, is only for the purposes of initiating the review, only the RMMR item should be claimed.

If the RMMR is initiated during the course of a consultation undertaken for another purpose, the other consultation may be claimed as a separate service and the RMMR service would also apply.

If the general practitioner determines that an RMMR is not necessary, the RMMR item does not apply. In this case, relevant consultation items should be used.

FURTHER GUIDANCE

A RMMR should generally be undertaken by the resident's 'usual GP'. This is the general practitioner, or a general practitioner working in the medical practice, that has provided the majority of care to the resident over the previous 12 months and/or will be providing the majority of care to the resident over the next 12 months.

GPs who provide services on a facility-wide contract basis, and/or who are registered to provide services to RACFs as part of aged care panel arrangements, may also undertake RMMRs for residents as part of their services.

Generally, new residents should receive an RMMR as soon as possible after admission. Where a resident has a Comprehensive Medical Assessment (CMA), the RMMR should be undertaken preferably after the results of the CMA are available to inform the RMMR.

A RMMR service should be completed within a reasonable time-frame. As a general guide, it is expected that most RMMR services would be completed within four weeks of being initiated.

The resident's general practitioner may identify the potential need for an 'as required' RMMR for existing residents, including in the course of a consultation for another purpose. The potential need for an RMMR may also be identified by the reviewing pharmacist, supply pharmacist, Residential Aged Care Facility staff, the resident, the resident's carer or other members of the resident's health care team.

The general practitioner should assess the clinical need for an RMMR from a quality use of medicines perspective with the resident as the focus, and initiate an RMMR if appropriate, in collaboration with the reviewing pharmacist.

The general practitioner and reviewing pharmacist should agree on a preferred means for communicating issues and information relating to the provision of an RMMR service. This should include the method(s) of initiating the RMMR, exceptions to the post review discussion, and the preferred method of communication. This can be done on a facility basis rather than on a case-by-case basis.

Where the provision of RMMR services involves consultation with a resident it should be read as including consultation with the resident and/or their carer or representative where appropriate.

RMMRs do not count for the purposes of derived fee arrangements that apply to other consultations in a Residential Aged Care Facility.

Related Items: 900 903

AN.0.53 Taking a Cervical Screen from a Person who is Unscreened or Significantly Underscreened - (Items 2497 - 2509 and 2598 - 2616)

The item numbers 2497, 2501, 2503, 2504, 2506, 2507, 2509, 2598, 2600, 2603, 2606, 2610, 2613 and 2616 should be used in place of the usual attendance item where as part of a consultation, a sample for cervical screening is collected from a person between the ages of 24 years and 9 months and 74 years inclusive who has not had a cervical smear in the last four years. Cervical Screening in accordance with the National Cervical Screening Policy at P.16.11.

Self collection of a sample for screening is only available for women between the ages of 30 and 74 years of age who are overdue for screening by two or more years (i.e. being 4 years since their last Pap test). Self collection should only be offered to an eligible person who refuses to have a sample collected by their requesting practitioner.

When providing this service, the doctor must satisfy themselves that the person has not had a cervical screening test in the last four years by:

- (a) asking the person if they can remember having a cervical screening test in the last four years;
- (b) checking their own practice's medical records; and
- (c) checking the National Cancer Screening Register.

A person from the following groups are more likely than the general population to be unscreened or significantly underscreened - low socioeconomic status, culturally and linguistically diverse backgrounds, Indigenous communities, rural and remote areas and older people.

Vault smears are not eligible for items 2497 - 2509 and 2598 - 2616.

In addition to attracting a Medicare rebate, the use of these items will initiate a Cervical Screening SIP through the PIP.

A PIP Cervical Screening SIP is available for taking a cervical screen from a person who has not been screened in the last for four years. The SIP will be paid to the medical practitioner who provided the service if the service was provided in a general practice participating in the PIP Cervical Screening Incentive. A further PIP Cervical Screening Incentive payment is paid to practices which reach target levels of cervical screening for their patients aged 24 years and 9 months of age to 74 years inclusive. More detailed information on the PIP Cervical Screening Incentive is available from the Department of Human Services PIP enquiry line on 1800 222 032 or from the Department of Human Services website.

AN.0.54 Completion of the Annual Diabetes Cycle of Care for Patients with Established Diabetes Mellitus - (Items 2517 - 2526 and 2620 - 2635)

The item numbers 2517, 2518, 2521, 2522, 2525, 2526, and 2620, 2622, 2624, 2631, 2633, 2635, should be used in place of the usual attendance item when a consultation completes the minimum requirements of the annual Diabetes Cycle of Care for a patient with established diabetes mellitus.

The annual Diabetes Cycle of Care must be completed over a period of 11 months and up to 13 months, and at a minimum must include:

Assess diabetes control by measuring HbA1c	At least once every year
Ensure that a comprehensive eye examination is carried out*	At least once every two years
Measure weight and height and calculate BMI**	At least twice every cycle of care
Measure blood pressure	At least twice every cycle of care
Examine feet***	At least twice every cycle of care
Measure total cholesterol, triglycerides and HDL cholesterol	At least once every year
Test for microalbuminuria	At least once every year
Test for estimated Glomerular Filtration Rate (eGFR)	At least once every year
Provide self-care education	Patient education regarding diabetes management
Review diet	Reinforce information about appropriate dietary choices
Review levels of physical activity	Reinforce information about appropriate levels of physical activity
Check smoking status	Encourage cessation of smoking (if relevant)
Review of Medication	Medication review

- * Not required if the patient is blind or does not have both eyes.
- ** Initial visit: measure height and weight and calculate BMI as part of the initial assessment.

Subsequent visits: measure weight.

*** Not required if the patient does not have both feet.

These requirements are generally based on the current general practice guidelines produced by Diabetes Australia and the Royal Australian College of General Practitioners (Diabetes Management in General Practice). Doctors using these items should familiarise themselves with these guidelines and with subsequent editions of these guidelines as they become available.

Use of these items certifies that the minimum requirements of the Diabetes Cycle of Care have been completed for a patient with established diabetes mellitus in accordance with the guidelines above.

These items should only be used once per cycle per patient of either A18 Subgroup 2 or A19 Subgroup 2. For example, if item 2517 is claimed for a patient then no other diabetes item in groups A18 or A19 can be used for this patient in the same cycle.

The requirements for claiming these items are the minimum needed to provide good care for a patient with diabetes. Additional levels of care will be needed by insulin-dependent patients and those with abnormal review findings, complications and/or co-morbidities.

In addition to attracting a Medicare rebate, recording a completion of a Diabetes Cycle of Care through the use of these items will initiate a Diabetes Service Incentive Payment (SIP) through the Practice Incentives Program (PIP).

All visits should be billed under the normal attendance items with the exception of the visit that completes all of the minimum requirements of the Diabetes Cycle of Care.

A PIP Diabetes SIP is available for completing the minimum requirements of the Diabetes Cycle of Care for individual patients as specified above. The Diabetes SIP is only paid once every 11-13 month period per patient. The SIP will be paid to the medical practitioner who provided the service if the service was provided in a general practice participating in the PIP Diabetes Incentive. A further PIP Diabetes Incentive payment is paid to practices

which reach target levels of care for their patients with diabetes mellitus. More detailed information on the PIP Diabetes Incentive is available from the Department of Human Services PIP enquiry line on 1800 222 032 or the Department of Human Services website.

AN.0.55 Completion of the Asthma Cycle of Care - (Items 2546 - 2559 and 2664 - 2677)

The item numbers 2546, 2547, 2552, 2553, 2558, 2559 and 2664, 2666, 2668, 2673, 2675 and 2677 should be used in place of the usual attendance item when a consultation completes the minimum requirements of the Asthma Cycle of Care. The Practice Incentives Program (PIP) Asthma Incentive is for patients with moderate to severe asthma who in the opinion of the doctor could benefit from review, eg those whose asthma management could be improved.

At a minimum the Asthma Cycle of Care must include:

- At least 2 asthma related consultations within 12 months for a patient with moderate to severe asthma (at least 1 of which (the review consultation) is a consultation that was planned at a previous consultation),
- Documented diagnosis and assessment of level of asthma control and severity of asthma,
- Review of the patient's use of and access to asthma-related medication and devices,
- Provision to the patient of a written asthma action plan (if the patient is unable to use a written asthma action plan discussion with the patient about an alternative method of providing an asthma action plan, and documentation of the discussion in the patient's medical records),
- Provision of asthma self-management education to the patient, and
- Review of the written or documented asthma action plan.

The Asthma Cycle of Care should be provided to a patient by one GP or in exceptional circumstances by another GP within the same practice. In most cases, this will be the patient's usual medical practitioner. Completion of the Asthma Cycle of Care does not preclude referral to a specialist, but a specialist consultation cannot be counted as one of the two visits.

The patient's medical record should include documentation of each of these requirements and the clinical content of the patient-held written asthma action plan.

These items will only be payable for the completion of one Asthma Cycle of Care for each eligible patient per 12 month period, unless a further Asthma Cycle of Care is clinically indicated by exceptional circumstances.

If a subsequent Asthma Cycle of Care is indicated and the incentive item is to be claimed more than once per 12 month period for a patient, then the patient's invoice or Medicare voucher should be annotated to indicate that the Asthma Cycle of Care was required to be provided within 12 months of another Asthma Cycle of Care.

The minimum requirements of the Asthma Cycle of Care may be carried out in two (2) visits or if necessary as many visits as clinically required. The National Asthma Council's website provides a guide for completion of the Asthma Cycle of Care.

The visit that completes the Asthma Cycle of Care should be billed using the appropriate item listed in Group A18 Subgroup 3 and Group A19 Subgroup 3.

In addition to attracting a Medicare rebate, recording a completion of an Asthma Cycle of Care through the use of these items, will initiate an Asthma Service Incentive Payment (SIP) through the PIP.

All visits should be billed under the normal attendance items with the exception of the visit that completes all of the minimum requirements of the Asthma Cycle of Care.

A PIP Asthma SIP is available for completing the minimum requirements of the Asthma Cycle of Care for individual patients as specified above. The SIP will be paid to the medical practitioner who provided the service if the service was provided in a general practice participating in the PIP Asthma Incentive. More detailed information on the PIP Asthma Incentive is available from the Department of Human Services PIP enquiry line on 1800222032 or from the Department of Human Services website.

For more detailed information regarding asthma diagnosis, assessment and best practice management refer to the National Asthma Council's website.

Assessment of Severity

Generally, patients who meet the following criteria can be assumed to have been assessed as having moderate to severe asthma:

- Symptoms on most days, OR
- Use of preventer medication, OR
- Bronchodilator use at least 3 times per week, OR
- Hospital attendance or admission following an acute exacerbation of asthma.

Where the general rule does not apply to a particular patient, the classification of severity described by the current edition of the National Asthma Council's *Asthma Management Handbook* can be used. Visit the <u>National Asthma Council's website</u> for more details.

AN.0.56 GP Mental Health Treatment Items - (Items 2700 to 2717)

This note provides information on the GP Mental Health Treatment items 2700, 2701, 2712, 2713, 2715 and 2717. It includes an overview of the items, patient and provider eligibility, what activities are involved in providing services rebated by these items, links to other Medicare items and additional claiming information.

Overview

The GP Mental Health Treatment items define services for which Medicare rebates are payable where GPs undertake early intervention, assessment and management of patients with mental disorders. They include referral pathways for treatment by psychiatrists, clinical psychologists and other allied mental health workers. These items complement the mental health items for psychiatrists (items 296 - 299), clinical psychologists (items 80000 - 80021) and allied mental health providers (items 80100 - 80171).

The GP Mental Health Treatment items incorporate a model for best practice primary health treatment of patients with mental disorders, including patients with both chronic or non-chronic disorders, that comprises:

- · assess and plan;
- · provide and/or refer for appropriate treatment and services;
- · review and ongoing management as required.

Who can provide

The GP Mental Health Treatment Plan, Review and Consultation items are available for use in general practice by general practitioner. The term 'GP' is used in these notes as a generic reference to general practitioners able to claim these items.

Training Requirements (item 2715 and 2717)

GPs providing Mental Health Treatment Plans, and who have undertaken mental health skills training recognised through the General Practice Mental Health Standards Collaboration, have access to items 2715 and 2717. For GPs who have not undertaken training, items 2700 and 2701 are available. Items 2715 provides for a Mental Health Treatment Plan lasting at least 20 minutes and item 2717 provides for a Mental Health Treatment Plan lasting at least 40 minutes. It is strongly recommended that GPs providing mental health treatment have appropriate mental health training. GP organisations support the value of appropriate mental health training for GPs using these items.

What patients are eligible - Mental Disorder

These items are for patients with a mental disorder who would benefit from a structured approach to the management of their treatment needs. Mental disorder is a term used to describe a range of clinically diagnosable disorders that significantly interfere with an individual's cognitive, emotional or social abilities (Refer to the World Health Organisation, 1996, Diagnostic and Management Guidelines for Mental Disorders in Primary Care: ICD-10 Chapter V Primary Care Version). Dementia, delirium, tobacco use disorder and mental retardation are not regarded as mental disorders for the purposes of the GP Mental Health Treatment items.

These GP services are available to eligible patients in the community. GP Mental Health Treatment Plan and Review services can also be provided to private in-patients (including private in-patients who are residents of aged care facilities) being discharged from hospital. Where the GP who provides the GP Mental Health Treatment item is providing in-patient treatment the item is claimed as an in-hospital service (at 75% MBS rebate). GPs are able to contribute to care plans for patients using item 729, Contribution to a Multidisciplinary Care Plan, and to care plans for residents of aged care facilities using item 731.

PREPARING A GP MENTAL HEALTH TREATMENT PLAN - (Item 2700, 2701, 2715 or 2717)

What is involved - Assess and Plan

A rebate can be claimed once the GP has undertaken an assessment and prepared a GP Mental Health Treatment Plan by completing the steps from Assessment to the point where patients do not require a new plan after their initial plan has been prepared, and meeting the relevant requirements listed under 'Additional Claiming Information'. This item covers both the assessment and preparation of the GP Mental Health Treatment Plan. Where the patient has a carer, the general practitioner may find it useful to consider having the carer present for the assessment and preparation of the GP Mental Health Treatment Plan or components thereof (subject to patient agreement).

Assessment

An assessment of a patient must include:

- · recording the patient's agreement for the GP Mental Health Treatment Plan service;
- taking relevant history (biological, psychological, social) including the presenting complaint;
- · conducting a mental state examination;
- · assessing associated risk and any co-morbidity;
- · making a diagnosis and/or formulation; and
- administering an outcome measurement tool, except where it is considered clinically inappropriate.

The assessment can be part of the same consultation in which the GP Mental Health Treatment Plan is developed, or can be undertaken in different visits. Where separate visits are undertaken for the purpose of assessing the patient and developing the GP Mental Health Treatment Plan, they are part of the GP Mental Health Treatment Plan service and are included in item 2700, 2701, 2715 or 2717.

In order to facilitate ongoing patient focussed management, an outcome measurement tool should be utilised during the assessment and the review of the GP Mental Health Treatment Plan, except where it is considered clinically inappropriate. The choice of outcome measurement tools to be used is at the clinical discretion of the practitioner. GPs using such tools should be familiar with their appropriate clinical use, and if not, should seek appropriate education and training.

Preparation of a GP Mental Health Treatment Plan

In addition to assessment of the patient, preparation of a GP Mental Health Treatment Plan must include:

- · discussing the assessment with the patient, including the mental health formulation and diagnosis or provisional diagnosis;
- · identifying and discussing referral and treatment options with the patient, including appropriate support services;
- agreeing goals with the patient what should be achieved by the treatment and any actions the patient will take;
- · provision of psycho-education;
- · a plan for crisis intervention and/or for relapse prevention, if appropriate at this stage;
- · making arrangements for required referrals, treatment, appropriate support services, review and follow-up; and
- · documenting this (results of assessment, patient needs, goals and actions, referrals and required treatment/services, and review date) in the patient's GP Mental Health Treatment Plan.

Treatment options can include referral to a psychiatrist; referral to a clinical psychologist for psychological therapies, or to an appropriately trained GP or allied mental health professional for provision of focussed psychological strategy services; pharmacological treatments; and coordination with community support and rehabilitation agencies, mental health services and other health professionals.

Once a GP Mental Health Treatment Plan has been completed and claimed on Medicare either through item 2700, 2701, 2715 or 2717 a patient is eligible to be referred for up to 10 Medicare rebateable allied mental health services per calendar year for psychological therapy or focussed psychological strategy services. Patients will also be eligible to claim up to 10 separate services for the provision of group therapy (either as part of psychological therapy or focussed psychological strategies).

When referring patients GPs should provide similar information as per normal GP referral arrangements. This could include providing a copy of the patient's GP Mental Health Treatment Plan, where appropriate and with the patient's agreement. The necessary referrals should be made after the steps above have been addressed and the patient's GP Mental Health Treatment Plan has been completed. It should be noted that the patient's mental health treatment plan should be treated as a living document for updating as required. In particular, the plan can be updated at any time to incorporate relevant information, such as feedback or advice from other health professionals on the diagnosis or treatment of the patient.

On completion of a course of treatment provided through Medicare rebateable services, the service provider must provide a written report on the course of treatment to the GP. For the purposes of the Medicare rebateable allied mental health items, a course of treatment will consist of the number of services stated on the patient's referral (up to a maximum of six in any one referral). There may be two or more courses of treatment within a patient's entitlement of up to 10 services per calendar year. The number of services that the patient is being referred for is at the discretion of the referring practitioner (eg. GP).

Many patients will not require a new plan after their initial plan has been prepared. A new plan should not be prepared unless clinically required, and generally not within 12 months of a previous plan. Ongoing management can be provided through the GP Mental Health Treatment Consultation and standard consultation items, as required, and reviews of progress through the GP Mental Health Treatment Plan Review item. A rebate for preparation of a GP Mental Health Treatment Plan will not be paid within 12 months of a previous claim for the patient for the same

or another Mental Health Treatment Plan item or within three months following a claim for a GP Mental Health Treatment Review (item 2712 or former item 2719).

REVIEWING A GP MENTAL HEALTH TREATMENT PLAN - (Item 2712)

The review item is a key component for assessing and managing the patient's progress once a GP Mental Health Treatment Plan has been prepared, along with ongoing management through the GP Mental Health Treatment Consultation item and/or standard consultation items. A patient's GP Mental Health Treatment Plan should be reviewed at least once.

A rebate can be claimed once the GP who prepared the patient's GP Mental Health Treatment Plan (or another GP in the same practice or in another practice where the patient has changed practices) has undertaken a systematic review of the patient's progress against the GP Mental Health Treatment Plan by completing the activities that must be included in a review and meeting the relevant requirements listed under 'Additional Claiming Information'. The review item can also be used where a psychiatrist has prepared a referred assessment and management plan (item 291), as if that patient had a GP Mental Health Treatment Plan. The review service must include a personal attendance by the GP with the patient.

The review must include:

- · recording the patient's agreement for this service;
- · a review of the patient's progress against the goals outlined in the GP Mental Health Treatment Plan;
- · modification of the documented GP Mental Health Treatment Plan if required;
- · checking, reinforcing and expanding education;
- · a plan for crisis intervention and/or for relapse prevention, if appropriate and if not previously provided; and
- \cdot re-administration of the outcome measurement tool used in the assessment stage, except where considered clinically inappropriate.

Note: This review is a formal review point only and it is expected that in most cases there will be other consultations between the patient and the GP as part of ongoing management.

The recommended frequency for the review service, allowing for variation in patients' needs, is:

- · an initial review, which should occur between four weeks to six months after the completion of a GP Mental Health Treatment Plan; and
- · if required, a further review can occur three months after the first review.

In general, most patients should not require more than two reviews in a 12 month period, with ongoing management through the GP Mental Health Treatment Consultation and standard consultation items, as required.

A rebate will not be paid within three months of a previous claim for the same item/s or within four weeks following a claim for a GP Mental Health Treatment Plan item.

GP MENTAL HEALTH TREATMENT CONSULTATION - (Item 2713)

The GP Mental Health Treatment Consultation item is for an extended consultation with a patient where the primary treating problem is related to a mental disorder, including for a patient being managed under a GP Mental Health Treatment Plan. This item may be used for ongoing management of a patient with a mental disorder. This item should not be used for the development of a GP Mental Health Treatment Plan.

A GP Mental Health Treatment Consultation must include:

- taking relevant history and identifying the patient's presenting problem(s) (if not previously documented);
- · providing treatment, advice and/or referral for other services or treatment; and
- · documenting the outcomes of the consultation in the patient's medical records and other relevant mental health plan (where applicable).

A patient may be referred from a GP Mental Health Treatment Consultation for other treatment and services as per normal GP referral arrangements. This does not include referral for Medicare rebateable services for focussed psychological strategy services, clinical psychology or other allied mental health services, unless the patient is being managed by the GP under a GP Mental Health Treatment Plan or under a referred psychiatrist assessment and management plan (item 291).

Consultations associated with this item must be at least 20 minutes duration.

REFERRAL

Once a GP Mental Health Treatment Plan has been completed and claimed on Medicare, or a GP is managing a patient under a referred psychiatrist assessment and management plan (item 291), a patient is eligible for up to 10 Medicare rebateable allied mental health services per calendar year for services by:

- · clinical psychologists providing psychological therapies; or
- · appropriately trained GPs or allied mental health professionals providing focussed psychological strategy (FPS) services.

In addition to the above services, patients will also be eligible to claim up to 10 separate services for the provision of group therapy.

When referring patients, GPs should provide similar information as per normal GP referral arrangements, and specifically consider including both a statement identifying that a GP Mental Health Treatment Plan has been completed for the patient (including, where appropriate and with the patient's agreement, attaching a copy of the patient's GP Mental Health Treatment Plan) and clearly identifying the specific number of sessions the patient is being referred for. Referrals for patients with either a GP Mental Health Treatment Plan or referred psychiatrist assessment and management plan (item 291) should be provided, as required, for an initial course of treatment (a maximum of six services in any one referral but may be less depending on the referral and the patient's clinical need). There may be two or more courses of treatment within a patient's entitlement of up to 10 services per calendar year. The GP should consider the patient's clinical need for further sessions after the initial referral. This can be done using a GP Mental Health Treatment Plan Review, a GP Mental Health Treatment Consultation or a standard consultation item.

In the instance where a patient has received the 10 psychological therapy services (items 80000 to 80021), focussed psychological services-allied mental health services (items 80100 to 80171) or GP focussed psychological strategies services (items 2721 to 2727) available under the Better Access to Psychiatrists, Psychologists and General Practitioners through the Medicare Benefits Schedule initiative per calendar year and is considered to clinically benefit from some additional services, the patient may be eligible for Primary Health Networks (PHNs) funded psychological therapies if they meet relevant eligibility criteria for the PHN commissioned services. It is recommended that providers refer to their PHN for further guidance.

ADDITIONAL CLAIMING INFORMATION

Before proceeding with any GP Mental Health Treatment Plan or Review service the GP must ensure that:

(a) the steps involved in providing the service are explained to the patient and (if appropriate and with the patient's permission) to the patient's carer; and

(b) the patient's agreement to proceed is recorded.

Before completing any GP Mental Health Treatment Plan or Review service and claiming a benefit for that service, the GP must offer the patient a copy of the treatment plan or reviewed treatment plan and add the document to the patient's records. This should include, subject to the patient's agreement, offering a copy to their carer, where appropriate. The GP may, with the permission of the patient, provide a copy of the GP Mental Health Treatment Plan, or relevant parts of the plan, to other providers involved in the patient's treatment.

The GP Mental Health Treatment Plan, Review and Consultation items cover the consultations at which the relevant items are undertaken, noting that:

- · if a GP Mental Health Treatment item is undertaken or initiated during the course of a consultation for another purpose, the GP Mental Health Treatment Plan, Review or Consultation item and the relevant item for the other consultation may both be claimed;
- · if a GP Mental Health Treatment Plan is developed over more than one consultation, and those consultations are for the purposes of developing the plan, only the GP Mental Health Treatment Plan item should be claimed; and
- · if a consultation is for the purpose of a GP Mental Health Treatment Plan, Review or Consultation item, a separate and additional consultation should not be undertaken in conjunction with the mental health consultation, unless it is clinically indicated that a separate problem must be treated immediately.

Where separate consultations are undertaken in conjunction with mental health consultations, the patient's invoice or Medicare voucher (assignment of benefit form) for the separate consultation should be annotated (e.g. separate consultation clinically required/indicated).

A benefit is not claimable and an account should not be rendered until all components of the relevant item have been provided.

All consultations conducted as part of the GP Mental Health Treatment items must be rendered by the GP and include a personal attendance with the patient. A specialist mental health nurse, other allied health practitioner, Aboriginal and Torres Strait Islander health practitioner or Aboriginal Health Worker with appropriate mental health qualifications and training may provide general assistance to GPs in provision of mental health care.

Links to other Medicare Services

It is preferable that wherever possible patients have only one plan for primary care management of their mental disorder. As a general principle the creation of multiple plans should be avoided, unless the patient clearly requires an additional plan for the management of a separate medical condition.

The Chronic Disease Management (CDM) care plan items (items 721, 723, 729, 731 and 732) continue to be available for patients with chronic medical conditions, including patients with complex needs.

- · Where a patient has a mental health condition only, it is anticipated that they will be managed under the new GP Mental Health Treatment items.
- · Where a patient has a separate chronic medical condition, it may be appropriate to manage the patient's medical condition through a GP Management Plan, and to manage their mental health condition through a GP Mental Health Treatment Plan. In this case, both items can be used.
- · Where a patient has a mental health condition as well as significant co-morbidities and complex needs requiring team-based care, the GP is able to use both the CDM items (for team-based care) and the GP Mental Health Treatment items.

The Department of Human Services (DHS) has developed a **Health Practitioner Guideline to substantiate the preparation of a valid GP Mental Health treatment Plan** which is located on the DHS website.

AN.0.57 Provision of Focussed Psychological Strategies - (Items 2721 to 2731)

Focussed psychological strategies are specific mental health care management strategies, derived from evidence based psychological therapies that have been shown to integrate the best research evidence of clinical effectiveness with general practice clinical expertise. The decision to recommend Focussed Psychological Strategies to a patient must be made either in the context of a GP Mental Health Treatment Plan, shared care plan or a psychiatrist assessment and management plan.

Minimum Requirements

All consultations providing Focussed Psychological Strategies must be rendered by a medical practitioner (including a general practitioner, but not including a specialist or consultant physician).

To ensure appropriate standards for the provision of Focussed Psychological Strategies, payment of Medicare rebates for these items will be limited to medical practitioners who are registered with the Department of Human Services as having satisfied the requirements for higher level mental health skills for provision of the service, as determined by the General Practice Mental Health Standards Collaboration.

Continued access to item numbers 2721 - 2731 will be dependent on the practitioner meeting the ongoing mental health education requirements as determined by the General Practice Mental Health Standards Collaboration.

Patients will be permitted to claim Medicare rebates for up to 10 allied mental health services under these item numbers per calendar year. The 10 services may consist of: GP focussed psychological strategies services (items 2721 to 2731 or non-specialist medical practitioner items 283 to 287, 371 and 372); and/or psychological therapy services (items 80000 to 80015); and/or focussed psychological strategies – allied mental health services (items 80100 to 80115; 80125 to 80140; 80150 to 80165).

Out-of-Surgery Consultation

It is expected that this service would be provided only for patients who are unable to attend the practice.

Telehealth Consultation

A **telehealth eligible area** means an area that is a Modified Monash 4 area, Modified Monash 5 area, Modified Monash 6 area or Modified Monash 7 area.

Specific Modified Monash locations can be looked up at **DoctorConnect**

Specific Focussed Psychological Strategies

A range of acceptable strategies has been approved for use by medical practitioners in this context. These are:

1. Psycho-education

(including motivational interviewing)

2. Cognitive-behavioural therapy including:

- · Behavioural interventions
- Behaviour modification
- Exposure techniques
- Activity scheduling
- · Cognitive interventions
- Cognitive therapy

3. Relaxation strategies

- Progressive muscle relaxation
- Controlled breathing
- 4. Skills training
- Problem solving skills and training
- Anger management
- Social skills training
- Communication training

- Stress management
- Parent management training
- 5. Interpersonal therapy

Mental Disorder

A mental disorder may be defined as a significant impairment of an individual's cognitive, affective and/or relational abilities which may require intervention and may be a recognised, medically diagnosable illness or disorder – this definition is informed by the World Health Organisation, 1996, Diagnostic and Management Guidelines for Mental Disorders in Primary Care:ICD - 10 Chapter V Primary Health Care Version.

Dementia, delirium, tobacco use disorder and mental retardation are not regarded as mental disorders for the purposes of these items.

AN.0.58 Pain and Palliative Medicine (Items 2801 to 3093)

Attendance by a recognised specialist or consultant physician in the specialty of pain medicine (2801, 2806, 2814, 2824, 2832, 2840) and Case conference by a recognised specialist or consultant physician in the specialty of pain medicine (2946, 2949, 2954, 2958, 2972, 2974, 2978, 2984, 2988, 2992, 2996, 3000).

Items 2801, 2806, 2814, 2824, 2832, 2840, 2946, 2949, 2954, 2958, 2972, 2974, 2978, 2984, 2988, 2992, 2996, 3000, apply only to a service provided by a recognised specialist or consultant physician in the specialty of pain medicine, in relation to a pain patient referred from another practitioner (see Paragraph 6 of the General Explanatory notes).

The conditions that apply to the Case Conferences items (2946, 2949, 2954, 2958, 2972, 2974, 2978, 2984, 2988, 2992, 2996, 3000) are the same as those for the Case Conferences by consultant physicians (Items 820 to 838). See explanatory note A.25 for details of these conditions.

Where the service provided to a referred patient is by a medical practitioner who is a recognised specialist or consultant physician in the specialty of pain medicine and that service is pain medicine, then the relevant items from the pain specialist group (2801, 2806, 2814, 2824, 2832, 2840, 2946, 2949, 2954, 2958, 2972, 2974, 2978, 2984, 2988, 2992, 2996, 3000) must be claimed. Services to patients who are not receiving pain medicine services should be claimed using the relevant attendance or case conferencing items.

Attendance by a recognised specialist or consultant physician in the specialty of palliative medicine (3005, 3010, 3014, 3018, 3023, 3028) and Case conference by a recognised specialist or consultant physician in the specialty of palliative medicine (3032, 3040, 3044, 3051, 3055, 3062, 3069, 3074, 3078, 3083, 3088, 3093).

Items 3005, 3010, 3014, 3018, 3023, 3028, 3032, 3040, 3044, 3051, 3055, 3062, 3069, 3074, 3078, 3083, 3088, 3093, apply only to a service provided by a recognised specialist or consultant physician in the specialty of palliative medicine, in relation to a palliative patient referred from another practitioner (see Paragraph 6 of the General Explanatory notes).

General Practitioners who are recognised specialist in the specialty of palliative medicine and are treating a referred palliative patient and claiming items 3005, 3010, 3014, 3018, 3023, 3028, 3032, 3040, 3044, 3051, 3055, 3062, 3069, 3074, 3078, 3083, 3088, 3093 cannot access the GP Management Plan items (721 and 732) or Team Care Arrangement items (723 and 732) for that patient. The referring practitioner is able to provide these services.

The conditions that apply to the Case Conferences items (3032, 3040, 3044, 3051, 3055, 3062, 3069, 3074, 3078, 3083, 3088, 3093) are the same as those for the Case Conferences by consultant physicians (Items 820 to 838). See explanatory note A.25 for details of these conditions.

Where the service provided to a referred patient is by a medical practitioner who is a recognised specialist or consultant physician in the specialty of palliative medicine and that service is a palliative medicine service, then the relevant items from the palliative specialist group 3005, 3010, 3014, 3018, 3023, 3028, 3032, 3040, 3044, 3051, 3055, 3062, 3069, 3074, 3078, 3083, 3088, 3093) must be claimed. Services to patients who are not receiving palliative care services should be claimed using the relevant attendance or case conferencing items.

AN.0.59 Telepsychiatry - (Items 353 to 370)

Telepsychiatry is defined as electronic transmission of psychiatric consultations, advice or services in digital form from one location to another using a data communication link provided by a third party carrier, or carriers. It requires the providers to comply with the International Telecommunications Union Standards which cover all types of videoconferencing from massive bandwidth to internet use. If X-rays are required for a psychiatric consultation then the consultant psychiatrist must comply with the DICOM Standards.

Support and Resourcing

The Royal Australian and New Zealand College of Psychiatrists encourages best practice in telepsychiatry and to this end has developed a Telepsychiatry Position Statement. To obtain a copy of this document and/or further information, assistance and support, practitioners are able to contact the College by email cpd@ranzcp.org or by visiting www.ranzcp.org.

Duration of Telepsychiatry Consultation

For items 353 to 358 the **time** provides a range of options equal to those provided in items 300 to 308 to allow for the appropriate treatment depending on the requirements of the treatment plan.

Number of Consultations in a Calendar Year

Items 353 to 358 may only be claimed for up to a maximum of 12 consultations in aggregate for each patient in a calendar year. Items 364 to 370 are to be claimed where face-to-face consultations are clinically indicated. Items 364 to 370 must be used to ensure that Medicare payments continue for further telepsychiatry consultations.

If the number of attendances in aggregate to which items 296 to 299, 300 to 308, 353 to 358 and 361 to 370 apply exceeds 50 for a single patient in any calendar year, any further attendances on that patient in that calendar year would be covered by items 310 to 318.

Documenting the Telepsychiatry Session

For items 353 to 370 the psychiatrist must keep a record of the treatment provided during an episode of care via telepsychiatry sessions or face-to-face consultations and must convey this in writing to the referring practitioner after the first session and then, at a minimum, after every six consultations.

Geographical

Telepsychiatry items 353 to 361 are available for use when a referred patient is located in a regional, rural or remote area. A regional, rural or remote area is classified as a RRMA 3-7 area under the Rural Remote Metropolitan Areas classification system.

Referred Patient Assessment and Management Plan review (Item 359)

Referral for item 359 should be through the GP or participating nurse practitioner for the management of patients with mental illness. In the event that a specialist of another discipline wishes to refer a patient for this item the referral should take place through the GP or participating nurse practitioner. Item 359 is available in instances where the GP or participating nurse practitioner initiates a review of the management plan provided under item 291, usually where the current plan is not achieving the anticipated outcome. It is expected that when a plan is reviewed, any modifications necessary will be made.

The Royal Australian and New Zealand College of Psychiatrists (RANZCP) Referred Patient Assessment and Management Plan Guidelines` (Note: An electronic version of the Guidelines is available on the RANZCP website at www.ranzcp.org)

Initial Consultations for NEW PATIENTS (Item 361)

The rationale for item 361 is to improve access to psychiatric services by encouraging an increase in the number of new patients seen by each psychiatrist, while acknowledging that ongoing care of patients with severe mental illness

is integral to the role of the psychiatrist. Referral for item 361 may be from a participating nurse practitioner, medical practitioner practising in general practice, a specialist or another consultant physician. It is intended that item 361 will apply once only for each new patient on the first occasion that the patient is seen by a consultant psychiatrist. It is not generally intended that item 361 will be used in conjunction with, or prior to, item 291.

The use of items 361 and 296-299 by one consultant psychiatrist does not preclude them being used by another consultant psychiatrist for the same patient.

AN.0.60 Attendances by Medical Practitioners who are Emergency Physicians - (Items 501 to 536) Items 501 to 536 relate specifically to attendances rendered by medical practitioners who are holders of the Fellowship of the Australasian College for Emergency Medicine (FACEM) and who participate in, and meet the requirements for, quality assurance and maintenance of professional standards by the ACEM.

Items 501 to 511 cover five categories of attendance based largely on the tasks undertaken in a recognised emergency medicine department of a private hospital by the practitioner during the attendance on the patient rather than simply on the time spent with the patient. The emergency department must be part of a hospital and this department must be licensed as an "emergency department" by the appropriate State government authority.

The attendances for items 501 to 515 are divided into five categories relating to the level of complexity, namely:

- (i) Level 1
- (ii) Level 2
- (iii) Level 3
- (iv) Level 4
- (v) Level 5

To assist medical practitioners who are emergency physicians in selecting the appropriate item number for Medicare benefit purposes the following notes in respect of the various levels are given.

LEVEL 1

This item is for the obvious and straightforward cases and the practitioner's records would reflect this. In this context "limited examination", means examination of the affected part if required, and management of the action taken.

LEVEL 2

The description of this item introduces the words "expanded problem focussed history" and "formulation and documentation of a diagnosis and management plan in relation to one or more problems". In this context an "expanded problem focussed history" means a history relating to a specific problem or condition; and "formulation and documentation of a management plan" includes formulation of the decision or plan of management and any immediate action necessary such as advising or counselling the patient, ordering tests, or referring the patient to a specialist medical practitioner or other allied health professional. The essential difference between Levels 1 and 2 relate not to time but to complexity.

LEVEL 3

Further levels of complexity are implied in these terms by the introduction of "medical decision making of moderate complexity".

LEVEL 4

This item covers more difficult problems requiring the taking of a "detailed history" and "detailed examination of one or more systems", with or without liaison with other health care professionals and subsequent discussion with the patient, his or her agent and/or relatives.

LEVEL 5

This item covers the difficult problems where the diagnosis is elusive and highly complex, requiring consideration of several possible differential diagnoses, and the making of decisions about the most appropriate investigations and the order in which they are performed. These items also cover cases which need prolonged discussion. It involves the taking of a comprehensive history, comprehensive examination and involving medical decision making of high complexity.

In relation to the time in recording appropriate details of the service, only clinical details recorded at the time of the attendance count towards the time of consultation. It does not include information added at a later time, such as reports of investigations.

AN.0.61 Prolonged Attendance by an Emergency Physician in Treatment of a Critical Condition - (Items 519 to 536)

The conditions to be met before services covered by items 519 to 536 attract benefits are:

- (i) the patient must be in imminent danger of death;
- (ii) the times relate to the total time spent with a single patient, even if the time spent by the physician is not continuous.

AN.0.62 Case Conferences by Consultant Psychiatrists - (Items 855 to 866)

A range of new items has been introduced for case conferences by consultant psychiatrists in community settings and for discharge planning for hospital in-patients. These items are introduced to improve the effectiveness of psychiatric case conferences and make it easier for psychiatrists to work with general practitioners and allied health professionals, thereby ensuring better coordinated care for patients. Three new items (855, 857 and 858) cover the organisation of a community case conference and a further three (861, 864 and 866) cover the organisation of a discharge case conference. Where a consultant psychiatrist organises a case conference a multidisciplinary team requires the involvement of a minimum of three formal care providers from different disciplines. The consultant psychiatrist and one other medical practitioner (other than a specialist or a consultant physician) are counted towards the minimum of three.

Items 855, 857, and 858 apply to a community case conference (including a case conference conducted in a residential aged care facility) organised to discuss one patient in detail and applies only to a service in relation to a patient who suffers from at least one medical condition that has been (or is likely to be) present for at least 6 months, or that is terminal. Items 855, 857, and 858 do not apply to an in-patient of a hospital.

For items 861, 864 and 866 a discharge case conference is a case conference carried out in relation to a patient before the patient is discharged from a hospital. Items 861, 864 or 866 are payable not more than once for each hospital admission.

The purpose of a case conference is to establish and coordinate the management of the care needs of the patient.

A case conference is a process by which a multidisciplinary team carries out the following activities:

- discusses a patient's history;
- identifies the patient's multidisciplinary care needs;

- identifies outcomes to be achieved by members of the case conference team giving care and service to the patient;
- identifies tasks that need to be undertaken to achieve these outcomes, and allocates those tasks to members of the case conference team; and assesses whether previously identified outcomes (if any) have been achieved.

For the purposes of items 855 to 866, a multidisciplinary team requires the involvement of a minimum of three formal care providers from different disciplines, each of whom provides a different kind of care or service to the patient, and one of whom must be the patient's usual medical practitioner. The consultant psychiatrist and the medical practitioner are counted toward the minimum of three.

The patient's carer may be included as a member of the team (See A.49.8 below), in addition to the minimum of three health or care providers but do not count towards the minimum of three for Medicare purposes.

For the purposes of items 855 to 866 a consultant psychiatrist should generally be the consultant psychiatrist that has provided the majority of services to the patient over the previous 12 months and/or will provide the majority of services to the patient over the coming 12 months.

For the purposes of A.49.5, "formal care provider" includes in addition to the consultant psychiatrist and a medical practitioner (other than a specialist or consultant physician):

- allied health professionals such as, but not limited to: Aboriginal health care workers; asthma educators; audiologists; dental therapists; dentists; diabetes educators; dieticians; mental health workers; occupational therapists; optometrists; orthoptists; orthotists or prosthetists; pharmacists; physiotherapists; podiatrists; psychologists; registered nurses; social workers; speech pathologists.
- home and community service providers, or care organisers, such as: education providers; "meals on wheels" providers; personal care workers (workers who are paid to provide care services); probation officers.

The involvement of a patient's carer, such as a friend or family member, in a multidisciplinary case conference team can provide significant benefits in terms of coordination of care for the patient. Where the patient has a carer, the consultant psychiatrist should consider inviting the carer to be an additional member of the multidisciplinary case conference team, with the patient's agreement and where the carer's input is likely to be relevant to the subject matter of the case conference. The involvement of the patient's carer is not counted towards the minimum of three members.

Where the patient's carer is not a member of the multidisciplinary team, the practitioner should involve the carer and provide information to the carer where appropriate and with the patient's agreement. However, the practitioner should take account of the impact of the tasks identified in the case conference on the capacity of the carer to provide support to the patient. Additional responsibilities should not be assigned to the patient's carer without the carer's agreement.

Organisation of a case conference

Organise and coordinate a case conference means undertaking the following activities in relation to a case conference:

- explaining to the patient the nature of a case conference, and asking the patient whether the patient agrees to the case conference taking place; and
- recording the patient's agreement to the case conference; and
- recording the day on which the conference was held, and the times at which the conference started and ended; and
- recording the names of the participants; and

- recording the matters mentioned in A.49.4 and putting a copy of that record in the patient's medical records; and
- offering the patient (and the patient's carer, if appropriate and with the patient's agreement), and giving each other member of the team a summary of the conference; and
- discussing the outcomes of the case conference with the patient.

General requirements

In circumstances where the patient's usual medical practitioner, is not available to be a member of the case conference team, another medical practitioner known to the patient may be substituted.

It is expected that a patient would not normally require more than 5 case conferences in a 12-month period.

The case conference must be arranged in advance within a time frame that allows for all the participants to attend. The minimum three care providers must be present for the whole of the case conference. All participants must be in communication with each other throughout the conference, either face to face, by telephone or by video link, or a combination of these.

In explaining to the patient the nature of a case conference and asking the patient whether he or she agrees to the case conference taking place, the medical practitioner should:

- Inform the patient that his or her medical history, diagnosis and care preferences will be discussed with other care providers;
- Provide an opportunity for the patient to specify what medical and personal information he or she wants to be conveyed to or withheld from the other case conference team members; and
- Inform the patient that he or she will incur a charge for the service provided by the practitioner for which a Medicare rebate will be payable.
- Inform the patient of any additional costs he or she will incur. The benefit is not claimable (and an account should not be rendered) until all components of these items have been provided. (See General Notes 7.6)

AN.0.63 Case Conference by Consultant Physicians in Geriatric/Rehabilitation Medicine - (Item 880)

Item 880 applies only to a service provided by a consultant physician or a specialist in the specialty of Geriatric or Rehabilitation Medicine who has completed the additional requirements of the Royal Australasian College of Physicians for recognition in the subspecialty of geriatric medicine or rehabilitation medicine. The service must be in relation to an admitted patient in a hospital (not including a patient in a residential aged care facility) who is receiving one of the following types of specialist care:

- · geriatric evaluation and management (GEM), in which the clinical intent is to maximise health status and/or optimise the living arrangements for a patient with multidimensional medical conditions with disabilities and psychosocial problems, who is usually (but not always) an older patient; or
- \cdot rehabilitation care, in which the clinical intent is to improve the functional status of a patient with an impairment or disability.

Both types of care are evidenced by multi-disciplinary management and regular assessments against a plan with negotiated goals and indicative time-frames. A case conference is usually held on each patient once a week throughout the patient's admission, usually as part of a regular scheduled team meeting, at which all the inpatients under the consultant physician's care are discussed in sequence.

The specific responsibilities of the coordinating consultant physician or specialist are defined as:

- coordinating and facilitating the multidisciplinary team meeting;
- resolving any disagreement or conflict so that management consensus can be achieved;
- clarifying responsibilities; and
- ensuring that the input of participants and the outcome of the case conference is appropriately recorded.

The multidisciplinary team participating in the case conference must include a minimum of three formal inpatient care providers from different disciplines, including at least two providers from different allied health disciplines (listed at dot point 2 of A24.7). The consultant physician or specialist is counted toward the minimum of three. Although they may attend the case conference, neither the patient nor his or her informal carer, or any other medical practitioner can be counted toward the minimum of three.

The case conference must be arranged in advance, within a time frame that allows for all the participants to attend. The minimum of three formal inpatient care providers must be present for the whole of the case conference.

Prior informed consent must be obtained from the patient, or the patient's agent including informing the patient that he or she will incur a charge for the service for which a Medicare rebate will be payable.

Item 880 is not payable more than once a week or on the same day as a claim for any of the physician discharge case conferencing items 830, 832, 834, 835, 837 and 838, in respect of a particular patient.

AN.0.64 Neurosurgery Specialist Referred Consultation - (Items 6007 to 6015)

Referred consultations provided by specialist neurosurgeons will be covered under items 6007 to 6015. These new items replace the use of specialist items 104 and 105 for referred consultations by neurosurgeons.

The neurosurgical consultation structure comprises an initial consultation (item 6007) and four categories of subsequent consultations (items 6009-6015). These categories relate to the time AND level of complexity of the attendance i.e

- (i) Level 1 6009
- (ii) Level 2 6011
- (iii) Level 3 6013
- (iv) Level 4 6015

The following provides further guidance for neurosurgeons in utilising the appropriate items in common clinical situations:

- (i) Initial consultation item 6007 will replace item 104.
- (ii) Subsequent consultation items 6009-6015 will replace item 105

Item 6009 (subsequent consultation on a patient for 15 mins or less) covers a minor subsequent attendance which is straightforward in nature. Some examples of a minor attendance would include consulting with the patient for the purpose of issuing a repeat script for anticonvulsant medications or the routine review of a patient with a ventriculoperitoneal shunt.

Item 6011 (subsequent consultation on a patient for a duration of between 16 to 30 mins) would involve an detailed and comprehensive examination of the patient which is greater in complexity than would be provided under item 6009, arranging or evaluating any necessary investigations and include detailed relevant patient notes. Where a management plan is formulated it is expected that this plan is discussed in detail with the patient and a written record included in the patient notes. Some examples of a detailed neurosurgical attendance would include:

- the reviewing of neuroimaging for the monitoring of a tumour or lesion and discussion of the results with the patient (e.g. meningiomaglioma, spinal cord tumour);
- \cdot consultation on a patient to review imaging for spinal cord/cauda equina/ nerve root compression from a disc prolapse and discussion of results; or
- · consultation on a patient prior to insertion of a ventriculo-peritoneal shunt)

Item 6013 (subsequent consultation on a patient with complex neurological conditions for the duration of between 31 to 45 mins) should involve a extensive and comprehensive examination of the patient greater in complexity than under item 6011, arranging or evaluating any necessary investigations and include detailed relevant patient notes. Item 6013 would be expected to cover complications, adverse outcomes, or review of chronic conditions. Where a management plan is formulated it is expected that this plan is discussed in detail with the patient and a written record be included in the patient notes. Some examples of an extensive neurosurgical attendance would include:

- · an attendance on a patient prior to a craniotomy for cerebral tumour;
- · surgery for spinal tumour;
- · revision of spinal surgery;
- · epilepsy surgery; or
- · for the treatment of cerebral aneurysm.

Examination of such patients would include full cranial nerve examination or examination of upper and lower limb nervous system.

Item 6015 (subsequent consultation on a patient with complex neurological conditions for a duration of more than 45 mins) should involve an exhaustive examination of the patient that is more comprehensive than 6013 and any ordering or evaluation of investigations and include detailed relevant patient notes. It would be expected to cover complications, adverse outcomes, or review of chronic conditions. Where a management plan is formulated it is expected that this plan is thoroughly discussed with the patient and a written record be included in the patient notes. An exhaustive neurosurgical consultation includes:

- · managing adverse neurological outcomes;
- · detailed discussion when multiple modalities are available for treatment (e.g. clipping versus coiling for management of a cerebral aneurysm, surgical resection versus radiosurgery for cerebral tumour); or
- · discussion where surgical intervention is likely to result in a neurological deficit but surgery is critical to patient's life or to stop progressive neurologic decline (e.g. cranial nerve dysfunction, motor dysfunction secondary to a cerebral or spinal cord lesion).

Examination of such patients would include exhaustive neurosurgical examination includings full neurological examination (cranial nerves and limbs) or detailed 'focused examination' (e.g.: brachial plexus examination)

Complex neurosurgical problems referred to in items 6013 and 6015 include:

- · deterioration in neurologic function following cranial or spinal surgery;
- · presentation with new neurologic signs/symptoms; multifocal spinal and cranial disease (e.g. neurofibromatosis); or
- · chronic pain states following spinal surgery (including discussion of other treatment options and referral to pain management)

NOTE: It is expected that informed financial consent be obtained from the patient where possible.

AN.0.65 Cancer Care Case Conference - (Items 871 and 872)

For the purposes of these items:

- · private patients in public or private hospitals or the community with a malignancy of a solid organ or tissue or a systemic cancer such as a leukaemia or lymphoma are covered, with the exception of patients whose only cancer is a non-melanoma skin cancer;
- the billing general practitioner, specialist or consultant physician may be from any area of medical practice and must be a treating doctor of the patient discussed at the case conference. A treating doctor should generally have treated or provided a formal diagnosis of the patient's cancer in the past 12 months or expect to do so within the next 12 months. Attending non-treating clinicians, allied health providers or support staff are not eligible to bill the item.
- · only one practitioner is eligible to claim item 871 for each patient case conference. This should be the doctor who assumes responsibility for leading and coordinating the case conference, ensures that records are kept and that the patient is informed of the outcome of the case conference. In most cases this will be the lead treating doctor.
- each billing practitioner must ensure that his or her patient is informed that a charge will be incurred for the case conference for which a Medicare rebate will be payable;
- · participants must be in communication with each other throughout the case conference, either face-to-face, or by telephone or video link;
- · suitable allied health practitioners would generally be from one of the following disciplines: aboriginal health care worker; asthma educator; audiologist; dental therapist; dentist; diabetes educator; dietician; mental health worker; occupational therapist; optometrist; orthoptist; orthotist or prosthetist; pharmacist; physiotherapist; podiatrist; psychologist; registered nurse; social worker; or, speech pathologist;
- · in general, it is expected that no more than two case conferences per patient per year will be billed by a practitioner; and
- · cancer care case conferences are for the purpose of developing a cancer treatment plan in a multidisciplinary team meeting and should not be billed against case conference items for other purposes eg community or discharge case conferences

AN.0.66 Non-directive Pregnancy Support Counselling Service - (Item 4001) Overview

The Pregnancy Support Counselling initiative provides for Medicare benefits to be paid for non-directive pregnancy support counselling services provided to a person who is:

- pregnant; or
- who has been pregnant in the 12 months preceding the first service to which this item, item 792 or item 81000, 81005 or 81010 applies in relation to that pregnancy.

There are five MBS items for the provision of non-directive pregnancy support counselling services:

Item 4001 - services provided by an eligible GP. The term 'GP' is used hereafter as a generic reference to general practitioners;

Item 792 – services provided by an eligible medical practitioner (not including a specialist or consultant physician)

Item 81000 - services provided by an eligible psychologist:

Item 81005 - services provided by an eligible social worker; and

Item 81010 - services provided by an eligible mental health nurse.

This notes relate to provision of a non-directive pregnancy support counselling service by an eligible GP.

Non-directive counselling is a form of counselling based on the understanding that, in many situations, people can resolve their own problems without being provided with a solution by the counsellor. The counsellor's role is to encourage the person to express their feelings but not suggest what decision the person should make. By listening and reflecting back what the person reveals to them, the counsellor helps them to explore and understand their feelings. With this understanding, the person is able to make the decision which is best for them.

The service involves the GP undertaking a safe, confidential process that helps the patient explore concerns they have about a current pregnancy or a pregnancy that occurred in the preceding 12 months. This includes providing, on request, unbiased, evidence-based information about all options and services available to the patient.

The service may be used to address any pregnancy related issues for which non-directive counselling is appropriate.

Patient eligibility

Medicare rebates for non-directive pregnancy support counselling services provided using item 4001 are available to a person who is:

- pregnant; or
- who has been pregnant in the 12 months preceding the first service to which this item, item 792 or item 81000, 81005 or 81010 applies in relation to that pregnancy.

Partners of eligible patients may attend each or any counselling session, however, only one fee applies to each service provided.

Medicare benefits

Medicare benefits are payable for up to three non-directive pregnancy support counselling services per patient, per pregnancy, from any of the following items - 792, 4001, 81000, 81005 and 81010.

Where the patient is unsure of the number of Medicare rebated non-directive pregnancy support counselling services they have already accessed, the patient may check with the Department of Human Services on 132 011. Alternatively, the GP may check with the Department of Human Services (although the patient must be present to give permission).

Item 10990 or item 10991 can also be claimed in conjunction with item 4001 provided the conditions of the relevant item, 10990 or 10991, are satisfied.

Minimum Requirements

This service may only be provided by a GP who has completed appropriate non-directive pregnancy counselling training.

AN.0.67 Telehealth Patient-end Support Services by Health Professionals

These notes provide information on the telehealth MBS attendance items for general practitioners, specialists and consultant physicians to provide clinical support to their patients, when clinically relevant, during video consultations with specialists or consultant physicians under items 2100, 2122, 2125, 2126, 2137, 2138, 2143, 2147, 2179, 2195, 2199 and 2220 in Group A30.

Telehealth patient-end support services can only be claimed where:

- a Medicare eligible specialist service is claimed;
- the service is rendered in Australia; and
- where this is necessary for the provision of the specialist service.

A video consultation will involve a single specialist or consultant physician attending to the patient, with the participation of another general practitioner, specialist or consultant physician, at the patient end. The above timetiered items provide for patient-end support services in various settings including, consulting rooms, other than consulting rooms, eligible residential aged care services and Aboriginal Medical Services.

Clinical indications

The specialist or consultant physician must be satisfied that it is clinically appropriate to provide a video consultation to a patient. The decision to provide clinically relevant support to the patient is the responsibility of the specialist or physician.

Telehealth specialist services can be provided to patients when there is no patient-end support service provided.

Collaborative Consultation

The practitioner, who provides assistance to the patient where this is necessary for the provision of the specialist service, may seek assistance from a health professional (e.g. a practice nurse, Aboriginal or Torres Strait Islander health practitioner or Aboriginal health worker) but only one item is billable for the patient-end support service. The practitioner must be present during part or all of the consultation in order to bill an appropriate time-tiered MBS item. Any time spent by another health professional called to assist with the consultation may not be counted against the overall time taken to complete the video consultation.

Restrictions

The MBS telehealth attendance items are not payable for services to an admitted hospital patient (this includes Hospital in the Home patients). Benefits are not payable for telephone or email consultations. In order to fulfill the item descriptor there must be a visual and audio link between the patient and the remote practitioner. If the remote practitioner is unable to establish both a video and audio link with the patient, a MBS rebate for a telehealth attendance is not payable.

Eligible Geographical Areas

Geographic eligibility for telehealth services funded under Medicare are determined according to the Australian Standard Geographical Classification Remoteness Area (ASGC-RA) classifications. Telehealth Eligible Areas are those areas that are outside a Major City (RA1) according to ASGC-RA (RA2-5). Patients and providers are able to check their eligibility by following the links on the MBS Online website (www.mbsonline.gov.au/telehealth).

There is a requirement for the patient and specialist to be located a minimum of 15km apart at the time of the consultation. Minimum distance between specialist and patient video consultations are measured by the most direct (ie least distance) route by road. The patient or the specialist is not permitted to travel to an area outside the minimum 15 km distance in order to claim a video conference.

This rule will not apply to specialist video consultation with patients who are a care recipient in an eligible residential care service; or at an eligible Aboriginal Medical Service or Aboriginal Community Controlled Health Service for which a direction, made under subsection 19(2) of the Health Insurance Act 1973, as these patients are able to receive telehealth services anywhere in Australia.

Telehealth Eligible Service Areas are defined at www.mbsonline.gov.au/ telehealth eligible areas

Record Keeping

Participating telehealth practitioners must keep contemporaneous notes of the consultation including documenting that the service was performed by video conference, the date, time and the people who participated.

Only clinical details recorded at the time of the attendance count towards the time of the consultation. It does not include information added at a later time, such as reports of investigations.

Multiple attendances on the same day

In some situations a patient may receive a telehealth consultation and a face to face consultation by the same or different practitioner on the same day.

Medicare benefits may be paid for more than one video consultation on a patient on the same day by the same practitioner, provided the second (and any following) video consultations are not a continuation of the initial or earlier video consultations. Practitioners will need to provide the times of each consultation on the patient's account or bulk billing voucher.

Extended Medicare Safety Net (EMSN)

Items which provide for telehealth patient-end support services are subject to EMSN caps equal to 300% of the schedule fee (to a maximum of \$500). This is consistent with Government policy relating to capping EMSN for MBS consultation services.

Aftercare Rule

Video consultations are subject to the same aftercare rules as face to face consultations.

Referrals

The referral procedure for a video consultation is the same as for conventional face-to-face consultations.

Technical requirements

In order to fulfill the item descriptor there must be a visual and audio link between the patient and the remote practitioner. If the remote practitioner is unable to establish both a video and audio link with the patient, a MBS rebate for a specialist video consultation is not payable.

Individual clinicians must be confident that the technology used is able to satisfy the item descriptor and that software and hardware used to deliver a videoconference meets the applicable laws for security and privacy.

Bulk billing

Bulk bill incentive items 10990 or 10991 may be billed in conjunction with the telehealth items 2100, 2122, 2125, 2126, 2137, 2138, 2143, 2147, 2179, 2195, 2199 and 2220.

Duration of attendance

The practitioner attending at the patient end of the video consultation does not need to be present for the entire consultation, only as long as is clinically relevant - this can be established in consultation with the specialist. The MBS fee payable for the supporting practitioner will be determined by the total time spent assisting the patient. This time does not need to be continuous.

AN.0.68 Telehealth Specialist Services

These notes provide information on the telehealth MBS video consultation items by specialists, consultant physicians and psychiatrists. A video consultation involves a single specialist, consultant physician or psychiatrist attending a patient, with the possible support of another medical practitioner, a participating optometrist, a participating nurse practitioner, a participating midwife, practice nurse, Aboriginal and Torres Strait Islander health practitioner or Aboriginal health worker at the patient end of the video conference. The decision as to whether the patient requires clinical support at the patient end of the specialist service is based on whether the support is necessary for the provision of the specialist service. Telehealth specialist services can be provided to patients when there is no patient-end support service provided.

MBS items numbers 99, 112, 149, 288, 389, 2820, 3015, 6016, 13210, 16399 and 17609 allow a range of existing MBS attendance items to be provided via video conferencing. These items have a derived fee which is equal to 50%

of the schedule fee for the consultation item claimed (e.g. 50% of the schedule fee for item 104) when billed with one of the associated consultation items (such as 104). A patient rebate of 85% for the derived fee is payable.

Six MBS item numbers (113, 114, 384, 2799, 3003 and 6004) provide for an initial attendance via videoconferencing by a specialist, consultant physician, consultant occupational physician, pain medicine specialist/consultant physician, palliative medicine specialist/consultant physician or neurosurgeon where the service is 10 minutes or less. The items are stand-alone items and do not have a derived fee.

Where an attendance is more than 10 minutes, practitioners should use the existing item numbers consistent with the current arrangements. Normal restrictions which apply for initial consultations will also apply for these items. For example, if a patient has an initial consultation via telehealth, they cannot also claim an initial face-to-face consultation as part of the same course of treatment.

Clinical indications

The specialist, consultant physician or psychiatrist must be satisfied that it is clinically appropriate to provide a video consultation to a patient. The decision to provide clinically relevant support to the patient is the responsibility of the specialist, consultant physician or psychiatrist.

Telehealth specialist services can be provided to patients when there is no patient-end support service provided.

Restrictions

The MBS telehealth attendance items are not payable for services to an admitted hospital patient (this includes hospital in the home patients). Benefits are not payable for telephone or email consultations. In order to fulfill the item descriptor there must be a visual and audio link between the patient and the remote practitioner. If the remote practitioner is unable to establish both a video and audio link with the patient, a MBS rebate for a telehealth attendance is not payable.

Billing Requirements

All video consultations provided by specialists, consultant physicians or psychiatrists must be **separately billed**. That is, only the relevant telehealth MBS consultation item and the associated derived item are to be itemised on the account/bill/voucher. Any other service/item billed should be itemised on a separate account/bill/voucher. This will ensure the claim is accurately assessed as being a video consultation and paid accordingly.

Practitioners should not use the notation 'telehealth', 'verbal consent' or 'Patient unable to sign' to overcome administrative difficulties to obtaining a patient signature for bulk billed claims (for further information see mbsonline.gov.au/telehealth).

Eligible Geographical Areas

Geographic eligibility for telehealth services funded under Medicare are determined according to the Australian Standard Geographical Classification Remoteness Area (ASGC-RA) classifications. Telehealth Eligible Areas are those areas that are outside a Major City (RA1) according to ASGC-RA (RA2-5). Patients and providers are able to check their eligibility by following the links on the MBS Online website (www.mbsonline.gov.au/telehealth).

There is a requirement for the patient and specialist to be located a minimum of 15km apart at the time of the consultation. Minimum distance between specialist and patient video consultations are measured by the most direct (ie least distance) route by road. The patient or the specialist is not permitted to travel to an area outside the minimum 15 km distance in order to claim a video conference.

This rule will not apply to specialist video consultation with patients who are a care recipient in a residential care service; or at an Aboriginal Medical Service or an Aboriginal Community Controlled Health Service for which a direction made under subsection 19(2) of the *Health Insurance Act 1973* as these patients are able to receive telehealth services anywhere in Australia.

Telehealth Eligible Service Areas are defined at www.mbsonline.gov.au/telehealth eligible areas

Record Keeping

Participating telehealth practitioners must keep contemporaneous notes of the consultation including documenting that the service was performed by video conference, the date, time and the people who participated.

Only clinical details recorded at the time of the attendance count towards the time of the consultation. It does not include information added at a later time, such as reports of investigations.

Extended Medicare Safety Net (EMSN)

All telehealth consultations (with the exception of the participating optometrist telehealth items) are subject to EMSN caps. The EMSN caps for ART and Obstetric telehealth items 13210 and 16399 were set in reference to the EMSN caps applying to the base ART and Obstetric consultation items.

The EMSN caps for all other telehealth consultation items are equal to 300% of the schedule fee (to a maximum of \$500). The maximum EMSN benefit for a telehealth consultation is equal to the sum of the EMSN cap for the base item and the EMSN cap for the telehealth items.

Aftercare Rule

Video consultations are subject to the same aftercare rules as practitioners providing face-to-face consultations.

Multiple attendances on the same day

In some situations a patient may receive a telehealth consultation and a face to face consultation by the same or different practitioner on the same day.

Medicare benefits may be paid for more than one video consultation on a patient on the same day by the same practitioner, provided the second (and any following) video consultations are not a continuation of the initial or earlier video consultations. Practitioners will need to provide the times of each consultation on the patient's account or bulk billing voucher.

Referrals

The referral procedure for a video consultation is the same as for conventional face-to-face consultations.

Technical requirements

In order to fulfill the item descriptor there must be a visual and audio link between the patient and the remote practitioner. If the remote practitioner is unable to establish both a video and audio link with the patient, a MBS rebate for a telehealth attendance is not payable.

Individual clinicians must be confident that the technology used is able to satisfy the item descriptor and that software and hardware used to deliver a videoconference meets the applicable laws for security and privacy.

AN.0.69 Australian Defence Force Post-discharge GP Health Assessment

Items 701, 703, 705 and 707 may be used to undertake a health assessment for a former serving member of the Australian Defence Force, including a former member of permanent and reserve forces.

A health assessment for a former serving member of the Australian Defence Force is an assessment of:

- a. a patient's physical and psychological health and social function; and
- b. whether health care, education and other assistance should be offered to the patient to improve their physical, psychological health or social function.

This health assessment must include:

a. a personal attendance by a general practitioner; and

- b. taking the patient's history, including the following:
 - i. the patient's service with the Australian Defence Force, including service type, years of service, field of work, number of deployments and reason for discharge;
 - ii. the patient's social history, including relationship status, number of children (if any) and current occupation;
 - iii. the patient's current medical conditions;
 - iv. whether the patient suffers from hearing loss or tinnitus;
 - v. the patient's use of medication, including medication prescribed by another doctor and medication obtained without a prescription;
 - vi. the patient's smoking, if applicable;
 - vii. the patient's alcohol use, if applicable;
 - viii. the patient's substance use, if applicable;
 - ix. the patient's level of physical activity;
 - x. whether the patient has bodily pain;
 - xi. whether the patient has difficulty getting to sleep or staying asleep;
 - xii. whether the patient has psychological distress;
 - xiii. whether the patient has posttraumatic stress disorder;
 - xiv. whether the patient is at risk of harm to self or others;
 - xv. whether the patient has anger problems;
 - xvi. the patient's sexual health;
 - xvii. any other health concerns the patient has.

The assessment must also include the following:

- i. measuring the patient's height;
- ii. weighing the patient and ascertaining, or asking the patient, whether the patient's weight has changed in the last 12 months;
- iii. measuring the patient's waist circumference;
- iv. taking the patient's blood pressure;
- v. using information gained in the course of taking the patient's history to assess whether any further assessment of the patient's health is necessary;
- vi. either making the further assessment or referring the patient to another medical practitioner who can make the further assessment;
- vii. documenting a strategy for improving the patient's health;
- viii. offering to give the patient a written report of the assessment that makes recommendations for treating the patient including preventive health measures;
 - ix. keeping a record of the assessment.

A general practitioner may use the 'ADF Post-discharge GP Health Assessment Tool' as a screening tool for the health assessment. This assessment tool can be viewed on the At Ease portal of the Department of Veterans' Affairs' website at: http://at-ease.dva.gov.au. Other assessment tools mentioned in the Department of Veteran's Affairs Mental Health Advice Book may be relevant and can also be viewed on the At Ease portal.

This health assessment may only be claimed once by an eligible patient.

The health assessment must not be performed in conjunction with a separate consultation in relation to the patient unless the consultation is clinically necessary.

The health assessment must be performed by the patient's usual doctor.

AN.0.70 Limitation of items—certain attendances by specialists and consultant physicians Medicare benefits are not payable for items 105, 116, 119, 386, 2806, 2814, 3010, 3014, 6019, 6052 and 16404 when claimed in association with an item in group T8 with a schedule fee of \$300 or more.

The restriction applies when the procedure is performed by the same practitioner, on the same patient, on the same day.

AN.0.71 General practitioner attendances and Aftercare

Vocationally and non-vocationally registered general practitioners providing post-operative treatment to a patient during an aftercare period are eligible for Medicare benefits. This rule applies only in the circumstance whereby the vocationally or non-vocationally registered general practitioner did not perform the initial procedure requiring post-operative treatment.

Normal aftercare rules still apply when it is the vocationally or non-vocationally registered general practitioner who rendered the initial procedure requiring post-operative treatment.

AN.7.1 Attendances by Medical Practitioners

Items 179-181, 185-187, 189-197, 203-206, 215-287, 371, 372, 733-789, 792, 812-892, 899-906, 90092-93, 90095-96, 90183, 90188, 90202, and 90212 relate to attendances rendered by a medical practitioner who is not a general practitioner, specialist or consultant physician, and who:

- (a) is registered under section 3GA of the Act, to the extent that the person is practising during the period in respect of which, and in the location in respect of which, he or she is registered, and insofar as the circumstances specified for paragraph 19AA(3)(b) of the Act apply; or
- (b) is covered by an exemption under subsection 19AB(3) of the Act; or
- (c) first became a medical practitioner before 1 November 1996.

AN.7.2 Medical Practitioner Attendances To Which No Other Item Applies Eligibility

Items 179 to 212 are available to medical practitioners providing services in eligible areas.

Eligible area means an area that is a Modified Monash 2 area, Modified Monash 3 area, Modified Monash 4 area, Modified Monash 5 area, Modified Monash 6 area or Modified Monash 7 area.

Medical practitioners providing services in a Modified Monash 1 area should use the items in Group A2.

A locator map to identify a medical practice's Modified Monash Model Area location is available at the DoctorConnect website at http://www.doctorconnect.gov.au/internet/otd/publishing.nsf/Content/locator

Guidance Notes

To assist medical practitioners in selecting the appropriate item number for Medicare benefit purposes the following notes in respect of the various levels are given.

Professional consultation of not more than 5 minutes duration

The item will be used for obvious and straightforward cases and this should be reflected in the practitioner's records. In this context, the practitioner should undertake the necessary examination of the affected part if required, and note the action taken.

Professional consultation of more than 5 minutes but not more than 25 minutes

The item will be used for a consultation lasting more than 5 minutes but less than 25 minutes for cases that are not obvious or straightforward in relation to one or more health related issues. This should be reflected in the practitioner's record. In the item descriptor singular also means plural and vice versa.

Professional consultation of more than 25 minutes but not more than 45 minutes

The item will be used for a consultation lasting more than 25 minutes but less than 45 minutes for cases in relation to one or more complex health related issues. This should be reflected in the practitioner's record. In the item descriptor singular also means plural and vice versa.

Professional consultation of more than 45 minutes

The item will be used for a consultation lasting at least 40 minutes for cases in relation to one or more very complex health related issues. This should be reflected in the practitioner's record. In the item descriptor singular also means plural and vice versa.

Creating and Updating a Personally Controlled Electronic Health Record (PCEHR)

The time spent by a medical practitioner on the following activities may be counted towards the total consultation time:

- Reviewing a patient's clinical history, in the patient's file and/or the PCEHR, and preparing or updating a Shared Health Summary where it involves the exercise of clinical judgement about what aspects of the clinical history are relevant to inform ongoing management of the patient's care by other providers; or
- Preparing an Event Summary for the episode of care.

Preparing or updating a Shared Health Summary and preparing an Event Summary are clinically relevant activities. When either of these activities are undertaken with any form of patient history taking and/or the other clinically relevant activities that can form part of a consultation, the item that can be billed is the one with the time period that matches the total consultation time.

MBS rebates are not available for creating or updating a Shared Health Summary as a stand-alone service.

Recording Clinical Notes

In relation to the time taken in recording appropriate details of the service, only clinical details recorded at the time of the attendance count towards the time of consultation. It does not include information added at a later time, such as reports of investigations.

Other Services at the Time of Attendance

Where, during the course of a single attendance by a medical practitioner, both a consultation and another medical service are rendered, Medicare benefits are generally payable for both the consultation and the other service. Exceptions are in respect of medical services which form part of the normal consultative process, or services which include a component for the associated consultation (see the General Explanatory Notes for further information on the interpretation of the Schedule).

AN.7.3 Medical Practitioner Prolonged Attendance in Treatment of a Critical Condition (Items 214 to 220)

The conditions to be met before services covered by items 214-220 attract benefits are:-

- (i) the patient must be in imminent danger of death;
- (ii) if the personal attendance is not continuous, the occasion on which the service is provided is taken to be the total time of the attendance; and
- (iii) if personal attendance on a single patient is provided by 1 or more medical practitioners concurrently, each practitioner may claim an attendance fee.

Note: Medicare benefits are not payable for the issue of a death certificate, although an attendance on a patient at which it is determined that life is extinct can be claimed under the appropriate attendance item. The outcome of the

attendance may be that a death certificate is issued, however, Medicare benefits are only payable for the attendance component of the service.

AN.7.4 Medical Practitioner Family Group Therapy (Items 221, 222 and 223)

These items refer to family group therapy supervised by medical practitioners other than consultant psychiatrists. To be used, these items require that a formal intervention with a specific therapeutic outcome, such as improved family function and/or communication, is undertaken. Other types of group attendances do not attract benefits. It should be noted that only one fee applies in respect of each group of patients.

Telephone consultations, letters of advice by medical practitioners, the issue of repeat prescriptions when the patient is not in attendance, post mortem examinations, the issue of death certificates, cremation certificates, counselling of relatives (note - items 348, 350 and 352 are not counselling services), group attendances (other than group attendances covered by items 170, 171, 172, 221, 222, 223, 342, 344 and 346) such as group counselling, health education, weight reduction or fitness classes do not qualify for benefit.

Although Medicare benefits are not payable for the issue of a death certificate, an attendance on a patient at which it is determined that life is extinct can be claimed under the appropriate attendance item. The outcome of the attendance may be that a death certificate is issued, however, Medicare benefits are only payable for the attendance component of the service.

AN.7.5 Medical Practitioner Health Assessments (Items 224 to 227)

There are four time-based health assessment items, consisting of brief, standard, long and prolonged consultations.

Brief Health Assessment (MBS Item 224)

A brief health assessment is used to undertake simple health assessments. The health assessment should take no more than 30 minutes to complete.

Standard Health Assessment (MBS Item 225)

A standard health assessment is used for straightforward assessments where the patient does not present with complex health issues but may require more attention than can be provided in a brief assessment. The assessment lasts more than 30 minutes but takes less than 45 minutes.

Long Health Assessment (MBS Item 226)

A long health assessment is used for an extensive assessment, where the patient has a range of health issues that require more in-depth consideration, and longer-term strategies for managing the patient's health may be necessary. The assessment lasts at least 45 minutes but less than 60 minutes.

Prolonged Health Assessment (MBS Item 227)

A prolonged health assessment is used for a complex assessment of a patient with significant, long-term health needs that need to be managed through a comprehensive preventive health care plan. The assessment takes 60 minutes or more to complete.

Medical practitioners may select one of the MBS health assessment items to provide a health assessment service to a member of any of the target groups listed in the table below. The health assessment item that is selected will depend on the time taken to complete the health assessment service. This is determined by the complexity of the patient's presentation and the specific requirements that have been established for each target group eligible for health assessments.

MBS Items 224, 225, 226 and 227 may be used to undertake a health assessment for the following target groups:

Target Group	Frequency of Service
A type 2 diabetes risk evaluation for people aged 40-49 years (inclusive) with a high risk of developing type 2 diabetes as determined by the Australian Type 2 Diabetes Risk Assessment Tool	Once every three years to an eligible patient
A health assessment for people aged 45-49 years (inclusive) who are at risk of developing chronic disease	Once only to an eligible patient
A health assessment for people aged 75 years and older	Provided annually to an eligible patient
A comprehensive medical assessment for permanent residents of residential aged care facilities	Provided annually to an eligible patient
A health assessment for people with an intellectual disability	Provided annually to an eligible patient
A health assessment for refugees and other humanitarian entrants	Once only to an eligible patient
A health assessment for former serving members of the Australian Defence Force	Once only to an eligible patient

Frequency of service

The frequency with which patients in different population groups may receive a health assessment is described in the table above. Patients may not have more services than they are eligible for under the frequency provisions that apply to specific types of health assessment.

Important Note: patients may receive services using MBS items 224 to 227 and 701 to 707. However, once a patient has received a service using an MBS item from **either** group of MBS health assessment items, the patient may not receive another MBS health assessment until the appropriate time period has expired. In the case of health assessment services that are provided only once in a patient's lifetime, the patient would not be eligible for another health assessment.

The only exception is patients who are eligible for more than one type of health assessment (that is, the patient belongs to more than one eligible patient category). However, the frequency of service restrictions also apply to these services.

If a medical practitioner is not sure if a patient is eligible for an MBS health assessment service, they may telephone the Department of Human Services on 132011, with the patient present, to check eligibility.

Guidance Notes

A health assessment means the assessment of a patient's health and physical, psychological and social function and consideration of whether preventive health care and education should be offered to the patient, to improve that patient's health and physical, psychological and social function.

Health assessments are not available to people who are in-patients of a hospital or care recipients in a residential aged care facility (with the exception of a comprehensive medical assessment provided to a permanent resident of a residential aged care facility).

Before a health assessment is commenced, the patient (and/or his or her parent(s), carer or representative, as appropriate) must be given an explanation of the health assessment process and its likely benefits. The patient must be asked whether he or she consents to the health assessment being performed. In cases where the patient is not capable of giving consent, consent must be given by his or her parent(s), carer or representative. Consent to the health assessment must be noted in the patient's records.

A health assessment must include the following elements:

- a. information collection, including taking a patient history and undertaking or arranging examinations and investigations as required;
- b. making an overall assessment of the patient;
- c. recommending appropriate interventions;
- d. providing advice and information to the patient;
- e. keeping a record of the health assessment, and offering the patient a written report about the health assessment, with recommendations about matters covered by the health assessment; and
- f. offering the patient's carer (if any, and if the medical practitioner considers it appropriate and the patient agrees) a copy of the report or extracts of the report relevant to the carer.

Restrictions on billing the health assessment items

A health assessment may only be billed by a medical practitioner (not including a specialist or consultant physician).

A health assessment should generally be undertaken by the patient's 'usual doctor'. For the purpose of the health assessment items, 'usual doctor' means the medical practitioner, or a medical practitioner working in the same medical practice, which has provided the majority of primary health care to the patient over the previous twelve months and/or will be providing the majority of care to the patient over the next twelve months.

A health assessment should not take the form of a health screening service.

MBS health assessment items 224, 225, 226 and 227 must be provided by a medical practitioner personally attending upon a patient. Suitably qualified health professionals, such as practice nurses or Aboriginal and Torres Strait Islander health practitioners, employed and/or otherwise engaged by a medical practice or health service, may assist medical practitioners in performing health assessments. Such assistance must be provided in accordance with accepted medical practice and under the supervision of the medical practitioner. This may include activities associated with:

- information collection; and
- providing patients with information about recommended interventions at the direction of the medical practitioner.

The medical practitioner should be satisfied that the assisting health professional has the necessary skills, expertise and training to collect the information required for the health assessment.

Medical practitioners should not conduct a separate consultation for another health-related issue in conjunction with a health assessment unless it is clinically necessary (ie. the patient has an acute problem that needs to be managed separately from the assessment). The only exception is the comprehensive medical assessment, where, if this health assessment is undertaken during the course of a consultation for another purpose, the health assessment item and the relevant item for the other consultation may both be claimed.

Items 224, 225, 226 and 227 do not apply for services that are provided by any other Commonwealth or State funded services. However, where an exemption under subsection 19(2) of the Health Insurance Act 1973 has been granted to an Aboriginal Community Controlled Health Service or State/Territory Government health clinic, items 224, 225, 226 and 227 can be claimed for services provided by medical practitioners salaried by or contracted to, the Service or health clinic. All other requirements of the items must be met.

Item 10990 or 10991 (bulk billing incentives) can be claimed in conjunction with any health assessment, provided the conditions of item 10990 and 10991 are satisfied.

AN.7.6 Medical Practitioner Health Assessment Provided as a Type 2 Diabetes Risk Evaluation for People Aged 40-49 Years with a High Risk of Developing Type 2 Diabetes as Determined by the Australian Type 2 Diabetes Risk Assessment Tool

Items 224, 225, 226 and 227 may be used to undertake a type 2 diabetes risk evaluation for people aged 40-49 years (inclusive) with a high risk of developing type 2 diabetes, as determined by the Australian Type 2 Diabetes Risk Assessment Tool.

The aim of this health assessment is to review the factors underlying the 'high risk' score identified by the Australian Type 2 Diabetes Risk Assessment Tool to instigate early interventions, such as lifestyle modification programs, to assist with the prevention of type 2 diabetes.

The Australian Type 2 Diabetes Risk Assessment Tool has been developed to provide a basis for both health professionals and health consumers to assess the risk of type 2 diabetes. It consists of a short list of questions which, when completed, provides a guide to a patient's current level of risk of developing type 2 diabetes. The item scores and risk rating calculations in the tool have been developed using demographic, lifestyle, anthropometric and biomedical data from the 2000 Australian Diabetes, Obesity and Lifestyle baseline survey and the AusDiab 2005 follow-up study.

The Australian Type 2 Diabetes Risk Assessment Tool can be obtained from the Department's prevention of diabetes web page.

Clinical risk factors that the medical practitioner must consider when providing this health assessment include:

- (a) lifestyle, such as smoking, physical inactivity and poor nutrition;
- (b) biomedical risk factors, such as high blood pressure, impaired glucose metabolism and excess weight;
- (c) any relevant recent diagnostic test results; and
- (d) a family history of chronic disease.

The health assessment must include the following:

- (a) evaluating a patient's high risk score, as determined by the Australian Type 2 Diabetes Risk Assessment Tool which has been completed by the patient within a period of 3 months prior to undertaking the health assessment;
- (b) updating the patient's history and undertaking physical examinations and clinical investigations in accordance with relevant guidelines;
- (c) making an overall assessment of the patient's risk factors and of the results of relevant examinations and investigations; and
- (d) initiating interventions, if appropriate, including referral to a lifestyle modification program and follow-up relating to the management of any risk factors identified (further information is available at the Department's prevention of diabetes web page).

The completion of the Australian Type 2 Diabetes Risk Assessment Tool is mandatory for patient access to this health assessment. The tool can be completed either by the patient or with the assistance of a health professional or practice staff. Patients with a 'high' score result are eligible for the health assessment, and subsequent referral to the subsidised lifestyle modification programs if appropriate (further information is available at <a href="https://doi.org/10.1001/journal

A health assessment for a type 2 diabetes risk evaluation for people aged 40-49 years with a high risk of developing type 2 diabetes as determined by the Australian Type 2 Diabetes Risk Assessment Tool may only be claimed once every three years by an eligible patient.

AN.7.7 Medical Practitioner Health Assessment Provided for People Aged 45-49 Years Who are at Risk of Developing Chronic Disease

Items 224, 225, 226 and 227 may be used to undertake a health assessment for people aged 45-49 years (inclusive) who are at risk of developing chronic disease.

For the purposes of this health assessment, a patient is at risk of developing a chronic disease if, in the clinical judgement of the attending medical practitioner, a specific risk factor for chronic disease is identified.

Risk factors that the medical practitioner can consider include, but are not limited to:

- (a) lifestyle risk factors, such as smoking, physical inactivity, poor nutrition or alcohol use;
- (b) biomedical risk factors, such as high cholesterol, high blood pressure, impaired glucose metabolism or excess weight; or
- (c) family history of a chronic disease.

A chronic disease or condition is one that has been or is likely to be present for at least six months, including but not limited to asthma, cancer, cardiovascular illness, diabetes mellitus, mental health conditions, arthritis and musculoskeletal conditions.

If, after receiving this health assessment, a patient is identified as having a high risk of type 2 diabetes as determined by the Australian Type 2 Diabetes Risk Assessment Tool, the medical practitioner may refer that person to a subsidised lifestyle modification program, along with other possible strategies to improve the health status of the patient (further information is available at http://www.health.gov.au/preventionoftype2diabetes).

The Australian Type 2 Diabetes Risk Assessment Tool can be obtained from http://www.health.gov.au/preventionoftype2diabetes.

A health assessment for people aged 45-49 years who are at risk of developing chronic disease may only be claimed once by an eligible patient.

AN.7.8 Medical Practitioner Health Assessment Provided for People Aged 75 Years and Older Items 224, 225, 226 and 227 may be used to undertake a health assessment for people aged 75 years and older.

A health assessment for people aged 75 years and older is an assessment of a patient's health and physical, psychological and social function for the purpose of initiating preventive health care and/or medical interventions as appropriate.

This health assessment must include:

- (a) measurement of the patient's blood pressure, pulse rate and rhythm;
- (b) an assessment of the patient's medication;
- (c) an assessment of the patient's continence;
- (d) an assessment of the patient's immunisation status for influenza, tetanus and pneumococcus;
- (e) an assessment of the patient's physical function, including the patient's activities of daily living, and whether or not the patient has had a fall in the last 3 months;
- (f) an assessment of the patient's psychological function, including the patient's cognition and mood; and
- (g) an assessment of the patient's social function, including the availability and adequacy of paid and unpaid help, and whether the patient is responsible for caring for another person.

(h) A health assessment for people aged 75 years and older may be claimed once every twelve months by an eligible patient.

AN.7.9 Medical Practitioner Health Assessment Provided as a Comprehensive Medical Assessment for Residents of Residential Aged Care Facilities

Items 224, 225, 226 and 227 may be used to undertake a comprehensive medical assessment of a resident of a residential aged care facility

This health assessment requires assessment of the resident's health and physical and psychological function, and must include:

- (a) making a written summary of the comprehensive medical assessment;
- (b) developing a list of diagnoses and medical problems based on the medical history and examination;
- (c) providing a copy of the summary to the residential aged care facility; and
- (d) offering the resident a copy of the summary.

A residential aged care facility is a facility in which residential care services, as defined in the Aged Care Act 1997, are provided. This includes facilities that were formerly known as nursing homes and hostels. A person is a resident of a residential aged care facility if the person has been admitted as a permanent resident of that facility.

This health assessment is available to new residents on admission into a residential aged care facility. It is recommended that new residents should receive the health assessment as soon as possible after admission, preferably within six weeks following admission into a residential aged care facility.

A health assessment for the purpose of a comprehensive medical assessment of a resident of a residential aged care facility may be claimed by an eligible patient:

- (a) on admission to a residential aged care facility, provided that a comprehensive medical assessment has not already been provided in another residential aged care facility within the previous 12 months; and
- (b) at 12 month intervals thereafter.

AN.7.10 Medical Practitioner Health Assessment Provided for People with an Intellectual Disability Items 224, 225, 226 and 227 may be used to undertake a health assessment for people with an intellectual disability.

A person is considered to have an intellectual disability if they have significantly sub-average general intellectual functioning (two standard deviations below the average intelligence quotient [IQ]) and would benefit from assistance with daily living activities. Where medical practitioners wish to confirm intellectual disability and a patient's need for assistance with activities of daily living, they may seek verification from a paediatrician registered to practice in Australia (if the patient is a child) or from a government-provided or funded disability service that has assessed the patient's intellectual function.

The health assessment provides a structured clinical framework for medical practitioners to comprehensively assess the physical, psychological and social function of patients with an intellectual disability and to identify any medical intervention and preventive health care required. The health assessment must include the following items as relevant to the patient or his or her representative:

- (a) Check dental health (including dentition);
- (b) Conduct aural examination (arrange formal audiometry if audiometry has not been conducted within 5 years);
- (c) Assess ocular health (arrange review by an ophthalmologist or optometrist if a comprehensive eye examination has not been conducted within 5 years);

- (d) Assess nutritional status (including weight and height measurements) and a review of growth and development;
- (e) Assess bowel and bladder function (particularly for incontinence or chronic constipation);
- (f) Assess medications (including non-prescription medicines taken by the patient, prescriptions from other doctors, medications prescribed but not taken, interactions, side effects and review of indications);
 - Advise carers of the common side effects and interactions.
 - Consider the need for a formal medication review.
- (g) Check immunisation status, including influenza, tetanus, hepatitis A and B, Measles, Mumps and Rubella (MMR) and pneumococcal vaccinations;
- (h) Check exercise opportunities (with the aim of moderate exercise for at least 30 minutes per day);
- (i) Check whether the support provided for activities of daily living adequately and appropriately meets the patient's needs, and consider formal review if required;
- (j) Consider the need for breast examination, mammography, cervical screening, testicular examination, lipid measurement and prostate assessment as for the general population;
- (k) Check for dysphagia and gastro-oesophageal disease (especially for patients with cerebral palsy), and arrange for investigation or treatment as required;
- (l) Assess risk factors for osteoporosis (including diet, exercise, Vitamin D deficiency, hormonal status, family history, medication fracture history) and arrange for investigation or treatment as required;
- (m) For patients diagnosed with epilepsy, review of seizure control (including anticonvulsant drugs) and consider referral to a neurologist at appropriate intervals;
- (n) Check for thyroid disease at least every two years (or yearly for patients with Down syndrome);
- (o) For patients without a definitive aetiological diagnosis, consider referral to a genetic clinic every 5 years;
- (p) Assess or review treatment for co-morbid mental health issues;
- (q) Consider timing of puberty and management of sexual development, sexual activity and reproductive health; and
- (r) Consider whether there are any signs of physical, psychological or sexual abuse.

A health assessment for people with an intellectual disability may be claimed once every twelve months by an eligible patient.

AN.7.11 Medical Practitioner Health Assessment Provided for Refugees and Other Humanitarian Entrants

Items 224, 225, 226 and 227 may be used to undertake a health assessment for refugees and other humanitarian entrants.

The purpose of this health assessment is to introduce new refugees and other humanitarian entrants to the Australian primary health care system, as soon as possible after their arrival in Australia (within twelve months of arrival).

The health assessment applies to humanitarian entrants who are resident in Australia with access to Medicare services. This includes Refugees, Special Humanitarian Program and Protection Program entrants with the following visas:

Offshore Refugee Category including:

- (a) 200 Refugee
- (b) 201 In Country Special Humanitarian
- (c) 203 Emergency rescue
- (d) 204 Women at Risk
- (e) Offshore Special Humanitarian Program
- (f) 202 Global Special Humanitarian

Offshore - Temporary Humanitarian Visas (THV) including:

- (g) Subclass 695 (Return Pending)
- (h) Subclass 070 (Removal Pending Bridging)

Onshore Protection Program including:

- (i) 866 Permanent Protection Visa (PPV)
- (j) 785 Temporary Protection Visa (TPV)

Patients should be asked to provide proof of their visa status and date of arrival in Australia. Alternatively, medical practitioners may telephone the Department of Human Services on 132011, with the patient present, to check eligibility.

The medical practitioner and patient can use the service of a translator by accessing the Commonwealth Government's Translating and Interpreting Service (TIS) and the Doctors Priority Line. To be eligible for the feefree TIS and Doctors Priority Line, the medical examiner must be in a private practice and provide a Medicare service to patients who do not speak English and are permanent residents.

A health assessment for refugees and other humanitarian entrants may only be claimed once by an eligible patient.

AN.7.12 Medical Practitioner Australian Defence Force Post-Discharge Health Assessment Items 224, 225, 226 and 227 may be used to undertake a health assessment for a former serving member of the Australian Defence Force, including a former member of permanent and reserve forces.

A health assessment for a former serving member of the Australian Defence Force is an assessment of:

- a patient's physical and psychological health and social function; and
- whether health care, education and other assistance should be offered to the patient to improve their physical, psychological health or social function.

This health assessment must include:

- 1. a personal attendance by a medical practitioner; and
- 2. taking the patient's history, including the following:
- i the patient's service with the Australian Defence Force, including service type, years of service, field of work, number of deployments and reason for discharge;
- ii the patient's social history, including relationship status, number of children (if any) and current occupation;

- iii the patient's current medical conditions;
- iv whether the patient suffers from hearing loss or tinnitus;
- v the patient's use of medication, including medication prescribed by another doctor and medication obtained without a prescription;
- vi the patient's smoking, if applicable;
- vii the patient's alcohol use, if applicable;
- viii the patient's substance use, if applicable;
- ix the patient's level of physical activity;
- x whether the patient has bodily pain;
- xi whether the patient has difficulty getting to sleep or staying asleep;
- xii whether the patient has psychological distress;
- xiii whether the patient has posttraumatic stress disorder;
- xiv whether the patient is at risk of harm to self or others;
- xv whether the patient has anger problems;
- xvi the patient's sexual health;

xvii any other health concerns the patient has.

The assessment must also include the following:

- 1. measuring the patient's height;
- 2. weighing the patient and ascertaining, or asking the patient, whether the patient's weight has changed in the last 12 months;
- 3. measuring the patient's waist circumference;
- 4. taking the patient's blood pressure;
- 5. using information gained in the course of taking the patient's history to assess whether any further assessment of the patient's health is necessary;
- 6. either making the further assessment or referring the patient to another medical practitioner who can make the further assessment:
- 7. documenting a strategy for improving the patient's health;
- 8. offering to give the patient a written report of the assessment that makes recommendations for treating the patient including preventive health measures;
- 9. keeping a record of the assessment.

A medical practitioner may use the 'ADF Post-discharge GP Health Assessment Tool' as a screening tool for the health assessment. This assessment tool can be viewed on the At Ease portal of the Department of Veterans' Affairs' website at: http://at-ease.dva.gov.au. Other assessment tools mentioned in the Department of Veteran's Affairs Mental Health Advice Book may be relevant and can also be viewed on the At Ease portal.

This health assessment may only be claimed once by an eligible patient.

The health assessment must not be performed in conjunction with a separate consultation in relation to the patient unless the consultation is clinically necessary.

The health assessment must be performed by the patient's usual doctor.

AN.7.13 Medical Practitioner Health Assessment for an Aboriginal and Torres Strait Islander People (Item 228)

This health assessment is available to all people of Aboriginal and Torres Strait Islander descent and should be used for health assessments for the following age categories:

- An Aboriginal or Torres Strait Islander child who is less than 15 years.
- An Aboriginal or Torres Strait Islander person who is aged between 15 years and 54 years.
- An Aboriginal or Torres Strait Islander older person who is aged 55 years and over.

A health assessment means the assessment of a patient's health and physical, psychological and social function and consideration of whether preventive health care and education should be offered to the patient, to improve that patient's health and physical, psychological and social function.

MBS item 228 must include the following elements:

- (a) information collection, including taking a patient history and undertaking examinations and investigations as required;
- (b) making an overall assessment of the patient;
- (c) recommending appropriate interventions;
- (d) providing advice and information to the patient; and
- (e) keeping a record of the health assessment, and offering the patient, and/or patient's carer, a written report about the health assessment with recommendations about matters covered by the health assessment; and
- (f) offering the patient's carer (if any, and if the medical practitioner considers it appropriate and the patient agrees) a copy of the report or extracts of the report relevant to the carer.

If, after receiving this health assessment, a patient who is aged fifteen years and over but under the age of 55 years, is identified as having a high risk of developing type 2 diabetes as determined by the Australian Type 2 Diabetes Risk Assessment Tool, the medical practitioner may refer that person to a subsidised lifestyle modification program, along with other possible strategies to improve the health status of the patient.

The Australian Type 2 Diabetes Risk Assessment Tool can be obtained from http://www.health.gov.au/preventionoftype2diabetes

A health assessment may only be claimed by a medical practitioner (not including a specialist or consultant physician).

A health assessment should generally be undertaken by the patient's 'usual doctor'. For the purpose of the health assessment, "usual doctor" means the medical practitioner, or a medical practitioner working in the same medical practice, which has provided the majority of primary health care to the patient over the previous twelve months and/or will be providing the majority of care to the patient over the next twelve months.

The health assessment for Aboriginal and Torres Strait Islander People is not available to people who are in-patients of a hospital or care recipients in a residential aged care facility.

A health assessment should not take the form of a health screening service (see General Explanatory Notes G.13.1).

MBS health assessment item 228 must be provided by a medical practitioner personally attending upon a patient. Suitably qualified health professionals, such as practice nurses, Aboriginal health workers or Aboriginal and Torres Strait Islander health practitioners employed and/or otherwise engaged by a general practice or health service, may assist medical practitioners in performing this health assessment. Such assistance must be provided in accordance with accepted medical practice and under the supervision of the medical practitioner. This may include activities associated with:

- information collection; and
- providing patients with information about recommended interventions at the direction of the medical practitioner.

The medical practitioner should be satisfied that the assisting health professional has the necessary skills, expertise and training to collect the information required for the health assessment.

Medical practitioners should not conduct a separate consultation in conjunction with a health assessment unless it is clinically necessary (ie. the patient has an acute problem that needs to be managed separately from the assessment).

Item 228 does not apply for services that are provided by any other Commonwealth or State funded services. However, where an exemption under subsection 19(2) of the Health Insurance Act 1973 has been granted to an Aboriginal Community Controlled Health Service or State/Territory Government health clinic, item 228 can be claimed for services provided by medical practitioners salaried by or contracted to, the Service or health clinic. All requirements of the item must be met.

Item 10990 or 10991 (bulk billing incentives) can be claimed in conjunction with any health assessment provided to an Aboriginal and Torres Strait Islander person, provided the conditions of item 10990 and 10991 are satisfied.

An eligible patient may only receive the Health Assessment for Aboriginal and Torres Strait Islander People using either item 228 or item 715 once in a 9 month period.

AN.7.14 Medical Practitioner Health Assessment for an Aboriginal and Torres Strait Islander Child less than 15 years of age (Item 228)

An Aboriginal and Torres Strait Islander child health assessment must include:

- a. a personal attendance by a medical practitioner;
- b. taking the patient's medical history, including the following:
- i. mother's pregnancy history;
- ii. birth and neo-natal history:
- iii. breastfeeding history;
- iv. weaning, food access and dietary history;
- v. physical activity;
- vi. previous presentations, hospital admissions and medication usage;
- vii. relevant family medical history;
- viii. immunisation status;
- ix. vision and hearing (including neonatal hearing screening);
- x. development (including achievement of age appropriate milestones);

- xi. family relationships, social circumstances and whether the person is cared for by another person;
- xii. exposure to environmental factors (including tobacco smoke);
- xiii. environmental and living conditions;
- xiv. educational progress;
- xv. stressful life events;
- xvi. mood (including incidence of depression and risk of self-harm);
- xvii.substance use;
- xviii. sexual and reproductive health; and
- xix. dental hygiene (including access to dental services).
- c. examination of the patient, including the following:
- i. measurement of height and weight to calculate body mass index and position on the growth curve;
- ii. newborn baby check (if not previously completed);
- iii. vision (including red reflex in a newborn);
- iv. ear examination (including otoscopy);
- v. oral examination (including gums and dentition);
- vi. trachoma check, if indicated;
- vii. skin examination, if indicated;
- viii. respiratory examination, if indicated;
- ix. cardiac auscultation, if indicated;
- x. development assessment, if indicated, to determine whether age appropriate milestones have been achieved;
- xi. assessment of parent and child interaction, if indicated; and
- xii. other examinations in accordance with national or regional guidelines or specific regional needs, or as indicated by a previous child health assessment.
- d. undertaking or arranging any required investigation, considering the need for the following tests, in particular:
- i. haemoglobin testing for those at a high risk of anaemia; and
- ii. audiometry, if required, especially for those of school age
- e. assessing the patient using the information gained in the child health check; and
- f. making or arranging any necessary interventions and referrals, and documenting a simple strategy for the good health of the patient.

AN.7.15 Medical Practitioner Health Assessment for an Aboriginal and Torres Strait Islander Adult Aged 15 Years to 54 Years (Item 228)

An Aboriginal and Torres Strait Islander adult health assessment must include:

- a. a personal attendance by a medical practitioner;
- b. taking the patient's medical history, including the following:
- i. current health problems and risk factors;
- ii. relevant family medical history;
- iii. medication usage (including medication obtained without prescription or from other doctors);
- iv. immunisation status, by reference to the appropriate current age and sex immunisation schedule;
- v. sexual and reproductive health;
- vi. physical activity, nutrition and alcohol, tobacco or other substance use;
- vii. hearing loss;
- viii. mood(including incidence of depression and risk of self-harm);
- ix. family relationships and whether the patient is a carer, or is cared for by another person; and
- x. vision
- c. examination of the patient, including the following:
- i. measurement of the patient's blood pressure, pulse rate and rhythm;
- ii. measurement of height and weight to calculate body mass index and, if indicated, measurement of waist circumference for central obesity;
- iii. oral examination (including gums and dentition);
- iv. ear and hearing examination (including otoscopy and, if indicated, a whisper test); and
- v. urinalysis (by dipstick) for proteinurea;
- vi. eye examination;
- d. undertaking or arranging any required investigation, considering the need for the following tests, in particular, (in accordance with national or regional guidelines or specific regional needs):
- i. fasting blood sugar and lipids (by laboratory based test on venous sample) or, if necessary, random blood glucose levels;
- ii. cervical screening;
- iii. examination for sexually transmitted infection (by urine or endocervical swab for chlamydia and gonorrhoea, especially for those aged from 15 to 35years); and
- iv. mammography, if eligible (by scheduling appointments with visiting services or facilitating direct referral).
- e. assessing the patient using the information gained in the adult health assessment; and

f. making or arranging any necessary interventions and referrals, and documenting a simple strategy for the good health of the patient.

An Aboriginal and Torres Strait Islander Older Person's health assessment must also include:

- a. keeping a record of the health assessment; and
- b. offering the patient a written report on the health assessment, with recommendations on matters covered by the health assessment.

AN.7.16 Medical Practitioner Health Assessment for an Aboriginal and Torres Strait Islander Older Person Aged 55 Years and Over (Item 228)

An Aboriginal and Torres Strait Islander Older Person's health assessment must include:

- a. a personal attendance by the medical practitioner;
- b. measurement of the patient's blood pressure, pulse rate and rhythm;
- c. an assessment of the patient's medication;
- d. an assessment of the patient's continence;
- e. an assessment of the patient's immunisation status for influenza, tetanus and pneumococcus;
- f. an assessment of the patient's physical function, including the patient's activities of daily living and whether or not the patient has had a fall in the last 3months;
- g. an assessment of the patient's psychological function, including the patient's cognition and mood;
- h. an assessment of the patient's social function, including:
- i. the availability and adequacy of paid, and unpaid, help;
- ii. whether the patient is responsible for caring for another person;
- i. an eye examination

An Aboriginal and Torres Strait Islander Older Person's health assessment must also include:

- a. keeping a record of the health assessment; and
- b. offering the patient a written report on the health assessment, with
- c. recommendations on matters covered by the health assessment; and
- d. offering the patient's carer (if any, and if the practitioner considers it appropriate and the patient agrees) a copy of the report or extracts of the report relevant to the carer.

AN.7.17 Medical Practitioner Chronic Disease Management (Items 229 to 233)

Description	Item No	Minimum claiming period*
Preparation of a GP Management Plan (GPMP)	229	12 months
Coordination of Team Care Arrangements (TCAs)	230	12 months
Contribution to a Multidisciplinary Care Plan, or to a Review of a Multidisciplinary Care Plan, for a patient who is not a care recipient in a residential aged care facility	231	3 months
Contribution to a Multidisciplinary Care Plan, or to a review of a multidisciplinary care plan, for a resident in an aged care facility	232	3 months
Review of a GP Management Plan or Coordination of a Review of Team Care Arrangements	233	3 months

^{*} CDM services may be provided more frequently in the exceptional circumstances defined below.

Exceptional circumstances exist for a patient if there has been a significant change in the patient's clinical condition or care requirements that necessitates the performance of the service for the patient.

Regulatory requirements

Items 229, 230, 231, 232 and 233 provide rebates for medical practitioners to manage chronic or terminal medical conditions by preparing, coordinating, reviewing or contributing to chronic disease management (CDM) plans. They apply for a patient who suffers from at least one medical condition that has been present (or is likely to be present) for at least six months or is terminal.

Restrictions on claiming multiple Chronic Disease Management Items

Patients may receive chronic disease management services using MBS items 229 to 223 and 721 to 732. However, once a patient has received a service using an MBS item from **either** group of MBS chronic disease management items, the patient may not receive another MBS chronic disease management service until the minimum claiming period has expired. The only exception is where there are exceptional circumstances necessitating an earlier performance of the service (see **Claiming of benefits** below).

If a medical practitioner is not sure if a patient is eligible for an MBS chronic disease management service, they may telephone the Department of Human Services on 132011, with the patient present, to check eligibility.

Restriction of Co-claiming of Chronic Disease and General Consultation Items

Co-claiming of MBS general consultation items 3, 4, 23, 24, 36, 37, 44, 47, 52, 53, 54, 57, 58, 59, 60, 65, 179, 181, 185, 187, 189, 191, 203, 206, 585, 588, 591, 594, 599, 600, 733, 737, 741, 745, 761, 763, 766, 769, 5000, 5020, 5023, 5040, 5043, 5060, 5063, 5200, 5203, 5207, 5208, 5220, 5223, 5227, 5228 with chronic disease management items 229, 230 and 233 is not permitted for the same patient, on the same day.

Patient eligibility

CDM items 229, 230 and 233 are available to:

- i patients in the community; and
- ii private in-patients of a hospital (including private in-patients who are residents of aged care facilities) being discharged from hospital.

CDM items 229, 230 and 233 are not available to:

- i public in-patients of a hospital; or
- ii care recipients in a residential aged care facility.

CDM item 231 is available to:

- i patients in the community;
- ii both private and public in-patients being discharged from hospital.

CDM item 231 is not available to:

i care recipients in a residential aged care facility.

CDM item 232 is available to care recipients in a residential aged care facility only.

Components of service

Item 229

A comprehensive written plan must be prepared describing:

- a. the patient's health care needs, health problems and relevant conditions;
- b. management goals with which the patient agrees;
- c. actions to be taken by the patient;
- d. treatment and services the patient is likely to need;
- e. arrangements for providing this treatment and these services; and
- f. arrangements to review the plan by a date specified in the plan.

In preparing the plan, the medical practitioner must:

- a. explain to the patient and the patient's carer (if any, and if the medical practitioner considers it appropriate and the patient agrees) the steps involved in preparing the plan; and
- b. record the plan; and
- c. record the patient's agreement to the preparation of the plan; and
- d. offer a copy of the plan to the patient and the patient's carer (if any, and if the medical practitioner considers it appropriate and the patient agrees); and
- e. add a copy of the plan to the patient's medical records.

Item 230

When coordinating the development of Team Care Arrangements (TCAs), the medical practitioner must:

- a. consult with at least two collaborating providers, each of whom will provide a different kind of treatment or service to the patient, and one of whom may be another medical practitioner, when making arrangements for the multidisciplinary care of the patient; and
- b. prepare a document that describes:

- i treatment and service goals for the patient;
- ii treatment and services that collaborating providers will provide to the patient; and
- iii actions to be taken by the patient;
- iv arrangements to review (i), (ii) and (iii) by a date specified in the document; and
- c. explain the steps involved in the development of the arrangements to the patient and the patient's carer (if any, and if the medical practitioner considers it appropriate and the patient agrees);
- d. discuss with the patient the collaborating providers who will contribute to the development of the TCAs and provide treatment and services to the patient under those arrangements; and
- e. record the patient's agreement to the development of TCAs;
- f. give copies of the relevant parts of the document to the collaborating providers;
- g. offer a copy of the document to the patient and the patient's carer (if any, and if the medical practitioner considers it appropriate and the patient agrees); and
- h. add a copy of the document to the patient's medical records.

One of the minimum two service providers collaborating with the medical practitioner can be another medical practitioner. The patient's informal or family carer can be included in the collaborative process but does not count towards the minimum of three collaborating providers.

Item 231

A multidisciplinary care plan means a written plan that:

- a. is prepared for a patient by:
- i a medical practitioner in consultation with two other collaborating providers, each of whom provides a different kind of treatment or service to the patient, and one of whom may be another medical practitioner; or
- ii a collaborating provider (other than a medical practitioner) in consultation with at least two other collaborating providers, each of whom provides a different kind of treatment or services to the patient; and
- b. describes, at least, treatment and services to be provided to the patient by the collaborating providers.

When contributing to a multidisciplinary care plan or to a review of the care plan, the medical practitioner must:

- i. prepare part of the plan or amendments to the plan and add a copy to the patient's medical records; or
- j. give advice to a person who prepares or reviews the plan and record in writing, on the patient's medical records, any advice provided to such a person.

Item 232

A multidisciplinary care plan in a Residential Aged Care Facility (RACF) means a written plan that:

- a. is prepared for a patient by a collaborating provider (other than a medical practitioner, e.g. a RACF), in consultation with at least two other collaborating providers, each of whom provides a different kind of treatment or services to the patient; and
- b. describes, at least, treatment and services to be provided to the patient by the collaborating providers.

When contributing to a multidisciplinary care plan or to a review of the care plan, the medical practitioner must:

- a. prepare part of the plan or amendments to the plan and add a copy to the patient's medical records; or
- b. give advice to a person who prepares or reviews the plan and record in writing, on the patient's medical records, any advice provided to such a person.

Item 232 can also be used for contribution to a multidisciplinary care plan prepared for a resident by another provider before the resident is discharged from a hospital or an approved day-hospital facility, or to a review of such a plan prepared by another provider (not being a service associated with a service to which items 235 to 240 apply).

Item 233

An "associated medical practitioner" is a medical practitioner who, if not engaged in the same general practice as the medical practitioner mentioned in that item, performs the service mentioned in the item at the request of the patient (or the patient's guardian).

When reviewing a GP Management Plan, the medical practitioner must:

- a. explain to the patient and the patient's carer (if any, and if the medical practitioner considers it appropriate and the patient agrees) the steps involved in the review;
- b. record the patient's agreement to the review of the plan;
- c. review all the matters set out in the relevant plan;
- d. make any required amendments to the patient's plan;
- e. offer a copy of the amended document to the patient and the patient's carer (if any, and if the medical practitioner considers it appropriate and the patient agrees);
- f. add a copy of the amended document to the patient's records; and
- g. provide for further review of the amended plan by a date specified in the plan.

When coordinating a review of Team Care Arrangements, a multidisciplinary community care plan or a multidisciplinary discharge care plan, the medical practitioner must:

- a. explain the steps involved in the review to the patient and the patient's carer (if any, and if the medical practitioner considers it appropriate and the patient agrees);
- b. record the patient's agreement to the review of the TCAs or plan;
- c. consult with at least two health or care providers (each of whom provides a service or treatment to the patient that is different from each other and different from the service or treatment provided by the medical practitioner who is coordinating the TCAs or plan) to review all the matters set out in the relevant plan;
- d. make any required amendments to the patient's plan;
- e. offer a copy of the amended document to the patient and the patient's carer (if any, and if the medical practitioner considers it appropriate and the patient agrees);
- f. provide for further review of the amended plan by a date specified in the plan;
- g. give copies of the relevant parts of the amended plan to the collaborating providers; and
- h. add a copy of the amended document to the patient's records.

Item 233 can also be used to COORDINATE A REVIEW OF a Multidisciplinary Community Care Plan or to COORDINATE REVIEW OF A Discharge Care, where these services were coordinated or prepared by that medical

practitioner (or an associated medical practitioner), and not being a service associated with a service to which items 235 to 240 apply.

Claiming of benefits

Each service to which item 233 applies (i.e. Review of a GP Management Plan and Review of Team Care Arrangements) may be claimed once in a three-month period, except where there are exceptional circumstances arising from a significant change in the patient's clinical condition or care circumstances that necessitates earlier performance of the service for the patient.

Where a service is provided in exceptional circumstances, the patient's invoice or Medicare voucher should be annotated to indicate the reason why the service was required earlier than the minimum time interval for the relevant item. Payment can then be made.

Item 233 can be claimed twice on the same day providing an item 233 for reviewing a GP Management Plan and another 233 for reviewing Team Care Arrangements (TCAs) are both delivered on the same day as per the MBS item descriptors and explanatory notes.

Medicare requirements when item 233 is claimed twice on the same day

If a GPMP and TCAs are both reviewed on the same date and item 233 is to be claimed twice on the same day, both electronic claims and manual claims need to indicate they were rendered at different times:

Non electronic Medicare claiming of items 233 on the same date

The time that each item 233 commenced should be indicated next to each item

Electronic Medicare claiming of item 233 on the same date

Medicare Easyclaim: use the 'ItemOverrideCde" set to 'AP', which flags the item as not duplicate services Medicare Online/ECLIPSE: set the 'DuplicateServiceOverrideIND' to 'Y', which flags the item as not duplicate

Items 229, 230 233

The GP Management Plan items (229 and 233) and the Team Care Arrangement items (230 and 233) cannot be claimed by medical practitioners when they are a recognised specialist in the specialty of palliative medicine and treating a referred palliative care patient under items 3005-3093. The referring practitioner is able to provide the CDM services.

Additional information

Advice on the items and further guidance are available at http://www.health.gov.au/mbsprimarycareitems

Items 229-233 should generally be undertaken by the patient's usual medical practitioner. This means the medical practitioner, or a medical practitioner working in the same medical practice, who has provided the majority of care to the patient over the previous twelve months and/or will be providing the majority of medical services to the patient over the next twelve months. The term "usual medical practitioner" would not generally apply to a practice that provides only one specific CDM service.

A practice nurse, Aboriginal and Torres Strait Islander health practitioner, Aboriginal health worker or other health professional may assist with items 229, 230 and 233 (e.g. in patient assessment, identification of patient needs and making arrangements for services). However, the medical practitioner must meet all regulatory requirements, review and confirm all assessments and see the patient.

Patients being managed under the chronic disease management items may be eligible for:

- individual allied health services (items 10950 to 10970); and/or
- group allied health services (items 81100 to 81125).

More information on eligibility requirements can be found in the explanatory note for individual allied health services and group allied health services.

Further information is also available for providers from the Department of Human Services provider inquiry line on 132 150.

AN.7.18 Medical Practitioner Medication Management Reviews (Items 245 and 249) Item 245 - Domiciliary Medication Management Review

A Domiciliary Medication Management Review (DMMR) (Item 245), also known as Home Medicines Review, is intended to maximise an individual patient's benefit from their medication regimen, and prevent medication-related problems through a team approach, involving the patient's medical practitioner and preferred community pharmacy or accredited pharmacist.

Patient eligibility

The item is available to people living in the community who meet the criteria for a DMMR.

The item is not available for in-patients of a hospital, or care recipients in residential aged care facilities.

DMMRs are targeted at patients who are likely to benefit from such a review:

- patients for whom quality use of medicines may be an issue or;
- patients who are at risk of medication misadventure because of factors such as their co-morbidities, age or social circumstances, the characteristics of their medicines, the complexity of their medication treatment regimen, or a lack of knowledge and skills to use medicines to their best effect.

DMMR's are targeted at patients who are:

- currently taking five or more regular medications;
- taking more than 12 doses of medication per day;
- have had significant changes made to medication treatment regimen in the last three months;
- taking medication with a narrow therapeutic index or medications requiring therapeutic monitoring;
- experiencing symptoms suggestive of an adverse drug reaction;
- displaying sub-optimal response to treatment with medicines:
- suspected of non-compliance or inability to manage medication related therapeutic devices;
- having difficulty managing their own medicines because of literacy or language difficulties, dexterity problems or impaired sight, confusion/dementia or other cognitive difficulties;
- attending a number of different doctors, both medical practitioners and specialists; and/or
- recently discharged from a facility / hospital (in the last four weeks).

In referring a patient for a DMMR, medical practitioners should note that only patients meeting the following criteria will have the pharmacist portion funded through a Community Pharmacy Agreement program:

- Is a Medicare and/or Department of Veterans' Affairs (DVA) cardholder or a person who is eligible for a Medicare card;
- Is subject to a chronic condition and/or complex medication regimen; and
- Is failing to respond to treatment in the expected manner.

If the patient does not meet these criteria, the medical practitioner can still issue a referral under this item. However, the remainder of the service will be on a "user pays" basis as determined by the accredited pharmacist.

REGULATORY REQUIREMENTS

In conducting a DMMR, a medical practitioner must, with the patient's consent:

- (a) assess a patient is subject to a chronic medical condition and/or complex medication regimen but their therapeutic goals are not being met; and
- (b) following that assessment, refer the patient to a community pharmacy or an accredited pharmacist for a DMMR and provide the relevant clinical information required for the review; and
- (c) discuss with the reviewing pharmacist the result of that review including suggested medication management strategies; and
- (d) develop a written medication management plan following discussion with the patient; and
- (e) provide the written medication management plan to a community pharmacy chosen by the patient.

For any particular patient - applicable not more than once in each 12 month period, except if there has been a significant change in the patient's condition or medication regimen requiring a new DMMR.

Claiming

A DMMR includes all DMMR-related services provided by the medical practitioner from the time the patient is identified as potentially needing a medication management review to the preparation of a draft medication management plan, and discussion and agreement with the patient.

The benefit is not claimable until all the components of the item have been rendered.

Benefits for a DMMR service under item 245 are payable only once in each 12 month period, except where there has been a significant change in the patient's condition or medication regimen requiring a new DMMR (e.g. diagnosis of a new condition or recent discharge from hospital involving significant changes in medication). In such cases the patient's invoice or Medicare voucher should be annotated to indicate that the DMMR service was required to be provided within 12 months of another DMMR service.

Provision of a subsequent DMMR must not be made solely by reaching an anniversary date, and the service is not intended to be undertaken on an ongoing review cycle.

If the DMMR is initiated during the course of a consultation undertaken for another purpose, this consultation may also be claimed separately.

If the consultation at which the medication management review is initiated is only for the purposes of initiating the review, only item 245 may be claimed.

If the medical practitioner determines that a DMMR is not necessary, item 245 does not apply. In this case, normal consultation items should be used.

Where a DMMR cannot be completed due to circumstances beyond the control of the medical practitioner (e.g. because the patient decides to not proceed further with the DMMR, or because of a change in the circumstances of the patient), the relevant MBS attendance items should be used.

FURTHER GUIDANCE

A DMMR should generally be undertaken by the patient's usual medical practitioner. This is the medical practitioner, or a medical practitioner working in the same medical practice, that has provided the majority of services to the patient over the previous 12 months and/or will be providing the majority of services to the patient over the coming 12 months.

The potential need for a DMMR may be identified either by the medical practitioner in the process of a consultation or by receipt of advice from the patient, a carer or another health professional including a pharmacist.

The process of referral to a community pharmacy or an accredited pharmacist includes:

- Obtaining consent from the patient, consistent with normal clinical practice, for a pharmacist to undertake the medication management review and for a charge to be incurred for the service for which a Medicare rebate is payable. The patient must be clearly informed of the purpose and possible outcomes of the DMMR, the process involved (including that the pharmacist will visit the patient at home, unless exceptional circumstances apply or they are an Aboriginal or Torres Strait Islander patient), what information will be provided to the pharmacist as part of the DMMR, and any additional costs that may be incurred; and
- Provision to the patient's preferred community pharmacy or accredited pharmacist, of relevant clinical
 information, by the medical practitioner for each individual patient, covering the patient's diagnosis,
 relevant test results and medication history, and current prescribed medications.

A DMMR referral form is available for this purpose. If this form is not used, the medical practitioner must provide patient details and relevant clinical information to the patient's preferred community pharmacy or accredited pharmacist.

The discussion of the review findings and report including suggested medication management strategies with the reviewing pharmacist includes:

- Receiving a written report from the reviewing pharmacist; and
- Discussing the relevant findings and suggested management strategies with the pharmacist (either by phone or face to face); and
- Developing a summary of the relevant review findings as part of the draft medication management plan.

Development of a written medication management plan following discussion with the patient includes:

- Developing a draft medication management plan and discussing this with the patient; and
- Once agreed, offering a copy of the written medication management plan to the patient and providing a copy to the community pharmacy or accredited pharmacist.

The agreed plan should identify the medication management goals and the proposed medication regimen for the patient.

Item 249 - Residential Medication Management Review

A Residential Medication Management Review (RMMR) is a collaborative service available to permanent residents of a Residential Aged Care facility (RACF) who are likely to benefit from such a review. This includes residents for whom quality use of medicines may be an issue or residents who are at risk of medication misadventure because of a significant change in their condition or medication regimen.

Patient eligibility

RMMRs are available to:

- new residents on admission into a RACF; and
- existing residents on an 'as required' basis, where in the opinion of the resident's medical practitioner, it is required because of a significant change in medical condition or medication regimen.

RMMRs are not available to people receiving respite care in a RACF. Domiciliary Medicines Reviews are available to these people when they are living in the community setting.

REGULATORY REQUIREMENTS

When conducting a RMMR, a medical practitioner must:

(a) discuss the proposed review with the resident and seek the resident's consent to the review; and

- (b) collaborate with the reviewing pharmacist about the pharmacist's involvement in the review; and
- (c) provide input from the resident's most recent comprehensive medical assessment or, if such an assessment has not been undertaken, provide relevant clinical information for the review and for the resident's records; and
- (d) If recommended changes to the resident's medication management arise out of the review, participate in a post-review discussion (either face-to-face or by telephone) with the pharmacist to discuss the outcomes of the review including:
- (i) the findings; and
- (ii) medication management strategies; and
- (iii) means to ensure that the strategies are implemented and reviewed, including any issues for implementation and follow-up; and
- (iv) develop or revise the resident's medication management plan after discussion with the reviewing pharmacist; and
- (v) finalise the plan after discussion with the resident.

A medical practitioner's involvement in a residential medication management review also includes:

- (a) offering a copy of the medication management plan to the resident (or the resident's carer or representative if appropriate); and
- (b) providing copies of the plan for the resident's records and for the nursing staff of the residential aged care facility; and
- (c) discussing the plan with nursing staff if necessary.

A post-review discussion is not required if:

- (a) there are no recommended changes to the resident's medication management arising out of the review; or
- (b) any changes are minor in nature and do not require immediate discussion; or
- (c) the pharmacist and medical practitioner agree that issues arising out of the review should be considered in a case conference.

A RMMR comprises all activities to be undertaken by the medical practitioner from the time the resident is identified as potentially needing a medication management review up to the development of a written medication management plan for the resident.

Claiming

A maximum of one RMMR rebate is payable for each resident in any 12 month period, except where there has been a significant change in the resident's medical condition or medication regimen requiring a new RMMR.

Benefits are payable when all the activities of a RMMR have been completed. A RMMR service covers the consultation at which the results of the medication management review are discussed and the medication management plan agreed with the resident:

- any immediate action required to be done at the time of completing the RMMR, based on and as a direct result of information gathered in the RMMR, should be treated as part of the RMMR item;
- any subsequent follow up should be treated as a separate consultation item;

• an additional consultation in conjunction with completing the RMMR should not be undertaken unless it is clinically indicated that a problem must be treated immediately.

In some cases a RMMR may not be able to be completed due to circumstances beyond the control of the medical practitioner (e.g. because the resident decides not to proceed with the RMMR or because of a change in the circumstances of the resident). In these cases the relevant MBS attendance item should be used in relation to any consultation undertaken with the resident

If the consultation at which the RMMR is initiated, including discussion with resident and obtaining consent for the RMMR, is only for the purposes of initiating the review, only the RMMR item should be claimed.

If the RMMR is initiated during the course of a consultation undertaken for another purpose, the other consultation may be claimed as a separate service and the RMMR service would also apply.

If the medical practitioner determines that an RMMR is not necessary, the RMMR item does not apply. In this case, relevant consultation items should be used.

FURTHER GUIDANCE

A RMMR should generally be undertaken by the resident's 'usual medical practitioner'. This is the medical practitioner, or a medical practitioner working in the same medical practice, that has provided the majority of care to the resident over the previous 12 months and/or will be providing the majority of care to the resident over the next 12 months.

Medical practitioners who provide services on a facility-wide contract basis, and/or who are registered to provide services to RACFs as part of aged care panel arrangements, may also undertake RMMRs for residents as part of their services.

Generally, new residents should receive an RMMR as soon as possible after admission. Where a resident has a Comprehensive Medical Assessment (CMA), the RMMR should be undertaken preferably after the results of the CMA are available to inform the RMMR.

A RMMR service should be completed within a reasonable time-frame. As a general guide, it is expected that most RMMR services would be completed within four weeks of being initiated.

The resident's medical practitioner may identify the potential need for an 'as required' RMMR for existing residents, including in the course of a consultation for another purpose. The potential need for an RMMR may also be identified by the reviewing pharmacist, supply pharmacist, Residential Aged Care Facility staff, the resident, the resident's carer or other members of the resident's health care team.

The medical practitioner should assess the clinical need for an RMMR from a quality use of medicines perspective with the resident as the focus, and initiate an RMMR if appropriate, in collaboration with the reviewing pharmacist.

The medical practitioner and reviewing pharmacist should agree on a preferred means for communicating issues and information relating to the provision of an RMMR service. This should include the method(s) of initiating the RMMR, exceptions to the post review discussion, and the preferred method of communication. This can be done on a facility basis rather than on a case-by-case basis.

Where the provision of RMMR services involves consultation with a resident it should be read as including consultation with the resident and/or their carer or representative where appropriate.

RMMRs do not count for the purposes of derived fee arrangements that apply to other consultations in a Residential Aged Care Facility.

AN.7.19 Medical Practitioner Cervical Screen from a Person Who is Unscreened or Significantly Under-Screened (Items 251 to 257) Eligibility

Items 251 to 257 are available to medical practitioners providing services in eligible areas.

Eligible area means an area that is a Modified Monash 2 area, Modified Monash 3 area, Modified Monash 4 area, Modified Monash 5 area, Modified Monash 6 area or Modified Monash 7 area.

Medical practitioners providing services in a Modified Monash 1 area should use the items in Group A19, Subgroup 1

A locator map to identify a medical practice's Modified Monash Model Area location is available at the DoctorConnect website at http://www.doctorconnect.gov.au/internet/otd/publishing.nsf/Content/locator

Guidance Notes

Item numbers 251, 252, 253, 254, 255, 256 and 257 should be used in place of the usual attendance item where as part of a consultation, a sample for cervical screening is collected from a person between the ages of 24 years and 9 months and 74 years inclusive who has not had a cervical smear in the last four years. Cervical Screening in accordance with the National Cervical Screening Policy at P.16.11.

Self-collection of a sample for screening is only available for women between the ages of 30 and 74 years of age who are overdue for screening by two or more years (i.e. being 4 years since their last Pap test). Self-collection should only be offered to an eligible person who refuses to have a sample collected by their requesting practitioner.

When providing this service, the medical practitioner must satisfy themselves that the person has not had a cervical screening test in the last four years by:

- (a) asking the person if they can remember having a cervical screening test in the last four years;
- (b) checking their own practice's medical records; and
- (c) checking the National Cancer Screening Register.

A person from the following groups are more likely than the general population to be unscreened or significantly under screened - low socio-economic status, culturally and linguistically diverse backgrounds, Indigenous communities, rural and remote areas and older people.

Vault smears are not eligible for items 251 to 257.

In addition to attracting a Medicare rebate, the use of these items will initiate a Cervical Screening SIP through the PIP.

A PIP Cervical Screening SIP is available for taking a cervical screen from a person who has not been screened in the last for four years. The SIP will be paid to the medical practitioner who provided the service if the service was provided in a medical practice participating in the PIP Cervical Screening Incentive. A further PIP Cervical Screening Incentive payment is paid to medical practices which reach target levels of cervical screening for their patients aged 24 years and 9 months of age to 74 years inclusive. More detailed information on the PIP Cervical Screening Incentive is available from the Department of Human Services PIP enquiry line on 1800 222 032 or from the Department of Human Services website.

AN.7.20 Medical Practitioner Completion of the Annual Diabetes Cycle of Care for Patients with Established Diabetes Mellitus (Items 259 to 264) Eligibility

Items 259 to 264 are available to medical practitioners providing services in eligible areas.

Eligible area means an area that is a Modified Monash 2 area, Modified Monash 3 area, Modified Monash 4 area, Modified Monash 5 area, Modified Monash 6 area or Modified Monash 7 area.

Medical practitioners providing services in a Modified Monash 1 area should use the items in Group A19, Subgroup 2.

A locator map to identify a medical practice's Modified Monash Model Area location is available at the DoctorConnect website at http://www.doctorconnect.gov.au/internet/otd/publishing.nsf/Content/locator

Guidance Notes

Item numbers 259, 260, 261, 262, 263 and 264 should be used in place of the usual attendance item when a consultation completes the minimum requirements of the annual Diabetes Cycle of Care for a patient with established diabetes mellitus.

The annual Diabetes Cycle of Care must be completed over a period of 11 months and up to 13 months, and at a minimum must include:

Assess diabetes control by measuring HbA1c	At least once every year
Ensure that a comprehensive eye examination is carried out*	At least once every two years
Measure weight and height and calculate BMI**	At least twice every cycle of care
Measure blood pressure	At least twice every cycle of care
Examine feet***	At least twice every cycle of care
Measure total cholesterol, triglycerides and HDL cholesterol	At least once every year
Test for microalbuminuria	At least once every year
Test for estimated Glomerular Filtration Rate (eGFR)	At least once every year
Provide self-care education	Patient education regarding diabetes management
Review diet	Reinforce information about appropriate dietary choices
Review levels of physical activity	Reinforce information about appropriate levels of physical activity
Check smoking status	Encourage cessation of smoking (if relevant)
Review of Medication	Medication review

^{*}Not required if the patient is blind or does not have both eyes.

Subsequent visits: measure weight.

These requirements are generally based on the current guidelines produced by Diabetes Australia and the Royal Australian College of General Practitioners (Diabetes Management in General Practice). Medical practitioners using these items should familiarise themselves with these guidelines and with subsequent editions of these guidelines as they become available.

Use of these items certifies that the minimum requirements of the Diabetes Cycle of Care have been completed for a patient with established diabetes mellitus in accordance with the guidelines above.

These items should only be used once per cycle per patient: A7 Subgroup 8, A18 Subgroup 2 or A19 Subgroup 2. For example, if item 259 is claimed for a patient then no other diabetes item in groups A18 or A19 can be used for this patient in the same cycle.

^{**}Initial visit: measure height and weight and calculate BMI as part of the initial assessment.

^{***}Not required if the patient does not have both feet.

The requirements for claiming these items are the minimum needed to provide good care for a patient with diabetes. Additional levels of care will be needed by insulin-dependent patients and those with abnormal review findings, complications and/or co-morbidities.

In addition to attracting a Medicare rebate, recording a completion of a Diabetes Cycle of Care through the use of these items will initiate a Diabetes Service Incentive Payment (SIP) through the Practice Incentives Program (PIP).

All visits should be billed under the normal attendance items with the exception of the visit that completes all of the minimum requirements of the Diabetes Cycle of Care.

A PIP Diabetes SIP is available for completing the minimum requirements of the Diabetes Cycle of Care for individual patients as specified above. The Diabetes SIP is only paid once every 11-13 month period per patient. The SIP will be paid to the medical practitioner who provided the service if the service was provided in a medical practice participating in the PIP Diabetes Incentive. A further PIP Diabetes Incentive payment is paid to medical practices which reach target levels of care for their patients with diabetes mellitus. More detailed information on the PIP Diabetes Incentive is available from the Department of Human Services PIP enquiry line on 1800 222 032 or the Department of Human Services website.

AN.7.21 Medical Practitioner Completion of the Asthma Cycle of Care (Items 265 to 271) Eligibility

Items 265 to 271 are available to medical practitioners providing services in eligible areas.

Eligible area means an area that is a Modified Monash 2 area, Modified Monash 3 area, Modified Monash 4 area, Modified Monash 5 area, Modified Monash 6 area or Modified Monash 7 area.

Medical practitioners providing services in a Modified Monash 1 area should use the items in Group A19, Subgroup 3.

A locator map to identify a medical practice's Modified Monash Model Area location is available at the DoctorConnect website at http://www.doctorconnect.gov.au/internet/otd/publishing.nsf/Content/locator

Guidance Notes

Item numbers 265, 266, 268, 269, 270 and 271 should be used in place of the usual attendance item when a consultation completes the minimum requirements of the Asthma Cycle of Care. The Practice Incentives Program (PIP) Asthma Incentive is for patients with moderate to severe asthma who in the opinion of the medical practitioner could benefit from review, eg those whose asthma management could be improved.

At a minimum the Asthma Cycle of Care must include:

- At least 2 asthma related consultations within 12 months for a patient with moderate to severe asthma (at least 1 of which (the review consultation) is a consultation that was planned at a previous consultation);
- Documented diagnosis and assessment of level of asthma control and severity of asthma;
- Review of the patient's use of and access to asthma-related medication and devices;
- Provision to the patient of a written asthma action plan (if the patient is unable to use a written asthma action plan discussion with the patient about an alternative method of providing an asthma action plan, and documentation of the discussion in the patient's medical records);
- Provision of asthma self-management education to the patient, and
- Review of the written or documented asthma action plan.

The Asthma Cycle of Care should be provided to a patient by one medical practitioner or in exceptional circumstances by another medical practitioner within the same practice. In most cases, this will be the patient's usual medical practitioner. Completion of the Asthma Cycle of Care does not preclude referral to a specialist, but a specialist consultation cannot be counted as one of the two visits.

The patient's medical record should include documentation of each of these requirements and the clinical content of the patient-held written asthma action plan.

These items will only be payable for the completion of one Asthma Cycle of Care for each eligible patient per 12 month period, unless a further Asthma Cycle of Care is clinically indicated by exceptional circumstances.

If a subsequent Asthma Cycle of Care is indicated and the incentive item is to be claimed more than once per 12 month period for a patient, then the patient's invoice or Medicare voucher should be annotated to indicate that the Asthma Cycle of Care was required to be provided within 12 months of another Asthma Cycle of Care.

The minimum requirements of the Asthma Cycle of Care may be carried out in two (2) visits or if necessary as many visits as clinically required. The National Asthma Council's website provides a guide for completion of the Asthma Cycle of Care.

The visit that completes the Asthma Cycle of Care should be billed using the appropriate item listed in Group A7 Subgroup 8.

All visits should be billed under the normal attendance items with the exception of the visit that completes all of the minimum requirements of the Asthma Cycle of Care.

In addition to attracting a Medicare rebate, recording a completion of an Asthma Cycle of Care through the use of these items, will initiate an Asthma Service Incentive Payment (SIP) through the PIP.

A PIP Asthma SIP is available for completing the minimum requirements of the Asthma Cycle of Care for individual patients as specified above. The SIP will be paid to the medical practitioner who provided the service if the service was provided in a medical practice participating in the PIP Asthma Incentive. More detailed information on the PIP Asthma Incentive is available from the Department of Human Services PIP enquiry line on 1800222032 or from the Department of Human Services website.

For more detailed information regarding asthma diagnosis, assessment and best practice management refer to the National Asthma Council's <u>website</u>.

Assessment of Severity

Generally, patients who meet the following criteria can be assumed to have been assessed as having moderate to severe asthma:

- Symptoms on most days, OR
- Use of preventer medication, OR
- Bronchodilator use at least 3 times per week, OR
- Hospital attendance or admission following an acute exacerbation of asthma.

Where the general rule does not apply to a particular patient, the classification of severity described by the current edition of the National Asthma Council's Asthma Management Handbook can be used. Visit the National Asthma Council's website for more details.

AN.7.22 Medical Practitioner Mental Health Treatment (Items 272 to 282)

This note provides information on the Mental Health Treatment items 272, 276, 277, 279, 281 and 282. It includes an overview of the items, patient and provider eligibility, what activities are involved in providing services rebated by these items, links to other Medicare items and additional claiming information.

Overview

The Mental Health Treatment items define services for which Medicare rebates are payable where medical practitioners undertake early intervention, assessment and management of patients with mental disorders. They include referral pathways for treatment by psychiatrists, clinical psychologists and other allied mental health workers. These items complement the mental health items for psychiatrists (items 296 - 299), clinical psychologists (items 80000 - 80021) and allied mental health providers (items 80100 - 80171).

The Mental Health Treatment items incorporate a model for best practice primary health treatment of patients with mental disorders, including patients with both chronic or non-chronic disorders, that comprises:

- assess and plan;
- provide and/or refer for appropriate treatment and services; and
- review and ongoing management as required.

Who can provide

The GP Mental Health Treatment Plan, Review and Consultation items are available for use in general practice by medical practitioners, but excluding specialists or consultant physicians.

Training Requirements (item 281 and 282)

Medical practitioner providing GP Mental Health Treatment Plans, and who have undertaken mental health skills training recognised through the General Practice Mental Health Standards Collaboration, have access to items 281 and 282. For medical practitioners who have not undertaken training, items 272 and 276 are available. Items 272 provides for a GP Mental Health Treatment Plan lasting at least 20 minutes and item 276 provides for a GP Mental Health Treatment Plan lasting at least 40 minutes. It is strongly recommended that medical practitioners providing mental health treatment have appropriate mental health training. Medical professional organisations support the value of appropriate mental health training for medical practitioners using these items.

Which patients are eligible - Mental Disorder

These items are for patients with a mental disorder who would benefit from a structured approach to the management of their treatment needs. Mental disorder is a term used to describe a range of clinically diagnosable disorders that significantly interfere with an individual's cognitive, emotional or social abilities (Refer to the World Health Organisation, 1996, Diagnostic and Management Guidelines for Mental Disorders in Primary Care: ICD-10 Chapter V Primary Care Version). Dementia, delirium, tobacco use disorder and mental retardation are not regarded as mental disorders for the purposes of the Mental Health Treatment items.

These services are available to eligible patients in the community. Mental Health Treatment Plan and Review services can also be provided to private in-patients (including private in-patients who are residents of aged care facilities) being discharged from hospital. Where the medical practitioner who provides the Mental Health Treatment item is providing in-patient treatment the item is claimed as an in-hospital service (at 75% MBS rebate). Medical practitioners are able to contribute to care plans for patients using item 231, Contribution to a Multidisciplinary Care Plan, and to care plans for residents of aged care facilities using item 232.

PREPARING A GP MENTAL HEALTH TREATMENT PLAN (Item 272, 276, 281 or 282)

What is involved - Assess and Plan

A rebate can be claimed once the medical practitioner has undertaken an assessment and prepared a GP Mental Health Treatment Plan by completing the steps from Assessment to the point where patients do not require a new

plan after their initial plan has been prepared, and meeting the relevant requirements listed under 'Additional Claiming Information'. This item covers both the assessment and preparation of the GP Mental Health Treatment Plan. Where the patient has a carer, the practitioner may find it useful to consider having the carer present for the assessment and preparation of the GP Mental Health Treatment Plan or components thereof (subject to patient agreement).

Assessment

An assessment of a patient must include:

- recording the patient's agreement for the GP Mental Health Treatment Plan service;
- taking relevant history (biological, psychological, social) including the presenting complaint;
- conducting a mental state examination;
- assessing associated risk and any co-morbidity;
- making a diagnosis and/or formulation; and
- administering an outcome measurement tool, except where it is considered clinically inappropriate.

The assessment can be part of the same consultation in which the GP Mental Health Treatment Plan is developed, or can be undertaken in different visits. Where separate visits are undertaken for the purpose of assessing the patient and developing the GP Mental Health Treatment Plan, they are part of the GP Mental Health Treatment Plan service and are included in item 272, 276, 281 or 282.

In order to facilitate ongoing patient focussed management, an outcome measurement tool should be utilised during the assessment and the review of the GP Mental Health Treatment Plan, except where it is considered clinically inappropriate. The choice of outcome measurement tools to be used is at the clinical discretion of the practitioner. Medical practitioners using such tools should be familiar with their appropriate clinical use, and if not, should seek appropriate education and training.

Preparation of a GP Mental Health Treatment Plan

In addition to assessment of the patient, preparation of a GP Mental Health Treatment Plan must include:

- discussing the assessment with the patient, including the mental health formulation and diagnosis or provisional diagnosis;
- identifying and discussing referral and treatment options with the patient, including appropriate support services;
- agreeing goals with the patient what should be achieved by the treatment and any actions the patient will take;
- provision of psycho-education;
- a plan for crisis intervention and/or for relapse prevention, if appropriate at this stage;
- making arrangements for required referrals, treatment, appropriate support services, review and follow-up;
 and
- documenting this (results of assessment, patient needs, goals and actions, referrals and required treatment/services, and review date) in the patient's GP Mental Health Treatment Plan.

Treatment options can include referral to a psychiatrist; referral to a clinical psychologist for psychological therapies, or to an appropriately trained medical practitioner or allied mental health professional for provision of

focussed psychological strategy services; pharmacological treatments; and coordination with community support and rehabilitation agencies, mental health services and other health professionals.

Once a GP Mental Health Treatment Plan has been completed and claimed on Medicare either through items 272, 276, 281 or 282 or through GP items 2700, 2701, 2715 or 2717, a patient is eligible to be referred for up to 10 Medicare rebateable allied mental health services per calendar year for psychological therapy or focussed psychological strategy services. Patients will also be eligible to claim up to 10 separate services for the provision of group therapy (either as part of psychological therapy or focussed psychological strategies).

When referring patients medical practitioners should provide similar information as per normal referral arrangements. This could include providing a copy of the patient's GP Mental Health Treatment Plan, where appropriate and with the patient's agreement. The necessary referrals should be made after the steps above have been addressed and the patient's GP Mental Health Treatment Plan has been completed. It should be noted that the patient's mental health treatment plan should be treated as a living document for updating as required. In particular, the plan can be updated at any time to incorporate relevant information, such as feedback or advice from other health professionals on the diagnosis or treatment of the patient.

On completion of a course of treatment provided through Medicare rebateable services, the service provider must provide a written report on the course of treatment to the medical practitioner. For the purposes of the Medicare rebateable allied mental health items, a course of treatment will consist of the number of services stated on the patient's referral (up to a maximum of six in any one referral). There may be two or more courses of treatment within a patient's entitlement of up to 10 services per calendar year. The number of services that the patient is being referred for is at the discretion of the referring medical practitioner.

Many patients will not require a new plan after their initial plan has been prepared. A new plan should not be prepared unless clinically required, and generally not within 12 months of a previous plan. Ongoing management can be provided through the GP Mental Health Treatment Consultation and standard consultation items, as required, and reviews of progress through the GP Mental Health Treatment Plan Review item. A rebate for preparation of a GP Mental Health Treatment Plan will not be paid within 12 months of a previous claim for the patient for the same or another Mental Health Treatment Plan item or within three months following a claim for a GP Mental Health Treatment Review (item 277 or GP item 2712).

REVIEWING A GP MENTAL HEALTH TREATMENT PLAN (Item 277)

The review item is a key component for assessing and managing the patient's progress once a GP Mental Health Treatment Plan has been prepared, along with ongoing management through the GP Mental Health Treatment Consultation item and/or standard consultation items. A patient's GP Mental Health Treatment Plan should be reviewed at least once.

A rebate can be claimed once the medical practitioner who prepared the patient's GP Mental Health Treatment Plan (or another medical practitioner in the same practice or in another practice where the patient has changed practices) has undertaken a systematic review of the patient's progress against the GP Mental Health Treatment Plan by completing the activities that must be included in a review and meeting the relevant requirements listed under 'Additional Claiming Information'. The review item can also be used where a psychiatrist has prepared a referred assessment and management plan (item 291), as if that patient had a GP Mental Health Treatment Plan. The review service must include a personal attendance by the medical practitioner with the patient.

The review must include:

- recording the patient's agreement for this service:
- a review of the patient's progress against the goals outlined in the GP Mental Health Treatment Plan;
- modification of the documented GP Mental Health Treatment Plan if required;
- checking, reinforcing and expanding education;

- a plan for crisis intervention and/or for relapse prevention, if appropriate and if not previously provided;
 and
- re-administration of the outcome measurement tool used in the assessment stage, except where considered clinically inappropriate.

Note: This review is a formal review point only and it is expected that in most cases there will be other consultations between the patient and the medical practitioner as part of ongoing management.

The recommended frequency for the review service, allowing for variation in patients' needs, is:

- an initial review, which should occur between four weeks to six months after the completion of a GP Mental Health Treatment Plan; and
- if required, a further review can occur three months after the first review.

In general, most patients should not require more than two reviews in a 12 month period, with ongoing management through the GP Mental Health Treatment Consultation and standard consultation items, as required.

A rebate will not be paid within three months of a previous claim for the same item/s or within four weeks following a claim for a GP Mental Health Treatment Plan item.

GP MENTAL HEALTH TREATMENT CONSULTATION (Item 279)

The GP Mental Health Treatment Consultation item is for an extended consultation with a patient where the primary treating problem is related to a mental disorder, including for a patient being managed under a GP Mental Health Treatment Plan. This item may be used for ongoing management of a patient with a mental disorder. This item should not be used for the development of a GP Mental Health Treatment Plan.

A GP Mental Health Treatment Consultation must include:

- taking relevant history and identifying the patient's presenting problem(s) (if not previously documented);
- providing treatment, advice and/or referral for other services or treatment; and
- documenting the outcomes of the consultation in the patient's medical records and other relevant mental health plan (where applicable).

A patient may be referred from a GP Mental Health Treatment Consultation for other treatment and services as per normal referral arrangements. This does not include referral for Medicare rebateable services for focussed psychological strategy services, clinical psychology or other allied mental health services, unless the patient is being managed by the medical practitioner under a GP Mental Health Treatment Plan or under a referred psychiatrist assessment and management plan (item 291).

Consultations associated with this item must be at least 20 minutes duration.

REFERRAL

Once a GP Mental Health Treatment Plan has been completed and claimed on Medicare, or a medical practitioner is managing a patient under a referred psychiatrist assessment and management plan (item 291), a patient is eligible for up to 10 Medicare rebateable allied mental health services per calendar year for services by:

- clinical psychologists providing psychological therapies; or
- appropriately trained medical practitioners or allied mental health professionals providing focussed psychological strategy (FPS) services.

In addition to the above services, patients will also be eligible to claim up to 10 separate services for the provision of group therapy.

When referring patients, medical practitioners should provide similar information as per normal referral arrangements, and specifically consider including both a statement identifying that a GP Mental Health Treatment Plan has been completed for the patient (including, where appropriate and with the patient's agreement, attaching a copy of the patient's GP Mental Health Treatment Plan) and clearly identifying the specific number of sessions the patient is being referred for. Referrals for patients with either a GP Mental Health Treatment Plan or referred psychiatrist assessment and management plan (item 291) should be provided, as required, for an initial course of treatment (a maximum of six services in any one referral but may be less depending on the referral and the patient's clinical need). There may be two or more courses of treatment within a patient's entitlement of up to 10 services per calendar year. The medical practitioner should consider the patient's clinical need for further sessions after the initial referral. This can be done using a GP Mental Health Treatment Plan Review, a GP Mental Health Treatment Consultation or a standard consultation item.

In the instance where a patient has received the 10 psychological therapy services (items 80000 to 80021), focussed psychological services-allied mental health services (items 80100 to 80171) or GP focussed psychological strategies services (items 283 to 287 or GP items 2721 to 2727) available under the Better Access to Psychiatrists, Psychologists and General Practitioners through the Medicare Benefits Schedule initiative per calendar year and is considered to clinically benefit from some additional services, the patient may be eligible for Primary Health Networks (PHNs) funded psychological therapies if they meet relevant eligibility criteria for the PHN commissioned services. It is recommended that providers refer to their PHN for further guidance.

ADDITIONAL CLAIMING INFORMATION

Before proceeding with any GP Mental Health Treatment Plan or Review service the medical practitioner must ensure that:

- (a) the steps involved in providing the service are explained to the patient and (if appropriate and with the patient's permission) to the patient's carer; and
- (b) the patient's agreement to proceed is recorded.

Before completing any GP Mental Health Treatment Plan or Review service and claiming a benefit for that service, the medical practitioner must offer the patient a copy of the treatment plan or reviewed treatment plan and add the document to the patient's records. This should include, subject to the patient's agreement, offering a copy to their carer, where appropriate. The medical practitioner may, with the permission of the patient, provide a copy of the GP Mental Health Treatment Plan, or relevant parts of the plan, to other providers involved in the patient's treatment.

The GP Mental Health Treatment Plan, Review and Consultation items cover the consultations at which the relevant items are undertaken, noting that:

- if a GP Mental Health Treatment item is undertaken or initiated during the course of a consultation for another purpose, the GP Mental Health Treatment Plan, Review or Consultation item and the relevant item for the other consultation may both be claimed;
- if a GP Mental Health Treatment Plan is developed over more than one consultation, and those consultations are for the purposes of developing the plan, only the GP Mental Health Treatment Plan item should be claimed; and
- if a consultation is for the purpose of a GP Mental Health Treatment Plan, Review or Consultation item, a separate and additional consultation should not be undertaken in conjunction with the mental health consultation, unless it is clinically indicated that a separate problem must be treated immediately.

Where separate consultations are undertaken in conjunction with mental health consultations, the patient's invoice or Medicare voucher (assignment of benefit form) for the separate consultation should be annotated (e.g. separate consultation clinically required/indicated).

A benefit is not claimable and an account should not be rendered until all components of the relevant item have been provided.

All consultations conducted as part of the GP Mental Health Treatment items must be rendered by the medical practitioner and include a personal attendance with the patient. A specialist mental health nurse, other allied health practitioner, Aboriginal and Torres Strait Islander health practitioner or Aboriginal Health Worker with appropriate mental health qualifications and training may provide general assistance to medical practitioners in provision of mental health care.

Links to other Medicare Services

It is preferable that wherever possible patients have only one plan for primary care management of their mental disorder. As a general principle the creation of multiple plans should be avoided, unless the patient clearly requires an additional plan for the management of a separate medical condition.

The Chronic Disease Management (CDM) care plan items (items 229, 230, 231, 232 and 233, and GP items 721, 723, 729, 731 and 732) continue to be available for patients with chronic medical conditions, including patients with complex needs.

- Where a patient has a mental health condition only, it is anticipated that they will be managed under the GP Mental Health Treatment items.
- Where a patient has a separate chronic medical condition, it may be appropriate to manage the patient's medical condition through a GP Management Plan, and to manage their mental health condition through a GP Mental Health Treatment Plan. In this case, both items can be used.
- Where a patient has a mental health condition as well as significant co-morbidities and complex needs requiring team-based care, the medical practitioner is able to use both the CDM items (for team-based care) and the GP Mental Health Treatment items.

AN.7.23 Medical Practitioner Provision of Focussed Psychological Strategies (Items 283 to 287, 371 and 372)

Focussed psychological strategies are specific mental health care management strategies, derived from evidence based psychological therapies that have been shown to integrate the best research evidence of clinical effectiveness with general practice clinical expertise. The decision to recommend Focussed Psychological Strategies to a patient must be made either in the context of a GP Mental Health Treatment Plan, shared care plan or a psychiatrist assessment and management plan.

Minimum Requirements

All consultations providing Focussed Psychological Strategies must be rendered by a medical practitioner (but not including a specialist or consultant physician).

To ensure appropriate standards for the provision of Focussed Psychological Strategies, payment of Medicare rebates for these items will be limited to medical practitioners who are registered with the Department of Human Services as having satisfied the requirements for higher level mental health skills for provision of the service, as determined by the General Practice Mental Health Standards Collaboration.

Continued access to item numbers 283 to 287, 371 and 372 will be dependent on the practitioner meeting the ongoing mental health education requirements as determined by the General Practice Mental Health Standards Collaboration.

Patients will be permitted to claim Medicare rebates for up to 10 allied mental health services under these item numbers per calendar year. The 10 services may consist of: GP focussed psychological strategies services (items 283 to 287, 371 and 372 or GP items 2721 to 2731); and/or psychological therapy services (items 80000 to 80015);

and/or focussed psychological strategies – allied mental health services (items 80100 to 80115; 80125 to 80140; 80150 to 80165).

Out-of-Surgery Consultation

It is expected that this service would be provided only for patients who are unable to attend the practice.

Telehealth Consultation

A **telehealth area** means an area that is a Modified Monash 4 area, Modified Monash 5 area, Modified Monash 6 area or Modified Monash 7 area.

Specific Modified Monash locations can be looked up at **DoctorConnect**

Specific Focussed Psychological Strategies

A range of acceptable strategies has been approved for use by medical practitioners in this context. These are:

1. Psycho-education

(including motivational interviewing)

2. Cognitive-behavioural therapy including:

- · Behavioural interventions
- Behaviour modification
- Exposure techniques
- Activity scheduling
- Cognitive interventions
- Cognitive therapy

3. Relaxation strategies

- Progressive muscle relaxation
- Controlled breathing

4. Skills training

- Problem solving skills and training
- Anger management
- Social skills training
- Communication training
- Stress management
- Parent management training
- 5. Interpersonal therapy

Mental Disorder

A mental disorder may be defined as a significant impairment of an individual's cognitive, affective and/or relational abilities which may require intervention and may be a recognised, medically diagnosable illness or disorder – this definition is informed by the World Health Organisation, 1996, Diagnostic and Management Guidelines for Mental Disorders in Primary Care:ICD - 10 Chapter V Primary Health Care Version.

Dementia, delirium, tobacco use disorder and mental retardation are not regarded as mental disorders for the purposes of these items.

AN.7.24 Medical Practitioner After-Hours Attendances To Which No Other Item Applies (Items 733 to 789)

After-hours attendance items may be claimed as follows:

Items **733**, **737**, **741** and **745** apply only to a professional attendance on 1 patient on 1 occasion that is provided:

- on a public holiday;
- on a Sunday;

- before 8am, or after 1 pm on a Saturday;
- before 8am, or after 8pm on any day other than a Saturday, Sunday or public holiday.

Items **761**, **763**, **766**, **769**, **772**, **776**, **788** and **789** apply to a professional attendance on 1 or more patients on 1 occasion that is provided:

- on a public holiday;
- on a Sunday;
- before 8am, or after 12 noon on a Saturday;
- before 8am, or after 6pm on any day other than a Saturday, Sunday or public holiday.

AN.7.25 Medical Practitioner Non-Directive Pregnancy Support Counselling Service (Item 792)

The Pregnancy Support Counselling initiative provides for Medicare benefits to be paid for non-directive pregnancy support counselling services provided to a person who is pregnant or who has been pregnant in the 12 months preceding the first service to which this item or items 4001, 81000, 81005 or 81010 applies in relation to that pregnancy, by an eligible medical practitioner (not including a specialist or consultant physician) or allied health professional on referral from a medical practitioner.

There are five MBS items for the provision of non-directive pregnancy support counselling services:

- Item 792 services provided by an eligible medical practitioner;
- Item 4001 services provided by an eligible GP;
- Item 81000 services provided by an eligible psychologist;
- Item 81005 services provided by an eligible social worker; and
- Item 81010 services provided by an eligible mental health nurse.

This note relates to the provision of a non-directive pregnancy support counselling service by an eligible medical practitioner.

Non-directive counselling is a form of counselling based on the understanding that, in many situations, people can resolve their own problems without being provided with a solution by the counsellor. The counsellor's role is to encourage the person to express their feelings but not suggest what decision the person should make. By listening and reflecting back what the person reveals to them, the counsellor helps them to explore and understand their feelings. With this understanding, the person is able to make the decision which is best for them.

The service involves the medical practitioner undertaking a safe, confidential process that helps the patient explore concerns they have about a current pregnancy or a pregnancy that occurred in the preceding 12 months. This includes providing, on request, unbiased, evidence-based information about all options and services available to the patient.

The service may be used to address any pregnancy related issues for which non-directive counselling is appropriate.

Patient eligibility

Medicare rebates for non-directive pregnancy support counselling services provided using item 792 are available to a person who is pregnant or who has been pregnant in the 12 months preceding the first service to which this item or item 4001, 81000, 81005 or 81010 applies in relation to that pregnancy.

Partners of eligible patients may attend each or any counselling session, however, only one fee applies to each service provided.

Medicare benefits

Medicare benefits are payable for up to three non-directive pregnancy support counselling services per patient, per pregnancy, from any of the following items – 792, 4001, 81000, 81005 and 81010.

Where the patient is unsure of the number of Medicare rebated non-directive pregnancy support counselling services they have already accessed, the patient may check with the Department of Human Services on 132 011. Alternatively, the medical practitioner may check with the Department of Human Services (although the patient must be present to give permission).

Item 10990 or item 10991 can also be claimed in conjunction with item 792 provided the conditions of the relevant item, 10990 or 10991, are satisfied.

Minimum Requirements

This service may only be provided by a medical practitioner who has completed appropriate non-directive pregnancy counselling training.

AN.7.26 Medical Practitioner Telehealth Patient-End Support Services (Items 812 to 892)

This note provides information on the telehealth MBS attendance items for medical practitioners to provide clinical support to their patients, when clinically relevant, during video consultations with specialists or consultant physicians under items 812, 827, 829, 867, 868, 869, 873, 876, 881, 885 and 892.

Telehealth patient-end support services can only be claimed where:

- a Medicare eligible specialist service is claimed;
- the service is rendered in Australia; and
- where this is necessary for the provision of the specialist service.

A video consultation will involve a single specialist or consultant physician attending to the patient, with the possible participation of another medical practitioner, a participating optometrist, a participating nurse practitioner, a participating midwife, practice nurse, Aboriginal and Torres Strait Islander health practitioner or Aboriginal health worker at the patient end. The above time-tiered items provide for patient-end support services by a medical practitioner in various settings including consulting rooms, other than consulting rooms, eligible residential aged care services and Aboriginal Medical Services.

Clinical indications

The specialist or consultant physician must be satisfied that it is clinically appropriate to provide a video consultation to a patient. The decision to provide clinically relevant support to the patient is the responsibility of the specialist or physician.

Telehealth specialist services can be provided to patients when there is no patient-end support service provided.

Collaborative Consultation

The medical practitioner, who provides assistance to the patient where this is necessary for the provision of the specialist service, may seek assistance from a health professional (e.g. a practice nurse, Aboriginal or Torres Strait Islander health practitioner or Aboriginal health worker) but only one item is billable for the patient-end support service. The medical practitioner must be present during part or all of the consultation in order to bill an appropriate time-tiered MBS item. Any time spent by another health professional called to assist with the consultation may not be counted against the overall time taken to complete the video consultation.

Restrictions

The MBS telehealth attendance items are not payable for services to an admitted hospital patient (this includes Hospital in the Home patients). Benefits are not payable for telephone or email consultations. In order to fulfil the item descriptor there must be a visual and audio link between the patient and the remote practitioner. If the remote practitioner is unable to establish both a video and audio link with the patient, a MBS rebate for a telehealth attendance is not payable.

Eligible Geographical Areas

Geographic eligibility for telehealth services funded under Medicare is determined according to the Australian Standard Geographical Classification Remoteness Area (ASGC-RA) classifications. Telehealth Eligible Areas are those areas that are outside a Major City (RA1) according to ASGC-RA (RA2-5). Patients and providers are able to check their eligibility by following the links on the MBS Online website (www.mbsonline.gov.au/telehealth).

There is a requirement for the patient and specialist to be located a minimum of 15km apart at the time of the consultation. Minimum distance between specialist and patient video consultations are measured by the most direct (ie least distance) route by road. The patient or the specialist is not permitted to travel to an area outside the minimum 15 km distance in order to claim a video conference.

This rule will not apply to specialist video consultation with patients who are a care recipient in an eligible residential care service; or at an eligible Aboriginal Medical Service or Aboriginal Community Controlled Health Service for which there is a direction, made under subsection 19(2) of the Health Insurance Act 1973, as these patients are able to receive telehealth services anywhere in Australia.

Telehealth Eligible Service Areas are defined at www.mbsonline.gov.au/telehealtheligibleareas

Record Keeping

Participating telehealth medical practitioners must keep contemporaneous notes of the consultation including documenting that the service was performed by video conference, the date, time and the people who participated.

Only clinical details recorded at the time of the attendance count towards the time of the consultation. It does not include information added at a later time, such as reports of investigations.

Multiple attendances on the same day

In some situations a patient may receive a telehealth consultation and a face to face consultation by the same or different medical practitioner on the same day.

Medicare benefits may be paid for more than one video consultation on a patient on the same day by the same medical practitioner, provided the second (and any following) video consultations are not a continuation of the initial or earlier video consultations. Medical practitioners will need to provide the times of each consultation on the patient's account or bulk billing voucher.

Extended Medicare Safety Net (EMSN)

Items which provide for telehealth patient-end support services are subject to EMSN caps equal to 300% of the schedule fee (to a maximum of \$500). This is consistent with Government policy relating to capping EMSN for MBS consultation services.

Aftercare Rule

Video consultations are subject to the same aftercare rules as face to face consultations.

Referrals

The referral procedure for a video consultation is the same as for conventional face-to-face consultations.

Technical requirements

In order to fulfil the item descriptor there must be a visual and audio link between the patient and the remote practitioner. If the remote practitioner is unable to establish both a video and audio link with the patient, a MBS rebate for a specialist video consultation is not payable.

Individual clinicians must be confident that the technology used is able to satisfy the item descriptor and that software and hardware used to deliver a videoconference meets the applicable laws for security and privacy.

Bulk billing

Bulk bill incentive items 10990 or 10991 may be billed in conjunction with the telehealth items 812, 827, 829, 867, 868, 869, 873, 876, 881, 885 and 892.

Duration of attendance

The medical practitioner attending at the patient end of the video consultation does not need to be present for the entire consultation, only as long as is clinically relevant - this can be established in consultation with the specialist. The MBS fee payable for the supporting medical practitioner will be determined by the total time spent assisting the patient. This time does not need to be continuous.

AN.7.27 Non-Specialist Practitioner Multidisciplinary Case Conferences (Items 235 to 244)

Items 235 to 244 provide rebates for medical practitioners to organise and coordinate, or participate in, multidisciplinary case conferences for patients in the community or patients being discharged into the community from hospital or people living in residential aged care facilities. This group of items include two items for medical practitioners participating in cancer care case conferences.

REGULATORY REQUIREMENTS

To organise and coordinate case conference items 235, 236 and 237, the medical practitioner must:

- (a) explain to the patient the nature of a multidisciplinary case conference, and ask the patient for their agreement to the conference taking place; and
- (b) record the patient's agreement to the conference; and
- (c) record the day on which the conference was held, and the times at which the conference started and ended; and
- (d) record the names of the participants; and
- (e) offer the patient and the patient's carer (if any, and if the medical practitioner considers it appropriate and the patient agrees) a summary of the conference and provide this summary to other team members; and
- (f) discuss the outcomes of the conference with the patient and the patient's carer (if any, and if the medical practitioner considers it appropriate and the patient agrees); and
- (g) record all matters discussed and identified by the case conferencing team and put a copy of that record in the patient's medical records.

To participate in multidisciplinary case conference items 238, 239 and 240, the medical practitioner must:

- (a) explain to the patient the nature of a multidisciplinary case conference, and ask the patient whether they agree to the medical practitioner's participation in the conference; and
- (b) record the patient's agreement to the medical practitioner's participation; and
- (c) record the day on which the conference was held, and the times at which the conference started and ended; and

- (d) record the names of the participants; and
- (e) record all matters discussed and identified by the case conferencing team and put a copy of that record in the patient's medical records.

Cancer care case conference items 243 and 244

For the purposes of these items:

- private patients in public or private hospitals or the community with a malignancy of a solid organ or tissue or a systemic cancer such as a leukaemia or lymphoma are covered, with the exception of patients whose only cancer is a non-melanoma skin cancer;
- the billing medical practitioner must be a treating doctor of the patient discussed at the case conference. A treating doctor should generally have treated or provided a formal diagnosis of the patient's cancer in the past 12 months or expect to do so within the next 12 months. Attending non-treating clinicians, allied health providers or support staff are not eligible to bill the item;
- only one medical practitioner is eligible to claim item 243 for each patient case conference. This should be the medical practitioner who assumes responsibility for leading and coordinating the case conference, ensures that records are kept and that the patient is informed of the outcome of the case conference. In most cases this will be the lead treating medical practitioner;
- each billing medical practitioner must ensure that his or her patient is informed that a charge will be incurred for the case conference for which a Medicare rebate will be payable;
- participants must be in communication with each other throughout the case conference, either face-to-face, or by telephone or video link;
- suitable allied health practitioners would generally be from one of the following disciplines: aboriginal health care worker; asthma educator; audiologist; dental therapist; dentist; diabetes educator; dietitian; mental health worker; occupational therapist; optometrist; orthoptist; orthotist or prosthetist; pharmacist; physiotherapist; podiatrist; psychologist; registered nurse; social worker; or speech pathologist;
- in general, it is expected that no more than two case conferences per patient per year will be billed by a medical practitioner; and
- cancer care case conferences are for the purpose of developing a cancer treatment plan in a multidisciplinary team meeting and should not be billed against case conference items for other purposes (eg. community or discharge case conferences).

ADDITIONAL INFORMATION

Usual medical practitioner

Items 235 to 244 should generally be undertaken by the patient's usual medical practitioner. This is a medical practitioner, or a medical practitioner working in the same medical practice that has provided the majority of services to the patient over the previous 12 months and/or will be providing the majority of services to the patient over the coming 12 months.

Multidisciplinary case conference team members

Examples of persons who, for the purposes of care planning and case conferencing may be included in a multidisciplinary care team are allied health professionals such as, but not limited to: Aboriginal health care workers; asthma educators; audiologists; dental therapists; dentists; diabetes educators; dietitians; mental health workers; occupational therapists; optometrists; orthoptists; orthotists or prosthetists; pharmacists; physiotherapists; podiatrists; psychologists; registered nurses; social workers; speech pathologists.

A team may also include home and community service providers, or care organisers, such as: education providers; "meals on wheels" providers; personal care workers (workers who are paid to provide care services); probation officers.

The patient's informal or family carer may be included as a formal member of the team in addition to the minimum of three health or care providers. The patient and the informal or family carer do not count towards the minimum of three.

Discharge case conference

Organisation and coordination of a multidisciplinary discharge case conference (items 235, 236 and 237) may be provided for private in-patients being discharged into the community from hospital.

Further sources of information

Advice on the items and further guidance are available at: www.health.gov.au/mbsprimarycareitems

Further information is also available for providers from the Department of Human Services provider inquiry line on 132 150.

AN.7.28 Telehealth services for people living in flood-affected communities in Queensland

New telehealth consultation items for non-specialist medical practitioners to provide general attendance services by videoconference to patients living in flood-affected Local Government Areas in Queensland receiving disaster recovery allowance.

Item numbers 899, 901, 905 and 906 will be available until 30 June 2019, to enable non-specialist medical practitioners to provide videoconference consultations in Local Government Areas in Queensland listed at https://www.humanservices.gov.au/individuals/services/centrelink/far-north-queensland-floods-february-2019-disaster-recovery-allowance.

The items replicate the clinical requirements and fee/rebate structures of Level A to D items provided in consulting rooms. Eligibility for the service is determined on the basis of patient location. It is a requirement that the attendance be by videoconference, and that the patient be located in a flood affected eligible area.

AN.30.1 MBS mental health and well-being telehealth support items for general practitioners

These notes provide information on the MBS mental health and well-being telehealth support items for general practitioners (GPs) under items 2121, 2150 and 2196 in Group A30, Subgroup 3.

Requirements

The mental health and well-being telehealth support items can only be claimed where:

- the patient lives in an area belonging to a declared council under the Drought Communities Programme (DCP);
- the GP works in an area belonging to the declared councils under the DCP in a Modified Monash area 3 to 7; and
- the patient and the GP have an existing relationship.

A list of declared councils and more information about the Drought Communities Programme is available at: http://regional.gov.au/regional/programs/drought-communities.aspx

Information about Modified Monash is available at http://www.doctorconnect.gov.au/internet/otd/publishing.nsf/Content/locator

In addition:

- the attendance must be by video conference; and
- the patient must not be an admitted patient; and
- the patient must be, at the time of the attendance, at least 15 kilometres by road from the GP.

Minimum Distance

The minimum distance between the GP and the patient is measured by the most direct (ie least distance) route by road. The patient or the GP is not permitted to travel to an area outside the minimum 15 km distance in order to claim a video conference.

Record Keeping

Participating GPs must keep contemporaneous notes of the consultation including documenting that the service was performed by video conference, the date and the time.

Only clinical details recorded at the time of the attendance count towards the time of the consultation. It does not include information added at a later time, such as reports of investigations.

In some situations a patient may receive a telehealth consultation and a face to face consultation by the same or different GP on the same day.

Medicare benefits may be paid for more than one video consultation on a patient on the same day by the GP, provided the second (and any following) video consultations are not a continuation of the initial or earlier video consultations. GPs will need to provide the times of each consultation on the patient's account or bulk billing voucher.

Extended Medicare Safety Net (EMSN)

Items which provide for telehealth patient-end support services are subject to EMSN caps equal to 300% of the schedule fee (to a maximum of \$500). This is consistent with Government policy relating to capping EMSN for MBS consultation services.

Aftercare Rule

Video consultations are subject to the same aftercare rules as face to face consultations.

Technical requirements

In order to fulfil the item descriptor there must be a visual and audio link between the patient and the GP. If the GP is unable to establish both a video and audio link with the patient, a MBS rebate for a video consultation is not payable.

Individual GPs must be confident that the technology used is able to satisfy the item descriptor and that software and hardware used to deliver a video conference meets the applicable laws for security and privacy.

AN.30.2 Telehealth services for people living in flood-affected communities in Queensland

New telehealth consultation items for GPs to provide general attendance services by videoconference to patients living in flood-affected Local Government Areas in Queensland receiving disaster recovery allowance.

Item numbers 2095, 2144, 2180 and 2193 will be available until 30 June 2019, to enable GPs to provide videoconference consultations in Local Government Areas in Queensland listed at https://www.humanservices.gov.au/individuals/services/centrelink/far-north-queensland-floods-february-2019-disaster-recovery-allowance.

The items replicate the clinical requirements and fee/rebate structures of Level A to D items provided in consulting rooms. Eligibility for the service is determined on the basis of patient location. It is a requirement that the attendance be by videoconference, and that the patient be located in a flood affected eligible area.

AN.33.1 TAVI CASE CONFERENCE - (ITEMS 6080 AND 6081)

Items 6080 and 6081 apply to a TAVI Case Conference organised to discuss a patient's suitability to receive the service described in Item 38495 for Transcatheter Aortic Valve Implantation (TAVI).

For items 6080 and 6081 a TAVI Case Conference is a process by which:

- (a) there is a team of 3 or more participants, where:
 - (i) the first participant is a cardiothoracic surgeon; and
 - (ii) the second participant is an interventional cardiologist; and
- (iii) the third participant is a specialist or consultant physician who does not perform a service described in Item 38495 for the patient being assessed; and
 - (iv) either the first or the second participant is also a TAVI Practitioner; and
- (b) the team assesses a patient's risk and technical suitability to receive the service described in Item 38495, taking into account matters such as:
 - (i) the patient's risk and technical suitability for a surgical aortic valve replacement; and
 - (ii) the patient's cognitive function and frailty; and
- (c) the result of the assessment is that the team makes a recommendation about whether or not the patient is suitable to receive the service described in Item 38495; and
- (d) the particulars of the assessment and recommendation are recorded in writing.

TAVI Practitioner

For items 6080 and 6081 a TAVI Practitioner is either a cardiothoracic surgeon or interventional cardiologist who is accredited by Cardiac Accreditation Services Limited.

Accreditation by Cardiac Accreditation Services Limited must be valid prior to the service being undertaken in order for benefits to be payable under item 38495.

The process for accreditation and re-accreditation is outlined in the *Transcatheter Aortic Valve Implantation - Rules* for the Accreditation of TAVI Practitioners, issued by Cardiac Accreditation Services Limited, and is available on the Cardiac Accreditation Services Limited website, www.tavi.org.au.

Cardiac Accreditation Services Limited is a national body comprising representatives from the Australian & New Zealand Society of Cardiac & Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ).

Coordination of a TAVI Case Conference

For item 6080, coordination means undertaking all of the following activities in relation to a TAVI Case Conference:

- a. ensuring that the patient is aware of the purpose and nature of the patient's TAVI Case Conference and has consented to their TAVI Case Conference:
- b. recording the day the conference was held, and the times the conference started and ended;
- c. recording the names of the participants of the conference;

- d. provision of expertise to inform the recommendation resulting from the case conference;
- e. recording minutes of the TAVI Case Conference including the recommendation resulting from the conference;
- f. ensuring that the patient is aware of the recommendation.

Attendance at a TAVI Case Conference

For item 6081, attendance means undertaking all of the following activities in relation to a TAVI Case Conference:

- a. retaining a record of the day the conference was held, and the times the conference started and ended;
- b. retaining a record of the names of the participants;
- c. provision of expertise to inform the recommendation resulting from the case conference;
- d. retaining a record of the recommendation resulting from the conference.

General requirements

The TAVI Case Conference must be arranged in advance, within a time frame that allows for all the participants to attend. A TAVI Case Conference is to last at least 10 minutes and a minimum of three suitable participants (as defined under the item requirements), must be present for the whole of the case conference. All participants must be in communication with each other throughout the conference, either face to face, by telephone or by video link, or a combination of these.

A record of the TAVI Case Conference which contains: a list of the participants; the times the conference commenced and concluded; a description of the assessment of suitability; and a summary of the outcomes must be kept in the patient's record. The notes and summary of outcomes must be provided to all participants.

Prior informed consent must be obtained from the patient, or the patient's agent. In obtaining informed consent the TAVI Practitioner coordinating the TAVI Case Conference should ensure the patient has been:

- Informed that his or her medical history, diagnosis and care preferences will be discussed with other case conference participants;
- Informed that he or she may incur a charge for the service for which a Medicare rebate will be payable.

Medicare benefits are only payable in respect of the service provided by the coordinating TAVI Practitioner or the attending interventional cardiologist, cardiothoracic surgeon or independent specialist or consultant physician. Benefits are not payable for another medical practitioner organising a case conference or for attendance by other medical practitioners at a TAVI Case Conference.

It is expected that a patient would not normally require more than one TAVI Case Conference in determining suitability for the services described in Item 38495. As such, item 6080 is only payable once per patient in a five year period. Item 6081 is payable only twice per patient in a five year period.

Items 6080 and 6081 do not preclude the claiming of a consultation on the same day if other clinically relevant services are provided.

AN.34.1 HEALTH CARE HOMES

HEALTH CARE HOMES The Health Care Homes Program is administered by the Department of Health. A Health Care Homes trial site means a medical practice participating in the Health Care Homes Program. Commonwealth subsidy for the provision of services under the Health Care Homes Program is paid through bundled payments to the Health Care Home.

Item 6087 has been established so that, when claimed, it will record when a Health Care Home patient incurs an out-of-pocket expense. The out-of-pocket cost will then count toward their or their family's Extended Medicare Safety Net.

Item 6087 should only be claimed in the event that a Health Care Home charges a Health Care Home patient an out-of-pocket cost. Item 6087 must not be used for any other purpose.

Item 6087 cannot be claimed as a bulk-billed service.

AN.35.1 Flag fall amount for residential aged care facility attendance by a general practitioner Medicare item 90001 provides a call-out fee for the initial attendance by a general practitioner at one RACF, on one occasion, applicable only to the first patient seen on the RACF visit.

The Medicare benefit for the single call-out fee and the associated general consultation (either Level A to D) applies only for patients within a RACF who have a general consultation with a doctor in person.

If doctors do not bill the single call-out fee, the benefit will not be paid.

If a doctor has to return to the RACF facility twice or more on the same day and the attendances are not a continuation of an earlier episode of treatment, another call-out fee would apply per subsequent RACF visit.

When claiming the new attendance items there is no longer a requirement to transmit the number of patients seen. A doctor would claim each attendance item like any other consultation service.

MBS items 90001 is not to be used with existing derived fee services such as for afterhours, urgent afterhours, or telehealth services. The bulk billing incentive only applies to the attendance item, not to the single call-out fee.

AN.35.2 Flag fall amount for residential aged care facility attendance by a medical practitioner Medicare item 90002 provides a call-out fee for the initial attendance by a medical practitioner at one RACF, on one occasion, applicable only to the first patient seen on the RACF visit.

The Medicare benefit for the single call-out fee and the associated general consultation (either Level A to D) applies only for patients within a RACF who have a general consultation with a doctor in person.

If doctors do not bill the single call-out fee, the benefit will not be paid.

If a doctor has to return to the RACF facility twice or more on the same day and the attendances are not a continuation of an earlier episode of treatment, another call-out fee would apply per subsequent RACF visit.

When claiming the new attendance items there is no longer a requirement to transmit the number of patients seen. A doctor would claim each attendance item like any other consultation service.

MBS items 90002 is not to be used with existing derived fee services such as for afterhours, urgent afterhours, or telehealth services. The bulk billing incentive only applies to the attendance item, not to the single call-out fee.

1. FEES AND BENEFITS FOR GP ATTENDANCES AT A RESIDENTIAL AGED CARE FACILITY

LEVEL A - ITEM 5010		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	75.70	75.70
TWO	52.35	52.35
THREE	44.55	44.55
FOUR	40.65	40.65
FIVE	38.35	38.35
SIX	36.80	36.80
SEVEN	32.30	32.30

LEVEL B - ITEM 5028		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	95.70	95.70
TWO	72.35	72.35
THREE	64.55	64.55
FOUR	60.65	60.65
FIVE	58.35	58.35
SIX	56.80	56.80
SEVEN	52.30	52.30

LEVEL C - ITEM 5049		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	130.65	130.65
TWO	107.30	107.30
THREE	99.50	99.50
FOUR	95.60	95.60
FIVE	93.30	93.30
SIX	91.75	91.75
SEVEN	87.25	87.25

LEVEL D - ITEM 5067		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	164.45	164.45
TWO	141.10	141.10
THREE	133.30	133.30
FOUR	129.40	129.40
FIVE	127.10	127.10
SIX	125.55	125.55
SEVEN	121.05	121.05

2. FEES AND BENEFITS FOR OTHER NON REFERRED ATTENDANCES AT A RESIDENTIAL AGED CARE FACILITY

BRIEF - ITEM 5260		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	46.45	46.45
TWO	32.45	32.45
THREE	27.80	27.80
FOUR	25.50	25.50
FIVE	24.10	24.10
SIX	23.15	23.15
SEVEN	19.75	19.75

STANDARD - ITEM 5263		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	57.55	57.55
TWO	41.75	41.75
THREE	36.50	36.50
FOUR	33.90	33.90
FIVE	32.30	32.30
SIX	31.25	31.25
SEVEN	27.25	27.25

LONG - ITEM 5265		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	73.45	73.45
TWO	59.45	59.45
THREE	54.80	54.80
FOUR	52.50	52.50
FIVE	51.10	51.10
SIX	50.15	50.15
SEVEN	46.75	46.75

PROLONGED - ITEM 5267		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	95.45	95.45
TWO	81.45	81.45
THREE	76.80	76.80
FOUR	74.50	74.50
FIVE	73.10	73.10
SIX	72.15	72.15
SEVEN	68.75	68.75

3. FEES AND BENEFITS FOR GP ATTENDANCES (OTHER THAN CONSULTING ROOMS) AT A HOSPITAL, INSTITUTION OR HOME

LEVEL A - ITEM 4		
NUMBER OF PATIENTS	FEE (PER PATIENT)	75% BENEFIT (PER PATIENT)
ONE	43.55	32.70
TWO	30.35	22.80
THREE	26.00	19.50
FOUR	23.80	17.85
FIVE	22.45	16.85
SIX	21.60	16.20
SEVEN	19.25	14.45

LEVEL B - ITEM 2503, 2518, 2547		
NUMBER OF PATIENTS	FEE (PER PATIENT)	75% BENEFIT (PER PATIENT)
ONE	63.00	47.25
TWO	50.00	37.50
THREE	45.70	34.30
FOUR	43.55	32.70
FIVE	42.25	31.70
SIX	41.35	31.05
SEVEN	39.05	29.30

LEVEL C – ITEM 2506, 2522, 2553		
NUMBER OF PATIENTS	FEE (PER PATIENT)	75% BENEFIT (PER PATIENT)
ONE	97.65	73.25
TWO	84.65	63.50
THREE	80.35	60.30
FOUR	78.20	58.65
FIVE	76.90	57.70
SIX	76.00	57.00
SEVEN	73.70	55.30

LEVEL B - ITEM 24		
NUMBER OF PATIENTS	FEE (PER PATIENT)	75% BENEFIT (PER PATIENT)
ONE	63.95	48.00
TWO	50.75	38.10
THREE	46.40	34.80
FOUR	44.20	33.15
FIVE	42.85	32.15
SIX	42.00	31.50
SEVEN	39.65	29.75

LEVEL C – ITEM 37		
NUMBER OF PATIENTS	FEE (PER PATIENT)	75% BENEFIT (PER PATIENT)
ONE	99.15	74.40
TWO	85.95	64.50
THREE	81.60	61.20
FOUR	79.40	59.55
FIVE	78.05	58.55
SIX	77.20	57.90
SEVEN	74.85	56.15

LEVEL D – ITEM 47		
NUMBER OF PATIENTS	FEE (PER PATIENT)	75% BENEFIT (PER PATIENT)
ONE	133.50	100.15
TWO	120.30	90.25
THREE	115.95	87.00
FOUR	113.75	85.35
FIVE	112.40	84.30
SIX	111.55	83.70
SEVEN	109.20	81.90

LEVEL D – ITEM 2509, 2526, 2559		
NUMBER OF PATIENTS	FEE (PER PATIENT)	75% BENEFIT (PER PATIENT)
ONE	131.50	98.65
TWO	118.50	88.90
THREE	114.20	85.65
FOUR	112.05	84.05
FIVE	110.75	83.10
SIX	109.85	82.40
SEVEN	107.55	80.70

4. FEES AND BENEFITS FOR OTHER NON-REFERRED ATTENDANCES (OTHER THAN CONSULTING ROOMS) AT A HOSPITAL, INSTITUTION OR HOME

BRIEF – ITEM 58		
NUMBER OF PATIENTS	FEE (PER PATIENT)	75% BENEFIT (PER PATIENT)
ONE	24.00	18.00
TWO	16.25	12.20
THREE	13.65	10.25
FOUR	12.35	9.30
FIVE	11.60	8.70
SIX	11.10	8.35
SEVEN	9.20	6.90

LONG – ITEM 60, 2613, 2633, 2675		
NUMBER OF PATIENTS	FEE (PER PATIENT)	75% BENEFIT (PER PATIENT)
ONE	51.00	38.25
TWO	43.25	32.45
THREE	40.65	30.50
FOUR	39.35	29.55
FIVE	38.60	28.95
SIX	38.10	28.60
SEVEN	36.20	27.15

STANDARD - ITEM 59, 2610, 2631, 2673		
NUMBER OF PATIENTS	FEE (PER PATIENT)	75% BENEFIT (PER PATIENT)
ONE	33.50	25.15
TWO	24.75	18.60
THREE	21.85	16.40
FOUR	20.35	15.30
FIVE	19.50	14.65
SIX	18.90	14.20
SEVEN	16.70	12.55

PROLONGED – ITEM 65, 2616, 2635, 2677		
NUMBER OF PATIENTS	FEE (PER PATIENT)	75% BENEFIT (PER PATIENT)
ONE	73.00	54.75
TWO	65.25	48.95
THREE	62.65	47.00
FOUR	61.35	46.05
FIVE	60.60	45.45
SIX	60.10	45.10
SEVEN	58.20	43.65

AFTER HOURS ATTENDANCES

5. FEES AND BENEFITS FOR GP ATTENDANCES (OTHER THAN CONSULTING ROOMS) AT AN INSTITUTION OR HOME

LEVEL A – ITEM 5003		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	54.95	54.95
TWO	41.95	41.95
THREE	37.65	37.65
FOUR	35.50	35.50
FIVE	34.20	34.20
SIX	33.30	33.30
SEVEN	31.00	31.00

LEVEL B – ITEM 5023		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	74.95	74.95
TWO	61.95	61.95
THREE	57.65	57.65
FOUR	55.50	55.50
FIVE	54.20	54.20
SIX	53.30	53.30
SEVEN	51.00	51.00

LEVEL C – ITEM 5043		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	109.90	109.90
TWO	96.90	96.90
THREE	92.60	92.60
FOUR	90.45	90.45
FIVE	89.15	89.15
SIX	88.25	88.25
SEVEN	85.95	85.95

LEVEL D – ITEM 5063			
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)	
ONE	143.70	143.70	
TWO	130.70	130.70	
THREE	126.40	126.40	
FOUR	124.25	124.25	
FIVE	122.95	122.95	
SIX	122.05	122.05	
SEVEN	119.75	119.75	

6. FEES AND BENEFITS FOR OTHER NON REFERRED ATTENDANCES (OTHER THAN CONSULTING ROOMS) AT AN INSTITUTION OR HOME

BRIEF – ITEM 5220			
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)	
ONE	34.00	34.00	
TWO	26.25	26.25	
THREE	23.65	23.65	
FOUR	22.35	22.35	
FIVE	21.60	21.60	
SIX	21.10	21.10	
SEVEN	19.20	19.20	

STANDARD – ITEM 5223			
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)	
ONE	43.50	43.50	
TWO	34.75	34.75	
THREE	31.85	31.85	
FOUR	30.35	30.35	
FIVE	29.50	29.50	
SIX	28.90	28.90	
SEVEN	26.70	26.70	

LONG – ITEM 5227		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	61.00	61.00
TWO	53.25	53.25
THREE	50.65	50.65
FOUR	49.35	49.35
FIVE	48.60	48.60
SIX	48.10	48.10
SEVEN	46.20	46.20

PROLONGED – ITEM 5228		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	83.00	83.00
TWO	75.25	75.25
THREE	72.65	72.65
FOUR	71.35	71.35
FIVE	70.60	70.60
SIX	70.10	70.10
SEVEN	68.20	68.20

7. PUBLIC HEALTH PHYSICIAN ATTENDANCES

ITEM 414		
NUMBER OF PATIENTS	FEE (PER PATIENT)	75% BENEFIT (PER PATIENT)
ONE	45.70	34.30
TWO	32.75	24.60
THREE	28.45	21.35
FOUR	26.30	19.75
FIVE	25.00	18.75
SIX	24.15	18.15
SEVEN	21.85	16.40

ITEM 416		
NUMBER OF PATIENTS	FEE (PER PATIENT)	75% BENEFIT (PER PATIENT)
ONE	109.75	82.35
TWO	96.80	72.60
THREE	92.50	69.40
FOUR	90.35	67.80
FIVE	89.05	66.80
SIX	88.20	66.15
SEVEN	85.90	64.45

ITEM 415		
NUMBER OF PATIENTS	FEE (PER PATIENT)	75% BENEFIT (PER PATIENT)
ONE	69.25	51.95
TWO	56.30	42.25
THREE	52.00	39.00
FOUR	49.85	37.40
FIVE	48.55	36.45
SIX	47.70	35.80
SEVEN	45.40	34.05

ITEM 417		
NUMBER OF PATIENTS	FEE (PER PATIENT)	75% BENEFIT (PER PATIENT)
ONE	149.40	112.05
TWO	136.45	102.35
THREE	132.15	99.15
FOUR	130.00	97.50
FIVE	128.70	96.55
SIX	127.85	95.90
SEVEN	125.55	94.20

8. FOCUSSED PSYCHOLOGICAL STRATEGIES

ITEM 2723		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	118.70	118.70
TWO	105.70	105.70
THREE	101.40	101.40
FOUR	99.25	99.25
FIVE	97.95	97.95
SIX	97.05	97.05
SEVEN	94.75	94.75

	ITEM 2727		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)	
ONE	158.70	158.70	
TWO	145.70	145.70	
THREE	141.40	141.40	
FOUR	139.25	139.25	
FIVE	137.95	137.95	
SIX	137.05	137.05	
SEVEN	134.75	134.75	

TELEHEALTH DERIVED FEES

9. FEES AND BENEFITS FOR MEDICAL PRACTITIONER TELEHEALTH ATTENDANCES (OTHER THAN CONSULTING ROOMS) AT A HOME OR OTHER INSTITUTION

LEVEL A – ITEM 2122		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	48.85	48.85
TWO	35.85	35.85
THREE	31.55	31.55
FOUR	29.40	29.40
FIVE	28.10	28.10
SIX	27.20	27.20
SEVEN	24.90	24.90

LEVEL C – ITEM 2147		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	122.80	122.80
TWO	109.80	109.80
THREE	105.50	105.50
FOUR	103.35	103.35
FIVE	102.05	102.05
SIX	101.15	101.15
SEVEN	98.85	98.85

LEVEL B – ITEM 2137		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	75.90	75.90
TWO	62.90	62.90
THREE	58.60	58.60
FOUR	56.45	56.45
FIVE	55.15	55.15
SIX	54.25	54.25
SEVEN	51.95	51.95

LEVEL D – ITEM 2199		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	168.45	168.45
TWO	155.45	155.45
THREE	151.15	151.15
FOUR	149.00	149.00
FIVE	147.70	147.70
SIX	146.80	146.80
SEVEN	144.50	144.50

10. FEES AND BENEFITS FOR MEDICAL PRACTITIONER TELEHEALTH ATTENDANCES AT A RESIDENTIAL AGED CARE FACILITY

LEVEL A – ITEM 2125		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	69.60	69.60
TWO	46.25	46.25
THREE	38.45	38.45
FOUR	34.55	34.55
FIVE	32.25	32.25
SIX	30.70	30.70
SEVEN	26.20	26.20

LEVEL C – ITEM 2179		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	143.55	143.55
TWO	120.20	120.20
THREE	112.40	112.40
FOUR	108.50	108.50
FIVE	106.20	106.20
SIX	104.65	104.65
SEVEN	100.15	100.15

11. ACUPUNCTURE

LEVEL A – ITEM 195			
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)	
ONE	63.00	63.00	
TWO	50.00	50.00	
THREE	45.70	45.70	
FOUR	43.55	43.55	
FIVE	42.25	42.25	
SIX	41.35	41.35	
SEVEN	39.05	39.05	

LEVEL B – ITEM 2138		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	96.65	96.65
TWO	73.30	73.30
THREE	65.50	65.50
FOUR	61.60	61.60
FIVE	59.30	59.30
SIX	57.75	57.75
SEVEN	53.25	53.25

LEVEL D – ITEM 2220		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	189.20	189.20
TWO	165.85	165.85
THREE	158.05	158.05
FOUR	154.15	154.15
FIVE	151.85	151.85
SIX	150.30	150.30
SEVEN	145.80	145.80

12. FEES AND BENEFITS FOR NON-SPECIALIST PRACTITIONER ATTENDANCES TO WHICH NO OTHER ITEM APPLIES

ITEM 181		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	34.85	34.85
TWO	24.30	24.30
THREE	20.80	20.80
FOUR	19.00	19.00
FIVE	17.95	17.95
SIX	17.25	17.25
SEVEN	15.40	15.40

ITEM 187		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	51.20	51.20
TWO	40.65	40.65
THREE	37.15	37.15
FOUR	35.35	35.35
FIVE	34.30	34.30
SIX	33.60	33.60
SEVEN	31.75	31.75

ITEM 191		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	79.35	79.35
TWO	68.80	68.80
THREE	65.30	65.30
FOUR	63.50	63.50
FIVE	62.45	62.45
SIX	61.75	61.75
SEVEN	59.90	59.90

ITEM 206		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	106.80	106.80
TWO	96.25	96.25
THREE	92.75	92.75
FOUR	90.95	90.95
FIVE	89.90	89.90
SIX	89.20	89.20
SEVEN	87.35	87.35

13. FEES AND BENEFITS FOR NON-SPECIALIST PRACTITIONER ATTENDANCES ASSOCIATED WITH PRACTICE INCENTIVE PROGRAM PAYMENTS

ITEM 253, 260, 266		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	50.40	50.40
TWO	40.00	40.00
THREE	36.55	36.55
FOUR	34.85	34.85
FIVE	33.80	33.80
SIX	33.10	33.10
SEVEN	31.25	31.25

ITEM 255, 262, 269		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	78.10	78.10
TWO	67.70	67.70
THREE	64.25	64.25
FOUR	62.55	62.55
FIVE	61.50	61.50
SIX	60.80	60.80
SEVEN	58.95	58.95

ITEM 257, 264, 271			
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)	
ONE	105.20	105.20	
TWO	94.80	94.80	
THREE	91.35	91.35	
FOUR	89.65	89.65	
FIVE	88.60	88.60	
SIX	87.90	87.90	
SEVEN	86.05	86.05	

14. FEES AND BENEFITS FOR NON-SPECIALIST PRACTITIONER MENTAL HEALTH CARE

ITEM 285		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	94.95	94.95
TWO	84.55	84.55
THREE	81.10	81.10
FOUR	79.40	79.40
FIVE	78.35	78.35
SIX	77.65	77.65
SEVEN	75.80	75.80

ITEM 287		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	126.95	126.95
TWO	116.55	116.55
THREE	113.10	113.10
FOUR	111.40	111.40
FIVE	110.35	110.35
SIX	109.65	109.65
SEVEN	107.80	107.80

15. FEES AND BENEFITS FOR NON-SPECIALIST PRACTITIONER AFTER-HOURS ATTENDANCES TO WHICH NO OTHER ITEM APPLIES

ITEM 761		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	43.95	43.95
TWO	33.55	33.55
THREE	30.10	30.10
FOUR	28.40	28.40
FIVE	27.35	27.35
SIX	26.65	26.65
SEVEN	24.80	24.80

ITEM 763		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	59.95	59.95
TWO	49.55	49.55
THREE	46.10	46.10
FOUR	44.40	44.40
FIVE	43.35	43.35
SIX	42.65	42.65
SEVEN	40.80	40.80

ITEM 766		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	87.90	87.90
TWO	77.50	77.50
THREE	74.05	74.05
FOUR	72.35	72.35
FIVE	71.30	71.30
SIX	70.60	70.60
SEVEN	68.75	68.75

ITEM 769		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	114.95	114.95
TWO	104.55	104.55
THREE	101.10	101.10
FOUR	99.40	99.40
FIVE	98.35	98.35
SIX	97.65	97.65
SEVEN	95.80	95.80

ITEM 772		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	60.55	60.55
TWO	41.85	41.85
THREE	35.65	35.65
FOUR	32.55	32.55
FIVE	30.65	30.65
SIX	29.40	29.40
SEVEN	25.85	25.85

ITEM 776		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	76.55	76.55
TWO	57.85	57.85
THREE	51.65	51.65
FOUR	48.55	48.55
FIVE	46.65	46.65
SIX	45.40	45.40
SEVEN	41.85	41.85

ITEM 788		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	104.50	104.50
TWO	85.80	85.80
THREE	79.60	79.60
FOUR	76.50	76.50
FIVE	74.60	74.60
SIX	73.35	73.35
SEVEN	69.80	69.80

ITEM 789		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	131.55	131.55
TWO	112.85	112.85
THREE	106.65	106.65
FOUR	103.55	103.55
FIVE	101.65	101.65
SIX	100.40	100.40
SEVEN	96.85	96.85

16. FEES AND BENEFITS FOR NON-SPECIALIST PRACTITIONER VIDEO CONFERENCING CONSULTATION

ITEM 827		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	39.05	39.05
TWO	28.65	28.65
THREE	25.20	25.20
FOUR	23.50	23.50
FIVE	22.45	22.45
SIX	21.75	21.75
SEVEN	19.90	19.90

ITEM 829		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	55.65	55.65
TWO	36.95	36.95
THREE	30.75	30.75
FOUR	27.65	27.65
FIVE	25.75	25.75
SIX	24.50	24.50
SEVEN	20.95	20.95

ITEM 868		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	60.70	60.70
TWO	50.30	50.30
THREE	46.85	46.85
FOUR	45.15	45.15
FIVE	44.10	44.10
SIX	43.40	43.40
SEVEN	41.55	41.55

ITEM 869		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	77.30	77.30
TWO	58.60	58.60
THREE	52.40	52.40
FOUR	49.30	49.30
FIVE	47.40	47.40
SIX	46.15	46.15
SEVEN	42.60	42.60

ITEM 876		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	98.25	98.25
TWO	87.85	87.85
THREE	84.40	84.40
FOUR	82.70	82.70
FIVE	81.65	81.65
SIX	80.95	80.95
SEVEN	79.10	79.10

ITEM 881		
NUMBER OF FEE (PER PATIENTS PATIENT)		100% BENEFIT (PER PATIENT)
ONE	114.85	114.85
TWO	96.15	96.15
THREE	89.95	89.95
FOUR	86.85	86.85
FIVE	84.95	84.95
SIX	83.70	83.70
SEVEN	80.15	80.15

ITEM 891		
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)
ONE	134.75	134.75
TWO	124.35	124.35
THREE	120.90	120.90
FOUR	119.20	119.20
FIVE	118.15	118.15
SIX	117.45	117.45
SEVEN	115.60	115.60

ITEM 892			
NUMBER OF PATIENTS	FEE (PER PATIENT)	100% BENEFIT (PER PATIENT)	
ONE	151.35	151.35	
TWO	132.65	132.65	
THREE	126.45	126.45	
FOUR	123.35	123.35	
FIVE	121.45	121.45	
SIX	120.20	120.20	
SEVEN	116.65	116.65	

Services that attract the 100% Medicare rebate – as at 1 March 2019

Medicare Benefits Schedule (MBS) Group	Name of Subgroup	Item numbers
Group A1	General practitioner attendances to which no other item applies	3, 4, 23, 24, 36, 37, 44, 47
Group A2	Other non-referred attendances to which no other item applies	52, 53, 54, 57, 58, 59, 60, 65
Group A5	Prolonged attendances to which no other item applies	160, 161, 162, 163, 164
Group A6	Group therapy	170, 171, 172
Group A7	Acupuncture	173, 193, 195, 197, 199
Group A7	Non-Specialist Practitioner attendances to which no other item applies	179, 181, 185, 187, 189, 191, 203, 206
Group A7	Non-Specialist Practitioner prolonged attendances to which no other item applies	214, 215, 218, 219, 220
Group A7	Non-Specialist Practitioner group therapy	221, 222, 223
Group A7	Non-Specialist Practitioner health assessments	224, 225, 226, 227, 228
Group A7	Non-Specialist Practitioner management plans, team care arrangements and multidisciplinary care plans and case conferences	229, 230, 231, 232, 233, 235, 236, 237, 238, 239, 240, 243, 244
Group A7	Non-Specialist Practitioner domiciliary and residential medication management review	245, 249
Group A7	Non-Specialist Practitioner attendances associated with Practice Incentive Program payments	251, 252, 253, 254, 255, 256, 257, 259, 260, 261, 262, 263, 264, 265, 266, 268, 269, 270, 271
Group A7	Non-Specialist Practitioner mental health care	272, 276, 277, 279, 281, 282, 283, 285, 286, 287
Group A7	Non-Specialist Practitioner after-hours attendances to which no other item applies	733, 737, 741, 745, 761, 763, 766, 769, 772, 776, 788, 789
Group A7	Non-Specialist Practitioner pregnancy support counselling	792
Group A7	Non-Specialist Practitioner video conferencing consultation	812, 827, 829, 867, 868, 869, 873, 876, 881, 885, 891, 892
Group A11	Urgent Attendances After hours	585, 588, 591, 594, 599, 600
Group A14	Health assessments	701, 703, 705, 707, 715
Group A15	GP care plans and multidisciplinary case conferences	721, 723, 729, 731, 732, 735, 739, 743, 747, 750, 758
Group A17	Medication management review	900, 903

Group A18	General practitioner attendances	2497, 2501, 2503, 2504,
	associated with Practice Incentives	2506, 2507, 2509, 2517,
	Program (PIP) payments	2518, 2521, 2522, 2525,
		2526, 2546, 2547, 2552,
		2553, 2558, 2559,
Group A19	Other non-referred attendances	2598, 2600, 2603, 2606,
	associated with Practice Incentives	2610, 2613, 2616, 2620,
	Program (PIP) payments to which no	2622, 2624, 2631, 2633,
	other item applies	2635, 2664, 2666, 2668,
		2673, 2675, 2677
Group A20	GP mental health care	2700, 2701, 2712, 2713,
_		2715, 2717, 2721, 2723,
		2725, 2727
Group A22	General practitioner after-hours	5000, 5003, 5010, 5020,
	attendances to which no other item	5023, 5028, 5040, 5043,
	applies	5049, 5060, 5063, 5067
Group A23	Other non-referred after-hours	5200, 5203, 5207, 5208,
	attendances to which no other item	5220, 5223, 5227, 5228,
	applies	5260, 5263, 5265, 5267
Group A27	Pregnancy support couselling	4001
Group A29	Early intervention services for children	139
	with autism, pervasive developmental	
	disorder or disability	
Group A30	Medical Practitioners – Telehealth	2100, 2122, 2125, 2126,
	Atendances	2137, 2138, 2143, 2147,
		2179, 2195, 2199, 2220
Group A35	Services For Patients in Residential	90001, 90002, 90020,
	Aged Care Facilities	90035, 90043, 90051,
		90092, 90093, 90095,
		90096, 90183, 90188,
		90202, 90212
Group M12	Services provided by a practice nurse or	10983, 10984, 10987,
	registered Aboriginal Health Worker on	10988, 10989, 10997
	behalf of a medical practitioner	

PROFESSIONAL ATTENDANCES ITEMS

	Group A1. General Practitioner Attendances To Which No Other Item Applies
	LEVEL A Professional attendance for an obvious problem characterised by the straightforward nature of the task that requires a short patient history and, if required, limited examination and management.
	Professional attendance at consulting rooms (other than a service to which another item applies) by a general practitioner for an obvious problem characterised by the straightforward nature of the task that requires a short patient history and, if required, limited examination and management-each attendance
3	(See para AN.0.9 of explanatory notes to this Category) Fee: \$17.20 Benefit: 100% = \$17.20 Extended Medicare Safety Net Cap: \$51.60
<u> </u>	Professional attendance by a general practitioner (other than attendance at consulting rooms or a residential aged care facility or a service to which another item in the table applies) that requires a short patient history and, if necessary, limited examination and management-an attendance on one or more patients at one place on one occasion-each patient
4	(See para AN.0.11, AN.0.13, AN.0.9 of explanatory notes to this Category) Derived Fee: The fee for item 3, plus \$26.35 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 3 plus \$2.05 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the
4	lesser amount LEVEL B
	Professional attendance by a general practitioner (not being a service to which any other item in this table applies) lasting less than 20 minutes, including any of the following that are clinically relevant: a) taking a patient history; b) performing a clinical examination; c) arranging any necessary investigation; d) implementing a management plan; e) providing appropriate preventive health care; in relation to 1 or more health-related issues, with appropriate documentation.
	Professional attendance by a general practitioner at consulting rooms (other than a service to which another item in the table applies), lasting less than 20 minutes and including any of the following that are clinically relevant:
	(a) taking a patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation-each attendance
	(See para AN.0.9 of explanatory notes to this Category) Fee: \$37.60 Benefit: 100% = \$37.60

	ERAL PRACTITIONER ATTENDANCES CH NO OTHER ITEM APPLIES
	residential aged care facility or a service to which another item in the table applies), lasting less than 20 minutes and including any of the following that are clinically relevant:
	(a) taking a patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation-an attendance on one or more patients at one place on one occasion-each patient
	(See para AN.0.11, AN.0.13, AN.0.9 of explanatory notes to this Category) Derived Fee: The fee for item 23, plus \$26.35 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 23 plus \$2.05 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	LEVEL C
	Professional attendance by a general practitioner (not being a service to which any other item in this table applies) lasting at least 20 minutes, including any of the following that are clinically relevant: a) taking a detailed patient history; b) performing a clinical examination; c) arranging any necessary investigation; d) implementing a management plan; e) providing appropriate preventive health care; in relation to 1 or more health-related issues, with appropriate documentation.
	Professional attendance by a general practitioner at consulting rooms (other than a service to which another item in the table applies), lasting at least 20 minutes and including any of the following that are clinically relevant:
	(a) taking a detailed patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation-each attendance
36	(See para AN.0.9 of explanatory notes to this Category) Fee: \$72.80 Benefit: 100% = \$72.80 Extended Medicare Safety Net Cap: \$218.40
30	Professional attendance by a general practitioner (other than attendance at consulting rooms or a residential aged care facility or a service to which another item in the table applies), lasting at least 20 minutes and including any of the following that are clinically relevant:
37	(a) taking a detailed patient history;

	ERAL PRACTITIONER ATTENDANCES THINO OTHER ITEM APPLIES
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation-an attendance on one or more patients at one place on one occasion-each patient
	(See para AN.0.11, AN.0.13, AN.0.9 of explanatory notes to this Category) Derived Fee: The fee for item 36, plus \$26.35 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 36 plus \$2.05 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	LEVEL D Professional attendance by a general practitioner (not being a service to which any other item in this table applies) lasting at least 40 minutes, including any of the following that are clinically relevant: a) taking an extensive patient history; b) performing a clinical examination; c) arranging any necessary investigation; d) implementing a management plan; e) providing appropriate preventive health care; in relation to 1 or more health-related issues, with appropriate documentation.
	Professional attendance by a general practitioner at consulting rooms (other than a service to which another item in the table applies), lasting at least 40 minutes and including any of the following that are clinically relevant:
	(a) taking an extensive patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation-each attendance
	(See para AN.0.9 of explanatory notes to this Category) Fee: \$107.15 Benefit: 100% = \$107.15
44	Extended Medicare Safety Net Cap: \$321.45 Professional attendance by a general practitioner (other than attendance at consulting rooms or a residential aged care facility or a service to which another item in the table applies), lasting at least 40 minutes and including any of the following that are clinically relevant:
	(a) taking an extensive patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
47	(d) implementing a management plan;

A1. GENERAL PRACTITIONER ATTENDANCES TO WHICH NO OTHER ITEM APPLIES (e) providing appropriate preventive health care; for one or more health-related issues, with appropriate documentation-an attendance on one or more patients at one place on one occasion-each patient (See para AN.0.11, AN.0.13, AN.0.9 of explanatory notes to this Category) **Derived Fee:** The fee for item 44, plus \$26.35 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 44 plus \$2.05 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount A2. OTHER NON-REFERRED ATTENDANCES TO 1. OTHER MEDICAL PRACTITIONER WHICH NO OTHER ITEM APPLIES **ATTENDANCES** Group A2. Other Non-Referred Attendances To Which No Other Item Applies Subgroup 1. Other Medical Practitioner Attendances CONSULTATION AT CONSULTING ROOMS Professional attendance at consulting rooms Professional attendance at consulting rooms of not more than 5 minutes in duration (other than a service to which any other item applies)-each attendance, by: (a) a medical practitioner (who is not a general practitioner); or (b) a general practitioner to whom clause 2.3.1 applies **Benefit:** 100% = \$11.00Fee: \$11.00 52 Extended Medicare Safety Net Cap: \$33.00 Professional attendance at consulting rooms of more than 5 minutes in duration but not more than 25 minutes (other than a service to which any other item applies)-each attendance, by: (a) a medical practitioner (who is not a general practitioner); or (b) a general practitioner to whom clause 2.3.1 applies **Benefit:** 100% = \$21.00Fee: \$21.00 53 Extended Medicare Safety Net Cap: \$63.00 Professional attendance at consulting rooms of more than 25 minutes in duration but not more than 45 minutes (other than a service to which any other item applies)-each attendance, by: (a) a medical practitioner (who is not a general practitioner); or (b) a general practitioner to whom clause 2.3.1 applies Fee: \$38.00 **Benefit:** 100% = \$38.00Extended Medicare Safety Net Cap: \$114.00 54 Professional attendance at consulting rooms of more than 45 minutes in duration (other than a service to which any other item applies)-each attendance, by: (a) a medical practitioner (who is not a general practitioner); or (b) a general practitioner to whom clause 2.3.1 applies 57

	IER NON-REFERRED ATTENDANCES TO 1. OTHER MEDICAL PRACTITIONER NO OTHER ITEM APPLIES ATTENDANCES
	Fee: \$61.00 Benefit: 100% = \$61.00
	Extended Medicare Safety Net Cap: \$183.00
	CONSULTATION AT A PLACE OTHER THAN CONSULTING ROOMS OR A RESIDENTIAL AGED CARE FACILITY
	Professional attendance by a medical practitioner (other than a general practitioner) on 1 or more patients on 1 occasion at a place other than consulting rooms or a residential aged care facility.
	Professional attendance (other than an attendance at consulting rooms or a residential aged care facility or a service to which any other item in the table applies), not more than 5 minutes in duration-an attendance on one or more patients at one place on one occasion-each patient, by:
	(a) a medical practitioner (who is not a general practitioner); or
	(b) a general practitioner to whom clause 2.3.1 applies
58	Derived Fee: An amount equal to \$8.50, plus \$15.50 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - an amount equal to \$8.50 plus \$.70 per patient Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
30	Professional attendance (other than an attendance at consulting rooms or a residential aged care facility or a service to which any other item in the table applies) of more than 5 minutes in duration but not more than 25 minutes-an attendance on one or more patients at one place on one occasion-each patient, by:
	(a) a medical practitioner (who is not a general practitioner); or
	(b) a general practitioner to whom clause 2.3.1 applies
59	Derived Fee: An amount equal to \$16.00, plus \$17.50 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - an amount equal to \$16.00 plus \$.70 per patient Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	Professional attendance (other than an attendance at consulting rooms or a residential aged care facility or a service to which any other item in the table applies) of more than 25 minutes in duration but not more than 45 minutes-an attendance on one or more patients at one place on one occasion-each patient, by:
	(a) a medical practitioner (who is not a general practitioner); or
	(b) a general practitioner to whom clause 2.3.1 applies
60	Derived Fee: An amount equal to \$35.50, plus \$15.50 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - an amount equal to \$35.50 plus \$.70 per patient Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	Professional attendance (other than an attendance at consulting rooms or a residential aged care facility or a service to which any other item in the table applies) of more than 45 minutes in duration-an attendance on one or more patients at one place on one occasion-each patient, by:
	(a) a medical practitioner (who is not a general practitioner); or
	(b) a general practitioner to whom clause 2.3.1 applies
65	Derived Fee: An amount equal to \$57.50, plus \$15.50 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - an amount equal to \$57.50 plus \$.70 per patient Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount

	CIALIST ATTENDANCES TO WHICH NO TEM APPLIES
	Group A3. Specialist Attendances To Which No Other Item Applies
	Professional attendance on a patient by a specialist practising in his or her specialty if:
	(a) the attendance is by video conference; and
	(b) the attendance is for a service:
	(i) provided with item 104 lasting more than 10 minutes; or
	(ii) provided with item 105; and
	(c) the patient is not an admitted patient; and
	(d) the patient:
	(i) is located both:
	(A) within a telehealth eligible area; and
	(B) at the time of the attendance-at least 15 kms by road from the specialist; or
	(ii) is a care recipient in a residential care service; or
	(iii) is a patient of:
	(A) an Aboriginal Medical Service; or
	(B) an Aboriginal Community Controlled Health Service;
	for which a direction made under subsection 19(2) of the Act applies
99	(See para AN.0.68 of explanatory notes to this Category) Derived Fee: 50% of the fee for item 104 or 105. Benefit: 85% of the derived fee Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	Professional attendance at consulting rooms or hospital by a specialist in the practice of his or her specialty after referral of the patient to him or her-each attendance, other than a second or subsequent attendance, in a single course of treatment, other than a service to which item 106, 109 or 16401 applies
104	(See para TN.1.4 of explanatory notes to this Category) Fee: \$86.85 Benefit: 75% = \$65.15 85% = \$73.85 Extended Medicare Safety Net Cap: \$260.55
	Professional attendance by a specialist in the practice of his or her specialty following referral of the patient to him or her-an attendance after the first in a single course of treatment, if that attendance is at consulting rooms or hospital, other than a service to which item 16404 applies (See para TN.1.4, AN.0.70 of explanatory notes to this Category)
105	Fee: \$43.65 Benefit: 75% = \$32.75 85% = \$37.15 Extended Medicare Safety Net Cap: \$130.95
106	Professional attendance by a specialist in the practice of his or her specialty of ophthalmology and following referral of the patient to him or her-an attendance (other than a second or subsequent attendance in a single course of treatment) at which the only service provided is refraction testing for the issue of a prescription for spectacles or contact lenses, if that attendance is at consulting rooms or hospital (other than a service to which any of items 104, 109 and 10801 to 10816 applies)
106	

	ECIALIST ATTENDANCES TO WHICH NO
OTTILL	Fee: \$72.05 Benefit: 75% = \$54.05 85% = \$61.25
	Extended Medicare Safety Net Cap: \$216.15
	Professional attendance by a specialist in the practice of his or her specialty following referral of the patient to him or her-an attendance (other than a second or subsequent attendance in a single course of treatment), if that attendance is at a place other than consulting rooms or hospital
107	Fee: \$127.40 Benefit: 75% = \$95.55 85% = \$108.30 Extended Medicare Safety Net Cap: \$382.20
	Professional attendance by a specialist in the practice of his or her specialty following referral of the patient to him or her-each attendance after the first in a single course of treatment, if that attendance is at a place other than consulting rooms or hospital
108	Fee: \$80.65 Benefit: 75% = \$60.50 85% = \$68.60 Extended Medicare Safety Net Cap: \$241.95
	Professional attendance by a specialist in the practice of his or her specialty of ophthalmology following referral of the patient to him or her-an attendance (other than a second or subsequent attendance in a single course of treatment) at which a comprehensive eye examination, including pupil dilation, is performed on:
	(a) a patient aged 9 years or younger; or
	(b) a patient aged 14 years or younger with developmental delay;
	(other than a service to which any of items 104, 106 and 10801 to 10816 applies)
109	Fee: \$195.70 Benefit: 75% = \$146.80 85% = \$166.35 Extended Medicare Safety Net Cap: \$500.00
	Professional attendance at consulting rooms or in hospital by a specialist in the practice of his or her specialty following referral of the patient to him or her by a referring practitioner—an attendance after the first attendance in a single course of treatment, if:
	(a) during the attendance, the specialist determines the need to perform an operation on the patient that had not otherwise been scheduled; and
	(b) the specialist subsequently performs the operation on the patient, on the same day; and
	(c) the operation is a service to which an item in Group T8 applies; and
	(d) the amount specified in the item in Group T8 as the fee for a service to which that item applies is \$300 or more
	For any particular patient, once only on the same day
111	Fee: \$43.65 Benefit: 75% = \$32.75 85% = \$37.15 Extended Medicare Safety Net Cap: \$130.95
	Initial professional attendance of 10 minutes or less in duration on a patient by a specialist in the practice of his or her speciality if:
	(a) the attendance is by video conference; and
	(b) the patient is not an admitted patient; and
113	(c) the patient:

	CIALIST ATTENDANCES TO WHICH NO TEM APPLIES
	(i) is located both:
	(A) within a telehealth eligible area; and
	(B) at the time of the attendance-at least 15 kms by road from the specialist; or
	(ii) is a care recipient in a residential care service; or
	(iii) is a patient of:
	(A) an Aboriginal Medical Service; or
	(B) an Aboriginal Community Controlled Health Service;
	for which a direction made under subsection 19(2) of the Act applies; and
	(d) no other initial consultation has taken place for a single course of treatment
	(See para AN.0.68 of explanatory notes to this Category) Fee: \$65.15 Benefit: \$5% = \$55.40
	Extended Medicare Safety Net Cap: \$195.45
	SULTANT PHYSICIAN ATTENDANCES CH NO OTHER ITEM APPLIES
	Group A4. Consultant Physician Attendances To Which No Other Item Applies
	Professional attendance at consulting rooms or hospital, by a consultant physician in the practice of his or her specialty (other than psychiatry) following referral of the patient to him or her by a referring
	practitioner-initial attendance in a single course of treatment
110	Fee: \$153.15 Benefit: 75% = \$114.90 85% = \$130.20 Extended Medicare Safety Net Cap: \$459.45
110	Fee: \$153.15 Benefit: 75% = \$114.90 85% = \$130.20
110	Fee: \$153.15 Benefit: 75% = \$114.90 85% = \$130.20 Extended Medicare Safety Net Cap: \$459.45
110	Fee: \$153.15 Benefit: 75% = \$114.90 85% = \$130.20 Extended Medicare Safety Net Cap: \$459.45 Professional attendance on a patient by a consultant physician practising in his or her specialty if:
110	Fee: \$153.15 Benefit: 75% = \$114.90 85% = \$130.20 Extended Medicare Safety Net Cap: \$459.45 Professional attendance on a patient by a consultant physician practising in his or her specialty if: (a) the attendance is by video conference; and
110	Fee: \$153.15 Benefit: 75% = \$114.90 85% = \$130.20 Extended Medicare Safety Net Cap: \$459.45 Professional attendance on a patient by a consultant physician practising in his or her specialty if: (a) the attendance is by video conference; and (b) the attendance is for a service:
110	Fee: \$153.15 Benefit: 75% = \$114.90 85% = \$130.20 Extended Medicare Safety Net Cap: \$459.45 Professional attendance on a patient by a consultant physician practising in his or her specialty if: (a) the attendance is by video conference; and (b) the attendance is for a service: (i) provided with item 110 lasting more than 10 minutes; or
110	Fee: \$153.15 Benefit: 75% = \$114.90 85% = \$130.20 Extended Medicare Safety Net Cap: \$459.45 Professional attendance on a patient by a consultant physician practising in his or her specialty if: (a) the attendance is by video conference; and (b) the attendance is for a service: (i) provided with item 110 lasting more than 10 minutes; or (ii) provided with item 116, 119, 132 or 133; and
110	Fee: \$153.15 Benefit: 75% = \$114.90 85% = \$130.20 Extended Medicare Safety Net Cap: \$459.45 Professional attendance on a patient by a consultant physician practising in his or her specialty if: (a) the attendance is by video conference; and (b) the attendance is for a service: (i) provided with item 110 lasting more than 10 minutes; or (ii) provided with item 116, 119, 132 or 133; and (c) the patient is not an admitted patient; and
110	Fee: \$153.15 Benefit: 75% = \$114.90 85% = \$130.20 Extended Medicare Safety Net Cap: \$459.45 Professional attendance on a patient by a consultant physician practising in his or her specialty if: (a) the attendance is by video conference; and (b) the attendance is for a service: (i) provided with item 110 lasting more than 10 minutes; or (ii) provided with item 116, 119, 132 or 133; and (c) the patient is not an admitted patient; and (d) the patient:
110	Fee: \$153.15 Benefit: 75% = \$114.90 85% = \$130.20 Extended Medicare Safety Net Cap: \$459.45 Professional attendance on a patient by a consultant physician practising in his or her specialty if: (a) the attendance is by video conference; and (b) the attendance is for a service: (i) provided with item 110 lasting more than 10 minutes; or (ii) provided with item 116, 119, 132 or 133; and (c) the patient is not an admitted patient; and (d) the patient: (i) is located both:
110	Fee: \$153.15 Benefit: 75% = \$114.90 85% = \$130.20 Extended Medicare Safety Net Cap: \$459.45 Professional attendance on a patient by a consultant physician practising in his or her specialty if: (a) the attendance is by video conference; and (b) the attendance is for a service: (i) provided with item 110 lasting more than 10 minutes; or (ii) provided with item 116, 119, 132 or 133; and (c) the patient is not an admitted patient; and (d) the patient: (i) is located both: (A) within a telehealth eligible area; and

_	SULTANT PHYSICIAN ATTENDANCES H NO OTHER ITEM APPLIES
	(A) an Aboriginal Medical Service; or
	(B) an Aboriginal Community Controlled Health Service;
	for which a direction made under subsection 19(2) of the Act applies
	(See para AN.0.68 of explanatory notes to this Category) Derived Fee: 50% of the fee for the associated item. Benefit: 85% of derived fee. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	Initial professional attendance of 10 minutes or less in duration on a patient by a consultant physician practising in his or her specialty if:
	(a) the attendance is by video conference; and
	(b) the patient is not an admitted patient; and
	(c) the patient:
	(i) is located both:
	(A) within a telehealth eligible area; and
	(B) at the time of the attendance-at least 15 kms by road from the physician; or
	(ii) is a care recipient in a residential care service; or
	(iii) is a patient of:
	(A) an Aboriginal Medical Service; or
	(B) an Aboriginal Community Controlled Health Service;
	for which a direction made under subsection 19(2) of the Act applies; and
	(d) no other initial consultation has taken place for a single course of treatment
114	(See para AN.0.68 of explanatory notes to this Category) Fee: \$114.90 Benefit: 85% = \$97.70 Extended Medicare Safety Net Cap: \$344.70
	Professional attendance at consulting rooms or hospital, by a consultant physician in the practice of his or her specialty (other than psychiatry) following referral of the patient to him or her by a referring practitioner-each attendance (other than a service to which item 119 applies) after the first in a single course of treatment
116	(See para AN.0.70 of explanatory notes to this Category) Fee: \$76.65 Benefit: 75% = \$57.50 85% = \$65.20 Extended Medicare Safety Net Cap: \$229.95
	Professional attendance at consulting rooms or in hospital, by a consultant physician in the practice of his or her specialty (other than psychiatry) following referral of the patient to him or her by a referring practitioner—an attendance after the first attendance in a single course of treatment, if:
	(a) the attendance is not a minor attendance; and
117	(b) during the attendance, the consultant physician determines the need to perform an operation on the

	NSULTANT PHYSICIAN ATTENDANCES CH NO OTHER ITEM APPLIES
	patient that had not otherwise been scheduled; and
	(c) the consultant physician subsequently performs the operation on the patient, on the same day; and
	(d) the operation is a service to which an item in Group T8 applies; and
	(e) the amount specified in the item in Group T8 as the fee for a service to which that item applies is \$300 or more
	For any particular patient, once only on the same day
	Fee: \$76.65 Benefit: 75% = \$57.50 85% = \$65.20 Extended Medicare Safety Net Cap: \$229.95
	Professional attendance at consulting rooms or hospital, by a consultant physician in the practice of his or her specialty (other than psychiatry) following referral of the patient to him or her by a referring practitioner-each minor attendance after the first in a single course of treatment
119	(See para AN.0.21, AN.0.70 of explanatory notes to this Category) Fee: \$43.65 Benefit: 75% = \$32.75 Extended Medicare Safety Net Cap: \$130.95
	Professional attendance at consulting rooms or in hospital by a consultant physician in the practice of his or her specialty (other than psychiatry) following referral of the patient to him or her by a referring practitioner—an attendance after the first attendance in a single course of treatment, if:
	(a) the attendance is a minor attendance; and
	(b) during the attendance, the consultant physician determines the need to perform an operation on the patient that had not otherwise been scheduled; and
	(c) the consultant physician subsequently performs the operation on the patient, on the same day; and
	(d) the operation is a service to which an item in Group T8 applies; and
	(e) the amount specified in the item in Group T8 as the fee for a service to which that item applies is \$300 or more
	For any particular patient, once only on the same day
120	(See para AN.0.21 of explanatory notes to this Category) Fee: \$43.65 Benefit: 75% = \$32.75 85% = \$37.15 Extended Medicare Safety Net Cap: \$130.95
120	Professional attendance at a place other than consulting rooms or hospital, by a consultant physician in the practice of his or her specialty (other than psychiatry) following referral of the patient to him or her by a referring practitioner-initial attendance in a single course of treatment
122	Fee: \$185.85 Benefit: 75% = \$139.40 85% = \$158.00 Extended Medicare Safety Net Cap: \$500.00
	Professional attendance at a place other than consulting rooms or hospital, by a consultant physician in the practice of his or her specialty (other than psychiatry) following referral of the patient to him or her by a referring practitioner-each attendance (other than a service to which item 131 applies) after the first in a single course of treatment
	Fee: \$112.40 Benefit: 75% = \$84.30 85% = \$95.55
128	Extended Medicare Safety Net Cap: \$337.20
131	Professional attendance at a place other than consulting rooms or hospital, by a consultant physician in

A4. CONSULTANT PHYSICIAN ATTENDANCES TO WHICH NO OTHER ITEM APPLIES the practice of his or her specialty (other than psychiatry) following referral of the patient to him or her by a referring practitioner-each minor attendance after the first in a single course of treatment (See para AN.0.21 of explanatory notes to this Category) Fee: \$80.95 **Benefit:** 75% = \$60.75 85% = \$68.85 Extended Medicare Safety Net Cap: \$242.85 Professional attendance by a consultant physician in the practice of his or her specialty (other than psychiatry) of at least 45 minutes in duration for an initial assessment of a patient with at least 2 morbidities (which may include complex congenital, developmental and behavioural disorders) following referral of the patient to him or her by a referring practitioner, if: (a) an assessment is undertaken that covers: (i) a comprehensive history, including psychosocial history and medication review; and (ii) comprehensive multi or detailed single organ system assessment; and (iii) the formulation of differential diagnoses; and (b) a consultant physician treatment and management plan of significant complexity is prepared and provided to the referring practitioner, which involves: (i) an opinion on diagnosis and risk assessment; and (ii) treatment options and decisions; and (iii) medication recommendations; and (c) an attendance on the patient to which item 110, 116 or 119 applies did not take place on the same day by the same consultant physician; and (d) this item has not applied to an attendance on the patient in the preceding 12 months by the same consultant physician Not being an attendance on the patient in respect of whom, in the preceding 12 months, payment has been made under this item for attendance by the same consultant physician. (See para AN.0.23 of explanatory notes to this Category) Fee: \$267.85 **Benefit:** 75% = \$200.90 85% = \$227.70 Extended Medicare Safety Net Cap: \$500.00 132 Professional attendance of at least 20 minutes duration subsequent to the first attendance in a single course of treatment for a review of a patient with at least two morbidities (this can include complex congenital, developmental and behavioural disorders), where a) a review is undertaken that covers: - review of initial presenting problem/s and results of diagnostic investigations - review of responses to treatment and medication plans initiated at time of initial consultation comprehensive multi or detailed single organ system assessment. - review of original and differential diagnoses; and b) a modified consultant physician treatment and management plan is provided to the referring 133

A4. CONSULTANT PHYSICIAN ATTENDANCES TO WHICH NO OTHER ITEM APPLIES practitioner that involves, where appropriate: - a revised opinion on the diagnosis and risk assessment - treatment options and decisions revised medication recommendations Not being an attendance on a patient in respect of whom, an attendance under item 110, 116 and 119 has been received on the same day by the same consultant physician or locum tenens. Being an attendance on a patient in respect of whom, in the preceding 12 months, payment has been made under item 132. Item 133 can be provided by either the same consultant physician or a locum tenens. Payable no more than twice in any 12 month period. (See para AN.0.23 of explanatory notes to this Category) Fee: \$134.10 **Benefit:** $75\% = \$100.60 \quad 85\% = \114.00 Extended Medicare Safety Net Cap: \$402.30 A5. PROLONGED ATTENDANCES TO WHICH NO **OTHER ITEM APPLIES** Group A5. Prolonged Attendances To Which No Other Item Applies PROLONGED PROFESSIONAL ATTENDANCE Professional attendance (not being a service to which another item in this Category applies) on a patient in imminent danger of death. The time period relates to the total time spent with a single patient, even if the time spent by the practitioner is not continuous. Attendance on one patient at risk of imminent death may be provided by one or more general practitioners, specialists or consultant physicians on the one occasion. Professional attendance by a general practitioner, specialist or consultant physician for a period of not less than 1 hour but less than 2 hours (other than a service to which another item applies) on a patient in imminent danger of death (See para AN.0.27 of explanatory notes to this Category) Fee: \$221.50 **Benefit:** 75% = \$166.15 100% = \$221.50 160 Extended Medicare Safety Net Cap: \$500.00 Professional attendance by a general practitioner, specialist or consultant physician for a period of not less than 2 hours but less than 3 hours (other than a service to which another item applies) on a patient in imminent danger of death (See para AN.0.27 of explanatory notes to this Category) Fee: \$369.15 **Benefit:** 75% = \$276.90 100% = \$369.15 161 Extended Medicare Safety Net Cap: \$500.00 Professional attendance by a general practitioner, specialist or consultant physician for a period of not less than 3 hours but less than 4 hours (other than a service to which another item applies) on a patient in imminent danger of death 162

A5. PR	OLONGED ATTENDANCES TO WHICH NO
	RITEM APPLIES
	(See para AN.0.27 of explanatory notes to this Category)
	Fee: \$516.65 Benefit: 75% = \$387.50 100% = \$516.65
	Extended Medicare Safety Net Cap: \$500.00
	Professional attendance by a general practitioner, specialist or consultant physician for a period of not less than 4 hours but less than 5 hours (other than a service to which another item applies) on a patient in imminent danger of death
	(See para AN.0.27 of explanatory notes to this Category) Fee: \$664.55 Benefit: 75% = \$498.45 100% = \$664.55
163	Extended Medicare Safety Net Cap: \$500.00
	Professional attendance by a general practitioner, specialist or consultant physician for a period of 5 hours or more (other than a service to which another item applies) on a patient in imminent danger of death
	(See para AN.0.27 of explanatory notes to this Category)
	Fee: \$738.40 Benefit: 75% = \$553.80 100% = \$738.40
164	Extended Medicare Safety Net Cap: \$500.00
A6. GF	ROUP THERAPY
	Group A6. Group Therapy
	Professional attendance for the purpose of Group therapy of not less than 1 hour in duration given under the direct continuous supervision of a general practitioner, specialist or consultant physician (other than a consultant physician in the practice of his or her speciality of psychiatry) involving members of a family and persons with close personal relationships with that family-each Group of 2 patients
170	(See para AN.0.28, AN.0.5 of explanatory notes to this Category) Fee: \$117.55 Benefit: 75% = \$88.20 100% = \$117.55 Extended Medicare Safety Net Cap: \$352.65
170	Professional attendance for the purpose of Group therapy of not less than 1 hour in duration given under the direct continuous supervision of a general practitioner, specialist or consultant physician (other than a consultant physician in the practice of his or her specialty of psychiatry) involving members of a family and persons with close personal relationships with that family-each Group of 3 patients
	(See para AN.0.28, AN.0.5 of explanatory notes to this Category) Fee: \$123.85 Benefit: 75% = \$92.90 100% = \$123.85
171	Extended Medicare Safety Net Cap: \$371.55
	Professional attendance for the purpose of Group therapy of not less than 1 hour in duration given under the direct continuous supervision of a general practitioner, specialist or consultant physician (other than a consultant physician in the practice of his or her specialty of psychiatry) involving members of a family and persons with close personal relationships with that family-each Group of 4 or more patients
	(See para AN.0.28, AN.0.5 of explanatory notes to this Category) Fee: \$150.70 Benefit: 75% = \$113.05 100% = \$150.70
172	Extended Medicare Safety Net Cap: \$452.10
	CUPUNCTURE AND NON-SPECIALIST TITIONER ITEMS 1. ACUPUNCTURI
	Group A7. Acupuncture and Non-Specialist Practitioner Items
	Subgroup 1. Acupuncture
173	Professional attendance at which acupuncture is performed by a medical practitioner by application of stimuli on or through the surface of the skin by any means, including any consultation on the same occasion and another attendance on the same day related to the condition for which the acupuncture was

	PUNCTURE AND NON-SPECIALIST FIONER ITEMS 1. ACUPUNCTURE
	performed
	(See para AN.0.29 of explanatory notes to this Category) Fee: \$21.65 Benefit: 75% = \$16.25 100% = \$21.65 Extended Medicare Safety Net Cap: \$64.95
	Professional attendance by a general practitioner who is a qualified medical acupuncturist, at a place other than a hospital, lasting less than 20 minutes and including any of the following that are clinically relevant:
	(a) taking a patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation, at which acupuncture is performed by the qualified medical acupuncturist by the application of stimuli on or through the skin by any means, including any consultation on the same occasion and another attendance on the same day related to the condition for which the acupuncture is performed
193	(See para AN.0.29, AN.0.9 of explanatory notes to this Category) Fee: \$37.05 Benefit: 100% = \$37.05 Extended Medicare Safety Net Cap: \$111.15
	Professional attendance by a general practitioner who is a qualified medical acupuncturist, on one or more patients at a hospital, lasting less than 20 minutes and including any of the following that are clinically relevant:
	(a) taking a patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation, at which acupuncture is performed by the qualified medical acupuncturist by the application of stimuli on or through the skin by any means, including any consultation on the same occasion and another attendance on the same day related to the condition for which the acupuncture is performed
195	(See para AN.0.29, AN.0.9 of explanatory notes to this Category) Derived Fee: The fee for item 193, plus \$25.95 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 193 plus \$2.00 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
197	Professional attendance by a general practitioner who is a qualified medical acupuncturist, at a place other than a hospital, lasting at least 20 minutes and including any of the following that are clinically

	UPUNCTURE AND NON-SPECIALIST
PRACT	ITIONER ITEMS 1. ACUPUNCTURE relevant:
	(a) taking a detailed patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation, at which acupuncture is performed by the qualified medical acupuncturist by the application of stimuli on or through the skin by any means, including any consultation on the same occasion and another attendance on the same day related to the condition for which the acupuncture is performed
	(See para AN.0.29, AN.0.9 of explanatory notes to this Category) Fee: \$71.70 Extended Medicare Safety Net Cap: \$215.10
	Professional attendance by a general practitioner who is a qualified medical acupuncturist, at a place other than a hospital, lasting at least 40 minutes and including any of the following that are clinically relevant:
	(a) taking an extensive patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation, at which acupuncture is performed by the qualified medical acupuncturist by the application of stimuli on or through the skin by any means, including any consultation on the same occasion and another attendance on the same day related to the condition for which the acupuncture is performed
199	(See para AN.0.29, AN.0.9 of explanatory notes to this Category) Fee: \$105.55 Benefit: 100% = \$105.55 Extended Medicare Safety Net Cap: \$316.65
	2. NON-SPECIALIST PRACTITIONER UPUNCTURE AND NON-SPECIALIST ATTENDANCES TO WHICH NO OTHER ITEM ITIONER ITEMS APPLIES
	Group A7. Acupuncture and Non-Specialist Practitioner Items
	Subgroup 2. Non-Specialist Practitioner attendances to which no other item applies
	Professional attendance at consulting rooms of not more than 5 minutes in duration (other than a service to which any other item applies)—each attendance, by a medical practitioner in an eligible area.
170	(See para GN.7.17, AN.7.1, AN.7.2 of explanatory notes to this Category) Fee: \$13.75 Benefit: 100% = \$13.75 Extended Medicare Sefety Net Con: \$41.25
179 181	Extended Medicare Safety Net Cap: \$41.25 Professional attendance (other than an attendance at consulting rooms or a residential aged care facility

	2. NON-SPECIALIST PRACTITIONER
A7. ACUPUNCTURE AND NON-SPECI. PRACTITIONER ITEMS	ALIST ATTENDANCES TO WHICH NO OTHER ITEM APPLIES
	tem in the table applies), not more than 5 minutes in duration—an atts at one place on one occasion—each patient, by a medical practitioner
Derived Fee: The fee for item 179 patients. For seven or more patients	of explanatory notes to this Category) 1, plus \$21.10 divided by the number of patients seen, up to a maximum of six 1- the fee for item 179 plus \$1.65 per patient. 1. Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the
	lting rooms of more than 5 minutes in duration but not more than 25 which any other item applies)—each attendance, by a medical
Fee: \$30.10 Benefit: 10	of explanatory notes to this Category) $0\% = \$30.10$ Carry 500.20
or a service to which any other it	an an attendance at consulting rooms or a residential aged care facility em in the table applies) of more than 5 minutes in duration but not more on one or more patients at one place on one occasion—each patient, by
Derived Fee: The fee for item 185 patients. For seven or more patients	of explanatory notes to this Category) , plus \$21.10 divided by the number of patients seen, up to a maximum of six - the fee for item 185 plus \$1.65 per patient. Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the
Professional attendance at consul	lting rooms of more than 25 minutes in duration but not more than 45 which any other item applies)—each attendance, by a medical
(See para GN.7.17, AN.7.1, AN.7.2 Fee: \$58.25 Benefit: 10	of explanatory notes to this Category) 0% = \$58.25
189 Extended Medicare Safety Net	
or a service to which any other it	an an attendance at consulting rooms or a residential aged care facility tem in the table applies) of more than 25 minutes in duration but not clance on one or more patients at one place on one occasion—each in an eligible area
Derived Fee: The fee for item 189 patients. For seven or more patients	of explanatory notes to this Category) g, plus \$21.10 divided by the number of patients seen, up to a maximum of six the fee for item 189 plus \$1.65 per patient. Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the
Professional attendance at consul	lting rooms of more than 45 minutes in duration (other than a service to each attendance, by a medical practitioner in an eligible area
Fee: \$85.70 Benefit: 10	of explanatory notes to this Category) $0\% = \$85.70$ Cana \$257,10
203 Extended Medicare Safety Net Professional attendance (other th	an an attendance at consulting rooms or a residential aged care facility
or a service to which any other it	em in the table applies) of more than 45 minutes in duration—an at at one place on one occasion—each patient, by a medical practitioner
206	

	2. NON-SPECIALIST PRACTITIONER CUPUNCTURE AND NON-SPECIALIST ATTENDANCES TO WHICH NO OTHER ITEM TITIONER ITEMS APPLIES
	(See para GN.7.17, AN.7.1, AN.7.2 of explanatory notes to this Category) Derived Fee: The fee for item 203, plus \$21.10 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 203 plus \$1.65 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	3. NON-SPECIALIST PRACTITIONER CUPUNCTURE AND NON-SPECIALIST PROLONGED ATTENDANCES TO WHICH NO TITIONER ITEMS OTHER ITEM APPLIES
	Group A7. Acupuncture and Non-Specialist Practitioner Items
	Subgroup 3. Non-Specialist Practitioner prolonged attendances to which no other item applies
	Professional attendance by a medical practitioner for a period of not less than 1 hour but less than 2 hours (other than a service to which another item applies) on a patient in imminent danger of death
214	(See para AN.7.1, AN.7.3 of explanatory notes to this Category) Fee: \$177.20 Benefit: 75% = \$132.90 100% = \$177.20
214	Extended Medicare Safety Net Cap: \$500.00 Professional attendance by a medical practitioner for a period of not less than 2 hours but less than 3 hours (other than a service to which another item applies) on a patient in imminent danger of death
	(See para AN.7.1, AN.7.3 of explanatory notes to this Category) Fee: \$295.30 Benefit: 75% = \$221.50 100% = \$295.30
215	Extended Medicare Safety Net Cap: \$500.00
	Professional attendance by a medical practitioner for a period of not less than 3 hours but less than 4 hours (other than a service to which another item applies) on a patient in imminent danger of death
218	(See para AN.7.1, AN.7.3 of explanatory notes to this Category) Fee: \$413.30 Benefit: 75% = \$310.00 100% = \$413.30 Extended Medicare Safety Net Cap: \$500.00
	Professional attendance by a medical practitioner for a period of not less than 4 hours but less than 5 hours (other than a service to which another item applies) on a patient in imminent danger of death
210	(See para AN.7.1, AN.7.3 of explanatory notes to this Category) Fee: \$531.65 Benefit: 75% = \$398.75 100% = \$531.65
219	Extended Medicare Safety Net Cap: \$500.00 Professional attendance by a medical practitioner for a period of 5 hours or more (other than a service to which another item applies) on a patient in imminent danger of death
220	(See para AN.7.1, AN.7.3 of explanatory notes to this Category) Fee: \$590.70 Benefit: 75% = \$443.05 100% = \$590.70 Extended Medicare Safety Net Cap: \$500.00
A7. A0	CUPUNCTURE AND NON-SPECIALIST 4. NON-SPECIALIST PRACTITIONER GROUP THERAPY
	Group A7. Acupuncture and Non-Specialist Practitioner Items
	Subgroup 4. Non-Specialist Practitioner group therapy
	Professional attendance for the purpose of group therapy of not less than 1 hour in duration given under the direct continuous supervision of a medical practitioner involving members of a family and persons with close personal relationships with that family—each Group of 2 patients
221	(See para AN.7.1, AN.7.4 of explanatory notes to this Category) Fee: \$94.05 Benefit: 75% = \$70.55 100% = \$94.05

	PUNCTURE AND NON-SPECIALIST 4. NON-SPECIALIST PRACTITIONER GROUP
PRACTIT	TIONER ITEMS THERAPY
	Extended Medicare Safety Net Cap: \$282.15 Professional attendance for the purpose of group therapy of not less than 1 hour in duration given under the direct continuous supervision of a medical practitioner involving members of a family and persons with close personal relationships with that family—each Group of 3 patients
222	(See para AN.7.1, AN.7.4 of explanatory notes to this Category) Fee: \$99.10 Benefit: 75% = \$74.35 100% = \$99.10 Extended Medicare Safety Net Cap: \$297.30
	Professional attendance for the purpose of group therapy of not less than 1 hour in duration given under the direct continuous supervision of a medical practitioner involving members of a family and persons with close personal relationships with that family—each Group of 4 or more patients
223	(See para AN.7.1, AN.7.4 of explanatory notes to this Category) Fee: \$120.55 Benefit: 75% = \$90.45 100% = \$120.55 Extended Medicare Safety Net Cap: \$361.65
	PUNCTURE AND NON-SPECIALIST 5. NON-SPECIALIST PRACTITIONER HEALTH ASSESSMENTS
	Group A7. Acupuncture and Non-Specialist Practitioner Items
	Subgroup 5. Non-Specialist Practitioner health assessments
	Professional attendance by a medical practitioner to perform a brief health assessment, lasting not more than 30 minutes and including:
	(a) collection of relevant information, including taking a patient history; and
	(b) a basic physical examination; and
	(c) initiating interventions and referrals as indicated; and
	(d) providing the patient with preventive health care advice and information
224	(See para AN.7.1, AN.7.5, AN.7.6, AN.7.7, AN.7.8, AN.7.9, AN.7.10, AN.7.11, AN.7.12 of explanatory notes to this Category) Fee: \$47.50 Extended Medicare Safety Net Cap: \$142.50
224	Professional attendance by a medical practitioner to perform a standard health assessment, lasting more than 30 minutes but less than 45 minutes, including:
	(a) detailed information collection, including taking a patient history; and
	(b) an extensive physical examination; and
	(c) initiating interventions and referrals as indicated; and
	(d) providing a preventive health care strategy for the patient
225	(See para AN.7.1, AN.7.5, AN.7.6, AN.7.7, AN.7.8, AN.7.9, AN.7.10, AN.7.11, AN.7.12 of explanatory notes to this Category) Fee: \$110.30 Benefit: 100% = \$110.30 Extended Medicare Safety Net Cap: \$330.90
	Professional attendance by a medical practitioner to perform a long health assessment, lasting at least 45 minutes but less than 60 minutes, including:
226	(a) comprehensive information collection, including taking a patient history; and

	CUPUNCTURE AND NON-SPECIALIST 5. NON-SPECIALIST PRACTITIONER HEALTH ASSESSMENTS
	(b) an extensive examination of the patient's medical condition and physical function; and
	(c) initiating interventions and referrals as indicated; and
	(d) providing a basic preventive health care management plan for the patient
	(See para AN.7.1, AN.7.5, AN.7.6, AN.7.7, AN.7.8, AN.7.9, AN.7.10, AN.7.11, AN.7.12 of explanatory notes to this Category) Fee: \$152.25 Benefit: 100% = \$152.25
	Extended Medicare Safety Net Cap: \$456.75
	Professional attendance by a medical practitioner to perform a prolonged health assessment (lasting at least 60 minutes) including:
	(a) comprehensive information collection, including taking a patient history; and
	(b) an extensive examination of the patient's medical condition, and physical, psychological and social function; and
	(c) initiating interventions or referrals as indicated; and
	(d) providing a comprehensive preventive health care management plan for the patient
	(See para AN.7.1, AN.7.5, AN.7.6, AN.7.7, AN.7.8, AN.7.9, AN.7.10, AN.7.11, AN.7.12 of explanatory notes to this Category)
227	Fee: \$215.05 Benefit: 100% = \$215.05 Extended Medicare Safety Net Cap: \$500.00
	Professional attendance by a medical practitioner at consulting rooms or in another place other than a hospital or residential aged care facility, for a health assessment of a patient who is of Aboriginal or Torres Strait Islander descent—this item or item 715 not more than once in a 9 month period
228	(See para AN.7.1, AN.7.13, AN.7.14, AN.7.15, AN.7.16 of explanatory notes to this Category) Fee: \$169.80 Benefit: 100% = \$169.80 Extended Medicare Safety Net Cap: \$500.00
	6. NON-SPECIALIST PRACTITIONER MANAGEMENT PLANS, TEAM CARE CUPUNCTURE AND NON-SPECIALIST TITIONER ITEMS ARRANGEMENTS AND MULTIDISCIPLINARY CARE PLANS AND CASE CONFERENCES
	Group A7. Acupuncture and Non-Specialist Practitioner Items
	Subgroup 6. Non-Specialist Practitioner management plans, team care arrangements and multidisciplinary care plans and case conferences
	Attendance by a medical practitioner, for preparation of a GP management plan for a patient (other than a service associated with a service to which any of items 735 to 758 and items 235 to 240 apply)
229	(See para AN.7.1, AN.7.17 of explanatory notes to this Category) Fee: \$115.40 Benefit: 75% = \$86.55 100% = \$115.40 Extended Medicare Safety Net Cap: \$346.20
	Attendance by a medical practitioner, to coordinate the development of team care arrangements for a patient (other than a service associated with a service to which any of items 735 to 758 and items 235 to 240 apply)
	(See para AN.7.1, AN.7.17 of explanatory notes to this Category) Fee: \$91.45 Benefit: 75% = \$68.60 100% = \$91.45
230	Extended Medicare Safety Net Cap: \$274.35

A7. ACUPUNCTURE AND NON-SPECIALIST PRACTITIONER ITEMS

6. NON-SPECIALIST PRACTITIONER MANAGEMENT PLANS, TEAM CARE ARRANGEMENTS AND MULTIDISCIPLINARY CARE PLANS AND CASE CONFERENCES

Contribution by a medical practitioner, to a multidisciplinary care plan prepared by another provider or a
review of a multidisciplinary care plan prepared by another provider (other than a service associated with a service to which any of items 735 to 758 and items 235 to 240 apply)
(See para AN.7.1, AN.7.17 of explanatory notes to this Category) Fee: \$56.30 Benefit: 75% = \$42.25 100% = \$56.30 Extended Medicare Safety Net Cap: \$168.90
Contribution by a medical practitioner, to:
(a) a multidisciplinary care plan for a patient in a residential aged care facility, prepared by that facility, or to a review of such a plan prepared by such a facility; or
(b) a multidisciplinary care plan prepared for a patient by another provider before the patient is discharged from a hospital, or to a review of such a plan prepared by another provider
(other than a service associated with a service to which items 735 to 758 and items 235 to 240 apply)
(See para AN.7.1, AN.7.17 of explanatory notes to this Category) Fee: \$56.30 Benefit: 75% = \$42.25 100% = \$56.30 Extended Medicare Safety Net Cap: \$168.90
Attendance by a medical practitioner to review or coordinate a review of:
(a) a GP management plan prepared by a medical practitioner (or an associated medical practitioner) to which item 721 or item 229 applies; or
(b) team care arrangements which have been coordinated by the medical practitioner (or an associated medical practitioner) to which item 723 or item 230 applies
(See para AN.7.1, AN.7.17 of explanatory notes to this Category) Fee: \$57.65 Benefit: 75% = \$43.25 100% = \$57.65 Extended Medicare Safety Net Cap: \$172.95
Attendance by a medical practitioner, as a member of a multidisciplinary case conference team, to organise and coordinate:
(a) a community case conference; or
(b) a multidisciplinary case conference in a residential aged care facility; or
(c) a multidisciplinary discharge case conference;
if the conference lasts for at least 15 minutes, but for less than 20 minutes (other than a service associated with a service to which items 721 to 732 or items 229 to 233 apply)
(See para AN.7.1, AN.7.27 of explanatory notes to this Category) Fee: \$56.50 Benefit: 75% = \$42.40 100% = \$56.50
Extended Medicare Safety Net Cap: \$169.50
Attendance by a medical practitioner, as a member of a multidisciplinary case conference team, to organise and coordinate:
(a) a community case conference; or
(b) a multidisciplinary case conference in a residential aged care facility; or

	MANAGEMENT PLANS, TEAM CARE PUNCTURE AND NON-SPECIALIST ARRANGEMENTS AND MULTIDISCIPLINARY CARE PLANS AND CASE CONFERENCES
	(c) a multidisciplinary discharge case conference;
	if the conference lasts for at least 20 minutes, but for less than 40 minutes (other than a service associated with a service to which items 721 to 732 or items 229 to 233 apply)
	(See para AN.7.1, AN.7.27 of explanatory notes to this Category) Fee: \$96.75
	Attendance by a medical practitioner, as a member of a multidisciplinary case conference team, to organise and coordinate:
	(a) a community case conference; or
	(b) a multidisciplinary case conference in a residential aged care facility; or
	(c) a multidisciplinary discharge case conference;
	if the conference lasts for at least 40 minutes (other than a service associated with a service to which items 721 to 732 or items 229 to 233 apply)
237	(See para AN.7.1, AN.7.27 of explanatory notes to this Category) Fee: \$161.30
	Attendance by a medical practitioner, as a member of a multidisciplinary case conference team, to participate in:
	(a) a community case conference; or
	(b) a multidisciplinary case conference in a residential aged care facility; or
	(c) a multidisciplinary discharge case conference;
	if the conference lasts for at least 15 minutes, but for less than 20 minutes (other than a service associated with a service to which items 721 to 732 or items 229 to 233 apply)
238	(See para AN.7.1, AN.7.27 of explanatory notes to this Category) Fee: \$41.50
	Attendance by a medical practitioner, as a member of a multidisciplinary case conference team, to participate in:
	(a) a community case conference; or
	(b) a multidisciplinary case conference in a residential aged care facility; or
	(c) a multidisciplinary discharge case conference;
	if the conference lasts for at least 20 minutes, but for less than 40 minutes (other than a service associated with a service to which items 721 to 732 or items 229 to 233 apply)
239	(See para AN.7.1, AN.7.27 of explanatory notes to this Category) Fee: \$71.20 Benefit: 75% = \$53.40 100% = \$71.20 Extended Medicare Safety Net Cap: \$213.60

6. NON-SPECIALIST PRACTITIONER

240

Attendance by a medical practitioner, as a member of a multidisciplinary case conference team, to

	6. NON-SPECIALIST PRACTITIONER MANAGEMENT PLANS, TEAM CARE UPUNCTURE AND NON-SPECIALIST ARRANGEMENTS AND MULTIDISCIPLINARY ITIONER ITEMS CARE PLANS AND CASE CONFERENCES			
	participate in:			
	(a) a community case conference; or			
	(b) a multidisciplinary case conference in a residential aged care facility; or			
	(c) a multidisciplinary discharge case conference;			
	if the conference lasts for at least 40 minutes (other than a service associated with a service to which items 721 to 732 or items 229 to 233 apply)			
	(See para AN.7.1, AN.7.27 of explanatory notes to this Category) Fee: \$118.55 Benefit: 75% = \$88.95 100% = \$118.55 Extended Medicare Safety Net Cap: \$355.65			
	Attendance by a medical practitioner, as a member of a case conference team, to lead and coordinate a multidisciplinary case conference on a patient with cancer to develop a multidisciplinary treatment plan, if the case conference is of at least 10 minutes, with a multidisciplinary team of at least 3 other medical practitioners from different areas of medical practice (which may include general practice), and, in addition, allied health providers			
243	(See para AN.7.1, AN.7.27 of explanatory notes to this Category) Fee: \$65.20 Benefit: 75% = \$48.90 100% = \$65.20 Extended Medicare Safety Net Cap: \$195.60			
	Attendance by a medical practitioner, as a member of a case conference team, to participate in a multidisciplinary case conference on a patient with cancer to develop a multidisciplinary treatment plan, if the case conference is of at least 10 minutes, with a multidisciplinary team of at least 4 medical practitioners from different areas of medical practice (which may include general practice), and, in addition, allied health providers			
244	(See para AN.7.1, AN.7.27 of explanatory notes to this Category) Fee: \$30.35 Benefit: 75% = \$22.80 100% = \$30.35 Extended Medicare Safety Net Cap: \$91.05			
	7. NON-SPECIALIST PRACTITIONER UPUNCTURE AND NON-SPECIALIST DOMICILIARY AND RESIDENTIAL MEDICATION ITIONER ITEMS MANAGEMENT REVIEW			
	Group A7. Acupuncture and Non-Specialist Practitioner Items			
	Subgroup 7. Non-Specialist Practitioner domiciliary and residential medication management review			
	Participation by a medical practitioner in a Domiciliary Medication Management Review (DMMR) for a patient living in a community setting, in which the medical practitioner, with the patient's consent:			
	(a) assesses the patient as:			
	(i) having a chronic medical condition or a complex medication regimen; and			
	(ii) not having their therapeutic goals met; and			
	(b) following that assessment:			
	(i) refers the patient to a community pharmacy or an accredited pharmacist for the DMMR; and			
Í				

7. NON-SPECIALIST PRACTITIONER A7. ACUPUNCTURE AND NON-SPECIALIST DOMICILIARY AND RESIDENTIAL MEDICATION PRACTITIONER ITEMS **MANAGEMENT REVIEW** (c) discusses with the reviewing pharmacist the results of the DMMR including suggested medication management strategies; and (d) develops a written medication management plan following discussion with the patient; and (e) provides the written medication management plan to a community pharmacy chosen by the patient For any particular patient—this item or item 900 is applicable not more than once in each 12 month period, except if there has been a significant change in the patient's condition or medication regimen requiring a new DMMR (See para AN.7.1, AN.7.18 of explanatory notes to this Category) Fee: \$123.85 **Benefit:** 100% = \$123.85Extended Medicare Safety Net Cap: \$371.55 Participation by a medical practitioner in a residential medication management review (RMMR) for a patient who is a permanent resident of a residential aged care facility—other than an RMMR for a resident in relation to whom, in the preceding 12 months, this item or item 903 has applied, unless there has been a significant change in the resident's medical condition or medication management plan requiring a new RMMR (See para AN.7.1, AN.7.18 of explanatory notes to this Category) **Benefit:** 100% = \$84.80 Fee: \$84.80 249 Extended Medicare Safety Net Cap: \$254.40 8. NON-SPECIALIST PRACTITIONER ATTENDANCES ASSOCIATED WITH PRACTICE A7. ACUPUNCTURE AND NON-SPECIALIST **PRACTITIONER ITEMS INCENTIVE PROGRAM PAYMENTS** Group A7. Acupuncture and Non-Specialist Practitioner Items Subgroup 8. Non-Specialist Practitioner attendances associated with Practice Incentive Program payments Professional attendance at consulting rooms of less than 5 minutes in duration by a medical practitioner in an eligible area at which a specimen for a cervical screening service is collected from the patient, if the patient is at least 24 years and 9 months of age but is less than 75 years of age and has not been provided with a cervical screening service or a cervical smear service in the last 4 years (See para AN.7.1, AN.7.19 of explanatory notes to this Category) Fee: \$13.55 **Benefit:** 100% = \$13.55251 Extended Medicare Safety Net Cap: \$40.65 Professional attendance at consulting rooms of more than 5 minutes, but not more than 25 minutes in duration by a medical practitioner in an eligible area, at which a specimen for a cervical screening

212

service is collected from the patient, if the patient is at least 24 years and 9 months of age but is less than 75 years of age and has not been provided with a cervical screening service or a cervical smear service

Professional attendance at a place other than consulting rooms of more than 5 minutes, but not more than 25 minutes in duration by a medical practitioner in an eligible area, at which a specimen for a cervical screening service is collected from the patient, if the patient is at least 24 years and 9 months of age but is less than 75 years of age and has not been provided with a cervical screening service or a

in the last 4 years

Fee: \$29.65

252

253

(See para AN.7.1, AN.7.19 of explanatory notes to this Category) **Benefit:** 100% = \$29.65

Extended Medicare Safety Net Cap: \$88.95

cervical smear service in the last 4 years

	TITIONER ITEMS	8. NON-SPECIALIST PRACTITIONER TENDANCES ASSOCIATED WITH PRACTICE INCENTIVE PROGRAM PAYMENTS
	(See para AN.7.1, AN.7.19 of explanatory notes to this Ca Derived Fee: The fee for item 252, plus \$20.75 divided patients. For seven or more patients - the fee for item 252 Extended Medicare Safety Net Cap: 300% of the D lesser amount	by the number of patients seen, up to a maximum of six plus \$1.60 per patient.
	Professional attendance at consulting rooms of more duration by a medical practitioner in an eligible area service is collected from the patient, if the patient is 75 years of age and has not been provided with a cer in the last 4 years	, at which a specimen for a cervical screening at least 24 years and 9 months of age but is less than
254	(See para AN.7.1, AN.7.19 of explanatory notes to this Ca Fee: \$57.35 Benefit: 100% = \$57.35 Extended Medicare Safety Net Cap: \$172.05	itegory)
	Professional attendance at a place other than consult than 45 minutes in duration by a medical practitione cervical screening service is collected from the patie age but is less than 75 years of age and has not been cervical smear service in the last 4 years	r in an eligible area, at which a specimen for a nt, if the patient is at least 24 years and 9 months of
	(See para AN.7.1, AN.7.19 of explanatory notes to this Ca Derived Fee: The fee for item 254, plus \$20.75 divided patients. For seven or more patients - the fee for item 254 Extended Medicare Safety Net Cap: 300% of the D	by the number of patients seen, up to a maximum of six plus \$1.60 per patient.
255	lesser amount	erived fee for this item, or \$500.00, whichever is the
	Professional attendance at consulting rooms of more practitioner in an eligible area, at which a specimen patient, if the patient is at least 24 years and 9 month been provided with a cervical screening service or a	for a cervical screening service is collected from the as of age but is less than 75 years of age and has not cervical smear service in the last 4 years
	(See para AN.7.1, AN.7.19 of explanatory notes to this Ca Fee: \$84.45 Benefit: 100% = \$84.45	itegory)
256	Extended Medicare Safety Net Cap: \$253.35	
200	Professional attendance at a place other than consult medical practitioner in an eligible area, at which a sp from the patient, if the patient is at least 24 years and	becimen for a cervical screening service is collected
257	(See para AN.7.1, AN.7.19 of explanatory notes to this Ca Derived Fee: The fee for item 256, plus \$20.75 divided patients. For seven or more patients - the fee for item 256 Extended Medicare Safety Net Cap: 300% of the D lesser amount	by the number of patients seen, up to a maximum of six plus \$1.60 per patient
231	Professional attendance at consulting rooms of more duration by a medical practitioner in an eligible area cycle of care of a patient with established diabetes m (See para AN.7.1, AN.7.20 of explanatory notes to this Ca	, that completes the minimum requirements for a nellitus
	Fee: \$29.65 Benefit: 100% = \$29.65	negory)
259	Extended Medicare Safety Net Cap: \$88.95	
	Professional attendance at a place other than consult than 25 minutes in duration by a medical practitione requirements for a cycle of care of a patient with esta	r in an eligible area, that completes the minimum
260	_	

	8. NON-SPECIALIST PRACTITIONER UPUNCTURE AND NON-SPECIALIST ATTENDANCES ASSOCIATED WITH PRACTICE ITIONER ITEMS INCENTIVE PROGRAM PAYMENTS	
	(See para AN.7.1, AN.7.20 of explanatory notes to this Category) Derived Fee: The fee for item 259, plus \$20.75 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 259 plus \$1.60 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount	
	Professional attendance at consulting rooms of more than 25 minutes, but not more than 45 minutes in duration by a medical practitioner in an eligible area, that completes the requirements for a cycle of care of a patient with established diabetes mellitus	
	(See para AN.7.1, AN.7.20 of explanatory notes to this Category) Fee: \$57.35 Benefit: 100% = \$57.35	
261	Extended Medicare Safety Net Cap: \$172.05	
	Professional attendance at a place other than consulting rooms of more than 25 minutes but not more than 45 minutes, in duration by a medical practitioner in an eligible area, that completes the minimum requirements for a cycle of care of a patient with established diabetes mellitus	
262	(See para AN.7.1, AN.7.20 of explanatory notes to this Category) Derived Fee: The fee for item 261, plus \$20.75 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 261 plus \$1.60 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount	
202	Professional attendance at consulting rooms of more than 45 minutes in duration by a medical practitioner in an eligible area, that completes the minimum requirements for a cycle of care of a patient with established diabetes mellitus	
	(See para AN.7.1, AN.7.20 of explanatory notes to this Category) Fee: \$84.45 Benefit: 100% = \$84.45	
263	Extended Medicare Safety Net Cap: \$253.35 Professional attendance at a place other than consulting rooms of more than 45 minutes in duration by a	
	medical practitioner in an eligible area, that completes the minimum requirements for a cycle of care of a patient with established diabetes mellitus	
	(See para AN.7.1, AN.7.20 of explanatory notes to this Category)	
	Derived Fee: The fee for item 263, plus \$20.75 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 263 plus \$1.60 per patient.	
264	Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount	
	Professional attendance at consulting rooms of more than 5 minutes, but not more than 25 minutes in duration by a medical practitioner in an eligible area, that completes the minimum requirements of the Asthma Cycle of Care	
	(See para AN.7.1, AN.7.21 of explanatory notes to this Category) Fee: \$29.65 Benefit: 100% = \$29.65	
265	Extended Medicare Safety Net Cap: \$88.95	
	Professional attendance at a place other than consulting rooms of more than 5 minutes, but not more than 25 minutes in duration by a medical practitioner in an eligible area, that completes the minimum requirements of the Asthma Cycle of Care	
	(See para AN.7.1, AN.7.21 of explanatory notes to this Category) Derived Fee: The fee for item 265, plus \$20.75 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 265 plus \$1.60 per patient.	
266	Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount	
268	Professional attendance at consulting rooms of more than 25 minutes, but not more than 45 minutes in	
200	1 Total Strain and Indiana and Indiana of Indiana and	

	8. NON-SPECIALIST PRACTITIONER JPUNCTURE AND NON-SPECIALIST ATTENDANCES ASSOCIATED WITH PRACTICE TIONER ITEMS INCENTIVE PROGRAM PAYMENTS
	duration by a medical practitioner in an eligible area, that completes the minimum requirements of the Asthma Cycle of Care
	(See para AN.7.1, AN.7.21 of explanatory notes to this Category) Fee: \$57.35 Benefit: 100% = \$57.35 Extended Medicare Safety Net Cap: \$172.05
	Professional attendance at a place other than consulting rooms of more than 25 minutes, but not more than 45 minutes in duration by a medical practitioner in an eligible area, that completes the minimum requirements of the Asthma Cycle of Care
269	(See para AN.7.1, AN.7.21 of explanatory notes to this Category) Derived Fee: The fee for item 268, plus \$20.75 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 268 plus \$1.60 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
209	Professional attendance at consulting rooms of more than 45 minutes in duration by a medical practitioner in an eligible area, that completes the minimum requirements of the Asthma Cycle of Care
270	(See para AN.7.1, AN.7.21 of explanatory notes to this Category) Fee: \$84.45 Benefit: 100% = \$84.45 Extended Medicare Safety Net Cap: \$253.35
210	Professional attendance at a place other than consulting rooms of more than 45 minutes in duration by a medical practitioner in an eligible area, that completes the minimum requirements of the Asthma Cycle of Care
271	(See para AN.7.1, AN.7.21 of explanatory notes to this Category) Derived Fee: The fee for item 270, plus \$20.75 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 270 plus \$1.60 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
A7. ACL	JPUNCTURE AND NON-SPECIALIST 9. NON-SPECIALIST PRACTITIONER MENTAL TIONER ITEMS HEALTH CARE
	Group A7. Acupuncture and Non-Specialist Practitioner Items
	Subgroup 9. Non-Specialist Practitioner mental health care
	Professional attendance by a medical practitioner (who has not undertaken mental health skills training) of at least 20 minutes but less than 40 minutes in duration for the preparation of a GP mental health treatment plan for a patient
272	(See para AN.7.1, AN.7.22 of explanatory notes to this Category) Fee: \$57.35 Benefit: 75% = \$43.05 100% = \$57.35 Extended Medicare Safety Net Cap: \$172.05
	Professional attendance by a medical practitioner (who has not undertaken mental health skills training) of at least 40 minutes in duration for the preparation of a GP mental health treatment plan for a patient
276	(See para AN.7.22, AN.7.1 of explanatory notes to this Category) Fee: \$84.45 Benefit: 75% = \$63.35 100% = \$84.45 Extended Medicare Safety Net Cap: \$253.35
2,0	Professional attendance by a medical practitioner to review a GP mental health treatment plan which he or she, or an associated medical practitioner has prepared, or to review a Psychiatrist Assessment and Management Plan

	PUNCTURE AND NON-SPECIALIST 9. NON-SPECIALIST PRACTITIONER MENTAL HEALTH CARE	
	Fee: \$57.35 Benefit: 75% = \$43.05	
	Professional attendance by a medical practitioner in relation to a mental disorder and of at least 20 minutes in duration, involving taking relevant history and identifying the presenting problem (to the extent not previously recorded), providing treatment and advice and, if appropriate, referral for other services or treatments, and documenting the outcomes of the consultation	
279	(See para AN.7.22, AN.7.1 of explanatory notes to this Category) Fee: \$57.35 Benefit: 75% = \$43.05 100% = \$57.35 Extended Medicare Safety Net Cap: \$172.05	
219	Professional attendance by a medical practitioner (who has undertaken mental health skills training) of	
	at least 20 minutes but less than 40 minutes in duration for the preparation of a GP mental health treatment plan for a patient	
	(See para AN.7.22, AN.7.1 of explanatory notes to this Category) Fee: \$72.85 Benefit: 75% = \$54.65 100% = \$72.85	
281	Extended Medicare Safety Net Cap: \$218.55	
	Professional attendance by a medical practitioner (who has undertaken mental health skills training) of at least 40 minutes in duration for the preparation of a GP mental health treatment plan for a patient	
• • •	(See para AN.7.22, AN.7.1 of explanatory notes to this Category) Fee: \$107.30 Benefit: 75% = \$80.50 100% = \$107.30	
282	Extended Medicare Safety Net Cap: \$321.90	
	Professional attendance at consulting rooms by a medical practitioner, for providing focussed psychological strategies for assessed mental disorders by a medical practitioner registered with the Chief Executive Medicare as meeting the credentialing requirements for provision of this service, and lasting at least 30 minutes, but less than 40 minutes	
	(See para AN.7.23, AN.7.1 of explanatory notes to this Category) Fee: \$74.20 Benefit: 100% = \$74.20	
283	Extended Medicare Safety Net Cap: \$222.60	
	Professional attendance at a place other than consulting rooms by a medical practitioner, for providing focussed psychological strategies for assessed mental disorders by a medical practitioner registered with the Chief Executive Medicare as meeting the credentialing requirements for provision of this service, and lasting at least 30 minutes, but less than 40 minutes	
	(See para AN.7.23, AN.7.1 of explanatory notes to this Category) Derived Fee: The fee for item 283, plus \$20.75 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 283 plus \$1.60 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the	
285	lesser amount	
	Professional attendance at consulting rooms by a medical practitioner, for providing focussed psychological strategies for assessed mental disorders by a medical practitioner registered with the Chief Executive Medicare as meeting the credentialing requirements for provision of this service, and lasting at least 40 minutes	
286	(See para AN.7.23, AN.7.1 of explanatory notes to this Category) Fee: \$106.20 Extended Medicare Safety Net Cap: \$318.60	
	Professional attendance at a place other than consulting rooms by a medical practitioner, for providing focussed psychological strategies for assessed mental disorders by a medical practitioner registered with the Chief Executive Medicare as meeting the credentialing requirements for provision of this service, and lasting at least 40 minutes	
287	(See para AN.7.23, AN.7.1 of explanatory notes to this Category)	

	PUNCTURE AND NON-SPECIALIST 9. NON-SPECIALIST PRACTITIONER MENTAL HEALTH CARE
	Derived Fee: The fee for item 286, plus \$20.75 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 286 plus \$1.60 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	Professional attendance at consulting rooms by a medical practitioner, for providing focussed psychological strategies for assessed mental disorders by a medical practitioner registered with the Chief Executive Medicare as meeting the credentialing requirements for provision of this service, and lasting at least 30 minutes, but less than 40 minutes if:
	(a) the attendance is by video conference; and
	(b) the patient is not an admitted patient; and
	(c) the patient is located within a telehealth area; and
	(d) the patient is, at the time of the attendance, at least 15 kilometres by road from the medical practitioner.
271	(See para AN.7.23, AN.7.1 of explanatory notes to this Category) Fee: \$74.20 Benefit: 100% = \$74.20 Extended Medicare Sefety Net Corp. \$232.60
371	Extended Medicare Safety Net Cap: \$222.60 Professional attendance at consulting rooms by a medical practitioner, for providing focussed
	psychological strategies for assessed mental disorders by a medical practitioner registered with the Chief Executive Medicare as meeting the credentialing requirements for provision of this service, and lasting at least 40 minutes if:
	(a) the attendance is by video conference; and
	(b) the patient is not an admitted patient; and
	(c) the patient is located within a telehealth area; and
	(d) the patient is, at the time of the attendance, at least 15 kilometres by road from the medical practitioner.
272	(See para AN.7.23, AN.7.1 of explanatory notes to this Category) Fee: \$106.20 Benefit: 100% = \$106.20
372	Extended Medicare Safety Net Cap: \$318.60 10. NON-SPECIALIST PRACTITIONER AFTER-
	IPUNCTURE AND NON-SPECIALIST HOURS ATTENDANCES TO WHICH NO OTHER TIONER ITEMS ITEM APPLIES
	Group A7. Acupuncture and Non-Specialist Practitioner Items
	Subgroup 10. Non-Specialist Practitioner after-hours attendances to which no other item applies
	Professional attendance at consulting rooms of not more than 5 minutes in duration (other than a service to which another item applies) by a medical practitioner—each attendance
733	(See para AN.7.24, GN.7.17, AN.7.1 of explanatory notes to this Category) Fee: \$23.20 Extended Medicare Safety Net Cap: \$69.60
133	Professional attendance at consulting rooms of more than 5 minutes in duration but not more than 25 minutes in duration (other than a service to which another item applies) by a medical practitioner—each attendance

	10. NON-SPECIALIST PRACTITIONER AFTER- RUPUNCTURE AND NON-SPECIALIST HOURS ATTENDANCES TO WHICH NO OTHER RITIONER ITEMS ITEM APPLIES
	Fee: \$39.20 Benefit: 100% = \$39.20
	Extended Medicare Safety Net Cap: \$117.60
	Professional attendance at consulting rooms of more than 25 minutes in duration but not more than 45 minutes in duration (other than a service to which another item applies) by a medical practitioner—each attendance
741	(See para AN.7.24, GN.7.17, AN.7.1 of explanatory notes to this Category) Fee: \$67.15 Benefit: 100% = \$67.15
741	Extended Medicare Safety Net Cap: \$201.45
	Professional attendance at consulting rooms of more than 45 minutes in duration (other than a service to which another item applies) by a medical practitioner—each attendance
	(See para AN.7.24, GN.7.17, AN.7.1 of explanatory notes to this Category) Fee: \$94.20 Benefit: 100% = \$94.20
745	Extended Medicare Safety Net Cap: \$282.60
	Professional attendance by a medical practitioner (other than attendance at consulting rooms, a hospital or a residential aged care facility or a service to which another item in the table applies), lasting not more than 5 minutes—an attendance on one or more patients on one occasion—each patient
	(See para AN.7.24, GN.7.17, AN.7.1 of explanatory notes to this Category) Derived Fee: The fee for item 733, plus \$20.75 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 733 plus \$1.60 per patient.
7.61	Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the
761	lesser amount
	Professional attendance by a medical practitioner (other than attendance at consulting rooms, a hospital or a residential aged care facility or a service to which another item in the table applies), lasting more than 5 minutes, but not more than 25 minutes—an attendance on one or more patients on one occasion—each patient
763	(See para AN.7.24, GN.7.17, AN.7.1 of explanatory notes to this Category) Derived Fee: The fee for item 737, plus \$20.75 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 737 plus \$1.60 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	Professional attendance by a medical practitioner (other than attendance at consulting rooms, a hospital or a residential aged care facility or a service to which another item in the table applies), lasting more than 25 minutes, but not more than 45 minutes—an attendance on one or more patients on one occasion—each patient
766	(See para AN.7.24, GN.7.17, AN.7.1 of explanatory notes to this Category) Derived Fee: The fee for item 741, plus \$20.75 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 741 plus \$1.60 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
, 50	Professional attendance by a medical practitioner (other than attendance at consulting rooms, a hospital
	or a residential aged care facility or a service to which another item in the table applies), lasting more than 45 minutes—an attendance on one or more patients on one occasion—each patient
7(0	(See para AN.7.24, GN.7.17, AN.7.1 of explanatory notes to this Category) Derived Fee: The fee for item 745, plus \$20.75 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 745 plus \$1.60 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the
769	lesser amount Drafessional attendance (other than a gerries to which another item annlies) at a residential aged age.
772	Professional attendance (other than a service to which another item applies) at a residential aged care

	PUNCTURE AND NON-SPECIALIST FIONER ITEMS	10. NON-SPECIALIST PRACTITIONER AFTER- HOURS ATTENDANCES TO WHICH NO OTHER ITEM APPLIES
	consulting rooms situated within such a complex care facility (other than accommodation in a self	self contained unit) or professional attendance at a if the patient is accommodated in the residential aged contained unit) of not more than 5 minutes in duration or more patients at one residential aged care facility on
	patients. For seven or more patients - the fee for item Extended Medicare Safety Net Cap: 300% of the	ded by the number of patients seen, up to a maximum of six
	facility (other than a professional attendance at a consulting rooms situated within such a complex care facility (other than accommodation in a self	which another item applies) at a residential aged care a self contained unit) or professional attendance at a if the patient is accommodated in the residential aged contained unit) of more than 5 minutes in duration but all practitioner—an attendance on one or more patients ion—each patient
776	patients. For seven or more patients - the fee for item	ded by the number of patients seen, up to a maximum of six
	Professional attendance (other than a service to vertically (other than a professional attendance at a consulting rooms situated within such a complex care facility (other than accommodation in a self-	which another item applies) at a residential aged care a self contained unit) or professional attendance at a if the patient is accommodated in the residential aged contained unit) of more than 25 minutes in duration but ther—an attendance on one or more patients at one each patient
788	patients. For seven or more patients - the fee for item	ded by the number of patients seen, up to a maximum of six
700	Professional attendance (other than a service to vertically (other than a professional attendance at a consulting rooms situated within such a complex care facility (other than accommodation in a self-	which another item applies) at a residential aged care a self contained unit) or professional attendance at a if the patient is accommodated in the residential aged contained unit) of more than 45 minutes in duration by more patients at one residential aged care facility on
789	patients. For seven or more patients - the fee for item	ded by the number of patients seen, up to a maximum of six
	PUNCTURE AND NON-SPECIALIST	11. NON-SPECIALIST PRACTITIONER PREGNANCY SUPPORT COUNSELLING
	Group A7. Acupuncture and Non-Specialist P	ractitioner Items
		ractitioner pregnancy support counselling
792	Professional attendance of at least 20 minutes in	duration at consulting rooms by a medical practitioner

A7. ACUPUNCTURE AND NON-SPECIALIST 11. NON-SPECIALIST PRACTITIONER PRACTITIONER ITEMS PREGNANCY SUPPORT COUNSELLING who is registered with the Chief Executive Medicare as meeting the credentialing requirements for provision of this service for the purpose of providing non-directive pregnancy support counselling to a person who: (a) is currently pregnant; or (b) has been pregnant in the 12 months preceding the provision of the first service to which this item or items 4001, 81000, 81005 or 81010 applies in relation to that pregnancy (See para AN.7.25, AN.7.1 of explanatory notes to this Category) Fee: \$61.30 **Benefit:** 100% = \$61.30Extended Medicare Safety Net Cap: \$183.90 A7. ACUPUNCTURE AND NON-SPECIALIST 12. NON-SPECIALIST PRACTITIONER VIDEO **PRACTITIONER ITEMS CONFERENCING CONSULTATION** Group A7. Acupuncture and Non-Specialist Practitioner Items Subgroup 12. Non-Specialist Practitioner video conferencing consultation Professional attendance at consulting rooms of at least 5 minutes in duration (whether or not continuous) by a medical practitioner providing clinical support to a patient who: (a) is participating in a video conferencing consultation with a specialist or consultant physician; and (b) is not an admitted patient; and (c) either: (i) is located both: (A) within a telehealth eligible area; and (B) at the time of the attendance—at least 15 kms by road from the specialist or physician mentioned in paragraph (a); or (ii) is a patient of: (A) an Aboriginal Medical Service; or (B) an Aboriginal Community Controlled Health Service: for which a direction made under subsection 19(2) of the Act applies (See para AN.7.26, AN.7.1 of explanatory notes to this Category) Fee: \$18.30 **Benefit:** 100% = \$18.30812 Extended Medicare Safety Net Cap: \$54.90 Professional attendance not in consulting rooms of at least 5 minutes in duration (whether or not continuous) by a medical practitioner providing clinical support to a patient who: (a) is participating in a video conferencing consultation with a specialist or consultant physician; and (b) is not an admitted patient; and

(c) is not a care recipient in a residential care service; and

(d) is located both:

827

	PUNCTURE AND NON-SPECIALIST FIONER ITEMS	12. NON-SPECIALIST PRACTITIONER VIDEO CONFERENCING CONSULTATION
	(i) within a telehealth eligible area; and	
	(ii) at the time of the attendance—at least 15 kms paragraph (a);	by road from the specialist or physician mentioned in
	for an attendance on one or more patients at one p	lace on one occasion—each patient
	(See para AN.7.26, AN.7.1 of explanatory notes to this Derived Fee: The fee for item 812, plus \$20.75 divided patients. For seven or more patients - the fee for item 81 Extended Medicare Safety Net Cap: 300% of the	nd by the number of patients seen, up to a maximum of six 2 plus \$1.60 per patient.
	Professional attendance of at least 5 minutes in du practitioner providing clinical support to a patient	
		ation with a specialist or consultant physician; and
	(b) is a care recipient in a residential care service;	and
	(c) is not a resident of a self-contained unit;	
	for an attendance on one or more patients at one p	lace on one occasion—each patient
829	(See para AN.7.26, AN.7.1 of explanatory notes to this Derived Fee: The fee for item 812, plus \$37.35 divide patients. For seven or more patients - the fee for item 81 Extended Medicare Safety Net Cap: 300% of the lesser amount	ed by the number of patients seen, up to a maximum of six 2 plus \$2.65 per patient.
	Professional attendance at consulting rooms of les continuous) by a medical practitioner providing cl	s than 20 minutes in duration (whether or not inical support to a patient who:
	(a) is participating in a video conferencing consult	ation with a specialist or consultant physician; and
	(b) is not an admitted patient; and	
	(c) either:	
	(i) is located both:	
	(A) within a telehealth eligible area; and	
	(B) at the time of the attendance—at least 15 kms paragraph (a); or	by road from the specialist or physician mentioned in
	(ii) is a patient of:	
	(A) an Aboriginal Medical Service; or	
	(B) an Aboriginal Community Controlled Health S	Service;
	for which a direction made under subsection	on 19(2) of the Act applies
867	(See para AN.7.26, AN.7.1 of explanatory notes to this Fee: \$39.95 Benefit: 100% = \$39.95 Extended Medicare Safety Net Cap: \$119.85	Category)
868	Professional attendance not in consulting rooms of	f less than 20 minutes in duration (whether or not

	PUNCTURE AND NON-SPECIALIST TIONER ITEMS	12. NON-SPECIALIST PRACTITIONER VIDEO CONFERENCING CONSULTATION
	continuous) by a medical practitioner providing	g clinical support to a patient who:
	(a) is participating in a video conferencing con	sultation with a specialist or consultant physician; and
	(b) is not an admitted patient; and	
	(c) is not a care recipient in a residential care s	ervice; and
	(d) is located both:	
	(i) within a telehealth eligible area; and	
	(ii) at the time of the attendance—at least 15 k paragraph (a);	ms by road from the specialist or physician mentioned in
	for an attendance on one or more patients at or	ne place on one occasion—each patient
	patients. For seven or more patients - the fee for iter	vided by the number of patients seen, up to a maximum of six
	Professional attendance of less than 20 minutes practitioner providing clinical support to a pati	s in duration (whether or not continuous) by a medical ent who:
	(a) is participating in a video conferencing con	sultation with a specialist or consultant physician; and
	(b) is a care recipient in a residential care servi	ce; and
	(c) is not a resident of a self-contained unit;	
	for an attendance on one or more patients at or	ne place on one occasion—each patient
869	patients. For seven or more patients - the fee for iter	vided by the number of patients seen, up to a maximum of six
	Professional attendance at consulting rooms of continuous) by a medical practitioner who pro-	at least 20 minutes in duration (whether or not wides clinical support to a patient who:
	(a) is participating in a video conferencing con	sultation with a specialist or consultant physician; and
	(b) is not an admitted patient; and	
	(c) either:	
	(i) is located both:	
	(A) within a telehealth eligible area; and	
	(B) at the time of the attendance—at least 15 k paragraph (a); or	ms by road from the specialist or physician mentioned in
873	(ii) is a patient of:	

	JPUNCTURE AND NON-SPECIALIST TIONER ITEMS	12. NON-SPECIALIST PRACTITIONER VIDEO CONFERENCING CONSULTATION
	(A) an Aboriginal Medical Service; or	
	(B) an Aboriginal Community Controlled Hea	alth Service:
	for which a direction made under subs	ection 19(2) of the Act applies
	(See para AN.7.26, AN.7.1 of explanatory notes to Fee: \$77.50 Benefit: 100% = \$77.50	
	Extended Medicare Safety Net Cap: \$232.50	ns of at least 20 minutes in duration (whether or not
	continuous) by a medical practitioner providir	
	(a) is participating in a video conferencing con	nsultation with a specialist or consultant physician; and
	(b) is not an admitted patient; and	
	(c) is not a care recipient in a residential care s	service; and
	(d) is located both:	
	(i) within a telehealth eligible area; and	
	(ii) at the time of the attendance—at least 15 k paragraph (a);	kms by road from the specialist or physician mentioned in
	for an attendance on one or more patients at o	ne place on one occasion—each patient
876	patients. For seven or more patients - the fee for ite	divided by the number of patients seen, up to a maximum of six
		in duration (whether or not continuous) by a medical tient who:
	(a) is participating in a video conferencing con	nsultation with a specialist or consultant physician; and
	(b) is a care recipient in a residential care serv	rice; and
	(c) is not a resident of a self-contained unit;	
	for an attendance on one or more patients at o	ne place on one occasion—each patient
001	patients. For seven or more patients - the fee for ite Extended Medicare Safety Net Cap: 300% of	livided by the number of patients seen, up to a maximum of six
881	lesser amount Professional attendance at consulting rooms of	of at least 40 minutes in duration (whether or not
	continuous) by a medical practitioner providir	,
	(a) is participating in a video conferencing con	nsultation with a specialist or consultant physician; and
	(b) is not an admitted patient; and	
885	(c) either:	

	PUNCTURE AND NON-SPECIALIST 12. NON-SPECIALIST PRACTITIONER VIDEO CONFERENCING CONSULTATION
	(i) is located both:
	(A) within a telehealth eligible area; and
	(B) at the time of the attendance—at least 15 kms by road from the specialist or physician mentioned in paragraph (a); or
	(ii) is a patient of:
	(A) an Aboriginal Medical Service; or
	(B) an Aboriginal Community Controlled Health Service;
	for which a direction made under subsection 19(2) of the Act applies
	(See para AN.7.26, AN.7.1 of explanatory notes to this Category) Fee: \$114.00 Benefit: 100% = \$114.00 Extended Medicare Safety Net Cap: \$342.00
	Professional attendance not in consulting rooms of at least 40 minutes in duration (whether or not continuous) by a medical practitioner providing clinical support to a patient who:
	(a) is participating in a video conferencing consultation with a specialist or consultant physician; and
	(b) is not an admitted patient; and
	(c) is not a care recipient in a residential care service; and
	(d) is located both:
	(i) within a telehealth eligible area; and
	(ii) at the time of the attendance—at least 15 kms by road from the specialist or physician mentioned in paragraph (a);
	for an attendance on one or more patients at one place on one occasion—each patient
	(See para AN.7.26, AN.7.1 of explanatory notes to this Category) Derived Fee: The fee for item 885, plus \$20.75 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 885 plus \$1.60 per patient.
891	Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	Professional attendance of at least 40 minutes in duration (whether or not continuous) by a medical practitioner providing clinical support to a patient who:
	(a) is participating in a video conferencing consultation with a specialist or consultant physician; and
	(b) is a care recipient in a residential care service; and
	(c) is not a resident of a self-contained unit;
	for an attendance on one or more patients at one place on one occasion—each patient
892	(See para AN.7.26, AN.7.1 of explanatory notes to this Category) Derived Fee: The fee for item 885, plus \$37.35 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 885 plus \$2.65 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount

	JPUNCTURE AND NON-SPECIALIST 12. I TIONER ITEMS	NON-SPECIALIST PRACTITIONER VIDEO CONFERENCING CONSULTATION
	Professional attendance at consulting rooms by a medica not more than 25 minutes, for providing mental health se	
	(a) the attendance is by video conference; and	
	(b) the patient is not an admitted patient; and	
	(c) the patient and the medical practitioner are located	,
	(d) the patient is, at the time of the attendance, at least practitioner; and	15 kilometres by road from the medical
	(e) the patient has an existing relationship with the me	dical practitioner.
894	Fee: \$35.40 Benefit: 85% = \$30.10 Extended Medicare Safety Net Cap: \$106.20	
	Professional attendance at consulting rooms by a medica not more than 45 minutes, for providing mental health se	
	(a) the attendance is by video conference; and	
	(b) the patient is not an admitted patient; and	
	(c) the patient and the medical practitioner are located	within a drought affected eligible area; and
	(d) the patient is, at the time of the attendance, at least practitioner; and	15 kilometres by road from the medical
	(e) the patient has an existing relationship with the me	dical practitioner.
896	Fee: \$68.50 Benefit: 85% = \$58.25 Extended Medicare Safety Net Cap: \$205.50	
	Professional attendance at consulting rooms by a medica providing mental health services to a patient with mental	
	(a) the attendance is by video conference; and	
	(b) the patient is not an admitted patient; and	
	(c) the patient and the medical practitioner are located	within a drought affected eligible area; and
	(d) the patient is, at the time of the attendance, at least practitioner; and	15 kilometres by road from the medical
	(e) the patient has an existing relationship with the me	dical practitioner.
000	Fee: \$100.80 Benefit: 85% = \$85.70	
898	Extended Medicare Safety Net Cap: \$302.40 Professional attendance at consulting rooms by a medica duration, if:	l practitioner, lasting not more than 5 minutes in
	 the attendance is by video conference; and the patient is located within a flood affected elig 	vible area
Now	(See para AN.7.28, AN.7.1 of explanatory notes to this Category	
New 899	Fee: \$16.15 Benefit: 85% = \$13.75	*3)

	PUNCTURE AND NON-SPECIALIST TIONER ITEMS	12. NON-SPECIALIST PRACTITIONER VIDEO CONFERENCING CONSULTATION
	Extended Medicare Safety Net Cap: \$48.45	
	Professional attendance at consulting rooms by a n not more than 25 minutes, if:	nedical practitioner, lasting more than 5 minutes but
	 the attendance is by video conference; and the patient is located within a flood affect 	
New 901	(See para AN.7.28, AN.7.1 of explanatory notes to this G Fee: \$35.40 Benefit: 85% = \$30.10 Extended Medicare Safety Net Cap: \$106.20	Category)
		nedical practitioner, lasting more than 25 minutes but
	 the attendance is by video conference; and the patient is located within a flood affect 	
New 905	(See para AN.7.28, AN.7.1 of explanatory notes to this G Fee: \$68.50 Benefit: 85% = \$58.25 Extended Medicare Safety Net Cap: \$205.50	Category)
, , ,		nedical practitioner, lasting more than 45 minutes, if:
	 the attendance is by video conference; and the patient is located within a flood affect 	
New 906	(See para AN.7.28, AN.7.1 of explanatory notes to this G Fee: \$100.80 Benefit: 85% = \$85.70 Extended Medicare Safety Net Cap: \$302.40	Category)
	SULTANT PSYCHIATRIST ANCES TO WHICH NO OTHER ITEM	
	Group A8. Consultant Psychiatrist Attendances	To Which No Other Item Applies
	Professional attendance on a patient by a consultar psychiatry if:	at physician practising in his or her specialty of
	(a) the attendance is by video conference; and	
	(b) item 291, 293, 296, 300, 302, 304, 306, 308, 31 the attendance; and	0, 312, 314, 316, 318, 319, 348, 350 or 352 applies to
	(c) the patient is not an admitted patient; and	
	(d) the patient:	
	(i) is located both:	
	(A) within a telehealth eligible area; and	
	(B) at the time of the attendance-at least	15 kms by road from the physician; or
	(ii) is a care recipient in a residential care se	ervice; or
288	(iii) is a patient of:	

A8. CONSULTANT PSYCHIATRIST ATTENDANCES TO WHICH NO OTHER ITEM APPLIES

- (A) an Aboriginal Medical Service; or
- (B) an Aboriginal Community Controlled Health Service;

for which a direction made under subsection 19(2) of the Act applies

(See para AN.0.68 of explanatory notes to this Category)

Derived Fee: 50% of the fee for item 291, 293,296, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 319, 348, 350 or 352.Benefit: 85% of derived fee.

Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount

Professional attendance of at least 45 minutes in duration at consulting rooms or hospital, by a consultant physician in the practice of his or her specialty of psychiatry, following referral of the patient to the consultant by a referring practitioner, for assessment, diagnosis and preparation of a treatment and management plan for a patient under 13 years with autism or another pervasive developmental disorder, if the consultant psychiatrist does all of the following:

- (a) undertakes a comprehensive assessment and makes a diagnosis (if appropriate, using information provided by an eligible allied health provider);
- (b) develops a treatment and management plan which must include the following:
 - (i) an assessment and diagnosis of the patient's condition;
 - (ii) a risk assessment;
 - (iii) treatment options and decisions;
 - (iv) if necessary-medication recommendations;
- (c) provides a copy of the treatment and management plan to the referring practitioner;
- (d) provides a copy of the treatment and management plan to one or more allied health providers, if appropriate, for the treatment of the patient;

(other than attendance on a patient for whom payment has previously been made under this item or item 135, 137 or 139)

(See para AN.0.24 of explanatory notes to this Category)

Fee: \$267.85 **Benefit:** 75% = \$200.90 85% = \$227.70

Extended Medicare Safety Net Cap: \$500.00

Professional attendance by a consultant physician in the practice of his or her speciality of PSYCHIATRY where the patient is referred for the provision of an assessment and management plan by a medical practitioner practising in general practice (including a general practitioner, but not including a specialist or consultant physician) or participating nurse practitioner, where the attendance is initiated by the referring practitioner and where the consultant psychiatrist provides the referring practitioner with an assessment and management plan to be undertaken by that practitioner for the patient, where clinically appropriate.

An attendance of more than 45 minutes duration at consulting rooms during which:

- An outcome tool is used where clinically appropriate
- A mental state examination is conducted

291

289

A8. CONSULTANT PSYCHIATRIST ATTENDANCES TO WHICH NO OTHER ITEM APPLIES

- A psychiatric diagnosis is made
- The consultant psychiatrist decides that the patient can be appropriately managed by the referring practitioner without the need for ongoing treatment by the psychiatrist
- A 12 month management plan, appropriate to the diagnosis, is provided to the referring practitioner which must:
 - a) comprehensively evaluate biological, psychological and social issues;
 - b) address diagnostic psychiatric issues;
 - c) make management recommendations addressing biological, psychological and social issues; and
 - d) be provided to the referring practitioner within two weeks of completing the assessment of the patient.
- The diagnosis and management plan is explained and provided, unless clinically inappropriate, to the patient and/or the carer (with the patient's agreement)
- The diagnosis and management plan is communicated in writing to the referring practitioner

Not being an attendance on a patient in respect of whom, in the preceding 12 months, payment has been made under this item

(See para AN.0.30 of explanatory notes to this Category)

Fee: \$459.45 Benefit: 85% = \$390.55 Extended Medicare Safety Net Cap: \$500.00

Professional attendance by a consultant physician in the practice of his or her speciality of PSYCHIATRY to review a management plan previously prepared by that consultant psychiatrist for a patient and claimed under item 291, where the review is initiated by the referring medical practitioner practising in general practice or participating nurse practitioner.

An attendance of more than 30 minutes but not more than 45 minutes duration at consulting rooms where that attendance follows item 291 and during which:

- An outcome tool is used where clinically appropriate
- A mental state examination is conducted
- A psychiatric diagnosis is made
- A management plan provided under Item 291 is reviewed and revised
- The reviewed management plan is explained and provided, unless clinically inappropriate, to the patient and/or the carer (with the patient's agreement)
- The reviewed management plan is communicated in writing to the referring medical practitioner or participating nurse practitioner

Being an attendance on a patient in respect of whom, in the preceding 12 months, payment has been made under item 291, and no payment has been made under item 359, payable no more than once in any 12 month period.

293 (See para AN.0.30 of explanatory notes to this Category)

	NSULTANT PSYCHIATRIST DANCES TO WHICH NO OTHER ITEM S
711 - 11-	Fee: \$287.20 Benefit: 85% = \$244.15 Extended Medicare Safety Net Cap: \$500.00
	Professional attendance of more than 45 minutes in duration by a consultant physician in the practice of his or her speciality of psychiatry following referral of the patient to him or her by a referring practitioner-an attendance at consulting rooms if the patient:
	(a) is a new patient for this consultant psychiatrist; or
	(b) has not received a professional attendance from this consultant psychiatrist in the preceding 24 months;
	other than attendance on a patient in relation to whom this item, item 297 or 299, or any of items 300 to 346, 353 to 358 and 361 to 370, has applied in the preceding 24 months
207	(See para AN.0.30 of explanatory notes to this Category) Fee: \$264.20 Benefit: 75% = \$198.15 85% = \$224.60
296	Extended Medicare Safety Net Cap: \$500.00
	Professional attendance of more than 45 minutes by a consultant physician in the practice of his or her speciality of psychiatry following referral of the patient to him or her by a referring practitioner-an attendance at hospital if the patient:
	(a) is a new patient for this consultant psychiatrist; or
	(b) has not received a professional attendance from this consultant psychiatrist in the preceding 24 months;
	other than attendance on a patient in relation to whom this item, item 296 or 299, or any of items 300 to 346, 353 to 358 and 361 to 370, has applied in the preceding 24 months (H)
	(See para AN.0.30 of explanatory notes to this Category) Fee: \$264.20 Benefit: 75% = \$198.15 85% = \$224.60
297	Extended Medicare Safety Net Cap: \$500.00
	Professional attendance of more than 45 minutes by a consultant physician in the practice of his or her speciality of psychiatry following referral of the patient to him or her by a referring practitioner-an attendance at a place other than consulting rooms or a hospital if the patient:
	(a) is a new patient for this consultant psychiatrist; or
	(b) has not received a professional attendance from this consultant psychiatrist in the preceding 24 months;
	other than attendance on a patient in relation to whom this item, item 296 or 297, or any of items 300 to 346, 353 to 358 and 361 to 370, has applied in the preceding 24 months
200	(See para AN.0.30 of explanatory notes to this Category) Fee: \$315.95 Benefit: 75% = \$237.00 85% = \$268.60
299	Extended Medicare Safety Net Cap: \$500.00 Professional attendance by a consultant physician in the practice of his or her specialty of psychiatry
	Professional attendance by a consultant physician in the practice of his or her specialty of psychiatry following referral of the patient to him or her by a referring practitioner-an attendance of not more than 15 minutes in duration at consulting rooms, if that attendance and another attendance to which any of items 296, 300 to 308, 353 to 358 and 361 to 370 applies have not exceeded 50 attendances in a calendar year for the patient
300	Fee: \$44.00 Benefit: 75% = \$33.00 85% = \$37.40
200	2 00. 4 Delicité 10.70 400.00 00.70 401.10

40.00	ANOUL TANT DOVOULATRICT
	DNSULTANT PSYCHIATRIST IDANCES TO WHICH NO OTHER ITEM
APPLI	
	Extended Medicare Safety Net Cap: \$132.00
	Professional attendance by a consultant physician in the practice of his or her specialty of psychiatry following referral of the patient to him or her by a referring practitioner-an attendance of more than 15
	minutes, but not more than 30 minutes, in duration at consulting rooms, if that attendance and another
	attendance to which any of items 296, 300 to 308, 353 to 358 and 361 to 370 applies have not exceeded
	50 attendances in a calendar year for the patient
	The second secon
	Fee: \$87.75 Benefit: 75% = \$65.85 85% = \$74.60
302	Extended Medicare Safety Net Cap: \$263.25
	Professional attendance by a consultant physician in the practice of his or her specialty of psychiatry
	following referral of the patient to him or her by a referring practitioner-an attendance of more than 30
	minutes, but not more than 45 minutes, in duration at consulting rooms), if that attendance and another
	attendance to which any of items 296, 300 to 308, 353 to 358 and 361 to 370 applies have not exceeded
	50 attendances in a calendar year for the patient
	Fee: \$135.10 Benefit: 75% = \$101.35 85% = \$114.85
304	Extended Medicare Safety Net Cap: \$405.30
	Professional attendance by a consultant physician in the practice of his or her specialty of psychiatry
	following referral of the patient to him or her by a referring practitioner-an attendance of more than 45
	minutes, but not more than 75 minutes, in duration at consulting rooms, if that attendance and another
	attendance to which any of items 296, 300 to 308, 353 to 358 and 361 to 370 applies have not exceeded
	50 attendances in a calendar year for the patient
	Fee: \$186.40 Benefit: 75% = \$139.80 85% = \$158.45
306	Fee: \$186.40 Benefit: 75% = \$139.80 85% = \$158.45 Extended Medicare Safety Net Cap: \$500.00
300	Professional attendance by a consultant physician in the practice of his or her specialty of psychiatry
	following referral of the patient to him or her by a referring practitioner-an attendance of more than 75
	minutes in duration at consulting rooms), if that attendance and another attendance to which any of
	items 296, 300 to 308, 353 to 358 and 361 to 370 applies have not exceeded 50 attendances in a calendar
	year for the patient
	To design the many days are only design to
200	Fee: \$216.35 Benefit: 75% = \$162.30 85% = \$183.90
308	Extended Medicare Safety Net Cap: \$500.00 Professional attendance by a consultant physician in the practice of his or her specialty of psychiatry
	following referral of the patient to him or her by a referring practitioner-an attendance of not more than
	15 minutes in duration at consulting rooms, if that attendance and another attendance to which any of
	items 296, 300 to 308, 353 to 358 and 361 to 370 applies exceed 50 attendances in a calendar year for
	the patient
	Fee: \$21.90 Benefit: 75% = \$16.45 85% = \$18.65
310	Extended Medicare Safety Net Cap: \$65.70
	Professional attendance by a consultant physician in the practice of his or her specialty of psychiatry
	following referral of the patient to him or her by a referring practitioner-an attendance of more than 15 minutes, but not more than 30 minutes, in duration at consulting rooms, if that attendance and another
	attendance to which any of items 296, 300 to 308, 353 to 358 and 361 to 370 applies exceed 50
	attendances in a calendar year for the patient
	Fee: \$44.00 Benefit: 75% = \$33.00 85% = \$37.40
312	Extended Medicare Safety Net Cap: \$132.00
	Professional attendance by a consultant physician in the practice of his or her specialty of psychiatry
	following referral of the patient to him or her by a referring practitioner-an attendance of more than 30
	minutes, but not more than 45 minutes, in duration at consulting rooms, if that attendance and another
314	attendance to which any of items 296, 300 to 308, 353 to 358 and 361 to 370 applies exceed 50

A8 CO	NSULTANT PSYCHIATRIST
	IDANCES TO WHICH NO OTHER ITEM
APPLI	
	attendances in a calendar year for the patient
	Fee: \$67.65 Benefit: 75% = \$50.75 85% = \$57.55
	Extended Medicare Safety Net Cap: \$202.95
	Professional attendance by a consultant physician in the practice of his or her specialty of psychiatry
	following referral of the patient to him or her by a referring practitioner-an attendance of more than 45
	minutes, but not more than 75 minutes, in duration at consulting rooms, if that attendance and another
	attendance to which any of items 296, 300 to 308, 353 to 358 and 361 to 370 applies exceed 50
	attendances in a calendar year for the patient
	Fee: \$93.35 Benefit: 75% = \$70.05 85% = \$79.35
316	Extended Medicare Safety Net Cap: \$280.05
	Professional attendance by a consultant physician in the practice of his or her specialty of psychiatry
	following referral of the patient to him or her by a referring practitioner-an attendance of more than 75
	minutes in duration at consulting rooms, if that attendance and another attendance to which any of items
	296, 300 to 308, 353 to 358 and 361 to 370 applies exceed 50 attendances in a calendar year for the patient
	patient
	Fee: \$108.20 Benefit: 75% = \$81.15 85% = \$92.00
318	Extended Medicare Safety Net Cap: \$324.60
	Professional attendance by a consultant physician in the practice of his or her specialty of psychiatry
	following referral of the patient to him or her by a referring practitioner-an attendance of more than 45
	minutes in duration at consulting rooms, if the patient has:
	(a) been diagnosed as suffering severe personality disorder, anorexia nervosa, bulimia nervosa, dysthymic disorder, substance-related disorder, somatoform disorder or a pervasive development disorder; and
	(b) for persons 18 years and over-been rated with a level of functional impairment within the range 1 to 50 according to the Global Assessment of Functioning Scale;
	if that attendance and another attendance to which any of items 296, 300 to 319, 353 to 358 and 361 to 370 applies have not exceeded 160 attendances in a calendar year for the patient
	(See para AN.0.31 of explanatory notes to this Category)
	Fee: \$186.40 Benefit: 75% = \$139.80 85% = \$158.45
319	Extended Medicare Safety Net Cap: \$500.00
	Professional attendance by a consultant physician in the practice of his or her specialty of psychiatry
	following referral of the patient to him or her by a referring practitioner-an attendance of not more than 15 minutes in duration at hospital
	Fee: \$44.00 Benefit: 75% = \$33.00 85% = \$37.40
320	Extended Medicare Safety Net Cap: \$132.00
520	Professional attendance by a consultant physician in the practice of his or her specialty of psychiatry
	following referral of the patient to him or her by a referring practitioner-an attendance of more than 15
	minutes, but not more than 30 minutes, in duration at hospital
	Fee: \$87.75 Benefit: 75% = \$65.85 85% = \$74.60
322	Extended Medicare Safety Net Cap: \$263.25
	Professional attendance by a consultant physician in the practice of his or her specialty of psychiatry
	following referral of the patient to him or her by a referring practitioner-an attendance of more than 30
224	minutes, but not more than 45 minutes, in duration at hospital
324	

Δ8 CO	NSULTANT PSYCHIATRIST
	DANCES TO WHICH NO OTHER ITEM
APPLIE	
	Fee: \$135.10 Benefit: 75% = \$101.35 85% = \$114.85
	Extended Medicare Safety Net Cap: \$405.30
	Professional attendance by a consultant physician in the practice of his or her specialty of psychiatry following referral of the patient to him or her by a referring practitioner-an attendance of more than 45 minutes, but not more than 75 minutes, in duration at hospital
	Fee: \$186.40 Benefit: 75% = \$139.80 85% = \$158.45
326	Extended Medicare Safety Net Cap: \$500.00
	Professional attendance by a consultant physician in the practice of his or her specialty of psychiatry following referral of the patient to him or her by a referring practitioner-an attendance of more than 75 minutes in duration at hospital
220	Fee: \$216.35 Benefit: 75% = \$162.30 85% = \$183.90
328	Extended Medicare Safety Net Cap: \$500.00
	Professional attendance by a consultant physician in the practice of his or her specialty of psychiatry following referral of the patient to him or her by a referring practitioner-an attendance of not more than 15 minutes in duration if that attendance is at a place other than consulting rooms or hospital
330	Fee: \$80.75 Benefit: 75% = \$60.60 85% = \$68.65 Extended Medicare Safety Net Cap: \$242.25
	Professional attendance by a consultant physician in the practice of his or her specialty of psychiatry following referral of the patient to him or her by a referring practitioner-an attendance of more than 15 minutes, but not more than 30 minutes, in duration if that attendance is at a place other than consulting rooms or hospital
332	Fee: \$126.50 Benefit: 75% = \$94.90 85% = \$107.55 Extended Medicare Safety Net Cap: \$379.50
	Professional attendance by a consultant physician in the practice of his or her specialty of psychiatry following referral of the patient to him or her by a referring practitioner-an attendance of more than 30 minutes, but not more than 45 minutes, in duration if that attendance is at a place other than consulting rooms or hospital
334	Fee: \$184.35 Benefit: 75% = \$138.30 85% = \$156.70 Extended Medicare Safety Net Cap: \$500.00
	Professional attendance by a consultant physician in the practice of his or her specialty of psychiatry following referral of the patient to him or her by a referring practitioner-an attendance of more than 45 minutes, but not more than 75 minutes, in duration if that attendance is at a place other than consulting rooms or hospital
226	Fee: \$223.05 Benefit: 75% = \$167.30 85% = \$189.60
336	Extended Medicare Safety Net Cap: \$500.00 Professional attendance by a consultant physician in the practice of his or her specialty of psychiatry
	following referral of the patient to him or her by a referring practitioner-an attendance of more than 75 minutes in duration if that attendance is at a place other than consulting rooms or hospital
338	Fee: \$253.30 Benefit: 75% = \$190.00 85% = \$215.35 Extended Medicare Safety Net Cap: \$500.00
338	· · ·
242	Group psychotherapy (including any associated consultations with a patient taking place on the same occasion and relating to the condition for which Group therapy is conducted) of not less than 1 hour in duration given under the continuous direct supervision of a consultant physician in the practice of his or her specialty of psychiatry, involving a Group of 2 to 9 unrelated patients or a family Group of more
342	than 3 patients, each of whom is referred to the consultant physician by a referring practitioner-each

same hour in of his or the
hour in of his or
hour in of his or
hour in of his or
of his or
the
same
hour in
of his or the
uic
lty of
terview
luration,
ooms,
14 o.C
lty of terview
terview stic
care
care
niatry,
a person
nent of a
or

	ISULTANT PSYCHIATRIST DANCES TO WHICH NO OTHER ITEM S
	treatment and is located in a regional, rural or remote area (RRMA3-7),
	-that consultation and any other consultation to which items 353 to 361 apply, have not exceeded 12 consultations in a calendar year,
	-any other attendance to which items 300 to 308 and 353 to 358 or 361 to 370 apply, have not exceeded the sum of 50 attendances in a calendar year.
	A telepsychiatry consultation of not more than 15 minutes duration.
	(See para AN.0.59 of explanatory notes to this Category) Fee: \$58.05 Benefit: 75% = \$43.55 85 % = \$49.35 Extended Medicare Safety Net Cap: \$174.15
	A telepsychiatry consultation of more than 15 minutes duration but not more than 30 minutes duration.
	(See para AN.0.59 of explanatory notes to this Category)
355	Fee: \$116.15 Benefit: 75% = \$87.15 85% = \$98.75 Extended Medicare Safety Net Cap: \$348.45
333	A telepsychiatry consultation of more than 30 minutes duration but not more than 45 minutes duration.
	(See para AN.0.59 of explanatory notes to this Category)
256	Fee: \$170.30 Benefit: 75% = \$127.75 85% = \$144.80
356	Extended Medicare Safety Net Cap: \$500.00 A telepsychiatry consultation of more than 45 minutes duration but not more than 75 minutes duration
	(See para AN.0.59 of explanatory notes to this Category) Fee: \$234.90 Benefit: 75% = \$176.20 85% = \$199.70
357	Extended Medicare Safety Net Cap: \$500.00
	A telepsychiatry consultation of more than 75 minutes duration
	(See para AN.0.59 of explanatory notes to this Category)
	Fee: \$286.25 Benefit: 75% = \$214.70 85% = \$243.35
358	Extended Medicare Safety Net Cap: \$500.00
	A telepsychiatry consultation of more than 30 minutes but not more than 45 minutes duration by a consultant physician in the practice of his or her specialty of PSYCHIATRY where:
	- the patient is located in a regional, rural or remote area (RRMA 3-7)
	- in the preceding 12 months, payment has been made under item 291
	- an outcome tool is used where clinically appropriate
	- a mental state examination is conducted
	- a psychiatric diagnosis is made
	- a management plan provided under Item 291 is reviewed and revised
	- the reviewed management plan is explained and provided, unless clinically inappropriate, to the patient and/or the carer (with the patient's agreement)
	- the reviewed management plan is communicated in writing to the referring practitioner
359	Not being an attendance on a patient in respect of whom payment has been made under this item or item

48 CO	NSULTANT PSYCHIATRIST
	DANCES TO WHICH NO OTHER ITEM
APPLIE	
	293 in the preceding 12 month period.
	(See para AN.0.59 of explanatory notes to this Category)
	Fee: \$330.25 Benefit: 75% = \$247.70 85% = \$280.75
	Extended Medicare Safety Net Cap: \$500.00 Professional attendance by a consultant physician in the practice of his or her specialty of psychiatry
	following referral of the patient to him or her by a referring practitioner-a telepsychiatry consultation of more than 45 minutes in duration, if the patient:
	(a) either:
	(i) is a new patient for this consultant psychiatrist; or
	(ii) has not received a professional attendance from this consultant psychiatrist in the preceding 24 months; and
	(b) is located in a regional, rural or remote area;
	other than attendance on a patient in relation to whom this item, item 296, 297 or 299, or any of items 300 to 346 and 353 to 370, has applied in the preceding 24 month period
361	(See para AN.0.59 of explanatory notes to this Category) Fee: \$303.80 Benefit: 75% = \$227.85 85% = \$258.25 Extended Medicare Safety Net Cap: \$500.00
301	Professional attendance by a consultant physician in the practice of his or her specialty of
	PSYCHIATRY, where:
	- the patient is referred to him or her by a referring practitioner,
	- that attendance occurs following a telepsychiatry consultation (items 353 to 361),
	- that attendance and any other attendance to which items 300 to 308 and 353 to 358 or 361 to 370 apply, have not exceeded the sum of 50 attendances in a calendar year.
	These items may only be used after telepsychiatry consultation(s) have been conducted in accordance with items 353 to 361.
	A face-to-face attendance of not more than 15 minutes duration.
	(See para AN.0.59 of explanatory notes to this Category)
264	Fee: \$44.00 Benefit: 75% = \$33.00 85% = \$37.40
364	Extended Medicare Safety Net Cap: \$132.00 A face-to-face attendance of more than 15 minutes duration but not more than 30 minutes duration
	(See para AN.0.59 of explanatory notes to this Category) Fee: \$87.75 Benefit: 75% = \$65.85 85% = \$74.60
366	Extended Medicare Safety Net Cap: \$263.25
	A face-to-face attendance of more than 30 minutes duration but not more than 45 minutes duration.
	(See para AN.0.59 of explanatory notes to this Category)
267	Fee: \$135.10 Benefit: 75% = \$101.35 85% = \$114.85
367	Extended Medicare Safety Net Cap: \$405.30 A face-to-face attendance of more than 45 minutes duration but not more than 75 minutes duration
360	
369	(See para AN.0.59 of explanatory notes to this Category)

ATTEND	A8. CONSULTANT PSYCHIATRIST ATTENDANCES TO WHICH NO OTHER ITEM APPLIES	
	Fee: \$186.55 Benefit: 75% = \$139.95 85% = \$158.60	
	Extended Medicare Safety Net Cap: \$500.00	
	A face-to-face attendance of more than 75 minutes duration.	
	(See para AN.0.59 of explanatory notes to this Category)	
	Fee: \$216.35 Benefit: 75% = \$162.30 85% = \$183.90	
370	Extended Medicare Safety Net Cap: \$500.00	
A9. CON	ITACT LENSES - ATTENDANCES	
	Group A9. Contact Lenses - Attendances	
	Attendance for the investigation and evaluation of a patient for the fitting of contact lenses, with	
	keratometry and testing with trial lenses and the issue of a prescription-one service in any period of 36 months-patient with myopia of 5.0 dioptres or greater (spherical equivalent) in one eye	
	(See para AN.0.34 of explanatory notes to this Category)	
	Fee: \$123.45 Benefit: 75% = \$92.60 85% = \$104.95	
10801	Extended Medicare Safety Net Cap: \$370.35	
	Attendance for the investigation and evaluation of a patient for the fitting of contact lenses, with	
	keratometry and testing with trial lenses and the issue of a prescription-one service in any period of 36 months-patient with manifest hyperopia of 5.0 dioptres or greater (spherical equivalent) in one eye	
	(See para AN.0.34 of explanatory notes to this Category) Fee: \$123.45 Benefit: 75% = \$92.60 85% = \$104.95	
10802	Extended Medicare Safety Net Cap: \$370.35	
	Attendance for the investigation and evaluation of a patient for the fitting of contact lenses, with	
	keratometry and testing with trial lenses and the issue of a prescription-one service in any period of 36	
	months-patient with astigmatism of 3.0 dioptres or greater in one eye	
	(See para AN.0.34 of explanatory notes to this Category)	
10002	Fee: \$123.45 Benefit: 75% = \$92.60 85% = \$104.95	
10803	Extended Medicare Safety Net Cap: \$370.35	
	Attendance for the investigation and evaluation of a patient for the fitting of contact lenses, with keratometry and testing with trial lenses and the issue of a prescription-one service in any period of 36 months-patient with irregular astigmatism in either eye, being a condition the existence of which has been confirmed by keratometric observation, if the maximum visual acuity obtainable with spectacle correction is worse than 0.3 logMAR (6/12) and if that corrected acuity would be improved by an additional 0.1 logMAR by the use of a contact lens	
	(See para AN.0.34 of explanatory notes to this Category) Fee: \$123.45 Benefit: 75% = \$92.60 85% = \$104.95	
10804	Extended Medicare Safety Net Cap: \$370.35	
10004	Attendance for the investigation and evaluation of a patient for the fitting of contact lenses, with	
	keratometry and testing with trial lenses and the issue of a prescription-one service in any period of 36	
	months-patient with anisometropia of 3.0 dioptres or greater (difference between spherical equivalents)	
	(See para AN.0.34 of explanatory notes to this Category)	
	Fee: \$123.45 Benefit: 75% = \$92.60 85% = \$104.95	
10805	Extended Medicare Safety Net Cap: \$370.35	
	Attendance for the investigation and evaluation of a patient for the fitting of contact lenses, with	
	keratometry and testing with trial lenses and the issue of a prescription-one service in any period of 36	
	months-patient with corrected visual acuity of 0.7 logMAR (6/30) or worse in both eyes and for whom a	
10006	contact lens is prescribed as part of a telescopic system	
10806		

A9. CON	ITACT LENSES - ATTENDANCES
	(See para AN.0.34 of explanatory notes to this Category)
	Fee: \$123.45 Benefit: 75% = \$92.60 85% = \$104.95
	Extended Medicare Safety Net Cap: \$370.35
	Attendance for the investigation and evaluation of a patient for the fitting of contact lenses, with keratometry and testing with trial lenses and the issue of a prescription-one service in any period of 36 months-patient for whom a wholly or segmentally opaque contact lens is prescribed for the alleviation of dazzle, distortion or diplopia caused by pathological mydriasis, aniridia, coloboma of the iris, pupillary malformation or distortion, significant ocular deformity or corneal opacity-whether congenital, traumatic
	or surgical in origin
10807	(See para AN.0.34 of explanatory notes to this Category) Fee: \$123.45 Benefit: 75% = \$92.60 85% = \$104.95 Extended Medicare Safety Net Cap: \$370.35
10007	Attendance for the investigation and evaluation of a patient for the fitting of contact lenses, with
	keratometry and testing with trial lenses and the issue of a prescription-one service in any period of 36 months-patient who, because of physical deformity, are unable to wear spectacles
	(See para AN.0.34 of explanatory notes to this Category)
	Fee: \$123.45 Benefit: 75% = \$92.60 85% = \$104.95
10808	Extended Medicare Safety Net Cap: \$370.35
	Attendance for the investigation and evaluation of a patient for the fitting of contact lenses, with keratometry and testing with trial lenses and the issue of a prescription-one service in any period of 36 months-patient with a medical or optical condition (other than myopia, hyperopia, astigmatism, anisometropia or a condition to which item 10806, 10807 or 10808 applies) requiring the use of a
	contact lens for correction, if the condition is specified on the patient's account (See para AN.0.34 of explanatory notes to this Category)
	Fee: \$123.45 Benefit: 75% = \$92.60 85% = \$104.95
10809	Extended Medicare Safety Net Cap: \$370.35
	Attendance for the refitting of contact lenses with keratometry and testing with trial lenses and the issue of a prescription, if the patient requires a change in contact lens material or basic lens parameters, other than simple power change, because of a structural or functional change in the eye or an allergic response within 36 months after the fitting of a contact lens to which items 10801 to 10809 apply
	(See para AN.0.35 of explanatory notes to this Category) Fee: \$123.45 Benefit: 75% = \$92.60 85% = \$104.95
10816	Extended Medicare Safety Net Cap: \$370.35
A10. OP	TOMETRICAL SERVICES 1. GENERAL
	Group A10. Optometrical Services
	Subgroup 1. General
	REFERRED COMPREHENSIVE INITIAL CONSULTATION
	Professional attendance of more than 15 minutes duration, being the first in a course of attention, where the patient has been <u>referred</u> by another optometrist who is not associated with the optometrist to whom the patient is referred
10905	(See para AN.0.10 of explanatory notes to this Category) Fee: \$66.80 Benefit: 85% = \$56.80
	COMPREHENSIVE INITIAL CONSULTATION BY ANOTHER PRACTITIONER
10907	

A10. OP	TOMETRICAL SERVICES 1. GENER	RAL
	Professional attendance of more than 15 minutes in duration, being the first in a course of attention in patient has attended another optometrist for an attendance to which this item or item 10905, 10910, 10911, 10912, 10913, 10914 or 10915 applies, or to which old item 10900 applied:	f the
	(a) for a patient who is less than 65 years of age-within the previous 36 months; or	
	(b) for a patient who is at least 65 years or age-within the previous 12 months	
	(See para AN.0.10 of explanatory notes to this Category) Fee: \$33.45 Benefit: 85% = \$28.45	
	COMPREHENSIVE INITIAL CONSULTATION - PATIENT IS LESS THAN 65 YEARS OF AGI	Ē
	Professional attendance of more than 15 minutes in duration, being the first in a course of attention, it	if:
	(a) the patient is less than 65 years of age; and	
	(b) the patient has not, within the previous 36 months, received a service to which:	
	(i) this item or item 10905, 10907, 10912, 10913, 10914 or 10915 applies; or	
	(ii) old item 10900 applied	
10910	(See para AN.0.10 of explanatory notes to this Category) Fee: \$66.80 Benefit: \$5% = \$56.80	
	COMPREHENSIVE INITIAL CONSULTATION - PATIENT IS AT LEAST 65 YEARS OF AGE	
	Professional attendance of more than 15 minutes in duration, being the first in a course of attention, i	if:
	(a) the patient is at least 65 years of age; and	
	(b) the patient has not, within the previous 12 months, received a service to which:	
	(i) this item, or item 10905, 10907, 10910, 10912, 10913, 10914 or 10915 applies; or	
	(ii) old item 10900 applied	
10911	(See para AN.0.10 of explanatory notes to this Category) Fee: \$66.80 Benefit: 85% = \$56.80	
	OTHER COMPREHENSIVE CONSULTATIONS	
	Professional attendance of more than 15 minutes in duration, being the first in a course of attention, it the patient has suffered a significant change of visual function requiring comprehensive reassessmen	
	(a) for a patient who is less than 65 years of age-within 36 months of an initial consultation to which	:
	(i) this item, or item 10905, 10907, 10910, 10913, 10914 or 10915 at the same practice applies; or	r
	(ii) old item 10900 at the same practice applied; or	
	(b) for a patient who is at least 65 years of age-within 12 months of an initial consultation to which:	
10912	(i) this item, or item 10905, 10907, 10910, 10911, 10913, 10914 or 10915 at the same practice	

A10. OP	TOMETRICAL SERVICES 1. GENERAL
	applies; or
	(ii) old item 10900 at the same practice applied
	(See para AN.0.10 of explanatory notes to this Category) Fee: \$66.80 Benefit: 85% = \$56.80
	Professional attendance of more than 15 minutes in duration, being the first in a course of attention, if the patient has new signs or symptoms, unrelated to the earlier course of attention, requiring comprehensive reassessment:
	(a) for a patient who is less than 65 years of age-within 36 months of an initial consultation to which:
	(i) this item, or item 10905, 10907, 10910, 10912, 10914 or 10915 at the same practice applies; or
	(ii) old item 10900 at the same practice applied; or
	(b) for a patient who is at least 65 years of age-within 12 months of an initial consultation to which:
	(i) this item, or item 10905, 10907, 10910, 10911, 10912, 10914 or 10915 at the same practice applies; or
	(ii) old item 10900 at the same practice applied
10913	(See para AN.0.10 of explanatory notes to this Category) Fee: \$66.80 Benefit: 85% = \$56.80
	Professional attendance of more than 15 minutes in duration, being the first in a course of attention, if the patient has a progressive disorder (excluding presbyopia) requiring comprehensive reassessment:
	(a) for a patient who is less than 65 years of age-within 36 months of an initial consultation to which:
	(i) this item, or item 10905, 10907, 10910, 10912, 10913 or 10915 applies; or
	(ii) old item 10900 applied; or
	(b) for a patient who is at least 65 years of age-within 12 months of an initial consultation to which:
	(i) this item, or item 10905, 10907, 10910, 10911, 10912, 10913 or 10915 applies; or
	(ii) old item 10900 applied
10914	(See para AN.0.10 of explanatory notes to this Category) Fee: \$66.80 Benefit: \$5% = \$56.80
	Professional attendance of more than 15 minutes duration, being the first in a course of attention involving the examination of the eyes, with the instillation of a mydriatic, of a patient with diabetes mellitus requiring comprehensive reassessment.
10915	(See para AN.0.10 of explanatory notes to this Category) Fee: \$66.80 Benefit: 85% = \$56.80
	Professional attendance, being the first in a course of attention, of not more than 15 minutes duration, not being a service associated with a service to which item 10931, 10932, 10933, 10940, 10941, 10942 or 10943 applies
10916	(See para AN.0.10 of explanatory notes to this Category)

A10. OP	TOMETRICAL SERVICES 1. GENERA	4L
	Fee: \$33.45 Benefit: 85% = \$28.45	
	SUBSEQUENT CONSULTATION	
	Professional attendance being the second or subsequent in a course of attention not related to the prescription and fitting of contact lenses, not being a service associated with a service to which item 10940 or 10941 applies	
	(See para AN.0.10 of explanatory notes to this Category)	
10918	Fee: \$33.45 Benefit: 85% = \$28.45	
	CONTACT LENSES FOR SPECIFIED CLASSES OF PATIENTS - BULK ITEMS FOR ALL SUBSEQUENT CONSULTATIONS	
	All professional attendances after the first, being those attendances regarded as a single service, in a single course of attention involving the prescription and fitting of contact lenses, being a course of attention for which the first attendance is a service to which:	
	(a) item 10905, 10907, 10910, 10911, 10912, 10913, 10914, 10915 or 10916 applies; or	
	(b) old item 10900 applied	
	Payable once in a period of 36 months for	
	- patients with myopia of 5.0 dioptres or greater (spherical equivalent) in one eye	
10921	(See para AN.0.2 of explanatory notes to this Category) Fee: \$165.80 Benefit: 85% = \$140.95	
	All professional attendances after the first, being those attendances regarded as a single service, in a single course of attention involving the prescription and fitting of contact lenses, being a course of attention for which the first attendance is a service to which:	
	(a) item 10905, 10907, 10910, 10911, 10912, 10913, 10914, 10915 or 10916 applies; or	
	(b) old item 10900 applied	
	Payable once in a period of 36 months for	
	- patients with manifest hyperopia of 5.0 dioptres or greater (spherical equivalent) in one eye	
10922	(See para AN.0.2 of explanatory notes to this Category) Fee: \$165.80 Benefit: \$5% = \$140.95	
	All professional attendances after the first, being those attendances regarded as a single service, in a single course of attention involving the prescription and fitting of contact lenses, being a course of attention for which the first attendance is a service to which:	
	(a) item 10905, 10907, 10910, 10911, 10912, 10913, 10914, 10915 or 10916 applies; or	
	(b) old item 10900 applied	
	Payable once in a period of 36 months for	
	- patients with astigmatism of 3.0 dioptres or greater in one eye	
10923	(See para AN.0.2 of explanatory notes to this Category)	

A10. OP	PTOMETRICAL SERVICES 1. GENE	₹AI
	Fee: \$165.80 Benefit: 85% = \$140.95	
	All professional attendances after the first, being those attendances regarded as a single service, in a single course of attention involving the prescription and fitting of contact lenses, being a course of attention for which the first attendance is a service to which:	
	(a) item 10905, 10907, 10910, 10911, 10912, 10913, 10914, 10915 or 10916 applies; or	
	(b) old item 10900 applied	
	Payable once in a period of 36 months for	
	- patients with irregular astigmatism in either eye, being a condition the existence of which has beer confirmed by keratometric observation, if the maximum visual acuity obtainable with spectacle correction is worse than 0.3 logMAR (6/12) and if that corrected acuity would be improved by an additional 0.1 logMAR by the use of a contact lens	l
10924	(See para AN.0.2 of explanatory notes to this Category) Fee: \$209.20 Benefit: \$5% = \$177.85	
	All professional attendances after the first, being those attendances regarded as a single service, in a single course of attention involving the prescription and fitting of contact lenses, being a course of attention for which the first attendance is a service to which:	
	(a) item 10905, 10907, 10910, 10911, 10912, 10913, 10914, 10915 or 10916 applies; or	
	(b) old item 10900 applied	
	Payable once in a period of 36 months for	
	- patients with anisometropia of 3.0 dioptres or greater (difference between spherical equivalents)	
10925	(See para AN.0.2 of explanatory notes to this Category) Fee: \$165.80 Benefit: 85% = \$140.95	
	All professional attendances after the first, being those attendances regarded as a single service, in a single course of attention involving the prescription and fitting of contact lenses, being a course of attention for which the first attendance is a service to which:	
	(a) item 10905, 10907, 10910, 10911, 10912, 10913, 10914, 10915 or 10916 applies; or	
	(b) old item 10900 applied	
	Payable once in a period of 36 months for	
	- patients with corrected visual acuity of 0.7 logMAR (6/30) or worse in both eyes, being patients whom a contact lens is prescribed as part of a telescopic system	or
10926	(See para AN.0.2 of explanatory notes to this Category) Fee: \$165.80 Benefit: 85% = \$140.95	
	All professional attendances after the first, being those attendances regarded as a single service, in a single course of attention involving the prescription and fitting of contact lenses, being a course of attention for which the first attendance is a service to which:	
	(a) item 10905, 10907, 10910, 10911, 10912, 10913, 10914, 10915 or 10916 applies; or	
	(b) old item 10900 applied	
10927	Payable once in a period of 36 months for	

A10. OP1	TOMETRICAL SERVICES 1. GENERAL
	- patients for whom a wholly or segmentally opaque contact lens is prescribed for the alleviation of dazzle, distortion or diplopia caused by:
	i. pathological mydriasis; or
	ii. aniridia; or
	iii. coloboma of the iris; or
	iv. pupillary malformation or distortion; or
	v. significant ocular deformity or corneal opacity
	-whether congenital, traumatic or surgical in origin
	(See para AN.0.2 of explanatory notes to this Category) Fee: \$209.20 Benefit: 85% = \$177.85
	All professional attendances after the first, being those attendances regarded as a single service, in a single course of attention involving the prescription and fitting of contact lenses, being a course of attention for which the first attendance is a service to which:
	(a) item 10905, 10907, 10910, 10911, 10912, 10913, 10914, 10915 or 10916 applies; or
	(b) old item 10900 applied
	Payable once in a period of 36 months for
	- patients who, because of physical deformity, are unable to wear spectacles
10928	(See para AN.0.2 of explanatory notes to this Category) Fee: \$165.80 Benefit: 85% = \$140.95
	All professional attendances after the first, being those attendances regarded as a single service, in a single course of attention involving the prescription and fitting of contact lenses, being a course of attention for which the first attendance is a service to which:
	(a) item 10905, 10907, 10910, 10911, 10912, 10913, 10914, 10915 or 10916 applies; or
	(b) old item 10900 applied
	Payable once in a period of 36 months for
	- patients who have a medical or optical condition (other than myopia, hyperopia, astigmatism, anisometropia or a condition to which item 10926, 10927 or 10928 applies) requiring the use of a contact lens for correction, if the condition is specified on the patient's account
	Note: Benefits may not be claimed under Item 10929 where the patient wants the contact lenses for appearance, sporting, work or psychological reasons - see paragraph 06 of explanatory notes to this category.
10929	(See para AN.0.2 of explanatory notes to this Category) Fee: \$209.20 Benefit: 85% = \$177.85
10930	All professional attendances regarded as a single service in a single course of attention involving the prescription and fitting of contact lenses where the patient meets the requirements of an item in the range 10921-10929 and requires a change in contact lens material or basic lens parameters, other than a simple power change, because of a structural or functional change in the eye or an allergic response within 36 months of the fitting of a contact lens covered by item 10921 to 10929

A10. OI	PTOMETRICAL SERVICES 1. GENERAL
	Fee: \$165.80 Benefit: 85% = \$140.95 DOMICILIARY VISITS
	DOMICILIARY VISITS
	An optometric service to which an item in Group A10 of this table (other than this item or item 10916, 10932, 10933, 10940 or 10941) applies (the applicable item) if the service is:
	a) rendered at a place other than consulting rooms, being at:
	(i) a patient's home: or
	(ii) residential aged care facility: or
	(iii) an institution; and
	b) performed on one patient at a single location on one occasion, and
	c) either:
	(i) bulk-billed in respect of the fees for both:
	- this item; and
	- the applicable item; or
	(ii) not bulk-billed in respect of the fees for both:
	- this item; and
	- the applicable item
10931	(See para AN.0.10 of explanatory notes to this Category) Fee: \$23.30 Benefit: 85% = \$19.85
	An optometric service to which an item in Group A10 of this table (other than this item or item 10916, 10931, 10933, 10940 or 10941) applies (the applicable item) if the service is:
	a) rendered at a place other than consulting rooms, being at:
	(i) a patient's home: or
	(ii) residential aged care facility: or
	(iii) an institution; and
	b) performed on two patients at the same location on one occasion, and
	c) either:
	(i) bulk-billed in respect of the fees for both:
	- this item; and
	- the applicable item; or
	(ii) not bulk-billed in respect of the fees for both:
10932	

A10. OP	TOMETRICAL SERVICES	1. GENERAL
	- this item; and	
	- the applicable item	
	(See para AN.0.10 of explanatory notes to this Category) Fee: \$11.60 Benefit: 85% = \$9.90	
	An optometric service to which an item in Group A10 of this table (other than this item o 10931, 10932, 10940 or 10941) applies (the applicable item) if the service is:	r item 10916,
	a) rendered at a place other than consulting rooms, being at:	
	(i) a patient's home: or	
	(ii) residential aged care facility: or	
	(iii) an institution; and	
	b) performed on three patients at the same location on one occasion, and	
	c) either:	
	(i) bulk-billed in respect of the fees for both:	
	- this item; and	
	- the applicable item; or	
	(ii) not bulk-billed in respect of the fees for both:	
	- this item; and	
	- the applicable item	
10933	(See para AN.0.10 of explanatory notes to this Category) Fee: \$7.70 Benefit: 85% = \$6.55	
	COMPUTERISED PERIMETRY	
	Full quantitative computerised perimetry (automated absolute static threshold) not being a involving multifocal multichannel objective perimetry, performed by an optometrist, when the presence of relevant ocular disease or suspected pathology of the visual pathways or the assessment and report, bilateral - to a maximum of 2 examinations (including examination item 10941 applies) in any 12 month period, not being a service associated with a service 10916, 10918, 10931, 10932 or 10933 applies	ore indicated by brain with ns to which
10940	(See para AN.0.10, DN.1.6 of explanatory notes to this Category) Fee: \$63.75 Benefit: 85% = \$54.20	
	Full quantitative computerised perimetry (automated absolute static threshold) not being involving multifocal multichannel objective perimetry, performed by an optometrist, whe the presence of relevant ocular disease or suspected pathology of the visual pathways or the assessment and report, unilateral - to a maximum of 2 examinations (including examination item 10940 applies) in any 12 month period, not being a service associated with a service 10916, 10918, 10931, 10932 or 10933 applies	ore indicated by orain with ons to which
10941	(See para AN.0.10, DN.1.6 of explanatory notes to this Category) Fee: \$38.45 Benefit: 85% = \$32.70	

A10. OI	PTOMETRICAL SERVICES 1. GENERA	L
	LOW VISION ASSESSMENT	
	Testing of residual vision to provide optimum visual performance involving one or more of spectacle correction, determination of contrast sensitivity, determination of glare sensitivity and prescription of magnification aids in a patient who has best corrected visual acuity of 6/15 or N.12 or worse in the bette eye, or horizontal visual field of less than 120 degrees within 10 degrees above and below the horizontal midline, not being a service associated with a service to which item 10916 or 10921 to 10930 applies, payable twice in a 12 month period	
	(See para AN.0.10 of explanatory notes to this Category)	
10942	Fee: \$33.45 Benefit: 85% = \$28.45	
	CHILDREN'S VISION ASSESSMENT	
	Additional testing to confirm diagnosis of, or establish a treatment regime for, a significant binocular or accommodative dysfunction, including assessment of one or more of accommodation, ocular motility, vergences, or fusional reserves and/or cycloplegic refraction, in a patient aged 3 to 14 years, not to be used for the assessment of learning difficulties or learning disabilities, not being a service associated with a service to which item 10916 or 10921 to 10930 applies, payable once only in a 12 month period	r
	(See para AN.0.10 of explanatory notes to this Category)	
10943	Fee: \$33.45 Benefit: 85% = \$28.45	
	CORNEA, complete removal of embedded foreign body from - not more than once on the same day by the same practitioner (excluding aftercare)	
	The item is not to be billed on the same occasion as MBS items 10905, 10907, 10910, 10911, 10912, 10913, 10914, 10915, 10916 or 10918. If the embedded foreign body is not completely removed, this item does not apply but item 10916 may apply.	
10944	Fee: \$72.15 Benefit: 85% = \$61.35	
A10. OI	PTOMETRICAL SERVICES 2. TELEHEALTH ATTENDANC	E
	Group A10. Optometrical Services	
	Subgroup 2. Telehealth Attendance	
	TELEHEALTH ATTENDANCE AT CONSULTING ROOMS, HOME VISITS OR OTHER INSTITUTIONS	<u></u>
	A professional attendance of less than 15 minutes (whether or not continuous) by an attending optometrist that requires the provision of clinical support to a patient who:	
	(a) is participating in a video conferencing consultation with a specialist practising in his or her speciality of ophthalmology; and	
	(b) is not an admitted patient; and	
	(c) either:	
	(i) is located within a telehealth eligible area and, at the time of the attendance, is at least 15 kilometres by road from the specialist mentioned in paragraph (a); or	
10945	(ii) is a patient of an Aboriginal Medical Service, or an Aboriginal Community Controlled Healt	th

A10. OP	TOMETRICAL SERVICES 2. TELEHEALTH ATTENDANCE
	Service, for which a direction under subsection 19(2) of the Act applies
	(See para AN.0.22 of explanatory notes to this Category) Fee: \$33.45 Benefit: 85% = \$28.45
	A professional attendance of at least 15 minutes (whether or not continuous) by an attending optometrist that requires the provision of clinical support to a patient who:
	(a) is participating in a video conferencing consultation with a specialist practising in his or her speciality of ophthalmology; and
	(b) is not an admitted patient; and
	(c) either:
	(i) is located within a telehealth eligible area and, at the time of the attendance, is at least 15 kilometres by road from the specialist mentioned in paragraph (a); or
	(ii) is a patient of an Aboriginal Medical Service, or an Aboriginal Community Controlled Health Service, for which a direction under subsection 19(2) of the Act applies
10946	(See para AN.0.22 of explanatory notes to this Category) Fee: \$66.80 Benefit: \$5% = \$56.80
	A professional attendance (not being a service to which any other item applies) of less than 15 minutes (whether or not continuous) by an attending optometrist that requires the provision of clinical support to a patient who:
	a) is participating in a video conferencing consultation with a specialist practising in his or her speciality of ophthalmology; and
	b) at the time of the attendance, is located at a residential aged care facility (whether or not at consulting rooms situated within the facility); and
	c) is a care recipient in the facility; and
	d) is not a resident of a self-contained unit;
	for an attendance on one occasion-each patient
10947	(See para AN.0.22 of explanatory notes to this Category) Fee: \$33.45 Benefit: 85% = \$28.45
	A professional attendance (not being a service to which any other item applies) of at least 15 minutes (whether or not continuous) by an attending optometrist that requires the provision of clinical support to a patient who:
	a) is participating in a video conferencing consultation with a specialist practising in his or her speciality of ophthalmology; and
	b) at the time of the attendance, is located at a residential aged care facility (whether or not at consulting rooms situated within the facility); and
	c) is a care recipient in the facility; and
	d) is not a resident of a self-contained unit;
	for an attendance on one occasion-each patient
10948	(See para AN.0.22 of explanatory notes to this Category)

A10. OP	TOMETRICAL SERVICES 2. TELEHEALTH ATTENDANCE
	Fee: \$66.80 Benefit: 85% = \$56.80
A11. UR	GENT ATTENDANCE AFTER HOURS 1. URGENT ATTENDANCE - AFTER HOURS
	Group A11. Urgent Attendance After Hours
	Subgroup 1. Urgent Attendance - After Hours
	Professional attendance by a general practitioner on one patient on one occasion—each attendance (other than an attendance in unsociable hours) in an after-hours period if:
	(a) the attendance is requested by the patient or a responsible person in the same unbroken after-hours period; and
	(b) the patient's medical condition requires urgent assessment; and
	(c) if the attendance is at consulting rooms—it is necessary for the practitioner to return to, and specially open, the consulting rooms for the attendance
585	(See para AN.0.19, AN.0.9 of explanatory notes to this Category) Fee: \$129.80 Benefit: 75% = \$97.35 100% = \$129.80 Extended Medicare Safety Net Cap: \$389.40
	Professional attendance by a medical practitioner (other than a general practitioner) on one patient on one occasion—each attendance (other than an attendance in unsociable hours) in an after-hours period if:
	(a) the attendance is requested by the patient or a responsible person in the same unbroken after-hours period; and
	(b) the patient's medical condition requires urgent assessment; and
	(c) the attendance is in an after-hours rural area; and
	(d) if the attendance is at consulting rooms—it is necessary for the practitioner to return to, and specially open, the consulting rooms for the attendance
588	(See para AN.0.19 of explanatory notes to this Category) Fee: \$129.80 Benefit: 75% = \$97.35 100% = \$129.80 Extended Medicare Safety Net Cap: \$389.40
	Professional attendance by a medical practitioner (other than a general practitioner) on one patient on one occasion—each attendance (other than an attendance in unsociable hours) in an after-hours period if:
	(a) the attendance is requested by the patient or a responsible person in the same unbroken after-hours period; and
	(b) the patient's medical condition requires urgent assessment; and
	(c) the attendance is not in an after-hours rural area; and
	(d) if the attendance is at consulting rooms—it is necessary for the practitioner to return to, and specially open, the consulting rooms for the attendance
	(See para AN.0.19 of explanatory notes to this Category) Fee: \$100.00 Benefit: 75% = \$75.00 100% = \$100.00
591	Extended Medicare Safety Net Cap: \$300.00 Professional attendance by a medical practitioner—each additional patient at an attendance that qualifies for item 585, 588 or 591 in relation to the first patient
594	

A11. UF	GENT ATTENDANCE AFTER HOURS 1. URGENT ATTENDANCE - AFTER HOURS
	(See para AN.0.9, AN.0.19 of explanatory notes to this Category)
	Fee: \$41.95 Benefit: 75% = \$31.50 100% = \$41.95 Extended Medicare Safety Net Cap: \$125.85
A11. UF	2. URGENT ATTENDANCE UNSOCIABLE AFTER GENT ATTENDANCE AFTER HOURS HOURS
	Group A11. Urgent Attendance After Hours
	Subgroup 2. Urgent Attendance Unsociable After Hours
	Professional attendance by a general practitioner on not more than one patient on one occasion—each attendance in unsociable hours if:
	(a) the attendance is requested by the patient or a responsible person in the same unbroken after-hours period; and
	(b) the patient's medical condition requires urgent assessment; and
	(c) if the attendance is at consulting rooms—it is necessary for the practitioner to return to, and specially open, the consulting rooms for the attendance
599	(See para AN.0.19, AN.0.9 of explanatory notes to this Category) Fee: \$153.00 Benefit: 75% = \$114.75 100% = \$153.00 Extended Medicare Safety Net Cap: \$459.00
	Professional attendance by a medical practitioner (other than a general practitioner) on not more than one patient on one occasion—each attendance in unsociable hours if:
	(a) the attendance is requested by the patient or a responsible person in the same unbroken after-hours period; and
	(b) the patient's medical condition requires urgent assessment; and
	(c) if the attendance is at consulting rooms—it is necessary for the practitioner to return to, and specially open, the consulting rooms for the attendance
	(See para AN.0.19 of explanatory notes to this Category) Fee: \$124.25 Benefit: 75% = \$93.20 100% = \$124.25
600	Extended Medicare Safety Net Cap: \$372.75 ONSULTANT OCCUPATIONAL PHYSICIAN
	DANCES TO WHICH NO OTHER ITEM
	Group A12. Consultant Occupational Physician Attendances To Which No Other Item Applies
	Initial professional attendance of 10 minutes or less in duration on a patient by a consultant occupational physician practising in his or her specialty of occupational medicine if:
	(a) the attendance is by video conference; and
	(b) the patient is not an admitted patient; and
	(c) the patient:
	(i) is located both:
	(A) within a telehealth eligible area; and
384	(B) at the time of the attendance-at least 15 kms by road from the physician; or
J0 4	

	NSULTANT OCCUPATIONAL PHYSICIAN ANCES TO WHICH NO OTHER ITEM
	(ii) is a care recipient in a residential care service; or
	(iii) is a patient of:
	(A) an Aboriginal Medical Service; or
	(B) an Aboriginal Community Controlled Health Service;
	for which a direction made under subsection 19(2) of the Act applies; and
	(d) no other initial consultation has taken place for a single course of treatment
	(See para AN.0.68 of explanatory notes to this Category) Fee: \$65.15 Benefit: 85% = \$55.40
	Extended Medicare Safety Net Cap: \$195.45
	Professional attendance at consulting rooms or hospital by a consultant occupational physician in the
	practice of his or her specialty of occupational medicine following referral of the patient to him or her by a referring practitioner-initial attendance in a single course of treatment
	(See para AN.0.33 of explanatory notes to this Category)
	Fee: \$86.85 Benefit: 75% = \$65.15 85% = \$73.85
385	Extended Medicare Safety Net Cap: \$260.55
	Professional attendance at consulting rooms or hospital by a consultant occupational physician in the practice of his or her specialty of occupational medicine following referral of the patient to him or her by a referring practitioner-each attendance after the first in a single course of treatment
	with the production of the state of the stat
	(See para AN.0.33, AN.0.70 of explanatory notes to this Category)
	Fee: \$43.65 Benefit: 75% = \$32.75 85% = \$37.15
386	Extended Medicare Safety Net Cap: \$130.95
	Professional attendance at a place other than consulting rooms or hospital by a consultant occupational physician in the practice of his or her specialty of occupational medicine following referral of the patient to him or her by a referring practitioner-initial attendance in a single course of treatment
	(See para AN.0.33 of explanatory notes to this Category) Fee: \$127.40 Benefit: 75% = \$95.55 85% = \$108.30
387	Extended Medicare Safety Net Cap: \$382.20
	Professional attendance at a place other than consulting rooms or hospital by a consultant occupational physician in the practice of his or her specialty of occupational medicine following referral of the patient to him or her by a referring practitioner-each attendance after the first in a single course of treatment
	(See para AN.0.33 of explanatory notes to this Category)
	Fee: \$80.65 Benefit: 75% = \$60.50 85% = \$68.60
388	Extended Medicare Safety Net Cap: \$241.95
	Professional attendance on a patient by a consultant occupational physician practising in his or her specialty of occupational medicine if:
	(a) the attendance is by video conference; and
	(b) the attendance is for a service:
	(i) provided with item 385 lasting more than 10 minutes; or
389	(ii) provided with item 386; and

A12. CONSULTANT OCCUPATIONAL PHYSICIAN ATTENDANCES TO WHICH NO OTHER ITEM APPLIES

- (c) the patient is not an admitted patient; and
- (d) the patient:
 - (i) is located both:
 - (A) within a telehealth eligible area; and
 - (B) at the time of the attendance-at least 15 kms by road from the physician; or
 - (ii) is a care recipient in a residential care service; or
 - (iii) is a patient of:
 - (A) an Aboriginal Medical Service; or
 - (B) an Aboriginal Community Controlled Health Service;

for which a direction made under subsection 19(2) of the Act applies

(See para AN.0.68 of explanatory notes to this Category)

Derived Fee: 50% of the fee for item 385 or 386. Benefit: 85% of the derived fee

Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the

lesser amount

A13. PUBLIC HEALTH PHYSICIAN ATTENDANCES TO WHICH NO OTHER ITEM APPLIES

	Group A13. Public Health Physician Attendances To Which No Other Item Applies
	PUBLIC HEALTH PHYSICIAN ATTENDANCES - AT CONSULTING ROOMS Professional attendance at consulting rooms by a public health physician in the practice of his or her specialty of public health medicine
	LEVEL A
	Professional attendance at consulting rooms by a public health physician in the practice of his or her specialty of public health medicine for an obvious problem characterised by the straightforward nature of the task that requires a short patient history and, if required, limited examination and management.
	(See para AN.0.50 of explanatory notes to this Category) Fee: \$19.85 Benefit: 75% = \$14.90 85% = \$16.90
410	Extended Medicare Safety Net Cap: \$59.55
	LEVEL B
	Professional attendance by a public health physician in the practice of his or her specialty of public health medicine at consulting rooms lasting less than 20 minutes, including any of the following that are clinically relevant:
	a) taking a patient history;
	b) performing a clinical examination;
411	c) arranging any necessary investigation;

DI IC LIEAL TU DUVCICIANI
BLIC HEALTH PHYSICIAN DANCES TO WHICH NO OTHER ITEM S
d) implementing a management plan;
e) providing appropriate preventive health care;
in relation to 1 or more health-related issues, with appropriate documentation.
(See para AN.0.50 of explanatory notes to this Category) Fee: \$43.40 Benefit: 75% = \$32.55 85% = \$36.90 Extended Medicare Safety Net Cap: \$130.20
LEVEL C
Professional attendance by a public health physician in the practice of his or her specialty of public health medicine at consulting rooms lasting at least 20 minutes, including any of the following that are clinically relevant:
a) taking a detailed patient history;
b) performing a clinical examination;
c) arranging any necessary investigation;
d) implementing a management plan;
e) providing appropriate preventive health care;
in relation to 1 or more health-related issues, with appropriate documentation.
(See para AN.0.50 of explanatory notes to this Category) Fee: \$83.90 Benefit: 75% = \$62.95 85% = \$71.35 Extended Medicare Safety Net Cap: \$251.70
LEVEL D
Professional attendance by a public health physician in the practice of his or her specialty of public health medicine at consulting rooms lasting at least 40 minutes, including any of the following that are clinically relevant:
a) taking an extensive patient history;
b) performing a clinical examination;
c) arranging any necessary investigation;
d) implementing a management plan;
e) providing appropriate preventive health care;
in relation to 1 or more health-related issues, with appropriate documentation.
(See para AN.0.50 of explanatory notes to this Category) Fee: \$123.55 Benefit: 75% = \$92.70 85% = \$105.05 Extended Medicare Safety Net Cap: \$370.65
PUBLIC HEALTH PHYSICIAN ATTENDANCES - OTHER THAN AT CONSULTING ROOMS Professional attendance other than at consulting rooms by a public health physician in the practice of his or her specialty of public health medicine.
)

	BLIC HEALTH PHYSICIAN
ATTENI APPLIE	DANCES TO WHICH NO OTHER ITEM S
ALLE	LEVEL A
	Professional attendance by a public health physician in the practice of his or her specialty of public health medicine other than at consulting rooms for an obvious problem characterised by the straightforward nature of the task that requires a short patient history and, if required, limited examination and management
414	(See para AN.0.50 of explanatory notes to this Category) Derived Fee: The fee for item 410, plus \$25.85 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 410 plus \$2.00 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	LEVEL B
	Professional attendance by a public health physician in the practice of his or her specialty of public health medicine other than at consulting rooms, lasting less than 20 minutes, including any of the following that are clinically relevant:
	a) taking a patient history;
	b) performing a clinical examination;
	c) arranging any necessary investigation;
	d) implementing a management plan;
	e) providing appropriate preventive health care;
	in relation to 1 or more health-related issues, with appropriate documentation.
	(See para AN.0.50 of explanatory notes to this Category) Derived Fee: The fee for item 411, plus \$25.85 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 411 plus \$2.00 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the
415	lesser amount LEVEL C
	Professional attendance by a public health physician in the practice of his or her specialty of public health medicine other than at consulting rooms lasting at least 20 minutes, including any of the following that are clinically relevant:
	a) taking a detailed patient history;
	b) performing a clinical examination;
	c) arranging any necessary investigation;
	d) implementing a management plan;
	e) providing appropriate preventive health care;
	in relation to 1 or more health-related issues, with appropriate documentation.
416	(See para AN.0.50 of explanatory notes to this Category) Derived Fee: The fee for item 412, plus \$25.85 divided by the number of patients seen, up to a maximum of six

	BLIC HEALTH PHYSICIAN DANCES TO WHICH NO OTHER ITEM
APPLIE	
	patients. For seven or more patients - the fee for item 412 plus \$2.00 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	LEVEL D
	Professional attendance by a public health physician in the practice of his or her specialty of public health medicine other than at consulting rooms lasting at least 40 minutes, including any of the following that are clinically relevant:
	a) taking an extensive patient history;
	b) performing a clinical examination;
	c) arranging any necessary investigation;
	d) implementing a management plan;
	e) providing appropriate preventive health care;
	in relation to 1 or more health-related issues, with appropriate documentation.
417	(See para AN.0.50 of explanatory notes to this Category) Derived Fee: The fee for item 413, plus \$25.85 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 413 plus \$2.00 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount.
A14. HE	ALTH ASSESSMENTS
	Group A14. Health Assessments
	HEALTH ASSESSMENTS The category of people eligible for health assessments are: a) People aged 40 to 49 years (inclusive) with a high risk of developing type 2 diabetes as determined by the Australian Type 2 Diabetes Risk Assessment Tool b) People between the age of 45 and 49 (inclusive) who are at risk of developing a chronic disease c) People aged 75 years and older d) Permanent residents of a Residential Aged Care Facility e) People who have an intellectual disability f) Humanitarian entrants who are resident in Australia with access to Medicare services, including Refugees and Special Humanitarian Program and Protection Program entrants g) Former serving members of the Australian Defence Force including former members of permanent and reserve forces
	Professional attendance by a general practitioner to perform a brief health assessment, lasting not more than 30 minutes and including:
	(a) collection of relevant information, including taking a patient history; and
	(b) a basic physical examination; and
	(c) initiating interventions and referrals as indicated; and
	(d) providing the patient with preventive health care advice and information
	(See para AN.0.40, AN.0.38, AN.0.42, AN.0.69, AN.0.39, AN.0.36, AN.0.37, AN.0.41 of explanatory notes to this Category)
701	Fee: \$59.35 Benefit: 100% = \$59.35

A14. HE	EALTH ASSESSMENTS
	Extended Medicare Safety Net Cap: \$178.05
	Professional attendance by a general practitioner to perform a standard health assessment, lasting more than 30 minutes but less than 45 minutes, including:
	(a) detailed information collection, including taking a patient history; and
	(b) an extensive physical examination; and
	(c) initiating interventions and referrals as indicated; and
	(d) providing a preventive health care strategy for the patient
	(See para AN.0.40, AN.0.38, AN.0.42, AN.0.69, AN.0.39, AN.0.36, AN.0.37, AN.0.41 of explanatory notes to this Category)
703	Fee: \$137.90 Benefit: 100% = \$137.90 Extended Medicare Safety Net Cap: \$413.70
	Professional attendance by a general practitioner to perform a long health assessment, lasting at least 45 minutes but less than 60 minutes, including:
	(a) comprehensive information collection, including taking a patient history; and
	(b) an extensive examination of the patient's medical condition and physical function; and
	(c) initiating interventions and referrals as indicated; and
	(d) providing a basic preventive health care management plan for the patient
	(See para AN.0.40, AN.0.38, AN.0.42, AN.0.69, AN.0.39, AN.0.36, AN.0.37, AN.0.41 of explanatory notes to this Category)
705	Fee: \$190.30 Benefit: 100% = \$190.30 Extended Medicare Safety Net Cap: \$500.00
703	Professional attendance by a general practitioner to perform a prolonged health assessment (lasting at least 60 minutes) including:
	(a) comprehensive information collection, including taking a patient history; and
	(b) an extensive examination of the patient's medical condition, and physical, psychological and social function; and
	(c) initiating interventions or referrals as indicated; and
	(d) providing a comprehensive preventive health care management plan for the patient
	(See para AN.0.40, AN.0.38, AN.0.42, AN.0.69, AN.0.39, AN.0.36, AN.0.37, AN.0.41 of explanatory notes to this Category)
707	Fee: \$268.80 Benefit: 100% = \$268.80 Extended Medicare Safety Net Cap: \$500.00
101	ABORIGINAL AND TORRES STRAIT ISLANDER PEOPLES HEALTH ASSESSMENT Details of the requirements for the Aboriginal and Torres Strait Islander Peoples Health Assessment, The Aboriginal and Torres Strait Islander Peoples Health Assessment is available to: a) Children between ages of 0 and 14 years,
	 b) Adults between the ages of 15 and 54 years, c) Older people over the age of 55 years.
715	Professional attendance by a general practitioner at consulting rooms or in another place other than a hospital or residential aged care facility, for a health assessment of a patient who is of Aboriginal or

Δ14 H	EALTH ASSESSMENTS
	Torres Strait Islander descent-not more than once in a 9 month period
	Torres strait islander descent-not more than once in a 7 month period
	(See para AN.0.44, AN.0.46, AN.0.43, AN.0.45 of explanatory notes to this Category)
	Fee: \$212.25 Benefit: 100% = \$212.25
	Extended Medicare Safety Net Cap: \$500.00
	P MANAGEMENT PLANS, TEAM CARE NGEMENTS, MULTIDISCIPLINARY CARE ARRANGEMENTS AND MULTIDISCIPLINARY CARE PLANS
	Group A15. GP Management Plans, Team Care Arrangements, Multidisciplinary Care Plans
	Subgroup 1. GP Management Plans, Team Care Arrangements And Multidisciplinary Care Plans
	Attendance by a general practitioner for preparation of a GP management plan for a patient (other than a service associated with a service to which any of items 735 to 758 apply)
	(See para AN.0.47 of explanatory notes to this Category) Fee: \$144.25 Benefit: 75% = \$108.20 100% = \$144.25
721	Extended Medicare Safety Net Cap: \$432.75
	Attendance by a general practitioner to coordinate the development of team care arrangements for a patient (other than a service associated with a service to which any of items 735 to 758 apply)
	(See para AN.0.47 of explanatory notes to this Category)
	Fee: \$114.30 Benefit: 75% = \$85.75 100% = \$114.30
723	Extended Medicare Safety Net Cap: \$342.90
	Contribution by a general practitioner to a multidisciplinary care plan prepared by another provider or a review of a multidisciplinary care plan prepared by another provider (other than a service associated with a service to which any of items 735 to 758 apply)
	(See para AN.0.47 of explanatory notes to this Category) Fee: \$70.40 Benefit: 100% = \$70.40
729	Extended Medicare Safety Net Cap: \$211.20
	Contribution by a general practitioner to:
	(a) a multidisciplinary care plan for a patient in a residential aged care facility, prepared by that facility, or to a review of such a plan prepared by such a facility; or
	(b) a multidisciplinary care plan prepared for a patient by another provider before the patient is discharged from a hospital, or to a review of such a plan prepared by another provider
	(other than a service associated with a service to which items 735 to 758 apply)
	(See para AN.0.47 of explanatory notes to this Category) Fee: \$70.40 Benefit: 100% = \$70.40
731	Extended Medicare Safety Net Cap: \$211.20
	Attendance by a general practitioner to review or coordinate a review of:
	(a) a GP management plan prepared by a general practitioner (or an associated general practitioner) to which item 721 applies; or
	(b) team care arrangements which have been coordinated by the general practitioner (or an associated general practitioner) to which item 723 applies
722	(See para AN.0.47 of explanatory notes to this Category) Fee: \$72.05 Benefit: 75% = \$54.05 100% = \$72.05 Extended Medicana Sefety Net Cone \$216.15
732	Extended Medicare Safety Net Cap: \$216.15

ARRAI PLANS	NGEMENTS, MULTIDISCIPLINARY CARE 2. CASE CONFERENC
	Group A15. GP Management Plans, Team Care Arrangements, Multidisciplinary Care Plans
	Subgroup 2. Case Conferences
	Attendance by a general practitioner, as a member of a multidisciplinary case conference team, to organise and coordinate:
	(a) a community case conference; or
	(b) a multidisciplinary case conference in a residential aged care facility; or
	(c) a multidisciplinary discharge case conference;
	if the conference lasts for at least 15 minutes, but for less than 20 minutes (other than a service associated with a service to which items 721 to 732 apply)
735	(See para AN.0.49 of explanatory notes to this Category) Fee: \$70.65 Benefit: 75% = \$53.00 100% = \$70.65 Extended Medicare Safety Net Cap: \$211.95
	Attendance by a general practitioner, as a member of a multidisciplinary case conference team, to organise and coordinate:
	(a) a community case conference; or
	(b) a multidisciplinary case conference in a residential aged care facility; or
	(c) a multidisciplinary discharge case conference;
	if the conference lasts for at least 20 minutes, but for less than 40 minutes (other than a service associated with a service to which items 721 to 732 apply)
739	(See para AN.0.49 of explanatory notes to this Category) Fee: \$120.95 Benefit: 75% = \$90.75 100% = \$120.95 Extended Medicare Safety Net Cap: \$362.85
	Attendance by a general practitioner, as a member of a multidisciplinary case conference team, to organise and coordinate:
	(a) a community case conference; or
	(b) a multidisciplinary case conference in a residential aged care facility; or
	(c) a multidisciplinary discharge case conference;
	if the conference lasts for at least 40 minutes (other than a service associated with a service to which items 721 to 732 apply)
	(See para AN.0.49 of explanatory notes to this Category) Fee: \$201.65 Benefit: 75% = \$151.25 100% = \$201.65
743	Extended Medicare Safety Net Cap: \$500.00 Attendance by a general practitioner, as a member of a multidisciplinary case conference team, to participate in:
747	(a) a community case conference; or

A15. GP	MANAGEMENT PLANS, TEAM CARE
ARRAN	GEMENTS, MULTIDISCIPLINARY CARE
PLANS	2. CASE CONFERENCES
	(b) a multidisciplinary case conference in a residential aged care facility; or
	(c) a multidisciplinary discharge case conference;
	if the conference lasts for at least 15 minutes, but for less than 20 minutes (other than a service associated with a service to which items 721 to 732 apply)
	(See para AN.0.49 of explanatory notes to this Category) Fee: \$51.90 Benefit: 75% = \$38.95 100% = \$51.90 Extended Medicare Safety Net Cap: \$155.70
	Attendance by a general practitioner, as a member of a multidisciplinary case conference team, to participate in:
	(a) a community case conference; or
	(b) a multidisciplinary case conference in a residential aged care facility; or
	(c) a multidisciplinary discharge case conference;
	if the conference lasts for at least 20 minutes, but for less than 40 minutes (other than a service associated with a service to which items 721 to 732 apply)
750	(See para AN.0.49 of explanatory notes to this Category) Fee: \$89.00 Benefit: 75% = \$66.75 100% = \$89.00 Extended Medicare Safety Net Cap: \$267.00
	Attendance by a general practitioner, as a member of a multidisciplinary case conference team, to participate in:
	(a) a community case conference; or
	(b) a multidisciplinary case conference in a residential aged care facility; or
	(c) a multidisciplinary discharge case conference;
	if the conference lasts for at least 40 minutes (other than a service associated with a service to which items 721 to 732 apply)
758	Fee: \$148.20 Benefit: 75% = \$111.15 100% = \$148.20 Extended Medicare Safety Net Cap: \$444.60
	Attendance by a consultant physician in the practice of his or her specialty, as a member of a case conference team, to organise and coordinate a community case conference of at least 15 minutes but less than 30 minutes, with a multidisciplinary team of at least 3 other formal care providers of different disciplines
	(See para AN.0.51 of explanatory notes to this Category)
820	Fee: \$141.20 Benefit: 75% = \$105.90 85% = \$120.05 Extended Medicare Safety Net Cap: \$423.60
820	Attendance by a consultant physician in the practice of his or her specialty, as a member of a case conference team, to organise and coordinate a community case conference of at least 30 minutes but less than 45 minutes, with a multidisciplinary team of at least 3 other formal care providers of different disciplines
822	(See para AN.0.51 of explanatory notes to this Category) Fee: \$211.85 Benefit: 75% = \$158.90 85% = \$180.10 Extended Medicare Safety Net Cap: \$500.00
044	Distributed Productic Safety 13ct Cap. \$500.00

A15. GP MANAGEMENT PLANS, TEAM CARE		
	ARRANGEMENTS, MULTIDISCIPLINARY CARE	
PLANS	2. CASE CONFERENCES	
	Attendance by a consultant physician in the practice of his or her specialty, as a member of a case	
	conference team, to organise and coordinate a community case conference of at least 45 minutes, with a	
	multidisciplinary team of at least 3 other formal care providers of different disciplines	
	(See para AN.0.51 of explanatory notes to this Category)	
	Fee: \$282.30 Benefit: 75% = \$211.75 85% = \$240.00	
823	Extended Medicare Safety Net Cap: \$500.00	
	Attendance by a consultant physician in the practice of his or her specialty, as a member of a	
	multidisciplinary case conference team of at least 2 other formal care providers of different disciplines,	
	to participate in a community case conference (other than to organise and coordinate the conference) of	
	at least 15 minutes but less than 30 minutes, with the multidisciplinary case conference team	
	(See para AN.0.51 of explanatory notes to this Category)	
	Fee: \$101.40 Benefit: 75% = \$76.05 85% = \$86.20	
825	Extended Medicare Safety Net Cap: \$304.20	
	Attendance by a consultant physician in the practice of his or her specialty, as a member of a	
	multidisciplinary case conference team of at least 2 other formal care providers of different disciplines,	
	to participate in a community case conference (other than to organise and coordinate the conference) of	
	at least 30 minutes but less than 45 minutes, with the multidisciplinary case conference team	
	(See para AN.0.51 of explanatory notes to this Category)	
926	Fee: \$161.70 Benefit: 75% = \$121.30 85% = \$137.45	
826	Extended Medicare Safety Net Cap: \$485.10 Attendance by a consultant physician in the practice of his or her specialty, as a member of a	
	multidisciplinary case conference team of at least 2 other formal care providers of different disciplines,	
	to participate in a community case conference (other than to organise and coordinate the conference) of	
	at least 45 minutes, with the multidisciplinary case conference team	
	at reast 45 minutes, with the marrialscriptmary case conference team	
	(See para AN.0.51 of explanatory notes to this Category)	
	Fee: \$222.05 Benefit: 75% = \$166.55 85% = \$188.75	
828	Extended Medicare Safety Net Cap: \$500.00	
	Attendance by a consultant physician in the practice of his or her specialty, as a member of a case	
	conference team, to organise and coordinate a discharge case conference of at least 15 minutes but less	
	than 30 minutes, with a multidisciplinary team of at least 3 other formal care providers of different	
	disciplines	
	(See para AN.0.51 of explanatory notes to this Category)	
	Fee: \$141.20 Benefit: 75% = \$105.90 85% = \$120.05	
830	Extended Medicare Safety Net Cap: \$423.60	
	Attendance by a consultant physician in the practice of his or her specialty, as a member of a case	
	conference team, to organise and coordinate a discharge case conference of at least 30 minutes but less	
	than 45 minutes, with a multidisciplinary team of at least 3 other formal care providers of different	
	disciplines	
	(See para AN.0.51 of explanatory notes to this Category)	
022	Fee: \$211.85	
832	Extended Medicare Safety Net Cap: \$500.00	
	Attendance by a consultant physician in the practice of his or her specialty, as a member of a case	
	conference team, to organise and coordinate a discharge case conference of at least 45 minutes, with a	
	multidisciplinary team of at least 3 other formal care providers of different disciplines	
	(See para AN.0.51 of explanatory notes to this Category)	
	Fee: \$282.30 Benefit: 75% = \$211.75 85% = \$240.00	
834	Extended Medicare Safety Net Cap: \$500.00	

	MANAGEMENT PLANS, TEAM CARE GEMENTS, MULTIDISCIPLINARY CARE
PLANS	2. CASE CONFERENCES
	Attendance by a consultant physician in the practice of his or her specialty, as a member of a case
	conference team, to participate in a discharge case conference (other than to organise and coordinate the
	conference) of at least 15 minutes but less than 30 minutes, with a multidisciplinary team of at least 2
	other formal care providers of different disciplines
	other formal care providers of different disciplines
	(See para AN.0.51 of explanatory notes to this Category)
	Fee: \$101.40 Benefit: 75% = \$76.05 85% = \$86.20
835	Extended Medicare Safety Net Cap: \$304.20
	Attendance by a consultant physician in the practice of his or her specialty, as a member of a case
	conference team, to participate in a discharge case conference (other than to organise and coordinate the
	conference) of at least 30 minutes but less than 45 minutes, with a multidisciplinary team of at least 2
	other formal care providers of different disciplines
	other formal care providers of different disciplines
	(See para AN.0.51 of explanatory notes to this Category)
	Fee: \$161.70 Benefit: 75% = \$121.30 85% = \$137.45
837	Extended Medicare Safety Net Cap: \$485.10
037	Attendance by a consultant physician in the practice of his or her specialty, as a member of a case
	conference team, to participate in a discharge case conference (other than to organise and coordinate the
	conference) of at least 45 minutes, with a multidisciplinary team of at least 2 other formal care providers
	of different disciplines
	of unferent disciplines
	(See para AN.0.51 of explanatory notes to this Category)
	Fee: \$222.05 Benefit: 75% = \$166.55 85% = \$188.75
838	Extended Medicare Safety Net Cap: \$500.00
030	Attendance by a consultant physician in the practice of his or her specialty of psychiatry, as a member of
	a multidisciplinary case conference team of at least 2 other formal care providers of different disciplines,
	to organise and coordinate a community case conference of at least 15 minutes but less than 30 minutes,
	with the multidisciplinary case conference team
	(See para AN.0.62 of explanatory notes to this Category)
	Fee: \$141.20 Benefit: 75% = \$105.90 85% = \$120.05
855	Extended Medicare Safety Net Cap: \$423.60
033	Attendance by a consultant physician in the practice of his or her specialty of psychiatry, as a member of
	a multidisciplinary case conference team of at least 2 other formal care providers of different disciplines,
	to organise and coordinate a community case conference of at least 30 minutes but less than 45 minutes,
	with the multidisciplinary case conference team
	with the mutualscipinary case conference team
	(See para AN.0.62 of explanatory notes to this Category)
	Fee: \$211.85 Benefit: 75% = \$158.90 85% = \$180.10
857	Extended Medicare Safety Net Cap: \$500.00
	Attendance by a consultant physician in the practice of his or her specialty of psychiatry, as a member of
	a multidisciplinary case conference team of at least 2 other formal care providers of different disciplines,
	to organise and coordinate a community case conference of at least 45 minutes, with the
	multidisciplinary case conference team
	mattation primary case conference team
	(See para AN.0.62 of explanatory notes to this Category)
	Fee: \$282.30 Benefit: 75% = \$211.75 85% = \$240.00
858	Extended Medicare Safety Net Cap: \$500.00
0.20	Attendance by a consultant physician in the practice of his or her specialty of psychiatry, as a member of
	a case conference team, to organise and coordinate a discharge case conference of at least 15 minutes
	but less than 30 minutes, with a multidisciplinary team of at least 2 other formal care providers of
	different disciplines
861	(See para AN.0.62 of explanatory notes to this Category)
001	(See para Art. 0.02 of Explanatory notes to this Category)

	GEMENTS, MULTIDISCIPLINARY CARE 2. CASE CONFERENCES
PLANS	
	Fee: \$141.20 Benefit: 75% = \$105.90 85% = \$120.05 Extended Medicare Safety Net Cap: \$423.60
	Attendance by a consultant physician in the practice of his or her specialty of psychiatry, as a member of
	a case conference team, to organise and coordinate a discharge case conference of at least 30 minutes but less than 45 minutes, with a multidisciplinary team of at least 2 other formal care providers of different disciplines
	(See para AN.0.62 of explanatory notes to this Category) Fee: \$211.85 Benefit: 75% = \$158.90 85% = \$180.10
864	Extended Medicare Safety Net Cap: \$500.00
004	Attendance by a consultant physician in the practice of his or her specialty of psychiatry, as a member of
	a case conference team, to organise and coordinate a discharge case conference of at least 45 minutes, with a multidisciplinary team of at least 2 other formal care providers of different disciplines
	(See para AN.0.62 of explanatory notes to this Category) Fee: \$282.30 Benefit: 75% = \$211.75 85% = \$240.00
866	Extended Medicare Safety Net Cap: \$500.00
	Attendance by a general practitioner, specialist or consultant physician as a member of a case conference team, to lead and coordinate a multidisciplinary case conference on a patient with cancer to develop a multidisciplinary treatment plan, if the case conference is of at least 10 minutes, with a multidisciplinary team of at least 3 other medical practitioners from different areas of medical practice (which may include general practice), and, in addition, allied health providers
	(See para AN.0.65 of explanatory notes to this Category)
	Fee: \$80.30 Benefit: 75% = \$60.25 85% = \$68.30
871	Extended Medicare Safety Net Cap: \$240.90
	Attendance by a general practitioner, specialist or consultant physician as a member of a case conference team, to participate in a multidisciplinary case conference on a patient with cancer to develop a multidisciplinary treatment plan, if the case conference is of at least 10 minutes, with a multidisciplinary team of at least 4 medical practitioners from different areas of medical practice (which may include general practice), and, in addition, allied health providers
972	(See para AN.0.65 of explanatory notes to this Category) Fee: \$37.40 Benefit: 75% = \$28.05 85% = \$31.80 Extended Medicara Sefety Net Cont. \$112.20
872	Extended Medicare Safety Net Cap: \$112.20 Attendance by a specialist, or consultant physician, in the practice of his or her specialty of geriatric or rehabilitation medicine, as a member of a case conference team, to coordinate a case conference of at least 10 minutes but less than 30 minutes-for any particular patient, one attendance only in a 7 day period (other than attendance on the same day as an attendance for which item 832, 834, 835, 837 or 838 was applicable in relation to the patient) (H)
000	(See para AN.0.63 of explanatory notes to this Category) Fee: \$49.40 Benefit: 75% = \$37.05
880	Extended Medicare Safety Net Cap: \$148.20
	DMICILIARY AND RESIDENTIAL SEMENT REVIEWS
	Group A17. Domiciliary And Residential Management Reviews
	Participation by a general practitioner in a Domiciliary Medication Management Review (DMMR) for a patient living in a community setting, in which the general practitioner, with the patient's consent:
	(a) assesses the patient as:
900	$\mathcal{L}_{\mathcal{L}}$

A17. DOMICILIARY AND RESIDENTIAL MANAGEMENT REVIEWS (i) having a chronic medical condition or a complex medication regimen; and (ii) not having their therapeutic goals met; and (b) following that assessment: (i) refers the patient to a community pharmacy or an accredited pharmacist for the DMMR; and (ii) provides relevant clinical information required for the DMMR; and (c) discusses with the reviewing pharmacist the results of the DMMR including suggested medication management strategies; and (d) develops a written medication management plan following discussion with the patient; and (e) provides the written medication management plan to a community pharmacy chosen by the patient For any particular patient—applicable not more than once in each 12 month period, except if there has been a significant change in the patient's condition or medication regimen requiring a new DMMR (See para AN.0.52 of explanatory notes to this Category) **Benefit:** 100% = \$154.80 Fee: \$154.80 Extended Medicare Safety Net Cap: \$464.40 Participation by a general practitioner in a residential medication management review (RMMR) for a patient who is a permanent resident of a residential aged care facility-other than an RMMR for a resident in relation to whom, in the preceding 12 months, this item has applied, unless there has been a significant change in the resident's medical condition or medication management plan requiring a new RMMR (See para AN.0.52 of explanatory notes to this Category) **Benefit:** 100% = \$106.00 Fee: \$106.00 903 Extended Medicare Safety Net Cap: \$318.00 1. TAKING OF A CERVICAL SMEAR FROM AN A18. GENERAL PRACTITIONER ATTENDANCE **UNSCREENED OR SIGNIFICANTLY ASSOCIATED WITH PIP INCENTIVE PAYMENTS** UNDERSCREENED PERSON Group A18. General Practitioner Attendance Associated With Pip Incentive Payments Subgroup 1. Taking Of A Cervical Smear From An Unscreened Or Significantly Underscreened Person LEVEL A Professional attendance involving taking a short patient history and, if required, limited examination and management and at which a cervical screening test is taken from a person at least 24 years and 9 months of age but is less than 75 years of age, who has not had a cervical screening test in the last 4 years. Professional attendance at consulting rooms by a general practitioner:

(b) at which a specimen for a cervical screening service is collected from the patient;

2497

(a) involving taking a short patient history and, if required, limited examination and management; and

if the patient is at least 24 years and 9 months of age but is less than 75 years of age and has not been

1. TAKING OF A CERVICAL SMEAR FROM AN A18. GENERAL PRACTITIONER ATTENDANCE UNSCREENED OR SIGNIFICANTLY **ASSOCIATED WITH PIP INCENTIVE PAYMENTS UNDERSCREENED PERSON** provided with a cervical screening service or a cervical smear service in the last 4 years. (See para AN.0.53, AN.0.9 of explanatory notes to this Category) **Benefit:** 100% = \$16.95 Fee: \$16.95 **Extended Medicare Safety Net Cap: \$50.85** LEVEL B Professional attendance by a general practitioner (not being a service to which any other item in this table applies) lasting less than 20 minutes, including any of the following that are clinically relevant: taking a patient history: performing a clinical examination: b) arranging any necessary investigation; c) implementing a management plan; d) providing appropriate preventive health care; in relation to 1 or more health-related issues, with appropriate documentation and at which a cervical screening test is taken from a person at least 24 years and 9 months of age but is less than 75 years of age, who has not had a cervical screening test in the last 4 years. Professional attendance by a general practitioner at consulting rooms, lasting less than 20 minutes and including any of the following that are clinically relevant: (a) taking a patient history; (b) performing a clinical examination; (c) arranging any necessary investigation; (d) implementing a management plan; (e) providing appropriate preventive health care; for one or more health-related issues, with appropriate documentation, and at which a specimen for a cervical screening service is collected from the patient, if the patient is at least 24 years and 9 months of age but is less than 75 years of age and has not been provided with a cervical screening service or a cervical smear service in the last 4 years. (See para AN.0.53, AN.0.9 of explanatory notes to this Category) Fee: \$37.05 **Benefit:** 100% = \$37.052501 Extended Medicare Safety Net Cap: \$111.15 Professional attendance by a general practitioner at a place other than consulting rooms, lasting less than 20 minutes and including any of the following that are clinically relevant: (a) taking a patient history; (b) performing a clinical examination; (c) arranging any necessary investigation; (d) implementing a management plan; (e) providing appropriate preventive health care; for one or more health-related issues, with appropriate documentation, and at which a specimen for a cervical screening service is collected from the patient, if the patient is at least 24 years and 9 months of age but is less than 75 years of age and has not been provided with a cervical screening service or a 2503

	1. TAKING OF A CERVICAL SMEAR FROM AN NERAL PRACTITIONER ATTENDANCE UNSCREENED OR SIGNIFICANTLY ATED WITH PIP INCENTIVE PAYMENTS UNDERSCREENED PERSON
	cervical smear service in the last 4 years.
	(See para AN.0.53, AN.0.9 of explanatory notes to this Category) Derived Fee: The fee for item 2501, plus \$25.95 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 2501 plus \$2.00 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	LEVEL C Professional attendance by a general practitioner (not being a service to which any other item in this table applies) lasting at least 20 minutes, including any of the following that are clinically relevant: f) taking a detailed patient history; g) performing a clinical examination; h) arranging any necessary investigation; i) implementing a management plan; j) providing appropriate preventive health care; in relation to 1 or more health-related issues, with appropriate documentation
	and at which a cervical screening test is taken from a person at least 24 years and 9 months of age but is less than 75 years of age, who has not had a cervical screening test in the last 4 years.
	Professional attendance by a general practitioner at consulting rooms, lasting at least 20 minutes and including any of the following that are clinically relevant:
	(a) taking a detailed patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation, and at which a specimen for a cervical screening service is collected from the patient, if the patient is at least 24 years and 9 months of age but is less than 75 years of age and has not been provided with a cervical screening service or a cervical smear service in the last 4 years
2504	(See para AN.0.53, AN.0.9 of explanatory notes to this Category) Fee: \$71.70 Extended Medicare Safety Net Cap: \$215.10
	Professional attendance by a general practitioner at a place other than consulting rooms, lasting at least 20 minutes and including any of the following that are clinically relevant:
	(a) taking a detailed patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
2506	for one or more health-related issues, with appropriate documentation, and at which a specimen for a cervical screening service is collected from the patient, if the patient is at least 24 years and 9 months of

	1. TAKING OF A CERVICAL SMEAR FROM AN UNSCREENED OR SIGNIFICANTLY UNDERSCREENED PERSON
	age but is less than 75 years of age and has not been provided with a cervical screening service or a cervical smear service in the last 4 years
	(See para AN.0.53, AN.0.9 of explanatory notes to this Category) Derived Fee: The fee for item 2504, plus \$25.95 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 2504 plus \$2.00 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	LEVEL D Professional attendance by a general practitioner (not being a service to which any other item in this table applies) lasting at least 40 minutes, including any of the following that are clinically relevant: a) taking an extensive patient history; b) performing a clinical examination; c) arranging any necessary investigation; d) implementing a management plan; e) providing appropriate preventive health care; in relation to 1 or more health-related issues, with appropriate documentation
	and at which a cervical screening test is taken from a person at least 24 years and 9 months of age but is less than 75 years of age, who has not had a cervical screening test in the last 4 years.
	Professional attendance by a general practitioner at consulting rooms, lasting at least 40 minutes and including any of the following that are clinically relevant:
	(a) taking an extensive patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation, and at which a specimen for a cervical screening service is collected from the patient, if the patient is at least 24 years and 9 months of age but is less than 75 years of age and has not been provided with a cervical screening service or a cervical smear service in the last 4 years
2507	(See para AN.0.53, AN.0.9 of explanatory notes to this Category) Fee: \$105.55 Benefit: 100% = \$105.55 Extended Medicare Safety Net Cap: \$316.65
	Professional attendance by a general practitioner at a place other than consulting rooms, lasting at least 40 minutes and including any of the following that are clinically relevant:
	(a) taking an extensive patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
2509	for one or more health-related issues, with appropriate documentation, and at which a specimen for a

A18. GENERAL PRACTITIONER ATTENDANCE ASSOCIATED WITH PIP INCENTIVE PAYMENTS

1. TAKING OF A CERVICAL SMEAR FROM AN UNSCREENED OR SIGNIFICANTLY UNDERSCREENED PERSON

cervical screening service is collected from the patient, if the patient is at least 24 years and 9 months of age but is less than 75 years of age and has not been provided with a cervical screening service or a cervical smear service in the last 4 years

(See para AN.0.53, AN.0.9 of explanatory notes to this Category)

Derived Fee: The fee for item 2507, plus \$25.95 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 2507 plus \$2.00 per patient.

Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount

A18. GENERAL PRACTITIONER ATTENDANCE ASSOCIATED WITH PIP INCENTIVE PAYMENTS

2. COMPLETION OF A CYCLE OF CARE FOR PATIENTS WITH ESTABLISHED DIABETES MELLITUS

ASSOCI	ATED WITH PIP INCENTIVE PAYMENTS MELLITUS
	Group A18. General Practitioner Attendance Associated With Pip Incentive Payments
	Subgroup 2. Completion Of A Cycle Of Care For Patients With Established Diabetes Mellitus
	LEVEL B Professional attendance by a general practitioner (not being a service to which any other item in this table applies) lasting less than 20 minutes, including any of the following that are clinically relevant: a) taking a patient history; b) performing a clinical examination; c) arranging any necessary investigation; d) implementing a management plan; e) providing appropriate preventive health care; in relation to 1 or more health-related issues, with appropriate documentation
	AND which <u>completes</u> the minimum requirements of a cycle of care for a patient with established diabetes mellitus.
	Professional attendance by a general practitioner at consulting rooms, lasting less than 20 minutes and including any of the following that are clinically relevant:
	(a) taking a patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation, and completes the minimum requirements of a cycle of care for a patient with established diabetes mellitus
2517	(See para AN.0.9, AN.0.54 of explanatory notes to this Category) Fee: \$37.05 Benefit: 100% = \$37.05 Extended Medicare Safety Net Cap: \$111.15
	Professional attendance by a general practitioner at a place other than consulting rooms, lasting less than 20 minutes and including any of the following that are clinically relevant:
	(a) taking a patient history;
2518	(b) performing a clinical examination;

2. COMPLETION OF A CYCLE OF CARE FOR A18. GENERAL PRACTITIONER ATTENDANCE PATIENTS WITH ESTABLISHED DIABETES **ASSOCIATED WITH PIP INCENTIVE PAYMENTS** MELLITUS (c) arranging any necessary investigation; (d) implementing a management plan; (e) providing appropriate preventive health care; for one or more health-related issues, with appropriate documentation, and completes the minimum requirements of a cycle of care for a patient with established diabetes mellitus (See para AN.0.9, AN.0.54 of explanatory notes to this Category) **Derived Fee:** The fee for item 2517, plus \$25.95 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 2517 plus \$2.00 per patient. **Extended Medicare Safety Net Cap:** 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount LEVEL C Professional attendance by a general practitioner (not being a service to which any other item in this table applies) lasting at least 20 minutes, including any of the following that are clinically relevant: taking a detailed patient history; performing a clinical examination; b) arranging any necessary investigation; C) d) implementing a management plan; providing appropriate preventive health care; e) in relation to 1 or more health-related issues, with appropriate documentation AND which completes the minimum requirements of a cycle of care for a patient with established diabetes mellitus. Professional attendance by a general practitioner at consulting rooms, lasting at least 20 minutes and including any of the following that are clinically relevant: (a) taking a detailed patient history; (b) performing a clinical examination; (c) arranging any necessary investigation; (d) implementing a management plan; (e) providing appropriate preventive health care; for one or more health-related issues, with appropriate documentation, and that completes the minimum requirements of a cycle of care for a patient with established diabetes mellitus (See para AN.0.9, AN.0.54 of explanatory notes to this Category) Fee: \$71.70 **Benefit:** 100% = \$71.702521 Extended Medicare Safety Net Cap: \$215.10 Professional attendance by a general practitioner at a place other than consulting rooms, lasting at least 20 minutes and including any of the following that are clinically relevant: (a) taking a detailed patient history; (b) performing a clinical examination; (c) arranging any necessary investigation; 2522

2. COMPLETION OF A CYCLE OF CARE FOR A18. GENERAL PRACTITIONER ATTENDANCE PATIENTS WITH ESTABLISHED DIABETES **ASSOCIATED WITH PIP INCENTIVE PAYMENTS MELLITUS** (d) implementing a management plan; (e) providing appropriate preventive health care; for one or more health-related issues, with appropriate documentation, and that completes the minimum requirements of a cycle of care for a patient with established diabetes mellitus (See para AN.0.9, AN.0.54 of explanatory notes to this Category) **Derived Fee:** The fee for item 2521, plus \$25.95 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for 2521 plus \$2.00 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount I FVFI D Professional attendance by a general practitioner (not being a service to which any other item in this table applies) lasting at least 40 minutes, including any of the following that are clinically relevant: taking an extensive patient history: performing a clinical examination; b) arranging any necessary investigation; c) implementing a management plan; d) providing appropriate preventive health care; in relation to 1 or more health-related issues, with appropriate documentation AND which completes the minimum requirements of a cycle of care for a patient with established diabetes mellitus. Professional attendance by a general practitioner at consulting rooms, lasting at least 40 minutes and including any of the following that are clinically relevant: (a) taking an extensive patient history; (b) performing a clinical examination; (c) arranging any necessary investigation; (d) implementing a management plan; (e) providing appropriate preventive health care; for one or more health-related issues, with appropriate documentation, and that completes the minimum requirements of a cycle of care for a patient with established diabetes mellitus (See para AN.0.9, AN.0.54 of explanatory notes to this Category) Fee: \$105.55 **Benefit:** 100% = \$105.552525 Extended Medicare Safety Net Cap: \$316.65 Professional attendance by a general practitioner at a place other than consulting rooms, lasting at least 40 minutes and including any of the following that are clinically relevant: (a) taking an extensive patient history; (b) performing a clinical examination; (c) arranging any necessary investigation; (d) implementing a management plan; 2526

2. COMPLETION OF A CYCLE OF CARE FOR A18. GENERAL PRACTITIONER ATTENDANCE PATIENTS WITH ESTABLISHED DIABETES **ASSOCIATED WITH PIP INCENTIVE PAYMENTS MELLITUS** (e) providing appropriate preventive health care; for one or more health-related issues, with appropriate documentation, and that completes the minimum requirements of a cycle of care for a patient with established diabetes mellitus (See para AN.0.54 of explanatory notes to this Category) **Derived Fee:** The fee for item 2525, plus \$25.95 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for 2525 plus \$2.00 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount A18. GENERAL PRACTITIONER ATTENDANCE 3. COMPLETION OF THE ASTHMA CYCLE OF **ASSOCIATED WITH PIP INCENTIVE PAYMENTS CARE** Group A18. General Practitioner Attendance Associated With Pip Incentive Payments Subgroup 3. Completion Of The Asthma Cycle Of Care LEVEL B Professional attendance by a general practitioner (not being a service to which any other item in this table applies) lasting less than 20 minutes, including any of the following that are clinically relevant: taking a patient history: performing a clinical examination; arranging any necessary investigation; c) implementing a management plan: d) providing appropriate preventive health care; in relation to 1 or more health-related issues, with appropriate documentation AND which completes the minimum requirements of the Asthma Cycle of Care. Professional attendance by a general practitioner at consulting rooms, lasting less than 20 minutes and including any of the following that are clinically relevant: (a) taking a patient history; (b) performing a clinical examination; (c) arranging any necessary investigation; (d) implementing a management plan; (e) providing appropriate preventive health care; for one or more health-related issues, with appropriate documentation, and that completes the minimum requirements of the Asthma Cycle of Care (See para AN.0.55, AN.0.9 of explanatory notes to this Category) **Benefit:** 100% = \$37.05Fee: \$37.05 2546 Extended Medicare Safety Net Cap: \$111.15 Professional attendance by a general practitioner at a place other than consulting rooms, lasting less than 20 minutes and including any of the following that are clinically relevant: (a) taking a patient history;

(b) performing a clinical examination;

2547

(c) arranging any necessary investigation;

	NERAL PRACTITIONER ATTENDANCE ATED WITH PIP INCENTIVE PAYMENTS 3. COMPLETION OF THE ASTHMA CYCLE OF CARE
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation, and that completes the minimum requirements of the Asthma Cycle of Care
	(See para AN.0.55, AN.0.9 of explanatory notes to this Category) Derived Fee: The fee for item 2546, plus \$25.95 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 2546 plus \$2.00 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	LEVEL C Professional attendance by a general practitioner (not being a service to which any other item in this table applies) lasting at least 20 minutes, including any of the following that are clinically relevant: a) taking a detailed patient history; b) performing a clinical examination; c) arranging any necessary investigation; d) implementing a management plan; e) providing appropriate preventive health care; in relation to 1 or more health-related issues, with appropriate documentation
	AND which <u>completes</u> the minimum requirements of the Asthma Cycle of Care.
	Professional attendance by a general practitioner at consulting rooms, lasting at least 20 minutes and including any of the following that are clinically relevant:
	(a) taking a detailed patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation, and that completes the minimum requirements of the Asthma Cycle of Care
2552	(See para AN.0.55, AN.0.9 of explanatory notes to this Category) Fee: \$71.70 Benefit: 100% = \$71.70 Extended Medicare Safety Net Cap: \$215.10
2002	Professional attendance by a general practitioner at a place other than consulting rooms, lasting at least 20 minutes and including any of the following that are clinically relevant:
	(a) taking a detailed patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
2553	for one or more health-related issues, with appropriate documentation, and that completes the minimum

	NERAL PRACTITIONER ATTENDANCE 3. COMPLETION OF THE ASTHMA CYCLE OF ATED WITH PIP INCENTIVE PAYMENTS CARE
	requirements of the Asthma Cycle of Care
	(See para AN.0.55 of explanatory notes to this Category) Derived Fee: The fee for item 2552, plus \$25.95 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 2552 plus \$2.00 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	LEVEL D Professional attendance by a general practitioner (not being a service to which any other item in this table applies) lasting at least 40 minutes, including any of the following that are clinically relevant: a) taking an extensive patient history; b) performing a clinical examination; c) arranging any necessary investigation; d) implementing a management plan; e) providing appropriate preventive health care; in relation to 1 or more health-related issues, with appropriate documentation
	AND which <u>completes</u> the minimum requirements of the Asthma Cycle of Care.
	Professional attendance by a general practitioner at consulting rooms, lasting at least 40 minutes and including any of the following that are clinically relevant:
	(a) taking an extensive patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation, and that completes the minimum requirements of the Asthma Cycle of Care
2558	(See para AN.0.55, AN.0.9 of explanatory notes to this Category) Fee: \$105.55 Benefit: 100% = \$105.55 Extended Medicare Safety Net Cap: \$316.65
2330	Professional attendance by a general practitioner at a place other than consulting rooms, lasting at least 40 minutes and including any of the following that are clinically relevant:
	(a) taking an extensive patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation, and that completes the minimum requirements of the Asthma Cycle of Care
2559	(See para AN.0.55, AN.0.9 of explanatory notes to this Category) Derived Fee: The fee for item 2558, plus \$25.95 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 2558 plus \$2.00 per patient.

	GENERAL PRACTITIONER ATTENDANCE 3. COMPLE CIATED WITH PIP INCENTIVE PAYMENTS	ETION OF THE ASTHMA CYCLE OF CARE
	Extended Medicare Safety Net Cap: 300% of the Derived fee fo lesser amount	r this item, or \$500.00, whichever is the
ASSOC		OF A CERVICAL SMEAR FROM AN UNSCREENED OR SIGNIFICANTLY UNDERSCREENED PERSON
	Group A19. Other Non-Referred Attendances Associated William No Other Item Applies	ith Pip Incentive Payments To Which
	Subgroup 1. Taking Of A Cervical Smear From An Unscreene	ed Or Significantly Underscreened Persor
	Professional attendance at consulting rooms of less than 5 minu who practices in general practice (other than a general practition screening service is collected from the patient, if the patient is a is less than 75 years of age and has not been provided with a cersmear service in the last 4 years	ner) at which a specimen for a cervical t least 24 years and 9 months of age but
	(See para AN.0.53 of explanatory notes to this Category) Fee: \$11.00 Benefit: 100% = \$11.00	
2598	Extended Medicare Safety Net Cap: \$33.00 Professional attendance at consulting rooms of more than 5, but a medical practitioner who practises in general practice (other the specimen for a cervical screening service is collected from the pand 9 months of age but is less than 75 years of age and has not service or a cervical smear service in the last 4 years	nan a general practitioner), at which a patient, if the patient is at least 24 years
	(See para AN.0.53 of explanatory notes to this Category) Fee: \$21.00 Benefit: 100% = \$21.00	
2600	Extended Medicare Safety Net Cap: \$63.00	
	Professional attendance at consulting rooms of more than 25 mi duration by a medical practitioner who practises in general prac which a specimen for a cervical screening service is collected fr 24 years and 9 months of age but is less than 75 years of age an screening service or a cervical smear service in the last 4 years	tice (other than a general practitioner), at com the patient, if the patient is at least
	(See para AN.0.53 of explanatory notes to this Category) Fee: \$38.00 Benefit: 100% = \$38.00	
2603	Extended Medicare Safety Net Cap: \$114.00 Professional attendance at consulting rooms of more than 45 mi practitioner who practises in general practice (other than a gene a cervical screening service is collected from the patient, if the pof age but is less than 75 years of age and has not been provided cervical smear service in the last 4 years	ral practitioner), at which a specimen for patient is at least 24 years and 9 months
2606	(See para AN.0.53 of explanatory notes to this Category) Fee: \$61.00 Benefit: 100% = \$61.00 Extended Medicare Safety Net Cap: \$183.00	
2000	Professional attendance at a place other than consulting rooms of than 25 minutes in duration by a medical practitioner who pract general practitioner), at which a specimen for a cervical screening the patient is at least 24 years and 9 months of age but is less that provided with a cervical screening service or a cervical smear service.	ises in general practice (other than a ng service is collected from the patient, i an 75 years of age and has not been

ASSOC	THER NON-REFERRED ATTENDANCES 1. TAKING OF A CERVICAL SMEAR FROM AN IATED WITH PIP INCENTIVE PAYMENTS UNSCREENED OR SIGNIFICANTLY CH NO OTHER ITEM APPLIES UNDERSCREENED PERSON
	Derived Fee: An amount equal to \$16.00, plus \$17.50 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - an amount equal to \$16.00 plus \$0.70 per patient
	Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	Professional attendance at a place other than consulting rooms of more than 25 minutes, but not more than 45 minutes in duration by a medical practitioner who practises in general practice (other than a general practitioner), at which a specimen for a cervical screening service is collected from the patient, if the patient is at least 24 years and 9 months of age but is less than 75 years of age and has not been provided with a cervical screening service or a cervical smear service in the last 4 years
2613	(See para AN.0.53 of explanatory notes to this Category) Derived Fee: An amount equal to \$35.50, plus \$15.50 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - an amount equal to \$35.50 plus \$0.70 per patient Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	Professional attendance at a place other than consulting rooms of more than 45 minutes in duration by a medical practitioner who practises in general practice (other than a general practitioner), at which a
	specimen for a cervical screening service is collected from the patient, if the patient is at least 24 years and 9 months of age but is less than 75 years of age and has not been provided with a cervical screening service or a cervical smear service in the last 4 years
2616	(See para AN.0.53 of explanatory notes to this Category) Derived Fee: An amount equal to \$57.50, plus \$15.50 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - an amount equal to \$57.50 plus \$0.70 per patient Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
A19. O1 ASSOC	THER NON-REFERRED ATTENDANCES IATED WITH PIP INCENTIVE PAYMENTS CH NO OTHER ITEM APPLIES 2. COMPLETION OF AN ANNUAL CYCLE OF CARE FOR PATIENTS WITH ESTABLISHED DIABETES MELLITUS
	Group A19. Other Non-Referred Attendances Associated With Pip Incentive Payments To Which No Other Item Applies
	Subgroup 2. Completion Of An Annual Cycle Of Care For Patients With Established Diabetes Mellitus
	Professional attendance at consulting rooms of more than 5 minutes, but not more than 25 minutes in duration by a medical practitioner who practises in general practice (other than a general practitioner), that completes the minimum requirements for a cycle of care of a patient with established diabetes mellitus
2(20	(See para AN.0.54 of explanatory notes to this Category) Fee: \$21.00 Benefit: 100% = \$21.00 Extended Medicare Sefety Not Cons \$63.00
2620	Extended Medicare Safety Net Cap: \$63.00 Professional attendance at consulting rooms of more than 25 minutes, but not more than 45 minutes in duration by a medical practitioner who practises in general practice (other than a general practitioner), that completes the requirements for a cycle of care of a patient with established diabetes mellitus
	(See para AN.0.54 of explanatory notes to this Category) Fee: \$38.00 Benefit: 100% = \$38.00
2622	Extended Medicare Safety Net Cap: \$114.00

ASSOCIA	HER NON-REFERRED ATTENDANCES ATED WITH PIP INCENTIVE PAYMENTS CH NO OTHER ITEM APPLIES 2. COMPLETION OF AN ANNUAL CYCLE OF CARE FOR PATIENTS WITH ESTABLISHED DIABETES MELLITUS
	practitioner who practises in general practice (other than a general practitioner), that completes the minimum requirements for a cycle of care of a patient with established diabetes mellitus
	(See para AN.0.54 of explanatory notes to this Category) Fee: \$61.00 Benefit: 100% = \$61.00
	Extended Medicare Safety Net Cap: \$183.00
	Professional attendance at a place other than consulting rooms of more than 5 minutes, but not more than 25 minutes in duration by a medical practitioner who practises in general practice (other than a general practitioner), that completes the minimum requirements for a cycle of care of a patient with established diabetes mellitus
2631	(See para AN.0.54 of explanatory notes to this Category) Derived Fee: An amount equal to \$16.00, plus \$17.50 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - an amount equal to \$16.00 plus \$0.70 per patient Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	Professional attendance at a place other than consulting rooms of more than 25 minutes but not more than 45 minutes, in duration by a medical practitioner who practises in general practice (other than a general practitioner), that completes the minimum requirements for a cycle of care of a patient with established diabetes mellitus
2633	(See para AN.0.54 of explanatory notes to this Category) Derived Fee: An amount equal to \$35.50, plus \$15.50 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - an amount equal to \$35.50 plus \$0.70 per patient Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	Professional attendance at a place other than consulting rooms of more than 45 minutes in duration by a medical practitioner who practises in general practice (other than a general practitioner), that completes the minimum requirements for a cycle of care of a patient with established diabetes mellitus
2635	(See para AN.0.54 of explanatory notes to this Category) Derived Fee: An amount equal to \$57.50, plus \$15.50 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - an amount equal to \$57.50 plus \$0.70 per patient Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
A19. OTH	HER NON-REFERRED ATTENDANCES ATED WITH PIP INCENTIVE PAYMENTS CH NO OTHER ITEM APPLIES CARE
	Group A19. Other Non-Referred Attendances Associated With Pip Incentive Payments To Which No Other Item Applies
	Subgroup 3. Completion Of The Asthma Cycle Of Care
	Professional attendance at consulting rooms of more than 5 minutes, but not more than 25 minutes in duration by a medical practitioner who practises in general practice (other than a general practitioner), that completes the minimum requirements of the Asthma Cycle of Care
2664	(See para AN.0.55 of explanatory notes to this Category) Fee: \$21.00 Benefit: 100% = \$21.00 Extended Medicare Safety Net Cap: \$63.00
2666	* *

ASSOC	THER NON-REFERRED ATTENDANCES IATED WITH PIP INCENTIVE PAYMENTS 3. COMPLETION OF THE ASTHMA CYCLE OF ICH NO OTHER ITEM APPLIES CARE
	Professional attendance at consulting rooms of more than 25 minutes, but not more than 45 minutes in duration by a medical practitioner who practises in general practice (other than a general practitioner), that completes the minimum requirements of the Asthma Cycle of Care
	(See para AN.0.55 of explanatory notes to this Category) Fee: \$38.00 Benefit: 100% = \$38.00 Extended Medicare Safety Net Cap: \$114.00
	Professional attendance at consulting rooms of more than 45 minutes in duration by a medical practitioner who practises in general practice (other than a general practitioner), that completes the minimum requirements of the Asthma Cycle of Care
	(See para AN.0.55 of explanatory notes to this Category) Fee: \$61.00 Benefit: 100% = \$61.00
2668	Extended Medicare Safety Net Cap: \$183.00 Professional attendance at a place other than consulting rooms of more than 5 minutes, but not more than 25 minutes in duration by a medical practitioner who practises in general practice (other than a general practitioner), that completes the minimum requirements of the Asthma Cycle of Care
2673	(See para AN.0.55 of explanatory notes to this Category) Derived Fee: An amount equal to \$16.00, plus \$17.50 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - an amount equal to \$16.00 plus \$0.70 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	Professional attendance at a place other than consulting rooms of more than 25 minutes, but not more than 45 minutes in duration by a medical practitioner who practises in general practice (other than a general practitioner), that completes the minimum requirements of the Asthma Cycle of Care
2675	(See para AN.0.55 of explanatory notes to this Category) Derived Fee: An amount equal to \$35.50, plus \$15.50 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - an amount equal to \$35.50 plus \$0.70 per patient Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	Professional attendance at a place other than consulting rooms of more than 45 minutes in duration by a medical practitioner who practises in general practice (other than a general practitioner), that completes the minimum requirements of the Asthma Cycle of Care
2677	(See para AN.0.55 of explanatory notes to this Category) Derived Fee: An amount equal to \$57.50, plus \$15.50 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - an amount equal to \$57.50 plus \$0.70 per patient Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	P MENTAL HEALTH TREATMENT 1. GP MENTAL HEALTH TREATMENT PLANS
	Group A20. GP Mental Health Treatment
	Subgroup 1. GP Mental Health Treatment Plans
2700	Professional attendance by a general practitioner (including a general practitioner who has not undertaken mental health skills training) of at least 20 minutes but less than 40 minutes in duration for

A20. G	MENTAL HEALTH TREATMENT 1. GP MENTAL HEALTH TREATMENT PLANS
	the preparation of a GP mental health treatment plan for a patient
	(See many ANI 0.5% of similar standards to this Cotagon)
	(See para AN.0.56 of explanatory notes to this Category) Fee: \$71.70 Benefit: 75% = \$53.80 100% = \$71.70
	Extended Medicare Safety Net Cap: \$215.10
	Professional attendance by a general practitioner (including a general practitioner who has not undertaken mental health skills training) of at least 40 minutes in duration for the preparation of a GP mental health treatment plan for a patient
	(See para AN.0.56 of explanatory notes to this Category) Fee: \$105.55 Benefit: 75% = \$79.20 100% = \$105.55
2701	Extended Medicare Safety Net Cap: \$316.65
	Professional attendance by a general practitioner to review a GP mental health treatment plan which he
	or she, or an associated general practitioner has prepared, or to review a Psychiatrist Assessment and Management Plan
	(See para AN.0.56 of explanatory notes to this Category)
	Fee: \$71.70 Benefit: 75% = \$53.80 100% = \$71.70
2712	Extended Medicare Safety Net Cap: \$215.10
	Professional attendance by a general practitioner in relation to a mental disorder and of at least 20
	minutes in duration, involving taking relevant history and identifying the presenting problem (to the
	extent not previously recorded), providing treatment and advice and, if appropriate, referral for other services or treatments, and documenting the outcomes of the consultation
	(See para AN.0.56 of explanatory notes to this Category)
	Fee: \$71.70 Benefit: 100% = \$71.70
2713	Extended Medicare Safety Net Cap: \$215.10
	Professional attendance by a general practitioner (including a general practitioner who has undertaken mental health skills training of at least 20 minutes but less than 40 minutes in duration for the preparation of a GP mental health treatment plan for a patient
	(See para AN.0.56 of explanatory notes to this Category) Fee: \$91.05 Benefit: 75% = \$68.30 100% = \$91.05
2715	Extended Medicare Safety Net Cap: \$273.15
	Professional attendance by a general practitioner (including a general practitioner who has undertaken mental health skills training) of at least 40 minutes in duration for the preparation of a GP mental health treatment plan for a patient
	(See para AN.0.56 of explanatory notes to this Category)
	Fee: \$134.10 Benefit: $75\% = $100.60 \ 100\% = 134.10
2717	Extended Medicare Safety Net Cap: \$402.30
A20. G	P MENTAL HEALTH TREATMENT 2. FOCUSSED PSYCHOLOGICAL STRATEGIES
	Group A20. GP Mental Health Treatment
	Subgroup 2. Focussed Psychological Strategies
	Professional attendance at consulting rooms by a general practitioner, for providing focussed
	psychological strategies for assessed mental disorders by a general practitioner registered with the Chief Executive Medicare as meeting the credentialling requirements for provision of this service, and lasting at least 30 minutes, but less than 40 minutes
	(See para AN.0.57 of explanatory notes to this Category)
	Fee: \$92.75 Benefit: 100% = \$92.75
2721	Extended Medicare Safety Net Cap: \$278.25
2723	Professional attendance at a place other than consulting rooms by a general practitioner, for providing focussed psychological strategies for assessed mental disorders by a general practitioner registered with

A20. GP	MENTAL HEALTH TREATMENT 2. FOCUSSED PSYCHOLOGICAL STRATEGIES
	the Chief Executive Medicare as meeting the credentialling requirements for provision of this service, and lasting at least 30 minutes, but less than 40 minutes
	(See para AN.0.57 of explanatory notes to this Category) Derived Fee: The fee for item 2721, plus \$25.95 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 2721 plus \$2.00 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	Professional attendance at consulting rooms by a general practitioner, for providing focussed psychological strategies for assessed mental disorders by a general practitioner registered with the Chief Executive Medicare as meeting the credentialling requirements for provision of this service, and lasting at least 40 minutes
2725	(See para AN.0.57 of explanatory notes to this Category) Fee: \$132.75 Benefit: 100% = \$132.75 Extended Medicare Safety Net Cap: \$398.25
	Professional attendance at a place other than consulting rooms by a general practitioner, for providing focussed psychological strategies for assessed mental disorders by a general practitioner registered with the Chief Executive Medicare as meeting the credentialling requirements for provision of this service, and lasting at least 40 minutes
2727	(See para AN.0.57 of explanatory notes to this Category) Derived Fee: The fee for item 2725, plus \$25.95 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 2725 plus \$2.00 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	Professional attendance at consulting rooms by a general practitioner, for the purpose of providing focussed psychological strategies for assessed mental disorders by a general practitioner registered with the Chief Executive Medicare as meeting the credentialing requirements for provision of this service, and lasting at least 30 minutes, but less than 40 minutes if:
	(a) the attendance is by video conference; and
	(b) the patient is not an admitted patient; and
	(c) the patient is located within a telehealth eligible area; and
	(d) the patient is, at the time of the attendance, at least 15 kilometres by road from the general practitioner.
2729	(See para AN.0.57 of explanatory notes to this Category) Fee: \$92.75 Benefit: 100% = \$92.75 Extended Medicare Safety Net Cap: \$278.25
	Professional attendance at consulting rooms by a general practitioner, for the purpose of providing focussed psychological strategies for assessed mental disorders by a general practitioner registered with the Chief Executive Medicare as meeting the credentialing requirements for provision of this service, and lasting at least 40 minutes if:
	(a) the attendance is by video conference; and
	(b) the patient is not an admitted patient; and
	(c) the patient is located within a telehealth eligible area; and
2731	(d) the patient is, at the time of the attendance, at least 15 kilometres by road from the general practitioner

A20. G	P MENTAL HEALTH TREATMENT 2. FOCUSSED PSYCHOLOGICAL STRATEGIES
	(See para AN.0.57 of explanatory notes to this Category)
	Fee: \$132.75
A21. M	EDICAL PRACTITIONER (EMERGENCY
PHYSIC	CIAN) ATTENDANCES TO WHICH NO
OTHER	R ITEM APPLIES 1. CONSULTATIONS
	Group A21. Medical Practitioner (Emergency Physician) Attendances To Which No Other Item Applies
	Subgroup 1. Consultations
	Professional attendance at a recognised emergency department of a private hospital by a specialist in the practice of his or her specialty of emergency medicine-attendance for the unscheduled evaluation and management of a patient, involving straightforward medical decision making that requires:
	(a) taking a problem focussed history; and
	(b) limited examination; and
	(c) diagnosis; and
	(d) initiation of appropriate treatment interventions
501	(See para AN.0.60 of explanatory notes to this Category) Fee: \$34.70 Benefit: 75% = \$26.05 85% = \$29.50 Extended Medicare Safety Net Cap: \$104.10
	Professional attendance at a recognised emergency department of a private hospital by a specialist in the practice of his or her specialty of emergency medicine-attendance for the unscheduled evaluation and management of a patient, involving medical decision making of low complexity that requires:
	(a) taking an expanded problem focussed history; and
	(b) expanded examination of one or more systems; and
	(c) formulation and documentation of a diagnosis and management plan in relation to one or more problems; and
	(d) initiation of appropriate treatment interventions
503	(See para AN.0.60 of explanatory notes to this Category) Fee: \$58.65 Benefit: 75% = \$44.00 85% = \$49.90 Extended Medicare Safety Net Cap: \$175.95
	Professional attendance at a recognised emergency department of a private hospital by a specialist in the practice of his or her specialty of emergency medicine-attendance for the unscheduled evaluation and management of a patient, involving medical decision making of moderate complexity that requires:
	(a) taking an expanded problem focussed history; and
	(b) expanded examination of one or more systems; and
	(c) ordering and evaluation of appropriate investigations; and
	(d) formulation and documentation of a diagnosis and management plan in relation to one or more problems; and
507	(e) initiation of appropriate treatment interventions

A21. MEI	DICAL PRACTITIONER (EMERGENCY
PHYSICI	AN) ATTENDANCES TO WHICH NO
OTHER I	TEM APPLIES 1. CONSULTATIONS
	(See para AN.0.60 of explanatory notes to this Category) Fee: \$98.50 Benefit: 75% = \$73.90 85% = \$83.75
	Extended Medicare Safety Net Cap: \$295.50
	Professional attendance at a recognised emergency department of a private hospital by a specialist in the practice of his or her specialty of emergency medicine-attendance for the unscheduled evaluation and management of a patient, involving medical decision making of moderate complexity that requires:
	(a) taking a detailed history; and
	(b) detailed examination of one or more systems; and
	(c) ordering and evaluation of appropriate investigations; and
	(d) formulation and documentation of a diagnosis and management plan in relation to one or more problems; and
	(e) initiation of appropriate treatment interventions; and
	(f) liaison with relevant health care professionals and discussion with, as appropriate, the patient or the patient's relatives or agent
511	(See para AN.0.60 of explanatory notes to this Category) Fee: \$139.35 Benefit: 75% = \$104.55 85% = \$118.45 Extended Medicare Safety Net Cap: \$418.05
	Professional attendance at a recognised emergency department of a private hospital by a specialist in the practice of his or her specialty of emergency medicine-attendance for the unscheduled evaluation and management of a patient, involving medical decision making of high complexity that requires:
	(a) taking a comprehensive history; and
	(b) comprehensive examination of one or more systems; and
	(c) ordering and evaluation of appropriate investigations; and
	(d) formulation and documentation of a diagnosis and management plan in relation to one or more problems; and
	(e) initiation of appropriate treatment interventions; and
	(f) liaison with relevant health care professionals and discussion with, as appropriate, the patient or the patient's relatives or agent
515	(See para AN.0.60 of explanatory notes to this Category) Fee: \$215.80 Benefit: 75% = \$161.85 85% = \$183.45
515 A21 MEI	Extended Medicare Safety Net Cap: \$500.00 DICAL PRACTITIONER (EMERGENCY 2. PROLONGED PROFESSIONAL
PHYSICI	AN) ATTENDANCES TO WHICH NO ATTENDANCES TO WHICH NO OTHER GROUP TEM APPLIES APPLIES
	Group A21. Medical Practitioner (Emergency Physician) Attendances To Which No Other Item Applies
	Subgroup 2. Prolonged Professional Attendances To Which No Other Group Applies
519	Professional attendance at a recognised emergency department of a private hospital by a specialist in the practice of his or her specialty of emergency medicine-attendance for a total period (whether or not
217	product of the opening of emergency medicine attendance for a total period (whether of not

PHYSICI	DICAL PRACTITIONER (EMERGENCY AN) ATTENDANCES TO WHICH NO TEM APPLIES 2. PROLONGED PROFESSIONAL ATTENDANCES TO WHICH NO OTHER GROUP APPLIES
	continuous) of at least 30 minutes but less than 1 hour (before the patient's admission to an in-patient hospital bed) for emergency evaluation of a critically ill patient with an immediately life threatening problem
	(See para AN.0.61 of explanatory notes to this Category) Fee: \$148.40 Benefit: 75% = \$111.30 85% = \$126.15 Extended Medicare Safety Net Cap: \$445.20
	Professional attendance at a recognised emergency department of a private hospital by a specialist in the practice of his or her specialty of emergency medicine-attendance for a total period (whether or not continuous) of at least 1 hour but less than 2 hours (before the patient's admission to an in-patient hospital bed) for emergency evaluation of a critically ill patient with an immediately life threatening problem
520	(See para AN.0.61 of explanatory notes to this Category) Fee: \$285.05 Benefit: 75% = \$213.80 85% = \$242.30 Extended Medicare Safety Net Cap: \$500.00
320	Professional attendance at a recognised emergency department of a private hospital by a specialist in the practice of his or her specialty of emergency medicine-attendance for a total period (whether or not continuous) of at least 2 hours but less than 3 hours (before the patient's admission to an in-patient hospital bed) for emergency evaluation of a critically ill patient with an immediately life threatening problem
	(See para AN.0.61 of explanatory notes to this Category) Fee: \$467.20 Benefit: 75% = \$350.40 85% = \$397.15
530	Extended Medicare Safety Net Cap: \$500.00
	Professional attendance at a recognised emergency department of a private hospital by a specialist in the practice of his or her specialty of emergency medicine-attendance for a total period (whether or not continuous) of at least 3 hours but less than 4 hours (before the patient's admission to an in-patient hospital bed) for emergency evaluation of a critically ill patient with an immediately life threatening problem
532	(See para AN.0.61 of explanatory notes to this Category) Fee: \$649.35 Benefit: 75% = \$487.05 Extended Medicare Safety Net Cap: \$500.00
	Professional attendance at a recognised emergency department of a private hospital by a specialist in the practice of his or her specialty of emergency medicine-attendance for a total period (whether or not continuous) of at least 4 hours but less than 5 hours (before the patient's admission to an in-patient hospital bed) for emergency evaluation of a critically ill patient with an immediately life threatening problem
	(See para AN.0.61 of explanatory notes to this Category) Fee: \$831.65 Benefit: 75% = \$623.75 85% = \$748.25
534	Extended Medicare Safety Net Cap: \$500.00 Professional attendance at a recognized emergency department of a private hospital by a specialist in the
	Professional attendance at a recognised emergency department of a private hospital by a specialist in the practice of his or her specialty of emergency medicine-attendance for a total period (whether or not continuous) of at least 5 hours (before the patient's admission to an in-patient hospital bed) for emergency evaluation of a critically ill patient with an immediately life threatening problem
	(See para AN.0.61 of explanatory notes to this Category) Fee: \$922.75 Benefit: 75% = \$692.10 85% = \$839.35
536	Extended Medicare Safety Net Cap: \$500.00

ATTEN	A22. GENERAL PRACTITIONER AFTER-HOURS ATTENDANCES TO WHICH NO OTHER ITEM APPLIES	
	Group A22. General Practitioner After-Hours Attendances To Which No Other Item Applies	
	LEVEL A Professional attendance by a general practitioner for an obvious problem characterised by the straightforward nature of the task that requires a short patient history and, if required, limited examination and management.	
	Professional attendance at consulting rooms (other than a service to which another item applies) by a general practitioner for an obvious problem characterised by the straightforward nature of the task that requires a short patient history and, if required, limited examination and management-each attendance	
	(See para AN.0.19, AN.0.9 of explanatory notes to this Category) Fee: \$29.00 Benefit: 100% = \$29.00	
5000	Extended Medicare Safety Net Cap: \$87.00 Professional attendance by a general practitioner (other than attendance at consulting rooms, a hospital or a residential aged care facility or a service to which another item in the table applies) that requires a short patient history and, if necessary, limited examination and management-an attendance on one or more patients on one occasion-each patient	
	(See para AN.0.19, AN.0.11, AN.0.9 of explanatory notes to this Category) Derived Fee: The fee for item 5000, plus \$25.95 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 5000 plus \$2.00 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the	
5003	Professional attendance (other than a service to which another item applies) at a residential aged care facility (other than a professional attendance at a self-contained unit) or professional attendance at consulting rooms situated within such a complex, if the patient is accommodated in a residential aged care facility (other than accommodation in a self-contained unit) by a general practitioner for an obvious problem characterised by the straightforward nature of the task that requires a short patient history and, if required, limited examination and management-an attendance on one or more patients at one residential aged care facility on one occasion-each patient	
	(See para AN.0.19, AN.0.15, AN.0.9 of explanatory notes to this Category) Derived Fee: The fee for item 5000, plus \$46.70 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 5000 plus \$3.30 per patient.	
5010	Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount	
3010	LEVEL B Professional attendance by a general practitioner (not being a service to which any other item in this table applies) lasting less than 20 minutes, including any of the following that are clinically relevant: a) taking a patient history; b) performing a clinical examination; c) arranging any necessary investigation; d) implementing a management plan; e) providing appropriate preventive health care; in relation to 1 or more health-related issues, with appropriate documentation.	
	Professional attendance by a general practitioner at consulting rooms (other than a service to which another item in the table applies), lasting less than 20 minutes and including any of the following that are clinically relevant:	
5020	(a) taking a patient history;	

	NERAL PRACTITIONER AFTER-HOURS ANCES TO WHICH NO OTHER ITEM
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation-each attendance
	(See para AN.0.19, AN.0.9 of explanatory notes to this Category) Fee: \$49.00 Benefit: 100% = \$49.00 Extended Medicare Safety Net Cap: \$147.00
	Professional attendance by a general practitioner (other than attendance at consulting rooms, a hospital or a residential aged care facility or a service to which another item in the table applies), lasting less than 20 minutes and including any of the following that are clinically relevant:
	(a) taking a patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation-an attendance on one or more patients on one occasion-each patient
5023	(See para AN.0.19, AN.0.11, AN.0.9 of explanatory notes to this Category) Derived Fee: The fee for item 5020, plus \$25.95 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 5020 plus \$2.00 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	Professional attendance by a general practitioner (other than a service to which another item in the table applies), at a residential aged care facility to residents of the facility, lasting less than 20 minutes and including any of the following that are clinically relevant:
	(a) taking a patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation-an attendance on one or more patients at one residential aged care facility on one occasion-each patient
5028	(See para AN.0.19, AN.0.15, AN.0.9 of explanatory notes to this Category) Derived Fee: The fee for item 5020, plus \$46.70 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 5020 plus \$3.30 per patient.

A22. GE	NERAL PRACTITIONER AFTER-HOURS
ATTENE APPLIES	DANCES TO WHICH NO OTHER ITEM S
741 - 1124	Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the
	lesser amount LEVEL C
	Professional attendance by a general practitioner (not being a service to which any other item in this table applies) lasting at least 20 minutes, including any of the following that are clinically relevant: a) taking a detailed patient history; b) performing a clinical examination; c) arranging any necessary investigation; d) implementing a management plan; e) providing appropriate preventive health care; in relation to 1 or more health-related issues, with appropriate documentation.
	Professional attendance by a general practitioner at consulting rooms (other than a service to which another item in the table applies), lasting at least 20 minutes and including any of the following that are clinically relevant:
	(a) taking a detailed patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation-each attendance
5040	(See para AN.0.19, AN.0.9 of explanatory notes to this Category) Fee: \$83.95 Benefit: 100% = \$83.95 Extended Medicare Safety Net Cap: \$251.85
	Professional attendance by a general practitioner (other than attendance at consulting rooms, a hospital or a residential aged care facility or a service to which another item in the table applies), lasting at least 20 minutes and including any of the following that are clinically relevant:
	(a) taking a detailed patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation-an attendance on one or more patients on one occasion-each patient
5043	(See para AN.0.19, AN.0.11, AN.0.9 of explanatory notes to this Category) Derived Fee: The fee for item 5040, plus \$25.95 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 5040 plus \$2.00 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
5049	Professional attendance by a general practitioner at a residential aged care facility to residents of the facility (other than a service to which another item in the table applies), lasting at least 20 minutes and

A22. GENERAL PRACTITIONER AFTER-HOURS ATTENDANCES TO WHICH NO OTHER ITEM APPLIES	
	including any of the following that are clinically relevant:
	(a) taking a detailed patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation-an attendance on one or more patients at one residential aged care facility on one occasion-each patient
	(See para AN.0.19, AN.0.15, AN.0.9 of explanatory notes to this Category) Derived Fee: The fee for item 5040, plus \$46.70 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 5040 plus \$3.30 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	LEVEL D
	Professional attendance by a general practitioner (not being a service to which any other item in this table applies) lasting at least 40 minutes, including any of the following that are clinically relevant: a) taking an extensive patient history; b) performing a clinical examination; c) arranging any necessary investigation; d) implementing a management plan; e) providing appropriate preventive health care; in relation to 1 or more health-related issues, with appropriate documentation.
	Professional attendance by a general practitioner at consulting rooms (other than a service to which another item in the table applies), lasting at least 40 minutes and including any of the following that are clinically relevant:
	(a) taking an extensive patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation-each attendance
5060	(See para AN.0.19, AN.0.9 of explanatory notes to this Category) Fee: \$117.75 Benefit: 100% = \$117.75 Extended Medicare Safety Net Cap: \$353.25
	Professional attendance by a general practitioner (other than attendance at consulting rooms, a hospital or a residential aged care facility or a service to which another item in the table applies), lasting at least 40 minutes and including any of the following that are clinically relevant:
5063	(a) taking an extensive patient history;

	NERAL PRACTITIONER AFTER-HOURS PANCES TO WHICH NO OTHER ITEM S
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation-an attendance on one or more patients on one occasion-each patient
	(See para AN.0.19, AN.0.11, AN.0.9 of explanatory notes to this Category) Derived Fee: The fee for item 5060, plus \$25.95 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 5060 plus \$2.00 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	Professional attendance by a general practitioner at a residential aged care facility to residents of the facility (other than a service to which another item in the table applies), lasting at least 40 minutes and including any of the following that are clinically relevant:
	(a) taking an extensive patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation-an attendance on one or more patients at one residential aged care facility on one occasion-each patient
5067	(See para AN.0.19, AN.0.15, AN.0.9 of explanatory notes to this Category) Derived Fee: The fee for item 5060, plus \$46.70 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 5060 plus \$3.30 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	HER NON-REFERRED AFTER-HOURS ANCES TO WHICH NO OTHER ITEM
APPLIES	
	Group A23. Other Non-Referred After-Hours Attendances To Which No Other Item Applies
	CONSULTATION AT CONSULTING ROOMS Professional attendance by a medical practitioner (other than a general practitioner) at consulting rooms
	Professional attendance at consulting rooms of not more than 5 minutes in duration (other than a service to which another item applies) by a medical practitioner (other than a general practitioner)-each attendance
5200	Fee: \$21.00 Benefit: 100% = \$21.00 Extended Medicara Sefety Not Cap: \$63.00

Extended Medicare Safety Net Cap: \$63.00
Professional attendance at consulting rooms of more than 5 minutes in duration but not more than 25

A23. OTHER NON-REFERRED AFTER-HOURS	
	DANCES TO WHICH NO OTHER ITEM
APPLIE	
	minutes in duration (other than a service to which another item applies) by a medical practitioner (other
	than a general practitioner)-each attendance
	Fee: \$31.00 Benefit: 100% = \$31.00
	Extended Medicare Safety Net Cap: \$93.00
	Professional attendance at consulting rooms of more than 25 minutes in duration but not more than 45
	minutes in duration (other than a service to which another item applies) by a medical practitioner (other
	than a general practitioner)-each attendance
	F 01000 P 64 4000/ 01000
5007	Fee: \$48.00 Benefit: 100% = \$48.00
5207	Extended Medicare Safety Net Cap: \$144.00
	Professional attendance at consulting rooms of more than 45 minutes in duration (other than a service to
	which another item applies) by a medical practitioner (other than a general practitioner)-each attendance
	Fee: \$71.00 Benefit: 100% = \$71.00
5208	Extended Medicare Safety Net Cap: \$213.00
	CONSULTATION AT A PLACE OTHER THAN CONSULTING ROOMS, HOSPITAL OR A RESIDENTIAL
	AGED CARE FACILITY
	Professional attendance by a medical practitioner (other than a general practitioner) on 1 or more
	patients on 1 occasion at a place other than consulting rooms, a hospital or residential aged care facility.
	Professional attendance by a medical practitioner who is not a general practitioner (other than attendance
	at consulting rooms, a hospital or a residential aged care facility or a service to which another item in the
	table applies), lasting not more than 5 minutes-an attendance on one or more patients on one occasion-
	each patient
	Cach patient
	(See para AN.0.11 of explanatory notes to this Category)
	Derived Fee: An amount equal to \$18.50, plus \$15.50 divided by the number of patients seen, up to a maximum
	of six patients. For seven or more patients - an amount equal to \$18.50 plus \$.70 per patient
	Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the
5220	lesser amount
	Professional attendance by a medical practitioner who is not a general practitioner (other than attendance
	at consulting rooms, a hospital or a residential aged care facility or a service to which another item in the
	table applies), lasting more than 5 minutes, but not more than 25 minutes-an attendance on one or more
	patients on one occasion-each patient
	(See para AN.0.11 of explanatory notes to this Category)
	Derived Fee: An amount equal to \$26.00, plus \$17.50 divided by the number of patients seen, up to a maximum
	of six patients. For seven or more patients - an amount equal to \$26.00 plus \$.70 per patient
	Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the
5223	lesser amount
	Professional attendance by a medical practitioner who is not a general practitioner (other than attendance
	at consulting rooms, a hospital or a residential aged care facility or a service to which another item in the
	table applies), lasting more than 25 minutes, but not more than 45 minutes-an attendance on one or more
	patients on one occasion-each patient
	(See para AN.0.11 of explanatory notes to this Category)
	Derived Fee: An amount equal to \$45.50, plus \$15.50 divided by the number of patients seen, up to a maximum
	of six patients. For seven or more patients - an amount equal to \$45.50 plus \$.70 per patient
	Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the
5227	lesser amount
	Professional attendance by a medical practitioner who is not a general practitioner (other than attendance
	at consulting rooms, a hospital or a residential aged care facility or a service to which another item in the
5228	table applies), lasting more than 45 minutes-an attendance on one or more patients on one occasion-each
_	

A23. OTHER NON-REFERRED AFTER-HOURS	
ATTENDANCES TO WHICH NO OTHER ITEM APPLIES	
7	patient
	(See para AN.0.11 of explanatory notes to this Category)
	Derived Fee: An amount equal to \$67.50, plus \$15.50 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - an amount equal to \$67.50 plus \$.70 per patient
	Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	CONSULTATION AT A RESIDENTIAL AGED CARE FACILITY
	Professional attendance on 1 or more patients on 1 residential aged care facility (but excluding a professional attendance at a self-contained unit) or attendance at consulting rooms situated within such a complex where the patient is accommodated in the residential aged care facility (excluding accommodation in a self-contained unit) on 1 occasion – each patient
	Professional attendance (other than a service to which another item applies) at a residential aged care
	facility (other than a professional attendance at a self-contained unit) or professional attendance at consulting rooms situated within such a complex if the patient is accommodated in the residential aged
	care facility (other than accommodation in a self-contained unit) of not more than 5 minutes in duration
	by a medical practitioner (other than a general practitioner)-an attendance on one or more patients at one residential aged care facility on one occasion-each patient
	(See para AN.0.15 of explanatory notes to this Category)
	Derived Fee: An amount equal to \$18.50, plus \$27.95 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - an amount equal to \$18.50 plus \$1.25 per patient
	Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the
5260	lesser amount Description of a strong description of
	Professional attendance (other than a service to which another item applies) at a residential aged care facility (other than a professional attendance at a self-contained unit) or professional attendance at consulting rooms situated within such a complex if the patient is accommodated in the residential aged care facility (other than accommodation in a self-contained unit) of more than 5 minutes in duration but not more than 25 minutes in duration by a medical practitioner (other than a general practitioner)-an attendance on one or more patients at one residential aged care facility on one occasion-each patient
	(See para AN.0.15 of explanatory notes to this Category)
	Derived Fee: An amount equal to \$26.00, plus \$31.55 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - an amount equal to \$26.00 plus \$1.25 per patient Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the
5263	lesser amount Professional ettendorge (other then a cornice to which enother item applies) et a regidential aged eers
	Professional attendance (other than a service to which another item applies) at a residential aged care facility (other than a professional attendance at a self-contained unit) or professional attendance at consulting rooms situated within such a complex if the patient is accommodated in the residential aged care facility (other than accommodation in a self-contained unit) of more than 25 minutes in duration but not more than 45 minutes by a medical practitioner (other than a general practitioner)-an attendance on one or more patients at one residential aged care facility on one occasion-each patient
5265	(See para AN.0.15 of explanatory notes to this Category) Derived Fee: An amount equal to \$45.50, plus \$27.95 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - an amount equal to \$45.50 plus \$1.25 per patient Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	Professional attendance (other than a service to which another item applies) at a residential aged care
5267	facility (other than a professional attendance at a self-contained unit) or professional attendance at consulting rooms situated within such a complex if the patient is accommodated in the residential aged care facility (other than accommodation in a self-contained unit) of more than 45 minutes in duration by a medical practitioner (other than a general practitioner)-an attendance on one or more patients at one
3401	a medical practitioner (outer than a general practitioner)-an attenuance on one or more patients at one

	HER NON-REFERRED AFTER-HOURS
ATTENI APPLIE	DANCES TO WHICH NO OTHER ITEM S
, <u></u>	residential aged care facility on one occasion-each patient
	(See para AN.0.15 of explanatory notes to this Category) Derived Fee: An amount equal to \$67.50, plus \$27.95 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - an amount equal to \$67.50 plus \$1.25 per patient Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the
404 DA	lesser amount
A24. PA	IN AND PALLIATIVE MEDICINE 1. PAIN MEDICINE ATTENDANCES Group A24. Pain And Palliative Medicine
	· · · · · · · · · · · · · · · · · · ·
	Subgroup 1. Pain Medicine Attendances Initial professional attendance of 10 minutes or less in duration on a patient by a specialist or consultant physician practising in his or her specialty of pain medicine if:
	(a) the attendance is by video conference; and
	(b) the patient is not an admitted patient; and
	(c) the patient:
	(i) is located both:
	(A) within a telehealth eligible area; and
	(B) at the time of the attendance-at least 15 kms by road from the specialist or physician; or
	(ii) is a care recipient in a residential care service; or
	(iii) is a patient of:
	(A) an Aboriginal Medical Service; or
	(B) an Aboriginal Community Controlled Health Service;
	for which a direction made under subsection 19(2) of the Act applies; and
	(d) no other initial consultation has taken place for a single course of treatment
2799	(See para AN.0.68 of explanatory notes to this Category) Fee: \$114.90 Benefit: 85% = \$97.70 Extended Medicare Safety Net Cap: \$344.70
	Professional attendance at consulting rooms or hospital by a specialist, or consultant physician, in the practice of his or her specialty of pain medicine following referral of the patient to him or her by a referring practitioner-initial attendance in a single course of treatment
2801	(See para AN.0.58 of explanatory notes to this Category) Fee: \$153.15 Benefit: 75% = \$114.90 85% = \$130.20 Extended Medicare Safety Net Cap: \$459.45
	Professional attendance at consulting rooms or hospital by a specialist, or consultant physician, in the practice of his or her specialty of pain medicine following referral of the patient to him or her by a referring practitioner-each attendance (other than a service to which item 2814 applies) after the first in a single course of treatment
2806	(See para AN.0.58, AN.0.70 of explanatory notes to this Category)

A24. PA	IN AND PALLIATIVE MEDICINE 1. PAIN MEDICINE ATTENDANCES
	Fee: \$76.65 Benefit: 75% = \$57.50 85% = \$65.20
	Extended Medicare Safety Net Cap: \$229.95
	Professional attendance at consulting rooms or hospital by a specialist, or consultant physician, in the practice of his or her specialty of pain medicine following referral of the patient to him or her by a referring practitioner-each minor attendance after the first attendance in a single course of treatment
2814	(See para AN.0.58, AN.0.70 of explanatory notes to this Category) Fee: \$43.65 Benefit: 75% = \$32.75 Extended Medicare Safety Net Cap: \$130.95
	Professional attendance on a patient by a specialist or consultant physician practising in his or her specialty of pain medicine if:
	(a) the attendance is by video conference; and
	(b) the attendance is for a service:
	(i) provided with item 2801 lasting more than 10 minutes; or
	(ii) provided with item 2806 or 2814; and
	(c) the patient is not an admitted patient; and
	(d) the patient:
	(i) is located both:
	(A) within a telehealth eligible area; and
	(B) at the time of the attendance-at least 15 kms by road from the specialist or physician; or
	(ii) is a care recipient in a residential care service; or
	(iii) is a patient of:
	(A) an Aboriginal Medical Service; or
	(B) an Aboriginal Community Controlled Health Service;
	for which a direction made under subsection 19(2) of the Act applies
2820	(See para AN.0.68 of explanatory notes to this Category) Derived Fee: 50% of the fee for item 2801, 2806 or 2814. Benefit: 85% of the derived fee Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	Professional attendance at a place other than consulting rooms or hospital by a specialist, or consultant physician, in the practice of his or her specialty of pain medicine following referral of the patient to him or her by a referring practitioner-initial attendance in a single course of treatment
2824	(See para AN.0.58 of explanatory notes to this Category) Fee: \$185.85 Benefit: 85% = \$158.00 Extended Medicare Safety Net Cap: \$500.00
	Professional attendance at a place other than consulting rooms or hospital by a specialist, or consultant physician, in the practice of his or her specialty of pain medicine following referral of the patient to him or her by a referring practitioner-each attendance (other than a service to which item 2840 applies) after the first in a single course of treatment
2832	(See para AN.0.58 of explanatory notes to this Category)

A24. P	AIN AND PALLIATIVE MEDICINE 1. PAIN MEDICINE ATTENDANCES
	Fee: \$112.40 Benefit: 85% = \$95.55
	Extended Medicare Safety Net Cap: \$337.20
	Professional attendance at a place other than consulting rooms or hospital by a specialist, or consultant physician, in the practice of his or her specialty of pain medicine following referral of the patient to him or her by a referring practitioner-each minor attendance after the first attendance in a single course of treatment
	(See para AN.0.58 of explanatory notes to this Category) Fee: \$80.95 Benefit: 85% = \$68.85
2840	Extended Medicare Safety Net Cap: \$242.85
	AIN AND PALLIATIVE MEDICINE 2. PAIN MEDICINE CASE CONFERENCES
	Group A24. Pain And Palliative Medicine
	Subgroup 2. Pain Medicine Case Conferences
	Attendance by a specialist, or consultant physician, in the practice of his or her specialty of pain medicine, as a member of a multidisciplinary case conference team, to organise and coordinate a community case conference of at least 15 minutes but less than 30 minutes
	(See para AN.0.58 of explanatory notes to this Category) Fee: \$141.20 Benefit: 75% = \$105.90 85% = \$120.05
2946	Extended Medicare Safety Net Cap: \$423.60
	Attendance by a specialist, or consultant physician, in the practice of his or her specialty of pain medicine, as a member of a multidisciplinary case conference team, to organise and coordinate a community case conference of at least 30 minutes but less than 45 minutes
	(See para AN.0.58 of explanatory notes to this Category) Fee: \$211.85 Benefit: 75% = \$158.90 85% = \$180.10
2949	Extended Medicare Safety Net Cap: \$500.00
	Attendance by a specialist, or consultant physician, in the practice of his or her specialty of pain medicine, as a member of a multidisciplinary case conference team, to organise and coordinate a community case conference of at least 45 minutes
	(See para AN.0.58 of explanatory notes to this Category) Fee: \$282.30 Benefit: 75% = \$211.75 85% = \$240.00
2954	Extended Medicare Safety Net Cap: \$500.00
	Attendance by a specialist, or consultant physician, in the practice of his or her specialty of pain medicine, as a member of a multidisciplinary case conference team, to participate in a community case conference (other than to organise and coordinate the conference) of at least 15 minutes but less than 30 minutes
2958	(See para AN.0.58 of explanatory notes to this Category) Fee: \$101.40 Benefit: 75% = \$76.05 85% = \$86.20 Extended Medicare Safety Net Cap: \$304.20
2730	Attendance by a specialist, or consultant physician, in the practice of his or her specialty of pain medicine, as a member of a multidisciplinary case conference team, to participate in a community case conference (other than to organise and coordinate the conference) of at least 30 minutes but less than 45 minutes
2972	(See para AN.0.58 of explanatory notes to this Category) Fee: \$161.70 Benefit: 75% = \$121.30 85% = \$137.45 Extended Medicare Safety Net Cap: \$485.10
	Attendance by a specialist, or consultant physician, in the practice of his or her specialty of pain medicine, as a member of a multidisciplinary case conference team, to participate in a community case conference (other than to organise and coordinate the conference) of at least 45 minutes
2974	

atory notes to this Category) efit: 75% = \$166.55 85% = \$188.75 ety Net Cap: \$500.00
ety Net Cap: \$500.00
t, or consultant physician, in the practice of his or her specialty of pain a multidisciplinary case conference team, to organise and coordinate a of at least 15 minutes but less than 30 minutes, before the patient is 1 (H)
atory notes to this Category) efit: 75% = \$105.90 85% = \$120.05
ety Net Cap: \$423.60
t, or consultant physician, in the practice of his or her specialty of pain a multidisciplinary case conference team, to organise and coordinate a of at least 30 minutes but less than 45 minutes, before the patient is 1 (H)
atory notes to this Category) efit: 75% = \$158.90 85% = \$180.10
ety Net Cap: \$500.00
t, or consultant physician, in the practice of his or her specialty of pain a multidisciplinary case conference team, to organise and coordinate a
e of at least 45 minutes, before the patient is discharged from a hospital (H) atory notes to this Category)
efit: 75% = \$211.75 85% = \$240.00
ety Net Cap: \$500.00
t, or consultant physician, in the practice of his or her specialty of pain a multidisciplinary case conference team, to participate in a discharge case organise and coordinate the conference) of at least 15 minutes but less than 30 tt is discharged from a hospital (H)
atory notes to this Category) efit: 75% = \$76.05 85% = \$86.20
ety Net Cap: \$304.20
t, or consultant physician, in the practice of his or her specialty of pain a multidisciplinary case conference team, to participate in a discharge case organise and coordinate the conference) of at least 30 minutes but less than 45 t is discharged from a hospital (H)
atory notes to this Category) efit: 75% = \$121.30 85% = \$137.45
ety Net Cap: \$485.10
t, or consultant physician, in the practice of his or her specialty of pain a multidisciplinary case conference team, to participate in a discharge case organise and coordinate the conference) of at least 45 minutes, before the a hospital (H)
atory notes to this Category) efit: 75% = \$166.55 85% = \$188.75
ety Net Cap: \$500.00
DICINE 3. PALLIATIVE MEDICINE ATTENDANCES
Iliative Medicine
Subgroup 3. Palliative Medicine Attendances
ance of 10 minutes or less in duration on a patient by a specialist or consultant
n ne fe si fe e n ne fe si fe n ne fe si fe e

A24. PA	IN AND PALLIATIVE MEDICINE 3. PALLIATIVE MEDICINE ATTENDANCES
	physician practising in his or her specialty of palliative medicine if:
	(a) the attendance is by video conference; and
	(b) the patient is not an admitted patient; and
	(c) the patient:
	(i) is located both:
	(A) within a telehealth eligible area; and
	(B) at the time of the attendance-at least 15 kms by road from the specialist or physician; or
	(ii) is a care recipient in a residential care service; or
	(iii) is a patient of:
	(A) an Aboriginal Medical Service; or
	(B) an Aboriginal Community Controlled Health Service;
	for which a direction made under subsection 19(2) of the Act applies; and
	(d) no other initial consultation has taken place for a single course of treatment
	(See para AN.0.68 of explanatory notes to this Category) Fee: \$114.90 Benefit: 85% = \$97.70
	Extended Medicare Safety Net Cap: \$344.70
	Professional attendance at consulting rooms or hospital by a specialist, or consultant physician, in the practice of his or her specialty of palliative medicine following referral of the patient to him or her by a referring practitioner-initial attendance in a single course of treatment
3005	(See para AN.0.58 of explanatory notes to this Category) Fee: \$153.15 Benefit: 75% = \$114.90 85% = \$130.20 Extended Medicare Safety Net Cap: \$459.45
	Professional attendance at consulting rooms or hospital by a specialist, or consultant physician, in the practice of his or her specialty of palliative medicine following referral of the patient to him or her by a referring practitioner-each attendance (other than a service to which item 3014 applies) after the first in a single course of treatment
3010	(See para AN.0.58, AN.0.70 of explanatory notes to this Category) Fee: \$76.65 Benefit: 75% = \$57.50 85% = \$65.20 Extended Medicare Safety Net Cap: \$229.95
	Professional attendance at consulting rooms or hospital by a specialist, or consultant physician, in the practice of his or her specialty of palliative medicine following referral of the patient to him or her by a referring practitioner-each minor attendance after the first attendance in a single course of treatment
	(See para AN.0.58, AN.0.70 of explanatory notes to this Category) Fee: \$43.65 Benefit: 75% = \$32.75 85% = \$37.15
3014	Extended Medicare Safety Net Cap: \$130.95
	Professional attendance on a patient by a specialist or consultant physician practising in his or her specialty of palliative medicine if:
3015	(a) the attendance is by video conference; and

A24. PA	IN AND PALLIATIVE MEDICINE	3. PALLIATIVE MEDICINE ATTENDANCES
	(b) the attendance is for a service:	
	(i) provided with item 3005 lasting r	nore than 10 minutes; or
	(ii) provided with item 3010 or 3014	; and
	(c) the patient is not an admitted patient; an	d
	(d) the patient:	
	(i) is located both:	
	(A) within a telehealth eligible are	ea; and
	(B) at the time of the attendance-a	at least 15 kms by road from the specialist or physician; or
	(ii) is a care recipient in a residential	care service; or
	(iii) is a patient of:	
	(A) an Aboriginal Medical Service	e; or
	(B) an Aboriginal Community Co	ontrolled Health Service;
	for which a direction made under subsect	tion 19(2) of the Act applies
	(See para AN.0.68 of explanatory notes to this C Derived Fee: 50% of the fee for item 3005, 30 Extended Medicare Safety Net Cap: 300% lesser amount	
	Professional attendance at a place other tha	n consulting rooms or hospital by a specialist, or consultant alty of palliative medicine following referral of the patient to attendance in a single course of treatment
3018	(See para AN.0.58 of explanatory notes to this C Fee: \$185.85 Benefit: 85% = \$158.00 Extended Medicare Safety Net Cap: \$500	0
3010	Professional attendance at a place other that physician, in the practice of his or her speci	n consulting rooms or hospital by a specialist, or consultant alty of palliative medicine following referral of the patient to attendance (other than a service to which item 3028 applies)
3023	(See para AN.0.58 of explanatory notes to this C Fee: \$112.40 Benefit: 85% = \$95.55 Extended Medicare Safety Net Cap: \$337	
	physician, in the practice of his or her speci	n consulting rooms or hospital by a specialist, or consultant alty of palliative medicine following referral of the patient to minor attendance after the first attendance in a single course
2020	(See para AN.0.58 of explanatory notes to this C Fee: \$80.95 Benefit: 85% = \$68.85	
3028 A24. PA	Extended Medicare Safety Net Cap: \$242 IN AND PALLIATIVE MEDICINE	4. PALLIATIVE MEDICINE CASE CONFERENCES
	Group A24. Pain And Palliative Medicine	

A24. PA	IN AND PALLIATIVE MEDICINE 4. PALLIATIVE MEDICINE CASE CONFERENCES
	Subgroup 4. Palliative Medicine Case Conferences
	Attendance by a specialist, or consultant physician, in the practice of his or her specialty of palliative medicine, as a member of a multidisciplinary case conference team, to organise and coordinate a community case conference of at least 15 minutes but less than 30 minutes
	(See para AN.0.58 of explanatory notes to this Category) Fee: \$141.20 Benefit: 75% = \$105.90 85% = \$120.05
3032	Extended Medicare Safety Net Cap: \$423.60
	Attendance by a specialist, or consultant physician, in the practice of his or her specialty of palliative medicine, as a member of a multidisciplinary case conference team, to organise and coordinate a community case conference of at least 30 minutes but less than 45 minutes
20.40	(See para AN.0.58 of explanatory notes to this Category) Fee: \$211.85 Benefit: 75% = \$158.90 85% = \$180.10
3040	Extended Medicare Safety Net Cap: \$500.00
	Attendance by a specialist, or consultant physician, in the practice of his or her specialty of palliative medicine, as a member of a multidisciplinary case conference team, to organise and coordinate a community case conference of at least 45 minutes
	(See para AN.0.58 of explanatory notes to this Category)
	Fee: \$282.30 Benefit: 75% = \$211.75 85% = \$240.00
3044	Extended Medicare Safety Net Cap: \$500.00
	Attendance by a specialist, or consultant physician, in the practice of his or her specialty of palliative medicine, as a member of a multidisciplinary case conference team, to participate in a community case conference (other than to organise and coordinate the conference) of at least 15 minutes but less than 30 minutes
3051	(See para AN.0.58 of explanatory notes to this Category) Fee: \$101.40 Benefit: 75% = \$76.05 85% = \$86.20 Extended Medicare Safety Net Cap: \$304.20
3031	Attendance by a specialist, or consultant physician, in the practice of his or her specialty of palliative
	medicine, as a member of a multidisciplinary case conference team, to participate in a community case conference (other than to organise and coordinate the conference) of at least 30 minutes but less than 45 minutes, with a multidisciplinary team of at least 2 other formal care providers of different disciplines
	(See para AN.0.58 of explanatory notes to this Category) Fee: \$161.70 Benefit: 75% = \$121.30 85% = \$137.45
3055	Extended Medicare Safety Net Cap: \$485.10
	Attendance by a specialist, or consultant physician, in the practice of his or her specialty of palliative medicine, as a member of a multidisciplinary case conference team, to participate in a community case conference (other than to organise and coordinate the conference) of at least 45 minutes
	(See para AN.0.58 of explanatory notes to this Category) Fee: \$222.05 Benefit: 75% = \$166.55 85% = \$188.75
3062	Extended Medicare Safety Net Cap: \$500.00
	Attendance by a specialist, or consultant physician, in the practice of his or her specialty of palliative medicine, as a member of a multidisciplinary case conference team, to organise and coordinate a
	discharge case conference of at least 15 minutes but less than 30 minutes, before the patient is discharged from a hospital (H)
	(See para AN.0.58 of explanatory notes to this Category)
3069	Fee: \$141.20 Benefit: 75% = \$105.90 85% = \$120.05 Extended Medicare Safety Net Cap: \$423.60
3074	Attendance by a specialist, or consultant physician, in the practice of his or her specialty of palliative medicine, as a member of a case conference team, to organise and coordinate a discharge case

A24. PAI	N AND PALLIATIVE MEDICINE 4. PALLIATIVE MEDICINE CASE CONFERENCES
	conference of at least 30 minutes but less than 45 minutes, before the patient is discharged from a
	hospital (H)
	(See para AN.0.58 of explanatory notes to this Category)
	Fee: \$211.85 Benefit: 75% = \$158.90 85% = \$180.10
	Extended Medicare Safety Net Cap: \$500.00
	Attendance by a specialist, or consultant physician, in the practice of his or her specialty of palliative medicine, as a member of a multidisciplinary case conference team, to organise and coordinate a discharge case conference of at least 45 minutes, before the patient is discharged from a hospital (H)
	(See para AN.0.58 of explanatory notes to this Category)
2079	Fee: \$282.30 Benefit: 75% = \$211.75 85% = \$240.00
3078	Extended Medicare Safety Net Cap: \$500.00 Attendance by a specialist, or consultant physician, in the practice of his or her specialty of palliative
	medicine, as a member of a case conference team, to participate in a discharge case conference (other
	than to organise and coordinate the conference) of at least 15 minutes but less than 30 minutes, before
	the patient is discharged from a hospital (H)
	(See para AN.0.58 of explanatory notes to this Category)
	Fee: \$101.40 Benefit: 75% = \$76.05 85% = \$86.20
3083	Extended Medicare Safety Net Cap: \$304.20
	Attendance by a specialist, or consultant physician, in the practice of his or her specialty of palliative
	medicine, as a member of a multidisciplinary case conference team, to participate in a discharge case
	conference (other than to organise and coordinate the conference) of at least 30 minutes but less than 45 minutes, before the patient is discharged from a hospital (H)
	(See para AN.0.58 of explanatory notes to this Category)
	Fee: \$161.70 Benefit: 75% = \$121.30 85% = \$137.45
3088	Extended Medicare Safety Net Cap: \$485.10
	Attendance by a specialist, or consultant physician, in the practice of his or her specialty of palliative medicine, as a member of a multidisciplinary case conference team, to participate in a discharge case conference (other than to organise and coordinate the conference) of at least 45 minutes, before the
	patient is discharged from a hospital (H)
	(See para AN.0.58 of explanatory notes to this Category)
	Fee: \$222.05 Benefit: 75% = \$166.55 85% = \$188.75
3093	Extended Medicare Safety Net Cap: \$500.00
	UROSURGERY ATTENDANCES TO NO OTHER ITEM APPLIES
	Group A26. Neurosurgery Attendances To Which No Other Item Applies
	Initial professional attendance of 10 minutes or less in duration on a patient by a specialist practising in his or her specialty of neurosurgery if:
	(a) the attendance is by video conference; and
	(b) the patient is not an admitted patient; and
	(c) the patient:
	(i) is located both:
	(A) within a telehealth eligible area; and
	(B) at the time of the attendance-at least 15 kms by road from the specialist; or
6004	(2) at the time of the attendance at least 15 kms by four from the specialist, of

	JROSURGERY ATTENDANCES TO NO OTHER ITEM APPLIES
71110111	(ii) is a care recipient in a residential care service; or
	(iii) is a patient of:
	(A) an Aboriginal Medical Service; or
	(B) an Aboriginal Community Controlled Health Service;
	for which a direction made under subsection 19(2) of the Act applies; and
	(d) no other initial consultation has taken place for a single course of treatment
	(See para AN.0.68 of explanatory notes to this Category) Fee: \$98.65 Benefit: 85% = \$83.90 Extended Medicare Safety Net Cap: \$295.95
	Professional attendance by a specialist in the practice of neurosurgery following referral of the patient to him or her-an attendance (other than a second or subsequent attendance in a single course of treatment) at consulting rooms or hospital
	(See para AN.0.64 of explanatory notes to this Category) Fee: \$131.55 Benefit: 75% = \$98.70 85% = \$111.85
6007	Extended Medicare Safety Net Cap: \$394.65
	Professional attendance by a specialist in the practice of neurosurgery following referral of the patient to him or her-a minor attendance after the first in a single course of treatment at consulting rooms or hospital
6009	(See para AN.0.64 of explanatory notes to this Category) Fee: \$43.65 Benefit: 75% = \$32.75 Extended Medicare Safety Net Cap: \$130.95
000)	Professional attendance by a specialist in the practice of neurosurgery following referral of the patient to him or her-an attendance after the first in a single course of treatment, involving an extensive and comprehensive examination, arranging any necessary investigations in relation to one or more complex problems and of more than 15 minutes in duration but not more than 30 minutes in duration at consulting rooms or hospital
	(See para AN.0.64 of explanatory notes to this Category) Fee: \$86.85 Benefit: 75% = \$65.15 85% = \$73.85
6011	Extended Medicare Safety Net Cap: \$260.55
	Professional attendance by a specialist in the practice of neurosurgery following referral of the patient to him or her-an attendance after the first in a single course of treatment, involving a detailed and comprehensive examination, arranging any necessary investigations in relation to one or more complex problems and of more than 30 minutes in duration but not more than 45 minutes in duration at consulting rooms or hospital
(012	(See para AN.0.64 of explanatory notes to this Category) Fee: \$120.30 Benefit: 75% = \$90.25 85% = \$102.30
6013	Extended Medicare Safety Net Cap: \$360.90 Professional attendance by a specialist in the practice of neurosurgery following referral of the patient to
	him or her-an attendance after the first in a single course of treatment, involving an exhaustive and comprehensive examination, arranging any necessary investigations in relation to one or more complex problems and of more than 45 minutes in duration at consulting rooms or hospital
	(See para AN.0.64 of explanatory notes to this Category) Fee: \$153.15 Benefit: 75% = \$114.90 85% = \$130.20
6015	Extended Medicare Safety Net Cap: \$459.45

A26. NEUROSURGERY ATTENDANCES TO WHICH NO OTHER ITEM APPLIES

Professional attendance on a patient by a specialist practising in his or her specialty of neurosurgery if:

- (a) the attendance is by video conference; and
- (b) the attendance is for a service:
 - (i) provided with item 6007 lasting more than 10 minutes; or
 - (ii) provided with item 6009, 6011, 6013 or 6015; and
- (c) the patient is not an admitted patient; and
- (d) the patient:
 - (i) is located both:
 - (A) within a telehealth eligible area; and
 - (B) at the time of the attendance-at least 15 kms by road from the specialist; or
 - (ii) is a care recipient in a residential care service; or
 - (iii) is a patient of:
 - (A) an Aboriginal Medical Service; or
 - (B) an Aboriginal Community Controlled Health Service;

for which a direction made under subsection 19(2) of the Act applies

(See para AN.0.68 of explanatory notes to this Category)

Derived Fee: 50% of the fee for item 6007, 6009, 6011, 6013 or 6015. Benefit: 85% of the derived fee **Extended Medicare Safety Net Cap:** 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount

6016

A27. PREGNANCY SUPPORT COUNSELLING

Group A27. Pregnancy Support Counselling

Professional attendance of at least 20 minutes in duration at consulting rooms by a general practitioner who is registered with the Chief Executive Medicare as meeting the credentialing requirements for provision of this service for the purpose of providing non-directive pregnancy support counselling to a person who:

- (a) is currently pregnant; or
- (b) has been pregnant in the 12 months preceding the provision of the first service to which this item or item 81000, 81005 or 81010 applies in relation to that pregnancy

Note: For items 81000, 81005 and 81010, see the determination about allied health services under subsection 3C(1) of the Act.

(See para AN.0.66 of explanatory notes to this Category)

Fee: \$76.60 **Benefit:** 100% = \$76.60 **Extended Medicare Safety Net Cap:** \$229.80

A28. GERIATRIC MEDICINE

Group A28. Geriatric Medicine

A28. GERIATRIC MEDICINE

Professional attendance of more than 60 minutes in duration at consulting rooms or hospital by a consultant physician or specialist in the practice of his or her specialty of geriatric medicine, if:

- (a) the patient is at least 65 years old and referred by a medical practitioner practising in general practice (including a general practitioner, but not including a specialist or consultant physician) or a participating nurse practitioner; and
- (b) the attendance is initiated by the referring practitioner for the provision of a comprehensive assessment and management plan; and
- (c) during the attendance:
 - (i) the medical, physical, psychological and social aspects of the patient's health are evaluated in detail using appropriately validated assessment tools if indicated (the *assessment*); and
 - (ii) the patient's various health problems and care needs are identified and prioritised (the *formulation*); and
 - (iii) a detailed management plan is prepared (the management plan) setting out:
 - (A) the prioritised list of health problems and care needs; and
 - (B) short and longer term management goals; and
 - (C) recommended actions or intervention strategies to be undertaken by the patient's general practitioner or another relevant health care provider that are likely to improve or maintain health status and are readily available and acceptable to the patient and the patient's family and carers; and
 - (iv) the management plan is explained and discussed with the patient and, if appropriate, the patient's family and any carers; and
 - (v) the management plan is communicated in writing to the referring practitioner; and
- (d) an attendance to which item 104, 105, 107, 108, 110, 116 or 119 applies has not been provided to the patient on the same day by the same practitioner; and
- (e) an attendance to which this item or item 145 applies has not been provided to the patient by the same practitioner in the preceding 12 months

(See para AN.0.26 of explanatory notes to this Category)

Fee: \$459.45 **Benefit:** 75% = \$344.60 85% = \$390.55

Extended Medicare Safety Net Cap: \$500.00

Professional attendance of more than 30 minutes in duration at consulting rooms or hospital by a consultant physician or specialist in the practice of his or her specialty of geriatric medicine to review a management plan previously prepared by that consultant physician or specialist under item 141 or 145, if:

- (a) the review is initiated by the referring medical practitioner practising in general practice or a participating nurse practitioner; and
- (b) during the attendance:
 - (i) the patient's health status is reassessed; and
 - (ii) a management plan prepared under item 141 or 145 is reviewed and revised; and

143

A28. GERIATRIC MEDICINE

- (iii) the revised management plan is explained to the patient and (if appropriate) the patient's family and any carers and communicated in writing to the referring practitioner; and
- (c) an attendance to which item 104, 105, 107, 108, 110, 116 or 119 applies was not provided to the patient on the same day by the same practitioner; and
- (d) an attendance to which item 141 or 145 applies has been provided to the patient by the same practitioner in the preceding 12 months; and
- (e) an attendance to which this item or item 147 applies has not been provided to the patient in the preceding 12 months, unless there has been a significant change in the patient's clinical condition or care circumstances that requires a further review

(See para AN.0.26 of explanatory notes to this Category)

Fee: \$287.20 **Benefit:** 75% = \$215.40 85% = \$244.15

Extended Medicare Safety Net Cap: \$500.00

Professional attendance of more than 60 minutes in duration at a place other than consulting rooms or hospital by a consultant physician or specialist in the practice of his or her specialty of geriatric medicine, if:

- (a) the patient is at least 65 years old and referred by a medical practitioner practising in general practice (including a general practitioner, but not including a specialist or consultant physician) or a participating nurse practitioner; and
- (b) the attendance is initiated by the referring practitioner for the provision of a comprehensive assessment and management plan; and
- (c) during the attendance:
 - (i) the medical, physical, psychological and social aspects of the patient's health are evaluated in detail utilising appropriately validated assessment tools if indicated (the *assessment*); and
 - (ii) the patient's various health problems and care needs are identified and prioritised (the *formulation*); and
 - (iii) a detailed management plan is prepared (the *management plan*) setting out:
 - (A) the prioritised list of health problems and care needs; and
 - (B) short and longer term management goals; and
 - (C) recommended actions or intervention strategies, to be undertaken by the patient's general practitioner or another relevant health care provider that are likely to improve or maintain health status and are readily available and acceptable to the patient, the patient's family and any carers; and
 - (iv) the management plan is explained and discussed with the patient and, if appropriate, the patient's family and any carers; and
 - (v) the management plan is communicated in writing to the referring practitioner; and
- (d) an attendance to which item 104, 105, 107, 108, 110, 116 or 119 applies has not been provided to the patient on the same day by the same practitioner; and
- (e) an attendance to which this item or item 141 applies has not been provided to the patient by the same practitioner in the preceding 12 months

A28. GE	RIATRIC MEDICINE
	(See para AN.0.26 of explanatory notes to this Category)
	Fee: \$557.10 Benefit: 85% = \$473.70
	Extended Medicare Safety Net Cap: \$500.00 Professional attendance of more than 30 minutes in duration at a place other than consulting rooms or hospital by a consultant physician or specialist in the practice of his or her specialty of geriatric medicine to review a management plan previously prepared by that consultant physician or specialist under items 141 or 145, if:
	(a) the review is initiated by the referring medical practitioner practising in general practice or a participating nurse practitioner; and
	(b) during the attendance:
	(i) the patient's health status is reassessed; and
	(ii) a management plan that was prepared under item 141 or 145 is reviewed and revised; and
	(iii) the revised management plan is explained to the patient and (if appropriate) the patient's family and any carers and communicated in writing to the referring practitioner; and
	(c) an attendance to which item 104, 105, 107, 108, 110, 116 or 119 applies has not been provided to the patient on the same day by the same practitioner; and
	(d) an attendance to which item 141 or 145 applies has been provided to the patient by the same practitioner in the preceding 12 months; and
	(e) an attendance to which this item or 143 applies has not been provided by the same practitioner in the preceding 12 months, unless there has been a significant change in the patient's clinical condition or care circumstances that requires a further review
147	(See para AN.0.26 of explanatory notes to this Category) Fee: \$348.25 Benefit: 85% = \$296.05 Extended Medicare Safety Net Cap: \$500.00
	Professional attendance on a patient by a consultant physician or specialist practising in his or her specialty of geriatric medicine if:
	(a) the attendance is by video conference; and
	(b) item 141 or 143 applies to the attendance; and
	(c) the patient is not an admitted patient; and
	(d) the patient:
	(i) is located both:
	(A) within a telehealth eligible area; and
	(B) at the time of the attendance-at least 15 kms by road from the physician or specialist; or
	(ii) is a care recipient in a residential care service; or
	(iii) is a patient of:
149	(A) an Aboriginal Medical Service; or
- 17	

A28. GERIATRIC MEDICINE (B) an Aboriginal Community Controlled Health Service: for which a direction made under subsection 19(2) of the Act applies (See para AN.0.68 of explanatory notes to this Category) Derived Fee: 50% of the fee for item 141 or 143. Benefit: 85% of the derived fee Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount A29. EARLY INTERVENTION SERVICES FOR CHILDREN WITH AUTISM, PERVASIVE **DEVELOPMENTAL DISORDER OR DISABILITY** Group A29. Early Intervention Services For Children With Autism, Pervasive Developmental **Disorder Or Disability** Professional attendance of at least 45 minutes in duration at consulting rooms or hospital, by a consultant physician in the practice of his or her specialty of paediatrics, following referral of the patient to the consultant by a referring practitioner, for assessment, diagnosis and preparation of a treatment and management plan for a patient aged under 13 years with autism or another pervasive developmental disorder, if the consultant paediatrician does all of the following: (a) undertakes a comprehensive assessment and makes a diagnosis (if appropriate, using information provided by an eligible allied health provider); (b) develops a treatment and management plan, which must include the following: (i) an assessment and diagnosis of the patient's condition; (ii) a risk assessment; (iii) treatment options and decisions; (iv) if necessary-medical recommendations; (c) provides a copy of the treatment and management plan to: (i) the referring practitioner; and (ii) one or more allied health providers, if appropriate, for the treatment of the patient; (other than attendance on a patient for whom payment has previously been made under this item or item 137, 139 or 289) (See para AN.0.24 of explanatory notes to this Category) **Benefit:** 75% = \$200.90 85% = \$227.70 Fee: \$267.85 135 Extended Medicare Safety Net Cap: \$500.00 Professional attendance of at least 45 minutes duration, at consulting rooms or hospital, by a specialist or consultant physician, for assessment, diagnosis and the preparation of a treatment and management plan for a child aged under 13 years, with an eligible disability, who has been referred to the specialist or consultant physician by a referring practitioner, if the specialist or consultant physician does the following: (a) undertakes a comprehensive assessment of the child and forms a diagnosis (using the assistance of one or more allied health providers where appropriate) (b) develops a treatment and management plan which must include the following: 137

A29. EARLY INTERVENTION SERVICES FOR CHILDREN WITH AUTISM, PERVASIVE DEVELOPMENTAL DISORDER OR DISABILITY

- (i) the outcomes of the assessment;
- (ii) the diagnosis or diagnoses;
- (iii) opinion on risk assessment;
- (iv) treatment options and decisions;
- (v) appropriate medication recommendations, where necessary.
- (c) provides a copy of the treatment and management plan to the:
 - (i) referring practitioner; and
 - (ii) relevant allied health providers (where appropriate).

Not being an attendance on a child in respect of whom payment has previously been made under this item or items 135, 139 or 289.

(See para AN.0.25 of explanatory notes to this Category)

Fee: \$267.85 **Benefit:** 75% = \$200.90 85% = \$227.70

Extended Medicare Safety Net Cap: \$500.00

Professional attendance of at least 45 minutes in duration at consulting rooms only, by a general practitioner (not including a specialist or consultant physician) for assessment, diagnosis and preparation of a treatment and management plan for a patient under 13 years with an eligible disability if the general practitioner does all of the following:

- (a) undertakes a comprehensive assessment and makes a diagnosis (if appropriate, using information provided by an eligible allied health provider);
- (b) develops a treatment and management plan, which must include the following:
 - (i) an assessment and diagnosis of the patient's condition;
 - (ii) a risk assessment;
 - (iii) treatment options and decisions;
 - (iv) if necessary-medication recommendations;
- (c) provides a copy of the treatment and management plan to one or more allied health providers, if appropriate, for the treatment of the patient;

(other than attendance on a patient for whom payment has previously been made under this item or item 135, 137 or 289)

(See para AN.0.25 of explanatory notes to this Category)

Fee: \$134.50 **Benefit:** 100% = \$134.50

Extended Medicare Safety Net Cap: \$403.50

A30. MEDICAL PRACTITIONER (INCLUDING A GENERAL PRACTITIONER, SPECIALIST OR CONSULTANT PHYSICIAN) TELEHEALTH ATTENDANCES

139

1. TELEHEALTH ATTENDANCE AT CONSULTING ROOMS, HOME VISITS OR OTHER INSTITUTIONS

Group A30. Medical Practitioner (Including A General Practitioner, Specialist Or Consultant

1. TELEHEALTH ATTENDANCE AT CONSULTING ROOMS, HOME VISITS OR OTHER INSTITUTIONS

ns inuous) and
inuous) and
and
ı
ı
ı
ı
1
-
and
of six he

1. TELEHEALTH ATTENDANCE AT CONSULTING ROOMS, HOME VISITS OR OTHER INSTITUTIONS

ANCES
continuous) by a medical practitioner providing clinical support to a patient who:
(a) is participating in a video conferencing consultation with a specialist or consultant physician; and
(b) is not an admitted patient; and
(c) either:
(i) is located both:
(A) within a telehealth eligible area; and
(B) at the time of the attendance-at least 15 kms by road from the specialist or physician mentioned in paragraph (a); or
(ii) is a patient of:
(A) an Aboriginal Medical Service; or
(B) an Aboriginal Community Controlled Health Service;
for which a direction made under subsection 19(2) of the Act applies
(See para AN.0.67 of explanatory notes to this Category) Fee: \$49.95 Benefit: 100% = \$49.95 Extended Medicare Safety Net Cap: \$149.85
Professional attendance not in consulting rooms of less than 20 minutes in duration (whether or not continuous) by a medical practitioner providing clinical support to a patient who:
(a) is participating in a video conferencing consultation with a specialist or consultant physician; and
(b) is not an admitted patient; and
(c) is not a care recipient in a residential care service; and
(d) is located both:
(i) within a telehealth eligible area; and
(ii) at the time of the attendance-at least 15 kms by road from the specialist or physician mentioned in paragraph (a);
for an attendance on one or more patients at one place on one occasion-each patient
(See para AN.0.67 of explanatory notes to this Category) Derived Fee: The fee for item 2126 plus \$25.95 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 2126 plus \$2.00 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
Professional attendance at consulting rooms of at least 20 minutes in duration (whether or not continuous) by a medical practitioner who provides clinical support to a patient who:
(a) is participating in a video conferencing consultation with a specialist or consultant physician; and

1. TELEHEALTH ATTENDANCE AT CONSULTING ROOMS, HOME VISITS OR OTHER INSTITUTIONS

ATTENI	DANCES INSTITUTIONS
	(b) is not an admitted patient; and
	(c) either:
	(i) is located both:
	(A) within a telehealth eligible area; and
	(B) at the time of the attendance-at least 15 kms by road from the specialist or physician mentioned in paragraph (a); or
	(ii) is a patient of:
	(A) an Aboriginal Medical Service; or
	(B) an Aboriginal Community Controlled Health Service:
	for which a direction made under subsection 19(2) of the Act applies
	(See para AN.0.67 of explanatory notes to this Category) Fee: \$96.85 Benefit: 100% = \$96.85 Extended Medicare Safety Net Cap: \$290.55
	Professional attendance not in consulting rooms of at least 20 minutes in duration (whether or not continuous) by a medical practitioner providing clinical support to a patient who:
	(a) is participating in a video conferencing consultation with a specialist or consultant physician; and
	(b) is not an admitted patient; and
	(c) is not a care recipient in a residential care service; and
	(d) is located both:
	(i) within a telehealth eligible area; and
	(ii) at the time of the attendance-at least 15 kms by road from the specialist or physician mentioned in paragraph (a);
	for an attendance on one or more patients at one place on one occasion-each patient
2147	(See para AN.0.67 of explanatory notes to this Category) Derived Fee: The fee for item 2143 plus \$25.95 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 2143 plus \$2.00 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	Professional attendance at consulting rooms of at least 40 minutes in duration (whether or not continuous) by a medical practitioner providing clinical support to a patient who:
	(a) is participating in a video conferencing consultation with a specialist or consultant physician; and
	(b) is not an admitted patient; and
2195	(c) either:

GENERA	DICAL PRACTITIONER (INCLUDING A IL PRACTITIONER, SPECIALIST OR TANT PHYSICIAN) TELEHEALTH ANCES 1. TELEHEALTH ATTENDANCE AT CONSULTING ROOMS, HOME VISITS OR OTHER INSTITUTIONS
	(i) is located both:
	(A) within a telehealth eligible area; and
	(B) at the time of the attendance-at least 15 kms by road from the specialist or physician mentioned in paragraph (a); or
	(ii) is a patient of:
	(A) an Aboriginal Medical Service; or
	(B) an Aboriginal Community Controlled Health Service;
	for which a direction made under subsection 19(2) of the Act applies
	(See para AN.0.67 of explanatory notes to this Category) Fee: \$142.50 Extended Medicare Safety Net Cap: \$427.50
	Professional attendance not in consulting rooms of at least 40 minutes in duration (whether or not continuous) by a medical practitioner providing clinical support to a patient who:
	(a) is participating in a video conferencing consultation with a specialist or consultant physician; and
	(b) is not an admitted patient; and
	(c) is not a care recipient in a residential care service; and
	(d) is located both:
	(i) within a telehealth eligible area; and
	(ii) at the time of the attendance-at least 15 kms by road from the specialist or physician mentioned in paragraph (a);
	for an attendance on one or more patients at one place on one occasion-each patient
2199	(See para AN.0.67 of explanatory notes to this Category) Derived Fee: The fee for item 2195 plus \$25.95 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 2195 plus \$2.00 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
A30. MEI	DICAL PRACTITIONER (INCLUDING A
	IL PRACTITIONER, SPECIALIST OR TANT PHYSICIAN) TELEHEALTH 2. TELEHEALTH ATTENDANCE AT A ANCES RESIDENTIAL AGED CARE FACILITY
	Group A30. Medical Practitioner (Including A General Practitioner, Specialist Or Consultant Physician) Telehealth Attendances
	Subgroup 2. Telehealth Attendance At A Residential Aged Care Facility
2125	Professional attendance of at least 5 minutes in duration (whether or not continuous) by a general practitioner, specialist or consultant physician providing clinical support to a patient who:
_140	I .

2. TELEHEALTH ATTENDANCE AT A RESIDENTIAL AGED CARE FACILITY

ATTEND	PANCES RESIDENTIAL AGED CARE FACILITY
	(a) is participating in a video conferencing consultation with a specialist or consultant physician; and
	(b) is a care recipient in a residential care service; and
	(c) is not a resident of a self-contained unit;
	for an attendance on one or more patients at one place on one occasion-each patient
	(See para AN.0.67 of explanatory notes to this Category) Derived Fee: The fee for item 2100 plus \$46.70 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 2100 plus \$3.30 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	Professional attendance of less than 20 minutes in duration (whether or not continuous) by a general practitioner, specialist or consultant physician providing clinical support to a patient who:
	(a) is participating in a video conferencing consultation with a specialist or consultant physician; and
	(b) is a care recipient in a residential care service; and
	(c) is not a resident of a self-contained unit;
	for an attendance on one or more patients at one place on one occasion-each patient
	(See para AN.0.67 of explanatory notes to this Category) Derived Fee: The fee for item 2126 plus \$46.70 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 2126 plus \$3.30 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the
2138	lesser amount
	Professional attendance of at least 20 minutes in duration (whether or not continuous) by a general practitioner, specialist or consultant physician providing clinical support to a patient who:
	(a) is participating in a video conferencing consultation with a specialist or consultant physician; and
	(b) is a care recipient in a residential care service; and
	(c) is not a resident of a self-contained unit;
	for an attendance on one or more patients at one place on one occasion-each patient
	(See para AN.0.67 of explanatory notes to this Category) Derived Fee: The fee for item 2143 plus \$46.70 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 2143 plus \$3.30 per patient. Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the
2179	lesser amount
	Professional attendance of at least 40 minutes in duration (whether or not continuous) by a general practitioner, specialist or consultant physician providing clinical support to a patient who:
	(a) is participating in a video conferencing consultation with a specialist or consultant physician; and
	(b) is a care recipient in a residential care service; and
2220	(c) is not a resident of a self-contained unit;
	·

2. TELEHEALTH ATTENDANCE AT A RESIDENTIAL AGED CARE FACILITY

for an attendance on one or more patients at one place on one occasion-each patient

(See para AN.0.67 of explanatory notes to this Category)

Derived Fee: The fee for item 2195 plus \$46.70 divided by the number of patients seen, up to a maximum of six patients. For seven or more patients - the fee for item 2195 plus \$3.30 per patient.

Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount

A30. MEDICAL PRACTITIONER (INCLUDING A GENERAL PRACTITIONER, SPECIALIST OR CONSULTANT PHYSICIAN) TELEHEALTH

3. MENTAL HEALTH AND WELL-BEING VIDEO CONFERENCING CONSULTATION

ATTENI	DANCES CONFERENCING CONSULTATION
	Group A30. Medical Practitioner (Including A General Practitioner, Specialist Or Consultant Physician) Telehealth Attendances
	Subgroup 3. Mental Health and Well-being Video Conferencing Consultation
	Professional attendance at consulting rooms by a general practitioner, lasting less than 20 minutes, for providing mental health services to a patient with mental health issues, if:
	(a) the attendance is by video conference; and
	(b) the patient is not an admitted patient; and
	(c) the patient and the general practitioner are located within a drought affected eligible area; and
	(d) the patient is, at the time of the attendance, at least 15 kilometres by road from the general practitioner; and
	(e) the patient has an existing relationship with the general practitioner.
2121	(See para AN.30.1 of explanatory notes to this Category) Fee: \$44.20 Benefit: 85% = \$37.60 Extended Medicare Safety Net Cap: \$132.60
2121	Professional attendance at consulting rooms by a general practitioner, lasting at least 20 minutes, for providing mental health services to a patient with mental health issues, if:
	(a) the attendance is by video conference; and
	(b) the patient is not an admitted patient; and
	(c) the patient and the general practitioner are located within a drought affected eligible area; and
	(d) the patient is, at the time of the attendance, at least 15 kilometres by road from the general practitioner; and
	(e) the patient has an existing relationship with the general practitioner.
21.50	(See para AN.30.1 of explanatory notes to this Category) Fee: \$85.60 Benefit: \$5% = \$72.80
2150	Extended Medicare Safety Net Cap: \$256.80 Professional attendance at consulting rooms by a general practitioner, lasting at least 40 minutes, for providing mental health services to a patient with mental health issues, if:

	DICAL PRACTITIONER (INCLUDING A L PRACTITIONER, SPECIALIST OR	
	TANT PHYSICIAN) TELEHEALTH	3. MENTAL HEALTH AND WELL-BEING VIDEO CONFERENCING CONSULTATION
	(a) the attendance is by video conference; and	
	(b) the patient is not an admitted patient; and	
	(c) the patient and the general practitioner are	located within a drought affected eligible area; and
	(d) the patient is, at the time of the attendance practitioner; and	, at least 15 kilometres by road from the general
	(e) the patient has an existing relationship with	n the general practitioner.
	(See para AN.30.1 of explanatory notes to this Catego Fee: \$126.05 Benefit: 85% = \$107.15 Extended Medicare Safety Net Cap: \$378.15	ry)
GENERA	DICAL PRACTITIONER (INCLUDING A L PRACTITIONER, SPECIALIST OR TANT PHYSICIAN) TELEHEALTH	4. NON-REFERRED TELEHEALTH CONSULTATIONS TO WHICH NO OTHER ITEM APPLIES
	Group A30. Medical Practitioner (Including A Physician) Telehealth Attendances	General Practitioner, Specialist Or Consultant
	Subgroup 4. Non-referred Telehealth	Consultations To Which No Other Item Applies
	Professional attendance at consulting rooms by a general practitioner, for an obvious problem characterised by the straightforward nature of the task that requires a short patient history and, if required, limited examination and management, if:	
	 the attendance is by video conference; and the patient is located within a flood affected eligible area. (See para AN.30.2, AN.0.9 of explanatory notes to this Category) Fee: \$20.20 Benefit: 85% = \$17.20	
New		
2095	Extended Medicare Safety Net Cap: \$60.60	1 (1) 1 (1 20 1 (1 20
	Professional attendance at consulting rooms by a	general practitioner, lasting less than 20 minutes, if:
	(a) the attendance is by video conference; and(b) the patient is located within a flood affected eligible area.	
New	(See para AN.30.2, AN.0.9 of explanatory notes to thi Fee: \$44.20 Benefit: 85% = \$37.60	s Category)
2144	Extended Medicare Safety Net Cap: \$132.60	
		general practitioner, lasting at least 20 minutes, if:
	 the attendance is by video conference; a the patient is located within a flood affer 	
Now	(See para AN.30.2, AN.0.9 of explanatory notes to thi Fee: \$85.60 Benefit: \$85% = \$72.80	s Category)
New 2180	Extended Medicare Safety Net Cap: \$256.80	
	, ,	ganaral practitioner lasting at least 40 minutes, if

Professional attendance at consulting rooms by a general practitioner, lasting at least 40 minutes, if:

the attendance is by video conference; and

New 2193

4. NON-REFERRED TELEHEALTH CONSULTATIONS TO WHICH NO OTHER ITEM APPLIES

	ILTANT PHYSICIAN) TELEHEALTH CONSULTATIONS TO WHICH NO OTHER ITEM APPLIES	
	ii. the patient is located within a flood affected eligible area.	
	(See para AN.30.2, AN.0.9 of explanatory notes to this Category) Fee: \$126.05 Benefit: 85% = \$107.15 Extended Medicare Safety Net Cap: \$378.15	
A31. AE	DDICTION MEDICINE 1. ADDICTION MEDICINE ATTENDANCES	
	Group A31. Addiction Medicine	
	Subgroup 1. Addiction Medicine Attendances	
	Professional attendance by an addiction medicine specialist in the practice of his or her specialty following referral of the patient to him or her by a referring practitioner, if the attendance:	
	(a) includes a comprehensive assessment; and	
	(b) is the first or only time in a single course of treatment that a comprehensive assessment is provided	
6018	Fee: \$153.15 Benefit: 75% = \$114.90 85% = \$130.20	
	Professional attendance by an addiction medicine specialist in the practice of his or her specialty following referral of the patient to him or her by a referring practitioner, if the attendance is a patient assessment:	
	(a) before or after a comprehensive assessment under item 6018 in a single course of treatment; or	
	(b) that follows an initial assessment under item 6023 in a single course of treatment; or	
	(c) that follows a review under item 6024 in a single course of treatment	
6019	(See para AN.0.70 of explanatory notes to this Category) Fee: \$76.65 Benefit: 75% = \$57.50 85% = \$65.20	
	Professional attendance by an addiction medicine specialist in the practice of his or her specialty of at least 45 minutes for an initial assessment of a patient with at least 2 morbidities, following referral of the patient to him or her by a referring practitioner, if:	
	(a) an assessment is undertaken that covers:	
	(i) a comprehensive history, including psychosocial history and medication review; and	
	(ii) a comprehensive multi or detailed single organ system assessment; and	
	(iii) the formulation of differential diagnoses; and	
(b) an addiction medicine specialist treatment and management plan of significant complexit includes the following is prepared and provided to the referring practitioner:		
	(i) an opinion on diagnosis and risk assessment;	
	(ii) treatment options and decisions;	
	(iii) medication recommendations; and	
6023	(c) an attendance on the patient to which item 104, 105, 110, 116, 119, 132, 133, 6018 or 6019 applies did not take place on the same day by the same addiction medicine specialist; and	

A31. AD	DICTION MEDICINE 1. ADDICTION MEDICINE ATTENDANCES
	(d) neither this item nor item 132 has applied to an attendance on the patient in the preceding 12 months by the same addiction medicine specialist
	Fee: \$267.85 Benefit: 75% = \$200.90 85% = \$227.70
	Professional attendance by an addiction medicine specialist in the practice of his or her specialty of at least 20 minutes, after the first attendance in a single course of treatment, for a review of a patient with at least 2 morbidities if:
	(a) a review is undertaken that covers:
	(i) review of initial presenting problems and results of diagnostic investigations; and
	(ii) review of responses to treatment and medication plans initiated at time of initial consultation; and
	(iii) comprehensive multi or detailed single organ system assessment; and
	(iv) review of original and differential diagnoses; and
	(b) the modified addiction medicine specialist treatment and management plan is provided to the referring practitioner, which involves, if appropriate:
	(i) a revised opinion on diagnosis and risk assessment; and
	(ii) treatment options and decisions; and
	(iii) revised medication recommendations; and
	(c) an attendance on the patient to which item 104, 105, 110, 116, 119, 132, 133, 6018 or 6019 applies did not take place on the same day by the same addiction medicine specialist; and
	(d) item 6023 applied to an attendance claimed in the preceding 12 months; and
	(e) the attendance under this item is claimed by the same addiction medicine specialist who claimed item 6023 or by a locum tenens; and
	(f) this item has not applied more than twice in any 12 month period
6024	Fee: \$134.10 Benefit: 75% = \$100.60 85% = \$114.00
	Initial professional attendance of 10 minutes or less, on a patient by an addiction medicine specialist in the practice of his or her specialty, if:
	(a) the attendance is by video conference; and
	(b) the patient is not an admitted patient; and
	(c) the patient:
	(i) is located both:
	(A) within a telehealth eligible area; and
	(B) at the time of the attendance-at least 15 km by road from the addiction medicine specialist; or
6025	(ii) is a care recipient in a residential care service; or

A31. AD	DICTION MEDICINE	1. ADDICTION MEDICINE ATTENDANCES
	(iii) is a patient of:	
	(A) an Aboriginal Medical Ser	rvice; or
	(B) an Aboriginal Community	Controlled Health Service;
	for which a direction made und	der subsection 19(2) of the Act applies; and
	(d) no other initial consultation has taken place for a single course of treatment	
	Fee: \$114.90 Benefit: 85% = \$97	7.70
	Professional attendance on a patient by specialty, if:	an addiction medicine specialist in the practice of his or her
	(a) the attendance is by video conference	e; and
	(b) the attendance is for a service:	
	(i) provided with item 6018 or 60	019 and lasting more than 10 minutes; or
	(ii) provided with item 6023 or 6	024; and
	(c) the patient is not an admitted patient	; and
	(d) the patient:	
	(i) is located both:	
	(A) within a telehealth eligible	e area; and
	(B) at the time of the attendance-at least 15 km by road from the addiction med or	
	(ii) is a care recipient in a resider	ntial care service; or
	(iii) is a patient of:	
(A) an Aboriginal Medical Service; or		rvice; or
	(B) an Aboriginal Community	Controlled Health Service;
	for which a direction made under subsection 19 (2) of the Act applies	
6026		
	DICTION MEDICINE	2. GROUP THERAPY
	Group A31. Addiction Medicine	
		Subgroup 2. Group Therapy
	and relating to the condition for which g the continuous direct supervision of an a specialty for a group of 2 to 9 unrelated	I consultation with a patient taking place on the same occasion group therapy is conducted) of not less than 1 hour, given under addiction medicine specialist in the practice of his or her patients, or a family group of more than 2 patients, each of ine specialist by a referring practitioner-for each patient
6028	Fee: \$50.05 Benefit: 75% = \$37	7.55 85% = \$42.55
A31. AD	DICTION MEDICINE	3. ADDICTION MEDICINE CASE CONFERENCES

A31. Al	DDICTION MEDICINE 3. ADDICTION MEDICINE CASE CONFERENCES
	Group A31. Addiction Medicine
	Subgroup 3. Addiction Medicine Case Conferences
	Attendance by an addiction medicine specialist in the practice of his or her specialty, as a member of a multidisciplinary case conference team of at least 2 other formal care providers of different disciplines, to organise and coordinate a community case conference of less than 15 minutes, with the multidisciplinary case conference team
6029	(See para AN.0.51 of explanatory notes to this Category) Fee: \$43.35 Benefit: 75% = \$32.55 85% = \$36.85
	Attendance by an addiction medicine specialist in the practice of his or her specialty, as a member of a multidisciplinary case conference team of at least 2 other formal care providers of different disciplines, to organise and coordinate a community case conference of at least 15 minutes but less than 30 minutes, with the multidisciplinary case conference team
6031	(See para AN.0.51 of explanatory notes to this Category) Fee: \$76.65 Benefit: 75% = \$57.50 85% = \$65.20
	Attendance by an addiction medicine specialist in the practice of his or her specialty, as a member of a multidisciplinary case conference team of at least 2 other formal care providers of different disciplines, to organise and coordinate a community case conference of at least 30 minutes but less than 45 minutes, with the multidisciplinary case conference team
6032	(See para AN.0.51 of explanatory notes to this Category) Fee: \$115.00 Benefit: 75% = \$86.25 85% = \$97.75
	Attendance by an addiction medicine specialist in the practice of his or her specialty, as a member of a multidisciplinary case conference team of at least 2 other formal care providers of different disciplines, to organise and coordinate the multidisciplinary case conference of at least 45 minutes, with the multidisciplinary case conference team
6034	(See para AN.0.51 of explanatory notes to this Category) Fee: \$153.15 Benefit: 75% = \$114.90 85% = \$130.20
	Attendance by an addiction medicine specialist in the practice of his or her specialty, as a member of a multidisciplinary case conference team of at least 2 other formal care providers of different disciplines, to participate in a community case conference (other than to organise and coordinate the conference) of less than 15 minutes, with the multidisciplinary case conference team
6035	(See para AN.0.51 of explanatory notes to this Category) Fee: \$34.65 Benefit: 75% = \$26.00 85% = \$29.50
	Attendance by an addiction medicine specialist in the practice of his or her specialty, as a member of a multidisciplinary case conference team of at least 2 other formal care providers of different disciplines, to participate in a community case conference (other than to organise and coordinate the conference) of at least 15 minutes but less than 30 minutes, with the multidisciplinary case conference team
6037	(See para AN.0.51 of explanatory notes to this Category) Fee: \$61.30 Benefit: 75% = \$46.00 85% = \$52.15
	Attendance by an addiction medicine specialist in the practice of his or her specialty, as a member of a multidisciplinary case conference team of at least 2 other formal care providers of different disciplines, to participate in a community case conference (other than to organise and coordinate the conference) of at least 30 minutes but less than 45 minutes, with the multidisciplinary case conference team
6038	(See para AN.0.51 of explanatory notes to this Category) Fee: \$92.00 Benefit: 75% = \$69.00 85% = \$78.20
6042	Attendance by an addiction medicine specialist in the practice of his or her specialty, as a member of a multidisciplinary case conference team of at least 2 other formal care providers of different disciplines, to participate in a community case conference (other than to organise and coordinate the conference) of

A31. A	DDICTION MEDICINE 3. ADDICTION MEDICINE CASE CONFERENCES	
_	at least 45 minutes, with the multidisciplinary case conference team	
	(See para AN.0.51 of explanatory notes to this Category)	
100.0	Fee: \$122.55 Benefit: 75% = \$91.95 85% = \$104.20	
A32. S	EXUAL HEALTH MEDICINE 1. SEXUAL HEALTH MEDICINE ATTENDANCES	
	Group A32. Sexual Health Medicine	
	Subgroup 1. Sexual Health Medicine Attendances	
	Professional attendance by a sexual health medicine specialist in the practice of his or her specialty following referral of the patient to him or her by a referring practitioner, if the attendance:	
	(a) includes a comprehensive assessment; and	
	(b) is the first or only time in a single course of treatment that a comprehensive assessment is provided	
6051	Fee: \$153.15 Benefit: 75% = \$114.90 85% = \$130.20	
	Professional attendance by a sexual health medicine specialist in the practice of his or her specialty following referral of the patient to him or her by a referring practitioner, if the attendance is a patient assessment:	
	(a) before or after a comprehensive assessment under item 6051 in a single course of treatment; or	
	(b) that follows an initial assessment under item 6057 in a single course of treatment; or	
	(c) that follows a review under item 6058 in a single course of treatment	
6052	(See para AN.0.70 of explanatory notes to this Category) Fee: \$76.65 Benefit: 75% = \$57.50 85% = \$65.20	
	Professional attendance by a sexual health medicine specialist in the practice of his or her specialty of at least 45 minutes for an initial assessment of a patient with at least 2 morbidities, following referral of the patient to him or her by a referring practitioner, if:	
	(a) an assessment is undertaken that covers:	
	(i) a comprehensive history, including psychosocial history and medication review; and	
	(ii) a comprehensive multi or detailed single organ system assessment; and	
	(iii) the formulation of differential diagnoses; and	
	(b) a sexual health medicine specialist treatment and management plan of significant complexity that includes the following is prepared and provided to the referring practitioner:	
	(i) an opinion on diagnosis and risk assessment;	
	(ii) treatment options and decisions;	
	(iii) medication recommendations; and	
	(c) an attendance on the patient to which item 104, 105, 110, 116, 119, 132, 133, 6051 or 6052 applies did not take place on the same day by the same sexual health medicine specialist; and	
	(d) neither this item nor item 132 has applied to an attendance on the patient in the preceding 12 months by the same sexual health medicine specialist	
6057	Fee: \$267.85 Benefit: 75% = \$200.90 85% = \$227.70	

1. SEXUAL HEALTH MEDICINE ATTENDANCES A32. SEXUAL HEALTH MEDICINE Professional attendance by a sexual health medicine specialist in the practice of his or her specialty of at least 20 minutes, after the first attendance in a single course of treatment, for a review of a patient with at least 2 morbidities if: (a) a review is undertaken that covers: (i) review of initial presenting problems and results of diagnostic investigations; and (ii) review of responses to treatment and medication plans initiated at time of initial consultation; and (iii) comprehensive multi or detailed single organ system assessment; and (iv) review of original and differential diagnoses; and (b) the modified sexual health medicine specialist treatment and management plan is provided to the referring practitioner, which involves, if appropriate: (i) a revised opinion on diagnosis and risk assessment; and (ii) treatment options and decisions; and (iii) revised medication recommendations; and (c) an attendance on the patient, being an attendance to which item 104, 105, 110, 116, 119, 132, 133, 6051 or 6052 applies did not take place on the same day by the same sexual health medicine specialist; and (d) item 6057 applied to an attendance claimed in the preceding 12 months; and (e) the attendance under this item is claimed by the same sexual health medicine specialist who claimed item 6057 or by a locum tenens; and (f) this item has not applied more than twice in any 12 month period 6058 **Benefit:** 75% = \$100.60 85% = \$114.00Fee: \$134.10 Initial professional attendance of 10 minutes or less, on a patient by a sexual health medicine specialist in the practice of his or her specialty, if: (a) the attendance is by video conference; and (b) the patient is not an admitted patient; and (c) the patient: (i) is located both: (A) within a telehealth eligible area; and (B) at the time of the attendance-at least 15 km by road from the sexual health medicine specialist; or (ii) is a care recipient in a residential care service; or (iii) is a patient of: (A) an Aboriginal Medical Service; or

A32. SEX	TUAL HEALTH MEDICINE 1. SEXUAL HEALTH MEDICINE ATTENDANCES
	(B) an Aboriginal Community Controlled Health Service;
	for which a direction made under subsection 19(2) of the Act applies; and
	(d) no other initial consultation has taken place for a single course of treatment
	Fee: \$114.90 Benefit: 85% = \$97.70
	Professional attendance on a patient by a sexual health medicine specialist in the practice of his or her specialty if:
	(a) the attendance is by video conference; and
	(b) the attendance is for a service:
	(i) provided with item 6051 or 6052 and lasting more than 10 minutes; or
	(ii) provided with item 6057 or 6058; and
	(c) the patient is not an admitted patient; and
	(d) the patient:
	(i) is located both:
	(A) within a telehealth eligible area; and
(B) at the time of the attendance-at least 15 km by road from the sexual healt specialist; or	
	(ii) is a care recipient in a residential care service; or
	(iii) is a patient of:
	(A) an Aboriginal Medical Service; or
	(B) an Aboriginal Community Controlled Health Service;
	for which a direction made under subsection 19 (2) of the Act applies
6060	Derived Fee: 50% of the fee for item 6051, 6052, 6057 or 6058 Benefit: 85% of the derived fee
A32. SEX	CUAL HEALTH MEDICINE 2. HOME VISITS
	Group A32. Sexual Health Medicine
	Subgroup 2. Home Visits
	Professional attendance at a place other than consulting rooms or a hospital by a sexual health medicine specialist in the practice of his or her specialty following referral of the patient to him or her by a referring practitioner-initial attendance in a single course of treatment
6062	Fee: \$185.85 Benefit: 85% = \$158.00
	Professional attendance at a place other than consulting rooms or a hospital by a sexual health medicine specialist in the practice of his or her specialty following referral of the patient to him or her by a referring practitioner-each attendance after the attendance under item 6062 in a single course of treatment
6063	Fee: \$112.40 Benefit: 85% = \$95.55

A32. SI	3. SEXUAL HEALTH MEDICINE CASE EXUAL HEALTH MEDICINE CONFERENCES
	Group A32. Sexual Health Medicine
	Subgroup 3. Sexual Health Medicine Case Conferences
	Attendance by a sexual health medicine specialist in the practice of his or her specialty, as a member of a multidisciplinary case conference team of at least 2 other formal care providers of different disciplines, to organise and coordinate a community case conference of less than 15 minutes, with the multidisciplinary case conference team
6064	(See para AN.0.51 of explanatory notes to this Category) Fee: \$43.35 Benefit: 75% = \$32.55 85% = \$36.85
	Attendance by a sexual health medicine specialist in the practice of his or her specialty, as a member of a multidisciplinary case conference team of at least 2 other formal care providers of different disciplines, to organise and coordinate a community case conference of at least 15 minutes but less than 30 minutes, with the multidisciplinary case conference team
6065	(See para AN.0.51 of explanatory notes to this Category) Fee: \$76.65 Benefit: 75% = \$57.50 85% = \$65.20
0002	Attendance by a sexual health medicine specialist in the practice of his or her specialty, as a member of a multidisciplinary case conference team of at least 2 other formal care providers of different disciplines, to organise and coordinate a community case conference of at least 30 minutes but less than 45 minutes, with the multidisciplinary case conference team
6067	(See para AN.0.51 of explanatory notes to this Category) Fee: \$115.00 Benefit: 75% = \$86.25 85% = \$97.75
	Attendance by a sexual health medicine specialist in the practice of his or her specialty, as a member of a multidisciplinary case conference team of at least 2 other formal care providers of different disciplines, to organise and coordinate a community case conference of at least 45 minutes, with the multidisciplinary case conference team
6068	(See para AN.0.51 of explanatory notes to this Category) Fee: \$153.15 Benefit: 75% = \$114.90 85% = \$130.20
	Attendance by a sexual health medicine specialist in the practice of his or her specialty, as a member of a multidisciplinary case conference team of at least 2 other formal care providers of different disciplines, to participate in a community case conference (other than to organise and coordinate the conference) of less than 15 minutes, with the multidisciplinary case conference team
6071	(See para AN.0.51 of explanatory notes to this Category) Fee: \$34.65 Benefit: 75% = \$26.00 85% = \$29.50
0071	Attendance by a sexual health medicine specialist in the practice of his or her specialty, as a member of a multidisciplinary case conference team of at least 2 other formal care providers of different disciplines, to participate in a community case conference (other than to organise and coordinate the conference) of at least 15 minutes but less than 30 minutes, with the multidisciplinary case conference team
6072	(See para AN.0.51 of explanatory notes to this Category) Fee: \$61.30 Benefit: 75% = \$46.00 85% = \$52.15
	Attendance by a sexual health medicine specialist in the practice of his or her specialty, as a member of a multidisciplinary case conference team of at least 2 other formal care providers of different disciplines, to participate in a community case conference (other than to organise and coordinate the conference) of at least 30 minutes but less than 45 minutes, with the multidisciplinary case conference team
6074	(See para AN.0.51 of explanatory notes to this Category) Fee: \$92.00 Benefit: 75% = \$69.00 85% = \$78.20
6075	Attendance by a sexual health medicine specialist in the practice of his or her specialty, as a member of a multidisciplinary case conference team of at least 2 other formal care providers of different disciplines,

A32 SF	3. SEXUAL HEALTH MEDICINE CASE XUAL HEALTH MEDICINE CONFERENCES		
AGE. GE	to participate in a community case conference (other than to organise and coordinate the conference) of at least 45 minutes, with the multidisciplinary case conference team		
	(See para AN.0.51 of explanatory notes to this Category) Fee: \$122.55 Benefit: 75% = \$91.95 85% = \$104.20		
	ANSCATHETER AORTIC VALVE		
IMPLAN	TATION CASE CONFERENCE		
	Group A33. Transcatheter Aortic Valve Implantation Case Conference		
	Coordination of a TAVI Case Conference by a TAVI Practitioner where the TAVI Case Conference has a duration of 10 minutes or more.		
	(Not payable more than once per patient in a five year period.)		
6080	(See para AN.33.1, TN.8.135 of explanatory notes to this Category) Fee: \$50.90 Benefit: 75% = \$38.20 85% = \$43.30		
0080	Attendance at a TAVI Case Conference by a specialist or consultant physician who does not also perform the service described in item 6080 for the same case conference where the TAVI Case Conference has a duration of 10 minutes or more.		
	(Not payable more than twice per patient in a five year period.)		
6081	(See para AN.33.1, TN.8.135 of explanatory notes to this Category) Fee: \$37.95 Benefit: 75% = \$28.50 85% = \$32.30		
A34. HE	ALTH CARE HOMES		
	Group A34. Health Care Homes		
	A professional attendance, including by telephone or videoconference, on a patient participating in the Health Care Homes Program by or on behalf of a medical practitioner (including a general practitioner but not including a specialist or consultant physician) or participating nurse practitioner employed or otherwise engaged by the Health Care Home trial site at which the patient is enrolled - each patient.		
	The service must be provided to the patient for the purposes of the Health Care Homes Program and the service may be provided to the patient individually or as part of a group.		
6087	(See para AN.34.1 of explanatory notes to this Category) Fee: \$1.15 Benefit: 85% = \$1.00		
	RVICES FOR PATIENTS IN RESIDENTIAL 1. FLAG FALL AMOUNT FOR RESIDENTIAL ARE FACILITIES AGED CARE FACILITIES		
	Group A35. Services For Patients in Residential Aged Care Facilities		
	Subgroup 1. Flag Fall Amount For Residential Aged Care Facilities		
	A flag fall service to which item 90020, 90035, 90043 or 90051 applies. For the initial attendance at one residential aged care facility on one occasion, applicable to a maximum of one patient attended on.		
New 90001	(See para AN.35.1 of explanatory notes to this Category) Fee: \$55.00 Benefit: 100% = \$55.00		
	A flag fall service to which item 90092, 90093, 90095, 90096, 90183, 90188, 90202 or 90212 applies. For the initial attendance at one residential aged care facility on one occasion, applicable to a maximum of one patient attended on.		
New 90002	(See para AN.35.2 of explanatory notes to this Category)		

	RVICES FOR PATIENTS IN RESIDER CARE FACILITIES	NTIAL 1. FLAG FALL AMOUNT FOR RESIDENTIAL AGED CARE FACILITIES
	Fee: \$40.00 Benefit: 100% = \$40.00	40.00
	RVICES FOR PATIENTS IN RESIDER	2. GENERAL PRACTITIONER NON-REFERRED NTIAL ATTENDANCE AT A RESIDENTIAL AGED CARE FACILITY
	Group A35. Services For Patients in I	Residential Aged Care Facilities
	Subgroup 2. General Practitioner	Non-Referred Attendance At A Residential Aged Care Facility
	facility (other than a professional attended consulting rooms situated within such a care facility (other than accommodation problem characterised by the straightform)	rvice to which another item applies) at a residential aged care lance at a self-contained unit) or professional attendance at complex if the patient is accommodated in a residential aged in a self-contained unit) by a general practitioner for an obvious ward nature of the task that requires a short patient history and, nagement—an attendance on one or more patients at one asion - each patient.
New 90020	(See para AN.0.9, AN.35.1 of explanatory n Fee: \$17.20 Benefit: 100% = \$	
		actitioner at a residential aged care facility to residents of the nother item in the table applies), lasting less than 20 minutes and clinically relevant:
	(a) taking a patient history;	
	(b) performing a clinical examination;	
	(c) arranging any necessary investigation	n;
	(d) implementing a management plan;	
	(e) providing appropriate preventive her	alth care;
	for one or more health-related issues, w patients at one residential aged care fac	ith appropriate documentation—an attendance on one or more ility on one occasion—each patient
New 90035	(See para AN.0.9, AN.35.1 of explanatory n Fee: \$37.60 Benefit: 100% = \$3	
	Professional attendance by a general pra-	actitioner at a residential aged care facility to residents of the nother item in the table applies), lasting at least 20 minutes and
	(a) taking a detailed patient history;	
	(b) performing a clinical examination;	
	(c) arranging any necessary investigation	n;
	(d) implementing a management plan;	
	(e) providing appropriate preventive her	alth care;
	for one or more health-related issues, w patients at one residential aged care fac-	ith appropriate documentation—an attendance on one or more ility on one occasion—each patient
New 90043	(See para AN.0.9, AN.35.1 of explanatory n Fee: \$72.80 Benefit: 100% = \$'	

	2. GENERAL PRACTITIONER NON-REFERRED RVICES FOR PATIENTS IN RESIDENTIAL ATTENDANCE AT A RESIDENTIAL AGED CARE FACILITIES FACILITY
	Professional attendance by a general practitioner at a residential aged care facility to residents of the facility (other than a service to which another item in the table applies), lasting at least 40 minutes and including any of the following that are clinically relevant:
	(a) taking an extensive patient history;
	(b) performing a clinical examination;
	(c) arranging any necessary investigation;
	(d) implementing a management plan;
	(e) providing appropriate preventive health care;
	for one or more health-related issues, with appropriate documentation—an attendance on one or more patients at one residential aged care facility on one occasion—each patient
New 90051	(See para AN.0.9, AN.35.1 of explanatory notes to this Category) Fee: \$107.15 Benefit: 100% = \$107.15
	3. OTHER MEDICAL PRACTITIONER NON- RVICES FOR PATIENTS IN RESIDENTIAL REFERRED ATTENDANCE AT A RESIDENTIAL ARE FACILITIES AGED CARE FACILITY
	Group A35. Services For Patients in Residential Aged Care Facilities
	Subgroup 3. Other Medical Practitioner Non-Referred Attendance At A Residential Aged Care Facility
	Professional attendance (other than a service to which any other item applies) at a residential aged care facility (other than a professional attendance at a self-contained unit) or professional attendance at consulting rooms situated within such a complex where the patient is accommodated in the residential aged care facility (that is not accommodation in a self-contained unit) of not more than 5 minutes in duration—an attendance on one or more patients at one residential aged care facility on one occasion—each patient, by:
	(a) a medical practitioner (who is not a general practitioner); or
	(b) a general practitioner to whom clause 2.3.1 applies.
New	(See para AN.7.1, AN.35.2 of explanatory notes to this Category)
Professional attendance (other than a service to which any other item applies) at a residuality (other than a professional attendance at a self-contained unit) or professional at consulting rooms situated within such a complex where the patient is accommodated i aged care facility (that is not accommodation in a self-contained unit) of more than 5 multiple to the patient of the patients at one residential facility on one occasion—each patient, by:	
	(a) a medical practitioner (who is not a general practitioner); or
	(b) a general practitioner to whom clause 2.3.1 applies.
New 90093	(See para AN.7.1, AN.35.2 of explanatory notes to this Category) Fee: \$16.00 Benefit: 100% = \$16.00
New 90095	Professional attendance (other than a service to which any other item applies) at a residential aged care facility (other than a professional attendance at a self-contained unit) or professional attendance at

3. OTHER MEDICAL PRACTITIONER NON-A35. SERVICES FOR PATIENTS IN RESIDENTIAL REFERRED ATTENDANCE AT A RESIDENTIAL **AGED CARE FACILITIES AGED CARE FACILITY** consulting rooms situated within such a complex where the patient is accommodated in the residential aged care facility (that is not accommodation in a self-contained unit) of more than 25 minutes in duration but not more than 45 minutes—an attendance on one or more patients at one residential aged care facility on one occasion—each patient, by: (a) a medical practitioner (who is not a general practitioner); or (b) a general practitioner to whom clause 2.3.1 applies. (See para AN.7.1, AN.35.2 of explanatory notes to this Category) Fee: \$35.50 **Benefit:** 100% = \$35.50Professional attendance (other than a service to which any other item applies) at a residential aged care facility (other than a professional attendance at a self-contained unit) or professional attendance at consulting rooms situated within such a complex where the patient is accommodated in the residential aged care facility (that is not accommodation in a self-contained unit) of more than 45 minutes in duration—an attendance on one or more patients at one residential aged care facility on one occasioneach patient, by: (a) a medical practitioner (who is not a general practitioner); or (b) a general practitioner to whom clause 2.3.1 applies. (See para AN.7.1, AN.35.2 of explanatory notes to this Category) New 90096 Fee: \$57.50 **Benefit:** 100% = \$57.50 4. NON-SPECIALIST PRACTITIONER NON-A35. SERVICES FOR PATIENTS IN RESIDENTIAL REFERRED ATTENDANCE AT A RESIDENTIAL **AGED CARE FACILITIES** AGED CARE FACILITY Group A35. Services For Patients in Residential Aged Care Facilities Subgroup 4. Non-Specialist Practitioner Non-Referred Attendance At A Residential Aged Care Facility Professional attendance (other than a service to which any other item applies) at a residential aged care facility (other than a professional attendance at a self-contained unit) or professional attendance at consulting rooms situated within such a complex where the patient is accommodated in the residential aged care facility (that is not accommodation in a self-contained unit) of not more than 5 minutes in duration—an attendance on one or more patients at one residential aged care facility on one occasion each patient, by medical practitioner in an eligible area. (See para AN.7.1, AN.35.2 of explanatory notes to this Category) New **Benefit:** 100% = \$13.75 90183 Fee: \$13.75 Professional attendance (other than a service to which any other item applies) at a residential aged care facility (other than a professional attendance at a self-contained unit) or professional attendance at consulting rooms situated within such a complex where the patient is accommodated in the residential aged care facility (that is not accommodation in a self-contained unit) of more than 5 minutes in duration

Fee: \$30.10 Benefit: 100% = \$30.10

Professional attendance (other than a service to which any other item applies) at a residential aged care facility (other than a professional attendance at a self-contained unit) or professional attendance at consulting rooms situated within such a complex where the patient is accommodated in the residential aged care facility (that is not accommodation in a self-contained unit) of more than 25 minutes in duration but not more than 45 minutes—an attendance on one or more patients at one residential aged

but not more than 25 minutes—an attendance on one or more patients at one residential aged care

facility on one occasion—each patient, by a medical practitioner in an eligible area.

(See para AN.7.1, AN.35.2 of explanatory notes to this Category)

New 90188

New

	RVICES FOR PATIENTS IN RESIDENTIAL ARE FACILITIES	AGED CARE FACILITY
	care facility on one occasion—each patient, by	a medical practitioner in an eligible area.
	(See para AN.7.1, AN.35.2 of explanatory notes to the	nis Category)
	Fee: \$58.25 Benefit: 100% = \$58.25 Professional attendance (other than a service to which any other item applies) at a residential aged care facility (other than a professional attendance at a self-contained unit) or professional attendance at consulting rooms situated within such a complex where the patient is accommodated in the residential aged care facility (that is not accommodation in a self-contained unit) of more than 45 minutes in duration—an attendance on one or more patients at one residential aged care facility on one occasion—each patient, by a medical practitioner in an eligible area.	
New	(See para AN.7.1, AN.35.2 of explanatory notes to this Category)	
90212	Fee: \$85.70 Benefit: 100% = \$85.70	

INDEX

Α	G
acupuncture 173, 193, 195, 197, 199 Acupuncture, by a medical practitioner 173, 193, 195 addiction medicine 6018-6019, 6023-6026, 6028-6029 6031-6032, 6034-6035, 6037-6038, 6042	Group psychotherapy 34. group therapy 602 group therapy 170-17. health assessments 224-22.
at a place other than a hospital 197, 199 attendance 6018-6019, 6023-6026, 6051-6052, 6057-6060 Attendance, acupuncture 173, 193, 195	Н
Autism, pervasive developmental disorder, consultant physicians 135, 289	home visit 6062-6060 incentive items - PIP - general practitioner 250 2503-2504, 2506-2507, 2509, 2517-2518, 2521-2522
С	2525-2526, 2546-2547, 2552-2553, 2558-2559
	incentive items - PIP - other non-preferred 251-25' 259-266, 268-271, 2600, 2603, 2606, 2610, 2613, 2616
Care planning 721, 723, 729, 731	2620, 2622, 2624, 2631, 2633, 2635, 2664, 2666, 2668
care planning 721, 723, 729, 731 Care planning 721, 723, 729, 731	2673, 2675, 2677
case conference 6029, 6031-6032, 6034-6035, 6037-6038, 6042	other non-specialist 52-54, 57-60, 65, 92-93, 95-96
6064-6065, 6067-6068, 6071-6072, 6074-6075	•
case conference - consultant psychiatrist 855, 857-858 861, 864, 866	Р
case conference, consultant physician 820, 822-823 825-826, 828, 830, 832, 834-835, 837-838	Pervasive developmental disorder, autism, consultant physicians 135, 289
Case Conference, Consultant Psychiatrist 855, 857-858, 861	Pregnancy support counselling 792
864, 866	Professional attendances 179, 181, 183, 185, 187-189, 19
Case conferencing by geriatrician/rehabilitation physician 880 consultant occupational physician 385-388	202-203, 206, 212, 214-215, 218-233, 235-240, 243-245, 249 251-257, 259-266, 268-272, 276-277, 279, 281-283, 285-287
consultant occupational physician 385-388 consultant physician (not psychiatry) 110, 116, 119, 122 128, 131	733, 737, 741, 745, 761, 763, 766, 769, 772, 776, 788-789 792, 812, 827, 829, 867-869, 873, 876, 881, 885, 891-892
consultant physician treatment and management plan 132-133	Prolonged professional attendance, lifesaving 160-16-
consultant psychiatrist 300, 302, 304, 306, 308, 310, 312	214-215, 218-220
314, 316, 318-320, 322, 324, 326, 328, 330, 332, 334	prolonged, lifesaving treatment 160-16-
336, 338, 342, 344, 346, 348, 350, 352	psychotherapy, family 342, 344, 34
consultant public health medicine 410-417	public health physicians 410-41'
contact lenses 10801-10809, 10816 Contact lenses, attendances 10801-10809, 10816	Public health physicians - attendances 410-41′ sexual health 6051-6052, 6057-6060, 6062-6065, 6067-6066 6071-6072, 6074-6075
D	specialist 104-103
J	telepsychiatry 353, 355-359, 361, 364, 366-367, 369-370
Domiciliary Medication Management Review 245, 249 emergency physician 501, 503, 507, 511, 515, 519-520, 530 532, 534, 536	therapy, family 170-172
F	
Family group psychotherapy 342, 344, 346	
family group therapy 170-172 focussed psychological strategies 2721, 2723, 2725, 2727	
for aboriginal and Torres Strait Islander people 715	
general practitioner 3-4, 20, 23-24, 35-37, 43-44, 47, 51 2501, 2503-2504, 2506-2507, 2509, 2517-2518, 2521-2522	
2525-2526, 2546-2547, 2552-2553, 2558-2559 geriatrician comprehensive assessment and management plan141,	
143, 145, 147	
geriatrician or rehabilitation physician 880	

CATEGORY 2: DIAGNOSTIC PROCEDURES AND INVESTIGATIONS

SUMMARY OF CHANGES FROM 01/03/2019

The 01/03/2019 changes to the MBS are summarised below and are identified in the Schedule pages by one or more of the following words appearing above the item number:

(a) new item	New
(b) amended description	Amend
(c) fee amended	Fee
(d) item number changed	Renum
(e) EMSN changed	EMSN

There are no changes to this Category for 01/03/2019.

DIAGNOSTIC PROCEDURES AND INVESTIGATIONS NOTES

DN.1.1 Electroencephalography (EEG), Prolonged Recording - (item 11003)

Item 11003 covers an extended EEG recording of at least 3 hours duration, other than ambulatory or video recording.

DN.1.2 Electroencephalography (EEG), Ambulatory or Video - (Items 11004 and 11005)

Items 11004 and 11005 cover prolonged ambulatory or video EEG, recording of at least 3 hours duration for:

- Diagnosing the basis of episodic neurological dysfunction;
- Characterising the nature of a patient's epileptic seizures;
- Localising seizures in patients with uncontrolled epilepsy, with a view to surgery; or
- Assessing treatment response where subclinical seizures are suspected.

DN.1.3 Neuromuscular Diagnosis - (Item 11012)

Based on advice from the Australian Association of Neurologists, Medicare benefits are not payable under Item 11012 for quantitative sensory nerve testing using "Neurometer CPT" diagnostic devices. The advice indicated that the device was still in the evaluation and research stage and did not have widespread clinical application.

DN.1.4 Investigation of Central Nervous System Evoked Responses - (Items 11024 and 11027)

In the context of these items a study refers to one or more averaged samples of electrical activity recorded from one or more sites in the central nervous system in response to the same stimulus.

Second or subsequent studies refer to either stimulating the point of stimulation (e.g. right eye or left median nerve) with a different stimulus or stimulating another point of stimulation (e.g. left eye or right median nerve).

NOTE: Items 11024 and 11027 are not intended to cover bio-feedback techniques.

DN.1.5 Electroretinography - (Items 11204, 11205, 11210 and 11211)

Current professional guidelines and standards for electroretinography, electroculography and pattern retinography are produced by the International Society for Clinical Electrophysiology of Vision (ISCEV).

DN.1.6 Computerised Perimetry Printed Results - (Items 11221 and 11224)

Computerised perimetry performed by optometrists is covered by MBS items 10940 and 10941. Items 11221 and 11224 should not be used to repeat perimetry unless clinically necessary - such as where the results of the perimetry have been provided by the optometrist referring the patient to an ophthalmologist.

DN.1.7 Computerised Perimetry - (Items 11221 and 11224)

Item 11221 for bilateral procedures cannot be claimed for patients who are totally blind in one eye. In this instance, item 11224 for unilateral procedures should be claimed, where appropriate.

DN.1.8 Orbital Contents - (Items 11240, 11241, 11242 and 11243)

Items 11240 and 11241 may only be utilised once per patient per practitioner. Where an additional service is necessary items 11242 and 11243 should be utilised.

Partial coherence interferometry may also be referred to as optical (or ocular) coherence biometry or laser Doppler interferometry.

DN.1.9 Brain Stem Evoked Response Audiometry - (Item 11300)

Item 11300 can be claimed for the programming of a cochlear speech processor.

DN.1.10 Electrocochleography - (Item 11304)

Item 11304 refers to electrocochleography with insertion of electrodes through the tympanic membrane.

DN.1.11 Non-determinate Audiometry - (Item 11306)

This refers to screening audiometry covering those services, one or more, referred to in Items 11309-11318 when not performed under the conditions set out in paragraph D1.13.

DN.1.12 Audiology Services - (Items 11309 to 11318)

A medical service specified in Items 11309 to 11318 shall be taken to be a medical service for the purposes of payment of benefits if, and only if, it is rendered:

- (a) in conditions that allow the establishment of determinate thresholds;
- (b) in a sound attenuated environment with background noise conditions that comply with Australian Standard AS/NZS 1269.3-2005; and
- (c) using calibrated equipment that complies with Australian Standard AS IEC 60645.1-22002, AS IEC 60645.2-2002 and AS IEC 60645.3-2002.

DN.1.13 Oto-Acoustic Emission Audiometry - (Item 11332)

Medicare benefits are not payable under Item 11332 for routine screening of infants. The equipment used to provide this service must be capable of displaying the recorded emission and not just a pass/fail indicator.

DN.1.14 Respiratory Function Tests - (Item 11503)

Fractional exhaled nitric oxide (FeNO) testing cannot be claimed under item 11503.

When laboratory based spirometry (item 11512) is performed on the same day as a test approved under item 11503, then only 11503 must be claimed. When spirometry is the only laboratory test performed then 11512 must be claimed.

Maximum inspiratory and expiratory flow-volume loop testing for the purpose of diagnosing central airways obstruction is to be performed under item 11512 not 11503. Item 11503 is not for the purpose of investigation of sleep disorders. Polygraphic data obtained as part of a sleep study item in the range 12203 to 12250 cannot be used for the purpose of claiming item 11503.

DN.1.15 Capsule Endoscopy - (Item 11820 and 11823)

Capsule endoscopy is primarily used to view the small bowel, which cannot be viewed by upper gastrointestinal endoscopy and colonoscopy.

Capsule endoscopy imaging must be kept in a manner that facilitates retrieval on the basis of the patient's name and date of service. Records must be retained for a period of 2 years commencing on the day on which the service was rendered.

Conjoint committee

The Conjoint Committee comprises representatives from the Gastroenterological Society of Australia (GESA), the Royal Australasian College of Physicians (RACP) and the Royal Australasian College of Surgeons (RACS). For the purposes of Items 11820 and 11823, specialists or consultant physicians performing this procedure must have

endoscopic training recognised by The Conjoint Committee for the Recognition of Training in Gastrointestinal Endoscopy, and the Department of Human Services notified of that recognition.

DN.1.16 Administration of Thyrotropin Alfa-rch for the Detection of Recurrent Well-differentiated Thyroid Cancer - (Item 12201)

Thyrotropin alfa-rch is a diagnostic agent that allows patients to remain on thyroid hormone therapy while being assessed for recurrent cancer. This item was introduced following an assessment by the Medical Services Advisory Committee (MSAC) of the available evidence relating to the safety, effectiveness and cost-effectiveness of thyrotropin alfa-rch. MSAC found that the use of thyrotropin alfa-rch is associated with a lower diagnostic accuracy than when the patient has withdrawn from thyroid hormone therapy. Accordingly, benefits are payable under the item only for patients in whom thyroid hormone therapy withdrawal is medically contraindicated and where concurrent whole body study using radioactive iodine and serum thyroglobulin are undertaken. Services provided to patients who do not demonstrate the indications set out in item 12201 do not attract benefits under the item.

"Severe psychiatric illness" is defined as patients with a severe pre-existing psychiatric illness who are currently under specialist psychiatric care.

The item includes the cost of supplying thyrotropin alfa-rch and the equivalent of a subsequent specialist attendance. "Administration" means an attendance by the specialist or consultant physician (the administering practitioner) that includes:

- an assessment that the patient meets the criteria prescribed by the item;
 - the supply of thyrotropin alfa-rch;
- ensuring that thyrotropin alfa-rch is injected (either by the administering practitioner or by another practitioner) in two doses at 24 hour intervals, with the second dose being administered 72 hours prior to whole body study with radioactive iodine and serum thyroglobulin test; and
- arranging the whole body radioactive iodine study and the serum thyroglobulin test.

Where thyrotropin alfa-rch is injected by the administering practitioner, benefits are not payable for an attendance on the day the second dose is administered. Where thyrotropin alfa-rch is injected by: a general practitioner - benefits are payable under a Level A consultation (item 3); other practitioners - benefits are payable under item 52.

DN.1.17 Investigations for sleep disorders (Items 12203 to 12250)

Items 12203 and 12250 are applicable for patients who require a diagnostic sleep study. They enable direct GP referral to testing without personal assessment by a sleep or respiratory physician, when validated screening questionnaires suggest a high pre-test probability for diagnosis of symptomatic, moderate to severe obstructive sleep apnoea (OSA). The screening questionnaires should be administered by the referring practitioner. Alternatively, the need for testing can be determined by a sleep or respiratory physician following direct clinical assessment (either face-to-face or by video conference).

Out-dated or incomplete referrals (Items 12203 and 12250)

Referrals made prior to 1 November 2018 (or after 1 November 2018 but without the screening questionnaires) remain valid for the purposes of a service performed under items 12203 and 12250 from 1 November 2018 – providing:

- The patient is assessed by a qualified sleep medicine practitioner or consultant respiratory physician to determine the necessity for the sleep study; or
- The validated screening tools are administered to the patient by the sleep medicine practitioner, sleep technician or other practice staff. If the screening tools indicate a high pre-test probability for the diagnosis of symptomatic, moderate to severe OSA, the patient can proceed to testing. If there remains any

uncertainty about the necessity for the study, a qualified sleep medicine practitioner or consultant respiratory physician should assess the patient.

Referrals for attended (Level 1) diagnostic studies

Where a patient with suspected OSA has been directly referred for a Level 1 sleep study under item 12203, but there is insufficient information to indicate if there are any contraindications for a Level 2 study, the following options are available:

- The patient can be assessed by a qualified sleep medicine practitioner or consultant respiratory physician to determine the most suitable study (i.e. Level 1 or Level 2); or
- The validated screening tools can be administered to the patient by the sleep medicine practitioner, sleep technician or practice staff. If the screening tools indicate a high pre-test probability for the diagnosis of symptomatic, moderate to severe obstructive sleep apnoea, the sleep provider can either arrange for the patient to have a Level 2 study (notifying the referring practitioner of this decision); or seek additional information from the referring practitioner on why a Level 1 study is required (e.g. whether the patient has any contraindications for a Level 2 study). If there remains any uncertainty about the type of study which the patient should receive, a qualified sleep medicine practitioner or consultant respiratory physician should assess the patient.

Referrals made without (or incomplete) screening questionnaires (Items 12203 and 12250)

If a patient has been directly referred for testing without the use of the screening questionnaires, they can be administered to the patient by the sleep provider (e.g. by a sleep technician or other practice staff). Where the screening questionnaires have been provided with the referral but they are incomplete, the sleep provider may wish to contact the patient to determine what their responses were to the relevant questions.

Attended versus unattended sleep studies

Determination of the need for testing should conform with Australasian Sleep Association guidelines.

Unattended sleep studies are suitable for many patients with suspected OSA but patients with other sleep disorders should undergo an attended study. Assessment for potential contraindications to an unattended sleep study can be undertaken by either the referring practitioner, qualified adult sleep medicine practitioner or consultant respiratory physician. Standardised referrals should request sufficient information to enable such assessment.

In accordance with the Australasian Sleep Association's Guidelines for Sleep Studies in Adults, relative contraindications for an unattended sleep study to investigate suspected OSA include but are not limited to:

- (a) intellectual disability or cognitive impairment;
- (b) physical disability with inadequate carer attendance;
- (c) significant co-morbid conditions including neuromuscular disease, heart failure or advanced respiratory disease where more complex disorders are likely;
- (d) suspected respiratory failure where attended measurements are required, including measurement of carbon dioxide partial pressures;
- (e) suspected parasomnia or seizure disorder;
- (f) suspected condition where recording of body position is considered to be essential and would not be recorded as part of an unattended sleep study;
- (g) previously failed or inconclusive unattended sleep study;
- (h) unsuitable home environment including unsafe environments or where patients are homeless; and

(i) consumer preference based on a high level of anxiety about location of study or where there is unreasonable cost or disruption based on distance to be travelled, or home circumstances.

Patients who have these features may be suitable for either attended (Level 1) or unattended (Level 2) studies.

Treatments options following testing

The results and treatment options following any diagnostic sleep study should be discussed during a professional attendance with a medical practitioner before the initiation of any therapy. If there is uncertainty about the significance of test results or the appropriate management for that individual then referral to a sleep or respiratory medicine specialist is recommended.

Any professional attendance by a qualified adult sleep medicine practitioner or consultant respiratory physician associated with this service may be undertaken face-to-face or by video conference.

Treatment effectiveness study (Item 12205)

The necessity for a treatment effectiveness sleep study is determined by a qualified adult sleep medicine practitioner or consultant respiratory physician where:

- (a) The patient has undergone a therapeutic intervention including but not limited to PAP, upper airway surgery, appropriate oral appliance, >10% weight loss in the previous 6 months, oxygen therapy; and
- (b) There is clinical evidence of sub-optimal response, OR uncertainty regarding control of sleep disordered breathing.

Meaning of 'at least 8 hours duration'

The requirement 'for a period of at least 8 hours duration' means the overnight investigation (including patient set-up time and actual period of recording) must be of at least 8 hours duration. Providers must keep evidence of the duration of the overnight investigation (including set-up time and period of recording) as part of their administrative records for MBS sleep studies.

Polygraphic data

Item 11503 is not for the purpose of investigation of sleep disorders. Polygraphic data obtained as part of a sleep study item in the range 12203 to 12250 cannot be used for the purpose of claiming item 11503.

Billing requirements for sleep studies

Items 12203 to 12250 do not support a figurehead billing arrangement. Figurehead or 'headline' billing is where one practitioner's provider number is used to bill patients for the services provided by other practitioners.

While individual components of the sleep study service (e.g. supervision of the investigation and interpretation and preparation of a permanent report) do not need to be performed by the same qualified sleep medicine practitioner, it is an MBS requirement that the qualified sleep medicine practitioner who prepared the report on the results of the investigation bill the relevant item.

Benefits are not payable for items 12203 to 12250 where the interpretation and preparation of a permanent report is provided by a technician or supervised staff rather than by a qualified adult sleep medicine practitioner.

Where the date of service for a sleep study item is the same as the date of service of any items 11000 to 11005, 11503, 11700 to 11709, 11713 and 12203/12250, for a benefit to be payable, there must be written notification on the account identifying that the service under any of those items was not provided on the same occasion as the sleep study item.

The date of service for the purposes of items 12203 to 12250 is deemed to be the day of the morning the overnight investigation is completed. Billing for the service must only occur once all of the requirements of the item have been fulfilled.

DN.1.18 Bone Densitometry - (Items 12306 to 12322)

Definitions

Low bone mineral density is present when the bone (organ) mineral density falls more than 1.5 standard deviations below the age matched mean or more than 2.5 standard deviations below the young normal mean at the same site and in the same gender.

Item 12321 is intended to allow for bone mineral density measurement following a significant change in therapy - e.g. a change in the class of drugs - rather than for a change in the dosage regimen.

Items 12320 and 12322 enable the payment of a Medicare benefit for a bone densitometry service performed on a patient aged 70 years or over. Patients 70 years and over are eligible for an initial screening study.

Patients assessed as having a normal study or mild osteopenia as measured by a t-score down to -1.5 are eligible for one scan every 5 years (item 12320).

Patients with moderate to marked osteopenia as measured by a T-score of -1.5 to -2.5 are eligible for one scan every two years (item 12322).

An examination under any of these items covers the measurement of 2 or more sites, interpretation and provision of a report; all performed by a specialist or consultant physician in the practice of his or her specialty. Two or more sites must include the measurement of bone density of the lumbar spine and proximal femur. The measurement of bone mineral density at either forearms or both heels or in combination is excluded for the purpose of Medicare benefit, unless necessary for specific clinical indications (see below).

Patients unable to have a lumbar spine or proximal femur measurement taken

The recommended alternative measurement for patients who have been referred for a dual energy x-ray absorptiometry (DEXA) bone densitometry scan who are unable to have a lumbar spine or proximal femur measurement taken is the distal forearm, e.g. patients with spinal fusions or bilateral hip prostheses. Patients unable to have a lumbar spine or proximal femur measurement taken who have been referred for a quantitative computed tomography (QCT) scan are not subject to the two site measurements requirement. For these patients one site for which a QCT measurement can be appropriately referenced is sufficient.

Professional Supervision and Interpretation and Reporting

The interpretation and report for all bone densitometry services must be provided by a specialist or consultant physician.

Items 12306, 12312, 12315, 12321 and Items 12320 and 12322 (when performed using Dual Energy X-ray Absorptiometry) must be performed by a:

- (a) specialist or consultant physician; or
- (b) person who holds a State or Territory radiation license, and who is under the supervision of a specialist or consultant physician.

Items 12320 and 12322 (when performed using Quantitative Computed Tomography) must be performed by a:

(a) specialist or consultant physician; or

(b) a radiation licence holder who is registered as a medical radiation practitioner under a law of a State or Territory; and the specialist or consultant physician is available to monitor and influence the conduct and diagnostic quality of the examination and, if necessary, to attend on the patient personally.

Referrals

Bone densitometry services are available on the basis of referral by a medical practitioner to a specialist or consultant physician. However, providers of bone densitometry to whom a patient is referred for management may determine that a bone densitometry service is required in line with the provisions of Items 12306, 12312, 12315, 12320, 12321 and 12322.

For Item 12306 the referral should specify the indication for the test, namely:

- (a) 1 or more fractures occurring after minimal trauma; or
- (b) monitoring of low bone mineral density proven by previous bone densitometry.

For Item 12312 the referral should specify the indication for the test, namely:

- (a) prolonged glucocorticoid therapy;
- (b) conditions associated with excess glucocorticoid secretion;
- (c) male hypogonadism; or
- (d) female hypogonadism lasting more than 6 months before the age of 45.

For Item 12315 the referral should specify the indication for the test, namely:

- (a) primary hyperparathyroidism;
- (b) chronic liver disease:
- (c) chronic renal disease;
- (d) proven malabsorptive disorders;
- (e) rheumatoid arthritis; or
- (f) conditions associated with thyroxine excess.

For Item 12312

- (a) 'Prolonged glucocorticoid therapy' is defined as the commencement of a dosage of inhaled glucocorticoid equivalent to or greater than 800 micrograms beclomethasone dipropionate or budesonide per day; or
- (b) a supraphysiological glucocorticoid dosage equivalent to or greater than 7.5 mg prednisolone in an adult taken orally per day;

for a period anticipated to last for at least 4 months.

Glucocorticoid therapy must be contemporaneous with the current scan. Patients no longer on steroids would not qualify for benefits.

For Item 12312

- (a) Male hypogonadism is defined as serum testosterone levels below the age matched normal range.
- (b) Female hypogonadism is defined as serum oestrogen levels below the age matched normal range.

For Item 12315

A malabsorptive disorder is defined as one or more of the following:

- (a) malabsorption of fat, defined as faecal fat estimated at greater than 18 gm per 72 hours on a normal fat diet; or
- (b) bowel disease with presumptive vitamin D malabsorption as indicated by a sub-normal circulating 25-hydroxyvitamin D level; or
- (c) histologically proven Coeliac disease.

DN.1.19 Retinal Photography with a Non-Mydriatic Retinal Camera

This service is separated into two items, MBS item 12325 and MBS item 12326, in line with NHMRC guidelines' recommended frequency of repeat testing in persons of Aboriginal andTorres Strait Islander descent and the general population.

This item is intended for the provision of retinal photography with a non-mydriatic retinal camera. Mydriasis is permitted if adequate photographs cannot be obtained through an undiated pupil.

Presenting distance vision means unaided distance vision or the vision obtained with the current spectacles or contact lenses, if normally worn for distance vision.

Detection of any diabetic retinopathy should be followed by referral to an optometrist or ophthalmologist in accordance with the NHMRC guidelines.

Where images are inadequate quality for detection of diabetic retinopathy, referral to an optometrist or ophthalmologist for further assessment is indicated.

Any element(s) of the service may be performed by appropriately trained or qualified personnel under the direction of the medical practitioner co-ordinating the patient's care, who retains overall responsibility for claiming of the service.

DN.1.20 Spirometry (Items 11505, 11506 and 11512)

Spirometry services billed to the MBS should meet international quality standards (Eur Respir J 2005; 26: 319–338).

The National Asthma Council's Australia Asthma Handbook (2016) and Lung Foundation Australia's and Thoracic Society of Australia and New Zealand's COPD-X Plan (2016) advise that properly performed spirometry is required to confirm airflow limitation and the diagnosis of asthma and/or COPD. Reversibility testing is the standard required for asthma diagnosis. The diagnosis of COPD is confirmed with post bronchodilator spirometry. Item 11505 should not be repeated when diagnosis has been previously confirmed by properly performed spirometry. To meet quality requirements patients must have three acceptable tests for each testing period (pre/post bronchodilator), and meet repeatability criteria with the best effort recorded. Spirometry should be performed by a person who has undergone training and is qualified to perform it to recommended standards (see Spirometry Handbook, National Asthma Council of Australia (https://www.nationalasthma.org.au/living-with-asthma/resources/health-professionals/information-paper/spirometry-handbook) and ATS/ERS Standardisation of spirometry paper (http://erj.ersjournals.com/content/erj/26/2/319.full.pdf).

DN.1.21 Fraction of Exhaled Nitric Oxide (Item 11507) and Cardiopulmonary Exercise Testing (Item 11508)

Services billed to item 11507 should meet the following quality standards:

 An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications: Am J Respir Crit Care Med Vol 184. pp 602–615, 2011 DOI: 10.1164/rccm.912011ST. ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005: Am J Respir Crit Care Med Vol 171. pp 912–930, 2005 DOI: 10.1164/rccm.200406-710ST
 Fewer than three traces will be accepted as billable under item 11507 if three reproducible loops are difficult to achieve for clinical reasons. The clinical reason(s) for not achieving three reproducible loops must be documented.

Services billed to item 11508 should meet the following quality standards:

• ATS/ACCP Statement on Cardiopulmonary Exercise Testing: Am J Respir Crit Care Med Vol 167. pp 211–277, 2003 DOI: 10.1164/rccm.167.2.211.

DN.1.22 Skin Prick Testing (items 12000-12005)

Skin prick testing and Intradermal testing should always be performed in a medical setting with the ready availability of medical practitioners competent to treat systemic allergic reactions, and appropriate resuscitation equipment. Because intradermal testing carries a higher risk of anaphylaxis it should only be performed in a hospital setting (or equivalent) by either a specialist or consultant physician with proficiency and experience in all aspects of skin testing for allergy.

Item 12003 should only be used by appropriately trained doctors such as allergist immunologists or equivalently trained medical practitioners. An alternative to Skin Prick Testing (SPT) is serum specific IgE food allergen testing. Serum specific IgE (ssIgE) allergy blood testing to food panels is not recommended.

Item 12004 should only be used by appropriately trained doctors such as allergist immunologists or equivalently trained medical practitioners.

Item 12005 should only be used by appropriately trained doctors such as allergist immunologists, anaesthetists or equivalently trained medical practitioners.

DN.1.23 Multiple sleep latency testing and Maintenance of wakefulness testing

Determination of the need for testing and testing procedures should be performed in accordance with current Australasian Sleep Association guidelines. Not to be used as part of an occupational health service or preemployment assessment.

The date of service for the purposes of items 12254 to 12272 is deemed to be the day on which the daytime investigation component of the test is completed. Billing for the service must only occur once all of the requirements of the item have been fulfilled.

DIAGNOSTIC PROCEDURES AND INVESTIGATIONS ITEMS

	CELLANEOUS DIAGNOSTIC 1. NEUROLOGY DURES AND INVESTIGATIONS
	Group D1. Miscellaneous Diagnostic Procedures And Investigations
	Subgroup 1. Neurology
	ELECTROENCEPHALOGRAPHY, not being a service:
	(a) associated with a service to which item 11003, 11006 or 11009 applies; or
	(b) involving quantitative topographic mapping using neurometrics or similar devices (Anaes.)
11000	Fee: \$123.10 Benefit: 75% = \$92.35 85% = \$104.65 ELECTROENCEPHALOGRAPHY, prolonged recording of at least 3 hours duration, not being a service:
	(a) associated with a service to which item 11000, 11004, 11005, 11006 or 11009 applies; and
	(b) involving quantitative topographic mapping using neurometrics or similar devices
11003	(See para DN.1.1 of explanatory notes to this Category) Fee: \$325.70 Benefit: 75% = \$244.30 85% = \$276.85
	ELECTROENCEPHALOGRAPHY, ambulatory or video, prolonged recording of at least 3 hours duration up to 24 hours duration, recording on the first day, not being a service:
	(a) associated with a service to which item 11000, 11003, 11005, 11006 or 11009 applies; and
	(b) involving quantitative topographic mapping using neurometrics or similar devices
11004	(See para DN.1.2 of explanatory notes to this Category) Fee: \$325.70 Benefit: 75% = \$244.30 85% = \$276.85
	ELECTROENCEPHALOGRAPHY, ambulatory or video, prolonged recording of at least 3 hours duration up to 24 hours duration, recording on each day subsequent to the first day, not being a service:
	(a) associated with a service to which item 11000, 11003, 11004, 11006 or 11009 applies; or
	(b) involving quantitative topographic mapping using neurometrics or similar devices
11005	(See para DN.1.2 of explanatory notes to this Category) Fee: \$325.70 Benefit: 75% = \$244.30 85% = \$276.85
11002	ELECTROENCEPHALOGRAPHY, temporosphenoidal, not being a service involving quantitative topographic mapping using neurometrics or similar devices
11006	Fee: \$167.00 Benefit: 75% = \$125.25 85% = \$141.95
	ELECTROCORTICOGRAPHY
11009	Fee: \$227.75 Benefit: 75% = \$170.85 85% = \$193.60
	NEUROMUSCULAR ELECTRODIAGNOSIS conduction studies on 1 nerve OR ELECTROMYOGRAPHY of 1 or more muscles using concentric needle electrodes OR both these examinations (not being a service associated with a service to which item 11015 or 11018 applies)
11012	(See para DN.1.3 of explanatory notes to this Category) Fee: \$112.00 Benefit: 75% = \$84.00 85% = \$95.20
11012	NEUROMUSCULAR ELECTRODIAGNOSIS conduction studies on 2 or 3 nerves with or without electromyography (not being a service associated with a service to which item 11012 or 11018 applies)
11015	Fee: \$149.90 Benefit: 75% = \$112.45 85% = \$127.45

NEUROMUSCULAR ELECTRODIAGNOSIS conduction studies on 4 or more nerves with or without electromyography OR recordings from single fibres of nerves and muscles OR both of these examinations (not being a service associated with a service to which item 11012 or 11015 applies) 11018 Fee: \$233.95 Renefit: 75% = \$168.00 85% = \$190.40 NEUROMUSCULAR ELECTRODIAGNOSIS repetitive stimulation for study of neuromuscular conduction OR electromyography with quantitative computerised analysis OR both of these examinations 11021 Fee: \$149.90 Benefit: 75% = \$112.45 85% = \$127.45 CFNTRAL NERVOUS SYSTEM EVOKED RESPONSES, INVESTIGATION OF, by computerised averaging techniques, not being a service involving quantitative topographic mapping of event-related potentials or multifocal multichannel objective perimetry - 1 or 2 studies (See para DN.1.4 of explanatory notes to this Category)		D1. MISCELLANEOUS DIAGNOSTIC 1. NEUROLOGY	
electromyography OR recordings from single fibres of nerves and muscles OR both of these examinations (not being a service associated with a service to which item 11012 or 11015 applies) Fee: \$223.95 Benefit: 75% = \$168.00 NEUROMUSCULAR ELECTRODIAGNOSIS repetitive stimulation for study of neuromuscular conduction OR electromyography with quantitative computerised analysis OR both of these examinations Pee: \$149.90 Benefit: 75% = \$112.45 Ees: \$149.90 Benefit: 75% = \$122.45 Ees: \$149.90 Ees: \$140.85 Ees: \$140	PROCEI		
examinations (not being a service associated with a service to which item 11012 or 11015 applies) Fee: \$223.95			
NEUROMUSCULAR ELECTRODIAGNOSIS repetitive stimulation for study of neuromuscular conduction OR electromyography with quantitative computerised analysis OR both of these examinations NEUROMUSCULAR ELECTRODIAGNOSIS repetitive stimulation for study of neuromuscular conduction OR electromyography with quantitative computerised analysis OR both of these examinations CENTRAL NERVOUS SYSTEM EVOKED RESPONSES, INVESTIGATION OF, by computerised averaging techniques, not being a service involving quantitative topographic mapping of event-related potentials or multifocal multichannel objective perimetry - 1 or 2 studies (See para DN.1.4 of explanatory notes to this Category) Fee: \$113.85 Benefit: 75% = 885.40 85% = \$96.80 CENTRAL NERVOUS SYSTEM EVOKED RESPONSES, INVESTIGATION OF, by computerised averaging techniques, not being a service involving quantitative topographic mapping of event-related potentials or multifocal multichannel objective perimetry - 3 or more studies (See para DN.1.4 of explanatory notes to this Category)			
NEUROMUSCULAR ELECTRODIAGNOSIS repetitive stimulation for study of neuromuscular conduction OR electromyography with quantitative computerised analysis OR both of these examinations Fee: \$149.90		examinations (not being a service associated with a service to which item 11012 or 11015 applies)	
NEUROMUSCULAR ELECTRODIAGNOSIS repetitive stimulation for study of neuromuscular conduction OR electromyography with quantitative computerised analysis OR both of these examinations Fee: \$149.90			
conduction OR electromyography with quantitative computerised analysis OR both of these examinations Fee: \$149.90 Benefit: 75% = \$112.45 CENTRAL NERVOUS SYSTEM EVOKED RESPONSES, INVESTIGATION OF, by computerised averaging techniques, not being a service involving quantitative topographic mapping of event-related potentials or multifocal multichannel objective perimetry - 1 or 2 studies (See para DN 1.4 of explanatory notes to this Category) Fee: \$113.85 Benefit: 75% = \$85.40 CENTRAL NERVOUS SYSTEM EVOKED RESPONSES, INVESTIGATION OF, by computerised averaging techniques, not being a service involving quantitative topographic mapping of event-related potentials or multifocal multichannel objective perimetry - 3 or more studies (See para DN 1.4 of explanatory notes to this Category) Fee: \$168.90 Benefit: 75% = \$126.70 Benefit: 75% = \$143.60 D1. MISCELLANEOUS DIAGNOSTIC PROCEDURES AND INVESTIGATIONS 2. OPHTHALMOLOGY Group D1. Miscellaneous Diagnostic Procedures And Investigations PROVOCATIVE TEST OR TESTS FOR OPEN ANGLE GLAUCOMA, including water drinking Fee: \$40.80 Benefit: 75% = \$30.60 Sys = \$34.70 ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 Sys = \$92.05 PATTERN ELECTROCULOGRAPHY of one or both eyes performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 Sys = \$92.05 PATTERN ELECTROCETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards, perfo	11018	Fee: \$223.95 Benefit: 75% = \$168.00 85% = \$190.40	
examinations Fee: \$149.90 Benefit: 75% = \$112.45 85% = \$127.45			
Fee: \$149.90 Benefit: 75% = \$112.45 85% = \$127.45 CENTRAL NERVOUS SYSTEM EVOKED RESPONSES, INVESTIGATION OF, by computerised averaging techniques, not being a service involving quantitative topographic mapping of event-related potentials or multifocal multichannel objective perimetry - 1 or 2 studies			
CENTRAL NERVOUS SYSTEM EVOKED RESPONSES, INVESTIGATION OF, by computerised averaging techniques, not being a service involving quantitative topographic mapping of event-related potentials or multifocal multichannel objective perimetry - 1 or 2 studies (See para DN.1.4 of explanatory notes to this Category) Fee: \$113.85 Renefit: 75% = \$85.40 RS% = \$96.80 CENTRAL NERVOUS SYSTEM EVOKED RESPONSES, INVESTIGATION OF, by computerised averaging techniques, not being a service involving quantitative topographic mapping of event-related potentials or multifocal multichannel objective perimetry - 3 or more studies (See para DN.1.4 of explanatory notes to this Category) Fee: \$168.90 D1. MISCELLANEOUS DIAGNOSTIC PROCEDURES AND INVESTIGATIONS Croup D1. Miscellaneous Diagnostic Procedures And Investigations Subgroup 2. Ophthalmology PROVOCATIVE TEST OR TESTS FOR OPEN ANGLE GLAUCOMA, including water drinking PROVOCATIVE TEST OR TESTS FOR OPEN ANGLE GLAUCOMA, including water drinking Fee: \$40.80 Benefit: 75% = \$30.60 S5% = \$34.70 ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 S5% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes performed according to current professional guidelines or standards, performed by or on behalf of a speciality of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 S5% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes performed according to current professional guidelines or standards, performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 S5% = \$92.05 DARK ADAPIOMETRY of one or both eyes with a quantitative (log cd		examinations	
CENTRAL NERVOUS SYSTEM EVOKED RESPONSES, INVESTIGATION OF, by computerised averaging techniques, not being a service involving quantitative topographic mapping of event-related potentials or multifocal multichannel objective perimetry - 1 or 2 studies (See para DN.1.4 of explanatory notes to this Category) Fee: \$113.85 Renefit: 75% = \$85.40 RS% = \$96.80 CENTRAL NERVOUS SYSTEM EVOKED RESPONSES, INVESTIGATION OF, by computerised averaging techniques, not being a service involving quantitative topographic mapping of event-related potentials or multifocal multichannel objective perimetry - 3 or more studies (See para DN.1.4 of explanatory notes to this Category) Fee: \$168.90 D1. MISCELLANEOUS DIAGNOSTIC PROCEDURES AND INVESTIGATIONS Croup D1. Miscellaneous Diagnostic Procedures And Investigations Subgroup 2. Ophthalmology PROVOCATIVE TEST OR TESTS FOR OPEN ANGLE GLAUCOMA, including water drinking PROVOCATIVE TEST OR TESTS FOR OPEN ANGLE GLAUCOMA, including water drinking Fee: \$40.80 Benefit: 75% = \$30.60 S5% = \$34.70 ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 S5% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes performed according to current professional guidelines or standards, performed by or on behalf of a speciality of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 S5% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes performed according to current professional guidelines or standards, performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 S5% = \$92.05 DARK ADAPIOMETRY of one or both eyes with a quantitative (log cd			
averaging techniques, not being a service involving quantitative topographic mapping of event-related potentials or multifocal multichannel objective perimetry - 1 or 2 studies (See para DN.1.4 of explanatory notes to this Category) Fee: \$113.85 Benefit: 75% = \$88.40 CENTRAL NERVOUS SYSTEM EVOKED RESPONSES, INVESTIGATION OF, by computerised averaging techniques, not being a service involving quantitative topographic mapping of event-related potentials or multifocal multichannel objective perimetry - 3 or more studies (See para DN.1.4 of explanatory notes to this Category) Fee: \$168.90 Benefit: 75% = \$126.70 85% = \$143.60 D1. MISCELLANEOUS DIAGNOSTIC ROCEDURES AND INVESTIGATIONS Croup D1. Miscellaneous Diagnostic Procedures And Investigations Subgroup 2. Ophthalmology PROVOCATIVE TEST OR TESTS FOR OPEN ANGLE GLAUCOMA, including water drinking Fee: \$40.80 Benefit: 75% = \$30.60 85% = \$34.70 ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 4	11021		
potentials or multifocal multichannel objective perimetry - 1 or 2 studies (See para DN.1.4 of explanatory notes to this Category) Fee: \$113.85 Benefit: 75% = \$85.40 CENTRAL NERVOUS SYSTEM EVOKED RESPONSES, INVESTIGATION OF, by computerised averaging techniques, not being a service involving quantitative topographic mapping of event-related potentials or multichannel objective perimetry - 3 or more studies (See para DN.1.4 of explanatory notes to this Category) Fee: \$168.90 Benefit: 75% = \$126.70 85% = \$143.60 D1. MISCELLANEOUS DIAGNOSTIC PROCEDURES AND INVESTIGATIONS Croup D1. Miscellaneous Diagnostic Procedures And Investigations Subgroup 2. Ophthalmology PROVOCATIVE TEST OR TESTS FOR OPEN ANGLE GLAUCOMA, including water drinking Fee: \$40.80 Benefit: 75% = \$30.60 85% = \$34.70 ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes performed according to current professional guidelines or standards, performed by or on behalf of a speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposure			
(See para DN.1.4 of explanatory notes to this Category) Fee: \$113.85 Benefit: 75% = \$85.40 ENTRAL NERVOUS SYSTEM EVOKED RESPONSES, INVESTIGATION OF, by computerised averaging techniques, not being a service involving quantitative topographic mapping of event-related potentials or multifocal multichannel objective perimetry - 3 or more studies (See para DN.1.4 of explanatory notes to this Category) Fee: \$168.90 Benefit: 75% = \$126.70 85% = \$143.60 D1. MISCELLANEOUS DIAGNOSTIC PROCEDURES AND INVESTIGATIONS Croup D1. Miscellaneous Diagnostic Procedures And Investigations Subgroup 2. Ophthalmology PROVOCATIVE TEST OR TESTS FOR OPEN ANGLE GLAUCOMA, including water drinking 11200 Fee: \$40.80 Benefit: 75% = \$30.60 85% = \$34.70 ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 ELECTROCULOGRAPHY of one or both eyes performed according to current professional guidelines or standards, performed by or on behalf of a specialist, or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log c			
Fee: \$113.85 Benefit: 75% = \$85.40 85% = \$96.80		potentials or multifocal multichannel objective perimetry - 1 or 2 studies	
Fee: \$113.85 Benefit: 75% = \$85.40 85% = \$96.80		(See more DN 1.4 of conference materials this Cotagon)	
CENTRAL NERVOUS SYSTEM EVOKED RESPONSES, INVESTIGATION OF, by computerised averaging techniques, not being a service involving quantitative topographic mapping of event-related potentials or multifocal multichannel objective perimetry - 3 or more studies (See para DN.1.4 of explanatory notes to this Category) Fee: \$168.90 Benefit: 75% = \$126.70 85% = \$143.60 D1. MISCELLANEOUS DIAGNOSTIC PROCEDURES AND INVESTIGATIONS 2. OPHTHALMOLOGY Group D1. Miscellaneous Diagnostic Procedures And Investigations Subgroup 2. Ophthalmology PROVOCATIVE TEST OR TESTS FOR OPEN ANGLE GLAUCOMA, including water drinking 11200 Fee: \$40.80 Benefit: 75% = \$30.60 85% = \$34.70 ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 ELECTROCULOGRAPHY of one or both eyes performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection	11024		
averaging techniques, not being a service involving quantitative topographic mapping of event-related potentials or multifocal multichannel objective perimetry - 3 or more studies (See para DN.1.4 of explanatory notes to this Category) Pee: \$168.90 Benefit: 75% = \$126.70 85% = \$143.60 D1. MISCELLANEOUS DIAGNOSTIC PROCEDURES AND INVESTIGATIONS 2. OPHTHALMOLOGY Group D1. Miscellaneous Diagnostic Procedures And Investigations Subgroup 2. Ophthalmology PROVOCATIVE TEST OR TESTS FOR OPEN ANGLE GLAUCOMA, including water drinking 11200 Fee: \$40.80 Benefit: 75% = \$30.60 85% = \$34.70 ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection	11024		
potentials or multifocal multichannel objective perimetry - 3 or more studies (See para DN.1.4 of explanatory notes to this Category) Fee: \$168.90 Benefit: 75% = \$126.70 85% = \$143.60 D1. MISCELLANEOUS DIAGNOSTIC PROCEDURES AND INVESTIGATIONS Coup D1. Miscellaneous Diagnostic Procedures And Investigations Subgroup 2. Ophthalmology PROVOCATIVE TEST OR TESTS FOR OPEN ANGLE GLAUCOMA, including water drinking 11200 Fee: \$40.80 Benefit: 75% = \$30.60 85% = \$34.70 ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 ELECTROCULOGRAPHY of one or both eyes performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection			
(See para DN.1.4 of explanatory notes to this Category) Fee: \$168.90 Benefit: 75% = \$126.70 85% = \$143.60 D1. MISCELLANEOUS DIAGNOSTIC PROCEDURES AND INVESTIGATIONS 2. OPHTHALMOLOGY			
D1. MISCELLANEOUS DIAGNOSTIC PROCEDURES AND INVESTIGATIONS Group D1. Miscellaneous Diagnostic Procedures And Investigations Subgroup 2. Ophthalmology PROVOCATIVE TEST OR TESTS FOR OPEN ANGLE GLAUCOMA, including water drinking 1200 Fee: \$40.80 Benefit: 75% = \$30.60 85% = \$34.70 ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 ELECTROOCULOGRAPHY of one or both eyes performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection		potentials of multifocal multichannel objective perimetry - 3 of more studies	
D1. MISCELLANEOUS DIAGNOSTIC PROCEDURES AND INVESTIGATIONS Group D1. Miscellaneous Diagnostic Procedures And Investigations Subgroup 2. Ophthalmology PROVOCATIVE TEST OR TESTS FOR OPEN ANGLE GLAUCOMA, including water drinking 1200 Fee: \$40.80 Benefit: 75% = \$30.60 85% = \$34.70 ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 ELECTROOCULOGRAPHY of one or both eyes performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection		(See para DN 1.4 of explanatory notes to this Category)	
D1. MISCELLANEOUS DIAGNOSTIC PROCEDURES AND INVESTIGATIONS 2. OPHTHALMOLOGY	11027		
PROCEDURES AND INVESTIGATIONS Subgroup 2. Ophthalmology			
Subgroup 2. Ophthalmology PROVOCATIVE TEST OR TESTS FOR OPEN ANGLE GLAUCOMA, including water drinking Fee: \$40.80 Benefit: 75% = \$30.60 85% = \$34.70 ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 ELECTROOCULOGRAPHY of one or both eyes performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection			
PROVOCATIVE TEST OR TESTS FOR OPEN ANGLE GLAUCOMA, including water drinking Fee: \$40.80 Benefit: 75% = \$30.60 ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 ELECTROOCULOGRAPHY of one or both eyes performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection		Group D1. Miscellaneous Diagnostic Procedures And Investigations	
PROVOCATIVE TEST OR TESTS FOR OPEN ANGLE GLAUCOMA, including water drinking Fee: \$40.80 Benefit: 75% = \$30.60 ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 ELECTROOCULOGRAPHY of one or both eyes performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection		Subgroup 2. Ophthalmology	
ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 ELECTROOCULOGRAPHY of one or both eyes performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection			
ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 ELECTROOCULOGRAPHY of one or both eyes performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection		TRO VOCATIVE TEST OR TESTS FOR OTERVANOEE GENTOCOMA, including water drinking	
ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 ELECTROOCULOGRAPHY of one or both eyes performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection	11200	Fee: \$40.80 Benefit: 75% = \$30.60 85% = \$34.70	
more studies performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 ELECTROOCULOGRAPHY of one or both eyes performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection			
behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 ELECTROOCULOGRAPHY of one or both eyes performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection			
(See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 ELECTROOCULOGRAPHY of one or both eyes performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection			
Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 ELECTROOCULOGRAPHY of one or both eyes performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection			
ELECTROOCULOGRAPHY of one or both eyes performed according to current professional guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection			
guidelines or standards, performed by or on behalf of a specialist or consultant physician in the practice of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection	11204		
of his or her speciality. (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection			
(See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection			
Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection		of his or her speciality.	
Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection			
PATTERN ELECTRORETINOGRAPHY of one or both eyes by computerised averaging techniques, including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection	11267		
including 3 or more studies performed according to current professional guidelines or standards (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection	11205		
(See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection			
11210 Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection		including 3 or more studies performed according to current professional guidelines or standards	
11210 Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection		(See pare DN 1.5 of explanatory notes to this Cotogony)	
DARK ADAPTOMETRY of one or both eyes with a quantitative (log cd/m2) estimation of threshold in log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection	11210		
log lumens at 45 minutes of dark adaptations (See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection	11210		
(See para DN.1.5 of explanatory notes to this Category) Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection			
11211 Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection		log runions at 43 minutes of wark adaptations	
11211 Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05 RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection		(See para DN 1.5 of explanatory notes to this Category)	
RETINAL ANGIOGRAPHY, multiple exposures of 1 eye with intravenous dye injection	11211		
	11211		
11215 Fee: \$123.00 Benefit: 75% = \$92.25 85% = \$104.55		The first of the first of the state of the s	
	11215	Fee: \$123.00 Benefit: 75% = \$92.25 85% = \$104.55	

D1. MISCELLANEOUS DIAGNOSTIC		
	PROCEDURES AND INVESTIGATIONS 2. OPHTHALMOLOG	
	RETINAL ANGIOGRAPHY, multiple exposures of both eyes with intravenous dye injection	
11218	Fee: \$151.95 Benefit: 75% = \$114.00 85% = \$129.20	
11210	OPTICAL COHERENCE TOMOGRAPHY for diagnosis of ocular conditions for which a medication is	
	listed on the Pharmaceutical Benefits Scheme for intraocular administration	
	Maximum of one service in a 12 month period	
11219	Fee: \$40.00 Benefit: 75% = \$30.00 85% = \$34.00	
	OPTICAL COHERENCE TOMOGRAPHY for the assessment of the need for treatment following	
	provision of pharmaceutical benefits scheme-subsidised ocriplasmin.	
	Maximum of one service per eye per lifetime.	
11220	Fee: \$40.00 Benefit: 75% = \$30.00 85% = \$34.00	
11220	Full quantitative computerised perimetry (automated absolute static threshold), other than a service	
	involving multifocal multichannel objective perimetry, performed by or on behalf of a specialist in the	
	practice of his or her specialty, if indicated by the presence of relevant ocular disease or suspected	
	pathology of the visual pathways or brain with assessment and report, bilateral—to a maximum of 3	
	examinations (including examinations to which item 11224 applies) in any 12 month period	
	(See para DN.1.6, DN.1.7 of explanatory notes to this Category)	
11221	Fee: \$67.75 Benefit: 75% = \$50.85 85% = \$57.60	
	Full quantitative computerised perimetry (automated absolute static threshold), other than a service involving multifocal multichannel objective perimetry, performed by or on behalf of a specialist in the	
	practice of his or her specialty, if indicated by the presence of relevant ocular disease or suspected	
	pathology of the visual pathways or brain with assessment and report, unilateral—to a maximum of 3	
	examinations (including examinations to which item 11221 applies) in any 12 month period	
	(See para DN.1.6, DN.1.7 of explanatory notes to this Category)	
11224	Fee: \$40.85 Benefit: 75% = \$30.65 85% = \$34.75	
	EXAMINATION OF THE EYE BY IMPRESSION CYTOLOGY OF CORNEA for the investigation of	
	ocular surface dysplasia, including the collection of cells, processing and all cytological examinations and preparation of report	
	and preparation of report	
11235	Fee: \$122.75 Benefit: 75% = \$92.10 85% = \$104.35	
	OCULAR CONTENTS, simultaneous ultrasonic echography by both unidimensional and bidimensional	
	techniques, for the diagnosis, monitoring or measurement of choroidal and ciliary body melanomas, retinoblastoma or suspicious naevi or simulating lesions, one eye, not being a service associated with a	
	service to which items in Group I1 apply	
11237	Fee: \$81.45 Benefit: 75% = \$61.10 85% = \$69.25 ORBITAL CONTENTS, unidimensional ultrasonic echography or partial coherence interferometry of,	
	for the measurement of one eye prior to lens surgery on that eye, not being a service associated with a	
	service to which items in Group I1 apply	
11240	(See para DN.1.8 of explanatory notes to this Category) Fee: \$81.45 Benefit: 75% = \$61.10 85% = \$69.25	
11210	ORBITAL CONTENTS, unidimensional ultrasonic echography or partial coherence interferometry of,	
	for bilateral eye measurement prior to lens surgery on both eyes, not being a service associated with a	
	service to which items in Group I1 apply	
11241	(See para DN.1.8 of explanatory notes to this Category)	
	1 \ 1 \ J \ U J/	

D1. MISC	CELLANEOUS DIAGNOSTIC
PROCE	DURES AND INVESTIGATIONS 2. OPHTHALMOLOG
	Fee: \$103.65 Benefit: 75% = \$77.75 85% = \$88.15
	ORBITAL CONTENTS, unidimensional ultrasonic echography or partial coherence interferometry of, for the measurement of an eye previously measured and on which lens surgery has been performed, and where further lens surgery is contemplated in that eye, not being a service associated with a service to which items in Group I1 apply
11242	(See para DN.1.8 of explanatory notes to this Category) Fee: \$80.10 Benefit: 75% = \$60.10 85% = \$68.10
	ORBITAL CONTENTS, unidimensional ultrasonic echography or partial coherence interferometry of, for the measurement of a second eye where surgery for the first eye has resulted in more than 1 dioptre of error or where more than 3 years have elapsed since the surgery for the first eye, not being a service associated with a service to which items in Group I1 apply
11243	(See para DN.1.8 of explanatory notes to this Category) Fee: \$80.10 Benefit: 75% = \$60.10 85% = \$68.10
	Orbital contents, diagnostic B-scan of, by a specialist practising in his or her speciality of ophthalmology, not being a service associated with a service to which an item in Group I1 of the diagnostic imaging services table applies.
11244	Fee: \$77.00 Benefit: 75% = \$57.75 85% = \$65.45
	CELLANEOUS DIAGNOSTIC
PROCE	DURES AND INVESTIGATIONS 3. OTOLARYNGOLOG
	Group D1. Miscellaneous Diagnostic Procedures And Investigations
	Subgroup 3. Otolaryngology
	BRAIN stem evoked response audiometry (Anaes.)
11300	(See para DN.1.9 of explanatory notes to this Category) Fee: \$192.45 Benefit: 75% = \$144.35 85% = \$163.60
	ELECTROCOCHLEOGRAPHY, extratympanic method, 1 or both ears
11303	Fee: \$192.45 Benefit: 75% = \$144.35 85% = \$163.60
	ELECTROCOCHLEOGRAPHY, transtympanic membrane insertion technique, 1 or both ears
	(See para DN.1.10 of explanatory notes to this Category)
11304	Fee: \$316.95 Benefit: 75% = \$237.75 85% = \$269.45
	Nondeterminate AUDIOMETRY
	(See para DN.1.11 of explanatory notes to this Category)
11306	Fee: \$21.90 Benefit: 75% = \$16.45 85% = \$18.65
	AUDIOGRAM, air conduction
	(See para DN.1.12, DN.1.11 of explanatory notes to this Category)
11309	Fee: \$26.30 Benefit: 75% = \$19.75 85% = \$22.40
	AUDIOGRAM, air and bone conduction or air conduction and speech discrimination
	(See para DN.1.12, DN.1.11 of explanatory notes to this Category)
11312	Fee: \$37.15 Benefit: 75% = \$27.90 85% = \$31.60
	AUDIOGRAM, air and bone conduction and speech
11315	(See para DN.1.12, DN.1.11 of explanatory notes to this Category) Fee: \$49.20 Benefit: 75% = \$36.90 85% = \$41.85
-	AUDIOGRAM, air and bone conduction and speech, with other Cochlear tests
11318	(See para DN.1.12, DN.1.11 of explanatory notes to this Category)

	D1. MISCELLANEOUS DIAGNOSTIC PROCEDURES AND INVESTIGATIONS 3. OTOLARYNGOLOGY	
	Fee: \$60.75 Benefit: 75% = \$45.60 85% = \$51.65	
	IMPEDANCE AUDIOGRAM involving tympanometry and measurement of static compliance and acoustic reflex performed by, or on behalf of, a specialist in the practice of his or her specialty, where the patient is referred by a medical practitioner - not being a service associated with a service to which item 11309, 11312, 11315 or 11318 applies	
11324	Fee: \$32.85 Benefit: 75% = \$24.65 85% = \$27.95	
	IMPEDANCE AUDIOGRAM involving tympanometry and measurement of static compliance and acoustic reflex performed by, or on behalf of, a specialist in the practice of his or her specialty, where the patient is referred by a medical practitioner - being a service associated with a service to which item 11309, 11312, 11315 or 11318 applies	
11327	Fee: \$19.75 Benefit: 75% = \$14.85 85% = \$16.80	
	IMPEDANCE AUDIOGRAM where the patient is not referred by a medical practitioner - 1 examination in any 4 week period	
11330	Fee: \$7.90 Benefit: 75% = \$5.95 85% = \$6.75	
	OTO-ACOUSTIC EMISSION AUDIOMETRY for the detection of permanent congenital hearing impairment, performed by or on behalf of a specialist or consultant physician, on an infant or child who is at risk due to one or more of the following factors:-	
	(i) admission to a neonatal intensive care unit; or	
	(ii) family history of hearing impairment; or	
	(iii) intra-uterine or perinatal infection (either suspected or confirmed); or	
	(iv) birthweight less than 1.5kg; or	
	(v) craniofacial deformity: or	
	(vi) birth asphyxia; or	
	(vii) chromosomal abnormality, including Down's Syndrome; or	
	(viii) exchange transfusion;	
	and where:-	
	- the patient is referred by another medical practitioner; and	
	- middle ear pathology has been excluded by specialist opinion	
11332	(See para DN.1.13 of explanatory notes to this Category) Fee: \$58.55 Benefit: 75% = \$43.95 CALORIC TEST OF LABYRINTH OR LABYRINTHS	
11333	Fee: \$44.60 Benefit: 75% = \$33.45 85% = \$37.95	

	SCELLANEOUS DIAGNOSTIC
PROCE	EDURES AND INVESTIGATIONS SIMULTANEOUS BITHERMAL CALORIC TEST OF LABYRINTHS 3. OTOLARYNGOLOGY
11336	Fee: \$44.60 Benefit: 75% = \$33.45 85% = \$37.95 ELECTRONYSTAGMOGRAPHY
	ELECTRON I STAGMOGRAPH I
11339	Fee: \$44.60 Benefit: 75% = \$33.45 85% = \$37.95
	SCELLANEOUS DIAGNOSTIC EDURES AND INVESTIGATIONS 4. RESPIRATORY
11.00	Group D1. Miscellaneous Diagnostic Procedures And Investigations
	Subgroup 4. Respiratory
	Complex measurement of properties of the respiratory system, including the lungs and respiratory
	muscles, that is performed:
	(a) in a respiratory laboratory; and
	(b) under the supervision of a consultant respiratory physician who is responsible for staff training, supervision, quality assurance and the issuing of written reports on tests performed; and
	(c) using any of the following tests:
	(i) measurement of absolute lung volumes by any method;
	(ii) measurement of carbon monoxide diffusing capacity by any method;
	(iii) measurement of airway or pulmonary resistance by any method;
	(iv) inhalation provocation testing, including pre-provocation spirometry and the construction of a dose response curve, using a recognised direct or indirect bronchoprovocation agent and post-bronchodilator spirometry;
	(v) provocation testing involving sequential measurement of lung function at baseline and after exposure to specific sensitising agents, including drugs, or occupational asthma triggers;
	(vi) spirometry performed before and after simple exercise testing undertaken as a provocation test for the investigation of asthma, in premises equipped with resuscitation equipment and personnel trained in Advanced Life Support;
	(vii) measurement of the strength of inspiratory and expiratory muscles at multiple lung volumes;
	(viii) simulated altitude test involving exposure to hypoxic gas mixtures and oxygen saturation at rest and/or during exercise with or without an observation of the effect of supplemental oxygen;
	(ix) calculation of pulmonary or cardiac shunt by measurement of arterial oxygen partial pressure and haemoglobin concentration following the breathing of an inspired oxygen concentration of 100% for a duration of 15 minutes or greater;
	(x) if the measurement is for the purpose of determining eligibility for pulmonary arterial hypertension medications subsidised under the Pharmaceutical Benefits Scheme or eligibility for the provision of portable oxygen—functional exercise test by any method (including 6 minute walk test and shuttle walk test);
	each occasion at which one or more tests are performed
11503	Not applicable to a service performed in association with a spirometry or sleep study service to which

D1. MISC	CELLANEOUS DIAGNOSTIC
PROCE	DURES AND INVESTIGATIONS 4. RESPIRATORY
	item 11505, 11506, 11507, 11508, 11512, 12203, 12204, 12205, 12207, 12208, 12210, 12213, 12215, 12217 or 12250 applies
	Not applicable to a service to which item 11507 applies
	(See para DN.1.14 of explanatory notes to this Category) Fee: \$138.65 Benefit: 75% = \$104.00 85% = \$117.90
	Measurement of spirometry, that:
	(a) involves a permanently recorded tracing, performed before and after inhalation of a bronchodilator; and
	(b) is performed to confirm diagnosis of:
	(i) asthma; or
	(ii) chronic obstructive pulmonary disease (COPD); or
	(iii) another cause of airflow limitation;
	each occasion at which 3 or more recordings are made
	Applicable only once in any 12 month period
11505	(See para DN.1.20 of explanatory notes to this Category) Fee: \$41.10 Benefit: 75% = \$30.85 85% = \$34.95
	Measurement of spirometry, that:
	(a) involves a permanently recorded tracing, performed before and after inhalation of a bronchodilator; and
	(b) is performed to:
	(i) confirm diagnosis of chronic obstructive pulmonary disease (COPD); or
	(ii) assess acute exacerbations of asthma; or
	(iii) monitor asthma and COPD; or
	(iv) assess other causes of obstructive lung disease or the presence of restrictive lung disease;
	each occasion at which recordings are made
11506	(See para DN.1.20 of explanatory notes to this Category) Fee: \$20.55 Benefit: 75% = \$15.45 85% = \$17.50
	Measurement of spirometry:
	(a) that includes continuous measurement of the relationship between flow and volume during expiration or during expiration and inspiration, performed before and after inhalation of a bronchodilator; and
	(b) fractional exhaled nitric oxide (FeNO) concentration in exhaled breath;
	if:
11507	(c) the measurement is performed:

D1. MISCELLANEOUS DIAGNOSTIC PROCEDURES AND INVESTIGATIONS 4. RESPIRATORY (i) under the supervision of a specialist or consultant physician; and (ii) with continuous attendance by a respiratory scientist; and (iii) in a respiratory laboratory equipped to perform complex lung function tests; and (d) a permanently recorded tracing and written report is provided; and (e) 3 or more spirometry recordings are performed unless difficult to achieve for clinical reasons; each occasion at which one or more such tests are performed Not applicable to a service associated with a service to which item 11503, 11512 or 22018 applies (See para DN.1.21 of explanatory notes to this Category) **Benefit:** 75% = \$75.15 85% = \$85.20 Fee: \$100.20 Maximal symptom-limited incremental exercise test using a calibrated cycle ergometer or treadmill, if: (a) the test is performed for the evaluation of: (i) breathlessness of uncertain cause from tests performed at rest; or (ii) breathlessness out of proportion with impairment due to known conditions; or (iii) functional status and prognosis in a patient with significant cardiac or pulmonary disease for whom complex procedures such as organ transplantation are considered; or (iv) anaesthetic and peri-operative risks in a patient undergoing major surgery who is assessed as substantially above average risk after standard evaluation; and (b) the test has been requested by a specialist or consultant physician following professional attendance on the patient by the specialist or consultant physician; and (c) a respiratory scientist and a medical practitioner are in constant attendance during the test; and (d) the test is performed in a respiratory laboratory equipped with airway management and defibrillator equipment; and (e) there is continuous measurement of at least the following: (i) work rate; (ii) pulse oximetry; (iii) respired oxygen and carbon dioxide partial pressures and respired volumes; (iv) ECG; (v) heart rate and blood pressure; and (f) interpretation and preparation of a permanent report is provided by a consultant respiratory physician who is also responsible for the supervision of technical staff and quality assurance (See para DN.1.21 of explanatory notes to this Category) **Benefit:** 75% = \$218.10 85% = \$247.20 11508 Fee: \$290.80 Measurement of spirometry: 11512

D1. MISCELLANEOUS DIAGNOSTIC PROCEDURES AND INVESTIGATIONS 4. RESPIRATORY (a) that includes continuous measurement of the relationship between flow and volume during expiration or during expiration and inspiration, performed before and after inhalation of a bronchodilator; and (b) that is performed with a respiratory scientist in continuous attendance; and (c) that is performed in a respiratory laboratory equipped to perform complex lung function tests; and (d) that is performed under the supervision of a consultant physician practising respiratory medicine who is responsible for staff training, supervision, quality assurance and the issuing of written reports; and (e) for which a permanently recorded tracing and written report is provided; and (f) for which 3 or more spirometry recordings are performed; each occasion at which one or more such tests are performed Not applicable for a service associated with a service to which item 11503, 11507 or 22018 applies (See para DN.1.20 of explanatory notes to this Category) **Benefit:** 75% = \$46.35 85% = \$52.50 Fee: \$61.75 **D1. MISCELLANEOUS DIAGNOSTIC** PROCEDURES AND INVESTIGATIONS 5. VASCULAR Group D1. Miscellaneous Diagnostic Procedures And Investigations Subgroup 5. Vascular BLOOD PRESSURE MONITORING (central venous, pulmonary arterial, systemic arterial or cardiac intracavity), by indwelling catheter - once only for each type of pressure on any calendar day up to a maximum of 4 pressures (not being a service to which item 13876 applies and where not performed in association with the administration of general anaesthesia) (See para TN.1.11, TN.1.10 of explanatory notes to this Category) **Benefit:** 75% = \$52.00 85% = \$58.95 11600 Fee: \$69.30 Investigation of venous reflux or obstruction in one or more limbs at rest by CW Doppler or pulsed Doppler involving examination at multiple sites along each limb using intermittent limb compression or Valsalva manoeuvres, or both, to detect prograde and retrograde flow, other than a service associated with a service to which item 32500 applies—hard copy trace and written report, the report component of which must be performed by a medical practitioner, maximum of 2 examinations in a 12 month period, not to be used in conjunction with sclerotherapy 11602 **Benefit:** 75% = \$43.35 85% = \$49.10Investigation of chronic venous disease in the upper and lower extremities, one or more limbs, by plethysmography (excluding photoplethysmography)—examination, hard copy trace and written report, not being a service associated with a service to which item 32500 applies 11604 Fee: \$75.70 **Benefit:** 75% = \$56.80 85% = \$64.35 Investigation of complex chronic lower limb reflux or obstruction, in one or more limbs, by infrared photoplethysmography, during and following exercise to determine surgical intervention or the conservative management of deep venous thrombotic disease—hard copy trace, calculation of 90% recovery time and written report, not being a service associated with a service to which item 32500 applies 11605 Fee: \$75.70 **Benefit:** 75% = \$56.80 85% = \$64.35 MEASUREMENT OF ANKLE: BRACHIAL INDICES AND ARTERIAL WAVEFORM ANALYSIS. measurement of posterior tibial and dorsalis pedis (or toe) and brachial arterial pressures bilaterally 11610 using Doppler or plethysmographic techniques, the calculation of ankle (or toe) brachial systolic

	CELLANEOUS DIAGNOSTIC DURES AND INVESTIGATIONS 5. VASCULAR
	pressure indices and assessment of arterial waveforms for the evaluation of lower extremity arterial disease, examination, hard copy trace and report.
	Fee: \$63.75 Benefit: 75% = \$47.85 85% = \$54.20
	MEASUREMENT OF WRIST: BRACHIAL INDICES AND ARTERIAL WAVEFORM ANALYSIS, measurement of radial and ulnar (or finger) and brachial arterial pressures bilaterally using Doppler or plethysmographic techniques, the calculation of the wrist (or finger) brachial systolic pressure indices and assessment of arterial waveforms for the evaluation of upper extremity arterial disease, examination, hard copy trace and report.
11611	Fee: \$63.75 Benefit: 75% = \$47.85 85% = \$54.20
	EXERCISE STUDY FOR THE EVALUATION OF LOWER EXTREMITY ARTERIAL DISEASE, measurement of posterior tibial and dorsalis pedis (or toe) and brachial arterial pressures bilaterally using Doppler or plethysmographic techniques, the calculation of ankle (or toe) brachial systolic pressure indices for the evaluation of lower extremity arterial disease at rest and following exercise using a treadmill or bicycle ergometer or other such equipment where the exercise workload is quantifiably documented, examination and report.
11612	Fee: \$112.40 Benefit: 75% = \$84.30 85% = \$95.55
	TRANSCRANIAL DOPPLER, examination of the intracranial arterial circulation using CW Doppler or pulsed Doppler with hard copy recording of waveforms, examination and report, not associated with a service to which item 55280 applies.
11614	Fee: \$75.70 Benefit: 75% = \$56.80 85% = \$64.35
	MEASUREMENT OF DIGITAL TEMPERATURE, 1 or more digits, (unilateral or bilateral) and report, with hard copy recording of temperature before and for 10 minutes or more after cold stress testing.
11615	Fee: \$75.90 Benefit: 75% = \$56.95 85% = \$64.55
	PULMONARY ARTERY pressure monitoring during open heart surgery, in a person under 12 years of age
11627	Fee: \$228.65 Benefit: 75% = \$171.50 85% = \$194.40 CELLANEOUS DIAGNOSTIC
_	DURES AND INVESTIGATIONS 6. CARDIOVASCULAR
	Group D1. Miscellaneous Diagnostic Procedures And Investigations
	Subgroup 6. Cardiovascular
	TWELVE-LEAD ELECTROCARDIOGRAPHY, tracing and report
11700	Fee: \$31.25 Benefit: 75% = \$23.45 85% = \$26.60 Extended Medicare Safety Net Cap: \$25.00
11700	TWELVE-LEAD ELECTROCARDIOGRAPHY, report only where the tracing has been forwarded to
	another medical practitioner, not in association with a consultation on the same occasion
11701	Fee: \$15.55 Benefit: 75% = \$11.70 85% = \$13.25 TWELVE-LEAD ELECTROCARDIOGRAPHY, tracing only
11702	Fee: \$15.55 Benefit: 75% = \$11.70 85% = \$13.25
	Continuous ECG recording of ambulatory patient for 12 or more hours (including resting ECG and the recording of parameters), not in association with ambulatory blood pressure monitoring, involving microprocessor based analysis equipment, interpretation and report of recordings by a specialist physician or consultant physician.
11708	

	CELLANEOUS DIAGNOSTIC DURES AND INVESTIGATIONS 6. CARDIOVASCULAR
	Not being a service to which item 11709 applies.
	The changing of a tape or batteries does not constitute a separate service. Where a recording is analysed and reported on and a decision is made to undertake a further period of monitoring, the second episode is regarded as a separate service.
	Fee: \$127.90 Benefit: 75% = \$95.95 85% = \$108.75
	Continuous ECG recording (Holter) of ambulatory patient for 12 or more hours (including resting ECG and the recording of parameters), not in association with ambulatory blood pressure monitoring, utilising a system capable of superimposition and full disclosure printout of at least 12 hours of recorded ECG data, microprocessor based scanning analysis, with interpretation and report by a specialist physician or consultant physician.
	The changing of a tape or batteries does not constitute a separate service. Where a recording is analysed and reported on and a decision is made to undertake a further period of monitoring, the second episode is regarded as a separate service.
11709	Fee: \$167.45 Benefit: 75% = \$125.60 85% = \$142.35
	AMBULATORY ECG MONITORING, patient activated, single or multiple event recording, utilising a looping memory recording device which is connected continuously to the patient for 12 hours or more and is capable of recording for at least 20 seconds prior to each activation and for 15 seconds after each activation, including transmission, analysis, interpretation and report - payable once in any 4 week period
11710	Fee: \$51.90 Benefit: 75% = \$38.95 85% = \$44.15
	AMBULATORY ECG MONITORING for 12 hours or more, patient activated, single or multiple event recording, utilising a memory recording device which is capable of recording for at least 30 seconds after each activation, including transmission, analysis, interpretation and report - payable once in any 4 week period
11711	Fee: \$28.30 Benefit: 75% = \$21.25 85% = \$24.10
11/11	MULTI CHANNEL ECG MONITORING AND RECORDING during exercise (motorised treadmill or cycle ergometer capable of quantifying external workload in watts) or pharmacological stress, involving the continuous attendance of a medical practitioner for not less than 20 minutes, with resting ECG, and with or without continuous blood pressure monitoring and the recording of other parameters, on premises equipped with mechanical respirator and defibrillator
11712	Fee: \$152.15 Benefit: 75% = \$114.15 85% = \$129.35
	SIGNAL AVERAGED ECG RECORDING involving not more than 300 beats, using at least 3 leads with data acquisition at not less than 1000Hz of at least 100 QRS complexes, including analysis, interpretation and report of recording by a specialist physician or consultant physician
11713	Fee: \$69.75 Benefit: 75% = \$52.35 85% = \$59.30
	BLOOD DYE DILUTION INDICATOR TEST
11715	Fee: \$120.75 Benefit: 75% = \$90.60 85% = \$102.65
11,13	IMPLANTED PACEMAKER TESTING involving electrocardiography, measurement of rate, width and amplitude of stimulus, including reprogramming when required, not being a service associated with a service to which item 11700, 11719, 11720, 11721, 11725 or 11726 applies
11718	

	CELLANEOUS DIAGNOSTIC	
PROCE	DURES AND INVESTIGATIONS	6. CARDIOVASCULAR
	Fee: \$34.75 Benefit: 75% = \$26.10 85% = \$29.55	managed and DEMOTE
	IMPLANTED PACEMAKER (including cardiac resynchronisation MONITORING involving reviews (without patient attendance) or a	
	parameters, if at least one remote review is provided in a 12 month	
	parameters, if at least one remote review is provided in a 12 month	period.
	Payable only once in any 12 month period	
11719	Fee: \$66.85 Benefit: 75% = \$50.15 85% = \$56.85	
11/1/	IMPLANTED PACEMAKER TESTING, with patient attendance,	following detection of abnormality
	by remote monitoring involving electrocardiography, measurement	
	stimulus including reprogramming when required, not being a servi	
	item 11718 or 11721 applies.	
11500	D 00000 D 0000000000000000000000000000	
11720	Fee: \$66.85 Benefit: 75% = \$50.15 85% = \$56.85	aguantial rata ragnomaiya an
	IMPLANTED PACEMAKER TESTING of atrioventricular (AV) s antitachycardia pacemakers, including reprogramming when require	
	with a service to which Item 11700, 11718 11719, 11720, 11725 or	
	, , , , , , , , , , , , , , , , , , ,	11,20 mpp1100
11721	Fee: \$69.75 Benefit: 75% = \$52.35 85% = \$59.30	
	IMPLANTED ECG LOOP RECORDING, for investigation of recu	
	re-programming of device, retrieval of stored data, analysis, interpre	etation and report, not in association
	with item 38285	
11722	Fee: \$34.75 Benefit: 75% = \$26.10 85% = \$29.55	
	UP-RIGHT TILT TABLE TESTING for the investigation of synco	pe of suspected cardiothoracic origin,
	including blood pressure monitoring, continuous ECG monitoring a	
	and involving an established intravenous line and the continuous att	
	physician - on premises equipped with a mechanical respirator and	defibrillator
11724	Fee: \$168.90 Benefit: 75% = \$126.70 85% = \$143.60	
11/24	IMPLANTED DEFIBRILLATOR (including cardiac resynchronisa	tion defibrillator) REMOTE
	MONITORING involving reviews (without patient attendance) of a	
	parameters, if at least 2 remote reviews are provided in a 12 month	
	Danahla anku anaa in anu 12 manth nania d	
	Payable only once in any 12 month period	
11725	Fee: \$189.50 Benefit: 75% = \$142.15 85% = \$161.10	
	IMPLANTED DEFIBRILLATOR TESTING with patient attendance	ce following detection of
	abnormality by remote monitoring involving electrocardiography, n	
	amplitude of stimulus, not being a service associated with a service	to which item 11727 applies.
11726	Foo: \$04.75 Ponofit: 750/ - \$71.10 950/ - \$90.55	
11726	Fee: \$94.75 Benefit: 75% = \$71.10 85% = \$80.55 IMPLANTED DEFIBRILLATOR TESTING involving electrocard	ingraphy assessment of pacing and
	sensing thresholds for pacing and defibrillation electrodes, downloa	
	and electrograms, including programming when required, not being	
	to which item 11700, 11718, 11719, 11720, 11721, 11725 or 11720	
11727	Fee: \$94.75 Benefit: 75% = \$71.10 85% = \$80.55	Called marking the second for
11720	Implanted loop recording for the investigation of atrial fibrillation in	
11728	provided has been diagnosed as having had an embolic stroke of un	determined source, including

	CELLANEOUS DIAGNOSTIC DURES AND INVESTIGATIONS 6. CARDIOVASCULAR	
FROOL	reprogramming when required, retrieval of stored data, analysis, interpretation and report, other than a service to which item 38288 applies	
	For any particular patient—applicable not more than 4 times in any 12 months	
	Fee: \$34.75 Benefit: 75% = \$26.10 85% = \$29.55	
	MISCELLANEOUS DIAGNOSTIC DCEDURES AND INVESTIGATIONS 7. GASTROENTEROLOGY & COLORECTAL	
111001	Group D1. Miscellaneous Diagnostic Procedures And Investigations	
	Subgroup 7. Gastroenterology & Colorectal	
	OESOPHAGEAL MOTILITY TEST, manometric	
11800	Fee: \$174.45 Benefit: 75% = \$130.85 85% = \$148.30 CLINICAL ASSESSMENT OF GASTRO-OESOPHAGEAL REFLUX DISEASE that involves 48 hour catheter-free wireless ambulatory oesophageal pH monitoring including administration of the device and associated endoscopy procedure for placement, analysis and interpretation of the data and all attendances for providing the service, if	
	(a) a cathetter-based ambulatory oesophageal pH-mnitoring:	
	(i) has been attempted on the patient but failed due to clinical complications, or	
	(ii) is not clinically appropriate for the patient due to anatomical reasons (nasopharyngeal anatomy)	
	preventing the use of catheter-based pH monitoring; and	
	(b) the services is performed by a specialist or consultant physician with endoscopic training that is recognised by The Conjoint Committee for the Recognition of Training in Gastrointestinal Endoscopy.	
	Not in association with another item in Category 2, sub-group 7 (Anaes.)	
11801	Fee: \$263.00 Benefit: 75% = \$197.25 85% = \$223.55	
	CLINICAL ASSESSMENT of GASTRO-OESOPHAGEAL REFLUX DISEASE involving 24 hour pH monitoring, including analysis, interpretation and report and including any associated consultation	
11810	Fee: \$174.45 Benefit: 75% = \$130.85 85% = \$148.30	
	Capsule endoscopy to investigate an episode of obscure gastrointestinal bleeding, using a capsule endoscopy device (including administration of the capsule, associated endoscopy procedure if required for placement, imaging, image reading and interpretation, and all attendances for providing the service on the day the capsule is administered) if:	
	(a) the service is provided to a patient who:	
	(i) has overt gastrointestinal bleeding; or	
	(ii) has gastrointestinal bleeding that is recurrent or persistent, and iron deficiency anaemia that is not due to coeliac disease, and, if the patient also has menorrhagia, has had the menorrhagia considered and managed; and	
11820	(b) an upper gastrointestinal endoscopy and a colonoscopy have been performed on the patient and have not identified the cause of the	

D1. MISC	CELLANEOUS DIAGNOSTIC
PROCEE	PURES AND INVESTIGATIONS 7. GASTROENTEROLOGY & COLORECTAL
	bleeding; and
	(c) the service has not been provided to the same patient on more than 2 occasions in the preceding 12 months; and
	(d) the service is performed by a specialist or consultant physician with endoscopic training that is recognised by the Conjoint Committee for the Recognition of Training in Gastrointestinal Endoscopy; and
	(e) the service is not associated with a service to which item 30680, 30682, 30684 or 30686 applies
	(See para DN.1.15 of explanatory notes to this Category) Fee: \$1,229.35 Benefit: 75% = \$922.05 85% = \$1145.95
	Capsule endoscopy to conduct small bowel surveillance of a patient diagnosed with Peutz-Jeghers Syndrome, using a
	capsule endoscopy device approved by the Therapeutic Goods Administration (including administration of the capsule, imaging, image reading and interpretation, and all attendances for providing the service on the day the capsule is administered) if:
	(a) the service is performed by a specialist or consultant physician with endoscopic training that is recognised by
	the Conjoint Committee for the Recognition of Training in Gastrointestinal Endoscopy; and
	(b) the item is performed only once in any 2 year period; and
	(c) the service is not associated with balloon enteroscopy.
11823	(See para DN.1.15 of explanatory notes to this Category) Fee: \$1,229.35 Benefit: 75% = \$922.05 85% = \$1145.95
11023	DIAGNOSIS of ABNORMALITIES of the PELVIC FLOOR involving anal manometry or
	measurement of anorectal sensation or measurement of the rectosphincteric reflex
11830	Fee: \$186.80 Benefit: 75% = \$140.10 85% = \$158.80
	DIAGNOSIS of ABNORMALITIES of the PELVIC FLOOR and sphincter muscles involving electromyography or measurement of pudendal and spinal nerve motor latency
11833	Fee: \$249.75 Benefit: 75% = \$187.35 85% = \$212.30
	ELLANEOUS DIAGNOSTIC 8. GENITO/URINARY PHYSIOLOGICAL DURES AND INVESTIGATIONS INVESTIGATIONS
	Group D1. Miscellaneous Diagnostic Procedures And Investigations
	Subgroup 8. Genito/Urinary Physiological Investigations
	URINE FLOW STUDY including peak urine flow measurement, not being a service associated with a service to which item 11919 applies
11900	Fee: \$27.55 Benefit: 75% = \$20.70 85% = \$23.45
11903	CYSTOMETROGRAPHY, not being a service associated with a service to which any of items 11012-11027, 11912, 11915, 11919, 11921 and 36800 or any item in Group I3 applies
	1

	DURES AND INVESTIGATIONS 8. GENITO/URINARY PHYSIOLOGICAL INVESTIGATIONS	
	Fee: \$111.10 Benefit: 75% = \$83.35 85% = \$94.45	
	URETHRAL PRESSURE PROFILOMETRY, not being a service associated with a service to which any of items 11012-11027, 11909, 11919, 11921 and 36800 or any item in Group I3 applies	
11906	Fee: \$111.10 Benefit: 75% = \$83.35 85% = \$94.45	
	URETHRAL PRESSURE PROFILOMETRY WITH simultaneous measurement of urethral sphincter electromyography, not being a service associated with a service to which item 11906, 11915, 11919, 36800 or any item in Group I3 applies	
11909	Fee: \$165.15 Benefit: 75% = \$123.90 85% = \$140.40	
	CYSTOMETROGRAPHY with simultaneous measurement of rectal pressure, not being a service associated with a service to which any of items 11012-11027, 11903, 11915, 11919, 11921 and 36800 or any item in Group I3 applies (Anaes.)	
11912	Fee: \$165.15 Benefit: 75% = \$123.90 85% = \$140.40	
	CYSTOMETROGRAPHY with simultaneous measurement of urethral sphincter electromyography, not being a service associated with a service to which any of items 11012-11027, 11903, 11909, 11912, 11919, 11921 and 36800 or any item in Group I3 applies (Anaes.)	
11915	Fee: \$165.15 Benefit: 75% = \$123.90 85% = \$140.40	
	CYSTOMETROGRAPHY IN CONJUNCTION WITH ULTRASOUND OF 1 OR MORE COMPONENTS OF THE URINARY TRACT, with measurement of any 1 or more of urine flow rate, urethral pressure profile, rectal pressure, urethral sphincter electromyography; including all imaging associated with cystometrography, not being a service associated with a service to which items 11012-11027, 11900-11915, 11919, 11921 and 36800 apply. (Anaes.)	
11917	Fee: \$428.35 Benefit: 75% = \$321.30 85% = \$364.10	
	CYSTOMETROGRAPHY IN CONJUNCTION WITH CONTRAST MICTURATING CYSTOURETHROGRAPHY, with measurement of any 1 or more of urine flow rate, urethral pressure profile, rectal pressure, urethral sphincter electromyography; including all imaging associated with cystometrography, not being a service associated with a service to which items 11012-11027, 11900-11917, 11921 and 36800 apply (Anaes.)	
11919	Fee: \$428.35 Benefit: 75% = \$321.30 85% = \$364.10	
	BLADDER WASHOUT TEST for localisation of urinary infection not including bacterial counts for organisms in specimens	
11921	Fee: \$75.05 Benefit: 75% = \$56.30 85% = \$63.80	
	CELLANEOUS DIAGNOSTIC	
PROCEE	DURES AND INVESTIGATIONS 9. ALLERGY TESTING	
	Group D1. Miscellaneous Diagnostic Procedures And Investigations	
	Subgroup 9. Allergy Testing	
	Skin prick testing for aeroallergens by a specialist or consultant physician in the practice of the specialist or consultant physician's specialty, including all allergens tested on the same day, not being a service associated with a service to which item 12001, 12002, 12005, 12012, 12017, 12021, 12022 or 12024 applies	
12000	(See para DN.1.22 of explanatory notes to this Category) Fee: \$38.95 Benefit: 75% = \$29.25 85% = \$33.15	
	Skin prick testing for aeroallergens, including all allergens tested on the same day, not being a service associated with a service to which item 12000, 12002, 12005, 12012, 12017, 12021, 12022 or 12024 applies.	
12001		

D1. MIS	SCELLANEOUS DIAGNOSTIC	
PROCE	DURES AND INVESTIGATIONS	9. ALLERGY TESTING
	Applicable only once in any 12 month period	
	(See para DN.1.22 of explanatory notes to this Category)	
	Fee: \$38.95 Benefit: 75% = \$29.25 85% = \$33.15	
	Repeat skin prick testing of a patient for aeroallergens, inc	luding all allergens tested on the same day, if:
	(a) further testing for aeroallergens is indicated in the same applies to a service for the patient; and	e 12 month period to which item 12001
	(b) the service is not associated with a service to which ite 12021, 12022 or 12024 applies	m 12000, 12001, 12005, 12012, 12017,
	Applicable only once in any 12 month period	
12002	(See para DN.1.22 of explanatory notes to this Category) Fee: \$38.95 Benefit: 75% = \$29.25 85% = \$33.15	
12002	Skin prick testing for food and latex allergens, including a service associated with a service to which item 12012, 120	ll allergens tested on the same day, not being a
12003	(See para DN.1.22 of explanatory notes to this Category) Fee: \$38.95 Benefit: 75% = \$29.25 85% = \$33.15	
	Skin testing for medication allergens (antibiotics or non go (including prick testing and intradermal testing with a num on the same day, not being a service associated with a serv 12022 or 12024 applies	eneral anaesthetics agents) and venoms aber of dilutions), including all allergens tested
12004	(See para DN.1.22 of explanatory notes to this Category) Fee: \$58.85 Benefit: 75% = \$44.15 85% = \$50.05	
	Skin testing:	
	(a) performed by or on behalf of a specialist or consultant consultant physician's specialty; and	physician in the practice of the specialist or
	(b) for agents used in the perioperative period (including p number of dilutions), to investigate anaphylaxis in a patier or cardiovascular collapse associated with the administrati	nt with a history of prior anaphylactic reaction
	(c) including all allergens tested on the same day; and	
	(d) not being a service associated with a service to which i 12017, 12021, 12022 or 12024 applies	tem 12000, 12001, 12002, 12003, 12012,
12005	(See para DN.1.22 of explanatory notes to this Category) Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35	
	Epicutaneous patch testing in the investigation of allergic	
12012	Fee: \$20.80 Benefit: 75% = \$15.60 85% = \$17.70	
	Epicutaneous patch testing in the investigation of allergic not more than 50 allergens	dermatitis using more than 25 allergens but
12017	Fee: \$70.30 Benefit: 75% = \$52.75 85% = \$59.80	
1201,	Epicutaneous patch testing in the investigation of allergic specialist, or consultant physician, in the practice of his or but not more than 75 allergens	dermatitis, performed by or on behalf of a
12021	Fee: \$115.50 Benefit: 75% = \$86.65 85% = \$98.20	

	CELLANEOUS DIAGNOSTIC DURES AND INVESTIGATIONS 9. ALLERGY TESTING		
	Epicutaneous patch testing in the investigation of allergic dermatitis, performed by or on behalf of a specialist, or consultant physician, in the practice of his or her specialty, using more than 75 allergens but not more than 100 allergens		
12022	Fee: \$135.65 Benefit: 75% = \$101.75 85% = \$115.35		
	Epicutaneous patch testing in the investigation of allergic dermatitis, performed by or on behalf of a specialist, or consultant physician, in the practice of his or her specialty, using more than 100 allergens		
12024	Fee: \$154.50 Benefit: 75% = \$115.90 85% = \$131.35		
	CELLANEOUS DIAGNOSTIC 10. OTHER DIAGNOSTIC PROCEDURES AND DURES AND INVESTIGATIONS INVESTIGATIONS		
TROOL	Group D1. Miscellaneous Diagnostic Procedures And Investigations		
	Subgroup 10. Other Diagnostic Procedures And Investigations		
	COLLECTION OF SPECIMEN OF SWEAT by iontophoresis		
12200	Fee: \$37.20 Benefit: 75% = \$27.90 85% = \$31.65		
12200	Administration, by a specialist or consultant physician in the practice of his or her specialty, of thyrotropin alfa-rch (recombinant human thyroid-stimulating hormone), and arranging services to which both items 61426 and 66650 apply,		
	for the detection of recurrent well-differentiated thyroid cancer in a patient who:		
	(a) has had a total thyroidectomy and one ablative dose of radioactive iodine; and		
	(b) is maintained on thyroid hormone therapy; and		
	(c) is at risk of recurrence; and		
	(d) on at least one previous whole body scan or serum thyroglobulin test when withdrawn from thyroid hormone therapy did not have evidence of well differentiated thyroid cancer; and		
	(i) withdrawal from thyroid hormone therapy resulted in severe psychiatric disturbances when hypothyroid; or		
	(ii) withdrawal is medically contraindicated because the patient has:		
	- unstable coronary artery disease; or		
	- hypopituitarism; or		
	- a high risk of relapse or exacerbation of a previous severe psychiatric illness		
	payable once only in any twelve month period.		
12201	(See para DN.1.16 of explanatory notes to this Category) Fee: \$2,392.90 Benefit: 75% = \$1794.70 85% = \$2309.50		

10. OTHER DIAGNOSTIC PROCEDURES AND INVESTIGATIONS

Overnight diagnostic assessment of sleep, for a period of at least 8 hours duration, for a patient aged 18 years or more, to confirm diagnosis of a sleep disorder, if:

- (a) either:
 - (i) the patient has been referred by a medical practitioner to a qualified sleep medicine practitioner or a consultant respiratory physician who has determined that the patient has a high probability for symptomatic, moderate to severe obstructive sleep apnoea based on a STOP-Bang score of 4 or more, an OSA50 score of 5 or more or a high risk score on the Berlin Questionnaire, and an Epworth Sleepiness Scale score of 8 or more; or
 - (ii) following professional attendance on the patient (either face-to-face or by video conference) by a qualified sleep medicine practitioner or a consultant respiratory physician, the qualified sleep medicine practitioner or consultant respiratory physician determines that assessment is necessary to confirm the diagnosis of a sleep disorder; and
- (b) the overnight diagnostic assessment is performed to investigate:
 - (i) suspected obstructive sleep apnoea syndrome where the patient is assessed as not suitable for an unattended sleep study; or
 - (ii) suspected central sleep apnoea syndrome; or
 - (iii) suspected sleep hypoventilation syndrome; or
 - (iv) suspected sleep-related breathing disorders in association with non-respiratory co-morbid conditions including heart failure, significant cardiac arrhythmias, neurological disease, acromegaly or hypothyroidism; or
 - (v) unexplained hypersomnolence which is not attributed to inadequate sleep hygiene or environmental factors; or
 - (vi) suspected parasomnia or seizure disorder where clinical diagnosis cannot be established on clinical features alone (including associated atypical features, vigilance behaviours or failure to respond to conventional therapy); or
 - (vii) suspected sleep related movement disorder, where the diagnosis of restless legs syndrome is not evident on clinical assessment; and
- (c) a sleep technician is in continuous attendance under the supervision of a qualified sleep medicine practitioner; and
- (d) there is continuous monitoring and recording, performed in accordance with current professional guidelines, of the following measures:
 - (i) airflow;
 - (ii) continuous EMG;
 - (iii) anterior tibial EMG;
 - (iv) continuous ECG;
 - (v) continuous EEG;

10. OTHER DIAGNOSTIC PROCEDURES AND INVESTIGATIONS

- (vi) EOG;
- (vii) oxygen saturation;
- (viii) respiratory movement (chest and abdomen);
- (ix) position; and
- (e) polygraphic records are:
 - (i) analysed (for assessment of sleep stage, arousals, respiratory events, cardiac abnormalities and limb movements) with manual scoring, or manual correction of computerised scoring in epochs of not more than 1 minute; and
 - (ii) stored for interpretation and preparation of report; and
- (f) interpretation and preparation of a permanent report is provided by a qualified sleep medicine practitioner with personal direct review of raw data from the original recording of polygraphic data from the patient; and
- (g) the overnight diagnostic assessment is not provided to the patient on the same occasion that a service mentioned in any of items 11000 to 11005, 11503, 11700 to 11709, 11713 or 12250 is provided to the patient

Applicable only once in any 12 month period

(See para DN.1.17 of explanatory notes to this Category)

Fee: \$588.00 **Benefit:** 75% = \$441.00 85% = \$504.60

Overnight assessment of positive airway pressure, for a period of at least 8 hours duration, for a patient aged 18 years or more, if:

- (a) the necessity for an intervention sleep study is determined by a qualified sleep medicine practitioner or consultant respiratory physician where a diagnosis of a sleep-related breathing disorder has been made; and
- (b) the patient has not undergone positive airway pressure therapy in the previous 6 months; and
- (c) following professional attendance on the patient by a qualified sleep medicine practitioner or a consultant respiratory physician (either face-to-face or by video conference), the qualified sleep medicine practitioner or consultant respiratory physician establishes that the sleep-related breathing disorder is responsible for the patient's symptoms; and
- (d) a sleep technician is in continuous attendance under the supervision of a qualified sleep medicine practitioner; and
- (e) there is continuous monitoring and recording, performed in accordance with current professional guidelines, of the following measures:
 - (i) airflow;
 - (ii) continuous EMG;
 - (iii) anterior tibial EMG;
 - (iv) continuous ECG;

10. OTHER DIAGNOSTIC PROCEDURES AND INVESTIGATIONS

- (v) continuous EEG;
- (vi) EOG;
- (vii) oxygen saturation;
- (viii) respiratory movement;
- (ix) position; and
- (f) polygraphic records are:
 - (i) analysed (for assessment of sleep stage, arousals, respiratory events, cardiac abnormalities and limb movements) with manual scoring, or manual correction of computerised scoring in epochs of not more than 1 minute; and
 - (ii) stored for interpretation and preparation of a report; and
- (g) interpretation and preparation of a permanent report is provided by a qualified sleep medicine practitioner with personal direct review of raw data from the original recording of polygraphic data from the patient; and
- (h) the overnight assessment is not provided to the patient on the same occasion that a service mentioned in any of items 11000 to 11005, 11503, 11700 to 11709, 11713 or 12250 is provided to the patient

Applicable only once in any 12 month period

(See para DN.1.17 of explanatory notes to this Category)

Fee: \$588.00 **Benefit:** 75% = \$441.00 85% = \$504.60

Follow-up study for a patient aged 18 years or more with a sleep-related breathing disorder, following professional attendance on the patient by a qualified sleep medicine practitioner or consultant respiratory physician, if:

- (a) either:
 - (i) there has been a recurrence of symptoms not explained by known or identifiable factors such as inadequate usage of treatment, sleep duration or significant recent illness; or
 - (ii) there has been a significant change in weight or changes in co-morbid conditions that could affect sleep-related breathing disorders and other means of assessing treatment efficacy (including review of data stored by a therapy device used by the patient) are unavailable, or have been equivocal; and
- (b) a sleep technician is in continuous attendance under the supervision of a qualified sleep medicine practitioner; and
- (c) there is continuous monitoring and recording, performed in accordance with current professional guidelines, of the following measures:
 - (i) airflow;
 - (ii) continuous EMG;
 - (iii) anterior tibial EMG;

D1. MISCELLANEOUS DIAGNOSTIC 10. OTHER DIAGNOSTIC PROCEDURES AND PROCEDURES AND INVESTIGATIONS **INVESTIGATIONS** (iv) continuous ECG; (v) continuous EEG; (vi) EOG; (vii) oxygen saturation; (viii) respiratory movement (chest and abdomen); (ix) position; and (d) polygraphic records are: (i) analysed (for assessment of sleep stage, arousals, respiratory events, cardiac abnormalities and limb movements) with manual scoring, or manual correction of computerised scoring in epochs of not more than 1 minute; and (ii) stored for interpretation and preparation of report; and (e) interpretation and preparation of a permanent report is provided by a qualified sleep medicine practitioner with personal direct review of raw data from the original recording of polygraphic data from the patient; and (f) the follow-up study is not provided to the patient on the same occasion that a service mentioned in any of items 11000 to 11005, 11503, 11700 to 11709, 11713 or 12250 is provided to the patient Applicable only once in any 12 month period (See para DN.1.17 of explanatory notes to this Category) Fee: \$588.00 **Benefit:** 75% = \$441.00 85% = \$504.60 Overnight investigation, for a patient aged 18 years or more, for a sleep-related breathing disorder, following professional attendance by a qualified sleep medicine practitioner or a consultant respiratory physician (either face-to-face or by video conference), if: (a) the patient is referred by a medical practitioner; and (b) the necessity for the investigation is determined by a qualified sleep medicine practitioner before the investigation; and (c) there is continuous monitoring and recording, in accordance with current professional guidelines, of the following measures: (i) airflow; (ii) continuous EMG; (iii) anterior tibial EMG; (iv) continuous ECG; (v) continuous EEG; (vi) EOG; (vii) oxygen saturation; 12207

10. OTHER DIAGNOSTIC PROCEDURES AND INVESTIGATIONS

- (viii) respiratory movement (chest and abdomen)
- (ix) position; and
- (d) a sleep technician is in continuous attendance under the supervision of a qualified sleep medicine practitioner; and
- (e) polygraphic records are:
- (i) analysed (for assessment of sleep stage, arousals, respiratory events and assessment of clinically significant alterations in heart rate and limb movement) with manual scoring, or manual correction of computerised scoring in epochs of not more than 1 minute; and
- (ii) stored for interpretation and preparation of report; and
- (f) interpretation and preparation of a permanent report is provided by a qualified sleep medicine practitioner with personal direct review of raw data from the original recording of polygraphic data from the patient; and
- (g) the investigation is not provided to the patient on the same occasion that a service mentioned in any of items 11000 to 11005, 11503, 11700 to 11709, 11713 or 12250 is provided to the patient; and
- (h) previous studies have demonstrated failure of continuous positive airway pressure or oxygen; and
- (i) if the patient has severe cardio-respiratory failure—a further investigation is indicated in the same 12 month period to which items 12204 and 12205 apply to a service for the patient, for the adjustment or testing, or both, of the effectiveness of a positive pressure ventilatory support device (other than continuous positive airway pressure) in sleep

Applicable only once in the same 12 month period to which item 12204 or 12205 applies

(See para DN.1.17 of explanatory notes to this Category)

Fee: \$588.00 **Benefit:** 75% = \$441.00 85% = \$504.60

Overnight investigation for sleep apnoea for a period of at least 8 hours duration, for a patient aged 18 years or more, if:

- (a) a qualified sleep medicine practitioner or consultant respiratory physician has determined that the investigation is necessary to confirm the diagnosis of a sleep disorder; and
- (b) a sleep technician is in continuous attendance under the supervision of a qualified sleep medicine practitioner; and
- (c) there is continuous monitoring and recording, in accordance with current professional guidelines, of the following measures:
 - (i) airflow;
 - (ii) continuous EMG;
 - (iii) anterior tibial EMG;
 - (iv) continuous ECG;
 - (v) continuous EEG;

10. OTHER DIAGNOSTIC PROCEDURES AND INVESTIGATIONS

- (vi) EOG;
- (vii) oxygen saturation;
- (viii) respiratory movement (chest and abdomen);
- (ix) position; and
- (d) polygraphic records are:
 - (i) analysed (for assessment of sleep stage, arousals, respiratory events, cardiac abnormalities and limb movements) with manual scoring, or manual correction of computerised scoring in epochs of not more than 1 minute; and
 - (ii) stored for interpretation and preparation of report; and
- (e) interpretation and preparation of a permanent report is provided by a qualified sleep medicine practitioner with personal direct review of raw data from the original recording of polygraphic data from the patient; and
- (f) a further investigation is indicated in the same 12 month period to which item 12203 applies to a service for the patient because insufficient sleep was acquired, as evidenced by a sleep efficiency of 25% or less, during the previous investigation to which that item applied; and
- (g) the investigation is not provided to the patient on the same occasion that a service mentioned in any of items 11000 to 11005, 11503, 11700 to 11709, 11713 or 12250 is provided to the patient

Applicable only once in the same 12 month period to which item 12203 applies

(See para DN.1.17 of explanatory notes to this Category)

Fee: \$588.00 **Benefit:** 75% = \$441.00 85% = \$504.60

Overnight paediatric investigation, for a period of at least 8 hours in duration, for a patient less than 12 years of age, if:

- (a) the patient is referred by a medical practitioner; and
- (b) the necessity for the investigation is determined by a qualified sleep medicine practitioner before the investigation; and
- (c) there is continuous monitoring of oxygen saturation and breathing using a multi-channel polygraph, and recordings of the following are made, in accordance with current professional guidelines:
 - (i) airflow;
 - (ii) continuous EMG;
 - (iii) ECG;
 - (iv) EEG (with a minimum of 4 EEG leads or, in selected investigations, a minimum of 6 EEG leads);
 - (v) EOG;
 - (vi) oxygen saturation;

12210 (vii) respiratory movement of rib and abdomen (whether movement of rib is recorded separately

10. OTHER DIAGNOSTIC PROCEDURES AND INVESTIGATIONS

from, or together with, movement of abdomen);

- (viii) measurement of carbon dioxide (either end-tidal or transcutaneous); and
- (d) a sleep technician, or registered nurse with sleep technology training, is in continuous attendance under the supervision of a qualified sleep medicine practitioner; and
- (e) polygraphic records are:
 - (i) analysed (for assessment of sleep stage, and maturation of sleep indices, arousals, respiratory events and assessment of clinically significant alterations in heart rate and body movement) with manual scoring, or manual correction of computerised scoring in epochs of not more than 1 minute; and
 - (ii) stored for interpretation and preparation of report; and
- (f) interpretation and report are provided by a qualified sleep medicine practitioner based on reviewing the direct original recording of polygraphic data from the patient

For each particular patient—applicable only in relation to each of the first 3 occasions the investigation is performed in any 12 month period

(See para DN.1.17 of explanatory notes to this Category)

Fee: \$701.85 **Benefit:** 75% = \$526.40 85% = \$618.45

Overnight paediatric investigation, for a period of at least 8 hours in duration, for a patient aged at least 12 years but less than 18 years, if:

- (a) the patient is referred by a medical practitioner; and
- (b) the necessity for the investigation is determined by a qualified sleep medicine practitioner before the investigation; and
- (c) there is continuous monitoring of oxygen saturation and breathing using a multi-channel polygraph, and recordings of the following are made, in accordance with current professional guidelines:
 - (i) airflow;
 - (ii) continuous EMG;
 - (iii) ECG;
 - (iv) EEG (with a minimum of 4 EEG leads or, in selected investigations, a minimum of 6 EEG leads);
 - (v) EOG;
 - (vi) oxygen saturation;
 - (vii) respiratory movement of rib and abdomen (whether movement of rib is recorded separately from, or together with, movement of abdomen);
 - (viii) measurement of carbon dioxide (either end-tidal or transcutaneous); and
- (d) a sleep technician, or registered nurse with sleep technology training, is in continuous attendance under the supervision of a qualified sleep medicine practitioner; and

10. OTHER DIAGNOSTIC PROCEDURES AND INVESTIGATIONS

- (e) polygraphic records are:
 - (i) analysed (for assessment of sleep stage, and maturation of sleep indices, arousals, respiratory events and assessment of clinically significant alterations in heart rate and body movement) with manual scoring, or manual correction of computerised scoring in epochs of not more than 1 minute; and
 - (ii) stored for interpretation and preparation of report; and
- (f) interpretation and report are provided by a qualified sleep medicine practitioner based on reviewing the direct original recording of polygraphic data from the patient

For each particular patient—applicable only in relation to each of the first 3 occasions the investigation is performed in any 12 month period

(See para DN.1.17 of explanatory notes to this Category)

Fee: \$632.30 **Benefit:** 75% = \$474.25 85% = \$548.90

Overnight paediatric investigation, for a period of at least 8 hours in duration, for a patient less than 12 years of age, if:

- (a) the patient is referred by a medical practitioner; and
- (b) the necessity for the investigation is determined by a qualified sleep medicine practitioner before the investigation; and
- (c) there is continuous monitoring of oxygen saturation and breathing using a multi-channel polygraph, and recordings of the following are made, in accordance with current professional guidelines:
 - (i) airflow;
 - (ii) continuous EMG;
 - (iii) ECG;
 - (iv) EEG (with a minimum of 4 EEG leads or, in selected investigations, a minimum of 6 EEG leads);
 - (v) EOG;
 - (vi) oxygen saturation;
 - (vii) respiratory movement of rib and abdomen (whether movement of rib is recorded separately from, or together with, movement of abdomen);
 - (viii) measurement of carbon dioxide (either end-tidal or transcutaneous); and
- (d) a sleep technician, or registered nurse with sleep technology training, is in continuous attendance under the supervision of a qualified sleep medicine practitioner; and
- (e) polygraphic records are:
 - (i) analysed (for assessment of sleep stage, and maturation of sleep indices, arousals, respiratory events and assessment of clinically significant alterations in heart rate and body movement) with manual scoring, or manual correction of computerised scoring in epochs of not more than 1 minute; and

10. OTHER DIAGNOSTIC PROCEDURES AND INVESTIGATIONS

- (ii) stored for interpretation and preparation of report; and
- (f) interpretation and report are provided by a qualified sleep medicine practitioner based on reviewing the direct original recording of polygraphic data from the patient; and
- (g) a further investigation is indicated in the same 12 month period to which item 12210 applies to a service for the patient, for a patient using Continuous Positive Airway Pressure (CPAP) or non-invasive or invasive ventilation, or supplemental oxygen, in either or both of the following circumstances:
 - (i) there is ongoing hypoxia or hypoventilation on the third study to which item 12210 applied for the patient, and further titration of respiratory support is needed to optimise therapy;
 - (ii) there is clear and significant change in clinical status (for example lung function or functional status) or an intervening treatment that may affect ventilation in the period since the third study to which item 12210 applied for the patient, and repeat study is therefore required to determine the need for or the adequacy of respiratory support

Applicable only once in the same 12 month period to which item 12210 applies

(See para DN.1.17 of explanatory notes to this Category)

Fee: \$701.85 **Benefit:** 75% = \$526.40 85% = \$618.45

Overnight paediatric investigation for a period of at least 8 hours in duration for a patient aged at least 12 years but less than 18 years, if:

- (a) the patient is referred by a medical practitioner; and
- (b) the necessity for the investigation is determined by a qualified sleep medicine practitioner before the investigation; and
- (c) there is continuous monitoring of oxygen saturation and breathing using a multi-channel polygraph, and recordings of the following are made, in accordance with current professional guidelines:
 - (i) airflow;
 - (ii) continuous EMG;
 - (iii) ECG;
 - (iv) EEG (with a minimum of 4 EEG leads or, in selected investigations, a minimum of 6 EEG leads);
 - (v) EOG;
 - (vi) oxygen saturation;
 - (vii) respiratory movement of rib and abdomen (whether movement of rib is recorded separately from, or together with, movement of abdomen);
 - (viii) measurement of carbon dioxide (either end-tidal or transcutaneous); and
- (d) a sleep technician, or registered nurse with sleep technology training, is in continuous attendance under the supervision of a qualified sleep medicine practitioner; and
- (e) polygraphic records are:

12217 (i) analysed (for assessment of sleep stage, and maturation of sleep indices, arousals, respiratory

10. OTHER DIAGNOSTIC PROCEDURES AND INVESTIGATIONS

events and assessment of clinically significant alterations in heart rate and body movement) with manual scoring, or manual correction of computerised scoring in epochs of not more than 1 minute; and

- (ii) stored for interpretation and preparation of report; and
- (f) interpretation and report are provided by a qualified sleep medicine practitioner based on reviewing the direct original recording of polygraphic data from the patient; and
- (g) a further investigation is indicated in the same 12 month period to which item 12213 applies to a service for the patient, for a patient using Continuous Positive Airway Pressure (CPAP) or non-invasive or invasive ventilation, or supplemental oxygen, in either or both of the following circumstances:
 - (i) there is ongoing hypoxia or hypoventilation on the third study to which item 12213 applied for the patient, and further titration is needed to optimise therapy;
 - (ii) there is clear and significant change in clinical status (for example lung function or functional status) or an intervening treatment that may affect ventilation in the period since the third study to which item 12213 applied for the patient, and repeat study is therefore required to determine the need for or the adequacy of respiratory support

Applicable only once in the same 12 month period to which item 12213 applies

(See para DN.1.17 of explanatory notes to this Category)

Fee: \$632.30 **Benefit:** 75% = \$474.25 85% = \$548.90

Overnight investigation of sleep for a period of at least 8 hours of a patient aged 18 years or more to confirm diagnosis of obstructive sleep apnoea, if:

- (a) either:
 - (i) the patient has been referred by a medical practitioner to a qualified sleep medicine practitioner or a consultant respiratory physician who has determined that the patient has a high probability for symptomatic, moderate to severe obstructive sleep apnoea based on a STOP-Bang score of 4 or more, an OSA50 score of 5 or more or a high risk score on the Berlin Questionnaire, and an Epworth Sleepiness Scale score of 8 or more; or
 - (ii) following professional attendance on the patient (either face-to-face or by video conference) by a qualified sleep medicine practitioner or a consultant respiratory physician, the qualified sleep medicine practitioner or consultant respiratory physician determines that investigation is necessary to confirm the diagnosis of obstructive sleep apnoea; and
- (b) during a period of sleep, there is continuous monitoring and recording, performed in accordance with current professional guidelines, of the following measures:
 - (i) airflow;
 - (ii) continuous EMG;
 - (iii) continuous ECG;
 - (iv) continuous EEG;
 - (v) EOG;
 - (vi) oxygen saturation;

10. OTHER DIAGNOSTIC PROCEDURES AND INVESTIGATIONS

- (vii) respiratory effort; and
- (c) the investigation is performed under the supervision of a qualified sleep medicine practitioner; and
- (d) either:
 - (i) the equipment is applied to the patient by a sleep technician; or
 - (ii) if this is not possible—the reason it is not possible for the sleep technician to apply the equipment to the patient is documented and the patient is given instructions on how to apply the equipment by a sleep technician supported by written instructions; and
- (e) polygraphic records are:
 - (i) analysed (for assessment of sleep stage, arousals, respiratory events and cardiac abnormalities) with manual scoring, or manual correction of computerised scoring in epochs of not more than 1 minute; and
 - (ii) stored for interpretation and preparation of report; and
- (f) interpretation and preparation of a permanent report is provided by a qualified sleep medicine practitioner with personal direct review of raw data from the original recording of polygraphic data from the patient; and
- (g) the investigation is not provided to the patient on the same occasion that a service mentioned in any of items 11000 to 11005, 11503, 11700 to 11709, 11713 and 12203 is provided to the patient

Applicable only once in any 12 month period

(See para DN.1.17 of explanatory notes to this Category)

Fee: \$335.30 **Benefit:** 75% = \$251.50 85% = \$285.05

Multiple sleep latency test for the assessment of unexplained hypersomnolence in a patient aged 18 years or more, if:

- (a) a qualified sleep medicine practitioner or neurologist determines that testing is necessary to confirm the diagnosis of a central disorder of hypersomnolence or to determine whether the eligibility criteria for drugs relevant to treat that condition under the Pharmaceutical Benefits Scheme are fulfilled; and
- (b) an overnight diagnostic assessment of sleep, for a period of at least 8 hours duration is performed, with continuous monitoring and recording, in accordance with current professional guidelines, of the following measures:
 - (i) airflow;
 - (ii) continuous EMG;
 - (iii) anterior tibial EMG:
 - (iv) continuous ECG;
 - (v) continuous EEG;
 - (vi) EOG;
 - (vii) oxygen saturation;

12254

10. OTHER DIAGNOSTIC PROCEDURES AND INVESTIGATIONS

- (viii) respiratory movement (chest and abdomen);
- (ix) position; and
- (c) immediately following the overnight investigation a daytime investigation is performed where at least 4 nap periods are conducted, during which there is continuous recording of EEG, EMG, EOG and ECG; and
- (d) a sleep technician is in continuous attendance under the supervision of a qualified sleep medicine practitioner; and
- (e) polygraphic records are:
 - (i) analysed (for assessment of sleep stage, arousals, respiratory events, cardiac abnormalities and limb movements) with manual scoring, or manual correction of computerised scoring in epochs of not more than 1 minute; and
 - (ii) stored for interpretation and preparation of report; and
- (f) interpretation and preparation of a permanent report is provided by a qualified sleep medicine practitioner with personal direct review of raw data from the original recording of polygraphic data from the patient; and
- (g) the diagnostic assessment is not provided to the patient on the same occasion that a service mentioned in any of items 11003, 12203, 12204, 12205, 12208, 12250 or 12258 is provided to the patient

Applicable only once in a 12 month period

(See para DN.1.23 of explanatory notes to this Category)

Fee: \$913.70 **Benefit:** 75% = \$685.30 85% = \$830.30

Maintenance of wakefulness test for the assessment of the ability to maintain wakefulness in a patient aged 18 years or more, if:

- (a) a qualified sleep medicine practitioner or neurologist determines that testing is necessary to objectively confirm the ability to maintain wakefulness; and
- (b) an overnight diagnostic assessment of sleep, for a period of at least 8 hours duration is performed, with continuous monitoring and recording, in accordance with current professional guidelines, of the following measures:
 - (i) airflow;
 - (ii) continuous EMG;
 - (iii) anterior tibial EMG;
 - (iv) continuous ECG;
 - (v) continuous EEG;
 - (vi) EOG;
 - (vii) oxygen saturation;

12258

10. OTHER DIAGNOSTIC PROCEDURES AND INVESTIGATIONS

- (viii) respiratory movement (chest and abdomen);
- (ix) position; and
- (c) immediately following the overnight investigation, a daytime investigation is performed where at least 4 wakefulness trials are conducted, during which there is continuous recording of EEG, EMG, EOG and ECG; and
- (d) a sleep technician is in continuous attendance under the supervision of a qualified sleep medicine practitioner; and
- (e) polygraphic records are:
 - (i) analysed (for assessment of sleep stage, arousals, respiratory events, cardiac abnormalities and limb movements) with manual scoring, or manual correction of computerised scoring in epochs of not more than 1 minute; and
 - (ii) stored for interpretation and preparation of report; and
- (f) interpretation and preparation of a permanent report is provided by a qualified sleep medicine practitioner with personal direct review of raw data from the original recording of polygraphic data from the patient; and
- (g) the diagnostic assessment is not provided to the patient on the same occasion that a service mentioned in any of items 11003, 12203, 12204, 12205, 12208, 12250 or 12254 is provided to the patient

Applicable only once in a 12 month period

(See para DN.1.23 of explanatory notes to this Category)

Fee: \$913.70 **Benefit:** 75% = \$685.30 85% = \$830.30

Multiple sleep latency test for the assessment of unexplained hypersomnolence in a patient aged at least 12 years but less than 18 years, if:

- (a) a qualified sleep medicine practitioner determines that testing is necessary to confirm the diagnosis of a central disorder of hypersomnolence or to determine whether the eligibility criteria for drugs relevant to treat that condition under the Pharmaceutical Benefits Scheme are fulfilled; and
- (b) an overnight diagnostic assessment of sleep, for a period of at least 8 hours duration where continuous monitoring of oxygen saturation and breathing using a multi-channel polygraph, and recordings of the following are made, in accordance with current professional guidelines:
 - (i) airflow;
 - (ii) continuous EMG;
 - (iii) ECG;
 - (iv) EEG (with a minimum of 4 EEG leads or, in selected investigations, a minimum of 6 EEG leads);
 - (v) EOG;
 - (vi) oxygen saturation;
- 12261 (vii) respiratory movement of rib and abdomen (whether movement of rib is recorded separately

10. OTHER DIAGNOSTIC PROCEDURES AND INVESTIGATIONS

from, or together with, movement of abdomen);

- (viii) measurement of carbon dioxide (either end-tidal or transcutaneous); and
- (c) immediately following the overnight investigation, a daytime investigation is performed where at least 4 nap periods are conducted, during which there is continuous recording of EEG, EMG, EOG and ECG; and
- (d) a sleep technician is in continuous attendance under the supervision of a qualified sleep medicine practitioner; and
- (e) polygraphic records are:
 - (i) analysed (for assessment of sleep stage, and maturation of sleep indices, arousals, respiratory events and assessment of clinically significant alterations in heart rate and body movement) with manual scoring, or manual correction of computerised scoring in epochs of not more than 1 minute; and
 - (ii) stored for interpretation and preparation of report; and
- (f) interpretation and preparation of a permanent report is provided by a qualified sleep medicine practitioner with personal direct review of raw data from the original recording of polygraphic data from the patient; and
- (g) the diagnostic assessment is not provided to the patient on the same occasion that a service mentioned in any of items 11003, 12213, 12217 or 12265 is provided to the patient

Applicable only once in a 12 month period

(See para DN.1.23 of explanatory notes to this Category)

Fee: \$958.00 **Benefit:** 75% = \$718.50 85% = \$874.60

Maintenance of wakefulness test for the assessment of the ability to maintain wakefulness in a patient aged at least 12 years but less than 18 years, if:

- (a) a qualified sleep medicine practitioner determines that testing to objectively confirm the ability to maintain wakefulness is necessary; and
- (b) an overnight diagnostic assessment of sleep, for a period of at least 8 hours duration where continuous monitoring of oxygen saturation and breathing using a multi-channel polygraph, and recordings of the following are made, in accordance with current professional guidelines:
 - (i) airflow;
 - (ii) continuous EMG;
 - (iii) ECG;
 - (iv) EEG (with a minimum of 4 EEG leads or, in selected investigations, a minimum of 6 EEG leads);
 - (v) EOG;
 - (vi) oxygen saturation;
- 12265 (vii) respiratory movement of rib and abdomen (whether movement of rib is recorded separately

10. OTHER DIAGNOSTIC PROCEDURES AND INVESTIGATIONS

from, or together with, movement of abdomen);

- (viii) measurement of carbon dioxide (either end-tidal or transcutaneous); and
- (c) immediately following the overnight investigation, a daytime investigation is performed where at least 4 wakefulness trials are conducted, during which there is continuous recording of EEG, EMG, EOG and ECG; and
- (d) a sleep technician is in continuous attendance under the supervision of a qualified sleep medicine practitioner; and
- (e) polygraphic records are:
 - (i) analysed (for assessment of sleep stage, arousals, respiratory events, cardiac abnormalities and limb movements) with manual scoring, or manual correction of computerised scoring in epochs of not more than 1 minute; and
 - (ii) stored for interpretation and preparation of report; and
- (f) interpretation and preparation of a permanent report is provided by a qualified sleep medicine practitioner with personal direct review of raw data from the original recording of polygraphic data from the patient; and
- (g) the diagnostic assessment is not provided to the patient on the same occasion that a service mentioned in any of items 11003, 12213, 12217 or 12261 or is provided to the patient

Applicable only once in a 12 month period

(See para DN.1.23 of explanatory notes to this Category)

Fee: \$958.00 **Benefit:** 75% = \$718.50 85% = \$874.60

Multiple sleep latency test for the assessment of unexplained hypersomnolence for a patient less than 12 years of age, if:

- (a) a qualified sleep medicine practitioner determines that testing is necessary to confirm the diagnosis of a central disorder of hypersomnolence or to determine whether the eligibility criteria for drugs relevant to treat that condition under the Pharmaceutical Benefits Scheme are fulfilled; and
- (b) an overnight diagnostic assessment of sleep, for a period of at least 8 hours duration where there is continuous monitoring of oxygen saturation and breathing using a multi-channel polygraph, and recordings of the following are made, in accordance with current professional guidelines:
 - (i) airflow;
 - (ii) continuous EMG;
 - (iii) ECG;
 - (iv) EEG (with a minimum of 4 EEG leads or, in selected investigations, a minimum of 6 EEG leads);
 - (v) EOG;
 - (vi) oxygen saturation;

12268 (vii) respiratory movement of rib and abdomen (whether movement of rib is recorded separately

10. OTHER DIAGNOSTIC PROCEDURES AND INVESTIGATIONS

from, or together with, movement of abdomen);

- (viii) measurement of carbon dioxide (either end-tidal or transcutaneous); and
- (c) immediately following the overnight investigation, a daytime investigation is performed where at least 4 nap periods are conducted, during which there is continuous recording of EEG, EMG, EOG and ECG; and
- (d) a sleep technician is in continuous attendance under the supervision of a qualified sleep medicine practitioner; and
- (e) polygraphic records are:
 - (i) analysed (for assessment of sleep stage, arousals, respiratory events, cardiac abnormalities and limb movements) with manual scoring, or manual correction of computerised scoring in epochs of not more than 1 minute; and
 - (ii) stored for interpretation and preparation of report; and
- (f) interpretation and preparation of a permanent report is provided by a qualified sleep medicine practitioner with personal direct review of raw data from the original recording of polygraphic data from the patient; and
- (g) the diagnostic assessment is not provided to the patient on the same occasion that a service mentioned in any of items 11003, 12210, 12215 or 12272 is provided to the patient

Applicable only once in a 12 month period

(See para DN.1.23 of explanatory notes to this Category)

Fee: \$1,027.55 **Benefit:** 75% = \$770.70 85% = \$944.15

Maintenance of wakefulness test for the assessment of the ability to maintain wakefulness for a patient less than 12 years of age, if:

- (a) a qualified sleep medicine practitioner determines that testing to objectively confirm the ability to maintain wakefulness is necessary; and
- (b) an overnight diagnostic assessment of sleep, for a period of at least 8 hours duration where there is continuous monitoring of oxygen saturation and breathing using a multi-channel polygraph, and recordings of the following are made, in accordance with current professional guidelines:
 - (i) airflow;
 - (ii) continuous EMG;
 - (iii) ECG;
 - (iv) EEG (with a minimum of 4 EEG leads or, in selected investigations, a minimum of 6 EEG leads);
 - (v) EOG;
 - (vi) oxygen saturation;
 - (vii) respiratory movement of rib and abdomen (whether movement of rib is recorded separately from, or together with, movement of abdomen);

12272

D1. MISCELLANEOUS DIAGNOSTIC 10. OTHER DIAGNOSTIC PROCEDURES AND PROCEDURES AND INVESTIGATIONS **INVESTIGATIONS** (viii) measurement of carbon dioxide (either end-tidal or transcutaneous); and (c) immediately following the overnight investigation, a daytime investigation is performed where at least 4 wakefulness trials are conducted, during which there is continuous recording of EEG, EMG, EOG and ECG; and (d) a sleep technician is in continuous attendance under the supervision of a qualified sleep medicine practitioner; and (e) polygraphic records are: (i) analysed (for assessment of sleep stage, arousals, respiratory events, cardiac abnormalities and limb movements) with manual scoring, or manual correction of computerised scoring in epochs of not more than 1 minute; and (ii) stored for interpretation and preparation of report; and (f) interpretation and preparation of a permanent report is provided by a qualified sleep medicine practitioner with personal direct review of raw data from the original recording of polygraphic data from the patient; and (g) the diagnostic assessment is not provided to the patient on the same occasion that a service mentioned in any of items 11003, 12210, 12215 or 12268 is provided to the patient Applicable only once in a 12 month period (See para DN.1.23 of explanatory notes to this Category) **Benefit:** 75% = \$770.70 85% = \$944.15 Fee: \$1.027.55 Bone densitometry, using dual energy X-ray absorptiometry, involving the measurement of 2 or more sites (including interpretation and reporting), for: (a) confirmation of a presumptive diagnosis of low bone mineral density made on the basis of one or more fractures occurring after minimal trauma; or (b) monitoring of low bone mineral density proven by bone densitometry at least 12 months previously; other than a service associated with a service to which item 12312, 12315 or 12321 applies For any particular patient, once only in a 24 month period (See para DN.1.18 of explanatory notes to this Category) 12306 Fee: \$102.40 **Benefit:** $75\% = \$76.80 \quad 85\% = \87.05 Bone densitometry, using dual energy X-ray absorptiometry, involving the measurement of 2 or more sites (including interpretation and reporting) for diagnosis and monitoring of bone loss associated with one or more of the following: (a) prolonged glucocorticoid therapy; (b) any condition associated with excess glucocorticoid secretion; (c) male hypogonadism; (d) female hypogonadism lasting more than 6 months before the age of 45: other than a service associated with a service to which item 12306, 12315 or 12321 applies 12312

	CELLANEOUS DIAGNOSTIC 10. OTHER DIAGNOSTIC PROCEDURES AND DURES AND INVESTIGATIONS INVESTIGATIONS
TROOLE	For any particular patient, once only in a 12 month period
	(See para DN.1.18 of explanatory notes to this Category) Fee: \$102.40 Benefit: 75% = \$76.80 85% = \$87.05
	Bone densitometry, using dual energy X-ray absorptiometry, involving the measurement of 2 or more sites (including interpretation and reporting) for diagnosis and monitoring of bone loss associated with one or more of the following conditions:
	(a) primary hyperparathyroidism;
	(b) chronic liver disease;
	(c) chronic renal disease;
	(d) any proven malabsorptive disorder;
	(e) rheumatoid arthritis;
	(f) any condition associated with thyroxine excess;
	other than a service associated with a service to which item 12306, 12312 or 12321 applies
	For any particular patient, once only in a 24 month period
12315	(See para DN.1.18 of explanatory notes to this Category) Fee: \$102.40 Benefit: 75% = \$76.80 85% = \$87.05 Bone densitometry, using dual energy X-ray absorptiometry or quantitative computed tomography, involving the measurement of 2 or more sites (including interpretation and reporting) for measurement of bone mineral density, if:
	(a) the patient is 70 years of age or over, and
	(b) either:
	(i) the patient has not previously had bone densitometry; or
	(ii) the t-score for the patient's bone mineral density is -1.5 or more;
	other than a service associated with a service to which item 12306, 12312, 12315, 12321 or 12322 applies
	For any particular patient, once only in a 5 year period
12320	(See para DN.1.18 of explanatory notes to this Category) Fee: \$102.40 Benefit: 75% = \$76.80 85% = \$87.05
	Bone densitometry, using dual energy X-ray absorptiometry, involving the measurement of 2 or more sites at least 12 months after a significant change in therapy (including interpretation and reporting), for:
	(a) established low bone mineral density; or
12321	(b) confirming a presumptive diagnosis of low bone mineral density made on the basis of one or more fractures occurring after minimal trauma;

	CELLANEOUS DIAGNOSTIC 10. OTHER DIAGNOSTIC PROCEDURES AND DURES AND INVESTIGATIONS INVESTIGATIONS
	other than a service associated with a service to which item 12306, 12312 or 12315 applies
	For any particular patient, once only in a 12 month period
	(See para DN.1.18 of explanatory notes to this Category) Fee: \$102.40 Benefit: 75% = \$76.80 85% = \$87.05
	Bone densitometry, using dual energy X-ray absorptiometry or quantitative computed tomography, involving the measurement of 2 or more sites (including interpretation and reporting) for measurement of bone mineral density, if:
	(a) the patient is 70 years of age or over; and
	(b) the t-score for the patient's bone mineral density is less than -1.5 but more than -2.5;
	other than a service associated with a service to which item 12306, 12312, 12315, 12320 or 12321 applies
	For any particular patient, once only in a 2 year period
12322	(See para DN.1.18 of explanatory notes to this Category) Fee: \$102.40 Benefit: 75% = \$76.80 85% = \$87.05
12322	Assessment of visual acuity and bilateral retinal photography with a non mydriatic retinal camera, including analysis and reporting of the images for initial or repeat assessment for presence or absence of diabetic retinopathy, in a patient with medically diagnosed diabetes, if:
	(a) the patient is of Aboriginal and Torres Strait Islander descent; and
	(b) the assessment is performed by the medical practitioner (other than an optometrist or ophthalmologist) providing
	the primary glycaemic management of the patient's diabetes; and
	(c) this item and item 12326 have not applied to the patient in the preceding 12 months; and
	(d) the patient does not have:
	(i) an existing diagnosis of diabetic retinopathy; or
	(ii) visual acuity of less than 6/12 in either eye; or
	(iii) a difference of more than 2 lines of vision between the 2 eyes at the time of presentation
12325	(See para DN.1.19 of explanatory notes to this Category) Fee: \$50.00 Benefit: 75% = \$37.50 85% = \$42.50
	Assessment of visual acuity and bilateral retinal photography with a non-mydriatic retinal camera, including analysis and reporting of the images for initial or repeat assessment for presence or absence of diabetic retinopathy, in a patient with medically diagnosed diabetes, if:
	(a) the assessment is performed by the medical practitioner (other than an optometrist or ophthalmologist) providing
	the primary glycaemic management of the patient's diabetes; and
	(b) this item and item 12325 have not applied to the patient in the preceding 24 months; and
12326	(c) the patient does not have:

	CELLANEOUS DIAGNOSTIC 10. OTHER DIAGNOSTIC PROCEDURES AND	
PROCEL	OURES AND INVESTIGATIONS (i) an existing diagnosis of diabetic retinopathy; or	
	(1) all existing diagnosis of diabetic retinopatity, of	
	(ii) visual acuity of less than 6/12 in either eye; or	
	(iii) a difference of more than 2 lines of vision between the 2 eyes at the time of presentation	
	(See para DN.1.19 of explanatory notes to this Category) Fee: \$50.00 Benefit: 75% = \$37.50 85% = \$42.50	
D2. NUC	ELEAR MEDICINE (NON-IMAGING)	
_	Group D2. Nuclear Medicine (Non-Imaging)	
	BLOOD VOLUME ESTIMATION	
12500	Fee: \$216.65	
	ERYTHROCYTE RADIOACTIVE UPTAKE SURVIVAL TIME TEST OR IRON KINETIC TEST	
12503	Fee: \$424.75 Benefit: 75% = \$318.60 85% = \$361.05	
	GASTROINTESTINAL BLOOD LOSS ESTIMATION involving examination of stool specimens	
12506	Fee: \$303.30 Benefit: 75% = \$227.50 85% = \$257.85	
	GASTROINTESTINAL PROTEIN LOSS	
12509	Fee: \$216.65 Benefit: 75% = \$162.50 85% = \$184.20	
	RADIOACTIVE B12 ABSORPTION TEST 1 isotope	
12512	Fee: \$105.05 Benefit: 75% = \$78.80 85% = \$89.30	
	RADIOACTIVE B12 ABSORPTION TEST 2 isotopes	
12515	Fee: \$229.85 Benefit: 75% = \$172.40 85% = \$195.40	
	THYROID UPTAKE (using probe)	
12518	Fee: \$105.05 Benefit: 75% = \$78.80 85% = \$89.30	
	PERCHLORATE DISCHARGE STUDY	
12521	Fact \$127 (5 Page \$14, 7597 - \$05.00, 9597 - \$107.70	
12521	Fee: \$126.65 Benefit: 75% = \$95.00 85% = \$107.70 RENAL FUNCTION TEST (without imaging procedure)	
12524	Fee: \$158.35	
	RENAL FUNCTION TEST (with imaging and at least 2 blood samples)	
12527	Fee: \$84.95 Benefit: 75% = \$63.75 85% = \$72.25	
	WHOLE BODY COUNT not being a service associated with a service to which another item applies	
12530	Fee: \$126.65 Benefit: 75% = \$95.00 85% = \$107.70	
	CARBON-LABELLED UREA BREATH TEST using oral C-13 or C-14 urea, performed by a specialist or consultant physician, including the measurement of exhaled ¹³ CO ₂ or ¹⁴ CO ₂ , for either:-	
	(a) the confirmation of <i>Helicobacter pylori</i> colonisation, OR	
	(b) the monitoring of the success of eradication of <i>Helicobacter pylori</i> .	
	not being a service to which 66900 applies	
12533	Fee: \$84.65 Benefit: 75% = \$63.50 85% = \$72.00	

INDEX

Α

allergens Allergens, epicutaneous patch testing	12000, 12003 12012, 12017	Evoked response audiometry, brain stem floor abnormalities, diagnosis of	11300 11830, 11833
12021-12022, 12024	12012, 12017	floor abhormatities, diagnosis of	11030, 11033
artery pressure monitoring, open heart	11627	F	
	1309, 11312, 11315, 11318		
Audiometry, brain stem evoked respons	e 11300	Flow volume loops	11512
В		function test	12524, 12527
Brain stem evoked response audiometry	11300	G	
С		Gastrointestinal blood loss estimation impedance	12506 11324, 11327, 11330
		Implantable Cardioverter Defibrillator test	
C-13 or C-14 urea breath test	12533	implanted, testing of	11718, 11721
Caloric test of labyrinth(s)	11333, 11336	infection, bladder washout test	11921
Capsule endoscopy for Peutz-Jeghers sy		investigation of ocular surface dysplasia	11235
Capsule endoscopy, for obscure gastroir capsule endoscopy, investigation of ob	ntestinal bleeding 11820 scure bleeding 11820		
capsule, for obscure gastrointestinal blo		·	
coherence biometry/tomography	11240-11243	Iontophoresis, collection of specimen of sw	eat by 12200
Computerised perimetry	11221, 11224	Iron kinetic test	12503
conduction studies	11012, 11015, 11018	labelled urea breath test	12533
contents, partial coherence interferome			
contents, ultrasonic echography of Cystometrography	11240-11243 11903	L	
Cystometrography	11703		
D		Labyrinths, caloric test of	11333, 11336
		loop recorder for investigation of syncope Lung compliance, estimation of	11722 11503
Dark Adaptometry	11211	Lung comphance, estimation of	11303
	2306, 12312, 12315, 12321	M	
Diffusing capacity	11503		
dioxide output, estimation of Doppler interferometry of eyes	11503 11240-11243	Manometric oesophageal motility test	11800
	1602, 11610-11612, 11614	manometry, pelvic floor abnormalities	11830
dye - dilution indicator test	11715	motility test, manometric	11800
,		Motility test, manometric, of oesophagus muscle and pelvic floor abnormalities, dia	11800 gnosis of 11833
E		Muscle, activity sampling (electromyograph	
		11018	11012, 11013
	1700-11702, 11708-11713	nervous system evoked responses	11024, 11027
E.E.G.	11000, 11003-11006		
E.M.G. E.N.G.	11012, 11021, 11833 11339	N	
	1700-11702, 11708-11713		
Electrocochleography	11303-11304		2, 11015, 11018, 11021
Electrocorticography	11009	non-determinate	11306
	1012, 11015, 11018, 11021	0	
Electroencephalography (E.E.G)	11000, 11003-11006	•	
Electromyography (E.M.G.) Electroneurography of facial nerve	11012, 11021, 11833 11015	Optical coherence biometry/tomography	11240-11243
Electronystagmography (E.N.G.)	11339	Optical coherence tomography	11219-11220
Electrooculography (E.iv.G.)	11205	Oto-acoustic emission audiometry	11332
Electroretinography	11204-11205, 11210	oto-acoustic emission audiometry	11332
	2017, 12021-12022, 12024	Overnight paediatric investigation	12210, 12213, 12215
Ergometry, with electrocardiography	11712	12217 Oxygen consumption, estimation of	11503
Erythrocyte radioactive uptake survival	time 12503	pace maker testing	11718, 11721
		1 777	,10,11,21

Ρ

Partial coherence interferometry of eyes 11240-11243 patch testing, epicutaneous 12012, 12017, 12021-12022, 12024 Perchlorate discharge study 12521 Plethysmography 11604-11605, 11610-11612 pressure monitoring, indwelling catheter 11600 pressure profilometry 11906, 11909 Profilometry, urethral pressure 11906, 11909 protein loss 12509 Provocative test for glaucoma 11200 provocative tests for 11200 Pudendal and spinal nerve motor latency, measurement 11833 quantitative, computerised 11221, 11224	Urine flow study vessels, examination of volume estimation, nuclear volumes vashout test of W Urine flow study vessels, examination of 11604-11605, 11610-11612 12500 11503 11921 W Whole body count with other procedures 12530 11912, 11915, 11917, 11919
R	
Radioactive B12 absorption test Rectosphincteric reflex, measurement of reflux, clinical assessment of 11830 Respiratory function, estimation of responses, central nervous system 11024, 11027 Retinal angiography 11215, 11218 Retinal photography 12325-12326	
S	
0.139	
Schilling test screening test, volume Cr51 sensation, measurement of sensitivity testing for allergens skin skin sensitivity testing Sleep apnoea, overnight investigation for 12512, 12515 12500 12600 12800 12800-12005 12000-12005 12000-12005	
Small bowel, capsule endoscopy, investigation of obscure bleeding 11820	
Specimen of sweat, collection of, by iontophoresis 12200 Spinal and pudendal nerve motor latency, measurement 11833 Spirometry 11506 surface dysplasia, investigation 11235	
Sweat, collection of specimen of, by iontophoresis 12200	
т	
Temperature, digital, measurement of 11615 temperature, measurement of 11615 Temporosphenoidal electroencephalography 11006 tests 11318 Thyroid uptake 12518 Thyrotropin alfa-rch, administration of 12201 Tilt table testing for investigation of syncope 11724 Transcranial doppler 11614	
U	
Upright tilt table testing for syncope Urea breath test 11724 12533	

CATEGORY 3: THERAPEUTIC PROCEDURES

SUMMARY OF CHANGES FROM 01/03/2019

The 01/03/2019 changes to the MBS are summarised below and are identified in the Schedule pages by one or more of the following words appearing above the item number:

(a) new item	New
(b) amended description	Amend
(c) fee amended	Fee
(d) item number changed	Renum
(e) EMSN changed	EMSN

Amended Fee effective 8 March 2019

51011

Amended Note

TN.7.4

Correct fee on MBS online from \$1,435.30 to \$1,435.50

The fee for item 51011 on MBS online does not match the fee outlined in the Health Insurance (General Medical Services Tables) Regulations 2018, or the fee administered by the Department of Human Services. This change will align MBS Online with the legislation.

THERAPEUTIC PROCEDURES NOTES

TN.1.1 Hyperbaric Oxygen Therapy - (Items 13015, 13020, 13025 and 13030)

Hyperbaric Oxygen Therapy not covered by these items would attract benefits on an attendance basis. For the purposes of these items, a comprehensive hyperbaric medicine facility means a separate hospital area that, on a 24 hour basis:

- (a) is equipped and staffed so that it is capable of providing to a patient:
- (i) hyperbaric oxygen therapy at a treatment pressure of at least 2.8 atmospheric pressure absolute (180 kilopascal gauge pressure); and
- (ii) mechanical ventilation and invasive cardiovascular monitoring within a monoplace or multiplace chamber for the duration of the hyperbaric treatment; and
- (b) is under the direction of at least 1 medical practitioner who is rostered, and immediately available, to the facility during the facility's ordinary working hours if the practitioner:
- (i) is a specialist with training in diving and hyperbaric medicine; or
- (ii) holds a Diploma of Diving and Hyperbaric Medicine of the South Pacific Underwater Medicine Society; and
- (c) is staffed by:
- (i) at least 1 medical practitioner with training in diving and hyperbaric medicine who is present in the facility and immediately available at all times when patients are being treated at the facility; and
- (ii) at least 1 registered nurse with specific training in hyperbaric patient care to the published standards of the Hyperbaric Technicians and Nurses Association, who is present during hyperbaric oxygen therapy; and
- (d) has admission and discharge policies in operation.

TN.1.2 Haemodialysis - (Items 13100 and 13103)

Item 13100 covers the supervision in hospital by a medical specialist for the management of dialysis, haemofiltration, haemoperfusion or peritoneal dialysis in the patient who is not stabilised where the total attendance time by the supervising medical specialist exceeds 45 minutes.

Item 13103 covers the supervision in hospital by a medical specialist for the management of dialysis, haemofiltration, haemoperfusion or peritoneal dialysis in a stabilised patient, or in the case of an unstabilised patient, where the total attendance time by the supervising medical specialist does not exceed 45 minutes.

TN.1.3 Consultant Physician Supervision of Home Dialysis - (Item 13104)

Item 13104 covers the planning and management of dialysis and the supervision of a patient on home dialysis by a consultant physician in the practice of his or her specialty of renal medicine. Planning and management would cover the consultant physician participating in patient management discussions coordinated by renal centres. Supervision of the patient at home can be undertaken by telephone or other electronic medium, and includes:

- Regular ordering, performance and interpretation of appropriate biochemical and haematological studies (generally monthly);
- Feed-back of results to the home patient and his or her treating general physician;
- Adjustments to medications and dialysis therapies based upon these results;

- Co-ordination of regular investigations required to keep patient on active transplantation lists, where relevant;
- Referral to, and communication with, other specialists involved in the care of the patient; and
- Being available to advise the patient or the patient's agent.

A record of the services provided should be made in the patient's clinical notes.

The schedule fee equates to one hour of time spent undertaking these activities. It is expected that the item will be claimed once per month, to a maximum of 12 claims per year. The patient should be informed that he or she will incur a charge for which a Medicare rebate will be payable.

This item includes dialysis conducted in a residential aged care facility. In remote areas, where a patient's home is an unsuitable environment for home dialysis due to a lack of space, or the absence of telecommunication, electricity and water utilities, the item includes dialysis in a community facility such as the local primary health care clinic.

TN.1.4 Assisted Reproductive Technology ART Services - (Items 13200 to 13221)

Medicare benefits are not payable in respect of ANY other item in the Medicare Benefits Schedule (including Pathology and Diagnostic Imaging) in lieu of or in connection with items 13200 - 13221. Specifically, Medicare benefits are not payable for these items in association with items 104, 105, 14203, 14206, 35637, pathology tests or diagnostic imaging.

A treatment cycle that is a series of treatments for the purposes of ART services is defined as beginning either on the day on which treatment by superovulatory drugs is commenced or on the first day of the patient's menstrual cycle, and ending either; not more than 30 days later, or if a service mentioned in item 13212, 13215 or 13321 is provided in connection with the series of treatments-on the day after the day on which the last of those services is provided.

The date of service in respect of treatment covered by Items 13200, 13201, 13203, 13206, 13209 and 13218 is **DEEMED** to be the **FIRST DAY** of the treatment cycle.

Items 13200, 13201, 13202 and 13203 are linked to the supply of hormones under the Section 100 (National Health Act) arrangements. Providers must notify the Department of Human Services of Medicare card numbers of patients using hormones under this program, and hormones are only supplied for patients claiming one of these four items.

Medicare benefits are not payable for assisted reproductive services rendered in conjunction with surrogacy arrangements where surrogacy is defined as 'an arrangement whereby a woman agrees to become pregnant and to bear a child for another person or persons to whom she will transfer guardianship and custodial rights at or shortly after birth'.

NOTE: Items 14203 and 14206 are not payable for artificial insemination.

TN.1.5 Intracytoplasmic Sperm Injection - (Item 13251)

Item 13251 provides for intracytoplasmic sperm injection for male factor infertility under the following circumstances:

- where fertilisation with standard IVF is highly unlikely to be successful; or
- where in a previous cycle of IVF, the fertilisation rate has failed due to low or no fertilisation.

Item 13251 excludes a service to which item 13218 applies. Sperm retrieval procedures associated with intracytoplasmic sperm injection are covered under items 37605 and 37606.

Items 13251, 37605, 37606 do not include services provided in relation to artificial insemination using the husband's or donated sperm.

TN.1.6 Peripherally Inserted Central Catheters

Peripherally inserted central catheters (PICC) are an alternative to standard percutaneous central venous catheter placement or surgically placed intravenous catheters where long-term venous access is required for ongoing patient therapy.

Medicare benefits for PICC can be claimed under central vein catheterisation items 13318, 13319, 13815 and 22020.

These items are for central vein catheterisation (where the tip of the catheter is positioned in a central vein) and cannot be used for venous catheters where the tip is positioned in a peripheral vein.

TN.1.7 Administration of Blood or Bone Marrow already Collected (Item 13706)

Item 13706 is payable for the transfusion of blood, or platelets or white blood cells or bone marrow or gamma globulins. This item is not payable when gamma globulin is administered intramuscularly.

TN.1.8 Collection of Blood - (Item 13709)

Medicare benefits are payable under Item 13709 for collection of blood for autologous transfusions in respect of an impending operation (whether or not the blood is used), or when homologous blood is required in an emergency situation.

Medicare benefits are not payable under Item 13709 for collection of blood for long-term storage for possible future autologous transfusion, or for other forms of directed blood donation.

TN.1.9 Intensive Care Units - (Items 13870 to 13888)

'Intensive Care Unit' means a separate hospital area that:

- (a) is equipped and staffed so as to be capable of providing to a patient:
- (i) mechanical ventilation for a period of several days; and
- (ii) invasive cardiovascular monitoring; and
- (b) is supported by:
- (i) at least one specialist or consultant physician in the specialty of intensive care who is immediately available and exclusively rostered to the ICU during normal working hours; and
- (ii) a registered medical practitioner who is present in the hospital and immediately available to the unit at all times; and
- (iii) a registered nurse for at least 18 hours in each day; and
- (c) has defined admission and discharge policies.

"**immediately available**" means that the intensivist must be predominantly present in the ICU during normal working hours. Reasonable absences from the ICU would be acceptable to attend conferences, meetings and other commitments which might involve absences of up to 2 hours during the working day.

"exclusively rostered" means that the specialist's sole clinical commitment is to intensive care associated activities and is not involved in any other duties that may preclude immediate availability to intensive care if required.

For Neonatal Intensive Care Units an 'Intensive Care Unit' means a separate hospital area that:

- (a) is equipped and staffed so as to be capable of providing to a patient, being a newly-born child:
- (i) mechanical ventilation for a period of several days; and

- (ii) invasive cardiovascular monitoring; and
- (b) is supported by:
- (i) at least one consultant physician in the specialty of paediatric medicine, appointed to manage the unit, and who is immediately available and exclusively rostered to the ICU during normal working hours; and
- (ii) a registered medical practitioner who is present in the hospital and immediately available to the unit at all times; and
- (iii) a registered nurse for at least 18 hours in each day; and
- (c) has defined admission and discharge policies.

Medicare benefits are payable under the 'management' items only once per day irrespective of the number of intensivists involved with the patient on that day. However, benefits are also payable for an attendance by another specialist/consultant physician who is not managing the patient but who has been asked to attend the patient. Where appropriate, accounts should be endorsed to the effect that the consultation was not part of the patient's intensive care management in order to identify which consultations should attract benefits in addition to the intensive care items.

In respect of Neonatal Intensive Care Units, as defined above, benefits are payable for admissions of babies who meet the following criteria:-

- (i) all babies weighing less than 1000gms;
- (ii) all babies with an endotracheal tube, and for the 24 hours following endotracheal tube removal;
- (iii) all babies requiring Constant Positive Airway Pressure (CPAP) for acute respiratory instability;
- (iv) all babies requiring more than 40% oxygen for more than 4 hours;
- (v) all babies requiring an arterial line for blood gas or pressure monitoring; or
- (vi) all babies having frequent seizures.

Cases may arise where babies admitted to a Neonatal Intensive Care Unit under the above criteria who, because they no longer satisfy the criteria are ready for discharge, in accordance with accepted discharge policies, but who are physically retained in the Neonatal Intensive Care Unit for other reasons. For benefit purposes such babies must be deemed as being discharged from the Neonatal Intensive Care Unit and not eligible for benefits under items 13870, 13873, 13876, 13881, 13882, 13885 and 13888.

Likewise, Medicare benefits are not payable under items 13870, 13873, 13876, 13881 13882, 13885 and 13888 in respect of babies not meeting the above criteria, but who, for whatever other reasons, are physically located in a Neonatal Intensive Care Unit.

Medicare benefits are payable for admissions to an Intensive Care Unit following surgery only where clear clinical justification for post-operative intensive care exists.

TN.1.10 Procedures Associated with Intensive Care - (Items 13818, 13842, 13847, 13848 and 13857) Item 13818 covers the insertion of a right heart balloon catheter (Swan-Ganz catheter). Benefits are payable under this item only once per day except where a second discrete operation is performed on that day.

Benefits are payable under items 13876 (within an ICU) and 11600 (outside an ICU) once only for each type of pressure, up to a maximum of 4 pressures per patient per calendar day, and irrespective of the number of the practitioners involoved in monitoring the pressures.

If a service covered by Item 13842 is provided outside of an ICU, in association with, for example, an anaesthetic, benefits are payable for Item 13842 in addition to Item 13870 where the services are performed on the same day. Where this occurs, accounts should be endorsed "performed outside of an Intensive Care Unit" against Item 13842.

Items 13847 and 13848

Item 13847 covers management of counterpulsation by intraaortic balloon on the first day and includes initial and subsequent consultations and monitoring of parameters. Insertion of the intraaortic balloon is covered under item 38609 Management on each day subsequent to the first is covered under item 13848.

"management" of counterpulsation of intraaortic balloon means full heamodynamic assessment and management on several occasions during the day.

Item 13857 covers the establishment of airway access and initiation of ventilation on a patient outside intensive care for the purpose of subsequent ventilatory support in intensive care. Benefits are not payable under Item 13857 where airway access and ventilation is initiated in the context of an anaesthetic for surgery even if it is likely that following surgery the patient will be ventilated in an ICU. In such cases the appropriate anaesthetic item/s should be itemised.

Medicare benefits are not payable for sampling by arterial puncture under Item 13839 in addition to Item 13870 (and 13873) on the same day. Benefits are payable under Item 13842 (Intra-arterial cannulation) in addition to Item 13870 (and 13873) when performed on the same day.

TN.1.11 Management and Procedures in Intensive Care Unit - (Items 13870, 13873, 13876)

Medicare benefits are only payable for management and procedures in intensive care covered by items 13870, 13873, 13876, 13882, 13885 and 13888 where the service is provided by a specialist or consultant physician who is immediately available and exclusively rostered for intensive care.

Items 13870 and 13873

Medicare Benefits Schedule fees for Items 13870 and 13873 represent global daily fees covering all attendances by the intensivist in the ICU (and attendances provided by support medical personnel) and all electrocardiographic monitoring, arterial sampling and, bladder catheterisation.performed on the patient on the one day. If a patient is transferred from one ICU to another it would be necessary for an arrangement to be made between the two ICUs regarding the billing of the patient.

Items 13870 and 13873 should be itemised on accounts according to each calendar day and not per 24 hour period. For periods when patients are in an ICU for very short periods (say less than 2 hours) with minimal ICU management during that time, a fee should not be raised.

Item 13876

Item 13876 covers the monitoring of pressures in an ICU. Benefits are paid only once for each type of pressure, up to a maximum of 4 pressures per patient per calendar day and irrespective of the number of medical practitioners involved in the monitoring of pressures in an ICU.

Item 11600

Item 11600 covers the monitoring of pressures outside the ICU by practitioners not associated with the ICU. Benefits are paid only once for each type of pressure, up to a maximum of 4 pressures per patient per calendar day and irrespective of the number of practitioners involved in monitoring the pressures.

TN.1.12 Cytotoxic Chemotherapy Administration - (Item 13915)

Following a recommendation of a National Health and Medical Research Council review committee in 2005, Medicare benefits are no longer payable for professional services rendered for the purpose of administering microwave (UHF radiowave) cancer therapy, including the intravenous injection of drugs used in the therapy.

TN.1.13 Implanted Pump or Reservoir/Drug Delivery Device - (Items 13939 and 13942)

The schedule fee for Items 13939 and 13942 includes a component to cover accessing of the drug delivery device. Accordingly, benefits are not payable under Item 13945 (Long-term implanted drug delivery device, accessing of) in addition to Items 13939 and 13942.

TN.1.14 PUVA or UVB Therapy - (Item 14050)

A component for any necessary subsequent consultation has been included in the Schedule fee for this item. However, the initial consultation preceding commencement of a course of therapy would attract benefits.

Phototherapy should only be used when:

- Topical therapy has failed or is inappropriate.
- The severity of the condition as assessed by specialist opinion (including symptoms, extent of involvement and quality of life impairment) warrants its use.

Narrow band UVB should be the preferred option for phototherapy unless there is documented evidence of superior efficacy of UVA phototherapy for the condition being treated.

Phototherapy treatment for psoriasis and palmoplantar pustulosis should consider the National Institute of Health and Care Excellence's Guidelines at https://pathways.nice.org.uk/pathways/psoriasis

Involvement by a specialist in the specialty of dermatology at a minimum should include a letter stating the diagnosis, need for phototherapy, estimated time of treatment and review date.

TN.1.15 Laser Photocoagulation - (Items 14100 to 14124)

All laser equipment used for services under items 14100-14124 must be listed on the Australian Register of Therapeutic Goods.

The Australasian College of Dermatologists has advised that the following ranges (applicable to an average 4 year old child and an adult) should be used as a reference to the treatment areas specified in Items 14106 - 14124:

Entire forehead	50 -75 cm ²
Cheek	55 - 85 cm ²
Nose	10 -25 cm ²
Chin	$10 - 30 \text{ cm}^2$
Unilateral midline anterior - posterior neck	60 - 220 cm ²
Dorsum of hand	25 - 80 cm ²
Forearm	100 - 250 cm ²
Upper arm	$105 - 320 \text{ cm}^2$

TN.1.16 Facial Injections of Poly-L-Lactic Acid - (Items 14201 and 14202)

Poly-L-lactic acid is listed within the standard arrangements on the Pharmaceutical Benefits Scheme (PBS) as an Authority Required listing for initial and maintenance treatments, for facial administration only, of severe facial lipoatrophy caused by therapy for HIV infection.

TN.1.17 Hormone and Living Tissue Implantation - (Items 14203 and 14206)

Items 14203 and 14206 are not payable for artificial insemination.

TN.1.18 Implantable Drug Delivery System for the Treatment of Severe Chronic Spasticity - (Items 14227 to 14242)

Baclofen is provided under Section 100 of the Pharmaceutical Benefits Scheme for the following indications: Severe chronic spasticity, where oral agents have failed or have caused unacceptable side effects, in patients with chronic spasticity:

- (a) of cerebral origin; or
- (b) due to multiple sclerosis; or
- (c) due to spinal cord injury; or
- (d) due to spinal cord disease.

Items 14227 to 14242 should be used in accordance with these restrictions.

TN.1.19 Immunomodulating Agent - (Item 14245)

Item 14245 applies only to a service provided by a medical practitioner who is registered by the Department of Human Services CEO to participate in the arrangements made, under paragraph 100 (1) (b) of the National Health Act 1953, for the purpose of providing an adequate pharmaceutical service for persons requiring treatment with an immunomodulating agent.

These drugs are associated with risk of anaphylaxis which must be treated by a medical practitioner. For this reason a medical practitioner needs to be available at all times during the infusion in case of an emergency.

TN.1.20 Therapeutic procedures may be provided by a specialist trainee (Items 13015 to 51318)

- (1) Items 13015 to 51318 (excluding 13209 (T1) 16400 to 16500 (T4), 16590 to 16591 (T4), 17610 to 17690 (T6) and 18350 to 18373 (T11) apply to a medical service provided by;
 - (a) A medical practitioner, or;
 - (b) A specialist trainee under the direct supervision of a medical practitioner.
- (2) For paragraph (1) (b), a medical service provided by a specialist trainee is taken to have been provided by the supervising medical practitioner.
- (3) In this rule: Specialist trainee means a medical practitioner who is undertaking an Australian Medical Council (AMC) accredited Medical College Training Program. Direct Supervision means personal and continuous attendance for the duration of the service.

TN.1.21 Telehealth Specialist Services

These notes provide information on the telehealth MBS video consultation items by specialists, consultant physicians and psychiatrists. A video consultation involves a single specialist, consultant physician or psychiatrist attending a patient, with the possible support of another medical practitioner, a participating optometrist, a participating nurse practitioner, a participating midwife, practice nurse, Aboriginal and Torres Strait Islander health practitioner or Aboriginal health worker at the patient end of the video conference. The decision as to whether the patient requires clinical support at the patient end of the specialist service is based on whether the support is necessary for the provision of the specialist service. Telehealth specialist services can be provided to patients when there is no patient-end support service provided.

MBS items numbers 99, 112, 149, 288, 389, 2820, 3015, 6016, 13210, 16399 and 17609 allow a range of existing MBS attendance items to be provided via video conferencing. These items have a derived fee which is equal to 50% of the schedule fee for the consultation item claimed (e.g. 50% of the schedule fee for item 104) when billed with one of the associated consultation items (such as 104). A patient rebate of 85% for the derived fee is payable.

Six MBS item numbers (113, 114, 384, 2799, 3003 and 6004) provide for an initial attendance via videoconferencing by a specialist, consultant physician, consultant occupational physician, pain medicine specialist/consultant physician, palliative medicine specialist/consultant physician or neurosurgeon where the service is 10 minutes or less. The items are stand-alone items and do not have a derived fee.

Where an attendance is more than 10 minutes, practitioners should use the existing item numbers consistent with the current arrangements. Normal restrictions which apply for initial consultations will also apply for these items. For example, if a patient has an initial consultation via telehealth, they cannot also claim an initial face-to-face consultation as part of the same course of treatment.

Clinical indications

The specialist, consultant physician or psychiatrist must be satisfied that it is clinically appropriate to provide a video consultation to a patient. The decision to provide clinically relevant support to the patient is the responsibility of the specialist, consultant physician or psychiatrist.

Telehealth specialist services can be provided to patients when there is no patient-end support service provided.

Restrictions

The MBS telehealth attendance items are not payable for services to an admitted hospital patient (this includes hospital in the home patients). Benefits are not payable for telephone or email consultations. In order to fulfill the item descriptor there must be a visual and audio link between the patient and the remote practitioner. If the remote practitioner is unable to establish both a video and audio link with the patient, a MBS rebate for a telehealth attendance is not payable.

Billing Requirements

All video consultations provided by specialists, consultant physicians or psychiatrists must be **separately billed**. That is, only the relevant telehealth MBS consultation item and the associated derived item are to be itemised on the account/bill/voucher. Any other service/item billed should be itemised on a separate account/bill/voucher. This will ensure the claim is accurately assessed as being a video consultation and paid accordingly.

Practitioners should not use the notation 'telehealth', 'verbal consent' or 'Patient unable to sign' to overcome administrative difficulties to obtaining a patient signature for bulk billed claims (for further information see mbsonline.gov.au/telehealth).

Eligible Geographical Areas

Geographic eligibility for telehealth services funded under Medicare are determined according to the Australian Standard Geographical Classification Remoteness Area (ASGC-RA) classifications. Telehealth Eligible Areas are areas that are outside a Major City (RA1) according to ASGC-RA (RA2-5). Patients and providers are able to check their eligibility by following the links on the MBS Online website (www.mbsonline.gov.au/telehealth).

There is a requirement for the patient and specialist to be located a minimum of 15km apart at the time of the consultation. Minimum distance between specialist and patient video consultations are measured by the most direct (ie least distance) route by road. The patient or the specialist is not permitted to travel to an area outside the minimum 15 km distance in order to claim a video conference.

This rule will not apply to specialist video consultation with patients who are a care recipient in a residential care service; or at an Aboriginal Medical Service or an Aboriginal Community Controlled Health Service for which a direction made under subsection 19(2) of the *Health Insurance Act 1973* as these patients are able to receive telehealth services anywhere in Australia.

Telehealth Eligible Service Areas are defined at www.mbsonline.gov.au/ telehealth eligible areas

Record Keeping

Participating telehealth practitioners must keep contemporaneous notes of the consultation including documenting that the service was performed by video conference, the date, time and the people who participated.

Only clinical details recorded at the time of the attendance count towards the time of the consultation. It does not include information added at a later time, such as reports of investigations.

Extended Medicare Safety Net (EMSN)

All telehealth consultations (with the exception of the participating optometrist telehealth items) are subject to EMSN caps. The EMSN caps for ART and Obstetric telehealth items 13210 and 16399 were set in reference to the EMSN caps applying to the base ART and Obstetric consultation items.

The EMSN caps for all other telehealth consultation items are equal to 300% of the schedule fee (to a maximum of \$500). The maximum EMSN benefit for a telehealth consultation is equal to the sum of the EMSN cap for the base item and the EMSN cap for the telehealth items.

Aftercare Rule

Video consultations are subject to the same aftercare rules as practitioners providing face-to-face consultations.

Multiple attendances on the same day

In some situations a patient may receive a telehealth consultation and a face to face consultation by the same or different practitioner on the same day.

Medicare benefits may be paid for more than one video consultation on a patient on the same day by the same practitioner, provided the second (and any following) video consultations are not a continuation of the initial or earlier video consultations. Practitioners will need to provide the times of each consultation on the patient's account or bulk billing voucher.

Referrals

The referral procedure for a video consultation is the same as for conventional face-to-face consultations.

Technical requirements

In order to fulfill the item descriptor there must be a visual and audio link between the patient and the remote practitioner. If the remote practitioner is unable to establish both a video and audio link with the patient, a MBS rebate for a telehealth attendance is not payable.

Individual clinicians must be confident that the technology used is able to satisfy the item descriptor and that software and hardware used to deliver a videoconference meets the applicable laws for security and privacy.

TN.1.22 Cryopreservation of semen (Item 13260)

A semen cycle collection process involves obtaining up to 3 semen samples on alternate days producing up to 50 cryopreserved straws of frozen sperm.

Maximum of two semen collection cycles, one cycle collected prior to a patient undergoing the first cytotoxic/radiation treatment and the second cycle to be collected if the patient has relapsed and requires treatment.

TN.1.23 MBS Item 13105 - Haemodialysis in very remote areas

The purpose of item 13105 is for the management of haemodialysis to a person with end-stage renal disease. The service is provided in very remote areas (defined as Modified Monash 7) by a registered nurse, an Aboriginal health

worker or an Aboriginal and Torres Strait Islander health practitioner on behalf of a medical practitioner. The service is supervised by a medical practitioner (either in person or remotely).

As a condition of receiving the Medicare-funded dialysis treatment, the patient's care must be managed by a nephrologist, with the patient being treated or reviewed by the nephrologist every 3 to 6 months (either in person or remotely).

The patient is not an admitted patient of a hospital and the service is provided in a primary care setting.

Item 13104 should not be claimed if item 13105 is claimed.

TN.2.1 Radiation Oncology - General

The level of benefits for radiotherapy depends on the number of fields irradiated and the number of times treatment is given.

Treatment by rotational therapy (including rotational therapy using volumetric modulated arc therapy or intensity modulated arc therapy) is considered to be equivalent to the irradiation of three fields (i.e., irradiation of one field plus two additional fields). For example, each attendance for orthovoltage rotational therapy at the rate of 3 or more treatments per week would attract benefit under Item 15100 plus twice Item 15103. Similarly, each attendance for arc therapy of the prostate using a dual photon linear accelerator would attract benefits under 15248 plus twice 15263. Benefits are payable once only per attendance for treatment irrespective of whether one or more arcs are involved.

Benefits for consultations rendered on the same day as treatment and/or planning services are only payable where they are clinically relevant. A clinically relevant service is one that is generally accepted by the relevant profession as being necessary for the appropriate treatment of the patient.

From 1 January 2016, separate items were listed for intensity-modulated radiotherapy (IMRT) and image-guided radiotherapy (IGRT). Previously, these services were delivered and billed against the existing MBS three-dimensional radiotherapy items.

Definitions have been inserted into the Health Insurance (General Medical Services Table) Regulation as follows:

In items 15275, 15555, 15565 and 15715:

IMRT means intensity modulated radiation therapy, being a form of external beam radiation therapy that uses high energy megavoltage x rays to allow the radiation dose to conform more closely to the shape of a tumour by changing the intensity of the radiation beam.

In item 15275:

IGRT means image guided radiation therapy, being a process in which frequent 2 and 3 dimensional imaging is captured as close as possible to the time of treatment by using x rays and scans (similar to CT scans) before and during radiotherapy treatment, in order to show the size, shape and position of a cancer as well as the surrounding tissues and bones.

TN.2.2 Brachytherapy of the Prostate - (Item 15338)

One of the requirements of item 15338 is that patients have a Gleason score of less than or equal to 7. However, where the patient has a score of 7, comprising a primary score of 4 and a secondary score of 3 (ie. 4+3=7), it is recommended that low dose rate brachytherapy form part of a combined modality treatment.

Low dose brachytherapy of the prostate should be performed in patients with favourable anatomy allowing adequate access to the prostate without pubic arch interference and who have a life expectancy of at least greater than 10 years.

An 'approved site' for the purposes of this item is one at which radiation oncology services may be performed lawfully under the law of the State or Territory in which the site is located.

TN.2.3 Planning Services - (Items 15500 to 15565 and 15850)

A planning episode involves field setting and dosimetry. One plan only will attract Medicare benefits in a course of treatment. However, benefits are payable for a plan for brachytherapy and a plan for megavoltage or teletherapy treatment, when rendered in the same course of treatment.

- further planning items where planning is undertaken in respect of a different tumour site to that (or those) specified in the original prescription by the radiation oncologist; and
- a plan for brachytherapy and a plan for megavoltage or teletherapy treatment, when rendered in the same course of treatment.

Items 15500 to 15533 (inclusive) are for a planning episode for 2D conformal radiotherapy. Items 15550 to 15562 (excluding item 15555) are for a planning episode for 3D conformal radiotherapy. Items 15555 and 15565 are for a planning episode for intensity modulated radiotherapy (IMRT).

It is expected that the 2D simulation items (15500, 15503, and 15506) would be used in association with the 2D planning items (15518, 15521, and 15524) in a planning episode. However there may be instances where it may be appropriate to use the 3D Planning items (15556, 15559, and 15562) in association with the 2D simulation items (15500, 15503, and 15506) in a planning episode. The 3D simulation items (15550 and 15553) can only be billed in association with the 3D planning items (15556, 15559, and 15562) in a planning episode. However there may be instances where it may be appropriate to use the 3D Planning items (15556, 15559, and 15562) in association with the 2D simulation items (15500, 15503, and 15506) in a planning episode. The 3D simulation items (15550 and 15553) can only be billed in association with the 3D planning items (15556, 15559, and 15562) in a planning episode. The IMRT simulation item (15555) and IMRT dosimetry item (15565) can only be billed in association with each other and only for IMRT (i.e. neither IMRT simulation items for an episode of care).

Item 15850 covers radiation source localisation for high dose brachytherapy treatment. Item 15850 applies to brachytherapy provided to any part of the body.

TN.2.4 Treatment Verification - (Items 15700 to 15705, 15710, 15715 and 15800)

In these items, 'treatment verification' means:

A quality assurance procedure designed to facilitate accurate and reproducible delivery of the radiotherapy/brachytherapy to the prescribed site(s) or region(s) of the body as defined in the treatment prescription and/or associated dose plan(s) and which utilises the capture and assessment of appropriate images using:

- (a) x-rays (this includes portal imaging, either megavoltage or kilovoltage, using a linear accelerator)
- (b) computed tomography; or
- (c) ultrasound, where the ultrasound equipment is capable of producing images in at least three dimensions (unidimensional ultrasound is not covered); together with a record of the assessment(s) and any correction(s) of significant treatment delivery inaccuracies detected.

Item 15700 covers the acquisition of images in one plane and incorporates both single or double exposures. The item may be itemised once only per attendance for treatment, irrespective of the number of treatment sites verified at that attendance.

Item 15705 (multiple projections) applies where images in more that one plane are taken, for example orthogonal views to confirm the isocentre. It can be itemised only where verification is undertaken of treatments involving three or more fields. It can be itemised where single projections are acquired for multiple sites, eg multiple

metastases for palliative patients. Item 15705 can be itemized only once per attendance for treatment, irrespective of the number of treatment sites verified at that attendance.

15710 applies to volumetric verification imaging using acquisition by computed tomography. It can be itemised only where verification is undertaken of treatments involving three or more fields and only once per attendance for treatment, irrespective of the number of treatment sites verified at that attendance.

Items 15700, 15705, 15710 and 15715:

- may not claimed together for the same attendance at which treatment is rendered
- must only be itemised when the verification procedure has been prescribed in the treatment plan and the image has been reviewed by a radiation oncologist

Item 15800 - Benefits are payable once only per attendance at which treatment is verified.

TN.3.1 Therapeutic Dose of Yttrium 90 - (Item 16003)

This item cannot be claimed for selective internal radiation therapy (SIRT).

See items 35404, 35406 and 35408 for SIRT using SIR_Spheres (yttrium-90 microspheres).

TN.4.1 Antenatal Service Provided by a Nurse, Midwife or an Aboriginal and Torres Strait Islander health practitioner - (Item 16400)

Item 16400 can only be claimed by a medical practitioner (including a vocationally registered or non-vocationally registered GP, a specialist or a consultant physician) where an antenatal service is provided to a patient by a midwife, nurse or Aboriginal and Torres Strait Islander health practitioner on behalf of the medical practitioner at, or from an eligible practice location in a regional, rural or remote area.

A regional, rural or remote area is classified as a RRMA 3-7 area under the Rural Remote Metropolitan Areas classification system.

Evidence based national or regional guidelines should be used in the delivery of this antenatal service.

An eligible practice location is the place associated with the medical practitioner's Medicare provider number from which the service has been provided. If you are unsure if the location is in an eligible area you can call the Department of Human Services on 132 150.

A midwife means a registered midwife who holds a current practising certificate as a midwife issued by a State or Territory regulatory authority and who is employed by, or whose services are otherwise retained by, the medical practitioner or their practice.

A nurse means a registered or enrolled nurse who holds a current practising certificate as a nurse issued by a State or Territory regulatory authority and who is employed by, or whose services are otherwise retained by, the medical practitioner or their practice. The nurse must have appropriate training and skills to provide an antenatal service.

An Aboriginal and Torres Strait Islander health practitioner means a person who has been registered as an Aboriginal and Torres Strait Islander health practitioner by the Aboriginal and Torres Strait Islander Health Practice Board of Australia and meets the Board's registration standards. The Aboriginal and Torres Strait Islander health practitioner must be employed or retained by a general practice, or by a health service that has an exemption to claim Medicare benefits under subsection 19(2) of the Health Insurance Act 1973.

An Aboriginal and Torres Strait Islander health practitioner may use any of the titles authorised by the Aboriginal and Torres Strait Islander Health Practice Board: Aboriginal health practitioner; Aboriginal and Torres Strait Islander health practitioner; or Torres Strait Islander health practitioner.

The midwife, nurse or Aboriginal and Torres Strait Islander health practitioner must also comply with any relevant legislative or regulatory requirements regarding the provision of the antenatal service.

The medical practitioner under whose supervision the antenatal service is provided retains responsibility for the health, safety and clinical outcomes of the patient. The medical practitioner must be satisfied that the midwife, nurse or Aboriginal and Torres Strait Islander health practitioner is appropriately registered, qualified and trained, and covered by indemnity insurance to undertake antenatal services.

Supervision at a distance is recognised as an acceptable form of supervision. This means that the medical practitioner does not have to be physically present at the time the service is provided. However, the medical practitioner should be able to be contacted if required.

The medical practitioner is not required to see the patient or to be present while the antenatal service is being provided by the midwife, nurse or Aboriginal and Torres Strait Islander health practitioner. It is up to the medical practitioner to decide whether they need to see the patient. Where a consultation with the medical practitioner has taken place prior to or following the antenatal service, the medical practitioner is entitled to claim for their own professional service, but item 16400 cannot be claimed in these circumstances.

Item 16400 cannot be claimed in conjunction with another antenatal attendance item for the same patient, on the same day by the same practitioner.

A bulk billing incentive item (10990, 10991 or 10992) cannot be claimed in conjunction with item 16400. An incentive payment is incorporated into the schedule fee.

Item 16400 can only be claimed 10 times per pregnancy.

Item 16400 cannot be claimed for an admitted patient of a hospital.

TN.4.2 Items for Initial and Subsequent Obstetric Attendances (Items 16401 and 16404)

16401 and 16404 replace items 104 and 105 for any specialist obstetric attendance relating to pregnancy. This includes any initial and subsequent attendance with a specialist obstetrician for discussion of pregnancy or pregnancy related conditions or complications, or any postnatal care provided to the patient subsequent to the expiration of normal aftercare period. Item 16500 is still claimed for routine antenatal attendances. These items are subject to Extended Medicare Safety Net caps.

TN.4.3 Antenatal Care - (Item 16500)

In addition to routine antenatal attendances covered by Item 16500 the following services, where rendered during the antenatal period, attract benefits:-

- (a) Items 16501, 16502, 16505, 16508, 16509 (but not normally before the 24th week of pregnancy), 16511, 16512, 16514, 16533, 16534 and 16600 to 16627.
- (b) The initial consultation at which pregnancy is diagnosed.
- (c) The first referred consultation by a specialist obstetrician when called in to advise on the pregnancy.
- (d) All other services, excluding those in Category 1 and Group T4 of Category 3 not mentioned above.
- (e) Treatment of an intercurrent condition not directly related to the pregnancy.

Item 16514 relates to antenatal cardiotocography in the management of high risk pregnancy. Benefits for this service are not attracted when performed during the course of the labour and birth.

TN.4.4 External Cephalic Version for Breech Presentation - (Item 16501)

Contraindications for this item are as follows:

- antepartum haemorrhage (APH)
- multiple pregnancy,
- fetal anomaly,
- fetal growth restriction,
- caesarean section scar,
- uterine anomalies.
- obvious cephalopelvic disproportion,
- isoimmunization,
- premature rupture of the membranes.

TN.4.5 Labour and Birth - (Items 16515, 16518, 16519, 16530 and 16531)

Benefits for management of labour and birth covered by Items 16515, 16518, 16519, 16530 and 16531 includes the following (where indicated):-

- surgical and/or intravenous infusion induction of labour;
- forceps or vacuum extraction;
- evacuation of products of conception by manual removal (not being an independent procedure);
- episiotomy or repair of tears.

Item 16519 covers birth by any means including Caesarean section. If, however, a patient is referred, or her care is transferred to another medical practitioner for the specific purpose of birth by Caesarean section, whether because of an emergency situation or otherwise, then Item 16520 would be the appropriate item.

In some instances the obstetrician may not be able to be present at all stages of confinement. In these circumstances, Medicare benefits are payable under Item 16519 provided that the doctor attends the patient as soon as possible during the confinement and assumes full responsibility for the mother and baby.

Two items in Group T9 provide benefits for assistance by a medical practitioner at a Caesarean section. Item 51306 relates to those instances where the Caesarean section is the only procedure performed, while Item 51309 applies when other operative procedures are performed at the same time.

Where, during labour, a medical practitioner hands the patient over to another medical practitioner, benefits are payable under Item 16518 for the referring practitioner's services. The second practitioner's services would attract benefits under Item 16515 (i.e., management of vaginal birth) or Item 16520 (Caesarean section). If another medical practitioner is called in for the management of the labour and birth, benefits for the referring practitioner's services should be assessed under Item 16500 for the routine antenatal attendances and on a consultation basis for the postnatal attendances, if performed.

At a high risk birth benefits will be payable for the attendance of any medical practitioner (called in by the doctor in charge of the birth) for the purposes of resuscitation and subsequent supervision of the neonate. Examples of high risk births include cases of difficult vaginal birth, Caesarean section or the birth of babies with Rh problems and babies of toxaemic mothers.

TN.4.6 Caesarean Section - (Item 16520)

Benefits under this item are attracted only where the patient has been specifically referred to another medical practitioner for the management of the birth by Caesarean section and the practitioner carrying out the procedure has not rendered any antenatal care. Caesarean sections performed in any other circumstances attract benefits under Item 16519.

TN.4.7 Complicated Confinement - (Item 16522)

A record of the clinical indication/s that constitute billing under item 16522 should be retained on the patient's medical record.

TN.4.8 Labour and Birth Where Care is Transferred by a Participating Midwife - (Items 16527 to 16528)

Where the intrapartum care of a patient is transferred to a medical practitioner by a participating midwife for the management of birth, item 16527 or 16528 would apply depending on the service provided.

Where care is transferred by a participating midwife prior to the commencement of labour, items 16519 or 16522 would apply.

TN.4.9 Items for Planning and Management of a Pregnancy (Item 16590 and 16591)

Item 16590 is intended to provide for the planning and management of pregnancy that has progressed beyond 28 weeks, where the medical practitioner is intending to undertake the birth for a privately admitted patient.

Item 16591 is for the planning and management of a pregnancy that has progressed beyond 28 weeks and the medical practitioner is providing shared antenatal care and is not intending to undertake the birth.

Items 16590 and 16591 are to include the provision of a mental health assessment of the patient. Both items are subject to Extended Medicare Safety Net caps and should only be claimed by a patient once per pregnancy.

TN.4.10 Post-Partum Care - (Items 16515 to 16520 and 16564 to 16573)

The Schedule fees and benefits payable for Items 16519 and 16520 cover all postnatal attendances on the mother and the baby, except in the following circumstances:-

- (i) where the medical services rendered are outside those covered by a consultation, e.g., blood transfusion;
- (ii) where the condition of the mother and/or baby is such as to require the services of another practitioner (e.g., paediatrician, gynaecologist, etc);
- (iii) where the patient is transferred, at arms length, to another medical practitioner for routine post-partum, care (eg mother and/or baby returning from a larger centre to a country town or transferring between hospitals following confinement). In such cases routine postnatal attendances attract benefits on an attendance basis. The transfer of a patient within a group practice would not qualify for benefits under this arrangement except in the case of Items 16515 and 16518. These items cover those occasions when a patient is handed over while in labour from the practitioner who under normal circumstances would have delivered the baby, but because of compelling circumstances decides to transfer the patient to another practitioner for the birth;
- (iv) where during the postnatal period a condition occurs which requires treatment outside the scope of normal postnatal care;
- (v) in the management of premature babies (i.e. babies born prior to the end of the 37th week of pregnancy or where the birth weight of the baby is less than 2500 grams) during the period that close supervision is necessary.

Normal postnatal care by a medical practitioner would include:-

(i) uncomplicated care and check of

- lochia
- fundus
- perineum and vulva/episiotomy site
- temperature
- bladder/urination
- bowels
- (ii) advice and support for establishment of breast feeding
- (iii) psychological assessment and support
- (iv) Rhesus status
- (v) Rubella status and immunisation
- (vi) contraception advice/management

Examinations of apparently normal newborn infants by consultant or specialist paediatricians do not attract benefits

Items 16564 to 16573 relate to postnatal complications and should not be itemised in respect of a normal birth. To qualify for benefits under these items, the patient is required to be transferred to theatre, or be administered general anaesthesia or epidural injection for the performance of the procedure. Utilisation of the items will be closely monitored to ensure appropriate usage.

TN.4.11 Interventional Techniques - (Items 16600 to 16627, 35518 and 35674)

For Items 16600 to 16627, 35518 and 35674 there is no component in the Schedule fee for the associated ultrasound. Benefits are attracted for the ultrasound under the appropriate items in Group I1 of the Diagnostic Imaging Services Table. If diagnostic ultrasound is performed on a separate occasion to the procedure, benefits would be payable under the appropriate ultrasound item.

Item 51312 provides a benefit for assistance by a medical practitioner at interventional techniques covered by Items 16606, 16609, 16612, 16615, and 16627.

TN.4.12 Telehealth Specialist Services

These notes provide information on the telehealth MBS video consultation items by specialists, consultant physicians and psychiatrists. A video consultation involves a single specialist, consultant physician or psychiatrist attending a patient, with the possible support of another medical practitioner, a participating optometrist, a participating nurse practitioner, a participating midwife, practice nurse, Aboriginal and Torres Strait Islander health practitioner or Aboriginal health worker at the patient end of the video conference. The decision as to whether the patient requires clinical support at the patient end of the specialist service is based on whether the support is necessary for the provision of the specialist service. Telehealth specialist services can be provided to patients when there is no patient-end support service provided.

MBS items numbers 99, 112, 149, 288, 389, 2820, 3015, 6016, 13210, 16399 and 17609 allow a range of existing MBS attendance items to be provided via video conferencing. These items have a derived fee which is equal to 50% of the schedule fee for the consultation item claimed (e.g. 50% of the schedule fee for item 104) when billed with one of the associated consultation items (such as 104). A patient rebate of 85% for the derived fee is payable.

Six MBS item numbers (113, 114, 384, 2799, 3003 and 6004) provide for an initial attendance via videoconferencing by a specialist, consultant physician, consultant occupational physician, pain medicine

specialist/consultant physician, palliative medicine specialist/consultant physician or neurosurgeon where the service is 10 minutes or less. The items are stand alone items and do not have a derived fee.

Where an attendance is more than 10 minutes, practitioners should use the existing item numbers consistent with the current arrangements. Normal restrictions which apply for initial consultations will also apply for these items. For example, if a patient has an initial consultation via telehealth, they cannot also claim an initial face-to-face consultation as part of the same course of treatment.

Clinical indications

The specialist, consultant physician or psychiatrist must be satisfied that it is clinically appropriate to provide a video consultation to a patient. The decision to provide clinically relevant support to the patient is the responsibility of the specialist, consultant physician or psychiatrist.

Telehealth specialist services can be provided to patients when there is no patient-end support service provided.

Restrictions

The MBS telehealth attendance items are not payable for services to an admitted hospital patient (this includes hospital in the home patients). Benefits are not payable for telephone or email consultations. In order to fulfill the item descriptor there must be a visual and audio link between the patient and the remote practitioner. If the remote practitioner is unable to establish both a video and audio link with the patient, a MBS rebate for a telehealth attendance is not payable.

Billing Requirements

All video consultations provided by specialists, consultant physicians or psychiatrists must be **separately billed**. That is, only the relevant telehealth MBS consultation item and the associated derived item are to be itemised on the account/bill/voucher. Any other service/item billed should be itemised on a separate account/bill/voucher. This will ensure the claim is accurately assessed as being a video consultation and paid accordingly.

Practitioners should not use the notation 'telehealth', 'verbal consent' or 'Patient unable to sign' to overcome administrative difficulties to obtaining a patient signature for bulk billed claims (for further information see mbsonline.gov.au/telehealth).

Eligible Geographical Areas

Geographic eligibility for telehealth services funded under Medicare are determined according to the Australian Standard Geographical Classification Remoteness Area (ASGC-RA) classifications. Telehealth Eligible Areas are areas that are outside a Major City (RA1) according to ASGC-RA (RA2-5). Patients and providers are able to check their eligibility by following the links on the MBS Online website (www.mbsonline.gov.au/telehealth).

There is a requirement for the patient and specialist to be located a minimum of 15km apart at the time of the consultation. Minimum distance between specialist and patient video consultations are measured by the most direct (ie least distance) route by road. The patient or the specialist is not permitted to travel to an area outside the minimum 15 km distance in order to claim a video conference.

This rule will not apply to specialist video consultation with patients who are a care recipient in a residential care service; or at an Aboriginal Medical Service or an Aboriginal Community Controlled Health Service for which a direction made under subsection 19(2) of the *Health Insurance Act 197*, as these patients are able to receive telehealth services anywhere in Australia.

Telehealth Eligible Service Areas are defined at www.mbsonline.gov.au/ telehealth eligible areas

Record Keeping

Participating telehealth practitioners must keep contemporaneous notes of the consultation including documenting that the service was performed by video conference, the date, time and the people who participated.

Only clinical details recorded at the time of the attendance count towards the time of the consultation. It does not include information added at a later time, such as reports of investigations.

Extended Medicare Safety Net (EMSN)

All telehealth consultations (with the exceptions of the participating optometrist telehealth items) are subject to EMSN caps. The EMSN caps for ART and Obstetric telehealth items 13210 and 16399 were set in reference to the EMSN caps applying to the base ART and Obstetric consultation items.

The EMSN caps for all other telehealth consultation items are equal to 300% of the schedule fee (to a maximum of \$500). The maximum EMSN benefit for a telehealth consultation is equal to the sum of the EMSN cap for the base item and the EMSN cap for the telehealth items.

Aftercare Rule

Video consultations are subject to the same aftercare rules as practitioners providing face-to-face consultations.

Multiple attendances on the same day

In some situations a patient may receive a telehealth consultation and a face to face consultation by the same or different practitioner on the same day.

Medicare benefits may be paid for more than one video consultation on a patient on the same day by the same practitioner, provided the second (and any following) video consultations are not a continuation of the initial or earlier video consultations. Practitioners will need to provide the times of each consultation on the patient's account or bulk billing voucher.

Referrals

The referral procedure for a video consultation is the same as for conventional face-to-face consultations.

Technical requirements

In order to fulfill the item descriptor there must be a visual and audio link between the patient and the remote practitioner. If the remote practitioner is unable to establish both a video and audio link with the patient, a MBS rebate for a telehealth attendance is not payable.

Individual clinicians must be confident that the technology used is able to satisfy the item descriptor and that software and hardware used to deliver a videoconference meets the applicable laws for security and privacy.

TN.4.13 Mental Health Assessments for Obstetric Patients (Items 16590, 16591, 16407)

Items for the planning and management of pregnancy (16590 and 16591) and for a postnatal attendance between 4 and 8 weeks after birth (16407), include a mental health assessment of the patient, including screening for drug and alcohol use and domestic violence, to be performed by the clinician or another suitably qualified health professional on behalf of the clinician. A mental health assessment must be offered to each patient, however, if the patient chooses not to undertake the assessment, this does not preclude a rebate being payable for these items.

It is recommended that mental health assessments associated with items 16590, 16591, and 16407 be conducted in accordance with the National Health and Medical Research Council (NHMRC) endorsed guideline: *Mental Health Care in the Perinatal Period: Australian Clinical Practice Guideline* – October 2017, Centre for Perinatal Excellence.

Results of the mental health assessment must be recorded in the patient's medical record. A record of a patient's decision not to undergo a mental health assessment must be recorded in the patient's clinical notes.

TN.4.14 Extended Medicare Safety Net (EMSN) for Obstetric Services (Items 16531, 16533 and 16534)

The Extended Medicare Safety Net (EMSN) benefit is capped at 65% of the schedule fee for obstetric items 16531, 16533, and 16534. However, as these items are for in-hospital services only, the EMSN does not apply

TN.6.1 Pre-anaesthesia Consultations by an Anaesthetist - (Items 17610 to 17625)

Pre-anaesthesia consultations are covered by items in the range 17610 - 17625.

Pre-anaesthesia consultations comprise 4 time-based items utilising 15 minute increments up to and exceeding 45 minutes, in conjunction with content-based descriptors. A pre-anaesthesia consultation will attract benefits under the appropriate items based on **BOTH** the duration of the consultation **AND** the complexity of the consultation in accordance with the requirements outlined in the content-based item descriptions.

Whether or not the proposed procedure proceeds, the pre-anaesthetic attendance will attract benefits under the appropriate consultation item in the range 17610 - 17625, as determined by the duration and content of the consultation.

The following provides further guidance on utilisation of the appropriate items in common clinical situations:

- (i) Item 17610 (15 mins or less) a pre-anaesthesia consultation of a straightforward nature occurring prior to investigative procedures and other routine surgery. This item covers routine pre-anaesthesia consultation services including the taking of a brief history, a limited examination of the patient including the cardio-respiratory system and brief discussion of an anaesthesia plan with the patient.
- (ii) Item 17615 (16-30 mins) a pre-anaesthesia consultation of between 16 to 30 minutes duration AND of significantly greater complexity than that required under item 17610. To qualify for benefits patients will be undergoing advanced surgery or will have complex medical problems. The consultation will involve a more extensive examination of the patient, for example: the cardio-respiratory system, the upper airway, anatomy relevant to regional anaesthesia and invasive monitoring. An anaesthesia plan of management should be formulated, of which there should be a written record included in the patient notes.
- (iii) Item 17620 (31-45 mins) a pre-anaesthesia consultation of high complexity involving all of the requirements of item 17615 and of between 31 to 45 minutes duration. The pre-anaesthesia consultation will also involve evaluation of relevant patient investigations and the formulation of an anaesthesia plan of management of which there should be a written record in the patient notes.
- (iv) Item 17625 (more than 45 mins) a pre-anaesthesia consultation of high complexity involving all of the requirements of item 17615 and item 17620 and of more than 45 minutes duration. The pre-anaesthesia consultation will also involve evaluation of relevant patient investigations as well as discussion of the patient's medical condition and/or anaesthesia plan of management with other relevant healthcare professionals. An anaesthesia plan of management should be formulated, of which there should be a written record included in the patient notes.

Some examples of advanced surgery that may require a longer consultation under items 17615-17625 would include:

- · Bowel resection
- · Caesarean section
- · Neonatal surgery
- · Major laparotomies
- · Radical cancer resection
- · Major reconstructive surgery eg free flap transfers, breast reconstruction

- · major joint arthroplasty
- · joint reconstruction
- · Thoracotomy
- · Craniotomy
- · Spinal surgery eg spinal fusion, discectomy
- · Major vascular surgery eg aortic aneurysm repair, arterial bypass surgery, carotid artery endarterectomy

Some examples of complex medical problems in relation to items 17615-17625 would include:

- · Major cardiac problems e.g cardiomyopathy, unstable ischaemic heart disease, heart failure
- · Major respiratory disease e.g COPD, respiratory failure, acute lung conditions eg. infection and asthma,
- · Major neurological conditions CVA, intra/extra cerebral haemorrhage, cerebral palsy and/or major intellectual disability, degenerative conditions of the CNS
- $\cdot \ \text{Major metabolic conditions e.g unstable diabetes, uncontrolled hyperthyroidism, renal failure, liver failure, immune deficiency$
- · Anaesthetic problems eg past history of awareness, known or anticipated difficulty with securing the airway, malignant hyperpyrexia, drug allergy,
- · Other conditions -
- patients with history of stroke/TIA's presenting for vascular surgery
- patients on anti-platelet agents presenting for major surgery requiring management of anticoagulant status
- patients with poor respiratory/cardiac function presenting for major surgery requiring management of perioperative medications, analgaesia and monitoring

NOTE I:

It is important to note that:

- · patients undergoing the types of advanced surgery listed above but who are otherwise of reasonable health and who, therefore, do not require a longer pre-anaesthesia consultation as provided for under items 17615-17625, would qualify for benefits under item 17610; and
- · not all patients with complex medical problems will qualify for a longer consultation under items 17615-17625. For example, patients who have reasonably stable diabetes may only require a short consultation, covered under item 17610. Similarly, patients with reasonably well controlled emphysema (COPD) undergoing minor surgery may only require a short pre-anaesthesia consultation (item 17610), whereas the same patient scheduled for an upper abdominal laparotomy and with recent onset angina with the possible need for ICU postoperatively may require a longer consultation.

NOTE II:

- · Consultation services covered by pain specialists items in the range 2801-3000 cannot be claimed in conjunction with items 17610-17625
- · The consultation time under items 17610 17625 only applies to the period of active attendance on the patient and does not include time spent in discussion with other health care practitioners.

· The requirement of a written patient management plan in items 17615-17625 or the discussion of the management plan with other health care professions, where this occurs, does not relate to and cannot be claimed in conjunction GP Management Plans, Team Care Arrangements, Multidisciplinary Care Plans or Case Conference items in Group A15 of the MBS

TN.6.2 Referred Anaesthesia Consultations - (Items 17640 to 17655)

Referred anaesthesia consultations (other than pre-anaesthesia attendances) where the patient is referred will be covered by new items in the range 17640 - 17655. These new items replace the use of specialist referred items 104 and 105. Items 104 and 105 will no longer apply to referred anaesthesia consultations provided by specialist anaesthetists.

Referred anaesthesia consultations comprise 4 time-based items utilising 15 minute increments up to and exceeding 45 minutes, in conjunction with content-based descriptors. Services covered by these specialist referred items include consultations in association with the following:

- (i) Acute pain management
- · Postoperative, utilising specialised techniques eg Patient Controlled Analgesia System (PCAS)
- · as an independent service eg pain control following fractured ribs requiring nerve blocks
- · obstetric pain management
- (ii) Perioperative management of patients
- · postoperative management of cardiac, respiratory and fluid balance problems following major surgery
- · vascular access procedures (other than intra-operative peripheral vascular access procedures)

Items 17645 - 17655 will involve the examination of multiple systems and the formulation of a written management plan. Items 17650 and 17655 would also entail the ordering and/or evaluation of relevant patient investigations.

NOTE:

- · It should be noted that the consultation time under items 17640 17655 only applies to the period of active attendance on the patient and does not include time spent in discussion with other health care practitioners.
- \cdot Consultation services covered by pain medicine specialist items in the range 2801-3000 cannot be claimed in conjunction with items 17640 17655.
- · The requirement of a written patient management plan in items 17645-17655 or the discussion of the management plan with other health care professions, where this occurs, does not relate to and cannot be claimed in conjunction GP Management Plans, Team Care Arrangements, Multidisciplinary Care Plans or Case Conference items in Group A15 of the MBS.

It would be expected that in the vast majority of cases, the insertion of a peripheral venous cannula (other than in association with anaesthesia) where the patient is referred, would attract benefit under item 17640. However, in exceptional clinical circumstances, where the procedure is considerably more difficult and exceeds 15 minutes, such as for patients with chronic disease undergoing long term intravenous therapy, paediatric patients or patients having chemotherapy, item 17645 would apply.

TN.6.3 Anaesthetist Consultations - Other - (Items 17680, 17690)

A consultation occurring immediately before the institution of major regional blockade for a patient in labour is covered by item 17680.

Item 17690 can only be claimed where all of the conditions set out in (a) to (d) of item 17690 have been met.

Item 17690 can only be claimed in conjunction with a service covered by items 17615, 17620, or 17625.

Item 17690 cannot be claimed where the pre-anaesthesia consultation covered by items 17615, 17620 or 17625 is provided on the same day as admission to hospital for the subsequent episode of care involving anaesthesia services.

NOTE: Consultation services covered by pain medicine specialist items in the range 2801-3000 cannot be claimed in conjunction with anaesthesia consultation items 17610 - 17690.

TN.6.4 Telehealth Specialist Services

These notes provide information on the telehealth MBS video consultation items by specialists, consultant physicians and psychiatrists. A video consultation involves a single specialist, consultant physician or psychiatrist attending a patient, with the possible support of another medical practitioner, a participating optometrist, a participating nurse practitioner, a participating midwife, practice nurse or Aboriginal health worker at the patient end of the video conference. The decision as to whether the patient requires clinical support at the patient end of the specialist service is based on whether the support is necessary for the provision of the specialist service. Telehealth specialist services can be provided to patients when there is no patient-end support service provided.

MBS items numbers 99, 112, 149, 288, 389, 2820, 3015, 6016, 13210, 16399 and 17609 allow a range of existing MBS attendance items to be provided via video conferencing. These items have a derived fee which is equal to 50% of the schedule fee for the consultation item claimed (e.g. 50% of the schedule fee for item 104) when billed with one of the associated consultation items (such as 104). A patient rebate of 85% for the derived fee is payable.

Six MBS item numbers (113, 114, 384, 2799, 3003 and 6004) provide for an initial attendance via videoconferencing by a specialist, consultant physician, consultant occupational physician, pain medicine specialist/consultant physician, palliative medicine specialist/consultant physician or neurosurgeon where the service is 10 minutes or less. The items are stand-alone items and do not have a derived fee.

Where an attendance is more than 10 minutes, practitioners should use the existing item numbers consistent with the current arrangements. Normal restrictions which apply for initial consultations will also apply for these items. For example, if a patient has an initial consultation via telehealth, they cannot also claim an initial face-to-face consultation as part of the same course of treatment.

Clinical indications

The specialist, consultant physician or psychiatrist must be satisfied that it is clinically appropriate to provide a video consultation to a patient. The decision to provide clinically relevant support to the patient is the responsibility of the specialist, consultant physician or psychiatrist.

Telehealth specialist services can be provided to patients when there is no patient-end support service provided.

Restrictions

The MBS telehealth attendance items are not payable for services to an admitted hospital patient (this includes hospital in the home patients). Benefits are not payable for telephone or email consultations. In order to fulfill the item descriptor there must be a visual and audio link between the patient and the remote practitioner. If the remote practitioner is unable to establish both a video and audio link with the patient, a MBS rebate for a telehealth attendance is not payable.

Billing Requirements

All video consultations provided by specialists, consultant physicians or psychiatrists must be **separately billed**. That is, only the relevant telehealth MBS consultation item and the associated derived item are to be itemised on the account/bill/voucher. Any other service/item billed should be itemised on a separate account/bill/voucher. This will ensure the claim is accurately assessed as being a video consultation and paid accordingly.

Practitioners should not use the notation 'telehealth', 'verbal consent' or 'Patient unable to sign' to overcome administrative difficulties to obtaining a patient signature for bulk billed claims (for further information see mbsonline.gov.au/telehealth).

Eligible Geographical Areas

Geographic eligibility for telehealth services funded under Medicareare determined according to the Australian Standard Geographical Classification Remoteness Area (ASGC-RA) classifications. Telehealth Eligible Areas are areas that are outside a Major City (RA1) according to ASGC-RA (RA2-5). Patients and providers are able to check their eligibility by following the links on the MBS Online website (www.mbsonline.gov.au/telehealth).

There is a requirement for the patient and specialist to be located a minimum of 15km apart at the time of the consultation. Minimum distance between specialist and patient video consultations are measured by the most direct (ie least distance) route by road. The patient or the specialist is not permitted to travel to an area outside the minimum 15 km distance in order to claim a video conference.

This rule will not apply to specialist video consultation with patients who are a care recipient in a residential care service; or at an Aboriginal Medical Service or an Aboriginal Community Controlled Health Service for which a direction made under subsection 19(2) of the *Health Insurance Act 1973* as these patients are able to receive telehealth services anywhere in Australia.

Telehealth Eligible Service Areas are defined at www.mbsonline.gov.au/ telehealth eligible areas

Record Keeping

Participating telehealth practitioners must keep contemporaneous notes of the consultation including documenting that the service was performed by video conference, the date, time and the people who participated.

Only clinical details recorded at the time of the attendance count towards the time of the consultation. It does not include information added at a later time, such as reports of investigations.

Extended Medicare Safety Net (EMSN)

All telehealth consultations (with the exceptions of the participating optometrist telehealth items) are subject to EMSN caps. The EMSN caps for ART and Obstetric telehealth items 13210 and 16399 were set in reference to the EMSN caps applying to the base ART and Obstetric consultation items.

The EMSN caps for all other telehealth consultation items are equal to 300% of the schedule fee (to a maximum of \$500). The maximum EMSN benefit for a telehealth consultation is equal to the sum of the EMSN cap for the base item and the EMSN cap for the telehealth items.

Aftercare Rule

Video consultations are subject to the same aftercare rules as practitioners providing face-to-face consultations.

Multiple attendances on the same day

In some situations a patient may receive a telehealth consultation and a face to face consultation by the same or different practitioner on the same day.

Medicare benefits may be paid for more than one video consultation on a patient on the same day by the same practitioner, provided the second (and any following) video consultations are not a continuation of the initial or earlier video consultations. Practitioners will need to provide the times of each consultation on the patient's account or bulk billing voucher.

Referrals

The referral procedure for a video consultation is the same as for conventional face-to-face consultations.

Technical requirements

In order to fulfill the item descriptor there must be a visual and audio link between the patient and the remote practitioner. If the remote practitioner is unable to establish both a video and audio link with the patient, a MBS rebate for a telehealth attendance is not payable.

Individual clinicians must be confident that the technology used is able to satisfy the item descriptor and that software and hardware used to deliver a videoconference meets the applicable laws for security and privacy.

TN.7.1 Regional or Field Nerve Blocks - General

A nerve block is interpreted as the anaesthetising of a substantial segment of the body innervated by a large nerve or an area supplied by a smaller nerve where the technique demands expert anatomical knowledge and a high degree of precision.

Where anaesthesia combines a regional nerve block with general anaesthesia for an operative procedure, benefit will be paid only under the relevant anaesthesia item as set out in Group T10.

Where a regional or field nerve block is administered by a medical practitioner other than the practitioner carrying out the operation, the block attracts benefits under the Group T10 anaesthesia item and not the block item in Group T7.

Where a regional or field nerve block which is covered by an item in Group T7 is administered by a medical practitioner in the course of a surgical procedure undertaken by that practitioner, then such a block will attract benefit under the appropriate Group T7 item.

When a block is carried out in cases not associated with an operation, such as for intractable pain or during labour, the service falls under Group T7.

Digital ring analgesia, local infiltration into tissue surrounding a lesion or paracervical (uterine) analgesia are not eligible for the payment of Medicare benefits under items within Group T7. Where procedures are carried out with local infiltration or digital block as the means of anaesthesia, that anaesthesia is considered to be part of the procedure.

TN.7.2 Maintenance of Regional or Field Nerve Block - (Items 18222 and 18225)

Medicare benefit is attracted under these items only when the service is performed other than by the operating surgeon. This does not preclude benefits for an obstetrician performing an epidural block during labour.

When the service is performed by the operating surgeon during the post-operative period of an operation it is considered to be part of the normal aftercare. In these circumstances a Medicare benefit is not attracted.

TN.7.3 Intrathecal or Epidural Injection - (Item 18232)

This items covers caudal infusion/injection.

TN.7.4 Intrathecal or Epidural Infusion - (Items 18226 and 18227)

Items 18226 and 18227 apply where intrathecal or epidural analgesia is required for obstetric patients in the after hours period. For these items, the after hours period is defined as the period from 8pm to 8am on any weekday, or any time on a Saturday, Sunday or a public holiday.

Medicare benefits are only payable under item 18227 where more than 50% of the service is provided in the after hours period, benefits would be payable under item 18219.

TN.7.5 Regional or Field Nerve Blocks - (Items 18234 to 18298)

Items in the range 18234 - 18298 are intended to cover the injection of anaesthetic into the nerve or nerve sheath and not for the treatment of carpal tunnel or similar compression syndromes.

Paravertebral nerve block items 18274 and 18276 cover the provision of regional anaesthesia for surgical and related procedures for the management acute pain or of chronic pain related to radiculopathy. Infiltration of the soft tissue of the paravertebral area for the treatment of other pain symptoms does not attract benefit under these items. Additionally, items 18274 and 18276 do not cover facet joint blocks/injections. This procedure is covered under item 39013.

Item 18292 may not be claimed for the injection of botulinum toxin, but may be claimed where a neurolytic agent (such as phenol) is used to treat the obturator nerve in patients receiving botulinum toxin injections under item 18354 for a dynamic foot deformity.

TN.8.1 Surgical Operations

Many items in Group T8 of the Schedule are qualified by one of the following phrases:

- · "as an independent procedure";
- · "not being a service associated with a service to which another item in this Group applies"; or
- · "not being a service to which another item in this Group applies"

An explanation of each of these phrases is as follows.

As an Independent Procedure

The inclusion of this phrase in the description of an item precludes payment of benefits when:-

- (i) a procedure so qualified is associated with another procedure that is performed through the same incision, e.g. nephrostomy (Item 36552) in the course of an open operation on the kidney for another purpose;
- (ii) such procedure is combined with another in the same body area, e.g. direct examination of larynx (Item 41846) with another operation on the larynx or trachea;
- (iii) the procedure is an integral part of the performance of another procedure, e.g. removal of foreign body (Item 30067/30068) in conjunction with debridement of deep or extensive contaminated wound of soft tissue, including suturing of that wound when performed under general anaesthetic (Item 30023).

Not Being a Service Associated with a Service to which another Item in this Group Applies

"Not being a service associated with a service to which another item in this Group applies" means that benefit is not payable for any other item in that Group when it is performed on the same occasion as this item. eg item 30106.

"Not being a service associated with a service to which Item applies" means that when this item is performed on the same occasion as the reference item no benefit is payable. eg item 39330.

Not Being a Service to which another Item in this Group Applies

"Not being a service to which another item in this Group applies" means that this item may be itemised if there is no specific item relating to the service performed, e.g. Item 30387 (Laparotomy involving operation on abdominal viscera (including pelvic viscera), not being a service to which another item in this Group applies). Benefits may be attracted for an item with this qualification as well as benefits for another service during the course of the same operation.

TN.8.2 Multiple Operation Rule

The fees for two or more operations, listed in Group T8 (other than Subgroup 12 of that Group), performed on a patient on the one occasion (except as provided in paragraph T8.2.3) are calculated by the following rule:-

- 100% for the item with the greatest Schedule fee

plus 50% for the item with the next greatest Schedule fee

plus 25% for each other item.

Note:

- (a) Fees so calculated which result in a sum which is not a multiple of 5 cents are to be taken to the next higher multiple of 5 cents.
- (b) Where two or more operations performed on the one occasion have Schedule fees which are equal, one of these amounts shall be treated as being greater than the other or others of those amounts.
- (c) The Schedule fee for benefits purposes is the aggregate of the fees calculated in accordance with the above formula.
- (d) For these purposes the term "operation" only refers to all items in Group T8 (other than Subgroup 12 of that Group).

This rule does not apply to an operation which is one of two or more operations performed under the one anaesthetic on the same patient if the medical practitioner who performed the operation did not also perform or assist at the other operation or any of the other operations, or administer the anaesthetic. In such cases the fees specified in the Schedule apply.

Where two medical practitioners operate independently and either performs more than one operation, the method of assessment outlined above would apply in respect of the services performed by each medical practitioner.

If the operation comprises a combination of procedures which are commonly performed together and for which a specific combined item is provided in the Schedule, it is regarded as the one item and service in applying the multiple operation rule.

There are a number of items in the Schedule where the description indicates that the item applies only when rendered in association with another procedure. The Schedule fees for such items have therefore been determined on the basis that they would always be subject to the "multiple operation rule".

Where the need arises for the patient to be returned to the operating theatre on the same day as the original procedure for further surgery due to post-operative complications, which would not be considered as normal aftercare - see paragraph T8.2, such procedures would generally not be subject to the "multiple operation rule". Accounts should be endorsed to the effect that they are separate procedures so that a separate benefit may be paid.

Extended Medicare Safety Net Cap

The Extended Medicare Safety Net (EMSN) benefit cap for items subject to the multiple operations rule, where all items in that claim are subject to a cap are calculated from the abated (reduced) schedule fee.

For example, if an item has a Schedule fee of \$100 and an EMSN benefit cap equal to 80 per cent of the schedule fee, the calculated EMSN benefit cap would be \$80. However, if the schedule fee for the item is reduced by 50 per cent in accordance with the multiple operations rule provisions, and all items in that claim carry a cap, the calculated EMSN benefit cap for the item is \$40 (50% of \$100*80%).

TN.8.3 Procedure Performed with Local Infiltration or Digital Block

It is to be noted that where a procedure is carried out with local infiltration or digital block as the means of anaesthesia, that anaesthesia is considered to be part of the procedure and an additional benefit is therefore not payable.

TN.8.4 Aftercare (Post-operative Treatment) Definition

Section 3(5) of the Health Insurance Act 1973 states that services included in the Schedule (other than attendances) include all professional attendances necessary for the purposes of post-operative treatment of the patient. For the purposes of this book, post-operative treatment is generally referred to as "aftercare".

Aftercare is deemed to include all post-operative treatment rendered by medical specialists and consultant physicians, and includes all attendances until recovery from the operation, the final check or examination, regardless of whether the attendances are at the hospital, private rooms, or the patient's home. Aftercare need not necessarily be limited to treatment given by the surgeon or to treatment given by any one medical practitioner.

If the initial procedure is performed by a general practitioner, normal aftercare rules apply to any post-operative service provided by the same practitioner.

The medical practitioner determines each individual aftercare period depending on the needs of the patient as the amount and duration of aftercare following an operation may vary between patients for the same operation, as well as between different operations.

Private Patients

Medicare will not normally pay for any consultations during an aftercare period as the Schedule fee for most operations, procedures, fractures and dislocations listed in the MBS item includes a component of aftercare.

There are some instances where the aftercare component has been excluded from the MBS item and this is clearly indicated in the item description.

There are also some minor operations that are merely stages in the treatment of a particular condition. As such, attendances subsequent to these services should not be regarded as aftercare but rather as a continuation of the treatment of the original condition and attract benefits. Likewise, there are a number of services which may be performed during the aftercare period for pain relief which would also attract benefits. This includes all items in Groups T6 and T7, and items 39013, 39100, 39115, 39118, 39121, 39127, 39130, 39133, 39136, 39324 and 39327.

Where there may be doubt as to whether an item actually does include the aftercare, the item description includes the words "including aftercare".

If a service is provided during the aftercare phase for a condition not related to the operation, then this can be claimed, provided the account identifies the service as 'Not normal aftercare', with a brief explanation of the reason for the additional services.

If a patient was admitted as a private patient in a public hospital, then unless the MBS item does not include aftercare, no Medicare benefits are payable for aftercare.

Medicare benefits are not payable for surgical procedures performed primarily for cosmetic reasons. However, benefits are payable for certain procedures when performed for specific medical reasons, such as breast reconstruction following mastectomy. Surgical procedures not listed on the MBS do not attract a Medicare benefit.

Where an initial or subsequent consultation relates to the assessment and discussion of options for treatment and, a cosmetic or other non-rebatable service are discussed, this would be considered a rebatable service under Medicare. Where a consultation relates entirely to a cosmetic or other non-Medicare rebatable service (either before or after that service has taken place), then that consultation is not rebatable under Medicare. Any aftercare associated with a cosmetic or non-Medicare rebatable service is also not rebatable under Medicare.

Public Patients

All care directly related to a public in-patient's care should be provided free of charge. Where a patient has received in-patient treatment in a hospital as a public patient (as defined in Section 3(1) of the Health Insurance Act 1973), routine and non-routine aftercare directly related to that episode of admitted care will be provided free of charge as part of the public hospital service, regardless of where it is provided, on behalf of the state or territory as required by the National Healthcare Agreement. In this case no Medicare benefit is payable.

Notwithstanding this, where a public patient independently chooses to consult a private medical practitioner for aftercare, then the clinically relevant service provided during this professional attendance will attract Medicare benefits.

Where a public patient independently chooses to consult a private medical practitioner for aftercare following treatment from a public hospital emergency department, then the clinically relevant service provided during this professional attendance will attract Medicare benefits.

Fractures

Where the aftercare for fractures is delegated to a doctor at a place other than where the initial reduction was carried out, then Medicare benefits may be apportioned on a 50:50 basis rather than on the 75:25 basis for surgical operations.

Where the reduction of a fracture is carried out by hospital staff in the out-patient or emergency department of a public hospital, and the patient is then referred to a private practitioner for aftercare, Medicare benefits are payable for the aftercare on an attendance basis.

The following table shows the period which has been adopted as reasonable for the after-care of fractures:-

Treatment of fracture of	After-care Period
Terminal phalanx of finger or thumb	6 weeks
Proximal phalanx of finger or thumb	6 weeks
Middle phalanx of finger	6 weeks
One or more metacarpals not involving base of first carpometacarpal joint	6 weeks
First metacarpal involving carpometacarpal joint (Bennett's fracture)	8 weeks
Carpus (excluding navicular)	6 weeks
Navicular or carpal scaphoid	3 months
Colles'/Smith/Barton's fracture of wrist	3 months
Distal end of radius or ulna, involving wrist	8 weeks
Radius	8 weeks
Ulna	8 weeks
Both shafts of forearm or humerus	3 months
Clavicle or sternum	4 weeks
Scapula	6 weeks
Pelvis (excluding symphysis pubis) or sacrum	4 months
Symphysis pubis	4 months
Femur	6 months
Fibula or tarsus (excepting os calcis or os talus)	8 weeks
Tibia or patella	4 months

Both shafts of leg, ankle (Potts fracture) with or without dislocation, os calcis (calcaneus) or os talus	4 months
Metatarsals - one or more	6 weeks
Phalanx of toe (other than great toe)	6 weeks
More than one phalanx of toe (other than great toe)	6 weeks
Distal phalanx of great toe	8 weeks
Proximal phalanx of great toe	8 weeks
Nasal bones, requiring reduction	4 weeks
Nasal bones, requiring reduction and involving osteotomies	4 weeks
Maxilla or mandible, unilateral or bilateral, not requiring splinting	6 weeks
Maxilla or mandible, requiring splinting or wiring of teeth	3 months
Maxilla or mandible, circumosseous fixation of	3 months
Maxilla or mandible, external skeletal fixation of	3 months
Zygoma	6 weeks
Spine (excluding sacrum), transverse process or bone other than vertebral body requiring immobilisation in plaster or traction by skull calipers	3 months
Spine (excluding sacrum), vertebral body, without involvement of cord, requiring immobilisation in plaster or traction by skull calipers	6 months
Spine (excluding sacrum), vertebral body, with involvement of cord	6 months

Note: This list is a guide only and each case should be judged on individual merits.

TN.8.5 Abandoned surgery - (Item 30001)

Item 30001 applies where the procedure has been commenced but is then discontinued for medical reasons or for other reasons which are beyond the surgeon's control (eg equipment failure).

An operative procedure commences when the:

- a) patient is in the procedure room or on the bed or operation table where the procedure is to be performed; and
- b) patient is anaesthetised or operative site is sufficiently anaesthetised for the procedure to commence; and
- c) patient is positioned or the operative site is prepared with antiseptic or draping.

Where an abandoned procedure eligible for a benefit under item 30001 attracts an assistant under the provisions of the items listed in Group T9 (Assistance at Operations), the fee for the surgical assistant is calculated as 50% of the assistance fee that would have applied under the relevant item from Group T9.

Practitioners claiming an assistant fee for abandoned surgery should itemise their accounts with the relevant item from group T9. Such claims should include an account endorsement "assistance at abandoned surgery" or similar and should be accompanied by details of the surgery proposed and the reasons for the operation being discontinued or abandoned.

TN.8.6 Repair of Wound - (Items 30023 to 30049)

The repair of wound referred to in these items must be undertaken by suture, tissue adhesive resin (such as methyl methacrylate) or clips. These items do not cover repair of wound at time of surgery.

Item 30023 covers debridement of traumatic, "deep or extensively contaminated" wound. Benefits are not payable under this item for debridement which would be expected to be encountered as part of an operative approach to the treatment of fractures.

For the purpose of items 30026 to 30049 the term 'superficial' means affecting skin and subcutaneous tissue including fat and the term 'deeper tissue' means all tissues deep to but not including subcutaneous tissue such as fascia and muscle.

TN.8.7 Biopsy for Diagnostic Purposes - (Items 30071 to 30096)

Needle aspiration biopsy attracts benefits on an attendance basis and not under item 30078.

Item 30071 (diagnostic biopsy of the skin) or 30072 (diagnostic biopsy of mucous membrane) should be used when a biopsy (including shave) of a lesion is required to confirm a diagnosis and would facilitate the appropriate management of that lesion. If the shave biopsy results in a definitive excision of the lesion, only 30071 or 30072 can be claimed.

Items 30071-30096 require that the specimen be sent for pathological examination.

The aftercare period for item 30071 or 30072 is 2 days rather than the standard aftercare period for skin excision of 10 days.

TN.8.8 Lipectomy - (Items 30165 to 30179)

Lipectomy is not intended as a primary bariatric procedure to correct obesity. MBS benefits are not available for surgery performed for cosmetic purposes.

For the purpose of informing patient eligibility for lipectomy items (30165-30172, 30177, 30179) that are for the management of significant weight loss (SWL), SWL is defined as a weight loss equivalent of at least five BMI units. Weight must be stable for at least six months following significant weight loss prior to lipectomy. For significant weight loss that has occurred following pregnancy, the products of conception must not be included in the calculation of baseline weight to measure weight loss against.

Multiple lipectomies of redundant non-abdominal skin and fat as a direct consequence of mass weight loss (for example on both buttocks and both thighs), attracts a Medicare benefit only once against the relevant item (30171 or 30172). The schedule fee for multiple lipectomies for excision of redundant non-abdominal skin and fat following massive weight loss is the same regardless of the number of excisions.

The lipectomy items cannot be claimed in association with items 45564, 45565 or 45530. Where the abdomen requires surgical closure with reconstruction of the umbilicus following free tissue transfer (45564, 45565) or breast reconstruction (45530), item 45569 is to be claimed.

TN.8.9 Treatment of Keratoses, Warts etc (Items 30187, 30189, 30192 and 36815)

Treatment of seborrheic keratoses by any means, attracts benefits on an attendance basis only.

Treatment of fewer than 10 solar keratoses by ablative techniques such as cryotherapy attracts benefits on an attendance basis only. Where 10 or more solar keratoses are treated by ablative techniques, benefits are payable under item 30192.

Warts and molluscum contagiosum where treated by any means attract benefits on an attendance basis except where:

- (a) admission for treatment in an operating theatre of an accredited day surgery facility or hospital is required. In this circumstance, benefits are paid under item 30189 where a definitive removal of the wart or molluscum contagiosum is to be undertaken.
- (b) benefits have been paid under item 30189, and recurrence occurs.

(c) palmar and plantar warts are treated by laser and require treatment in an operating theatre of an accredited day surgery facility or hospital. In this circumstance, benefits are paid under item 30187.

TN.8.10 Cryotherapy and Serial Curettage Excision - (Items 30196 and 30202)

In item 30196, serial curettage excision, as opposed to simple curettage, refers to the technique where the margin having been defined, the lesion is carefully excised by a skin curette using a series of dissections and cauterisations so that all extensions and infiltrations of the lesion are removed.

For the purposes of items 30196 and 30202, the requirement for histopathological proof of malignancy is satisfied where multiple lesions are to be removed from the one anatomical region if a single lesion from that region is histologically tested and proven for malignancy.

For the purposes of items 30196 and 30202, an anatomical region is defined as: hand, forearm, upper arm, shoulder, upper trunk or chest (anterior and posterior), lower trunk (anterior or posterior) or abdomen (anterior lower trunk), buttock, genital area/perineum, upper leg, lower leg and foot, neck, face (six sections: left/right lower, left/right mid and left/right upper third) and scalp.

For Medicare benefits to be payable for item 30196, the provider performing the service must also retain documented evidence that malignancy has been proven by histopathology.

For Medicare benefits to be payable for item 30202, the provider performing the service must also retain documented evidence that malignancy has either been proven by histopathology or confirmed by opinion of a specialist in the specialty of dermatology.

The Department of Human Services (DHS) has developed a <u>Health Practitioner Guideline to substantiate proof of</u> malignancy where required for MBS items which is located on the DHS website.

TN.8.12 Sentinel Node Biopsy for Breast Cancer - (Items 30299 to 30303)

The Medical Services Advisory Committee (MSAC) evaluated the available evidence and found that sentinel lymph node biopsy is safe and effective in identifying sentinel lymph nodes, but that the long term outcomes of sentinel lymph node biopsy compared to lymph node clearance are uncertain. As a result, interim Medicare funding is available for these items pending the outcome of clinical trials and further consideration by the MSAC.

For items 30299 and 30300, both lymphoscintigraphy and lymphotropic dye injection must be used, unless the patient has an allergy to the lymphotropic dye.

For the purposes of these items, the axillary lymph node levels referred to are as follows:

- **Level I** axillary lymph nodes up to the inferior border of pectoralis minor.
- Level II -axillary lymph nodes up to the superior border of pectoralis minor.
- **Level III** axillary lymph nodes extending above the superior border of pectoralis minor.

TN.8.13 Dissection of Axillary Lymph Nodes - (Items 30335 and 30336)

For the purposes of Items 30335 and 30336, the definitions of lymph node levels referred to are set out below.

Anatomically, the dissection extends from below upwards as follows:

- Level I dissection of axillary lymph nodes up to the inferior border of pectoralis minor.
- Level II dissection of axillary lymph nodes up to the superior border of pectoralis minor.
- Level III dissection of axillary lymph nodes extending above the superior border of pectoralis minor.

TN.8.14 Laparotomy and Other Procedures on the Abdominal Viscera - (Items 30375 and 30622)

Procedures on the abdominal viscera may be performed by laparotomy or laparoscopically. Both items 30375 and 30622 cover several operations on abdominal viscera. Where more than one of the procedures referrec to in these items are performed during the one operation, each procedure may be itemised according to the multiple operation formula.

TN.8.15 Diagnostic Laparoscopy - (Items 30390 and 30627)

If a diagnostic laparoscopy procedure is performed at a different time on the same day to another laparoscopic service, the procedures are considered to be un-associated services. The claim for benefits should be annotated to indicate that the two services were performed on separate occasions, otherwise the claims will be considered to be a single service.

TN.8.16 Major Abdominal Incision - (Item 30396)

A major abdominal incision is one that gives access through an open wound to all compartments of the abdominal cavity. Item 30396 is intended for open surgical incisions only and not those performed laparoscopically.

TN.8.17 Gastrointestinal Endoscopic Procedures - (Items 30473 to 30481, 30484, 30485, 30490 to 30494, 30680 to 32023, 32084 to 32095, 32103, 32104 and 32106)

The following are guidelines for appropriate minimum standards for the performance of GI endoscopy in relation to (a) cleaning, disinfection and sterilisation procedures, and (b) anaesthetic and resuscitation equipment.

These guidelines are based on the advice of the Gastroenterological Society of Australia, the Sections of HPB and Upper GI and of Colon and Rectal Surgery of the Royal Australasian College of Surgeons, and the Colorectal Surgical Society of Australia.

Cleaning, disinfection and sterilisation procedures

Endoscopic procedures should be performed in facilities where endoscope and accessory reprocessing protocols follow procedures outlined in:

- iii. Infection Control in Endoscopy, Gastroenterological Society of Australia and Gastroenterological Nurses College of Australia, 2011;
- iv. Australian Guidelines for the Prevention and Control of Infection in Healthcare (NHMRC, 2010);
- v. Australian Standard AS 4187-2014 (and Amendments), Standards Association of Australia.

Anaesthetic and resuscitation equipment

Where the patient is anaesthetised, anaesthetic equipment, administration and monitoring, and post-operative and resuscitation facilities should conform to the standards outlined in 'Guidelines on Sedation and/or Analgesia for Diagnostic and Interventional Medical, Dental or Surgical Procedures' (PS09), Australian & New Zealand College of Anaesthetists, Gastroenterological Society of Australia and Royal Australasian College of Surgeons.

Conjoint Committee

For the purposes of Item 32023, the procedure is to be performed by a colorectal surgeon or gastroenterologist with endoscopic training who is recognised by the Conjoint Committee for the Recognition of Training in Gastrointestinal Endoscopy.

TN.8.18 Gastrectomy, Sub-total Radical - (Item 30523)

The item differs from total radical Gastrectomy (Item 30524) in that a small part of the stomach is left behind. It involves resection of the greater omentum and posterior abdominal wall lymph nodes with or without splenectomy.

TN.8.19 Anti reflux Operations - (Items 30527 to 30533, 31464 and 31466)

These items cover various operations for reflux oesophagitis. Where the only procedure performed is the simple closure of a diaphragmatic hiatus benefit would be attracted under Item 30387 (Laparotomy involving operation on abdominal viscera, including pelvic viscera, not being a service to which another item in this Group applies).

TN.8.20 Radiofrequency ablation of mucosal metaplasia for the treatment of Barrett's Oesophagus (Item 30687)

The diagnosis of high grade dysplasia is recommended to be confirmed by two expert pathologists with experience in upper gastrointestinal pathology.

A multidisciplinary team should review treatment options for patients with high grade dysplasia and would typically include upper gastrointestinal surgeons and/or interventional gastroenterologists.

TN.8.21 Endoscopic or Endobronchial Ultrasound +/- Fine Needle Aspiration - (Items 30688 - 30710)

For the purposes of these items the following definitions apply:

Biopsy means the removal of solid tissue by core sampling or forceps

FNA means aspiration of cellular material from solid tissue via a small gauge needle.

The provider should make a record of the findings of the ultrasound imaging in the patient's notes for any service claimed against items 30688 to 30710.

Endoscopic ultrasound is an appropriate investigation for patients in whom there is a strong clinical suspicion of pancreatic neoplasia with negative imaging (such as CT scanning). Scenarios include, but are not restricted to:

- A middle aged or elderly patient with a first attack of otherwise unexplained (eg negative abdominal CT) first episode of acute pancreatitis; or
- A patient with biochemical evidence of a neuroendocrine tumour.

The procedure is not claimable for periodic surveillance of patients at increased risk of pancreatic cancer, such as chronic pancreatitis. However, EUS would be appropriate for a patient with chronic pancreatitis in whom there was a clinical suspicion of pancreatic cancer (eg. a pancreatic mass occurring on a background of chronic pancreatitis).

TN.8.22 Removal of Skin Lesions - (Items 31356 to 31376)

The excision of warts and seborrheic keratoses attracts benefits on an attendance basis with the exceptions outlined in T8.13 of the explanatory notes to this category. Excision of pre-malignant lesions including solar keratoses where clinically indicated are covered by items 31357, 31360, 31362, 31364, 31366, 31368 and 31370.

The excision of suspicious pigmented lesions for diagnostic purposes attract benefits under items 31357, 31360, 31362, 31364, 31366, 31368 and 31370.

Malignant tumours are covered by items 31356, 31358, 31359, 31361, 31363, 31365, 31367, 31369 and 31371 to 31376.

Items 31357, 31360, 31362, 31364, 31366, 31368, 31370 *require*that the specimen be sent for histological examination. Items 31356, 31358, 31359, 31361, 31363, 31365, 31367, 31369, 31371-31376 also *require*that a specimen has been sent for histological confirmation of malignancy, and any subsequent specimens are sent for histological examination. Confirmation of malignancy *must* be received before itemisation of accounts for Medicare benefits purposes.

Where histological results are available at the time of issuing accounts, the histological diagnosis will decide the appropriate itemisation. If the histological report shows the lesion to be benign, items 31357, 31360, 31362, 31364, 31366, 31368 or 31370 should be used.

It will be necessary for practitioners to retain copies of histological reports.

TN.8.23 Removal of Skin Lesion From Face - (Items 31245, 31361 to 31364, 31372 and 31373)

For the purposes of these items, the face is defined as that portion of the head anterior to the hairline and above the jawline.

TN.8.24 Dissection of Lymph Nodes of Neck - (Items 30618, 31423 to 31438)

For the purposes of these items, the lymph node levels referred to are as follows:

Level I	Submandibular and submental lymph nodes	
Level II	Lymph nodes of the upper aspect of the neck including the jugulodigastric node, upper jugular chain nodes and upper spinal accessory nodes	
Level III	Lymph nodes deep to the middle third of the sternomastoid muscle consisting of mid jugular chain nodes, the lower most of which is the jugulo-omohyoid node, lying at the level where the omohyoid muscle crosses the internal jugular vein	
Level IV	Lower jugular chain nodes, including those nodes overlying the scalenus anterior muscle	
Level V	Posterior triangle nodes, which are usually distributed along the spinal accessory nerve in the posterior triangle	

Comprehensive dissection involves all 5 neck levels while *selective* dissection involves the removal of only certain lymph node groups, for example:-

Item 31426 (removal of 3 lymph node levels) - e.g. supraomohyoid neck dissection (levels I-III) or lateral neck dissection (levels II-IV).

Item 31429 (removal of 4 lymph node levels) - e.g. posterolateral neck dissection (levels II-V) or anterolateral neck dissection (levels I-IV)

Other combinations of node levels may be removed according to clinical circumstances.

TN.8.25 Excision of Breast Lesions, Abnormalities or Tumours - Malignant or Benign - (Items 31500 to 31515)

Therapeutic biopsy or excision of breast lesions, abnormalities or tumours under Items: 31500, 31503, 31506, 31509, 31512, 31515 either singularly or in combination should not be claimed when using the Advanced Breast Biopsy Instrumentation (ABBI) procedure, or any other large core breast biopsy device.

TN.8.26 Fine Needle Aspiration of Breast Lesion - (Item 31533)

An impalpable lesion includes those lesions that clinically require definition by ultrasound or mammography for accurate or safe sampling, eg. lesions in association with breast prostheses or in areas of breast thickening.

TN.8.27 Diagnostic Biopsy of Breast using Advanced Breast Biopsy Instrumentation - (Items 31539 and 31545)

For the purposes of Items 31539 and 31545, surgeons performing this procedure should have evidence of appropriate training via a course approved by the Breast Section of the Royal Australasian College of Surgeons, have experience in the procedure, and the Department of Human Services notified of their eligibility to perform this procedure.

The ABBI procedure is contraindicated and should not be performed on the following subset of patients:

- Patients with mass, asymmetry or clustered microcalcifications that cannot be targeted using digital imaging equipment;
- Patients unable to lie prone and still for 30 to 60 minutes;
- Breasts less than 20mm in thickness when compressed;
- Women on anticoagulants;
- Lesions that are too close to the chest wall to allow cannula access;
- Patients weighing more than 135kg;
- Women with prosthetic breast implants.

TN.8.28 Preoperative Localisation of Breast Lesion Prior to the Use of Advanced Breast Biopsy Instrumentation - (Item 31542)

For the purposes of item 31542, radiologists eligible to perform the procedure must have been identified by the Royal Australian and New Zealand College of Radiologists as having sufficient training and experience in this procedure, and the Department of Human Services notified of their eligibility to perform this procedure.

TN.8.29 Bariatric Procedures - (Items 31569 to 31581, anaesthesia item 20791)

Items 31569 to 31581 and item 20791 provide for surgical treatment of clinically severe obesity and the accompanying anaesthesia service (or similar). The term clinically severe obesity generally refers to a patient with a Body Mass Index (BMI) of 40kg/m^2 or more, or a patient with a BMI of 35kg/m^2 or more with other major medical co-morbidities (such as diabetes, cardiovascular disease, cancer). The BMI values in different population groups may vary due, in part, to different body proportions which affect the percentage of body fat and body fat distribution. Consequently, different ethnic groups may experience major health risks at a BMI that is below the 35-40 kg/m² provided for in the definition. The decision to undertake obesity surgery remains a matter for the clinical judgment of the surgeon.

If crural repair taking 45 minutes or less is performed in association with the bariatric procedure, additional hernia repair items cannot be claimed for the same service.

TN.8.30 Reversal of a Bariatric Procedure (item 31584)

If a revisional procedure requires the reversal of the existing bariatric procedure, item 31584 can be claimed with items 31569 to 31581 for the new procedure for the same patient on the same occasion. For example, item 31584 could be claimed for the reversal of a gastric band, and 31572 for conversion to gastric bypass or 31575 for conversion to sleeve gastrectomy.

TN.8.31 Per Anal Excision of Rectal Tumour using Rectoscopy - (Items 32103, 32104 and 32106)

Surgeons performing these procedures should be colorectal surgeons and have undergone appropriate training which is recognised by the Colorectal Surgical Society of Australasia.

Items 32103, 32104 and 32106 cannot be claimed in conjunction with each other or with anterior resection items 32024 or 32025 for the same patient, on the same day, by any practitioner.

TN.8.32 Varicose veins - (Items 32500 to 32517)

In relation to endovenous laser therapy (ELT) and/or radiofrequency diathermy/ablation, Rule 2.44.14 of the *Health Insurance (General Medical Services Table) Regulations* (GMST) means the following:

- ELT and/or radiofrequency diathermy/ablation are not payable if they are billed under any varicose vein items (32500 to 32517) or vascular item 35321.
- If ELT and/or radiofrequency diathermy/ablation are provided on the same occasion as these MBS items, the ELT and radiofrequency diathermy/ablation services must be itemised separately on the invoice, showing the full fees for each service separately to the fees billed against the MBS items.
- We strongly recommend that a practitioner who intends to bill ELT and/or radiofrequency diathermy/ablation on the same occasion as providing MBS services contact Department of Human Services' provider information line on 132 150 to confirm the Department of Human Services' requirements for correct itemisation of MBS and non-MBS services on a single invoice.
- The Department of Human Services monitors billing practices associated with MBS items and any billing
 which stands out as being out of line with most practitioners may warrant the attention of the Department
 of Human Services.
- In light of the policy clarification of GMST Rule 2.44.14, with effect from 1 May 2009, the Department of Human Services will be able to track any apparent cost-shifting (of ELT and/or radiofrequency diathermy/ablation) to the MBS items detailed in GMST Rule 2.44.14 or to other MBS items.

TN.8.33 Cyanoacrylate Embolisation (Items 32528 and 32529), Endovenous Laser Therapy (Items 32520 and 32522) and Radiofrequency Ablation (Items 32523 and 32526)

It is recommended that the medical practitioner performing cyanoacrylate embolisation (CAE), endovenous laser therapy (ELT) or radiofrequency ablation (RFA) has successfully completed a substantial course of study and training in the management of venous disease, which has been endorsed by their relevant professional organisation.

Medicare-funded CAE, ELT and RFA can only be performed in cases where it is documented by duplex ultrasound that the great or small saphenous vein (and major tributaries of saphenous veins as necessary) demonstrates reflux of 0.5 seconds or longer.

TN.8.34 Uterine Artery Embolisation - (Item 35410)

This item was introduced on an interim basis in November 2006 following a recommendation of the Medical Services Advisory Committee (MSAC), pending the outcome of clinical trials and further consideration by the MSAC. The requirement for specialist referral by a gynaecologist for uterine artery embolisation was a MSAC recommendation. Providers should retain the instrument of specialist referral for each patient from the date of the procedure, as this may be subject to audit by the Department of Human Services.

TN.8.35 Endovascular Coiling of Intracranial Aneurysms - (Item 35412)

This service includes balloon angioplasty and insertion of stents (assisted coiling) associated with intracranial aneurysm coiling. The use of liquid embolics alone is not covered by this item. Digital Subtraction Angiography (DSA) done to diagnose the aneurysm (items 60009 and either 60072, 60075 or 60078) is claimable, however this must be clearly noted on the claim and in the clinical notes as separate from the intra-operative DSA done with the coiling procedure.

TN.8.36 Arterial and Venous Patches - (Items 33545 to 33551 and 34815)

Vascular surgery items have been constructed on the basis that arteriotomy and venotomy wounds are closed by simple suture without the use of a patch.

Where a patch angioplasty is used to enlarge a narrowed vein, artery or arteriovenous fistula, the correct item would be 34815 or 34518. If the vein is harvested for the patch through a separate incision, Item 33551 would also apply, in accordance with the multiple operation rule.

If a patch graft is involved in conjunction with an operative procedure included in Items 33500 - 33542, 33803, 33806, 33815, 33833 or 34142, the patch graft would attract benefits under Item 33545 or 33548 in addition to the item for the primary operation (under the multiple operation rule). Where vein is harvested for the patch through a separate incision Item 33551 would also apply.

TN.8.37 Carotid Disease - (Item 32700, 32703, 32760, 33500, 33545, 33548, 33551, 33554, 35303, 35307)

Interventional procedures for the management of carotid disease should be performed in accordance with the NHMRC endorsed *Clinical Guidelines for Stroke Management 2010*.

Carotid Percutaneous Transluminal Angioplasty with Stenting (CPTAS), under item 35307 is only funded under the MBS for patients who meet the criteria for carotid endarterectomy but are unfit for open surgery.

TN.8.38 Peripheral Arterial or Venous Catheterisation - (Item 35317)

Item 35317 is restricted to the regional delivery of thrombolytic, vasoactive or chemotherapeutic oncologic agents in association with a radiological service. This item in not intended for infusions with systemic affect.

TN.8.39 Peripheral Arterial or Venous Embolisation - (Item 35321)

As set out in Rule 2.44.14 in the *Health Insurance (General Medical Services Table) Regulations,* item 35321 does not apply to the service described in that item if the service is provided at the same time as, or in connection with, endovenous laser treatment for varicose veins.

TN.8.40 Selective Internal Radiation Therapy (SIRT) using SIR-Spheres - (Items 35404, 35406 and 35408)

These items were introduced into the Schedule on an interim basis in May 2006 following a recommendation of the Medical Services Advisory Committee (MSAC) pending the outcome of clinical trials and further consideration by the MSAC. SIRT should not be performed in an outpatient or day patient setting to ensure patient and radiation safety requirements are met.

TN.8.41 Percutaneous Transluminal Coronary Angioplasty - (Items 38309, 38312, 38315 and 38318)

A coronary artery lesion is considered to be complex when the lesion is a chronic total occlusion, located at an ostial site, angulated, tortuous or greater than 1cm in length. Percutaneous transluminal coronary rotational atherectomy is suitable for revascularisation of complex and heavily calcified coronary artery stenoses in patients for whom coronary artery bypass graft surgery is contraindicated.

Each of the items 38309, 38312, 38315 and 38318 describes an episode of service. As such, only one item in this range can be claimed in a single episode.

TN.8.42 Colposcopic Examination - (Item 35614)

It should be noted that colposcopic examination (screening) of a person during the course of a consultation does not attract Medicare benefits under Item 35614 except in the following circumstances:

- (a) where the patient has had an abnormal cervical screen result;
- (b) where there is a history of ingestion of oestrogen by the patient's mother during their pregnancy; or
- (c) where the patient has been referred by another medical practitioner because of suspicious signs of genital cancer.

TN.8.43 Hysteroscopy - (Item 35626)

Hysteroscopy undertaken in the office/consulting rooms can be claimed under this item where the conditions set out in the description of the item are met.

TN.8.44 Curettage of Uterus under GA or Major Nerve Block - (Items 35639 and 35640)

Uterine scraping or biopsy using small curettes (e.g. Sharman's or Zeppelin's) and requiring minimal dilatation of the cervix, not necessitating a general anaesthesia, does not attract benefits under these items but would be paid under Item 35620 where malignancy is suspected, or otherwise on an attendance basis.

TN.8.45 Neoplastic Changes of the Cervix - (Items 35644-35648)

The term "previously confirmed intraepithelial neoplastic changes of the cervix" in these items refers to diagnosis made by either cytologic, colposcopic or histologic methods. This may also include persistent human papilloma virus (HPV) changes of the cervix.

TN.8.46 Sterilisation of Minors - Legal Requirements - (Items 35657, 35687, 35688, 35691, 37622 and 37623)

- (i) It is unlawful throughout Australia to conduct a sterilisation procedure on a minor which is not a byproduct of surgery appropriately carried out to treat malfunction or disease (eg malignancies of the reproductive tract) unless legal authorisation has been obtained.
- (ii) Practitioners are liable to be subject to criminal and civil action if such a sterilisation procedure is performed on a minor (a person under 18 years of age) which is not authorised by the Family Court of Australia or another court or tribunal with jurisdiction to give such authorisation.
- (iii) Parents/guardians have no legal authority to consent on behalf of minors to such sterilisation procedures. Medicare Benefits are only payable for sterilisation procedures that are clinically relevant professional services as defined in Section 3 (1) of the *Health Insurance Act 1973*.

TN.8.47 Debulking of Uterus - (Item 35658)

Benefits are payable under Item 35658, using the multiple operation rule, in addition to vaginal hysterectomy.

TN.8.48 Nephrectomy - (Items 36526 and 36527)

Items 36526 and 36527 are only claimable where the practitioner has a high index of suspicion of malignancy which cannot be confirmed by biopsy prior to surgery being performed, due to the biopsy being either clinically inappropriate, or the specimen provided showing an inconclusive diagnosis.

TN.8.50 Sacral Nerve Stimulation (items 36663-36668)

A two-stage process of testing and treatment is required to ensure suitability for Sacral Nerve Stimulation for detrusor overactivity or non obstructive urinary retention where urethral obstruction has been urodynamically excluded. The testing phase involves acute and sub-chronic testing. The first stage includes peripheral nerve evaluation and patients who achieve greater than 50% improvement in urinary incontinence or retention episodes during testing will be eligible to receive permanent SNS treatment.

TN.8.51 Ureteroscopy - (Item 36803)

Item 36803 refers to ureteroscopy of one ureter when performed for the purpose of inspection alone. It may not be used when one of the other ureteroscopy numbers (Items 36806 or 36809) or pyeloscopy numbers (Items 36652, 36654 or 36656) is used for a ureteroscopic procedure performed in the same ureter or collecting system. It may be used when inspection alone is carried out in one ureter independently from a ureteroscopic or pyeloscopic procedure in another ureter or collecting system. If Item number 36803 is used with one of the other above 5 numbers, it must be specified that item number 36803 refers to ureteroscopy performed in another ureter eg 36654 (Right side) and 36803 (Left side). 36803 may also be used in this way if there is a partial or complete duplex collecting system eg 36809 (Lower pole moiety ureter, Left side) and 36803 (Upper pole moiety ureter, Left side).

Item numbers 36806 and 36809 may only be used together when 2 independent ureteroscopic procedures are performed in separate ureters. These separate ureters may be components of a complete or partial duplex system. If both these numbers are used together, the Regulations require qualification of these item numbers by the site, as is necessary with 36803 eg 36806 (Right side) and 36809 (Left side).

TN.8.52 Selective Coronary Angiography - (Items 38215 to 38246)

Each item in the range 38215-38240 describes an episode of service. As such, only one item in this range can be claimed in a single episode.

Item 38243 may be billed once only immediately prior to any coronary interventional procedure, including situations where a second operator performs any coronary interventional procedure after diagnostic angiography by the first operator.

Item 38246 may be billed when the same operator performs diagnostic coronary angiography and then proceeds directly with any coronary interventional procedure during the same occasion of service. Consequently, it may not be billed in conjunction with items 38215, 38218, 38220, 38222, 38225, 38228, 38231, 38234, 38237, 38240 or 38243. In the event that the same operator performed any coronary interventional procedure immediately after the diagnostic procedure described by item 38231, 38237 or 38240, that item may be billed as an alternative to item 38246.

Items in the range 38215 - 38246 cannot be claimed for any intravascular ultrasound (IVUS) procedure therefore Medicare Benefits are not payable for IVUS.

TN.8.53 Transurethral Needle Ablation (TUNA) of the Prostate - (Items 37201 and 37202)

Moderate to severe lower urinary tract symptoms are defined using the American Urological Association (AUA) Symptom Score or the International Prostate Symptom Score (IPSS).

Patients not medically fit for transurethral resection of the prostate (TURP) can be defined as:

- (i) Those patients who have a high risk of developing a serious complication from the surgery. Retrograde ejaculation is **not** considered to be a serious complication of TURP.
- (ii) Those patients with a co-morbidity which may substantially increase the risk of TURP or the risk of the anaesthetic necessary for TURP.

TN.8.54 Gold Fiducial Markers into the Prostate - (item 37217)

Item 37217 is for the insertion of gold fiducial markers into the prostate or prostate surgical bed as markers for radiotherapy. The service can not be claimed under item 37218 or any other surgical item.

This item is introduced into the Schedule on an interim basis pending the outcome of an evaluation being undertaken by the Medical Services Advisory Committee (MSAC).

Further information on the review of this service is available from the MSAC Secretariat.

TN.8.55 Brachytherapy of the Prostate - (Item 37220)

One of the requirements of item 37220 is that patients have a Gleason score of less than or equal to 7. However, where the patient has a score of 7, comprising a primary score of 4 and a secondary score of 3 (ie. 4+3=7), it is recommended that low dose rate brachytherapy form part of a combined modality treatment.

Low dose rate brachytherapy of the prostate should be performed in patients, with favourable anatomy allowing adequate access to the prostate without pubic arch interference, and who have a life expectancy of greater than 10 years.

An 'approved site' for the purposes of this item is one at which radiation oncology services may be performed lawfully under the law of the State or Territory in which the site is located.

TN.8.56 High Dose Rate Brachytherapy - (Item 37227)

Item 37227 covers the service undertaken by an urologist or radiation oncologist as part of the High Dose Rate Brachytherapy procedure, in association with a radiation oncologist. If the service is undertaken by an urologist, a

radiation oncologist must be present in person at the time of the service. The removal of the catheters following completion of the Brachytherapy is also covered under this item.

TN.8.57 Radical or Debulking Operation for Ovarian Tumour - (Item 35720)

This item refers to the operation for carcinoma of the ovary where the bulk of the tumour and the omentum are removed. Where this procedure is undertaken in association with hysterectomy benefits are payable under both item numbers with the application of the multiple operation formula.

TN.8.58 Transcutaneous Sperm Retrieval - (Item 37605)

Item 37605 covers transcutaneous sperm retrieval for the purposes of intracytoplasmic sperm injection (item 13251) for male factor infertility, in association with assisted reproductive technologies.

Item 37605 provides for the procedure to be performed unilaterally. Where it is clinically necessary to perform the service bilaterally, the multiple operation rule would apply, in accordance with point T8.5 of these Explanatory Notes.

Where the procedure is carried out under local infiltration as the means of anaesthesia, additional benefit is not payable for the anaesthesia component as this is considered to be part of the procedure.

TN.8.59 Surgical Sperm Retrieval, by Open Approach - (Item 37606)

Item 37606 covers open sperm retrieval for the purposes of intracytoplasmic sperm injection (item 13251) for male factor infertility, in association with assisted reproductive technologies. Item 37606 provides for the procedure to be performed unilaterally. Where it is clinically necessary to perform the service bilaterally, the multiple operation rule would apply.

Benefits for item 37606 may be claimed in conjunction with a service or services provided under item 37605, where an open approach is clinically necessary following an unsuccessful percutaneous approach. Likewise, such services would be subject to the multiple operation rule.

Benefit is not payable for item 37606 in conjunction with item 37604.

TN.8.60 Cardiac Pacemaker Insertion - (Items 38209, 38212, 38350, 38353 and 38356)

The fees for the insertion of a pacemaker (Items 38350, 38353 and 38356) cover the testing of cardiac conduction or conduction threshold, etc related to the pacemaker and pacemaker function.

Accordingly, additional benefits are not payable for such routine testing under Item 38209 or 38212 (Cardiac electrophysiological studies).

TN.8.61 Implantable ECG Loop Recorder - (Item 38285)

The fee for implantation of the loop recorder (item 38285) covers the initial programming and testing of the device for satisfactory rhythm capture. Benefits are payable only once per day.

The term "recurrent" refers to more than one episode of syncope, where events occur at intervals of 1 week or longer. The term "other available cardiac investigations" includes the following:

- a complete history and physical examination that excludes a primary neurological cause of syncope and does not exclude a cardiac cause;
- electrocardiography (ECG) (items 1170-11702);
- echocardiography (items 55113-55115);
- continuous ECG recording or ambulatory ECG monitoring (items 11708-11711);

- up-right tilt table test (item 11724); and
- cardiac electrophysiological study, unless there is reasonable medical reason to waive this requirement (item 38209).

TN.8.62 Transluminal Insertion of Stent or Stents - (Item 38306)

Item 38306 should only be billed once per occlusional site. It is not appropriate to bill item 38306 multiple times for the insertion of more than one stent at the same occlusional site in the same artery. However, it would be appropriate to claim this item multiple times for insertion of stents into the same artery at different occlusional sites or into another artery or occlusional site. It is expected that the practitioner will note the details of the artery or site into which the stents were placed, in order for the Department of Human Services to process the claims.

TN.8.63 Permanent Cardiac Synchronisation Device (Items 38365, 38368 and 38654)

Items 38365, 38368 and 38654 apply only to patients who meet the criteria listed in the item descriptor, and to patients who do not meet the criteria listed in the descriptor but have previously had a CRT device and transvenous left ventricular electrode inserted and who prior to its insertion met the criteria and now need the device replaced.

TN.8.64 Intravascular Extraction of Permanent Pacing Leads - (Item 38358)

For the purposes of Item 38358 specialists or consultant physicians claiming this item must have training recognised by the Lead Extraction Advisory Committee of the Cardiac Society of Australia and New Zealand, and the Department of Human Services notified of that recognition. The procedure should only be undertaken in a hospital capable of providing cardiac surgery.

TN.8.65 Cardiac Resynchronisation Therapy - (Item 38371)

Item 38371 applies only to patients who meet the criteria listed in the item descriptor, and to patients who do not meet the criteria listed in the descriptor but have previously had an CRT device capable of defibrillation inserted and who prior to its insertion met the criteria and now need the device replaced.

TN.8.66 Implantable Cardioverter Defibrillator - (Items 38384 and 38387)

Items 38384 and 38387 apply only to patients who meet the criteria listed in the item descriptor, and to patients who do not meet the criteria listed in the descriptor but have previously had an ICD device inserted and who prior to its insertion met the criteria and now need the device replaced.

TN.8.67 Cardiac and Thoracic Surgical Items - (Items 38470 to 38766)

Items 38470 to 38766 must be performed using open exposure or minimally invasive surgery which excludes percutaneous and transcatheter techniques unless otherwise stated in the item.

TN.8.68 Coronary Artery Bypass - (Items 38497 to 38504)

The fees for Items 38497 and 38498 include the harvesting of vein graft material. Harvesting of internal mammary artery and/or vein graft material is covered in the fees for Items 38500, 38501, 38503 and 38504. Where harvesting of an artery other than the internal mammary artery is undertaken, benefits are payable under Item 38496 on the multiple operation basis. The procedure of coronary artery bypass grafting using arterial graft is covered by Item 38500, 38501, 38503 or 38504 irrespective of the origin of the arterial graft.

Items 38498, 38501 and 38504 require that either a clinical or medical perfusionist are present in the operating theatre throughout the procedure in case it is necessary to convert to an on-pump procedure and cardiopulmonary bypass is required.

If it is necessary to provide cardiopulmonary bypass items 38498, 38501 and 38504 cannot be claimed. The procedure should be claimed under items 38497, 38500 or 38503 as appropriate in conjunction with the relevant cardiopulmonary bypass procedures.

TN.8.69 Re-operation via Median Sternotomy - (Item 38640)

Medicare benefits are payable for Item 38640 plus the item/s covering the major surgical procedure/s performed at the time of the re-operation, using the multiple operation formula. Benefits are not payable for Item 38640 in association with Item 38656, 38643 or 38647.

TN.8.70 Skull Base Surgery - (Items 39640 to 39662)

The surgical management of lesions involving the skull base (base of anterior, middle and posterior fossae) often requires the skills of several surgeons or a number of surgeons from different surgical specialties working together or in tandem during the operative session. These operations are usually not staged because of the need for definitive closure of the dura, subcutaneous tissues, and skin to avoid serious infections such as osteomyelitis and/or meningitis.

Items 39640 to 39662 cover the removal of the tumour, which would normally be performed by a neurosurgeon. Other items are available to cover procedures performed as a part of skull base surgery by practitioners in other specialities, such as ENT and plastic and reconstructive surgery.

TN.8.71 Intradiscal Injection of Chymopapain - (Item 40336)

The fee for this item includes routine post-operative care. Associated radiological services attract benefits under the appropriate item in Group I3.

TN.8.72 Removal of Ventilating Tube from Ear - (Item 41500)

Benefits are not payable under Item 41500 for removal of ventilating tube. This service attracts benefits on an attendance basis.

TN.8.73 Meatoplasty - (Item 41515)

When this procedure is associated with Item 41530, 41548, 41557, 41560 or 41563 the multiple operation rule applies.

TN.8.74 Reconstruction of Auditory Canal - (Item 41524)

When associated with Item 41557, 41560 or 41563 the multiple operation rule applies.

TN.8.75 Removal of Nasal Polyp or Polypi - (Items 41662 and 41668)

Where such polyps are removed in association with another intranasal procedure, Medicare benefit is paid under Item 41662. However where the associated procedure is of lesser value than Item 41668, benefit for removal of polypi would be paid under Item 41668.

Services performed under item 41668 require admission to hospital.

TN.8.76 Larynx, Direct Examination - (Item 41846)

Benefit is not attracted under this item when an anaesthetist examines the larynx during the course of administration of a general anaesthetic.

TN.8.77 Microlaryngoscopy - (Item 41858)

This item covers the removal of "juvenile papillomata" by mechanical means, e.g. cup forceps. Item 41861 refers to the removal by laser surgery.

TN.8.78 Imbedded Foreign Body - (Item 42644)

For the purpose of item 42644, an imbedded foreign body is one that is sub-epithelial or intra-epithelial and is completely removed using a hypodermic needle, foreign body gouge or similar surgical instrument with magnification provided by a slit lamp biomicroscope, loupe or similar device.

Item 42644 also provides for the removal of rust rings from the cornea, which requires the use of a dental burr, foreign body gouge or similar instrument with magnification by a slit lamp biomicroscope.

Where the imbedded foreign body is not completely removed, benefits are payable under the relevant attendance item

TN.8.79 Corneal Incisions - (Item 42672)

The description of this item refers to two sets of calculations, one performed some time prior to the operation, the other during the course of the operation. Both of these measurements are included in the Schedule fee and benefit for Item 42672.

TN.8.80 Cataract surgery (Items 42698 and 42701)

Items 42698 and 42701 provide for intraocular lens extraction and replacement as a separate procedure to be used in instances when lens removal and replacements are contraindicated at the same operation, such as in patients presenting with proliferative diabetic retinopathy or recurrent uveitis.

TN.8.81 Posterior Juxtascleral Depot injection - (Item 42741)

For the purpose of item 42741, the therapeutic substance must be registered with the Therapeutic Goods Administration (or listed on the Pharmaceutical Benefits Schedule, if so listed) as being suitable for injection for the treatment of predominantly (greater than or equal to 50%) classic, subfoveal choroidal neovascularisation due to age-related macular degeneration, as diagnosed by fluorescein angiography, in a patient with a baseline visual acuity equal to or better than 6/60.

TN.8.82 Cyclodestructive Procedures - (Items 42770)

Item 42770 is restricted to a maximum of 2 treatments in a 2 year period.

TN.8.83 Insertion of drainage device for glaucoma (Item 42752)

Item 42752 provides for the insertion of a drainage device for the treatment of glaucoma patients who are at high risk of failure of trabeculectomy (such as patients who have aggressive neovascular glaucoma or extensive conjunctival scarring); have iridocorneal endothelial syndrome; inflammatory (uveitic) glaucoma; or aphakic glaucoma.

TN.8.84 Laser Trabeculoplasty - (Item 42782)

Item 42782 is restricted to a maximum of 4 treatments in a 2 year period.

TN.8.85 Laser Iridotomy - (Item 42785)

Item 42785 is restricted to a maximum of 3 treatments in a 2 year period.

TN.8.86 Laser Capsulotomy - (Items 42788)

Item 42788 is restricted to a maximum of 2 treatments in a 2 year period.

TN.8.87 Laser Vitreolysis or Corticolysis of Lens Material or Fibrinolysis - (Item 42791)

Item 42791 is restricted to a maximum of 3 treatments in a 2 year period.

TN.8.88 Division of Suture by Laser - (Item 42794)

Benefits under this item are restricted to a maximum of 2 treatments in a 2 year period. There is no provision for additional treatments in that period.

TN.8.89 Ophthalmic Sutures - (Item 42845)

This item refers to the occasion when readjustment has to be made to the sutures to vary the angle of deviation of the eye. It does not cover the mere tightening of the loosely tied sutures without repositioning, or adjustment performed prior to the patient leaving the operating theatre.

TN.8.91 Abrasive Therapy/Resurfacing - (Items 45021 to 45026)

For the purposes of the above items, one aesthetic area is any of the following of the whole face (considered to be divided into six segments):- forehead; right cheek; left cheek; nose; upper lip; and chin.

Items 45021 and 45024 cover abrasive therapy only. For the purposes of these items, abrasive therapy requires the removal of the epidermis and into the deeper papillary dermis. Services performed using a laser are not eligible for benefits under these items.

Items 45025 and 45026 do not cover the use of fractional (Fraxel[®]) laser therapy.

TN.8.92 Escharotomy - (Item 45054)

Benefits are payable once only under Item 45054 for each limb (or chest) regardless of the number of incisions to each of these areas.

TN.8.93 Local Skin Flap - Definition

Medicare benefits for flaps are only payable when clinically appropriate. Clinically appropriate in this instance means that the flap or graft is required to close the defect because the defect cannot be closed directly, or because the flap is required to adapt scar position optimally with regard to skin creases or landmarks, maintain contour on the face or neck, or prevent distortion of adjacent structures or apertures.

A local skin flap is an area of skin and subcutaneous tissue designed to be elevated from the skin adjoining a defect requiring closure. The flap remains partially attached by its pedicle and is moved into the defect by rotation, advancement or transposition, or a combination of these manoeuvres. A benefit is only payable when the flap is required for adequate wound closure. A secondary defect will be created which may be closed by direct suture, skin grafting or sometimes a further local skin flap. This later procedure will also attract benefit if closed by graft or flap repair but not when closed by direct suture.

By definition, direct wound closure (e.g. by suture) does not constitute skin flap repair. Similarly, angled, curved or trapdoor incisions which are used for exposure and which are sutured back in the same position relative to the adjacent tissues are not skin flap repairs. Undermining of the edges of a wound prior to suturing is considered a normal part of wound closure and is not considered a skin flap repair.

A "Z" plasty is a particular type of transposition flap repair. Although 2 flaps are created, benefit will be paid on the basis of Item 45201, claimable once per defect. Additional flaps are to be claimed under Item 45202, if clinically indicated.

Note: refer to T8.128 for MBS item 45202 for circumstances where other services might involve flap repair.

TN.8.94 Free Grafting to Burns - (Items 45406 to 45418)

Items 45406 to 45418 cover split skin grafting using autografts, homografts or xenografts.

TN.8.95 Revision of Scar - (Items 45506 to 45518)

For the purposes of items 45506 to 45518, revision of scar refers to modification of existing scars (traumatic, surgical or pathological) that is designed to decrease scar width, adapt scar position with regard to skin creases and landmarks, release scars from adhering to underlying structures, improve scar contour in keeping with undamaged skin or restore the shape of facial aperture.

Items 45506 to 45518 are only claimable when performed by a specialist in the practice of his or her specialty or where undertaken in the operating theatre of a hospital.

Only items 45506 and 45512, for the face and neck, can be claimed in association with items providing for graft or flap services.

For excision of scar services which do not meet the requirements of the revision of scar items as defined, the appropriate item in the range 31206 to 31225 should be claimed.

TN.8.96 Augmentation Mammaplasty - (Items 45524, 45527 and 45528)

A Medicare benefit is generally not attracted under item 45524 unless the asymmetry in breast size is greater than 10%. Augmentation of a second breast sometime after an initial augmentation of one side would not attract benefits. Benefits are not payable for augmentation mammaplasty services performed using fat transfer to the breast.

Item 45528 applies where bilateral mammaplasty is indicated because of malformation of breast tissue, disease or trauma of the breast, (but not as a result of previous cosmetic surgery) other than covered under item 45524 or 45527.

Volumetric measurement of the breasts should be performed using a technique which has been reported in a published study.

TN.8.97 Breast Reconstruction, Myocutaneous Flap - (Item 45530)

When a prosthesis is inserted in conjunction with this operation, benefit would be attracted under Item 45527, the multiple operation rule applying. Benefits would also be payable for nipple reconstruction (Item 45545) when performed.

When claiming item 45530 for a rectus abdominis flap; item 45569 should be claimed for closure of the abdomen and reconstruction of the umbilicus, and item 45570 may be claimed if repair of the musculoaponeurotic layer is required. When claiming item 45530 for a latissimus dorsi flap, no item for the closure of the musculoaponeurotic layer should be claimed as it is expected that repair will be by direct suture. In the small number of cases, when a latissimus dorsi flap is used, and repair by means other than direct suture is required, use of item 45203 would be appropriate.

Items 30165-30179 (lipectomy items) should not be claimed in association with item 45530 as stated in the Health Insurance (General Medical Services Table) Regulations.

TN.8.98 Breast Prosthesis, Removal and Replacement of - (Items 45553 and 45554)

It is generally expected that the replacement prosthesis will be the same size as the prosthesis that is removed. Medicare benefits are not payable for services under items 45553-45554 where the procedure is performed solely to increase breast size.

Where the original implant was not inserted in the context of breast cancer or developmental abnormality, intraoperative photographs need to demonstrate significant evidence of substantial skin laxity to justify replacement of the prosthesis.

In the context of eligibility for item 45553 and 45554, an unacceptable deformity would not include asymmetry caused as a result of implant removal.

Where a rupture has been established through imaging and reported, items 45553 and 45554 will still apply even if intra-operatively the implant is found to be structurally intact.

Full clinical details must be documented in patient notes, including pre-operative photographic and / or diagnostic imaging evidence demonstrating the clinical need for the service as this may be subject to audit.

TN.8.99 Breast Ptosis - (Items 45556 and 45558)

For the purposes of item 45556, Medicare benefit is only payable for the correction of breast ptosis when performed unilaterally, in the context of breast cancer or developmental breast abnormality to match the position of the contralateral breast. This item is payable only once per patient. Additional benefit is not payable if this procedure is also performed on the contralateral breast.

Item 45558 applies where correction of breast ptosis is indicated because at least two-thirds of the breast tissue, including the nipple, lies inferior to the infra-mammary fold where the nipple is located at the most dependent, inferior part of the breast contour.

Full clinical details must be documented in patient notes, including pre-operative photographic evidence (including anterior, left lateral and right lateral views) as specified in the item descriptor which demonstrates the clinical need for the service, as this may be subject to audit.

TN.8.100 Nipple and/or Areola Reconstruction - (Items 45545 and 45546)

Item 45545 involves the taking of tissue from, for example, the other breast, the ear lobe and the inside of the upper thigh with or without local flap.

Item 45546 covers the non-surgical creation of nipple or areola by intradermal colouration.

TN.8.101 Liposuction - (Items 45584 and 45585)

Medicare benefits for liposuction are generally attracted under item 45584, that is for the treatment of post-traumatic pseudolipoma. Such trauma must be significant and result in large haematoma and localised swelling. Only on very rare occasions would benefits be payable for bilateral liposuction.

Where liposuction is indicated for the treatment of Barraquer-Simons Syndrome, lymphoedema or macrodystrophia lipomatosa, or the reduction of buffalo hump, item 45585 applies. One regional area is defined as one limb or trunk. If liposuction is required on more than one limb, item 45585 can be claimed once per limb.

Full clinical details must be documented in patient notes, including pre-operative photographic and / or diagnostic imaging evidence demonstrating the clinical need for the service as this may be subject to audit.

TN.8.102 Meloplasty for Correction of Facial Asymmetry - (Items 45587 and 45588)

Benefits are payable under items 45587 and 45588 for face lift operations performed in hospital to correct soft tissue abnormalities of the face due to causes other than the ageing process, including trauma, a congenital condition or disease.

Where bilateral meloplasty is indicated because of congenital malformation for conditions such as drooling from the angles of the mouth and deep pitting of the skin resulting from severe acne scarring, disease or trauma (but not as a result of previous cosmetic surgery), item 45588 applies.

Full clinical details must be documented in patient notes, including pre-operative photographic and/or diagnostic imaging evidence demonstrating the clinical need for the service as this may be subject to audit.

TN.8.103 Reduction of Eyelids - (Items 45617 and 45620)

Where a reduction is performed for a medical condition of one eyelid, it may be necessary to undertake a similar compensating procedure on the other eyelid to restore symmetry. The latter operation would also attract benefits.

Medicare benefits are not payable for non-therapeutic cosmetic services. Full clinical details must be documented in patient notes, including pre-operative photographic and / or diagnostic evidence demonstrating the clinical need for the service as this may be subject to audit.

TN.8.104 Rhinoplasty - (Items 45632 to 45644, and 45650)

Benefits are payable for septoplasty (item 41671) where performed in conjunction with rhinoplasty.

A Medicare benefit for items 45632 – 45644 and 45650 is payable where the indication for surgery is for:

- (i) airway obstruction and the patient has a self-reported NOSE Scale score of greater than 45; or
- (ii) significant acquired, congenital or developmental deformity.

The NOSE Scale refers to the Nasal Obstruction Symptom Evaluation Scale, developed by Stewart et al, as published in the Otolaryngology-Head and Neck Surgery, 130: 2.

The NOSE Scale can be accessed here: https://www.entnet.org//content/facial-plasticsrhinology-outcome-tool-nose-scale

Full clinical details must be documented in patient notes, including pre-operative photographic and / or NOSE Scale evidence demonstrating the clinical need for the service as this may be subject to audit.

TN.8.105 Contour Restoration - (Item 45647)

For the purpose of item 45647, a region in relation to the face is defined as either being upper left or right, mid left or right or lower left or right. Accounts should be annotated with region/s to which the service applies.

TN.8.106 Vermilionectomy - (Item 45669)

Item 45669 covers treatment of the entire lip.

TN.8.107 Osteotomy of Jaw - (Items 45720 to 45752)

The fee and benefit for these items include the various forms of internal or dental fixation, jaw immobilisation, the transposition of nerves and vessels and bone grafts taken from the same site. Bone grafts taken from a separate site, eg iliac crest, would attract additional benefit under Item 47726 or 47729 for the harvesting, plus Item 48239 or 48242 for the grafting.

For the purposes of these items, a reference to maxilla includes the zygoma.

Item 75621 for the provision of fitting of surgical templates may be claimed in association with the appropriate orthognathic surgical items in the range of 45720 to 45754 for prescribed dental patients registered under the Cleft Lip and Cleft Palate Scheme.

TN.8.108 Genioplasty - (Item 45761)

Genioplasty attracts benefit once only although a section is made on both sides of the symphysis of the mandible.

TN.8.109 Tumour, Cyst, Ulcer or Scar - (Items 45801 to 45813)

It is recognised that odontogenic keratocysts, although not neoplastic, often require the same surgical management as benign tumours.

TN.8.110 Fracture of Mandible or Maxilla - (Items 45975 to 45996)

There are two maxillae in the skull and for the purpose of these items the mandible is regarded as comprising two bones.

TN.8.111 Reduction of Dislocation or Fracture

Closed reduction means treatment of a dislocation or fracture by non-operative reduction, and includes the use of percutaneous fixation or external splintage by cast or splints.

Open reduction means treatment of a dislocation or fracture by either operative exposure including the use of any internal or external fixation; or non-operative (closed reduction) where intra-medullary or external fixation is used.

Where the treatment of a fracture requires reduction on more than one occasion to achieve an adequate alignment, benefits are payable for each separate occasion at which reduction is performed under the appropriate item covering the fracture being treated.

The treatment of fractures/dislocations not specifically covered by an item in Subgroup 15 (Orthopaedic) attracts benefits on an attendance basis.

TN.8.112 Removal of Multiple Exostoses (Items 47933 and 47936)

Items 47933 and 47936 provide for removal of multiple exostoses when undertaken via the same incision.

TN.8.116 Wrist Surgery - (Items 49200 to 49227)

For the purposes of these items, the wrist includes both the radiocarpal joint and the midcarpal joint.

TN.8.117 Diagnostic Arthroscopy and Arthroscopic Surgery of the Knee (Items 49557 and 49563)

The Medical Services Advisory Committee (MSAC) evaluated the available evidence and did not support public funding for matrix-induced autologous chondrocyte implantation (MACI) or autologous chondrocyte implantation (ACI) for the treatment of chondral defects in the knee and other joints, due to the increased cost compared to existing procedures and the lack of evidence showing short term or long-term improvements in clinical outcomes. Medicare benefits are not payable in association with this technology.

TN.8.118 Paediatric Patients - (Items 50450 to 50658)

For the purpose of Medicare benefits a paediatric patient is considered to be a patient under the age of eighteen years, except in those instances where an item provides further specifications (i.e. fracture items for paediatric patients which state "with open growth plates").

TN.8.119 Treatment of Fractures in Paediatric Patients - (Items 50500 to 50588)

Items 50552 and 50560 apply to fractures that may arise during delivery and at an age when anaesthesia poses a significant risk and thus reduction is usually performed in the neonatal unit or nursery.

Item 50576 provides for closed reduction in the skeletally immature patient and will require application of a hip spica cast and related aftercare.

Medicare benefits are payable for services that specify reduction with or without internal fixation by open or percutaneous means, where reduction is carried out on the growth plate or joint surface or both.

TN.8.120 Unresectable primary malignant tumour of the liver destruction of by open or laparoscopic radiofrequency ablation or microwave tissue ablation- (Item 50952)

A multi-disciplinary team for the purposes of item 50952 would include a hepatobilliary surgeon, interventional radiologist and a gastroenterologist or oncologist.

TN.8.121 Paracentesis of anterior chamber or vitreous cavity and/or intravitreal injection - (Items 42738 to 42740)

Items 42738 and 42739 provide for paracentesis for the injection of therapeutic substances and/or the removal of aqueous or vitreous, when undertaken as an independent procedure. That is, not in conjunction with other intraocular surgery.

Item 42739 should be claimed for patients requiring anaesthetic services for the procedure. Advice from the Royal Australian and New Zealand College of Ophthalmologists is that independent injections require only topical anaesthesia, with or without subconjunctival anaesthesia, except in specific circumstances as outlined below where additional anaesthetic services may be indicated:

- nystagmus or eye movement disorder;
- cognitive impairment precluding safe intravitreal injection without sedation;
- a patient under the age of 18 years;
- a patient unable to tolerate intravitreal injection under local anaesthetic without sedation; or
- endophthalmitis or other inflammation requiring more extensive anaesthesia (eg peribulbar).

Practitioners billing item 42739 must keep clinical notes outlining the basis for the use of anaesthetic.

Item 42740 provides for intravitreal injection of therapeutic substances and/or the removal of vitreous for diagnostic purposes when performed in conjunction with other intraocular surgery including with a service to which Item 42809 (retinal photocoagulation) applies.

TN.8.122 Bone Graft (Items 48200-48242 and 48642-48651)

Bone graft substitute materials can be used for the purpose of bone graft for items 48200-48242 and 48642-48651.

TN.8.123 Vulvoplasty and Labioplasty - (Items 35533 and 35534)

Item 35533 is intended to cover the surgical repair of female genital mutilation or a major congenital anomaly of the uro-gynaecological tract which is not covered by existing MBS items. For example, this item would apply where a patient who has previously received treatment for cloacal extrophy, bladder exstrophy or congenital adrenal hyperplasia requires additional or follow-up treatment.

Item 35534 is intended to cover services for a structural abnormality causing significant functional impairment and is restricted to patients aged 18 years and over.

A detailed clinical history outlining the structural abnormality and the medical need for surgery of the vulva and/or labia must be included in patient notes, as this may be subject to audit.

Medicare benefits are not payable for non-therapeutic cosmetic services.

TN.8.124 Treatment of Wrist and Finger Fractures - (Items 47301 to 47319, and 47361 to 47373)

- For the purposes of these items, fixation includes internal and external.
- Regarding item 47362, major regional anaesthesia includes bier block.

TN.8.125 Removal of Skin Lesions - Necessary Excision Diameter - (Items 31356 to 31376)

The necessary excision diameter (or defect size) refers to the lesion size plus a clinically appropriate margin of healthy tissue required with the intent of complete surgical excision. Measurements should be taken prior to excision. Margin size should be determined in line with NHMRC guidelines:

Clinical practice guide - Basal cell carcinoma, squamous cell carcinoma(and related lesions)-a guide to clinical management in Australia. November 2008. Cancer Council Australia and; Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand (2008).

For the purpose of Items 31356 to 31376 the defect size is calculated by the average of the width and the length of the skin lesion and an appropriate margin. The necessary excision diameter is calculated as shown in the Factsheet at this link: Determining lesion size for MBS item selection.

Practitioners must retain copies of histological reports and any other supporting evidence (patient notes, photographs etc). Photographs should include scale.

An episode of care includes both the excision and closure for the same defect, even when excision and closure occur at separate attendances.

Definitive surgical excision for items 31371 to 31376 means surgical removal with adequate margins as part of the curative management of the malignancies specified in these items.

An incomplete surgical excision of a malignant skin lesion with curative intent should be billed as a malignant skin lesion excision item even when further surgery is needed. Wide excision of the primary tumour bed following local excision of a primary melanoma, appendageal carcinoma, malignant connective tissue or merkel cell carcinoma of the skin may be claimed using item 31371, 31372, 31373, 31374, 31375 or 31376, depending on the location of the malignancy and the size of the excision diameter.

For Items 31356 to 31370, a malignant skin lesion is defined as a basal cell carcinoma; a squamous cell carcinoma (including keratoacanthoma); a cutaneous deposit of lymphoma; or a cutaneous metastasis from an internal malignancy.

TN.8.126 Flap Repair - (Item 45202)

Practitioners must only perform a muscle or skin flap repair where clinical need can be clearly evidenced (i.e. where a patient hassevere pre-existing scarring, severe skin atrophy, sclerodermoid changes or where the defect is contiguous witha free margin).

Clinical evidence may be supported by patient notes, photographs of the affected area and pathology reports.

TN.8.127 Interpretation of femoroacetabular impingement (FAI) restriction (items 48424, 49303,49366)

Patients presenting with hip dysplasia, Perthes Disease and Slipped Upper Femoral Epiphysis (SUFE) are eligible for treatment under items 49366, 49303 and 48424.

TN.8.132 Transcatheter occlusion of left atrial appendage for stroke prevention (item 38276) Explanatory Note

A contraindication to lifelong anticoagulation is defined as:

- i) a previous major bleeding complication experienced whilst undergoing treatment with oral anticoagulation therapy,
- ii) a blood dyscrasia, or
- iii) a vascular abnormality predisposing to potentially life threatening haemorrhage

The procedure is performed as a hospital service.

TN.8.133 Endoscopic upper gastrointestinal strictures (item 30475)

Endoscopic upper GI stricture services 41819 and 41820 have been consolidated under item 30475. This consolidated item will allow any endoscopic technique to be performed for oesophageal through to gastroduodenal procedures and will include imaging intensification if done. The fee is the same as item 41819 which higher than item 30475 but lower than 41820.

TN.8.134 Application of items 32084, 32087, 32090 and 32093

If a service to which item 32084, 32087, 32090 or 32093 applies is provided by a practitioner to a patient on more than one occasion on a day, the second service is taken to be a separate service for the purposes of the item if the second service is provided under a second episode of anaesthesia or other sedation.

TN.8.135 Transcatheter Aortic Valve Implantation (Item 38495)

Item 38495 applies only to a service for Transcatheter Aortic Valve Implantation (TAVI) for the treatment of symptomatic severe aortic stenosis, that is to be provided in a TAVI Hospital by a TAVI Practitioner on a patient who has been assessed as suitable to receive the procedure.

TAVI Practitioner

For item 38495 a TAVI Practitioner is either a cardiothoracic surgeon or interventional cardiologist who is accredited by Cardiac Accreditation Services Limited.

Accreditation by Cardiac Accreditation Services Limited must be valid prior to the service being undertaken in order for benefits to be payable under item 38495.

The process for accreditation and re-accreditation is outlined in the *Transcatheter Aortic Valve Implantation - Rules* for the Accreditation of TAVI Practitioners, issued by Cardiac Accreditation Services Limited, and is available on the Cardiac Accreditation Services Limited website, www.tavi.org.au.

Cardiac Accreditation Services Limited is a national body comprising representatives from the Australian & New Zealand Society of Cardiac & Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ).

TAVI Hospital

For item 38495 a TAVI Hospital means a hospital, as defined by subsection 121-5(5) of the *Private Health Insurance Act 2007*, that is clinically accepted as being a facility that is suitable for TAVI procedures to be performed at.

The Transcatheter Aortic Valve Implantation - Rules for the Accreditation of TAVI Practitioners developed by Cardiac Accreditation Services Limited provides guidance on what are considered by the sector as minimum requirements that must be met in order to be a clinically acceptable facility that is suitable for TAVI procedures to be performed at.

Transcatheter Aortic Valve Implantation - Rules for the Accreditation of TAVI Practitioners can be accessed via www.tavi.org.au.

TAVI Patient

For item 38495 a TAVI Patient is a patient who, as a result of a TAVI Case Conference, has been recommended as being suitable to receive the service described in item 38495.

A TAVI Case Conference is a process by which:

- (a) there is a team of 3 or more participants, where:
 - (i) the first participant is a cardiothoracic surgeon; and

- (ii) the second participant is an interventional cardiologist; and
- (iii) the third participant is a specialist or consultant physician who does not perform a service described in Item 38495 for the patient being assessed; and
 - (iv) either the first or the second participant is also a TAVI Practitioner; and
- (b) the team assesses a patient's risk and technical suitability to receive the service described in Item 38495, taking into account matters such as:
 - (i) the patient's risk and technical suitability for a surgical aortic valve replacement; and
 - (ii) the patient's cognitive function and frailty; and
- (c) the result of the assessment is that the team makes a recommendation about whether or not the patient is suitable to receive the service described in Item 38495; and
- (d) the particulars of the assessment and recommendation are recorded in writing.

While benefits are payable for an eligible TAVI Case Conference under Items 6080 and 6081, a claim for these services does not have to be made in order for a benefit to be paid under Item 38495. Item 38495 is only payable once per patient in a five year period.

TN.8.136 Corneal Collagen Cross Linking (Item 42652)

Evidence of progression in patients over the age of twenty five is determined by the patient history including an objective change in tomography or refraction over time. Evidence of progression in patients aged twenty five years or younger is determined by patient history including an objective change in tomography or refraction over time and/or posterior elevation data and objective documented progression at a subclinical level.

TN.8.137 Thyroidectomy and hemithyroidectomy procedures (items 30296, 30306, and 30310)

Total thyroidectomy or total hemithyroidectomy are the most appropriate procedures in the majority of circumstances when a thyroidectomy is required. The preferred procedure for thyrotoxicosis is total thyroidectomy (item 30296). Item 30310 is to be used only in uncommon circumstances where a subtotal or partial thyroidectomy is indicated and includes a subtotal lobectomy, nodulectomy, or isthmusectomy or equivalent partial thyroidectomy.

TN.8.138 Re-exploratory thyroid surgery (item 30297)

Item 30297 is for re-exploratory thyroid surgery where prior thyroid surgery and associated scar tissue increases the complexity of surgery. For completion hemithyroidectomy on the contralateral side to a previous hemithyroidectomy for thyroid cancer, item 30306 is the appropriate item.

TN.8.139 Personal performance of a Synacthen Stimulation Test (item 30097)

A 0900h serum cortisol (0830-0930) less than 100 nmol/L indicates adrenal deficiency and a Synacthen Test is not required.

A 0900h serum cortisol (0830-0930) greater than 400 nmol/L indicates adrenal sufficiency and a Synacthen Test is not required. An exception to this is when testing women on oral contraception where cortisol levels may be higher due to increases in cortisol-binding globulin and this threshold may not exclude women with adrenal insufficiency.

TN.8.140 Excision of graft material - Items 35581 and 35582

For items 35581 and 35582 the size of the excised graft material must be histologically tested and confirmed.

TN.8.141 Application of items 51011 to 51171 (Sub-group 17)

Spinal surgery items 51011 to 51171 cannot be performed in conjunction with any other item (outside of subgroup 17) in Group T8 of the MBS (surgical operation items 30001 to 50952), when that surgical item is related to spinal surgery.

Meaning of Motion Segment

Motion segment is defined as including all anatomical structures (including traversing and exiting nerve roots) between and including the top of the pedicle above to the bottom of the pedicle below.

Combined Anterior and Posterior Surgery

Combined anterior/ posterior surgery items 51061, 51062, 51063, 51064, 51065 and 51066 cannot be claimed with any item between 51020 and 51045 (i.e. items for spinal instrumentation, posterior bone graft and/or anterior column fusion).

Interpretation of Spinal Fusion

Lumbar spinal fusion may not be claimed for chronic low back pain for which a diagnosis has not been made.

TN.8.142 Spinal Decompression - Items 51011 to 51015

Items 51011 to 51015 are for services which include discectomy, decompression of central spinal canal by laminectomy or partial corpectomy (vertebral spurs and osteophytes; less than 50% of the vertebral body), and decompression of the subfacetal recess, the exit foramen and far lateral (intertransverse) space.

For decompression procedures, only one item is selected from 51011 to 51015.

For posterolateral spinal fusion without instrumentation, if a decompression procedure is combined with the fusion, two items numbers can be selected: one from 51011 to 51015 and one from 51031 to 51036.

For posterolateral spinal fusion with instrumentation, two item numbers can be selected: one from 51020 to 51026 and one from 51031 to 51036. If decompression is also performed, three items can be selected: one from 51011 to 51015, one from 51020 to 51026 and one from 51031 to 51036.

For instrumented spinal fusion with interbody and posterolateral bone graft (with or without cages) and decompression, four item numbers can be selected: one from one from 51011 to 51015, one from 51020 to 51026, one from 51031 to 51036 and one from 51041 to 51045.

If more than 50% of a vertebral body is resected (piecemeal vertebrectomy) an item from 51051 to 51059 can be selected in addition to an item from 51011 to 51015.

Items 51011 to 51015 can be used when the purpose of the laminectomy is exposure or posterior spinal release.

TN.8.143 Spinal Instrumentation (cervical, thoracic and lumbar) - Items 51020 to 51026

Items 51020 to 51026 are intended for spinal instrumentation at any level. The appropriate item is determined by the number of motion segments instrumented, barring item 51020 which applies to one vertebra.

For posterolateral spinal fusion with instrumentation, two item numbers are selected: one from 51020 to 51026 and one from 51031 to 51036. If decompression is also performed, three items are selected: one from 51011 to 51015, one from 51020 to 51026 and one from 51031 to 51036.

For instrumented spinal fusion with interbody and posterolateral bone graft (with or without cages) and decompression, four item numbers are selected: one from one from 51011 to 51015, one from 51020 to 51026, one from 51031 to 51036 and one from 51041 to 51045.

TN.8.144 Posterior and/or Posterolateral (intertransverse or facet joint) bone graft (cervical, thoracic and lumbar) - Items 51031 to 51036

Items 51031 to 51036 are for services which include local morcellized, artificial or harvested bone graft with or without bone morphogenic protein (BMP).

For posterolateral spinal fusion without instrumentation, if a decompression is combined with the fusion, two items numbers are selected: one from 51011 to 51015 and one from 51031 to 51036.

For posterolateral spinal fusion with instrumentation, two item numbers are selected: one from 51020 to 51026 and one from 51031 to 51036. If decompression is also performed, three items are selected: one from 51011 to 51015, one from 51020 to 51026 and one from 51031 to 51036.

For instrumental spinal fusion with interbody and posterolateral bone graft (with or without cages) and decompression, four item numbers are selected: one from one from 51011 to 51015, one from 51020 to 51026, one from 51031 to 51036 and one from 51041 to 51045.

TN.8.145 Anterior column fusion, with or without implant, or limited vertebrectomy (less than 50%) and anterior fusion (cervical, thoracic and lumbar) - Items 51041 to 51045

Items 51041 to 51045 are for services which include placement of local morcellized, artificial, harvested bone graft, bone morphogenic protein (BMP) and prosthetic devices into the invertebral space. Artificial bone grafting materials must be used in accordance with the manufacturer's instructions.

Items 51041 to 51045 are to be selected irrespective of surgical approach (anterior, direct lateral or posterior via open or minimally invasive techniques).

For instrumented spinal fusion with interbody and posterolateral bone graft (with or without cages) and decompression, four item numbers are selected: one from one from 51011 to 51015, one from 51020 to 51026, one from 51031 to 51036 and one from 51041 to 51045.

For and instrumented anterior cervical decompression and fusion, (with or without cage) three items are selected: one from 51011 to 51015, one from 51020 to 51026, and one from 51041 to 51045.

Items 51041 to 51045 cannot be claimed with any item between 51051 and 51059 if performed at the same motion segment.

If an assisting surgeon is used at any time during the procedure, then 51160 or 51165 should be used in isolation by the assisting surgeon. If the assisting surgeon needs to perform complex non-spinal surgery, they may use a more appropriate item from outside the spinal surgery schedule.

TN.8.146 Spinal Osteotomy and/or vertebrectomy - Items 51051 to 51059

Items 51051 to 51059 are intended for spinal osteotomy and/or vertebrectomy at any level.

For the purpose of items 51054, 51055 and 51056, the definition of piecemeal or subtotal excision is the removal of at least 50% of the vertebral body.

Items 51051 to 51059 cannot be claimed with any item between 51041 and 51045 if performed at the same motion segment.

TN.8.147 Anterior and Posterior (combined) Spinal fusion under one anaesthetic via separate incisions - Items 51061 to 51066

Only one of these items should be billed for any appropriate combined anterior and posterior surgeries which are completed under one anaesthetic. The appropriate item is determined by the number of motion segments to which grafting and fusion occur.

These items cannot be claimed with any item between 51020 to 51026, 51031 to 51036 and 51041 to 51045.

If a laminectomy is included, an item from 51011 to 51015 can also be used appropriate to the level of decompression.

If spinal osteotomy or vertebrectomy (>50%) is performed as part of the combined anterior/posterior approach, it is appropriate to claim one item between 51051 to 51056 in addition to an item between 51061 to 51066.

TN.8.148 Odontoid Screw fixation - Item 51103

This item is not for use when another item is claimed for the management of the odontoid fracture.

TN.8.149 Application of items 51160 and 51166

If the spine surgeon performs their own exposure to the thoracic or lumbar spine then 51160 or 51165 can be added to the claim for the overall surgery. If an assisting surgeon is used at any time during the procedure, then 51160 or 51165 should be used in isolation by the assisting surgeon. If the assisting surgeon needs to perform complex non-spinal surgery, they may use a more appropriate item but not in combination with 51160 or 51165. If an exposure surgeon claims a number from any section of the MBS schedule, the spinal surgeon cannot claim 51160 or 51165.

TN.8.150 Correction of Developmental Breast Abnormality - (Items 45060 to 45062)

Full clinical details must be documented in patient notes, including pre-operative photographic and / or diagnostic imaging evidence as specified in the item descriptor which demonstrates the clinical need for the service, as this may be subject to audit.

Volumetric measurement of the breasts should be performed using a technique which has been reported in a published study.

TN.8.151 Mohs surgery service caseload

Services under items 31000, 31001 and 31002 should make up at least 90% of a Mohs surgeon's caseload of items 31000-31005 annually.

TN.9.1 Assistance at Operations - (Items 51300 to 51318)

Items covering operations which are eligible for benefits for surgical assistance have been identified by the inclusion of the word "Assist." in the item description. Medicare benefits are not payable for surgical assistance associated with procedures which have not been so identified.

The assistance must be rendered by a medical practitioner other than the surgeon, the anaesthetist or the assistant anaesthetist.

Where more than one practitioner provides assistance to a surgeon no additional benefits are payable. The assistance benefit payable is the same irrespective of the number of practitioners providing surgical assistance.

NOTE: The Benefit in respect of assistance at an operation is not payable unless the assistance is rendered by a medical practitioner other than the anaesthetist or assistant anaesthetist. The amount specified is the amount payable whether the assistance is rendered by one or more medical practitioners.

Assistance at Multiple Operations

Where surgical assistance is provided at two or more operations performed on a patient on the one occasion the multiple operation formula is applied to all the operations to determine the surgeon's fee for Medicare benefits purposes. The multiple-operation formula is then applied to those items at which assistance was rendered and for which Medicare benefits for surgical assistance is payable to determine the abated fee level for assistance. The abated fee is used to determine the appropriate Schedule item covering the surgical assistance (ie either Item 51300 or 51303).

Multiple Operation Rule - Surgeon	Multiple Operation Rule - Assistant
Item A - \$300@100%	Item A (Assist.) - \$300@100%
Item B - \$250@50%	Item B (No Assist.)
Item C - \$200@25%	Item C (Assist.) - \$200@50%
Item D - \$150@25%	Item D (Assist.) - \$150@25%

The derived fee applicable to Item 51303 is calculated on the basis of one-fifth of the abated Schedule fee for the surgery which attracts an assistance rebate.

Surgeons Operating Independently

Where two surgeons operate independently (ie neither assists the other or administers the anaesthetic) the procedures they perform are considered as two separate operations, and therefore, where a surgical assistant is engaged by each, or one of the surgeons, benefits for surgical assistance are payable in the same manner as if the surgeons were operating separately.

TN.9.2 Benefits Payable under Item 51300

Medicare benefits are payable under item 51300 for assistance rendered at any operation identified by the word "Assist." for which the fee does not exceed the fee threshold specified in the item descriptor, or at a series or combination of operations identified by the word "Assist." for which the aggregate Schedule fee threshold specified in the item descriptor has not been exceeded.

TN.9.3 Benefits Payable Under Item 51303

Medicare benefits are payable under item 51303 for assistance rendered at any operation identified by the word "Assist." for which the fee exceeds the fee threshold specified in the item descriptor or at a series or combination of operations identified by the word "Assist." for which the aggregate Schedule fee exceeds the threshold specified in the item descriptor.

TN.9.4 Benefits Payable Under Item 51309

Medicare benefits are payable under item 51309 for assistance rendered at any operation identified by the word "Assist." or a series or combination of operations identified by the word "Assist." and assistance at a birth involving Caesarean section.

Where assistance is provided at a Caesarean section birth and at a procedure or procedures which have not been identified by the word "Assist.", benefits are payable under item 51306.

TN.9.5 Assistance at Cataract and Intraocular Lens Surgery - (Item 51318)

The reference to "previous significant surgical complication" covers vitreous loss, rupture of posterior capsule, loss of nuclear material into the vitreous, intraocular haemorrhage, intraocular infection (endophthalmitis), cystoid macular oedema, corneal decompensation or retinal detachment.

TN.10.1 Relative Value Guide For Anaesthetics - (Group T10) Overview of the RVG

The RVG groups anaesthesia services within anatomical regions. These items are listed in the MBS under Group T10, Subgroups 1-16 Anaesthesia for radiological and other therapeutic and diagnostic services are grouped separately under Subgroup 17. Also included in the RVG format are certain additional monitoring and therapeutic services, such as blood pressure monitoring (item 22012) and central vein catheterisation (item 22020) when performed in association with the administration of anaesthesia. These services are listed at subgroup 19. The RVG also provides for assistance at anaesthesia under certain circumstances. These items are listed at subgroup 26.

Details of the billing requirements for the RVG are available from the Department of Human Services website.

The RVG is based on an anaesthesia unit system reflecting the complexity of the service and the total time taken for the service. Each unit has been assigned a dollar value.

Under the RVG, the MBS fee for anaesthesia in connection with a procedure is comprised of up to three components:

- 1. The basic units allocated to each anaesthetic procedure, reflecting the complexity of the procedure (an item in the range 20100-21997);
- 2. The time unit allocation reflecting the total time of the anaesthesia (an item in the range 23010-24136); and
- 3. Where appropriate, modifying units recognising certain added complexities in anaesthesia (an item/s in the range 25000-25020).

Assistance at anaesthesia

To establish the fee for the assistant service items 25200 and 25205, both services have been allocated a number of base units. The total time that the assistant anaesthetist was in active attendance on the patient is then added, along with modifiers as appropriate to determine the MBS fee.

Whole body perfusion

Where whole body perfusion is performed, the MBS fee is determined by adding together the following:

- 1. The base units allocated to the service (item 22060);
- 2. The time unit allocation reflecting the total time of the perfusion (an item in the range 23010 24136); and
- 3. Where appropriate, modifying units recognising certain added complexities in perfusion (an item/s in the range 25000 25020).

TN.10.2 Eligible Services

Generally, a Medicare benefit is only payable for anaesthesia which is performed in connection with an "eligible" service. An "eligible" service is defined as a clinically relevant professional service which is listed in the Schedule and which has been identified as attracting an anaesthetic fee.

TN.10.3 RVG Unit Values

Basic Units

The RVG basic unit allocation represents the complexity of the anaesthetic procedure relative to the anatomical site and physiological impact of the surgery.

Time Units

The number of time units is calculated from the total time of the anaesthesia service, the assistant at anaesthesia service or the whole body perfusion service:

- for anaesthesia, time is considered to begin when the anaesthetist commences exclusive and continuous care of the patient for anaesthesia. Time ends when the anaesthetist is no longer in professional attendance, that is, when the patient is safely placed under the supervision of other personnel;
- for assistance at anaesthesia, time is taken to be the period that the assistant anaesthetist is in active attendance on the patient during anaesthesia; and

• for perfusion, perfusion time begins with the commencement of anaesthesia and finishes with the closure of the chest.

For up to and including the first - 2 hours of time, each 15 minutes (or part thereof) constitutes 1 time unit. For time beyond 2 hours, each time unit equates to 10 minutes (or part thereof).

For statistical purposes, a separate MBS item applies to every 5 minute increment for anaesthetic services between 15 minutes and 2 hours duration. For or these services, the appropriate 5 minute item number should be included on accounts.

Modifying Units (25000 - 25050)

Modifying units have been included in the RVG to recognise added complexities in anaesthesia or perfusion, associated with the patient's age, physical status or the requirement for emergency surgery. These cover the following clinical situations:

ASA physical status indicator 3 - A patient with severe systemic disease that significantly limits activity (item 25000). This would include: severely limiting heart disease; severe diabetes with vascular complications or moderate to severe degrees of pulmonary insufficiency.

Some examples of clinical situations to which ASA 3 would apply are:

- a patient with ischaemic heart disease such that they encounter angina frequently on exertion thus significantly limiting activities;
- a patient with chronic airflow limitation who gets short of breath such that the patient cannot complete one flight of stairs without pausing;
- a patient who has suffered a stroke and is left with a residual neurological deficit to the extent that is significantly limits normal activity, such as hemiparesis; or
- a patient who has renal failure requiring regular dialysis.

ASA physical status indicator 4 - A patient with severe systemic disease which is a constant threat to life (item 25005). This covers patients with severe systemic disorders that are already life-threatening, not always correctable by an operation. This would include: patients with heart disease showing marked signs of cardiac failure; persistent angina or advanced degrees of pulmonary, hepatic, renal or endocrine insufficiency.

ASA physical status indicator 4 would be characterised by the following clinical examples:

- a person with coronary disease such that they get angina daily on minimum exertion thus severely curtailing their normal activities;
- a person with end stage emphysema who is breathless on minimum exertion such as brushing their hair or walking less than 20 metres; or
- a person with severe diabetes which affects multiple organ systems where they may have one or more of the following examples:
- severe visual impairment or significant peripheral vascular disease such that they may get intermittent claudication on walking less than 20 metres; or
- severe coronary artery disease such that they suffer from cardiac failure and/or angina whereby they are limited to minimal activity.

ASA physical status indicator 5 - a moribund patient who is not expected to survive for 24 hours with or without the operation (item 25010). This would include: a burst abdominal aneurysm with profound shock; major cerebral trauma with rapidly increasing intracranial pressure or massive pulmonary embolus.

The following are some examples that would equate to ASA physical status indicator 5

- a burst abdominal aneurysm with profound shock;
- major cerebral trauma with increasing intracranial pressure; or
- massive pulmonary embolus.
- **NOTE:** It should be noted that the Medicare Benefits Schedule does NOT include modifying units for patients assessed as ASA physical status indicator 2. Some examples of ASA 2 would include:
- a patient with controlled hypertension which has no affect on the patient's normal lifestyle;
- a patient with coronary artery disease that results in angina occurring on substantial exertion but not limiting normal activity; or
- a patient with insulin dependant diabetes which is well controlled and has minimal effect on normal lifestyle.
- Where the patient is less than 12 months or age or 70 years or greater (item 25015).
- For anaesthesia, assistance at anaesthesia or a perfusion service in association with an *emergency procedure (item 25020).
- For anaesthesia or assistance at anaesthesia in association with an *after hours emergency procedure (items 25025 and 25030).
- For a perfusion service in association with *after hours emergency surgery (item 25050).
- * **NOTE:** It should be noted that the emergency modifier and the after hours emergency modifiers cannot both be claimed in the one anaesthesia assistance at anaesthesia or perfusion episode.

It should also be noted that modifiers are not stand alone services and can only be claimed in association with anaesthesia, assistance at anaesthesia or with a perfusion service covered by item 22060.

Definition of Emergency

For the purposes of both the emergency modifier and the after hours emergency modifiers, emergency is defined as existing where the patient requires immediate treatment without which there would be significant threat to life or body part.

Definition of After Hours

For the purposes of the after hours emergency modifier items, the after hours period is defined as being the period from 8pm to 8am on any weekday or at any time on a Saturday, a Sunday or a public holiday. Benefit for the After Hours Emergency Modifiers is only payable where more than 50% of the time for the emergency anaesthesia, the assistance at emergency anaesthesia or the perfusion service is provided in the after hours period. In situations where less than the 50% of the time for the service falls in the after hours period, the emergency modifier rather than the after hours emergency modifier applies. For information about deriving the fee for the service where the after hours emergency modifier applies.

TN.10.4 Deriving the Schedule Fee under the RVG

The Schedule fee for each component of anaesthesia (base items, time items and modifier items) in the RVG Schedule is derived by applying the unit value to the total number of anaesthesia units for each component. For example:

ITEM	DESCRIPTION		SCHEDULE FEE
RVG	Anaesthesia Service		SCHEDULE FEE (Units x \$ 19.45)
20840	Anaesthesia for resection of perforated bowel		\$116.70
23200	Time - 4 hours 40 minutes		\$466.80
25000	Modifier - Physical status		\$19.45
22012	Central Venous Pressure Monitoring		\$58.35

After Hours Emergency Services

When deriving the fee for the after hours emergency modifier for anaesthesia or assistance at anaesthesia, the 50% loading applies to the anaesthesia or assistance service from Group T10 and to any additional clinically relevant therapeutic or diagnostic service from Group T10, Subgroup 18, provided during the anaesthesia episode. For example:

ITEM	DESCRIPTION		SCHEDULE FEE (Units x \$19.45)
20840	Anaesthesia for resection of perforated bowel		\$ 116.70
23190	Time - 4 hours 40 minutes		\$466.80
25000	0 Modifier - Physical status		\$19.45
22012	Central Venous Pressure Monitoring	3	\$58.35
	TOTAL UNITS	34	Schedule fee = \$661.30
25025	Anaesthesia After Hours Emergency Modifier		Schedule Fee \$661.30 x 50% = \$330.65

Definition of Radical Surgery for the RVG

Where the term radical appears in an item description, it refers to an extensive surgical procedure, performed for the treatment of malignancy. It usually denotes extensive block dissection not only of the malignant tissue, but also of the surrounding tissue, particularly fat and lymphatic drainage systems. See notes T10.18 and T10.22 which clarify the definitions of the words "extensive" and "radical" used in items 20192 and 20474.

Multiple Anaesthesia Services

Where anaesthesia is provided for services covered by multiple items in the RVG, Medicare benefit is only payable for the RVG item with the highest basic unit value. However, the time component should include the total anaesthesia time taken for all services. For example:

ITEM	DESCRIPTION	UNITS	SCHEDULE FEE
20790	Anaesthesia for Cholecystectomy	8	\$155.60
20752	Incisional Hernia	6	(lower value - fee not payable) \$116.70
23111	Time - 2hrs 30mins	11	\$213.95
25015	Physical Status - Over 70	1	\$19.45

Prolonged Anaesthesia

Under the RVG, the previous rules that related to prolonged anaesthesia no longer apply. Where anaesthesia is prolonged beyond that which an anaesthetist would normally encounter for a particular service, the RVG provides for the anaesthetist to claim the total anaesthesia time for the procedure/s.

TN.10.5 Minimum Requirements for Claiming Benefits under Items in the RVG (including sedation) Medicare benefits for RVG services (including sedation) are only payable where both the staffing and the facility in which the service was rendered meets the following minimum guidelines. These guidelines are based on protocols established by the Australian and New Zealand College of Anaesthetists (ANZCA).

Staffing

- Techniques intended to produce loss of consciousness must not be used unless an anaesthetist is present to care exclusively for the patient;
- Where the patient is a young child, is elderly or has any serious medical condition (such as significant cardio-respiratory disease or danger of airway compromise), an anaesthetist should be present to administer sedation and monitor the patient;
- In all other cases, an appropriately trained medical practitioner, other than the proceduralist, is required to be in exclusive attendance on the patient during the procedure, to administer sedation and to monitor the patient; and
- There must be sufficient equipment (including oxygen, suction and appropriate medication), to enable resuscitation should it become necessary.

Facilities

The procedure must be performed in a location which is adequate in size and staffed and equipped to deal with a cardiopulmonary emergency. This must include:

- An operating table, trolley or chair which can be readily tilted;
- Adequate uncluttered floor space to perform resuscitation, should this become necessary;
- Adequate suction and room lighting;
- A supply of oxygen and suitable devices for the administration of oxygen to a spontaneously breathing patient;
- A self inflating bag suitable for artificial ventilation together with a range of equipment for advance airway management;
- Appropriate drugs for cardiopulmonary resuscitation;
- A pulse oximeter; and
- Ready access to a defibrillator.

These requirements apply equally to dental anaesthesia or sedation services provided under items in Group T10, Subgroup 20 of the RVG.

TN.10.6 Account Requirements

Before a benefit will be paid for the administration of anaesthesia, or for the services of an assistant anaesthetist, a number of details additional to those set out at paragraph 7.1 of the General Explanatory Notes of the Medicare Benefits Schedule are required on the anaesthetist's account:

- **the anaesthetist's account** must show the name/s of the medical practitioner/s who performed the associated operation/s. In addition, where the after hours emergency modifier applies to the anaesthesia service, the account must include the start time, the end time and total time of the anaesthetic.
- **the assistant anaesthetist's account** must show the names/s of the medical practitioners who performed the associated operation/s, as well as the name of the principal anaesthetist. In addition, where the after hours emergency modifier applies, the assistant anaesthetist's account must record the start time, the end time and the total time for which he or she was providing professional attention to the patient during the anaesthetic.
- **the perfusionist's account** must record the start time, end time and total time of the perfusion service where the after hours emergency modifier is claimed.

TN.10.7 General Information

The Health Insurance Act provides that where anaesthesia is administered to a patient, the premedication of the patient in preparation for anaesthesia is deemed to form part of the administration of anaesthesia. The administration of anaesthesia also includes the pre-anaesthesia consultation with the patient in preparation for that administration, except where such consultation entails a separate attendance carried out at a place other than an operating theatre or an anaesthesia induction room. The pre-anaesthesia consultation for a patient should be performed in association with a clinically relevant service.

Except in special circumstances, benefit is not payable for the administration of anaesthesia listed in Subgroups 1-18, unless the anaesthesia is administered by a medical practitioner other than the medical practitioner who renders the medical service in connection with which anaesthesia is administered.

Fees and benefits for anaesthesia services under the RVG cover all essential components in the administration of the anaesthesia service. Separate benefit may be attracted, however, for complementary services such as central venous pressure and direct arterial pressure monitoring (see note T10.9).

It should be noted that additional benefit is not payable for intravenous infusion or electrocardiographic monitoring, provision for which has been made in the value determined for the anaesthetic units.

The Medicare benefit derived under the RVG for the administration of anaesthesia is the benefit payable for that service irrespective of whether one or more than one medical practitioner administers it. However, benefit is provided under Subgroup 24 for the services of one assistant anaesthetist (who must not be either the surgeon or assistant surgeon (see Note 10.9)

Where a regional nerve block or field nerve block is administered by a medical practitioner other than the practitioner carrying out the operation, the block is assessed as an anaesthesia item according to the advice in paragraph T10.4. When a block is carried out in cases not associated with an operation, such as for intractable pain or during labour, the service falls under Group T7.

When a regional nerve block or field nerve block covered by an item in Group T7 of the Schedule is administered by a medical practitioner in the course of a surgical procedure undertaken by him/her, then such a block will attract benefit under the appropriate item in Group T7.

It should be noted that where a procedure is carried out with local infiltration or digital block as the means of anaesthesia, that anaesthesia is considered to be part of the procedure and an additional benefit is therefore not payable.

It may happen that the professional service for which the anaesthesia is administered does not itself attract a benefit because it is part of the after-care of an operation. This does not, however, affect the benefit payable for the anaesthesia service. Benefit is payable for anaesthesia administered in connection with such a professional service (or combination of services) even though no benefit is payable for the associated professional service.

The administration of epidural anaesthesia during labour is covered by Item 18216 or 18219 in Group T7 of the Schedule whether administered by the medical practitioner undertaking the confinement or by another medical practitioner. Subsequent "top-ups" are covered by Item 18222 or 18225.

TN.10.8 Additional Services Performed in Connection with Anaesthesia - Subgroup 19

Included in the RVG format are a number of additional or complimentary services which may be provided in connection with anaesthesia such as pulmonary artery pressure monitoring (item 22012) and intra-arterial cannulation (item 22025).

These items (with the exception of peri-operative nerve blocks (22030-22050)) and perfusion services (22055-22075) have also been retained in the MBS in the non-RVG format, for use by practitioners who provide these services other than in association with anaesthesia.

Where an anaesthetist provides an additional (clinically relevant) service during anaesthesia that is not one listed in Subgroup 19 (excluding intravenous infusion or electrocardiographic monitoring) the relevant non-RVG item should be claimed.

Items 22012 and 22014

Benefits are payable under items 22012 and 22014 only once for each type of pressure, up to a maximum of 4 pressures per patient per calendar day, and irrespective of the number of practitioners involved in monitoring the pressures.

TN.10.9 Assistance in the Administration of Anaesthesia

The RVG provides for a separate benefit to be paid for the services of an assistant anaesthetist in connection with an operation or series of operations in specified circumstances, as outlined below. This benefit is payable only in respect of one assistant anaesthetist who must not be the surgeon or assistant surgeon.

Therapeutic and Diagnostic services covered by Subgroup 19 items (such as blood transfusion, pressure monitoring, insertion of CVC, etc) are payable only once per patient per anaesthetic episode. Where these services are provided by the assistant anaesthetist these services are eligible for Medicare benefits only where the same service is not also claimed by the primary anaesthetist.

Assistance at anaesthesia in connection with emergency treatment (Item 25200)

Item 25200 provides for assistance at anaesthesia where the patient is in imminent danger of death. Situations where imminent danger of death requiring an assistant anaesthetist might arise include: complex airway problems, anaphylaxis or allergic reactions, malignant hyperpyrexia, neonatal and complicated paediatric anaesthesia, massive blood loss and subsequent resuscitation, intra-operative cardiac arrest, critically ill patients from intensive care units or inability to wean critically ill patients from pulmonary bypass.

Assistance in the administration of elective anaesthesia (Item 25205)

A separate benefit is payable under Item 25205 for the services of an assistant anaesthetist in connection with elective anaesthesia in the circumstances outlined in the item descriptor. This benefit is only payable in respect of one assistant anaesthetist who must not be the surgeon or assistant surgeon.

For the purposes of Item 25205, a 'complex paediatric case' involves one or more of the following:-

- (i) the need for invasive monitoring (intravascular or transoesophageal); or
- (ii) organ transplantation; or
- (iii) craniofacial surgery; or
- (iv) major tumour resection; or

(v) separation of conjoint twins.

TN.10.10 Perfusion Services - (Items 22055 to 22075)

Perfusion services covered by items 22055-22075 have been included in the RVG format.

As with anaesthesia, where whole body perfusion is performed, the Schedule fee is determined on the base units allocated to the service (item 22060), the total time for the perfusion, and modifying units, as appropriate, i.e.

(a) the basic units allocated to whole body perfusion under item 22060:

22060 WHOLE BODY PERFUSION, CARDIAC BYPASS, where the heart-lung machine or equivalent is continuously operated by a medical perfusionist, other than a service associated with anaesthesia to which an item in Subgroup 21 applies. (20 basic units) (See para T10.10 of explanatory notes to this Category)

(b) plus, the time unit allocation reflecting the total time of the perfusion (an item in the range 23010 - 24136), for example:

23033	41 MINUTES TO 45 MINUTES (3 basic units)
-------	--

plus, where appropriate

(c) modifying units recognising certain added complexities in perfusion (an item/s in the range 25000 - 25020), for example:

25014	ANAESTHESIA, PERFUSION OR ASSISTANCE AT ANAESTHESIA - where the patient's age is up to one year or 70 years or greater (1 basic unit)
23013	the patient's age is up to one year or 70 years or greater (1 basic unit)

The time component for item 22060 is defined as beginning with the commencement of anaesthesia and finishing with the closure of the chest.

Items 22065 and 22070 may only be used in association with item 22060.

Medicare benefits are not payable for perfusion unless the perfusion is performed by a medical practitioner other than the medical practitioner who renders the associated medical service in Group T8 or the medical practitioner who administers the anaesthesia listed in the RVG in Group T10.

The medical practitioner providing the service must comply with the training requirements in the Australian and New Zealand College of Anaesthetists (ANZCA) *Guidelines for Major Extracorporeal Perfusion* (PS27 2015).

Benefits are not payable if another person primarily and/or continuously operates the HLM.

TN.10.12 Discontinued Procedure - (Item 21990)

Claims for benefits under Item 21990 should be submitted to Medicare for approval of benefits. Claims should include details of the surgery/procedure which had been proposed and the reason for it being discontinued or abandoned.

TN.10.13 Anaesthesia in Connection with a Procedure not Identified as Attracting a Medicare Benefit for Anaesthesia - (Item 21997)

Payment of benefit for Item 21997 is not restricted to the service being performed in connection with a surgical service in Group T8. Item 21997 may be performed with any item in the Medicare Benefits Schedule that has not been identified as attracting a Medicare benefit for anaesthesia (including attendances) in circumstances where anaesthesia is considered clinically necessary.

TN.10.14 Anaesthesia in Connection with a Dental Service - (Items 22900 and 22905)

Items 22900 and 22905 cover the administration of anaesthesia in connection with a dental service that is not a service covered by an item in the Medicare Benefits Schedule i.e removal of teeth and restorative dental work. Therefore, the requirement that anaesthesia be performed in association with an 'eligible' service (as defined in point T10.2) does not apply to dental anaesthesia items 22900 and 22905.

TN.10.15 Anaesthesia in Connection with Cleft Lip and Cleft Palate Repair - (Items 20102 and 20172)

Anaesthesia associated with cleft lip and cleft palate repair is covered in Subgroup 1 of the RVG Schedule, under items 20102 and 20172.

TN.10.16 Anaesthesia in Connection with an Oral and Maxillofacial Service - (Category 4 of the Medicare Benefits Schedule)

Benefit for anaesthesia provided by a medical practitioner in association with an Oral and Maxillofacial service (Category 4 of the Medicare Benefits Schedule) is derived using the RVG. Benefit for anaesthesia for oral and maxillofacial services should be claimed under the appropriate RVG item from Subgroup 1 or 2.

TN.10.17 Intra-operative Blocks for Post Operative Pain - (Items 22031 to 22050)

Benefits are only payable for intra-operative nerve blocks performed for the management of post-operative pain that are specifically catered for under items 22031 to 22050.

TN.10.18 Anaesthesia in Connection with Extensive Surgery on Facial Bones - (Item 20192)

The term 'extensive' in relation to this item is defined as major facial bone surgery or reconstruction including major resection or osteotomies or osteotomies of mandibles and/or maxillae, surgery for prognathism or surgery for Le Fort II or III fractures.

TN.10.19 Intrathecal or Epidural Injection for Control of Post-operative Pain - Initial - (Item 22031)

Benefits are payable under item 22031 for the initial intrathecal or epidural injection of a therapeutic substance/s, in association with anaesthesia and surgery, for the control of post-operative pain. Benefit is not payable for subsequent intra-operative intrathecal and epidural injection (item 22036) in the same anaesthetic episode. Where subsequent infusion is provided post operatively, to maintain analgesia, benefit would be payable under items 18222 or 18225.

TN.10.20 Intrathecal or Epidural Injection for Control of Post-operative Pain - Subsequent - (Item 22036)

Benefits are payable under item 22036 for subsequent intrathecal or epidural injection of a therapeutic substance/s, in association with anaesthesia and surgery, performed intra-operatively, for postoperative pain management, where the catheter is already in-situ. Benefits are not payable under this item where the initial injection was performed intra-operatively, under item 22031, in the same anaesthetic episode.

TN.10.21 Regional or Field Nerve Blocks for Post-operative Pain - (Items 22040 - 22050)

Benefits are payable under Items 22040 to 22050 in addition to the general anaesthesia for the related procedure.

TN.10.22 Anaesthesia for Radical Procedures on the Chest Wall - (Item 20474)

Radical procedures on the chest wall referred to in item 20474 would include procedures such as pectus excavatum.

TN.10.23 Anaesthesia for Extensive Spine or Spinal Cord Procedures - (Item 20670)

This item covers major spinal surgery involving multiple levels of the spinal cord and spinal fusion where performed. Procedures covered under this item would include the Harrington Rod technique. Surgery on individual spinal levels would be covered under items 20600, 20620 and 20630.

TN.10.24 Anaesthesia for Femoral Artery Embolectomy - (Item 21274)

Item 21274 covers anaesthesia for femoral artery embolectomy. Grafts involving intra-abdominal vessels would be covered under item 20880.

TN.10.25 Anaesthesia for Cardiac Catheterisation - (Item 21941)

Item 21941 does not include either central vein catheterisation or insertion of right heart balloon catheter. Anaesthesia for these procedures is covered under item 21943.

TN.10.26 Anaesthesia for 2 Dimensional Real Time Transoesophageal Echocardiography - (Item 21936)

Benefits are payable for anaesthesia in connection with 2 dimensional real time transoesophageal echocardiography, (including intra-operative echocardiography) which includes doppler techniques, real time colour flow mapping and recording onto video tape or digital medium.

TN.10.27 Anaesthesia for Services on the Upper and Lower Abdomen - (Subgroups 6 and7)

Establishing whether an RVG anaesthetic item pertains to the upper or lower abdomen, depends on whether the majority of the associated surgery was performed in the region above or below the umbilicus.

Some examples of upper abdomen would be:

- laparoscopy on upper abdominal viscera;
- laparoscopy with operative focus superior to the umbilical port;
- surgery to the liver, gallbladder and ducts, stomach, pancreas, small bowel to DJ flexure;
- the kidneys in their normal location (as opposed to pelvic kidney); or
- spleen or bowel (where it involves a diaphragmatic hernia or adhesions to gallbladder bed).

Some examples of lower abdomen would be:

- abdominal wall below the umbilicus;
- laparoscopy on lower abdominal viscera;
- laparoscopy with operative focus inferior to the umbilical port;
- surgery on the jejunum, ileum, or colon;
- surgery on the appendix; or
- surgery associated with the female reproductive system.

TN.10.28 Anaesthesia for Microvascular Free Tissue Flap Surgery - (Items 20230, 20355, 20475, 20704, 20804, 20905, 21155, 21275, 21455, 21535, 21685, 21785 and 21865)

Benefits are only payable where complete free tissue flap surgery is undertaken involving microsurgical arterial and venous anastomoses. Benefits do not apply for microsurgical rotation flaps or for re-implementation of digits or either the hand or the foot.

TN.10.29 Anaesthesia for Endoscopic Ureteric Surgery - Including Laser Procedure - (Item 20911) Benefits are not payable under item 20911 for diagnostic ureteroscopy.

TN.11.1 Botulinum Toxin - (Items 18350 to 18379)

The Therapeutic Goods Administration (TGA) assesses each indication for the therapeutic use of botulinum toxin on an individual basis. There are currently three botulinum toxin agents with TGA registration (Botox®, Dysport® and Xeomin®). Each has undergone a separate evaluation of its safety and efficacy by the TGA as they are neither bioequivalent, nor dose equivalent. When claiming under an item for the injection of botulinum toxin, only the botulinum toxin agent specified in the item can be used. Benefits are not payable where an agent other than that specified in the item is used.

The TGA assesses each indication for the therapeutic use of botulinum toxin by assessment of clinical evidence for its use in paediatric or adult patients. Where an indication has been assessed for adult use, data has generally been assessed using patients over 12 years of age. Paediatric indications have been assessed using data from patients under 18 years of age. Botulinum toxin should only be administered to patients under the age of 18 where an item is for a paediatric indication, and patients over 12 years of age where the item is for an adult indication, unless otherwise specified.

Items for the administration of botulinum toxin can only be claimed by a medical practitioner who is recognised as an eligible medical practitioner for the relevant indication under the arrangements under Section 100 of the *National Health Act 1953* (the Act) relating to the use and supply of botulinum toxin. The specialist qualifications required to administer botulinum toxin vary across the indications for which the medicine is listed on the PBS, and are detailed within the relevant PBS restrictions available at: www.pbs.gov.au/browse/section100-mf

Item 18354 for the treatment of equinus, equinovarus or equinovalgus is limited to a maximum of 4 injections per patient on any day (2 per limb). Accounts should be annotated with the limb which has been treated. Item 18292 may not be claimed for the injection of botulinum toxin, but may be claimed where a neurolytic agent (such as phenol) is used, in addition to botulinum toxin injection(s), to treat the obturator nerve in patients with a dynamic foot deformity.

Treatment under item 18375 or 18379 can only continue if the patient achieves at least a 50% reduction in urinary incontinence episodes from baseline from the start of week 6 through to the end of week 12 after the first treatment. The term 'continue' means the patient can be retreated under item 18375 or 18379 at some point after the 12 week period (for example; 6 to 12 months after the first treatment). This requirement is in line with the PBS listing for the supply of the medicine for this indication under Section 100 of the *Act*.

Item 18362 for the treatment of severe primary axillary hyperhidrosis allows for a maximum number of 3 treatments per patient in a 12 month period, with no less than 4 months to elapse between treatments.

Botulinum toxin which is not supplied and administered in accordance with the arrangements under Section 100 of the *Act* is not required to be provided free of charge to patients. Where a charge is made for the botulinum toxin administered, it must be separately listed on the account and not billed to Medicare. Since 1 September 2015, PBS patient co-payments have applied to botulinum toxin supplied and administered in accordance with the arrangements under Section 100 of the Act.

The Department of Human Services (DHS) has developed a <u>Health Practitioner Guideline to substantiate that a patient had a pre-existing condition at the time of the service</u> which is located on the DHS website.

TR.8.1 Mechanical thrombectomy - (Item 35414)

For the purposes of this item, *eligible stroke centre* means a facility that:

- (a) has a designated stroke unit;
- (b) is equipped and has staff available or on call so that it is capable of providing the following to a patient on a 24-hour basis:
 - (i) the services of a specialist or consultant physician who has the training required under paragraph (b) of item 35414;
 - (ii) diagnostic imaging services using advanced imaging techniques, which must include computed tomography, computed tomography angiography, digital subtraction angiography, magnetic resonance imaging, and magnetic resonance angiography; and
 - (iii) care from a team of health practitioners which includes a stroke physician, a neurologist, a neurosurgeon, a radiologist, an anaesthetist, an intensive care unit specialist, a medical imaging technologist, and a nurse;
- (c) has dedicated endovascular angiography facilities; and
- (d) has written procedures for assessing and treating patients who have, or may have, experienced a stroke.

Note: A health practitioner may fulfil the role of more than one of the types of health practitioner specified in paragraph (b)(iii). For example, a neurologist may also be a stroke physician.

Conjoint Committee for Recognition of Training in Interventional Neuroradiology (CCINR)

CCINR comprises representatives from the Australian and New Zealand Society of Neuroradiology (ANZSNR), the Neurosurgical Society of Australasia (NSA) and the Australian and New Zealand Association of Neurologists (ANZAN). For the purposes of this item, specialists or consultant physicians performing this procedure must have training recognised by CCINR, and the Department of Human Services notified of that recognition.

THERAPEUTIC PROCEDURES ITEMS

T1. MIS PROCE	CELLANEOUS THERAPEUTIC DURES 1. HYPERBARIC OXYGEN THERAPY	
	Group T1. Miscellaneous Therapeutic Procedures	
	Subgroup 1. Hyperbaric Oxygen Therapy	
	HYPERBARIC, OXYGEN THERAPY, for treatment of localised non-neurological soft tissue radiation injuries excluding radiation-induced soft tissue lymphoedema of the arm after treatment for breast cancer, performed in a comprehensive hyperbaric medicine facility, under the supervision of a medical practitioner qualified in hyperbaric medicine, for a period in the hyperbaric chamber of between 1 hour 30 minutes and 3 hours, including any associated attendance.	
13015	(See para TN.1.1 of explanatory notes to this Category) Fee: \$254.75 Benefit: 75% = \$191.10 85% = \$216.55	
	HYPERBARIC OXYGEN THERAPY, for treatment of decompression illness, gas gangrene, air or gas embolism; diabetic wounds including diabetic gangrene and diabetic foot ulcers; necrotising soft tissue infections including necrotising fasciitis or Fournier's gangrene; or for the prevention and treatment of osteoradionecrosis, performed in a comprehensive hyperbaric medicine facility, under the supervision of a medical practitioner qualified in hyperbaric medicine, for a period in the hyperbaric chamber of between 1 hour 30 minutes and 3 hours, including any associated attendance	
13020	(See para TN.1.1 of explanatory notes to this Category) Fee: \$258.85 Benefit: 75% = \$194.15 85% = \$220.05	
	HYPERBARIC OXYGEN THERAPY for treatment of decompression illness, air or gas embolism, performed in a comprehensive hyperbaric medicine facility, under the supervision of a medical practitioner qualified in hyperbaric medicine, for a period in the hyperbaric chamber greater than 3 hours, including any associated attendance - per hour (or part of an hour)	
13025	(See para TN.1.1 of explanatory notes to this Category) Fee: \$115.70 Benefit: 75% = \$86.80 85% = \$98.35	
	HYPERBARIC OXYGEN THERAPY performed in a comprehensive hyperbaric medicine facility where the medical practitioner is pressurised in the hyperbaric chamber for the purpose of providing continuous life saving emergency treatment, including any associated attendance - per hour (or part of an hour)	
13030	(See para TN.1.1 of explanatory notes to this Category) Fee: \$163.45 Benefit: 75% = \$122.60 85% = \$138.95	
T1. MIS PROCE	CELLANEOUS THERAPEUTIC DURES 2. DIALYSIS	
	Group T1. Miscellaneous Therapeutic Procedures	
	Subgroup 2. Dialysis	
	SUPERVISION IN HOSPITAL by a medical specialist of haemodialysis, haemofiltration, haemoperfusion or peritoneal dialysis, including all professional attendances, where the total attendance time on the patient by the supervising medical specialist exceeds 45 minutes in 1 day	
13100	(See para TN.1.2 of explanatory notes to this Category) Fee: \$136.65 Benefit: 75% = \$102.50 85% = \$116.20	
13103	SUPERVISION IN HOSPITAL by a medical specialist of haemodialysis, haemofiltration, haemoperfusion or peritoneal dialysis, including all professional attendances, where the total attendance	

T1. MISC	CELLANEOUS THERAPEUTIC DURES 2. DIALYSIS			
FROCE	time on the patient by the supervising medical specialist does not exceed 45 minutes in 1 day			
	(See para TN.1.2 of explanatory notes to this Category) Fee: \$71.20 Benefit: 75% = \$53.40 85% = \$60.55			
	Planning and management of home dialysis (either haemodialysis or peritoneal dialysis), by a consultar physician in the practice of his or her specialty of renal medicine, for a patient with end-stage renal disease, and supervision of that patient on self-administered dialysis, to a maximum of 12 claims per year			
13104	(See para TN.1.3, TN.1.23 of explanatory notes to this Category) Fee: \$147.95 Benefit: 85% = \$125.80			
	Haemodialysis for a patient with end-stage renal disease if:			
	(a) the service is provided by a registered nurse, an Aboriginal health worker or an Aboriginal and Torres Strait Islander health practitioner on behalf of a medical practitioner; and			
	(b) the service is supervised by the medical practitioner (either in person or remotely); and			
	(c) the patient's care is managed by a nephrologist; and			
	(d) the patient is treated or reviewed by the nephrologist every 3 to 6 months (either in person or remotely); and			
	(e) the patient is not an admitted patient of a hospital; and			
	(f) the service is provided in a Modified Monash 7 area			
13105 G	Fee: \$592.00 Benefit: 100% = \$592.00			
	DECLOTTING OF AN ARTERIOVENOUS SHUNT			
13106	Fee: \$121.35 Benefit: 75% = \$91.05 85% = \$103.15			
13 100	INDWELLING PERITONEAL CATHETER (Tenckhoff or similar) FOR DIALYSIS INSERTION AND FIXATION OF (Anaes.)			
13109	Fee: \$227.75 Benefit: 75% = \$170.85 85% = \$193.60			
	INDWELLING PERITONEAL CATHETER (Tenckhoff or similar) FOR DIALYSIS, removal of (including catheter cuffs) (Anaes.)			
13110	Fee: \$228.50 Benefit: 75% = \$171.40 85% = \$194.25			
T1. MISC PROCED	CELLANEOUS THERAPEUTIC DURES 3. ASSISTED REPRODUCTIVE SERVICES			
	Group T1. Miscellaneous Therapeutic Procedures			
	Subgroup 3. Assisted Reproductive Services			
13200	ASSISTED REPRODUCTIVE TECHNOLOGIES SUPEROVULATED TREATMENT CYCLE PROCEEDING TO OOCYTE RETRIEVAL, involving the use of drugs to induce superovulation, and including quantitative estimation of hormones, semen preparation, ultrasound examinations, all treatment counselling and embryology laboratory services but excluding artificial insemination or transfer of frozen embryos or donated embryos or ova or a service to which item 13201, 13202, 13203, 13206, 13218 applies - being services rendered during 1 treatment cycle - INITIAL cycle in a single			

	CELLANEOUS THERAPEUTIC DURES 3. ASSISTED REPRODUCTIVE SERVICES
	calendar year
	(See para TN.1.4 of explanatory notes to this Category) Fee: \$3,110.75 Benefit: 75% = \$2333.10 85% = \$3027.35 Extended Medicare Safety Net Cap: \$1,675.50
	ASSISTED REPRODUCTIVE TECHNOLOGIES SUPEROVULATED TREATMENT CYCLE PROCEEDING TO OOCYTE RETRIEVAL, involving the use of drugs to induce superovulation, and including quantitative estimation of hormones, semen preparation, ultrasound examinations, all treatment counselling and embryology laboratory services but excluding artificial insemination or transfer of frozen embryos or donated embryos or ova or a service to which item 13200, 13202, 13203, 13206, 13218 applies - being services rendered during 1 treatment cycle - each cycle SUBSEQUENT to the first in a single calendar year
13201	(See para TN.1.4 of explanatory notes to this Category) Fee: \$2,909.75 Benefit: 75% = \$2182.35 85% = \$2826.35 Extended Medicare Safety Net Cap: \$2,432.15
	ASSISTED REPRODUCTIVE TECHNOLOGIES SUPEROVULATED TREATMENT CYCLE THAT IS CANCELLED BEFORE OOCYTE RETRIEVAL, involving the use of drugs to induce superovulation and including quantitative estimation of hormones, semen preparation, ultrasound examinations, but excluding artificial insemination or transfer of frozen embryos or donated embryos or ova or a service to which Item 13200, 13201, 13203, 13206, 13218, applies being services rendered during 1 treatment cycle
13202	(See para TN.1.4 of explanatory notes to this Category) Fee: \$465.55 Benefit: 75% = \$349.20 85% = \$395.75 Extended Medicare Safety Net Cap: \$64.95
	OVULATION MONITORING SERVICES, for artificial insemination - including quantitative estimation of hormones and ultrasound examinations, being services rendered during 1 treatment cycle but excluding a service to which Item 13200, 13201, 13202, 13206, 13212, 13215, 13218, applies
13203	(See para TN.1.4 of explanatory notes to this Category) Fee: \$486.75 Benefit: 75% = \$365.10 85% = \$413.75 Extended Medicare Safety Net Cap: \$108.15
	ASSISTED REPRODUCTIVE TECHNOLOGIES TREATMENT CYCLE using either the natural cycle or oral medication only to induce oocyte growth and development, and including quantitative estimation of hormones, semen preparation, ultrasound examinations, all treatment counselling and embryology laboratory services but excluding artificial insemination, frozen embryo transfer or donated embryos or ova or treatment involving the use of injectable drugs to induce superovulation being services rendered during 1 treatment cycle but only if rendered in conjunction with a service to which item 13212 applies
13206	(See para TN.1.4 of explanatory notes to this Category) Fee: \$465.55 Benefit: 75% = \$349.20 85% = \$395.75 Extended Medicare Safety Net Cap: \$64.95
	PLANNING and MANAGEMENT of a referred patient by a specialist for the purpose of treatment by assisted reproductive technologies or for artificial insemination payable once only during 1 treatment cycle
13209	(See para TN.1.4 of explanatory notes to this Category) Fee: \$84.70 Benefit: 75% = \$63.55 85% = \$72.00 Extended Medicare Safety Net Cap: \$10.90
13210	Professional attendance on a patient by a specialist practising in his or her specialty if:

	CELLANEOUS THERAPEUTIC DURES 3. ASSISTED REPRODUCTIVE SERVICES
	(a) the attendance is by video conference; and
	(b) item 13209 applies to the attendance; and
	(c) the patient is not an admitted patient; and
	(d) the patient:
	(i) is located both:
	(A) within a telehealth eligible area; and
	(B) at the time of the attendance-at least 15 kms by road from the specialist; or
	(ii) is a care recipient in a residential care service; or
	(iii) is a patient of:
	(A) an Aboriginal Medical Service; or
	(B) an Aboriginal Community Controlled Health Service for which a direction made under subsection 19 (2) of the Act applies
	(See para TN.1.21 of explanatory notes to this Category) Derived Fee: 50% of the fee for item 13209. Benefit: 85% of the derived fee Extended Medicare Safety Net Cap: \$5.30
	Oocyte retrieval for the purpose of assisted reproductive technologies-only if rendered in connection with a service to which item 13200, 13201 or 13206 applies (Anaes.)
13212	(See para TN.1.4 of explanatory notes to this Category) Fee: \$354.45 Benefit: 75% = \$265.85 85% = \$301.30 Extended Medicare Safety Net Cap: \$70.35
	Transfer of embryos or both ova and sperm to the uterus or fallopian tubes, excluding artificial insemination-only if rendered in connection with a service to which item 13200, 13201, 13206 or 13218 applies, being services rendered in one treatment cycle (Anaes.)
13215	(See para TN.1.4 of explanatory notes to this Category) Fee: \$111.10 Benefit: 75% = \$83.35 Extended Medicare Safety Net Cap: \$48.70
	PREPARATION of frozen or donated embryos or donated oocytes for transfer to the uterus or fallopian tubes, by any means and including quantitative estimation of hormones and all treatment counselling but excluding artificial insemination services rendered in 1 treatment cycle and excluding a service to which item 13200, 13201, 13202, 13203, 13206, 13212 applies (Anaes.)
13218	(See para TN.1.4, TN.1.5 of explanatory notes to this Category) Fee: \$793.55 Benefit: 75% = \$595.20 85% = \$710.15 Extended Medicare Safety Net Cap: \$702.65
	Preparation of semen for the purpose of artificial insemination-only if rendered in connection with a service to which item 13203 applies
13221	(See para TN.1.4 of explanatory notes to this Category) Fee: \$50.80 Benefit: 75% = \$38.10 85% = \$43.20 Extended Medicare Safety Net Cap: \$21.70
12221	Entertueur interteur Cup. (21.70

	CELLANEOUS THERAPEUTIC DURES 3. ASSISTED REPRODUCTIVE SERVICE
	INTRACYTOPLASMIC SPERM INJECTION for the purposes of assisted reproductive technologies, for male factor infertility, excluding a service to which Item 13203 or 13218 applies
13251	(See para TN.1.5 of explanatory notes to this Category) Fee: \$417.95 Benefit: 75% = \$313.50 85% = \$355.30 Extended Medicare Safety Net Cap: \$108.15
	Processing and cryopreservation of semen for fertility preservation treatment before or after completion of gonadotoxic treatment for malignant or non-malignant conditions, in a post-pubertal male in Tanner stages II-V, up to 60 years old, if the patient is referred by a specialist or consultant physician, initial cryopreservation of semen (not including storage) - one of a maximum of two semen collection cycles per patient in a lifetime.
13260	(See para TN.1.22 of explanatory notes to this Category) Fee: \$415.00 Benefit: 75% = \$311.25 85% = \$352.75 Extended Medicare Safety Net Cap: \$269.75
	SEMEN, collection of, from a patient with spinal injuries or medically induced impotence, for the purposes of analysis, storage or assisted reproduction, by a medical practitioner using a vibrator or electro-ejaculation device including catheterisation and drainage of bladder where required
13290	Fee: \$204.25 Benefit: 75% = \$153.20 85% = \$173.65
	SEMEN, collection of, from a patient with spinal injuries or medically induced impotence, for the purposes of analysis, storage or assisted reproduction, by a medical practitioner using a vibrator or
	electro-ejaculation device including catheterisation and drainage of bladder where required, under general anaesthetic, in a hospital (Anaes.)
13292	
T1. MIS	general anaesthetic, in a hospital (Anaes.)
T1. MIS	general anaesthetic, in a hospital (Anaes.) Fee: \$408.70 Benefit: 75% = \$306.55 85% = \$347.40 CELLANEOUS THERAPEUTIC
T1. MIS	general anaesthetic, in a hospital (Anaes.) Fee: \$408.70 Benefit: 75% = \$306.55 85% = \$347.40 CELLANEOUS THERAPEUTIC DURES 4. PAEDIATRIC & NEONATA
T1. MIS	general anaesthetic, in a hospital (Anaes.) Fee: \$408.70 Benefit: 75% = \$306.55 85% = \$347.40 CELLANEOUS THERAPEUTIC DURES 4. PAEDIATRIC & NEONATA Group T1. Miscellaneous Therapeutic Procedures
T1. MIS PROCE	general anaesthetic, in a hospital (Anaes.) Fee: \$408.70 Benefit: 75% = \$306.55 85% = \$347.40 CELLANEOUS THERAPEUTIC DURES 4. PAEDIATRIC & NEONATA Group T1. Miscellaneous Therapeutic Procedures Subgroup 4. Paediatric & Neonatal UMBILICAL OR SCALP VEIN CATHETERISATION in a NEONATE with or without infusion; or
T1. MIS PROCE	general anaesthetic, in a hospital (Anaes.) Fee: \$408.70 Benefit: 75% = \$306.55 85% = \$347.40 CELLANEOUS THERAPEUTIC DURES 4. PAEDIATRIC & NEONATA Group T1. Miscellaneous Therapeutic Procedures Subgroup 4. Paediatric & Neonatal UMBILICAL OR SCALP VEIN CATHETERISATION in a NEONATE with or without infusion; or cannulation of a vein in a neonate
T1. MIS PROCE	general anaesthetic, in a hospital (Anaes.) Fee: \$408.70 Benefit: 75% = \$306.55 85% = \$347.40 CELLANEOUS THERAPEUTIC DURES 4. PAEDIATRIC & NEONATA Group T1. Miscellaneous Therapeutic Procedures Subgroup 4. Paediatric & Neonatal UMBILICAL OR SCALP VEIN CATHETERISATION in a NEONATE with or without infusion; or cannulation of a vein in a neonate Fee: \$56.95 Benefit: 75% = \$42.75 85% = \$48.45
T1. MIS PROCE	general anaesthetic, in a hospital (Anaes.) Fee: \$408.70 Benefit: 75% = \$306.55 85% = \$347.40 CELLANEOUS THERAPEUTIC DURES 4. PAEDIATRIC & NEONATA Group T1. Miscellaneous Therapeutic Procedures Subgroup 4. Paediatric & Neonatal UMBILICAL OR SCALP VEIN CATHETERISATION in a NEONATE with or without infusion; or cannulation of a vein in a neonate Fee: \$56.95 Benefit: 75% = \$42.75 85% = \$48.45 UMBILICAL ARTERY CATHETERISATION with or without infusion
13300 13303	general anaesthetic, in a hospital (Anaes.) Fee: \$408.70 Benefit: 75% = \$306.55 85% = \$347.40 CELLANEOUS THERAPEUTIC DURES 4. PAEDIATRIC & NEONATA Group T1. Miscellaneous Therapeutic Procedures Subgroup 4. Paediatric & Neonatal UMBILICAL OR SCALP VEIN CATHETERISATION in a NEONATE with or without infusion; or cannulation of a vein in a neonate Fee: \$56.95 Benefit: 75% = \$42.75 85% = \$48.45 UMBILICAL ARTERY CATHETERISATION with or without infusion Fee: \$84.40 Benefit: 75% = \$63.30 85% = \$71.75 BLOOD TRANSFUSION with venesection and complete replacement of blood, including collection
13300 13303	general anaesthetic, in a hospital (Anaes.) Fee: \$408.70 Benefit: 75% = \$306.55 85% = \$347.40 CELLANEOUS THERAPEUTIC DURES 4. PAEDIATRIC & NEONATA Group T1. Miscellaneous Therapeutic Procedures Subgroup 4. Paediatric & Neonatal UMBILICAL OR SCALP VEIN CATHETERISATION in a NEONATE with or without infusion; or cannulation of a vein in a neonate Fee: \$56.95 Benefit: 75% = \$42.75 85% = \$48.45 UMBILICAL ARTERY CATHETERISATION with or without infusion Fee: \$84.40 Benefit: 75% = \$63.30 85% = \$71.75 BLOOD TRANSFUSION with venesection and complete replacement of blood, including collection from donor
	general anaesthetic, in a hospital (Anaes.) Fee: \$408.70 Benefit: 75% = \$306.55 85% = \$347.40 CELLANEOUS THERAPEUTIC DURES 4. PAEDIATRIC & NEONATA Group T1. Miscellaneous Therapeutic Procedures Subgroup 4. Paediatric & Neonatal UMBILICAL OR SCALP VEIN CATHETERISATION in a NEONATE with or without infusion; or cannulation of a vein in a neonate Fee: \$56.95 Benefit: 75% = \$42.75 85% = \$48.45 UMBILICAL ARTERY CATHETERISATION with or without infusion Fee: \$84.40 Benefit: 75% = \$63.30 85% = \$71.75 BLOOD TRANSFUSION with venesection and complete replacement of blood, including collection from donor Fee: \$334.10 Benefit: 75% = \$250.60 85% = \$284.00 BLOOD TRANSFUSION with venesection and complete replacement of blood, using blood already

_	CELLANEOUS T DURES	IERAPEUTIC 4. PAEDIATRIC & NEONATAL	
	Fee: \$28.45	Benefit: 75% = \$21.35 85% = \$24.20	
	CENTRAL VEI	CATHETERISATION - by open exposure in a person under 12 years of age (Anaes.)	
13318	(See para TN.1.6 of explanatory notes to this Category) Fee: \$227.45 Benefit: 75% = \$170.60 85% = \$193.35		
	CENTRAL VEIN CATHETERISATION in a neonate via peripheral vein (Anaes.)		
13319	Fee: \$227.45 Benefit: 75% = \$170.60 85% = \$193.35		
	CELLANEOUS T DURES	IERAPEUTIC 5. CARDIOVASCULAI	
	Group T1. Misco	llaneous Therapeutic Procedures	
		Subgroup 5. Cardiovascular	
		OF CARDIAC RHYTHM by electrical stimulation (cardioversion), other than in the surgery (Anaes.)	
13400	Fee: \$96.80	Benefit: 75% = \$72.60 85% = \$82.30	
	CELLANEOUS T DURES	IERAPEUTIC 6. GASTROENTEROLOG	
	Group T1. Misco	llaneous Therapeutic Procedures	
		Subgroup 6. Gastroenterology	
	GASTRO-OESC	PHAGEAL balloon intubation, for control of bleeding from gastric oesophageal varice	
13506	Fee: \$184.50	Benefit: 75% = \$138.40 85% = \$156.85	
	CELLANEOUS T DURES	IERAPEUTIC 8. HAEMATOLOG	
	Group T1. Misco	llaneous Therapeutic Procedures	
		Subgroup 8. Haematology	
		OF HOMOLOGOUS (including allogeneic) or AUTOLOGOUS bone marrow for the	
	purpose of transp	lantation (Anaes.)	
13700	Fee: \$333.25	Benefit: 75% = \$249.95 85% = \$283.30	
	TRANSFUSION	OF BLOOD, including collection from donor	
13703	Fee: \$119.50	Benefit: 75% = \$89.65 85% = \$101.60	
	TRANSFUSION	OF BLOOD or bone marrow already collected	
13706	(See para TN.1.7 c Fee: \$83.35	f explanatory notes to this Category) Benefit: $75\% = \$62.55$ $85\% = \$70.85$	
		OF BLOOD for autologous transfusion or when homologous blood is required for usion in emergency situation	
	i		

	DURES		8. HAEMATOLOGY	
	Fee: \$48.45	Benefit: 75% = \$36.35	85% = \$41.20	
	utilising continuviability studies, other parameters	ous or intermittent flow tec if performed; continuous is with continuous registered	the removal of plasma or cellular (or both) elements of blood, chniques; including morphological tests for cell counts and monitoring of vital signs, fluid balance, blood volume and d nurse attendance under the supervision of a consultant ith a service to which item 13755 applies -payable once per	
13750	Fee: \$136.65	Benefit: 75% = \$102.5	0 85% = \$116.20	
	intermittent flow continuous mon registered nurse	techniques; including more toring of vital signs, fluid lattendance under the super	ction of blood products for transfusion, utilising continuous or rphological tests for cell counts and viability studies; balance, blood volume and other parameters; with continuous vision of a consultant physician; not being a service (50 applies - payable once per day	
13755	Fee: \$136.65	Benefit: 75% = \$102.5	0 85% = \$116.20	
	THERAPEUTIC porphyria cutane		management of haemochromatosis, polycythemia vera or	
13757	Fee: \$72.95	Benefit: 75% = \$54.75	85% = \$62.05	
	IN VITRO PROCESSING (and cryopreservation) of bone marrow or peripheral blood for autologous stem cell transplantation as an adjunct to high dose chemotherapy for:			
	. chemosensitive intermediate or high grade non-Hodgkin's lymphoma at high risk of relapse following first line chemotherapy; or			
	. Hodgkin's disease which has relapsed following, or is refractory to, chemotherapy; or			
	. acute myelogenous leukaemia in first remission, where suitable genotypically matched sibling donor is not available for allogeneic bone marrow transplant; or			
	. multiple myeloma in remission (complete or partial) following standard dose chemotherapy; or			
	. small round cell sarcomas; or			
	. primitive neuroectodermal tumour; or			
	. germ cell tumours which have relapsed following, or are refractory to, chemotherapy;			
	. germ cell tumours which have had an incomplete response to first line therapy.			
	- performed under the supervision of a consultant physician - each day.			
13760	Fee: \$762.60	Benefit: 75% = \$571.9	5 85% = \$679.20	
	CELLANEOUS T DURES	HERAPEUTIC	9. PROCEDURES ASSOCIATED WITH INTENSIVE CARE AND CARDIOPULMONARY SUPPORT	
	Group T1. Misc	ellaneous Therapeutic Pr	ocedures	
	Subgroup 9. Procedures Associated With Intensive Care And Cardiopulmonary Support			
13815	CENTRAL VEIN CATHETERISATION by percutaneous or open exposure not being a service to			

	CELLANEOUS THERAPEUTIC	9. PROCEDURES ASSOCIATED WITH INTENSIVE CARE AND CARDIOPULMONARY SUPPORT	
	which item 13318 applies (Anaes.)		
	(See para TN.1.6 of explanatory notes to this Ca Fee: \$85.25 Benefit: 75% = \$63.95		
	RIGHT HEART BALLOON CATHETER, cardiac output measurement (Anaes.)	insertion of, including pulmonary wedge pressure and	
13818	(See para TN.1.10 of explanatory notes to this C Fee: \$113.70 Benefit: 75% = \$85.30		
	INTRACRANIAL PRESSURE, monitoring bolt or similar, by a specialist or consultant	g of, by intraventricular or subdural catheter, subarachnoid physician - each day	
13830	Fee: \$75.35 Benefit: 75% = \$56.55	85% = \$64.05	
	ARTERIAL PUNCTURE and collection of	blood for diagnostic purposes	
13839	Fee: \$23.05 Benefit: 75% = \$17.30	85% = \$19.60	
	INTRAARTERIAL CANNULATION for the purpose of taking multiple arterial blood samples for blood gas analysis		
13842	(See para TN.1.10 of explanatory notes to this C Fee: \$69.30 Benefit: 75% = \$52.00		
	COUNTERPULSATION BY INTRAAOR initial and subsequent consultations and mo	TIC BALLOON management on the first day including nitoring of parameters (Anaes.)	
13847	(See para TN.1.10 of explanatory notes to this C Fee: \$156.10 Benefit: 75% = \$117.10		
	COUNTERPULSATION BY INTRAAOR' first, including associated consultations and	TIC BALLOON management on each day subsequent to the monitoring of parameters	
13848	(See para TN.1.10 of explanatory notes to this Category) Fee: \$131.05 Benefit: 75% = \$98.30 85% = \$111.40		
	CIRCULATORY SUPPORT DEVICE, management of, on first day		
13851	Fee: \$493.65 Benefit: 75% = \$370.25	5 85% = \$419.65	
	CIRCULATORY SUPPORT DEVICE, management of, on each day subsequent to the first		
13854	Fee: \$114.85 Benefit: 75% = \$86.15	85% = \$97.65	
	AIRWAY ACCESS, ESTABLISHMENT OF AND INITIATION OF MECHANICAL VENTILATION (other than in the context of an anaesthetic for surgery), outside an Intensive Care Unit, for the purpose of subsequent ventilatory support in an Intensive Care Unit		
13857	(See para TN.1.10 of explanatory notes to this C Fee: \$146.40 Benefit: 75% = \$109.80		
	CELLANEOUS THERAPEUTIC	10. MANAGEMENT AND PROCEDURES UNDERTAKEN IN AN INTENSIVE CARE UNIT	
	Group T1. Miscellaneous Therapeutic Pro	ocedures	
	Subgroup 10. Management An	d Procedures Undertaken In An Intensive Care Unit	

	CELLANEOUS THERAPEUTIC 10. MANAGEMENT AND PROCEDURE UNDERTAKEN IN AN INTENSIVE CARE UN		
	(Note: See para T1.8 of Explanatory Notes to this		
	Category for definition of an Intensive Care Unit)		
	MANAGEMENT of a patient in an Intensive Care Unit by a specialist or consultant physician who is immediately available and exclusively rostered for intensive care - including initial and subsequent attendances, electrocardiographic monitoring, arterial sampling and bladder catheterisation - management on the first day (H) (See para TN.1.9, TN.1.11, TN.1.10 of explanatory notes to this Category)		
13870	Fee: \$362.10 Benefit: 75% = \$271.60		
	MANAGEMENT of a patient in an Intensive Care Unit by a specialist or consultant physician who is immediately available and exclusively rostered for intensive care - including all attendances, electrocardiographic monitoring, arterial sampling and bladder catheterisation - management on each day subsequent to the first day (H)		
13873	(See para TN.1.9, TN.1.11 of explanatory notes to this Category) Fee: \$268.60 Benefit: 75% = \$201.45		
	CENTRAL VENOUS PRESSURE, pulmonary arterial pressure, systemic arterial pressure or cardiac intracavity pressure, continuous monitoring by indwelling catheter in an intensive care unit and manage by a specialist or consultant physician who is immediately available and exclusively rostered for intensive care - once only for each type of pressure on any calendar day (up to a maximum of 4 pressures) (H)		
13876	(See para TN.1.9, TN.1.11, TN.1.10 of explanatory notes to this Category) Fee: \$76.90 Benefit: 75% = \$57.70		
	AIRWAY ACCESS, ESTABLISHMENT OF AND INITIATION OF MECHANICAL VENTILATION, in an Intensive Care Unit, not in association with any anaesthetic service, by a specialist or consultant physician for the purpose of subsequent ventilatory support (H)		
13881	(See para TN.1.9, TN.1.11 of explanatory notes to this Category) Fee: \$146.40 Benefit: 75% = \$109.80		
	VENTILATORY SUPPORT in an Intensive Care Unit, management of, by invasive means, or by non-invasive means where the only alternative to non-invasive ventilatory support would be invasive ventilatory support, by a specialist or consultant physician who is immediately available and exclusively rostered for intensive care, each day (H)		
13882	(See para TN.1.9, TN.1.11 of explanatory notes to this Category) Fee: \$115.25 Benefit: 75% = \$86.45		
	CONTINUOUS ARTERIO VENOUS OR VENO VENOUS HAEMOFILTRATION, in an intensive care unit, management by a specialist or consultant physician who is immediately available and exclusively rostered for intensive care - on the first day (H)		
13885	(See para TN.1.9, TN.1.11 of explanatory notes to this Category) Fee: \$153.65 Benefit: 75% = \$115.25		
13888	CONTINUOUS ARTERIO VENOUS OR VENO VENOUS HAEMOFILTRATION, in an intensive care unit, management by a specialist or consultant physician who is immediately available and		

T1. MISCELLANEOUS THERAPEUTIC 10. MANAGEMENT AND PROCEDURES **PROCEDURES UNDERTAKEN IN AN INTENSIVE CARE UNIT** exclusively rostered for intensive care - on each day subsequent to the first day (H) (See para TN.1.9, TN.1.11 of explanatory notes to this Category) **Benefit:** 75% = \$57.70Fee: \$76.90 T1. MISCELLANEOUS THERAPEUTIC **PROCEDURES** 11. CHEMOTHERAPEUTIC PROCEDURES **Group T1. Miscellaneous Therapeutic Procedures** Subgroup 11. Chemotherapeutic Procedures CYTOTOXIC CHEMOTHERAPY, administration of, either by intravenous push technique (directly into a vein, or a butterfly needle, or the side-arm of an infusion) or by intravenous infusion of not more than 1 hours duration - payable once only on the same day, not being a service associated with photodynamic therapy with verteporfin or for the administration of drugs used immediately prior to, or with microwave (UHF radiowave) cancer therapy alone (See para TN.1.12 of explanatory notes to this Category) **Benefit:** 75% = \$48.80 85% = \$55.30 13915 Fee: \$65.05 CYTOTOXIC CHEMOTHERAPY, administration of, by intravenous infusion of more than 1 hours duration but not more than 6 hours duration - payable once only on the same day 13918 **Benefit:** $75\% = \$73.50 \quad 85\% = \83.30 Fee: \$97.95 CYTOTOXIC CHEMOTHERAPY, administration of, by intravenous infusion of more than 6 hours duration - for the first day of treatment 13921 Fee: \$110.80 **Benefit:** $75\% = \$83.10 \quad 85\% = \94.20 CYTOTOXIC CHEMOTHERAPY, administration of, by intravenous infusion of more than 6 hours duration - on each day subsequent to the first in the same continuous treatment episode 13924 Fee: \$65.25 **Benefit:** 75% = \$48.95 85% = \$55.50 CYTOTOXIC CHEMOTHERAPY, administration of, either by intra-arterial push technique (directly into an artery, a butterfly needle or the side-arm of an infusion) or by intra-arterial infusion of not more than 1 hours duration - payable once only on the same day 13927 **Benefit:** 75% = \$63.30 85% = \$71.75 Fee: \$84.40 CYTOTOXIC CHEMOTHERAPY, administration of, by intra-arterial infusion of more than 1 hours duration but not more than 6 hours duration - payable once only on the same day 13930 **Benefit:** 75% = \$88.35 85% = \$100.15 Fee: \$117.80 CYTOTOXIC CHEMOTHERAPY, administration of, by intra-arterial infusion of more than 6 hours duration - for the first day of treatment Fee: \$130.70 **Benefit:** 75% = \$98.05 85% = \$111.10 13933 CYTOTOXIC CHEMOTHERAPY, administration of, by intra-arterial infusion of more than 6 hours duration - on each day subsequent to the first in the same continuous treatment episode **Benefit:** 75% = \$63.90 85% = \$72.40 13936 IMPLANTED PUMP OR RESERVOIR, loading of, with a cytotoxic agent or agents, not being a service

associated with a service to which item 13915, 13918, 13921, 13924, 13927, 13930, 13933, 13936 or

13939

T1. MIS PROCE	CELLANEOUS THERAPEUTIC DURES 11. CHEMOTHERAPEUTIC PROCEDURES				
	13945 applies				
	(See para TN.1.13 of explanatory notes to this Category) Fee: \$97.95 Benefit: 75% = \$73.50 85% = \$83.30				
	AMBULATORY DRUG DELIVERY DEVICE, loading of, with a cytotoxic agent or agents for the infusion of the agent or agents via the intravenous, intra-arterial or spinal routes, not being a service associated with a service to which item 13915, 13918, 13921, 13924, 13927, 13930, 13933, 13936 or 13945 applies				
13942	(See para TN.1.13 of explanatory notes to this Category) Fee: \$65.25 Benefit: 75% = \$48.95 85% = \$55.50				
	LONG-TERM IMPLANTED DRUG DELIVERY DEVICE FOR CYTOTOXIC CHEMOTHERAPY, accessing of				
13945	Fee: \$52.50 Benefit: 75% = \$39.40 85% = \$44.65				
	CYTOTOXIC AGENT, instillation of, into a body cavity				
13948	Fee: \$65.25 Benefit: 75% = \$48.95 85% = \$55.50				
T1. MIS PROCE	CELLANEOUS THERAPEUTIC DURES 12. DERMATOLOGY				
	Group T1. Miscellaneous Therapeutic Procedures				
	Subgroup 12. Dermatology				
	UVA or UVB phototherapy administered in a whole body cabinet or hand and foot cabinet including associated consultations other than the initial consultation, if treatment is initiated and supervised by a specialist in the specialty of dermatology				
	Applicable not more than 150 times in a 12 month period				
14050	(See para TN.1.14 of explanatory notes to this Category) Fee: \$52.75 Benefit: 75% = \$39.60 85% = \$44.85				
	Laser photocoagulation using laser radiation in the treatment of vascular abnormalities of the head or neck, including any associated consultation, if:				
	(a) the abnormality is visible from 3 metres; and				
	(b) photographic evidence demonstrating the need for this service is documented in the patient notes;				
	to a maximum of 4 sessions (including any sessions to which this item or any of items 14106 to 14118 apply) in any 12 month period (Anaes.)				
14100	(See para TN.1.15 of explanatory notes to this Category) Fee: \$152.50 Benefit: 75% = \$114.40 85% = \$129.65 Extended Medicare Safety Net Cap: \$122.00				
14107	Laser photocoagulation using laser radiation in the treatment of vascular malformations, infantile haemangiomas, café au lait macules and naevi of Ota, other than melanocytic naevi (common moles), if the abnormality is visible from 3 metres, including any associated consultation, up to a maximum of 6 sessions (including any sessions to which this item or any of items 14100 to 14118 apply) in any 12 month period—area of treatment less than 150 cm ² (Anaes.)				
14106					

	CELLANEOUS THERAPEUTIC DURES 12. DERMATOLOG		
	(See para TN.1.15 of explanatory notes to this Category) Fee: \$160.15 Benefit: 75% = \$120.15 85% = \$136.15		
	Laser photocoagulation using laser radiation in the treatment of vascular malformations, infantile haemangiomas, café au lait macules and naevi of Ota, other than melanocytic naevi (common moles), including any associated consultation, up to a maximum of 6 sessions (including any sessions to which this item or any of items 14100 to 14118 apply) in any 12 month period—area of treatment 150 cm ² to 300 cm ² (Anaes.)		
14115	(See para TN.1.15 of explanatory notes to this Category) Fee: \$256.50 Benefit: 75% = \$192.40 85% = \$218.05		
	Laser photocoagulation using laser radiation in the treatment of vascular malformations, infantile haemangiomas, café au lait macules and naevi of Ota, other than melanocytic naevi (common moles), including any associated consultation, up to a maximum of 6 sessions (including any sessions to which this item or any of items 14100 to 14115 apply) in any 12 month period—area of treatment more than 300 cm ² (Anaes.)		
14118	(See para TN.1.15 of explanatory notes to this Category) Fee: \$325.75 Benefit: 75% = \$244.35 85% = \$276.90		
	Laser photocoagulation using laser radiation in the treatment of vascular malformations, infantile haemangiomas, café-au-lait macules and naevi of Ota, other than melanocytic naevi (common moles), including any associated consultation, if:		
	(a) a seventh or subsequent session (including any sessions to which this item or any of items 14100 to 14118 apply) is indicated in a 12 month period commencing on the day of the first session; and		
	(b) photographic evidence demonstrating the need for this service is documented in the patient notes (Anaes.)		
14124	(See para TN.1.15 of explanatory notes to this Category) Fee: \$152.50 Benefit: 75% = \$114.40 85% = \$129.65		
	CELLANEOUS THERAPEUTIC DURES 13. OTHER THERAPEUTIC PROCEDURE		
	Group T1. Miscellaneous Therapeutic Procedures		
	Subgroup 13. Other Therapeutic Procedures		
	GASTRIC LAVAGE in the treatment of ingested poison		
14200	Fee: \$59.80 Benefit: 75% = \$44.85 85% = \$50.85		
	POLY-L-LACTIC ACID, one or more injections of, for the initial session only, for the treatment of severe facial lipoatrophy caused by antiretroviral therapy, when prescribed in accordance with the National Health Act 1953 - once per patient		
14201	(See para TN.1.16 of explanatory notes to this Category) Fee: \$236.85		
14202	POLY-L-LACTIC ACID, one or more injections of (subsequent sessions), for the continuation of treatment of severe facial lipoatrophy caused by antiretroviral therapy, when prescribed in accordance with the National Health Act 1953		

	CELLANEOUS THERAPEUTIC DURES 13. OTHER THERAPEUTIC PROCEDURES		
	(See para TN.1.16 of explanatory notes to this Category) Fee: \$119.90 Benefit: 75% = \$89.95 85% = \$101.95 Extended Medicare Safety Net Cap: \$18.00		
	HORMONE OR LIVING TISSUE IMPLANTATION, by direct implantation involving incision and suture (Anaes.)		
14203	(See para TN.1.4, TN.1.17 of explanatory notes to this Category) Fee: \$51.15 Benefit: 75% = \$38.40 85% = \$43.50		
	HORMONE OR LIVING TISSUE IMPLANTATION by cannula		
14206	(See para TN.1.4, TN.1.17 of explanatory notes to this Category) Fee: \$35.60 Benefit: 75% = \$26.70 85% = \$30.30		
	INTRAARTERIAL INFUSION or retrograde intravenous perfusion of a sympatholytic agent		
14209	Fee: \$88.70 Benefit: 75% = \$66.55 85% = \$75.40		
	INTUSSUSCEPTION, management of fluid or gas reduction for (Anaes.)		
14212	Fee: \$185.30 Benefit: 75% = \$139.00 85% = \$157.55		
	IMPLANTED INFUSION PUMP REFILLING OF reservoir, with a therapeutic agent or agents, for infusion to the subarachnoid or epidural space, with or without re-programming of a programmable pump, for the management of chronic intractable pain		
14218	Fee: \$97.95 Benefit: 75% = \$73.50 85% = \$83.30		
	LONG-TERM IMPLANTED DEVICE FOR DELIVERY OF THERAPEUTIC AGENTS, accessing of, not being a service associated with a service to which item 13945 applies		
14221	Fee: \$52.50 Benefit: 75% = \$39.40 85% = \$44.65		
	ELECTROCONVULSIVE THERAPY, with or without the use of stimulus dosing techniques, including any electroencephalographic monitoring and associated consultation (Anaes.)		
14224	Fee: \$70.35 Benefit: 75% = \$52.80 85% = \$59.80		
	IMPLANTED INFUSION PUMP, REFILLING of reservoir, with baclofen, for infusion to the subarachnoid or epidural space, with or without re-programming of a programmable pump, for the management of severe chronic spasticity		
14227	(See para TN.1.18 of explanatory notes to this Category) Fee: \$97.95 Benefit: 75% = \$73.50 85% = \$83.30		
	Intrathecal or epidural SPINAL CATHETER insertion or replacement of, for connection to a subcutaneous implanted infusion pump, for the management of severe chronic spasticity with baclofen (Anaes.) (Assist.)		
14230	(See para TN.1.18 of explanatory notes to this Category) Fee: \$298.05 Benefit: 75% = \$223.55		
	INFUSION PUMP, subcutaneous implantation or replacement of, and connection to intrathecal or epidural catheter, and loading of reservoir with baclofen, with or without programming of the pump, for the management of severe chronic spasticity (Anaes.) (Assist.)		
14233	(See para TN.1.18 of explanatory notes to this Category) Fee: \$361.90 Benefit: 75% = \$271.45		
14236	INFUSION PUMP, subcutaneous implantation of, AND intrathecal or epidural SPINAL CATHETER		

PROCE	CELLANEOUS THERAPEUTIC DURES 13. OTHER THERAPEUTIC PROCEDURES				
	insertion, and connection of pump to catheter and loading of reservoir with baclofen, with or without programming of the pump, for the management of severe chronic spasticity (Anaes.) (Assist.)				
	(See para TN.1.18 of explanatory notes to this Category) Fee: \$659.95 Benefit: 75% = \$495.00				
İ	Removal of subcutaneously IMPLANTED INFUSION PUMP, OR removal or repositioning of intrathecal or epidural SPINAL CATHETER, for the management of severe chronic spasticity (Anaes				
14239	(See para TN.1.18 of explanatory notes to this Category) Fee: \$159.40 Benefit: 75% = \$119.55				
	SUBCUTANEOUS RESERVOIR AND SPINAL CATHETER, insertion of, for the management of severe chronic spasticity (Anaes.)				
14242	(See para TN.1.18 of explanatory notes to this Category) Fee: \$473.65 Benefit: 75% = \$355.25				
	IMMUNOMODULATING AGENT, administration of, by intravenous infusion for at least 2 hours duration - payable once only on the same day and where the agent is provided under section 100 of the Pharmaceutical Benefits Scheme				
14245	(See para TN.1.19 of explanatory notes to this Category) Fee: $$97.95$ Benefit: $75\% = 73.50 $85\% = 83.30				
T2. RAI	DIATION ONCOLOGY 1. SUPERFICIAL				
	Group T2. Radiation Oncology				
	Subgroup 1. Superficial				
	(Benefits for administration of general anaesthetic for radiotherapy are payable under Group T10)				
	RADIOTHERAPY, SUPERFICIAL (including treatment with xrays, radium rays or other radio substances), not being a service to which another item in this Group applies each attendance at fractionated treatment is given				
ı	fractionated treatment is given				
	fractionated treatment is given - 1 field				
15000					
15000	- 1 field				
15000 15003	- 1 field Fee: \$42.55 Benefit: 75% = \$31.95 85% = \$36.20				
	- 1 field Fee: \$42.55 Benefit: 75% = \$31.95 85% = \$36.20 - 2 or more fields up to a maximum of 5 additional fields				
	- 1 field Fee: \$42.55 Benefit: 75% = \$31.95 85% = \$36.20 - 2 or more fields up to a maximum of 5 additional fields Derived Fee: The fee for item 15000 plus for each field in excess of 1, an amount of \$17.10				
	- 1 field Fee: \$42.55 Benefit: 75% = \$31.95 85% = \$36.20 - 2 or more fields up to a maximum of 5 additional fields Derived Fee: The fee for item 15000 plus for each field in excess of 1, an amount of \$17.10 RADIOTHERAPY, SUPERFICIAL, attendance at which single dose technique is applied				
15003	- 1 field Fee: \$42.55 Benefit: 75% = \$31.95 85% = \$36.20 - 2 or more fields up to a maximum of 5 additional fields Derived Fee: The fee for item 15000 plus for each field in excess of 1, an amount of \$17.10 RADIOTHERAPY, SUPERFICIAL, attendance at which single dose technique is applied - 1 field				
15003	- 1 field Fee: \$42.55 Benefit: 75% = \$31.95 85% = \$36.20 - 2 or more fields up to a maximum of 5 additional fields Derived Fee: The fee for item 15000 plus for each field in excess of 1, an amount of \$17.10 RADIOTHERAPY, SUPERFICIAL, attendance at which single dose technique is applied - 1 field Fee: \$94.35 Benefit: 75% = \$70.80 85% = \$80.20				
15003	- 1 field Fee: \$42.55 Benefit: 75% = \$31.95 85% = \$36.20 - 2 or more fields up to a maximum of 5 additional fields Derived Fee: The fee for item 15000 plus for each field in excess of 1, an amount of \$17.10 RADIOTHERAPY, SUPERFICIAL, attendance at which single dose technique is applied - 1 field Fee: \$94.35 Benefit: 75% = \$70.80 85% = \$80.20 - 2 or more fields up to a maximum of 5 additional fields				

T2. RAI	DIATION ONCOLOGY 2. ORTHOVOLTAGE		
	Group T2. Radiation Oncology		
	Subgroup 2. Orthovoltage		
	RADIOTHERAPY, DEEP OR ORTHOVOLTAGE each attendance at which fractionated treatment is given at 3 or more treatments per week		
	- 1 field		
15100	(See para TN.2.1 of explanatory notes to this Category) Fee: \$47.70 Benefit: 75% = \$35.80 85% = \$40.55		
	- 2 or more fields up to a maximum of 5 additional fields (rotational therapy being 3 fields)		
15103	(See para TN.2.1 of explanatory notes to this Category) Derived Fee: The fee for item 15100 plus for each field in excess of 1, an amount of \$18.80		
	RADIOTHERAPY, DEEP OR ORTHOVOLTAGE each attendance at which fractionated treatment is given at 2 treatments per week or less frequently		
	- 1 field		
15106	Fee: \$56.30 Benefit: 75% = \$42.25 85% = \$47.90		
	- 2 or more fields up to a maximum of 5 additional fields (rotational therapy being 3 fields)		
15109	Derived Fee: The fee for item 15106 plus for each field in excess of 1, an amount of \$22.70		
	RADIOTHERAPY, DEEP OR ORTHOVOLTAGE attendance at which single dose technique is applied 1 field		
15112	Fee: \$120.25 Benefit: 75% = \$90.20 85% = \$102.25		
	- 2 or more fields up to a maximum of 5 additional fields (rotational therapy being 3 fields)		
15115	Derived Fee: The fee for item 15112 plus for each field in excess of 1, an amount of \$47.30		
T2. RAI	DIATION ONCOLOGY 3. MEGAVOLTAGE		
	Group T2. Radiation Oncology		
	Subgroup 3. Megavoltage		
	RADIATION ONCOLOGY TREATMENT, using cobalt unit or caesium teletherapy unit each attendance at which treatment is given		
	- 1 field		
15211	Fee: \$54.70 Benefit: 75% = \$41.05 85% = \$46.50		
	- 2 or more fields up to a maximum of 5 additional fields (rotational therapy being 3 fields)		
15214	Derived Fee: The fee for item 15211 plus for each field in excess of 1, an amount of \$31.90		
	RADIATION ONCOLOGY TREATMENT, using a single photon energy linear accelerator with or without electron facilities - each attendance at which treatment is given - 1 field - treatment delivered to primary site (lung)		
15215	Fee: \$59.65 Benefit: 75% = \$44.75 85% = \$50.75		
15218	RADIATION ONCOLOGY TREATMENT, using a single photon energy linear accelerator with or		

T2. RAI	DIATION ONCOLOGY 3. MEGAVOLTAGE		
	without electron facilities - each attendance at which treatment is given - 1 field - treatment delivered to primary site (prostate)		
	Fee: \$59.65 Benefit: 75% = \$44.75 85% = \$50.75		
	RADIATION ONCOLOGY TREATMENT, using a single photon energy linear accelerator with or without electron facilities - each attendance at which treatment is given - 1 field - treatment delivered to primary site (breast)		
15221	Fee: \$59.65 Benefit: 75% = \$44.75 85% = \$50.75		
	RADIATION ONCOLOGY TREATMENT, using a single photon energy linear accelerator with or without electron facilities - each attendance at which treatment is given - 1 field - treatment delivered to primary site for diseases and conditions not covered by items 15215, 15218 and 15221		
15224	Fee: \$59.65 Benefit: 75% = \$44.75 85% = \$50.75		
	RADIATION ONCOLOGY TREATMENT, using a single photon energy linear accelerator with or without electron facilities - each attendance at which treatment is given - 1 field - treatment delivered to secondary site		
15227	Fee: \$59.65 Benefit: 75% = \$44.75 85% = \$50.75		
	RADIATION ONCOLOGY TREATMENT, using a single photon energy linear accelerator with or without electron facilities - each attendance at which treatment is given - 2 or more fields up to a maximum of 5 additional fields (rotational therapy being 3 fields) - treatment delivered to primary site (lung)		
15230	Derived Fee: The fee for item 15215 plus for each field in excess of 1, an amount of \$37.95		
	RADIATION ONCOLOGY TREATMENT, using a single photon energy linear accelerator with or without electron facilities - each attendance at which treatment is given - 2 or more fields up to a maximum of 5 additional fields (rotational therapy being 3 fields) - treatment delivered to primary site (prostate)		
15233	Derived Fee: The fee for item 15218 plus for each field in excess of 1, an amount of \$37.95		
	RADIATION ONCOLOGY TREATMENT, using a single photon energy linear accelerator with or without electron facilities - each attendance at which treatment is given - 2 or more fields up to a maximum of 5 additional fields (rotational therapy being 3 fields) - treatment delivered to primary site (breast)		
15236	Derived Fee: The fee for item 15221 plus for each field in excess of 1, an amount of \$37.95		
	RADIATION ONCOLOGY TREATMENT, using a single photon energy linear accelerator with or without electron facilities - each attendance at which treatment is given - 2 or more fields up to a maximum of 5 additional fields (rotational therapy being 3 fields) - treatment delivered to primary site for diseases and conditions not covered by items 15230, 15233 or 15236		
15239	Derived Fee: The fee for item 15224 plus for each field in excess of 1, an amount of \$37.95		
	RADIATION ONCOLOGY TREATMENT, using a single photon energy linear accelerator with or without electron facilities - each attendance at which treatment is given - 2 or more fields up to a maximum of 5 additional fields (rotational therapy being 3 fields) - treatment delivered to secondary site		
15242	Derived Fee: The fee for item 15227 plus for each field in excess of 1, an amount of \$37.95		
15245	RADIATION ONCOLOGY TREATMENT, using a dual photon energy linear accelerator with a minimum higher energy of at least 10MV photons, with electron facilities - each attendance at which treatment is given - 1 field - treatment delivered to primary site (lung)		

T2. RAI	DIATION ONCOLOGY		3. MEGAVOLTAGE	
	Fee: \$59.65	Benefit: 75% = \$44.75	85% = \$50.75	
	RADIATION ONCOLOGY TREATMENT, using a dual photon energy linear accelerator with a minimum higher energy of at least 10MV photons, with electron facilities - each attendance at which treatment is given - 1 field - treatment delivered to primary site (prostate)			
15248	Fee: \$59.65	Benefit: 75% = \$44.75	85% = \$50.75	
	RADIATION ONCOLOGY TREATMENT, using a dual photon energy linear accelerator with a minimum higher energy of at least 10MV photons, with electron facilities - each attendance at which treatment is given - 1 field - treatment delivered to primary site (breast)			
15251	Fee: \$59.65	Benefit: 75% = \$44.75	85% = \$50.75	
	minimum highe treatment is give	r energy of at least 10MV pl	, using a dual photon energy linear accelerator with a notons, with electron facilities - each attendance at which ered to primary site for diseases and conditions not covered	
15254	Fee: \$59.65	Benefit: 75% = \$44.75	85% = \$50.75	
	minimum highe		, using a dual photon energy linear accelerator with a notons, with electron facilities - each attendance at which ered to secondary site	
15257	Fee: \$59.65	Benefit: 75% = \$44.75	85% = \$50.75	
	RADIATION ONCOLOGY TREATMENT, using a dual photon energy linear accelerator with a minimum higher energy of at least 10MV photons, with electron facilities - each attendance at which treatment is given - 2 or more fields up to a maximum of 5 additional fields (rotational therapy being fields) - treatment delivered to primary site (lung)		notons, with electron facilities - each attendance at which maximum of 5 additional fields (rotational therapy being 3	
15260	Derived Fee: T	he fee for item 15245 plus for e	ach field in excess of 1, an amount of \$37.95	
	RADIATION ONCOLOGY TREATMENT, using a dual photon energy linear accelerator with a minimum higher energy of at least 10MV photons, with electron facilities - each attendance at which treatment is given - 2 or more fields up to a maximum of 5 additional fields (rotational therapy being 3 fields) - treatment delivered to primary site (prostate)			
15263			ach field in excess of 1, an amount of \$37.95	
	RADIATION ONCOLOGY TREATMENT, using a dual photon energy linear accelerator with a minimum higher energy of at least 10MV photons, with electron facilities - each attendance at which treatment is given - 2 or more fields up to a maximum of 5 additional fields (rotational therapy being 3 fields) - treatment delivered to primary site (breast)			
15266	Derived Fee: T	he fee for item 15251 plus for e	ach field in excess of 1, an amount of \$37.95	
	minimum highe treatment is give	r energy of at least 10MV pl en - 2 or more fields up to a nt delivered to primary site	r, using a dual photon energy linear accelerator with a motons, with electron facilities - each attendance at which maximum of 5 additional fields (rotational therapy being 3 for diseases and conditions not covered by items 15260,	
15269	Derived Fee: T	he fee for item 15254 plus for e	ach field in excess of 1, an amount of \$37.95	
15272	RADIATION C minimum highe	NCOLOGY TREATMENT renergy of at least 10MV pl	, using a dual photon energy linear accelerator with a notons, with electron facilities - each attendance at which maximum of 5 additional fields (rotational therapy being 3	

T2. RAI	DIATION ONCOLOGY	3. MEGAVOLTAGE			
	fields) - treatment delivered to secondary site				
	Derived Fee: The fee for item 15257 plus for each field in excess of 1, an amount of \$37.95				
	RADIATION ONCOLOGY TREATMENT with IGRT imaging facilities undertaken:				
	(a) to implement an IMRT dosimetry plan prepared in accordance with	item 15565; and			
	(b) utilising an intensity modulated treatment delivery mode (delivered by a fixed or dynamic gantry linear accelerator or by a helical non C-arm based linear accelerator), once only at each attendance at which treatment is given.				
15275	Fee: \$182.90 Benefit: 75% = \$137.20 85% = \$155.50				
T2. RAI	DIATION ONCOLOGY	4. BRACHYTHERAP			
	Group T2. Radiation Oncology				
	Subgroup 4. Brachytherapy				
	INTRAUTERINE TREATMENT ALONE using radioactive sealed southan 115 days using manual afterloading techniques (Anaes.)	rces having a half-life greater			
15303	Fee: \$357.00 Benefit: 75% = \$267.75 85% = \$303.45				
	INTRAUTERINE TREATMENT ALONE using radioactive sealed sources having a half-life greater than 115 days using automatic afterloading techniques (Anaes.)				
15304	Fee: \$357.00 Benefit: 75% = \$267.75 85% = \$303.45				
	INTRAUTERINE TREATMENT ALONE using radioactive sealed sources having a half-life of less than 115 days including iodine, gold, iridium or tantalum using manual afterloading techniques (Anaes.)				
15307	Fee: \$676.80 Benefit: 75% = \$507.60 85% = \$593.40				
	INTRAUTERINE TREATMENT ALONE using radioactive sealed sources having a half-life of less than 115 days including iodine, gold, iridium or tantalum using automatic afterloading techniques (Anaes.)				
15308	Fee: \$676.80 Benefit: 75% = \$507.60 85% = \$593.40				
	INTRAVAGINAL TREATMENT ALONE using radioactive sealed so than 115 days using manual afterloading techniques (Anaes.)	urces having a half-life greater			
15311	Fee: \$333.20 Benefit: 75% = \$249.90 85% = \$283.25				
	INTRAVAGINAL TREATMENT ALONE using radioactive sealed sources having a half-life greater than 115 days using automatic afterloading techniques (Anaes.)				
15312	Fee: \$330.80 Benefit: 75% = \$248.10 85% = \$281.20				
	INTRAVAGINAL TREATMENT ALONE using radioactive sealed sources having a half-life of than 115 days including iodine, gold, iridium or tantalum using manual afterloading techniques (
15315	Fee: \$654.25 Benefit: 75% = \$490.70 85% = \$570.85				
	INTRAVAGINAL TREATMENT ALONE using radioactive sealed sources having a half-life of less than 115 days including iodine, gold, iridium or tantalum using automatic afterloading techniques (Anaes.)				
15316	Fee: \$654.25 Benefit: 75% = \$490.70 85% = \$570.85				

T2. RAD	DIATION ONCOLO	OGY	4. BRACHYTHERAPY	
			RAVAGINAL TREATMENT using radioactive sealed ays using manual afterloading techniques (Anaes.)	
15319	Fee: \$406.05	Benefit: 75% = \$304.55	85% = \$345.15	
			RAVAGINAL TREATMENT using radioactive sealed ays using automatic afterloading techniques (Anaes.)	
15320	Fee: \$406.05	Benefit: 75% = \$304.55	85% = \$345.15	
		half-life of less than 115 da	RAVAGINAL TREATMENT using radioactive sealed ays including iodine, gold, iridium or tantalum using manual	
15323	Fee: \$722.00	Benefit: 75% = \$541.50	85% = \$638.60	
	sources having a		RAVAGINAL TREATMENT using radioactive sealed ays including iodine, gold, iridium or tantalum using	
15324	Fee: \$722.00	Benefit: 75% = \$541.50	85% = \$638.60	
	including iodine,	, gold, iridium or tantalum)	ACTIVE SOURCE (having a half-life of less than 115 days to a region, under general anaesthesia, or epidural or spinal exposure and using manual afterloading techniques (Anaes.)	
15327	Fee: \$785.45	Benefit: 75% = \$589.10	85% = \$702.05	
	IMPLANTATION OF A SEALED RADIOACTIVE SOURCE (having a half-life of less than 115 days including iodine, gold, iridium or tantalum) to a region, under general anaesthesia, or epidural or spinal (intrathecal) nerve block, requiring surgical exposure and using automatic afterloading techniques (Anaes.)			
15328	Fee: \$785.45	Benefit: 75% = \$589.10	85% = \$702.05	
	IMPLANTATION OF A SEALED RADIOACTIVE SOURCE (having a half-life of less than 115 days including iodine, gold, iridium or tantalum) to a site (including the tongue, mouth, salivary gland, axilla, subcutaneous sites), where the volume treated involves multiple planes but does not require surgical exposure and using manual afterloading techniques (Anaes.)			
15331	Fee: \$745.80	Benefit: 75% = \$559.35	85% = \$662.40	
	IMPLANTATION OF A SEALED RADIOACTIVE SOURCE (having a half-life of less than 115 days including iodine, gold, iridium or tantalum) to a site (including the tongue, mouth, salivary gland, axilla, subcutaneous sites), where the volume treated involves multiple planes but does not require surgical exposure and using automatic afterloading techniques (Anaes.)			
15332	Fee: \$745.80	Benefit: 75% = \$559.35	85% = \$662.40	
	IMPLANTATION OF A SEALED RADIOACTIVE SOURCE (having a half-life of less than 115 days including iodine, gold, iridium or tantalum) to a site where the volume treated involves only a single plane but does not require surgical exposure and using manual afterloading techniques (Anaes.)			
15335	Fee: \$676.80	Benefit: 75% = \$507.60	85% = \$593.40	
	including iodine,	, gold, iridium or tantalum)	ACTIVE SOURCE (having a half-life of less than 115 days to a site where the volume treated involves only a single and using automatic afterloading techniques (Anaes.)	
	P	ot require surgical exposure	and using automatic arterioading techniques (rinaes.)	

T2. RAI	DIATION ONCOL	OGY	4. BRACHYTHERAPY	
	PROSTATE, radioactive seed implantation of, radiation oncology component, using transrectal ultrasound guidance, for localised prostatic malignancy at clinical stages T1 (clinically inapparen tumour not palpable or visible by imaging) or T2 (tumour confined within prostate), with a Gleas score of less than or equal to 7 and a prostate specific antigen (PSA) of less than or equal to 10ng the time of diagnosis. The procedure must be performed at an approved site in association with a urologist.			
15338	(See para TN.2.2 o Fee: \$935.60	of explanatory notes to this Category) Benefit: $75\% = \$701.70 85\% = \8	352.20	
	REMOVAL OF spinal nerve bloc		CE under general anaesthesia, or under epidural or	
15339	Fee: \$76.20	Benefit: 75% = \$57.15 85% = \$64	1.80	
		ON AND APPLICATION OF A RAD e of greater than 115 days, to treat intra	IOACTIVE MOULD using a sealed source acavity, intraoral or intranasal site	
15342	Fee: \$190.30	Benefit: 75% = \$142.75 85% = \$1	61.80	
		e of less than 115 days including iodin	IOACTIVE MOULD using a sealed source e, gold, iridium or tantalum to treat intracavity,	
15345	Fee: \$507.80	Benefit: 75% = \$380.85 85% = \$4	131.65	
	SUBSEQUENT APPLICATIONS OF RADIOACTIVE MOULD referred to in item 15342 or 15345 each attendance			
15348	Fee: \$58.40	Benefit: 75% = \$43.80 85% = \$49.	0.65	
		ON WITH OR WITHOUT INITIAL A diameter to an external surface	PPLICATION OF RADIOACTIVE MOULD not	
15351	Fee: \$116.60	Benefit: 75% = \$87.45 85% = \$99	0.15	
	CONSTRUCTION diameter to an ex		F RADIOACTIVE MOULD 5 cm. or more in	
15354	Fee: \$141.50	Benefit: 75% = \$106.15 85% = \$1	20.30	
	SUBSEQUENT 15354 each atte		E MOULD referred to in item 15351 or	
15357	Fee: \$40.05	Benefit: 75% = \$30.05 85% = \$34	1.05	
T2. RAI	DIATION ONCOL	OGY	5. COMPUTERISED PLANNING	
	Group T2. Radia	ation Oncology		
Subgroup 5. Computerised Plann			uterised Planning	
	RADIOTHERAPY PLANNING			
	RADIATION FIELD SETTING using a simulator or isocentric xray or megavoltage machine single area for treatment by a single field or parallel opposed fields (not being a service associate service to which item 15509 applies)			
15500	(See para TN.2.3 o Fee: \$242.65	of explanatory notes to this Category) Benefit: 75% = \$182.00 85% = \$2	206.30	

T2. RADIATION ONCOLOGY 5. Co		5. COMPUTERISED PLANNING
	RADIATION FIELD SETTING using a simulator or isocentric single area, where views in more than 1 plane are required for (not being a service associated with a service to which item 1	r treatment by multiple fields, or of 2 areas
15503	(See para TN.2.3 of explanatory notes to this Category) Fee: \$311.55 Benefit: 75% = \$233.70 85% = \$264.85	
	RADIATION FIELD SETTING using a simulator or isocentror more areas, or of total body or half body irradiation, or of irregularly shaped fields using multiple blocks, or of offaxis service associated with a service to which item 15515 applies	mantle therapy or inverted Y fields, or of fields or several joined fields (not being a
15506	(See para TN.2.3 of explanatory notes to this Category) Fee: \$465.30 Benefit: 75% = \$349.00 85% = \$395.55	
	RADIATION FIELD SETTING using a diagnostic xray unit field or parallel opposed fields (not being a service associated applies)	
15509	(See para TN.2.3 of explanatory notes to this Category) Fee: \$210.30 Benefit: 75% = \$157.75 85% = \$178.80	
	RADIATION FIELD SETTING using a diagnostic xray unit 1 plane are required for treatment by multiple fields, or of 2 a service to which item 15503 applies)	
15512	(See para TN.2.3 of explanatory notes to this Category) Fee: \$271.10 Benefit: 75% = \$203.35 85% = \$230.45	
	RADIATION SOURCE LOCALISATION using a simulator where views in more than 1 plane are required, for brachythe implantation of localised prostate cancer, in association with	rapy treatment planning for I125 seed
15513	(See para TN.2.3 of explanatory notes to this Category) Fee: \$306.55 Benefit: 75% = \$229.95 85% = \$260.60	
	RADIATION FIELD SETTING using a diagnostic xray unit body irradiation, or of mantle therapy or inverted Y fields, or blocks, or of offaxis fields or several joined fields (not being item 15506 applies)	of irregularly shaped fields using multiple
15515	(See para TN.2.3 of explanatory notes to this Category) Fee: \$392.50 Benefit: 75% = \$294.40 85% = \$333.65	
	RADIATION DOSIMETRY by a CT interfacing planning coradiotherapy by a single field or parallel opposed fields to 1 a	
15518	(See para TN.2.3 of explanatory notes to this Category) Fee: \$77.00 Benefit: 75% = \$57.75 85% = \$65.45	
	RADIATION DOSIMETRY by a CT interfacing planning coradiotherapy to a single area by 3 or more fields, or by a single or where wedges are used	
15521	(See para TN.2.3 of explanatory notes to this Category) Fee: \$339.90 Benefit: 75% = \$254.95 85% = \$288.95	
15524	RADIATION DOSIMETRY by a CT interfacing planning coradiotherapy to 3 or more areas, or by mantle fields or inverte shaped fields using multiple blocks, or offaxis fields, or sever	ed Y fields or tangential fields or irregularly

T2. RADIATION ONCOLOGY 5. COMPUTERISED PLAN		5. COMPUTERISED PLANNING
	(See para TN.2.3 of explanatory notes to this Category) Fee: \$637.35 Benefit: 75% = \$478.05 85% = \$553.95	
	RADIATION DOSIMETRY by a non CT interfacing planning radiotherapy by a single field or parallel opposed fields to 1 are	
15527	(See para TN.2.3 of explanatory notes to this Category) Fee: \$78.95 Benefit: 75% = \$59.25 85% = \$67.15	
	RADIATION DOSIMETRY by a non CT interfacing planning radiotherapy to a single area by 3 or more fields, or by a single or where wedges are used	
15530	(See para TN.2.3 of explanatory notes to this Category) Fee: \$352.15 Benefit: 75% = \$264.15 85% = \$299.35	
	RADIATION DOSIMETRY by a non CT interfacing planning radiotherapy to 3 or more areas, or by mantle fields or inverted irregularly shaped fields using multiple blocks, or offaxis field	d Y fields, or tangential fields or
15533	(See para TN.2.3 of explanatory notes to this Category) Fee: \$667.70 Benefit: 75% = \$500.80 85% = \$584.30	
	BRACHYTHERAPY PLANNING, computerised radiation do	osimetry
15536	(See para TN.2.3 of explanatory notes to this Category) Fee: \$266.90 Benefit: 75% = \$200.20 85% = \$226.90	
	BRACHYTHERAPY PLANNING, computerised radiation do localised prostate cancer, in association with item 15338	osimetry for I125 seed implantation of
15539	(See para TN.2.3 of explanatory notes to this Category) Fee: \$627.30 Benefit: 75% = \$470.50 85% = \$543.90	
	SIMULATION FOR THREE DIMENSIONAL CONFORMA contrast medium, where:	AL RADIOTHERAPY without intravenous
	(a) treatment set up and technique specifications are in preparadiotherapy dose planning; and	arations for three dimensional conformal
	(b) patient set up and immobilisation techniques are suitable acquisition and three dimensional conformal radiotherapy trea	
	(c) a high-quality CT-image volume dataset must be acquire planned and treated; and	ed for the relevant region of interest to be
	(d) the image set must be suitable for the generation of quali	ity digitally reconstructed radiographic
15550	(See para TN.2.3 of explanatory notes to this Category) Fee: \$658.60 Benefit: 75% = \$493.95 85% = \$575.20	
	SIMULATION FOR THREE DIMENSIONAL CONFORMA intravenous contrast medium, where:	L RADIOTHERAPY pre and post
	(a) treatment set up and technique specifications are in preparadiotherapy dose planning; and	arations for three dimensional conformal
15553	(b) patient set up and immobilisation techniques are suitable	for reliable CT image volume data

T2. RAD	IATION ONCOLOGY 5. COMPUTERISED PLANNING
	acquisition and three dimensional conformal radiotherapy treatment; and
	(c) a high-quality CT-image volume dataset must be acquired for the relevant region of interest to be planned and treated; and
	(d) the image set must be suitable for the generation of quality digitally reconstructed radiographic images
	(See para TN.2.3 of explanatory notes to this Category) Fee: \$710.55 Benefit: 75% = \$532.95 85% = \$627.15
	SIMULATION FOR INTENSITY-MODULATED RADIATION THERAPY (IMRT), with or without intravenous contrast medium, if:
	1. treatment set-up and technique specifications are in preparations for three-dimensional conformal radiotherapy dose planning; and
	2. patient set-up and immobilisation techniques are suitable for reliable CT-image volume data acquisition and three-dimensional conformal radiotherapy; and
	3. a high-quality CT-image volume dataset is acquired for the relevant region of interest to be planned and treated; and
	4. the image set is suitable for the generation of quality digitally-reconstructed radiographic images.
15555	(See para TN.2.3 of explanatory notes to this Category) Fee: \$710.55 Benefit: 75% = \$532.95 85% = \$627.15
	DOSIMETRY FOR THREE DIMENSIONAL CONFORMAL RADIOTHERAPY OF LEVEL 1 COMPLEXITY where:
	(a) dosimetry for a single phase three dimensional conformal treatment plan using CT image volume dataset and having a single treatment target volume and organ at risk; and
	(b) one gross tumour volume or clinical target volume, plus one planning target volume plus at least one relevant organ at risk as defined in the prescription must be rendered as volumes; and
	(c) the organ at risk must be nominated as a planning dose goal or constraint and the prescription must specify the organ at risk dose goal or constraint; and
	(d) dose volume histograms must be generated, approved and recorded with the plan; and
	(e) a CT image volume dataset must be used for the relevant region to be planned and treated; and
	(f) the CT images must be suitable for the generation of quality digitally reconstructed radiographic images
15556	(See para TN.2.3 of explanatory notes to this Category) Fee: \$664.40 Benefit: 75% = \$498.30 85% = \$581.00
	DOSIMETRY FOR THREE DIMENSIONAL CONFORMAL RADIOTHERAPY OF LEVEL 2 COMPLEXITY where:
	(a) dosimetry for a two phase three dimensional conformal treatment plan using CT image volume dataset(s) with at least one gross tumour volume, two planning target volumes and one organ at risk defined in the prescription; or
15559	(b) dosimetry for a one phase three dimensional conformal treatment plan using CT image volume

T2. RADIATION ONCOLOGY

5. COMPUTERISED PLANNING

datasets with at least one gross tumour volume, one planning target volume and two organ at risk dose goals or constraints defined in the prescription; or

(c) image fusion with a secondary image (CT, MRI or PET) volume dataset used to define target and organ at risk volumes in conjunction with and as specified in dosimetry for three dimensional conformal radiotherapy of level 1 complexity.

All gross tumour targets, clinical targets, planning targets and organs at risk as defined in the prescription must be rendered as volumes. The organ at risk must be nominated as planning dose goals or constraints and the prescription must specify the organs at risk as dose goals or constraints. Dose volume histograms must be generated, approved and recorded with the plan. A CT image volume dataset must be used for the relevant region to be planned and treated. The CT images must be suitable for the generation of quality digitally reconstructed radiographic images

(See para TN.2.3 of explanatory notes to this Category)

Fee: \$866.55 **Benefit:** 75% = \$649.95 85% = \$783.15

DOSIMETRY FOR THREE DIMENSIONAL CONFORMAL RADIOTHERAPY OF LEVEL 3 COMPLEXITY - where:

- (a) dosimetry for a three or more phase three dimensional conformal treatment plan using CT image volume dataset(s) with at least one gross tumour volume, three planning target volumes and one organ at risk defined in the prescription; or
- (b) dosimetry for a two phase three dimensional conformal treatment plan using CT image volume datasets with at least one gross tumour volume, and
 - (i) two planning target volumes; or
 - (ii) two organ at risk dose goals or constraints defined in the prescription.

or

(c) dosimetry for a one phase three dimensional conformal treatment plan using CT image volume datasets with at least one gross tumour volume, one planning target volume and three organ at risk dose goals or constraints defined in the prescription;

or

(d) image fusion with a secondary image (CT, MRI or PET) volume dataset used to define target and organ at risk volumes in conjunction with and as specified in dosimetry for three dimensional conformal radiotherapy of level 2 complexity.

All gross tumour targets, clinical targets, planning targets and organs at risk as defined in the prescription must be rendered as volumes. The organ at risk must be nominated as planning dose goals or constraints and the prescription must specify the organs at risk as dose goals or constraints. Dose volume histograms must be generated, approved and recorded with the plan. A CT image volume dataset must be used for the relevant region to be planned and treated. The CT images must be suitable for the generation of quality digitally reconstructed radiographic images

(See para TN.2.3 of explanatory notes to this Category)

Fee: \$1,120.75 **Benefit:** 75% = \$840.60 85% = \$1037.35

T2. RADIATION ONCOLOGY 5. COMPUTERISED PLANNING Preparation of an IMRT DOSIMETRY PLAN, which uses one or more CT image volume datasets, if: (a) in preparing the IMRT dosimetry plan: (i) the differential between target dose and normal tissue dose is maximised, based on a review and assessment by a radiation oncologist; and (ii) all gross tumour targets, clinical targets, planning targets and organs at risk are rendered as volumes as defined in the prescription; and (iii) organs at risk are nominated as planning dose goals or constraints and the prescription specifies the organs at risk as dose goals or constraints; and (iv) dose calculations and dose volume histograms are generated in an inverse planned process, using a specialised calculation algorithm, with prescription and plan details approved and recorded in the plan; and (v) a CT image volume dataset is used for the relevant region to be planned and treated; and (vi) the CT images are suitable for the generation of quality digitally reconstructed radiographic images; and (b) the final IMRT dosimetry plan is validated by the radiation therapist and the medical physicist, using robust quality assurance processes that include: (i) determination of the accuracy of the dose fluence delivered by the multi-leaf collimator and gantryposition (static or dynamic); and (ii) ensuring that the plan is deliverable, data transfer is acceptable and validation checks are completed on a linear accelerator; and (iii) validating the accuracy of the derived IMRT dosimetry plan; and (c) the final IMRT dosimetry plan is approved by the radiation oncologist prior to delivery. (See para TN.2.3 of explanatory notes to this Category) 15565 Fee: \$3.313.85 **Benefit:** 75% = \$2485.40 85% = \$3230.45 **T2. RADIATION ONCOLOGY** 6. STEREOTACTIC RADIOSURGERY **Group T2. Radiation Oncology** Subgroup 6. Stereotactic Radiosurgery STEREOTACTIC RADIOSURGERY, including all radiation oncology consultations, planning, simulation, dosimetry and treatment 15600 Fee: \$1,702.30 **Benefit:** 75% = \$1276.75 85% = \$1618.90 7. RADIATION ONCOLOGY TREATMENT T2. RADIATION ONCOLOGY **VERIFICATION Group T2. Radiation Oncology** Subgroup 7. Radiation Oncology Treatment Verification 15700 RADIATION ONCOLOGY TREATMENT VERIFICATION - single projection (with single or double

T2. RAI	7. RADIATION ONCOLOGY TREATMENT DIATION ONCOLOGY VERIFICATION
	exposures) - when prescribed and reviewed by a radiation oncologist and not associated with item 15705 or 15710 - each attendance at which treatment is verified (ie maximum one per attendance).
	(See para TN.2.4 of explanatory notes to this Category) Fee: \$45.95 Benefit: 75% = \$34.50 85% = \$39.10
	RADIATION ONCOLOGY TREATMENT VERIFICATION - multiple projection acquisition when prescribed and reviewed by a radiation oncologist and not associated with item 15700 or 15710 - each attendance at which treatment involving three or more fields is verified (ie maximum one per attendance).
15705	(See para TN.2.4 of explanatory notes to this Category) Fee: \$76.60 Benefit: 75% = \$57.45 85% = \$65.15
	RADIATION ONCOLOGY TREATMENT VERIFICATION - volumetric acquisition, when prescribed and reviewed by a radiation oncologist and not associated with item 15700 or 15705 - each attendance at which treatment involving three fields or more is verified (ie maximum one per attendance).
	(see para T2.5 of explanatory notes to this Category)
15710	(See para TN.2.4 of explanatory notes to this Category) Fee: \$76.60 Benefit: 75% = \$57.45 85% = \$65.15
	RADIATION ONCOLOGY TREATMENT VERIFICATION of planar or volumetric IGRT for IMRT, involving the use of at least 2 planar image views or projections or 1 volumetric image set to facilitate a 3-dimensional adjustment to radiation treatment field positioning, if:
	(a) the treatment technique is classified as IMRT; and
	(b) the margins applied to volumes (clinical target volume or planning target volume) are tailored or reduced to minimise treatment related exposure of healthy or normal tissues; and
	(c) the decisions made using acquired images are based on action algorithms and are given effect immediately prior to or during treatment delivery by qualified and trained staff considering complex competing factors and using software driven modelling programs; and
	(d) the radiation treatment field positioning requires accuracy levels of less than 5mm (curative cases) or up to 10mm (palliative cases) to ensure accurate dose delivery to the target; and
	(e) the image decisions and actions are documented in the patient's record; and
	(f) the radiation oncologist is responsible for supervising the process, including specifying the type and frequency of imaging, tolerance and action levels to be incorporated in the process, reviewing the trend analysis and any reports and relevant images during the treatment course and specifying action protocols as required; and
	(g) when treatment adjustments are inadequate to satisfy treatment protocol requirements, replanning is required; and
	(h) the imaging infrastructure (hardware and software) is linked to the treatment unit and networked to an image database, enabling both on line and off line reviews.
15715	(See para TN.2.4 of explanatory notes to this Category) Fee: \$76.60 Benefit: 75% = \$57.45 85% = \$65.15

T2. RADIATION ONCOLOGY

8. BRACHYTHERAPY PLANNING AND VERIFICATION

T2. RAI	8. BRACHYTHERAPY PLANNING AND VERIFICATION
	Group T2. Radiation Oncology
	Subgroup 8. Brachytherapy Planning And Verification
	BRACHYTHERAPY TREATMENT VERIFICATION - maximum of one only for each attendance.
15800	(See para TN.2.4 of explanatory notes to this Category) Fee: \$96.30 Benefit: 75% = \$72.25 85% = \$81.90
	RADIATION SOURCE LOCALISATION using a simulator, x-ray machine, CT or ultrasound of a single area, where views in more than one plane are required, for brachytherapy treatment planning, not being a service to which Item 15513 applies.
15850	Fee: \$199.50 Benefit: 75% = \$149.65 85% = \$169.60
T2. RAI	10. TARGETTED INTRAOPERATIVE RADIOTHERAPY
	Group T2. Radiation Oncology
	Subgroup 10. Targetted Intraoperative Radiotherapy
	INTRAOPERATIVE RADIOTHERAPY
	BREAST, MALIGNANT TUMOUR, targeted intraoperative radiotherapy, using an Intrabeam® device, delivered at the time of breast-conserving surgery (partial mastectomy or lumpectomy) for a patient who:
	a) is 45 years of age or more; and
	b) has a T1 or small T2 (less than or equal to 3cm in diameter) primary tumour; and
	c) has an histologic Grade 1 or 2 tumour; and
	d) has an oestrogen-receptor positive tumour; and
	e) has a node negative malignancy; and
	f) is suitable for wide local excision of a primary invasive ductal carcinoma that was diagnosed as unifocal on conventional examination and imaging; and
	g) has no contra-indications to breast irradiation
15900	Fee: \$250.00 Benefit: 75% = \$187.50
T3. THE	RAPEUTIC NUCLEAR MEDICINE
	Group T3. Therapeutic Nuclear Medicine
	INTRACAVITY ADMINISTRATION OF A THERAPEUTIC DOSE OF YTTRIUM 90 not including preliminary paracentesis, not being a service associated with selective internal radiation therapy or to which item 35404, 35406 or 35408 applies (Anaes.)
16003	(See para TN.3.1 of explanatory notes to this Category) Fee: \$650.50 Benefit: 75% = \$487.90 85% = \$567.10
16006	ADMINISTRATION OF A THERAPEUTIC DOSE OF IODINE 131 for thyroid cancer by single dose

T3. THE	RAPEUTIC NUCLEAR MEDICINE
	technique
	Fee: \$499.85 Benefit: 75% = \$374.90 85% = \$424.90
	ADMINISTRATION OF A THERAPEUTIC DOSE OF IODINE 131 for thyrotoxicosis by single dose technique
16009	Fee: \$341.15 Benefit: 75% = \$255.90 85% = \$290.00
	INTRAVENOUS ADMINISTRATION OF A THERAPEUTIC DOSE OF PHOSPHOROUS 32
16012	Fee: \$295.15 Benefit: 75% = \$221.40 85% = \$250.90
	ADMINISTRATION OF STRONTIUM 89 for painful bony metastases from carcinoma of the prostate where hormone therapy has failed and either:
	(i) the disease is poorly controlled by conventional radiotherapy; or
	(ii) conventional radiotherapy is inappropriate, due to the wide distribution of sites of bone pain
16015	Fee: \$4,085.70 Benefit: 75% = \$3064.30 85% = \$4002.30
	ADMINISTRATION OF ¹⁵³ SM-LEXIDRONAM for the relief of bone pain due to skeletal metastases (as indicated by a positive bone scan) where hormonal therapy and/or chemotherapy have failed and either the disease is poorly controlled by conventional radiotherapy or conventional radiotherapy is inappropriate, due to the wide distribution of sites of bone pain.
16018	Fee: \$2,442.45 Benefit: 75% = \$1831.85 85% = \$2359.05
T4. OB	STETRICS
	Group T4. Obstetrics
	Professional attendance on a patient by a specialist practising in his or her specialty of obstetrics if:
	(a) the attendance is by video conference; and
	(b) item 16401, 16404, 16406, 16500, 16590 or 16591 applies to the attendance; and
	(c) the patient is not an admitted patient; and
	(d) the patient:
	(i) is located both:
	(A) within a telehealth eligible area; and
	(B) at the time of the attendance-at least 15 kms by road from the specialist; or
	(ii) is a care recipient in a residential care service; or
	(iii) is a patient of:
	(A) an Aboriginal Medical Service; or
	(B) an Aboriginal Community Controlled Health Service for which a direction made under subsection 19 (2) of the Act applies
16399	(See para TN.4.12 of explanatory notes to this Category)

T4. OB	STETRICS
	Derived Fee: 50% of the fee for item 16401,16404,16406,16500,16590 or 16591. Benefit: 85% of the derived fee Extended Medicare Safety Net Cap: \$24.10
	ANTENATAL CARE
	Antenatal service provided by a midwife, nurse or an Aboriginal and Torres Strait Islander health practitioner if:
	(a) the service is provided on behalf of, and under the supervision of, a medical practitioner;
	(b) the service is provided at, or from, a practice location in a regional, rural or remote area RRMA 3-7;
	(c) the service is not performed in conjunction with another antenatal attendance item (same patient, same practitioner on the same day);
	(d) the service is not provided for an admitted patient of a hospital; and
	to a maximum of 10 service per pregnancy
16400	(See para TN.4.1 of explanatory notes to this Category) Fee: \$27.25 Benefit: 85% = \$23.20 Extended Medicare Safety Net Cap: \$11.05
	Professional attendance at consulting rooms or a hospital by a specialist in the practice of his or her specialty of obstetrics, after referral of the patient to him or her - each attendance, other than a second or subsequent attendance in a single course of treatment
16401	(See para TN.4.2 of explanatory notes to this Category) Fee: \$85.55 Benefit: 75% = \$64.20 85% = \$72.75 Extended Medicare Safety Net Cap: \$54.90
	Professional attendance at consulting rooms or a hospital by a specialist in the practice of his or her specialty of obstetrics after referral of the patient to him or her - each attendance SUBSEQUENT to the first attendance in a single course of treatment.
16404	(See para AN.0.70, TN.4.2 of explanatory notes to this Category) Fee: \$43.00 Benefit: 75% = \$32.25 85% = \$36.55 Extended Medicare Safety Net Cap: \$32.95
	Antenatal professional attendance, by an obstetrician or general practitioner, as part of a single course of treatment when the patient is referred by a participating midwife. Payable only once for a pregnancy
16406	Fee: \$133.95 Benefit: 75% = \$100.50 85% = \$113.90 Extended Medicare Safety Net Cap: \$108.15
	Postnatal professional attendance (other than a service to which any other item applies) if the attendance:
	(a) is by an obstetrician or general practitioner; and
	(b) is in hospital or at consulting rooms; and
	(c) is between 4 and 8 weeks after the birth; and
	(d) lasts at least 20 minutes; and
16407	(e) includes a mental health assessment (including screening for drug and alcohol use and domestic

T4. OB	STETRICS
	violence) of the patient; and
	(f) is for a pregnancy in relation to which a service to which item 82140 applies is not provided Payable once only for a pregnancy
	(See para TN.4.13 of explanatory notes to this Category) Fee: \$71.70 Benefit: 75% = \$53.80 85% = \$60.95 Extended Medicare Safety Net Cap: \$46.65
	Postnatal attendance (other than attendance at consulting rooms, a hospital or a residential aged care facility or a service to which any other item applies) if the attendance:
	(a) is by:
	(i) a midwife (on behalf of and under the supervision of the medical practitioner who attended the birth); or
	(ii) an obstetrician; or
	(iii) a general practitioner; and
	(b) is between 1 week and 4 weeks after the birth; and
	(c) lasts at least 20 minutes; and
	(d) is for a patient who was privately admitted for the birth; and
	(e) is for a pregnancy in relation to which a service to which item 82130, 82135 or 82140 applies is not provided Payable once only for a pregnancy
16408	Fee: \$53.40 Benefit: 85% = \$45.40 Extended Medicare Safety Net Cap: \$34.75
	ANTENATAL ATTENDANCE
16500	(See para TN.4.3 of explanatory notes to this Category) Fee: \$47.15 Benefit: 75% = \$35.40 85% = \$40.10 Extended Medicare Safety Net Cap: \$32.95
	EXTERNAL CEPHALIC VERSION for breech presentation, after 36 weeks where no contraindication exists, in a Unit with facilities for Caesarean Section, including pre- and post version CTG, with or without tocolysis, not being a service to which items 55718 to 55728 and 55768 to 55774 apply - chargeable whether or not the version is successful and limited to a maximum of 2 ECV's per pregnancy
16501	(See para TN.4.3, TN.4.4 of explanatory notes to this Category) Fee: \$140.55 Benefit: 75% = \$105.45 85 % = \$119.50 Extended Medicare Safety Net Cap: \$65.90
	POLYHYDRAMNIOS, UNSTABLE LIE, MULTIPLE PREGNANCY, PREGNANCY COMPLICATED BY DIABETES OR ANAEMIA, THREATENED PREMATURE LABOUR treated by bed rest only or oral medication, requiring admission to hospital each attendance that is not a routine antenatal attendance, to a maximum of 1 visit per day
16502	(See para TN.4.3 of explanatory notes to this Category) Fee: \$47.15 Benefit: 75% = \$35.40 Extended Medicare Safety Net Cap: \$22.00
16505	THREATENED ABORTION, THREATENED MISCARRIAGE OR HYPEREMESIS

T4. OBS	STETRICS
	GRAVIDARUM, requiring admission to hospital, treatment of each attendance that is not a routine antenatal attendance
	(See para TN.4.3 of explanatory notes to this Category) Fee: \$47.15 Benefit: 75% = \$35.40 Extended Medicare Safety Net Cap: \$22.00
	Pregnancy complicated by acute intercurrent infection, fetal growth restriction, threatened premature labour with ruptured membranes or threatened premature labour treated by intravenous therapy, requiring admission to hospital - each professional attendance (other than a service to which item 16533 applies) that is not a routine antenatal attendance, to a maximum of one visit per day
16508	(See para TN.4.3 of explanatory notes to this Category) Fee: \$47.15 Benefit: 75% = \$35.40 85% = \$40.10 Extended Medicare Safety Net Cap: \$22.00
	Pre-eclampsia, eclampsia or antepartum haemorrhage, treatment of - each professional attendance (other than a service to which item 16534 applies) that is not a routine antenatal attendance
16509	(See para TN.4.3 of explanatory notes to this Category) Fee: \$47.15 Benefit: 75% = \$35.40 85% = \$40.10 Extended Medicare Safety Net Cap: \$22.00
	CERVIX, purse string ligation of (Anaes.)
16511	(See para TN.4.3 of explanatory notes to this Category) Fee: \$219.95 Benefit: 75% = \$165.00 Extended Medicare Safety Net Cap: \$109.75
	CERVIX, removal of purse string ligature of (Anaes.)
16512	(See para TN.4.3 of explanatory notes to this Category) Fee: \$63.50 Benefit: 75% = \$47.65 Extended Medicare Safety Net Cap: \$32.95
10012	ANTENATAL CARDIOTOCOGRAPHY in the management of high risk pregnancy (not during the course of the confinement)
16514	(See para TN.4.3 of explanatory notes to this Category) Fee: \$36.65 Benefit: 75% = \$27.50 Extended Medicare Safety Net Cap: \$16.55
	Management of vaginal birth as an independent procedure, if the patient's care has been transferred by another medical practitioner for management of the birth and the attending medical practitioner has not provided antenatal care to the patient, including all attendances related to the birth (Anaes.)
16515	(See para TN.4.5, TN.4.10 of explanatory notes to this Category) Fee: \$630.85 Benefit: 75% = \$473.15 85% = \$547.45 Extended Medicare Safety Net Cap: \$175.60
	Management of labour, incomplete, if the patient's care has been transferred to another medical practitioner for completion of the birth (Anaes.)
16518	(See para TN.4.5, TN.4.10 of explanatory notes to this Category) Fee: \$450.65 Benefit: 75% = \$338.00 85% = \$383.10 Extended Medicare Safety Net Cap: \$175.60
	Management of labour and birth by any means (including Caesarean section) including post-partum care for 5 days (Anaes.)
16519	(See para TN.4.5, TN.4.6, TN.4.10 of explanatory notes to this Category)

	Fee: \$693.95 Benefit: 75% = \$520.50 85% = \$610.55
	Extended Medicare Safety Net Cap: \$329.15
	Caesarean section and post-operative care for 7 days, if the patient's care has been transferred by another medical practitioner for management of the confinement and the attending medical practitioner has not provided any of the antenatal care (Anaes.)
16520	(See para TN.4.6, TN.4.10 of explanatory notes to this Category) Fee: \$630.85 Benefit: 75% = \$473.15 85% = \$547.45 Extended Medicare Safety Net Cap: \$329.15
	Management of labour and birth, or birth alone, (including caesarean section), on or after 23 weeks gestation, if in the course of antenatal supervision or intrapartum management one or more of the following conditions is present, including postnatal care for 7 days:
	(a) fetal loss;
	(b) multiple pregnancy;
	(c) antepartum haemorrhage that is:
	(i) of greater than 200 ml; or
	(ii) associated with disseminated intravascular coagulation;
	(d) placenta praevia on ultrasound in the third trimester with the placenta within 2 cm of the internal cervical os;
	(e) baby with a birth weight less than or equal to 2,500 g;
	(f) trial of vaginal birth in a patient with uterine scar where there has been a planned vaginal birth after caesarean section;
	(g) trial of vaginal breech birth where there has been a planned vaginal breech birth;
	(h) prolonged labour greater than 12 hours with partogram evidence of abnormal cervimetric progress as evidenced by cervical dilatation at less than 1 cm/hr in the active phase of labour (after 3 cm cervical dilatation and effacement until full dilatation of the cervix);
	(i) acute fetal compromise evidenced by:
	(i) scalp pH less than 7.15; or
	(ii) scalp lactate greater than 4.0;
	(j) acute fetal compromise evidenced by at least one of the following significant cardiotocograph abnormalities:
	(i) prolonged bradycardia (less than 100 bpm for more than 2 minutes);
	(ii) absent baseline variability (less than 3 bpm);
	(iii) sinusoidal pattern;
	(iv) complicated variable decelerations with reduced (3 to 5 bpm) or absent baseline variability;
16522	(v) late decelerations;
16522	

T4. OBSTETRICS

- (k) pregnancy induced hypertension of at least 140/90 mm Hg associated with:
 - (i) at least 2+ proteinuria on urinalysis; or
 - (ii) protein-creatinine ratio greater than 30 mg/mmol; or
 - (iii) platelet count less than 150×10^9 /L; or
 - (iv) uric acid greater than 0.36 mmol/L;
- (1) gestational diabetes mellitus requiring at least daily blood glucose monitoring;
- (m) mental health disorder (whether arising prior to pregnancy, during pregnancy or postpartum) that is demonstrated by:
 - (i) the patient requiring hospitalisation; or
 - (ii) the patient receiving ongoing care by a psychologist or psychiatrist to treat the symptoms of a mental health disorder; or
 - (iii) the patient having a GP mental health treatment plan; or
 - (iv) the patient having a management plan prepared in accordance with item 291;
- (n) disclosure or evidence of domestic violence;
- (o) any of the following conditions either diagnosed pre-pregnancy or evident at the first antenatal visit before 20 weeks gestation:
 - (i) pre-existing hypertension requiring antihypertensive medication prior to pregnancy;
 - (ii) cardiac disease (co-managed with a specialist physician and with echocardiographic evidence of myocardial dysfunction);
 - (iii) previous renal or liver transplant;
 - (iv) renal dialysis;
 - (v) chronic liver disease with documented oesophageal varices;
 - (vi) renal insufficiency in early pregnancy (serum creatinine greater than 110 mmol/L);
 - (vii) neurological disorder that confines the patient to a wheelchair throughout pregnancy;
 - (viii) maternal height of less than 148 cm;
 - (ix) a body mass index greater than or equal to 40;
 - (x) pre-existing diabetes mellitus on medication prior to pregnancy;
 - (xi) thyrotoxicosis requiring medication;
 - (xii) previous thrombosis or thromboembolism requiring anticoagulant therapy through pregnancy and the early puerperium;
 - (xiii) thrombocytopenia with platelet count of less than 100,000 prior to 20 weeks gestation;

T4. OB	STETRICS
	(xiv) HIV, hepatitis B or hepatitis C carrier status positive;
	(xv) red cell or platelet iso-immunisation;
	(xvi) cancer with metastatic disease;
	(xvii) illicit drug misuse during pregnancy (Anaes.)
	(See para TN.4.7 of explanatory notes to this Category) Fee: \$1,629.35 Benefit: 75% = \$1222.05 Extended Medicare Safety Net Cap: \$438.90
	Management of vaginal birth, if the patient's care has been transferred by a participating midwife for management of the birth, including all attendances related to the birth. Payable once only for a pregnancy.
	(Anaes.)
16527	(See para TN.4.8 of explanatory notes to this Category) Fee: \$630.85 Benefit: 75% = \$473.15 85% = \$547.45 Extended Medicare Safety Net Cap: \$175.60
	Caesarean section and post-operative care for 7 days, if the patient's care has been transferred by a participating midwife for management of the birth. Payable once only for a pregnancy. (Anaes.)
16528	(See para TN.4.8 of explanatory notes to this Category) Fee: \$630.85 Benefit: 75% = \$473.15 Extended Medicare Safety Net Cap: \$329.15
	Management of pregnancy loss, from 14 weeks to 15 weeks and 6 days gestation, other than a service to which item 16531, 35640 or 35643 applies (Anaes.)
16530	(See para TN.4.5 of explanatory notes to this Category) Fee: \$384.35 Benefit: 75% = \$288.30 85% = \$326.70 Extended Medicare Safety Net Cap: \$249.85
	Management of pregnancy loss, from 16 weeks to 22 weeks and 6 days gestation, other than a service to which item 16530, 35640 or 35643 applies (Anaes.)
16531	(See para TN.4.5, TN.4.14 of explanatory notes to this Category) Fee: \$768.70 Benefit: 75% = \$576.55 Extended Medicare Safety Net Cap: \$499.70
	Pregnancy complicated by acute intercurrent infection, fetal growth restriction, threatened premature labour with ruptured membranes or threatened premature labour treated by intravenous therapy, requiring admission to hospital—each professional attendance lasting at least 40 minutes that is not a routine antenatal attendance, to a maximum of 3 services per pregnancy
	(See para TN.4.3, TN.4.14 of explanatory notes to this Category) Fee: \$105.55 Benefit: 75% = \$79.20
16533	Extended Medicare Safety Net Cap: \$68.65
	Pre-eclampsia, eclampsia or antepartum haemorrhage, treatment of—each professional attendance lasting at least 40 minutes that is not a routine antenatal attendance, to a maximum of 3 services per pregnancy
	(See para TN.4.3, TN.4.14 of explanatory notes to this Category) Fee: \$105.55 Benefit: 75% = \$79.20
16534	Extended Medicare Safety Net Cap: \$68.65

T4. OB	STETRICS
	POST-PARTUM CARE
	EVACUATION OF RETAINED PRODUCTS OF CONCEPTION (placenta, membranes or mole) as a complication of confinement, with or without curettage of the uterus, as an independent procedure (Anaes.)
16564	(See para TN.4.10 of explanatory notes to this Category) Fee: \$218.00 Benefit: 75% = \$163.50 85% = \$185.30 Extended Medicare Safety Net Cap: \$219.45
	MANAGEMENT OF POSTPARTUM HAEMORRHAGE by special measures such as packing of uterus, as an independent procedure (Anaes.)
16567	(See para TN.4.10 of explanatory notes to this Category) Fee: \$318.80 Benefit: 75% = \$239.10 85% = \$271.00 Extended Medicare Safety Net Cap: \$219.45
	ACUTE INVERSION OF THE UTERUS, vaginal correction of, as an independent procedure (Anaes.)
16570	(See para TN.4.10 of explanatory notes to this Category) Fee: \$416.05 Benefit: 75% = \$312.05 85% = \$353.65 Extended Medicare Safety Net Cap: \$219.45
	CERVIX, repair of extensive laceration or lacerations (Anaes.)
16571	(See para TN.4.10 of explanatory notes to this Category) Fee: \$318.80 Benefit: 75% = \$239.10 85% = \$271.00 Extended Medicare Safety Net Cap: \$219.45
	THIRD DEGREE TEAR, involving anal sphincter muscles and rectal mucosa, repair of, as an independent procedure (Anaes.)
16573	(See para TN.4.10 of explanatory notes to this Category) Fee: \$259.80 Benefit: 75% = \$194.85 Extended Medicare Safety Net Cap: \$219.45
	Planning and management, by a practitioner, of a pregnancy if:
	(a) the practitioner intends to take primary responsibility for management of the pregnancy and any complications, and to be available for the birth; and
	(b) the patient intends to be privately admitted for the birth; and
	(c) the pregnancy has progressed beyond 28 weeks gestation; and
	(d) the practitioner has maternity privileges at a hospital or birth centre; and
	(e) the service includes a mental health assessment (including screening for drug and alcohol use and domestic violence) of the patient; and
	(f) a service to which item 16591 applies is not provided in relation to the same pregnancy
	Payable once only for a pregnancy
16590	(See para TN.4.13, TN.4.9 of explanatory notes to this Category) Fee: \$372.75 Benefit: 75% = \$279.60 85% = \$316.85

TETRICS
Extended Medicare Safety Net Cap: \$219.45
Planning and management, by a practitioner, of a pregnancy if:
(a) the pregnancy has progressed beyond 28 weeks gestation; and
(b) the service includes a mental health assessment (including screening for drug and alcohol use and domestic violence) of the patient; and
(c) a service to which item 16590 applies is not provided in relation to the same pregnancy
Payable once only for a pregnancy
(See para TN.4.13, TN.4.9 of explanatory notes to this Category) Fee: \$142.65 Benefit: 75% = \$107.00 85% = \$121.30 Extended Medicare Safety Net Cap: \$109.75
INTERVENTIONAL TECHNIQUES
AMNIOCENTESIS, diagnostic
(See para TN.4.11, TN.4.3 of explanatory notes to this Category)
Fee: \$63.50 Benefit: 75% = \$47.65 85% = \$54.00 Extended Medicare Safety Net Cap: \$32.95
CHORIONIC VILLUS SAMPLING, by any route
(See para TN.4.11, TN.4.3 of explanatory notes to this Category) Fee: \$121.85 Benefit: 75% = \$91.40 85% = \$103.60 Extended Medicare Safety Net Cap: \$65.90
Fetal blood sampling, using interventional techniques from umbilical cord or fetus, including fetal
neuromuscular blockade and amniocentesis (Anaes.)
(See para TN.4.11, TN.4.3 of explanatory notes to this Category) Fee: \$243.25 Benefit: 75% = \$182.45 85% = \$206.80
Extended Medicare Safety Net Cap: \$131.75
FOETAL INTRAVASCULAR BLOOD TRANSFUSION, using blood already collected, including neuromuscular blockade, amniocentesis and foetal blood sampling (Anaes.)
(See para TN.4.11, TN.4.3 of explanatory notes to this Category)
Fee: \$496.00 Benefit: 75% = \$372.00 85% = \$421.60 Extended Medicare Safety Net Cap: \$252.40
FOETAL INTRAPERITONEAL BLOOD TRANSFUSION, using blood already collected, including
neuromuscular blockade, amniocentesis and foetal blood sampling - not performed in conjunction with a service described in item 16609 (Anaes.)
(See para TN.4.11, TN.4.3 of explanatory notes to this Category) Fee: \$390.25 Benefit: 75% = \$292.70 85% = \$331.75
FOETAL INTRAPERITONEAL BLOOD TRANSFUSION, using blood already collected, including neuromuscular blockade, amniocentesis and foetal blood sampling - performed in conjunction with a service described in item 16609 (Anaes.)
(See para TN.4.11, TN.4.3 of explanatory notes to this Category)

T4. OB	STETRICS
	Fee: \$207.85 Benefit: 75% = \$155.90 85% = \$176.70
	AMNIOCENTESIS, THERAPEUTIC, when indicated because of polyhydramnios with at least 500ml being aspirated
	(See para TN.4.11, TN.4.3 of explanatory notes to this Category) Fee: \$207.85 Benefit: 75% = \$155.90 85% = \$176.70
16618	Extended Medicare Safety Net Cap: \$104.30
	AMNIOINFUSION, for diagnostic or therapeutic purposes in the presence of severe oligohydramnios
16621	(See para TN.4.11, TN.4.3 of explanatory notes to this Category) Fee: \$207.85 Benefit: 75% = \$155.90 85% = \$176.70
	FOETAL FLUID FILLED CAVITY, drainage of
16624	(See para TN.4.11, TN.4.3 of explanatory notes to this Category) Fee: \$299.10 Benefit: 75% = \$224.35 85% = \$254.25 Extended Medicare Safety Net Cap: \$142.65
	FETO-AMNIOTIC SHUNT, insertion of, into fetal fluid filled cavity, including neuromuscular blockade and amniocentesis
	(See para TN.4.11, TN.4.3 of explanatory notes to this Category)
16627	Fee: \$608.95 Benefit: 75% = \$456.75 85% = \$525.55 Extended Medicare Safety Net Cap: \$307.25
T6. AN	AESTHETICS 1. ANAESTHESIA CONSULTATIONS
	Group T6. Anaesthetics
	Subgroup 1. Anaesthesia Consultations
	Professional attendance on a patient by a specialist practising in his or her specialty of anaesthesia if:
	(a) the attendance is by video conference; and
	(b) item 17610, 17615, 17620, 17625, 17640, 17645, 17650, or 17655 applies to the attendance; and
	(c) the patient is not an admitted patient; and
	(d) the patient:
	(i) is located both:
	(A) within a telehealth eligible area; and
	(B) at the time of the attendance-at least 15 kms by road from the specialist; or
	(ii) is a care recipient in a residential care service; or
	(iii) is a patient of:
	(A) an Aboriginal Medical Service; or
	(B) an Aboriginal Community Controlled Health Service;
	for which a direction made under subsection 19 (2) of the Act applies
17609	(See para TN.6.4 of explanatory notes to this Category)

T6. AN	AESTHETICS 1. ANAESTHESIA CONSULTATIONS
	Derived Fee: 50% of the fee for item 17610, 17615, 17620, 17625, 17640, 17645, 17650, or 17655. Benefit: 85% of the derived fee
	Extended Medicare Safety Net Cap: 300% of the Derived fee for this item, or \$500.00, whichever is the lesser amount
	ANAESTHETIST, PRE-ANAESTHESIA CONSULTATION
	(Professional attendance by a medical practitioner in the practice of ANAESTHESIA)
	- a BRIEF consultation involving a targeted history and limited examination (including the cardio-respiratory system)
	- AND of not more than 15 minutes s duration, not being a service associated with a service to which items 2801 - 3000 apply
17610	(See para TN.6.1 of explanatory notes to this Category) Fee: \$43.65 Benefit: 75% = \$32.75 85% = \$37.15 Extended Medicare Safety Net Cap: \$130.95
	- a consultation on a patient undergoing advanced surgery or who has complex medical problems, involving a selective history and an extensive examination of multiple systems and the formulation of a written patient management plan documented in the patient notes
	- AND of more than 15 minutes but not more than 30 minutes duration, not being a service associated with a service to which items 2801 - 3000 applies
17615	(See para TN.6.1 of explanatory notes to this Category) Fee: \$86.85 Benefit: 75% = \$65.15 Extended Medicare Safety Net Cap: \$260.55
	- a consultation on a patient undergoing advanced surgery or who has complex medical problems involving a detailed history and comprehensive examination of multiple systems and the formulation of a written patient management plan documented in the patient notes
	- AND of more than 30 minutes but not more than 45 minutes duration, not being a service associated with a service to which items 2801 - 3000 apply
17620	(See para TN.6.1 of explanatory notes to this Category) Fee: \$120.30 Benefit: 75% = \$90.25 85% = \$102.30 Extended Medicare Safety Net Cap: \$360.90
	- a consultation on a patient undergoing advanced surgery or who has complex medical problems involving an exhaustive history and comprehensive examination of multiple systems, the formulation of a written patient management plan following discussion with relevant health care professionals and/or the patient, involving medical planning of high complexity documented in the patient notes
17625	

T6. ANAESTHETICS 1. ANAESTHESIA CONSULT	
	- <i>AND of more than 45 minutes duration</i> , not being a service associated with a service to which items 2801 - 3000 apply
	(See para TN.6.1 of explanatory notes to this Category) Fee: \$153.15 Benefit: 75% = \$114.90 85% = \$130.20 Extended Medicare Safety Net Cap: \$459.45
	ANAESTHETIST, REFERRED CONSULTATION (other than prior to anaesthesia)
	(Professional attendance by a specialist anaesthetist in the practice of ANAESTHESIA where the patient is referred to him or her)
	- a BRIEF consultation involving a short history and limited examination
	- <i>AND of not more than 15 minutes duration</i> , not being a service associated with a service to which items 2801 - 3000 apply
17640	(See para TN.6.2 of explanatory notes to this Category) Fee: \$43.65 Benefit: 75% = \$32.75 Extended Medicare Safety Net Cap: \$130.95
	- a consultation involving a selective history and examination of multiple systems and the formulation of a written patient management plan
	- <i>AND of more than 15 minutes but not more than 30 minutes duration</i> , not being a service associated with a service to which items 2801 - 3000 apply.
17645	(See para TN.6.2 of explanatory notes to this Category) Fee: \$86.85 Benefit: 75% = \$65.15 Extended Medicare Safety Net Cap: \$260.55
	- a consultation involving a detailed history and comprehensive examination of multiple systems and the formulation of a written patient management plan
	- <i>AND of more than 30 minutes but not more than 45 minutes duration</i> , not being a service associated with a service to which items 2801 - 3000 apply
17650	(See para TN.6.2 of explanatory notes to this Category) Fee: \$120.30 Benefit: 75% = \$90.25 85% = \$102.30 Extended Medicare Safety Net Cap: \$360.90
17655	- a consultation involving an exhaustive history and comprehensive examination of multiple systems and the formulation of a written patient management plan following discussion with relevant health care professionals and/or the patient, involving medical planning of high complexity,

T6. ANA	AESTHETICS 1. ANAESTHESIA CONSULTATIONS
	- <i>AND of more than 45 minutes duration</i> , not being a service associated with a service to which items 2801 - 3000 apply. (See para TN.6.2 of explanatory notes to this Category) Fee: \$153.15 Benefit: 75% = \$114.90 85% = \$130.20 Extended Medicare Safety Net Cap: \$459.45
	ANAESTHETIST, CONSULTATION, OTHER
	(Professional attendance by an anaesthetist in the practice of ANAESTHESIA)
	- a consultation immediately prior to the institution of a major regional blockade in a patient in labour, where no previous anaesthesia consultation has occurred, not being a service associated with a service to which items 2801 - 3000 apply.
17680	(See para TN.6.3 of explanatory notes to this Category) Fee: \$86.85 Benefit: 75% = \$65.15 85% = \$73.85 Extended Medicare Safety Net Cap: \$260.55
	- Where a pre-anaesthesia consultation covered by an item in the range 17615-17625 is performed in- rooms if:
	(a) the service is provided to a patient prior to an admitted patient episode of care involving anaesthesia; and
	(b) the service is not provided to an admitted patient of a hospital; and
	(c) the service is not provided on the day of admission to hospital for the subsequent episode of care involving anaesthesia services; and
	(d) the service is of more than 15 minutes duration
	not being a service associated with a service to which items 2801 - 3000 apply.
17690	(See para TN.6.3 of explanatory notes to this Category) Fee: \$40.15 Benefit: 75% = \$30.15 Extended Medicare Safety Net Cap: \$120.45
T7. RE0	GIONAL OR FIELD NERVE BLOCKS

T7. REC	GIONAL OR FIELD NERVE BLOCKS
	Group T7. Regional Or Field Nerve Blocks
	INTRAVENOUS REGIONAL ANAESTHESIA of limb by retrograde perfusion
18213	Fee: \$88.65 Benefit: 75% = \$66.50 85% = \$75.40
	INTRATHECAL OR EPIDURAL INFUSION of a therapeutic substance, initial injection or commencement of, including up to 1 hour of continuous attendance by the medical practitioner (Anaes.)
18216	Fee: \$189.90 Benefit: 75% = \$142.45 85% = \$161.45
	INTRATHECAL or EPIDURAL INFUSION of a therapeutic substance, initial injection or commencement of, where continuous attendance by the medical practitioner extends beyond the first hour (Anaes.)
18219	Derived Fee: The fee for item 18216 plus \$19.00 for each additional 15 minutes or part thereof beyond the first hour of attendance by the medical practitioner.
	INFUSION OF A THERAPEUTIC SUBSTANCE to maintain regional anaesthesia or analgesia, subsequent injection or revision of, where the period of continuous medical practitioner attendance is 15 minutes or less
18222	(See para TN.7.2 of explanatory notes to this Category) Fee: \$37.65 Benefit: 75% = \$28.25 85% = \$32.05
	INFUSION OF A THERAPEUTIC SUBSTANCE to maintain regional anaesthesia or analgesia, subsequent injection or revision of, where the period of continuous medical practitioner attendance is more than 15 minutes
18225	(See para TN.7.2 of explanatory notes to this Category) Fee: \$50.05 Benefit: 75% = \$37.55 85% = \$42.55
	INTRATHECAL OR EPIDURAL INFUSION of a therapeutic substance, initial injection or commencement of, including up to 1 hour of continuous attendance by the medical practitioner, for a patient in labour, where the service is provided in the after hours period, being the period from 8pm to 8am on any weekday, or any time on a Saturday, a Sunday or a public holiday.
18226	(See para TN.7.4 of explanatory notes to this Category) Fee: \$284.80 Benefit: 75% = \$213.60 85% = \$242.10
	INTRATHECAL OR EPIDURAL INFUSION of a therapeutic substance, initial injection or commencement of, where continuous attendance by a medical practitioner extends beyond the first hour, for a patient in labour, where the service is provided in the after hours period, being the period from 8pm to 8am on any weekday, or any time on a Saturday, a Sunday or a public holiday.
18227	(See para TN.7.4 of explanatory notes to this Category) Derived Fee: The fee for item 18226 plus \$28.60 for each additional 15 minutes or part there of beyond the first hour of attendance by the medical practitioner.
	INTERPLEURAL BLOCK, initial injection or commencement of infusion of a therapeutic substance
18228	Fee: \$62.50 Benefit: 75% = \$46.90 85% = \$53.15
	INTRATHECAL or EPIDURAL INJECTION of neurolytic substance (Anaes.)
18230	Fee: \$238.45 Benefit: 75% = \$178.85 85% = \$202.70
	INTRATHECAL or EPIDURAL INJECTION of substance other than anaesthetic, contrast or neurolytic solutions, not being a service to which another item in this Group applies (Anaes.)
18232	(See para TN.7.3 of explanatory notes to this Category)

T7. REC	GIONAL OR FIELD NERVE BLOCKS		
	Fee: \$189.90 Benefit: 75% = \$142.45 85% = \$161.45		
	EPIDURAL INJECTION of blood for blood patch (Anaes.)		
18233	Fee: \$189.90 Benefit: 75% = \$142.45 85% = \$161.45		
	TRIGEMINAL NERVE, primary division of, injection of an anaesthetic agent (Anaes.)		
18234	(See para TN.7.5 of explanatory notes to this Category) Fee: \$124.85 Benefit: 75% = \$93.65 85% = \$106.15		
	TRIGEMINAL NERVE, peripheral branch of, injection of an anaesthetic agent (Anaes.)		
18236	(See para TN.7.5 of explanatory notes to this Category) Fee: \$62.50 Benefit: 75% = \$46.90 85% = \$53.15		
	FACIAL NERVE, injection of an anaesthetic agent, not being a service associated with a servi which item 18240 applies	ce to	
18238	(See para TN.7.5 of explanatory notes to this Category) Fee: \$37.65 Benefit: 75% = \$28.25 85% = \$32.05		
	RETROBULBAR OR PERIBULBAR INJECTION of an anaesthetic agent		
18240	(See para TN.7.5 of explanatory notes to this Category) Fee: \$93.60 Benefit: 75% = \$70.20 85% = \$79.60		
	GREATER OCCIPITAL NERVE, injection of an anaesthetic agent (Anaes.)		
18242	(See para TN.7.5 of explanatory notes to this Category) Fee: \$37.65 Benefit: 75% = \$28.25 85% = \$32.05		
	VAGUS NERVE, injection of an anaesthetic agent		
18244	(See para TN.7.5 of explanatory notes to this Category) Fee: \$100.80		
	PHRENIC NERVE, injection of an anaesthetic agent		
18248	(See para TN.7.5 of explanatory notes to this Category) Fee: \$88.65 Benefit: 75% = \$66.50 85% = \$75.40		
	SPINAL ACCESSORY NERVE, injection of an anaesthetic agent		
18250	(See para TN.7.5 of explanatory notes to this Category) Fee: \$62.50 Benefit: 75% = \$46.90 85% = \$53.15		
	CERVICAL PLEXUS, injection of an anaesthetic agent		
18252	(See para TN.7.5 of explanatory notes to this Category) Fee: \$100.80 Benefit: 75% = \$75.60 85% = \$85.70		
	BRACHIAL PLEXUS, injection of an anaesthetic agent		
18254	(See para TN.7.5 of explanatory notes to this Category) Fee: \$100.80 Benefit: 75% = \$75.60 85% = \$85.70		
	SUPRASCAPULAR NERVE, injection of an anaesthetic agent		
18256	(See para TN.7.5 of explanatory notes to this Category) Fee: \$62.50 Benefit: 75% = \$46.90 85% = \$53.15		
	INTERCOSTAL NERVE (single), injection of an anaesthetic agent		
18258	(See para TN.7.5 of explanatory notes to this Category)		

Fact \$62.50		
INTERCOSTAL NERVES (multiple), injection of an anaesthetic agent		
(See para TN.7.5 of explanatory notes to this Category)		
ILIO-INGUINAL, ILIOHYPOGASTRIC OR GENITOFEMORAL NERVES, 1 or more of, injection of an anaesthetic agent (Anaes.)		
(See para TN.7.5 of explanatory notes to this Category) Fee: \$62.50 Benefit: 75% = \$46.90 85% = \$53.15		
PUDENDAL NERVE and or dorsal nerve, injection of anaesthetic agent		
(See para TN 7.5 of explanatory notes to this Category)		
Fee: \$100.80 Benefit: 75% = \$75.60 85% = \$85.70		
ULNAR, RADIAL OR MEDIAN NERVE, MAIN TRUNK OF, 1 or more of, injection of an anaestl	hetic	
agent, not being associated with a brachial plexus block		
(See para TN.7.5 of explanatory notes to this Category)		
Fee: \$62.50 Benefit: 75% = \$46.90 85% = \$53.15		
OBTURATOR NERVE, injection of an anaesthetic agent		
(See para TN 7.5 of explanatory notes to this Category)		
Fee: \$88.65 Benefit: 75% = \$66.50 85% = \$75.40		
FEMORAL NERVE, injection of an anaesthetic agent		
(See para TN.7.5 of explanatory notes to this Category)		
Fee: \$88.65 Benefit: 75% = \$66.50 85% = \$75.40		
SAPHENOUS, SURAL, POPLITEAL OR POSTERIOR TIBIAL NERVE, MAIN TRUNK OF, 1 or more of, injection of an anaesthetic agent	r	
(See para TN.7.5 of explanatory notes to this Category)		
Fee: \$62.50 Benefit: 75% = \$46.90 85% = \$53.15		
PARAVERTEBRAL, CERVICAL, THORACIC, LUMBAR, SACRAL OR COCCYGEAL NERVE injection of an anaesthetic agent, (single vertebral level)	ES,	
(See para TN 7.5 of explanatory notes to this Category)		
Fee: \$88.65 Benefit: 75% = \$66.50 85% = \$75.40		
PARAVERTEBRAL NERVES, injection of an anaesthetic agent, (multiple levels)		
(See para TN.7.5 of explanatory notes to this Category)		
Fee: \$124.85 Benefit: 75% = \$93.65 85% = \$106.15		
SCIATIC NERVE, injection of an anaesthetic agent		
(See para TN.7.5 of explanatory notes to this Category)		
Fee: \$88.65 Benefit: 75% = \$66.50 85% = \$75.40		
SPHENOPALATINE GANGLION, injection of an anaesthetic agent (Anaes.)		
(See para TN.7.5 of explanatory notes to this Category) Fee: \$124.85 Benefit: 75% = \$93.65 85% = \$106.15		
CAROTID SINUS, injection of an anaesthetic agent, as an independent percutaneous procedure		
	Fee: \$88.65 Benefit: 75% = \$66.50 85% = \$75.40	

	Fee: \$100.80 Benefit: 75% = \$75.60 85% = \$85.70		
	STELLATE GANGLION, injection of an anaesthetic agent, (cervical sympathetic block) (Anaes.)		
18284	(See para TN.7.5 of explanatory notes to this Category) Fee: \$147.65 Benefit: 75% = \$110.75 85% = \$125.55		
	LUMBAR OR THORACIC NERVES, injection of an anaesthetic agent, (paravertebral sympathetic block) (Anaes.)		
18286	(See para TN.7.5 of explanatory notes to this Category) Fee: \$147.65 Benefit: 75% = \$110.75 85% = \$125.55		
	COELIAC PLEXUS OR SPLANCHNIC NERVES, injection of an anaesthetic agent (Anaes.)		
18288	(See para TN.7.5 of explanatory notes to this Category) Fee: \$147.65 Benefit: 75% = \$110.75 85% = \$125.55		
	CRANIAL NERVE OTHER THAN TRIGEMINAL, destruction by a neurolytic agent, not being a service associated with the injection of botulinum toxin (Anaes.)		
18290	Fee: \$249.75 Benefit: 75% = \$187.35 85% = \$212.30		
	NERVE BRANCH, destruction by a neurolytic agent, not being a service to which any other item in the Group applies or a service associated with the injection of botulinum toxin except those services to which item 18354 applies (Anaes.)		
18292	(See para TN.7.5 of explanatory notes to this Category) Fee: \$124.85 Benefit: 75% = \$93.65 85% = \$106.15		
	COELIAC PLEXUS OR SPLANCHNIC NERVES, destruction by a neurolytic agent (Anaes.)		
18294	Fee: \$176.00 Benefit: 75% = \$132.00 85% = \$149.60		
	LUMBAR SYMPATHETIC CHAIN, destruction by a neurolytic agent (Anaes.)		
18296	Fee: \$150.55 Benefit: 75% = \$112.95 85% = \$128.00		
	CERVICAL OR THORACIC SYMPATHETIC CHAIN, destruction by a neurolytic agent (Anaes.)		
18298	Fee: \$176.00 Benefit: 75% = \$132.00 85% = \$149.60		
T8. SUF	RGICAL OPERATIONS 1. GENERA		
	Group T8. Surgical Operations		
	Subgroup 1. General		
	OPERATIVE PROCEDURE, not being a service to which any other item in this Group applies, being a service to which an item in this Group would have applied had the procedure not been discontinued on medical grounds		
30001	(See para TN.8.5 of explanatory notes to this Category) Derived Fee: 50% of the fee which would have applied had the procedure not been discontinued		
	LOCALISED BURNS, dressing of, (not involving grafting) each attendance at which the procedure is performed, including any associated consultation		
30003	Fee: \$36.30 Benefit: 75% = \$27.25 85% = \$30.90		
30003			

T8. SUF	RGICAL OPERAT	TONS 1. GER	NERAL	
	Fee: \$46.50	Benefit: 75% = \$34.90 85% = \$39.55		
	LOCALISED B	URNS, dressing of, under general anaesthesia (not involving grafting) (Anaes.)		
30010	Fee: \$73.90	Benefit: 75% = \$55.45		
	EXTENSIVE B	EXTENSIVE BURNS, dressing of, under general anaesthesia (not involving grafting) (Anaes.)		
30014	Fee: \$155.40	Benefit: 75% = \$116.55		
		on of, under general anaesthesia, involving not more than 10 per cent of body surf s not carried out during the same operation (Anaes.) (Assist.)	face,	
30017	Fee: \$326.05	Benefit: 75% = \$244.55 85% = \$277.15		
		on of, under general anaesthesia, involving more than 10 per cent of body surface arried out during the same operation (Anaes.) (Assist.)	, where	
30020	Fee: \$635.00	Benefit: 75% = \$476.25	ļ	
		OFT TISSUE, traumatic, deep or extensively contaminated, debridement of, undersia or regional or field nerve block, including suturing of that wound when perform.)		
30023	(See para TN.8.6 Fee: \$326.05	of explanatory notes to this Category) Benefit: 75% = \$244.55 85% = \$277.15		
	Gangrene, under	OFT TISSUE, debridement of extensively infected post-surgical incision or Fourner general anaesthesia or regional or field nerve block, including suturing of that w I (Anaes.) (Assist.)		
30024	Fee: \$326.05	Benefit: 75% = \$244.55 85% = \$277.15		
	other than woun	BCUTANEOUS TISSUE OR MUCOUS MEMBRANE, REPAIR OF WOUND d closure at time of surgery, not on face or neck, small (NOT MORE THAN 7 Cloial, not being a service to which another item in Group T4 applies (Anaes.)		
30026	(See para TN.8.6 Fee: \$52.20	of explanatory notes to this Category) Benefit: 75% = \$39.15 85% = \$44.40		
	other than woun	BCUTANEOUS TISSUE OR MUCOUS MEMBRANE, REPAIR OF WOUND d closure at time of surgery, not on face or neck, small (NOT MORE THAN 7 Cl ng deeper tissue, not being a service to which another item in Group T4 applies (A	M	
30029	(See para TN.8.6 Fee: \$90.00	of explanatory notes to this Category) Benefit: $75\% = \$67.50 85\% = \76.50		
		BCUTANEOUS TISSUE OR MUCOUS MEMBRANE, REPAIR OF WOUND d closure at time of surgery, on face or neck, small (NOT MORE THAN 7 CM L es.)		
30032	(See para TN.8.6 Fee: \$82.50	of explanatory notes to this Category) Benefit: 75% = \$61.90 85% = \$70.15		
	other than woun	BCUTANEOUS TISSUE OR MUCOUS MEMBRANE, REPAIR OF WOUND d closure at time of surgery, on face or neck, small (NOT MORE THAN 7 CM L r tissue (Anaes.)		
30035	(See para TN.8.6 Fee: \$117.55	of explanatory notes to this Category) Benefit: 75% = \$88.20 85% = \$99.95		
30038	SKIN AND SU	BCUTANEOUS TISSUE OR MUCOUS MEMBRANE, REPAIR OF WOUND	OF,	

T8. SUF	RGICAL OPERATION	ONS	1. GENERAL
		closure at time of surgery, not on face or neck, large (MORE THAN ing a service to which another item in Group T4 applies (Anaes.)	7 CM LONG),
	(See para TN.8.6 of Fee: \$90.00	explanatory notes to this Category) Benefit: $75\% = \$67.50$ $85\% = \$76.50$	
	other than wound	CUTANEOUS TISSUE OR MUCOUS MEMBRANE, REPAIR OF closure at time of surgery, other than on face or neck, large (MORE 3 deeper tissue, other than a service to which another item in Group To	THAN 7 CM
30042	(See para TN.8.6 of Fee: \$185.60	explanatory notes to this Category) Benefit: 75% = \$139.20 85% = \$157.80	
		CUTANEOUS TISSUE OR MUCOUS MEMBRANE, REPAIR OF closure at time of surgery, on face or neck, large (MORE THAN 7 Co.)	
30045	(See para TN.8.6 of Fee: \$117.55	explanatory notes to this Category) Benefit: 75% = \$88.20 85% = \$99.95	
		CUTANEOUS TISSUE OR MUCOUS MEMBRANE, REPAIR OF closure at time of surgery, on face or neck, large (MORE THAN 7 Cissue (Anaes.)	
30049	(See para TN.8.6 of Fee: \$185.60	explanatory notes to this Category) Benefit: 75% = \$139.20 85% = \$157.80	
		SS LACERATION OF EAR, EYELID, NOSE OR LIP, repair of, we layer of tissue (Anaes.) (Assist.)	ith accurate
30052	Fee: \$254.00	Benefit: 75% = \$190.50 85% = \$215.90	
	WOUNDS, DRESSING OF, under general anaesthesia, with or without removal of sutures, not being a service associated with a service to which another item in this Group applies (Anaes.)		
30055	Fee: \$73.90	Benefit: 75% = \$55.45 85% = \$62.85	
	POSTOPERATIV procedure (Anaes	E HAEMORRHAGE, control of, under general anaesthesia, as an ir)	ndependent
30058	Fee: \$144.35	Benefit: 75% = \$108.30 85% = \$122.70	
	SUPERFICIAL Findependent proces	OREIGN BODY, REMOVAL OF, (including from cornea or sclera) dure (Anaes.)), as an
30061	Fee: \$23.50	Benefit: 75% = \$17.65 85% = \$20.00	
	Etonogestrel subc	utaneous implant, removal of, as an independent procedure (Anaes.)	
30062	Fee: \$60.75	Benefit: 75% = \$45.60 85% = \$51.65	
		US FOREIGN BODY, removal of, requiring incision and exploration rmed, as an independent procedure (Anaes.)	, including closure
30064	Fee: \$109.90	Benefit: 75% = \$82.45 85% = \$93.45	
	FOREIGN BODY procedure (Anaes	IN MUSCLE, TENDON OR OTHER DEEP TISSUE, removal of, (Assist.)	as an independent
30068	Fee: \$276.80	Benefit: 75% = \$207.60 85% = \$235.30	

T8. SUF	RGICAL OPERATIONS 1. GENERAL
	Diagnostic biopsy of skin, as an independent procedure, if the biopsy specimen is sent for pathological examination (Anaes.)
30071	(See para TN.8.7 of explanatory notes to this Category) Fee: \$52.20 Benefit: 75% = \$39.15 Extended Medicare Safety Net Cap: \$41.80
50071	Diagnostic biopsy of mucous membrane, as an independent procedure, if the biopsy specimen is sent for pathological examination (Anaes.)
30072	(See para TN.8.7 of explanatory notes to this Category) Fee: \$52.20 Benefit: 75% = \$39.15 85% = \$44.40
	DIAGNOSTIC BIOPSY OF LYMPH GLAND, MUSCLE OR OTHER DEEP TISSUE OR ORGAN, as an independent procedure, if the biopsy specimen is sent for pathological examination (Anaes.)
30075	Fee: \$149.75 Benefit: 75% = \$112.35 85% = \$127.30
	DIAGNOSTIC DRILL BIOPSY OF LYMPH GLAND, DEEP TISSUE OR ORGAN, as an independent procedure, where the biopsy specimen is sent for pathological examination (Anaes.)
30078	(See para TN.8.7 of explanatory notes to this Category) Fee: \$48.45 Benefit: 75% = \$36.35 85% = \$41.20
	DIAGNOSTIC BIOPSY OF BONE MARROW by trephine using open approach, where the biopsy specimen is sent for pathological examination (Anaes.)
30081	(See para TN.8.7 of explanatory notes to this Category) Fee: \$109.90 Benefit: 75% = \$82.45 85% = \$93.45
	DIAGNOSTIC BIOPSY OF BONE MARROW by trephine using percutaneous approach where the biopsy is sent for pathological examination (Anaes.)
30084	(See para TN.8.7 of explanatory notes to this Category) Fee: $$58.80$ Benefit: $75\% = 44.10 $85\% = 50.00
	DIAGNOSTIC BIOPSY OF BONE MARROW by aspiration or PUNCH BIOPSY OF SYNOVIAL MEMBRANE, where the biopsy is sent for pathological examination (Anaes.)
30087	(See para TN.8.7 of explanatory notes to this Category) Fee: \$29.45 Benefit: 75% = \$22.10 85% = \$25.05
	DIAGNOSTIC BIOPSY OF PLEURA, PERCUTANEOUS 1 or more biopsies on any 1 occasion, where the biopsy is sent for pathological examination (Anaes.)
30090	(See para TN.8.7 of explanatory notes to this Category) Fee: \$128.55 Benefit: 75% = \$96.45 85% = \$109.30
	DIAGNOSTIC NEEDLE BIOPSY OF VERTEBRA, where the biopsy is sent for pathological examination (Anaes.)
30093	(See para TN.8.7 of explanatory notes to this Category) Fee: \$171.55 Benefit: 75% = \$128.70 85% = \$145.85
	DIAGNOSTIC PERCUTANEOUS ASPIRATION BIOPSY of deep organ using interventional imaging techniques - but not including imaging, where the biopsy is sent for pathological examination (Anaes.)
30094	(See para TN.8.7 of explanatory notes to this Category) Fee: \$189.40 Benefit: 75% = \$142.05 85% = \$161.00
30096	DIAGNOSTIC SCALENE NODE BIOPSY, by open procedure, where the specimen excised is sent for

T8. SUF	RGICAL OPERATIONS 1. GEN	ERAL
	pathological examination (Anaes.)	
	(See para TN.8.7 of explanatory notes to this Category) Fee: \$183.90 Benefit: 75% = \$137.95 85% = \$156.35	
	Personal performance of a Synacthen Stimulation Test, including associated consultation; by a mer practitioner with resuscitation training and access to facilities where life support procedures can be implemented, if:	
	 serum cortisol at 0830-0930 hours on any day in the preceding month has been measured greater than 100 nmol/L but less than 400 nmol/L; or in a patient who is acutely unwell and adrenal insufficiency is suspected. 	at
30097	(See para TN.8.139 of explanatory notes to this Category) Fee: \$97.15 Benefit: 75% = \$72.90 85% = \$82.60	
	SINUS, excision of, involving superficial tissue only (Anaes.)	
30099	Fee: \$90.00 Benefit: 75% = \$67.50 85% = \$76.50	
	SINUS, excision of, involving muscle and deep tissue (Anaes.)	
30103	Fee: \$183.90 Benefit: 75% = \$137.95 85% = \$156.35	
	PRE-AURICULAR SINUS, on a person 10 years of age or over. Excision of, (Anaes.)	
30104	Fee: \$126.90 Benefit: 75% = \$95.20 85% = \$107.90	
	PRE-AURICULAR SINUS, on a person under 10 years of age. Excision of, (Anaes.)	
30105	Fee: \$164.95 Benefit: 75% = \$123.75 85% = \$140.25	
	GANGLION OR SMALL BURSA, excision of, other than a service associated with a service to wanother item in this Group applies (Anaes.)	hich
30107	Fee: \$219.95 Benefit: 75% = \$165.00 85% = \$187.00	
	BURSA (LARGE), INCLUDING OLECRANON, CALCANEUM OR PATELLA, excision of (A (Assist.)	naes.)
30111	Fee: \$371.50 Benefit: 75% = \$278.65 85% = \$315.80	
	BURSA, SEMIMEMBRANOSUS (Baker's cyst), excision of (Anaes.) (Assist.)	
30114	Fee: \$371.50 Benefit: 75% = \$278.65	
	Lipectomy, wedge excision of abdominal apron that is a direct consequence of significant weight I not being a service associated with a service to which item 30168, 30171, 30172, 30176, 30177, 3045530, 45564 or 45565 applies, if:	
	(a) there is intertrigo or another skin condition that risks loss of skin integrity and has failed 3 mon conventional (or non surgical) treatment; and	ths of
	(b) the abdominal apron interferes with the activities of daily living; and	
	(c) the weight has been stable for at least 6 months following significant weight loss prior to the lipectomy	
	(H) (Anaes.) (Assist.)	
30165	(See para TN.8.8 of explanatory notes to this Category)	

T8. SUF	RGICAL OPERATIONS	1. GENERAL
	Fee: \$454.85 Benefit: 75% = \$341.15	
	Lipectomy, wedge excision of redundant non abdominal skin and fat that is a direct significant weight loss, not being a service associated with a service to which item 30172, 30176, 30177, 30179, 45530, 45564 or 45565 applies, if:	
	(a) there is intertrigo or another skin condition that risks loss of skin integrity and has conventional (or non surgical) treatment; and	as failed 3 months of
	(b) the redundant skin and fat interferes with the activities of daily living; and	
	(c) the weight has been stable for at least 6 months following significant weight loss lipectomy; and	s prior to the
	(d) the procedure involves 1 excision only	
	(H) (Anaes.) (Assist.)	
30168	(See para TN.8.8 of explanatory notes to this Category) Fee: \$454.85 Benefit: 75% = \$341.15	
	Lipectomy, wedge excision of redundant non abdominal skin and fat that is a direct significant weight loss, not being a service associated with a service to which item 3 30176, 30177, 30179, 45530, 45564 or 45565 applies, if:	
	(a) there is intertrigo or another skin condition that risks loss of skin integrity and has conventional (or non surgical) treatment; and	as failed 3 months of
	(b) the redundant skin and fat interferes with the activities of daily living; and	
	(c) the weight has been stable for at least 6 months following significant weight loss lipectomy; and	s prior to the
	(d) the procedure involves 2 excisions only	
	(H) (Anaes.) (Assist.)	
30171	(See para TN.8.8 of explanatory notes to this Category) Fee: \$691.75 Benefit: 75% = \$518.85	
	Lipectomy, wedge excision of redundant non abdominal skin and fat that is a direct significant weight loss, not being a service associated with a service to which item 3 30176, 30177, 30179, 45530, 45564 or 45565 applies, if:	
	(a) there is intertrigo or another skin condition that risks loss of skin integrity and h conventional (or non surgical) treatment; and	as failed 3 months of
	(b) the redundant skin and fat interferes with the activities of daily living; and	
	(c) the weight has been stable for at least 6 months following significant weight loss lipectomy; and	s prior to the
	(d) the procedure involves 3 or more excisions	
	(H) (Anaes.) (Assist.)	
30172	(See para TN.8.8 of explanatory notes to this Category) Fee: \$691.75 Benefit: 75% = \$518.85	

T8. SUF	RGICAL OPERATIONS 1. GENERAL		
	Lipectomy, radical abdominoplasty (Pitanguy type or similar), with excision of skin and subcutaneous tissue, repair of musculoaponeurotic layer and transposition of umbilicus, not being a service associated with a service to which item 30165, 30168, 30171, 30172, 30177, 30179, 45530, 45564 or 45565 applies, if the patient has previously had a massive intra-abdominal or pelvic tumour surgically removed (Anaes.) (Assist.)		
30176	(See para TN.8.8 of explanatory notes to this Category) Fee: \$985.70 Benefit: 75% = \$739.30		
	Lipectomy, excision of skin and subcutaneous tissue associated with redundant abdominal skin and fat that is a direct consequence of significant weight loss, in conjunction with a radical abdominoplasty (Pitanguy type or similar), with or without repair of musculoaponeurotic layer and transposition of umbilicus, not being a service associated with a service to which item 30165, 30168, 30171, 30172, 30176, 30179, 45530, 45564 or 45565 applies, if:		
	(a) there is intertrigo or another skin condition that risks loss of skin integrity and has failed 3 months of conventional (or non surgical) treatment; and		
	(b) the redundant skin and fat interferes with the activities of daily living; and		
	(c) the weight has been stable for at least 6 months following significant weight loss prior to the lipectomy		
	(H) (Anaes.) (Assist.)		
30177	(See para TN.8.8 of explanatory notes to this Category) Fee: \$985.70 Benefit: 75% = \$739.30		
	Circumferential lipectomy, as an independent procedure, to correct circumferential excess of redundant skin and fat that is a direct consequence of significant weight loss, with or without a radical abdominoplasty (Pitanguy type or similar), not being a service associated with a service to which item 30165, 30168, 30171, 30172, 30176, 30177, 45530, 45564 or 45565 applies, if:		
	(a) the circumferential excess of redundant skin and fat is complicated by intertrigo or another skin condition that risks loss of skin integrity and has failed 3 months of conventional (or non surgical) treatment; and		
	(b) the circumferential excess of redundant skin and fat interferes with the activities of daily living; and		
	(c) the weight has been stable for at least 6 months following significant weight loss prior to the lipectomy		
	(H) (Anaes.) (Assist.)		
30179	(See para TN.8.8 of explanatory notes to this Category) Fee: \$1,213.15 Benefit: 75% = \$909.90		
	AXILLARY HYPERHIDROSIS, partial excision for (Anaes.)		
30180	Fee: \$136.50 Benefit: 75% = \$102.40 85% = \$116.05		
	AXILLARY HYPERHIDROSIS, total excision of sweat gland bearing area (Anaes.)		
30183	Fee: \$246.50 Benefit: 75% = \$184.90 85% = \$209.55		
30187	PALMAR OR PLANTAR WARTS, removal of, by carbon dioxide laser or erbium laser, requiring admission to a hospital, or when performed by a specialist in the practice of his/her specialty, (5 or more warts) (Anaes.)		
2010/			

10. 501	RGICAL OPERATIONS	1. GENERAL
	(See para TN.8.9 of explanatory notes to this Category) Fee: \$256.95 Benefit: 75% = \$192.75 85% = \$218.45	
	WARTS or MOLLUSCUM CONTAGIOSUM (one or more), removal of, by any chemical means), where undertaken in the operating theatre of a hospital, not being with a service to which another item in this Group applies (H) (Anaes.)	
30189	(See para TN.8.9 of explanatory notes to this Category) Fee: \$147.30 Benefit: 75% = \$110.50	
	Angiofibromas, trichoepitheliomas or other severely disfiguring tumours of the factomelanocytic naevi, sebaceous hyperplasia, dermatosis papulosa nigra, Campbell D and seborrheic or viral warts), suitable for laser ablation as confirmed by the opinion the specialty of dermatology—removal of, by carbon dioxide laser or erbium laser associated resurfacing (10 or more tumours) (Anaes.)	e Morgan angiomas on of a specialist in
30190	Fee: \$397.75 Benefit: 75% = \$298.35 85% = \$338.10	
	Angiofibromas, trichoepithelioma, epidermal naevi, xanthelasma, pyogenic granul angiokeratomas, hereditary haemorrhagic telangiectasia and other severely disfiguibleeding tumours (excluding melanocytic naevi, sebaceous hyperplasia, dermatosis Campbell De Morgan angiomas and seborrheic or viral warts), treatment of, with or other appropriate laser (or curettage and fine point diathermy for pyogenic granu confirmed by the opinion of a specialist in the specialty of dermatology, one or more	ring or recurrently s papulosa nigra, carbon dioxide/erbium uloma only), if
30191	Fee: \$63.50 Benefit: 75% = \$47.65 85% = \$54.00	
	PREMALIGNANT SKIN LESIONS (including solar keratoses), treatment of, by a or more lesions) (Anaes.) (See para TN.8.9 of explanatory notes to this Category)	ablative technique (10
30192	Fee: \$39.55 Benefit: 75% = \$29.70 85% = \$33.65	
	Malignant neoplasm of skin or mucous membrane that has been:	
	(a) proven by histopathology; or	
	(b) confirmed by the opinion of a specialist in the specialty of dermatology where submitted for histologic confirmation;	a specimen has been
	removal of, by serial curettage, or carbon dioxide laser or erbium laser excision-ab associated cryotherapy or diathermy (Anaes.)	lation, including any
30196	(See para TN.8.10 of explanatory notes to this Category) Fee: \$126.30 Benefit: 75% = \$94.75 85% = \$107.40	
	Malignant neoplasm of skin or mucous membrane proven by histopathology or cor of a specialist in the specialty of dermatology—removal of, by liquid nitrogen cryo freeze thaw cycles	
30202	(See para TN.8.10 of explanatory notes to this Category) Fee: \$48.35 Benefit: 75% = \$36.30 85% = \$41.10	
	Skin lesions, multiple injections with glucocorticoid preparations (Anaes.)	
30207	Fee: \$44.60 Benefit: 75% = \$33.45 85% = \$37.95	
	Keloid and other skin lesions, extensive, multiple injections of glucocorticoid prep in the operating theatre of a hospital on a patient less than 16 years of age (Anaes.)	
30210	Fee: \$162.95 Benefit: 75% = \$122.25	

RGICAL OPERAT	IONS 1. GENERAL
НАЕМАТОМА	, aspiration of (Anaes.)
Fee: \$27.35	Benefit: 75% = \$20.55 85% = \$23.25
	, FURUNCLE, SMALL ABSCESS OR SIMILAR LESION not requiring admission to ISION WITH DRAINAGE OF (excluding aftercare)
(See para TN.8.4 o Fee: \$27.35	of explanatory notes to this Category) Benefit: 75% = \$20.55 85% = \$23.25
	ATOMA, LARGE ABSCESS, CARBUNCLE, CELLULITIS or similar lesion, sion to a hospital, INCISION WITH DRAINAGE OF (excluding aftercare) (Anaes.)
(See para TN.8.4 o Fee: \$162.95	of explanatory notes to this Category) Benefit: 75% = \$122.25
	US DRAINAGE OF DEEP ABSCESS using interventional imaging techniques - but aging (Anaes.)
Fee: \$237.60	Benefit: 75% = \$178.20 85% = \$202.00
	INAGE TUBE, exchange of using interventional imaging techniques - but not including)
Fee: \$267.65	Benefit: 75% = \$200.75 85% = \$227.55
MUSCLE, excis	ion of (LIMITED), or fasciotomy (Anaes.)
Fee: \$149.75	Benefit: 75% = \$112.35 85% = \$127.30
MUSCLE, excis	ion of (EXTENSIVE) (Anaes.) (Assist.)
Fee: \$272.95	Benefit: 75% = \$204.75 85% = \$232.05
MUSCLE, RUP	TURED, repair of (limited), not associated with external wound (Anaes.)
Fee: \$223.60	Benefit: 75% = \$167.70 85% = \$190.10
MUSCLE, RUP	TURED, repair of (extensive), not associated with external wound (Anaes.) (Assist.)
Fee: \$295.70	Benefit: 75% = \$221.80 85% = \$251.35
FASCIA, DEEP	, repair of, FOR HERNIATED MUSCLE (Anaes.)
Fee: \$149.75	Benefit: 75% = \$112.35 85% = \$127.30
	R, INNOCENT, excision of, not being a service to which another item in this Group (Assist.)
Fee: \$356.35	Benefit: 75% = \$267.30 85% = \$302.90
STYLOID PRO	CESS OF TEMPORAL BONE, removal of (Anaes.) (Assist.)
Fee: \$356.35	Benefit: 75% = \$267.30
PAROTID DUC	T, repair of, using micro-surgical techniques (Anaes.) (Assist.)
Fee: \$689.80	Benefit: 75% = \$517.35
PAROTID GLA	ND, total extirpation of (Anaes.) (Assist.)
Fee: \$739.35	Benefit: 75% = \$554.55
	ND, total extirpation of, with preservation of facial nerve (Anaes.) (Assist.)
	HAEMATOMA Fee: \$27.35 HAEMATOMA a hospital - INCI (See para TN.8.4 or Fee: \$27.35 LARGE HAEM requiring admiss (See para TN.8.4 or Fee: \$162.95 PERCUTANEO not including imaging (Anaes.) Fee: \$237.60 ABSCESS DRA imaging (Anaes.) Fee: \$267.65 MUSCLE, excis Fee: \$149.75 MUSCLE, excis Fee: \$272.95 MUSCLE, RUP Fee: \$223.60 MUSCLE, RUP Fee: \$295.70 FASCIA, DEEP Fee: \$149.75 BONE TUMOU applies (Anaes.) Fee: \$356.35 STYLOID PROCE Fee: \$356.35 PAROTID DUC Fee: \$689.80 PAROTID GLA

T8. SUF	RGICAL OPERATI	ONS 1. GENERAL
	Fee: \$1,251.10	Benefit: 75% = \$938.35
	RECURRENT PA	AROTID TUMOUR, excision of, with preservation of facial nerve (Anaes.) (Assist.)
30251	Fee: \$1,921.75	Benefit: 75% = \$1441.35 85% = \$1838.35
		ND, SUPERFICIAL LOBECTOMY OF, with exposure of facial nerve (Anaes.)
30253	Fee: \$834.05	Benefit: 75% = \$625.55
	SUBMANDIBUI	LAR DUCTS, relocation of, for surgical control of drooling (Anaes.) (Assist.)
30255	Fee: \$1,110.65	Benefit: 75% = \$833.00
30233		LAR GLAND, extirpation of (Anaes.) (Assist.)
30256	Fee: \$445.40	Benefit: 75% = \$334.05
30230	<u> </u>	GLAND, extirpation of (Anaes.)
30259	Fee: \$198.50	Benefit: 75% = \$148.90 85% = \$168.75
	SALIVARY GLA	AND, DILATATION OR DIATHERMY of duct (Anaes.)
30262	Fee: \$58.80	Benefit: 75% = \$44.10 85% = \$50.00
	Salivary gland, reprocedures. (Ana	emoval of calculus from duct or meatotomy or marsupialisation, 1 or more such es.)
30266	Fee: \$149.75	Benefit: 75% = \$112.35 85% = \$127.30
	SALIVARY GLA	AND, repair of CUTANEOUS FISTULA OF (Anaes.)
30269	Fee: \$149.75	Benefit: 75% = \$112.35 85% = \$127.30
	TONGUE, partia	l excision of (Anaes.) (Assist.)
30272	Fee: \$295.70	Benefit: 75% = \$221.80 85% = \$251.35
		ISION OF INTRAORAL TUMOUR INVOLVING RESECTION OF MANDIBLE
	AND LYMPH G	LANDS OF NECK (commandotype operation) (Anaes.) (Assist.)
30275	Fee: \$1,762.75	Benefit: 75% = \$1322.10
	TONGUE TIE, re	epair of, not being a service to which another item in this Group applies (Anaes.)
30278	Fee: \$46.50	Benefit: 75% = \$34.90 85% = \$39.55
	TONGUE TIE, N	MANDIBULAR FRENULUM or MAXILLARY FRENULUM, repair of, in a person over, under general anaesthesia (Anaes.)
30281	Fee: \$119.50	Benefit: 75% = \$89.65 85% = \$101.60
		UCOUS CYST OF MOUTH, removal of (Anaes.)
30283	Fee: \$204.70	Benefit: 75% = \$153.55 85% = \$174.00
20203		YST, on a person 10 years of age or over. Removal of, (Anaes.) (Assist.)
20207		
30286	Fee: \$397.85	Benefit: 75% = \$298.40 85% = \$338.20 YST, on a person under 10 years of age. Removal of, (Anaes.) (Assist.)
30287	Fee: \$517.20	Benefit: 75% = \$387.90 85% = \$439.65

T8. SUF	RGICAL OPERATIONS	1. GENERAL
	BRANCHIAL FISTULA, on a person 10 years of age or over. Removal	of, (Anaes.) (Assist.)
30289	Fee: \$502.25 Benefit: 75% = \$376.70	
30203	CERVICAL OESOPHAGOSTOMY or CLOSURE OF CERVICAL OES without plastic repair (Anaes.) (Assist.)	OPHAGOSTOMY with or
30293	Fee: \$445.40 Benefit: 75% = \$334.05 85% = \$378.60	
	CERVICAL OESOPHAGECTOMY with tracheostomy and oesophagostoreconstruction; or LARYNGOPHARYNGECTOMY with tracheostomy a (Anaes.) (Assist.)	
30294	Fee: \$1,762.75 Benefit: 75% = \$1322.10	
	THYROIDECTOMY, total (Anaes.) (Assist.)	
30296	(See para TN.8.137 of explanatory notes to this Category) Fee: \$1,023.70 Benefit: 75% = \$767.80	
	THYROIDECTOMY following previous thyroid surgery (Anaes.) (Assist	t.)
30297	(See para TN.8.138 of explanatory notes to this Category) Fee: \$1,023.70 Benefit: 75% = \$767.80	
	SENTINEL LYMPH NODE BIOPSY OR BIOPSIES for breast cancer, in axilla, using preoperative lymphoscintigraphy and lymphotropic dye inject associated with a service to which item 30300, 30302 or 30303 applies (A (See para TN.8.12 of explanatory notes to this Category)	etion, not being a service
30299	Fee: \$637.45 Benefit: 75% = \$478.10	
	SENTINEL LYMPH NODE BIOPSY OR BIOPSIES for breast cancer, in III/III axilla, using preoperative lymphoscintigraphy and lymphotropic dye associated with a service to which item 30299, 30302 or 30303 applies (A	injection, not being a service
30300	(See para TN.8.12 of explanatory notes to this Category) Fee: \$764.90 Benefit: 75% = \$573.70	
	SENTINEL LYMPH NODE BIOPSY OR BIOPSIES for breast cancer, in axilla, using lymphotropic dye injection, not being a service associated wi 30299, 30300 or 30303 applies (Anaes.) (Assist.)	
30302	(See para TN.8.12 of explanatory notes to this Category) Fee: \$509.95 Benefit: 75% = \$382.50	
	SENTINEL LYMPH NODE BIOPSY OR BIOPSIES for breast cancer, in II/III axilla, using lymphotropic dye injection, not being a service associatitem 30299, 30300 or 30302 applies (Anaes.) (Assist.)	
30303	(See para TN.8.12 of explanatory notes to this Category) Fee: \$611.85 Benefit: 75% = \$458.90	
_	TOTAL HEMITHYROIDECTOMY (Anaes.) (Assist.)	
30306	(See para TN.8.137, TN.8.138 of explanatory notes to this Category) Fee: \$798.65 Benefit: 75% = \$599.00	
	Partial or subtotal thyroidectomy (Anaes.) (Assist.)	
30310	(See para TN.8.137 of explanatory notes to this Category) Fee: \$798.65 Benefit: 75% = \$599.00	

T8. SUF	RGICAL OPERATIO	NS	1. GENERAL
		CYST or FISTULA or both, on a person 10 years of age or over. glossal duct and portion of hyoid bone (Anaes.) (Assist.)	Radical removal
30314	Fee: \$457.40	Benefit: 75% = \$343.05	
		parathyroidectomy. Removal of 1 or more parathyroid adenoma to an image localised adenoma, including thymectomy.	through a small
	For any particular p	atient - applicable only once per occasion on which the service is	provided.
	Not in association v	with a service to which item 30318, 30317 or 30320 applies. (Anac	es.) (Assist.)
30315	Fee: \$1,139.90	Benefit: 75% = \$854.95	
	Redo parathyroidectomy. Cervical re-exploration for persistent or recurrent hyperparathyroidism, including thymectomy and cervical exploration of the mediastinum.		
	For any particular p	atient - applicable only once per occasion on which the service is	provided.
	Not in association v	with a service to which item 30315, 30318 or 30320 applies. (Anac	es.) (Assist.)
30317	Fee: \$1,364.90	Benefit: 75% = \$1023.70	
		ctomy, exploration and removal of 1 or more adenoma or hyperplached the cluding thymectomy and cervical exploration of the mediastinum	
	For any particular p	atient - applicable only once per occasion on which the service is	provided.
	Not in association v	with a service to which item 30315, 30317 or 30320 applies. (Anac	es.) (Assist.)
30318	Fee: \$1,139.90	Benefit: 75% = \$854.95	
	Removal of a media	astinal parathyroid adenoma via sternotomy or mediastinal thorasc	copic approach.
	For any particular p	atient - applicable only once per occasion on which the service is	provided.
	Not in association v	with a service to which item 30315, 30317 or 30318 applies. (Anac	es.) (Assist.)
30320	Fee: \$1,364.90	Benefit: 75% = \$1023.70	
	Excision of phaeoc (Anaes.) (Assist.)	hromocytoma or extraadrenal paraganglioma via endoscopic or op	en approach.
30323	Fee: \$1,364.90	Benefit: 75% = \$1023.70	
	Excision of an adre	nocortical tumour or hyperplasia via endoscopic or open approach	n. (Anaes.) (Assist.)
30324	Fee: \$1,364.90	Benefit: 75% = \$1023.70	
		CYST or FISTULA or both, radical removal of, including thyrogne, on a person under 10 years of age (Anaes.) (Assist.)	glossal duct and
30326	Fee: \$594.60	Benefit: 75% = \$445.95	
	LYMPH GLANDS	of GROIN, limited excision of (Anaes.)	
30329	Fee: \$246.95	Benefit: 75% = \$185.25 85% = \$209.95	
	LYMPH GLANDS	of GROIN, radical excision of (Anaes.) (Assist.)	
30330	Fee: \$718.75	Benefit: 75% = \$539.10	

RGICAL OPERATIONS 1. GENERAL
LYMPH NODES of AXILLA, limited excision of (sampling) (Anaes.) (Assist.)
Fee: \$346.75 Benefit: 75% = \$260.10
LYMPH NODES of AXILLA, complete excision of, to level I (Anaes.) (Assist.)
(See para TN.8.13 of explanatory notes to this Category) Fee: \$866.85 Benefit: 75% = \$650.15
LYMPH NODES of AXILLA, complete excision of, to level II or level III (Anaes.) (Assist.)
(See para TN.8.13 of explanatory notes to this Category)
Fee: \$1,040.25 Benefit: 75% = \$780.20
LAPAROTOMY (exploratory), including associated biopsies, where no other intra-abdominal procedure is performed (Anaes.) (Assist.)
Fee: \$483.25 Benefit: 75% = \$362.45
Caecostomy, Enterostomy, Colostomy, Enterotomy, Colotomy, Cholecystostomy, Gastrostomy, Gastrotomy, on a person 10 years of age or over. Reduction of intussusception, Removal of Meckel's diverticulum, Suture of perforated peptic ulcer, Simple repair of ruptured viscus, Reduction of volvulus, Pyloroplasty (adult) or Drainage of pancreas (Anaes.) (Assist.)
(See para TN.8.14 of explanatory notes to this Category) Fee: \$521.25 Benefit: 75% = \$390.95
LAPAROTOMY INVOLVING DIVISION OF PERITONEAL ADHESIONS (where no other intraabdominal procedure is performed) on a person 10 years of age or over (Anaes.) (Assist.)
Fee: \$521.25 Benefit: 75% = \$390.95
LAPAROTOMY involving division of adhesions in conjunction with another intraabdominal procedure where the time taken to divide the adhesions is between 45 minutes and 2 hours, on a person 10 years of age or over (Anaes.) (Assist.)
Fee: \$523.70 Benefit: 75% = \$392.80
LAPAROTOMY WITH DIVISION OF EXTENSIVE ADHESIONS (duration greater than 2 hours) with or without insertion of long intestinal tube (Anaes.) (Assist.)
Fee: \$928.15 Benefit: 75% = \$696.15
ENTEROCUTANEOUS FISTULA, radical repair of, involving extensive dissection and resection of bowel (Anaes.) (Assist.)
Fee: \$1,306.90 Benefit: 75% = \$980.20
LAPAROTOMY FOR GRADING OF LYMPHOMA, including splenectomy, liver biopsies, lymph node biopsies and oophoropexy (Anaes.) (Assist.)
Fee: \$1,099.40 Benefit: 75% = \$824.55
LAPAROTOMY FOR CONTROL OF POSTOPERATIVE HAEMORRHAGE, where no other procedure is performed (Anaes.) (Assist.)
Fee: \$563.30 Benefit: 75% = \$422.50
Fee: \$563.30 Benefit: 75% = \$422.50 LAPAROTOMY INVOLVING OPERATION ON ABDOMINAL VISCERA (including pelvic viscera), not being a service to which another item in this Group applies (Anaes.) (Assist.)

T8. SUF	JRGICAL OPERATIONS	1. GENERAL
	LAPAROTOMY for trauma involving 3 or more organs (Anaes.) (Assist.)	
30388	Fee: \$1,597.55 Benefit: 75% = \$1198.20	
	LAPAROSCOPY, diagnostic, not being a service associated with any other laparoscopi person 10 years of age or over (Anaes.)	c procedure, on a
30390	(See para TN.8.15 of explanatory notes to this Category) Fee: \$219.95 Benefit: 75% = \$165.00	
	LAPAROSCOPY with biopsy (Anaes.) (Assist.)	
30391	Fee: \$284.35 Benefit: 75% = \$213.30	
	RADICAL OR DEBULKING OPERATION for advanced intra-abdominal malignancy omentectomy, as an independent procedure (Anaes.) (Assist.)	, with or without
30392	Fee: \$674.50 Benefit: 75% = \$505.90	
	LAPAROSCOPIC DIVISION OF ADHESIONS in association with another intra-abdowhere the time taken to divide the adhesions exceeds 45 minutes (Anaes.) (Assist.)	minal procedure
30393	Fee: \$523.70 Benefit: 75% = \$392.80	
	LAPAROTOMY for drainage of subphrenic abscess, pelvic abscess, appendiceal abscess appendix or for peritonitis from any cause, with or without appendicectomy (Anaes.) (A	
30394	Fee: \$492.85 Benefit: 75% = \$369.65	
	LAPAROTOMY for gross intra peritoneal sepsis requiring debridement of fibrin, with or removal of foreign material or enteric contents, with lavage of the entire peritoneal cavit abdominal incision, with or without closure of abdomen and with or without mesh or zij (Anaes.) (Assist.)	ty via a major
30396	(See para TN.8.16 of explanatory notes to this Category) Fee: \$1,016.55 Benefit: 75% = \$762.45	
	LAPAROSTOMY, via wound previously made and left open or closed with zipper, invedressings or packs, and with or without drainage of loculated collections (Anaes.)	olving change of
30397	Fee: \$232.35 Benefit: 75% = \$174.30	
	LAPAROSTOMY, final closure of wound made at previous operation, after removal of packs and removal of mesh or zipper if previously inserted (Anaes.) (Assist.)	dressings or
30399	Fee: \$319.60 Benefit: 75% = \$239.70	
	LAPAROTOMY WITH INSERTION OF PORTACATH for administration of cytotoxi including placement of reservoir (Anaes.) (Assist.)	c therapy
30400	Fee: \$632.50 Benefit: 75% = \$474.40	
	RETROPERITONEAL ABSCESS, drainage of, not involving laparotomy (Anaes.) (As	sist.)
30402	Fee: \$464.60 Benefit: 75% = \$348.45	
	VENTRAL, INCISIONAL, OR RECURRENT HERNIA OR BURST ABDOMEN, rep without mesh (Anaes.) (Assist.)	air of with or
30403	Fee: \$521.25 Benefit: 75% = \$390.95	
	VENTRAL OR INCISIONAL HERNIA, (excluding recurrent inguinal or femoral herni	

T8. SUF	RGICAL OPERATION	NS 1. GENERAL
	requiring muscle tra	nsposition, mesh hernioplasty or resection of strangulated bowel (Anaes.) (Assist.)
	Fee: \$914.95	Benefit: 75% = \$686.25
	PARACENTESIS A	ABDOMINIS (Anaes.)
30406	Fee: \$52.20	Benefit: 75% = \$39.15 85% = \$44.40
	PERITONEOVENO	OUS shunt, insertion of (Anaes.) (Assist.)
30408	Fee: \$392.10	Benefit: 75% = \$294.10
	LIVER BIOPSY, pe	ercutaneous (Anaes.)
30409	Fee: \$174.45	Benefit: 75% = \$130.85 85% = \$148.30
	LIVER BIOPSY by procedure (Anaes.)	wedge excision when performed in conjunction with another intraabdominal
30411	Fee: \$88.80	Benefit: 75% = \$66.60
	LIVER BIOPSY by (Anaes.)	core needle, when performed in conjunction with another intra-abdominal procedure
30412	Fee: \$52.35	Benefit: 75% = \$39.30 85% = \$44.50
	LIVER, subsegment	tal resection of, (local excision), other than for trauma (Anaes.) (Assist.)
30414	Fee: \$689.80	Benefit: 75% = \$517.35
	LIVER, segmental r	resection of, other than for trauma (Anaes.) (Assist.)
30415	Fee: \$1,379.50	Benefit: 75% = \$1034.65
	LIVER CYST, lapa diameter (Anaes.) (A	roscopic marsupialisation of, where the size of the cyst is greater than 5cm in Assist.)
30416	Fee: \$748.95	Benefit: 75% = \$561.75
	LIVER CYSTS, lap diameter (Anaes.) (A	aroscopic marsupialisation of 5 or more, including any cyst greater than 5cm in Assist.)
30417	Fee: \$1,123.40	Benefit: 75% = \$842.55
	LIVER, lobectomy	of, other than for trauma (Anaes.) (Assist.)
30418	Fee: \$1,597.55	Benefit: 75% = \$1198.20
		, destruction of, by hepatic cryotherapy, not being a service associated with a service or 50952 applies (Anaes.) (Assist.)
30419	Fee: \$817.10	Benefit: 75% = \$612.85 85% = \$733.70
	LIVER, TRI-SEGM (Assist.)	ENTAL RESECTION (extended lobectomy) of, other than for trauma (Anaes.)
30421	Fee: \$1,996.55	Benefit: 75% = \$1497.45
	LIVER, repair of su	perficial laceration of, for trauma (Anaes.) (Assist.)
30422	Fee: \$675.35	Benefit: 75% = \$506.55
30425	LIVER, repair of de	ep multiple lacerations of, or debridement of, for trauma (Anaes.) (Assist.)

RGICAL OPERATION	ONS 1. GENERAL			
Fee: \$1,306.90	Benefit: 75% = \$980.20			
LIVER, segmenta	ll resection of, for trauma (Anaes.) (Assist.)			
Fee: \$1,560.95	Benefit: 75% = \$1170.75			
LIVER, lobectomy of, for trauma (Anaes.) (Assist.)				
Fee: \$1,670.00	Benefit: 75% = \$1252.50 85% = \$1586.60			
LIVER, extended	lobectomy (tri-segmental resection) of, for trauma (Anaes.) (Assist.)			
Fee: \$2,323.30	Benefit: 75% = \$1742.50 85% = \$2239.90			
LIVER ABSCES	S, open abdominal drainage of (Anaes.) (Assist.)			
Fee: \$521.25	Benefit: 75% = \$390.95 85% = \$443.10			
LIVER ABSCES	S (multiple), open abdominal drainage of (Anaes.) (Assist.)			
Fee: \$726.05	Benefit: 75% = \$544.55			
	OF LIVER, peritoneum or viscus, complete removal of contents of, with or without adicles (Anaes.) (Assist.)			
Fee: \$588.15	Benefit: 75% = \$441.15			
	OF LIVER, peritoneum or viscus, complete removal of contents of, with or without adicles, with omentoplasty or myeloplasty (Anaes.) (Assist.)			
Fee: \$653.45	Benefit: 75% = \$490.10			
	OF LIVER, total excision of, by cysto-pericystectomy (membrane plus fibrous wall)			
Fee: \$813.30	Benefit: 75% = \$610.00			
HYDATID CYST	OF LIVER, excision of, with drainage and excision of liver tissue (Anaes.) (Assist.)			
Fee: \$1,150.85	Benefit: 75% = \$863.15 85% = \$1067.45			
OPERATIVE UL	OLANGIOGRAPHY OR OPERATIVE PANCREATOGRAPHY OR INTRA TRASOUND of the biliary tract (including 1 or more examinations performed during Anaes.) (Assist.)			
Fee: \$185.60	Benefit: 75% = \$139.20			
interventional ima	AAM, percutaneous transhepatic, and insertion of biliary drainage tube, using aging techniques - but not including imaging, not being a service associated with a tem 30451 applies (Anaes.) (Assist.)			
Fee: \$526.40	Benefit: 75% = \$394.80 85% = \$447.45			
INTRA OPERAT	TVE ULTRASOUND for staging of intra abdominal tumours (Anaes.)			
Fee: \$136.25	Benefit: 75% = \$102.20			
CHOLEDOCHOS	SCOPY in conjunction with another procedure (Anaes.)			
Fee: \$185.60	Benefit: 75% = \$139.20			
	TOMY (Anaes.) (Assist.)			
Fee: \$739.35	Benefit: 75% = \$554.55			
	LIVER, segmenta Fee: \$1,560.95 LIVER, lobectom Fee: \$1,670.00 LIVER, extended Fee: \$2,323.30 LIVER ABSCESS Fee: \$521.25 LIVER ABSCESS Fee: \$726.05 HYDATID CYST suture of biliary ra Fee: \$588.15 HYDATID CYST suture of biliary ra Fee: \$653.45 HYDATID CYST (Anaes.) (Assist.) Fee: \$813.30 HYDATID CYST (Anaes.) (Assist.) Fee: \$1,150.85 OPERATIVE CH OPERATIVE CH OPERATIVE UL the 1 operation) (A Fee: \$185.60 CHOLANGIOGR interventional ima service to which i Fee: \$526.40 INTRA OPERATI Fee: \$136.25 CHOLEDOCHOS Fee: \$185.60			

T8. SUF	RGICAL OPERATI	ONS 1. GENERAL			
	LAPAROSCOPI	C CHOLECYSTECTOMY (Anaes.) (Assist.)			
30445	Fee: \$739.35	Benefit: 75% = \$554.55			
	•	C CHOLECYSTECTOMY when procedure is completed by laparotomy (Anaes.)			
30446	Fee: \$739.35	Benefit: 75% = \$554.55			
	LAPAROSCOPIC CHOLECYSTECTOMY, involving removal of common duct calculi via the cystic duct (Anaes.) (Assist.)				
30448	Fee: \$972.90	Benefit: 75% = \$729.70			
		C CHOLECYSTECTOMY with removal of common duct calculi via laparoscopic (Anaes.) (Assist.)			
30449	Fee: \$1,081.85	Benefit: 75% = \$811.40			
		BILIARY OR RENAL TRACT, extraction of, using interventional imaging techniques ice associated with a service to which items 36627, 36630, 36645 or 36648 applies			
30450	Fee: \$524.40	Benefit: 75% = \$393.30 85% = \$445.75			
	BILIARY DRAINAGE TUBE, exchange of, using interventional imaging techniques - but not inclimaging, not being a service associated with a service to which item 30440 applies (Anaes.) (Assist				
30451	Fee: \$267.65	Benefit: 75% = \$200.75 85% = \$227.55			
	CHOLEDOCHO (Anaes.) (Assist.)	SCOPY with balloon dilation of a stricture or passage of stent or extraction of calculi			
30452	Fee: \$377.50	Benefit: 75% = \$283.15			
	CHOLEDOCHO (Assist.)	TOMY (with or without cholecystectomy), with or without removal of calculi (Anaes.)			
30454	Fee: \$862.50	Benefit: 75% = \$646.90			
		TOMY (with or without cholecystectomy), with removal of calculi including biliary nosis (Anaes.) (Assist.)			
30455	Fee: \$1,014.05	Benefit: 75% = \$760.55			
	CHOLEDOCHO (Assist.)	TOMY, intrahepatic, involving removal of intrahepatic bile duct calculi (Anaes.)			
30457	Fee: \$1,379.50	Benefit: 75% = \$1034.65 85% = \$1296.10			
	TRANSDUODENAL OPERATION ON SPHINCTER OF ODDI, involving 1 or more of, removal calculi, sphincterotomy, sphincteroplasty, biopsy, local excision of peri-ampullary or duodenal tum sphincteroplasty of the pancreatic duct, pancreatic duct septoplasty, with or without choledochotom (Anaes.) (Assist.)				
30458	Fee: \$1,014.05	Benefit: 75% = \$760.55			
		DUODENOSTOMY, CHOLECYSTOENTEROSTOMY, JEJUNOSTOMY or Roux-en-Y as a bypass procedure when no prior biliary surgery s.) (Assist.)			
1	Fee: \$862.50	Benefit: 75% = \$646.90			

T8. SUF	RGICAL OPERATION	ONS	1. GENERAL
		CTION of porta hepatis with biliary-enteric anastomoses, not be service to which item 30443, 30454, 30455, 30458 or 30460 app	
30461	Fee: \$1,478.40	Benefit: 75% = \$1108.80	
	RADICAL RESEGUANTES (Ana	CTION of common hepatic duct and right and left hepatic ducts es.) (Assist.)	, with 2 duct
30463	Fee: \$1,815.20	Benefit: 75% = \$1361.40	
		CTION of common hepatic duct and right and left hepatic ducts resection of segment or major portion of segment of liver (Anae	
30464	Fee: \$2,178.25	Benefit: 75% = \$1633.70	
	INTRAHEPATIC system (Anaes.) (A	biliary bypass of left hepatic ductal system by Roux-en-Y loop Assist.)	to peripheral ductal
30466	Fee: \$1,256.05	Benefit: 75% = \$942.05	
	INTRAHEPATIC system (Anaes.) (A	BYPASS of right hepatic ductal system by Roux-en-Y loop to Assist.)	peripheral ductal
30467	Fee: \$1,553.70	Benefit: 75% = \$1165.30	
	BILIARY STRIC	ΓURE, repair of, after 1 or more operations on the biliary tree (A	Anaes.) (Assist.)
30469	Fee: \$1,720.90	Benefit: 75% = \$1290.70 85% = \$1637.50	
		MMON BILE DUCT, repair of, as the primary procedure subset bile duct or ducts (Anaes.) (Assist.)	equent to partial or
30472	Fee: \$929.35	Benefit: 75% = \$697.05 85% = \$845.95	
	gastroscopy, duod	not being a service to which item 41816 or 41822 applies), enoscopy or panendoscopy (1 or more such procedures), with or sociated with a service to which item 30478 or 30479 applies. (A	
30473	(See para TN.8.17 o Fee: \$177.10	f explanatory notes to this Category) Benefit: 75% = \$132.85 85% = \$150.55	
		ion of stricture of upper gastrointestinal tract (including the use ere clinically indicated) (Anaes.)	of imaging
30475	(See para TN.8.17, 7 Fee: \$348.95	FN.8.133 of explanatory notes to this Category) Benefit: 75% = \$261.75 85% = \$296.65	
		other than a service to which item 41816, 41822 or 41825 applianendoscopy or push enteroscopy, one or more such procedures,	
	(a) the procedures	are performed using one or more of the following endoscopic p	rocedures:
	(i) polypectomy;		
	(ii) sclerosing or adrenalin injections;		
	(iii) banding;		
	(iv) endoscopic cli	ips;	
30478	(v) haemostatic po	owders;	

T8. SU	RGICAL OPERATIONS	1. GENERAL
	(vi) diathermy;	
	(vii) argon plasma coagulation; and	
	(b) the procedures are for the treatment of one or more of the following:	
	(i) upper gastrointestinal tract bleeding;	
	(ii) polyps;	
	(iii) removal of foreign body;	
	(iv) oesophageal or gastric varices;	
	(v) peptic ulcers;	
	(vi) neoplasia;	
	(vii) benign vascular lesions;	
	(viii) strictures of the gastrointestinal tract;	
	(ix) tumorous overgrowth through or over oesophageal stents;	
	other than a service associated with a service to which item 30473 or 30479 applies	(Anaes.)
	(See para TN.8.17 of explanatory notes to this Category) Fee: \$245.55 Benefit: 75% = \$184.20 85% = \$208.75	
	Endoscopy with laser therapy, for the treatment of one or more of the following:	
	(a) neoplasia;	
	(b) benign vascular lesions;	
	(c) strictures of the gastrointestinal tract;	
	(d) tumorous overgrowth through or over oesophageal stents;	
	(e) peptic ulcers;	
	(f) angiodysplasia;	
	(g) gastric antral vascular ectasia;	
	(h) post-polypectomy bleeding;	
	other than a service associated with a service to which item 30473 or 30478 applies ((Anaes.)
30479	(See para TN.8.17 of explanatory notes to this Category) Fee: \$476.10 Benefit: 75% = \$357.10 85% = \$404.70	

T8. SUF	RGICAL OPERATIONS	1. GENERAL
	PERCUTANEOUS GASTROSTOMY (initial procedure):	
	(a) including any associated imaging services; and	
	(b) excluding the insertion of a device for the purpose of facilitating weight loss (Anaes.)
30481	(See para TN.8.17 of explanatory notes to this Category) Fee: \$357.00 Benefit: 75% = \$267.75 85% = \$303.45	
	PERCUTANEOUS GASTROSTOMY (repeat procedure):	
	(a) including any associated imaging services; and	
	(b) excluding the insertion of a device for the purpose of facilitating weight loss (Anaes.)
30482	Fee: \$253.85 Benefit: 75% = \$190.40 85% = \$215.80	
	GASTROSTOMY BUTTON, CAECOSTOMY ANTEGRADE ENEMA DEVICE (CH STOMAL INDWELLING DEVICE:	AIT etc.) or
	(a) non-endoscopic insertion of; or	
	(b) non-endoscopic replacement of;	
	on a person 10 years of age or over, excluding the insertion of a device for the purpose of weight loss (Anaes.)	of facilitating
30483	Fee: \$177.05 Benefit: 75% = \$132.80 85% = \$150.50	
	ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (Anaes.)	
30484	(See para TN.8.17 of explanatory notes to this Category) Fee: \$364.90 Benefit: 75% = \$273.70 85% = \$310.20	
	ENDOSCOPIC SPHINCTEROTOMY with or without extraction of stones from commo (Anaes.)	on bile duct
30485	(See para TN.8.17 of explanatory notes to this Category) Fee: \$563.30 Benefit: 75% = \$422.50 85% = \$479.90	
	SMALL BOWEL INTUBATION as an independent procedure (Anaes.)	
30488	Fee: \$90.00 Benefit: 75% = \$67.50 85% = \$76.50	
	OESOPHAGEAL PROSTHESIS, insertion of, including endoscopy and dilatation (Ana	es.)
30490	(See para TN.8.17 of explanatory notes to this Category) Fee: \$526.40 Benefit: 75% = \$394.80 85% = \$447.45	
	BILE DUCT, ENDOSCOPIC STENTING OF (including endoscopy and dilatation) (An	aes.)
30491	(See para TN.8.17 of explanatory notes to this Category) Fee: \$555.35 Benefit: 75% = \$416.55 85% = \$472.05	
	BILE DUCT, PERCUTANEOUS STENTING OF (including dilatation when performed interventional imaging techniques - but not including imaging (Anaes.)	l), using
30492	Fee: \$787.30 Benefit: 75% = \$590.50	
	ENDOSCOPIC BILIARY DILATATION (Anaes.)	
30494	(See para TN.8.17 of explanatory notes to this Category)	

T8. SUF	RGICAL OPERAT	IONS 1. GENERAL	
	Fee: \$420.50	Benefit: 75% = \$315.40	
		US BILIARY DILATATION for biliary stricture, using interventional imaging	
	techniques - but	not including imaging (Anaes.)	
30495	Fee: \$787.30	Benefit: 75% = \$590.50	
	VAGOTOMY, t	runcal or selective, with or without pyloroplasty or gastroenterostomy (Anaes.) (Assist.)	
30496	Fee: \$588.15	Benefit: 75% = \$441.15 85% = \$504.75	
	VAGOTOMY at	nd ANTRECTOMY (Anaes.) (Assist.)	
30497	Fee: \$701.30	Benefit: 75% = \$526.00	
		nighly selective (Anaes.) (Assist.)	
30499	Fee: \$834.05	Benefit: 75% = \$625.55	
30 177		highly selective with duodenoplasty for peptic stricture (Anaes.) (Assist.)	
20500	Fee: \$893.10		
30500	· ·	Benefit: 75% = \$669.85 85% = \$809.70	
	VAGOTOM1, II	highly selective, with dilatation of pylorus (Anaes.) (Assist.)	
30502	Fee: \$985.70	Benefit: 75% = \$739.30	
	VAGOTOMY or ANTRECTOMY, or both, for peptic ulcer following previous operation for peptic ulcer (Anaes.) (Assist.)		
30503	Fee: \$1,103.80	Benefit: 75% = \$827.85 85% = \$1020.40	
	BLEEDING PER (Assist.)	PTIC ULCER, control of, involving suture of bleeding point or wedge excision (Anaes.)	
30505	Fee: \$551.85	Benefit: 75% = \$413.90	
		PTIC ULCER, control of, involving suture of bleeding point or wedge excision, and ploroplasty or gastroenterostomy (Anaes.) (Assist.)	
30506	Fee: \$965.75	Benefit: 75% = \$724.35	
	BLEEDING PEPTIC ULCER, control of, involving suture of bleeding point or wedge excision, an highly selective vagotomy (Anaes.) (Assist.)		
30508	Fee: \$1,016.55	Benefit: 75% = \$762.45	
	BLEEDING PEI (Anaes.) (Assist.	PTIC ULCER, control of, involving gastric resection (other than wedge resection)	
30509	Fee: \$1,016.55	Benefit: 75% = \$762.45 85% = \$933.15	
		ny (including gastroduodenostomy) or enterocolostomy or enteroenterostomy, not being h any of items 31569 to 31581 apply (Anaes.) (Assist.)	
30515	Fee: \$704.35	Benefit: 75% = \$528.30	
	GASTROENTE (Anaes.) (Assist.	ROSTOMY, PYLOROPLASTY or GASTRODUODENOSTOMY, reconstruction of)	
30517	Fee: \$922.20	Benefit: 75% = \$691.65	
30518	Partial gastrector	my, not being a service associated with a service to which any of items 31569 to 31581	

T8. SUF	GICAL OPERATIONS 1. GENERA
	apply (Anaes.) (Assist.)
	Fee: \$987.50 Benefit: 75% = \$740.65
	GASTRIC TUMOUR, removal of, by local excision, not being a service to which item 30518 applies (Anaes.) (Assist.)
30520	Fee: \$675.35 Benefit: 75% = \$506.55
	GASTRECTOMY, TOTAL, for benign disease (Anaes.) (Assist.)
30521	Fee: \$1,444.90 Benefit: 75% = \$1083.70
	GASTRECTOMY, SUBTOTAL RADICAL, for carcinoma, (including splenectomy when performed) (Anaes.) (Assist.)
30523	(See para TN.8.18 of explanatory notes to this Category) Fee: \$1,510.10 Benefit: 75% = \$1132.60
	GASTRECTOMY, TOTAL RADICAL, for carcinoma (including extended node dissection and distal pancreatectomy and splenectomy when performed) (Anaes.) (Assist.)
30524	Fee: \$1,662.65 Benefit: 75% = \$1247.00
	GASTRECTOMY, TOTAL, and including lower oesophagus, performed by left thoraco-abdominal incision or opening of diaphragmatic hiatus, (including splenectomy when performed) (Anaes.) (Assist.
30526	Fee: \$2,156.35 Benefit: 75% = \$1617.30
	ANTIREFLUX OPERATION by fundoplasty, via abdominal or thoracic approach, with or without closure of the diaphragmatic hiatus not being a service to which item 30601 applies (Anaes.) (Assist.)
30527	(See para TN.8.19 of explanatory notes to this Category) Fee: \$871.30 Benefit: 75% = \$653.50
	ANTIREFLUX operation by fundoplasty, with OESOPHAGOPLASTY for stricture or short oesophagu (Anaes.) (Assist.)
30529	(See para TN.8.19 of explanatory notes to this Category) Fee: \$1,306.90 Benefit: 75% = \$980.20
	ANTIREFLUX operation by cardiopexy, with or without fundoplasty (Anaes.) (Assist.)
30530	(See para TN.8.19 of explanatory notes to this Category) Fee: \$784.20 Benefit: 75% = \$588.15
	OESOPHAGOGASTRIC MYOTOMY (Heller's operation) via abdominal or thoracic approach, with or without closure of the diaphragmatic hiatus, by laparoscopy or open operation (Anaes.) (Assist.)
30532	(See para TN.8.19 of explanatory notes to this Category) Fee: \$900.45 Benefit: 75% = \$675.35
	OESOPHAGOGASTRIC MYOTOMY (Heller's operation) via abdominal or thoracic approach, WITH FUNDOPLASTY, with or without closure of the diaphragmatic hiatus, by laparoscopy or open operatio (Anaes.) (Assist.)
30533	(See para TN.8.19 of explanatory notes to this Category) Fee: \$1,071.00 Benefit: 75% = \$803.25
	OESOPHAGECTOMY with gastric reconstruction by abdominal mobilisation and thoracotomy (Anaes.) (Assist.)
30535	Fee: \$1,696.65 Benefit: 75% = \$1272.50

T8. SUF	RGICAL OPERATION	DNS 1. GENER
		OMY involving gastric reconstruction by abdominal mobilisation, thoracotomy and neck or chest - 1 surgeon (Anaes.) (Assist.)
30536	Fee: \$1,720.90	Benefit: 75% = \$1290.70
		OMY involving gastric reconstruction by abdominal mobilisation, thoracotomy and neck or chest- conjoint surgery, principal surgeon (including aftercare) (Anaes.)
30538	Fee: \$1,190.80	Benefit: 75% = \$893.10
		OMY involving gastric reconstruction by abdominal mobilisation, thoracotomy and neck or chest - conjoint surgery, co-surgeon (Assist.)
30539	Fee: \$871.30	Benefit: 75% = \$653.50
		OMY, by trans-hiatal oesophagectomy (cervical and abdominal mobilisation, posterior or anterior mediastinal placement - 1 surgeon (Anaes.) (Assist.)
30541	Fee: \$1,517.50	Benefit: 75% = \$1138.15
	anastomosis) with	OMY, by trans-hiatal oesophagectomy (cervical and abdominal mobilisation, posterior or anterior mediastinal placement - conjoint surgery, principal surgeon re) (Anaes.) (Assist.)
30542	Fee: \$1,031.10	Benefit: 75% = \$773.35
		OMY, by trans-hiatal oesophagectomy (cervical and abdominal mobilisation, posterior or anterior mediastinal placement - conjoint surgery, co-surgeon (Assist.)
30544	Fee: \$755.20	Benefit: 75% = \$566.40
		OMY with colon or jejunal anastomosis, (abdominal and thoracic mobilisation with sis) - 1 surgeon (Anaes.) (Assist.)
30545	Fee: \$1,837.10	Benefit: 75% = \$1377.85
		OMY with colon or jejunal anastomosis, (abdominal and thoracic mobilisation with sis) - conjoint surgery, principal surgeon (including aftercare) (Anaes.) (Assist.)
30547	Fee: \$1,263.35	Benefit: 75% = \$947.55 85% = \$1179.95
		OMY with colon or jejunal anastomosis, (abdominal and thoracic mobilisation with sis) - conjoint surgery, co-surgeon (Assist.)
30548	Fee: \$943.80	Benefit: 75% = \$707.85 85% = \$860.40
30548	OESOPHAGECT	Benefit: 75% = \$707.85 85% = \$860.40 OMY with colon or jejunal replacement (abdominal and thoracic mobilisation with dicle in the neck) - 1 surgeon (Anaes.) (Assist.)
30548	OESOPHAGECT	OMY with colon or jejunal replacement (abdominal and thoracic mobilisation with
	OESOPHAGECT anastomosis of peo Fee: \$2,062.20 OESOPHAGECT	OMY with colon or jejunal replacement (abdominal and thoracic mobilisation with dicle in the neck) - 1 surgeon (Anaes.) (Assist.)
	OESOPHAGECT anastomosis of peo Fee: \$2,062.20 OESOPHAGECT anastomosis of peo	OMY with colon or jejunal replacement (abdominal and thoracic mobilisation with dicle in the neck) - 1 surgeon (Anaes.) (Assist.) Benefit: 75% = \$1546.65 OMY with colon or jejunal replacement (abdominal and thoracic mobilisation with
30550	OESOPHAGECT anastomosis of peo Fee: \$2,062.20 OESOPHAGECT anastomosis of peo (Assist.) Fee: \$1,423.15 OESOPHAGECT	OMY with colon or jejunal replacement (abdominal and thoracic mobilisation with dicle in the neck) - 1 surgeon (Anaes.) (Assist.) Benefit: 75% = \$1546.65 OMY with colon or jejunal replacement (abdominal and thoracic mobilisation with dicle in the neck) - conjoint surgery, principal surgeon (including aftercare) (Anaes.)

T8. SUF	RGICAL OPERATION	ONS 1. GENERAL	
	OESOPHAGECT	OMY with reconstruction by free jejunal graft - 1 surgeon (Anaes.) (Assist.)	
30554	Fee: \$2,294.45	Benefit: 75% = \$1720.85	
		OMY with reconstruction by free jejunal graft - conjoint surgery, principal surgeon re) (Anaes.) (Assist.)	
30556	Fee: \$1,582.80	Benefit: 75% = \$1187.10	
	OESOPHAGECT	OMY with reconstruction by free jejunal graft - conjoint surgery, co-surgeon (Assist.)	
30557	Fee: \$1,169.00	Benefit: 75% = \$876.75	
	OESOPHAGUS,	local excision for tumour of (Anaes.) (Assist.)	
30559	Fee: \$849.55	Benefit: 75% = \$637.20 85% = \$766.15	
	OESOPHAGEAL	PERFORATION, repair of, by thoracotomy (Anaes.) (Assist.)	
30560	Fee: \$943.80	Benefit: 75% = \$707.85	
		Y or COLOSTOMY, closure of (not involving resection of bowel), on a person 10 er (Anaes.) (Assist.)	
30562	Fee: \$595.00	Benefit: 75% = \$446.25	
	COLOSTOMY O (Assist.)	R ILEOSTOMY, refashioning of, on a person 10 years of age or over (Anaes.)	
30563	Fee: \$595.00	Benefit: 75% = \$446.25 85% = \$511.60	
	SMALL BOWEL	STRICTUREPLASTY for chronic inflammatory bowel disease (Anaes.) (Assist.)	
30564	Fee: \$772.30	Benefit: 75% = \$579.25	
	SMALL INTESTINE, resection of, without anastomosis (including formation of stoma) ((Assist.)		
30565	Fee: \$871.30	Benefit: 75% = \$653.50	
	SMALL INTEST (Assist.)	INE, resection of, with anastomosis, on a person 10 years of age or over (Anaes.)	
30566	Fee: \$967.85	Benefit: 75% = \$725.90	
	INTRAOPERATI (Assist.)	VE ENTEROTOMY for visualisation of the small intestine by endoscopy (Anaes.)	
30568	Fee: \$726.05	Benefit: 75% = \$544.55	
		XAMINATION of SMALL BOWEL with flexible endoscope passed at laparotomy, opsies (Anaes.) (Assist.)	
30569	Fee: \$370.20	Benefit: 75% = \$277.65	
	APPENDICECTOMY, not being a service to which item 30574 applies on a person 10 years of age or over (Anaes.) (Assist.)		
30571	Fee: \$445.40	Benefit: 75% = \$334.05	
	LAPAROSCOPIO	C APPENDICECTOMY, on a person 10 years of age or over (Anaes.) (Assist.)	
30572	Fee: \$445.40	Benefit: 75% = \$334.05	

T8. SUF	RGICAL OPERATION	ONS 1. GENERAL
	NOTE: Multiple (Operation and Multiple Anaesthetic rules apply to this item
	APPENDICECTO through the same	DMY, when performed in conjunction with any other intraabdominal procedure incision (Anaes.)
30574	Fee: \$123.25	Benefit: 75% = \$92.45
	PANCREATIC A dissection (Anaes	BSCESS, laparotomy and external drainage of, not requiring retro-pancreatic .) (Assist.)
30575	Fee: \$512.70	Benefit: 75% = \$384.55
		IECROSECTOMY for PANCREATIC NECROSIS or ABSCESS FORMATION ancreatic or retro-pancreatic dissection, excluding aftercare (Anaes.) (Assist.)
30577	Fee: \$1,089.15	Benefit: 75% = \$816.90
		JMOUR, exploration of pancreas or duodenum, followed by local excision of (Anaes.) (Assist.)
30578	Fee: \$1,147.20	Benefit: 75% = \$860.40
	ENDOCRINE TU tumour (Anaes.) (JMOUR, exploration of pancreas or duodenum, followed by local excision of duodenal Assist.)
30580	Fee: \$1,045.40	Benefit: 75% = \$784.05
	ENDOCRINE TU (Assist.)	UMOUR, exploration of pancreas or duodenum for, but no tumour found (Anaes.)
30581	Fee: \$762.35	Benefit: 75% = \$571.80
	DISTAL PANCR	EATECTOMY (Anaes.) (Assist.)
30583	Fee: \$1,194.25	Benefit: 75% = \$895.70
	PANCREATICO pylorus (Anaes.)	-DUODENECTOMY, WHIPPLE'S OPERATION, with or without preservation of (Assist.)
30584	Fee: \$1,762.75	Benefit: 75% = \$1322.10
	PANCREATIC C means (Anaes.) (A	YST ANASTOMOSIS TO STOMACH OR DUODENUM - by open or endoscopic Assist.)
30586	Fee: \$701.30	Benefit: 75% = \$526.00
	PANCREATIC C	YST, anastomosis to Roux loop of jejunum (Anaes.) (Assist.)
30587	Fee: \$726.05	Benefit: 75% = \$544.55
	PANCREATICO	-JEJUNOSTOMY for pancreatitis or trauma (Anaes.) (Assist.)
30589	Fee: \$1,251.10	Benefit: 75% = \$938.35
/		-JEJUNOSTOMY following previous pancreatic surgery (Anaes.) (Assist.)
30590	Fee: \$1,379.50	Benefit: 75% = \$1034.65
30370		OMY, near total or total (including duodenum), with or without splenectomy (Anaes.)
30593	Fee: \$1,887.75	Benefit: 75% = \$1415.85 85% = \$1804.35
30594		OMY for pancreatitis following previously attempted drainage procedure or partial

T8. SUF	RGICAL OPERATIO	NS 1. GENERAL
	resection (Anaes.)	(Assist.)
	Fee: \$2,178.25	Benefit: 75% = \$1633.70
	SPLENORRHAPH	Y OR PARTIAL SPLENECTOMY (Anaes.) (Assist.)
30596	Fee: \$897.30	Benefit: 75% = \$673.00
	SPLENECTOMY ((Anaes.) (Assist.)
30597	Fee: \$720.20	Benefit: 75% = \$540.15
	SPLENECTOMY, incision (Anaes.) (A	for massive spleen (weighing more than 1500 grams) or involving thoraco-abdominal Assist.)
30599	Fee: \$1,306.90	Benefit: 75% = \$980.20
	DIAPHRAGMATI	C HERNIA, TRAUMATIC, repair of (Anaes.) (Assist.)
30600	Fee: \$777.10	Benefit: 75% = \$582.85
		nia, congential repair of, by thoracic or abdominal approach, not being a service to 31569 to 31581 apply, on a person 10 years of age or over (Anaes.) (Assist.)
30601	Fee: \$957.30	Benefit: 75% = \$718.00
	PORTAL HYPER	TENSION, porto-caval shunt for (Anaes.) (Assist.)
30602	Fee: \$1,553.70	Benefit: 75% = \$1165.30
	PORTAL HYPER	TENSION, meso-caval shunt for (Anaes.) (Assist.)
30603	Fee: \$1,640.90	Benefit: 75% = \$1230.70 85% = \$1557.50
	PORTAL HYPER	TENSION, selective spleno-renal shunt for (Anaes.) (Assist.)
30605	Fee: \$1,865.95	Benefit: 75% = \$1399.50
		TENSION, oesophageal transection via stapler or oversew of gastric varices with or isation (Anaes.) (Assist.)
30606	Fee: \$1,110.80	Benefit: 75% = \$833.10
	SMALL INTESTIN (Assist.)	NE, resection of, with anastomosis, on a person under 10 years of age (Anaes.)
30608	Fee: \$1,258.20	Benefit: 75% = \$943.65
		GUINAL HERNIA, laparoscopic repair of, not being a service associated with a em 30614 applies (Anaes.) (Assist.)
30609	Fee: \$464.50	Benefit: 75% = \$348.40
	BENIGN TUMOUR of SOFT TISSUE, excluding tumours of skin, cartilage, and bone, simple lipom covered by item 31345 and lipomata - removal of by surgical excision, where the specimen excised is sent for histological confirmation of diagnosis, on a person under 10 years of age, not being a service which another item in this Group applies (Anaes.) (Assist.)	
30611	Fee: \$563.35	Benefit: 75% = \$422.55 85% = \$479.95
		GUINAL HERNIA OR INFANTILE HYDROCELE, repair of, not being a service to or 30615 applies, on a person 10 years of age or over (Anaes.) (Assist.)
30614	Fee: \$464.50	Benefit: 75% = \$348.40
	1	

T8. SUF	RGICAL OPERATIONS	1. GENERAL
	STRANGULATED, INCARCERATED OR OBSTRUCTED HERNIA, repair of, with resection, on a person 10 years of age or over (Anaes.) (Assist.)	out bowel
30615	Fee: \$521.25 Benefit: 75% = \$390.95	
	LYMPH NODES OF NECK, selective dissection of 1 or 2 lymph node levels involving tissue and lymph nodes from one side of the neck, on a person under 10 years of age (a	
30618	(See para TN.8.24 of explanatory notes to this Category) Fee: \$522.25 Benefit: 75% = \$391.70 85% = \$443.95	
	LAPAROSCOPIC SPLENECTOMY, on a person under 10 years of age (Anaes.) (Ass	ist.)
30619	Fee: \$936.25 Benefit: 75% = \$702.20	
	Repair of symptomatic umbilical, epigastric or linea alba hernia requiring mesh or othe in a person 10 years of age or over, other than a service to which item 30403 or 30405 (Assist.)	
30621	Fee: \$407.50 Benefit: 75% = \$305.65	
	Caecostomy, Enterostomy, Colostomy, Enterotomy, Colotomy, Cholecystostomy, Gast Gastrotomy, Reduction of intussusception, Removal of Meckel's diverticulum, Suture of peptic ulcer, Simple repair of ruptured viscus, Reduction of volvulus, Pyloroplasty or Epancreas on a person under 10 years of age (Anaes.) (Assist.)	of perforated
30622	(See para TN.8.14 of explanatory notes to this Category) Fee: \$677.65 Benefit: 75% = \$508.25	
	LAPAROTOMY INVOLVING DIVISION OF PERITONEAL ADHESIONS (where a intraabdominal procedure is performed) on a person under 10 years of age (Anaes.) (Astronomy of the contract of	
30623	Fee: \$677.65 Benefit: 75% = \$508.25	
	LAPAROTOMY involving division of adhesions in conjunction with another intraabdo where the time taken to divide the adhesions is between 45 minutes and 2 hours, on a p years of age (Anaes.) (Assist.)	
30626	Fee: \$680.80 Benefit: 75% = \$510.60	
	LAPAROSCOPY, diagnostic, not being a service associated with any other laparoscop person under 10 years of age (Anaes.)	ic procedure, on a
30627	(See para TN.8.15 of explanatory notes to this Category) Fee: \$285.95 Benefit: 75% = \$214.50	
	HYDROCELE, tapping of	
30628	Fee: \$35.60 Benefit: 75% = \$26.70 85% = \$30.30	
	Hydrocele, removal of, other than a service associated with a service to which item 30641, 30642 or 30644 applies (Anaes.)	
30631	Fee: \$236.65 Benefit: 75% = \$177.50 85% = \$201.20	
	Varicocele, surgical correction of, other than a service associated with a service to whice 30642 or 30644 applies—one procedure (Anaes.) (Assist.)	ch item 30641,
30635	Fee: \$291.80 Benefit: 75% = \$218.85	
30636	GASTROSTOMY BUTTON, caecostomy antegrade enema device (chait etc) and/or st device, non-endoscopic insertion of, or non-endoscopic replacement of, on a person un	

T8. SUF	RGICAL OPERATI	ONS 1. GENERAL
	age (Anaes.)	
	Fee: \$233.15	Benefit: 75% = \$174.90 85% = \$198.20
	ENTEROSTOM years of age (Ana	Y or COLOSTOMY, closure of not involving resection of bowel, on a person under 10 aes.) (Assist.)
30637	Fee: \$773.50	Benefit: 75% = \$580.15
	COLOSTOMY (OR ILEOSTOMY, refashioning of, on a person under 10 years of age (Anaes.) (Assist.)
30639	Fee: \$773.50	Benefit: 75% = \$580.15 85% = \$690.10
		nd irreducible scrotal hernia, where duration of surgery exceeds 2 hours, in a person 10 ver, other than a service to which item 30403, 30405, 30614, 30615 or 30621 applies
30640	Fee: \$914.95	Benefit: 75% = \$686.25
	ORCHIDECTON (Anaes.) (Assist.)	MY, simple or subscapsular, unilateral with or without insertion of testicular prosthesis
30641	Fee: \$407.50	Benefit: 75% = \$305.65
		idical, unilateral, with or without insertion of testicular prosthesis, other than a service service to which item 30631, 30635, 30641, 30643 or 30644 applies (Anaes.) (Assist.)
30642	Fee: \$521.25	Benefit: 75% = \$390.95
		OF SPERMATIC CORD, inguinal approach, with or without testicular biopsy and xcision of spermatic cord and testis on a person under 10 years of age (Anaes.) (Assist.)
30643	Fee: \$677.65	Benefit: 75% = \$508.25
	EXPLORATION OF SPERMATIC CORD, inguinal approach, with or without testicular biopsy and with or without excision of spermatic cord and testis on a person 10 years of age or over (Anaes.) (Assist.)	
30644	Fee: \$521.25	Benefit: 75% = \$390.95
	APPENDICECTOMY, not being a service to which item 30574 applies, on a person under 10 years of age (Anaes.) (Assist.)	
30645	Fee: \$579.00	Benefit: 75% = \$434.25
	LAPAROSCOPI	C APPENDICECTOMY, on a person under 10 years of age (Anaes.) (Assist.)
30646	Fee: \$579.00	Benefit: 75% = \$434.25
	HAEMORRHAC years of age (Ana	GE, arrest of, following circumcision requiring general anaesthesia on a person under 10 aes.)
30649	Fee: \$187.65	Benefit: 75% = \$140.75 85% = \$159.55
	Circumcision of	the penis (other than a service to which item 30658 applies)
30654	Fee: \$46.50	Benefit: 75% = \$34.90 85% = \$39.55
	Circumcision of to Group T10 app	the penis, when performed in conjunction with a service to which an item in Group T7 plies (Anaes.)
30658	Fee: \$142.00	Benefit: 75% = \$106.50 85% = \$120.70
30663	HAEMORRHAC	GE, arrest of, following circumcision requiring general anaesthesia on a person 10 years

T8. SUF	RGICAL OPERATION	ons	1. GENERAL
	of age or over (Ar	naes.)	
	Fee: \$144.35	Benefit: 75% = \$108.30 85% = \$122.70	
		S or PHIMOSIS, reduction of, under general anaesthesia, with or with g a service associated with a service to which another item in this Grant G	
30666	Fee: \$47.45	Benefit: 75% = \$35.60 85% = \$40.35	
	COCCYX, excision	on of (Anaes.) (Assist.)	
30672	Fee: \$445.40	Benefit: 75% = \$334.05	
	PILONIDAL SIN	US OR CYST, OR SACRAL SINUS OR CYST, excision of (Anaes	S.)
30676	Fee: \$379.05	Benefit: 75% = \$284.30 85% = \$322.20	
	PILONIDAL SIN	US, injection of sclerosant fluid under anaesthesia (Anaes.)	
30679	Fee: \$96.30	Benefit: 75% = \$72.25 85% = \$81.90	
	WITHOUT intrap in association with	opy, examination of the small bowel (oral approach), with or without procedural therapy, for diagnosis of patients with obscure gastrointes the another item in this subgroup (with the exception of item 30682 or on the service is provided must:	tinal bleeding, not
		•	
	(i) have recurrent or persistent bleeding; and		
	(ii) be anaemic	or have active bleeding; and	
	(iii) have had an upper gastrointestinal endoscopy and a colonoscopy performed which did not id the cause of the bleeding. (Anaes.)		ich did not identify
30680	(See para TN.8.17 o Fee: \$1,170.00	of explanatory notes to this Category) Benefit: 75% = \$877.50 85% = \$1086.60	
	WITHOUT intrap	opy, examination of the small bowel (anal approach), with or without procedural therapy, for diagnosis of patients with obscure gastrointes in another item in this subgroup (with the exception of item 30680 or	tinal bleeding, not
	The patient to who	om the service is provided must:	
	(i) have recurren	nt or persistent bleeding; and	
	(ii) be anaemic	or have active bleeding; and	
		n upper gastrointestinal endoscopy and a colonoscopy performed whi e bleeding.	ich did not identify
	(Anaes.)		
30682	(See para TN.8.17 o Fee: \$1,170.00	of explanatory notes to this Category) Benefit: 75% = \$877.50 85% = \$1086.60	

T8. SURC	GICAL OPERATIONS	1. GENERAL
	Balloon enteroscopy, examination of the small bowel (oral approach), with or without to rmore of the following procedures (snare polypectomy, removal of foreign body, diat probe, laser coagulation or argon plasma coagulation), for diagnosis and management of obscure gastrointestinal bleeding, not in association with another item in this subgroup exception of item 30682 or 30686)	hermy, heater of patients with
	The patient to whom the service is provided must:	
	(i) have recurrent or persistent bleeding; and	
	(ii) be anaemic or have active bleeding; and	
	(iii) have had an upper gastrointestinal endoscopy and a colonoscopy performed which the cause of the bleeding.	h did not identify
	(Anaes.)	
30684	(See para TN.8.17 of explanatory notes to this Category) Fee: \$1,439.85 Benefit: 75% = \$1079.90 85% = \$1356.45	
	Balloon enteroscopy, examination of the small bowel (anal approach), with or without or more of the following procedures (snare polypectomy, removal of foreign body, diat probe, laser coagulation or argon plasma coagulation), for diagnosis and management obscure gastrointestinal bleeding, not in association with another item in this subgroup exception of item 30680 or 30684)	hermy, heater of patients with
	The patient to whom the service is provided must:	
	(i) have recurrent or persistent bleeding; and	
	(ii) be anaemic or have active bleeding; and(iii) have had an upper gastrointestinal endoscopy and a colonoscopy performed which the cause of the bleeding. (Anaes.)	h did not identify
30686	(See para TN.8.17 of explanatory notes to this Category) Fee: \$1,439.85 Benefit: 75% = \$1079.90 85% = \$1356.45	
	ENDOSCOPY with RADIOFREQUENCY ABLATION of mucosal metaplasia for the Barrett's Oesophagus in a single course of treatment, following diagnosis of high grade confirmed by histological examination (Anaes.)	
30687	(See para TN.8.17, TN.8.20 of explanatory notes to this Category) Fee: \$476.10 Benefit: 75% = \$357.10 85% = \$404.70	
	Endoscopic ultrasound (endoscopy with ultrasound imaging), with or without biopsy, for more of oesophageal, gastric or pancreatic cancer, not in association with another ite Subgroup (other than item 30484, 30485, 30491 or 30494) and other than a service assoroutine monitoring of chronic pancreatitis. (Anaes.)	m in this
30688	(See para TN.8.21, TN.8.17 of explanatory notes to this Category) Fee: \$364.90 Benefit: 75% = \$273.70 85% = \$310.20	
30690	Endoscopic ultrasound (endoscopy with ultrasound imaging), with or without biopsy,	with fine needle

T8. SUF	RGICAL OPERATIONS 1. GENERA
	aspiration, including aspiration of the locoregional lymph nodes if performed, for the staging of 1 or more of oesophageal, gastric or pancreatic cancer, not in association with another item in this Subgroup (other than item 30484, 30485, 30491 or 30494) and other than a service associated with the routine monitoring of chronic pancreatitis. (Anaes.)
	(See para TN.8.21, TN.8.17 of explanatory notes to this Category) Fee: \$563.30 Benefit: 75% = \$422.50 85% = \$479.90
	Endoscopic ultrasound (endoscopy with ultrasound imaging), with or without biopsy, for the diagnosis of 1 or more of pancreatic, biliary or gastric submucosal tumours, not in association with another item in this Subgroup (other than item 30484, 30485, 30491 or 30494) and other than a service associated with the routine monitoring of chronic pancreatitis. (Anaes.)
30692	(See para TN.8.21, TN.8.17 of explanatory notes to this Category) Fee: \$364.90 Benefit: 75% = \$273.70 85% = \$310.20
	Endoscopic ultrasound (endoscopy with ultrasound imaging), with or without biopsy, with fine needle aspiration, for the diagnosis of 1 or more of pancreatic, biliary or gastric submucosal tumours, not in association with another item in this Subgroup (other than item 30484, 30485, 30491 or 30494) and other than a service associated with the routine monitoring of chronic pancreatitis. (Anaes.)
30694	(See para TN.8.21, TN.8.17 of explanatory notes to this Category) Fee: \$563.30 Benefit: 75% = \$422.50 85% = \$479.90
	ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE ASPIRATION BIOPSY(S) (endoscopy with ultrasound imaging) to obtain one or more specimens from either:
	(a) mediastinal mass(es) or
	(b) locoregional nodes to stage non-small cell lung carcinoma
	not being a service associated with another item in this subgroup or to which items 30710 and 55054 apply (Anaes.)
30696	(See para TN.8.21 of explanatory notes to this Category) Fee: \$563.30 Benefit: 75% = \$422.50 85% = \$479.90
	ENDOBRONCHIAL ULTRASOUND GUIDED BIOPSY(S) (bronchoscopy with ultrasound imaging, with or without associated fluoroscopic imaging) to obtain one or more specimens by either:
	(a) transbronchial biopsy(s) of peripheral lung lesions; or
	(b) fine needle aspiration(s) of a mediastinal mass(es); or
	(c) fine needle aspiration(s) of locoregional nodes to stage non-small cell lung carcinoma
	not being a service associated with another item in this subgroup or to which items 30696, 41892, 41898, and 60500 to 60509 applies (Anaes.)
30710	(See para TN.8.21 of explanatory notes to this Category) Fee: \$563.30 Benefit: 75% = \$422.50 85% = \$479.90
31000	Mohs surgery of skin tumour located on the head, neck, genitalia, hand, digits, leg (below knee) or foot,

T8. SUF	RGICAL OPERATIONS	1. GENERAL
	utilising horizontal frozen sections with mapping of all excised tissue, and histological excised tissue by the specialist performing the procedure, if the specialist is recognized Australasian College of Dermatologists as an approved Mohs surgeon—6 or fewer sections.	gnised by the
	(See para TN.8.151 of explanatory notes to this Category) Fee: \$580.90 Benefit: 75% = \$435.70 85% = \$497.50	
	Mohs surgery of skin tumour located on the head, neck, genitalia, hand, digits, leg (tutilising horizontal frozen sections with mapping of all excised tissue, and histological excised tissue by the specialist performing the procedure, if the specialist is recognised all excised tissue of Dermatologists as an approved Mohs surgeon—7 to 12 sect (Anaes.)	cal examination of gnised by the
31001	(See para TN.8.151 of explanatory notes to this Category) Fee: \$726.05 Benefit: 75% = \$544.55 85% = \$642.65	
	Mohs surgery of skin tumour located on the head, neck, genitalia, hand, digits, leg (lutilising horizontal frozen sections with mapping of all excised tissue, and histologicall excised tissue by the specialist performing the procedure, if the specialist is recognized Australasian College of Dermatologists as an approved Mohs surgeon—13 or more	cal examination of gnised by the
31002	(See para TN.8.151 of explanatory notes to this Category) Fee: \$871.30 Benefit: 75% = \$653.50 85% = \$787.90	
	Mohs surgery of skin tumour utilising horizontal frozen sections with mapping of all histological examination of all excised tissue by the specialist performing the proced is recognised by the Australasian College of Dermatologists as an approved Mohs suspections	dure, if the specialist
	Not applicable to a service performed in association with a service to which item 31	000 applies (Anaes.)
31003	(See para TN.8.151 of explanatory notes to this Category) Fee: \$580.90 Benefit: 75% = \$435.70 85% = \$497.50	
	Mohs surgery of skin tumour utilising horizontal frozen sections with mapping of all histological examination of all excised tissue by the specialist performing the process is recognised by the Australasian College of Dermatologists as an approved Mohs suspections (inclusive)	dure, if the specialist
	Not applicable to a service performed in association with a service to which item 31	001 applies (Anaes.)
31004	(See para TN.8.151 of explanatory notes to this Category) Fee: \$726.05 Benefit: 75% = \$544.55 85% = \$642.65	
	Mohs surgery of skin tumour utilising horizontal frozen sections with mapping of all histological examination of all excised tissue by the specialist performing the proced is recognised by the Australasian College of Dermatologists as an approved Mohs sections	dure, if the specialist
	Not applicable to a service performed in association with a service to which item 31	002 applies (Anaes.)
31005	(See para TN.8.151 of explanatory notes to this Category) Fee: \$871.30 Benefit: 75% = \$653.50 85% = \$787.90	
	Tumour, cyst, ulcer or scar (other than a scar removed during the surgical approach removal of and suture, if:	at an operation),
31206	(a) the lesion size is not more than 10 mm in diameter; and	

T8. SUF	GICAL OPERATIONS 1. GENERA
	(b) the removal is from a mucous membrane by surgical excision (other than by shave excision); and
	(c) the specimen excised is sent for histological examination (Anaes.)
	Fee: \$95.45 Benefit: 75% = \$71.60 85% = \$81.15
	Tumour, cyst, ulcer or scar (other than a scar removed during the surgical approach at an operation), removal of and suture, if:
	(a) the lesion size is more than 10 mm, but not more than 20 mm, in diameter; and
	(b) the removal is from a mucous membrane by surgical excision (other than by shave excision); and
	(c) the specimen excised is sent for histological examination (Anaes.)
31211	Fee: \$123.10 Benefit: 75% = \$92.35 85% = \$104.65
	Tumour, cyst, ulcer or scar (other than a scar removed during the surgical approach at an operation), removal of and suture, if:
	(a) the lesion size is more than 20 mm in diameter; and
	(b) the removal is from a mucous membrane by surgical excision (other than by shave excision); and
	(c) the specimen excised is sent for histological examination (Anaes.)
31216	Fee: \$143.55 Benefit: 75% = \$107.70 85% = \$122.05
	Tumours (other than viral verrucae (common warts) and seborrheic keratoses), cysts, ulcers or scars (other than scars removed during the surgical approach at an operation), removal of 4 to 10 lesions and suture, if:
	(a) the size of each lesion is not more than 10 mm in diameter; and
	(b) each removal is from cutaneous or subcutaneous tissue by surgical excision (other than by shave excision); and
	(c) all of the specimens excised are sent for histological examination (Anaes.)
31220	Fee: \$214.55 Benefit: 75% = \$160.95 85% = \$182.40
	Tumours, cysts, ulcers or scars (other than scars removed during the surgical approach at an operation), removal of 4 to 10 lesions, if:
	(a) the size of each lesion is not more than 10 mm in diameter; and
	(b) each removal is from a mucous membrane by surgical excision (other than by shave excision); are
	(c) each site of excision is closed by suture; and
	(d) all of the specimens excised are sent for histological examination (Anaes.)
31221	Fee: \$214.55 Benefit: 75% = \$160.95 85% = \$182.40
	Tumours (other than viral verrucae (common warts) and seborrheic keratoses), cysts, ulcers or scars (other than scars removed during the surgical approach at an operation), removal of more than 10 lesions, if:
31225	(a) the size of each lesion is not more than 10 mm in diameter; and

T8. SUF	RGICAL OPERATIONS 1. GENERAL
	(b) each removal is from cutaneous or subcutaneous tissue or mucous membrane by surgical excision (other than by
	shave excision); and
	(c) each site of excision is closed by suture; and
	(d) all of the specimens excised are sent for histological examination (Anaes.)
	Fee: \$381.30 Benefit: 75% = \$286.00 85% = \$324.15
	SKIN AND SUBCUTANEOUS TISSUE, extensive excision of, in the treatment of SUPPURATIVE HIDRADENITIS (excision from axilla, groin or natal cleft) or SYCOSIS BARBAE or NUCHAE (excision from face or neck) (Anaes.)
31245	(See para TN.8.23 of explanatory notes to this Category) Fee: \$369.00 Benefit: 75% = \$276.75 85% = \$313.65
	GIANT HAIRY or COMPOUND NAEVUS, excision of an area at least 1 percent of body surface where the specimen excised is sent for histological confirmation of diagnosis (Anaes.)
31250	Fee: \$369.00 Benefit: 75% = \$276.75 85% = \$313.65
	Muscle, bone or cartilage, excision of one or more of, if clinically indicated, and if:
	(a) the specimen excised is sent for histological confirmation; and
	(b) a malignant tumour of skin covered by item 31000, 31001, 31002, 31003, 31004, 31005, 31356, 31358, 31359, 31361, 31363, 31365, 31367, 31369, 31371, 31372, 31373, 31374, 31375 or 31376 is excised (Anaes.)
31340	Derived Fee: 75% of the fee for excision of malignant tumour
	LIPOMA, removal of by surgical excision or liposuction, where lesion is subcutaneous and 50mm or more in diameter, or is sub-fascial, where the specimen is sent for histological confirmation of diagnosis (Anaes.)
31345	Fee: \$210.95 Benefit: 75% = \$158.25 85% = \$179.35
	Liposuction (suction assisted lipolysis) to one regional area for contour problems of abdominal, upper arm or thigh fat because of repeated insulin injections, if:
	(a) the lesion is subcutaneous; and
	(b) the lesion is 50 mm or more in diameter; and
	(c) photographic and/or diagnostic imaging evidence demonstrating the need for this service is documented in the patient notes (Anaes.)
31346	(See para TN.8.101 of explanatory notes to this Category) Fee: \$210.95 Benefit: 75% = \$158.25 85% = \$179.35
	BENIGN TUMOUR of SOFT TISSUE, excluding tumours of skin, cartilage, and bone, simple lipomas covered by item 31345 and lipomata, removal of by surgical excision, where the specimen excised is sent for histological confirmation of diagnosis, on a person 10 years of age or over, not being a service to which another item in this Group applies (Anaes.) (Assist.)
31350	Fee: \$433.35 Benefit: 75% = \$325.05 85% = \$368.35
31355	MALIGNANT TUMOUR of SOFT TISSUE, excluding tumours of skin, cartilage and bone, removal of

T8. SUF	RGICAL OPERATIONS	1. GENERAL
	by surgical excision, where histological proof of malignancy has be which another item in this Group applies (Anaes.) (Assist.)	een obtained, not being a service to
	Fee: \$714.45 Benefit: 75% = \$535.85 85% = \$631.05	
	Malignant skin lesion (other than a malignant skin lesion covered by 31375 or 31376), surgical excision (other than by shave excision) a	
	(a) the lesion is excised from nose, eyelid, eyebrow, lip, ear, digitarea; and	it or genitalia, or from a contiguous
	(b) the necessary excision diameter is less than 6 mm; and	
	(c) the excised specimen is sent for histological examination; and	d
	(d) malignancy is confirmed from the excised specimen or previous	ous biopsy;
	not in association with item 45201 (Anaes.)	
31356	(See para TN.8.22, TN.8.125 of explanatory notes to this Category) Fee: \$221.35 Benefit: 75% = \$166.05 85% = \$188.15	
	Non-malignant skin lesion (other than viral verrucae (common war including a cyst, ulcer or scar (other than a scar removed during the surgical excision (other than by shave excision) and repair of, if:	
	(a) the lesion is excised from nose, eyelid, eyebrow, lip, ear, digitarea; and	it or genitalia, or from a contiguous
	(b) the necessary excision diameter is less than 6 mm; and	
	(c) the excised specimen is sent for histological examination;	
	not in association with item 45201 (Anaes.)	
31357	(See para TN.8.22, TN.8.125 of explanatory notes to this Category) Fee: \$109.70 Benefit: 75% = \$82.30 85% = \$93.25	
	Malignant skin lesion (other than a malignant skin lesion covered by 31375 or 31376), surgical excision (other than by shave excision) a	
	(a) the lesion is excised from nose, eyelid, eyebrow, lip, ear, digitarea; and	t or genitalia, or from a contiguous
	(b) the necessary excision diameter is 6 mm or more; and	
	(c) the excised specimen is sent for histological examination; and	d
	(d) malignancy is confirmed from the excised specimen or previous	ous biopsy (Anaes.)
31358	(See para TN.8.22, TN.8.125 of explanatory notes to this Category) Fee: \$270.85 Benefit: 75% = \$203.15 85% = \$230.25	
	Malignant skin lesion (other than a malignant skin lesion covered by 31375 or 31376), surgical excision (other than by shave excision),	
31359	(a) the lesion is excised from nose, eyelid, eyebrow, lip, ear, digital the lesion is excised from nose, eyelid, eyebrow, lip, ear, digital the lesion is excised from nose, eyelid, eyebrow, lip, ear, digital the lesion is excised from nose, eyelid, eyebrow, lip, ear, digital the lesion is excised from nose, eyelid, eyebrow, lip, ear, digital the lesion is excised from nose, eyelid, eyebrow, lip, ear, digital the lesion is excised from nose, eyelid, eyebrow, lip, ear, digital the lesion is excised from nose, eyelid, eyebrow, lip, ear, digital the lesion is excised from nose, eyelid, eyebrow, lip, ear, digital the lesion is excised from nose, eyelid, eyebrow, lip, ear, digital the lesion is excised from nose, eyelid, eyebrow, lip, ear, digital the lesion is excised from the lesion of the les	it or genitalia (the applicable site); and

T8. SURC	GICAL OPERATIONS 1. G	ENERAL
	(b) the necessary excision area is at least one third of the surface area of the applicable site;	and
	(c) the excised specimen is sent for histological examination; and	
	(d) malignancy is confirmed from the excised specimen or previous biopsy	
	(H) (Anaes.)	
	(See para TN.8.22, TN.8.125 of explanatory notes to this Category) Fee: \$330.15 Benefit: 75% = \$247.65	
	Non-malignant skin lesion (other than viral verrucae (common warts) and seborrheic keratoses including a cyst, ulcer or scar (other than a scar removed during the surgical approach at an op surgical excision (other than by shave excision) and repair of, if:	
	(a) the lesion is excised from nose, eyelid, eyebrow, lip, ear, digit or genitalia, or from a con area; and	tiguous
	(b) the necessary excision diameter is 6 mm or more; and	
	(c) the excised specimen is sent for histological examination (Anaes.)	
31360	(See para TN.8.22, TN.8.125 of explanatory notes to this Category) Fee: \$168.05 Benefit: 75% = \$126.05 85% = \$142.85	
	Malignant skin lesion (other than a malignant skin lesion covered by item 31371, 31372, 3137, 31375 or 31376), surgical excision (other than by shave excision) and repair of, if:	3, 31374,
	(a) the lesion is excised from face, neck, scalp, nipple-areola complex, distal lower limb (distinctuding, the	stal to, and
	knee) or distal upper limb (distal to, and including, the ulnar styloid); and	
	(b) the necessary excision diameter is less than 14 mm; and	
	(c) the excised specimen is sent for histological examination; and	
	(d) malignancy is confirmed from the excised specimen or previous biopsy;	
	not in association with item 45201 (Anaes.)	
31361	(See para TN.8.23, TN.8.22, TN.8.125 of explanatory notes to this Category) Fee: \$186.70 Benefit: 75% = \$140.05 85% = \$158.70	
	Non-malignant skin lesion (other than viral verrucae (common warts) and seborrheic keratoses including a cyst, ulcer or scar (other than a scar removed during the surgical approach at an op surgical excision (other than by shave excision) and repair of, if:	
	(a) the lesion is excised from face, neck, scalp, nipple-areola complex, distal lower limb (disincluding, the	stal to, and
	knee) or distal upper limb (distal to, and including, the ulnar styloid); and	
	(b) the necessary excision diameter is less than 14 mm; and	
	(c) the excised specimen is sent for histological examination;	
31362	not in association with item 45201 (Anaes.)	

T8. SUF	RGICAL OPERATIONS	1. GENERAL
	(See para TN.8.23, TN.8.22, TN.8.125 of explanatory notes to this Category) Fee: \$133.90 Benefit: 75% = \$100.45 85% = \$113.85	
	Malignant skin lesion (other than a malignant skin lesion covered by item 31371, 31372 31375 or 31376), surgical excision (other than by shave excision) and repair of, if:	2, 31373, 31374,
	(a) the lesion is excised from face, neck, scalp, nipple-areola complex, distal lower lincluding, the	mb (distal to, and
	knee) or distal upper limb (distal to, and including, the ulnar styloid); and	
	(b) the necessary excision diameter is 14 mm or more; and	
	(c) the excised specimen is sent for histological examination; and	
	(d) malignancy is confirmed from the excised specimen or previous biopsy (Anaes.)	
31363	(See para TN.8.23, TN.8.22, TN.8.125 of explanatory notes to this Category) Fee: \$244.30 Benefit: 75% = \$183.25 85% = \$207.70	
	Non-malignant skin lesion (other than viral verrucae (common warts) and seborrheic keincluding a cyst, ulcer or scar (other than a scar removed during the surgical approach a surgical excision (other than by shave excision) and repair of, if:	
	(a) the lesion is excised from face, neck, scalp, nipple-areola complex, distal lower lincluding, the	mb (distal to, and
	knee) or distal upper limb (distal to, and including, the ulnar styloid); and	
	(b) the necessary excision diameter is 14 mm or more; and	
	(c) the excised specimen is sent for histological examination (Anaes.)	
31364	(See para TN.8.23, TN.8.22, TN.8.125 of explanatory notes to this Category) Fee: \$168.05 Benefit: 75% = \$126.05 85% = \$142.85	
	Malignant skin lesion (other than a malignant skin lesion covered by item 31369, 31370 or 31373), surgical excision (other than by shave excision) and repair of, if:), 31371, 31372
	(a) the lesion is excised from any part of the body not covered by item 31356, 31358, 31363; and	, 31359, 31361 or
	(b) the necessary excision diameter is less than 15 mm; and	
	(c) the excised specimen is sent for histological examination; and	
	(d) malignancy is confirmed from the excised specimen or previous biopsy;	
	not in association with item 45201 (Anaes.)	
31365	(See para TN.8.22, TN.8.125 of explanatory notes to this Category) Fee: \$158.30 Benefit: 75% = \$118.75 85% = \$134.60	
	Non-malignant skin lesion (other than viral verrucae (common warts) and seborrheic ke including a cyst, ulcer or scar (other than a scar removed during the surgical approach a surgical excision (other than by shave excision) and repair of, if:	
31366	(a) the lesion is excised from any part of the body not covered by item 31357, 31360.	, 31362 or 31364;

T8. SUR	GICAL OPERATIONS 1. GENERAL
	and
	(b) the necessary excision diameter is less than 15 mm; and
	(c) the excised specimen is sent for histological examination;
	not in association with item 45201 (Anaes.)
	(See para TN.8.22, TN.8.125 of explanatory notes to this Category) Fee: \$95.45 Benefit: 75% = \$71.60 85% = \$81.15
	Malignant skin lesion (other than a malignant skin lesion covered by item 31371, 31372, 31373, 31374, 31375 or 31376), surgical excision (other than by shave excision) and repair of, if:
	(a) the lesion is excised from any part of the body not covered by item 31356, 31358, 31359, 31361 or 31363; and
	(b) the necessary excision diameter is at least 15 mm but not more than 30 mm; and
	(c) the excised specimen is sent for histological examination; and
	(d) malignancy is confirmed from the excised specimen or previous biopsy;
	not in association with item 45201 (Anaes.)
31367	(See para TN.8.22, TN.8.125 of explanatory notes to this Category) Fee: \$213.60 Benefit: 75% = \$160.20 85% = \$181.60
	Non-malignant skin lesion (other than viral verrucae (common warts) and seborrheic keratoses), including a cyst, ulcer or scar (other than a scar removed during the surgical approach at an operation), surgical excision (other than by shave excision) and repair of, if:
	(a) the lesion is excised from any part of the body not covered by item 31357, 31360, 31362 or 31364; and
	(b) the necessary excision diameter is at least 15 mm but not more than 30mm; and
	(c) the excised specimen is sent for histological examination;
	not in association with item 45201 (Anaes.)
31368	(See para TN.8.22, TN.8.125 of explanatory notes to this Category) Fee: \$125.55 Benefit: 75% = \$94.20 85% = \$106.75
	Malignant skin lesion (other than a malignant skin lesion covered by item 31371, 31372, 31373, 31374, 31375 or 31376), surgical excision (other than by shave excision) and repair of, if:
	(a) the lesion is excised from any part of the body not covered by item 31356, 31358, 31359, 31361 or 31363; and
	(b) the necessary excision diameter is more than 30 mm; and
	(c) the excised specimen is sent for histological examination; and
	(d) malignancy is confirmed from the excised specimen or previous biopsy (Anaes.)
31369	(See para TN.8.22, TN.8.125 of explanatory notes to this Category) Fee: \$245.90 Benefit: 75% = \$184.45 85% = \$209.05

T8. SUR	GICAL OPERATIONS	1. GENERAL
	Non-malignant skin lesion (other than viral verrucae (common warts) and seborrheic kera including a cyst, ulcer or scar (other than a scar removed during the surgical approach at a surgical excision (other than by shave excision) and repair of, if:	
	(a) the lesion is excised from any part of the body not covered by item 31357, 31360, 3 and	31362 or 31364;
	(b) the necessary excision diameter is more than 30 mm; and	
	(c) the excised specimen is sent for histological examination (Anaes.)	
31370	(See para TN.8.22, TN.8.125 of explanatory notes to this Category) Fee: \$143.55 Benefit: 75% = \$107.70 85% = \$122.05	
	Malignant melanoma, appendageal carcinoma, malignant connective tissue tumour of ski carcinoma of skin, definitive surgical excision (other than by shave excision) and repair of	
	(a) the tumour is excised from nose, eyelid, eyebrow, lip, ear, digit or genitalia, or from area; and	n a contiguous
	(b) the necessary excision diameter is 6 mm or more; and	
	(c) the excised specimen is sent for histological examination; and	
	(d) malignancy is confirmed from the excised specimen or previous biopsy (Anaes.)	
31371	(See para TN.8.22, TN.8.125 of explanatory notes to this Category) Fee: \$357.00 Benefit: 75% = \$267.75 85% = \$303.45	
	Malignant melanoma, appendageal carcinoma, malignant connective tissue tumour of ski carcinoma of skin, definitive surgical excision (other than by shave excision) and repair of	
	(a) the tumour is excised from face, neck, scalp, nipple-areola complex, distal lower lin and including,	mb (distal to,
	the knee) or distal upper limb (distal to, and including, the ulnar styloid); and	
	(b) the necessary excision diameter is less than 14 mm; and	
	(c) the excised specimen is sent for histological examination; and	
	(d) malignancy is confirmed from the excised specimen or previous biopsy;	
	not in association with item 45201 (Anaes.)	
31372	(See para TN.8.23, TN.8.22, TN.8.125 of explanatory notes to this Category) Fee: \$308.70 Benefit: 75% = \$231.55 85% = \$262.40	
	Malignant melanoma, appendageal carcinoma, malignant connective tissue tumour of ski carcinoma of skin, definitive surgical excision (other than by shave excision) and repair of	
	(a) the tumour is excised from face, neck, scalp, nipple-areola complex, distal lower lin and including,	mb (distal to,
	the knee) or distal upper limb (distal to, and including, the ulnar styloid); and	
31373	(b) the necessary excision diameter is 14 mm or more; and	

T8. SUR	GICAL OPERATIONS 1. GENERAL
	(c) the excised specimen is sent for histological examination; and
	(d) malignancy is confirmed from the excised specimen or previous biopsy (Anaes.)
	(See para TN.8.23, TN.8.22, TN.8.125 of explanatory notes to this Category) Fee: \$356.80 Benefit: 75% = \$267.60 85% = \$303.30
	Malignant melanoma, appendageal carcinoma, malignant connective tissue tumour of skin or merkel cell carcinoma of skin, definitive surgical excision (other than by shave excision) and repair of, if:
	(a) the tumour is excised from any part of the body not covered by item 31371, 31372 or 31373; and
	(b) the necessary excision diameter is less than 15 mm; and
	(c) the excised specimen is sent for histological examination; and
	(d) malignancy is confirmed from the excised specimen or previous biopsy;
	not in association with item 45201 (Anaes.)
31374	(See para TN.8.125, TN.1.21 of explanatory notes to this Category) Fee: \$281.90 Benefit: 75% = \$211.45 85% = \$239.65
	Malignant melanoma, appendageal carcinoma, malignant connective tissue tumour of skin or merkel cell carcinoma of skin, definitive surgical excision (other than by shave excision) and repair of, if:
	(a) the tumour is excised from any part of the body not covered by item 31371, 31372 or 31373; and
	(b) the necessary excision diameter is at least 15 mm but not more than 30 mm; and
	(c) the excised specimen is sent for histological examination; and
	(d) malignancy is confirmed from the excised specimen or previous biopsy;
	not in association with item 45201 (Anaes.)
31375	(See para TN.8.22, TN.8.125 of explanatory notes to this Category) Fee: \$303.40 Benefit: 75% = \$227.55 85% = \$257.90
	Malignant melanoma, appendageal carcinoma, malignant connective tissue tumour of skin or merkel cell carcinoma of skin, definitive surgical excision (other than by shave excision) and repair of, if:
	(a) the tumour is excised from any part of the body not covered by item 31371, 31372 or 31373; and
	(b) the necessary excision diameter is more than 30 mm; and
	(c) the excised specimen is sent for histological examination; and
	(d) malignancy is confirmed from the excised specimen or previous biopsy (Anaes.)
31376	(See para TN.8.22, TN.8.125 of explanatory notes to this Category) Fee: \$351.60 Benefit: 75% = \$263.70 85% = \$298.90
	MALIGNANT UPPER AERODIGESTIVE TRACT TUMOUR up to and including 20mm in diameter (excluding tumour of the lip), excision of, where histological confirmation of malignancy has been obtained (Anaes.) (Assist.)
31400	Fee: \$261.05 Benefit: 75% = \$195.80 85% = \$221.90
31403	MALIGNANT UPPER AERODIGESTIVE TRACT TUMOUR more than 20mm and up to and

T8. SUF	RGICAL OPERATIONS	1. GENERAL
	including 40mm in diameter (excluding tumour of the lip), excision of of malignancy has been obtained (Anaes.) (Assist.)	f, where histological confirmation
	Fee: \$301.35 Benefit: 75% = \$226.05	
	MALIGNANT UPPER AERODIGESTIVE TRACT TUMOUR more (excluding tumour of the lip), excision of, where histological confirmation obtained (Anaes.) (Assist.)	
31406	Fee: \$502.15 Benefit: 75% = \$376.65 85% = \$426.85	
	PARAPHARYNGEAL TUMOUR, excision of, by cervical approach	(Anaes.) (Assist.)
31409	Fee: \$1,560.15 Benefit: 75% = \$1170.15	
	RECURRENT OR PERSISTENT PARAPHARYNGEAL TUMOUR (Anaes.) (Assist.)	, excision of, by cervical approach
31412	Fee: \$1,921.75 Benefit: 75% = \$1441.35	
	LYMPH NODE OF NECK, biopsy of (Anaes.)	
31420	Fee: \$183.90 Benefit: 75% = \$137.95 85% = \$156.35	
	LYMPH NODES OF NECK, selective dissection of 1 or 2 lymph nod tissue and lymph nodes from one side of the neck, on a person 10 year	
31423	(See para TN.8.24 of explanatory notes to this Category) Fee: \$401.75 Benefit: 75% = \$301.35 85% = \$341.50	
	LYMPH NODES OF NECK, selective dissection of 3 lymph node lever tissue and lymph nodes from one side of the neck (Anaes.) (Assist.)	vels involving removal of soft
31426	(See para TN.8.24 of explanatory notes to this Category) Fee: \$803.45 Benefit: 75% = \$602.60	
	LYMPH NODES OF NECK, selective dissection of 4 lymph node lever preservation of one or more of: internal jugular vein, sternocleido-mass nerve (Anaes.) (Assist.)	
21.420	(See para TN.8.24 of explanatory notes to this Category)	
31429	Fee: \$1,252.10 Benefit: 75% = \$939.10 LYMPH NODES OF NECK, bilateral selective dissection of levels I, dissections) (Anaes.) (Assist.)	II and III (bilateral supraomohyoid
31432	(See para TN.8.24 of explanatory notes to this Category) Fee: \$1,339.15 Benefit: 75% = \$1004.40	
	LYMPH NODES OF NECK, comprehensive dissection of all 5 lympl neck (Anaes.) (Assist.)	h node levels on one side of the
31435	(See para TN.8.24 of explanatory notes to this Category) Fee: \$984.30 Benefit: 75% = \$738.25	
	LYMPH NODES OF NECK, comprehensive dissection of all 5 lympl neck with preservation of one or more of: internal jugular vein, sterno accessory nerve (Anaes.) (Assist.)	
31438	(See para TN.8.24 of explanatory notes to this Category) Fee: \$1,560.15 Benefit: 75% = \$1170.15	
31450	LAPAROSCOPIC DIVISION OF ADHESIONS, as an independent p	procedure, where the time taken is 1

T8. SUF	RGICAL OPERATIONS 1.	GENERAL
	hour or less (Anaes.) (Assist.)	
	Fee: \$406.65 Benefit: 75% = \$305.00	
	LAPAROSCOPIC DIVISION OF ADHESIONS, as an independent procedure, where the time more than 1 hour (Anaes.) (Assist.)	ne taken in
31452	Fee: \$711.50 Benefit: 75% = \$533.65	
	LAPAROSCOPY with drainage of pus, bile or blood, as an independent procedure (Anaes.)	(Assist.)
31454	Fee: \$563.30 Benefit: 75% = \$422.50	
	GASTROSCOPY and insertion of nasogastric or nasoenteral feeding tube, where blind inser feeding tube has failed or is inappropriate due to the patient's medical condition (Anaes.)	tion of the
31456	Fee: \$245.55 Benefit: 75% = \$184.20	
	GASTROSCOPY and insertion of nasogastric or nasoenteral feeding tube, where blind inserfeeding tube has failed or is inappropriate due to the patient's medical condition, and where timaging intensification is clinically indicated (Anaes.)	
31458	Fee: \$294.65 Benefit: 75% = \$221.00	
	PERCUTANEOUS GASTROSTOMY TUBE, jejunal extension to, including any associated imaging services (Anaes.) (Assist.)	
31460	Fee: \$357.00 Benefit: 75% = \$267.75	
	OPERATIVE FEEDING JEJUNOSTOMY performed in conjunction with major upper gastr resection (Anaes.) (Assist.)	ro-intestinal
31462	Fee: \$521.25 Benefit: 75% = \$390.95	
	ANTIREFLUX OPERATION BY FUNDOPLASTY, via abdominal or thoracic approach, with or without closure of the diaphragmatic hiatus, by laparoscopic technique - not being a service to which item 30601 applies (Anaes.) (Assist.)	
31464	(See para TN.8.19 of explanatory notes to this Category) Fee: \$871.30 Benefit: 75% = \$653.50	
	ANTIREFLUX OPERATION BY FUNDOPLASTY, via abdominal or thoracic approach, w without closure of the diaphragmatic hiatus, revision procedure, by laparoscopy or open open (Anaes.) (Assist.)	
31466	(See para TN.8.19 of explanatory notes to this Category) Fee: \$1,306.95 Benefit: 75% = \$980.25	
	PARA-OESOPHAGEAL HIATUS HERNIA, repair of, with complete reduction of hernia, resection of sac and repair of hiatus, with or without fundoplication (Anaes.) (Assist.)	
31468	Fee: \$1,435.85 Benefit: 75% = \$1076.90	
	LAPAROSCOPIC SPLENECTOMY, on a person 10 years of age or over (Anaes.) (Assist.)	
31470	Fee: \$720.20 Benefit: 75% = \$540.15	
	CHOLECYSTODUODENOSTOMY, CHOLECYSTOENTEROSTOMY, CHOLEDOCHOJEJUNOSTOMY OR ROUX-EN-Y as a bypass procedure where prior biling has been performed (Anaes.) (Assist.)	ary surgery
31472	Fee: \$1,169.80 Benefit: 75% = \$877.35	

T8. SUF	RGICAL OPERATIONS	1. GENERAL
	BREAST, BENIGN LESION up to and including 50mm in diameter, including sin fibroadenoma or fibrocystic disease, open surgical biopsy or excision of, with or v histology (Anaes.)	1 2 ,
31500	(See para TN.8.25 of explanatory notes to this Category) Fee: \$260.05 Benefit: 75% = \$195.05 85% = \$221.05	
	BREAST, BENIGN LESION more than 50mm in diameter, excision of (Anaes.) ((Assist.)
31503	(See para TN.8.25 of explanatory notes to this Category) Fee: \$346.75 Benefit: 75% = \$260.10 85% = \$294.75	
	BREAST, ABNORMALITY detected by mammography or ultrasound where guid localisation procedure is performed, excision biopsy of (Anaes.) (Assist.)	lewire or other
31506	(See para TN.8.25 of explanatory notes to this Category) Fee: \$390.10 Benefit: 75% = \$292.60	
	BREAST, MALIGNANT TUMOUR, open surgical biopsy of, with or without fro (Anaes.)	zen section histology
31509	(See para TN.8.25 of explanatory notes to this Category) Fee: \$346.75 Benefit: 75% = \$260.10 85% = \$294.75	
	BREAST, MALIGNANT TUMOUR, complete local excision of, with or without histology (Anaes.) (Assist.)	frozen section
31512	Fee: \$650.15 Benefit: 75% = \$487.65	
	BREAST, TUMOUR SITE, re-excision of following open biopsy or incomplete entumour (Anaes.) (Assist.)	xcision of malignant
31515	(See para TN.8.25 of explanatory notes to this Category) Fee: \$436.15 Benefit: 75% = \$327.15	
	BREAST, MALIGNANT TUMOUR, complete local excision of, with or without histology when targeted intraoperative radiotherapy (using an Intrabeam® device) concurrently, if the requirements of item 15900 are met for the patient (Anaes.) (A	is performed
31516	Fee: \$867.00 Benefit: 75% = \$650.25	
	BREAST, total mastectomy (H) (Anaes.) (Assist.)	
31519	Fee: \$736.05 Benefit: 75% = \$552.05	
	BREAST, subcutaneous mastectomy (H) (Anaes.) (Assist.)	
31524	Fee: \$1,040.25 Benefit: 75% = \$780.20	
	BREAST, mastectomy for gynecomastia, with or without liposuction (suction assibeing a service associated with a service to which item 45585 applies (H) (Anaes.)	
31525	Fee: \$520.00 Benefit: 75% = \$390.00	
	BREAST, BIOPSY OF SOLID TUMOUR OR TISSUE OF, using a vacuum-assis device under imaging guidance, for histological examination, where imaging has one of the control of the	
	(a) microcalcification of lesion; or	
	(b) impalpable lesion less than 1cm in diameter	
31530	- including pre-operative localisation of lesion where performed, not being a ser	vice to which items

T8. SUF	RGICAL OPERATI	ONS 1. GENERAL
	31539, 31545 or	31548 apply
	Fee: \$595.65	Benefit: 75% = \$446.75 85% = \$512.25
		ASPIRATION of an impalpable breast lesion detected by mammography or ultrasound, but not including imaging (Anaes.)
31533	(See para TN.8.26 Fee: \$137.90	of explanatory notes to this Category) Benefit: 75% = \$103.45 85% = \$117.25
		erative localisation of lesion of, by hookwire or similar device, using interventional les - but not including imaging, not being a service to which item 31539, 31542 or naes.)
31536	Fee: \$189.40	Benefit: 75% = \$142.05 85% = \$161.00
	histological exam of Surgeons, and	SY OF SOLID TUMOUR OR TISSUE OF, using a bore-enbloc stereotactic biopsy, for nination, when conducted by a surgeon as determined by the Royal Australasian College where imaging has demonstrated an impalpable lesion of less than 15mm in diameter, see to which item 31530, 31536 or 31548 applies (Anaes.)
31539	(See para TN.8.27 Fee: \$398.80	of explanatory notes to this Category) Benefit: 75% = \$299.10
	radiologist as det interventional im	guidewire localisation of lesion, by hookwire or similar device, when conducted by a ermined by the Royal Australian and New Zealand College of Radiologists, using aging techniques prior to using a bore-enbloc stereotactic biopsy - including imaging the associated with a service to which item 31536 applies (Anaes.)
31542	(See para TN.8.28 Fee: \$196.95	of explanatory notes to this Category) Benefit: 75% = \$147.75 85% = \$167.45
	histological exam of Surgeons; whe including initial g imaging techniqu	SY OF SOLID TUMOUR OR TISSUE OF, using a bore-enbloc stereotactic biopsy, for initiation, when conducted by a surgeon as determined by the Royal Australasian College are imaging has demonstrated an impalpable lesion of less than 15mm in diameter, guidewire localisation of lesion, by hookwire or similar device, using interventional less and including imaging not being a service associated with a service to which item 31548 applies (Anaes.)
31545		of explanatory notes to this Category) Benefit: 75% = \$446.75 85% = \$512.25
310.10	BREAST, BIOPS	SY OF SOLID TUMOUR OR TISSUE OF, using mechanical biopsy device, for nination, not being a service to which items 31530, 31539 or 31545 apply (Anaes.)
31548	Fee: \$137.90	Benefit: 75% = \$103.45 85% = \$117.25
	granulomatous m	MATOMA, SEROMA OR INFLAMMATORY CONDITION including abscess, astitis or similar, exploration and drainage of when undertaken in the operating theatre luding aftercare (Anaes.)
31551	Fee: \$216.75	Benefit: 75% = \$162.60
	BREAST, micro	dochotomy of, for benign or malignant condition (Anaes.) (Assist.)
31554	Fee: \$433.50	Benefit: 75% = \$325.15
	BREAST CENT	RAL DUCTS, excision of, for benign condition (Anaes.) (Assist.)
	Fee: \$346.75	Benefit: 75% = \$260.10 85% = \$294.75

T8. SUF	RGICAL OPERATIONS	1. GENERAL
	ACCESSORY BREAST TISSUE, excision of (Anaes.) (Assist.)	
31560	Fee: \$346.75 Benefit: 75% = \$260.10 85% = \$294.75 Extended Medicare Safety Net Cap: \$277.40	
	INVERTED NIPPLE, surgical eversion of (Anaes.)	
31563	Fee: \$259.75 Benefit: 75% = \$194.85 85% = \$220.80	
	ACCESSORY NIPPLE, excision of (Anaes.)	
31566	Fee: \$129.95 Benefit: 75% = \$97.50 85% = \$110.50	
	BARIATRIC	
	Adjustable gastric band, placement of, with or without crural repair taking 45 minu patient with clinically severe obesity (Anaes.) (Assist.)	tes or less, for a
31569	(See para TN.8.29 of explanatory notes to this Category) Fee: \$849.55 Benefit: 75% = \$637.20	
	Gastric bypass by Roux-en-Y including associated anastomoses, with or without cr minutes or less, for a patient with clinically severe obesity not being associated wit item 30515 applies (Anaes.) (Assist.)	
31572	(See para TN.8.29 of explanatory notes to this Category) Fee: \$1,045.40 Benefit: 75% = \$784.05	
	Sleeve gastrectomy, with or without crural repair taking 45 minutes or less, for a pasevere obesity (Anaes.) (Assist.)	ntient with clinically
31575	(See para TN.8.29 of explanatory notes to this Category) Fee: \$849.55 Benefit: 75% = \$637.20	
	Gastroplasty (excluding by gastric plication), with or without crural repair taking 4 a patient with clinically severe obesity (Anaes.) (Assist.)	5 minutes or less, for
31578	(See para TN.8.29 of explanatory notes to this Category) Fee: \$849.55 Benefit: 75% = \$637.20	
	Gastric bypass by biliopancreatic diversion with or without duodenal switch includ and anastomoses, with or without crural repair taking 45 minutes or less, for a patie severe obesity (Anaes.) (Assist.)	
31581	(See para TN.8.29 of explanatory notes to this Category) Fee: \$1,045.40 Benefit: 75% = \$784.05	
	Surgical reversal of adjustable gastric banding (removal or replacement of gastric b gastroplasty (excluding by gastric plication) or biliopancreatic diversion being serv 31569 to 31581 apply (Anaes.) (Assist.)	
31584	(See para TN.8.30 of explanatory notes to this Category) Fee: \$1,539.10 Benefit: 75% = \$1154.35	
	Adjustment of gastric band as an independent procedure including any associated of	onsultation
31587	Fee: \$97.95 Benefit: 75% = \$73.50 85% = \$83.30	
	Adjustment of gastric band reservoir, repair, revision or replacement of (Anaes.) (A	Assist.)
31590	Fee: \$251.70 Benefit: 75% = \$188.80 85% = \$213.95	
T8. SUF	RGICAL OPERATIONS	2. COLORECTAL

T8. SUF	RGICAL OPERATIONS 2. COLORECTAL		
	Group T8. Surgical Operations		
	Subgroup 2. Colorectal		
	LARGE INTESTINE, resection of, without anastomosis, including right hemicolectomy (including formation of stoma) (Anaes.) (Assist.)		
32000	Fee: \$1,031.35 Benefit: 75% = \$773.55		
	LARGE INTESTINE, resection of, with anastomosis, including right hemicolectomy (Anaes.) (Assist.)		
32003	Fee: \$1,078.80 Benefit: 75% = \$809.10		
	LARGE INTESTINE, subtotal colectomy (resection of right colon, transverse colon and splenic flexure) without anastomosis, not being a service associated with a service to which item 32000, 32003, 32005 or 32006 applies (Anaes.) (Assist.)		
32004	Fee: \$1,150.35 Benefit: 75% = \$862.80		
	LARGE INTESTINE, subtotal colectomy (resection of right colon, transverse colon and splenic flexure) with anastomosis, not being a service associated with a service to which item 32000, 32003, 32004 or 32006 applies (Anaes.) (Assist.)		
32005	Fee: \$1,299.55 Benefit: 75% = \$974.70		
	LEFT HEMICOLECTOMY, including the descending and sigmoid colon (including formation of stoma) (Anaes.) (Assist.)		
32006	Fee: \$1,150.35 Benefit: 75% = \$862.80		
	TOTAL COLECTOMY AND ILEOSTOMY (Anaes.) (Assist.)		
32009	Fee: \$1,364.60 Benefit: 75% = \$1023.45		
	TOTAL COLECTOMY AND ILEORECTAL ANASTOMOSIS (Anaes.) (Assist.)		
32012	Fee: \$1,507.40 Benefit: 75% = \$1130.55		
	TOTAL COLECTOMY WITH EXCISION OF RECTUM AND ILEOSTOMY 1 surgeon (Anaes.) (Assist.)		
32015	Fee: \$1,852.50 Benefit: 75% = \$1389.40		
	TOTAL COLECTOMY WITH EXCISION OF RECTUM AND ILEOSTOMY, COMBINED SYNCHRONOUS OPERATION; ABDOMINAL RESECTION (including aftercare) (Anaes.) (Assist.)		
32018	Fee: \$1,570.85 Benefit: 75% = \$1178.15		
	TOTAL COLECTOMY WITH EXCISION OF RECTUM AND ILEOSTOMY, COMBINED SYNCHRONOUS OPERATION; PERINEAL RESECTION (Assist.)		
32021	Fee: \$563.30 Benefit: 75% = \$422.50		
	Endoscopic insertion of stent or stents for large bowel obstruction, stricture or stenosis, including colonoscopy and any image intensification, where the obstruction is due to:		
	a) a pre-diagnosed colorectal cancer, or cancer of an organ adjacent to the bowel; or		
	b) an unknown diagnosis (Anaes.)		
32023	(See para TN.8.17 of explanatory notes to this Category) Fee: \$555.35 Benefit: 75% = \$416.55		

T8. SUF	RGICAL OPERATIONS	2. COLORECTAL
	ANASTOMOSIS (of the rectum) greater	ERIOR RESECTION WITH INTRAPERITONEAL than 10 centimetres from the anal verge excluding resection of associated with a service to which item 32103, 32104 or 32106
32024	Fee: \$1,364.60 Benefit: 75% = \$1023	3.45
	ANASTOMOSIS (of the rectum) less than	ERIOR RESECTION WITH EXTRAPERITONEAL in 10 centimetres from the anal verge, with or without covering a service to which item 32103, 32104 or 32106 applies
32025	Fee: \$1,825.30 Benefit: 75% = \$1369	9.00
		YE RESECTION, with or without covering stoma, where the n and is 6cm or less from the anal verge (Anaes.) (Assist.)
32026	Fee: \$1,965.65 Benefit: 75% = \$1474	1.25
	RECTUM, LOW OR ULTRA LOW RES anastomosis, with or without covering sto	TORATIVE RESECTION, with peranal sutured coloanal ma (Anaes.) (Assist.)
32028	Fee: \$2,106.20 Benefit: 75% = \$1579	9.65
	COLONIC RESERVOIR, construction of item in this Subgroup applies (Anaes.) (A	being a service associated with a service to which any other ssist.)
32029	Fee: \$421.20 Benefit: 75% = \$315.	90
	RECTOSIGMOIDECTOMY (Hartmann'	s operation) (Anaes.) (Assist.)
32030	Fee: \$1,031.35 Benefit: 75% = \$773.	55
	RESTORATION OF BOWEL following stoma (Anaes.) (Assist.)	Hartmann's or similar operation, including dismantling of the
32033	Fee: \$1,507.40 Benefit: 75% = \$1130	0.55
	SACROCOCCYGEAL AND PRESACRA	AL TUMOUR excision of (Anaes.) (Assist.)
32036	Fee: \$1,911.80 Benefit: 75% = \$1433	3.85
	RECTUM AND ANUS, ABDOMINOPE	RINEAL RESECTION OF 1 surgeon (Anaes.) (Assist.)
32039	Fee: \$1,535.05 Benefit: 75% = \$115	1.30
		RINEAL RESECTION OF, COMBINED SYNCHRONOUS
32042	Fee: \$1,293.15 Benefit: 75% = \$969.	90
	RECTUM AND ANUS, ABDOMINOPE OPERATION perineal resection (Assist.)	RINEAL RESECTION OF, COMBINED SYNCHRONOUS
32045	Fee: \$483.95 Benefit: 75% = \$363.	00
		resection of, combined synchronous operation - perineal provides assistance to the abdominal surgeon (Assist.)
32046	Fee: \$747.90 Benefit: 75% = \$560.	95
32047	PERINEAL PROCTECTOMY (Anaes.) (Assist.)

T8. SUF	RGICAL OPERATI	ONS 2. COLORECTAL		
	Fee: \$871.30	Benefit: 75% = \$653.50		
		TOMY with excision of rectum and ileoanal anastomosis with formation of ileal without creation of temporary ileostomy 1 surgeon (Anaes.) (Assist.)		
32051	Fee: \$2,316.60	Benefit: 75% = \$1737.45		
	reservoir, with or	TOMY with excision of rectum and ileoanal anastomosis with formation of ileal without creation of temporary ileostomy conjoint surgery, abdominal surgeon are) (Anaes.) (Assist.)		
32054	Fee: \$2,126.20	Benefit: 75% = \$1594.65		
		TOMY with excision of rectum and ileoanal anastomosis with formation of ileal at surgery, perineal surgeon (Assist.)		
32057	Fee: \$563.30	Benefit: 75% = \$422.50		
		LOSURE with rectal resection and mucosectomy and ileoanal anastomosis with reservoir, with or without temporary loop ileostomy 1 surgeon (Anaes.) (Assist.)		
32060	Fee: \$2,316.60	Benefit: 75% = \$1737.45		
	ILEOSTOMY CLOSURE with rectal resection and mucosectomy and ileoanal anastomosis with formation of ileal reservoir, with or without temporary loop ileostomy conjoint surgery, abdominal surgeon (including aftercare) (Anaes.) (Assist.)			
32063	Fee: \$2,126.20	Benefit: 75% = \$1594.65		
		LOSURE with rectal resection and mucosectomy and ileoanal anastomosis with reservoir, with or without temporary loop ileostomy conjoint surgery, perineal		
32066	Fee: \$563.30	Benefit: 75% = \$422.50		
	ILEOSTOMY RI where appropriate	ESERVOIR, continent type, creation of, including conversion of existing ileostomy e (Anaes.)		
32069	Fee: \$1,713.65	Benefit: 75% = \$1285.25		
	SIGMOIDOSCO	PIC EXAMINATION (with rigid sigmoidoscope), with or without biopsy		
32072	Fee: \$47.85	Benefit: 75% = \$35.90 85% = \$40.70		
	SIGMOIDOSCO ANAESTHESIA	PIC EXAMINATION (with rigid sigmoidoscope), UNDER GENERAL, with or without biopsy, not being a service associated with a service to which another p applies (Anaes.)		
32075	Fee: \$75.05	Benefit: 75% = \$56.30 85% = \$63.80		
		c sigmoidoscopy or fibreoptic colonoscopy up to the hepatic flexure, with or without a service associated with a service to which item 32090 or 32093 applies.		
	(Anaes.)			
32084	(See para TN.8.17, Fee: \$111.35	TN.8.134 of explanatory notes to this Category) Benefit: 75% = \$83.55 85% = \$94.65		
32087		nination of the colon up to the hepatic flexure by flexible fibreoptic sigmoidoscopy or scopy for the removal of 1 or more polyps or the treatment of radiation proctitis,		

T8. SUF	RGICAL OPERATIONS	2. COLORECTAL
	angiodysplasia or post-polypectomy bleeding by argon plasma coagulation, one or service associated with a service to which item 32090 or 32093 applies	more of, other than a
	(Anaes.)	
	(See para TN.8.17, TN.8.134 of explanatory notes to this Category) Fee: $$204.70$ Benefit: $75\% = 153.55 $85\% = 174.00	
	FIBREOPTIC COLONOSCOPY examination of the colon beyond the hepatic flex WITHOUT BIOPSY, following a positive faecal occult blood test for a participant National Bowel Cancer Screening Program. (Anaes.)	
32088	(See para TN.8.17 of explanatory notes to this Category) Fee: \$334.35 Benefit: 75% = \$250.80 85% = \$284.20	
	Endoscopic examination of the colon beyond the hepatic flexure by FIBREOPTIC the REMOVAL OF 1 OR MORE POLYPS, following a positive faecal occult bloc registered on the National Bowel Cancer Screening Program. (Anaes.)	
32089	(See para TN.8.17 of explanatory notes to this Category) Fee: \$469.20 Benefit: 75% = \$351.90 85% = \$398.85	
	FIBREOPTIC COLONOSCOPY examination of colon beyond the hepatic flexure WITHOUT BIOPSY (Anaes.)	e WITH or
32090	(See para TN.8.17, TN.8.134 of explanatory notes to this Category) Fee: \$334.35 Benefit: 75% = \$250.80 85% = \$284.20	
	Endoscopic examination of the colon beyond the hepatic flexure by FIBREOPTIC the REMOVAL OF 1 OR MORE POLYPS, or the treatment of radiation proctitis, post-polypectomy bleeding by ARGON PLASMA COAGULATION, 1 or more o	angiodysplasia or
32093	(See para TN.8.17, TN.8.134 of explanatory notes to this Category) Fee: \$469.20 Benefit: 75% = \$351.90 85% = \$398.85	
	ENDOSCOPIC DILATATION OF COLORECTAL STRICTURES including colo	onoscopy (Anaes.)
32094	(See para TN.8.17 of explanatory notes to this Category) Fee: \$551.85 Benefit: 75% = \$413.90	
	ENDOSCOPIC EXAMINATION of SMALL BOWEL with flexible endoscope pa or without biopsies (Anaes.)	ssed by stoma, with
32095	(See para TN.8.17 of explanatory notes to this Category) Fee: \$127.80 Benefit: 75% = \$95.85 85% = \$108.65	
	RECTAL BIOPSY, full thickness, under general anaesthesia, or under epidural or nerve block where undertaken in a hospital (Anaes.) (Assist.)	spinal (intrathecal)
32096	Fee: \$256.95 Benefit: 75% = \$192.75	
	RECTAL TUMOUR of 5 centimetres or less in diameter, per anal submucosal exc (Assist.)	ision of (Anaes.)
32099	Fee: \$333.20 Benefit: 75% = \$249.90	
32102	RECTAL TUMOUR of greater than 5 centimetres in diameter, indicated by pathol	ogical examination,

T8. SUF	RGICAL OPERAT	IONS	2. COLORECTAL
	per anal submuce	osal excision of (Anaes.) (Assist.)	
	Fee: \$634.70	Benefit: 75% = \$476.05	
	either 3 dimension during colonosco	DUR, of less than 4 cm in diameter, per anal excision of onal or 2 dimensional optic viewing systems, if removatory or by local excision, other than a service associated 2104 or 32106 applies (Anaes.) (Assist.)	l is unable to be performed
32103	(See para TN.8.31, Fee: \$772.30	TN.8.17 of explanatory notes to this Category) Benefit: 75% = \$579.25	
	incorporating eit performed during	DUR, of 4 cm or greater in diameter, per anal excision of the r 3 dimensional or 2 dimensional optic viewing systems colonoscopy or by local excision, other than a service 4, 32025, 32103 or 32106 applies (Anaes.) (Assist.)	ems, if removal is unable to be
32104	(See para TN.8.31, Fee: \$999.65	TN.8.17 of explanatory notes to this Category) Benefit: 75% = \$749.75	
	ANORECTAL O	CARCINOMA per anal full thickness excision of (Ana	es.) (Assist.)
32105	Fee: \$483.95	Benefit: 75% = \$363.00 85% = \$411.40	
	ANTEROLATERAL INTRAPERITONEAL RECTAL TUMOUR, per anal excision of, using rectoscopy incorporating either 3 dimensional or 2 dimensional optic viewing systems, if removal is unable to be performed during colonoscopy and if removal requires dissection within the peritoneal cavity, other than a service associated with a service to which item 32024, 32025, 32103 or 32104 applies (Anaes.) (Assist.)		
32106	(See para TN.8.31, Fee: \$1,364.60	TN.8.17 of explanatory notes to this Category) Benefit: 75% = \$1023.45 85% = \$1281.20	
	RECTAL TUMO	OUR, transsphincteric excision of (Kraske or similar op	eration) (Anaes.) (Assist.)
32108	Fee: \$999.65	Benefit: 75% = \$749.75	
	RECTAL PROL	APSE Delorme procedure for (Anaes.) (Assist.)	
32111	Fee: \$634.70	Benefit: 75% = \$476.05	
	RECTAL PROL	APSE, perineal recto-sigmoidectomy for (Anaes.) (Ass	sist.)
32112	Fee: \$772.30	Benefit: 75% = \$579.25	
		CTURE, per anal release of (Anaes.)	
32114	Fee: \$174.45	Benefit: 75% = \$130.85 85% = \$148.30	
		CTURE, dilatation of (Anaes.)	
32115	Fee: \$126.85	Benefit: 75% = \$95.15	
		APSE, abdominal rectopexy of (Anaes.) (Assist.)	
32117	Fee: \$999.65	Benefit: 75% = \$749.75	
		APSE, perineal repair of (Anaes.) (Assist.)	
32120	Fee: \$256.95	Benefit: 75% = \$192.75	
		URE, anoplasty for (Anaes.) (Assist.)	
32123			

T8. SUF	RGICAL OPERAT	TIONS 2. COLORECTAL
	Fee: \$333.20	Benefit: 75% = \$249.90 85% = \$283.25
	ANAL INCONT	ΓΙΝΕΝCE, Parks' intersphincteric procedure for (Anaes.) (Assist.)
32126	Fee: \$483.95	Benefit: 75% = \$363.00
	ANAL SPHING	TER, direct repair of (Anaes.) (Assist.)
32129	Fee: \$634.70	Benefit: 75% = \$476.05
	RECTOCELE, 1	transanal repair of rectocele (Anaes.) (Assist.)
32131	Fee: \$533.60	Benefit: 75% = \$400.20
	HAEMORRHO	IDS OR RECTAL PROLAPSE sclerotherapy for (Anaes.)
32132	Fee: \$45.10	Benefit: 75% = \$33.85 85% = \$38.35
		IDS OR RECTAL PROLAPSE rubber band ligation of, with or without sclerotherapy, nfra red therapy for (Anaes.)
32135	Fee: \$67.50	Benefit: 75% = \$50.65 85% = \$57.40
	HAEMORRHO	IDECTOMY including excision of anal skin tags when performed (Anaes.)
32138	Fee: \$367.75	Benefit: 75% = \$275.85 85% = \$312.60
		IDECTOMY involving third or fourth degree haemorrhoids, including excision of anal performed (Anaes.) (Assist.)
32139	Fee: \$367.75	Benefit: 75% = \$275.85
	ANAL SKIN TA	AGS or ANAL POLYPS, excision of 1 or more of (Anaes.)
32142	Fee: \$67.50	Benefit: 75% = \$50.65 85% = \$57.40
	ANAL SKIN Ta a hospital (Anae	AGS or ANAL POLYPS, excision of 1 or more of, undertaken in the operating theatre of es.)
32145	Fee: \$135.05	Benefit: 75% = \$101.30
	PERIANAL TH	ROMBOSIS, incision of (Anaes.)
32147	Fee: \$45.10	Benefit: 75% = \$33.85 85% = \$38.35
	OPERATION F only (Anaes.) (A	OR FISSUREINANO, including excision or sphincterotomy, but excluding dilatation assist.)
32150	Fee: \$256.95	Benefit: 75% = \$192.75 85% = \$218.45
		ATION OF, under general anaesthesia, with or without disimpaction of faeces, not being ated with a service to which another item in this Group applies (Anaes.)
32153	Fee: \$70.10	Benefit: 75% = \$52.60
	FISTULA-IN-A	NO, SUBCUTANEOUS, excision of (Anaes.)
32156	Fee: \$131.75	Benefit: 75% = \$98.85 85% = \$112.00
		A, treatment of, by excision or by insertion of a Seton, or by a combination of both olving the lower half of the anal sphincter mechanism (Anaes.) (Assist.)
32159	Fee: \$333.20	Benefit: 75% = \$249.90
32162	ANAL FISTUL	A, treatment of, by excision or by insertion of a Seton, or by a combination of both

T8. SUF	RGICAL OPERAT	ONS 2. COLORECTAL
	procedures, invo	ving the upper half of the anal sphincter mechanism (Anaes.) (Assist.)
	Fee: \$483.95	Benefit: 75% = \$363.00
	ANAL FISTUL	, repair of, by mucosal flap advancement (Anaes.) (Assist.)
32165	Fee: \$634.70	Benefit: 75% = \$476.05 85% = \$551.30
	ANAL FISTUL	- readjustment of Seton (Anaes.)
32166	Fee: \$206.20	Benefit: 75% = \$154.65 85% = \$175.30
	FISTULA WOU (Anaes.)	ND, review of, under general or regional anaesthetic, as an independent procedure
32168	Fee: \$131.75	Benefit: 75% = \$98.85
		XAMINATION, with or without biopsy, under general anaesthetic, not being a service service to which another item in this Group applies (Anaes.)
32171	Fee: \$88.80	Benefit: 75% = \$66.60
	INTR-AANAL,	perianal or ischiorectal abscess, drainage of (excluding aftercare) (Anaes.)
32174	Fee: \$88.80	Benefit: 75% = \$66.60 85% = \$75.50
		PERIANAL or ISCHIO-RECTAL ABSCESS, draining of, undertaken in the operating tal (excluding aftercare) (Anaes.)
32175	Fee: \$162.65	Benefit: 75% = \$122.00
	(excluding pude	removal of, under general anaesthesia, or under regional or field nerve block dal block) requiring admission to a hospital, where the time taken is less than or equal of being a service associated with a service to which item 35507 or 35508 applies
32177	Fee: \$174.25	Benefit: 75% = \$130.70
	(excluding pude	removal of, under general anaesthesia, or under regional or field nerve block dal block) requiring admission to a hospital, where the time taken is greater than 45 ng a service associated with a service to which item 35507 or 35508 applies (Anaes.)
32180	Fee: \$256.95	Benefit: 75% = \$192.75
	INTESTINAL S	LING PROCEDURE prior to radiotherapy (Anaes.) (Assist.)
32183	Fee: \$561.65	Benefit: 75% = \$421.25
	COLONIC LAV	AGE, total, intra operative (Anaes.) (Assist.)
32186	Fee: \$561.65	Benefit: 75% = \$421.25
	DISTAL MUSC	E, devascularisation of (Anaes.) (Assist.)
32200	Fee: \$295.70	Benefit: 75% = \$221.80 85% = \$251.35
	ANAL OR PER	NEAL GRACILOPLASTY (Anaes.) (Assist.)
32203	Fee: \$635.00	Benefit: 75% = \$476.25
	STIMULATOR	AND ELECTRODES, insertion of, following previous graciloplasty (Anaes.) (Assist.)
32206	Fee: \$573.70	Benefit: 75% = \$430.30

T8. SUF	RGICAL OPERATIO	NS	2. COLORECTAL	
	ANAL OR PERINI (Assist.)	EAL GRACILOPLASTY with	insertion of stimulator and electrodes (Anaes.)	
32209	Fee: \$921.95	Benefit: 75% = \$691.50		
	GRACILIS NEOSF	PHINCTER PACEMAKER, re	placement of (Anaes.)	
32210	Fee: \$255.45	Benefit: 75% = \$191.60 85%	o = \$217.15	
		PLICATION OF FORMALIN or ating theatre of a hospital, experience of the second	in the treatment of radiation proctitis, where scluding aftercare (Anaes.)	
32212	Fee: \$136.25	Benefit: 75% = \$102.20		
		r leads, percutaneous placemen timulation, to manage faecal in	t using fluoroscopic guidance (or open placement) and acontinence in a patient who:	
	a) has an anatomica	ally intact but functionally defic	cient anal sphincter; and	
	b) has faecal incont months;	inence that has been refractory	to conservative non-surgical treatment for at least 12	
	other than a patient who:			
	c) is medically unfit for surgery; or			
	d) is pregnant or planning pregnancy; or			
	e) has irritable bow	el syndrome; or		
	f) has congenital anorectal malformations; or			
	g) has active anal abscesses or fistulas; or			
	h) has anorectal organic bowel disease, including cancer; or			
	i) has functional effects of previous pelvic irradiation; or			
	j) has congenital or acquired malformations of the sacrum; or			
	k) has had rectal or	anal surgery within the previous	us 12 months (Anaes.)	
32213	Fee: \$660.95	Benefit: 75% = \$495.75		
			ent of, involving placement and connection of an aoroscopic guidance, to manage faecal incontinence in	
	a) has an anatomically intact but functionally deficient anal sphincter; and			
	b) has faecal incontinence that has been refractory to conservative non-surgical treatment for at least 12 months;			
	other than a patient who:			
	c) is medically unfit for surgery; or			
32214	d) is pregnant or pla	anning pregnancy; or		

T8. SUR	GICAL OPERATIONS 2. COLORECTAI
	e) has irritable bowel syndrome; or
	f) has congenital anorectal malformations; or
	g) has active anal abscesses or fistulas; or
	h) has anorectal organic bowel disease, including cancer; or
	i) has functional effects of previous pelvic irradiation; or
	j) has congenital or acquired malformations of the sacrum; or
	k) has had rectal or anal surgery within the previous 12 months
	(Anaes.) (Assist.)
	Fee: \$334.00 Benefit: 75% = \$250.50
	Sacral nerve electrode or electrodes, management, adjustment and electronic programming of the neurostimulator by a medical practitioner, to manage faecal incontinence, other than in a patient who:
	a) is medically unfit for surgery; or
	b) is pregnant or planning pregnancy; or
	c) has irritable bowel syndrome; or
	d) has congenital anorectal malformations; or
	e) has active anal abscesses or fistulas; or
	f) has anorectal organic bowel disease, including cancer; or
	g) has functional effects of previous pelvic irradiation; or
	h) has congenital or acquired malformations of the sacrum; or
	i) has had rectal or anal surgery within the previous 12 months
	–each day
32215	Fee: \$125.40 Benefit: 75% = \$94.05 85% = \$106.60
	Sacral nerve lead or leads, percutaneous surgical repositioning of, using fluoroscopic guidance (or open surgical repositioning of) and interoperative test stimulation, to correct displacement or unsatisfactory positioning, if the lead was inserted to manage faecal incontinence in a patient who:
	a) has an anatomically intact but functionally deficient anal sphincter; and
	b) has faecal incontinence that has been refractory to conservative non-surgical treatment for at least 12 months;
	other than a patient who:
	c) is medically unfit for surgery; or
32216	d) is pregnant or planning pregnancy; or

T8. SUR	RGICAL OPERATIONS 2. COLORECTAL
	e) has irritable bowel syndrome; or
	f) has congenital anorectal malformations; or
	g) has active anal abscesses or fistulas; or
	h) has anorectal organic bowel disease, including cancer; or
	i) has functional effects of previous pelvic irradiation; or
	j) has congenital or acquired malformations of the sacrum; or
	k) has had rectal or anal surgery within the previous 12 months
	other than a service to which item 32213 applies
	(Anaes.)
	Fee: \$593.55 Benefit: 75% = \$445.20
	Neurostimulator or receiver, removal of, if the neurostimulator or receiver was inserted to manage faecal incontinence in a patient who:
	a) has an anatomically intact but functionally deficient anal sphincter; and
	b) has faecal incontinence that has been refractory to conservative non-surgical treatment for at least 12 months;
	other than a patient who:
	c) is medically unfit for surgery; or
	d) is pregnant or planning pregnancy; or
	e) has irritable bowel syndrome; or
	f) has congenital anorectal malformations; or
	g) has active anal abscesses or fistulas; or
	h) has anorectal organic bowel disease, including cancer; or
	i) has functional effects of previous pelvic irradiation; or
	j) has congenital or acquired malformations of the sacrum; or
	k) has had rectal or anal surgery within the previous 12 months
	(Anaes.)
32217	Fee: \$156.30 Benefit: 75% = \$117.25
	Sacral nerve lead or leads, removal of, if the lead was inserted to manage faecal incontinence in a patient who:
	a) has an anatomically intact but functionally deficient anal sphincter; and
32218	b) has faecal incontinence that has been refractory to conservative non-surgical treatment for at least 12

T8. SUF	RGICAL OPERATIONS	2. COLORECTAL
	months;	
	other than a patient who:	
	c) is medically unfit for surgery; or	
	d) is pregnant or planning pregnancy; or	
	e) has irritable bowel syndrome; or	
	f) has congenital anorectal malformations; or	
	g) has active anal abscesses or fistulas; or	
	h) has anorectal organic bowel disease, including cancer; or	
	i) has functional effects of previous pelvic irradiation; or	
	j) has congenital or acquired malformations of the sacrum; or	
	k) has had rectal or anal surgery within the previous 12 months	
	(Anaes.)	
	Fee: \$156.30 Benefit: 75% = \$117.25	
	Insertion of an artificial bowel sphincter for severe faecal incontinence in the trea whom conservative and other less invasive forms of treatment are contraindicated failed. Contraindicated in:	
	(a) patients with inflammatory bowel disease, pelvic sepsis, pregnancy, progress diseases or a scarred or fragile perineum; and	sive degenerative
	(b) patients who have had an adverse reaction or radiopaque solution; and	
	(c) patients who enage in receptive anal intercourse (Anaes.) (Assist.)	
32220	Fee: \$903.90 Benefit: 75% = \$677.95 85% = \$820.50	
	Removal or revision of an artificial bowel sphincter (with or without replacement incontinence in the treatment of a patient for whom conservative and other less in treatment are contraindicated or have failed. Contraindicated in:	
	(a) patients with inflammatory bowel disease, pelvic sepsis, pregnancy, progress diseases or a scarred or fragile perineum; and	sive degenerative
	(b) patients who have had an adverse reaction to radiopaque solution; and	
	(c) patients who engage in receptive anal intercourse (Anaes.) (Assist.)	
32221	Fee: \$903.90 Benefit: 75% = \$677.95 85% = \$820.50	
T8. SUF	RGICAL OPERATIONS	3. VASCULAR
	Group T8. Surgical Operations	
	Subgroup 3. Vascular	
	1	

T8. SUF	RGICAL OPERATIONS 3. VASCULAR
	VARICOSE VEINS
	VARICOSE VEINS where varicosity measures 2.5mm or greater in diameter, multiple injections of sclerosant using continuous compression techniques, including associated consultation - 1 or both legs - not being a service associated with any other varicose vein operation on the same leg (excluding aftercare) - to a maximum of 6 treatments in a 12 month period (Anaes.)
32500	(See para TN.8.4, TN.8.32 of explanatory notes to this Category) Fee: \$109.80 Benefit: 75% = \$82.35 85% = \$93.35 Extended Medicare Safety Net Cap: \$120.80
	VARICOSE VEINS, multiple excision of tributaries, with or without division of 1 or more perforating veins - 1 leg - not being a service associated with a service to which item 32507, 32508, 32511, 32514 or 32517 applies on the same leg (Anaes.)
32504	(See para TN.8.32 of explanatory notes to this Category) Fee: \$267.65 Benefit: 75% = \$200.75 Extended Medicare Safety Net Cap: \$214.15
	VARICOSE VEINS, sub-fascial surgical exploration of one or more incompetent perforating veins - 1 leg - not being a service associated with a service to which item 32508, 32511, 32514 or 32517 applies on the same leg (Anaes.) (Assist.)
32507	(See para TN.8.32 of explanatory notes to this Category) Fee: \$533.60 Benefit: 75% = \$400.20 85% = \$453.60 Extended Medicare Safety Net Cap: \$426.90
	VARICOSE VEINS, complete dissection at the sapheno-femoral OR sapheno-popliteal junction - 1 leg - with or without either ligation or stripping, or both, of the long or short saphenous veins, for the first time on the same leg, including excision or injection of either tributaries or incompetent perforating veins, or both (Anaes.) (Assist.)
32508	(See para TN.8.32 of explanatory notes to this Category) Fee: \$533.60 Benefit: 75% = \$400.20
	VARICOSE VEINS, complete dissection at the sapheno-femoral AND sapheno-popliteal junction - 1 leg - with or without either ligation or stripping, or both, of the long or short saphenous veins, for the first time on the same leg, including excision or injection of either tributaries or incompetent perforating veins, or both (Anaes.) (Assist.)
32511	(See para TN.8.32 of explanatory notes to this Category) Fee: \$793.30 Benefit: 75% = \$595.00
	VARICOSE VEINS, ligation of the long or short saphenous vein on the same leg, with or without stripping, by re-operation for recurrent veins in the same territory - 1 leg - including excision or injection of either tributaries or incompetent perforating veins, or both (Anaes.) (Assist.)
32514	(See para TN.8.32 of explanatory notes to this Category) Fee: \$926.80 Benefit: 75% = \$695.10
	VARICOSE VEINS, ligation of the long and short saphenous vein on the same leg, with or without stripping, by re-operation for recurrent veins in either territory - 1 leg - including excision or injection of either tributaries or incompetent perforating veins, or both (Anaes.) (Assist.)
32517	(See para TN.8.32 of explanatory notes to this Category) Fee: \$1,193.40 Benefit: 75% = \$895.05
32520	Varicose veins, abolition of venous reflux by occlusion of a primary or recurrent great (long) or small (short) saphenous vein of one leg (and major tributaries of saphenous veins as necessary), using a laser probe introduced by an endovenous catheter, if it is documented by duplex ultrasound that the great or

T8. SURG	GICAL OPERATIONS	3. VASCULAR
	small saphenous vein (whichever is to be treated) demonstrates reflux of 0.5 seconds or	longer:
	(a) including all preparation and immediate clinical aftercare (including excision or injutributaries or incompetent perforating veins, or both); and	ection of either
	(b) not including radiofrequency diathermy, radiofrequency ablation or cyanoacrylate e	embolisation; and
	(c) not provided on the same occasion as a service described in any of items 32500, 325 (Anaes.)	504 and 32507
	(See para TN.8.33 of explanatory notes to this Category) Fee: \$533.60 Benefit: 75% = \$400.20 85% = \$453.60 Extended Medicare Safety Net Cap: \$80.05	
	Varicose veins, abolition of venous reflux by occlusion of a primary or recurrent great (short) saphenous vein of one leg (and major tributaries of saphenous veins as necessar probe introduced by an endovenous catheter, if it is documented by duplex ultrasound t small saphenous veins demonstrate reflux of 0.5 seconds or longer:	y), using a laser
	(a) including all preparation and immediate clinical aftercare (including excision or injutributaries or incompetent perforating veins, or both); and	ection of either
	(b) not including radiofrequency diathermy, radiofrequency ablation or cyanoacrylate enot provided on the same occasion as a service described in any of items 32500, 32504 (Anaes.)	
32522	(See para TN.8.33 of explanatory notes to this Category) Fee: \$793.30 Benefit: 75% = \$595.00 85% = \$709.90 Extended Medicare Safety Net Cap: \$79.35	
	Varicose veins, abolition of venous reflux by occlusion of a primary or recurrent great (short) saphenous vein of one leg (and major tributaries of saphenous veins as necessar radiofrequency catheter introduced by an endovenous catheter, if it is documented by d that the great or small saphenous vein (whichever is to be treated) demonstrates reflux longer:	y), using a uplex ultrasound
	(a) including all preparation and immediate clinical aftercare (including excision or injutributaries or incompetent perforating veins, or both); and	ection of either
	(b) not including endovenous laser therapy or cyanoacrylate embolisation; and	
	(c) not provided on the same occasion as a service described in any of items 32500, 325 (Anaes.)	504 and 32507
32523	(See para TN.8.33 of explanatory notes to this Category) Fee: \$533.60 Benefit: 75% = \$400.20 85% = \$453.60 Extended Medicare Safety Net Cap: \$80.05	
	Varicose veins, abolition of venous reflux by occlusion of a primary or recurrent great (short) saphenous vein of one leg (and major tributaries of saphenous veins as necessar radiofrequency catheter introduced by an endovenous catheter, if it is documented by d that the great and small saphenous veins demonstrate reflux of 0.5 seconds or longer:	y), using a
	(a) including all preparation and immediate clinical aftercare (including excision or injutributaries or incompetent perforating veins, or both); and	ection of either
32526	(b) not including endovenous laser therapy or cyanoacrylate embolisation; and	

T8. SUF	RGICAL OPERATIONS 3. VASCULA	٩R
	(c) not provided on the same occasion as a service described in any of items 32500, 32504 and 32507 (Anaes.)	
	(See para TN.8.33 of explanatory notes to this Category) Fee: \$793.30 Benefit: 75% = \$595.00 85% = \$709.90 Extended Medicare Safety Net Cap: \$79.35	
	Varicose veins, abolition of venous reflux by occlusion of a primary or recurrent great (long) or small (short) saphenous vein of one leg (and major tributaries of saphenous veins as necessary), using cyanoacrylate adhesive, if it is documented by duplex ultrasound that the great or small saphenous veir (whichever is to be treated) demonstrates reflux of 0.5 seconds or longer:	1
	(a) including all preparation and immediate clinical aftercare (including excision or injection of either tributaries or incompetent perforating veins, or both); and	
	(b) not including radiofrequency diathermy, radiofrequency ablation or endovenous laser therapy; and	
	(c) not provided on the same occasion as a service described in any of items 32500, 32504 and 32507	
	(Anaes.)	
32528	(See para TN.8.33 of explanatory notes to this Category) Fee: \$533.60 Benefit: 75% = \$400.20 85% = \$453.60 Extended Medicare Safety Net Cap: \$80.05	
	Varicose veins, abolition of venous reflux by occlusion of a primary or recurrent great (long) and smal (short) saphenous vein of one leg (and major tributaries of saphenous veins as necessary), using cyanoacrylate adhesive, if it is documented by duplex ultrasound that the great and small saphenous veins demonstrate reflux of 0.5 seconds or longer:	1
	(a) including all preparation and immediate clinical aftercare (including excision or injection of either tributaries or incompetent perforating veins, or both); and	
	(b) not including radiofrequency diathermy, radiofrequency ablation or endovenous laser therapy; and	
	(c) not provided on the same occasion as a service described in any of items 32500, 32504 and 32507	
	(Anaes.)	
32529	(See para TN.8.33 of explanatory notes to this Category) Fee: \$793.30 Benefit: 75% = \$595.00 Extended Medicare Safety Net Cap: \$79.35	
	BYPASS OR ANASTOMOSIS FOR OCCLUSIVE ARTERIAL DISEASE	
	ARTERY OF NECK, bypass using vein or synthetic material (Anaes.) (Assist.)	
32700	Fee: \$1,436.30 Benefit: 75% = \$1077.25	
	INTERNAL CAROTID ARTERY, transection and reanastomosis of, or resection of small length and reanastomosis of - with or without endarterectomy (Anaes.) (Assist.)	_
32703	Fee: \$1,188.20 Benefit: 75% = \$891.15	
	AORTIC BYPASS for occlusive disease using a straight non-bifurcated graft (Anaes.) (Assist.)	
32708	Fee: \$1,421.35 Benefit: 75% = \$1066.05	
32710	AORTIC BYPASS for occlusive disease using a bifurcated graft with 1 or both anastomoses to the ilia	ıc

T8. SUF	RGICAL OPERATIO	DNS 3. VASCULAR
	arteries (Anaes.) (A	Assist.)
	Fee: \$1,579.30	Benefit: 75% = \$1184.50
	AORTIC BYPASS	S for occlusive disease using a bifurcated graft with 1 or both anastomoses to the profunda femoris arteries (Anaes.) (Assist.)
32711	Fee: \$1,737.25	Benefit: 75% = \$1302.95
	ILIO-FEMORAL	BYPASS GRAFTING (Anaes.) (Assist.)
32712	Fee: \$1,255.80	Benefit: 75% = \$941.85
	AXILLARY or SU ARTERIES (Anae	UBCLAVIAN TO FEMORAL BYPASS GRAFTING to 1 or both FEMORAL s.) (Assist.)
32715	Fee: \$1,255.80	Benefit: 75% = \$941.85
	FEMORO-FEMO	RAL OR ILIO-FEMORAL CROSS-OVER BYPASS GRAFTING (Anaes.) (Assist.)
32718	Fee: \$1,188.20	Benefit: 75% = \$891.15
	RENAL ARTERY	, bypass grafting to (Anaes.) (Assist.)
32721	Fee: \$1,887.35	Benefit: 75% = \$1415.55
	-	ES (both), bypass grafting to (Anaes.) (Assist.)
32724	Fee: \$2,143.10	Benefit: 75% = \$1607.35
32721	-	ESSEL (single), bypass grafting to (Anaes.) (Assist.)
32730	Fee: \$1,624.30	Benefit: 75% = \$1218.25
32730	-	ESSELS (multiple), bypass grafting to (Anaes.) (Assist.)
32733	Fee: \$1,887.35	Benefit: 75% = \$1415.55
32133	INFERIOR MESE	ENTERIC ARTERY, operation on, when performed in conjunction with another intrar operation (Anaes.) (Assist.)
32736	Fee: \$413.55	Benefit: 75% = \$310.20
		ERY BYPASS GRAFTING using vein, including harvesting of vein (when it is the shenous vein) with above knee anastomosis (Anaes.) (Assist.)
32739	Fee: \$1,293.40	Benefit: 75% = \$970.05
		ERY BYPASS GRAFTING using vein, including harvesting of vein (when it is the shenous vein) with distal anastomosis to below knee popliteal artery (Anaes.) (Assist.)
32742	Fee: \$1,481.50	Benefit: 75% = \$1111.15
		ERY BYPASS GRAFTING using vein, including harvesting of vein (when it is the phenous vein) with distal anastomosis to tibio peroneal trunk or tibial or peroneal ssist.)
32745	Fee: \$1,691.95	Benefit: 75% = \$1269.00
		ERY BYPASS GRAFTING using vein, including harvesting of vein (when it is the shenous vein) with distal anastomosis within 5cms of the ankle joint (Anaes.) (Assist.)
32748	Fee: \$1,834.80	Benefit: 75% = \$1376.10

T8. SUF	RGICAL OPERATIO	NS	3. VASCULAR
	FEMORAL ARTE below the knee (Ar	RY BYPASS GRAFTING using synthetic graft, with lonaes.) (Assist.)	ower anastomosis above or
32751	Fee: \$1,188.20	Benefit: 75% = \$891.15	
		RY BYPASS GRAFTING, using a composite graft (synabove or below the knee, including use of a cuff or sleeps.) (Assist.)	
32754	Fee: \$1,481.50	Benefit: 75% = \$1111.15	
	an additional anast	RY SEQUENTIAL BYPASS GRAFTING, (using a veromosis is made to separately revascularise more than 1 and a femoral bypass (Anaes.) (Assist.)	
32757	Fee: \$413.55	Benefit: 75% = \$310.20	
		ING OF, FROM LEG OR ARM for bypass or replacem is the subject of the bypass or graft - each vein (Anaes.)	
32760	Fee: \$406.05	Benefit: 75% = \$304.55	
		ASS GRAFTING, using vein or synthetic material, not be Sub-group applies (Anaes.) (Assist.)	eing a service to which
32763	Fee: \$1,188.20	Benefit: 75% = \$891.15	
		ENOUS ANASTOMOSIS, not being a service to which independent procedure (Anaes.) (Assist.)	another item in this Sub-
32766	Fee: \$789.65	Benefit: 75% = \$592.25	
		ENOUS ANASTOMOSIS not being a service to which n performed in combination with another vascular operates.) (Assist.)	
32769	Fee: \$273.65	Benefit: 75% = \$205.25	
		BYPASS, REPLACEMENT, LIGATION OF ANEUR	YSMS
		NG to replace a popliteal aneurysm using vein, includin saphenous vein) (Anaes.) (Assist.)	g harvesting vein (when it is
33050	Fee: \$1,455.30	Benefit: 75% = \$1091.50	
	BYPASS GRAFTI	NG to replace a popliteal aneurysm using a synthetic gr	aft (Anaes.) (Assist.)
33055	Fee: \$1,167.05	Benefit: 75% = \$875.30	
	ANEURYSM IN T (Anaes.) (Assist.)	THE EXTREMITIES, ligation, suture closure or excision	n of, without bypass grafting
33070	Fee: \$842.00	Benefit: 75% = \$631.50 85% = \$758.60	
	ANEURYSM IN T (Assist.)	THE NECK, ligation, suture closure or excision of, with	out bypass grafting (Anaes.)
33075	Fee: \$1,071.05	Benefit: 75% = \$803.30	
	INTRA-ABDOMI bypass grafting (A	NAL OR PELVIC ANEURYSM, ligation, suture closur naes.) (Assist.)	e or excision of, without
33080	Fee: \$1,307.45	Benefit: 75% = \$980.60	

T8. SUF	RGICAL OPERATIO	NS	3. VASCULAR		
		COMMON OR INTERNAL CAROTID ARTERY material (Anaes.) (Assist.)	, OR BOTH, replacement by graft		
33100	Fee: \$1,436.30	Benefit: 75% = \$1077.25 85% = \$1352.90			
	THORACIC ANEU	JRYSM, replacement by graft (Anaes.) (Assist.)			
33103	Fee: \$2,015.30	Benefit: 75% = \$1511.50			
	THORACO-ABDOMINAL ANEURYSM, replacement by graft including re-implantation of arteries (Anaes.) (Assist.)				
33109	Fee: \$2,436.50	Benefit: 75% = \$1827.40 85% = \$2353.10			
	SUPRARENAL Al of arteries (Anaes.)	BDOMINAL AORTIC ANEURYSM, replacemen (Assist.)	t by graft including re-implantation		
33112	Fee: \$2,113.10	Benefit: 75% = \$1584.85			
		DOMINAL AORTIC ANEURYSM, replacement rvice to which item 33116 applies (Anaes.) (Assis			
33115	Fee: \$1,421.35	Benefit: 75% = \$1066.05			
		DOMINAL AORTIC ANEURYSM, replacement cluding associated radiological services (Anaes.)			
33116	Fee: \$1,399.00	Benefit: 75% = \$1049.25 85% = \$1315.60			
	arteries (with or wi	DOMINAL AORTIC ANEURYSM, replacement hout excision of common iliac aneurysms) not be m 33119 applies (Anaes.) (Assist.)			
33118	Fee: \$1,579.30	Benefit: 75% = \$1184.50			
		DOMINAL AORTIC ANEURYSM, replacement endovascular repair procedure, excluding associate			
33119	Fee: \$1,554.55	Benefit: 75% = \$1165.95 85% = \$1471.15			
		DOMINAL AORTIC ANEURYSM, replacement th or without excision or bypass of common iliac			
33121	Fee: \$1,737.25	Benefit: 75% = \$1302.95			
	ANEURYSM OF I (Anaes.) (Assist.)	LIAC ARTERY (common, external or internal), re	eplacement by graft - unilateral		
33124	Fee: \$1,210.80	Benefit: 75% = \$908.10			
	ANEURYSMS OF (Anaes.) (Assist.)	ILIAC ARTERIES (common, external or internal), replacement by graft - bilateral		
33127	Fee: \$1,586.75	Benefit: 75% = \$1190.10 85% = \$1503.35			
	ANEURYSM OF V graft (Anaes.) (Ass	ISCERAL ARTERY, excision and repair by dire st.)	ct anastomosis or replacement by		
33130	Fee: \$1,383.65	Benefit: 75% = \$1037.75			
33133		VISCERAL ARTERY, dissection and ligation of a			

T8. SUF	RGICAL OPERATION	ONS 3. VASCULAR
	continuity (Anaes	.) (Assist.)
	Fee: \$1,037.65	Benefit: 75% = \$778.25
	FALSE ANEURY (Assist.)	YSM, repair of, at aortic anastomosis following previous aortic surgery (Anaes.)
33136	Fee: \$2,616.75	Benefit: 75% = \$1962.60
	FALSE ANEURY	YSM, repair of, in iliac artery and restoration of arterial continuity (Anaes.) (Assist.)
33139	Fee: \$1,586.75	Benefit: 75% = \$1190.10
	FALSE ANEURY	YSM, repair of, in femoral artery and restoration of arterial continuity (Anaes.) (Assist.)
33142	Fee: \$1,481.50	Benefit: 75% = \$1111.15 85% = \$1398.10
	RUPTURED THO	ORACIC AORTIC ANEURYSM, replacement by graft (Anaes.) (Assist.)
33145	Fee: \$2,549.20	Benefit: 75% = \$1911.90
	RUPTURED THO (Assist.)	ORACO-ABDOMINAL AORTIC ANEURYSM, replacement by graft (Anaes.)
33148	Fee: \$3,165.80	Benefit: 75% = \$2374.35
	RUPTURED SUF (Assist.)	PRARENAL ABDOMINAL AORTIC ANEURYSM, replacement by graft (Anaes.)
33151	Fee: \$3,007.90	Benefit: 75% = \$2255.95
	RUPTURED INF (Anaes.) (Assist.)	RARENAL ABDOMINAL AORTIC ANEURYSM, replacement by tube graft
33154	Fee: \$2,225.90	Benefit: 75% = \$1669.45
		RARENAL ABDOMINAL AORTIC ANEURYSM, replacement by bifurcation graft with or without excision or bypass of common iliac aneurysms) (Anaes.) (Assist.)
33157	Fee: \$2,481.50	Benefit: 75% = \$1861.15
		RARENAL ABDOMINAL AORTIC ANEURYSM, replacement by bifurcation graft ral arteries (Anaes.) (Assist.)
33160	Fee: \$2,481.50	Benefit: 75% = \$1861.15
	RUPTURED ILIA	AC ARTERY ANEURYSM, replacement by graft (Anaes.) (Assist.)
33163	Fee: \$2,105.70	Benefit: 75% = \$1579.30
	RUPTURED AND (Assist.)	EURYSM OF VISCERAL ARTERY, replacement by anastomosis or graft (Anaes.)
33166	Fee: \$2,105.70	Benefit: 75% = \$1579.30 85% = \$2022.30
	RUPTURED AN	EURYSM OF VISCERAL ARTERY, simple ligation of (Anaes.) (Assist.)
33169	Fee: \$1,639.35	Benefit: 75% = \$1229.55
		MAJOR ARTERY, replacement by graft, not being a service to which another item in plies (Anaes.) (Assist.)
33172	Fee: \$1,278.35	Benefit: 75% = \$958.80

T8. SUF	RGICAL OPERATION	ONS 3. VASCULAR		
		EURYSM IN THE EXTREMITIES, ligation, suture closure or excision of, without		
	bypass grafting (A	Anaes.) (Assist.)		
33175	Fee: \$1,178.10	Benefit: 75% = \$883.60		
	RUPTURED ANd grafting (Anaes.)	EURYSM IN THE NECK, ligation, suture closure or excision of, without bypass (Assist.)		
33178	Fee: \$1,498.20	Benefit: 75% = \$1123.65		
		RA-ABDOMINAL OR PELVIC ANEURYSM, ligation, suture closure or excision of, afting (Anaes.) (Assist.)		
33181	Fee: \$1,831.70	Benefit: 75% = \$1373.80		
		ENDARTERECTOMY AND ARTERIAL PATCH		
		TERIES OF NECK, endarterectomy of, including closure by suture (where f 1 or more arteries is undertaken through 1 arteriotomy incision) (Anaes.) (Assist.)		
33500	Fee: \$1,135.40	Benefit: 75% = \$851.55		
	INNOMINATE ((Assist.)	OR SUBCLAVIAN ARTERY, endarterectomy of, including closure by suture (Anaes.)		
33506	Fee: \$1,270.90	Benefit: 75% = \$953.20		
		RTERECTOMY, including closure by suture, not being a service associated with on the aorta (Anaes.) (Assist.)		
33509	Fee: \$1,421.35	Benefit: 75% = \$1066.05		
		ENDARTERECTOMY (1 or both iliac arteries), including closure by suture not being a with a service to which item 33515 applies (Anaes.) (Assist.)		
33512	Fee: \$1,579.30	Benefit: 75% = \$1184.50		
	AORTO-FEMORAL ENDARTERECTOMY (1 or both femoral arteries) or BILA' FEMORAL ENDARTERECTOMY, including closure by suture, not being a service service to which item 33512 applies (Anaes.) (Assist.)			
33515	Fee: \$1,737.25	Benefit: 75% = \$1302.95		
	ILIAC ENDART	ERECTOMY, including closure by suture, not being a service associated with another iliac artery (Anaes.) (Assist.)		
33518	Fee: \$1,270.90	Benefit: 75% = \$953.20 85% = \$1187.50		
		ENDARTERECTOMY (1 side), including closure by suture (Anaes.) (Assist.)		
33521	Fee: \$1,376.10	Benefit: 75% = \$1032.10		
	-	Y, endarterectomy of (Anaes.) (Assist.)		
33524	Fee: \$1,624.30	Benefit: 75% = \$1218.25		
22221	-	ES (both), endarterectomy of (Anaes.) (Assist.)		
22525				
33527	Fee: \$1,887.35	Benefit: 75% = \$1415.55 JPERIOR MESENTERIC ARTERY, endarterectomy of (Anaes.) (Assist.)		
33530	Fee: \$1,624.30	Benefit: 75% = \$1218.25		

T8. SUF	RGICAL OPERATIO	NS	3. VASCULAR	
	COELIAC AND SU	JPERIOR MESENTERIC ARTERY, endarterectomy	y of (Anaes.) (Assist.)	
33533	Fee: \$1,887.35	Benefit: 75% = \$1415.55		
		NTERIC ARTERY, endarterectomy of, not being a seem in this Sub-group applies (Anaes.) (Assist.)	ervice associated with a service	
33536	Fee: \$1,346.10	Benefit: 75% = \$1009.60		
	ARTERY OF EXT	REMITIES, endarterectomy of, including closure by	suture (Anaes.) (Assist.)	
33539	Fee: \$970.05	Benefit: 75% = \$727.55		
	EXTENDED DEER (Anaes.) (Assist.)	P FEMORAL ENDARTERECTOMY where the enda	arterectomy is at least 7cms long	
33542	Fee: \$1,383.65	Benefit: 75% = \$1037.75		
	ARTERY, VEIN O less than 3cm long	R BYPASS GRAFT, patch grafting to by vein or syn (Anaes.) (Assist.)	thetic material where patch is	
33545	(See para TN.8.36 of Fee: \$273.65	explanatory notes to this Category) Benefit: 75% = \$205.25		
	ARTERY, VEIN OR BYPASS GRAFT, patch grafting to by vein or synthetic material where patch is 3cm long or greater (Anaes.) (Assist.)			
33548	(See para TN.8.36 of Fee: \$556.60	explanatory notes to this Category) Benefit: 75% = \$417.45		
	VEIN, harvesting o (Anaes.) (Assist.)	f from leg or arm for patch when not performed throu	igh same incision as operation	
33551	(See para TN.8.36 of Fee: \$273.65	explanatory notes to this Category) Benefit: 75% = \$205.25		
		MY, in conjunction with an arterial bypass operation site (Anaes.) (Assist.)	to prepare the site for	
33554	Fee: \$272.40	Benefit: 75% = \$204.30		
		EMBOLECTOMY, THROMBECTOMY AND VASCUL	AR TRAUMA	
	EMBOLUS, remov	al of, from artery of neck (Anaes.) (Assist.)		
33800	Fee: \$1,180.60	Benefit: 75% = \$885.45 85% = \$1097.20		
	EMBOLECTOMY trunk (Anaes.) (Ass	or THROMBECTOMY, by abdominal approach, of ist.)	an artery or bypass graft of	
33803	Fee: \$1,128.05	Benefit: 75% = \$846.05		
	or bypass graft of e	rombectomy (including the infusion of thrombolytic oxtremities, or embolectomy of abdominal artery via the termity, regardless of the number of incisions require (st.)	he femoral artery, item to be	
33806	Fee: \$812.15	Benefit: 75% = \$609.15 85% = \$728.75		
	INFERIOR VENA (Anaes.) (Assist.)	CAVA OR ILIAC VEIN, closed thrombectomy by c	atheter via the femoral vein	
33810	Fee: \$592.45	Benefit: 75% = \$444.35 85% = \$509.05		

T8. SUF	RGICAL OPERATIONS 3. VASCULAR
	INFERIOR VENA CAVA OR ILIAC VEIN, open removal of thrombus or tumour (Anaes.) (Assist.)
33811	Fee: \$1,763.80 Benefit: 75% = \$1322.85
	THROMBUS, removal of, from femoral or other similar large vein (Anaes.) (Assist.)
33812	Fee: \$932.45 Benefit: 75% = \$699.35 85% = \$849.05
	MAJOR ARTERY OR VEIN OF EXTREMITY, repair of wound of, with restoration of continuity, by lateral suture (Anaes.) (Assist.)
33815	Fee: \$857.30 Benefit: 75% = \$643.00
	MAJOR ARTERY OR VEIN OF EXTREMITY, repair of wound of, with restoration of continuity, by direct anastomosis (Anaes.) (Assist.)
33818	Fee: \$1,000.15 Benefit: 75% = \$750.15
	MAJOR ARTERY OR VEIN OF EXTREMITY, repair of wound of, with restoration of continuity, by interposition graft of synthetic material or vein (Anaes.) (Assist.)
33821	Fee: \$1,143.00 Benefit: 75% = \$857.25
	MAJOR ARTERY OR VEIN OF NECK, repair of wound of, with restoration of continuity, by lateral suture (Anaes.) (Assist.)
33824	Fee: \$1,090.35 Benefit: 75% = \$817.80
	MAJOR ARTERY OR VEIN OF NECK, repair of wound of, with restoration of continuity, by direct anastomosis (Anaes.) (Assist.)
33827	Fee: \$1,278.35 Benefit: 75% = \$958.80
	MAJOR ARTERY OR VEIN OF NECK, repair of wound of, with restoration of continuity, by interposition graft of synthetic material or vein (Anaes.) (Assist.)
33830	Fee: \$1,466.30 Benefit: 75% = \$1099.75
	MAJOR ARTERY OR VEIN OF ABDOMEN, repair of wound of, with restoration of continuity by lateral suture (Anaes.) (Assist.)
33833	Fee: \$1,331.15 Benefit: 75% = \$998.40
	MAJOR ARTERY OR VEIN OF ABDOMEN, repair of wound of, with restoration of continuity by direct anastomosis (Anaes.) (Assist.)
33836	Fee: \$1,586.75 Benefit: 75% = \$1190.10
	MAJOR ARTERY OR VEIN OF ABDOMEN, repair of wound of, with restoration of continuity by means of interposition graft (Anaes.) (Assist.)
33839	Fee: \$1,857.40 Benefit: 75% = \$1393.05
	ARTERY OF NECK, re-operation for bleeding or thrombosis after carotid or vertebral artery surgery (Anaes.) (Assist.)
33842	Fee: \$917.40 Benefit: 75% = \$688.05
	LAPAROTOMY for control of post operative bleeding or thrombosis after intra-abdominal vascular procedure, where no other procedure is performed (Anaes.) (Assist.)
33845	Fee: \$639.20 Benefit: 75% = \$479.40
33848	EXTREMITY, re-operation on, for control of bleeding or thrombosis after vascular procedure, where no

T8. SUF	RGICAL OPERATION	ONS 3. VA	SCULAR
	other procedure is	performed (Anaes.) (Assist.)	
	Fee: \$639.20	Benefit: 75% = \$479.40	
		TION, EXCISION, ELECTIVE REPAIR, DECOMPRESSION OF VESSELS	
		OF NECK, elective ligation or exploration of, not being a service associate procedure (Anaes.) (Assist.)	d with
34100	Fee: \$707.00	Benefit: 75% = \$530.25	
	Great artery (aorta or pulmonary artery) or great vein (superior or inferior vena cava), ligation or exploration of immediate branches or tributaries, or ligation or exploration of the subclavian, axillary, iliac, femoral or popliteal arteries or veins, if the service is not associated with item 32508, 32511, 32520, 32522, 32523, 32526, 32528 or 32529 - for a maximum of 2 services provided to the same patient on the same occasion (H) (Anaes.) (Assist.)		
34103	Fee: \$413.55	Benefit: 75% = \$310.20	
	exploration of, not	N (including brachial, radial, ulnar or tibial), ligation of, by elective operation being a service associated with any other vascular procedure except those sets, 32511, 32514 or 32517 apply (Anaes.) (Assist.)	
	Fee: \$291.70	Benefit: 75% = \$218.80 85% = \$247.95	
34106		re Safety Net Cap: \$233.40	
		TERY, biopsy of (Anaes.) (Assist.)	
34109	Fee: \$338.35	Benefit: 75% = \$253.80 85% = \$287.60	
	ARTERIO-VENO	US FISTULA OF AN EXTREMITY, dissection and ligation (Anaes.) (Assis	st.)
34112	Fee: \$857.30	Benefit: 75% = \$643.00	
	ARTERIO-VENO	US FISTULA OF THE NECK, dissection and ligation (Anaes.) (Assist.)	
34115	Fee: \$970.05	Benefit: 75% = \$727.55	
	ARTERIO-VENO	US FISTULA OF THE ABDOMEN, dissection and ligation (Anaes.) (Assis	t.)
34118	Fee: \$1,383.65	Benefit: 75% = \$1037.75 85% = \$1300.25	
	ARTERIO-VENOUS FISTULA OF AN EXTREMITY, dissection and repair of, with restoration of continuity (Anaes.) (Assist.)		on of
34121	Fee: \$1,105.35	Benefit: 75% = \$829.05	
	ARTERIO-VENO (Anaes.) (Assist.)	US FISTULA OF THE NECK, dissection and repair of, with restoration of o	continuity
34124	Fee: \$1,210.80	Benefit: 75% = \$908.10	
	ARTERIO-VENOUS FISTULA OF THE ABDOMEN, dissection and repair of, with restoration of continuity (Anaes.) (Assist.)		on of
34127	Fee: \$1,586.75	Benefit: 75% = \$1190.10	
	SURGICALLY CI (Assist.)	REATED ARTERIO-VENOUS FISTULA OF AN EXTREMITY, closure o	f (Anaes.)
34130	Fee: \$496.30	Benefit: 75% = \$372.25 85% = \$421.90	
	SCALENOTOMY	(Anaes.) (Assist.)	

T8. SUF	URGICAL OPERATIONS 3. VASC		
	Fee: \$556.60	Benefit: 75% = \$417.45	
	FIRST RIB, rese	ction of portion of (Anaes.) (Assist.)	
34136	Fee: \$894.75	Benefit: 75% = \$671.10	
		, removal of, or other operation for removal of thoracic outlet compression, not being a another item in this Sub-group applies (Anaes.) (Assist.)	
34139	Fee: \$894.75	Benefit: 75% = \$671.10	
	COELIAC ART	ERY, decompression of, for coeliac artery compression syndrome, as an independent s.) (Assist.)	
34142	Fee: \$1,105.35	Benefit: 75% = \$829.05	
		TERY, exploration of, for popliteal entrapment, with or without division of fibrous e (Anaes.) (Assist.)	
34145	Fee: \$804.65	Benefit: 75% = \$603.50	
		OCIATED TUMOUR, resection of, with or without repair or reconstruction of internal id arteries, when tumour is 4cm or less in maximum diameter (Anaes.) (Assist.)	
34148	Fee: \$1,436.30	Benefit: 75% = \$1077.25	
		OCIATED TUMOUR, resection of, with or without repair or reconstruction of internal id arteries, when tumour is greater than 4cm in maximum diameter (Anaes.) (Assist.)	
34151	Fee: \$1,962.65	Benefit: 75% = \$1472.00	
		AROTID ASSOCIATED TUMOUR, resection of, with or without repair or ortion of internal or common carotid arteries (Anaes.) (Assist.)	
34154	Fee: \$2,338.75	Benefit: 75% = \$1754.10 85% = \$2255.35	
	NECK, excision	of infected bypass graft, including closure of vessel or vessels (Anaes.) (Assist.)	
34157	Fee: \$1,188.20	Benefit: 75% = \$891.15	
	AORTO-DUOD (Assist.)	ENAL FISTULA, repair of, by suture of aorta and repair of duodenum (Anaes.)	
34160	Fee: \$2,225.90	Benefit: 75% = \$1669.45	
	AORTO-DUOD (Anaes.) (Assist.	ENAL FISTULA, repair of, by insertion of aortic graft and repair of duodenum	
34163	Fee: \$2,857.55	Benefit: 75% = \$2143.20	
		ENAL FISTULA, repair of, by oversewing of abdominal aorta, repair of duodenum and grafting (Anaes.) (Assist.)	
34166	Fee: \$2,857.55	Benefit: 75% = \$2143.20	
	INFECTED BYI (Assist.)	PASS GRAFT FROM TRUNK, excision of, including closure of arteries (Anaes.)	
34169	Fee: \$1,586.75	Benefit: 75% = \$1190.10	
	INFECTED AXI arteries (Anaes.)	LLO-FEMORAL OR FEMORO-FEMORAL GRAFT, excision of, including closure of (Assist.)	
34172	Fee: \$1,293.40	Benefit: 75% = \$970.05	

T8. SUF	RGICAL OPERATION	ONS	3. VASCULA	
	INFECTED BYP (Anaes.) (Assist.)	ASS GRAFT FROM EXTREMITIES, ex	xcision of including closure of arteries	
34175	Fee: \$1,188.20	Benefit: 75% = \$891.15		
		OPERATIONS FOR VASC	ULAR ACCESS	
	ARTERIOVENO	US SHUNT, EXTERNAL, insertion of ((Anaes.) (Assist.)	
34500	Fee: \$308.40	Benefit: 75% = \$231.30 85% = \$262.	15	
	ARTERIOVENO	US ANASTOMOSIS OF UPPER OR LO	OWER LIMB, in conjunction with another	
	venous or arterial	operation (Anaes.) (Assist.)		
34503	Fee: \$413.55	Benefit: 75% = \$310.20		
	ARTERIOVENO	US SHUNT, EXTERNAL, removal of (A	Anaes.) (Assist.)	
34506	Fee: \$210.45	Benefit: 75% = \$157.85		
	ARTERIOVENO	US ANASTOMOSIS OF UPPER OR LO	OWER LIMB, not in conjunction with	
	another venous or	arterial operation (Anaes.) (Assist.)	•	
34509	Fee: \$977.55	Benefit: 75% = \$733.20		
	ARTERIOVENO	US ACCESS DEVICE, insertion of (Ana	aes.) (Assist.)	
34512	Fee: \$1,075.40	Benefit: 75% = \$806.55		
	ARTERIOVENO	US ACCESS DEVICE, thrombectomy o	of (Anaes.) (Assist.)	
34515	Fee: \$767.00	Benefit: 75% = \$575.25		
2.010			STHETIC ARTERIOVENOUS ACCESS	
	DEVICE, correction of (Anaes.) (Assist.)			
34518	Fee: \$1,285.75	Benefit: 75% = \$964.35		
		INAL ARTERY OR VEIN, cannulation	of, for infusion chemotherapy, by open	
	operation (exclud	ing aftercare) (Anaes.) (Assist.)		
		explanatory notes to this Category)		
34521	Fee: \$789.95	Benefit: 75% = \$592.50		
		INULATION for infusion chemotherapy applies (excluding after-care) (Anaes.) (by open operation, not being a service to (Assist.)	
	(See para TN.8.4 of	explanatory notes to this Category)		
34524	Fee: \$413.55	Benefit: 75% = \$310.20		
		, i	ue, using subcutaneous tunnel with pump or	
		neous central vein catheter or other chancous central vein catheterization, on a p	emotherapy delivery device, including any person 10 years of age or over (Anaes.)	
34527	Fee: \$551.60	Benefit: 75% = \$413.70 85% = \$468.9	90	
			s technique, using subcutaneous tunnel with	
	pump or access port as with central venous line catheter or other chemotherapy delivery device, on a person 10 years of age or over (Anaes.)			
34528	Fee: \$272.40	Benefit: 75% = \$204.30 85% = \$231.	55	
	- 		ue, using subcutaneous tunnel with pump or	
34529			emotherapy delivery device, including any	

T8. SUF	GICAL OPERATION	ONS	3. VASCULAR
	associated percutar	neous central vein cathete	rization, on a person under 10 years of age (Anaes.)
	Fee: \$717.10	Benefit: 75% = \$537.85	85% = \$633.70
			CHEMOTHERAPY DEVICE, removal of, by open surgical tal on a person 10 years of age or over (Anaes.)
34530	Fee: \$204.25	Benefit: 75% = \$153.20	85% = \$173.65
	procedure, regiona	PERFUSION, including l perfusion for chemother edure (excluding aftercare	cannulation of artery and vein at commencement of apy, or other therapy, repair of arteriotomy and venotomy at e) (Anaes.) (Assist.)
34533	Fee: \$1,240.65	Benefit: 75% = \$930.50	85% = \$1157.25
	pump or access por		y percutaneous technique, using subcutaneous tunnel with ine catheter or other chemotherapy delivery device, on a
34534	Fee: \$354.10	Benefit: 75% = \$265.60	85% = \$301.00
			by percutaneous technique, using subcutaneous tunnelled ninistration of haemodialysis or parenteral nutrition (Anaes.)
34538	Fee: \$272.40	Benefit: 75% = \$204.30	85% = \$231.55
	TUNNELLED CU (Anaes.)	FFED CATHETER, OR	SIMILAR DEVICE, removal of, by open surgical procedure
34539	Fee: \$204.25	Benefit: 75% = \$153.20	85% = \$173.65
			CHEMOTHERAPY DEVICE, removal of, by open surgical tal, on a person under 10 years of age (Anaes.)
34540	Fee: \$265.50	Benefit: 75% = \$199.15	85% = \$225.70
		COMPLE	X VENOUS OPERATIONS
	INFERIOR VENA	CAVA, plication, ligation	on, or application of caval clip (Anaes.) (Assist.)
34800	Fee: \$812.15	Benefit: 75% = \$609.15	85% = \$728.75
	INFERIOR VENA	CAVA, reconstruction o	f or bypass by vein or synthetic material (Anaes.) (Assist.)
34803	Fee: \$1,789.85	Benefit: 75% = \$1342.4	0
			nous to iliac or femoral vein (Anaes.) (Assist.)
34806	Fee: \$970.05	Benefit: 75% = \$727.55	
3 1000			emoral or popliteal vein for femoral vein bypass (Anaes.)
34809	Fee: \$970.05	Benefit: 75% = \$727.55	
			ein bypass for, using vein or synthetic material, not being a em 34806 or 34809 applies (Anaes.) (Assist.)
34812	Fee: \$1,173.05	Benefit: 75% = \$879.80	
	VEIN STENOSIS, (Anaes.) (Assist.)	patch angioplasty for, (ex	xcluding vein graft stenosis)-using vein or synthetic material
34815	(See para TN 8 36 of	Explanatory notes to this Ca	ategory)

T8. SUF	RGICAL OPERAT	IONS 3. VASCULAR			
	Fee: \$970.05	Benefit: 75% = \$727.55			
	VENOUS VALV	/E, plication or repair to restore valve competency (Anaes.) (Assist.)			
34818	Fee: \$1,067.80	Benefit: 75% = \$800.85			
	-	LANT to restore valvular function (Anaes.) (Assist.)			
34821	Fee: \$1,451.45	Benefit: 75% = \$1088.60 85% = \$1368.05			
34021	-	ENT, application of, to restore venous valve competency to superficial vein - 1 stent			
	(Anaes.) (Assist.)				
34824	Fee: \$496.30	Benefit: 75% = \$372.25			
	EXTERNAL ST	ENTS, application of, to restore venous valve competency to superficial vein or veins -			
	more than 1 stent	t (Anaes.) (Assist.)			
34827	Fee: \$601.65	Benefit: 75% = \$451.25			
		ENT, application of, to restore venous valve competency to deep vein (1 stent) (Anaes.)			
	(Assist.)				
34830	Fee: \$707.00	Benefit: 75% = \$530.25 85% = \$623.60			
	EXTERNAL STENTS, application of, to restore venous valve competency to deep vein or veins (more				
	than 1 stent) (An	aes.) (Assist.)			
34833	Fee: \$917.40	Benefit: 75% = \$688.05			
		SYMPATHECTOMY			
	LUMBAR SYM	PATHECTOMY (Anaes.) (Assist.)			
35000	Fee: \$707.00	Benefit: 75% = \$530.25 85% = \$623.60			
		UPPER THORACIC SYMPATHECTOMY by any surgical approach (Anaes.)			
	(Assist.)				
35003	Fee: \$917.40	Benefit: 75% = \$688.05			
		UPPER THORACIC SYMPATHECTOMY, where operation is a reoperation for			
	previous incomp	lete sympathectomy by any surgical approach (Anaes.) (Assist.)			
35006	Fee: \$1,150.55	Benefit: 75% = \$862.95			
		PATHECTOMY, where operation is following chemical sympathectomy or for			
	previous incomp	lete surgical sympathectomy (Anaes.) (Assist.)			
35009	Fee: \$894.75	Benefit: 75% = \$671.10			
	SACRAL or PRI	E-SACRAL SYMPATHECTOMY (Anaes.) (Assist.)			
35012	Fee: \$707.00	Benefit: 75% = \$530.25			
		DEBRIDEMENT AND AMPUTATIONS FOR VASCULAR DISEASE			
		MB, debridement of necrotic material, gangrenous tissue, or slough in, in the operating ital, when debridement includes muscle, tendon or bone (Anaes.) (Assist.)			
35100	Fee: \$368.55	Benefit: 75% = \$276.45			
	ISCHAEMIC LI	MB, debridement of necrotic material, gangrenous tissue, or slough in, in the operating ital, superficial tissue only (Anaes.)			
35103					

	RGICAL OPERAT	IONS	3. VASCULAR	
	Fee: \$234.55	Benefit: 75% = \$175.95		
		MISCELLANEOUS VASCUL	AR PROCEDURES	
		RTERIOGRAPHY OR VENOGRAPHY cedure on an artery or vein, 1 site (Anaes	7, 1 or more of, performed during the course of s.)	
35200	Fee: \$171.50	Benefit: 75% = \$128.65		
		RIES OR VEINS IN THE NECK, ABDO N after prior surgery on these vessels (A	OMEN OR EXTREMITIES, access to, as part of naes.) (Assist.)	
35202	Fee: \$817.10	Benefit: 75% = \$612.85		
		ENDOVASCULAR INTERVENT	IONAL PROCEDURES	
		sure, excluding associated radiological se	eripheral artery or vein of 1 limb, percutaneous ervices or preparation, and excluding aftercare	
35300	Fee: \$515.35	Benefit: 75% = \$386.55 85% = \$438	3.05	
	more than 1 peri		tic arch branches, aortic visceral branches, or eous or by open exposure, excluding associated are (Anaes.) (Assist.)	
35303	Fee: \$660.80	Benefit: 75% = \$495.60 85% = \$577	7.40	
	peripheral artery		nts, including associated balloon dilatation for 1 pen exposure, excluding associated radiological (Assist.)	
35306	Fee: \$609.90	Benefit: 75% = \$457.45 85% = \$526	5.50	
	associated balloo	AL STENT INSERTION, 1 or more steron dilatation, for 1 carotid artery, percuta on device, in patients who:	nts (not drug-eluting), with or without meous (not direct), with or without the use of an	
	- meet the indi	cations for carotid endarterectomy; and		
		or surgical comorbidities that would ma om carotid endarterectomy,	ke them at high risk of perioperative	
	excluding associated radiological services or preparation, and excluding aftercare (Anaes.) (Assist.)			
35307	(See para TN.8.37 Fee: \$1,121.15	of explanatory notes to this Category) Benefit: 75% = \$840.90		
	visceral arteries	or veins, or more than 1 peripheral artery	nts, including associated balloon dilatation for v or vein of 1 limb, percutaneous or by open reparation, and excluding aftercare. (Anaes.)	
35309	Fee: \$762.35	Benefit: 75% = \$571.80 85% = \$678	3.95	
55507	PERIPHERAL A	ARTERIAL ATHERECTOMY including		
33307	percutaneous or	by open exposure, excluding associated are (Anaes.) (Assist.)		
35312	percutaneous or			

T8. SUF	RGICAL OPERATIONS 3. VASCULAI
	or by open exposure, excluding associated radiological services or preparation, and excluding aftercare (Anaes.) (Assist.)
	Fee: \$864.05 Benefit: 75% = \$648.05
	PERIPHERAL ARTERIAL OR VENOUS CATHETERISATION with administration of thrombolytic or chemotherapeutic agents, BY CONTINUOUS INFUSION, using percutaneous approach, excluding associated radiological services or preparation, and excluding aftercare (not being a service associated with a service to which another item in Subgroup 11 of Group T1 or items 35319 or 35320 applies and not being a service associated with photodynamic therapy with verteporfin) (Anaes.) (Assist.)
35317	(See para TN.8.38 of explanatory notes to this Category) Fee: \$355.80 Benefit: 75% = \$266.85 85% = \$302.45
	PERIPHERAL ARTERIAL OR VENOUS CATHETERISATION with administration of thrombolytic or chemotherapeutic agents, BY PULSE SPRAY TECHNIQUE, using percutaneous approach, excluding associated radiological services or preparation, and excluding aftercare (not being a service associated with a service to which another item in Subgroup 11 of Group T1 or items 35317 or 35320 applies and not being a service associated with photodynamic therapy with verteporfin) (Anaes.) (Assist.)
35319	Fee: \$637.80 Benefit: 75% = \$478.35 85% = \$554.40
	PERIPHERAL ARTERIAL OR VENOUS CATHETERISATION with administration of thrombolytic or chemotherapeutic agents, BY OPEN EXPOSURE, excluding associated radiological services or preparation, and excluding aftercare (not being a service associated with a service to which another item in Subgroup 11 of Group T1 or items 35317 or 35319 applies and not being a service associated with photodynamic therapy with verteporfin) (Anaes.) (Assist.)
35320	Fee: \$856.70 Benefit: 75% = \$642.55 85% = \$773.30
	PERIPHERAL ARTERIAL OR VENOUS CATHETERISATION to administer agents to occlude arteries, veins or arterio-venous fistulae or to arrest haemorrhage, (but not for the treatment of uterine fibroids or varicose veins) percutaneous or by open exposure, excluding associated radiological services or preparation, and excluding aftercare, not being a service associated with photodynamic therapy with verteporfin (Anaes.) (Assist.)
35321	(See para TN.8.39 of explanatory notes to this Category) Fee: \$813.30 Benefit: 75% = \$610.00 85% = \$729.90
	ANGIOSCOPY not combined with any other procedure, excluding associated radiological services or preparation, and excluding aftercare (Anaes.) (Assist.)
35324	Fee: \$304.95 Benefit: 75% = \$228.75
	ANGIOSCOPY combined with any other procedure, excluding associated radiological services or preparation, and excluding aftercare (Anaes.) (Assist.)
35327	Fee: \$408.70 Benefit: 75% = \$306.55
	INSERTION of INFERIOR VENA CAVAL FILTER, percutaneous or by open exposure, excluding associated radiological services or preparation, and excluding aftercare (Anaes.) (Assist.)
35330	Fee: \$515.35 Benefit: 75% = \$386.55 85% = \$438.05
	RETRIEVAL OF INFERIOR VENA CAVAL FILTER, percutaneous or by open exposure, not including associated radiological services or preparation, and not including aftercare (Anaes.)
35331	Fee: \$592.45 Benefit: 75% = \$444.35

T8. SUI	RGICAL OPERATIONS	3. VASCULAR
	associated radiological services or preparation, and not including aftercare	
	(foreign body does not include an instrument inserted for the purpose of a service (Anaes.) (Assist.)	being rendered)
	Fee: \$828.20 Benefit: 75% = \$621.15	
	Retrieval of foreign body in RIGHT ATRIUM, percutaneous or by open exposure associated radiological services or preparation, and not including aftercare	, not including
	(foreign body does not include an instrument inserted for the purpose of a service (Anaes.) (Assist.)	being rendered)
35361	Fee: \$710.30 Benefit: 75% = \$532.75	
	Retrieval of foreign body in INFERIOR VENA CAVA or AORTA, percutaneous not including associated radiological services or preparation, and not including aft	
	(foreign body does not include an instrument inserted for the purpose of a service (Anaes.) (Assist.)	being rendered)
35362	Fee: \$592.45 Benefit: 75% = \$444.35	
	Retrieval of foreign body in PERIPHERAL VEIN or PERIPHERAL ARTERY, polynomer, not including associated radiological services or preparation, and not including associated radiological services or preparation.	
	(foreign body does not include an instrument inserted for the purpose of a service (Anaes.) (Assist.)	being rendered)
35363	Fee: \$474.65 Benefit: 75% = \$356.00	
	INTERVENTIONAL RADIOLOGY PROCEDURES	
	DOSIMETRY, HANDLING AND INJECTION OF SIR-SPHERES for selective therapy of hepatic metastases which are secondary to colorectal cancer and are not or ablation, used in combination with systemic chemotherapy using 5-fluorouracil not being a service to which item 35317, 35319, 35320 or 35321 applies	t suitable for resection
	The procedure must be performed by a specialist or consultant physician recognise nuclear medicine or radiation oncology on an admitted patient in a hospital. To be patient's lifetime only.	
35404	(See para TN.3.1, TN.8.40 of explanatory notes to this Category) Fee: \$346.60 Benefit: 75% = \$259.95	
25404	Trans-femoral catheterisation of the hepatic artery to administer SIR-Spheres to en microvasculature of hepatic metastases which are secondary to colorectal cancer a resection or ablation, for selective internal radiation therapy used in combination vechemotherapy using 5-fluorouracil (5FU) and leucovorin, not being a service to w 35319, 35320 or 35321 applies	nd are not suitable for with systemic
35406		

T8. SUF	RGICAL OPERATIONS	3. VASCULAR	
	excluding associated radiological services or preparation, and excluding aft	tercare (Anaes.) (Assist.)	
	(See para TN.3.1, TN.8.40 of explanatory notes to this Category) Fee: \$813.30 Benefit: 75% = \$610.00		
	Catheterisation of the hepatic artery via a permanently implanted hepatic are Spheres to embolise the microvasculature of hepatic metastases which are sand are not suitable for resection or ablation, for selective internal radiation with systemic chemotherapy using 5-fluorouracil (5FU) and leucovorin, no item 35317, 35319, 35320 or 35321 applies	secondary to colorectal cancer therapy used in combination	
	excluding associated radiological services or preparation, and excluding aff	tercare (Anaes.) (Assist.)	
35408	(See para TN.3.1, TN.8.40 of explanatory notes to this Category) Fee: \$610.10 Benefit: 75% = \$457.60		
	UTERINE ARTERY CATHETERISATION with percutaneous administra the treatment of symptomatic uterine fibroids in a patient who has been refe embolisation by a specialist gynaecologist, excluding associated radiologic excluding aftercare (Anaes.) (Assist.)	erred for uterine artery	
35410	(See para TN.8.34 of explanatory notes to this Category) Fee: \$813.30 Benefit: 75% = \$610.00 85% = \$729.90		
	Intracranial aneurysm, ruptured or unruptured, endovascular occlusion with assisted coiling if performed, with parent artery preservation, not for use wincluding aftercare, including intra-operative imaging, but in association window operative diagnostic imaging items:	ith liquid embolics only,	
	- either 60009 or 60010; and		
	- either 60072, 60073, 60075, 60076, 60078 or 60079 (Anaes.) (Assist.)		
35412	(See para TN.8.35 of explanatory notes to this Category) Fee: \$2,857.55 Benefit: 75% = \$2143.20 85% = \$2774.15		
	Mechanical thrombectomy, in a patient with a diagnosis of acute ischaemic of a large vessel of the anterior cerebral circulation, including intra-operative		
	(a) the diagnosis is confirmed by an appropriate imaging modality such as a magnetic resonance imaging or angiography; and	computed tomography,	
	(b) the service is performed by a specialist or consultant physician with apprecognised by the Conjoint Committee for Recognition of Training in Internand		
	(c) the service is provided in an eligible stroke centre.		
	For any particular patient - applicable once per presentation by the patient a regardless of the number of times mechanical thrombectomy is attempted of (Anaes.) (Assist.)		
35414	(See para TR.8.1 of explanatory notes to this Category) Fee: \$3,500.00 Benefit: 75% = \$2625.00		
	RGICAL OPERATIONS	4. GYNAECOLOGICAL	
	Group T8. Surgical Operations		

T8. SUF	GICAL OPERAT	TIONS	4. GYNAECOLOGICAL
		Sub	ogroup 4. Gynaecological
		GICAL EXAMINATION U	JNDER ANAESTHESIA, not being a service associated with up applies (Anaes.)
35500	Fee: \$81.30	Benefit: 75% = \$61.00	85% = \$69.15
	ENDOMETRI <i>A</i>		TION OF, for the control of idiopathic menorrhagia, AND ometrial pathology, not being a service associated with a papplies (Anaes.)
35502	Fee: \$80.15	Benefit: 75% = \$60.15	85% = \$68.15
			tion of, if the service is not associated with a service to which an a service mentioned in item 30062) (Anaes.)
35503	Fee: \$53.55	Benefit: 75% = \$40.20	85% = \$45.55
		A, not being a service assoc	EVICE, REMOVAL OF UNDER GENERAL ciated with a service to which another item in this Group
35506	Fee: \$53.70	Benefit: 75% = \$40.30	85% = \$45.65
	VULVAL OR VAGINAL WARTS, removal of under general anaesthesia, or under reginerve block (excluding pudendal block) requiring admission to a hospital, where the time than or equal to 45 minutes - not being a service associated with a service to which item applies (Anaes.)		
35507	Fee: \$174.45	Benefit: 75% = \$130.85	5 85% = \$148.30
	nerve block (ex	cluding pudendal block) req minutes - not being a servic	ral of under general anaesthesia, or under regional or field quiring admission to a hospital, where the time taken is the associated with a service to which item 32177 or 32180
35508	Fee: \$256.95	Benefit: 75% = \$192.73	5 85% = \$218.45
	HYMENECTO	MY (Anaes.)	
35509	Fee: \$89.45	Benefit: 75% = \$67.10	85% = \$76.05
	BARTHOLIN'S	CYST, excision of (Anaes	s.)
35513	Fee: \$221.70	Benefit: 75% = \$166.30	0 85% = \$188.45
	BARTHOLIN'S	CYST OR GLAND, marsu	upialisation of (Anaes.)
35517	Fee: \$146.00	Benefit: 75% = \$109.56	0 85% = \$124.10
	least 2cm in dia	meter in a postmenopausal	s of at least 4cm in diameter in a premenopausal person and at person, by abdominal or vaginal route, using interventional a services provided for assisted reproductive techniques
35518	(See para TN.4.11) Fee: \$207.85	of explanatory notes to this C Benefit: 75% = \$155.96	
	BARTHOLIN'S	S ABSCESS, incision of (Ar	naes.)
35520	Fee: \$58.30	Benefit: 75% = \$43.75	85% - \$40.60

T8. SUF	RGICAL OPERAT	IONS	4. GYNAECOLOGICAL
	URETHRA OR	URETHRAL CARUNCLE, cauterisation of (Anaes.))
35523	Fee: \$58.30	Benefit: 75% = \$43.75 85% = \$49.60	
		RUNCLE, excision of (Anaes.)	
35527	Fee: \$146.00	Benefit: 75% = \$109.50 85% = \$124.10	
33321		utation of, where medically indicated (Anaes.) (Assis	st.)
35530	Fee: \$269.85	Benefit: 75% = \$202.40	,
33330		abioplasty, for repair of:	
	(a) female genita	I mutilation; or	
	(b) an anomaly a	ssociated with a major congenital anomaly of the urc	o-gynaecological tract
	other than a serv 43882 applies (A	ice associated with a service to which item 35536, 37 (naes.)	7836, 37050, 37842, 37851 or
35533	(See para TN.8.12. Fee: \$349.85	B of explanatory notes to this Category) Benefit: 75% = \$262.40	
	Vulvoplasty or labioplasty, in a patient aged 18 years or more, performed by a specialist in the pracof the specialist's specialty, for a structural abnormality that is causing significant functional impair if the patient's labium extends more than 8 cm below the vaginal introitus while the patient is in a standing resting position (Anaes.)		g significant functional impairment,
35534	(See para TN.8.12) Fee: \$349.85	3 of explanatory notes to this Category) Benefit: 75% = \$262.40	
	VULVA, wide lo (Anaes.) (Assist.	ocal excision of suspected malignancy or hemivulvec)	etomy, 1 or both procedures
35536	Fee: \$348.45	Benefit: 75% = \$261.35 85% = \$296.20	
	neoplastic chang	ALLY DIRECTED CO ² LASER THERAPY for prees of the cervix, vagina, vulva, urethra or anal canal, mical site (Anaes.)	
35539	Fee: \$272.95	Benefit: 75% = \$204.75 85% = \$232.05	
	COLPOSCOPIC neoplastic chang	ALLY DIRECTED CO ² LASER THERAPY for preges of the cervix, vagina, vulva, urethra or anal canal, are anatomical sites (Anaes.) (Assist.)	
35542	Fee: \$319.60	Benefit: 75% = \$239.70 85% = \$271.70	
	COLPOSCOPIC by other methods	ALLY DIRECTED CO2 LASER THERAPY for cor	ndylomata, unsuccessfully treated
35545	Fee: \$183.60	Benefit: 75% = \$137.70 85% = \$156.10	
		r, radical, for malignancy (Anaes.) (Assist.)	
35548	Fee: \$834.05	Benefit: 75% = \$625.55	
		H GLANDS, excision of (radical) (Anaes.) (Assist.)	
25551	Fee: \$683.90	Benefit: 75% = \$512.95	
35551 35554		TATION OF, as an independent procedure including	any associated consultation
JJJJ7	THOMAS, DILA	11111011 01, as an independent procedure including	5 4117 4000014104 00110411411011

T8. SUF	RGICAL OPERATI	ONS	4. GYNAECOLOGICAL	
	(Anaes.)			
	Fee: \$43.50	Benefit: 75% = \$32.65 85% = \$37.00		
		ral of simple tumour (including Gartner duct cyst) (An	naes.)	
35557	Fee: \$214.50	Benefit: 75% = \$160.90 85% = \$182.35		
		or complete removal of (Anaes.) (Assist.)		
35560	Fee: \$683.90	Benefit: 75% = \$512.95		
		Y, radical, for proven invasive malignancy - 1 surgeor	n (Anaes.) (Assist.)	
35561	Fee: \$1,379.50	Benefit: 75% = \$1034.65		
33301	VAGINECTOM	Y, radical, for proven invasive malignancy, conjoint stare) (Anaes.) (Assist.)	urgery - abdominal surgeon	
35562	Fee: \$1,132.60	Benefit: 75% = \$849.45		
		Y, radical, for proven invasive malignancy, conjoint so	urgery - perineal surgeon (Assist.)	
35564	Fee: \$522.85	Benefit: 75% = \$392.15		
		ONSTRUCTION for congenital absence, gynatresia o	r urogenital sinus (Anaes.)	
35565	Fee: \$683.90	Benefit: 75% = \$512.95		
	VAGINAL SEPT	TUM, excision of, for correction of double vagina (An	aes.) (Assist.)	
35566	Fee: \$397.25	Benefit: 75% = \$297.95		
	SACROSPINOU (Assist.)	S COLPOPEXY FOR MANAGEMENT OF UPPER	VAGINAL PROLAPSE (Anaes.)	
35568	Fee: \$624.60	Benefit: 75% = \$468.45		
	PLASTIC REPA	IR TO ENLARGE VAGINAL ORIFICE (Anaes.)		
35569	Fee: \$160.85	Benefit: 75% = \$120.65 85% = \$136.75		
	urethrocele and c	compartment repair by vaginal approach for pelvic orgystocele), using native tissue without graft, other than item 35573, 35577 or 35578 applies.		
	(Anaes.) (Assist	<i>i.</i>)		
35570	Fee: \$553.85	Benefit: 75% = \$415.40		
	Posterior vaginal compartment repair by vaginal approach for pelvic organ prolapse involving repair of one or more of the following:			
	(a) perineum;			
	(b) rectocoele;			
	(c) enterocoele;			
		e without graft, other than a service associated with a	service to which item 35573,	
35571	333// 01 333/8 8	ippnes.		

T8. SUF	RGICAL OPERATIONS 4. GYNAECOLOGICAL
	(Anaes.) (Assist.)
	Fee: \$553.85 Benefit: 75% = \$415.40
	COLPOTOMY not being a service to which another item in this Group applies (Anaes.)
35572	Fee: \$123.80 Benefit: 75% = \$92.85
	Anterior and posterior vaginal compartment repair by vaginal approach for pelvic organ prolapse (involving anterior and posterior compartment defects), using native tissue without graft, other than a service associated with a service to which item 35577 or 35578 applies.
	(Anaes.) (Assist.)
35573	Fee: \$830.90 Benefit: 75% = \$623.20
	Manchester (Donald Fothergill) operation for pelvic organ prolapse (includes cervical amputation, anterior and posterior native tissue vaginal wall repairs without graft).
	(Anaes.) (Assist.)
35577	Fee: \$674.50 Benefit: 75% = \$505.90
	LE FORT OPERATION for genital prolapse, not being a service associated with a service to which another item in this Subgroup applies (Anaes.) (Assist.)
35578	Fee: \$674.50 Benefit: 75% = \$505.90
	Vaginal procedure for excision of graft material in symptomatic patients with graft related complications, including graft related pain or discharge and bleeding related to graft exposure, less than 2cm ² in its maximum area, either singly or in multiple pieces, other than a service associated with a service to which item 35582 or 35585 applies.
	(Anaes.) (Assist.)
35581	(See para TN.8.140 of explanatory notes to this Category) Fee: \$553.85 Benefit: 75% = \$415.40
	Vaginal procedure for excision of graft material in symptomatic patients with graft related complications, including graft related pain or discharge and bleeding related to graft exposure, more than
	2cm² in its maximum area, either singly or in multiple pieces, other than a service associated with a service to which item 35581 or 35585 applies.
	(Anaes.) (Assist.)
35582	(See para TN.8.140 of explanatory notes to this Category) Fee: \$830.90 Benefit: 75% = \$623.20
	Abdominal procedure either open, laparoscopic or robotic, for removal of graft material in patients symptomatic with graft related complications, including graft related pain or discharge and bleeding related to graft exposure or where the graft has penetrated adjacent organs such as the bladder (including urethra) or bowel, including retroperitoneal dissection and mobilisation of bladder and/or bowel, other than a service associated with a service to which item 35581 or 35582 applies.
35585	(Anaes.) (Assist.)

T8. SUF	RGICAL OPERATI	ONS	4. GYNAECOLOGICAL	
	Fee: \$1,473.20	Benefit: 75% = \$1104.90		
	FIXATION OF T	C OR ABDOMINAL PELVIC FLOOR REPAIR THE UTEROSACRAL AND CARDINAL LIGAN LL FASCIA for symptomatic upper vaginal vault p	MENTS TO RECTOVAGINAL AND	
35595	Fee: \$1,155.00	Benefit: 75% = \$866.25		
		VEEN GENITAL AND URINARY OR ALIMEN h item 37029, 37333 or 37336 applies (Anaes.) (A		
35596	Fee: \$683.90	Benefit: 75% = \$512.95		
		OPEXY, laparoscopic or open procedure where graph and to sacrum for correction of sympton		
35597	Fee: \$1,473.20	Benefit: 75% = \$1104.90		
		TINENCE, sling operation for, with or without m service to which item 30405 applies (Anaes.) (As		
35599	Fee: \$674.50	Benefit: 75% = \$505.90		
	procedure, with o	TINENCE, combined synchronous ABDOMINO or without mesh, (including aftercare), not being a 5 applies (Anaes.) (Assist.)		
35602	Fee: \$674.50	Benefit: 75% = \$505.90		
	procedure, with o	TINENCE, combined synchronous ABDOMINO or without mesh, (including aftercare), not being a 5 applies (Assist.)		
35605	Fee: \$365.95	Benefit: 75% = \$274.50 85% = \$311.10		
		sation (other than by chemical means), ionisation, of cervix (Anaes.)	, diathermy or biopsy of, with or	
35608	Fee: \$64.00	Benefit: 75% = \$48.00 85% = \$54.40		
		al of polyp or polypi, with or without dilatation of which item 35608 applies (Anaes.)	cervix, not being a service associated	
35611	Fee: \$64.00	Benefit: 75% = \$48.00 85% = \$54.40		
	CERVIX, RESID	DUAL STUMP, removal of, by abdominal approach	ch (Anaes.) (Assist.)	
35612	Fee: \$506.00	Benefit: 75% = \$379.50 85% = \$430.10		
	CERVIX, RESID	DUAL STUMP, removal of, by vaginal approach (Anaes.) (Assist.)	
35613	Fee: \$404.80	Benefit: 75% = \$303.60		
	EXAMINATION abnormal cervica	NOF LOWER TRACT by a Hinselmanntype colpil smear screen result or a history of maternal ingenious signs of cancer, has been referred by another	stion of oestrogen or where a patient,	
35614	(See para TN.8.42 Fee: \$63.90	of explanatory notes to this Category) Benefit: 75% = \$47.95 85% = \$54.35		
35615	VULVA, biopsy	of, when performed in conjunction with a service	to which item 35614 applies	

T8. SUF	RGICAL OPERATION	ONS	4. GYNAECOLOGICAL
	Fee: \$53.70	Benefit: 75% = \$40.30 85	% = \$45.65
	radiofrequency ele		and ablation of, by microwave or thermal balloon or ctory menorrhagia including any hysteroscopy rine curettage (Anaes.)
35616	Fee: \$449.60	Benefit: 75% = \$337.20	
	CERVIX, cone bi applies (Anaes.)	opsy, amputation or repair of,	other than a service to which item 35577 or 35578
35618	Fee: \$218.00	Benefit: 75% = \$163.50 8:	5% = \$185.30
	ENDOMETRIAL post menopausal b		s suspected in patients with abnormal uterine bleeding or
35620	Fee: \$53.35	Benefit: 75% = \$40.05 85	% = \$45.35
	including any hys		aser or diathermy, for chronic refractory menorrhagia ume day, with or without uterine curettage, not being a 30390 applies (Anaes.)
35622	Fee: \$602.45	Benefit: 75% = \$451.85	
		IC RESECTION of myoma, oved by endometrial ablation by	or myoma and uterine septum resection (where both are y laser or diathermy (Anaes.)
35623	Fee: \$819.25	Benefit: 75% = \$614.45	
	where the patient	is referred to him or her for the	ed by a specialist in the practice of his or her specialty e investigation of suspected intrauterine pathology (with e associated with a service to which item 35627 or 35630
35626	(See para TN.8.43 o Fee: \$82.80	f explanatory notes to this Categoral Benefit: 75% = \$62.10 85°	
			s performed in the operating theatre of a hospital - not ch item 35626 or 35630 applies (Anaes.)
35627	Fee: \$107.15	Benefit: 75% = \$80.40	
			erformed in the operating theatre of a hospital - not being n 35626 or 35627 applies (Anaes.)
35630	Fee: \$183.00	Benefit: 75% = \$137.25	
			polypectomy or tubal catheterisation (including for of IUD which cannot be removed by other means, 1 or
35633	Fee: \$218.00	Benefit: 75% = \$163.50 8:	5% = \$185.30
	HYSTEROSCOP diathermy (Anaes		ptum followed by endometrial ablation by laser or
35634	Fee: \$685.70	Benefit: 75% = \$514.30 8:	5% = \$602.30
	HYSTEROSCOP	Y involving resection of the u	terine septum (Anaes.)
35635	Fee: \$299.45	Benefit: 75% = \$224.60	
35636	HYSTEROSCOP	Y, involving resection of myo	ma, or resection of myoma and uterine septum (where

T8. SUF	RGICAL OPERATION	DNS	4. GYNAECOLOGICAL
	both are performed	d) (Anaes.)	
	Fee: \$433.00	Benefit: 75% = \$324.75	
	of adhesions or sin		of endometriosis, ventrosuspension, division with or without biopsy - not being a service rectomy (Anaes.) (Assist.)
35637	(See para TN.1.4 of Fee: \$406.65	explanatory notes to this Category) Benefit: 75% = \$305.00	
	of the following pr salpingostomy, abl or division of utero	ocedures; oophorectomy, ovarian cysted ation of moderate or severe endometrio	sis requiring more than 1 hours operating time, norrhoea - not being a service associated with
35638	Fee: \$711.50	Benefit: 75% = \$533.65	
	miscarriage) under	TTAGE OF, with or without dilatation (in general anaesthesia, or under epidural of the item 35626, 35627 or 35630 applies,	or spinal (intrathecal) nerve block, including
35640	(See para TN.8.44 of Fee: \$183.00	f explanatory notes to this Category) Benefit: 75% = \$137.25	
	following procedutissue from the ure than 2 cms in diam	res, resection of the pelvic side wall incl ter, resection of the Pouch of Douglas, r	RESECTION OF, involving any two of the luding dissection of endometriosis or scar resection of an ovarian endometrioma greater om the level of the endocervical junction or es.) (Assist.)
35641	Fee: \$1,242.65	Benefit: 75% = \$932.00	
	EVACUATION O CURETTAGE oth		O UTERUS BY CURETTAGE OR SUCTION pplies, including procedures to which item
35643	Fee: \$218.00	Benefit: 75% = \$163.50 85% = \$185.	30
	neoplastic changes	oagulation diathermy with colposcopy, of the cervix, including any local anaest ervice to which item 35640 or 35647 ap	sthesia and biopsies, other than a service
35644	(See para TN.8.45 of Fee: \$203.65	f explanatory notes to this Category) Benefit: 75% = \$152.75 85% = \$173.	15
	neoplastic changes ablative therapy of		sthesia and biopsies, in conjunction with ge in 1 or more sites of vagina, vulva, urethra
35645	(See para TN.8.45 of Fee: \$318.70	f explanatory notes to this Category) Benefit: 75% = \$239.05 85% = \$270.5	90
		opy with radical diathermy of, with or w thelial neoplastic changes of the cervix	
35646	(See para TN.8.45 of Fee: \$203.65	f explanatory notes to this Category) Benefit: 75% = \$152.75 85% = \$173.	15

T8. SUF	RGICAL OPERATIONS	4. GYNAECOLOGICAL
	CERVIX, large loop excision of transformation zone together wintraepithelial neoplastic changes of the cervix, including any loservice associated with a service to which item 35644 applies (A	cal anaesthesia and biopsies, not being a
35647	(See para TN.8.45 of explanatory notes to this Category) Fee: \$203.65 Benefit: 75% = \$152.75 85% = \$173.15	
	CERVIX, large loop excision diathermy for previously confirme the cervix, including any local anaesthesia and biopsies, in conju- additional areas of intraepithelial change of 1 or more sites of va- service associated with a service to which item 35645 applies (A	unction with ablative treatment of agina, vulva, urethra or anus, not being a
35648	(See para TN.8.45 of explanatory notes to this Category) Fee: \$318.70 Benefit: 75% = \$239.05 85% = \$270.90	
	HYSTEROTOMY or UTERINE MYOMECTOMY, abdominal	(Anaes.) (Assist.)
35649	Fee: \$536.00 Benefit: 75% = \$402.00	
	HYSTERECTOMY, ABDOMINAL, SUBTOTAL or TOTAL, adnexae (Anaes.) (Assist.)	with or without removal of uterine
35653	Fee: \$674.70 Benefit: 75% = \$506.05	
	HYSTERECTOMY, VAGINAL, with or without uterine curette 35673 applies NOTE: Strict legal requirements apply in relation to sterilisation benefits are not payable for services not rendered in accordance and Territory law. Observe the explanatory note before submitted.	on procedures on minors. Medicare e with relevant Commonwealth and State
35657	(See para TN.8.46 of explanatory notes to this Category) Fee: \$674.70 Benefit: 75% = \$506.05	
	UTERUS (at least equivalent in size to a 10 week gravid uterus) at hysterectomy (Anaes.) (Assist.)	, debulking of, prior to vaginal removal
35658	(See para TN.8.47 of explanatory notes to this Category) Fee: \$416.05 Benefit: 75% = \$312.05	
	HYSTERECTOMY, ABDOMINAL, requiring extensive retrope exposure of 1 or both ureters, for the management of severe end or benign pelvic tumours, with or without conservation of the ov	ometriosis, pelvic inflammatory disease
35661	Fee: \$871.30 Benefit: 75% = \$653.50	
	RADICAL HYSTERECTOMY with radical excision of pelvic l of uterine adnexae) for proven malignancy including excision of paracolpos, upper vagina or contiguous pelvic peritoneum and in (Anaes.) (Assist.)	f any 1 or more of parametrium,
35664	Fee: \$1,452.20 Benefit: 75% = \$1089.15	
	RADICAL HYSTERECTOMY without gland dissection (with o	
	for proven malignancy including excision of any 1 or more of particular contiguous pelvic peritoneum and involving ureterolysis where	arametrium, paracolpos, upper vagina or

T8. SUF	RGICAL OPERATI	ons	4. GYNAECOLOGICAL
		MY, abdominal, with radical excision of pelvic lyne (Anaes.) (Assist.)	nph glands, with or without removal
35670	Fee: \$1,016.30	Benefit: 75% = \$762.25	
		MY, VAGINAL (with or without uterine curettage trian cyst, 1 or more, 1 or both sides (Anaes.) (Ass	
35673	Fee: \$757.80	Benefit: 75% = \$568.35	
	ULTRASOUND	GUIDED NEEDLING and injection of ectopic pr	regnancy
35674	(See para TN.4.11 o Fee: \$207.85	of explanatory notes to this Category) Benefit: 75% = \$155.90 85% = \$176.70	
	ECTOPIC PREG	NANCY, removal of (Anaes.) (Assist.)	
35677	Fee: \$536.00	Benefit: 75% = \$402.00	
	ECTOPIC PREG	NANCY, laparoscopic removal of (Anaes.) (Assis	st.)
35678	Fee: \$646.25	Benefit: 75% = \$484.70	
	BICORNUATE U	JTERUS, plastic reconstruction for (Anaes.) (Ass	ist.)
35680	Fee: \$582.05	Benefit: 75% = \$436.55 85% = \$498.65	
	UTERUS, SUSPI	ENSION OR FIXATION OF, as an independent p	procedure (Anaes.) (Assist.)
35684	Fee: \$471.15	Benefit: 75% = \$353.40	
		N BY TRANSECTION OR RESECTION OF FAI via laparoscopy using diathermy or any other met	
	benefits are not p	ral requirements apply in relation to sterilisation payable for services not rendered in accordance was. Observe the explanatory note before submitting	ith relevant Commonwealth and State
35688	(See para TN.8.46 (Fee: \$397.25	of explanatory notes to this Category) Benefit: 75% = \$297.95	
	STERILISATION with Caesarean so	N BY INTERRUPTION OF FALLOPIAN TUBE ection	S, when performed in conjunction
	benefits are not p	ral requirements apply in relation to sterilisation p ayable for services not rendered in accordance w v. Observe the explantory note before submitting o	ith relevant Commonwealth and State
35691	(See para TN.8.46 o Fee: \$158.70	of explanatory notes to this Category) Benefit: 75% = \$119.05	
		salpingostomy, salpingolysis or tubal implantation or more procedures (Anaes.) (Assist.)	n into uterus), UNILATERAL or
35694	Fee: \$637.70	Benefit: 75% = \$478.30	
35697	MICROSURGIC	AL TUBOPLASTY (salpingostomy, salpingolysis	s or tubal implantation into uterus),

T8. SUF	RGICAL OPERAT	IONS	4. GYNAECOLOGICAL
	UNILATERAL	or BILATERAL, 1 or more procedure	s (Anaes.) (Assist.)
	Fee: \$946.20	Benefit: 75% = \$709.65	
	FALLOPIAN TO (Assist.)	JBES, unilateral microsurgical anasto	mosis of, using operating microscope (Anaes.)
35700	Fee: \$730.05	Benefit: 75% = \$547.55	
		TION OF FALLOPIAN TUBES as a r service to which another item in this	onrepetitive procedure not being a service Sub-group applies (Anaes.)
35703	Fee: \$67.50	Benefit: 75% = \$50.65 85% = \$5	7.40
	RUBIN TEST F	OR PATENCY OF FALLOPIAN TU	BES (Anaes.)
35706	Fee: \$67.50	Benefit: 75% = \$50.65 85% = \$5	7.40
	FALLOPIAN T	JBES, hydrotubation of, as a repetitiv	e postoperative procedure (Anaes.)
35709	Fee: \$43.50	Benefit: 75% = \$32.65 85% = \$3	7.00
	FALLOPOSCOI (Assist.)	PY, unilateral or bilateral, including h	ysteroscopy and tubal catheterization (Anaes.)
35710	Fee: \$463.30	Benefit: 75% = \$347.50	
	OOPHORECTO		LPINGECTOMY, SALPINGO- VARIAN, FIMBRIAL or BROAD LIGAMENT ciated with hysterectomy (Anaes.) (Assist.)
35713	Fee: \$452.85	Benefit: 75% = \$339.65	
	OOPHORECTO	e such procedures, unilateral or bilate	LPINGECTOMY, SALPINGO- VARIAN, FIMBRIAL or BROAD LIGAMENT ral, other than a service associated with
35717	Fee: \$545.30	Benefit: 75% = \$409.00	
	RADICAL OR I omentectomy (A		nced gynaecological malignancy, with or without
35720	(See para TN.8.57 Fee: \$674.50	of explanatory notes to this Category) Benefit: 75% = \$505.90	
		NEAL LYMPH NODE BIOPSIES fring of gynaecological malignancy (Ar	om above the level of the aortic bifurcation, for naes.) (Assist.)
35723	Fee: \$483.10	Benefit: 75% = \$362.35	
		MENTECTOMY with multiple perit nalignancy (Anaes.) (Assist.)	oneal biopsies for staging or restaging of
35726	Fee: \$483.10	Benefit: 75% = \$362.35	
	OVARIAN TRA	<u> </u>	injunction with radical hysterectomy for invasive
35729	Fee: \$217.80	Benefit: 75% = \$163.35	
35730			ve ovarian function, prior to gonadotoxic adiation have a high probability of causing

T8. SUF	RGICAL OPERATIONS	3	4. GYNAECOLOGICAL
	infertility (Anaes.)		
	Fee: \$217.80	Benefit: 75% = \$163.35	
	LAPAROSCOPICAL (Anaes.) (Assist.)	LY ASSISTED HYSTERECT	OMY, including any associated laparoscopy
35750	Fee: \$784.60	Benefit: 75% = \$588.45	
	procedures: salpingec	tomy, oophorectomy, excision	OMY with one or more of the following of ovarian cyst or treatment of moderate ciated laparoscopy (Anaes.) (Assist.)
35753	Fee: \$867.60 I	Benefit: 75% = \$650.70	
	or other pathology, frowhen performed with	om the ureter, one or both sides one or more of the following p	OMY which requires dissection of endometriosis, including any associated laparoscopy, including procedures: salpingectomy, oophorectomy, excision ring a service to which item 35641 applies (Anaes.)
35754	Fee: \$1,091.90 F	Benefit: 75% = \$818.95	
		LY ASSISTED HYSTERECT ng any associated laparoscopy	OMY, when procedure is completed by open (Anaes.) (Assist.)
35756	Fee: \$784.60	Benefit: 75% = \$588.45	
		esia, utilising a vaginal or abdo	EMORRHAGE following gynaecological surgery, ominal and vaginal approach where no other
35759	Fee: \$563.30 H	Benefit: 75% = \$422.50	
T8. SUF	RGICAL OPERATIONS	}	5. UROLOGICAL
	Group T8. Surgical O	perations	
		Subgroup	5. Urological
		GENI	ERAL
	PELVIC LYMPHADI (Assist.)	ENECTOMY, open or laparos	copic, or both, unilateral or bilateral (Anaes.)
36502	Fee: \$683.90 I	Benefit: 75% = \$512.95	
	RENAL TRANSPLA	NT (not being a service to whi	ch item 36506 or 36509 applies) (Anaes.) (Assist.)
36503	Fee: \$1,391.15	Benefit: 75% = \$1043.40	
		NT, performed by vascular sur aftercare (Anaes.) (Assist.)	geon and urologist operating together vascular
36506	Fee: \$924.70	Benefit: 75% = \$693.55	
		NT, performed by vascular sur al anastomosis including afterc	

T8. SUF	RGICAL OPERATION	ONS 5. UROLOGICAL
	NEPHRECTOMY	, complete (Anaes.) (Assist.)
36516	Fee: \$924.70	Benefit: 75% = \$693.55
30310		, complete, complicated by previous surgery on the same kidney (Anaes.) (Assist.)
36519	Fee: \$1,291.10	Benefit: 75% = \$968.35
	NEPHRECIOMY	, partial (Anaes.) (Assist.)
36522	Fee: \$1,107.95	Benefit: 75% = \$831.00
	NEPHRECTOMY	, partial, complicated by previous surgery on the same kidney (Anaes.) (Assist.)
36525	Fee: \$1,574.45	Benefit: 75% = \$1180.85
	tumour less than 1	r, radical with en bloc dissection of lymph nodes, with or without adrenalectomy, for a 0cms in diameter, where performed if malignancy is clinically suspected but not epathological examination (Anaes.) (Assist.)
36526	(See para TN.8.48 o Fee: \$1,291.10	f explanatory notes to this Category) Benefit: $75\% = \$968.35$ $85\% = \$1207.70$
	tumour 10cms or same kidney, whe	r, radical with en bloc dissection of lymph nodes, with or without adrenalectomy, for a more in diameter, or complicated by previous open or laparoscopic surgery on the re performed if malignancy is clinically suspected but not confirmed by examination (Anaes.) (Assist.)
36527	(See para TN.8.48 o Fee: \$1,593.40	f explanatory notes to this Category) Benefit: $75\% = 1195.05 $85\% = 1510.00
		, radical with en bloc dissection of lymph nodes, with or without adrenalectomy, for a 0 cms in diameter (Anaes.) (Assist.)
36528	Fee: \$1,291.10	Benefit: 75% = \$968.35
		r, radical with en bloc dissection of lymph nodes, with or without adrenalectomy, for a more in diameter, or complicated by previous open or laparoscopic surgery on the es.) (Assist.)
36529	Fee: \$1,593.40	Benefit: 75% = \$1195.05
		RECTOMY, complete, including associated bladder repair and any associated ures (Anaes.) (Assist.)
36531	Fee: \$1,157.85	Benefit: 75% = \$868.40
		RECTOMY, for tumour, with or without en bloc dissection of lymph nodes, including repair and any associated endoscopic procedures (Anaes.) (Assist.)
36532	Fee: \$1,661.85	Benefit: 75% = \$1246.40
	associated bladder	RECTOMY, for tumour, with or without en bloc dissection of lymph nodes, including repair and any associated endoscopic procedures, complicated by previous open or ry on the same kidney or ureter (Anaes.) (Assist.)
36533	Fee: \$1,964.15	Benefit: 75% = \$1473.15
	VIDNEY OD DEI	INEPHRIC AREA, EXPLORATION OF, with or without drainage of, by open
		g a service to which another item in this Sub-group applies (Anaes.) (Assist.)

T8. SUF	RGICAL OPERATION	ONS	5. UROLOGICAL
	NEPHROLITHO stones (Anaes.) (A	TOMY OR PYELOLITHOTOMY, or both, through the Assist.)	same skin incision, for 1 or 2
36540	Fee: \$1,107.95	Benefit: 75% = \$831.00 85% = \$1024.55	
	stones, including	TOMY OR PYELOLITHOTOMY, or both, extended, for more of the following: nephrostomy, pyelostomy, paphy or pyeloplasty (Anaes.) (Assist.)	
36543	Fee: \$1,291.10	Benefit: 75% = \$968.35 85% = \$1207.70	
		EAL SHOCK WAVE LITHOTRIPSY (ESWL) to uring ing pretreatment consultation, unilateral (Anaes.)	ary tract and posttreatment care
36546	Fee: \$691.40	Benefit: 75% = \$518.55 85% = \$608.00	
	URETEROLITHO	OTOMY (Anaes.) (Assist.)	
36549	Fee: \$833.10	Benefit: 75% = \$624.85	
	NEPHROSTOMY	or pyelostomy, open, as an independent procedure (An	aes.) (Assist.)
36552	Fee: \$741.50	Benefit: 75% = \$556.15	
	RENAL CYST O	R CYSTS, excision or unroofing of (Anaes.) (Assist.)	
36558	Fee: \$649.80	Benefit: 75% = \$487.35 85% = \$566.40	
	RENAL BIOPSY		
36561	Fee: \$172.50	Benefit: 75% = \$129.40 85% = \$146.65	
	PYELOPLASTY	(plastic reconstruction of the pelvi-ureteric junction) by sisted techniques (Anaes.) (Assist.)	open exposure, laparoscopy
36564	Fee: \$924.70	Benefit: 75% = \$693.55	
		in a kidney that is congenitally abnormal in addition to ta solitary kidney, by open exposure (Anaes.) (Assist.)	he presence of PUJ
36567	Fee: \$1,016.30	Benefit: 75% = \$762.25	
	PYELOPLASTY (Assist.)	complicated by previous surgery on the same kidney, b	y open exposure (Anaes.)
36570	Fee: \$1,291.10	Benefit: 75% = \$968.35	
	DIVIDED URET	ER, repair of (Anaes.) (Assist.)	
36573	Fee: \$924.70	Benefit: 75% = \$693.55	
		re and exploration of, including repair or nephrectomy, by other procedure performed on the kidney, renal pelvis	
36576	Fee: \$1,157.85	Benefit: 75% = \$868.40	
		IY, COMPLETE OR PARTIAL, with or without associate with a service to which item 37000 applies (Anaes.) (A	
36579	Fee: \$741.50	Benefit: 75% = \$556.15	
26595	URETER, transpl	antation of, into skin (Anaes.) (Assist.)	
36585			

T8. SUF	RGICAL OPERATI	ons	5. UROLOGICAL	
	Fee: \$741.50	Benefit: 75% = \$556.15		
	URETER, reimp	antation into bladder (Anaes.) (Assist.)		
36588	Fee: \$924.70	Benefit: 75% = \$693.55		
	URETER, reimpl	antation into bladder with psoas hitch or Boari f.	lap or both (Anaes.) (Assist.)	
36591	Fee: \$1,107.95	Benefit: 75% = \$831.00		
	URETER, transp	lantation of, into intestine (Anaes.) (Assist.)		
36594	Fee: \$924.70	Benefit: 75% = \$693.55		
	URETER, transp	lantation of, into another ureter (Anaes.) (Assist.)	
36597	Fee: \$924.70	Benefit: 75% = \$693.55		
	URETER, transp	lantation of, into isolated intestinal segment, unil	lateral (Anaes.) (Assist.)	
36600	Fee: \$1,107.95	Benefit: 75% = \$831.00 85% = \$1024.55		
	- '	plantation of, into isolated intestinal segment, bi	lateral (Anaes.) (Assist.)	
36603	Fee: \$1,291.10	Benefit: 75% = \$968.35		
30003	-	NT, passage of through percutaneous nephrostor	my tube, using interventional imaging	
	techniques (Anae			
36604	Fee: \$267.65	Benefit: 75% = \$200.75 85% = \$227.55		
	URETERIC STENT, insertion of, with removal of calculus from:			
	(a) the pelvicalyceal system; or			
	(b) ureter; or			
	(c) the pelvicalyceal system and ureter;			
	through a nephro	stomy tube using interventional imaging techniq	ues (Anaes.)	
36605	Fee: \$690.70	Benefit: 75% = \$518.05		
		RINARY RESERVOIR, continent, formation of ntation of ureters (1 or both) into reservoir (Anae		
36606	Fee: \$2,315.80	Benefit: 75% = \$1736.85		
	URETERIC STE	NT insertion of, with baloon dilatation of:		
	(a) the pelvicalyceal system; or			
	(b) ureter; or			
	(c) the pelvica	(c) the pelvicalyceal system and ureter;		
	through a nephro	stomy tube using interventional imaging techniq	ues (Anaes.)	
36607	Fee: \$690.70	Benefit: 75% = \$518.05		
36608		NT, exchange of, percutaneously through either aging techniques, not being a service associated		

T8. SUF	RGICAL OPERAT	IONS 5. UROLOGICAL
	36854 apply (An	aes.)
	Fee: \$267.65	Benefit: 75% = \$200.75
	INTESTINAL U	RINARY CONDUIT OR URETEROSTOMY, revision of (Anaes.) (Assist.)
36609	Fee: \$741.50	Benefit: 75% = \$556.15
3000)		ration of, with or without drainage of, as an independent procedure (Anaes.) (Assist.)
36612	Fee: \$649.80	Benefit: 75% = \$487.35
	URETEROLYSI either radiologic	S, with or without repositioning of the ureter, for obstruction of the ureter, evident ally or by proximal ureteric dilatation at operation, secondary to retroperitoneal fibrosis, fon (Anaes.) (Assist.)
36615	Fee: \$741.50	Benefit: 75% = \$556.15
	REDUCTION U	RETEROPLASTY (Anaes.) (Assist.)
36618	Fee: \$649.80	Benefit: 75% = \$487.35
	CLOSURE OF C	CUTANEOUS URETEROSTOMY (Anaes.) (Assist.)
36621	Fee: \$464.50	Benefit: 75% = \$348.40
	NEPHROSTOM	Y, percutaneous, using interventional imaging techniques (Anaes.) (Assist.)
36624	Fee: \$558.10	Benefit: 75% = \$418.60 85% = \$474.70
		Y, percutaneous, with or without any 1 or more of; stone extraction, biopsy or eing a service to which item 36639, 36642, 36645 or 36648 applies (Anaes.)
36627	Fee: \$691.40	Benefit: 75% = \$518.55
	substantial portion	Y, BEING A SERVICE TO WHICH ITEM 36627 APPLIES, WHERE, after a on of the procedure has been performed, IT IS NECESSARY TO DISCONTINUE THE UE TO BLEEDING (Anaes.) (Assist.)
36630	Fee: \$341.50	Benefit: 75% = \$256.15
	ureter and includ	Y, percutaneous, with incision of any 1 or more of; renal pelvis, calyx or calyces or ing antegrade insertion of ureteric stent, not being a service associated with a service to 7, 36639, 36642, 36645 or 36648 applies (Anaes.) (Assist.)
36633	Fee: \$741.50	Benefit: 75% = \$556.15 85% = \$658.10
	ureter and includ	Y, percutaneous, with incision of any 1 or more of; renal pelvis, calyx or calyces or ing antegrade insertion of ureteric stent, being a service associated with a service to 7, 36639, 36642, 36645 or 36648 applies (Anaes.) (Assist.)
36636	Fee: \$399.90	Benefit: 75% = \$299.95
		Y, percutaneous, with destruction and extraction of 1 or 2 stones using ultrasound or shock waves or lasers (not being a service to which item 36645 or 36648 applies)
36639	Fee: \$833.10	Benefit: 75% = \$624.85
36642	substantial portion	Y, BEING A SERVICE TO WHICH ITEM 36639 APPLIES, WHERE, after a on of the procedure has been performed, IT IS NECESSARY TO DISCONTINUE THE UE TO BLEEDING (Anaes.) (Assist.)

T8. SUF	RGICAL OPERATI	ONS	5. UROLOGICAL
	Fee: \$416.45	Benefit: 75% = \$312.35	
		7, percutaneous, with removal or destruction of a 3 or more stones (Anaes.) (Assist.)	stone greater than 3 cm in any
36645	Fee: \$1,066.30	Benefit: 75% = \$799.75	
		V, being a service to which item 36645 applies, V s been performed, IT IS NECESSARY TO DISC	
36648	Fee: \$949.60	Benefit: 75% = \$712.20	
	NEPHROSTOM	Y DRAINAGE TUBE, exchange of - but not inc	cluding imaging (Anaes.) (Assist.)
36649	Fee: \$267.65	Benefit: 75% = \$200.75 85% = \$227.55	
		Y TUBE, removal of, if the ureter has been stent in place, using interventional imaging techniques	
36650	Fee: \$149.70	Benefit: 75% = \$112.30	
	ureteric meatotor	retrograde, of one collecting system, with or with ny, ureteric dilatation, not being a service associated applies (Anaes.) (Assist.)	
36652	Fee: \$649.80	Benefit: 75% = \$487.35	
	1 or more of extra pelvis or calyces,	retrograde, of one collecting system, being a servaction of stone from the renal pelvis or calyces, or not being a service associated with a service to med in the same collecting system (Anaes.) (Assign	or biopsy or diathermy of the renal which item 36656 applies to a
36654	Fee: \$833.10	Benefit: 75% = \$624.85	
	extraction of 2 or electrohydraulic fragments, not be	retrograde, of one collecting system, being a server more stones in the renal pelvis or calyces or desport kinetic lithotripsy, or laser in the renal pelvis or sing a service associated with a service to which is same collecting system (Anaes.) (Assist.)	truction of stone with ultrasound, or calyces, with or without extraction of
36656	Fee: \$1,066.30	Benefit: 75% = \$799.75	
		OPERATIONS ON BLADDE	:R
	Both:		
	(a) percutaneous of sacral nerve le	placement of sacral nerve lead or leads using flu ad or leads; and	oroscopic guidance, or open placement
	(b) intra-operativ	e test stimulation, to manage:	
	(i) detrusor treatment; o	over-activity that has been refractory to at least in	12 months conservative non-surgical
	(ii) non-obs non-surgica	tructive urinary retention that has been refractory	y to at least 12 months conservative
	(Anaes.)		
36663	Fee: \$660.95	Benefit: 75% = \$495.75 85% = \$577.55	

T8. SUF	RGICAL OPERATIONS	5. UROLOGICAL
	Both:	
	(a) percutaneous repositioning of sacral nerve repositioning of sacral nerve lead or leads; and	ead or leads using fluoroscopic guidance, or open
	(b) intra-operative test stimulation, to correct d the management of:	isplacement or unsatisfactory positioning, if inserted for
	(i) detrusor over-activity that has been re treatment; or	fractory to at least 12 months conservative non-surgical
	(ii) non-obstructive urinary retention that non-surgical treatment	has been refractory to at least 12 months conservative
	—other than a service to which item 366	63 applies (Anaes.)
36664	Fee: \$593.55 Benefit: 75% = \$445.20	85% = \$510.15
	Sacral nerve electrode or electrodes, managem practitioner, to manage detrusor overactivity or	ent and adjustment of the pulse generator by a medical roon obstructive urinary retention - each day
36665	Fee: \$125.40 Benefit: 75% = \$94.05 8.	5% = \$106.60
	Pulse generator, subcutaneous placement of, an sacral nerve electrode or electrodes, for the ma	nd placement and connection of extension wire or wires to nagement of:
	(a) detrusor over-activity that has been refractor treatment; or	bry to at least 12 months conservative non-surgical
	(b) non-obstructive urinary retention that has b non-surgical treatment (Anaes.)	een refractory to at least 12 months conservative
36666	Fee: \$334.00 Benefit: 75% = \$250.50	35% = \$283.90
	Sacral nerve lead or leads, removal of, if the le	ad was inserted to manage:
	(a) detrusor over-activity that has been refractor treatment; or	ry to at least 12 months conservative non-surgical
	(b) non-obstructive urinary retention that has b non-surgical treatment	een refractory to at least 12 months conservative
	(Anaes.)	
36667	Fee: \$156.30 Benefit: 75% = \$117.25	35% = \$132.90
	Pulse generator, removal of, if the pulse genera	
	(a) detrusor over-activity that has been refractory to at least 12 months conservative non-surgical treatment; or	
	(b) non-obstructive urinary retention that has b non-surgical treatment	een refractory to at least 12 months conservative
	(Anaes.)	
36668	Fee: \$156.30 Benefit: 75% = \$117.25	85% = \$132.90

T8. SURGICAL OPERATIONS

5. UROLOGICAL

Percutaneous tibial nerve stimulation, initial treatment protocol, for the treatment of overactive bladder, by a specialist urologist, gynaecologist or urogynaecologist, if:

- (a) the patient has been diagnosed with idiopathic overactive bladder; and
- (b) the patient has been refractory to, is contraindicated or otherwise not suitable for conservative treatments (including anti-cholinergic agents); and
- (c) the patient is contraindicated or otherwise not a suitable candidate for botulinum toxin type A therapy; and
- (d) the patient is contraindicated or otherwise not a suitable candidate for sacral nerve stimulation; and
- (e) the patient is willing and able to comply with the treatment protocol; and
- (f) the initial treatment protocol comprises 12 sessions, delivered over a 3 month period; and
- (g) each session lasts for a minimum of 45 minutes, of which neurostimulation lasts for 30 minutes.

For each patient—applicable only once, unless the patient achieves at least a 50% reduction in overactive bladder symptoms from baseline at any time during the 3 month treatment period.

Not applicable for a service associated with a service to which item 36672 or 36673 applies

36671 S **Fee:** \$200.00

Benefit: $75\% = \$150.00 \quad 85\% = \170.00

Percutaneous tibial nerve stimulation, tapering treatment protocol, for the treatment of overactive bladder, including any associated consultation at the time the percutaneous tibial nerve stimulation treatment is administered, if:

- (a) the patient responded to the percutaneous tibial nerve stimulation initial treatment protocol and has achieved at least a 50% reduction in overactive bladder symptoms from baseline at any time during the treatment period for the initial treatment protocol; and
- (b) the tapering treatment protocol comprises no more than 5 sessions, delivered over a 3 month period, and the interval between sessions is adjusted with the aim of sustaining therapeutic benefit of the treatment: and
- (c) each session lasts for a minimum of 45 minutes, of which neurostimulation lasts for 30 minutes.

Not applicable for a service associated with a service to which item 36671 or 36673 applies

36672 G

Fee: \$200.00

Benefit: 75% = \$150.00 85% = \$170.00

Percutaneous tibial nerve stimulation, maintenance treatment protocol, for the treatment of overactive bladder, including any associated consultation at the time the percutaneous tibial nerve stimulation treatment is administered, if:

(a) the patient responded to the percutaneous tibial nerve stimulation initial treatment protocol and to the tapering treatment protocol, and has achieved at least a 50% reduction in overactive bladder symptoms from baseline at any time during the treatment period for the initial treatment protocol; and

36673 G

(b) the maintenance treatment protocol comprises no more than 12 sessions, delivered over a 12 month

T8. SUF	RGICAL OPERATION	ONS	5. UROLOGICAL
	period, and the interestment; and	terval between sessions is adjusted with the aim	of sustaining therapeutic benefit of the
	(c) each session la	asts for a minimum of 45 minutes, of which neur	rostimulation lasts for 30 minutes.
	Not applicable for	service associated with a service to which item	36671 or 36672 applies
	Fee: \$200.00	Benefit: 75% = \$150.00 85% = \$170.00	
	BLADDER, cathe	eterisation of, where no other procedure is perfor	rmed (Anaes.)
36800	Fee: \$27.60	Benefit: 75% = \$20.70 85% = \$23.50	
	or ureteric dilatati	Y, of one ureter, with or without any one or mor on, not being a service associated with a service 809, 36812, 36824, 36848 or 36857 applies (An	to which item 36652, 36654,
36803	(See para TN.8.51 c Fee: \$466.35	of explanatory notes to this Category) Benefit: 75% = \$349.80 85% = \$396.40	
	or ureteric dilatati the ureter, not bei service associated	Y, of one ureter, with or without any one or mor on, plus one or more of extraction of stone from ng a service associated with a service to which it with a service to which item 36809, 36824, 368 same ureter (Anaes.) (Assist.)	the ureter, or biopsy or diathermy of tem 36803 or 36812 applies, or a
36806	Fee: \$649.80	Benefit: 75% = \$487.35	
	or ureteric dilatati lithotripsy, or lase to which item 368	Y, of one ureter, with or without any one or mor on, PLUS destruction of stone in the ureter with er, with or without extraction of fragments, not b 303 or 36812 applies, or a service associated with 36857 applies to a procedure performed on the sa	ultrasound, electrohydraulic or kinetic eing a service associated with a service h a service to which item 36806,
36809	Fee: \$833.10	Benefit: 75% = \$624.85	
	CYSTOSCOPY v	with insertion of urethral prosthesis (Anaes.)	
36811	Fee: \$323.40	Benefit: 75% = \$242.55 85% = \$274.90	
		with urethroscopy with or without urethral dilatar plogical endoscopic procedure on the lower uring maes.)	
36812	Fee: \$166.70	Benefit: 75% = \$125.05 85% = \$141.70	
		with or without urethroscopy, for the treatment of sociated with a service to which item 30189 app	
36815	(See para TN.8.9 of Fee: \$237.90	explanatory notes to this Category) Benefit: 75% = \$178.45 85% = \$202.25	
		with ureteric catheterisation including fluoroscoperal, not being a service associated with a service	
36818	Fee: \$276.60	Benefit: 75% = \$207.45 85% = \$235.15	

T8. SUF	RGICAL OPERAT	TIONS	5. UROLOGICAL	
		elvis, unilateral, not being a service asso	sertion of ureteric stent, or brush biopsy of ciated with a service to which item 36824 or	
36821	Fee: \$323.20	Benefit: 75% = \$242.40 85% = \$27-	4.75	
		, with ureteric catheterisation, unilateral ch item 36818 or 36821 applies (Anaes.)	or bilateral, not being a service associated with	
36824	Fee: \$213.15	Benefit: 75% = \$159.90 85% = \$18	1.20	
	removal or repla		ic junction or ureteric stricture, including vice associated with a service to which item Assist.)	
36825	Fee: \$581.30	Benefit: 75% = \$436.00		
	CYSTOSCOPY	, with controlled hydrodilatation of the b	oladder (Anaes.)	
36827	Fee: \$229.85	Benefit: 75% = \$172.40 85% = \$19	5.40	
	CYSTOSCOPY	, with ureteric meatotomy (Anaes.)		
36830	Fee: \$203.25	Benefit: 75% = \$152.45		
	CYSTOSCOPY	, with removal of ureteric stent or other	foreign body (Anaes.) (Assist.)	
36833	Fee: \$276.60	Benefit: 75% = \$207.45 85% = \$23.	5.15	
30033	CYSTOSCOPY		vice associated with a service to which item	
36836	Fee: \$229.85	Benefit: 75% = \$172.40 85% = \$19.	5.40	
		, with resection, diathermy or visual lase of being a service to which item 36845 ε	er destruction of bladder tumour or other lesion applies (Anaes.)	
36840	Fee: \$323.20	Benefit: 75% = \$242.40 85% = \$27	4.75	
	or bladder and n		r including any associated diathermy of prostate ice to which item 36812, 36827 to 36863, 37203	
36842	Fee: \$325.20	Benefit: 75% = \$243.90		
		, with diathermy, resection or visual lase bladder or solitary tumour greater than 2	er destruction of multiple tumours in more than 2 2cm in diameter (Anaes.)	
36845	Fee: \$691.40	Benefit: 75% = \$518.55 85% = \$60	8.00	
	CYSTOSCOPY	, with resection of ureterocele (Anaes.)		
36848	Fee: \$229.85	Benefit: 75% = \$172.40		
		Cystoscopy, with injection into bladder wall, other than a service associated with a service to which item 18375 or 18379 applies (H) (Anaes.)		
36851	Fee: \$229.85	Benefit: 75% = \$172.40		
		, with endoscopic incision or resection o	f external sphincter, bladder neck or both	
	(Anaes.)			

T8. SUF	RGICAL OPERATI	ONS	5. UROLOGICAL
	ENDOSCOPIC N	MANIPULATION OR EXTRACTION of ureteric calculus (Anac	es.)
36857	Fee: \$366.45	Benefit: 75% = \$274.85	
	ENDOSCOPIC E	EXAMINATION of intestinal conduit or reservoir (Anaes.)	
36860	Fee: \$166.70	Benefit: 75% = \$125.05 85% = \$141.70	
	LITHOLAPAXY	, with or without cystoscopy (Anaes.) (Assist.)	
36863	Fee: \$466.35	Benefit: 75% = \$349.80	
	BLADDER, parti	ial excision of (Anaes.) (Assist.)	
37000	Fee: \$741.50	Benefit: 75% = \$556.15	
	BLADDER, repa	ir of rupture (Anaes.) (Assist.)	
37004	Fee: \$649.80	Benefit: 75% = \$487.35	
		OR CYSTOTOMY, suprapubic, not being a service to which ite e associated with other open bladder procedure (Anaes.)	m 37011 applies and
37008	Fee: \$416.45	Benefit: 75% = \$312.35 85% = \$354.00	
	SUPRAPUBIC S 37200 to 37221 a	TAB CYSTOTOMY, not being a service associated with a service pply (Anaes.)	ce to which items
37011	Fee: \$93.35	Benefit: 75% = \$70.05 85% = \$79.35	
	BLADDER, total	excision of (Anaes.) (Assist.)	
37014	Fee: \$1,066.30	Benefit: 75% = \$799.75	
	BLADDER DIVI	ERTICULUM, excision or obliteration of (Anaes.) (Assist.)	
37020	Fee: \$741.50	Benefit: 75% = \$556.15	
	VESICAL FISTU	JLA, cutaneous, operation for (Anaes.)	
37023	Fee: \$416.45	Benefit: 75% = \$312.35	
	CUTANEOUS V	ESICOSTOMY, establishment of (Anaes.) (Assist.)	
37026	Fee: \$416.45	Benefit: 75% = \$312.35	
	VESICOVAGINA	AL FISTULA, closure of, by abdominal approach (Anaes.) (Assi	st.)
37029	Fee: \$924.70	Benefit: 75% = \$693.55	
		TINAL FISTULA, closure of, excluding bowel resection (Anaes.)	(Assist.)
37038	Fee: \$691.75	Benefit: 75% = \$518.85	
	Bladder stress inc	continence, sling procedure for, using a non-adjustable synthetic nesh, other than a service associated with a service to which item naes.) (Assist.)	
37040	Fee: \$911.30	Benefit: 75% = \$683.50	
		IRATION by needle	
37041	Fee: \$46.60	Benefit: 75% = \$34.95 85% = \$39.65	
37042		ESS INCONTINENCE, sling procedure for, using autologous fas	scial sling, including

T8. SUF	RGICAL OPERAT	IONS	5. UROLOGICAL
	_	ng, with or without mesh, not bein applies (Anaes.) (Assist.)	g a service associated with a service to which item
	Fee: \$911.30	Benefit: 75% = \$683.50	
		ot being a service associated with	or similar type needle colposuspension, with or a service to which item 30405 or 35599 applies
37043	Fee: \$674.50	Benefit: 75% = \$505.90	
		ot being a service associated with	oic procedure for, eg Burch colposuspension, with or a service to which item 30405 or 35599 applies
37044	Fee: \$691.75	Benefit: 75% = \$518.85	
	CONTINENT C. (Assist.)	ATHETERISATION BLADDER	STOMAS (eg. Mitrofanoff), formation of (Anaes.)
37045	Fee: \$1,428.75	Benefit: 75% = \$1071.60	
	BLADDER ENL	ARGEMENT using intestine (Ar	naes.) (Assist.)
37047	Fee: \$1,666.05	Benefit: 75% = \$1249.55	
	BLADDER EXS	TROPHY CLOSURE, not involv	ing sphincter reconstruction (Anaes.) (Assist.)
37050	Fee: \$741.50	Benefit: 75% = \$556.15	
	BLADDER TRA	NSECTION AND RE-ANASTO	MOSIS TO TRIGONE (Anaes.) (Assist.)
37053	Fee: \$856.70	Benefit: 75% = \$642.55	
		OPERATION	S ON PROSTATE
	PROSTATECTO	OMY, open (Anaes.) (Assist.)	
37200	Fee: \$1,016.30	Benefit: 75% = \$762.25	
	without urethrosomedically fit for punch) and inclu or 37324 applies	copy, in patients with moderate to transurethral resection of the pros ding services to which item 36854 (Anaes.)	ablation of, with or without cystoscopy and with or severe lower urinary tract symptoms who are not tate (that is, prostatectomy using diathermy or cold 4, 37203, 37206, 37207, 37208, 37245, 37303, 37321
37201	(See para TN.8.53 Fee: \$828.85	of explanatory notes to this Category Benefit: 75% = \$621.65	
	without urethroso medically fit for punch) and inclu of, within 10 day	copy, in patients with moderate to transurethral resection of the pros- ding services to which item 36854	ablation of, with or without cystoscopy and with or severe lower urinary tract symptoms who are not tate (that is prostatectomy using diathermy or cold 4, 37245, 37303, 37321 or 37324 applies, continuation em 37201, 37203 or 37207 which had to be
37202	(See para TN.8.53 Fee: \$416.05	of explanatory notes to this Category Benefit: 75% = \$312.05 85%	
37203			y or cold punch), with or without cystoscopy and with which item 36854, 37201, 37202, 37207, 37208,

T8. SUF	RGICAL OPERAT	ONS 5. UROLOGICAI
	37245, 37303, 37	7321 or 37324 applies (Anaes.)
	Fee: \$1,042.15	Benefit: 75% = \$781.65
	or without urethr	DMY (endoscopic, using diathermy or cold punch), with or without cystoscopy and with oscopy, and including services to which item 36854, 37303, 37321 or 37324 applies, within 10 days of the procedure described by item 37201, 37203, 37207 or 37245 which inued for medical reasons (Anaes.)
37206	Fee: \$558.10	Benefit: 75% = \$418.60
	with or without u	loscopic non-contact (side firing) visual laser ablation, with or without cystoscopy and rethroscopy, and including services to which items 36854, 37201, 37202, 37203, 2321 or 37324 applies (Anaes.)
37207	Fee: \$866.45	Benefit: 75% = \$649.85
	with or without uapplies, continua	loscopic non-contact (side firing) visual laser ablation, with or without cystoscopy and rethroscopy, and including services to which item 36854, 37303, 37321 or 37324 tion of, within 10 days of the procedure described by items 37201, 37203, 37207 or to be discontinued for medical reasons (Anaes.)
37208	Fee: \$416.05	Benefit: 75% = \$312.05
		Vor SEMINAL VESICLE/AMPULLA OF VAS, unilateral or bilateral, total excision rvice associated with a service to which item number 37210 or 37211 applies (Anaes.)
37209	Fee: \$1,291.10	Benefit: 75% = \$968.35
	bladder and blad	DMY, radical, involving total excision of the prostate, sparing of nerves around the der neck reconstruction, not being a service associated with a service to which item 37375 applies (Anaes.) (Assist.)
37210	Fee: \$1,593.40	Benefit: 75% = \$1195.05
	bladder and blad	DMY, radical, involving total excision of the prostate, sparing of nerves around the der neck reconstruction, <i>with pelvic lymphadenectomy</i> , not being a service associated which item 35551, 36502 or 37375 applies (Anaes.) (Assist.)
37211	Fee: \$1,935.20	Benefit: 75% = \$1451.40
	PROSTATE, ope	en perineal biopsy or open drainage of abscess (Anaes.) (Assist.)
37212	Fee: \$276.60	Benefit: 75% = \$207.45
	PROSTATE, bio	psy of, endoscopic, with or without cystoscopy (Anaes.) (Assist.)
37215	Fee: \$416.45	Benefit: 75% = \$312.35 85% = \$354.00
	Prostate, implant (Anaes.)	ation of radio-opaque fiducial markers into the prostate gland or prostate surgical bed
37217	(See para TN.8.54 Fee: \$138.30	of explanatory notes to this Category) Benefit: 75% = \$103.75 85% = \$117.60
	PROSTATE, nee	dle biopsy of, or injection into, excluding for insertion of radiopaque markers (Anaes.)
37218	Fee: \$138.30	Benefit: 75% = \$103.75 85% = \$117.60
37219		dle biopsy of, using prostatic ultrasound techniques and obtaining 1 or more prostatic a service associated with a service to which item 55600 or 55603 applies (Anaes.)

T8. SUF	RGICAL OPERAT	IONS	5. UROLOGICAL
	(Assist.)		
	Fee: \$280.85	Benefit: 75% = \$210.65	5 85% = \$238.75
	guidance, for loc palpable or visib than or equal to diagnosis. The p	alised prostatic malignancy le by imaging) or T2 (tumo 7 and a prostate specific ant procedure must be performe	of, urological component, using transrectal ultrasound of at clinical stages T1 (clinically inapparent tumour not our confined within prostate), with a Gleason score of less tigen (PSA) of less than or equal to 10ng/ml at the time of ed by a urologist at an approved site in association with a a service to which item 55603 applies. (Anaes.)
37220	(See para TN.8.55 Fee: \$1,044.20	of explanatory notes to this Ca Benefit: 75% = \$783.15	
	PROSTATIC AI	BSCESS, endoscopic draina	age of (Anaes.) (Assist.)
37221	Fee: \$466.35	Benefit: 75% = \$349.80	
	PROSTATIC CO	OIL, insertion of, under ultr	rasound control (Anaes.)
37223	Fee: \$206.25	Benefit: 75% = \$154.70)
		3	ruction of lesion of, not being a service associated with a 37206, 37207, 37208 or 37215 applies (Anaes.)
37224	Fee: \$323.20	Benefit: 75% = \$242.40	85% = \$274.75
	guidance includi	ng any associated cystoscop a radiation oncologist, and	eters into, for high dose rate brachytherapy using ultrasound py. The procedure must be performed at an approved site in be associated with a service to which item 15331 or 15332
37227	(See para TN.8.56 Fee: \$565.85	of explanatory notes to this Ca Benefit: 75% = \$424.40	
	with or without i		rowave thermotherapy of, with or without cystoscopy and services to which item 36854, 37203, 37206, 37207, 37208,
37230	Fee: \$1,042.15	Benefit: 75% = \$781.65	5 85% = \$958.75
	with or without unapplies, continua	rethroscopy and including	rowave thermotherapy of, with or without cystoscopy and services to which item 36854, 37303, 37321 or 37324 he procedure described by item 37201, 37203, 37207, 37230 easons (Anaes.)
37233	Fee: \$558.10	Benefit: 75% = \$418.60	85% = \$474.70
	Prostate, endoscopic enucleation of, using high powered Holmium:YAG laser and an end-firing, non-contact fibre, with or without tissue morcellation, cystoscopy or urethroscopy, for the treatment of benign prostatic hyperplasia, and other than a service associated with a service to which item 36854, 37201, 37202, 37203, 37206, 37207, 37208, 37303, 37321, or 37324 applies. (Anaes.)		ation, cystoscopy or urethroscopy, for the treatment of a service associated with a service to which item 36854,
37245	Fee: \$1,262.15	Benefit: 75% = \$946.65	5
	-		I URETHRA, PENIS OR SCROTUM
	URETHRAL SC	UNDS, passage of, as an ir	ndependent procedure (Anaes.)
37300	Fee: \$46.60	Benefit: 75% = \$34.95	85% = \$39.65

T8. SUF	RGICAL OPERAT	IONS 5. UROLOGICAL
	URETHRAL ST	RICTURE, dilatation of (Anaes.)
37303	Fee: \$74.05	Benefit: 75% = \$55.55 85% = \$62.95
	URETHRA, rep	air of rupture of distal section (Anaes.) (Assist.)
37306	Fee: \$649.80	Benefit: 75% = \$487.35
	URETHRA, rep	air of rupture of prostatic or membranous segment (Anaes.) (Assist.)
37309	Fee: \$924.70	Benefit: 75% = \$693.55
	URETHROSCO	PY, as an independent procedure (Anaes.)
37315	Fee: \$138.30	Benefit: 75% = \$103.75 85% = \$117.60
		PY with any 1 or more of - biopsy, diathermy, visual laser destruction of stone or gn body or stone (Anaes.) (Assist.)
37318	Fee: \$276.60	Benefit: 75% = \$207.45 85% = \$235.15
	URETHRAL M	EATOTOMY, EXTERNAL (Anaes.)
37321	Fee: \$93.35	Benefit: 75% = \$70.05 85% = \$79.35
	URETHROTON	MY OR URETHROSTOMY, internal or external (Anaes.)
37324	Fee: \$229.85	Benefit: 75% = \$172.40
	URETHROTON	MY, optical, for urethral stricture (Anaes.) (Assist.)
37327	Fee: \$323.20	Benefit: 75% = \$242.40
		MY, partial or complete, for removal of tumour (Anaes.) (Assist.)
37330	Fee: \$649.80	Benefit: 75% = \$487.35
2,220	-	GINAL FISTULA, closure of (Anaes.) (Assist.)
37333	Fee: \$558.10	Benefit: 75% = \$418.60
31333		TAL FISTULA, closure of (Anaes.) (Assist.)
37336	Fee: \$741.50	Benefit: 75% = \$556.15
37330	Urethral synthet following previous	ic male sling system, division or removal of, for urethral obstruction or erosion, our surgery for urinary incontinence, other than a service associated with a service to 0 or 37341 applies (Anaes.) (Assist.)
37338	Fee: \$911.30	Benefit: 75% = \$683.50
		ransurethral injection of materials for the treatment of urinary incontinence, including arethroscopy, other than a service associated with a service to which item 18375 or Anaes.)
37339	Fee: \$239.85	Benefit: 75% = \$179.90 85% = \$203.90
	surgery for urina	ING, division or removal of, for urethral obstruction or erosion, following previous ary incontinence, vaginal approach, not being a service associated with a service to ber 37341 applies (Anaes.) (Assist.)
37340	Fee: \$425.00	Benefit: 75% = \$318.75
37341	URETHRAL SI	ING, division or removal of, for urethral obstruction or erosion, following previous

T8. SUF	RGICAL OPERATI	ONS	5. UROLOGICAL
		ry incontinence, suprapubic or combined suprapil with a service to which item number 37340 ap	
	Fee: \$911.30	Benefit: 75% = \$683.50	
	URETHROPLAS	STY single stage operation (Anaes.) (Assist.)	
37342	Fee: \$833.10	Benefit: 75% = \$624.85	
	below the symphy	STY, single stage operation, transpubic approacysis pubis, excluding laparotomy, symphysectog of the urethra around the crura (Anaes.) (Assi	my and suprapubic cystotomy, with or
37343	Fee: \$1,391.15	Benefit: 75% = \$1043.40	
	URETHROPLAS	STY 2 stage operation first stage (Anaes.) (Ass	sist.)
37345	Fee: \$691.40	Benefit: 75% = \$518.55	
	URETHROPLAS	STY 2 stage operation second stage (Anaes.) (Assist.)
37348	Fee: \$691.40	Benefit: 75% = \$518.55	
		STY, not being a service to which another item	in this Group applies (Anaes.) (Assist.)
37351	Fee: \$276.60	Benefit: 75% = \$207.45	
		, meatotomy and hemicircumcision (Anaes.) (A	assist.)
37354	Fee: \$323.20	Benefit: 75% = \$242.40	
	URETHRA, exci	sion of prolapse of (Anaes.)	
37369	Fee: \$186.60	Benefit: 75% = \$139.95	
	URETHRAL DIV	VERTICULUM, excision of (Anaes.) (Assist.)	
37372	Fee: \$466.35	Benefit: 75% = \$349.80	
	URETHRAL SPI (Anaes.) (Assist.)	HINCTER, reconstruction by bladder tubularisa	ation technique or similar procedure
37375	Fee: \$1,157.85	Benefit: 75% = \$868.40	
	ARTIFICIAL UR	RINARY SPHINCTER, insertion of cuff, perind	eal approach (Anaes.) (Assist.)
37381	Fee: \$741.50	Benefit: 75% = \$556.15	
		RINARY SPHINCTER, insertion of cuff, abdor	minal approach (Anaes.) (Assist.)
37384	Fee: \$1,157.85	Benefit: 75% = \$868.40	
	ARTIFICIAL UR (Assist.)	RINARY SPHINCTER, insertion of pressure re	gulating balloon and pump (Anaes.)
37387	Fee: \$323.20	Benefit: 75% = \$242.40	
	ARTIFICIAL UF (Assist.)	RINARY SPHINCTER, revision or removal of,	with or without replacement (Anaes.)
37390	Fee: \$924.70	Benefit: 75% = \$693.55	
37393	PRIAPISM, deco	impression by glanular stab cavernosospongios	um shunt or penile aspiration with or

T8. SUF	RGICAL OPERAT	IONS 5. UROLOGICAL
	without lavage (Anaes.)
	Fee: \$229.85	Benefit: 75% = \$172.40 85% = \$195.40
	PRIAPISM, shu	nt operation for, not being a service to which item 37393 applies (Anaes.) (Assist.)
37396	Fee: \$741.50	Benefit: 75% = \$556.15
	PENIS, partial a	mputation of (Anaes.) (Assist.)
37402	Fee: \$466.35	Benefit: 75% = \$349.80
	PENIS, complete	e or radical amputation of (Anaes.) (Assist.)
37405	Fee: \$924.70	Benefit: 75% = \$693.55
	PENIS, repair of	Placeration of cavernous tissue, or fracture involving cavernous tissue (Anaes.) (Assist.)
37408	Fee: \$466.35	Benefit: 75% = \$349.80
	PENIS, repair of	avulsion (Anaes.) (Assist.)
37411	Fee: \$924.70	Benefit: 75% = \$693.55 85% = \$841.30
	PENIS, injection consecutive mor	of, for the investigation and treatment of impotence - 2 services only in a period of 36 of ths
37415	Fee: \$46.60	Benefit: 75% = \$34.95 85% = \$39.65
	PENIS, correction grafting (Anaes.)	on of chordee, with or without excision of fibrous plaque or plaques and with or without (Assist.)
37417	Fee: \$558.10	Benefit: 75% = \$418.60
		on of chordee, with or without excision of fibrous plaque or plaques and with or without ng mobilization of the urethra (Anaes.) (Assist.)
37418	Fee: \$741.50	Benefit: 75% = \$556.15 85% = \$658.10
		to inhibit rapid penile drainage causing impotence, by ligation of veins deep to Buck's 1 or more deep cavernosal veins with or without pharmacological erection test (Anaes.)
37420	Fee: \$366.45	Benefit: 75% = \$274.85
	PENIS, lengthen	ing by translocation of corpora (Anaes.) (Assist.)
37423	Fee: \$924.70	Benefit: 75% = \$693.55
	PENIS, artificial	erection device, insertion of, into 1 or both corpora (Anaes.) (Assist.)
37426	Fee: \$974.55	Benefit: 75% = \$730.95
	PENIS, artificial	erection device, insertion of pump and pressure regulating reservoir (Anaes.) (Assist.)
37429	Fee: \$323.20	Benefit: 75% = \$242.40
	PENIS, artificial replacement (An	erection device, complete or partial revision or removal of components, with or without aes.) (Assist.)
37432	Fee: \$924.70	Benefit: 75% = \$693.55
37435	PENIS, frenulop	lasty as an independent procedure (Anaes.)

T8. SUF	RGICAL OPERAT	IONS	5. UROLOGICAL
	Fee: \$93.35	Benefit: 75% = \$70.05 85% = \$79.35	
	SCROTUM, par	tial excision of (Anaes.) (Assist.)	
37438	Fee: \$276.60	Benefit: 75% = \$207.45 85% = \$235.15	
	URETEROLITH ureter (Anaes.) (IOTOMY COMPLICATED BY PREVIOUS SURGERY at Assist.)	t the same site of the same
37444	Fee: \$999.65	Benefit: 75% = \$749.75 85% = \$916.25	
		OPERATIONS ON TESTES, VASA OR SEMINAL VES	SICLES
	SPERMATOCE	LE OR EPIDIDYMAL CYST, excision of, 1 or more of, or	1 side (Anaes.)
37601	Fee: \$276.60	Benefit: 75% = \$207.45 85% = \$235.15	
		N OF SCROTAL CONTENTS, with or without fixation and eing a service associated with sperm harvesting for IVF (An	
37604	Fee: \$276.60	Benefit: 75% = \$207.45 85% = \$235.15	
		sperm retrieval, unilateral, from either the testis or the epidimic sperm injection, for male factor infertility, excluding a	
37605	(See para TN.8.58 Fee: \$373.45	TN.1.5 of explanatory notes to this Category) Benefit: 75% = \$280.10 85% = \$317.45	
37606	biopsy, for the proposed hospital, excludi	nerm retrieval, unilateral, including the exploration of scrota surposes of intracytoplasmic sperm injection, for male factor ing a service to which item 13218 or 37604 applies. (Anaes TN.8.59 of explanatory notes to this Category) Benefit: 75% = \$415.95 85% = \$471.40	infertility, performed in a
37000	RETROPERITO	NEAL LYMPH NODE DISSECTION, unilateral, not bein	g a service associated with a
	service to which	item 36528 applies (Anaes.) (Assist.)	
37607	Fee: \$924.70	Benefit: 75% = \$693.55	
	service to which	NEAL LYMPH NODE DISSECTION, unilateral, not being item 36528 applies, following previous similar retroperiton radiation or chemotherapy (Anaes.) (Assist.)	
37610	Fee: \$1,391.15	Benefit: 75% = \$1043.40	
	EPIDIDYMECT	OMY (Anaes.)	
37613	Fee: \$276.60	Benefit: 75% = \$207.45 85% = \$235.15	
	VASOVASOST	OMY or VASOEPIDIDYMOSTOMY, unilateral, using opersociated with sperm harvesting for IVF (Anaes.) (Assist.)	erating microscope, not
37616	Fee: \$691.40	Benefit: 75% = \$518.55	
		OMY or VASOEPIDIDYMOSTOMY, unilateral, not being	g a service associated with
		g for IVF (Anaes.) (Assist.)	
37619	Fee: \$276.60 Extended Medic	Benefit: 75% = \$207.45 85% = \$235.15 care Safety Net Cap: \$221.30	
37623		R VASECTOMY, unilateral or bilateral	

T8. SUF	RGICAL OPERAT	IONS 5. URG	OLOGICAL
	benefits are not	gal requirements apply in relation to sterilisation procedures on minors. M payable for services not rendered in accordance with relevant Commonweal w. Observe the explanatory note before submitting a claim. (Anaes.)	
	(See para TN.8.46 Fee: \$229.85	of explanatory notes to this Category) Benefit: 75% = \$172.40 85% = \$195.40	
		PAEDIATRIC GENITURINARY SURGERY	
	PATENT URAC	CHUS, excision of, on a person 10 years of age or over. (Anaes.) (Assist.)	
37800	Fee: \$521.25	Benefit: 75% = \$390.95	
	PATENT URAC	CHUS, excision of, when performed on a person under 10 years of age (Anac	es.) (Assist.)
37801	Fee: \$677.65	Benefit: 75% = \$508.25	
37001	UNDESCENDE	ED TESTIS, orchidopexy for, not being a service to which item 37806 applie of age or over. (Anaes.) (Assist.)	es, on a
37803	Fee: \$521.25	Benefit: 75% = \$390.95	
		ED TESTIS, orchidopexy for, not being a service to which item 37807 applie years of age (Anaes.) (Assist.)	s, on a
37804	Fee: \$677.65	Benefit: 75% = \$508.25	
		D TESTIS in inguinal canal close to deep inguinal ring or within abdominal, on a person 10 years of age or over (Anaes.) (Assist.)	cavity,
37806	Fee: \$602.25	Benefit: 75% = \$451.70 85% = \$518.85	
		D TESTIS in inguinal canal close to deep inguinal ring or within abdominal, on a person under 10 years of age (Anaes.) (Assist.)	cavity,
37807	Fee: \$782.95	Benefit: 75% = \$587.25 85% = \$699.55	
	UNDESCENDE (Assist.)	ED TESTIS, revision orchidopexy for, on a person 10 years of age or over. (A	Anaes.)
37809	Fee: \$602.25	Benefit: 75% = \$451.70	
	UNDESCENDE (Assist.)	ED TESTIS, revision orchidopexy for, on a person under 10 years of age (An	aes.)
37810	Fee: \$782.95	Benefit: 75% = \$587.25	
		TESTIS, exploration of groin for, not being a service associated with a service and 37809 applies, on a person 10 years of age or over. (Anaes.) (Assist.	
37812	Fee: \$556.00	Benefit: 75% = \$417.00	
		TESTIS, exploration of groin for, not being a service associated with a service associated with a service and 37810 applies, on a person under 10 years of age (Anaes.) (Assist.)	ce to which
37813	Fee: \$722.80	Benefit: 75% = \$542.10	
	HYPOSPADIAS (Anaes.)	S, examination under anaesthesia with erection test on a person 10 years of a	ge or over.
37815	Fee: \$92.75	Benefit: 75% = \$69.60	

T8. SUF	RGICAL OPERATI	ONS 5. UROLOGICAL
	HYPOSPADIAS (Anaes.)	, examination under anaesthesia with erection test, on a person under 10 years of age
37816	Fee: \$120.60	Benefit: 75% = \$90.45
	HYPOSPADIAS (Anaes.) (Assist.)	, glanuloplasty incorporating meatal advancement, on a person 10 years of age or over
37818	Fee: \$491.45	Benefit: 75% = \$368.60 85% = \$417.75
	HYPOSPADIAS (Anaes.) (Assist.)	, glanuloplasty incorporating meatal advancement, on a person under 10 years of age
37819	Fee: \$638.90	Benefit: 75% = \$479.20 85% = \$555.50
	HYPOSPADIAS	, distal, 1 stage repair, on a person 10 years of age or over. (Anaes.) (Assist.)
37821	Fee: \$833.10	Benefit: 75% = \$624.85
	HYPOSPADIAS	, distal, 1 stage repair, on a person under 10 years of age (Anaes.) (Assist.)
37822	Fee: \$1,083.05	Benefit: 75% = \$812.30
	HYPOSPADIAS	, proximal, 1 stage repair on a person 10 years of age or over. (Anaes.) (Assist.)
37824	Fee: \$1,158.30	Benefit: 75% = \$868.75
	HYPOSPADIAS	, proximal, 1 stage repair, on a person under 10 years of age (Anaes.) (Assist.)
37825	Fee: \$1,505.80	Benefit: 75% = \$1129.35
	HYPOSPADIAS	, staged repair, first stage, on a person 10 years of age or over. (Anaes.) (Assist.)
37827	Fee: \$533.60	Benefit: 75% = \$400.20
	HYPOSPADIAS	, staged repair, first stage, on a person under 10 years of age (Anaes.) (Assist.)
37828	Fee: \$693.70	Benefit: 75% = \$520.30
	HYPOSPADIAS, staged repair, second stage, on a person 10 years of age or over. (Anaes.) (Assis	
37830	Fee: \$691.40 Benefit: 75% = \$518.55 85% = \$608.00	
	HYPOSPADIAS	, staged repair, second stage, on a person under 10 years of age. (Anaes.) (Assist.)
37831	Fee: \$898.90	Benefit: 75% = \$674.20 85% = \$815.50
	HYPOSPADIAS (Assist.)	, repair of post-operative urethral fistula, on a person 10 years of age or over. (Anaes.)
37833	Fee: \$329.95	Benefit: 75% = \$247.50
	HYPOSPADIAS (Assist.)	, repair of post-operative urethral fistula, on a person under 10 years of age (Anaes.)
37834	Fee: \$428.95	Benefit: 75% = \$321.75
	EPISPADIAS, sta	aged repair, first stage (Anaes.) (Assist.)
37836	Fee: \$695.00	Benefit: 75% = \$521.25
	EPISPADIAS, sta	aged repair, second stage (Anaes.) (Assist.)
37839	Fee: \$787.60	Benefit: 75% = \$590.70
2.007	2 222 \$707.00	

T8. SUF	GICAL OPERATIONS	5. UROLOGICAL		
	EXSTROPHY OF BLADDER OR or without ureteric reimplantation (EPISPADIAS, secondary repair with bladder neck tightening, with Anaes.) (Assist.)		
37842	Fee: \$1,529.10 Benefit: 75% =	= \$1146.85		
	AMBIGUOUS GENITALIA WITH endoscopy (Anaes.) (Assist.)	I UROGENITAL SINUS, reduction clitoroplasty, with or without		
37845	Fee: \$695.00 Benefit: 75% =	= \$521.25		
	AMBIGUOUS GENITALIA WITH and vaginoplasty (Anaes.) (Assist.)	I UROGENITAL SINUS, reduction clitoroplasty with endoscopy		
37848	Fee: \$1,251.05 Benefit: 75% =	= \$938.30		
	CONGENITAL ADRENAL HYPE vaginoplasty for, with or without en	RPLASIA, mixed gonadal dysgenesis or similar condition, doscopy (Anaes.) (Assist.)		
37851	Fee: \$926.80 Benefit: 75% =	= \$695.10		
_ 	URETHRAL VALVE, destruction	of, including cystoscopy and urethroscopy (Anaes.) (Assist.)		
37854	Fee: \$366.45 Benefit: 75% =	= \$274.85		
T8. SUF	GICAL OPERATIONS	6. CARDIO-THORACIC		
	Group T8. Surgical Operations			
	Subgroup 6. Cardio-Thoracic			
	CARDIOLOGY PROCEDURES			
	RIGHT HEART CATHETERISATION, with any one or more of the following: fluoroscopy, oximetry dye dilution curves, cardiac output measurement by any method, shunt detection or exercise stress test (Anaes.)			
38200	Fee: \$445.40 Benefit: 75% =	= \$334.05 85% = \$378.60		
	left ventricular puncture with any or	ON by percutaneous arterial puncture, arteriotomy or percutaneous ne or more of the following: fluoroscopy, oximetry, dye dilution s by any method, shunt detection or exercise stress test (Anaes.)		
38203	Fee: \$531.55 Benefit: 75% =	= \$398.70 85% = \$451.85		
	or by any other procedure with any	ION WITH LEFT HEART CATHETERISATION via the right heart one or more of the following: fluoroscopy, oximetry, dye dilution s by any method, shunt detection or exercise stress test (Anaes.)		
38206	Fee: \$642.65 Benefit: 75% =	= \$482.00 85% = \$559.25		
	CARDIAC ELECTROPHYSIOLOGICAL STUDY up to and including 3 catheter investigation of 1 or more of syncope, atrioventricular conduction, sinus node function or simple ventricular tachy studies, not being a service associated with a service to which item 38212 or 38213 applies (Anaest			
38209	(See para TN.8.60 of explanatory notes Fee: \$825.15 Benefit: 75% =	to this Category) = \$618.90 85% = \$741.75		
38212	investigation; or complex tachycard antiarrhythmic drug testing with pre	GICAL STUDY 4 or more catheter supraventricular tachycardia ia inductions, or multiple catheter mapping, or acute intravenous and post drug inductions; or catheter ablation to intentionally induce we mapping; or electrophysiological services during defibrillator		

T8. SUF	RGICAL OPERATIONS	6. CARDIO-THORACIC
	implantation not being a service associated with a service to wh (Anaes.)	nich item 38209 or 38213 applies
	(See para TN.8.60 of explanatory notes to this Category) Fee: \$1,372.45 Benefit: 75% = \$1029.35 85% = \$1289.05	
	CARDIAC ELECTROPHYSIOLOGICAL STUDY, for follow- being a service associated with a service to which item 38209 or	
38213	Fee: \$408.70 Benefit: 75% = \$306.55 85% = \$347.40	
	SELECTIVE CORONARY ANGIOGRAPHY, placement of ca into the native coronary arteries, not being a service associated 38220, 38222, 38225, 38228, 38231, 38234, 38237, 38240 or 38	with a service to which item 38218,
38215	(See para TN.8.52 of explanatory notes to this Category) Fee: \$354.90 Benefit: 75% = \$266.20 85% = \$301.70	
	SELECTIVE CORONARY ANGIOGRAPHY, placement of ca with right or left heart catheterisation or both, or aortography, ne service to which item 38215, 38220, 38222, 38225, 38228, 3822 applies (Anaes.)	ot being a service associated with a
38218	(See para TN.8.52 of explanatory notes to this Category) Fee: \$532.25 Benefit: 75% = \$399.20 85% = \$452.45	
	SELECTIVE CORONARY GRAFT ANGIOGRAPHY placem material into free coronary graft(s) attached to the aorta (irrespe a service associated with a service to which item 38215, 38218, 38237, 38240 or 38246 applies (Anaes.)	ctive of the number of grafts), not being
38220	(See para TN.8.52 of explanatory notes to this Category) Fee: \$177.40 Benefit: 75% = \$133.05 85% = \$150.80	
	SELECTIVE CORONARY GRAFT ANGIOGRAPHY, placer opaque material into direct internal mammary artery graft(s) to (irrespective of the number of grafts), not being a service associ 38218, 38220, 38225, 38228, 38231, 38234, 38237, 38240 or 38	one or more coronary arteries ated with a service to which item 38215,
38222	(See para TN.8.52 of explanatory notes to this Category) Fee: \$354.90 Benefit: 75% = \$266.20 85% = \$301.70	
	SELECTIVE CORONARY ANGIOGRAPHY, placement of ca into the native coronary arteries and placement of catheter(s) an coronary graft(s) attached to the aorta (irrespective of the number associated with a service to which item 38215, 38218, 38220, 3 38240 or 38246 applies (Anaes.)	d injection of opaque material into free er of grafts), not being a service
38225	(See para TN.8.52 of explanatory notes to this Category) Fee: \$532.35 Benefit: 75% = \$399.30 85% = \$452.50	
	SELECTIVE CORONARY ANGIOGRAPHY, placement of ca into the native coronary arteries and placement of catheter(s) an internal mammary artery graft(s) to one or more coronary arterie not being a service associated with a service to which item 3821 38234, 38237, 38240 or 38246 applies (Anaes.)	d injection of opaque material into direct es (irrespective of the number of grafts),
38228	(See para TN.8.52 of explanatory notes to this Category) Fee: \$709.90 Benefit: 75% = \$532.45 85% = \$626.50	

SELECTIVE CORONARY ANGIOGRAPHY, placement of catheters and injection of opaque into the native coronary arteries and placement of catheter(s) and injection of opaque material free coronary graft(s) attached to the aorta (irrespective of the number of grafts), and placement catheter(s) and injection of opaque material into direct internal mammary artery graft(s) to one coronary arteries (irrespective of the number of grafts), not being a service associated with a set which item 38215, 38218, 38220, 38222, 38225, 38228, 38234, 38237, 38240 or 38246 applies (See para TN.8.52 of explanatory notes to this Category) Fee: \$887.25 Benefit: 75% = \$665.45 SELECTIVE CORONARY ANGIOGRAPHY, placement of catheters and injection of opaque with right or left heart catheterisation or both, or aortography and placement of catheter(s) and of opaque material into free coronary graft(s) attached to the aorta (irrespective of the number not being a service associated with a service to which item 38215, 38218, 38220, 38222, 38223, 38231, 38237, 38240 or 38246 applies (Anaes.) (See para TN.8.52 of explanatory notes to this Category) Fee: \$709.75 Benefit: 75% = \$532.35 SELECTIVE CORONARY ANGIOGRAPHY, placement of catheters and injection of opaque with right or left heart catheterisation or both, or aortography and placement of catheter(s) and with right or left heart catheterisation or both, or aortography and placement of catheter(s) and	into the at of e or more ervice to s (Anaes.) e material injection of grafts), 5, 38228,
SELECTIVE CORONARY ANGIOGRAPHY, placement of catheters and injection of opaque with right or left heart catheterisation or both, or aortography and placement of catheter(s) and of opaque material into free coronary graft(s) attached to the aorta (irrespective of the number not being a service associated with a service to which item 38215, 38218, 38220, 38222, 38231, 38237, 38240 or 38246 applies (Anaes.) (See para TN.8.52 of explanatory notes to this Category) Fee: \$709.75 Benefit: 75% = \$532.35 85% = \$626.35 SELECTIVE CORONARY ANGIOGRAPHY, placement of catheters and injection of opaque with right or left heart catheterisation or both, or aortography and placement of catheter(s) and	injection of grafts), 5, 38228,
with right or left heart catheterisation or both, or aortography and placement of catheter(s) and of opaque material into free coronary graft(s) attached to the aorta (irrespective of the number not being a service associated with a service to which item 38215, 38218, 38220, 38222, 38223 38231, 38237, 38240 or 38246 applies (Anaes.) (See para TN.8.52 of explanatory notes to this Category) Fee: \$709.75 Benefit: 75% = \$532.35 SELECTIVE CORONARY ANGIOGRAPHY, placement of catheters and injection of opaque with right or left heart catheterisation or both, or aortography and placement of catheter(s) and	injection of grafts), 5, 38228,
38234 Fee: \$709.75 Benefit: 75% = \$532.35 85% = \$626.35 SELECTIVE CORONARY ANGIOGRAPHY, placement of catheters and injection of opaque with right or left heart catheterisation or both, or aortography and placement of catheter(s) and	
with right or left heart catheterisation or both, or aortography and placement of catheter(s) and	
of opaque material into direct internal mammary artery graft(s) to one or more coronary arterie (irrespective of the number of grafts), not being a service associated with a service to which ite 38218, 38220, 38222, 38225, 38228, 38231, 38234, 38240 or 38246 applies (Anaes.)	es
(See para TN.8.52 of explanatory notes to this Category) Fee: \$887.20 Benefit: 75% = \$665.40 85% = \$803.80	
SELECTIVE CORONARY ANGIOGRAPHY, placement of catheters and injection of opaque with right or left heart catheterisation or both, or aortography and placement of catheter(s) and of opaque material into free coronary graft(s) attached to the aorta (irrespective of the number of and placement of catheter(s) and injection of opaque material into direct internal mammary art graft(s) to one or more coronary arteries (irrespective of the number of grafts), not being a serv associated with a service to which item 38215, 38218, 38220, 38222, 38225, 38228, 38231, 38 38237 or 38246 applies (Anaes.)	injection of grafts) ery vice
(See para TN.8.52 of explanatory notes to this Category) Fee: \$1,064.60 Benefit: 75% = \$798.45 85% = \$981.20	
USE OF A CORONARY PRESSURE WIRE during selective coronary angiography to measure fractional flow reserve (FFR) and coronary flow reserve (CFR) in one or more intermediate contact artery or graft lesions (stenosis of 30-70%), to determine whether revascularisation should be previous stress testing has either not been performed or the results are inconclusive (Analysis).	oronary performed
38241 Fee: \$469.70 Benefit: 75% = \$352.30 85% = \$399.25	
PLACEMENT OF CATHETER(S) and injection of opaque material into any coronary vessel(s graft(s) prior to any coronary interventional procedure, not being a service associated with a se which item 38246 applies (Anaes.)	
(See para TN.8.52 of explanatory notes to this Category) Fee: \$443.60 Benefit: 75% = \$332.70 85% = \$377.10	
SELECTIVE CORONARY ANGIOGRAPHY, placement of catheters and injection of opaque with right or left heart catheterisation or both, or aortography followed by placement of cathete any coronary interventional procedure, not being a service associated with a service to which it 38215, 38218, 38220, 38222, 38225, 38228, 38231, 38234, 38237, 38240 or 38243 applies (An	ers prior to tem
(See para TN.8.52 of explanatory notes to this Category)	

T8. SUF	RGICAL OPERAT	TIONS	6. CARDIO-THORACIC	
	Fee: \$887.20	Benefit: 75% = \$665.40	85% = \$803.80	
	TEMPORARY	TRANSVENOUS PACEMA	AKING ELECTRODE, insertion of (Anaes.)	
38256	Fee: \$267.25	Benefit: 75% = \$200.45	85% = \$227.20	
		LVULOPLASTY OR ISOL before and after balloon dila	ATED ATRIAL SEPTOSTOMY, including cardiac tation (Anaes.) (Assist.)	
38270	Fee: \$912.30	Benefit: 75% = \$684.25	85% = \$828.90	
	ATRIAL SEPTA approach (Anae		eptal occluder or other similar device, by transcatheter	
38272	Fee: \$912.30	Benefit: 75% = \$684.25	85% = \$828.90	
		teriosus, transcatheter closur the service (Anaes.) (Assist.	re of, including cardiac catheterisation and any imaging	
38273	Fee: \$912.30	Benefit: 75% = \$684.25		
	Ventricular sept (Assist.)	al defect, transcatheter closu	re of, with imaging and cardiac catheterisation (Anaes.)	
38274	Fee: \$912.30	Benefit: 75% = \$684.25		
	MYOCARDIAI	BIOPSY, by cardiac cather	terisation (Anaes.)	
38275	Fee: \$298.20	Benefit: 75% = \$223.65	85% = \$253.50	
	Transcatheter occlusion of left atrial appendage, and cardiac catheterisation performed by the same practitioner, for stroke prevention in a patient who has non-valvular atrial fibrillation and a contraindication to life-long oral anticoagulation therapy, and is at increased risk of thromboembolism demonstrated by:			
	(a) a prior stroke (whether of an ischaemic or unknown type), transient ischaemic attack or non-central nervous system systemic embolism; or			
	(b) at least 2 of the following risk factors:			
	(i) an age of 65 years or more;			
	(ii) hypertension;			
	(iii) diabetes mellitus;			
	(iv) heart failure or left ventricular ejection fraction of 35% or less (or both);			
	(v) vascular disease (prior myocardial infarction, peripheral artery disease or aortic plaque)			
	(Anaes.) (Assis	st.) 2 of explanatory notes to this C	'ategory')	
38276	Fee: \$912.30	Benefit: $75\% = 684.25		
38285		E ECG LOOP RECORDER nexplained syncope where:	, insertion of, for diagnosis of primary disorder in patients	

T8. SUR	GICAL OPERATIONS	6. CARDIO-THORACIC
	- a diagnosis has not been achieved through all other available cardia	c investigations; and
	- a neurogenic cause is not suspected; and	
	- it has been determined that the patient does not have structural hear risk of sudden cardiac death.	t disease associated with a high
	including initial programming and testing, as an admitted patient in an ap	proved hospital (Anaes.)
	(See para TN.8.61 of explanatory notes to this Category) Fee: \$192.90 Benefit: 75% = \$144.70 85% = \$164.00	
	IMPLANTABLE ECG LOOP RECORDER, removal of, as an admitted p (Anaes.)	patient in an approved hospital
38286	Fee: \$173.75 Benefit: 75% = \$130.35 85% = \$147.70	
	Implantable loop recorder, insertion of, for diagnosis of atrial fibrillation,	if:
	(a) the patient to whom the service is provided has been diagnosed as have undetermined source; and	ring had an embolic stroke of
	(b) the bases of the diagnosis included the following:	
	(i) the medical history of the patient;	
	(ii) physical examination;	
	(iii) brain and carotid imaging;	
	(iv) cardiac imaging;	
	(v) surface ECG testing including 24-hour Holter monitoring; and	
	(c) atrial fibrillation is suspected; and	
	(d) the patient:	
	(i) does not have a permanent indication for oral anticoagulants; or	
	(ii) does not have a permanent oral anticoagulants contraindication;	
	including initial programming and testing	
	(Anaes.)	
38288	Fee: \$192.90 Benefit: 75% = \$144.70 85% = \$164.00	
	CATHETER BASED ARRHYTHMIA ABLATI	ON
	ABLATION OF ARRHYTHMIA CIRCUIT OR FOCUS or isolation prochamber (Anaes.) (Assist.)	ocedure involving 1 atrial
38287	Fee: \$2,098.45 Benefit: 75% = \$1573.85 85% = \$2015.05	
38290	ABLATION OF ARRHYTHMIA CIRCUITS OR FOCI, or isolation prochambers and including curative procedures for atrial fibrillation (Anaes.	

T8. SUF	RGICAL OPERATION	ONS	6. CARDIO-THORACIC	
	Fee: \$2,671.95	Benefit: 75% = \$2004.00		
		ARRHYTHMIA with mapping at cal studies performed on the same	nd ablation, including all associated day (Anaes.) (Assist.)	
38293	Fee: \$2,868.05	Benefit: 75% = \$2151.05 85%	= \$2784.65	
		ENDOVASCULAR INTER\	/ENTIONAL PROCEDURES	
			of 1 coronary artery, percutaneous or by open s or preparation, and excluding aftercare (Anaes.)	
38300	Fee: \$515.35	Benefit: 75% = \$386.55 85% =	= \$438.05	
			of more than 1 coronary artery, percutaneous or by rvices or preparation and excluding aftercare	
38303	Fee: \$660.80	Benefit: 75% = \$495.60 85% =	= \$577.40	
	Transluminal insertion of stent or stents into one occlusional site, including associated balloon dilatation of coronary artery, percutaneous or by open exposure, excluding associated radiological services, radiological preparation and after-care (Anaes.) (Assist.)			
38306	(See para TN.8.62 o Fee: \$762.35	of explanatory notes to this Category) Benefit: 75% = \$571.80 85% =	= \$678.95	
		S TRANSLUMINAL ROTATIO angioplasty with no stent insertion	NAL ATHERECTOMY of 1 coronary artery, 1, where:	
	- no lesion of the coronary artery has been stented; and			
	- each lesion of the coronary artery is complex and heavily calcified; and			
	- balloon angioplasty with or without stenting is not suitable;			
	excluding associated radiological services or preparation, and excluding aftercare (Anaes.) (Assist.)			
38309	(See para TN.8.41 c Fee: \$885.45	of explanatory notes to this Category) Benefit: 75% = \$664.10 85% =	= \$802.05	
		S TRANSLUMINAL ROTATIO angioplasty with insertion of 1 or	NAL ATHERECTOMY of 1 coronary artery, more stents, where:	
	- no lesion of the coronary artery has been stented; and			
	- each lesion of the coronary artery is complex and heavily calcified; and			
	- balloon angiop	lasty with or without stenting is n	ot suitable;	
	excluding associated radiological services or preparation, and excluding aftercare (Anaes.) (Assist.)			
38312	(See para TN.8.41 of explanatory notes to this Category) Fee: \$1,132.35 Benefit: 75% = \$849.30 85% = \$1048.95			
		S TRANSLUMINAL ROTATIO calloon angioplasty with no stent i	NAL ATHERECTOMY of more than 1 coronary nsertion, where:	
38315	- no lesion of th	e coronary arteries has been stente	d; and	

T8. SURGICAL OPERATIONS	6. CARDIO-THORACIC
- each lesion of the coronary arteries is complex and heavily calcifi	ied; and
- balloon angioplasty with or without stenting is not suitable;	
excluding associated radiological services or preparation, and exclud	ing aftercare (Anaes.) (Assist.)
(See para TN.8.41 of explanatory notes to this Category) Fee: \$1,215.85 Benefit: 75% = \$911.90 85% = \$1132.45	
PERCUTANEOUS TRANSLUMINAL ROTATIONAL ATHEREC artery, including balloon angioplasty, with insertion of 1 or more ster	
- no lesion of the coronary arteries has been stented; and	
- each lesion of the coronary arteries is complex and heavily calcifi	ied; and
- balloon angioplasty with or without stenting is not suitable,	
excluding associated radiological services or preparation, and exclud	ing aftercare (Anaes.) (Assist.)
(See para TN.8.41 of explanatory notes to this Category) Fee: \$1,586.35 Benefit: 75% = \$1189.80 85% = \$1502.95	
MISCELLANEOUS CARDIAC PROCED	DURES
SINGLE CHAMBER PERMANENT TRANSVENOUS ELECTROP replacement of, including cardiac electrophysiological services where (Anaes.)	
(See para TN.8.60 of explanatory notes to this Category) Fee: \$638.65 Benefit: 75% = \$479.00	
PERMANENT CARDIAC PACEMAKER, insertion, removal or represynchronisation therapy, including cardiac electrophysiological ser implantation (Anaes.)	
(See para TN.8.60 of explanatory notes to this Category) Fee: \$255.45 Benefit: 75% = \$191.60	
DUAL CHAMBER PERMANENT TRANSVENOUS ELECTRODI replacement of, including cardiac electrophysiological services where (Anaes.)	
(See para TN.8.60 of explanatory notes to this Category) Fee: \$837.35 Benefit: 75% = \$628.05	
Extraction of chronically implanted transvenous pacing or defibrillate method where the leads have been in situ for greater than six months stylets, snares and/or extraction sheaths in a facility where cardiac su with item 61109 or 60509 (Anaes.) (Assist.)	and require removal with locking
(See para TN.8.64 of explanatory notes to this Category) Fee: \$2,868.05 Benefit: 75% = \$2151.05	
PERICARDIUM, paracentesis of (excluding aftercare) (Anaes.)	
38359 Fee: \$133.55 Benefit: 75% = \$100.20 85% = \$113.55	
INTRA-AORTIC BALLOON PUMP, percutaneous insertion of (An	aes.)
` •	
38362 Fee: \$384.95 Benefit: 75% = \$288.75 85% = \$327.25	

T8. SURGICAL OPERATIONS 6. CARDIO-THORACIC Permanent cardiac synchronisation device (including a cardiac synchronisation device that is capable of defibrillation), insertion, removal or replacement of, for a patient who: (a) has: (i) moderate to severe chronic heart failure (New York Heart Association (NYHA) class III or IV) despite optimised medical therapy; and (ii) sinus rhythm; and (iii) a left ventricular ejection fraction of less than or equal to 35%; and a QRS duration greater than or equal to 120 ms; or (b) satisfied the requirements mentioned in paragraph (a) immediately before the insertion of a cardiac resynchronisation therapy device and transvenous left ventricle electrode (Anaes.) (See para TN.8.63 of explanatory notes to this Category) 38365 Fee: \$255.45 **Benefit:** 75% = \$191.60Permanent transvenous left ventricular electrode, insertion, removal or replacement of through the coronary sinus, for the purpose of cardiac resynchronisation therapy, including right heart catheterisation and any associated venogram of left ventricular veins, other than a service associated with a service to which item 35200 or 38200 applies, for a patient who: (a) has: (i) moderate to severe chronic heart failure (New York Heart Association (NYHA) class III or IV) despite optimised medical therapy; and (ii) sinus rhythm; and a left ventricular ejection fraction of less than or equal to 35%; and (iv) a QRS duration greater than or equal to 120 ms; or (b) has: (i) mild chronic heart failure (New York Heart Association (NYHA) class II) despite optimised medical therapy; and sinus rhythm; and a left ventricular ejection fraction of less than or equal to 35%; and (iv) a QRS duration greater than or equal to 150 ms; or (c) satisfied the requirements mentioned in paragraph (a) or (b) immediately before the insertion of a cardiac resynchronisation therapy device and transvenous left ventricle electrode (Anaes.) (See para TN.8.63 of explanatory notes to this Category) Fee: \$1,224.60 **Benefit:** 75% = \$918.45 38368 Permanent cardiac synchronisation device capable of defibrillation, insertion, removal or replacement of, for a patient who: (a) has: 38371

T8. SURGICAL OPERATIONS 6. CARDIO-THORACIC moderate to severe chronic heart failure (New York Heart Association ((NYHA) class III or IV) despite optimised medical therapy; and sinus rhythm; and a left ventricular ejection fraction of less than or equal to 35%; and a QRS duration greater than or equal to 120 ms; or (b) has: (i) mild chronic heart failure (New York Heart Association (NYHA) class II) despite optimised medical therapy; and (ii) sinus rhythm; and a left ventricular ejection fraction of less than or equal to 35%; and a QRS duration greater than or equal to 150 ms (Anaes.) (See para TN.8.65 of explanatory notes to this Category) Fee: \$287.85 **Benefit:** 75% = \$215.90 AUTOMATIC DEFIBRILLATOR, insertion of patches for, or insertion of transvenous endocardial defibrillation electrodes for, primary prevention of sudden cardiac death in: - patients with a left ventricular ejection fraction of less than or equal to 30% at least one month after a myocardial infarct when the patient has received optimised medical therapy; or - patients with chronic heart failure associated with mild to moderate symptoms (NYHA II and III) and a left ventricular ejection fraction less than or equal to 35% when the patient has received optimised medical therapy. Not being a service associated with a service to which item 38213 applies (Anaes.) (Assist.) 38384 Fee: \$1.052.65 **Benefit:** 75% = \$789.50 85% = \$969.25 AUTOMATIC DEFIBRILLATOR GENERATOR, insertion or replacement of for, primary prevention of sudden cardiac death in: - patients with a left ventricular ejection fraction of less than or equal to 30% at least one month after a myocardial infarct when the patient has received optimised medical therapy; or - patients with chronic heart failure associated with mild to moderate symptoms (NYHA II and III) and a left ventricular ejection fraction less than or equal to 35% when the patient has received optimised medical therapy. 38387

T8. SUF	RGICAL OPERATION	NS	6. CARDIO-THORACIC	
	_	associated with a service onisation therapy (Anaes.	e to which item 38213 applies, not for defibrillators capable .) (Assist.)	
	Fee: \$287.85	Benefit: 75% = \$215.90	85% = \$244.70	
	defibrillation electro	des for - not for patients	n of patches for, or insertion of transvenous endocardial s with heart failure or as primary prevention for tachycardia with a service to which item 38213 applies (Anaes.)	
38390	Fee: \$1,052.65	Benefit: 75% = \$789.50	85% = \$969.25	
	heart failure or as pr		ATOR, insertion or replacement of for - not for patients with chycardia arrhythmias. Not being a service associated with a s.) (Assist.)	
38393	Fee: \$287.85	Benefit: 75% = \$215.90	85% = \$244.70	
		THO	ORACIC SURGERY	
	EMPYEMA, radica	l operation for, involving	g resection of rib (Anaes.) (Assist.)	
38415	Fee: \$399.35	Benefit: 75% = \$299.55	85% = \$339.45	
	THORACOTOMY,	exploratory, with or wit	chout biopsy (Anaes.) (Assist.)	
38418	Fee: \$958.40	Benefit: 75% = \$718.80		
30110			cation (Anaes.) (Assist.)	
38421	Fee: \$1,532.00	Benefit: 75% = \$1149.0		
30121			eurodesis, OR ENUCLEATION OF HYDATID cysts	
38424	Fee: \$958.40	Benefit: 75% = \$718.80		
	THORACOPLAST	Y (complete) - 3 or more	e ribs (Anaes.) (Assist.)	
38427	Fee: \$1,183.40	Benefit: 75% = \$887.55		
30427	- '	Y (in stages) each stage		
20.420				
38430	Fee: \$609.90	Benefit: $75\% = 457.45		
	THORACOSCOPY, with or without division of pleural adhesions, including insertion of intercostal catheter where necessary, with or without biopsy (Anaes.)			
38436	Fee: \$249.75	Benefit: 75% = \$187.35		
30130	PNEUMONECTOMY or LOBECTOMY or SEGMENTECTOMY not being a service associated with service to which Item 38418 applies (Anaes.) (Assist.)		SEGMENTECTOMY not being a service associated with a	
38438	Fee: \$1,532.00	Benefit: 75% = \$1149.0	0	
		etion of (Anaes.) (Assist.)	
38440	Fee: \$1 147 20	Renefit: 75% = \$860.40		
38441	Fee: \$1,147.20 Benefit: 75% = \$860.40 RADICAL LOBECTOMY or PNEUMONECTOMY including resection of chest wall, diaphragm, pericardium, or formal mediastinal node dissection (Anaes.) (Assist.)			

T8. SUF	RGICAL OPERATI	ons	6. CARDIO-THORACIC	
	Fee: \$1,815.20	Benefit: 75% = \$1361.40		
	THORACOTOM	Y or STERNOTOMY, for removal of thymus or	mediastinal tumour (Anaes.) (Assist.)	
38446	Fee: \$1,183.40	Benefit: 75% = \$887.55		
	PERICARDIECT (Anaes.) (Assist.)	OMY via sternotomy or anterolateral thoracotom	y without cardiopulmonary bypass	
38447	Fee: \$1,532.00	Benefit: 75% = \$1149.00		
	MEDIASTINUM	, cervical exploration of, with or without biopsy ((Anaes.) (Assist.)	
38448	Fee: \$363.05	Benefit: 75% = \$272.30		
	PERICARDIECT (Anaes.) (Assist.)	OMY via sternotomy or anterolateral thoracotom	y with cardiopulmonary bypass	
38449	Fee: \$2,143.20	Benefit: 75% = \$1607.40		
	PERICARDIUM,	transthoracic open surgical drainage of (Anaes.)	(Assist.)	
38450	Fee: \$856.65	Benefit: 75% = \$642.50		
	PERICARDIUM	subxiphoid open surgical drainage of (Anaes.) (A	Assist.)	
38452	Fee: \$573.70	Benefit: 75% = \$430.30		
	TRACHEAL exc	ision and repair without cardiopulmonary bypass	(Anaes.) (Assist.)	
38453	Fee: \$1,720.90	Benefit: 75% = \$1290.70		
		CISION AND REPAIR OF, with cardiopulmonar	ry bypass (Anaes.) (Assist.)	
38455	Fee: \$2,327.70	Benefit: 75% = \$1745.80		
	INTRATHORACIC OPERATION on heart, lungs, great vessels, bronchial tree, oesophagus or mediastinum, or on more than 1 of those organs, not being a service to which another item in this Group applies (Anaes.) (Assist.)			
38456	Fee: \$1,532.00	Benefit: 75% = \$1149.00		
		ATUM or PECTUS CARINATUM, repair or rad	dical correction of (Anaes.) (Assist.)	
38457	Fee: \$1,430.25	Benefit: 75% = \$1072.70		
		ATUM, repair of, with implantation of subcutant	eous prosthesis (Anaes.) (Assist.)	
38458	Fee: \$762.35	Benefit: 75% = \$571.80		
20.00	- 	E OR WIRES, removal of (Anaes.)		
38460	Fee: \$275.40	Benefit: 75% = \$206.55		
30400		WOUND, debridement of, not involving reopening	ng of the mediastinum (Anaes.)	
38462	Fee: \$326.45	Benefit: 75% = \$244.85		
36402	STERNOTOMY	WOUND, debridement of, involving curettage of but not involving reopening of the mediastinum (
38464	Fee: \$354.80	Benefit: 75% = \$266.10		
38466		eration on, for dehiscence or infection involving i	reopening of the mediastinum, with or	

T8. SUF	RGICAL OPERATI	ONS	6. CARDIO-THORACIC	
	without rewiring	(Anaes.) (Assist.)		
	Fee: \$958.00	Benefit: 75% = \$718.50		
	STERNUM AND	MEDIASTINUM, reoperation for infe m (Anaes.) (Assist.)	ection of, involving muscle advancement flaps	
38468	Fee: \$1,476.15	Benefit: 75% = \$1107.15		
	STERNUM AND MEDIASTINUM, reoperation for infection of, involving muscle advancement and greater omentum (Anaes.) (Assist.)			
38469	Fee: \$1,720.90	Benefit: 75% = \$1290.70		
		CARDIAC SURGERY F	PROCEDURES	
	PERMANENT M (Assist.)	IYOCARDIAL ELECTRODE, insertio	n of, by thoracotomy or sternotomy (Anaes.)	
38470	(See para TN.8.67 o Fee: \$958.40	of explanatory notes to this Category) Benefit: 75% = \$718.80		
	PERMANENT P.	ACEMAKER ELECTRODE, insertion	by open surgical approach (Anaes.) (Assist.)	
38473	(See para TN.8.67 o Fee: \$573.70	of explanatory notes to this Category) Benefit: 75% = \$430.30		
		VALVULAR PROC	CEDURES	
	which item 38480	or 38481 applies (Anaes.) (Assist.)	ot being a service associated with a service to	
38475	(See para TN.8.67 o Fee: \$831.75	of explanatory notes to this Category) Benefit: 75% = \$623.85		
	VALVE ANNUL (Anaes.) (Assist.)		eing a service to which item 38478 applies	
38477	(See para TN.8.67 o Fee: \$2,003.35	of explanatory notes to this Category) Benefit: 75% = \$1502.55		
	-	OPLASTY with insertion of ring perfo	rmed in conjunction with item 38480 or 38481	
38478	(See para TN.8.67 o Fee: \$970.40	of explanatory notes to this Category) Benefit: 75% = \$727.80		
	VALVE REPAIR	t, 1 leaflet (Anaes.) (Assist.)		
38480	(See para TN.8.67 o Fee: \$2,003.35	of explanatory notes to this Category) Benefit: 75% = \$1502.55		
	VALVE REPAIR	2, 2 or more leaflets (Anaes.) (Assist.)		
38481	(See para TN.8.67 o Fee: \$2,280.65	of explanatory notes to this Category) Benefit: 75% = \$1710.50		
		E LEAFLET OR LEAFLETS, decalcifi 480, 38481, 38488 or 38489 applies (A	cation of, not being a service to which item naes.) (Assist.)	
38483	(See para TN.8.67 o Fee: \$1,720.90	of explanatory notes to this Category) Benefit: 75% = \$1290.70		
38485	MITRAL ANNU	LUS, reconstruction of, after decalcific	ation, when performed in association with valve	

T8. SUF	RGICAL OPERATIONS 6. CARDIO-THORACIC
	surgery (Anaes.) (Assist.)
	(See para TN.8.67 of explanatory notes to this Category) Fee: \$817.10 Benefit: 75% = \$612.85
	MITRAL VALVE, open valvotomy of (Anaes.) (Assist.)
38487	(See para TN.8.67 of explanatory notes to this Category) Fee: \$1,720.90 Benefit: 75% = \$1290.70
	VALVE REPLACEMENT with BIOPROSTHESIS OR MECHANICAL PROSTHESIS (Anaes.) (Assist.)
38488	(See para TN.8.67 of explanatory notes to this Category) Fee: \$1,909.60 Benefit: 75% = \$1432.20
	VALVE REPLACEMENT with allograft (subcoronary or cylindrical implant), or unstented xenograft (Anaes.) (Assist.)
38489	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,271.05 Benefit: 75% = \$1703.30
	SUB-VALVULAR STRUCTURES, reconstruction and re-implantation of, associated with mitral and tricuspid valve replacement (Anaes.) (Assist.)
38490	(See para TN.8.67 of explanatory notes to this Category) Fee: \$554.55 Benefit: 75% = \$415.95
	OPERATIVE MANAGEMENT of acute infective endocarditis, in association with heart valve surgery (Anaes.) (Assist.)
38493	(See para TN.8.67 of explanatory notes to this Category) Fee: \$1,957.60 Benefit: 75% = \$1468.20
	TAVI, for the treatment of symptomatic severe aortic stenosis, performed via transfemoral delivery, unless transfemoral delivery is contraindicated or not feasible, in a TAVI Hospital on a TAVI Patient by a TAVI Practitioner – includes all intraoperative diagnostic imaging that the TAVI Practitioner performs upon the TAVI Patient.
	(Not payable more than once per patient in a five year period.) (Anaes.) (Assist.)
38495	(See para AN.33.1, TN.8.135 of explanatory notes to this Category) Fee: \$1,432.20 Benefit: 75% = \$1074.15 85% = \$1348.80
	SURGERY FOR ISCHAEMIC HEART DISEASE
	ARTERY HARVESTING (other than internal mammary), for coronary artery bypass (Anaes.) (Assist.)
38496	(See para TN.8.67 of explanatory notes to this Category) Fee: \$623.95 Benefit: 75% = \$468.00
	CORONARY ARTERY BYPASS with cardiopulmonary bypass, using saphenous vein graft or grafts only, including harvesting of vein graft material where performed, not being a service associated with a service to which items 38498, 38500, 38501, 38503 or 38504 apply (Anaes.) (Assist.)
38497	(See para TN.8.68, TN.8.67 of explanatory notes to this Category) Fee: \$2,047.60 Benefit: 75% = \$1535.70
38498	CORONARY ARTERY BYPASS with the aid of tissue stabilisers, performed without cardiopulmonary bypass, using saphenous vein graft or grafts only, including harvesting of vein graft material where performed, either via a median sternotomy or other minimally invasive technique and where a stand-by perfusionist is present, not being a service associated with a service to which items 38497, 38500,

T8. SUF	RGICAL OPERATIONS	6. CARDIO-THORACIC	
	38501, 38503, 38504 or 38600 apply (Anaes.) (Assist.)		
	(See para TN.8.68, TN.8.67 of explanatory notes to this Category) Fee: \$2,047.60 Benefit: 75% = \$1535.70		
	CORONARY ARTERY BYPASS with cardiopulmonary bypass, using without vein graft or grafts, including harvesting of internal mammary at where performed, not being a service associated with a service to which 38503 or 38504 apply (Anaes.) (Assist.)	rtery or vein graft material	
38500	(See para TN.8.68, TN.8.67 of explanatory notes to this Category) Fee: \$2,200.00 Benefit: 75% = \$1650.00		
	CORONARY ARTERY BYPASS with the aid of tissue stabilisers, performed without cardiopulmonary bypass, using single arterial graft, with or without vein graft or grafts, including harvesting of internal mammary artery or vein graft material where performed, either via a median sternotomy or other minimally invasive technique and where a stand-by perfusionist is present, not being a service associated with a service to which items 38497, 38498, 38500, 38503, 38504 or 38600 apply (Anaes.) (Assist.)		
38501	(See para TN.8.68, TN.8.67 of explanatory notes to this Category) Fee: \$2,200.00 Benefit: 75% = \$1650.00		
	CORONARY ARTERY BYPASS with cardiopulmonary bypass, using without vein graft or grafts, including harvesting of internal mammary at where performed, not being a service associated with a service to which 38501 or 38504 apply (Anaes.) (Assist.)	rtery or vein graft material	
38503	(See para TN.8.68, TN.8.67 of explanatory notes to this Category) Fee: \$2,388.70 Benefit: 75% = \$1791.55		
	CORONARY ARTERY BYPASS with the aid of tissue stabilisers, performed without cardiopulmonal bypass, using 2 or more arterial grafts, with or without vein graft or grafts, including harvesting of internal mammary artery or vein graft material where performed, either via a median sternotomy or ot minimally invasive technique and where a stand-by perfusionist is present, not being a service associal with a service to which items 38497, 38498, 38500, 38501, 38503 or 38600 apply (Anaes.) (Assist.)		
38504	(See para TN.8.68, TN.8.67 of explanatory notes to this Category) Fee: \$2,388.70 Benefit: 75% = \$1791.55		
	CORONARY ENDARTERECTOMY, by open operation, including repair with 1 or more patch grafts each vessel (Anaes.) (Assist.)		
38505	(See para TN.8.67 of explanatory notes to this Category) Fee: \$277.25 Benefit: 75% = \$207.95		
	LEFT VENTRICULAR ANEURYSM, plication of (Anaes.) (Assist.)		
38506	(See para TN.8.67 of explanatory notes to this Category) Fee: \$1,626.25 Benefit: 75% = \$1219.70		
	LEFT VENTRICULAR ANEURYSM resection with primary repair (An	naes.) (Assist.)	
38507	(See para TN.8.67 of explanatory notes to this Category) Fee: \$1,909.20 Benefit: 75% = \$1431.90		
	LEFT VENTRICULAR ANEURYSM resection with patch reconstruction (Assist.)	on of the left ventricle (Anaes.)	
38508	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,388.70 Benefit: 75% = \$1791.55		

T8. SUF	RGICAL OPERATIONS 6. CARDIO-THORAC		
	ISCHAEMIC VENTRICULAR SEPTAL RUPTURE, repair of (Anaes.) (Assist.)		
38509	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,388.70 Benefit: 75% = \$1791.55		
	ARRHYTHMIA SURGERY		
	DIVISION OF ACCESSORY PATHWAY, isolation procedure, procedure on atrioventricular node or perinodal tissues involving 1 atrial chamber only (Anaes.) (Assist.)		
38512	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,098.45 Benefit: 75% = \$1573.85		
	DIVISION OF ACCESSORY PATHWAY, isolation procedure, procedure on atrioventricular node or perinodal tissues involving both atrial chambers and including curative surgery for atrial fibrillation (Anaes.) (Assist.)		
38515	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,671.95 Benefit: 75% = \$2004.00		
	VENTRICULAR ARRHYTHMIA with mapping and muscle ablation, with or without aneurysmeoton (Anaes.) (Assist.)		
38518	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,868.05 Benefit: 75% = \$2151.05		
	PROCEDURES ON THORACIC AORTA		
	ASCENDING THORACIC AORTA, repair or replacement of, not involving valve replacement or rep or coronary artery implantation (Anaes.) (Assist.)		
38550	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,146.15 Benefit: 75% = \$1609.65		
	ASCENDING THORACIC AORTA, repair or replacement of, with aortic valve replacement or repair without implantation of coronary arteries (Anaes.) (Assist.)		
38553	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,719.75 Benefit: 75% = \$2039.85		
	ASCENDING THORACIC AORTA, repair or replacement of, with aortic valve replacement or repair and implantation of coronary arteries (Anaes.) (Assist.)		
38556	(See para TN.8.67 of explanatory notes to this Category) Fee: \$3,104.70 Benefit: 75% = \$2328.55		
	AORTIC ARCH and ASCENDING THORACIC AORTA, repair or replacement of, not involving val replacement or repair or coronary artery implantation (Anaes.) (Assist.)		
38559	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,531.00 Benefit: 75% = \$1898.25		
	AORTIC ARCH and ASCENDING THORACIC AORTA, repair or replacement of, with aortic valve replacement or repair, without implantation of coronary arteries (Anaes.) (Assist.)		
38562	(See para TN.8.67 of explanatory notes to this Category) Fee: \$3,104.70 Benefit: 75% = \$2328.55		
	AORTIC ARCH and ASCENDING THORACIC AORTA, repair or replacement of, with aortic valve replacement or repair, and implantation of coronary arteries (Anaes.) (Assist.)		
38565	(See para TN.8.67 of explanatory notes to this Category) Fee: \$3,482.25 Benefit: 75% = \$2611.70		

T8. SUF	RGICAL OPERATIONS	6. CARDIO-THORACIC	
	DESCENDING THORACIC AORTA, repair or replacement of, without shunt or cardiopulmonal bypass, by open exposure, percutaneous or endovascular means (Anaes.) (Assist.)		
38568	(See para TN.8.67 of explanatory notes to this Category) Fee: \$1,862.95 Benefit: 75% = \$1397.25		
	DESCENDING THORACIC AORTA, repair or replacement of, using (Anaes.) (Assist.)	shunt or cardiopulmonary bypass	
38571	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,051.75 Benefit: 75% = \$1538.85		
	OPERATIVE MANAGEMENT OF ACUTE RUPTURE OR DISSECTION, in conjunction with procedures on the thoracic aorta (Anaes.) (Assist.)		
38572	(See para TN.8.67 of explanatory notes to this Category) Fee: \$1,987.05 Benefit: 75% = \$1490.30		
	CANNULATION FOR, and supervision and monitoring of, the administration of retrograde cerebral perfusion during deep hypothermic arrest (Assist.)		
38577	(See para TN.8.67 of explanatory notes to this Category) Fee: \$554.55 Benefit: 75% = \$415.95		
	TECHNIQUES FOR PRESERVATION OF ARRES	STED HEART	
	CANNULATION of the coronary sinus for, and supervision of, the retrograde administration of b crystalloid for cardioplegia, including pressure monitoring (Assist.)		
38588	(See para TN.8.67 of explanatory notes to this Category) Fee: \$416.05 Benefit: 75% = \$312.05		
	CIRCULATORY SUPPORT PROCEDURES		
	CENTRAL CANNULATION for cardiopulmonary bypass excluding post-operative management, not being a service associated with a service to which another item in this Subgroup applies (Anaes.) (Assist.)		
38600	(See para TN.8.67 of explanatory notes to this Category) Fee: \$1,532.00 Benefit: 75% = \$1149.00		
	PERIPHERAL CANNULATION for cardiopulmonary bypass excluding post-operative management (Anaes.) (Assist.)		
38603	(See para TN.8.67 of explanatory notes to this Category) Fee: \$958.40 Benefit: 75% = \$718.80		
	INTRA-AORTIC BALLOON PUMP, insertion of, by arteriotomy (Anaes.) (Assist.)		
38609	(See para TN.8.67 of explanatory notes to this Category) Fee: \$479.15 Benefit: 75% = \$359.40		
	INTRA-AORTIC BALLOON PUMP, removal of, with closure of arter (Assist.)	ry by direct suture (Anaes.)	
38612	(See para TN.8.67 of explanatory notes to this Category) Fee: \$537.10 Benefit: 75% = \$402.85 85% = \$456.55		
	INTRA-AORTIC BALLOON PUMP, removal of, with closure of artery by patch graft (Anaes.) (Assist.)		
38613	(See para TN.8.67 of explanatory notes to this Category) Fee: \$674.05 Benefit: 75% = \$505.55		

T8. SURG	SICAL OPERATIONS	6. CARDIO-THORACIC
	Insertion of a left or right ventricular assist device, for use as:	
	(a) a bridge to cardiac transplantation in patients with refractory heart failur	e who are:
	(i) currently on a heart transplant waiting list, or	
	(ii) expected to be suitable candidates for cardiac transplantation following the ventricular	ng a period of support on
	assist device; or	
	(b) acute post cardiotomy support for failure to wean from cardiopulmonary	y transplantation; or
	(c) cardio-respiratory support for acute cardiac failure which is likely to rec support of less than 6	over with short term
	weeks;	
	not being a service associated with the use of a ventricular assist device as demanagement of patients with heart failure who are not expected to be suitable transplantation (Anaes.) (Assist.)	
38615	(See para TN.8.67 of explanatory notes to this Category) Fee: \$1,532.00 Benefit: 75% = \$1149.00	
	Insertion of a left and right ventricular assist device, for use as:	
	(a) a bridge to cardiac transplantation in patients with refractory heart failur	re who are:
	(i) currently on a heart transplant waiting list, or	
	(ii) expected to be suitable candidates for cardiac transplantation following the ventricular	ng a period of support on
	assist device; or	
	(b) acute post cardiotomy support for failure to wean from cardiopulmonary	ransplantation; or
	(c) cardio-respiratory support for acute cardiac failure which is likely to rec support of less than 6	over with short term
	weeks;	
	not being a service associated with the use of a ventricular assist device as demanagement of patients with heart failure who are not expected to be suitable transplantation (Anaes.) (Assist.)	stination therapy in the candidates for cardiac
38618	(See para TN.8.67 of explanatory notes to this Category) Fee: \$1,909.60 Benefit: 75% = \$1432.20	
	LEFT OR RIGHT VENTRICULAR ASSIST DEVICE, removal of, as an ind (Anaes.) (Assist.)	lependent procedure
38621	(See para TN.8.67 of explanatory notes to this Category) Fee: \$762.35 Benefit: 75% = \$571.80	
38624	LEFT AND RIGHT VENTRICULAR ASSIST DEVICE, removal of, as an in	ndependent procedure

T8. SUF	RGICAL OPERATIONS 6. CARDIO-THORACIO		
	(Anaes.) (Assist.)		
	(See para TN.8.67 of explanatory notes to this Category) Fee: \$856.65 Benefit: 75% = \$642.50		
	EXTRA-CORPOREAL MEMBRANE OXYGENATION, BYPASS OR VENTRICULAR ASSIST DEVICE CANNULAE, adjustment and re-positioning of, by open operation, in patients supported by these devices (Anaes.) (Assist.)		
38627	(See para TN.8.67 of explanatory notes to this Category) Fee: \$669.60 Benefit: 75% = \$502.20		
	RE-OPERATION		
	PATENT DISEASED coronary artery bypass vein graft or grafts, dissection, disconnection and oversewing of (Anaes.) (Assist.)		
38637	(See para TN.8.67 of explanatory notes to this Category) Fee: \$554.55 Benefit: 75% = \$415.95		
	RE-OPERATION via median sternotomy, for any procedure, including any divisions of adhesions where the time taken to divide the adhesions is 45 minutes or less (Anaes.) (Assist.)		
38640	(See para TN.8.69, TN.8.67 of explanatory notes to this Category) Fee: \$958.40 Benefit: 75% = \$718.80		
	MISCELLANEOUS CARDIOTHORACIC SURGICAL PROCEDURES		
	THORACOTOMY OR STERNOTOMY involving division of adhesions where the time taken to divide the adhesions exceeds 45 minutes (Anaes.) (Assist.)		
38643	(See para TN.8.67 of explanatory notes to this Category) Fee: \$1,067.40 Benefit: 75% = \$800.55		
	THORACOTOMY OR STERNOTOMY involving division of extensive adhesions where the time taker to divide the adhesions exceeds 2 hours (Anaes.) (Assist.)		
38647	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,134.50 Benefit: 75% = \$1600.90		
	MYOMECTOMY or MYOTOMY for hypertrophic obstructive cardiomyopathy (Anaes.) (Assist.)		
38650	(See para TN.8.67 of explanatory notes to this Category) Fee: \$1,909.60 Benefit: 75% = \$1432.20		
	OPEN HEART SURGERY, not being a service to which another item in this Group applies (Anaes.) (Assist.)		
38653	(See para TN.8.67 of explanatory notes to this Category) Fee: \$1,909.60 Benefit: 75% = \$1432.20		
	Permanent left ventricular electrode, insertion, removal or replacement of via open thoracotomy, for the purpose of cardiac resynchronisation therapy, for a patient who:		
	(a) has:		
	(i) moderate to severe chronic heart failure (New York Heart Association (NYHA) class III or IV) despite optimised medical therapy; and		
	(ii) sinus rhythm; and		
38654	(iii) a left ventricular ejection fraction of less than or equal to 35%; and		

T8. SUF	RGICAL OPERATIONS 6. CARDIO-THORACI	
	(iv) a QRS duration greater than or equal to 120 ms; or	
	(b) has:	
	(i) mild chronic heart failure (New York Heart Association (NYHA) class II) despite optimised medical therapy; and	
	(ii) sinus rhythm; and	
	(iii) a left ventricular ejection fraction of less than or equal to 35%; and	
	(iv) a QRS duration greater than or equal to 150 ms; or	
	(c) satisfied the requirements mentioned in paragraph (a) or (b) immediately before the insertion of a cardiac resynchronisation therapy device and transvenous left ventricle electrode	
	(Anaes.) (Assist.)	
	(See para TN.8.63, TN.8.67 of explanatory notes to this Category) Fee: \$1,224.60 Benefit: 75% = \$918.45	
	THORACOTOMY or median sternotomy for post-operative bleeding (Anaes.) (Assist.)	
38656	(See para TN.8.67 of explanatory notes to this Category) Fee: \$958.40 Benefit: 75% = \$718.80	
	CARDIAC TUMOURS	
	CARDIAC TUMOUR, excision of, involving the wall of the atrium or inter-atrial septum, without pate or conduit reconstruction (Anaes.) (Assist.)	
38670	(See para TN.8.67 of explanatory notes to this Category) Fee: \$1,909.20 Benefit: 75% = \$1431.90	
	CARDIAC TUMOUR, excision of, involving the wall of the atrium or inter-atrial septum, requiring reconstruction with patch or conduit (Anaes.) (Assist.)	
38673	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,148.85 Benefit: 75% = \$1611.65	
	CARDIAC TUMOUR arising from ventricular myocardium, partial thickness excision of (Anaes.) (Assist.)	
38677	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,010.35 Benefit: 75% = \$1507.80	
	CARDIAC TUMOUR arising from ventricular myocardium, full thickness excision of including repa or reconstruction (Anaes.) (Assist.)	
38680	(See para TN.8.70 of explanatory notes to this Category) Fee: \$2,384.55 Benefit: 75% = \$1788.45 85% = \$2301.15	
	CONGENITAL CARDIAC SURGERY	
	PATENT DUCTUS ARTERIOSUS, shunt, collateral or other single large vessel, division or ligation o without cardiopulmonary bypass, for congenital heart disease (Anaes.) (Assist.)	
38700	(See para TN.8.67 of explanatory notes to this Category) Fee: \$1,067.40 Benefit: 75% = \$800.55	
	PATENT DUCTUS ARTERIOSUS, shunt, collateral or other single large vessel, division or ligation or	

T8. SUF	RGICAL OPERATIONS 6. CARDIO-THORA	6. CARDIO-THORACIC	
	with cardiopulmonary bypass, for congenital heart disease (Anaes.) (Assist.)		
	(See para TN.8.67 of explanatory notes to this Category) Fee: \$1,924.10 Benefit: 75% = \$1443.10		
	AORTA, anastomosis or repair of, without cardiopulmonary bypass, for congenital heart disease (Anaes.) (Assist.)		
38706	(See para TN.8.67 of explanatory notes to this Category) Fee: \$1,822.40 Benefit: 75% = \$1366.80		
	AORTA, anastomosis or repair of, with cardiopulmonary bypass, for congenital heart disease (Anae (Assist.)	s.)	
38709	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,134.50 Benefit: 75% = \$1600.90		
	AORTIC INTERRUPTION, repair of, for congenital heart disease (Anaes.) (Assist.)		
38712	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,563.15 Benefit: 75% = \$1922.40		
	MAIN PULMONARY ARTERY, banding, debanding or repair of, without cardiopulmonary bypass congenital heart disease (Anaes.) (Assist.)	s, for	
38715	(See para TN.8.67 of explanatory notes to this Category) Fee: \$1,706.30 Benefit: 75% = \$1279.75		
	MAIN PULMONARY ARTERY, banding, debanding or repair of, with cardiopulmonary bypass, for congenital heart disease (Anaes.) (Assist.)	r	
38718	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,134.50 Benefit: 75% = \$1600.90		
	VENA CAVA, anastomosis or repair of, without cardiopulmonary bypass, for congenital heart disea (Anaes.) (Assist.)	ise	
38721	(See para TN.8.67 of explanatory notes to this Category) Fee: \$1,495.80 Benefit: 75% = \$1121.85		
	VENA CAVA, anastomosis or repair of, with cardiopulmonary bypass, for congenital heart disease (Anaes.) (Assist.)		
38724	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,134.50 Benefit: 75% = \$1600.90		
	INTRATHORACIC VESSELS, anastomosis or repair of, without cardiopulmonary bypass, not bein service to which item 38700, 38703, 38706, 38709, 38712, 38715, 38718, 38721 or 38724 applies, f congenital heart disease (Anaes.) (Assist.)		
38727	(See para TN.8.67 of explanatory notes to this Category) Fee: \$1,495.80 Benefit: 75% = \$1121.85		
	INTRATHORACIC VESSELS, anastomosis or repair of, with cardiopulmonary bypass, not being a service to which item 38700, 38703, 38706, 38709, 38712, 38715, 38718, 38721 or 38724 applies, for congenital heart disease (Anaes.) (Assist.)		
38730	Fee: \$2,134.50 Benefit: 75% = \$1600.90		
38733	SYSTEMIC PULMONARY or CAVO-PULMONARY SHUNT, creation of, without cardiopulmonary bypass, for congenital heart disease (Anaes.) (Assist.)		

T8. SUF	RGICAL OPERATIONS	6. CARDIO-THORACIC
	(See para TN.8.67 of explanatory notes to this Category) Fee: \$1,495.80 Benefit: 75% = \$1121.85	
	SYSTEMIC PULMONARY or CAVO-PULMONARY SHUNT, creation of, bypass, for congenital heart disease (Anaes.) (Assist.)	with cardiopulmonary
38736	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,134.50 Benefit: 75% = \$1600.90	
	ATRIAL SEPTECTOMY, with or without cardiopulmonary bypass, for cong (Anaes.) (Assist.)	enital heart disease
38739	(See para TN.8.67 of explanatory notes to this Category) Fee: \$1,924.10 Benefit: 75% = \$1443.10	
	ATRIAL SEPTAL DEFECT, closure by open exposure direct suture or patch disease (Anaes.) (Assist.)	, for congenital heart
38742	(See para TN.8.67 of explanatory notes to this Category) Fee: \$1,924.10 Benefit: 75% = \$1443.10	
	INTRA-ATRIAL BAFFLE, insertion of, for congenital heart disease (Anaes.)	(Assist.)
38745	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,134.50 Benefit: 75% = \$1600.90	
	VENTRICULAR SEPTECTOMY, for congenital heart disease (Anaes.) (Ass	ist.)
38748	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,134.50 Benefit: 75% = \$1600.90	
	Ventricular septal defect, closure by direct suture or patch (Anaes.) (Assist.)	
38751	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,134.50 Benefit: 75% = \$1600.90	
	INTRAVENTRICULAR BAFFLE OR CONDUIT, insertion of, for congenita (Assist.)	al heart disease (Anaes.)
38754	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,671.95 Benefit: 75% = \$2004.00	
	EXTRACARDIAC CONDUIT, insertion of, for congenital heart disease (Ana	aes.) (Assist.)
38757	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,134.50 Benefit: 75% = \$1600.90	
	EXTRACARDIAC CONDUIT, replacement of, for congenital heart disease (Anaes.) (Assist.)
38760	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,134.50 Benefit: 75% = \$1600.90	
	VENTRICULAR MYECTOMY, for relief of ventricular obstruction, right or disease (Anaes.) (Assist.)	left, for congenital heart
38763	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,134.50 Benefit: 75% = \$1600.90	
	VENTRICULAR AUGMENTATION, right or left, for congenital heart disea	se (Anaes.) (Assist.)
38766	(See para TN.8.67 of explanatory notes to this Category) Fee: \$2,134.50 Benefit: 75% = \$1600.90	
	MISCELLANEOUS PROCEDURES ON THE CHES	T

T8. SUF	RGICAL OPERAT	TIONS	6. CARDIO-THORACIC
	THORACIC CAVITY, aspiration of, for diagnostic purposes, not being a service asso service to which item 38803 applies		
38800	Fee: \$38.50	Benefit: 75% = \$28.90 85% = \$32.75	
	THORACIC Cardiagnostic samp	AVITY, aspiration of, with therapeutic drainage (ple	paracentesis), with or without
38803	Fee: \$76.90	Benefit: 75% = \$57.70 85% = \$65.40	
	INTERCOSTA	L DRAIN, insertion of, not involving resection of	Frib (excluding aftercare) (Anaes.)
38806	Fee: \$133.55	Benefit: 75% = \$100.20 85% = \$113.55	
	INTERCOSTAL DRAIN, insertion of, with pleurodesis and not involving resection of rib (excluding aftercare) (Anaes.)		
38809	Fee: \$164.55	Benefit: 75% = \$123.45 85% = \$139.90	
	PERCUTANEO	OUS NEEDLE BIOPSY of lung (Anaes.)	
38812	Fee: \$209.15	Benefit: 75% = \$156.90 85% = \$177.80	
T8. SUF	RGICAL OPERAT	TIONS	7. NEUROSURGICAL
	Group T8. Surgical Operations Subgroup 7. Neurosurgical GENERAL		
	LUMBAR PUNCTURE (Anaes.)		
39000	Fee: \$75.30	Benefit: 75% = \$56.50 85% = \$64.05	
	CISTERNAL PUNCTURE (Anaes.)		
39003	Fee: \$85.65	ee: \$85.65 Benefit: 75% = \$64.25 85% = \$72.85	
	VENTRICULAR PUNCTURE (not including burr-hole) (Anaes.))
39006	Fee: \$159.40	Benefit: 75% = \$119.55 85% = \$135.50	
	SUBDURAL H	AEMORRHAGE, tap for, each tap (Anaes.)	
39009	Fee: \$59.35	Benefit: 75% = \$44.55	
	BURR-HOLE, single, preparatory to ventricular puncture or for inspection purpose - not being a service to which another item applies (Anaes.)		nspection purpose - not being a service
39012	Fee: \$237.60	Benefit: 75% = \$178.20	
	INJECTION UNDER IMAGE INTENSIFICATION with 1 or more of contrast media, local and or corticosteroid into 1 or more zygo-apophyseal or costo-transverse joints or 1 or more primary posterior rami of spinal nerves (Anaes.)		
39013	(See para TN.8.4 Fee: \$109.15	of explanatory notes to this Category) Benefit: 75% = \$81.90 85% = \$92.80	
39015		R RESERVOIR, EXTERNAL VENTRICULAR DNITORING DEVICE, insertion of - including b	

T8. SUR	RGICAL OPERATIONS 7. NEUROSURGICA	
	(Assist.)	
İ	(See para TN.8.4 of explanatory notes to this Category) Fee: \$376.00 Benefit: 75% = \$282.00	
<u> </u>	CEREBROSPINAL FLUID reservoir, insertion of (Anaes.) (Assist.)	
39018	Fee: \$376.00 Benefit: 75% = \$282.00	
	PAIN RELIEF	
ĺ	INJECTION OF PRIMARY BRANCH OF TRIGEMINAL NERVE with alcohol, cortisone, phenol, or similar substance (Anaes.)	
39100	(See para TN.8.4 of explanatory notes to this Category) Fee: \$237.60 Benefit: 75% = \$178.20 85% = \$202.00	
Ì	NEURECTOMY, INTRACRANIAL, for trigeminal neuralgia (Anaes.) (Assist.)	
39106	Fee: \$1,188.20 Benefit: 75% = \$891.15	
	TRIGEMINAL GANGLIOTOMY by radiofrequency, balloon or glycerol (Anaes.)	
39109	Fee: \$443.70 Benefit: 75% = \$332.80 85% = \$377.15	
	CRANIAL NERVE, intracranial decompression of, using microsurgical techniques (Anaes.) (Assist.)	
39112	Fee: \$1,541.50 Benefit: 75% = \$1156.15	
	PERCUTANEOUS NEUROTOMY of posterior divisions (or rami) of spinal nerves by any method, including any associated spinal, epidural or regional nerve block (payable once only in a 30 day period) (Anaes.)	
39115	(See para TN.8.4 of explanatory notes to this Category) Fee: \$75.30 Benefit: 75% = \$56.50 85% = \$64.05	
	PERCUTANEOUS NEUROTOMY for facet joint denervation by radio-frequency probe or cryoprobe using radiological imaging control (Anaes.) (Assist.)	
39118	(See para TN.8.4 of explanatory notes to this Category) Fee: \$297.85 Benefit: 75% = \$223.40 85% = \$253.20	
	PERCUTANEOUS CORDOTOMY (Anaes.) (Assist.)	
39121	(See para TN.8.4 of explanatory notes to this Category) Fee: \$631.75 Benefit: 75% = \$473.85 85% = \$548.35	
	CORDOTOMY OR MYELOTOMY, partial or total laminectomy for, or operation for dorsal root entry zone (Drez) lesion (Anaes.) (Assist.)	
39124	Fee: \$1,616.80 Benefit: 75% = \$1212.60	
	Intrathecal or epidural SPINAL CATHETER insertion or replacement of, and connection to a subcutaneous implanted infusion pump, for the management of chronic intractable pain (Anaes.) (Assist.)	
39125	Fee: \$298.05 Benefit: 75% = \$223.55	
	INFUSION PUMP, subcutaneous implantation or replacement of, and connection of the pump to an intrathecal or epidural catheter, and filling of reservoir with a therapeutic agent or agents, with or without programming the pump, for the management of chronic intractable pain (Anaes.) (Assist.)	
ļi		

T8. SUF	RGICAL OPERATIONS	7. NEUROSURGICAL	
	SUBCUTANEOUS RESERVOIR AND SPINAL CATHET chronic intractable pain (Anaes.)	TER, insertion of, for the management of	
39127	(See para TN.8.4 of explanatory notes to this Category) Fee: \$473.65 Benefit: 75% = \$355.25		
	INFUSION PUMP, subcutaneous implantation of, AND intinsertion of, and connection of pump to catheter, and filling agents, with or without programming the pump, for the man (Assist.)	of reservoir with a therapeutic agent or	
39128	Fee: \$659.95 Benefit: 75% = \$495.00		
	EPIDURAL LEAD, percutaneous placement of, including is management of chronic intractable neuropathic pain or pain maximum of 4 leads (Anaes.)		
39130	(See para TN.8.4 of explanatory notes to this Category) Fee: \$674.15 Benefit: 75% = \$505.65		
	ELECTRODES, epidural or peripheral nerve, management of neurostimulator by a medical practitioner, for the manage or pain from refractory angina pectoris - each day		
39131	Fee: \$127.80 Benefit: 75% = \$95.85 85% = \$108.65		
	Removal of subcutaneously IMPLANTED INFUSION PUN intrathecal or epidural SPINAL CATHETER, for the manag		
39133	(See para TN.8.4 of explanatory notes to this Category) Fee: \$159.40 Benefit: 75% = \$119.55		
	NEUROSTIMULATOR or RECEIVER, subcutaneous plac connection of extension wires to epidural or peripheral nerv intractable neuropathic pain or pain from refractory angina p	e electrodes, for the management of chronic	
39134	Fee: \$340.60 Benefit: 75% = \$255.45		
	NEUROSTIMULATOR or RECEIVER, that was inserted for neuropathic pain or pain from refractory angina pectoris, report a hospital (Anaes.)		
39135	Fee: \$159.40 Benefit: 75% = \$119.55		
	LEAD, epidural or peripheral nerve that was inserted for the neuropathic pain or pain from refractory angina pectoris, report a hospital (Anaes.)		
39136	(See para TN.8.4 of explanatory notes to this Category) Fee: \$159.40 Benefit: 75% = \$119.55		
	LEAD, epidural or peripheral nerve that was inserted for the neuropathic pain or pain from refractory angina pectoris, sur or unsatisfactory positioning, including intraoperative test st 39130, 39138 or 39139 applies (Anaes.)	rgical repositioning to correct displacement	
39137	Fee: \$605.35 Benefit: 75% = \$454.05		
39138	PERIPHERAL NERVE LEAD, surgical placement of, including intraoperative test stimulation, for the management of chronic intractable neuropathic pain or pain from refractory angina pectoris, to a		

T8. SUF	RGICAL OPERAT	ONS	7. NEUROSURGICAL
	maximum of 4 le	ads (Anaes.) (Assist.)	
	Fee: \$674.15	Benefit: 75% = \$505.65	
	Epidural lead, su intraoperative tes	rgical placement of one or more by partial or to t stimulation, for the management of chronic pectoris—to a maximum of 4 leads (H) (Anameter)	intractable neuropathic pain or pain from
39139	Fee: \$905.10	Benefit: 75% = \$678.85	
		THETER, insertion of, under imaging control, ion for lysis of adhesions (Anaes.)	with epidurogram and epidural
39140	Fee: \$292.85	Benefit: 75% = \$219.65 85% = \$248.95	
		PERIPHERAL NERVE	S
	CUTANEOUS N (Anaes.) (Assist.	IERVE (including digital nerve), primary repa	ir of, using microsurgical techniques
39300	Fee: \$353.35	Benefit: 75% = \$265.05	
	CUTANEOUS N (Anaes.) (Assist.	ERVE (including digital nerve), secondary re	pair of, using microsurgical techniques
39303	Fee: \$466.10	Benefit: 75% = \$349.60	
	NERVE TRUNK	, primary repair of, using microsurgical techn	iques (Anaes.) (Assist.)
39306	Fee: \$676.80	Benefit: 75% = \$507.60	
	NERVE TRUNK	, secondary repair of, using microsurgical tec	hniques (Anaes.) (Assist.)
39309	Fee: \$714.35	Benefit: 75% = \$535.80	
	NERVE TRUNK	, (interfascicular), neurolysis of, using micros	surgical techniques (Anaes.) (Assist.)
39312	Fee: \$398.55	Benefit: 75% = \$298.95	
	NERVE TRUNK techniques (Anac	c, nerve graft to, (cable graft) including harves es.) (Assist.)	ting of nerve graft using microsurgical
39315	Fee: \$1,030.20	Benefit: 75% = \$772.65	
	CUTANEOUS N (Anaes.) (Assist.	IERVE (including digital nerve), nerve graft to	o, using microsurgical techniques
39318	Fee: \$639.20	Benefit: 75% = \$479.40	
	NERVE, transpo	sition of (Anaes.) (Assist.)	
39321	Fee: \$473.65	Benefit: 75% = \$355.25	
		US NEUROTOMY by cryotherapy or radiofre another item applies (Anaes.) (Assist.)	equency lesion generator, not being a
39323	Fee: \$276.80	Benefit: 75% = \$207.60 85% = \$235.30	
	NEURECTOMY operation (Anaes	, NEUROTOMY or removal of tumour from (.) (Assist.)	superficial peripheral nerve, by open
39324	(See para TN.8.4 c Fee: \$276.80	f explanatory notes to this Category) Benefit: 75% = \$207.60 85% = \$235.30	

T8. SUF	RGICAL OPERATI	ONS	7. NEUROSURGICAL
			al of tumour from deep peripheral or cranial nerve, by open 41575, 41576, 41578 or 41579 applies (Anaes.) (Assist.)
39327	(See para TN.8.4 o Fee: \$473.75	f explanatory notes to this Cate Benefit: 75% = \$355.35	
		y open operation without tr 2 applies (Anaes.) (Assist.)	ransposition, not being a service associated with a service to
39330	Fee: \$276.80	Benefit: 75% = \$207.60	
	CARPAL TUNN	EL RELEASE (division of	transverse carpal ligament), by any method (Anaes.)
39331	Fee: \$276.80	Benefit: 75% = \$207.60	85% = \$235.30
	BRACHIAL PLE (Anaes.) (Assist.)		being a service to which another item in this Group applies
39333	Fee: \$398.55	Benefit: 75% = \$298.95	85% = \$338.80
		С	RANIAL NERVES
	VESTIBULAR N	NERVE, section of, via post	terior fossa (Anaes.) (Assist.)
39500	Fee: \$1,270.90	Benefit: 75% = \$953.20	
	FACIO-HYPOG	LOSSAL nerve or FACIO-	ACCESSORY nerve, anastomosis of (Anaes.) (Assist.)
39503	Fee: \$955.00	Benefit: 75% = \$716.25	
	CRANIO-CEREBRAL INJURIES		
	INTRACRANIA (Assist.)	L HAEMORRHAGE, burr	-hole craniotomy for - including burr-holes (Anaes.)
39600	Fee: \$473.65	Benefit: 75% = \$355.25	
	INTRACRANIAL HAEMORRHAGE, osteoplastic craniotomy or extensive craniectomy and removal of haematoma (Anaes.) (Assist.)		oplastic craniotomy or extensive craniectomy and removal
39603	Fee: \$1,195.70	Benefit: 75% = \$896.80	
	FRACTURED S	KULL, depressed or comm	inuted, operation for (Anaes.) (Assist.)
39606	Fee: \$797.10	Benefit: 75% = \$597.85	
	+		dural penetration, operation for (Anaes.) (Assist.)
39609	Fee: \$955.00	Benefit: 75% = \$716.25	
	FRACTURED SKULL, compound, depressed or complicated, with dural penetration and brain laceration, operation for (Anaes.) (Assist.)		
39612	Fee: \$1,120.45	Benefit: 75% = \$840.35	
	FRACTURED SI (Anaes.) (Assist.)		otorrhoea, repair of by cranioplasty or endoscopic approach
39615	Fee: \$1,195.70	Benefit: 75% = \$896.80	
	-		ILL BASE SURGERY
39640		DLVING ANTERIOR CRA cull base, and dural repair (A	NIAL FOSSA, removal of, involving craniotomy, radical Anaes.) (Assist.)

T8. SUF	RGICAL OPERATIONS 7. NEUROSURGICAL
	(See para TN.8.70 of explanatory notes to this Category) Fee: \$3,031.65 Benefit: 75% = \$2273.75
	TUMOUR INVOLVING ANTERIOR CRANIAL FOSSA, removal of, involving frontal craniotomy with lateral rhinotomy for clearance of paranasal sinus extension (intracranial procedure) (Anaes.) (Assist.)
39642	(See para TN.8.70 of explanatory notes to this Category) Fee: \$3,187.25 Benefit: 75% = \$2390.45
	TUMOUR INVOLVING ANTERIOR CRANIAL FOSSA, removal of, involving frontal craniotomy with lateral rhinotomy and radical clearance of paranasal sinus and orbital fossa extensions, with intracranial decompression of the optic nerve, (intracranial procedure) (Anaes.) (Assist.)
39646	(See para TN.8.70 of explanatory notes to this Category) Fee: \$3,653.60 Benefit: 75% = \$2740.20
	TUMOUR INVOLVING MIDDLE CRANIAL FOSSA AND INFRA-TEMPORAL FOSSA, removal of, craniotomy and radical or sub-total radical excision, with division and reconstruction of zygomatic arch, (intracranial procedure) (Anaes.) (Assist.)
39650	(See para TN.8.70 of explanatory notes to this Category) Fee: \$2,642.95 Benefit: 75% = \$1982.25
	PETRO-CLIVAL AND CLIVAL TUMOUR, removal of, by supra and infratentorial approaches for radical or sub-total radical excision (intracranial procedure), not being a service to which item 39654 or 39656 applies (Anaes.) (Assist.)
39653	(See para TN.8.70 of explanatory notes to this Category) Fee: \$4,703.15 Benefit: 75% = \$3527.40
	PETRO-CLIVAL AND CLIVAL TUMOUR, removal of, by supra and infratentorial approaches for radical or sub-total radical excision, (intracranial procedure), conjoint surgery, principal surgeon (Anaes.) (Assist.)
39654	(See para TN.8.70 of explanatory notes to this Category) Fee: \$3,420.50 Benefit: 75% = \$2565.40
	PETRO-CLIVAL AND CLIVAL TUMOUR, removal of, by supra and infratentorial approaches for radical or sub-total radical excision, (intracranial procedure) conjoint surgery, co-surgeon (Assist.)
39656	(See para TN.8.70 of explanatory notes to this Category) Fee: \$2,565.30 Benefit: 75% = \$1924.00
	TUMOUR INVOLVING THE CLIVUS, radical or sub-total radical excision of, involving transoral or transmaxillary approach (Anaes.) (Assist.)
39658	(See para TN.8.70 of explanatory notes to this Category) Fee: \$3,031.65 Benefit: 75% = \$2273.75
	TUMOUR OR VASCULAR LESION OF CAVERNOUS SINUS, radical excision of, involving craniotomy with or without intracranial carotid artery exposure (Anaes.) (Assist.)
39660	(See para TN.8.70 of explanatory notes to this Category) Fee: \$3,031.65 Benefit: 75% = \$2273.75
	TUMOUR OR VASCULAR LESION OF FORAMEN MAGNUM, radical excision of, via transcondylar or far lateral suboccipital approach (Anaes.) (Assist.)
39662	(See para TN.8.70 of explanatory notes to this Category) Fee: \$3,031.65 Benefit: 75% = \$2273.75

T8. SUF	RGICAL OPERATI	IONS	7. NEUROSURGICAL
		INTRA-CRAN	IIAL NEOPLASMS
	SKULL TUMOU	JR, benign or malignant, excision	of, excluding cranioplasty (Anaes.) (Assist.)
39700	Fee: \$556.60	Benefit: 75% = \$417.45	
	INTRACRANIA (Anaes.) (Assist.)	•	ue, burr-hole and biopsy of, or drainage of, or both
39703	Fee: \$519.00	Benefit: 75% = \$389.25	
		L tumour, biopsy or decompressif via osteoplastic flap (Anaes.) (A	on of via osteoplastic flap OR biopsy and assist.)
39706	Fee: \$1,112.85	Benefit: 75% = \$834.65	
			c carcinoma or any other tumour in cerebrum, which another item in this Sub-group applies (Anaes.)
39709	Fee: \$1,586.75	Benefit: 75% = \$1190.10	
	intraventricular to		IOMA, pinealoma, cranio-pharyngioma, imour, not being a service to which another item in this
39712	Fee: \$2,865.00	Benefit: 75% = \$2148.75	
	PITUITARY TU	MOUR, removal of, by transcran	ial or transphenoidal approach (Anaes.) (Assist.)
39715	Fee: \$1,985.30	Benefit: 75% = \$1489.00	
	-	L CYST, craniotomy for (Anaes.) (Assist.)
39718	Fee: \$872.30	Benefit: 75% = \$654.25	
	CRANIOTOMY etc (Anaes.) (Ass		re-opening post-operatively for haemorrhage, swelling,
39721	Fee: \$797.10	Benefit: 75% = \$597.85	
		CEREBROVA	SCULAR DISEASE
	ANEURYSM, cl	ipping or reinforcement of sac (A	anaes.) (Assist.)
39800	Fee: \$2,857.55	Benefit: 75% = \$2143.20	
	INTRACRANIA	L ARTERIOVENOUS MALFO	RMATION, excision of (Anaes.) (Assist.)
39803	Fee: \$2,857.55	Benefit: 75% = \$2143.20	
	- i		racranial proximal artery clipping of (Anaes.) (Assist.)
39806	Fee: \$1,285.75	Benefit: 75% = \$964.35	
	· ·		fistula, ligation of cervical vessel or vessels (Anaes.)
39812	Fee: \$631.75	Benefit: 75% = \$473.85	
		ERNOUS FISTULA, obliteration	n of - combined cervical and intracranial procedure
	1		

T8. SUF	RGICAL OPERATI	ONS 7. NEUROSURGIO	CAL		
	EXTRACRANIA	L TO INTRACRANIAL BYPASS using superficial temporal artery (Anaes.) (Ass	ist.)		
39818	Fee: \$1,827.25	Benefit: 75% = \$1370.45			
	EXTRACRANIA	AL TO INTRACRANIAL BYPASS using saphenous vein graft (Anaes.) (Assist.)			
39821	Fee: \$2,169.75	Benefit: 75% = \$1627.35			
		INFECTION			
	INTRACRANIA	L INFECTION, drainage of, via burr-hole - including burr-hole (Anaes.) (Assist.)			
39900	Fee: \$519.00	Benefit: 75% = \$389.25			
	INTRACRANIA	L ABSCESS, excision of (Anaes.) (Assist.)			
39903	Fee: \$1,586.75	Benefit: 75% = \$1190.10			
	OSTEOMYELIT	IS OF SKULL or removal of infected bone flap, craniectomy for (Anaes.) (Assist.)	1		
39906	Fee: \$797.10	Benefit: 75% = \$597.85			
		CEREBROSPINAL FLUID CIRCULATION DISORDERS			
	VENTRICULO-0	CISTERNOSTOMY (Torkildsen's operation) (Anaes.) (Assist.)			
40000	Fee: \$917.40	Benefit: 75% = \$688.05			
	CRANIAL OR C	ISTERNAL SHUNT DIVERSION, insertion of (Anaes.) (Assist.)			
40003	Fee: \$917.40	Benefit: 75% = \$688.05			
	LUMBAR SHUN	VT DIVERSION, insertion of (Anaes.) (Assist.)			
40006	Fee: \$721.95	Benefit: 75% = \$541.50			
	CRANIAL, CIST	ERNAL OR LUMBAR SHUNT, revision or removal of (Anaes.) (Assist.)			
40009	Fee: \$526.40	Benefit: 75% = \$394.80			
	THIRD VENTRI	CULOSTOMY (open or endoscopic) with or without endoscopic septum			
	pellucidotomy (Anaes.) (Assist.)				
40012	Fee: \$1,030.20	Benefit: 75% = \$772.65			
	SUBTEMPORAL	L DECOMPRESSION (Anaes.) (Assist.)			
40015	Fee: \$638.65	Benefit: 75% = \$479.00			
	LUMBAR CERE	BROSPINAL FLUID DRAIN, insertion of (Anaes.)			
40018	Fee: \$159.40	Benefit: 75% = \$119.55 85% = \$135.50			
		CONGENITAL DISORDERS			
	MENINGOCELE	E, excision and closure of (Anaes.) (Assist.)			
40100	Fee: \$691.75	Benefit: 75% = \$518.85			
	MYELOMENINGOCELE, excision and closure of, including skin flaps or Z plasty where performed				
	(Anaes.) (Assist.)				
40103	Fee: \$1,015.25	Benefit: 75% = \$761.45			
	ARNOLD-CHIA	RI MALFORMATION, decompression of (Anaes.) (Assist.)	_		
40106	Fee: \$1,030.20	Benefit: 75% = \$772.65			
	1				

T8. SUF	RGICAL OPERATI	ons	7. NEUROSURGICAL	
	ENCEPHALOCO	DELE, excision and closure of (Anaes.) (Assist.)		
40109	Fee: \$1,112.85	Benefit: 75% = \$834.65		
1010)		RD, release of, including lipomeningocele or diaster	matomyelia (Anaes.) (Assist.)	
40112	Fee: \$1,428.75	Benefit: 75% = \$1071.60		
40112		SIS, operation for - single suture (Anaes.) (Assist.)		
40115	Fee: \$721.95	Benefit: 75% = \$541.50		
40113		SIS, operation for - more than 1 suture (Anaes.) (As	ssist)	
40110			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
40118	Fee: \$955.00	Benefit: 75% = \$716.25 SKULL RECONSTRUCTION		
	CRANIOPLAST	Y, reconstructive (Anaes.) (Assist.)		
40600	Fee: \$955.00	Benefit: 75% = \$716.25		
40000	Pec. \$755.00	EPILEPSY		
	CORPUS CALLO	OSUM, anterior section of, for epilepsy (Anaes.) (As	ssist.)	
40700	Fee: \$1,744.65	Benefit: 75% = \$1308.50		
10700	Vagus nerve stimulation therapy through stimulation of the left vagus nerve, subcutaneous placement of electrical pulse generator, for:			
	(a) management of	of refractory generalised epilepsy; or		
	(b) treatment of re	efractory focal epilepsy not suitable for resective epi	ilepsy surgery (Anaes.) (Assist.)	
40701	Fee: \$340.60	Benefit: 75% = \$255.45		
		ulation therapy through stimulation of the left vagus cal pulse generator inserted for:	s nerve, surgical repositioning or	
	(a) management of	of refractory generalised epilepsy; or		
	(b) treatment of re	efractory focal epilepsy not suitable for resective epi	ilepsy surgery (Anaes.) (Assist.)	
40702	Fee: \$159.40	Benefit: 75% = \$119.55		
	CORTICECTOM	Y, TOPECTOMY or PARTIAL LOBECTOMY for	r epilepsy (Anaes.) (Assist.)	
40703	Fee: \$1,466.30	Benefit: 75% = \$1099.75		
	Vagus nerve stimulation therapy through stimulation of the left vagus nerve, surgical placement of lead, including connection of lead to left vagus nerve and intra-operative test stimulation, for:			
	(a) management of	of refractory generalised epilepsy; or		
	(b) treatment of re	efractory focal epilepsy not suitable for resective epi	ilepsy surgery (Anaes.) (Assist.)	
40704	Fee: \$674.15	Benefit: 75% = \$505.65		
		ulation therapy through stimulation of the left vagus ttached to left vagus nerve for:	s nerve, surgical repositioning or	
40705	(a) management of	of refractory generalised epilepsy; or		

T8. SUF	RGICAL OPERATI	ONS	7. NEUROSURGICAL
	(b) treatment of r	efractory focal epilepsy not suitable for res	sective epilepsy surgery (Anaes.) (Assist.)
	Fee: \$605.35	Benefit: 75% = \$454.05	
		TOMY for intractable epilepsy (Anaes.) (A	Assist.)
40706	Fee: \$2,143.10	Benefit: 75% = \$1607.35 85% = \$2059	•
40700	Vagus nerve stim	ulation therapy through stimulation of the vagus nerve stimulation therapy device usi	left vagus nerve, electrical analysis and
	(a) management of	of refractory generalised epilepsy; or	
	(b) treatment of r	efractory focal epilepsy not suitable for res	sective epilepsy surgery
40707	Fee: \$189.70	Benefit: 75% = \$142.30 85% = \$161.25	5
		ulation therapy through stimulation of the al pulse generator inserted for:	left vagus nerve, surgical replacement of
	(a) management	of refractory generalised epilepsy; or	
	(b) treating refrac	tory focal epilepsy not suitable for resective	ve epilepsy surgery (Anaes.) (Assist.)
40708	Fee: \$340.60	Benefit: 75% = \$255.45	
	BURR-HOLE PI	ACEMENT of intracranial depth or surface	ce electrodes (Anaes.) (Assist.)
40709	Fee: \$519.00	Benefit: 75% = \$389.25	
	INTRACRANIA	L ELECTRODE PLACEMENT via cranic	otomy (Anaes.) (Assist.)
40712	Fee: \$1,045.20	Benefit: 75% = \$783.90	
		STEREOTACTIC PROC	CEDURES
	STEREOTACTION	C ANATOMICAL LOCALISATION, as a	nn independent procedure (Anaes.) (Assist.)
40800	Fee: \$638.65	Benefit: 75% = \$479.00 85% = \$555.25	5
	physiological loc	<u> •</u>	
40801	Fee: \$1,745.80	Benefit: 75% = \$1309.35	
		L STEREOTACTIC PROCEDURE BY A 801 applies (Anaes.) (Assist.)	NY METHOD, not being a service to which
40803	Fee: \$1,195.70	Benefit: 75% = \$896.80 85% = \$1112.3	30
	assisted anatomic	FIMULATION (unilateral) functional stere al localisation, physiological localisation i insertion of electrodes for the treatment of	ncluding twist drill, burr hole craniotomy or
40850		se where the patient's response to medical motor fluctuations; or	therapy is not sustained and is accompanied

T8. SUF	RGICAL OPERATIONS	7. NEUROSURGICAL
	Essential tremor or dystonia where the patient's symptoms cause seve	re disability (Anaes.) (Assist.)
	Fee: \$2,264.45 Benefit: 75% = \$1698.35	
	DEEP BRAIN STIMULATION (bilateral) functional stereotactic pro anatomical localisation, physiological localisation including twist dril craniectomy and insertion of electrodes for the treatment of:	
	Parkinson's disease where the patient's response to medical therapy is by unacceptable motor fluctuations; or	not sustained and is accompanied
	Essential tremor or dystonia where the patient's symptoms cause seve	re disability. (Anaes.) (Assist.)
40851	Fee: \$3,963.00 Benefit: 75% = \$2972.25	
	DEEP BRAIN STIMULATION (unilateral) subcutaneous placement pulse generator for the treatment of:	of neurostimulator receiver or
	Parkinson's disease where the patient's response to medical therapy is by unacceptable motor fluctuations; or	not sustained and is accompanied
	Essential tremor or dystonia where the patient's symptoms cause seve	re disability. (Anaes.) (Assist.)
40852	Fee: \$340.60 Benefit: 75% = \$255.45	
	DEEP BRAIN STIMULATION (unilateral) revision or removal of br	rain electrode for the treatment of:
	Parkinson's disease where the patient's response to medical therapy is by unacceptable motor fluctuations; or	not sustained and is accompanied
	Essential tremor or dystonia where the patient's symptoms cause seve	re disability. (Anaes.)
40854	Fee: \$526.40 Benefit: 75% = \$394.80	
	DEEP BRAIN STIMULATION (unilateral) removal or replacement of generator for the treatment of:	of neurostimulator receiver or pulse
	Parkinson's disease where the patient's response to medical therapy is by unacceptable motor fluctuations; or	not sustained and is accompanied
Essential tremor or dystonia where the patient's symptoms cause severe disability.		re disability. (Anaes.)
40856	Fee: \$255.45 Benefit: 75% = \$191.60	
	DEEP BRAIN STIMULATION (unilateral) placement, removal or re the treatment of:	eplacement of extension lead for
40858	Parkinson's disease where the patient's response to medical therapy is by unacceptable motor fluctuations; or	not sustained and is accompanied

T8. SUF	RGICAL OPERATIONS 7. NEUROSURGIO	CAL		
	Essential tremor or dystonia where the patient's symptoms cause severe disability. (Anaes.)			
	Fee: \$526.40 Benefit: 75% = \$394.80			
	DEEP BRAIN STIMULATION (unilateral) target localisation incorporating anatomical and physiological techniques, including intra-operative clinical evaluation, for the insertion of a single neurostimulation wire for the treatment of:			
	Parkinson's disease where the patient's response to medical therapy is not sustained and is accompaniby unacceptable motor fluctuations; or	ied		
	Essential tremor or dystonia where the patient's symptoms cause severe disability. (Anaes.)			
40860	Fee: \$2,022.70 Benefit: 75% = \$1517.05			
	DEEP BRAIN STIMULATION (unilateral) electronic analysis and programming of neurostimulator pulse generator for the treatment of:			
	Parkinson's disease where the patient's response to medical therapy is not sustained and is accompaniby unacceptable motor fluctuations; or	ied		
	Essential tremor or dystonia where the patient's symptoms cause severe disability. (Anaes.)			
40862	Fee: \$189.70 Benefit: 75% = \$142.30 85% = \$161.25			
	MISCELLANEOUS			
	NEUROENDOSCOPY, for inspection of an intraventricular lesion, with or without biopsy including burr hole (Anaes.) (Assist.)	,		
40903	Fee: \$554.55 Benefit: 75% = \$415.95			
	CRANIOTOMY, performed in association with items 45767, 45776, 45782 and 45785 for the correct of craniofacial abnormalities (Anaes.)	tion		
40905	Fee: \$601.70 Benefit: 75% = \$451.30 85% = \$518.30			
T8. SUF	RGICAL OPERATIONS 8. EAR, NOSE AND THRO	TAC		
	Group T8. Surgical Operations			
	Subgroup 8. Ear, Nose And Throat			
	EAR, foreign body (other than ventilating tube) in, removal of, other than by simple syringing (Anae	s.)		
41500	(See para TN.8.72 of explanatory notes to this Category) Fee: \$82.50 Benefit: 75% = \$61.90 85% = \$70.15			
	EAR, foreign body in, removal of, involving incision of external auditory canal (Anaes.)			
41503	Fee: \$238.80 Benefit: 75% = \$179.10 85% = \$203.00			
	AURAL POLYP, removal of (Anaes.)			
41506	Fee: \$144.00 Benefit: 75% = \$108.00 85% = \$122.40			
41509	EXTERNAL AUDITORY MEATUS, surgical removal of keratosis obturans from, not being a service to which another item in this Group applies (Anaes.)	ce		

T8. SUF	URGICAL OPERATIONS		8. EAR, NOSE AND THROAT	
	Fee: \$162.95	Benefit: 75% = \$122.25	85% = \$138.55	
		Y involving removal of cartil 515 applies (Anaes.) (Assist.)	age or bone or both cartilage and bone, not being a service	
41512	Fee: \$585.90	Benefit: 75% = \$439.45		
			age or bone or both cartilage and bone, being a service 41548, 41557, 41560 or 41563 applies (Anaes.) (Assist.)	
41515	(See para TN.8.73 Fee: \$384.55	of explanatory notes to this Cate Benefit: 75% = \$288.45	egory)	
	EXTERNAL AU	JDITORY MEATUS, remova	al of EXOSTOSES IN (Anaes.) (Assist.)	
41518	Fee: \$928.75	Benefit: 75% = \$696.60		
	Correction of AU (Anaes.) (Assist.		SIS, including meatoplasty, with or without grafting	
41521	Fee: \$988.85	Benefit: 75% = \$741.65		
		TION OF EXTERNAL AUD 1557, 41560 and 41563 apply	TTORY CANAL, being a service associated with a service (Anaes.) (Assist.)	
41524	(See para TN.8.74 Fee: \$285.70	of explanatory notes to this Cate Benefit: 75% = \$214.30	egory)	
	MYRINGOPLA	STY, transcanal approach (Re	osen incision) (Anaes.) (Assist.)	
41527	Fee: \$587.60	Benefit: 75% = \$440.70		
	MYRINGOPLA	STY, postaural or endaural ap	oproach with or without mastoid inspection (Anaes.)	
41530	Fee: \$957.30	Benefit: 75% = \$718.00		
	ATTICOTOMY (Assist.)	without reconstruction of the	bony defect, with or without myringoplasty (Anaes.)	
41533	Fee: \$1,144.30	Benefit: 75% = \$858.25		
	ATTICOTOMY	with reconstruction of the bo	ny defect, with or without myringoplasty (Anaes.) (Assist.)	
41536	Fee: \$1,281.70	Benefit: 75% = \$961.30		
	OSSICULAR CI	HAIN RECONSTRUCTION	(Anaes.) (Assist.)	
41539	Fee: \$1,089.90	Benefit: 75% = \$817.45		
			AND MYRINGOPLASTY (Anaes.) (Assist.)	
41542	Fee: \$1,194.25	Benefit: 75% = \$895.70		
- 1	MASTOIDECTOMY (CORTICAL) (Anaes.) (Assist.)			
41545	Fee: \$521.25	Benefit: 75% = \$390.95		
		N OF THE MASTOID CAV	ITY (Anaes.) (Assist.)	
41548	Fee: \$691.75	Benefit: 75% = \$518.85		
+1348			with myringoplasty (Anaes.) (Assist.)	
41.551		•		
41551	Fee: \$1,593.05	Benefit: 75% = \$1194.80		

T8. SUF	RGICAL OPERATIO	NS	8. EAR, NOSE AND THROAT
	MASTOIDECTON (Anaes.) (Assist.)	MY, intact wall technique, wi	th myringoplasty and ossicular chain reconstruction
41554	Fee: \$1,876.95	Benefit: 75% = \$1407.75	
	MASTOIDECTON	MY (RADICAL OR MODIFI	ED RADICAL) (Anaes.) (Assist.)
41557	Fee: \$1,089.90	Benefit: 75% = \$817.45	
			ED RADICAL) AND MYRINGOPLASTY (Anaes.)
41560	Fee: \$1,194.25	Benefit: 75% = \$895.70	
41300	MASTOIDECTON	***************************************	ED RADICAL), MYRINGOPLASTY AND Anaes.) (Assist.)
41563	Fee: \$1,478.40	Benefit: 75% = \$1108.80	
	CAVITY, BLIND		ED RADICAL), OBLITERATION OF THE MASTOID NAL AUDITORY CANAL AND OBLITERATION
41564	Fee: \$1,911.80	Benefit: 75% = \$1433.85	
	REVISION OF M. (Anaes.) (Assist.)	ASTOIDECTOMY (radical, 1	modified radical or intact wall), including myringoplasty
41566	Fee: \$1,089.90	Benefit: 75% = \$817.45	
	DECOMPRESSIO	N OF FACIAL NERVE in it	s mastoid portion (Anaes.) (Assist.)
41569	Fee: \$1,194.25	Benefit: 75% = \$895.70	
	LABYRINTHOTO	OMY OR DESTRUCTION O	F LABYRINTH (Anaes.) (Assist.)
41572	Fee: \$1,033.20	Benefit: 75% = \$774.90	
	transmastoid, trans		removal of by 2 surgeons operating conjointly, by approach transmastoid, translabyrinthine or retromastoid.)
41575	Fee: \$2,435.70	Benefit: 75% = \$1826.80	
	retromastoid appro		, removal of, by transmastoid, translabyrinthine or including aftercare) not being a service to which item
41576	Fee: \$3,653.60	Benefit: 75% = \$2740.20	
			removal of, by transmastoid, translabyrinthine or - conjoint surgery, principal surgeon (Anaes.) (Assist.)
41578	Fee: \$2,435.70	Benefit: 75% = \$1826.80	
			removal of, by transmastoid, translabyrinthine or - conjoint surgery, co-surgeon (Assist.)
41579	Fee: \$1,826.75	Benefit: 75% = \$1370.10	
	TUMOUR INVOL excision of (Anaes		FOSSA, removal of, involving craniotomy and radical
41581	Fee: \$2,801.55	Benefit: 75% = \$2101.20	

T8. SUF	GICAL OPERATIONS	8. EAR, NOSE AND THROAT		
	PARTIAL TEMPORAL BONE RE without decompression of facial ne	SECTION for removal of tumour involving mastoidectomy with or ve (Anaes.) (Assist.)		
41584	Fee: \$1,922.65 Benefit: 75%	= \$1442.00		
	TOTAL TEMPORAL BONE RES	ECTION for removal of tumour (Anaes.) (Assist.)		
41587	Fee: \$2,618.60 Benefit: 75%	= \$1963.95		
	ENDOLYMPHATIC SAC, TRANS (Anaes.) (Assist.)	SMASTOID DECOMPRESSION with or without drainage of		
41590	Fee: \$1,194.25 Benefit: 75%	= \$895.70		
	TRANSLABYRINTHINE VESTI	BULAR NERVE SECTION (Anaes.) (Assist.)		
41593	Fee: \$1,556.50 Benefit: 75%	= \$1167.40		
	RETROLABYRINTHINE VESTIB BOTH (Anaes.) (Assist.)	BULAR NERVE SECTION or COCHLEAR NERVE SECTION, or		
41596	Fee: \$1,739.50 Benefit: 75%	= \$1304.65		
	INTERNAL AUDITORY MEATU decompression (Anaes.) (Assist.)	S, exploration by middle cranial fossa approach with cranial nerve		
41599	Fee: \$1,739.50 Benefit: 75%	= \$1304.65		
	OSSEO-INTEGRATION PROCEDURE - implantation of titanium fixture for use with implantable bone conduction hearing system device, in patients:			
	- With a permanent or long term	nearing loss; and		
	- Unable to utilise conventional a and	r or bone conduction hearing aid for medical or audiological reasons;		
	- With bone conduction threshold conduction hearing device being in	s that accord to recognised criteria for the implantable bone serted.		
	Not being a service associated with	a service to which items 41554, 45794 or 45797 (Anaes.)		
41603	Fee: \$503.85 Benefit: 75%	= \$377.90 85% = \$428.30		
		PURE - fixation of transcutaneous abutment implantation of titanium the conduction hearing system device, in patients:		
	- With a permanent or long term	nearing loss; and		
	- Unable to utilise conventional air or bone conduction hearing aid for medical or audiological reasons; and			
	- With bone conduction thresholds that accord to recognised criteria for the implantable bone conduction hearing device being inserted.			
	Not being a service associated with	a service to which items 41554, 45794 or 45797 (Anaes.)		
41604	Fee: \$186.50 Benefit: 75%	= \$139.90 85% = \$158.55		
	STAPEDECTOMY (Anaes.) (Assis			
41608	Fee: \$1,089.90 Benefit: 75%	- \$817.45		

T8. SUF	RGICAL OPERATIO	NS	8. EAR, NOSE AND THROAT	
	STAPES MOBILIS	SATION (Anaes.) (Assist	t.)	
41611	Fee: \$701.30	Benefit: 75% = \$526.00		
	ROUND WINDOW	V SURGERY including I	repair of cochleotomy (Anaes.) (Assist.)	
41614	Fee: \$1,089.90	Benefit: 75% = \$817.45	5 85% = \$1006.50	
		SURGERY, including re item in this Group applie	epair of fistula, not being a service associated with a service es (Anaes.) (Assist.)	
41615	Fee: \$1,089.90	Benefit: 75% = \$817.45	5 85% = \$1006.50	
	COCHLEAR IMPI	LANT, insertion of, inclu	ding mastoidectomy (Anaes.) (Assist.)	
41617	Fee: \$1,895.20	Benefit: 75% = \$1421.4	10	
	Middle ear implant	, partially implantable, in	nsertion of, via mastoidectomy, for patients with:	
	(a) stable sensorine	ural hearing loss; and		
	(b) outer ear pathol	ogy that prevents the use	of a conventional hearing aid; and	
	(c) a PTA4 of less t	han 80 dBHL; and		
	(d) bilateral, symmetrical hearing loss with PTA thresholds in both ears within 20 dBHL (0.5-4kHz) of each other; and			
	(e) speech perception discrimination of at least 65% correct for word lists with appropriately amplified sound; and			
	(f) a normal middle ear; and			
	(g) normal tympanometry; and			
	(h) on audiometry, an air-bone gap of less than 10 dBHL (0.5-4kHz) across all frequencies; and			
	(i) no other inner ear disorders			
	(Anaes.) (Assist.)			
41618	Fee: \$1,876.95	Benefit: 75% = \$1407.7	75	
	-	JR, transtympanic remov	val of (Anaes.) (Assist.)	
41620	Fee: \$824.55	Benefit: 75% = \$618.45	5	
		JR, transmastoid remova	al of, including mastoidectomy (Anaes.) (Assist.)	
41623	Fee: \$1,194.25	Benefit: 75% = \$895.70		
	·		DDLE EAR, operation for (excluding aftercare) (Anaes.)	
41626	(See para TN.8.4 of e Fee: \$144.00	xplanatory notes to this Cat Benefit: 75% = \$108.00		
	MIDDLE EAR, EX	XPLORATION OF (Anac	es.) (Assist.)	
41629	Fee: \$521.25	Benefit: 75% = \$390.95	5	
41632	MIDDLE EAR, ins	ertion of tube for DRAIN	NAGE OF (including myringotomy) (Anaes.)	

T8. SUF	RGICAL OPERAT	IONS	8. EAR, NOSE AND THROAT	
	Fee: \$238.80	Benefit: 75% = \$179.	10 85% = \$203.00	
	CLEARANCE C	OF MIDDLE EAR FOR G	GRANULOMA, CHOLESTEATOMA and POLYP, 1 or more,	
	with or without r	myringoplasty (Anaes.) (A	Assist.)	
41635	Fee: \$1,144.30	Benefit: 75% = \$858.2	25 85% = \$1060.90	
			GRANULOMA, CHOLESTEATOMA and POLYP, 1 or more, lar chain reconstruction (Anaes.) (Assist.)	
41638	Fee: \$1,428.35	Benefit: 75% = \$1071	.30	
	PERFORATION	OF TYMPANUM, caute	erisation or diathermy of (Anaes.)	
41641	Fee: \$47.45	Benefit: 75% = \$35.60	0 85% = \$40.35	
	EXCISION OF I myringoplasty (A		RFORATION, not being a service associated with	
41644	Fee: \$142.80	Benefit: 75% = \$107.	10 85% = \$121.40	
		equiring use of operating ral anaesthesia (Anaes.)	nicroscope and microinspection of tympanic membrane with	
41647	Fee: \$109.90	Benefit: 75% = \$82.4	5 85% = \$93.45	
		, <u> </u>	ion of 1 or both ears under general anaesthesia, not being a another item in this Group applies (Anaes.)	
41650	Fee: \$109.90	Benefit: 75% = \$82.4:	5 85% = \$93.45	
	POSTNASAL S		or POSTNASAL SPACE, or NASAL CAVITY AND AL ANAESTHESIA, not being a service associated with a p applies (Anaes.)	
41653	Fee: \$71.95	Benefit: 75% = \$54.00	0 85% = \$61.20	
			R, ARREST OF, with posterior nasal packing with or without pack (excluding aftercare) (Anaes.)	
		of explanatory notes to this C		
41656	Fee: \$122.85	Benefit: 75% = \$92.13		
	NOSE, removal	of FOREIGN BODY IN,	other than by simple probing (Anaes.)	
41659	Fee: \$77.55	Benefit: 75% = \$58.20	0 85% = \$65.95	
	NASAL POLYP	OR POLYPI (SIMPLE),	removal of	
	(See para TN.8.75	of explanatory notes to this	Category)	
41662	Fee: \$82.50	Benefit: 75% = \$61.90		
	NASAL POLYP	OR POLYPI, removal of	f (Anaes.)	
41668	(See para TN.8.75 Fee: \$219.95	of explanatory notes to this Benefit: 75% = \$165.0		
	NASAL SEPTU (Anaes.)	M, SEPTOPLASTY, SUI	BMUCOUS RESECTION or closure of septal perforation	
41671	(See para TN.8.10- Fee: \$483.25	4 of explanatory notes to this Benefit: 75% = \$362.4	- ··	

T8. SUF	RGICAL OPERATI	ONS 8. EAR, NOSE AND THROAT	
	NASAL SEPTU	M, reconstruction of (Anaes.) (Assist.)	
41672	Fee: \$602.85	Benefit: 75% = \$452.15	
	general anaesthes	er than by chemical means) or cauterisation by chemical means when performed under it or diathermy of septum or turbinates—one or more of these procedures (including on the same occasion) other than a service associated with another operation on the	
41674	Fee: \$100.50	Benefit: 75% = \$75.40 85% = \$85.45	
	NASAL HAEMO packing or both (RRHAGE, arrest of during an episode of epistaxis by cauterisation or nasal cavity Anaes.)	
41677	Fee: \$90.00	Benefit: 75% = \$67.50 85% = \$76.50	
		ASAL ADHESIONS, with or without stenting not being a service associated with any a the nose and not performed during the postoperative period of a nasal operation	
41683	Fee: \$117.20	Benefit: 75% = \$87.90 85% = \$99.65	
		OF TURBINATE OR TURBINATES, 1 or both sides, not being a service associated which another item in this Group applies (Anaes.)	
41686	Fee: \$71.95	Benefit: 75% = \$54.00 85% = \$61.20	
	TURBINECTOM	Y or turbinectomies, partial or total, unilateral (Anaes.)	
41689	Fee: \$136.50	Benefit: 75% = \$102.40	
	TURBINATES, s	ubmucous resection of, unilateral (Anaes.)	
41692	Fee: \$178.05	Benefit: 75% = \$133.55	
	MAXILLARY A	NTRUM, PROOF PUNCTURE AND LAVAGE OF (Anaes.)	
41698	Fee: \$32.55	Benefit: 75% = \$24.45 85% = \$27.70	
	MAXILLARY A	NTRUM, proof puncture and lavage of, under general anaesthesia (requiring admission ring a service associated with a service to which another item in this Group applies	
41701	Fee: \$91.90	Benefit: 75% = \$68.95	
	MAXILLARY ANTRUM, LAVAGE OF each attendance at which the procedure is performed, including any associated consultation (Anaes.)		
41704	Fee: \$36.30	Benefit: 75% = \$27.25 85% = \$30.90	
	MAXILLARY A	RTERY, transantral ligation of (Anaes.) (Assist.)	
41707	Fee: \$448.55	Benefit: 75% = \$336.45	
	ANTROSTOMY	(RADICAL) (Anaes.) (Assist.)	
41710	Fee: \$521.25	Benefit: 75% = \$390.95	
		(RADICAL) with transantral ethmoidectomy or transantral vidian neurectomy	
41713	Fee: \$606.50	Benefit: 75% = \$454.90	
11/13	Σ . ψ000.30		

T8. SUF	RGICAL OPERAT	IONS 8. EAR, NOSE AND THROAT
	ANTRUM, intra	nasal operation on, or removal of foreign body from (Anaes.) (Assist.)
41716	Fee: \$295.70	Benefit: 75% = \$221.80
	ANTRUM, drain	age of, through tooth socket (Anaes.)
41719	Fee: \$117.55	Benefit: 75% = \$88.20 85% = \$99.95
		FISTULA, plastic closure of (Anaes.) (Assist.)
41722	Fee: \$587.60	Benefit: 75% = \$440.70 85% = \$504.20
11722		RTERY OR ARTERIES, transorbital ligation of (unilateral) (Anaes.) (Assist.)
41725	Fee: \$448.55	Benefit: 75% = \$336.45
41723		NOTOMY with removal of tumour (Anaes.) (Assist.)
41728	Fee: \$897.30	Benefit: 75% = \$673.00
41/28	***************************************	NOSE, excision of, with intranasal extension (Anaes.) (Assist.)
41720		
41729	Fee: \$568.65	Benefit: 75% = \$426.50 L ETHMOIDECTOMY by external approach with or without sphenoidectomy (Anaes.)
	(Assist.)	E ETTIMOIDE TOWLT by external approach with or without sphenoidectomy (Anaes.)
41731	Fee: \$777.10	Benefit: 75% = \$582.85
	RADICAL FRO	NTOETHMOIDECTOMY with osteoplastic flap (Anaes.) (Assist.)
41734	Fee: \$1,014.05	Benefit: 75% = \$760.55
	-	JS, OR ETHMOIDAL SINUSES ON THE ONE SIDE, intranasal operation on
	(Anaes.) (Assist.)	
41737	Fee: \$483.25	Benefit: 75% = \$362.45
	FRONTAL SINU	JS, catheterisation of (Anaes.)
41740	Fee: \$58.80	Benefit: 75% = \$44.10
	FRONTAL SINU	JS, trephine of (Anaes.) (Assist.)
41743	Fee: \$337.45	Benefit: 75% = \$253.10
	FRONTAL SINU	JS, radical obliteration of (Anaes.) (Assist.)
41746	Fee: \$777.10	Benefit: 75% = \$582.85 85% = \$693.70
	ETHMOIDAL S	INUSES, external operation on (Anaes.) (Assist.)
41749	Fee: \$606.50	Benefit: 75% = \$454.90
	SPHENOIDAL S	SINUS, intranasal operation on (Anaes.) (Assist.)
41752	Fee: \$295.70	Benefit: 75% = \$221.80
		ΓUBE, catheterisation of (Anaes.)
41755	Fee: \$46.50	Benefit: 75% = \$34.90 85% = \$39.55
11/33		PY or SINOSCOPY or FIBREOPTIC EXAMINATION of NASOPHARYNX and
41764		r more of these procedures, unilateral or bilateral examination (Anaes.)
41764		

T8. SUF	RGICAL OPERAT	ONS	8. EAR, NOSE AND THROAT
	Fee: \$122.85	Benefit: 75% = \$92.15	85% = \$104.45
	NASOPHARYN	GEAL ANGIOFIBROMA,	removal of (Anaes.) (Assist.)
41767	Fee: \$737.00	Benefit: 75% = \$552.75	85% = \$653.60
	PHARYNGEAL	POUCH, removal of, with o	or without cricopharyngeal myotomy (Anaes.) (Assist.)
41770	Fee: \$701.30	Benefit: 75% = \$526.00	
11,70			ESECTION OF (Dohlman's operation) (Anaes.) (Assist.)
41773	Fee: \$587.60	Benefit: 75% = \$440.70	•
41//3			or without inversion of pharyngeal pouch (Anaes.) (Assist.)
41776			(abbon)
41776	Fee: \$585.90	Benefit: 75% = \$439.45	at total excision of tongue (Anaes.) (Assist.)
		, , , ,	it total excision of toligue (Aliaes.) (Assist.)
41779	Fee: \$701.30	Benefit: 75% = \$526.00	
	PARTIAL PHAI	RYNGECTOMY via PHAR	YNGOTOMY (Anaes.) (Assist.)
41782	Fee: \$952.10	Benefit: 75% = \$714.10	85% = \$868.70
		RYNGECTOMY via PHAR	YNGOTOMY with partial or total glossectomy (Anaes.)
	(Assist.)		
41785	Fee: \$1,181.15	Benefit: 75% = \$885.90	
	UVULOPALAT (Assist.)	OPHARYNGOPLASTY, w	ith or without tonsillectomy, by any means (Anaes.)
41786	Fee: \$737.00	Benefit: 75% = \$552.75	
		onsillectomy, 1 or more stag	CTOMY WITH LASER INCISION OF THE PALATE, es, including any revision procedures within 12 months
41787	Fee: \$568.65	Benefit: 75% = \$426.50	85% = \$485.25
	examination of the		n a person aged less than 12 years (including any sharynx and the infiltration of local anaesthetic), not being a
	(Anaes.)		
41789	Fee: \$295.70	Benefit: 75% = \$221.80	
	examination of the		n a person 12 years of age or over (including any pharynx and the infiltration of local anaesthetic), not being a
41793	Fee: \$371.50	Benefit: 75% = \$278.65	
		ONSILS AND ADENOIDS, owing removal of (Anaes.)	ARREST OF HAEMORRHAGE requiring general
41797	Fee: \$144.00	Benefit: 75% = \$108.00	
41801		al of (including any examina	ation of the postnasal space and nasopharynx and the

T8. SUF	RGICAL OPERAT	TIONS 8. EAR, NOSE AND THROAT
	infiltration of lo	cal anaesthetic), not being a service to which item 41764 applies (Anaes.)
	Fee: \$162.95	Benefit: 75% = \$122.25
		VSIL OR LATERAL PHARYNGEAL BANDS, removal of (Anaes.)
41004		
41804	Fee: \$90.00	Benefit: 75% = \$67.50 AR ABSCESS (quinsy), incision of (Anaes.)
41807	Fee: \$70.10	Benefit: 75% = \$52.60 85% = \$59.60
	UVULOTOMY	or UVULECTOMY (Anaes.)
41810	Fee: \$35.60	Benefit: 75% = \$26.70 85% = \$30.30
	VALLECULAR	OR PHARYNGEAL CYSTS, removal of (Anaes.) (Assist.)
41813	Fee: \$356.35	Benefit: 75% = \$267.30
	OESOPHAGOS	SCOPY (with rigid oesophagoscope) (Anaes.)
41816	Fee: \$185.60	Benefit: 75% = \$139.20 85% = \$157.80
		SCOPY (with rigid oesophagoscope), with biopsy (Anaes.)
41822	Fee: \$238.80	Benefit: 75% = \$179.10
41022		CCOPY (with rigid oesophagoscope), with removal of foreign body (Anaes.) (Assist.)
41825	Fee: \$356.35	Benefit: 75% = \$267.30
	OESOPHAGEA	AL STRICTURE, dilatation of, without oesophagoscopy (Anaes.)
41828	Fee: \$52.20	Benefit: 75% = \$39.15 85% = \$44.40
	Oesophagus, en	doscopic pneumatic dilatation of, for treatment of achalasia (Anaes.) (Assist.)
41831	Fee: \$357.00	Benefit: 75% = \$267.75 85% = \$303.45
	OESOPHAGUS	s, balloon dilatation of, using interventional imaging techniques (Anaes.)
41832	Fee: \$228.50	Benefit: 75% = \$171.40 85% = \$194.25
		DMY (TOTAL) (Anaes.) (Assist.)
41834	Fee: \$1,289.15	Benefit: 75% = \$966.90
11034		MILARYNGECTOMY including tracheostomy (Anaes.) (Assist.)
41025		
41837	Fee: \$1,236.05	Benefit: 75% = \$927.05 TC LARYNGECTOMY including tracheostomy (Anaes.) (Assist.)
	SUPRAGLOTT	
41840	Fee: \$1,519.80	Benefit: 75% = \$1139.85
		ARYNGECTOMY or PRIMARY RESTORATION OF ALIMENTARY CONTINUITY aryngectomy USING STOMACH OR BOWEL (Anaes.) (Assist.)
41843	Fee: \$1,336.45	Benefit: 75% = \$1002.35
41846		et examination of the supraglottic, glottic and subglottic regions, not being a service any other procedure on the larynx or with the administration of a general anaesthetic

T8. SUF	RGICAL OPERAT	IONS	8. EAR, NOSE AND THROAT
	(See para TN.8.76 Fee: \$185.60	of explanatory notes to this Category) Benefit: 75% = \$139.20 85% = \$157.80	
	MICROLARYN	GOSCOPY (Anaes.) (Assist.)	
41855	Fee: \$288.20	Benefit: 75% = \$216.15	
	MICROLARYN	GOSCOPY with removal of juvenile papillom	ata (Anaes.) (Assist.)
	` *	of explanatory notes to this Category)	
41858	Fee: \$494.15	Benefit: 75% = \$370.65	(1. 1
	(Assist.)	GOSCOPY with removal of benign lesions of	the larynx by laser surgery (Anaes.)
41861	Fee: \$604.30	Benefit: 75% = \$453.25	
	MICROLARYN	GOSCOPY WITH REMOVAL OF TUMOUR	R (Anaes.) (Assist.)
41864	Fee: \$407.50	Benefit: 75% = \$305.65	
	MICROLARYN	GOSCOPY with arytenoidectomy (Anaes.) (A	.ssist.)
41867	Fee: \$613.40	Benefit: 75% = \$460.05	
	LARYNGEAL '	WEB, division of, using microlarygoscopic tech	hniques (Anaes.)
41868	Fee: \$388.70	Benefit: 75% = \$291.55	
		VOCAL CORD BY TEFLON, FAT, COLLA	GEN OR GELFOAM (Anaes.) (Assist.)
41870	Fee: \$454.85	Benefit: 75% = \$341.15	
41070		CTURED, operation for (Anaes.) (Assist.)	
41873	Fee: \$587.60	Benefit: 75% = \$440.70 85% = \$504.20	
410/3		nal operation on, OR LARYNGOFISSURE wi	ith or without cordectomy (Anaes.)
	(Assist.)	op	
41876	Fee: \$587.60	Benefit: 75% = \$440.70 85% = \$504.20	
	LARYNGOPLA	STY or TRACHEOPLASTY, including trache	eostomy (Anaes.) (Assist.)
41879	Fee: \$952.10	Benefit: 75% = \$714.10	
		MY by a percutaneous technique using sequen n of a cuffed tracheostomy tube (Anaes.)	tial dilatation or partial splitting method
41880	Fee: \$254.15	Benefit: 75% = \$190.65	
		MY by open exposure of the trachea, including ayroid isthmus, where performed (Anaes.) (Ass	
41881	Fee: \$401.75	Benefit: 75% = \$301.35	
		STOMY by direct stab or Seldinger technique,	using mini tracheostomy device (Anaes.)
41884	Fee: \$91.05	Benefit: 75% = \$68.30	
<u> </u>	TRACHE-OESO	DPHAGEAL FISTULA, formation of, as a seconcluding associated endoscopic procedures (An	
A1885			, ()
41885	Fee: \$287.90	Benefit: 75% = \$215.95 85% = \$244.75	

T8. SUF	RGICAL OPERAT	ONS 8. EAR, NOSE AND THROAT		
	TRACHEA, rem	oval of foreign body in (Anaes.)		
41886	Fee: \$178.05	Benefit: 75% = \$133.55 85% = \$151.35		
	BRONCHOSCO	PY, as an independent procedure (Anaes.)		
41889	Fee: \$178.05	Benefit: 75% = \$133.55 85% = \$151.35		
	BRONCHOSCO (Anaes.)	PY with 1 or more endobronchial biopsies or other diagnostic or therapeutic procedures		
41892	Fee: \$235.05	Benefit: 75% = \$176.30 85% = \$199.80		
	BRONCHUS, re	moval of foreign body in (Anaes.) (Assist.)		
41895	Fee: \$367.75	Benefit: 75% = \$275.85		
		RONCHOSCOPY with 1 or more transbronchial lung biopsies, with or without choalveolar lavage, with or without the use of interventional imaging (Anaes.) (Assist.)		
41898	Fee: \$256.95	Benefit: 75% = \$192.75 85% = \$218.45		
		ASER RESECTION OF ENDOBRONCHIAL TUMOURS for relief of obstruction ociated endoscopic procedures (Anaes.) (Assist.)		
41901	Fee: \$604.30	Benefit: 75% = \$453.25		
	BRONCHOSCO	PY with dilatation of tracheal stricture (Anaes.)		
41904	Fee: \$246.50	Benefit: 75% = \$184.90 85% = \$209.55		
	TRACHEA OR	BRONCHUS, dilatation of stricture and endoscopic insertion of stent (Anaes.) (Assist.)		
41905	Fee: \$453.35	Benefit: 75% = \$340.05		
	NASAL SEPTU	M BUTTON, insertion of (Anaes.)		
41907	Fee: \$122.85	Benefit: 75% = \$92.15 85% = \$104.45		
	DUCT OF MAJ	OR SALIVARY GLAND, transposition of (Anaes.) (Assist.)		
41910	Fee: \$390.25	Benefit: 75% = \$292.70		
T8. SUF	RGICAL OPERAT	ONS 9. OPHTHALMOLOGY		
	Group T8. Surgical Operations			
		Subgroup 9. Ophthalmology		
		OGICAL EXAMINATION under general anaesthesia, not being a service associated which another item in this Group applies (Anaes.)		
42503	Fee: \$102.50 Benefit: 75% = \$76.90			
	Complete removal from the eye of a trans-trabecular drainage device or devices, with or without replacement, following device related medical complications necessitating complete removal.			
	(Anaes.)			
42505	Fee: \$300.75 Extended Medic	Benefit: 75% = \$225.60 85% = \$255.65 are Safety Net Cap: \$45.15		

T8. SUF	RGICAL OPERATI	ONS	9. OPHTHALMOLOGY
	EYE, ENUCLEA	ATION OF, with or without sphere implant (An	naes.) (Assist.)
42506	Fee: \$481.25	Benefit: 75% = \$360.95 85% = \$409.10	
	EYE, ENUCLEA	ATION OF, with insertion of integrated implan	at (Anaes.) (Assist.)
42509	Fee: \$609.05	Benefit: 75% = \$456.80	
.2003		n of, with insertion of hydroxy apatite implant	or similar coralline implant (Anaes.)
42510	Fee: \$702.05	Benefit: 75% = \$526.55	
	GLOBE, EVISC	ERATION OF (Anaes.) (Assist.)	
42512	Fee: \$481.25	Benefit: 75% = \$360.95 85% = \$409.10	
	GLOBE, EVISC (Anaes.) (Assist.)	ERATION OF, AND INSERTION OF INTRA	ASCLERAL BALL OR CARTILAGE
42515	Fee: \$609.05	Benefit: 75% = \$456.80	
	procedure, or RE	IIC ORBIT, INSERTION OF CARTILAGE C MOVAL OF IMPLANT FROM SOCKET, or PEG by drilling into an existing orbital implan	PLACEMENT OF A MOTILITY
42518	Fee: \$353.35	Benefit: 75% = \$265.05	
		IIC SOCKET, treatment of, by insertion of a was a secondary procedure (Anaes.) (Assist.)	vired-in conformer, integrated implant or
42521	Fee: \$1,203.20	Benefit: 75% = \$902.40	
	ORBIT, SKIN G	RAFT TO, as a delayed procedure (Anaes.)	
42524	Fee: \$204.60	Benefit: 75% = \$153.45 85% = \$173.95	
		SOCKET, RECONSTRUCTION INCLUDIN OULD (Anaes.) (Assist.)	IG MUCOUS MEMBRANE GRAFTING
42527	Fee: \$406.05	Benefit: 75% = \$304.55	
	ORBIT, EXPLO	RATION with or without biopsy, requiring RE	EMOVAL OF BONE (Anaes.) (Assist.)
42530	Fee: \$631.75	Benefit: 75% = \$473.85	
	ORBIT, EXPLO	RATION OF, with drainage or biopsy not requ	uiring removal of bone (Anaes.) (Assist.)
42533	Fee: \$406.05	Benefit: 75% = \$304.55	
	ORBIT, EXENT transplant (Anaes	ERATION OF, with or without skin graft and s.) (Assist.)	with or without temporalis muscle
42536	Fee: \$834.60	Benefit: 75% = \$625.95	
	ORBIT, EXPLO	RATION OF, with removal of tumour or forei	gn body, requiring removal of bone
42539	Fee: \$1,188.20	Benefit: 75% = \$891.15	
	ORBIT, explorat	ion of anterior aspect with removal of tumour	or foreign body (Anaes.) (Assist.)
	Fee: \$503.85	Benefit: 75% = \$377.90	

T8. SUF	RGICAL OPERATION	ONS 9. OPHTHALMOLOGY
	ORBIT, explorati	on of retrobulbar aspect with removal of tumour or foreign body (Anaes.) (Assist.)
42543	Fee: \$883.85	Benefit: 75% = \$662.90
		ession of, for dysthyroid eye disease, by fenestration of 2 or more walls, or by the rbital peribulbar and retrobulbar fat from each quadrant of the orbit, 1 eye (Anaes.)
42545	Fee: \$1,278.35	Benefit: 75% = \$958.80
	OPTIC NERVE N	MENINGES, incision of (Anaes.) (Assist.)
42548	Fee: \$759.40	Benefit: 75% = \$569.55
		TING WOUND OR RUPTURE OF, not involving intraocular structures repair of cornea or sclera, or both, not being a service to which item 42632 applies (Anaes.)
42551	Fee: \$631.75	Benefit: 75% = \$473.85 85% = \$548.35
	EYE, PENETRA repair (Anaes.) (A	TING WOUND OR RUPTURE OF, with incarceration or prolapse of uveal tissue assist.)
42554	Fee: \$737.00	Benefit: 75% = \$552.75
	EYE, PENETRA' (Anaes.) (Assist.)	TING WOUND OR RUPTURE OF, with incarceration of lens or vitreous repair
42557	Fee: \$1,030.20	Benefit: 75% = \$772.65
	INTRAOCULAR	FOREIGN BODY, removal from anterior segment (Anaes.) (Assist.)
42563	Fee: \$519.00	Benefit: 75% = \$389.25 85% = \$441.15
	INTRAOCULAR	FOREIGN BODY, removal from posterior segment (Anaes.) (Assist.)
42569	Fee: \$1,030.20	Benefit: 75% = \$772.65
	ORBITAL ABSO	ESS OR CYST, drainage of (Anaes.)
42572	Fee: \$117.35	Benefit: 75% = \$88.05 85% = \$99.75
	DERMOID, periorbital, excision of, on a person 10 years of age or over (Anaes.)	
42573	Fee: \$227.45	Benefit: 75% = \$170.60 85% = \$193.35
	DERMOID, orbital, excision of (Anaes.) (Assist.)	
42574	Fee: \$483.25	Benefit: 75% = \$362.45 85% = \$410.80
		extirpation of (Anaes.)
42575	Fee: \$82.75	Benefit: 75% = \$62.10 85% = \$70.35
		orbital, excision of, on a person under 10 years of age (Anaes.)
42576	Fee: \$295.70	Benefit: 75% = \$221.80 85% = \$251.35
		ENTROPION, tarsal cauterisation of (Anaes.)
42581	Fee: \$117.35	Benefit: 75% = \$88.05 85% = \$99.75
12331		IY (Anaes.) (Assist.)
42584		

T8. SUR	GICAL OPERAT	IONS	9. OPHTHALMOLOGY	
	Fee: \$276.80	Benefit: 75% = \$207.60 85% = \$235	5.30	
	TRICHIASIS (deach eyelid (Ana		nent of by cryotherapy, laser or electrolysis -	
42587	Fee: \$51.95	Benefit: 75% = \$39.00 85% = \$44.20	0	
	TRICHIASIS (d	ue to trachoma), treatment of by cryother	rapy, laser or electrolysis - each eyelid (Anaes.)	
42588 S	Fee: \$51.95	Benefit: 75% = \$39.00 85% = \$44.2	0	
	CANTHOPLAS	TY, medial or lateral (Anaes.) (Assist.)		
42590	Fee: \$338.35 Extended Medi	Benefit: 75% = \$253.80 85% = \$287 care Safety Net Cap: \$270.70	7.60	
	LACRIMAL GI	AND, excision of palpebral lobe (Anaes	s.)	
42593	Fee: \$204.60	Benefit: 75% = \$153.45		
	LACRIMAL SA	C, excision of, or operation on (Anaes.)	(Assist.)	
42596	Fee: \$503.85	Benefit: 75% = \$377.90 85% = \$428	3.30	
		NALICULAR SYSTEM, establishment 1 eye (Anaes.) (Assist.)	of patency by closed operation using silicone	
42599	Fee: \$631.75	Benefit: 75% = \$473.85 85% = \$548	3.35	
	LACRIMAL CA (Assist.)	NALICULAR SYSTEM, establishment	of patency by open operation, 1 eye (Anaes.)	
42602	Fee: \$631.75	Benefit: 75% = \$473.85 85% = \$548	3.35	
	LACRIMAL CA	NALICULUS, immediate repair of (Ana	aes.) (Assist.)	
42605	Fee: \$466.10	Benefit: 75% = \$349.60 85% = \$396	5.20	
	LACRIMAL DI	RAINAGE by insertion of glass tube, as a	an independent procedure (Anaes.) (Assist.)	
42608	Fee: \$300.75	Benefit: 75% = \$225.60 85% = \$255	5.65	
	NASOLACRIMAL TUBE (unilateral), removal or replacement of, or LACRIMAL PASSAGES, probing for obstruction, unilateral, with or without lavage - under general anaesthesia (Anaes.)			
42610	Fee: \$96.25	Benefit: 75% = \$72.20 85% = \$81.8.	5	
		AL TUBE (bilateral), removal or replace bilateral, with or without lavage - under g	ement of, or LACRIMAL PASSAGES, probing general anaesthesia (Anaes.)	
42611	Fee: \$144.35	Benefit: 75% = \$108.30 85% = \$122	2.70	
	probing to estab	ish patency of the lacrimal passage and/o	cement of, or LACRIMAL PASSAGES, or site of obstruction, unilateral, including hich item 42610 applies (excluding aftercare)	
42614	(See para TN.8.4 Fee: \$48.30	of explanatory notes to this Category) Benefit: 75% = \$36.25 85% = \$41.10	0	
	to establish pate		ement of, or LACRIMAL PASSAGES, probing f obstruction, bilateral, including lavage, not 2611 applies (excluding aftercare)	
42615	Fee: \$72.25	Benefit: 75% = \$54.20 85% = \$61.4	5	

T8. SUF	RGICAL OPERATIO	NS 9. OPHTHALMOLOGY
	PUNCTUM SNIP	operation (Anaes.)
42617	Fee: \$136.95	Benefit: 75% = \$102.75 85% = \$116.45
	PUNCTUM, occlu	sion of, by use of a plug (Anaes.)
42620	Fee: \$52.65	Benefit: 75% = \$39.50 85% = \$44.80
12020		anent occlusion of, by use of electrical cautery (Anaes.)
42622	Fee: \$82.75	Benefit: 75% = \$62.10 85% = \$70.35
42022		RHINOSTOMY (Anaes.) (Assist.)
42623	Fee: \$699.45	Benefit: 75% = \$524.60
42023		RHINOSTOMY where a previous dacryocystorhinostomy has been performed
42626	Fee: \$1,128.05	Benefit: 75% = \$846.05 85% = \$1044.65
	CONJUNCTIVOR (Anaes.) (Assist.)	HINOSTOMY including dacryocystorhinostomy and fashioning of conjunctival flaps
42629	Fee: \$849.70	Benefit: 75% = \$637.30
	CONJUNCTIVAL (Anaes.)	PERITOMY OR REPAIR OF CORNEAL LACERATION by conjunctival flap
42632	Fee: \$117.35	Benefit: 75% = \$88.05 85% = \$99.75
	CORNEAL PERFO	DRATIONS, sealing of, with tissue adhesive (Anaes.) (Assist.)
42635	Fee: \$300.75	Benefit: 75% = \$225.60 85% = \$255.65
	CONJUNCTIVAL	GRAFT OVER CORNEA (Anaes.) (Assist.)
42638	Fee: \$376.00	Benefit: 75% = \$282.00 85% = \$319.60
	AUTOCONJUNC	TIVAL TRANSPLANT, or mucous membrane graft (Anaes.) (Assist.)
42641	Fee: \$488.75	Benefit: 75% = \$366.60 85% = \$415.45
		ERA, complete removal of embedded foreign body from - not more than once on the me practitioner (excluding aftercare) (Anaes.)
42644	(See para TN.8.78, T Fee: \$72.15	N.8.4 of explanatory notes to this Category) Benefit: 75% = \$54.15 85% = \$61.35
	CORNEAL SCAR which item 42686	S, removal of, by partial keratectomy, not being a service associated with a service to applies (Anaes.)
42647	Fee: \$204.60	Benefit: 75% = \$153.45 85% = \$173.95
	CORNEA, epitheli	al debridement for corneal ulcer or corneal erosion (excluding aftercare) (Anaes.)
42650	(See para TN.8.4 of 6 Fee: \$72.15	explanatory notes to this Category) Benefit: $75\% = \$54.15$ $85\% = \$61.35$
	CORNEA, epitheli	al debridement for eliminating band keratopathy (Anaes.)
42651	Fee: \$160.80	Benefit: 75% = \$120.60 85% = \$136.70
42652	Corneal collagen c	ross linking, on a person with a corneal ectatic disorder, with evidence of

	RGICAL OPERATIO	NS 9. OPHTHALMOLOGY			
	progression—per eg	re. (Anaes.)			
	(See para TN.8.136 o Fee: \$1,200.00	Explanatory notes to this Category) Benefit: 75% = \$900.00 85% = \$1116.60			
	CORNEA transplar	tation of (Anaes.) (Assist.)			
42653	Fee: \$1,307.75	Benefit: 75% = \$980.85			
	CORNEA, transpla	ntation of, second and subsequent procedures (Anaes.) (Assist.)			
42656	Fee: \$1,669.45	Benefit: 75% = \$1252.10			
	-	tation of, full thickness, including collection of donor material (Anaes.) (Assist.)			
42662	Fee: \$902.30	Benefit: 75% = \$676.75			
		tation of, superficial or lamellar, including collection of donor material (Anaes.)			
42665	Fee: \$601.65	Benefit: 75% = \$451.25 85% = \$518.25			
		EAL SUTURE, manipulation of, performed within 4 months of corneal grafting, to where a reduction of 2 dioptres of astigmatism is obtained, including any associated			
42667	Fee: \$141.95	Benefit: 75% = \$106.50 85% = \$120.70			
	CORNEAL SUTURES, removal of, not earlier than 6 weeks after operation requiring use of slit lamp or operating microscope (Anaes.)				
42668	Fee: \$75.30	Benefit: 75% = \$56.50 85% = \$64.05			
	CORNEAL INCISONS, to correct corneal astigmatism of more than 1 ^{1/} ₂ dioptres following anterior segment surgery, including appropriate measurements and calculations, performed as an independent procedure (Anaes.) (Assist.)				
	segment surgery, in	cluding appropriate measurements and calculations, performed as an independent			
42672	segment surgery, in procedure (Anaes.)	cluding appropriate measurements and calculations, performed as an independent			
42672	segment surgery, in procedure (Anaes.) (See para TN.8.79 of Fee: \$902.30 ADDITIONAL CO	cluding appropriate measurements and calculations, performed as an independent (Assist.) explanatory notes to this Category) Benefit: 75% = \$676.75 85% = \$818.90 RNEAL INCISIONS, to correct corneal astigmatism of more than 1 \(^{1}/_{2}\) dioptres, the measurements and calculations, performed in conjunction with other anterior			
	segment surgery, in procedure (Anaes.) (See para TN.8.79 of Fee: \$902.30 ADDITIONAL CO including appropria	cluding appropriate measurements and calculations, performed as an independent (Assist.) explanatory notes to this Category) Benefit: 75% = \$676.75 85% = \$818.90 RNEAL INCISIONS, to correct corneal astigmatism of more than 1 \(^{1}/_{2}\) dioptres, the measurements and calculations, performed in conjunction with other anterior			
42672	segment surgery, in procedure (Anaes.) (See para TN.8.79 of Fee: \$902.30 ADDITIONAL CO including appropria segment surgery (A	cluding appropriate measurements and calculations, performed as an independent (Assist.) explanatory notes to this Category) Benefit: 75% = \$676.75 85% = \$818.90 RNEAL INCISIONS, to correct corneal astigmatism of more than 1 ½ dioptres, the measurements and calculations, performed in conjunction with other anterior maes.) (Assist.)			
	segment surgery, in procedure (Anaes.) (See para TN.8.79 of Fee: \$902.30 ADDITIONAL CO including appropria segment surgery (A	cluding appropriate measurements and calculations, performed as an independent (Assist.) explanatory notes to this Category) Benefit: 75% = \$676.75 85% = \$818.90 RNEAL INCISIONS, to correct corneal astigmatism of more than 1 \(^1/2\) dioptres, the measurements and calculations, performed in conjunction with other anterior maes.) (Assist.) Benefit: 75% = \$338.35 85% = \$383.45			
42673	segment surgery, in procedure (Anaes.) (See para TN.8.79 of Fee: \$902.30 ADDITIONAL CO including appropria segment surgery (AFee: \$451.10 CONJUNCTIVA, but Fee: \$115.70 CONJUNCTIVA, conjunctiva, co	cluding appropriate measurements and calculations, performed as an independent (Assist.) explanatory notes to this Category) Benefit: $75\% = \$676.75 85\% = \818.90 RNEAL INCISIONS, to correct corneal astigmatism of more than $1^{1}/_{2}$ dioptres, the measurements and calculations, performed in conjunction with other anterior maes.) (Assist.) Benefit: $75\% = \$338.35 85\% = \383.45 iopsy of, as an independent procedure			
42673	segment surgery, in procedure (Anaes.) (See para TN.8.79 of Fee: \$902.30 ADDITIONAL CO including appropria segment surgery (AFee: \$451.10 CONJUNCTIVA, but Fee: \$115.70 CONJUNCTIVA, conjunctiva, co	cluding appropriate measurements and calculations, performed as an independent (Assist.) explanatory notes to this Category) Benefit: 75% = \$676.75 85% = \$818.90 RNEAL INCISIONS, to correct corneal astigmatism of more than 1 ½ dioptres, the measurements and calculations, performed in conjunction with other anterior maes.) (Assist.) Benefit: 75% = \$338.35 85% = \$383.45 iopsy of, as an independent procedure Benefit: 75% = \$86.80 85% = \$98.35 EAUTERY OF, INCLUDING TREATMENT OF PANNUS each attendance at			
42673 42676	segment surgery, in procedure (Anaes.) (See para TN.8.79 of Fee: \$902.30 ADDITIONAL CO including appropria segment surgery (AFee: \$451.10 CONJUNCTIVA, EFee: \$115.70 CONJUNCTIVA, Which treatment is \$15.70	cluding appropriate measurements and calculations, performed as an independent (Assist.) explanatory notes to this Category) Benefit: 75% = \$676.75 85% = \$818.90 RNEAL INCISIONS, to correct corneal astigmatism of more than 1 ½ dioptres, the measurements and calculations, performed in conjunction with other anterior maes.) (Assist.) Benefit: 75% = \$338.35 85% = \$383.45 iopsy of, as an independent procedure Benefit: 75% = \$86.80 85% = \$98.35 EAUTERY OF, INCLUDING TREATMENT OF PANNUS each attendance at given including any associated consultation (Anaes.)			
42673 42676	segment surgery, in procedure (Anaes.) (See para TN.8.79 of Fee: \$902.30 ADDITIONAL CO including appropria segment surgery (AFee: \$451.10 CONJUNCTIVA, EFee: \$115.70 CONJUNCTIVA, Which treatment is \$15.70	cluding appropriate measurements and calculations, performed as an independent (Assist.) explanatory notes to this Category) Benefit: 75% = \$676.75 85% = \$818.90 RNEAL INCISIONS, to correct corneal astigmatism of more than 1 ½ dioptres, the measurements and calculations, performed in conjunction with other anterior maes.) (Assist.) Benefit: 75% = \$338.35 85% = \$383.45 iopsy of, as an independent procedure Benefit: 75% = \$86.80 85% = \$98.35 EAUTERY OF, INCLUDING TREATMENT OF PANNUS each attendance at given including any associated consultation (Anaes.) Benefit: 75% = \$45.75 85% = \$51.85			
42673 42676 42677	segment surgery, in procedure (Anaes.) (See para TN.8.79 of Fee: \$902.30 ADDITIONAL CO including appropria segment surgery (A Fee: \$451.10 CONJUNCTIVA, to Fee: \$115.70 CONJUNCTIVA, to which treatment is given the second of	cluding appropriate measurements and calculations, performed as an independent (Assist.) explanatory notes to this Category) Benefit: 75% = \$676.75 85% = \$818.90 RNEAL INCISIONS, to correct corneal astigmatism of more than 1 of performed in conjunction with other anterior maes.) (Assist.) Benefit: 75% = \$338.35 85% = \$383.45 iopsy of, as an independent procedure Benefit: 75% = \$86.80 85% = \$98.35 EAUTERY OF, INCLUDING TREATMENT OF PANNUS each attendance at given including any associated consultation (Anaes.) Benefit: 75% = \$45.75 85% = \$51.85 ryotherapy to, for melanotic lesions or similar using CO2 or N20 (Anaes.)			

T8. SUF	RGICAL OPERAT	TONS	9. OPHTHALMOLOGY
	PTERYGIUM, removal of (Anaes.)		
42686	Fee: \$273.65	Benefit: 75% = \$205.25 85% = \$232.65	
	PINGUECULA,	, removal of, not being a service associated with the	e fitting of contact lenses (Anaes.)
42689	Fee: \$117.35	Benefit: 75% = \$88.05 85% = \$99.75	
	LIMBIC TUMOUR, removal of, excluding Pterygium (Anaes.) (Assist.)		
42692	Fee: \$276.80	Benefit: 75% = \$207.60 85% = \$235.30	
	LIMBIC TUMC (Assist.)	OUR, excision of, requiring keratectomy or sclerector	omy, excluding Pterygium (Anaes.)
42695	Fee: \$451.10	Benefit: 75% = \$338.35 85% = \$383.45	
		CTION, excluding surgery performed for the correct creater than 3 dioptres following the removal of cate	
42698	(See para TN.8.80 Fee: \$594.75	of explanatory notes to this Category) Benefit: 75% = \$446.10 85% = \$511.35	
		R LENS, insertion of, excluding surgery performed anisometropia greater than 3 dioptres following th	
42701	(See para TN.8.80 Fee: \$331.70	of explanatory notes to this Category) Benefit: 75% = \$248.80 85% = \$281.95	
	for the correction	CTION AND INSERTION OF INTRAOCULAR LI n of refractive error except for anisometropia greate ract in the first eye (Anaes.)	
42702	Fee: \$760.65 Extended Medi	Benefit: 75% = \$570.50 85% = \$677.25 (care Safety Net Cap: \$114.10	
INTRAOCULAR LENS or IRIS PROSTHESIS insertion of, into the posterior the iris or sclera (Anaes.) (Assist.)			ne posterior chamber with fixation to
42703	Fee: \$572.05	Benefit: 75% = \$429.05 85% = \$488.65	
		R LENS, REMOVAL or REPOSITIONING of by a service to which item 42701 applies (Anaes.)	open operation, not being a service
42704	Fee: \$466.10	Benefit: 75% = \$349.60 85% = \$396.20	
	LENS EXTRACTION AND INSERTION OF INTRAOCULAR LENS, excluding surgery per for the correction of refractive error except for anisometropia greater than 3 dioptres following removal of cataract in the first eye, performed in association with insertion of a trans-trabecula device or devices, in a patient diagnosed with open angle glaucoma who is not adequately resp topical anti-glaucoma medications or who is intolerant of anti-glaucoma medication. (Anaes.)		
42705	Fee: \$911.10 Extended Medi	Benefit: 75% = \$683.35 85% = \$827.70 (care Safety Net Cap: \$136.70	
	performed for th	R LENS, REMOVAL of and REPLACEMENT with the correction of refractive error except for anisometry moval of cataract in the first eye (Anaes.)	
42707	Fee: \$797.10	Benefit: 75% = \$597.85 85% = \$713.70	

T8. SUF	RGICAL OPERATI	ONS	9. OPHTHALMOLOGY	
		LENS, removal of, and replairis or sclera (Anaes.) (Assist	acement with a lens inserted into the posterior chamber	
42710	Fee: \$902.30	Benefit: 75% = \$676.75	85% = \$818.90	
	IRIS SUTURINO (Anaes.) (Assist.)		nilar, for fixation of intraocular lens or repair of iris defect	
42713	Fee: \$376.00	Benefit: 75% = \$282.00	35% = \$319.60	
	CATARACT, JU	VENILE, removal of, includi	ng subsequent needlings (Anaes.) (Assist.)	
42716	Fee: \$1,195.70	Benefit: 75% = \$896.80	35% = \$1112.30	
		sociated with a service to wh	AR or LENS MATERIAL, via a limbal approach, not ich item 42698, 42702, 42716, 42725 or 42731 applies	
42719	Fee: \$519.00	Benefit: 75% = \$389.25	35% = \$441.15	
	Vitrectomy via pa	ars plana sclerotomy, includin	g one or more of the following:	
	(a) removal of vit	reous;		
	(b) division of vit	reous bands;		
	(c) removal of epiretinal membranes;			
	(d) capsulotomy	(Anaes.) (Assist.)		
42725	Fee: \$1,338.45	Benefit: 75% = \$1003.85		
		RS PLANA LENSECTOMY , 42702, 42719, or 42725 (An	combined with vitrectomy, not being a service associated aes.) (Assist.)	
42731	Fee: \$1,519.00	Benefit: 75% = \$1139.25		
		ner than by laser, and other that (Anaes.) (Assist.)	in a service associated with a service to which item 42725	
42734	Fee: \$300.75	Benefit: 75% = \$225.60	35% = \$255.65	
	PARACENTESIS OF ANTERIOR CHAMBER OR VITREOUS CAVITY, or both, for the injection of therapeutic substances, or the removal of aqueous or vitreous humours for diagnostic or therapeutic purposes, 1 or more of, as an independent procedure.			
42738	Fee: \$300.75	of explanatory notes to this Cate Benefit: 75% = \$225.60 8 are Safety Net Cap: \$240.60		
	therapeutic substa	ances, or the removal of aqueo	R OR VITREOUS CAVITY, or both, for the injection of ous or vitreous humours for diagnostic or therapeutic edure, for a patient requiring anaesthetic services.	
40.500	Fee: \$300.75	of explanatory notes to this Cate Benefit: 75% = \$225.60		
42739		are Safety Net Cap: \$240.60	UITIC SUBSTANCES or the removal of vitroous	
	IINIKAVIIKEAI	LINJECTION OF THEKAPE	EUTIC SUBSTANCES, or the removal of vitreous	

T8. SUF	RGICAL OPERATION	ONS	9. OPHTHALMOLOGY	
	(Anaes.)			
	Fee: \$300.75	of explanatory notes to this Category) Benefit: 75% = \$225.60 85% = \$255.6 re Safety Net Cap: \$240.60	65	
		eral depot injection of a therapeutic substant due to age-related macular degeneration	tance, for the treatment of subfoveal choroidal n, 1 or more of (Anaes.)	
42741	(See para TN.8.81 o Fee: \$300.75	f explanatory notes to this Category) Benefit: 75% = \$225.60 85% = \$255.6	65	
	ANTERIOR CHA (Assist.)	MBER, IRRIGATION OF BLOOD FR	OM, as an independent procedure (Anaes.)	
42743	Fee: \$631.75	Benefit: 75% = \$473.85 85% = \$548.3	35	
	Needle revision o	f glaucoma filtration bleb, following glau	ucoma filtering procedure (Anaes.)	
42744	Fee: \$300.55	Benefit: 75% = \$225.45 85% = \$255.5	50	
	GLAUCOMA, fill contraindicated (A		therapies have failed, are likely to fail, or are	
42746	Fee: \$955.00	Benefit: 75% = \$716.25		
	GLAUCOMA, filtering operation for, where previous filtering operation has been performed (Anaes.) (Assist.)			
42749	Fee: \$1,195.70	Benefit: 75% = \$896.80		
	GLAUCOMA, insertion of drainage device incorporating an extraocular reservoir for, such as a Molteno device (Anaes.) (Assist.)			
42752	(See para TN.8.83 c Fee: \$1,338.45	f explanatory notes to this Category) Benefit: 75% = \$1003.85		
	GLAUCOMA, re device (Anaes.)	moval of drainage device incorporating a	an extraocular reservoir for, such as a Molteno	
42755	Fee: \$165.45	Benefit: 75% = \$124.10 85% = \$140.6	65	
		e treatment of primary congenital glaucoraucoma drainage devices (Anaes.) (Assis		
42758	Fee: \$699.45	Benefit: 75% = \$524.60		
	DIVISION OF ANTERIOR OR POSTERIOR SYNECHIAE, as an independent procedure by laser (Anaes.) (Assist.)		AE, as an independent procedure, other than	
42761	Fee: \$519.00	Benefit: 75% = \$389.25 85% = \$441.1	15	
	IRIDECTOMY (including excision of tumour of iris) OR IRIDOTOMY, as an independent procedure, other than by laser (Anaes.) (Assist.)			
42764	Fee: \$519.00	Benefit: 75% = \$389.25 85% = \$441.	15	
	TUMOUR, INVO	LVING CILIARY BODY OR CILIARY	Y BODY AND IRIS, excision of (Anaes.)	
42767	Fee: \$1,090.35	Benefit: 75% = \$817.80		
42770		CTIVE procedures for the treatment of i	ntractable glaucoma, treatment to 1 eye, to a	

T8. SUF	RGICAL OPERATIONS 9. OPHTHALMOLOG
	maximum of 2 treatments to that eye in a 2 year period (Anaes.) (Assist.)
	(See para TN.8.82 of explanatory notes to this Category) Fee: \$294.80 Benefit: 75% = \$221.10 85% = \$250.60
	DETACHED RETINA, pneumatic retinopexy for, not being a service associated with a service to whic item 42776 applies (Anaes.) (Assist.)
42773	Fee: \$902.30 Benefit: 75% = \$676.75 85% = \$818.90
	DETACHED RETINA, buckling or resection operation for (Anaes.) (Assist.)
42776	Fee: \$1,338.45 Benefit: 75% = \$1003.85
	DETACHED RETINA, revision of scleral buckling operation for (Anaes.) (Assist.)
42779	Fee: \$1,669.45 Benefit: 75% = \$1252.10
	LASER TRABECULOPLASTY, for the treatment of glaucoma. Each treatment to 1 eye, to a maximum of 4 treatments to that eye in a 2 year period (Anaes.) (Assist.)
42782	(See para TN.8.84 of explanatory notes to this Category) Fee: \$451.10 Benefit: 75% = \$338.35 85% = \$383.45
	LASER IRIDOTOMY - each treatment episode to 1 eye, to a maximum of 3 treatments to that eye in a year period (Anaes.) (Assist.)
42785	(See para TN.8.85 of explanatory notes to this Category) Fee: \$353.35 Benefit: 75% = \$265.05 85% = \$300.35
	Laser capsulotomy—each treatment episode to one eye, to a maximum of 2 treatments to that eye in a 2 year period—other than a service associated with a service to which item 42702 applies (Anaes.) (Assist.)
42788	(See para TN.8.86 of explanatory notes to this Category) Fee: \$353.35 Benefit: 75% = \$265.05 85% = \$300.35
	Laser vitreolysis or corticolysis of lens material or fibrinolysis, excluding vitreolysis in the posterior vitreous cavity—each treatment to one eye, to a maximum of 3 treatments to that eye in a 2 year period (Anaes.) (Assist.)
42791	(See para TN.8.87 of explanatory notes to this Category) Fee: \$353.35 Benefit: 75% = \$265.05 85% = \$300.35
	DIVISION OF SUTURE BY LASER following glaucoma filtration surgery, each treatment to 1 eye, to a maximum of 2 treatments to that eye in a 2 year period (Anaes.)
42794	(See para TN.8.88 of explanatory notes to this Category) Fee: \$67.65 Benefit: 75% = \$50.75 85% = \$57.55
	EPISCLERAL RADIOACTIVE PLAQUE (Ruthenium 106 or Iodine 125), for the treatment of choroidal melanomas, insertion of (Anaes.) (Assist.)
42801	Fee: \$1,049.70 Benefit: 75% = \$787.30
	EPISCLERAL RADIOACTIVE PLAQUE (Ruthenium 106 or Iodine 125), for the treatment of choroidal melanomas, removal of (Anaes.) (Assist.)
42802	Fee: \$524.70 Benefit: 75% = \$393.55
42805	TANTALUM MARKERS, surgical insertion to the sclera to localise the tumour base to assist in planning of radiotherapy of choroidal melanomas, 1 or more (Anaes.) (Assist.)

18. 501	RGICAL OPERAT	TIONS 9. OPHTHALMOLOGY		
	Fee: \$586.50	Benefit: 75% = \$439.90 85% = \$503.10		
	IRIS TUMOUR	, laser photocoagulation of (Anaes.) (Assist.)		
42806	Fee: \$353.35	Benefit: 75% = \$265.05 85% = \$300.35		
	PHOTOMYDR	IASIS, laser		
42807	Fee: \$355.80	Benefit: 75% = \$266.85 85% = \$302.45		
	Laser peripheral			
42808	Fee: \$355.80	Benefit: 75% = \$266.85 85% = \$302.45		
.2000		coagulation of, not being a service associated with photodynamic therapy with		
42809	Fee: \$451.10	Benefit: 75% = \$338.35 85% = \$383.45		
	PHOTOTHERA for refractive err	PEUTIC KERATECTOMY, by laser, for corneal scarring or disease, excluding surgery for (Anaes.)		
42810	Fee: \$567.70	Benefit: 75% = \$425.80 85% = \$484.30		
	TRANSPUPILL malformations (ARY THERMOTHERAPY, for treatment of choroidal and retinal tumours or vascular Anaes.)		
42811	Fee: \$451.10	Benefit: 75% = \$338.35 85% = \$383.45		
	Removal of scle (Anaes.)	ral buckling material, from an eye having undergone previous scleral buckling surgery		
42812	Fee: \$165.45	Benefit: 75% = \$124.10 85% = \$140.65		
		VITY, removal of silicone oil or other liquid vitreous substitutes from, during a than that in which the vitreous substitute is inserted (Anaes.) (Assist.)		
42815	Fee: \$631.75	Benefit: 75% = \$473.85		
	RETINA, CRYOTHERAPY TO, as an independent procedure, or when performed in conjunction with item 42809 or 42770 (Anaes.)			
42818	Fee: \$586.50	Benefit: 75% = \$439.90 85% = \$503.10		
	OCULAR TRAI (Anaes.)	NSILLUMINATION, for the diagnosis and measurement of intraocular tumours		
42821	Fee: \$90.35	Benefit: 75% = \$67.80 85% = \$76.80		
	RETROBULBA	R INJECTION OF ALCOHOL OR OTHER DRUG, as an independent procedure		
42824	Fee: \$69.90	Benefit: 75% = \$52.45 85% = \$59.45		
	SQUINT, OPERATION FOR, ON 1 OR BOTH EYES, the operation involving a total of 1 OR 2 MUSCLES on a patient aged 15 years or over (Anaes.) (Assist.)			
42833	Fee: \$586.50	Benefit: 75% = \$439.90		
	MUSCLES, on a extra ocular ope	RATION FOR, ON 1 OR BOTH EYES, the operation involving a total of 1 OR 2 a patient aged 14 years or under, or where the patient has had previous squint, retinal or rations on the eye or eyes, or on a patient with concurrent thyroid eye disease (Anaes.)		
	(Assist.)			

T8. SUF	RGICAL OPERATIONS	9. OPHTHALMOLOGY
	SQUINT, OPERATION FOR, ON 1 OR BOTH EYES, the operate MUSCLES on a patient aged 15 years or over (Anaes.) (Assist.)	cion involving a total of 3 OR MORE
42839	Fee: \$699.45 Benefit: 75% = \$524.60	
	SQUINT, OPERATION FOR, ON 1 OR BOTH EYES, the operat MUSCLES, on a patient aged 14 years or under, or where the patiextra ocular operations on the eye or eyes, or on a patient with cor (Assist.)	ent has had previous squint, retinal or
42842	Fee: \$872.30 Benefit: 75% = \$654.25	
	READJUSTMENT OF ADJUSTABLE SUTURES, 1 or both eye following an operation for correction of squint (Anaes.)	s, as an independent procedure
42845	(See para TN.8.89 of explanatory notes to this Category) Fee: \$189.40 Benefit: 75% = \$142.05 85% = \$161.00	
	SQUINT, muscle transplant for (Hummelsheim type, or similar op over (Anaes.) (Assist.)	peration) on a patient aged 15 years or
42848	Fee: \$699.45 Benefit: 75% = \$524.60	
	SQUINT, muscle transplant for (Hummelsheim type, or similar or under, or where the patient has had previous squint, retinal or extra or on a patient with concurrent thyroid eye disease (Anaes.) (Assis	a ocular operations on the eye or eyes,
42851	Fee: \$872.30 Benefit: 75% = \$654.25	
	RUPTURED MEDIAL PALPEBRAL LIGAMENT or ruptured E (Anaes.) (Assist.)	XTRAOCULAR MUSCLE, repair of
42854	Fee: \$406.05 Benefit: 75% = \$304.55 85% = \$345.15	
	RESUTURING OF WOUND FOLLOWING INTRAOCULAR Pexcision of prolapsed iris (Anaes.) (Assist.)	ROCEDURES with or without
42857	Fee: \$406.05 Benefit: 75% = \$304.55 85% = \$345.15	
	EYELID (upper or lower), scleral or Goretex or other non-autogenetractors (Anaes.) (Assist.)	nous graft to, with recession of the lid
42860	Fee: \$902.30 Benefit: 75% = \$676.75 85% = \$818.90	
	EYELID, recession of (Anaes.) (Assist.)	
42863	Fee: \$774.55 Benefit: 75% = \$580.95 85% = \$691.15	
	ENTROPION or TARSAL ECTROPION, repair of, by tightening retractors by open operation across the entire width of the eyelid (
42866	Fee: \$751.85 Benefit: 75% = \$563.90 85% = \$668.45	
	EYELID closure in facial nerve paralysis, insertion of foreign imp	plant for (Anaes.) (Assist.)
42869	Fee: \$549.00 Benefit: 75% = \$411.75 85% = \$466.65	
	EYEBROW, elevation of, by skin excision, to correct for a reduce involutional, or traumatic eyebrow descent/ptosis to a position bel	
42872	Fee: \$240.70 Benefit: 75% = \$180.55 85% = \$204.60	
43021	Photodynamic therapy, one eye, including the infusion of Vertepo	rfin continuously through a peripheral

GICAL OPERAT	ONS	9. OPHTHALMOLOGY
	•	f 689nm, for the treatment of choroidal
Fee: \$455.05	Benefit: 75% = \$341.30 859	% = \$386.80
peripheral vein, u	ising a non-thermal laser at a wa	nfusion of Verteporfin continuously through a velength of 689nm, for the treatment of choroidal
Fee: \$546.15	Benefit: 75% = \$409.65 859	% = \$464.25
		namic therapy, where a session of therapy which would as been discontinued on medical grounds.
Fee: \$88.50	Benefit: 75% = \$66.40 85%	9 = \$75.25
GICAL OPERAT	ONS	10. OPERATIONS FOR OSTEOMYELITIS
Group T8. Surgi	cal Operations	
	Subgroup 10. Op	erations For Osteomyelitis
	,	ACUTE
OPERATION O	N PHALANX (Anaes.)	
Fee: \$123.35	Benefit: 75% = \$92.55	
		B, ULNA, RADIUS, CARPUS, TIBIA, FIBULA, (other than alveolar margins) 1 BONE (Anaes.)
Fee: \$204.70	Benefit: 75% = \$153.55	
OPERATION O	N HUMERUS OR FEMUR 1 B	ONE (Anaes.) (Assist.)
Fee: \$356.35	Benefit: 75% = \$267.30	
OPERATION O	N SPINE OR PELVIC BONES	1 BONE (Anaes.) (Assist.)
Fee: \$356.35	Benefit: 75% = \$267.30	
		HRONIC
CARPUS, PHAI	ANX, TIBIA, FIBULA, META	AVICLE, RIB, ULNA, RADIUS, METACARPUS, TARSUS, TARSUS, MANDIBLE OR MAXILLA COMBINATION OF ADJOINING BONES (Anaes.)
Fee: \$356.35	Benefit: 75% = \$267.30	
OPERATION O	N HUMERUS OR FEMUR 1 B	ONE (Anaes.) (Assist.)
Fee: \$356.35	Benefit: 75% = \$267.30 859	% = \$302.90
OPERATION O	N SPINE OR PELVIC BONES	1 BONE (Anaes.) (Assist.)
Fee: \$587.60	Benefit: 75% = \$440.70	
	, , , , , ,	
		DIOINING BONES being bones referred to in item
	neovascularisation Fee: \$455.05 Photodynamic the peripheral vein, uneovascularisation Fee: \$546.15 Infusion of Vertee have been provided Fee: \$88.50 RGICAL OPERATION OF The search of the searc	Photodynamic therapy, both eyes, including the inperipheral vein, using a non-thermal laser at a walk neovascularisation. Fee: \$546.15 Benefit: 75% = \$409.65 S55 Infusion of Verteporfin for discontinued photody have been provided under item 43021 or 43022 h Fee: \$88.50 Benefit: 75% = \$66.40 S57 BIGICAL OPERATIONS Group T8. Surgical Operations Subgroup 10. Operations Pee: \$123.35 Benefit: 75% = \$92.55 OPERATION ON PHALANX (Anaes.) Fee: \$123.35 Benefit: 75% = \$153.55 OPERATION ON HUMERUS OR FEMUR 1 B Fee: \$356.35 Benefit: 75% = \$267.30 OPERATION ON SCAPULA, STERNUM, CLAVICARPUS, PHALANX, TIBIA, FIBULA, META (other than alveolar margins) 1 BONE or ANY (Assist.) Fee: \$356.35 Benefit: 75% = \$267.30 OPERATION ON HUMERUS OR FEMUR 1 B Fee: \$356.35 Benefit: 75% = \$267.30 OPERATION ON HUMERUS OR FEMUR 1 B Fee: \$356.35 Benefit: 75% = \$267.30 OPERATION ON HUMERUS OR FEMUR 1 B Fee: \$356.35 Benefit: 75% = \$267.30 OPERATION ON HUMERUS OR FEMUR 1 B Fee: \$356.35 Benefit: 75% = \$267.30 OPERATION ON SPINE OR PELVIC BONES Fee: \$356.35 Benefit: 75% = \$267.30 OPERATION ON SPINE OR PELVIC BONES Fee: \$356.35 Benefit: 75% = \$267.30 OPERATION ON SPINE OR PELVIC BONES Fee: \$356.35 Benefit: 75% = \$267.30 OPERATION ON SPINE OR PELVIC BONES Fee: \$356.35 OPERATION ON SPINE OR PELVIC BONES

T8. SUF	RGICAL OPERAT	IONS	10. OPERATIONS FOR OSTEOMYELITIS	
	43515, 43518 or	43521 (Anaes.) (Assist.)		
	Fee: \$587.60	Benefit: 75% = \$440.70 85%	= \$504.20	
T8. SUF	RGICAL OPERAT	IONS	11. PAEDIATRIC	
	Group T8. Surg	ical Operations		
		Subgroup	o 11. Paediatric	
		SURGERY IN NEON	ATE OR YOUNG CHILD	
	INTESTINAL M resection (Anaes		volvulus, laparotomy for, not involving bowel	
43801	Fee: \$957.30	Benefit: 75% = \$718.00		
		MALROTATION with or without who or without formation of stoma (A	volvulus, laparotomy for, with bowel resection and Anaes.) (Assist.)	
43804	Fee: \$1,019.25	Benefit: 75% = \$764.45		
	UMBILICAL, E (Anaes.)	PIGASTRIC OR LINEA ALBA H	IERNIA, repair of, on a person under 10 years of age	
43805	Fee: \$356.35	Benefit: 75% = \$267.30		
	DUODENAL A' (Assist.)	TRESIA or STENOSIS, duodenod	uodenostomy or duodenojejunostomy for (Anaes.)	
43807	Fee: \$1,112.00	Benefit: 75% = \$834.00		
	JEJUNAL ATRI	ESIA, bowel resection and anaston	nosis for, with or without tapering (Anaes.) (Assist.)	
43810	Fee: \$1,297.35	Benefit: 75% = \$973.05		
		EUS, laparotomy for, complicated or without meconium peritonitis (by 1 or more of associated volvulus, atresia, intesinal Anaes.) (Assist.)	
43813	Fee: \$1,297.35	Benefit: 75% = \$973.05		
		A, COLONIC ATRESIA OR MEC	CONIUM ILEUS not being a service associated with for (Anaes.) (Assist.)	
43816	Fee: \$1,204.60	Benefit: 75% = \$903.45		
	Agangliosis Coli (Anaes.) (Assist.		rozen section biopsies and formation of stoma	
43819	Fee: \$972.95	Benefit: 75% = \$729.75		
	ANORECTAL N	MALFORMATION, laparotomy an	nd colostomy for (Anaes.) (Assist.)	
43822	Fee: \$972.95	Benefit: 75% = \$729.75		
	NEONATAL ALIMENTARY OBSTRUCTION, laparotomy for, not being a service to which any other item in this Subgroup applies (Anaes.) (Assist.)			
43825	Fee: \$1,112.00	Benefit: 75% = \$834.00		
43828	ACUTE NEONA	ATAL NECROTISING ENTEROO	COLITIS, laparotomy for, with resection, including	

T8. SUF	RGICAL OPERATION	DNS	11. PAEDIATRIC
	any anastomoses of	or stoma formation (Anaes.) (Assist.)	
	Fee: \$1,228.55	Benefit: 75% = \$921.45	
	ACUTE NEONA laparotomy for (A	TAL NECROTISING ENTEROCOLITIS where no definitive naes.) (Assist.)	procedure is possible,
43831	Fee: \$957.30	Benefit: 75% = \$718.00	
	BRANCHIAL FIS	TULA, on a person under 10 years of age. Removal of, (Ana	es.) (Assist.)
43832	Fee: \$652.95	Benefit: 75% = \$489.75	
	BOWEL RESECT stoma formation (TON for necrotising enterocolitis stricture or strictures, includ Anaes.) (Assist.)	ing any anastomoses or
43834	Fee: \$1,112.00	Benefit: 75% = \$834.00	
		D, INCARCERATED OR OBSTRUCTED HERNIA, repair of son under 10 years of age (Anaes.) (Assist.)	f, without bowel
43835	Fee: \$677.65	Benefit: 75% = \$508.25	
		IAPHRAGMATIC HERNIA, repair by thoracic or abdominal ed in the first 24 hours of life (Anaes.) (Assist.)	approach, with
43837	Fee: \$1,389.90	Benefit: 75% = \$1042.45	
		rnia, congential repair of, by thoracic or abdominal approach, is 31569 to 31581 apply, on a person under 10 years of age (Ar	
43838	Fee: \$1,244.50	Benefit: 75% = \$933.40	
		IAPHRAGMATIC HERNIA, repair by thoracic or abdominal of life and before 20 days of age (Anaes.) (Assist.)	approach, diagnosed
43840	Fee: \$1,204.60	Benefit: 75% = \$903.45	
		NGUINAL HERNIA OR INFANTILE HYDROCELE, repair or 43835 applies, on a person under 10 years of age (Anaes.)	
43841	Fee: \$603.85	Benefit: 75% = \$452.90	
		ATRESIA (with or without repair of tracheo-oesophageal fist being a service to which item 43846 applies (Anaes.) (Assist.)	ula), complete
43843	Fee: \$1,853.35	Benefit: 75% = \$1390.05	
		ATRESIA (with or without repair of tracheo-oesophageal fist fant of birth weight less than 1500 grams (Anaes.) (Assist.)	ula), complete
43846	Fee: \$1,992.30	Benefit: 75% = \$1494.25	
	OESOPHAGEAL	ATRESIA, gastrostomy for (Anaes.) (Assist.)	
43849	Fee: \$509.65	Benefit: 75% = \$382.25	
	OESOPHAGEAL anastomosis (Ana	ATRESIA, thoracotomy for, and division of tracheo-oesophases.) (Assist.)	geal fistula without
43852	Fee: \$1,621.55	Benefit: 75% = \$1216.20	
43855	OESOPHAGEAL	ATRESIA, delayed primary anastomosis for (Anaes.) (Assist.)

T8. SUF	RGICAL OPERATI	ons	11. PAEDIATRIC	
	Fee: \$1,714.35	Benefit: 75% = \$1285.80		
	OESOPHAGEAI	ATRESIA, cervical oesophagostomy for (Anaes.) (Assist.)		
43858	Fee: \$602.25	Benefit: 75% = \$451.70		
		CYSTADENOMATOID MALFORMATION OR CONGEN horacotomy and lung resection for (Anaes.) (Assist.)	ITAL LOBAR	
43861	Fee: \$1,668.05	Benefit: 75% = \$1251.05		
	GASTROSCHIS	(S, operation for (Anaes.) (Assist.)		
43864	Fee: \$1,251.05	Benefit: 75% = \$938.30		
	-	IS or Exomphalos, secondary operation for, with removal of	silo (Anaes.) (Assist.)	
43867	Fee: \$695.00	Benefit: 75% = \$521.25		
.5007		containing small bowel only, operation for (Anaes.) (Assist.)		
43870	Fee: \$972.95	Benefit: 75% = \$729.75		
430/0	-	containing small bowel and other viscera, operation for (Ana	nes) (Assist)	
12.072		•	(* 188181.)	
43873	Fee: \$1,297.35	Benefit: 75% = \$973.05 GEAL TERATOMA, excision of, by posterior approach (Ana	agg) (Aggigt)	
	SACROCOCCY	JEAL TERATOMA, excision of, by posterior approach (An	aes.) (Assist.)	
43876	Fee: \$1,112.00	Benefit: 75% = \$834.00		
	SACROCOCCY (Anaes.) (Assist.)	GEAL TERATOMA, excision of, by combined posterior and	abdominal approach	
43879	Fee: \$1,297.35	Benefit: 75% = \$973.05		
	CLOACAL EXS	TROPHY, operation for (Anaes.) (Assist.)		
43882	Fee: \$1,668.05	Benefit: 75% = \$1251.05 85% = \$1584.65		
		THORACIC SURGERY		
	TRACHEO-OES	OPHAGEAL FISTULA without atresia, division and repair of	of (Anaes.) (Assist.)	
43900	Fee: \$1,112.00	Benefit: 75% = \$834.00		
		ATRESIA or CORROSIVE OESOPHAGEAL STRICTUR atilizing gastric tube, jejunum or colon (Anaes.) (Assist.)	E, oesophageal	
43903	Fee: \$1,853.35	Benefit: 75% = \$1390.05		
		resection of congenital, anastomic or corrosive stricture and tem 43903 applies (Anaes.) (Assist.)	anastomosis, not being a	
43906	Fee: \$1,621.55	Benefit: 75% = \$1216.20		
	TRACHEOMALACIA, aortopexy for (Anaes.) (Assist.)			
43909	Fee: \$1,621.55	Benefit: 75% = \$1216.20		
-		Y and excision of 1 or more of bronchogenic or enterogenou	s cyst or mediastinal	
43912	Fee: \$1,532.00	(ASSISL.) Benefit: 75% = \$1149.00		

T8. SUF	RGICAL OPERATI	ONS 11. PAEDIATRIC			
	EVENTRATION	, plication of diaphragm for (Anaes.) (Assist.)			
43915	Fee: \$1,158.30	Benefit: 75% = \$868.75			
73713	1.00.91,130.30	ABDOMINAL SURGERY			
	HYPERTROPHI	C PYLORIC STENOSIS, pyloromyotomy for (Anaes.) (Assist.)			
43930	Fee: \$445.40	Benefit: 75% = \$334.05			
	IDIOPATHIC IN	TUSSUSCEPTION, laparotomy and manipulative reduction of (Anaes.) (Assist.)			
43933	Fee: \$521.40	Benefit: 75% = \$391.05			
	INTUSSUSCEPT	TION, laparotomy and resection with anastomosis (Anaes.) (Assist.)			
43936	Fee: \$972.95	Benefit: 75% = \$729.75			
	VENTRAL HER (Assist.)	NIA following neonatal closure of exomphalos or gastroschisis, repair of (Anaes.)			
43939	Fee: \$741.30	Benefit: 75% = \$556.00			
	ABDOMINAL W	VALL VITELLO INTESTINAL REMNANT, excision of (Anaes.)			
43942	Fee: \$231.70	Benefit: 75% = \$173.80			
13712		LO INTESTINAL DUCT, excision of (Anaes.) (Assist.)			
43945	Fee: \$972.95	Benefit: 75% = \$729.75			
	UMBILICAL GRANULOMA, excision of, under general anaesthesia (Anaes.)				
43948	Fee: \$139.10	Benefit: 75% = \$104.35			
		PHAGEAL REFLUX with or without hiatus hernia, laparotomy and fundoplication for, my (Anaes.) (Assist.)			
43951	Fee: \$871.30	Benefit: 75% = \$653.50			
		PHAGEAL REFLUX with or without hiatus hernia, laparotomy and fundoplication for, (Anaes.) (Assist.)			
43954	Fee: \$1,065.75	Benefit: 75% = \$799.35			
		PHAGEAL REFLUX, LAPAROTOMY AND FUNDOPLICATION for, with or rnia, in child with neurological disease, with gastrostomy (Anaes.) (Assist.)			
43957	Fee: \$1,158.30	Benefit: 75% = \$868.75			
	ANORECTAL M	MALFORMATION, perineal anoplasty of (Anaes.) (Assist.)			
43960	Fee: \$407.50	Benefit: 75% = \$305.65			
		IALFORMATION, posterior sagittal anorectoplasty of (Anaes.) (Assist.)			
43963	Fee: \$1,621.55	Benefit: 75% = \$1216.20			
+3703		MALFORMATION, posterior sagittal anorectoplasty of, with laparotomy (Anaes.)			
	(Assist.)	TALL OKIVIA FION, posicion saginal anotectopiasty of, with tapatotomy (Alides.)			
43966	Fee: \$1,853.35	Benefit: 75% = \$1390.05			
43969	PERSISTENT CI	LOACA, total correction of, with genital repair using posterior sagittal approach, with			

T8. SUF	RGICAL OPERATION	DNS 11. PAEDIATRIC		
	or without laparot	omy (Anaes.) (Assist.)		
	Fee: \$2,548.35	Benefit: 75% = \$1911.30		
	CHOLEDOCHAI	CYST, resection of, with 1 duct anastomosis (Anaes.) (Assist.)		
43972	Fee: \$1,853.35	Benefit: 75% = \$1390.05		
	-	CYST, resection of, with 2 duct anastomoses (Anaes.) (Assist.)		
43975	Fee: \$2,177.70	Benefit: 75% = \$1633.30		
		SIA, portoenterostomy for (Anaes.) (Assist.)		
43978	Fee: \$1,853.35	Benefit: 75% = \$1390.05		
		OMA, NEUROBLASTOMA OR OTHER MALIGNANT TUMOUR, laparotomy uding associated biopsies, where no other intra-abdominal procedure is performed		
43981	Fee: \$509.65	Benefit: 75% = \$382.25		
	NEPHROBLAST	OMA, radical nephrectomy for (Anaes.) (Assist.)		
43984	Fee: \$1,297.35	Benefit: 75% = \$973.05		
	NEUROBLASTO	MA, radical excision of (Anaes.) (Assist.)		
43987	Fee: \$1,436.40	Benefit: 75% = \$1077.30		
		li, definitive resection with pull-through anastomosis, with or without frozen section anglionic segment extends to sigmoid colon (Anaes.) (Assist.)		
43990	Fee: \$1,760.75	Benefit: 75% = \$1320.60		
		li, definitive resection with pull-through anastomosis, with or without frozen section anglionic segment extends into descending or transverse colon with or without resiting (Assist.)		
43993	Fee: \$1,899.65	Benefit: 75% = \$1424.75		
		li, total colectomy for total colonic aganglionosis with ileoanal pull-through, with or e ileocolic anastomosis (Anaes.) (Assist.)		
43996	Fee: \$2,131.35	Benefit: 75% = \$1598.55		
	Aganglionosis Co	li, anal sphincterotomy as an independent procedure for (Anaes.) (Assist.)		
43999	Fee: \$266.55	Benefit: 75% = \$199.95		
	RECTUM, examination of, on a person under 2 years of age, under general anaesthesia with full thickness biopsy or removal of polyp or similar lesion (Anaes.) (Assist.)			
44101	Fee: \$334.05	Benefit: 75% = \$250.55		
	RECTUM, examination of, on a person 2 years of age or over, under general anaesthesia with full thickness biopsy or removal of polyp or similar lesion (Anaes.) (Assist.)			
44102	Fee: \$256.95	Benefit: 75% = \$192.75		
	RECTAL PROLA under general ana	PSE, SUBMUCOSAL or perirectal injection for, on a person under 2 years of age, esthesia (Anaes.)		
44104	Fee: \$58.65	Benefit: 75% = \$44.00 85% = \$49.90		

T8. SUF	RGICAL OPERATI	ONS	11. PAEDIATRIC
	RECTAL PROLA		perirectal injection for, on a person 2 years of age or over,
44105	Fee: \$45.10	Benefit: 75% = \$33.85	85% = \$38.35
	INGUINAL HER	NIA repair at age less than	12 months (Anaes.) (Assist.)
44108	Fee: \$491.45	Benefit: 75% = \$368.60	
		OR STRANGULATED IN pexy when performed (Ana	GUINAL HERNIA, repair, at age, less than 12 months tes.) (Assist.)
44111	Fee: \$575.65	Benefit: 75% = \$431.75	85% = \$492.25
	INGUINAL HER (Assist.)	NIA repair at age less than	12 months when orchidopexy also required (Anaes.)
44114	Fee: \$575.65	Benefit: 75% = \$431.75	
		MISCEI	LANEOUS SURGERY
	LYMPHADENE (Assist.)	CTOMY, for atypical myco	bacterial infection or other granulomatous disease (Anaes.)
44130	Fee: \$463.30	Benefit: 75% = \$347.50	85% = \$393.85
	TORTICOLLIS,	open division of sternomast	oid muscle for (Anaes.) (Assist.)
44133	Fee: \$367.75	Benefit: 75% = \$275.85	
	INGROWN TOE	NAIL, operation for, under	general anaesthesia (Anaes.)
44136	Fee: \$169.50	Benefit: 75% = \$127.15	85% = \$144.10
T8. SUF	RGICAL OPERATI	ONS	12. AMPUTATIONS
	Group T8. Surgio	cal Operations	
		Sub	group 12. Amputations
	HAND, MIDCAI	RPAL OR TRANSMETAC	ARPAL, amputation of (Anaes.) (Assist.)
44325	Fee: \$295.70	Benefit: 75% = \$221.80	85% = \$251.35
	HAND, FOREA	RM OR THROUGH ARM,	amputation of (Anaes.) (Assist.)
44328	Fee: \$356.35	Benefit: 75% = \$267.30	
	AMPUTATION .	AT SHOULDER (Anaes.) (Assist.)
44331	Fee: \$587.60	Benefit: 75% = \$440.70	
	INTERSCAPULO	OTHORACIC AMPUTATI	ON (Anaes.) (Assist.)
44334	Fee: \$1,194.25	Benefit: 75% = \$895.70	85% = \$1110.85
	-	amputation of (Anaes.)	
44338	Fee: \$144.00	Benefit: 75% = \$108.00	85% = \$122.40
		ot, amputation of (Anaes.)	
44342	Fee: \$219.95	Benefit: 75% = \$165.00	
77374	1 (0. φ417.73	Denema /3/0 - \$103.00	

T8. SUF	RGICAL OPERA	IONS 12. AMPUTATIONS			
	3 DIGITS of 1	oot, amputation of (Anaes.) (Assist.)			
44346	Fee: \$254.00	Benefit: 75% = \$190.50			
	4 DIGITS of 1	oot, amputation of (Anaes.) (Assist.)			
44350	Fee: \$288.20	Benefit: 75% = \$216.15 85% = \$245.00			
	5 DIGITS of 1	oot, amputation of (Anaes.) (Assist.)			
44354	Fee: \$329.80	Benefit: 75% = \$247.35			
	TOE, including	netatarsal or part of metatarsal each toe, amputation of (Anaes.)			
44358	Fee: \$183.90	Benefit: 75% = \$137.95			
		TOES OF ONE FOOT, amputation of, including if performed, excision of 1 or more of the foot, performed for diabetic or other microvascular disease, excluding aftercare			
44359	Fee: \$263.95	Benefit: 75% = \$198.00			
	FOOT AT ANK	LE (Syme, Pirogoff types), amputation of (Anaes.) (Assist.)			
44361	Fee: \$356.35	Benefit: 75% = \$267.30			
	FOOT, MIDTA	RSAL OR TRANSMETATARSAL, amputation of (Anaes.) (Assist.)			
44364	Fee: \$295.70	Benefit: 75% = \$221.80			
	AMPUTATION	THROUGH THIGH, AT KNEE OR BELOW KNEE (Anaes.) (Assist.)			
44367	Fee: \$521.95	Benefit: 75% = \$391.50			
	AMPUTATION	AT HIP (Anaes.) (Assist.)			
44370	Fee: \$720.20	Benefit: 75% = \$540.15			
	HINDQUARTH	R, amputation of (Anaes.) (Assist.)			
44373	Fee: \$1,478.40	Benefit: 75% = \$1108.80 85% = \$1395.00			
	AMPUTATION	STUMP, reamputation of, to provide adequate skin and muscle cover (Assist.)			
44376	Derived Fee: 7	% of the original amputation fee			
T8. SUF	RGICAL OPERA	IONS 13. PLASTIC AND RECONSTRUCTIVE SURGERY			
	Group T8. Surgical Operations				
	Subgroup 13. Plastic And Reconstructive Surgery				
	GENERAL				
	Single stage local muscle flap repair, on eyelid, nose, lip, neck, hand, thumb, finger or genitals association with any of items 31356 to 31376 (Anaes.)				
45000	Fee: \$541.35	Benefit: 75% = \$406.05 85% = \$460.15			
Single stage local myocutaneous flap repair to one defect, simple and small not in of items 31356 to 31376 (Anaes.)		l myocutaneous flap repair to one defect, simple and small not in association with any o 31376 (Anaes.)			
45003	Fee: \$601.65	Benefit: 75% = \$451.25 85% = \$518.25			

T8. SUF	RGICAL OPERATI	ONS '	13. PLASTIC AND RECONSTRUCTIVE SURGERY		
	Extended Medic	are Safety Net Cap: \$481.35			
		LARGE MYOCUTANEOUS arge muscle) (Anaes.) (Assist.)	FLAP REPAIR to 1 defect, (pectoralis major, latissimus		
45006	Fee: \$1,037.65	Benefit: 75% = \$778.25			
	SINGLE STAGE	LOCAL muscle flap repair to	1 defect, simple and small (Anaes.) (Assist.)		
45009	Fee: \$379.05	Benefit: 75% = \$284.30			
		LARGE MUSCLE FLAP RE large muscle) (Anaes.) (Assis	PAIR to 1 defect, (pectoralis major, gastrocnemius, t.)		
45012	Fee: \$635.00	Benefit: 75% = \$476.25			
	MUSCLE OR M	YOCUTANEOUS FLAP, dela	y of (Anaes.)		
45015	Fee: \$300.75	Benefit: 75% = \$225.60			
			sfer of fat by injection), if the service is not associated mentioned in any of items 51011 to 51171 (Anaes.)		
45018	Fee: \$473.65	Benefit: 75% = \$355.25 8.	5% = \$402.65		
	Full face chemica	al peel for severely sun-damage	ed skin, if:		
	(a) the damage affects at least 75% of the facial skin surface area; and				
	(b) the damage involves photo-damage (dermatoheliosis); and				
	(c) the photo-damage involves:				
	(i) a solar k	(i) a solar keratosis load exceeding 30 individual lesions; or			
	(ii) solar ler	(ii) solar lentigines; or			
	(iii) frecklin	(iii) freckling, yellowing or leathering of the skin; or			
	(iv) solar kertoses which have proven refractory to, or recurred following, medical therapies; and				
	(d) at least medium depth peeling agents are used; and				
(e) the chemical peel is performed in the operating theatre of a hospital by a marecognised as a specialist in the specialty of dermatology or plastic surgery.					
	Applicable once	only in any 12 month period (A	Anaes.)		
45019	Fee: \$396.70	Benefit: 75% = \$297.55			
	ABRASIVE THE to 1 aesthetic area		g scarring resulting from trauma, burns or acne - limited		
45021	(See para TN.8.91 (Fee: \$177.35	of explanatory notes to this Categorean Benefit: 75% = \$133.05 8.			
	ABRASIVE THE than 1 aesthetic a		g scarring resulting from trauma, burns or acne - more		
45024	(See para TN.8.91	of explanatory notes to this Categor	ory)		

T8. SUF	RGICAL OPERAT	IONS 13. PLASTIC AND RECONSTRUCTIVE SURGERY		
	Fee: \$398.55	Benefit: 75% = \$298.95 85% = \$338.80		
		AIDE LASER OR ERBIUM LASER (not including fractional laser therapy) resurfacing ck for severely disfiguring scarring resulting from trauma, burns or acne - limited to 1 naes.)		
45025	Fee: \$177.35	of explanatory notes to this Category) Benefit: 75% = \$133.05 85% = \$150.75 care Safety Net Cap: \$141.90		
45025		KIDE LASER OR ERBIUM LASER (not including fractional laser therapy) resurfacing		
		ck for severely disfiguring scarring resulting from trauma, burns or acne - more than 1		
45026	Fee: \$398.55	of explanatory notes to this Category) Benefit: 75% = \$298.95 85% = \$338.80		
45026		care Safety Net Cap: \$318.85		
	(Anaes.)	terisation of or injection into, where undertaken in the operating theatre of a hospital		
45027	Fee: \$120.35	Benefit: 75% = \$90.30 85% = \$102.30		
		emangioma or lymphangioma or both) of skin and subcutaneous tissue (excluding facial) or mucous surface, small, excision and suture of (Anaes.)		
45030	Fee: \$129.25	Benefit: 75% = \$96.95 85% = \$109.90		
		emangioma or lymphangioma or both), large or involving deeper tissue including facial, excision and suture of (Anaes.)		
45033	Fee: \$240.70	Benefit: 75% = \$180.55 85% = \$204.60		
	ANGIOMA (hae excision of (Ana	emangioma or lymphangioma or both), large and deep, involving muscles or nerves, es.) (Assist.)		
45035	Fee: \$702.05	Benefit: 75% = \$526.55		
	ANGIOMA (hae	emangioma or lymphangioma or both) of neck, deep, excision of (Anaes.) (Assist.)		
45036	Fee: \$1,128.05	Benefit: 75% = \$846.05		
	,	OUS MALFORMATION (3 centimetres or less) of superficial tissue, excision of		
45039	Fee: \$240.70	Benefit: 75% = \$180.55 85% = \$204.60		
	ARTERIOVENO	OUS MALFORMATION, (greater than 3 centimetres), excision of (Anaes.) (Assist.)		
45042	Fee: \$308.40	Benefit: 75% = \$231.30 85% = \$262.15		
		OUS MALFORMATION on eyelid, nose, lip, ear, neck, hand, thumb, finger or genitals,		
45045	Fee: \$308.40	Benefit: 75% = \$231.30 85% = \$262.15		
	LYMPHOEDEMATOUS tissue or lymphangiectasis, of lower leg and foot, or thigh, or upper arm, or forearm and hand, major excision of (Anaes.) (Assist.)			
45048	Fee: \$774.55	Benefit: 75% = \$580.95		
45051	Contour reconstr	ruction by open repair of contour defects, due to deformity, if:		
45051				

T8. SUF	RGICAL OPERATIONS 13. PLASTIC AND RECONSTRUCTIVE SURGERY
	(a) contour reconstructive surgery is indicated because the deformity is secondary to congenital absence of tissue or has arisen from trauma (other than trauma from previous cosmetic surgery); and
	(b) insertion of a non-biological implant is required, other than one or more of the following:
	(i) insertion of a non-biological implant that is a component of another service specified in Group T8;
	(ii) injection of liquid or semisolid material;
	(iii) an oral and maxillofacial implant service to which item 52321 applies;
	(iv) a service to insert mesh; and
	(c) photographic and/or diagnostic imaging evidence demonstrating the clinical need for this service is documented in the patient notes (Anaes.) (Assist.)
	Fee: \$473.75 Benefit: 75% = \$355.35
	LIMB OR CHEST, decompression escharotomy of (including all incisions), for acute compartment syndrome secondary to burn (Anaes.) (Assist.)
45054	(See para TN.8.92 of explanatory notes to this Category) Fee: \$246.10 Benefit: 75% = \$184.60
	Developmental breast abnormality, single stage correction of, if:
	(a) the correction involves either:
	(i) bilateral mastopexy for symmetrical tubular breasts; or
	(ii) surgery on both breasts with a combination of insertion of one or more implants (which must have at least a 10% volume difference), mastopexy or reduction mammaplasty, if there is a difference in breast volume, as demonstrated by an appropriate volumetric measurement technique, of at least 20% in normally shaped breasts, or 10% in tubular breasts or in breasts with abnormally high inframammary folds; and
	(b) photographic and/or diagnostic imaging evidence demonstrating the clinical need for this service is documented in the patient notes
	Applicable only once per occasion on which the service is provided (Anaes.) (Assist.)
45060	Fee: \$1,271.30 Benefit: 75% = \$953.50
	Developmental breast abnormality, 2 stage correction of, first stage, involving surgery on both breasts with a combination of insertion of one or more tissue expanders, mastopexy or reduction mammaplasty, if:
	(a) there is a difference in breast volume, as demonstrated by an appropriate volumetric measurement technique, of at least:
	(i) 20% in normally shaped breasts; or
	(ii) 10% in tubular breasts or in breasts with abnormally high inframammary folds; and
15061	(b) photographic and/or diagnostic imaging evidence demonstrating the clinical need for this service is documented in the patient notes.
45061	

T8. SUR	GICAL OPERATIONS	13. PLASTIC AND RECONSTRUCTIVE SURGERY			
	Applicable only once per occasion on	which the service is provided (Anaes.) (Assist.)			
	Fee: \$1,271.30 Benefit: 75% = \$	3953.50			
	with a combination of exchange of on	stage correction of, second stage, involving surgery on both breasts to or more tissue expanders for one or more implants (which must be), mastopexy or reduction mammaplasty, if:			
	(a) there is a difference in breast volume technique, of at least:	me, as demonstrated by an appropriate volumetric measurement			
	(i) 20% in normally shaped brea	ists; or			
	(ii) 10% in tubular breasts or in	breasts with abnormally high inframammary folds; and			
	(b) photographic and/or diagnostic im documented in the patient notes.	aging evidence demonstrating the clinical need for this service is			
	Applicable only once per occasion on	which the service is provided (Anaes.) (Assist.)			
45062	Fee: \$920.00 Benefit: 75% = \$	6690.00			
		SKIN FLAP SURGERY			
45200	31376 (Anaes.) (See para TN.8.93 of explanatory notes to	\$213.30 85% = \$241.70			
13200	Muscle, myocutaneous or skin flap, w removal of a malignant or non-malign	where clinically indicated to repair one surgical excision made in the nant skin lesion (only in association with items 31000, 31001, 31359, 31360, 31363, 31364, 31369, 31370, 31371, 31373 or edefect (Anaes.)			
45201		3310.50 85% = \$351.90			
		where clinically indicated to repair one surgical excision made in the nant skin lesion in a patient, if the clinical relevance of the patient's record and either:			
	(a) item 45201 applies and addition	nal flap repair is required for the same defect; or			
	(b) item 45201 does not apply and of	either:			
	(i) the patient has severe pre-exis	sting scarring, severe skin atrophy or sclerodermoid changes; or			
	(ii) the repair is contiguous with a free margin (Anaes.)				
45202	(See para TN.8.93, TN.8.126 of explanato Fee: \$413.95 Benefit: 75% = \$	ory notes to this Category) 3310.50 85% = \$351.90			
		repair one defect, complicated or large, excluding flap for male or double advancement flap not in association with any of items			
45203	(See para TN.8.93 of explanatory notes to				

T8. SUF	RGICAL OPERAT	IONS 13. PLASTIC AND RECONSTRUCTIVE SURGERY
	Fee: \$406.05 Extended Medi	Benefit: 75% = \$304.55 85% = \$345.15 care Safety Net Cap: \$324.85
		al flap if indicated to repair one defect, on eyelid, nose, lip, ear, neck, hand, thumb, and excluding H-flap or double advancement flap not in association with any of items (Anaes.)
45206	Fee: \$383.55	of explanatory notes to this Category) Benefit: 75% = \$287.70 85% = \$326.05 care Safety Net Cap: \$306.85
		advancement flap if indicated to repair one defect, on eyelid, eyebrow or forehead not th any of items 31356 to 31376 (Anaes.)
45207	Fee: \$383.55	Benefit: 75% = \$287.70 85% = \$326.05
	DIRECT FLAP	REPAIR (cross arm, abdominal or similar), first stage (Anaes.) (Assist.)
45209	Fee: \$473.75	Benefit: 75% = \$355.35 85% = \$402.70
	DIRECT FLAP	REPAIR (cross arm, abdominal or similar), second stage (Anaes.)
45212	Fee: \$235.05	Benefit: 75% = \$176.30 85% = \$199.80
73212	_	REPAIR, cross leg, first stage (Anaes.) (Assist.)
45015		
45215	Fee: \$1,014.05	Benefit: 75% = \$760.55 REPAIR, cross leg, second stage (Anaes.) (Assist.)
45218	Fee: \$454.85	Benefit: 75% = \$341.15
	DIRECT FLAP	REPAIR, small (cross finger or similar), first stage (Anaes.)
45221	Fee: \$261.55	Benefit: 75% = \$196.20 85% = \$222.35
	DIRECT FLAP	REPAIR, small (cross finger or similar), second stage (Anaes.)
45224	Fee: \$117.55	Benefit: 75% = \$88.20 85% = \$99.95
	INDIRECT FLA	P OR TUBED PEDICLE, formation of (Anaes.) (Assist.)
45227	Fee: \$445.40	Benefit: 75% = \$334.05 85% = \$378.60
		DIRECT FLAP OR TUBED PEDICLE, delay of (Anaes.)
45230	Fee: \$222.75	Benefit: 75% = \$167.10 85% = \$189.35
43230	INDIRECT FLAP OR TUBED PEDICLE, preparation of intermediate or final site and attachment to the site (Anaes.) (Assist.)	
45233	Fee: \$473.75	Benefit: 75% = \$355.35 85% = \$402.70
		P OR TUBED PEDICLE, spreading of pedicle, as a separate procedure (Anaes.)
45236	Fee: \$371.50	Benefit: 75% = \$278.65
230	DIRECT, INDIF	RECT OR LOCAL FLAP, revision of, by incision and suture, not being a service to 0 applies (Anaes.)
45239	Fee: \$261.55	Benefit: 75% = \$196.20 85% = \$222.35
45240		RECT OR LOCAL FLAP, revision of, by liposuction, not being a service to which item

T8. SUF	RGICAL OPERAT	IONS	13. PLASTIC AND RECONSTRUCTIVE SURGERY
	45239, 45497, 4	5498 or 45499 applies (Anae	es.)
	Fee: \$261.55	Benefit: 75% = \$196.20	85% = \$222.35
			FREE GRAFTS
	FREE GRAFTI	NG (split skin) of a granulati	ng area, small (Anaes.)
45400	Fee: \$204.70	Benefit: 75% = \$153.55	85% = \$174.00
			ng area, extensive (Anaes.) (Assist.)
45403	Fee: \$407.50	Benefit: 75% = \$305.65	85% = \$346.40
			uding excision of burnt tissue - involving not more than 3
45406	(See para TN.8.94 Fee: \$451.10	of explanatory notes to this Ca Benefit: 75% = \$338.35	
			uding excision of burnt tissue - involving 3 per cent or more
45409	Fee: \$601.65	of explanatory notes to this Ca Benefit: 75% = \$451.25	
		NG (split skin) to burns, inclear cent of total body surface	uding excision of burnt tissue - involving 6 per cent or more (Anaes.) (Assist.)
45412	(See para TN.8.94 Fee: \$827.30	of explanatory notes to this Ca Benefit: 75% = \$620.50	tegory)
		NG (split skin) to burns, incluper cent of total body surface	uding excision of burnt tissue - involving 9 per cent or more e (Anaes.) (Assist.)
45415	(See para TN.8.94 Fee: \$902.30	of explanatory notes to this Ca Benefit: 75% = \$676.75	tegory)
		NG (split skin) to burns, incl an 15 per cent of total body s	uding excision of burnt tissue - involving 12 per cent or surface (Anaes.) (Assist.)
45418	(See para TN.8.94 Fee: \$977.55	of explanatory notes to this Ca Benefit: 75% = \$733.20	tegory)
	FREE GRAFTI	NG (split skin) to 1 defect, in	acluding elective dissection, small (Anaes.)
45439	Fee: \$284.35	Benefit: 75% = \$213.30	85% = \$241.70
	FREE GRAFTII	NG (split skin) to 1 defect, in	ncluding elective dissection, extensive (Anaes.) (Assist.)
45442	Fee: \$586.50	Benefit: 75% = \$439.90	85% = \$503.10
		NG (split skin) as inlay graft ion of, and removal of moule	to 1 defect including elective dissection using a mould d) (Anaes.) (Assist.)
45445	Fee: \$556.60	Benefit: 75% = \$417.45	85% = \$473.20
			ncluding elective dissection on eyelid, nose, lip, ear, neck, ervice to which item 45442 or 45445 applies (Anaes.)
45448	Fee: \$376.00	Benefit: 75% = \$282.00	85% = \$319.60
45451	FREE GRAFTI	NG (full thickness), to 1 defe	ect, excluding grafts for male pattern baldness (Anaes.)

T8. SUF	RGICAL OPERATIONS	13. PLASTIC AND RECONSTRUCTIVE SURGERY
	(Assist.)	
	Fee: \$473.75 Benefit: 75% = \$355.35	85% = \$402.70
	FREE GRAFTING (split skin) to burns, inc more but less than 20 percent of total body	luding excision of burnt tissue - involving 15 percent or surface - one surgeon (Anaes.) (Assist.)
45460	Fee: \$1,253.30 Benefit: 75% = \$940.00	
		luding excision of burnt tissue - involving 15 percent or surface - conjoint surgery, principal surgeon (Anaes.)
45461	Fee: \$893.25 Benefit: 75% = \$669.95	
		luding excision of burnt tissue - involving 15 percent or surface - conjoint surgery, co- surgeon (Assist.)
45462	Fee: \$674.05 Benefit: 75% = \$505.55	
	FREE GRAFTING (split skin) to burns, inc more but less than 30 percent of total body	luding excision of burnt tissue - involving 20 percent or surface - one surgeon (Anaes.) (Assist.)
45464	Fee: \$1,913.10 Benefit: 75% = \$1434.8	5
		luding excision of burnt tissue - involving 20 percent or surface - conjoint surgery, principal surgeon (Anaes.)
45465	Fee: \$1,363.00 Benefit: 75% = \$1022.2	5 85% = \$1279.60
		luding excision of burnt tissue - involving 20 percent or surface - conjoint surgery, co-surgeon (Assist.)
45466	Fee: \$1,027.95 Benefit: 75% = \$771.00	85% = \$944.55
		luding excision of burnt tissue - involving 30 percent or surface - conjoint surgery, principal surgeon (Anaes.)
45468	Fee: \$1,832.65 Benefit: 75% = \$1374.5	0
		luding excision of burnt tissue - involving 30 percent or surface - conjoint surgery, co-surgeon (Assist.)
45469	Fee: \$1,382.70 Benefit: 75% = \$1037.0	5 85% = \$1299.30
	` 1 /	luding excision of burnt tissue - involving 40 percent or surface - conjoint surgery, principal surgeon (Anaes.)
45471	Fee: \$2,303.65 Benefit: 75% = \$1727.7	25 85% = \$2220.25
		luding excision of burnt tissue - involving 40 percent or surface - conjoint surgery, co-surgeon (Assist.)
45472	Fee: \$1,737.60 Benefit: 75% = \$1303.2	0 85% = \$1654.20
		luding excision of burnt tissue - involving 50 percent or surface - conjoint surgery, principal surgeon (Anaes.)
45474		

GICAL OPERATI	ONS	13. PLASTIC AND RECONSTRUCTIVE SURGERY
Fee: \$2,773.30	Benefit: 75% = \$2080.00	85% = \$2689.90
		ding excision of burnt tissue - involving 50 percent or urface - conjoint surgery, co-surgeon (Assist.)
Fee: \$2,092.45	Benefit: 75% = \$1569.35	85% = \$2009.05
		ding excision of burnt tissue - involving 60 percent or urface - conjoint surgery, principal surgeon (Anaes.)
Fee: \$3,243.00	Benefit: 75% = \$2432.25	85% = \$3159.60
		ding excision of burnt tissue - involving 60 percent or urface - conjoint surgery, co-surgeon (Assist.)
Fee: \$2,446.05	Benefit: 75% = \$1834.55	85% = \$2362.65
	` .	ding excision of burnt tissue - involving 70 percent or rface - conjoint surgery, principal surgeon (Anaes.)
Fee: \$3,712.60	Benefit: 75% = \$2784.45	85% = \$3629.20
		ding excision of burnt tissue - involving 70 percent or urface - conjoint surgery, co-surgeon (Assist.)
Fee: \$2,801.10	Benefit: 75% = \$2100.85	85% = \$2717.70
		ding excision of burnt tissue - involving 80 percent or principal surgeon (Anaes.) (Assist.)
Fee: \$4,229.95	Benefit: 75% = \$3172.50	85% = \$4146.55
		ding excision of burnt tissue - involving 80 percent or co-surgeon (Assist.)
Fee: \$3,191.50	Benefit: 75% = \$2393.65	85% = \$3108.10
FREE GRAFTING (split skin) to burns, including excision of burnt tissue - upper eyelid, nose, lip, ear or palm of the hand (Anaes.) (Assist.)		ding excision of burnt tissue - upper eyelid, nose, lip, ear
Fee: \$527.70	Benefit: 75% = \$395.80	
		ding excision of burnt tissue - forehead, cheek, anterior foot, heel or genitalia (Anaes.) (Assist.)
Fee: \$451.10	Benefit: 75% = \$338.35	
FREE GRAFTIN (Assist.)	G (split skin) to burns, inclu	ding excision of burnt tissue - whole of toe (Anaes.)
Fee: \$406.05	Benefit: 75% = \$304.55	85% = \$345.15
		ding excision of burnt tissue - the whole of 1 digit of the
Fee: \$451.10	Benefit: 75% = \$338.35	
		ding excision of burnt tissue - the whole of 2 digits of the
i i		
	Fee: \$2,773.30 FREE GRAFTIN more but less that (Assist.) Fee: \$3,243.00 FREE GRAFTIN more but less that (Assist.) Fee: \$3,2446.05 FREE GRAFTIN more but less that (Assist.) Fee: \$2,446.05 FREE GRAFTIN more but less that (Assist.) Fee: \$3,712.60 FREE GRAFTIN more but less that (Assist.) Fee: \$2,801.10 FREE GRAFTIN more of total bod Fee: \$4,229.95 FREE GRAFTIN more of total bod Fee: \$3,191.50 FREE GRAFTIN more of total bod Fee: \$3,191.50 FREE GRAFTIN more of total bod Fee: \$4,229.95 FREE GRAFTING (split skin) to burns, inclumore but less than 60 percent of total body surface systems of the systems of the surface of total body surface - conjoint surgery, Fee: \$4,229.95 FREE GRAFTING (split skin) to burns, inclumore but less than 70 percent of total body surface - conjoint surgery, Fee: \$3,712.60 Benefit: 75% = \$2784.45 FREE GRAFTING (split skin) to burns, inclumore but less than 80 percent of total body surface - conjoint surgery, Fee: \$4,229.95 FREE GRAFTING (split skin) to burns, inclumore of total body surface - conjoint surgery, Fee: \$3,191.50 Benefit: 75% = \$3172.50 FREE GRAFTING (split skin) to burns, inclumore of total body surface - conjoint surgery, Fee: \$3,191.50 Benefit: 75% = \$3395.80 FREE GRAFTING (split skin) to burns, inclumore of total body surface - conjoint surgery, Fee: \$4,229.95 FREE GRAFTING (split skin) to burns, inclumore of total body surface - conjoint surgery, Fee: \$4,229.95 FREE GRAFTING (split skin) to burns, inclumore of total body surface - conjoint surgery, Fee: \$4,210.00 FREE GRAFTING (split skin) to burns, inclumore palm of the hand (Anaes.) (Assist.) Fee: \$451.10 Benefit: 75% = \$338.35 FREE GRAFTING (split skin) to burns, inclumore contains the part of the neck, chin, plantar aspect of the neck, chin, plantar	

SURGI	CAL OPERATIO	NS 13. PLASTIC AND RECONSTRUCTIVE SURGERY
	FREE GRAFTING hand (Anaes.) (Ass	(split skin) to burns, including excision of burnt tissue - the whole of 3 digits of the ist.)
0 1	Fee: \$902.50	Benefit: 75% = \$676.90
	FREE GRAFTING (split skin) to burns, including excision of burnt tissue - the whole of 4 digits of the hand (Anaes.) (Assist.)	
1 1	Fee: \$1,128.05	Benefit: 75% = \$846.05
	FREE GRAFTING nand (Anaes.) (Ass	(split skin) to burns, including excision of burnt tissue - the whole of 5 digits of the ist.)
2 1	Fee: \$1,353.60 Benefit: 75% = \$1015.20	
	FREE GRAFTING (Anaes.) (Assist.)	(split skin) to burns, including excision of burnt tissue - portion of digit of hand
3 1	Fee: \$406.05	Benefit: 75% = \$304.55
	FREE GRAFTING ears) (Anaes.) (Ass	(split skin) to burns, including excision of burnt tissue - whole of face (excluding ist.)
4 1	Fee: \$1,638.70	Benefit: 75% = \$1229.05 85% = \$1555.30
		OTHER GRAFTS AND MISCELLANEOUS PROCEDURES
I	FLAP, free tissue t	ransfer using microvascular techniques - revision of, by open operation (Anaes.)
6 1	Fee: \$416.05	Benefit: 75% = \$312.05
	FLAP, free tissue transfer using microvascular techniques, <i>or</i> any autogenous breast reconstruction - <i>complete revision of</i> , by liposuction (Anaes.)	
7 1	Fee: \$324.95	Benefit: 75% = \$243.75
		ransfer using microvascular techniques, <i>or</i> any autogenous breast reconstruction - by liposuction - first stage (Anaes.)
8 Fee: \$261.55 Benefit: 75% = \$196.20		Benefit: 75% = \$196.20
	FLAP, free tissue transfer using microvascular techniques, <i>or</i> any autogenous breast reconstruction - <i>staged revision of</i> , by liposuction - second stage (Anaes.)	
9 Fee: \$195.00 Benefit: 75% = \$146.25		Benefit: 75% = \$146.25
	MICROVASCULAR REPAIR using microsurgical techniques, with restoration of continuity of artery or vein of distal extremity or digit (Anaes.) (Assist.)	
45500 Fee: \$1,090.35 Benefit: 75% = \$817.80 MICROVASCULAR ANASTOMOSIS of artery using microsurgical techniques, for relimb or digit (Anaes.) (Assist.)		Benefit: 75% = \$817.80
45501 Fee: \$1,774.70 Benefit: 75% = \$1331.05		Benefit: 75% = \$1331.05
		AR ANASTOMOSIS of vein using microsurgical techniques, for re-implantation of
1	limb or digit (Anae	s.) (Assist.)
2 1	Fee: \$1,774.70	Benefit: 75% = \$1331.05
1	MICRO-ARTERIA	AL OR MICRO-VENOUS GRAFT using microsurgical techniques (Anaes.) (Assist.)
3	Fee: \$2,030.35	Benefit: 75% = \$1522.80
1	MICRO-ARTERIAL OR MICRO-VENOUS GRAFT using microsurgical techniques (Anaes.) (A	

T8. SUF	RGICAL OPERATIONS 13. PLASTIC AND RECONSTRUCTIVE SURGERY		
	MICROVASCULAR ANASTOMOSIS of artery using microsurgical techniques, for free transfer of tissue including setting in of free flap (Anaes.) (Assist.)		
45504	Fee: \$1,774.70 Benefit: 75% = \$1331.05		
	MICROVASCULAR ANASTOMOSIS of vein using microsurgical techniques, for free transfer of tissue including setting in of free flap (Anaes.) (Assist.)		
45505	Fee: \$1,774.70 Benefit: 75% = \$1331.05		
	SCAR, of face or neck, not more than 3 cm in length, revision of, where undertaken in the operating theatre of a hospital, or where performed by a specialist in the practice of his or her specialty (Anaes.)		
45506	(See para TN.8.95 of explanatory notes to this Category) Fee: \$219.95 Benefit: 75% = \$165.00 85% = \$187.00		
	SCAR, of face or neck, more than 3 cm in length, revision of, where undertaken in the operating theatre of a hospital, or where performed by a specialist in the practice of his or her specialty (Anaes.)		
45512	(See para TN.8.95 of explanatory notes to this Category) Fee: \$295.70 Benefit: 75% = \$221.80 85% = \$251.35		
	SCAR, other than on face or neck, not more than 7 cms in length, revision of, as an independent procedure, where undertaken in the operating theatre of a hospital or where performed by a specialist in the practice of his or her specialty (Anaes.)		
45515	(See para TN.8.95 of explanatory notes to this Category) Fee: \$186.50 Benefit: 75% = \$139.90 85% = \$158.55		
	SCAR, other than on face or neck, more than 7 cms in length, revision of, as an independent procedure, where undertaken in the operating theatre of a hospital, or where performed by a specialist in the practice of his or her speciality (Anaes.)		
45518	(See para TN.8.95 of explanatory notes to this Category) Fee: \$225.70 Benefit: 75% = \$169.30 85% = \$191.85		
	EXTENSIVE BURN SCARS OF SKIN (more than 1 percent of body surface area), excision of, for correction of scar contracture (Anaes.) (Assist.)		
45519	Fee: \$429.05 Benefit: 75% = \$321.80		
	Reduction mammaplasty (unilateral) with surgical repositioning of nipple, in the context of breast cancer or developmental abnormality of the breast (Anaes.) (Assist.)		
45520	Fee: \$900.45 Benefit: 75% = \$675.35		
	Reduction mammaplasty (unilateral) without surgical repositioning of the nipple:		
	(a) excluding the treatment of gynaecomastia; and		
	(b) not with insertion of any prosthesis (Anaes.) (Assist.)		
45522	Fee: \$631.75 Benefit: 75% = \$473.85		
	Reduction mammaplasty (bilateral) with surgical repositioning of the nipple:		
	(a) for patients with macromastia and experiencing pain in the neck or shoulder region; and		
	(b) not with insertion of any prosthesis (Anaes.) (Assist.)		
45523	Fee: \$1,350.70 Benefit: 75% = \$1013.05		

T8. SUR	GICAL OPERATIONS	13. PLASTIC AND RECONSTRUCTIVE SURGERY	
	Mammaplasty, augmentation (unilateral) in t	he context of:	
	(a) breast cancer; or		
	(b) developmental abnormality of the breast, an appropriate volumetric measurement technique.	if there is a difference in breast volume, as demonstrated by nique, of at least:	
	(i) 20% in normally shaped breasts; or	y shaped breasts; or	
	(ii) 10% in tubular breasts or in breasts	breasts or in breasts with abnormally high inframammary folds.	
	Applicable only once per occasion on which	the service is provided (Anaes.) (Assist.)	
45524	(See para TN.8.96 of explanatory notes to this Cat Fee: \$741.65 Benefit: 75% = \$556.25	egory)	
	Breast reconstruction (unilateral), following	mastectomy, using a permanent prosthesis (Anaes.) (Assist.)	
45527	(See para TN.8.96 of explanatory notes to this Cat Fee: \$741.65 Benefit: 75% = \$556.25	regory)	
		than a service to which item 45527 applies), if:	
	(a) reconstructive surgery is indicated because	e of:	
	(i) developmental malformation of brea	st tissue (excluding hypomastia); or	
	(ii) disease of or trauma to the breast (o surgery); or	ther than trauma resulting from previous elective cosmetic	
	(iii) amastia secondary to a congenital e	endocrine disorder; and	
	(b) photographic and/or diagnostic imaging evidence demonstrating the clinical need for this servi documented in the patient notes (Anaes.) (Assist.)		
45528	(See para TN.8.96 of explanatory notes to this Category) Fee: \$1,112.35 Benefit: 75% = \$834.30		
	Breast reconstruction (unilateral), using a latissimus dorsi or other large muscle or myocutaneous flap including repair of secondary skin defect, if required, excluding repair of muscular aponeurotic layer, other than a service associated with a service to which item 30165, 30168, 30171, 30172, 30176, 3017 or 30179 applies		
	(H) (Anaes.) (Assist.)		
45530	(See para TN.8.97 of explanatory notes to this Category) Fee: \$1,099.40 Benefit: 75% = \$824.55		
	BREAST RECONSTRUCTION using breast sharing technique (first stage) including breast reduction, transfer of complex skin and breast tissue flap, split skin graft to pedicle of flap or other similar procedure (Anaes.) (Assist.)		
45533	(See para TN.8.8 of explanatory notes to this Category) Fee: \$1,245.10 Benefit: 75% = \$933.85		
		sharing technique (second stage) including division of of donor site or other similar procedure (Anaes.) (Assist.)	
45536	Fee: \$457.85 Benefit: 75% = \$343.40		

T8. SUF	RGICAL OPERATIONS 13. PLASTIC AND RECONSTRUCTIVE SURGERY	
	BREAST RECONSTRUCTION (unilateral), following mastectomy, using tissue expansion - insertion of tissue expansion unit and all attendances for subsequent expansion injections (Anaes.) (Assist.)	
45539	Fee: \$1,071.20 Benefit: 75% = \$803.40	
	BREAST RECONSTRUCTION (unilateral), following mastectomy, using tissue expansion - removal of tissue expansion unit and insertion of permanent prosthesis (Anaes.) (Assist.)	
45542	Fee: \$613.40 Benefit: 75% = \$460.05	
	NIPPLE OR AREOLA or both, reconstruction of, by any surgical technique (Anaes.) (Assist.)	
45545	(See para TN.8.100 of explanatory notes to this Category) Fee: \$622.55 Benefit: 75% = \$466.95 85 % = \$539.15 Extended Medicare Safety Net Cap: \$498.05	
43343	NIPPLE OR AREOLA or both, intradermal colouration of, following breast reconstruction after	
	mastectomy or for congenital absence of nipple	
45546	(See para TN.8.100 of explanatory notes to this Category) Fee: \$197.85 Benefit: 75% = \$148.40 85% = \$168.20	
	BREAST PROSTHESIS, removal of, as an independent procedure (Anaes.)	
45548	Fee: \$276.80 Benefit: 75% = \$207.60 85% = \$235.30	
	Breast prosthesis, removal of, with excision of at least half of the fibrous capsule, not with insertion of any prosthesis. The excised specimen must be sent for histopathology and the volume removed must be documented in the histopathology report (Anaes.) (Assist.)	
45551	Fee: \$443.70 Benefit: 75% = \$332.80	
	Breast prosthesis, removal of and replacement with another prosthesis, following medical complications (for rupture, migration of prosthetic material or symptomatic capsular contracture), if:	
	(a) either:	
	(i) it is demonstrated by intra-operative photographs post-removal that removal alone would cause unacceptable deformity; or	
	(ii) the original implant was inserted in the context of breast cancer or developmental abnormality; and	
	(b) photographic and/or diagnostic imaging evidence demonstrating the clinical need for this service is documented in the patient notes (Anaes.) (Assist.)	
45553	(See para TN.8.98 of explanatory notes to this Category) Fee: \$571.60 Benefit: 75% = \$428.70	
	Breast prosthesis, removal and replacement with another prosthesis, following medical complications (for rupture, migration of prosthetic material or symptomatic capsular contracture), including excision of at least half of the fibrous capsule or formation of a new pocket, or both, if:	
	(a) either:	
	(i) it is demonstrated by intra-operative photographs post-removal that removal alone would cause unacceptable deformity; or	

T8. SUF	RGICAL OPERATIONS	13. PLASTIC AND RECONSTRUCTIVE SURGERY	
	and		
	(b) the excised specimen is sent for hi histopathology report; and	stopathology and the volume removed is documented in the	
	(c) photographic and/or diagnostic im documented in the patient notes (Anac	aging evidence demonstrating the clinical need for this service is es.) (Assist.)	
	(See para TN.8.98 of explanatory notes to Fee: \$699.45 Benefit: 75% = \$		
	photographic evidence (including ante), in the context of breast cancer or developmental abnormality, if erior, left lateral and right lateral views) and/or diagnostic imaging eed for this service is documented in the patient notes	
	Applicable only once per occasion on	which the service is provided (Anaes.) (Assist.)	
45556	(See para TN.8.99 of explanatory notes to Fee: \$766.05 Benefit: 75% = \$		
	Breast ptosis, correction by mastopex	y of (bilateral), if:	
	\ \ /	sue, including the nipple, lies inferior to the infra-mammary fold t dependent, inferior part of the breast contour; and	
	(b) if the patient has been pregnant—the correction is performed not less than 1 year, or more than 7 years, after completion of the most recent pregnancy of the patient; and		
		anterior, left lateral and right lateral views), with a marker at the onstrating the clinical need for this service, is documented in the	
	Applicable only once per lifetime (Ar	naes.) (Assist.)	
45558	(See para TN.8.99 of explanatory notes to this Category) Fee: \$1,148.95 Benefit: 75% = \$861.75		
		e treatment of alopecia of congenital or traumatic origin or due to ess, not being a service to which another item in this Group applies	
45560	Fee: \$473.65 Benefit: 75% = \$ Extended Medicare Safety Net Cap	\$355.25 85% = \$402.65 : \$165.80	
	MICROVASCULAR ANASTOMOSIS of artery or vein using microsurgical techniques, for supercharging of pedicled flaps (Anaes.) (Assist.)		
45561	Fee: \$1,774.70 Benefit: 75% = \$	\$1331.05	
		lving raising of tissue on vascular or neurovascular pedicle, utaneous defect if performed, excluding flap for male pattern	
45562	Fee: \$1,099.40 Benefit: 75% = \$	8824.55 85% = \$1016.00	
	NEUROVASCULAR ISLAND FLAI performed, excluding flap for male pa	P, including direct repair of secondary cutaneous defect if uttern baldness (Anaes.) (Assist.)	
45563	Fee: \$1,099.40 Benefit: 75% = \$	8824.55 85% = \$1016.00	

T8. SUF	RGICAL OPERATIO	NS 13. PLASTIC AND RECONSTRUCTIVE SURGERY
	deformity, surgery and including raisin transfer of tissue, in performed, other th 30176, 30177, 3017	sue reconstructive surgery for the repair of major tissue defect due to congenital or trauma, involving anastomoses of up to 2 vessels using microvascular techniques and of tissue on a vascular or neurovascular pedicle, preparation of recipient vessels, assetting of tissue at recipient site and direct repair of secondary cutaneous defect if than a service associated with a service to which item 30165, 30168, 30171, 30172, 79, 45501, 45502, 45504, 45505 or 45562 applies-conjoint surgery, principal (H) (Anaes.) (Assist.)
45564	(See para TN.8.8 of e Fee: \$2,546.30	explanatory notes to this Category) Benefit: 75% = \$1909.75
	Free transfer of tissue reconstructive surgery for the repair of major tissue defect due to congenital deformity, surgery or trauma, involving anastomoses of up to 2 vessels using microvascular techniques and including raising of tissue on a vascular or neurovascular pedicle, preparation of recipient vessels, transfer of tissue, insetting of tissue at recipient site and direct repair of secondary cutaneous defect if performed, other than a service associated with a service to which item 30165, 30168, 30171, 30172, 30176, 30177, 30179, 45501, 45502, 45504, 45505 or 45562 applies-conjoint surgery, conjoint specialist surgeon (H) (Assist.)	
45565	(See para TN.8.8 of e Fee: \$1,909.80	explanatory notes to this Category) Benefit: 75% = \$1432.35
	TISSUE EXPANS	ION not being a service to which item 45539 or 45542 applies - insertion of tissue all attendances for subsequent expansion injections (Anaes.) (Assist.)
45566	Fee: \$1,071.20	Benefit: 75% = \$803.40
	TISSUE EXPAND	ER, removal of, with complete excision of fibrous capsule (Anaes.) (Assist.)
45568	Fee: \$443.70	Benefit: 75% = \$332.80
	CLOSURE OF ABDOMEN WITH RECONSTRUCTION OF UMBILICUS, with or without lipectomy being a service associated with items 45562, 45564, 45565 or 45530 (Anaes.) (Assist.)	
45569	Fee: \$677.60	Benefit: 75% = \$508.20
	CLOSURE OF ABDOMEN, repair of musculoaponeurotic layer, being a service associated with item 45569 (Anaes.) (Assist.)	
45570	Fee: \$914.95	Benefit: 75% = \$686.25 85% = \$831.55
	INTRA OPERATIVE TISSUE EXPANSION performed during an operation when combined with a service to which another item in Group T8 applies including expansion injections and excluding treatment of male pattern baldness (Anaes.)	
45572	Fee: \$291.70 Benefit: 75% = \$218.80 85% = \$247.95	
	FACIAL NERVE PARALYSIS, free fascia graft for (Anaes.) (Assist.)	
45575 Fee: \$720.20 Benefit: 75% = \$540.15 85% = \$636.80		Benefit: 75% = \$540.15 85% = \$636.80
	FACIAL NERVE PARALYSIS, muscle transfer for (Anaes.) (Assist.)	
45578	Fee: \$834.05 Benefit: 75% = \$625.55	
	FACIAL NERVE I	PALSY, excision of tissue for (Anaes.)
45581	Fee: \$276.80	Benefit: 75% = \$207.60 85% = \$235.30
45584	Liposuction (suction assisted lipolysis) to one regional area (one limb or trunk), for treatment of post traumatic pseudolipoma, if photographic and/or diagnostic imaging evidence demonstrating the clinical	

T8. SUF	GICAL OPERATIONS	13. PLASTIC AND RECONSTRUCTIVE SURGERY	
	need for this service is documented in the	ne patient notes (Anaes.)	
	(See para TN.8.8, TN.8.101 of explanatory r Fee: \$631.75 Benefit: 75% = \$47		
	Liposuction (suction assisted lipolysis) to one regional area (one limb or trunk), other than a service associated with a service to which item 31525 applies, if:		
	(a) the liposuction is for:		
	(i) the treatment of Barraquer-Sim	ons syndrome, lymphoedema or macrodystrophia lipomatosa; or	
	(ii) the reduction of a buffalo hum treatment of a medical condition; a	p that is secondary to an endocrine disorder or pharmacological and	
	(b) photographic and/or diagnostic imag documented in the patient notes (Anaes.	ring evidence demonstrating the clinical need for this service is	
45585	(See para TN.8.8, TN.8.101 of explanatory r Fee: \$631.75 Benefit: 75% = \$47		
	Meloplasty for correction of facial asym	metry if:	
	(a) the asymmetry is secondary to traum medical condition (such as facial nerve	a (including previous surgery), a congenital condition or a palsy); and	
	(b) the meloplasty is limited to one side	of the face (Anaes.) (Assist.)	
45587	(See para TN.8.102 of explanatory notes to t Fee: \$890.85 Benefit: 75% = \$66		
	Meloplasty (excluding browlifts and chi	nlift platysmaplasties), bilateral, if:	
		tional impairment due to a congenital condition, disease a (other than trauma resulting from previous elective cosmetic	
	(b) photographic and/or diagnostic imaging evidence demonstrating the clinical need for this documented in the patient notes (Anaes.) (Assist.)		
45588	(See para TN.8.102 of explanatory notes to this Category) Fee: \$1,336.40 Benefit: 75% = \$1002.30		
	ORBITAL CAVITY, reconstruction of	a wall or floor, with or without foreign implant (Anaes.) (Assist.)	
45590	Fee: \$483.25 Benefit: 75% = \$36	22.45	
	ORBITAL CAVITY, bone or cartilage graft to orbital wall or floor including reduction of prolapsed or entrapped orbital contents (Anaes.) (Assist.)		
45593	Fee: \$567.65 Benefit: 75% = \$42	25.75	
	MAXILLA, total resection of (Anaes.) ((Assist.)	
45596	Fee: \$900.45 Benefit: 75% = \$67	75.35	
	MAXILLA, total resection of both maxi	illae (Anaes.) (Assist.)	
45597	Fee: \$1,205.40 Benefit: 75% = \$90	04.05	

T8. SUR	GICAL OPERATIONS 13. PLASTIC AND RECONSTRUCTIVE SURGERY		
	MANDIBLE, total resection of both sides, including condylectomies where performed (Anaes.) (Assist.)		
45599	Fee: \$936.55 Benefit: 75% = \$702.45 85% = \$853.15		
	MANDIBLE, including lower border, OR MAXILLA, sub-total resection of (Anaes.) (Assist.)		
45602	Fee: \$699.45 Benefit: 75% = \$524.60		
	MANDIBLE OR MAXILLA, segmental resection of, for tumours or cysts (Anaes.) (Assist.)		
45605	Fee: \$587.60 Benefit: 75% = \$440.70		
	MANDIBLE, hemimandibular reconstruction with bone graft, not being a service associated with a service to which item 45599 applies (Anaes.) (Assist.)		
45608	Fee: \$827.30 Benefit: 75% = \$620.50		
	MANDIBLE, condylectomy (Anaes.) (Assist.)		
45611	Fee: \$473.75 Benefit: 75% = \$355.35		
	EYELID, WHOLE THICKNESS RECONSTRUCTION OF other than by direct suture only (Anaes.) (Assist.)		
45614	Fee: \$587.60 Benefit: 75% = \$440.70 85% = \$504.20 Extended Medicare Safety Net Cap: \$470.10		
	Upper eyelid, reduction of, if:		
	(a) the reduction is for any of the following:		
	(i) skin redundancy that causes a visual field defect (confirmed by an optometrist or ophthalmologist) or intertriginous inflammation of the eyelid;		
	(ii) herniation of orbital fat in exophthalmos;		
	(iii) facial nerve palsy;		
	(iv) post-traumatic scarring;		
	(v) the restoration of symmetry of contralateral upper eyelid in respect of one of the conditions mentioned in subparagraphs (i) to (iv); and		
	(b) photographic and/or diagnostic imaging evidence demonstrating the clinical need for this service is documented in the patient notes (Anaes.)		
45617	(See para TN.8.103 of explanatory notes to this Category) Fee: \$235.05 Benefit: 75% = \$176.30 85% = \$199.80 Extended Medicare Safety Net Cap: \$188.05		
	Lower eyelid, reduction of, if:		
	(a) the reduction is for:		
	(i) herniation of orbital fat in exophthalmos, facial nerve palsy or post-traumatic scarring; or		
	(ii) the restoration of symmetry of the contralateral lower eyelid in respect of one of these conditions; and		
45620	(b) photographic and/or diagnostic imaging evidence demonstrating the clinical need for this service is		

T8. SUF	RGICAL OPERATIONS	13. PLASTIC AND RECONSTRUCTIVE SURGERY		
	documented in the patient notes (Ar	naes.)		
	(See para TN.8.103 of explanatory note: Fee: \$326.05 Benefit: 75% = Extended Medicare Safety Net Ca	= \$244.55 85% = \$277.15		
	Ptosis of upper eyelid (unilateral), correction of, by:			
	(a) sutured elevation of the tarsal plate on the eyelid retractors (Muller's or levator muscle or levator aponeurosis); or			
	(b) sutured suspension to the brow/f	rontalis muscle;		
	Not applicable to a service for repai	r of mechanical ptosis to which item 45617 applies (Anaes.) (Assist.)		
45623	Fee: \$723.05 Benefit: 75% = Extended Medicare Safety Net Ca	= \$542.30 85% = \$639.65 p: \$578.45		
	Ptosis of upper eyelid, correction of	, by:		
	(a) sutured elevation of the tarsal pla aponeurosis); or	ate on the eyelid retractors (Muller's or levator muscle or levator		
	(b) sutured suspension to the brow/f	rontalis muscle;		
	if a previous ptosis surgery has been	performed on that side (Anaes.) (Assist.)		
45624	Fee: \$937.40 Benefit: 75% = Extended Medicare Safety Net Ca	= \$703.05 85% = \$854.00 ap: \$749.95		
		lid height by revision of levator sutures within one week of primary cement, performed in the operating theatre of a hospital (Anaes.)		
45625	Fee: \$187.55 Benefit: 75% =	= \$140.70		
	ECTROPION OR ENTROPION, co	prrection of (unilateral) (Anaes.)		
45626	Fee: \$326.05 Benefit: 75% =	= \$244.55 85% = \$277.15		
	SYMBLEPHARON, grafting for (A	anaes.) (Assist.)		
45629	Fee: \$473.75 Benefit: 75% =	= \$355.35 85% = \$402.70		
	Rhinoplasty, partial, involving corre	ection of lateral or alar cartilages, if:		
	(a) the indication for surgery is:			
	(i) airway obstruction and the	(i) airway obstruction and the patient has a self-reported NOSE Scale score of greater than 45; or		
	(ii) significant acquired, congenital or developmental deformity; and			
	(b) photographic and/or NOSE Scale evidence demonstrating the clinical need for this service is documented in the patient notes (Anaes.)			
45632	(See para TN.8.104 of explanatory notes to this Category) Fee: \$511.95 Benefit: 75% = \$384.00 Extended Medicare Safety Net Cap: \$409.60			
45635	Rhinoplasty, partial, involving corre	•		
	1			

T8. SUR	GICAL OPERATIONS	13. PLASTIC AND RECONSTRUCTIVE SURGERY		
	(a) the indication for surgery is:			
	(i) airway obstruction and the pa	atient has a self-reported NOSE Scale score of greater than 45; or		
	(ii) significant acquired, congen	ital or developmental deformity; and		
	(b) photographic and/or NOSE Scale documented in the patient notes (Anac	evidence demonstrating the clinical need for this service is es.)		
	(See para TN.8.104 of explanatory notes to this Category) Fee: \$587.60 Benefit: 75% = \$440.70 85% = \$504.20 Extended Medicare Safety Net Cap: \$470.10			
	Rhinoplasty, total, including correction or without autogenous cartilage or both	on of all bony and cartilaginous elements of the external nose, with ne graft from a local site (nasal), if:		
	(a) the indication for surgery is:			
	(i) airway obstruction and the pa	atient has a self-reported NOSE Scale score of greater than 45; or		
	(ii) significant acquired, congen	ital or developmental deformity; and		
	(b) photographic and/or NOSE Scale documented in the patient notes (Anac	evidence demonstrating the clinical need for this service is es.)		
45641	(See para TN.8.104 of explanatory notes t Fee: \$1,066.00 Benefit: 75% = \$			
		on of all bony and cartilaginous elements of the external nose ge graft obtained from distant donor site, including obtaining of		
	(a) the indication for surgery is:			
	(i) airway obstruction and the pa	atient has a self-reported NOSE Scale score of greater than 45; or		
	(ii) significant acquired, congen	ital or developmental deformity; and		
	(b) photographic and/or NOSE Scale documented in the patient notes (Anac	evidence demonstrating the clinical need for this service is es.) (Assist.)		
45644	(See para TN.8.104 of explanatory notes t Fee: \$1,279.45 Benefit: 75% = \$			
	CHOANAL ATRESIA, repair of by p			
45645	Fee: \$223.60 Benefit: 75% = \$	5167.70		
	CHOANAL ATRESIA - correction by	y open operation with bone removal (Anaes.) (Assist.)		
45646	Fee: \$900.45 Benefit: 75% = \$	\$675.35 85% = \$817.05		
	FACE, contour restoration of 1 region which item 45644 applies) (Anaes.) (Anaes.)	n, using autogenous bone or cartilage graft (not being a service to Assist.)		
45647	(See para TN.8.105 of explanatory notes t Fee: \$1,279.45 Benefit: 75% = \$			
45650	Rhinoplasty, revision of, if:			
L	į.			

T8. SUR	GICAL OPERATION	NS	13. PLASTIC AND RECONSTRUCTIVE SURGERY
	(a) the indication for	r surgery is:	
	(i) airway obst	ruction and the patient h	as a self-reported NOSE Scale score of greater than 45; or
	(ii) significant	acquired, congenital or	developmental deformity; and
		d/or NOSE Scale evident natient notes (Anaes.)	ce demonstrating the clinical need for this service is
	(See para TN.8.104 of Fee: \$147.80	explanatory notes to this C Benefit: 75% = \$110.85	
	Rhinophyma of a mo (Anaes.)	oderate or severe degree	, carbon dioxide laser or erbium laser excision - ablation of
45652	Fee: \$356.35 Extended Medicard	Benefit: 75% = \$267.30 e Safety Net Cap: \$285.	
	RHINOPHYMA, sh	naving of (Anaes.)	
45653	Fee: \$356.35	Benefit: 75% = \$267.30	85% = \$302.90
	COMPOSITE GRA	FT (Chondrocutaneous o	or chondromucosal) to nose, ear or eyelid (Anaes.) (Assist.)
45656	Fee: \$502.25	Benefit: 75% = \$376.70	85% = \$426.95
	Correction of a congenital deformity of the ear if:		
	(a) the patient is less than 18 years of age; and		
	(b) the deformity is characterised by an absence of the antihelical fold and/or large scapha and/or large concha; and		
	(c) photographic evidence demonstrating the clinical need for this service is documented in the notes (Anaes.) (Assist.)		e clinical need for this service is documented in the patient
45659	Fee: \$521.25	Benefit: 75% = \$390.95	
	EXTERNAL EAR, COMPLEX TOTAL RECONSTRUCTION OF, using multiple costal cartilage grafts to form a framework, including the harvesting and sculpturing of the cartilage and its insertion, fo congenital absence, microtia or post-traumatic loss of entire or substantial portion of pinna (first stage) - performed by a specialist in the practice of his or her specialty (Anaes.) (Assist.)		
45660	Fee: \$2,878.75	Benefit: 75% = \$2159.1	0
	EXTERNAL EAR, COMPLEX TOTAL RECONSTRUCTION OF, elevation of costal cartilage framework using cartilage previously stored in abdominal wall, including the use of local skin and fasci flaps and full thickness skin graft to cover cartilage (second stage) - performed by a specialist in the practice of his or her specialty (Anaes.) (Assist.)		
45661	Fee: \$1,279.45	Benefit: 75% = \$959.60	
	CONGENITAL AT	RESIA, reconstruction of	of external auditory canal (Anaes.) (Assist.)
45662	Fee: \$701.30	Benefit: 75% = \$526.00	
	LIP, EYELID OR E (Anaes.)	AR, FULL THICKNES	S WEDGE EXCISION OF, with repair by direct sutures
45665	Fee: \$326.05	Benefit: 75% = \$244.55	85% = \$277.15

T8. SURGICAL OPERATIONS		IONS	13. PLASTIC AND RECONSTRUCTIVE SURGERY	
	VERMILIONEO	CTOMY, by surgical excision	n (Anaes.)	
45668	Fee: \$326.05	Benefit: 75% = \$244.55	85% = \$277.15	
	Vermilionectom excision - ablation		lar atypia, using carbon dioxide laser or erbium laser	
45669	(See para TN.8.10 Fee: \$326.05	6 of explanatory notes to this Ca Benefit: 75% = \$244.55		
	LIP OR EYELII (Assist.)	RECONSTRUCTION usin	g full thickness flap (Abbe or similar), first stage (Anaes.)	
45671	Fee: \$834.05	Benefit: 75% = \$625.55	85% = \$750.65	
	LIP OR EYELII (Anaes.)	RECONSTRUCTION usin	g full thickness flap (Abbe or similar), second stage	
45674	Fee: \$242.55	Benefit: 75% = \$181.95	85% = \$206.20	
	MACROCHEIL	IA or macroglossia, operatio	n for (Anaes.) (Assist.)	
45675	Fee: \$483.25	Benefit: 75% = \$362.45		
	MACROSTOM	(A, operation for (Anaes.)	ssist.)	
45676	Fee: \$575.30	Benefit: 75% = \$431.50		
	CLEFT LIP, uni	lateral primary repair, 1 stag	ge, without anterior palate repair (Anaes.) (Assist.)	
45677	Fee: \$541.35	Benefit: 75% = \$406.05		
	CLEFT LIP, uni	lateral - primary repair, 1 sta	ge, with anterior palate repair (Anaes.) (Assist.)	
45680	Fee: \$676.80	Benefit: 75% = \$507.60		
	CLEFT LIP, bila	teral - primary repair, 1 stag	e, without anterior palate repair (Anaes.) (Assist.)	
45683	Fee: \$751.85	Benefit: 75% = \$563.90		
	CLEFT LIP, bila	ateral - primary repair, 1 stag	e, with anterior palate repair (Anaes.) (Assist.)	
45686	Fee: \$887.50	Benefit: 75% = \$665.65		
	CLEFT LIP, lip	adhesion procedure, unilater	al or bilateral (Anaes.) (Assist.)	
45689	Fee: \$261.75	Benefit: 75% = \$196.35		
	CLEFT LIP, partial revision, including minor flap revision alignment and adjustment, including revisio of minor whistle deformity if performed (Anaes.)			
45692	Fee: \$300.75	Benefit: 75% = \$225.60	85% = \$255.65	
	CLEFT LIP, total revision, including major flap revision, muscle reconstruction and revision of major whistle deformity (Anaes.) (Assist.)			
45695	Fee: \$488.75	Benefit: 75% = \$366.60		
	CLEFT LIP, pri	nary columella lengthening p	procedure, bilateral (Anaes.)	
45698	Fee: \$458.75	Benefit: 75% = \$344.10		
45701	CLEFT LIP RECONSTRUCTION using full thickness flap (Abbe or similar), first stage (Anaes.) (Assist.)			

T8. SUF	T8. SURGICAL OPERATIONS		13. PLASTIC AND RECONSTRUCTIVE SURGERY		
	Fee: \$827.30	Benefit: 75% = \$620.50			
	CLEFT LIP REC	CONSTRUCTION using ful	l thickness flap (Abbe or similar), second stage (Anaes.)		
45704	Fee: \$300.75	Benefit: 75% = \$225.60	85% = \$255.65		
	CLEFT PALATE, primary repair (Anaes.) (Assist.)				
45707	Fee: \$781.95	Benefit: 75% = \$586.50			
	CLEFT PALAT	E, secondary repair, closure	of fistula using local flaps (Anaes.)		
45710	Fee: \$488.75	Benefit: 75% = \$366.60			
	CLEFT PALAT	E, secondary repair, lengther	ning procedure (Anaes.) (Assist.)		
45713	Fee: \$556.60	Benefit: 75% = \$417.45			
	ORO-NASAL F applies (Anaes.)		including services to which item 45200, 45203 or 45239		
45714	Fee: \$781.95	Benefit: 75% = \$586.50			
	VELO-PHARY	NGEAL INCOMPETENCE	, pharyngeal flap for, or pharyngoplasty for (Anaes.)		
45716	Fee: \$781.95	Benefit: 75% = \$586.50			
	and vessels and 47936 apply (Ar	MANDIBLE OR MAXILLA, unilateral osteotomy or osteectomy of, including transposition of nerves and vessels and bone grafts taken from the same site and excluding services to which item 47933or 47936 apply (Anaes.) (Assist.) (See para TN.8.107 of explanatory notes to this Category)			
45720	Fee: \$966.80				
and vessels and bone grafts taken from the same site a		bone grafts taken from the sa	notomy or osteectomy of, including transposition of nerves ame site and stabilisation with fixation by wires, screws, adding services to which item 47933 or 47936 apply (Anaes.)		
45723	(See para TN.8.10 Fee: \$1,090.35	7 of explanatory notes to this C Benefit: 75% = \$817.80	Category)		
		bone grafts taken from the sa	stomy or osteectomy of, including transposition of nerves ame site, and excluding services to which item 47933 or		
45726	(See para TN.8.10 Fee: \$1,232.05	7 of explanatory notes to this C Benefit: 75% = \$924.05	Category)		
	and vessels and	bone grafts taken from the sa	stomy or osteectomy of, including transposition of nerves ame site and stabilisation with fixation by wires, screws, ading services to which item 47933 or 47936 apply (Anaes.)		
45729	(See para TN.8.10 Fee: \$1,383.65	7 of explanatory notes to this C Benefit: 75% = \$1037.75			
	1 jaw, including	transposition of nerves and	osteectomies of, involving 3 or more such procedures on the vessels and bone grafts taken from the same site, and 7936 apply (Anaes.) (Assist.)		
45731	(See para TN.8.10 Fee: \$1,402.70	7 of explanatory notes to this C Benefit: 75% = \$1052.0			

T8. SUR	GICAL OPERATIONS	13. PLASTIC AND RECONSTRUCTIVE SURGERY
	the 1 jaw, including transposition of nerve	s or osteectomies of, involving 3 or more such procedures on s and vessels and bone grafts taken from the same site and s, plates or pins, or any combination, and excluding services to (Assist.)
45732	(See para TN.8.107 of explanatory notes to this Fee: \$1,579.20 Benefit: 75% = \$1184	
		es or osteectomies of, involving 2 such procedures of each vessels and bone grafts taken from the same site, and 47936 apply (Anaes.) (Assist.)
45735	(See para TN.8.107 of explanatory notes to this Fee: \$1,611.05 Benefit: 75% = \$1208	
	jaw, including transposition of nerves and	es or osteectomies of, involving 2 such procedures of each vessels and bone grafts taken from the same site and s, plates or pins, or any combination, and excluding services to (Assist.)
45738	(See para TN.8.107 of explanatory notes to this Fee: \$1,812.40 Benefit: 75% = \$1359	
	such procedures of 1 jaw and 2 such proce	pilateral osteotomies or osteectomies of, involving 3 or more dures of the other jaw, including genioplasty when performed d bone grafts taken from the same site, and excluding services es.) (Assist.)
45741	(See para TN.8.107 of explanatory notes to this Fee: \$1,772.30 Benefit: 75% = \$1329	
	such procedures of 1 jaw and 2 such proce and transposition of nerves and vessels and	pilateral osteotomies or osteectomies of, involving 3 or more dures of the other jaw, including genioplasty when performed d bone grafts taken from the same site and stabilisation with r any combination, and excluding services to which item
45744	(See para TN.8.107 of explanatory notes to this Fee: \$1,992.70 Benefit: 75% = \$1494	
	such procedures of each jaw, including ge	bilateral osteotomies or osteectomies of, involving 3 or more nioplasty (when performed) and transposition of nerves and ne site, and excluding services to which item 47933 or 47936
45747	(See para TN.8.107 of explanatory notes to this Fee: \$1,933.55 Benefit: 75% = \$1450	
	such procedures of each jaw, including ge- vessels and bone grafts taken from the san	pilateral osteotomies or osteectomies of, involving 3 or more nioplasty when performed and transposition of nerves and ne site and stabilisation with fixation by wires, screws, plates g services to which item 47933 or 47936 apply (Anaes.)
45752	(See para TN.8.107 of explanatory notes to this Fee: \$2,165.75 Benefit: 75% = \$1624	
45753		II, Modified Le Fort III (Nasomalar), Modified Le Fort g 3 or more osteotomies of the midface including transposition

T8. SUF	RGICAL OPERATION	ONS 13. PLASTIC AND RECONSTRUCTIVE SURGERY
	of nerves and vess	sels and bone grafts taken from the same site (Anaes.) (Assist.)
	Fee: \$2,178.60	Benefit: 75% = \$1633.95 85% = \$2095.20
	(Malar-Maxillary) nerves and vessels	TEOTOMIES - Le Fort II, Modified Le Fort III (Nasomalar), Modified Le Fort III), Le Fort III involving 3 or more osteotomies of the midface including transposition of s and bone grafts taken from the same site and stabilisation with fixation by wires, bins, or any combination (Anaes.) (Assist.)
45754	Fee: \$2,611.60	Benefit: 75% = \$1958.70
	TEMPOROMAN	DIBULAR PARTIAL OR TOTAL MENISCECTOMY (Anaes.) (Assist.)
45755	Fee: \$367.75	Benefit: 75% = \$275.85 85% = \$312.60
	TEMPORO-MAN	NDIBULAR JOINT, arthroplasty (Anaes.) (Assist.)
45758	Fee: \$658.05	Benefit: 75% = \$493.55
	GENIOPLASTY, (Anaes.) (Assist.)	including transposition of nerves and vessels and bone grafts taken from the same site
45761	(See para TN.8.108 Fee: \$748.65	of explanatory notes to this Category) Benefit: 75% = \$561.50
	HYPERTELORIS	SM, correction of, intracranial (Anaes.) (Assist.)
45767	Fee: \$2,511.65	Benefit: 75% = \$1883.75 85% = \$2428.25
	HYPERTELORIS	SM, correction of, subcranial (Anaes.) (Assist.)
45770	Fee: \$1,923.90	Benefit: 75% = \$1442.95
	TREACHER COI grafts (Anaes.) (A	LLINS SYNDROME, PERIORBITAL CORRECTION OF, with rib and iliac bone ssist.)
45773	Fee: \$1,753.40	Benefit: 75% = \$1315.05 85% = \$1670.00
	ORBITAL DYST intracranial (Anae	OPIA (UNILATERAL), CORRECTION OF, with total repositioning of 1 orbit, ss.) (Assist.)
45776	Fee: \$1,753.40	Benefit: 75% = \$1315.05
	ORBITAL DYST extracranial (Anac	OPIA (UNILATERAL), CORRECTION OF, with total repositioning of 1 orbit, es.) (Assist.)
45779	Fee: \$1,289.15	Benefit: 75% = \$966.90
	FRONTOORBIT	AL ADVANCEMENT, UNILATERAL (Anaes.) (Assist.)
45782	Fee: \$985.70	Benefit: 75% = \$739.30 85% = \$902.30
		T RECONSTRUCTION for oxycephaly, brachycephaly, turricephaly or similar al frontoorbital advancement) (Anaes.) (Assist.)
45785	Fee: \$1,668.10	Benefit: 75% = \$1251.10
		A, ZYGOMATIC ARCH AND TEMPORAL BONE, RECONSTRUCTION OF, ique) (Anaes.) (Assist.)
45788	Fee: \$1,649.10	Benefit: 75% = \$1236.85
45791	ABSENT COND	YLE AND ASCENDING RAMUS in hemifacial microsomia, CONSTRUCTION OF,

T8. SUF	RGICAL OPERATION	NS	13. PLASTIC AND RECONSTRUCTIVE SURGERY
	not including harves	sting of graft material (A	anaes.) (Assist.)
	Fee: \$890.85	Benefit: 75% = \$668.15	;
		TION PROCEDURE - eonduction hearing system	extra-oral, implantation of titanium fixture, not for n device (Anaes.)
45794	Fee: \$503.85	Benefit: 75% = \$377.90	85% = \$428.30
		TION PROCEDURE, fi system device (Anaes.)	xation of transcutaneous abutment, not for implantable bone
45797	Fee: \$186.50	Benefit: 75% = \$139.90	85% = \$158.55
		ORAL AND	MAXILLOFACIAL SURGERY
			V CYSTS as an independent procedure to obtain material for associated with an operative procedure on the same day
45799	Fee: \$29.45	Benefit: 75% = \$22.10	85% = \$25.05
	operation), in the ora subcutaneous tissue	al and maxillofacial region	ner than a scar removed during the surgical approach at an on, up to 3 cm in diameter, removal from cutaneous or rane, where the removal is by surgical excision and suture, plies (Anaes.)
45801	(See para TN.8.109 of Fee: \$126.90	Fexplanatory notes to this G Benefit: 75% = \$95.20	
	an operation), in the subcutaneous tissue	oral and maxillofacial r	S, (other than a scar removed during the surgical approach at region, up to 3 cm in diameter, removal from cutaneous or rane, where the removal is by surgical excision and suture, in 3 but not more than 10 lesions (Anaes.) (Assist.)
45803	(See para TN.8.109 of Fee: \$326.05	F explanatory notes to this G Benefit: 75% = \$244.55	± • ·
	operation), in the or		ner than a scar removed during the surgical approach at an ion, more than 3 cm in diameter, removal from cutaneous or rane (Anaes.)
45805	(See para TN.8.109 of Fee: \$172.50	F explanatory notes to this G Benefit: 75% = \$129.40	
	established by radio lining and tooth stru ULCER OR SCAR and maxillofacial re	logical examination that acture or where a tumour (other than a scar remov	the ted with a tooth or tooth fragment unless it has been there is a minimum of 5mm separation between the cyst or cyst has been proven by positive histopathology), yed during the surgical approach at an operation), in the oral ing a service to which another item in this Subgroup applies, to (Anaes.)
45807	(See para TN.8.109 of Fee: \$246.50	Explanatory notes to this G Benefit: 75% = \$184.90	
45809	been established by cyst lining and tooth the oral and maxillo	radiological examination structure or where a tur	yst associated with a tooth or tooth fragment unless it has n that there is a minimum of 5mm separation between the mour or cyst has been proven by positive histopathology), in f, requiring wide excision, not being a service to which es.) (Assist.)

T8. SURGICAL OPERATIONS			13. PLASTIC AND RECONSTRUCTIVE SURGERY	
	(See para TN.8.109 of expla Fee: \$371.50 Ben	natory notes to this Ca efit: $75\% = 278.65		
			on, removal of, from soft tissue (including muscle, fascia without skin or mucosal graft (Anaes.) (Assist.)	
45811	(See para TN.8.109 of expla Fee: \$502.25 Ben	natory notes to this Ca efit: 75% = \$376.70		
			on, removal of, from soft tissue (including muscle, fascia with skin or mucosal graft (Anaes.) (Assist.)	
45813	(See para TN.8.109 of expla Fee: \$587.60 Ben	natory notes to this Ca efit: $75\% = 440.70		
	OPERATION ON MANI - 1 bone or in combination		LA (other than alveolar margins) for chronic osteomyelitis nes (Anaes.) (Assist.)	
45815	Fee: \$356.35 Ben	efit: 75% = \$267.30	85% = \$302.90	
	OPERATION on SKULI	for OSTEOMYEL	ITIS (Anaes.) (Assist.)	
45817	Fee: \$464.50 Ben	efit: 75% = \$348.40	85% = \$394.85	
			of ADJOINING BONES IN THE ORAL AND referred to in item 45817 (Anaes.) (Assist.)	
45819	Fee: \$587.55 Ben	efit: 75% = \$440.70	85% = \$504.15	
	BONE GROWTH STIM (Anaes.) (Assist.)	JLATOR IN THE (ORAL AND MAXILLOFACIAL REGION, insertion of	
45821	Fee: \$380.80 Ben	efit: 75% = \$285.60	85% = \$323.70	
			d for dental fixation purposes to the maxilla or mandible, ere undertaken in the operating theatre of a hospital	
45823	Fee: \$108.90 Ben	efit: 75% = \$81.70		
	MANDIBULAR OR PAI	LATAL EXOSTOS	IS, excision of (Anaes.) (Assist.)	
45825	Fee: \$338.35 Ben	efit: 75% = \$253.80	85% = \$287.60	
	MYLOHYOID RIDGE, 1	eduction of (Anaes.	(Assist.)	
45827	Fee: \$323.40 Ben	efit: 75% = \$242.55	85% = \$274.90	
	MAXILLARY TUBEROSITY, reduction of (Anaes.)			
45829	Fee: \$246.70 Ben	efit: 75% = \$185.05	85% = \$209.70	
		ASIA OF THE PAI	LATE, removal of - less than 5 lesions (Anaes.) (Assist.)	
45831	Fee: \$323.40 Ben	efit: 75% = \$242.55	85% = \$274.90	
			LATE, removal of - 5 to 20 lesions (Anaes.) (Assist.)	
45833	Fee: \$406.05 Ben	efit: 75% = \$304.55	85% = \$345.15	
.5055			LATE, removal of - more than 20 lesions (Anaes.) (Assist.)	
45835		efit: 75% = \$377.90		
12022	1 CC. \$505.05 Dell	υπτ. 13/0 — φ3/1.90	05/0 \$\psi \psi \D\0.5\0	

T8. SUF	RGICAL OPERATIONS 13. PLASTIC AND RECONSTRUCTIVE SURGER
	VESTIBULOPLASTY, submucosal or open, including excision of muscle and skin or mucosal graft when performed - unilateral or bilateral (Anaes.) (Assist.)
45837	Fee: \$586.50 Benefit: 75% = \$439.90 85% = \$503.10
	FLOOR OF MOUTH LOWERING (Obwegeser or similar procedure), including excision of muscle and skin or mucosal graft when performed - unilateral (Anaes.) (Assist.)
45839	Fee: \$586.50 Benefit: 75% = \$439.90 85% = \$503.10
	ALVEOLAR RIDGE AUGMENTATION with bone or alloplast or both - unilateral (Anaes.) (Assist.)
45841	Fee: \$473.65 Benefit: 75% = \$355.25 85% = \$402.65
	ALVEOLAR RIDGE AUGMENTATION - unilateral, insertion of tissue expanding device into maxillary or mandibular alveolar ridge region for (Anaes.) (Assist.)
45843	Fee: \$290.50 Benefit: 75% = \$217.90 85% = \$246.95
	OSSEO-INTEGRATION PROCEDURE - intra-oral implantation of titanium fixture to facilitate restoration of the dentition following resection of part of the maxilla or mandible for benign or malignant tumours (Anaes.)
45845	Fee: \$503.85 Benefit: 75% = \$377.90 85% = \$428.30
	OSSEO-INTEGRATION PROCEDURE - fixation of transmucosal abutment to fixtures placed following resection of part of the maxilla or mandible for benign or malignant tumours (Anaes.)
45847	Fee: \$186.50 Benefit: 75% = \$139.90 85% = \$158.55
	MAXILLARY SINUS, BONE GRAFT to floor of maxillary sinus following elevation of mucosal lining (sinus lift procedure), (unilateral) (Anaes.) (Assist.)
45849	Fee: \$580.90 Benefit: 75% = \$435.70 85% = \$497.50
	TEMPOROMANDIBULAR JOINT, manipulation of, performed in the operating theatre of a hospital, not being a service associated with a service to which another item in this Subgroup applies (Anaes.)
45851	Fee: \$142.95 Benefit: 75% = \$107.25
	ABSENT CONDYLE and ASCENDING RAMUS in hemifacial microsomia, construction of, not including harvesting of graft material (Anaes.) (Assist.)
45853	Fee: \$890.85 Benefit: 75% = \$668.15 85% = \$807.45
	TEMPOROMANDIBULAR JOINT, arthroscopy of, with or without biopsy, not being a service associated with any other arthroscopic procedure of that joint (Anaes.) (Assist.)
45855	Fee: \$408.70 Benefit: 75% = \$306.55 85% = \$347.40
	TEMPOROMANDIBULAR JOINT, arthroscopy of, removal of loose bodies, debridement, or treatment of adhesions - 1 or more such procedure of that joint, not being a service associated with any other arthroscopic procedure of the temporomandibular joint (Anaes.) (Assist.)
45857	Fee: \$653.80 Benefit: 75% = \$490.35 85% = \$570.40
	TEMPOROMANDIBULAR JOINT, arthrotomy of, not being a service to which another item in this Subgroup applies (Anaes.) (Assist.)
45859	Fee: \$329.60 Benefit: 75% = \$247.20 85% = \$280.20
45861	TEMPOROMANDIBULAR JOINT, open surgical exploration of, with or without microsurgical

T8. SUF	RGICAL OPERATIONS	13. PLASTIC AND RECONSTRUCTIVE SURGERY
	techniques (Anaes.) (Assist.)	
	Fee: \$872.30 Benefit: 75% = \$6.	54.25 85% = \$788.90
	TEMPOROMANDIBULAR JOINT, of with or without microsurgical technique	pen surgical exploration of, with condylectomy or condylotomy, es (Anaes.) (Assist.)
45863	Fee: \$967.00 Benefit: 75% = \$72	25.25 85% = \$883.60
	ARTHROCENTESIS, irrigation of tem appropriate joint space(s) (Anaes.) (Ass	poromandibular joint after insertion of 2 cannuli into the sist.)
45865	Fee: \$290.50 Benefit: 75% = \$2	17.90 85% = \$246.95
	TEMPOROMANDIBULAR JOINT, sy Subgroup applies (Anaes.) (Assist.)	novectomy of, not being a service to which another item in this
45867	Fee: \$312.30 Benefit: 75% = \$2.	34.25 85% = \$265.50
		pen surgical exploration of, with or without meniscus or capsular cectomy when performed, with or without microsurgical
45869	Fee: \$1,188.20 Benefit: 75% = \$89	91.15 85% = \$1104.80
	TEMPOROMANDIBULAR JOINT, on head surgery, with or without microsurg	pen surgical exploration of, with meniscus, capsular and condylar gical techniques (Anaes.) (Assist.)
45871	Fee: \$1,338.45 Benefit: 75% = \$10	003.85 85% = \$1255.05
		argery of, involving procedures to which items 45863, 45867, ing the use of tissue flaps, or cartilage graft, or allograft implants, es (Anaes.) (Assist.)
45873	Fee: \$1,504.05 Benefit: 75% = \$1	128.05 85% = \$1420.65
		abilisation of, involving 1 or more of: repair of capsule, repair of a service to which another item in this Subgroup applies (Anaes.)
45875	Fee: \$470.70 Benefit: 75% = \$3.	53.05 85% = \$400.10
	TEMPOROMANDIBULAR JOINT, ar to which another item in this Subgroup	throdesis of, with synovectomy if performed, not being a service applies (Anaes.) (Assist.)
45877	Fee: \$470.70 Benefit: 75% = \$33	53.05 85% = \$400.10
	TEMPOROMANDIBULAR JOINT OI treatment of fractures (Anaes.) (Assist.)	R JOINTS, application of external fixator to, other than for
45879	Fee: \$312.30 Benefit: 75% = \$2.	34.25 85% = \$265.50
	The treatment of a premalignant lesion or carbon dioxide laser.	of the oral mucosa by a treatment using cryotherapy, diathermy
45882	Fee: \$43.00 Benefit: 75% = \$33	2.25 85% = \$36.55
	Facial, mandibular or lingual artery or vein or artery and vein, ligation of, not being a service to whic item 41707 applies (Anaes.) (Assist.)	
45885	Fee: \$443.70 Benefit: 75% = \$33	32.80 85% = \$377.15
		illofacial region, deep, removal of using interventional imaging

T8. SUF	RGICAL OPERATI	ONS 13. PLASTIC AND RECONSTRUCTIVE SURGERY
	techniques (Anae	s.) (Assist.)
	Fee: \$413.55	Benefit: 75% = \$310.20 85% = \$351.55
	SINGLE-STAGE (Assist.)	LOCAL FLAP where indicated, repair to 1 defect, using temporalis muscle (Anaes.)
45891	Fee: \$602.45	Benefit: 75% = \$451.85 85% = \$519.05
	FREE GRAFTIN (Anaes.)	G, in the oral and maxillofacial region, (mucosa or split skin) of a granulating area
45894	Fee: \$204.70	Benefit: 75% = \$153.55 85% = \$174.00
		EFT (congenital) unilateral, grafting of, including plastic closure of associated oro- ridge augmentation (Anaes.) (Assist.)
45897	Fee: \$1,069.10	Benefit: 75% = \$801.85 85% = \$985.70
	MANDIBLE, fixa	ation by intermaxillary wiring, excluding wiring for obesity
45900	Fee: \$241.15	Benefit: 75% = \$180.90 85% = \$205.00
	PERIPHERAL B (Assist.)	RANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain relief (Anaes.)
45939	Fee: \$447.10	Benefit: 75% = \$335.35 85% = \$380.05
	MANDIBLE, trea	atment of a dislocation of, requiring open reduction (Anaes.)
45945	Fee: \$118.70	Benefit: 75% = \$89.05 85% = \$100.90
	MAXILLA, unila	teral or bilateral, treatment of fracture of, not requiring splinting
45975	(See para TN.8.110 Fee: \$129.20	of explanatory notes to this Category) Benefit: 75% = \$96.90 85% = \$109.85
	MANDIBLE, trea	atment of fracture of, not requiring splinting
45978	(See para TN.8.110 Fee: \$157.85	of explanatory notes to this Category) Benefit: 75% = \$118.40 85% = \$134.20
	ZYGOMATIC B	ONE, treatment of fracture of, not requiring surgical reduction
45981	(See para TN.8.110 Fee: \$85.65	of explanatory notes to this Category) Benefit: 75% = \$64.25 85% = \$72.85
		ment of a complicated fracture of, involving viscera, blood vessels or nerves requiring of involving plate(s) (Anaes.) (Assist.)
45984	(See para TN.8.110 Fee: \$616.65	of explanatory notes to this Category) Benefit: 75% = \$462.50 85% = \$533.25
		atment of a complicated fracture of, involving viscera, blood vessels or nerves, duction not involving plate(s) (Anaes.) (Assist.)
45987	(See para TN.8.110 Fee: \$616.65	of explanatory notes to this Category) Benefit: 75% = \$462.50 85% = \$533.25
		ment of a complicated fracture of, involving viscera, blood vessels or nerves requiring volving the use of plate(s) (Anaes.) (Assist.)
45990	(See para TN.8.110	of explanatory notes to this Category)

T8. SUF	RGICAL OPERAT	IONS	13. PLASTIC AND RECONSTRUCTIVE SURGERY	
	Fee: \$842.25	Benefit: 75% = \$631.70	85% = \$758.85	
		eatment of a complicated fraceduction involving the use of	cture of, involving viscera, blood vessels or nerves, f plate(s) (Anaes.) (Assist.)	
45993	(See para TN.8.11) Fee: \$842.25	0 of explanatory notes to this C Benefit: 75% = \$631.70		
	MANDIBLE, tre	eatment of a closed fracture of	of, involving a joint surface (Anaes.)	
45996	(See para TN.8.11) Fee: \$238.80	0 of explanatory notes to this C Benefit: 75% = \$179.10		
T8. SUF	RGICAL OPERAT	IONS	14. HAND SURGERY	
	Group T8. Surg	ical Operations		
		Subg	group 14. Hand Surgery	
	Note: Items 4630	00 to 46534 are restricted to	surgery on the hand/s.	
		NGEAL JOINT or METAC performed (Anaes.) (Assist.)	ARPOPHALANGEAL JOINT, arthrodesis of, with	
46300	Fee: \$338.40	Benefit: 75% = \$253.80		
	CARPOMETAC	CARPAL JOINT, arthrodesis	of, with synovectomy if performed (Anaes.) (Assist.)	
46303	Fee: \$376.10	Benefit: 75% = \$282.10		
			ARPOPHALANGEAL JOINT, interposition arthroplasty of t on the 1 ray (Anaes.) (Assist.)	
46306	Fee: \$526.50	Benefit: 75% = \$394.90		
			CARPOPHALANGEAL JOINT - volar plate arthroplasty for realignment on the 1 ray (Anaes.) (Assist.)	
46307	Fee: \$526.50	Benefit: 75% = \$394.90		
	INTERPHALANGEAL JOINT or METACARPOPHALANGEAL JOINT, total replacement arthroplasty or hemiarthroplasty of, including associated synovectomy, tendon transfer or realignment - 1 joint (Anaes.) (Assist.)			
46309	Fee: \$526.50	Benefit: 75% = \$394.90		
	INTERPHALANGEAL JOINT or METACARPOPHALANGEAL JOINT, total replacement arthroplasty or hemiarthroplasty of, including associated synovectomy, tendon transfer or realig 2 joints (Anaes.) (Assist.)			
46312	Fee: \$676.95	Benefit: 75% = \$507.75		
		emiarthroplasty of, including	ARPOPHALANGEAL JOINT, total replacement g associated synovectomy, tendon transfer or realignment -	
46315	Fee: \$902.55	Benefit: 75% = \$676.95		
46318	INTERPHALAN	GEAL JOINT or METACA	ARPOPHALANGEAL JOINT, total replacement	

1 2	miarthroplasty of, including associated synovectomy, tendon transfer or realignment - Assist.)
Fee: \$1,128.25	Benefit: 75% = \$846.20
arthroplasty or he	GEAL JOINT OR METACARPOPHALANGEAL JOINT, total replacement miarthroplasty of, including associated synovectomy, tendon transfer or realignment - Anaes.) (Assist.)
Fee: \$1,353.90	Benefit: 75% = \$1015.45 85% = \$1270.50
	REPLACEMENT ARTHROPLASTY including associated tendon transfer or performed (Anaes.) (Assist.)
Fee: \$807.35	Benefit: 75% = \$605.55
	REPLACEMENT OR RESECTION ARTHROPLASTY using adjacent tendon or cluding associated tendon transfer or realignment when performed (Anaes.) (Assist.)
Fee: \$842.50	Benefit: 75% = \$631.90
INTER-PHALAN	GEAL JOINT or METACARPOPHALANGEAL JOINT, arthrotomy of (Anaes.)
Fee: \$203.15	Benefit: 75% = \$152.40 85% = \$172.70
	GEAL JOINT or METACARPOPHALANGEAL JOINT, ligamentous or capsular nout arthrotomy (Anaes.) (Assist.)
Fee: \$346.10	Benefit: 75% = \$259.60
	GEAL JOINT or METACARPOPHALANGEAL JOINT, ligamentous repair of, using implant (Anaes.) (Assist.)
Fee: \$564.05	Benefit: 75% = \$423.05
	GEAL JOINT or METACARPOPHALANGEAL JOINT, synovectomy, ebridement of, not being a service associated with any procedure related to that joint
Fee: \$263.30	Benefit: 75% = \$197.50 85% = \$223.85
EXTENSOR TEN	DONS or FLEXOR TENDONS of hand or wrist, synovectomy of (Anaes.) (Assist.)
Fee: \$466.20	Benefit: 75% = \$349.65 85% = \$396.30
DISTAL RADIO (Anaes.) (Assist.)	JLNAR JOINT or CARPOMETACARPAL JOINT OR JOINTS, synovectomy of
Fee: \$466.20	Benefit: 75% = \$349.65
	JLNAR JOINT, reconstruction or stabilisation of, including fusion, or ligamentous acision of distal ulna, when performed (Anaes.) (Assist.)
Fee: \$564.05	Benefit: 75% = \$423.05
DIGIT, synovecto	my of flexor tendon or tendons - 1 digit (Anaes.)
Fee: \$244.45	Benefit: 75% = \$183.35 85% = \$207.80
+	my of flexor tendon or tendons - 2 digits (Anaes.) (Assist.)
Fee: \$364.80	Benefit: 75% = \$273.60
	4 joints (Anaes.) (Anaes.) (Anaes.) (Anaes.) (Anaes.) (Anaes.) (Anaes.) (Anaes.) (Anaes.) (Anaes.) (Anaes.) (Anaes.) (Anaes.) (Anaes.) (Assist.) Fee: \$466.20 DISTAL RADIOU (Anaes.) (Assist.) Fee: \$466.20 DISTAL RADIOU (Anaes.) (Assist.) Fee: \$466.20 DISTAL RADIOU (Anaes.) (Assist.) Fee: \$466.20 DISTAL RADIOU (Anaes.) (Assist.) Fee: \$466.20 DISTAL RADIOU (Anaes.) (Assist.) Fee: \$466.20 DISTAL RADIOU (Anaes.) (Assist.)

GICAL OPERAT	IONS 14. HAND SURGER
DIGIT, synovect	omy of flexor tendon or tendons - 3 digits (Anaes.) (Assist.)
Fee: \$488.85	Benefit: 75% = \$366.65
	omy of flexor tendon or tendons - 4 digits (Anaes.) (Assist.)
Fee: \$609.20	Benefit: 75% = \$456.90
	omy of flexor tendon or tendons - 5 digits (Anaes.) (Assist.)
	Benefit: 75% = \$550.05 ATH OF HAND OR WRIST, open operation on, for STENOSING TENOVAGINITIS
(Anaes.)	THE TIAND OR WRIST, open operation on, for STENOSHVO TENOVACHVITIS
Fee: \$210.60	Benefit: 75% = \$157.95 85% = \$179.05
DUPUYTREN'S	CONTRACTURE, subcutaneous fasciotomy for - each hand (Anaes.)
Fee: \$127.90	Benefit: 75% = \$95.95 85% = \$108.75
	CONTRACTURE, palmar fasciectomy for - 1 hand (Anaes.)
	Benefit: 75% = \$157.95 85% = \$179.05
	CONTRACTURE, fasciectomy for, from 1 ray, including dissection of nerves - 1 hand
	, , , , , , , , , , , , , , , , , , , ,
Fee: \$427.95	Benefit: 75% = \$321.00 85% = \$363.80
	CONTRACTURE, fasciectomy for, from 2 rays, including dissection of nerves - 1
hand (Anaes.) (A	.ssist.)
Fee: \$507.70	Benefit: 75% = \$380.80 85% = \$431.55
	CONTRACTURE, fasciectomy for, from 3 or more rays, including dissection of
	Benefit: 75% = \$507.75 NGEAL JOINT, joint capsule release when performed in conjunction with operation fo
	tracture - each procedure (Anaes.) (Assist.)
Fee: \$300.80	Benefit: 75% = \$225.60
	imilar local flap procedure) when performed in conjunction with operation for
Dupuytren's Con	tracture - 1 such procedure (Anaes.) (Assist.)
Fee: \$300.80	Benefit: 75% = \$225.60
	CONTRACTURE, fasciectomy for, from 1 ray, including dissection of nerves -
operation for rec	urrence in that ray (Anaes.) (Assist.)
Fee: \$620.60	Benefit: 75% = \$465.45 85% = \$537.20
	CONTRACTURE, fasciectomy for, from 2 rays, including dissection of nerves - urrence in those rays (Anaes.) (Assist.)
	Benefit: 75% = \$620.65
	CONTRACTURE, fasciectomy for, from 3 or more rays, including dissection of
	n for recurrence in those rays (Anaes.) (Assist.)
Fee: \$959.00	Benefit: 75% = \$719.25
	Fee: \$488.85 DIGIT, synovect Fee: \$609.20 DIGIT, synovect Fee: \$733.35 TENDON SHEA (Anaes.) Fee: \$210.60 DUPUYTREN'S Fee: \$127.90 DUPUYTREN'S (Anaes.) (Assist.) Fee: \$427.95 DUPUYTREN'S hand (Anaes.) (A Fee: \$507.70 DUPUYTREN'S nerves - 1 hand (G Fee: \$676.95 INTER-PHALAI Dupuytren's Con Fee: \$300.80 Z PLASTY (or s Dupuytren's Con Fee: \$300.80 DUPUYTREN'S operation for record Fee: \$620.60 DUPUYTREN'S operation for record Fee: \$827.50 DUPUYTREN'S operation for record Fee: \$827.50 DUPUYTREN'S operation for record Fee: \$827.50

T8. SUF	RGICAL OPERAT	IONS 14. HAND SURGERY	
		METACARPAL OF THE HAND, osteotomy or osteectomy of, and excluding services 7933 or 47936 apply (Anaes.) (Assist.)	
46396	Fee: \$329.60	Benefit: 75% = \$247.20 85% = \$280.20	
	PHALANX OR (Assist.)	METACARPAL OF THE HAND, osteotomy of, with internal fixation (Anaes.)	
46399	Fee: \$517.80	Benefit: 75% = \$388.35	
	PHALANX or N graft material (A	METACARPAL, bone grafting of, for pseudarthrosis (non-union), including obtaining of naes.) (Assist.)	
46402	Fee: \$517.80	Benefit: 75% = \$388.35	
		METACARPAL, bone grafting of, for pseudarthrosis (non-union), involving internal uding obtaining of graft material (Anaes.) (Assist.)	
46405	Fee: \$631.90	Benefit: 75% = \$473.95	
	TENDON, recor	nstruction of, by tendon graft (Anaes.) (Assist.)	
46408	Fee: \$692.00	Benefit: 75% = \$519.00	
	FLEXOR TEND	OON PULLEY, reconstruction of, by graft (Anaes.) (Assist.)	
46411	Fee: \$406.15	Benefit: 75% = \$304.65	
		ENDON PROSTHESIS, INSERTION OF, in preparation for tendon grafting (Anaes.)	
46414	Fee: \$526.40	Benefit: 75% = \$394.80 85% = \$447.45	
	TENDON transf	er for restoration of hand function, each transfer (Anaes.) (Assist.)	
46417	Fee: \$488.85	Benefit: 75% = \$366.65	
	EXTENSOR TE	NDON OF HAND OR WRIST, primary repair of, each tendon (Anaes.)	
46420	Fee: \$204.60	Benefit: 75% = \$153.45 85% = \$173.95	
		ENDON OF HAND OR WRIST, secondary repair of, each tendon (Anaes.) (Assist.)	
46423	Fee: \$327.15	Benefit: 75% = \$245.40 85% = \$278.10	
10123	Fee: \$327.15 Benefit: 75% = \$245.40 85% = \$278.10 FLEXOR TENDON OF HAND OR WRIST, primary repair of, proximal to A1 pulley, each tendon (Anaes.) (Assist.)		
46426	Fee: \$338.40	Benefit: 75% = \$253.80	
	FLEXOR TEND (Anaes.) (Assist	OON OF HAND OR WRIST, secondary repair of, proximal to A1 pulley, each tendon)	
46429	Fee: \$413.65	Benefit: 75% = \$310.25 85% = \$351.65	
	FLEXOR TEND	OON OF HAND, primary repair of, distal to A1 pulley, each tendon (Anaes.) (Assist.)	
46432	Fee: \$451.35	Benefit: 75% = \$338.55	
		OON OF HAND, secondary repair of, distal to A1 pulley, each tendon (Anaes.) (Assist.)	
46435	Fee: \$526.50	Benefit: 75% = \$394.90	
.0.55	1 00. \$320.30	2000 10 /V 400 100	

T8. SUF	RGICAL OPERAT	IONS 14. HAND SURGERY
	MALLET FING	ER, closed pin fixation of (Anaes.)
46438	Fee: \$135.45	Benefit: 75% = \$101.60 85% = \$115.15
	MALLET FING	ER, open repair of, including pin fixation when performed (Anaes.) (Assist.)
46441	Fee: \$327.15	Benefit: 75% = \$245.40 85% = \$278.10
		ER with intra articular fracture involving more than one third of base of terminal eduction (Anaes.) (Assist.)
46442	Fee: \$280.85	Benefit: 75% = \$210.65
	BOUTONNIER	E DEFORMITY without joint contracture, reconstruction of (Anaes.) (Assist.)
46444	Fee: \$488.85	Benefit: 75% = \$366.65
	BOUTONNIER	E DEFORMITY with joint contracture, reconstruction of (Anaes.) (Assist.)
46447	Fee: \$609.20	Benefit: 75% = \$456.90
	EXTENSOR TE	NDON, TENOLYSIS OF, following tendon injury, repair or graft (Anaes.)
46450	Fee: \$225.70	Benefit: 75% = \$169.30
	FLEXOR TEND	ON, TENOLYSIS OF, following tendon injury, repair or graft (Anaes.) (Assist.)
46453	Fee: \$376.10	Benefit: 75% = \$282.10
.0.00		aneous tenotomy of (Anaes.)
46456	Fee: \$97.80	Benefit: 75% = \$73.35 85% = \$83.15
10 130	· ·	or OSTEOMYELITIS on distal phalanx (Anaes.)
46459	Fee: \$188.05	Benefit: 75% = \$141.05 85% = \$159.85
10 10 5		r OSTEOMYELITIS on middle or proximal phalanx, metacarpal or carpus (Anaes.)
46462	Fee: \$300.80	Benefit: 75% = \$225.60 85% = \$255.70
	AMPUTATION	of a supernumerary complete digit (Anaes.)
46464	Fee: \$225.70	Benefit: 75% = \$169.30 85% = \$191.85
		of SINGLE DIGIT, proximal to nail bed, involving section of bone or joint and sue cover (Anaes.)
46465	Fee: \$225.70	Benefit: 75% = \$169.30 85% = \$191.85
	AMPUTATION tissue cover (An	of 2 DIGITS, proximal to nail bed, involving section of bone or joint and requiring soft aes.) (Assist.)
46468	Fee: \$394.90	Benefit: 75% = \$296.20
	AMPUTATION tissue cover (An	of 3 DIGITS, proximal to nail bed, involving section of bone or joint and requiring soft aes.) (Assist.)
46471	Fee: \$564.05	Benefit: 75% = \$423.05 85% = \$480.65
46474	AMPUTATION tissue cover (Ana	of 4 DIGITS, proximal to nail bed, involving section of bone or joint and requiring soft aes.) (Assist.)

T8. SUF	RGICAL OPERAT	ONS 14. HAND SURGERY
	Fee: \$733.35	Benefit: 75% = \$550.05
		of 5 DIGITS, proximal to nail bed, involving section of bone or joint and requiring soft
	tissue cover (Ana	es.) (Assist.)
46477	Fee: \$902.55	Benefit: 75% = \$676.95
		of SINGLE DIGIT, proximal to nail bed, involving section of bone or joint and the cover, including metacarpal (Anaes.) (Assist.)
46480	Fee: \$376.10	Benefit: 75% = \$282.10 85% = \$319.70
	REVISION of A	MPUTATION STUMP to provide adequate soft tissue cover (Anaes.) (Assist.)
46483	Fee: \$300.80	Benefit: 75% = \$225.60 85% = \$255.70
		rate reconstruction of nail bed laceration using magnification, undertaken in the of a hospital (Anaes.)
46486	Fee: \$225.70	Benefit: 75% = \$169.30
		ndary exploration and accurate repair of nail bed deformity using magnification, operating theatre of a hospital (Anaes.) (Assist.)
46489	Fee: \$263.30	Benefit: 75% = \$197.50
		E OF DIGITS OF HAND, flexor or extensor, correction of, involving tissues deeper cutaneous tissue (Anaes.) (Assist.)
46492	Fee: \$361.05	Benefit: 75% = \$270.80
	GANGLION OF in this Group app	HAND, excision of, not being a service associated with a service to which another item lies (Anaes.)
46494	Fee: \$219.95	Benefit: 75% = \$165.00 85% = \$187.00
		MUCOUS CYST OF DISTAL DIGIT, excision of, other than a service associated which item 30107 applies (Anaes.)
46495	Fee: \$203.15	Benefit: 75% = \$152.40 85% = \$172.70
		FLEXOR TENDON SHEATH, excision of, other than a service associated with a item 30107 applies (Anaes.)
46498	Fee: \$219.95	Benefit: 75% = \$165.00 85% = \$187.00
		DORSAL WRIST JOINT, excision of, other than a service associated with a service to 7 applies (Anaes.) (Assist.)
46500	Fee: \$263.30	Benefit: 75% = \$197.50 85% = \$223.85
		VOLAR WRIST JOINT, excision of, other than a service associated with a service to 7 applies (Anaes.) (Assist.)
46501	Fee: \$329.20	Benefit: 75% = \$246.90 85% = \$279.85
		ANGLION OF DORSAL WRIST JOINT, excision of, other than a service associated
	with a service to	which item 30107 applies (Anaes.) (Assist.)
46502	Fee: \$302.95	Benefit: 75% = \$227.25 85% = \$257.55
46503		ANGLION OF VOLAR WRIST JOINT, excision of, other than a service associated which item 30107 applies (Anaes.) (Assist.)

T8. SUF	RGICAL OPERAT	IONS 14. HAND SURGERY		
	Fee: \$378.40	Benefit: 75% = \$283.80 85% = \$321.65		
	NEUROVASCU	LAR ISLAND FLAP, for pulp innervation (Anaes.) (Assist.)		
46504	Fee: \$1,105.55	Benefit: 75% = \$829.20 85% = \$1022.15		
		, transposition or transfer of, on vascular pedicle, complete procedure (Anaes.) (Assist.)		
46507	Fee: \$1,286.20	Benefit: 75% = \$964.65		
46307	-	YLY, surgical reduction of enlarged elements - each digit (Anaes.) (Assist.)		
46510	Fee: \$351.00	Benefit: 75% = \$263.25		
	DIGITAL NAIL (Anaes.)	OF FINGER OR THUMB, removal of, not being a service to which item 46516 applies		
46513	Fee: \$56.50	Benefit: 75% = \$42.40 85% = \$48.05		
	DIGITAL NAIL	OF FINGER OR THUMB, removal of, in the operating theatre of a hospital (Anaes.)		
46516	Fee: \$112.85	Benefit: 75% = \$84.65		
	MIDDLE PALM aftercare) (Anaes	IAR, THENAR OR HYPOTHENAR SPACES OF HAND, drainage of (excluding s.)		
46519	Fee: \$141.25	Benefit: 75% = \$105.95 85% = \$120.10		
	FLEXOR TEND (Anaes.) (Assist.)	ON SHEATH OF FINGER OR THUMB, open operation and drainage for infection		
46522	Fee: \$421.20	Benefit: 75% = \$315.90		
		NFECTION, PARONYCHIA OF HAND, incision for, when performed in an operating ital, not being a service to which another item in this Group applies (excluding after-		
46525	Fee: \$56.50	Benefit: 75% = \$42.40 85% = \$48.05		
		AIL OF FINGER OR THUMB, wedge resection for, including removal of segment of and portion of the nail bed (Anaes.)		
46528	Fee: \$169.50	Benefit: 75% = \$127.15 85% = \$144.10		
		AIL OF FINGER OR THUMB, partial resection of nail, including phenolisation but cision of nail bed (Anaes.)		
46531	Fee: \$85.15	Benefit: 75% = \$63.90 85% = \$72.40		
	NAIL PLATE IN	NJURY OR DEFORMITY, radical excision of nail germinal matrix (Anaes.)		
46534	Fee: \$235.50	Benefit: 75% = \$176.65 85% = \$200.20		
	RGICAL OPERAT			
	Group T8. Surgi			
		Subgroup 15. Orthopaedic		
		TREATMENT OF DISLOCATIONS		
47000	MANDIBLE, tre	eatment of dislocation of, by closed reduction (Anaes.)		

T8. SUF	RGICAL OPERA	TIONS 15. ORTHOPAEDIC
	Fee: \$70.65	Benefit: 75% = \$53.00 85% = \$60.10
	CLAVICLE, tre	eatment of dislocation of, by closed reduction (Anaes.)
47003	Fee: \$84.80	Benefit: 75% = \$63.60 85% = \$72.10
	CLAVICLE, tre	eatment of dislocation of, by open reduction (Anaes.)
47006	Fee: \$170.25	Benefit: 75% = \$127.70 85% = \$144.75
	SHOULDER, to item 47012 app	reatment of dislocation of, requiring general anaesthesia, not being a service to which lies (Anaes.)
47009	Fee: \$169.50	Benefit: 75% = \$127.15 85% = \$144.10
	SHOULDER, tr (Assist.)	reatment of dislocation of, requiring general anaesthesia, open reduction (Anaes.)
47012	Fee: \$338.85	Benefit: 75% = \$254.15
	SHOULDER, to	reatment of dislocation of, not requiring general anaesthesia
47015	Fee: \$84.80	Benefit: 75% = \$63.60 85% = \$72.10
	ELBOW, treatn	nent of dislocation of, by closed reduction (Anaes.)
47018	Fee: \$197.60	Benefit: 75% = \$148.20 85% = \$168.00
	ELBOW, treatn	nent of dislocation of, by open reduction (Anaes.) (Assist.)
47021	Fee: \$263.60	Benefit: 75% = \$197.70
.,,,	RADIOULNA	R JOINT, DISTAL or PROXIMAL, treatment of dislocation of, by closed reduction, not associated with fracture or dislocation in the same region (Anaes.)
47024	Fee: \$197.60	Benefit: 75% = \$148.20 85% = \$168.00
		R JOINT, DISTAL or PROXIMAL, treatment of dislocation of, by open reduction, not associated with fracture or dislocation in the same region (Anaes.) (Assist.)
47027	Fee: \$263.60	Benefit: 75% = \$197.70
		ARPUS on RADIUS and ULNA, or CARPOMETACARPAL JOINT, treatment of by closed reduction (Anaes.)
47030	Fee: \$197.60	Benefit: 75% = \$148.20 85% = \$168.00
		ARPUS on RADIUS and ULNA, or CARPOMETACARPAL JOINT, treatment of by open reduction (Anaes.) (Assist.)
47033	Fee: \$263.60	Benefit: 75% = \$197.70 85% = \$224.10
	INTERPHALA	NGEAL JOINT, treatment of dislocation of, by closed reduction (Anaes.)
47036	Fee: \$84.80	Benefit: 75% = \$63.60 85% = \$72.10
	INTERPHALA	NGEAL JOINT, treatment of dislocation of, by open reduction (Anaes.)
47039	Fee: \$112.85	Benefit: 75% = \$84.65 85% = \$95.95
		PHALANGEAL JOINT, treatment of dislocation of, by closed reduction (Anaes.)
47042	Fee: \$112.85	Benefit: 75% = \$84.65 85% = \$95.95
	1 ,	***************************************

T8. SUF	RGICAL OPERATI	ONS		15. ORTHOPAEDIC
	METACARPOP	HALANGEAL JOINT, tre	eatment of dislocation of, by open re	eduction (Anaes.)
47045	Fee: \$150.75	Benefit: 75% = \$113.10	0 85% = \$128.15	
	HIP, treatment of	dislocation of, by closed i	reduction (Anaes.)	
47048	Fee: \$324.80	Benefit: 75% = \$243.60	0 85% = \$276.10	
	HIP, treatment of	dislocation of, by open re	duction (Anaes.) (Assist.)	
47051	Fee: \$432.95	Benefit: 75% = \$324.75	5	
	KNEE, treatment	of dislocation of, by close	ed reduction (Anaes.) (Assist.)	
47054	Fee: \$324.80	Benefit: 75% = \$243.60	0 85% = \$276.10	
	PATELLA, treats	ment of dislocation of, by	closed reduction (Anaes.)	
47057	Fee: \$127.00	Benefit: 75% = \$95.25	85% = \$107.95	
	PATELLA, treats	ment of dislocation of, by	open reduction (Anaes.)	
47060	Fee: \$169.50	Benefit: 75% = \$127.15	5 85% = \$144.10	
	ANKLE or TAR	SUS, treatment of dislocati	ion of, by closed reduction (Anaes.))
47063	Fee: \$254.20	Benefit: 75% = \$190.65	5 85% = \$216.10	
	ANKLE or TAR	SUS, treatment of dislocati	ion of, by open reduction (Anaes.)	(Assist.)
47066	Fee: \$338.85	Benefit: 75% = \$254.15	5	
	TOE, treatment of	f dislocation of, by closed	reduction (Anaes.)	
47069	Fee: \$70.65	Benefit: 75% = \$53.00	85% = \$60.10	
	TOE, treatment of	of dislocation of, by open re	eduction (Anaes.)	
47072	Fee: \$94.00	Benefit: 75% = \$70.50	85% = \$79.90	
		TREAT	MENT OF FRACTURES	
			racture of, by closed reduction, requescribed in item 47304, 47307, 47	
47301	(See para TN.8.124 Fee: \$86.80	of explanatory notes to this Benefit: $75\% = 65.10		
			sed reduction, requiring anaesthesia n 47301, 47307, 47310, 47313, 473	
47304	(See para TN.8.124 Fee: \$98.90	of explanatory notes to this Benefit: $75\% = 74.20	Category)	
	Phalanx or metac (Anaes.) (Assist.)		e of, by closed reduction with percu	itaneous K wire fixation
47307	(See para TN.8.124 Fee: \$200.00	of explanatory notes to this Benefit: 75% = \$150.00		
	Phalanx or metac	arpal, treatment of fracture	e of, by open reduction with fixation	n (Anaes.) (Assist.)
47310	(See para TN.8.124 Fee: \$330.00	of explanatory notes to this Benefit: 75% = \$247.50		

T8. SUF	RGICAL OPERATIONS 15. ORTHOPAE	EDIC
	Phalanx or metacarpal, treatment of intra articular fracture of, by closed reduction with percutaneous wire fixation (Anaes.) (Assist.)	s K
47313	(See para TN.8.124 of explanatory notes to this Category) Fee: \$320.00 Benefit: 75% = \$240.00	
	Phalanx or metacarpal, treatment of intra articular fracture of, by open reduction with fixation, not provided on the same occasion as a service to which item 47319 applies (Anaes.) (Assist.)	
47316	(See para TN.8.124 of explanatory notes to this Category) Fee: \$635.00 Benefit: 75% = \$476.25	
	Middle phalanx, proximal end, treatment of intra articular fracture of, by open reduction with fixation not provided on the same occasion as a service to which item 47316 applies (Anaes.) (Assist.)	'n,
47319	(See para TN.8.124 of explanatory notes to this Category) Fee: \$650.00 Benefit: 75% = \$487.50	
	CARPUS (excluding scaphoid), treatment of fracture of, not being a service to which item 47351 ap (Anaes.)	plies
47348	Fee: \$94.00 Benefit: 75% = \$70.50 85% = \$79.90	
	CARPUS (excluding scaphoid), treatment of fracture of, by open reduction (Anaes.)	
47351	Fee: \$235.50 Benefit: 75% = \$176.65 85% = \$200.20	
	CARPAL SCAPHOID, treatment of fracture of, not being a service to which item 47357 applies (Anaes.)	
47354	Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10	
	CARPAL SCAPHOID, treatment of fracture of, by open reduction (Anaes.) (Assist.)	
47357	Fee: \$376.55 Benefit: 75% = \$282.45 85% = \$320.10	
	Radius or ulna, or radius and ulna, distal end of, treatment of fracture of, by cast immobilisation, oth than a service associated with a service to which item 47362, 47364, 47367, 47370 or 47373 applies	
47361	(See para TN.8.124 of explanatory notes to this Category) Fee: \$131.85 Benefit: 75% = \$98.90 85% = \$112.10	
	Radius or ulna, or radius and ulna, distal end of, treatment of fracture of, by closed reduction, requir general or major regional anaesthesia, but excluding local infiltration, other than a service associated with a service to which item 47361, 47364, 47367, 47370 or 47373 applies (Anaes.)	
47362	(See para TN.8.124 of explanatory notes to this Category) Fee: \$197.60 Benefit: 75% = \$148.20 85% = \$168.00	
	Radius or ulna, distal end of, not involving joint surface, treatment of fracture of, by open reduction fixation, other than a service associated with a service to which item 47361 or 47362 applies (Anaes (Assist.)	
47364	(See para TN.8.124 of explanatory notes to this Category) Fee: \$280.00 Benefit: 75% = \$210.00	
	Radius, distal end of, treatment of fracture of, by closed reduction with percutaneous fixation, other a service associated with a service to which item 47361 or 47362 applies (Anaes.) (Assist.)	than
47367	(See para TN.8.124 of explanatory notes to this Category) Fee: \$223.60 Benefit: 75% = \$167.70	
47370	Radius, distal end of, treatment of intra articular fracture of, by open reduction with fixation, other the	nan a

T8. SUF	RGICAL OPERAT	TIONS	15. ORTHOPAEDIC
	service associate	ed with a service to which item 47361 or 47362 a	applies (Anaes.) (Assist.)
	(See para TN.8.12 Fee: \$406.00	24 of explanatory notes to this Category) Benefit: 75% = \$304.50	
		of, treatment of intra articular fracture of, by oped with a service to which item 47361 or 47362 a	
47373	(See para TN.8.12 Fee: \$290.00	24 of explanatory notes to this Category) Benefit: 75% = \$217.50	
		LNA, shaft of, treatment of fracture of, by cast in 81, 47384, 47385 or 47386 applies (Anaes.)	nmobilisation, not being a service to
47378	Fee: \$169.50	Benefit: 75% = \$127.15 85% = \$144.10	
	RADIUS OR Utheatre of a hosp	LNA, shaft of, treatment of fracture of, by closed pital (Anaes.)	reduction undertaken in the operating
47381	Fee: \$254.20	Benefit: 75% = \$190.65	
	RADIUS OR U	LNA, shaft of, treatment of fracture of, by open I	reduction (Anaes.) (Assist.)
47384	Fee: \$338.85	Benefit: 75% = \$254.15	
	ulnar joint or pro	LNA, shaft of, treatment of fracture of, in conjunction of the conjunc	gia injury), by closed reduction
47385	Fee: \$291.75	Benefit: 75% = \$218.85	
		LNA, shaft of, treatment of fracture of, in conjunctional radio-humeral joint (Galeazzi or Montegge) (Assist.)	
47386	Fee: \$470.70	Benefit: 75% = \$353.05	
		ULNA, shafts of, treatment of fracture of, by cas 90 or 47393 applies (Anaes.) (Assist.)	t immobilisation, not being a service to
47387	Fee: \$272.95	Benefit: 75% = \$204.75 85% = \$232.05	
		ULNA, shafts of, treatment of fracture of, by cloe of a hospital (Anaes.)	sed reduction undertaken in the
47390	Fee: \$409.55	Benefit: 75% = \$307.20	
	RADIUS AND	ULNA, shafts of, treatment of fracture of, by ope	en reduction (Anaes.) (Assist.)
47393	Fee: \$546.00	Benefit: 75% = \$409.50	
	OLECRANON,	treatment of fracture of, not being a service to v	which item 47399 applies (Anaes.)
47396	Fee: \$188.20	Benefit: 75% = \$141.15 85% = \$160.00	
	OLECRANON,	treatment of fracture of, by open reduction (Ana	es.) (Assist.)
47399	Fee: \$376.55	Benefit: 75% = \$282.45	
	OLECRANON, tendon (Anaes.)	treatment of fracture of, involving excision of ol (Assist.)	ecranon fragment and reimplantation of
	Fee: \$282.35	Benefit: 75% = \$211.80 85% = \$240.00	

	RGICAL OPERAT	TIONS 15. ORTHOPAEDIC
	RADIUS, treatm	nent of fracture of head or neck of, closed reduction of (Anaes.)
47405	Fee: \$188.20	Benefit: 75% = \$141.15 85% = \$160.00
		nent of fracture of head or neck of, open reduction of, including internal fixation and performed (Anaes.) (Assist.)
47408	Fee: \$376.55	Benefit: 75% = \$282.45
	HUMERUS, trea (Anaes.)	atment of fracture of tuberosity of, not being a service to which item 47417 applies
47411	Fee: \$112.85	Benefit: 75% = \$84.65 85% = \$95.95
	HUMERUS, trea	atment of fracture of tuberosity of, by open reduction (Anaes.)
47414	Fee: \$226.00	Benefit: 75% = \$169.50 85% = \$192.10
	HUMERUS, trea	atment of fracture of tuberosity of, and associated dislocation of shoulder, by closed s.) (Assist.)
47417	Fee: \$263.60	Benefit: 75% = \$197.70 85% = \$224.10
	HUMERUS, trea	atment of fracture of tuberosity of, and associated dislocation of shoulder, by open s.) (Assist.)
47420	Fee: \$517.80	Benefit: 75% = \$388.35
	HUMERUS, pro 47432 applies (A	oximal, treatment of fracture of, not being a service to which item 47426, 47429 or Anaes.)
47423	Fee: \$216.50	Benefit: 75% = \$162.40 85% = \$184.05
	HUMERUS, pro of a hospital (Ar	eximal, treatment of fracture of, by closed reduction, undertaken in the operating theatre naes.)
47426	Fee: \$324.80	Benefit: 75% = \$243.60
	HUMERUS, pro	oximal, treatment of fracture of, by open reduction (Anaes.) (Assist.)
47429	Fee: \$432.95	Benefit: 75% = \$324.75
	HUMERUS, pro	eximal, treatment of intra-articular fracture of, by open reduction (Anaes.) (Assist.)
47432	Fee: \$541.30	Benefit: 75% = \$406.00
	HUMERUS, pro	oximal, treatment of fracture of, and associated dislocation of shoulder, by closed s.) (Assist.)
1		
47435	Fee: \$414.25	Benefit: 75% = \$310.70 85% = \$352.15
47435		oximal, treatment of fracture of, and associated dislocation of shoulder, by open
47435 47438	HUMERUS, pro	oximal, treatment of fracture of, and associated dislocation of shoulder, by open
	HUMERUS, proreduction (Anaes Fee: \$659.15 HUMERUS, pro	eximal, treatment of fracture of, and associated dislocation of shoulder, by open s.) (Assist.)
	HUMERUS, proreduction (Anaes Fee: \$659.15 HUMERUS, pro	eximal, treatment of fracture of, and associated dislocation of shoulder, by open s.) (Assist.) Benefit: 75% = \$494.40 eximal, treatment of intra-articular fracture of, and associated dislocation of shoulder, by

T8. SUF	RGICAL OPERAT	ONS 15. ORTHOPAED	
	Fee: \$226.00	Benefit: 75% = \$169.50 85% = \$192.10	
	HUMERUS, sha a hospital (Anae	ft of, treatment of fracture of, by closed reduction, undertaken in the operating theatre s.)	
47447	Fee: \$338.85	Benefit: 75% = \$254.15	
	HUMERUS, sha	ft of, treatment of fracture of, by internal or external fixation (Anaes.) (Assist.)	
47450	Fee: \$451.95	Benefit: 75% = \$339.00	
	HUMERUS, sha	ft of, treatment of fracture of, by intramedullary fixation (Anaes.) (Assist.)	
47451	Fee: \$544.80	Benefit: 75% = \$408.60	
		al, (supracondylar or condylar), treatment of fracture of, not being a service to which 459 applies (Anaes.) (Assist.)	
47453	Fee: \$263.60	Benefit: 75% = \$197.70 85% = \$224.10	
		al (supracondylar or condylar), treatment of fracture of, by closed reduction, undertak heatre of a hospital (Anaes.)	
47456	Fee: \$395.50	Benefit: 75% = \$296.65	
		al (supracondylar or condylar), treatment of fracture of, by open reduction, undertaken heatre of a hospital (Anaes.) (Assist.)	
47459	Fee: \$527.25	Benefit: 75% = \$395.45	
	CLAVICLE, tre	tment of fracture of, not being a service to which item 47465 applies (Anaes.)	
47462	Fee: \$112.85	Benefit: 75% = \$84.65 85% = \$95.95	
	CLAVICLE, tre	tment of fracture of, by open reduction (Anaes.) (Assist.)	
47465	Fee: \$226.00	Benefit: 75% = \$169.50 85% = \$192.10	
	STERNUM, treatment of fracture of, not being a service to which item 47467 applies (Anaes.)		
47466	Fee: \$112.85	Benefit: 75% = \$84.65 85% = \$95.95	
	STERNUM, trea	tment of fracture of, by open reduction (Anaes.)	
47467	Fee: \$226.00	Benefit: 75% = \$169.50	
	SCAPULA, nec	or glenoid region of, treatment of fracture of, by open reduction (Anaes.) (Assist.)	
47468	Fee: \$432.95	Benefit: 75% = \$324.75 85% = \$368.05	
	RIBS (1 or more), treatment of fracture of - each attendance	
47471	Fee: \$43.00	Benefit: 75% = \$32.25 85% = \$36.55	
	PELVIC RING,	reatment of fracture of, not involving disruption of pelvic ring or acetabulum	
47474	Fee: \$188.20	Benefit: 75% = \$141.15 85% = \$160.00	
		reatment of fracture of, with disruption of pelvic ring or acetabulum	
47477	Fee: \$235.50	Benefit: 75% = \$176.65 85% = \$200.20	
,		reatment of fracture of, requiring traction (Anaes.) (Assist.)	
47480	Fee: \$470.70	Benefit: 75% = \$353.05	
T / TOU	1 φτ/0./0	Delicite 13/0 4333.03	

T8. SUF	RGICAL OPERATI	ONS	15. ORTHOPAEDIC
	PELVIC RING, t	reatment of fracture of, requiring	control by external fixation (Anaes.) (Assist.)
47483	Fee: \$564.85	Benefit: 75% = \$423.65	
		reatment of fracture of, by open g diastasis of pubic symphysis (reduction and involving internal fixation of anterior Anaes.) (Assist.)
47486	Fee: \$941.45	Benefit: 75% = \$706.10	
			reduction and involving internal fixation of posterior out fixation of anterior segment (Anaes.) (Assist.)
47489	Fee: \$1,412.20	Benefit: 75% = \$1059.15	
	ACETABULUM	, treatment of fracture of, and ass	sociated dislocation of hip (Anaes.)
47492	Fee: \$235.50	Benefit: 75% = \$176.65 85%	6 = \$200.20
	ACETABULUM (Assist.)	, treatment of fracture of, and ass	sociated dislocation of hip, requiring traction (Anaes.)
47495	Fee: \$470.70	Benefit: 75% = \$353.05 85%	6 = \$400.10
		, treatment of fracture of, and ass action (Anaes.) (Assist.)	sociated dislocation of hip, requiring internal fixation,
47498	Fee: \$706.05	Benefit: 75% = \$529.55	
	including any ost		ture of, by open reduction and internal fixation, my required for exposure and subsequent repair, and apply (Anaes.) (Assist.)
47501	Fee: \$941.45	Benefit: 75% = \$706.10	
	any osteotomy, os		f, by open reduction and internal fixation, including ed for exposure and subsequent repair, and excluding nes.) (Assist.)
47504	Fee: \$1,412.20	Benefit: 75% = \$1059.15 85	% = \$1328.80
	any osteotomy, os		of, by open reduction and internal fixation, including ed for exposure and subsequent repair, and excluding ees.) (Assist.)
47507	Fee: \$1,412.20	Benefit: 75% = \$1059.15	
	including any ost		cture of, by open reduction and internal fixation, my required for exposure and subsequent repair, and apply (Anaes.) (Assist.)
47510	Fee: \$1,412.20	Benefit: 75% = \$1059.15	
		OINT DISRUPTION, treatment service to which items 47501 to	of, requiring internal fixation, being a service 47510 apply (Anaes.) (Assist.)
47513	Fee: \$376.55	Benefit: 75% = \$282.45	
	FEMUR, treatme	nt of fracture of, by closed reduc	tion or traction (Anaes.) (Assist.)
47516	Fee: \$432.95	Benefit: 75% = \$324.75 85%	6 = \$368.05
47519			racture of, by internal fixation (Anaes.) (Assist.)

T8. SUF	RGICAL OPERAT	IONS 15. ORTHOPAEDIC	
	Fee: \$866.20	Benefit: 75% = \$649.65	
	FEMUR, treatme	ent of subcapital fracture of, by hemi-arthroplasty (Anaes.) (Assist.)	
47522	Fee: \$753.25	Benefit: 75% = \$564.95	
	FEMUR, treatme	ent of fracture of, for slipped capital femoral epiphysis (Anaes.) (Assist.)	
47525	Fee: \$866.20	Benefit: 75% = \$649.65	
	FEMUR, treatme	ent of fracture of, by internal fixation or external fixation (Anaes.) (Assist.)	
47528	Fee: \$753.25	Benefit: 75% = \$564.95	
	FEMUR, treatme	ent of fracture of shaft, by intramedullary fixation and cross fixation (Anaes.) (Assist.)	
47531	Fee: \$960.25	Benefit: 75% = \$720.20	
		ar region of, treatment of intra-articular (T-shaped condylar) fracture of, requiring with or without internal fixation of 1 or more osteochondral fragments (Anaes.)	
47534	Fee: \$1,082.70	Benefit: 75% = \$812.05	
		ar region of, treatment of fracture of, requiring internal fixation of 1 or more agments, not being a service associated with a service to which item 47534 applies)	
47537	Fee: \$432.95	Benefit: 75% = \$324.75 85% = \$368.05	
	HIP SPICA OR	SHOULDER SPICA, application of, as an independent procedure (Anaes.)	
47540	Fee: \$216.50	Benefit: 75% = \$162.40 85% = \$184.05	
	TIBIA, plateau of, treatment of medial or lateral fracture of, not being a service to which item 47546 or 47549 applies (Anaes.)		
47543	Fee: \$226.00	Benefit: 75% = \$169.50 85% = \$192.10	
	TIBIA, plateau o	of, treatment of medial or lateral fracture of, by closed reduction (Anaes.)	
47546	Fee: \$338.85	Benefit: 75% = \$254.15 85% = \$288.05	
	TIBIA, plateau o	of, treatment of medial or lateral fracture of, by open reduction (Anaes.) (Assist.)	
47549	Fee: \$451.95	Benefit: 75% = \$339.00	
	TIBIA, plateau of, treatment of both medial and lateral fractures of, not being a service to which it 47555 or 47558 applies (Anaes.) (Assist.)		
47552	Fee: \$376.55	Benefit: 75% = \$282.45 85% = \$320.10	
	TIBIA, plateau o	of, treatment of both medial and lateral fractures of, by closed reduction (Anaes.)	
47555	Fee: \$564.85	Benefit: 75% = \$423.65	
	TIBIA, plateau o	of, treatment of both medial and lateral fractures of, by open reduction (Anaes.) (Assist.)	
47558	Fee: \$753.25	Benefit: 75% = \$564.95	
		treatment of fracture of, by cast immobilisation, not being a service to which item 7570 or 47573 applies (Anaes.)	
47561	Fee: \$272.95	Benefit: 75% = \$204.75 85% = \$232.05	

Tibla, shaft of, treatment of fracture of, by closed reduction, with or without treatment of fibula fracture (Anaes.) Fee: \$409.55	PAEDIC		
TIBIA, shaft of, treatment of fracture of, by internal fixation or external fixation (Anaes.) (Assist Fee: \$712.40 Benefit: 75% = \$534.30 TIBIA, shaft of, treatment of fracture of, by intramedullary fixation and cross fixation (Anaes.) (Fee: \$908.05 Benefit: 75% = \$681.05 TIBIA, shaft of, treatment of intra-articular fracture of, by closed reduction, with or without treat fibular fracture (Anaes.) (Assist.) 47567 Fee: \$475.35 Benefit: 75% = \$356.55 85% = \$404.05 TIBIA, shaft of, treatment of fracture of, by open reduction, with or without treatment of fibular (Anaes.) (Assist.) Fee: \$456.00 Benefit: 75% = \$409.50 85% = \$464.10 TIBIA, shaft of, treatment of intra-articular fracture of, by open reduction, with or without treatment in the fibular fracture (Anaes.) (Assist.) Fee: \$682.55 Benefit: 75% = \$511.95 FIBULA, treatment of fracture of (Anaes.) Fee: \$112.85 Benefit: 75% = \$84.65 85% = \$95.95 PATELLA, treatment of fracture of, not being a service to which item 47582 or 47585 applies (Arsist.) Fee: \$160.05 Benefit: 75% = \$120.05 85% = \$136.05 PATELLA, treatment of fracture of, by excision of patella or pole with reattachment of tendon (Assist.) 47582 Fee: \$329.60 Benefit: 75% = \$247.20 PATELLA, treatment of fracture of, by internal fixation (Anaes.) (Assist.) 47585 Fee: \$423.75 Benefit: 75% = \$317.85 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar or tibial articular surfaces and requiring repair or reconstruction of 1 or more ligaments (Anaes.) (Assist.) KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar and tibial articular surfaces and requiring repair or reconstruction of 1 or more ligaments (Anaes.) (Assist.)	r		
TiblA, shaft of, treatment of fracture of, by intramedullary fixation and cross fixation (Anaes.) (47566 Fee: \$908.05 Benefit: 75% = \$681.05 TiblA, shaft of, treatment of intra-articular fracture of, by closed reduction, with or without treatibular fracture (Anaes.) (Assist.) 47567 Fee: \$475.35 Benefit: 75% = \$356.55 85% = \$404.05 TiblA, shaft of, treatment of fracture of, by open reduction, with or without treatment of fibular (Anaes.) (Assist.) 47570 Fee: \$456.00 Benefit: 75% = \$409.50 85% = \$464.10 TiblA, shaft of, treatment of intra-articular fracture of, by open reduction, with or without treatment in fibular fracture (Anaes.) (Assist.) 47573 Fee: \$682.55 Benefit: 75% = \$511.95 FIBULA, treatment of fracture of (Anaes.) 47574 Fee: \$112.85 Benefit: 75% = \$84.65 85% = \$95.95 PATELLA, treatment of fracture of, not being a service to which item 47582 or 47585 applies (Assist.) 47579 Fee: \$160.05 Benefit: 75% = \$120.05 85% = \$136.05 PATELLA, treatment of fracture of, by excision of patella or pole with reattachment of tendon (Assist.) 47582 Fee: \$329.60 Benefit: 75% = \$247.20 PATELLA, treatment of fracture of, by internal fixation (Anaes.) (Assist.) 47585 Fee: \$423.75 Benefit: 75% = \$317.85 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar and tibial articular surfaces and requiring repair or reconstruction of 1 or more ligaments (Anaes.) (Assist.) 47588 Fee: \$1,317.80 Benefit: 75% = \$988.35 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar and tibial articular surfaces and requiring repair or reconstruction of 1 or more ligaments (Anaes.) (Assist.)			
TIBIA, shaft of, treatment of fracture of, by intramedullary fixation and cross fixation (Anaes.) (Fee: \$908.05)		
47566 Fee: \$908.05 Benefit: 75% = \$681.05 TIBIA, shaft of, treatment of intra-articular fracture of, by closed reduction, with or without treat fibular fracture (Anaes.) (Assist.) 47567 Fee: \$475.35 Benefit: 75% = \$356.55 85% = \$404.05 TIBIA, shaft of, treatment of fracture of, by open reduction, with or without treatment of fibular (Anaes.) (Assist.) 47570 Fee: \$546.00 Benefit: 75% = \$409.50 85% = \$464.10 TIBIA, shaft of, treatment of intra-articular fracture of, by open reduction, with or without treatment in fibular fracture (Anaes.) (Assist.) 47573 Fee: \$682.55 Benefit: 75% = \$511.95 FIBULA, treatment of fracture of (Anaes.) 47576 Fee: \$112.85 Benefit: 75% = \$84.65 85% = \$95.95 PATELLA, treatment of fracture of, not being a service to which item 47582 or 47585 applies (Anaes.) 47579 Fee: \$160.05 Benefit: 75% = \$120.05 85% = \$136.05 PATELLA, treatment of fracture of, by excision of patella or pole with reattachment of tendon (Assist.) 47582 Fee: \$329.60 Benefit: 75% = \$247.20 PATELLA, treatment of fracture of, by internal fixation (Anaes.) (Assist.) 47585 Fee: \$423.75 Benefit: 75% = \$317.85 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar or tibial articular surfaces and requiring repair or reconstruction of 1 or more ligaments (Anaes.) (Assist.) 47588 Fee: \$1,317.80 Benefit: 75% = \$988.35 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar and tibial articular surfaces and requiring repair or reconstruction of 1 or more ligaments (Anaes.) (Assist.)			
TIBIA, shaft of, treatment of intra-articular fracture of, by closed reduction, with or without treat fibular fracture (Anaes.) (Assist.) Fee: \$475.35 Benefit: 75% = \$356.55 85% = \$404.05 TIBIA, shaft of, treatment of fracture of, by open reduction, with or without treatment of fibular (Anaes.) (Assist.) Fee: \$546.00 Benefit: 75% = \$409.50 85% = \$464.10 TIBIA, shaft of, treatment of intra-articular fracture of, by open reduction, with or without treatment of fibular fracture (Anaes.) (Assist.) Fee: \$682.55 Benefit: 75% = \$\$11.95 FIBULA, treatment of fracture of (Anaes.) Fee: \$112.85 Benefit: 75% = \$84.65 85% = \$95.95 PATELLA, treatment of fracture of, not being a service to which item 47582 or 47585 applies (Anaes.) Fee: \$160.05 Benefit: 75% = \$12.0.05 85% = \$136.05 PATELLA, treatment of fracture of, by excision of patella or pole with reattachment of tendon (Assist.) Fee: \$329.60 Benefit: 75% = \$247.20 PATELLA, treatment of fracture of, by internal fixation (Anaes.) (Assist.) Fee: \$423.75 Benefit: 75% = \$317.85 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar or tibial articular surfaces and requiring repair or reconstruction of 1 or more ligaments (Anaes.) (Assist.) Fee: \$1,317.80 Benefit: 75% = \$988.35 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar and tibial articular surfaces and requiring repair or reconstruction of 1 or more ligaments (Anaes.) (Assist.)	Assist.)		
fibular fracture (Anaes.) (Assist.) Fee: \$475.35 Benefit: 75% = \$356.55 85% = \$404.05 TIBIA, shaft of, treatment of fracture of, by open reduction, with or without treatment of fibular (Anaes.) (Assist.) Fee: \$546.00 Benefit: 75% = \$409.50 85% = \$464.10 TIBIA, shaft of, treatment of intra-articular fracture of, by open reduction, with or without treatment of fibular fracture (Anaes.) (Assist.) Fee: \$682.55 Benefit: 75% = \$\$11.95 FIBULA, treatment of fracture of (Anaes.) Fee: \$112.85 Benefit: 75% = \$84.65 85% = \$95.95 PATELLA, treatment of fracture of, not being a service to which item 47582 or 47585 applies (Anaes.) Fee: \$160.05 Benefit: 75% = \$12.005 85% = \$136.05 PATELLA, treatment of fracture of, by excision of patella or pole with reattachment of tendon (Assist.) Fee: \$329.60 Benefit: 75% = \$247.20 PATELLA, treatment of fracture of, by internal fixation (Anaes.) (Assist.) Fee: \$423.75 Benefit: 75% = \$317.85 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar or tibial articular surfaces and requiring repair or reconstruction of 1 or more ligaments (Anaes.) (Assist.) Fee: \$1,317.80 Benefit: 75% = \$988.35 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar and tibial articular surfaces and requiring repair or reconstruction of 1 or more ligaments (Anaes.) (Assist.)			
TIBIA, shaft of, treatment of fracture of, by open reduction, with or without treatment of fibular (Anaes.) (Assist.) Fee: \$546.00 Benefit: 75% = \$409.50 85% = \$464.10 TIBIA, shaft of, treatment of intra-articular fracture of, by open reduction, with or without treatment in the fibula fracture (Anaes.) (Assist.) Fee: \$682.55 Benefit: 75% = \$511.95 FIBULA, treatment of fracture of (Anaes.) Fee: \$112.85 Benefit: 75% = \$84.65 85% = \$95.95 PATELLA, treatment of fracture of, not being a service to which item 47582 or 47585 applies (Anaes.) Fee: \$160.05 Benefit: 75% = \$120.05 85% = \$136.05 PATELLA, treatment of fracture of, by excision of patella or pole with reattachment of tendon (Anaes.) Fee: \$329.60 Benefit: 75% = \$247.20 PATELLA, treatment of fracture of, by internal fixation (Anaes.) (Assist.) Fee: \$423.75 Benefit: 75% = \$317.85 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar or tibial articular surfaces and requiring repair or reconstruction of 1 or more ligaments (Anaes.) (Assist.) Fee: \$1,317.80 Benefit: 75% = \$988.35 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar and tibial articular surfaces and requiring repair or reconstruction of 1 or more ligamen (Anaes.) (Assist.)	ment of		
(Anaes.) (Assist.) Fee: \$546.00 Benefit: 75% = \$409.50 85% = \$464.10 TIBIA, shaft of, treatment of intra-articular fracture of, by open reduction, with or without treatment of fibula fracture (Anaes.) (Assist.) Fee: \$682.55 Benefit: 75% = \$511.95 FIBULA, treatment of fracture of (Anaes.) 47576 Fee: \$112.85 Benefit: 75% = \$84.65 85% = \$95.95 PATELLA, treatment of fracture of, not being a service to which item 47582 or 47585 applies (Anaes.) Fee: \$160.05 Benefit: 75% = \$120.05 85% = \$136.05 PATELLA, treatment of fracture of, by excision of patella or pole with reattachment of tendon (Anaes.) 47582 Fee: \$329.60 Benefit: 75% = \$247.20 PATELLA, treatment of fracture of, by internal fixation (Anaes.) (Assist.) Fee: \$423.75 Benefit: 75% = \$317.85 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar or tibial articular surfaces and requiring repair or reconstruction of 1 or more ligaments (Anaes.) (Assist.) Fee: \$1,317.80 Benefit: 75% = \$988.35 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar and tibial articular surfaces and requiring repair or reconstruction of 1 or more ligament (Anaes.) (Assist.)			
TIBIA, shaft of, treatment of intra-articular fracture of, by open reduction, with or without treatn fibula fracture (Anaes.) (Assist.) Fee: \$682.55 Benefit: 75% = \$511.95 FIBULA, treatment of fracture of (Anaes.) Fee: \$112.85 Benefit: 75% = \$84.65 85% = \$95.95 PATELLA, treatment of fracture of, not being a service to which item 47582 or 47585 applies (Anaes.) Fee: \$160.05 Benefit: 75% = \$120.05 85% = \$136.05 PATELLA, treatment of fracture of, by excision of patella or pole with reattachment of tendon (Assist.) Fee: \$329.60 Benefit: 75% = \$247.20 PATELLA, treatment of fracture of, by internal fixation (Anaes.) (Assist.) Fee: \$423.75 Benefit: 75% = \$317.85 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar or tibial articular surfaces and requiring repair or reconstruction of 1 or more ligaments (Anaes.) (Assist.) Fee: \$1,317.80 Benefit: 75% = \$988.35 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar and tibial articular surfaces and requiring repair or reconstruction of 1 or more ligament (Anaes.) (Assist.)	fracture		
fibula fracture (Anaes.) (Assist.) Fee: \$682.55 Benefit: 75% = \$511.95 FIBULA, treatment of fracture of (Anaes.) Fee: \$112.85 Benefit: 75% = \$84.65 85% = \$95.95 PATELLA, treatment of fracture of, not being a service to which item 47582 or 47585 applies (Anaes.) Fee: \$160.05 Benefit: 75% = \$120.05 85% = \$136.05 PATELLA, treatment of fracture of, by excision of patella or pole with reattachment of tendon (Anaes.) Fee: \$329.60 Benefit: 75% = \$247.20 PATELLA, treatment of fracture of, by internal fixation (Anaes.) (Assist.) Fee: \$423.75 Benefit: 75% = \$317.85 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar or tibial articular surfaces and requiring repair or reconstruction of 1 or more ligaments (Anaes.) (Assist.) Fee: \$1,317.80 Benefit: 75% = \$988.35 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar and tibial articular surfaces and requiring repair or reconstruction of 1 or more ligament condylar and tibial articular surfaces and requiring repair or reconstruction of 1 or more ligament (Anaes.) (Assist.)			
FIBULA, treatment of fracture of (Anaes.) Fee: \$112.85 Benefit: 75% = \$84.65 85% = \$95.95 PATELLA, treatment of fracture of, not being a service to which item 47582 or 47585 applies (Anaes.) Fee: \$160.05 Benefit: 75% = \$120.05 85% = \$136.05 PATELLA, treatment of fracture of, by excision of patella or pole with reattachment of tendon (Assist.) Fee: \$329.60 Benefit: 75% = \$247.20 PATELLA, treatment of fracture of, by internal fixation (Anaes.) (Assist.) Fee: \$423.75 Benefit: 75% = \$317.85 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar or tibial articular surfaces and requiring repair or reconstruction of 1 or more ligaments (Anaes.) (Assist.) Fee: \$1,317.80 Benefit: 75% = \$988.35 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar and tibial articular surfaces and requiring repair or reconstruction of 1 or more ligament (Anaes.) (Assist.)	nent of		
Fee: \$112.85 Benefit: 75% = \$84.65 85% = \$95.95 PATELLA, treatment of fracture of, not being a service to which item 47582 or 47585 applies (A 47579 Fee: \$160.05 Benefit: 75% = \$120.05 85% = \$136.05 PATELLA, treatment of fracture of, by excision of patella or pole with reattachment of tendon (A (Assist.)) 47582 Fee: \$329.60 Benefit: 75% = \$247.20 PATELLA, treatment of fracture of, by internal fixation (Anaes.) (Assist.) 47585 Fee: \$423.75 Benefit: 75% = \$317.85 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar or tibial articular surfaces and requiring repair or reconstruction of 1 or more ligaments (Anaes.) (Assist.) 47588 Fee: \$1,317.80 Benefit: 75% = \$988.35 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar and tibial articular surfaces and requiring repair or reconstruction of 1 or more ligament (Anaes.) (Assist.)			
PATELLA, treatment of fracture of, not being a service to which item 47582 or 47585 applies (A Fee: \$160.05	FIBULA, treatment of fracture of (Anaes.)		
Fee: \$160.05 Benefit: 75% = \$120.05 85% = \$136.05 PATELLA, treatment of fracture of, by excision of patella or pole with reattachment of tendon (Assist.) Fee: \$329.60 Benefit: 75% = \$247.20 PATELLA, treatment of fracture of, by internal fixation (Anaes.) (Assist.) Fee: \$423.75 Benefit: 75% = \$317.85 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar or tibial articular surfaces and requiring repair or reconstruction of 1 or more ligaments (Anaes.) (Assist.) Fee: \$1,317.80 Benefit: 75% = \$988.35 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar and tibial articular surfaces and requiring repair or reconstruction of 1 or more ligamen (Anaes.) (Assist.)	Benefit: 75% = \$84.65 85% = \$95.95		
PATELLA, treatment of fracture of, by excision of patella or pole with reattachment of tendon (Assist.) Fee: \$329.60 Benefit: 75% = \$247.20 PATELLA, treatment of fracture of, by internal fixation (Anaes.) (Assist.) Fee: \$423.75 Benefit: 75% = \$317.85 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar or tibial articular surfaces and requiring repair or reconstruction of 1 or more ligaments (Anaes.) (Assist.) Fee: \$1,317.80 Benefit: 75% = \$988.35 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar and tibial articular surfaces and requiring repair or reconstruction of 1 or more ligamen (Anaes.) (Assist.)	(naes.)		
(Assist.) Fee: \$329.60 Benefit: 75% = \$247.20 PATELLA, treatment of fracture of, by internal fixation (Anaes.) (Assist.) Fee: \$423.75 Benefit: 75% = \$317.85 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar or tibial articular surfaces and requiring repair or reconstruction of 1 or more ligaments (Anaes.) (Assist.) Fee: \$1,317.80 Benefit: 75% = \$988.35 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar and tibial articular surfaces and requiring repair or reconstruction of 1 or more ligamen (Anaes.) (Assist.)			
PATELLA, treatment of fracture of, by internal fixation (Anaes.) (Assist.) Fee: \$423.75 Benefit: 75% = \$317.85 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar or tibial articular surfaces and requiring repair or reconstruction of 1 or more ligaments (Anaes.) (Assist.) Fee: \$1,317.80 Benefit: 75% = \$988.35 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar and tibial articular surfaces and requiring repair or reconstruction of 1 or more ligamen (Anaes.) (Assist.)	Anaes.)		
47585 Fee: \$423.75 Benefit: 75% = \$317.85 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar or tibial articular surfaces and requiring repair or reconstruction of 1 or more ligaments (Anaes.) (Assist.) Fee: \$1,317.80 Benefit: 75% = \$988.35 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar and tibial articular surfaces and requiring repair or reconstruction of 1 or more ligamen (Anaes.) (Assist.)			
KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar or tibial articular surfaces and requiring repair or reconstruction of 1 or more ligaments (Anaes.) (Assist.) Fee: \$1,317.80 Benefit: 75% = \$988.35 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar and tibial articular surfaces and requiring repair or reconstruction of 1 or more ligamen (Anaes.) (Assist.)			
condylar or tibial articular surfaces and requiring repair or reconstruction of 1 or more ligaments (Anaes.) (Assist.) Fee: \$1,317.80 Benefit: 75% = \$988.35 KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar and tibial articular surfaces and requiring repair or reconstruction of 1 or more ligamen (Anaes.) (Assist.)			
KNEE JOINT, treatment of fracture of, by internal fixation of intra-articular fractures of femoral condylar and tibial articular surfaces and requiring repair or reconstruction of 1 or more ligamen (Anaes.) (Assist.)			
condylar and tibial articular surfaces and requiring repair or reconstruction of 1 or more ligamen (Anaes.) (Assist.)			
47591 Fee: \$1,600.65 Benefit: 75% = \$1200.50			
ANKLE JOINT, treatment of fracture of, not being a service to which item 47597 applies (Anaes	s.)		
47594 Fee: \$216.50 Benefit: 75% = \$162.40 85% = \$184.05			
ANKLE JOINT, treatment of fracture of, by closed reduction (Anaes.)			
47597 Fee: \$324.80 Benefit: 75% = \$243.60 85% = \$276.10			

T8. SUF	RGICAL OPERATI	ONS 15. ORTHOPAEDIC	
	ANKLE JOINT, (Anaes.) (Assist.)	treatment of fracture of, by internal fixation of 1 of malleolus, fibula or diastasis	
47600	Fee: \$432.95	Benefit: 75% = \$324.75	
	ANKLE JOINT, diastasis (Anaes.)	treatment of fracture of, by internal fixation of more than 1 of malleolus, fibula or (Assist.)	
47603	Fee: \$564.85	Benefit: 75% = \$423.65	
		OR TALUS, treatment of fracture of, not being a service to which item 47609, 47612, applies, with or without dislocation (Anaes.)	
47606	Fee: \$235.50	Benefit: 75% = \$176.65 85% = \$200.20	
	CALCANEUM ((Anaes.) (Assist.)	OR TALUS, treatment of fracture of, by closed reduction, with or without dislocation	
47609	Fee: \$353.05	Benefit: 75% = \$264.80 85% = \$300.10	
	CALCANEUM (dislocation (Anae	OR TALUS, treatment of intra-articular fracture of, by closed reduction, with or without es.) (Assist.)	
47612	Fee: \$409.55	Benefit: 75% = \$307.20 85% = \$348.15	
	CALCANEUM ((Anaes.) (Assist.)	OR TALUS, treatment of fracture of, by open reduction, with or without dislocation	
47615	Fee: \$470.70	Benefit: 75% = \$353.05 85% = \$400.10	
	CALCANEUM OR TALUS, treatment of intra-articular fracture of, by open reduction, with or without dislocation (Anaes.) (Assist.)		
47618	Fee: \$588.45	Benefit: 75% = \$441.35	
	TARSO-METATARSAL, treatment of intra-articular fracture of, by closed reduction, with or without dislocation (Anaes.) (Assist.)		
47621	Fee: \$409.55	Benefit: 75% = \$307.20 85% = \$348.15	
	TARSO-METATARSAL, treatment of fracture of, by open reduction, with or without dislocation (Anaes.) (Assist.)		
47624	Fee: \$564.85	Benefit: 75% = \$423.65	
	TARSUS (excluding calcaneum or talus), treatment of fracture of (Anaes.)		
47627	Fee: \$160.05	Benefit: 75% = \$120.05 85% = \$136.05	
	TARSUS (excluding calcaneum or talus), treatment of fracture of, by open reduction, with or without dislocation (Anaes.) (Assist.)		
47630	Fee: \$338.85	Benefit: 75% = \$254.15 85% = \$288.05	
	METATARSAL,	1 of, treatment of fracture of (Anaes.)	
47633	Fee: \$112.85	Benefit: 75% = \$84.65 85% = \$95.95	
		1 of, treatment of fracture of, by closed reduction (Anaes.)	
47636	Fee: \$169.50	Benefit: 75% = \$127.15 85% = \$144.10	
., 550		1 of, treatment of fracture of, by open reduction (Anaes.)	
47639	ĺ		

T8. SUF	RGICAL OPERAT	IONS 15. ORTHOPAEDIC
	Fee: \$226.00	Benefit: 75% = \$169.50 85% = \$192.10
	METATARSAL	S, 2 of, treatment of fracture of (Anaes.)
47642	Fee: \$150.75	Benefit: 75% = \$113.10 85% = \$128.15
	METATARSAL	S, 2 of, treatment of fracture of, by closed reduction (Anaes.)
47645	Fee: \$226.00	Benefit: 75% = \$169.50 85% = \$192.10
.,,,,,,		S, 2 of, treatment of fracture of, by open reduction (Anaes.) (Assist.)
47648	Fee: \$301.05	Benefit: 75% = \$225.80
47040		S, 3 or more of, treatment of fracture of (Anaes.)
47651		
47651	Fee: \$235.50	Benefit: 75% = \$176.65 85% = \$200.20 S, 3 or more of, treatment of fracture of, by closed reduction (Anaes.) (Assist.)
47654	Fee: \$353.05	Benefit: 75% = \$264.80 85% = \$300.10
	METATARSAL	S, 3 or more of, treatment of fracture of, by open reduction (Anaes.) (Assist.)
47657	Fee: \$470.70	Benefit: 75% = \$353.05
	PHALANX OF	GREAT TOE, treatment of fracture of, by closed reduction (Anaes.)
47663	Fee: \$141.25	Benefit: 75% = \$105.95 85% = \$120.10
	PHALANX OF	GREAT TOE, treatment of fracture of, by open reduction (Anaes.)
47666	Fee: \$235.50	Benefit: 75% = \$176.65 85% = \$200.20
	PHALANX OF	TOE (other than great toe), 1 of, treatment of fracture of, by open reduction (Anaes.)
47672	Fee: \$112.85	Benefit: 75% = \$84.65 85% = \$95.95
	PHALANX OF TOE (other than great toe), more than 1 of, treatment of fracture of, by open reduction (Anaes.)	
47678	Fee: \$169.50	Benefit: 75% = \$127.15 85% = \$144.10
	BONE GRAFT, harvesting of, via separate incision, in conjunction with another service - autogenous - small quantity (Anaes.)	
47726	Fee: \$141.25	Benefit: 75% = \$105.95
	BONE GRAFT, harvesting of, via separate incision, in conjunction with another service - autogenous - large quantity (Anaes.)	
47729	Fee: \$235.50	Benefit: 75% = \$176.65
	VASCULARISED PEDICLE BONE GRAFT, harvesting of, in conjunction with another service (Anaes.) (Assist.)	
47732	Fee: \$376.55	Benefit: 75% = \$282.45
	NASAL BONES, treatment of fracture of, not being a service to which item 47738 or 47741 applies - each attendance	
47735	Fee: \$43.05	Benefit: 75% = \$32.30 85% = \$36.60
		S, treatment of fracture of, by reduction (Anaes.)
47738		

T8. SUF	RGICAL OPERAT	IONS	15. ORTHOPAEDIC
	Fee: \$235.50	Benefit: 75% = \$176.65 85% = \$200.2	20
	NASAL BONES	s, treatment of fracture of, by open reduction	on involving osteotomies (Anaes.) (Assist.)
47741	Fee: \$480.35	Benefit: 75% = \$360.30	
		tment of fracture of, requiring splinting, w (Anaes.) (Assist.)	iring of teeth, circumosseous fixation or
47753	Fee: \$406.65	Benefit: 75% = \$305.00	
		eatment of fracture of, requiring splinting, (Anaes.) (Assist.)	wiring of teeth, circumosseous fixation or
47756	Fee: \$406.65	Benefit: 75% = \$305.00	
	ZYGOMATIC I other approach (surgical reduction by a temporal, intra-oral or
47762	Fee: \$238.80	Benefit: 75% = \$179.10 85% = \$203.0	00
		BONE, treatment of fracture of, requiring s at 1 site (Anaes.) (Assist.)	surgical reduction and involving internal or
47765	Fee: \$392.10	Benefit: 75% = \$294.10	
	ZYGOMATIC BONE, treatment of fracture of, requiring surgical reduction and involving internal or external fixation or both at 2 sites (Anaes.) (Assist.)		
47768	Fee: \$480.35	Benefit: 75% = \$360.30	
	ZYGOMATIC BONE, treatment of fracture of, requiring surgical reduction and involving internal or external fixation or both at 3 sites (Anaes.) (Assist.)		
47771	Fee: \$551.85	Benefit: 75% = \$413.90	
	MAXILLA, trea	tment of fracture of, requiring open operat	ion (Anaes.) (Assist.)
47774	Fee: \$435.65	Benefit: 75% = \$326.75	
	MANDIBLE, treatment of fracture of, requiring open reduction (Anaes.) (Assist.)		
47777	Fee: \$435.65	Benefit: 75% = \$326.75	
	MAXILLA, trea (Anaes.) (Assist		ion and internal fixation not involving plate(s)
47780	Fee: \$566.35	Benefit: 75% = \$424.80	
	MANDIBLE, treatment of fracture of, requiring open reduction and internal fixation not involving plate(s) (Anaes.) (Assist.)		
47783	Fee: \$566.35	Benefit: 75% = \$424.80 85% = \$482.9	95
	MAXILLA, trea (Anaes.) (Assist	, 1 0 1	ion and internal fixation involving plate(s)
47786	Fee: \$718.75	Benefit: 75% = \$539.10	
	MANDIBLE, tro (Anaes.) (Assist		ction and internal fixation involving plate(s)
47789	Fee: \$718.75	Benefit: 75% = \$539.10	

T8. SUF	RGICAL OPERATIONS	15. ORTH	HOPAEDIC
		GENERAL	
	BONE CYST, injection into or aspir	ration of (Anaes.)	
47900	Fee: \$169.50 Benefit: 75% =	= \$127.15 85% = \$144.10	
	EPICONDYLITIS, open operation f	for (Anaes.)	
47903	Fee: \$235.50 Benefit: 75% =	= \$176.65 85% = \$200.20	
	DIGITAL NAIL OF TOE, removal	of, not being a service to which item 47906 applies (Anac	es.)
47904	Fee: \$56.50 Benefit: 75% =	= \$42.40 85% = \$48.05	
	DIGITAL NAIL OF TOE, removal	of, in the operating theatre of a hospital (Anaes.)	
47906	Fee: \$112.85 Benefit: 75% =	= \$84.65	
	PULP SPACE INFECTION, PARO another item in this Group applies (e	ONYCHIA of FOOT, incision for, not being a service to we excluding aftercare) (Anaes.)	hich
47912	(See para TN.8.4 of explanatory notes to Fee: \$56.50 Benefit: 75% =	o this Category) = \$42.40 85% = \$48.05	
	INGROWING NAIL OF TOE, wed portion of the nail bed (Anaes.)	ge resection for, with removal of segment of nail, ungual	fold and
47915	Fee: \$169.50 Benefit: 75% =	= \$127.15 85% = \$144.10	
	INGROWING NAIL OF TOE, partial resection of nail, with destruction of nail matrix by phenolisation, electrocautery, laser, sodium hydroxide or acid but not including excision of nail bed (Anaes.)		
47916	Fee: \$85.15 Benefit: 75% =	= \$63.90 85% = \$72.40	
	INGROWING TOENAIL, radical excision of nailbed (Anaes.)		
47918	Fee: \$235.50 Benefit: 75% = \$176.65 85% = \$200.20		
	BONE GROWTH STIMULATOR, insertion of (Anaes.) (Assist.)		
47920	Fee: \$380.80 Benefit: 75% =	= \$285.60	
	ORTHOPAEDIC PIN OR WIRE, in	nsertion of, as an independent procedure (Anaes.)	
47921	Fee: \$112.85 Benefit: 75% =	= \$84.65 85% = \$95.95	
		1 or more of, which were inserted for internal fixation putture, not being a service to which item 47927 or 47930 ap	
47924	Fee: \$37.65 Benefit: 75% =	= \$28.25 85% = \$32.05	
	BURIED WIRE, PIN OR SCREW, 1 or more of, which were inserted for internal fixation purposes, removal of, in the operating theatre of a hospital - per bone (Anaes.)		
47927	Fee: \$141.25 Benefit: 75% =	= \$105.95	
		SOCIATED WIRES, PINS OR SCREWS, 1 or more of, a urposes, <u>removal of</u> , not being a service associated with a - per bone (Anaes.) (Assist.)	
47930	Fee: \$263.60 Benefit: 75% =	= \$197.70	
47933	SMALL EXOSTOSIS (NOT MORE	E THAN 20MM OF GROWTH ABOVE BONE), excisio	on of, or

T8. SUF	RGICAL OPERAT	IONS	15. ORTHOPAEDIC
	simple removal removal of bursa	of bunion and any associated bursa, not being a service a (Anaes.)	associated with a service for
	(See para TN.8.11 Fee: \$207.00	2 of explanatory notes to this Category) Benefit: 75% = \$155.25 85% = \$175.95	
	LARGE EXOST (Assist.)	TOSIS (GREATER THAN 20MM GROWTH ABOVE	BONE), excision of (Anaes.)
47936	(See para TN.8.11 Fee: \$254.20	2 of explanatory notes to this Category) Benefit: 75% = \$190.65	
	EXTERNAL FI	XATION, removal of, in the operating theatre of a hosp	oital (Anaes.)
47948	Fee: \$160.05	Benefit: 75% = \$120.05	
	EXTERNAL FI grafting or both	XATION, removal of, in conjunction with operations in (Anaes.)	nvolving internal fixation or bone
47951	Fee: \$188.20	Benefit: 75% = \$141.15 85% = \$160.00	
	TENDON, repa	ir of, as an independent procedure (Anaes.) (Assist.)	
47954	Fee: \$376.55	Benefit: 75% = \$282.45 85% = \$320.10	
	TENDON, large	e, lengthening of, as an independent procedure (Anaes.)	(Assist.)
47957			
.,,,,,	TENOTOMY, SUBCUTANEOUS, not being a service to which another item in this Group applies (Anaes.)		
47960	Fee: \$131.85	Benefit: 75% = \$98.90 85% = \$112.10	
	TENOTOMY, O Group applies (A	OPEN, with or without tenoplasty, not being a service to Anaes.)	o which another item in this
47963	Fee: \$216.50	Benefit: 75% = \$162.40 85% = \$184.05	
	TENDON OR I	IGAMENT, TRANSFER, as an independent procedure	e (Anaes.) (Assist.)
47966	Fee: \$432.95	Benefit: 75% = \$324.75	
	TENOSYNOVE (Assist.)	ECTOMY, not being a service to which another item in	this Group applies (Anaes.)
47969	Fee: \$263.60	Benefit: 75% = \$197.70	
	TENDON SHEATH, open operation for teno-vaginitis, not being a service to which another item in the Group applies (Anaes.)		vice to which another item in this
47972	Fee: \$210.60	Benefit: 75% = \$157.95	
		CALF, decompression fasciotomy of, for acute compacte and deep tissue (Anaes.) (Assist.)	rtment syndrome, requiring
47975	Fee: \$369.15	Benefit: 75% = \$276.90	
		CALF, decompression fasciotomy of, for chronic comcle and deep tissue (Anaes.)	partment syndrome, requiring
47978	Fee: \$224.20	Benefit: 75% = \$168.15	
47981		ALF OR INTEROSSEOUS MUSCLE SPACE OF HAN	ND, decompression fasciotomy of,

T8. SUF	RGICAL OPERAT	TIONS 15. ORTHOPAEDIC	
	not being a serv	ice to which another item applies (Anaes.)	
	Fee: \$150.55	Benefit: 75% = \$112.95 85% = \$128.00	
	FORAGE (Drill	decompression), of NECK OR HEAD of FEMUR, or BOTH (Anaes.) (Assist.)	
47982	Fee: \$364.90	Benefit: 75% = \$273.70	
.,,,,,		BONE GRAFTS	
	FEMUR, bone g	graft to (Anaes.) (Assist.)	
48200	Fee: \$753.25	Benefit: 75% = \$564.95	
	FEMUR, bone g	graft to, with internal fixation (Anaes.) (Assist.)	
48203	Fee: \$913.25	Benefit: 75% = \$684.95	
		aft to (Anaes.) (Assist.)	
48206	Fee: \$565.45	Benefit: 75% = \$424.10	
40200		off to, with internal fixation (Anaes.) (Assist.)	
40200			
48209	Fee: \$724.95	Benefit: 75% = \$543.75 ne graft to (Anaes.) (Assist.)	
48212	Fee: \$565.45	Benefit: 75% = \$424.10	
	HUMERUS, bone graft to, with internal fixation (Anaes.) (Assist.)		
48215	Fee: \$724.95	Benefit: 75% = \$543.75	
	RADIUS AND	ULNA, bone graft to (Anaes.) (Assist.)	
48218	Fee: \$565.45	Benefit: 75% = \$424.10	
	RADIUS AND ULNA, bone graft to, with internal fixation of 1 or both bones (Anaes.) (Assist.)		
48221	Fee: \$753.25	Benefit: 75% = \$564.95	
	RADIUS OR U	LNA, bone graft to (Anaes.) (Assist.)	
48224	Fee: \$376.55	Benefit: 75% = \$282.45	
	RADIUS OR ULNA, bone graft to, with internal fixation of 1 or both bones (Anaes.) (Assist.)		
48227	Fee: \$489.55	Benefit: 75% = \$367.20	
	SCAPHOID, bone graft to, for non-union (Anaes.) (Assist.)		
48230	Fee: \$423.75	Benefit: 75% = \$317.85	
10230	SCAPHOID, bone graft to, for non-union, with internal fixation (Anaes.) (Assist.)		
48233	Fee: \$611.90 Benefit: 75% = \$458.95		
10233		ne graft to, for mal-union, including osteotomy, bone graft and internal fixation (Anaes.)	
	(Assist.)	5 , ,	
48236	Fee: \$800.20	Benefit: 75% = \$600.15	
		not being a service to which another item in this Group applies (Anaes.) (Assist.)	
48239	Fee: \$442.45	Benefit: 75% = \$331.85	
70437	1 cc. \$442.43	Denotit. 1370 - \$331.03	

T8. SUF	RGICAL OPERATI	ONS 15. ORTHOPAEDIC	
	BONE GRAFT, v (Anaes.) (Assist.)	with internal fixation, not being a service to which another item in this Group applies	
48242	Fee: \$611.90	Benefit: 75% = \$458.95	
		OSTEOTOMY AND OSTEECTOMY	
		TATARSAL, ACCESSORY BONE OR SESAMOID BONE, osteotomy or osteectomy vices to which item 49848 or 49851 applies, any of items 49848, 49851, 47933 or aes.) (Assist.)	
48400	Fee: \$329.60	Benefit: 75% = \$247.20	
		METATARSAL, osteotomy or osteectomy of, with internal fixation, and excluding items 47933 or 47936 apply (Anaes.) (Assist.)	
48403	Fee: \$517.80	Benefit: 75% = \$388.35	
		US, ULNA, CLAVICLE, SCAPULA (other than acromion), RIB, TARSUS OR omy or osteectomy of, excluding services to which items 47933 or 47936 apply	
48406	Fee: \$329.60	Benefit: 75% = \$247.20	
	FIBULA, RADIUS, ULNA, CLAVICLE, SCAPULA (other than Acromion), RIB, TARSUS OR CARPUS, osteotomy or osteectomy of, with internal fixation, and excluding services to which items 47933 or 47936 apply (Anaes.) (Assist.)		
48409	Fee: \$517.80	Benefit: 75% = \$388.35	
	HUMERUS, osteotomy or osteectomy of, excluding services to which items 47933 or 47936 apply (Anaes.) (Assist.)		
48412	Fee: \$630.65	Benefit: 75% = \$473.00	
	HUMERUS, osteotomy or osteectomy of, with internal fixation, and excluding services to which items 47933 or 47936 apply (Anaes.) (Assist.)		
48415	Fee: \$800.20	Benefit: 75% = \$600.15	
	TIBIA, osteotomy or osteectomy of, excluding services to which items 47933 or 47936 apply (Anaes.) (Assist.)		
48418	Fee: \$630.65	Benefit: 75% = \$473.00	
	TIBIA, osteotomy or osteectomy of, with internal fixation, and excluding services to which items 47933 or 47936 apply (Anaes.) (Assist.)		
48421	Fee: \$800.20	Benefit: 75% = \$600.15	
	Femur or pelvis, osteotomy or osteectomy of, other than a service associated with surgery for femoroacetabular impingement, or to which item 47933 or 47936 applies (H) (Anaes.) (Assist.)		
48424	(See para TN.8.127 Fee: \$753.25	of explanatory notes to this Category) Benefit: 75% = \$564.95	
		VIS, osteotomy or osteectomy of, with internal fixation, and excluding services to 33 or 47936 apply (Anaes.) (Assist.)	
	i i		
48427	Fee: \$913.25	Benefit: 75% = \$684.95	

T8. SUF	RGICAL OPERATI	ONS 15. ORTHOPAEDIC	
	FEMUR, epiphys	iodesis of (Anaes.) (Assist.)	
48500	Fee: \$329.60	Benefit: 75% = \$247.20	
	TIBIA AND FIBULA, epiphysiodesis of (Anaes.) (Assist.)		
48503	Fee: \$329.60	Benefit: 75% = \$247.20	
	FEMUR, TIBIA	AND FIBULA, epiphysiodesis of (Anaes.) (Assist.)	
48506	Fee: \$489.55	Benefit: 75% = \$367.20	
	EPIPHYSIODES	(S, staple arrest of hemiepiphysis (Anaes.)	
48509	Fee: \$235.50	Benefit: 75% = \$176.65	
	EPIPHYSIOLYS	S, operation to prevent closure of plate (Anaes.) (Assist.)	
48512	Fee: \$894.40	Benefit: 75% = \$670.80	
		SHOULDER	
	SHOULDER, exc (Anaes.) (Assist.)	ision of coraco-acromial ligament or removal of calcium deposit from cuff or both	
48900	Fee: \$282.35	Benefit: 75% = \$211.80 85% = \$240.00	
	SHOULDER, decompression of subacromial space by acromioplasty, excision of coraco-acromial ligament and distal clavicle, or any combination (Anaes.) (Assist.)		
48903	Fee: \$564.85	Benefit: 75% = \$423.65	
	SHOULDER, repair of rotator cuff, including excision of coraco-acromial ligament or removal of calcium deposit from cuff, or both - not being a service associated with a service to which item 48900 applies (Anaes.) (Assist.)		
48906	Fee: \$564.85	Benefit: 75% = \$423.65	
	SHOULDER, repair of rotator cuff, including decompression of subacromial space by acromioplasty, excision of coraco-acromial ligament and distal clavicle, or any combination, not being a service associated with a service to which item 48903 applies (Anaes.) (Assist.)		
48909	Fee: \$753.25	Benefit: 75% = \$564.95	
	SHOULDER, arthrotomy of (Anaes.) (Assist.)		
48912	Fee: \$329.60	Benefit: 75% = \$247.20 85% = \$280.20	
	SHOULDER, hemi-arthroplasty of (Anaes.) (Assist.)		
48915	Fee: \$753.25	Benefit: 75% = \$564.95	
	SHOULDER, total replacement arthroplasty of, including any associated rotator cuff repair (Anaes.) (Assist.)		
48918	Fee: \$1,506.45	Benefit: 75% = \$1129.85	
	SHOULDER, total replacement arthroplasty, revision of (Anaes.) (Assist.)		
48921	Fee: \$1,553.40	Benefit: 75% = \$1165.05	
49024	SHOULDER, total replacement arthroplasty, revision of, requiring bone graft to scapula or humerus, or both (Anaes.) (Assist.)		
48924			

T8. SUF	RGICAL OPERATION	ONS 15. ORTHOPAEDIC			
	Fee: \$1,788.85	Benefit: 75% = \$1341.65			
	SHOULDER pros	sthesis, removal of (Anaes.) (Assist.)			
48927	Fee: \$367.05	Benefit: 75% = \$275.30			
	SHOULDER, stal	bilisation procedure for recurrent anterior or posterior dislocation (Anaes.) (Assist.)			
48930	Fee: \$753.25	Benefit: 75% = \$564.95			
.0,20		bilisation procedure for multi-directional instability, including anterior or posterior (or			
		performed (Anaes.) (Assist.)			
48933	Fee: \$988.55	Benefit: 75% = \$741.45			
	SHOULDER, syn	novectomy of, as an independent procedure (Anaes.) (Assist.)			
48936	Fee: \$753.25	Benefit: 75% = \$564.95			
	SHOULDER, artl	hrodesis of, with synovectomy if performed (Anaes.) (Assist.)			
48939	Fee: \$1,082.70	Benefit: 75% = \$812.05			
40/3/		hrodesis of, with synovectomy if performed, with removal of prosthesis, requiring bone			
		al fixation (Anaes.) (Assist.)			
48942	Fee: \$1,412.20	Benefit: 75% = \$1059.15			
	SHOULDER, diagnostic arthroscopy of (including biopsy) - not being a service associated with any				
	other arthroscopic procedure of the shoulder region (Anaes.) (Assist.)				
48945	Fee: \$272.95	Benefit: 75% = \$204.75			
	SHOULDER, arthroscopic surgery of, involving any 1 or more of: removal of loose bodies;				
	decompression of calcium deposit; debridement of labrum, synovium or rotator cuff; or chondroplasty - not being a service associated with any other arthroscopic procedure of the shoulder region (Anaes.)				
	(Assist.)				
48948	Fee: \$611.90	Benefit: 75% = \$458.95			
	SHOULDER, arthroscopic division of coraco-acromial ligament including acromioplasty - ne				
	service associated with any other arthroscopic procedure of the shoulder region (Anaes.) (Assist.)				
48951	Fee: \$894.40	Benefit: 75% = \$670.80			
		proscopic total synovectomy of, including release of contracture when performed - not			
	(Assist.)	sociated with any other arthroscopic procedure of the shoulder region (Anaes.)			
48954	Fee: \$941.45	Benefit: 75% = \$706.10			
46934		hroscopic stabilisation of, for recurrent instability including labral repair or			
	reattachment when performed - not being a service associated with any other arthroscopic procedure of				
	the shoulder region (Anaes.) (Assist.)				
48957	Fee: \$1,082.70	Benefit: 75% = \$812.05			
	SHOULDER, reconstruction or repair of, including repair of rotator cuff by arthroscopic, arthroscopic				
	assisted or mini open means; arthroscopic acromioplasty; or resection of acromioclavicular joint by separate approach when performed - not being a service associated with any other procedure of the				
	shoulder region (A				
48960	Fee: \$941.45	Benefit: 75% = \$706.10			

ELBOW, arthrotomy of, involving 1 or more of lavage, removal of loose body of (Anaes.) (Assist.) Fee: \$329.60 Benefit: 75% = \$247.20 ELBOW, ligamentous stabilisation of (Anaes.) (Assist.) Fee: \$706.05 Benefit: 75% = \$529.55 ELBOW, arthrodesis of, with synovectomy if performed (Anaes.) (Assist.) Fee: \$941.45 Benefit: 75% = \$706.10 Fee: \$941.45 Benefit: 75% = \$706.10 Fee: \$706.05 Benefit: 75% = \$529.55 ELBOW, silastic or other replacement of radial head (Anaes.) (Assist.) Fee: \$706.05 Benefit: 75% = \$529.55 ELBOW, total joint replacement of (Anaes.) (Assist.)	r division of contracture		
(Anaes.) (Assist.) Fee: \$329.60 Benefit: 75% = \$247.20 ELBOW, ligamentous stabilisation of (Anaes.) (Assist.) Fee: \$706.05 Benefit: 75% = \$529.55 ELBOW, arthrodesis of, with synovectomy if performed (Anaes.) (Assist.) Fee: \$941.45 Benefit: 75% = \$706.10 85% = \$858.05 ELBOW, total synovectomy of (Anaes.) (Assist.) Fee: \$706.05 Benefit: 75% = \$529.55 ELBOW, silastic or other replacement of radial head (Anaes.) (Assist.) Fee: \$706.05 Benefit: 75% = \$529.55 ELBOW, total joint replacement of (Anaes.) (Assist.)	r division of contracture		
ELBOW, ligamentous stabilisation of (Anaes.) (Assist.) Fee: \$706.05 Benefit: 75% = \$529.55 ELBOW, arthrodesis of, with synovectomy if performed (Anaes.) (Assist.) Fee: \$941.45 Benefit: 75% = \$706.10 85% = \$858.05 ELBOW, total synovectomy of (Anaes.) (Assist.) Fee: \$706.05 Benefit: 75% = \$529.55 ELBOW, silastic or other replacement of radial head (Anaes.) (Assist.) Fee: \$706.05 Benefit: 75% = \$529.55 ELBOW, total joint replacement of (Anaes.) (Assist.)			
49103			
ELBOW, arthrodesis of, with synovectomy if performed (Anaes.) (Assist.) Fee: \$941.45 Benefit: 75% = \$706.10 ELBOW, total synovectomy of (Anaes.) (Assist.) Fee: \$706.05 Benefit: 75% = \$529.55 ELBOW, silastic or other replacement of radial head (Anaes.) (Assist.) Fee: \$706.05 Benefit: 75% = \$529.55 ELBOW, total joint replacement of (Anaes.) (Assist.)			
49106			
ELBOW, total synovectomy of (Anaes.) (Assist.) Fee: \$706.05 Benefit: 75% = \$529.55 ELBOW, silastic or other replacement of radial head (Anaes.) (Assist.) Fee: \$706.05 Benefit: 75% = \$529.55 ELBOW, total joint replacement of (Anaes.) (Assist.)			
49109 Fee: \$706.05 Benefit: 75% = \$529.55 ELBOW, silastic or other replacement of radial head (Anaes.) (Assist.) 49112 Fee: \$706.05 Benefit: 75% = \$529.55 ELBOW, total joint replacement of (Anaes.) (Assist.)			
ELBOW, silastic or other replacement of radial head (Anaes.) (Assist.) Fee: \$706.05 Benefit: 75% = \$529.55 ELBOW, total joint replacement of (Anaes.) (Assist.)			
49112 Fee: \$706.05 Benefit: 75% = \$529.55 ELBOW, total joint replacement of (Anaes.) (Assist.)			
ELBOW, total joint replacement of (Anaes.) (Assist.)			
40115 Face \$1 120 (5 Page \$1, 750) \$0.47.25			
49115 Fee: \$1,129.65 Benefit: 75% = \$847.25			
ELBOW, total replacement arthroplasty of, revision procedure, including remov (Assist.)	ELBOW, total replacement arthroplasty of, revision procedure, including removal of prosthesis (Anaes.)		
49116 Fee: \$1,491.15 Benefit: 75% = \$1118.40			
ELBOW, total replacement arthroplasty of, revision procedure, requiring bone g removal of prosthesis (Anaes.) (Assist.)	ELBOW, total replacement arthroplasty of, revision procedure, requiring bone grafting, including removal of prosthesis (Anaes.) (Assist.)		
49117 Fee: \$1,789.35 Benefit: 75% = \$1342.05			
ELBOW, diagnostic arthroscopy of, including biopsy and lavage, not being a ser other arthroscopic procedure of the elbow (Anaes.) (Assist.)	ELBOW, diagnostic arthroscopy of, including biopsy and lavage, not being a service associated with any other arthroscopic procedure of the elbow (Anaes.) (Assist.)		
49118 Fee: \$272.95 Benefit: 75% = \$204.75			
ELBOW, arthroscopic surgery involving any 1 or more of: drilling of defect, ren release of contracture or adhesions; chondroplasty; or osteoplasty - not being a sany other arthroscopic procedure of the elbow (Anaes.) (Assist.)			
49121 Fee: \$611.90 Benefit: 75% = \$458.95			
WRIST			
WRIST, arthrodesis of, with synovectomy if performed, with or without bone gr of the radiocarpal joint (Anaes.) (Assist.)	aft and internal fixation		
(See para TN.8.116 of explanatory notes to this Category) Fee: \$818.95 Benefit: 75% = \$614.25			
WRIST, limited arthrodesis of the intercarpal joint, with synovectomy if perform bone graft (Anaes.) (Assist.)	ed, with or without		
(See para TN.8.116 of explanatory notes to this Category) Fee: \$611.90 Benefit: 75% = \$458.95			
WRIST, proximal carpectomy of, including styloidectomy when performed (Ana	nes.) (Assist.)		
49206 (See para TN.8.116 of explanatory notes to this Category)			

T8. SUF	RGICAL OPERATI	ONS	15. ORTHOPAEDIC
	Fee: \$564.85	Benefit: 75% = \$423.65	
	WRIST, total rep	lacement arthroplasty of (Anaes.) (Assist.)	
49209	(See para TN.8.116 Fee: \$753.25	of explanatory notes to this Category) Benefit: 75% = \$564.95	
	WRIST, total rep (Assist.)	lacement arthroplasty of, revision procedur	re, including removal of prosthesis (Anaes.)
49210	Fee: \$994.30	Benefit: 75% = \$745.75	
		lacement arthroplasty of, revision proceduresis (Anaes.) (Assist.)	re, requiring bone grafting, including
49211	Fee: \$1,193.15	Benefit: 75% = \$894.90	
	WRIST, arthroton	my of (Anaes.)	
49212	(See para TN.8.116 Fee: \$235.50	of explanatory notes to this Category) Benefit: 75% = \$176.65	
		oution of, including repair of single or multiony (Anaes.) (Assist.)	iple ligaments or capsules, including
49215	(See para TN.8.116 Fee: \$649.70	of explanatory notes to this Category) Benefit: 75% = \$487.30	
		ic arthroscopy of, including radiocarpal or ice associated with any other arthroscopic	midcarpal joints, or both (including biopsy) procedure of the wrist joint (Anaes.)
49218	(See para TN.8.116 Fee: \$272.95	of explanatory notes to this Category) Benefit: 75% = \$204.75	
	release of adhesio	opic surgery of, involving any 1 or more of ons; local synovectomy; or debridement of hroscopic procedure of the wrist joint (Ana	
49221	(See para TN.8.116 Fee: \$611.90	of explanatory notes to this Category) Benefit: 75% = \$458.95	
			s; or osteoplasty including excision of the ated with any other arthroscopic procedure of
49224	(See para TN.8.116 Fee: \$706.05	of explanatory notes to this Category) Benefit: 75% = \$529.55	
		opic pinning of osteochondral fragment or eing a service associated with any other art	
49227	(See para TN.8.116 Fee: \$706.05	of explanatory notes to this Category) Benefit: 75% = \$529.55	
-		HIP	
	SACROILIAC JO	OINT arthrodesis of (Anaes.) (Assist.)	
49300	Fee: \$521.25	Benefit: 75% = \$390.95	
49303	Hip, arthrotomy of	of, including lavage, drainage or biopsy wh	en performed, other than a service

T8. SUF	RGICAL OPERATION	ONS	15. ORTHOPAEDIC
	associated with su	argery for femoroacetabular impingeme	ent (H) (Anaes.) (Assist.)
	(See para TN.8.127 Fee: \$546.00	of explanatory notes to this Category) Benefit: 75% = \$409.50	
	HIP arthrodesis of	of, with synovectomy if performed (An	aes.) (Assist.)
49306	Fee: \$1,082.70	Benefit: 75% = \$812.05	
	HIP, arthrectomy (non cement)) (A		emoval of prosthesis (Austin Moore or similar
49309	Fee: \$753.25	Benefit: 75% = \$564.95	
	HIP, arthrectomy or similar) (Anaes	1	emoval of prosthesis (cemented, porous coated
49312	Fee: \$941.45	Benefit: 75% = \$706.10	
	HIP, arthroplasty	of, unipolar or bipolar (Anaes.) (Assist	.)
49315	Fee: \$847.35	Benefit: 75% = \$635.55	
	HIP, total replace	ment arthroplasty of, including minor b	oone grafting (Anaes.) (Assist.)
49318	Fee: \$1,317.80	Benefit: 75% = \$988.35	
	HIP, total replace (Anaes.) (Assist.)	ment arthroplasty of, including associa	ted minor grafting, if performed - bilateral
49319	Fee: \$2,315.30	Benefit: 75% = \$1736.50	
	HIP, total replace (Anaes.) (Assist.)	ment arthroplasty of, including major b	one grafting, including obtaining of graft
49321	Fee: \$1,600.65	Benefit: 75% = \$1200.50	
	HIP, total replace (Assist.)	ment arthroplasty of, revision procedur	e including removal of prosthesis (Anaes.)
49324	Fee: \$1,882.95	Benefit: 75% = \$1412.25	
	I	ment arthroplasty of, revision proceduring of graft (Anaes.) (Assist.)	e requiring bone grafting to acetabulum,
49327	Fee: \$2,165.35	Benefit: 75% = \$1624.05	
	, 1	ment arthroplasty of, revision procedur (Anaes.) (Assist.)	e requiring bone grafting to femur, including
49330	Fee: \$2,165.35	Benefit: 75% = \$1624.05	
		ment arthroplasty of, revision proceduring obtaining of graft (Anaes.) (Assist.	e requiring bone grafting to both acetabulum)
49333	Fee: \$2,447.85	Benefit: 75% = \$1835.90	
	treatment of the fr		total hip replacement is required as part of the acture), being a service associated with a service
49336	Fee: \$357.70	Benefit: 75% = \$268.30	
49339	HIP, revision tota	l replacement of, requiring anatomic sp	pecific allograft of proximal femur greater than 5

T8. SUF	RGICAL OPERATI	ONS 15. ORTHOPAEDIC	
	cm in length (Ana	nes.) (Assist.)	
	Fee: \$2,777.30	Benefit: 75% = \$2083.00	
	HIP, revision tota	l replacement of, requiring anatomic specific allograft of acetabulum (Anaes.) (Assist.)	
49342	Fee: \$2,777.30	Benefit: 75% = \$2083.00	
		l replacement of, requiring anatomic specific allograft of both femur and acetabulum	
49345	Fee: \$3,295.10	Benefit: 75% = \$2471.35	
		roplasty with replacement of acetabular liner or ceramic head, not requiring removal of nt or acetabular shell (Anaes.) (Assist.)	
49346	Fee: \$847.35	Benefit: 75% = \$635.55	
	HIP, diagnostic at the hip (Anaes.) (rthroscopy of, not being a service associated with any other arthroscopic procedure of Assist.)	
49360	Fee: \$343.95	Benefit: 75% = \$258.00	
	HIP, diagnostic arthroscopy of, with synovial biopsy, not being a service associated with any other arthroscopic procedure of the hip (Anaes.) (Assist.)		
49363	Fee: \$414.20	Benefit: 75% = \$310.65 85% = \$352.10	
		surgery of, other than a service associated with another arthroscopic procedure of the ssociated with surgery for femoroacetabular impingement (H) (Anaes.) (Assist.)	
49366	(See para TN.8.127 Fee: \$611.90	of explanatory notes to this Category) Benefit: 75% = \$458.95	
		KNEE	
		y of, involving 1 or more of; capsular release, biopsy or lavage, or removal of loose ody (Anaes.) (Assist.)	
49500	Fee: \$376.55	Benefit: 75% = \$282.45	
	chondroplasty of,	total meniscectomy of, repair of collateral or cruciate ligament, patellectomy of, osteoplasty of, patellofemoral stabilisation or single transfer of ligament or tendon (not which another item in this Group applies) - any 1 procedure (Anaes.) (Assist.)	
49503	Fee: \$489.55	Benefit: 75% = \$367.20	
	chondroplasty of,	total meniscectomy of, repair of collateral or cruciate ligament, patellectomy of, osteoplasty of, patellofemoral stabilisation or single transfer of ligament or tendon (not which another item in this Group applies) - any 2 or more procedures (Anaes.)	
49506	Fee: \$734.40	Benefit: 75% = \$550.80	
	KNEE, total syno	vectomy or arthrodesis with synovectomy if performed (Anaes.) (Assist.)	
49509	Fee: \$753.25	Benefit: 75% = \$564.95	
	KNEE, arthrodesi	is of, with synovectomy if performed, with removal of prosthesis (Anaes.) (Assist.)	
49512	Fee: \$1,082.70	Benefit: 75% = \$812.05	
49515	KNEE, removal o	of prosthesis, cemented or uncemented, including associated cement, as the first stage	

T8. SUF	RGICAL OPERATION	ONS 15. ORTHOPAEDIC
	of a 2 stage proce	dure (Anaes.) (Assist.)
	Fee: \$847.35	Benefit: 75% = \$635.55
		oplasty of (Anaes.) (Assist.)
49517	Fee: \$1,206.35	Benefit: 75% = \$904.80
	-	cement arthroplasty of (Anaes.) (Assist.)
49518	Fee: \$1,317.80	Benefit: 75% = \$988.35
	- i	cement arthroplasty of, including associated minor grafting, if performed - bilateral
49519	Fee: \$2,315.30	Benefit: 75% = \$1736.50
	KNEE, total repla obtaining of graft	cement arthroplasty of, requiring major bone grafting to femur or tibia, including (Anaes.) (Assist.)
49521	Fee: \$1,600.65	Benefit: 75% = \$1200.50
	KNEE, total repla obtaining of graft	cement arthroplasty of, requiring major bone grafting to femur and tibia, including (Anaes.) (Assist.)
49524	Fee: \$1,882.95	Benefit: 75% = \$1412.25
	KNEE, total repla (Assist.)	cement arthroplasty of, revision procedure, including removal of prosthesis (Anaes.)
49527	Fee: \$1,600.65	Benefit: 75% = \$1200.50
		cement arthroplasty of, revision procedure, requiring bone grafting to femur or tibia, eg of graft and including removal of prosthesis (Anaes.) (Assist.)
49530	Fee: \$1,977.20	Benefit: 75% = \$1482.90
		cement arthroplasty of, revision procedure, requiring bone grafting to both femur and training of graft and including removal of prosthesis (Anaes.) (Assist.)
49533	Fee: \$2,259.65	Benefit: 75% = \$1694.75
	KNEE, patello-fer	moral joint of, total replacement arthroplasty as a primary procedure (Anaes.) (Assist.)
49534	Fee: \$449.55	Benefit: 75% = \$337.20
	cruciate or collate	econstruction of, for chronic instability (open or arthroscopic, or both) involving either ral ligaments, including notchplasty when performed, not being a service associated hroscopic procedure of the knee (Anaes.) (Assist.)
49536	Fee: \$941.45	Benefit: 75% = \$706.10
	including notchpla	etive surgery of cruciate ligament or ligaments (open or arthroscopic, or both), asty when performed and surgery to other internal derangements, not being a service to m in this Group applies or a service associated with any other arthroscopic procedure s.) (Assist.)
49539	Fee: \$941.45	Benefit: 75% = \$706.10
49542	including notchpla	etive surgery to cruciate ligament or ligaments (open or arthroscopic, or both), asty, meniscus repair, extracapsular procedure and debridement when performed, not sociated with any other arthroscopic procedure of the knee (Anaes.) (Assist.)

T8. SUF	RGICAL OPERATION	ONS	15. ORTHOPAEDIC
	Fee: \$1,317.80	Benefit: 75% = \$988.35	
	KNEE, revision a	rthrodesis of, with synovectom	y if performed (Anaes.) (Assist.)
49545	Fee: \$753.25	Benefit: 75% = \$564.95	
	KNEE, revision o	f patello-femoral stabilisation (Anaes.) (Assist.)
49548	Fee: \$941.45	Benefit: 75% = \$706.10	
	KNEE, revision o	f procedures to which item 495	36, 49539 or 49542 applies (Anaes.) (Assist.)
49551	Fee: \$1,317.80	Benefit: 75% = \$988.35	
	KNEE, revision of total replacement of, by anatomic specific allograft of tibia or femur (Anaes.) (Assist.)		
49554	Fee: \$1,882.95	Benefit: 75% = \$1412.25	
	being a service as	sociated with autologous chon-	osy, simple trimming of meniscal margin or plica) - not drocyte implantation or matrix-induced autologous pic procedure of the knee region (Anaes.) (Assist.)
49557	(See para TN.8.117 Fee: \$272.95	of explanatory notes to this Categ Benefit: 75% = \$204.75	ory)
			ore of: debridement, osteoplasty or chondroplasty - not of the knee region (Anaes.) (Assist.)
49558	Fee: \$272.95	Benefit: 75% = \$204.75	
	similar) implant;		roplasty requiring multiple drilling or carbon fibre (or lement or oestoplasty - not associated with any other s.) (Assist.)
49559	Fee: \$408.70	Benefit: 75% = \$306.55	
		ease - not being a service associate	nore of: partial or total meniscectomy, removal of loose ciated with any other arthroscopic procedure of the knee
49560	Fee: \$551.60	Benefit: 75% = \$413.70	
	removal of loose	body or lateral release; where to ondroplasty - not associated with	lving 1 or more of: partial or total meniscectomy, he procedure includes associated debridement, h any other arthroscopic procedure of the knee region
49561	Fee: \$674.00	Benefit: 75% = \$505.50	
	removal of loose drilling or carbon	body or lateral release; where t	lving 1 or more of: partial or total meniscectomy, he procedure includes chondroplasty requiring multiple associated debridement or osteoplasty - not associated e region (Anaes.) (Assist.)
49562	Fee: \$735.50	Benefit: 75% = \$551.65	
49563	chondral graft (ex	cluding autologous chondrocytantation) -not associated with a	nore of: meniscus repair; osteochondral graft; or te implantation or matrix-induced autologous ny other arthroscopic procedure of the knee region

T8. SUF	GICAL OPERATION	NS 15. ORTHOPAEDIC		
	(See para TN.8.117 (Fee: \$796.70	of explanatory notes to this Category) Benefit: 75% = \$597.55		
	release, medial cap	noral stabilisation of, combined arthroscopic and open procedure, including lateral sulorrhaphy and tendon transfer, not being a service associated with any other dure of the knee (Anaes.) (Assist.)		
49564	Fee: \$919.05	Benefit: 75% = \$689.30		
	,	te total synovectomy of, not being a service associated with any other arthroscopic nee (Anaes.) (Assist.)		
49566	Fee: \$753.25	Benefit: 75% = \$564.95		
	KNEE, mobilisatio (Anaes.) (Assist.)	n for post-traumatic stiffness, by multiple muscle or tendon release (quadricepsplasty		
49569	Fee: \$753.25	Benefit: 75% = \$564.95		
		ANKLE		
	ANKLE, diagnost	c arthroscopy of, including biopsy (Anaes.) (Assist.)		
49700	Fee: \$272.95	Benefit: 75% = \$204.75		
	ANKLE, arthroscopic surgery of, not being a service associated with any other arthroscopic procedure of the ankle (Anaes.) (Assist.)			
49703	Fee: \$611.90	Benefit: 75% = \$458.95		
	ANKLE, arthrotor (Anaes.) (Assist.)	ny of, involving 1 or more of: lavage, removal of loose body or division of contracture		
49706	Fee: \$329.60	Benefit: 75% = \$247.20		
	ANKLE, ligament	ous stabilisation of (Anaes.) (Assist.)		
49709	Fee: \$706.05	Benefit: 75% = \$529.55		
	ANKLE, arthrodes	is of, with synovectomy if performed (Anaes.) (Assist.)		
49712	Fee: \$753.25	Benefit: 75% = \$564.95		
	ANKLE, total join	t replacement of (Anaes.) (Assist.)		
49715	Fee: \$1,129.65	Benefit: 75% = \$847.25		
.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	·	accement arthroplasty of, revision procedure, including removal of prosthesis (Anaes.)		
49716	Fee: \$1,491.15	Benefit: 75% = \$1118.40		
	ANKLE, total repl	acement arthroplasty of, revision procedure, requiring bone grafting, including sis (Anaes.) (Assist.)		
49717	Fee: \$1,789.35	Benefit: 75% = \$1342.05		
		tendon or other major tendon, repair of (Anaes.) (Assist.)		
49718	Fee: \$376.55	Benefit: 75% = \$282.45		
		tendon rupture managed by non-operative treatment		
49721	Fee: \$235.50	Benefit: 75% = \$176.65 85% = \$200.20		

T8. SUF	RGICAL OPERATI	ONS 15. ORTHOPAEDIC	
	ANKLE, Achilles	s' tendon, secondary repair or reconstruction of (Anaes.) (Assist.)	
49724	Fee: \$659.15	Benefit: 75% = \$494.40	
	ANKLE, Achille	s' tendon, operation for lengthening (Anaes.) (Assist.)	
49727	Fee: \$282.35	Benefit: 75% = \$211.80	
		ning of the gastrocnemius aponeurosis and soleus fascia, for the correction of equinus dren with cerebral palsy (Anaes.) (Assist.)	
49728	Fee: \$564.70	Benefit: 75% = \$423.55	
		FOOT	
	FOOT, flexor or	extensor tendon, primary repair of (Anaes.)	
49800	Fee: \$131.85	Benefit: 75% = \$98.90 85% = \$112.10	
	FOOT, flexor or	extensor tendon, secondary repair of (Anaes.)	
49803	Fee: \$169.50	Benefit: 75% = \$127.15 85% = \$144.10	
	FOOT, subcutane	eous tenotomy of, 1 or more tendons (Anaes.)	
49806	Fee: \$131.85	Benefit: 75% = \$98.90 85% = \$112.10	
	<u> </u>	otomy of, with or without tenoplasty (Anaes.)	
49809	Fee: \$216.50	Benefit: 75% = \$162.40	
	FOOT, tendon or ligament transplantation of, not being a service to which another item in this Group applies (Anaes.) (Assist.)		
49812	Fee: \$432.95	Benefit: 75% = \$324.75	
	FOOT, triple arth	prodesis of, with synovectomy if performed (Anaes.) (Assist.)	
49815	Fee: \$753.25	Benefit: 75% = \$564.95	
	FOOT, excision of calcaneal spur (Anaes.) (Assist.)		
49818	Fee: \$272.95	Benefit: 75% = \$204.75	
	FOOT, correction	n of hallux valgus or hallux rigidus by excision arthroplasty (Keller's or similar ateral (Anaes.) (Assist.)	
49821	Fee: \$432.95	Benefit: 75% = \$324.75	
		n of hallux valgus or hallux rigidus by excision arthroplasty (Keller's or similar teral (Anaes.) (Assist.)	
49824	Fee: \$757.95	Benefit: 75% = \$568.50	
	FOOT, correction	n of hallux valgus by transfer of adductor hallucis tendon - unilateral (Anaes.) (Assist.)	
49827	Fee: \$470.70	Benefit: 75% = \$353.05	
		n of hallux valgus by transfer of adductor hallucis tendon - bilateral (Anaes.) (Assist.)	
49830	Fee: \$823.75	Benefit: 75% = \$617.85	
49833	FOOT, correction	n of hallux valgus by osteotomy of first metatarsal with or without internal fixation and accision of exostoses associated with the first metatarsophalangeal joint - unilateral	
.,055	or without o		

T8. SUF	RGICAL OPERATION	ONS 15. ORTHOPAEDIC	
	(Anaes.) (Assist.)		
	Fee: \$517.80	Benefit: 75% = \$388.35	
	FOOT, correction	of hallux valgus by osteotomy of first metatarsal with or without internal fixation and cision of exostoses associated with the first metatarsophalangeal joint - bilateral	
49836	Fee: \$894.40	Benefit: 75% = \$670.80	
	tendon, with or wi	of hallux valgus by osteotomy of first metatarsal and transfer of adductor hallicus thout internal fixation and with or without excision of exostoses associated with the angeal joint - unilateral (Anaes.) (Assist.)	
49837	Fee: \$647.25	Benefit: 75% = \$485.45	
	tendon, with or wi	of hallux valgus by osteotomy of first metatarsal and transfer of adductor hallicus thout internal fixation and with or without excision of exostoses associated with the angeal joint - bilateral (Anaes.) (Assist.)	
49838	Fee: \$1,117.75	Benefit: 75% = \$838.35	
	FOOT, correction (Assist.)	of hallux rigidus or hallux valgus by prosthetic arthroplasty - unilateral (Anaes.)	
49839	Fee: \$517.80	Benefit: 75% = \$388.35	
	FOOT, correction (Assist.)	of hallux rigidus or hallux valgus by prosthetic arthroplasty - bilateral (Anaes.)	
49842	Fee: \$894.40	Benefit: 75% = \$670.80	
	FOOT, arthrodesis	of, first metatarso-phalangeal joint, with synovectomy if performed (Anaes.) (Assist.)	
49845	Fee: \$470.70	Benefit: 75% = \$353.05	
	FOOT, correction	of claw or hammer toe (Anaes.)	
49848	Fee: \$160.05	Benefit: 75% = \$120.05 85% = \$136.05	
	FOOT, correction	of claw or hammer toe with internal fixation (Anaes.)	
49851	Fee: \$207.00	Benefit: 75% = \$155.25	
	FOOT, radical pla	ntar fasciotomy or fasciectomy of (Anaes.) (Assist.)	
49854	Fee: \$376.55	Benefit: 75% = \$282.45	
		phalangeal joint replacement (Anaes.) (Assist.)	
49857	Fee: \$348.35	Benefit: 75% = \$261.30	
		my of metatarso-phalangeal joint, single joint (Anaes.) (Assist.)	
49860	Fee: \$282.35	Benefit: 75% = \$211.80	
		my of metatarso-phalangeal joint, 2 or more joints (Anaes.) (Assist.)	
49863	Fee: \$423.75	Benefit: 75% = \$317.85	
.,,,,,,	FOOT, neurectomy for plantar or digital neuritis (Morton's or Bett's syndrome) (Anaes.) (Assist.)		
49866			
49866	Fee: \$301.05	Benefit: 75% = \$225.80	

T8. SUF	RGICAL OPERAT	ONS 15. ORTHOPAEDIO		
		NOVARUS, calcaneo valgus or metatarus varus, treatment by cast, splint or ch attendance (Anaes.)		
49878	Fee: \$56.50	Benefit: 75% = \$42.40 85% = \$48.05		
		OTHER JOINTS		
		c arthroscopy of (including biopsy), not being a service to which another item in this d not being a service associated with any other arthroscopic procedure (Anaes.)		
50100	Fee: \$272.95	Benefit: 75% = \$204.75 85% = \$232.05		
	JOINT, arthrosc (Assist.)	pic surgery of, not being a service to which another item in this Group applies (Anaes.)		
50102	Fee: \$611.90	Benefit: 75% = \$458.95		
	JOINT, arthroto	y of, not being a service to which another item in this Group applies (Anaes.) (Assist.)		
50103	Fee: \$329.60	Benefit: 75% = \$247.20		
	JOINT, synovec (Assist.)	omy of, not being a service to which another item in this Group applies (Anaes.)		
50104	Fee: \$312.30	Benefit: 75% = \$234.25 85% = \$265.50		
	JOINT, stabilisation of, involving 1 or more of: repair of capsule, repair of ligament or internal fixation, not being a service to which another item in this Group applies (Anaes.) (Assist.)			
50106	Fee: \$470.70	Benefit: 75% = \$353.05		
	JOINT, arthrodesis of, not being a service to which another item in this Group applies, with synovectomy if performed (Anaes.) (Assist.)			
50109	Fee: \$470.70	Benefit: 75% = \$353.05		
	CICATRICIAL FLEXION OR EXTENSION CONTRACTION OF JOINT, correction of tissues deeper than skin and subcutaneous tissue, not being a service to which another iten applies (Anaes.) (Assist.)			
50112	Fee: \$361.05	Benefit: 75% = \$270.80		
		S, manipulation of, performed in the operating theatre of a hospital, not being a service service to which another item in this Group applies (Anaes.)		
50115	Fee: \$142.95	Benefit: 75% = \$107.25		
	SUBTALAR JC	NT, arthrodesis of, with synovectomy if performed (Anaes.) (Assist.)		
50118	Fee: \$432.95	Benefit: 75% = \$324.75		
	GREATER TROCHANTER, transplantation of ileopsoas tendon to (Anaes.) (Assist.)			
50121	Fee: \$847.35	Benefit: 75% = \$635.55		
	JOINT OR JOIN (Anaes.) (Assist	ΓS, arthroplasty of, by any technique not being a service to which another item applies		
50127	Fee: \$702.50	Benefit: 75% = \$526.90		
		ΓS, application of external fixator to, other than for treatment of fractures (Anaes.)		
50130				

T8. SUF	RGICAL OPERAT	IONS	15. ORTHOPAEDIC
	Fee: \$312.30	Benefit: 75% = \$234.25	
		MALIGNANT	DISEASE
		OR POTENTIALLY MALIGNANT Foluding aftercare) (Anaes.)	BONE OR DEEP SOFT TISSUE TUMOUR,
50200	Fee: \$188.20	Benefit: 75% = \$141.15 85% = \$1	160.00
			BONE OR DEEP SOFT TISSUE TUMOUR, t including aftercare) (Anaes.) (Assist.)
50201	Fee: \$329.50	Benefit: 75% = \$247.15	
	BONE OR MAI (Assist.)	IGNANT DEEP SOFT TISSUE TUN	MOUR, lesional or marginal excision of (Anaes.)
50203	Fee: \$414.25	Benefit: 75% = \$310.70 85% = \$3	352.15
		R, lesional or marginal excision of, co aft or cementation (Anaes.) (Assist.)	mbined with any 1 of: liquid nitrogen freezing,
50206	Fee: \$611.90	Benefit: 75% = \$458.95	
		R, lesional or marginal excision of, co ft, allograft or cementation (Anaes.) (A	mbined with any 2 or more of: liquid nitrogen Assist.)
50209	Fee: \$753.25	Benefit: 75% = \$564.95	
			MOUR affecting the long bones of leg or arm, ion of soft tissue, without reconstruction (Anaes.)
50212	Fee: \$1,647.55	Benefit: 75% = \$1235.70	
	enbloc resection		MOUR affecting the long bones of leg or arm, ion of soft tissue, with intercalary reconstruction
50215	Fee: \$2,071.20	Benefit: 75% = \$1553.40	
		TUMOUR of LONG BONE, enbloc re ith synovectomy if performed (Anaes.	section of, with replacement or arthrodesis of (Assist.)
50218	Fee: \$2,730.30	Benefit: 75% = \$2047.75	
		or AGGRESSIVE SOFT TISSUE TUN SHOULDER, enbloc resection of (Ana	MOUR of PELVIS, SACRUM or SPINE; or aes.) (Assist.)
50221	Fee: \$2,541.85	Benefit: 75% = \$1906.40	
		SHOULDER, enbloc resection of, with	MOUR of PELVIS, SACRUM or SPINE; or h reconstruction by prosthesis, allograft or
50224	Fee: \$2,824.35	Benefit: 75% = \$2118.30 85% = \$	\$2740.95
	MALIGNANT BONE TUMOUR, enbloc resection of, with massive anatomic specific allograft or autograft, with or without prosthetic replacement (Anaes.) (Assist.)		
50227	Fee: \$3,295.10	Benefit: 75% = \$2471.35	
50230	BENIGN TUMO	OUR, resection of, requiring anatomic	specific allograft, with or without internal fixation

T8. SUF	RGICAL OPERATIO	NS 15. ORTHOPAEDIC
	(Anaes.) (Assist.)	
	Fee: \$1,694.60	Benefit: 75% = \$1270.95
	MALIGNANT TU	MOUR, amputation for, hemipelvectomy or interscapulo-thoracic (Anaes.) (Assist.)
50233	Fee: \$2,165.35	Benefit: 75% = \$1624.05
	MALIGNANT TU femur (Anaes.) (As	MOUR, amputation for, hip disarticulation, shoulder disarticulation or proximal third sist.)
50236	Fee: \$1,694.60	Benefit: 75% = \$1270.95
	MALIGNANT TU applies (Anaes.) (A	MOUR, amputation for, not being a service to which another item in this Group .ssist.)
50239	Fee: \$1,129.65	Benefit: 75% = \$847.25
		LIMB LENGTHENING AND DEFORMITY CORRECTION
		ΓY, slow correction of, using ring fixator or similar device, including all associated ble only once in any 12 month period (Anaes.) (Assist.)
50300	Fee: \$1,157.70	Benefit: 75% = \$868.30
		NING, 5cm or less, by gradual distraction, with application of an external fixator or vice, in the operating theatre of a hospital - payable only once per limb in any 12 es.) (Assist.)
50303	Fee: \$1,580.60	Benefit: 75% = \$1185.45
		NING, where the lengthening is bipolar, or bone transport is performed or where the to correct an adjacent joint deformity, or where the lengthening is greater than 5cm
50306	Fee: \$2,467.90	Benefit: 75% = \$1850.95 85% = \$2384.50
	fixation pins, perfo	OR SIMILAR DEVICE, adjustment of, with or without insertion or removal of rmed under general anaesthesia in the operating theatre of a hospital, not being a cm 50303 or 50306 applies (Anaes.) (Assist.)
50309	Fee: \$305.05	Benefit: 75% = \$228.80
		omy of, by arthroscopic or open means - not associated with any other arthroscopic kle (Anaes.) (Assist.)
50312	Fee: \$700.10	Benefit: 75% = \$525.10
	TALIPES EQUINO	OVARUS, posterior release of (Anaes.) (Assist.)
50315	Fee: \$693.30	Benefit: 75% = \$520.00
	TALIPES EQUINO	OVARUS, medial release of (Anaes.) (Assist.)
50318	Fee: \$693.30	Benefit: 75% = \$520.00
		OVARUS, combined postero-medial release of (Anaes.) (Assist.)
50321	Fee: \$928.85	Benefit: 75% = \$696.65
30321		OVARUS, combined postero-medial release of, revision procedure (Anaes.) (Assist.)
50224		
50324	Fee: \$1,324.15	Benefit: 75% = \$993.15

(Anaes.) maes.)
(Anaes.)
(Anaes.)
naes.)
naes.)
naes.)
naes.)
membrane to
membrane to
engthening of
general
- each
naes.)
_ - t

T8. SUF	SURGICAL OPERATIONS 15. ORTHOPAEDI		
	TIBIA, pseudarthro	osis of, congenital, resection and internal fixation (Anaes.) (Assist.)	
50354	Fee: \$1,310.15	Benefit: 75% = \$982.65 85% = \$1226.75	
	KNEE, LEG OR T (Anaes.) (Assist.)	HIGH, rectus femoris tendon transfer, or medial or lateral hamstring tendon transfer	
50357	Fee: \$561.55	Benefit: 75% = \$421.20	
	KNEE, LEG OR T	HIGH, combined medial and lateral hamstring tendon transfer (Anaes.) (Assist.)	
50360	Fee: \$651.60	Benefit: 75% = \$488.70	
	KNEE, contracture (Anaes.) (Assist.)	of, posterior release involving multiple tendon lengthening or tenotomies, unilateral	
50363	Fee: \$499.05	Benefit: 75% = \$374.30	
	KNEE, contracture (Anaes.) (Assist.)	of, posterior release involving multiple tendon lengthening or tenotomies, bilateral	
50366	Fee: \$873.45	Benefit: 75% = \$655.10	
		of, posterior release involving multiple tendon lengthening with or without case of joint capsule with or without cruciate ligaments, unilateral (Anaes.) (Assist.)	
50369	Fee: \$651.60	Benefit: 75% = \$488.70	
		of, posterior release involving multiple tendon lengthening with or without case of joint capsule with or without cruciate ligaments, bilateral (Anaes.) (Assist.)	
50372	Fee: \$1,143.80	Benefit: 75% = \$857.85	
		, medial release, involving lengthening of, or division of the adductors and psoas with of the obturator nerve, unilateral (Anaes.) (Assist.)	
50375	Fee: \$499.05	Benefit: 75% = \$374.30	
		, medial release, involving lengthening of, or division of the adductors and psoas with of the obturator nerve, bilateral (Anaes.) (Assist.)	
50378	Fee: \$873.45	Benefit: 75% = \$655.10	
	-	, anterior release, involving lengthening of, or division of the hip flexors and psoas ision of the joint capsule, unilateral (Anaes.) (Assist.)	
50381	Fee: \$651.60	Benefit: 75% = \$488.70	
	-	, anterior release, involving lengthening of, or division of the hip flexors and psoas ision of the joint capsule, bilateral (Anaes.) (Assist.)	
50384	Fee: \$1,143.80	Benefit: 75% = \$857.85	
		on transfer to greater trochanter, or transfer of abdominal musculature to greater fer of adductors to ischium (Anaes.) (Assist.)	
50387	Fee: \$651.60	Benefit: 75% = \$488.70	
		BRAL PALSY, or other neuromuscular conditions, affecting hips or knees, under general anaesthesia, performed in the operating theatre of a hospital (Anaes.)	

PELVIS hone gr	
I LE vis, cone gr	aft or shelf procedures for acetabular dysplasia (Anaes.) (Assist.)
Fee: \$845.60	Benefit: 75% = \$634.20
ACETABULAR DYSPLASIA, treatment of, by multiple peri-acetabular osteotomy, including internativation where performed (Anaes.) (Assist.)	
Fee: \$2,777.30	Benefit: 75% = \$2083.00
	SHOULDER, ARM AND FOREARM PROCEDURES
	al abnormalities or duplication of digits, amputation or splitting of phalanx or igament or joint reconstruction (Anaes.) (Assist.)
Fee: \$464.55	Benefit: 75% = \$348.45
	DIAL APLASIA OR DYSPLASIA (radial club hand), centralisation or radialisation of
Fee: \$922.05	Benefit: 75% = \$691.55
TORTICOLLIS, bipolar release of sternocleidomastoid muscle and associated soft tissue (Anaes.) (Assist.)	
Fee: \$422.95	Benefit: 75% = \$317.25
Fee: \$422.95 Benefit: 75% = \$317.25 ELBOW, flexorplasty, or tendon transfer to restore elbow function (Anaes.) (Assist.)	
Fee: \$575.40	Benefit: 75% = \$431.55
SHOULDER, con	ngenital or developmental dislocation, open reduction of (Anaes.) (Assist.)
Fee: \$998.25	Benefit: 75% = \$748.70
AMPU	UTATIONS OR RECONSTRUCTIONS FOR CONGENITAL DEFORMITIES
	DEFICIENCY, treatment of congenital deficiency of the femur by resection of the distal nal tibia followed by knee fusion (Anaes.) (Assist.)
Fee: \$1,310.15	Benefit: 75% = \$982.65 85% = \$1226.75
LOWER LIMB DEFICIENCY, treatment of congenital deficiency of the femur by resection of the disference and proximal tibia followed by knee fusion and rotationplasty (Anaes.) (Assist.)	
Fee: \$1,767.60	Benefit: 75% = \$1325.70 85% = \$1684.20
LOWER LIMB DEFICIENCY, treatment of congenital deficiency of the tibia by reconstruction of knee, involving transfer of fibula or tibia, and repair of quadriceps mechanism (Anaes.) (Assist.)	
Fee: \$1,310.15	Benefit: 75% = \$982.65 85% = \$1226.75
PATELLA, cong	enital dislocation of, reconstruction of the quadriceps (Anaes.) (Assist.)
Fee: \$1,081.35	Benefit: 75% = \$811.05
TIBIA, FIBULA OR BOTH, congenital deficiency of, transfer of the fibula to tibia, with internal fixation (Anaes.) (Assist.)	
	ACETABULAR fixation where per Fee: \$2,777.30 HAND, congenitate phalanges, with list Fee: \$464.55 FOREARM, RAI (Anaes.) (Assist.) Fee: \$922.05 TORTICOLLIS, (Assist.) Fee: \$422.95 ELBOW, flexorp Fee: \$575.40 SHOULDER, conference \$998.25 AMPO LOWER LIMB In femur and proximing Fee: \$1,310.15 LOWER LIMB In femur and proximing Fee: \$1,767.60

T8. SUF	RGICAL OPERATIONS 15. ORTHOP	AEDIC	
	Fee: \$998.25 Benefit: 75% = \$748.70 85% = \$914.85		
	TUMOROUS CONDITIONS		
	DIAPHYSEAL ACLASIA, removal of lesion or lesions from bone - 1 approach (Anaes.) (Assist.))	
50426	Fee: \$464.55 Benefit: 75% = \$348.45		
	SINGLE EVEN MULTILEVEL SURGERY FOR CHILDREN WITH CEREBRAL PALSY		
	UNILATERAL SINGLE EVENT MULTILEVEL SURGERY for patients less than 18 years of as hemiplegic cerebral palsy comprising three or more of the following:	ge with	
	(a) Lengthening of one or more contracted muscle tendon units by tendon lengthening, muscle recession, fractional lengthening or intramuscular lengthening.		
	(b) Correction of muscle imbalance by tendon transfer/transfers.		
	(c) Correction of femoral torsion by rotational osteotomy of the femur.		
	(d) Correction of tibial torsion by rotational osteotomy of the tibia.		
	(e) Correction of joint instability by varus derotation osteotomy of the femur, subtalar arthrodesis, synovectomy if performed, or os calcis lengthening.		
	Conjoint surgery, principal specialist surgeon, including fluoroscopy and aftercare (Anaes.) (Assist.)		
50450	(See para TN.8.118 of explanatory notes to this Category) Fee: \$1,226.90 Benefit: 75% = \$920.20		
	UNILATERAL SINGLE EVENT MULTILEVEL SURGERY for patients less than 18 years of as hemiplegic cerebral palsy comprising three or more of the following:	ge with	
	(a) Lengthening of one or more contracted muscle tendon units by tendon lengthening, muscle recession, fractional lengthening or intramuscular lengthening.		
	(b) Correction of muscle imbalance by tendon transfer/transfers.		
	(c) Correction of femoral torsion by rotational osteotomy of the femur.		
	(d) Correction of tibial torsion by rotational osteotomy of the tibia.		
	(e) Correction of joint instability by varus derotation osteotomy of the femur, subtalar arthrodesi synovectomy if performed, or os calcis lengthening.	s, with	
	Conjoint surgery, conjoint specialist surgeon, including fluoroscopy and excluding aftercare (Anae (Assist.)	es.)	
50451	(See para TN.8.118 of explanatory notes to this Category) Fee: \$1,226.90 Benefit: 75% = \$920.20		
	BILATERAL SINGLE EVENT MULTILEVEL SURGERY for patients less than 18 years of age diplegic cerebral palsy that comprises:	with	
50455	(') Lengthening of one or more contracted muscle tendon units by tendon lengthening, muscle recession, fractional lengthening or intramuscular lengthening.		

T8. SUR	RGICAL OPERATIONS	15. ORTHOPAEDIC
	(`) Correction of muscle imbalance by tendon transfer/transfers.	
	Conjoint surgery, principal specialist surgeon, including fluoroscopy and aftercare	(Anaes.) (Assist.)
	(See para TN.8.118 of explanatory notes to this Category) Fee: \$1,389.40 Benefit: 75% = \$1042.05	
	BILATERAL SINGLE EVENT MULTILEVEL SURGERY for patients less than diplegic cerebral palsy that comprises:	18 years of age with
	(a) Lengthening of one or more contracted muscle tendon units by tendon length recession, fractional lengthening or intramuscular lengthening.	ening, muscle
	(b) Correction of muscle imbalance by tendon transfer/transfers.	
	Conjoint surgery, conjoint specialist surgeon, including fluoroscopy and excluding (Assist.)	g aftercare (Anaes.)
50456	(See para TN.8.118 of explanatory notes to this Category) Fee: \$1,389.40 Benefit: 75% = \$1042.05	
	BILATERAL SINGLE EVENT MULTILEVEL SURGERY for patients less than diplegic cerebral palsy that comprises bilateral soft tissue surgery and bilateral fem	
	(`) Lengthening of one or more contracted muscle tendon units by tendon lengther recession, fractional lengthening or intramuscular lengthening.	ening, muscle
	(`) Correction of muscle imbalance by tendon transfer/transfers.	
	(`) Correction of torsional abnormality of the femur by rotational osteotomy and	internal fixation.
	Conjoint surgery, principal specialist surgeon, including fluoroscopy and aftercare	(Anaes.) (Assist.)
50460	(See para TN.8.118 of explanatory notes to this Category) Fee: \$2,074.45 Benefit: 75% = \$1555.85	
	BILATERAL SINGLE EVENT MULTILEVEL SURGERY for patients less than diplegic cerebral palsy that comprises bilateral soft tissue surgery and bilateral fem	
	(a) Lengthening of one or more contracted muscle tendon units by tendon lengther recession, fractional lengthening or intramuscular lengthening.	ening, muscle
	(b) Correction of muscle imbalance by tendon transfer/transfers.	
	(c) Correction of torsional abnormality of the femur by rotational osteotomy and	internal fixation.
	Conjoint surgery, conjoint specialist surgeon, including fluoroscopy and excluding (Assist.)	g aftercare (Anaes.)
50461	(See para TN.8.118 of explanatory notes to this Category) Fee: \$2,074.45 Benefit: 75% = \$1555.85	
	BILATERAL SINGLE EVENT MULTILEVEL SURGERY for patients less than diplegic cerebral palsy that comprises bilateral soft tissue surgery, bilateral femora bilateral tibial osteotomies.	
50465	(`) Lengthening of one or more contracted muscle tendon units by tendon lengther recession, fractional lengthening or intramuscular lengthening.	ening, muscle

T8. SUR	RGICAL OPERATIONS	15. ORTHOPAEDIC
	(`) Correction of muscle imbalance by tendon transfer/transfers.	
	(`) Correction of abnormal torsion of the femur by rotational osteotomy with inter	rnal fixation.
	(') Correction of abnormal torsion of the tibia by rotational osteotomy with intern	al fixation.
	Conjoint surgery, principal specialist surgeon, including fluoroscopy and aftercare ((Anaes.) (Assist.)
	(See para TN.8.118 of explanatory notes to this Category) Fee: \$2,921.80 Benefit: 75% = \$2191.35	
	BILATERAL SINGLE EVENT MULTILEVEL SURGERY for patients less than I diplegic cerebral palsy that comprises bilateral soft tissue surgery, bilateral femoral bilateral tibial osteotomies.	
	(a) Lengthening of one or more contracted muscle tendon units by tendon lengther recession, fractional lengthening or intramuscular lengthening.	ning, muscle
	(b) Correction of muscle imbalance by tendon transfer/transfers.	
	(c) Correction of abnormal torsion of the femur by rotational osteotomy with inter-	rnal fixation.
	(d) Correction of abnormal torsion of the tibia by rotational osteotomy with interru	al fixation.
	Conjoint surgery, conjoint specialist surgeon, including fluoroscopy and excluding (Assist.)	aftercare (Anaes.)
50466	(See para TN.8.118 of explanatory notes to this Category) Fee: \$2,921.80 Benefit: 75% = \$2191.35	
	BILATERAL SINGLE EVENT MULTILEVEL SURGERY for patients less than cerebral palsy that comprises bilateral soft tissue surgery, bilateral femoral osteotom osteotomies and bilateral foot stabilisation.	
	(`) Lengthening of one or more contracted muscle tendon units by tendon lengthe recession, fractional lengthening or intramuscular lengthening.	ning, muscle
	(') Correction of muscle imbalance by tendon transfer/transfers.	
	(') Correction of abnormal torsion of the femur by rotational osteotomy with inter-	rnal fixation.
	(') Correction of abnormal torsion of the tibia by rotational osteotomy with intern	al fixation.
	(') Correction of bilateral pes valgus by os calcis lengthening or subtalar fusion.	
	Conjoint surgery, principal specialist surgeon, including fluoroscopy and aftercare ((Anaes.) (Assist.)
50470	(See para TN.8.118 of explanatory notes to this Category) Fee: \$3,705.55 Benefit: 75% = \$2779.20	
	BILATERAL SINGLE EVENT MULTILEVEL SURGERY for patients less than a cerebral palsy that comprises bilateral soft tissue surgery, bilateral femoral osteotom osteotomies and bilateral foot stabilisation.	
50471	(a) Lengthening of one or more contracted muscle tendon units by tendon lengther recession, fractional lengthening or intramuscular lengthening.	ning, muscle

T8. SURGICAL OPERATIONS 15. ORTHOPAEDIC Correction of muscle imbalance by tendon transfer/transfers. Correction of abnormal torsion of the femur by rotational osteotomy with internal fixation. Correction of abnormal torsion of the tibia by rotational osteotomy with internal fixation. Correction of bilateral pes valgus by os calcis lengthening or subtalar fusion. Conjoint surgery, conjoint specialist surgeon, including fluoroscopy and excluding aftercare (Anaes.) (Assist.) (See para TN.8.118 of explanatory notes to this Category) Fee: \$3,705.55 **Benefit:** 75% = \$2779.20SINGLE EVENT MULTILEVEL SURGERY for patients less than 18 years of age with diplegic cerebral palsy for the correction of crouch gait including: Lengthening of one or more contracted muscle tendon units by tendon lengthening, muscle recession, fractional lengthening or intramuscular lengthening. Correction of muscle imbalance by tendon transfer/transfers. Correction of flexion deformity at the knee by extension osteotomy of the distal femur including internal fixation. Correction of patella alta and quadriceps insufficiency by patella tendon shortening/reconstruction. Correction of tibial torsion by rotational osteotomy of the tibia with internal fixation. Correction of foot instability by os calcis lengthening or subtalar fusion. Conjoint surgery, principal specialist surgeon, including fluoroscopy and aftercare (Anaes.) (Assist.) (See para TN.8.118 of explanatory notes to this Category) 50475 Fee: \$4.275.85 **Benefit:** 75% = \$3206.90 SINGLE EVENT MULTILEVEL SURGERY for patients less than 18 years of age with diplegic cerebral palsy for the correction of crouch gait including: (a) Lengthening of one or more contracted muscle tendon units by tendon lengthening, muscle recession, fractional lengthening or intramuscular lengthening. Correction of muscle imbalance by tendon transfer/transfers. Correction of flexion deformity at the knee by extension osteotomy of the distal femur including internal fixation. Correction of patella alta and quadriceps insufficiency by patella tendon shortening/reconstruction. Correction of tibial torsion by rotational osteotomy of the tibia with internal fixation. Correction of foot instability by os calcis lengthening or subtalar fusion. Conjoint surgery, conjoint specialist surgeon, including fluoroscopy and excluding aftercare (Anaes.) (Assist.) (See para TN.8.118 of explanatory notes to this Category) **Benefit:** 75% = \$3206.90 50476 Fee: \$4,275.85

T8. SUF	RGICAL OPERATIONS 15. ORTHOPAEDI	
	TREATMENT OF FRACTURES IN PAEDIATRIC PATIENTS	
	RADIUS OR ULNA, distal end of, with open growth plate, treatment of fracture of, by closed reduction (Anaes.)	
50500	(See para TN.8.119, TN.8.118 of explanatory notes to this Category) Fee: \$276.65 Benefit: 75% = \$207.50 85% = \$235.20	
	RADIUS OR ULNA, distal end of, with open growth plate, treatment of fracture of, by open reduction (Anaes.) (Assist.)	
50504	(See para TN.8.119, TN.8.118 of explanatory notes to this Category) Fee: \$369.05 Benefit: 75% = \$276.80 85% = \$313.70	
	RADIUS, distal end of, with open growth plate, treatment of Colles', Smith's or Barton's fracture, by closed reduction (Anaes.)	
50508	(See para TN.8.119, TN.8.118 of explanatory notes to this Category) Fee: \$395.25 Benefit: 75% = \$296.45 85% = \$336.00	
	RADIUS, distal end of, with open growth plate, treatment of Colles', Smith's or Barton's fracture of, by open reduction (Anaes.) (Assist.)	
50512	(See para TN.8.119, TN.8.118 of explanatory notes to this Category) Fee: \$527.30 Benefit: 75% = \$395.50	
	RADIUS OR ULNA, shaft of, with open growth plate, treatment of fracture of, by closed reduction undertaken in the operating theatre of a hospital (Anaes.)	
50516	(See para TN.8.119, TN.8.118 of explanatory notes to this Category) Fee: \$355.85 Benefit: 75% = \$266.90	
	RADIUS OR ULNA, shaft of, with open growth plate, treatment of fracture of, by open reduction (Anaes.) (Assist.)	
50520	(See para TN.8.119, TN.8.118 of explanatory notes to this Category) Fee: \$474.40 Benefit: 75% = \$355.80	
	RADIUS OR ULNA, shaft of, with open growth plate, treatment of fracture of, in conjunction with dislocation of distal radio-ulnar joint or proximal radio-humeral joint (Galeazzi or Monteggia injury), closed reduction undertaken in the operating theatre of a hospital (Anaes.) (Assist.)	
50524	(See para TN.8.119, TN.8.118 of explanatory notes to this Category) Fee: \$408.50 Benefit: 75% = \$306.40	
	RADIUS OR ULNA, shaft of, with open growth plate, treatment of fracture of, in conjunction with dislocation of distal radio-ulnar joint or proximal radio-humeral joint (Galeazzi or Monteggia injury), by reduction with or without internal fixation by open or percutaneous means (Anaes.) (Assist.)	
50528	(See para TN.8.119, TN.8.118 of explanatory notes to this Category) Fee: \$659.00 Benefit: 75% = \$494.25	
	RADIUS AND ULNA, shafts of, with open growth plates, treatment of fracture of, by closed reduction undertaken in the operating theatre of a hospital (Anaes.)	
50532	(See para TN.8.119, TN.8.118 of explanatory notes to this Category) Fee: \$573.40 Benefit: 75% = \$430.05	
	RADIUS AND ULNA, shafts of, with open growth plates, treatment of fracture of, by open reduction (Anaes.) (Assist.)	
50536	(See para TN.8.119, TN.8.118 of explanatory notes to this Category)	

T8. SUF	RGICAL OPERATIONS 15. ORTHOPAEDIC		
	Fee: \$764.40 Benefit: 75% = \$573.30		
	OLECRANON, with open growth plate, treatment of fracture of, by open reduction (Anaes.) (Assist.)		
50540	(See para TN.8.119, TN.8.118 of explanatory notes to this Category) Fee: \$527.30 Benefit: 75% = \$395.50		
	RADIUS, with open growth plate, treatment of fracture of head or neck of, by closed reduction of (Anaes.)		
50544	(See para TN.8.119, TN.8.118 of explanatory notes to this Category) Fee: \$263.60 Benefit: 75% = \$197.70 85% = \$224.10		
	RADIUS, with open growth plate, treatment of fracture of head or neck of, by reduction with or without internal fixation by open or percutaneous means (Anaes.) (Assist.)		
50548	(See para TN.8.119, TN.8.118 of explanatory notes to this Category) Fee: \$527.30 Benefit: 75% = \$395.50		
	HUMERUS, proximal, with open growth plate, treatment of fracture of, by closed reduction, undertaken in the operating theatre, neonatal unit or nursery of a hospital (Anaes.)		
50552	(See para TN.8.119, TN.8.118 of explanatory notes to this Category) Fee: \$454.75 Benefit: 75% = \$341.10		
	HUMERUS, proximal, with open growth plate, treatment of fracture of, by open reduction (Anaes.) (Assist.)		
50556	(See para TN.8.119, TN.8.118 of explanatory notes to this Category) Fee: \$606.20 Benefit: 75% = \$454.65		
	HUMERUS, shaft of, with open growth plate, treatment of fracture of, by closed reduction, undertaken in the operating theatre, neonatal unit or nursery of a hospital (Anaes.)		
50560	(See para TN.8.119, TN.8.118 of explanatory notes to this Category) Fee: \$474.40 Benefit: 75% = \$355.80		
	HUMERUS, shaft of, with open growth plate, treatment of fracture of, by internal or external fixation (Anaes.) (Assist.)		
50564	(See para TN.8.119, TN.8.118 of explanatory notes to this Category) Fee: \$632.65 Benefit: 75% = \$474.50		
	HUMERUS, with open growth plate, supracondylar or condylar, treatment of fracture of, by closed reduction, undertaken in the operating theatre of a hospital (Anaes.)		
50568	(See para TN.8.119, TN.8.118 of explanatory notes to this Category) Fee: \$553.60 Benefit: 75% = \$415.20		
	HUMERUS, with open growth plate, supracondylar or condylar, treatment of fracture of, by reduction with or without internal fixation by open or percutaneous means, undertaken in the operating theatre of a hospital (Anaes.) (Assist.)		
50572	(See para TN.8.119, TN.8.118 of explanatory notes to this Category) Fee: \$738.10 Benefit: 75% = \$553.60		
	FEMUR, with open growth plate, treatment of fracture of, by closed reduction or traction (Anaes.) (Assist.)		
50576	(See para TN.8.119, TN.8.118 of explanatory notes to this Category) Fee: \$606.20 Benefit: 75% = \$454.65 85% = \$522.80		
50580	TIBIA, with open growth plate, plateau or condyles, medial or lateral, treatment of fracture of, by		

T8. SURGICAL OPERATIONS 15. OF		RTHOPAEDIC
	reduction with or without internal fixation by open or percutaneous means (Anaes.) (Assist.)	
	(See para TN.8.119, TN.8.118 of explanatory notes to this Category) Fee: \$632.65 Benefit: 75% = \$474.50	
	TIBIA, distal, with open growth plate, treatment of fracture of, by reduction with or without internal fixation by open or percutaneous means (Anaes.) (Assist.)	l
50584	(See para TN.8.119, TN.8.118 of explanatory notes to this Category) Fee: \$606.20 Benefit: 75% = \$454.65	
	TIBIA AND FIBULA, with open growth plates, treatment of fracture of, by internal fixation (Anaes (Assist.)	i.)
50588	(See para TN.8.119, TN.8.118 of explanatory notes to this Category) Fee: \$790.70 Benefit: 75% = \$593.05	
	SPINE SURGERY FOR SCOLIOSIS AND KYPHOSIS IN PAEDIATRIC PATIENTS	
	SCOLIOSIS OR KYPHOSIS, in a growing child, manipulation of deformity and application of a localiser cast, under general anaesthesia, in a hospital (Anaes.) (Assist.)	
50600	(See para TN.8.118 of explanatory notes to this Category) Fee: \$434.70 Benefit: 75% = \$326.05	
	SCOLIOSIS or KYPHOSIS, in a child or adolescent, spinal fusion for (without instrumentation) (Anaes.) (Assist.)	
50604	(See para TN.8.118 of explanatory notes to this Category) Fee: \$1,845.05 Benefit: 75% = \$1383.80	
	SCOLIOSIS OR KYPHOSIS, in a child or adolescent, treatment by segmental instrumentation and fusion of the spine, not being a service to which item 51011 to 51171 applies (Anaes.) (Assist.)	
50608	(See para TN.8.118 of explanatory notes to this Category) Fee: \$3,426.95 Benefit: 75% = \$2570.25	
	SCOLIOSIS OR KYPHOSIS, in a child or adolescent, with spinal deformity, treatment by segmental instrumentation, utilising separate anterior and posterior approaches, not being a service to which item 51011 to 51171 applies (Anaes.) (Assist.)	
50612	(See para TN.8.118 of explanatory notes to this Category) Fee: \$4,874.50 Benefit: 75% = \$3655.90	
	SCOLIOSIS, in a child or adolescent, re-exploration for adjustment or removal of segmental instrumentation used for correction of spine deformity (Anaes.) (Assist.)	
50616	(See para TN.8.118 of explanatory notes to this Category) Fee: \$619.35 Benefit: 75% = \$464.55	
	SCOLIOSIS, in a child or adolescent, revision of failed scoliosis surgery, involving more than 1 of osteotomy, fusion, removal of instrumentation or instrumentation, not being a service to which item 51011 to 51171 applies (Anaes.) (Assist.)	
50620	(See para TN.8.118 of explanatory notes to this Category) Fee: \$3,426.95 Benefit: 75% = \$2570.25	
	SCOLIOSIS, in a child or adolescent, anterior correction of, with fusion and segmental fixation (Dw Zielke or similar) - not more than 4 levels (Anaes.) (Assist.)	vyer,
50624	(See para TN.8.118 of explanatory notes to this Category) Fee: \$3,426.95 Benefit: 75% = \$2570.25	

T8. SUR	GICAL OPERATIONS 15. ORTHOPAEDIC	
	SCOLIOSIS, in a child or adolescent, anterior correction of, with fusion and segmental fixation (Dwyer, Zielke or similar) - more than 4 levels (Anaes.) (Assist.)	
50628	(See para TN.8.118 of explanatory notes to this Category) Fee: \$4,233.20 Benefit: 75% = \$3174.90	
	SCOLIOSIS OR KYPHOSIS, in a child or adolescent, requiring segmental instrumentation and fusion of the spine down to and including the pelvis or sacrum, not being a service to which item 51011 to 51171 applies (Anaes.) (Assist.)	
50632	(See para TN.8.118 of explanatory notes to this Category) Fee: \$3,558.65 Benefit: 75% = \$2669.00	
	SCOLIOSIS, in a child or adolescent, requiring anterior decompression of the spinal cord with vertebral resection and instrumentation in the presence of spinal cord involvement, not being a service to which item 51011 to 51171 applies (Anaes.) (Assist.)	
50636	(See para TN.8.118 of explanatory notes to this Category) Fee: \$3,954.10 Benefit: 75% = \$2965.60	
	SCOLIOSIS, in a child or adolescent, congenital, resection and fusion of abnormal vertebra via an anterior or posterior approach, not being a service to which item 51011 to 51171 applies (Anaes.) (Assist.)	
50640	(See para TN.8.118 of explanatory notes to this Category) Fee: \$2,185.80 Benefit: 75% = \$1639.35	
	SPINE, bone graft to, for a child or adolescent, associated with surgery for correction of scoliosis or kyphosis or both (Anaes.) (Assist.)	
50644	(See para TN.8.118 of explanatory notes to this Category) Fee: \$2,108.95 Benefit: 75% = \$1581.75	
	TREATMENT OF HIP DYSPLASIA OR DISLOCATION IN PAEDIATRIC PATIENTS	
	HIP DYSPLASIA or DISLOCATION, in a child, examination, manipulation and arthrography of the hip under anaesthesia (Anaes.)	
50650	(See para TN.8.118 of explanatory notes to this Category) Fee: \$414.75 Benefit: 75% = \$311.10 85% = \$352.55	
	HIP DYSPLASIA or DISLOCATION, in a child, application or reapplication of a hip spica, including examination of the hip (Anaes.) (Assist.)	
50654	(See para TN.8.118 of explanatory notes to this Category) Fee: \$496.65 Benefit: 75% = \$372.50	
	HIP DYSPLASIA or DISLOCATION, in a child, examination and manipulation of the hip under anaesthesia (Anaes.)	
50658	(See para TN.8.118 of explanatory notes to this Category) Fee: \$197.75 Benefit: 75% = \$148.35 85% = \$168.10	
T8. SUR	16. RADIOFREQUENCY AND MICROWAVE RGICAL OPERATIONS 16. RADIOFREQUENCY AND MICROWAVE	
	Group T8. Surgical Operations	
	Subgroup 16. Radiofrequency And Microwave Tissue Ablation	
50950	Unresectable primary malignant tumour of the liver, destruction of, by percutaneous radiofrequency	

T8. SUF	16. RADIOFREQUENCY AND MICROWAVE RGICAL OPERATIONS TISSUE ABLATION		
	ablation or percutaneous microwave tissue ablation (including any associated imaging services), other than a service associated with a service to which item 30419 or 50952 applies		
	(Anaes.)		
	Fee: \$817.10 Benefit: 75% = \$612.85 85% = \$733.70		
	Unresectable primary malignant tumour of the liver, destruction of, by open or laparoscopic radiofrequency ablation or open or laparoscopic microwave tissue ablation (including any associated imaging services), if a multi-disciplinary team has assessed that percutaneous radiofrequency ablation or percutaneous microwave tissue ablation cannot be performed or is not practical because of one or more of the following clinical circumstances:		
	(a) percutaneous access cannot be achieved;		
	(b) vital organs or tissues are at risk of damage from the percutaneous radiofrequency ablation or percutaneous microwave tissue ablation procedure;		
	(c) resection of one part of the liver is possible, however there is at least one primary liver tumour in an unresectable portion of the liver that is suitable for radiofrequency ablation or microwave tissue ablation;		
	other than a service associated with a service to which item 30419 or 50950 applies.		
	(Anaes.)		
50952	(See para TN.8.120 of explanatory notes to this Category) Fee: \$817.10 Benefit: 75% = \$612.85 85% = \$733.70		
T8. SUF	RGICAL OPERATIONS 17. SPINAL SURGERY		
	Group T8. Surgical Operations		
	Subgroup 17. Spinal Surgery		
	Spinal decompression or exposure via partial or total laminectomy, partial vertebrectomy or posterior spinal release, one motion segment, not being a service associated with a service to which item 51012, 51013, 51014 or 51015 applies (Anaes.) (Assist.)		
Fee 51011	(See para TN.8.141, TN.8.142 of explanatory notes to this Category) Fee: \$1,435.50 Benefit: 75% = \$1076.50		
	Spinal decompression or exposure via partial or total laminectomy, partial vertebrectomy or posterior spinal release, 2 motion segments, not being a service associated with a service to which item 51011, 51013, 51014 or 51015 applies (Anaes.) (Assist.)		
	·		
51012	(See para TN.8.141, TN.8.142 of explanatory notes to this Category) Fee: \$1,913.80 Benefit: 75% = \$1435.35		
51012			

T8. SUF	RGICAL OPERATIONS	17. SPINAL SURGERY	
	Fee: \$2,392.25 Benefit: 75% = \$1794.20		
	Spinal decompression or exposure via partial or total laminectomy, spinal release, 4 motion segments, not being a service associated wi 51012, 51013 or 51015 applies (Anaes.) (Assist.)		
51014	(See para TN.8.141, TN.8.142 of explanatory notes to this Category) 1014 Fee: \$2,870.70 Benefit: 75% = \$2153.05		
	Spinal decompression or exposure via partial or total laminectomy, spinal release, more than 4 motion segments, not being a service ass 51011, 51012, 51013 or 51014 applies (Anaes.) (Assist.)		
51015	(See para TN.8.141, TN.8.142 of explanatory notes to this Category) Fee: \$3,349.15 Benefit: 75% = \$2511.90		
	Simple fixation of part of one vertebra (not motion segment) includi process or pedicle, or simple interspinous wiring between 2 adjacen associated with:		
	(a) interspinous dynamic stabilisation devices; or		
	(b) a service to which item 51021, 51022, 51023, 51024, 51025 or 5	51026 applies (Anaes.) (Assist.)	
51020	(See para TN.8.141, TN.8.143 of explanatory notes to this Category) Fee: \$765.45 Benefit: 75% = \$574.10		
	Fixation of motion segment with vertebral body screw, pedicle screw or hook instrumentation sublaminar tapes or wires, one motion segment, not being a service associated with a service item 51020, 51022, 51023, 51024, 51025 or 51026 applies (Anaes.) (Assist.)		
51021	(See para TN.8.141, TN.8.143 of explanatory notes to this Category) Fee: \$1,281.20 Benefit: 75% = \$960.90		
	Fixation of motion segment with vertebral body screw, pedicle scressublaminar tapes or wires, 2 motion segments, not being a service as item 51020, 51021, 51023, 51024, 51025 or 51026 applies (Anaes.)	ssociated with a service to which	
51022	(See para TN.8.141, TN.8.143 of explanatory notes to this Category) Fee: \$1,593.70 Benefit: 75% = \$1195.30		
	Fixation of motion segment with vertebral body screw, pedicle screw or hook instrumentation inclusublaminar tapes or wires, 3 or 4 motion segments, not being a service associated with a service to item 51020, 51021, 51022, 51024, 51025 or 51026 applies (Anaes.) (Assist.)		
51023	(See para TN.8.141, TN.8.143 of explanatory notes to this Category) Fee: \$1,896.60 Benefit: 75% = \$1422.45		
	Fixation of motion segment with vertebral body screw, pedicle scressublaminar tapes or wires, 5 or 6 motion segments, not being a servitem 51020, 51021, 51022, 51023, 51025 or 51026 applies (Anaes.)	ice associated with a service to which	
51024	(See para TN.8.141, TN.8.143 of explanatory notes to this Category) Fee: \$2,189.60 Benefit: 75% = \$1642.20		
	Fixation of motion segment with vertebral body screw, pedicle scresublaminar tapes or wires, 7 to 12 motion segments, not being a serve which item 51020, 51021, 51022, 51023, 51024 or 51026 applies (A	vice associated with a service to	
51025	(See para TN.8.141, TN.8.143 of explanatory notes to this Category) Fee: \$2,559.20 Benefit: 75% = \$1919.40		

T8. SUF	RGICAL OPERATIONS	17. SPINAL SURGERY
	Fixation of motion segment with vertebral body screw, pedicle screw of sublaminar tapes or wires, more than 12 motion segments, not being a strong to which item 51020, 51021, 51022, 51023, 51024 or 51025 applies (A	service associated with a service
51026	(See para TN.8.141, TN.8.143 of explanatory notes to this Category) Fee: \$2,801.90 Benefit: 75% = \$2101.45	
	Spine, posterior and/or posterolateral bone graft to, one motion segmen with a service to which item 51032, 51033, 51034, 51035 or 51036 app	
51031	(See para TN.8.141, TN.8.144 of explanatory notes to this Category) Fee: \$941.45 Benefit: 75% = \$706.10	
	Spine, posterior and/or posterolateral bone graft to, 2 motion segments, with a service to which item 51031, 51033, 51034, 51035 or 51036 app	
51032	(See para TN.8.141, TN.8.144 of explanatory notes to this Category) Fee: \$1,129.75 Benefit: 75% = \$847.35	
	Spine, posterior and/or posterolateral bone graft to, 3 motion segments, with a service to which item 51031, 51032, 51034, 51035 or 51036 app	
51033	(See para TN.8.141, TN.8.144 of explanatory notes to this Category) Fee: \$1,318.05 Benefit: 75% = \$988.55	
	Spine, posterior and/or posterolateral bone graft to, 4 to 7 motion segments, not being a service associated with a service to which item 51031, 51032, 51033, 51035 or 51036 applies (Anaes.) (Assist.	
51034	(See para TN.8.141, TN.8.144 of explanatory notes to this Category) Fee: \$1,412.20 Benefit: 75% = \$1059.15	
	Spine, posterior and/or posterolateral bone graft to, 8 to 11 motion segments, not being a service associated with a service to which item 51031, 51032, 51033, 51034 or 51036 applies (Anaes.) (Assist.)	
51035	(See para TN.8.141, TN.8.144 of explanatory notes to this Category) Fee: \$1,506.30 Benefit: 75% = \$1129.75	
	Spine, posterior and/or posterolateral bone graft to, 12 or more motion segments, not being a service associated with a service to which item 51031, 51032, 51033, 51034 or 51035 applies (Anaes.) (Assist.)	
51036	(See para TN.8.141, TN.8.144 of explanatory notes to this Category) Fee: \$1,600.50 Benefit: 75% = \$1200.40	
	Spinal fusion, anterior column (anterior, direct lateral or posterior interbeing a service associated with a service to which item 51042, 51043, 5 (Assist.)	
51041	(See para TN.8.141, TN.8.145 of explanatory notes to this Category) Fee: \$1,082.70 Benefit: 75% = \$812.05	
	Spinal fusion, anterior column (anterior, direct lateral or posterior interbody), 2 motion segments, not being a service associated with a service to which item 51041, 51043, 51044 or 51045 applies (Anaes.) (Assist.)	
51042	(See para TN.8.141, TN.8.145 of explanatory notes to this Category) Fee: \$1,515.80 Benefit: 75% = \$1136.85	
	Spinal fusion, anterior column (anterior, direct lateral or posterior interbeing a service associated with a service to which item 51041, 51042, 5 (Assist.)	
51043	(See para TN.8.141, TN.8.145 of explanatory notes to this Category)	

T8. SUF	RGICAL OPERATIONS		17. SPINAL SURGERY	
	Fee: \$1,894.75 Be	enefit: 75% = \$1421.10		
		column (anterior, direct lateral or posterior ed with a service to which item 51041, 510		
51044		145 of explanatory notes to this Category) enefit: 75% = \$1542.90		
	Spinal fusion, anterior column (anterior, direct lateral or posterior interbody), 5 or more moti segments, not being a service associated with a service to which item 51041, 51042, 51043 o applies (Anaes.) (Assist.)			
51045		.145 of explanatory notes to this Category) enefit: 75% = \$1624.05		
	Pedicle subtraction osteo	otomy, one motion segment, not being a s	ervice associated with:	
	(a) anterior column fusion	on when at the same motion segment; or		
	(b) a service to which ite (Assist.)	em 51052, 51053, 51054, 51055, 51056, 5	51057, 51058 or 51059 applies (Anaes.)	
51051		.146 of explanatory notes to this Category) enefit: 75% = \$1387.50		
	Pedicle subtraction osteo	otomy, 2 motion segments, not being a ser	rvice associated with:	
	(a) anterior column fusion	on when at the same motion segment; or		
	(b) a service to which ite (Assist.)	em 51051, 51053, 51054, 51055, 51056, 5	51057, 51058 or 51059 applies (Anaes.)	
(See para TN.8.141, TN.8.146 of explanatory notes to this Category) Fee: \$2,250.00 Benefit: 75% = \$1687.50				
	Vertebral column resect segment, not being a ser	ion osteotomy performed through single proice associated with:	posterior approach, one motion	
	(a) anterior column fusion	on when at the same motion segment; or		
	(b) a service to which ite (Assist.)	em 51051, 51052, 51054, 51055, 51056, 5	51057, 51058 or 51059 applies (Anaes.)	
51053		.146 of explanatory notes to this Category) mefit: 75% = \$1920.00		
		eal or subtotal excision of (where pieceme 0% of the vertebral body), one vertebra, no		
	(a) anterior column fusion	on when at the same motion segment; or		
	(b) a service to which ite (Assist.)	em 51051, 51052, 51053, 51055, 51056, 5	51057, 51058 or 51059 applies (Anaes.)	
51054		.146 of explanatory notes to this Category) enefit: 75% = \$1023.75		
51055		eal or subtotal excision of (where pieceme 0% of the vertebral body), 2 vertebrae, not		

T8. SUR	3. SURGICAL OPERATIONS 17. SPINAL SURG	
	(a) anterior column fusion when at the same motion segment; or	
	(b) a service to which item 51051, 51052, 51053, 51054, 51056, 51057, 51 (Assist.)	058 or 51059 applies (Anaes.)
	(See para TN.8.141, TN.8.146 of explanatory notes to this Category) Fee: \$2,047.50 Benefit: 75% = \$1535.65	
	Vertebral body, piecemeal or subtotal excision of (where piecemeal or subtremoval of more than 50% of the vertebral body), 3 or more vertebrae, not with:	
	(a) anterior column fusion when at the same motion segment; or	
	(b) a service to which item 51051, 51052, 51053, 51054, 51055, 51057, 51 (Assist.)	058 or 51059 applies (Anaes.)
51056	(See para TN.8.141, TN.8.146 of explanatory notes to this Category) Fee: \$2,388.75 Benefit: 75% = \$1791.60	
	Vertebral body, en bloc excision of (complete spondylectomy), one vertebral associated with:	ra, not being a service
	(a) anterior column fusion when at the same motion segment; or	
	(b) a service to which item 51051, 51052, 51053, 51054, 51055, 51056, 51 (Assist.)	058 or 51059 applies (Anaes.)
51057	(See para TN.8.141, TN.8.146 of explanatory notes to this Category) Fee: \$2,400.00 Benefit: 75% = \$1800.00	
	Vertebral body, en bloc excision of (complete spondylectomy), 2 vertebrae associated with:	e, not being a service
	(a) anterior column fusion when at the same motion segment; or	
	(b) a service to which item 51051, 51052, 51053, 51054, 51055, 51056, 51 (Assist.)	057 or 51059 applies (Anaes.)
51058	(See para TN.8.141, TN.8.146 of explanatory notes to this Category) Fee: \$2,700.50 Benefit: 75% = \$2025.40	
	Vertebral body, en bloc excision of (complete spondylectomy), 3 or more vassociated with:	vertebrae, not being a service
	(a) anterior column fusion when at the same motion segment; or	
	(b) a service to which item 51051, 51052, 51053, 51054, 51055, 51056, 51 (Assist.)	057 or 51058 applies (Anaes.)
51059	(See para TN.8.141, TN.8.146 of explanatory notes to this Category) Fee: \$3,300.00 Benefit: 75% = \$2475.00	
	Spine fusion, anterior and posterior, including spinal instrumentation at one and/or posterolateral bone graft, and anterior column fusion, not being a se to which item 51062, 51063, 51064, 51065 or 51066 applies (Anaes.) (Ass	rvice associated with a service
51061	(See para TN.8.141, TN.8.147 of explanatory notes to this Category) Fee: \$2,834.65 Benefit: 75% = \$2126.00	

T8. SUF	RGICAL OPERATIONS	17. SPINAL SURGERY
	Spine fusion, anterior and posterior, including spinal instrumentation a and/or posterolateral bone graft, and anterior column fusion, not being to which item 51061, 51063, 51064, 51065 or 51066 applies (Anaes.)	g a service associated with a service
51062	(See para TN.8.141, TN.8.147 of explanatory notes to this Category) Fee: \$3,674.35 Benefit: 75% = \$2755.80	
	Spine fusion, anterior and posterior, including spinal instrumentation a and/or posterolateral bone graft, and anterior column fusion, not being to which item 51061, 51062, 51064, 51065 or 51066 applies (Anaes.)	g a service associated with a service
51063	(See para TN.8.141, TN.8.147 of explanatory notes to this Category) Fee: \$4,450.35 Benefit: 75% = \$3337.80	
	Spine fusion, anterior and posterior, including spinal instrumentation a posterior and/or posterolateral bone graft, and anterior column fusion, with a service to which item 51061, 51062, 51063, 51065 or 51066 ap	not being a service associated
51064	(See para TN.8.141, TN.8.147 of explanatory notes to this Category) Fee: \$4,952.85 Benefit: 75% = \$3714.65	
	Spine fusion, anterior and posterior, including spinal instrumentation a posterior and/or posterolateral bone graft, and anterior column fusion, with a service to which item 51061, 51062, 51063, 51064 or 51066 ap	not being a service associated
51065	(See para TN.8.141, TN.8.147 of explanatory notes to this Category) Fee: \$5,477.80 Benefit: 75% = \$4108.35	
	Spine fusion, anterior and posterior, including spinal instrumentation a posterior and/or posterolateral bone graft, and anterior column fusion a service to which item 51061, 51062, 51063, 51064 or 51065 applies	not being a service associated with
51066	(See para TN.8.141, TN.8.147 of explanatory notes to this Category) Fee: \$5,767.50 Benefit: 75% = \$4325.65	
	Removal of intradural lesion, not being a service associated with a ser applies (Anaes.) (Assist.)	vice to which item 51072 or 51073
51071	(See para TN.8.141 of explanatory notes to this Category) Fee: \$2,500.00 Benefit: 75% = \$1875.00	
	Craniocervical junction lesion, transoral approach for, not being a service which item 51071 or 51073 applies (Anaes.) (Assist.)	vice associated with a service to
51072	(See para TN.8.141 of explanatory notes to this Category) Fee: \$2,600.00 Benefit: 75% = \$1950.00	
	Removal of intramedullary tumour or arteriovenous malformation, no service to which item 51071 or 51072 applies (Anaes.) (Assist.)	t being a service associated with a
51073	(See para TN.8.141 of explanatory notes to this Category) Fee: \$3,300.00 Benefit: 75% = \$2475.00	
	Thoracoplasty in combination with thoracic scoliosis correction—3 or	r more ribs (Anaes.) (Assist.)
51102	(See para TN.8.141 of explanatory notes to this Category) Fee: \$1,183.40 Benefit: 75% = \$887.55	
	Odontoid screw fixation (Anaes.) (Assist.)	
51103	(See para TN.8.141, TN.8.148 of explanatory notes to this Category) Fee: \$2,079.75 Benefit: 75% = \$1559.85	

T8. SUF	SURGICAL OPERATIONS 17. SPINAL SURGER		
	Spine, treatment of fracture, dislocation or fracture dislocation, with im not including application of skull tongs or calipers as part of operative p		
51110	(See para TN.8.141 of explanatory notes to this Category) Fee: \$753.25 Benefit: 75% = \$564.95 85% = \$669.85		
	Skull calipers or halo, insertion of, as an independent procedure (Anaes	s.)	
51111	(See para TN.8.141 of explanatory notes to this Category) Fee: \$320.15 Benefit: 75% = \$240.15		
	Plaster jacket, application of, as an independent procedure (Anaes.)		
51112	(See para TN.8.141 of explanatory notes to this Category) Fee: \$216.50 Benefit: 75% = \$162.40 85% = \$184.05		
	Halo, application of, in addition to spinal fusion for scoliosis, or other c	conditions (Anaes.)	
51113	(See para TN.8.141 of explanatory notes to this Category) Fee: \$240.05 Benefit: 75% = \$180.05		
	Halo thoracic orthosis—application of both halo and thoracic jacket (A	naes.)	
51114	(See para TN.8.141 of explanatory notes to this Category) Fee: \$423.75 Benefit: 75% = \$317.85		
	Halo femoral traction, as an independent procedure (Anaes.)		
51115	(See para TN.8.141 of explanatory notes to this Category) Fee: \$423.75 Benefit: 75% = \$317.85 85% = \$360.20		
	Bone graft, harvesting of autogenous graft, via separate incision or via sconjunction with spinal fusion, other than for the purposes of bone graft thoracic, lumbar or sacral spine (Anaes.)		
51120	(See para TN.8.141 of explanatory notes to this Category) Fee: \$235.50 Benefit: 75% = \$176.65		
	Lumbar artificial intervertebral total disc replacement, at one motion se disc and marginal osteophytes:	gment only, including removal of	
	(a) for a patient who:		
	(i) has not had prior spinal fusion surgery at the same lumbar level; and	I	
	(ii) does not have vertebral osteoporosis; and		
	(iii) has failed conservative therapy; and		
	(b) not being a service associated with a service to which item 51011, 5 applies (Anaes.) (Assist.)	51012, 51013, 51014 or 51015	
51130	(See para TN.8.141 of explanatory notes to this Category) Fee: \$1,793.65 Benefit: 75% = \$1345.25		
	Cervical artificial intervertebral total disc replacement, at one motion se of disc and marginal osteophytes, for a patient who:	egment only, including removal	
	(a) has not had prior spinal surgery at the same cervical level; and		
51131	(b) is skeletally mature; and		

T8. SUF	RGICAL OPERATIONS	17. SPINAL SURGERY
	(c) has symptomatic degenerative disc disease with radiculopathy; and	
	(d) does not have vertebral osteoporosis; and	
	(e) has failed conservative therapy (Anaes.) (Assist.)	
	(See para TN.8.141 of explanatory notes to this Category) Fee: \$1,082.70 Benefit: 75% = \$812.05	
	Previous spinal fusion, re-exploration for, involving adjustment or remomention segments, not being a service associated with a service to which (Assist.)	
51140	(See para TN.8.141 of explanatory notes to this Category) Fee: \$442.45 Benefit: 75% = \$331.85	
	Previous spinal fusion, re-exploration for, involving adjustment or remo 3 motion segments, not being a service associated with a service to whic (Assist.)	
51141	(See para TN.8.141 of explanatory notes to this Category) Fee: \$818.55 Benefit: 75% = \$613.95	
	Wound debridement or excision for post operative infection or haemator (Anaes.)	ma following spinal surgery
51145	(See para TN.8.141 of explanatory notes to this Category) Fee: \$442.45 Benefit: 75% = \$331.85	
	Coccyx, excision of (Anaes.) (Assist.)	
51150	(See para TN.8.141 of explanatory notes to this Category) Fee: \$445.40 Benefit: 75% = \$334.05	
	Anterior exposure of thoracic or lumbar spine, one motion segment, not 51165 applies (Anaes.) (Assist.)	being a service to which item
51160	(See para TN.8.141, TN.8.149 of explanatory notes to this Category) Fee: \$1,150.00 Benefit: 75% = \$862.50	
	Anterior exposure of thoracic or lumbar spine, more than one motion seg which item 51160 applies (Anaes.) (Assist.)	gment, not being a service to
51165	(See para TN.8.141, TN.8.149 of explanatory notes to this Category) Fee: \$1,450.00 Benefit: 75% = \$1087.50	
	Syringomyelia or hydromyelia, craniotomy for, with or without duraplas plugging of obex or local cerebrospinal fluid shunt (Anaes.) (Assist.)	sty, intradural dissection,
51170	(See para TN.8.141 of explanatory notes to this Category) Fee: \$2,184.60 Benefit: 75% = \$1638.45	
	Syringomyelia or hydromyelia, treatment by direct cerebrospinal fluid sl syringosubarachnoid shunt, syringopleural shunt or syringoperitoneal sh	
51171	(See para TN.8.141 of explanatory notes to this Category) Fee: \$917.40 Benefit: 75% = \$688.05	
T9. ASS	SISTANCE AT OPERATIONS	
	Group T9. Assistance At Operations	

T9. ASS	SISTANCE AT OPERATIONS
	Assistance at any operation identified by the word "Assist." for which the fee does not exceed \$558.30 or at a series or combination of operations identified by the word "Assist." where the fee for the series or combination of operations identified by the word "Assist." does not exceed \$558.30
51300	(See para TN.9.2, TN.9.1 of explanatory notes to this Category) Fee: \$86.30 Benefit: 75% = \$64.75 85% = \$73.40
	Assistance at any operation identified by the word "Assist." for which the fee exceeds \$558.30 or at a series of operations identified by the word "Assist." for which the aggregate fee exceeds \$558.30.
51303	(See para TN.9.1, TN.9.3 of explanatory notes to this Category) Derived Fee: one fifth of the established fee for the operation or combination of operations
	Assistance at a birth involving Caesarean section
51306	(See para TN.9.1 of explanatory notes to this Category) Fee: \$124.65 Benefit: 75% = \$93.50 85% = \$106.00
	Assistance at a series or combination of operations that include "(Assist.)" and assistance at a birth involving Caesarean section
51309	(See para TN.9.1, TN.9.4 of explanatory notes to this Category) Derived Fee: one fifth of the established fee for the operation or combination of operations (the fee for item 16520 being the Schedule fee for the Caesarean section component in the calculation of the established fee)
	Assistance at any interventional obstetric procedure covered by items 16606, 16609, 16612, 16615 and 16627
51312	(See para TN.4.11, TN.9.1 of explanatory notes to this Category) Derived Fee: one fifth of the established fee for the procedure or combination of procedures
	Assistance at cataract and intraocular lens surgery covered by item 42698, 42701, 42702, 42704 or 42707, when performed in association with services covered by item 42551 to 42569, 42653, 42656, 42725, 42746, 42749, 42752, 42776 or 42779
51315	(See para TN.9.1 of explanatory notes to this Category) Fee: \$272.40 Benefit: 75% = \$204.30 85% = \$231.55
	Assistance at cataract and intraocular lens surgery where patient has:
	- total loss of vision, including no potential for central vision, in the fellow eye; or
	- previous significant surgical complication in the fellow eye; or
	- pseudo exfoliation, subluxed lens, iridodonesis, phacodonesis, retinal detachment, corneal scarring, pre-existing uveitis, bound down miosed pupil, nanophthalmos, spherophakia, Marfan's syndrome, homocysteinuria or previous blunt trauma causing intraocular damage
51318	(See para TN.9.5, TN.9.1 of explanatory notes to this Category) Fee: \$179.75 Benefit: 75% = \$134.85 85% = \$152.80

1. HEAD

Group T10. Relative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For Anaesthesia Performed In Association With An Eligible Service

1. HEAD

Subgroup 1. Head
INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on the skin, subcutaneous tissue, muscles, salivary glands or superficial vessels of the head including biopsy, not being a service to which another item in this Subgroup applies (5 basic units)
Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15
INITIATION OF MANAGEMENT OF ANAESTHESIA for plastic repair of cleft lip (6 basic units)
Fee: \$118.80 Benefit: 75% = \$89.10 85% = \$101.00
INITIATION OF MANAGEMENT OF ANAESTHESIA for electroconvulsive therapy (4 basic units)
Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35
INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on external, middle or inner ear, including biopsy, not being a service to which another item in this Subgroup applies (5 basic units)
Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15
INITIATION OF MANAGEMENT OF ANAESTHESIA for otoscopy (4 basic units)
Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35
INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on eye, not being a service to which another item in this Group applies (5 basic units)
Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15
INITIATION OF MANAGEMENT OF ANAESTHESIA for lens surgery (6 basic units)
Fee: \$118.80 Benefit: 75% = \$89.10 85% = \$101.00 Extended Medicare Safety Net Cap: \$95.05
INITIATION OF MANAGEMENT OF ANAESTHESIA for retinal surgery (6 basic units)
Fee: \$118.80 Benefit: 75% = \$89.10 85% = \$101.00
INITIATION OF MANAGEMENT OF ANAESTHESIA for corneal transplant (8 basic units)
Fee: \$158.40 Benefit: 75% = \$118.80 85% = \$134.65
INITIATION OF MANAGEMENT OF ANAESTHESIA for vitrectomy (8 basic units)
Fee: \$158.40 Benefit: 75% = \$118.80 85% = \$134.65
INITIATION OF MANAGEMENT OF ANAESTHESIA for biopsy of conjunctiva (5 basic units)
Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15
INITIATION OF MANAGEMENT OF ANAESTHESIA for squint repair (6 basic units)
Fee: \$118.80 Benefit: 75% = \$89.10 85% = \$101.00
INITIATION OF MANAGEMENT OF ANAESTHESIA for ophthalmoscopy (4 basic units)
Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35

1. HEAD

	INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on nose or accessory sinuses, not being a service to which another item in this Subgroup applies (6 basic units)
20160	Fee: \$118.80 Benefit: 75% = \$89.10 85% = \$101.00
	INITIATION OF MANAGEMENT OF ANAESTHESIA for radical surgery on the nose and accessory sinuses (7 basic units)
20162	Fee: \$138.60 Benefit: 75% = \$103.95 85% = \$117.85
	INITIATION OF MANAGEMENT OF ANAESTHESIA for biopsy of soft tissue of the nose and accessory sinuses (4 basic units)
20164	Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35
	INITIATION OF MANAGEMENT OF ANAESTHESIA for intraoral procedures, including biopsy, not being a service to which another item in this Subgroup applies (6 basic units)
20170	Fee: \$118.80 Benefit: 75% = \$89.10 85% = \$101.00
	INITIATION OF MANAGEMENT OF ANAESTHESIA for repair of cleft palate (7 basic units)
20172	Fee: \$138.60 Benefit: 75% = \$103.95 85% = \$117.85
	INITIATION OF MANAGEMENT OF ANAESTHESIA for excision of retropharyngeal tumour (9 basic units)
20174	Fee: \$178.20 Benefit: 75% = \$133.65 85% = \$151.50
	INITIATION OF MANAGEMENT OF ANAESTHESIA for radical intraoral surgery (10 basic units)
20176	Fee: \$198.00 Benefit: 75% = \$148.50 85% = \$168.30
	INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on facial bones, not being a service to which another item in this Subgroup applies (5 basic units)
20190	Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15
	INITIATION OF MANAGEMENT OF ANAESTHESIA for extensive surgery on facial bones (including prognathism and extensive facial bone reconstruction) (10 basic units)
20192	Fee: \$198.00 Benefit: 75% = \$148.50 85% = \$168.30
	INITIATION OF MANAGEMENT OF ANAESTHESIA for intracranial procedures, not being a service to which another item in this Subgroup applies (15 basic units)
20210	Fee: \$297.00 Benefit: 75% = \$222.75 85% = \$252.45
	INITIATION OF MANAGEMENT OF ANAESTHESIA for subdural taps (5 basic units)
20212	Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15
	INITIATION OF MANAGEMENT OF ANAESTHESIA for burr holes of the cranium (9 basic units)
20214	Fee: \$178.20 Benefit: 75% = \$133.65 85% = \$151.50
20216	INITIATION OF MANAGEMENT OF ANAESTHESIA for intracranial vascular procedures including those for aneurysms or arterio-venous abnormalities (20 basic units)

1. HEAD

	Fee: \$396.00	Benefit: 75% = \$297.00 85% = \$336.60
	INITIATION OI units)	MANAGEMENT OF ANAESTHESIA for spinal fluid shunt procedures (10 basic
20220	Fee: \$198.00	Benefit: 75% = \$148.50 85% = \$168.30
	INITIATION OI units)	MANAGEMENT OF ANAESTHESIA for ablation of an intracranial nerve (6 basic
20222	Fee: \$118.80	Benefit: 75% = \$89.10 85% = \$101.00
	INITIATION OF	MANAGEMENT OF ANAESTHESIA for all cranial bone procedures (12 basic units
20225	Fee: \$237.60	Benefit: 75% = \$178.20 85% = \$202.00
		MANAGEMENT OF ANAESTHESIA for microvascular free tissue flap surgery d or face (12 basic units)
	(See para TN.10.2	of explanatory notes to this Category)
20230	Fee: \$237.60	Benefit: 75% = \$178.20 85% = \$202.00

T10. RELATIVE VALUE GUIDE FOR ANAESTHESIA - MEDICARE BENEFITS ARE ONLY PAYABLE FOR ANAESTHESIA PERFORMED IN ASSOCIATION WITH AN ELIGIBLE SERVICE

2. NECK

	Group T10. Relative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For Anaesthesia Performed In Association With An Eligible Service
	Subgroup 2. Neck
	INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on the skin or subcutaneous tissue of the neck not being a service to which another item in this Subgroup applies (5 basic units)
20300	Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15
	INITIATION OF MANAGEMENT OF ANAESTHESIA for incision and drainage of large haematoma, large abscess, cellulitis or similar lesion or epiglottitis causing life threatening airway obstruction (15 basic units)
20305	Fee: \$297.00 Benefit: 75% = \$222.75 85% = \$252.45
	INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on oesophagus, thyroid, larynx, trachea, lymphatic system, muscles, nerves or other deep tissues of the neck, not being a service to which another item in this Subgroup applies (6 basic units)
20320	Fee: \$118.80 Benefit: 75% = \$89.10 85% = \$101.00
	INITIATION OF MANAGEMENT OF ANAESTHESIA for laryngectomy, hemi laryngectomy, laryngopharyngectomy or pharyngectomy (10 basic units)
20321	Fee: \$198.00 Benefit: 75% = \$148.50 85% = \$168.30
20330	INITIATION OF MANAGEMENT OF ANAESTHESIA for laser surgery to the airway (excluding nose

ANAES ONLY F PERFO	PAYABLE FOR A	ARE BENEFITS ARE
	and mouth) (8 ba	sic units)
	Fee: \$158.40	Benefit: 75% = \$118.80 85% = \$134.65
		F MANAGEMENT OF ANAESTHESIA for procedures on major vessels of neck, not owhich another item in this Subgroup applies (10 basic units)
20350	Fee: \$198.00	Benefit: 75% = \$148.50 85% = \$168.30
	INITIATION OF basic units)	F MANAGEMENT OF ANAESTHESIA for simple ligation of major vessels of neck (
20352	Fee: \$99.00	Benefit: 75% = \$74.25 85% = \$84.15
		F MANAGEMENT OF ANAESTHESIA for microvascular free tissue flap surgery ck (12 basic units)
20355	(See para TN.10.28 Fee: \$237.60	8 of explanatory notes to this Category) Benefit: 75% = \$178.20 85% = \$202.00
PERFO	PAYABLE FOR AI RMED IN ASSOC LE SERVICE	
PERFO	RMED IN ASSOC LE SERVICE Group T10. Rela	NAESTHESIA IATION WITH AN
PERFO	RMED IN ASSOC LE SERVICE Group T10. Rela	NAESTHESIA IATION WITH AN 3. THORA ative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For
PERFO	RMED IN ASSOC LE SERVICE Group T10. Rela Anaesthesia Pe INITIATION OF	NAESTHESIA IATION WITH AN 3. THORA ative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For rformed In Association With An Eligible Service
PERFO	RMED IN ASSOC LE SERVICE Group T10. Rela Anaesthesia Pe INITIATION OF tissue of the ante	NAESTHESIA IATION WITH AN 3. THORA Ative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For rformed In Association With An Eligible Service Subgroup 3. Thorax F MANAGEMENT OF ANAESTHESIA for procedures on the skin or subcutaneous
PERFO	RMED IN ASSOC LE SERVICE Group T10. Rela Anaesthesia Pe INITIATION OF tissue of the ante (3 basic units) Fee: \$59.40 INITIATION OF	NAESTHESIA IATION WITH AN 3. THORA Ative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For rformed In Association With An Eligible Service Subgroup 3. Thorax F MANAGEMENT OF ANAESTHESIA for procedures on the skin or subcutaneous rior part of the chest, not being a service to which another item in this Subgroup applies
PERFO	RMED IN ASSOC LE SERVICE Group T10. Rela Anaesthesia Pe INITIATION OF tissue of the ante (3 basic units) Fee: \$59.40 INITIATION OF	ALATION WITH AN 3. THORA Ative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For reformed In Association With An Eligible Service Subgroup 3. Thorax F MANAGEMENT OF ANAESTHESIA for procedures on the skin or subcutaneous rior part of the chest, not being a service to which another item in this Subgroup applied Benefit: 75% = \$44.55 85% = \$50.50 F MANAGEMENT OF ANAESTHESIA for procedures on the breast, not being a
PERFO ELIGIB	RMED IN ASSOC LE SERVICE Group T10. Rela Anaesthesia Pe INITIATION OF tissue of the ante (3 basic units) Fee: \$59.40 INITIATION OF service to which Fee: \$79.20	ALAESTHESIA IATION WITH AN 3. THORA Active Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For reformed In Association With An Eligible Service Subgroup 3. Thorax F MANAGEMENT OF ANAESTHESIA for procedures on the skin or subcutaneous rior part of the chest, not being a service to which another item in this Subgroup applies Benefit: 75% = \$44.55 85% = \$50.50 F MANAGEMENT OF ANAESTHESIA for procedures on the breast, not being a another item in this Subgroup applies (4 basic units)
PERFO ELIGIB	RMED IN ASSOC LE SERVICE Group T10. Rela Anaesthesia Pe INITIATION OF tissue of the ante (3 basic units) Fee: \$59.40 INITIATION OF service to which Fee: \$79.20 INITIATION OF	ALAESTHESIA IATION WITH AN 3. THORA Active Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For reformed In Association With An Eligible Service Subgroup 3. Thorax F MANAGEMENT OF ANAESTHESIA for procedures on the skin or subcutaneous rior part of the chest, not being a service to which another item in this Subgroup applies Benefit: 75% = \$44.55 85% = \$50.50 F MANAGEMENT OF ANAESTHESIA for procedures on the breast, not being a another item in this Subgroup applies (4 basic units) Benefit: 75% = \$59.40 85% = \$67.35
20400 20401	RMED IN ASSOC LE SERVICE Group T10. Rela Anaesthesia Pe INITIATION OF tissue of the ante (3 basic units) Fee: \$59.40 INITIATION OF service to which Fee: \$79.20 INITIATION OF basic units) Fee: \$99.00 INITIATION OF	ALATION WITH AN 3. THORA attive Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For rformed In Association With An Eligible Service Subgroup 3. Thorax F MANAGEMENT OF ANAESTHESIA for procedures on the skin or subcutaneous rior part of the chest, not being a service to which another item in this Subgroup applies Benefit: 75% = \$44.55
20400 20401	RMED IN ASSOC LE SERVICE Group T10. Rela Anaesthesia Pe INITIATION OF tissue of the ante (3 basic units) Fee: \$59.40 INITIATION OF service to which Fee: \$79.20 INITIATION OF basic units) Fee: \$99.00 INITIATION OF	ALTION WITH AN 3. THORA ative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For reformed In Association With An Eligible Service Subgroup 3. Thorax F. MANAGEMENT OF ANAESTHESIA for procedures on the skin or subcutaneous rior part of the chest, not being a service to which another item in this Subgroup applies Benefit: 75% = \$44.55 85% = \$50.50 F. MANAGEMENT OF ANAESTHESIA for procedures on the breast, not being a another item in this Subgroup applies (4 basic units) Benefit: 75% = \$59.40 85% = \$67.35 F. MANAGEMENT OF ANAESTHESIA for reconstructive procedures on breast (5) Benefit: 75% = \$74.25 85% = \$84.15
20400 20401 20402	RMED IN ASSOC LE SERVICE Group T10. Rela Anaesthesia Pe INITIATION OF tissue of the ante (3 basic units) Fee: \$59.40 INITIATION OF service to which Fee: \$79.20 INITIATION OF basic units) Fee: \$99.00 INITIATION OF segmentectomy of Fee: \$99.00	ALATION WITH AN 3. THORA ative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For rformed In Association With An Eligible Service Subgroup 3. Thorax F. MANAGEMENT OF ANAESTHESIA for procedures on the skin or subcutaneous rior part of the chest, not being a service to which another item in this Subgroup applies Benefit: 75% = \$44.55 85% = \$50.50 F. MANAGEMENT OF ANAESTHESIA for procedures on the breast, not being a another item in this Subgroup applies (4 basic units) Benefit: 75% = \$59.40 85% = \$67.35 F. MANAGEMENT OF ANAESTHESIA for reconstructive procedures on breast (5) Benefit: 75% = \$74.25 85% = \$84.15 F. MANAGEMENT OF ANAESTHESIA for removal of breast lump or for breast where axillary node dissection is performed (5 basic units)
20400 20401 20402	RMED IN ASSOC LE SERVICE Group T10. Rela Anaesthesia Pe INITIATION OF tissue of the ante (3 basic units) Fee: \$59.40 INITIATION OF service to which Fee: \$79.20 INITIATION OF basic units) Fee: \$99.00 INITIATION OF segmentectomy of Fee: \$99.00	ALATION WITH AN 3. THORA Active Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For reformed In Association With An Eligible Service Subgroup 3. Thorax Thorax MANAGEMENT OF ANAESTHESIA for procedures on the skin or subcutaneous rior part of the chest, not being a service to which another item in this Subgroup applies Benefit: 75% = \$44.55

3. THORAX

ELIGID	LE SERVICE	3. ITURAX	
	using myocutaneous flaps (8 basic units)		
	Fee: \$158.40	Benefit: 75% = \$118.80 85% = \$134.65	
		F MANAGEMENT OF ANAESTHESIA for radical or modified radical procedures on nal mammary node dissection (13 basic units)	
20406	Fee: \$257.40	Benefit: 75% = \$193.05 85% = \$218.80	
	INITIATION Of basic units)	F MANAGEMENT OF ANAESTHESIA for electrical conversion of arrhythmias (5	
20410	Fee: \$99.00	Benefit: 75% = \$74.25 85% = \$84.15	
		F MANAGEMENT OF ANAESTHESIA for procedures on the skin or subcutaneous terior part of the chest not being a service to which another item in this Subgroup applies	
20420	Fee: \$99.00	Benefit: 75% = \$74.25 85% = \$84.15	
	INITIATION Of sternum (4 basic	F MANAGEMENT OF ANAESTHESIA for percutaneous bone marrow biopsy of the units)	
20440	Fee: \$79.20	Benefit: 75% = \$59.40 85% = \$67.35	
		F MANAGEMENT OF ANAESTHESIA for procedures on clavicle, scapula or sternum, ce to which another item in this Subgroup applies (5 basic units)	
20450	Fee: \$99.00	Benefit: 75% = \$74.25 85% = \$84.15	
	INITIATION Of sternum (6 basic	F MANAGEMENT OF ANAESTHESIA for radical surgery on clavicle, scapula or units)	
20452	Fee: \$118.80	Benefit: 75% = \$89.10 85% = \$101.00	
		F MANAGEMENT OF ANAESTHESIA for partial rib resection, not being a service to em in this Subgroup applies (6 basic units)	
20470	Fee: \$118.80	Benefit: 75% = \$89.10 85% = \$101.00	
	INITIATION O	F MANAGEMENT OF ANAESTHESIA for thoracoplasty (10 basic units)	
20472	Fee: \$198.00	Benefit: 75% = \$148.50 85% = \$168.30	
	INITIATION Of units)	F MANAGEMENT OF ANAESTHESIA for radical procedures on chest wall (13 basic	
20474	(See para TN.10.2 Fee: \$257.40	2 of explanatory notes to this Category) Benefit: 75% = \$193.05 85% = \$218.80	
		F MANAGEMENT OF ANAESTHESIA for microvascular free tissue flap surgery terior or posterior thorax (10 basic units)	
20475	(See para TN.10.2 Fee: \$198.00	8 of explanatory notes to this Category) Benefit: 75% = \$148.50 85% = \$168.30	

4. INTRATHORACIC

	Group T10. Relative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For Anaesthesia Performed In Association With An Eligible Service		
		Subgroup 4. Intrathoracic	
	INITIATION Of basic units)	F MANAGEMENT OF ANAESTHESIA for open procedures on the oesophagus (15	
20500	Fee: \$297.00	Benefit: 75% = \$222.75 85% = \$252.45	
		F MANAGEMENT OF ANAESTHESIA for all closed chest procedures (including rigid or bronchoscopy), not being a service to which another item in this Subgroup applies (6	
20520	Fee: \$118.80	Benefit: 75% = \$89.10 85% = \$101.00	
	INITIATION O	F MANAGEMENT OF ANAESTHESIA for needle biopsy of pleura (4 basic units)	
20522	Fee: \$79.20	Benefit: 75% = \$59.40 85% = \$67.35	
	INITIATION O	F MANAGEMENT OF ANAESTHESIA for pneumocentesis (4 basic units)	
20524	Fee: \$79.20	Benefit: 75% = \$59.40 85% = \$67.35	
	INITIATION O	F MANAGEMENT OF ANAESTHESIA for thoracoscopy (10 basic units)	
20526	Fee: \$198.00	Benefit: 75% = \$148.50 85% = \$168.30	
	INITIATION O	F MANAGEMENT OF ANAESTHESIA for mediastinoscopy (8 basic units)	
20528	Fee: \$158.40	Benefit: 75% = \$118.80 85% = \$134.65	
		F MANAGEMENT OF ANAESTHESIA for thoracotomy procedures involving lungs, m, or mediastinum, not being a service to which another item in this Subgroup applies	
20540	Fee: \$257.40	Benefit: 75% = \$193.05 85% = \$218.80	
	INITIATION O	F MANAGEMENT OF ANAESTHESIA for pulmonary decortication (15 basic units)	
20542	Fee: \$297.00	Benefit: 75% = \$222.75 85% = \$252.45	
	INITIATION Of (15 basic units)	F MANAGEMENT OF ANAESTHESIA for pulmonary resection with thoracoplasty	
20546	Fee: \$297.00	Benefit: 75% = \$222.75 85% = \$252.45	
	INITIATION OF MANAGEMENT OF ANAESTHESIA for intrathoracic repair of trauma to trachea and bronchi (15 basic units)		
20548	Fee: \$297.00	Benefit: 75% = \$222.75 85% = \$252.45	
	Initiation of the	management of anaesthesia for:	
	(a) open procedu	ires on the heart, pericardium or great vessels of the chest; or	
20560	(b) percutaneous	insertion of a valvular prosthesis (20 basic units)	

4. INTRATHORACIC

	Fee: \$396.00	Benefit: 7	75% = \$297.00	85% = \$336.60
--	---------------	------------	----------------	----------------

T10. RELATIVE VALUE GUIDE FOR ANAESTHESIA - MEDICARE BENEFITS ARE ONLY PAYABLE FOR ANAESTHESIA PERFORMED IN ASSOCIATION WITH AN

5. SPINE AND SPINAL CORD

ELIGIBI	LE SERVICE	5. SPINE AND SPINAL CORE
		tive Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For formed In Association With An Eligible Service
		Subgroup 5. Spine And Spinal Cord
	not being a servi	MANAGEMENT OF ANAESTHESIA for procedures on cervical spine and/or cord, the to which another item in this Subgroup applies (for myelography and discography and 21914) (10 basic units)
20600	Fee: \$198.00	Benefit: 75% = \$148.50 85% = \$168.30
		MANAGEMENT OF ANAESTHESIA for posterior cervical laminectomy with the ng position (13 basic units)
20604	Fee: \$257.40	Benefit: 75% = \$193.05 85% = \$218.80
		MANAGEMENT OF ANAESTHESIA for procedures on thoracic spine and/or cord, see to which another item in this Subgroup applies (10 basic units)
20620	Fee: \$198.00	Benefit: 75% = \$148.50 85% = \$168.30
	INITIATION Of units)	MANAGEMENT OF ANAESTHESIA for thoracolumbar sympathectomy (13 basic
20622	Fee: \$257.40	Benefit: 75% = \$193.05 85% = \$218.80
		MANAGEMENT OF ANAESTHESIA for procedures in lumbar region, not being a another item in this Subgroup applies (8 basic units)
20630	Fee: \$158.40	Benefit: 75% = \$118.80 85% = \$134.65
	INITIATION O	MANAGEMENT OF ANAESTHESIA for lumbar sympathectomy (7 basic units)
20632	Fee: \$138.60	Benefit: 75% = \$103.95 85% = \$117.85
	INITIATION O	MANAGEMENT OF ANAESTHESIA for chemonucleolysis (10 basic units)
20634	Fee: \$198.00	Benefit: 75% = \$148.50 85% = \$168.30
	INITIATION Of procedures (13 b	MANAGEMENT OF ANAESTHESIA for extensive spine and/or spinal cord asic units)
20670	(See para TN.10.2 Fee: \$257.40	Benefit: 75% = \$193.05 85% = \$218.80
		MANAGEMENT OF ANAESTHESIA for manipulation of spine when performed in atre of a hospital (3 basic units)
20680	Fee: \$59.40	Benefit: 75% = \$44.55 85% = \$50.50

5. SPINE AND SPINAL CORD

INITIATION OF MANAGEMENT OF ANAESTHESIA for percutaneous spinal procedures, not being a service to which another item in this Subgroup applies (5 basic units)

20690 **Fee:** \$99.00 **Benefit:** 75% = \$74.25 85% = \$84.15

T10. RELATIVE VALUE GUIDE FOR ANAESTHESIA - MEDICARE BENEFITS ARE ONLY PAYABLE FOR ANAESTHESIA PERFORMED IN ASSOCIATION WITH AN ELIGIBLE SERVICE

6. UPPER ABDOMEN

EL SERVICE 0. OFFER ADDOMEN
Group T10. Relative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For Anaesthesia Performed In Association With An Eligible Service
Subgroup 6. Upper Abdomen
INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on the skin or subcutaneous tissue of the upper anterior abdominal wall, not being a service to which another item in this Subgroup applies (3 basic units)
Fee: \$59.40 Benefit: 75% = \$44.55 85% = \$50.50
INITIATION OF MANAGEMENT OF ANAESTHESIA for percutaneous liver biopsy (4 basic units)
Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35
INITIATION OF MANAGEMENT OF ANAESTHESIA for all procedures on the nerves, muscles, tendons and fascia of the upper abdominal wall, not being a service to which another item in this Subgroup applies (4 basic units)
Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35
INITIATION OF MANAGEMENT OF ANAESTHESIA for microvascular free tissue flap surgery involving the anterior or posterior upper abdomen (10 basic units)
(See para TN.10.28 of explanatory notes to this Category)
Fee: \$198.00 Benefit: 75% = \$148.50 85% = \$168.30
INITIATION OF MANAGEMENT OF ANAESTHESIA for diagnostic laparoscopy procedures (6 basic units)
Fee: \$118.80 Benefit: 75% = \$89.10 85% = \$101.00
INITIATION OF MANAGEMENT OF ANAESTHESIA for laparoscopic procedures in the upper abdomen, not being a service to which another item in this Subgroup applies (7 basic units)
Fee: \$138.60 Benefit: 75% = \$103.95 85% = \$117.85
INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on the skin or subcutaneous tissue of the upper posterior abdominal wall, not being a service to which another item in this Subgroup applies (5 basic units)
Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15
INITIATION OF MANAGEMENT OF ANAESTHESIA for upper gastrointestinal endoscopic

6. UPPER ABDOMEN

LLIGID	LL SLIVICL	0. OFFER ABBOWIEN
	procedures (5 ba	nsic units)
	Fee: \$99.00	Benefit: 75% = \$74.25 85% = \$84.15
		F MANAGEMENT OF ANAESTHESIA for upper gastrointestinal endoscopic sociation with acute gastrointestinal haemorrhage (6 basic units)
20745	Fee: \$118.80	Benefit: 75% = \$89.10 85% = \$101.00
		F MANAGEMENT OF ANAESTHESIA for hernia repairs in upper abdomen, not being ch another item in this Subgroup applies (4 basic units)
20750	Fee: \$79.20	Benefit: 75% = \$59.40 85% = \$67.35
	INITIATION Of dehiscence (6 ba	F MANAGEMENT OF ANAESTHESIA for repair of incisional hernia and/or wound asic units)
20752	Fee: \$118.80	Benefit: 75% = \$89.10 85% = \$101.00
	INITIATION O units)	F MANAGEMENT OF ANAESTHESIA for procedures on an omphalocele (7 basic
20754	Fee: \$138.60	Benefit: 75% = \$103.95 85% = \$117.85
	INITIATION O hernia (9 basic u	F MANAGEMENT OF ANAESTHESIA for transabdominal repair of diaphragmatic units)
20756	Fee: \$178.20	Benefit: 75% = \$133.65 85% = \$151.50
	INITIATION O blood vessels (1	F MANAGEMENT OF ANAESTHESIA for procedures on major upper abdominal 5 basic units)
20770	Fee: \$297.00	Benefit: 75% = \$222.75 85% = \$252.45
		F MANAGEMENT OF ANAESTHESIA for procedures within the peritoneal cavity in including cholecystectomy, gastrectomy, laparoscopic nephrectomy or bowel shunts (8
20790	Fee: \$158.40	Benefit: 75% = \$118.80 85% = \$134.65
	Initiation of the obesity (10 basic	management of anaesthesia for bariatric surgery in a patient with clinically severe c units)
20791	(See para TN.8.29 Fee: \$198.00	O of explanatory notes to this Category) Benefit: $75\% = 148.50 $85\% = 168.30
	INITIATION OF MANAGEMENT OF ANAESTHESIA for partial hepatectomy (excluding liver biopsy) (13 basic units)	
20792	Fee: \$257.40	Benefit: 75% = \$193.05 85% = \$218.80
	INITIATION O basic units)	F MANAGEMENT OF ANAESTHESIA for extended or trisegmental hepatectomy (15
20793	Fee: \$297.00	Benefit: 75% = \$222.75 85% = \$252.45
20794	INITIATION O	F MANAGEMENT OF ANAESTHESIA for pancreatectomy, partial or total (12 basic

6. UPPER ABDOMEN

	units)	units)		
	Fee: \$237.60	Benefit: 75% = \$178.20 85% = \$202.00		
	INITIATION OF MANAGEMENT OF ANAESTHESIA for neuro endocrine tumour removal in the upper abdomen (10 basic units)			
20798	Fee: \$198.00	Benefit: 75% = \$148.50 85% = \$168.30		
		INITIATION OF MANAGEMENT OF ANAESTHESIA for percutaneous procedures on an intra- abdominal organ in the upper abdomen (6 basic units)		
20799	Fee: \$118.80	Benefit: 75% = \$89.10 85% = \$101.00		

T10. RELATIVE VALUE GUIDE FOR ANAESTHESIA - MEDICARE BENEFITS ARE ONLY PAYABLE FOR ANAESTHESIA PERFORMED IN ASSOCIATION WITH AN ELIGIBLE SERVICE

7. LOWER ABDOMEN

	Group T10. Relative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For Anaesthesia Performed In Association With An Eligible Service
	Subgroup 7. Lower Abdomen
	INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on the skin or subcutaneous tissue of the lower anterior abdominal walls, not being a service to which another item in this Subgroup applies (3 basic units)
20800	Fee: \$59.40 Benefit: 75% = \$44.55 85% = \$50.50
	INITIATION OF MANAGEMENT OF ANAESTHESIA for lipectomy of the lower abdomen (5 basic units)
20802	Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15
	INITIATION OF MANAGEMENT OF ANAESTHESIA for all procedures on the nerves, muscles, tendons and fascia of the lower abdominal wall, not being a service to which another item in this Subgroup applies (4 basic units)
20803	Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35
	INITIATION OF MANAGEMENT OF ANAESTHESIA for microvascular free tissue flap surgery involving the anterior or posterior lower abdomen (10 basic units)
20804	(See para TN.10.28 of explanatory notes to this Category) Fee: \$198.00 Benefit: 75% = \$148.50 85% = \$168.30
	INITIATION OF MANAGEMENT OF ANAESTHESIA for diagnostic laparoscopic procedures (6 basic units)
20805	Fee: \$118.80 Benefit: 75% = \$89.10 85% = \$101.00
20806	INITIATION OF MANAGEMENT OF ANAESTHESIA for laparoscopic procedures in the lower abdomen (7 basic units)

7. LOWER ABDOMEN

	Fee: \$138.60	Benefit: 75% = \$103.95 85% = \$117.85
	INITIATION OF basic units)	MANAGEMENT OF ANAESTHESIA for lower intestinal endoscopic procedures (4
20810	Fee: \$79.20	Benefit: 75% = \$59.40 85% = \$67.35
	INITIATION OF urinary tract (6 ba	MANAGEMENT OF ANAESTHESIA for extracorporeal shock wave lithotripsy to asic units)
20815	Fee: \$118.80	Benefit: 75% = \$89.10 85% = \$101.00
		MANAGEMENT OF ANAESTHESIA for procedures on the skin, its derivatives or sue of the lower posterior abdominal wall (5 basic units)
20820	Fee: \$99.00	Benefit: 75% = \$74.25 85% = \$84.15
		MANAGEMENT OF ANAESTHESIA for hernia repairs in lower abdomen, not being hanother item in this Subgroup applies (4 basic units)
20830	Fee: \$79.20	Benefit: 75% = \$59.40 85% = \$67.35
		MANAGEMENT OF ANAESTHESIA for repair of incisional herniae and/or wound lower abdomen (6 basic units)
20832	Fee: \$118.80	Benefit: 75% = \$89.10 85% = \$101.00
		MANAGEMENT OF ANAESTHESIA for all procedures within the peritoneal cavity in including appendicectomy, not being a service to which another item in this Subgroup units)
20840	Fee: \$118.80	Benefit: 75% = \$89.10 85% = \$101.00
		MANAGEMENT OF ANAESTHESIA for bowel resection, including laparoscopic not being a service to which another item in this Subgroup applies (8 basic units)
20841	Fee: \$158.40	Benefit: 75% = \$118.80 85% = \$134.65
	INITIATION OF	MANAGEMENT OF ANAESTHESIA for amniocentesis (4 basic units)
20842	Fee: \$79.20	Benefit: 75% = \$59.40 85% = \$67.35
		MANAGEMENT OF ANAESTHESIA for abdominoperineal resection, including pull res, ultra low anterior resection and formation of bowel reservoir (10 basic units)
20844	Fee: \$198.00	Benefit: 75% = \$148.50 85% = \$168.30
	INITIATION OF	MANAGEMENT OF ANAESTHESIA for radical prostatectomy (10 basic units)
20845	Fee: \$198.00	Benefit: 75% = \$148.50 85% = \$168.30
	INITIATION OF	MANAGEMENT OF ANAESTHESIA for radical hysterectomy (10 basic units)
20846	Fee: \$198.00	Benefit: 75% = \$148.50 85% = \$168.30
	INITIATION OF	MANAGEMENT OF ANAESTHESIA for ovarian malignancy (10 basic units)
20847	Fee: \$198.00	Benefit: 75% = \$148.50 85% = \$168.30

7. LOWER ABDOMEN

0.	
	INITIATION OF MANAGEMENT OF ANAESTHESIA for pelvic exenteration (10 basic units)
20848	Fee: \$198.00 Benefit: 75% = \$148.50 85% = \$168.30
	INITIATION OF MANAGEMENT OF ANAESTHESIA for Caesarean section (12 basic units)
20850	Fee: \$237.60 Benefit: 75% = \$178.20 85% = \$202.00
	INITIATION OF MANAGEMENT OF ANAESTHESIA for Caesarean hysterectomy or hysterectomy within 24 hours of birth (15 basic units)
20855	Fee: \$297.00 Benefit: 75% = \$222.75 85% = \$252.45
	INITIATION OF MANAGEMENT OF ANAESTHESIA for extraperitoneal procedures in lower abdomen, including those on the urinary tract, not being a service to which another item in this Subgroup applies (6 basic units)
20860	Fee: \$118.80 Benefit: 75% = \$89.10 85% = \$101.00
	INITIATION OF MANAGEMENT OF ANAESTHESIA for renal procedures, including upper 1/3 of ureter (7 basic units)
20862	Fee: \$138.60 Benefit: 75% = \$103.95 85% = \$117.85
	INITIATION OF MANAGEMENT OF ANAESTHESIA for nephrectomy (10 basic units)
20863	Fee: \$198.00 Benefit: 75% = \$148.50 85% = \$168.30
	INITIATION OF MANAGEMENT OF ANAESTHESIA for total cystectomy (10 basic units)
20864	Fee: \$198.00 Benefit: 75% = \$148.50 85% = \$168.30
	INITIATION OF MANAGEMENT OF ANAESTHESIA for adrenalectomy (10 basic units)
20866	Fee: \$198.00 Benefit: 75% = \$148.50 85% = \$168.30
	INITIATION OF MANAGEMENT OF ANAESTHESIA for neuro endocrine tumour removal in the lower abdomen (10 basic units)
20867	Fee: \$198.00 Benefit: 75% = \$148.50 85% = \$168.30
	INITIATION OF MANAGEMENT OF ANAESTHESIA for renal transplantation (donor or recipient) (10 basic units)
20868	Fee: \$198.00 Benefit: 75% = \$148.50 85% = \$168.30
	INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on major lower abdominal vessels, not being a service to which another item in this subgroup applies (15 basic units)
20880	Fee: \$297.00 Benefit: 75% = \$222.75 85% = \$252.45
	INITIATION OF MANAGEMENT OF ANAESTHESIA for inferior vena cava ligation (10 basic units)
20882	Fee: \$198.00 Benefit: 75% = \$148.50 85% = \$168.30
	INITIATION OF MANAGEMENT OF ANAESTHESIA for percutaneous umbrella insertion (5 basic units)
20884	Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15

7. LOWER ABDOMEN

INITIATION OF MANAGEMENT OF ANAESTHESIA for percutaneous procedures on an intra-
abdominal organ in the lower abdomen (6 basic units)

20886 **Fee:** \$118.80 **Benefit:** 75% = \$89.10 85% = \$101.00

T10. RELATIVE VALUE GUIDE FOR ANAESTHESIA - MEDICARE BENEFITS ARE ONLY PAYABLE FOR ANAESTHESIA PERFORMED IN ASSOCIATION WITH AN ELIGIBLE SERVICE

8. PERINEUM

	Group T10. Relative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For Anaesthesia Performed In Association With An Eligible Service
	Subgroup 8. Perineum
	INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on the skin or subcutaneous tissue of the perineum not being a service to which another item in this Subgroup applies (3 basic units)
20900	Fee: \$59.40 Benefit: 75% = \$44.55 85% = \$50.50
	INITIATION OF MANAGEMENT OF ANAESTHESIA for anorectal procedures (including endoscopy and/or biopsy) (4 basic units)
20902	Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35
	INITIATION OF MANAGEMENT OF ANAESTHESIA for radical perineal procedures including radical perineal prostatectomy or radical vulvectomy (7 basic units)
20904	Fee: \$138.60 Benefit: 75% = \$103.95 85% = \$117.85
	INITIATION OF MANAGEMENT OF ANAESTHESIA for microvascular free tissue flap surgery involving the perineum (10 basic units)
20905	(See para TN.10.28 of explanatory notes to this Category) Fee: \$198.00 Benefit: 75% = \$148.50 85% = \$168.30
	INITIATION OF MANAGEMENT OF ANAESTHESIA for vulvectomy (4 basic units)
20906	Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35
	INITIATION OF MANAGEMENT OF ANAESTHESIA for transurethral procedures (including urethrocystoscopy), not being a service to which another item in this Subgroup applies (4 basic units)
20910	Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35
	INITIATION OF MANAGEMENT OF ANAESTHESIA for endoscopic ureteroscopic surgery including laser procedures (5 basic units)
20911	(See para TN.10.29 of explanatory notes to this Category) Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15
	INITIATION OF MANAGEMENT OF ANAESTHESIA for transurethral resection of bladder tumour(s) (5 basic units)
20912	Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15

8. PERINEUM

INITIATION OF MANAGEMENT OF ANAESTHESIA for transurethral resection of prostate (7 basic units)
Fee: \$138.60 Benefit: 75% = \$103.95 85% = \$117.85
INITIATION OF MANAGEMENT OF ANAESTHESIA for bleeding post-transurethral resection (7 basic units)
Fee: \$138.60 Benefit: 75% = \$103.95 85% = \$117.85
Initiation of management of anaesthesia for procedures on external genitalia, not being a service to which another item in this Subgroup applies. (4 basic units)
Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35
INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on undescended testis, unilateral or bilateral (4 basic units)
Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35
INITIATION OF MANAGEMENT OF ANAESTHESIA for radical orchidectomy, inguinal approach (4 basic units)
Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35
INITIATION OF MANAGEMENT OF ANAESTHESIA for radical orchidectomy, abdominal approach (6 basic units)
Fee: \$118.80 Benefit: 75% = \$89.10 85% = \$101.00
INITIATION OF MANAGEMENT OF ANAESTHESIA for orchiopexy, unilateral or bilateral (4 basic units)
Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35
INITIATION OF MANAGEMENT OF ANAESTHESIA for complete amputation of penis (4 basic units)
Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35
INITIATION OF MANAGEMENT OF ANAESTHESIA for complete amputation of penis with bilateral inguinal lymphadenectomy (6 basic units)
Fee: \$118.80 Benefit: 75% = \$89.10 85% = \$101.00
INITIATION OF MANAGEMENT OF ANAESTHESIA for complete amputation of penis with bilateral inguinal and iliac lymphadenectomy (8 basic units)
Fee: \$158.40 Benefit: 75% = \$118.80 85% = \$134.65
INITIATION OF MANAGEMENT OF ANAESTHESIA for insertion of penile prosthesis (4 basic units)
Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35
INITIATION OF MANAGEMENT OF ANAESTHESIA for per vagina and vaginal procedures (including biopsy of vagina, cervix or endometrium), not being a service to which another item in this

8. PERINEUM

ELIGIDI	LE SERVICE	8. PERINEUM
	Subgroup applie	s (4 basic units)
	Fee: \$79.20	Benefit: 75% = \$59.40 85% = \$67.35
		F MANAGEMENT OF ANAESTHESIA for vaginal procedures including repair rinary incontinence procedures (perineal) (5 basic units)
20942	Fee: \$99.00	Benefit: 75% = \$74.25 85% = \$84.15
	INITIATION OI (4 basic units)	F MANAGEMENT OF ANAESTHESIA for transvaginal assisted reproductive services
20943	Fee: \$79.20	Benefit: 75% = \$59.40 85% = \$67.35
	INITIATION O	F MANAGEMENT OF ANAESTHESIA for vaginal hysterectomy (6 basic units)
20944	Fee: \$118.80	Benefit: 75% = \$89.10 85% = \$101.00
	INITIATION O	F MANAGEMENT OF ANAESTHESIA for vaginal birth (8 basic units)
20946	Fee: \$158.40	Benefit: 75% = \$118.80 85% = \$134.65
		F MANAGEMENT OF ANAESTHESIA for purse string ligation of cervix, or removal gature (4 basic units)
20948	Fee: \$79.20	Benefit: 75% = \$59.40 85% = \$67.35
	INITIATION O	F MANAGEMENT OF ANAESTHESIA for culdoscopy (5 basic units)
20950	Fee: \$99.00	Benefit: 75% = \$74.25 85% = \$84.15
	INITIATION O	F MANAGEMENT OF ANAESTHESIA for hysteroscopy (4 basic units)
20952	Fee: \$79.20	Benefit: 75% = \$59.40 85% = \$67.35
		F MANAGEMENT OF ANAESTHESIA for endometrial ablation or resection in hysteroscopy (5 basic units)
20953	Fee: \$99.00	Benefit: 75% = \$74.25 85% = \$84.15
	INITIATION OI units)	F MANAGEMENT OF ANAESTHESIA for correction of inverted uterus (10 basic
20954	Fee: \$198.00	Benefit: 75% = \$148.50 85% = \$168.30
		F MANAGEMENT OF ANAESTHESIA for evacuation of retained products of complication of confinement (4 basic units)
20956	Fee: \$79.20	Benefit: 75% = \$59.40 85% = \$67.35
		F MANAGEMENT OF ANAESTHESIA for manual removal of retained placenta or for or perineal tear following birth (5 basic units)
20958	Fee: \$99.00	Benefit: 75% = \$74.25 85% = \$84.15
		F MANAGEMENT OF ANAESTHESIA for vaginal procedures in the management of morrhage (blood loss > 500mls) (7 basic units)
20960	Fee: \$138.60	Benefit: 75% = \$103.95 85% = \$117.85

9. PELVIS (EXCEPT HIP)

	Group T10. Relative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For Anaesthesia Performed In Association With An Eligible Service			
	Subgroup 9. Pelvis (Except Hip)			
	INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on the skin or subcutaneous tissue of the anterior pelvic region (anterior to iliac crest), except external genitalia (3 basic units)			
21100	Fee: \$59.40 Benefit: 75% = \$44.55 85% = \$50.50			
	INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on the skin, its derivatives or subcutaneous tissue of the pelvic region (posterior to iliac crest), except perineum (5 basic units)			
21110	Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15			
	INITIATION OF MANAGEMENT OF ANAESTHESIA for percutaneous bone marrow biopsy of the anterior iliac crest (4 basic units)			
21112	Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35			
	INITIATION OF MANAGEMENT OF ANAESTHESIA for percutaneous bone marrow biopsy of the posterior iliac crest (5 basic units)			
21114	Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15			
	INITIATION OF MANAGEMENT OF ANAESTHESIA for percutaneous bone marrow harvesting from the pelvis (6 basic units)			
21116	Fee: \$118.80 Benefit: 75% = \$89.10 85% = \$101.00			
	INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on the bony pelvis (6 basic units)			
21120	Fee: \$118.80 Benefit: 75% = \$89.10 85% = \$101.00			
	INITIATION OF MANAGEMENT OF ANAESTHESIA for body cast application or revision when performed in the operating theatre of a hospital (3 basic units)			
21130	Fee: \$59.40 Benefit: 75% = \$44.55 85% = \$50.50			
	INITIATION OF MANAGEMENT OF ANAESTHESIA for interpelviabdominal (hind-quarter) amputation (15 basic units)			
21140	Fee: \$297.00 Benefit: 75% = \$222.75 85% = \$252.45			
	INITIATION OF MANAGEMENT OF ANAESTHESIA for radical procedures for tumour of the pelvis, except hind-quarter amputation (10 basic units)			
21150	Fee: \$198.00 Benefit: 75% = \$148.50 85% = \$168.30			
	INITIATION OF MANAGEMENT OF ANAESTHESIA for microvascular free tissue flap surgery involving the anterior or posterior pelvis (10 basic units)			
21155	(See para TN.10.28 of explanatory notes to this Category) Fee: \$198.00 Benefit: 75% = \$148.50 85% = \$168.30			
21160	INITIATION OF MANAGEMENT OF ANAESTHESIA for closed procedures involving symphysis			

9. PELVIS (EXCEPT HIP)

	pubis or sacroiliac joint when performed in the operating theatre of a hospital (4 basic units)				
	Fee: \$79.20	Benefit: 75% = \$59.40	85% = \$67.35		
	INITIATION OF MANAGEMENT OF ANAESTHESIA for open procedures involving symphysis pubis or sacroiliac joint (8 basic units)				
21170	Fee: \$158.40	Benefit: 75% = \$118.80	85% = \$134.65		

T10. RELATIVE VALUE GUIDE FOR ANAESTHESIA - MEDICARE BENEFITS ARE ONLY PAYABLE FOR ANAESTHESIA PERFORMED IN ASSOCIATION WITH AN ELIGIBLE SERVICE

10. UPPER LEG (EXCEPT KNEE)

		Group T10. Relative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For Anaesthesia Performed In Association With An Eligible Service Subgroup 10. Upper Leg (Except Knee)				
		F MANAGEMENT OF AN er leg (3 basic units)	AESTHESIA for procedures on the skin or subcutaneous			
21195	Fee: \$59.40	Benefit: 75% = \$44.55	85% = \$50.50			
		F MANAGEMENT OF AN of the upper leg (4 basic uni	AESTHESIA for procedures on nerves, muscles, tendons, tts)			
21199	Fee: \$79.20	Benefit: 75% = \$59.40	85% = \$67.35			
		INITIATION OF MANAGEMENT OF ANAESTHESIA for closed procedures involving hip joint when performed in the operating theatre of a hospital (4 basic units)				
21200	Fee: \$79.20	Benefit: 75% = \$59.40	85% = \$67.35			
	INITIATION Of basic units)	F MANAGEMENT OF AN	AESTHESIA for arthroscopic procedures of the hip joint (4			
21202	Fee: \$79.20	Benefit: 75% = \$59.40	85% = \$67.35			
	INITIATION OF MANAGEMENT OF ANAESTHESIA for open procedures involving hip joint, not being a service to which another item in this Subgroup applies (6 basic units)					
21210	Fee: \$118.80	Benefit: 75% = \$89.10	85% = \$101.00			
	INITIATION O	F MANAGEMENT OF AN	AESTHESIA for hip disarticulation (10 basic units)			
21212	Fee: \$198.00	Benefit: 75% = \$148.50	85% = \$168.30			
	INITIATION Of units)	F MANAGEMENT OF AN	AESTHESIA for total hip replacement or revision (10 basic			
21214	Fee: \$198.00	Benefit: 75% = \$148.50	85% = \$168.30			
21216	INITIATION Of units)	F MANAGEMENT OF AN	AESTHESIA for bilateral total hip replacement (14 basic			

10. UPPER LEG (EXCEPT KNEE)

		(,			
	Fee: \$277.20	Benefit: 75% = \$207.90 85% = \$235.65			
		MANAGEMENT OF ANAESTHESIA for closed procedures involving upper 2/3 of			
	femur when performed in the operating theatre of a hospital (4 basic units)				
21220	Fee: \$79.20	Benefit: 75% = \$59.40 85% = \$67.35			
		MANAGEMENT OF ANAESTHESIA for open procedures involving upper 2/3 of			
	femur, not being	a service to which another item in this Subgroup applies (6 basic units)			
21230	Fee: \$118.80	Benefit: 75% = \$89.10 85% = \$101.00			
	INITIATION OF	MANAGEMENT OF ANAESTHESIA for above knee amputation (5 basic units)			
21232	Fee: \$99.00	Benefit: 75% = \$74.25 85% = \$84.15			
		MANAGEMENT OF ANAESTHESIA for radical resection of the upper 2/3 of femur			
	(8 basic units)	WANAGEMENT OF ANAESTITESIA for radical resection of the upper 2/3 of female			
21224	E 0150.40	D C 750/ 0110.00 050/ 0101/5			
21234	Fee: \$158.40	Benefit: 75% = \$118.80 85% = \$134.65			
		MANAGEMENT OF ANAESTHESIA for procedures involving veins of upper leg, ation (4 basic units)			
	merading explora	tion (4 basic units)			
21260	Fee: \$79.20	Benefit: 75% = \$59.40 85% = \$67.35			
		MANAGEMENT OF ANAESTHESIA for procedures involving arteries of upper leg,			
	including bypass	graft, not being a service to which another item in this Subgroup applies (8 basic units)			
21270	Fee: \$158.40	Benefit: 75% = \$118.80 85% = \$134.65			
	INITIATION OF	MANAGEMENT OF ANAESTHESIA for femoral artery ligation (4 basic units)			
21272	Fee: \$79.20	Benefit: 75% = \$59.40 85% = \$67.35			
212/2		MANAGEMENT OF ANAESTHESIA for femoral artery embolectomy (6 basic units)			
	INITIATION OF	MANAGEMENT OF ANAESTHESIA for temoral aftery embolectomy (6 basic units)			
	(See para TN.10.24 of explanatory notes to this Category)				
21274	Fee: \$118.80	Benefit: 75% = \$89.10 85% = \$101.00			
	INITIATION OF MANAGEMENT OF ANAESTHESIA for microvascular free tissue flap surgery involving the upper leg (10 basic units)				
		B of explanatory notes to this Category)			
21275	Fee: \$198.00	Benefit: 75% = \$148.50 85% = \$168.30			
	INITIATION OF MANAGEMENT OF ANAESTHESIA for microsurgical reimplantation of upper leg (15 basic units)				
	(13 basic units)				
21280	Fee: \$297.00	Benefit: 75% = \$222.75 85% = \$252.45			

T10. RELATIVE VALUE GUIDE FOR ANAESTHESIA - MEDICARE BENEFITS ARE ONLY PAYABLE FOR ANAESTHESIA PERFORMED IN ASSOCIATION WITH AN ELIGIBLE SERVICE

11. KNEE AND POPLITEAL AREA

Group T10. Relative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For

11. KNEE AND POPLITEAL AREA

	Anaesthesia Performed In Association With An Eligible Service	
	Subgroup 11. Knee And Popliteal Area	
	INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on the skin or subcutaneout tissue of the knee and/or popliteal area (3 basic units)	us
21300	Fee: \$59.40 Benefit: 75% = \$44.55 85% = \$50.50	
	INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on nerves, muscles, tendor fascia or bursae of knee and/or popliteal area (4 basic units)	ns,
21321	Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35	
	INITIATION OF MANAGEMENT OF ANAESTHESIA for closed procedures on lower 1/3 of fen when performed in the operating theatre of a hospital (4 basic units)	nur
21340	Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35	
	INITIATION OF MANAGEMENT OF ANAESTHESIA for open procedures on lower 1/3 of femu basic units)	ır (5
21360	Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15	
	INITIATION OF MANAGEMENT OF ANAESTHESIA for closed procedures on knee joint when performed in the operating theatre of a hospital (3 basic units)	l
21380	Fee: \$59.40 Benefit: 75% = \$44.55 85% = \$50.50	
	INITIATION OF MANAGEMENT OF ANAESTHESIA for arthroscopic procedures of knee joint basic units)	(4
21382	Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35	
	INITIATION OF MANAGEMENT OF ANAESTHESIA for closed procedures on upper ends of til fibula, and/or patella when performed in the operating theatre of a hospital (3 basic units)	bia,
21390	Fee: \$59.40 Benefit: 75% = \$44.55 85% = \$50.50	
	INITIATION OF MANAGEMENT OF ANAESTHESIA for open procedures on upper ends of tibi fibula, and/or patella (4 basic units)	a,
21392	Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35	
	INITIATION OF MANAGEMENT OF ANAESTHESIA for open procedures on knee joint, not be service to which another item in this Subgroup applies (4 basic units)	ing a
21400	Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35	
	INITIATION OF MANAGEMENT OF ANAESTHESIA for knee replacement (7 basic units)	
21402	Fee: \$138.60 Benefit: 75% = \$103.95 85% = \$117.85	
	INITIATION OF MANAGEMENT OF ANAESTHESIA for bilateral knee replacement (10 basic u	ınits)
21403	Fee: \$198.00 Benefit: 75% = \$148.50 85% = \$168.30	
21404	INITIATION OF MANAGEMENT OF ANAESTHESIA for disarticulation of knee (5 basic units)	

11. KNEE AND POPLITEAL AREA

	Fee: \$99.00	Benefit: 75% = \$74.25 85% = \$84.15
	INITIATION O	F MANAGEMENT OF ANAESTHESIA for cast application, removal, or repair
	involving knee j	pint, undertaken in a hospital (3 basic units)
21420	Fee: \$59.40	Benefit: 75% = \$44.55 85% = \$50.50
		F MANAGEMENT OF ANAESTHESIA for procedures on veins of knee or popliteal service to which another item in this Subgroup applies (4 basic units)
21430	Fee: \$79.20	Benefit: 75% = \$59.40 85% = \$67.35
	INITIATION Of popliteal area (5	F MANAGEMENT OF ANAESTHESIA for repair of arteriovenous fistula of knee or basic units)
21432	Fee: \$99.00	Benefit: 75% = \$74.25 85% = \$84.15
		F MANAGEMENT OF ANAESTHESIA for procedures on arteries of knee or popliteal service to which another item in this Subgroup applies (8 basic units)
21440	Fee: \$158.40	Benefit: 75% = \$118.80 85% = \$134.65
	INITIATION O	F MANAGEMENT OF ANAESTHESIA for microvascular free tissue flap surgery
	involving the kn	ee and/or popliteal area (10 basic units)
	(See para TN.10.2	8 of explanatory notes to this Category)
21445	Fee: \$198.00	Benefit: 75% = \$148.50 85% = \$168.30

T10. RELATIVE VALUE GUIDE FOR ANAESTHESIA - MEDICARE BENEFITS ARE ONLY PAYABLE FOR ANAESTHESIA PERFORMED IN ASSOCIATION WITH AN ELIGIBLE SERVICE

12. LOWER LEG (BELOW KNEE)

LLIGIB	12. LOWER LEG (BLLOW RILL)
	Group T10. Relative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For Anaesthesia Performed In Association With An Eligible Service
	Subgroup 12. Lower Leg (Below Knee)
	INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on the skin or subcutaneous tissue of lower leg, ankle, or foot (3 basic units)
21460	Fee: \$59.40 Benefit: 75% = \$44.55 85% = \$50.50
	INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on nerves, muscles, tendons, or fascia of lower leg, ankle, or foot, not being a service to which another item in this Subgroup applies (4 basic units)
21461	Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35
	INITIATION OF MANAGEMENT OF ANAESTHESIA for closed procedures on lower leg, ankle, or foot (3 basic units)
21462	Fee: \$59.40 Benefit: 75% = \$44.55 85% = \$50.50
21464	INITIATION OF MANAGEMENT OF ANAESTHESIA for arthroscopic procedure of ankle joint (4

12. LOWER LEG (BELOW KNEE)

LLIOID.	L SLIVICE	12. LOWER ELG (BLLOW RIVE)
	basic units)	
	Fee: \$79.20	Benefit: 75% = \$59.40 85% = \$67.35
	INITIATION O	F MANAGEMENT OF ANAESTHESIA for repair of Achilles tendon (5 basic units)
21472	Fee: \$99.00	Benefit: 75% = \$74.25 85% = \$84.15
	INITIATION O	F MANAGEMENT OF ANAESTHESIA for gastrocnemius recession (5 basic units)
21474	Fee: \$99.00	Benefit: 75% = \$74.25 85% = \$84.15
		F MANAGEMENT OF ANAESTHESIA for open procedures on bones of lower leg, acluding amputation, not being a service to which another item in this Subgroup applies
21480	Fee: \$79.20	Benefit: 75% = \$59.40 85% = \$67.35
	INITIATION O leg, ankle or foo	F MANAGEMENT OF ANAESTHESIA for radical resection of bone involving lower of (5 basic units)
21482	Fee: \$99.00	Benefit: 75% = \$74.25 85% = \$84.15
	INITIATION O (5 basic units)	F MANAGEMENT OF ANAESTHESIA for osteotomy or osteoplasty of tibia or fibula
21484	Fee: \$99.00	Benefit: 75% = \$74.25 85% = \$84.15
	INITIATION O	F MANAGEMENT OF ANAESTHESIA for total ankle replacement (7 basic units)
21486	Fee: \$138.60	Benefit: 75% = \$103.95 85% = \$117.85
		F MANAGEMENT OF ANAESTHESIA for lower leg cast application, removal or en in a hospital (3 basic units)
21490	Fee: \$59.40	Benefit: 75% = \$44.55 85% = \$50.50
		F MANAGEMENT OF ANAESTHESIA for procedures on arteries of lower leg, s graft, not being a service to which another item in this Subgroup applies (8 basic units)
21500	Fee: \$158.40	Benefit: 75% = \$118.80 85% = \$134.65
	INITIATION O units)	F MANAGEMENT OF ANAESTHESIA for embolectomy of the lower leg (6 basic
21502	Fee: \$118.80	Benefit: 75% = \$89.10 85% = \$101.00
		F MANAGEMENT OF ANAESTHESIA for procedures on veins of lower leg, not to which another item in this Subgroup applies (4 basic units)
21520	Fee: \$79.20	Benefit: 75% = \$59.40 85% = \$67.35
	INITIATION O basic units)	F MANAGEMENT OF ANAESTHESIA for venous thrombectomy of the lower leg (5
21522	Fee: \$99.00	Benefit: 75% = \$74.25 85% = \$84.15
21530	INITIATION O	F MANAGEMENT OF ANAESTHESIA for microsurgical reimplantation of lower leg,

12. LOWER LEG (BELOW KNEE)

		·
	ankle or foot (15	basic units)
	Fee: \$297.00	Benefit: 75% = \$222.75 85% = \$252.45
	INITIATION Of basic units)	F MANAGEMENT OF ANAESTHESIA for microsurgical reimplantation of toe (8
21532	Fee: \$158.40	Benefit: 75% = \$118.80 85% = \$134.65
		F MANAGEMENT OF ANAESTHESIA for microvascular free tissue flap surgery ver leg (10 basic units)
	(See para TN.10.2	8 of explanatory notes to this Category)
21535	Fee: \$198.00	Benefit: 75% = \$148.50 85% = \$168.30

T10. RELATIVE VALUE GUIDE FOR ANAESTHESIA - MEDICARE BENEFITS ARE ONLY PAYABLE FOR ANAESTHESIA PERFORMED IN ASSOCIATION WITH AN ELIGIBLE SERVICE

13. SHOULDER AND AXILLA

	Group T10. Relative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For Anaesthesia Performed In Association With An Eligible Service
	Subgroup 13. Shoulder And Axilla
	INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on the skin or subcutaneous tissue of the shoulder or axilla (3 basic units)
21600	Fee: \$59.40 Benefit: 75% = \$44.55 85% = \$50.50
	INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on nerves, muscles, tendons, fascia or bursae of shoulder or axilla including axillary dissection (5 basic units)
21610	Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15
	INITIATION OF MANAGEMENT OF ANAESTHESIA for closed procedures on humeral head and neck, sternoclavicular joint, acromioclavicular joint, or shoulder joint when performed in the operating theatre of a hospital (4 basic units)
21620	Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35
	INITIATION OF MANAGEMENT OF ANAESTHESIA for arthroscopic procedures of shoulder joint (5 basic units)
21622	Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15
	INITIATION OF MANAGEMENT OF ANAESTHESIA for open procedures on humeral head and neck, sternoclavicular joint, acromioclavicular joint or shoulder joint, not being a service to which another item in this Subgroup applies (5 basic units)
21630	Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15
21632	INITIATION OF MANAGEMENT OF ANAESTHESIA for radical resection involving humeral head and neck, sternoclavicular joint, acromioclavicular joint or shoulder joint (6 basic units)

13. SHOULDER AND AXILLA

	Fee: \$118.80	Benefit: 75% = \$89.10 85% = \$101.00
	INITIATION OF	MANAGEMENT OF ANAESTHESIA for shoulder disarticulation (9 basic units)
21634	Fee: \$178.20	Benefit: 75% = \$133.65 85% = \$151.50
		MANAGEMENT OF ANAESTHESIA for interthoracoscapular (forequarter)
	amputation (15 ba	asic units)
21636	Fee: \$297.00	Benefit: 75% = \$222.75 85% = \$252.45
	INITIATION OF	MANAGEMENT OF ANAESTHESIA for total shoulder replacement (10 basic units)
21638	Fee: \$198.00	Benefit: 75% = \$148.50 85% = \$168.30
		MANAGEMENT OF ANAESTHESIA for procedures on arteries of shoulder or
	axilla, not being a	a service to which another item in this Subgroup applies (8 basic units)
21650	Fee: \$158.40	Benefit: 75% = \$118.80 85% = \$134.65
		MANAGEMENT OF ANAESTHESIA for procedures for axillary-brachial aneurysm
	(10 basic units)	
21652	Fee: \$198.00	Benefit: 75% = \$148.50 85% = \$168.30
	INITIATION OF axilla (8 basic un	MANAGEMENT OF ANAESTHESIA for bypass graft of arteries of shoulder or its)
21654	Fee: \$158.40	Benefit: 75% = \$118.80 85% = \$134.65
	INITIATION OF units)	MANAGEMENT OF ANAESTHESIA for axillary-femoral bypass graft (10 basic
21656	Fee: \$198.00	Benefit: 75% = \$148.50 85% = \$168.30
	INITIATION OF (4 basic units)	MANAGEMENT OF ANAESTHESIA for procedures on veins of shoulder or axilla
21670	Fee: \$79.20	Benefit: 75% = \$59.40 85% = \$67.35
		MANAGEMENT OF ANAESTHESIA for shoulder cast application, removal or a service to which another item in this Subgroup applies, when undertaken in a hospital
21680	Fee: \$59.40	Benefit: 75% = \$44.55 85% = \$50.50
		MANAGEMENT OF ANAESTHESIA for shoulder spica application when ospital (4 basic units)
21682	Fee: \$79.20	Benefit: 75% = \$59.40 85% = \$67.35
		MANAGEMENT OF ANAESTHESIA for microvascular free tissue flap surgery sulder or the axilla (10 basic units)
21685	(See para TN.10.28 Fee: \$198.00	8 of explanatory notes to this Category) Benefit: 75% = \$148.50 85% = \$168.30

14. UPPER ARM AND ELBOW

	Group T10. Relative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For Anaesthesia Performed In Association With An Eligible Service
	Subgroup 14. Upper Arm And Elbow
	INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on the skin or subcutaneous tissue of the upper arm or elbow (3 basic units)
21700	Fee: \$59.40 Benefit: 75% = \$44.55 85% = \$50.50
	INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on nerves, muscles, tendons, fascia or bursae of upper arm or elbow, not being a service to which another item in this Subgroup applies (4 basic units)
21710	Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35
	INITIATION OF MANAGEMENT OF ANAESTHESIA for open tenotomy of the upper arm or elbow (5 basic units)
21712	Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15
	INITIATION OF MANAGEMENT OF ANAESTHESIA for tenoplasty of the upper arm or elbow (5 basic units)
21714	Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15
	INITIATION OF MANAGEMENT OF ANAESTHESIA for tenodesis for rupture of long tendon of biceps (5 basic units)
21716	Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15
	INITIATION OF MANAGEMENT OF ANAESTHESIA for closed procedures on the upper arm or elbow when performed in the operating theatre of a hospital (3 basic units)
21730	Fee: \$59.40 Benefit: 75% = \$44.55 85% = \$50.50
	INITIATION OF MANAGEMENT OF ANAESTHESIA for arthroscopic procedures of elbow joint (4 basic units)
21732	Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35
	INITIATION OF MANAGEMENT OF ANAESTHESIA for open procedures on the upper arm or elbow, not being a service to which another item in this Subgroup applies (5 basic units)
21740	Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15
	INITIATION OF MANAGEMENT OF ANAESTHESIA for radical procedures on the upper arm or elbow (6 basic units)
21756	Fee: \$118.80 Benefit: 75% = \$89.10 85% = \$101.00
	INITIATION OF MANAGEMENT OF ANAESTHESIA for total elbow replacement (7 basic units)
21760	Fee: \$138.60 Benefit: 75% = \$103.95 85% = \$117.85
21770	INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on arteries of upper arm, not

14. UPPER ARM AND ELBOW

	being a service to	which another item in this Subgroup applies (8 basic units)
	Fee: \$158.40	Benefit: 75% = \$118.80 85% = \$134.65
	INITIATION OF 1 (6 basic units)	MANAGEMENT OF ANAESTHESIA for embolectomy of arteries of the upper arm
21772	Fee: \$118.80	Benefit: 75% = \$89.10 85% = \$101.00
		MANAGEMENT OF ANAESTHESIA for procedures on veins of upper arm, not which another item in this Subgroup applies (4 basic units)
21780	Fee: \$79.20	Benefit: 75% = \$59.40 85% = \$67.35
		MANAGEMENT OF ANAESTHESIA for microvascular free tissue flap surgery er arm or elbow (10 basic units)
	(See para TN.10.28	of explanatory notes to this Category)
21785	Fee: \$198.00	Benefit: 75% = \$148.50 85% = \$168.30
	INITIATION OF 1 (15 basic units)	MANAGEMENT OF ANAESTHESIA for microsurgical reimplantation of upper arm
21790	Fee: \$297.00	Benefit: 75% = \$222.75 85% = \$252.45

T10. RELATIVE VALUE GUIDE FOR ANAESTHESIA - MEDICARE BENEFITS ARE ONLY PAYABLE FOR ANAESTHESIA PERFORMED IN ASSOCIATION WITH AN ELIGIBLE SERVICE

15. FOREARM WRIST AND HAND

	Group T10. Relative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For
	Anaesthesia Performed In Association With An Eligible Service
	Subgroup 15. Forearm Wrist And Hand
	INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on the skin or subcutaneous tissue of the forearm, wrist or hand (3 basic units)
21800	Fee: \$59.40 Benefit: 75% = \$44.55 85% = \$50.50
	INITIATION OF MANAGEMENT OF ANAESTHESIA for procedures on the nerves, muscles, tendons, fascia, or bursae of the forearm, wrist or hand (4 basic units)
21810	Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35
	INITIATION OF MANAGEMENT OF ANAESTHESIA for closed procedures on the radius, ulna, wrist, or hand bones when performed in the operating theatre of a hospital (3 basic units)
21820	Fee: \$59.40 Benefit: 75% = \$44.55 85% = \$50.50
	INITIATION OF MANAGEMENT OF ANAESTHESIA for open procedures on the radius, ulna, wrist or hand bones, not being a service to which another item in this Subgroup applies (4 basic units)
21830	Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35

21878

15. FOREARM WRIST AND HAND

0.			10.1 01.2, 11.11 11.1101 7.112 17.112
	INITIATION O	F MANAGEMENT OF AN	NAESTHESIA for total wrist replacement (7 basic units)
21832	Fee: \$138.60	Benefit: 75% = \$103.9	5 85% = \$117.85
	INITIATION O (4 basic units)	F MANAGEMENT OF AN	NAESTHESIA for arthroscopic procedures of the wrist joint
21834	Fee: \$79.20	Benefit: 75% = \$59.40	85% = \$67.35
			NAESTHESIA for procedures on the arteries of forearm, wris er item in this Subgroup applies (8 basic units)
21840	Fee: \$158.40	Benefit: 75% = \$118.8	0 85% = \$134.65
	INITIATION Of hand (6 basic un		NAESTHESIA for embolectomy of artery of forearm, wrist or
21842	Fee: \$118.80	Benefit: 75% = \$89.10	85% = \$101.00
	INITIATION Of or hand, not bein	F MANAGEMENT OF AN	NAESTHESIA for procedures on the veins of forearm, wrist er item in this Subgroup applies (4 basic units)
21850	Fee: \$79.20	Benefit: 75% = \$59.40	85% = \$67.35
			NAESTHESIA for forearm, wrist, or hand cast application, ent as part of an episode of hospital treatment (3 basic units)
21860	Fee: \$59.40	Benefit: 75% = \$44.55	85% = \$50.50
		F MANAGEMENT OF AN rearm, wrist or hand (10 ba	NAESTHESIA for microvascular free tissue flap surgery sic units)
21865	(See para TN.10.2 Fee: \$198.00	28 of explanatory notes to this Benefit: $75\% = 148.5	
	INITIATION Of wrist or hand (1)		NAESTHESIA for microsurgical reimplantation of forearm,
21870	Fee: \$297.00	Benefit: 75% = \$222.7	5 85% = \$252.45
	INITIATION Of basic units)	F MANAGEMENT OF AN	NAESTHESIA for microsurgical reimplantation of a finger (8
21872	Fee: \$158.40	Benefit: 75% = \$118.8	0 85% = \$134.65
ANAES ONLY F PERFO	PAYABLE FOR A	ARE BENEFITS ARE	16. ANAESTHESIA FOR BURNS
		ative Value Guide For Ana erformed In Association W	aesthesia - Medicare Benefits Are Only Payable For Vith An Eligible Service
		Subgrou	up 16. Anaesthesia For Burns
	1		

INITIATION OF MANAGEMENT OF ANAESTHESIA for excision or debridement of burns, with or

16. ANAESTHESIA FOR BURNS

LLIGIB	LE SERVICE	10. ANAEST TESIA FOR BURNS
	without skin grafting v units)	where the area of burn involves not more than 3% of total body surface (3 basic
	Fee: \$59.40 B	enefit: 75% = \$44.55 85% = \$50.50
		NAGEMENT OF ANAESTHESIA for excision or debridement of burns, with or where the area of burn involves more than 3% but less than 10% of total body
21879	Fee: \$99.00 B	enefit: 75% = \$74.25 85% = \$84.15
		NAGEMENT OF ANAESTHESIA for excision or debridement of burns, with or where the area of burn involves 10% or more but less than 20% of total body
21880	Fee: \$138.60 B	enefit: 75% = \$103.95 85% = \$117.85
		NAGEMENT OF ANAESTHESIA for excision or debridement of burns, with or where the area of burn involves 20% or more but less than 30% of total body
21881	Fee: \$178.20 B	enefit: 75% = \$133.65 85% = \$151.50
		NAGEMENT OF ANAESTHESIA for excision or debridement of burns, with or where the area of burn involves 30% or more but less than 40% of total body
21882	Fee: \$217.80 B	enefit: 75% = \$163.35 85% = \$185.15
		NAGEMENT OF ANAESTHESIA for excision or debridement of burns, with or where the area of burn involves 40% or more but less than 50% of total body
21883	Fee: \$257.40 B	enefit: 75% = \$193.05 85% = \$218.80
		NAGEMENT OF ANAESTHESIA for excision or debridement of burns, with or where the area of burn involves 50% or more but less than 60% of total body
21884	Fee: \$297.00 B	enefit: 75% = \$222.75 85% = \$252.45
		NAGEMENT OF ANAESTHESIA for excision or debridement of burns, with or where the area of burn involves 60% or more but less than 70% of total body
21885	Fee: \$336.60 B	enefit: 75% = \$252.45 85% = \$286.15
		NAGEMENT OF ANAESTHESIA for excision or debridement of burns, with or where the area of burn involves 70% or more but less than 80% of total body
21006	Fee: \$376.20 B	enefit: 75% = \$282.15 85% = \$319.80
21886		
21880	INITIATION OF MAN	NAGEMENT OF ANAESTHESIA for excision or debridement of burns, with or where the area of burn involves 80% or more of total body surface (21 basic units)

17. ANAESTHESIA FOR RADIOLOGICAL OR OTHER DIAGNOSTIC OR THERAPEUTIC PROCEDURES

	Group T10. Relative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For Anaesthesia Performed In Association With An Eligible Service		
	Subgroup 17. Anaesthesia For Radiological Or Other Diagnostic Or Therapeutic Procedures		
	INITIATION OF MANAGEMENT OF ANAESTHESIA for injection procedure for hysterosalpingography (3 basic units)		
21900	Fee: \$59.40 Benefit: 75% = \$44.55 85% = \$50.50		
	INITIATION OF MANAGEMENT OF ANAESTHESIA for injection procedure for myelography: lumbar or thoracic (5 basic units)		
21906	Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15		
	INITIATION OF MANAGEMENT OF ANAESTHESIA for injection procedure for myelography: cervical (6 basic units)		
21908	Fee: \$118.80 Benefit: 75% = \$89.10 85% = \$101.00		
	INITIATION OF MANAGEMENT OF ANAESTHESIA for injection procedure for myelography: posterior fossa (9 basic units)		
21910	Fee: \$178.20 Benefit: 75% = \$133.65 85% = \$151.50		
	INITIATION OF MANAGEMENT OF ANAESTHESIA for injection procedure for discography: lumbar or thoracic (5 basic units)		
21912	Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15		
	INITIATION OF MANAGEMENT OF ANAESTHESIA for injection procedure for discography: cervical (6 basic units)		
21914	Fee: \$118.80 Benefit: 75% = \$89.10 85% = \$101.00		
	INITIATION OF MANAGEMENT OF ANAESTHESIA for peripheral arteriogram (5 basic units)		
21915	Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15		
	INITIATION OF MANAGEMENT OF ANAESTHESIA for arteriograms: cerebral, carotid or vertebral (5 basic units)		
21916	Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15		
	INITIATION OF MANAGEMENT OF ANAESTHESIA for retrograde arteriogram: brachial or femoral (5 basic units)		
21918	Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15		
	INITIATION OF MANAGEMENT OF ANAESTHESIA for computerised axial tomography scanning, magnetic resonance scanning, digital subtraction angiography scanning (7 basic units)		
21922	Fee: \$138.60 Benefit: 75% = \$103.95 85% = \$117.85		
21925	INITIATION OF MANAGEMENT OF ANAESTHESIA for retrograde cystography, retrograde urethrography or retrograde cystourethrography (4 basic units)		

17. ANAESTHESIA FOR RADIOLOGICAL OR OTHER DIAGNOSTIC OR THERAPEUTIC PROCEDURES

	Fee: \$79.20	Benefit: 75% = \$59.40	85% = \$67.35
	INITIATION O	F MANAGEMENT OF AN	AESTHESIA for fluoroscopy (5 basic units)
21926	Fee: \$99.00	Benefit: 75% = \$74.25	85% = \$84.15
		F MANAGEMENT OF AN	AESTHESIA for barium enema or other opaque study of the
21927	Fee: \$99.00	Benefit: 75% = \$74.25	85% = \$84.15
	INITIATION O	F MANAGEMENT OF AN	AESTHESIA for bronchography (6 basic units)
21930	Fee: \$118.80	Benefit: 75% = \$89.10	85% = \$101.00
	INITIATION O	F MANAGEMENT OF AN	AESTHESIA for phlebography (5 basic units)
21935	Fee: \$99.00	Benefit: 75% = \$74.25	85% = \$84.15
		F MANAGEMENT OF AN. l examination (6 basic units)	AESTHESIA for heart, 2 dimensional real time
21936	(See para TN.10.2 Fee: \$118.80	6 of explanatory notes to this C Benefit: 75% = \$89.10	
	INITIATION Ounits)	F MANAGEMENT OF AN.	AESTHESIA for peripheral venous cannulation (3 basic
21939	Fee: \$59.40	Benefit: 75% = \$44.55	85% = \$50.50
		entriculography, cardiac map	AESTHESIA for cardiac catheterisation including coronary oping, insertion of automatic defibrillator or transvenous
21941	(See para TN.10.2 Fee: \$138.60	5 of explanatory notes to this C Benefit: 75% = \$103.95	
		F MANAGEMENT OF AN. Trequency ablation (10 basic	AESTHESIA for cardiac electrophysiological procedures units)
21942	Fee: \$198.00	Benefit: 75% = \$148.50	85% = \$168.30
			AESTHESIA for central vein catheterisation or insertion of clavian or femoral vein) by percutaneous or open exposure
21943	Fee: \$99.00	Benefit: 75% = \$74.25	85% = \$84.15
	INITIATION O epidural injectio		AESTHESIA for lumbar puncture, cisternal puncture, or
21945	Fee: \$99.00	Benefit: 75% = \$74.25	85% = \$84.15
	INITIATION O of transplantatio		AESTHESIA for harvesting of bone marrow for the purpose
21949	Fee: \$99.00	Benefit: 75% = \$74.25	85% = \$84.15
21952	INITIATION O	F MANAGEMENT OF AN	AESTHESIA for muscle biopsy for malignant hyperpyrexia

17. ANAESTHESIA FOR RADIOLOGICAL OR OTHER DIAGNOSTIC OR THERAPEUTIC PROCEDURES

ELIGIB	LE SERVICE		PROCEDURES
	(10 basic units)		
	Fee: \$198.00	Benefit: 75% = \$148.50) 85% = \$168.30
	INITIATION OF	MANAGEMENT OF AN	JAESTHESIA for electroencephalography (5 basic units)
21955	Fee: \$99.00	Benefit: 75% = \$74.25	85% = \$84.15
	INITIATION OF basic units)	MANAGEMENT OF AN	VAESTHESIA for brain stem evoked response audiometry (5
21959	Fee: \$99.00	Benefit: 75% = \$74.25	85% = \$84.15
		F MANAGEMENT OF AN ympanic membrane insertio	AAESTHESIA for electrocochleography by extratympanic on method (5 basic units)
21962	Fee: \$99.00	Benefit: 75% = \$74.25	85% = \$84.15
		F MANAGEMENT OF AN esia, not for headache of an	AAESTHESIA as a therapeutic procedure if there is a clinical by etiology (5 basic units)
21965	Fee: \$99.00	Benefit: 75% = \$74.25	85% = \$84.15
			AAESTHESIA during hyperbaric therapy where the medical (including the administration of oxygen) (8 basic units)
21969	Fee: \$158.40	Benefit: 75% = \$118.80	85% = \$134.65
			JAESTHESIA during hyperbaric therapy where the medical auding the administration of oxygen) (15 basic units)
21970	Fee: \$297.00	Benefit: 75% = \$222.75	5 85% = \$252.45
	INITIATION OF sources (5 basic		VAESTHESIA for brachytherapy using radioactive sealed
21973	Fee: \$99.00	Benefit: 75% = \$74.25	85% = \$84.15
	INITIATION OF units)	MANAGEMENT OF AN	VAESTHESIA for therapeutic nuclear medicine (5 basic
21976	Fee: \$99.00	Benefit: 75% = \$74.25	85% = \$84.15
	INITIATION OF	MANAGEMENT OF AN	IAESTHESIA for radiotherapy (5 basic units)
21980	Fee: \$99.00	Benefit: 75% = \$74.25	85% = \$84.15
ANAES ONLY F PERFO	ELATIVE VALUE (STHESIA - MEDICA PAYABLE FOR AI RMED IN ASSOC LE SERVICE	ARE BENEFITS ARE NAESTHESIA	18. MISCELLANEOUS
	Group T10. Rela	ative Value Guide For Ana	nesthesia - Medicare Benefits Are Only Payable For

Subgroup 18. Miscellaneous

Anaesthesia Performed In Association With An Eligible Service

18. MISCELLANEOUS

	INITIATION OF MANAGEMENT OF ANAESTHESIA when no procedure ensues (3 basic units)	
	(See para TN.10.12 of explanatory notes to this Category)	
21990	Fee: \$59.40 Benefit: 75% = \$44.55 85% = \$50.50	
	INITIATION OF MANAGEMENT OF ANAESTHESIA performed on a person under the age of 10 years in connection with a procedure covered by an item which has not been identified as attracting an anaesthetic (4 basic units)	
21992	Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35	
	INITIATION OF MANAGEMENT OF ANAESTHESIA in connection with a procedure covered by an item that does not include the word "(Anaes.)", other than a service to which item 21965 or 21992 applies, if there is a clinical need for anaesthesia (4 basic units)	
	(See para TN.10.13 of explanatory notes to this Category)	
21997	Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35	

T10. RELATIVE VALUE GUIDE FOR ANAESTHESIA - MEDICARE BENEFITS ARE ONLY PAYABLE FOR ANAESTHESIA PERFORMED IN ASSOCIATION WITH AN ELIGIBLE SERVICE

19. THERAPEUTIC AND DIAGNOSTIC SERVICES

ELIGIB	LE SERVICE 19. THERAPEUTIC AND DIAGNOSTIC SERVICES
	Group T10. Relative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For Anaesthesia Performed In Association With An Eligible Service
	Subgroup 19. Therapeutic And Diagnostic Services
	COLLECTION OF BLOOD FOR AUTOLOGOUS TRANSFUSION or when homologous blood is required for immediate transfusion in an emergency situation, when performed in association with the administration of anaesthesia (3 basic units)
22001	(See para TN.10.8 of explanatory notes to this Category) Fee: \$59.40 Benefit: 75% = \$44.55 85% = \$50.50
22002	ADMINISTRATION OF BLOOD or bone marrow already collected when performed in association with the administration of anaesthesia (4 basic units) (See para TN.10.8 of explanatory notes to this Category) Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35
	ENDOTRACHEAL INTUBATION with flexible fibreoptic scope associated with difficult airway when performed in association with the administration of anaesthesia (4 basic units)
22007	Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35
	DOUBLE LUMEN ENDOBRONCHIAL TUBE OR BRONCHIAL BLOCKER, insertion of when performed in association with the administration of anaesthesia (4 basic units)
22008	Fee: \$79.20 Benefit: 75% = \$59.40 85% = \$67.35
22012	BLOOD PRESSURE MONITORING (central venous, pulmonary arterial, systemic arterial or cardiac intracavity), by indwelling catheter - once only for each type of pressure on any calendar day, up to a maximum of 4 pressures (not being a service to which item 13876 applies) when performed in

19. THERAPEUTIC AND DIAGNOSTIC SERVICES

ELIGIBL	BLE SERVICE 1	9. THERAPEUTIC AND DIAGNOSTIC SERVICES
	association with the administration of anaesthesi	a (3 basic units)
	(See para TN.10.8 of explanatory notes to this Catego Fee: \$59.40 Benefit: 75% = \$44.55 85%	
	intracavity), by indwelling catheter - once only f maximum of 4 pressures (not being a service to	enous, pulmonary arterial, systemic arterial or cardiac for each type of pressure on any calendar day, up to a which item 13876 applies) when performed in a relating to another discrete operation on the same day
22014	(See para TN.10.8 of explanatory notes to this Catego Fee: \$59.40 Benefit: 75% = \$44.55 85%	
		rtion of, including pulmonary wedge pressure and association with the administration of anaesthesia (6
22015	(See para TN.10.8 of explanatory notes to this Catego Fee: \$118.80 Benefit: 75% = \$89.10 85%	
	concentrations in inspired or expired air, alveola analysis and a written record of the results, when	R GAS EXCHANGE FUNCTION OF THE s of parameters, including pressures, volumes, flow, gas r gas or blood and incorporating serial arterial blood gas a performed in association with the administration of a service to which item 11503 applies (7 basic units)
22018	Fee: \$138.60 Benefit: 75% = \$103.95 85	5% = \$117.85
		rcutaneous or open exposure, not being a service to ssociation with the administration of anaesthesia (4 basic
22020	(See para TN.1.6, TN.10.8 of explanatory notes to this Fee: \$79.20 Benefit: 75% = \$59.40 85%	
	INTRAARTERIAL CANNULATION when per anaesthesia (4 basic units) (See para TN.10.8 of explanatory notes to this Catego	formed in association with the administration of
22025	Fee: \$79.20 Benefit: 75% = \$59.40 85%	
	without insertion of a catheter, in association wit management, not being a service associated with	initial) of a therapeutic substance or substances, with or th anaesthesia and surgery, for postoperative pain a service to which 22036 applies (5 basic units)
22031	(See para TN.10.19 of explanatory notes to this Categ Fee: \$99.00 Benefit: 75% = \$74.25 85%	
	using an in-situ catheter, in association with anac	subsequent) of a therapeutic substance or substances, esthesia and surgery, for postoperative pain a service to which 22031 applies (3 basic units)

19. THERAPEUTIC AND DIAGNOSTIC SERVICES

LLIGID	19. THERAPLOTIC AND DIAGNOSTIC SERVICES
	INTRODUCTION OF A REGIONAL OR FIELD NERVE BLOCK peri-operatively performed in the induction room theatre or recovery room for the control of post operative pain via the femoral OR sciatic nerves, in conjunction with hip, knee, ankle or foot surgery (2 basic units)
22040	(See para TN.10.17, TN.10.21 of explanatory notes to this Category) Fee: \$39.60 Benefit: 75% = \$29.70 85% = \$33.70
	INTRODUCTION OF A REGIONAL OR FIELD NERVE BLOCK peri-operatively performed in the induction room, theatre or recovery room for the control of post operative pain via the femoral AND sciatic nerves, in conjunction with hip, knee, ankle or foot surgery (3 basic units)
22045	(See para TN.10.17, TN.10.21 of explanatory notes to this Category) Fee: \$59.40 Benefit: 75% = \$44.55 85% = \$50.50
	INTRODUCTION OF A REGIONAL OR FIELD NERVE BLOCK peri-operatively performed in the induction room, theatre or recovery room for the control of post operative pain via the brachial plexus in conjunction with shoulder surgery (2 basic units)
22050	(See para TN.10.17, TN.10.21 of explanatory notes to this Category) Fee: \$39.60 Benefit: 75% = \$29.70 85% = \$33.70
	INTRA-OPERATIVE TRANSOESOPHAGEAL ECHOCARDIOGRAPHY - Monitoring in real time of the structure and function of the heart chambers, valves and surrounding structures, including assessment of blood flow, with appropriate permanent recording during procedures on the heart, pericardium or great vessels of the chest (not in association with items 55130, 55135 or 21936) (9 basic units)
22051	Fee: \$178.20 Benefit: 75% = \$133.65 85% = \$151.50
	PERFUSION OF LIMB OR ORGAN using heart-lung machine or equivalent, not being a service associated with anaesthesia to which an item in Subgroup 21 applies (12 basic units)
22055	(See para TN.10.10 of explanatory notes to this Category) Fee: \$237.60 Benefit: 75% = \$178.20 85% = \$202.00
	WHOLE BODY PERFUSION, CARDIAC BYPASS, where the heart-lung machine or equivalent is continuously operated by a medical perfusionist, other than a service associated with anaesthesia to which an item in Subgroup 21 applies. (20 basic units) (20 basic units)
22060	(See para TN.10.10 of explanatory notes to this Category) Fee: \$396.00 Benefit: 75% = \$297.00 85% = \$336.60
	INDUCED CONTROLLED HYPOTHERMIA total body, being a service to which item 22060 applies, not being a service associated with anaesthesia to which an item in Subgroup 21 applies (5 basic units)
22065	(See para TN.10.10 of explanatory notes to this Category) Fee: \$99.00 Benefit: 75% = \$74.25 85% = \$84.15
	CARDIOPLEGIA, blood or crystalloid, administration by any route, being a service to which item 22060 applies, not being a service associated with anaesthesia to which an item in Subgroup 21 applies (10 basic units)
22070	(See para TN.10.10 of explanatory notes to this Category) Fee: \$198.00 Benefit: 75% = \$148.50 85% = \$168.30
22075	DEEP HYPOTHERMIC CIRCULATORY ARREST, with core temperature less than 22°c, including management of retrograde cerebral perfusion if performed, not being a service associated with
22070	CARDIOPLEGIA, blood or crystalloid, administration by any route, being a service to which item 22060 applies, not being a service associated with anaesthesia to which an item in Subgroup 21 appl (10 basic units) (See para TN.10.10 of explanatory notes to this Category) Fee: \$198.00 Benefit: 75% = \$148.50 85% = \$168.30 DEEP HYPOTHERMIC CIRCULATORY ARREST, with core temperature less than 22°c, including the service of the

19. THERAPEUTIC AND DIAGNOSTIC SERVICES

anaesthesia to which an item in Subgroup 21 applies (15 basic

(See para TN.10.10 of explanatory notes to this Category)

Fee: \$297.00 **Benefit:** 75% = \$222.75 85% = \$252.45

T10. RELATIVE VALUE GUIDE FOR ANAESTHESIA - MEDICARE BENEFITS ARE ONLY PAYABLE FOR ANAESTHESIA PERFORMED IN ASSOCIATION WITH AN ELIGIBLE SERVICE

20. ADMINISTRATION OF ANAESTHESIA IN CONNECTION WITH A DENTAL SERVICE

	Group T10. Relative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For Anaesthesia Performed In Association With An Eligible Service
	Subgroup 20. Administration Of Anaesthesia In Connection With A Dental Service
	INITIATION OF MANAGEMENT BY A MEDICAL PRACTITIONER OF ANAESTHESIA for extraction of tooth or teeth with or without incision of soft tissue or removal of bone (6 basic units)
22900	(See para TN.10.14 of explanatory notes to this Category) Fee: \$118.80 Benefit: 75% = \$89.10 85% = \$101.00
	INITIATION OF MANAGEMENT OF ANAESTHESIA for restorative dental work (6 basic units)
	(See para TN.10.14 of explanatory notes to this Category)
22905	Fee: \$118.80 Benefit: 75% = \$89.10 85% = \$101.00

T10. RELATIVE VALUE GUIDE FOR ANAESTHESIA - MEDICARE BENEFITS ARE ONLY PAYABLE FOR ANAESTHESIA PERFORMED IN ASSOCIATION WITH AN ELIGIBLE SERVICE

	Group T10. Relative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For Anaesthesia Performed In Association With An Eligible Service				
	Subgroup 21. Anaesthesia/Perfusion Time Units				
	ANAESTHESIA, PERFUSION OR ASSISTANCE AT ANAESTHESIA				
	(a) administration of anaesthesia performed in association with an item in the range 20100 to 21997 or 22900 to 22905; or				
	(b) perfusion performed in association with item 22060; or				
	(c) for assistance at anaesthesia performed in association with items 25200 to 25205				
	For a period of:				
23010					

ELIGIBI	LE SERVICE		21. ANAESTHESIA/PERFUSION TIME UNITS
	(FIFTEEN MIN	UTES OR LESS) (1 basic u	nits)
	(See para TN.10.3 Fee: \$19.80	of explanatory notes to this Ca Benefit: 75% = \$14.85	
	16 MINUTES T	O 20 MINUTES (2 basic ur	nits)
23021	Fee: \$39.60	Benefit: 75% = \$29.70	85% = \$33.70
	21 MINUTES T	O 25 MINUTES (2 basic ur	nits)
23022	Fee: \$39.60	Benefit: 75% = \$29.70	85% = \$33.70
	26 MINUTES T	O 30 MINUTES (2 basic ur	nits)
23023	Fee: \$39.60	Benefit: 75% = \$29.70	85% = \$33.70
	31 MINUTES T	O 35 MINUTES (3 basic ur	nits)
23031	Fee: \$59.40	Benefit: 75% = \$44.55	85% = \$50.50
	36 MINUTES T	O 40 MINUTES (3 basic ur	nits)
23032	Fee: \$59.40	Benefit: 75% = \$44.55	
	41 MINUTES T	O 45 MINUTES (3 basic ur	nits)
23033	Fee: \$59.40	Benefit: 75% = \$44.55	
	46 MINUTES TO 50 MINUTES (4 basic units)		
23041	Fee: \$79.20	Benefit: 75% = \$59.40	
	51 MINUTES T	O 55 MINUTES (4 basic ur	nits)
23042	Fee: \$79.20	Benefit: 75% = \$59.40	
	56 MINUTES T	O 1:00 HOUR (4 basic unit	s)
23043	Fee: \$79.20	Benefit: 75% = \$59.40	
	1:01 HOURS TO 1:05 HOURS (5 basic units)		
23051	Fee: \$99.00	Benefit: 75% = \$74.25	
	1:06 HOURS TO	O 1:10 HOURS (5 basic uni	ts)
23052	Fee: \$99.00	Benefit: 75% = \$74.25	
	1:11 HOURS TO 1:15 HOURS (5 basic units)		
23053	Fee: \$99.00	Benefit: 75% = \$74.25	
		O 1:20 HOURS (6 basic uni	
23061	Fee: \$118.80	Benefit: 75% = \$89.10	
		O 1:25 HOURS (6 basic uni	,
23062	Fee: \$118.80	Benefit: 75% = \$89.10	85% = \$101.00

L SLIVICE	21. ANALSTITESIAFERI OSION TIME UNITS
1:26 HOURS TO	O 1:30 HOURS (6 basic units)
Fee: \$118.80	Benefit: 75% = \$89.10 85% = \$101.00
1:31 HOURS TO	O 1:35 HOURS (7 basic units)
Fee: \$138.60	Benefit: 75% = \$103.95 85% = \$117.85
1:36 HOURS TO	O 1:40 HOURS (7 basic units)
Fee: \$138.60	Benefit: 75% = \$103.95 85% = \$117.85
1:41 HOURS TO	O 1:45 HOURS (7 basic units)
Fee: \$138.60	Benefit: 75% = \$103.95 85% = \$117.85
1:46 HOURS TO	O 1:50 HOURS (8 basic units)
Fee: \$158.40	Benefit: 75% = \$118.80 85% = \$134.65
1:51 HOURS TO	O 1:55 HOURS (8 basic units)
Fee: \$158.40	Benefit: 75% = \$118.80 85% = \$134.65
1:56 HOURS TO	O 2:00 HOURS (8 basic units)
Fee: \$158.40	Benefit: 75% = \$118.80 85% = \$134.65
2:01 HOURS TO	O 2:10 HOURS (9 basic units)
Fee: \$178.20	Benefit: 75% = \$133.65 85% = \$151.50
2:11 HOURS TO	O 2:20 HOURS (10 basic units)
Fee: \$198.00	Benefit: 75% = \$148.50 85% = \$168.30
2:21 HOURS TO	O 2:30 HOURS (11 basic units)
Fee: \$217.80	Benefit: 75% = \$163.35 85% = \$185.15
2:31 HOURS TO	O 2:40 HOURS (12 basic units)
Fee: \$237.60	Benefit: 75% = \$178.20 85% = \$202.00
2:41 HOURS TO	O 2:50 HOURS (13 basic units)
Fee: \$257.40	Benefit: 75% = \$193.05 85% = \$218.80
2:51 HOURS TO	O 3:00 HOURS (14 basic units)
Fee: \$277.20	Benefit: 75% = \$207.90 85% = \$235.65
3:01 HOURS TO	O 3:10 HOURS (15 basic units)
Fee: \$297.00	Benefit: 75% = \$222.75 85% = \$252.45
3:11 HOURS TO	O 3:20 HOURS (16 basic units)
Fee: \$316.80	Benefit: 75% = \$237.60 85% = \$269.30
	1:26 HOURS TO Fee: \$118.80 1:31 HOURS TO Fee: \$138.60 1:36 HOURS TO Fee: \$138.60 1:41 HOURS TO Fee: \$138.60 1:46 HOURS TO Fee: \$158.40 1:51 HOURS TO Fee: \$158.40 1:56 HOURS TO Fee: \$158.40 2:01 HOURS TO Fee: \$178.20 2:11 HOURS TO Fee: \$178.20 2:11 HOURS TO Fee: \$217.80 2:31 HOURS TO Fee: \$237.60 2:41 HOURS TO Fee: \$237.60 2:41 HOURS TO Fee: \$257.40 2:51 HOURS TO Fee: \$277.20 3:01 HOURS TO Fee: \$297.00 3:11 HOURS TO

LLIGID	LL SLIVICL		ZI. ANALSTIILSIA/FLKI USION TIML UNITS
	3:21 HOURS TO	O 3:30 HOURS (17 basic unit	ts)
23117	Fee: \$336.60	Benefit: 75% = \$252.45	85% = \$286.15
	3:31 HOURS TO	O 3:40 HOURS (18 basic unit	ts)
23118	Fee: \$356.40	Benefit: 75% = \$267.30	85% = \$302.95
	3:41 HOURS TO	O 3:50 HOURS (19 basic unit	is)
23119	Fee: \$376.20	Benefit: 75% = \$282.15	85% = \$319.80
	3:51 HOURS TO	O 4:00 HOURS (20 basic unit	ts)
23121	Fee: \$396.00	Benefit: 75% = \$297.00	85% = \$336.60
	4:01 HOURS TO	O 4:10 HOURS (21 basic unit	ts)
23170	Fee: \$415.80	Benefit: 75% = \$311.85	85% = \$353.45
	4:11 HOURS TO	O 4:20 HOURS (22 basic unit	ts)
23180	Fee: \$435.60	Benefit: 75% = \$326.70	85% = \$370.30
	4:21 HOURS TO	O 4:30 HOURS (23 basic unit	ts)
23190	Fee: \$455.40	Benefit: 75% = \$341.55	85% = \$387.10
	4:31 HOURS TO	O 4:40 HOURS (24 basic unit	ts)
23200	Fee: \$475.20	Benefit: 75% = \$356.40	85% = \$403.95
	4:41 HOURS TO	O 4:50 HOURS (25 basic unit	ts)
23210	Fee: \$495.00	Benefit: 75% = \$371.25	85% = \$420.75
	4:51 HOURS TO	O 5:00 HOURS (26 basic unit	ts)
23220	Fee: \$514.80	Benefit: 75% = \$386.10	85% = \$437.60
	5:01 HOURS TO	O 5:10 HOURS (27 basic unit	ts)
23230	Fee: \$534.60	Benefit: 75% = \$400.95	85% = \$454.45
	5:11 HOURS TO	O 5:20 HOURS (28 basic unit	is)
23240	Fee: \$554.40	Benefit: 75% = \$415.80	85% = \$471.25
	5:21 HOURS TO	O 5:30 HOURS (29 basic unit	is)
23250	Fee: \$574.20	Benefit: 75% = \$430.65	85% = \$490.80
	5:31 HOURS TO	O 5:40 HOURS (30 basic unit	is)
23260	Fee: \$594.00	Benefit: 75% = \$445.50	85% = \$510.60
	5:41 HOURS TO	O 5:50 HOURS (31 basic unit	is)
23270	Fee: \$613.80	Benefit: 75% = \$460.35	85% = \$530.40

LL SLIVICL		ZI. ANALSTIILSIA/FLKI USION TIML UNITS
(5:51 HOURS T	O 6:00 HOURS (32 basic uni	its)
Fee: \$633.60	Benefit: 75% = \$475.20	85% = \$550.20
6:01 HOURS TO	6:10 HOURS (33 basic unit	s)
Fee: \$653.40	Benefit: 75% = \$490.05	85% = \$570.00
6:11 HOURS TO	6:20 HOURS (34 basic unit	s)
Fee: \$673.20	Benefit: 75% = \$504.90	85% = \$589.80
6:21 HOURS TO	6:30 HOURS (35 basic unit	s)
Fee: \$693.00	Benefit: 75% = \$519.75	85% = \$609.60
6:31 HOURS TO	6:40 HOURS (36 basic unit	s)
Fee: \$712.80	Benefit: 75% = \$534.60	85% = \$629.40
6:41 HOURS TO	6:50 HOURS (37 basic unit	s)
Fee: \$732.60	Benefit: 75% = \$549.45	85% = \$649.20
6:51 HOURS TO	7:00 HOURS (38 basic unit	s)
Fee: \$752.40	Benefit: 75% = \$564.30	85% = \$669.00
7:01 HOURS TO	7:10 HOURS (39 basic unit	s)
Fee: \$772.20	Benefit: 75% = \$579.15	85% = \$688.80
7:11 HOURS TO	7:20 HOURS (40 basic unit	s)
Fee: \$792.00	Benefit: 75% = \$594.00	85% = \$708.60
7:21 HOURS TO	7:30 HOURS (41 basic unit	s)
Fee: \$811.80	Benefit: 75% = \$608.85	85% = \$728.40
7:31 HOURS TO	7:40 HOURS (42 basic unit	s)
Fee: \$831.60	Benefit: 75% = \$623.70	85% = \$748.20
7:41 HOURS TO	7:50 HOURS (43 basic unit	s)
Fee: \$851.40	Benefit: 75% = \$638.55	85% = \$768.00
7:51 HOURS TO	8:00 HOURS (44 basic unit	s)
Fee: \$871.20	Benefit: 75% = \$653.40	85% = \$787.80
8:01 HOURS TO	8:10 HOURS (45 basic unit	s)
Fee: \$891.00	Benefit: 75% = \$668.25	85% = \$807.60
8:11 HOURS TO	8:20 HOURS (46 basic unit	s)
Fee: \$910.80	Benefit: 75% = \$683.10	85% = \$827.40
	(5:51 HOURS TO Fee: \$633.60 6:01 HOURS TO Fee: \$653.40 6:11 HOURS TO Fee: \$673.20 6:21 HOURS TO Fee: \$693.00 6:31 HOURS TO Fee: \$712.80 6:41 HOURS TO Fee: \$732.60 6:51 HOURS TO Fee: \$732.60 7:01 HOURS TO Fee: \$752.40 7:01 HOURS TO Fee: \$772.20 7:11 HOURS TO Fee: \$792.00 7:21 HOURS TO Fee: \$811.80 7:31 HOURS TO Fee: \$831.60 7:41 HOURS TO Fee: \$831.60 7:41 HOURS TO Fee: \$851.40 7:51 HOURS TO Fee: \$871.20 8:01 HOURS TO Fee: \$871.20 8:01 HOURS TO Fee: \$891.00 8:11 HOURS TO Fee: \$891.00	(5:51 HOURS TO 6:00 HOURS (32 basic unit Fee: \$633.60

LLIGID	LL SLIVICL		21. ANALSTIILSIA/FLIN USION TIME UNITS
	8:21 HOURS TO	8:30 HOURS (47 basic uni	rts)
23430	Fee: \$930.60	Benefit: 75% = \$697.95	85% = \$847.20
	8:31 HOURS TO	8:40 HOURS (48 basic uni	rts)
23440	Fee: \$950.40	Benefit: 75% = \$712.80	85% = \$867.00
	8:41 HOURS TO	8:50 HOURS (49 basic uni	its)
23450	Fee: \$970.20	Benefit: 75% = \$727.65	85% = \$886.80
	8:51 HOURS TO	9:00 HOURS (50 basic uni	its)
23460	Fee: \$990.00	Benefit: 75% = \$742.50	85% = \$906.60
	9:01 HOURS TO	9:10 HOURS (51 basic uni	ts)
23470	Fee: \$1,009.80	Benefit: 75% = \$757.35	85% = \$926.40
	9:11 HOURS TO	9:20 HOURS (52 basic uni	its)
23480	Fee: \$1,029.60	Benefit: 75% = \$772.20	85% = \$946.20
	9:21 HOURS TO	9:30 HOURS (53 basic uni	ts)
23490	Fee: \$1,049.40	Benefit: 75% = \$787.05	85% = \$966.00
	9:31 HOURS TO	9:40 HOURS (54 basic uni	ts)
23500	Fee: \$1,069.20	Benefit: 75% = \$801.90	85% = \$985.80
	9:41 HOURS TO	9:50 HOURS (55 basic uni	ts)
23510	Fee: \$1,089.00	Benefit: 75% = \$816.75	85% = \$1005.60
	9:51 HOURS TO	10:00 HOURS (56 basic ur	nits)
23520	Fee: \$1,108.80	Benefit: 75% = \$831.60	85% = \$1025.40
	10:01 HOURS T	O 10:10 HOURS (57 basic t	units)
23530	Fee: \$1,128.60	Benefit: 75% = \$846.45	· · · · · · · · · · · · · · · · · · ·
	10:11 HOURS T	O 10:20 HOURS (58 basic u	units)
23540	Fee: \$1,148.40	Benefit: 75% = \$861.30	85% = \$1065.00
	10:21 HOURS T	O 10:30 HOURS (59 basic u	units)
23550	Fee: \$1,168.20	Benefit: 75% = \$876.15	85% = \$1084.80
	10:31 HOURS T	O 10:40 HOURS (60 basic u	units)
23560	Fee: \$1,188.00	Benefit: 75% = \$891.00	85% = \$1104.60
	10:41 HOURS T	O 10:50 HOURS (61 basic u	units)
23570	Fee: \$1,207.80	Benefit: 75% = \$905.85	85% = \$1124.40

LLIGID	LL SLIVICL		21. ANALSTITESIA/FERT USION TIME UNITS
	10:51 HOURS TO	O 11:00 HOURS (62 basic ur	nits)
23580	Fee: \$1,227.60	Benefit: 75% = \$920.70	85% = \$1144.20
	11:01 HOURS TO	O 11:10 HOURS (63 basic ur	nits)
23590	Fee: \$1,247.40	Benefit: 75% = \$935.55	85% = \$1164.00
	11:11 HOURS TO	O 11:20 HOURS (64 basic ur	nits)
23600	Fee: \$1,267.20	Benefit: 75% = \$950.40	85% = \$1183.80
	11:21 HOURS TO	O 11:30 HOURS (65 basic ur	nits)
23610	Fee: \$1,287.00	Benefit: 75% = \$965.25	85% = \$1203.60
	11:31 HOURS TO	O 11:40 HOURS (66 basic ur	nits)
23620	Fee: \$1,306.80	Benefit: 75% = \$980.10	85% = \$1223.40
	11:41 HOURS TO	O 11:50 HOURS (67 basic ur	nits)
23630	Fee: \$1,326.60	Benefit: 75% = \$994.95	85% = \$1243.20
	11:51 HOURS TO	O 12:00 HOURS (68 basic ur	nits)
23640	Fee: \$1,346.40	Benefit: 75% = \$1009.80	85% = \$1263.00
	12:01 HOURS TO	O 12:10 HOURS (69 basic ur	nits)
23650	Fee: \$1,366.20	Benefit: 75% = \$1024.65	85% = \$1282.80
	12:11 HOURS TO	O 12:20 HOURS (70 basic ur	nits)
23660	Fee: \$1,386.00	Benefit: 75% = \$1039.50	85% = \$1302.60
	12:21 HOURS TO	O 12:30 HOURS (71 basic ur	nits)
23670	Fee: \$1,405.80	Benefit: 75% = \$1054.35	85% = \$1322.40
	12:31 HOURS TO	O 12:40 HOURS (72 basic ur	nits)
23680	Fee: \$1,425.60	Benefit: 75% = \$1069.20	85% = \$1342.20
	12:41 HOURS TO	O 12:50 HOURS (73 basic ur	nits)
23690	Fee: \$1,445.40	Benefit: 75% = \$1084.05	85% = \$1362.00
	12:51 HOURS TO	O 13:00 HOURS (74 basic ur	nits)
23700	Fee: \$1,465.20	Benefit: 75% = \$1098.90	85% = \$1381.80
	13:01 HOURS TO	O 13:10 HOURS (75 basic ur	nits)
23710	Fee: \$1,485.00	Benefit: 75% = \$1113.75	85% = \$1401.60
	13:11 HOURS TO	O 13:20 HOURS (76 basic ur	nits)
23720	Fee: \$1,504.80	Benefit: 75% = \$1128.60	85% = \$1421.40

ELIGIDI	LE SERVICE		21. ANAESTHESIA/PERFUSION TIME UNITS
	13:21 HOURS TO	13:30 HOURS (77 basic un	nits)
23730	Fee: \$1,524.60	Benefit: 75% = \$1143.45	85% = \$1441.20
	13:31 HOURS TO	13:40 HOURS (78 basic un	nits)
23740	Fee: \$1,544.40	Benefit: 75% = \$1158.30	85% = \$1461.00
	13:41 HOURS TO	13:50 HOURS (79 basic un	nits)
23750	Fee: \$1,564.20	Benefit: 75% = \$1173.15	85% = \$1480.80
	13:51 HOURS TO	14:00 HOURS (80 basic un	nits)
23760	Fee: \$1,584.00	Benefit: 75% = \$1188.00	85% = \$1500.60
	14:01 HOURS TO	14:10 HOURS (81 basic un	nits)
23770	Fee: \$1,603.80	Benefit: 75% = \$1202.85	85% = \$1520.40
	14:11 HOURS TO	14:20 HOURS (82 basic un	nits)
23780	Fee: \$1,623.60	Benefit: 75% = \$1217.70	85% = \$1540.20
	14:21 HOURS TO	14:30 HOURS (83 basic un	nits)
23790	Fee: \$1,643.40	Benefit: 75% = \$1232.55	85% = \$1560.00
	14:31 HOURS TO	14:40 HOURS (84 basic un	nits)
23800	Fee: \$1,663.20	Benefit: 75% = \$1247.40	85% = \$1579.80
	14:41 HOURS TO	14:50 HOURS (85 basic un	nits)
23810	Fee: \$1,683.00	Benefit: 75% = \$1262.25	85% = \$1599.60
	14:51 HOURS TO	15:00 HOURS (86 basic un	nits)
23820	Fee: \$1,702.80	Benefit: 75% = \$1277.10	85% = \$1619.40
	15:01 HOURS TO	15:10 HOURS (87 basic un	nits)
23830	Fee: \$1,722.60	Benefit: 75% = \$1291.95	85% = \$1639.20
	15:11 HOURS TO	15:20 HOURS (88 basic un	nits)
23840	Fee: \$1,742.40	Benefit: 75% = \$1306.80	85% = \$1659.00
	15:21 HOURS TO	15:30 HOURS (89 basic un	nits)
23850	Fee: \$1,762.20	Benefit: 75% = \$1321.65	85% = \$1678.80
	15:31 HOURS TO	15:40 HOURS (90 basic un	nits)
23860	Fee: \$1,782.00	Benefit: 75% = \$1336.50	85% = \$1698.60
	15:41 HOURS TO	15:50 HOURS (91 basic un	nits)
23870	Fee: \$1,801.80	Benefit: 75% = \$1351.35	85% = \$1718.40

LL SLIVICE		21. ANALSTILSIA/FLKI USION TIME UNITS
15:51 HOURS TO	16:00 HOURS (92 basic u	nits)
Fee: \$1,821.60	Benefit: 75% = \$1366.20	85% = \$1738.20
16:01 HOURS TO	16:10 HOURS (93 basic u	nits)
Fee: \$1,841.40	Benefit: 75% = \$1381.05	85% = \$1758.00
16:11 HOURS TO	16:20 HOURS (94 basic ui	nits)
Fee: \$1,861.20	Benefit: 75% = \$1395.90	85% = \$1777.80
16:21 HOURS TO	16:30 HOURS (95 basic ui	nits)
Fee: \$1,881.00	Benefit: 75% = \$1410.75	85% = \$1797.60
16:31 HOURS TO	16:40 HOURS (96 basic u	nits)
Fee: \$1,900.80	Benefit: 75% = \$1425.60	85% = \$1817.40
16:41 HOURS TO	16:50 HOURS (97 basic ui	nits)
Fee: \$1,920.60	Benefit: 75% = \$1440.45	85% = \$1837.20
16:51 HOURS TO	17:00 HOURS (98 basic ui	nits)
Fee: \$1,940.40	Benefit: 75% = \$1455.30	85% = \$1857.00
17:01 HOURS TO	17:10 HOURS (99 basic ui	nits)
Fee: \$1,960.20	Benefit: 75% = \$1470.15	85% = \$1876.80
17:11 HOURS TO	17:20 HOURS (100 basic 1	units)
Fee: \$1,980.00	Benefit: 75% = \$1485.00	85% = \$1896.60
17:21 HOURS TO	17:30 HOURS (101 basic u	units)
Fee: \$1,999.80	Benefit: 75% = \$1499.85	85% = \$1916.40
17:31 HOURS TO	17:40 HOURS (102 basic u	units)
Fee: \$2,019.60	Benefit: 75% = \$1514.70	85% = \$1936.20
17:41 HOURS TO	17:50 HOURS (103 basic t	units)
Fee: \$2,039.40	Benefit: 75% = \$1529.55	85% = \$1956.00
17:51 HOURS TO	18:00 HOURS (104 basic 1	units)
Fee: \$2,059.20	Benefit: 75% = \$1544.40	85% = \$1975.80
18:01 HOURS TO	18:10 HOURS (105 basic t	units)
Fee: \$2,079.00	Benefit: 75% = \$1559.25	85% = \$1995.60
18:11 HOURS TO	18:20 HOURS (106 basic 1	units)
Fee: \$2,098.80	Benefit: 75% = \$1574.10	85% = \$2015.40
	15:51 HOURS TO Fee: \$1,821.60 16:01 HOURS TO Fee: \$1,841.40 16:11 HOURS TO Fee: \$1,861.20 16:21 HOURS TO Fee: \$1,881.00 16:31 HOURS TO Fee: \$1,900.80 16:41 HOURS TO Fee: \$1,920.60 16:51 HOURS TO Fee: \$1,920.60 16:51 HOURS TO Fee: \$1,940.40 17:01 HOURS TO Fee: \$1,960.20 17:11 HOURS TO Fee: \$1,980.00 17:21 HOURS TO Fee: \$1,999.80 17:31 HOURS TO Fee: \$2,019.60 17:41 HOURS TO Fee: \$2,019.60 17:51 HOURS TO Fee: \$2,039.40 17:51 HOURS TO Fee: \$2,039.40 17:51 HOURS TO Fee: \$2,059.20 18:01 HOURS TO Fee: \$2,079.00 18:11 HOURS TO	15:51 HOURS TO 16:00 HOURS (92 basic to Fee: \$1,821.60 Benefit: 75% = \$1366.20 16:01 HOURS TO 16:10 HOURS (93 basic to Fee: \$1,841.40 Benefit: 75% = \$1381.05 16:11 HOURS TO 16:20 HOURS (94 basic to Fee: \$1,861.20 Benefit: 75% = \$1395.90 16:21 HOURS TO 16:30 HOURS (95 basic to Fee: \$1,881.00 Benefit: 75% = \$1410.75 16:31 HOURS TO 16:40 HOURS (96 basic to Fee: \$1,900.80 Benefit: 75% = \$1425.60 16:41 HOURS TO 16:50 HOURS (97 basic to Fee: \$1,920.60 Benefit: 75% = \$1440.45 16:51 HOURS TO 17:00 HOURS (98 basic to Fee: \$1,940.40 Benefit: 75% = \$1455.30 17:01 HOURS TO 17:10 HOURS (99 basic to Fee: \$1,960.20 Benefit: 75% = \$1470.15 17:11 HOURS TO 17:20 HOURS (100 basic to Fee: \$1,980.00 Benefit: 75% = \$1485.00 17:21 HOURS TO 17:30 HOURS (101 basic to Fee: \$1,999.80 Benefit: 75% = \$1499.85 17:31 HOURS TO 17:50 HOURS (103 basic to Fee: \$2,019.60 Benefit: 75% = \$1514.70 17:41 HOURS TO 17:50 HOURS (103 basic to Fee: \$2,039.40 Benefit: 75% = \$1592.55 17:51 HOURS TO 18:00 HOURS (105 basic to Fee: \$2,059.20 Benefit: 75% = \$1559.25 18:01 HOURS TO 18:20 HOURS (106 basic to Fee: \$2,079.00 Benefit: 75% = \$1559.25 18:11 HOURS TO 18:20 HOURS (106 basic to Fee: \$2,079.00 Benefit: 75% = \$1559.25 18:11 HOURS TO 18:20 HOURS (106 basic to Fee: \$2,079.00 Benefit: 75% = \$1559.25 18:11 HOURS TO 18:20 HOURS (106 basic to Fee: \$2,079.00 Benefit: 75% = \$1559.25 18:11 HOURS TO 18:20 HOURS (106 basic to Fee: \$2,079.00 Benefit: 75% = \$1559.25 18:11 HOURS TO 18:20 HOURS (106 basic to Fee: \$2,079.00 Benefit: 75% = \$1559.25 18:11 HOURS TO 18:20 HOURS (106 basic to Fee: \$2,079.00 Benefit: 75% = \$1559.25 18:11 HOURS TO 18:20 HOURS (106 basic to Fee: \$2,079.00 Benefit: 75% = \$1559.25 18:11 HOURS TO 18:20 HOURS (106 basic to Fee: \$2,079.00 Benefit: 75% = \$1559.25 18:11 HOURS TO 18:20 HOURS (106 basic to Fee: \$2,079.00 Benefit: 75% = \$1559.25 18:11 HOURS TO 18:20 HOURS (106 basic to Fee: \$2,079.00 Benefit: 75% = \$

18:21 HOURS TO 18:30 HOURS (107 basic units) Fee: \$2,118.60	
18:31 HOURS TO 18:40 HOURS (108 basic units) 24104	
24104 Fee: \$2,138.40 Benefit: 75% = \$1603.80 85% = \$2055.00 18:41 HOURS TO 18:50 HOURS (109 basic units) Fee: \$2,158.20 Benefit: 75% = \$1618.65 85% = \$2074.80	
18:41 HOURS TO 18:50 HOURS (109 basic units) Fee: \$2,158.20 Benefit: 75% = \$1618.65 85% = \$2074.80	
24105 Fee: \$2,158.20 Benefit: 75% = \$1618.65 85% = \$2074.80	
18:51 HOURS TO 10:00 HOURS (110 basic units)	
16.31 HOURS 10 19.00 HOURS (110 basic units)	
24106 Fee: \$2,178.00 Benefit: 75% = \$1633.50 85% = \$2094.60	
19:01 HOURS TO 19:10 HOURS (111 basic units)	
Fee: \$2,197.80 Benefit: 75% = \$1648.35 85% = \$2114.40	
19:11 HOURS TO 19:20 HOURS (112 basic units)	
24108 Fee: \$2,217.60 Benefit: 75% = \$1663.20 85% = \$2134.20	
19:21 HOURS TO 19:30 HOURS (113 basic units)	
24109 Fee: \$2,237.40 Benefit: 75% = \$1678.05 85% = \$2154.00	
19:31 HOURS TO 19:40 HOURS (114 basic units)	
Fee: \$2,257.20 Benefit: 75% = \$1692.90 85% = \$2173.80	
19:41 HOURS TO 19:50 HOURS (115 basic units)	
24111 Fee: \$2,277.00 Benefit: 75% = \$1707.75 85% = \$2193.60	
19:51 HOURS TO 20:00 HOURS (116 basic units)	
24112 Fee: \$2,296.80 Benefit: 75% = \$1722.60 85% = \$2213.40	
20:01 HOURS TO 20:10 HOURS (117 basic units)	
24113 Fee: \$2,316.60 Benefit: 75% = \$1737.45 85% = \$2233.20	
20:11 HOURS TO 20:20 HOURS (118 basic units)	
24114 Fee: \$2,336.40 Benefit: 75% = \$1752.30 85% = \$2253.00	
20:21 HOURS TO 20:30 HOURS (119 basic units)	
24115 Fee: \$2,356.20 Benefit: 75% = \$1767.15 85% = \$2272.80	
20:31 HOURS TO 20:40 HOURS (120 basic units)	
24116 Fee: \$2,376.00 Benefit: 75% = \$1782.00 85% = \$2292.60	
20:41 HOURS TO 20:50 HOURS (121 basic units)	
Pee: \$2,395.80 Benefit: 75% = \$1796.85 85% = \$2312.40	

LLIGID	LL SLIVICL		21. ANALSTITESIA/FERT USION TIME UNITS
	20:51 HOURS T	O 21:00 HOURS (122 basic t	units)
24118	Fee: \$2,415.60	Benefit: 75% = \$1811.70	85% = \$2332.20
	21:01 HOURS T	O 21:10 HOURS (123 basic u	units)
24119	Fee: \$2,435.40	Benefit: 75% = \$1826.55	85% = \$2352.00
	21:11 HOURS T	O 21:20 HOURS (124 basic 1	units)
24120	Fee: \$2,455.20	Benefit: 75% = \$1841.40	85% = \$2371.80
	21:21 HOURS T	O 21:30 HOURS (125 basic u	units)
24121	Fee: \$2,475.00	Benefit: 75% = \$1856.25	85% = \$2391.60
	21:31 HOURS T	O 21:40 HOURS (126 basic u	units)
24122	Fee: \$2,494.80	Benefit: 75% = \$1871.10	85% = \$2411.40
	21:41 HOURS T	O 21:50 HOURS (127 basic u	units)
24123	Fee: \$2,514.60	Benefit: 75% = \$1885.95	85% = \$2431.20
	21:51 HOURS T	O 22:00 HOURS (128 basic 1	units)
24124	Fee: \$2,534.40	Benefit: 75% = \$1900.80	85% = \$2451.00
	22:01 HOURS T	O 22:10 HOURS (129 basic u	units)
24125	Fee: \$2,554.20	Benefit: 75% = \$1915.65	85% = \$2470.80
	22:11 HOURS T	O 22:20 HOURS (130 basic u	units)
24126	Fee: \$2,574.00	Benefit: 75% = \$1930.50	85% = \$2490.60
	22:21 HOURS T	O 22:30 HOURS (131 basic t	units)
24127	Fee: \$2,593.80	Benefit: 75% = \$1945.35	85% = \$2510.40
	22:31 HOURS T	O 22:40 HOURS (132 basic t	units)
24128	Fee: \$2,613.60	Benefit: 75% = \$1960.20	85% = \$2530.20
	22:41 HOURS T	O 22:50 HOURS (133 basic t	units)
24129	Fee: \$2,633.40	Benefit: 75% = \$1975.05	85% = \$2550.00
	22:51 HOURS T	O 23:00 HOURS (134 basic t	units)
24130	Fee: \$2,653.20	Benefit: 75% = \$1989.90	85% = \$2569.80
	23:01 HOURS T	O 23:10 HOURS (135 basic t	units)
24131	Fee: \$2,673.00	Benefit: 75% = \$2004.75	85% = \$2589.60
	23:11 HOURS T	O 23:20 HOURS (136 basic t	units)
24132	Fee: \$2,692.80	Benefit: 75% = \$2019.60	85% = \$2609.40

21. ANAESTHESIA/PERFUSION TIME UNITS

	23:21 HOURS TO	O 23:30 HOURS (137 basic t	units)
24133	Fee: \$2,712.60	Benefit: 75% = \$2034.45	85% = \$2629.20
	23:31 HOURS TO	O 23:40 HOURS (138 basic u	units)
24134	Fee: \$2,732.40	Benefit: 75% = \$2049.30	85% = \$2649.00
	23:41 HOURS TO	O 23:50 HOURS (139 basic u	units)
24135	Fee: \$2,752.20	Benefit: 75% = \$2064.15	85% = \$2668.80
	23:51 HOURS TO	O 24:00 HOURS (140 basic u	units)
24136	Fee: \$2,772.00	Benefit: 75% = \$2079.00	85% = \$2688.60

T10. RELATIVE VALUE GUIDE FOR ANAESTHESIA - MEDICARE BENEFITS ARE ONLY PAYABLE FOR ANAESTHESIA PERFORMED IN ASSOCIATION WITH AN ELIGIBLE SERVICE

22. ANAESTHESIA/PERFUSION MODIFYING UNITS - PHYSICAL STATUS

LLIGID	LE SERVICE UNITS - PHYSICAL STATUS
	Group T10. Relative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For Anaesthesia Performed In Association With An Eligible Service
	Subgroup 22. Anaesthesia/Perfusion Modifying Units - Physical Status
	ANAESTHESIA, PERFUSION or ASSISTANCE AT ANAESTHESIA
	(a) for anaesthesia performed in association with an item in the range 20100 to 21997 or 22900 to 22905; or
	(b) for perfusion performed in association with item 22060; or
	(c) for assistance at anaesthesia performed in association with items 25200 to 25205
	Where the patient has severe systemic disease equivalent to ASA physical status indicator 3 (1 basic units)
25000	(See para TN.10.3 of explanatory notes to this Category) Fee: \$19.80 Benefit: 75% = \$14.85 85% = \$16.85
	Where the patient has severe systemic disease which is a constant threat to life equivalent to ASA physical status indicator 4 (2 basic units)
25005	(See para TN.10.3 of explanatory notes to this Category) Fee: \$39.60 Benefit: 75% = \$29.70 85% = \$33.70
	For a patient who is not expected to survive for 24 hours with or without the operation, equivalent to ASA physical status indicator 5 (3 basic units)
25010	(See para TN.10.3 of explanatory notes to this Category) Fee: \$59.40 Benefit: 75% = \$44.55 85% = \$50.50

PERFO	PAYABLE FOR ANAESTHESIA RMED IN ASSOCIATION WITH AN 23. ANAESTHESIA/PERFUSION MODIFYING LE SERVICE UNITS - OTHER		
	Group T10. Relative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For Anaesthesia Performed In Association With An Eligible Service		
	Subgroup 23. Anaesthesia/Perfusion Modifying Units - Other		
	ANAESTHESIA, PERFUSION OR ASSISTANCE AT ANAESTHESIA		
	- where the patient is less than 12 months of age or 70 years or greater (1 basic units)		
25015	Fee: \$19.80 Benefit: 75% = \$14.85 85% = \$16.85		
	ANAESTHESIA, PERFUSION OR ASSISTANCE AT ANAESTHESIA - where the patient requires immediate treatment without which there would be significant threat to life or body part - not being a service associated with a service to which item 25025 or 25030 or 25050 applies (2 basic units)		
25020	(See para TN.10.3 of explanatory notes to this Category) Fee: \$39.60 Benefit: 75% = \$29.70 85% = \$33.70		
ANAES ONLY F PERFO	ELATIVE VALUE GUIDE FOR THESIA - MEDICARE BENEFITS ARE PAYABLE FOR ANAESTHESIA RMED IN ASSOCIATION WITH AN 24. ANAESTHESIA AFTER HOURS EMERGENCY LE SERVICE MODIFIER		
	Group T10. Relative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For Anaesthesia Performed In Association With An Eligible Service		
	Subgroup 24. Anaesthesia After Hours Emergency Modifier		
	EMERGENCY ANAESTHESIA performed in the after hours period where the patient requires immediate treatment without which there would be significant threat to life or body part and where more than 50% of the time for the emergency anaesthesia service is provided in the after hours period, being the period from 8pm to 8am on any weekday, or at any time on a Saturday, a Sunday or a public holiday		

(See para TN.10.3 of explanatory notes to this Category)

Derived Fee: An additional amount of 50% of the fee for the anaesthetic service. That is: (a) an anaesthesia item/s in the range 20100 - 21997 or 22900, plus (b) an item in the range 23010 - 24136, plus (c) where applicable, an item in the range 25000-25015, plus (d) where performed, any associated therapeutic or diagnostic service/s in

- not being a service associated with a service to which item 25020, 25030 or 25050 applies (0 basic

the range 22001-22051

25025

ASSISTANCE AT AFTER HOURS EMERGENCY ANAESTHESIA where the patient requires immediate treatment without which there would be significant threat to life or body part and where more than 50% of the time for which the assistant is in professional attendance on the patient is provided in the after hours period, being the period from 8pm to 8am on any weekday, or at any time on a Saturday, a Sunday or a public holiday - not being a service associated with a service to which item 25020, 25025 or 25050 applies (0 basic units)

(See para TN.10.3 of explanatory notes to this Category)

25030 **Derived Fee:** An additional amount of 50% of the fee for assistance at anaesthesia. That is:

24. ANAESTHESIA AFTER HOURS EMERGENCY MODIFIER

- (a) an assistant anaesthesia item in the range 25200 25205, plus
- (b) an item in the range 23010 24136, plus
- (c) where applicable, an item in the range 25000-25015, plus
- (d) where performed, any associated therapeutic or diagnostic service/s in the range 22001-22051

T10. RELATIVE VALUE GUIDE FOR ANAESTHESIA - MEDICARE BENEFITS ARE ONLY PAYABLE FOR ANAESTHESIA PERFORMED IN ASSOCIATION WITH AN ELIGIBLE SERVICE

25. PERFUSION AFTER HOURS EMERGENCY MODIFIER

	Group T10. Relative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For Anaesthesia Performed In Association With An Eligible Service
	Subgroup 25. Perfusion After Hours Emergency Modifier
	AFTER HOURS EMERGENCY PERFUSION where the patient requires immediate treatment without which there would be significant threat to life or body part and where more than 50% of the perfusion service is provided in the after hours period, being the period from 8pm to 8am on any weekday, or at any time on a Saturday, a Sunday or a public holiday - not being a service associated with a service to which item 25020, 25025 or 25030 applies (0 basic units)
	(See para TN.10.3 of explanatory notes to this Category) Derived Fee: An additional amount of 50% of the fee for the perfusion service. That is: (a) item 22060, plus (b) an item in the range 23010 - 24136, plus (c) where applicable, an item in the range 25000 - 25015, plus
25050	(d) where performed, any associated therapeutic or diagnostic service/s in the range 22001-22051 or 22065-22075

T10. RELATIVE VALUE GUIDE FOR ANAESTHESIA - MEDICARE BENEFITS ARE ONLY PAYABLE FOR ANAESTHESIA PERFORMED IN ASSOCIATION WITH AN ELIGIBLE SERVICE

26. ASSISTANCE AT ANAESTHESIA

	Group T10. Relative Value Guide For Anaesthesia - Medicare Benefits Are Only Payable For Anaesthesia Performed In Association With An Eligible Service
	Subgroup 26. Assistance At Anaesthesia
	ASSISTANCE IN THE ADMINISTRATION OF ANAESTHESIA on a patient in imminent danger of death requiring continuous life saving emergency treatment, to the exclusion of all other patients (5 basic units)
	(See para TN.10.9 of explanatory notes to this Category)
25200	Derived Fee: An amount of \$99.0 (5 basic units) plus an item in the range 23010 - 24136 plus, where applicable - an item in the range 25000 - 25020 plus, where performed, any associated therapeutic or diagnostic service/s in the range 22001 - 22051
	ASSISTANCE IN THE ADMINISTRATION OF ELECTIVE ANAESTHESIA where:
25205	(i) the patient has complex airway problems; or

26. ASSISTANCE AT ANAESTHESIA

	• • \	.1	,			1	1	
- 11	ii)	the	nafient is	s a neonate	αr a	complex	paediatric (case. or
- 11	11,	uic	patient it	o a moomate	OI u	COMPLEA	pacaratre	case, or

- (iii) there is anticipated to be massive blood loss (greater than 50% of blood volume) during the procedure; or
- (iv) the patient is critically ill, with multiple organ failure; or
- (v) where the anaesthesia time exceeds 6 hours

and the assistance is provided to the exclusion of all other patients (5 basic units)

(See para TN.10.9 of explanatory notes to this Category)

Derived Fee: An amount of \$99.0 (5 basic units) plus an item in the range 23010 - 24136 plus, where applicable - an item in the range 25000 - 25020 plus, where performed, any associated therapeutic or diagnostic service/s in the range 22001 - 22051

	an item in the range 25000 - 25020 plus, where performed, any associated therapeutic or diagnostic service/s in the range 22001 - 22051
T11. B0	OTULINUM TOXIN INJECTIONS
	Group T11. Botulinum Toxin Injections
	Botulinum Toxin Type A Purified Neurotoxin Complex (Botox), injection of, for the treatment of hemifacial spasm in a patient who is at least 12 years of age, including all such injections on any one day
18350	(See para TN.11.1 of explanatory notes to this Category) Fee: \$124.85 Benefit: 75% = \$93.65 85% = \$106.15
	Clostridium Botulinum Type A Toxin-Haemagglutin Complex (Dysport), injection of, for the treatment of hemifacial spasm in a patient who is at least 18 years of age, including all such injections on any one day
18351	(See para TN.11.1 of explanatory notes to this Category) Fee: \$124.85 Benefit: 75% = \$93.65 85% = \$106.15
	Botulinum Toxin Type A Purified Neurotoxin Complex (Botox) or Clostridium Botulinum Type A Toxin-Haemagglutin Complex (Dysport) or IncobotulinumtoxinA (Xeomin), injection of, for the treatment of cervical dystonia (spasmodic torticollis), including all such injections on any one day
18353	(See para TN.11.1 of explanatory notes to this Category) Fee: \$249.75 Benefit: 75% = \$187.35 85% = \$212.30
	Botulinum Toxin Type A Purified Neurotixin Complex (Botox) or Clostridium Botulinum Type A Toxin-Haemagglutin Complex (Dysport), injection of, for the treatment of dynamic equinus foot deformity (including equinovarus and equinovalgus) due to spasticity in an ambulant cerebral palsy patient, if:
	(a) the patient is at least 2 years of age; and
	(b) the treatment is for all or any of the muscles subserving one functional activity and supplied by one motor nerve, with a maximum of 4 sets of injections for the patient on any one day (with a maximum of 2 sets of injections for each lower limb), including all injections per set (Anaes.)
18354	(See para TN.11.1 of explanatory notes to this Category) Fee: \$124.85 Benefit: 75% = \$93.65 85% = \$106.15
18360	Botulinum Toxin Type A Purified Neurotoxin Complex (Botox), or Clostridium Botulinum Type A

T11. BOT	ULINUM TOXIN INJECTIONS
	Toxin Haemagglutinin Complex (Dysport), injection of, for the treatment of moderate to severe focal spasticity, if:
	(a) the patient is at least 18 years of age; and
	(b) the spasticity is associated with a previously diagnosed neurological disorder; and
	(c) treatment is provided as:
	(i) second line therapy when standard treatment for the conditions has failed; or
	(ii) an adjunct to physical therapy; and
	(d) the treatment is for all or any of the muscles subserving one functional activity and supplied by one motor nerve, with a maximum of 4 sets of injections for the patient on any one day (with a maximum of 2 sets of injections for each limb), including all injections per set; and
	(e) the treatment is not provided on the same occasion as a service mentioned in item 18365
	(See para TN.11.1 of explanatory notes to this Category) Fee: \$124.85 Benefit: 75% = \$93.65 85% = \$106.15
	Botulinum Toxin Type A Purified Neurotoxin Complex (Botox), injection of, for the treatment of moderate to severe upper limb spasticity due to cerebral palsy if:
	(a) the patient is at least 2 years of age, and
	(b) for a patient who is at least 18 years of age - before the patient turned 18, the patient had commenced treatment for the spasticity with botulinum toxin supplied under the pharmaceutical benefits scheme; and
	(c) the treatment is for all or any of the muscles subserving one functional activity and supplied by one motor nerve, with a maximum of 4 sets of injections for the patient on any one day (with a maximum of 2 sets of injections for each upper limb), including all injections per set (Anaes.)
18361	(See para TN.11.1 of explanatory notes to this Category) Fee: \$124.85 Benefit: 75% = \$93.65 85% = \$106.15
	Botulinum Toxin type A Purified Neurotoxin Complex (Botox), injection of, for the treatment of severe primary axillary hyperhidrosis, including all injections on any one day, if:
	(a) the patient is at least 12 years of age; and
	(b) the patient has been intolerant of, or has not responded to, topical aluminium chloride hexahydrate; and
	(c) the patient has not had treatment with botulinum toxin within the immediately preceding 4 months; and
	(d) if the patient has had treatment with botulinum toxin within the previous 12 months - the patient had treatment on no more than 2 separate occasions (Anaes.)
18362	(See para TN.11.1 of explanatory notes to this Category) Fee: \$246.70 Benefit: 75% = \$185.05 85% = \$209.70
18365	Botulinum Toxin Type A Purified Neurotoxin Complex (Botox) or Clostridium Botulinum Type A Toxin-Haemagglutin Complex (Dysport) or IncobotulinumtoxinA (Xeomin), injection of, for the

T11. BO	TULINUM TOXIN INJECTIONS
	treatment of moderate to severe spasticity of the upper limb following a stroke, if:
	(a) the patient is at least 18 years of age; and
	(b) treatment is provided as:
	(i) second line therapy when standard treatment for the condition has failed; or
	(ii) an adjunct to physical therapy; and
	(c) the patient does not have established severe contracture in the limb that is to be treated; and
	(d) the treatment is for all or any of the muscles subserving one functional activity and supplied by one motor nerve, with a maximum of 4 sets of injections for the patient on any one day (with a maximum of 2 sets of injections for each upper limb), including all injections per set; and
	(e) for a patient who has received treatment on 2 previous separate occasions - the patient has responded to the treatment
	(See para TN.11.1 of explanatory notes to this Category) Fee: \$124.85 Benefit: 75% = \$93.65 85% = \$106.15
	Botulinum Toxin Type A Purified Neurotoxin Complex (Botox), injection of, for the treatment of strabismus, including all such injections on any one day and associated electromyography (Anaes.)
18366	(See para TN.11.1 of explanatory notes to this Category) Fee: \$156.40 Benefit: 75% = \$117.30 85% = \$132.95
	Botulinum Toxin Type A Purified Neurotoxin Complex (Botox), injection of, for the treatment of spasmodic dysphonia, including all such injections on any one day
18368	(See para TN.11.1 of explanatory notes to this Category) Fee: \$267.05 Benefit: 75% = \$200.30 85% = \$227.00
	Clostridium Botulinum Type A Toxin-Haemagglutin Complex (Dysport) or IncobotulinumtoxinA (Xeomin), injection of, for the treatment of unilateral blepharospasm in a patient who is at least 18 years of age, including all such injections on any one day (Anaes.)
18369	(See para TN.11.1 of explanatory notes to this Category) Fee: \$45.05 Benefit: 75% = \$33.80 85% = \$38.30
	Botulinum Toxin Type A Purified Neurotoxin Complex (Botox), injection of, for the treatment of unilateral blepharospasm in a patient who is at least 12 years of age, including all such injections on any one day (Anaes.)
18370	(See para TN.11.1 of explanatory notes to this Category) Fee: \$45.05 Benefit: 75% = \$33.80 85% = \$38.30
	Botulinum Toxin Type A Purified Neurotoxin Complex (Botox), injection of, for the treatment of bilateral blepharospasm, in a patient who is at least 12 years of age; including all such injections on any one day (Anaes.)
18372	(See para TN.11.1 of explanatory notes to this Category) Fee: \$124.85 Benefit: 75% = \$93.65 85% = \$106.15
	Clostridium Botulinum Type A Toxin-Haemagglutin Complex (Dysport) or IncobotulinumtoxinA (Xeomin), injection of, for the treatment of bilateral blepharospasm in a patient who is at least 18 years of age, including all such injections on any one day (Anaes.)
18374	(See para TN.11.1 of explanatory notes to this Category)

T11. BOT	ULINUM TOXIN INJECTIONS
	Fee: \$124.85 Benefit: 75% = \$93.65 85% = \$106.15
	Botulinum Toxin Type A Purified Neurotoxin Complex (Botox), intravesical injection of, with cystoscopy, for the treatment of urinary incontinence, including all such injections on any one day, if:
	(a) the urinary incontinence is due to neurogenic detrusor overactivity as demonstrated by urodynamic study of a patient with:
	(i) multiple sclerosis; or
	(ii) spinal cord injury; or
	(iii) spina bifida and who is at least 18 years of age; and
	(b) the patient has urinary incontinence that is inadequately controlled by anti-cholinergic therapy, as manifested by having experienced at least 14 episodes of urinary incontinence per week before commencement of treatment with botulinum toxin type A; and
	(c) the patient is willing and able to self-catheterise; and
	(d) the requirements relating to botulinum toxin type A under the Pharmaceutical Benefits Scheme are complied with; and
	(e) treatment is not provided on the same occasion as a service described in item 104, 105, 110, 116, 119, 11900 or 11919
	For each patient - applicable not more than once except if the patient achieves at least a 50% reduction in urinary incontinence episodes from baseline at any time during the period of 6 to 12 weeks after first treatment (Anaes.)
18375	(See para TN.11.1 of explanatory notes to this Category) Fee: \$229.85 Benefit: 75% = \$172.40
	Botulinum Toxin Type A Purified Neurotoxin Complex (Botox), injection of, for the treatment of chronic migraine, including all injections in 1 day, if:
18377	(a) the patient is at least 18 years of age; and

T11. BOTULINUM TOXIN INJECTIONS

- (b) the patient has experienced an inadequate response, intolerance or contraindication to at least 3 prophylactic migraine medications before commencement of treatment with botulinum toxin, as manifested by an average of 15 or more headache days per month, with at least 8 days of migraine, over a period of at least 6 months, before commencement of treatment with botulinum toxin; and
- (c) the requirements relating to botulinum toxin type A under the Pharmaceutical Benefits Scheme are complied with

For each patient-applicable not more than twice except if the patient achieves and maintains at least a 50% reduction in the number of headache days per month from baseline after 2 treatment cycles (each of 12 weeks duration)

(See para TN.11.1 of explanatory notes to this Category)

Fee: \$124.85 **Benefit:** 75% =

Benefit: 75% = \$93.65 85% = \$106.15

Botulinum Toxin Type A Purified Neurotoxin Complex (Botox), intravesical injection of, with cystoscopy, for the treatment of urinary incontinence, including all such injections on any one day, if:

- (a) the urinary incontinence is due to idiopathic overactive bladder in a patient: and
- (b) the patient is at least 18 years of age; and
- (c) the patient has urinary incontinence that is inadequately controlled by at least 2 alternative anti-

cholinergic agents, as manifested by having experienced at least 14 episodes of urinary incontinence per week

before commencement of treatment with botulinum toxin; and

- (d) the patient is willing and able to self-catheterise; and
- (e) treatment is not provided on the same occasion as a service mentioned in item 104, 105, 110, 116, 119, 11900 or 11919

For each patient-applicable not more than once except if the patient achieves at least a 50% reduction in urinary incontinence episodes from baseline at any time during the period of 6 to 12 weeks after first treatment

(H) (Anaes.)

(See para TN.11.1 of explanatory notes to this Category)

18379 **Fee:** \$229.85

Benefit: 75% = \$172.40

INDEX

(-4141	10100	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
	5, 48409	• • •	63, 47972
- controlled hydrodilatation of bladder	36827		50, 47963
- diathermy or resection of bladder tumour/s	36845		02, 16508
	, 36854	 tonsils/adenoids, arrest, under GA 	41797
- formation of	45227	- transfer of, to restore elbow function	50405
- injection into bladder wall	36851	- transfer of, to restore hand function	46417
- insertion of ureteric stent, or brush biopsy	36821	- translabyrinthine removal 41575-41576, 415	78-41579
- insertion of urethral prosthesis	36811	- transmastoid removal 41575-41576, 415	78-41579
- laser destruction of bladder tumours	36840	- transplantation of	47966
- lavage of blood clots from bladder	36842	- with arytenoidectomy	41867
- or primary restoration of alimentary continuity after	41843	- with division of laryngeal web	41868
- preparation of site and attachment to site	45233	- with mastoidectomy and ossicular chain recon	41554
- removal of foreign body	36833	41563	
- removal of, twelve years or over	41793	- with removal of juvenile papillomata	41858
- removal of, under twelve years	41789	- with removal of papillomata by laser surgery	41861
- resection of ureterocele	36848	- with removal of papinomiata by faser surgery	41864
- spreading of pedicle	45236		
	3, 36824	43/0	01, 45704
	36830		
- ureteric meatotomy		Α	
- urethroscopy with/without urethral dilatation	36812		
- with tracheostomy and plastic reconstruction	30294	Abbe flap, reconstruction of cleft lip	45701
- without litholapaxy	36863	Abdomen, burst, repair of	30403
- without urethroscopy	36815	abdomen, lower 20800, 20802-20806, 20810, 2081	15, 20820
- Achilles, repair of 49718, 49721, 49724		20830, 20832, 20840-20842, 20844-20848, 20850, 208	355
	, 41560	20860, 20862-20864, 20866-20868, 20880, 20882, 208	
- and ossicular chain reconstruction	41542	abdomen, upper 20700, 20702-20706, 20730, 2074	
- and revision of mastoidectomy	41566	20750, 20752, 20754, 20756, 20770, 20790-20794	.0, _0, .0
- artificial prosthesis, insertion of for grafting	46414	20798-20799	
- control under GA, independent	30058		16, 33119
- diabetes or anaemia	16502	Abdominal apron, wedge excision	30165
- following circumcision, with GA	30663	abdominal contouring post diabetic injections	31346
- following tonsillectomy, with GA	41797		
	, 49830	*	39, 32042
- foot, repair of 49800, 49803, 49806, 49809		32045-32046	25.605
- foreign body in, removal	30068		02, 35605
- hand/digit, synovectomy of 46336, 46339, 46342		ablation of, by radiofrequency electrosurgery	35616
46348, 46351, 46354, 46357, 46360	, 105 15	abnormality detected by mammography	31506
- hand/wrist, repair of 46420, 46423, 46426, 46429	16/32	Abortion, threatened, treatment of	16505
46435	, 40432	* ·	21, 45024
- insertion of pressure regulating balloon, pump	37387	, , ,	74-32175
		abscess, incision with drainage	30223
	3, 36591	abscess, laparotomy for drainage of	30394
- into intestine	36594	abscess, open drainage of	37212
	, 36603	access device, prosthetic, correction of	34518
- into skin	36585	access device, thrombectomy of	34515
- intrauterine growth retardation	16508	Accessory bone, osteotomy or osteectomy of	48400
- laparotomy for control of	30385	Acetabular dysplasia, pelvis, bone graft/shelf procedure	50393
- lengthening of 47957, 47960		Acetabulum, treatment of fracture of 47492, 4749	95, 47498
- major, of ankle, repair of 49718, 49721, 49724		47501, 47504, 47507, 47510	•
- or ligament transfer	47966	achilles tendon, repair of 49718, 4972	21, 49724
- prosthesis, artificial, insertion for grafting	46414	Achilles' tendon, operation for lengthening	49727
- reconstruction of, by tendon graft	46408	Acoustic neuroma, removal of 41575-41576, 415	
- reconstruction, congenital atresia	45662	additional incisions for astigmatism	42673
- removal of foreign body, incision	41503	Adductors to ischium transfer	50387
	, 49718		39, 41793
- retromastoid removal of 41575-41576, 41578		adhesiolysis, with hysteroscopy	35633
- revision or removal of	37390	Adhesions, division of, via laparoscope 31450, 3145	
		runesions, division of, via tapatoscope 51430, 514.	12, 33037

adhaniana lamananania disisian	25(29	21402 21404 21420 21420 21422 21440 2144	_
adhesions, laparoscopic division	35638	21402-21404, 21420, 21430, 21432, 21440, 2144	
Administration of	16018	21460-21462, 21464, 21472, 21474, 21480, 2148	-
adnexae, removal, with abdominal hysterectomy	35653	21486, 21490, 21500, 21502, 21520, 21522, 2153	
alba hernia, repair of, over 10 years	30621	21535, 21600, 21610, 21620, 21622, 21630, 2163	
alcohol, cortisone, phenol into trigeminal nerve	39100	21636, 21638, 21650, 21652, 21654, 21656, 2167	
Alcohol, injection of trigeminal nerve/s	39100	21682, 21685, 21700, 21710, 21712, 21714, 2171	
alcohol, retrobulbar	42824	21732, 21740, 21756, 21760, 21770, 21772, 2178	
Alimentary continuity, primary restoration	41843	21790, 21800, 21810, 21820, 21830, 21832, 2183	34, 21840
Alopecia, hair transplantation for	45560	21842, 21850, 21860, 21865, 21870, 21872, 2187	78-21887
Alveolar ridge augmentation	45841, 45843	21900, 21906, 21908, 21910, 21912, 21914-2191	6, 21918
Amnio-infusion	16621	21922, 21925-21927, 21930, 21935-21936, 21939	9, 21941-21943
Amniocentesis, diagnostic	16600	21945, 21949, 21952, 21955, 21959, 21962, 2196	55
Amputation, limb, digit etc. 44325, 44328	3, 44331, 44334	21969-21970, 21973, 21976, 21980, 21990, 2199	2, 21997
44338, 44342, 44346, 44350, 44354, 44358-44359	9, 44361	22001-22002, 22007-22008, 22012, 22014-22015	
44364, 44367, 44370, 44373, 44376		22025, 22031, 22036, 22040, 22045, 22050-2205	
anaesthesia in connection with burns	21878-21887	22060, 22065, 22070, 22075, 22900, 22905, 2301	
anaesthesia in connection with dental services	22900	23021-23023, 23031-23033, 23041-23043, 23051	
22905		23061-23063, 23071-23073, 23081-23083, 23091	
anaesthesia in connection with radiological diagno	ostic or	23111-23119, 23121, 23170, 23180, 23190, 2320	
therapeutic procedures 21900, 21906, 21908		23220, 23230, 23240, 23250, 23260, 23270, 2328	•
21914-21916, 21918, 21922, 21925-21927, 2193		23300, 23310, 23320, 23330, 23340, 23350, 2336	*
21935-21936, 21939, 21941-21943, 21945, 2194		23380, 23390, 23400, 23410, 23420, 23430, 2344	
21955, 21959, 21962, 21965, 21969-21970, 2197		23460, 23470, 23480, 23490, 23500, 23510, 2352	
21980	73, 21770	23540, 23570, 23560, 23570, 23580, 23510, 2352	
anaesthesia modifiers 25000, 25005, 25010	25015 25020	23620, 23630, 23640, 23650, 23660, 23670, 2368	
), 23013, 23020	23700, 23710, 23720, 23730, 23740, 23750, 2376	
25025, 25030 amounth originations 22010, 22021, 22022	2 22021 22022	23780, 23790, 23800, 23810, 23820, 23830, 2384	
anaesthesia time 23010, 23021-23023			
23041-23043, 23051-23053, 23061-23063, 23071		23860, 23870, 23880, 23890, 23900, 23910, 2392	
23081-23083, 23091, 23101, 23111-23119, 2312	•	23940, 23950, 23960, 23970, 23980, 23990, 2410	
23180, 23190, 23200, 23210, 23220, 23230, 2324		25000, 25005, 25010, 25015, 25020, 25025, 2503	30, 25050
23260, 23270, 23280, 23290, 23300, 23310, 2332	20, 23330	25200, 25205	
23340, 23350, 23360, 23370, 23380, 23390, 2340			9, 35542, 35545
23420, 23430, 23440, 23450, 23460, 23470, 2348	80, 23490	anal, excision/repair 32159, 3216	52, 32165-32166
23420, 23430, 23440, 23450, 23460, 23470, 2348 23500, 23510, 23520, 23530, 23540, 23550, 2356	80, 23490 60, 23570	anal, excision/repair 32159, 3216 anal, stretching of	52, 32165-32166 32153
23420, 23430, 23440, 23450, 23460, 23470, 2348 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2364	80, 23490 60, 23570 40, 23650	anal, excision/repair 32159, 3216 anal, stretching of anastomosis of upper or lower limb	52, 32165-32166 32153 34503, 34509
23420, 23430, 23440, 23450, 23460, 23470, 2348 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2362 23660, 23670, 23680, 23690, 23700, 23710, 2372	80, 23490 60, 23570 40, 23650 20, 23730	anal, excision/repair 32159, 3216 anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease	52, 32165-32166 32153 34503, 34509 38706, 38709
23420, 23430, 23440, 23450, 23460, 23470, 2348 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2362 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2380	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810	anal, excision/repair 32159, 3216 anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer	52, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342
23420, 23430, 23440, 23450, 23460, 23470, 2348 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2362 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2380 23820, 23830, 23840, 23850, 23860, 23870, 2388	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810 80, 23890	anal, excision/repair 32159, 3216 anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer and excision of cyst/teratoma	52, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342 43912
23420, 23430, 23440, 23450, 23460, 23470, 2348 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2362 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2380 23820, 23830, 23840, 23850, 23860, 23870, 2388 23900, 23910, 23920, 23930, 23940, 23950, 2396	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810 80, 23890	anal, excision/repair anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer and excision of cyst/teratoma and foot, tibialis tendon transfer	52, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342 43912 50339, 50342
23420, 23430, 23440, 23450, 23460, 23470, 2348 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2362 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2380 23820, 23830, 23840, 23850, 23860, 23870, 2388 23900, 23910, 23920, 23930, 23940, 23950, 2396 23980, 23990, 24100-24136	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810 80, 23890 60, 23970	anal, excision/repair anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer and excision of cyst/teratoma and foot, tibialis tendon transfer and sclerectomy, for glaucoma (Lagrange's op)	52, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342 43912 50339, 50342 42746
23420, 23430, 23440, 23450, 23460, 23470, 2348 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2362 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2380 23820, 23830, 23840, 23850, 23860, 23870, 2388 23900, 23910, 23920, 23930, 23940, 23950, 2396 23980, 23990, 24100-24136 Anaesthetic, Relative Value Guide 20100, 20102	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810 80, 23890 60, 23970 2, 20104, 20120	anal, excision/repair anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer and excision of cyst/teratoma and foot, tibialis tendon transfer and sclerectomy, for glaucoma (Lagrange's op) Aneurysm, cerebrovascular, clipping/reinforcemen	52, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342 43912 50339, 50342 42746 tt 39800
23420, 23430, 23440, 23450, 23460, 23470, 2348 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2362 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2380 23820, 23830, 23840, 23850, 23860, 23870, 2388 23900, 23910, 23920, 23930, 23940, 23950, 2396 23980, 23990, 24100-24136 Anaesthetic, Relative Value Guide 20100, 20102 20124, 20140, 20142-20148, 20160, 20162, 20164	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810 80, 23890 60, 23970 2, 20104, 20120 4, 20170	anal, excision/repair anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer and excision of cyst/teratoma and foot, tibialis tendon transfer and sclerectomy, for glaucoma (Lagrange's op) Aneurysm, cerebrovascular, clipping/reinforcemen aneurysm, clipping or reinforcement of sac	52, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342 43912 50339, 50342 42746 tt 39800 39800
23420, 23430, 23440, 23450, 23460, 23470, 2348 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2362 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2380 23820, 23830, 23840, 23850, 23860, 23870, 2388 23900, 23910, 23920, 23930, 23940, 23950, 2396 23980, 23990, 24100-24136 Anaesthetic, Relative Value Guide 20100, 20102	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810 80, 23890 60, 23970 2, 20104, 20120 4, 20170	anal, excision/repair anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer and excision of cyst/teratoma and foot, tibialis tendon transfer and sclerectomy, for glaucoma (Lagrange's op) Aneurysm, cerebrovascular, clipping/reinforcemen aneurysm, clipping or reinforcement of sac aneurysm, endovascular coiling	52, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342 43912 50339, 50342 42746 tt 39800
23420, 23430, 23440, 23450, 23460, 23470, 2348 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2362 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2380 23820, 23830, 23840, 23850, 23860, 23870, 2388 23900, 23910, 23920, 23930, 23940, 23950, 2396 23980, 23990, 24100-24136 Anaesthetic, Relative Value Guide 20100, 20102 20124, 20140, 20142-20148, 20160, 20162, 20164	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810 80, 23890 60, 23970 2, 20104, 20120 4, 20170 2, 20214	anal, excision/repair anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer and excision of cyst/teratoma and foot, tibialis tendon transfer and sclerectomy, for glaucoma (Lagrange's op) Aneurysm, cerebrovascular, clipping/reinforcemen aneurysm, clipping or reinforcement of sac	52, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342 43912 50339, 50342 42746 tt 39800 39800
23420, 23430, 23440, 23450, 23460, 23470, 2348 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2362 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2380 23820, 23830, 23840, 23850, 23860, 23870, 2388 23900, 23910, 23920, 23930, 23940, 23950, 2396 23980, 23990, 24100-24136 Anaesthetic, Relative Value Guide 20100, 20102 20124, 20140, 20142-20148, 20160, 20162, 20164 20172, 20174, 20176, 20190, 20192, 20210, 20212	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810 80, 23890 60, 23970 2, 20104, 20120 4, 20170 2, 20214 5	anal, excision/repair anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer and excision of cyst/teratoma and foot, tibialis tendon transfer and sclerectomy, for glaucoma (Lagrange's op) Aneurysm, cerebrovascular, clipping/reinforcemen aneurysm, clipping or reinforcement of sac aneurysm, endovascular coiling aneurysm, ligation of cervical vessel/s aneurysm, resection	52, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342 43912 50339, 50342 42746 at 39800 39800 35412 39812 38507-38508
23420, 23430, 23440, 23450, 23460, 23470, 2348 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2362 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2380 23820, 23830, 23840, 23850, 23860, 23870, 2388 23900, 23910, 23920, 23930, 23940, 23950, 2396 23980, 23990, 24100-24136 Anaesthetic, Relative Value Guide 20100, 20102 20124, 20140, 20142-20148, 20160, 20162, 20164 20172, 20174, 20176, 20190, 20192, 20210, 20212 20216, 20220, 20222, 20225, 20230, 20300, 20305	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810 80, 23890 60, 23970 2, 20104, 20120 4, 20170 2, 20214 5 0-20406	anal, excision/repair anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer and excision of cyst/teratoma and foot, tibialis tendon transfer and sclerectomy, for glaucoma (Lagrange's op) Aneurysm, cerebrovascular, clipping/reinforcemen aneurysm, clipping or reinforcement of sac aneurysm, endovascular coiling aneurysm, ligation of cervical vessel/s aneurysm, resection Angiofibroma, face/neck, removal by laser excision	52, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342 43912 50339, 50342 42746 at 39800 39800 35412 39812 38507-38508 n 30190
23420, 23430, 23440, 23450, 23460, 23470, 2348 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2362 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2380 23820, 23830, 23840, 23850, 23860, 23870, 2388 23900, 23910, 23920, 23930, 23940, 23950, 2396 23980, 23990, 24100-24136 Anaesthetic, Relative Value Guide 20100, 20102 20124, 20140, 20142-20148, 20160, 20162, 20164 20172, 20174, 20176, 20190, 20192, 20210, 20212 20216, 20220, 20222, 20225, 20230, 20300, 20305 20320-20321, 20330, 20350, 20352, 20355, 20400	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810 80, 23890 60, 23970 2, 20104, 20120 4, 20170 2, 20214 5 0-20406 2	anal, excision/repair anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer and excision of cyst/teratoma and foot, tibialis tendon transfer and sclerectomy, for glaucoma (Lagrange's op) Aneurysm, cerebrovascular, clipping/reinforcemen aneurysm, clipping or reinforcement of sac aneurysm, endovascular coiling aneurysm, ligation of cervical vessel/s aneurysm, resection Angiofibroma, face/neck, removal by laser excision	52, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342 43912 50339, 50342 42746 at 39800 39800 35412 39812 38507-38508
23420, 23430, 23440, 23450, 23460, 23470, 23482 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2364 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2380 23820, 23830, 23840, 23850, 23860, 23870, 2388 23900, 23910, 23920, 23930, 23940, 23950, 2396 23980, 23990, 24100-24136 Anaesthetic, Relative Value Guide 20100, 20102 20124, 20140, 20142-20148, 20160, 20162, 20164 20172, 20174, 20176, 20190, 20192, 20210, 20212 20216, 20220, 20222, 20225, 20230, 20300, 20305 20320-20321, 20330, 20350, 20352, 20355, 20400 20410, 20420, 20440, 20450, 20452, 20470, 20472	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810 80, 23890 60, 23970 2, 20104, 20120 4, 20170 2, 20214 5 0-20406 2 6, 20528	anal, excision/repair anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer and excision of cyst/teratoma and foot, tibialis tendon transfer and sclerectomy, for glaucoma (Lagrange's op) Aneurysm, cerebrovascular, clipping/reinforcemen aneurysm, clipping or reinforcement of sac aneurysm, endovascular coiling aneurysm, ligation of cervical vessel/s aneurysm, resection Angiofibroma, face/neck, removal by laser excision	52, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342 43912 50339, 50342 42746 at 39800 39800 35412 39812 38507-38508 n 30190 8, 38220, 38222
23420, 23430, 23440, 23450, 23460, 23470, 2348 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2362 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2380 23820, 23830, 23840, 23850, 23860, 23870, 2388 23900, 23910, 23920, 23930, 23940, 23950, 2396 23980, 23990, 24100-24136 Anaesthetic, Relative Value Guide 20100, 20102 20124, 20140, 20142-20148, 20160, 20162, 20164 20172, 20174, 20176, 20190, 20192, 20210, 20212 20216, 20220, 20222, 20225, 20230, 20300, 20305 20320-20321, 20330, 20350, 20352, 20355, 20400 20410, 20420, 20440, 20450, 20452, 20470, 20472 20474-20475, 20500, 20520, 20522, 20524, 20526	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810 80, 23890 60, 23970 2, 20104, 20120 4, 20170 2, 20214 5 0-20406 2 5, 20528 4, 20620	anal, excision/repair anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer and excision of cyst/teratoma and foot, tibialis tendon transfer and sclerectomy, for glaucoma (Lagrange's op) Aneurysm, cerebrovascular, clipping/reinforcemen aneurysm, clipping or reinforcement of sac aneurysm, endovascular coiling aneurysm, ligation of cervical vessel/s aneurysm, resection Angiofibroma, face/neck, removal by laser excision angiography, selected coronary 38215, 3821	52, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342 43912 50339, 50342 42746 at 39800 39800 35412 39812 38507-38508 n 30190 8, 38220, 38222
23420, 23430, 23440, 23450, 23460, 23470, 2348 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2362 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2380 23820, 23830, 23840, 23850, 23860, 23870, 2388 23900, 23910, 23920, 23930, 23940, 23950, 2396 23980, 23990, 24100-24136 Anaesthetic, Relative Value Guide 20100, 20102 20124, 20140, 20142-20148, 20160, 20162, 20164 20172, 20174, 20176, 20190, 20192, 20210, 20212 20216, 20220, 20222, 20225, 20230, 20300, 20305 20320-20321, 20330, 20350, 20352, 20355, 20400 20410, 20420, 20440, 20450, 20452, 20470, 20472 20474-20475, 20500, 20520, 20522, 20524, 20526 20540, 20542, 20546, 20548, 20560, 20600, 20604	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810 80, 23890 60, 23970 2, 20104, 20120 4, 20170 2, 20214 5 0-20406 2 6, 20528 4, 20620 0, 20700	anal, excision/repair anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer and excision of cyst/teratoma and foot, tibialis tendon transfer and sclerectomy, for glaucoma (Lagrange's op) Aneurysm, cerebrovascular, clipping/reinforcemen aneurysm, clipping or reinforcement of sac aneurysm, endovascular coiling aneurysm, ligation of cervical vessel/s aneurysm, resection Angiofibroma, face/neck, removal by laser excision angiography, selected coronary 38215, 3821 38225, 38228, 38231, 38234, 38237, 38240-3824	32, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342 43912 50339, 50342 42746 at 39800 39800 35412 39812 38507-38508 an 30190 8, 38220, 38222 -1, 38243
23420, 23430, 23440, 23450, 23460, 23470, 23482 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2364 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2380 23820, 23830, 23840, 23850, 23860, 23870, 2388 23900, 23910, 23920, 23930, 23940, 23950, 2396 23980, 23990, 24100-24136 Anaesthetic, Relative Value Guide 20100, 20102 20124, 20140, 20142-20148, 20160, 20162, 20164 20172, 20174, 20176, 20190, 20192, 20210, 20212 20216, 20220, 20222, 20225, 20230, 20300, 20305 20320-20321, 20330, 20350, 20352, 20355, 20400 20410, 20420, 20440, 20450, 20452, 20470, 20472 20474-20475, 20500, 20520, 20522, 20524, 20526 20540, 20542, 20546, 20548, 20560, 20600, 20604 20622, 20630, 20632, 20634, 20670, 20680, 20690	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810 80, 23890 60, 23970 2, 20104, 20120 4, 20170 2, 20214 5 0-20406 2 6, 20528 4, 20620 0, 20700 2, 20754	anal, excision/repair anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer and excision of cyst/teratoma and foot, tibialis tendon transfer and sclerectomy, for glaucoma (Lagrange's op) Aneurysm, cerebrovascular, clipping/reinforcemen aneurysm, clipping or reinforcement of sac aneurysm, endovascular coiling aneurysm, ligation of cervical vessel/s aneurysm, resection Angiofibroma, face/neck, removal by laser excision angiography, selected coronary 38215, 3821 38225, 38228, 38231, 38234, 38237, 38240-3824 38246	52, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342 43912 50339, 50342 42746 at 39800 39800 35412 39812 38507-38508 n 30190 8, 38220, 38222 1, 38243 0, 38222, 38225
23420, 23430, 23440, 23450, 23460, 23470, 23482 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2362 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2380 23820, 23830, 23840, 23850, 23860, 23870, 23882 23900, 23910, 23920, 23930, 23940, 23950, 2396 23980, 23990, 24100-24136 Anaesthetic, Relative Value Guide 20100, 20102 20124, 20140, 20142-20148, 20160, 20162, 20164 20172, 20174, 20176, 20190, 20192, 20210, 20212 20216, 20220, 20222, 20225, 20230, 20300, 20305 20320-20321, 20330, 20350, 20352, 20355, 20400 20410, 20420, 20440, 20450, 20452, 20470, 20472 20474-20475, 20500, 20520, 20522, 20524, 20526 20540, 20542, 20546, 20548, 20560, 20600, 20604 20622, 20630, 20632, 20634, 20670, 20680, 20690 20702-20706, 20730, 20790-20794, 20798-20800, 20802	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810 80, 23890 60, 23970 2, 20104, 20120 4, 20170 2, 20214 5 0-20406 2 6, 20528 4, 20620 0, 20700 2, 20754 2-20806, 20810	anal, excision/repair anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer and excision of cyst/teratoma and foot, tibialis tendon transfer and sclerectomy, for glaucoma (Lagrange's op) Aneurysm, cerebrovascular, clipping/reinforcemen aneurysm, clipping or reinforcement of sac aneurysm, endovascular coiling aneurysm, ligation of cervical vessel/s aneurysm, resection Angiofibroma, face/neck, removal by laser excision angiography, selected coronary 38215, 3821 38225, 38228, 38231, 38234, 38237, 38240-3824 38246 angiography, selective 38215, 38218, 3822 38228, 38231, 38234, 38237, 38240-38241, 382	52, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342 43912 50339, 50342 42746 at 39800 39800 35412 39812 38507-38508 n 30190 8, 38220, 38222 1, 38243 0, 38222, 38225
23420, 23430, 23440, 23450, 23460, 23470, 23482 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2362 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2380 23820, 23830, 23840, 23850, 23860, 23870, 2388 23900, 23910, 23920, 23930, 23940, 23950, 2396 23980, 23990, 24100-24136 Anaesthetic, Relative Value Guide 20100, 20102 20124, 20140, 20142-20148, 20160, 20162, 20164 20172, 20174, 20176, 20190, 20192, 20210, 20212 20216, 20220, 20222, 20225, 20230, 20300, 20305 20320-20321, 20330, 20350, 20352, 20355, 20400 20410, 20420, 20440, 20450, 20452, 20470, 20472 20474-20475, 20500, 20520, 20522, 20524, 20526 20540, 20542, 20546, 20548, 20560, 20600, 20604 20622, 20630, 20632, 20634, 20670, 20680, 20690 20702-20706, 20730, 20740, 20745, 20750, 20752	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810 80, 23890 60, 23970 2, 20104, 20120 4, 20170 2, 20214 5 0-20406 2 6, 20528 4, 20620 0, 20700 2, 20754 2-20806, 20810 4-20848	anal, excision/repair anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer and excision of cyst/teratoma and foot, tibialis tendon transfer and sclerectomy, for glaucoma (Lagrange's op) Aneurysm, cerebrovascular, clipping/reinforcemen aneurysm, clipping or reinforcement of sac aneurysm, endovascular coiling aneurysm, ligation of cervical vessel/s aneurysm, resection Angiofibroma, face/neck, removal by laser excision angiography, selected coronary 38215, 3821 38225, 38228, 38231, 38234, 38237, 38240-3824 38246 angiography, selective 38215, 38218, 3822	52, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342 43912 50339, 50342 42746 at 39800 35412 39802 38507-38508 n 30190 8, 38220, 38222 1, 38243 0, 38222, 38225 43, 38246
23420, 23430, 23440, 23450, 23460, 23470, 23482 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2362 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2380 23820, 23830, 23840, 23850, 23860, 23870, 2388 23900, 23910, 23920, 23930, 23940, 23950, 2396 23980, 23990, 24100-24136 Anaesthetic, Relative Value Guide 20100, 20102 20124, 20140, 20142-20148, 20160, 20162, 20164 20172, 20174, 20176, 20190, 20192, 20210, 20212 20216, 20220, 20222, 20225, 20230, 20300, 20305 20320-20321, 20330, 20350, 20352, 20355, 20400 20410, 20420, 20440, 20450, 20452, 20470, 20472 20474-20475, 20500, 20520, 20522, 20524, 20526 20540, 20542, 20546, 20548, 20560, 20600, 20604 20622, 20630, 20632, 20634, 20670, 20680, 20690 20702-20706, 20730, 20740, 20745, 20750, 20752 20756, 20770, 20790-20794, 20798-20800, 20802 20815, 20820, 20830, 20832, 20840-20842, 20844	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810 80, 23890 60, 23970 2, 20104, 20120 4, 20170 2, 20214 5 0-20406 2 6, 20528 4, 20620 0, 20700 2, 20754 2-20806, 20810 4-20848 8, 20880	anal, excision/repair anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer and excision of cyst/teratoma and foot, tibialis tendon transfer and sclerectomy, for glaucoma (Lagrange's op) Aneurysm, cerebrovascular, clipping/reinforcemen aneurysm, clipping or reinforcement of sac aneurysm, endovascular coiling aneurysm, ligation of cervical vessel/s aneurysm, resection Angiofibroma, face/neck, removal by laser excision angiography, selected coronary 38215, 3821 38225, 38228, 38231, 38234, 38237, 38240-3824 38246 angiography, selective 38215, 38218, 3822 38228, 38231, 38234, 38237, 38240-38241, 382 Angioma, cauterisation/injection into angioplasty, peripheral	52, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342 43912 50339, 50342 42746 at 39800 39800 35412 39812 38507-38508 an 30190 8, 38220, 38222 11, 38243 0, 38222, 38225 43, 38246 45027 35315
23420, 23430, 23440, 23450, 23460, 23470, 23482 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2362 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2380 23820, 23830, 23840, 23850, 23860, 23870, 23882 23900, 23910, 23920, 23930, 23940, 23950, 2396 23980, 23990, 24100-24136 Anaesthetic, Relative Value Guide 20100, 20102 20124, 20140, 20142-20148, 20160, 20162, 20164 20172, 20174, 20176, 20190, 20192, 20210, 20212 20216, 20220, 20222, 20225, 20230, 20300, 20302 20320-20321, 20330, 20350, 20352, 20355, 20400 20410, 20420, 20440, 20450, 20452, 20470, 20472 20474-20475, 20500, 20520, 20522, 20524, 20526 20540, 20542, 20546, 20548, 20560, 20600, 20604 20622, 20630, 20632, 20634, 20670, 20680, 20690 20702-20706, 20730, 20740, 20745, 20750, 20752 20756, 20770, 20790-20794, 20798-20800, 20802 20815, 20820, 20830, 20832, 20840-20842, 20844 20850, 20855, 20860, 20862-20864, 20866-20868 20882, 20884, 20886, 20900, 20902, 20904-20906	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810 80, 23890 60, 23970 2, 20104, 20120 4, 20170 2, 20214 5 0-20406 2 6, 20528 4, 20620 0, 20700 2, 20754 2-20806, 20810 4-20848 8, 20880 6	anal, excision/repair anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer and excision of cyst/teratoma and foot, tibialis tendon transfer and sclerectomy, for glaucoma (Lagrange's op) Aneurysm, cerebrovascular, clipping/reinforcemen aneurysm, clipping or reinforcement of sac aneurysm, endovascular coiling aneurysm, ligation of cervical vessel/s aneurysm, resection Angiofibroma, face/neck, removal by laser excision angiography, selected coronary 38215, 3821 38225, 38228, 38231, 38234, 38237, 38240-3824 38246 angiography, selective 38215, 38218, 3822 38228, 38231, 38234, 38237, 38240-38241, 382 Angioma, cauterisation/injection into angioplasty, peripheral Angioplasty, peripheral	52, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342 43912 50339, 50342 42746 at 39800 39800 35412 39812 38507-38508 an 30190 8, 38220, 38222 11, 38243 0, 38222, 38225 43, 38246 45027 35315 35315
23420, 23430, 23440, 23450, 23460, 23470, 23482 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2362 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2380 23820, 23830, 23840, 23850, 23860, 23870, 2386 23900, 23910, 23920, 23930, 23940, 23950, 2396 23980, 23990, 24100-24136 Anaesthetic, Relative Value Guide 20100, 20102 20124, 20140, 20142-20148, 20160, 20162, 20164 20172, 20174, 20176, 20190, 20192, 20210, 20212 20216, 20220, 20222, 20225, 20230, 20300, 20305 20320-20321, 20330, 20350, 20352, 20355, 20400 20410, 20420, 20440, 20450, 20452, 20470, 20472 20474-20475, 20500, 20520, 20522, 20524, 20526 20540, 20542, 20546, 20548, 20560, 20600, 20604 20622, 20630, 20632, 20634, 20670, 20680, 20690 20702-20706, 20730, 20740, 20745, 20750, 20752 20756, 20770, 20790-20794, 20798-20800, 20802 20815, 20820, 20830, 20832, 20840-20842, 20844 20850, 20855, 20860, 20862-20864, 20866-20868 20882, 20884, 20886, 20900, 20902, 20904-20906 20910-20912, 20914, 20916, 20920, 20924, 20926	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810 80, 23890 60, 23970 2, 20104, 20120 4, 20170 2, 20214 5 0-20406 2 6, 20528 4, 20620 0, 20700 2, 20754 2-20806, 20810 4-20848 8, 20880 66, 20928	anal, excision/repair anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer and excision of cyst/teratoma and foot, tibialis tendon transfer and sclerectomy, for glaucoma (Lagrange's op) Aneurysm, cerebrovascular, clipping/reinforcemen aneurysm, clipping or reinforcement of sac aneurysm, endovascular coiling aneurysm, ligation of cervical vessel/s aneurysm, resection Angiofibroma, face/neck, removal by laser excision angiography, selected coronary 38215, 38218, 38231, 38225, 38228, 38231, 38234, 38237, 38240-3824 38246 angiography, selective 38215, 38218, 3823 38228, 38231, 38234, 38237, 38240-38241, 382 Angioma, cauterisation/injection into angioplasty, peripheral Angioplasty, peripheral laser Angioscopy	52, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342 43912 50339, 50342 42746 at 39800 35412 39812 38507-38508 an 30190 8, 38220, 38222 11, 38243 0, 38222, 38225 43, 38246 45027 35315 35315 35324, 35327
23420, 23430, 23440, 23450, 23460, 23470, 23482 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2362 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2380 23820, 23830, 23840, 23850, 23860, 23870, 2386 23900, 23910, 23920, 23930, 23940, 23950, 2396 23980, 23990, 24100-24136 Anaesthetic, Relative Value Guide 20100, 20102 20124, 20140, 20142-20148, 20160, 20162, 20164 20172, 20174, 20176, 20190, 20192, 20210, 20212 20216, 20220, 20222, 20225, 20230, 20300, 20305 20320-20321, 20330, 20350, 20352, 20355, 20400 20410, 20420, 20440, 20450, 20452, 20470, 20472 20474-20475, 20500, 20520, 20522, 20524, 20526 20540, 20542, 20546, 20548, 20560, 20600, 20604 20622, 20630, 20632, 20634, 20670, 20680, 20690 20702-20706, 20730, 20740, 20745, 20750, 20752 20756, 20770, 20790-20794, 20798-20800, 20802 20815, 20820, 20830, 20832, 20840-20842, 20844 20850, 20855, 20860, 20862-20864, 20866-20868 20882, 20884, 20886, 20900, 20902, 20904-20906 20910-20912, 20914, 20916, 20920, 20924, 20926 20930, 20932, 20934, 20936, 20938, 20940, 20942	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810 80, 23890 60, 23970 2, 20104, 20120 4, 20170 2, 20214 5 0-20406 2 6, 20528 4, 20620 0, 20700 2, 20754 2-20806, 20810 4-20848 8, 20880 6 6, 20928 2-20944	anal, excision/repair anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer and excision of cyst/teratoma and foot, tibialis tendon transfer and sclerectomy, for glaucoma (Lagrange's op) Aneurysm, cerebrovascular, clipping/reinforcemen aneurysm, clipping or reinforcement of sac aneurysm, endovascular coiling aneurysm, ligation of cervical vessel/s aneurysm, resection Angiofibroma, face/neck, removal by laser excision angiography, selected coronary 38215, 3821 38225, 38228, 38231, 38234, 38237, 38240-3824 38246 angiography, selective 38215, 38218, 3822 38228, 38231, 38234, 38237, 38240-38241, 382 Angioma, cauterisation/injection into angioplasty, peripheral Angioplasty, peripheral Angioscopy Ankle, achilles tendon, operation for lengthening	52, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342 43912 50339, 50342 42746 at 39800 35412 39802 38507-38508 an 30190 8, 38220, 38222 11, 38243 0, 38222, 38225 43, 38246 45027 35315 35315 35324, 35327 49727
23420, 23430, 23440, 23450, 23460, 23470, 23482 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2364 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2388 23820, 23830, 23840, 23850, 23860, 23870, 2388 23900, 23910, 23920, 23930, 23940, 23950, 2396 23980, 23990, 24100-24136 Anaesthetic, Relative Value Guide 20100, 20102 20124, 20140, 20142-20148, 20160, 20162, 20164 20172, 20174, 20176, 20190, 20192, 20210, 20212 20216, 20220, 20222, 20225, 20230, 20300, 20305 20320-20321, 20330, 20350, 20352, 20355, 20400 20410, 20420, 20440, 20450, 20452, 20470, 20472 20474-20475, 20500, 20520, 20522, 20524, 20526 20540, 20542, 20546, 20548, 20560, 20600, 20604 20622, 20630, 20632, 20634, 20670, 20680, 20690 20702-20706, 20730, 20740, 20745, 20750, 20752 20756, 20770, 20790-20794, 20798-20800, 20802 20815, 20820, 20830, 20832, 20840-20842, 20844 20850, 20855, 20860, 20862-20864, 20866-20868 20882, 20884, 20886, 20900, 20902, 20904-20906 20910-20912, 20914, 20916, 20920, 20924, 20926 20930, 20932, 20934, 20936, 20938, 20940, 20942 20946, 20948, 20950, 20952-20954, 20956, 20958	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810 80, 23890 60, 23970 2, 20104, 20120 4, 20170 2, 20214 5 0-20406 2 6, 20528 4, 20620 0, 20700 2, 20754 2-20806, 20810 4-20848 8, 20880 6 6, 20928 2-20944 8, 20960	anal, excision/repair anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer and excision of cyst/teratoma and foot, tibialis tendon transfer and sclerectomy, for glaucoma (Lagrange's op) Aneurysm, cerebrovascular, clipping/reinforcemen aneurysm, clipping or reinforcement of sac aneurysm, endovascular coiling aneurysm, ligation of cervical vessel/s aneurysm, resection Angiofibroma, face/neck, removal by laser excision angiography, selected coronary 38215, 3821 38225, 38228, 38231, 38234, 38237, 38240-3824 38246 angiography, selective 38215, 38218, 3822 38228, 38231, 38234, 38237, 38240-38241, 382 Angioma, cauterisation/injection into angioplasty, peripheral Angioplasty, peripheral laser Angioscopy Ankle, achilles tendon, operation for lengthening Annuloplasty, heart valve 3847	52, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342 43912 50339, 50342 42746 at 39800 35412 39812 38507-38508 an 30190 8, 38220, 38222 11, 38243 0, 38222, 38225 43, 38246 45027 35315 35315 35315 35324, 35327 49727 75, 38477-38478
23420, 23430, 23440, 23450, 23460, 23470, 23482 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2362 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2380 23820, 23830, 23840, 23850, 23860, 23870, 2386 23900, 23910, 23920, 23930, 23940, 23950, 2396 23980, 23990, 24100-24136 Anaesthetic, Relative Value Guide 20100, 20102 20124, 20140, 20142-20148, 20160, 20162, 20164 20172, 20174, 20176, 20190, 20192, 20210, 20212 20216, 20220, 20222, 20225, 20230, 20300, 20302 20320-20321, 20330, 20350, 20352, 20355, 20400 20410, 20420, 20440, 20450, 20452, 20470, 20472 20474-20475, 20500, 20520, 20522, 20524, 20526 20540, 20542, 20546, 20548, 20560, 20600, 20604 20622, 20630, 20632, 20634, 20670, 20680, 20690 20702-20706, 20730, 20740, 20745, 20750, 20752 20756, 20770, 20790-20794, 20798-20800, 20802 20815, 20820, 20830, 20832, 20840-20842, 20844 20850, 20855, 20860, 20862-20864, 20866-20868 20882, 20884, 20886, 20900, 20902, 20904-20906 20910-20912, 20914, 20916, 20920, 20924, 20926 20930, 20932, 20934, 20936, 20938, 20940, 20942 20946, 20948, 20950, 20952-20954, 20956, 20958 21100, 21110, 21112, 21114, 21116, 21120, 21130	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810 80, 23890 60, 23970 2, 20104, 20120 4, 20170 2, 20214 5 0-20406 2 6, 20528 4, 20620 0, 20700 2, 20754 2-20806, 20810 4-20848 8, 20880 6, 20928 2-20944 8, 20960 0, 21140	anal, excision/repair anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer and excision of cyst/teratoma and foot, tibialis tendon transfer and sclerectomy, for glaucoma (Lagrange's op) Aneurysm, cerebrovascular, clipping/reinforcemen aneurysm, clipping or reinforcement of sac aneurysm, endovascular coiling aneurysm, ligation of cervical vessel/s aneurysm, resection Angiofibroma, face/neck, removal by laser excision angiography, selected coronary 38215, 38218, 38231, 38225, 38228, 38231, 38234, 38237, 38240-3824 38246 angiography, selective 38215, 38218, 3822 38228, 38231, 38234, 38237, 38240-38241, 382 Angioma, cauterisation/injection into angioplasty, peripheral Angioplasty, peripheral Angioscopy Ankle, achilles tendon, operation for lengthening Annuloplasty, heart valve 3847 Anophthalmic orbit, insertion cartilage/implant	52, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342 43912 50339, 50342 42746 at 39800 35412 39812 38507-38508 an 30190 8, 38220, 38222 11, 38243 0, 38222, 38225 43, 38246 45027 35315 35315 35324, 35327 49727 75, 38477-38478 42518
23420, 23430, 23440, 23450, 23460, 23470, 23482 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2362 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2380 23820, 23830, 23840, 23850, 23860, 23870, 2386 23900, 23910, 23920, 23930, 23940, 23950, 2396 23980, 23990, 24100-24136 Anaesthetic, Relative Value Guide 20100, 20102 20124, 20140, 20142-20148, 20160, 20162, 20164 20172, 20174, 20176, 20190, 20192, 20210, 20212 20216, 20220, 20222, 20225, 20230, 20300, 20302 20320-20321, 20330, 20350, 20352, 20355, 20400 20410, 20420, 20440, 20450, 20452, 20470, 20472 20474-20475, 20500, 20520, 20522, 20524, 20526 20540, 20542, 20546, 20548, 20560, 20600, 20604 20622, 20630, 20632, 20634, 20670, 20680, 20690 20702-20706, 20730, 20740, 20745, 20750, 20752 20756, 20770, 20790-20794, 20798-20800, 20802 20815, 20820, 20830, 20832, 20840-20842, 20844 20850, 20855, 20860, 20862-20864, 20866-20868 20882, 20884, 20886, 20900, 20902, 20904-20906 20910-20912, 20914, 20916, 20920, 20924, 20926 20930, 20932, 20934, 20936, 20938, 20940, 20942 20946, 20948, 20950, 20952-20954, 20956, 20958 21100, 21110, 21112, 21114, 21116, 21120, 21130 21150, 21155, 21160, 21170, 21195, 21199-21200	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810 80, 23890 60, 23970 2, 20104, 20120 4, 20170 2, 20214 5 0-20406 2 6, 20528 4, 20620 0, 20700 2, 20754 2-20806, 20810 4-20848 8, 20880 6 6, 20928 2-20944 8, 20960 0, 21140 0, 21202	anal, excision/repair anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer and excision of cyst/teratoma and foot, tibialis tendon transfer and sclerectomy, for glaucoma (Lagrange's op) Aneurysm, cerebrovascular, clipping/reinforcemen aneurysm, clipping or reinforcement of sac aneurysm, endovascular coiling aneurysm, ligation of cervical vessel/s aneurysm, resection Angiofibroma, face/neck, removal by laser excision angiography, selected coronary 38215, 38218, 38231, 38225, 38228, 38231, 38234, 38237, 38240-3824 38246 angiography, selective 38215, 38218, 3822 38228, 38231, 38234, 38237, 38240-38241, 382 Angioma, cauterisation/injection into angioplasty, peripheral Angioplasty, peripheral Angioscopy Ankle, achilles tendon, operation for lengthening Annuloplasty, heart valve 3847 Anophthalmic orbit, insertion cartilage/implant anophthalmic, placement of motility integrating p	52, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342 43912 50339, 50342 42746 at 39800 35412 39812 38507-38508 an 30190 8, 38220, 38222 11, 38243 0, 38222, 38225 43, 38246 45027 35315 35315 35324, 35327 49727 75, 38477-38478 42518 peg 42518
23420, 23430, 23440, 23450, 23460, 23470, 23482 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2362 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2380 23820, 23830, 23840, 23850, 23860, 23870, 2386 23900, 23910, 23920, 23930, 23940, 23950, 2396 23980, 23990, 24100-24136 Anaesthetic, Relative Value Guide 20100, 20102 20124, 20140, 20142-20148, 20160, 20162, 20164 20172, 20174, 20176, 20190, 20192, 20210, 20212 20216, 20220, 20222, 20225, 20230, 20300, 20302 20320-20321, 20330, 20350, 20352, 20355, 20400 20410, 20420, 20440, 20450, 20452, 20470, 20472 20474-20475, 20500, 20520, 20522, 20524, 20526 20540, 20542, 20546, 20548, 20560, 20600, 20604 20622, 20630, 20632, 20634, 20670, 20680, 20690 20702-20706, 20730, 20740, 20745, 20750, 20752 20756, 20770, 20790-20794, 20798-20800, 20802 20815, 20820, 20830, 20832, 20840-20842, 20844 20850, 20855, 20860, 20862-20864, 20866-20868 20882, 20884, 20886, 20900, 20902, 20904-20906 20910-20912, 20914, 20916, 20920, 20924, 20926 20930, 20932, 20934, 20936, 20938, 20940, 20942 20946, 20948, 20950, 20952-20954, 20956, 20958 21100, 21110, 21112, 21114, 21116, 21120, 21130 21150, 21155, 21160, 21170, 21195, 21199-21200 21210, 21212, 21214, 21216, 21220, 21230, 21230	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810 80, 23890 60, 23970 2, 20104, 20120 4, 20170 2, 20214 5 0-20406 2 6, 20528 4, 20620 0, 20700 2, 20754 2-20806, 20810 4-20848 8, 20880 6 6, 20928 2-20944 8, 20960 0, 21140 0, 21202 2, 21234	anal, excision/repair anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer and excision of cyst/teratoma and foot, tibialis tendon transfer and sclerectomy, for glaucoma (Lagrange's op) Aneurysm, cerebrovascular, clipping/reinforcemen aneurysm, clipping or reinforcement of sac aneurysm, endovascular coiling aneurysm, ligation of cervical vessel/s aneurysm, resection Angiofibroma, face/neck, removal by laser excision angiography, selected coronary 38215, 38218, 38231, 38225, 38228, 38231, 38234, 38237, 38240-3824 38246 angiography, selective 38215, 38218, 3822 38228, 38231, 38234, 38237, 38240-38241, 382 Angioma, cauterisation/injection into angioplasty, peripheral Angioplasty, peripheral Angioplasty, peripheral laser Angioscopy Ankle, achilles tendon, operation for lengthening Annuloplasty, heart valve 3847 Anophthalmic orbit, insertion cartilage/implant anophthalmic, placement of motility integrating p	52, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342 43912 50339, 50342 42746 at 39800 35412 39812 38507-38508 an 30190 8, 38220, 38222 11, 38243 0, 38222, 38225 43, 38246 45027 35315 35315 35324, 35327 49727 75, 38477-38478 42518 aug 42518 aug 42518 aug 42518 aug 42518
23420, 23430, 23440, 23450, 23460, 23470, 23482 23500, 23510, 23520, 23530, 23540, 23550, 2356 23580, 23590, 23600, 23610, 23620, 23630, 2362 23660, 23670, 23680, 23690, 23700, 23710, 2372 23740, 23750, 23760, 23770, 23780, 23790, 2380 23820, 23830, 23840, 23850, 23860, 23870, 2386 23900, 23910, 23920, 23930, 23940, 23950, 2396 23980, 23990, 24100-24136 Anaesthetic, Relative Value Guide 20100, 20102 20124, 20140, 20142-20148, 20160, 20162, 20164 20172, 20174, 20176, 20190, 20192, 20210, 20212 20216, 20220, 20222, 20225, 20230, 20300, 20302 20320-20321, 20330, 20350, 20352, 20355, 20400 20410, 20420, 20440, 20450, 20452, 20470, 20472 20474-20475, 20500, 20520, 20522, 20524, 20526 20540, 20542, 20546, 20548, 20560, 20600, 20604 20622, 20630, 20632, 20634, 20670, 20680, 20690 20702-20706, 20730, 20740, 20745, 20750, 20752 20756, 20770, 20790-20794, 20798-20800, 20802 20815, 20820, 20830, 20832, 20840-20842, 20844 20850, 20855, 20860, 20862-20864, 20866-20868 20882, 20884, 20886, 20900, 20902, 20904-20906 20910-20912, 20914, 20916, 20920, 20924, 20926 20930, 20932, 20934, 20936, 20938, 20940, 20942 20946, 20948, 20950, 20952-20954, 20956, 20958 21100, 21110, 21112, 21114, 21116, 21120, 21130 21150, 21155, 21160, 21170, 21195, 21199-21200	80, 23490 60, 23570 40, 23650 20, 23730 00, 23810 80, 23890 60, 23970 2, 20104, 20120 4, 20170 2, 20214 5 0-20406 2 6, 20528 4, 20620 0, 20700 2, 20754 2-20806, 20810 4-20848 8, 20880 6 6, 20928 2-20944 8, 20960 0, 21140 0, 21202 2, 21234 0, 21321	anal, excision/repair anal, stretching of anastomosis of upper or lower limb Anastomosis, aorta, congenital heart disease and ankle, tibialis tendon transfer and excision of cyst/teratoma and foot, tibialis tendon transfer and sclerectomy, for glaucoma (Lagrange's op) Aneurysm, cerebrovascular, clipping/reinforcemen aneurysm, clipping or reinforcement of sac aneurysm, endovascular coiling aneurysm, ligation of cervical vessel/s aneurysm, resection Angiofibroma, face/neck, removal by laser excision angiography, selected coronary 38215, 38218, 38231, 38225, 38228, 38231, 38234, 38237, 38240-3824 38246 angiography, selective 38215, 38218, 3822 38228, 38231, 38234, 38237, 38240-38241, 382 Angioma, cauterisation/injection into angioplasty, peripheral Angioplasty, peripheral Angioscopy Ankle, achilles tendon, operation for lengthening Annuloplasty, heart valve 3847 Anophthalmic orbit, insertion cartilage/implant anophthalmic, placement of motility integrating p	52, 32165-32166 32153 34503, 34509 38706, 38709 50339, 50342 43912 50339, 50342 42746 at 39800 35412 39812 38507-38508 an 30190 8, 38220, 38222 11, 38243 0, 38222, 38225 43, 38246 45027 35315 35315 35324, 35327 49727 75, 38477-38478 42518 peg 42518

antenatal		16500	arteriovenous, upper or lower limb	34503, 34509
Antenatal cardiotocography (restriction)		16514	artery bypass vein graft, dissection	38637
Antepartum haemorrhage, treatment of		16509	artery catheterisation	13818
Anterior chamber, irrigation of blood from		42743	artery catheterisation for SIRT	35406, 35408
anterior or posterior chamber or both		42740	artery embolisation	35410
	4-32026,		Artery, anastomosis of, microvascular	45502
antireflux operation by	31464,		Artery, great ligation/exploration,other	34103
	7, 30529-		artery, internal, transection/resection	32703
Antrectomy and/or vagotomy	30497,		artery, transantral ligation of	41707
Antrobuccal fistula operation		41722	arthrectomy	49309, 49312
antrobuccol, operation for		41722	arthrectomy or arthrodesis	48939, 48942
Antroscopy of temporomandibular joint	45855,		Arthrectomy, hip	49309, 49312
Antrostomy, radical	41710,		Arthrocentesis. with irrigation of temporomandibula	
Antrum, drainage of, through tooth socket		41719	arthrodesis arthrodesis of 49512, 49545, 49712, 49815	45877, 49306
antrum, proof puncture and lavage of	41698,	32153	, , , , , , , , , , , , , , , , , , , ,	49712
Anus, dilatation of (Lord's procedure) Aorta, anastomosis, congenital heart disease	38706,		Arthrodesis, ankle arthroplasty 49309, 49312, 49315, 4931	
aorta, operative management of rupture/dissection		38572	arthroplasty 49309, 49312, 49315, 49315 49324, 49327, 49330, 49333, 49336, 49339, 493	
aorta, repair or replacement procedures	38550,		49324, 49327, 49330, 49333, 49330, 49339, 493	+2
38556, 38559, 38562, 38565, 38568, 38571	36330,	36333	arthroplasty of 49209, 49518-49519, 49521	10524 10527
aortic aneurysm, endovascular repair of	33116,	33110	49530, 49533-49534	., 47324, 47321
	33110, 3, 32710-		arthroplasty of, not otherwise covered	50127
), 34163,		Arthroplasty, ankle	49715
), 34163,		arthroplasty, revision	49346
Aorto-femoral endarterectomy	,, 5 1105,	33515	arthroscopic surgery 48948, 48951, 48954	.,
Aorto-iliac endarterectomy		33512	49221, 49224, 49227	1, 10557, 10500
Aortopexy for tracheomalacia		43909	arthroscopic surgery of	49121, 49703
Appendiceal abscess, laparotomy for drainage		30394), 49363, 49366
appendiceal, laparotomy for drainage		30394	arthroscopy of 45855, 45857, 49218, 4955	
Appendicectomy 30571-30572	2, 30574,	30645	50100	,
Appendicectomy, laparoscopic		30646	arthroscopy of, diagnostic	49118, 49700
Appendix, ruptured, laparotomy for drainage		30394	Arthroscopy, ankle	49700, 49703
application of a localiser cast to		50600	arthrotomy 45859, 46327, 46330), 48912, 49303
application of formalin		32212	arthrotomy of 49100, 49212, 49500), 49706, 50103
Arachnoidal cyst, craniotomy for		39718	Arthrotomy, ankle	49706
Arch Bars, to maxilla or mandible, removal of		45823	artificial erection device, insertion	37426, 37429
area, exploration of		36537	Artificial erection device, insertion of	37426, 37429
Areola, reconstruction of	45545-		artificial erection device, revision or removal of	37432
Arm, amputation or disarticulation of		44328	artificial, removal and replacement	42707, 42710
arm, upper (and elbow) 21700, 21710, 21712			artificial, removal or repositioning	42704
21730, 21732, 21740, 21756, 21760, 21770, 2177	72, 21780	0	Arytenoidectomy with microlaryngoscopy	41867
21785, 21790		10106	aspiration biopsy of cyst/s	45799
Arnold Chiari malformation, decompression of		40106	Aspiration biopsy, bone marrow	30087
arrest of post-operative haemorrhage		30663	assist device, insertion of	38615, 38618
5	7, 38290,		assist device, removal of, independent	38621, 38624
arrhythmia, surgery for 38287, 38290, 38293	, 38390,	38393	assistance at anaesthesia	25200, 25205
38512, 38515, 38518	22766	22760	Assistance at operations 51300, 51303, 51306), 31309, 31312
Arterial anastomosis, not otherwise covered arterial catheterisation	32766,	35321	51315, 51318 assistance time 23010, 23021-2302;	2 22021 22022
arterial, collection for pathology	13839,		23041-23043, 23051-23053, 23061-23063, 2307	,
arterial/venous, independent		32766	23081-23083, 23091, 23101, 23111-23119, 2312	
arterial/venous, mith other operation		32769	23180, 23190, 23200, 23210, 23220, 23230, 2324	
Arteries, major, access as part of re-operation		35202	23260, 23270, 23280, 23290, 23300, 23310, 233	
Arteriography, operative		35202	23340, 23350, 23360, 23370, 23380, 23390, 234	
Arteriography, preparation for	38215,		23420, 23430, 23440, 23450, 23460, 23470, 234	
Arteriovenous access device, insertion of		34512	23500, 23510, 23520, 23530, 23540, 23550, 235	
arteriovenous malformation, excision of		39803	23580, 23590, 23600, 23610, 23620, 23630, 236	
	2, 34115,		23660, 23670, 23680, 23690, 23700, 23710, 237	
	, 34124,		23740, 23750, 23760, 23770, 23780, 23790, 238	
34130	,,	•	23820, 23830, 23840, 23850, 23860, 23870, 238	
arteriovenous, external, insertion/removal	34500,	34506	23900, 23910, 23920, 23930, 23940, 23950, 2396	•
arteriovenous, ligation cervical vessel/s	ĺ	39812	23980, 23990, 24100-24136	

assistance, modifiers 25000, 25005, 25010, 25015, 25020	biopsy of vertebra 30093
25025, 25030	biopsy of with hysteroscopy 35630
Assisted reproductive technologies 13200, 13203, 13206	biopsy of, with cystoscopy 36836
13209, 13212, 13215, 13218, 13221	biopsy of, with IUD insertion for idiopathic menorrhagia 35502
atherectomy, peripheral 35312	Biopsy, aggressive bone/deep tissue tumour 50200-50201
Atherectomy, peripheral arterial 35312	biopsy, by cardiac catherterisation 38275
atresia, auditory canal reconstruction 45662	biopsy, deep organ, imaging guided 30094
Atresia, choanal, repair/correction 45645-45646	biopsy, using ABBI 31539, 31545
atresia/corrosive stricture, replacement for 43903	bladder stress, suprapubic operation 37044
Atrial chamber/s, operations for arrhythmia 38512, 38515	Bladder, aspiration of, by needle 37041
Atticotomy 41533, 41536	bladder, cystoscopic removal of 36833
auditory canal, correction of 41521	bladder, diathermy/resection with cystoscopy 36840, 36845
Auditory canal, external 41524	bladder, endoscopic incision/resection 36854
auditory meatus, removal of exostoses 41518	bladder, laser destruction with cystoscopy 36840
augmentation 38766	bladder, removal of 36863
Augmentation mammaplasty 45524, 45527-45528	Bladder, stress incontinence, sling procedure 37040, 37338
Aural polyp, removal of 41506	blepharospasm 18369-18370, 18372, 18374
aural, removal of 41506, 41509	blood pressure monitoring 13876
Autoconjunctival transplant 42641	body tumour, resection of 34148, 34151, 34154
Avulsion, penis, repair of 37411	bone conduction hearing system 41603-41604
Axilla, lymph glands, excision of 30332	bone graft to 50644
Axillary hyperhidrosis, excision for 30180, 30183	bone grafting for pseudarthrosis 46405
Axillary hyperhidrosis, vessle, ligation/exploration, other 34103	bone grafting of phalanx for 46402, 46405
Axillofemoral graft, infected, excision of 34172	bone marrow 30081, 30084, 30087
	bone, benign, requiring allograft, resection of 50230
В	Bone, cysts, injection into or aspiration of 47900
	bone, fracture, treatment of 45981, 47762, 47765, 47768
Baker's cyst, excision of 30114	47771
Baker's, excision of 30114	bone, injection into or aspiration of 47900
Balloon catheter, right heart, insertion of 13818	bone, innocent, excision of 30241
balloon dilatation of 41832	bone, malignant, operations for 50200-50201, 50203, 50206
Balloon enteroscopy 30680, 30682, 30684, 30686	50209, 50212, 50215, 50218, 50221, 50224, 50227, 50230
balloon pump, insertion of 38362, 38609	50233, 50236, 50239
balloon pump, removal of 38612-38613	bone, operation on, for osteomyelitis 43509, 43518
bands or lingual tonsils, removal of 41804	bone, osteectomy or osteotomy of 48424, 48427
Bariatric Surgery 31569, 31572, 31575, 31578, 31581, 31584	bone, reconstruction of 45788
Bariatric surgery, surgical reversal of 31584	bone, removal of styloid process of 30244
Bartholin's abscess, incision of 35520	bone, resection for removal of tumour 41584, 41587
Bartholin's, cautery destruction of 35517	bones, bone grafting, pseudarthrosis 46402, 46405
Bartholin's, excision of 35513	bones, fracture, treatment of 47735, 47738, 47741
Bartholin's, incision of 35520	bones, operation for osteomyelitis 46462
Bartholin's, marsupialisation of 35517	bones, osteotomy/osteectomy 46396, 46399
base tumour, removal, infra-temporal 41581	Botulinum toxin, injection for 18350-18351, 18353-18354
Bat ear or similar deformity, correction of 45659	18360, 18362, 18365-18366, 18368-18370, 18372, 18374
bed, reconstruction of laceration 46486	18377, 18379
benign lesion 31500, 31503	Boutonniere deformity, reconstruction of 46444, 46447
benign, of soft tissue, removal 31350	bowel intubation 30488
Bicornuate uterus, plastic reconstruction for 35680	bowel stricture plasty 30564
bicornuate, plastic reconstruction for 35680	Bowel, colectomy, total 30608, 30622, 32009, 32012, 32015
Bile duct, common, radical resection 30461, 30463-30464	32018, 32021
Biliary atresia, paediatric, portoenterostomy for 43978	bowel, endoscopic examination of 32095
biliary dilatation 30495	Brachial fistula 43832
biliary drainage 30440, 30451, 30495	Brachial plexus, exploration of 39333
biliary stenting 30492	Brachial, removal of 30287
biliary/renal tract, extraction of 30450	Brachycephaly, cranial vault reconstruction for 45785
biopsies, multiple, with infracolic omentectomy 35726	Brachytherapy planning 15536
biopsy 30409, 30411-30412	brain, operations for 39703
biopsy (closed) 36561	Branchial cyst, removal of 30286-30287
biopsy of 30075, 30081, 30084, 30087, 42676	branchial, removal of 30286, 30289
biopsy of for suspected malignancy 35620	breast 31530, 31533, 31548 Proof biopey fine people imaging guided 31530
biopsy of prostate 37212, 37218	Breast, biopsy, fine needle, imaging guided 31533
biopsy of solid tumour, vacuum-assisted, image guided 31530	breast, correction of (unilateral) 45556

breast, exploration and drainage	31551	capsulotomy 42788
Breast, malignant tumour, targeted intraoperative ra		Capsulotomy, laser 42788
	15900	Carbon dioxide laser resurfacing, face or neck 45025-45026
Breast, malignant tumuor, complete local excision	31516	Carbuncle, incision and drainage, with GA 30223
breast, removal and/or replacement 45553-45554	45548, 45551	cardiac 38200, 38203, 38206, 38209, 38212-38213, 38215 38218, 38220, 38222
Broad ligament cyst/tumour, excision/removal	35713, 35717	Cardiac by-pass, whole body perfusion 22060
broad ligament, excision of	35713, 35717	cardiac, excision of 38670, 38673, 38677, 38680
broad ligament, removal of	35713, 35717	Cardiopexy, antireflux operation 30530
Brodie's abscess, operation for	43515	Cardioplegia, retrograde administration of 22070
bronchgenic, thoracotomy and excision	43912	Cardiopulmonary bypass, cannulation for 38600, 38603
Bronchial tree, intrathoracic operation on, other	38456	Cardiotocography, antenatal (restriction) 16514
Bronchoscopy, as an independent procedure	41889	Cardioversion 13400
Bronchus, dilatation of stricture and stent insertion	41905	care, independent of confinement 16500
bronchus, removal of	41895	Carotid artery, aneurysm, graft replacement 33100
Broviac catheter, insertion of, for chemotherapy	34527-34528	carotid body, resection of 34148, 34151, 34154
34540		carotid-cavernous, obliteration of 39815
Bubonocele operation	30614	carpal bone 46324-46325
Bunion, excision of	47933	Carpal bone, replacement arthroplasty 46324-46325
Burch colposuspension	37044	Carpometacarpal joint, arthrodesis of 46303
Burns, dressing of (not involving grafting)	30003, 30006	carpus 48406, 48409
30010, 30014	,	Carpus dislocation, treatment of 47030, 47033
Burr-hole craniotomy, intracranial haemorrhage	39600	carpus, operation for 46462
burr-hole for intracranial haemorrhage	39600	caruncle, cauterisation of 35523
Burst abdomen, repair of	30403	caruncle, excision of 35527
by open exposure of the trachea	41881	Caruncle, urethral, cauterisation of 35523
	6-30467, 38627	Cataract, juvenile, removal of 42716
bypass for venous stenosis or occlusion	34812	catheter, insertion and fixation of 13109
bypass grafting, occlusive arterial disease	32700, 32703	catheter, insertion of 39140
32708, 32710-32712, 32715, 32718, 32721, 3272	· ·	catheter, insertion of for infusion device 39125, 39128
32733, 32736, 32739, 32742, 32745, 32748, 3275		Catheter, peritoneal insertion and fixation 13109
32757, 32760, 32763		catheter, removal of 13110, 34530, 34540
Bypass, extracranial to intracranial	39818	catheterisation 38200, 38203, 38206, 38209, 38212-38213
	, 32703, 32708	38215, 38218, 38220, 38222
32710-32712, 32715, 32718, 32721, 32724, 3273		catheterisation - for myocardial biopsy 38275
32736, 32739, 32742, 32745, 32748, 32751, 3275		catheterisation of 36800, 38200, 38203, 38206
32760, 32763	,	catheterisation with cystoscopy 36818, 36824
,		Catheterisation, bladder, independent procedure 36800
С		catheterisation, peripheral 35317, 35319-35321
		cauterisation of, for ectropion or entropion 42581
Caecostomy,	30375, 30637	cauterisation of, other than by chemical means 35608
Caesarean section	16520, 16522	Cauterisation, angioma (restriction applies) 45027
calcaneal spur, excision of	49818	Cautery, conjunctiva, including treatment of pannus 42677
Calcaneal spur, of foot, excision of	49818	caval filter, insertion of 35330
Calcanean bursa, excision of	30111	cavernous fistula, obliteration of 39815
· · · · · · · · · · · · · · · · · · ·	, 47612, 47615	Cavernous sinus, tumour or vascular lesion, excision 39660
47618	, 47012, 47013	cavity and/or post nasal space, examination of 41653
	5, 30457-30458	cavity, aspiration of 38800, 38803
Caldwell-Luc operation	41710	cavity, packing for arrest of haemorrhage 41677
	5, 47978, 47981	cavity, reconstruction of 45590
canal external, blind sac closure	41564	Cavopulmonary shunt, creation of 38733, 38736
canal stenosis, correction of, with meatoplasty	41521	Cellulitis, incision with drainage, under GA 30223
canaliculus, immediate repair of	42605	Central cannulation for cardiopulmonary bypass 38600
Cancer of skin/mucous membrane, removal	30196, 30202	central ducts, excision for benign condition 31557
cancer, treatment of	30196, 30202	central vein 13318-13319, 13815
Cannulae, membrane oxygenation	38627	central vein, for haemodialysis or parenteral nutrition 34538
cannulation for cardiopulmonary bypass	38603	central vein, subcutaneous tunnel 34527-34528
cannulation for infusion chemotherapy, open	34524	central vein, tunnelled cuffed 34538
cannulation of, in a neonate	13300	central vein, tunnelled cuffed catheter 34538
Cannulation, arterial, for infusion chemotherapy	34524	central, catheterisation 13318-13319, 13815
Canthoplasty	42590	central, catheterisation, subcutaneous tunnel 34527-34528
Capsulectomy	42719, 42731	cephalic version 16501
Capsuiccioniy	74/17, 74/31	1

Caraballa nantina angla tumaur 41575 41576	11570 11570	alogue of	102 20562
	, 41578-41579 41575-41576	closure of closure of and repair of musculoaponeurotic layer	103, 30562 45570
cerebello-pontine angle, removal of	413/3-413/6		
41578-41579	1 64 50200	closure of, in conjunction with free tissue transfer or br	
Cerebral palsy, hips or knees, application of cast und		reconstruction	45569
Cerebrospinal fluid drain, lumbar, insertion of	40018		063, 32066
cervical	30294	closure of, without resection of bowel	30562
cervical, neonatal oesophageal atresia	43858	closure or plastic repair of	30293
cervix	35608, 35646	Club hand, radial, centralisation/radialisation	50399
Cervix, amputation or repair of	35618	coalition, excision of	50333
cervix, cone	35618	Coccyx, excision of	30672
cervix, punch	35608	Cochlear implant, insertion with mastoidectomy	41617
cervix, removal of	35611	Cochleotomy, or repair of round window	41614
cervix-residual, removal of, abdominal approach	35612	Coeliac artery, decompression of	34142
cervix-residual, removal of, vaginal approach	35613	coeliac, decompression of	34142
Chalazion, extirpation of	42575	coil, insertion of	37223
chamber, operation for arrhythmia	38518		004-32005
chemical peel	45019		503, 49506
Chemical peel, full face	45019	collection of blood for	13709
Chemotherapy 13915, 13918, 13921, 13924, 13927,	, 13930, 13933	collection of, for transfusion	13709
13936, 34529, 34534	24521 24524	collection of, in infants, for pathology	13312
chemotherapy, cannulation for	34521, 34524	Colonic atresia, neonatal, laparotomy for	43816
Chest, or limb, decompression escharotomy	45054	Colonic stent, insertion of	32023
Chloasma, full face chemical peel	45019	colonic, total, intra-operative	32186
Choanal atresia, repair/correction	45645-45646	colonoscopy 32084, 32087, 320	
cholangio-pancreatography	30484	Colonoscopy, fibreoptic 32084, 32087, 320)90, 32093
Cholangiogram, percutaneous transhepatic	30440	Colorectal strictures, endoscopic dilatation of	32094
cholangiography or pancreatography	30439	colostomy	30375
Cholangiography, operative	30439	Colostomy, closure of 305	562, 30639
Cholangiopancreatography	30484	Colotomy	30375
Cholecystectomy 30443, 30445-30446	, 30448-30449	Colpoperineorrhaphy 355	571, 35573
Cholecystoduodenostomy	30460, 31472	colpopexy	35597
Cholecystoenterostomy	30460, 31472	Colpopexy, sacral	35597
Cholecystostomy	30375	colposcopic examination of	35614
Choledochal cyst, resection of	43972, 43975	colposcopy with biopsy and diathermy	35646
choledochal, resection of	43972, 43975	Colposcopy, using Hinselmann-type instrument	35614
Choledochoduodenostomy	30460-30461	Colpotomy	35572
Choledochoenterostomy	30460-30461	compartment repair, anterior	35572
Choledochogastrostomy	30461	compartment repair, anterior/posterior	35573
	30460-30461		
Choledochojejunostomy		compartment repair, posterior	35571
Choledochoscopy	30442, 30452	complicated by previous surgery	37444
	-30455, 30457		638, 35641
Chondro-cutaneous or chondro-mucosal graft	45656	composite (chondro-cutaneous/mucosal)	45656
Chondroplasty of knee	49503, 49506	composite graft to	45656
Chordee, correction of	37417	Composite graft to nose, ear or eyelid	45656
Chorionic villus sampling	16603	conduit, revision of	36609
cicatricial flexion contracture of, correction	50112		406, 48424
Cicatricial flexion/extension contracture, joint, corre	ection 50112	Condylectomy/condylotomy	45863
Ciliary body and/or iris, excision of tumour	42767	cone biopsy of	35618
Circulatory support device, management of	13851, 13854	Cone biopsy of cervix	35618
Circumcision 30649,	30654, 30658	Confinement 16515, 16518-165	520, 16522
Cisternal puncture	39003	congenital abnormalities, amputation of phalanges	50396
clavicle	48406, 48409	congenital abnormalities, splitting of phalanges	50396
Clavicle, dislocation, treatment of	47003, 47006	Congenital absence of vagina, reconstruction for	35565
claw or hammer toe, correction of	49848, 49851		414, 50417
Claw toe, correction of	49848	50423	,
Cleft lip, operations for 45677, 45680, 45683,		congenital deformity, post-op manipulation, plaster	50348
45692, 45695, 45698, 45701, 45704	12000, 72009	congenital dislocation, open reduction	50348
Clitoris, amputation of, medically indicated	35530	congenital dislocation, open reduction congenital dislocation, reconstruction of quadriceps	50420
Clitoroplasty, reduction, ambiguous genitalia	37845, 37848	congenital dislocation, reconstruction of quadriceps congenital pseudarthritis, resection, fixation	50354
	, 39656, 39658	congenital, vertebral resection and fusion for	50640
Closes overtrephy property operation for	43969	conjunctive contagn of	42676
Cloacal exstrophy, neonatal, operation for	43882	Conjunctiva, cautery of	42677

	42677	cyst, anastomosis to Roux loop of jejunum	30587
conjunctiva, cautery of Conjunctival cysts, removal of	42677	cyst, anastomosis to Roux 100p of Jejunum cyst, anastomosis to stomach or duodenum	30586
	42638		
conjunctival graft		Cyst, arachnoidal, craniotomy for other, removal o	1 31220
conjunctival over cornea	42638 42629	31225, 39718	20702
Conjunctivorhinostomy		cyst, drainage of via burr-hole	39703
Contour reconstruction, insertion of foreign implan		cyst, excision of	35513, 36558
Contraceptive device, intra-uterine, introduction of		cyst, excision of, with hysterectomy	35673
contraceptive device, removal of under GA	35506	cyst, excision of, with laparotomy	35713, 35717
Contracted socket, reconstruction	42527	cyst, extirpation of	42575
contracture of, medial/anterior release	50375, 50378	cyst, liver, removal of contents of	30434, 30436
50381, 50384	2 50266 50260	cyst, lungs, enucleation of	38424
	3, 50366, 50369	cyst, puncture of, via laparoscope	35637
50372	.: 50110	cyst/s, laparoscopic marsupialisation	30416-30417
Contracture, cicatricial flexion/extension of joint, c		Cystadenomatoid malformation, neonatal, thoracot	,
cord, teflon injection into	41870	cystectomy, laparoscopic	35638
cordotomy	39121	Cystocoele, repair of	35570
Cordotomy, laminectomy for	39124	cystoscopy of	36825
core biopsy of solid tumour or tissue	31548	Cystoscopy, with	36836
cornea or sclera, imbedded, removal of	42644	cystostomy or cystotomy	37008
cornea or sclera, superficial, removal of	30061	Cystostomy, suprapubic	37008
Cornea, conjunctival graft over	42638	Cystotomy, suprapubic	37008, 37011
corneal	42653, 42656	cysts, removal of	41813
2 2 2 1	98, 38500-38501	Cytotoxic agent, instillation into body cavity	13948
38503-38504		_	
Coronary pressure wire	38241	D	
coronary sinus, for admin of blood or crystalloid	38588		
2 . 2	98, 38500-38501	D and C	35640
38503-38504		Dacryocystectomy	42596
coronary, open operation	38505	Dacryocystorhinostomy	42623, 42626
Corpus callosum, anterior section of, for epilepsy	40700	Debridement of contaminated wound	30023
correction of chordee	37417-37418	debridement/eliminating band keratyoplasty	42651
Corticectomy, for epilepsy	40703	Debulking operation, gynaecological malignancy	35720
Corticolysis of lens material	42791	debulking prior to vaginal hysterectomy	35658
corticolysis, laser, of lens material	42791	decompression fasciotomy	47981
Costo-transverse joint, injection into	39013	decompression fasciotomy of 4797	5, 47978, 47981
Counterpulsation, intra-aortic balloon, managemen		Decompression fasciotomy, calf/forearm 4797	5, 47978, 47981
Cranial nerve, intracranial decompression of	39112	decortication with thoracotomy	38421
cranial or cisternal, insertion of	40003	deep hypothermic circulatory arrest	22075
cranial or cisternal, revision or removal of	40009	Deep organ, percutaneous aspiration biopsy	30094
cranial, intracranial decompression	39112	deep, percutaneous drainage	20224
Craniectomy and removal of haematoma	39603		30224
		deep, peripheral nerve, removal of	30224 39327
Craniopharyngioma, craniotomy for removal of	39712	deep, peripheral nerve, removal of defect, ventricular, closure of	
Craniopharyngioma, craniotomy for removal of Cranioplasty and repair of fractured skull	39712 39615		39327
Craniopharyngioma, craniotomy for removal of Cranioplasty and repair of fractured skull Craniostenosis, operations for	39712 39615 40115, 40118	defect, ventricular, closure of	39327 38751
Craniopharyngioma, craniotomy for removal of Cranioplasty and repair of fractured skull Craniostenosis, operations for Craniotomy and tumour removal	39712 39615 40115, 40118 39709, 39712	defect, ventricular, closure of Defibrillator generator, insertion/replacement	39327 38751 38393
Craniopharyngioma, craniotomy for removal of Cranioplasty and repair of fractured skull Craniostenosis, operations for Craniotomy and tumour removal Cricopharyngeal myotomy	39712 39615 40115, 40118 39709, 39712 41776	defect, ventricular, closure of Defibrillator generator, insertion/replacement deformity, correction of	39327 38751 38393 50300
Craniopharyngioma, craniotomy for removal of Cranioplasty and repair of fractured skull Craniostenosis, operations for Craniotomy and tumour removal Cricopharyngeal myotomy Cricothyrostomy	39712 39615 40115, 40118 39709, 39712 41776 41884	defect, ventricular, closure of Defibrillator generator, insertion/replacement deformity, correction of Delorme procedure	39327 38751 38393 50300 32111
Craniopharyngioma, craniotomy for removal of Cranioplasty and repair of fractured skull Craniostenosis, operations for Craniotomy and tumour removal Cricopharyngeal myotomy Cricothyrostomy cruciate ligament reconstruction 4953	39712 39615 40115, 40118 39709, 39712 41776 41884 6, 49539, 49542	defect, ventricular, closure of Defibrillator generator, insertion/replacement deformity, correction of Delorme procedure Dermabrasion	39327 38751 38393 50300 32111 45021, 45024
Craniopharyngioma, craniotomy for removal of Cranioplasty and repair of fractured skull Craniostenosis, operations for Craniotomy and tumour removal Cricopharyngeal myotomy Cricothyrostomy cruciate ligament reconstruction 4953 Cruciate ligaments, reconstruction/repair	39712 39615 40115, 40118 39709, 39712 41776 41884	defect, ventricular, closure of Defibrillator generator, insertion/replacement deformity, correction of Delorme procedure Dermabrasion dermis, dermo-fat or fascia Dermo-fat or fascia	39327 38751 38393 50300 32111 45021, 45024 45018
Craniopharyngioma, craniotomy for removal of Cranioplasty and repair of fractured skull Craniostenosis, operations for Craniotomy and tumour removal Cricopharyngeal myotomy Cricothyrostomy cruciate ligament reconstruction 4953 Cruciate ligaments, reconstruction/repair 49542	39712 39615 40115, 40118 39709, 39712 41776 41884 6, 49539, 49542 49536, 49539	defect, ventricular, closure of Defibrillator generator, insertion/replacement deformity, correction of Delorme procedure Dermabrasion dermis, dermo-fat or fascia	39327 38751 38393 50300 32111 45021, 45024 45018 45018
Craniopharyngioma, craniotomy for removal of Cranioplasty and repair of fractured skull Craniostenosis, operations for Craniotomy and tumour removal Cricopharyngeal myotomy Cricothyrostomy cruciate ligament reconstruction 4953 Cruciate ligaments, reconstruction/repair 49542 Cryotherapy for detached retina	39712 39615 40115, 40118 39709, 39712 41776 41884 6, 49539, 49542 49536, 49539 42773	defect, ventricular, closure of Defibrillator generator, insertion/replacement deformity, correction of Delorme procedure Dermabrasion dermis, dermo-fat or fascia Dermo-fat or fascia graft dermoid of, congenital, excision of	39327 38751 38393 50300 32111 45021, 45024 45018 45018 41729
Craniopharyngioma, craniotomy for removal of Cranioplasty and repair of fractured skull Craniostenosis, operations for Craniotomy and tumour removal Cricopharyngeal myotomy Cricothyrostomy cruciate ligament reconstruction 4953 Cruciate ligaments, reconstruction/repair 49542 Cryotherapy for detached retina cryotherapy to	39712 39615 40115, 40118 39709, 39712 41776 41884 6, 49539, 49542 49536, 49539 42773 42680	defect, ventricular, closure of Defibrillator generator, insertion/replacement deformity, correction of Delorme procedure Dermabrasion dermis, dermo-fat or fascia Dermo-fat or fascia graft dermoid of, congenital, excision of dermoid, congenital, excision of	39327 38751 38393 50300 32111 45021, 45024 45018 45018 41729 42573-42574
Craniopharyngioma, craniotomy for removal of Cranioplasty and repair of fractured skull Craniostenosis, operations for Craniotomy and tumour removal Cricopharyngeal myotomy Cricothyrostomy cruciate ligament reconstruction Cruciate ligaments, reconstruction/repair 49542 Cryotherapy for detached retina cryotherapy to Crystalloid, retrograde admin for cardioplegia	39712 39615 40115, 40118 39709, 39712 41776 41884 6, 49539, 49542 49536, 49539 42773 42680 38588	defect, ventricular, closure of Defibrillator generator, insertion/replacement deformity, correction of Delorme procedure Dermabrasion dermis, dermo-fat or fascia Dermo-fat or fascia graft dermoid of, congenital, excision of dermoid, congenital, excision of Dermoid, excision of	39327 38751 38393 50300 32111 45021, 45024 45018 45018 41729 42573-42574 42576
Craniopharyngioma, craniotomy for removal of Cranioplasty and repair of fractured skull Craniostenosis, operations for Craniotomy and tumour removal Cricopharyngeal myotomy Cricothyrostomy cruciate ligament reconstruction 4953 Cruciate ligaments, reconstruction/repair 49542 Cryotherapy for detached retina cryotherapy to Crystalloid, retrograde admin for cardioplegia curettage of	39712 39615 40115, 40118 39709, 39712 41776 41884 6, 49539, 49542 49536, 49539 42773 42680 38588 35640	defect, ventricular, closure of Defibrillator generator, insertion/replacement deformity, correction of Delorme procedure Dermabrasion dermis, dermo-fat or fascia Dermo-fat or fascia graft dermoid of, congenital, excision of dermoid, excision of Dermoid, excision of dermoid, excision of	39327 38751 38393 50300 32111 45021, 45024 45018 45018 41729 42573-42574 42576 42573-42574
Craniopharyngioma, craniotomy for removal of Cranioplasty and repair of fractured skull Craniostenosis, operations for Craniotomy and tumour removal Cricopharyngeal myotomy Cricothyrostomy cruciate ligament reconstruction 4953 Cruciate ligaments, reconstruction/repair 49542 Cryotherapy for detached retina cryotherapy to Crystalloid, retrograde admin for cardioplegia curettage of curettage of uterus	39712 39615 40115, 40118 39709, 39712 41776 41884 6, 49539, 49542 49536, 49539 42773 42680 38588 35640 35640, 35643	defect, ventricular, closure of Defibrillator generator, insertion/replacement deformity, correction of Delorme procedure Dermabrasion dermis, dermo-fat or fascia Dermo-fat or fascia graft dermoid of, congenital, excision of dermoid, excision of Dermoid, excision of dermoid, excision of destruction by radiofrequency ablation	39327 38751 38393 50300 32111 45021, 45024 45018 45018 41729 42573-42574 42576 42573-574 50950, 50952
Craniopharyngioma, craniotomy for removal of Cranioplasty and repair of fractured skull Craniostenosis, operations for Craniotomy and tumour removal Cricopharyngeal myotomy Cricothyrostomy cruciate ligament reconstruction 4953 Cruciate ligaments, reconstruction/repair 49542 Cryotherapy for detached retina cryotherapy to Crystalloid, retrograde admin for cardioplegia curettage of curettage of uterus Curettage, for evacuation of gravid uterus	39712 39615 40115, 40118 39709, 39712 41776 41884 6, 49539, 49542 49536, 49539 42773 42680 38588 35640 35640, 35643 35643	defect, ventricular, closure of Defibrillator generator, insertion/replacement deformity, correction of Delorme procedure Dermabrasion dermis, dermo-fat or fascia Dermo-fat or fascia graft dermoid of, congenital, excision of dermoid, congenital, excision of Dermoid, excision of dermoid, excision of destruction by radiofrequency ablation destruction of bladder tumour with cystoscopy	39327 38751 38393 50300 32111 45021, 45024 45018 45018 41729 42573-42574 42576 42573-42574 50950, 50952 36840, 36845
Craniopharyngioma, craniotomy for removal of Cranioplasty and repair of fractured skull Craniostenosis, operations for Craniotomy and tumour removal Cricopharyngeal myotomy Cricothyrostomy cruciate ligament reconstruction 4953 Cruciate ligaments, reconstruction/repair 49542 Cryotherapy for detached retina cryotherapy to Crystalloid, retrograde admin for cardioplegia curettage of curettage of uterus Curettage, for evacuation of gravid uterus cutaneous, nerve graft to	39712 39615 40115, 40118 39709, 39712 41776 41884 6, 49539, 49542 49536, 49539 42773 42680 38588 35640 35640, 35643 39318	defect, ventricular, closure of Defibrillator generator, insertion/replacement deformity, correction of Delorme procedure Dermabrasion dermis, dermo-fat or fascia Dermo-fat or fascia graft dermoid of, congenital, excision of dermoid, congenital, excision of Dermoid, excision of dermoid, excision of destruction by radiofrequency ablation destruction of bladder tumour with cystoscopy destruction of stone with urethroscopy	39327 38751 38393 50300 32111 45021, 45024 45018 45018 41729 42573-42574 42576 42573-42574 50950, 50952 36840, 36845 37318
Craniopharyngioma, craniotomy for removal of Cranioplasty and repair of fractured skull Craniostenosis, operations for Craniotomy and tumour removal Cricopharyngeal myotomy Cricothyrostomy cruciate ligament reconstruction 4953 Cruciate ligaments, reconstruction/repair 49542 Cryotherapy for detached retina cryotherapy to Crystalloid, retrograde admin for cardioplegia curettage of curettage of uterus Curettage, for evacuation of gravid uterus cutaneous, nerve graft to cutaneous, repair of	39712 39615 40115, 40118 39709, 39712 41776 41884 6, 49539, 49542 49536, 49539 42773 42680 38588 35640 35640, 35643 39318 39300, 39303	defect, ventricular, closure of Defibrillator generator, insertion/replacement deformity, correction of Delorme procedure Dermabrasion dermis, dermo-fat or fascia Dermo-fat or fascia graft dermoid of, congenital, excision of dermoid, congenital, excision of Dermoid, excision of dermoid, excision of destruction by radiofrequency ablation destruction of stone with urethroscopy destruction/non-resectable liver cancer	39327 38751 38393 50300 32111 45021, 45024 45018 45018 41729 42573-42574 42576 42573-42574 50950, 50952 36840, 36845 37318 50950, 50952
Craniopharyngioma, craniotomy for removal of Cranioplasty and repair of fractured skull Craniostenosis, operations for Craniotomy and tumour removal Cricopharyngeal myotomy Cricothyrostomy cruciate ligament reconstruction 4953 Cruciate ligaments, reconstruction/repair 49542 Cryotherapy for detached retina cryotherapy to Crystalloid, retrograde admin for cardioplegia curettage of curettage of uterus Curettage, for evacuation of gravid uterus cutaneous, nerve graft to cutaneous, salivary gland, repair of	39712 39615 40115, 40118 39709, 39712 41776 41884 6, 49539, 49542 49536, 49539 42773 42680 38588 35640 35640, 35643 39318 39300, 39303 30269	defect, ventricular, closure of Defibrillator generator, insertion/replacement deformity, correction of Delorme procedure Dermabrasion dermis, dermo-fat or fascia Dermo-fat or fascia graft dermoid of, congenital, excision of dermoid, congenital, excision of Dermoid, excision of dermoid, excision of destruction by radiofrequency ablation destruction of bladder tumour with cystoscopy destruction/non-resectable liver cancer detached retina Detached retina, diathermy/cryotherapy	39327 38751 38393 50300 32111 45021, 45024 45018 45018 41729 42573-42574 42576 42573-42574 50950, 50952 36840, 36845 37318 50950, 50952 42773
Craniopharyngioma, craniotomy for removal of Cranioplasty and repair of fractured skull Craniostenosis, operations for Craniotomy and tumour removal Cricopharyngeal myotomy Cricothyrostomy cruciate ligament reconstruction 4953 Cruciate ligaments, reconstruction/repair 49542 Cryotherapy for detached retina cryotherapy to Crystalloid, retrograde admin for cardioplegia curettage of curettage of uterus Curettage, for evacuation of gravid uterus cutaneous, nerve graft to cutaneous, repair of	39712 39615 40115, 40118 39709, 39712 41776 41884 6, 49539, 49542 49536, 49539 42773 42680 38588 35640 35640, 35643 35643 39318 39300, 39303 30269 a 42770	defect, ventricular, closure of Defibrillator generator, insertion/replacement deformity, correction of Delorme procedure Dermabrasion dermis, dermo-fat or fascia Dermo-fat or fascia graft dermoid of, congenital, excision of dermoid, congenital, excision of Dermoid, excision of dermoid, excision of destruction by radiofrequency ablation destruction of bladder tumour with cystoscopy destruction/non-resectable liver cancer detached retina Detached retina, diathermy/cryotherapy detached, diathermy or cryotherapy for	39327 38751 38393 50300 32111 45021, 45024 45018 45018 41729 42573-42574 42576 42573-42574 50950, 50952 36840, 36845 37318 50950, 50952 42773 42773
Craniopharyngioma, craniotomy for removal of Cranioplasty and repair of fractured skull Craniostenosis, operations for Craniotomy and tumour removal Cricopharyngeal myotomy Cricothyrostomy cruciate ligament reconstruction 4953 Cruciate ligaments, reconstruction/repair 49542 Cryotherapy for detached retina cryotherapy to Crystalloid, retrograde admin for cardioplegia curettage of curettage of uterus Curettage, for evacuation of gravid uterus cutaneous, nerve graft to cutaneous, repair of cutaneous, salivary gland, repair of Cyclodestructive procedures treatment of glaucoma cyst aspiration	39712 39615 40115, 40118 39709, 39712 41776 41884 6, 49539, 49542 49536, 49539 42773 42680 38588 35640 35640, 35643 39318 39300, 39303 30269 a 42770 35518	defect, ventricular, closure of Defibrillator generator, insertion/replacement deformity, correction of Delorme procedure Dermabrasion dermis, dermo-fat or fascia Dermo-fat or fascia graft dermoid of, congenital, excision of dermoid, congenital, excision of Dermoid, excision of dermoid, excision of destruction by radiofrequency ablation destruction of bladder tumour with cystoscopy destruction/non-resectable liver cancer detached retina Detached retina, diathermy/cryotherapy detached, diathermy or cryotherapy for detached, removal of encircling silicone band	39327 38751 38393 50300 32111 45021, 45024 45018 45018 41729 42573-42574 42576 42573-42574 50950, 50952 36840, 36845 37318 50950, 50952 42773 42773 42773
Craniopharyngioma, craniotomy for removal of Cranioplasty and repair of fractured skull Craniostenosis, operations for Craniotomy and tumour removal Cricopharyngeal myotomy Cricothyrostomy cruciate ligament reconstruction Cruciate ligaments, reconstruction/repair 49542 Cryotherapy for detached retina cryotherapy to Crystalloid, retrograde admin for cardioplegia curettage of curettage of uterus Curettage, for evacuation of gravid uterus cutaneous, nerve graft to cutaneous, repair of cutaneous, salivary gland, repair of Cyclodestructive procedures treatment of glaucoma	39712 39615 40115, 40118 39709, 39712 41776 41884 6, 49539, 49542 49536, 49539 42773 42680 38588 35640 35640, 35643 35643 39318 39300, 39303 30269 a 42770	defect, ventricular, closure of Defibrillator generator, insertion/replacement deformity, correction of Delorme procedure Dermabrasion dermis, dermo-fat or fascia Dermo-fat or fascia graft dermoid of, congenital, excision of dermoid, congenital, excision of Dermoid, excision of dermoid, excision of destruction by radiofrequency ablation destruction of bladder tumour with cystoscopy destruction/non-resectable liver cancer detached retina Detached retina, diathermy/cryotherapy detached, diathermy or cryotherapy for	39327 38751 38393 50300 32111 45021, 45024 45018 45018 41729 42573-42574 42576 42573-42574 50950, 50952 36840, 36845 37318 50950, 50952 42773 42773 42773 42812

device for delivery of therapeutic agents 14221, 14224	division of, with laparoscopy 30393
14227, 14230, 14233, 14236, 14239, 14242	division of, with laparotomy 30376, 30378-30379
device for drug delivery, loading of 13939, 13942, 13945	Dohlman's operation 41773
device, automated, spinal, insertion of 39125-39128	Donald-Fothergill operation 35577
device, insertion, central vein catheterisation 34527-34529, 34534	Donor haemapheresis 13755
device, intra-uterine, removal under GA 35506	donor, continuous perfusion of 22055
device, introduction of, for idiopathic menorrhagia 35502	Double vagina, excision of septum 35566
device, removal of 34530	drainage by insertion of glass tube 42608
diagnostic 30390	drainage of deep abscess, imaging guided 30224
dialysis in hospital 13100, 13103	drainage of empyema, without rib resection 38806, 38809
Diaphragm, plication of for eventration 43915	drainage of, transthoracic 38450 drainage tube exchange, imaging guided 30451
Diaphragmatic hernia, neonatal, repair of 43837, 43840 diaphragmatic, neonatal, repair of 43837, 43840	6 67 6 66
diaphragmatic, neonatal, repair of 43837, 43840 diaphragmatic, repair of 30600-30601, 43838	drainage tube, exchange of 30225 drainage tube, exchange of, imaging guided 36649
Diaphyseal aclasia, removal of lesion/s from bone 50426	dramage tube, exchange or, imaging guided 30049 dressing and removal of, requiring GA 30055
Diastematomyelia, tethered cord, release of 40112	dressing of, requiring GA 30055 dressing of, requiring GA 30055
diathermy of 35608, 35646, 37318	Drez lesion, operation for 39124
Diathermy of bladder tumours 36840, 36845	Drill biopsy of lymph gland/deep tissue/organ 30078
diathermy or visual laser destruction of 37224	drill decompression of head/neck or both 47982
diathermy/visual laser for lesion of prostate 37224	drill, lymph gland, deep tissue/organ 30078
Digit, amputation of 46464-46465, 46468, 46471, 46474, 46477	Drug delivery device, loading of 13939, 13942, 13945
46480	drug delivery system 39125-39126, 39128, 39133
digital nail, removal of 46513, 46516	drug delivery system for spasticity management 14227
Digital nail, toe, removal of 47904, 47906	14230, 14233, 14236, 14239, 14242
digital, of finger or thumb, removal of 46513, 46516	drum perforation, excision of rim 41644
digital, of toe, removal of 47904, 47906	duct, common, repair of 30472
digits, flexor/extensor contracture, correction 46492	duct, endoscopic stenting of 30491
dilatation 36821	duct, meatotomy or marsupialisation 30266
dilatation of 41822, 41825, 41828, 41831	duct, patent vitello, excision of 43945
dilatation of colorectal strictures 32094	duct, removal of calculus 30266
dilatation of, as an independent procedure 35554	duct, repair of, 30246
dilatation with cystoscopy 36812	Duct, salivary gland, diathermy/dilatation 30262
dilatation, endoscopic 30494	Ducts submandibular, removal of 30255
dilatation, percutaneous 30495	ducts, relocation of 30255
Direct flap repair 45209, 45212, 45215, 45218, 45221, 45224	ducts, Roux-en-Y bypass 30466-30467
direct, indirect or local, revision of 45239-45240	ductus arteriosus, division/ligation 38700, 38703
discontinuation of surgical procedure on medical groups 30001	Duodenal atresia, duodeno-duodenostomy/jejunostomy 43807
disease, neonatal, laparotomy for 43819	duodenal, perforated, suture of 30375
disease, paediatric, operations for 43990, 43993, 43996	Duodenoduodenostomy for duodenal atresia/stenosis 43807
43999	Duodenojejunostomy for duodenal atresia/stenosis 43807
Disimpaction of faeces under GA 32153	Duodenoscopy 30473, 30478
dislocation, acetabulum fracture, treatment 47495, 47498	duplication of digits, amputation of phalanges 50396
dislocation, congenital, treatment of 50349, 50352	duplication of digits, splitting of phalanges 50396
dislocation, congenital, treatment of including paediatric 50650, 50654, 50658	Dupuytren's contracture, operations for 46366, 46369, 46372 46375, 46378, 46381, 46384, 46387, 46390, 46393
dislocation, treatment of 41686, 47009, 47012, 47015	Dupuytren's, subcutaneous fasciotomy for 46366
47018, 47021, 47024, 47027, 47030, 47033, 47036, 47039	dynamic equinus foot deformity 18354
47042, 47045, 47048, 47051, 47054, 47057, 47060, 47063	Dysthyroid eye disease, decompression of orbit 42545
47066, 47069, 47072	dystopia, correction of 45776, 45779
dislocations, treatment of 47000	_
Dissection, lymph nodes of neck 30618, 31423, 31426, 31429 31432, 31435, 31438	E
distal, devascularisation of 32200	E.C.T. 14224
distal, excision of ganglion/mucous cyst 46495	ear, complex total reconstruction of 45660-45661
distal, for osteomyelitis 46459	Ear, composite graft to 45656
diverticulum of, excision or obliteration 37020	ear, exploration of 41629
Diverticulum, bladder, excision/obliteration 37020	ear, insertion of tube for drainage of 41632
diverticulum, excision of 37372	ear, operation for abscess or inflammation of 41626
divided, repair of 36573	ear, removal of 41500, 41503
division of adhesions 30393, 35637 division of suture, eye 42794	Eclampsia, treatment of 16509
division of suture, eye 42/94 division of suture, laser 42794	Ectopic bladder, 'turning-in' operation 37842 ectopic, 'turning-in' operation 37842

ectropion or entropion, correction of	45626	Enterotomy, intra-operative, for endoscopy	30568
Ectropion, correction of	45626	Entropion, correction of	45626
elbow 49100, 49106,	49118, 49121		06, 42509-42510
Elbow, arthrodesis of	49106	Enucleation of eye	42506, 42509
electrical stimulation of	13400	Epicondylitis, open operation for	47903
electrocoagulation diathermy	35644-35645	Epididymal cyst, excision of	37601
electrocoagulation, of cervix	35644-35645	epididymal, removal of	37601
Electroconvulsive therapy	14224	Epididymectomy	37613
electrode placement	40709, 40712	Epidural blood patch	18233
Electrode(s), epidural, insertion by laminectomy	39139	epidural electrode, insertion	39130
electrode, insertion	39130, 39139	epidural electrodes, management of	39131
electrode, management, adjustment etc.	39131	epidural implant, removal	39136
Electrolysis epilation, for trichiasis	42587-42588	epidural, for pain management, removal of	39136
electrophysiological studies 38209	, 38212-38213	epidural, insertion of	39140
Electrophysiological studies, cardiac 38209	, 38212-38213	epidural, percutaneous insertion of	39130
Embolectomy	33803, 33806	epidural, percutaneous, management of	39131
	33803, 33806	Epigastric hernia, repair of	30621
Embolus, removal from artery of neck	33800	Epilation electrolysis, for trichiasis	42587-42588
Emphysema, lobar, neonatal, thoracotomy & lung re	section 43861		00-40709, 40712
Empyema, intercostal drainage of	38806, 38809		03, 48506, 48509
Enbloc resection of tumour 50212, 50215, 50218,	50221, 50224		00, 48503, 48506
50227			00, 48503, 48506
Encephalocoele, excision and closure of	40109	Epiphysiolysis, to prevent closure of plate	48512
Endarterectomy 33500, 33506, 33509, 33512,			36, 37839, 37842
33521, 33524, 33527, 33530, 33533, 33536, 33539		Epistaxis, treatment of	41656, 41677
endarterectomy	33509, 33521	Epithelial debridement for corneal ulcer/erosion	42650
endarterectomy of 33500, 33506, 33509, 33512,		epithelial debridement for corneal ulcer/erosion	42650
33521, 33524, 33527, 33530, 33533, 33536, 3353		epithelial debridement for keratoplasty	42651
endarterectomy, open operation	38505		18, 50321, 50324
Endobronchial tumour, endoscopic laser resection	41901	50327, 50330	
endobronchial ultrasound, lung tumours	30710	erection device, revision or removal of	37432
Endocarditis, operative management of	38493	ESWL	36546
	, 30580-30581	Ethmoidal artery, transorbital ligation of	41725
	, 30580-30581	ethmoidal, external operation on	41749
Endolymphatic sac, transmastoid decompression	41590	ethmoidal, transorbital ligation of	41725
endometrial	35616	Ethmoidectomy, fronto-nasal	41731
Endometrial biopsy for suspected malignancy	35620	Etonogestral, subcutaneous implant, removal of	30062
endometrial, for suspected malignancy	35620	eustachian tube	41755
Endometriosis, laparoscopic ablation	35638	Eustachian tube, catheterisation of	41755
Endometrium, ablation of, endoscopic	35622	Evacuation of retained products of conception	16564
endoscopic	30485, 36854	Eventration, plication of diaphragm for	43915
Endoscopic biliary dilatation	30494	Evisceration of globe of eye	42512, 42515
endoscopic examination and ablation by microwave		examination of intestinal conduit/reservoir	36860
balloon	35616	examination of small bowel	30569, 32095
endoscopic examination with cystoscopy	36812	examination under GA, paediatric	44101-44102
endoscopic gastrostomy	30481-30482	examination, under GA	32171
endoscopic laser ablation	37207-37208	excavatum, repair or radical correction	38457-38458
Endoscopic ultrasound fine needle aspiration	30696	excision of 30099, 30103, 30226, 30229, 304	
Endoscopy with balloon dilatation gastric stricture	30475	30448-30449, 30583, 37000, 37014, 45030, 450	033
enlargement of, using intestine	37047	45035-45036	24157
entero-	30515	excision of infected by-pass graft	34157
Enterocoele, repair of	35571	excision of lip, eyelid or ear, full thickness	45665
Enterocolitis, acute neonatal necrotising, laparotomy	43828		03-32104, 32106
43831 Enterpolacione	20515	excision of tumour of	42764
Enterocolostomy	30515	excision of under GA (not involving grafting)	30017, 30020
Enterocutaneous fistula, radical repair of	30382	excision of, in oral & maxillofacial region	45801, 45803
enterocutaneous, radical resection	30382	45805, 45807, 45809	15001 15002
Enteroenterostomy	30515	excision of, oral & maxillofacial region	45801, 45803
enterogenous, thoracotomy and excision	43912 30375	45805, 45807, 45809	31340
enterostomy Enterostomy, closure of	305/5	excision of, with melanoma excision of, with melanoma	31340
	30362	excision of, with metanoma excision, repair, without cardiopulmonary bypass	
enterotomy	303/3	excision, repair, without cardiopullionary bypass	5 30433

excision, tumours of face/neck Exenteration of orbit of eye	30190 42536	
	42 <i>33</i> 0 43870, 43873	
Exostoses in external auditory meatus, removal	41518	
	47933, 4793 <i>6</i>	
expander, insertion of	45566	
expander, insertion of expander, removal of	45568	** * *
expansion, intra-operative	45572	
	36612, 39330	5
	30318, 30320	
exploration/drainage, operating theatre	31551	
exploration/dramage, operating meante exploratory	30373	
exstrophy closure	37050	·
exstrophy crosure exstrophy of, repair of	37842	
Exstrophy, cloacal, neonatal, operation for	43882	r 8
extension, percutaneous gastrostomy tube	31460	
extension, percutaneous gastrostomy tube extensive, multiple injections of hydrocortisone	30210	
	30210 46420, 46423	
extensor tendon of, repair of extensor tendon of, tenolysis of	46420, 46423	•
	4645(41524 4566	
	41524, 45662	
external auditory canal, reconstruction	45662	
external auditory, removal of keratosis obturans	41509	, , , ,
External cephalic version	16501	
external operation on	41876	
, I	45660-45661	2 /
Extra digit, amputation of	46464	,
extra, amputation of	46464	2 , 1
extra-ocular, ruptured, repair of	42854	,
	38757, 38760	
Extracorporeal shock wave lithotripsy	36546	<i>U</i> ,
**	39818, 39821	
extraction	42698	
extraction and insertion of artificial lens	42702	<i>U</i> ,
extremity, reoperation for control of	33848	
Eye, capsulotomy, laser	42788	
eye, decompression of	42545	5 · · · · · · · · · · · · · · · · · · ·
eye, exenteration of	42536	3, 6 3 ,
	42530, 42533	
	42542-42543	
eye, skin graft to	42524	
	42554, 42557	
Eyebrow, elevation of	42872	· · · · · · · · · · · · · · · · · · ·
Eyelashes, ingrowing, operation for	45626	
Eyelid closure in facial nerve paralysis, implant insert		, 8
face or neck, revision of (restriction applies)	45506	
45512		fistula, removal of 30289
<u>_</u>		fistula, repair of 30269
F		fistula, repair or closure of 35596, 37029, 37333
		fistula, stenosis of, correction of 34518
Face, injections of poly-L-Lactic acid	14201	Fixation, external, removal of 47948, 47951
	45753-45754	fixation, orthopaedic, removal 47948, 47951
face/neck, laser excision	30190	
Facet joint denervation by percutaneous neurotomy	39118	flap repair 45000, 45003, 45006, 45009, 45012, 45200
Facial, nerve, decompression of	41569	45203, 45206
facio-hypoglossal or facio-accessory, anastomosis or	f 39503	
facio-hypoglossal/accessory nerve	39503	flap, delay of 45015
Facio-hypoglossal/accessory nerve, anastomosis of	39503	flap, infected, craniectomy for 39906
	32213-32218	flexor tendon of, repair of 46423, 46426, 46429, 46432
Fallopian tubes, catheterisation, with hysteroscopy	35633	46435
Falloposcopy, unilateral/bilateral	35710	flexor tendon of, tenolysis of 46453
Fascia, deep, repair of, for herniated muscle	30238	0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1

E1	46425	22770 22700 22700 22000 22010 22020 22020	22040
Flexor tendon, hand, repair of 46426, 46429, 46432,		23770, 23780, 23790, 23800, 23810, 23820, 23830	*
flexor/extensor contracture, correction of	46492	23850, 23860, 23870, 23880, 23890, 23900, 23910	
flexor/extensor, digits of hand, correction of	46492	23930, 23940, 23950, 23960, 23970, 23980, 23990	
Flexorplasty to restore elbow function	50405	24100-24136, 25000, 25005, 25010, 25015, 25020, 25030, 25050, 25200, 25205	, 25025
flexorplasty/tendon transfer to restore function	50405	25030, 25050, 25200, 25205	20710
floor repair, laparoscopic or abdominal	35595	for arachnoidal cyst	39718
Fluid Filled Cavity, drainage of	16624	for cardiopulmonary bypass	38600, 38603
fluid filled cavity, drainage of	16624	for congenital cystadenomatoid malformation	43861
fluid reservoir, insertion of	39018	for congenital lobar emphysema	43861
focal spasticity	18360	for control of post-operative haemorrhage	30385, 33845
following gynaecological surgery, under GA	35759	for cordotomy or myelotomy	39124
following intraocular procedures	42857	for drainage	30394
foot 49815, 49833, 49836-49839, 49842,		for grading of lymphoma	30384
foot deformities due to spasticity	18354	for gross intra-peritoneal sepsis	30396
Foot, amputation or disarticulation of 44359, 44361,		for implantable bone conduction hearing system	41603-41604
For anaesthesia 20100, 20102, 20104, 20120, 20124,	20140	for intussusception, paediatric	43933, 43936
20142-20148, 20160, 20162, 20164, 20170, 20172, 20174		for neonatal conditions 43801, 43804, 43807,	, 43810, 43813
20176, 20190, 20192, 20210, 20212, 20214, 20216, 20220	1	43816, 43819, 43822, 43825, 43828, 43831	
20222, 20225, 20230, 20300, 20305, 20320-20321, 20330		for oesophageal atresia, neonatal	43852
20350, 20352, 20355, 20400-20406, 20410, 20420, 20440		for osteomyelitis/removal infected bone	39906
20450, 20452, 20470, 20472, 20474-20475, 20500, 20520			, 15539, 37220
20522, 20524, 20526, 20528, 20540, 20542, 20546, 20548		for removal of thymus or mediastinal tumour	38446
20560, 20600, 20604, 20620, 20622, 20630, 20632, 20634		for reopening post-op for haemorrhage/swelling	39721
20670, 20680, 20690, 20700, 20702-20706, 20730, 20740		for retrograde cerebral perfusion	38577
20745, 20750, 20752, 20754, 20756, 20770, 20790-20794		for staging of gynaecological malignancy	35726
20798-20800, 20802-20806, 20810, 20815, 20820, 20830		for supercharging of pedicled flaps	45561
20832, 20840-20842, 20844-20848, 20850, 20855, 20860		for symblepharon	45629
		2 1	33845
20862-20864, 20866-20868, 20880, 20882, 20884, 20886		for thrombosis	
20900, 20902, 20904-20906, 20910-20912, 20914, 20916		for trauma, involving 3 or more organs	30388
20920, 20924, 20926, 20928, 20930, 20932, 20934, 20936		for trichiasis	42587-42588
20938, 20940, 20942-20944, 20946, 20948, 20950		for tumour	36532
20952-20954, 20956, 20958, 20960, 21100, 21110, 21112		for tumour, complicated	36533
21114, 21116, 21120, 21130, 21140, 21150, 21155, 21160		Foramen Magnum, tumour or vascular lesion, excisi	
21170, 21195, 21199-21200, 21202, 21210, 21212, 21214		Forearm, amputation or disarticulation of	44328
21216, 21220, 21230, 21232, 21234, 21260, 21270, 21272		forearm, wrist & hand 21800, 21810, 21820,	
21274-21275, 21280, 21300, 21321, 21340, 21360, 21380		21834, 21840, 21842, 21850, 21860, 21865, 2187	0, 21872
21382, 21390, 21392, 21400, 21402-21404, 21420, 21430		foreign body in cornea or sclera, removal of	42644
21432, 21440, 21445, 21460-21462, 21464, 21472, 21474		foreign body in, removal of	42563, 42569
21480, 21482, 21484, 21486, 21490, 21500, 21502, 21520	1	foreign body in, removal of, other than simple	41659
21522, 21530, 21532, 21535, 21600, 21610, 21620, 21622		foreign body in, superficial, removal of	30061
21630, 21632, 21634, 21636, 21638, 21650, 21652, 21654		Foreign body, antrum, removal of	41716
21656, 21670, 21680, 21682, 21685, 21700, 21710, 21712		foreign body, removal not otherwise covered	30064
21714, 21716, 21730, 21732, 21740, 21756, 21760, 21770		foreign body, removal of	42563, 42569
21772, 21780, 21785, 21790, 21800, 21810, 21820, 21830	ı	foreign, insertion for contour reconstruction	45051
21832, 21834, 21840, 21842, 21850, 21860, 21865, 21870		formation of, including enoscopic procedures	41885
21872, 21878-21887, 21900, 21906, 21908, 21910, 21912		fracture, treatment of 47348, 47351,	
21914-21916, 21918, 21922, 21925-21927, 21930, 21935-	21936	47384-47387, 47390, 47393, 47396, 47399, 47402	,
21939, 21941-21943, 21945, 21949, 21952, 21955, 21959		47408, 47411, 47414, 47417, 47420, 47423, 4742	
21962, 21965, 21969-21970, 21973, 21976, 21980, 21990		47432, 47435, 47438, 47441, 47444, 47447, 4745	
21992, 21997, 22001-22002, 22007-22008, 22012, 22014-	.22015	47453, 47456, 47459, 47462, 47465-47467, 4747	
22018, 22020, 22025, 22031, 22036, 22040, 22045	22013	47477, 47480, 47483, 47486, 47489, 47492, 4749	,
22050-22051, 22055, 22060, 22065, 22070, 22075, 22900		47501, 47504, 47507, 47510, 47516, 47519, 4752	
22905, 23010, 23021-23023, 23031-23033, 23041-23043		47528, 47531, 47534, 47537, 47543, 47546, 4754	
	22001	47555, 47558, 47561, 47564-47567, 47570, 4757	
23051-23053, 23061-23063, 23071-23073, 23081-23083, 23101, 23111, 23110, 23121, 23170, 23180, 23100, 23200	23091	, , , , , , , , , , , , , , , , , , , ,	,
23101, 23111-23119, 23121, 23170, 23180, 23190, 23200		47579, 47582, 47585, 47588, 47591, 47594, 4759	
23210, 23220, 23230, 23240, 23250, 23260, 23270, 23280		47603, 47627, 47630, 47633, 47636, 47639, 4764	*
23290, 23300, 23310, 23320, 23330, 23340, 23350, 23360		47648, 47651, 47654, 47657, 47735, 47738, 4774	
23370, 23380, 23390, 23400, 23410, 23420, 23430, 23440		50552, 50556, 50560, 50564, 50568, 50572, 5057	
23450, 23460, 23470, 23480, 23490, 23500, 23510, 23520			, 50504, 50508
23530, 23540, 23550, 23560, 23570, 23580, 23590, 23600		50512, 50516, 50520, 50524, 50528, 50532, 5053	0, 30340
23610, 23620, 23630, 23640, 23650, 23660, 23670, 23680		50544, 50548, 50580, 50584, 50588	110=0
23690, 23700, 23710, 23720, 23730, 23740, 23750, 23760		fractured, operation for	41873

fractured, operations for 39606, 39	609, 39612, 39615	Gastric bypass, by Biliopancreatic diversion, with	or without
	663, 47666, 47672	duodenal switch	31581
47678		gastric ulcer, suture of	30375
free fascia for facial nerve paralysis	45575, 45578	gastric, in the treatment of ingested poison	14200
free grafting 45406, 45409, 45412, 45		gastric, perforated, suture of	30375
45442, 45445, 45448, 45451, 45460-45462, 4		gastric, removal of	30520
45468-45469, 45471-45472, 45474-45475, 45	5477-45478	Gastro-camera investigation	30473
45480-45481, 45483-45494		Gastro-oesophageal balloon intubation	13506
Free grafts 45400, 45403, 45406, 45409, 45		gastrocnemius aponeurosis, operation for lengthe	
45439, 45442, 45445, 45448, 45451, 45460-45		Gastroduodenal stricture, balloon dilatation	30475
45464-45466, 45468-45469, 45471-45472, 454	1/4-454/5	Gastroontorootomy	30515 30515
45477-45478, 45480-45481, 45483-45494 free tissue transfer, complete revision of	45497	Gastroenterostomy Gastroplasty	31578
free tissue transfer, first stage revision of	45498	Gastropiasty Gastroschisis, operations for	43864, 43867
free tissue transfer, revision of	45496-45499	Gastroscopy	30473, 30478
free tissue transfer, second stage revision	45499	gastrosomy	30375
free transfer of	45563-45565	Gastrostomy button, non-endoscopic insertion/rep	
free, split skin 45400, 45403, 45406, 45	409, 45412, 45415	30636	ŕ
45418, 45439, 45442, 45445, 45448, 45451, 4	15460-45462	gastrostomy tube, jejunal extension	31460
45464-45466, 45468-45469, 45471-45472, 45	5474-45475	gastrostomy, percutaneous	30481-30482
45477-45478, 45480-45481, 45483-45494		Genioplasty	45761
frenuloplasty	37435	genito-urinary, repair	35596
Frenulum, mandibular or maxillary, repair	30281	Gilliam's operation	35684
frenulum, repair of	30281	gland bearing area, excision of	30180, 30183
frontal sinus	41740	gland tumour, excision of	30324
Frontal sinus, catheterisation of	41740 41740	gland, excision of palpebral lobe gland, extirpation of	42593 30256, 30259
frontal, catheterisation of frontal, radical obliteration of	41746	gland, extripation of gland, meatotomy or marsupialisation	30236, 30239
frontal, trephine of	41743		62, 30266, 30269
Fronto-ethmoidectomy, radical	41734	gland, superficial lobectomy/removal of tumour	30253
Fronto-nasal ethmoidectomy	41731	gland, total extirpation of	30247, 30250
Fronto-orbital advancement	45782, 45785	glands, biopsy of	30075, 30078
fronto-radical	41734	glands, groin, excision of	30329-30330
full face chemical peel	45019	glands, pelvic, radical excision of	35551
Full thickness grafts, free	45451	Glaucoma, filtering and allied operations for	42746, 42749
full thickness laceration, repair	30052	Glenoid fossa, reconstruction of	45788
full thickness laceration, repair of	30052	Glioma, craniotomy for removal of	39709
full thickness repair of laceration (restriction)	30052	Globe of eye, evisceration of	42512, 42515
full thickness wedge excision	45665	globe of, evisceration of	42512
full thickness wedge excision of	45665	Glomus tumour, transmastoid removal of	41623
Fundoplasty/plication, antireflux operation 30529-30530	30527	glomus, removal of	41620, 41623 41785
Funnel chest, elevation of	38457-38458	Glossectomy, with partial pharyngectomy Gonadal dysgenesis, vaginoplasty for	37851
Furuncle, incision with drainage of	30219, 30223	Goniotomy	42758
i didilete, illetsion with dramage of	30217, 30223	gracilis neosphincter	32210
G		graciloplasty	32203, 32209
•		Graciloplasty procedures 32200, 32203, 322	
Gallbladder, drainage of	30375	graciloplasty, insert. stimulator & electrode	32209
Galvanocautery of skin lesions	30192	graciloplasty, insertion of	32206
	203, 13206, 13209	graciloplasty, insertion of stimulator & electrode	
13212, 13215, 13218, 13221	, ,	Grafenberg's (or Graf) ring, introduction of	35503
Ganglion, excision of	30107	graft	45018
ganglion, excision of	46494	graft for priapism	37396
Gangliotomy, radiofrequency trigeminal	39109	graft over cornea	42638
Gangrenous tissue, debridement of	35100, 35103	graft to femur	48200, 48203
Gartner duct cyst, removal of	35557	graft to humerus	48212, 48215
Gastrectomy, partial	30518	graft to lid graft to nerve trunk	42860 39315
Gastrectomy, sleeve	31575	graft to herve trunk graft to orbit	42524
Gastric band reservoir, adjustment of	31590	graft to other bones	48239
Gastric band, adjustable, placement of	31569 31587	graft to other bones graft to phalanx or metacarpal	46402, 46405
Gastric band, adjustment of Gastric bypass by Roux-en-Y	31587 31572	graft to radius and ulna	48221
Gustile Oypuss by Mountell-1	313/4	5	

graft to radius or ulna	48218, 48224, 48227	harvesting, leg/arm, for bypass, not same limb	32760
graft to radius or ulna graft to scaphoid	48230, 48233, 48236		33551
graft to scaphold graft to tibia	48206, 48209	head 20100, 20102, 20104, 20120, 20124, 20140, 20142-	
Graft, axillo-femoral, infected, excision of	34172	20160, 20162, 20164, 20170, 20172, 20174, 20176, 20190	
graft, harvesting of	47726, 47729, 47732	20192, 20210, 20212, 20214, 20216, 20220, 20222, 20225	
graft, infected, excision of	34172	Heart arrhythmia, ablation of 38287, 38290,	
graft, infected, of extremities, excision of	34175	heart disease, operations for 38700, 38703, 38706,	
graft, infected, of neck, excision of	34157	38712, 38715, 38718, 38721, 38724, 38727, 38730, 38733	
graft, infected, of trunk, excision of	34169	38736, 38739, 38742, 38745, 38748, 38751, 38754, 38757	
graft, with internal fixation	48242	38760, 38763, 38766	
grafting for aneurysm	33050, 33055	Heller's operation 30532-	30533
grafting for symblepharon	45629	1 3	48915
grafting to artery or vein	33545, 33548	hemi-mandibular reconstruction with bone graft	45608
grafting, arterial, for occlusive arterial dise			49517
32703, 32708, 32710-32712, 32715, 327		Hemiarthroplasty, hand 46309, 46312, 46315, 46318,	
32730, 32733, 32736, 32739, 32742, 327	45, 32748, 32751	, 31 1	37354
32754, 32757, 32760, 32763		Hemicolectomy 32000, 32003,	
grafting, cross leg, saphenous to iliac or fe		hemicolectomy 32000, 32003,	
Granuloma, cautery of	42677		48509
granuloma, excision under GA	43948	,	45791
granulomatous disease	44130	hemifacial spasm 18350-	
granuloplasty, meatal advancement	37818-37819		41837
Gravid uterus, evacuation of contents by cu	•	1 11	40706
gravid, evacuation of contents	35643		30306
Great vessel, intrathoracic operation on, oth			35536
Great vessel, ligation or exploration, other		Hepatic duct, common, resection for carcinoma 30463-	30464
Greater trochanter, transplant of ileopsoas to greater trochanter, transplantation of	endon 50121 50121	hepatic, destruction of liver tumours Hernia, antireflux operations for 30527, 30529-30530,	
Groin, lymph, excision of	30329-30330	43841	43030
growth retardation, attendance for	16508		43805
growth stimulator	45821	hernia, repair of 30403, 30600-30601, 30609, 30614,	
Gunderson flap operation	42638	hernia, repair, age less than 3 months 44108, 44111,	
Gynaecological examination under GA	35500		30640
gynaecological, radical or debulking opera			30238
Gynatresia, vaginal reconstruction for	35565	Hiatus hernia, antireflux operations for 30527, 30529-	
, ,		Hickman catheter, insertion of, for chemotherapy 34527-	
Н			37227
		high energy transurethral microwave thermotherapy	37230
Haemangioma, cauterisation of (restriction)	45027	37233	
Haemapheresis	13750, 13755	1 / 1	44373
Haematoma, aspiration of	30216	1 1 7	35614
haematoma, drainage of	30387	hip 49303, 49306, 49309, 49312, 49315, 49318-49319,	
Haemochromatosis	13757	49324, 49327, 49330, 49333, 49346, 49360, 49363, 49366	
Haemodialysis, in hospital	13100, 13103		44370
Haemofiltration, continuous (ICU)	13885, 13888		30375
Haemoperfusion, in hospital	13100, 13103		13104 14206
Haemorrhage, antepartum, treatment of	16509	Hormone implantation, by cannula hormone or living tissue 14203,	
haemorrhage, arrest of	41656, 41677	humerus 48412,	
haemorrhage, burr-hole craniotomy for	39600, 39603	Humerus, bone graft to 48212,	
Haemorrhoidectomy	32138-32139		42848
Hair transplants, congenital/traumatic alope		Hydatid cyst, liver, total excision of 30437-	
Hallux rigidus/valgus, correction of 49830, 49833, 49836-49839, 49842	49821, 49824, 49827	hydatid cyst, removal of contents of 30434,	
hallux valgus or hallux rigidus, correction	of 49821	hydatid cyst, total excision of 30437-	
49824, 49827, 49830, 49833, 49836-498.			38424
hammer or claw, correction of	49848, 49851		38424
Hammer toe, correction of	49848	hydatid, liver, treatment of 30434, 30436-	
hamstring tendon transfer	50357, 50360		38424
Hand, amputation or disarticulation of	44325, 44328		31245
hand, excision of	46494-46495, 46498	Hydrocele, infantile, repair of	30614
Hartmann's operation	32030	Hydrocephalus, operations for 40000, 40003, 40006,	40009
harvesting for coronary bypass	38496	Hydrocortisone, injections into keloid with GA	30210

Hydrodilatation of bladder with cystoscopy 36827	in oral & maxillofacial, uncomplicated, removal of 45801
Hydrotubation of Fallopian tubes 35703, 35709	in oral & maxillofacial, uncomplicated, removal of 45801 45803, 45805, 45807, 45809
Hymenectomy 35509	in oral and maxillofacial region 45801, 45803, 45805
Hyperbaric oxygen therapy 13020, 13025, 13030	45807
Hyperemesis gravidarum, treatment of 16505	in relation to eye 42734
Hyperextension deformity of toe, release, lengthening 50345	in situ in drum, removal of 41500
hyperextension deformity, release, lengthening 50345	Incidental appendicectomy 30574
Hyperhidrosis, axillary, excision for 30180, 30183	incision and drainage, without GA 30219
Hyperparathyroidism, operations for 30315, 30317-30318	incision of palate 41787
30320	incision/resection, external sphincter/bladder neck 36854
hyperplasia, congenital, vaginoplasty for 37851	Incisional hernia, repair of 30403
Hyperplasia, papillary, of palate, removal of 45831, 45833	incisions for astigmatism 42672
45835	Incomplete confinement 16518
Hypertelorism, correction, intra/sub-cranial 45767, 45770 Hypertension, portal, treatment of 30602-30603, 30605-30606	incomplete, curettage for 35640 Incontinence, anal, Parks' intersphincteric procedure 32126
hypertension, portar, treatment of 30002-30003, 30003-30000 hypertrophic obstructive cardiomyopathy 38650	incontinence, Parks' procedure 32126
Hypertrophied tissue, removal of 45801, 45803, 45805, 45807	indirect 45227, 45230, 45233, 45236
Hypospadias, examination under GA 37815-37816, 37819, 37822	Indirect flap 45227, 45230, 45233, 45236, 45239
37825, 37828	Indwelling oesophageal tube, gastrostomy for fixation 30375
Hypothenar spaces of hand, drainage of 46519	Infantile hydrocele, repair of 30614
Hysterectomy 35653, 35657-35658, 35661, 35664, 35667, 35670	Infection, acute intercurrent, complicating pregnancy 16508
35673	infection, drainage of via burr-hole 39900
hysterectomy 35657, 35673	Inferior vena cava, thrombectomy 33810-33811
Hysteroscopic resection of myoma or uterine septum 35623	Inflammation of middle ear, operation for 41626
35634	Infliximab 14245
Hysteroscopy 35626-35627, 35630, 35633-35636	Infusion chemotherapy 13915, 13918, 13921, 13924, 13927
Hysterotomy 35649	13930, 13933, 13936 infusion chemotherapy 13927, 13930, 13933, 13936
1	infusion, cannulation for 34521, 34524
ı	infusion, of sympatholytic agent 14209
IGRT 15715	Ingrowing eyelashes, operation for 45626
Ileal atresia, neonatal, laparotomy for 43816	ingrowing nail, resection 46528, 46531
Ileo-femoral by-pass grafting 32712, 32718	ingrowing nail, resection of 46528, 46531
ileo-rectal, with total colectomy 32012	ingrowing, of finger or thumb, resection 46528, 46531
Ileorectal anastomosis 32012	ingrowing, of toe, excision/resection 47915-47916, 47918
Ileostomy 30639, 32009, 32012, 32015, 32018, 32021	ingrown, of toe, operation under GA, paediatric 44136
ileostomy closure/reservoir 32060, 32063, 32066, 32069	ingrown, operation with GA, paediatric 44136
Iliac endarterectomy 33518	Inguinal abscess, incision of 30223
Iliac vessel, ligation or exploration not otherwise covered 34103	inguinal, repair, age less than 3 months 44108, 44111
Iliopsoas tendon transfer to greater trochanter 50387	injection for impotence 37415
iliopsoas tendon transfer to greater trochanter 50387	injection of impotence 37413 injection of alcohol 42824
impalpable, exploration of groin 37812 Implanon, removal of 30062	injection of sclerosant fluid under anaesthesia 30679
Implant, cochlear, insertion of 41617	injection, peri-urethral 37339
implant, contour reconstruction, insertion 45051	Injections, multiple, for skin lesions 30207
implant, enucleation of eye 42506, 42509	Inlay graft, using a mould 45445
implant, evisceration of eye and insertion of 42515	inlay, using a mould 45445
implant, removal of 39136	Innocent bone tumour, excision of 30241
implantable bone conduction hearing system 41603-41604	Innominate artery, endarterectomy of 33506
Implantable Cardioverter Defibrillator 38371, 38384, 38387	insemination services 13203, 13209, 13221
implantation of Fallopian tubes into 35694, 35697	insertion of 41632 insertion of nasogastric/nasoenteral tube 31456, 31458
implantation, direct, incision and suture 14203	insertion of patches for 38390
Implantation, fallopian tubes into uterus 35694, 35697	insertion of patients for insertion of, for drainage of middle ear 41632
implanted drug delivery system 14227, 14230, 14233, 14236 14239, 14242	insertion or removal from eye socket 42518
Impotence, injection for investigation/treatment 37415	insertion, transluminal 35306-35307, 35309
IMRT 15275, 15555, 15565	insertion, transluminal, rotational atherectomy 38312
in ano, subcutaneous, excision of 32156	38318
in conjunction with Caesarean section 35691	Insufflation Fallopian tubes, for patency (Rubin test) 35706
in hospital 13100, 13103	intact wall technique, with myringoplasty 41551, 41554
in oral & maxillofacial, complicated, removal 45811	Intensive care management/procedures 13815, 13818, 13830
45813	13839, 13842, 13847-13848, 13851, 13854, 13857, 13870

13873, 13876, 13881-13882, 13885, 13888			20540, 20542, 20546, 20548, 20560	
intensive care unit (specialist)	13870.	13873	Intrathoracic operation on heart, lungs, etc, other	38456
Intercostal drain, insertion of		38809	intrathoracic operation on, not otherwise covered	38456
Internal auditory meatus, exploration of	•	41599	intrathoracic operation, not otherwise covered	38456
internal auditory, exploration of		41599	intrathoracic, congenital heart disease	38727, 38730
	, 35406,	35408	Intrauterine contraceptive device, introduction of	35503
interosseous muscle space of hand		47981	intravascular blood transfusion	16609
Interosseous muscle space of hand, fasciotomy of		47981	Intravenous infusion chemotherapy 13915, 13918,	, 13921, 13924
Interphalangeal joint, arthrodesis of		46300	Intraventricular baffle, insertion of	38754
interruption, repair of		38712	intubation	30488
Interscapulothoracic amputation or disarticulation		44334	intubation, gastro-oesophageal	13506
Interventional endovascular procedures		, 35303	Intubation, small bowel	30488
35306-35307, 35309, 35312, 35315, 35317, 35319	9-35321		Intussusception, reduction of	30375
35324, 35327, 35330, 35414, 38306			inverted, surgical eversion of	31563
Intestinal conduit or reservoir, endoscopic examinat	tion	36860	Invitro fertilisation 13200, 13203, 13206,	, 13209, 13212
intestinal remnant, abdominal wall, excision of		43942	13215, 13218, 13221	
intestine, resection of		-30566	involving ciliary body an/or iris, excision of	42767
intestine, subtotal colectomy	32004	-32005	involving division of adhesions	38643, 38647
into angioma (restriction applies)		45027	involving gynaecology (exc. hysterectomy)	35713, 35717
into prostate		37218	involving procedures via laparoscope	35637-35638
into spinal joints or nerves		39013	ionisation of	35608
Intra-abdominal artery/vein, cannulation, chemothe	rapy	34521	Ionisation, cervix	35608
intra-abdominal vessel, for chemotherapy		34521	Iridectomy	42764
intra-abdominal, cannulation, infusion chemothera		34521	iridectomy and sclerectomy for	42746
Intra-anal abscess, drainage of		-32175	iridectomy or iridotomy	42764
Intra-aortic balloon, counterpulsation, management Intra-arterial cannulisation for blood collection	1384/		Iridencleisis	42746
		13842	Iridocyclectomy	42767
intra-arterial, sympatholytic agent Intra-atrial baffle, insertion of		14209 38745	Iridotomy	42764 42785
Intra-atrial battle, insertion of Intra-epithelial neoplasia, laser therapy for	25520	38743	iridotomy iridotomy, laser	42785
35545	33339,	, 33342	Iris and ciliary body, excision of tumour of	42767
Intra-ocular excision of dermoid of eye		42574	iris tumour, laser photocoagulation	42806
intra-ocular, removal of	12563	, 42569	iris, excision of	42764
Intra-operative ultrasound, biliary tract	42303,	30439	Ischaemic limb, debridement of deep tissue	35100
Intra-oral tumour, radical excision of		30275	ischaemic, debridement of tissue	35100, 35103
intra-oral, radical excision of		30275	Ischio-rectal abscess, drainage of	32174-32175
Intra-orbital abscess, drainage of		42572	ischio-rectal, drainage of	32174-32175
intra-orbital, drainage of		42572	island flap, with vascular pedicle	45563
intra-temporal fossa, removal of		41578		
Intracerebral tumour, craniotomy and removal of		39709	J	
intracerebral, craniotomy and removal of		39709	•	
Intracranial abscess, excision of		39903	Jaw, dislocation, treatment of	47000
intracranial placement	40709.	40712	Jejunal atresia, bowel resection and anastomosis	43810
intracranial proximal artery clipping		39806	Jejunostomy, operative feeding	31462
intracranial, biopsy/decompression, osteoplastic fl	ар	39706	joint disruption, treatment of	47513
intracranial, burr-hole biopsy or drainage		39703	Joint, application of external fixator, not for fracture	
intracranial, burr-hole craniotomy for		39600	joint, arthroplasty 46306-46307, 46309.	
intracranial, craniotomy and removal of	39709,	, 39712	46318, 46321	,,
intracranial, excision of		39903	joint, arthrotomy	46327, 46330
intracranial, for pressure monitoring		13830	joint, arthrotomy of	46327, 46330
intracranial, for trigeminal neuralgia		39106		, 47033, 47036
intracranial, ligation cervical vessels		39812	47039, 47042, 47045	•
intracranial, needling and drainage of		39703	joint, distal, reconstruction/stabilisation	46345
Intrahepatic bypass	30466	-30467	joint, distal, synovectomy	46342
intranasal operation on		41737	joint, external fixation, application of	45879
Intranasal operation on antrum/removal offoreign b	ody	41716	joint, hemiarthroplasty 46309, 46312, 46315,	, 46318, 46321
intranasal, operation on		41716	joint, interposition arthroplasty of	46306
intraocular, repositioning of	1664-	42713	joint, irrigation of	45865
intraperitoneal blood transfusion	16612,	, 16615	joint, joint capsule release of	46381
Intrascleral ball or cartilage, insertion of		42515	joint, ligamentous repair	46333
Intrathecal infusion device, revision of intrathoracic 20500, 20520, 20522, 20524	20526	39133	joint, ligamentous repair of	46333
intrathoracic 20500, 20520, 20522, 20524	r, 20320,	, 20328	joint, Lisfranc's amputation of	44364

	45051	T 1 1 1: : :	41060
joint, manipulation of	45851	Laryngeal web, division of	41868
	361, 45863, 45865	Laryngectomy Laryngofissure, external operation on	41834
45867, 45869, 45871, 45873	02 50100 50127	Laryngonissure, external operation on Laryngopharyngectomy	41876 41843
joint, other 50100, 50102-501 joint, synovectomy of	46342	Laryngopharyngectomy Laryngoplasty	41876, 41879
joint, synovectomy/capsulectomy/debridement	46336	Laryngoscopy	41876, 41879
joint, total replacement arthroplasty of	46309, 46312	Larynx, direct examination of	41846
46315, 46318, 46321	10307, 10312	laser	30191, 42785
joint, total replacement of	49857	laser ablation of prostate	37207-37208
joint, volar plate arthroplasty	46307	laser angioplasty	35315
juice, collection of	30488	laser photocoagulation	42806
Juvenile cataract, removal of	42716	laser resection of endobronchial tumours	41901
juxtasceral Depot injection	42741	laser therapy (restriction applies) 3553	39, 35542, 35545
K		laser therapy for intraepithelial neoplasia 35545	35539, 35542
		laser therapy of gastrointestinal tract	30479
Keratectomy, partial, for corneal scars	42647	laser therapy, intraepithelial neoplasia	35539, 35542
Keratoplasty	42653, 42656	35545	
keratoplasty, epithelial debridement for	42651	Laser: ablation of prostate, endoscopic	37207-37208
Keratosis, obturans, surgical removal	41509	Lateral pharyngeal bands, removal of	41804
Kidney, dialysis, in hospital	13100, 13103	Lavage and proof puncture of maxillary antrum	41698, 41701
kidney, removal from	36558	lavage in the treatment of ingested poison	14200
kidney, removal of	36540, 36543	lavage, total, intra-operative	32186
Kirschner wire, insertion of	47921	Le Fort osteotomies	45753-45754
knee 49500, 49509, 49512, 49517-49519, 495		leaflet/s, aortic, decalcification of	38483
49530, 49533-49534, 49545, 49557-49564, 49		left ventricular, plication of left ventricular, resection	38506 38507-38508
knee & popliteal area 21300, 21321, 213		Leg, amputation	44367, 44370
21382, 21390, 21392, 21400, 21402-21404, 21	1420, 21430	leg, lower (below knee) 21460-21462, 2146	·
21432, 21440	44367	21480, 21482, 21484, 21486, 21490, 21500, 21	
Knee, amputation at or below knee, removal of	49515	21522, 21530, 21532	302, 21320
KIICC, ICIIIOVAI OI	7/313		00 21202 21210
•		leg,upper (except knee) 21195, 21199-2120	
L		21212, 21214, 21216, 21220, 21230, 21232, 21	
L		21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280	234, 21260
	41572	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora	234, 21260 37423
L Labyrinth, destruction of Labyrinthotomy	41572 41572	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora lengthening procedures	234, 21260 37423 50303, 50306
Labyrinth, destruction of	41572 pair 30052	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora lengthening procedures Lens, artificial, insertion of	234, 21260 37423 50303, 50306 42701, 42703
Labyrinth, destruction of Labyrinthotomy Laceration, ear/eyelid/nose/lip, full thickness, replacerations not involving sclera	41572 9air 30052 30032	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora lengthening procedures Lens, artificial, insertion of lens, insertion of	234, 21260 37423 50303, 50306 42701, 42703 42701
Labyrinth, destruction of Labyrinthotomy Laceration, ear/eyelid/nose/lip, full thickness, replacerations not involving sclera Lacrimal canalicular system, establishment paten	41572 9air 30052 30032	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora lengthening procedures Lens, artificial, insertion of lens, insertion of lens, removal of	234, 21260 37423 50303, 50306 42701, 42703 42701 42704
Labyrinth, destruction of Labyrinthotomy Laceration, ear/eyelid/nose/lip, full thickness, replacerations not involving sclera Lacrimal canalicular system, establishment paten 42602	41572 30052 30032 cy 42599	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora lengthening procedures Lens, artificial, insertion of lens, insertion of lens, removal of lens, removal, replacement different lens	234, 21260 37423 50303, 50306 42701, 42703 42701 42704 42707
Labyrinth, destruction of Labyrinthotomy Laceration, ear/eyelid/nose/lip, full thickness, replacerations not involving sclera Lacrimal canalicular system, establishment paten 42602 lacrimal, excision of palpebral lobe	41572 30052 30032 cy 42599 42593	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora lengthening procedures Lens, artificial, insertion of lens, insertion of lens, removal of lens, removal, replacement different lens lens, repositioning of, open operation	234, 21260 37423 50303, 50306 42701, 42703 42701 42704 42707 42704
Labyrinth, destruction of Labyrinthotomy Laceration, ear/eyelid/nose/lip, full thickness, replacerations not involving sclera Lacrimal canalicular system, establishment paten 42602 lacrimal, excision of palpebral lobe Lagrange's operation (iridectomy and sclerectom)	41572 30052 30032 cy 42599 42593 y) 42746	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora lengthening procedures Lens, artificial, insertion of lens, insertion of lens, removal of lens, removal, replacement different lens lens, repositioning of, open operation Lensectomy	234, 21260 37423 50303, 50306 42701, 42703 42701 42704 42707 42704 42731
Labyrinth, destruction of Labyrinthotomy Laceration, ear/eyelid/nose/lip, full thickness, replacerations not involving sclera Lacrimal canalicular system, establishment paten 42602 lacrimal, excision of palpebral lobe Lagrange's operation (iridectomy and sclerectomy Laminectomy and insertion of epidural implant	41572 30052 30032 cy 42599 42593 y) 42746 39139	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora lengthening procedures Lens, artificial, insertion of lens, insertion of lens, removal of lens, removal, replacement different lens lens, repositioning of, open operation Lensectomy lesion, pre-op localisation, for ABBI	234, 21260 37423 50303, 50306 42701, 42703 42701 42704 42707 42704 42731 31542
Labyrinth, destruction of Labyrinthotomy Laceration, ear/eyelid/nose/lip, full thickness, replacerations not involving sclera Lacrimal canalicular system, establishment paten 42602 lacrimal, excision of palpebral lobe Lagrange's operation (iridectomy and sclerectomy Laminectomy and insertion of epidural implant Laparascopic division of adhesions 314	41572 30052 30032 cy 42599 42593 y) 42746 39139 450, 31452, 35637	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora lengthening procedures Lens, artificial, insertion of lens, insertion of lens, removal of lens, removal, replacement different lens lens, repositioning of, open operation Lensectomy lesion, pre-op localisation, for ABBI lesion, pre-op localisation, imaging guided	234, 21260 37423 50303, 50306 42701, 42703 42701 42704 42707 42704 42731
Labyrinth, destruction of Labyrinthotomy Laceration, ear/eyelid/nose/lip, full thickness, replacerations not involving sclera Lacrimal canalicular system, establishment paten 42602 lacrimal, excision of palpebral lobe Lagrange's operation (iridectomy and sclerectomy Laminectomy and insertion of epidural implant Laparascopic division of adhesions 314 laparoscopic 303	41572 30052 30032 cy 42599 42599 y) 42746 39139 450, 31452, 35637 191, 31470, 35638	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora lengthening procedures Lens, artificial, insertion of lens, insertion of lens, removal of lens, removal, replacement different lens lens, repositioning of, open operation Lensectomy lesion, pre-op localisation, for ABBI	37423 50303, 50306 42701, 42703 42701 42704 42707 42704 42731 31542 31536
Labyrinth, destruction of Labyrinthotomy Laceration, ear/eyelid/nose/lip, full thickness, replacerations not involving sclera Lacrimal canalicular system, establishment paten 42602 lacrimal, excision of palpebral lobe Lagrange's operation (iridectomy and sclerectomy Laminectomy and insertion of epidural implant Laparascopic division of adhesions 314 laparoscopic 303 Laparoscopic resection of	41572 30052 30032 cy 42599 42599 y) 42746 39139 450, 31452, 35637 191, 31470, 35638 35641	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora lengthening procedures Lens, artificial, insertion of lens, insertion of lens, removal of lens, removal, replacement different lens lens, repositioning of, open operation Lensectomy lesion, pre-op localisation, for ABBI lesion, pre-op localisation, imaging guided lesion/s, removal, diaphyseal aclasia	37423 50303, 50306 42701, 42703 42701 42704 42707 42704 42731 31542 31536 50426
Labyrinth, destruction of Labyrinthotomy Laceration, ear/eyelid/nose/lip, full thickness, replacerations not involving sclera Lacrimal canalicular system, establishment paten 42602 lacrimal, excision of palpebral lobe Lagrange's operation (iridectomy and sclerectomy Laminectomy and insertion of epidural implant Laparascopic division of adhesions 314 laparoscopic 303 Laparoscopic resection of laparoscopically assisted 35750, 357	41572 30052 30032 cy 42599 42599 y) 42746 39139 450, 31452, 35637 191, 31470, 35638 35641 753-35754, 35756	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora lengthening procedures Lens, artificial, insertion of lens, insertion of lens, removal of lens, removal, replacement different lens lens, repositioning of, open operation Lensectomy lesion, pre-op localisation, for ABBI lesion, pre-op localisation, imaging guided lesion/s, removal, diaphyseal aclasia lesions, multiple injections for	37423 50303, 50306 42701, 42703 42701 42704 42707 42704 42731 31542 31536 50426 30207
Labyrinth, destruction of Labyrinthotomy Laceration, ear/eyelid/nose/lip, full thickness, replacerations not involving sclera Lacrimal canalicular system, establishment patent 42602 lacrimal, excision of palpebral lobe Lagrange's operation (iridectomy and sclerectomy Laminectomy and insertion of epidural implant Laparascopic division of adhesions 314 laparoscopic 303 Laparoscopic resection of laparoscopically assisted 35750, 357 laparoscopically assisted hysterectomy 357	41572 30052 30032 cy 42599 42599 y) 42746 39139 450, 31452, 35637 191, 31470, 35638 35641	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora lengthening procedures Lens, artificial, insertion of lens, insertion of lens, removal of lens, removal, replacement different lens lens, repositioning of, open operation Lensectomy lesion, pre-op localisation, for ABBI lesion, pre-op localisation, imaging guided lesion/s, removal, diaphyseal aclasia lesions, multiple injections for Lesions, skin, multiple injections for lesions, treatment of Leveen shunt, insertion of	37423 50303, 50306 42701, 42703 42701 42704 42707 42704 42731 31542 31536 50426 30207 30207 30192 30408
Labyrinth, destruction of Labyrinthotomy Laceration, ear/eyelid/nose/lip, full thickness, replacerations not involving sclera Lacrimal canalicular system, establishment patenta 42602 lacrimal, excision of palpebral lobe Lagrange's operation (iridectomy and sclerectomy Laminectomy and insertion of epidural implant Laparascopic division of adhesions 314 laparoscopic 303 Laparoscopic resection of laparoscopically assisted 35750, 357 laparoscopically assisted hysterectomy 35756	41572 30052 30032 cy 42599 42599 42593 y) 42746 39139 450, 31452, 35637 491, 31470, 35638 35641 753-35754, 35756 750, 35753-35754	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora lengthening procedures Lens, artificial, insertion of lens, insertion of lens, removal of lens, removal, replacement different lens lens, repositioning of, open operation Lensectomy lesion, pre-op localisation, for ABBI lesion, pre-op localisation, imaging guided lesion/s, removal, diaphyseal aclasia lesions, multiple injections for Lesions, skin, multiple injections for lesions, treatment of Leveen shunt, insertion of Lid, ophthalmic, suturing of	37423 50303, 50306 42701, 42703 42701 42704 42707 42704 42731 31542 31536 50426 30207 30207 30192 30408 42584
Labyrinth, destruction of Labyrinthotomy Laceration, ear/eyelid/nose/lip, full thickness, replacerations not involving sclera Lacrimal canalicular system, establishment paten 42602 lacrimal, excision of palpebral lobe Lagrange's operation (iridectomy and sclerectomy Laminectomy and insertion of epidural implant Laparascopic division of adhesions 314 laparoscopic 303 Laparoscopic resection of laparoscopically assisted 35750, 357 laparoscopically assisted hysterectomy 35756 Laparoscopy and hysteroscopy under GA	41572 30052 30032 cy 42599 42599 42593 y) 42746 39139 450, 31452, 35637 491, 31470, 35638 35641 753-35754, 35756 750, 35753-35754	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora lengthening procedures Lens, artificial, insertion of lens, insertion of lens, removal of lens, removal, replacement different lens lens, repositioning of, open operation Lensectomy lesion, pre-op localisation, for ABBI lesion, pre-op localisation, imaging guided lesion/s, removal, diaphyseal aclasia lesions, multiple injections for Lesions, skin, multiple injections for lesions, treatment of Leveen shunt, insertion of Lid, ophthalmic, suturing of ligament or tendon transfer	37423 50303, 50306 42701, 42703 42701 42704 42707 42704 42731 31542 31536 50426 30207 30207 30192 30408 42584 49503, 49506
Labyrinth, destruction of Labyrinthotomy Laceration, ear/eyelid/nose/lip, full thickness, replacerations not involving sclera Lacrimal canalicular system, establishment paten 42602 lacrimal, excision of palpebral lobe Lagrange's operation (iridectomy and sclerectomy Laminectomy and insertion of epidural implant Laparascopic division of adhesions 314 laparoscopic 303 Laparoscopic resection of laparoscopically assisted 35750, 357 laparoscopically assisted hysterectomy 35756 Laparoscopy and hysteroscopy under GA laparoscopy, complicated	41572 30052 30032 cy 42599 42599 42593 y) 42746 39139 450, 31452, 35637 491, 31470, 35638 35641 753-35754, 35756 750, 35753-35754	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora lengthening procedures Lens, artificial, insertion of lens, insertion of lens, removal of lens, removal, replacement different lens lens, repositioning of, open operation Lensectomy lesion, pre-op localisation, for ABBI lesion, pre-op localisation, imaging guided lesion/s, removal, diaphyseal aclasia lesions, multiple injections for Lesions, skin, multiple injections for lesions, treatment of Leveen shunt, insertion of Lid, ophthalmic, suturing of ligament or tendon transfer Ligament, finger joint, repair of	37423 50303, 50306 42701, 42703 42701 42704 42707 42704 42731 31542 31536 50426 30207 30207 30192 30408 42584 49503, 49506 46333
Labyrinth, destruction of Labyrinthotomy Laceration, ear/eyelid/nose/lip, full thickness, replacerations not involving sclera Lacrimal canalicular system, establishment paten 42602 lacrimal, excision of palpebral lobe Lagrange's operation (iridectomy and sclerectomy Laminectomy and insertion of epidural implant Laparascopic division of adhesions 314 laparoscopic 303 Laparoscopic resection of laparoscopically assisted 35750, 357 laparoscopically assisted hysterectomy 35756 Laparoscopy and hysteroscopy under GA laparoscopy, complicated Laparoscopy, diagnostic	41572 30052 30032 cy 42599 42599 42593 y) 42746 39139 450, 31452, 35637 491, 31470, 35638 35641 753-35754, 35756 750, 35753-35754	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora lengthening procedures Lens, artificial, insertion of lens, insertion of lens, removal of lens, removal, replacement different lens lens, repositioning of, open operation Lensectomy lesion, pre-op localisation, for ABBI lesion, pre-op localisation, imaging guided lesion/s, removal, diaphyseal aclasia lesions, multiple injections for Lesions, skin, multiple injections for lesions, treatment of Leveen shunt, insertion of Lid, ophthalmic, suturing of ligament or tendon transfer Ligament, finger joint, repair of ligament, transverse, division of	37423 50303, 50306 42701, 42703 42701 42704 42707 42704 42731 31542 31536 50426 30207 30207 30192 30408 42584 49503, 49506 46333 39331
Labyrinth, destruction of Labyrinthotomy Laceration, ear/eyelid/nose/lip, full thickness, replacerations not involving sclera Lacrimal canalicular system, establishment paten 42602 lacrimal, excision of palpebral lobe Lagrange's operation (iridectomy and sclerectomy Laminectomy and insertion of epidural implant Laparascopic division of adhesions 314 laparoscopic 303 Laparoscopic resection of laparoscopically assisted 35750, 353 laparoscopically assisted hysterectomy 35756 Laparoscopy and hysteroscopy under GA laparoscopy, complicated Laparoscopy, diagnostic Laparoscomy	41572 9air 30052 30032 cy 42599 42599 42593 y) 42746 39139 450, 31452, 35637 491, 31470, 35638 35641 753-35754, 35756 750, 35753-35754 35636 35641 30627	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora lengthening procedures Lens, artificial, insertion of lens, insertion of lens, removal of lens, removal, replacement different lens lens, repositioning of, open operation Lensectomy lesion, pre-op localisation, for ABBI lesion, pre-op localisation, imaging guided lesion/s, removal, diaphyseal aclasia lesions, multiple injections for Lesions, skin, multiple injections for lesions, treatment of Leveen shunt, insertion of Lid, ophthalmic, suturing of ligament or tendon transfer Ligament, finger joint, repair of ligament, transverse, division of ligamentous stabilisation of	37423 50303, 50306 42701, 42703 42701 42704 42707 42704 42731 31542 31536 50426 30207 30207 30192 30408 42584 49503, 49506 46333 39331 49103, 49709
Labyrinth, destruction of Labyrinthotomy Laceration, ear/eyelid/nose/lip, full thickness, replacerations not involving sclera Lacrimal canalicular system, establishment paten 42602 lacrimal, excision of palpebral lobe Lagrange's operation (iridectomy and sclerectomy Laminectomy and insertion of epidural implant Laparascopic division of adhesions 314 laparoscopic 303 Laparoscopic resection of laparoscopically assisted 35750, 353 laparoscopically assisted hysterectomy 35756 Laparoscopy and hysteroscopy under GA laparoscopy, complicated Laparoscopy, diagnostic Laparostomy Laparotomy and division of adhesions 30623, 30626	41572 30052 30032 cy 42599 42599 42593 y) 42746 39139 450, 31452, 35637 491, 31470, 35638 35641 753-35754, 35756 750, 35753-35754 35636 35641 30627 30397, 30399	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora lengthening procedures Lens, artificial, insertion of lens, insertion of lens, removal of lens, removal, replacement different lens lens, repositioning of, open operation Lensectomy lesion, pre-op localisation, for ABBI lesion, pre-op localisation, imaging guided lesion/s, removal, diaphyseal aclasia lesions, multiple injections for Lesions, skin, multiple injections for lesions, treatment of Leveen shunt, insertion of Lid, ophthalmic, suturing of ligament or tendon transfer Ligament, finger joint, repair of ligamentous stabilisation of ligamentous stabilisation of ligation of maxillary artery	37423 50303, 50306 42701, 42703 42701 42704 42707 42704 42731 31542 31536 50426 30207 30207 30192 30408 42584 49503, 49506 46333 39331 49103, 49709 41707
Labyrinth, destruction of Labyrinthotomy Laceration, ear/eyelid/nose/lip, full thickness, replacerations not involving sclera Lacrimal canalicular system, establishment paten 42602 lacrimal, excision of palpebral lobe Lagrange's operation (iridectomy and sclerectomy Laminectomy and insertion of epidural implant Laparascopic division of adhesions 314 laparoscopic 303 Laparoscopic resection of laparoscopically assisted 35750, 357 laparoscopically assisted hysterectomy 35756 Laparoscopy and hysteroscopy under GA laparoscopy, complicated Laparoscopy, diagnostic Laparostomy Laparotomy and division of adhesions 30623, 30626 laparotomy for drainage of	41572 30052 30032 cy 42599 42599 42593 y) 42746 39139 450, 31452, 35637 491, 31470, 35638 35641 753-35754, 35756 750, 35753-35754 35636 35641 30627 30397, 30399 376, 30378-30379 30394	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora lengthening procedures Lens, artificial, insertion of lens, insertion of lens, removal of lens, removal, replacement different lens lens, repositioning of, open operation Lensectomy lesion, pre-op localisation, for ABBI lesion, pre-op localisation, imaging guided lesion/s, removal, diaphyseal aclasia lesions, multiple injections for Lesions, skin, multiple injections for lesions, treatment of Leveen shunt, insertion of Lid, ophthalmic, suturing of ligament or tendon transfer Ligament, finger joint, repair of ligament, transverse, division of ligamentous stabilisation of ligation of maxillary artery ligation or exploration not otherwise covered	37423 50303, 50306 42701, 42703 42701 42704 42707 42704 42731 31542 31536 50426 30207 30207 30192 30408 42584 49503, 49506 46333 39331 49103, 49709 41707 34106
Labyrinth, destruction of Labyrinthotomy Laceration, ear/eyelid/nose/lip, full thickness, replacerations not involving sclera Lacrimal canalicular system, establishment paten 42602 lacrimal, excision of palpebral lobe Lagrange's operation (iridectomy and sclerectomy Laminectomy and insertion of epidural implant Laparascopic division of adhesions 314 laparoscopic 303 Laparoscopic resection of laparoscopically assisted 35750, 357 laparoscopically assisted hysterectomy 35756 Laparoscopy and hysteroscopy under GA laparoscopy, complicated Laparoscopy, diagnostic Laparostomy Laparotomy and division of adhesions 30623, 30626 laparotomy for drainage of Large intestine, resection of	41572 30052 30032 cy 42599 42599 42593 y) 42746 39139 450, 31452, 35637 491, 31470, 35638 35641 753-35754, 35756 750, 35753-35754 35636 35641 30627 30397, 30399 376, 30378-30379 30394 32000, 32003	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora lengthening procedures Lens, artificial, insertion of lens, insertion of lens, removal of lens, removal, replacement different lens lens, repositioning of, open operation Lensectomy lesion, pre-op localisation, for ABBI lesion, pre-op localisation, imaging guided lesion/s, removal, diaphyseal aclasia lesions, multiple injections for Lesions, skin, multiple injections for lesions, treatment of Leveen shunt, insertion of Lid, ophthalmic, suturing of ligament or tendon transfer Ligament, finger joint, repair of ligament, transverse, division of ligamentous stabilisation of ligation of maxillary artery ligation or exploration not otherwise covered Ligation, great vessel	37423 50303, 50306 42701, 42703 42701 42704 42707 42704 42731 31542 31536 50426 30207 30207 30192 30408 42584 49503, 49506 46333 39331 49103, 49709 41707 34106 34103
Labyrinth, destruction of Labyrinthotomy Laceration, ear/eyelid/nose/lip, full thickness, replacerations not involving sclera Lacrimal canalicular system, establishment patend 42602 lacrimal, excision of palpebral lobe Lagrange's operation (iridectomy and sclerectomy Laminectomy and insertion of epidural implant Laparascopic division of adhesions 314 laparoscopic 303 Laparoscopic resection of laparoscopically assisted 35750, 357 laparoscopically assisted hysterectomy 35756 Laparoscopy and hysteroscopy under GA laparoscopy, complicated Laparoscopy, diagnostic Laparostomy Laparotomy and division of adhesions 30623, 30626 laparotomy for drainage of Large intestine, resection of large loop excision	41572 30052 30032 cy 42599 42599 42593 y) 42746 39139 450, 31452, 35637 491, 31470, 35638 35641 753-35754, 35756 750, 35753-35754 35636 35641 30627 30397, 30399 376, 30378-30379 30394 32000, 32003 35647-35648	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora lengthening procedures Lens, artificial, insertion of lens, insertion of lens, removal of lens, removal, replacement different lens lens, repositioning of, open operation Lensectomy lesion, pre-op localisation, for ABBI lesion, pre-op localisation, imaging guided lesion/s, removal, diaphyseal aclasia lesions, multiple injections for Lesions, skin, multiple injections for lesions, treatment of Leveen shunt, insertion of Lid, ophthalmic, suturing of ligament or tendon transfer Ligament, finger joint, repair of ligament, transverse, division of ligamentous stabilisation of ligation of maxillary artery ligation or exploration not otherwise covered Ligation/exploration not otherwise covered	37423 50303, 50306 42701, 42703 42701 42704 42707 42704 42731 31542 31536 50426 30207 30207 30192 30408 42584 49503, 49506 46333 39331 49103, 49709 41707 34106 34103 34106
Labyrinth, destruction of Labyrinthotomy Laceration, ear/eyelid/nose/lip, full thickness, replacerations not involving sclera Lacrimal canalicular system, establishment patend 42602 lacrimal, excision of palpebral lobe Lagrange's operation (iridectomy and sclerectomy Laminectomy and insertion of epidural implant Laparascopic division of adhesions 314 laparoscopic 303 Laparoscopic resection of laparoscopically assisted 35750, 357 laparoscopically assisted hysterectomy 35756 Laparoscopy and hysteroscopy under GA laparoscopy, complicated Laparoscopy, diagnostic Laparostomy Laparotomy and division of adhesions 30623, 30626 laparotomy for drainage of Large intestine, resection of large loop excision large, excision of	41572 pair 30052 30032 cy 42599 42593 y) 42746 39139 450, 31452, 35637 491, 31470, 35638 35641 753-35754, 35756 750, 35753-35754 35636 35641 30627 30397, 30399 376, 30378-30379 30394 32000, 32003 35647-35648 30111	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora lengthening procedures Lens, artificial, insertion of lens, insertion of lens, removal of lens, removal, replacement different lens lens, repositioning of, open operation Lensectomy lesion, pre-op localisation, for ABBI lesion, pre-op localisation, imaging guided lesion/s, removal, diaphyseal aclasia lesions, multiple injections for Lesions, skin, multiple injections for lesions, treatment of Leveen shunt, insertion of Lid, ophthalmic, suturing of ligament or tendon transfer Ligament, finger joint, repair of ligament, transverse, division of ligamentous stabilisation of ligation of maxillary artery ligation or exploration not otherwise covered Ligation/exploration not otherwise covered Ligature of cervix, purse string, removal of	37423 50303, 50306 42701, 42703 42701 42704 42707 42704 42731 31542 31536 50426 30207 30207 30192 30408 42584 49503, 49506 46333 39331 49103, 49709 41707 34106 34103 34106 16512
Labyrinth, destruction of Labyrinthotomy Laceration, ear/eyelid/nose/lip, full thickness, replacerations not involving sclera Lacrimal canalicular system, establishment patend 42602 lacrimal, excision of palpebral lobe Lagrange's operation (iridectomy and sclerectomy Laminectomy and insertion of epidural implant Laparascopic division of adhesions 314 laparoscopic 303 Laparoscopic resection of laparoscopically assisted 35750, 357 laparoscopically assisted hysterectomy 35756 Laparoscopy and hysteroscopy under GA laparoscopy, complicated Laparoscopy, diagnostic Laparostomy Laparotomy and division of adhesions 30623, 30626 laparotomy for drainage of Large intestine, resection of large loop excision large, excision of large, incision and drainage, with GA	41572 pair 30052 30032 cy 42599 42593 y) 42746 39139 450, 31452, 35637 491, 31470, 35638 35641 753-35754, 35756 750, 35753-35754 35636 35641 30627 30397, 30399 376, 30378-30379 30394 32000, 32003 35647-35648 30111 30223	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora lengthening procedures Lens, artificial, insertion of lens, insertion of lens, removal of lens, removal, replacement different lens lens, repositioning of, open operation Lensectomy lesion, pre-op localisation, for ABBI lesion, pre-op localisation, imaging guided lesion/s, removal, diaphyseal aclasia lesions, multiple injections for Lesions, skin, multiple injections for lesions, treatment of Leveen shunt, insertion of Lid, ophthalmic, suturing of ligament or tendon transfer Ligament, finger joint, repair of ligament, transverse, division of ligamentous stabilisation of ligation of maxillary artery ligation or exploration not otherwise covered Ligation/exploration not otherwise covered Ligature of cervix, purse string, removal of light coagulation for	37423 50303, 50306 42701, 42703 42701 42704 42707 42704 42731 31542 31536 50426 30207 30207 30192 30408 42584 49503, 49506 46333 39331 49103, 49709 41707 34106 34103 34106
Labyrinth, destruction of Labyrinthotomy Laceration, ear/eyelid/nose/lip, full thickness, replacerations not involving sclera Lacrimal canalicular system, establishment patend 42602 lacrimal, excision of palpebral lobe Lagrange's operation (iridectomy and sclerectomy Laminectomy and insertion of epidural implant Laparascopic division of adhesions 314 laparoscopic 303 Laparoscopic resection of laparoscopically assisted 35750, 357 laparoscopically assisted hysterectomy 35756 Laparoscopy and hysteroscopy under GA laparoscopy, complicated Laparoscopy, diagnostic Laparostomy Laparotomy and division of adhesions 30623, 30626 laparotomy for drainage of Large intestine, resection of large loop excision large, excision of	41572 pair 30052 30032 cy 42599 42593 y) 42746 39139 450, 31452, 35637 491, 31470, 35638 35641 753-35754, 35756 750, 35753-35754 35636 35641 30627 30397, 30399 376, 30378-30379 30394 32000, 32003 35647-35648 30111	21212, 21214, 21216, 21220, 21230, 21232, 21 21270, 21272, 21274-21275, 21280 lengthening by translocation of corpora lengthening procedures Lens, artificial, insertion of lens, insertion of lens, removal of lens, removal, replacement different lens lens, repositioning of, open operation Lensectomy lesion, pre-op localisation, for ABBI lesion, pre-op localisation, imaging guided lesion/s, removal, diaphyseal aclasia lesions, multiple injections for Lesions, skin, multiple injections for lesions, treatment of Leveen shunt, insertion of Lid, ophthalmic, suturing of ligament or tendon transfer Ligament, finger joint, repair of ligament, transverse, division of ligamentous stabilisation of ligation of maxillary artery ligation or exploration not otherwise covered Ligation/exploration not otherwise covered Ligature of cervix, purse string, removal of	37423 50303, 50306 42701, 42703 42701 42704 42707 42704 42731 31542 31536 50426 30207 30207 30192 30408 42584 49503, 49506 46333 39331 49103, 49709 41707 34106 34103 34106 16512 42782

Limbic tumour, removal or excision of	42692, 42695		
limbic, removal of	42692, 42692	Macrocheilia, operation for	45675
line for blood pressure monitoring	13876	Macrodactyly, surgical reduction of enlarged eleme	
Lingual tonsil, removal of	41804	Macroglossia, operation for	45675
	45683, 45686, 45689	Macrostomia, operation for	45676
45692, 45695, 45698, 45701, 45704	12002, 12000, 12007), 33055, 33070
Lipectomy, circumferential	30179	33075, 33080, 33100, 33103, 33109, 33112, 331	
Lipectomy, radical abdominoplasty	30176-30177	33118-33119, 33121, 33124, 33127, 33130, 3313	
lipoma, liposuction or surgical removal of	31345	33139, 33142, 33145, 33148, 33151, 33154, 3315	
Lipomeningocoele, tethered cord, release of	40112	33163, 33166, 33169, 33172, 33175, 33178, 331	
Liposuction, for post-traumatic pseudolipoma		major tendon repair	49718
Lippe's loop, introduction of	35503	major, of neck, ligation/exploration, other	34100
Lisfranc's amputation	44364		3, 33821, 33824
Litholapaxy, with or without cystoscopy	36863	33827, 33830, 33833, 33836, 33839	,, 55021, 55021
Lithotripsy, extracorporeal shock wave (ESW		male urinary, injection for treatment of	37339
Little's Area, cautery of	41674		, 45042, 45045
liver	30409, 30411	malformation, intracranial artery clipping of	39806
Liver abscess, open abdominal drainage of	30431, 30433	malformation, intracranial, excision of	39803
liver biopsy	30409	malformation, neonatal, laparotomy and colostomy	
liver, destruction of by cryotherapy	30419		, 43963, 43966
liver, laparoscopic marsupialisation	30416-30417	malignancy, radical or debulking operation	30392
liver, open abdominal drainage of	30431	malignant of soft tissue, removal of	31355
liver, other than for trauma	30418, 30421	malignant tumour	31509, 31512
Living tissue, implantation of	14203, 14206	•), 31403, 31406
living, implantation of	14203, 14206	Malignant upper aerodigestive tract tumour	31400, 31403
Lobar emphysema, neonatal, thoracotomy &	lung resection 43861	31406	,
lobe of lacrimal gland, excision of	42593	malignant, bone, operations for 50200-50201	, 50203, 50206
lobectomy of, for trauma	30428, 30430	50209, 50212, 50215, 50218, 50221, 50224, 5022	27, 50230
lobectomy of, other than for trauma	30418, 30421	50233, 50236, 50239	
Lobectomy, liver, for trauma	30428, 30430	Mallet finger, closed pin fixation of	46438
local excision for tumour	30559	mallet, fixation/repair	46438, 46441
loop, removal of under GA	35506	malrotation, neonatal, laparotomy for	43801, 43804
Lop ear or similar deformity, correction of	45659	mammaplasty 45524	4, 45527-45528
lop, bat or similar deformity, correction of	45659		4, 45527-45528
Lord's procedure, massive dilatation of anus	32153	Mammary prosthesis, removal of	45548, 45551
lower, congenital deficiency, treatment of	50411, 50414	management fluid/gas reduction for	14212
50417		Manchester operation for genital prolapse	35577
Lumbar cerebrospinal fluid drain, insertion o			3, 45726, 45729
lumbar, insertion of	40006	45731-45732, 45735, 45738, 45741, 45744, 4574	
lumbar, revision or removal of	40009	Mandible, condylectomy	45611
Lunate bone, osteectomy or osteotomy of	48406	mandible, segmental resection for	45605
lung	38438, 38441	mandibular or palatal	45825
lung, percutaneous needle	38812	Mandibular, frenulum, repair of, under GA	30281
lymph gland, muscle, other deep tissue/orga		manipulation of	50115
Lymph glands, axilla, excision of lymph glands, excision of	30332, 30335-30336 35551, 35664, 35670	manipulation/extraction of ureteric calculus	36857
lymph node biopsies	35723	marrow, administration of	13706
lymph node dissection	37607, 37610	marrow, aspiration biopsy of	30087
lymph node of neck	31420	marrow, harvesting of for transplantation	13700
lymph nodes, excision of	30335-30336	marrow, in vitro processing/cryopreservation	13760
lymph, biopsy of	30075	Marshall-Marchetti operation for urethropexy	35599, 37044 35500, 37044
lymph, drill biopsy of	30078	Marshall-Marchetti, urethropexy	35599, 37044
lymph, pelvic, excision of	35551	Marsupialisation of Bartholin's cyst or gland Mastitis, granulomatous, exploration and drainage	35517 31551
lymph, pelvic, excision of with hysterecton		Mastoid cavity, obliteration of	41548, 41564
Lymphadenectomy, atypical mycobacterial in		Mastoidectomy, cortical	41545, 41545
Lymphangiectasis, limbs, major excision	45048	Maxilla, operation on, for acute osteomyelitis	43503
	, 45033, 45035-45036	maxillary antrum	41704
Lymphoedema, major excision of	45048	Maxillary antrum, lavage of	41704
	45803, 45805, 45807	maxillary sinus, removal of	41716
45809	, ,	maxillary, drainage of, through tooth socket	41719
		maxillary, lavage of	41704
M		maxillary, proof puncture, lavage	41698, 41701

111	4	1707		41.620
maxillary, transantral ligation of		1707	middle, exploration of	41629
Meatoplasty, with correction of auditory canal stenos		1521	middle, insertion of tube for drainage of	41632
meatotomy		6830	middle, operation for abscess or inflammation of	41626
meatotomy and hemi-circumcision	3'	7354	midfacial	45753-45754
Meatotomy and hemi-circumcision, hypospadias	3'	7354	Midtarsal amputation of foot	44364
Meatus, external auditory, removal of exostoses in	4	1518	Miles' operation	32039
meatus, external, removal of exostoses in	4	1518	Minitracheostomy insertion	41884
meatus, internal, exploration		1599	Minnesota tube, insertion of	13506
Meckel's diverticulum, removal of		0375	miscarriage, purse string ligation of cervix	16511
Meckel's, removal of		0375	miscarriage, purse string figurion of cervix	16505
Meconium ileus, laparotomy for	43813, 43		Mitral annulus, reconstruction after decalcification	38485
Medial palpebral ligament, ruptured, repair of		2854	mitral annulus, reconstruction after decalcification	38485
Median bar, endoscopic resection of	30	6854	mitral, open valvotomy of	38487
median, for post-operative bleeding	38	8656	Mitrofanoff continent valve, formation of	37045
mediastinal, removal by thoracotomy or sternotomy	y 38	8446	mobilisation, for post-traumatic stiffness	49569
Mediastinum, cervical exploration of		8448	Moh's procedure	31000-31005
Meibomian cyst, extirpation of		2575	Molluscum contagiosum, removal in operating theat	
Melasma, full face chemical peel		5019	Molteno valve, insertion of	42752
Meloplasty, for correction of facial asymmetry	45587-45		Molteno valve, removal of	42755
membrane, cancer, treatment	30196, 30		monitoring, intravascular	13876
membrane, graft		2641	mucous membrane	30072
membrane, micro-inspection with ear toilet		1647	mucous, of mouth, removal	30283
membrane, punch biopsy of	30	0087	multiple, attendance other than routine antenatal	16502
membrane, repair of recent wound 30026,	30029, 30	0032	Multiple, injections for varicose veins	32500
30035, 30038, 30042, 30045, 30049			muscle	30226
Membranes, retained, evacuation of	10	6564	muscle, repair of	30232, 30235
membranes, threatened premature labour		6508	muscle/deep tissue, removal of	30068
Meningeal haemorrhage, operations for	39600, 39		musculature transfer to greater trochanter	50387
Meningocele, excision and closure of		0100	Myelomeningocele, excision and closure of	40103
meniscectomy		5755	Myelotomy, laminectomy for	39124
meniscectomy of	49503, 49		Mylohyloid ridge, reduction of	45827
Meniscectomy, knee	49503, 49		Myocardial electrode, permanent, insertion, thoracot	
Mesenteric artery, inferior, operation on		2736	myocardial, by cardiac catherterisation	38275
Meso caval shunt for portal hypertension	30	0603	myocardial, permanent, insertion, thoracotomy	38470
Metacarpal bones, amputation of	44	4325	Myocutaneous flap, delay of	45015
metacarpal, operation for	40	6462	myocutaneous, delay of	45015
Metacarpophalangeal joint, arthrodesis	40	6300	myocutaneous, for breast reconstruction	45530
Metacarpus, operation on, for chronic osteomyelitis		3512	Myoma, hysteroscopic resection	35623
metastases, selective internal radiation therapy for		5404	myomectomy	35649, 38763
35406, 35408	٦.	J - 0-	Myomectomy, hypertrophic obstructive cardiomyop	
	20	0700		
Metastatic carcinoma, craniotomy for removal of		9709	Myotomy, cricopharyngeal	41770, 41776
metatarsal	48400, 48		Myringoplasty	41527, 41530
Metatarsal bones, osteotomy or osteectomy of	48400, 48		Myringotomy	41626
metatarso-phalangeal joint, replacement of		9857		
Metatarso-phalangeal joint, synovectomy of	49860, 49	9863	N	
metatarso-phalangeal joint, synovectomy of	49860, 49	9863		
Metatarsus, amputation or disarticulation of		4358	Nail bed, exploration and repair of deformity	46489
Micro-arterial graft	4	5503	nail of finger or thumb, resection of	46528, 46531
micro-arterial or micro-venous		5503		
microdochotomy		1554	nail of toe, resection of	47915-47916
Microdochotomy of breast, benign or malignant cond		1554	Nasal adhesions, division of	41683
, , , , ,			nasal, arrest of	41656, 41677
Microlaryngoscopy		1855	nasal, cauterisation/diathermy	41674
microlaryngoscopy with removal of		1864	nasal, division of	41683
Microsomia, construction of condyle and ramus		5791	nasal, excision of	41729
Microvascular anastomosis using microsurgical techniques	niques 4:	5502	nasal, for arrest of haemorrhage	41677
microvascular, in plastic surgery	4:	5502	nasal, reconstruction of	41672
Microvenous graft	4:	5503	nasal, removal of	41662, 41668
Middle ear, clearance of	41635, 4		nasal, septoplasty or submucous resection	41671
middle ear, operation for		1626		41764
middle or proximal, for osteomyelitis		6462	Nasendoscopy	
middle palmar/thenar/hypothenar spaces, drainage		6519		, 42614-42615
			Nasopharyngeal angiofibroma, transpalatal removal	41767
middle, clearance of	41635, 4	1038	nasopharyngeal, removal	41767

Nasopharynx, fibreoptic examination of	41764	Neurovascular island flap, for pulp innervation 46504
neck 20300, 20305, 20320-20321, 20330	, 20350, 20352	Nipple, accessory, excision of 31566
neck reconstruction, prostatectomy	37210-37211	nipple, accessory, excision of 31566
neck resection, endoscopic	36854	Noble type intestinal plication with enterolysis 30375
Neck, deep-seated haemangioma, excision of	45036	node biopsies, retroperitoneal 35723
neck, reoperation for bleeding/thrombosis	33842	node dissection, retroperitoneal 37607, 37610
necrosectomy	30577	node of neck, biopsy of 31420
Necrosectomy, pancreatic	30577	Node, lymph, biopsy of 30075
Necrotic material, debridement of	35100, 35103	nodes of axilla, excision of 30335-30336
necrotising stricture, bowel resection	43834	nodes of neck, dissection of 31423, 31426, 31429, 31432
needle biopsy of	38812	31435, 31438
needle biopsy of lung	38812	Nodes, lymph, pelvic, excision of 35551
Needling of cataract	42734	Non-gravid uterus, suction curettage of 35640
needling of encysted bleb	42744	Nose, cauterisation or packing, for haemorrhage 41677
Neonatal alimentary obstruction, laparotomy for	43825	nose, removal of 41659
neonatal, repair of	30387	not otherwise covered, removal of (OMS) 45801, 45803
Neoplasia, intraepithelial, laser therapy	35539, 35542	45805, 45807, 45809
35545		obliteration of 41564
Nephrectomy 36516, 36519, 36522		obstruction, neonatal, laparotomy for 43825
Nephro-ureterectomy, complete, with bladder repair		obstruction, surgical relief of 30387
Nephroblastoma, operations for	43981, 43984	
Nephrolithotomy	36540, 36543	0
Nephroscopy 36627, 36630, 36633, 36636, 36639	, 36642, 36645	
36648	24552	Ocular muscle, torn, repair of 42854
Nephrostomy	36552	ocular muscles 42833, 42839, 42851
nerve	39315, 39318	oesophageal atresia, neonatal 43855
Nerve block, regional or field 18213, 18216		Oesophageal atresia, neonatal, operations for 43843, 43846
18225-18228, 18230, 18232-18234, 18236, 18238,		43849, 43852, 43855, 43858
18242, 18244, 18248, 18250, 18252, 18254, 18256		oesophageal, insertion of 30490
18260, 18262, 18264, 18266, 18268, 18270, 18272		Oesophagectomy 30535-30536, 30538-30539, 30541-30542
18276, 18278, 18280, 18282, 18284, 18286, 18288	5, 18290	30544-30545, 30547-30548, 30550-30551, 30553-30554
18292, 18294, 18296, 18298	12510	30556-30557
nerve meninges, incision of	42548	oesophagectomy 30294
nerve palsy, excision of tissue for	45581	oesophagogastric (Heller's operation) 30532-30533
nerve paralysis, plastic operation for	45575, 45578	Oesophagogastric myotomy 30532-30533
nerve section, translabyrinthine nerve section, via posterior fossa	41593 39500	Oesophagoscopy 30473, 30475, 30478
nerve stimulation for faecal incontinence	32213-32218	Oesophagostomy, cervical 30293-30294
nerve, injection with alcohol, cortisone etc	39100	oesophagostomy, closure or plastic repair of 30293
nerve, nerve graft to	39318	oesophagus, removal of 41825
nerve, nerve graft to nerve, neurectomy/neurotomy/tumour	39324, 39327	Oesophagus, resection of stricture, paediatric 43906
nerve, repair of	39300, 39303	of Arnold-Chiari malformation 40106
nerves, injection into	39013	of artery or vein 33803, 33806, 33812
nerves, percutaneous neurotomy	39115	of bladder, closure 37050
neuralgia, intracranial neurectomy	39106	of bladder, needle 37041
neurectomy for plantar digital neuritis	49866	of bladder, repair of 37842 of elbow 49109
Neurectomy, foot, for plantar digital neuritis	49866	
neurectomy, for trigeminal neuralgia	39106	of facial nerve, mastoid portion 41569 of finger joints 46336
	, 43984, 43987	of foot, repair of 49812
neuroendocrine tumour, removal of	30323	of haematoma 30216
Neuroendocrine tumour, retroperitoneal, removal of		of hand tendons 46336, 46342
neuroendocrine, removal of	30323	of hand, incision for 46525
Neuroendoscopy	40903	of intracranial tumour 39706
Neurolysis, by open operation	39330	of joint, not otherwise covered 50104
	, 41578-41579	of joints 50115
Neurostimulator receiver, spinal, subcutaneous place		of limb or organ 22055
neurostimulator receiver, subcutaneous placement	39134	of mind of organ 22033 of mandible 45611
neurotomy for facet joint denervation	39118	of metatarso-phalangeal joint 49860, 49863
neurotomy of peripheral nerves	39323	of neck, deep-seated, excision of 45036
neurotomy of spinal nerves	39115	of nerve 39321
Neurotomy, of peripheral nerves	39327	of nerve trunk 39312
neurovascular island	45563, 46504	of Oddi, transduodenal operation on 30458
		or can, amountain operation on

of novimbored novices	39323	orbit, removal of implant from socket	42518
of peripheral nerves	48936		45593
of shoulder of skin lesions 30189		Orbital cavity, bone or cartilage graft to orbital, excision of	42574
	, 30192		42530, 42533
of tendons of digit 46348, 46351, 46354, 46357 of thoracic cavity 38800	, 38803	Orbitotomy Orchidectomy	30641-30642
	, 35103		1, 37806-37807
of tympanum	41626	37809-37810	f, 37800-37807
of ureteric calculus, endoscopic	36857	orifice, plastic repair to enlarge	35569
of xenon arc	42782	Oro-antral fistula, plastic closure of	41722
Olecranon, excision of bursa of	30111	oro-antral, plastic closure of	41722
Omentectomy, infra-colic	35726	Oro-nasal fistula, plastic closure of	45714
	, 30387	Orthopaedic pin or wire, insertion of	47921
oncology treatment 15211, 15214-15215, 15218, 15221	*		, 49503, 49506
15227, 15230, 15233, 15236, 15239, 15242, 15245, 1524		•	, 45797, 45847
15251, 15254, 15257, 15260, 15263, 15266, 15269, 1527		Ossicular chain reconstruction	41539, 41542
one or more jaw cysts	45799	Osteectomy of accessory bone	48400
Oophorectomy, laparoscopic	35638		, 45726, 45729
open	37200	45731-45732, 45735, 45738, 45741, 45744, 4574	
Open heart surgery, not otherwise covered	38653		, 45726, 45729
open reduction for congenital dislocation	50408	45731-45732, 45735, 45738, 45741, 45744, 4574	
open, of mitral valve	38487	46399, 48400, 48403, 48406, 48409, 48418, 4842	
operation (intrathoracic), other	38456	osteectomy/osteotomy 46396, 46399, 48406	
	, 31466	48415, 48424, 48427	
operation for 42833, 42836, 42839, 42842	, 44133	osteectomy/osteotomy of	48406, 48409
operation for acute osteomyelitis 43500	, 43503	Osteomyelitis, acute or chronic, operations for	43500, 43503
operation for chronic osteomyelitis	43512	43506, 43509, 43512, 43515, 43518, 43521, 43524	1
operation for genital prolapse	35578	osteomyelitis, acute, operation for	43503
	, 43515	osteomyelitis, chronic, operation for	43521
operation for priapism	37393	osteomyelitis, craniectomy for	39906
operation on frontal sinus or ethmoid sinuses	41737	osteoplasty	49224
operation on sphenoidal sinus	41752	Osteoplasty of knee	49503, 49506
	, 46462	Osteotomy of accessory bone	48400
	, 46462	osteotomy or osteectomy of	48424, 48427
operation on, for acute osteomyelitis 43500, 43503		other than face or neck, revision of (restriction)	45515
*	, 43518	45518	
45815	12.51.5	other than laser	42734
operation on, for osteomyelitis 43503, 43506, 43512		Otitis media, acute, operation for	41626
operations for, in oral and maxillofacial region	45815	outlet compression, removal operation	34139
45817	41005	Oval window surgery	41615
operations on 30663, 30666, 41889, 41892		Ovarian biopsy by laparoscopy	35637
operations, other 41659, 41662, 41668, 41671-41672 41677, 41683, 41686, 41689, 41692	, 416/4	ovarian, aspiration of	35518
	25200	ovarian, excision of, with laparotomy	35713, 35717
Operative arteriography or venography	35200 42502	ovarian, radical or debulking operation for	35720
Ophthalmological examination under GA optical, for urethral stricture	42503 37327	ovaries, operation for Ovaries, prolapse, operation for	30387 30387
or chest, decompression escharotomy	45054	Oxycephaly, cranial vault reconstruction for	45785
or mandible, fractures, treatment of 47753, 47756		Oxycephary, cramar vaunt reconstruction for	43703
47765, 47768, 47771, 47774, 47777, 47780, 47783, 4778		Р	
47789	50	•	
or maxilla, fractures, treatment of 47753, 47756	. 47762	Pacemaker electrode, permanent, insertion, sub-xyp	hoid 38473
47765, 47768, 47771, 47774, 47777, 47780, 47783, 4778		pacemaker, insertion/replacement	38353
47789		pacemaker, permanent, insertion sub xyphoid	38473
or median sternotomy for post-operative bleeding	38656	Pacemaking electrode, temporary transvenous, inser	
or palatal exostosis, excision of	45825	pacemaking electrode, temporary, insertion of	38256
or pump, loading of	14218	paediatric, operations for	43933, 43936
or ray, transposition/transfer, vascular pedicle	46507	paediatric/neonatal	13306, 13309
or tendon transfer	47966	Pain management, implanted drug delivery system	39125-39128
or tonsils and adenoids	41797	39130-39131, 39133	
oral and maxillofacial region 45801, 45803, 45805		Palatal exostosis, excision of	45825
Orbit, anophthalmic, insertion of cartilage or implant	42518		, 45710, 45713
orbit, insert/remove implant	42518		, 45710, 45713
orbit, placement of motility integrating peg	42518	palmar or plantar, removal of	30187
5, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7,		paintar of plantar, removar of	30107

palmar spaces of hand, drainage of	46519	Pedicle, tubed, or indirect flap 45230
Palmar warts, removal of	30187	Pelvi-ureteric junction, plastic procedures to 36564
Palpebral ligament, medial, ruptured, repair of	42854	pelvic 35551, 36502
Pancreas, drainage of	30375	Pelvic abscess, drainage via rectum or vagina 30223
	, 30593-30594	pelvic bone 48424
Pancreatic abscess, laparotomy and external drainage		Pelvic lymphadenectomy 36502
pancreatic, anastomosis	30586-30587	pelvic, drainage of 30387
pancreatic, laparotomy, external drainage	30575	pelvic, laparotomy for drainage of 30394
Pancreatico-duodenectomy (Whipple's operation)	30584	pelvic, operation involving laparotomy 30387
Pancreatico-jejunostomy	30589-30590	pelvis 48427
Pancreato-cholangiography, endoscopic	30484	pelvis (except hip) 21100, 21110, 21112, 21114, 21116
Pancreatography, operative	30439	21120, 21130, 21140, 21150, 21155, 21160, 21170
Panendoscopy	30473, 30478	Pelvis, bone graft/shelf procedure, acetabular dysplasia 50393
Panhysterectomy	35664	pelvis, brush biopsy of, with cystoscopy 36821
Pannus, treatment of, with cautery of conjunctiva	42677	penile or urethral, cystoscopy for treatment of 36815
papillary hyperplasia removal of 45831,	45833, 45835	Penile warts, cystoscopy for treatment of 36815
	36840, 36845	penis erection test with examination 37815
Papillomata, juvenile, removal with microlaryngosco		Penis, amputation of 37402, 37405
Para-oesophageal, hiatus hernia, repair of	31468	Penis, circumcision of 30654, 30658
para-oesophageal, repair of	31468	Peptic ulcer, bleeding, control of 30505-30506, 30508-30509
paracentesis	30406, 42734	peptic ulcer, suture of 30375
Paracentesis abdominis	30406	peptic, bleeding, control of 30505-30506, 30508-30509
Paralysis, facial nerve, plastic operations for	45575, 45578	peptic, perforated, suture of 30375
	31409, 31412	Per anal release, rectal stricture 32114
parapharyngeal, excision of, cervical approach	31409	percutaneous 39121
31412	20///	Percutaneous aspiration biopsy of deep organ 30094
Paraphimosis, reduction of under GA	30666	percutaneous aspiration, deep organ 30094
paraphimosis, reduction of under GA	30666	percutaneous endoscopic 30481-30482
Parathyroid operation for hyperparathyroidism	30315	percutaneous technique, sequential dilation, partial splitting
parathyroid, removal of	30306	method 41880
Paretic states, eyebrows, elevation of	42872	percutaneous tenotomy of 46456
Parks' intersphincteric operation	32126 47912	percutaneous transluminal angioplasty with stenting 35307
Paronychia of foot, incision for paronychia of, pulp space infection, incision	47912	percutaneous tube, jejunal extension 31460 percutaneous, for facet joint denervation 39118
paronychia/pulp space infection, incision for	46525	percutaneous, for facet joint denervation 39118 percutaneous, of finger 46456
Parotid duct, diathermy or dilatation	30262	percutaneous, of miger 40436 percutaneous, of spinal nerves 39115
parotid gland, removal of	30253	percutaneous, or spinal nerves 39113 percutaneous, using interventional imaging 36624
parotid gland, repair of	30269	Perforated duodenal ulcer, suture of 30375
parotid, excision of	30251	Perforating wound of eyeball, repair of 42551, 42554, 42557
parotid, superficial lobectomy/tumour removal	30253	perforation of tympanum 41641
parotid, total extirpation of	30247, 30250	perforation, closure of 41671
Parovarian cyst, removal of	35713, 35717	perforation, repair of, by thoracotomy 30560
parovarian, excision of, with laparotomy	35713, 35717	perforations, sealing of 42635
partial amputation of	37402	perfusion of 22055, 34533
partial excision of	37438	perfusion of a sympatholytic agent 14209
partial or complete removal of	35560	Perfusion of donor kidney, continuous 22055
partial, for epilepsy	40703	perfusion, modifiers 25000, 25005, 25010, 25015, 25020
passages, obstruction, probing for	42610-42611	25050
42614-42615		perfusion, retrograde, cannulation for 38577
Patch angioplasty for vein stenosis	34815	perfusion, time 23010, 23021-23023, 23031-23033
patch grafting to	33545, 33548	23041-23043, 23051-23053, 23061-23063, 23071-23073
patch, to artery or vein	33545, 33548	23081-23083, 23091, 23101, 23111-23119, 23121, 23170
Patella, bursa, excision of	30111	23180, 23190, 23200, 23210, 23220, 23230, 23240, 23250
Patellar bursa, excision of	30111	23260, 23270, 23280, 23290, 23300, 23310, 23320, 23330
Patellectomy	49503, 49506	23340, 23350, 23360, 23370, 23380, 23390, 23400, 23410
Patello-femoral stabilisation 49503,	49506, 49564	23420, 23430, 23440, 23450, 23460, 23470, 23480, 23490
patello-femoral stabilisation 49503,	49506, 49564	23500, 23510, 23520, 23530, 23540, 23550, 23560, 23570
patello-femoral stabilisation, revision of	49548	23580, 23590, 23600, 23610, 23620, 23630, 23640, 23650
Patent diseased coronary bypass vein graft, dissection		23660, 23670, 23680, 23690, 23700, 23710, 23720, 23730
Patent ductus arteriosus, transcatheter closure	38273	23740, 23750, 23760, 23770, 23780, 23790, 23800, 23810
Patent Urachus	37801	23820, 23830, 23840, 23850, 23860, 23870, 23880, 23890
Pectus carinatum, repair or radical correction	38457	23900, 23910, 23920, 23930, 23940, 23950, 23960, 23970

23980, 23990, 24100-24136		phototherapeutic keratectomy, laser	42810
perfusion, whole body, cardiac bypass	22060	Phototherapeutic, keratectomy	42810
Perianal abscess, drainage of	32174-32175	Pigeon chest, correction of	38457
Pericardectomy	38447, 38449	Pilonidal cyst or sinus, excision of	30676
Pericardium, drainage of, sub-xyphoid	38452	pilonidal, excision of	30676
Perineal anoplasty, ano-rectal malformation	43960		, 47927
perineal proctectomy	32047	pin or wire, insertion of	47921
perineal resection of	32047	Pin, orthopaedic, insertion of	47921
perineal, for rectal prolapse	32112	Pinealoma, craniotomy for removal of	39712
Perineorrhaphy	35571	Pinguecula, removal of	42689
Perinephric abscess, drainage of	36537	pinguecula, surgical excision	42689
perineum 20900, 20902, 20904-20906, 20910		Pinhole urinary meatus, dilatation of pinhole urinary, dilatation of	37300 37300
20916, 20920, 20924, 20926, 20928, 20930, 2093 20936, 20938, 20940, 20942-20944, 20946, 2094		Pirogoff's amputation of foot	44361
20952-20954, 20956, 20958, 20960	10, 20930	Pituitary tumour, removal of	39715
Periorbital correction of Treacher Collins Syndrome	e 45773	pituitary, hypophysectomy or removal of	39715
periorbital, excision of	42573, 42576	Placement of catheters 38220, 38222,	
	7, 35319-35321	placement of catheters and injection of opaque material	38243
Peripheral arterial atherectomy	35312	placement of intracranial electrodes	40709
peripheral nerve	39324, 39327	Placenta, retained, evacuation of	16564
peripheral nerve stimulation for pain 39131	1, 39133-39137	Placentography, preparation for	36800
peripheral nerve, removal from	39324, 39327	planning 15500, 15503, 15506, 15509, 15512-15513,	, 15515
peripheral venous 35317	7, 35319-35320	15518, 15521, 15524, 15527, 15530, 15533, 15536	
peripheral, invitro processing, cryopreservation	13760	Plantar fasciotomy, radical	49854
peripheral, removal of tumour from	39324, 39327	plantar, radical	49854
peritomy	42632	plastic operations 45632, 45635, 45641, 45644-45647	, 45650
Peritomy, conjunctival	42632	45652-45653	
Peritoneal adhesions, division, with laparotomy	30376	Plastic procedures to pelvi-ureteric junction	36564
30378-30379	12100 12110	plate injury/deformity, radical excision	46534
peritoneal, for dialysis	13109-13110	plate or rod, removal of	47930
Peritoneo venous (Leveen) shunt, insertion of	30408	plate, prevention of closure	48512
Peritonitis, laparotomy for Peritonsillar abscess, incision of	30394 41807	Plate, rod or nail, removal of pleura	47930 30090
peritonsillar, incision of	41807	Pleura, percutaneous biopsy of	30090
Periorishiar, incision of Periorethral injection for urinary incontinence	37339	Pleural effusion	38803
permanent, insertion or replacement	38353	Pleurectomy with thoracotomy	38424
Perthes, hips or knees, application of cast under GA			, 38436
Petro-clival and clival tumour, removal of	39653-39654	Plexus, brachial, exploration of	39333
39656		Plication, intestinal, with enterolysis, Noble type	30375
Peyronie's plaque, operation for	37417	plication, Noble type, with enterolysis	30375
Phalanges, amputation/splitting, congenital abnorma	alities 50396	Pneumonectomy 38438	, 38441
phalanx	48400, 48403	Poison, ingested, gastric-lavage in the treatment of	14200
phalanx of, operation for acute osteomyelitis	43500	Polycythemia	13757
Phalanx, bone grafting of, for pseudarthrosis	46402, 46405	Polyhydramnios, attendance, not routine antenatal	16502
phalanx, operation for	46459, 46462		, 41668
pharyngeal, for velo-pharyngeal incompetence	45716		, 32145
pharyngeal, removal of	41813	Polypectomy, with hysteroscopy	35633
Pharyngectomy, partial	41782, 41785	Popliteal artery, exploration of, for popliteal entrapment	34145
Pharyngoplasty	45716	Popliteal artery, vessel, ligation or exploration, other	34103
pharyngotomy	41779 41779	popliteal, exploration for popliteal entrapment	34145 30461
Pharyngotomy (lateral) photocoagulation of	42809	Porta hepatitis, radical resection for carcinoma Portacath, laparatomy with insertion of	30400
photocoagulation of photocoagulation of iris tumour	42806	Portal hypertension, operations for 30602-30603, 30605	
•	, 14106, 14115	portion, decompression of facial nerve	41569
14118, 14124	, 11100, 11113	Porto caval shunt for portal hypertension	30602
Photocoagulation, laser, vascular lesions	14100, 14106	Portoenterostomy for biliary atresia	43978
14115, 14118, 14124	,	post-op, control under GA, independent	30058
photoiridosyneresis	42808	post-operative, following gynaecological surgery	35759
Photoiridosyneresis, laser	42808	post-operative, laparotomy for	30385
photomydriasis	42807	Posterior chamber, removal of silicone oil	42815
Photomydriasis, laser	42807	Postnasal space, examination under GA	41653
phototherapeutic	42810	Postnatal care 16564, 16567, 16570-16571	, 16573

Postoperative haemorrhage	30058	ptosis, correction of	45623
Postpartum haemorrhage, treatment of	16567	ptosis, correction of (bilateral)	45558
postpartum, treatment of	16567	pulmonary artery	13818
pouch, endoscopic resection (Dohlman's op)	41773		715, 38718
pouch, removal of	41770	Pulp space infection of foot, incision for	47912 39134
Pre-auricular sinus, excision of Pre-auricular, excision of	30104-30105 30105	Pulse generator, subcutaneous placement pump or reservoir, loading of	14218
pre-auricular, excision of	30103	Pump or reservoir, loading of	14218
pre-detachment of, cryotherapy for	42818	punch biopsy	35608
Preeclampsia, treatment of	16509	Punch biopsy of synovial membrane	30087
Pregnancy, attendance for complication by	16508	punch, of synovial membrane	30087
pregnancy, removal of	35677-35678		620, 42622
pregnancy, ultrasound guided needling and injection			000, 39006
Premalignant skin lesions, treatment of	30192	puncture and blood collection, diagnostic	13839
Premature labour, attendances not routine antenatal	16502	purse string ligation	16511
16508		Purse string ligation, cervix	16511
premature labour, treatment of	16502, 16508	purse string, cervix	16511
Prepuce, breakdown of adhesions of	30649	Puva therapy	14050
Prepuce, operations on	30654, 30658	Pyelography retrograde, preparation for	36824
Presacral and sacrococcygeal tumour, excision of	32036		540, 36543
pressure monitoring	13876		567, 36570
pressure monitoring device, insertion of	39015		654, 36656
pressure monitoring, catheter/subarachnoid bolt	13830	Pyelostomy, open	36552
pressure monitoring, indwelling catheter (ICU only	13876	Pyloromyotomy for pyloric stenosis	43930
Pressure monitoring, intracranial	13830	Pyloroplasty	30375
Priapism, decompression of	37393	Pylorus, dilation of, with vagotomy	30502
Primary repair of cutaneous nerve	39300	Pyonephrosis, drainage of	36537
procedure, intestinal, prior to radiotherapy	32183		
procedures, resuturing of wound after	42857	Q	
processing of bone marrow	13760		
Proctectomy, perineal	32047	Quadriceps, patella, reconstruction, congenital dislocati	on 50420
proctitis, anorectal application of formalin	32212	Quadricepsplasty, for knee mobilisation	49569
	, 32018, 32021	Quinsy, incision of	41807
Products of conception, retained, evacuation of	16564	radial aplasia/dysplasia, centralisation/radialisation	50399
Progesterone implant	14203, 14206	radial head, replacement of	49112
prolapse, abdominal rectopexy of	32117	_	
prolapse, Delorme procedure for prolapse, paediatric, injection under GA	32111 44105	R	
prolapse, partial recto-sigmoidectomy for	32112		
prolapse, perineal repair of	32120	Radial vessel, ligation or exploration, other	34106
prolapse, rubber band ligation of	32135	Radiation dosimetry 15518, 15521, 15524, 15527, 15	530, 15533
prolapse, sclerotherapy for	32132	15536	
prolapsed, excision of	37369		7210-37211
Proof puncture of maxillary antrum	41698, 41701	radical for malignancy	35548
	, 37215, 37218	radical operation for	38415
-	, 37218-37219	radical or modified radical 41557, 41560, 41	
prostate, drainage of	37212, 37221	radical plantar fasciotomy or fasciectomy of	49854
Prostate, impantation of gold fiducial markers	37217	radical, for nephroblastoma, paediatric	43984
	, 37203, 37206	radioactive plaques, construction, insertion & removal	42801-
Prostatectomy, endoscopic	37203, 37206	42802	207 15200
Prostatic abscess, endoscopic drainage of	37221	radioactive sources, sealed 15303-15304, 15 15311-15312, 15315-15316, 15319-15320, 15323-15	
	, 45553-45554	15311-15312, 15315-15316, 15319-15320, 15325-15	
prosthesis, insertion of	30490	15342, 15345, 15348, 15351, 15354, 15357	1337
prosthesis, operation on	49315	radioactive sources, unsealed 16003, 16006, 16	009 16012
prosthesis, removal of	48927, 49515	16015, 16018	.002, 10012
prosthesis, replacement of	45553-45554	Radioisotope, therapeutic dose, administration of	16003
prosthesis, with cystoscopy	36811	16006, 16009, 16012	10002
proximal carpectomy	49206	Radiosurgery, stereotactic	15600
Pseudarthrosis, bone grafting of metatarsal for	46402, 46405		103, 15106
pstosis, correction of (unilateral)	45556	15109, 15112, 15115	,
Pterygium, removal of	42686		024, 47027
Ptosis of eyelid, correction of	45623-45625		406, 48409
			,

Radius, bone graft to 48218, 48221, 48224, 48227	removal of cyst from 42575
Ranula, removal of 30283	removal of foreign body from 30061, 30068, 41500, 41503
re-exploration for 50616	41716, 41886
re-exploration for hyperparathyroidism 30317 readjustment of adjustable sutures 42845	removal of foreign body in 41825, 41895 removal of glomus tumour 41623
reconstruction 45530, 45533, 45536, 45539, 45542, 45671	removal of imbedded foreign body 42644
45550, 45555, 45550, 45559, 45542, 45071 45674	removal of palmar/plantar warts 30187
reconstruction for bicornuate uterus 35680	removal of polyp from 35611
reconstruction of 30517, 45545-45546, 49215	removal of purse string ligature 16512
reconstruction of lacrimal canaliculus 42602	removal of simple tumour of 35557
reconstruction of lip or eyelid 45671	removal of superficial foreign body 30061
reconstruction of, whole thickness 45614, 45671, 45674	removal of tunnelled cuffed catheter 34539
reconstruction operation 45596-45597, 45599, 45602, 45605	removal of, by lateral rhinotomy 41728
45608, 45611	removal of, by neurectomy, neurotomy 39327
reconstruction with oesophagectomy 30535	removal of, by temporal bone resection 41584, 41587
reconstruction, congenital absence/gynatresia 35565	removal of, by urethrectomy 37330
reconstruction, hypospadias/epispadias 37815-37816	removal of, by urethroscopy 36540, 36543
37827-37828, 37830	removal of, in oral and maxillofacial region 45801, 45803
reconstruction/repair 49536, 49539	45805, 45807, 45809, 45811, 45813
reconstructive 40600	renal (closed) 36561
Rectal biopsy, full thickness 32096	Renal artery, aberrant, operation for 36537
Rectal prolapse, submucosal or perirectal injection 44104	renal, excision of 36558
rectal, dilatation of 32115	renal, extraction of 36627, 36630, 36633, 36636, 36639
rectal, excision of 32099, 32102, 32108	36642, 36645, 36648
recto-sigmoidectomy for rectal prolapse 32112	reoperation for dehiscence or infection 38466
Rectocele, perineal repair of 32131	reoperation on extremity for 33848
Rectopexy, abdominal, of rectal prolapse 32117	repair - H-flap or double advancement 45207
rectosigmoidectomy (Hartmann's op) 32030	repair and suturing of 30026, 30029, 30032, 30035, 30038
Rectosigmoidectomy (Hartmann's operation) 32030	30042, 30045, 30049
Rectovaginal fistula, repair of 35596	repair of 35570, 35573, 37821-37822, 37824-37825
Rectum and anus, abdomino-perineal resection of suction biopsy of 32039, 32042, 32045-32046, 44101	37827-37828, 37830, 37833, 42866 repair of abdominal aortic aneurysm 33116, 33119
of 32039, 32042, 32045-32046, 44101 rectum and anus, resection 32039, 32042, 32045-32046	repair of abdominal aortic aneurysm 33116, 33119 repair of avulsion 37411
rectum, abdominal rectopexy 32039, 32042, 32043-32040	repair of availsion 37411 repair of extensive laceration/s 16571
rectum, full thickness 32096	repair of extensive facetations 105/1 repair of extensor tendon of hand or wrist 46420
rectum, perineal repair of 32120	repair of flexor tendon of hand or wrist 46426, 46429
rectum, plastic operation to 30387	46432
rectum, resection of 32024-32026, 32028	repair of laceration of cavernous tissue, or fracture 37408
rectum, rubber band ligation of 32135	repair of laceration/s, for trauma 30422, 30425
rectum, sclerotherapy for 32132	repair of nerve trunk 39306
rectus femoris tendon transfer 50357	repair of recent wound of 30026, 30029, 30032, 30035
Recurrent hernia, repair of 30403	30038, 30042, 30045, 30049
recurrent, operation for 42851	repair of rectocele 32131
reduction 45520, 45522-45523	repair of rupture 37004
Reduction mammaplasty (unilateral) 45520, 45522-45523	repair of, not otherwise covered 35618
reduction of 45617, 45620	repair using microsurgical techniques 45500-45501, 45504
Reduction ureteroplasty 36618	repair, direct 45209, 45212, 45215, 45218, 45221, 45224
refashioning of 30563	repair, direct flap 45209, 45212, 45215, 45218, 45221
reflux, correction of 36588	45224
Reflux, gastro-oesophageal, correction 43951, 43954, 43957	repair, heart 38480-38481
reflux, operations for 43951, 43954, 43957	repair, local, single stage 45200, 45203, 45206
regional anaesthesia of limb 18213	repair, muscle, single stage 45000, 45003, 45006, 45009
remnant, abdominal wall vitello, excision of 43942	45012
removal removal from eye, surgical excision 42689	repair, of cervical oesophagostomy 30293 repair, rectal prolapse 32120
removal in operating theatre 30189	repair, single stage, local flap 45200, 45203, 45206
removal in oral & maxillofacial region 45801, 45803, 45805	repair, to enlarge vaginal orifice 35569
45807, 45809	replacement procedures 49318-49319, 49321, 49324, 49327
removal of 30631, 32138-32139, 41801, 47904, 47906	49330, 49333, 49336, 49339, 49342, 49345, 49518-49519
removal of by laser surgery 41861	49521, 49524, 49527, 49530, 49533-49534
removal of calcium deposit from cuff 48900	replacement, heart 38488-38489
removal of cancer of skin/mucous membrane 30196	requiring anterior decompression of spinal cord 50636

resection arthroplasty 46325	rib, removal of 34139
resection for enterocolitis stricture, neonatal 43834	right heart balloon 13818
resection for jejunal atresia, neonatal 43810	Ring fixator, adjustment of 50309
resection of 45599, 45602, 45605	ring fixator, adjustment of 50309
resection of pharyngeal pouch 41773	ring, fracture, treatment of 47474, 47477, 47480, 47483
resection of rectum 32024-32025	47486, 47489
resection of turbinates 41692	ring, removal under GA 35506
resection of uterine septem 35634	Rod, plate or nail, removal of 47930
resection of, segmental, for tumour/cyst 45605	Rosen incision, myringoplasty 41527
resection of, sub-total 45602	rotational atherectomy with stent insertion 38312, 38318
resection of, total 45596-45597	rotational atherectomy without stent insertion 38309
resection, congenital cystadenomatoid malformation 43861	38315
resection, congenital lobar emphysema 43861	Rotational atherectomy, of the coronary artery 38309, 38312
resection, large 32000, 32003	38315, 38318
resection, small 30565-30566	rotational, coronary artery 38309, 38312, 38315, 38318
resection, with radical operation for empyema 38415	Rotator cuff of shoulder, repair of 48906, 48909
reservoir or external drain, insertion of 39015	rotator cuff, repair of 48906, 48909
reservoir, construction of 32029	Round window repair or cochleotomy 41614
reservoir, continent type, creation of 32069	Roux-en-Y biliary bypass 30460, 30466-30467
reservoir, formation of 36606	Rovsing's operation 36537
residual stump, removal of, abdominal approach 35612	rubber band ligation of 32135
residual stump, removal of, vaginal approach 35613	rubber band, of haemorrhoids or rectal prolapse 32135
restoration following Hartmann's op 32029, 32033	Rubin test for patency of Fallopian tubes 35706
restoration of alimentary continuity 41843	Ruptured medial palpebral ligament, repair of 42854
restoration of face, autologous bone/cartilage graft 45647	ruptured medial palpebral, repair of 42854
resurfacing, carbon dioxide, face or neck 45025-45026	ruptured, exposure and exploration of 36576
resuturing following intraocular procedures 42857	ruptured, repair 30375
Resuturing of wound following intraocular procedures 42857	ruptured, repair of 30232, 30235, 37306, 37309
resynchronisation therapy 38365, 38368, 38371, 38654	sac, excision of 42596
	Sac, excision of 42390
,	•
Retina, cryotherapy of 42818	S
retina, removal of silicone band 42812	
retina, resection/buckling/revision 42776	Sacral nerve lead(s) 36663
retrieval of foreign body 35360-35363	Sacral sinus, excision of 30676
retrieval of inferior vena caval filter 35331	sacral, stimulation for faecal incontinence 32213-32218
Retrobulbar abscess, operation for 42572	sacro-iliac joint 49300
retrobulbar injection of 42824	Sacro-iliac joint, arthrodesis of 49300
retrocaval, correction of, by open exposure 36564, 36567	sacro-iliac, arthrodesis 49300
retrograde admin for cardioplegia 38588	sacro-iliac, disruption of 47513
retrograde, cerebral (if performed) 22075	
retrograde, intravenous, sympatholytic agent 14209	
Retrolabyrinthine vestibular nerve section 41596	sacrococcygeal and presacral, excision of 32036
Retroperitoneal abscess, drainage of 30402	sacrococcygeal, excision of 30676
, ,	sacrococcygeal, neonatal, excision of 43876, 43879
retroperitoneal, drainage of 30402	sacrospinous 35568
Retropharyngeal abscess, incision with drainage 30223	sacrospinous colpopexy 35568
Retropubic prostatectomy 37200	salivary gland 30266
Retroversion, operation for 35684	salivary gland duct 30262
revision arthroplasty 49116-49117, 49210-49211	salivary gland, major, transposition of 41910
49716-49717	Salivary gland, major, transposition of duct 41910
revision of 36609	salivary gland, marsupialisation 30266
revision of failed surgery 50620	salivary gland, meatotomy 30266
revision of orthopaedic procedures 49551, 49554	salivary gland, removal of calculus 30266
revision of, by incision and suture 45239	salivary, duct, dilatation or diathermy of 30262
revision of, by liposuction 45240	salivary, duct, dilatation of diametrily of 30262 salivary, duct, marsupialisation 30266
revision of, with myringoplasty 41566	
Rhinophyma, carbon dioxide laser ablation/excision 45652	salivary, duct, meatotomy 30266
	salivary, duct, removal of calculus 30266
Rhinoplasty procedures 45632, 45635, 45641, 45644, 45650	
	salivary, operations on 30262, 30266, 30269
rhinotomy with removal of tumour 41728	Salpingectomy, laparoscopic 35638
rhinotomy with removal of tumour 41728 Rhinotomy, lateral, with removal of tumour 41728	Salpingectomy, laparoscopic 35638 Salpingo-oophorectomy not with hysterectomy 35713, 35717
rhinotomy with removal of tumour 41728 Rhinotomy, lateral, with removal of tumour 41728 rhythm, restoration, electrical stimulation 13400	Salpingectomy, laparoscopic 35638
rhinotomy with removal of tumour 41728 Rhinotomy, lateral, with removal of tumour 41728 rhythm, restoration, electrical stimulation 13400 rib 48406, 48409	Salpingectomy, laparoscopic 35638 Salpingo-oophorectomy not with hysterectomy 35713, 35717
rhinotomy with removal of tumour 41728 Rhinotomy, lateral, with removal of tumour 41728 rhythm, restoration, electrical stimulation 13400	Salpingectomy, laparoscopic 35638 Salpingo-oophorectomy not with hysterectomy 35713, 35717 Salpingolysis 35694, 35697

Carl and a single superferment	24000	and a trademantal and the	25(22
Saphenous vein anastomosis	34809	septum, hysteroscopic resection	35623
saphenous vein, for femoral vein bypass	34809	septum, reconstruction of	41672
saphenous, cross leg by-pass graft	34806	septum, septoplasty or submucous resection	41671
scalene node	30096	Sequestrectomy 43512, 43515, 435	
Scalene node biopsy	30096	Seroma, breast, exploration, drainage, operating the	
scalene, biopsy	30096	service provided by a midwife, nurse or ATSI he	
Scalenotomy	34133		16400
Scalp vein catheterisation in a neonate	13300	sesamoid bone	48400
scalp, catheterisation of	13300	Sesamoid bone, osteotomy or osteectomy of	48400
	30, 48233, 48236	Seton, readjustment of, in anal fistula	32166
scaphoid, fracture, treatment of	47354, 47357	shaving of	45653
scapula (other than acromion)	48406, 48409	shirodkar	16511
Scapula, fracture, treatment of	47468	Shirodkar suture	16511
	25, 45021, 45024	shoulder 48912, 48915, 48918, 48921, 4892	24, 48939, 48942
scar, revision of (restriction applies)	45506, 45512	48945, 48948, 48951, 48954, 48957, 48960	00 01/00 01/00
Scars, corneal, removal of, by partial keratectomy	42647	shoulder & axilla 21600, 21610, 21620, 216	
scars, excision of	42647, 45519	21634, 21636, 21638, 21650, 21652, 21654, 21	656, 216/0
Sclera, removal of imbedded foreign body	42644	21680, 21682	
scleral graft to	42860	Shoulder, amputation or disarticulation at	44331
Sclerectomy and iridectomy for glaucoma	42746	shoulder, removal of	48927
sclerosant fluid into pilonidal sinus	30679	shunt diversion, insertion of	40003, 40006
Sclerosant fluid, injection of into pilonidal sinus	30679	shunt for hydrocephalus	40006
sclerotherapy for	32132	shunt operation for	37396
sclerotomy	42734	Shunt, aorto-pulmonary or cavo-pulmonary	38733, 38736
Screw, pin or wire, buried, removal of	47924, 47927	shunt, declotting of	13106
Scrotal contents, exploration of	37604	shunt, external, insertion/removal	34500, 34506
Scrotum, excision of abscess of	30223	shunt, revision or removal of	40009
secondary revision of	45650	Sigmoidoscopic examination	32072, 32075
Secondary, repair of extensor tendon of hand or w		Sigmoidoscopy, fibreoptic, flexible	32084, 32087
section of corpus callosum for epilepsy	40700	Silicone band, encircling, removal from detached	
section, retrolabyrinthine, vestibular/cochlear	41596		51, 50455-50456
section, translabyrinthine, vestibular	41593	50460-50461, 50465-50466, 50470-50471, 504	
	14-30415, 30427	single, preparatory to ventricular puncture	39012
segmental resection of, for tumours	45605	Sinoscopy	41764
Segmentectomy	38438	sinus lift procedure	45849
	8, 38220, 38222	sinus, drainage of, through tooth socket	41719
38225, 38228, 38231, 38234, 38237, 38240-3824	11, 38243	sinus, injection of sclerosant fluid	30679
38246		sinus, intranasal operation on	41737
Semen, collection of	13290, 13292	sinus, operations on 41710, 41713, 417	
Semimembranosus bursa, excision of	30114	sinus, radical obliteration of	41746
semimembranosus, excision of	30114	sinus, trephine of	41743
Seminal vesicle/ampulla of vas, total excision of	37209	sinuses, operation on	41737, 41749
Sengstaken-Blakemore tube, insertion of	13506		04, 35406, 35408
Sentinel lymph node biopsy for breast cancer	30299-30300		42, 45445, 45448
30302-30303		skin tags or polyps, excision of	32142, 32145
sentinel lymph node, for breast cancer	30299-30300	Skin, biopsy of	30071
30302-30303		skin, micrographic serial excision	31000-31005
sentinel node biopsy for breast cancer	30299-30300	skin, to orbit	42524
30302-30303		skin/subcutaneous/mucuous membrane, removal	
septal defect closure, surgical	38742	<u> </u>	40, 39642, 39646
septal defect closure, transcatheter approach	38272	39650, 39653-39654, 39656, 39658, 39660, 396	
Septal defect, atrial, closure of	38742		42, 39646, 39650
septal defect, closure of	38751	39653-39654, 39656, 39658, 39660, 39662	
septal rupture, ischaemic, repair of	38509	skull, craniectomy for	39906
septectomy	38739, 38748	skull, excision of	39700
Septectomy, cardiac	38739, 38748	sling operation	35599, 37042
Septoplasty of nasal septum	41671	Sling operation for stress incontinence	35599
Septostomy, or balloon valvuloplasty	38270	sling procedure prior to radiotherapy	32183
septum	41674	Slough, debridement of	35100, 35103
septum button, insertion of	41907	Small bone, exostosis, excision of	47933
Septum button, nasal, insertion of	41907	small, excision of	30107
septum, excision for correction of double vagina	35566	small, incision, drainage, without GA	30219

small, intubation	30488	Stent, external, application restore valve co	ompetency 34824
small, resection of	30565-30566	34827, 34830, 34833	inpetency 5 102 1
small, strictureplasty	30564	stent, insertion of	36605, 36607, 36821
Smith-Petersen nail, removal of	47924, 47927	stent, removal/replacement of	36825
snip operation	42617	stent, through nephrostomy tube	36604
Socket, eye, contracted, reconstruction of	42527	stenting of bile duct	30491
socket, treatment as secondary procedure	42521	stenting, percutaneous	30492
solitary, pyeloplasty by open exposure	36567	Stereotactic procedures	40800-40801, 40803
sounds, passage of, as an independent procedure	37300	stereotactic procedures	40800, 40803
space infection of hand, incision for	46525	Sterilisation (female)	35688
Spermatic cord, exploration of, inguinal approach	30643-30644	sterilisation via	35688
Spermatocele, excision of	37601	Sternal wire/s, removal of	38460
Sphenoidal sinus, intranasal operation on sphenoidal, intranasal operation on	41752	Sternocleidomastoid muscle, bipolar releas	se, torticollis 50402 38656
Sphincter, anal, direct repair of	41752 32129	sternotomy for post-operative bleeding Sternotomy for removal of thymus or medi	
sphincter, artificial	37381, 37384	Sternum and mediastinum, reoperation for	
sphincter, direct repair of	32129	steroid injection	18232
sphincter, ecconstruction of	37375		30-39131, 39133-39139
sphincterotomy	30485	stimulation, restoration cardiac rhythm	13400
Sphincterotomy, anal, independent procedure	43999	stimulator, revision of	39133
sphincterotomy, independent, Hirschsprung's	43999	Strabismus, operation for	42833, 42836, 42839
spica, application of	47540, 50564	strangulated, incarcerated or obstructed, r	
spica, application, congenital dislocation	50353, 50564	43835	
spigelian, repair of	30403, 30405	Stress incontinence, abdomino-vaginal ope	eration 35602, 35605
spinal and peripheral nerve stimulation	39130-39131	stress incontinence, sling procedure	37042
39133-39139		stress incontinence, Stamey or similar	37043
	1, 39133-39139	stress incontinence, suprapubic procedure	37044
spine & spinal cord 20600, 20604, 20620), 20622, 20630	stress, sling operation for	35599
20632, 20634, 20670, 20680, 20690		Stricture, anal, anoplasty for	32123
Spleen, ruptured, repair of	30375	stricture, anoplasty for	32123
*	7, 30599, 30619	stricture, dilatation of	32115, 37303
splenectomy	31470	stricture, dilatation of with bronchoscopy	
Spleno renal shunt, selective, for portal hypertensio		stricture, endoscopy with balloon dilatation	
Splenorrhaphy	30596	stricture, optical urethrotomy for	37327
Split skin free grafts, granulating areas	45400, 45403	stricture, per anal release of	32114
split skin, to burns 45460-45462, 45464-4546			42-37343, 37345, 37348
45471-45472, 45474-45475, 45477-45478, 4548	0-45481	37351	30469
45483-45493 Squint, muscle transplant (Hummelsheim type)	42848	stricture, repair of Strictureplasty, small bowel	30564
stab cystotomy	37011	string ligature of cervix, removal	16512
stabilisation of	45875	Strontium 89, administration of	16015
Stabilisation procedure for recurrent anterior or po		Stump, amputation, reamputation of	44376
dislocation	48930	stump, reamputation of	44376
stabilisation, for multidirection instability	48933	stump, revision of	46483
stabilisation, repair capsule/ligament	50106	Styloid process of temporal bone, removal	
stabilisation, revision of	49548	sub-total, radical, for carcinoma	30523
staghorn, nephrolithotomy and/or pyelolithotomy	36543	Sub-valvular structures, heart, reconstruction	on, re-implant 38490
Staging laparotomy for gynaecological malignancy	35726	Subclavian artery, endarterectomy	33506
staging of intra-abdominal tumours	30441	Subclavian artery, vessel, ligation/explora	tion, other 34103
Stamey or similar type needle colposuspension	37043	subcutaneous	31524
Stapedectomy	41608	Subcutaneous fasciotomy, Dupuytren's cor	
Stapes mobilisation	41611	subcutaneous tissue, extensive excision	31245
Staple arrest of hemi-epiphysis	48509	subcutaneous, Dupuytren's contracture	46366
staple arrest of hemi-epiphysis	48509	subcutaneous, removal of	30064
stem tumour, craniotomy for removal	39709	subcutaneous, repair of recent wound of	30026, 30029
Stenosing tendovaginitis, hand/wrist, open operatio		30032, 30035, 30038, 30042, 30045, 30	
stenosis or occlusion, vein bypass for	34812	Subdural haemorrhage, tap for	39009
Stenosis, arteriovenous fistula/access device, correc		subdural, tap for	39009
stenosis, duodeno-duodenostomy/jejunostomy	43807	Sublingual gland, duct, removal of calculus	
stenosis, patch angioplasty for stent insertion	34815	sublingual, extirpation of	30259 f 30266
	35306, 35309 7, 34830, 34833	sublingual/salivary gland duct, removal o Submandibular abscess, incision of	f 30266 30223
51011, application 54024, 54021	, 57050, 54055	Submandibular abscess, meision of	30223

	30256		16257 16260
submandibular, extirpation of	30269	synovectomy of tendon/s 46348, 46351, 46354	50104
Submaxillary gland, repair of cutaneous fistula		synovectomy of, not otherwise covered	
submucous resection of	41692	Synovectomy, of ankle	50312
Submucous resection of nasal septum	41671	tags, anal, excision of	32142, 32145
subperiosteal 43500, 43503, 43506, 43509, 43512	2, 43313	-	
43518, 43521, 43524 Submariantal absorption 42500, 42502, 42500, 42500	12512	T	
Subperiosteal abscess 43500, 43503, 43506, 43509	, 43512		
43515, 43518, 43521, 43524	20204	Talipes equinovarus, cast/manipulation/splint	49878
Subphrenic abscess, laparotomy for drainage of	30394		, 47612, 47615
subphrenic, laparotomy for drainage	30394	47618	
Subtalar arthrodesis	50118	tantalum marker, insertion and removal	42805
subtalar joint	50118	Tantalum markers, surgical insertion of	42805
subtalar, arthrodesis of	50118	tapping of	30628
subtemporal	40015	tarsal cauterisation for	42581
Subtemporal decompression	40015	tarsal, extirpation of	42575
Subungual haematoma, incision of	30219	Tarsometatarsal joint, fracture, treatment of	47621, 47624
subvalvular structures, reconstruction, re-implantation	38490	Tarsorrhaphy	42584
Suction biopsy of rectum	30071	tarsorrhaphy	42584
superficial 15000, 15003, 15006, 15009		tarsus	48406, 48409
superficial, of parotid gland	30253	Tarsus, dislocation, treatment of	47063, 47066
superficial, removal of	30061	tarsus, for ectropian/entropian	42581
supervision in home	13104		, 42614-42615
supervision in hospital 13100), 13103	Teflon injection, into vocal cord	41870
support procedures 13815, 13818, 13830, 13839), 13842	Temporal artery, biopsy of	34109
13847-13848, 13851, 13854, 13857, 38362, 38600, 3860)3	temporal, biopsy of	34109
38609, 38612-38613, 38615, 38618, 38621, 38624		temporo-mandibular	45755
supraglottic	41840	temporomandibular joint	45758
Supraglottic laryngectomy with tracheostomy	41840	Temporomandibular joint, arthroplasty	45758
Suprapubic cystostomy or cystotomy	37008	tenckhoff peritoneal dialysis, removal of	13110
suprapubic procedure for	37044		, 49724, 49727
surgery 38390, 38393, 38512, 38515, 38518, 42702	2. 43801	tendon of hand, tenolysis of	46450
43804, 43807, 43810, 43813, 43816, 43819, 43822	,	tendon of hand, tenorysis of tendon of, repair of	49800, 49803
surgery for congenital heart disease 38700, 38703	38706	tendon of, repair of tendon or ligament transplantation of	49800, 49803
38709, 38712, 38715, 38718, 38721, 38724, 38727, 387			46411
38733, 38736, 38739, 38742, 38745, 38748, 38751, 387		tendon pulley, reconstruction	46522
38757, 38760, 38763, 38766		tendon sheath, finger or thumb, open operation	
surgery for penile drainage causing impotence	37420	tendon sheath, open operation	46363
surgery, for congenital heart disease 38700, 38703		tendon sheath, operation for tendovaginitis	46363
38709, 38712, 38715, 38718, 38721, 38724, 38727, 387		tendon transfer for restoration of function	46417
38733, 38736, 38739, 38742, 38745, 38748, 38751, 387		tendon, hand, tenolysis of	46453
38757, 38760, 38763, 38766	<i>3</i> I	tendon, hand/wrist, synovectomy of	46339
surgery, open, not otherwise covered	38653	tendon, removal of	30068
surgery, re-operation via median sternotomy	38640	tendon, repair of 46420, 46423, 46426, 46429	, 46432, 46435
surgical 35000, 35003, 35006, 35009		49718, 49721, 49724	46220
Surgical reduction of enlarged elements, macrodactyly	46510	tendon, synovectomy of	46339
Suspension of uterus	35684	tendon, wrist, repair of	46426, 46429
suspension or fixation of	35684	, 8 , 3	, 46354, 46357
Suture, laser division of, eye, following trabeculoplasty	42794	46360	16150 16150
suture, running, manipulation of	42667	Tenolysis, hand	46450, 46453
Sutures, adjustable, readjustment of, for squint	42845	Tenoplasty	47963
	42668	Tenosynovectomy	47969
sutures, removal of Swann-Ganz catheterisation	13818	Tenosynovitis, open operation, tendon sheath hand/	
Sycosis barbae/nuchae, excision of	31245	•	, 49806, 49809
		tenotomy	47960
Symblepharon, grafting for	45629 44361	tenotomy of	49806, 49809
Syme's amputation of foot		Tenovaginitis, open operation for	46363, 47972
sympathectomy 35000, 35003, 35006, 35009		Teratoma, mediastinal, thoracotomy and excision	43912
Symphysis pubis, fracture, treatment of 47474, 47477	, 4/460	teratoma, neonatal, excision of	43876, 43879
47483, 47486, 47489	20007	Testicular implant	45051
Synacthen stimulation testing	30097		, 37810, 37813
Synechiae, division of	42761	Testopexy	37803
synechiae, division of	42761	Tethered cord, release of	40112
synovectomy of 45867, 48936, 49509	, 30312	Thenar spaces of hand, drainage of	46519

therapeutic Therapeutic haemapheresis	13757, 16618 13750	Tongue, partial or complete excision of 41785	30272, 41779, 41782
Therapeutic venesection	13757		41804
		Tonsils, lingual, removal of Topectomy, for epilepsy	40703
therapy for intraepithelial neoplasia	35539, 35542, 35545		40703
therapy, hyperbaric	13020, 13025, 13030	Torkildsen's operation	
thickness wedge excision of lip, eyelid or e		Torticollis, bipolar release sternocleidomas	
Thigh, amputation through	44367	total	30521, 30524, 30526
Third degree tear, repair of	16573	total body	22065
third degree, repair of	16573	total excision of	37209-37211
Thompson arthroplasty of hip	49315	total joint replacement	49715
Thoracic aneurysm, replacement by graft	33103		8, 48921, 48924, 49115
thoracic aorta, operative management of	38572	total synovectomy of	49109
thoracic cavity	38803 38572	total, for Hirschsprung's, paediatric total, of knee	43996 49509
thoracic, management of rupture/dissection thoracic, repair/replacement procedures	38550, 38553	total, of wrist	49309
		total, with excision rectum/anastomosis	
38556, 38559, 38562, 38565, 38568, 3857		32057	32051, 32054
Thoracoplasty Thoracoscopy	38427, 38430 38436	total, with excision rectum/ileostomy	22015 22019 22021
Thoracotomy	38418, 38421, 38424	total, with ileo-rectal anastomosis	32015, 32018, 32021 32012
thorax 20400-20406, 20410, 20420		total, with ileo-fectal anastomosis	32012
20470, 20472, 20474	, 20440, 20430, 20432	Trabeculectomy for glaucoma	42746
Threatened abortion, treatment of	16505	trabeculoplasty	42782
threatened, ligation of cervix	16511	trabeculoplasty, laser	42782
threatened, treatment of	16505	Trabeculoplasty, laser, of eye	42782
Three snip operation	42617	Trachea, dilatation of stricture and stent in	
	3, 33806, 33810-33812	trachea, removal of	41886
Thrombectomy of arteriovenous access devi		Tracheal excision, repair, with cardiopulm	
thrombosis, incision of	32147	tracheal, dilatation of, with bronchoscopy	
Thrombosis, peri-anal, incision of	32147	Trachelorrhaphy	35618
Thrombus, removal of	33803, 33806, 33812	Tracheo-oesophageal fistula, division and	
Thumb, digital nail, removal of	46513, 46516	tracheo-oesophageal, division and repair	43900
Thymectomy	38456	Tracheomalacia, aortopexy for	43909
Thymoma, malignant, removal from medias		Tracheoplasty or laryngoplasty with trache	
Thymus, removal of by thoracotomy or sterr		transanal endoscopic microsurgery	32103-32104, 32106
Thyroglossal cyst and/or fistula, removal of	30314, 30326	Transantral ethmoidectomy with radical ar	
Thyroglossal, radical removal of	30326	transantral vidian, with antrostomy	41713
thyroglossal, radical removal of	30314	transantral, of maxillary artery	41707
thyroglossal, removal of	30314	transantral, with radical antrostomy	41713
thyroid, removal of	30310	transection for portal hypertension	30606
Thyroidectomy 30296-30297, 30299-30300), 30302-30303, 30306	transection, with re-anastomosis to trigon	
30310	•	transfer for facial nerve paralysis	45578
tibia	48418, 48421	transfer of abdominal musculature to grea	ter trochanter 50387
Tibia, bone graft to	48206, 48209	transfer of adductors to ischium	50387
Tibial vessel, ligation/exploration not otherw	vise covered 34106	transfer of tissue	45562-45565
tibialis tendon transfer	50339, 50342	transfer of tissue, anastomosis artery/vein	45502
Tic douloureux, injection for	39100	Transfusion	13703, 13706
tie, repair of	30278, 30281	transfusion	13703, 13706
tissue or organ, biopsy of	30075, 30078	transfusion, fetal	16609, 16612, 16615
tissue, accessory, excision of	31560	transfusion, paediatric/neonatal	13306, 13309
Tissue, expansion for breast reconstruction	45539, 45542	transhepatic cholangiogram, imaging guid	ded 30440
tissue, repair of recent wound of 30035, 30038, 30042, 30045, 30049	30026, 30029, 30032	Transillumination, ocular transillumuination	42821 42821
to femoral bypass grafting	32715	Translabyrinthine vestibular nerve section	41593
to haemorrhoids with rubber band ligation	32135	transluminal balloon	35300, 35303
to prepare bypass site for anastomosis	33554	Transluminal balloon angioplasty	35300, 35303
to retina, independent procedure	42818	Transmastoid decompression of endolymp	
Toe, amputation or disarticulation of	44338, 44342, 44346	Transmetacarpal amputation of hand	44325
44350, 44354, 44358	,,	Transmetatarsal amputation of foot	44364
	, 47666, 47672, 47678	Transorbital ligation of ethmoidal arteries	41725
Toenail, ingrowing, excision or resection for		transplant	36503, 36506, 36509
47918		transplant (Hummelsheim type), for squir	
toilet, using operating microscope	41647	transplant to restore valvular function	34821

transplantation	47966	tumour, malignant, operations for 50200-5	0201, 50203
transplantation of 36597, 42653, 4265		50206, 50209, 50212, 50215, 50218, 50221, 50224,	
Transplantation, cornea	42653, 42656	50230, 50233, 50236, 50239	30227
transposition of	39321	tumour, radical or debulking operation for	35720
Transposition of digit	46507	tumour, removal of	30520
transposition with hysterectomy for malignancy	35729	tumour, removal of by urethrectomy	37330
transposition/transfer, vascular pedicle	46507	tumour, transtympanic, removal of	41620
Transpupilliary thermotherapy	42811		6840, 36845
Transthoracic drainage of pericardium	38450	tumour/s, laser destruction with cystoscopy	36840
Transtympanic removal of glomus tumour	41620	tumours destruction by radiofrequency ablation	50950
Transurethral injection for urinary incontinence	37339	50952	
transurethral microwave thermotherapy	37230, 37233	tumours, destruction of by cryotherapy	30419
Transvenous electrode/s, permanent, insertion of	38350	tunnel release	39331
38356	20200	turbinates	41674
transvenous, insertion of	38256, 38356	Turbinates, cauterisation or diathermy of	41674
traumatic wounds 30026, 30029, 30032, 3003	·	Turbinectomy	41689
30045, 30049	, ,	Turricephaly, cranial vault reconstruction for	45785
traumatic, suture of 30026, 30029, 3003	32, 30035, 30038	Tympani, paracentesis of	41626
30042, 30045, 30049	,	Tympanic membrane, micro-inspection of	41650
Treacher Collins Syndrome, peri-orbital correction	n of 45773	Tympanum, perforation, cauterisation or diathermy	41641
• • •	00, 50604, 50608		
50612, 50616, 50620, 50624, 50628, 50632, 50		U	
50644, 50650, 50654, 50658	•		
treatment of paediatric	50508, 50512	Ulcer, corneal, epithelial debridement for 3	1220, 31225
treatment, eye 42782, 42785, 4278	88, 42791, 42794	42650	1220, 31223
42801-42802, 42805-42806		ulcer, epithelial debridement of cornea for	42650
Trephine of frontal sinus	41743	ulcer, perforated, suture	30375
Trichiasis, treatment of	42587-42588	ulcer, perforated, suture of	30375
Trichoepitheliomas, face/neck, removal by laser e	xcision 30190		8406, 48409
Trigeminal gangliotomy, radiofrequency/balloon/g	glycerol 39109	Ulna, bone graft to 48218, 48221, 4	
trigeminal, primary branch, injection with alcohol	ol etc 39100	Ulnar vessel, ligation/exploration not otherwise covered	
Trigger finger, correction of	46363	ultrasound 30688, 30690, 3	
trigger, correction of	46363	Ultrasound, intraoperative, biliary tract	30439
trunk, internal (interfasicular), neurolysis of	39312	umbilical artery	13303
trunk, microsurgical repair	39306, 39309	Umbilical artery catheterisation	13303
trunk, nerve graft to	39315	umbilical or scalp vein in a neonate	13300
tube, indwelling, gastrostomy for fixation	30375	umbilical, catheterisation of	13300
Tubed pedicle or indirect flap	45230	umbilical, epigastric, or linea alba, repair of	30621
tuberosity, reduction of	45829	umbilical, excision under GA	43948
tubes, hydrotubation of	35703, 35709	umbilical/scalp vein in neonate	13300
tubes, implantation of, into uterus	35694, 35697	Undescended testis, orchidopexy for 37803-37804, 3	37806-37807
tubes, insufflation of, for patency (Rubin test)	35706	37809-37810	
tubes, microsurgical anastomosis	35700	undescended, orchidopexy for 37803, 37806, 3	37809-37810
tubes, Rubin test for patency	35706	Unstable lie, attendances other than routine antenatal	16502
tubes, sterilisation	35688	upper prolapse, sacrospinous colpopexy for	35568
tubes, sterilisation with Caesarean section	35691	upper recession of	42863
Tuboplasty	35694, 35697	upper vault prolapse, pelvic floor repair	35595
tubuerous, tubular or constricted breast, treatment		upper vault prolapse, sacral colpopexy	35597
tubuerous, tubular or constricted, correction of	45060-45062	urachus, excision of	37800
tumour site, re-excision	31515	Urachus, patent, excision of	37800
Tumour, adrenal gland, excision of other, removal	of 30324	ureter 36585, 36588, 36591, 36594, 36597, 3	
31220, 31225	20611	Ureter, brush biopsy of, with cystoscopy	36821
Tumour, benign of soft tissue removal	30611 50230	ureter, removal of	36549
tumour, benign, resection of tumour, biopsy and/or decompression	50230 39706	Ureterectomy	36579
tumour, burr-hole biopsy for	39703, 39706	Ureteric calculus, endoscopic extraction/manipulation	
tumour, craniotomy and removal of	39703, 39706	ureteric stent exchange	36608
tumour, craniotomy for removal		ureteric, endoscopic removal/manipulation	36857
	49/1/		
filmolir excision of 30751 37000 371	39712 02-32104 32106	ureteric, passage through nephrostomy tube	36604
	02-32104, 32106	ureteric, with cystoscopy 30266, 3	6824, 36830
32108, 38670, 38673, 38677, 38680, 39700	02-32104, 32106	ureteric, with cystoscopy 30266, 3 Ureterolithotomy	6824, 36830 36549
		ureteric, with cystoscopy 30266, 3	6824, 36830

Ureteroscopy	36803, 36806, 36809		9-30500, 30502-30503
ureterostomy, closure of	36621	Vallecular cysts, removal of	41813
Ureterostomy, cutaneous, closure of	36621	vallecular, removal of	41813
urethra	35570, 35573, 37318	Valve annuloplasty, heart	38475, 38477-38478
urethra or urethral caruncle	35523	valve leaflet/s, decalcification of	38483
Urethra, cauterisation of	35523	valve replacement	38488-38489
urethra, excision of	37369	valve, open valvotomy of	38487
urethra, removal of	37318	valve, plication or repair to restore compete	
urethra, repair of	37306, 37309	valve, repair	38480-38481
urethral	37321	valves, destruction of	37854
Urethral abscess, drainage of	30223, 37816, 37828	Valvotomy for pulmonary stenosis	38456
urethral fistula repair	37833	valvuloplasty or septostomy	38270
Urethral sling, division or removal of	37340-37341	Valvuloplasty, balloon or septostomy	38270
urethral, closure of	37833	Varicocele, surgical correction of	30635
urethral, dilatation of	37303		, 32526, 32528-32529
urethral, excision of	35527, 37372	varicose, multiple injections	32500
urethral, reconstruction	37375	varicose, operations for	32500
Urethrectomy	37330	Vas deferens, operations on	37616, 37619, 37623
urethro-rectal	37336	Vasectomy	37623
urethro-vaginal	37333	Vasoepididymostomy (unilateral)	37616, 37619
Urethrocoele, repair of	35570	Vasotomy	37623
Urethropexy (Marshall-Marchetti operation		Vasovasotomy	37616, 37619
	5, 37345, 37348, 37351	vault reconstruction	45785
Urethroscopy, as an independent procedure	37315	vein catheterisation	13318-13319, 13815
Urethrostomy	37324	vein catheterisation in a neonate	13300
Urethrotomy, external or internal	37324	vein catheterisation, via subcutaneous tunne	
Urinary conduit or reservoir, endoscopic exa		vein puncture in infants, blood collection	13312
urinary conduit, revision	36609	Vein, anastomosis, microsurgical	45502
urinary reservoir, continent, formation	36606	Vein, great, ligation or exploration not othe	
urinary sphincter, insertion	37381, 37384, 37387	vein, thrombectomy	33810-33811
urinary sphincter, revision/removal	37390	Veins, major, access as part of re-operation	35202
urinary, artificial, insertion	37381, 37384, 37387	veins, multiple injections	32500
urinary, artificial, revision or removal	37390		, 32507-32508, 32511
Urogenital sinus, vaginal reconstruction for	35565	32514, 32517	1
urogenital, vaginal reconstruction for	35565	Velopharyngeal incompetence, flap or phary	
using Minitrach or similar device	41884	vena cava, for congenital heart disease	38721, 38724
Uterine adenomyoma, excision of	35649 35649	Vena cava, inferior, operations on vena caval filter, insertion of	34800, 34803
uterine, laboragaania	35638		35330
uterine, laparoscopic Utero-sacral ligaments, laparoscopic divisio		Venography, operative Venous anastomosis, not otherwise covered	35200 32766, 32769
uterus (D and C)	35640	venous catheterisation	35317, 35319-35320
Uterus, acute inversion, vaginal correction	16570	venous cameter sation venous, operations for	34812, 34815
uterus, removal of	35640	Ventilation, mechanical, intensive care	13857, 13881-13882
UVB therapy	14050	Ventral hernia following closure exomphalos	
Uvula, excision of	41810	ventral or incisional, repair of	30403, 30405
Uvulectomy and partial palatectomy	41787	ventral, following closure exomphalos, repa	
Uvulopalatopharyngoplasty	41786	ventricle, puncture of	39006
Uvulotomy	41810	Ventricular aneurysm, plication of	38506
Ovulotomy	41010	ventricular assist	38627
V		Ventricular assist Ventricular septal defect, transcatheter closus	
•		ventricular septal rupture, repair of	38509
Varior antificial formation of	25565	Ventriculo-cisternostomy	40000
Vagina, artificial formation of	35565 35557	ventriculostomy	40012
vagina, simple, removal of vaginal compartment repair	35557 35571, 35573	Ventriculostomy, third	40012
		Vermilionectomy	45668-45669
vaginal compartment repair of Vaginal correction of acute inversion of uter	35571 rus 16570	Version, external cephalic	16501
	0-35573, 35577-35578	vertebra, needle	30093
vaginal repair 3557 vaginal, excision of	35557	Vertebra, needle biopsy of	30093
vaginal, excision of vaginal, excision of, for correction of doub		vertical, congenital, reconstruction	50336
	7-35578, 35595-35597	Vesical fistula, cutaneous, operation for	37023
Vaginat, repair of 33308-33373, 3337 Vaginectomy, radical, for malignancy	35561-35562, 35564	vesical fistula, operation for	37023
Vaginoplasty for congenital adrenal hyperpl		vesical, cutaneous, operation for	37023
. agmopiasi, for congenial actional hyperpi	3/031		

Vesico-intestinal fistula, closure of	37038	with laparotomy, neonatal anorectal malformation	43822
vesico-intestinal, closure of	37038	with laparotomy, not with hysterectomy	35713, 35717
vesico-ureteric, correction	36588	with laryngoplasty or tracheoplasty	41879
vesico-vaginal, closure of	37029	with laser destruction of stone	37318
Vesicostomy, cutaneous, establishment of	37026	with other procedures	35644-35647
vesicostomy, establishment of	37026	with ovarian transposition, malignancy	35729
Vesicovaginal fistula, closure of	37029	with proctocolectomy	32015
vessel, ligation/exploration, other	34106	with removal of cartilage and/or bone	41512, 41515
vessels, anastomosis/repair	38727, 38730	with rigid oesophagoscope 41816	, 41822, 41825
vessels, by-pass grafting to	32730, 32733	with supraglottic laryngectomy	41840
Vestibular nerve section, retrolabyrinthine	41596	with surgical repositioning of nipple	45520, 45523
vestibular, section of, via posterior fossa	39500	with total colectomy	32009
Vestibuloplasty, unilaterla or bilateral	45837	with transbronchial lung biopsy	41898
vidian neurectomy	41713	with transection/resection Fallopian tubes	35688
Vidian neurectomy, transantral, with antrostomy	41713	with transmastoid removal of glomus tumour	41623
Villus, chorionic, sampling	16603	with vaginal hysterectomy	35673
Viscera, abdominal, operation involving laparotomy		with vertical hemi-laryngectomy	41837
viscera, operations involving laparotomy	30387	without surgical repositioning of nipple	45522
Viscus, ruptured, simple repair of	30375	Wolfe graft	45451
viscus, simple repair of	30375	wound, debridement of	38462, 38464
Vitello intestinal duct, patent, excision of	43945	Wound, debridement under GA or major block	30023
Viterio intestinai duct, patent, excision of Vitrectomy	42719, 42725	wound, debridement under GA of major block wound, review under GA, independent	32168
Vitreolysis of lens material	42791	wrist 49200, 49203, 49209, 49212, 49218	, 49221, 49224
vitreolysis, laser, of lens material	42791	49227	16500 16502
vitreolysis/corticolysis	42791	wrist joint, excision of	46500-46503
Volvulus, reduction of	30375	Wrist, arthrodesis of	49200, 49203
Vulva, biopsy of, with colposcopy	35615	Wry neck, operation for	44133
Vulval warts, removal under GA or nerve block	35507-35508	•	
vulval/vaginal, removal, GA or nerve block	35507-35508	X	
Vulvectomy, hemi	35536		
Vulvoplasty, for localised gigantism	35534	Xenon arc photo-coagulation	42782
Vulvoplasty, for repair of female genital mutilation	or anomalies		
of the uro-gyn	35533	Z	
		Z	
of the uro-gyn wall vitello intestinal remnant, excision of	35533		re 46384
of the uro-gyn	35533	Z-plasty, in association with Dupuytren's Contracture	
of the uro-gyn wall vitello intestinal remnant, excision of	35533	Z-plasty, in association with Dupuytren's Contractur Zygo-apophyseal joint, injection into	39013
of the uro-gyn wall vitello intestinal remnant, excision of	35533	Z-plasty, in association with Dupuytren's Contractur Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720	39013 , 45723, 45726
of the uro-gyn wall vitello intestinal remnant, excision of W Warts, anal, removal under GA or nerve block	35533 43942	Z-plasty, in association with Dupuytren's Contracture Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720, 45729, 45731-45732, 45735, 45738, 45741, 45744	39013 , 45723, 45726
of the uro-gyn wall vitello intestinal remnant, excision of W Warts, anal, removal under GA or nerve block warts, cystoscopy for the treatment of	35533 43942 32177, 32180 36815	Z-plasty, in association with Dupuytren's Contracture Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720, 45729, 45731-45732, 45735, 45738, 45741, 45744 45752	39013 , 45723, 45726 , 45747
of the uro-gyn wall vitello intestinal remnant, excision of W Warts, anal, removal under GA or nerve block warts, cystoscopy for the treatment of warts, removal of	35533 43942 32177, 32180 36815 30187	Z-plasty, in association with Dupuytren's Contracture Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720, 45729, 45731-45732, 45735, 45738, 45741, 45744	39013 , 45723, 45726
wall vitello intestinal remnant, excision of W Warts, anal, removal under GA or nerve block warts, cystoscopy for the treatment of warts, removal of warts, removal under GA or nerve block	35533 43942 32177, 32180 36815	Z-plasty, in association with Dupuytren's Contracture Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720, 45729, 45731-45732, 45735, 45738, 45741, 45744 45752	39013 , 45723, 45726 , 45747
wall vitello intestinal remnant, excision of W Warts, anal, removal under GA or nerve block warts, cystoscopy for the treatment of warts, removal of warts, removal under GA or nerve block 35507-35508	35533 43942 32177, 32180 36815 30187 32177, 32180	Z-plasty, in association with Dupuytren's Contracture Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720, 45729, 45731-45732, 45735, 45738, 45741, 45744 45752	39013 , 45723, 45726 , 45747
wall vitello intestinal remnant, excision of W Warts, anal, removal under GA or nerve block warts, cystoscopy for the treatment of warts, removal of warts, removal under GA or nerve block 35507-35508 wedge excision 30165, 30168	35533 43942 32177, 32180 36815 30187 32177, 32180 8, 30171-30172	Z-plasty, in association with Dupuytren's Contracture Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720, 45729, 45731-45732, 45735, 45738, 45741, 45744 45752	39013 , 45723, 45726 , 45747
wall vitello intestinal remnant, excision of W Warts, anal, removal under GA or nerve block warts, cystoscopy for the treatment of warts, removal of warts, removal under GA or nerve block 35507-35508 wedge excision Wedge excision 30165, 30168	35533 43942 32177, 32180 36815 30187 32177, 32180 8, 30171-30172 30180	Z-plasty, in association with Dupuytren's Contracture Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720, 45729, 45731-45732, 45735, 45738, 45741, 45744 45752	39013 , 45723, 45726 , 45747
wall vitello intestinal remnant, excision of W Warts, anal, removal under GA or nerve block warts, cystoscopy for the treatment of warts, removal of warts, removal under GA or nerve block 35507-35508 wedge excision Wedge excision 30165, 30168 Wedge excision for axillary hyperhidrosis wedge resection of	35533 43942 32177, 32180 36815 30187 32177, 32180 3, 30171-30172 30180 38440	Z-plasty, in association with Dupuytren's Contracture Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720, 45729, 45731-45732, 45735, 45738, 45741, 45744 45752	39013 , 45723, 45726 , 45747
wall vitello intestinal remnant, excision of W Warts, anal, removal under GA or nerve block warts, cystoscopy for the treatment of warts, removal of warts, removal under GA or nerve block 35507-35508 wedge excision Wedge excision 30165, 30168 Wedge resection of Wertheim's operation	35533 43942 32177, 32180 36815 30187 32177, 32180 3, 30171-30172 30180 38440 35664	Z-plasty, in association with Dupuytren's Contracture Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720, 45729, 45731-45732, 45735, 45738, 45741, 45744 45752	39013 , 45723, 45726 , 45747
wall vitello intestinal remnant, excision of W Warts, anal, removal under GA or nerve block warts, cystoscopy for the treatment of warts, removal of warts, removal under GA or nerve block 35507-35508 wedge excision 30165, 30168 Wedge excision for axillary hyperhidrosis wedge resection of Wertheim's operation (pancreatico-duodenectomy)	35533 43942 32177, 32180 36815 30187 32177, 32180 3, 30171-30172 30180 38440 35664 30584	Z-plasty, in association with Dupuytren's Contracture Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720, 45729, 45731-45732, 45735, 45738, 45741, 45744 45752	39013 , 45723, 45726 , 45747
wall vitello intestinal remnant, excision of W Warts, anal, removal under GA or nerve block warts, cystoscopy for the treatment of warts, removal of warts, removal under GA or nerve block 35507-35508 wedge excision 30165, 30168 Wedge excision for axillary hyperhidrosis wedge resection of Wertheim's operation (pancreatico-duodenectomy) whole body	35533 43942 32177, 32180 36815 30187 32177, 32180 3, 30171-30172 30180 38440 35664 30584 22060	Z-plasty, in association with Dupuytren's Contracture Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720, 45729, 45731-45732, 45735, 45738, 45741, 45744 45752	39013 , 45723, 45726 , 45747
wall vitello intestinal remnant, excision of W Warts, anal, removal under GA or nerve block warts, cystoscopy for the treatment of warts, removal of warts, removal under GA or nerve block 35507-35508 wedge excision 30165, 30168 Wedge excision for axillary hyperhidrosis wedge resection of Wertheim's operation Whipple's operation (pancreatico-duodenectomy) whole body wide local excision of suspected malignancy	35533 43942 32177, 32180 36815 30187 32177, 32180 3, 30171-30172 30180 38440 35664 30584 22060 35536	Z-plasty, in association with Dupuytren's Contracture Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720, 45729, 45731-45732, 45735, 45738, 45741, 45744 45752	39013 , 45723, 45726 , 45747
wall vitello intestinal remnant, excision of W Warts, anal, removal under GA or nerve block warts, cystoscopy for the treatment of warts, removal of warts, removal under GA or nerve block 35507-35508 wedge excision 30165, 30168 Wedge excision for axillary hyperhidrosis wedge resection of Wertheim's operation Whipple's operation (pancreatico-duodenectomy) whole body wide local excision of suspected malignancy wire or screw, buried, removal of	35533 43942 32177, 32180 36815 30187 32177, 32180 3, 30171-30172 30180 38440 35664 30584 22060 35536 47924, 47927	Z-plasty, in association with Dupuytren's Contracture Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720, 45729, 45731-45732, 45735, 45738, 45741, 45744 45752	39013 , 45723, 45726 , 45747
wall vitello intestinal remnant, excision of W Warts, anal, removal under GA or nerve block warts, cystoscopy for the treatment of warts, removal of warts, removal under GA or nerve block 35507-35508 wedge excision 30165, 30168 Wedge excision for axillary hyperhidrosis wedge resection of Wertheim's operation Whipple's operation (pancreatico-duodenectomy) whole body wide local excision of suspected malignancy wire or screw, buried, removal of Wire, orthopaedic, insertion of	35533 43942 32177, 32180 36815 30187 32177, 32180 3, 30171-30172 30180 38440 35664 30584 22060 35536 47924, 47927 47921	Z-plasty, in association with Dupuytren's Contracture Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720, 45729, 45731-45732, 45735, 45738, 45741, 45744 45752	39013 , 45723, 45726 , 45747
wall vitello intestinal remnant, excision of W Warts, anal, removal under GA or nerve block warts, cystoscopy for the treatment of warts, removal of warts, removal under GA or nerve block 35507-35508 wedge excision 30165, 30168 Wedge excision for axillary hyperhidrosis wedge resection of Wertheim's operation Whipple's operation (pancreatico-duodenectomy) whole body wide local excision of suspected malignancy wire or screw, buried, removal of Wire, orthopaedic, insertion of with biopsy	35533 43942 32177, 32180 36815 30187 32177, 32180 3, 30171-30172 30180 38440 35664 30584 22060 35536 47924, 47927 47921 30391	Z-plasty, in association with Dupuytren's Contracture Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720, 45729, 45731-45732, 45735, 45738, 45741, 45744 45752	39013 , 45723, 45726 , 45747
wall vitello intestinal remnant, excision of W Warts, anal, removal under GA or nerve block warts, cystoscopy for the treatment of warts, removal of warts, removal under GA or nerve block 35507-35508 wedge excision 30165, 30168 Wedge excision for axillary hyperhidrosis wedge resection of Wertheim's operation Whipple's operation (pancreatico-duodenectomy) whole body wide local excision of suspected malignancy wire or screw, buried, removal of Wire, orthopaedic, insertion of with biopsy with biopsy or other procedure	35533 43942 32177, 32180 36815 30187 32177, 32180 3, 30171-30172 30180 38440 35664 30584 22060 35536 47924, 47927 47921 30391 41892	Z-plasty, in association with Dupuytren's Contracture Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720, 45729, 45731-45732, 45735, 45738, 45741, 45744 45752	39013 , 45723, 45726 , 45747
wall vitello intestinal remnant, excision of W Warts, anal, removal under GA or nerve block warts, cystoscopy for the treatment of warts, removal of warts, removal under GA or nerve block 35507-35508 wedge excision 30165, 30168 Wedge excision for axillary hyperhidrosis wedge resection of Wertheim's operation Whipple's operation Whipple's operation (pancreatico-duodenectomy) whole body wide local excision of suspected malignancy wire or screw, buried, removal of Wire, orthopaedic, insertion of with biopsy with biopsy or other procedure with biopsy/diathermy/foreign body/stone	35533 43942 32177, 32180 36815 30187 32177, 32180 3, 30171-30172 30180 38440 35664 30584 22060 35536 47924, 47927 47921 30391 41892 37318	Z-plasty, in association with Dupuytren's Contracture Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720, 45729, 45731-45732, 45735, 45738, 45741, 45744 45752	39013 , 45723, 45726 , 45747
of the uro-gyn wall vitello intestinal remnant, excision of W Warts, anal, removal under GA or nerve block warts, cystoscopy for the treatment of warts, removal of warts, removal under GA or nerve block 35507-35508 wedge excision 30165, 30168 Wedge excision for axillary hyperhidrosis wedge resection of Wertheim's operation Whipple's operation (pancreatico-duodenectomy) whole body wide local excision of suspected malignancy wire or screw, buried, removal of Wire, orthopaedic, insertion of with biopsy with biopsy or other procedure with biopsy/diathermy/foreign body/stone with cystoscopy	35533 43942 32177, 32180 36815 30187 32177, 32180 3, 30171-30172 30180 38440 35664 30584 22060 35536 47924, 47927 47921 30391 41892 37318 36812	Z-plasty, in association with Dupuytren's Contracture Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720, 45729, 45731-45732, 45735, 45738, 45741, 45744 45752	39013 , 45723, 45726 , 45747
of the uro-gyn wall vitello intestinal remnant, excision of W Warts, anal, removal under GA or nerve block warts, cystoscopy for the treatment of warts, removal of warts, removal under GA or nerve block 35507-35508 wedge excision 30165, 30168 Wedge excision for axillary hyperhidrosis wedge resection of Wertheim's operation Whipple's operation (pancreatico-duodenectomy) whole body wide local excision of suspected malignancy wire or screw, buried, removal of Wire, orthopaedic, insertion of with biopsy with biopsy or other procedure with biopsy/diathermy/foreign body/stone with cystoscopy with cystoscopy and injection for incontinence	35533 43942 32177, 32180 36815 30187 32177, 32180 3, 30171-30172 30180 38440 35664 30584 22060 35536 47924, 47927 47921 30391 41892 37318 36812 37339	Z-plasty, in association with Dupuytren's Contracture Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720, 45729, 45731-45732, 45735, 45738, 45741, 45744 45752	39013 , 45723, 45726 , 45747
wall vitello intestinal remnant, excision of W Warts, anal, removal under GA or nerve block warts, cystoscopy for the treatment of warts, removal of warts, removal under GA or nerve block 35507-35508 wedge excision 30165, 30168 Wedge excision for axillary hyperhidrosis wedge resection of Wertheim's operation Whipple's operation (pancreatico-duodenectomy) whole body wide local excision of suspected malignancy wire or screw, buried, removal of Wire, orthopaedic, insertion of with biopsy with biopsy or other procedure with biopsy/diathermy/foreign body/stone with cystoscopy with cystoscopy and injection for incontinence with debulking operation	35533 43942 32177, 32180 36815 30187 32177, 32180 3, 30171-30172 30180 38440 35664 30584 22060 35536 47924, 47927 47921 30391 41892 37318 36812 37339 35720	Z-plasty, in association with Dupuytren's Contracture Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720, 45729, 45731-45732, 45735, 45738, 45741, 45744 45752	39013 , 45723, 45726 , 45747
of the uro-gyn wall vitello intestinal remnant, excision of W Warts, anal, removal under GA or nerve block warts, cystoscopy for the treatment of warts, removal of warts, removal under GA or nerve block 35507-35508 wedge excision 30165, 30168 Wedge excision for axillary hyperhidrosis wedge resection of Wertheim's operation Whipple's operation (pancreatico-duodenectomy) whole body wide local excision of suspected malignancy wire or screw, buried, removal of Wire, orthopaedic, insertion of with biopsy with biopsy or other procedure with biopsy/diathermy/foreign body/stone with cystoscopy with eystoscopy and injection for incontinence with debulking operation with dilatation of tracheal stricture	35533 43942 32177, 32180 36815 30187 32177, 32180 3, 30171-30172 30180 38440 35664 30584 22060 35536 47924, 47927 47921 30391 41892 37318 36812 37339 35720 41904	Z-plasty, in association with Dupuytren's Contracture Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720, 45729, 45731-45732, 45735, 45738, 45741, 45744 45752	39013 , 45723, 45726 , 45747
wall vitello intestinal remnant, excision of W Warts, anal, removal under GA or nerve block warts, cystoscopy for the treatment of warts, removal of warts, removal under GA or nerve block 35507-35508 wedge excision 30165, 30168 Wedge excision for axillary hyperhidrosis wedge resection of Wertheim's operation Whipple's operation (pancreatico-duodenectomy) whole body wide local excision of suspected malignancy wire or screw, buried, removal of Wire, orthopaedic, insertion of with biopsy with biopsy or other procedure with biopsy/diathermy/foreign body/stone with cystoscopy with eystoscopy and injection for incontinence with debulking operation with dilatation of tracheal stricture with division of extensive adhesions	35533 43942 32177, 32180 36815 30187 32177, 32180 3, 30171-30172 30180 38440 35664 30584 22060 35536 47924, 47927 47921 30391 41892 37318 36812 37339 35720 41904 30379	Z-plasty, in association with Dupuytren's Contracture Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720, 45729, 45731-45732, 45735, 45738, 45741, 45744 45752	39013 , 45723, 45726 , 45747
of the uro-gyn wall vitello intestinal remnant, excision of W Warts, anal, removal under GA or nerve block warts, cystoscopy for the treatment of warts, removal of warts, removal under GA or nerve block 35507-35508 wedge excision 30165, 30168 Wedge excision for axillary hyperhidrosis wedge resection of Wertheim's operation Whipple's operation (pancreatico-duodenectomy) whole body wide local excision of suspected malignancy wire or screw, buried, removal of Wire, orthopaedic, insertion of with biopsy with biopsy or other procedure with biopsy/diathermy/foreign body/stone with cystoscopy with cystoscopy and injection for incontinence with debulking operation with dilatation of tracheal stricture with division of extensive adhesions with drainage of pus	35533 43942 32177, 32180 36815 30187 32177, 32180 3, 30171-30172 30180 38440 35664 30584 22060 35536 47924, 47927 47921 30391 41892 37318 36812 37339 35720 41904 30379 31454	Z-plasty, in association with Dupuytren's Contracture Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720, 45729, 45731-45732, 45735, 45738, 45741, 45744 45752	39013 , 45723, 45726 , 45747
wall vitello intestinal remnant, excision of W Warts, anal, removal under GA or nerve block warts, cystoscopy for the treatment of warts, removal of warts, removal under GA or nerve block 35507-35508 wedge excision 30165, 30168 Wedge excision for axillary hyperhidrosis wedge resection of Wertheim's operation Whipple's operation (pancreatico-duodenectomy) whole body wide local excision of suspected malignancy wire or screw, buried, removal of Wire, orthopaedic, insertion of with biopsy with biopsy or other procedure with biopsy/diathermy/foreign body/stone with cystoscopy with cystoscopy and injection for incontinence with debulking operation with dilatation of tracheal stricture with division of extensive adhesions with drainage of pus with insertion of cochlear implant	35533 43942 32177, 32180 36815 30187 32177, 32180 3, 30171-30172 30180 38440 35664 30584 22060 35536 47924, 47927 47921 30391 41892 37318 36812 37339 35720 41904 30379 31454 41617	Z-plasty, in association with Dupuytren's Contracture Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720, 45729, 45731-45732, 45735, 45738, 45741, 45744 45752	39013 , 45723, 45726 , 45747
of the uro-gyn wall vitello intestinal remnant, excision of W Warts, anal, removal under GA or nerve block warts, cystoscopy for the treatment of warts, removal of warts, removal under GA or nerve block 35507-35508 wedge excision 30165, 30168 Wedge excision for axillary hyperhidrosis wedge resection of Wertheim's operation Whipple's operation (pancreatico-duodenectomy) whole body wide local excision of suspected malignancy wire or screw, buried, removal of Wire, orthopaedic, insertion of with biopsy with biopsy or other procedure with biopsy/diathermy/foreign body/stone with cystoscopy with cystoscopy and injection for incontinence with debulking operation with dilatation of tracheal stricture with division of extensive adhesions with drainage of pus	35533 43942 32177, 32180 36815 30187 32177, 32180 3, 30171-30172 30180 38440 35664 30584 22060 35536 47924, 47927 47921 30391 41892 37318 36812 37339 35720 41904 30379 31454	Z-plasty, in association with Dupuytren's Contracture Zygo-apophyseal joint, injection into Zygoma, osteotomy or osteectomy of 45720, 45729, 45731-45732, 45735, 45738, 45741, 45744 45752	39013 , 45723, 45726 , 45747

CATEGORY 4: ORAL AND MAXILLOFACIAL SERVICES

SUMMARY OF CHANGES FROM 01/03/2019

The 01/03/2019 changes to the MBS are summarised below and are identified in the Schedule pages by one or more of the following words appearing above the item number:

(a) new item	New
(b) amended description	Amend
(c) fee amended	Fee
(d) item number changed	Renum
(e) EMSN changed	EMSN

There are no changes to this Category for 01/03/2019.

ORAL AND MAXILLOFACIAL SERVICES NOTES

ON.1.1 Benefits for Medical Services Performed by Approved Dental Practitioners

Under the provisions of the *Health Insurance Act 1973* (the Act), Medicare benefits are payable where an eligible person incurs medical expenses in respect of certain professional services rendered by a approved dental practitioner approved before 1 November 2004.

Category 4 is restricted to those dental practitioners who were approved by the Minister prior to 1November2004 for the provision of oral and maxillofacial surgery services and relevant attendances.

Approved dental practitioners may also request certain diagnostic imaging services - refer to Category 5 - Diagnostic Imaging Services for more information.

ON.1.2 Changes to the Scheme Effective from 1 November 2004

From 1 November 2004, access to Category 4 is restricted to those dental practitioners who were approved by the Minister prior to 1 November 2004. No new approvals will be granted after that date.

Background

Since 2000, practitioners performing oral and maxillofacial surgery in Australia are required to have both dental and medical qualifications in order to sit for their FRACDS(OMS) exam. This effectively means that since then, any practitioner who has obtained an FRACDS(OMS) or equivalent can access Category 3 of the MBS because they are medically qualified. The Government, in consultation with the Australian and New Zealand Association of Oral and Maxillofacial Surgeons, the Australian Dental Association, the Royal Australian College of Surgeons, the Royal Australian College of Dental Surgeons and the Australian Medical Association, has agreed that access by new practitioners to Category 4 will be withdrawn from 1November2004. Practitioners who were approved prior to that date will continue to have access to Category 4. The long-term proposal is that once all practitioners who currently access Category 4 have left the workforce, Category 4 will be removed from the Medicare Benefits Schedule.

Details of the services attracting Medicare benefits are set out in the Medicare Benefits Schedule.

ON.2.1 Definition of Oral and Maxillofacial Surgery

Oral and Maxillofacial Surgery is defined as the surgical specialty which deals with the diagnosis, surgical and adjunctive treatment of diseases, injuries and defects of the oral and maxillofacial region.

ON.2.2 Services That Can Be Provided

Dental practitioners holding the FRACDS (OMS) or equivalent who were approved by the Minister prior to 1November2004 may perform prescribed oral and maxillofacial services listed in this category. All dental practitioners approved for the purposes of subsection 3(1) of the Act are also recognised to perform those items of oral and maxillofacial surgery listed in Group C2 of the booklet "Medicare Benefits for Treatment of Cleft Lip and Cleft Palate Conditions".

It is emphasised that -

- the sole purpose of granting approval to dental practitioners is to enable payment of Medicare benefits;
- the services set out in Groups 01 to 011 of the Medicare Benefits Schedule book, and in the Cleft Lip and Cleft Palate Schedule are the only ones for which Medicare benefits are payable when the services are performed by an eligible dental practitioner.

ON.3.1 Principles of Interpretation

Each professional service listed in the Schedule is a complete medical service in itself. Where a service is rendered partly by one practitioner and partly by another, only the one amount of benefit is payable.

ON.3.2 Multiple Operation Rule

The Schedule fees for two or more operations performed on a patient on the one occasion are calculated by the following rule:-

100% for the item with the greatest Schedule fee, plus 50% for the item with the next greatest Schedule fee, plus 25% for each other item.

NOTE:

- 1. Fees so calculated which result in a sum which is not a multiple of 5 cents are to be taken to the next higher multiple of 5 cents
- 2. Where two or more operations performed on the one occasion have fees which are equal, one of these amounts shall be treated as being greater than the other or others of those amounts.
- 3. The Schedule fee for benefits purposes is the aggregate of the fees calculated in accordance with the above formula.

The above rule does not apply to an operation which is one of two or more operations performed under the one anaesthetic on the same patient by different dental practitioners unless either practitioner assists the other. In this case, the fees and benefits specified in the Schedule apply. For these purposes the term "operation" includes all services in Groups O3 to O9.

If the operation comprises a combination of procedures which are commonly performed together and for which a specific combined item is provided in the Schedule, it is regarded as the one item and service in applying the multiple operation rule.

ON.3.3 After Care (Post-operative Treatment)

The fee specified for each of the operations listed in the Schedule contains a component for the consequential after-care customarily provided unless otherwise indicated. After-care is deemed to include all post-operative treatment rendered by practitioners and need not necessarily be limited to treatment given by the approved dental practitioner or to treatment given by any one practitioner. This does not preclude, however, the payment of benefit for professional services for the treatment by a dental practitioner of an intercurrent condition or an unusual complication arising from the operation.

Some minor operations are merely stages in the treatment of a particular condition. Professional services by dental practitioners subsequent to such operations should not be regarded as after-care but rather as continuation of the treatment of the original condition and should attract benefit. Item 52057 is a service to which this policy applies.

ON.3.4 Administration of Anaesthetics by Medical Practitioners

When a medical practitioner administers an anaesthetic in connection with a procedure prescribed for the payment of Medicare benefits (and the procedure has been performed by an approved dental practitioner), Medicare benefits are payable for the administration of the anaesthetic on the same basis as if the procedure had been rendered by a medical practitioner.

The Schedule fee for anaesthesia is established using the RVG schedule at Category 3 - Group T10.

Before the payment of benefits for the administration of anaesthesia, or for the services of an assistant anaesthetist, a number of additional details are required on the anaesthetist's account:

- The anaesthetist's account must show the name/s of the medical practitioner/s who performed the associated operation/s. Also, where the after hours emergency modifier applies to the anaesthesia service, the account must include the start time, the end time and the total time of the anaesthesia;
- The assistant anaesthetist's account must show the name/s of the medical practitioners who performed the associated operation/s, as well as the name of the principle anaesthetist. In addition, where the after hours

emergency modifier applies, the assistant anaesthetist's account must record the start time, the end time and the total time for which he or she was providing professional attention to the patient during the anaesthesia.

ON.4.1 Consultations - (Items 51700 and 51703)

The consultation item numbers (51700 and 51703) are to be used by approved dental practitioners in the practice of oral and maxillofacial surgery.

The referral must be from a registered dental practitioner or a medical practitioner.

ON.4.2 Assistance at Operations - (Items 51800 and 51803)

Items covering operations which are eligible for benefits for assistance by an approved dental practitioner in the practice of oral and maxillofacial surgery or surgical assistance have been identified by the inclusion of the word "Assist" in the item description. Medicare benefits are not payable for surgical assistance associated with procedures which have not been so identified.

The assistance must be rendered by a practitioner other than the surgeon, the anaesthetist or the assistant anaesthetist.

Where more than one practitioner provides assistance to an approved dental practitioner no additional benefits are payable. The assistance benefit is the same irrespective of the number of practitioners providing assistance.

Benefits payable under item 51800

Medicare benefits are payable under Item 51800 for assistance rendered at the following procedures:

```
51900, 51904, 52010, 52018, 52039, 52048, 52051, 52062, 52063, 52066, 52078, 52090, 52092, 52095, 52105, 52108, 52111, 52130, 52138, 52141, 52144, 52147, 52182, 52300, 52303, 52312, 52315, 52321, 52324, 52336, 52339, 52424, 52440, 52452, 52480, 52482, 52600, 52603, 52609, 52612, 52615, 52624, 52626, 52627, 52800, 52803, 52806, 52809, 52818, 52824, 52828, 52830, 53006, 53009, 53016, 53215, 53220, 53225, 53226, 53236, 53239, 53242, 53406, 53409, 53412, 53413, 53415, 53416, 53453, 53460.
```

Where assistance with any of the above procedures is provided by a medical practitioner, benefits are payable under item 51300.

Benefits payable under Item 51803

Medicare benefits are payable under Item 51803 for assistance rendered at the following procedures:

```
51906, 52054, 52094, 52114, 52117, 52120, 52122, 52123, 52126, 52129, 52131, 52148, 52158, 52184, 52186, 52306, 52330, 52333, 52337, 52342, 52345, 52348, 52351, 52354, 52357, 52360, 52363, 52366, 52369, 52372, 52375, 52378, 52379, 52380, 52382, 52430, 52442, 52444, 52446, 52456, 52484, 52618, 52621, 52812, 52815, 52821, 52832, 53015, 53017, 53019, 53209, 53212, 53218, 53221, 53224, 53227, 53230, 53233, 53414, 53418, 53419, 53422, 53423, 53424, 53425, 53427, 53429, 53455.
```

or at a combination of procedures (including those identified as payable under item 51800 above) for which the aggregate fee exceeds the amount specified in the item.

Where assistance with any of the above procedures is provided by a medical practitioner, benefits are payable under Item 51303

Assistance at multiple operations

Where assistance is provided at two or more operations performed on a patient on the one occasion the multi operation formula is applied to all the operations to determine the surgical fee payable to each approved dental practitioner. The multi-operation formula is then applied to those items at which assistance was rendered and for which Medicare benefits for assistance is payable to determine the abated fee level for assistance. The abated fee is

used to determine the appropriate Schedule item covering the surgical assistance (ie either Items 51800/51300 or 51803/51303).

The derived fee applicable to Item 51803/51303 is calculated on the basis of one-fifth of the abated Schedule fee for the surgery.

ON.4.3 Repair of Wound - (Item 51900)

Item 51900 covers debridement of "deep and extensively contaminated" wound. Benefits are not payable under this item for debridement which would be expected to be encountered as part of an operative approach to the treatment of fractures.

ON.4.4 Lipectomy, Wedge Excision - Two or More Excisions - (Item 51906)

Multiple lipectomies attract benefits under Item 51906 once only, i.e. the multiple operation rule does not apply.

Medicare benefits are not payable in respect of liposuction.

ON.4.5 Upper Aerodigestive Tract Endoscopic Procedure - (Item 52035)

The following are guidelines of appropriate minimum standards for the performance of GI endoscopy in relation to (a) cleaning, disinfection and sterilisation procedures, and (b) anaesthetic and resuscitation equipment. These guidelines are based on the advice of the Gastroenterological Society of Australia, the Sections of HPB and Upper GI and of Colon and Rectal Surgery of the Royal Australasian College of Surgeons, and the Colorectal Surgical Society of Australia.

Cleaning, disinfection and sterilisation procedures

Endoscopic procedures should be performed in facilities where endoscope and accessory reprocessing protocols follow procedures outlined in:-

- (i) 'Infection and Endoscopy' (3rd edition), Gastroenterological Society of Australia;
- (ii) 'Infection control in the health care setting Guidelines for the prevention of transmission of infectious diseases', National Health and Medical Research Council; and
- (iii) Australian Standard AS 4187-1994 (and Amendments), Standards Association of Australia.

Anaesthetic and resuscitation equipment

Where the patient is anaesthetised, anaesthetic equipment, administration and monitoring, and post operative and resuscitation facilities should conform to the standards outlined in 'Sedation for Endoscopy', Australian & New Zealand College of Anaesthetists, Gastroenterological Society of Australia and Royal Australasian College of Surgeons. These guidelines will be taken into account in determining appropriate practice in the context of the Professional Services Review process.

ON.4.6 Tumour, cyst, Ulcer or Scar - (Items 52036 to 52054)

It is recognised that odontogenic keratocysts, although not neoplastic, often require the surgical management of benign tumours.

ON.4.7 Aspiration of Haematoma - (Item 52056)

Aspiration of haematoma is indicated in clinical situations where incision may leave an unsightly scar or where access is difficult for conventional drainage.

ON.4.8 Osteotomy of Jaw - (Items 52342 to 52375)

The fee and benefit for these items include the various forms of internal or dental fixation, jaw immobilisation, the transposition of nerves and vessels and bone grafts taken from the same site.

Bone grafts taken from a separate site, e.g. iliac crest, would attract additional benefit under Item 52318 or 52319 for the harvesting, plus item 52130 or 52131 for the grafting.

Where the site of grafting under item 52131 requires closure by single stage local flap, item 52300 may be claimed where clinically appropriate. Clinically appropriate in this instance means that the flap is required to close defects because the defect cannot be closed directly.

A local skin flap is an area of skin or subcutaneous tissue designed to be elevated from the skin adjoining a defect requiring closure. The flap remains partially attached by pedicle and is moved to the defect by rotation, advancement or transposition, or a combination of these manoeuvres.

Benefits are only payable where the flap is required for adequate wound closure. A secondary defect will be created which may be closed by direct suture, skin grafting or sometimes a further local skin flap. This latter procedure will also attract benefit if closed by graft or flap repair but not been closed by direct suture.

By definition, direct wound closure (e.g. by suture) does not constitute skin flap. Similarly, angled, curved or trapdoor incisions which are used for exposure and which are sutured back into the same position relative to the adjacent tissues are not skin flap repairs. Undermining of the edges of the wound prior to suturing is considered a normal part of wound closure and is not considered to skin flap repair.

For the purposes of these items, a reference to maxilla includes the zygoma.

ON.4.9 Genioplasty - (Item 52378)

Genioplasty attracts benefit once only although a section is made on both sides of the symphysis of the mandible.

ON.4.10 Fracture of Mandible or Maxilla - (Items 53400 to 53439)

There are two maxillae in the skull and for the purpose of these items the mandible is regarded as comprising two bones.

Hence a bilateral fracture of the mandible would be assessed as:

- · Item 53409 x 1½;
- two maxillae and one side of the mandible as Item 53406 x $1\frac{1}{2}$ + 53409 x $\frac{1}{4}$.

Splinting in Item 53406 or 53409 refers to cap splints, arch bars, silver (cast metal) or acrylic splints.

ON.4.12 Destruction of Nerve Branch by Neurolytic Agent - (Item 53706)

Item 53706 includes the use of botulinum toxin as a neurolytic agent.

ORAL AND MAXILLOFACIAL SERVICES ITEMS

O1. CON	ISULTATIONS
	Group O1. Consultations
	APPROVED DENTAL PRACTITIONER, REFERRED CONSULTATION - SURGERY, HOSPITAL OR RESIDENTIAL AGED CARE FACILITY
	Professional attendance (other than a second or subsequent attendance in a single course of treatment) by an approved dental practitioner, at consulting rooms, hospital or residential aged care facility where the patient is referred to him or her
51700	(See para ON.4.1 of explanatory notes to this Category) Fee: \$85.55 Benefit: 75% = \$64.20 85% = \$72.75
	Professional attendance by an approved dental practitioner, each attendance subsequent to the first in a single course of treatment at consulting rooms, hospital or residential aged care facility where the patient is referred to him or her
51703	(See para ON.4.1 of explanatory notes to this Category) Fee: \$43.00 Benefit: 75% = \$32.25 85% = \$36.55
	ISTANCE AT OPERATION
	Group O2. Assistance At Operation
	Assistance by an approved dental practitioner in the practice of oral and maxillofacial surgery at any operation identified by the word "Assist." for which the fee does not exceed \$558.30 or at a series or combination of operations identified by the word "Assist." where the fee for the series or combination of operations identified by the word "Assist." does not exceed \$558.30
51800	(See para ON.4.2 of explanatory notes to this Category) Fee: \$86.30 Benefit: 75% = \$64.75 85% = \$73.40
	Assistance by an approved dental practitioner in the practice of oral and maxillofacial surgery at any operation identified by the word "Assist." for which the fee exceeds \$558.30 or at a series or combination of operations identified by the word "Assist." where the aggregate fee exceeds \$558.30
51803	(See para ON.4.2 of explanatory notes to this Category) Derived Fee: one fifth of the established fee for the operation or combination of operations
	IERAL SURGERY
	Group O3. General Surgery
	WOUND OF SOFT TISSUE, deep or extensively contaminated, debridement of, under general anaesthesia or regional or field nerve block, including suturing of that wound when performed (Anaes.) (Assist.)
51900	(See para ON.4.3 of explanatory notes to this Category) Fee: \$326.05 Benefit: 75% = \$244.55 85% = \$277.15 WOLINDS DRESSING OF under general appeathesis, with an without removal of sutures, not being a
	WOUNDS, DRESSING OF, under general anaesthesia, with or without removal of sutures, not being a service associated with a service to which another item in Groups O3 to O9 applies (Anaes.)
51902	Fee: \$73.90 Benefit: 75% = \$55.45 85% = \$62.85 LIPECTOMY - wedge excision of skin or fat - 1 EXCISION (Anaes.) (Assist.)
	En Letowit - wedge excision of skin of lat - 1 Excision (Anaes.) (Assist.)
51904	Fee: \$454.85 Benefit: 75% = \$341.15 85% = \$386.65 LIPECTOMY - wedge excision of skin or fat - 2 OR MORE EXCISIONS (Anaes.) (Assist.)
51906	(See para ON.4.4 of explanatory notes to this Category)

O3. GEN	NERAL SURGERY
	Fee: \$691.75 Benefit: 75% = \$518.85 85% = \$608.35
	SKIN AND SUBCUTANEOUS TISSUE OR MUCOUS MEMBRANE, REPAIR OF RECENT
	WOUND OF, on face or neck, small (NOT MORE THAN 7 CM LONG), superficial (Anaes.)
52000	Fee: \$82.50 Benefit: 75% = \$61.90 85% = \$70.15
	SKIN AND SUBCUTANEOUS TISSUE OR MUCOUS MEMBRANE, REPAIR OF RECENT
	WOUND OF, on face or neck, small (NOT MORE THAN 7 CM LONG), involving deeper tissue (Anaes.)
52003	Fee: \$117.55 Benefit: 75% = \$88.20 85% = \$99.95
	SKIN AND SUBCUTANEOUS TISSUE OR MUCOUS MEMBRANE, REPAIR OF RECENT WOUND OF, on face or neck, large (MORE THAN 7 CM LONG), superficial (Anaes.)
52006	Fee: \$117.55 Benefit: 75% = \$88.20 85% = \$99.95
	SKIN AND SUBCUTANEOUS TISSUE OR MUCOUS MEMBRANE, REPAIR OF RECENT
	WOUND OF, on face or neck, large (MORE THAN 7 CM LONG), involving deeper tissue (Anaes.)
52009	Fee: \$185.60 Benefit: 75% = \$139.20 85% = \$157.80
	FULL THICKNESS LACERATION OF EAR, EYELID, NOSE OR LIP, repair of, with accurate
	apposition of each layer of tissue (Anaes.) (Assist.)
52010	Fee: \$254.00 Benefit: 75% = \$190.50 85% = \$215.90
	SUPERFICIAL FOREIGN BODY, removal of, as an independent procedure (Anaes.)
	F
52012	Fee: \$23.50 Benefit: 75% = \$17.65 85% = \$20.00 SUBCUTANEOUS FOREIGN BODY, removal of, requiring incision and suture, as an independent
	procedure (Anaes.)
52015	Fee: \$109.90 Benefit: 75% = \$82.45 85% = \$93.45
	FOREIGN BODY IN MUSCLE, TENDON OR OTHER DEEP TISSUE, removal of, as an independent procedure (Anaes.) (Assist.)
52018	Fee: \$276.80 Benefit: 75% = \$207.60 85% = \$235.30
	ASPIRATION BIOPSY of 1 or MORE JAW CYSTS as an independent procedure to obtain material for diagnostic purposes and not being a service associated with an operative procedure on the same day (Anaes.)
52021	Fee: \$29.45 Benefit: 75% = \$22.10 85% = \$25.05
32021	BIOPSY OF SKIN OR MUCOUS MEMBRANE, as an independent procedure (Anaes.)
52024	Fee: \$52.20 Benefit: 75% = \$39.15 85% = \$44.40
	LYMPH NODE OF NECK, biopsy of (Anaes.)
52025	Fee: \$183.90 Benefit: 75% = \$137.95 85% = \$156.35
	BIOPSY OF LYMPH GLAND, MUSCLE OR OTHER DEEP TISSUE OR ORGAN, as an independent
	procedure and not being a service to which item 52025 applies (Anaes.)
52027	Fee: \$149.75 Benefit: 75% = \$112.35 85% = \$127.30
	SINUS, excision of, involving superficial tissue only (Anaes.)
52030	Fee: \$90.00 Benefit: 75% = \$67.50 85% = \$76.50
	SINUS, excision of, involving muscle and deep tissue (Anaes.)
52033	Fee: \$183.90 Benefit: 75% = \$137.95 85% = \$156.35

O3. GEI	NERAL SURGERY
	dioxide laser
	Fee: \$43.00 Benefit: 75% = \$32.25 85% = \$36.55
	ENDOSCOPIC LASER THERAPY for neoplasia and benign vascular lesions of the oral cavity (Anaes.)
	(See para ON.4.5 of explanatory notes to this Category)
52035	Fee: \$476.10 Benefit: 75% = \$357.10 85% = \$404.70
	TUMOUR, CYST, ULCER OR SCAR, (other than a scar removed during the surgical approach at an
	operation), up to 3 cm in diameter, removal from cutaneous or subcutaneous tissue or from mucous
	membrane, where the removal is by surgical excision and suture, not being a service to which item
	52039 applies (Anaes.)
52026	(See para ON.4.6 of explanatory notes to this Category)
52036	Fee: \$126.90 Benefit: 75% = \$95.20 85% = \$107.90
	TUMOURS, CYSTS, ULCERS OR SCARS, (other than a scar removed during the surgical approach at an operation), up to 3 cm in diameter, removal from cutaneous or subcutaneous tissue or from mucous
	membrane, where the removal is by surgical excision and suture, and the procedure is performed on
	more than 3 but not more than 10 lesions (Anaes.) (Assist.)
	more than 5 but not more than 10 lesions (Amaes.) (Assist.)
	(See para ON.4.6 of explanatory notes to this Category)
52039	Fee: \$326.05 Benefit: 75% = \$244.55 85% = \$277.15
	TUMOUR, CYST, ULCER OR SCAR, (other than a scar removed during the surgical approach at an
	operation), more than 3 cm in diameter, removal from cutaneous or subcutaneous tissue or from mucous
	membrane (Anaes.)
	(See para ON.4.6 of explanatory notes to this Category)
52042	Fee: \$172.50 Benefit: 75% = \$129.40 85% = \$146.65
	TUMOUR, CYST (other than a cyst associated with a tooth or tooth fragment unless it has been
	established by radiological examination that there is a minimum of 5mm separation between the cyst
	lining and tooth structure or where a tumour or cyst has been proven by positive histopathology),
	ULCER OR SCAR (other than a scar removed during the surgical approach at an operation), removal of,
	not being a service to which another item in Groups O3 to O9 applies, involving muscle, bone, or other
	deep tissue (Anaes.)
	(See para ON.4.6 of explanatory notes to this Category)
52045	Fee: \$246.50 Benefit: 75% = \$184.90 85% = \$209.55
_	TUMOUR OR DEEP CYST (other than a cyst associated with a tooth or tooth fragment unless it has
	been established by radiological examination that there is a minimum of 5mm separation between the
	cyst lining and tooth structure or where a tumour or cyst has been proven by positive histopathology),
	removal of, requiring wide excision, not being a service to which another item in Groups O3 to O9
	applies (Anaes.) (Assist.)
	(See para ON.4.6 of explanatory notes to this Category)
52048	Fee: \$371.50 Benefit: 75% = \$278.65 85% = \$315.80
32010	TUMOUR, removal of, from soft tissue (including muscle, fascia and connective tissue), extensive
	excision of, without skin or mucosal graft (Anaes.) (Assist.)
	<i>y</i>
	(See para ON.4.6 of explanatory notes to this Category)
52051	Fee: \$502.25 Benefit: 75% = \$376.70 85% = \$426.95
	TUMOUR, removal of, from soft tissue (including muscle, fascia and connective tissue), extensive
	excision of, with skin or mucosal graft (Anaes.) (Assist.)
	(See para ON.4.6 of explanatory notes to this Category)
52054	Fee: \$587.60 Benefit: 75% = \$440.70 85% = \$504.20
52055	HAEMATOMA, SMALL ABSCESS OR CELLULITIS, not requiring admission to a hospital,

03. GE	NERAL SURGERY
	INCISION WITH DRAINAGE OF (excluding after care)
	Fee: \$27.35 Benefit: 75% = \$20.55 85% = \$23.25
	HAEMATOMA, aspiration of (Anaes.)
52056	(See para ON.4.7 of explanatory notes to this Category)
52056	Fee: \$27.35 Benefit: 75% = \$20.55 85% = \$23.25 LARGE HAEMATOMA, LARGE ABSCESS, CARBUNCLE, CELLULITIS or similar lesion,
	requiring admission to a hospital, INCISION WITH DRAINAGE OF (excluding aftercare) (Anaes.)
	(See para ON.3.3 of explanatory notes to this Category)
52057	Fee: \$162.95 Benefit: 75% = \$122.25 85% = \$138.55
	PERCUTANEOUS DRAINAGE OF DEEP ABSCESS, using interventional imaging techniques - but
	not including imaging (Anaes.)
52058	Fee: \$237.60 Benefit: 75% = \$178.20 85% = \$202.00
	ABSCESS, DRAINAGE TUBE, exchange of using interventional imaging techniques - but not including imaging (Anaes.)
52059	Fee: \$267.65 Benefit: 75% = \$200.75 85% = \$227.55
	MUSCLE, excision of (Anaes.)
52060	F
52060	Fee: \$189.40 Benefit: 75% = \$142.05 85% = \$161.00 MUSCLE, RUPTURED, repair of (limited), not associated with external wound (Anaes.)
	Wild Sells, Ref Torillo, repair of (minica), not associated with external would (maes.)
52061	Fee: \$223.60 Benefit: 75% = \$167.70 85% = \$190.10
	MUSCLE, RUPTURED, repair of (extensive), not associated with external wound (Anaes.) (Assist.)
52062	Fee: \$295.70 Benefit: 75% = \$221.80 85% = \$251.35
	BONE TUMOUR, INNOCENT, excision of, not being a service to which another item in Groups O3 to
	O9 applies (Anaes.) (Assist.)
52063	Fee: \$356.35 Benefit: 75% = \$267.30 85% = \$302.90
2002	BONE CYST, injection into or aspiration of (Anaes.)
52064	F 01/0.50 B 64 750/ 0107.15 050/ 0144.10
52064	Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 SUBMANDIBULAR GLAND, extirpation of (Anaes.) (Assist.)
	GODWANDIDOLAR GLAND, Campation of (Anacs.) (Assist.)
52066	Fee: \$445.40 Benefit: 75% = \$334.05 85% = \$378.60
	SUBLINGUAL GLAND, extirpation of (Anaes.)
52069	Fee: \$198.50 Benefit: 75% = \$148.90 85% = \$168.75
	SALIVARY GLAND, DILATATION OR DIATHERMY of duct (Anaes.)
52072	Fact 659 90 Parafit 750/ - 644 10 950/ 650 00
52072	Fee: \$58.80 Benefit: 75% = \$44.10 85% = \$50.00 SALIVARY GLAND, repair of CUTANEOUS FISTULA OF (Anaes.)
	DILLYTHET GLAND, repair of COTAINEOUS FISTOLA OF (Allacs.)
52073	Fee: \$149.75 Benefit: 75% = \$112.35 85% = \$127.30
	SALIVARY GLAND, removal of CALCULUS from duct or meatotomy or marsupialisation, 1 or more
	such procedures (Anaes.)
52075	Fee: \$149.75 Benefit: 75% = \$112.35 85% = \$127.30
	TONGUE, partial excision of (Anaes.) (Assist.)
52079	Fac: \$205.70 Ranafit: 75% - \$221.80 85% - \$251.25
52078	Fee: \$295.70 Benefit: 75% = \$221.80 85% = \$251.35

O3. GEI	NERAL SURGERY
	TONGUE TIE, division or excision of frenulum (Anaes.)
52081	Fee: \$46.50 Benefit: 75% = \$34.90 85% = \$39.55
32001	TONGUE TIE, MANDIBULAR FRENULUM OR MAXILLARY FRENULUM, division or excision of
	frenulum, in a person aged not less than 2 years (Anaes.)
52084	Fee: \$119.50 Benefit: 75% = \$89.65 85% = \$101.60
	RANULA OR MUCOUS CYST OF MOUTH, removal of (Anaes.)
52087	Fee: \$204.70 Benefit: 75% = \$153.55 85% = \$174.00
	OPERATION ON MANDIBLE OR MAXILLA (other than alveolar margins) for chronic osteomyelitis
	- 1 bone or in combination with adjoining bones (Anaes.) (Assist.)
52090	Fee: \$356.35 Benefit: 75% = \$267.30 85% = \$302.90
	OPERATION on SKULL for OSTEOMYELITIS (Anaes.) (Assist.)
52092	Fee: \$464.50 Benefit: 75% = \$348.40 85% = \$394.85
	OPERATION ON ANY COMBINATION OF ADJOINING BONES, being bones referred to in item
	52092 (Anaes.) (Assist.)
52094	Fee: \$587.55 Benefit: 75% = \$440.70 85% = \$504.15
	BONE GROWTH STIMULATOR, insertion of (Anaes.) (Assist.)
52095	Fee: \$380.80 Benefit: 75% = \$285.60 85% = \$323.70
	ORTHOPAEDIC PIN OR WIRE, insertion of, into maxilla or mandible or zygoma, as an independent
	procedure (Anaes.)
52096	Fee: \$112.85 Benefit: 75% = \$84.65 85% = \$95.95
	EXTERNAL FIXATION, removal of, in the operating theatre of a hospital (Anaes.)
52097	Fee: \$160.05 Benefit: 75% = \$120.05
320)	EXTERNAL FIXATION, removal of, in conjunction with operations involving internal fixation or bone
	grafting or both (Anaes.)
52098	Fee: \$188.20 Benefit: 75% = \$141.15 85% = \$160.00
	BURIED WIRE, PIN or SCREW, 1 or more, which were inserted for internal fixation purposes into
	maxilla or mandible or zygoma, removal of, requiring anaesthesia, incision, dissection and suturing, per
	bone, not being a service associated with a service to which item 52102 or 52105 applies (Anaes.)
52099	Fee: \$141.25 Benefit: 75% = \$105.95 85% = \$120.10
	BURIED WIRE, PIN or SCREW, 1 or more, which were inserted for internal fixation purposes into
	maxilla or mandible or zygoma, removal of, requiring anaesthesia, incision, dissection and suturing, where undertaken in the operating theatre of a hospital, per bone (Anaes.)
	where undertaken in the operating theatre of a nospital, per some (ringes.)
52102	Fee: \$141.25
	PLATE, 1 or more of, and associated screw and wire which were inserted for internal fixation purposes into maxilla or mandible or zygoma, removal of, requiring anaesthesia, incision, dissection and suturing,
	per bone, not being a service associated with a service to which item 52099 or 52102 applies (Anaes.)
	(Assist.)
52105	Fee: \$263.60 Benefit: 75% = \$197.70 85% = \$224.10
	ARCH BARS, 1 or more, which were inserted for dental fixation purposes to the maxilla or mandible,
	removal of, requiring general anaesthesia where undertaken in the operating theatre of a hospital
	(Anaes.)
52106	Fee: \$108.90 Benefit: 75% = \$81.70

O3. GE	NERAL SURGERY
	LIP, full thickness wedge excision of, with repair by direct sutures (Anaes.) (Assist.)
52100	E
52108	Fee: \$326.05 Benefit: 75% = \$244.55 85% = \$277.15 VERMILIONECTOMY (Anaes.) (Assist.)
	VERMILIONEE TOWT (Anaes.) (Assist.)
52111	Fee: \$326.05 Benefit: 75% = \$244.55 85% = \$277.15
	MANDIBLE or MAXILLA, segmental resection of, for tumours or cysts (Anaes.) (Assist.)
52114	Fee: \$587.60 Benefit: 75% = \$440.70 85% = \$504.20
	MANDIBLE, including lower border, or MAXILLA, sub-total resection of (Anaes.) (Assist.)
52117	Fee: \$699.45 Benefit: 75% = \$524.60 85% = \$616.05
32117	MANDIBLE, hemimandiblectomy of, including condylectomy where performed (Anaes.) (Assist.)
52120	Fee: \$827.30 Benefit: 75% = \$620.50 85% = \$743.90
	MANDIBLE, hemi-mandibular reconstruction of, OR MAXILLA, reconstruction of, with BONE GRAFT, PLATE, TRAY OR ALLOPLAST, not being a service associated with a service to which item
	52123 applies (Anaes.) (Assist.)
52122	Fee: \$827.30 Benefit: 75% = \$620.50 85% = \$743.90
32122	Fee: \$827.30 Benefit: 75% = \$620.50 85% = \$743.90 MANDIBLE, total resection of both sides, including condylectomies where performed (Anaes.) (Assist.)
52123	Fee: \$936.55 Benefit: 75% = \$702.45 85% = \$853.15
	MAXILLA, total resection of (Anaes.) (Assist.)
52126	Fee: \$900.45 Benefit: 75% = \$675.35 85% = \$817.05
	MAXILLA, total resection of both maxillae (Anaes.) (Assist.)
52129	Fee: \$1,205.40 Benefit: 75% = \$904.05 85% = \$1122.00
	BONE GRAFT, not being a service to which another item in Groups O3 to O9 applies (Anaes.) (Assist.)
52130	Fee: \$442.45 Benefit: 75% = \$331.85 85% = \$376.10
32130	BONE GRAFT WITH INTERNAL FIXATION, not being a service to which an item in the range
	3. The state of th
	(a) 51900 to 52186; or
	(b) 52303 to 53460 applies (Anaes.) (Assist.)
52131	Fee: \$611.90 Benefit: 75% = \$458.95 85% = \$528.50
	TRACHEOSTOMY (Anaes.)
52132	Fee: \$248.95 Benefit: 75% = \$186.75 85% = \$211.65
32132	CRICOTHYROSTOMY by direct stab or Seldinger technique, using Minitrach or similar device
	(Anaes.)
52133	Fee: \$91.05 Benefit: 75% = \$68.30 85% = \$77.40
32133	POST-OPERATIVE or POST-NASAL HAEMORRHAGE, or both, control of, where undertaken in the
	operating theatre of a hospital (Anaes.)
52135	Fee: \$144.35 Benefit: 75% = \$108.30
32133	MAXILLARY ARTERY, ligation of (Anaes.) (Assist.)
52138 52141	Fee: \$448.55 Benefit: 75% = \$336.45 85% = \$381.30 FACIAL, MANDIBULAR or LINGUAL ARTERY or VEIN or ARTERY and VEIN, ligation of, not
J4141	I Mente, manufactor of envolve antical of vent of action and vent, figurous of, not

O3. GEN	NERAL SURGERY
	being a service to which item 52138 applies (Anaes.) (Assist.)
	Fee: \$443.70 Benefit: 75% = \$332.80 85% = \$377.15
	FOREIGN BODY, deep, removal of using interventional imaging techniques (Anaes.) (Assist.)
52144	Fee: \$413.55 Benefit: 75% = \$310.20 85% = \$351.55 DUCT OF MAJOR SALIVARY GLAND, transposition of (Anaes.) (Assist.)
	DOCT OF WAJOR SALIVART GLAND, transposition of (Aliaes.) (Assist.)
52147	Fee: \$390.25 Benefit: 75% = \$292.70 85% = \$331.75
	PAROTID DUCT, repair of, using micro-surgical techniques (Anaes.) (Assist.)
52148	Fee: \$689.80 Benefit: 75% = \$517.35 85% = \$606.40
	SUBMANDIBULAR DUCTS, relocation of, for surgical control of drooling (Anaes.) (Assist.)
	F. (1) 110 (5. P. (2) (200 00 05) (200 05)
52158	Fee: \$1,110.65 Benefit: 75% = \$833.00 85% = \$1027.25 MALIGNANT DISEASE
	WILDOWINI DISEASE
	AGGRESSIVE OR POTENTIALLY MALIGNANT BONE OR DEEP SOFT TISSUE TUMOUR,
	biopsy of (not including aftercare) (Anaes.)
52180	Fee: \$188.20 Benefit: 75% = \$141.15 85% = \$160.00
	BONE OR MALIGNANT DEEP SOFT TISSUE TUMOUR, lesional or marginal excision of (Anaes.) (Assist.)
	(Abbiot.)
52182	Fee: \$414.25 Benefit: 75% = \$310.70 85% = \$352.15
	BONE TUMOUR, lesional or marginal excision of, combined with any 1 of: liquid nitrogen freezing, autograft, allograft or cementation (Anaes.) (Assist.)
	autograft, anograft of cementation (Aliaes.) (Assist.)
52184	Fee: \$611.90 Benefit: 75% = \$458.95 85% = \$528.50
	BONE TUMOUR, lesional or marginal excision of, combined with any 2 or more of: liquid nitrogen
	freezing, autograft, allograft or cementation (Anaes.) (Assist.)
52186	Fee: \$753.25 Benefit: 75% = \$564.95 85% = \$669.85
04. PL <i>A</i>	ASTIC & RECONSTRUCTIVE
	Group O4. Plastic & Reconstructive
	SINGLE-STAGE LOCAL FLAP, where indicated, repair to 1 defect, with skin or mucosa (Anaes.)
	(Assist.)
52300	Fee: \$284.35 Benefit: 75% = \$213.30 85% = \$241.70
32300	SINGLE-STAGE LOCAL FLAP, where indicated, repair to 1 defect, with buccal pad of fat (Anaes.)
	(Assist.)
52303	Fee: \$406.05 Benefit: 75% = \$304.55 85% = \$345.15
32303	SINGLE-STAGE LOCAL FLAP, where indicated, repair to 1 defect, using temporalis muscle (Anaes.)
	(Assist.)
50006	F
	Fee: \$602.45
52306	TER EE CIR A E LUNCI (MIICOSA OF SOIII SKID) OLA OFADIDATIO AFEA L'ADAES I
52306	FREE GRAFTING (mucosa or split skin) of a granulating area (Anaes.)
52306 52309	Fee: \$204.70 Benefit: 75% = \$153.55 85% = \$174.00

04. PL	ASTIC & RECONSTRUCTIVE
	Fee: \$284.35 Benefit: 75% = \$213.30 85% = \$241.70
	FREE GRAFTING, FULL THICKNESS, to 1 defect (mucosa or skin) (Anaes.) (Assist.)
	T. A
52315	Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70
	BONE GRAFT, harvesting of, via separate incision, being a service associated with a service to which
	another item in Groups O3 to O9 applies - Autogenous - small quantity (Anaes.)
52318	Fee: \$141.25 Benefit: 75% = \$105.95 85% = \$120.10
	BONE GRAFT, harvesting of, via separate incision, being a service associated with a service to which
	another item in Groups O3 to O9 applies - Autogenous - large quantity (Anaes.)
50010	E #225.50 B #4 #504 #14(65 0504 #200.20
52319	Fee: \$235.50 Benefit: 75% = \$176.65 85% = \$200.20 FOREIGN IMPLANT (NON-BIOLOGICAL), insertion of, for CONTOUR RECONSTRUCTION of
	pathological deformity, not being a service associated with a service to which item 52624 applies
	(Anaes.) (Assist.)
	(1 Macos.) (1 15515t.)
52321	Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70
	DIRECT FLAP REPAIR, using tongue, first stage (Anaes.) (Assist.)
52324	Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70
32324	DIRECT FLAP REPAIR, using tongue, second stage (Anaes.)
	DIRLETTEAT REPAIR, using tongue, second stage (Anaes.)
52327	Fee: \$235.05 Benefit: 75% = \$176.30 85% = \$199.80
	PALATAL DEFECT (oro-nasal fistula), plastic closure of, including services to which item 52300,
	52303, 52306 or 52324 applies (Anaes.) (Assist.)
52220	Foot \$791.05 Panastt, 750/ - \$59/ 50 950/ - \$609.55
52330	Fee: \$781.95 Benefit: 75% = \$586.50 85% = \$698.55 CLEFT PALATE, primary repair (Anaes.) (Assist.)
	CEET 1 17 EP (11), printary repair (1 states.) (1 soise.)
52333	Fee: \$781.95 Benefit: 75% = \$586.50 85% = \$698.55
	CLEFT PALATE, secondary repair, closure of fistula using local flaps (Anaes.) (Assist.)
50226	Face \$499.75 Parafite 750/ - \$2// (0. 950/ - \$415.45
52336	Fee: \$488.75 Benefit: 75% = \$366.60 85% = \$415.45 ALVEOLAR CLEFT (congenital) unilateral, grafting of, including plastic closure of associated oro-
	nasal fistulae and ridge augmentation (Anaes.) (Assist.)
	nusur ristatus una riago augmentation (rinaes.) (rissist.)
52337	Fee: \$1,069.10 Benefit: 75% = \$801.85 85% = \$985.70
	CLEFT PALATE, secondary repair, lengthening procedure (Anaes.) (Assist.)
50220	Frances (0) Power 1, 750/ 0417 45 050/ 0472 20
52339	Fee: \$556.60 Benefit: 75% = \$417.45 85% = \$473.20 MANDIBLE or MAXILLA, unilateral osteotomy or osteectomy of, including transposition of nerves
	and vessels and bone grafts taken from the same site (Anaes.) (Assist.)
	and respens and come grants taken from the same site (rindes.) (rissist.)
	(See para ON.4.8 of explanatory notes to this Category)
52342	Fee: \$966.80 Benefit: 75% = \$725.10
	MANDIBLE or MAXILLA, unilateral osteotomy or osteectomy of, including transposition of nerves
	and vessels and bone grafts taken from the same site and stabilisation with fixation by wires, screws, plates or pins, or any combination (Anaes.) (Assist.)
	places of phis, of any comoniation (Anacs.) (Assist.)
	(See para ON.4.8 of explanatory notes to this Category)
52345	Fee: \$1,090.35 Benefit: 75% = \$817.80
	MANDIBLE or MAXILLA, bilateral osteotomy or osteectomy of, including transposition of nerves and
	vessels and bone grafts taken from the same site (Anaes.) (Assist.)
	(See para ON.4.8 of explanatory notes to this Category)
52348	Fee: \$1,232.05 Benefit: 75% = \$924.05

04. PL	ASTIC & RECONSTRUCTIVE
	MANDIBLE or MAXILLA, bilateral osteotomy of osteectomy of, including transposition of nerves and
	vessels and bone grafts taken from the same site and stabilisation with fixation by wires, screws, plates
	or pins, or any combination (Anaes.) (Assist.)
	(See para ON.4.8 of explanatory notes to this Category)
52351	Fee: \$1,383.65 Benefit: 75% = \$1037.75
	MANDIBLE or MAXILLA, osteotomies or osteectomies of, involving 3 or more such procedures on the 1 jaw, including transposition of nerves and vessels and bone grafts taken from the same site (Anaes.) (Assist.)
52354	(See para ON.4.8 of explanatory notes to this Category) Fee: \$1,402.70 Benefit: 75% = \$1052.05
32334	MANDIBLE or MAXILLA, osteotomies or osteectomies of, involving 3 or more such procedures on the
	1 jaw, including transposition of nerves and vessels and bone grafts taken from the same site and stabilisation with fixation by wires, screws, plates or pins, or any combination (Anaes.) (Assist.)
52357	(See para ON.4.8 of explanatory notes to this Category) Fee: \$1,579.20 Benefit: 75% = \$1184.40
J2JJ1	MANDIBLE and MAXILLA, osteotomies or osteectomies of, involving 2 such procedures of each jaw,
	including transposition of nerves and vessels and bone grafts taken from the same site (Anaes.) (Assist.)
52360	(See para ON.4.8 of explanatory notes to this Category) Fee: \$1,611.05 Benefit: 75% = \$1208.30
32300	MANDIBLE and MAXILLA, osteotomies or osteectomies of, involving 2 such procedures of each jaw,
	including transposition of nerves and vessels and bone grafts taken from the same site and stabilisation
	with fixation by wires, screws, plates or pins, or any combination (Anaes.) (Assist.)
	(See para ON.4.8 of explanatory notes to this Category)
52363	Fee: \$1,812.40 Benefit: 75% = \$1359.30
	MANDIBLE and MAXILLA, complex bilateral osteotomies or osteectomies of, involving 3 or more such procedures of 1 jaw and 2 such procedures of the other jaw, including genioplasty when performed and transposition of nerves and vessels and bone grafts taken from the same site (Anaes.) (Assist.)
	(See para ON.4.8 of explanatory notes to this Category)
52366	Fee: \$1,772.30 Benefit: 75% = \$1329.25
	MANDIBLE and MAXILLA, complex bilateral osteotomies or osteectomies of, involving 3 or more such procedures of 1 jaw and 2 such procedures of the other jaw, including genioplasty when performed and transposition of nerves and vessels and bone grafts taken from the same site and stabilisation with fixation by wires, screws, plates or pins, or any combination (Anaes.) (Assist.)
	(See para ON.4.8 of explanatory notes to this Category)
52369	Fee: \$1,992.70 Benefit: 75% = \$1494.55
	MANDIBLE and MAXILLA, complex bilateral osteotomies or osteectomies of, involving 3 or more such procedures of each jaw, including genioplasty when performed and transposition of nerves and vessels and bone grafts taken from the same site (Anaes.) (Assist.)
	(See para ON.4.8 of explanatory notes to this Category)
52372	Fee: \$1,933.55 Benefit: 75% = \$1450.20
	MANDIBLE and MAXILLA, complex bilateral osteotomies or osteectomies of, involving 3 or more such procedures of each jaw, including genioplasty when performed and transposition of nerves and vessels and bone grafts taken from the same site and stabilisation with fixation by wires, screws, plates or pins, or any combination (H) (Anaes.) (Assist.)
	(See para ON.4.8 of explanatory notes to this Category)
52375	Fee: \$2,165.75 Benefit: 75% = \$1624.35
52378	GENIOPLASTY including transposition of nerves and vessels and bone grafts taken from the same site
	<u> </u>

O4. PL	ASTIC & RECONSTRUCTIVE
<u> </u>	(Anaes.) (Assist.)
	(Contrary ON 4.0 of anniholatory materials this Cottons)
	(See para ON.4.9 of explanatory notes to this Category) Fee: \$748.65 Benefit: 75% = \$561.50 85% = \$665.25
	FACE, contour reconstruction of 1 region, using autogenous bone or cartilage graft (Anaes.) (Assist.)
	(1 access)
52379	Fee: \$1,279.45 Benefit: 75% = \$959.60 85% = \$1196.05
	MIDFACIAL OSTEOTOMIES - Le Fort II, Modified Le Fort III (Nasomalar), Modified Le Fort III
	(Malar-Maxillary), Le Fort III involving 3 or more osteotomies of the midface including transposition of
	nerves and vessels and bone grafts taken from the same site (Anaes.) (Assist.)
52380	Fee: \$2,178.60 Benefit: 75% = \$1633.95 85% = \$2095.20
	MIDFACIAL OSTEOTOMIES - Le Fort II, Modified Le Fort III (Nasomalar), Modified Le Fort III
	(Malar-Maxillary), Le Fort III involving 3 or more osteotomies of the midface including transposition of
	nerves and vessels and bone grafts taken from the same site and stabilisation with fixation by wires,
	screws, plates or pins, or any combination (Anaes.) (Assist.)
52382	Fee: \$2,611.60 Benefit: 75% = \$1958.70 85% = \$2528.20
32302	MANDIBLE, fixation by intermaxillary wiring, excluding wiring for obesity
	The transfer of motion of
52420	Fee: \$241.15 Benefit: 75% = \$180.90 85% = \$205.00
	DERMIS, DERMOFAT OR FASCIA GRAFT (excluding transfer of fat by injection) (Anaes.) (Assist.)
52424	Fee: \$473.65 Benefit: 75% = \$355.25 85% = \$402.65
32424	MICROVASCULAR REPAIR OF, using microsurgical techniques, with restoration of continuity of
	artery or vein of distal extremity or digit (Anaes.) (Assist.)
52430	Fee: \$1,090.35 Benefit: 75% = \$817.80 85% = \$1006.95
	CLEFT LIP, unilateral - primary repair, 1 stage, without anterior palate repair (Anaes.) (Assist.)
52440	Fee: \$541.35 Benefit: 75% = \$406.05 85% = \$460.15
	CLEFT LIP, unilateral - primary repair, 1 stage, with anterior palate repair (Anaes.) (Assist.)
52442	Fee: \$676.80 Benefit: 75% = \$507.60 85% = \$593.40
	CLEFT LIP, bilateral - primary repair, 1 stage, without anterior palate repair (Anaes.) (Assist.)
52444	Fee: \$751.85 Benefit: 75% = \$563.90 85% = \$668.45
	CLEFT LIP, bilateral - primary repair, 1 stage, with anterior palate repair (Anaes.) (Assist.)
52446	Fee: \$887.50 Benefit: 75% = \$665.65 85% = \$804.10
	CLEFT LIP, partial revision, including minor flap revision alignment and adjustment, including revision of minor whistle deformity if performed (Anaes.)
	of filliof whistic deformity if performed (Andes.)
52450	Fee: \$300.75 Benefit: 75% = \$225.60 85% = \$255.65
	CLEFT LIP, total revision, including major flap revision, muscle reconstruction and revision of major
	whistle deformity (Anaes.) (Assist.)
52452	Fee: \$488.75 Benefit: 75% = \$366.60 85% = \$415.45
32732	CLEFT LIP RECONSTRUCTION using full thickness flap (Abbe or similar), first stage (Anaes.)
	(Assist.)
52456	Fee: \$827.30 Benefit: 75% = \$620.50 85% = \$743.90
	CLEFT LIP RECONSTRUCTION using full thickness flap (Abbe or similar), second stage (Anaes.)
52458	Fee: \$300.75 Benefit: 75% = \$225.60 85% = \$255.65

04. PL/	ASTIC & RECONSTRUCTIVE
	VELO-PHARYNGEAL INCOMPETENCE, pharyngeal flap for, or pharyngoplasty for (Anaes.)
52460	Fee: \$781.95 Benefit: 75% = \$586.50 85% = \$698.55
	COMPOSITE GRAFT (Chondro-cutaneous or chondro-mucosal) to nose, ear or eyelid (Anaes.) (Assist.)
52480	Fee: \$502.25 Benefit: 75% = \$376.70 85% = \$426.95
	MACROCHEILIA or macroglossia, operation for (Anaes.) (Assist.)
52482	Fee: \$483.25 Benefit: 75% = \$362.45 85% = \$410.80
	MACROSTOMIA, operation for (Anaes.) (Assist.)
52484	Fee: \$575.30 Benefit: 75% = \$431.50 85% = \$491.90
	EPROSTHETIC
	Group O5. Preprosthetic
	MANDIBULAR OR PALATAL EXOSTOSIS, excision of (Anaes.) (Assist.)
52600	Fee: \$338.35 Benefit: 75% = \$253.80 85% = \$287.60 MYLOHYOID RIDGE, reduction of (Anaes.) (Assist.)
	MYLOHYOID RIDGE, reduction of (Anaes.) (Assist.)
52603	Fee: \$323.40 Benefit: 75% = \$242.55 85% = \$274.90
	MAXILLARY TUBEROSITY, reduction of (Anaes.)
52606	Fee: \$246.70 Benefit: 75% = \$185.05 85% = \$209.70
	PAPILLARY HYPERPLASIA OF THE PALATE, removal of - less than 5 lesions (Anaes.) (Assist.)
52609	Fee: \$323.40 Benefit: 75% = \$242.55 85% = \$274.90
32009	PAPILLARY HYPERPLASIA OF THE PALATE, removal of - 5 to 20 lesions (Anaes.) (Assist.)
52612	Fee: \$406.05 Benefit: 75% = \$304.55 85% = \$345.15 PAPILLARY HYPERPLASIA OF THE PALATE, removal of - more than 20 lesions (Anaes.) (Assist.)
	PAPILLARY HYPERPLASIA OF THE PALATE, Tellioval of - Illore than 20 lesions (Aliaes.) (Assist.)
52615	Fee: \$503.85 Benefit: 75% = \$377.90 85% = \$428.30
	VESTIBULOPLASTY, submucosal or open, including excision of muscle and skin or mucosal graft
	when performed - unilateral or bilateral (Anaes.) (Assist.)
52618	Fee: \$586.50 Benefit: 75% = \$439.90 85% = \$503.10
	FLOOR OF MOUTH LOWERING (Obwegeser or similar procedure), including excision of muscle and
	skin or mucosal graft when performed - unilateral (Anaes.) (Assist.)
52621	Fee: \$586.50 Benefit: 75% = \$439.90 85% = \$503.10
	ALVEOLAR RIDGE AUGMENTATION with bone or alloplast or both - unilateral (Anaes.) (Assist.)
52624	Fee: \$473.65 Benefit: 75% = \$355.25 85% = \$402.65
32021	ALVEOLAR RIDGE AUGMENTATION - unilateral, insertion of tissue expanding device into
	maxillary or mandibular alveolar ridge region for (Anaes.) (Assist.)
52626	Fee: \$290.50 Benefit: 75% = \$217.90 85% = \$246.95
32020	OSSEO-INTEGRATION PROCEDURE - in the practice of oral and maxillofacial surgery, extra oral
	implantation of titanium fixture (Anaes.) (Assist.)
52627	Fee: \$503.85 Benefit: 75% = \$377.90 85% = \$428.30
32021	OSSEO-INTEGRATION PROCEDURE - in the practice of oral and maxillofacial surgery, fixation of
	transcutaneous abutment (Anaes.)
52630	

Fee: \$186.50 Benefit: 75% = \$139.90 85% = \$158.55	cilitate
restoration of the dentition following resection of part of the maxilla or mandible for bening malignant tumours (Anaes.) 52633 Fee: \$503.85 Benefit: 75% = \$377.90 85% = \$428.30 OSSEO-INTEGRATION PROCEDURE - fixation of transmucosal abutment to fixtures prollowing resection of part of the maxilla or mandible for benign or malignant tumours (A 52636 Fee: \$186.50 Benefit: 75% = \$139.90 85% = \$158.55 O6. NEUROSURGICAL Group O6. Neurosurgical NEUROLYSIS BY OPEN OPERATION, without transposition, not being a service associate which item \$2803 applies (Anaes.) (Assist.) 52800 Fee: \$276.80 Benefit: 75% = \$207.60 85% = \$235.30 NERVE TRUNK, internal (interfascicular), NEUROLYSIS of, using microsurgical technic (Assist.) 52803 Fee: \$398.55 Benefit: 75% = \$298.95 85% = \$338.80 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from superficial periphe (Anaes.) (Assist.) 52806 Fee: \$276.80 Benefit: 75% = \$207.60 85% = \$235.30 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from deep peripheral net (Assist.) 52809 Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE TRUNK, PRIMARY repair of, using microsurgical techniques (Anaes.) (Assist.) 52810 Fee: \$676.80 Benefit: 75% = \$507.60 85% = \$593.40 NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Assist.) 52811 Fee: \$714.35 Benefit: 75% = \$507.60 85% = \$593.40 NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Assist.) 52812 Fee: \$714.35 Benefit: 75% = \$535.80 85% = \$630.95 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) 52813 Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft using microsurgical techniques (Anaes.) (Assist.) 52811 Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain of the pain of the pain of the pain of the pain of the pain of the pain of the pain of the pain of the pain of the pain of the pain of the pain of the pain of the pain of the pain of the pain of th	cilitate
malignant tumours (Anaes.) Fee: \$503.85 Benefit: 75% = \$377.90 85% = \$428.30 OSSEO-INTEGRATION PROCEDURE - fixation of transmucosal abutment to fixtures p following resection of part of the maxilla or mandible for benign or malignant tumours (A 52636 Fee: \$186.50 Benefit: 75% = \$139.90 85% = \$158.55 O6. NEUROSURGICAL Group O6. Neurosurgical NEUROLYSIS BY OPEN OPERATION, without transposition, not being a service assoc service to which item 52803 applies (Anaes.) (Assist.) 52800 Fee: \$276.80 Benefit: 75% = \$207.60 85% = \$235.30 NERVE TRUNK, internal (interfascicular), NEUROLYSIS of, using microsurgical technic (Assist.) 52803 Fee: \$398.55 Benefit: 75% = \$298.95 85% = \$338.80 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from superficial peripher (Anaes.) (Assist.) 52806 Fee: \$276.80 Benefit: 75% = \$207.60 85% = \$235.30 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from deep peripheral net (Assist.) 52806 Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE TRUNK, PRIMARY repair of, using microsurgical techniques (Anaes.) (Assist.) 52812 Fee: \$676.80 Benefit: 75% = \$507.60 85% = \$593.40 NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Assist.) 52815 Fee: \$473.75 Benefit: 75% = \$505.80 85% = \$630.95 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) 52816 Fee: \$473.75 Benefit: 75% = \$555.55 85% = \$402.70 NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Assist.) 52817 See: \$473.75 Senefit: 75% = \$505.80 Ses = \$630.95 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) 52818 Fee: \$473.75 Benefit: 75% = \$555.55 85% = \$402.70 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft usincrosurgical techniques (Anaes.) (Assist.) Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain repair of the pain repairs of the pain repairs of the pain repairs of the pain repairs of the pain repairs of the pain repairs of the pain repairs of the pain repai	
See: \$503.85 Benefit: 75% = \$377.90	gn or
OSSEO-INTEGRATION PROCEDURE - fixation of transmucosal abutment to fixtures p following resection of part of the maxilla or mandible for benign or malignant tumours (A 52636 Fee: \$186.50 Benefit: 75% = \$139.90 85% = \$158.55 O6. NEUROSURGICAL Group O6. Neurosurgical NEUROLYSIS BY OPEN OPERATION, without transposition, not being a service assoc service to which item 52803 applies (Anaes.) (Assist.) 52800 Fee: \$276.80 Benefit: 75% = \$207.60 85% = \$235.30 NERVE TRUNK, internal (interfascicular), NEUROLYSIS of, using microsurgical technic (Assist.) 52803 Fee: \$398.55 Benefit: 75% = \$298.95 85% = \$338.80 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from superficial periphe (Anaes.) (Assist.) 52806 Fee: \$276.80 Benefit: 75% = \$207.60 85% = \$235.30 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from deep peripheral network (Assist.) 52809 Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE TRUNK, PRIMARY repair of, using microsurgical techniques (Anaes.) (Assist.) 52812 Fee: \$676.80 Benefit: 75% = \$507.60 85% = \$593.40 NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Assist.) 52815 Fee: \$714.35 Benefit: 75% = \$535.80 85% = \$630.95 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) 52816 Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft umicrosurgical techniques (Anaes.) (Assist.) 52816 Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain resurresurgery of resurresurgery of resurresurgery of resurresur	
OSSEO-INTEGRATION PROCEDURE - fixation of transmucosal abutment to fixtures p following resection of part of the maxilla or mandible for benign or malignant tumours (A 52636 Fee: \$186.50 Benefit: 75% = \$139.90 85% = \$158.55 O6. NEUROSURGICAL Group O6. Neurosurgical NEUROLYSIS BY OPEN OPERATION, without transposition, not being a service assoc service to which item 52803 applies (Anaes.) (Assist.) 52800 Fee: \$276.80 Benefit: 75% = \$207.60 85% = \$235.30 NERVE TRUNK, internal (interfascicular), NEUROLYSIS of, using microsurgical technic (Assist.) 52803 Fee: \$398.55 Benefit: 75% = \$298.95 85% = \$338.80 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from superficial periphe (Anaes.) (Assist.) 52806 Fee: \$276.80 Benefit: 75% = \$207.60 85% = \$235.30 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from deep peripheral network (Assist.) 52809 Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE TRUNK, PRIMARY repair of, using microsurgical techniques (Anaes.) (Assist.) 52812 Fee: \$676.80 Benefit: 75% = \$507.60 85% = \$593.40 NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Assist.) 52815 Fee: \$714.35 Benefit: 75% = \$535.80 85% = \$630.95 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) 52816 Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft umicrosurgical techniques (Anaes.) (Assist.) 52816 Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain resurresurgery of resurresurgery of,	
following resection of part of the maxilla or mandible for benign or malignant tumours (A 52636	11
See: \$186.50 Benefit: 75% = \$139.90 85% = \$158.55	
Group O6. Neurosurgical NEUROLYSIS BY OPEN OPERATION, without transposition, not being a service associated service to which item 52803 applies (Anaes.) (Assist.) Fee: \$276.80 Benefit: 75% = \$207.60 NERVE TRUNK, internal (interfascicular), NEUROLYSIS of, using microsurgical technic (Assist.) Fee: \$398.55 Benefit: 75% = \$298.95 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from superficial periphe (Anaes.) (Assist.) 52806 Fee: \$276.80 Benefit: 75% = \$207.60 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from deep peripheral net (Assist.) 52809 Fee: \$473.75 Benefit: 75% = \$355.35 NEURE TRUNK, PRIMARY repair of, using microsurgical techniques (Anaes.) (Assist.) 52812 Fee: \$676.80 Benefit: 75% = \$507.60 NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Assist.) 52815 Fee: \$714.35 Benefit: 75% = \$535.80 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) 52818 Fee: \$473.75 Benefit: 75% = \$355.35 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) 52818 Fee: \$473.75 Benefit: 75% = \$355.35 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft usincrosurgical techniques (Anaes.) (Assist.) 52818 Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain representations and the pain representation of the pain re	naes.)
Group O6. Neurosurgical NEUROLYSIS BY OPEN OPERATION, without transposition, not being a service associated service to which item 52803 applies (Anaes.) (Assist.) Fee: \$276.80 Benefit: 75% = \$207.60 NERVE TRUNK, internal (interfascicular), NEUROLYSIS of, using microsurgical technic (Assist.) Fee: \$398.55 Benefit: 75% = \$298.95 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from superficial periphe (Anaes.) (Assist.) 52806 Fee: \$276.80 Benefit: 75% = \$207.60 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from deep peripheral net (Assist.) 52809 Fee: \$473.75 Benefit: 75% = \$355.35 NEURE TRUNK, PRIMARY repair of, using microsurgical techniques (Anaes.) (Assist.) 52812 Fee: \$676.80 Benefit: 75% = \$507.60 NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Assist.) 52815 Fee: \$714.35 Benefit: 75% = \$535.80 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) 52818 Fee: \$473.75 Benefit: 75% = \$355.35 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) 52818 Fee: \$473.75 Benefit: 75% = \$355.35 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft usincrosurgical techniques (Anaes.) (Assist.) 52818 Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain representations and the pain representation of the pain re	
NEUROLYSIS BY OPEN OPERATION, without transposition, not being a service assoc service to which item 52803 applies (Anaes.) (Assist.) Fee: \$276.80 Benefit: 75% = \$207.60 85% = \$235.30 NERVE TRUNK, internal (interfascicular), NEUROLYSIS of, using microsurgical technic (Assist.) Fee: \$398.55 Benefit: 75% = \$298.95 85% = \$338.80 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from superficial peripher (Anaes.) (Assist.) Fee: \$276.80 Benefit: 75% = \$207.60 85% = \$235.30 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from deep peripheral necknown (Assist.) S2809 Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE TRUNK, PRIMARY repair of, using microsurgical techniques (Anaes.) (Assist.) S2812 Fee: \$676.80 Benefit: 75% = \$507.60 85% = \$593.40 NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Assist.) Fee: \$714.35 Benefit: 75% = \$535.80 85% = \$630.95 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft usincrosurgical techniques (Anaes.) (Assist.) Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain recovered to the pain of the pain	
NEUROLYSIS BY OPEN OPERATION, without transposition, not being a service assoc service to which item 52803 applies (Anaes.) (Assist.) Fee: \$276.80 Benefit: 75% = \$207.60 85% = \$235.30 NERVE TRUNK, internal (interfascicular), NEUROLYSIS of, using microsurgical technic (Assist.) Fee: \$398.55 Benefit: 75% = \$298.95 85% = \$338.80 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from superficial peripher (Anaes.) (Assist.) Fee: \$276.80 Benefit: 75% = \$207.60 85% = \$235.30 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from deep peripheral network (Assist.) S2809 Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE TRUNK, PRIMARY repair of, using microsurgical techniques (Anaes.) (Assist.) S2812 Fee: \$676.80 Benefit: 75% = \$507.60 85% = \$593.40 NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Assist.) Fee: \$714.35 Benefit: 75% = \$535.80 85% = \$630.95 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) S2818 Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft usincrosurgical techniques (Anaes.) (Assist.) Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain r	
Service to which item 52803 applies (Anaes.) (Assist.) Fee: \$276.80 Benefit: 75% = \$207.60 85% = \$235.30 NERVE TRUNK, internal (interfascicular), NEUROLYSIS of, using microsurgical technic (Assist.) 52803 Fee: \$398.55 Benefit: 75% = \$298.95 85% = \$338.80 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from superficial peripher (Anaes.) (Assist.) 52806 Fee: \$276.80 Benefit: 75% = \$207.60 85% = \$235.30 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from deep peripheral neck (Assist.) 52809 Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE TRUNK, PRIMARY repair of, using microsurgical techniques (Anaes.) (Assist.) 52812 Fee: \$676.80 Benefit: 75% = \$507.60 85% = \$593.40 NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Assist.) 52815 Fee: \$14.35 Benefit: 75% = \$535.80 85% = \$630.95 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) 52818 Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft usincrosurgical techniques (Anaes.) (Assist.) 52821 Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain r	piated with a
Fee: \$276.80 Benefit: 75% = \$207.60 85% = \$235.30 NERVE TRUNK, internal (interfascicular), NEUROLYSIS of, using microsurgical technic (Assist.) See: \$398.55 Benefit: 75% = \$298.95 85% = \$338.80 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from superficial periphe (Anaes.) (Assist.) See: \$276.80 Benefit: 75% = \$207.60 85% = \$235.30 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from deep peripheral necknown (Assist.) See: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE TRUNK, PRIMARY repair of, using microsurgical techniques (Anaes.) (Assist.) See: \$676.80 Benefit: 75% = \$507.60 85% = \$593.40 NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Assist.) Fee: \$714.35 Benefit: 75% = \$535.80 85% = \$630.95 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) See: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft using microsurgical techniques (Anaes.) (Assist.) See: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain results of the pair of the pa	nated with a
NERVE TRUNK, internal (interfascicular), NEUROLYSIS of, using microsurgical technical (Assist.) Fee: \$398.55 Benefit: 75% = \$298.95 S5% = \$338.80 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from superficial peripher (Anaes.) (Assist.) Fee: \$276.80 Benefit: 75% = \$207.60 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from deep peripheral net (Assist.) Fee: \$473.75 Benefit: 75% = \$355.35 S5% = \$402.70 NERVE TRUNK, PRIMARY repair of, using microsurgical techniques (Anaes.) (Assist.) Fee: \$676.80 Benefit: 75% = \$507.60 NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Assist.) Fee: \$714.35 Benefit: 75% = \$535.80 S5% = \$630.95 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) S2818 Fee: \$473.75 Benefit: 75% = \$355.35 S5% = \$402.70 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft usincrosurgical techniques (Anaes.) (Assist.) Fee: \$1,030.20 Benefit: 75% = \$772.65 S5% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain repairs of the pair of the p	
NERVE TRUNK, internal (interfascicular), NEUROLYSIS of, using microsurgical technic (Assist.) Fee: \$398.55 Benefit: 75% = \$298.95 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from superficial periphe (Anaes.) (Assist.) Fee: \$276.80 Benefit: 75% = \$207.60 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from deep peripheral net (Assist.) Fee: \$473.75 Benefit: 75% = \$355.35 NERVE TRUNK, PRIMARY repair of, using microsurgical techniques (Anaes.) (Assist.) Fee: \$676.80 Benefit: 75% = \$507.60 NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Assist.) Fee: \$714.35 Benefit: 75% = \$535.80 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) Fee: \$473.75 Benefit: 75% = \$355.35 NERVE, GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft usincrosurgical techniques (Anaes.) (Assist.) Fee: \$1,030.20 Benefit: 75% = \$772.65 S5% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain resurred to the pair of t	
(Assist.) Fee: \$398.55 Benefit: 75% = \$298.95 85% = \$338.80 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from superficial periphe (Anaes.) (Assist.) 52806 Fee: \$276.80 Benefit: 75% = \$207.60 85% = \$235.30 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from deep peripheral ne (Assist.) 52809 Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE TRUNK, PRIMARY repair of, using microsurgical techniques (Anaes.) (Assist.) 52812 Fee: \$676.80 Benefit: 75% = \$507.60 85% = \$593.40 NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Assist.) 52815 Fee: \$714.35 Benefit: 75% = \$535.80 85% = \$630.95 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) 52818 Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft usincrosurgical techniques (Anaes.) (Assist.) 52821 Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain results and results are results.	iques (Anaes.)
NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from superficial periphe (Anaes.) (Assist.) Fee: \$276.80 Benefit: 75% = \$207.60 85% = \$235.30 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from deep peripheral ne (Assist.) Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE TRUNK, PRIMARY repair of, using microsurgical techniques (Anaes.) (Assist.) Fee: \$676.80 Benefit: 75% = \$507.60 85% = \$593.40 NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Assist.) Fee: \$714.35 Benefit: 75% = \$535.80 85% = \$630.95 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft umicrosurgical techniques (Anaes.) (Assist.) Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain results and results are supported by the support of the pair o	- ' '
NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from superficial periphe (Anaes.) (Assist.) Fee: \$276.80 Benefit: 75% = \$207.60 85% = \$235.30 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from deep peripheral ne (Assist.) Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE TRUNK, PRIMARY repair of, using microsurgical techniques (Anaes.) (Assist.) Fee: \$676.80 Benefit: 75% = \$507.60 85% = \$593.40 NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Assist.) Fee: \$714.35 Benefit: 75% = \$535.80 85% = \$630.95 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft umicrosurgical techniques (Anaes.) (Assist.) Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain results and results are supported by the support of the pair o	
(Anaes.) (Assist.) Fee: \$276.80 Benefit: 75% = \$207.60 85% = \$235.30 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from deep peripheral ne (Assist.) Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE TRUNK, PRIMARY repair of, using microsurgical techniques (Anaes.) (Assist.) Fee: \$676.80 Benefit: 75% = \$507.60 85% = \$593.40 NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Assist.) Fee: \$714.35 Benefit: 75% = \$535.80 85% = \$630.95 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft u microsurgical techniques (Anaes.) (Assist.) Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain results and results are supported by the support of the pair of the p	
See: \$276.80 Benefit: 75% = \$207.60 85% = \$235.30 NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from deep peripheral net (Assist.) See: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE TRUNK, PRIMARY repair of, using microsurgical techniques (Anaes.) (Assist.) See: \$676.80 Benefit: 75% = \$507.60 85% = \$593.40 NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Assist.) See: \$714.35 Benefit: 75% = \$535.80 85% = \$630.95 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) See: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft unicrosurgical techniques (Anaes.) (Assist.) See: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain recognitions and recognitions are supported by the second secon	eral nerve
NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from deep peripheral net (Assist.) Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE TRUNK, PRIMARY repair of, using microsurgical techniques (Anaes.) (Assist.) Fee: \$676.80 Benefit: 75% = \$507.60 NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Assist.) Fee: \$714.35 Benefit: 75% = \$535.80 85% = \$630.95 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft umicrosurgical techniques (Anaes.) (Assist.) Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain respectively.	
NEURECTOMY, NEUROTOMY or REMOVAL OF TUMOUR from deep peripheral net (Assist.) Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE TRUNK, PRIMARY repair of, using microsurgical techniques (Anaes.) (Assist.) Fee: \$676.80 Benefit: 75% = \$507.60 NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Assist.) Fee: \$714.35 Benefit: 75% = \$535.80 85% = \$630.95 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft umicrosurgical techniques (Anaes.) (Assist.) Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain respectively.	
(Assist.) 52809 Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE TRUNK, PRIMARY repair of, using microsurgical techniques (Anaes.) (Assist.) 52812 Fee: \$676.80 Benefit: 75% = \$507.60 85% = \$593.40 NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Assist.) 52815 Fee: \$714.35 Benefit: 75% = \$535.80 85% = \$630.95 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) 52818 Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft using microsurgical techniques (Anaes.) (Assist.) 52821 Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain residual contents of the pair of the	erve (Anaes)
Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70	Ave (Finaes.)
NERVE TRUNK, PRIMARY repair of, using microsurgical techniques (Anaes.) (Assist.) Fee: \$676.80 Benefit: 75% = \$507.60 85% = \$593.40 NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Assist.) Fee: \$714.35 Benefit: 75% = \$535.80 85% = \$630.95 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft u microsurgical techniques (Anaes.) (Assist.) Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain r	
52812 Fee: \$676.80 Benefit: 75% = \$507.60 85% = \$593.40 NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Ass 52815 Fee: \$714.35 Benefit: 75% = \$535.80 85% = \$630.95 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) 52818 Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft unicrosurgical techniques (Anaes.) (Assist.) 52821 Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain respectively. For pain respectively.	
NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Ass 52815 Fee: \$714.35 Benefit: 75% = \$535.80 85% = \$630.95 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) 52818 Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft u microsurgical techniques (Anaes.) (Assist.) 52821 Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain r	1
NERVE TRUNK, SECONDARY repair of, using microsurgical techniques (Anaes.) (Ass 52815 Fee: \$714.35 Benefit: 75% = \$535.80 85% = \$630.95 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) 52818 Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft u microsurgical techniques (Anaes.) (Assist.) 52821 Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain r	
52815 Fee: \$714.35 Benefit: 75% = \$535.80 85% = \$630.95 NERVE, TRANSPOSITION OF (Anaes.) (Assist.) 52818 Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft u microsurgical techniques (Anaes.) (Assist.) 52821 Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain r	uist)
NERVE, TRANSPOSITION OF (Anaes.) (Assist.) Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft u microsurgical techniques (Anaes.) (Assist.) Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain r	ist.)
NERVE, TRANSPOSITION OF (Anaes.) (Assist.) Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft u microsurgical techniques (Anaes.) (Assist.) Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain r	
52818 Fee: \$473.75 Benefit: 75% = \$355.35 85% = \$402.70 NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft u microsurgical techniques (Anaes.) (Assist.) 52821 Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain r	
NERVE GRAFT TO NERVE TRUNK, (cable graft) including harvesting of nerve graft u microsurgical techniques (Anaes.) (Assist.) Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain r	
microsurgical techniques (Anaes.) (Assist.) 52821 Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain r	
52821 Fee: \$1,030.20 Benefit: 75% = \$772.65 85% = \$946.80 PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain r	sing
PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain r	
PERIPHERAL BRANCHES OF THE TRIGEMINAL NERVE, cryosurgery of, for pain r	
	elief (Anges)
(Assist.)	cher (Allacs.)
(* 100101.)	
52824 Fee: \$443.70 Benefit: 75% = \$332.80 85% = \$377.15	
INJECTION OF PRIMARY BRANCH OF TRIGEMINAL NERVE with alcohol, cortison	ne, phenol, or
similar substance (Anaes.)	
Francis D. 1844 750/ 0170 00 050/ 0000 00	
52826 Fee: \$237.60 Benefit: 75% = \$178.20 85% = \$202.00	:~4)
CUTANEOUS NERVE, primary repair of, using microsurgical techniques (Anaes.) (Ass	ist.)
CUTANEOUS NERVE, secondary repair of, using microsurgical techniques (Anaes.) (A	ssist)
(All the state of	
52830 Fee: \$466.10 Benefit: 75% = \$349.60 85% = \$396.20	*

O6. NE	UROSURGICAL
	CUTANEOUS NERVE, nerve graft to, using microsurgical techniques (Anaes.) (Assist.)
52832	Fee: \$639.20 Benefit: 75% = \$479.40 85% = \$555.80
	R, NOSE & THROAT
	Group O7. Ear, Nose & Throat
	MAXILLARY ANTRUM, PROOF PUNCTURE AND LAVAGE OF (Anaes.)
53000	Fee: \$32.55 Benefit: 75% = \$24.45 85% = \$27.70
	MAXILLARY ANTRUM, proof puncture and lavage of, under general anaesthesia (requiring admission to hospital) not being a service associated with a service to which another item in Groups O3 to O9 applies (Anaes.)
53003	Fee: \$91.90 Benefit: 75% = \$68.95 85% = \$78.15
	MAXILLARY ANTRUM, LAVAGE OF - each attendance at which the procedure is performed, including any associated consultation (Anaes.)
53004	Fee: \$35.60 Benefit: 75% = \$26.70 85% = \$30.30
	ANTROSTOMY (RADICAL) (Anaes.) (Assist.)
53006	Fee: \$521.25 Benefit: 75% = \$390.95 85% = \$443.10
33000	ANTRUM, intranasal operation on, or removal of foreign body from (Anaes.) (Assist.)
53009	Fee: \$295.70 Benefit: 75% = \$221.80 85% = \$251.35 ANTRUM, drainage of, through tooth socket (Anaes.)
	ANTROM, drainage of, through tooth socket (Anaes.)
53012	Fee: \$117.55 Benefit: 75% = \$88.20 85% = \$99.95
	ORO-ANTRAL FISTULA, plastic closure of (Anaes.) (Assist.)
53015	Fee: \$587.60 Benefit: 75% = \$440.70 85% = \$504.20
33013	NASAL SEPTUM, septoplasty, submucous resection or closure of septal perforation (Anaes.) (Assist.)
53016	Fee: \$483.25 Benefit: 75% = \$362.45 85% = \$410.80 NASAL SEPTUM, reconstruction of (Anaes.) (Assist.)
	IVASAL SEI TOW, Icconstruction of (Anaes.) (Assist.)
53017	Fee: \$602.85 Benefit: 75% = \$452.15 85% = \$519.45
	MAXILLARY SINUS, BONE GRAFT to floor of maxillary sinus following elevation of mucosal lining
	(sinus lift procedure), (unilateral) (Anaes.) (Assist.)
53019	Fee: \$580.90 Benefit: 75% = \$435.70 85% = \$497.50
	POST-NASAL SPACE, direct examination of, with or without biopsy (Anaes.)
53052	Fee: \$122.85 Benefit: 75% = \$92.15 85% = \$104.45
NASENDOSCOPY or SINOSCOPY or FIBREOPTIC EXAMINATION of NASOPHA	
	more of these procedures (Anaes.)
52054	Fee: \$122.85 Benefit: 75% = \$92.15 85% = \$104.45
53054	Fee: \$122.85 Benefit: 75% = \$92.15 85% = \$104.45 EXAMINATION OF NASAL CAVITY or POST-NASAL SPACE, or NASAL CAVITY AND POST-
	NASAL SPACE, UNDER GENERAL ANAESTHESIA, not being a service associated with a service to which another item in this Group applies (Anaes.)
53056	Fee: \$71.95 Benefit: 75% = \$54.00 85% = \$61.20
32333	NASAL HAEMORRHAGE, POSTERIOR, ARREST OF, with posterior nasal packing with or without
	cauterisation and with or without anterior pack (excluding aftercare) (Anaes.)
53058	Fee: \$122.85 Benefit: 75% = \$92.15 85% = \$104.45
22020	114.03 Denent. 13/0 = \$72.13

O7. EAF	R, NOSE & THROAT
	CAUTERISATION (other than by chemical means) OR CAUTERISATION by chemical means when performed under general anaesthesia OR DIATHERMY OF SEPTUM, TURBINATES FOR OBSTRUCTION OR HAEMORRHAGE SECONDARY TO SURGERY (OR TRAUMA) - 1 or more of these procedures (including any consultation on the same occasion) not being a service associated
	with any other operation on the nose (Anaes.)
53060	Fee: \$100.50 Benefit: 75% = \$75.40 85% = \$85.45
	POST SURGICAL NASAL HAEMORRHAGE, arrest of during an episode of epistaxis by cauterisation or nasal cavity packing or both (Anaes.)
53062	Fee: \$90.00 Benefit: 75% = \$67.50 85% = \$76.50
	CRYOTHERAPY TO NOSE in the treatment of nasal haemorrhage (Anaes.)
53064	Fee: \$162.95 Benefit: 75% = \$122.25 85% = \$138.55
	TURBINECTOMY or TURBINECTOMIES, partial or total, unilateral (Anaes.)
52069	Fee: \$136.50 Benefit: 75% = \$102.40 85% = \$116.05
53068	TURBINATES, submucous resection of, unilateral (Anaes.)
53070	Fee: \$178.05 Benefit: 75% = \$133.55 85% = \$151.35
O8. TEN	IPOROMANDIBULAR JOINT
	Group O8. Temporomandibular Joint
	MANDIBLE, treatment of a dislocation of, not requiring open reduction (Anaes.)
53200	Fee: \$70.65 Benefit: 75% = \$53.00 85% = \$60.10
33200	MANDIBLE, treatment of a dislocation of, requiring open reduction (Anaes.)
	D 64 70 00 00 00 000 000 000 000 000 000 00
53203	Fee: \$118.70 Benefit: 75% = \$89.05 85% = \$100.90 TEMPOROMANDIBULAR JOINT, manipulation of, performed in the operating theatre of a hospital,
	not being a service associated with a service to which another item in Groups O3 to O9 applies (Anaes.)
53206	Fee: \$142.95 Benefit: 75% = \$107.25
	GLENOID FOSSA, ZYGOMATIC ARCH and TEMPORAL BONE, reconstruction of (Obwegeser technique) (Anaes.) (Assist.)
53209	Fee: \$1,649.10 Benefit: 75% = \$1236.85 85% = \$1565.70
	ABSENT CONDYLE and ASCENDING RAMUS in hemifacial microsomia, construction of, not including harvesting of graft material (Anaes.) (Assist.)
53212	Fee: \$890.85 Benefit: 75% = \$668.15 85% = \$807.45
	TEMPOROMANDIBULAR JOINT, arthroscopy of, with or without biopsy, not being a service
	associated with any other arthroscopic procedure of that joint (Anaes.) (Assist.)
53215	Fee: \$408.70 Benefit: 75% = \$306.55 85% = \$347.40
	TEMPOROMANDIBULAR JOINT, arthroscopy of, removal of loose bodies, debridement, or treatment of adhesions - 1 or more such procedures (Anaes.) (Assist.)
53218	Fee: \$653.80 Benefit: 75% = \$490.35 85% = \$570.40
-	TEMPOROMANDIBULAR JOINT, arthrotomy of, not being a service to which another item in this Group applies (Anaes.) (Assist.)
53220	Fee: \$329.60 Benefit: 75% = \$247.20 85% = \$280.20
55220	TEMPOROMANDIBULAR JOINT, open surgical exploration of, with or without microsurgical techniques (Anaes.) (Assist.)
53221	

O8. TEN	// IPOROMANDIBULAR JOINT
	Fee: \$872.30 Benefit: 75% = \$654.25 85% = \$788.90
	TEMPOROMANDIBULAR JOINT, open surgical exploration of, with condylectomy or condylotomy,
	with or without microsurgical techniques (Anaes.) (Assist.)
53224	Fee: \$967.00 Benefit: 75% = \$725.25 85% = \$883.60
33221	ARTHROCENTESIS, irrigation of temporomandibular joint after insertion of 2 cannuli into the
	appropriate joint space(s) (Anaes.) (Assist.)
53225	Fee: \$290.50 Benefit: 75% = \$217.90 85% = \$246.95
	TEMPOROMANDIBULAR JOINT, synovectomy of, not being a service to which another item in this
	Group applies (Anaes.) (Assist.)
53226	Fee: \$312.30 Benefit: 75% = \$234.25 85% = \$265.50
00220	TEMPOROMANDIBULAR JOINT, open surgical exploration of, with or without meniscus or capsular
	surgery, including meniscectomy when performed, with or without microsurgical techniques (Anaes.)
	(Assist.)
53227	Fee: \$1,188.20 Benefit: 75% = \$891.15 85% = \$1104.80
	TEMPOROMANDIBULAR JOINT, open surgical exploration of, with meniscus, capsular and condylar head surgery, with or without microsurgical techniques (Anaes.) (Assist.)
	flead surgery, with or without flicrosurgical techniques (Aliaes.) (Assist.)
53230	Fee: \$1,338.45 Benefit: 75% = \$1003.85 85% = \$1255.05
	TEMPOROMANDIBULAR JOINT, surgery of, involving procedures to which items 53224, 53226,
	53227 and 53230 apply and also involving the use of tissue flaps, or cartilage graft, or allograft implants,
	with or without microsurgical techniques (Anaes.) (Assist.)
52222	Face \$1.504.05 Page \$1.750/ - \$1129.05 950/ - \$1420.65
53233	Fee: \$1,504.05 Benefit: 75% = \$1128.05 85% = \$1420.65 TEMPOROMANDIBULAR JOINT, stabilisation of, involving 1 or more of: repair of capsule, repair of
	ligament or internal fixation, not being a service to which another item in this Group applies (Anaes.)
	(Assist.)
53236	Fee: \$470.70 Benefit: 75% = \$353.05 85% = \$400.10
	TEMPOROMANDIBULAR JOINT, arthrodesis of, not being a service to which another item in this
	Group applies (Anaes.) (Assist.)
53239	Fee: \$470.70 Benefit: 75% = \$353.05 85% = \$400.10
	TEMPOROMANDIBULAR JOINT OR JOINTS, application of external fixator to, other than for
	treatment of fractures (Anaes.) (Assist.)
53242	Fee: \$312.30 Benefit: 75% = \$234.25 85% = \$265.50
O9. TRE	EATMENT OF FRACTURES
	Group O9. Treatment Of Fractures
	MAXILLA, unilateral or bilateral, treatment of fracture of, not requiring splinting
52.400	(See para ON.4.10 of explanatory notes to this Category)
53400	Fee: \$129.20 Benefit: 75% = \$96.90 85% = \$109.85 MANDIBLE, treatment of fracture of, not requiring splinting
	interval between the fracture of, not requiring splinting
	(See para ON.4.10 of explanatory notes to this Category)
53403	Fee: \$157.85 Benefit: 75% = \$118.40 85% = \$134.20
	MAXILLA, treatment of fracture of, requiring splinting, wiring of teeth, circumosseous fixation or
	external fixation (Anaes.) (Assist.)
	(See para ON 4.10 of explanatory notes to this Category)
53406	

O9. TRE	EATMENT OF FRACTURES
	MANDIBLE, treatment of fracture of, requiring splinting, wiring of teeth, circumosseous fixation or
	external fixation (Anaes.) (Assist.)
	(Limber) (Limber)
	(See para ON.4.10 of explanatory notes to this Category)
53409	Fee: \$406.65 Benefit: 75% = \$305.00 85% = \$345.70
	ZYGOMATIC BONE, treatment of fracture of, not requiring surgical reduction
	(See para ON.4.10 of explanatory notes to this Category)
53410	Fee: \$85.65 Benefit: 75% = \$64.25 85% = \$72.85
	ZYGOMATIC BONE, treatment of fracture of, requiring surgical reduction by a temporal, intra-oral or
	other approach (Anaes.)
	(Consequence ON 4.10 of simple materials to this Cotagons)
52411	(See para ON.4.10 of explanatory notes to this Category)
53411	Fee: \$238.80 Benefit: 75% = \$179.10 85% = \$203.00
	ZYGOMATIC BONE, treatment of fracture of, requiring surgical reduction and involving internal or
	external fixation at 1 site (Anaes.) (Assist.)
	(See para ON.4.10 of explanatory notes to this Category)
53412	Fee: \$392.10 Benefit: 75% = \$294.10 85% = \$333.30
33112	ZYGOMATIC BONE, treatment of fracture of, requiring surgical reduction and involving internal or
	external fixation or both at 2 sites (Anaes.) (Assist.)
	(1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1
	(See para ON.4.10 of explanatory notes to this Category)
53413	Fee: \$480.35 Benefit: 75% = \$360.30 85% = \$408.30
	ZYGOMATIC BONE, treatment of fracture of, requiring surgical reduction and involving internal or
	external fixation or both at 3 sites (Anaes.) (Assist.)
	(See para ON.4.10 of explanatory notes to this Category)
53414	Fee: \$551.85 Benefit: 75% = \$413.90 85% = \$469.10
	MAXILLA, treatment of fracture of, requiring open reduction (Anaes.) (Assist.)
	(See para ON.4.10 of explanatory notes to this Category)
53415	Fee: \$435.65 Benefit: 75% = \$326.75 85% = \$370.35
33113	MANDIBLE, treatment of fracture of, requiring open reduction (Anaes.) (Assist.)
	The result of fraction of fraction of fraction of fraction (rings) (rissist.)
	(See para ON.4.10 of explanatory notes to this Category)
53416	Fee: \$435.65 Benefit: 75% = \$326.75 85% = \$370.35
	MAXILLA, treatment of fracture of, requiring open reduction and internal fixation not involving plate(s)
	(Anaes.) (Assist.)
50.440	(See para ON.4.10 of explanatory notes to this Category)
53418	Fee: \$566.35 Benefit: 75% = \$424.80 85% = \$482.95
	MANDIBLE, treatment of fracture of, requiring open reduction and internal fixation not involving
	plate(s) (Anaes.) (Assist.)
	(See para ON.4.10 of explanatory notes to this Category)
53419	Fee: \$566.35 Benefit: 75% = \$424.80 85% = \$482.95
33117	MAXILLA, treatment of fracture of, requiring open reduction and internal fixation involving plate(s)
	(Anaes.) (Assist.)
	(See para ON.4.10 of explanatory notes to this Category)
53422	Fee: \$718.75 Benefit: 75% = \$539.10 85% = \$635.35
	MANDIBLE, treatment of fracture of, requiring open reduction and internal fixation involving plate(s)
	(Anaes.) (Assist.)
	(See para ON.4.10 of explanatory notes to this Category)
53423	Fee: \$718.75 Benefit: 75% = \$539.10 85% = \$635.35

O9. TRI	EATMENT OF FRACTURES		
	MAXILLA, treatment of a complicated fracture of, involving viscera, blood vessels or nerves, requiring		
	open reduction not involving plate(s) (Anaes.) (Assist.)		
53424	(See para ON.4.10 of explanatory notes to this Category) Fee: \$616.65 Benefit: 75% = \$462.50 85% = \$533.25		
33424	MANDIBLE, treatment of a complicated fracture of, involving viscera, blood vessels or nerves,		
	requiring open reduction not involving plate(s) (Anaes.) (Assist.)		
	requiring open reduction not involving place(s) (Timess.) (Tissist.)		
	(See para ON.4.10 of explanatory notes to this Category)		
53425	Fee: \$616.65 Benefit: 75% = \$462.50 85% = \$533.25		
	MAXILLA, treatment of a complicated fracture of, involving viscera, blood vessels or nerves, requiring		
	open reduction involving the use of plate(s) (Anaes.) (Assist.)		
	(See para ON.4.10 of explanatory notes to this Category)		
53427	Fee: \$842.25 Benefit: 75% = \$631.70 85% = \$758.85		
	MANDIBLE, treatment of a complicated fracture of, involving viscera, blood vessels or nerves,		
	requiring open reduction involving the use of plate(s) (Anaes.) (Assist.)		
	(See para ON.4.10 of explanatory notes to this Category)		
53429	Fee: $$842.25$ Benefit: $75\% = 631.70 $85\% = 758.85		
	MANDIBLE, treatment of a closed fracture of, involving a joint surface (Anaes.)		
53439	(See para ON.4.10 of explanatory notes to this Category) Fee: \$238.80 Benefit: 75% = \$179.10 85% = \$203.00		
33439	ORBITAL CAVITY, reconstruction of a wall or floor with or without foreign implant (Anaes.) (Assist.)		
	ORDITAL CITATITY, reconstruction of a want of moor with or without foreign implant (Anacs.) (Assist.)		
53453	Fee: \$483.25 Benefit: 75% = \$362.45 85% = \$410.80		
	ORBITAL CAVITY, bone or cartilage graft to orbital wall or floor including reduction of prolapsed or		
	entrapped orbital contents (Anaes.) (Assist.)		
53455	Fee: \$567.65 Benefit: 75% = \$425.75 85% = \$484.25		
33 133	NASAL BONES, treatment of fracture of, not being a service to which item 53459 or 53460 applies		
53458	Fee: \$43.05 Benefit: 75% = \$32.30 85% = \$36.60		
	NASAL BONES, treatment of fracture of, by reduction (Anaes.)		
53459	Fee: \$235.50 Benefit: 75% = \$176.65 85% = \$200.20		
33437	NASAL BONES, treatment of fractures of, by open reduction involving osteotomies (Anaes.) (Assist.)		
53460	Fee: \$480.35 Benefit: 75% = \$360.30 85% = \$408.30		
011. RE	EGIONAL OR FIELD NERVE BLOCKS		
Group O11. Regional Or Field Nerve Blocks			
	(Note. Where an anaesthetic combines a regional nerve block with a general anaesthetic for an operative		
	procedure, benefits will be paid only under the anaesthetic item relevant to the operation. The items in		
	this Group are to be used in the practice of oral and maxillofacial surgery and are not to be used for		
dental procedures (eg. restorative dentistry or dental extraction.))			
	TRIGEMINAL NERVE, primary division of, injection of an anaesthetic agent		
53700	Fee: \$124.85 Benefit: 75% = \$93.65 85% = \$106.15		
	TRIGEMINAL NERVE, peripheral branch of, injection of an anaesthetic agent		
53702	Fee: \$62.50 Benefit: 75% = \$46.90 85% = \$53.15		
,	1		

O11. REGIONAL OR FIELD NERVE BLOCKS			
	FACIAL NERVE, injection of an anaesthetic agent		
53704	Fee: \$37.65 Benefit: 75% = \$28.25 85% = \$32.05		
	NERVE BRANCH, destruction by a neurolytic agent, not being a service to which any other item in this		
	Group applies		
	(See para ON.4.12 of explanatory notes to this Category)		
53706	Fee: \$124.85 Benefit: 75% = \$93.65 85% = \$106.15		

INDEX

Α

Abcess, incision with drainage, requiring admission		
A 1	52055	Cutaneous nerve, nerve graft to 52832
Abscess, large, incision with drainage, requiring admission		Cutaneous nerve, repair of 52828, 52830
	4, 52626	Cyst, jaw, aspiration biopsy of, mandible or maxilla, segmental
Alveolar ridge augmentation, cleft grafting of	52337	resection of 52114
Antrobuccal fistula operation	53015	Cyst, jaw, not otherwise covered, removal of 52036, 52039
	5, 53218	52042, 52045, 52048
Antrostomy, radical	53006	Cyst, jaw, aspiration biopsy of 52021
Antrum, drainage of, through tooth socket	53012	
Antrum, intranasal operation, or removal of foreign body	53009	D
	0, 53003	
Antrum, maxillary, removal of foreign body from	53009	Deep tissue or organ, biopsy of 52027
Arch bars, to maxilla or mandible, removal of	52106	deep, percutaneous drainage 52058
Artery, facial, mandibular or lingual, ligation of	52141	Dermis, dermofat or fascia graft 52424
Artery, maxillary, ligation of	52138	Dermoid, excision 52036, 52039, 52042, 52045
Arthrocentesis, with irrigation of temporomandibular joint	53225	Diathermy, salivary gland duct 52072
Aspiration biopsy, one or more jaw cysts	52021	Dilatation, salivary gland duct 52072
Assistance at operation 51800	0, 51803	Dislocation, mandible, treatment of 53200, 53203
Attendance 51700	0, 51703	drainage tube, exchange of 52059
Axillary sinus, excision of	52033	Duct, salivary gland, diathermy or dilatation of 52072
		Duct, salivary gland, thathermy of unatation of 52072 Duct, salivary gland, removal of calculus from 52075
В		Duct, sublingual gland, removal of calculus from 52075
		Duct, sublingual gland, lemoval of calculus from
Basal cell carcinoma, complicated, removal 52051	1, 52054	E
	5, 52039	-
52045, 52048		Endo-biopsy 52024, 52027
Basal cell carcinoma,uncomplicated, removal	52042	Endoscopic, laser therapy of upper aerodigestive tract 52035
Biopsy, aspiration of jaw cysts	52021	Exostosis, mandibular or palatal, excision of 52600
Biopsy, aspiration of jaw cysts, lymph gland, muscle or oth	ner deep	External fixation, orthopaedic, removal 52097-52098
tissue or org	52027	External fixation, ofthopacute, femoval 32097-32098
Biopsy, aspiration of jaw cysts, skin or mucous membrane	52024	F
	0-53411	Г
Bone, graft, harvesting of, via separate incision	52210	
	52319	50050
Bone, graft, harvesting of, via separate incision		Face, contour reconstruction 52379
Bone, graft, harvesting of, via separate incision	52319 52318 52130	Facial artery or vein, ligation of 52141
Bone, graft, harvesting of, via separate incision Bone, graft, to other bones	52318	Facial artery or vein, ligation of Fibroma, removal of 52036, 52039, 52042, 52045
Bone, graft, harvesting of, via separate incision Bone, graft, to other bones Bone, graft, with internal fixation	52318 52130	Facial artery or vein, ligation of Fibroma, removal of Fistula, antrobuccal, operation for 52141 52036, 52039, 52042, 52045 53015
Bone, graft, harvesting of, via separate incision Bone, graft, to other bones Bone, graft, with internal fixation Bone, growth stimulator	52318 52130 52131 52095	Facial artery or vein, ligation of Fibroma, removal of Fistula, antrobuccal, operation for Fistula, oro-antral, plastic closure of 52141 52036, 52039, 52042, 52045 53015 53015
Bone, graft, harvesting of, via separate incision Bone, graft, to other bones Bone, graft, with internal fixation Bone, growth stimulator Bone, tumour, malignant, operations for 52180, 52182	52318 52130 52131 52095	Facial artery or vein, ligation of Fibroma, removal of Fistula, antrobuccal, operation for Fistula, oro-antral, plastic closure of Flap repair, direct 52141 52036, 52039, 52042, 52045 53015 53015 52324, 52327
Bone, graft, harvesting of, via separate incision Bone, graft, to other bones Bone, graft, with internal fixation Bone, growth stimulator Bone, tumour, malignant, operations for 52180, 52182 52186	52318 52130 52131 52095 2, 52184	Facial artery or vein, ligation of Fibroma, removal of Fistula, antrobuccal, operation for Fistula, oro-antral, plastic closure of Flap repair, direct Flap repair, single stage local 52036, 52039, 52042, 52045 53015 53015 52324, 52327 52300, 52303, 52306
Bone, graft, harvesting of, via separate incision Bone, graft, to other bones Bone, graft, with internal fixation Bone, growth stimulator Bone, tumour, malignant, operations for 52180, 52182	52318 52130 52131 52095	Facial artery or vein, ligation of Fibroma, removal of Fistula, antrobuccal, operation for Fistula, oro-antral, plastic closure of Flap repair, direct Flap repair, single stage local Foreign body, antrum, removal of Facial artery or vein, ligation of 52141 52036, 52039, 52042, 52045 53015 53015 52324, 52327 52300, 52303, 52306 53009
Bone, graft, harvesting of, via separate incision Bone, graft, to other bones Bone, graft, with internal fixation Bone, growth stimulator Bone, tumour, malignant, operations for 52180, 52182 52186 Bone,cyst, injection into or aspiration of	52318 52130 52131 52095 2, 52184	Facial artery or vein, ligation of Fibroma, removal of Fistula, antrobuccal, operation for Fistula, oro-antral, plastic closure of Flap repair, direct Flap repair, single stage local Foreign body, antrum, removal of Foreign body, deep, removal, interventional imaging 52141 52036, 52039, 52042, 52045 53015 53015 52324, 52327 52300, 52303, 52306 53009 Foreign body, deep, removal, interventional imaging 52144
Bone, graft, harvesting of, via separate incision Bone, graft, to other bones Bone, graft, with internal fixation Bone, growth stimulator Bone, tumour, malignant, operations for 52180, 52182 52186	52318 52130 52131 52095 2, 52184	Facial artery or vein, ligation of 52141 Fibroma, removal of 52036, 52039, 52042, 52045 Fistula, antrobuccal, operation for 53015 Fistula, oro-antral, plastic closure of 53015 Flap repair, direct 52324, 52327 Flap repair, single stage local 52300, 52303, 52306 Foreign body, antrum, removal of 53009 Foreign body, deep, removal, interventional imaging 52144 Foreign body, implants for contour reconstruction, insertion of
Bone, graft, harvesting of, via separate incision Bone, graft, to other bones Bone, graft, with internal fixation Bone, growth stimulator Bone, tumour, malignant, operations for 52180, 52182 52186 Bone,cyst, injection into or aspiration of	52318 52130 52131 52095 2, 52184 52064	Facial artery or vein, ligation of 52141 Fibroma, removal of 52036, 52039, 52042, 52045 Fistula, antrobuccal, operation for 53015 Fistula, oro-antral, plastic closure of 53015 Flap repair, direct 52324, 52327 Flap repair, single stage local 52300, 52303, 52306 Foreign body, antrum, removal of 53009 Foreign body, deep, removal, interventional imaging 52144 Foreign body, implants for contour reconstruction, insertion of 52321
Bone, graft, harvesting of, via separate incision Bone, graft, to other bones Bone, graft, with internal fixation Bone, growth stimulator Bone, tumour, malignant, operations for 52180, 52182 52186 Bone,cyst, injection into or aspiration of C Calculus, removal of, salivary gland duct	52318 52130 52131 52095 2, 52184 52064	Facial artery or vein, ligation of 52141 Fibroma, removal of 52036, 52039, 52042, 52045 Fistula, antrobuccal, operation for 53015 Fistula, oro-antral, plastic closure of 53015 Flap repair, direct 52324, 52327 Flap repair, single stage local 52300, 52303, 52306 Foreign body, antrum, removal of 53009 Foreign body, deep, removal, interventional imaging 52144 Foreign body, implants for contour reconstruction, insertion of 52321 Foreign body, maxillary sinus, removal of 53009
Bone, graft, harvesting of, via separate incision Bone, graft, to other bones Bone, graft, with internal fixation Bone, growth stimulator Bone, tumour, malignant, operations for 52180, 52182 52186 Bone,cyst, injection into or aspiration of C Calculus, removal of, salivary gland duct Caldwell-Luc's operation	52318 52130 52131 52095 2, 52184 52064 52075 53006	Facial artery or vein, ligation of 52141 Fibroma, removal of 52036, 52039, 52042, 52045 Fistula, antrobuccal, operation for 53015 Fistula, oro-antral, plastic closure of 53015 Flap repair, direct 52324, 52327 Flap repair, single stage local 52300, 52303, 52306 Foreign body, antrum, removal of 53009 Foreign body, deep, removal, interventional imaging 52144 Foreign body, implants for contour reconstruction, insertion of 52321 Foreign body, maxillary sinus, removal of 53009 Foreign body, muscle/other deep tissue, removal of 52018
Bone, graft, harvesting of, via separate incision Bone, graft, to other bones Bone, graft, with internal fixation Bone, growth stimulator Bone, tumour, malignant, operations for 52180, 52182 52186 Bone,cyst, injection into or aspiration of C Calculus, removal of, salivary gland duct Caldwell-Luc's operation Carbuncle, incision with drainage, in operating theatre	52318 52130 52131 52095 2, 52184 52064 52075 53006 52057	Facial artery or vein, ligation of Fibroma, removal of Fistula, antrobuccal, operation for Fistula, oro-antral, plastic closure of Flap repair, direct Foreign body, antrum, removal of Foreign body, implants for contour reconstruction, insertion of Foreign body, maxillary sinus, removal of Foreign body, muscle/other deep tissue, removal of Foreign body, subcutaneous, removal, other Foreign body, subcutaneous, removal, other Foreign body, subcutaneous, removal, other
Bone, graft, harvesting of, via separate incision Bone, graft, to other bones Bone, graft, with internal fixation Bone, growth stimulator Bone, tumour, malignant, operations for 52180, 52182 52186 Bone,cyst, injection into or aspiration of C Calculus, removal of, salivary gland duct Caldwell-Luc's operation Carbuncle, incision with drainage, in operating theatre Cauterisation, septum/turbinates/pharynx	52318 52130 52131 52095 2, 52184 52064 52075 53006 52057 53060	Facial artery or vein, ligation of 52141 Fibroma, removal of 52036, 52039, 52042, 52045 Fistula, antrobuccal, operation for 53015 Fistula, oro-antral, plastic closure of 53015 Flap repair, direct 52324, 52327 Flap repair, single stage local 52300, 52303, 52306 Foreign body, antrum, removal of 53009 Foreign body, deep, removal, interventional imaging 52144 Foreign body, implants for contour reconstruction, insertion of 52321 Foreign body, maxillary sinus, removal of 53009 Foreign body, muscle/other deep tissue, removal of 52018 Foreign body, subcutaneous, removal, other 52015 Foreign body, superficial removal, other 52012
Bone, graft, harvesting of, via separate incision Bone, graft, to other bones Bone, graft, with internal fixation Bone, growth stimulator Bone, tumour, malignant, operations for 52180, 52182 52186 Bone,cyst, injection into or aspiration of C Calculus, removal of, salivary gland duct Caldwell-Luc's operation Carbuncle, incision with drainage, in operating theatre Cauterisation, septum/turbinates/pharynx Cellulitis, incision with drainage, not requiring GA	52318 52130 52131 52095 2, 52184 52064 52075 53006 52057 53060 52055	Facial artery or vein, ligation of 52141 Fibroma, removal of 52036, 52039, 52042, 52045 Fistula, antrobuccal, operation for 53015 Fistula, oro-antral, plastic closure of 53015 Flap repair, direct 52324, 52327 Flap repair, single stage local 52300, 52303, 52306 Foreign body, antrum, removal of 53009 Foreign body, deep, removal, interventional imaging 52144 Foreign body, implants for contour reconstruction, insertion of 52321 Foreign body, maxillary sinus, removal of 53009 Foreign body, muscle/other deep tissue, removal of 52018 Foreign body, subcutaneous, removal, other 52015 Foreign body, tendon, removal of 52018, 52144
Bone, graft, harvesting of, via separate incision Bone, graft, to other bones Bone, graft, with internal fixation Bone, growth stimulator Bone, tumour, malignant, operations for 52180, 52182 52186 Bone,cyst, injection into or aspiration of C Calculus, removal of, salivary gland duct Caldwell-Luc's operation Carbuncle, incision with drainage, in operating theatre Cauterisation, septum/turbinates/pharynx Cellulitis, incision with drainage, not requiring GA Cleft lip, operations for 52440, 52442, 52444, 52446	52318 52130 52131 52095 2, 52184 52064 52075 53006 52057 53060 52055	Facial artery or vein, ligation of Fibroma, removal of Fibroma, removal of Fistula, antrobuccal, operation for Fistula, oro-antral, plastic closure of Flap repair, direct Foreign body, antrum, removal of Foreign body, implants for contour reconstruction, insertion of Foreign body, maxillary sinus, removal of Foreign body, muscle/other deep tissue, removal of Foreign body, subcutaneous, removal, other Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, 53403
Bone, graft, harvesting of, via separate incision Bone, graft, to other bones Bone, graft, with internal fixation Bone, growth stimulator Bone, tumour, malignant, operations for 52180, 52182 52186 Bone,cyst, injection into or aspiration of C Calculus, removal of, salivary gland duct Caldwell-Luc's operation Carbuncle, incision with drainage, in operating theatre Cauterisation, septum/turbinates/pharynx Cellulitis, incision with drainage, not requiring GA Cleft lip, operations for 52440, 52442, 52444, 52446, 52452, 52456, 52458	52318 52130 52131 52095 2, 52184 52064 52075 53006 52057 53060 52055 6, 52450	Facial artery or vein, ligation of 52141 Fibroma, removal of 52036, 52039, 52042, 52045 Fistula, antrobuccal, operation for 53015 Fistula, oro-antral, plastic closure of 53015 Flap repair, direct 52324, 52327 Flap repair, single stage local 52300, 52303, 52306 Foreign body, antrum, removal of 53009 Foreign body, deep, removal, interventional imaging 52144 Foreign body, implants for contour reconstruction, insertion of 52321 Foreign body, maxillary sinus, removal of 53009 Foreign body, muscle/other deep tissue, removal of 52018 Foreign body, subcutaneous, removal, other 52015 Foreign body, superficial removal, other 52012 Foreign body, tendon, removal of 52018, 52144 Fracture, mandible or maxilla, treatment of 53400, 53403 53406, 53409-53416, 53418-53419, 53422-53425, 53427, 53429
Bone, graft, harvesting of, via separate incision Bone, graft, to other bones Bone, graft, with internal fixation Bone, growth stimulator Bone, tumour, malignant, operations for 52180, 52182 52186 Bone,cyst, injection into or aspiration of C Calculus, removal of, salivary gland duct Caldwell-Luc's operation Carbuncle, incision with drainage, in operating theatre Cauterisation, septum/turbinates/pharynx Cellulitis, incision with drainage, not requiring GA Cleft lip, operations for 52440, 52442, 52444, 52446 52452, 52456, 52458 Cleft palate, palate, secondary repair, closure of fistula	52318 52130 52131 52095 2, 52184 52064 52075 53006 52057 53060 52055 6, 52450 52336	Facial artery or vein, ligation of 52141 Fibroma, removal of 52036, 52039, 52042, 52045 Fistula, antrobuccal, operation for 53015 Fistula, oro-antral, plastic closure of 53015 Flap repair, direct 52324, 52327 Flap repair, single stage local 52300, 52303, 52306 Foreign body, antrum, removal of 53009 Foreign body, deep, removal, interventional imaging 52144 Foreign body, implants for contour reconstruction, insertion of 52321 Foreign body, maxillary sinus, removal of 53009 Foreign body, muscle/other deep tissue, removal of 52018 Foreign body, subcutaneous, removal, other 52015 Foreign body, superficial removal, other 52012 Foreign body, tendon, removal of 53400, 53403 53406, 53409-53416, 53418-53419, 53422-53425, 53427, 53429 53439
Bone, graft, harvesting of, via separate incision Bone, graft, to other bones Bone, graft, with internal fixation Bone, growth stimulator Bone, tumour, malignant, operations for 52180, 52182 52186 Bone,cyst, injection into or aspiration of C Calculus, removal of, salivary gland duct Caldwell-Luc's operation Carbuncle, incision with drainage, in operating theatre Cauterisation, septum/turbinates/pharynx Cellulitis, incision with drainage, not requiring GA Cleft lip, operations for 52440, 52442, 52444, 52446, 52452, 52456, 52458 Cleft palate, palate, secondary repair, closure of fistula Cleft palate, palate, secondary repair, lengthening procedur	52318 52130 52131 52095 2, 52184 52064 52075 53006 52057 53060 52055 6, 52450 52336 re 52339	Facial artery or vein, ligation of Fibroma, removal of Fistula, antrobuccal, operation for Fistula, oro-antral, plastic closure of Flap repair, direct Foreign body, antrum, removal of Foreign body, implants for contour reconstruction, insertion of Foreign body, maxillary sinus, removal of Foreign body, subcutaneous, removal of Foreign body, subcutaneous, removal, other Foreign body, superficial removal, other Foreign body, tendon, removal of Foreign body, te
Bone, graft, harvesting of, via separate incision Bone, graft, to other bones Bone, graft, with internal fixation Bone, growth stimulator Bone, tumour, malignant, operations for 52180, 52182 52186 Bone,cyst, injection into or aspiration of C Calculus, removal of, salivary gland duct Caldwell-Luc's operation Carbuncle, incision with drainage, in operating theatre Cauterisation, septum/turbinates/pharynx Cellulitis, incision with drainage, not requiring GA Cleft lip, operations for 52440, 52442, 52444, 52446, 52452, 52456, 52458 Cleft palate, palate, secondary repair, closure of fistula Cleft palate, primary repair	52318 52130 52131 52095 2, 52184 52064 52075 53006 52057 53060 52055 6, 52450 52336 re 52339 52333	Facial artery or vein, ligation of Fibroma, removal of Fibroma, removal of Fistula, antrobuccal, operation for Fistula, oro-antral, plastic closure of Figure pair, direct Foreign body, antrum, removal of Foreign body, implants for contour reconstruction, insertion of Foreign body, maxillary sinus, removal of Foreign body, muscle/other deep tissue, removal of Foreign body, subcutaneous, removal, other Foreign body, tendon, removal of Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Fore
Bone, graft, harvesting of, via separate incision Bone, graft, to other bones Bone, graft, with internal fixation Bone, growth stimulator Bone, tumour, malignant, operations for 52180, 52182 52186 Bone,cyst, injection into or aspiration of C Calculus, removal of, salivary gland duct Caldwell-Luc's operation Carbuncle, incision with drainage, in operating theatre Cauterisation, septum/turbinates/pharynx Cellulitis, incision with drainage, not requiring GA Cleft lip, operations for 52440, 52442, 52444, 52446, 52452, 52456, 52458 Cleft palate, palate, secondary repair, closure of fistula Cleft palate, primary repair Composite graft to nose, ear or eyelid	52318 52130 52131 52095 2, 52184 52064 52075 53006 52057 53060 52055 6, 52450 52336 re 52339 52333 52482	Facial artery or vein, ligation of Fibroma, removal of Fibroma, removal of Fistula, antrobuccal, operation for Fistula, oro-antral, plastic closure of Flap repair, direct Foreign body, antrum, removal of Foreign body, implants for contour reconstruction, insertion of Foreign body, maxillary sinus, removal of Foreign body, subcutaneous, removal, other Foreign body, superficial removal, other Foreign body, tendon, removal of Foreign body, superficial removal, other Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, su
Bone, graft, harvesting of, via separate incision Bone, graft, to other bones Bone, graft, with internal fixation Bone, growth stimulator Bone, tumour, malignant, operations for 52180, 52182 52186 Bone, cyst, injection into or aspiration of C Calculus, removal of, salivary gland duct Caldwell-Luc's operation Carbuncle, incision with drainage, in operating theatre Cauterisation, septum/turbinates/pharynx Cellulitis, incision with drainage, not requiring GA Cleft lip, operations for 52440, 52442, 52444, 52446, 52452, 52456, 52458 Cleft palate, palate, secondary repair, closure of fistula Cleft palate, primary repair Composite graft to nose, ear or eyelid Condylectomy/condylotomy	52318 52130 52131 52095 2, 52184 52064 52075 53006 52057 53060 52055 6, 52450 52336 re 52339 52333 52482 53224	Facial artery or vein, ligation of Fibroma, removal of Fibroma, removal of Fistula, antrobuccal, operation for Fistula, oro-antral, plastic closure of Fistula, oro-antral, plastic closure of Flap repair, direct Foreign body, antrum, removal of Foreign body, deep, removal, interventional imaging Foreign body, implants for contour reconstruction, insertion of Foreign body, maxillary sinus, removal of Foreign body, muscle/other deep tissue, removal of Foreign body, subcutaneous, removal, other Foreign body, superficial removal, other Foreign body, tendon, removal of Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial re
Bone, graft, harvesting of, via separate incision Bone, graft, to other bones Bone, graft, with internal fixation Bone, growth stimulator Bone, tumour, malignant, operations for 52180, 52182 52186 Bone,cyst, injection into or aspiration of C Calculus, removal of, salivary gland duct Caldwell-Luc's operation Carbuncle, incision with drainage, in operating theatre Cauterisation, septum/turbinates/pharynx Cellulitis, incision with drainage, not requiring GA Cleft lip, operations for 52440, 52442, 52444, 52446, 52452, 52456, 52458 Cleft palate, palate, secondary repair, closure of fistula Cleft palate, primary repair Composite graft to nose, ear or eyelid	52318 52130 52131 52095 2, 52184 52064 52075 53006 52057 53060 52055 6, 52450 52336 re 52339 52333 52482	Facial artery or vein, ligation of Fibroma, removal of Fibroma, removal of Fistula, antrobuccal, operation for Fistula, oro-antral, plastic closure of Flap repair, direct Foreign body, antrum, removal of Foreign body, implants for contour reconstruction, insertion of Foreign body, maxillary sinus, removal of Foreign body, subcutaneous, removal, other Foreign body, superficial removal, other Foreign body, tendon, removal of Foreign body, superficial removal, other Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, tendon, removal of Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, superficial removal, other Foreign body, su

Furuncle, incision with drainage, in operating theatre	52057	Lingual artery or vein, ligation of	380, 52382 52141
G		Lip, full thickness wedge excision of	52108
		Lipoma, removal of 52036, 52039, 520	
Genioplasty	52378	Local flap repair, single stage 52300, 523	
Gland, lymph, biopsy of	52027	Lymph gland, muscle or other deep tissue or organ biops	sy of52027
Gland, salivary, incision of	52057	Lymph node, biopsy of	52025
Gland, salivary, meatotomy or marsupialisation	52075	Lymphoid patches, removal of 52036, 52039, 520)42, 52045
Gland, salivary, removal of calculus from duct	52075		
Gland, salivary, transportation of duct	52147	M	
Gland, salivary, dilation or diathermy of duct	52072		
Gland, sublingual, extirpation of	52069	Macrocheilia, operation for	52482
Gland, submandibular, extirpation of	52066	Macrostomia, operation for	52484
Gland, submaxillary, extirpation of	52066		200, 53203
	57, 52147	Mandible, fixation by intermaxillary wiring	52420
Glenoid fossa, zygomatic arch, temporal bone, reconstruc		Mandible, hemi-mandiblectomy of	52120
,	53209	Mandible, hemi-mandibular reconstruction with bone gr	
Grafts, composite (chondrocutaneous/mucosal)	52480	Mandible, operation on, for osteomyelitis	52090
Grafts, free, full thickness	52315		400, 53403
	09, 52312	53406, 53409-53416, 53418-53419, 53422-53425, 534	
	.,,	53439	_,,
Н		Mandible, osteectomy of osteotomy of 53400, 534	103 53406
.,		53409-53416, 53418-53419, 53422-53425, 53427, 534	*
Haematoma, aspiration of	52056		099, 52102
Haematoma, incision with drainage, not requiring GA	52055	Mandible, removal of one or more plates 52342, 523	,
Haematoma, large, incision with drainage, in operating th		52351, 52354, 52357, 52360, 52363, 52366, 52369, 52 52375	
Haemorrhage, post-nasal and/or post-operative, control of		Mandible, segmental resection of, for tumours or cysts	52114
Hemifacial microsomia, construction condyle and ramus		Mandible, sub-total resection of	52117
	09, 52612	Mandible, total resection of	52123
52615	09, 32012	Mandibular artery or vein, exostosis, excision of	52600
Hypertrophied tissue, removal of 52036, 52039, 520	42 52045	Mandibular artery or vein, frenulum, repair of	52084
11ypertropined tissue, removal of 32030, 32039, 320	42, 32043	Manidbular artery or vein, ligation of	52141
•		Maxilla, operation on, for osteomyelitis	52090
l			400, 53403
		53406, 53409-53416, 53418-53419, 53422-53425, 534	,
Innocent bone tumour, excision of	52063	53439	27,00.29
Intranasal operation on antrum/foreign body	53009	Maxilla, osteectomy or osteotomy of 52342, 523	345, 52348
J		52351, 52354, 52357, 52360, 52363, 52366, 52369, 52 52375	,
	533 00	Maxilla, removal of buried wire, pin or screw 520	099, 52102
Jaw dislocation, treatment of	53200	Maxilla, removal of one or more plates	52105
Jaw, aspiration biopsy of cyst/s	52021	Maxilla, sub-total resection of	52117
Jaw, dislocation, treatment of	53203	Maxilla, total resection of 521	126, 52129
Jaw, fracture, treatment of 53400, 53403, 53406, 534	109-53416	Maxillary antrum, artery, ligation of	52138
53418-53419, 53422-53425, 53427, 53429, 53439		Maxillary antrum, frenulum, repair of	52084
Jaw, operation on, for osteomyelitis	52090	Maxillary antrum, lavage of	53004
* 1	42, 52345	Maxillary antrum, proof puncture and lavage of 530	000, 53003
52348, 52351, 52354, 52357, 52360, 52363, 52366, 523	369	Maxillary antrum, sinus, drainage of, through tooth sock	et 53012
52372, 52375		Maxillary antrum, sinus, operations on 530	006, 53009
		Maxillary antrum, sinus, sinus lift procedure	53019
K		Maxillary antrum, tuberosity, reduction of	52606
		Melanoma, excision of 52036, 52039, 52042, 520)45, 52048
Keloid, excision of 52036, 52039, 520 Kirschner wire, insertion of	42, 52045 52096	Microvascular anastomosis repair using microsurgical te	
		Microvascular anastomosis using microsurgical technique	ies 52430
L		Mouth, lowering of floor of (Oswegeser or similar)	52621
		Mucous membrane, biopsy of	52024
Lacerations, ear/eyelid/nose/lip, full thickness, repair of	52010	Mucous membrane, repair of recent wound of 520	000, 52003
Lacerations, repair and suturing of 52000, 520	03, 52006	52006, 52009	
52009		Muscle, biopsy of	52027
Lavage and proof puncture of maxillary antrum 530	00, 53003	Muscle, excision of	52060
• • •			

Muscle, or other deep tissue, removal of foreign body 520(1.520(2.520))	Plastic repair, free grafts 52309, 52312, 52315
Muscle, ruptured repair of 52061-52062 Mylohyloid ridge, reduction of 52603	Plastic repair, single stage, local flap Plates, orthopaedic, removal of 52300, 52303, 52306 52015, 52018
	Post nasal space, direct examination of with/without biopsy 53052
N	Post nasal space, examination under GA 53056 preauricular sinus operation 52030
Naevus, excision of 52036, 52039, 52042, 52045	Premalignant lesions, cryotherapy, diathermy or carbon dioxide
Nasal bones, treatment of fracture/s 53458-53460	laser 52034
Nasal cavity and/or post nasal space, examination of 53056	Proof puncture of maxillary antrum 53000, 53003
Nasal cavity, packing for arrest of haemorrhage 53062	_
Nasal haemorrhage, arrest of 53058	R
Nasal haemorrhage, cryotherapy to 53064	Radical antrostomy 53006
Nasal septum, reconstruction 53017 Nasal septum, septoplasty 53016	Radical antrostomy 53006 Ranula, removal of 52087
Nasal, space, post, direct examination of 53052	Reduction, of dislocation of mandible 53200, 53203
Nasendoscopy 53054	Rodent ulcer, operation for 52036, 52039, 52042, 52045
Nerve, clock, regional or field 53700, 53702, 53704	
Nerve, peripheral, neurectomy/neurotomy/tumour 52806, 52809	S
Nerve, transposition of 52818	
Nerve, trigeminal, cryosurgery of 52824 Nerve, trunk, graft to 52821	Salivary gland duct, diathermy or dilatation of 52072
Nerve, trunk, neurolysis of 52803	Salivary gland duct, removal of calculus from 52075 Salivary gland duct, transposition of 52147
Nerve, trunk, repair of 52812, 52815	Salivary gland, incision of 52057
Neurectomy, peripheral nerve 52806, 52809	Salivary gland, repair of cutaneous fistula of 52073
Neurolysis by open operation 52800	Scar, removal of, not otherwise covered 52036, 52039, 52042
Neurolysis, of nerve trunk 52803 Node, lymph, biopsy of 52027	52045
Node, lymph, biopsy of 52027	Sebaceous cyst, removal of 52036, 52039, 52042, 52045
0	Segmental resection, of mandible or maxilla for tumours 52114 Single stage local flap repair 52303, 52306
-	Single stage local flap repair 52300 Single stage local flap repair 52300
Orbital cavity, bone or cartilage graft to wall or floor 53455	Sinus, excision of 52030, 52033
Orbital cavity, reconstruction of wall or floor 53453	Sinus, maxillary, drainage of, through tooth socket 53012
Oro-antral fistula, plastic closure of 53015	Skin biopsy repair of recent wound 52000, 52003, 52006
Orthopaedic pin or wire, insertion of 52096	52009 Shin kingga af
Orthopaedic pin or wire, removal of 52099, 52102 Orthopaedic, plates, removal of 52105	Skin biopsy, of 52024 Skull, operation on, for osteomyelitis 52092
Osseointegration procedure 52627, 52630, 52633, 52636	Subcutaneous, foreign body, removal, other 52015
Osteectomy of mandible or maxilla 52342, 52345, 52348, 52351 52354, 52357, 52360, 52363, 52366, 52369, 52372, 52375	Subcutaneous, tissue, repair of recent wound 52000, 52003 52006, 52009
Osteomyelitis, operation on mandible or maxilla 52090	Sublingual gland duct, removal of calculus from 52075
Osteomyelitis, operation on skull 52092	Sublingual gland, extirpation of 52069
Osteomyelitis, operation on combination of adjoining bones 52094 Osteotomies, mid-facial 52380, 52382	Submandibular abscess, incision of 52057 Submandibular ducts, relocation of 52158
Osteotomies, ind-racial 52360, 32362 Osteotomy, of mandible or maxilla 52342, 52345, 52348, 52351	Submandibular gland, extirpation of 52066
52354, 52357, 52360, 52363, 52366, 52369, 52372, 52375	Submandibular gland, incision of 52057
	Submaxillary gland, extirpation of 52066
Р	Submaxillary gland, incision of 52057
	Superficial foreign body, removal of 52012
Palatal exostosis, excision of 52600	Superficial, wound repair of 52000, 52009 Suture, of traumatic wounds 52000, 52003, 52006, 52009
Palate, cleft, repair of 52333, 52336, 52339 Palate, papillary hyperplasia removal of 52609, 52612, 52615	Suture, of traumatic woulds 52000, 52005, 52000, 52007
Palate, plastic closure of defect of 52330 Papillary hyperplasia of the palate, removal of 52609, 52612	Т
52615	Temporal, bone glenoid fossa/zygomatic arch, reconstruction of
papillary hyperplasia removal of 52609, 52612, 52615	53209
Papilloma, removal of 52036, 52039, 52042, 52045 Parotid duct, repair of 52148	Temporomandibular joint, arthrodesis 53239 Temporomandibular joint, arthroscopy of 53215, 53218
Pharyngeal flap for velo-pharyngeal incompetence 52460	Temporomandibular joint, arthrotomy 53220
Pin, orthopaedic removal of 52102	Temporomandibular joint, external fixation, application of 53242
Pin, orthopaedic, insertion of 52096	Temporomandibular joint, irrigation of 53225
Pin, orthopaedic, removal of 52099	Temporomandibular joint, manipulation of 53206

Temporomandibular joint, open surgical exploration 53224-53227, 53230, 53233	of	53221
Temporomandibular joint, stabilisation of		
Temporomandibular joint, synovectomy of		
Tendon, foreign body in, removal of		
Tendon, or other deep tissue, foreign body in, removal of		
Tissue, subcutaneous, repair of recent wound		52018 52003
52006, 52009	52000,	32003
Tongue, partial excision of		52078
Tongue, tie, repair of	52081	52084
Tracheostomy	32001,	52132
Traumatic wounds, repair of 52000, 52003	52006	
Trigeminal nerve, injection with alcohol, cortisone,		52826
Tuberosity, maxillary, reduction of	CiC	52606
Tumour, bone, innocent, excision of		52063
Tumour, mandible or maxilla, segmental resection of	£	52114
Tumour, not otherwise covered, removal of		
52042, 52045, 52048	32030,	52039
Tumour, peripheral nerve, removal of	52806,	52809
Tumour, soft tissue, excision of	52051,	52054
Turbinates, submucous resection of		53070
V		
•		
Vein, facial, mandibular or lingual, ligation of		52141
Vermilionectomy		52111
Vestibuloplasty, unilateral or bilateral		52618
w		
VV		
Washout, antrum	53000.	53003
wedge excision		51906
Wire, orthopaedic, insertion of	,	52096
Wire, orthopaedic, removal of	52099.	52102
Wound, debridement under GA or major block	<i></i> 0,,	51900
Wound, dressing of, requiring GA		51902
Wound, traumatic, suture of 52000, 52003	52006	
72000, 32000	, 52000,	52007
Z		
Zygomatic arch, reconstruction of		53209
2,50mane aren, reconstruction or		55207

CATEGORY 5: DIAGNOSTIC IMAGING SERVICES

SUMMARY OF CHANGES FROM 01/03/2019

The 01/03/2019 changes to the MBS are summarised below and are identified in the Schedule pages by one or more of the following words appearing above the item number:

(a) new item	New
(b) amended description	Amend
(c) fee amended	Fee
(d) item number changed	Renum
(e) EMSN changed	EMSN

There are no changes to this Category for 01/03/2019.

DIAGNOSTIC IMAGING SERVICES NOTES

IN.0.1 Requests For Diagnostic Imaging Services Request requirements

Medicare benefits are not payable for diagnostic imaging services that are classified as R-type (requested) services unless prior to commencing the relevant service, the practitioner receives a signed and dated request from a requesting practitioner who determined the service was necessary.

There are exemptions to the request requirements in specified circumstances. These circumstances are detailed below under 'Exemptions from the written request requirements for R-type diagnostic imaging services'.

Form of a diagnostic imaging request

A request for a diagnostic imaging service does not have to be in a particular form, however, the legislation provides that a request must be in writing and contain sufficient information, in terms that are generally understood by the profession, to clearly identify the item/s of service requested.

A request to a medical imaging specialist for a diagnostic imaging service should include sufficient clinical information to assist the service provider to accurately provide the diagnostic imaging service requested and:

- i. ensure compliance with the MBS item descriptors, and
- ii. where the requested service involves ionising radiation (x-ray, CT etc.), make a decision whether to expose the patient to radiation, consistent with the diagnostic imaging providers' obligations under the International Commission on Radiological Protection's (ICRP) doctrine of radiation protection.

Unless sufficient clinical information is provided, the requesting practitioner may be asked to provide additional information to the diagnostic imaging provider, which could result in delays for the patient.

The following should be provided on a request for a diagnostic imaging service:

- (a) A clear and legible request a request must be in writing, dated and be legible so that all information contained is transferred between requestor and provider without loss of content or meaning, or risk of misinterpretation. The use of abbreviations should be avoided. Where permitted, verbal referrals should ensure clear communication between the requestor and provider.
 - Under the Electronic Transactions Act 1999, this information can be provided in electronic form.
- (b) *Identity of the patient* a request should include details which confirm the identity of the patient, including their contact details.
- (c) *Identity of the requestor* a request should include the identity and contact details of the requesting practitioner, including their Medicare provider number, to ensure effective and timely communication.
- (d) *Clinical detail* a request should include a clinical justification for each examination requested and performed to support the performance of the diagnostic imaging examination.
 - Requests should contain information to enable the provider to confirm that the requested diagnostic imaging modality and examination are appropriate to that individual patient's presentation and circumstances, to answer the referrer's diagnostic question with the least number of diagnostic steps (with due regard for patient safety, radiation dose, local expertise and cost).
 - Where the request is for diagnostic imaging involving ionising radiation (e.g. x-ray, CT) the request should include clinical information for the provider to determine whether the expected clinical benefit to the patient of being exposed to diagnostic radiation outweighs the risk of radiation exposure ('justification for medical radiation exposure').

The provider must have sufficient information to justify and approve a medical radiation procedure. Where known, this information should include pregnancy status for women of child-bearing age.

Before requesting a diagnostic imaging service, the requesting practitioner must turn their mind to the clinical relevance of the request and determine that the service is necessary. For example, an ultrasound to determine the sex of a foetus is generally not a clinically relevant service, unless there is an indication this service will determine further courses of treatment (e.g. where there is a genetic risk of a sex-related disease or condition).

The requestor should consider whether:

- they are duplicating recent tests,
- the results would change the diagnosis, affect patient management or do more harm than good.
 - The Royal Australian and New Zealand College of Radiologists' Education Modules for Appropriate Imaging Referrals contains decision support tools for select clinical scenarios
 - The Australian Radiation Protection and Nuclear Safety Agency's Radiation Protection of the Patient Module provides information about diagnostic imaging for medical practitioners, to ensure radiation use is justified, and may aid in communicating benefits and risks of diagnostic imaging modalities to patients.
- the benefits and risks to the patient or carer have been communicated, including any alternatives available, and
- there is information available to the patient about the tests requested. Consumer resources available include the:
 - NPS MedicineWise Choosing Wisely program
 - Consumers Health Forum's Why do I even need this test? A Diagnostic Imaging and Informed Consumer Resource
 - The Royal Australian and New Zealand College of Radiologists' *Inside Radiology* website.
- (e) *MBS requirements* a request should meet any specific MBS item requirements. Failure to provide this information may mean that a Medicare benefit is not paid for the service.

Who may request a diagnostic imaging service

The following practitioners may request a diagnostic imaging service:

- Specialists and consultant physicians can request any diagnostic imaging service.
- Other medical practitioners can request any service and specific Magnetic Resonance Imaging Services see Note IN.0.18.
- A medical practitioner, on behalf of the treating practitioner, for example, by a resident medical officer at a hospital on behalf of the patient's treating practitioner.
- Dental Practitioners, Physiotherapists, Chiropractors, Osteopaths and Podiatrists registered or licensed under State or Territory laws
- Participating nurse practitioners and participating midwives.

All dental practitioners may request the following items:

57509, 57515, 57521, 57523, 57527, 57540, 57901, 57902, 57903, 57906, 57909, 57912, 57915, 57918, 57921, 57924, 57927, 57930, 57933, 57939, 57942, 57945, 57960, 57963, 57966, 57969, 58100, 58300, 58503, 58903, 59733, 59739, 59751, 60100, 60500, 60503.

Oral and maxillofacial surgeons, prosthodontists, dental specialists (periodontists, endodontists, pedeodontists, orthodontists) and specialists in oral medicine and oral pathology are also able to request the following items:

Oral and maxillofacial surgeons (without medical specialist registration)

55005, 55008, 55011, 55028, 55030, 55032, 56001 to 56220, 56224, 56227, 56230, 56259, 56301 to 56507, 56541, 56547, 56801 to 57007, 57041, 57047, 57341, 57345, 57703, 57705, 57709, 57711, 57712, 57714, 57715, 57717, 58103 to 58115, 58117, 58123, 58124, 58306, 58308, 58506, 58508, 58521 to 58527, 58529, 58909, 58911, 59103, 59104, 59703, 59704, 60000 to 60010, 60506, 60507, 60509, 60510, 61109, 61110, 61372, 61421, 61425, 61429, 61430, 61433, 61434, 61446, 61449, 61450, 61453, 61454, 61457, 61462, 61672, 61690, 61691, 61693, 61694, 61695, 61696, 61702, 61703, 61704, 61705, 61706, 61707, 61710, 63007, 63016, 63334 and 63346.

Oral and maxillofacial surgeons (with medical specialist registration)

Oral and maxillofacial surgeons who also have a medical qualification and are registered as medical specialist can request any item in the Diagnostic Imaging Services Table, subject to their scope of practice and any clauses or requirements relevant to the individual item.

Prosthodontists

55005, 55028, 56013, 56016, 56022, 56028, 56053, 56056, 56062, 56068, 57362, 57363, 58306, 58308, 61421, 61425, 61429, 61430, 61433, 61434, 61446, 61449, 61450, 61453, 61454, 61457, 61462, 61690, 61691, 61693, 61694, 61695, 61696, 61702, 61703, 61704, 61705, 61706, 61707, 61710, 63334 and 63346.

Dental specialists (periodontists, endodontists, pedeodontists, orthodontists).

56022, 56062, 57362, 57363, 58306, 58308, 61421, 61454, 61457, 61690, 61706, 61707, 63334, 63346.

Specialists in oral medicine and/or oral pathology

55005, 55008, 55011, 55028, 55030, 55032, 56001, 56007, 56010, 56013, 56016, 56022, 56028, 56041, 56047, 56050, 56053, 56056, 56062, 56068, 56101, 56107, 56141, 56147, 56301, 56307, 56341, 56347, 56401, 56407, 56441, 56447, 57341, 57345, 57362, 57363, 58306, 58308, 58506, 58508, 58909, 58911, 59103, 59104, 59703, 59704, 60000 to 60010, 60506, 60507 60509, 60510, 61109, 61110, 61372, 61421, 61425, 61429, 61430, 61433, 61434, 61446, 61449, 61450, 61453, 61454, 61457, 61462, 61672, 61690, 61691, 61693, 61694, 61695, 61696, 61702, 61703, 61704, 61705, 61706, 61707, 61710, 63007, 63016, 63334, and 66346.

Chiropractors may request:

57712, 57714, 57715, 57717, 58100 to 58106 (inclusive), 58109, 58111, 58112, 58117 and 58123.

See para IN.0.17 of explanatory notes

Physiotherapists and Osteopaths may request:

57712, 57714, 57715, 57717, 58100 to 58106 (inclusive), 58109, 58111, 58112, 58117, 58120, 58121, 58123, 58126 and 58127.

See para IN.0.17 of explanatory notes

Podiatrists may request:

55836, 55837, 55840, 55841, 55844, 55845, 57521, 57523, 57527, 57536, 57540, 57539.

Participating Nurse Practitioners may request:

```
55014, 55036, 55059, 55061, 55070, 55076, 55600, 55601, 55768, 55769, 55800, 55801, 55804, 55805, 55808, 55809, 55812, 55813, 55816, 55817, 55820, 55821, 55824, 55825, 55828, 55829, 55832, 55833, 55836, 55837, 55840, 55841, 55844, 55845, 55848, 55849, 55850, 55851, 55852, 55853, 57509, 57515, 57521, 57523, 57527, 57530, 57533, 57536, 57540, 57703, 57705, 57709, 57711, 57712, 57714, 57715, 57717, 57721, 58503 to 58527 (inclusive) and 58529
```

Participating Midwives may request:

55700, 55701, 55704, 55706, 55707, 55710, 55713, 55714, 55718, 55722.

Form of a request

Responsibility for the adequacy of requesting details rests with the requesting practitioner. A request for a diagnostic imaging service does not have to be in a particular form. However, the legislation provides that a request must be in writing and contain sufficient information, in terms that are generally understood by the profession, to clearly identify the item/s of service requested. This includes, where relevant, noting on the request the clinical indication(s) for the requested service. The provision of additional relevant clinical information can often assist the service provider and enhance the overall service provided to the patient. As such, this practice is actively encouraged.

A written request must be signed and dated and contain the name and address or name and provider number in respect of the place of practice of the requesting practitioner.

Referral to specified provider not required

It is not necessary that a written request for a diagnostic imaging service be addressed to a particular provider or that, if the request is addressed to a particular provider, the service must be rendered by that provider. Request forms containing relevant information about a diagnostic imaging provider supplied, or made available to, a requesting practitioner by a diagnostic imaging provider on, or after, 1 August 2012 must include a statement that informs the patient that the request may be taken to a diagnostic imaging provider of the patient's choice.

Request for more than one service and limit on time to render services

The requesting practitioner may use a single request to order a number of diagnostic imaging services. However, all services provided under this request must be rendered within seven days after the rendering of the first service.

Contravention of request requirements

A practitioner who, without reasonable excuse makes a request for a diagnostic imaging service that does not include the required information in his or her request or in a request made on his or her behalf is guilty of an offence under the Health Insurance Act 1973 punishable, upon conviction, by a fine of \$1000.

A practitioner who renders "R-type" diagnostic imaging services and who, without reasonable excuse, provides either directly or indirectly to a requesting practitioner a document to be used in the making of a request which would contravene the request information requirements is guilty of an offence under the Health Insurance Act 1973 punishable, upon conviction, by a fine of \$1000.

Exemptions from the written request requirements for R-type diagnostic imaging services

There are exemptions from the general written request requirements (R-type) diagnostic imaging services and these are outlined as follows:

Consultant physician or specialist

A consultant physician or specialist is a medical practitioner recognised for the purposes of the Health Insurance Act 1973 as a specialist or consultant physician, in a particular specialty.

Except for R-type items which in their description state that a referral is required (such as most R-type items in General Ultrasound and items 59300, 59303), a written request is not required for the payment of Medicare benefits when the diagnostic imaging service is provided by or on behalf of a consultant physician or a specialist (other than a specialist in diagnostic radiology) in his or her specialty and after clinical assessment he/she determines that the service was necessary. For details required for accounts/receipts see Note IN.0.7.

However, if in the referral to the consultant physician or specialist, the referring practitioner specifically requests a diagnostic imaging service (eg to a cardiologist to perform an echocardiogram) the service provided is a requested, not self-determined service. If further services are subsequently provided, these further services are self-determined - see "Additional services".

Additional services

A written request is not required for a diagnostic imaging service if that service was provided after one which has been formally requested and the providing practitioner determines that, on the basis of the results obtained from the requested service, that an additional service was necessary. However, the following services cannot be self-determined as "additional services":

- R-type items which in their description (such as most R-type items in General Ultrasound and items 59300, 59303) state that a referral is required (practitioners should claim the NR item in these circumstances);
- MRI services; and
- services not otherwise able to be requested by the original requesting practitioner.

For details required for accounts/receipts see Note IN.0.7.

Substituted services

- A provider may substitute a service for the service originally requested when:
- the provider determines, from the clinical information provided on the request, that the substituted service would be more appropriate for the diagnosis of the patient's condition; and
- the provider has consulted with the requesting practitioner or taken all reasonable steps to do so before providing the substituted service; and
- the substituted service was one that would be accepted as a more appropriate service in the circumstances by the practitioner's speciality group.

However, the following services cannot be substituted:

- R-type items which in their description (such as most R-type items in General Ultrasound and items 59300, 59303) state that a referral is required;
- MRI services; and
- services not otherwise able to be requested by the original requesting practitioner.

For details required for accounts/receipts see Note IN.0.7.

Remote areas

A written request is not required for the payment of Medicare benefits for a R-type diagnostic imaging service rendered by a medical practitioner in a remote area provided:

- the R-type service is not one for which there is a corresponding NR-type service; and
- the medical practitioner rendering the service has been granted a remote area exemption for that service.

For details required for accounts/receipts see Note IN.0.7.

Definition of remote area

The definition of a remote area is one that is more than 30 kilometres by road from:

- a) a hospital which provides a radiology service under the direction of a specialist in the specialty of diagnostic radiology; and
- b) a free-standing radiology facility under the direction of a specialist in the specialty of diagnostic radiology.

Application for remote area exemption

A medical practitioner, other than a consultant physician or specialist, who believes that he or she qualifies for exemption under the remote area definition, should obtain an application form from the Department of Human Services' website www.humanservices.gov.au or by contacting the Department of Human Services' Provider Eligibility Section, by email at sa.prov.elig@humanservices.gov.au or via phone on 1800 032 259 Monday to Friday, between 8.30 am and 5.00 pm, Australian Eastern Standard Time.

Quality assurance requirement for remote area exemption

Application for, or continuation of, a remote area exemption will be contingent on practitioners being enrolled in an approved continuing medical education and quality assurance program. For further information, please visit the Australian College of Rural and Remote Medicine (ACRRM) website at www.acrrm.org.au, or call the ACRRM on 1800 223 226.

Emergencies

The written request requirement does not apply if the providing practitioner determines that, because the need for the service arose in an emergency, the service should be performed as quickly as possible.

For details required for accounts/receipts see Note IN.0.7.

Lost requests

The written request requirement does not apply where:

- the person who received the diagnostic imaging service, or someone acting on that person's behalf, claimed that a written request had been made for such a service but that the request had been lost; and
- the provider of the diagnostic imaging service or that provider's agent or employee obtained confirmation from the requesting practitioner that the request had been made.

The lost request exemption is applicable only to services that the practitioner could originally request.

For details required for accounts/receipts see Note IN.0.7.

Pre-existing diagnostic imaging practices

The legislation provides for exemption from the written request requirement for services provided by practitioners who have operated pre-existing diagnostic imaging practices. The exemption applies to the services covered by the following Items: 57712, 57714, 57715, 57717, 57901, 57902, 57903, 57911, 57912, 57914, 57915, 57917, 57921, 57926, 57929, 57935, 58100 to 58115, 58117, 58123, 58124, 58521, 58523, 58524, 58526, 58527, 58529, 58700, 58702, 58924, 58926, 59103, and 59104.

To qualify for this "grandparent" exemption the providing practitioner must:

- a) be treating his or her own patient;
- b) have determined that the service was necessary;
- c) have rendered between 17 October 1988 and 16 October 1990 at least 50 services (which resulted in the payment of Medicare benefits) of the kind which have been designated "R-type" services from 1 May 1991;
- d) provide the exempted services at the practice location where the services which enabled the practitioner to qualify for the "grandparent" exemption were rendered; and
- e) be enrolled in an approved continuing medical education and quality assurance program from 1 January 2001. For further information, please contact the Royal Australian College of General Practitioners (RACGP), at www.racgp.org.au, on 1800 472 247 or via email to racgp@racgp.org.au, or the Australian College of Rural and Remote Medicine (ACRRM), at www.acrrm.org.au or by calling 1800 223 226.

Benefits are only payable for services exempted under these provisions where the service was provided by the exempted medical practitioner at the exempted location. Exemptions are not transferable.

For details required for accounts/receipts see Note IN.0.7.

Retention of requests

A medical practitioner who has rendered an R-type diagnostic imaging service in response to a written request must retain that request for a period of 18 months commencing on the day on which the service was rendered.

A medical practitioner must, if requested by the Department of Human Services CEO, produce written requests retained by that practitioner for an R-type diagnostic imaging service as soon as practicable and in any case by the end of the day after the day on which the Department of Human Services CEO's request was made. An employee of the Department of Human Services is authorised to make and retain copies of or take and retain extracts from written requests or written confirmations of lost requests.

A medical practitioner who, without reasonable excuse, fails to comply with the above requirements is guilty of an offence under the Health Insurance Act 1973 punishable, upon conviction, by a fine of \$1000.

The Department of Health has developed a <u>Health Practitioner Guideline to substantiate that a valid request existed</u> (pathology or diagnostic imaging), which is located online at <u>www.health.gov.au</u>.

IN.0.2 Who May Provide A Diagnostic Imaging Service

Unless otherwise stated, a diagnostic imaging service specified in the DIST may be provided by:

- a) a medical practitioner; or
- b) a person, other than a medical practitioner, who provides the service under the supervision of a medical practitioner in accordance with accepted medical practice.

For the purposes of Medicare, however, the rendering practitioner is the medical practitioner who provides the report.

Medicare benefits are not payable, for example, when a medical practitioner refers patients to self-employed paramedical personnel, such as radiographers or other persons, who either bill the patient or the practitioner requesting the service.

Reports provided by practitioners located outside Australia

Under the Act, Medicare benefits are only payable for services rendered in Australia. Where a service consists of a number of components, such as a diagnostic imaging service, all components need to be rendered in Australia in order to qualify for Medicare benefits. For diagnostic imaging services, this means that all elements of the service, including the preparation of report on the procedure, would need to be rendered in Australia.

As such, Medicare benefits are not payable for services which have been reported on by medical practitioners located outside Australia.

Who may perform a Diagnostic Radiology Procedure:

All items in Group I3 (excluding Sub-group 10) must be performed by:

- a) a medical practitioner;
- b) a medical radiation practitioner who provides the service under the supervision of a medical practitioner in accordance with accepted medical practice.

A medical radiation practitioner means a person registered or licenced as a medical radiation practitioner under a law of a State or Territory.

However, for a service mentioned in items 57901 to 57969, a diagnostic imaging procedure may also be performed by a dental practitioner who:

- (a) may request the service because of the operation of subsection 16B (2) of the Health Insurance Act 1973; and
- (b) provides the service under the supervision of a medical practitioner in accordance with accepted medical practice.

Exceptions to this requirement

Requirements on who must perform a diagnostic radiology procedure do not apply where the service is performed

in:

- a) RA2, RA3 OR RA4; OR
- b) both:
- i) in RA1; and
- ii) RRMA4 or RRMA5

RA1 means an inner regional area as classified by the ASGC.

RA2 means an outer regional area as classified by the ASGC.

RA3 means a remote area as classified by the ASGC.

RA4 means a very remote area as classified by the ASCG

RRMA4 means a small rural centre as classified by the Rural, Remote and Metropolitan Areas Classification.

RRMA5 means a rural centre with an urban centre population of less than 10,000 persons as classified by the Rural, Remote and Metropolitan Areas Classification.

However, diagnostic radiology procedures in these areas must also be performed by a medical practitioner; or a person, other than a medical practitioner, who provides the service under the supervision of a medical practitioner in accordance with accepted medical practice.

IN.0.3 Diagnostic Imaging Services - Overview

Section 4AA of the *Health Insurance Act 1973* (the Act) enables the *Health Insurance (Diagnostic Imaging Services Table) Regulations* to prescribe a table of diagnostic imaging services that sets out rules for interpretation of the table, items of diagnostic imaging services and the amount of fees applicable to each item.

For further information on diagnostic imaging, visit the Department of Health's website

IN.0.4 What Is A Diagnostic Imaging Service

A diagnostic imaging service is defined in the Act as meaning "an R-type diagnostic imaging service or an NR-type diagnostic imaging service to which an item in the DIST applies".

A diagnostic imaging procedure is defined in the Act as 'a procedure for the production of images (for example x-rays, computerised tomography scans, ultrasound scans, magnetic resonance imaging scans and nuclear scans) for use in the rendering of diagnostic imaging services'.

The Schedule fee for each diagnostic imaging service described in the DIST covers both the diagnostic imaging procedure and the reading and report on that procedure by the diagnostic imaging service provider. Exceptions to the reporting requirement are as follows:

- (a) where the service is provided in conjunction with a surgical procedure, the findings may be noted on the operation record (items 55054, 55130, 55135, 55848, 55850, 57341, 57345, 59312, 59314, 60506, 60509 and 61109);
- (b) where a service is provided in preparation of a radiological procedure (items 60918 and 60927).

As for all Medicare services, diagnostic imaging services have to be clinically relevant before they are eligible for Medicare benefits. A clinically relevant service is a service that is generally accepted in the profession as being necessary for the appropriate treatment of the patient.

For NR-type services (and R-type services provided without a request under the exemption provisions - see DID - 'Exemptions from the written request requirements for R-type diagnostic imaging services'), the clinical relevance of the service is determined by the providing practitioner. For R-type services rendered at the request of another practitioner, responsibility for determining the clinical relevance of the service lies with the requesting practitioner.

IN.0.5 Maintaining Records of Diagnostic Imaging Services

Providers of diagnostic imaging services must keep records of diagnostic imaging services in a manner that facilitates retrieval on the basis of the patient's name and date of service. Records of R-type diagnostic imaging services must be retained for a period of 18 months commencing on the day on which the service was rendered.

The records must include the report by the providing practitioner on the diagnostic imaging service. For ultrasound services, where the service is performed on behalf of a medical practitioner the report must record the name of the sonographer.

- Where the provider *substitutes* a service for the service originally requested, the provider's records must include:
- words indicating that the providing practitioner has consulted with the requesting practitioner and the date of consultation; or

- if the providing practitioner has not consulted with the requesting practitioner, sufficient information to demonstrate that he or she has taken all reasonable steps to do so.
 - For services rendered after a *lost request*, the records must include words to the effect that the request was lost but confirmed by the requesting practitioner and the manner of confirmation, eg. how and when.
 - For *emergency services*, the records must indicate the nature of the emergency.

If requested by the Managing Director, the Department of Human Services, records retained by a providing practitioner must be produced to an officer of the Department of Human Services as soon as practicable but in any event within seven days after the day the Managing Director requests the production of those records. the Department of Human Services officers may make and retain copies, or take and retain extracts, of such records.

A medical practitioner who, without reasonable excuse, contravenes any of the above provisions is guilty of an offence under the *Health Insurance Act 1973* punishable, upon conviction, by a fine of \$1000.

IN.0.6 Registration of Site Undertaking Diagnostic Imaging Procedures

All sites (including hospitals) and bases for mobile equipment at or from which diagnostic imaging procedures are performed need to be registered with the Department of Human Services for the purposes of Medicare.

Registered sites and bases for mobile equipment are allocated a Location Specific Practice Number (LSPN). The LSPN is a unique identifier comprising a six digit numeric and is required on all accounts, receipts and Medicare assignment of benefits forms for diagnostic imaging services before patients can receive Medicare benefits. In addition, benefits are not payable unless there is equipment of appropriate type listed on the register for the practice.

Sites or bases for mobile equipment need only register once. To maintain registration, sites are required to advise the Department of Human Services of any changes to their primary information within 28 days of the change occurring. Primary information is:

- proprietor details;
- ACN (for companies);
- business name and ABN:
- address of practice site or base for mobile equipment;
- type of equipment located at the site;
- information about any health care provider not employed at, or contracted to provide services for the site or base, who has an interest in any of the equipment listed on the register.

Registration will be suspended if a proprietor fails to respond to notices from the Department of Human Services about registration details. The suspension will be lifted as soon as the notices are responded to and Medicare benefits will be backdated for the period of suspension.

Registration will be cancelled after a continuous period of three months suspension. Cancellation under these circumstances is taken to have commenced from the date of suspension.

The proprietor may, at any time, request cancellation of the registration of a practice site or base for mobile equipment. Otherwise, registration may be cancelled by the Department of Human Services if the registration was obtained improperly (false information supplied) or if the proprietor fails to notify the Department of Human Services of primary information. A decision to cancel a registration will only be made following due consideration of a submission by the site or base. The proprietor may apply to the Administrative Appeals Tribunal for a review of this decision. If registration is cancelled involuntarily, the proprietor may not apply to re-register the site or base for a period of 12 months unless permitted to do so.

Proprietors of unregistered practices (including where the registration is under suspension or has been cancelled) need to either advise patients in writing or display a notice that no Medicare benefits will be payable for the diagnostic imaging services.

For full details about Location Specific Practice Numbers, including how to register a practice site. A list of LSPN registrations is available on the Department of Human Services' website at

www.medicaraustralia.gov.au/yourhealth/our_services/lspn_search.htm and this allows practitioners and the general public to verify the registration status of practice sites eligible for Medicare benefits.

From 1 July 2010 practices applying for an LSPN will also need to apply for and be accredited under the Stage II Diagnostic Imaging Accreditation Scheme in order to be eligible to provide diagnostic imaging services under Medicare

ACCREDITATION OF SITES UNDERTAKING DIAGNOSTIC IMAGING SERVICES

Background

In June 2007, legislation was enacted to amend the Health Insurance Act 1973 to establish a diagnostic imaging accreditation scheme under which mandatory accreditation would be linked to the payment of Medicare benefits for radiology and non-radiology services.

The Scheme commenced on 1 July 2008 and covered only practices providing radiology services. From 1 July 2010, the Scheme continued the accreditation arrangements for practices providing radiology services, and broadened the scope of the scheme to include practices providing non-radiology services such as cardiac ultrasound and angiography, obstetric and gynaecological ultrasound and nuclear medicine imaging services.

ACCREDITATION OF PRACTICES UNDERTAKING DIAGNOSTIC IMAGING SERVICES

Background

In 2007, the Diagnostic Imaging Accreditation Scheme (the Scheme) was established by the Health Insurance Amendment (Diagnostic Imaging Accreditation) Act 2007 to ensure Medicare funding is directed to diagnostic imaging services that are safe, effective and responsive to the needs of health care consumers.

The Scheme was implemented in two stages.

Stage 1

In 2008 Stage 1 of the Scheme commenced requiring practices providing radiology and some ultrasound services to meet a minimum of 3 entry level standards.

Stage 2

In 2009 the Scheme was broadened to mandate accreditation for all practices providing Medicare rebateable diagnostic imaging services and increasing the number of standards from 3 entry level Practice Standards to 15 full suite Practice Accreditation Standards.

The deadline for Practices to attain the full suite of accreditation standards was phased in to allow practices time to meet the increased number of standards. Practices accredited under Stage 1 of the Scheme were required to meet the new standard by 1 July 2012, whereas Practices who gained entry into the Scheme in Stage 2 have until 2013 to become fully accredited.

First time accreditation

New practices entering the Scheme may choose to be accredited against either three entry-level Practice Standards or the full suite of Practice Accreditation Standards. Practices initially choosing to be accredited against the entry level Standards have a further period two years to become accredited against the full suite of Standards.

Re-accreditation of Practices

Practices previously accredited must seek re-accreditation against the full suite of Practice Standards and cannot apply for re-accreditation against the entry level Standards.

Medicare rebateable diagnostic imaging services

All Practices intending to render any diagnostic imaging services for the purpose of Medicare benefits must be accredited under the Scheme. This includes non-radiology services such as cardiac ultrasound and angiography, obstetrics and gynaecological ultrasound and nuclear medicine imaging services.

Non-Accredited Practices

Practices may choose not to be accredited and still provide diagnostic imaging services, but these services do not attract a Medicare rebate.

Practices providing non Medicare funded diagnostic imaging services are bound by the requirements of the Health Insurance Act 1973 (Div 5/Section 23DZZIAE) to inform patients prior to carrying out the service, that the Practice is not accredited and as such the service does not attract a Medicare rebate.

The Medical Imaging Accreditation Program (MIAP)

For a number of years the Royal Australian and New Zealand College of Radiologist (RANZCR) has delivered a voluntary accreditation program jointly with the National Association of Testing Authorities, Australia.

Practices participating in MIAP can seek recognition of their MIAP accreditation under the Scheme. This recognition will grant MIAP Practices accreditation against the full suite of Standards until the date of the expiration of the recognised MIAP accreditation. By this date Practices will need to either provide their Approved Accreditor with evidence of renewal of MIAP accreditation or have been granted accreditation against the full suite of Standard.

The Accreditation Standards

The current Practice Accreditation Standards are made up of three entry level Practice Accreditation Standards and the full suite of Practice Accreditation Standards. If a practice is applying for accreditation against the entry level Practice Accreditation Standards, an accreditation decision will be made within 15 business days of the lodgement of an application for accreditation. If a practice is applying for accreditation against the full suite of Practice Accreditation Standards, an accreditation decision will be made within 30 business days of the lodgement of an application for accreditation.

From the date of being granted accreditation, the practice site can provide diagnostic imaging services under Medicare.

Entry Level Standards

- 1. Registration and Licensing Standard
- 2. Radiation and Safety Standard
- 3. Equipment Inventory Standard

Full Suite Accreditation Standards

Part 1- Organisational Standards

Part 2 - Pre-procedure Standards

Part 3 - Procedure Standards

Part 4 - Post Procedure Standards

Applying for accreditation

Whether a practice is applying for accreditation against entry-level standards or the full suite of Practice Accreditation Standards, the application process is the same. A practice is required to submit to an approved accreditor either:

- an application for accreditation providing written documentary evidence of compliance with the entry level accreditation standards or the full suite Practice Accreditation Standards; or
- written evidence of accreditation under the Medical Imaging Accreditation Program (MIAP) jointly administered by the Royal Australian and New Zealand College of Radiologists (RANZCR) and the National Association of Testing Authorities Australia (NATA).

Renewal of Accreditation

Practices awarded accreditation against the full suite of Practice Accreditation Standards enter the maintenance program which requires them to be re-accredited every 4 years.

Approved Accreditors

There are three Accreditation agencies approved by the Minister for Health to provide Accreditation services:

Health and Disability Auditing Australia Ph: 1800 601 696

(HDAAu)

National Association of Testing Authorities Ph: 1800 621 666

(NATA)

Quality Innovation Performance Ph: 1300 888 329

(QIP)

Further information

Website: www.diagnosticimaging.health.gov.au

Email: diagnosticimagingandaccreditation@health.gov.au

Phone: (02) 6289 8859

IN.0.7 Details Required on Accounts, Receipts and Medicare Assignment of Benefit Forms

In addition to the normal particulars of the patient, date of service, the services performed and the fees charged, the details which must be entered on accounts or receipts, and Medicare assignment of benefits forms in respect of diagnostic imaging services are as follows:

- the Location Specific Practice Number (LSPN) of the diagnostic imaging premises or mobile facility where the diagnostic imaging procedure was undertaken;
- if the professional service is provided by a specialist in diagnostic radiology the name and either the address of the place of practice, or the provider number, of that specialist;
- if the medical practitioner is not a specialist in diagnostic radiology the name and either the practice address or provider number of the practitioner who is claiming or receiving fees;

- for "R-type" (requested) services and services rendered subsequent to lost requests, the account or receipt or the Medicare assignment form must indicate the date of the request and the name and provider number, or the name and address, of the requesting practitioner.
- services that are *self-determined* must be endorsed with the letters 'SD' to indicate that the service was self-determined. Services are classified as self-determined when rendered:
- by a *consultant physician or specialist*, in the course of that consultant physician or specialist practicing his or her specialty (other than a specialist in diagnostic radiology), or
- to provide *additional services* to those specified in the original request and the additional services are of the type that would have otherwise required a referral from a specialist or consultant physician; or
- in a remote area, or
- under a pre-existing diagnostic imaging practice exemption.
- substituted services the account etc. must be endorsed 'SS'.
- *emergencies*, the account etc. must be endorsed "emergency".
- *lost requests* the account etc. must be endorsed "lost request".

IN.0.8 Contravention of State and Territory Laws and Disqualified Practitioners

Medicare benefits are not payable where a diagnostic imaging service is provided by, or on behalf of, a medical practitioner, and the provision of that service by that practitioner or any other person contravenes a State or Territory law which, directly or indirectly, relates to the use of diagnostic imaging procedures or equipment. The Managing Director of the Department of Human Services may notify the relevant State or Territory authorities if he/she believes that a person may have contravened a law of a State or Territory relating directly or indirectly to the use of diagnostic imaging procedures or equipment.

IN.0.9 Prohibited Practices

Changes have been made to legislation relating to diagnostic imaging services provided under Medicare.

Amendments to the Health Insurance Act 1973 (the Act) relating to diagnostic services funded under Medicare came into effect on 1 March 2008. The changes were implemented following measures introduced in the Health Insurance Amendment (Inappropriate and Prohibited Practices and other Measures) Act 2007.

Who might be affected?

- · Anyone who can provide or request a Medicare-funded diagnostic imaging service might be affected.
- · Anyone who has a relevant connection to a provider or a requester, including relatives, bodies corporate, trusts, partnerships and employees may also be affected.

What is prohibited?

- · It is unlawful to ask for, accept, offer or provide a benefit, or make a threat, that is reasonably likely to induce a requester to make diagnostic imaging requests, or is related to the business of providing diagnostic imaging services.
- · It is a criminal offence to ask for, accept, offer, or provide a benefit, or make a threat, that is intended to induce requests to a particular provider.
- The prohibitions apply to the provision of benefits, or the making of threats, that are directed to a requester by a provider, whether directly or through another person.

A requester of diagnostic imaging services means:

- · a medical practitioner;
- · a dental practitioner, a chiropractor, a physiotherapist, a podiatrist or an osteopath (in relation to certain types of services prescribed in Regulations);
- · a person who employs, or engages under a contract for services, one of the people mentioned above; or
- · a person who exercises control or direction over one of the people mentioned above (in his or her professional capacity).

A provider of a diagnostic imaging service means:

- · a person who renders that kind of service;
- · a person who carries on a business of rendering that kind of service;
- · a person who employs, or engages under a contract for services, one of the people detailed above; or
- · a person who exercises control or direction over a person who renders that kind of service or a person who carries on a business of rendering that kind of service.

What is permitted?

Under the Act it is permitted to:

- · share the profits of a diagnostic imaging business, provided the dividend is in proportion to the beneficiary's interest in the business;
- · accept or pay remuneration, including salary, wages, commission, provided the remuneration is not substantially different from the usual remuneration paid to people engaged in similar employment;
- · make or accept payments for property, goods or services, provided the amount paid is not substantially different from the market value of the property, goods or services;
- · make or accept payments for shared property, goods or services, provided the amount paid is proportionate to the person's share of the cost of the property, goods or services and shared staff and/or equipment are not used to provide diagnostic imaging services;
- · provide or accept property, goods or services, provided the benefit exchanged is not substantially different from the market value of the property, goods or services;

Are there any benefits, other than those described in the Act, that are permitted?

· The Minister has determined that certain types of benefit are permitted. These include items to support a requester to view diagnostic imaging reports, such as specially designed computer monitors. Modest gifts and hospitality may also be permitted, under certain circumstances.

Further information on the *Health Insurance (Permitted Benefits - diagnostic imaging services) Determination 2008* can be found on the Department of Health website at www.health.gov.au/legislativeamendments

What are the penalties for those not complying with the provisions?

· If you breach the provisions, you could potentially be subject to a range of penalties, depending on the kind of breach, including:

o civil penalties;

o criminal offences:

o referral to a Medicare Participation Review Committee (MPRC), possibly resulting in loss of access to Medicare.

For further information on Prohibited Practices visit the Department of Health website at www.health.gov.au/legislativeamendments

IN.0.10 Multiple Services Rules

Background

There are several rules that may apply when calculating Medicare benefits payable when multiple diagnostic imaging services are provided to a patient at the same attendance (same day). These rules were developed in association with the diagnostic imaging profession representative organisations and reflect that there are efficiencies to the provider when these services are performed on the same occasion. Unless there are clinical reasons for doing so, they should be provided to the patient at the one attendance and the efficiencies from doing this reflected in the overall fee charged.

General diagnostic imaging - multiples services

The diagnostic imaging multiple services rules apply to all diagnostic imaging services. There are three rules, and more than one rule may apply in a patient episode. The rules do not apply to diagnostic imaging services rendered in a remote area by a medical practitioner who has a remote area exemption for that area - see DID.

Rule A. When a medical practitioner renders two or more diagnostic imaging services to a patient on the same day, then:

the diagnostic imaging service with the highest Schedule fee has an unchanged Schedule fee; and

the Schedule fee for each additional diagnostic imaging service is reduced by \$5.

Rule B. When a medical practitioner renders at least one R-type diagnostic imaging service and at least one consultation to a patient on the same day, there is a deduction to the Schedule fee for the diagnostic imaging service with the highest Schedule fee as follows:

if the Schedule fee for the consultation is \$40 or more - by \$35; or

if the Schedule fee for the consultation is less than \$40 but more than \$15 - by \$15; or

if the Schedule fee for the consultation is less than \$15 - by the amount of that fee.

The deduction under Rule B is made once only. If there is more than one consultation, the consultation with the highest Schedule fee determines the deduction amount. There is no further deduction for additional consultations.

A 'consultation' is a service rendered under an item from Category 1 of the Medicare Benefits Schedule (MBS), that is, items 1 to 10816 inclusive.

Rule C. When a medical practitioner renders an R-type diagnostic imaging service and at least one non-consultation service to the same patient on the same day, the Schedule fee for the diagnostic imaging service with the highest Schedule fee is reduced by \$5.

A deduction under Rule C is made once only. There is no further deduction for any additional medical services.

For Rule C, a 'non-consultation' is defined as any following item from the MBS:

- Category 2, items 11000 to 12533;
- Category 3, items 13020 to 51318;
- Category 4, items 51700 to 53460;

- Cleft Lip and Palate services, items 75001 to 75854 (as specified in the 'Medicare Benefits for the treatment of cleft lip and cleft palate conditions' book.)

Pathology services are not included in Rule C.

When both Rules B and C apply, the sum of the deductions in the Schedule fee for the diagnostic imaging service with the highest Schedule fee is not to exceed that Schedule fee.

Ultrasound - Vascular

This rule applies to all vascular ultrasound items claimed on the same day of service ie whether performed at the same attendance by the same practitioner or at different attendances.

Where more than one vascular ultrasound service is provided to the same patient by the same practitioner on the same date of service, the following formula applies to the Schedule fee for each service:

- 100% for the item with the greatest Schedule fee
- plus 60% for the item with the next greatest Schedule fee
- plus 50% for each other item.

When the Schedule fee for some of the items are the same, the reduction is calculated in the following order:

- 100% for the item with the greatest Schedule fee and the lowest item number
- plus 60% for the item with the greatest Schedule fee and the second lowest item number
- plus 50% for each other item

Note: If 2 or more Schedule fees are equally the highest, the one with the lowest item number is taken to have the higher fee eg. Item 55238 and 55280, item 55238 would be considered the highest.

When calculating the benefit, it should be noted that despite the reduction, the collective items are treated as one service for the application of Rule A of the General Diagnostic Imaging Multiple Services rules and the patient gap. Examples can be found at the Department of Human Services' website.

Magnetic Resonance Imaging (MRI) - Musculoskeletal

If a medical practitioner performs 2 or more scans from subgroup 12 and 13 for the same patient on the same day, the fees specified for items that apply to the service are affected as follows:

- (a) the item with the highest schedule fee retains 100% of the schedule fee; and
- (b) any other fee, except the highest is reduced by 50%.

Note: If 2 or more Schedule fees are equally the highest, the one with the lowest item number is taken to have the higher fee eg. Item 63322 and 63331, item 63322 would be considered the highest.

If the reduced fee is not a multiple of 5 cents, the reduced fee is taken to be the nearest amount that is a multiple of 5 cents

In addition, the modifying item for contrast may only be claimed once for a group of services subject to this rule.

If a medical practitioner provides:

- (a) 2 or more MRI services from subgroups 12 and 13 for the same patient on the same day; and
- (b) 1 or more other diagnostic imaging services for that patient on that day

the amount of the fees payable for the MRI services is taken, for the purposes of this rule, to be an amount payable for 1 diagnostic imaging service in applying Rule A of the General Diagnostic Imaging Multiple Services rules.

IN.0.11 Capital Sensitivity Measure for Diagnostic Imaging Equipment

Almost all services listed in the Diagnostic Imaging Services Table of the Medicare Benefits Schedule (MBS), excluding Positron Emission Tomography (PET) services, have two different schedule fees - schedule '(K)' items (100 per cent of the MBS fee) and schedule '(NK)' items (approximately 50 per cent of the MBS fee) for diagnostic imaging services provided on aged equipment.

This is known as the 'capital sensitivity measure', and it is in place for almost all diagnostic imaging equipment providing services (excluding PET) under Medicare. The measure is intended to improve the quality of diagnostic imaging services by encouraging providers to upgrade and replace aged equipment as appropriate.

On 27 November 2013, the remote location exemptions provisions that apply to CT items 56001-57361 and angiography items 59903-59974 were amended so they are consistent with other diagnostic imaging modalities.

A regional exemption automatically applies if services are provided in a location in Remoteness Area (RA) outer regional, remote, or very remote. Exemptions may be granted by the Department of Health (subject to particular criteria) to practices located in RA inner regional areas, where the location was previously under the Rural, Remote and Metropolitan Area (RRMA) classification system, RRMA4 or RRMA5.

As there may be a number of diagnostic imaging providers which met the previous exemption criteria, but not the current criteria, a grandfathering provision will be implemented. A diagnostic imaging provider which was eligible to claim schedule '(K)' items for CT and angiography services because they met the previous exemption criteria prior to 27 November 2013, may claim schedule '(K)' items until 1 July 2016. This transition period will allow affected providers an opportunity to upgrade or replace their equipment.

As part of the 2014-15 Federal Budget the Government announced *the 'Medicare Benefits Schedule - revised capital sensitivity provisions for diagnostic imaging equipment'* measure, which will strenthen the quality and safety of MBS diagnostic imaging services through alignment and consistency of the capital sensitivity measure across all modalities (except PET).

This measure includes:

- \cdot the extension of the capital sensitivity measure to all angiography services, including the previously excluded MBS items 60000 to 60078;
 - introduction of a 'maximum extended life age' of 15 years for CT and angiography services; and
 - increasing the 'maximum extended life age' for MRI services to 20 years.

The changes will take effect on 1 January 2015.

After 1 January 2015, any CT and angiography machine that has not reached maximum extended life age (15 years) but has reached its new effective life age, and is upgraded before 1 January 2015 is eligible for K items from 1 January 2015, until the machine reached its maximum extended life age.

After 1 January 2015, any CT and angiography machine that has not reached its maximum extended life age (15 years) but has reached its new effective life age, and is upgraded between 1 January 2015 and 1 January 2016, is eligible for K items on and from the day that it is upgraded until the machine reached its maximum extended life age.

Further detail

For full details about the rules for claiming the schedule '(K)' and schedule '(NK)' items, the exemptions, and the definition of upgrade, providers should access the Department of Health's website at: www.health.gov.au/capitalsensitivity

IN.0.12 Group I2 - Computed Tomography (CT) Capital sensitivity items

A reduced Schedule fee applies to CT services provided on equipment that is 10 years old or older. This equipment must have been first installed in Australia ten or more years ago, or in the case of imported pre-used equipment, must have been first manufactured ten or more years ago. A range of items cover services provided on older equipment. These items are:

```
56041, 56047, 56050, 56053, 56056, 56062, 56068, 56070, 56076, 56141, 56147, 56259, 56341, 56347, 56441, 56447, 56449, 56452, 56541, 56547, 56659, 56665, 56841, 56847, 57041, 57047, 57247, 57345, 57355, 57361.
```

These items are identified by the addition of the letter '(NK)' at the end of the item. These items should be used where services are performed on equipment ten years old or older, except where equipment is located in a remote area when items with the letter "K", as described below, will apply.

Items 56001 to 57356 (which contain the symbol (K) at the end of the item should be used for services which are performed on a date which is less than ten years after the date on which the CT equipment used in performing the service was first installed in Australia. In the case of imported pre-used CT equipment, the services must have been performed on a date which is less than ten years from the first date of manufacture of the equipment.

Professional supervision

CT services (items 56001 to 57356) are not eligible for a Medicare rebate unless the service is performed:

- (a) under the professional supervision of a specialist in the specialty of diagnostic radiology who is available:
- (i) to monitor and influence the conduct and diagnostic quality of the examination; and
- (ii) if necessary, to personally attend on the patient; or
- (b) if paragraph (a) cannot be complied with
- (i) in an emergency, or
- (ii) because of medical necessity in a remote area refer to DID.4.4 for definition of remote area.

Note: Practitioners do not have to apply for a remote area exemption in these circumstances.

Items 57360 and 57361 apply only to a CT service that is:

- (a) performed under the professional supervision of a specialist or consultant physician recognised by the Conjoint Committee for the Recognition of Training in CT Coronary Angiography who is available:
- (i) to monitor and influence the conduct and diagnostic quality of the examination; and
 - (ii) if necessary, to attend on the patient personally; and
- (b) reported by a specialist or consultant physician recognised by the Conjoint Committee for the Recognition of Training in CT Coronary Angiography; or
- (c) if paragraph (a) and (b) cannot be complied with
- (i) in an emergency, or
- (ii) because of medical necessity in a remote area refer to DID.4.4 for definition of remote area.

Use of a hybrid PET/CT or SPECT/CT machine

CT scans rendered on hybrid Positron Emission Tomography (PET)/CT or hybrid Single Photon Emission Computed Tomography (SPECT)/CT units are eligible for a Medicare benefit provided:

- \cdot the CT scan is not solely used for the purposes of attenuation correction and anatomical correlation of any associated PET or SPECT scan; and
- the CT scan is rendered under the same conditions as those applying to services rendered on stand-alone CT equipment. For example, the service would need to be properly requested and performed under the professional supervision of a specialist radiologist, including specialist radiologists with dual nuclear medicine qualifications.

Scan of more than one area

Items have been provided to cover the common combinations of regions - see Multiple Regions below. However, where regions are scanned on the one occasion which are not covered by a combination item, for example, item 56220 (scan of the spine) with item 56619 (scan of extremities), both examinations would attract separate benefit.

Multiple regions

Items have been provided to cover the common combinations of regions. The items relating to the individual contiguous regions should not be used when scans of multiple regions are performed.

More than one attendance of the patient to complete a scan

Items 56220 to 56240 and 56619 to 56665 apply once only for a service described in any of those items, regardless of the number of patient attendances required to complete the service. For example, where a request relates to two or more regions of the spine and one region only is scanned on one occasion with the balance of regions being scanned on a subsequent occasion, benefits are payable for one combination service only upon completion.

Pre contrast scans

Pre contrast scans are included in an item of service with contrast medium only when the pre-contrast scans are of the same region.

Head

Exclusion of acoustic neuroma

If an axial scan is performed for the exclusion of acoustic neuroma, Medicare benefits are payable under item 56001 or 56007.

Assessment of headache

If the service described in item 56007 or 56047 is used for the assessment of headache of a patient, the fee mentioned in the item applies only if:

- (a) a scan without intravenous contrast medium has been undertaken on the patient; and
- (b) the service is required because the result of the scan is abnormal.

This rule applies to a patient who:

- (i) is under 50 years; and
- (ii) is (apart from the headache) otherwise well; and
- (iii) has no localising symptoms or signs; and

(iv) has no history of malignancy or immunosuppression.

Spine

CT items exist which separate the examination of the spine into the cervical, thoracic and lumbosacral regions. These items are 56220 to 56240 inclusive. They include items for CT scans of two regions of the spine (56233, 56234, 56235 and 56236) and for all three regions of the spine (56237, 56238, 56239 and 56240). Restrictions apply to the following items:

- (a) item 56233 is used where two examinations of the kind referred to in items 56220, 56221 and 56223 are performed. The item numbers of the examination which are performed must be shown on any accounts issued or patient assignment forms completed.
- (b) item 56234 is used where two examinations of the kind referred to in items 56224, 56225 and 56226 are performed. The item numbers of the examination which are performed must be shown on any accounts issued or patient assignment forms completed.
- (c) item 56235 is used where two examinations of the kind referred to in items 56227, 56228 and 56229 are performed. The item numbers of the examination which are performed must be shown on any accounts issued or patient assignment forms completed
- (d) item 56236 is used where two examinations of the kind referred to in items 56230, 56231 and 56232 are performed. The item numbers of the examination which are performed must be shown on any accounts issued or patient assignment forms completed

Example: for a CT examination of the spine where the cervical and thoracic regions are to be studied (item 56233), item numbers 56220 and 56221 must be specified.

With intrathecal contrast medium (Item 56219)

The item incorporates the cost of contrast medium for intrathecal injection and associated x-rays. Benefits are not payable for this item when rendered in association with myelograms (Item 59724). Where a myelogram is rendered under item 59724 and a CT is necessary, the relevant item would be scan of spine without intravenous contrast (Item 56220, 56221 or 56223).

Upper abdomen and pelvis

Items 56501, 56507, 56541 and 56547 are not eligible for Medicare Benefits if performed for the purpose of performing a virtual colonoscopy (otherwise known as CT colonography and CT colography). CT Colonography is covered by items 56553 and 56555.

Computed Tomography of the Colon (Items 56553 and 56555)

In items 56553 and 56555 the terms 'high risk' and 'incomplete colonoscopy' are defined as follows:

High Risk

Asymptomatic people fit into this category if they have:

- three or more first-degree or a combination of first-degree and second-degree relatives on the same side of the family diagnosed with bowel cancer (suspected hereditary non-polyposis colorectal cancer or NPCC), or
- two or more first-degree or second-degree relatives on the same side of the family diagnosed with bowel cancer, including any of the following high-risk features:
- multiple bowel cancers in the one person
- bowel cancer before the age of 50 years

- at least one relative with cancer of the endometrium, ovary, stomach, small bowel, ureter, biliary tract or brain
- at least one first-degree relative with a large number of adenomas throughout the large bowel (suspected familial adenomatis polyposis or FAP), or
- somebody in the family in whom the presence of a high-risk mutation in the adenomatis polyposis coli (APC) gene or one of the mismatch repair (MMR) genes has been identified.

Source: NHMRC 2005 Clinical Practice Guidelines for the Prevention, Early Detection and Management of Colorectal Cancer - Category 3 - those at potentially high risk.

Incomplete Colonoscopy

For audit purposes, an incomplete colonoscopy is defined as one that is not completed for technical or medical reasons and must have been performed in the preceding 3 months.

Spiral angiography

Items 57350 and 57355 and items 57351 and 57356

CT spiral angiography items 57351 and 57356 apply under certain circumstances specified in the items including where a service to which items 57350 or 57355 have been performed on the same patient within the previous 12 months, whereas items 57350 and 57355 apply under the circumstances specified in the items and where the service has not been performed on the same patient within the previous 12 months.

Computed tomography of the coronary arteries (Items 57360 and 57361)

Payment of Medicare rebates for items 57360 and 57361 is limited to specialists or consultant physicians who have fulfilled the training and credentialing requirements developed by the Conjoint Committee for the Recognition of Training in CT Coronary Angiography (CTCA). The descriptors for CT spiral angiography items 57350, 57351, 57355 and 57356 and CT chest items 56301, 56307, 56341, 56347, 56801, 56807, 56841, 56847, 57001, 57007, 57041 and 57047 clarify that they are not to be used to image the coronary arteries.

IN.0.13 Group I4 - Nuclear Medicine Imaging General

Benefits for a nuclear scanning service are only payable when the service is performed by a specialist or consultant physician, or by a person acting on behalf of the specialist and the final report of the service is compiled by the specialist or consultant physician who performed the preliminary examination of the patient and the estimation and administration of the dosage.

Additional benefits will only be attracted for specialist physician or consultant physician attendance under Category 1 of the Schedule where there is a request for a full medical examination accompanied by a referral letter or note of referral.

Credentialling for nuclear medicine imaging services

Payment of Medicare rebates for nuclear medicine imaging services is limited to specialists or consultant physicians who are credentialled by the Joint Nuclear Medicine Credentialling and Accreditation Committee of the Royal Australian College of Physicians (RACP) and the Royal Australian and New Zealand College of Radiologists (RANZCR). The scheme has been developed by the profession in consultation with Government to ensure that specialists in nuclear medicine are appropriately trained and licensed, provide appropriate personal supervision of procedures and are involved in ongoing continuing medical education.

For information regarding the Scheme and for application forms, please phone the RACP or RANZCR.

Radiopharmaceuticals

The Schedule fees for nuclear medicine imaging services incorporate the costs of radiopharmaceuticals.

Single Photon Emission Computed Tomography (SPECT)

Where SPECT has been performed in conjunction with another study and is not covered under the item descriptor or is not covered under Item 61462, no Medicare benefit is payable for the SPECT study.

Single myocardialperfusion studies (Items 61302 and 61303)

Items 61302 and 61303 apply to single myocardial perfusion studies which can only be used once and cannot be used in conjunction with any other myocardial perfusion study for an individual patient referral.

Myocardial perfusion (Items 61306 and 61307)

Items 61306 and 61307 refer to all myocardial perfusion studies involving two or more sets of imaging times related to an individual patient referral. This includes stress/rest, stress/re-injection, stress/rest and re-injection thallium studies, one or two-day technetium-based perfusion agent protocols, mixed technetium-based perfusion agent/thallium protocols and the use of gated SPECT when undertaken.

Hepatobiliary study (pre-treatment) (Item 61360)

Item 61360 - the standard hepatobiliary item - also includes allowance of the pre-procedural CCK administration for preparatory emptying of the gall bladder and also morphine augmentation.

Hepatobiliary study (infusion) (Item 61361)

Item 61361 applies specifically to a standard hepatobiliary study to which has been added an infusion of sinaclide (CCK-8) following which acquisition is continued and quantification of gallbladder ejection fraction and/or common bile duct activity time curves are performed.

Whole body studies (Items 61426-61438)

"Whole body" studies must include the trunk, head and upper and lower limbs down to the elbow and knee joints respectively, whether acquired as multiple overlapping camera views or whole body sweeps (runs) with additional camera views as required. Any study that does not fulfil these criteria is a localised study.

Repeat studies (Item 61462)

Item 61462 covers repeat planar (whole body or localised) and/or SPECT imaging performed on a separate occasion using the same administration of radiopharmaceutical. The repeat planar and SPECT imaging when performed on a separate occasion using the same administration of radiopharmaceutical should be itemised as item 61462 and the original item and date of service should be indicated for reference purposes.

This item does not apply to bone scans, adrenal studies or gastro-oesophageal reflux studies, myocardial perfusion studies, colonic transit or CFS transport studies, where allowance for performance of the delayed study is incorporated into the baseline benefit fee.

Thyroid study (Item 61473)

Item 61473 incorporates the measurement of thyroid uptake on a gamma camera using a proven technique, where clinically indicated.

Positron Emission Tomography (PET); (Items 61523 to 61647).

In patients with Hodgkin and non- Hodgkin lymphoma (excluding indolent non- Hodgkin lymphoma), whole body FDG PET studies should not to be used for surveillance nor for assessment of patients with suspected (as opposed to confirmed) disease recurrence.

Whole body FDG PET studies should be used as an alternative rather than additional to conventional CT scanning.

Payment of Medicare rebates for PET services is limited to credentialled specialists or consultant physicians who meet eligibility requirements in the *Diagnostic Imaging Services Table Regulations*. PET services must be:

- 1. performed under the supervision of:
- a) specialist or consultant physician credentialled under the Joint Nuclear Medicine Specialist Credentialling Program for the Recognition of the Credentials of Nuclear Medicine Specialists for Positron Emission Tomography overseen by the Joint Nuclear Medicine Credentialling and Accreditation Committee of the RACP and RANZCR; or
- b) practitioner who is a Fellow of either RACP or RANZCR, and who, prior to 1 November 2011, reported 400 or more studies forming part of PET services for which a Medicare benefit was payable, and who holds a current license from the relevant State radiation licensing body to prescribe and administer the intended PET radiopharmaceuticals to humans;
 - 2. provided in a comprehensive facility that can provide a full range of diagnostic imaging services (including PET, CT, X-Ray and diagnostic ultrasound) and cancer treatment services (including chemotherapy, radiation oncology and surgical oncology) at the one site;
 - provided using equipment that meets the Requirements for PET Accreditation (Instrumentation & Radiation Safety) 3nd Edition (2017) issued by the Australian and New Zealand Society of Nuclear Medicine Inc;
 - 4. only provided following referral from a recognised specialist or consultant physician.

All PET providers must complete a specific PET provider Statutory Declaration prior to being eligible to claim Medicare rebates. Statutory declarations can be obtained directly from the Department of Human Services.

IN.0.14 Management of bulk-billed services

Additional bulk billing payment for diagnostic imaging services (item 64990 and 64991)

Item 64990 operates in the same way as item 10990 and item 64991 operates in the same way as item 10991, apart from the following differences:

- · Item 64990 and 64991 can only be used in conjunction with items in the Diagnostic Imaging Services Table of the MBS;
- · Item 64990 and 64991 applies to diagnostic imaging services self determined by general practitioners and specialists with dual qualifications acting in their capacity as general practitioners;
- · Specialists and consultant physicians who provide diagnostic imaging services are not able to claim item 64990 or 64991 unless, for the purposes of the *Health Insurance Act 1973*, the medical practitioner is also a general practitioner and the service provided by the medical practitioner has not been referred to that practitioner by another medical practitioner or person with referring rights.

IN.0.15 Group I1 - Ultrasound

Professional supervision for ultrasound services - R-type eligible services

Ultrasound services (items 55028 to 55854) marked with the symbol (*R*) with the exception of items 55600 and 55603 are <u>not eligible</u> for a Medicare rebate unless the diagnostic imaging procedure is performed under the professional supervision of a:

- (a) specialist or a consultant physician in the practice of his or her specialty who is available to monitor and influence the conduct and diagnostic quality of the examination, and if necessary to personally attend the patient; or
- (b) practitioner who is not a specialist or consultant physician who meets the requirements of A or B hereunder, and who is available to monitor and influence the conduct and diagnostic quality of the examination and, if necessary, to personally attend the patient.
- A. Between 1 September 1997 and 31 August 1999, at least 50 services were rendered by or on behalf of the practitioner at the location where the service was rendered and the rendering of those services entitled the payment of Medicare benefits.
- B. Between 1 September 1997 and 31 August 1999, at least 50 services were rendered by or on behalf of the practitioner in nursing homes or patients' residences and the rendering of those services entitled payment of Medicare benefits.

If paragraph (a) or (b) cannot be complied with, ultrasound services are eligible for a Medicare rebate:

- (i) in an emergency; or
- (ii) in a location that is not less than 30 kilometres by the most direct road route from another practice where services that comply with paragraph (a) or (b) are available.

Note: Practitioners do not have to apply for a remote area exemption in these circumstances.

Sonographer accreditation

Sonographers performing medical ultrasound examinations (either R or NR type items) on behalf of a medical practitioner must be suitably qualified, involved in a relevant and appropriate Continuing Professional Development program and be Registered on the Register of Accredited Sonographers held by the Department of Human Services.

Eligibility for registration

To be eligible for registration on the Register of Accredited Sonographers held by the Department of Human Services, the person must be accredited with the Australian Sonographer Accreditation Registry. For accreditation with the Australian Sonographer Accreditation Registry the person must:

- hold an accredited postgraduate qualification in medical ultrasound; or
- be studying ultrasound.

For further information, please contact the Department of Human Services, Provider Liaison Section, on 132150 for the cost of a local call or the Australian Sonographer Accreditation Registry through its website at www.asar.com.au.

Report requirements

The sonographer's initial and surname is to be written on the report. The name of the sonographer is not required to be included on the copy of the report given to the patient. For the purpose of this rule, the "name" means the sonographer's initial and surname.

Benefits payable

As a rule, benefit is payable once only for ultrasonic examination at the one attendance, irrespective of the areas involved.

Except as indicated in the succeeding paragraphs, *attendance* means that there is a clear separation between one service and the next. For example, where there is a short time between one ultrasound and the next, benefits will be payable for one service only. As a guide, the Department of Human Services will look to a separation of three hours between services and this must be stated on accounts issued for more than one service on the one day.

Where more than one ultrasound service is rendered on the one occasion and the service relates to a non-contiguous body area, and they are "clinically relevant", (ie. the service is generally accepted in the medical profession as being necessary for the appropriate treatment or management of the patient to whom it is rendered), benefits greater than the single rate may be payable. Accounts should be marked "non-contiguous body areas".

Benefits for two contiguous areas may be payable where it is generally accepted that there are different preparation requirements for the patient and a clear difference in set-up time and scanning. Accounts should be endorsed "contiguous body area with different set-up requirements".

Subgroup 1 - General Ultrasound

Post-void residual items 55084 and 55085

When a post-void residual is the only service clinically indicated and/or rendered, it is inappropriate to report a pelvic, urinary or abdominal ultrasound, instead of or in addition to this service (55084 or 55085). Similarly, if a complete pelvic, urinary or abdominal ultrasound is billed, it is inappropriate to bill separately for a post-void residual determination, since payment of this has already been included in the payment for the complete scans.

The report must contain an entry denoting the post-void residual amount and/or bladder capacity as calculated/estimated from the ultrasound device. In addition, the medical record must contain documentation of the indication for the service and the number of times performed.

Subgroup 2 - Cardiac ultrasound

Transoesophageal echocardiography - Item 55135 and consequential amendment to Item 55130

The Medical Services Advisory Committee (MSAC) has reviewed intra-operative transoesophageal echocardiography and recommended that public funding for this procedure be supported on an interim basis and be restricted to assessment of cardiac valve competence following valve replacement or repair. Item 55135 has been developed for these indications in consultation with the Australian Society of Anaesthetists, the Australian Medical Association and the Cardiac Society of Australia and New Zealand. Indications other than those recommended by MSAC will continue to be funded under item 55130. Further research will be undertaken to assist MSAC in its future evaluation of the use of intra-operative transoesophageal echocardiography.

Subgroup 3 - Vascular ultrasound

Benefits payable

Medicare benefits are only payable for:

a maximum of two vascular ultrasound studies in a seven-day period. A vascular ultrasound study may include one or more items. Additionally where a patient is referred for a bilateral study of both arms or both legs (eg both arms for item 55238), the account should indicate 'bilateral' or 'left' and 'right' to enable benefit to be paid.

clinically relevant services, that is, the service is generally accepted in the medical profession as being necessary for the appropriate treatment or management of the patient to whom it is rendered. Any decision to have a patient return on a different day to complete a multi-area diagnostic imaging service should only be made on the basis of clinical necessity.

Multiple Vascular Ultrasound Services - refer to DIJ

Separation of services on the one day/contiguous and non-contiguous body areas

These rules do not apply to the vascular ultrasound items and therefore will not impact on the MVUSSR.

Examination of peripheral vessels

Vascular ultrasound services can be claimed in conjunction with item 11612.

Subgroup 4: Urological ultrasound

Prostrate ultrasound (Items 55600 to 55604)

Benefits for these items are payable where the service is rendered in the following circumstances:

- a digital rectal examination of the prostate was personally performed by the medical practitioner who also personally rendered the ultrasound service; and
- the transducer probe or probes used can obtain both axial and sagittal scans in 2 planes at right angles; and
- the patient was assessed prior to the service by a medical practitioner recognised in one or more of the specialties specified, not more than 60 days prior to the ultrasound service.

Items 55600 and 55601 cover the situation where the service was rendered by a medical practitioner who **did not** assess the patient, whereas items 55603 and 55604 cover the situation where the service was rendered by a medical practitioner who **did** assess the patient.

Subgroup 5: Obstetric and Gynaecological ultrasound

NR Services

Medicare benefits are not payable for more than three NR-type ultrasound services in Subgroup 5 of Group I1 (ultrasound) that are performed on the same patient in any one pregnancy.

Clinical indications

For items where clinical indications are listed (items 55700, 55704, 55707, 55718, 55759 and 55768), or where a clinical indication is required (items 55712, 55721, 55764 and 55772) for performance of subsequent scans the referral must identify the relevant clinical indication for the service.

It should be noted that a patient must have previously had either a 55706 or 55709 ultrasound in the same pregnancy to be eligible to claim for either a 55712 or 55715 obstetric service. To be eligible to claim for either a 55721 or 55725 obstetric service, a patient must have previously had either a 55718 or 55723 ultrasound in the same pregnancy.

If the service is self-determined (items 55703, 55705, 55708, 55715, 55723, 55725, 55762, 55766, 55770 and 55774), the clinical condition or indication must be recorded in the medical practitioner's clinical notes.

Dating of pregnancy

When dating a pregnancy for the purpose of items 55700 to 55774, a patient is:

- a) "less than 12 weeks of gestation" means up to 11 weeks and 6 days of pregnancy;
- b) "12 to 16 weeks of gestation" means from 12 weeks 0 days of pregnancy up to 16 weeks plus 6 days of pregnancy (inclusive);

- c) "17 to 22 weeks of gestation" means from 17 weeks 0 days of pregnancy up to 22 weeks plus 6 days of pregnancy (inclusive); or
- d) "after 22 weeks of gestation" means from 23 weeks 0 days of pregnancy onwards
- e) "after 24 weeks of gestation" means from 25 weeks 0 days of pregnancy onwards.

Nuchal Translucency Testing

Where a nuchal translucency measurement is performed when the pregnancy is dated by a crown rump length of 45-84mm in conjunction with items 55700 (R) or 55703 (NR) or 55704 (R) or 55705 (NR), then items 55707 (R) or 55708 (NR) should be claimed. If nuchal translucency measurement for risk of foetal abnormality is performed in conjunction with any additional condition in items 55700, 55703, 55704 or 55705, only one fee is payable.

It should be noted that the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) provides a credentialling program for providers of nuchal translucency scans. It is anticipated that use of items 55707 and 55708 will be restricted to credentialed medical practitioners and sonographers in the future.

Multiple pregnancies

Obstetric ultrasound items 55759 to 55774 cover scanning of a patient who is experiencing a multiple pregnancy. The items incorporate a fee adjustment in recognition of the added complexity and costs associated with scanning multiple pregnancies. Based on the recommendations of the profession, the items apply only to patients where a multiple pregnancy has been confirmed by ultrasound. The items include identical restrictions and provisions as the second and third trimester items (55706-55725), and include items for referred and non-referred services.

Obstetric ultrasound and non-metropolitan providers (Items 55712, 55721, 55764 and 55772)

Where a practitioner has obstetric privileges at a non-metropolitan hospital and refers for items 55712, 55721 and 55764 and 55772, the practitioner must confirm his/her eligibility by stating 'non-metropolitan obstetric privileges' on the referral form.

In relation to items 55712, 55721, 55764 and 55772, non-metropolitan area includes any location outside of the Sydney, Melbourne, Brisbane, Adelaide, Perth, Greater Hobart, Darwin or Canberra major statistical divisions, as defined in the Australian Standard Geographical Classification 2010 published by the Australian Bureau of Statistics (publication number 1216.0 of 2010).

Subgroup 6: Musculoskeletal (MSK) ultrasound

Personal attendance

Medicare Benefits are only payable for a musculoskeletal ultrasound service (items 55800 to 55854) if the medical practitioner responsible for the conduct and report of the examination personally attends during the performance of the scan and personally examines the patient. Services that are performed because of medical necessity in a remote location are exempt from this requirement - see DID for definition of remote area. Note: Practitioners do not have to apply for a remote area exemption in these circumstances.

Multiple Musculoskeletal Ultrasound Scans - items 55800 to 55846

Generally Medicare benefits are payable for more than one musculoskeletal ultrasound scan performed on the same day, however the scans are subject to Rule A of the general diagnostic imaging multiple services rules.

It is not permitted to split a bilateral scan. Where bilateral ultrasound scans are performed (or more than one area is scanned under items 55844 or 55646) the relevant item should be itemised once only on accounts and receipts or Medicare bulk billing forms. For example if both shoulders are scanned, Item 55808 (or 55810 as the case may be) should be claimed once only. This is because the item descriptor for these items covers one or both sides, or one or more areas. A patient should not be asked to make a second appointment in order to attract a benefit for multiple scans.

Shoulder and knee (Items 55808 and 55810 and 55828 and 55830)

Benefits for shoulder ultrasound items 55808 and 55810 are only payable when referral is based on the clinical indicators outlined in the item descriptions. Benefits are <u>not</u> payable when referred for non-specific shoulder pain alone.

Benefits for knee ultrasound items 55828 and 55830 are only payable when referral is based on the clinical indicators outlined in the item descriptions. Benefits are <u>not</u> payable when referred for non-specific knee pain alone or other knee conditions including:

- meniscal and cruciate ligament tears; and
- assessment of chondral surfaces.

IN.0.16 Restriction on item 55054

The Health Insurance (General Medical Services Table) Regulations now require that an item in Group T10 (Relative Value Guide) cannot be claimed in association with item 55054 (ultrasound when used in conjunction with procedures). This came into effect on 1 November 2012.

The use of ultrasound guidance provided in association with anaesthetic procedures is currently being assessed by the Medical Services Advisory Committee (MSAC) for safety, effectiveness and cost-effectiveness (MSAC Application 1183 - Ultrasound imaging in the practice of anaesthesia).

Medicare rebates will continue to be available for the procedures alone and whether individual anaesthetists choose to use ultrasound to assist with those procedures is a matter of clinical judgement for those providers.

IN.0.17 Group I3 - Diagnostic Radiology Examination and report

As for all diagnostic imaging services, the benefits allocated to each item from 57506 to 60509 inclusive cover the total service, ie. the image, reading and report. Separate benefits are not payable for individual components of the service, eg preliminary reading. Benefits are not separately payable for associated plain films involved with these items.

Exposure of more than one film

Where the radiographic examination of a specific area involves the exposure of more than one film, benefits are payable once only, except where special provision is made in the description of the item for the inclusion of all films taken for the purpose of the examination. This means that if an x-ray of the foot is requested, regardless of the number of exposures from different angles, the completed service comprises x-ray of the foot by one or more exposures and the report. The exception to this would be the plain x-ray of the spine items (58100 to 58115) where the item number differs dependent upon the regions of the spine that are examined at the same occasion, ie. 58112 applies where two regions are examined.

Comparison X-rays

Where it is necessary for one or more films of the opposite limb to be taken for comparison purposes, benefits are payable for radiographic examination and reporting of one limb only. Comparison views are considered to be part of the examination requested.

Subgroup 4: Radiographic examination of the spine

Multiple regions

Multiple region items require that the regions of the spine to be studied must be specified on any account issued or patient assignment form completed.

Item 58112 - spine, two regions

Where item 58112 is rendered (spine, two regions), the item numbers for the regions of the spine being studied must be specified (ie. from items 58100, 58103, 58106 and 58109).

Example: for a radiographic examination of the spine where the cervical and thoracic regions are to be studied, item numbers 58100 and 58103 must be specified on any account issued or patient assignment forms completed.

Item 58115 - spine, three region

Where item 58115 is rendered (spine, three regions), the item numbers for the regions of the spine being studied must be specified (items 58100, 58103, 58106 and 58109).

Example: for a radiographic examination of the spine where the cervical, the thoracic and the lumbosacral regions are to be studied, item numbers 58100, 58103 and 58106 must be specified on any accounts issued or patient assignment forms completed.

Item 58115 & 58108 - spine, three and four region - medical practitioner

Three and four region radiographic examinations items 58115 and 58108 only apply when requested by a medical practitioner.

Items 58120, 58121, 58126 and 58127 - spine, three and four region - non-medical practitioner

Items 58120, 58121, 58126 and 58127 apply to physiotherapists and osteopaths who request a three or four region x-ray and only allow a benefit for one of the items, per patient, per calendar year.

Hand and wrist combination X-ray

An examination of the hand and the wrist on the same side should be claimed as item 57512 (NR) or 57515 (R). If items 57506 (NR) or 57509 (R) are claimed for multiple non-adjacent areas on the same side, or areas on different sides, the account should include annotation on this eg L and R hand, hand and humerus.

Images produced using Dual Energy X-ray Absorptiometry (DEXA) equipment

X-ray items of the spine 58100 to 58115 and hip 57712 and 57715 cannot be claimed when images are produced using Dual Energy X-ray Absorptiometry (DEXA) equipment.

Subgroup 8: Radiographic examination of alimentary tract and biliary system

Plain abdominal film (Items 58900/58903)

Benefits are not attracted for Items 58900/58903 in association with barium meal examinations or cholecystograms whether provided on the same day or previous day. Preliminary plain films are covered in each study.

Subgroup 10: Radiographic examination of the breasts

Request requirements (items 59300 and 59303)

Benefits under items 59300 and 59303 are attracted only where the patient has been referred in specific circumstances as indicated in the description of the items. To facilitate these provisions, the requesting medical practitioner is required to include in the request the clinical indication for the procedure. The requesting practitioner must personally sign the request.

The reference to "with or without thermography" has been removed from the item descriptor for items 59300 and 59303 with effect from 1 November 2003. The Radiology Management Committee (RMC) at its meeting of 12 August 2003, agreed that there is no current scientific evidence to support the use of thermography in the early detection of breast cancer and in the reduction of mortality.

Professional supervision

Mammography services (items 59300 to 59318) are not eligible for a Medicare rebate unless the diagnostic imaging procedure is performed under the professional supervision of a:

- (a) specialist in the specialty of diagnostic radiology who is available to monitor and influence the conduct and diagnostic quality of the examination, and, if necessary, to personally attend on the patient; or
- (b) if paragraph (a) cannot be complied with:
- (i) in an emergency; or
- (ii) because of medical necessity in a remote location.

Note: Practitioners do not have to apply for a remote area exemption in these circumstances.

Subgroup 12: Radiographic examination with opaque or contrast media

Myelogram (Item 59724)

Benefits are not payable where a myelogram is rendered in association with a CT myelogram (Item 56219 - see DIL.9.1). Where it is necessary to render a CT and a myelogram, CT Items 56220, 56221 and 56223 would apply.

Subgroup 13: Angiography

Angiography services - meaning of (K) and (NK)

A reduced Schedule fees applies to cardiac angiography services provided on equipment that is 10 years old or older. This equipment must have been first installed in Australia ten or more years ago, or in the case of imported pre-used equipment, must have been first manufactured ten or more years ago.

A range of items cover services provided on older equipment. These items are 59971, 59972, 59973 and 59974, are identified by the addition of the letters '(NK)' at the end of the item and should be used where services are performed on equipment ten years old or older.

Items 59903, 59912, 59925 and 59970 have the letter '(K)' included at the end of the item. These items should be used where services are performed on equipment first installed in Australia less than ten years ago. In the case of imported pre-used equipment, the services must have been performed on a date which is less than ten years from the first date of manufacture of the equipment.

Digital subtraction angiography (DSA) (Items 60000-60078)

Benefits are payable only where these services are rendered in an angiography suite (a room that contains only equipment designed for angiography that is able to perform digital subtraction or rapid-sequence film angiography). Benefits are not payable when these services are rendered using mobile DSA imaging equipment as these services are covered by item 59970.

Each item includes all preparation and contrast injections other than for selective catheterisation. For Digital Subtraction Angiography (DSA), benefits are payable for a maximum of 1 DSA item (from Items 60000 to 60069). For selective DSA - 1 DSA item (from Items 60000 to 60069) and 1 item covering selective catheterisation (from 60072, 60075 or 60078).

If a DSA examination covers more than one of the specified regions/combinations, then the region/combination forming the major part of the examination should be selected, with itemisation to cover the total number of film runs obtained. A run is the injection of contrast, data acquisition, and the generation of a hard copy record.

Subgroup 16: Preparation for radiological procedure

Preparation items (Items 60918 and 60927)

Items 60918 and 60927 apply only to the preparation of a patient for a radiological procedure for a service to which any of items 59903 to 59974 apply. A report is not required for these services.

IN.0.18 Group I5 - Magnetic Resonance Imaging Itemisation

MRI items in Group I5 are divided into subgroups defined according to the area of the body to be scanned, (ie head, spine, musculoskeletal system, cardiovascular system or body) and the number of occasions in a defined period in which Medicare benefits may be claimed by a patient. Subgroups are divided into individual items, with each item being for a specific clinical indication.

Eligible services

Items in Subgroups 1 to 21 of Group I5 (other than items 63541 to 63544) apply to a MRI or MRA service performed:

- a. on request by a recognised specialist or consultant physician, where the request made in writing identifies the clinical indication for the service;
- b. under the professional supervision of an eligible provider; and
- c. with eligible equipment.

Items 63395 to 63398 and the items in Subgroups 19, 20 and 21 (other than items 63455 and 63461) of Group I5 apply to a MRI service performed:

- a. on request by a recognised specialist or consultant physician, where the request made in writing identifies the clinical indication for the service;
- b. under the professional supervision of an eligible provider; and
- c. with partial eligible equipment.

Items in Subgroup 22 of Group I5 apply to a MRI or MRA service performed:

- a. on request by a medical practitioner, where the request made in writing identifies the clinical indication for the service:
- b. under the professional supervision of an eligible provider; and
- c. with eligible equipment or partial eligible equipment.

Items in Subgroups 33 and 34 of Group I5 apply to a MRI service performed

- a. on request by a medical practitioner other than a specialist or consultant physician, where the request made in writing identifies the clinical indication for the service;
- b. under the professional supervision of an eligible provider; and
- c. with eligible equipment or partial eligible equipment.

Prostate Multiparametric MRI items 63541 to 63544 apply to a service performed:

- a. at the request of a specialist in the speciality of urology, radiation oncology, or medical oncology; and
- b. in a permissible circumstance; and
- c. using:
 - (i) eligible equipment; or
 - (ii) partial eligible equipment.

Requests

A request must be in writing and identify the clinical indications for the service.

MRI services can only be requested by a recognised specialist medical practitioner or consultant physician for the purpose of the Health Insurance Act 1973. However, there are exceptions to this provision for a limited number of MRI:

- All dental specialists, prosthodontists, oral and maxillofacial surgeons, oral medicine specialists and oral pathology specialists may request item 63334 scan of musculoskeletal system for derangement of the temporomandibular joint (s); and
- Oral and maxillofacial surgeons and oral medicine and oral pathology specialists can also request item 63007 scan of the head for skull base or orbital tumour; and
- Items in subgroup 33 and 34 may only be requested by a medical practitioner other than a specialist or a consultant physician.

For cardiac MRI items 63395 to 63398 (scan for diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC)), the request must specify that ARVC is suspected on the basis of diagnostic criteria endorsed by the Cardiac Society of Australia and New Zealand (CSANZ), in force at the time the service is requested.

Permissible circumstances for performance of service

Group I5 items must be performed as follows:

- (a) both:
 - i. under the professional supervision of an eligible provider who is available to monitor and influence the conduct and diagnostic quality of the examination, including, if necessary, by personal attendance on the patient; and
 - ii. reported by an eligible provider; or
- (b) if paragraph (a) is not complied with:
 - i. in an emergency; or
 - ii. because of medical necessity, in a remote location (refer to DID).

Note: Practitioners do not have to apply for a remote area exemption in these circumstances.

Eligible providers

For items in Group I5 (excluding cardiac MRI items 63395 to 63398), an eligible provider is a specialist in diagnostic radiology who satisfies the Chief Executive Medicare (Department of Human Services) that he or she is a participant of the Royal Australian and New Zealand College of Radiologists' (RANZCR) Quality and Accreditation Program.

For cardiac MRI items 63395 to 63398, an eligible provider is a specialist in diagnostic radiology or a consultant physician, who is recognised by the Conjoint Committee for Certification in Cardiac MRI. The conjoint committee is comprised of specialists from the Royal Australian and New Zealand College of Radiologists (RANZCR) and the Cardiac Society of Australia and New Zealand (CSANZ).

Eligible Provider declaration

The specialist must give the Department of Human Services a statutory declaration:

- a. stating that he or she is enrolled in the RANZCR Quality and Accreditation Program (except for providers only providing cardiac MRI (items 63395 to 63398));
- b. specifying the location of the MRI equipment;
- c. specifying the kinds of diagnostic imaging equipment offered at the location;

- d. stating the date of installation of the equipment (and the time of installation if this occurred on 12 May 1998); and
- e. if the equipment had not been installed before 7.30pm on 12 May 1998 (Eastern Standard Time), the specialist must also give the Department of Human Services a copy of the contract for the purchase or lease of the equipment.

In addition the Department of Human Services may request further supporting documentation or information. Specialists or consultant physicians are advised to contact the Provider Liaison Section, the Department of Human Services on 132 150 prior to lodging a declaration.

Eligible equipment is equipment which is:

- a. is located at premises of a comprehensive practice; and
- b. is made available to the practice by a person:
 - i. who is subject to a deed with the Commonwealth that relates to the equipment; and
 - ii. for whom the deed has not been terminated; and
- c. is not identified as partial eligible equipment in the deed

Partial eligible equipment is equipment which is:

Equipment that:

- a. is located at premises of a comprehensive practice; and
- b. is made available to the practice by a person:
 - i. who is subject to a deed with the Commonwealth that relates to the equipment; and
 - ii. for whom the deed has not been terminated; and
- c. is identified as partial eligible equipment in the deed

The location of Medicare-eligible MRI machines is available at the Department of Health's website at http://www.health.gov.au

Number of eligible services

Services in subgroups 1, 4, 6, 8, 11 and 18 have no frequency restriction.

For other MRI subgroups frequency restrictions on services are as follows:

MRI or MRA items	Limitation period	Maximum number of services
63040 to 63085	12 months	3
63101 and 63104	12 months	3
63125 to 63136	12 months	3
63161 to 63194	12 months	3
63219 to 63265	12 months	3
63271 to 63285	12 months	3
63322 to 63348	12 months	3
63361 and 63364	12 months	2
63385 to 63394	12 months	2
63395 and 63396	12 months	1
63397 and 63398	36 months	1
63401 to 63408	12 months	3
63416 and 63419	12 months	1
63425 to 63433	12 months	2
63455 to 63467	12 months	1

63547 and 63548	patient's lifetime	1
63482 and 63486	12 months	3
63507 to 63523 and 63551 to 63561	12 months	3

Items 63470 or 63473 in subgroup 20 may be claimed only once in a patient's lifetime.

Items in subgroup 22 (modifying items) may only be ordered in conjunction with an eligible MRI/MRA service.

Items 63501 and 63502 in subgroup 32 may only be claimed once in any 12-month period, and items 63504 and 63505 have no restrictions.

Example: Item 63271 in subgroup 10 can be claimed by a patient on three occasions in any 12 month period. If the patient had claimed Medicare benefits for the following:

Item	Date of Service
63271	10/12/04
63271	18/4/05
63271	16/10/05
63271	11/12/05

The following table provides examples of further dates of service would, and would not, be eligible:

Date of service	Claimable?	Why?
12/3/05	No	Between 10/12/04 and 9/12/05, the patient would have had 4 x 63271 in 12 months - 10/12/04, 12/3/05, 18/4/05 and 16/10/05
4/3/06	No	Between 5/3/05 and 4/3/06, the patient would have had 4 x 63271 in 12 months - 18/4/05, 16/10/05, 11/12/05 and 4/3/06
20/4/06	Yes	Between 21/4/05 and 20/4/06, the patient would have had 3x 63271 in 12 months - 16/10/05, 11/12/05 and 20/4/06

The frequency restrictions are therefore considered to be rolling restrictions and not based on calendar or financial years.

In addition, restrictions on the number of services of the kind described in subgroup 12 apply to specific anatomical sites. Where an item description applies to more than one anatomical site the restriction on the number of services applies to each site.

Item 63328, MRI scan for derangement of the knee or its supporting structures, applies to two specific anatomical sites, ie, right knee and left knee. Each anatomical site may be scanned up to 3 times in any 12-month period.

Prostate Multiparametric MRI items 63541 and 63542 are applicable not more than once in a 12 month period.

Prostate Multiparametric MRI items 63543 and 63544 may be claimed:

- a. at the time of diagnosis of prostate cancer; and
- b. 12 months following diagnosis; and
- c. every third year thereafter; or
- d. at any time if there is clinical concern from the specialist requesting the service.

Clinical concern means a clinical decision that the prostate cancer has progressed, and includes prostate specific antigen progression.

Items 63543 and 63544 are not applicable for the purposes of treatment planning or for monitoring after treatment of prostate cancer.

IN.0.19 Bulk Billing Incentive

To provide an incentive to bulk-bill, for out of hospital services that are bulk billed the schedule fee is reduced by 5% and rebates paid at 100% of this revised fee (except for item 61369, and all items in Group I5 - Magnetic Resonance Imaging). For items in Group I5 - Magnetic Resonance Imaging, the bulk billing incentive for out of hospital services is 100% of the Schedule Fee listed in the table.

DIAGNOSTIC IMAGING SERVICES ITEMS

I1. ULTI	RASOUND 1. GENERAL
	Group I1. Ultrasound
	Subgroup 1. General
	HEAD, ultrasound scan of, where:
	(a) the patient is referred by a medical practitioner for ultrasonic examination not being a service associated with a
	service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the referring medical practitioner is not a member of a group of practitioners of which the providing practitioner
	is a member (R) (NK)
55005	(See para IN.0.19 of explanatory notes to this Category) Fee: \$54.55 Benefit: 75% = \$40.95 85% = \$46.40
	HEAD, ultrasound scan of, where the patient is not referred by a medical practitioner, not being a service associated with a service to which an item in Subgroups 2 or 3 of this Group applies (NR) (NK)
55007	(See para IN.0.19 of explanatory notes to this Category) Fee: \$18.95 Benefit: 75% = \$14.25 85% = \$16.15
	ORBITAL CONTENTS, ultrasound scan of, where:
	(a) the patient is referred by a medical practitioner for ultrasonic examination not being a service associated with a
	service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the referring medical practitioner is not a member of a group of practitioners of which the providing practitioner
	is a member (R) (NK)
55008	(See para IN.0.19 of explanatory notes to this Category) Fee: \$54.55 Benefit: 75% = \$40.95 85% = \$46.40
	ORBITAL CONTENTS, ultrasound scan of, where the patient is not referred by a medical practitioner, not being a service associated with a service to which an item in Subgroups 2 or 3 of this Group applies (NR) (NK)
55010	(See para IN.0.19 of explanatory notes to this Category) Fee: \$18.95 Benefit: 75% = \$14.25 85% = \$16.15
	NECK, 1 or more structures of, ultrasound scan of, where:
	(a) the patient is referred by a medical practitioner for ultrasonic examination not being a service associated with a
	service to which an item in Subgroups 2 or 3 of this Group applies; and
55011	(b) the referring medical practitioner is not a member of a group of practitioners of which the providing practitioner
55011	

I1. ULT	RASOUND 1. GENERAL
	is a member (R) (NK)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$54.55 Benefit: 75% = \$40.95 85% = \$46.40
	NECK, 1 or more structures of, ultrasound scan of, where the patient is not referred by a medical practitioner, not being a service associated with a service to which an item in Subgroups 2 or 3 of this Group applies (NR) (NK)
55013	(See para IN.0.19 of explanatory notes to this Category) Fee: \$18.95 Benefit: 75% = \$14.25 85% = \$16.15
	Abdomen, ultrasound scan of (including scan of urinary tract when performed), if:
	(a) the patient is referred by a medical practitioner or participating nurse practitioner; and
	(b) if the patient is referred by a medical practitioner-the medical practitioner is not a member of a group of practitioners of which the providing practitioner is a member; and
	(c) if the patient is referred by a participating nurse practitioner-the nurse practitioner does not have a business or financial arrangement with the providing practitioner; and
	(d) the service is not associated with a service to which an item in Subgroup 2 or 3 applies; and
	(e) the service is not solely a transrectal ultrasonic examination of the prostate gland, bladder base and urethra, or any of those organs; and
	(f) within 24 hours of the service, a service mentioned in item 55017, 55038, 55067 or 55065 is not performed on the same patient by the providing practitioner (R) (NK)
55014	(See para IN.0.19 of explanatory notes to this Category) Fee: \$55.65 Benefit: 75% = \$41.75 85% = \$47.35
	ABDOMEN, ultrasound scan of, including scan of urinary tract when undertaken but not being a service associated with the service to which an item in Subgroup 4,applies where the patient is not referred by a medical practitioner, not being a service associated with a service to which an item in Subgroups 2 or 3 of this Group applies (NR) (NK)
55016	(See para IN.0.19 of explanatory notes to this Category) Fee: \$18.95 Benefit: 75% = \$14.25 85% = \$16.15
	Urinary tract, ultrasound scan of, if:
	(a) the patient is referred by a medical practitioner; and
	(b) the medical practitioner is not a member of a group of practitioners of which the providing practitioner is a member; and
	(c) the service is not associated with a service to which an item in Subgroup 2 or 3 applies; and
	(d) the service is not solely a transrectal ultrasonic examination of the prostate gland, bladder base and urethra, or any of those organs; and
	(e) within 24 hours of the service, a service mentioned in item 55014, 55038, 55067 or 55065 is not performed on the same patient by the providing practitioner (R) (NK)
55017	(See para IN.0.19 of explanatory notes to this Category) Fee: \$54.55 Benefit: 75% = \$40.95 85% = \$46.40

I1. ULT	RASOUND 1. GENERAL
	URINARY TRACT, ultrasound scan of, but not being a service associated with the service to which an item in Subgroup 4,applies, where the patient is not referred by a medical practitioner, not being a service associated with a service to which an item in Subgroups 2 or 3 of this Group applies (NR) (NK)
55019	(See para IN.0.19 of explanatory notes to this Category) Fee: \$18.95 Benefit: 75% = \$14.25 85% = \$16.15
	SCROTUM, ultrasound scan of, where:
	(a) the patient is referred by a medical practitioner for ultrasonic examination not being a service associated with a
	service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the referring medical practitioner is not a member of a group of practitioners of which the providing practitioner
	is a member (R) (NK)
55023	(See para IN.0.19 of explanatory notes to this Category) Fee: \$54.75 Benefit: 75% = \$41.10 85% = \$46.55
	SCROTUM, ultrasound scan of, where the patient is not referred by a medical practitioner, not being a service associated with a service to which an item in Subgroups 2 or 3 of this Group applies (NR) (NK)
55025	Fee: \$18.95 Benefit: 75% = \$14.25 85% = \$16.15
	ULTRASONIC CROSS-SECTIONAL ECHOGRAPHY, in conjunction with a surgical procedure using interventional techniques, not being a service associated with a service to which any other item in this Group applies (R) (NK)
55026	(See para IN.0.19 of explanatory notes to this Category) Fee: \$54.55 Benefit: 75% = \$40.95 85% = \$46.40
	HEAD, ultrasound scan of, where:
	(a) the patient is referred by a medical practitioner for ultrasonic examination not being a service associated with a
	service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the referring medical practitioner is not a member of a group of practitioners of which the providing practitioner
	is a member (R)
55028	(See para IN.0.19 of explanatory notes to this Category) Fee: \$109.10 Benefit: 75% = \$81.85 85% = \$92.75
	HEAD, ultrasound scan of, where the patient is not referred by a medical practitioner, not being a service associated with a service to which an item in Subgroups 2 or 3 of this Group applies (NR)
55029	(See para IN.0.19 of explanatory notes to this Category) Fee: \$37.85 Benefit: 75% = \$28.40 85% = \$32.20
	ORBITAL CONTENTS, ultrasound scan of, where:
55020	(a) the patient is referred by a medical practitioner for ultrasonic examination not being a service associated with a
55030	

I1. ULT	RASOUND 1. GENERAL
	service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the referring medical practitioner is not a member of a group of practitioners of which the providing practitioner
	is a member (R)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$109.10 Benefit: 75% = \$81.85 85% = \$92.75
	ORBITAL CONTENTS, ultrasound scan of, where the patient is not referred by a medical practitioner, not being a service associated with a service to which an item in Subgroups 2 or 3 of this Group applies (NR)
55031	(See para IN.0.19 of explanatory notes to this Category) Fee: \$37.85 Benefit: 75% = \$28.40 85% = \$32.20
	NECK, 1 or more structures of, ultrasound scan of, where:
	(a) the patient is referred by a medical practitioner for ultrasonic examination not being a service associated with a
	service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the referring medical practitioner is not a member of a group of practitioners of which the providing practitioner
	is a member (R)
55032	(See para IN.0.19 of explanatory notes to this Category) Fee: \$109.10 Benefit: 75% = \$81.85 85% = \$92.75
	NECK, 1 or more structures of, ultrasound scan of, where the patient is not referred by a medical practitioner, not being a service associated with a service to which an item in Subgroups 2 or 3 of this Group applies (NR)
55033	(See para IN.0.19 of explanatory notes to this Category) Fee: \$37.85 Benefit: 75% = \$28.40 85% = \$32.20
	Abdomen, ultrasound scan of (including scan of urinary tract when performed), if:
	(a) the patient is referred by a medical practitioner or participating nurse practitioner for ultrasonic examination; and
	(b) if the patient is referred by a medical practitioner-the medical practitioner is not a member of a group of
	practitioners of which the providing practitioner is a member; and
	(c) if the patient is referred by a participating nurse practitioner-the nurse practitioner does not have a business or financial arrangement with the providing practitioner; and
	(d) the service is not associated with a service to which an item in Subgroup 2 or 3 applies; and
	(e) the service is not solely a transrectal ultrasonic examination of the prostate gland, bladder base and urethra, or any of those organs; and
55036	(f) within 24 hours of the service, a service mentioned in item 55017, 55038, 55067 or 55065 is not

I1. ULT	RASOUND 1. GENERAL
	performed on the same patient by the providing practitioner (R) (K)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$111.30 Benefit: 75% = \$83.50 85% = \$94.65
	ABDOMEN, ultrasound scan of, including scan of urinary tract when undertaken but not being a service associated with the service described in item 55600 or item 55603, where the patient is not referred by a medical practitioner, not being a service associated with a service to which an item in Subgroups 2 or 3 of this Group applies (NR)
55037	(See para IN.0.19 of explanatory notes to this Category) Fee: \$37.85 Benefit: 75% = \$28.40 85% = \$32.20
	Urinary tract, ultrasound scan of, if:
	(a) the patient is referred by a medical practitioner for ultrasonic examination; and
	(b) the medical practitioner is not a member of a group of practitioners of which the providing practitioner is a member; and
	(c) the service is not associated with a service to which an item in Subgroup 2 or 3 applies; and
	(d) the service is not solely a transrectal ultrasonic examination of the prostate gland, bladder base and urethra, or any of those organs; and
	(e) within 24 hours of the service, a service mentioned in item 55017, 55036, 55067 or 55065 is not performed on the same patient by the providing practitioner (R) (K)
55038	(See para IN.0.19 of explanatory notes to this Category) Fee: \$109.10 Benefit: 75% = \$81.85 85% = \$92.75
	URINARY TRACT, ultrasound scan of, but not being a service associated with the service described in item 55600 or item 55603, where the patient is not referred by a medical practitioner, not being a service associated with a service to which an item in Subgroups 2 or 3 of this Group applies (NR)
55039	(See para IN.0.19 of explanatory notes to this Category) Fee: \$37.85 Benefit: 75% = \$28.40 85% = \$32.20
	SCROTUM, ultrasound scan of, where:
	(a) the patient is referred by a medical practitioner for ultrasonic examination not being a service associated with a
	service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the referring medical practitioner is not a member of a group of practitioners of which the providing practitioner
	is a member (R)
55048	(See para IN.0.19 of explanatory notes to this Category) Fee: \$109.50 Benefit: 75% = \$82.15 85% = \$93.10
	SCROTUM, ultrasound scan of, where the patient is not referred by a medical practitioner, not being a service associated with a service to which an item in Subgroups 2 or 3 of this Group applies (NR)
55049	(See para IN.0.19 of explanatory notes to this Category) Fee: \$37.85 Benefit: 75% = \$28.40 85% = \$32.20
55054	ULTRASONIC CROSS-SECTIONAL ECHOGRAPHY, in conjunction with a surgical procedure using

I1. ULTI	RASOUND 1. GENERAL
	interventional techniques, not being a service associated with a service to which any other item in this Group applies (R)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$109.10 Benefit: 75% = \$81.85 85% = \$92.75 Extended Medicare Safety Net Cap: \$87.30
	BREAST, one, ultrasound scan of, where:
	(a) the patient is referred by a medical practitioner; and
	(b) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and
	(c) the referring medical practitioner is not a member of a group of practitioners of which the providing practitioner is a
	member (R) (NK)
55059	(See para IN.0.19 of explanatory notes to this Category) Fee: \$49.15 Benefit: 75% = \$36.90 85% = \$41.80
	BREAST, one, ultrasound scan of, where:
	(a) the patient is not referred by a medical practitioner; and
	(b) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies (NR) (NK)
55060	(See para IN.0.19 of explanatory notes to this Category) Fee: \$17.05 Benefit: 75% = \$12.80 85% = \$14.50
	BREASTS, both, ultrasound scan of, where:
	(a) the patient is referred by a medical practitioner; and
	(b) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and
	(c) the referring medical practitioner is not a member of a group of practitioners of which the providing practitioner is a member (R) (NK)
55061	(See para IN.0.19 of explanatory notes to this Category) Fee: \$54.55 Benefit: 75% = \$40.95 85% = \$46.40
	BREASTS, both, ultrasound scan of, where:
	(a) the patient is not referred by a medical practitioner; and
	(b) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies (NR) (NK)
55062	(See para IN.0.19 of explanatory notes to this Category) Fee: \$18.95 Benefit: 75% = \$14.25 85% = \$16.15
	Urinary bladder, ultrasound scan of, by any or all approaches, if:
	(a) the patient is referred by a medical practitioner for ultrasonic examination; and
55063	(b) the medical practitioner is not a member of a group of practitioners of which the providing

I1. ULTF	RASOUND	1. GENERAL
	practitioner is a member; and	
	(c) the service is not associated with a service to which an item in Subgroup 2 or 3 ap	plies; and
	(d) within 24 hours of the service, a service mentioned in item 11917, 55014, 55017, 55600, 55601, 55603, 55604, 55067 or 55065 is not performed on the same pati providing practitioner (R) (NK)	
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$49.15 Benefit: 75% = \$36.90 85% = \$41.80	
	Urinary bladder, ultrasound scan of, by any or all approaches, if:	
	(a) the patient is not referred by a medical practitioner; and	
	(b) the service is not associated with a service to which an item in Subgroup 2 or 3 ap	plies; and
	(c) within 24 hours of the service, a service mentioned in item 11917, 55016, 55019, 55600, 55601, 55603, 55604, 55068 or 55069 is not performed on the same pati providing practitioner (NR) (NK)	
55064	(See para IN.0.19 of explanatory notes to this Category) Fee: \$17.05 Benefit: 75% = \$12.80 85% = \$14.50	
	PELVIS, ultrasound scan of, by any or all approaches, where:	
	(a) the patient is referred by a medical practitioner; and	
	(b) the service is not associated with a service to which an item in Subgroup 2, or 3, a	applies; and
	(c) the referring practitioner is not a member of a group of practitioners of which the practitioner is a member; and	e providing
	(d) the service is not solely a transrectal ultrasonic examination of the prostate gland, urethra, or any of those organs; and	bladder base and
	(e) the service is not performed with item 55014, 55017, 55036 or 55038 on the same hours (R)(K)	patient within 24
55065	(See para IN.0.19 of explanatory notes to this Category) Fee: \$98.25 Benefit: 75% = \$73.70 85% = \$83.55	
	PELVIS, ultrasound scan of, by any or all approaches, where:	
	a) the patient is referred by a medical practitioner; and	
	b) the medical practitioner is not a member of a group of practitioners of which the properties of a member; and	roviding
	c) the service is not associated with a service to which an item in Subgroup 2 or 3 app	olies; and
	d) the service is not solely a transrectal ultrasonic examination of the prostate gland, lurethra, or any of those organs; and	bladder base and
	e) within 24 hours of the service, a service mentioned in item 55014, 55017, 55036 o performed on the same patient by the providing practitioner (R) (NK)	r 55038 is not
55067	(See para IN.0.19 of explanatory notes to this Category)	

I1. ULT	RASOUND 1. GENERAL
	Fee: \$50.25 Benefit: 75% = \$37.70 85% = \$42.75
	PELVIS, ultrasound scan of, by any or all approaches, where:
	(a) the patient is not referred by a medical practitioner; and
	(b) the service is not associated with a service to which an item in Subgroup 2 or 3 of this Group applies; and
	(c) the service is not solely a transrectal ultrasonic examination of the prostate gland, bladder base and urethra, or any of those organs (NR)(K)
55068	(See para IN.0.19 of explanatory notes to this Category) Fee: \$35.00 Benefit: 75% = \$26.25 85% = \$29.75
	PELVIS, ultrasound scan of, by any or all approaches, where:
	(a) the patient is not referred by a medical practitioner; and
	(b) the service is not associated with a service to which an item in Subgroup 2 or 3 of this Group applies; and
	(c) the service is not solely a transrectal ultrasonic examination of the prostate gland, bladder base and urethra, or any of those organs (NR) (NK)
55069	(See para IN.0.19 of explanatory notes to this Category) Fee: \$17.85 Benefit: 75% = \$13.40 85% = \$15.20
	BREAST, one, ultrasound scan of, where:
	(a) the patient is referred by a referring practitioner; and
	(b) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and
	(c) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a
	member (R)
55070	(See para IN.0.19 of explanatory notes to this Category) Fee: \$98.25 Benefit: 75% = \$73.70 85% = \$83.55
	BREAST, one, ultrasound scan of, where:
	(a) the patient is not referred by a medical practitioner; and
	(b) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies (NR)
55073	(See para IN.0.19 of explanatory notes to this Category) Fee: \$34.05 Benefit: 75% = \$25.55 85% = \$28.95
	BREASTS, both, ultrasound scan of, where:
	(a) the patient is referred by a referring practitioner; and
	(b) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and
55076	

I1. ULTI	RASOUND 1. GENERAL
	(c) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a
	member (R)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$109.10 Benefit: 75% = \$81.85 85% = \$92.75
	BREASTS, both, ultrasound scan of, where:
	(a) the patient is not referred by a medical practitioner; and
	(b) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies (NR)
55079	(See para IN.0.19 of explanatory notes to this Category) Fee: \$37.85 Benefit: 75% = \$28.40 85% = \$32.20
	Urinary bladder, ultrasound scan of, by any or all approaches, if:
	(a) the patient is referred by a medical practitioner; and
	(b) the medical practitioner is not a member of a group of practitioners of which the providing practitioner is a member; and
	(c) the service is not associated with a service to which an item in Subgroup 2 or 3 applies; and
	(d) within 24 hours of the service, a service mentioned in item 11917, 55014, 55017, 55036, 55038, 55600, 55601, 55603, 55604, 55067 or 55065 is not performed on the same patient by the providing practitioner (R) (K)
55084	(See para IN.0.19 of explanatory notes to this Category) Fee: \$98.25 Benefit: 75% = \$73.70 85% = \$83.55
	Urinary bladder, ultrasound scan of, by any or all approaches, if:
	(a) the patient is not referred by a medical practitioner; and
	(b) the service is not associated with a service to which an item in Subgroup 2 or 3 applies; and
	(c) within 24 hours of the service, a service mentioned in item 11917, 55016, 55019, 55037, 55039, 55600, 55601, 55603, 55604, 55068 or 55069 is not performed on the same patient by the providing practitioner (NR) (K)
55085	(See para IN.0.19 of explanatory notes to this Category) Fee: \$34.05 Benefit: 75% = \$25.55 85% = \$28.95
I1. ULTI	RASOUND 2. CARDIAC
	Group I1. Ultrasound
	Subgroup 2. Cardiac
55113	M-MODE and 2 DIMENSIONAL REAL TIME ECHOCARDIOGRAPHIC EXAMINATION of the heart from at least 2 acoustic windows, with measurement of blood flow velocities across the cardiac valves using pulsed wave and continuous wave Doppler techniques, and real time colour flow mapping from at least 2 acoustic windows, with recordings on video tape or digital medium, not being a service associated with a service to which an item in Subgroups 1 (with the exception of item 55054) or 3, or another item in this Subgroup (with the exception of items 55118 and 55130), applies, for the

I1. ULT	RASOUND 2. CARDIAC
	investigation of symptoms or signs of cardiac failure, or suspected or known ventricular hypertrophy or dysfunction, or chest pain (R)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$230.65 Benefit: 75% = \$173.00 85% = \$196.10
	M-MODE and 2 DIMENSIONAL REAL TIME ECHOCARDIOGRAPHIC EXAMINATION of the heart from at least 2 acoustic windows, with measurement of blood flow velocities across the cardiac valves using pulsed wave and continuous wave Doppler techniques, and real time colour flow mapping from at least 2 acoustic windows, with recordings on video tape or digital medium, not being a service associated with a service to which an item in Subgroups 1 (with the exception of item 55054) or 3, or another item in this Subgroup (with the exception of items 55118 and 55130), applies, for the investigation of suspected or known acquired valvular, aortic, pericardial, thrombotic, or embolic disease, or heart tumour (R)
55114	(See para IN.0.19 of explanatory notes to this Category) Fee: \$230.65 Benefit: 75% = \$173.00 85% = \$196.10
	M-MODE and 2 DIMENSIONAL REAL TIME ECHOCARDIOGRAPHIC EXAMINATION of the heart from at least 2 acoustic windows, with measurement of blood flow velocities across the cardiac valves using pulsed wave and continuous wave Doppler techniques, and real time colour flow mapping from at least 2 acoustic windows, with recordings on video tape or digital medium, not being a service associated with a service to which an item in Subgroups 1 (with the exception of item 55054) or 3, or another item in this Subgroup (with the exception of items 55118 and 55130), applies, for the investigation of symptoms or signs of congenital heart disease (R)
55115	(See para IN.0.19 of explanatory notes to this Category) Fee: \$230.65 Benefit: 75% = \$173.00 85% = \$196.10
	EXERCISE STRESS ECHOCARDIOGRAPHY performed in conjunction with item 11712, with two-dimensional recordings before exercise (baseline) from at least three acoustic windows and matching recordings from the same windows at, or immediately after, peak exercise, not being a service associated with a service to which an item in Subgroups 1 (with the exception of item 55054) or 3, or another item in this Subgroup applies (with the exception of items 55118 and 55130). Recordings must be made on digital media with equipment permitting display of baseline and matching peak images on the same screen (R)
55116	(See para IN.0.19 of explanatory notes to this Category) Fee: \$261.65 Benefit: 75% = \$196.25 85% = \$222.45
	PHARMACOLOGICAL STRESS ECHOCARDIOGRAPHY performed in conjunction with item 11712, with two-dimensional recordings before drug infusion (baseline) from at least three acoustic windows and matching recordings from the same windows at least twice during drug infusion, including a recording at the peak drug dose not being a service associated with a service to which an item in Subgroups 1 (with the exception of item 55054) or 3, or another item in this Subgroup, applies (with the exception of items 55118 and 55130). Recordings must be made on digital media with equipment permitting display of baseline and matching peak images on the same screen (R)
55117	(See para IN.0.19 of explanatory notes to this Category) Fee: \$261.65 Benefit: 75% = \$196.25 85% = \$222.45
	HEART, 2 DIMENSIONAL REAL TIME TRANSOESOPHAGEAL EXAMINATION of, from at least two levels, and in more than one plane at each level:
	(a) with:
55118	(i) real time colour flow mapping and, if indicated, pulsed wave Doppler examination; and

I1. ULT	RASOUND 2. CARDIAC
	(ii) recordings on video tape or digital medium; and
	(b) not being an intra-operative service or a service associated with a service to which an item
	in Subgroups 1 (with the exception of item 55054) or 3, applies (R) (Anaes.)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$275.50 Benefit: 75% = \$206.65 85% = \$234.20
	M-MODE and 2 DIMENSIONAL REAL TIME ECHOCARDIOGRAPHIC EXAMINATION of the heart from at least 2 acoustic windows, with measurement of blood flow velocities across the cardiac valves using pulsed wave and continuous wave Doppler techniques, and real time colour flow mapping from at least 2 acoustic windows, with recordings on video tape or digital medium, not being a service associated with a service to which an item in Subgroups 1 (with the exception of items 55026 and 55054) or 3, or another item in this Subgroup (with the exception of items 55118, 55125, 55130 and 55131), applies, for the investigation of symptoms or signs of cardiac failure, or suspected or known ventricular hypertrophy or dysfunction, or chest pain (R) (NK)
55119	(See para IN.0.19 of explanatory notes to this Category) Fee: \$115.35 Benefit: 75% = \$86.55 85% = \$98.05
	M-MODE and 2 DIMENSIONAL REAL TIME ECHOCARDIOGRAPHIC EXAMINATION of the heart from at least 2 acoustic windows, with measurement of blood flow velocities across the cardiac valves using pulsed wave and continuous wave Doppler techniques, and real time colour flow mapping from at least 2 acoustic windows, with recordings on video tape or digital medium, not being a service associated with a service to which an item in Subgroups 1 (with the exception of items 55026 and 55054) or 3, or another item in this Subgroup (with the exception of items 55118, 55125, 55130 and 55131), applies, for the investigation of suspected or known acquired valvular, aortic, pericardial, thrombotic, or embolic disease, or heart tumour (R) (NK)
55120	(See para IN.0.19 of explanatory notes to this Category) Fee: \$115.35 Benefit: 75% = \$86.55 85% = \$98.05
	M-MODE and 2 DIMENSIONAL REAL TIME ECHOCARDIOGRAPHIC EXAMINATION of the heart from at least 2 acoustic windows, with measurement of blood flow velocities across the cardiac valves using pulsed wave and continuous wave Doppler techniques, and real time colour flow mapping from at least 2 acoustic windows, with recordings on video tape or digital medium, not being a service associated with a service to which an item in Subgroups 1 (with the exception of items 55026 and 55054) or 3, or another item in this Subgroup (with the exception of items 55118, 55125, 55130 and 55131), applies, for the investigation of symptoms or signs of congenital heart disease (R) (NK)
55121	(See para IN.0.19 of explanatory notes to this Category) Fee: \$115.35 Benefit: 75% = \$86.55 85% = \$98.05
	EXERCISE STRESS ECHOCARDIOGRAPHY performed in conjunction with item 11712, with two-dimensional recordings before exercise (baseline) from at least three acoustic windows and matching recordings from the same windows at, or immediately after, peak exercise, not being a service associated with a service to which an item in Subgroups 1 (with the exception of items 55026 and 55054) or 3, or another item in this Subgroup applies (with the exception of items 55118, 55125, 55130 and 55131). Recordings must be made on digital media with equipment permitting display of baseline and matching peak images on the same screen (R) (NK)
55122	(See para IN.0.19 of explanatory notes to this Category) Fee: \$130.85 Benefit: 75% = \$98.15 85% = \$111.25
	PHARMACOLOGICAL STRESS ECHOCARDIOGRAPHY performed in conjunction with item 11712, with two-dimensional recordings before drug infusion (baseline) from at least three acoustic
55123	windows and matching recordings from the same windows at least twice during drug infusion, including

I1. ULT	RASOUND 2. CARDIAC
	a recording at the peak drug dose not being a service associated with a service to which an item in Subgroups 1 (with the exception of items 55026 and 55054) or 3, or another item in this Subgroup, applies (with the exception of items 55118, 55125, 55130 and 55131). Recordings must be made on digital media with equipment permitting display of baseline and matching peak images on the same screen (R) (NK)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$130.85 Benefit: 75% = \$98.15 85% = \$111.25
	HEART, 2 DIMENSIONAL REAL TIME TRANSOESOPHAGEAL EXAMINATION of, from at least two levels, and in more than one plane at each level:
	(a) with:
	(i) real time colour flow mapping and, if indicated, pulsed wave Doppler examination; and
	(ii) recordings on video tape or digital medium; and
	(b) not being an intra-operative service or a service associated with a service to which an item
	in Subgroups 1 (with the exception of items 55026 and 55054) or 3, applies (R) (NK) (Anaes.)
55125	(See para IN.0.19 of explanatory notes to this Category) Fee: \$137.75 Benefit: 75% = \$103.35 85% = \$117.10
	INTRA-OPERATIVE 2 DIMENSIONAL REAL TIME TRANSOESOPHAGEAL ECHOCARDIOGRAPHY incorporating Doppler techniques with colour flow mapping and recording onto video tape or digital medium, performed during cardiac surgery incorporating sequential assessment of cardiac function before and after the surgical procedure - not associated with item 55135 (R) (Anaes.)
55130	(See para IN.0.19 of explanatory notes to this Category) Fee: \$170.00 Benefit: 75% = \$127.50 85% = \$144.50
	INTRA-OPERATIVE 2 DIMENSIONAL REAL TIME TRANSOESOPHAGEAL ECHOCARDIOGRAPHY incorporating Doppler techniques with colour flow mapping and recording onto video tape or digital medium, performed during cardiac surgery incorporating sequential assessment of cardiac function before and after the surgical procedure - not associated with items 55135 and 55136 (R) (NK) (Anaes.)
55131	(See para IN.0.19 of explanatory notes to this Category) Fee: \$85.00 Benefit: 75% = \$63.75 85% = \$72.25
	INTRA-OPERATIVE 2 DIMENSIONAL REAL TIME TRANSOESOPHAGEAL ECHOCARDIOGRAPHY incorporating Doppler techniques with colour flow mapping and recording onto video tape or digital medium, performed during cardiac valve surgery (repair or replacement) incorporating sequential assessment of cardiac function and valve competence before and after the surgical procedure - not associated with item 55130 (R) (Anaes.)
55135	(See para IN.0.19 of explanatory notes to this Category) Fee: \$353.60 Benefit: 75% = \$265.20 85% = \$300.60
	INTRA-OPERATIVE 2 DIMENSIONAL REAL TIME TRANSOESOPHAGEAL ECHOCARDIOGRAPHY incorporating Doppler techniques with colour flow mapping and recording onto video tape or digital medium, performed during cardiac valve surgery (repair or replacement) incorporating sequential assessment of cardiac function and valve competence before and after the surgical procedure - not associated with items 55130 and 55131 (R) (NK) (Anaes.)
55136	(See para IN.0.19 of explanatory notes to this Category)

I1. ULTF	ASOUND 2. CARDIA
	Fee: \$176.80 Benefit: 75% = \$132.60 85% = \$150.30
I1. ULTF	ASOUND 3. VASCULA
	Group I1. Ultrasound
	Subgroup 3. Vascular
	DUPLEX SCANNING, unilateral, involving B mode ultrasound imaging and integrated Doppler flow measurements by spectral analysis of arteries or bypass grafts in the lower limb OR of arteries and bypass grafts in the lower limb, below the inguinal ligament, not being a service associated with a service to which an item in Subgroups 1 (with the exception of items 55026 and 55054) or 4 of this Group applies (R) (NK)
55220	(See para IN.0.19 of explanatory notes to this Category) Fee: \$84.75 Benefit: 75% = \$63.60 85% = \$72.05
	DUPLEX SCANNING, unilateral, involving B mode ultrasound imaging and integrated Doppler flow measurements by spectral analysis of veins in the lower limb, below the inguinal ligament, for acute venous thrombosis, not being a service associated with a service to which an item in Subgroups 1 (with the exception of items 55026 and 55054) or 4 of this Group applies (R) (NK)
55221	(See para IN.0.19 of explanatory notes to this Category) Fee: \$84.75 Benefit: 75% = \$63.60 85% = \$72.05
	DUPLEX SCANNING, unilateral, involving B mode ultrasound imaging and integrated Doppler flow measurements by spectral analysis of veins in the lower limb, below the inguinal ligament, for chronic venous disease, not being a service associated with a service to which an item in Subgroups 1 (with the exception of items 55026 and 55054) or 4 of this Group applies (R) (NK)
55222	(See para IN.0.19 of explanatory notes to this Category) Fee: \$84.75 Benefit: 75% = \$63.60 85% = \$72.05
	DUPLEX SCANNING, unilateral, involving B mode ultrasound imaging and integrated Doppler flow measurements by spectral analysis of arteries or bypass grafts in the upper limb OR of arteries and bypass grafts in the upper limb, not being a service associated with a service to which an item in Subgroups 1 (with the exception of items 55026 and 55054) or 4 of this Group applies (R) (NK)
55223	(See para IN.0.19 of explanatory notes to this Category) Fee: \$84.75 Benefit: 75% = \$63.60 85% = \$72.05
	DUPLEX SCANNING, unilateral, involving B mode ultrasound imaging and integrated Doppler flow measurements by spectral analysis of veins in the upper limb, not being a service associated with a service to which an item in Subgroups 1 (with the exception of items 55026 and 55054) or 4 of this Group applies (R) (NK)
55224	(See para IN.0.19 of explanatory notes to this Category) Fee: \$84.75 Benefit: 75% = \$63.60 85% = \$72.05
	DUPLEX SCANNING, bilateral, involving B mode ultrasound imaging and integrated Doppler flow measurements by spectral analysis of extra-cranial bilateral carotid and vertebral vessels, with or without subclavian and innominate vessels, with or without oculoplethysmography or peri-orbital Doppler examination, not being a service associated with a service to which an item in Subgroups 1 (with the exception of items 55026 and 55054) or 4 of this Groups applies (R) (NK)
55226	(See para IN.0.19 of explanatory notes to this Category) Fee: \$84.75 Benefit: 75% = \$63.60 85% = \$72.05
55227	DUPLEX SCANNING involving B mode ultrasound imaging and integrated Doppler flow measurements by spectral analysis of intra-abdominal, aorta and iliac arteries or inferior vena cava and

I1. ULT	RASOUND 3. VASCULAR
	iliac veins OR of intra-abdominal, aorta and iliac arteries and inferior vena cava and iliac veins, excluding pregnancy related studies, not being a service associated with a service to which an item in Subgroups 1 (with the exception of items 55026 and 55054) or 4 of this Group applies (R) (NK)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$84.75 Benefit: 75% = \$63.60 85% = \$72.05
	DUPLEX SCANNING involving B mode ultrasound imaging and integrated Doppler flow measurements by spectral analysis of renal or visceral vessels OR of renal and visceral vessels, including aorta, inferior vena cava and iliac vessels as required excluding pregnancy related studies, not being a service associated with a service to which an item in Subgroups 1 (with the exception of items 55026 and 55054) or 4 of this Group applies (R) (NK)
55228	(See para IN.0.19 of explanatory notes to this Category) Fee: \$84.75 Benefit: 75% = \$63.60 85% = \$72.05
	DUPLEX SCANNING involving B mode ultrasound imaging and integrated Doppler flow measurements by spectral analysis of intra-cranial vessels, not being a service associated with a service to which an item in Subgroups 1 (with the exception of items 55026 and 55054) or 4 of this Group applies (R) (NK)
55229	(See para IN.0.19 of explanatory notes to this Category) Fee: \$84.75 Benefit: 75% = \$63.60 85% = \$72.05
	DUPLEX SCANNING involving B mode ultrasound imaging and integrated Doppler flow measurements by spectral analysis of cavernosal artery of the penis following intracavernosal administration of a vasoactive agent, performed during the period of pharmacological activity of the injected agent, to confirm a diagnosis of vascular aetiology for impotence, where a specialist in diagnostic radiology, nuclear medicine, urology, general surgery (sub-specialising in vascular surgery) or a consultant physician in nuclear medicine attends the patient in person at the practice location where the service is rendered, immediately prior to or for a period during the rendering of the service, and that specialist or consultant physician interprets the results and prepares a report, not being a service associated with a service to which an item in Subgroups 1 (with the exception of items 55026 and 55054) or 4 of this Group applies (R) (NK)
55230	(See para IN.0.19 of explanatory notes to this Category) Fee: \$84.75 Benefit: 75% = \$63.60 85% = \$72.05
	DUPLEX SCANNING involving B mode ultrasound imaging and integrated Doppler flow measurements by spectral analysis of cavernosal tissue of the penis to confirm a diagnosis and, where indicated, assess the progress and management of:
	(a) priapism; or
	(b) fibrosis of any type; or
	(c) fracture of the tunica; or
	(d) arteriovenous malformations;
	where a specialist in diagnostic radiology, nuclear medicine, urology, general surgery (sub-specialising in vascular surgery) or a consultant physician in nuclear medicine attends the patient in person at the practice location where the service is rendered, immediately prior to or for a period during the rendering of the service, and that specialist or consultant physician interprets the results and prepares a report, not being a service associated with a service to which an item in Subgroups 1 (with the exception of items 55026 and 55054) or 4 of this Groups applies (R) (NK)
55232	(See para IN.0.19 of explanatory notes to this Category)

I1. ULT	RASOUND		3	3. VASCULAR
	Fee: \$84.75	Benefit: 75% = \$63.60	85% = \$72.05	
	measurements b	y spectral analysis of surgic cess graft in the upper or lo	ng B mode ultrasound imaging and integrated I cally created arteriovenous fistula or surgically ower limb, not being a service associated with ception of items 55026 and 55054) or 4 of this	created a service to
55233	(See para IN.0.19 Fee: \$84.75	of explanatory notes to this Ca Benefit: 75% = \$63.60		
	measurements be conduit prior to Subgroups 1 (w.	y spectral analysis of arterious vascular surgery, not being	ultrasound imaging and integrated Doppler flores or veins OR arteries and veins, for mapping a service associated with a service to which at 5026 and 55054), 3 or 4 of this Group applies	of bypass n item in
55235	(See para IN.0.19 Fee: \$84.75	of explanatory notes to this Ca Benefit: 75% = \$63.60		
	spectral analysis vein surgery, no	s and marking of veins in that being a service associated ms 55026 and 55054), 3 or 4	ng B mode ultrasound imaging and integrated late lower limb below the inguinal ligament prior with a service to which an item in Subgroups 4 of this Group applies - including any associa	r to varicose 1 (with the
55236	(See para IN.0.19 Fee: \$55.55	of explanatory notes to this Ca Benefit: 75% = \$41.70		
	measurements b bypass grafts in	y spectral analysis of arterion the lower limb, below the in	ng B mode ultrasound imaging and integrated I es or bypass grafts in the lower limb OR of art inguinal ligament, not being a service associate with the exception of item 55054) or 4 of this G	eries and ed with a
55238	(See para IN.0.19 Fee: \$169.50	of explanatory notes to this Ca Benefit: 75% = \$127.15	e :,	
	measurements b	y spectral analysis of veins	ng B mode ultrasound imaging and integrated I in the lower limb, below the inguinal ligamen ociated with a service to which an item in Subgroup applies - (R)	t, for acute
55244	(See para IN.0.19 Fee: \$169.50	of explanatory notes to this Ca Benefit: 75% = \$127.13		
	measurements b venous disease,	y spectral analysis of veins	ng B mode ultrasound imaging and integrated leads in the lower limb, below the inguinal ligamented with a service to which an item in Subgroup applies - (R)	t, for chronic
55246	(See para IN.0.19 Fee: \$169.50	of explanatory notes to this Ca Benefit: 75% = \$127.13	- ··	
	measurements b bypass grafts in	y spectral analysis of arterion the upper limb, not being a	ng B mode ultrasound imaging and integrated I es or bypass grafts in the upper limb OR of art a service associated with a service to which an (5054) or 4 of this Group applies - (R)	eries and
55248	(See para IN.0.19	of explanatory notes to this Ca	ategory)	

I1. ULT	RASOUND		3. VASCULAR
	Fee: \$169.50	Benefit: 75% = \$127.15 85% = \$144.10	
	measurements b	NNING, unilateral, involving B mode ultrasoun y spectral analysis of veins in the upper limb, n an item in Subgroups 1 (with the exception of	ot being a service associated with a
55252	(See para IN.0.19 Fee: \$169.50	of explanatory notes to this Category) Benefit: 75% = \$127.15 85% = \$144.10	
	measurements b subclavian and i examination, no	NNING, bilateral, involving B mode ultrasound y spectral analysis of extra-cranial bilateral care nnominate vessels, with or without oculoplethy t being a service associated with a service to wl n 55054) or 4 of this Groups applies - (R)	otid and vertebral vessels, with or without vsmography or peri-orbital Doppler
55274	(See para IN.0.19 Fee: \$169.50	of explanatory notes to this Category) Benefit: 75% = \$127.15 85% = \$144.10	
	measurements b iliac veins OR o excluding pregn	NNING involving B mode ultrasound imaging a y spectral analysis of intra-abdominal, aorta and intra-abdominal, aorta and iliac arteries and ir ancy related studies, not being a service associate the the exception of item 55054) or 4 of this Ground in the exception of item 55054.	d iliac arteries or inferior vena cava and inferior vena cava and iliac veins, ated with a service to which an item in
55276	(See para IN.0.19 Fee: \$169.50	of explanatory notes to this Category) Benefit: 75% = \$127.15 85% = \$144.10	
	measurements b aorta, inferior ve	NNING involving B mode ultrasound imaging a y spectral analysis of renal or visceral vessels C ena cava and iliac vessels as required excluding ed with a service to which an item in Subgroups applies - (R)	OR of renal and visceral vessels, including pregnancy related studies, not being a
55278	(See para IN.0.19 Fee: \$169.50	of explanatory notes to this Category) Benefit: 75% = \$127.15 85% = \$144.10	
	measurements b	NNING involving B mode ultrasound imaging a y spectral analysis of intra-cranial vessels, not be in Subgroups 1 (with the exception of item 55)	being a service associated with a service
55280	(See para IN.0.19 Fee: \$169.50	of explanatory notes to this Category) Benefit: 75% = \$127.15 85% = \$144.10	
	measurements b administration o injected agent, to diagnostic radio or a consultant p the service is rer specialist or con	NNING involving B mode ultrasound imaging a y spectral analysis of cavernosal artery of the p f a vasoactive agent, performed during the period confirm a diagnosis of vascular aetiology for logy, nuclear medicine, urology, general surger physician in nuclear medicine attends the patient dered, immediately prior to or for a period dur sultant physician interprets the results and prep a service to which an item in Subgroups 1 (with (R)	enis following intracavernosal od of pharmacological activity of the impotence, where a specialist in ry (sub-specialising in vascular surgery) it in person at the practice location where ing the rendering of the service, and that wares a report, not being a service
55282	(See para IN.0.19 Fee: \$169.50	of explanatory notes to this Category) Benefit: 75% = \$127.15 85% = \$144.10	
55284	DUPLEX SCAN	NNING involving B mode ultrasound imaging a	and integrated Doppler flow

indicated, assess the progress and management of: (a) priapism; or (b) fibrosis of any type; or (c) fracture of the tunica; or (d) arteriovenous malformations; where a specialist in diagnostic radiology, nuclear medicine, urology, general surgery (sub-specialis in vascular surgery) or a consultant physician in nuclear medicine attends the patient in person at the practice location where the service is rendered, immediately prior to or for a period during the rende of the service, and that specialist or consultant physician interprets the results and prepares a report, being a service associated with a service to which an item in Subgroups 1 (with the exception of ites \$5054) or 4 of this Groups applies - (R) (See para IN 0.19 of explanatory notes to this Category) Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, unilateral, involving B mode ultrasound imaging and integrated Doppler flow measurements by spectral analysis of surgically created arteriovenous access graft in the upper or lower limb, not being a service associated with a service twhich an item in Subgroups 1 (with the exception of item \$5054) or 4 of this Group applies (R) (See para IN 0.19 of explanatory notes to this Category) Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, involving B mode ultrasound imaging and integrated Doppler flow measurements by spectral analysis of arteries or veins OR arteries and veins, for mapping of bypass conduit prior to vascular surgery, not being a service associated with a service to which an item in Subgroups 1 (with the exception of item \$5054), 3 or 4 of this Group applies - including any association marking (R) (See para IN 0.19 of explanatory notes to this Category) Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, unilateral, involving B mode ultrasound imaging and integrated Doppler flow measurements and the service associated with a service to which an item in Subgroups 1 (with the exception of item \$5054), 3 or 4 of this Group appli	I1. ULTF	RASOUND 3. VASCULAR
(b) fibrosis of any type; or (c) fracture of the tunica; or (d) arteriovenous malformations; where a specialist in diagnostic radiology, nuclear medicine, urology, general surgery (sub-specialis in vascular surgery) or a consultant physician in nuclear medicine attends the patient in person at the practice location where the service is rendered, immediately prior to or for a period during the rends of the service, and that specialist or consultant physician interprets the results and prepares a report, being a service associated with a service to which an item in Subgroups 1 (with the exception of ite 55054) or 4 of this Groups applies - (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, unilateral, involving B mode ultrasound imaging and integrated Doppler fit measurements by spectral analysis of surgically created arteriovenous fistula or surgically created arteriovenous access graft in the upper or lower limb, not being a service associated with a service twhich an item in Subgroups 1 (with the exception of item 55054) or 4 of this Group applies (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, involving B mode ultrasound imaging and integrated Doppler flow measurements by spectral analysis of arteries or veins OR arteries and veins, for mapping of bypass conduit prior to vascular surgery, not being a service associated with a service to which an item in Subgroups 1 (with the exception of item 55054), 3 or 4 of this Group applies - including any associated with a service to which an item in Subgroups 1 (with the exception of item 55054), 3 or 4 of this Group applies - including any associated with a service to which an item in Subgroups 1 (with the exception of item 55054), 3 or 4 of this Group applies - including any associated skin marking (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$111.05 Benefit: 75% = \$83.30 85%		measurements by spectral analysis of cavernosal tissue of the penis to confirm a diagnosis and, where indicated, assess the progress and management of:
(c) fracture of the tunica; or (d) arteriovenous malformations; where a specialist in diagnostic radiology, nuclear medicine, urology, general surgery (sub-specialis in vascular surgery) or a consultant physician in nuclear medicine attends the patient in person at the practice location where the service is rendered, immediately prior to or for a period during the render of the service, and that specialist or consultant physician interprets the results and prepares a report, being a service associated with a service to which an item in Subgroups I (with the exception of ite 55054) or 4 of this Groups applies - (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, unilateral, involving B mode ultrasound imaging and integrated Doppler flow measurements by spectral analysis of surgically created arteriovenous fistula or surgically created arteriovenous access graft in the upper or lower limb, not being a service associated with a service the which an item in Subgroups I (with the exception of item \$5054) or 4 of this Group applies (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, involving B mode ultrasound imaging and integrated Doppler flow measurements by spectral analysis of arteries or veins OR arteries and veins, for mapping of bypass conduit prior to vascular surgery, not being a service associated with a service to which an item in Subgroups I (with the exception of item \$5054), 3 or 4 of this Group applies - including any associated with a service to which an item in Subgroups I (with the exception of item \$5054), 3 or 4 of this Group applies - including any associated skin marking (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, unilateral, involving B mode ultrasound imaging and integrated Doppler flow the exception of item \$5054), 3 or 4 of this Group applies - in		(a) priapism; or
(d) arteriovenous malformations; where a specialist in diagnostic radiology, nuclear medicine, urology, general surgery (sub-specialis in vascular surgery) or a consultant physician in nuclear medicine attends the patient in person at the practice location where the service is rendered, immediately prior to or for a period during the rende of the service, and that specialist or consultant physician interprets the results and prepares a report, being a service associated with a service to which an item in Subgroups 1 (with the exception of ite 55054) or 4 of this Groups applies - (R) (See para IN 0.19 of explanatory notes to this Category) Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, unilateral, involving B mode ultrasound imaging and integrated Doppler flor measurements by spectral analysis of surgically created arteriovenous fistula or surgically created arteriovenous access graft in the upper or lower limb, not being a service associated with a service to which an item in Subgroups 1 (with the exception of item \$5054) or 4 of this Group applies (R) (See para IN 0.19 of explanatory notes to this Category) Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, involving B mode ultrasound imaging and integrated Doppler flow measurements by spectral analysis of arteries or veins OR arteries and veins, for mapping of bypass conduit prior to vascular surgery, not being a service associated with a service to which an item in Subgroups 1 (with the exception of item \$5054), 3 or 4 of this Group applies - including any associaskin marking (R) (See para IN 0.19 of explanatory notes to this Category) Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, unilateral, involving B mode ultrasound imaging and integrated Doppler flow in surgery, not being a service associated with a service to which an item in Subgroups 1 (with the exception of item \$5054), 3 or 4 of this Group applies - including any associated skin marking (R) (See para IN 0.19 of explanatory no		(b) fibrosis of any type; or
where a specialist in diagnostic radiology, nuclear medicine, urology, general surgery (sub-specialis in vascular surgery) or a consultant physician in nuclear medicine attends the patient in person at the practice location where the service is rendered, immediately prior to or for a period during the rends of the service and that specialist or consultant physician interprets the results and prepares a report, being a service associated with a service to which an item in Subgroups 1 (with the exception of item 55054) or 4 of this Groups applies - (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, unilateral, involving B mode ultrasound imaging and integrated Doppler flow measurements by spectral analysis of surgically created arteriovenous fistula or surgically created arteriovenous access graft in the upper or lower limb, not being a service associated with a service to which an item in Subgroups 1 (with the exception of item 55054) or 4 of this Group applies (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, involving B mode ultrasound imaging and integrated Doppler flow measurements by spectral analysis of arteries or veins OR arteries and veins, for mapping of bypass conduit prior to vascular surgery, not being a service associated with a service to which an item in Subgroups 1 (with the exception of item 55054), 3 or 4 of this Group applies - including any association marking (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, unilateral, involving B mode ultrasound imaging and integrated Doppler flow measurements and the exception of item 55054), 3 or 4 of this Group applies - including any associated skin marking (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$169.50 Benefit: 75% = \$83.30 85% = \$94.40 H. ULTRASOUND Subgroup 4. Urological Prostate		(c) fracture of the tunica; or
in vascular surgery) or a consultant physician in nuclear medicine attends the patient in person at the practice location where the service is rendered, immediately prior to or for a period during the rende of the service, and that specialist or consultant physician interprets the results and prepares a report, being a service associated with a service to which an item in Subgroups 1 (with the exception of itei 55054) or 4 of this Groups applies - (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, unilateral, involving B mode ultrasound imaging and integrated Doppler flow measurements by spectral analysis of surgically created arteriovenous access graft in the upper or lower limb, not being a service associated with a service the which an item in Subgroups 1 (with the exception of item 55054) or 4 of this Group applies (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, involving B mode ultrasound imaging and integrated Doppler flow measurements by spectral analysis of arteries or veins OR arteries and veins, for mapping of bypass conduit prior to vascular surgery, not being a service associated with a service to which an item in Subgroups 1 (with the exception of item 55054), 3 or 4 of this Group applies - including any associated in marking (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, unilateral, involving B mode ultrasound imaging and integrated Doppler flow measurements by a service associated with a service to which an item in Subgroups 1 (with the exception of item 55054), 3 or 4 of this Group applies - including any associated skin marking (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$110.5 Benefit: 75% = \$83.30 85% = \$94.40 H. ULTRASOUND 4. UROLOG Group 11. Ultrasound		(d) arteriovenous malformations;
Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, unilateral, involving B mode ultrasound imaging and integrated Doppler flow measurements by spectral analysis of surgically created arteriovenous fistula or surgically created arteriovenous access graft in the upper or lower limb, not being a service associated with a service the which an item in Subgroups 1 (with the exception of item 55054) or 4 of this Group applies (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, involving B mode ultrasound imaging and integrated Doppler flow measurements by spectral analysis of arteries or veins OR arteries and veins, for mapping of bypass conduit prior to vascular surgery, not being a service associated with a service to which an item in Subgroups 1 (with the exception of item 55054), 3 or 4 of this Group applies - including any association skin marking (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, unilateral, involving B mode ultrasound imaging and integrated Doppler flow spectral analysis and marking of veins in the lower limb below the inguinal ligament prior to varico vein surgery, not being a service associated with a service to which an item in Subgroups 1 (with the exception of item 55054), 3 or 4 of this Group applies - including any associated skin marking (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$111.05 Benefit: 75% = \$83.30 85% = \$94.40 11. ULTRASOUND Subgroup 4. Urological Prostate, bladder base and urethra, ultrasound scan of, if performed:		where a specialist in diagnostic radiology, nuclear medicine, urology, general surgery (sub-specialising in vascular surgery) or a consultant physician in nuclear medicine attends the patient in person at the practice location where the service is rendered, immediately prior to or for a period during the rendering of the service, and that specialist or consultant physician interprets the results and prepares a report, not being a service associated with a service to which an item in Subgroups 1 (with the exception of item 55054) or 4 of this Groups applies - (R)
measurements by spectral analysis of surgically created arteriovenous fistula or surgically created arteriovenous access graft in the upper or lower limb, not being a service associated with a service t which an item in Subgroups 1 (with the exception of item 55054) or 4 of this Group applies (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, involving B mode ultrasound imaging and integrated Doppler flow measurements by spectral analysis of arteries or veins OR arteries and veins, for mapping of bypass conduit prior to vascular surgery, not being a service associated with a service to which an item in Subgroups 1 (with the exception of item 55054), 3 or 4 of this Group applies - including any associaskin marking (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, unilateral, involving B mode ultrasound imaging and integrated Doppler flow spectral analysis and marking of veins in the lower limb below the inguinal ligament prior to varico vein surgery, not being a service associated with a service to which an item in Subgroups 1 (with the exception of item 55054), 3 or 4 of this Group applies - including any associated skin marking (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$111.05 Benefit: 75% = \$83.30 85% = \$94.40 11. ULTRASOUND 4. UROLOG Group 11. Ultrasound Subgroup 4. Urological		
55292 Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, involving B mode ultrasound imaging and integrated Doppler flow measurements by spectral analysis of arteries or veins OR arteries and veins, for mapping of bypass conduit prior to vascular surgery, not being a service associated with a service to which an item in Subgroups 1 (with the exception of item 55054), 3 or 4 of this Group applies - including any associate skin marking (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, unilateral, involving B mode ultrasound imaging and integrated Doppler flow spectral analysis and marking of veins in the lower limb below the inguinal ligament prior to various vein surgery, not being a service associated with a service to which an item in Subgroups 1 (with the exception of item 55054), 3 or 4 of this Group applies - including any associated skin marking (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$111.05 Benefit: 75% = \$83.30 85% = \$94.40 11. ULTRASOUND 4. UROLOG Group 11. Ultrasound Subgroup 4. Urological Prostate, bladder base and urethra, ultrasound scan of, if performed:		arteriovenous access graft in the upper or lower limb, not being a service associated with a service to
measurements by spectral analysis of arteries or veins OR arteries and veins, for mapping of bypass conduit prior to vascular surgery, not being a service associated with a service to which an item in Subgroups 1 (with the exception of item 55054), 3 or 4 of this Group applies - including any associated skin marking (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, unilateral, involving B mode ultrasound imaging and integrated Doppler flespectral analysis and marking of veins in the lower limb below the inguinal ligament prior to various vein surgery, not being a service associated with a service to which an item in Subgroups 1 (with the exception of item 55054), 3 or 4 of this Group applies - including any associated skin marking (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$111.05 Benefit: 75% = \$83.30 85% = \$94.40 11. ULTRASOUND 4. UROLOG Group 11. Ultrasound Subgroup 4. Urological Prostate, bladder base and urethra, ultrasound scan of, if performed:	55292	
55294 Fee: \$169.50 Benefit: 75% = \$127.15 85% = \$144.10 DUPLEX SCANNING, unilateral, involving B mode ultrasound imaging and integrated Doppler floor spectral analysis and marking of veins in the lower limb below the inguinal ligament prior to various vein surgery, not being a service associated with a service to which an item in Subgroups 1 (with the exception of item 55054), 3 or 4 of this Group applies - including any associated skin marking (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$111.05 Benefit: 75% = \$83.30 85% = \$94.40 I1. ULTRASOUND Group I1. Ultrasound Subgroup 4. Urological Prostate, bladder base and urethra, ultrasound scan of, if performed:		measurements by spectral analysis of arteries or veins OR arteries and veins, for mapping of bypass conduit prior to vascular surgery, not being a service associated with a service to which an item in Subgroups 1 (with the exception of item 55054), 3 or 4 of this Group applies - including any associated
spectral analysis and marking of veins in the lower limb below the inguinal ligament prior to varico vein surgery, not being a service associated with a service to which an item in Subgroups 1 (with the exception of item 55054), 3 or 4 of this Group applies - including any associated skin marking (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$111.05 Benefit: 75% = \$83.30 85% = \$94.40 4. UROLOG Group 11. Ultrasound Subgroup 4. Urological Prostate, bladder base and urethra, ultrasound scan of, if performed:	55294	
55296 Fee: \$111.05 Benefit: 75% = \$83.30 85% = \$94.40 I1. ULTRASOUND 4. UROLOG Group I1. Ultrasound Subgroup 4. Urological Prostate, bladder base and urethra, ultrasound scan of, if performed:		DUPLEX SCANNING, unilateral, involving B mode ultrasound imaging and integrated Doppler flow spectral analysis and marking of veins in the lower limb below the inguinal ligament prior to varicose vein surgery, not being a service associated with a service to which an item in Subgroups 1 (with the exception of item 55054), 3 or 4 of this Group applies - including any associated skin marking (R)
Group I1. Ultrasound Subgroup 4. Urological Prostate, bladder base and urethra, ultrasound scan of, if performed:	55296	
Subgroup 4. Urological Prostate, bladder base and urethra, ultrasound scan of, if performed:	I1. ULTF	RASOUND 4. UROLOGICAL
Prostate, bladder base and urethra, ultrasound scan of, if performed:		Group I1. Ultrasound
		Subgroup 4. Urological
		Prostate, bladder base and urethra, ultrasound scan of, if performed:
	55600	(a) personally by a medical practitioner (not being the medical practitioner who assessed the patient as specified in paragraph (c)) using one or more transducer probes that can obtain both axial and sagittal scans in 2 planes at right angles; and

I1. ULTF	RASO	UND 4. UROLOGICAL
	(b)	after a digital rectal examination of the prostate by that medical practitioner; and
	(c)	on a patient who has been assessed by:
		(i) a specialist in urology, radiation oncology or medical oncology; or
		(ii) a consultant physician in medical oncology;
		who has:
		(iii) examined the patient in the 60 days before the scan; and
		(iv) recommended the scan for the management of the patient's current prostatic disease
	(R)	(K)
		para IN.0.19 of explanatory notes to this Category) : \$109.10
	Pros	state, bladder base and urethra, ultrasound scan of, if performed:
		personally by a medical practitioner (not being the medical practitioner who assessed the patient as cified in paragraph (c)) using one or more transducer probes that can obtain both axial and sagittal as in 2 planes at right angles; and
	(b)	after a digital rectal examination of the prostate by that medical practitioner; and
	(c)	on a patient who has been assessed by:
		(i) a specialist in urology, radiation oncology or medical oncology; or
		(ii) a consultant physician in medical oncology;
		who has:
		(iii) examined the patient in the 60 days before the scan; and
		(iv) recommended the scan for the management of the patient's current prostatic disease
	(R)	(NK)
55601		para IN.0.19 of explanatory notes to this Category) : \$54.55 Benefit: 75% = \$40.95 85% = \$46.40
	Pros	state, bladder base and urethra, ultrasound scan of, if performed:
	(a) one and	personally by a medical practitioner who made the assessment mentioned in paragraph (c) using or more transducer probes that can obtain both axial and sagittal scans in 2 planes at right angles;
	(b)	after a digital rectal examination of the prostate by that medical practitioner; and
	(c)	on a patient who has been assessed by:
		(i) a specialist in urology, radiation oncology or medical oncology; or
		(ii) a consultant physician in medical oncology;
55603		

I1. ULTR	ASOUND 4. UROLOGICAL
	who has:
	(iii) examined the patient in the 60 days before the scan; and
	(iv) recommended the scan for the management of the patient's current prostatic disease
	(R)(K)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$109.10 Benefit: 75% = \$81.85 85% = \$92.75
	Prostate, bladder base and urethra, ultrasound scan of, if performed:
	(a) personally by a medical practitioner who made the assessment mentioned in paragraph (c) using one or more transducer probes that can obtain both axial and sagittal scans in 2 planes at right angles; and
	(b) after a digital rectal examination of the prostate by that medical practitioner; and
	(c) on a patient who has been assessed by:
	(i) a specialist in urology, radiation oncology or medical oncology; or
	(ii) a consultant physician in medical oncology;
	who has:
	(iii) examined the patient in the 60 days before the scan; and
	(iv) recommended the scan for the management of the patient's current prostatic disease
	(R) (NK)
55604	(See para IN.0.19 of explanatory notes to this Category) Fee: \$54.55 Benefit: 75% = \$40.95 85% = \$46.40
I1. ULTR	ASOUND 5. OBSTETRIC AND GYNAECOLOGICAL
	Group I1. Ultrasound
	Subgroup 5. Obstetric And Gynaecological
	PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, ultrasound scan of, by any or all approaches, if:
	(a) the patient is referred by a medical practitioner or participating midwife; and
	(b) the dating of the pregnancy (as confirmed by ultrasound) is less than 12 weeks of gestation; and
	(c) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and
	(d) if the patient is referred by a medical practitioner the referring medical practitioner is not a member of a group of practitioners of which the providing practitioner is a member; and
55700	(e) if the patient is referred by a participating midwife - the referring midwife does not have a business

I1. ULTRASOUND

5. OBSTETRIC AND GYNAECOLOGICAL

or financial arrangement with the providing practitioner; and

- (f) 1 or more of the following conditions are present:
 - (i) hyperemesis gravidarum;
 - (ii) diabetes mellitus;
 - (iii) hypertension;
 - (iv) toxaemia of pregnancy;
 - (v) liver or renal disease;
 - (vi) autoimmune disease;
 - (vii) cardiac disease;
 - (viii) alloimmunisation;
 - (ix) maternal infection;
 - (x) inflammatory bowel disease;
 - (xi) bowel stoma;
 - (xii) abdominal wall scarring;
 - (xiii) previous spinal or pelvic trauma or disease;
 - (xiv) drug dependency;
 - (xv) thrombophilia;
 - (xvi) significant maternal obesity;
 - (xvii) advanced maternal age;
 - (xviii) abdominal pain or mass;
 - (xix) uncertain dates;
 - (xx) high risk pregnancy;
 - (xxi) previous post dates delivery;
 - (xxii) previous caesarean section;
 - (xxiii) poor obstetric history;
 - (xxiv) suspicion of ectopic pregnancy;
 - (xxv) risk of miscarriage;
 - (xxvi) diminished symptoms of pregnancy;

11. ULTRASOUND 5. OBSTETRIC AND GYNAECOLOGICAL suspected or known cervical incompetence; (xxvii) suspected or known uterine abnormality; (xxviii) (xxix) pregnancy after assisted reproduction; (xxx) risk of fetal abnormality (R) Footnote: For nuchal translucency measurements performed when the pregnancy is dated by a crown rump length of 45 to 84mm, refer to item number 55707 (R). Fee is payable only for item 55700 or item 55707, not both items. (See para IN.0.19 of explanatory notes to this Category) **Benefit:** 75% = \$45.00 85% = \$51.00 Fee: \$60.00 **Extended Medicare Safety Net Cap: \$32.95** PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, ultrasound scan of, by any or all approaches, where: the patient is referred by a medical practitioner; and the dating of the pregnancy (as confirmed by ultrasound) is less than 12 weeks of gestation; and (c) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and (d) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member; and (e) one or more of the following conditions are present: (i) hyperemesis gravidarum; diabetes mellitus; hypertension; (iii) (iv) toxaemia of pregnancy; liver or renal disease; (v) autoimmune disease; (vi) (vii) cardiac disease; (viii) alloimmunisation; maternal infection; inflammatory bowel disease; (x) (xi) bowel stoma; (xii) abdominal wall scarring;

11. ULTRASOUND 5. OBSTETRIC AND GYNAECOLOGICAL previous spinal or pelvic trauma or disease; (xiii) drug dependency; (xiv) thrombophilia; (xv) (xvi) significant maternal obesity; advanced maternal age; (xvii) abdominal pain or mass; (xviii) uncertain dates; high risk pregnancy; (xx)previous post dates delivery; (xxi) (xxii) previous caesarean section; (xxiii) poor obstetric history; suspicion of ectopic pregnancy; (xxiv) (xxv) risk of miscarriage; (xxvi) diminished symptoms of pregnancy; (xxvii) suspected or known cervical incompetence; (xxviii) suspected or known uterine abnormality; (xxix) pregnancy after assisted reproduction; (xxx) risk of fetal abnormality (R) Footnote: For nuchal translucency measurements performed when the pregnancy is dated by a crown rump length of 45 to 84mm, refer to item number 55707 or 55714 (R) (NK). Fee is payable only for item 55700 or 55701, or, or item 55707 or 55714, not both items (See para IN.0.19 of explanatory notes to this Category) Fee: \$30.00 **Benefit:** 75% = \$22.50 85% = \$25.50 **Extended Medicare Safety Net Cap: \$16.50** PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, ultrasound scan of, by any or all approaches, where: the patient is not referred by a medical practitioner; and the dating of the pregnancy (as confirmed by ultrasound) is less than 12 weeks of gestation; and the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and 55702

I1. ULTRASOUND 5. OBSTETRIC AND GYNAECOLOGICAL one or more of the following conditions are present: hyperemesis gravidarum; diabetes mellitus; (ii) (iii) hypertension; toxaemia of pregnancy; (iv) (v) liver or renal disease; (vi) autoimmune disease; (vii) cardiac disease; (viii) alloimmunisation; (ix) maternal infection; inflammatory bowel disease; (x) (xi) bowel stoma; abdominal wall scarring; (xii) previous spinal or pelvic trauma or disease; (xiii) (xiv) drug dependency; (xv) thrombophilia; significant maternal obesity; (xvi) advanced maternal age; (xvii) (xviii) abdominal pain or mass; uncertain dates; high risk pregnancy; (xx)previous post dates delivery; (xxi) (xxii) previous caesarean section; (xxiii) poor obstetric history; (xxiv) suspicion of ectopic pregnancy; (xxv) risk of miscarriage;

(xxvi) diminished symptoms of pregnancy;

(xxvii) suspected or known cervical incompetence;

11. ULTRASOUND 5. OBSTETRIC AND GYNAECOLOGICAL suspected or known uterine abnormality; (xxviii) (xxix) pregnancy after assisted reproduction; risk of fetal abnormality (NR) (xxx) Footnote: For nuchal translucency measurements performed when the pregnancy is dated by a crown rump length of 45 to 84mm, refer to item number 55708 or 55716 (R) (NK). Fee is payable only for item 55702 or 55703, or, item 55707 or 55714, not both items (See para IN.0.19 of explanatory notes to this Category) Fee: \$17.50 **Benefit:** $75\% = \$13.15 \quad 85\% = \14.90 **Extended Medicare Safety Net Cap: \$8.30** PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, ultrasound scan of, by any or all approaches, where: the patient is not referred by a medical practitioner; and the dating of the pregnancy (as confirmed by ultrasound) is less than 12 weeks of gestation; and (c) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and (d) one or more of the following conditions are present: (i) hyperemesis gravidarum; (ii) diabetes mellitus; (iii) hypertension; (iv) toxaemia of pregnancy; liver or renal disease; autoimmune disease; cardiac disease; alloimmunisation; (ix) maternal infection; inflammatory bowel disease; (xi) bowel stoma; abdominal wall scarring; (xii) previous spinal or pelvic trauma or disease; (xiii) (xiv) drug dependency;

11. ULTRASOUND 5. OBSTETRIC AND GYNAECOLOGICAL thrombophilia; (xv) significant maternal obesity; (xvi) advanced maternal age; (xvii) (xviii) abdominal pain or mass; (xix) uncertain dates; high risk pregnancy; previous post dates delivery; previous caesarean section; (xxii) (xxiii) poor obstetric history; (xxiv) suspicion of ectopic pregnancy; (xxv) risk of miscarriage; (xxvi) diminished symptoms of pregnancy; (xxvii) suspected or known cervical incompetence; (xxviii) suspected or known uterine abnormality; (xxix) pregnancy after assisted reproduction; (xxx) risk of fetal abnormality (NR) Footnote: For nuchal translucency measurements performed when the pregnancy is dated by a crown rump length of 45 to 84mm, refer to item number 55708 (R). Fee is payable only for item 55703 or item 55707, not both items. (See para IN.0.19 of explanatory notes to this Category) Fee: \$35.00 **Benefit:** 75% = \$26.25 85% = \$29.75 Extended Medicare Safety Net Cap: \$16.55 PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan of, by any or all approaches, if: the patient is referred by a medical practitioner or participating midwife; and the dating of the pregnancy (as confirmed by ultrasound) is 12 to 16 weeks of gestation; and (c) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and (d) if the patient is referred by a medical practitioner -- the referring medical practitioner is not a member of a group of practitioners of which the providing practitioner is a member; and 55704 (e) if the patient is referred by a participating midwife -- the referring midwife does not have a business

I1. ULTRASOUND

5. OBSTETRIC AND GYNAECOLOGICAL

or financial arrangement with the providing practitioner; and

- (f) one or more of the following conditions are present:
 - (i) hyperemesis gravidarum;
 - (ii) diabetes mellitus;
 - (iii) hypertension;
 - (iv) toxaemia of pregnancy;
 - (v) liver or renal disease;
 - (vi) autoimmune disease;
 - (vii) cardiac disease;
 - (viii) alloimmunisation;
 - (ix) maternal infection;
 - (x) inflammatory bowel disease;
 - (xi) bowel stoma;
 - (xii) abdominal wall scarring;
 - (xiii) previous spinal or pelvic trauma or disease;
 - (xiv) drug dependency;
 - (xv) thrombophilia;
 - (xvi) significant maternal obesity;
 - (xvii) advanced maternal age;
 - (xviii) abdominal pain or mass;
 - (xix) uncertain dates;
 - (xx) high risk pregnancy;
 - (xxi) previous post dates delivery;
 - (xxii) previous caesarean section;
 - (xxiii) poor obstetric history;
 - (xxiv) suspicion of ectopic pregnancy;
 - (xxv) risk of miscarriage;
 - (xxvi) diminished symptoms of pregnancy;

11. ULTRASOUND 5. OBSTETRIC AND GYNAECOLOGICAL suspected or known cervical incompetence; (xxvii) suspected or known uterine abnormality; (xxviii) (xxix) pregnancy after assisted reproduction; (xxx) risk of fetal abnormality (R) Footnote: For nuchal translucency measurements performed when the pregnancy is dated by a crown rump length of 45 to 84mm, refer to item number 55707 (R). Fee is payable only for item 55704 or item 55707, not both items. (See para IN.0.19 of explanatory notes to this Category) **Benefit:** 75% = \$52.50 85% = \$59.50 Fee: \$70.00 **Extended Medicare Safety Net Cap: \$38.50** PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan of, by any or all approaches, where: the patient is not referred by a medical practitioner; and the dating of the pregnancy (as confirmed by ultrasound) is 12 to 16 weeks of gestation; and (c) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and (d) one or more of the following conditions are present: (i) hyperemesis gravidarum diabetes mellitus; (iii) hypertension; toxaemia of pregnancy; (iv) liver or renal disease; autoimmune disease; (vii) cardiac disease: (viii) alloimmunisation; (ix) maternal infection; inflammatory bowel disease; bowel stoma; (xi) (xii) abdominal wall scarring; previous spinal or pelvic trauma or disease;

11. ULTRASOUND 5. OBSTETRIC AND GYNAECOLOGICAL drug dependency; (xiv) thrombophilia; (xv) significant maternal obesity; (xvi) (xvii) advanced maternal age; (xviii) abdominal pain or mass; uncertain dates; (xix) high risk pregnancy; previous post dates delivery; (xxi) previous caesarean section; (xxii) (xxiii) poor obstetric history; (xxiv) suspicion of ectopic pregnancy; (xxv) risk of miscarriage; (xxvi) diminished symptoms of pregnancy; (xxvii) suspected or known cervical incompetence; (xxviii) suspected or known uterine abnormality; (xxix) pregnancy after assisted reproduction; (xxx) risk of fetal abnormality (NR) Footnote: For nuchal translucency measurements performed when the pregnancy is dated by a crown rump length of 45 to 84mm, refer to item number 55708 (R). Fee is payable only for item 55705 or item 55708, not both items. (See para IN.0.19 of explanatory notes to this Category) **Benefit:** 75% = \$26.25 85% = \$29.75 Fee: \$35.00 **Extended Medicare Safety Net Cap: \$16.55** PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan (not exceeding 1 service in any 1 pregnancy) of, by any or all approaches, with measurement of all parameters for dating purposes, if: the patient is referred by a medical practitioner or participating midwife; and the dating for the pregnancy (as confirmed by ultrasound) is 17 to 22 weeks of gestation; and the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and 55706 (d) if the patient is referred by a medical practitioner - the referring medical practitioner is not a member

11. ULTRASOUND 5. OBSTETRIC AND GYNAECOLOGICAL of a group of practitioners of which the providing practitioner is a member; and (e) if the patient is referred by a participating midwife - the referring midwife does not have a business or financial arrangement with the providing practitioner; and the service is not performed in the same pregnancy as item 55709 (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$100.00 **Benefit:** 75% = \$75.00 85% = \$85.00 **Extended Medicare Safety Net Cap: \$54.90** PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan (not exceeding 1 service in any 1 pregnancy) of, by any or all approaches, if; the patient is referred by a medical practitioner or participating midwife; and the pregnancy (as confirmed by ultrasound) is dated by a crown rump length of 45 to 84mm; and the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and (d) if the patient is referred by a medical practitioner - the referring medical practitioner is not a member of a group of practitioners of which the providing practitioner is a member; and (e) if the patient is referred by a participating midwife - the referring midwife does not have a business or financial arrangement with the providing practitioner; and at least 1 condition mentioned in paragraph (f) of item 55704 is present; and nuchal translucency measurement is performed to assess the risk of fetal abnormality; and (h) the service is not performed with item 55700, 55703, 55704 or 55705 on the same patient within 24 hours (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$70.00 **Benefit:** 75% = \$52.50 85% = \$59.5055707 Extended Medicare Safety Net Cap: \$38.50 PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan (not exceeding 1 service in any 1 pregnancy) of, by any or all approaches, where: the patient is not referred by a medical practitioner; and the pregnancy (as confirmed by ultrasound) is dated by a crown rump length of 45 to 84mm; and (c) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and (d) one or more of the conditions in subparagraphs (e) (i) to (xxx) of item 55704 are present; and nuchal translucency measurement is performed to assess the risk of fetal abnormality; and the service is not performed in conjunction with item 55700, 55703, 55704 or 55705 on the same

Benefit: 75% = \$26.25 85% = \$29.75

patient within 24 hours (NR)

Fee: \$35.00

55708

(See para IN.0.19 of explanatory notes to this Category)

I1. ULT	RASOUND 5. OBSTETRIC AND GYNAECOLOGICAL
	Extended Medicare Safety Net Cap: \$16.55
	PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan (not exceeding 1 service in any 1 pregnancy) of, by any or all approaches, with measurement of all parameters for dating purposes, where:
	(a) the patient is not referred by a medical practitioner; and
	(b) the dating of the pregnancy (as confirmed by ultrasound) is 17 to 22 weeks of gestation; and
	(c) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and
	(d) the service is not performed in the same pregnancy as item 55706 (NR)
55709	(See para IN.0.19 of explanatory notes to this Category) Fee: \$38.00 Benefit: 75% = \$28.50 Extended Medicare Safety Net Cap: \$22.00
	PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan of, by any or all approaches, where:
	(a) the patient is referred by a medical practitioner; and
	(b) the dating of the pregnancy (as confirmed by ultrasound) is 12 to 16 weeks of gestation; and
	(c) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and
	(d) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member;
	and
	(e) one or more of the following conditions are present:
	(i) hyperemesis gravidarum;
	(ii) diabetes mellitus;
	(iii) hypertension;
	(iv) toxaemia of pregnancy;
	(v) liver or renal disease;
	(vi) autoimmune disease;
	(vii) cardiac disease;
	(viii) alloimmunisation;
	(ix) maternal infection;
	(x) inflammatory bowel disease;
55710	(xi) bowel stoma;

11. ULTRASOUND 5. OBSTETRIC AND GYNAECOLOGICAL abdominal wall scarring; (xii) previous spinal or pelvic trauma or disease; (xiii) drug dependency; (xiv) thrombophilia; (xv) (xvi) significant maternal obesity; advanced maternal age; (xvii) (xviii) abdominal pain or mass; uncertain dates; (xix) high risk pregnancy; (xx) previous post dates delivery; (xxi) previous caesarean section; (xxii) (xxiii) poor obstetric history; suspicion of ectopic pregnancy; (xxiv) (xxv) risk of miscarriage; (xxvi) diminished symptoms of pregnancy; (xxvii) suspected or known cervical incompetence; (xxviii) suspected or known uterine abnormality; (xxix) pregnancy after assisted reproduction; (xxx) risk of fetal abnormality (R) Footnote: For nuchal translucency measurements performed when the pregnancy is dated by a crown rump length of 45 to 84mm, refer to item 55704 or 55707 (R) (NK). Fee is payable only for item 55704 or 55710, or, item 55707 or 55714, not both items (See para IN.0.19 of explanatory notes to this Category) Fee: \$35.00 **Benefit:** 75% = \$26.25 85% = \$29.75 **Extended Medicare Safety Net Cap: \$19.30** PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan of, by any or all approaches, where: the patient is not referred by a medical practitioner; and the dating of the pregnancy (as confirmed by ultrasound) is 12 to 16 weeks of gestation; and 55711 the service is not associated with a service to which an item in Subgroup 2 or 3 of this group

I1. ULTRASOUND 5. OBSTETRIC AND GYNAECOLOGICAL applies; and (d) one or more of the following conditions are present: hyperemesis gravidarum diabetes mellitus; (ii) hypertension; (iii) (iv) toxaemia of pregnancy; liver or renal disease; (vi) autoimmune disease; (vii) cardiac disease; (viii) alloimmunisation; (ix) maternal infection; inflammatory bowel disease; (x) bowel stoma; (xi) abdominal wall scarring; (xii) (xiii) previous spinal or pelvic trauma or disease; drug dependency; (xiv) (xv) thrombophilia; significant maternal obesity; (xvi) advanced maternal age; (xvii) (xviii) abdominal pain or mass; uncertain dates; (xix) high risk pregnancy; (xx)(xxi) previous post dates delivery; (xxii) previous caesarean section; (xxiii) poor obstetric history; (xxiv) suspicion of ectopic pregnancy;

(xxv) risk of miscarriage;

(xxvi) diminished symptoms of pregnancy;

11. ULTRASOUND 5. OBSTETRIC AND GYNAECOLOGICAL (xxvii) suspected or known cervical incompetence; suspected or known uterine abnormality; (xxviii) (xxix) pregnancy after assisted reproduction; (xxx) risk of fetal abnormality (NR) Footnote: For nuchal translucency measurements performed when the pregnancy is dated by a crown rump length of 45 to 84mm, refer to item 55708 or 55716 (R) (NK). Fee is payable only for item 55705 or 55711, or, item 55708 or 55716, not both items (See para IN.0.19 of explanatory notes to this Category) Fee: \$17.50 **Benefit:** 75% = \$13.15 85% = \$14.90 **Extended Medicare Safety Net Cap: \$8.30** PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan of, by any or all approaches, with measurement of all parameters for dating purposes, where: (a) the patient is referred by a medical practitioner who is a Member or a Fellow of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists or who has a Diploma of Obstetrics or has a qualification recognised by the Royal Australian and New Zealand College of Obstetricians and Gynaecologists as being equivalent to a Diploma of Obstetrics or has obstetric privileges at a non-metropolitan hospital; and the dating of the pregnancy (as confirmed by ultrasound) is 17 to 22 weeks of gestation; and (c) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and (d) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member: and (e) further examination is clinically indicated in the same pregnancy to which item 55706 or 55709 applies (R) (See para IN.0.19 of explanatory notes to this Category) **Benefit:** 75% = \$86.25 85% = \$97.75 Fee: \$115.00 55712 **Extended Medicare Safety Net Cap: \$65.90** PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan (not exceeding 1 service in any 1 pregnancy) of, by any or all approaches, with measurement of all parameters for dating purposes, where: the patient is referred by a medical practitioner; and the dating for the pregnancy (as confirmed by ultrasound) is 17 to 22 weeks of gestation; and the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and 55713 the referring practitioner is not a member of a group of practitioners of which the providing

I1. ULTR	ASOUND 5. OBSTETRIC AND GYNAECOLOGICAL
	practitioner is a member; and
	(e) the service is not performed in the same pregnancy as item 55709 or 55717 (R) (NK)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$50.00 Benefit: 75% = \$37.50 85% = \$42.50 Extended Medicare Safety Net Cap: \$27.50
	PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan (not exceeding 1 service in any 1 pregnancy) of, by any or all approaches, where;
	(a) the patient is referred by a medical practitioner; and
	(b) the pregnancy (as confirmed by ultrasound) is dated by a crown rump length of 45 to 84mm; and
	(c) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and
	(d) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member; and
	(e) one or more of the conditions mentioned in subparagraphs (e) (i) to (xxx) of item 55704 or 55710 are present; and
	(f) nuchal translucency measurement is performed to assess the risk of fetal abnormality; and
	(g) the service is not performed with item 55700, 55701, 55702, 55703, 55704, 55705, 55710 or 55711 on the same patient within 24 hours (R) (NK)
55714	(See para IN.0.19 of explanatory notes to this Category) Fee: \$35.00 Benefit: 75% = \$26.25 85% = \$29.75 Extended Medicare Safety Net Cap: \$19.30
	PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan of, by any or all approaches, with measurement of all parameters for dating purposes, performed by or on behalf of a medical practitioner who is a Member or a Fellow of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists, where:
	(a) the patient is not referred by a medical practitioner; and
	(b) the dating of the pregnancy (as confirmed by ultrasound) is 17 to 22 weeks of gestation; and
	(c) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and
	(d) further examination is clinically indicated in the same pregnancy to which item 55706 or 55709 applies (NR)
55715	(See para IN.0.19 of explanatory notes to this Category) Fee: \$40.00 Benefit: 75% = \$30.00 85% = \$34.00 Extended Medicare Safety Net Cap: \$22.00
	PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan (not exceeding 1 service in any 1 pregnancy) of, by any or all approaches, where;
55716	

11. ULTRASOUND 5. OBSTETRIC AND GYNAECOLOGICAL the patient is not referred by a medical practitioner; and the pregnancy (as confirmed by ultrasound) is dated by a crown rump length of 45 to 84mm; and the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and one or more of the conditions in subparagraphs (e) (i) to (xxx) of item 55704 or 55710 are present; and (e) nuchal translucency measurement is performed to assess the risk of fetal abnormality; and (f) the service is not performed in conjunction with item 55700, 55701, 55702, 55703, 55704, 55705, 55710 or 55711 on the same patient within 24 hours (NR) (NK) (See para IN.0.19 of explanatory notes to this Category) Fee: \$17.50 **Benefit:** $75\% = \$13.15 \quad 85\% = \14.90 Extended Medicare Safety Net Cap: \$8.30 PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan (not exceeding 1 service in any 1 pregnancy) of, by any or all approaches, with measurement of all parameters for dating purposes, where: (a) the patient is not referred by a medical practitioner; and the dating of the pregnancy (as confirmed by ultrasound) is 17 to 22 weeks of gestation; and (c) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and the service is not performed in the same pregnancy as item 55706 or 55713 (NR) (NK) (See para IN.0.19 of explanatory notes to this Category) Fee: \$19.00 **Benefit:** 75% = \$14.25 85% = \$16.15 55717 Extended Medicare Safety Net Cap: \$11.05 PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan (not exceeding 1 service in any 1 pregnancy) of, by any or all approaches, if: the patient is referred by a medical practitioner or participating midwife; and the dating of the pregnancy (as confirmed by ultrasound) is after 22 weeks of gestation; and (c) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and (d) if the patient is referred by a medical practitioner -- the referring medical practitioner is not a member of a group of practitioners of which the providing practitioner is a member; and (e) if the patient is referred by a participating midwife -- the referring midwife does not have a business or financial arrangement with the providing practitioner; and (f) the service is not performed in the same pregnancy as item 55723; and (g) 1 or more of the following conditions are present: known or suspected fetal abnormality or fetal cardiac arrhythmia; (i) 55718

I1. ULTRASOUND	5. OBSTETRIC AND GYNAECOLOGICAL
(ii)	fetal anatomy (late booking or incomplete mid-trimester scan);
(iii)	malpresentation;
(iv)	cervical assessment;
(v)	clinical suspicion of amniotic fluid abnormality;
(vi)	clinical suspicion of placental or umbilical cord abnormality;
(vii)	previous complicated delivery;
(viii)	uterine scar assessment;
(ix)	uterine fibroid;
(x)	previous fetal death in utero or neonatal death;
(xi)	antepartum haemorrhage;
(xii)	clinical suspicion of intrauterine growth retardation;
(xiii)	clinical suspicion of macrosomia;
(xiv)	reduced fetal movements;
(xv)	suspected fetal death;
(xvi)	abnormal cardiotocography;
(xvii)	prolonged pregnancy;
(xviii)	premature labour;
(xix)	fetal infection;
(xx)	pregnancy after assisted reproduction;
(xxi)	trauma;
(xxii)	diabetes mellitus;
(xxiii)	hypertension;
(xxiv)	toxaemia of pregnancy;
(xxv)	liver or renal disease;
(xxvi)	autoimmune disease;
(xxvii)	cardiac disease;
(xxviii)	alloimmunisation;
(xxix)	maternal infection;

I1. ULTR	ASOUND 5. OBSTETRIC AND GYNAECOLOGICAL
	(xxx) inflammatory bowel disease;
	(xxxi) bowel stoma;
	(xxxii) abdominal wall scarring;
	(xxxiii) previous spinal or pelvic trauma or disease;
	(xxxiv) drug dependency;
	(xxxv) thrombophilia;
	(xxxvi) significant maternal obesity;
	(xxxvii) advanced maternal age;
	(xxxviii) abdominal pain or mass (R)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$100.00 Benefit: 75% = \$75.00 85% = \$85.00 Extended Medicare Safety Net Cap: \$54.90
	PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan of, by any or all approaches, with measurement of all parameters for dating purposes, where:
	(a) the patient is referred by a medical practitioner who is a Member or a Fellow of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists or who has a Diploma of Obstetrics or has a qualification recognised by the Royal Australian and New Zealand College of Obstetricians and Gynaecologists as being equivalent to a Diploma of Obstetrics or has obstetric privileges at a non-metropolitan hospital; and
	(b) the dating of the pregnancy (as confirmed by ultrasound) is 17 to 22 weeks of gestation; and
	(c) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and
	(d) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member; and
	(e) further examination is clinically indicated in the same pregnancy to which item 55706, 55709, 55713 or 55717 applies (R) (NK)
55719	(See para IN.0.19 of explanatory notes to this Category) Fee: \$57.50 Benefit: 75% = \$43.15 85% = \$48.90 Extended Medicare Safety Net Cap: \$32.95
	PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan of, by any or all approaches, with measurement of all parameters for dating purposes, performed by or on behalf of a medical practitioner who is a Member or a Fellow of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists, where:
	(a) the patient is not referred by a medical practitioner; and
	(b) the dating of the pregnancy (as confirmed by ultrasound) is 17 to 22 weeks of gestation; and
55720	(c) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group

11. ULTRASOUND 5. OBSTETRIC AND GYNAECOLOGICAL applies; and (d) further examination is clinically indicated in the same pregnancy to which item 55706, 55709, 55713 or 55717 applies (NR) (NK) (See para IN.0.19 of explanatory notes to this Category) Fee: \$20.00 **Benefit:** 75% = \$15.00 85% = \$17.00 **Extended Medicare Safety Net Cap: \$11.05** PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan of by any or all approaches, where: the patient is referred by a medical practitioner who is a Member or a Fellow of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists or who has a Diploma of Obstetrics or has qualifications recognised by the Royal Australian and New Zealand College of Obstetricians and Gynaecologists as being equivalent to a Diploma of obstetrics or has obstetric privileges at a non-metropolitan hospital; and the dating of the pregnancy (as confirmed by ultrasound) is after 22 weeks of gestation; and the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and (d) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member; and (e) further examination is clinically indicated in the same pregnancy to which item 55718 or 55723 applies (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$115.00 **Benefit:** 75% = \$86.25 85% = \$97.75 **Extended Medicare Safety Net Cap: \$65.90** 55721 PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan (not exceeding 1 service in any 1 pregnancy) of, by any or all approaches, where: the patient is referred by a medical practitioner; and the dating of the pregnancy (as confirmed by ultrasound) is after 22 weeks of gestation; and the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and (d) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member; and the service is not performed in the same pregnancy as item 55723 or 55726; and one or more of the following conditions are present:

55722

(i)

(ii)

known or suspected fetal abnormality or fetal cardiac arrhythmia;

fetal anatomy (late booking or incomplete mid-trimester scan);

I1. ULTRASOUND	5. OBSTETRIC AND GYNAECOLOGICAL
(iii)	malpresentation;
(iv)	cervical assessment;
(v)	clinical suspicion of amniotic fluid abnormality;
(vi)	clinical suspicion of placental or umbilical cord abnormality;
(vii)	previous complicated delivery;
(viii)	uterine scar assessment;
(ix)	uterine fibroid;
(x)	previous fetal death in utero or neonatal death;
(xi)	antepartum haemorrhage;
(xii)	clinical suspicion of intrauterine growth retardation;
(xiii)	clinical suspicion of macrosomia;
(xiv)	reduced fetal movements;
(xv)	suspected fetal death;
(xvi)	abnormal cardiotocography;
(xvii)	prolonged pregnancy;
(xviii)	premature labour;
(xix)	fetal infection;
(xx)	pregnancy after assisted reproduction;
(xxi)	trauma;
(xxii)	diabetes mellitus;
(xxiii)	hypertension;
(xxiv)	toxaemia of pregnancy;
(xxv)	liver or renal disease;
(xxvi)	autoimmune disease;
(xxvii)	cardiac disease;
(xxviii)	alloimmunisation;
(xxix)	maternal infection;
(xxx)	inflammatory bowel disease;

I1. ULTRASOUND	5. OBSTETRIC AND GYNAECOLOGICAL
(xxxi)	bowel stoma;
(xxxii)	abdominal wall scarring;
(xxxiii)	previous spinal or pelvic trauma or disease;
(xxxiv)	drug dependency;
(xxxv)	thrombophilia;
(xxxvi)	significant maternal obesity;
(xxxvii)	advanced maternal age;
(xxxviii)	abdominal pain or mass (R) (NK)
Fee: \$50.00	.0.19 of explanatory notes to this Category) Benefit: 75% = \$37.50 85% = \$42.50 Medicare Safety Net Cap: \$27.50
	R ABDOMEN, pregnancy related or pregnancy complication, fetal development and trasound scan (not exceeding 1 service in any 1 pregnancy) of, by any or all approaches,
(a) the par	tient is not referred by a medical practitioner; and
(b) the da	ting of the pregnancy (as confirmed by ultrasound) is after 22 weeks of gestation; and
(c) the ser applies; and	rvice is not associated with a service to which an item in Subgroup 2 or 3 of this group
(d) the ser	rvice is not performed in the same pregnancy as item 55718; and
(e) one or	more of the following conditions are present:
(i) kı	nown or suspected fetal abnormality or fetal cardiac arrhythmia;
(ii) f	etal anatomy (late booking or incomplete mid-trimester scan);
(iii)	malpresentation;
(iv)	cervical assessment;
(v) c	linical suspicion of amniotic fluid abnormality;
(vi)	clinical suspicion of placental or umbilical cord abnormality;
(vii)	previous complicated delivery;
(viii)	uterine scar assessment;
(ix) t	uterine fibroid;
(x) p	revious fetal death in utero or neonatal death;
55723 (xi) a	antepartum haemorrhage;

I1. ULTRASOUND	5. OBSTETRIC AND GYNAECOLOGICAL
(xii)	clinical suspicion of intrauterine growth retardation;
(xiii)	clinical suspicion of macrosomia;
(xiv)	reduced fetal movements;
(xv)	suspected fetal death;
(xvi)	abnormal cardiotocography;
(xvii)	prolonged pregnancy;
(xviii)	premature labour;
(xix)	fetal infection;
(xx)	pregnancy after assisted reproduction;
(xxi)	trauma;
(xxii)	diabetes mellitus;
(xxiii)	hypertension;
(xxiv)	toxaemia of pregnancy;
(xxv)	liver or renal disease;
(xxvi)	autoimmune disease;
(xxvii)	cardiac disease;
(xxviii)	alloimmunisation;
(xxix)	maternal infection;
(xxx)	inflammatory bowel disease;
(xxxi)	bowel stoma;
(xxxii)	abdominal wall scarring;
(xxxiii)	previous spinal or pelvic trauma or disease;
(xxxiv)	drug dependency;
(xxxv)	thrombophilia;
(xxxvi)	significant maternal obesity;
(xxxvii)	advanced maternal age;
(xxxviii)	abdominal pain or mass (NR)
Fee: \$38.00	N.0.19 of explanatory notes to this Category) Benefit: 75% = \$28.50 85% = \$32.30 Medicare Safety Net Cap: \$22.00

11. ULTRASOUND 5. OBSTETRIC AND GYNAECOLOGICAL PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan of by any or all approaches, where: the patient is referred by a medical practitioner who is a Member or a Fellow of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists or who has a Diploma of Obstetrics or has qualifications recognised by the Royal Australian and New Zealand College of Obstetricians and Gynaecologists as being equivalent to a Diploma of obstetrics or has obstetric privileges at a non-metropolitan hospital; and the dating of the pregnancy (as confirmed by ultrasound) is after 22 weeks of gestation; and the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and (d) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member: and (e) further examination is clinically indicated in the same pregnancy to which item 55718, 55722, 55723 or 55726 applies (R) NK) (See para IN.0.19 of explanatory notes to this Category) Fee: \$57.50 **Benefit:** 75% = \$43.15 85% = \$48.90 55724 **Extended Medicare Safety Net Cap: \$32.95** PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan of, by any or all approaches, performed by or on behalf of a medical practitioner who is a Member or a Fellow of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists, where: the patient is not referred by a medical practitioner; and the dating of the pregnancy (as confirmed by ultrasound) is after 22 weeks of gestation; and (c) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and (d) further examination is clinically indicated in the same pregnancy to which item 55718 or 55723 applies (NR) (See para IN.0.19 of explanatory notes to this Category) Fee: \$40.00 **Benefit:** $75\% = \$30.00 \quad 85\% = \34.00 55725 Extended Medicare Safety Net Cap: \$22.00 PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and

anatomy, ultrasound scan (not exceeding 1 service in any 1 pregnancy) of, by any or all approaches, where:

- the patient is not referred by a medical practitioner; and (a)
- the dating of the pregnancy (as confirmed by ultrasound) is after 22 weeks of gestation; and
- the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and
- (d) the service is not performed in the same pregnancy as item 55718 or 55722; and

I1. ULTRASOUND 5. OBSTETRIC AND GYNAECOLOGICAL one or more of the following conditions are present: (e) (i) known or suspected fetal abnormality or fetal cardiac arrhythmia; (ii) fetal anatomy (late booking or incomplete mid-trimester scan); (iii) malpresentation; (iv) cervical assessment; (v) clinical suspicion of amniotic fluid abnormality; (vi) clinical suspicion of placental or umbilical cord abnormality; (vii) previous complicated delivery; (viii) uterine scar assessment; (ix) uterine fibroid; (x) previous fetal death in utero or neonatal death; (xi) antepartum haemorrhage; (xii) clinical suspicion of intrauterine growth retardation; (xiii) clinical suspicion of macrosomia; (xiv) reduced fetal movements; suspected fetal death; (xv) (xvi) abnormal cardiotocography; (xvii) prolonged pregnancy; (xviii) premature labour; (xix) fetal infection; (xx)pregnancy after assisted reproduction; (xxi) trauma; (xxii) diabetes mellitus; (xxiii) hypertension; (xxiv) toxaemia of pregnancy; (xxv) liver or renal disease; (xxvi) autoimmune disease;

(xxvii)

cardiac disease;

I1. ULTI	RASOUND	5. OBSTETRIC AND GYNAECOLOGICAL
	(xxviii)	alloimmunisation;
	(xxix)	maternal infection;
	(xxx)	inflammatory bowel disease;
	(xxxi)	bowel stoma;
	(xxxii)	abdominal wall scarring;
	(xxxiii)	previous spinal or pelvic trauma or disease;
	(xxxiv)	drug dependency;
	(xxxv)	thrombophilia;
	(xxxvi)	significant maternal obesity;
	(xxxvii)	advanced maternal age;
	(xxxviii)	abdominal pain or mass (NR) (NK)
	Fee: \$19.00	0.19 of explanatory notes to this Category) Benefit: 75% = \$14.25 85% = \$16.15 Medicare Safety Net Cap: \$11.05
	anatomy, ul practitioner	A ABDOMEN, pregnancy related or pregnancy complication, fetal development and trasound scan of, by any or all approaches, performed by or on behalf of a medical who is a Member or a Fellow of the Royal Australian and New Zealand College of as and Gynaecologists, where:
	(a) the pat	ient is not referred by a medical practitioner; and
	(b) the dat	ring of the pregnancy (as confirmed by ultrasound) is after 22 weeks of gestation; and
	(c) the ser applies; and	vice is not associated with a service to which an item in Subgroup 2 or 3 of this group
		examination is clinically indicated in the same pregnancy to which item 55718, 55722, 726 applies (NR) (NK)
55727	Fee: \$20.00	0.19 of explanatory notes to this Category) Benefit: 75% = \$15.00 85% = \$17.00 Medicare Safety Net Cap: \$11.05
	spectral ana 24 th week of where there	lysis of the umbilical artery, and measured assessment of amniotic fluid volume after the f gestation where the patient is referred by a medical practitioner for this procedure and is reason to suspect intrauterine growth retardation or a significant risk of foetal death, not ice associated with a service to which an item in this Group applies - (R)
55729	Fee: \$27.25	0.19 of explanatory notes to this Category) Benefit: 75% = \$20.45 85% = \$23.20 Idedicare Safety Net Cap: \$16.55
55730	spectral ana	uning involving B mode ultrasound imaging and integrated Doppler flow measurements by lysis of the umbilical artery, and measured assessment of amniotic fluid volume after the of gestation where the patient is referred by a medical practitioner for this procedure and

I1. ULTI	RASOUND 5. OBSTETRIC AND GYNAECOLOGICAL
	where there is reason to suspect intrauterine growth retardation or a significant risk of foetal death, not being a service associated with a service to which an item in this Group applies (R) (NK)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$13.65 Benefit: 75% = \$10.25 Extended Medicare Safety Net Cap: \$8.30
	PELVIS, ultrasound scan of, in association with saline infusion of the endometrial cavity, by any or all approaches, where:
	(a) the patient is referred by a medical practitioner; and
	(b) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and
	(c) the referring medical practitioner is not a member of a group of medical practitioners of which the providing
	practitioner is a member; and
	(d) a previous transvaginal ultrasound has revealed an abnormality of the uterus or fallopian tube (R) (NK)
55735	(See para IN.0.19 of explanatory notes to this Category) Fee: \$63.50 Benefit: 75% = \$47.65 85% = \$54.00
	PELVIS, ultrasound scan of, in association with saline infusion of the endometrial cavity, by any or all approaches, where:
	(a) the patient is referred by a medical practitioner; and
	(b) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and
	(c) the referring medical practitioner is not a member of a group of medical practitioners of which the providing
	practitioner is a member; and
	(d) a previous transvaginal ultrasound has revealed an abnormality of the uterus or fallopian tube (R)
55736	(See para IN.0.19 of explanatory notes to this Category) Fee: \$127.00 Benefit: 75% = \$95.25 85% = \$107.95
	PELVIS, ultrasound scan of, in association with saline infusion of the endometrial cavity, by any or all approaches, where:
	(a) the patient is not referred by a medical practitioner; and
	(b) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and
	(c) a previous transvaginal ultrasound has revealed an abnormality of the uterus or fallopian tube (NR) (NK)
55737	(See para IN.0.19 of explanatory notes to this Category) Fee: \$28.50 Benefit: 75% = \$21.40 85% = \$24.25
55739	PELVIS, ultrasound scan of, in association with saline infusion of the endometrial cavity, by any or all

11. ULTRASOUND 5. OBSTETRIC AND GYNAECOLOGICAL approaches, where: the patient is not referred by a medical practitioner; and the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and a previous transvaginal ultrasound has revealed an abnormality of the uterus or fallopian tube (NR) (See para IN.0.19 of explanatory notes to this Category) **Benefit:** 75% = \$42.75 85% = \$48.45Fee: \$57.00 PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan (not exceeding 1 service in any 1 pregnancy) of, by any or all approaches, with measurement of all parameters for dating purposes, where: the patient is referred by a medical practitioner; and ultrasound of the same pregnancy confirms a multiple pregnancy; and the dating of the pregnancy (as confirmed by ultrasound) is 17 to 22 weeks gestation; and (d) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and (e) the referring practitioner is not a member of a group of practitioners to which the providing practitioner is a member: and (f) the service is not performed in conjunction with item 55706, 55709, 55712, 55715 or 55762 during the same pregnancy (R) (See para IN.0.19 of explanatory notes to this Category) **Benefit:** $75\% = \$112.50 \quad 85\% = \127.50 55759 Fee: \$150.00 PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan (not exceeding 1 service in any 1 pregnancy) of, by any or all approaches, with measurement of all parameters for dating purposes, where: the patient is referred by a medical practitioner; and ultrasound of the same pregnancy confirms a multiple pregnancy; and the dating of the pregnancy (as confirmed by ultrasound) is 17 to 22 weeks gestation; and the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and (e) the referring practitioner is not a member of a group of practitioners to which the providing practitioner is a member; and (f) the service is not performed in conjunction with item 55706, 55709, 55712, 55713, 55715, 55717, 55719, 57721, 55762 or 55763 during the same pregnancy (R) (NK) (See para IN.0.19 of explanatory notes to this Category) Fee: \$75.00 **Benefit:** 75% = \$56.25 85% = \$63.75 55760

5. OBSTETRIC AND GYNAECOLOGICAL **11. ULTRASOUND** PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan (not exceeding 1 service in any 1 pregnancy) of, by any or all approaches, with measurement of all parameters for dating purposes, where: the patient is not referred by a medical practitioner; and ultrasound of the same pregnancy confirms a multiple pregnancy; and the dating of the pregnancy (as confirmed by ultrasound) is 17 to 22 weeks gestation; and (d) the service is not performed in conjunction with item 55706, 55709, 55712, 55715 or 55759during the same pregnancy; and (e) the service is not associated with a service to which an item in Subgroups 2 or 3 of this group applies (NR) (See para IN.0.19 of explanatory notes to this Category) **Benefit:** 75% = \$45.00 85% = \$51.00 Fee: \$60.00 **Extended Medicare Safety Net Cap: \$32.95** 55762 PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan (not exceeding 1 service in any 1 pregnancy) of, by any or all approaches, with measurement of all parameters for dating purposes, where: the patient is not referred by a medical practitioner; and ultrasound of the same pregnancy confirms a multiple pregnancy; and the dating of the pregnancy (as confirmed by ultrasound) is 17 to 22 weeks gestation; and (d) the service is not performed in conjunction with item 55706, 55709, 55712, 55713, 55715, 55717, 55719, 55720, 55759 or 55760 during the same pregnancy; and (e) the service is not associated with a service to which an item in Subgroups 2 or 3 of this group applies (NR) (NK) (See para IN.0.19 of explanatory notes to this Category) Fee: \$30.00 **Benefit:** 75% = \$22.50 85% = \$25.50 55763 **Extended Medicare Safety Net Cap: \$16.50** PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan of, by any or all approaches, with measurement of all parameters for dating purposes, where: the patient is referred by a medical practitioner who is a Member or Fellow of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists or who has a Diploma of Obstetrics or has a qualification recognised by the Royal Australian and New Zealand College of Obstetricians and Gynaecologists as equivalent to a Diploma of obstetrics or has obstetric privileges at a non-metropolitan hospital; and ultrasound of the same pregnancy confirms a multiple pregnancy; and the dating of the pregnancy (as confirmed by ultrasound) is 17 to 22 weeks gestation; and (d) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and 55764

I1. ULTRASOUND

5. OBSTETRIC AND GYNAECOLOGICAL

- (e) the referring practitioner is not a member of a group of practitioners to which the providing practitioner is a member; and
- (f) further examination is clinically indicated in the same pregnancy to which item 55759 or 55762 has been performed; and
- (g) not performed in conjunction with item 55706, 55709, 55712 or 55715 during the same pregnancy (R)

(See para IN.0.19 of explanatory notes to this Category)

Fee: \$160.00 **Benefit:** 75% = \$120.00 85% = \$136.00

Extended Medicare Safety Net Cap: \$87.85

PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan of, by any or all approaches, with measurement of all parameters for dating purposes, where:

- (a) the patient is referred by a medical practitioner who is a Member or Fellow of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists or who has a Diploma of Obstetrics or has a qualification recognised by the Royal Australian and New Zealand College of Obstetricians and Gynaecologists as equivalent to a Diploma of obstetrics or has obstetric privileges at a non-metropolitan hospital; and
- (b) ultrasound of the same pregnancy confirms a multiple pregnancy; and
- (c) the dating of the pregnancy (as confirmed by ultrasound) is 17 to 22 weeks gestation; and
- (d) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; and
- (e) the referring practitioner is not a member of a group of practitioners to which the providing practitioner is a member; and
- (f) further examination is clinically indicated in the same pregnancy to which item 55759, 55760, 55762 or 55763 has been performed; and
- (g) not performed in conjunction with item 55706, 55709, 55712, 55713, 55715, 55717, 55719 during the same pregnancy (R) (NK)

(See para IN.0.19 of explanatory notes to this Category)

Fee: \$80.00 **Benefit:** 75% = \$60.00 85% = \$68.00

55765 Extended Medicare Safety Net Cap: \$44.00

PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan of, by any or all approaches, with measurement of all parameters for dating purposes, performed by or on behalf of a medical practitioner who is a Member or Fellow of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists, where:

- (a) the patient is not referred by a medical practitioner; and
- (b) ultrasound of the same pregnancy confirms a multiple pregnancy; and
- (c) the dating of the pregnancy (as confirmed by ultrasound) is 17 to 22 weeks of gestation; and
- (d) the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies;

55766

11. ULTRASOUND 5. OBSTETRIC AND GYNAECOLOGICAL further examination is clinically indicated in the same pregnancy to which item 55759, or 55762 has been performed; and (f) not performed in conjunction with item 55706, 55709, 55712 or 55715 during the same pregnancy (NR) (See para IN.0.19 of explanatory notes to this Category) Fee: \$65.00 **Benefit:** 75% = \$48.75 85% = \$55.25 **Extended Medicare Safety Net Cap: \$32.95** PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan of, by any or all approaches, with measurement of all parameters for dating purposes, performed by or on behalf of a medical practitioner who is a Member or Fellow of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists, where: the patient is not referred by a medical practitioner; and ultrasound of the same pregnancy confirms a multiple pregnancy; and the dating of the pregnancy (as confirmed by ultrasound) is 17 to 22 weeks of gestation; and the service is not associated with a service to which an item in Subgroup 2 or 3 of this group applies; (e) further examination is clinically indicated in the same pregnancy to which item 55759, 55760, 55762 or 55763 has been performed; and (f) not performed in conjunction with item 55706, 55709, 55712, 55713, 55715, 55717, 55719 or 55720 during the same pregnancy (NR) (NK) (See para IN.0.19 of explanatory notes to this Category) Fee: \$32.50 **Benefit:** 75% = \$24.40 85% = \$27.6555767 **Extended Medicare Safety Net Cap: \$16.50** PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan (not exceeding 1 service in any 1 pregnancy) of, by any or all approaches, where: dating of the pregnancy (as confirmed by ultrasound) is after 22 weeks of gestation; and the ultrasound confirms a multiple pregnancy; and the patient is referred by a medical practitioner; and the service is not performed in the same pregnancy as item 55770; and (e) the service is not associated with a service to which an item in Subgroups 2 or 3 of this group applies; and (f) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member;

(See para IN.0.19 of explanatory notes to this Category)

and

same pregnancy (R)

(g) the service is not performed in conjunction with item 55718, 55721, 55723 or 55725 during the

I1. ULTI	1. ULTRASOUND 5. OBSTETRIC AND GYNAECOLOGIC	
	Fee: \$150.00 Benefit: 75% = \$112.50 Extended Medicare Safety Net Cap: \$82.40	
		or pregnancy complication, fetal development and rvice in any 1 pregnancy) of, by any or all approaches,
	(a) dating of the pregnancy (as confirmed by	y ultrasound) is after 22 weeks of gestation; and
	(b) the ultrasound confirms a multiple pregr	nancy; and
	(c) the patient is referred by a medical pract	itioner; and
	(d) the service is not performed in the same	pregnancy as item 55770 or 55771; and
	(e) the service is not associated with a service applies; and	ce to which an item in Subgroups 2 or 3 of this group
	(f) the referring practitioner is not a member practitioner is a member;	r of a group of practitioners of which the providing
	and	
	(g) the service is not performed in conjuncti 55726 or 55727 during the same pregnancy (I	on with item 55718, 55721, 55722, 55723, 55724, 55725, R) (NK)
55769	(See para IN.0.19 of explanatory notes to this Cate Fee: \$75.00 Benefit: 75% = \$56.25 Extended Medicare Safety Net Cap: \$41.25	
		or pregnancy complication, fetal development and rvice in any 1 pregnancy), by any or all approaches, where:
	(a) dating of the pregnancy as confirmed by	ultrasound is after 22 weeks of gestation; and
	(b) the patient is not referred by a medical p	ractitioner; and
	(c) the service is not performed in the same	pregnancy as item 55768; and
	(d) the pregnancy as confirmed by ultrasour	nd is a multiple pregnancy; and
	(e) the service is not associated with a service applies; and	ce to which an item in Subgroups 2 or 3 of this group
	(f) the service is not performed in conjunction same	on with item 55718, 55721, 55723 or 55725 during the
	pregnancy (NR)	
55770	(See para IN.0.19 of explanatory notes to this Cate Fee: \$60.00 Benefit: 75% = \$45.00 Extended Medicare Safety Net Cap: \$32.95	
22770	PELVIS OR ABDOMEN, pregnancy related	or pregnancy complication, fetal development and rvice in any 1 pregnancy), by any or all approaches, where:
55771	(a) dating of the pregnancy as confirmed by	ultrasound is after 22 weeks of gestation; and

11. ULTRASOUND

5. OBSTETRIC AND GYNAECOLOGICAL

- (b) the patient is not referred by a medical practitioner; and
- (c) the service is not performed in the same pregnancy as item 55768 or 55759; and
- (d) the pregnancy as confirmed by ultrasound is a multiple pregnancy; and
- (e) the service is not associated with a service to which an item in Subgroups 2 or 3 of this group applies; and
- (f) the service is not performed in conjunction with item 55718, 55721, 55723, 55724,,55725, 55726 or 55727 during the same pregnancy (NR) (NK)

(See para IN.0.19 of explanatory notes to this Category)

Fee: \$30.00 **Benefit:** 75% = \$22.50 85% = \$25.50

Extended Medicare Safety Net Cap: \$16.50

PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan of, by any or all approaches, where:

- (a) dating of the pregnancy as confirmed by ultrasound is after 22 weeks of gestation; and
- (b) the patient is referred by a medical practitioner who is a Member or Fellow of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists or who has a Diploma of Obstetrics or has a qualification recognised by the Royal Australian and New Zealand College of Obstetricians and Gynaecologists as equivalent to a Diploma of obstetrics or has obstetric privileges at a non-metropolitan hospital; and
- (c) further examination is clinically indicated in the same pregnancy to which item 55768 or 55770 has been performed; and
- (d) the pregnancy as confirmed by ultrasound is a multiple pregnancy; and
- (e) the service is not associated with a service to which an item in Subgroups 2 or 3 of this group applies; and
- (f) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member; and
- (g) the service is not performed in conjunction with item 55718, 55721, 55723 or 55725 during the same pregnancy (R)

(See para IN.0.19 of explanatory notes to this Category)

Fee: \$160.00 Benefit: 75% = \$120.00 85% = \$136.00

55772 Extended Medicare Safety Net Cap: \$87.85

PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan of, by any or all approaches, where:

- (a) dating of the pregnancy as confirmed by ultrasound is after 22 weeks of gestation; and
- (b) the patient is referred by a medical practitioner who is a Member or Fellow of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists or who has a Diploma of Obstetrics or has a qualification recognised by the Royal Australian and New Zealand College of Obstetricians and Gynaecologists as equivalent to a Diploma of obstetrics or has obstetric privileges at a non-metropolitan hospital; and
- (c) further examination is clinically indicated in the same pregnancy to which item 55768, 55769,

11. ULTRASOUND applies; and practitioner is a member; and Fee: \$80.00

5. OBSTETRIC AND GYNAECOLOGICAL

55770 or 55771 has been performed; and

- the pregnancy as confirmed by ultrasound is a multiple pregnancy; and
- the service is not associated with a service to which an item in Subgroups 2 or 3 of this group
- the referring practitioner is not a member of a group of practitioners of which the providing
- (g) the service is not performed in conjunction with item 55718, 55721, 55722, 55723, 55724, 55725, 55726 or 55727 during the same pregnancy (R) (NK)

(See para IN.0.19 of explanatory notes to this Category)

Benefit: $75\% = \$60.00 \quad 85\% = \68.00

Extended Medicare Safety Net Cap: \$44.00

PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan of, by any or all approaches, performed by or on behalf of a medical practitioner who is a Member or a Fellow of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists, where:

- dating of the pregnancy as confirmed by ultrasound is after 22 weeks of gestation; and
- the patient is not referred by a medical practitioner; and
- (c) further examination is clinically indicated in the same pregnancy to which item 55768 or 55770 has been performed

;and

- the pregnancy as confirmed by ultrasound is a multiple pregnancy; and
- the service is not associated with a service to which an item in Subgroups 2 or 3 of this group applies; and
- (f) the service is not performed in conjunction with item 55718, 55721 55723 or 55725 during the same

pregnancy (NR)

(See para IN.0.19 of explanatory notes to this Category)

Fee: \$65.00 **Benefit:** 75% = \$48.75 85% = \$55.25

Extended Medicare Safety Net Cap: \$38.50 55774

> PELVIS OR ABDOMEN, pregnancy related or pregnancy complication, fetal development and anatomy, ultrasound scan of, by any or all approaches, performed by or on behalf of a medical practitioner who is a Member or a Fellow of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists, where:

- dating of the pregnancy as confirmed by ultrasound is after 22 weeks of gestation; and
- the patient is not referred by a medical practitioner; and
- (c) further examination is clinically indicated in the same pregnancy to which item 55768, 55769, 55770 or 5571 has been performed; and

55775

I1. ULT	RASOUND 5. OBSTETRIC AND GYNAECOLOGICA
	(d) the pregnancy as confirmed by ultrasound is a multiple pregnancy; and
	(e) the service is not associated with a service to which an item in Subgroups 2 or 3 of this group applies; and
	(f) the service is not performed in conjunction with item 55718, 55721, 55722, 55723, 55724, 55725, 55726 or 55727 during the same pregnancy (NR) (NK)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$32.50 Benefit: 75% = \$24.40 85% = \$27.65 Extended Medicare Safety Net Cap: \$19.30
I1. ULT	RASOUND 6. MUSCULOSKELETA
	Group I1. Ultrasound
	Subgroup 6. Musculoskeletal
	HAND OR WRIST, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member (R)
55800	(See para IN.0.19 of explanatory notes to this Category) Fee: \$109.10 Benefit: 75% = \$81.85 85% = \$92.75
	HAND OR WRIST, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member (R) (NK)
55801	(See para IN.0.19 of explanatory notes to this Category) Fee: \$54.55 Benefit: 75% = \$40.95 85% = \$46.40
	HAND OR WRIST, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the patient is not referred by a medical practitioner (NR)
55802	(See para IN.0.19 of explanatory notes to this Category) Fee: \$37.85 Benefit: 75% = \$28.40 85% = \$32.20
	HAND OR WRIST, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the patient is not referred by a medical practitioner (NR) (NK)
55803	(See para IN.0.19 of explanatory notes to this Category) Fee: \$18.95 Benefit: 75% = \$14.25 85% = \$16.15

I1. ULTRASOUND 6. MUSCULOSKELE	
	FOREARM OR ELBOW, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member (R)
55804	(See para IN.0.19 of explanatory notes to this Category) Fee: \$109.10 Benefit: 75% = \$81.85 85% = \$92.75
	FOREARM OR ELBOW, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member (R) (NK)
55805	(See para IN.0.19 of explanatory notes to this Category) Fee: \$54.55 Benefit: 75% = \$40.95 85% = \$46.40
	FOREARM OR ELBOW, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the patient is not referred by a medical practitioner (NR)
55806	(See para IN.0.19 of explanatory notes to this Category) Fee: \$37.85 Benefit: 75% = \$28.40 85% = \$32.20
	FOREARM OR ELBOW, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the patient is not referred by a medical practitioner (NR) (NK)
55807	(See para IN.0.19 of explanatory notes to this Category) Fee: \$18.95 Benefit: 75% = \$14.25 85% = \$16.15
	SHOULDER OR UPPER ARM, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member,
	and where the service is provided, for the assessment of one or more of the following conditions or suspected
	conditions:
55808	- evaluation of injury to tendon, muscle or muscle/tendon junction; or

11. ULTRASOUND 6. MUSCULOSKELETAL rotator cuff tear/calcification/tendinosis (biceps, subscapular, suspraspinatus, infraspinatus); or biceps subluxation; or capsulitis and bursitis; or evaluation of mass including ganglion; or occult fracture; or acromioclavicular joint pathology.(R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$109.10 **Benefit:** 75% = \$81.85 85% = \$92.75 Note: Benefits are only payable when referred based on the clinical indicators outlined in the item descriptions. Benefits are not payable when referred for non-specific shoulder pain alone. SHOULDER OR UPPER ARM, 1 or both sides, ultrasound scan of, where: the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and (b) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member, and where the service is provided, for the assessment of one or more of the following conditions or suspected conditions: evaluation of injury to tendon, muscle or muscle/tendon junction; or rotator cuff tear/calcification/tendinosis (biceps, subscapular, suspraspinatus, infraspinatus); or biceps subluxation; or capsulitis and bursitis; or evaluation of mass including ganglion; or occult fracture; or acromioclavicular joint pathology (R) (NK) (See para IN.0.19 of explanatory notes to this Category) 55809 Fee: \$54.55 **Benefit:** 75% = \$40.95 85% = \$46.40 SHOULDER OR UPPER ARM, 1 or both sides, ultrasound scan of, where: the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and (b) the patient is not referred by a medical practitioner,

55810

and where the service is provided, for the assessment of one or more of the following conditions or

I1. ULTR	ASOUND 6. MUSCULOSKELETAL
	suspected
	conditions:
	- evaluation of injury to tendon, muscle or muscle/tendon junction; or
	- rotator cuff tear/calcification/tendinosis (biceps, subscapular, suspraspinatus, infraspinatus); or
	- biceps subluxation; or
	- capsulitis and bursitis; or
	- evaluation of mass including ganglion; or
	- occult fracture; or
	- acromioclavicular joint pathology.(NR)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$37.85 Benefit: 75% = \$28.40 85% = \$32.20
	Note: Benefits are only payable when referred based on the clinical indicators outlined in the item descriptions. Benefits are not payable when referred for non-specific shoulder pain alone.
	SHOULDER OR UPPER ARM, 1 or both sides, ultrasound scan of, where: (a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group
	applies; and
	(b) the patient is not referred by a medical practitioner,
	and where the service is provided, for the assessment of one or more of the following conditions or suspected
	conditions:
	- evaluation of injury to tendon, muscle or muscle/tendon junction; or
	- rotator cuff tear/calcification/tendinosis (biceps, subscapular, suspraspinatus, infraspinatus); or
	- biceps subluxation; or
	- capsulitis and bursitis; or
	- evaluation of mass including ganglion; or
	- occult fracture; or
	- acromioclavicular joint pathology (NR) (NK)
55811	(See para IN.0.19 of explanatory notes to this Category) Fee: \$18.95 Benefit: 75% = \$14.25 85% = \$16.15
	CHEST OR ABDOMINAL WALL, 1 or more areas, ultrasound scan of, where:
55812	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group

I1. ULTI	I1. ULTRASOUND 6. MUSCULOSKELET	
	applies; and	
	(b) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member (R)	
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$109.10 Benefit: 75% = \$81.85 85% = \$92.75	
	CHEST OR ABDOMINAL WALL, 1 or more areas, ultrasound scan of, where:	
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and	
	(b) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member (R) (NK)	
55813	(See para IN.0.19 of explanatory notes to this Category) Fee: \$54.55 Benefit: 75% = \$40.95 85% = \$46.40	
	CHEST OR ABDOMINAL WALL, 1 or more areas, ultrasound scan of, where:	
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and	
	(b) the patient is not referred by a medical practitioner (NR)	
55814	(See para IN.0.19 of explanatory notes to this Category) Fee: \$37.85 Benefit: 75% = \$28.40 85% = \$32.20	
	CHEST OR ABDOMINAL WALL, 1 or more areas, ultrasound scan of, where:	
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and	
	(b) the patient is not referred by a medical practitioner (NR) (NK)	
55815	(See para IN.0.19 of explanatory notes to this Category) Fee: \$18.95 Benefit: 75% = \$14.25 85% = \$16.15	
	HIP OR GROIN, 1 or both sides, ultrasound scan of, where:	
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and	
	(b) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member (R)	
55816	(See para IN.0.19 of explanatory notes to this Category) Fee: \$109.10 Benefit: 75% = \$81.85 85% = \$92.75	
	HIP OR GROIN, 1 or both sides, ultrasound scan of, where:	
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and	
	(b) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member (R) (NK)	
55817	(See para IN.0.19 of explanatory notes to this Category) Fee: \$54.55 Benefit: 75% = \$40.95 85% = \$46.40	

I1. ULTRASOUND 6. MUSCULOSKELETA	
	HIP OR GROIN, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies: and
	(b) the patient is not referred by a medical practitioner (NR)
55818	(See para IN.0.19 of explanatory notes to this Category) Fee: \$37.85 Benefit: 75% = \$28.40 85% = \$32.20
	HIP OR GROIN, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies: and
	(b) the patient is not referred by a medical practitioner (NR) (NK)
55819	(See para IN.0.19 of explanatory notes to this Category) Fee: \$18.95 Benefit: 75% = \$14.25 85% = \$16.15
	PAEDIATRIC HIP EXAMINATION FOR DYSPLASIA, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member (R)
55820	(See para IN.0.19 of explanatory notes to this Category) Fee: \$109.10 Benefit: 75% = \$81.85 85% = \$92.75
	PAEDIATRIC HIP EXAMINATION FOR DYSPLASIA, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member (R) (NK)
55821	(See para IN.0.19 of explanatory notes to this Category) Fee: \$54.55 Benefit: 75% = \$40.95 85% = \$46.40
	PAEDIATRIC HIP EXAMINATION FOR DYSPLASIA, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the patient is not referred by a medical practitioner (NR)
55822	(See para IN.0.19 of explanatory notes to this Category) Fee: \$37.85 Benefit: 75% = \$28.40 85% = \$32.20
	PAEDIATRIC HIP EXAMINATION FOR DYSPLASIA, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the patient is not referred by a medical practitioner (NR) (NK)
55823	(See para IN.0.19 of explanatory notes to this Category)

I1. ULT	RASOUND 6. MUSCULOSKELETAL
	Fee: \$18.95 Benefit: 75% = \$14.25 85% = \$16.15
	BUTTOCK OR THIGH, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member (R)
55824	(See para IN.0.19 of explanatory notes to this Category) Fee: \$109.10 Benefit: 75% = \$81.85 85% = \$92.75
	BUTTOCK OR THIGH, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member (R) (NK)
55825	(See para IN.0.19 of explanatory notes to this Category) Fee: \$54.55 Benefit: 75% = \$40.95 85% = \$46.40
	BUTTOCK OR THIGH, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the patient is not referred by a medical practitioner (NR)
55826	(See para IN.0.19 of explanatory notes to this Category) Fee: \$37.85 Benefit: 75% = \$28.40 85% = \$32.20
	BUTTOCK OR THIGH, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the patient is not referred by a medical practitioner (NR) (NK)
55827	Fee: \$18.95 Benefit: 75% = \$14.25 85% = \$16.15
	Note: Benefits are only payable when referred based on the clinical indicators outlined in the item descriptions. Benefits are not payable when referred for non-specific knee pain alone or other knee condition including:
	- meniscal and cruciate ligament tears
	- assessment of chondral surfaces
	KNEE, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
55828	(b) the referring practitioner is not a member of a group of practitioners of which the providing

11. ULTRASOUND 6. MUSCULOSKELETAL practitioner is a member, and where the service is provided for the assessment of one or more of the following conditions or suspected conditions: abnormality of tendons or bursae about the knee; or meniscal cyst, popliteal fossa cyst, mass or pseudomass; or nerve entrapment, nerve or nerve sheath tumour; or injury of collateral ligaments.(R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$109.10 **Benefit:** 75% = \$81.85 85% = \$92.75 Note: Benefits are only payable when referred based on the clinical indicators outlined in the item descriptions. Benefits are not payable when referred for non-specific knee pain alone or other knee condition including: meniscal and cruciate ligament tears assessment of chondral surfaces KNEE, 1 or both sides, ultrasound scan of, where: (a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and (b) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member. and where the service is provided for the assessment of one or more of the following conditions or suspected conditions: abnormality of tendons or bursae about the knee; or meniscal cyst, popliteal fossa cyst, mass or pseudomass; or nerve entrapment, nerve or nerve sheath tumour; or injury of collateral ligaments (R) (NK) (See para IN.0.19 of explanatory notes to this Category) **Benefit:** 75% = \$40.95 85% = \$46.40 55829 Fee: \$54.55 Note: Benefits are only payable when referred based on the clinical indicators outlined in the item descriptions. Benefits are not payable when referred for non-specific knee pain alone or other knee

meniscal and cruciate ligament tears

condition including:

55830

11. ULTRASOUND 6. MUSCULOSKELETAL assessment of chondral surfaces KNEE, 1 or both sides, ultrasound scan of, where: (a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and (b) the patient is not referred by a medical practitioner and where the service is provided for the assessment of one or more of the following conditions or suspected conditions: abnormality of tendons or bursae about the knee; or meniscal cyst, popliteal fossa cyst, mass or pseudomass; or nerve entrapment, nerve or nerve sheath tumour; or injury of collateral ligaments.(NR) (See para IN.0.19 of explanatory notes to this Category) Fee: \$37.85 **Benefit:** 75% = \$28.40 85% = \$32.20 Note: Benefits are only payable when referred based on the clinical indicators outlined in the item descriptions. Benefits are not payable when referred for non-specific knee pain alone or other knee condition including: meniscal and cruciate ligament tears assessment of chondral surfaces KNEE, 1 or both sides, ultrasound scan of, where: (a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and (b) the patient is not referred by a medical practitioner and where the service is provided for the assessment of one or more of the following conditions or suspected conditions: abnormality of tendons or bursae about the knee; or meniscal cyst, popliteal fossa cyst, mass or pseudomass; or nerve entrapment, nerve or nerve sheath tumour; or injury of collateral ligaments (NR) (NK) (See para IN.0.19 of explanatory notes to this Category) 55831 Fee: \$18.95 **Benefit:** $75\% = \$14.25 \quad 85\% = \16.15 LOWER LEG, 1 or both sides, ultrasound scan of, where: 55832

I1. ULTRASOUND 6. MUSCULOSKELE	
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member (R)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$109.10 Benefit: 75% = \$81.85 85% = \$92.75
	LOWER LEG, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member (R) (NK)
55833	(See para IN.0.19 of explanatory notes to this Category) Fee: \$54.55 Benefit: 75% = \$40.95 85% = \$46.40
	LOWER LEG, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the patient is not referred by a medical practitioner (NR)
55834	(See para IN.0.19 of explanatory notes to this Category) Fee: \$37.85 Benefit: 75% = \$28.40 85% = \$32.20
	LOWER LEG, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the patient is not referred by a medical practitioner (NR) (NK)
55835	(See para IN.0.19 of explanatory notes to this Category) Fee: \$18.95 Benefit: 75% = \$14.25 85% = \$16.15
	ANKLE OR HIND FOOT, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member (R)
55836	(See para IN.0.19 of explanatory notes to this Category) Fee: \$109.10 Benefit: 75% = \$81.85 85% = \$92.75
	ANKLE OR HIND FOOT, 1 or both sides, ultrasound scan of, where:
	(a) the services is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
55837	(b) the referring practitioner is not a member of a group of practitioners of which the providing

I1. ULTI	RASOUND 6. MUSCULOSKELETAL
	practitioner is a member (R) (NK)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$54.55 Benefit: 75% = \$40.95 85% = \$46.40
	ANKLE OR HIND FOOT, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the patient is not referred by a medical practitioner (NR)
55838	(See para IN.0.19 of explanatory notes to this Category) Fee: \$37.85 Benefit: 75% = \$28.40 85% = \$32.20
	ANKLE OR HIND FOOT, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the patient is not referred by a medical practitioner (NR) (NK)
55839	(See para IN.0.19 of explanatory notes to this Category) Fee: \$18.95 Benefit: 75% = \$14.25 85% = \$16.15
	MID FOOT OR FORE FOOT, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member (R)
55840	(See para IN.0.19 of explanatory notes to this Category) Fee: \$109.10 Benefit: 75% = \$81.85 85% = \$92.75
	MID FOOT OR FORE FOOT, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member (R) (NK)
55841	(See para IN.0.19 of explanatory notes to this Category) Fee: \$54.55 Benefit: 75% = \$40.95 85% = \$46.40
	MID FOOT OR FORE FOOT, 1 or both sides, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the patient is not referred by a medical practitioner (NR)
55842	(See para IN.0.19 of explanatory notes to this Category) Fee: \$37.85 Benefit: 75% = \$28.40 85% = \$32.20
	MID FOOT OR FORE FOOT, 1 or both sides, ultrasound scan of, where:
55843	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group

I1. ULTRASOUND 6. MUSCULOSKELE	
	applies; and
	(b) the patient is not referred by a medical practitioner (NR) (NK)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$18.95 Benefit: 75% = \$14.25 85% = \$16.15
	ASSESSMENT OF A MASS ASSOCIATED WITH THE SKIN OR SUBCUTANEOUS STRUCTURES, NOT BEING A PART OF THE MUSCULOSKELETAL SYSTEM, 1 or more areas, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member (R)
55844	(See para IN.0.19 of explanatory notes to this Category) Fee: \$87.35 Benefit: 75% = \$65.55 85% = \$74.25
	ASSESSMENT OF A MASS ASSOCIATED WITH THE SKIN OR SUBCUTANEOUS STRUCTURES, NOT BEING A PART OF THE MUSCULOSKELETAL SYSTEM, 1 or more areas, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member (R) (NK)
55845	(See para IN.0.19 of explanatory notes to this Category) Fee: \$43.70 Benefit: 75% = \$32.80 85% = \$37.15
	ASSESSMENT OF A MASS ASSOCIATED WITH THE SKIN OR SUBCUTANEOUS STRUCTURES, NOT BEING A PART OF THE MUSCULOSKELETAL SYSTEM, 1 or more areas, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the patient is not referred by a medical practitioner (NR)
55846	(See para IN.0.19 of explanatory notes to this Category) Fee: \$37.85 Benefit: 75% = \$28.40 85% = \$32.20
	ASSESSMENT OF A MASS ASSOCIATED WITH THE SKIN OR SUBCUTANEOUS STRUCTURES, NOT BEING A PART OF THE MUSCULOSKELETAL SYSTEM, 1 or more areas, ultrasound scan of, where:
	(a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	(b) the patient is not referred by a medical practitioner (NR) (NK)
55847	(See para IN.0.19 of explanatory notes to this Category) Fee: \$18.95 Benefit: 75% = \$14.25 85% = \$16.15
55848	MUSCULOSKELETAL CROSS-SECTIONAL ECHOGRAPHY, in conjunction with a surgical procedure using interventional techniques, not being a service associated with a service to which any

I1. ULTI	RASOUND 6. MUSCULOSKELETAL
	other item in this group applies, and not performed in conjunction with item 55054 (R)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$109.10 Benefit: 75% = \$81.85 85% = \$92.75
	MUSCULOSKELETAL CROSS-SECTIONAL ECHOGRAPHY, in conjunction with a surgical procedure using interventional techniques, not being a service associated with a service to which any other item in this group applies, and not performed in conjunction with item 55054 or 55026 (R) (NK)
55849	(See para IN.0.19 of explanatory notes to this Category) Fee: \$54.55 Benefit: 75% = \$40.95 85% = \$46.40
	MUSCULOSKELETAL CROSS-SECTIONAL ECHOGRAPHY, in conjunction with a surgical procedure using interventional techniques, inclusive of a diagnostic musculoskeletal ultrasound service, where:
	(a) the referring practitioner has indicated on a referral for a musculoskeletal ultrasound that a ultrasound guided
	intervention be performed if clinically indicated;
	(b) the service is not performed in conjunction with items 55054, or 55800 to 55848, and
	(c) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member (R)
55850	(See para IN.0.19 of explanatory notes to this Category) Fee: \$152.85 Benefit: 75% = \$114.65 85% = \$129.95
	MUSCULOSKELETAL CROSS-SECTIONAL ECHOGRAPHY, in conjunction with a surgical procedure using interventional techniques, inclusive of a diagnostic musculoskeletal ultrasound service, where:
	(a) the referring practitioner has indicated on a referral for a musculoskeletal ultrasound that a ultrasound guided
	intervention be performed if clinically indicated;
	(b) the service is not performed in conjunction with items 55026, 55054, or 55800 to 55849, and
	(c) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member (R) (NK)
55851	(See para IN.0.19 of explanatory notes to this Category) Fee: \$76.45 Benefit: 75% = \$57.35 85% = \$65.00
	PAEDIATRIC SPINE, SPINAL CORD AND OVERLYING SUBCUTANEOUS TISSUES, Ultrasound scan of, where:
	a) the patient is referred by a referring practitioner
	b) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	c) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member (R)
55852	(See para IN.0.19 of explanatory notes to this Category) Fee: \$109.10 Benefit: 75% = \$81.85 85% = \$92.75

I1. ULT	RASOUND 6. MUSCULOSKELETAL
	PAEDIATRIC SPINE, SPINAL CORD AND OVERLYING SUBCUTANEOUS TISSUES, Ultrasound scan of, where:
	a) the patient is referred by a medical practitioner
	b) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	c) the referring practitioner is not a member of a group of practitioners of which the providing practitioner is a member (R) (NK)
55853	(See para IN.0.19 of explanatory notes to this Category) Fee: \$54.55 Benefit: 75% = \$40.95 85% = \$46.40
	PAEDIATRIC SPINE, SPINAL CORD AND OVERLYING SUBCUTANEOUS TISSUES, Ultrasound scan of, where:
	a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	b) the patient is not referred by a medical practitioner (NR)
55854	(See para IN.0.19 of explanatory notes to this Category) Fee: \$37.85 Benefit: 75% = \$28.40 85% = \$32.20
	PAEDIATRIC SPINE, SPINAL CORD AND OVERLYING SUBCUTANEOUS TISSUES, Ultrasound scan of, where:
	a) the service is not associated with a service to which an item in Subgroups 2 or 3 of this Group applies; and
	b) the patient is not referred by a medical practitioner (NR) (NK)
55855	(See para IN.0.19 of explanatory notes to this Category) Fee: \$18.95 Benefit: 75% = \$14.25 85% = \$16.15
I2. CON	IPUTED TOMOGRAPHY 1. HEAD
	Group I2. Computed Tomography
	Subgroup 1. Head
	COMPUTED TOMOGRAPHY - scan of brain without intravenous contrast medium, not being a service to which item 57001 applies (R) (K) (Anaes.)
56001	(See para IN.0.19 of explanatory notes to this Category) Fee: \$195.05 Benefit: 75% = \$146.30 85% = \$165.80
	COMPUTED TOMOGRAPHY - scan of brain with intravenous contrast medium and with any scans of the brain prior to intravenous contrast injection, when undertaken, not being a service to which item 57007 applies (R) (K) (Anaes.)
56007	(See para IN.0.19 of explanatory notes to this Category) Fee: \$250.00 Benefit: 75% = \$187.50 85% = \$212.50
	COMPUTED TOMOGRAPHY - scan of pituitary fossa with or without intravenous contrast medium and with or without brain scan when undertaken (R) (K) (Anaes.)
56010	(See para IN.0.19 of explanatory notes to this Category)

I2. CON	IPUTED TOMOGRAPHY 1. HEAD
	Fee: \$252.10 Benefit: 75% = \$189.10 85% = \$214.30
	COMPUTED TOMOGRAPHY - scan of orbits with or without intravenous contrast medium and with or without brain scan when undertaken (R) (K) (Anaes.)
56013	(See para IN.0.19 of explanatory notes to this Category) Fee: \$250.00 Benefit: 75% = \$187.50 85% = \$212.50
	COMPUTED TOMOGRAPHY - scan of petrous bones in axial and coronal planes in 1 mm or 2 mm sections, with or without intravenous contrast medium, with or without scan of brain (R) (K) (Anaes.)
56016	(See para IN.0.19 of explanatory notes to this Category) Fee: \$290.00 Benefit: 75% = \$217.50 85% = \$246.50
	COMPUTED TOMOGRAPHY - scan of facial bones, para nasal sinuses or both without intravenous contrast medium (R) (K) (Anaes.)
56022	(See para IN.0.19 of explanatory notes to this Category) Fee: \$225.00 Benefit: 75% = \$168.75 85% = \$191.25
	COMPUTED TOMOGRAPHY - scan of facial bones, para nasal sinuses or both with intravenous contrast medium and with any scans of the facial bones, para nasal sinuses or both prior to intravenous contrast injection, when undertaken (R) (K) (Anaes.)
56028	(See para IN.0.19 of explanatory notes to this Category) Fee: \$336.80 Benefit: 75% = \$252.60 85% = \$286.30
	COMPUTED TOMOGRAPHY - scan of facial bones, paranasal sinuses or both, with scan of brain, without intravenous contrast medium (R) (K) (Anaes.)
56030	(See para IN.0.19 of explanatory notes to this Category) Fee: \$225.00 Benefit: 75% = \$168.75 85% = \$191.25
	COMPUTED TOMOGRAPHY - scan of facial bones, paranasal sinuses or both, with scan of brain, with intravenous contrast medium, where:
	(a) a scan without intravenous contrast medium has been undertaken; and
	(b) the service is required because the result of the scan mentioned in paragraph (a) is abnormal (R) (K) (Anaes.)
56036	(See para IN.0.19 of explanatory notes to this Category) Fee: \$336.80 Benefit: 75% = \$252.60 85% = \$286.30
	COMPUTED TOMOGRAPHY - scan of brain without intravenous contrast medium, not being a service to which item 57041 applies (R) (NK) (Anaes.)
56041	(See para IN.0.19 of explanatory notes to this Category) Fee: \$98.75 Benefit: 75% = \$74.10 85% = \$83.95
	COMPUTED TOMOGRAPHY - scan of brain with intravenous contrast medium and with any scans of the brain prior to intravenous contrast injection, when undertaken, not being a service to which item 57047 applies (R) (NK) (Anaes.)
56047	(See para IN.0.19 of explanatory notes to this Category) Fee: \$126.10 Benefit: 75% = \$94.60 85% = \$107.20
	COMPUTED TOMOGRAPHY - scan of pituitary fossa with or without intravenous contrast medium and with or without brain scan when undertaken (R) (NK) (Anaes.)
56050	(See para IN.0.19 of explanatory notes to this Category) Fee: \$128.20 Benefit: 75% = \$96.15 85% = \$109.00

I2. COM	IPUTED TOMOGRAPHY 1. HEA			
	COMPUTED TOMOGRAPHY - scan of orbits with or without intravenous contrast medium and with or without brain scan when undertaken (R) (NK) (Anaes.)			
56053	(See para IN.0.19 of explanatory notes to this Category) Fee: \$128.20 Benefit: 75% = \$96.15 85% = \$109.00			
	COMPUTED TOMOGRAPHY - scan of petrous bones in axial and coronal planes in 1 mm or 2 mm sections, with or without intravenous contrast medium, with or without scan of brain (R) (NK) (Anaes.)			
56056	(See para IN.0.19 of explanatory notes to this Category) Fee: \$155.45 Benefit: 75% = \$116.60 85% = \$132.15			
	COMPUTED TOMOGRAPHY - scan of facial bones, para nasal sinuses or both without intravenous contrast medium (R) (NK) (Anaes.)			
56062	(See para IN.0.19 of explanatory notes to this Category) Fee: \$113.15 Benefit: 75% = \$84.90 85% = \$96.20			
	COMPUTED TOMOGRAPHY - scan of facial bones, para nasal sinuses or both with intravenous contrast medium and with any scans of the facial bones, para nasal sinuses or both prior to intravenous contrast injection, when undertaken (R) (NK) (Anaes.)			
56068	(See para IN.0.19 of explanatory notes to this Category) Fee: \$168.40 Benefit: 75% = \$126.30 85% = \$143.15			
	COMPUTED TOMOGRAPHY - scan of facial bones, paranasal sinuses or both, with scan of brain, without intravenous contrast medium (R) (NK) (Anaes.)			
56070	(See para IN.0.19 of explanatory notes to this Category) Fee: \$113.15 Benefit: 75% = \$84.90 85% = \$96.20			
	COMPUTED TOMOGRAPHY - scan of facial bones, paranasal sinuses or both, with scan of brain, wi intravenous contrast medium, where:			
	(a) a scan without intravenous contrast medium has been undertaken; and			
	(b) the service is required because the result of the scan mentioned in paragraph (a) is abnormal (R) (NK) (Anaes.)			
56076	(See para IN.0.19 of explanatory notes to this Category) Fee: \$168.40 Benefit: 75% = \$126.30 85% = \$143.15			
I2. COM	PUTED TOMOGRAPHY 2. NEC			
	Group I2. Computed Tomography			
	Subgroup 2. Neck			
	COMPUTED TOMOGRAPHY - scan of soft tissues of neck, including larynx, pharynx, upper oesophagus and salivary glands (not associated with cervical spine) without intravenous contrast medium, not being a service to which item 56801 applies (R) (K) (Anaes.)			
56101	(See para IN.0.19 of explanatory notes to this Category) Fee: \$230.00 Benefit: 75% = \$172.50 85% = \$195.50			
56107	COMPUTED TOMOGRAPHY - scan of soft tissues of neck, including larynx, pharynx, upper oesophagus and salivary glands (not associated with cervical spine) - with intravenous contrast medium and with any scans of soft tissues of neck including larynx, pharynx, upper oesophagus and salivary glands (not associated with cervical spine) prior to intravenous contrast injection, when undertaken, not			

I2. COM	MPUTED TOMOGRAPHY 2	2. NECK
	being a service associated with a service to which item 56807 applies (R) (K) (Anaes.)	
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$340.00 Benefit: 75% = \$255.00 85% = \$289.00	
	COMPUTED TOMOGRAPHY - scan of soft tissues of neck, including larynx, pharynx, upper oesophagus and salivary glands (not associated with cervical spine) without intravenous contras medium, not being a service to which item 56841 applies (R) (NK) (Anaes.)	t
56141	(See para IN.0.19 of explanatory notes to this Category) Fee: \$116.45 Benefit: 75% = \$87.35 85% = \$99.00	
	COMPUTED TOMOGRAPHY - scan of soft tissues of neck, including larynx, pharynx, upper oesophagus and salivary glands (not associated with cervical spine) - with intravenous contrast medium and with any scans of soft tissues of neck including larynx, pharynx, upper oesophagus and salivary glands (not associated with cervical spine) prior to intravenous contrast injection, when undertaken, not being a service associated with a service to which item 56847 applies (R) (NK) (Anaes.)	
56147	(See para IN.0.19 of explanatory notes to this Category) Fee: \$171.60 Benefit: 75% = \$128.70 85% = \$145.90	
I2. CON	MPUTED TOMOGRAPHY 3	3. SPINE
	Group I2. Computed Tomography	
	Subgroup 3. Spine	
	COMPUTED TOMOGRAPHY - scan of spine, 1 or more regions with intrathecal contrast med including the preparation for intrathecal injection of contrast medium and any associated plain X not being a service to which item 59724 applies (R) (K) (Anaes.)	
56219	(See para IN.0.19 of explanatory notes to this Category) Fee: \$326.20 Benefit: 75% = \$244.65 85% = \$277.30	
	COMPUTED TOMOGRAPHY - scan of spine, cervical region, without intravenous contrast me payable once only, whether 1 or more attendances are required to complete the service (R) (K) (
56220	(See para IN.0.19 of explanatory notes to this Category) Fee: \$240.00 Benefit: 75% = \$180.00 85% = \$204.00	
	COMPUTED TOMOGRAPHY - scan of spine, thoracic region, without intravenous contrast may payable once only, whether 1 or more attendances are required to complete the service (R) (K) (
56221	(See para IN.0.19 of explanatory notes to this Category) Fee: \$240.00 Benefit: 75% = \$180.00 85% = \$204.00	
	COMPUTED TOMOGRAPHY - scan of spine, lumbosacral region, without intravenous contrast medium, payable once only, whether 1 or more attendances are required to complete the service (R) (Anaes.)	
56223	(See para IN.0.19 of explanatory notes to this Category) Fee: $$240.00$ Benefit: $75\% = 180.00 $85\% = 204.00	
	COMPUTED TOMOGRAPHY - scan of spine, cervical region, with intravenous contrast media with any scans of the cervical region of the spine prior to intravenous contrast injection when undertaken; only 1 benefit payable whether 1 or more attendances are required to complete the s (R) (K) (Anaes.)	
56224	(See para IN.0.19 of explanatory notes to this Category) Fee: \$351.40 Benefit: 75% = \$263.55 85% = \$298.70	

I2. CON	IPUTED TOMOGRAPHY 3. SPINE	
	COMPUTED TOMOGRAPHY - scan of spine, thoracic region, with intravenous contrast medium and with any scans of the thoracic region of the spine prior to intravenous contrast injection when undertaken, only 1 benefit payable whether 1 or more attendances are required to complete the service (R) (K) (Anaes.)	
56225	(See para IN.0.19 of explanatory notes to this Category) Fee: \$351.40 Benefit: 75% = \$263.55 85% = \$298.70	
	COMPUTED TOMOGRAPHY - scan of spine, lumbosacral region, with intravenous contrast medium and with any scans of the lumbosacral region of the spine prior to intravenous contrast injection when undertaken; only 1 benefit payable whether 1 or more attendances are required to complete the service (R) (K) (Anaes.)	
56226	(See para IN.0.19 of explanatory notes to this Category) Fee: \$351.40 Benefit: 75% = \$263.55 85% = \$298.70	
	COMPUTED TOMOGRAPHY - scan of spine, cervical region, without intravenous contrast medium, payable once only, whether 1 or more attendances are required to complete the service (R) (NK) (Anaes.)	
56227	(See para IN.0.19 of explanatory notes to this Category) Fee: \$122.50 Benefit: 75% = \$91.90 85% = \$104.15	
	COMPUTED TOMOGRAPHY - scan of spine, thoracic region, without intravenous contrast medium, payable once only, whether 1 or more attendances are required to complete the service (R) (NK) (Anaes.)	
56228	(See para IN.0.19 of explanatory notes to this Category) Fee: \$122.50 Benefit: 75% = \$91.90 85% = \$104.15	
	COMPUTED TOMOGRAPHY - scan of spine, lumbosacral region, without intravenous contrast medium, payable once only, whether 1 or more attendances are required to complete the service (R) (NK) (Anaes.)	
56229	(See para IN.0.19 of explanatory notes to this Category) Fee: \$122.50 Benefit: 75% = \$91.90 85% = \$104.15	
	COMPUTED TOMOGRAPHY - scan of spine, cervical region, with intravenous contrast medium, and with any scans to the cerival region of the spine prior to intravenous contrast injection when undertaker only 1 benefit payable whether 1 or more attendances are required to complete the service (R) (NK) (Anaes.)	
56230	(See para IN.0.19 of explanatory notes to this Category) Fee: \$177.45 Benefit: 75% = \$133.10 85% = \$150.85	
	COMPUTED TOMOGRAPHY - scan of spine, thoracic region, with intravenous contrast medium and with any scans of the thoracic region of the spine prior to intravenous contrast injection when undertaken; only 1 benefit payable whether 1 or more attendances are required to complete the service (R) (NK) (Anaes.)	
56231	(See para IN.0.19 of explanatory notes to this Category) Fee: \$177.45 Benefit: 75% = \$133.10 85% = \$150.85	
	COMPUTED TOMOGRAPHY - scan of spine, lumbosacral region, with intravenous contrast medium and with any scans of the lumbosacral region of the spine prior to intravenous contrast injection when undertaken; only 1 benefit payable whether 1 or more attendances are required to complete the service (R) (NK) (Anaes.)	
56232	(See para IN.0.19 of explanatory notes to this Category) Fee: \$177.45 Benefit: 75% = \$133.10 85% = \$150.85	

I2. CON	MPUTED TOMOGRAPHY 3. SPINE
	NOTE: An account issued or a patient assignment form must show the item numbers of the examinations performed under this item
	COMPUTED TOMOGRAPHY - scan of spine, two examinations of the kind referred to in items 56220, 56221 and 56223 without intravenous contrast medium payable once only, whether 1 or more attendances are required to complete the service (R) (K) (Anaes.)
56233	(See para IN.0.19 of explanatory notes to this Category) Fee: \$240.00 Benefit: 75% = \$180.00 85% = \$204.00
	NOTE: An account issued or a patient assignment form must show the item numbers of the examinations performed under this item
	COMPUTED TOMOGRAPHY - scan of spine, two examinations of the kind referred to in items 56224, 56225 and 56226 with intravenous contrast medium and with any scans of these regions of the spine prior to intravenous contrast injection when undertaken; only 1 benefit payable whether 1 or more attendances are required to complete the service (R) (K) (Anaes.)
56234	(See para IN.0.19 of explanatory notes to this Category) Fee: \$351.40 Benefit: 75% = \$263.55 85% = \$298.70
	NOTE: An account issued or a patient assignment form must show the item numbers of the examinations performed under this item
	COMPUTED TOMOGRAPHY - scan of spine, two examinations of the kind referred to in items 56227, 56228 and 56229 without intravenous contrast medium payable once only, whether 1 or more attendances are required to complete the service (R) (NK) (Anaes.)
56235	(See para IN.0.19 of explanatory notes to this Category) Fee: \$122.45 Benefit: 75% = \$91.85 85% = \$104.10
	NOTE: An account issued or a patient assignment form must show the item numbers of the examinations performed under this item
	COMPUTED TOMOGRAPHY - scan of spine, two examinations of the kind referred to in items 56230, 56231 and 56232 with intravenous contrast medium and with any scans of these regions of the spine prior to intravenous contrast injection when undertaken; only 1 benefit payable whether 1 or more attendances are required to complete the service (R) (NK) (Anaes.)
56236	(See para IN.0.19 of explanatory notes to this Category) Fee: \$177.45 Benefit: 75% = \$133.10 85% = \$150.85
	COMPUTED TOMOGRAPHY - scan of spine, three regions cervical, thoracic and lumbosacral, without intravenous contrast medium, payable once only, whether 1 or more attendances are required to complete the service (R) (K) (Anaes.)
56237	(See para IN.0.19 of explanatory notes to this Category) Fee: \$240.00 Benefit: 75% = \$180.00 85% = \$204.00
56238	COMPUTED TOMOGRAPHY - scan of spine, three regions cervical, thoracic and lumbosacral, with

IZ. CUIV	MPUTED TOMOGRAPHY	3. SPINE
	intravenous contrast medium and with any scans of the contrast injection when undertaken; only 1 benefit, put to complete the service (R) (K) (Anaes.)	
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$351.40 Benefit: 75% = \$263.55 85% =	\$298.70
	COMPUTED TOMOGRAPHY - scan of spine, three intravenous contrast medium, payable once only, who complete the service (R) (NK) (Anaes.)	
56239	(See para IN.0.19 of explanatory notes to this Category) Fee: \$122.45 Benefit: 75% = \$91.85 85% = \$	104.10
	COMPUTED TOMOGRAPHY - scan of spine, three intravenous contrast medium and with any scans of the contrast injection when undertaken; only 1 benefit, put to complete the service (R) (NK) (Anaes.)	hese regions of the spine prior to intravenous
56240	(See para IN.0.19 of explanatory notes to this Category) Fee: \$177.45 Benefit: 75% = \$133.10 85% =	\$150.85
	COMPUTED TOMOGRAPHY - scan of spine, 1 or including the preparation for intrathecal injection of a not being a service to which item 59724 applies (R) (contrast medium and any associated plain X-rays,
56259	(See para IN.0.19 of explanatory notes to this Category) Fee: \$164.80 Benefit: 75% = \$123.60 85% =	\$140.10
I2. COM	MPUTED TOMOGRAPHY	4. CHEST AND UPPER ABDOMEN
	Group I2. Computed Tomography	
	Subgroup 4. Chest	and upper abdomen
	Subgroup 4. Chest COMPUTED TOMOGRAPHY - scan of chest, inclu with or without scans of the upper abdomen, without which item 56801 or 57001 applies and not including calcification or image the coronary arteries (R) (K) (A	ding lungs, mediastinum, chest wall and pleura, intravenous contrast medium, not being a service to g a study performed to exclude coronary artery
56301	COMPUTED TOMOGRAPHY - scan of chest, incluwith or without scans of the upper abdomen, without which item 56801 or 57001 applies and not including	ding lungs, mediastinum, chest wall and pleura, intravenous contrast medium, not being a service to g a study performed to exclude coronary artery Anaes.)
56301	COMPUTED TOMOGRAPHY - scan of chest, incluwith or without scans of the upper abdomen, without which item 56801 or 57001 applies and not including calcification or image the coronary arteries (R) (K) (A) (See para IN.0.19 of explanatory notes to this Category)	iding lungs, mediastinum, chest wall and pleura, intravenous contrast medium, not being a service to g a study performed to exclude coronary artery Anaes.) \$250.75 Iding lungs, mediastinum, chest wall and pleura, ravenous contrast medium and with any scans of pleura and upper abdomen prior to intravenous ice to which item 56807 or 57007 applies and not
56301	COMPUTED TOMOGRAPHY - scan of chest, including with or without scans of the upper abdomen, without which item 56801 or 57001 applies and not including calcification or image the coronary arteries (R) (K) (A) (See para IN.0.19 of explanatory notes to this Category) Fee: \$295.00 Benefit: 75% = \$221.25 85% = COMPUTED TOMOGRAPHY - scan of chest, including or without scans of the upper abdomen, with interest the chest including lungs, mediastinum, chest wall or contrast injection, when undertaken, not being a serv including a study performed to exclude coronary arterest.	ding lungs, mediastinum, chest wall and pleura, intravenous contrast medium, not being a service to a study performed to exclude coronary artery Anaes.) \$250.75 ding lungs, mediastinum, chest wall and pleura, ravenous contrast medium and with any scans of pleura and upper abdomen prior to intravenous ice to which item 56807 or 57007 applies and not rry calcification or image the coronary arteries (R)
	COMPUTED TOMOGRAPHY - scan of chest, including with or without scans of the upper abdomen, without which item 56801 or 57001 applies and not including calcification or image the coronary arteries (R) (K) (A) (See para IN.0.19 of explanatory notes to this Category) Fee: \$295.00 Benefit: 75% = \$221.25 85% = COMPUTED TOMOGRAPHY - scan of chest, including or without scans of the upper abdomen, with interest the chest including lungs, mediastinum, chest wall or contrast injection, when undertaken, not being a serv including a study performed to exclude coronary arter (K) (Anaes.) (See para IN.0.19 of explanatory notes to this Category)	ding lungs, mediastinum, chest wall and pleura, intravenous contrast medium, not being a service to g a study performed to exclude coronary artery Anaes.) \$250.75 ding lungs, mediastinum, chest wall and pleura, ravenous contrast medium and with any scans of pleura and upper abdomen prior to intravenous ice to which item 56807 or 57007 applies and not rry calcification or image the coronary arteries (R) \$340.00 ding lungs, mediastinum, chest wall and pleura, intravenous contrast medium, not being a service to g a study performed to exclude coronary artery

I2. COM	COMPUTED TOMOGRAPHY 4. CHEST AND UPPER ABO	
	Fee: \$149.45 Benefit: 75% = \$112.10	85% = \$127.05
COMPUTED TOMOGRAPHY - scan of chest, including lungs, mediastinum, chest wall with or without scans of the upper abdomen, with intravenous contrast medium and with a the chest including lungs, mediastinum, chest wall or pleura and upper abdomen prior to i contrast injection, when undertaken, not being a service to which item 56847 or 57047 ap including a study performed to exclude coronary artery calcification or image the coronary (NK) (Anaes.)		with intravenous contrast medium and with any scans of st wall or pleura and upper abdomen prior to intravenous ng a service to which item 56847 or 57047 applies and not
56347	(See para IN.0.19 of explanatory notes to this Category) Fee: \$202.00 Benefit: 75% = \$151.50 85% = \$171.70	
I2. COM	PUTED TOMOGRAPHY	5. UPPER ABDOMEN ONL
	Group I2. Computed Tomography	
	Subgro	oup 5. Upper abdomen only
		oper abdomen only (diaphragm to iliac crest) without ervice to which item 56301, 56501, 56801 or 57001 applies
56401	(See para IN.0.19 of explanatory notes to this Ca Fee: \$250.00 Benefit: 75% = \$187.50	
	COMPUTED TOMOGRAPHY - scan of upper abdomen only (diaphragm to iliac crest) with intravenous contrast medium and with any scans of upper abdomen (diaphragm to iliac crest) printravenous contrast injection, when undertaken, not being a service to which item 56307, 565 or 57007 applies (R) (K) (Anaes.)	
56407	(See para IN.0.19 of explanatory notes to this Ca Fee: \$360.00 Benefit: 75% = \$270.00	
		elvis only (iliac crest to pubic symphysis) without rvice associated with a service to which item 56401 applies
56409	(See para IN.0.19 of explanatory notes to this Ca Fee: \$250.00 Benefit: 75% = \$187.50	
	contrast medium and with any scans of pelv	elvis only (iliac crest to pubic symphysis) with intravenous is (iliac crest to pubic symphysis) prior to intravenous ng a service to which item 56407 applies (R) (K) (Anaes.)
56412	(See para IN.0.19 of explanatory notes to this Ca Fee: \$360.00 Benefit: 75% = \$270.00	- · ·
		oper abdomen only (diaphragm to iliac crest), without ervice to which item 56341, 56541, 56841 or 57041 applies
56441	(See para IN.0.19 of explanatory notes to this Ca Fee: \$126.80 Benefit: 75% = \$95.10	C 17
	intravenous contrast medium, and with any	oper abdomen only (diaphragm to iliac crest) with scans of upper abdomen (diaphragm to iliac crest) prior to aken, not being a service to which item 56347, 56547, 5684
56447	(See para IN.0.19 of explanatory notes to this Ca	utegory)

I2. CON	OMPUTED TOMOGRAPHY 5.		5. UPPER ABDOMEN ONLY
	Fee: \$181.50	Benefit: 75% = \$13	6.15 85% = \$154.30
			of pelvis only (iliac crest to pubic symphysis) without a service to which item 56441 applies (R) (NK) (Anaes.)
(See para IN.0.19 of explanatory notes to this Category) Fee: \$126.80 Benefit: 75% = \$95.10 85% = \$107.80			
	COMPUTED TOMOGRAPHY - scan of pelvis only (iliac crest to pubic symphysis) with intravenous contrast medium, and with any scans of pelvis (iliac crest to pubic symphysis) prior to intravenous contrast injection, when undertaken, not being a service to which item 56447 applies (R) (NK) (Anaes.		
56452	(See para IN.0.19 o Fee: \$181.50	of explanatory notes to this Benefit: 75% = \$13	s Category) 6.15 85% = \$154.30
I2. CON	IPUTED TOMOGR	RAPHY	6. UPPER ABDOMEN AND PELVIS
	Group I2. Comp	uted Tomography	
		Subgro	oup 6. Upper abdomen and pelvis
		the purposes of virtual of	of upper abdomen and pelvis without intravenous contrast colonoscopy, not being a service to which item 56801 or 57001
56501	(See para IN.0.19 o Fee: \$385.00	of explanatory notes to this Benefit: 75% = \$28	s Category) 8.75 85% = \$327.25
	COMPUTED TOMOGRAPHY - scan of upper abdomen and pelvis with intravenous contrast mediand with any scans of upper abdomen and pelvis prior to intravenous contrast injection, when undertaken, not for the purposes of virtual colonoscopy, not being a service to which item 56807 or 57007 applies (R) (K) (Anaes.)		nd pelvis prior to intravenous contrast injection, when
56507	(See para IN.0.19 o Fee: \$480.05	of explanatory notes to this Benefit: 75% = \$36	s Category) 0.05 85% = \$408.05
		the purposes of virtual of	of upper abdomen and pelvis without intravenous contrast colonoscopy, not being a service to which item 56841 or 57041
56541	(See para IN.0.19 o Fee: \$193.15	of explanatory notes to this Benefit: 75% = \$14	s Category) 4.90 85% = \$164.20
	and with any scar	ns of upper abdomen ar for the purposes of virtu	of upper abdomen and pelvis with intravenous contrast medium, and pelvis prior to intravenous contrast injection, when all colonoscopy, not being a service to which item 56847 or
56547	(See para IN.0.19 o Fee: \$243.75	of explanatory notes to this Benefit: 75% = \$18	s Category) 2.85 85% = \$207.20
	Computed tomog or high risk paties		r exclusion or diagnosis of colorectal neoplasia in a symptomatic
	(a) one [or more	re] of the following app	olies:
	(i) the patien	t has had an incomplete	e colonoscopy in the 3 months before the scan;
56553	(ii) there is a	a high-grade colonic ob	estruction;

I2. COM	PUTED TOMOGRAPHY 6. UPPER ABDOMEN AND PELVIS
	(iii) the patient is referred by a specialist or consultant physician who performs colonoscopies [in the practice of
	his or her speciality]; and
	(b) the service is not a service to which item 56301, 56307, 56401, 56407, 56409, 56412, 56501, 56507, 56801, 56807 or 57001 applies; and
	(c) the service has not been performed on the patient in the 36 months before the scan (R) (K) (Anaes.)
	(See para IN.0.12 of explanatory notes to this Category) Fee: \$520.00 Benefit: 75% = \$390.00 85% = \$442.00
	Computed tomography-scan of colon for exclusion or diagnosis of colorectal neoplasia in a symptomatic or high risk patient if:
	(a) one [or more] of the following applies:
	(i) the patient has had an incomplete colonoscopy in the 3 months before the scan;
	(ii) there is a high-grade colonic obstruction;
	(iii) the patient is referred by a specialist or consultant physician who performs colonoscopies [in the practice
	of his or her speciality]; and
	(b) the service is not a service to which item 56301, 56307, 56401, 56407, 56409, 56412, 56501, 56507, 56801,
	56807 or 57001 applies; and
	(c) the service has not been performed on the patient in the 36 months before the scan (R) (NK) (Anaes.)
56555	(See para IN.0.12 of explanatory notes to this Category) Fee: \$260.00 Benefit: 75% = \$195.00 85% = \$221.00
I2. COM	PUTED TOMOGRAPHY 7. EXTREMITIES
	Group I2. Computed Tomography
	Subgroup 7. Extremities
	COMPUTED TOMOGRAPHY - scan of extremities, one region (other than knee), or more than one region (which may include knee), without intravenous contrast medium. Payable once only whether one or more attendances are required to complete the service, not being a service to which any of items 56620, 56626, 56660 or 56666 apply (R) (K) (Anaes.)
56619	(See para IN.0.19 of explanatory notes to this Category) Fee: \$220.00 Benefit: 75% = \$165.00 85% = \$187.00
	COMPUTED TOMOGRAPHY - scan of knee, without intravenous contrast medium. Payable once only whether one or more attendances are required to complete the service, not being a service to which any of items 56619, 56625, 56659 or 56665 apply (R) (K) (Anaes.)
56620	(See para IN.0.19 of explanatory notes to this Category) Fee: \$220.00 Benefit: 75% = \$165.00 85% = \$187.00

I2. COM	IPUTED TOMOGRAPHY	7. EXTREMITIES	
	COMPUTED TOMOGRAPHY - scan of extremities, one region (other region (which may include knee), with intravenous contrast medium an before intravenous contrast injection, when performed. Payable once of attendances are required to complete the service, not being a service to 56626, 56660 or 56666 apply. (R) (K) (Anaes.)	d with any scans of extremities anly whether one or more	
56625	(See para IN.0.19 of explanatory notes to this Category) Fee: \$334.65 Benefit: 75% = \$251.00 85% = \$284.50		
	COMPUTED TOMOGRAPHY - scan of the knee, with intravenous co of the knee prior to intravenous contrast injection, when undertaken. Pa more attendances are required to complete the service, not being a service 56625, 56659 or 56665 apply (R) (K) (Anaes.).	yable once only whether one or	
56626	(See para IN.0.19 of explanatory notes to this Category) Fee: \$334.65 Benefit: 75% = \$251.00 85% = \$284.50		
	COMPUTED TOMOGRAPHY - scan of extremities, one region (other region (which may include knee), without intravenous contrast medium or more attendances are required to complete the service, not being a seitems 56620, 56626, 56660 or 56666 apply (R) (NK) (Anaes.).	n. Payable once only whether one	
56659	(See para IN.0.19 of explanatory notes to this Category) Fee: \$112.10 Benefit: 75% = \$84.10 85% = \$95.30		
	COMPUTED TOMOGRAPHY - scan of the knee, without intravenous only whether one or more attendances are required to complete the servany of items 56619, 56625, 56659 or 56665 apply (R) (NK) (Anaes.)		
56660	(See para IN.0.19 of explanatory notes to this Category) Fee: \$112.10 Benefit: 75% = \$84.10 85% = \$95.30		
	COMPUTED TOMOGRAPHY - scan of extremities, one region (other region (which may include knee), with intravenous contrast medium an before intravenous contrast injection, when performed. Payable once or attendances are required to complete the service, not being a service to 56626, 56660 or 56666 apply (R) (NK) (Anaes.).	nd with any scans of extremities only whether one or more	
56665	(See para IN.0.19 of explanatory notes to this Category) Fee: \$167.40 Benefit: 75% = \$125.55 85% = \$142.30		
	COMPUTED TOMOGRAPHY - scan of knee, with intravenous contrate the knee prior to intravenous contrast injection, when performed. Payals more attendances are required to complete the service, not being a service 56625, 56659 or 56665 apply (R) (NK) (Anaes.)	ole once only whether one or	
56666	(See para IN.0.19 of explanatory notes to this Category) Fee: \$167.40 Benefit: 75% = \$125.55 85% = \$142.30		
I2. COM	COMPUTED TOMOGRAPHY 8. CHEST, ABDOMEN, PELVIS AND NECH		
	Group I2. Computed Tomography		
	Subgroup 8. Chest, abdomen, pelvis and	i neck	
56801	COMPUTED TOMOGRAPHY - scan of chest, abdomen and pelvis with of neck without intravenous contrast medium, not including a study per artery calcification or image the coronary arteries (R) (K) (Anaes.)		

I2. CON	MPUTED TOMOGRAPHY	8. CHEST, ABDOMEN, PELVIS AND NECK
	(See para IN.0.19 of explanatory notes to this Category Fee: \$466.55 Benefit: 75% = \$349.95 85%	
	of neck with intravenous contrast medium and wi without scans of soft tissue of neck prior to intrav	bdomen and pelvis with or without scans of soft tissues th any scans of chest, abdomen and pelvis with or enous contrast injection, when undertaken, not artery calcification or image the coronary arteries (R)
56807	(See para IN.0.19 of explanatory notes to this Category Fee: $$560.00$ Benefit: $75\% = 420.00 85%	
		bdomen and pelvis with or without scans of soft tissues including a study performed to exclude coronary artery JK) (Anaes.)
56841	(See para IN.0.19 of explanatory notes to this Category Fee: \$233.35 Benefit: 75% = \$175.05 85%	
	of neck with intravenous contrast medium and wi without scans of soft tissue of neck prior to intrav	bdomen and pelvis with or without scans of soft tissues th any scans of chest, abdomen and pelvis with or renous contrast injection, when undertaken, not artery calcification or image the coronary arteries (R)
56847	(See para IN.0.19 of explanatory notes to this Category Fee: \$283.85 Benefit: 75% = \$212.90 85%	
I2. CON	IPUTED TOMOGRAPHY	9. BRAIN, CHEST AND UPPER ABDOMEN
	Group I2. Computed Tomography	
	Subgroup 9. Brain	, chest and upper abdomen
	COMPUTED TOMOGRAPHY - scan of brain ar without intravenous contrast medium, not includicalcification or image the coronary arteries (R) (K)	ng a study performed to exclude coronary artery
57001	(See para IN.0.19 of explanatory notes to this Category Fee: \$466.65 Benefit: 75% = \$350.00 85%	
	intravenous contrast medium and with any scans	not including a study performed to exclude coronary
57007	(See para IN.0.19 of explanatory notes to this Category Fee: \$567.75 Benefit: 75% = \$425.85 85%	
	COMPUTED TOMOGRAPHY- scan of brain an without intravenous contrast medium, not including calcification or image the coronary arteries (R) (N	ng a study performed to exclude coronary artery
57041	(See para IN.0.19 of explanatory notes to this Category Fee: \$233.40 Benefit: 75% = \$175.05 85%	
57047	intravenous contrast medium and with any scans	d chest with or without scans of upper abdomen with of brain and chest and upper abdomen prior to not including a study performed to exclude coronary

I2. CON	PUTED TOMOGRAPHY	9. BRAIN, CHEST AND UPPER ABDOMEN	
	artery calcification or image the coronary art	eries (R) (NK) (Anaes.)	
	(See para IN.0.19 of explanatory notes to this Cate	egory)	
	Fee: \$283.90 Benefit: 75% = \$212.95		
I2. CON	IPUTED TOMOGRAPHY	10. PELVIMETRY	
	Group I2. Computed Tomography		
	Subgroup 10. Pelvimetry		
	COMPUTED TOMOGRAPHY - PELVIME	TRY (R) (K) (Anaes.)	
57201	(See para IN.0.19 of explanatory notes to this Cate Fee: \$155.20 Benefit: 75% = \$116.40		
	COMPUTED TOMOGRAPHY - PELVIME	TRY (R) (NK) (Anaes.)	
57247	(See para IN.0.19 of explanatory notes to this Cate Fee: \$77.55 Benefit: 75% = \$58.20		
I2. CON	PUTED TOMOGRAPHY	11. INTERVENTIONAL TECHNIQUES	
	Group I2. Computed Tomography		
	Subgroup	11. Interventional techniques	
		on with a surgical procedure using interventional th a service to which another item in this table applies (R)	
57341	(See para IN.0.19 of explanatory notes to this Cate Fee: \$470.00 Benefit: 75% = \$352.50	- ··	
		on with a surgical procedure using interventional th a service to which another item in this table applies (R)	
57345	(See para IN.0.19 of explanatory notes to this Category) Fee: \$241.60 Benefit: 75% = \$181.20 85% = \$205.40		
	MPUTED TOMOGRAPHY	12. SPIRAL ANGIOGRAPHY	
	Group I2. Computed Tomography		
	Subgro	up 12. Spiral angiography	
	COMPUTED TOMOGRAPHY - spiral angiography with intravenous contrast medium, scans performed before intravenous contrast injection - 1 or more spiral data acquisitions image editing, and maximum intensity projections or 3 dimensional surface shaded displantacopy recording of multiple projections, where:		
	(a) the service is not a service to which ano	ther item in this group applies; and	
	(b) the service is performed for the exclusion and	on of arterial stenosis, occlusion, aneurysm or embolism;	
57350	(c) the service has not been performed on the	he same patient within the previous 12 months; and	

I2. COMPUTED TOMOGRAPHY		12. SPIRAL ANGIOGRAPHY	
	(d) the service is not a study performed to image the coronary a	arteries (R) (K) (Anaes.)	
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$510.00 Benefit: 75% = \$382.50 85% = \$433.50		
	COMPUTED TOMOGRAPHY - spiral angiography with intravescans performed before intravenous contrast injection - 1 or more image editing, and maximum intensity projections or 3 dimension hardcopy recording of multiple projections, where:	e spiral data acquisitions, including	
	(a) the service is not a service to which another item in this gro	oup applies; and	
	(b) the service is performed for the exclusion of acute or recurr symptomatic arterial occlusion; post operative complication of a or acute dissection of the aorta, carotid or vertebral artery; and		
	(c) the services to which 57350 or 57355 apply have been perference 12 months; and	ormed on the same patient within the	
	(d) the service is not a study performed to image the coronary a	arteries (R) (K) (Anaes.)	
57351	(See para IN.0.19 of explanatory notes to this Category) Fee: \$510.00 Benefit: 75% = \$382.50 85% = \$433.50		
	COMPUTED TOMOGRAPHY - spiral angiography with intraversans performed before intravenous contrast injection - 1 or more image editing, and maximum intensity projections or 3 dimension hardcopy recording of multiple projections, where:	e spiral data acquisitions, including	
	(a) the service is not a service to which another item in this gro	up applies; and	
	(b) the service is performed for the exclusion of arterial stenosiand	s, occlusion, aneurysm or embolism;	
	(c) the service has not been performed on the same patient with	nin the previous 12 months; and	
	(d) the service is not a study performed to image the coronary a	arteries (R) (NK) (Anaes.)	
57355	(See para IN.0.19 of explanatory notes to this Category) Fee: \$264.15 Benefit: 75% = \$198.15 85% = \$224.55		
	COMPUTED TOMOGRAPHY - spiral angiography with intravescans performed before intravenous contrast injection - 1 or more image editing, and maximum intensity projections or 3 dimension hardcopy recording of multiple projections, where:	e spiral data acquisitions, including	
	a) the service is not a service to which another item in this grou	ip applies; and	
	b) the service is performed for the exclusion of acute or recurre symptomatic arterial	ent pulmonary embolism; acute	
	occlusion; post operative complication of arterial surgery; or a dissection of the aorta,	cute ruptured aneurysm; acute	
57356	carotid or vertebral artery; and		

I2. CON	PUTED TOMOGRAPHY	12. SPIRAL ANGIOGRAPHY		
	(c) the services to which 57350 or 57355 previous 12 months; and	apply have been performed on the same patient within the		
	(d) the service is not a study performed t	o image the coronary arteries (R) (NK) (Anaes.)		
	(See para IN.0.19 of explanatory notes to this C Fee: \$264.15 Benefit: 75% = \$198.			
		CORONARY ARTERIES performed on a minimum of a 64 quest is made by a specialist or consultant physician, and:		
		stent with coronary ischaemia, is at low to intermediate risk of we been considered for coronary angiography; or		
	b) the patient requires exclusion of coror	nary artery anomaly or fistula; or		
	c) the patient will be undergoing non-con	ronary cardiac surgery (R) (K) (Anaes.)		
57360	(See para IN.0.12, IN.0.19 of explanatory notes Fee: \$700.00 Benefit: 75% = \$525.0			
		CORONARY ARTERIES performed on a minimum of a 64 quest is made by a specialist or consultant physician, and:		
		stent with coronary ischaemia, is at low to intermediate risk of we been considered for coronary angiography; or		
	b) the patient requires exclusion of coror	nary artery anomaly or fistula; or		
	c) the patient will be undergoing non-coronary cardiac surgery (R) (NK) (Anaes.) (See para IN.0.12, IN.0.19 of explanatory notes to this Category) Fee: \$350.00 Benefit: 75% = \$262.50 85% = \$297.50			
57361				
I2. COM	PUTED TOMOGRAPHY	13. CONE BEAM COMPUTED TOMOGRAPHY		
	Group I2. Computed Tomography			
	Subgroup 13	. Cone beam computed tomography		
		ng for diagnosis and management of mandibular and dento- , orthodontics, endodontic, periodontal and temporo- ast medium.		
	equipment located in practices accredited dedicated (rather than hybrid) CBCT units	sts and medical practitioners and must be performed on under the Diagnostic Imaging Accreditation Scheme using . Claims for more than one CBCT per patient per day are imaging in the same episode (items 57959-57969) and with 61) are also excluded.		
	(K)			
57362	Fee: \$113.15 Benefit: 75% = \$84.96	0 85% = \$96.20		
57363		ng for diagnosis and management of mandibular and dento- , orthodontics, endodontic, periodontal and temporo-		

I2. CON	IPUTED TOMOGRAPHY	13. CONE BEAM COMPUTED TOMOGRAPHY
	mandibular joint conditions: without co	ontrast medium.
	equipment located in practices accredit dedicated (rather than hybrid) CBCT u	ialists and medical practitioners and must be performed on ted under the Diagnostic Imaging Accreditation Scheme using units. Claims for more than one CBCT per patient per day are onal imaging in the same episode (items 57959-57969) and with 57361) are also excluded.
	(NK)	
	Fee: \$56.60 Benefit: 75% = \$4	42.45 85% = \$48.15
I3. DIAC	SNOSTIC RADIOLOGY	1. RADIOGRAPHIC EXAMINATION OF EXTREMITIES
	Group I3. Diagnostic Radiology	
	Subgroup 1	. Radiographic Examination Of Extremities
	HAND, WRIST, FOREARM, ELBOV	V OR HUMERUS (NR)
57506	(See para IN.0.19 of explanatory notes to the recomposition of the second secon	his Category) 22.35 85% = \$25.30
	HAND, WRIST, FOREARM, ELBOV	V OR HUMERUS (R)
57509	(See para IN.0.19 of explanatory notes to the ree: \$39.75 Benefit: 75% = \$2	his Category) 29.85 85% = \$33.80
	HAND AND WRIST OR HAND, WR ELBOW AND HUMERUS (NR)	IST AND FOREARM OR FOREARM AND ELBOW OR
57512	(See para IN.0.19 of explanatory notes to the Fee: \$40.50 Benefit: 75% = \$3	his Category) 30.40 85% = \$34.45
	HAND AND WRIST OR HAND, WR ELBOW AND HUMERUS (R)	IST AND FOREARM OR FOREARM AND ELBOW OR
57515	(See para IN.0.19 of explanatory notes to the Fee: \$54.00 Benefit: 75% = \$4.00	his Category) 40.50 85% = \$45.90
	FOOT, ANKLE, LEG, OR FEMUR (N	NR)(K)
57518	(See para IN.0.19 of explanatory notes to the ree: \$32.50 Benefit: 75% = \$2	his Category) 24.40 85% = \$27.65
	FOOT, ANKLE, LEG, OR FEMUR (F	
57521	(See para IN.0.19 of explanatory notes to the result of the see: \$43.40 Benefit: 75% = \$3	his Category) 32.55 85% = \$36.90
	Knee (NR)(K)	
57522	(See para IN.0.19 of explanatory notes to the ree: \$32.50 Benefit: 75% = \$2	his Category) 24.40 85% = \$27.65
	Knee (R)(K)	
57523	(See para IN.0.19 of explanatory notes to the	his Category)

I3. DIAC	1. RADIOGRAPHIC EXAMINATION OF EXTREMITIES			
	Fee: \$43.40 Benefit: 75% = \$32.55 85% = \$36.90			
	FOOT AND ANKLE, OR ANKLE AND LEG, OR LEG AND KNEE, OR KNI	EE AND FEMUR (NR)		
57524	(See para IN.0.19 of explanatory notes to this Category) Fee: \$49.40 Benefit: 75% = \$37.05 85% = \$42.00			
	FOOT AND ANKLE, OR ANKLE AND LEG, OR LEG AND KNEE, OR KNI	EE AND FEMUR (R)		
57527	(See para IN.0.19 of explanatory notes to this Category) Fee: \$65.75 Benefit: 75% = \$49.35 85% = \$55.90			
	HAND, WRIST, FOREARM, ELBOW OR HUMERUS (NR) (NK)			
57529	(See para IN.0.19 of explanatory notes to this Category) Fee: \$14.90 Benefit: 75% = \$11.20 85% = \$12.70			
	HAND, WRIST, FOREARM, ELBOW OR HUMERUS (R) (NK)			
57530	(See para IN.0.19 of explanatory notes to this Category) Fee: \$19.90 Benefit: 75% = \$14.95 85% = \$16.95			
	HAND AND WRIST OR HAND, WRIST AND FOREARM OR FOREARM A ELBOW AND HUMERUS (NR) (NK)	AND ELBOW OR		
57532	(See para IN.0.19 of explanatory notes to this Category) Fee: \$20.25 Benefit: 75% = \$15.20 85% = \$17.25			
	HAND AND WRIST OR HAND, WRIST AND FOREARM OR FOREARM A ELBOW AND HUMERUS (R) (NK)	AND ELBOW OR		
57533	(See para IN.0.19 of explanatory notes to this Category) Fee: \$27.00 Benefit: 75% = \$20.25 85% = \$22.95			
	FOOT, ANKLE, LEG, OR FEMUR (NR) (NK)			
57535	(See para IN.0.19 of explanatory notes to this Category) Fee: \$16.25 Benefit: 75% = \$12.20 85% = \$13.85			
	FOOT, ANKLE, LEG, OR FEMUR (R) (NK)			
57536	(See para IN.0.19 of explanatory notes to this Category) Fee: \$21.70 Benefit: 75% = \$16.30 85% = \$18.45			
	Knee (NR)(NK)			
57537	(See para IN.0.19 of explanatory notes to this Category) Fee: \$16.25 Benefit: 75% = \$12.20 85% = \$13.85			
	FOOT AND ANKLE, OR ANKLE AND LEG, OR LEG AND KNEE, OR KNI(NK)	EE AND FEMUR (NR)		
57538	(See para IN.0.19 of explanatory notes to this Category) Fee: \$24.70 Benefit: 75% = \$18.55 85% = \$21.00			
	FOOT AND ANKLE, OR ANKLE AND LEG, OR LEG AND KNEE, OR KNI (NK)	EE AND FEMUR (R)		
57539	(See para IN.0.19 of explanatory notes to this Category) Fee: \$32.90 Benefit: 75% = \$24.70 85% = \$28.00			
57540	Knee (R)(NK)			

1. RADIOGRAPHIC EXAMINATION OF 13. DIAGNOSTIC RADIOLOGY **EXTREMITIES** (See para IN.0.19 of explanatory notes to this Category) **Benefit:** 75% = \$16.30 85% = \$18.45 Fee: \$21.70 2. RADIOGRAPHIC EXAMINATION OF 13. DIAGNOSTIC RADIOLOGY **SHOULDER OR PELVIS Group I3. Diagnostic Radiology** Subgroup 2. Radiographic Examination Of Shoulder Or Pelvis SHOULDER OR SCAPULA (NR) (See para IN.0.19 of explanatory notes to this Category) 57700 Fee: \$40.50 **Benefit:** $75\% = \$30.40 \quad 85\% = \34.45 SHOULDER OR SCAPULA (NR) (NK) (See para IN.0.19 of explanatory notes to this Category) 57702 **Benefit:** 75% = \$15.20 85% = \$17.25 Fee: \$20.25 SHOULDER OR SCAPULA (R) (See para IN.0.19 of explanatory notes to this Category) 57703 Fee: \$54.00 **Benefit:** 75% = \$40.50 85% = \$45.90 SHOULDER OR SCAPULA (R) (NK) (See para IN.0.19 of explanatory notes to this Category) **Benefit:** 75% = \$20.25 85% = \$22.95 57705 Fee: \$27.00 CLAVICLE (NR) (See para IN.0.19 of explanatory notes to this Category) **Benefit:** 75% = \$24.40 85% = \$27.65 57706 Fee: \$32.50 CLAVICLE (NR) (NK) (See para IN.0.19 of explanatory notes to this Category) 57708 **Benefit:** 75% = \$12.20 85% = \$13.85Fee: \$16.25 CLAVICLE (R) (See para IN.0.19 of explanatory notes to this Category) Fee: \$43.40 **Benefit:** 75% = \$32.55 85% = \$36.90 57709 CLAVICLE (R) (NK) (See para IN.0.19 of explanatory notes to this Category) **Benefit:** 75% = \$16.30 85% = \$18.45 57711 Fee: \$21.70 HIP JOINT (R) (See para IN.0.19 of explanatory notes to this Category) **Benefit:** $75\% = \$35.40 \quad 85\% = \40.10 57712 Fee: \$47.15 HIP JOINT (R) (NK) (See para IN.0.19 of explanatory notes to this Category) 57714 Fee: \$23.60 **Benefit:** $75\% = \$17.70 \quad 85\% = \20.10 PELVIC GIRDLE (R) 57715

I3. DIAG	2. RADIOGRAPHIC EXAMINATION OF SHOULDER OR PELVIS
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$60.90 Benefit: 75% = \$45.70 85% = \$51.80
	PELVIC GIRDLE (R) (NK)
57717	(See para IN.0.19 of explanatory notes to this Category) Fee: \$30.45 Benefit: 75% = \$22.85 85% = \$25.90
	FEMUR, internal fixation of neck or intertrochanteric (pertrochanteric) fracture (R)
57721	(See para IN.0.19 of explanatory notes to this Category) Fee: \$99.25 Benefit: 75% = \$74.45 85% = \$84.40
	FEMUR, internal fixation of neck or intertrochanteric (pertrochanteric) fracture (R) (NK)
57723	(See para IN.0.19 of explanatory notes to this Category) Fee: \$49.65 Benefit: 75% = \$37.25 85% = \$42.25
I3. DIAG	GNOSTIC RADIOLOGY 3. RADIOGRAPHIC EXAMINATION OF HEAD
	Group I3. Diagnostic Radiology
	Subgroup 3. Radiographic Examination Of Head
	SKULL, not in association with item 57902 (R)
57901	(See para IN.0.19 of explanatory notes to this Category) Fee: \$64.50 Benefit: 75% = \$48.40 85% = \$54.85
	CEPHALOMETRY, not in association with item 57901 (R)
57902	(See para IN.0.19 of explanatory notes to this Category) Fee: \$64.50 Benefit: 75% = \$48.40 85% = \$54.85
	SINUSES (R)
57903	(See para IN.0.19 of explanatory notes to this Category) Fee: \$47.30 Benefit: 75% = \$35.50 85% = \$40.25
	MASTOIDS (R)
57906	(See para IN.0.19 of explanatory notes to this Category) Fee: \$64.50 Benefit: 75% = \$48.40 85% = \$54.85
	PETROUS TEMPORAL BONES (R)
57909	(See para IN.0.19 of explanatory notes to this Category) Fee: \$64.50 Benefit: 75% = \$48.40 85% = \$54.85
	SKULL, not in association with item 57902 or 57914 (R) (NK)
57911	(See para IN.0.19 of explanatory notes to this Category) Fee: \$32.25 Benefit: 75% = \$24.20 85% = \$27.45
	FACIAL BONES orbit, maxilla or malar, any or all (R)
57912	(See para IN.0.19 of explanatory notes to this Category) Fee: \$47.15 Benefit: 75% = \$35.40 85% = \$40.10
	CEPHALOMETRY, not in association with item 57901 or 57911 (R) (NK)
57914	(See para IN.0.19 of explanatory notes to this Category)

I3. DIA	GNOSTIC RADIOLOGY	3. RADIOGRAPHIC EXAMINATION OF HEAD	
	Fee: \$32.25 Benefit: 75% = \$24	1.20 85% = \$27.45	
	MANDIBLE, not by orthopantomography technique (R)		
57915	(See para IN.0.19 of explanatory notes to thi Fee: \$47.15 Benefit: 75% = \$35		
	SINUSES (R) (NK)		
57917	(See para IN.0.19 of explanatory notes to thi Fee: \$23.65 Benefit: 75% = \$17		
	SALIVARY CALCULUS (R)		
57918	(See para IN.0.19 of explanatory notes to thi Fee: \$47.15 Benefit: 75% = \$35		
	MASTOIDS (R) (NK)		
57920	(See para IN.0.19 of explanatory notes to thi Fee: \$32.25 Benefit: 75% = \$24		
	NOSE (R)		
57921	(See para IN.0.19 of explanatory notes to thi Fee: \$47.15 Benefit: 75% = \$35		
	PETROUS TEMPORAL BONES (R) (1	NK)	
57923	(See para IN.0.19 of explanatory notes to thi Fee: \$32.25 Benefit: 75% = \$24		
	EYE (R)		
57924	(See para IN.0.19 of explanatory notes to thi Fee: \$47.15 Benefit: 75% = \$35	C 17	
	FACIAL BONES orbit, maxilla or mala	ar, any or all (R) (NK)	
57926	(See para IN.0.19 of explanatory notes to thi Fee: \$23.60 Benefit: 75% = \$17		
	TEMPOROMANDIBULAR JOINTS (F	R)	
57927	(See para IN.0.19 of explanatory notes to thi Fee: \$49.65 Benefit: 75% = \$37		
	MANDIBLE, not by orthopantomography technique (R) (NK)		
57929	(See para IN.0.19 of explanatory notes to thi Fee: \$23.60 Benefit: 75% = \$17	± • ·	
	TEETH SINGLE AREA (R)		
57930	(See para IN.0.19 of explanatory notes to thi Fee: \$32.90 Benefit: 75% = \$24	± • ·	
	SALIVARY CALCULUS (R) (NK)		
57932	(See para IN.0.19 of explanatory notes to thi Fee: \$23.60 Benefit: 75% = \$17	± • ·	
	TEETH FULL MOUTH (R)		
57933	(See para IN.0.19 of explanatory notes to thi	s Category)	
	(-17 plants of emplantatory notes to thi	<i>01)</i>	

I3. DIA	NOSTIC RADIO	LOGY	3. RADIOGRAPHIC EXAMINATION OF HEAD
	Fee: \$78.25	Benefit: 75% = \$58.70	85% = \$66.55
	NOSE (R) (NK)		
57935	(See para IN.0.19 Fee: \$23.60	of explanatory notes to this Ca Benefit: 75% = \$17.70	
	EYE (R) (NK)		
57938	(See para IN.0.19 Fee: \$23.60	of explanatory notes to this Ca Benefit: 75% = \$17.70	
	PALATOPHAR	YNGEAL STUDIES with f	fluoroscopic screening (R)
57939	(See para IN.0.19 Fee: \$64.50	of explanatory notes to this Ca Benefit: 75% = \$48.40	
	TEMPOROMA	NDIBULAR JOINTS (R) (1	NK)
57941	(See para IN.0.19 Fee: \$24.85	of explanatory notes to this Ca Benefit: 75% = \$18.65	
	PALATOPHAR	YNGEAL STUDIES witho	ut fluoroscopic screening (R)
57942	(See para IN.0.19 Fee: \$49.65	of explanatory notes to this Ca Benefit: 75% = \$37.25	G 17
	TEETH SINGL	E AREA (R) (NK)	
57944	(See para IN.0.19 Fee: \$16.45	of explanatory notes to this Ca Benefit: 75% = \$12.35	
		ERAL AIRWAYS AND Son service to which item 5793	OFT TISSUES OF THE NECK, not being a service 39 or 57942 applies (R)
57945	(See para IN.0.19 Fee: \$43.40	of explanatory notes to this Ca Benefit: 75% = \$32.55	
	TEETH FULL	MOUTH (R) (NK)	
57947	(See para IN.0.19 Fee: \$39.15	of explanatory notes to this Ca Benefit: 75% = \$29.40	
	PALATOPHAR	YNGEAL STUDIES with f	fluoroscopic screening (R) (NK)
57950	(See para IN.0.19 Fee: \$32.25	of explanatory notes to this Ca Benefit: 75% = \$24.20	
	PALATOPHAR	YNGEAL STUDIES witho	ut fluoroscopic screening (R) (NK)
57953	(See para IN.0.19 Fee: \$24.85	of explanatory notes to this Ca Benefit: 75% = \$18.65	
			OFT TISSUES OF THE NECK, not being a service 39, 57942, 57950 or 57953 applies (R) (NK)
57956	(See para IN.0.19 Fee: \$21.70	of explanatory notes to this Ca Benefit: 75% = \$16.30	
			management of trauma, infection, tumours, congenital n or maxillofacial region (R) (NK)
57959	(See para IN.0.19 Fee: \$23.70	of explanatory notes to this Ca Benefit: 75% = \$17.80	

I3. DIAG	SNOSTIC RADIOLOGY 3. RADIOGRAPHIC EXAMINATION OF HEAD	
	Orthopantomography, for diagnosis and/or management of trauma, infection, tumours, congenital conditions or surgical conditions of the teeth or maxillofacial region (R)	
57960	(See para IN.0.19 of explanatory notes to this Category) Fee: \$47.40 Benefit: 75% = \$35.55 85% = \$40.30	
	Orthopantomography, for diagnosis and/or management of impacted teeth, caries, periodontal or peripical pathology where signs or symptoms of those conditions are evident (R) (NK)	
57962	(See para IN.0.19 of explanatory notes to this Category) Fee: \$23.70 Benefit: 75% = \$17.80 85% = \$20.15	
	Orthopantomography, for diagnosis and/or management of impacted teeth, caries, periodontal or peripical pathology where signs or symptoms of those conditions are evident (R)	
57963	(See para IN.0.19 of explanatory notes to this Category) Fee: \$47.40 Benefit: 75% = \$35.55 85% = \$40.30	
	Orthopantomography, for diagnosis and/or management of missing or crowded teeth, or developmental anomalies of the teeth or jaws (R) (NK)	
57965	(See para IN.0.19 of explanatory notes to this Category) Fee: \$23.70 Benefit: 75% = \$17.80 85% = \$20.15	
	Orthopantomography, for diagnosis and/or management of missing or crowded teeth, or developmental anomalies of the teeth or jaws (R)	
57966	(See para IN.0.19 of explanatory notes to this Category) Fee: \$47.40 Benefit: 75% = \$35.55 85% = \$40.30	
	Orthopantomography, for diagnosis and/or management of temporomandibular joint arthroses or dysfunction (R) (NK)	
57968	(See para IN.0.19 of explanatory notes to this Category) Fee: \$23.70 Benefit: 75% = \$17.80 85% = \$20.15	
	Orthopantomography, for diagnosis and/or management of temporomandibular joint arthroses or dysfunction (R)	
57969	(See para IN.0.19 of explanatory notes to this Category) Fee: \$47.40 Benefit: 75% = \$35.55 85% = \$40.30	
I3. DIAG	SNOSTIC RADIOLOGY 4. RADIOGRAPHIC EXAMINATION OF SPINE	
	Group I3. Diagnostic Radiology	
	Subgroup 4. Radiographic Examination Of Spine	
	SPINE CERVICAL (R)	
58100	(See para IN.0.19 of explanatory notes to this Category) Fee: \$67.15 Benefit: 75% = \$50.40 85% = \$57.10	
	SPINE CERVICAL (R) (NK)	
58102	(See para IN.0.19 of explanatory notes to this Category) Fee: \$33.60 Benefit: 75% = \$25.20 85% = \$28.60	
	SPINE THORACIC (R)	
58103	(See para IN.0.19 of explanatory notes to this Category) Fee: \$55.10 Benefit: 75% = \$41.35 85% = \$46.85	

I3. DIA	GNOSTIC RADIOLOGY	. RADIOGRAPHIC EXAMINATION OF SPINE
	SPINE THORACIC (R) (NK)	
58105	(See para IN.0.19 of explanatory notes to this Category) Fee: \$27.55 Benefit: 75% = \$20.70 85% = \$	23.45
	SPINE LUMBOSACRAL (R)	
58106	(See para IN.0.19 of explanatory notes to this Category) Fee: \$77.00 Benefit: 75% = \$57.75 85% = \$	65.45
	Spine, four regions, cervical, thoracic, lumbosacral at	nd sacrococcygeal (R)
58108	(See para IN.0.19 of explanatory notes to this Category) Fee: $$110.00$ Benefit: $75\% = 82.50 $85\% = $$	93.50
	SPINE SACROCOCCYGEAL (R)	
58109	(See para IN.0.19 of explanatory notes to this Category) Fee: \$47.00 Benefit: 75% = \$35.25 85% = \$	39.95
	SPINE LUMBOSACRAL (R) (NK)	
58111	(See para IN.0.19 of explanatory notes to this Category) Fee: \$38.50 Benefit: 75% = \$28.90 85% = \$	32.75
	NOTE: An account issued or a patient assignment for examinations performed under this item	rm must show the item numbers of the
58112	Spine, two examinations of the kind referred to in ite (See para IN.0.19 of explanatory notes to this Category) Fee: \$97.25 Benefit: 75% = \$72.95 85% = \$	
00112	Spine, four regions, cervical, thoracic, lumbosacral and sacrococcygeal (R) (NK)	
58114	(See para IN.0.19 of explanatory notes to this Category) Fee: \$55.00 Benefit: 75% = \$41.25 85% = \$	
	NOTE: An account issued or a patient assignment for examinations performed under this item	rm must show the item numbers of the
	Spine, three examinations of the kind mentioned in it	ems 58100, 58103, 58106 and 58109 (R)
58115	(See para IN.0.19 of explanatory notes to this Category) Fee: \$110.00 Benefit: 75% = \$82.50 85% = \$	93.50
	SPINE SACROCOCCYGEAL (R) (NK)	
58117	(See para IN.0.19 of explanatory notes to this Category) Fee: \$23.50 Benefit: 75% = \$17.65 85% = \$20.00	
	Spine, four regions, cervical, thoracic, lumbosacral at 58120 or 58121 applies has not been performed on the	
58120	Fee: \$110.00 Benefit: 75% = \$82.50 85% = \$93.50	
58121	NOTE: An account issued or a patient assignment for	rm must show the item numbers of the

I3. DIAC	GNOSTIC RADIOLOGY 4. RADIOGRAPHIC EXAMINATION OF SPINE	
	examinations performed under this item	
	Spine, three examinations of the kind mentioned in items 58100, 58103, 58106 and 58109 (R), if the service to which item 58120 or 58121 applies has not been performed on the same patient within the same calendar year	
	Fee: \$110.00 Benefit: 75% = \$82.50 85% = \$93.50	
	NOTE: An account issued or a patient assignment form must show the item numbers of the examinations performed under this item	
	Spine, two examinations of the kind referred to in items 58100, 58102, 58103, 58105, 58106, 58109, 58111 and 58117 (R) (NK)	
58123	(See para IN.0.19 of explanatory notes to this Category) Fee: \$48.65 Benefit: 75% = \$36.50 85% = \$41.40	
	NOTE: An account issued or a patient assignment form must show the item numbers of the examinations performed under this item	
	Spine, three examinations of the kind mentioned in items 58100, 58102, 58103, 58105, 58106, 58109, 58111 and 58117 (R) (NK)	
58124	(See para IN.0.19 of explanatory notes to this Category) Fee: \$55.00 Benefit: 75% = \$41.25 85% = \$46.75	
	Spine, four regions, cervical, thoracic, lumbosacral and sacrococcygeal, if the service to which item 58120, 58121, 58126 or 58127 applies has not been performed on the same patient within the same calendar year (R) (NK)	
58126	(See para IN.0.19 of explanatory notes to this Category) Fee: \$55.00 Benefit: 75% = \$41.25 85% = \$46.75	
	NOTE: An account issued or a patient assignment form must show the item numbers of the examinations performed under this item	
	Spine, three examinations of the kind mentioned in items 58100, 58102, 58103, 58105, 58106 and 58109, 58111 and 58117 if the service to which item 58120, 58121, 58126 or 58127 applies has not been performed on the same patient within the same calendar year (R) (NK)	
58127	(See para IN.0.19 of explanatory notes to this Category) Fee: \$55.00 Benefit: 75% = \$41.25 85% = \$46.75	
I3. DIAC	SNOSTIC RADIOLOGY 5. BONE AGE STUDY AND SKELETAL SURVEYS	
	Group I3. Diagnostic Radiology	
	Subgroup 5. Bone Age Study And Skeletal Surveys	

I3. DIAC	NOSTIC RADIOLOGY	5. BONE AGE STUDY AND SKELETAL SURVEYS
	BONE AGE STUDY (R)	
58300	(See para IN.0.19 of explanatory notes to this Fee: \$40.10 Benefit: 75% = \$30.1	
	BONE AGE STUDY (R) (NK)	
58302	(See para IN.0.19 of explanatory notes to this G Fee: \$20.05 Benefit: 75% = \$15.0	C 17
	SKELETAL SURVEY (R)	
58306	(See para IN.0.19 of explanatory notes to this G Fee: \$89.40 Benefit: 75% = \$67.0	
	SKELETAL SURVEY (R) (NK)	
58308	(See para IN.0.19 of explanatory notes to this Fee: \$44.70 Benefit: 75% = \$33.5	
I3. DIAC	SNOSTIC RADIOLOGY	6. RADIOGRAPHIC EXAMINATION OF THORACIC REGION
	Group I3. Diagnostic Radiology	
	Subgroup 6. Radi	ographic Examination Of Thoracic Region
	CHEST (lung fields) by direct radiograph	y (NR)
58500	(See para IN.0.19 of explanatory notes to this 6 Fee: \$35.35 Benefit: 75% = \$26.5	
	CHEST (lung fields) by direct radiograph	y (NR) (NK)
58502	(See para IN.0.19 of explanatory notes to this Fee: \$17.70 Benefit: 75% = \$13.3	
	CHEST (lung fields) by direct radiograph	y(R)
58503	(See para IN.0.19 of explanatory notes to this Fee: \$47.15 Benefit: 75% = \$35.4	
	CHEST (lung fields) by direct radiograph	y (R) (NK)
58505	(See para IN.0.19 of explanatory notes to this Fee: \$23.60 Benefit: 75% = \$17.7	
	CHEST (lung fields) by direct radiograph	y with fluoroscopic screening (R)
58506	(See para IN.0.19 of explanatory notes to this Category) Fee: \$60.75 Benefit: 75% = \$45.60 85% = \$51.65	
	CHEST (lung fields) by direct radiograph	y with fluoroscopic screening (R) (NK)
58508	(See para IN.0.19 of explanatory notes to this 6 Fee: \$30.40 Benefit: 75% = \$22.8	
	THORACIC INLET OR TRACHEA (R)	
58509	(See para IN.0.19 of explanatory notes to this G Fee: \$39.75 Benefit: 75% = \$29.8	

I3. DIA	6. RADIOGRAPHIC EXAMINATION O THORACIC REGIO
	THORACIC INLET OR TRACHEA (R) (NK)
58511	(See para IN.0.19 of explanatory notes to this Category) Fee: \$19.90 Benefit: 75% = \$14.95 85% = \$16.95
	LEFT RIBS, RIGHT RIBS OR STERNUM (R)
58521	(See para IN.0.19 of explanatory notes to this Category) Fee: \$43.40 Benefit: 75% = \$32.55 85% = \$36.90
	LEFT RIBS, RIGHT RIBS OR STERNUM (R) (NK)
58523	(See para IN.0.19 of explanatory notes to this Category) Fee: \$21.70 Benefit: 75% = \$16.30 85% = \$18.45
	LEFT AND RIGHT RIBS, LEFT RIBS AND STERNUM, OR RIGHT RIBS AND STERNUM (R)
58524	(See para IN.0.19 of explanatory notes to this Category) Fee: \$56.50 Benefit: 75% = \$42.40 85% = \$48.05
	LEFT AND RIGHT RIBS, LEFT RIBS AND STERNUM, OR RIGHT RIBS AND STERNUM (R) (NK)
58526	(See para IN.0.19 of explanatory notes to this Category) Fee: \$28.25 Benefit: 75% = \$21.20 85% = \$24.05
	LEFT RIBS, RIGHT RIBS AND STERNUM (R)
58527	(See para IN.0.19 of explanatory notes to this Category) Fee: \$69.40 Benefit: 75% = \$52.05 85% = \$59.00
	LEFT RIBS, RIGHT RIBS AND STERNUM (R) (NK)
58529	(See para IN.0.19 of explanatory notes to this Category) Fee: \$34.70 Benefit: 75% = \$26.05 85% = \$29.50
I3. DIA	7. RADIOGRAPHIC EXAMINATION OF URINAR GNOSTIC RADIOLOGY TRAC
	Group I3. Diagnostic Radiology
	Subgroup 7. Radiographic Examination Of Urinary Tract
	PLAIN RENAL ONLY (R)
58700	(See para IN.0.19 of explanatory notes to this Category) Fee: \$46.05 Benefit: 75% = \$34.55 85% = \$39.15
	PLAIN RENAL ONLY (R) (NK)
58702	(See para IN.0.19 of explanatory notes to this Category) Fee: \$23.05 Benefit: 75% = \$17.30 85% = \$19.60
	INTRAVENOUS PYELOGRAPHY, with or without preliminary plain films and with or without tomography - (R)
58706	(See para IN.0.19 of explanatory notes to this Category) Fee: \$157.90 Benefit: 75% = \$118.45 85% = \$134.25
58708	INTRAVENOUS PYELOGRAPHY, with or without preliminary plain films and with or without

I3. DIAC	7. RADIOGRAPHIC EXAMINATION OF URINARY SNOSTIC RADIOLOGY TRACT	
	tomography - (R) (NK)	
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$78.95 Benefit: 75% = \$59.25 85% = \$67.15	
	ANTEGRADE OR RETROGRADE PYELOGRAPHY, with or without preliminary plain films and with preparation and contrast injection - 1 side - (R)	
58715	(See para IN.0.19 of explanatory notes to this Category) Fee: \$151.55 Benefit: 75% = \$113.70 85% = \$128.85	
	ANTEGRADE OR RETROGRADE PYELOGRAPHY, with or without preliminary plain films and with preparation and contrast injection - 1 side - (R) (NK)	
58717	(See para IN.0.19 of explanatory notes to this Category) Fee: \$75.80 Benefit: 75% = \$56.85 85% = \$64.45	
	RETROGRADE CYSTOGRAPHY OR RETROGRADE URETHROGRAPHY with or without preliminary plain films and with preparation and contrast injection - (R) (Anaes.)	
58718	(See para IN.0.19 of explanatory notes to this Category) Fee: \$126.10 Benefit: 75% = \$94.60 85% = \$107.20	
	RETROGRADE CYSTOGRAPHY OR RETROGRADE URETHROGRAPHY with or without preliminary plain films and with preparation and contrast injection - (R) (NK) (Anaes.)	
58720	(See para IN.0.19 of explanatory notes to this Category) Fee: \$63.05 Benefit: 75% = \$47.30 85% = \$53.60	
	RETROGRADE MICTURATING CYSTOURETHROGRAPHY, with preparation and contrast injection - (R) (Anaes.)	
58721	(See para IN.0.19 of explanatory notes to this Category) Fee: \$138.25 Benefit: 75% = \$103.70 85% = \$117.55	
	RETROGRADE MICTURATING CYSTOURETHROGRAPHY, with preparation and contrast injection - (R) (NK) (Anaes.)	
58723	(See para IN.0.19 of explanatory notes to this Category) Fee: \$69.15 Benefit: 75% = \$51.90 85% = \$58.80	
I3. DIA	8. RADIOGRAPHIC EXAMINATION OF ALIMENTARY TRACT AND BILIARY SYSTEM	
	Group I3. Diagnostic Radiology	
	Subgroup 8. Radiographic Examination Of Alimentary Tract And Biliary System	
	PLAIN ABDOMINAL ONLY, not being a service associated with a service to which item 58909, 5891 or 58915 applies (NR)	
58900	(See para IN.0.19 of explanatory notes to this Category) Fee: \$35.70 Benefit: 75% = \$26.80 85% = \$30.35	
	PLAIN ABDOMINAL ONLY, not being a service associated with a service to which item 58909, 58911, 58912, 58914, 58915 or 58917 applies (NR) (NK)	
58902	(See para IN.0.19 of explanatory notes to this Category) Fee: \$17.85 Benefit: 75% = \$13.40 85% = \$15.20	

I3. DIAC	8. RADIOGRAPHIC EXAMINATION OF ALIMENTARY TRACT AND BILIARY SYSTEM		
	PLAIN ABDOMINAL ONLY, not being a service associated with a service to which item 58909, 58912 or 58915 applies (R)		
58903	(See para IN.0.19 of explanatory notes to this Category) Fee: \$47.60 Benefit: 75% = \$35.70 85% = \$40.50		
	PLAIN ABDOMINAL ONLY, not being a service associated with a service to which item 58909, 58911, 58912, 58914, 58915 or 58917 applies (R) (NK)		
58905	(See para IN.0.19 of explanatory notes to this Category) Fee: \$23.80 Benefit: 75% = \$17.85 85% = \$20.25		
	BARIUM or other opaque meal of 1 or more of PHARYNX, OESOPHAGUS, STOMACH OR DUODENUM, with or without preliminary plain films of pharynx, chest or duodenum, not being a service associated with a service to which item 57939 or 57942 or 57945 applies - (R)		
58909	(See para IN.0.19 of explanatory notes to this Category) Fee: \$89.95 Benefit: 75% = \$67.50 85% = \$76.50		
	BARIUM or other opaque meal of 1 or more of PHARYNX, OESOPHAGUS, STOMACH OR DUODENUM, with or without preliminary plain films of pharynx, chest or duodenum, not being a service associated with a service to which item 57939, 57942, 57945, 57950, 57953 or 57956 applies - (R) (NK)		
58911	(See para IN.0.19 of explanatory notes to this Category) Fee: \$45.00 Benefit: 75% = \$33.75 85% = \$38.25		
	BARIUM or other opaque meal OF OESOPHAGUS, STOMACH, DUODENUM AND FOLLOW THROUGH TO COLON, with or without screening of chest, with or without preliminary plain film (R)		
58912	(See para IN.0.19 of explanatory notes to this Category) Fee: \$110.25 Benefit: 75% = \$82.70 85% = \$93.75		
	BARIUM or other opaque meal OF OESOPHAGUS, STOMACH, DUODENUM AND FOLLOW THROUGH TO COLON, with or without screening of chest, with or without preliminary plain film (R) (NK)		
58914	(See para IN.0.19 of explanatory notes to this Category) Fee: \$55.15 Benefit: 75% = \$41.40 85% = \$46.90		
	BARIUM or other opaque meal, SMALL BOWEL SERIES ONLY, with or without preliminary plain film (R)		
58915	(See para IN.0.19 of explanatory notes to this Category) Fee: \$78.95 Benefit: 75% = \$59.25 85% = \$67.15		
	SMALL BOWEL ENEMA, barium or other opaque study of the small bowel, including DUODENAL INTUBATION, with or without preliminary plain films, not being a service associated with a service to which item 30488 applies - (R) (Anaes.)		
58916	(See para IN.0.19 of explanatory notes to this Category) Fee: \$138.50 Benefit: 75% = \$103.90 85% = \$117.75		
	BARIUM or other opaque meal, SMALL BOWEL SERIES ONLY, with or without preliminary plain film (R) (NK)		
58917	(See para IN.0.19 of explanatory notes to this Category) Fee: \$39.50 Benefit: 75% = \$29.65 85% = \$33.60		
58920	SMALL BOWEL ENEMA, barium or other opaque study of the small bowel, including DUODENAL		

I3. DIAC	8. RADIOGRAPHIC EXAMINATION OF ALIMENTARY TRACT AND BILIARY SYSTEM	
	INTUBATION, with or without preliminary plain films, not being a service associated with a service to which item 30488 applies - (R) (NK) (Anaes.)	
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$69.25 Benefit: 75% = \$51.95 85% = \$58.90	
	OPAQUE ENEMA, with or without air contrast study and with or without preliminary plain films - (R)	
58921	(See para IN.0.19 of explanatory notes to this Category) Fee: \$135.25 Benefit: 75% = \$101.45 85% = \$115.00	
	OPAQUE ENEMA, with or without air contrast study and with or without preliminary plain films - (R) (NK)	
58923	(See para IN.0.19 of explanatory notes to this Category) Fee: \$67.65 Benefit: 75% = \$50.75 85% = \$57.55	
	CHOLEGRAPHY DIRECT, with or without preliminary plain films and with preparation and contrast injection, not being a service associated with a service to which item 30439 applies - (R)	
58927	(See para IN.0.19 of explanatory notes to this Category) Fee: \$76.45 Benefit: 75% = \$57.35 85% = \$65.00	
	CHOLEGRAPHY DIRECT, with or without preliminary plain films and with preparation and contrast injection, not being a service associated with a service to which item 30439 applies - (R) (NK)	
58929	(See para IN.0.19 of explanatory notes to this Category) Fee: \$38.25 Benefit: 75% = \$28.70 85% = \$32.55	
	CHOLEGRAPHY, percutaneous transhepatic, with or without preliminary plain films and with preparation and contrast injection - (R)	
58933	(See para IN.0.19 of explanatory notes to this Category) Fee: \$205.60 Benefit: 75% = \$154.20 85% = \$174.80	
	CHOLEGRAPHY, percutaneous transhepatic, with or without preliminary plain films and with preparation and contrast injection - (R) (NK)	
58935	(See para IN.0.19 of explanatory notes to this Category) Fee: \$102.80 Benefit: 75% = \$77.10 85% = \$87.40	
	CHOLEGRAPHY, drip infusion, with or without preliminary plain films, with preparation and contrast injection and with or without tomography - (R)	
58936	(See para IN.0.19 of explanatory notes to this Category) Fee: \$195.95 Benefit: 75% = \$147.00 85% = \$166.60	
	CHOLEGRAPHY, drip infusion, with or without preliminary plain films, with preparation and contrast injection and with or without tomography - (R) (NK)	
58938	(See para IN.0.19 of explanatory notes to this Category) Fee: \$98.00 Benefit: 75% = \$73.50 85% = \$83.30	
	DEFAECOGRAM (R)	
58939	(See para IN.0.19 of explanatory notes to this Category) Fee: \$139.30 Benefit: 75% = \$104.50 85% = \$118.45	
	DEFAECOGRAM (R) (NK)	
58941	(See para IN.0.19 of explanatory notes to this Category)	

I3. DIAC	SNOSTIC RADIOLOGY	8. RADIOGRAPHIC EXAMINATION OF ALIMENTARY TRACT AND BILIARY SYSTEM	
101 211 10		: 75% = \$52.25	
I3. DIAC	NOSTIC RADIOLOGY	9. RADIOGRAPHIC EXAMINATION FOR LOCALISATION OF FOREIGN BODIES	
	Group I3. Diagnostic Rad	logy	
	Subgroup	Radiographic Examination For Localisation Of Foreign Bodies	
	Localisation of foreign bod Group I3 (R)	if provided in conjunction with a service described in Subgroups 1 to 12 of	
59103	(See para IN.0.19 of explanator Fee: \$21.30 Benef	notes to this Category) : 75% = \$16.00 85% = \$18.15	
	Localisation of foreign bod Group I3 (R) (NK)	if provided in conjunction with a service described in Subgroups 1 to 12 of	
59104	(See para IN.0.19 of explanator Fee: \$10.65 Benef	v notes to this Category) • 75% = \$8.00 85% = \$9.10	
I3. DIAC	NOSTIC RADIOLOGY	10. RADIOGRAPHIC EXAMINATION OF BREASTS	
	Group I3. Diagnostic Rad	logy	
		Subgroup 10. Radiographic Examination Of Breasts	
		led for use in the investigation of a clinical abnormality of the breast/s and opportunistic screening of asymptomatic patients)	
	MAMMOGRAPHY OF Bobecause of:	ΓΗ BREASTS, if there is a reason to suspect the presence of malignancy	
	(i) the past occurrence	breast malignancy in the patient or members of the patient's family; or	
		ons of malignancy found on an examination of the patient by a medical se indicated, mammography includes both breasts (R)	
59300	(See para IN.0.19 of explanatory notes to this Category) Fee: \$89.50 Benefit: 75% = \$67.15 85% = \$76.10		
		led for use in the investigation of a clinical abnormality of the breast/s and opportunistic screening of asymptomatic patients)	
	MAMMOGRAPHY OF Bobecause of:	ΓΗ BREASTS, if there is a reason to suspect the presence of malignancy	
59301	(i) the past occurrence	f breast malignancy in the patient or members of the patient's family; or	

I3. DIAG	10. RADIOGRAPHIC EXAMINATION O AGNOSTIC RADIOLOGY BREAST	
	(ii) symptoms or indications of malignancy found on an examination of the patient by a medical practitioner. Unless otherwise indicated, mammography includes both breasts (R) (NK)	
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$44.75 Benefit: 75% = \$33.60 85% = \$38.05	
	Three dimensional tomosynthesis of both breasts, not being a service associated with item 59300 or 59301, if there is reason to suspect the presence of malignancy because of:	
	 a. the past occurrence of breast malignancy in the patient or members of the patient's family; or b. symptoms or indications of malignancy found on examination of the patient by a medical practitioner (R) (K) 	
59302	(See para IN.0.19 of explanatory notes to this Category) Fee: \$202.00 Benefit: 75% = \$151.50 85% = \$171.70	
	MAMMOGRAPHY OF ONE BREAST, if:	
	(a) the patient is referred with a specific request for a unilateral mammogram; and	
	(b) there is reason to suspect the presence of malignancy because of:	
	(i) the past occurrence of breast malignancy in the patient or members of the patient's family; or	
	(ii) symptoms or indications of malignancy found on an examination of the patient by a medical practitioner (R)	
59303	(See para IN.0.19 of explanatory notes to this Category) Fee: \$53.95 Benefit: 75% = \$40.50 85% = \$45.90	
	MAMMOGRAPHY OF ONE BREAST, if:	
	(a) the patient is referred with a specific request for a unilateral mammogram; and	
	(b) there is reason to suspect the presence of malignancy because of:	
	(i) the past occurrence of breast malignancy in the patient or members of the patient's family; or	
	(ii) symptoms or indications of malignancy found on an examination of the patient by a medical practitioner (R) (NK)	
59304	(See para IN.0.19 of explanatory notes to this Category) Fee: \$27.00 Benefit: 75% = \$20.25 85% = \$22.95	
	Three dimensional tomosynthesis of one breast, not being a service associated with item 59303 or 59304, if there is reason to suspect the presence of malignancy because of:	
	 a. the past occurrence of breast malignancy in the patient or members of the patient's family; or b. symptoms or indications of malignancy found on examination of the patient by a medical practitioner (R) (K) 	
59305	(See para IN.0.19 of explanatory notes to this Category) Fee: \$114.00 Benefit: 75% = \$85.50 85% = \$96.90	
	MAMMARY DUCTOGRAM (galactography) - 1 breast (R)	
59306	(See para IN.0.19 of explanatory notes to this Category) Fee: \$100.30 Benefit: 75% = \$75.25 85% = \$85.30	

I3. DIA	10. RADIOGRAPHIC EXAMINATION O 3. DIAGNOSTIC RADIOLOGY BREAST	
	MAMMARY DUCTOGRAM (galactography) - 1 breast (R) (NK)	
59307	(See para IN.0.19 of explanatory notes to this Category) Fee: \$50.15 Benefit: 75% = \$37.65 85% = \$42.65	
	MAMMARY DUCTOGRAM (galactography) - 2 breasts (R)	
59309	(See para IN.0.19 of explanatory notes to this Category) Fee: \$200.60 Benefit: 75% = \$150.45 85% = \$170.55	
	MAMMARY DUCTOGRAM (galactography) - 2 breasts (R) (NK)	
59310	(See para IN.0.19 of explanatory notes to this Category) Fee: \$100.30 Benefit: 75% = \$75.25 85% = \$85.30	
	RADIOGRAPHIC EXAMINATION OF BOTH BREASTS, in conjunction with a surgical procedure on each breast, using interventional techniques - (R)	
59312	(See para IN.0.19 of explanatory notes to this Category) Fee: \$87.00 Benefit: 75% = \$65.25 85% = \$73.95	
	RADIOGRAPHIC EXAMINATION OF BOTH BREASTS, in conjunction with a surgical procedure on each breast, using interventional techniques - (R) (NK)	
59313	(See para IN.0.19 of explanatory notes to this Category) Fee: \$43.50 Benefit: 75% = \$32.65 85% = \$37.00	
	RADIOGRAPHIC EXAMINATION OF 1 BREAST, in conjunction with a surgical procedure using interventional techniques - (R)	
59314	(See para IN.0.19 of explanatory notes to this Category) Fee: \$52.50 Benefit: 75% = \$39.40 85% = \$44.65	
	RADIOGRAPHIC EXAMINATION OF 1 BREAST, in conjunction with a surgical procedure using interventional techniques - (R) (NK)	
59315	(See para IN.0.19 of explanatory notes to this Category) Fee: \$26.25 Benefit: 75% = \$19.70 85% = \$22.35	
	RADIOGRAPHIC EXAMINATION OF EXCISED BREAST TISSUE to confirm satisfactory excision of 1 or more lesions in 1 breast or both following pre-operative localisation in conjunction with a service under item 31536 - (R)	
59318	(See para IN.0.19 of explanatory notes to this Category) Fee: \$47.05 Benefit: 75% = \$35.30 85% = \$40.00	
	RADIOGRAPHIC EXAMINATION OF EXCISED BREAST TISSUE to confirm satisfactory excision of 1 or more lesions in 1 breast or both following pre-operative localisation in conjunction with a service under item 31536 - (R) (NK)	
59319	(See para IN.0.19 of explanatory notes to this Category) Fee: \$23.55 Benefit: 75% = \$17.70 85% = \$20.05	
I3. DIA	12. RADIOGRAPHIC EXAMINATION WITH OPAQUE OR CONTRAST MEDIA	
	Group I3. Diagnostic Radiology	
	Subgroup 12. Radiographic Examination With Opaque Or Contrast Media	

I3. DIA	12. RADIOGRAPHIC EXAMINATION WIT 3. DIAGNOSTIC RADIOLOGY OPAQUE OR CONTRAST MED	
	DISCOGRAPHY, each disc, with or without preliminary plain films and with preparation and contrast injection - (R) (Anaes.)	
59700	(See para IN.0.19 of explanatory notes to this Category) Fee: \$96.55 Benefit: 75% = \$72.45 85% = \$82.10	
	DISCOGRAPHY, each disc, with or without preliminary plain films and with preparation and contrast injection - (R) (NK) (Anaes.)	
59701	(See para IN.0.19 of explanatory notes to this Category) Fee: \$48.30 Benefit: 75% = \$36.25 85% = \$41.10	
	DACRYOCYSTOGRAPHY, 1 side, with or without preliminary plain film and with preparation and contrast injection - (R)	
59703	(See para IN.0.19 of explanatory notes to this Category) Fee: \$75.90 Benefit: 75% = \$56.95 85% = \$64.55	
	DACRYOCYSTOGRAPHY, 1 side, with or without preliminary plain film and with preparation and contrast injection - (R) (NK)	
59704	(See para IN.0.19 of explanatory notes to this Category) Fee: \$37.95 Benefit: 75% = \$28.50 85% = \$32.30	
	HYSTEROSALPINGOGRAPHY, with or without preliminary plain films and with preparation and contrast injection - (R) (Anaes.)	
59712	(See para IN.0.19 of explanatory notes to this Category) Fee: \$113.70 Benefit: 75% = \$85.30 85% = \$96.65	
	HYSTEROSALPINGOGRAPHY, with or without preliminary plain films and with preparation and contrast injection - (R) (NK) (Anaes.)	
59713	(See para IN.0.19 of explanatory notes to this Category) Fee: \$56.85 Benefit: 75% = \$42.65 85% = \$48.35	
	BRONCHOGRAPHY, one side, with or without preliminary plain films and with preparation and contrast injection, on a person under 16 years of age - (R) (K) (Anaes.)	
59715	(See para IN.0.19 of explanatory notes to this Category) Fee: \$143.55 Benefit: 75% = \$107.70 85% = \$122.05	
	BRONCHOGRAPHY, one side, with or without preliminary plain films and with preparation and contrast injection, on a person under 16 years of age - (R) (NK) (Anaes.)	
59716	(See para IN.0.19 of explanatory notes to this Category) Fee: \$71.80 Benefit: 75% = \$53.85 85% = \$61.05	
	PHLEBOGRAPHY, 1 side, with or without preliminary plain films and with preparation and contrast injection - (R) (Anaes.)	
59718	(See para IN.0.19 of explanatory notes to this Category) Fee: \$134.65 Benefit: 75% = \$101.00 85% = \$114.50	
	PHLEBOGRAPHY, 1 side, with or without preliminary plain films and with preparation and contrast injection - (R) (NK) (Anaes.)	
59719	(See para IN.0.19 of explanatory notes to this Category) Fee: \$67.35 Benefit: 75% = \$50.55 85% = \$57.25	
59724	MYELOGRAPHY, 1 or more regions, with or without preliminary plain films and with preparation and	

I3. DIAC	12. RADIOGRAPHIC EXAMINATION WI 3. DIAGNOSTIC RADIOLOGY OPAQUE OR CONTRAST MEI	
	contrast injection, not being a service associated with a service to which item 56219 applies - (R) (Anaes.)	
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$226.45 Benefit: 75% = \$169.85 85% = \$192.50	
	MYELOGRAPHY, 1 or more regions, with or without preliminary plain films and with preparation and contrast injection, not being a service associated with a service to which item 56219 or 56259 applies - (R) (NK) (Anaes.)	
59725	(See para IN.0.19 of explanatory notes to this Category) Fee: \$113.25 Benefit: 75% = \$84.95 85% = \$96.30	
	SIALOGRAPHY, 1 side, with preparation and contrast injection, not being a service associated with a service to which item 57918 applies - (R)	
59733	(See para IN.0.19 of explanatory notes to this Category) Fee: \$107.70 Benefit: 75% = \$80.80 85% = \$91.55	
	SIALOGRAPHY, 1 side, with preparation and contrast injection, not being a service associated with a service to which item 57918 or 57932 applies - (R) (NK)	
59734	(See para IN.0.19 of explanatory notes to this Category) Fee: \$53.85 Benefit: 75% = \$40.40 85% = \$45.80	
	SINOGRAM OR FISTULOGRAM, 1 or more regions, with or without preliminary plain films and with preparation and contrast injection - (R)	
59739	(See para IN.0.19 of explanatory notes to this Category) Fee: \$73.75 Benefit: 75% = \$55.35 85% = \$62.70	
	SINOGRAM OR FISTULOGRAM, 1 or more regions, with or without preliminary plain films and with preparation and contrast injection - (R) (NK)	
59740	(See para IN.0.19 of explanatory notes to this Category) Fee: \$36.90 Benefit: 75% = \$27.70 85% = \$31.40	
	ARTHROGRAPHY, each joint, excluding the facet (zygapophyseal) joints of the spine, single or double contrast study, with or without preliminary plain films and with preparation and contrast injection - (R)	
59751	(See para IN.0.19 of explanatory notes to this Category) Fee: \$139.15 Benefit: 75% = \$104.40 85% = \$118.30	
	ARTHROGRAPHY, each joint, excluding the facet (zygapophyseal) joints of the spine, single or double contrast study, with or without preliminary plain films and with preparation and contrast injection - (R) (NK)	
59752	(See para IN.0.19 of explanatory notes to this Category) Fee: \$69.60 Benefit: 75% = \$52.20 85% = \$59.20	
	LYMPHANGIOGRAPHY, one or both sides, with preliminary plain films and follow-up radiography and with preparation and contrast injection - (R)	
59754	(See para IN.0.19 of explanatory notes to this Category) Fee: \$219.35 Benefit: 75% = \$164.55 85% = \$186.45	
	LYMPHANGIOGRAPHY, one or both sides, with preliminary plain films and follow-up radiography and with preparation and contrast injection - (R) (NK)	
59755	(See para IN.0.19 of explanatory notes to this Category) Fee: \$109.70 Benefit: 75% = \$82.30 85% = \$93.25	

I3. DIAG	12. RADIOGRAPHIC EXAMINATION WITH OPAQUE OR CONTRAST MEDIA
	AIR INSUFFLATION during video - fluoroscopic imaging including associated consultation (R)
59763	(See para IN.0.19 of explanatory notes to this Category) Fee: \$133.90 Benefit: 75% = \$100.45 85% = \$113.85
	AIR INSUFFLATION during video - fluoroscopic imaging including associated consultation (R) (NK)
59764	(See para IN.0.19 of explanatory notes to this Category) Fee: \$66.95 Benefit: 75% = \$50.25 85% = \$56.95
I3. DIAG	SNOSTIC RADIOLOGY 13. ANGIOGRAPHY
	Group I3. Diagnostic Radiology
	Subgroup 13. Angiography
	Angiocardiography, including the service mentioned in item 59970, 59974, 61109 or 61110, not being a service to which item 59912 or 59925 applies (R) (K) (Anaes.)
59903	(See para IN.0.19 of explanatory notes to this Category) Fee: \$114.55 Benefit: 75% = \$85.95 85% = \$97.40
	Selective coronary arteriography, including the service mentioned in item 59970, 59974, 61109 or 61110, not being a service to which item 59903 or 59925 applies
	(R) (K) (Anaes.)
59912	(See para IN.0.19 of explanatory notes to this Category) Fee: \$305.20 Benefit: 75% = \$228.90 85% = \$259.45
	Selective coronary arteriography and angiocardiography, including a service mentioned in item 59903, 59912, 59970, 59974, 61109 or 61110 (R) (K) (Anaes.)
59925	(See para IN.0.19 of explanatory notes to this Category) Fee: \$362.45 Benefit: 75% = \$271.85 85% = \$308.10
	ANGIOGRAPHY AND/OR DIGITAL SUBTRACTION ANGIOGRAPHY with fluoroscopy and image acquisition using a mobile image intensifier, 1 or more regions including any preliminary plain films, preparation and contrast injection (R) (K) (Anaes.)
59970	(See para IN.0.19 of explanatory notes to this Category) Fee: \$168.30 Benefit: 75% = \$126.25 85% = \$143.10
	Angiocardiography, including the service mentioned in item 59970, 59974, 61109 or 61110, not being a service to which item 59972 or 59973 applies (R) (NK) (Anaes.)
59971	(See para IN.0.19 of explanatory notes to this Category) Fee: \$57.30 Benefit: 75% = \$43.00 85% = \$48.75
	Selective coronary arteriography, including the service mentioned in item 59970, 59974, 61109 or 61110, not being a service to which item 59971 or 59973 applies
	(R) (NK) (Anaes.)
59972	(See para IN.0.19 of explanatory notes to this Category) Fee: \$152.60 Benefit: 75% = \$114.45 85% = \$129.75
59973	Selective coronary arteriography and angiocardiography, including a service mentioned in item 59970,

I3. DIA	3. DIAGNOSTIC RADIOLOGY 13. ANGIOGRAPH	
	59971, 59972, 59974, 61109 or 61110 (R) (NK) (Anaes.)	
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$181.25 Benefit: 75% = \$135.95 85% = \$154.10	
	ANGIOGRAPHY AND/OR DIGITAL SUBTRACTION ANGIOGRAPHY with fluore acquisition using a mobile image intensifier, 1 or more regions including any preliminal preparation and contrast injection (R) (NK) (Anaes.)	
59974	(See para IN.0.19 of explanatory notes to this Category) Fee: \$84.20 Benefit: 75% = \$63.15 85% = \$71.60	
	BY DIGITAL SUBTRACTION TECHNIQUE	
	DIGITAL SUBTRACTION ANGIOGRAPHY, examination of head and neck with or vaortography - 1 to 3 data acquisition runs (R) (K) (Anaes.)	vithout arch
60000	(See para IN.0.19 of explanatory notes to this Category) Fee: \$564.00 Benefit: 75% = \$423.00 85% = \$480.60	
	Digital subtraction angiography, examination of head and neck with or without arch aor data acquisition runs (R) (NK) (Anaes.)	tography - 1 to 3
60001	(See para IN.0.19 of explanatory notes to this Category) Fee: \$282.00 Benefit: 75% = \$211.50 85% = \$239.70	
	DIGITAL SUBTRACTION ANGIOGRAPHY, examination of head and neck with or variography - 4 to 6 data acquisition runs (R) (K) (Anaes.)	vithout arch
60003	(See para IN.0.19 of explanatory notes to this Category) Fee: \$827.10 Benefit: 75% = \$620.35 85% = \$743.70	
	Digital subtraction angiography, examination of head and neck with or without arch aor data acquisition runs (R) (NK) (Anaes.)	tography - 4 to 6
60004	(See para IN.0.19 of explanatory notes to this Category) Fee: \$413.55 Benefit: 75% = \$310.20 85% = \$351.55	
	DIGITAL SUBTRACTION ANGIOGRAPHY, examination of head and neck with or valortography - 7 to 9 data acquisition runs (R) (K) (Anaes.)	vithout arch
60006	(See para IN.0.19 of explanatory notes to this Category) Fee: \$1,176.10 Benefit: 75% = \$882.10 85% = \$1092.70	
	Digital subtraction angiography, examination of head and neck with or without arch aor data acquisition runs (R) (NK) (Anaes.)	tography - 7 to 9
60007	(See para IN.0.19 of explanatory notes to this Category) Fee: \$588.05 Benefit: 75% = \$441.05 85% = \$504.65	
	DIGITAL SUBTRACTION ANGIOGRAPHY, examination of head and neck with or variography - 10 or more data acquisition runs (R) (K) (Anaes.)	vithout arch
60009	(See para IN.0.19 of explanatory notes to this Category) Fee: \$1,376.30 Benefit: 75% = \$1032.25 85% = \$1292.90	
	Digital subtraction angiography, examination of head and neck with or without arch aor more data acquisition runs (R) (NK) (Anaes.)	tography - 10 or
60010	(See para IN.0.19 of explanatory notes to this Category)	

I3. DIAC	13. DIAGNOSTIC RADIOLOGY 13. ANGIOGRAF	
	Fee: \$688.15 Benefit: 75% = \$516.15 85% = \$604.75	
	DIGITAL SUBTRACTION ANGIOGRAPHY, examination of thorax - 1 to 3 data acquisition r (K) (Anaes.)	runs (R)
60012	(See para IN.0.19 of explanatory notes to this Category) Fee: \$564.00 Benefit: 75% = \$423.00 85% = \$480.60	
	Digital subtraction angiography, examination of thorax - 1 to 3 data acquisition runs (R) (NK) (A	Anaes.)
60013	(See para IN.0.19 of explanatory notes to this Category) Fee: \$282.00 Benefit: 75% = \$211.50 85% = \$239.70	
	DIGITAL SUBTRACTION ANGIOGRAPHY, examination of thorax - 4 to 6 data acquisition r (K) (Anaes.)	runs (R)
60015	(See para IN.0.19 of explanatory notes to this Category) Fee: \$827.10 Benefit: 75% = \$620.35 85% = \$743.70	
	Digital subtraction angiography, examination of thorax - 4 to 6 data acquisition runs (R) (NK) (A	Anaes.)
60016	(See para IN.0.19 of explanatory notes to this Category) Fee: \$413.55 Benefit: 75% = \$310.20 85% = \$351.55	
	DIGITAL SUBTRACTION ANGIOGRAPHY, examination of thorax - 7 to 9 data acquisition r (K) (Anaes.)	runs (R)
60018	(See para IN.0.19 of explanatory notes to this Category) Fee: \$1,176.10 Benefit: 75% = \$882.10 85% = \$1092.70	
	Digital subtraction angiography, examination of thorax - 7 to 9 data acquisition runs (R) (NK) (A	Anaes.)
60019	(See para IN.0.19 of explanatory notes to this Category) Fee: \$588.05 Benefit: 75% = \$441.05 85% = \$504.65	
	DIGITAL SUBTRACTION ANGIOGRAPHY, examination of thorax - 10 or more data acquisi (R) (K) (Anaes.)	tion runs
60021	(See para IN.0.19 of explanatory notes to this Category) Fee: \$1,376.30 Benefit: 75% = \$1032.25 85% = \$1292.90	
	Digital subtraction angiography, examination of thorax - 10 or more data acquisition runs (R) (N (Anaes.)	IK)
60022	(See para IN.0.19 of explanatory notes to this Category) Fee: \$688.15 Benefit: 75% = \$516.15 85% = \$604.75	
	DIGITAL SUBTRACTION ANGIOGRAPHY, examination of abdomen - 1 to 3 data acquisitio (R) (K) (Anaes.)	n runs
60024	(See para IN.0.19 of explanatory notes to this Category) Fee: \$564.00 Benefit: 75% = \$423.00 85% = \$480.60	
	Digital subtraction angiography, examination of abdomen - 1 to 3 data acquisition runs (R) (NK (Anaes.))
60025	(See para IN.0.19 of explanatory notes to this Category) Fee: \$282.00 Benefit: 75% = \$211.50 85% = \$239.70	
	DIGITAL SUBTRACTION ANGIOGRAPHY, examination of abdomen - 4 to 6 data acquisitio (R) (K) (Anaes.)	n runs
60027	(See para IN.0.19 of explanatory notes to this Category)	

I3. DIAC	DIAGNOSTIC RADIOLOGY 13. ANGIOGRAPI		
	Fee: \$827.10 Benefit: 75	5% = \$620.35 85% = \$743.70	
	Digital subtraction angiography, (Anaes.)	, examination of abdomen - 4 to 6 data acq	uisition runs (R) (NK)
60028	(See para IN.0.19 of explanatory not Fee: \$413.55 Benefit: 75	otes to this Category) 5% = \$310.20 85% = \$351.55	
	DIGITAL SUBTRACTION AN(R) (K) (Anaes.)	IGIOGRAPHY, examination of abdomen -	- 7 to 9 data acquisition runs
60030	(See para IN.0.19 of explanatory not Fee: \$1,176.10 Benefit: 75	otes to this Category) 5% = \$882.10	
	Digital subtraction angiography, (Anaes.)	, examination of abdomen - 7 to 9 data acq	uisition runs (R) (NK)
60031	(See para IN.0.19 of explanatory not Fee: \$588.05 Benefit: 75	otes to this Category) 5% = \$441.05	
	DIGITAL SUBTRACTION ANd runs (R) (K) (Anaes.)	IGIOGRAPHY, examination of abdomen -	- 10 or more data acquisition
60033	(See para IN.0.19 of explanatory not Fee: \$1,376.30 Benefit: 75	otes to this Category) 5% = \$1032.25 85% = \$1292.90	
	Digital subtraction angiography, (Anaes.)	, examination of abdomen - 10 or more dat	ta acquisition runs (R) (NK)
60034	(See para IN.0.19 of explanatory not Fee: \$688.15 Benefit: 75	otes to this Category) 5% = \$516.15 85% = \$604.75	
	DIGITAL SUBTRACTION AN acquisition runs (R) (K) (Anaes.)	IGIOGRAPHY, examination of upper limb)	o or limbs - 1 to 3 data
60036	(See para IN.0.19 of explanatory not Fee: \$564.00 Benefit: 75	otes to this Category) 5% = \$423.00 85% = \$480.60	
	Digital subtraction angiography, (NK) (Anaes.)	, examination of upper limb or limbs - 1 to	3 data acquisition runs (R)
60037	(See para IN.0.19 of explanatory not Fee: \$282.00 Benefit: 75	otes to this Category) 5% = \$211.50 85% = \$239.70	
	DIGITAL SUBTRACTION AN acquisition runs (R) (K) (Anaes.)	IGIOGRAPHY, examination of upper limb)	or limbs - 4 to 6 data
60039	(See para IN.0.19 of explanatory not Fee: \$827.10 Benefit: 75	otes to this Category) 5% = \$620.35 85% = \$743.70	
	Digital subtraction angiography, (NK) (Anaes.)	, examination of upper limb or limbs - 4 to	6 data acquisition runs (R)
60040	(See para IN.0.19 of explanatory not Fee: \$413.55 Benefit: 75	otes to this Category) 5% = \$310.20 85% = \$351.55	
	DIGITAL SUBTRACTION AN acquisition runs (R) (K) (Anaes.)	IGIOGRAPHY, examination of upper limb	o or limbs - 7 to 9 data
60042	(See para IN.0.19 of explanatory not Fee: \$1,176.10 Benefit: 75	otes to this Category) 5% = \$882.10 85% = \$1092.70	
60043	Digital subtraction angiography,	, examination of upper limb or limbs - 7 to	9 data acquisition runs (R)

I3. DIAC	IAGNOSTIC RADIOLOGY 13. ANGIOGRAPHY		
	(NK) (Anaes.)		
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$588.05 Benefit: 75% = \$441.05 85% = \$504.65		
	DIGITAL SUBTRACTION ANGIOGRAPHY, examination of upper limb or limbs - 10 or more data acquisition runs (R) (K) (Anaes.)		
60045	(See para IN.0.19 of explanatory notes to this Category) Fee: \$1,376.30 Benefit: 75% = \$1032.25 85% = \$1292.90		
	Digital subtraction angiography, examination of upper limb or limbs - 10 or more data acquisition runs (R) (NK) (Anaes.)		
50046	(See para IN.0.19 of explanatory notes to this Category) Fee: \$688.15 Benefit: 75% = \$516.15 85% = \$604.75		
	DIGITAL SUBTRACTION ANGIOGRAPHY, examination of lower limb or limbs - 1 to 3 data acquisition runs (R) (K) (Anaes.)		
60048	(See para IN.0.19 of explanatory notes to this Category) Fee: \$564.00 Benefit: 75% = \$423.00 85% = \$480.60		
	Digital subtraction angiography, examination of lower limb or limbs - 1 to 3 data acquisition runs (R) (NK) (Anaes.)		
60049	(See para IN.0.19 of explanatory notes to this Category) Fee: \$282.00 Benefit: 75% = \$211.50 85% = \$239.70		
	DIGITAL SUBTRACTION ANGIOGRAPHY, examination of lower limb or limbs - 4 to 6 data acquisition runs (R) (K) (Anaes.)		
60051	(See para IN.0.19 of explanatory notes to this Category) Fee: \$827.10 Benefit: 75% = \$620.35 85% = \$743.70		
	Digital subtraction angiography, examination of lower limb or limbs - 4 to 6 data acquisition runs (R) (NK) (Anaes.)		
60052	(See para IN.0.19 of explanatory notes to this Category) Fee: \$413.55 Benefit: 75% = \$310.20 85% = \$351.55		
	DIGITAL SUBTRACTION ANGIOGRAPHY, examination of lower limb or limbs - 7 to 9 data acquisition runs (R) (K) (Anaes.)		
60054	(See para IN.0.19 of explanatory notes to this Category) Fee: \$1,176.10 Benefit: 75% = \$882.10 85% = \$1092.70		
	Digital subtraction angiography, examination of lower limb or limbs - 7 to 9 data acquisition runs (R) (NK) (Anaes.)		
60055	(See para IN.0.19 of explanatory notes to this Category) Fee: \$588.05 Benefit: 75% = \$441.05 85% = \$504.65		
	DIGITAL SUBTRACTION ANGIOGRAPHY, examination of lower limb or limbs - 10 or more data acquisition runs (R) (K) (Anaes.)		
60057	(See para IN.0.19 of explanatory notes to this Category) Fee: \$1,376.30 Benefit: 75% = \$1032.25 85% = \$1292.90		
60058	Digital subtraction angiography, examination of lower limb or limbs - 10 or more data acquisition runs (R) (NK) (Anaes.)		

I3. DIAGNOSTIC RADIOLOGY 13. ANGIOGR		13. ANGIOGRAPHY
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$688.15 Benefit: 75% = \$516.15 85% = \$604.75	
	DIGITAL SUBTRACTION ANGIOGRAPHY, examination of aorta and lower li data acquisition runs (R) (K) (Anaes.)	mb or limbs - 1 to 3
60060	(See para IN.0.19 of explanatory notes to this Category) Fee: \$564.00 Benefit: 75% = \$423.00 85% = \$480.60	
	Digital subtraction angiography, examination of aorta and lower limb or limbs - 1 runs (R) (NK) (Anaes.)	to 3 data acquisition
60061	(See para IN.0.19 of explanatory notes to this Category) Fee: \$282.00 Benefit: 75% = \$211.50 85% = \$239.70	
	DIGITAL SUBTRACTION ANGIOGRAPHY, examination of aorta and lower li data acquisition runs (R) (K) (Anaes.)	mb or limbs - 4 to 6
60063	(See para IN.0.19 of explanatory notes to this Category) Fee: \$827.10 Benefit: 75% = \$620.35 85% = \$743.70	
	Digital subtraction angiography, examination of aorta and lower limb or limbs - 4 runs (R) (NK) (Anaes.)	to 6 data acquisition
60064	(See para IN.0.19 of explanatory notes to this Category) Fee: \$413.55 Benefit: 75% = \$310.20 85% = \$351.55	
	DIGITAL SUBTRACTION ANGIOGRAPHY, examination of aorta and lower li data acquisition runs (R) (K) (Anaes.)	mb or limbs - 7 to 9
60066	(See para IN.0.19 of explanatory notes to this Category) Fee: \$1,176.10 Benefit: 75% = \$882.10 85% = \$1092.70	
	Digital subtraction angiography, examination of aorta and lower limb or limbs - 7 runs (R) (NK) (Anaes.)	to 9 data acquisition
60067	(See para IN.0.19 of explanatory notes to this Category) Fee: \$588.05 Benefit: 75% = \$441.05 85% = \$504.65	
	DIGITAL SUBTRACTION ANGIOGRAPHY, examination of aorta and lower li more data acquisition runs (R) (K) (Anaes.)	mb or limbs - 10 or
60069	(See para IN.0.19 of explanatory notes to this Category) Fee: \$1,376.30 Benefit: 75% = \$1032.25 85% = \$1292.90	
	Digital subtraction angiography, examination of aorta and lower limb or limbs - 1 acquisition runs (R) (NK) (Anaes.)	0 or more data
60070	(See para IN.0.19 of explanatory notes to this Category) Fee: \$688.15 Benefit: 75% = \$516.15 85% = \$604.75	
	SELECTIVE ARTERIOGRAPHY or SELECTIVE VENOGRAPHY by digital st technique - 1 vessel (NR) (K) (Anaes.)	ubtraction angiography
60072	(See para IN.0.19 of explanatory notes to this Category) Fee: \$48.10 Benefit: 75% = \$36.10 85% = \$40.90	
	Selective arteriography or selective venography by digital subtraction angiography vessel (NR) (NK) (Anaes.)	y technique - one
60073	(See para IN.0.19 of explanatory notes to this Category) Fee: \$24.05 Benefit: 75% = \$18.05 85% = \$20.45	

I3. DIAG	SNOSTIC RADIOLOGY 13. ANGIOGRAP	ΉΥ
	SELECTIVE ARTERIOGRAPHY or SELECTIVE VENOGRAPHY by digital subtraction angiograp technique - 2 vessels (NR) (K) (Anaes.)	hy
60075	(See para IN.0.19 of explanatory notes to this Category) Fee: \$96.10 Benefit: 75% = \$72.10 85% = \$81.70	
	Selective arteriography or selective venography by digital subtraction angiography technique - 2 vess (NR) (NK) (Anaes.)	els
60076	(See para IN.0.19 of explanatory notes to this Category) Fee: \$48.05 Benefit: 75% = \$36.05 85% = \$40.85	
	SELECTIVE ARTERIOGRAPHY or SELECTIVE VENOGRAPHY by digital subtraction angiograp technique - 3 or more vessels (NR) (K) (Anaes.)	hy
60078	(See para IN.0.19 of explanatory notes to this Category) Fee: \$144.25 Benefit: 75% = \$108.20 85% = \$122.65	
	Selective arteriography or selective venography by digital subtraction angiography technique - 3 or m vessels (NR) (NK) (Anaes.)	iore
60079	(See para IN.0.19 of explanatory notes to this Category) Fee: \$72.15 Benefit: 75% = \$54.15 85% = \$61.35	
13. DIAGNOSTIC RADIOLOGY 15. FLUOROSCOPIC EXAMINATIO		ON
	Group I3. Diagnostic Radiology	
	Subgroup 15. Fluoroscopic Examination	
	FLUOROSCOPY, with general anaesthesia (not being a service associated with a radiographic examination) (R) (Anaes.)	
60500	(See para IN.0.19 of explanatory notes to this Category) Fee: \$43.40 Benefit: 75% = \$32.55 85% = \$36.90	
	FLUOROSCOPY, with general anaesthesia (not being a service associated with a radiographic examination) (R) (NK) (Anaes.)	
60501	(See para IN.0.19 of explanatory notes to this Category) Fee: \$21.70 Benefit: 75% = \$16.30 85% = \$18.45	
	FLUOROSCOPY, without general anaesthesia (not being a service associated with a radiographic examination) (R)	
60503	(See para IN.0.19 of explanatory notes to this Category) Fee: \$29.75 Benefit: 75% = \$22.35 85% = \$25.30	
	FLUOROSCOPY, without general anaesthesia (not being a service associated with a radiographic examination) (R) (NK)	
60504	Fee: \$14.90 Benefit: 75% = \$11.20 85% = \$12.70	
	FLUOROSCOPY using a mobile image intensifier, in conjunction with a surgical procedure lasting lethan 1 hour, not being a service associated with a service to which another item in this Table applies (
60506	(See para IN.0.19 of explanatory notes to this Category) Fee: \$63.75 Benefit: 75% = \$47.85 85% = \$54.20	
60507	FLUOROSCOPY using a mobile image intensifier, in conjunction with a surgical procedure lasting lethan 1 hour, not being a service associated with a service to which another item in this Table applies (

I3. DIA	GNOSTIC RADIOLOGY 15. FLUOROSCOPIC EXAMINATION
	(NK)
	Fee: \$31.90 Benefit: 75% = \$23.95 85% = \$27.15
	FLUOROSCOPY using a mobile image intensifier, in conjunction with a surgical procedure lasting 1 hour or more, not being a service associated with a service to which another item in this Table applies (R)
60509	(See para IN.0.19 of explanatory notes to this Category) Fee: \$98.90 Benefit: 75% = \$74.20 85% = \$84.10
	FLUOROSCOPY using a mobile image intensifier, in conjunction with a surgical procedure lasting 1 hour or more, not being a service associated with a service to which another item in this Table applies (R) (NK)
60510	(See para IN.0.19 of explanatory notes to this Category) Fee: \$49.45 Benefit: 75% = \$37.10 85% = \$42.05
I3. DIA	16. PREPARATION FOR RADIOLOGICAL SNOSTIC RADIOLOGY PROCEDURE
	Group I3. Diagnostic Radiology
	Subgroup 16. Preparation For Radiological Procedure
	ARTERIOGRAPHY (peripheral) or PHLEBOGRAPHY 1 vessel, when used in association with a service to which items 59903, 59912, 59925, 59970, 59971 59972, 59973 or 59974 applies, not being a service associated with a service to which items 60000 to 60079 inclusive apply (NR) (Anaes.)
60918	(See para IN.0.19 of explanatory notes to this Category) Fee: \$47.15 Benefit: 75% = \$35.40 85% = \$40.10
	SELECTIVE ARTERIOGRAM or PHLEBOGRAM, when used in association with a service to which items 59903, 59912, 59925, 59970, 59971 59972, 59973 or 59974 applies, not being a service associated with a service to which items 60000 to 60079 inclusive apply (NR) (Anaes.)
60927	(See para IN.0.19 of explanatory notes to this Category) Fee: \$38.05 Benefit: 75% = \$28.55 85% = \$32.35
I3. DIA	GNOSTIC RADIOLOGY 17. INTERVENTIONAL TECHNIQUES
	Group I3. Diagnostic Radiology
	Subgroup 17. Interventional Techniques
	FLUOROSCOPY in an ANGIOGRAPHY SUITE with image intensification, in conjunction with a surgical procedure, using interventional techniques, not being a service associated with a service to which another item in this Table applies (R)
61109	(See para IN.0.19 of explanatory notes to this Category) Fee: \$258.90 Benefit: 75% = \$194.20 85% = \$220.10
	FLUOROSCOPY in an ANGIOGRAPHY SUITE with image intensification, in conjunction with a surgical procedure, using interventional techniques, not being a service associated with a service to which another item in this Table applies (R) (NK)
61110	(See para IN.0.19 of explanatory notes to this Category) Fee: \$129.45 Benefit: 75% = \$97.10 85% = \$110.05

I4. NUC	LEAR MEDICINE IMAGING 1. NUCLEAR MEDICINE - NON PET	
	Group I4. Nuclear Medicine Imaging	
	Subgroup 1. Nuclear medicine - non PET	
	SINGLE STRESS OR REST MYOCARDIAL PERFUSION STUDY - planar imaging (R)	
61302	(See para IN.0.19 of explanatory notes to this Category) Fee: \$448.85 Benefit: 75% = \$336.65 85% = \$381.55	
	SINGLE STRESS OR REST MYOCARDIAL PERFUSION STUDY - with single photon emission tomography and with planar imaging when undertaken (R)	
61303	(See para IN.0.19 of explanatory notes to this Category) Fee: \$565.30 Benefit: 75% = \$424.00 85% = \$481.90	
	COMBINED STRESS AND REST, stress and re-injection or rest and redistribution myocardial perfusion study, including delayed imaging or re-injection protocol on a subsequent occasion - planar imaging (R)	
61306	(See para IN.0.19 of explanatory notes to this Category) Fee: \$709.70 Benefit: 75% = \$532.30 85% = \$626.30	
	COMBINED STRESS AND REST, stress and re-injection or rest and redistribution myocardial perfusion study, including delayed imaging or re-injection protocol on a subsequent occasion - with single photon emission tomography and with planar imaging when undertaken (R)	
61307	(See para IN.0.19 of explanatory notes to this Category) Fee: \$834.90 Benefit: 75% = \$626.20 85% = \$751.50	
	MYOCARDIAL INFARCT-AVID-STUDY, with planar imaging and single photon emission tomography, OR planar imaging or single photon emission tomography (R)	
61310	(See para IN.0.19 of explanatory notes to this Category) Fee: \$367.30 Benefit: 75% = \$275.50 85% = \$312.25	
	GATED CARDIAC BLOOD POOL STUDY, (equilibrium), with planar imaging and single photon emission tomography OR planar imaging or single photon emission tomography (R)	
61313	(See para IN.0.19 of explanatory notes to this Category) Fee: \$303.35 Benefit: 75% = \$227.55 85% = \$257.85	
	GATED CARDIAC BLOOD POOL STUDY, and first pass blood flow or cardiac shunt study, with planar imaging and single photon emission tomography, OR planar imaging, or single photon emission tomography (R)	
61314	(See para IN.0.19 of explanatory notes to this Category) Fee: \$420.00 Benefit: 75% = \$315.00 85% = \$357.00	
	GATED CARDIAC BLOOD POOL STUDY, with intervention, with planar imaging and single photon emission tomography, OR planar imaging, or single photon emission tomography (R)	
61316	(See para IN.0.19 of explanatory notes to this Category) Fee: \$381.15 Benefit: 75% = \$285.90 85% = \$324.00	
	GATED CARDIAC BLOOD POOL STUDY, with intervention and first pass blood flow study or cardiac shunt study, with planar imaging and single photon emission tomography OR planar imaging, or single photon emission tomography (R)	
61317	(See para IN.0.19 of explanatory notes to this Category) Fee: \$492.40 Benefit: 75% = \$369.30 85% = \$418.55	

I4. NUC	LEAR MEDICINE IMAGING 1. NUCLEAR MEDICINE - NON PET
	CARDIAC FIRST PASS BLOOD FLOW STUDY OR CARDIAC SHUNT STUDY, not being a service to which another item in this Group applies (R)
61320	(See para IN.0.19 of explanatory notes to this Category) Fee: \$228.90 Benefit: 75% = \$171.70 85% = \$194.60
	LUNG PERFUSION STUDY, with planar imaging and single photon emission tomography OR planar imaging, or single photon emission tomography (R)
61328	(See para IN.0.19 of explanatory notes to this Category) Fee: \$227.65 Benefit: 75% = \$170.75 85% = \$193.55
	LUNG VENTILATION STUDY using aerosol, technegas or xenon gas, with planar imaging and single photon emission tomography OR planar imaging or single photon emission tomography (R)
61340	(See para IN.0.19 of explanatory notes to this Category) Fee: \$253.00 Benefit: 75% = \$189.75 85% = \$215.05
	LUNG PERFUSION STUDY AND LUNG VENTILATION STUDY using aerosol, technegas or xenon gas, with planar imaging and single photon emission tomography, OR planar imaging, or single photon emission tomography (R)
61348	(See para IN.0.19 of explanatory notes to this Category) Fee: \$443.35 Benefit: 75% = \$332.55 85% = \$376.85
	LIVER AND SPLEEN STUDY (colloid) - planar imaging (R)
61352	(See para IN.0.19 of explanatory notes to this Category) Fee: \$259.35 Benefit: 75% = \$194.55 85% = \$220.45
	LIVER AND SPLEEN STUDY (colloid), with single photon emission tomography and with planar imaging when undertaken (R)
61353	(See para IN.0.19 of explanatory notes to this Category) Fee: \$386.60 Benefit: 75% = \$289.95 85% = \$328.65
	RED BLOOD CELL SPLEEN OR LIVER STUDY, including single photon emission tomography when undertaken (R)
61356	(See para IN.0.19 of explanatory notes to this Category) Fee: \$392.80 Benefit: 75% = \$294.60 85% = \$333.90
	HEPATOBILIARY STUDY, including morphine administration or pre-treatment with a cholagogue when performed (R) (K)
61360	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.35 Benefit: 75% = \$302.55 85% = \$342.85
	HEPATOBILIARY STUDY with formal quantification following baseline imaging, using a cholagogue (R) (K)
61361	(See para IN.0.19 of explanatory notes to this Category) Fee: \$461.40 Benefit: 75% = \$346.05 85% = \$392.20
	BOWEL HAEMORRHAGE STUDY (R)
61364	(See para IN.0.19 of explanatory notes to this Category) Fee: \$496.95 Benefit: 75% = \$372.75 85% = \$422.45
	MECKEL'S DIVERTICULUM STUDY (R)
61368	(See para IN.0.19 of explanatory notes to this Category)

I4. NUC	LEAR MEDICINE IMAGING	1. NUCLEAR MEDICINE - NON PE		
	Fee: \$223.10 Benefit: 75	5% = \$167.35 85% = \$189.65		
	INDIUM-LABELLED OCTRE undertaken, where:	OTIDE STUDY - including single photon emission tomography when		
	(a) there is a suspected gastro- with negative or	entero-pancreatic endocrine tumour, based on biochemical evidence,		
	equivocal conventional imaging; or			
	(b) a surgically amenable gastr conventional	ro-entero-pancreatic endocrine tumour has been identified based on		
	techniques, in order to exclud	e additional disease sites. (R)		
61369	Fee: \$2,015.75 Benefit: 75	5% = \$1511.85 85% = \$1932.35		
	SALIVARY STUDY (R)			
61372	(See para IN.0.19 of explanatory no Fee: \$223.10 Benefit: 75	tes to this Category) % = \$167.35 85% = \$189.65		
	GASTRO-OESOPHAGEAL REwhen undertaken (R)	EFLUX STUDY, including delayed imaging on a separate occasion		
61373	(See para IN.0.19 of explanatory no Fee: \$489.70 Benefit: 75	tes to this Category) 5% = \$367.30 85% = \$416.25		
	OESOPHAGEAL CLEARANC	E STUDY (R)		
61376	(See para IN.0.19 of explanatory no Fee: \$143.35 Benefit: 75	tes to this Category) % = \$107.55 85% = \$121.85		
	GASTRIC EMPTYING STUDY	, using single tracer (R)		
61381	(See para IN.0.19 of explanatory no Fee: \$574.35 Benefit: 75	tes to this Category) 5% = \$430.80		
	COMBINED SOLID AND LIQUID GASTRIC EMPTYING STUDY using dual isotope technique the same isotope on separate days (R)			
61383	(See para IN.0.19 of explanatory no Fee: \$624.95 Benefit: 75	tes to this Category) % = \$468.75 85% = \$541.55		
	RADIONUCLIDE COLONIC T	TRANSIT STUDY (R)		
61384	(See para IN.0.19 of explanatory no Fee: \$687.70 Benefit: 75	tes to this Category) 5% = \$515.80 85% = \$604.30		
	RENAL STUDY, including pertuit with planar imaging (R)	fusion and renogram images and computer analysis OR cortical study		
61386	(See para IN.0.19 of explanatory no Fee: \$332.50 Benefit: 75	tes to this Category) 5% = \$249.40 85% = \$282.65		
	RENAL CORTICAL STUDY, v	with single photon emission tomography and planar quantification (R)		
61387	(See para IN.0.19 of explanatory no Fee: \$430.75 Benefit: 75	tes to this Category) 5% = \$323.10 85% = \$366.15		
	SINGLE RENAL STUDY with enzyme (ACE) inhibitor (R)	pre-procedural administration of a diuretic or angiotensin converting		

I4. NUC	CLEAR MEDICINE IMAGING 1.	NUCLEAR MEDICINE - NON PET	
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$370.55 Benefit: 75% = \$277.95 85% = \$315.00		
	RENAL STUDY with diuretic administration following a baseline	study (R)	
61390	(See para IN.0.19 of explanatory notes to this Category) Fee: \$409.95 Benefit: 75% = \$307.50 85% = \$348.50		
	COMBINED EXAMINATION INVOLVING A RENAL STUDY following angiotensin converting enzyme (ACE) inhibitor provocation and a baseline study, in either order and related to a single referral episode (R)		
61393	(See para IN.0.19 of explanatory notes to this Category) Fee: \$605.50 Benefit: 75% = \$454.15 85% = \$522.10		
	CYSTOURETEROGRAM (R)		
61397	(See para IN.0.19 of explanatory notes to this Category) Fee: \$246.85 Benefit: 75% = \$185.15 85% = \$209.85		
	TESTICULAR STUDY (R)		
61401	(See para IN.0.19 of explanatory notes to this Category) Fee: \$162.30 Benefit: 75% = \$121.75 85% = \$138.00		
	CEREBRAL PERFUSION STUDY, with single photon emission t when undertaken (R)	omography and with planar imaging	
61402	(See para IN.0.19 of explanatory notes to this Category) Fee: \$605.05 Benefit: 75% = \$453.80 85% = \$521.65		
	BRAIN STUDY WITH BLOOD BRAIN BARRIER AGENT, with emission tomography, OR planar imaging, or single photon emission		
61405	(See para IN.0.19 of explanatory notes to this Category) Fee: \$346.00 Benefit: 75% = \$259.50 85% = \$294.10		
	CEREBRO-SPINAL FLUID TRANSPORT STUDY, with imaging	g on 2 or more separate occasions (R)	
61409	(See para IN.0.19 of explanatory notes to this Category) Fee: \$873.50 Benefit: 75% = \$655.15 85% = \$790.10		
	CEREBRO-SPINAL FLUID SHUNT PATENCY STUDY (R)		
61413	(See para IN.0.19 of explanatory notes to this Category) Fee: \$225.95 Benefit: 75% = \$169.50 85% = \$192.10		
	DYNAMIC BLOOD FLOW STUDY OR REGIONAL BLOOD V not being a service associated with a service to which another item		
61417	(See para IN.0.19 of explanatory notes to this Category) Fee: \$118.85 Benefit: 75% = \$89.15 85% = \$101.05		
	BONE STUDY - whole body, with, when undertaken, blood flow, separate occasion (R)	blood pool and delayed imaging on a	
61421	(See para IN.0.19 of explanatory notes to this Category) Fee: \$479.80 Benefit: 75% = \$359.85 85% = \$407.85		
	BONE STUDY - whole body and single photon emission tomograph flow, blood pool and delayed imaging on a separate occasion (R)	bhy, with, when undertaken, blood	
61425	(See para IN.0.19 of explanatory notes to this Category)		

I4. NUC	LEAR MEDICINE IMAGING	1. NUCLEAR MEDICINE - NON PET
	Fee: \$600.70 Benefit: 75% = \$4	450.55 85% = \$517.30
	WHOLE BODY STUDY using iodine	(R)
61426	(See para IN.0.19 of explanatory notes to the Fee: \$554.80 Benefit: 75% = \$4	his Category) 416.10 85% = \$471.60
	WHOLE BODY STUDY using galliur	m (R)
61429	(See para IN.0.19 of explanatory notes to the Fee: \$543.00 Benefit: 75% = \$4	his Category) 407.25 85% = \$461.55
	WHOLE BODY STUDY using galliur	m, with single photon emission tomography (R)
61430	(See para IN.0.19 of explanatory notes to the ree: \$659.45 Benefit: 75% = \$4	his Category) 494.60 85% = \$576.05
	WHOLE BODY STUDY using cells la	abelled with technetium (R)
61433	(See para IN.0.19 of explanatory notes to the Fee: \$496.95 Benefit: 75% = \$3	his Category) 372.75 85% = \$422.45
	WHOLE BODY STUDY using cells la (R)	abelled with technetium, with single photon emission tomography
61434	(See para IN.0.19 of explanatory notes to the Fee: \$615.40 Benefit: 75% = \$4	his Category) 461.55 85% = \$532.00
	WHOLE BODY STUDY using thalliu	nm (R)
61437	(See para IN.0.19 of explanatory notes to the Fee: \$542.75 Benefit: 75% = \$4	his Category) 407.10 85% = \$461.35
	WHOLE BODY STUDY using thalliu	ım, with single photon emission tomography (R)
61438	(See para IN.0.19 of explanatory notes to the Fee: \$672.95 Benefit: 75% = \$5	his Category) 504.75 85% = \$589.55
	BONE MARROW STUDY - whole body using technetium labelled bone marrow agents (R)	
61441	(See para IN.0.19 of explanatory notes to the Fee: \$489.70 Benefit: 75% = \$3	his Category) 367.30 85% = \$416.25
	WHOLE BODY STUDY, using galliu regions acquired separately (R)	m - with single photon emission tomography of 2 or more body
	(See para IN.0.19 of explanatory notes to the	
61442	Fee: \$752.35 Benefit: 75% = \$564.30 85% = \$668.95	
	BONE MARROW STUDY - localised	I using technetium labelled agent (R)
61445	(See para IN.0.19 of explanatory notes to the ree: \$286.80 Benefit: 75% = \$2	his Category) 215.10 85% = \$243.80
01443		DY, including when undertaken, blood flow, blood pool and
61446	(See para IN.0.19 of explanatory notes to the ree: \$333.55 Benefit: 75% = \$2	his Category) 250.20 85% = \$283.55
		DY and single photon emission tomography, including when
61449		. ,
/	(See para IN.0.19 of explanatory notes to this Category)	

I4. NUC	LEAR MEDICINE	IMAGING	1. NUCLEAR MEDICINE - NON PET
	Fee: \$456.20	Benefit: 75% = \$342.15	85% = \$387.80
	LOCALISED S'	ΓUDY using gallium (R)	
61450	(See para IN.0.19 Fee: \$397.55	of explanatory notes to this Cate Benefit: 75% = \$298.20	
	LOCALISED S	TUDY using gallium, with si	ngle photon emission tomography (R)
61453	(See para IN.0.19 Fee: \$514.70	of explanatory notes to this Cate Benefit: 75% = \$386.05	
	LOCALISED S'	ΓUDY using cells labelled w	ith technetium (R)
61454	(See para IN.0.19 Fee: \$348.10	of explanatory notes to this Cate Benefit: 75% = \$261.10	
	LOCALISED S'	TUDY using cells labelled w	ith technetium, with single photon emission tomography
61457	Fee: \$470.45	of explanatory notes to this Cate Benefit: 75% = \$352.85	C 27
	LOCALISED S	TUDY using thallium (R)	
61458	(See para IN.0.19 Fee: \$396.95	of explanatory notes to this Cate Benefit: 75% = \$297.75	
	LOCALISED S	TUDY using thallium, with s	ingle photon emission tomography (R)
61461	(See para IN.0.19 Fee: \$527.85	of explanatory notes to this Cate Benefit: 75% = \$395.90	
	REPEAT PLANAR AND SINGLE PHOTON EMISSION TOMOGRAPHY IMAGING, OR REPEAT PLANAR IMAGING OR SINGLE PHOTON EMISSION TOMOGRAPHY IMAGING on an occasion subsequent to the performance of any one of items 61364, 61426, 61429, 61430, 61442, 61450, 61453, 61469, 61484 or 61485 where there is no additional administration of radiopharmaceutical and where the previous radionuclide scan was abnormal or equivocal. (R)		N EMISSION TOMOGRAPHY IMAGING on an occasion items 61364, 61426, 61429, 61430, 61442, 61450, 61453, litional administration of radiopharmaceutical and where the
61462	(See para IN.0.19 Fee: \$129.00	of explanatory notes to this Cate Benefit: 75% = \$96.75	
	LYMPHOSCIN	TIGRAPHY (R)	
61469	(See para IN.0.19 Fee: \$348.10	of explanatory notes to this Cate Benefit: 75% = \$261.10	-
	THYROID STUDY including uptake measurement when undertaken (R)		rement when undertaken (R)
61473	(See para IN.0.19 Fee: \$175.40	of explanatory notes to this Cate Benefit: 75% = \$131.55	-
	PARATHYROID STUDY, planar imaging and single photon emission tomography when undertaken (R)		nd single photon emission tomography when undertaken
61480	(See para IN.0.19 Fee: \$386.85	of explanatory notes to this Cate Benefit: 75% = \$290.15	
	ADRENAL STU	JDY (R)	
61484	(See para IN.0.19 Fee: \$880.85	of explanatory notes to this Cate Benefit: 75% = \$660.65	

I4. NUC	LEAR MEDICINE IMAGING 1. NUCLEAR MEDICINE - NON PE	
	ADRENAL STUDY, with single photon emission tomography (R)	
61485	(See para IN.0.19 of explanatory notes to this Category) Fee: \$999.20 Benefit: 75% = \$749.40 85% = \$915.80	
	TEAR DUCT STUDY (R)	
61495	(See para IN.0.19 of explanatory notes to this Category) Fee: \$223.10 Benefit: 75% = \$167.35 85% = \$189.65	
	PARTICLE PERFUSION STUDY (intra-arterial) or Le Veen shunt study (R)	
61499	(See para IN.0.19 of explanatory notes to this Category) Fee: \$253.00 Benefit: 75% = \$189.75 85% = \$215.05	
	CT scan performed at the same time and covering the same body area as single photon emission tomography for the purpose of anatomic localisation or attenuation correction where no separate diagnostic CT report is issued and only in association with items 61302 - 61650 (R)	
61505	(See para IN.0.19 of explanatory notes to this Category) Fee: \$100.00 Benefit: 75% = \$75.00 85% = \$85.00	
	LEUKOSCAN STUDY, for use in diagnostic imaging of the long bones and feet in patients with suspected osteomyelitis, and where patients do not have access to <u>ex-vivo WBC scanning</u> . (R)	
	Note LeukoScan is only indicated for diagnostic imaging in patients suspected of infection in the long bones and feet, including those with diabetic ulcers. The descriptor does not cover patients who are being investigated for other sites of infection	
61650	(See para IN.0.19 of explanatory notes to this Category) Fee: \$878.70 Benefit: 75% = \$659.05 85% = \$795.30	
	SINGLE STRESS OR REST MYOCARDIAL PERFUSION STUDY - planar imaging (R) (NK)	
61651	(See para IN.0.19 of explanatory notes to this Category) Fee: \$224.45 Benefit: 75% = \$168.35 85% = \$190.80	
	SINGLE STRESS OR REST MYOCARDIAL PERFUSION STUDY - with single photon emission tomography and with planar imaging when undertaken (R) (NK)	
61652	(See para IN.0.19 of explanatory notes to this Category) Fee: \$282.65 Benefit: 75% = \$212.00 85% = \$240.30	
	COMBINED STRESS AND REST, stress and re-injection or rest and redistribution myocardial perfusion study, including delayed imaging or re-injection protocol on a subsequent occasion - planar imaging (R) (NK)	
51653	(See para IN.0.19 of explanatory notes to this Category) Fee: \$354.85 Benefit: 75% = \$266.15 85% = \$301.65	
61653		
61653	Fee: \$354.85 Benefit: 75% = \$266.15 85% = \$301.65 COMBINED STRESS AND REST, stress and re-injection or rest and redistribution myocardial perfusion study, including delayed imaging or re-injection protocol on a subsequent occasion - with	

I4. NUC	LEAR MEDICINE IMAGING	1. NUCLEAR MEDICINE - NON PET
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$183.65 Benefit: 75% = \$137.75 85% = \$156.15	
	GATED CARDIAC BLOOD POOL STUDY, (equilibrium), emission tomography OR planar imaging or single photon e	
61656	(See para IN.0.19 of explanatory notes to this Category) Fee: \$151.70 Benefit: 75% = \$113.80 85% = \$128.95	
	GATED CARDIAC BLOOD POOL STUDY, and first pass planar imaging and single photon emission tomography, OR tomography (R) (NK)	
61657	(See para IN.0.19 of explanatory notes to this Category) Fee: \$210.00 Benefit: 75% = \$157.50 85% = \$178.50	
	GATED CARDIAC BLOOD POOL STUDY, with intervent emission tomography, OR planar imaging, or single photon of	
61658	(See para IN.0.19 of explanatory notes to this Category) Fee: \$190.60 Benefit: 75% = \$142.95 85% = \$162.05	
	GATED CARDIAC BLOOD POOL STUDY, with intervent cardiac shunt study, with planar imaging and single photon estingle photon emission tomography (R) (NK)	
61659	(See para IN.0.19 of explanatory notes to this Category) Fee: \$246.20 Benefit: 75% = \$184.65 85% = \$209.30	
	CARDIAC FIRST PASS BLOOD FLOW STUDY OR CAR to which another item in this Group applies (R) (NK)	RDIAC SHUNT STUDY, not being a service
61660	(See para IN.0.19 of explanatory notes to this Category) Fee: \$114.45 Benefit: 75% = \$85.85 85% = \$97.30	
	LUNG PERFUSION STUDY, with planar imaging and single photon emission tomography OR planar imaging, or single photon emission tomography (R) (NK)	
61661	(See para IN.0.19 of explanatory notes to this Category) Fee: \$113.85 Benefit: 75% = \$85.40 85% = \$96.80	
	LUNG VENTILATION STUDY using aerosol, technegas of photon emission tomography OR planar imaging or single planar imaging	
61662	(See para IN.0.19 of explanatory notes to this Category) Fee: \$126.50 Benefit: 75% = \$94.90 85% = \$107.55	
	LUNG PERFUSION STUDY AND LUNG VENTILATION gas, with planar imaging and single photon emission tomography (R) (NK)	, ,
61663	(See para IN.0.19 of explanatory notes to this Category) Fee: \$221.70 Benefit: 75% = \$166.30 85% = \$188.45	
	LIVER AND SPLEEN STUDY (colloid) - planar imaging (l	R) (NK)
61664	(See para IN.0.19 of explanatory notes to this Category) Fee: \$129.70 Benefit: 75% = \$97.30 85% = \$110.25	
	LIVER AND SPLEEN STUDY (colloid), with single photon imaging when undertaken (R) (NK)	n emission tomography and with planar
61665		

I4. NUC	LEAR MEDICINE II	MAGING	1. NUCLEAR MEDICINE - NON PET
	(See para IN.0.19 of Fee: \$193.30	explanatory notes to this Ca Benefit: 75% = \$145.00	
	RED BLOOD CEI undertaken (R) (NI		STUDY, including single photon emission tomography when
61666	(See para IN.0.19 of Fee: \$196.40	explanatory notes to this Ca Benefit: 75% = \$147.30	
	HEPATOBILIARY when performed (F		rphine administration or pre-treatment with a cholagogue
61667	Fee: \$201.70	explanatory notes to this Ca Benefit: 75% = \$151.30	0 85% = \$171.45
	HEPATOBILIAR' (R) (NK)	Y STUDY with formal q	uantification following baseline imaging, using a cholagogue
61668	(See para IN.0.19 of Fee: \$230.70	explanatory notes to this Ca Benefit: 75% = \$173.00	
	BOWEL HAEMO	RRHAGE STUDY (R) (NK)
61669	(See para IN.0.19 of Fee: \$248.50	explanatory notes to this Ca Benefit: 75% = \$186.40	
	MECKEL'S DIVE	RTICULUM STUDY (R	(NK)
61670	(See para IN.0.19 of Fee: \$111.55	explanatory notes to this Ca Benefit: 75% = \$83.70	
	INDIUM-LABELI undertaken, where		UDY - including single photon emission tomography when
	(a) there is a susp with negative or	pected gastro-entero-pand	creatic endocrine tumour, based on biochemical evidence,
	equivocal conve	entional imaging; or	
	(b) a surgically amenable gastro-entero-pancreatic endocrine tumour has been identified based or conventional		ancreatic endocrine tumour has been identified based on
	techniques, in or	rder to exclude additional	disease sites. (Ministerial Determination) (R) (NK)
61671	(See para IN.0.19 of explanatory notes to this Category) Fee: \$1,007.90 Benefit: 75% = \$755.95 85% = \$924.50		C 27
	SALIVARY STUDY (R) (NK)		
61672	(See para IN.0.19 of explanatory notes to this Category) Fee: \$111.55 Benefit: 75% = \$83.70 85% = \$94.85		
	GASTRO-OESOPHAGEAL REFLUX STUDY, including delayed imaging on a separate occasion when undertaken (R) (NK)		UDY, including delayed imaging on a separate occasion
61673	(See para IN.0.19 of Fee: \$244.85	explanatory notes to this Ca Benefit: 75% = \$183.65	± ±:
	OESOPHAGEAL	CLEARANCE STUDY	(R) (NK)
61674	(See para IN.0.19 of Fee: \$71.70	explanatory notes to this Ca Benefit: 75% = \$53.80	

I4. NUC	LEAR MEDICINE IMAGING 1. NUCLEAR MEDICINE - NON P
	GASTRIC EMPTYING STUDY, using single tracer (R) (NK)
	(See para IN.0.19 of explanatory notes to this Category)
61675	Fee: \$287.20 Benefit: 75% = \$215.40 85% = \$244.15
	COMBINED SOLID AND LIQUID GASTRIC EMPTYING STUDY using dual isotope technique or the same isotope on separate days (R) (NK)
61676	(See para IN.0.19 of explanatory notes to this Category) Fee: \$312.50 Benefit: 75% = \$234.40 85% = \$265.65
	RADIONUCLIDE COLONIC TRANSIT STUDY (R) (NK)
61677	(See para IN.0.19 of explanatory notes to this Category) Fee: \$343.85 Benefit: 75% = \$257.90 85% = \$292.30
	RENAL STUDY, including perfusion and renogram images and computer analysis OR cortical study with planar imaging (R) (NK)
61678	(See para IN.0.19 of explanatory notes to this Category) Fee: \$166.25 Benefit: 75% = \$124.70 85% = \$141.35
	RENAL CORTICAL STUDY, with single photon emission tomography and planar quantification (R) (NK)
61679	(See para IN.0.19 of explanatory notes to this Category) Fee: \$215.40 Benefit: 75% = \$161.55 85% = \$183.10
	SINGLE RENAL STUDY with pre-procedural administration of a diuretic or angiotensin converting enzyme (ACE) inhibitor (R) (NK)
61680	(See para IN.0.19 of explanatory notes to this Category) Fee: \$185.30 Benefit: 75% = \$139.00 85% = \$157.55
	RENAL STUDY with diuretic administration following a baseline study (R) (NK)
61681	(See para IN.0.19 of explanatory notes to this Category) Fee: \$205.00 Benefit: 75% = \$153.75 85% = \$174.25
	COMBINED EXAMINATION INVOLVING A RENAL STUDY following angiotensin converting enzyme (ACE) inhibitor provocation and a baseline study, in either order and related to a single referrate pisode (R) (NK)
61682	(See para IN.0.19 of explanatory notes to this Category) Fee: \$302.75 Benefit: 75% = \$227.10 85% = \$257.35
	CYSTOURETEROGRAM (R) (NK)
61683	(See para IN.0.19 of explanatory notes to this Category) Fee: \$123.45 Benefit: 75% = \$92.60 85% = \$104.95
	TESTICULAR STUDY (R) (NK)
61684	(See para IN.0.19 of explanatory notes to this Category) Fee: \$81.15 Benefit: 75% = \$60.90 85% = \$69.00
	CEREBRAL PERFUSION STUDY, with single photon emission tomography and with planar imaging when undertaken (R) (NK)
61685	(See para IN.0.19 of explanatory notes to this Category) Fee: \$302.55 Benefit: 75% = \$226.95 85% = \$257.20
61686	BRAIN STUDY WITH BLOOD BRAIN BARRIER AGENT, with planar imaging and single photon

I4. NUC	LEAR MEDICINE IMAGING 1. NUCLEAR MEDICINE - NON PE
	emission tomography, OR planar imaging, or single photon emission tomography (R) (NK)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$173.00 Benefit: 75% = \$129.75 85% = \$147.05
	CEREBRO-SPINAL FLUID TRANSPORT STUDY, with imaging on 2 or more separate occasions (R (NK)
61687	(See para IN.0.19 of explanatory notes to this Category) Fee: \$436.75 Benefit: 75% = \$327.60 85% = \$371.25
	CEREBRO-SPINAL FLUID SHUNT PATENCY STUDY (R) (NK)
61688	(See para IN.0.19 of explanatory notes to this Category) Fee: \$113.00 Benefit: 75% = \$84.75 85% = \$96.05
	DYNAMIC BLOOD FLOW STUDY OR REGIONAL BLOOD VOLUME QUANTITATIVE STUDY not being a service associated with a service to which another item in this Group applies (R) (NK)
61689	(See para IN.0.19 of explanatory notes to this Category) Fee: \$59.45 Benefit: 75% = \$44.60 85% = \$50.55
	BONE STUDY - whole body, with, when undertaken, blood flow, blood pool and delayed imaging on a separate occasion (R) (NK)
61690	(See para IN.0.19 of explanatory notes to this Category) Fee: \$239.90 Benefit: 75% = \$179.95 85% = \$203.95
	BONE STUDY - whole body and single photon emission tomography, with, when undertaken, blood flow, blood pool and delayed imaging on a separate occasion (R) (NK)
61691	(See para IN.0.19 of explanatory notes to this Category) Fee: \$300.35 Benefit: 75% = \$225.30 85% = \$255.30
	WHOLE BODY STUDY using iodine (R) (NK)
61692	(See para IN.0.19 of explanatory notes to this Category) Fee: \$277.40 Benefit: 75% = \$208.05 85% = \$235.80
	WHOLE BODY STUDY using gallium (R) (NK)
61693	(See para IN.0.19 of explanatory notes to this Category) Fee: \$271.50 Benefit: 75% = \$203.65 85% = \$230.80
	WHOLE BODY STUDY using gallium, with single photon emission tomography (R) (NK)
61694	(See para IN.0.19 of explanatory notes to this Category) Fee: \$329.75 Benefit: 75% = \$247.35 85% = \$280.30
	WHOLE BODY STUDY using cells labelled with technetium (R) (NK)
61695	(See para IN.0.19 of explanatory notes to this Category) Fee: \$248.50 Benefit: 75% = \$186.40 85% = \$211.25
	WHOLE BODY STUDY using cells labelled with technetium, with single photon emission tomography (R) (NK)
61696	(See para IN.0.19 of explanatory notes to this Category) Fee: \$307.70 Benefit: 75% = \$230.80 85% = \$261.55
	WHOLE BODY STUDY using thallium (R) (NK)
61697	(See para IN.0.19 of explanatory notes to this Category)

I4. NUC	LEAR MEDICINE IMAGING	1. NUCLEAR MEDICINE - NON PET
	Fee: \$271.40 Benefit: 75% = \$203.55	85% = \$230.70
	WHOLE BODY STUDY using thallium, wi	th single photon emission tomography (R) (NK)
61698	(See para IN.0.19 of explanatory notes to this Cat Fee: \$336.50 Benefit: 75% = \$252.40	
	BONE MARROW STUDY - whole body us	ing technetium labelled bone marrow agents (R) (NK)
61699	(See para IN.0.19 of explanatory notes to this Category) Fee: \$244.85 Benefit: 75% = \$183.65 85% = \$208.15	
	WHOLE BODY STUDY, using gallium - w regions acquired separately (R) (NK)	ith single photon emission tomography of 2 or more body
61700	(See para IN.0.19 of explanatory notes to this Cat Fee: \$376.20 Benefit: 75% = \$282.15	± • ·
	BONE MARROW STUDY - localised using	technetium labelled agent (R) (NK)
61701	(See para IN.0.19 of explanatory notes to this Cat Fee: \$143.40 Benefit: 75% = \$107.55	
	LOCALISED BONE OR JOINT STUDY, in repeat imaging on a separate occasion (R) (N	ncluding when undertaken, blood flow, blood pool and IK)
61702	(See para IN.0.19 of explanatory notes to this Cat Fee: \$166.80 Benefit: 75% = \$125.10	
	LOCALISED BONE OR JOINT STUDY an undertaken, blood flow, blood pool and imag	d single photon emission tomography, including when ging on a separate occasion (R) (NK)
61703	(See para IN.0.19 of explanatory notes to this Cat Fee: \$228.10 Benefit: 75% = \$171.10	
	LOCALISED STUDY using gallium (R) (N	K)
61704	(See para IN.0.19 of explanatory notes to this Cat Fee: \$198.80 Benefit: 75% = \$149.10	-
	LOCALISED STUDY using gallium, with single photon emission tomography (R) (NK)	
61705	(See para IN.0.19 of explanatory notes to this Cat Fee: \$257.35 Benefit: 75% = \$193.05	
	LOCALISED STUDY using cells labelled w	with technetium (R) (NK)
61706	(See para IN.0.19 of explanatory notes to this Cat Fee: \$174.05 Benefit: 75% = \$130.55	C 17
	LOCALISED STUDY using cells labelled w (R) (NK)	vith technetium, with single photon emission tomography
61707	(See para IN.0.19 of explanatory notes to this Cat Fee: \$235.25 Benefit: 75% = \$176.45	
	LOCALISED STUDY using thallium (R) (N	IK)
61708	(See para IN.0.19 of explanatory notes to this Cat Fee: \$198.50 Benefit: 75% = \$148.90	
	LOCALISED STUDY using thallium, with s	single photon emission tomography (R) (NK)
61709	(See para IN.0.19 of explanatory notes to this Cat	egory)

I4. NUC	LEAR MEDICINE	IMAGING	1. NUCLEAR MEDICINE - NON PET
	Fee: \$263.95	Benefit: 75% = \$198.0	00 85% = \$224.40
	PLANAR IMAC subsequent to th 61469, 61484, 6 there is no addit	GING OR SINGLE PHOT e performance of any one 1485, 61669, 61692, 6169	ON EMISSION TOMOGRAPHY IMAGING, OR REPEAT ON EMISSION TOMOGRAPHY IMAGING on an occasion of items 61364, 61426, 61429, 61430, 61442, 61450, 61453, 3, 61694, 61700, 61704, 61705, 61712, 61715 or 61716 where iopharmaceutical and where the previous radionuclide scan
61710	(See para IN.0.19 Fee: \$64.50	of explanatory notes to this G Benefit: 75% = \$48.46	
	LYMPHOSCIN	TIGRAPHY (R) (NK)	
61712	(See para IN.0.19 Fee: \$174.05	of explanatory notes to this C Benefit: 75% = \$130.	
	THYROID STU	DY including uptake mea	surement when undertaken (R) (NK)
61713	(See para IN.0.19 Fee: \$87.70	of explanatory notes to this G Benefit: 75% = \$65.86	
	PARATHYROI (R) (NK)	D STUDY, planar imaginş	g and single photon emission tomography when undertaken
61714	(See para IN.0.19 Fee: \$193.45	of explanatory notes to this C Benefit: 75% = \$145.	
	ADRENAL STU	UDY (R) (NK)	
61715	(See para IN.0.19 Fee: \$440.45	of explanatory notes to this C Benefit: 75% = \$330	
	ADRENAL STU	UDY, with single photon e	mission tomography (R) (NK)
61716	(See para IN.0.19 Fee: \$499.60	of explanatory notes to this G Benefit: 75% = \$374.	
	TEAR DUCT S	TUDY (R) (NK)	
61717	(See para IN.0.19 Fee: \$111.55	of explanatory notes to this G Benefit: 75% = \$83.76	
	PARTICLE PER	RFUSION STUDY (intra-	arterial) or Le Veen shunt study (R) (NK)
61718	(See para IN.0.19 Fee: \$126.50	of explanatory notes to this O Benefit: 75% = \$94.90	
	tomography for	the purpose of anatomic lo	overing the same body area as single photon emission ocalisation or attenuation correction where no separate association with items 61302 - 61729 (R) (NK)
61719	(See para IN.0.19 Fee: \$50.00	of explanatory notes to this G Benefit: 75% = \$37.56	
		myelitis, and where patient	stic imaging of the long bones and feet in patients with s do not have access to ex-vivo WBC scanning. (Ministerial
61729	Note LeukoScar	n is only indicated for diag	nostic imaging in patients suspected of infection in the long

14. NUCLEAR MEDICINE IMAGING 1. NUCLEAR MEDICINE - NON PET bones and feet, including those with diabetic ulcers. The descriptor does not cover patients who are being investigated for other sites of infection (See para IN.0.19 of explanatory notes to this Category) Fee: \$439.35 **Benefit:** 75% = \$329.55 85% = \$373.45 14. NUCLEAR MEDICINE IMAGING 2. PET Group I4. Nuclear Medicine Imaging Subgroup 2. PET Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.(R) (See para IN.0.19 of explanatory notes to this Category) **Benefit:** 75% = \$714.75 85% = \$869.60 61523 Fee: \$953.00 Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned (R) (See para IN.0.19 of explanatory notes to this Category) 61529 Fee: \$953.00 **Benefit:** 75% = \$714.75 85% = \$869.60 FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy. (R) 61538 Fee: \$901.00 **Benefit:** 75% = \$675.75 85% = \$817.60 Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy (R) (See para IN.0.19 of explanatory notes to this Category) 61541 Fee: \$953.00 **Benefit:** 75% = \$714.75 85% = \$869.60 Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy (R) (See para IN.0.19 of explanatory notes to this Category) 61553 Fee: \$999.00 **Benefit:** 75% = \$749.25 85% = \$915.60 FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery (R) (See para IN.0.19 of explanatory notes to this Category) 61559 Fee: \$918.00 **Benefit:** 75% = \$688.50 85% = \$834.60 Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy. (R) (See para IN.0.19 of explanatory notes to this Category) **Benefit:** 75% = \$714.75 85% = \$869.60 Fee: \$953.00 61565 Whole body FDG PET study, for the further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent. (R) Fee: \$953.00 **Benefit:** 75% = \$714.75 85% = \$869.60 61571

I4. NUC	LEAR MEDICINE IMAGING	2. PET
	Whole body FDG PET study, for the further staging of patients with confirmed local carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradioth exenteration with curative intent. (R)	
61575	Fee: \$953.00 Benefit: 75% = \$714.75 85% = \$869.60	
	Whole body FDG PET study, performed for the staging of proven oesophageal or C patients considered suitable for active therapy (R).	GEJ carcinoma, in
61577	Fee: \$953.00 Benefit: 75% = \$714.75 85% = \$869.60	
	Whole body FDG PET study performed for the staging of biopsy-proven newly dia head and neck cancer (R).	gnosed or recurrent
61598	Fee: \$953.00 Benefit: 75% = \$714.75 85% = \$869.60	
	Whole body FDG PET study performed for the evaluation of patients with suspecte neck cancer after definitive treatment, and who are suitable for active therapy (R).	d residual head and
61604	Fee: \$953.00 Benefit: 75% = \$714.75 85% = \$869.60	
	Whole body FDG PET study performed for the evaluation of metastatic squamous of unknown primary site involving cervical nodes (R).	cell carcinoma of
61610	Fee: \$953.00 Benefit: 75% = \$714.75 85% = \$869.60	
	Whole body FDG PET study for the initial staging of newly diagnosed or previously or non-Hodgkin lymphoma (R)	y untreated Hodgkin
61620	(See para IN.0.19 of explanatory notes to this Category) Fee: \$953.00 Benefit: 75% = \$714.75 85% = \$869.60	
	Whole body FDG PET study to assess response to first line therapy either during treatment months of completing definitive first line treatment for Hodgkin or non-Hodgin	
61622	(See para IN.0.19 of explanatory notes to this Category) Fee: \$953.00 Benefit: 75% = \$714.75 85% = \$869.60	
	Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin lymphoma (R)	Hodgkin or non-
61628	(See para IN.0.19 of explanatory notes to this Category) Fee: \$953.00 Benefit: 75% = \$714.75 85% = \$869.60	
	Whole body FDG PET study to assess response to second-line chemotherapy if hae transplantation is being considered for Hodgkin or non-Hodgkin lymphoma (R)	mopoietic stem cell
61632	(See para IN.0.19 of explanatory notes to this Category) Fee: \$953.00 Benefit: 75% = \$714.75 85% = \$869.60	
	Whole body FDG PET study for initial staging of patients with biopsy-proven bone sarcoma (excluding gastrointestinal stromal tumour) considered by conventional stacurable. (R)	
61640	Fee: \$999.00 Benefit: 75% = \$749.25 85% = \$915.60	
	Whole body FDG PET study for the evaluation of patients with suspected residual of (excluding gastrointestinal stromal tumour) after the initial course of definitive them suitability for subsequent therapy with curative intent. (R)	
61646	Fee: \$999.00 Benefit: 75% = \$749.25 85% = \$915.60	

I4. NUCLEAR MEDICINE IMAGING 2.		
	Whole body ⁶⁸ Ga-DOTA-peptide PET study (including any associated computed tomography scans for anatomic localisation and attenuation correction), if:	
	(a) a gastro-entero-pancreatic neuroendocrine tumour is suspected on the basis of biochemical evidence with negative or equivocal conventional imaging; or	
	(b) both:	
	(i) a surgically amenable gastro-entero-pancreatic neuroendocrine tumour has been identified on the basis of conventional techniques; and	
	(ii) the study is for excluding additional disease sites	
	(R)	
61647	(See para IN.0.19, IN.0.13 of explanatory notes to this Category) Fee: \$1,053.00 Benefit: 75% = \$789.75 85% = \$969.60	

15. MAGNETIC RESONANCE IMAGING

1. SCAN OF HEAD - FOR SPECIFIED CONDITIONS

IJ. WIAC	INETIC RESONANCE IMAGING CONDITIONS
	Group I5. Magnetic Resonance Imaging
	Subgroup 1. Scan Of Head - For Specified Conditions
	MAGNETIC RESONANCE IMAGING (including Magnetic Resonance Angiography if performed), performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of head for:
	- tumour of the brain or meninges (R) (Contrast) (Anaes.)
63001	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
03001	- inflammation of the brain or meninges (R) (Contrast) (Anaes.)
63004	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	- skull base or orbital tumour (R) (Contrast) (Anaes.)
63007	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	- stereotactic scan of brain, with Fiducials in place, for the sole purpose to allow planning for stereotactic neurosurgery (R) (Contrast) (Anaes.)
63010	(See para IN.0.19 of explanatory notes to this Category) Fee: \$336.00 Benefit: 75% = \$252.00 85% = \$285.60
	MAGNETIC RESONANCE IMAGING (including Magnetic Resonance Angiography if performed), performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of head for:
63013	

I5. MAG	1. SCAN OF HEAD - FOR SPECIFIED CONDITIONS
	- tumour of the brain or meninges (R) (NK) (Contrast) (Anaes.)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
	- inflammation of the brain or meninges (R) (NK) (Contrast) (Anaes.)
63014	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60
	- skull base or orbital tumour (R) (NK) (Contrast) (Anaes.)
63016	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60
	- stereotactic scan of brain, with Fiducials in place, for the sole purpose to allow planning for stereotactic neurosurgery (R) (NK) (Contrast) (Anaes.)
63017	(See para IN.0.19 of explanatory notes to this Category) Fee: \$168.00 Benefit: 75% = \$126.00 85% = \$142.80
	2. SCAN OF HEAD - FOR SPECIFIED
I5. MAG	NETIC RESONANCE IMAGING CONDITIONS
	Group I5. Magnetic Resonance Imaging
	Subgroup 2. Scan Of Head - For Specified Conditions
	NOTE: Benefits are payable for each service included by Subgroup 2 on three occasions only in any 12 month period
	MAGNETIC RESONANCE IMAGING (including Magnetic Resonance Angiography if performed), performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of head for:
	- acoustic neuroma (R) (Contrast) (Anaes.)
63040	(See para IN.0.19 of explanatory notes to this Category) Fee: \$336.00 Benefit: 75% = \$252.00 85% = \$285.60
	- pituitary tumour (R) (Contrast) (Anaes.)
63043	(See para IN.0.19 of explanatory notes to this Category) Fee: \$358.40 Benefit: 75% = \$268.80 85% = \$304.65
	- toxic or metabolic or ischaemic encephalopathy (R) (Contrast) (Anaes.)
63046	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	- demyelinating disease of the brain (R) (Contrast) (Anaes.)
63049	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75

I5. MAG	2. SCAN OF HEAD - FOR SPECIFIED CONDITIONS
	- congenital malformation of the brain or meninges (R) (Contrast) (Anaes.)
63052	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	- venous sinus thrombosis (R) (Contrast) (Anaes.)
63055	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	- head trauma (R) (Contrast) (Anaes.)
63058	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	- epilepsy (R) (Contrast) (Anaes.)
63061	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	- stroke (R) (Contrast) (Anaes.)
63064	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	- carotid or vertebral artery desection (R) (Contrast) (Anaes.)
63067	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	- intracranial aneurysm (R) (Contrast) (Anaes.)
63070	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	- intracranial arteriovenous malformation (R) (Contrast) (Anaes.)
63073	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	NOTE: Benefits are payable for each service included by Subgroup 2 on three occasions only in any 12 month period
	MAGNETIC RESONANCE IMAGING (including Magnetic Resonance Angiography if performed), performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of head for:
	- acoustic neuroma (R) (NK) (Contrast) (Anaes.)
63074	(See para IN.0.19 of explanatory notes to this Category) Fee: \$168.00 Benefit: 75% = \$126.00 85% = \$142.80
	- pituitary tumour (R) (NK) (Contrast) (Anaes.)
63075	(See para IN.0.19 of explanatory notes to this Category) Fee: \$179.20 Benefit: 75% = \$134.40 85% = \$152.35

I5. MAG	2. SCAN OF HEAD - FOR SPECIFIED CONDITIONS
	- toxic or metabolic or ischaemic encephalopathy (R) (NK) (Contrast) (Anaes.)
63076	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
	- demyelinating disease of the brain (R) (NK) (Contrast) (Anaes.)
63077	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60
	- congenital malformation of the brain or meninges (R) (NK) (Contrast) (Anaes.)
63078	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
	- venous sinus thrombosis (R) (NK) (Contrast) (Anaes.)
63079	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60
	- head trauma (R) (NK) (Contrast) (Anaes.)
63080	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
	- epilepsy (R) (NK) (Contrast) (Anaes.)
63081	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
	- stroke (R) (NK) (Contrast) (Anaes.)
63082	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60
	- carotid or vertebral artery desection (R) (NK) (Contrast) (Anaes.)
63083	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60
	- intracranial aneurysm (R) (NK) (Contrast) (Anaes.)
63084	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60
	- intracranial arteriovenous malformation (R) (NK) (Contrast) (Anaes.)
63085	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
I5. MAG	3. SCAN OF HEAD AND NECK VESSELS - FOR NETIC RESONANCE IMAGING SPECIFIED CONDITIONS
	Group I5. Magnetic Resonance Imaging
	Subgroup 3. Scan Of Head And Neck Vessels - For Specified Conditions
	NOTE: Benefits are payable for each service included by Subgroup 3 on three occasions only in any 12 month period
63101	

I5. MAG	3. SCAN OF HEAD AND NECK VESSELS - FOR SPECIFIED CONDITIONS
	MAGNETIC RESONANCE IMAGING AND MAGNETIC RESONANCE ANGIOGRAPHY of extra and/or intracranial circulation, performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of head and neck vessels for:
	- stroke (R) (Contrast) (Anaes.)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$492.80 Benefit: 75% = \$369.60 85% = \$418.90
	NOTE: Benefits are payable for each service included by Subgroup 3 on three occasions only in any 12 month period
	MAGNETIC RESONANCE IMAGING AND MAGNETIC RESONANCE ANGIOGRAPHY of extra and/or intracranial circulation, performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of head and neck vessels for:
63104	- stroke (R) (NK) (Contrast) (Anaes.) (See para IN.0.19 of explanatory notes to this Category) Fee: \$246.40 Benefit: 75% = \$184.80 85% = \$209.45
03104	MAGNETIC RESONANCE IMAGING (including Magnetic Resonance Angiography if performed), performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of head and cervical spine for:
	- tumour of the central nervous system or meninges (R) (NK) (Contrast) (Anaes.)
63117	(See para IN.0.19 of explanatory notes to this Category) Fee: \$246.40 Benefit: 75% = \$184.80 85% = \$209.45
	- inflammation of the central nervous system or meninges (R) (NK) (Contrast) (Anaes.)
63119	(See para IN.0.19 of explanatory notes to this Category) Fee: \$246.40 Benefit: 75% = \$184.80 85% = \$209.45
I5. MAG	4. SCAN OF HEAD AND CERVICAL SPINE - FOR NETIC RESONANCE IMAGING SPECIFIED CONDITIONS
	Group I5. Magnetic Resonance Imaging
	Subgroup 4. Scan Of Head And Cervical Spine - For Specified Conditions
63111	MAGNETIC RESONANCE IMAGING (including Magnetic Resonance Angiography if performed), performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of head and cervical spine for:

I5. MAG	4. SCAN OF HEAD AND CERVICAL SPINE - FOR SPECIFIED CONDITIONS SPECIFIED CONDITIONS
	- tumour of the central nervous system or meninges (R) (Contrast) (Anaes.)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$492.80 Benefit: 75% = \$369.60 85% = \$418.90
	- inflammation of the central nervous system or meninges (R) (Contrast) (Anaes.)
63114	(See para IN.0.19 of explanatory notes to this Category) Fee: \$492.80 Benefit: 75% = \$369.60 85% = \$418.90
I5. MAG	5. SCAN OF HEAD AND CERVICAL SPINE - FOR NETIC RESONANCE IMAGING SPECIFIED CONDITIONS
	Group I5. Magnetic Resonance Imaging
	Subgroup 5. Scan Of Head And Cervical Spine - For Specified Conditions
	NOTE: Benefits are payable for each service included by Subgroup 5 on three occasions only in any 12 month period
	MAGNETIC RESONANCE IMAGING (including Magnetic Resonance Angiography if performed), performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of head and cervical spine for:
	- demyelinating disease of the central nervous system (R) (Contrast) (Anaes.)
63125	(See para IN.0.19 of explanatory notes to this Category) Fee: \$492.80 Benefit: 75% = \$369.60 85% = \$418.90
	- congenital malformation of the central nervous system or meninges (R) (Contrast) (Anaes.)
63128	(See para IN.0.19 of explanatory notes to this Category) Fee: \$492.80 Benefit: 75% = \$369.60 85% = \$418.90
	- syrinx (congenital or acquired) (R) (Contrast) (Anaes.)
63131	(See para IN.0.19 of explanatory notes to this Category) Fee: \$492.80 Benefit: 75% = \$369.60 85% = \$418.90
	NOTE: Benefits are payable for each service included by Subgroup 5 on three occasions only in any 12 month period
	MAGNETIC RESONANCE IMAGING (including Magnetic Resonance Angiography if performed), performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of head and cervical spine for:
63134	

I5. MAG	5. SCAN OF HEAD AND CERVICAL SPINE - FOR SPECIFIED CONDITIONS
	- demyelinating disease of the central nervous system (R) (NK) (Contrast) (Anaes.)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$246.40 Benefit: 75% = \$184.80 85% = \$209.45
	- congenital malformation of the central nervous system or meninges (R) (NK) (Contrast) (Anaes.)
63135	(See para IN.0.19 of explanatory notes to this Category) Fee: \$246.40 Benefit: 75% = \$184.80 85% = \$209.45
	- syrinx (congenital or acquired) (R) (NK) (Contrast) (Anaes.)
63136	(See para IN.0.19 of explanatory notes to this Category) Fee: \$246.40 Benefit: 75% = \$184.80 85% = \$209.45
I5. MAG	6. SCAN OF SPINE - ONE REGION OR TWO CONTIGUOUS REGIONS - FOR SPECIFIED NETIC RESONANCE IMAGING CONDITIONS
	Group I5. Magnetic Resonance Imaging
	Subgroup 6. Scan Of Spine - One Region Or Two Contiguous Regions - For Specified Conditions
	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician scan of one region or two contiguous regions of the spine for:
	- infection (R) (Contrast) (Anaes.)
63151	(See para IN.0.19 of explanatory notes to this Category) Fee: \$358.40 Benefit: 75% = \$268.80 85% = \$304.65
	- tumour (R) (Contrast) (Anaes.)
63154	(See para IN.0.19 of explanatory notes to this Category) Fee: \$358.40 Benefit: 75% = \$268.80 85% = \$304.65
	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician scan of one region or two contiguous regions of the spine for:
	- infection (R) (NK) (Contrast) (Anaes.)
63157	(See para IN.0.19 of explanatory notes to this Category) Fee: \$179.20 Benefit: 75% = \$134.40 85% = \$152.35
	- tumour (R) (NK) (Contrast) (Anaes.)
63158	(See para IN.0.19 of explanatory notes to this Category) Fee: \$179.20 Benefit: 75% = \$134.40 85% = \$152.35
I5. MAG	7. SCAN OF SPINE - ONE REGION OR TWO CONTIGUOUS REGIONS - FOR SPECIFIED NETIC RESONANCE IMAGING CONDITIONS

15. MAG	7. SCAN OF SPINE - ONE REGION OR TWO CONTIGUOUS REGIONS - FOR SPECIFIED SNETIC RESONANCE IMAGING CONDITIONS
	Group I5. Magnetic Resonance Imaging
	Subgroup 7. Scan Of Spine - One Region Or Two Contiguous Regions - For Specified Conditions
	NOTE: Benefits are payable for each service included by Subgroup 7 on three occasions only in any 12 month period
	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of one region or two contiguous regions of the spine for:
	- demyelinating (R) (Contrast) (Anaes.)
63161	(See para IN.0.19 of explanatory notes to this Category) Fee: \$358.40 Benefit: 75% = \$268.80 85% = \$304.65
	- congenital malformation of the spinal cord or the cauda equina or the meninges (R) (Contrast) (Anaes.)
63164	(See para IN.0.19 of explanatory notes to this Category) Fee: \$358.40 Benefit: 75% = \$268.80 85% = \$304.65
	myelopathy (R) (Contrast) (Anaes.)
63167	(See para IN.0.19 of explanatory notes to this Category) Fee: \$358.40 Benefit: 75% = \$268.80 85% = \$304.65
	- syrinx (congenital or acquired) (R) (Contrast) (Anaes.)
63170	(See para IN.0.19 of explanatory notes to this Category) Fee: \$358.40 Benefit: 75% = \$268.80 85% = \$304.65
	- cervical radiculopathy (R) (Contrast) (Anaes.)
63173	(See para IN.0.19 of explanatory notes to this Category) Fee: \$358.40 Benefit: 75% = \$268.80 85% = \$304.65
	- sciatica (R) (Contrast) (Anaes.)
63176	(See para IN.0.19 of explanatory notes to this Category) Fee: \$358.40 Benefit: 75% = \$268.80 85% = \$304.65
	- spinal canal stenosis (R) (Contrast) (Anaes.)
63179	(See para IN.0.19 of explanatory notes to this Category) Fee: \$358.40 Benefit: 75% = \$268.80 85% = \$304.65
	- previous spinal surgery (R) (Contrast) (Anaes.)
63182	(See para IN.0.19 of explanatory notes to this Category) Fee: \$358.40 Benefit: 75% = \$268.80 85% = \$304.65
	- trauma (R) (Anaes.)
63185	(See para IN.0.19 of explanatory notes to this Category) Fee: \$358.40 Benefit: 75% = \$268.80 85% = \$304.65

7. SCAN OF SPINE - ONE REGION OR TWO CONTIGUOUS REGIONS - FOR SPECIFIED CONDITIONS

15. MAGNETIC RESONANCE IMAGING

	NOTE: Benefits are payable for each service included by Subgroup 7 on three occasions only in any 12 month period
	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of one region or two contiguous regions of the spine for:
	- demyelinating (R) (NK) (Contrast) (Anaes.)
63186	(See para IN.0.19 of explanatory notes to this Category) Fee: \$179.20 Benefit: 75% = \$134.40 85% = \$152.35
	- congenital malformation of the spinal cord or the cauda equina or the meninges (R) (NK) (Contrast) (Anaes.)
63187	(See para IN.0.19 of explanatory notes to this Category) Fee: \$179.20 Benefit: 75% = \$134.40 85% = \$152.35
	- myelopathy (R) (NK) (Contrast) (Anaes.)
63188	(See para IN.0.19 of explanatory notes to this Category) Fee: \$179.20 Benefit: 75% = \$134.40 85% = \$152.35
	- syrinx (congenital or acquired) (R) (NK) (Contrast) (Anaes.)
63189	(See para IN.0.19 of explanatory notes to this Category) Fee: \$179.20 Benefit: 75% = \$134.40 85% = \$152.35
	- cervical radiculopathy (R) (NK) (Contrast) (Anaes.)
63190	(See para IN.0.19 of explanatory notes to this Category) Fee: \$179.20 Benefit: 75% = \$134.40 85% = \$152.35
	- sciatica (R) (NK) (Contrast) (Anaes.)
63191	(See para IN.0.19 of explanatory notes to this Category) Fee: \$179.20 Benefit: 75% = \$134.40 85% = \$152.35
	- spinal canal stenosis (R) (NK) (Contrast) (Anaes.)
63192	(See para IN.0.19 of explanatory notes to this Category) Fee: \$179.20 Benefit: 75% = \$134.40 85% = \$152.35
	- previous spinal surgery (R) (NK) (Contrast) (Anaes.)
63193	(See para IN.0.19 of explanatory notes to this Category) Fee: \$179.20 Benefit: 75% = \$134.40 85% = \$152.35
	- trauma (R) (NK) (Anaes.)
63194	(See para IN.0.19 of explanatory notes to this Category) Fee: \$179.20 Benefit: 75% = \$134.40 85% = \$152.35

15. MAG	8. SCAN OF SPINE - THREE CONTIGUOUS REGIONS OR TWO NON-CONTIGUOUS BNETIC RESONANCE IMAGING REGIONS - FOR SPECIFIED CONDITIONS
	Group I5. Magnetic Resonance Imaging
	Subgroup 8. Scan Of Spine - Three Contiguous Regions Or Two Non-Contiguous Regions - For Specified Conditions
	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of three contiguous regions or two non contiguous regions of the spine for:
	- infection (R) (Contrast) (Anaes.)
63201	(See para IN.0.19 of explanatory notes to this Category) Fee: \$448.00 Benefit: 75% = \$336.00 85% = \$380.80
	- tumour (R) (Contrast) (Anaes.)
63204	(See para IN.0.19 of explanatory notes to this Category) Fee: \$448.00 Benefit: 75% = \$336.00 85% = \$380.80
	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of three contiguous regions or two non contiguous regions of the spine for:
	- infection (R) (NK) (Contrast) (Anaes.)
63207	(See para IN.0.19 of explanatory notes to this Category) Fee: \$224.00 Benefit: 75% = \$168.00 85% = \$190.40
	- tumour (R) (NK) (Contrast) (Anaes.)
63208	(See para IN.0.19 of explanatory notes to this Category) Fee: \$224.00 Benefit: 75% = \$168.00 85% = \$190.40
15. MAG	9. SCAN OF SPINE - THREE CONTIGUOUS REGIONS OR TWO NON-CONTIGUOUS REGIONS - FOR SPECIFIED CONDITIONS
	Group I5. Magnetic Resonance Imaging
	Subgroup 9. Scan Of Spine - Three Contiguous Regions Or Two Non-Contiguous Regions - For Specified Conditions
	NOTE: Benefits are payable for each service included by Subgroup 9 on three occasions only in any 12 month period
63219	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of three contiguous regions or two non contiguous regions of the spine for:

15. MAG	9. SCAN OF SPINE - THREE CONTIGUOUS REGIONS OR TWO NON-CONTIGUOUS SNETIC RESONANCE IMAGING REGIONS - FOR SPECIFIED CONDITIONS
	domicalizating diseases (B) (Contract) (Amoss.)
	- demyelinating disease (R) (Contrast) (Anaes.) (See para IN.0.19 of explanatory notes to this Category)
	Fee: \$448.00 Benefit: 75% = \$336.00 85% = \$380.80 - congenital malformation of the spinal cord or the cauda equina or the meninges (R) (Contrast) (Anaes.)
	(See para IN.0.19 of explanatory notes to this Category)
63222	Fee: \$448.00 Benefit: 75% = \$336.00 85% = \$380.80
	- myelopathy (R) (Contrast) (Anaes.)
63225	(See para IN.0.19 of explanatory notes to this Category) Fee: \$448.00 Benefit: 75% = \$336.00 85% = \$380.80
03223	- syrinx (congenital or acquired) (R) (Contrast) (Anaes.)
	(See para IN.0.19 of explanatory notes to this Category)
63228	Fee: \$448.00 Benefit: 75% = \$336.00 85% = \$380.80
	- cervical radiculopathy (R) (Contrast) (Anaes.)
63231	(See para IN.0.19 of explanatory notes to this Category) Fee: \$448.00 Benefit: 75% = \$336.00 85% = \$380.80
	- sciatica (R) (Contrast) (Anaes.)
(2224	(See para IN.0.19 of explanatory notes to this Category)
63234	Fee: \$448.00 Benefit: 75% = \$336.00 85% = \$380.80 - spinal canal stenosis (R) (Contrast) (Anaes.)
63237	(See para IN.0.19 of explanatory notes to this Category) Fee: \$448.00 Benefit: 75% = \$336.00 85% = \$380.80
	- previous spinal surgery (R) (Contrast) (Anaes.)
	(See para IN.0.19 of explanatory notes to this Category)
63240	Fee: \$448.00 Benefit: 75% = \$336.00 85% = \$380.80 - trauma (R) (Anaes.)
63243	(See para IN.0.19 of explanatory notes to this Category) Fee: \$448.00 Benefit: 75% = \$336.00 85% = \$380.80
	NOTE: Benefits are payable for each service included by Subgroup 9 on three occasions only in any 12 month period
	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of three contiguous regions or two non contiguous regions of the spine for:
63257	- demyelinating disease (R) (NK) (Contrast) (Anaes.)

15. MAG	9. SCAN OF SPINE - THREE CONTIGUOUS REGIONS OR TWO NON-CONTIGUOUS REGIONS - FOR SPECIFIED CONDITIONS
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$224.00 Benefit: 75% = \$168.00 85% = \$190.40
	- congenital malformation of the spinal cord or the cauda equina or the meninges (R) (NK) (Contrast) (Anaes.)
63258	(See para IN.0.19 of explanatory notes to this Category) Fee: \$224.00 Benefit: 75% = \$168.00 85% = \$190.40
	- myelopathy (R) (NK) (Contrast) (Anaes.)
63259	(See para IN.0.19 of explanatory notes to this Category) Fee: \$224.00 Benefit: 75% = \$168.00 85% = \$190.40
	- syrinx (congenital or acquired) (R) (NK) (Contrast) (Anaes.)
63260	(See para IN.0.19 of explanatory notes to this Category) Fee: \$224.00 Benefit: 75% = \$168.00 85% = \$190.40
	- cervical radiculopathy (R) (NK) (Contrast) (Anaes.)
63261	(See para IN.0.19 of explanatory notes to this Category) Fee: \$224.00 Benefit: 75% = \$168.00 85% = \$190.40
	- sciatica (R) (NK) (Contrast) (Anaes.)
63262	(See para IN.0.19 of explanatory notes to this Category) Fee: \$224.00 Benefit: 75% = \$168.00 85% = \$190.40
	- spinal canal stenosis (R) (NK) (Contrast) (Anaes.)
63263	(See para IN.0.19 of explanatory notes to this Category) Fee: \$224.00 Benefit: 75% = \$168.00 85% = \$190.40
	- previous spinal surgery (R) (NK) (Contrast) (Anaes.)
63264	(See para IN.0.19 of explanatory notes to this Category) Fee: \$224.00 Benefit: 75% = \$168.00 85% = \$190.40
	- trauma (R) (NK) (Anaes.)
63265	(See para IN.0.19 of explanatory notes to this Category) Fee: \$224.00 Benefit: 75% = \$168.00 85% = \$190.40
15. MAG	10. SCAN OF CERVICAL SPINE AND BRACHIAL SNETIC RESONANCE IMAGING PLEXUS - FOR SPECIFIED CONDITIONS
	Group I5. Magnetic Resonance Imaging
	Subgroup 10. Scan Of Cervical Spine And Brachial Plexus - For Specified Conditions
	NOTE: Benefits are payable for each service included by Subgroup 10 on three occasions only in any 12 month period
63271	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of cervical spine and brachial plexus for:

I5. MAG	NETIC RESONANCE IMAGING 10. SCAN OF CERVICAL SPINE AND BRACHIAL PLEXUS - FOR SPECIFIED CONDITIONS
	- tumour (R) (Contrast) (Anaes.)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$492.80 Benefit: 75% = \$369.60 85% = \$418.90
	- trauma (R) (Contrast) (Anaes.)
63274	(See para IN.0.19 of explanatory notes to this Category) Fee: \$492.80 Benefit: 75% = \$369.60 85% = \$418.90
	- cervical radiculopathy (R) (Contrast) (Anaes.)
63277	(See para IN.0.19 of explanatory notes to this Category) Fee: \$492.80 Benefit: 75% = \$369.60 85% = \$418.90
	- previous surgery (R) (Contrast) (Anaes.)
63280	(See para IN.0.19 of explanatory notes to this Category) Fee: \$492.80 Benefit: 75% = \$369.60 85% = \$418.90
	NOTE: Benefits are payable for each service included by Subgroup 10 on three occasions only in any 12 month period
	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of cervical spine and brachial plexus for:
	- tumour (R) (NK) (Contrast) (Anaes.)
63282	(See para IN.0.19 of explanatory notes to this Category) Fee: \$246.40 Benefit: 75% = \$184.80 85% = \$209.45
	- trauma (R) (NK) (Contrast) (Anaes.)
63283	(See para IN.0.19 of explanatory notes to this Category) Fee: \$246.40 Benefit: 75% = \$184.80 85% = \$209.45
	- cervical radiculopathy (R) (NK) (Contrast) (Anaes.)
63284	(See para IN.0.19 of explanatory notes to this Category) Fee: \$246.40 Benefit: 75% = \$184.80 85% = \$209.45
	- previous surgery (R) (NK) (Contrast) (Anaes.)
63285	(See para IN.0.19 of explanatory notes to this Category) Fee: \$246.40 Benefit: 75% = \$184.80 85% = \$209.45
I5. MAG	11. SCAN OF MUSCULOSKELETAL SYSTEM - NETIC RESONANCE IMAGING FOR SPECIFIED CONDITIONS
	Group I5. Magnetic Resonance Imaging
	Subgroup 11. Scan Of Musculoskeletal System - For Specified Conditions

15. MAG	11. SCAN OF MUSCULOSKELETAL SYSTEM - GNETIC RESONANCE IMAGING FOR SPECIFIED CONDITIONS
	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of musculoskeletal system for:
	- tumour arising in bone or musculoskeletal system, this excludes tumours arising in breast, prostate or rectum (R) (Contrast) (Anaes.)
63301	(See para IN.0.19 of explanatory notes to this Category) Fee: \$380.80 Benefit: 75% = \$285.60 85% = \$323.70
	- infection arising in bone or musculoskeletal system, this excludes infection arising in breast, prostate or rectum (R) (Contrast) (Anaes.)
63304	(See para IN.0.19 of explanatory notes to this Category) Fee: \$380.80 Benefit: 75% = \$285.60 85% = \$323.70
	- osteonecrosis (R) (Contrast) (Anaes.)
63307	(See para IN.0.19 of explanatory notes to this Category) Fee: \$380.80 Benefit: 75% = \$285.60 85% = \$323.70
	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of musculoskeletal system for:
	- tumour arising in bone or musculoskeletal system, this excludes tumours arising in breast, prostate or rectum (R) (NK) (Contrast) (Anaes.)
63310	(See para IN.0.19 of explanatory notes to this Category) Fee: \$190.40 Benefit: 75% = \$142.80 85% = \$161.85
	- infection arising in bone or musculoskeletal system, this excludes infection arising in breast, prostate or rectum (R) (NK) (Contrast) (Anaes.)
63311	(See para IN.0.19 of explanatory notes to this Category) Fee: \$190.40 Benefit: 75% = \$142.80 85% = \$161.85
	- osteonecrosis (R) (NK) (Contrast) (Anaes.)
63313	(See para IN.0.19 of explanatory notes to this Category) Fee: \$190.40 Benefit: 75% = \$142.80 85% = \$161.85
15. MAG	12. SCAN OF MUSCULOSKELETAL SYSTEM - GNETIC RESONANCE IMAGING FOR SPECIFIED CONDITIONS
	Group I5. Magnetic Resonance Imaging
	Subgroup 12. Scan Of Musculoskeletal System - For Specified Conditions
	NOTE: Benefits are payable for each service included by Subgroup 12 on three occasions only in any 12 month period
63322	

15. MAG	12. SCAN OF MUSCULOSKELETAL SYSTEM - FOR SPECIFIED CONDITIONS
	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of musculoskeletal system for:
	- derangement of hip or its supporting structures (R) (Contrast) (Anaes.)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	- derangment of shoulder or its supporting structures (R) (Contrast) (Anaes.)
63325	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	- derangment of knee or its supporting structures (R) (Contrast) (Anaes.)
63328	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	- derangment of ankle and/or foot or its supporting structures (R) (Contrast) (Anaes.)
63331	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	- derangment of one or both temporomandibular joints or their supporting structures (R) (Contrast) (Anaes.)
63334	(See para IN.0.19 of explanatory notes to this Category) Fee: \$336.00 Benefit: 75% = \$252.00 85% = \$285.60
	- derangment of wrist and/or hand or its supporting structures (R) (Contrast) (Anaes.)
63337	(See para IN.0.19 of explanatory notes to this Category) Fee: \$448.00 Benefit: 75% = \$336.00 85% = \$380.80
	- derangment of elbow or its supporting structures (R) (Contrast) (Anaes.)
63340	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	NOTE: Benefits are payable for each service included by Subgroup 12 on three occasions only in any 12 month period
	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of musculoskeletal system for:
	- derangement of hip or its supporting structures (R) (NK) (Contrast) (Anaes.)
63341	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40

I5. MAG	12. SCAN OF MUSCULOSKELETAL SYSTEM FOR SPECIFIED CONDITIONS
	- derangement of shoulder or its supporting structures (R) (NK) (Contrast) (Anaes.)
63342	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
	- derangement of knee or its supporting structures (R) (NK) (Contrast) (Anaes.)
63343	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
	- derangement of ankle and/or foot or its supporting structures (R) (NK) (Contrast) (Anaes.)
63345	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
	- derangement of one or both temporomandibular joints or their supporting structures (R) (NK) (Contrast) (Anaes.)
63346	(See para IN.0.19 of explanatory notes to this Category) Fee: \$168.00 Benefit: 75% = \$126.00 85% = \$142.80
	- derangement of wrist and/or hand or its supporting structures (R) (NK) (Contrast) (Anaes.)
63347	(See para IN.0.19 of explanatory notes to this Category) Fee: \$224.00 Benefit: 75% = \$168.00 85% = \$190.40
	- derangement of elbow or its supporting structures (R) (NK) (Contrast) (Anaes.)
	(See para IN.0.19 of explanatory notes to this Category)
63348	Fee: $$201.60$ Benefit: $75\% = 151.20 $85\% = 171.40
	Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40 13. SCAN OF MUSCULOSKELETAL SYSTEM
	Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40 13. SCAN OF MUSCULOSKELETAL SYSTEM FOR SPECIFIED CONDITIONS FOR SPECIFIED CONDITIONS
	Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40 13. SCAN OF MUSCULOSKELETAL SYSTEM FOR SPECIFIED CONDITIONS Group I5. Magnetic Resonance Imaging
	Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40 13. SCAN OF MUSCULOSKELETAL SYSTEM FOR SPECIFIED CONDITIONS Group I5. Magnetic Resonance Imaging Subgroup 13. Scan Of Musculoskeletal System - For Specified Conditions NOTE: Benefits are payable for each service included by Subgroup 13 on two occasions only in any 12
	33. SCAN OF MUSCULOSKELETAL SYSTEM FOR SPECIFIED CONDITIONS Group I5. Magnetic Resonance Imaging Subgroup 13. Scan Of Musculoskeletal System - For Specified Conditions NOTE: Benefits are payable for each service included by Subgroup 13 on two occasions only in any 12 month period MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician -
	SOURTIC RESONANCE IMAGING 13. SCAN OF MUSCULOSKELETAL SYSTEM FOR SPECIFIED CONDITIONS
I5. MAG	Subgroup 13. Scan Of Musculoskeletal System - For Specified Conditions

ETAL SYSTEM - ED CONDITIONS
n of an eligible sultant physician -
R SYSTEM - FOR ED CONDITIONS
tions
ons only in any 12
y if performed), ation where the system for:
ons only in any 12
y if performed), ation where the system for:

I5. MAG	14. SCAN OF CARDIOVASCULAR SYSTEM - FOR SPECIFIED CONDITIONS
	- congenital disease of the heart or a great vessel (R) (NK) (Contrast) (Anaes.)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$224.00 Benefit: 75% = \$168.00 85% = \$190.40
	- tumour of the heart or a great vessel (R) (NK) (Contrast) (Anaes.)
63393	(See para IN.0.19 of explanatory notes to this Category) Fee: \$224.00 Benefit: 75% = \$168.00 85% = \$190.40
	- abnormality of thoracic aorta (R) (NK) (Contrast) (Anaes.)
63394	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
	MRI scan of the cardiovascular system, performed by a person who is:
	(a) a specialist in diagnostic radiology or a consultant physician; and
	(b) recognised by the Conjoint Committee for Certification in Cardiac MRI
	for the assessment of myocardial structure and function involving:
	(a) dedicated right ventricular views; and
	(b) 3D volumetric assessment of the right ventricle; and
	(c) reporting of end-diastolic and end-systolic volumes, ejection fraction and BSA-indexed values;
	if the request for the scan indicates that:
	(d) the patient presented with symptoms consistent with arrhythmogenic right ventricular cardiomyopathy (ARVC); or
	(e) investigative findings in relation to the patient are consistent with ARVC
	NOTE: benefits are payable once in 12 months
	(R) (K) (Contrast)
	(Anaes.)
63395	(See para IN.0.19, IN.0.18 of explanatory notes to this Category) Fee: \$855.20 Benefit: 75% = \$641.40 85% = \$771.80

14. SCAN OF CARDIOVASCULAR SYSTEM - FOR SPECIFIED CONDITIONS

15. MAGNETIC RESONANCE IMAGING

MRI scan of the cardiovascular system, performed by a person who is: (a) a specialist in diagnostic radiology or a consultant physician; and (b) recognised by the Conjoint Committee for Certification in Cardiac MRI for the assessment of myocardial structure and function involving: (a) dedicated right ventricular views; and (b) 3D volumetric assessment of the right ventricle; and (c) reporting of end-diastolic and end-systolic volumes, ejection fraction and BSA-indexed values; if the request for the scan indicates that: (d) the patient presented with symptoms consistent with arrhythmogenic right ventricular cardiomyopathy (ARVC); or (e) investigative findings in relation to the patient are consistent with ARVC NOTE: benefits are payable once in 12 months (R) (NK) (Contrast) (Anaes.) (See para IN.0.18, IN.0.19 of explanatory notes to this Category) 63396 Fee: \$427.60 **Benefit:** 75% = \$320.70 85% = \$363.50 MRI scan of the cardiovascular system, performed by a person who is: (a) a specialist in diagnostic radiology or a consultant physician; and (b) recognised by the Conjoint Committee for Certification in Cardiac MRI for the assessment of myocardial structure and function involving: (a) dedicated right ventricular views; and (b) 3D volumetric assessment of the right ventricle; and (c) reporting of end-diastolic and end-systolic volumes, ejection fraction and BSA-indexed values; 63397

14. SCAN OF CARDIOVASCULAR SYSTEM - FOR SPECIFIED CONDITIONS

15. MAGNETIC RESONANCE IMAGING

if the request for the scan indicates that the patient:

- (d) is asymptomatic; and
- (e) has one or more first degree relatives diagnosed with confirmed arrhythmogenic right ventricular cardiomyopathy (ARVC)

NOTE: benefits are payable once in 36 months

(R) (K) (Contrast) (Anaes.)

(See para IN.0.19, IN.0.18 of explanatory notes to this Category) **Fee:** \$855.20 **Benefit:** 75% = \$641.40 85% = \$771.80

MRI scan of the cardiovascular system, performed by a person who is:

- (a) a specialist in diagnostic radiology or a consultant physician; and
- (b) recognised by the Conjoint Committee for Certification in Cardiac MRI

for the assessment of myocardial structure and function involving:

- (a) dedicated right ventricular views; and
- (b) 3D volumetric assessment of the right ventricle; and
- (c) reporting of end-diastolic and end-systolic volumes, ejection fraction and BSA-indexed values;

if the request for the scan indicates that the patient:

- (d) is asymptomatic; and
- (e) has one or more first degree relatives diagnosed with confirmed arrhythmogenic right ventricular cardiomyopathy (ARVC)

NOTE: benefits are payable once in 36 months

(R) (NK) (Contrast)

(Anaes.)

(See para IN.0.19, IN.0.18 of explanatory notes to this Category) **Fee:** \$427.60 **Benefit:** 75% = \$320.70 85% = \$363.50

63398

I5. MAG	15. MAGNETIC RESONANCE ANGIOGRAPHY - SCAN OF CARDIOVASCULAR SYSTEM - FOR SPECIFIED CONDITIONS
	Group I5. Magnetic Resonance Imaging
	Subgroup 15. Magnetic Resonance Angiography - Scan Of Cardiovascular System - For Specified Conditions
	NOTE: Benefits are payable for each service included by Subgroup 15 on three occasions only in any 12 month period
	MAGNETIC RESONANCE ANGIOGRAPHY performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician and where the request for the scan specifically identifies the clinical indication for the scan scan of cardiovascular system for:
	- vascular abnormality in a patient with a previous anaphylactic reaction to an iodinated contrast medium (R) (Contrast) (Anaes.)
63401	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	- obstruction of the superior vena cava, inferior vena cava or a major pelvic vein (R) (Contrast) (Anaes.)
63404	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	NOTE: Benefits are payable for each service included by Subgroup 15 on three occasions only in any 12 month period
	MAGNETIC RESONANCE ANGIOGRAPHY performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician and where the request for the scan specifically identifies the clinical indication for the scan scan of cardiovascular system for:
	- vascular abnormality in a patient with a previous anaphylactic reaction to an iodinated contrast medium (R) (NK) (Contrast) (Anaes.)
63407	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
	- obstruction of the superior vena cava, inferior vena cava or a major pelvic vein (R) (NK) (Contrast) (Anaes.)
63408	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
	16. MAGNETIC RESONANCE ANGIOGRAPHY - FOR SPECIFIED CONDITIONS - PERSON UNDER

1032

15. MAGNETIC RESONANCE IMAGING

THE AGE OF 16 YEARS

15. MAC	16. MAGNETIC RESONANCE ANGIOGRAPHY - FOR SPECIFIED CONDITIONS - PERSON UNDER SNETIC RESONANCE IMAGING THE AGE OF 16 YEARS
	Group I5. Magnetic Resonance Imaging
	Subgroup 16. Magnetic Resonance Angiography - For Specified Conditions - Person Under The Age Of 16 Years
	NOTE: Benefits are payable for each service included by Subgroup 16 on one occasion only in any 12 month period
	MAGNETIC RESONANCE ANGIOGRAPHY performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of person under the age of 16 for:
	- the vasculature of limbs prior to limb or digit transfer surgery in congenital limb deficiency syndrome (R) (Contrast) (Anaes.)
63416	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	NOTE: Benefits are payable for each service included by Subgroup 16 on one occasion only in any 12 month period
	MAGNETIC RESONANCE ANGIOGRAPHY performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of person under the age of 16 for:
	- the vasculature of limbs prior to limb or digit transfer surgery in congenital limb deficiency syndrome (R) NK) (Contrast) (Anaes.)
63419	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
15. MAC	17. MAGNETIC RESONANCE IMAGING - FOR SPECIFIED CONDITIONS - PERSON UNDER THE SNETIC RESONANCE IMAGING AGE OF 16 YEARS
	Group I5. Magnetic Resonance Imaging
	Subgroup 17. Magnetic Resonance Imaging - For Specified Conditions - Person Under The Age Of 16 Years
	NOTE: Benefits are payable for each service included by Subgroup 17 on two occasions only in any 12 month period, for previously diagnosed conditions
63425	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible

15. MAC	17. MAGNETIC RESONANCE IMAGING - FOR SPECIFIED CONDITIONS - PERSON UNDER THE SNETIC RESONANCE IMAGING AGE OF 16 YEARS
	provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of person under the age of 16 for:
	- post-inflammatory or post-traumatic physeal fusion (R) (Anaes.)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	- Gaucher disease (R) (Anaes.)
63428	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	NOTE: Benefits are payable for each service included by Subgroup 17 on two occasions only in any 12 month period, for previously diagnosed conditions
	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of person under the age of 16 for:
	- post-inflammatory or post-traumatic physeal fusion (R) (NK) (Anaes.)
63432	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
	- Gaucher disease (R) (NK) (Anaes.)
63433	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
15. MAC	18. MAGNETIC RESONANCE IMAGING - FOR SPECIFIED CONDITIONS - PERSON UNDER THE SNETIC RESONANCE IMAGING AGE OF 16 YEARS
	Group I5. Magnetic Resonance Imaging
	Subgroup 18. Magnetic Resonance Imaging - For Specified Conditions - Person Under The Age Of 16 Years
	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of person under the age of 16 for:
	- pelvic or abdominal mass (R) (Contrast) (Anaes.)
63440	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75

15. MAG	18. MAGNETIC RESONANCE IMAGING - FOR SPECIFIED CONDITIONS - PERSON UNDER THE GNETIC RESONANCE IMAGING AGE OF 16 YEARS
	- mediastinal mass (R) (Contrast) (Anaes.)
63443	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	- congenital uterine or anorectal abnormality (R) (Contrast) (Anaes.)
63446	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of person under the age of 16 for:
	- pelvic or abdominal mass (R) (NK) (Contrast) (Anaes.)
63447	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
	- mediastinal mass (R) (NK) (Contrast) (Anaes.)
63448	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
	- congenital uterine or anorectal abnormality (R) (NK) (Contrast) (Anaes.)
63449	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
15. MAG	19. SCAN OF BODY - FOR SPECIFIED CONDITIONS
	Group I5. Magnetic Resonance Imaging
	Subgroup 19. Scan Of Body - For Specified Conditions
	NOTE: Benefits are payable for each service included by Subgroup 19 on one occasion only in any 12 month period
	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of body for:
	- adrenal mass in a patient with malignancy which is otherwise resectable (R) (NK) (Anaes.)
63455	(See para IN.0.19 of explanatory notes to this Category) Fee: \$179.20 Benefit: 75% = \$134.40 85% = \$152.35
63457	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician

19. SCAN OF BODY - FOR SPECIFIED CONDITIONS

15. MAGNETIC RESONANCE IMAGING

and where:

- (a) a dedicated breast coil is used; and
- (b) the request for scan identifies that the person is asymptomatic and is less than 50 years of age; and
- (c) the request for scan identifies either:
 - (i) that the patient is at high risk of developing breast cancer, due to 1 of the following:
 - (A) 3 or more first or second degree relatives on the same side of the family diagnosed with breast or ovarian cancer;
 - (B) 2 or more first or second degree relatives on the same side of the family diagnosed with breast or ovarian cancer, if any of the following applies to at least 1 of the relatives:
 - has been diagnosed with bilateral breast cancer;
 - had onset of breast cancer before the age of 40 years;
 - had onset of ovarian cancer before the age of 50 years;
 - has been diagnosed with breast and ovarian cancer, at the same time or at different times;
 - has Ashkenazi Jewish ancestry;
 - is a male relative who has been diagnosed with breast cancer;
- (C) 1 first or second degree relative diagnosed with breast cancer at age 45 years or younger, plus another first or second degree relative on the same side of the family with bone or soft tissue sarcoma at age 45 years or younger; or
 - (ii) that genetic testing has identified the presence of a high risk breast cancer gene mutation.

Scan of both breasts for:

- detection of cancer (R)

NOTE: Benefits are payable on one occasion only in any 12 month period

(NK) (Anaes.)

(See para IN.0.19 of explanatory notes to this Category)

Fee: \$345.00 **Benefit:** 75% = \$258.75 85% = \$293.25

19. SCAN OF BODY - FOR SPECIFIED 15. MAGNETIC RESONANCE IMAGING CONDITIONS MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician and where: a dedicated breast coil is used; and (a) (b) the person has had an abnormality detected as a result of a service described in item 63464 or 63457 performed in the previous 12 months Scan of both breasts for: - detection of cancer (R) NOTE 1: Benefits are payable on one occasion only in any 12 month period NOTE 2: This item is intended for follow-up imaging of abnormalities diagnosed on a scan described by item 63464 or 63457 (NK) (Anaes.) (See para IN.0.19 of explanatory notes to this Category) **Benefit:** 75% = \$258.75 85% = \$293.25 63458 Fee: \$345.00 NOTE: Benefits are payable for each service included by Subgroup 19 on one occasion only in any 12 month period MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician scan of body for: adrenal mass in a patient with malignancy which is otherwise resectable (R) (Anaes.) (See para IN.0.19 of explanatory notes to this Category) 63461 Fee: \$358.40 **Benefit:** 75% = \$268.80 85% = \$304.65 MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician and where: a dedicated breast coil is used; and (a) the request for scan identifies that the person is asymptomatic and is less than 50 years of age; and 63464

19. SCAN OF BODY - FOR SPECIFIED CONDITIONS

15. MAGNETIC RESONANCE IMAGING

- (c) the request for scan identifies either:
 - (i) that the patient is at high risk of developing breast cancer, due to 1 of the following:
 - (A) 3 or more first or second degree relatives on the same side of the family diagnosed with breast or ovarian cancer;
 - (B) 2 or more first or second degree relatives on the same side of the family diagnosed with breast or ovarian cancer, if any of the following applies to at least 1 of the relatives:
 - has been diagnosed with bilateral breast cancer;
 - had onset of breast cancer before the age of 40 years;
 - had onset of ovarian cancer before the age of 50 years;
 - has been diagnosed with breast and ovarian cancer, at the same time or at different times;
 - has Ashkenazi Jewish ancestry;
 - is a male relative who has been diagnosed with breast cancer;
- (C) 1 first or second degree relative diagnosed with breast cancer at age 45 years or younger, plus another first or second degree relative on the same side of the family with bone or soft tissue sarcoma at age 45 years or younger; or
 - (ii) that genetic testing has identified the presence of a high risk breast cancer gene mutation.

Scan of both breasts for:

- detection of cancer (R)

NOTE: Benefits are payable on one occasion only in any 12 month period (Anaes.)

(See para IN.0.19 of explanatory notes to this Category)

Fee: \$690.00 **Benefit:** 75% = \$517.50 85% = \$606.60

MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician and where:

- (a) a dedicated breast coil is used; and
- (b) the person has had an abnormality detected as a result of a service described in item 63464

15. MAC	19. SCAN OF BODY - FOR SPECIFIED CONDITIONS
	performed in the previous 12 months
	Scan of both breasts for:
	- detection of cancer (R)
	NOTE 1: Benefits are payable on one occasion only in any 12 month period
	NOTE 2: This item is intended for follow-up imaging of abnormalities diagnosed on a scan described
	by item 63464 (Anaes.)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$690.00 Benefit: 75% = \$517.50 85% = \$606.60
	MRI-performed under the professional supervision of an eligible provider at an eligible location, if:
	(a) the patient is referred by a specialist or a consultant physician; and
	(b) a dedicated breast coil is used; and
	(c) the request for the scan identifies that:
	(i) the patient has been diagnosed with metastatic cancer restricted to the regional lymph nodes; and
	(ii) clinical examination and conventional imaging have failed to identify the primary cancer (R) (K) (Anaes)
63487	Fee: \$690.00 Benefit: 75% = \$517.50 85% = \$606.60
	MRI-performed under the professional supervision of an eligible provider at an eligible location, if:
	(a) the patient is referred by a specialist or a consultant physician; and
	(b) a dedicated breast coil is used; and
	(c) the request for the scan identifies that:
	(i) the patient has been diagnosed with metastatic cancer restricted to the regional lymph nodes; and
	(ii) clinical examination and conventional imaging have failed to identify the primary cancer
	(R) (NK) (Anaes)
63488	Fee: \$345.00 Benefit: 75% = \$258.75 85% = \$293.25
	MRI-guided biopsy, performed under the professional supervision of an eligible provider at an eligible location, if:
63489	1-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0

19. SCAN OF BODY - FOR SPECIFIED **CONDITIONS**

15. MAGNETIC RESONANCE IMAGING

- (a) the patient is referred by a specialist or a consultant physician; and
- (b) a dedicated breast coil is used; and
- (c) the request for the scan identifies that:
 - (i) the patient has a suspicious lesion seen on MRI but not on conventional imaging; and
 - (ii) the lesion is not amenable to biopsy guided by conventional imaging; and
- (d) a repeat ultrasound scan of the affected breast is performed:
 - (i) before the guided biopsy is performed; and
 - (ii) as part of the service under this item (R) (K) (Anaes.)

Fee: \$1,440.00 **Benefit:** 75% = \$1080.00 85% = \$1356.60

MRI-guided biopsy performed under the professional supervision of an eligible provider at an eligible location, if:

- (a) the patient is referred by a specialist or a consultant physician; and
- (b) a dedicated breast coil is used; and
- (c) the request for the scan identifies that:
 - (i) the patient has a suspicious lesion seen on MRI but not on conventional imaging; and
 - (ii) the lesion is not amenable to biopsy guided by conventional imaging; and
- (d) a repeat ultrasound scan of the affected breast is performed:
 - (i) before the guided biopsy is performed; and
 - (ii) as part of the service under this item (R) (NK) (Anaes.)

63490 **Fee:** \$720.00 **Benefit:** 75% = \$540.00 85% = \$636.60

Multiparametric Magnetic Resonance Imaging scan of the prostate for the detection of cancer, if the patient is referred by an urologist, radiation oncologist, or medical oncologist and the request for the scan identifies:

that the patient is suspected of developing prostate cancer, due to one of the following:

- (i) a digital rectal examination which is suspicious for prostate cancer; or
- (ii) in a person under 70 years, at least two prostate specific antigen (PSA) tests performed within an interval of 1-3 months are greater than 3.0 ng/ml, and the free/total PSA ratio is less than 25% or the repeat PSA exceeds 5.5 ng/ml; or
- (iii) in a person under 70 years, whose risk of developing prostate cancer based on relevant family history is at least double the average risk, at least two PSA tests performed within an interval of 1-3 months are greater than 2.0 ng/ml, and the free/total PSA ratio is less than 25%; or
- (iv) in a person 70 years or older, at least two PSA tests performed within an interval of 1-3 months are greater than 5.5ng/ml and the free/total PSA ratio is less than 25%.

using a standardised image acquisition protocol involving T2 Weighted Imaging, Diffusion Weighted Imaging, and Dynamic Contrast Enhancement (unless contraindicated)

63541

19. SCAN OF BODY - FOR SPECIFIED CONDITIONS

15. MAGNETIC RESONANCE IMAGING

(R)(K)

Note: Benefits are payable on one occasion only in any 12 month period.

Relevant family history is a first degree relative with prostate cancer, or suspected of carrying a BRCA 1 or BRCA 2 mutation.

(Anaes.)

(See para IN.0.19, IN.0.18 of explanatory notes to this Category) **Fee:** \$450.00 **Benefit:** 75% = \$337.50 85% = \$382.50

Multiparametric Magnetic Resonance Imaging scan of the prostate for the detection of cancer, if the patient is referred by an urologist, radiation oncologist, or medical oncologist and the request for the scan identifies:

that the patient is suspected of developing prostate cancer, due to one of the following:

- (i) a digital rectal examination which is suspicious for prostate cancer; or
- (ii) in a person under 70 years, at least two prostate specific antigen (PSA) tests performed within an interval of 1-3 months are greater than 3.0 ng/ml, and the free/total PSA ratio is less than 25% or the repeat PSA exceeds 5.5 ng/ml; or
- (iii) in a person under 70 years, whose risk of developing prostate cancer based on relevant family history is at least double the average risk, at least two PSA tests performed within an interval of 1-3 months are greater than 2.0 ng/ml, and the free/total PSA ratio is less than 25%; or
- (iv) in a person 70 years or older, at least two PSA tests performed within an interval of 1-3 months are greater than 5.5ng/ml and the free/total PSA ratio is less than 25%.

using a standardised image acquisition protocol involving T2 Weighted Imaging, Diffusion Weighted Imaging, and Dynamic Contrast Enhancement (unless contraindicated) (R) (NK)

Note: Benefits are payable on one occasion only in any 12 month period.

Relevant family history is a first degree relative with prostate cancer, or suspected of carrying a BRCA 1 or BRCA 2 mutation. (Anaes.)

(See para IN.0.18, IN.0.19 of explanatory notes to this Category)

63542 **Fee:** \$225.00 **Benefit:** 75% = \$168.75 85% = \$191.25

Multiparametric Magnetic Resonance Imaging scan of the prostate for the assessment of cancer, if the patient is referred by an urologist, radiation oncologist, or medical oncologist and:

the request for the scan identifies:

- (i) the patient is under active surveillance following a confirmed diagnosis of prostate cancer by biopsy histopathology; and
- (ii) the patient is not planning or undergoing treatment for prostate cancer.

using a standardised image acquisition protocol involving T2 Weighted Imaging, Diffusion Weighted Imaging, and Dynamic Contrast Enhancement (unless contraindicated) (R) (K)

Note: Benefits are payable at the time of diagnosis of prostate cancer, 12 months following diagnosis and then every 3rd year thereafter or at any time, if there is a clinical concern, including PSA progression. This item is not to be used for the purposes of treatment planning or for monitoring after treatment.

(Anaes.)

63543

I5. MAG	19. SCAN OF BODY - FOR SPECIFIED NETIC RESONANCE IMAGING CONDITIONS
	(See para IN.0.18, IN.0.19 of explanatory notes to this Category) Fee: \$450.00 Benefit: 75% = \$337.50 85% = \$382.50
	Multiparametric Magnetic Resonance Imaging scan of the prostate for the assessment of cancer, if the patient is referred by an urologist, radiation oncologist, or medical oncologist and:
	the request for the scan identifies: (i) the patient is under active surveillance following a confirmed diagnosis of prostate cancer by biopsy histopathology; and (ii) the patient is not planning or undergoing treatment for prostate cancer. using a standardised image acquisition protocol involving T2 Weighted Imaging, Diffusion Weighted Imaging, and Dynamic Contrast Enhancement (unless contraindicated) (R) (NK)
	Note: Benefits are payable at the time of diagnosis of prostate cancer, 12 months following diagnosis and then every 3rd year thereafter or at any time, if there is a clinical concern, including PSA progression. This item is not to be used for the purposes of treatment planning or for monitoring after treatment (Anaes.)
63544	(See para IN.0.19, IN.0.18 of explanatory notes to this Category) Fee: \$225.00 Benefit: 75% = \$168.75 85% = \$191.25
	MRI scan of both breasts for the detection of cancer, if
	(a) a dedicated breast coil is used; and
	(b) the request for the scan identifies that:
	(i) the patient has a breast implant in situ; and
	(ii) anaplastic large cell lymphoma has been diagnosed
	NOTE: benefits are payable once in a patient's lifetime
	(R) (K) (Contrast) (Anaes.)
63547	(See para IN.0.18, IN.0.19 of explanatory notes to this Category) Fee: \$690.00 Benefit: 75% = \$517.50 85% = \$606.60
	MRI scan of both breasts for the detection of cancer, if
	(a) a dedicated breast coil is used; and
	(b) the request for the scan identifies that:
	(i) the patient has a breast implant in situ; and
	(ii) anaplastic large cell lymphoma has been diagnosed
63548	NOTE: benefits are payable once in a patient's lifetime (R) (NK) (Contrast) (Anaes.)

19. SCAN OF BODY - FOR SPECIFIED 15. MAGNETIC RESONANCE IMAGING CONDITIONS (See para IN.0.19, IN.0.18 of explanatory notes to this Category) **Benefit:** 75% = \$258.75 85% = \$293.25 Fee: \$345.00 20. SCAN OF PELVIS AND UPPER ABDOMEN 15. MAGNETIC RESONANCE IMAGING FOR SPECIFIED CONDITIONS Group I5. Magnetic Resonance Imaging Subgroup 20. Scan Of Pelvis And Upper Abdomen - For Specified Conditions NOTE: Benefits are payable for a service under items 63470 and 63473 on one occasion only. MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where: the patient is referred by a specialist or by a consultant physician and the request for scan identifies that (i) a histological diagnosis of carcinoma of the cervix has been made and (ii) the patient has been diagnosed with cervical cancer at FIGO stage 1B or greater Scan of: Pelvis for the staging of histologically diagnosed cervical cancer at FIGO stages 1B or greater (R) (Contrast) (Anaes.) (See para IN.0.19 of explanatory notes to this Category) 63470 Fee: \$403.20 **Benefit:** 75% = \$302.40 85% = \$342.75 Pelvis and upper abdomen, in a single examination, for the staging of histologically diagnosed cervical cancer at FIGO stages 1B or greater (R) (Contrast) (Anaes.) (See para IN.0.19 of explanatory notes to this Category) 63473 Fee: \$627.20 **Benefit:** 75% = \$470.40 85% = \$543.80 NOTE: benefits are payable for a service under item 63476 on one occasion only. MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician and where: a phased array body coil is used, and (a) the request for scan identifies that the indication is for the initial staging of rectal cancer (including cancer of the rectosigmoid and anorectum). Scan of: 63476

I5. MAG	20. SCAN OF PELVIS AND UPPER ABDOMEN - NETIC RESONANCE IMAGING FOR SPECIFIED CONDITIONS
	- Pelvis for the initial staging of rectal cancer (R) (contrast) (Anaes.)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	NOTE: Benefits are payable for a service included by Subgroup 20 on one occasion only.
	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where:
	(a) the patient is referred by a specialist or by a consultant physician and
	(b) the request for scan identifies that (i) a histological diagnosis of carcinoma of the cervix has been made and (ii) the patient has been diagnosed with cervical cancer at FIGO stage 1B or greater
	Scan of:
	- Pelvis for the staging of histologically diagnosed cervical cancer at FIGO stages 1B or greater (R) (NK) (Contrast) (Anaes.)
63479	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
	- Pelvis and upper abdomen, in a single examination, for the staging of histologically diagnosed cervical cancer at FIGO stages 1B or greater (R) (NK) (Contrast) (Anaes.)
63481	(See para IN.0.19 of explanatory notes to this Category) Fee: \$313.60 Benefit: 75% = \$235.20 85% = \$266.60
	NOTE: benefits are payable for a service included by Subgroup 20 on one occasion only.
	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician and where:
	(a) a phased array body coil is used, and
	(b) the request for scan identifies that the indication is for the initial staging of rectal cancer (including cancer of the rectosigmoid and anorectum).
	Scan of:
	- Pelvis for the initial staging of rectal cancer (R) (NK) (contrast) (Anaes.)
63484	(See para IN.0.19 of explanatory notes to this Category)

15. MAC	ONETIC RESONAL	NCE IMAGING	20. SCAN OF PELVIS AND UPPER ABDOMEN - FOR SPECIFIED CONDITIONS			
	Fee: \$201.60	Benefit: 75% = \$151.20	85% = \$171.40			
	MRI to evaluate service is provide		. Medicare benefits are only payable for this item if the			
	(a) Evaluation of	disease extent at time of init	tial diagnosis of Crohn's disease			
	(b) Evaluation of exacerbation/suspected complications of known Crohn's disease					
	(c) Evaluation of known or suspected Crohn's disease in pregnancy					
	(d) Assessment o	f change to therapy in patie	nts with small bowel Crohn's disease			
	Assessment of ch		claimed once in a 12 month period.			
63740	Fee: \$457.20	Benefit: 75% = \$342.90	950/ ₄ = \$388 65			
03/40		for Crohn's disease. Medica	are benefits are only payable for this item if the service is			
63741	Fee: \$265.25	Benefit: 75% = \$198.95	85% = \$225.50			
	MRI for fistulising service is provided		Medicare benefits are only payable for this item if the			
	- Evaluation of p	elvic sepsis and fistulas asso	ociated with established or suspected Crohn's disease			
	- Assessment of o	change to therapy of pelvis s	sepsis and fistulas from Crohn's disease			
	Assessment of ch	nange to therapy can only be	claimed once in a 12 month period.			
	(R) (K) (Contrast	<u>(</u>)				
63743	Fee: \$403.20	Benefit: 75% = \$302.40	85% = \$342.75			
	MRI to evaluate service is provide		. Medicare benefits are only payable for this item if the			
	(a) Evaluation of	disease extent at time of init	tial diagnosis of Crohn's disease			
	(b) Evaluation of	exacerbation/suspected com	nplications of known Crohn's disease			
	(c) Evaluation of	known or suspected Crohn's	s disease in pregnancy			
	(d) Assessment o	f change to therapy in patie	nts with small bowel Crohn's disease			
	Assessment of ch	ange to therapy can only be	claimed once in a 12 month period. (R) (NK) (Contrast)			
63744	Fee: \$228.60	Benefit: 75% = \$171.45	85% = \$194.35			
	MRI enteroclysis related to item 63		are benefits are only payable for this item if the service is			
63746	Fee: \$132.65	Benefit: 75% = \$99.50	85% = \$112.80			

15. MAG	20. SCAN OF PELVIS AND UPPER ABDOMEN - SNETIC RESONANCE IMAGING FOR SPECIFIED CONDITIONS
	MRI for fistulising perianal Crohn's disease. Medicare benefits are only payable for this item if the service is provided to patients for:
	- Evaluation of pelvic sepsis and fistulas associated with established or suspected Crohn's disease
	- Assessment of change to therapy of pelvis sepsis and fistulas from Crohn's disease
	Assessment of change to therapy can only be claimed once in a 12 month period. (R) (NK) (Contrast)
63747	Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
15. MAG	21. SCAN OF BODY - FOR SPECIFIED CONDITIONS
	Group I5. Magnetic Resonance Imaging
	Subgroup 21. Scan Of Body - For Specified Conditions
	NOTE: Benefits are only payable for each service included by Subgroup 21 on three occasions only in any 12 month period
	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of pancreas and biliary tree for:
	- suspected biliary or pancreatic pathology (R) (Anaes.)
63482	(See para IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	NOTE: Benefits are only payable for each service included by Subgroup 21 on three occasions only in any 12 month period
	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician - scan of pancreas and biliary tree for:
	- suspected biliary or pancreatic pathology (R) (NK) (Anaes.)
63486	(See para IN.0.19 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
I5. MAG	ENETIC RESONANCE IMAGING 22. MODIFYING ITEMS
	Group I5. Magnetic Resonance Imaging
	Subgroup 22. Modifying Items
	NOTE: Benefits in Subgroup 22 are only payable for modifying items where claimed simultaneously with MRI services. Modifiers for sedation and anaesthesia may not be claimed for the same service.
63491	

I5. MAG	ENETIC RESONANCE IMAGING	22. MODIFYING ITEMS
	Modifying items for use with MAGNETIC RESONANCE IMAGING or ANGIOGRAPHY performed under the professional supervision of an eli location where the service requested by a medical practitioner. Scan performance	gible provider at an eligible
	- involves the use of contrast agent for eligible Magnetic Resonance Imag denotes an item eligible for use with this item)	ging items (Note: (Contrast)
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$44.80 Benefit: 75% = \$33.60 85% = \$38.10	
	- involves use of intravenous or intramuscular sedation on a patient	
63494	(See para IN.0.19 of explanatory notes to this Category) Fee: \$44.80 Benefit: 75% = \$33.60 85% = \$38.10	
	- on a patient under anaesthetic in the presence of a medical practitioner canaesthetic	qualified to perform an
63497	(See para IN.0.19 of explanatory notes to this Category) Fee: \$156.80 Benefit: 75% = \$117.60 85% = \$133.30	
	MRI service to which item 63501, 63502, 63504 or 63505 applies if:	
	(a) the service is performed in accordance with the determination; and	
	(b) the service is performed on a person using intravenous or intra muscu	lar sedation
63498	(See para IN.0.19 of explanatory notes to this Category) Fee: \$44.80 Benefit: 75% = \$33.60 85% = \$38.10	
	MRI service to which item 63501, 63502, 63504 or 63505 applies if:	
	(a) the service is performed in accordance with the determination; and	
	(b) the service is performed on a person under anaesthetic in the presence is qualified to perform an anaesthetic.	of a medical practitioner who
63499	(See para IN.0.19 of explanatory notes to this Category) Fee: \$156.80 Benefit: 75% = \$117.60 85% = \$133.30	
I5. MAG	32. MAGNETIC R GNETIC RESONANCE IMAGING	ESONANCE IMAGING - PIP BREAST IMPLANT
	Group I5. Magnetic Resonance Imaging	
	Subgroup 32. Magnetic Resonance Imaging - Pip B	reast Implant
	MRI - scan of one or both breasts for the evaluation of implant integrity v	where:
	(a) a dedicated breast coil is used; and	
	(b) the request for the scan identifies that the patient:	
63501	(i) has or is suspected of having a silicone breast implant manufactured by and	y Poly Implant Prosthese (PIP);

I5. MAG	32. MAGNETIC RESONANCE IMAGING - PIP NETIC RESONANCE IMAGING BREAST IMPLANT
	(ii) the result of the scan confirms a loss of integrity of the implant (R)
	Note: Benefits are payable on one occasion only in any 12 Month Period
	(See para IN.0.19 of explanatory notes to this Category) Fee: \$500.00 Benefit: 75% = \$375.00 85% = \$425.00
	MRI - scan of one or both breasts for the evaluation of implant integrity where:
	(a) a dedicated breast coil is used; and
	(b) the request for the scan identifies that the patient:
	(i) has or is suspected of having a silicone breast implant manufactured by Poly Implant Prosthese (PIP); and
	(ii) the result of the scan does not demonstrate a loss of integrity of the implant (R)
	Note: Benefits are payable on one occasion only in any 12 Month Period
63502	(See para IN.0.19 of explanatory notes to this Category) Fee: \$500.00 Benefit: 75% = \$375.00 85% = \$425.00
	MRI - scan of one or both breasts for the evaluation of implant integrity where:
	(a) a dedicated breast coil is used; and
	(b) the request for the scan identifies that the patient:
	(i) has or is suspected of having a silicone breast implant manufactured by Poly Implant Prosthese (PIP); and
	(ii) presents with symptoms where implant rupture is suspected; and
	(iii) the result of the scan confirms a loss of integrity of the implant (R)
63504	(See para IN.0.19 of explanatory notes to this Category) Fee: \$500.00 Benefit: 75% = \$375.00 85% = \$425.00
	MRI - scan of one or both breasts for the evaluation of implant integrity where:
	(a) a dedicated breast coil is used; and
	(b) the request for the scan identifies that the patient:
	(i) has or is suspected of having a silicone breast implant manufactured by Poly Implant Prosthese (PIP); and
	(ii) presents with symptoms where implant rupture is suspected; and
	(iii) the result of the scan does not demonstrate a loss of integrity of the implant (R)
63505	(See para IN.0.19 of explanatory notes to this Category)

I5. MAGN	ETIC RESONA	NCE IMAGING	32. MAGNETIC RESONANCE IMAGING - PIP BREAST IMPLANT
	Fee: \$500.00	Benefit: 75% = \$375.00	85% = \$425.00
I5. MAGN	ETIC RESONA	NCE IMAGING	33. MAGNETIC RESONANCE IMAGING - FOR SPECIFIED CONDITIONS - PERSON UNDER THE AGE OF 16YRS
	Group I5. Magn	etic Resonance Imaging	
	Subgroup 33	3. Magnetic Resonance Imag	ing - For Specified Conditions - Person Under The Age Of 16yrs
		medical practitioner (exclude under 16 years for any of the	ling a specialist or consultant physician) for a scan of head e following:
	- unexplai	ned seizure(s) (R) (Contrast)	(Anaes.); or
	- unexplai	ned headache where significa	ant pathology is suspected (R) (Contrast) (Anaes.); or
	- paranasa (Anaes.		not responded to conservative therapy (R) (Contrast)
63507	(See para IN.0.18 Fee: \$403.20	of explanatory notes to this Cate Benefit: 75% = \$302.40	C 27
		medical practitioner (exclude under 16 years for any of the	ling a specialist or consultant physician) for a scan of head e following:
	- unexplai	ned seizure(s) (R) (NK) (Cor	ntrast) (Anaes.); or
	- unexplai	ned headache where significa	ant pathology is suspected (R) (NK) (Contrast) (Anaes.); or
	- paranasa (Anaes.		not responded to conservative therapy (R) (NK) (Contrast)
63508	(See para IN.0.18 Fee: \$201.60	of explanatory notes to this Cate Benefit: 75% = \$151.20	
		dical practitioner (excluding a years following radiographic	a specialist or consultant physician) for a scan of spine for a c examination for:
	- significa	nt trauma (R) (Contrast) (An	aes.); or
	- unexplai	ned neck or back pain with a	ssociated neurological signs (R) (Contrast) (Anaes.); or
	- unexplai	ned back pain where signific	ant pathology is suspected (R) (Contrast) (Anaes.)
63510	(See para IN.0.18 Fee: \$448.00	of explanatory notes to this Cate Benefit: 75% = \$336.00	
		lical practitioner (excluding a years following radiographic	a specialist or consultant physician) for a scan of spine for a c examination for:
	- significa	nt trauma (R) (NK) (Contras	t) (Anaes.); or
	- unexplai	ned neck or back pain with a	ssociated neurological signs (R) (NK) (Contrast) (Anaes.);
63511	-		

I5. MAGI	33. MAGNETIC RESONANCE IMAGING - FOR SPECIFIED CONDITIONS - PERSON UNDER THE NETIC RESONANCE IMAGING AGE OF 16YRS
	- unexplained back pain where significant pathology is suspected (R) (NK) (Contrast) (Anaes.)
	(See para IN.0.18 of explanatory notes to this Category) Fee: \$224.00 Benefit: 75% = \$168.00 85% = \$190.40
	MRI - referral by a medical practitioner (excluding a specialist or consultant physician) for a scan of knee for a patient aged under 16 years for internal joint derangement (R) (K) (Contrast) (Anaes.)
63513	(See para IN.0.19, IN.0.18 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	MRI - referral by a medical practitioner (excluding a specialist or consultant physician) for a scan of knee for a patient aged under 16 years for internal joint derangement (R) (NK) (Contrast) (Anaes.)
63514	(See para IN.0.18, IN.0.19 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
	referral by a medical practitioner (excluding a specialist or consultant physician) for a scan of hip for a patient under 16 years following radiographic examination for:
	- suspected septic arthritis (R) (Contrast) (Anaes.); or
	- suspected slipped capital femoral epiphysis (R) (Contrast) (Anaes.); or
	- suspected Perthes disease (R) (Contrast) (Anaes.)
63516	(See para IN.0.18 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	referral by a medical practitioner (excluding a specialist or consultant physician) for a scan of hip for a patient under 16 years following radiographic examination for:
	- suspected septic arthritis (R) (NK) (Contrast) (Anaes.); or
	- suspected slipped capital femoral epiphysis (R) (NK) (Contrast) (Anaes.); or
	- suspected Perthes disease (R) (NK) (Contrast) (Anaes.)
63517	(See para IN.0.18 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
	referral by a medical practitioner (excluding a specialist or consultant physician) for a scan of elbow for a patient under 16 years following radiographic examination where a significant fracture or avulsion injury is suspected that will change management (R) (Contrast) (Anaes.)
63519	(See para IN.0.18 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	referral by a medical practitioner (excluding a specialist or consultant physician) for a scan of elbow for a patient under 16 years following radiographic examination where a significant fracture or avulsion injury is suspected that will change management (R) (NK) (Contrast) (Anaes.)
63520	(See para IN.0.18 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
63522	referral by a medical practitioner (excluding a specialist or consultant physician) for a scan of wrist for a patient under 16 years following radiographic examination where scaphoid fracture is suspected (R) (Contrast) (Anaes.)

15. MAG	33. MAGNETIC RESONANCE IMAGING - FOR SPECIFIED CONDITIONS - PERSON UNDER THE ENETIC RESONANCE IMAGING AGE OF 16YRS
	(See para IN.0.18 of explanatory notes to this Category) Fee: \$448.00 Benefit: 75% = \$336.00 85% = \$380.80
	referral by a medical practitioner (excluding a specialist or consultant physician) for a scan of wrist for a patient under 16 years following radiographic examination where scaphoid fracture is suspected (R) (NK) (Contrast) (Anaes.)
63523	(See para IN.0.18 of explanatory notes to this Category) Fee: \$224.00 Benefit: 75% = \$168.00 85% = \$190.40
15. MAG	34. MAGNETIC RESONANCE IMAGING - FOR SPECIFIED CONDITIONS
	Group I5. Magnetic Resonance Imaging
	Subgroup 34. Magnetic Resonance Imaging - For Specified Conditions
	referral by a medical practitioner (excluding a specialist or consultant physician) for a scan of head for a patient 16 years or older for any of the following:
	- unexplained seizure(s) (R) (Contrast) (Anaes.) - unexplained chronic headache with suspected intracranial pathology (R) (Contrast) (Anaes.)
63551	(See para IN.0.18 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	referral by a medical practitioner (excluding a specialist or consultant physician) for a scan of head for a patient 16 years or older for any of the following:
	- unexplained seizure(s) (R) (NK) (Contrast) (Anaes.)
	- unexplained chronic headache with suspected intracranial pathology (R) (NK) (Contrast) (Anaes.)
63552	(See para IN.0.18 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
	referral by a medical practitioner (excluding a specialist or consultant physician) for a scan of spine for a patient 16 years or older for suspected:
	- cervical radiculopathy (R) (Contrast) (Anaes.)
63554	(See para IN.0.18 of explanatory notes to this Category) Fee: \$358.40 Benefit: 75% = \$268.80 85% = \$304.65
	referral by a medical practitioner (excluding a specialist or consultant physician) for a scan of spine for a patient 16 years or older for suspected:
63555	

I5. MAG	34. MAGNETIC RESONANCE IMAGING - FOR SPECIFIED CONDITIONS
	- cervical radiculopathy (R) (NK) (Contrast) (Anaes.)
	(See para IN.0.18 of explanatory notes to this Category) Fee: \$179.20 Benefit: 75% = \$134.40 85% = \$152.35
	referral by a medical practitioner (excluding a specialist or consultant physician) for a scan of spine for a patient 16 years or older for suspected:
	- cervical spine trauma (R) (Contrast) (Anaes.)
63557	(See para IN.0.18 of explanatory notes to this Category) Fee: \$492.80 Benefit: 75% = \$369.60 85% = \$418.90
	referral by a medical practitioner (excluding a specialist or consultant physician) for a scan of spine for a patient 16 years or older for suspected:
	- cervical spine trauma (R) (NK) (Contrast) (Anaes.)
63558	(See para IN.0.18 of explanatory notes to this Category) Fee: \$246.40 Benefit: 75% = \$184.80 85% = \$209.45
	MRI - scan of knee following acute knee trauma, after referral by a medical practitioner (other than a specialist or consultant physician), for a patient aged 16 to 49 years with:
	 inability to extend the knee suggesting the possibility of acute meniscal tear; or clinical findings suggesting acute anterior cruciate ligament tear.
	(R) (K) (Contrast) (Anaes.)
63560	(See para IN.0.18, IN.0.19 of explanatory notes to this Category) Fee: \$403.20 Benefit: 75% = \$302.40 85% = \$342.75
	MRI - scan of knee following acute knee trauma, after referral by a medical practitioner (other than a specialist or consultant physician), for a patient aged 16 to 49 years with:
	 inability to extend the knee suggesting the possibility of acute meniscal tear; or clinical findings suggesting acute anterior cruciate ligament tear.
	(R) (NK) (Contrast) (Anaes.)
63561	(See para IN.0.18, IN.0.19 of explanatory notes to this Category) Fee: \$201.60 Benefit: 75% = \$151.20 85% = \$171.40
I6. MAN	AGEMENT OF BULK-BILLED SERVICES
	Group I6. Management Of Bulk-Billed Services
64990	A diagnostic imaging service to which an item in this table (other than this item or item 64991) applies if:

16. MANAGEMENT OF BULK-BILLED SERVICES the service is an unreferred service; and the service is provided to a person who is under the age of 16 or is a Commonwealth concession card holder; the person is not an admitted patient of a hospital; and (d) the service is bulk-billed in respect of the fees for: (i) this item; and (ii) the other item in this table applying to the service (See para IN.0.19, IN.0.14 of explanatory notes to this Category) **Benefit:** 85% = \$6.00 Fee: \$7.05 A diagnostic imaging service to which an item in this table (other than this item or item 64990) applies if: the service is an unreferred service; and the service is provided to a person who is under the age of 16 or is a Commonwealth concession card holder; the person is not an admitted patient of a hospital; and (d) the service is bulk-billed in respect of the fees for: (i) this item; and (ii) the other item in this table applying to the service; and (e) the service is provided at, or from, a practice location in: (i) a regional, rural or remote area; or (ii) Tasmania; or (iii) A geographical area included in any of the following SSD spatial units: (A) Beaudesert Shire Part A (B) Belconnen (C) Darwin City (D) Eastern Outer Melbourne (E) East Metropolitan, Perth (F) Frankston City

64991

(G) Gosford-Wyong

(I) Gungahlin-Hall

Greater Geelong City Part A

16. MANAGEMENT OF BULK-BILLED SERVICES

- (J) Ipswich City (part in BSD)
- (K) Litchfield Shire
- (L) Melton-Wyndham
- (M) Mornington Peninsula Shire
- (N) Newcastle
- (O) North Canberra
- (P) Palmerston-East Arm
- (Q) Pine Rivers Shire
- (R) Queanbeyan
- (S) South Canberra
- (T) South Eastern Outer Melbourne
- (U) Southern Adelaide
- (V) South West Metropolitan, Perth
- (W) Thuringowa City Part A
- (X) Townsville City Part A
- (Y) Tuggeranong
- (Z) Weston Creek-Stromlo
- (ZA) Woden Valley
- (ZB) Yarra Ranges Shire Part A; or
- (iv) the geographical area included in the SLA spatial unit of Palm Island (AC)

(See para IN.0.19, IN.0.14 of explanatory notes to this Category)

Fee: \$10.65 **Benefit:** 85% = \$9.10

INDEX

			Α	
Abdomen, barium X-ray			58909	
Abdominal x-ray, plain		58900.	58903	
Air contrast study, with opaque enem	na		58921	
Air insufflation			59763	
Alimentary tract, x-ray of 58915-58916, 58921	58900, 58903,	, 58909,	58912	
Angiocardiography			59903	
Angiography, cerebral, preparation for	or		60918	
Angiography, coronary			59912	
Angiography, digital subtraction (DS	A)	60000	-60001	
60003-60004, 60006-60007, 60009				
60015-60016, 60018-60019, 60021				
60027-60028, 60030-60031, 60033				
60039-60040, 60042-60043, 60045				
60051-60052, 60054-60055, 60057-		60061		
60063-60064, 60066-60067, 60069			50050	
Angiography, with mobile image into		57504	59970	
Ankle, x-ray of	57518, 57521,	, 5/524,		
Antegrade pyelography	5750C 57500	57510	58715	
Arm, x-ray of Arteriogram - selective, preparation	57506, 57509,	, 3/312,	60927	
Arteriography			59912	
Arteriography or venography, selecti	ve	60072	-60073	
60075-60076, 60078-60079	VC	00072		
Arteriography, preparation for			60918	
Arteriography, selective			59912	
Arthrography			59751	
			В	
Barium, alimentary tract	58000	, 58912,	58015	
Biliary system, x-ray of		, 58912, , 58933,		
Bone, age study	36727,	, 50755,	58300	
Bowel - small, barium x-ray of		58912,		
Bowel - small, enema		,	58916	
Breast x-ray, excised tissue			59318	
Breast x-ray, restriction applies		59300,	59303	
Breast x-ray, with surgical procedure	:	59312,	59314	
Bronchography			59715	
Bulk-billing		64990	-64991	
			С	
Colombia coliment y may of			57918	
Calculus, salivary, x-ray of CBCT dental imaging		57362	57363-	
Cephalometry, x-ray		31302	57902	
Cerebral angiography, preparation fo	r		60918	
Cervical spine, x-ray of	1		58100	
Chest, x-ray of	58500, 58503,	58506		
Cholegraphy		, 58933,		
Clavicle, x-ray of			57709	
Coccyx, x-ray of		- ,	58109	
Colon, x-ray of		58912,	58921	
Computed Tomography of the colon			56555	
Computerised tomography, brain, ch	est and upper al	odomen	57001,	57007, 57041, 57047

Computerised tomography, facial bones 56022, 56028, 56062 56068 Computerised tomography, facial bones 56022, 56028, 56062 56068 Computerised tomography, head, brain 56001, 56007, 56041 56047 Computerised tomography, interventional technique 57341 57345 Computerised tomography, middle ear 56016, 56056 Computerised tomography, neck 56101, 56107, 56141, 56147 Computerised tomography, pelvimetry 57201, 57247 Computerised tomography, pelvimetry 57201, 57247 Computerised tomography, pelvimetry 57201, 57247 Computerised tomography, pelvis 56409, 56412, 56429, 56452 Computerised tomography, spine 56219-56221, 56223-56240 56259 Computerised tomography, spine 56219-56221, 5623-56240 56259 Computerised tomography, upper abdomen 56401, 56407, 56441 56447 Computerised tomography, upper abdomen \$6401, 56407, 56441 56541, 56547 Computerised tomography, thest, abdomen, pelvis, neck 56801 56807, 56841, 56847 Computerised tomography, selective 59912 Cysto-urethrography, retrograde micturating 58721 Cysto-graphy 59703 Dacryocystography 59703 Defaccogram 58939 Digits & phalanges 57506, 57509, 57512, 57515, 57518, 57521 57524, 57527 Discography 59700 Dudenum, barium x-ray of 58909, 58912 Duplex scanning, of addominal aorta, arteries, iliac arteries and veins 55276 Duplex scanning, of arteries/grafts lower limb 55238 Duplex scanning, of arteries/grafts lower limb 55248 Duplex scanning, of penis, cavernosal tissue 55280 Duplex scanning, of penis, cavernosal artery 55282 Duplex scanning, of penis, cavernosal artery 55282 Duplex scanning, of penis, cavernosal artery 55282 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning,	Computerised tomography, chest and upper abdomer 56307, 56341, 56347	1	56301
Computerised tomography, facial bones 56022, 56028, 56062 56068 Computerised tomography, head, brain 56001, 56007, 56041 56047 Computerised tomography, interventional technique 57341 57345 Computerised tomography, middle ear 56016, 56056 Computerised tomography, neck 56101, 56107, 56141, 56147 Computerised tomography, orbits 56013, 56053 Computerised tomography, pelvimetry 57201, 57247 Computerised tomography, plevimetry 57201, 57247 Computerised tomography, pituitary fossa 56010, 56050 Computerised tomography, spiral orbital formulation of 56010, 56050 Computerised tomography, spiral angiography 57350-57351 57355-57356 Computerised tomography, upper abdomen 56401, 56407, 56441 56447 Computerised tomography, upper abdomen & pelvis 56501, 56507 56541, 56547 Computerised tomography, thest, abdomen, pelvis, neck 56801 56807, 56841, 56847 Computerised tomography, selective 59912 Cysto-urethrography, retrograde micturating 58721 Cystography, retrograde micturating 58721 Cystography, retrograde micturating 58721 Digits & phalanges 57506, 57509, 57512, 57515, 57518, 57521 57524, 57527 Discography 59700 Duodenum, barium x-ray of 58909, 58912 Duplex scanning, of atteries/grafts lower limb 55238 Duplex scanning, of atteries/grafts upper limb 55248 Duplex scanning, of remal/visceral vessels 55246 Duplex scanning, of penis, cavernosal artery 55282 Duplex scanning, of penis, cavernosal artery 55282 Duplex scanning, of penis, cavernosal artery 55282 Duplex scanning, of penis, cavernosal artery 55282 Duplex scanning, of penis, cavernosal artery 55282 Duplex scanning, of penis, cavernosal tissue 55246 Duplex scanning, of penis, cavernosal artery 55282 Duplex scanning, of penis, cavernosal artery 55282 Duplex scanning, of penis cavernosal artery 55282 Duplex scanning, of penis, cavernosal artery 55284 Duplex scanning, of penis penis lower limb, venous thrombrosis 55244 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, of veins lower limb, venous thrombrosis 55245 Duplex scanning, of penis cavernosa	Computerised tomography, coronary arteries	57360-	57361
56047 Computerised tomography, interventional technique 57341 57345 Computerised tomography, middle ear 56016, 56056 Computerised tomography, neck 56101, 56107, 56141, 56147 Computerised tomography, orbits 56013, 56053 Computerised tomography, pelvimetry 57201, 57247 Computerised tomography, pelvimetry 57201, 57247 Computerised tomography, pituitary fossa 56010, 56050 Computerised tomography, spine 56219-56221, 56223-56240 56259 Computerised tomography, spine 56219-56221, 56223-56240 56259 Computerised tomography, spine angiography 57350-57351 57355-57356 Computerised tomography, upper abdomen 56407, 56441 56447 Computerised tomography, upper abdomen & pelvis, neck 56801 56807, 56541, 56547 Computerised tomography, chest, abdomen, pelvis, neck 56801 56807, 56841, 56847 Computerised tomography, spine angiography 69918 Cornary arteriography, retrograde micturating 58721 Cysto-urethrography, retrograde micturating 58721 Cysto-graphy, retrograde micturating 58721 Cysto-graphy	Computerised tomography, facial bones 56022,	56028,	56062
S7345		56007,	56041
Computerised tomography, neck Computerised tomography, orbits Computerised tomography, pelvimetry Computerised tomography, pelvimetry Computerised tomography, pelvimetry Sosa Source So			57341
Computerised tomography, neck Computerised tomography, orbits Computerised tomography, pelvimetry Computerised tomography, pelvimetry Computerised tomography, pelvimetry Sosa Source So	Computerised tomography, middle ear	56016,	56056
Computerised tomography, orbits Computerised tomography, pelvimetry Computerised tomography, pelvimetry Computerised tomography, pivis S6409, 56412, 56449, 56452 Computerised tomography, pituitary fossa S6010, 56050 Computerised tomography, spine S6219-56221, 56223-56240 56259 Computerised tomography, spiral angiography S7350-57351 S7355-S7356 Computerised tomography, upper abdomen S6401, 56407, 56441 S6447 Computerised tomography, upper abdomen & pelvis 56501, 56507 S6541, 56547 Computerised tomography, upper abdomen & pelvis 56501, 56507 S6541, 56847 Computerised tomography, ehest, abdomen, pelvis, neck S6801 S6807, 56841, 56847 Computerised tomography, ehest, abdomen, pelvis, neck S6801 S6807, 56841, 56847 Computerised tomography, selective S9912 Cysto-urethrography, retrograde micturating S8721 Cystography, retrograde S8718 D D Dacryocystography S9703 Defaecogram S8909 Digits & phalanges S7506, 57509, 57512, 57515, 57518, 57521 S7524, 57527 Discography S9700 Duodenum, barium x-ray of S8909, 58912 Duplex scanning, carotid and vertebral vessels S5274 Duplex scanning, of abdominal aorta, arteries, iliac arteries and veins 55276 Duplex scanning, of arteries/grafts lower limb S5238 Duplex scanning, of arteries/grafts upper limb Duplex scanning, of intra-cranial vessels S5280 Duplex scanning, of veins lower limb, venous disease S5280 Duplex scanning, of veins lower limb, venous thrombrosis S5278 Duplex scanning, of veins lower limb, venous thrombrosis S5244 Duplex scanning, of veins lower limb, venous thrombrosis S5244 Duplex scanning, of veins lower limb, venous thrombrosis S5244 Duplex scanning, of veins lower limb, venous thrombrosis S5244 Duplex scanning, of veins lower limb, venous thrombrosis S5244 Duplex scanning, of veins lower limb, venous thrombrosis S5245 Duplex scanning, of veins lower limb, venous thrombrosis S5246 Duplex scanning, of veins lower limb, venous thrombrosis S5245 Duplex scanning, of veins lower limb, venous thrombrosis S5246 Duplex scanning, of veins lower limb, venous thrombrosis S524		56141,	56147
Computerised tomography, pelvimetry 57201, 57247 Computerised tomography, pelvis 56409, 56412, 56449, 56452 Computerised tomography, pituitary fossa 56010, 56050 Computerised tomography, spine 56219-56221, 56223-56240 56259 Computerised tomography, spiral angiography 57350-57351 57355-57356 Computerised tomography, upper abdomen 56401, 56407, 56441 56447 Computerised tomography, upper abdomen & pelvis 56501, 56507 56541, 56547 Computerised tomography, chest, abdomen, pelvis, neck 56801 56807, 56841, 56847 Contrast media, intro for radiology 60918 Coronary arteriography, selective 59912 Cysto-urethrography, retrograde micturating 58721 Cystography, retrograde 58718 D D Dacryocystography 59703 Defaecogram 58939 Digits & phalanges 57506, 57509, 57512, 57515, 57518, 57521 57524, 57527 Discography 59700 Duodenum, barium x-ray of 58909, 58912 Duplex scanning, carotid and vertebral vessels 55274 Duplex scanning, of abdominal aorta, arteries, iliac arteries and veins 55238 Duplex scanning, of arteries/grafts upper limb 55248 Duplex scanning, of penis, cavernosal artery 55282 Duplex scanning, of penis, cavernosal artery 55282 Duplex scanning, of renal/visceral vessels 55278 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of veins lower limb, venous thrombrosis 55246 Duplex scanning, of veins lower limb, venous thrombrosis 55246 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, of spenis, cavernosal tissue 55252 E Echocardiographic, exam of heart 55113-55118, 55130, 55135 Echography, ultrasonic 55028-55033, 55036-55039, 55048-55049 55054, 55070, 55073, 55076, 55079, 55084-55085 55113-55118			
Computerised tomography, pelvis 56409, 56412, 56449, 56452 Computerised tomography, pituitary fossa 56010, 56050 Computerised tomography, spine 56219-56221, 56223-56240 56259 Computerised tomography, spiral angiography 57350-57351 57355-57356 Computerised tomography, upper abdomen 56401, 56407, 56441 56447 Computerised tomography, upper abdomen & pelvis 56501, 56507 56541, 56547 Computerised tomography, chest, abdomen, pelvis, neck 56801 56807, 56841, 56847 Computerised tomography, chest, abdomen, pelvis, neck 56801 56807, 56841, 56847 Contrast media, intro for radiology 60918 Coronary arteriography, selective 59912 Cysto-urethrography, retrograde micturating 58721 Cystography, retrograde 58718 D D Dacryocystography 59703 Defaecogram 58939 Digits & phalanges 57506, 57509, 57512, 57515, 57518, 57521 57524, 57527 Discography 59700 Duodenum, barium x-ray of 58909, 58912 Duplex scanning, of abdominal aorta, arteries, iliac arteries and veins 55276 Duplex scanning, of arteries/grafts lower limb 55238 Duplex scanning, of arteries/grafts upper limb 55248 Duplex scanning, of penis, cavernosal artery 55282 Duplex scanning, of penis, cavernosal artery 55282 Duplex scanning, of penis, cavernosal artery 55282 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of veins lower limb, venous thrombrosis 55246 Duplex scanning, of veins lower limb, venous thrombrosis 55246 Duplex scanning, of veins lower limb, venous thrombrosis 55246 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, of veins lower limb, venous thrombrosis 55246 Duplex scanning, of veins lower limb, venous thrombrosis 55246 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, of 55028-55033, 55036-55039, 55048-55049 55054, 55070, 55073, 55076, 55079, 55084-55085 55113-55118			
Computerised tomography, pituitary fossa 56010, 56050 Computerised tomography, spine 56219-56221, 56223-56240 56259 Computerised tomography, spiral angiography 57350-57351 57355-57356 Computerised tomography, upper abdomen 56401, 56407, 56441 56447 Computerised tomography, upper abdomen & pelvis 56501, 56507 56541, 56547 Computerised tomography, chest, abdomen, pelvis, neck 56801 56807, 56841, 56847 Contrast media, intro for radiology 60918 Coronary arteriography, selective 59912 Cysto-urethrography, retrograde micturating 58721 Cystography, retrograde 58718 D D Dacryocystography 59703 Defaecogram 58939 Digits & phalanges 57506, 57509, 57512, 57515, 57518, 57521 57524, 57527 Discography 59700 Duodenum, barium x-ray of 58909, 58912 Duplex scanning, carotid and vertebral vessels 55274 Duplex scanning, of atteries/grafts lower limb 55238 Duplex scanning, of arteries/grafts upper limb 55248 Duplex scanning, of fernis, cavernosal tissue 55280 Duplex scanning, of penis, cavernosal tissue 55284 Duplex scanning, of renal/visceral vessels 55278 Duplex scanning, of veins lower limb, venous disease 5246 Duplex scanning, of veins lower limb, venous thrombrosis 55246 Duplex scanning, of veins lower limb, venous thrombrosis 55246 Duplex scanning, of steries/grafts upper limb 55224 Duplex scanning, of renal/visceral vessels 55278 Duplex scanning, of steries/grafts lower limb, venous thrombrosis 55246 Duplex scanning, of steries/grafts lower limb, venous thrombrosis 55246 Duplex scanning, of steries/grafts lower limb, venous thrombrosis 55246 Duplex scanning, of steries/grafts lower limb, venous thrombrosis 55246 Duplex scanning, of steries/grafts lower limb, venous thrombrosis 55246 Duplex scanning, of steries/grafts sower limb, venous thrombrosis 55246 Duplex scanning, of steries/sceral vessels 55278 Duplex scanning, of steries/sceral vessels 55252 E Echocardiographic, exam of heart 55113-55118, 55130, 55135 Echography, ultrasonic 55028-55033, 55036-55039, 55048-55049 55054, 55070, 55073, 55076, 55079, 55084-55085 55113			
Computerised tomography, spine 56219-56221, 56223-56240 56259 Computerised tomography, spiral angiography 57350-57351 57355-57356 Computerised tomography, upper abdomen 56401, 56407, 56441 56447 Computerised tomography, upper abdomen & pelvis 56501, 56507 56541, 56547 Computerised tomography, chest, abdomen, pelvis, neck 56801 56807, 56841, 56847 Computerised tomography, chest, abdomen, pelvis, neck 56801 56807, 56841, 56847 Contrast media, intro for radiology 60918 Coronary arteriography, selective 59912 Cysto-urethrography, retrograde micturating 58721 Cystography, retrograde 58718 D D Dacryocystography 59703 Defaecogram 58939 Digits & phalanges 57506, 57509, 57512, 57515, 57518, 57521 57524, 57527 Discography 59700 Duodenum, barium x-ray of 58909, 58912 Duplex scanning, carotid and vertebral vessels 55274 Duplex scanning, of abdominal aorta, arteries, iliac arteries and veins 55276 Duplex scanning, of arteries/grafts lower limb 55238 Duplex scanning, of arteries/grafts upper limb 55248 Duplex scanning, of penis, cavernosal artery 55282 Duplex scanning, of penis, cavernosal artery 55282 Duplex scanning, of penis, cavernosal tissue 55284 Duplex scanning, of veins lower limb, venous disease 5246 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, veins upper limb 55252 E Echocardiographic, exam of heart 55113-55118, 55130, 55135 Echography, ultrasonic 55028-55033, 55036-55039, 55048-55049 55054, 55070, 55073, 55076, 55079, 55084-55085 55113-55118			
57355-57356 Computerised tomography, upper abdomen 56401, 56407, 56441 56447 Computerised tomography, upper abdomen & pelvis 56501, 56507 56541, 56547 Computerised tomography, chest, abdomen, pelvis, neck 56801 56807, 56841, 56847 Contrast media, intro for radiology 60918 Coronary arteriography, selective 59912 Cysto-urethrography, retrograde micturating 58721 Cystography, retrograde 58718 D D Dacryocystography 59703 Defaecogram 58939 Digits & phalanges 57506, 57509, 57512, 57515, 57518, 57521 57524, 57527 Discography 59700 Duodenum, barium x-ray of 58909, 58912 Duplex scanning, carotid and vertebral vessels 55274 Duplex scanning, of abdominal aorta, arteries, iliac arteries and veins 55238 Duplex scanning, of arteries/grafts lower limb 55248 Duplex scanning, of arteries/grafts upper limb 55248 Duplex scanning, of penis, cavernosal trery 55282 Duplex scanning, of penis, cavernosal trery 55282 Duplex scanning, of penis, cavernosal tissue 55284 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, of seins lower limb, venous thrombrosis 55244 Duplex scanning, of seins lower limb, venous thrombrosis 55244 Duplex scanning, veins upper limb 55252 E Echocardiographic, exam of heart 55113-55118, 55130, 55135 Echography, ultrasonic 55028-55033, 55036-55039, 55048-55049 55054, 55070, 55073, 55076, 55079, 55084-55085 55113-55118	Computerised tomography, spine 56219-56221,		
Computerised tomography, upper abdomen & pelvis 56501, 56507 56541, 56547 Computerised tomography, chest, abdomen, pelvis, neck 56801, 56841, 56847 Contrast media, intro for radiology Coronary arteriography, selective Cysto-urethrography, retrograde micturating Cystography, retrograde D Dacryocystography Sefaccogram Segage Digits & phalanges S7506, 57509, 57512, 57515, 57518, 57521 S7524, 57527 Discography Segage Duplex scanning, carotid and vertebral vessels Duplex scanning, of abdominal aorta, arteries, iliac arteries and veins 55274 Duplex scanning, of arteries/grafts lower limb S5238 Duplex scanning, of arteries/grafts upper limb Duplex scanning, of penis, cavernosal trisue Duplex scanning, of penis, cavernosal trisue S5284 Duplex scanning, of renal/visceral vessels S5278 Duplex scanning, of veins lower limb, venous disease Duplex scanning, of veins lower limb, venous disease S5246 Duplex scanning, of veins lower limb, venous disease S5246 Duplex scanning, of veins lower limb, venous thrombrosis S5246 Duplex scanning, of veins lower limb, venous disease S5246 Duplex scanning, of veins lower limb, venous thrombrosis S5244 Duplex scanning, of veins lower limb, venous disease S5246 Duplex scanning, of veins lower limb, venous thrombrosis S5244 Duplex scanning, of veins lower limb, venous disease S5246 Duplex scanning, of veins lower limb, venous disease S5246 Duplex scanning, of veins lower limb, venous disease S5246 Duplex scanning, of veins lower limb, venous disease S5246 Duplex scanning, of veins lower limb, venous disease S5246 Duplex scanning, of veins lower limb, venous disease S5246 Duplex scanning, of veins lower limb, venous disease S5246 Duplex scanning, of veins lower limb, venous disease S5246 Duplex scanning, of veins lower limb, venous disease S5246 Duplex scanning, of veins lower limb, venous disease S5246 Duplex scanning, of veins lower limb, venous disease S5246 Diplex scanning, of veins lower limb, venous disease S5246 Diplex scanning, of veins lower limb, venous disease S5246 Diplex sca		57350-	57351
Computerised tomography, chest, abdomen, pelvis, neck 56801 56807, 56841, 56847 Contrast media, intro for radiology 60918 Coronary arteriography, selective 59912 Cysto-urethrography, retrograde micturating 58721 Cystography, retrograde 58718 D Dacryocystography 59703 Defaecogram 58939 Digits & phalanges 57506, 57509, 57512, 57515, 57518, 57521 57524, 57527 Discography 59700 Duodenum, barium x-ray of 58909, 58912 Duplex scanning, carotid and vertebral vessels 55274 Duplex scanning, of addominal aorta, arteries, iliac arteries and veins 55276 Duplex scanning, of arteries/grafts lower limb 55238 Duplex scanning, of arteries/grafts upper limb 55248 Duplex scanning, of penis, cavernosal artery 55282 Duplex scanning, of penis, cavernosal artery 55284 Duplex scanning, of renal/visceral vessels 55274 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of venous disease 55246 Duplex scanning, of venous disease 55246 Duplex scanning, of ve	Computerised tomography, upper abdomen 56401,	56407,	56441
Contrast media, intro for radiology Coronary arteriography, selective Cysto-urethrography, retrograde micturating Cystography, retrograde B D Dacryocystography Defaecogram Digits & phalanges S7506, 57509, 57512, 57515, 57518, 57521 S7524, 57527 Discography Duodenum, barium x-ray of Duplex scanning, carotid and vertebral vessels Duplex scanning, of arteries/grafts lower limb Duplex scanning, of arteries/grafts upper limb Duplex scanning, of penis, cavernosal artery Duplex scanning, of penis, cavernosal tissue Duplex scanning, of penis, cavernosal tissue Duplex scanning, of renal/visceral vessels Duplex scanning, of veins lower limb, venous disease Duplex scanning, of veins lower limb, venous disease Duplex scanning, of veins lower limb, venous thrombrosis Duplex scanning, of veins lower limb, venous thrombrosis Duplex scanning, veins upper limb S5248 Duplex scanning, of veins lower limb, venous thrombrosis Duplex scanning, veins upper limb S5252 E Echocardiographic, exam of heart S5113-55118, 55130, 55135 Echography, ultrasonic S5028-55033, 55036-55039, 55048-55049 S5054, 55070, 55073, 55076, 55079, 55084-55085 S5113-55118		56501,	56507
Contrast media, intro for radiology Coronary arteriography, selective Cysto-urethrography, retrograde micturating Cystography, retrograde B D Dacryocystography Defaecogram S8939 Digits & phalanges S7506, 57509, 57512, 57515, 57518, 57521 S7524, 57527 Discography S9700 Duodenum, barium x-ray of Duplex scanning, carotid and vertebral vessels S5274 Duplex scanning, of abdominal aorta, arteries, iliac arteries and veins 55276 Duplex scanning, of arteries/grafts lower limb S5238 Duplex scanning, of firtra-cranial vessels S5248 Duplex scanning, of penis, cavernosal artery Duplex scanning, of penis, cavernosal tissue S5284 Duplex scanning, of renal/visceral vessels S5284 Duplex scanning, of veins lower limb, venous disease S5246 Duplex scanning, of veins lower limb, venous thrombrosis S5244 Duplex scanning, of veins lower limb, venous thrombrosis S5244 Duplex scanning, of veins lower limb, venous thrombrosis S5244 Duplex scanning, of veins lower limb, venous thrombrosis S5244 Duplex scanning, of veins lower limb, venous thrombrosis S5244 Duplex scanning, of solower limb, venous thrombrosis S5244 Duplex scanning, veins upper limb E Echocardiographic, exam of heart S5113-55118, 55130, 55135 Echography, ultrasonic S5028-55033, 55036-55039, 55048-55049 S5054, 55070, 55073, 55076, 55079, 55084-55085 S5113-55118		eck	56801
Coronary arteriography, selective Cysto-urethrography, retrograde micturating Cystography, retrograde D D Dacryocystography Defaecogram Digits & phalanges S7506, 57509, 57512, 57515, 57518, 57521 S7524, 57527 Discography Duodenum, barium x-ray of Duplex scanning, carotid and vertebral vessels S5274 Duplex scanning, of abdominal aorta, arteries, iliac arteries and veins 55276 Duplex scanning, of arteries/grafts lower limb S5238 Duplex scanning, of arteries/grafts upper limb Duplex scanning, of intra-cranial vessels S5280 Duplex scanning, of penis, cavernosal artery Duplex scanning, of penis, cavernosal tissue S5284 Duplex scanning, of renal/visceral vessels S5278 Duplex scanning, of veins lower limb, venous disease Duplex scanning, of veins lower limb, venous disease Duplex scanning, of veins lower limb, venous thrombrosis S5244 Duplex scanning, veins upper limb S5252 E Echocardiographic, exam of heart S5113-55118, 55130, 55135 Echography, ultrasonic S5028-55033, 55036-55039, 55048-55049 S5054, 55070, 55073, 55076, 55079, 55084-55085 S5113-55118			60918
Cystography, retrograde micturating Cystography, retrograde D Dacryocystography Defaecogram Digits & phalanges S7506, 57509, 57512, 57515, 57518, 57521 S7524, 57527 Discography Duodenum, barium x-ray of Duplex scanning, carotid and vertebral vessels S5274 Duplex scanning, of abdominal aorta, arteries, iliac arteries and veins 55276 Duplex scanning, of arteries/grafts lower limb S5238 Duplex scanning, of arteries/grafts upper limb Duplex scanning, of intra-cranial vessels S5280 Duplex scanning, of penis, cavernosal artery Duplex scanning, of penis, cavernosal tissue S5284 Duplex scanning, of renal/visceral vessels S5278 Duplex scanning, of veins lower limb, venous disease Duplex scanning, of veins lower limb, venous disease Duplex scanning, of veins lower limb, venous thrombrosis S5244 Duplex scanning, veins upper limb S5252 E Echocardiographic, exam of heart S5113-55118, 55130, 55135 Echography, ultrasonic S5028-55033, 55036-55039, 55048-55049 S5054, 55070, 55073, 55076, 55079, 55084-55085 S5113-55118			59912
Dacryocystography	Cysto-urethrography, retrograde micturating		58721
Dacryocystography 59703 Defaecogram 58939 Digits & phalanges 57506, 57509, 57512, 57515, 57518, 57521 57524, 57527 Discography 59700 Duodenum, barium x-ray of 58909, 58912 Duplex scanning, carotid and vertebral vessels 55274 Duplex scanning, of abdominal aorta, arteries, iliac arteries and veins 55276 Duplex scanning, of arteries/grafts lower limb 55238 Duplex scanning, of arteries/grafts upper limb 55248 Duplex scanning, of intra-cranial vessels 55280 Duplex scanning, of penis, cavernosal artery 55282 Duplex scanning, of penis, cavernosal tissue 55284 Duplex scanning, of renal/visceral vessels 55278 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, veins upper limb 55252 E Echocardiographic, exam of heart 55113-55118, 55130, 55135 Echography, ultrasonic 55028-55033, 55036-55039, 55048-55049 55054, 55070, 55073, 55076, 55079, 55084-55085 55113-55118			50710
Defaecogram 58939 Digits & phalanges 57506, 57509, 57512, 57515, 57518, 57521 57524, 57527 Discography 59700 Duodenum, barium x-ray of 58909, 58912 Duplex scanning, carotid and vertebral vessels 55274 Duplex scanning, of abdominal aorta, arteries, iliac arteries and veins 55276 Duplex scanning, of arteries/grafts lower limb 55238 Duplex scanning, of arteries/grafts upper limb 55248 Duplex scanning, of intra-cranial vessels 55280 Duplex scanning, of penis, cavernosal artery 55282 Duplex scanning, of penis, cavernosal tissue 55284 Duplex scanning, of renal/visceral vessels 55278 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, veins upper limb 55252 E Echocardiographic, exam of heart 55113-55118, 55130, 55135 Echography, ultrasonic 55028-55033, 55036-55039, 55048-55049 55054, 55070, 55073, 55076, 55079, 55084-55085 55113-55118			58/18
Defaecogram 58939 Digits & phalanges 57506, 57509, 57512, 57515, 57518, 57521 57524, 57527 Discography 59700 Duodenum, barium x-ray of 58909, 58912 Duplex scanning, carotid and vertebral vessels 55274 Duplex scanning, of abdominal aorta, arteries, iliac arteries and veins 55276 Duplex scanning, of arteries/grafts lower limb 55238 Duplex scanning, of arteries/grafts upper limb 55248 Duplex scanning, of intra-cranial vessels 55280 Duplex scanning, of penis, cavernosal artery 55282 Duplex scanning, of penis, cavernosal tissue 55284 Duplex scanning, of renal/visceral vessels 55278 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, veins upper limb 55252 E Echocardiographic, exam of heart 55113-55118, 55130, 55135 Echography, ultrasonic 55028-55033, 55036-55039, 55048-55049 55054, 55070, 55073, 55076, 55079, 55084-55085 55113-55118			
Digits & phalanges 57506, 57509, 57512, 57515, 57518, 57521 57524, 57527 59700 Discography 59700 Duodenum, barium x-ray of 58909, 58912 Duplex scanning, carotid and vertebral vessels 55274 Duplex scanning, of abdominal aorta, arteries, iliac arteries and veins 55276 55238 Duplex scanning, of arteries/grafts lower limb 55238 Duplex scanning, of arteries/grafts upper limb 55248 Duplex scanning, of intra-cranial vessels 55280 Duplex scanning, of penis, cavernosal artery 55282 Duplex scanning, of penis, cavernosal tissue 55284 Duplex scanning, of veins lower limb, venous disease 55278 Duplex scanning, of veins lower limb, venous thrombrosis 55246 Duplex scanning, veins upper limb 55252 E Echocardiographic, exam of heart 55113-55118, 55130, 55135 Echography, ultrasonic 55028-55033, 55036-55039, 55048-55049 55054, 55070, 55073, 55076, 55079, 55084-55085 55113-55118			D
Duodenum, barium x-ray of 58909, 58912 Duplex scanning, carotid and vertebral vessels 55274 Duplex scanning, of abdominal aorta, arteries, iliac arteries and veins 55276 Duplex scanning, of arteries/grafts lower limb 55238 Duplex scanning, of arteries/grafts upper limb 55248 Duplex scanning, of intra-cranial vessels 55280 Duplex scanning, of penis, cavernosal artery 55282 Duplex scanning, of penis, cavernosal tissue 55284 Duplex scanning, of renal/visceral vessels 55278 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, veins upper limb 55252 E Echocardiographic, exam of heart 55113-55118, 55130, 55135 Echography, ultrasonic 55028-55033, 55036-55039, 55048-55049 55054, 55070, 55073, 55076, 55079, 55084-55085 55113-55118	Dacryocystography		D 59703
Duplex scanning, carotid and vertebral vessels Duplex scanning, of abdominal aorta, arteries, iliac arteries and veins 55276 Duplex scanning, of arteries/grafts lower limb Duplex scanning, of arteries/grafts upper limb Duplex scanning, of intra-cranial vessels Duplex scanning, of penis, cavernosal artery Duplex scanning, of penis, cavernosal tissue Duplex scanning, of renal/visceral vessels Duplex scanning, of veins lower limb, venous disease Duplex scanning, of veins lower limb, venous thrombrosis Duplex scanning, of veins upper limb E Echocardiographic, exam of heart 55113-55118, 55130, 55135 Echography, ultrasonic 55028-55033, 55036-55039, 55048-55049 55054, 55070, 55073, 55076, 55079, 55084-55085 55113-55118	Dacryocystography Defaecogram Digits & phalanges 57506, 57509, 57512, 57515,	57518,	D 59703 58939
Duplex scanning, of abdominal aorta, arteries, iliac arteries and veins 55276 Duplex scanning, of arteries/grafts lower limb 55238 Duplex scanning, of arteries/grafts upper limb 55248 Duplex scanning, of intra-cranial vessels 55280 Duplex scanning, of penis, cavernosal artery 55282 Duplex scanning, of penis, cavernosal tissue 55284 Duplex scanning, of renal/visceral vessels 55278 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, veins upper limb 55252 E Echocardiographic, exam of heart 55113-55118, 55130, 55135 Echography, ultrasonic 55028-55033, 55036-55039, 55048-55049 55054, 55070, 55073, 55076, 55079, 55084-55085 55113-55118	Dacryocystography Defaecogram Digits & phalanges 57524, 57527 57524, 57527		D 59703 58939 57521 59700
Duplex scanning, of abdominal aorta, arteries, iliac arteries and veins 55276 Duplex scanning, of arteries/grafts lower limb 55238 Duplex scanning, of arteries/grafts upper limb 55248 Duplex scanning, of intra-cranial vessels 55280 Duplex scanning, of penis, cavernosal artery 55282 Duplex scanning, of penis, cavernosal tissue 55284 Duplex scanning, of renal/visceral vessels 55278 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, veins upper limb 55252 E Echocardiographic, exam of heart 55113-55118, 55130, 55135 Echography, ultrasonic 55028-55033, 55036-55039, 55048-55049 55054, 55070, 55073, 55076, 55079, 55084-55085 55113-55118	Dacryocystography Defaecogram Digits & phalanges 57524, 57527 Discography 57506, 57509, 57512, 57515,		D 59703 58939 57521 59700
Duplex scanning, of arteries/grafts lower limb Duplex scanning, of arteries/grafts upper limb Duplex scanning, of intra-cranial vessels Duplex scanning, of penis, cavernosal artery Duplex scanning, of penis, cavernosal tissue Duplex scanning, of penis, cavernosal tissue Duplex scanning, of renal/visceral vessels Duplex scanning, of veins lower limb, venous disease Duplex scanning, of veins lower limb, venous thrombrosis Duplex scanning, veins upper limb E Echocardiographic, exam of heart 55113-55118, 55130, 55135 Echography, ultrasonic 55028-55033, 55036-55039, 55048-55049 55054, 55070, 55073, 55076, 55079, 55084-55085 55113-55118	Dacryocystography Defaecogram Digits & phalanges 57506, 57509, 57512, 57515, 57524, 57527 Discography Duodenum, barium x-ray of		D 59703 58939 57521 59700 58912
Duplex scanning, of arteries/grafts upper limb Duplex scanning, of intra-cranial vessels Duplex scanning, of penis, cavernosal artery Duplex scanning, of penis, cavernosal tissue Duplex scanning, of penis, cavernosal tissue Duplex scanning, of renal/visceral vessels Duplex scanning, of veins lower limb, venous disease Duplex scanning, of veins lower limb, venous thrombrosis Duplex scanning, veins upper limb E Echocardiographic, exam of heart 55113-55118, 55130, 55135 Echography, ultrasonic 55028-55033, 55036-55039, 55048-55049 55054, 55070, 55073, 55076, 55079, 55084-55085 55113-55118	Dacryocystography Defaecogram Digits & phalanges 57506, 57509, 57512, 57515, 57524, 57527 Discography Duodenum, barium x-ray of Duplex scanning, carotid and vertebral vessels	58909,	D 59703 58939 57521 59700 58912 55274
Duplex scanning, of intra-cranial vessels Duplex scanning, of penis, cavernosal artery Duplex scanning, of penis, cavernosal tissue Duplex scanning, of penis, cavernosal tissue Duplex scanning, of renal/visceral vessels Duplex scanning, of veins lower limb, venous disease Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, veins upper limb E Echocardiographic, exam of heart 55113-55118, 55130, 55135 Echography, ultrasonic 55028-55033, 55036-55039, 55048-55049 55054, 55070, 55073, 55076, 55079, 55084-55085 55113-55118	Dacryocystography Defaecogram Digits & phalanges 57506, 57509, 57512, 57515, 57524, 57527 Discography Duodenum, barium x-ray of Duplex scanning, carotid and vertebral vessels Duplex scanning, of abdominal aorta, arteries, iliac a	58909,	59703 58939 57521 59700 58912 55274 and veins 55276
Duplex scanning, of penis, cavernosal artery Duplex scanning, of penis, cavernosal tissue S5284 Duplex scanning, of penis, cavernosal tissue S5278 Duplex scanning, of renal/visceral vessels S5278 Duplex scanning, of veins lower limb, venous disease S5246 Duplex scanning, of veins lower limb, venous thrombrosis S5244 Duplex scanning, veins upper limb E Echocardiographic, exam of heart S5113-55118, 55130, 55135 Echography, ultrasonic 55028-55033, 55036-55039, 55048-55049 S5054, 55070, 55073, 55076, 55079, 55084-55085 S5113-55118	Dacryocystography Defaecogram Digits & phalanges 57506, 57509, 57512, 57515, 57524, 57527 Discography Duodenum, barium x-ray of Duplex scanning, carotid and vertebral vessels Duplex scanning, of abdominal aorta, arteries, iliac a Duplex scanning, of arteries/grafts lower limb	58909, rteries a	59703 58939 57521 59700 58912 55274 and veins 55276 55238
Duplex scanning, of penis, cavernosal tissue 55284 Duplex scanning, of renal/visceral vessels 55278 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, veins upper limb 55252 E Echocardiographic, exam of heart 55113-55118, 55130, 55135 Echography, ultrasonic 55028-55033, 55036-55039, 55048-55049 55054, 55070, 55073, 55076, 55079, 55084-55085 55113-55118	Dacryocystography Defaecogram Digits & phalanges 57506, 57509, 57512, 57515, 57524, 57527 Discography Duodenum, barium x-ray of Duplex scanning, carotid and vertebral vessels Duplex scanning, of abdominal aorta, arteries, iliac a Duplex scanning, of arteries/grafts lower limb Duplex scanning, of arteries/grafts upper limb	58909, rteries a	59703 58939 57521 59700 58912 55274 and veins 55276 55238 55248
Duplex scanning, of renal/visceral vessels 55278 Duplex scanning, of veins lower limb, venous disease 55246 Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, veins upper limb 55252 E Echocardiographic, exam of heart 55113-55118, 55130, 55135 Echography, ultrasonic 55028-55033, 55036-55039, 55048-55049 55054, 55070, 55073, 55076, 55079, 55084-55085 55113-55118	Dacryocystography Defaecogram Digits & phalanges 57506, 57509, 57512, 57515, 57524, 57527 Discography Duodenum, barium x-ray of Duplex scanning, carotid and vertebral vessels Duplex scanning, of abdominal aorta, arteries, iliac a Duplex scanning, of arteries/grafts lower limb Duplex scanning, of arteries/grafts upper limb Duplex scanning, of intra-cranial vessels	58909, rteries a	59703 58939 57521 59700 58912 55274 and veins 55276 55238 55248 55280
Duplex scanning, of veins lower limb, venous disease Duplex scanning, of veins lower limb, venous thrombrosis Duplex scanning, veins upper limb E Echocardiographic, exam of heart Echography, ultrasonic 55028-55033, 55036-55039, 55048-55049 55054, 55070, 55073, 55076, 55079, 55084-55085 55113-55118	Dacryocystography Defaecogram Digits & phalanges 57506, 57509, 57512, 57515, 57524, 57527 Discography Duodenum, barium x-ray of Duplex scanning, carotid and vertebral vessels Duplex scanning, of abdominal aorta, arteries, iliac a Duplex scanning, of arteries/grafts lower limb Duplex scanning, of arteries/grafts upper limb Duplex scanning, of intra-cranial vessels Duplex scanning, of penis, cavernosal artery	58909, rteries a	59703 58939 57521 59700 58912 55274 and veins 55276 55238 55248 55280 55282
Duplex scanning, of veins lower limb, venous thrombrosis 55244 Duplex scanning, veins upper limb 55252 E Echocardiographic, exam of heart 55113-55118, 55130, 55135 Echography, ultrasonic 55028-55033, 55036-55039, 55048-55049 55054, 55070, 55073, 55076, 55079, 55084-55085 55113-55118	Dacryocystography Defaecogram Digits & phalanges 57506, 57509, 57512, 57515, 57524, 57527 Discography Duodenum, barium x-ray of Duplex scanning, carotid and vertebral vessels Duplex scanning, of abdominal aorta, arteries, iliac a Duplex scanning, of arteries/grafts lower limb Duplex scanning, of arteries/grafts upper limb Duplex scanning, of intra-cranial vessels Duplex scanning, of penis, cavernosal artery Duplex scanning, of penis, cavernosal tissue	58909, rteries a	59703 58939 57521 59700 58912 55274 and veins 55276 55238 55248 55280 55282 55284
Duplex scanning, veins upper limb 55252 E Echocardiographic, exam of heart 55113-55118, 55130, 55135 Echography, ultrasonic 55028-55033, 55036-55039, 55048-55049 55054, 55070, 55073, 55076, 55079, 55084-55085 55113-55118	Dacryocystography Defaecogram Digits & phalanges 57506, 57509, 57512, 57515, 57524, 57527 Discography Duodenum, barium x-ray of Duplex scanning, carotid and vertebral vessels Duplex scanning, of abdominal aorta, arteries, iliac a Duplex scanning, of arteries/grafts lower limb Duplex scanning, of arteries/grafts upper limb Duplex scanning, of intra-cranial vessels Duplex scanning, of penis, cavernosal artery Duplex scanning, of penis, cavernosal tissue Duplex scanning, of renal/visceral vessels	58909, rteries a	59703 58939 57521 59700 58912 55274 and veins 55276 55238 55248 55280 55282 55284 55278
Echocardiographic, exam of heart 55113-55118, 55130, 55135 Echography, ultrasonic 55028-55033, 55036-55039, 55048-55049 55054, 55070, 55073, 55076, 55079, 55084-55085 55113-55118	Dacryocystography Defaecogram Digits & phalanges 57506, 57509, 57512, 57515, 57524, 57527 Discography Duodenum, barium x-ray of Duplex scanning, carotid and vertebral vessels Duplex scanning, of abdominal aorta, arteries, iliac a Duplex scanning, of arteries/grafts lower limb Duplex scanning, of arteries/grafts upper limb Duplex scanning, of intra-cranial vessels Duplex scanning, of penis, cavernosal artery Duplex scanning, of penis, cavernosal tissue Duplex scanning, of renal/visceral vessels Duplex scanning, of veins lower limb, venous disease	58909, rteries a	59703 58939 57521 59700 58912 55274 and veins 55276 55238 55248 55280 55282 55284 55278 55278
Echocardiographic, exam of heart 55113-55118, 55130, 55135 Echography, ultrasonic 55028-55033, 55036-55039, 55048-55049 55054, 55070, 55073, 55076, 55079, 55084-55085 55113-55118	Dacryocystography Defaecogram Digits & phalanges 57506, 57509, 57512, 57515, 57524, 57527 Discography Duodenum, barium x-ray of Duplex scanning, carotid and vertebral vessels Duplex scanning, of abdominal aorta, arteries, iliac a Duplex scanning, of arteries/grafts lower limb Duplex scanning, of arteries/grafts upper limb Duplex scanning, of intra-cranial vessels Duplex scanning, of penis, cavernosal artery Duplex scanning, of penis, cavernosal tissue Duplex scanning, of renal/visceral vessels Duplex scanning, of veins lower limb, venous diseas. Duplex scanning, of veins lower limb, venous throm	58909, rteries a	59703 58939 57521 59700 58912 55274 and veins 55276 55238 55248 55280 55282 55284 55278 55246 55244
Echography, ultrasonic 55028-55033, 55036-55039, 55048-55049 55054, 55070, 55073, 55076, 55079, 55084-55085 55113-55118	Dacryocystography Defaecogram Digits & phalanges 57506, 57509, 57512, 57515, 57524, 57527 Discography Duodenum, barium x-ray of Duplex scanning, carotid and vertebral vessels Duplex scanning, of abdominal aorta, arteries, iliac a Duplex scanning, of arteries/grafts lower limb Duplex scanning, of arteries/grafts upper limb Duplex scanning, of intra-cranial vessels Duplex scanning, of penis, cavernosal artery Duplex scanning, of penis, cavernosal tissue Duplex scanning, of renal/visceral vessels Duplex scanning, of veins lower limb, venous diseas. Duplex scanning, of veins lower limb, venous throm	58909, rteries a	59703 58939 57521 59700 58912 55274 and veins 55276 55238 55248 55280 55282 55284 55278 55246 55244
Echography, ultrasonic 55028-55033, 55036-55039, 55048-55049 55054, 55070, 55073, 55076, 55079, 55084-55085 55113-55118	Dacryocystography Defaecogram Digits & phalanges 57506, 57509, 57512, 57515, 57524, 57527 Discography Duodenum, barium x-ray of Duplex scanning, carotid and vertebral vessels Duplex scanning, of abdominal aorta, arteries, iliac a Duplex scanning, of arteries/grafts lower limb Duplex scanning, of arteries/grafts upper limb Duplex scanning, of intra-cranial vessels Duplex scanning, of penis, cavernosal artery Duplex scanning, of penis, cavernosal tissue Duplex scanning, of renal/visceral vessels Duplex scanning, of veins lower limb, venous diseas. Duplex scanning, of veins lower limb, venous throm	58909, rteries a	59703 58939 57521 59700 58912 55274 and veins 55276 55238 55248 55280 55282 55284 55278 55246 55244 55252
	Dacryocystography Defaecogram Digits & phalanges 57506, 57509, 57512, 57515, 57524, 57527 Discography Duodenum, barium x-ray of Duplex scanning, carotid and vertebral vessels Duplex scanning, of abdominal aorta, arteries, iliac a Duplex scanning, of arteries/grafts lower limb Duplex scanning, of arteries/grafts upper limb Duplex scanning, of intra-cranial vessels Duplex scanning, of penis, cavernosal artery Duplex scanning, of penis, cavernosal tissue Duplex scanning, of renal/visceral vessels Duplex scanning, of veins lower limb, venous diseas: Duplex scanning, of veins lower limb, venous thromb Duplex scanning, veins upper limb	58909, rteries a e e brosis	59703 58939 57521 59700 58912 55274 and veins 55276 55238 55248 55280 55282 55284 55278 55246 55244 55252
	Dacryocystography Defaecogram Digits & phalanges 57506, 57509, 57512, 57515, 57524, 57527 Discography Duodenum, barium x-ray of Duplex scanning, carotid and vertebral vessels Duplex scanning, of abdominal aorta, arteries, iliac a Duplex scanning, of arteries/grafts lower limb Duplex scanning, of arteries/grafts upper limb Duplex scanning, of penis, cavernosal artery Duplex scanning, of penis, cavernosal tissue Duplex scanning, of renal/visceral vessels Duplex scanning, of veins lower limb, venous diseas: Duplex scanning, of veins lower limb, venous thromb Duplex scanning, veins upper limb Echocardiographic, exam of heart 55113-55118, Echography, ultrasonic 55028-55033, 55036-55039, 55054, 55070, 55073, 55076, 55079, 55084-55085	58909, rteries a e brosis	59703 58939 57521 59700 58912 55274 and veins 55276 55238 55248 55280 55282 55284 55278 55246 55244 55252 E

Enema, opaque x-ray Eye, x-ray of	589 579	921 924
		F
	57518, 57527, 577 597 0503, 60506, 60509, 611 7518, 57521, 57524, 575 57506, 575	739 109 527
		G
Gallbladder, x-ray of	58927, 58933, 589	936
		Н
Hip joint, x-ray of	7506, 57509, 57512, 575	712
Intravenous pyelogram	587	706
		К
Knee/foot/ankle/leg/femur x-ray 5	7518, 57521, 57524, 575	527
		L
Larynx, neck tissues, x-ray of Leg, x-ray of Lumbo-sacral spine, x-ray of Lung fields, x-ray of Lymphangiography	7518, 57521, 57524, 575 581 58500, 58503, 585 597	106
Magnetic Resonance Angiography, care	liovascular system 634	401
63404 Magnetic Resonance Angiography, per Magnetic Resonance Imaging, body Magnetic Resonance Imaging, cardiova 63388, 63391 Magnetic Resonance Imaging, cervical Magnetic Resonance Imaging, Head	scular system 633 spine and brachial plexu 630	461 385 as 63271, 63274, 63277, 63280 001
Magnetic Resonance Imaging, head 6 63043, 63046, 63049, 63052, 63055, 6 63067, 63070, 63073	3058, 63061, 63064	
Magnetic Resonance Imaging, head and 63128, 63131	•	125
Magnetic Resonance Imaging, head and Magnetic Resonance Imaging, modifyin 63497-63499		
Magnetic Resonance Imaging, musculo 63304, 63307, 63322, 63325, 63328, 63340, 63361		301

Magnetic Resonance Imaging, pelvis and upper abdomen 63470 63473 Magnetic Resonance Imaging, person under 16 years 63425 63428, 63440, 63443, 63446 Magnetic Resonance Imaging, PIP Breast Implant 63501-63502 63504-63505 Magnetic Resonance Imaging, spine - one region or two contiguous regions 63151, 63154, 63161, 63164, 63167, 63170, 63173 63176, 63179, 63182, 63185 Magnetic Resonance Imaging, spine - three contiguous or two non contiguous regio 63201, 63204, 63219, 63222, 63225 63228, 63231, 63234, 63237 Malar bones, x-ray of 57912 Mammary ductogram 59306, 59309 59300, 59303 Mammography, (restriction applies) Mandible, X-ray of 57915 Mastoids, X-ray of 57906 Maxilla, X-ray of 57912 Myelography 59724 Ν Nephography 58700, 58715 Nose, X-ray of 57921 Nuclear Medicine Imaging, brain study 61402, 61405 Nuclear medicine imaging, cardiovascular, cardiac blood flow, shunt/output study 61320 Nuclear medicine imaging, cardiovascular, gated cardiac study - 1st pass/cardiac 61314 Nuclear medicine imaging, cardiovascular, gated cardiac study - intervention 61316 Nuclear medicine imaging, cardiovascular, gated cardiac study-planar or spect 61313 Nuclear Medicine Imaging, cerebro spinal fluid study 61409 61413 Nuclear Medicine Imaging, endocrine, adrenal study 61484-61485 Nuclear Medicine Imaging, endocrine, parathyroid study 61480 Nuclear Medicine Imaging, endocrine, thyroid study 61473 Nuclear Medicine Imaging, gastrointestinal, bowel haemorrhage study 61364 Nuclear Medicine Imaging, gastrointestinal, colonic transit study61384 Nuclear Medicine Imaging, gastrointestinal, gastric emptying 61381, 61383 Nuclear Medicine Imaging, gastrointestinal, gastro-oesophageal reflux study 61373 Nuclear Medicine Imaging, gastrointestinal, hepatobiliary study61360-61361 Nuclear Medicine Imaging, gastrointestinal, oesophageal clearance study 61376 Nuclear Medicine Imaging, genitourinary, cystoureterogram 61397 Nuclear Medicine Imaging, genitourinary, renal cortical study61387 Nuclear Medicine Imaging, genitourinary, renal study 61386 61389-61390, 61393 Nuclear Medicine Imaging, genitourinary, renal study including renogram or plana 61386 Nuclear Medicine Imaging, genitourinary, testicular study 61401 Nuclear Medicine Imaging, Indium, labelled octreotide study61369 Nuclear Medicine Imaging, Indium, Meckel's diverticulum study61368 Nuclear Medicine Imaging, Indium, red blood cell spleen/liver SPECT 61356 Nuclear Medicine Imaging, Indium, salivary study 61372 Nuclear Medicine Imaging, liver and spleen study 61352-61353 Nuclear Medicine Imaging, localised study, gallium 61450 61453 Nuclear Medicine Imaging, localised study, technetium 61454 61457 Nuclear Medicine Imaging, localised study, thallium 61461 Nuclear Medicine Imaging, localised study,thallium 61458 Nuclear Medicine Imaging, lymphoscintigraphy 61469 Nuclear Medicine Imaging, myocardial infarct-avid imaging 61310 Nuclear Medicine Imaging, myocardial perfusion central nervous61302-61303, 61306-61307 Nuclear Medicine Imaging, positron emission tomography 61523 61529, 61541, 61553, 61559, 61565, 61575, 61577, 61598

61604, 61610, 61620, 61632

Nuclear Medicine Imaging, pulmonary, lung perfusion & ventilation 61348 Nuclear Medicine Imaging, pulmonary, lung perfusion study61328 Nuclear Medicine Imaging, pulmonary, lung ventilation study61340 Nuclear Medicine Imaging, repeat planar or SPECT 61462 Nuclear Medicine Imaging, skeletal, bone marrow study 61441 61445 Nuclear Medicine Imaging, skeletal, bone study 61421, 61425 Nuclear Medicine Imaging, skeletal, bone/joint localised 61446 Nuclear Medicine Imaging, tear duct study 61495 Nuclear Medicine Imaging, vascular, dynamic flow/volume study61417 Nuclear Medicine Imaging, vascular, particle perfusion or Le Veen 61499 Nuclear Medicine Imaging, whole body study, gallium61429-61430, 61442 Nuclear Medicine Imaging, whole body study, iodine 61426 Nuclear Medicine Imaging, whole body study, technetium61433-61434 Nuclear Medicine Imaging, whole body study, thallium61437-61438 Oesophagus, barium X-ray of 58909, 58912 Opaque enema 58921 Opaque enema, meal 58909, 58912, 58915 Opaque enema, media, radiology prep 60918, 60927 Orbit, facial bones, X-ray of 57912 57960, 57963, 57966, 57969 Orthopantomography Palato-pharyngeal studies 57942 Paloat-pharyngeal studies 57939 Pelvic girdle, X-ray of 57715 57715 Pelvis, X-ray of Petrous temporal bones, X-ray of Phalanges & digits 57506, 57509, 57512, 57515, 57518, 57521 57524, 57527 Pharynx, barium X-ray of 58909 Phlebogram, preparation 60927 Phlebography 59718 Phlebography, preparation for 60918 Plain abdominal X-ray 58900 Plain, abdominal X-ray 58903 Plain, renal X-ray 58700 Pleura, X-ray of 58503 Pleura, X-ray of 58500 Positron emission tomography 61523, 61529, 61538, 61541 61553, 61559, 61565, 61571, 61575, 61577, 61598, 61604 61610, 61620, 61622, 61628, 61632, 61640, 61646 Prep, for radiological procedure 60918, 60927 Prostate, bladder base and urethra, ultrasound scan of 55600 Pyelography - intravenous 58706 Pyelography - intravenous, retrograde/antegrade 58715 R 58700 Renal, plain X-ray Retrograde - pyelography 58715 Retrograde - pyelography, cysto-urethography 58721 Retrograde - pyelography, cystography 58718 58521, 58524, 58527 Ribs, X-ray of

S

Sacro-coccygeal spine, X-ray of Salivary calculus, X-ray of Scapula, X-ray of Screening with x-ray of chest Screening, palate/pharynx, x-ray Serial, angiocardiography Shoulder or scapula, X-ray of Sialography Sinogram, or fistulogram Sinus, X-ray of Skeletal survey Skull, X-ray Small bowel series, barium, X-ray Spine, X-ray of 58100, 58103, 58106, 58108 58115 Sternum, X-ray of Stomach, barium X-ray	, 58524, 58527 58909, 58912
Teeth, orthopantomography Teeth, X-ray of Temporo-mandibular joints, X-ray of Thigh (femur), X-ray of Thoracic inlet, spine, X-ray of Thoracic inlet, X-ray of Trachea, X-ray of	57966, 57969 57930, 57933 57927 57518, 57521 58103 58509 58509
Ultrasound, cardiac examination 55113-55118, Ultrasound, general 55028-55033, 55036-55039 55054, 55065, 55067, 55070, 55073, 55076, 55079 55084-55085 Ultrasound, musculoskeletal Ultrasound, obstetric and gynaecological 55700 55712, 55715, 55718, 55721, 55723, 55725, 55729 55739, 55759, 55762, 55764, 55766, 55768, 55770	55800, 55854 , 55703-55709 , 55736
55774 Ultrasound, urological Ultrasound, vascular 55238, 55244, 55246, 55274, 55276, 55278, 55280, 55282, 55284, 55292 55296	55603 , 55248, 55252 2, 55294
Upper forearm & elbow, leg and knee, X-ray of Upper forearm & elbow, X-ray Urethrography, retrograde Urinary tract, X-ray of 58700, 58706, 58715,	57524, 57527 57512, 57515 58718 , 58718, 58721
Venography, selective 60072-60073, 60075-60076	-
Wrist/hand/forearm/elbow/humerus X-ray of 57512, 57515	W 57506, 57509
X-ray, alimentary tract and biliary system 58909, 58912, 58915-58916, 58921, 58927, 58933	58900, 58903 , 58936

58939			
X-ray, bone age study and skeletal surveys	58300, 58306		
X-ray, breasts	59300, 59303		
X-ray, breasts - mammary ductogram	59306, 59309		
X-ray, breasts, in conjunction with a surgical proceed	lure59312, 59314		
X-ray, extremeties 57509, 57512, 57515, 57518 57527	, 57521, 57524		
X-ray, extremities	57506		
X-ray, head 57901-57903, 57906, 57909, 57912	, 57915, 57918		
57921, 57924, 57927, 57930, 57933, 57939, 57942	2, 57945		
57960, 57963, 57966, 57969			
X-ray, image intensification	60500, 60503		
X-ray, of excised breast tissue	59318		
X-ray, shoulder or pelvis 57700, 57703, 57706 57715, 57721	, 57709, 57712		
X-ray, spine 58100, 58103, 58106, 58108-58109	, 58112, 58115		
X-ray, thoracic region 58500, 58503, 58506	, 58509, 58521		
58524, 58527, 58706, 58715, 58718, 58721			
X-ray, Urinary tract	58700		
37 1 1	, 59703, 59712		
59715, 59718, 59724, 59733, 59739, 59751, 59754, 59763			

CATEGORY 6: PATHOLOGY SERVICES

SUMMARY OF CHANGES FROM 01/03/2019

The 01/03/2019 changes to the MBS are summarised below and are identified in the Schedule pages by one or more of the following words appearing above the item number:

(a) new item	New
(b) amended description	Amend
(c) fee amended	Fee
(d) item number changed	Renum
(e) EMSN changed	EMSN

Amended Item

73343

Amendment to 73343 - Addition of Venetoclax

This change amends MBS Item 73343 to determine eligibility for venetoclax on the Pharmaceutical Benefits Scheme.

PATHOLOGY SERVICES NOTES

PN.0.1 Changes to the Pathology Services Table Health Insurance Regulations

The *Health Insurance Act 1973* allows the Minister for Health to determine an appropriate Pathology Services Table which is then prescribed by Regulation.

The Minister has established the Pathology Services Table Committee (PSTC) to assist in determining changes to the Table (except new medical services and technologies - see below). Any person or organisation seeking to make a submission to this Committee can contact the PSTC Secretariat on (02) 6289 4080 or e-mail pstc.secretariat@health.gov.au and/or write to: Secretary, PSTC, MDP 107, Department of Health and Ageing, GPO Box 9848, CANBERRA ACT 2601.

Pathology submissions relating to new medical services and technologies should be forwarded to the Medical Services Advisory Committee (MSAC). MSAC has been established to advise the Minister on the strength of evidence pertaining to new and emerging medical technologies and procedures in relation to their safety, effectiveness and cost effectiveness, and under what circumstances public funding should be supported.

Any person or organisation seeking to make a submission to MSAC can contact the MSAC Secretariat on (02) 6289 7550 or email msac.secretariat@health.gov.au and/or write to: MSAC Secretariat, Australian Government, Department of Health, MDP 106, GPO Box 9848, CANBERRA ACT 2601. The application form and guidelines for applying can also be obtained from MSAC's website - www.msac.gov.au

PN.0.2 Explanatory Notes - Definitions

Excessive Pathology Service

This means a pathology service for which a Medicare benefit has become or may become payable and which is not reasonably necessary for the adequate medical or dental care of the patient concerned.

PN.0.3 Group of Practitioners

This means:

- (i) a practitioner conducting a medical practice or a dental practice, or a participating nurse practitioner practice, or a participating midwife practice together with another practitioner, or other practitioners, participating (whether as employees or otherwise) in the provision of professional services as part of that practice; or
- (ii) two or more practitioners conducting a medical practice or a dental practice, or a participating nurse practitioner practice, or a participating midwife practice as partners; or
- (iii) those partners together with any other practitioner who participates (whether as an employee or otherwise) in the provision of professional services as part of that practice.

PN.0.4 Initiate

In relation to a pathology service this means to request the provision of pathology services for a patient.

PN.0.5 Patient Episode

A patient episode comprises a pathology service or services specified in one or more items which are provided for a single patient, the need for which was determined under subsection 16A(1) of the Act on the same day, whether they were provided by one or more approved pathology practitioners on one day or over several days and whether they are requested by one or more treating practitioners. Even if a treating practitioner writes separate request forms to cover the collection of specimens at different times, where the decision to collect the multiple specimens was made at the same time, the multiple tests are deemed to belong to the same patient episode. In addition, if more than one

request is made, on the same or different days, for tests on the same specimen within 14 days, they are part of the same patient episode.

Rule 4 of the Pathology Services Table provides an exemption to the above and enables services requested on one day which are performed under strictly limited circumstances for seriously or chronically ill patients with certain specified conditions to each be classified as a patient episode. See PD.2 for further information on exemptions.

Rule 14.(8) also provides that only a single patient episode initiation fee will be payable for all the specimens collected on one day from one patient in or by one Approved Pathology Authority.

PN.0.7 Personal Supervision

This means that an Approved Pathology Practitioner will, to the fullest extent possible, be responsible for exercising an acceptable level of control over the rendering of pathology services. See PM.1 to PM.3 for a full description of the responsibilities involved in personal supervision.

PN.0.8 Prescribed Pathology Service

These are simple basic pathology services which are included in Group P9 and may be performed by a medical practitioner in the practitioner's surgery without the need to obtain Approved Pathology Authority, Approved Pathology Practitioner or Accredited Pathology Laboratory status.

PN.0.9 Proprietor of a Laboratory

This means in relation to a pathology laboratory the person, authority or body of persons having effective control of:

- (i) the laboratory premises, whether or not the holder of an estate or interest in the premises;
- (ii) the use of equipment used in the laboratory; and
- (iii) the employment of staff in the laboratory.

PN.0.10 Specialist Pathologist

This means a medical practitioner recognised for the purposes of the Health Insurance Act 1973 as a specialist in pathology (see 5.1 of the "General Explanatory Notes" in Section 1 of this book). The principal specialty of pathology includes a number of sectional specialties. Accordingly, a medical practitioner who is recognised as a specialist in a sectional specialty of pathology is recognised as a specialist pathologist for this purpose.

PN.0.11 Designated Pathology Service

This means a pathology service specified in items 65150, 65175 66650, 66695, 66711, 66722, 66785, 66800, 66812, 66819, 66825, 69384, 69494, 71089, 71153 or 71165. Where one Approved Pathology Practitioner in an Approved Pathology Authority has performed some but not all the estimations in a coned item and has requested another Approved Pathology Practitioner in another Approved Pathology Authority to do the rest, the service provided by the second practitioner is deemed to be the "designated pathology service". Thus the first practitioner claims under the appropriate item for the services which he/she provides while the second practitioner claims one of items 65150, 65175, 66650, 66695, 66711, 66722, 66785, 66800, 66812, 66819, 66825, 69384, 69494, 71089, 71153 or 71165. Where one Approved Pathology Practitioner in an Approved Pathology Authority has performed some, but not all estimations and has requested another Approved Pathology Practitioner in another Approved Pathology Authority to do the remainder, the first Approved Pathology Practitioner can raise a "patient episode initiation fee". The second Approved Pathology Practitioner who receives the specimen can raise a "specimen referred fee".

PN.0.12 Interpretation of The Schedule - Items Referring to 'The Detection Of'

Items that contain the term 'detection of' should be taken to mean 'testing for the presence of'.

PN.0.13 Blood Grouping - (Item 65096)

Where a request includes 'Group and Hold' or 'Group and Save', the appropriate item is 65096.

PN.0.14 Glycosylated Haemoglobin - (Item 66551)

The requirement of "established diabetes" in this item may be satisfied by:

- (a) a statement of the diagnosis by the ordering practitioner on the current request form or on a previous request form held in the database of the Approved Pathology Authority; or
- (b) two or more blood glucose levels that are in the diabetic range and is contained in the database of the Approved Pathology Authority; or
- (c) an oral glucose tolerance test result that is in the diabetic range and is contained in the database of the Approved Pathology Authority.

PN.0.15 Iron Studies - (Item 66596)

Where a request includes 'Iron Studies', 'IS', 'Fe', '% saturation' or 'Iron', the relevant item is 66596.

PN.0.16 Faecal Occult Blood - (Items 66764 to 66770)

PN.0.17 Antibiotics/Antimicrobial Chemotherapeutic Agents

A test for the quantitation of antibiotics/antimicrobial chemotherapeutic agents is claimable under item 66800 or 66812 - 'quantitation of a drug being used therapeutically'.

PN.0.18 Human Immunodeficiency Virus (HIV) Diagnostic Tests - (lincluded in Items 69384, 69387, 69390, 69393, 69396, 69405, 69408, 69411, 69413 and 69415)

Prior to ordering an HIV diagnostics tests (included in items 69384, 69387, 69390, 69393, 69396, 69405, 69408, 69411, 69413, 69415) the ordering practitioner should ensure that the patient has given informed consent. Appropriate discussion should be provided to the patient. Further discussion may be necessary upon receipt of the test results.

PN.0.19 Hepatitis - (Item 69481)

Benefits for item 69481 are payable only if the request from the ordering practitioner indicates in writing that the patient is suspected of suffering from acute or chronic hepatitis; either by the use of the provisional diagnosis of hepatitis or by relevant clinical or laboratory information eg "hepatomegaly", "jaundice" or "abnormal liver function tests".

PN.0.20 Eosinophil Cationic Protein - (Item 71095)

Item 71095 applies to children aged less than 12 years who cannot be reliably monitored by spirometry or flowmeter readings.

PN.0.21 Tissue Pathology and Cytology - (Items 72813 to 73061)

When services described in Group P5 need to be performed upon material which is submitted for cytology items listed in Group P6 only the fee for the P6 item can be claimed.

PN.0.22 Cervical and Vaginal Screening - (Items 73070 to 73076)

It is the responsibility of the treating healthcare practitioner to determine if the sample is being collected as part of the routine screening program under 73070 or 73071 or represents a sample falling under 73072 or 73073 or 73074 or 73075 or 73076, and to indicate this on the request form. Unless a co-test is specifically requested, requiring the pathology laboratory to perform both a human papillomavirus (HPV) test and a liquid based cytology (LBC) test on

the same specimen, the pathology laboratory will by default perform an HPV test and then only undertake reflex LBC testing if oncogenic HPV (any type) is detected. The pathology laboratory will issue the HPV test result, the LBC test result and overall screening risk rating as a combined report as prescribed by the National Pathology Accreditation Advisory Council (NPAAC) Requirements for Laboratories reporting tests for the National Cervical Screening Program (NPAAC Requirements).

The test used for detecting oncogenic HPV must allow partial HPV genotyping to identify HPV16, HPV18 with or without HPV45 as well as meet the criteria for a population based screening test as prescribed by the NPAAC Requirements.

When used together, the self-collection device and the HPV test must meet the NPAAC Requirements, including the HPV test must be a polymerase chain reaction (PCR) test.

73070 applies to an HPV test on a cervical specimen for primary screening purposes and collected by a healthcare practitioner (or an accredited test provider under the supervision of a healthcare practitioner) from an asymptomatic patient as part of routine five yearly screening recommended by the National Cervical Screening Program. The Health Insurance Act 1973 excludes payment of Medicare Benefits for health screening services except where Ministerial directions have been issued to enable benefits to be paid, this includes HPV testing that is performed in accordance with the policy of the National Cervical Screening Program (available at www.cancerscreening.gov.au). This policy provides for a screening interval of five years for an asymptomatic patient commencing at 24 years and 9 months of age and for a patient aged between 70 to 74 years of age to cease cervical screening if the last test result is normal (i.e. low risk). A patient aged 75 years of age or older who has never had a cervical screening test or has not had one in the previous five years, may request a cervical screening test and be screened.

In accordance with the national policy for the National Cervical Screening Program, where oncogenic HPV (any type) is detected, the pathology laboratory will conduct reflex LBC automatically under 73076 (a) without requiring an additional request by the treating healthcare professional.

73071 only applies to HPV tests for primary screening purposes requested by a healthcare practitioner on a self-collected vaginal specimen if a specimen collected by a healthcare practitioner has been declined.

HPV testing on self collected vaginal specimens carried out under 73071 should be in accordance with the agreed National Cervical Screening Program Self Collection Policy. The Policy allows self collection where a patient is \geq 30 years of age and has either never screened or is under screened (i.e. overdue for cervical screening by at least two years, being greater than 7 years since the patient's last HPV screening test). A patient aged 75 years of age or older who has never had a cervical screening test or has not had one in the previous seven years, may request a self collected vaginal sample and be screened.

During the early years of the transition, this may include a patient who is overdue since the patient's last conventional Pap test (i.e. greater than four years since last conventional Pap).

It is the intention of the National Cervical Screening Program where oncogenic HPV has previously been detected under this Item, the healthcare practitioner collected liquid based sample from the cervix that follows, can be claimed under 73076 (a) with a further request by the treating healthcare practitioner.

73072 applies to HPV tests where the specimen has been collected in accordance with the National Cervical Screening Program: Guidelines for the Management of Screen Detected Abnormalities, Screening in Specific Populations and Investigation of Abnormal Vaginal Bleeding (2016 Guidelines) which provides for:

- (a) an HPV test (and reflex LBC) performed on a patient within a specific population suggestive of a higher risk of pre cancerous or cancerous cervical changes. HPV tests carried out in specific populations under Item 73072 should be in accordance with the 2016 Guidelines including:
- (i) screening with a primary HPV test (and reflex LBC) every 3 years for an immune-deficient patient; or

- (ii) a single HPV test between 20 and 24 years of age could be considered by healthcare practitioners on a case by case basis for a patient who experienced first sexual activity at a young age (less than 14 years of age) and who has not received the HPV vaccine before sexual debut; or
- (b) an HPV test (and reflex LBC) performed for the follow up management of previously detected oncogenic HPV infection with a negative or possible/low grade squamous intraepithelial lesion (LSIL) cytology result; or
- (c) a co-test (HPV+LBC) for the investigation of symptoms of cervical cancer, most commonly abnormal vaginal bleeding; or
- (d) co-test (HPV+LBC) for the management of a patient following treatment of high grade squamous intraepithelial lesions (HSIL) of the cervix as part of a 'test of cure' process performed at 12 months after treatment and annually thereafter, until receiving a negative co-test on two separate consecutive occasions, then the patient can return to routine five yearly screening. In accordance with the 2016 Guidelines this also applies to a patient undergoing follow up or post-treatment for a glandular abnormality as part of annual surveillance performed indefinitely; or
- (e) a co-test (HPV+LBC) for the follow up management of glandular abnormalities; or
- (f) a co-test (HPV+LBC) for screening a patient exposed to diethylstilbestrol (DES) in utero and daughters of patients exposed to DES in utero, if requested.

A co-test requires both HPV and LBC tests to be performed irrespective of the HPV test result. A reflex LBC is only required if oncogenic HPV (any type) is detected; where oncogenic HPV (any type) has been detected in a liquid based sample from the cervix by a healthcare professional, the pathology laboratory will conduct LBC automatically without requiring an additional request.

73073 applies to the management of a patient with previously detected oncogenic HPV (any type) infection on a self collected vaginal sample if a specimen collected by a healthcare practitioner has been declined. It may only be claimed when the test is performed within in a 21 month period following detection of oncogenic HPV (any type) associated with 73071.

It is expected that most patients who are undergoing follow up, after detection of oncogenic HPV (any type) on a self collected vaginal sample, will agree to have a clinician collected cervical sample at the follow up visit. Some patients may decline and this Item applies to this group of patients. It is the intention of the National Cervical Screening Program where oncogenic HPV has previously been detected under this Item, the healthcare practitioner collected liquid based sample from the cervix that follows, can be claimed under 73076 (a) with a further request by the treating healthcare practitioner.

73074 applies to an HPV test on a vaginal vault specimen collected by a healthcare practitioner (or an accredited test provider under the supervision of a healthcare practitioner) from a patient with past history of total hysterectomy, in accordance with the 2016 Guidelines which provides for:

- (a) an HPV test for a patient who has no evidence of cervical pathology and the patient's screening history is not available, performed at 12 months following a total hysterectomy and annually thereafter until a patient has two negative HPV tests (i.e. oncogenic HPV not detected) on two separate consecutive occasions and can be advised that no further testing is required; or
- (b) a co-test (HPV+LBC) for a patient who has had a total hysterectomy, performed at 12 months following a total hysterectomy and annually thereafter until two consecutive co-tests are negative:
- (i) if unexpected LSIL or HSIL is identified in the cervix at the time of total hysterectomy after completed 'test of cure' process; or
- (ii) if the total hysterectomy was for treatment of high-grade cervical intraepithelial neoplasia in the presence of benign gynaecological disease; or

- (iii) if the total hysterectomy was after histologically confirmed HSIL without Test of Cure and there is no cervical pathology; or
- (c) indefinite co-testing (HPV+LBC) for a patient who has had a total hysterectomy, performed at 12 months after treatment and annually thereafter if the total hysterectomy was after adenocarcinoma in situ (AIS).

73075 applies to HPV tests repeated due to an unsatisfactory HPV test under 73070 or 73071 or 73072 or 73073 or 73074.

73076 applies to a liquid-based cytology (LBC) test on a cervical or vaginal vault specimen:

- (a) as part of a reflex test following detection of oncogenic HPV described in the national policy and 2016 Guidelines associated with items 73070 or 73071 or 73072 (a) or (b) or 73073 or 73074 or 73075; or
- (b) as part of a co-test described in the national policy and 2016 Guidelines under 73072 (c) or (d) or (e) of (f) or 73074; or
- (c) where the previous specimen collected is unsatisfactory; or
- (d) for the follow up management of a patient with a past history of total hysterectomy for endometrial adenocarcinoma.

PN.0.23 Detection of mutation tests (Items 73297, 73300, 73305, 73334, 73339 and 73340)

Prior to ordering these tests (73297, 73300, 73305, 73334, 73339 and 73340) the ordering practitioner should ensure the patient (or approximate proxy) has given informed consent. Testing should only be performed after genetic counselling. Appropriate genetic counselling should be provided to the patient either by the specialist treating practitioner, a genetic counselling service or a clinical geneticist on referral. Further counselling may be necessary upon receipt of the test results.

PN.0.24 Additional Bulk Billing Payment for Pathology Services - (Item 74990 and 74991)

Item 74990 operates in the same way as item 10990 and item 74991 operates in the same way as item 10991, apart from the following differences:

- · Item 74990 and 74991 can only be used in conjunction with items in the Pathology Services Table of the MBS;
- · Item 74990 and 74991 applies to unreferred pathology services performed by a medical practitioner which are included in Group P9 of the Pathology Services Table, and unreferred pathology services provided by category M laboratories;
- · Item 74990 and item 74991 applies to pathology services self determined by general practitioners and specialists with dual qualifications acting in their capacity as general practitioners;
- · Specialists and consultant physicians who provide pathology services are not able to claim item 74990 or item 74991 unless, for the purposes of the Health Insurance Act, the medical practitioner is also a general practitioner and the service provided by the medical practitioner has not been referred to that practitioner by another medical practitioner or person with referring rights.

Rules 3 and 18 of the *Health Insurance (Pathology Services Table) Regulations 2003* have been amended to exclude item 74990 and 74991 from the Multiple Services Rule and the Coning Rule.

Item 74991 can only be used where the service is provided at, or from, a practice location in a regional, rural or remote area (RRMA 3 to 7 under the Rural Remote Metropolitan Areas classification system), or in all of Tasmania.

PN.0.25 Transfer of Existing Items from Group P1 (Haematology) to Group P7 Genetics Effective 1 May 2006.

P16.14 has been created to note the transfer of existing items from Group P1 (Haematology) items 65168, 65174, 65200 and item 66794 from Group P2 (Chemistry) to Group P7 (Genetics) as items 73308, 73311, 73314, 73317 and the introduction of the new item in Group P7 (Genetics) item 73320 HLA-B27 typing by nucleic acid amplification (NAA) which was effective as of 1 May 2006.

PN.0.26 RAS gene mutation status (Item 73338)

Item 73338 provides for testing of RAS mutations to limit subsidy of anti-EGFR antibodies to only those patients demonstrated to have no RAS mutations.

For a Medicare benefit to be payable, the test must be conducted for all clinically relevant mutations on KRAS exons 2, 3 and 4 and NRAS exons 2, 3 and 4, or until a RAS mutation is found.

Enabling the requirements of the item descriptor to be met once any RAS mutation is found means that once the test indicates that the patient is not RAS wild-type and therefore not suitable for access to cetuximab and panitumumab under the PBS, a pathologist is not required to continue testing for other clinically relevant mutations.

PN.0.27 Germline BRCA gene mutation tests (Items 73295, 73296 and 73333)

Patients who are found to have any form of affected allele should be referred for post-test genetic counselling as there may be implications for other family members. Appropriate genetic counselling should be provided to the patient either by the specialist treating practitioner, a genetic counselling service or a clinical geneticist on referral.

PN.0.28 Abbreviations, Groups of Tests

As stated at P3.2 of the Outline, details that must be recorded on accounts, receipts or assignment forms of an Approved Pathology Practitioner/Authority include a description of the pathology service that is of sufficient detail to identify the specific service rendered. The lists of abbreviations for group tests are contained in PQ.4. The lists of abbreviations for individual tests are contained in the Index to this Section. The abbreviations are provided to allow users to identify and refer to particular pathology services, or particular groups of pathology services, more accurately and conveniently.

The above requirements may be used for billing purposes but treating practitioners requesting pathology services are encouraged to use the approved abbreviations. In this regard treating practitioners should note that:

- pathology services cannot be self determined by a rendering pathologist responding to a request. This places the onus for medical necessity on the treating practitioner who, in normal circumstances would, if he or she was unclear in deciding the appropriate test for a clinical situation, consult a pathologist for assistance; and
- Approved Pathology Practitioners/Authorities undertake not to issue accounts etc unless the pathology service was rendered in response to an unambiguous request.

PN.0.29 Tests not Listed

Tests which are not listed in the Pathology Services Table do not attract Medicare benefits. As explained at PN.1 of the Outline, changes to the Pathology Services Table can only be made by the Minister for Health and Ageing.

PN.0.30 Audit of Claims

The Department of Human Services is undertaking routine audits of claims for pathology benefits against requested services to ensure compliance with the provisions of the Health Insurance Act 1973.

PN.0.31 Groups of Tests

For the purposes of recording a description of the pathology service on accounts etc, an Approved Pathology Practitioner /Authority may use group abbreviations or group descriptions for the following specified groups of

tests. These groups consist of two or more tests within the same item. These groups exclude abbreviations such as MBA and TORCH.

Treating practitioners are encouraged to use these group abbreviations or group descriptions where appropriate.

For ease of identification of group tests, it is recommended that practitioners use the following abbreviations. Tests requested individually may attract Medicare benefits.

Group	Estimations included in Group	Group Abbreviation	Item Numbers
Cardiac enzymes or cardiac markers	Creatine kinase isoemzymes, Myoglobin, Troponin	CE / CM	66518, 66519
Coagulation studies	Full blood count, Prothrombin time, Activated partial thromboplastin time and two or more of the following tests - Fibrinogen, Thrombin, Clotting time, Fibrinogen degradation products, Fibrin monomer, D-dimer factor XIII screening tests	COAG	65129, 65070
Electrolytes	Sodium (NA), Potassium (K), Chloride (CL) and Bicarbonate (HCO3)	Е	66509
Full Blood Examination	Erythrocyte count, Haematocrit, Haemoglobin, Platelet count, Red cell count, Leucocyte count, Manual or instrument generated differential, Morphological assessment of blood film where appropriate	FBE, FBC, CBC	65070
Lipid studies	Cholesterol (CHOL) and Triglycerides (TRIG)	FATS	66503
Liver function tests	Alkaline phosphatase (ALP), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Albumin (ALB), Bilirubin (BIL), Gamma glutamyl transpeptidase (GGT), Lactate dehydrogenase (LDH), and Protein (PROT)	LFT	66512
Syphilis serology	Rapid plasma regain test (RPR), or Venereal disease research laboratory test (VDRL), and Treponema pallidum haemagglutin test (TPHA), or Fluorescent treponemal antibody-absorption test (FTA)	STS	69387
Urea, Electrolytes,	Urea, Electrolytes, Creatinine	U&E	66512
Creatinine			

PN.0.32 Complexity Levels for Histopathology Items

Only one of these histopathology examination items (72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838) can be claimed in a patient episode.

The remaining items (72844, 72846, 72847, 72848, 72849, 72850, 72851, 72852, 72855, 72856 and 72857) are add-on items, covering enzyme histochemistry and immunohistochemistry, electron microscopy and frozen sections, which can be claimed in addition to the main item.

The list of complexity levels by type of specimen are contained at the back of this Section.

PN.0.33 Pathology Services Table Rules for the Interpretation of the Pathology Services Table

Please note that in the Health Insurance (Pathology Services Table) Regulations 2010 (effective 1 November 2010) rules and sub-rules are referred to as clauses and sub-clauses. In addition in the Regulations a rule that refers to specific items within a pathology group, for example Group P1 Haemotology, is listed directly above the Schedule of Services for that group. A table cross referencing the following rules with the clauses in the Regulations is at the end of this section.

1. (1) In this table

patient episode means:

- (a) a pathology service or pathology services (other than a pathology service to which paragraph 1 (1) (b) refers) provided for a single patient whose need for the service or services was determined under section 16A of the Act:
- (i) on the same day; or
- (ii) if more than 1 test is performed on the 1 specimen within 14 days on the same or different days;

whether the services:

- (iii) are requested by 1 or more practitioners; or
- (iv) are described in a single item or in more than 1 item; or
- (v) are rendered by 1 approved pathology practitioner or more than 1 approved pathology practitioner; or
- (vi) are rendered on the same or different days; or
- (b) a pathology service to which rule 4 refers that is provided in the circumstances set out in that rule that relates to the service.

receiving APP means an approved pathology practitioner in an approved pathology authority who performs one or more pathology services in respect of a single patient episode following receipt of a request for those services from a referring APP.

recognised pathologist means a medical practitioner recognised as a specialist in pathology by a determination under section 3D, 3DB or 3E of the Act.

referring APP means an approved pathology practitioner in an approved pathology authority who:

- (i) has been requested to render 1 or more pathology services, all of which are requested in a single patient episode; and
- (ii) is unable, because of the lack of facilities in, or expertise or experience of the staff of, the laboratory of the authority, to render 1 or more of the pathology services; and
- (iii) requests an approved pathology practitioner (the *receiving APP*) in another approved pathology authority to render the pathology service or services that the referring APP is unable to render; and

(iv) renders each pathology service (if any) included in that patient episode, other than the pathology service or services in respect of which the request mentioned in subparagraph (iii) is made.

serial examinations means a series of examinations requested on 1 occasion whether or not:

- (a) the materials are received on different days by the approved pathology practitioner; or
- (b) the examinations or cultures were requested on 1 or more request forms by the treating practitioner.

the Act means the Health Insurance Act 1973.

- **1. (2)** In these rules, a reference to a request to an approved pathology practitioner includes a reference to a request for a pathologist-determinable service to which subsection 16A (6) of the Act applies.
- 1. (3) A reference in this table by number to an item that is not included in this table is a reference to the item that has that number in the general medical services table or the diagnostic imaging services table, as the case requires.
- **1. (4)** A reference to a **Group** in the table includes every item in the Group and a reference to a **Subgroup** in the table includes every item in the Subgroup.

Precedence of items

- **2. (1)** If a service is described:
- (a) in an item in general terms; and
- (b) in another item in specific terms;

only the item that describes the service in specific terms applies to the service.

- **2. (2)** Subject to subrule (3), if:
- (a) subrule (1) does not apply; and
- (b) a service is described in 2 or more items;

only the item that provides the lower or lowest fee for the service applies to the service.

2. (3) If an item is expressed to include a pathology service that is described in another item, the other item does not apply to the service in addition to the first-mentioned item, whether or not the services described in the 2 items are requested separately.

Application of item 74990 and 74991

- **2. (4)** Despite subrules (1), (2) and (3):
- (a) if the pathology service described in item 74991 is provided to a person, either that item or item 74990, but not both those items, applies to the service; and
- (b) if item 74990 or 74991 applies to a pathology service, the fee specified in that item applies in addition to the fee specified in any other item in the table that applies to the service.
- **2. (5)** For items 74990 and 74991:

bulk-billed, in relation to a pathology service, means:

(a) a medicare benefit is payable to a person in respect of the service; and

- (b) under an agreement entered into under section 20A of the Act:
- (i) the person assigns to the practitioner by whom, or on whose behalf, the service is provided, his or her right to the payment of the medicare benefit; and
- (ii) the practitioner accepts the assignment in full payment of his or her fee for the service provided.

Commonwealth concession card holder means a person who is a concessional beneficiary within the meaning given by subsection 84(1) of the *National Health Act 1953*.

unreferred service means a pathology service that:

- (a) is provided to a person by, or on behalf of, a medical practitioner, being a medical practitioner who is not a consultant physician, or specialist, in any speciality (other than a medical practitioner who is, for the purposes of the Act, both a general practitioner and a consultant physician, or specialist, in a particular speciality); and
- (b) has not been referred to the medical practitioner by another medical practitioner or person with referring rights.
- **2. (6)** For item 74991:

ASGC means the document titled Australian Standard Geographical Classification (ASGC) 2002, published by the Australian Bureau of Statistics, as in force on 1 July 2002.

practice location, in relation to the provision of a pathology service, means the place of practice in respect of which the practitioner by whom, or on whose behalf, the service is provided, has been allocated a provider number by the Commission.

Regional, rural or remote area means an area classified as RRMAs 3-7 under the Rural, Remote and Metropolitan Areas Classification.

Rural, Remote and Metropolitan Areas Classification has the meaning given by subrule 3 (1) of Part 2 of Schedule 1 to the general medical services table.

SLA means a Statistical Local Area specified in the ASGC.

SSD mean a Statistical Subdivision specified in the ASGC.

Circumstances in which services rendered following 2 requests to be taken to have been rendered following 1 request

- **3.** (1) In subrule 3(2), *service* includes assay, estimation and test.
- **3. (2)** Two or more pathology services (other than services to which, under rule 4, this rule does not apply) rendered for a patient following 2 or more requests are taken to have been rendered following a single request if:
- (a) the services are listed in the same item; and
- (ab) that item is not item 74990 or 74991; and
- (b) the patient's need for the services was determined under subsection 16A (1) of the Act on the same day even if the services are rendered by an approved pathology practitioner on more than one day.

Services to which rule 3 does not apply

- **4. (1)** Rule 3 does not apply to a pathology service described in item 65060, 65070, 65120, 65123, 65126, 65129, 65150, 65153, 65156, 66500, 66503, 66506, 66509, 66512, 66584 or 66800, if:
- (a) the service is rendered in relation to one or more specimens taken on each of not more than 6 separate occasions in a period of 24 hours; and

- (b) the service is rendered to an inpatient in a hospital; and
- (c) each service must be rendered as soon as possible after collection and after authorization of the result of the previous specimen; and
- (d) the account for the service is endorsed 'Rule 3 Exemption'.
- **4. (2)** Rule 3 does not apply to any of the following pathology services:
- (a) estimation of prothrombin time (INR) in respect of a patient undergoing anticoagulant therapy;
- (b) quantitative estimation of lithium in respect of a patient undergoing lithium therapy;
- (c) a service described in item 65070 in relation to a patient undergoing chemotherapy for neoplastic disease or immunosuppressant therapy;
- (d) a service described in item 65070 in relation to clozaril, ticlopidine hydrochloride, methotrexate, gold, sulphasalazine or penicillamine therapy of a patient;
- (e) a service described in item 66500 66512 in relation to methotrexate or leflunomide therapy of a patient;
- (f) quantitative estimation of urea, creatinine and electrolytes in relation to:
- (i) cis-platinum or cyclosporin therapy of a patient; or
- (ii) chronic renal failure of a patient being treated in a dialysis program conducted by a recognised hospital;
- (g) quantitative estimation of albumin and calcium in relation to therapy of a patient with vitamin D, its metabolites or analogues;
- (h) quantitative estimation of calcium, phosphate, magnesium, urea, creatinine and electrolytes in cancer patients receiving bisphosphonate infusions.

if

- (i) under a request for a service, other than a request for a service described in paragraph (a), no more than 6 tests are requested; and
- (ii) the tests are performed within 6 months of the request; and
- (iii) the account for the service is endorsed "Rule 3 Exemption".
- **4. (3)** Rule 3 does not apply to a pathology service described in items 65109 or 65110 if:
- (a) The service is rendered on not more than 5 separate occasions in the case of item 65109 and 2 separate occasions in the case of item 65110 in a period of 24 hours; and
- (b) The service is rendered in response to a written request separated in time from the previous request; and
- (c) The account for the service is endorsed "Rule 3 Exemption".

Item taken to refer only to the first service of a particular kind

- **5. (1)** For an item in Group P1 (Haematology):
- (a) if pathology services of a kind referred to in item 65090 or 65093 are rendered for a patient during a period when the patient is in hospital, the item applies only to the first pathology service of that kind rendered for the patient during the period; and

- (b) if:
- (i) tests (except tests mentioned in item 65099, 65102, 65105 and 65108) are carried out in relation to a patient episode; and
- (ii) specimen material from the patient episode is stored; and
- (iii) in response to a request made within 14 days of the patient episode, further tests (except tests mentioned in item 65099, 65102, 65105 and 65108) are carried out on the stored material; the later tests and the earlier tests are taken to be part of one patient episode.
- **5. (2)** Benefits for items 65102 and 65108 are payable only if a minimum of 6 units are issued for the patient's care in any 1 day.
- **5.(3)** For items 65099 and 65102:

compatibility tests by crossmatch means that, in addition to all the tests described in paragraphs (a) and (b) of the item, donor red cells from each unit must have been tested directly against the serum of the patient by 1 or more accepted crossmatching techniques.

Certain items not to apply to a service referred by one pathology practitioner to another

6. (1) In this rule:

designated pathology service means a pathology service in respect of tests relating to a single patient episode that are tests of the kind described in item 65150, 65175, 66650, 66695, 66711, 66722, 66785, 66800, 66812, 66819, 66825, 69384, 69494, 71089, 71153 or 71165.

- **6. (2)** This rule applies in respect of a designated pathology service where:
 - (a) an approved pathology practitioner (*practitioner A*) in an approved pathology authority:
- (i) has been requested to render the designated pathology service; and
- (ii) is unable, because of the lack of facilities in, or expertise or experience of the staff of, the laboratory of the authority, to render 1 or more of the tests included in the service; and
- (iii) requests an approved pathology practitioner *(practitioner B)* in another approved pathology authority to render the test or tests that practitioner A is unable to render; and
- (iv) renders each test (if any) included in the service, other than the test or tests in respect of which the request mentioned in subparagraph (iii) is made; and
- (b) the tests mentioned in subparagraph (a) (iv) that practitioner A renders are not tests constituting a service described in item 65156, 65179, 66653, 66712, 66734, 66788, 66806, 66815, 66822, 66828, 69496, 71093, 71159 or 71168.
- **6. (3)** If this rule applies in respect of a designated pathology service:
- (a) item 65150, 65153, 65175, 65176, 65177, 65178, 66650, 66695, 66698, 66701, 66704, 66707, 66711, 66722, 66725, 66728, 66731, 66785, 66800, 66803, 66812, 66819, 66825, 69384, 69387, 69390, 69393, 69396, 69494, 69495, 71089, 71091, 71153, 71155, 71157, 71165, 71166 or 71167 (as the case requires) applies in respect of the test or tests rendered by practitioner A; and
- (b) where practitioner B renders a service under a request referred to in subparagraph (2) (a) (iii) and:
- (i) practitioner A has rendered one or more of the tests that the service comprises subject to subrule (4), the amount specified in item 65158, 65181, 66652, 66697, 66715, 66724, 66790, 66805, 66817, 66821, 66827, 69401,

69498, 71092, 71156 or 71170 (as the case requires) shall be taken to be the fee for each test that the service comprises; or

- (ii) practitioner A has not rendered any of the tests that the service comprises -
- (A) the amount specified in item 65157, 65180, 66651, 66696, 66714, 66723, 66789, 66804, 66816, 66820, 66826, 69400, 69497, 71090, 71154 or 71169 (as the case requires) shall be taken to be the fee for the first test that the service comprises; and
- (B) subject to subrule (4), the amount specified in item 65158, 65181, 66652, 66697, 66715, 66724, 66790, 66805, 66817, 66821, 66827, 69401, 69498, 71092, 71156 or 71170 (as the case requires) shall be taken to be the fee for each subsequent test that the service comprises.
- **6. (4)** For paragraph (3) (b), the maximum number of tests to which item 65158, 65181, 66652, 66697, 66715, 66724, 66790, 66805, 66817, 66821, 66827, 69401, 69498, 71092, 71156 or 71170 applies is:
- (a) for item 66652, 66715, 66790, 66817, 66821 or 66827:
- 2 X; and
 - (b) for item 65158, 66805, 69498 or 71092:
- 3 X; and
 - (c) for item 71156 or 71170:
- 4 X; and
 - (d) for item 65181 or 66724:
- 5 X; and

where X is the number of tests rendered by practitioner A in relation to the designated pathology service in respect of which the request mentioned in that paragraph is made.

6. (5) Items in Group P10 (Patient episode initiation) do not apply to the second mentioned approved pathology practitioner in subrule (2).

Items not to be split

7. Except as stated in rule 6, the amount specified in an item is payable only to one approved pathology practitioner in respect of a single patient episode.

Creatinine ratios - Group P2 (chemical)

- **8.** A pathology service mentioned in an item (except item 66500) in Group P2 (chemical) that:
- (a) involves the measurement of a substance in urine; and
- (b) requires calculation of a substance/creatinine ratio;

is taken to include the measurement of creatinine necessary for the calculation.

Thyroid function testing

9. (1) For item 66719:

abnormal level of TSH means a level of TSH that is outside the normal reference range in respect of the particular method of assay used to determine the level.

- 9. (2) Except where paragraph (a) of item 66719 is satisfied, the amount specified in the item is not payable in respect of a pathology service described in the item unless the pathologist who renders the service has a written statement from the medical practitioner who requested the service that satisfies subrule (3).
- **9. (3)** The written statement from the medical practitioner must indicate:
- (a) that the tests are required for a particular purpose, being a purpose specified in paragraph (b) of item 66719; or
- (b) that the medical practitioner who requested the tests suspects the patient has pituitary dysfunction; or
- (c) that the patient is on drugs that interfere with thyroid hormone metabolism or function.

Meaning of "serial examinations or cultures"

- **10.** For an item in Group P3 (Microbiology):
- (a) serial examinations or cultures means a series of examinations or cultures requested on 1 occasion whether or not:
- (i) the materials are received on different days by the approved pathology practitioner; or
- (ii) the examinations or cultures were requested on 1 or more request forms by the treating practitioner; and
- (b) if:
- (i) tests are carried out in relation to a patient episode; and
- (ii) specimen material from the patient episode is stored; and
- (iii)in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material:

the later tests and the earlier tests are taken to be part of one patient episode.

Investigation for hepatitis serology

11. A medicare benefit is not payable in respect of more than one of items 69475, 69478 and 69481 in a patient episode.

Tests in Group P4 (Immunology) relating to antibodies

- **12.** For items in Group P4 (Immunology), in items 71119, 71121, 71123 and 71125, if:
- (a) tests are carried out in relation to a patient episode; and
- (b) specimen material from the patient episode is stored; and
- (c) in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;

the later tests and the earlier tests are taken to be part of one patient episode.

Tests on biopsy material - Group P5 (Tissue pathology) and Group P6 (Cytology)

- **13. (1)** For items in Group P5 (Tissue pathology):
- (a) biopsy material means all tissue received by the Approved Pathology Practitioner:
- (i) from a medical procedure or group of medical procedures performed on a patient at the same time; or

- (ii) after being expelled spontaneously from a patient.
- (b) *cytology* means microscopic examination of 1 or more stained preparations of cells separated naturally or artificially from their normal environment by methods recognised as adequate to demonstrate their structure to a degree sufficient to enable an opinion to be formed about whether they are likely to be normal, abnormal but benign, or abnormal and malignant but, in accordance with customary laboratory practice, does not include examination of a blood film and a bone marrow aspirate; and
- (c) *separately identified specimen* means an individual specimen collected, identified so that it is clearly distinguished from any other specimen, and sent for testing by or on behalf of the treating practitioner responsible for the procedure in which the specimen was taken.
- **13. (2)** For Groups P5 and P6 of the pathology services table, services in Group P6 include any services described in Group P5 on the material submitted for a test in Group P6.
- **13. (3)** For subrule (2), any sample submitted for cytology from which a cell block is prepared does not qualify for a Group P5 item.
- **13.(4)** If more than 1 of the services mentioned in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838 are performed in a single patient episode, only the fee for the item performed having the highest specified fee is applicable to the services.
- **13.(5)** If more than 1 histopathological examinations are performed on separate specimens, of different complexity levels, from a single patient episode, a medicare benefit is payable only for the examination that has the highest schedule fee.
- **13.(6)** In items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838 a reference to a *complexity level* is a reference to the level given to a specimen type mentioned in Part 4 of this Table.
- **13.(7)** If more than 1 of the services mentioned in items 72846, 72847, 72848; 72849 and 72850 or 73059, 73060, 73061, 73064 and 73065 are performed in a single patient episode, a medicare benefit is payable only for the item performed that has the highest scheduled fee.
- **13.(8)** If more than 1 of the services mentioned in items 73049, 73051, 73062, 73063, 73066 and 73067 are performed in a single patient episode, only the fee for the item performed having the higher or highest specified fee applies to the services.

Items in Groups P10 (Patient episode initiation) and P11 (Specimen referred) not to apply in certain circumstances

14. (1) For this rule and items in Groups P10 (Patient episode initiation) and P11 (Specimen referred):

approved collection centre has the same meaning as in Part IIA of the Act.

institution means a place at which residential accommodation or day care is, or both residential accommodation and day care are, made available to:

- (a) disadvantaged children; or
- (b) juvenile offenders; or
- (c) aged persons; or
- (d) chronically ill psychiatric patients; or
- (e) homeless persons; or

- (f) unemployed persons; or
- (g) persons suffering from alcoholism; or
- (h) persons addicted to drugs; or
- (i) physically or mentally handicapped persons;

but does not include:

- (j) a hospital; or
- (k) a residential aged care home; or
- (1) accommodation for aged persons that is attached to a residential aged care home or situated within a residential aged care home.

prescribed laboratory means a laboratory operated by:

- (a) the Australian Government; or
- (b) an authority of the Commonwealth; or
- (c) a State or internal Territory; or
- (d) an authority of a State or internal Territory; or
- (e) an Australian tertiary education institution.

specimen collection centre has the same meaning as in Part IIA of the Act.

treating practitioner has the same meaning as in paragraph 16A(1)(a) of the Act.

- **14. (2)** If a service described in an item in Group P10 is rendered by, or on behalf of, an approved pathology practitioner who is a recognised pathologist, the relevant one of those items does not apply to the service if:
- (a) the service is rendered upon a request made in the course of a service provided to a public patient in a recognised hospital or when attending an outpatient service of a recognised hospital.
- **14. (3)** An item in Group P10 or P11 does not apply to a pathology service to which subsection 16A(7) of the Act applies.
- **14. (4)** An item in Group P10 or P11 does not apply to a pathology service unless at least 1 item in Groups P1 to P8 also applies to the service.
- **14. (5)** Subject to subrule (7), if one item in Group P10 applies to a patient episode, no other item in the Group applies to the patient episode.
- **14. (6)** An item in Group P11 applies only to the approved pathology practitioner or approved pathology authority to whom the specimen mentioned in the item was referred.
- **14. (7)** If, in respect of the same patient episode:
- (a) services referred to in 1 or more items in Group P5 and 1 or more of Groups P1, P2, P3, P4, P6, P7 and P8 are rendered by an approved pathology practitioner in the laboratory of another approved pathology authority; or
- (b) services referred to in 1 or more items in Group P6 and 1 or more of Groups P1, P2, P3, P4, P5, P7 and P8 are rendered by another approved pathology practitioner in the laboratory of another approved pathology authority;

the fee specified in the applicable item in Group P10 is payable to both approved pathology practitioners.

- **14. (8)** If more than one specimen is collected from a person on the same day for the provision of pathology services:
- (a) in accordance with more than 1 request; and
- (b) in or by a single approved pathology authority;

the fee specified in the applicable item in Group P10 applies once only to the services unless an exemption listed in Rule 4 applies or an exemption has been granted under Rule 3 "S4B(3)".

14. (9) The amount specified in item 73940 is payable only once in respect of a single patient episode.

Application of an item in Group P11 (Specimen referred) to a service excludes certain other items

15. If item 73940 applies to a patient episode, none of the items in Group P10 applies to any pathology service rendered by the approved pathology authority or approved pathology practitioner who claimed item 73940 in respect of the patient episode.

Circumstances in which an item in Group P11 (Specimen referred) does not apply

- **16. (1)** An item in Group P11 does not apply to a referral if:
- (a) a service in respect of the same patient episode has been carried out by the referring approved pathology authority; and
- (b) the approved pathology authority to which the referral is made is related to the referring approved pathology authority.
- **16. (2)** An approved pathology authority is *related to* another approved pathology authority for subrule (1) if:
- (a) both approved pathology authorities are employed (including employed under contract) by the same person, whether or not the person is also an approved pathology authority; or
- (b) either of the approved pathology authorities is employed (including employed under contract) by the other; or
- (c) both approved pathology authorities are corporations and are related corporations within the meaning of the Corporations Act; or
- (d) the approved pathology authorities are partners (whether or not either or both of the approved pathology authorities are individuals and whether or not other persons are in partnership with either or both of the approved pathology authorities; or
- (e) both approved pathology authorities are operated by the Commonwealth or an authority of the Commonwealth; or
- (f) both approved pathology authorities are operated by the same State or internal Territory or an authority of the same State or internal Territory.
- **16. (3)** An item in Group P11 does not apply to a referral if the following common tests are referred either singly or in combination (except if the following items are referred in combination with other items not similarly specified): 65060, 65070, 65120, 66500, 66503, 66506, 66509, 66512, 66536, 66596, 69300, 69303, 69333 or 73527.

Abbreviations

17. (1) The abbreviations in Part 4 of this table may be used to identify particular pathology services or groups of pathology services.

17. (2) The names of services or drugs not listed in Part 4 of this table must be written in full.

Certain pathology services to be treated as 1 service

18. (1) In this rule:

general practitioner means a medical practitioner who:

- (a) is not a consultant physician in any specialty; and
- (b) is not a specialist in any specialty.

set of pathology services means a group of pathology services:

- (a) that consists of services that are described in at least 4different items; and
- (b) all of which are requested in a single patient episode; and
- (c) each of which relates to a patient who is not an admitted patient of a hospital; and
- (d) excludes services referred to in an item in Group P10, Group P11, Group P12 or

Group P13, items 66900, 69484, 73070, 73071, 73072, 73073, 73074, 73075 or 73076; and

(e) excludes services described in the following items:

```
65079, 65082, 65157, 65158, 65166, 65180, 65181, 66606, 66610, 66639, 66642, 66651, 66652, 66663, 66666, 66696, 66697, 66714, 66715, 66723, 66724, 66780, 66783, 66789, 66790, 66792, 66804, 66805, 66816, 66817, 66820, 66821, 66826, 66827, 66832, 66834, 66837, 69325, 69328, 69331, 69379, 69383, 69400, 69401, 69451, 69500, 69484, 69489, 69492, 69497, 69498, 71076, 71090, 71092, 71096, 71148, 71154, 71156, 71169, 71170, 73309, 73312, 73315, 73318, 73321 and 73324;
```

where those services are performed by an approved pathology practitioner in an accredited pathology laboratory of an approved pathology authority following referral by another approved pathology practitioner in an accredited pathology laboratory of an approved pathology authority which is not **related to** the first mentioned approved pathology authority.

- (1A) An approved pathology authority is **related to** another approved pathology authority for the purposes of paragraph 18(1)(e) if that approved pathology authority would be related to the other approved pathology authority for the purposes of rule 16(2).
- **18. (2)** If a general practitioner requests a set of pathology services, the pathology services in the set are to be treated as individual pathology services in accordance with this rule.
- **18. (3)** If the fee specified in 1 item that describes any of the services in the set of pathology services is higher than the fees specified in the other items that describe the services in the set:
- (a) the pathology service described in the first-mentioned item is to be treated as 1 pathology service; and
 - (b) either:
- (i) the pathology service in the set that is described in the item that specifies the second-highest fee is to be treated as 1 pathology service; or
- (ii) if 2 or more items that describe any of those services specify the second-highest fee ξ the pathology service described in the item that specifies the second-highest fee, and has the lowest item number, is to be treated as 1 pathology service; and

- (c) the pathology services in the set, other than the services that are to be treated as 1 pathology service under paragraphs (a) and (b), are to be treated as 1 pathology service.
- **18. (4)** If the fees specified in 2 or more items that describe any of the services in the set of pathology services are the same, and higher than the fees specified in the other items that describe the services in the set:
- (a) the pathology service in the set that is described in the item that specifies the highest fee, and has the lowest item number, is to be treated as 1 pathology service; and
- (b) the pathology service in the set that is described in the item that specifies the highest fee, and has the second-lowest item number, is to be treated as 1 pathology service; and
- (c) the pathology services in the set, other than the services that are to be treated as 1 pathology service under paragraphs (a) and (b), are to be treated as 1 pathology service.
- **18. (5)** If pathology services are to be treated as 1 pathology service under paragraph (3)(c) or (4)(c), the fee for the 1 pathology service is the highest fee specified in any of the items that describe the pathology services that are to be treated as the 1 pathology service.

Hepatitis C viral RNA testing

19. For item 69499 and 69500:

Hepatitis C sero-positive, for a patient, means 2 different assays of Hepatitis C antibodies are positive.

serological status is uncertain, for a patient, means any result where 2 different assays of Hepatitis C antibodies are inconclusive.

Haemochromatosis testing

20. For items 73317 and 73318:

elevated serum ferritin for a patient, means a level of ferritin above the normal reference range in respect of the particular method of assay used to determine the level.

Nutritional and toxicity metals testing

22. (1) For this rule:

nutritional metals testing group means items 66819, 66820, 66821 and 66822.

metal toxicity testing group means items 66825, 66826, 66827, 66828, 66831 and 66832.

- 22. (2) An item in the nutritional metals testing group or the metal toxicity testing group does not apply in relation to a service performed if medicare benefits are paid or payable for tests that are performed for the same patient in 3 patient episodes requested within 6 months before the request for that service, under any of:
- (a) that item; or
- (b) the other item in the same group; or
- (c) an item in the other group.

Antineutrophil Cytoplasmic Antibody

23. A request for Antineutrophil Cytoplasmic Antibody immunofluorescence test (ANCA) shall be deemed to include requests for antineutrophil proteinase 3 antibody test (PR-3 ANCA) and antimyeloperoxidase antibody test (MPO ANCA) where the immunofluorescence test for ANCA is abnormal, or has been abnormal, or those specific antibodies have been previously detected.

Satisfying Requirements Described in Items

- 24. Unless stated elsewhere in these rules, where an item contains a requirement, this requirement is satisfied if:
- (a) The requirement/s as stipulated in the item descriptor are contained in the request form; or
- (b) The requirement/s as stipulated in the item descriptor were supplied previously in writing to the APA and this documentation is retained by the APA; or
- (c) The results of other laboratory tests performed in the same episode meet the requirement/s as stipulated in the item descriptor; or
- (d) The results of laboratory tests that meet the requirement/s as stipulated in the item descriptor are supplied on the request form; or

The results of laboratory tests that meet the requirement/s as stipulated in the item descriptor are contained in the APA's records.

Limitation on certain items

- **25.** (a) For any particular patient, items 66539, 66605, 66606, 66607, 66610, 69380, 69488, 69489, 71075, 71127, 71135 or 71137 is applicable not more than twice in a 12 month period.
 - (b) For any particular patient, item 66626 is applicable not more than 36 times in a 12 month period.
- (c) For any particular patient, items 66655, 66659, 66838, 66841, 69482, 69491, 69499 or 69500 are applicable not more than once in a 12 month period.
 - (d) For any particular patient, item 66750 or 66751 is applicable not more than once in a pregnancy.
 - (e) For any particular patient, item 69336 is applicable not more than once in each period of 7 days.
- (f) For any particular patient, items 66551, 66660, 69445, 69451, 69483, 71079 or 73523 are applicable not more than 4 times in a 12 month period.
- (g) For any particular patient, items 66554, 66830 and 71077 are applicable not more than 6 times in a 12 month period.
- (h) For any particular patient, item 66819, 66820, 66821, 66825, 66826, 66827 or 66828 is applicable not more than 3 times in a 6 month period.
 - (i) For any particular patient, items 73339 and 73340 are applicable not more than once.

Antigen Detection - Group P3 (Microbiology)

- 26. If the service listed in 69316, 69317, 69319, 69494, 69495, 69496, 69497 or 69498 is a pathologist determinable service the specialist pathologist is required to record the reasons for determining the need for this service.
- **27.** If the service rendered in 71148, 73320 or 73321 is a pathologist determinable service, the specialist pathologist is required to record the reason for determining the need for this service including the result of the service in 71147.

Second Opinion morphology, limitations on items 72858 and 72859

- **28.1** Items 72858 and 72859 apply:
 - (a) only to a service that is covered by:
 - (i) item 65084 or 65087; or

- (ii) item 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 or 72838; or
- (iii) an item in Group P6 (other than item 73070, 73071, 73072, 73073, 73074, 73075 or 73076); and
- (b) only if the treating practitioner and the approved pathology practitioner who provided the original opinion on the patient specimen agree that a second opinion is reasonably necessary for diagnostic purposes.
- **28.2** Items 72858 and 72859 do not apply if the accredited pathology laboratory in which the second opinion is provided is the same laboratory in which the original opinion was provided.

Table for Cross Referencing Rules and Clauses appearing in Regulations

1 Nov 2010 MBS Book Rules		ance (Patholo	gy Services Tab	Services Table) Regulations 2010 Clauses			
1	Dictionary						
2	1.2.1	2.12.1					
3	1.2.2						
4	1.2.3	2.1.1	2.2.2				
5	2.1.2						
6	1.2.4						
7	1.2.5						
8	2.2.1						
9	2.2.5						
10	2.3.1						
11	2.3.3						
12	2.4.2						
13	2.5.1	2.6.1					
14	2.10.1	2.11.1					
15	2.11.2						
16	2.11.3						
17	1.1.1						
18	1.2.6						
18A	1.2.7						
19	2.3.5						
20	2.7.1						
21	2.2.4						
22	2.2.7						
23	2.4.4						
24	1.2.8	2.4.5					
25	2.2.3	2.2.6	2.2.7	2.3.4	2.4.1	2.8.1	
26	2.3.2						
27	2.4.3	2.7.2					

PN.1.1 Pathology Services in Relation to Medicare Benefits - Outline of Arrangements Basic Requirements

Determination of Necessity of Service

The treating practitioner must determine that the pathology service is necessary.

Request for Service

The service may only be provided:

- (i) in response to a request from the treating practitioner, including a participating midwife or a participating nurse practitioner, or from another Approved Pathology Practitioner and the request must be in writing (or, if oral, confirmed in writing within fourteen days); or
- (ii) if determined to be necessary by an Approved Pathology Practitioner who is treating the patient.

Services requested by participating midwives and participating nurse practitioners:

(i) A participating midwife can request the following services:

Items 65060, 65070, 65090 to 65099 (inclusive), 65114, 66500 to 66512 (inclusive), 66545, 66548, 66566, 66743, 66750, 66751, 69303 to 69317 (inclusive), 69324, 69384 to 69415 (inclusive), 73070, 73071, 73075, 73076 and 73529.

(ii) A participating nurse practitioner can request items in the range 65060 to 73529 (inclusive).

Provision of Service

The following conditions relate to provision of services:

- (i) the service has to be provided by or on behalf of an Approved Pathology Practitioner;
- (ii) the service has to be provided in a pathology laboratory accredited for that kind of service;
- (iii) the proprietor of the laboratory where the service is performed must be an Approved Pathology Authority;
- (iv) the Approved Pathology Practitioner providing the service must either be the proprietor of the laboratory or party to an agreement, either by way of contract of employment or otherwise, with the proprietor of the laboratory in which the service is provided; and
- (v) no benefit will be payable for services provided by an Approved Pathology Practitioner on behalf of an Approved Pathology Authority if they are not performed in the laboratories of that particular Approved Pathology Authority.

Therapeutic Goods Act 1989

For any service listed in the MBS to be eligible for a Medicare rebate, the service must be rendered in accordance with the provisions of the relevant Commonwealth and State and Territory laws. Approved Pathology Practitioners have the responsibility to ensure that the supply of medicines or medical devices used in the provision of pathology services is strictly in accordance with the provisions of the *Therapeutic Goods Act 1989*.

PN.1.2 Exemptions to Basic Requirements Satisfying requirements described in pathology service

Unless the contrary intention appears, a requirement contained in the description of a pathology service in Part 2 is satisfied if:

- (a) for a requirement for information the information:
- (i) is included in the request for the service; or
- (ii) was supplied in writing on an earlier occasion to the approved pathology authority that rendered the service, and has been kept by the approved pathology authority; or
- (b) for a requirement for laboratory test results *i*, the results are:
- (i) included in the request for the service; or
- (ii) obtained from another laboratory test performed in the same patient episode; or
- (iii) included in results from an earlier laboratory test that have been kept by the approved pathology authority.

Services Where Request Not Required

- (i) a pathologist determinable service. A pathologist-determinable service is a pathology service:
- (a) that is rendered by or on behalf of an approved pathology practitioner for a person who is a patient of that approved pathology practitioner who has determined that the service is necessary; or
- (b) that is specified in item 73332, 73336, 73337, 73342 or only one immunohistochemistry items 72846, 72847, 72848, 72849 and 72850, or electronmicroscopy items 72851 and 72852 or immunocytochemistry items 73059, 73060 or 73061 and is considered necessary by the approved pathology practitioner as a consequence of information resulting from a pathology service contained in tissue examination items 72813 72838 or cytology items 73045 73051 respectively.

Please note: a written request is required for a service contained in items 72813 to 72838 and items 73045 to 73051.

(c) that is specified in one of the antigen detection items 69494, 69495 or 69496 is considered necessary by the approved pathology practitioner as a consequence of information provided by the requesting practitioner or by the nature or appearance of the specimen or as a consequence of information resulting from a pathology service contained in items 69303, 69306, 69312, 69318, 69321 and 69345.

Please note: a written request is required for a service contained in items 69303, 69306, 69312, 69318, 69321 and 69345.

- (d) that is specified in item 73320, HLA-B27 typing by nucleic acid amplification, and is considered necessary by the approved pathology practitioner because the results of HLA-B27 typing described in item 71147 are unsatisfactory.
- (e) that is specified in item 73305, detection of mutation of the FMRI gene by Southern Blot analysis where the results in item 73300 are inconclusive.

PN.1.3 Circumstances Where Medicare Benefits Not Attracted Services Rendered by Disqualified Practitioner

Medicare benefits are not payable for pathology services if at the time the service is rendered, the person, by or on whose behalf the service is rendered, is a person in relation to whom a determination is in force in relation to that class of services. That is, where an Approved Pathology Practitioner has breached an undertaking, and a determination has been made that Medicare benefits should not be paid during a specified period (of up to five years) in respect of specified pathology services rendered by the practitioner.

Note: An Approved Pathology Practitioner may be disqualified for reasons other than a breach of undertaking.

Certain Pathology Tests Do Not Attract Medicare Benefits

Certain tests of public health significance do not qualify for payment of Medicare benefits. Examples of services in this category are:

- examination by animal inoculation;
- Guthrie test for phenylketonuria;
- neonatal screening for hypothyroidism (T4/TSH estimation);
- neonatal screening for Cystic Fibrosis;
- neonatal screening for Galactosemia;
- pathology services used with the intention of monitoring the performance enhancing effects of any substance;
- pathology tests carried out on specimens collected from persons occupationally exposed to sexual transmission of disease where the purpose of the collection of specimens is for testing in accordance with conditions determined by the health authority of the State or Territory in which the service is performed.

In addition to the above, certain other tests do not qualify for payment of Medicare benefits. These include:

- cytotoxic food testing;
- pathology services performed for the purposes of control estimation, repeat tests (eg. for confirmation of earlier tests on the same specimen, etc);
- preparation of autogenous vaccines;
- tissue banking and preparation procedures;
- pathology services performed on stillborn babies or cadavers;
- pathology services which are performed routinely in association with the termination of pregnancy without there being any indication for the necessity of the services.

However, benefits will be paid for the following pathology tests:

- item 65060 haemoglobin estimation;
- item 65090 blood grouping ABO and Rh (D antigen);
- item 65096 examination of serum for Rh and other blood group antibodies.

PN.2.1 Responsibilities of Treating/Requesting Practitioners Form of Request

A treating practitioner may request a pathology service either orally or in writing but oral requests must be confirmed in writing within fourteen days from the day when the oral request was made.

Pathology request forms and combined pathology request/offer to assign forms which are prepared by the pathologists and distributed to requesting practitioners on or after 1 August 2012 must include the minimum information detailed under P.2.2.

All written requests for pathology services should contain the following particulars:

- (i) a description of the individual pathology services, or recognised groups of pathology tests to be rendered (see P.17.4 and the Index for acceptable terms and abbreviations). The description must be sufficient to enable the item in which the service is specified to be identified;
- (ii) the date of request;
- (iii) the name of the requesting practitioner and their practice address or provider number;
- (iv) the patient's name and address;
- (v) details of the hospital status of the patient, as follows (for benefit rate assessment). That is, whether the patient was or will be, at the time of the service and when the specimen is obtained:
- (a) a private patient in a private hospital, or approved day hospital facility;
- (b) a private patient in a recognised hospital;
- (c) a public patient in a recognised hospital;
- (d) an outpatient of a recognised hospital;

Offence Not to Confirm an Oral Request

A requesting practitioner who, without reasonable excuse, does not confirm in writing an oral request within fourteen days of making the oral request is guilty of an offence under the *Health Insurance Act 1973* punishable, upon conviction, by a fine not exceeding \$1,100 (10 Penalty Units in accordance with the Crimes Act 1914), and the request is deemed never to have been made.

The Department of Human Services (DHS) has developed a <u>Health Practitioner Guideline to substantiate that a valid request existed (pathology or diagnostic imaging)</u> which is located on the DHS website.

PN.2.2 Responsibilities of Approved Pathology Practitioners Form of Request

There is no official "request in writing" form, and the requesting practitioner's own stationery, or pre-printed forms supplied by Approved Pathology Practitioners/Authorities are acceptable.

For the purposes of Medicare eligible services, the minimum information requirements for a pre -printed pathology request and combined pathology request/offer to assign are detailed within the: *Health Insurance Act 1973*; *Health Insurance Regulations 2018*; and the *Privacy Act 1988*.

The following table presents the minimum details that pre-printed pathology request forms and combined pathology request/offer to assign forms must contain for the purposes of a subsequent Medicare claim:

Requesting Practitioner

a) name

b) practice address or provider number

Patient Details

a) name - surname, first name

b) address

c) date of birth

d) sex

e) Medicare card number

f) hospital status

Two acceptable versions are as follows:

State the patient's status at the time of the service or when the specimen was collected:

OR cross out the statements that do not apply

Was or will the patient be, at the time of the service or when the specimen is obtained:

(a) a private patient in a private hospital or approved day hospital facility

(b) a private patient in a recognised hospital

(c) a public patient in a recognised hospital

(d) an outpatient of a recognised hospital

Tests Requested

a) an area titled "Tests Requested"

Self Determined (SD)

A tick box is required for SD. This is used when the APP determines that pathologist-determinable tests are necessary. This tick box can be put in the Clinical Notes area.

Mandatory patient advisory statement

One of the following statements:

'Your doctor has recommended that you use (insert name of pathology provider). You are free to choose your own pathology provider. However, if your doctor has specified a particular pathologist on clinical grounds, a Medicare rebate will only be payable if that pathologist performs the service. You should discuss this with your doctor.' 'Your treating practitioner has recommended that you use (insert name of pathology provider). You are free to choose your own pathology provider. However, if your treating practitioner has specified a particular pathologist on clinical grounds, a Medicare rebate will only be payable if that pathologist performs the service. You should discuss this with your treating practitioner.'

Privacy Note

The wording of the note must be:

"Privacy Note: The information provided will be used to assess any Medicare benefit payable for the services rendered and to facilitate the proper administration of government health programs, and may be used to update enrolment records. Its collection is authorised by the provisions of the *Health Insurance Act 1973*. The information may be disclosed to the Department of Health or to a person in the medical practice associated with this claim, or as authorised/required by law." The placement of the note is only necessary on the patient's copy and could be incorporated into the clinical notes area. Alternatively, the back of the patient copy could be used if that is more practicable.

The Department of Human Services (DHS) has developed a <u>Health Practitioner Guideline to substantiate that a valid request existed (pathology or diagnostic imaging)</u> which is located on the DHS website.

An Approved Pathology Practitioner or Approved Pathology Authority who, without reasonable excuse, provides to practitioners (directly or indirectly) combined request/assignment forms which are not in accordance with the legislation is guilty of an offence under the *Health Insurance Act 1973* punishable, upon conviction, by a fine not exceeding \$1,100 (10 Penalty Units in accordance with the Crimes Act 1914).

Patient Copy

Assignment of benefits requires the patient to receive a copy of the request. The doctor must cause the particulars relating to the professional service (tests requested) to be set out on the assignment form, before the patient signs the form and cause the patient to receive a copy of the form as soon as practicable after the patient signs it.

Authority to lodge a Patient Claim electronically

Where an Approved Pathology Practitioner or Approved Pathology Authority renders a service and the patient has not assigned the benefit the Approved Pathology Practitioner or Approved Pathology Authority can lodge a claim electronically to the Department of Human Services on behalf of the patient where consent is provided. This consent can be provided verbally.

Combined Online Patient Claiming Authority

Authority for APP/APA to submit an electronic patient claim on behalf of the claimant

An example of wording that could be used is:

'I authorise the approved pathology practitioner who will render the requested pathology services, and any further pathology services which the practitioner determines to be necessary, to submit my unpaid account to Medicare, so that Medicare can assess my claim and issue me a cheque made payable to the practitioner, for the Medicare benefit.'

Patient Signature Date / /	
----------------------------	--

Verbal consent was provided by patient to submit unpaid account to Medicare. No signature available.

Request to Approved Pathology Authority

It is acceptable for a request to be made to an Approved Pathology Authority who is the proprietor or one of the proprietors of a laboratory instead of making the request to the Approved Pathology Practitioner who renders the service or on whose behalf the service is rendered.

Holding, Retention, Recording and Production of Request Forms

Approved Pathology Practitioners must hold a request in writing for all services requested by any other practitioner before billing patients. An Approved Pathology Practitioner is required to retain written requests/confirmation of requests for pathology services for 18 months from the day when the service was rendered. This also applies to requests which an Approved Pathology Practitioner receives of which only some tests are referred to another Approved Pathology Practitioner (the first Approved Pathology Practitioner would retain the request for 18 months). If all tests were referred, the second pathologist would retain the original request.

If the written request or written confirmation has been recorded on film or other magnetic medium approved by the Minister for Health and Ageing, for the purposes of storage and subsequent retrieval, the record so made shall be deemed to be a retention of the request or confirmation. The production or reproduction of such a record shall be deemed to be a production of the written request or written confirmation.

An Approved Pathology Practitioner or an Approved Pathology Authority is required to produce, on request from the Department of Human Services CEO, no later than the end of the day following the request from the CEO, a written request or written confirmation retained pursuant to the above paragraphs. An employee of the Department of Human Services is authorised to make and retain copies of or take and retain extracts from written requests or written confirmations.

Offences in Relation to Retaining and Producing Request Forms

The following offences are punishable upon conviction by a fine not exceeding \$1000:

- an Approved Pathology Practitioner who, without reasonable excuse, does not keep request forms for 18 months;
- an Approved Pathology Practitioner who, without reasonable excuse, does not produce a request form to an
 employee of the Department of Human Services before the end of the day following the day of the
 Department of Human Services CEO's request.

Referral From An Approved Pathology Practitioner To Another Approved Pathology Practitioner

Where an Approved Pathology Practitioner refers some or all services requested to another Approved Pathology Practitioner not associated with the same Approved Pathology Authority the following apply:

- where all the services are referred, the first Approved Pathology Practitioner should forward the original request to the second Approved Pathology Practitioner, and the document bearing the patient's assignment voucher so that the second Approved Pathology Authority can direct-bill Medicare;
- where some of the services which are listed in different items in the Schedule are referred, the first Approved Pathology Practitioner must issue his/her own request in writing listing the tests to be performed, and when necessary, forward a photocopy of the patient's assignment voucher so that the second Approved Pathology Authority can direct-bill Medicare

in addition to the details of the first Approved Pathology Practitioner, the second Approved Pathology Practitioner must show on the account/receipt/assignment form:

- o name and provider number of the original requesting practitioner; and
- o date of original request;
- under the item coning rules (which limit benefits for multiple services) only one Medicare benefit is payable for services included in coned items except for estimations covered by Rule 6 entitled "designated pathology services". The exemption allows payment of more than one Medicare benefit where various components of the one item number from the same request e.g. drug assays (items 66800 and 66812) are performed by two Approved Pathology Authorities.

Although the provisions concerning designated pathology services in Rule 6 permit similar services (e.g. hormone estimations) to be performed by 2 or more laboratories, with different Approved Pathology Authorities, the sum of

the Medicare benefit payable for services provided by the laboratories concerned will not exceed the maximum amount payable under the item coning rules when a single laboratory performs all the estimations.

Notes:

- the patient should be billed by each Approved Pathology Practitioner only for those services rendered by or on his/her behalf;
- photocopies of requests are not acceptable;
- in the case of "designated pathology services" 65150, 65175, 66650, 66695, 66711, 66722, 66785, 66800,66812, 66819, 66825, 69384, 69494, 71089, 71153 or 71165 a patient episode initiation fee (PEI) is payable for the services provided by the laboratory which receives the original request and performs one or more of the estimations. However, no PEI is payable for services provided by the other laboratory which performs the remainder of the estimations. A "specimen referred fee" is payable instead. One Approved Pathology Practitioner cannot claim both a PEI and a "specimen referred fee" in relation to the same patient episode.

Offence Not To Confirm An Oral Request

An Approved Pathology Practitioner who, without reasonable excuse, does not confirm in writing an oral request to another Approved Pathology Practitioner within fourteen days of making the oral request is guilty of an offence under the *Health Insurance Act 1973* punishable, upon conviction, by a fine not exceeding \$1000, and the request is deemed never to have been made.

PN.2.3 Pathology Tests not Covered by Request

An Approved Pathology Practitioner, who has been requested to perform one or more pathology services, may consider it necessary, in the interest of the patient, that additional tests to those requested be carried out. The Approved Pathology Practitioner must discuss this need with the requesting practitioner, and if the requesting practitioner determines that additional tests are necessary, the Approved Pathology Practitioner must arrange with the requesting practitioner to forward an amended or second request for those services. The account will then be issued in the ordinary way and the additional services will attract benefits providing the Approved Pathology Practitioner is a recognised specialist pathologist.

PN.3.1 Details Required on Accounts, Receipts or Assignment Forms General

Medicare benefit is not payable in respect of a pathology service unless specified details are provided, by the practitioner rendering the service, on his or her account, receipt or assignment form.

PN.3.2 Approved Pathology Practitioners

In addition to holding a request in writing from the treating medical or dental practitioner or from another Approved Pathology Practitioner, the following additional details must be recorded on the account, receipt or assignment form of the Approved Pathology Practitioner providing the service:

- (i) the surname and initials of the Approved Pathology Practitioner who performed the service and either his/her practice address or the provider number for the address;
- (ii) the name of the person to whom the service was rendered;
- (iii) the date on which the service was rendered;
- (iv) the name of the requesting practitioner; or in the case of a referred test, the name of the original requesting practitioner;
- (v) the date on which the request was made; or in the case of a referred test, the date on which the original request was made;

- (vi) the requesting practitioner's provider number;
- (vii) a description of the pathology service in words which are derived from the item description in the Schedule and are of sufficient detail to identify the specific test in the Schedule that was rendered. Instead of such a full description, the abbreviations contained in the index and the group abbreviations listed at PQ.4 are acceptable alternatives (see PQ.1);
- (viii) where the Approved Pathology Practitioner determines or provides a pathology service on his/her own patient, the account must be endorsed "sd"; and
- (ix) provide collection centre identification number if the specimen was collected in a licensed collection centre (or approved pathology collection centre).

Where some services are referred from one Approved Pathology Practitioner to another Approved Pathology Practitioner, the request details to be shown on the second Approved Pathology Practitioner's account, receipt or assignment form must be identical to those of the original requesting practitioner including the date of request.

PN.3.3 Prescribed Pathology Services

For Prescribed Pathology Services (that is, pathology items in Group P9) the medical practitioner who renders the service must ensure his or her account, receipt or assignment form includes his or her name, address or provider number, the date of the service, and a description to clearly identify the service in the Schedule that was rendered.

If the service was determined necessary by another medical practitioner who is a member of the same group practice as the practitioner who rendered the service, the name of the requesting practitioner, sufficient to identify the practitioner from other practitioners in the same group practice with the same surname, must also be included together with the date on which the request was made.

PN.3.4 Interferon Gamma Release Assay (IGRA) for detection of latent tuberculosis - (Item 69471)

Before undertaking testing it is advisable to consult with a medical practitioner experienced in the management of tuberculosis. Neither IGRA tests or the tuberculin skin test (Mantoux) can absolutely exclude latent tuberculosis and following close contact exposure preventative therapy should always be considered in young children and immunosuppressed patients.

IGRA testing for the diagnosis of latent tuberculosis should be requested in compliance with recommendations made by the National Tuberculosis Advisory Committee in 2016 or later. http://www.health.gov.au/internet/main/publishing.nsf/Content/cdna-ntac-pubs.htm including:

- IGRAs have no place in the initial investigation of active TB disease and cannot and should not be used to exclude suspected TB disease.
- IGRA should not be used for the purpose of screening prior to BCG vaccination.
- While IGRA tests can be used in children less than 5 years of age, there may be a higher proportion of indeterminate test results and tuberculin skin testing is preferred, unless there is a history of BCG.

At least eight weeks should elapse following last possible TB exposure before testing of a contact of a confirmed case of active tuberculosis – testing of contacts should be performed only after discussion with appropriate State or Territory public health authorities.

PN.4.1 Inbuilt Multiple Services Rule

The term "Multiple Services Rule" (Rule 3 of the Pathology Services Table) describes an arrangement which places limits on the benefits payable for items in the Pathology Services Table depending on the range of services performed during a single patient episode. A patient episode is defined in PO.4 of these notes.

PN.4.2 Exemptions

Under Rule 4 of the Pathology Services Table, exemptions to the multiple services rule have been granted for certain specified tests. In some circumstances tests which are repeated up to 6 times over a 24 hour period, or tests which are requested up to 6 times on a single request form and are performed within 6 months of the date of request may be eligible for separate Medicare benefits. The services to which the exemptions apply are listed under Rule 4.(1 and 2) and cover seriously or chronically ill patients who require particular tests under specified circumstances. In order to claim the exemptions, accounts should be endorsed "Rule 3 Exemption".

Where a practitioner seeks an exemption to the multiple services rule for a patient whose condition requires a series of pathology investigations at various times throughout any one day or over a longer period of time, and the services required are not exempted under Rule 4, an application for exemption can be made which is endorsed "S4B(3)". Some factors that the delegate of the Minister may take into consideration in approving an exemption are: the patient is seriously ill; there are distinct and separate collections and performances of tests; and the services involve substantial additional expenses for the Approved Pathology Practitioner. These, and other clinical details, should be supplied by the practitioner when seeking an S4B(3) exemption.

If Rule 3 exemptions are endorsed "S4B(3)", claim assessment could take longer as all S4B(3) claims are passed to the delegate for assessment. S4B(3) covers all exemptions to the multiple services rule but, where applicable, specific "Rule 3 exemption" endorsements will speed up the payment of claims. Rule 3 and S4B(3) exemptions cannot be used to overcome time based restrictions within items e.g. "-. each test to a maximum of 4 tests in a 12 month period".

PN.5.1 Episode Cone Description of Rule 18

The term "Episode Cone" describes an arrangement under which Medicare benefits payable in a patient episode for a set of pathology services, containing more than three items, ordered by a general practitioner for a non-hospitalised patient, will be equivalent to the sum of the benefits for the three items with the highest Schedule fees. Further information on the episode coning arrangements is provided in PO.5 of these notes.

PN.5.2 Exemptions

Some items are not included in the count of the items performed when applying episode coning. The items which have been exempted from the cone include all the items identified in Rule 18.(1)(d) and (e).

PN.6.1 Bulk Billing Incentives for Episodes Consisting of a P10 Service P19.1

Pathology Services Table

Rules for the Interpretation of the Pathology Services Table

Please note that in the Health Insurance (Pathology Services Table) Regulations 2010 (effective 1 November 2010) rules and sub-rules are referred to as clauses and sub-clauses. In addition in the Regulations a rule that refers to specific items within a pathology group, for example Group P1 Haemotology, is listed directly above the Schedule of Services for that group. A table cross referencing the following rules with the clauses in the Regulations is at the end of this section.

• (1) In this table

patient episode means:

- (a) a pathology service or pathology services (other than a pathology service to which paragraph 1 (1) (b) refers) provided for a single patient whose need for the service or services was determined under section 16A of the Act:
- (i) on the same day; or

- (ii) if more than 1 test is performed on the 1 specimen within 14 days on the same or different days; whether the services:
- (iii) are requested by 1 or more practitioners; or
- (iv) are described in a single item or in more than 1 item; or
- (v) are rendered by 1 approved pathology practitioner or more than 1 approved pathology practitioner; or
- (vi) are rendered on the same or different days; or
- (b) a pathology service to which rule 4 refers that is provided in the circumstances set out in that rule that relates to the service.

receiving APP means an approved pathology practitioner in an approved pathology authority who performs one or more pathology services in respect of a single patient episode following receipt of a request for those services from a referring APP.

recognised pathologist means a medical practitioner recognised as a specialist in pathology by a determination under section 3D, 3DB or 3E of the Act.

referring APP means an approved pathology practitioner in an approved pathology authority who:

- (i) has been requested to render 1 or more pathology services, all of which are requested in a single patient episode; and
- (ii) is unable, because of the lack of facilities in, or expertise or experience of the staff of, the laboratory of the authority, to render 1 or more of the pathology services; and
- (iii) requests an approved pathology practitioner (the *receiving APP*) in another approved pathology authority to render the pathology service or services that the referring APP is unable to render; and
- (iv) renders each pathology service (if any) included in that patient episode, other than the pathology service or services in respect of which the request mentioned in subparagraph (iii) is made.

serial examinations means a series of examinations requested on 1 occasion whether or not:

- (a) the materials are received on different days by the approved pathology practitioner; or
- (b) the examinations or cultures were requested on 1 or more request forms by the treating practitioner.

the Act means the Health Insurance Act 1973.

- g. (2) In these rules, a reference to a request to an approved pathology practitioner includes a reference to a request for a pathologist-determinable service to which subsection 16A (6) of the Act applies.
- g. (3) A reference in this table by number to an item that is not included in this table is a reference to the item that has that number in the general medical services table or the diagnostic imaging services table, as the case requires.
- ii. **(4)** A reference to a **Group** in the table includes every item in the Group and a reference to a **Subgroup** in the table includes every item in the Subgroup.

Precedence of items

- ii. (1) If a service is described:
- (a) in an item in general terms; and

(b) in another item in specific terms;

only the item that describes the service in specific terms applies to the service.

- g. **(2)** Subject to subrule (3), if:
- (a) subrule (1) does not apply; and
- (b) a service is described in 2 or more items;

only the item that provides the lower or lowest fee for the service applies to the service.

ii. (3) If an item is expressed to include a pathology service that is described in another item, the other item does not apply to the service in addition to the first-mentioned item, whether or not the services described in the 2 items are requested separately.

Application of item 74990 and 74991

- ii. **(4)** Despite subrules (1), (2) and (3):
- (a) if the pathology service described in item 74991 is provided to a person, either that item or item 74990, but not both those items, applies to the service; and
- (b) if item 74990 or 74991 applies to a pathology service, the fee specified in that item applies in addition to the fee specified in any other item in the table that applies to the service.
 - c. **(5)** For items 74990 and 74991:

bulk-billed, in relation to a pathology service, means:

- (a) a medicare benefit is payable to a person in respect of the service; and
- (b) under an agreement entered into under section 20A of the Act:
- (i) the person assigns to the practitioner by whom, or on whose behalf, the service is provided, his or her right to the payment of the medicare benefit; and
- (ii) the practitioner accepts the assignment in full payment of his or her fee for the service provided.

Commonwealth concession card holder means a person who is a concessional beneficiary within the meaning given by subsection 84 (1) of the *National Health Act 1953*.

unreferred service means a pathology service that:

- (a) is provided to a person by, or on behalf of, a medical practitioner, being a medical practitioner who is not a consultant physician, or specialist, in any speciality (other than a medical practitioner who is, for the purposes of the Act, both a general practitioner and a consultant physician, or specialist, in a particular speciality); and
- (b) has not been referred to the medical practitioner by another medical practitioner or person with referring rights.
 - j. **(6)** For item 74991:

ASGC means the document titled Australian Standard Geographical Classification (ASGC) 2002, published by the Australian Bureau of Statistics, as in force on 1 July 2002.

practice location, in relation to the provision of a pathology service, means the place of practice in respect of which the practitioner by whom, or on whose behalf, the service is provided, has been allocated a provider number by the Commission.

Regional, rural or remote area means an area classified as RRMAs 3-7 under the Rural, Remote and Metropolitan Areas Classification.

Rural, Remote and Metropolitan Areas Classification has the meaning given by subrule 3 (1) of Part 2 of Schedule 1 to the general medical services table.

SLA means a Statistical Local Area specified in the ASGC.

SSD mean a Statistical Subdivision specified in the ASGC.

Circumstances in which services rendered following 2 requests to be taken to have been rendered following 1 request

- e. (1) In subrule 3(2), *service* includes assay, estimation and test.
- iii. (2) Two or more pathology services (other than services to which, under rule 4, this rule does not apply) rendered for a patient following 2 or more requests are taken to have been rendered following a single request if:
- (a) the services are listed in the same item; and
- (ab) that item is not item 74990 or 74991; and
- (b) the patient's need for the services was determined under subsection 16A (1) of the Act on the same day even if the services are rendered by an approved pathology practitioner on more than one day.

Services to which rule 3 does not apply

- iii. (1) Rule 3 does not apply to a pathology service described in item 65060, 65070, 65120, 65123, 65126, 65129, 65150, 65153, 65156, 66500, 66503, 66506, 66509, 66512, 66584 or 66800, if:
- (a) the service is rendered in relation to one or more specimens taken on each of not more than 6 separate occasions in a period of 24 hours; and
- (b) the service is rendered to an inpatient in a hospital; and
- (c) each service must be rendered as soon as possible after collection and after authorization of the result of the previous specimen; and
- (d) the account for the service is endorsed 'Rule 3 Exemption'.
 - iii. (2) Rule 3 does not apply to any of the following pathology services:
- (a) estimation of prothrombin time (INR) in respect of a patient undergoing anticoagulant therapy;
- (b) quantitative estimation of lithium in respect of a patient undergoing lithium therapy;
- (c) a service described in item 65070 in relation to a patient undergoing chemotherapy for neoplastic disease or immunosuppressant therapy;
- (d) a service described in item 65070 in relation to clozaril, ticlopidine hydrochloride, methotrexate, gold, sulphasalazine or penicillamine therapy of a patient;
- (e) a service described in item 66500 66512 in relation to methotrexate or leflunomide therapy of a patient;
- (f) quantitative estimation of urea, creatinine and electrolytes in relation to:
- (i) cis-platinum or cyclosporin therapy of a patient; or

- (ii) chronic renal failure of a patient being treated in a dialysis program conducted by a recognised hospital;
- (g) quantitative estimation of albumin and calcium in relation to therapy of a patient with vitamin D, its metabolites or analogues;
- (h) quantitative estimation of calcium, phosphate, magnesium, urea, creatinine and electrolytes in cancer patients receiving bisphosphonate infusions.

if:

- (i) under a request for a service, other than a request for a service described in paragraph (a), no more than 6 tests are requested; and
- (ii) the tests are performed within 6 months of the request; and
- (iii) the account for the service is endorsed "Rule 3 Exemption".
 - g. (3) Rule 3 does not apply to a pathology service described in items 65109 or 65110 if:
- (a) The service is rendered on not more than 5 separate occasions in the case of item 65109 and 2 separate occasions in the case of item 65110 in a period of 24 hours; and
- (b) The service is rendered in response to a written request separated in time from the previous request; and
- (c) The account for the service is endorsed "Rule 3 Exemption".

Item taken to refer only to the first service of a particular kind

- f. (1) For an item in Group P1 (Haematology):
- (a) if pathology services of a kind referred to in item 65090 or 65093 are rendered for a patient during a period when the patient is in hospital, the item applies only to the first pathology service of that kind rendered for the patient during the period; and
- (b) if:
- (i) tests (except tests mentioned in item 65099, 65102, 65105 and 65108) are carried out in relation to a patient episode; and
- (ii) specimen material from the patient episode is stored; and
- (iii) in response to a request made within 14 days of the patient episode, further tests (except tests mentioned in item 65099, 65102, 65105 and 65108) are carried out on the stored material; the later tests and the earlier tests are taken to be part of one patient episode.
 - i. (2) Benefits for items 65102 and 65108 are payable only if a minimum of 6 units are issued for the patient's care in any 1 day.
- **5.(3)** For items 65099 and 65102:

compatibility tests by crossmatch means that, in addition to all the tests described in paragraphs (a) and (b) of the item, donor red cells from each unit must have been tested directly against the serum of the patient by 1 or more accepted crossmatching techniques.

Certain items not to apply to a service referred by one pathology practitioner to another

c. (1) In this rule:

designated pathology service means a pathology service in respect of tests relating to a single patient episode that are tests of the kind described in item 65150, 65175, 66650, 66695, 66711, 66722, 66785, 66800, 66812, 66819, 66825, 69384, 69494, 71089, 71153 or 71165.

- c. (2) This rule applies in respect of a designated pathology service where:
 - (a) an approved pathology practitioner (practitioner A) in an approved pathology authority:
- (i) has been requested to render the designated pathology service; and
- (ii) is unable, because of the lack of facilities in, or expertise or experience of the staff of, the laboratory of the authority, to render 1 or more of the tests included in the service; and
- (iii) requests an approved pathology practitioner *(practitioner B)* in another approved pathology authority to render the test or tests that practitioner A is unable to render; and
- (iv) renders each test (if any) included in the service, other than the test or tests in respect of which the request mentioned in subparagraph (iii) is made; and
- (b) the tests mentioned in subparagraph (a) (iv) that practitioner A renders are not tests constituting a service described in item 65156, 65179, 66653, 66712, 66734, 66788, 66806, 66815, 66822, 66828, 69496, 71093, 71159 or 71168.
 - c. (3) If this rule applies in respect of a designated pathology service:
- (a) item 65150, 65153, 65175, 65176, 65177, 65178, 66650, 66695, 66698, 66701, 66704, 66707, 66711, 66722, 66725, 66728, 66731, 66785, 66800, 66803, 66812, 66819, 66825, 69384, 69387, 69390, 69393, 69396, 69494, 69495, 71089, 71091, 71153, 71155, 71157, 71165, 71166 or 71167 (as the case requires) applies in respect of the test or tests rendered by practitioner A; and
- (b) where practitioner B renders a service under a request referred to in subparagraph (2) (a) (iii) and:
- (i) practitioner A has rendered one or more of the tests that the service comprises subject to subrule (4), the amount specified in item 65158, 65181, 66652, 66697, 66715, 66724, 66790, 66805, 66817, 66821, 66827, 69401, 69498, 71092, 71156 or 71170 (as the case requires) shall be taken to be the fee for each test that the service comprises; or
 - (ii) practitioner A has not rendered any of the tests that the service comprises -
- (A) the amount specified in item 65157, 65180, 66651, 66696, 66714, 66723, 66789, 66804, 66816, 66820, 66826, 69400, 69497, 71090, 71154 or 71169 (as the case requires) shall be taken to be the fee for the first test that the service comprises; and
- (B) subject to subrule (4), the amount specified in item 65158, 65181, 66652, 66697, 66715, 66724, 66790, 66805, 66817, 66821, 66827, 69401, 69498, 71092, 71156 or 71170 (as the case requires) shall be taken to be the fee for each subsequent test that the service comprises.
 - c. **(4)** For paragraph (3) (b), the maximum number of tests to which item 65158, 65181, 66652, 66697, 66715, 66724, 66790, 66805, 66817, 66821, 66827, 69401, 69498, 71092, 71156 or 71170 applies is:
- (a) for item 66652, 66715, 66790, 66817, 66821 or 66827:
- 2 X; and

- (b) for item 65158, 66805, 69498 or 71092:
- 3 X; and
 - (c) for item 71156 or 71170:
- 4 X; and
 - (d) for item 65181 or 66724:
- 5 X; and

where X is the number of tests rendered by practitioner A in relation to the designated pathology service in respect of which the request mentioned in that paragraph is made.

h. (5) Items in Group P10 (Patient episode initiation) do not apply to the second mentioned approved pathology practitioner in subrule (2).

Items not to be split

i. Except as stated in rule 6, the amount specified in an item is payable only to one approved pathology practitioner in respect of a single patient episode.

Creatinine ratios - Group P2 (chemical)

- A pathology service mentioned in an item (except item 66500) in Group P2 (chemical) that:
- (a) involves the measurement of a substance in urine; and
- (b) requires calculation of a substance/creatinine ratio;

is taken to include the measurement of creatinine necessary for the calculation.

Thyroid function testing

• **(1)** For item 66719:

abnormal level of TSH means a level of TSH that is outside the normal reference range in respect of the particular method of assay used to determine the level.

- (2) Except where paragraph (a) of item 66719 is satisfied, the amount specified in the item is not payable in respect of a pathology service described in the item unless the pathologist who renders the service has a written statement from the medical practitioner who requested the service that satisfies subrule (3).
- c. (3) The written statement from the medical practitioner must indicate:
- (a) that the tests are required for a particular purpose, being a purpose specified in paragraph (b) of item 66719; or
- (b) that the medical practitioner who requested the tests suspects the patient has pituitary dysfunction; or
- (c) that the patient is on drugs that interfere with thyroid hormone metabolism or function.

Meaning of "serial examinations or cultures"

- c. For an item in Group P3 (Microbiology):
- (a) *serial examinations or cultures* means a series of examinations or cultures requested on 1 occasion whether or not:

- (i) the materials are received on different days by the approved pathology practitioner; or
- (ii) the examinations or cultures were requested on 1 or more request forms by the treating practitioner; and
- (b) if:
- (i) tests are carried out in relation to a patient episode; and
- (ii) specimen material from the patient episode is stored; and
- (iii)in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;

the later tests and the earlier tests are taken to be part of one patient episode.

Investigation for hepatitis serology

x. A medicare benefit is not payable in respect of more than one of items 69475, 69478 and 69481 in a patient episode.

Tests in Group P4 (Immunology) relating to antibodies

- For items in Group P4 (Immunology), in items 71119, 71121, 71123 and 71125, if:
- (a) tests are carried out in relation to a patient episode; and
- (b) specimen material from the patient episode is stored; and
- (c) in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;

the later tests and the earlier tests are taken to be part of one patient episode.

Tests on biopsy material - Group P5 (Tissue pathology) and Group P6 (Cytology)

- (1) For items in Group P5 (Tissue pathology):
- (a) *biopsy material* means all tissue received by the Approved Pathology Practitioner:
- (i) from a medical procedure or group of medical procedures performed on a patient at the same time; or
- (ii) after being expelled spontaneously from a patient.
- (b) *cytology* means microscopic examination of 1 or more stained preparations of cells separated naturally or artificially from their normal environment by methods recognised as adequate to demonstrate their structure to a degree sufficient to enable an opinion to be formed about whether they are likely to be normal, abnormal but benign, or abnormal and malignant but, in accordance with customary laboratory practice, does not include examination of a blood film and a bone marrow aspirate; and
- (c) *separately identified specimen* means an individual specimen collected, identified so that it is clearly distinguished from any other specimen, and sent for testing by or on behalf of the treating practitioner responsible for the procedure in which the specimen was taken.
 - (2) For Groups P5 and P6 of the pathology services table, services in Group P6 include any services described in Group P5 on the material submitted for a test in Group P6.
 - (3) For subrule (2), any sample submitted for cytology from which a cell block is prepared does not qualify for a Group P5 item.

- **13.(4)** If more than 1 of the services mentioned in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838 are performed in a single patient episode, only the fee for the item performed having the highest specified fee is applicable to the services.
- **13.(5)** If more than 1 histopathological examinations are performed on separate specimens, of different complexity levels, from a single patient episode, a medicare benefit is payable only for the examination that has the highest schedule fee.
- **13.(6)** In items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838 a reference to a *complexity level* is a reference to the level given to a specimen type mentioned in Part 4 of this Table.
- **13.(7)** If more than 1 of the services mentioned in items 72846, 72847, 72848; 72849 and 72850 or 73059, 73060, 73061, 73064 and 73065 are performed in a single patient episode, a medicare benefit is payable only for the item performed that has the highest scheduled fee.
- **13.(8)** If more than 1 of the services mentioned in items 73049, 73051, 73062, 73063, 73066 and 73067 are performed in a single patient episode, only the fee for the item performed having the higher or highest specified fee applies to the services.

Items in Groups P10 (Patient episode initiation) and P11 (Specimen referred) not to apply in certain circumstances

• (1) For this rule and items in Groups P10 (Patient episode initiation) and P11 (Specimen referred):

approved collection centre has the same meaning as in Part IIA of the Act.

institution means a place at which residential accommodation or day care is, or both residential accommodation and day care are, made available to:

- (a) disadvantaged children; or
- (b) juvenile offenders; or
- (c) aged persons; or
- (d) chronically ill psychiatric patients; or
- (e) homeless persons; or
- (f) unemployed persons; or
- (g) persons suffering from alcoholism; or
- (h) persons addicted to drugs; or
- (i) physically or mentally handicapped persons;

but does not include:

- (i) a hospital; or
- (k) a residential aged care home; or
- (l) accommodation for aged persons that is attached to a residential aged care home or situated within a residential aged care home.

prescribed laboratory means a laboratory operated by:

- (a) the Australian Government; or
- (b) an authority of the Commonwealth; or
- (c) a State or internal Territory; or
- (d) an authority of a State or internal Territory; or
- (e) an Australian tertiary education institution.

specimen collection centre has the same meaning as in Part IIA of the Act.

treating practitioner has the same meaning as in paragraph 16A(1)(a) of the Act.

- (2) If a service described in an item in Group P10 is rendered by, or on behalf of, an approved pathology practitioner who is a recognised pathologist, the relevant one of those items does not apply to the service if:
- (a) the service is rendered upon a request made in the course of a service provided to a public patient in a recognised hospital or when attending an outpatient service of a recognised hospital.
 - (3) An item in Group P10 or P11 does not apply to a pathology service to which subsection 16A (7) of the Act applies.
 - (4) An item in Group P10 or P11 does not apply to a pathology service unless at least 1 item in Groups P1 to P8 also applies to the service.
 - (5) Subject to subrule (7), if one item in Group P10 applies to a patient episode, no other item in the Group applies to the patient episode.
 - (6) An item in Group P11 applies only to the approved pathology practitioner or approved pathology authority to whom the specimen mentioned in the item was referred.
 - (7) If, in respect of the same patient episode:
- (a) services referred to in 1 or more items in Group P5 and 1 or more of Groups P1, P2, P3, P4, P6, P7 and P8 are rendered by an approved pathology practitioner in the laboratory of another approved pathology authority; or
- (b) services referred to in 1 or more items in Group P6 and 1 or more of Groups P1, P2, P3, P4, P5, P7 and P8 are rendered by another approved pathology practitioner in the laboratory of another approved pathology authority;

the fee specified in the applicable item in Group P10 is payable to both approved pathology practitioners.

- (8) If more than one specimen is collected from a person on the same day for the provision of pathology services:
- (a) in accordance with more than 1 request; and
- (b) in or by a single approved pathology authority;

the fee specified in the applicable item in Group P10 applies once only to the services unless an exemption listed in Rule 4 applies or an exemption has been granted under Rule 3 "S4B(3)".

• (9) The amount specified in item 73940 is payable only once in respect of a single patient episode.

Application of an item in Group P11 (Specimen referred) to a service excludes certain other items

• If item 73940 applies to a patient episode, none of the items in Group P10 applies to any pathology service rendered by the approved pathology authority or approved pathology practitioner who claimed item 73940 in respect of the patient episode.

Circumstances in which an item in Group P11 (Specimen referred) does not apply

- (1) An item in Group P11 does not apply to a referral if:
- (a) a service in respect of the same patient episode has been carried out by the referring approved pathology authority; and
- (b) the approved pathology authority to which the referral is made is related to the referring approved pathology authority.
 - (2) An approved pathology authority is *related to* another approved pathology authority for subrule (1) if:
- (a) both approved pathology authorities are employed (including employed under contract) by the same person, whether or not the person is also an approved pathology authority; or
- (b) either of the approved pathology authorities is employed (including employed under contract) by the other; or
- (c) both approved pathology authorities are corporations and are related corporations within the meaning of the Corporations Act; or
- (d) the approved pathology authorities are partners (whether or not either or both of the approved pathology authorities are individuals and whether or not other persons are in partnership with either or both of the approved pathology authorities; or
- (e) both approved pathology authorities are operated by the Commonwealth or an authority of the Commonwealth; or
- (f) both approved pathology authorities are operated by the same State or internal Territory or an authority of the same State or internal Territory.
 - (3) An item in Group P11 does not apply to a referral if the following common tests are referred either singly or in combination (except if the following items are referred in combination with other items not similarly specified): 65060, 65070, 65120, 66500, 66503, 66506, 66509, 66512, 66536, 66596, 69300, 69303, 69333 or 73527.

Abbreviations

- (1) The abbreviations in Part 4 of this table may be used to identify particular pathology services or groups of pathology services.
- (2) The names of services or drugs not listed in Part 4 of this table must be written in full.

Certain pathology services to be treated as 1 service

• (1) In this rule:

general practitioner means a medical practitioner who:

- (a) is not a consultant physician in any specialty; and
- (b) is not a specialist in any specialty.

set of pathology services means a group of pathology services:

- (a) that consists of services that are described in at least 4 different items; and
- (b) all of which are requested in a single patient episode; and
- (c) each of which relates to a patient who is not an admitted patient of a hospital; and
- (d) excludes services referred to in an item in Group P10, Group P11, Group P12 or

Group P13, items 66900, 69484, 73053, 73055 and 73069; and

(e) excludes services described in the following items: 65079, 65082, 65157, 65158, 65166, 65180, 65181, 66606, 66610, 66639, 66642, 66651, 66652, 66663, 66666, 66696, 66697, 66714, 66715, 66723, 66724, 66780, 66783, 66789, 66790, 66792, 66804, 66805, 66816, 66817, 66820, 66821, 66826, 66827, 66832, 66834, 66837, 69325, 69328, 69331, 69379, 69383, 69400, 69401, 69451, 69500, 69484, 69489, 69492, 69497, 69498, 71076, 71090, 71092, 71096, 71148, 71154, 71156, 71169, 71170, 73309, 73312, 73315, 73318, 73321 and 73324;

where those services are performed by an approved pathology practitioner in an accredited pathology laboratory of an approved pathology authority following referral by another approved pathology practitioner in an accredited pathology laboratory of an approved pathology authority which is not **related to** the first mentioned approved pathology authority.

- (1A) An approved pathology authority is **related to** another approved pathology authority for the purposes of paragraph 18(1)(e) if that approved pathology authority would be related to the other approved pathology authority for the purposes of rule 16(2).
 - (2) If a general practitioner requests a set of pathology services, the pathology services in the set are to be treated as individual pathology services in accordance with this rule.
 - (3) If the fee specified in 1 item that describes any of the services in the set of pathology services is higher than the fees specified in the other items that describe the services in the set:
- (a) the pathology service described in the first-mentioned item is to be treated as 1 pathology service; and
 - (b) either:
- (i) the pathology service in the set that is described in the item that specifies the second-highest fee is to be treated as 1 pathology service; or
- (ii) if 2 or more items that describe any of those services specify the second-highest fee δ the pathology service described in the item that specifies the second-highest fee, and has the lowest item number, is to be treated as 1 pathology service; and
- (c) the pathology services in the set, other than the services that are to be treated as 1 pathology service under paragraphs (a) and (b), are to be treated as 1 pathology service.
 - (4) If the fees specified in 2 or more items that describe any of the services in the set of pathology services are the same, and higher than the fees specified in the other items that describe the services in the set:
- (a) the pathology service in the set that is described in the item that specifies the highest fee, and has the lowest item number, is to be treated as 1 pathology service; and
- (b) the pathology service in the set that is described in the item that specifies the highest fee, and has the second-lowest item number, is to be treated as 1 pathology service; and

- (c) the pathology services in the set, other than the services that are to be treated as 1 pathology service under paragraphs (a) and (b), are to be treated as 1 pathology service.
 - (5) If pathology services are to be treated as 1 pathology service under paragraph (3) (c) or (4) (c), the fee for the 1 pathology service is the highest fee specified in any of the items that describe the pathology services that are to be treated as the 1 pathology service.

Hepatitis C viral RNA testing

• For item 69499 and 69500:

Hepatitis C sero-positive, for a patient, means 2 different assays of Hepatitis C antibodies are positive.

serological status is uncertain, for a patient, means any result where 2 different assays of Hepatitis C antibodies are inconclusive.

Haemochromatosis testing

• For items 73317 and 73318:

elevated serum ferritin for a patient, means a level of ferritin above the normal reference range in respect of the particular method of assay used to determine the level.

Nutritional and toxicity metals testing

• (1) For this rule:

nutritional metals testing group means items 66819, 66820, 66821 and 66822.

metal toxicity testing group means items 66825, 66826, 66827, 66828, 66831 and 66832.

- (2) An item in the nutritional metals testing group or the metal toxicity testing group does not apply in relation to a service performed if medicare benefits are paid or payable for tests that are performed for the same patient in 3 patient episodes requested within 6 months before the request for that service, under any of:
- (a) that item; or
- (b) the other item in the same group; or
- (c) an item in the other group.

Antineutrophil Cytoplasmic Antibody

• A request for Antineutrophil Cytoplasmic Antibody immunofluorescence test (ANCA) shall be deemed to include requests for antineutrophil proteinase 3 antibody test (PR-3 ANCA) and antimyeloperoxidase antibody test (MPO ANCA) where the immunofluorescence test for ANCA is abnormal, or has been abnormal, or those specific antibodies have been previously detected.

Satisfying Requirements Described in Items

- Unless stated elsewhere in these rules, where an item contains a requirement, this requirement is satisfied if:
- (a) The requirement/s as stipulated in the item descriptor are contained in the request form; or
- (b) The requirement/s as stipulated in the item descriptor were supplied previously in writing to the APA and this documentation is retained by the APA; or

- (c) The results of other laboratory tests performed in the same episode meet the requirement/s as stipulated in the item descriptor; or
- (d) The results of laboratory tests that meet the requirement/s as stipulated in the item descriptor are supplied on the request form; or

The results of laboratory tests that meet the requirement/s as stipulated in the item descriptor are contained in the APA's records.

Limitation on certain items

- (a) For any particular patient, items 66539, 66605, 66606, 66607, 66610, 69380, 69488, 69489, 71075, 71127, 71135 or 71137 is applicable not more than twice in a 12 month period.
 - (b) For any particular patient, item 66626 is applicable not more than 36 times in a 12 month period.
- (c) For any particular patient, items 66655, 66659, 66838, 66841, 69482, 69491, 69499 or 69500 are applicable not more than once in a 12 month period.
 - (d) For any particular patient, item 66750 or 66751 is applicable not more than once in a pregnancy.
 - (e) For any particular patient, item 69336 is applicable not more than once in each period of 7 days.
- (f) For any particular patient, items 66551, 66660, 69445, 69451, 69483, 71079 or 73523 are applicable not more than 4 times in a 12 month period.
- (g) For any particular patient, items 66554, 66830 and 71077 are applicable not more than 6 times in a 12 month period.
- (h) For any particular patient, item 66819, 66820, 66821, 66825, 66826, 66827 or 66828 is applicable not more than 3 times in a 6 month period.
 - (i) For any particular patient, items 73339 and 73340 are applicable not more than once.

Antigen Detection - Group P3 (Microbiology)

- If the service listed in 69316, 69317, 69319, 69494, 69495, 69496, 69497 or 69498 is a pathologist determinable service the specialist pathologist is required to record the reasons for determining the need for this service.
- If the service rendered in 71148, 73320 or 73321 is a pathologist determinable service, the specialist pathologist is required to record the reason for determining the need for this service including the result of the service in 71147.

Second Opinion morphology, limitations on items 72858 and 72859

- **28.1** Items 72858 and 72859 apply:
 - (a) only to a service that is covered by:
 - (i) item 65084 or 65087; or
- (ii) item 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 or 72838; or
- (iii) an item in Group P6 (other than item 73070, 73071, 73072, 73073, 73074, 73075 or 73076); and

- (b) only if the treating practitioner and the approved pathology practitioner who provided the original opinion on the patient specimen agree that a second opinion is reasonably necessary for diagnostic purposes.
- **28.2** Items 72858 and 72859 do not apply if the accredited pathology laboratory in which the second opinion is provided is the same laboratory in which the original opinion was provided.

PN.6.2 Patient Episode Initiation Fees (PEIs)

Items in Groups P10 of the Pathology Services Table are only applicable to services performed:

- (i) by or on behalf of an Approved Pathology Practitioner who is a recognised specialist pathologist; and
- (ii) in private practice.

Accordingly, these fees are not payable for pathology services rendered by an Approved Pathology Practitioner, being a specialist pathologist when requested for a privately referred out-patient of a recognised hospital.

The patient episode initiation fees (PEIs) will be applicable on an episodic basis i.e. a claim may be made for the provision of pathology services requested by a practitioner in respect of one individual on the same day. For example, if a practitioner orders three pathology tests for a person on the one day, Medicare benefits will be payable for each of those tests but only one PEI will be applicable.

This Rule applies even when the treating practitioner has requested pathology tests from two or more Approved Pathology Practitioners. Thus a PEI will only be paid for the first account submitted unless an exemption listed in Rule 4 or 14.(7) applies or an exemption has been granted under "S4B(3)".

Under Rule 14.(7) two PEIs are payable in relation to the same patient episode where a referring practitioner refers two different specimens to two different Approved Pathology Authorities in the following circumstances:

- a tissue pathology specimen and any other non-tissue pathology specimen; or
- a cytopathology specimen and any other non-cytopathology specimen.

Rule 14.(8) also provides that only one PEI will be paid for the collection of specimens from a patient on one day in or by a single Approved Pathology Authority.

The patient episode initiation benefits are two-tiered. Higher benefits are paid for the collection of specimens from patients who are not private inpatients or private outpatients of a recognised hospital where the specimens are tested in a private laboratory.

A lower and uniform PEI benefit is paid where patients are private patients associated with a recognised hospital and the specimens are tested in a private laboratory or where the testing is performed by a prescribed laboratory on specimen collected from a patient eligible to claim Medicare benefits.

PN.6.3 Patient Episode Initiation Fees for Certain Tissue Pathology and Screening Items

Tissue Pathology items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72830 and 72836 and Cervical screening items 73070, 73071, 73072, 73073, 73074, 73075, 73076 will be subject to a different patient episode initiation fee structure - items 73922 to 73939 refer.

PN.6.4 Hospital, Government etc Laboratories

The following laboratories have been prescribed for the purposes of payment of Medicare benefits as outlined in paragraphs PF.2 and PF.3:

(i) laboratories operated by the Australian Government (these include health laboratories operated by the Australian Government Department of Health as well as the laboratories operated by other Departments, e.g. the Departments of Defence and Veterans' Affairs operate laboratories from which pathology services are provided);

- (ii) laboratories operated by a State Government or authority of a State (laboratories operated or associated with recognised hospitals are also included);
- (iii) laboratories operated by the Northern Territory and the Australian Capital Territory; and
- (iv) laboratories operated by Australian tertiary education institutions eg Universities.

PN.7.1 Assignment of Medicare Benefits - Patient Assignment

In addition to the general arrangements relating to the assignment of benefits, as outlined at paragraph 7 of the "General Explanatory Notes" in Section 1 of this book, it should be noted that, where the treating practitioner requests pathology services but the patient does not physically attend the Approved Pathology Practitioner, the patient may complete an assignment voucher at the time of the visit to the requesting doctor offering to assign benefits for the Approved Pathology Practitioner's services.

If an Approved Pathology Practitioner refers some of the tests requested by the treating practitioner to another Approved Pathology Authority, he/she should provide the second Approved Pathology Authority with a photocopy of the patient's assignment voucher so that the second Approved Pathology Authority can also direct-bill Medicare.

PN.7.2 Approved Pathology Practitioner Eligibility

If a practitioner requests an Approved Pathology Practitioner to perform a necessary pathology service, that Approved Pathology Practitioner must personally perform the service or have it performed on his/her behalf in order to be eligible to receive benefits by way of assignment. If, however, the first Approved Pathology Practitioner arranges for the service to be rendered by a second Approved Pathology Practitioner with the same Approved Pathology Authority, the second Approved Pathology Practitioner and not the first, is eligible to receive an assignment of the Medicare benefit for the service in question.

PN.7.3 Cystic fibrosis gene testing

- (1) For any particular patient, item 73345, 73347, 73348 and 73349 is applicable not more than once in a lifetime.
- (2) For any particular patient, item 73346 and 73350 is applicable not more than once in a pregnancy.
- (3) The testing laboratory used to undertake tests for items 73345, 73346, 73347, 73348, 73349 and 73350 must use a cystic fibrosis transmembrane conductance regulator methodology appropriate to the clinical setting with:
- (a) sufficient diagnostic range and sensitivity to detect at least 95% of pathogenic cystic fibrosis transmembrane conductance regulator variants likely to be present in the patient; and
- (b) with at least 25 of the most frequently encountered cystic fibrosis transmembrane conductance regulator variants in the Australian population.

PN.8.1 Accredited Pathology Laboratories - Need for Accreditation

A pathology service will not attract Medicare benefits unless that service is provided in a pathology laboratory which is accredited for that kind of service. Details of the administration of the pathology laboratory accreditation arrangements are set out below.

PN.8.2 Applying for Accreditation

To become an Accredited Pathology Laboratory it is necessary to lodge a completed application form with the Manager, Pathology Section, the Department of Human Services, PO Box 1001, TUGGERANONG ACT 2901. The prescribed fees for Approved Pathology Laboratories are:

- \$2500 for Category GX labs
- \$2000 for Category GY labs

- \$1500 for Category B labs
- \$ 750 for Category M & S labs.

It is necessary for an application for inspection be made to the National Association of Testing Authorities (NATA) NATA is the independent body chosen to act on the Australian Government's behalf as the primary inspection agency. The Royal Australian College of General Practitioners (RACGP) has also been appointed to inspect laboratories in Category M (general practitioner) in Victoria only.

Details of laboratory categories and associated supervisory requirements can be found on the Department's internet site (www.health.gov.au/pathology).

PN.8.3 Effective Period of Accreditation

Accreditation takes effect from the date of approval by the Minister for Health and Ageing. The Minister has no power to backdate an approval. Transitional accreditation may be given pending full accreditation. An application and fee are required annually.

PN.8.4 Assessment of Applications for Accreditation

The principles of accreditation for pathology laboratories as determined by the Minister are used to assess applications for accreditation. These principles also require pathology laboratories to address National Pathology Accreditation Advisory Council standards. Copies of the principles and standards are available from the Secretariat, National Pathology Accreditation Advisory Council (see PH.6) on (02) 6289 4017 or email npaac@health.gov.au.

PN.8.5 Refusal of Accreditation and Right of Review

An applicant who has been notified of the intention to refuse accreditation may, within 28 days of being notified, provide further information to the Minister which may be taken into consideration prior to a final decision being made.

Applicants refused accreditation or any person affected by the decision have the right to appeal to the Administrative Appeals Tribunal.

PN.8.6 National Pathology Accreditation Advisory Council (NPAAC)

NPAAC was established in 1979. Its functions are to develop policy for accreditation of pathology laboratories, introduce and maintain uniform standards of practice in pathology services throughout Australia and initiate and coordinate educational programs in relation to pathology practice. The agencies used to inspect laboratories on the Australian Government's behalf are required to conduct inspections using the standards set down by NPAAC. For further information the NPAAC Secretariat can be contacted on (02) 6289 4017 or email npaac@health.gov.au.

PN.8.7 Change of Address/Location

Laboratories are accredited for the particular premises given on the application form. Where a laboratory is relocated to other premises, any previously issued approvals for that Accredited Pathology Laboratory lapse. Medicare benefits are not payable for any pathology services performed at the new location until a new application has been approved by the Minister for Health and Ageing. Paragraph PH.2 sets out the method for applying for accreditation.

PN.8.8 Change of Ownership of a Laboratory

Part of the assessment of an application for an Accredited Pathology Laboratory relates to the Approved Pathology Authority status. Where the ownership, or some other material change occurs affecting the laboratory, the Minister for Health and Ageing must be provided with those changed details. Medicare benefits will not be payable for any pathology services performed on any premises other than those premises for which approval has been given.

PN.8.9 Approved Collection Centres (ACC)

New arrangements for specimen collection centres commenced on 1 December 2001 and replaced the Licensed Collection Centre (LCC) Scheme.

To enable the payment of Medicare benefits for pathology services performed on pathology specimens collected in a collection centre, the centre must first be approved. The exception to this rule is collection centres on the premises of recognised hospitals (recognised hospital in this context means the same as "recognized hospital" in Part 1 Section 3 of the Health Insurance Act 1973) as they do not need approval.

In order for a collection centre to be approved, a public or private Approved Pathology Authority must submit a completed application form to the Department of Human Services including details of the type of application (renewal, new or cancellation of collection centre), the location of the premises, the owner, and any leasing arrangements.

Application forms can be accessed by going to the <u>Department of Human Services website</u>. Completed application forms and any enquiries should be forwarded to Pathology Registration, PO Box 9822 MELBOURNE VIC 3001.

PN.9.1 Approved Pathology Practitioners Introduction

A pathology service will not attract Medicare benefits unless that service is provided by or on behalf of an Approved Pathology Practitioner. (Approved Pathology Practitioners must be registered medical practitioners.) Set out below is information which relates to Approved Pathology Practitioner requirements.

PN.9.2 Applying for Acceptance of the Approved Pathology Practitioner Undertaking

To apply for acceptance of an Approved Pathology Practitioner Undertaking, it is necessary to send:

- (i) a completed application for acceptance of an Approved Pathology Practitioner Undertaking; and
- (ii) a signed Approved Pathology Practitioner Undertaking to the Pathology Registration, the Department of Human Services,

PO Box 9822, Melbourne Victoria 3001.

An application form, undertaking and associated literature can be obtained from the Pathology Registration Coordinator.

Payment of Acceptance Fee

On receipt of advice that the Minister has accepted an undertaking, a cheque for \$500 should be sent to the Pathology Registration Coordinator. Applicants are required to pay this fee within 14 days of the notice being given. As there is no discretion under the *Health Insurance Act 1973* to accept late payments, failure to pay the fee within the required time means that:

- (i) acceptance of the undertaking will be revoked;
- (ii) a new application must be completed:
- (iii) acceptance of the new undertaking cannot be backdated; and
- (iv) there will therefore be a period during which Medicare benefits cannot be paid.

PN.9.3 Undertakings

Consideration of Undertakings

The Minister is unable to accept an undertaking from a person in respect of whom there is a determination in force that the person has breached the undertaking, or from a person who, if the undertaking were accepted, would be likely to carry on the business of a prescribed person or would enable a person to avoid the financial consequences of the disqualification (or likely disqualification) of that prescribed person. A 'prescribed person' includes, amongst other things, fully or partially disqualified persons (or persons likely to be so disqualified).

Similarly an undertaking cannot be accepted unless the Minister is satisfied that the person giving such undertaking is a fit and proper person to be an Approved Pathology Practitioner.

When an undertaking has been given, the Minister may require the person giving the undertaking to provide additional information within a fixed period of time and if the person does not comply the Minister may refuse to accept the undertaking.

Refusal of Undertaking and Rights of Review

Where the Minister refuses to accept an undertaking, for any of the reasons shown above, the Minister must notify the person of the decision. The notification must include advice of a right of internal review of the decision and a right of further appeal to the Administrative Appeals Tribunal if the internal review upholds the original decision to refuse the undertaking.

Effective Period of Undertaking

The following applies:

- (i) Date of Effect the earliest day from which the Minister or delegate can accept an undertaking is the day of the decision in respect of the undertaking. The day the undertaking is signed is to be the day it is actually signed and must not be backdated:
- (ii) Period of Effect in determining the period of effect of the undertaking the Minister shall, unless the Minister considers that special circumstances exist, determine that the period of effect shall be twelve months from the day on which the undertaking comes into force. There is a requirement for the Minister to notify persons giving undertakings of the period of time for which the undertaking is to have effect, and the notice is to advise persons whose interests are affected by the decision of their rights of appeal to the Administrative Appeals Tribunal against the Minister's decision:
- (iii) Renewals when an undertaking is given and accepted by the Minister while a former undertaking is current, the new undertaking does not take effect until the former undertaking ceases to be in force. When an undertaking is given while a former undertaking is current and the date on which the former undertaking is to expire passes without the Minister giving notice to accept or reject the new undertaking, the former undertaking remains in force until the Minister gives such notification. This provision does not apply when the renewal application is not received by the Department of Human Services until after the expiry of the existing undertaking. Under these circumstances there will be a period during which Medicare benefits cannot be paid unless the new application can be backdated to the expiry of the previous undertaking. This is a limited discretion for periods up to one month and special conditions apply; and
- (iv) Cessation of Undertaking the undertaking ceases to be in force if it is terminated, if the Minister revokes acceptance of the undertaking, or if the period of effect for the undertaking expires whichever event first occurs.

An Approved Pathology Practitioner may terminate an undertaking at any time providing that the practitioner gives at least 30 days notice of his/her intention to do so.

PN.9.4 Obligations and Responsibilities of Approved Pathology Practitioners

The requirements of the legislation and the undertaking impose a number of obligations and responsibilities on Approved Pathology Practitioners and the Minister. The more complex of these not already dealt with are

considered in PK, PL and PM dealing with Breaches of Undertakings, Excessive Pathology Services and Personal Supervision.

PN.10.1 Approved Pathology Authorities Introduction

A pathology service will not attract Medicare benefits unless the proprietor of the laboratory in which the pathology service is performed is an Approved Pathology Authority. Following is information which relates to Approved Pathology Authority requirements.

PN.10.2 Applying for Acceptance of an Approved Pathology Authority Undertaking

To apply for acceptance of an Approved Pathology Authority Undertaking, it is necessary to send:

- (i) a completed application for acceptance of an Approved Pathology Authority Undertaking; and
- (ii) a signed Approved Pathology Authority Undertaking to the Pathology Registration, the Department of Human Services,

PO Box 9822, Melbourne Victoria 3001.

An application form, undertaking and associated literature can be obtained from the Pathology Registration Coordinator.

Payment of Acceptance Fee

On receipt of advice that the Minister has accepted an undertaking, a cheque for \$1,500 should be sent to the Pathology Registration Coordinator. Applicants are required to pay this fee within 14 days of the notice being given. As there is no discretion under the *Health Insurance Act 1973* to accept late payments, failure to pay the fee within the required time means that:

- (i) acceptance of the undertaking will be revoked;
- (ii) a new application must be completed;
- (iii) acceptance of the new undertaking cannot be backdated; and
- (iv) there will therefore be a period during which Medicare benefits cannot be paid.

PN.10.3 Undertakings

Consideration of Undertakings

The Minister is unable to accept undertakings from a person in respect of whom there is a determination in force that the person has breached the undertaking, or from a person who, if the undertaking were accepted, would be likely to carry on the business of a prescribed person or would enable a person to avoid the financial consequences of the disqualification (or likely disqualification) of that prescribed person. A 'prescribed person' includes, inter alia, fully or partially disqualified persons (or persons likely to be so disqualified).

Similarly an undertaking cannot be accepted unless the Minister is satisfied that the person giving such undertaking is a fit and proper person to be an Approved Pathology Authority.

When an undertaking has been given the Minister may require the person giving the undertaking to provide additional information within a specified period of time and if the person does not comply the Minister may refuse to accept the undertaking.

Refusal of Undertaking and Rights of Review

Where the Minister refuses to accept an undertaking, the Minister must notify the person of the decision. The notification must include advice of a right of internal review of the decision and a right of further appeal to the Administrative Appeals Tribunal if the internal review upholds the original decision to refuse the undertaking.

Effective Period of Undertaking

The following applies:

- (i) Date of Effect the earliest day from which the Minister or delegate can accept an undertaking is the day of the decision in respect of the undertaking. The day the undertaking is signed is to be the day it is actually signed and must not be backdated;
- (ii) Period of Effect in determining the period of effect of the undertaking the Minister shall, unless the Minister considers that special circumstances exist, determine that the period of effect shall be twelve months from the day on which the undertaking comes into force. There is a requirement for the Minister to notify persons giving an undertaking of the period of time for which the undertaking is to have effect, and the notice is to advise persons whose interests are affected by the decision of their rights of appeal to the Administrative Appeals Tribunal against the Minister's decision;
- (iii) Renewals when an undertaking is given and accepted by the Minister while a former undertaking is current, the new undertaking does not take effect until the former undertaking ceases to be in force. When an undertaking is given while a former undertaking is current and the date on which the former undertaking is to expire passes without the Minister giving notice to accept or reject the new undertaking, the former undertaking remains in force until the Minister gives such notification. This provision does not apply when the renewal application is not received by the Department of Human Services until after the expiry of the existing undertaking. Under these circumstances there will be a period during which Medicare benefits cannot be paid unless the new application can be backdated to the expiry of the previous undertaking. This is a limited discretion for periods up to one month and special conditions apply; and
- (iv) Cessation of Undertaking the undertaking ceases to be in force if it is terminated, if the Minister revokes acceptance of the undertaking, or if the period of effect for the undertaking expires whichever event first occurs.

An Approved Pathology Authority may terminate an undertaking at any time providing that at least 30 days notice of the intention to terminate the undertaking is given.

PN.10.4 Obligations and Responsibilities of Approved Pathology Authorities

The requirements of the legislation and the undertaking impose a number of obligations and responsibilities on Approved Pathology Authorities and the Minister. The more complex of these which have not already been covered are considered in paragraphs PK and PL dealing with Breaches of Undertakings and Excessive Pathology Services.

PN.11.1 Breaches of Undertakings

Notice Required

Where the Minister has reasonable grounds for believing that an Approved Pathology Practitioner or an Approved Pathology Authority has breached the undertaking, the Minister is required to give notice in writing to the person explaining the grounds for that belief and inviting the person to put a submission to the Minister to show cause why no further action should be taken in the matter.

PN.11.2 Decisions by Minister

Where a person provides a submission, the Minister may decide to take no further action against the person. Alternatively the Minister may refer the matter to a Medicare Participation Review Committee, notifying the grounds for believing that the undertaking has been breached. If after 28 days no submission has been received from the person, the Minister must refer that matter to the Committee.

PN.11.3 Appeals

The Minister is empowered to suspend an undertaking where notice has been given to a Medicare Participation Review Committee of its possible breach, pending the outcome of the Committee's proceedings. The Minister must give notice in writing to the person who provided the undertaking of the determination to suspend it, and the notice shall inform the person of a right of appeal against the determination to the Administrative Appeals Tribunal. The Minister may also publish a notice of a determination in the Public Service Gazette. Rights of appeal to the Administrative Appeals Tribunal also exist in respect of any determination made by a Medicare Participation Review Committee.

PN.12.1 Initiation of Excessive Pathology Services Notice Required

Where the Minister has reasonable grounds for believing that a person, of a specified class of persons, has initiated, or caused or permitted the initiation of excessive pathology services the Minister is required to give notice in writing to the person explaining the grounds for the belief and inviting the person to put a submission to the Minister to show cause why no further action should be taken in the matter.

PN.12.2 Classes of Persons

The classes of persons are:

- (i) the practitioner who initiated the services;
- (ii) the employer of the practitioner who caused or permitted the practitioner to initiate the services; or
- (iii) an officer of the body corporate employing the practitioner who caused or permitted the practitioner to initiate the services.

PN.12.3 Decisions by Minister for Health and Ageing

Where a person provides a submission, the Minister may decide to take no further action against the person. Alternatively, the Minister may refer the matter to a Professional Services Review (PSR) Committee, notifying the grounds for believing that excessive pathology services have been initiated. If after 28 days no submission has been received from the person, the Minister must refer the matter to the Committee. The Minister must give to the person notice in writing of the decision.

PN.12.4 Appeals

Unlike the procedures relating to breaches of undertaking there is no power given to the Minister to determine a penalty. The Minister's role is either deciding to take no further action or referring the matter to a PSR Committee. Accordingly, there are no rights of appeal to the Administrative Appeals Tribunal applicable to the above procedures. However, rights of appeal to the Administrative Appeals Tribunal exist in respect of any determination made by a Medicare Participation Review Committee.

PN.13.1 Personal Supervision

Introduction

The *Health Insurance Act 1973* provides that the form of undertaking to be given by an Approved Pathology Practitioner may make provision for pathology services carried out under the personal supervision of the Approved Pathology Practitioner.

PN.13.2 Extract from Undertaking

The following is an extract from the Approved Pathology Practitioner (APP) undertaking:

Part 2 - Personal supervision

- 2.1 I acknowledge that it is my obligation, subject to Parts 2.2 and 2.4, personally to supervise any person who renders any service on my behalf and I undertake to accept personal responsibility for the rendering of that service under the following conditions of personal supervision:
- (i) Subject to the following conditions, I will usually be physically available in the laboratory while services are being provided at the laboratory;
- (ii) I may, subject to paragraph (vi) below, be physically absent from the laboratory while services are being rendered outside its normal hours of operation but in that event I will leave with the person rendering the service particulars of the manner in which I may be contacted while the service is being rendered and I must be able to personally attend at the laboratory while the service is being rendered or formally designate another APP present while I am absent:
- (iii) I may, subject to paragraph (vi) below, be absent from the laboratory for brief periods due to illness or other personal necessity, or to take part in activities which, in accordance with normal and accepted practice, relate to the provision of services by that laboratory;
- (iv) I will personally keep a written log of my absences from the laboratory that extend beyond one workday in respect of that laboratory and will retain that log in the laboratory for 18 months from date of last entry;
- (v) If I am to be absent from the laboratory for more than 7 consecutive workdays, I will arrange for another APP to personally supervise the rendering of services in the laboratory. That arrangement shall be recorded in writing and retained in the laboratory for 18 months from date of last entry. Until such person is appointed, and his or her appointment is recorded in writing, I will remain personally responsible to comply with this undertaking;
- (vi) If a service is being rendered on my behalf by a person who is not:
- (a) a medical practitioner;
- (b) a scientist; or
- (c) a person having special qualifications or skills relevant to the service being rendered;

and no person in the above groups is physically present in the laboratory, then I must be physically present in the laboratory and closely supervise the rendering of the service;

- (vii) I accept responsibility for taking all reasonable steps to ensure that in regard to services rendered by me or on my behalf:
- (a) all persons who render services are adequately trained;
- (b) all services which are to be rendered in the laboratory are allocated to persons employed by the APA and, these persons shall have appropriate qualifications and experience to render the services;
- (c) the methods and procedures in operation in the laboratory for the purpose of rendering services are in accordance with proper and correct practices;
- (d) for services rendered, proper quality control methods are established and reviewed to ensure their reliability and effectiveness; and
- (e) results of services and tests rendered are accurately recorded and sent to the treating practitioner and, where applicable, a referring practitioner;
- (viii) If I perform, or there is performed on my behalf, a service which consists of the analysis of a specimen which I know, or have reason to believe, has been taken other than in accordance with the provisions of section 16A(5AA) of the Act I will endorse, or cause to be endorsed, on the assignment form or the account for that service, as the case may be, particulars of the circumstances in which I believe, or have reason to believe, the specimen was taken.

- 2.2 Where services are to be rendered on my behalf in a Category B laboratory as defined in the Health Insurance (Accredited Pathology Laboratories Approval) Principles 2002, I undertake to take all reasonable measures to ensure that the service is rendered under the supervision of an appropriate person as required by those Principles as in force from time to time.
- 2.3 I acknowledge to the best of my ability that any act or omission by a person, when acting with my authority, whether express or implied, that would, had it been done by me, have resulted in a breach of this undertaking, constitutes a breach of this undertaking by me.
- 2.4 Parts 2.1(i) to 2.1(vi) and 2.2 of this undertaking do not apply where a laboratory is limited to services (and associated equipment for those services) as detailed in Schedule 3.

PN.13.3 Notes on the Above

Part 2 of the APP Undertaking outlines the requirements for the personal supervision by an Approved Pathology Practitioner where a pathology service is rendered by another person on behalf of the APP. It should be noted that "on behalf of" does not relieve an Approved Pathology Practitioner of professional responsibility for the service or from being personally involved in the supervision of services in the laboratory.

PR.6.1 Episode Cone

The episode cone is an arrangement, described in Rule 18, which effectively places an upper limit on the number of items for which Medicare benefits are payable in a patient episode. This cone only applies to services requested by general practitioners for their non-hospitalised patients. Pathology services requested for hospital in-patients, or ordered by specialists, are not subject to these coning arrangements.

When more than 3 items are requested by a general practitioner in a patient episode, the benefits payable will be equivalent to the sum of the benefits for the three items with the highest Schedule fees. Rule 18 provides that for the two items with the highest Schedule fees, Medicare benefits will be payable for each item. The remaining items are regarded as one service for which the benefit payable will be equivalent to that for the item with the third highest Schedule fee. Where items have the same Schedule fee, their item numbers are used as an artificial means to rank them.

The episode cone will apply even when the pathology services in a patient episode are performed by 2 or more Approved Pathology Authorities, with the exception of the services listed below.

The following items are not included in the count of the items performed when applying the episode cone:

- (i) all the items in Groups P10, P11, P12 and P13;
- (ii) Cervical Screening (items 73070, 73071, 73072, 73073, 73074, 73075, 73076);
- (iii) all the items detailed at Rule 18 (e) (items 65079, 65082, 65157, 65158, 65166, 65180, 65181, 66606, 66609, 66639, 66642, 66651, 66652, 66663, 66666, 66696, 66697, 66714, 66715, 66723, 66724, 66780, 66789, 66790, 66792, 66804, 66805, 66816, 66817, 66820, 66821, 66826, 66827, 69325, 69328, 69331, 69379, 69383, 69400, 69401, 69451, 69500, 69489, 69492, 69497, 69498, 71076, 71090, 71092, 71096, 71148, 71154, 71156, 71169, 71170, 73309, 73312, 73315, 73318);
- (iv) supplementary test for Hepatitis B and Hepatitis C (item 69484); and
- (v) the carbon-labelled urea breath test to confirm or monitor Helicobacter pylori (item 66900).

PR.9.1 Quality Assurance in Aboriginal Medical Servcies (QAAMS) Program items

Item numbers 73839, 73840 and 73844 can only be performed in the following circumstances:

- a) the service is rendered by or on behalf of a medical practitioner;
- b) the practitioner referred to in paragraph (a), or the organisation for which the practitioner works, is participating

- in the Quality Assurance in Aboriginal Medical Services Program; and c) the service is provided in accordance with that Program; and d) the practitioner referred to in paragraph (a) has determined the service to be necessary for his or her patient.

PATHOLOGY SERVICES ITEMS

P1. HA	EMATOLOGY
	Group P1. Haematology
	Haemoglobin, erythrocyte sedimentation rate, blood viscosity - 1 or more tests
65060	(See para PN.0.33, PN.1.1 of explanatory notes to this Category) Fee: \$7.85 Benefit: 75% = \$5.90 85% = \$6.70
	Examination of:
	(a) a blood film by special stains to demonstrate Heinz bodies, parasites or iron; or
	(b) a blood film by enzyme cytochemistry for neutrophil alkaline phosphatase, alpha-naphthyl acetate esterase or chloroacetate esterase; or
	(c) a blood film using any other special staining methods including periodic acid Schiff and Sudan Black; or
	(d) a urinary sediment for haemosiderin
	including a service described in item 65072
65066	Fee: \$10.40 Benefit: 75% = \$7.80 85% = \$8.85
	Erythrocyte count, haematocrit, haemoglobin, calculation or measurement of red cell index or indices, platelet count, leucocyte count and manual or instrument generated differential count - not being a service where haemoglobin only is requested - one or more instrument generated set of results from a single sample; and (if performed)
	(a) a morphological assessment of a blood film;
	(b) any service in item 65060 or 65072
65070	Fee: \$16.95 Benefit: 75% = \$12.75 85% = \$14.45
	Examination for reticulocytes including a reticulocyte count by any method - 1 or more tests
65072	Fee: \$10.20 Benefit: 75% = \$7.65 85% = \$8.70
	Haemolysis or metabolic enzymes - assessment by:
	(a) erythrocyte autohaemolysis test; or
	(b) erythrocyte osmotic fragility test; or
	(c) sugar water test; or
	(d) G-6-P D (qualitative or quantitative) test; or
	(e) pyruvate kinase (qualitative or quantitative) test; or
	(f) acid haemolysis test; or
	(g) quantitation of muramidase in serum or urine; or
	(h) Donath Landsteiner antibody test; or
65075	

P1. HAE	EMATOLOGY		
	(i) other erythrocyte metabolic enzyme tests		
	1 or more tests		
	Fee: \$51.95 Benefit: 75% = \$39.00 85% = \$44.20		
	Tests for the diagnosis of thalassaemia consisting of haemoglobin electrophoresis or chromatography and at least 2 of:		
	(a) examination for HbH; or		
	(b) quantitation of HbA2; or		
	(c) quantitation of HbF;		
	including (if performed) any service described in item 65060 or 65070		
65078	Fee: \$90.20 Benefit: 75% = \$67.65 85% = \$76.70		
	Tests described in item 65078 if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18)		
65079	Fee: \$90.20 Benefit: 75% = \$67.65 85% = \$76.70		
	Tests for the investigation of haemoglobinopathy consisting of haemoglobin electrophoresis or chromatography and at least 1 of:		
	(a) heat denaturation test; or		
	(b) isopropanol precipitation test; or		
	(c) tests for the presence of haemoglobin S; or		
	(d) quantitation of any haemoglobin fraction (including S, C, D, E);		
	including (if performed) any service described in item 65060, 65070 or 65078		
65081	Fee: \$96.60 Benefit: 75% = \$72.45 85% = \$82.15		
	Tests described in item 65081 if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18)		
65082	Fee: \$96.60 Benefit: 75% = \$72.45 85% = \$82.15		
	Bone marrow trephine biopsy - histopathological examination of sections of bone marrow and examination of aspirated material (including clot sections where necessary), including (if performed):		
	any test described in item 65060, 65066 or 65070		
65084	Fee: \$165.85 Benefit: 75% = \$124.40 85% = \$141.00		
	Bone marrow - examination of aspirated material (including clot sections where necessary), including (if performed):		
	any test described in item 65060, 65066 or 65070		
65087	Fee: \$83.10 Benefit: 75% = \$62.35 85% = \$70.65		
	Blood grouping (including back-grouping if performed) - ABO and Rh (D antigen)		
65090	(See para PN.0.33, PN.1.1 of explanatory notes to this Category)		

P1. HA	EMATOLOGY		
	Fee: \$11.15 Benefit: 75% = \$8.40 85% = \$9.50		
	Blood grouping - Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system - 1 or more systems, including item 65090 (if performed)		
65093	Fee: \$22.00 Benefit: 75% = \$16.50 85% = \$18.70		
	Blood grouping (including back-grouping if performed), and examination of serum for Rh and other blood group antibodies, including:		
	(a) identification and quantitation of any antibodies detected; and		
	(b) (if performed) any test described in item 65060 or 65070		
65096	(See para PN.1.1 of explanatory notes to this Category) Fee: \$41.00 Benefit: 75% = \$30.75 85% = \$34.85		
	Compatibility tests by crossmatch - all tests performed on any one day for up to 6 units, including:		
	(a) all grouping checks of the patient and donor; and		
	(b) examination for antibodies, and if necessary identification of any antibodies detected; and		
	(c) (if performed) any tests described in item 65060, 65070, 65090 or 65096		
	(Item is subject to rule 5)		
65099	Fee: \$108.90 Benefit: 75% = \$81.70 85% = \$92.60		
	Compatibility tests by crossmatch - all tests performed on any one day in excess of 6 units, including:		
	(a) all grouping checks of the patient and donor; and		
	(b) examination for antibodies, and if necessary identification of any antibodies detected; and		
	(c) (if performed) any tests described in item 65060, 65070, 65090, 65096, 65099 or 65105		
	(Item is subject to rule 5)		
65102	Fee: \$164.60 Benefit: 75% = \$123.45 85% = \$139.95		
	Compatibility testing using at least a 3 cell panel and issue of red cells for transfusion - all tests performed on any one day for up to 6 units, including:		
	(a) all grouping checks of the patient and donor; and		
	(b) examination for antibodies and, if necessary, identification of any antibodies detected; and		
	(c) (if performed) any tests described in item 65060, 65070, 65090 or 65096		
	(Item is subject to rule 5)		
65105	Fee: \$108.90 Benefit: 75% = \$81.70 85% = \$92.60		
	Compatibility testing using at least a 3 cell panel and issue of red cells for transfusion - all tests performed on any one day in excess of 6 units, including:		
65108	(a) all grouping checks of the patient and donor; and		

P1. HAI	EMATOLOGY
	(b) examination for antibodies and, if necessary, identification of any antibodies detected; and
	(c) (if performed) any tests described in item 65060, 65070, 65090, 65096, 65099 or 65105
	(Item is subject to rule 5)
	Fee: \$164.60 Benefit: 75% = \$123.45 85% = \$139.95
	Release of fresh frozen plasma or cryoprecipitate for the use in a patient for the correction of a coagulopathy - 1 release.
65109	Fee: \$12.90 Benefit: 75% = \$9.70 85% = \$11.00
	Release of compatible fresh platelets for the use in a patient for platelet support as prophylaxis to minimize bleeding or during active bleeding - 1 release.
65110	Fee: \$12.90 Benefit: 75% = \$9.70 85% = \$11.00
	Examination of serum for blood group antibodies (including identification and, if necessary, quantitation of any antibodies detected)
65111	Fee: \$23.20 Benefit: 75% = \$17.40 85% = \$19.75
	1 or more of the following tests:
	(a) direct Coombs (antiglobulin) test;
	(b) qualitative or quantitative test for cold agglutinins or heterophil antibodies
65114	Fee: \$9.10 Benefit: 75% = \$6.85 85% = \$7.75
	1 or more of the following tests:
	(a) Spectroscopic examination of blood for chemically altered haemoglobins;
	(b) detection of methaemalbumin (Schumm's test)
65117	Fee: \$20.25 Benefit: 75% = \$15.20 85% = \$17.25
	Prothrombin time (including INR where appropriate), activated partial thromboplastin time, thrombin time (including test for the presence of heparin), test for factor XIII deficiency (qualitative), Echis test, Stypven test, reptilase time, fibrinogen, or 1 of fibrinogen degradation products, fibrin monomer or D-dimer - 1 test
65120	Fee: \$13.70 Benefit: 75% = \$10.30 85% = \$11.65
	2 tests described in item 65120
65123	Fee: \$20.35 Benefit: 75% = \$15.30 85% = \$17.30
	3 tests described in item 65120
65126	Fee: \$27.85 Benefit: 75% = \$20.90 85% = \$23.70
	4 or more tests described in item 65120
65129	(See para PN.0.28 of explanatory notes to this Category) Fee: \$35.50 Benefit: 75% = \$26.65 85% = \$30.20
65137	Test for the presence of lupus anticoagulant not being a service associated with any service to which items 65175, 65176, 65177, 65178 and 65179 apply

escribed in item 65175, nces; or heparin, low g a low molecular cocetin cofactor assay), tor VIII, factor IX, lating coagulation			
g a low molecular socetin cofactor assay), tor VIII, factor IX,			
g a low molecular cocetin cofactor assay), tor VIII, factor IX,			
g a low molecular cocetin cofactor assay), tor VIII, factor IX,			
cocetin cofactor assay), tor VIII, factor IX,			
cocetin cofactor assay), tor VIII, factor IX,			
tor VIII, factor IX,			
tor VIII, factor IX,			
2 tests described in item 65150			
(Item is subject to rule 6)			
3 or more tests described in item 65150			
the item have been			
Tests described in item 65150, other than that described in 65157, if rendered by a receiving APP - each test to a maximum of 2 tests			
(Item is subject to rule 6 and 18)			
:			
eihauer test)			
etection of red cell ed in item 65070 or			

P1. HAI	EMATOLOGY		
	A test described in item 65165 if rendered by a receiving APP - 1 or more tests		
	(Item is subject to	rule 18)	
65166	Fee: \$34.45	Benefit: 75% = \$25.85 85% = \$29.30	
		ence of antithrombin III deficiency, protein C deficiency, protein S deficiency or C resistance in a first degree relative of a person who has a proven defect of any of the e tests	
65171	Fee: \$25.35	Benefit: 75% = \$19.05 85% = \$21.55	
	anticoagulant, act the patient has a l	ence of antithrombin III deficiency, protein C deficiency, protein S deficiency, lupus tivated protein C resistance - where the request for the test(s) specifically identifies that history of venous thromboembolism - quantitation by 1 or more techniques - 1 test	
	(Item is subject to	Kule 6)	
65175	Fee: \$25.35	Benefit: 75% = \$19.05 85% = \$21.55	
	2 tests described	in item 65175	
	(Item is subject to	rule 6)	
65176	Fee: \$48.65	Benefit: 75% = \$36.50 85% = \$41.40	
	3 tests described	in item 65175	
	(Item is subject to	o rule 6)	
65177	Fee: \$71.95	Benefit: 75% = \$54.00 85% = \$61.20	
	4 tests described	in item 65175	
	(Item is subject to	o rule 6)	
65178	Fee: \$95.20	Benefit: 75% = \$71.40 85% = \$80.95	
	5 tests described	in item 65175	
	(Item is subject to rule 6)		
65170			
65179	Fee: \$118.50	Benefit: 75% = \$88.90 85% = \$100.75 n item 65175, if rendered by a receiving APA, where no tests in the item have been	
	rendered by the referring APA - 1 test		
	(Item is subject to rule 6 and 18)		
65180	Fee: \$25.35	Benefit: 75% = \$19.05 85% = \$21.55	
03180	<u> </u>	n item 65175, other than that described in 65180, if rendered by a receiving APA - each	
		m of 4 tests (Item is subject to rule 6 and 18)	
65181	Fee: \$23.30	Benefit: 75% = \$17.50 85% = \$19.85	
P2. CHI	EMICAL		
	Group P2. Chem	ical	
66500	Quantitation in se	erum, plasma, urine or other body fluid (except amniotic fluid), by any method except reagent strip (with or without reflectance meter) of: acid phosphatase, alanine	

P2. CHE	EMICAL	
	bicarbonate, bil albumin), chlor dehydrogenase,	se, albumin, alkaline phosphatase, ammonia, amylase, aspartate aminotransferase, lirubin (total), bilirubin (any fractions), C-reactive protein, calcium (total or corrected for ide, creatine kinase, creatinine, gamma glutamyl transferase, globulin, glucose, lactate lipase, magnesium, phosphate, potassium, sodium, total protein, total cholesterol, rate or urea - 1 test
	Fee: \$9.70	Benefit: 75% = \$7.30 85% = \$8.25
	2 tests describe	d in item 66500
66503	Fee: \$11.65	Benefit: 75% = \$8.75 85% = \$9.95
	3 tests describe	d in item 66500
66506	Fee: \$13.65	Benefit: 75% = \$10.25 85% = \$11.65
	4 tests describe	d in item 66500
66509	Fee: \$15.65	Benefit: 75% = \$11.75 85% = \$13.35
	5 or more tests	described in item 66500
66512	Fee: \$17.70	Benefit: 75% = \$13.30 85% = \$15.05
	Quantitation of	bile acids in blood in pregnancy. To a maximum of 3 tests in a pregnancy.
66517	Fee: \$19.65	Benefit: 75% = \$14.75 85% = \$16.75
		f cardiac or skeletal muscle damage by quantitative measurement of creatine kinase oponin or myoglobin in blood - testing on 1 specimen in a 24 hour period
66518	Fee: \$20.05	Benefit: 75% = \$15.05 85% = \$17.05
		f cardiac or skeletal muscle damage by quantitative measurement of creatine kinase ponin or myoglobin in blood - testing on 2 or more specimens in a 24 hour period
66519	Fee: \$40.15	Benefit: 75% = \$30.15 85% = \$34.15
	Quantitation of	HDL cholesterol
66536	Fee: \$11.05	Benefit: 75% = \$8.30 85% = \$9.40
		of serum for demonstration of lipoprotein subclasses, if the cholesterol is >6.5 mmol/L >4.0 mmol/L or in the diagnosis of types III and IV hyperlipidaemia - (Item is subject to
66539	Fee: \$30.60	Benefit: 75% = \$22.95 85% = \$26.05
	Oral glucose to	lerance test for the diagnosis of diabetes mellitus that includes:
	(a) administra	ation of glucose; and
	(b) at least 2 i	measurements of blood glucose; and
		ned) any test described in item 66695
66540		
66542	Fee: \$18.95	Benefit: 75% = \$14.25 85% = \$16.15
		allenge test in pregnancy for the detection of gestational diabetes that includes:
66545	(a) administra	ation of glucose; and

P2. CHI	EMICAL
	(b) 1 or 2 measurements of blood glucose; and
	(c) (if performed) any test in item 66695
	Fee: \$15.80 Benefit: 75% = \$11.85 85% = \$13.45
	Oral glucose tolerance test in pregnancy for the diagnosis of gestational diabetes that includes:
	(a) administration of glucose; and
	(b) at least 3 measurements of blood glucose; and
	(c) any test in item 66695 (if performed)
66548	Fee: \$19.90 Benefit: 75% = \$14.95 85% = \$16.95
	Quantitation of glycated haemoglobin performed in the management of established diabetes - (Item is subject to rule 25)
66551	Fee: \$16.80 Benefit: 75% = \$12.60 85% = \$14.30
	Quantitation of glycated haemoglobin performed in the management of pre-existing diabetes where the patient is pregnant - including a service in item 66551 (if performed) - (Item is subject to rule 25)
66554	Fee: \$16.80 Benefit: 75% = \$12.60 85% = \$14.30
	Quantitation of fructosamine performed in the management of established diabetes - each test to a maximum of 4 tests in a 12 month period
66557	Fee: \$9.70 Benefit: 75% = \$7.30 85% = \$8.25
	Microalbumin - quantitation in urine
66560	Fee: \$20.10 Benefit: 75% = \$15.10 85% = \$17.10
	Osmolality, estimation by osmometer, in serum or in urine - 1 or more tests
66563	Fee: \$24.70 Benefit: 75% = \$18.55 85% = \$21.00
	Quantitation of:
	(a) blood gases (including pO ₂ , oxygen saturation and pCO ₂); and
	(b) bicarbonate and pH;
	including any other measurement (eg. haemoglobin, lactate, potassium or ionised calcium) or calculation performed on the same specimen - 1 or more tests on 1 specimen
66566	Fee: \$33.70 Benefit: 75% = \$25.30 85% = \$28.65
	Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 2 specimens performed within any 1 day
66569	Fee: \$42.60 Benefit: 75% = \$31.95 85% = \$36.25
	Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 3 specimens performed within any 1 day
66572	Fee: \$51.55 Benefit: 75% = \$38.70 85% = \$43.85
66575	Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 4 specimens performed

P2. CHI	EMICAL		
	within any 1 day		
	Fee: \$60.45 Benefit: 75% = \$45.35 85% = \$51.40		
	Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 5 specimens performed within any 1 day		
66578	Fee: \$69.35 Benefit: 75% = \$52.05 85% = \$58.95		
	Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 6 or more specimens performed within any 1 day		
66581	Fee: \$78.25 Benefit: 75% = \$58.70 85% = \$66.55		
	Quantitation of ionised calcium (except if performed as part of item 66566) - 1 test		
66584	Fee: \$9.70 Benefit: 75% = \$7.30 85% = \$8.25		
	Urine acidification test for the diagnosis of renal tubular acidosis including the administration of an acid load, and pH measurements on 4 or more urine specimens and at least 1 blood specimen		
66587	Fee: \$47.55 Benefit: 75% = \$35.70 85% = \$40.45		
	Calculus, analysis of 1 or more		
66590	Fee: \$30.60 Benefit: 75% = \$22.95 85% = \$26.05		
	Ferritin - quantitation, except if requested as part of iron studies		
66593	Fee: \$18.00 Benefit: 75% = \$13.50 85% = \$15.30		
	Iron studies, consisting of quantitation of:		
	(a) serum iron; and		
	(b) transferrin or iron binding capacity; and		
	(c) ferritin		
66596	Fee: \$32.55 Benefit: 75% = \$24.45 85% = \$27.70		
	Vitamins - quantitation of vitamins B1, B2, B3, B6 or C in blood, urine or other body fluid - 1 or more tests		
66605	Fee: \$30.60 Benefit: 75% = \$22.95 85% = \$26.05		
	A test described in item 66605 if rendered by a receiving APP - 1 or more tests		
	(Item is subject to rule 18 and 25)		
66606	Fee: \$30.60 Benefit: 75% = \$22.95 85% = \$26.05		
	Vitamins - quantitation of vitamins A or E in blood, urine or other body fluid - 1 or more tests within a month period		
66607	Fee: \$75.75 Benefit: 75% = \$56.85 85% = \$64.40		
	A test described in item 66607 if rendered by a receiving APP - 1 or more tests		
66610	Fee: \$75.75 Benefit: 75% = \$56.85 85% = \$64.40		
66623	All qualitative and quantitative tests on blood, urine or other body fluid for:		

P2. CHE	MICAL	
	(a) a drug or dappropriate dosa	rugs of abuse (including illegal drugs and legally available drugs taken other than in ge); or
	(b) ingested or	absorbed toxic chemicals;
	including a servi	ce described in item 66800, 66803, 66806, 66812 or 66815 (if performed), but
	(c) the surveill	ance of sports people and athletes for performance improving substances; and
	(d) the monitor	ring of patients participating in a drug abuse treatment program
	Fee: \$41.50	Benefit: 75% = \$31.15 85% = \$35.30
	withdrawal prog patient participa and athletes for p fluid	ntitation or both (not including the detection of nicotine and metabolites in smoking rams) of a drug, or drugs, of abuse or a therapeutic drug, on a sample collected from a ting in a drug abuse treatment program; but excluding the surveillance of sports people performance improving substances; including all tests on blood, urine or other body
	(Item is subject t	o rule 25)
66626	Fee: \$24.10	Benefit: 75% = \$18.10 85% = \$20.50
	Beta-2-microglo	bulin - quantitation in serum, urine or other body fluids - 1 or more tests
66629	Fee: \$20.10	Benefit: 75% = \$15.10 85% = \$17.10
	Caeruloplasmin, more tests	haptoglobins, or prealbumin - quantitation in serum, urine or other body fluids - 1 or
66632	Fee: \$20.10	Benefit: 75% = \$15.10 85% = \$17.10
	Alpha-1-antitryp	sin - quantitation in serum, urine or other body fluid - 1 or more tests
66635	Fee: \$20.10	Benefit: 75% = \$15.10 85% = \$17.10
	Isoelectric focus or more tests	sing or similar methods for determination of alpha-1-antitrypsin phenotype in serum - 1
66638	Fee: \$49.05	Benefit: 75% = \$36.80 85% = \$41.70
	A test described	in item 66638 if rendered by a receiving APP - 1 or more tests
	(Item is subject to	to rule 18)
66639	Fee: \$29.20	Benefit: 75% = \$21.90 85% = \$24.85
	Electrophoresis	of serum or other body fluid to demonstrate:
	(a) the isoenzy	mes of lactate dehydrogenase; or
	(b) the isoenzy	mes of alkaline phosphatase;
	including the pre	eliminary quantitation of total relevant enzyme activity - 1 or more tests
66641	Fee: \$29.20	Benefit: 75% = \$21.90 85% = \$24.85
66642	A test described	in item 66641 if rendered by a receiving APP - 1 or more tests

P2. CHE	MICAL
	(Item is subject to rule 18)
	Fee: \$29.20 Benefit: 75% = \$21.90 85% = \$24.85
	C-1 esterase inhibitor - quantitation
66644	Fee: \$20.15 Benefit: 75% = \$15.15 85% = \$17.15
	C-1 esterase inhibitor - functional assay
66647	Fee: \$45.10 Benefit: 75% = \$33.85 85% = \$38.35
	Alpha-fetoprotein, CA-15.3 antigen (CA15.3), CA-125 antigen (CA125), CA-19.9 antigen (CA19.9), cancer associated serum antigen (CASA), carcinoembryonic antigen (CEA), human chorionic gonadotrophin (HCG), neuron specific enolase (NSE), thyroglobulin in serum or other body fluid, in the monitoring of malignancy or in the detection or monitoring of hepatic tumours, gestational trophoblastic disease or germ cell tumour - quantitation - 1 test
	(Item is subject to rule 6)
66650	Fee: \$24.35 Benefit: 75% = \$18.30 85% = \$20.70
	A test described in item 66650 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP - 1 test
	(Item is subject to rule 6 and 18)
66651	Fee: \$24.35 Benefit: 75% = \$18.30 85% = \$20.70
	A test described in item 66650 if rendered by a receiving APP - other than that described in 66651, if rendered by a receiving APP, 1 test
	(Item is subject to rule 6 and 18)
66652	Fee: \$20.30 Benefit: 75% = \$15.25 85% = \$17.30
	2 or more tests described in item 66650
	(Item is subject to rule 6)
66653	Fee: \$44.60 Benefit: 75% = \$33.45 85% = \$37.95
	Prostate specific antigen - quantitation - 1 of this item in a 12 month period
	(Item is subject to rule 25)
66655	Fee: \$20.15 Benefit: 75% = \$15.15 85% = \$17.15
	Prostate specific antigen - quantitation in the monitoring of previously diagnosed prostatic disease (including a test described in item 66655)
66656	Fee: \$20.15 Benefit: 75% = \$15.15 85% = \$17.15
	Prostate specific antigen - quantitation of 2 or more fractions of PSA and any derived index including (if performed) a test described in item 66656, in the follow up of a PSA result that lies at or above the age related median but below the age related, method specific 97.5% reference limit - 1 of this item in a 12 month period
	(Item is subject to rule 25)
66659	Fee: \$37.30 Benefit: 75% = \$28.00 85% = \$31.75

P2. CHI	EMICAL
	Prostate specific antigen - quantitation of 2 or more fractions of PSA and any derived index including (if performed) a test described in item 66656, in the follow up of a PSA result that lies at or above the age related, method specific 97.5% reference limit, but below a value of 10 ug/L - 4 of this item in a 12 month period.
	(Item is subject to rule 25)
66660	Fee: \$37.30 Benefit: 75% = \$28.00 85% = \$31.75
	Quantitation of hormone receptors on proven primary breast or ovarian carcinoma or a metastasis from a breast or ovarian carcinoma or a subsequent lesion in the breast - 1 or more tests
66662	Fee: \$79.95 Benefit: 75% = \$60.00 85% = \$68.00
	A test described in item 66662 if rendered by a receiving APP - 1 or more tests
	(Item is subject to rule 18)
66663	Fee: \$79.95 Benefit: 75% = \$60.00 85% = \$68.00
	Lead quantitation in blood or urine (other than for occupational health screening purposes) to a maximum of 3 tests in a 6 month period - each test
66665	Fee: \$30.60 Benefit: 75% = \$22.95 85% = \$26.05
	A test described in item 66665 if rendered by a receiving APP - 1 or more tests
	(Item is subject to rule 18)
66666	Fee: \$30.60 Benefit: 75% = \$22.95 85% = \$26.05
	Quantitation of serum zinc in a patient receiving intravenous alimentation - each test
66667	Fee: \$30.60 Benefit: 75% = \$22.95 85% = \$26.05
	Quantitation of serum aluminium in a patient in a renal dialysis program - each test
66671	Fee: \$36.90 Benefit: 75% = \$27.70 85% = \$31.40
	Quantitation of:
	(a) faecal fat; or
	(b) breath hydrogen in response to loading with disaccharides;
	1 or more tests within a 28 day period
66674	Fee: \$39.95 Benefit: 75% = \$30.00 85% = \$34.00
	Test for tryptic activity in faeces in the investigation of diarrhoea of longer than 4 weeks duration in children under 6 years old
66677	Fee: \$11.15 Benefit: 75% = \$8.40 85% = \$9.50
	Quantitation of disaccharidases and other enzymes in intestinal tissue - 1 or more tests
66680	Fee: \$74.45 Benefit: 75% = \$55.85 85% = \$63.30
	Enzymes - quantitation in solid tissue or tissues other than blood elements or intestinal tissue - 1 or more tests
66683	Fee: \$74.45 Benefit: 75% = \$55.85 85% = \$63.30

P2. CHE	EMICAL
	Performance of 1 or more of the following procedures:
	(a) growth hormone suppression by glucose loading;
	(b) growth hormone stimulation by exercise;
	(c) dexamethasone suppression test;
	(d) sweat collection by iontophoresis for chloride analysis;
	(e) pharmacological stimulation of growth hormone
66686	Fee: \$50.65 Benefit: 75% = \$38.00 85% = \$43.10
	Quantitation in blood or urine of hormones and hormone binding proteins - ACTH, aldosterone, androstenedione, C-peptide, calcitonin, cortisol, DHEAS, 11-deoxycortisol, dihydrotestosterone, FSH, gastrin, glucagon, growth hormone, hydroxyprogesterone, insulin, LH, oestradiol, oestrone, progesterone, prolactin, PTH, renin, sex hormone binding globulin, somatomedin C(IGF-1), free or total testosterone, urine steroid fraction or fractions, vasoactive intestinal peptide, - 1 test (Item is subject to rule 6)
66695	(See para TN.1.4 of explanatory notes to this Category) Fee: \$30.50 Benefit: 75% = \$22.90 85% = \$25.95
	A test described in item 66695, if rendered by a receiving APP - where no tests in the item have been rendered by the referring APP
	(Item is subject to rule 6 and 18)
66696	Fee: \$30.50 Benefit: 75% = \$22.90 85% = \$25.95
	Tests described in item 66695, other than that described in 66696, if rendered by a receiving APP - each test to a maximum of 4 tests
	(Item is subject to rule 6 and 18)
66697	Fee: \$13.20 Benefit: 75% = \$9.90 85% = \$11.25
	2 tests described in item 66695
	(Item is subject to rule 6)
66698	(See para TN.1.4 of explanatory notes to this Category) Fee: \$43.70 Benefit: 75% = \$32.80 85% = \$37.15
00078	3 tests described in item 66695
	(Item is subject to rule 6) (See para TN.1.4 of explanatory notes to this Category)
66701	Fee: \$56.90 Benefit: 75% = \$42.70 85% = \$48.40
	4 tests described in item 66695
66704	

P2. CH	EMICAL	
	(This fee applies where 1 laboratory, or more than 1 laboratory belonging to the same APA, performs the only 4 tests specified on the request form or performs 4 tests and refers the rest to the laboratory of a separate APA)	
	(Item is subject to rule 6)	
	(See para TN.1.4 of explanatory notes to this Category) Fee: \$70.15 Benefit: 75% = \$52.65 85% = \$59.65	
	5 or more tests described in item 66695	
	(Item is subject to rule 6)	
66707	(See para TN.1.4 of explanatory notes to this Category) Fee: \$83.35 Benefit: 75% = \$62.55 85% = \$70.85	
	Quantitation in saliva of cortisol in:	
	(a) the investigation of Cushing's syndrome; or	
	(b) the management of children with congenital adrenal hyperplasia	
	(Item is subject to rule 6)	
66711	Fee: \$30.15 Benefit: 75% = \$22.65 85% = \$25.65	
	Two tests described in item 66711	
	(Item is subject to rule 6)	
66712	Fee: \$43.05 Benefit: 75% = \$32.30 85% = \$36.60	
	A test described in item 66711, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP	
	(Item is subject to rule 6 and 18)	
66714	Fee: \$30.15 Benefit: 75% = \$22.65 85% = \$25.65	
	Tests described in item 66711, other than that described in 66714, if rendered by a receiving APP, each test to a maximum of 1 test	
	(Item is subject to rule 6 and 18)	
66715	Fee: \$12.85 Benefit: 75% = \$9.65 85% = \$10.95	
	TSH quantitation	
66716	Fee: \$25.05 Benefit: 75% = \$18.80 85% = \$21.30	
	Thyroid function tests (comprising the service described in item 66716 and 1 or more of the following tests - free thyroxine, free T3, for a patient, if at least 1 of the following conditions is satisfied:	
	(a) the patient has an abnormal level of TSH;	
66719	(b) the tests are performed:	

P2. CHEN	MICAL	
	(i) for the purpose of monitoring thyroid disease in the patient; or	
	(ii) to investigate the sick euthyroid syndrome if the patient is an admitted patient; or	
	(iii) to investigate dementia or psychiatric illness of the patient; or	
	(iv) to investigate amenorrhoea or infertility of the patient;	
	(c) the medical practitioner who requested the tests suspects the patient has a pituitary dysfunction;	
	(d) the patient is on drugs that interfere with thyroid hormone metabolism or function	
	(Item is subject to rule 9)	
	Fee: \$34.80 Benefit: 75% = \$26.10 85% = \$29.60	
	TSH quantitation described in item 66716 and 1 test described in item 66695	
	(This fee applies where 1 laboratory, or more than 1 laboratory belonging to the same APA, performs the only 2 tests specified on the request form or performs 2 tests and refers the rest to the laboratory of a separate APA)	
	(Item is subject to rule 6)	
66722	Fee: \$37.90 Benefit: 75% = \$28.45 85% = \$32.25	
	Tests described in item 66722, that is, TSH quantitation and 1 test described in 66695, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP - 1 test	
	(Item is subject to rule 6 and 18)	
66723	Fee: \$37.90 Benefit: 75% = \$28.45 85% = \$32.25	
	Tests described in item 66722, if rendered by a receiving APP, other than that described in 66723. It is to include a quantitation of TSH - each test to a maximum of 4 tests described in item 66695	
	(Item is subject to rule 6 and 18)	
66724	Fee: \$13.15 Benefit: 75% = \$9.90 85% = \$11.20	
	TSH quantitation described in item 66716 and 2 tests described in item 66695	
	(This fee applies where 1 laboratory, or more than 1 laboratory belonging to the same APA, performs the only 3 tests specified on the request form or performs 3 tests and refers the rest to the laboratory of a separate APA)	
	(Item is subject to rule 6)	
66725	Fee: \$51.05 Benefit: 75% = \$38.30 85% = \$43.40	
	TSH quantitation described in item 66716 and 3 tests described in item 66695	
66728	(This fee applies where 1 laboratory, or more than 1 laboratory belonging to the same APA, performs the	

P2. CHI	EMICAL
	only 4 tests specified on the request form or performs 4 tests and refers the rest to the laboratory of a separate APA)
	(Item is subject to rule 6)
	Fee: \$64.20 Benefit: 75% = \$48.15 85% = \$54.60
	TSH quantitation described in item 66716 and 4 tests described in item 66695
	(This fee applies where 1 laboratory, or more than 1 laboratory belonging to the same APA, performs the only 5 tests specified on the request form or performs 5 tests and refers the rest to the laboratory of a separate APA)
	(Item is subject to rule 6)
66731	Fee: \$77.40 Benefit: 75% = \$58.05 85% = \$65.80
	TSH quantitation described in item 66716 and 5 tests described in item 66695
	(This fee applies where 1 laboratory, or more than 1 laboratory belonging to the same APA, performs 6 or more tests specified on the request form)
	(Item is subject to rule 6)
66734	Fee: \$90.55 Benefit: 75% = \$67.95 85% = \$77.00
	Quantitation of alpha-fetoprotein in serum or other body fluids during pregnancy except if requested as part of items 66750 or 66751
66743	Fee: \$20.10 Benefit: 75% = \$15.10 85% = \$17.10
	Amniotic fluid, spectrophotometric examination of, and quantitation of:
	(a) lecithin/sphingomyelin ratio; or
	(b) palmitic acid, phosphatidylglycerol or lamellar body phospholipid; or
	(c) bilirubin, including correction for haemoglobin
	1 or more tests
66749	Fee: \$32.95 Benefit: 75% = \$24.75 85% = \$28.05
00/17	Quantitation, in pregnancy, of any two of the following - total human chorionic gonadotrophin (total HCG), free alpha human chorionic gonadotrophin (free alpha HCG), free beta human chorionic gonadotrophin (free beta HCG), pregnancy associated plasma protein A (PAPP-A), unconjugated oestriol (uE ₃), alpha-fetoprotein (AFP) - to detect foetal abnormality, including a service described in 1 or more of items 73527 and 73529 (if performed) - (Item is subject to rule 25)
66750	Fee: \$39.75 Benefit: 75% = \$29.85 85% = \$33.80
	Quantitation, in pregnancy, of any three or more tests described in 66750
66751	(Item is subject to rule 25)

P2. CH	EMICAL		
	Fee: \$55.25	Benefit: 75% = \$41.45 85% = \$47.00	
	homocysteine, c	acetoacetate, beta-hydroxybutyrate, citrate, oxalate, total free fatty acids, cysteine, ystine, lactate, pyruvate or other amino acids and hydroxyproline (except if performed 6773 or 66776) - 1 test	
66752	Fee: \$24.70	Benefit: 75% = \$18.55 85% = \$21.00	
	2 or more tests of	described in item 66752	
66755	Fee: \$38.85	Benefit: 75% = \$29.15 85% = \$33.05	
		10 or more amino acids for the diagnosis of inborn errors of metabolism - up to 4 tests in od on specimens of plasma, CSF and urine.	
66756	Fee: \$98.30	Benefit: 75% = \$73.75 85% = \$83.60	
	Quantitation of metabolism in 1	10 or more amino acids for monitoring of previously diagnosed inborn errors of tissue type.	
66757	Fee: \$98.30	Benefit: 75% = \$73.75 85% = \$83.60	
	Quantitation of	angiotensin converting enzyme, or cholinesterase - 1 or more tests	
66758	Fee: \$24.70	Benefit: 75% = \$18.55 85% = \$21.00	
	Test for reducin	g substances in faeces by any method (except reagent strip or dipstick)	
66761	Fee: \$13.15	Benefit: 75% = \$9.90 85% = \$11.20	
	Examination for faecal occult blood (including tests for haemoglobin and its derivatives in the faeces except by reagent strip or dip stick methods)		
	with a maximum	n of 3 examinations on specimens collected on separate days in a 28 day period	
66764	Fee: \$8.90	Benefit: 75% = \$6.70 85% = \$7.60	
	2 examinations	described in item 66764 performed on separately collected and identified specimens	
66767	Fee: \$17.85	Benefit: 75% = \$13.40 85% = \$15.20	
	3 examinations	described in item 66764 performed on separately collected and identified specimens	
66770	Fee: \$26.70	Benefit: 75% = \$20.05 85% = \$22.70	
		products of collagen breakdown or formation for the monitoring of patients with proven al density, and if performed, a service described in item 66752 - 1 or more tests	
	(Low bone densitometry is defined in the explanatory notes to Category 2 - Diagnostic Procedures and Investigations of the Medicare Benefits Schedule)		
66773	Fee: \$24.65	Benefit: 75% = \$18.50 85% = \$21.00	
		products of collagen breakdown or formation for the monitoring of patients with disease or Paget's disease of bone, and if performed, a service described in item 66752 -	
66776	Fee: \$24.65	Benefit: 75% = \$18.50 85% = \$21.00	
66779	Adrenaline, norahydroxymethox	adrenaline, dopamine, histamine, hydroxyindoleacetic acid (5HIAA), ymandelic acid (HMMA), homovanillic acid (HVA), metanephrines,	

P2. CHI	EMICAL	
	methoxyhydrox or more tests	yphenylethylene glycol (MHPG), phenylacetic acid (PAA) or serotonin quantitation - 1
	Fee: \$39.95	Benefit: 75% = \$30.00 85% = \$34.00
	A test described	d in item 66779 if rendered by a receiving APP - 1 or more tests
	(Item is subject	to rule 18)
66780	Fee: \$39.95	Benefit: 75% = \$30.00 85% = \$34.00
	Porphyrins or po	orphyrins precursors - detection in plasma, red cells, urine or faeces - 1 or more tests
66782	Fee: \$13.15	Benefit: 75% = \$9.90 85% = \$11.20
	A test described	in item 66782 if rendered by a receiving APP - 1 or more tests
	(Item is subject	to rule 18)
66783	Fee: \$13.15	Benefit: 75% = \$9.90 85% = \$11.20
	Porphyrins or po	orphyrins precursors - quantitation in plasma, red cells, urine or faeces - 1 test
	(Item is subject	to rule 6)
66785	Fee: \$39.95	Benefit: 75% = \$30.00 85% = \$34.00
	Porphyrins or po	orphyrins precursors - quantitation in plasma, red cells, urine or faeces - 2 or more tests
	(Item is subject	to rule 6)
66788	Fee: \$65.85	Benefit: 75% = \$49.40 85% = \$56.00
		in item 66785 if rendered by a receiving APP, where no tests in the item have been referring APP - 1 test
	(Item is subject	to rule 6 and 18)
66789	Fee: \$39.95	Benefit: 75% = \$30.00 85% = \$34.00
	A test described maximum of 1 t	in item 66785 other than that described in 66789, if rendered by a receiving APP - to a est
	(Item is subject to rule 6 and 18)	
66790	Fee: \$25.90	Benefit: 75% = \$19.45 85% = \$22.05
	Porphyrin biosy	nthetic enzymes - measurement of activity in blood cells or other tissues - 1 or more tests
66791	Fee: \$74.45	Benefit: 75% = \$55.85 85% = \$63.30
	A test described	in item 66791 if rendered by a receiving APP - 1 or more tests
	(Item is subject	to rule 18)
66792	Fee: \$74.45	Benefit: 75% = \$55.85 85% = \$63.30
66800	any of the followamikacin, carba	blood, urine or other body fluid by any method (except reagent tablet or reagent strip) of wing being used therapeutically by the patient from whom the specimen was taken: mazepine, digoxin, disopyramide, ethanol, ethosuximide, gentamicin, lithium, micin, paracetamol, phenobarbitone, primidone, phenytoin, procainamide, quinidine,

P2. CHE	EMICAL		
	salicylate, theophylline, tobramycin, valproate or vancomycin - 1 test		
	(Item to be subject to rule 6)		
	(See para PN.0.17 of explanatory notes to this Category) Fee: \$18.15		
	2 tests described in item 66800		
	(Item is subject to rule 6)		
66803	Fee: \$30.50 Benefit: 75% = \$22.90 85% = \$25.95		
	A test described in item 66800 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP - 1 test		
	(Item is subject to rule 6 and 18)		
66804	Fee: \$18.15 Benefit: 75% = \$13.65 85% = \$15.45		
	A test described in item 66800 other than that described in 66804, if rendered by a receiving APP - each test to a maximum of 2 tests		
	(Item is subject to rule 6 and 18)		
66805	Fee: \$12.35 Benefit: 75% = \$9.30 85% = \$10.50		
	3 tests described in item 66800		
	(Item is subject to rule 6)		
66806	Fee: \$41.85 Benefit: 75% = \$31.40 85% = \$35.60		
	Quantitation, not elsewhere described in this Table by any method or methods, in blood, urine or other body fluid, of a drug being used therapeutically by the patient from whom the specimen was taken - 1 test		
	(This fee applies where 1 laboratory performs the only test specified on the request form or performs 1 test and refers the rest to the laboratory of a separate APA) (Item is subject to rule 6)		
66812	(See para PN.0.17 of explanatory notes to this Category) Fee: \$34.80 Benefit: 75% = \$26.10 85% = \$29.60		
	2 tests described in item 66812		
	(This fee applies where 1 laboratory, or more than 1 laboratory belonging to the same APA, performs the only 2 tests specified on the request form or performs 2 tests and refers the rest to the laboratory of a separate APA) (Item is subject to rule 6)		
66815	Fee: \$59.55 Benefit: 75% = \$44.70 85% = \$50.65		
	A test described in item 66812 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP - 1 test		
66816	(Item is subject to rule 6 and 18)		

P2. CHI	CHEMICAL		
	Fee: \$34.80 Benefit: 75% = \$26.10 85% = \$29.60		
	A test described in item 66812, other than that described in 66816, if rendered by a receiving APP - to a maximum of 1 test		
	(Item is subject to rule 6 and 18)		
66817	Fee: \$24.75 Benefit: 75% = \$18.60 85% = \$21.05		
	Quantitation of copper, manganese, selenium, or zinc (except if item 66667 applies), in blood, urine or other body fluid - 1 test.		
	(Item is subject to rule 6, 22 and 25)		
66819	Fee: \$30.60 Benefit: 75% = \$22.95 85% = \$26.05		
	A test described in item 66819 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP - 1 test		
	(Item is subject to rule 6, 18, 22 and 25)		
66820	Fee: \$30.60 Benefit: 75% = \$22.95 85% = \$26.05		
	A test described in item 66819 other than that described in 66820 if rendered by a receiving APP to a maximum of 1 test		
	(Item is subject to rule 6, 18, 22 and 25)		
66821	Fee: \$21.80 Benefit: 75% = \$16.35 85% = \$18.55		
	Quantitation of copper, manganese, selenium, or zinc (except if item 66667 applies), in blood, urine or other body fluid - 2 or more tests.		
	(Item is subject to rule 6, 22 and 25)		
66822	Fee: \$52.45 Benefit: 75% = \$39.35 85% = \$44.60		
	Quantitation of aluminium (except if item 66671 applies), arsenic, beryllium, cadmium, chromium, gold mercury, nickel, or strontium, in blood, urine or other body fluid or tissue - 1 test. To a maximum of 3 o this item in a 6 month period		
	(Item is subject to rule 6, 22 and 25)		
66825	Fee: \$30.60 Benefit: 75% = \$22.95 85% = \$26.05		
	A test described in item 66825 if rendered by a receiving APP where no tests have been rendered by the referring APP - 1 test		
	(Item is subject to rules 6, 18, 22 and 25)		
66826	Fee: \$30.60 Benefit: 75% = \$22.95 85% = \$26.05		
	A test described in item 66825, other than that described in 66826, if rendered by a receiving APP to a maximum of 1 test		
	(Item is subject to rules 6, 18, 22 and 25)		
66827	Fee: \$21.80 Benefit: 75% = \$16.35 85% = \$18.55		
66828	Quantitation of aluminium (except if item 66671 applies), arsenic, beryllium, cadmium, chromium, gold mercury, nickel, or strontium, in blood, urine or other body fluid or tissue - 2 or more tests. To a		

P2. CHE	EMICAL
	maximum of 3 of this item in a 6 month period
	(Item is subject to rule 6, 22 and 25)
	Fee: \$52.45 Benefit: 75% = \$39.35 85% = \$44.60
	Quantitation of BNP or NT-proBNP for the diagnosis of heart failure in patients presenting with dyspnoea to a hospital Emergency Department
	(Item is subject to rule 25)
66830	Fee: \$58.50 Benefit: 75% = \$43.90 85% = \$49.75
	Quantitation of copper or iron in liver tissue biopsy
66831	Fee: \$30.95 Benefit: 75% = \$23.25 85% = \$26.35
	A test described in item 66831 if rendered by a receiving APP
	(Item is subject to rule 18A and 22)
66832	Fee: \$30.95 Benefit: 75% = \$23.25 85% = \$26.35
	25-hydroxyvitamin D, quantification in serum, for the investigation of a patient who:
	(a) has signs or symptoms of osteoporosis or osteomalacia; or
	(b) has increased alkaline phosphatase and otherwise normal liver function tests; or
	(c) has hyperparathyroidism, hypo- or hypercalcaemia, or hypophosphataemia; or
	(d) is suffering from malabsorption (for example, because the patient has cystic fibrosis, short bowel syndrome, inflammatory bowel disease or untreated coeliac disease, or has had bariatric surgery); or
	(e) has deeply pigmented skin, or chronic and severe lack of sun exposure for cultural, medical, occupational or residential reasons; or
	(f) is taking medication known to decrease 25OH-D levels (for example, anticonvulsants); or
	(g) has chronic renal failure or is a renal transplant recipient; or
	(h) is less than 16 years of age and has signs or symptoms of rickets; or
	(i) is an infant whose mother has established vitamin D deficiency; or
	(j) is a exclusively breastfed baby and has at least one other risk factor mentioned in a paragraph in this item; or
	(k) has a sibling who is less than 16 years of age and has vitamin D deficiency
66833	Fee: \$30.05 Benefit: 75% = \$22.55 85% = \$25.55
	A test described in item 66833 if rendered by a receiving APP
	(Item is subject to Rule 18)
66834	Fee: \$30.05 Benefit: 75% = \$22.55 85% = \$25.55
66835	1, 25-dihydroxyvitamin D - quantification in serum, if the request for the test is made by, or on advice

P2. CHE	EMICAL		
	of, the specialist or consultant physician managing the treatment of the patient		
	Fee: \$39.05 Benefit: 75% = \$29.30 85% = \$33.20		
	1, 25-dihydroxyvitamin D-quantification in serum, if:		
	(a) the patient has hypercalcaemia; and		
	(b) the request for the test is made by a general practitioner managing the treatment of the patient		
66836	Fee: \$39.05 Benefit: 75% = \$29.30 85% = \$33.20		
	A test described in item 66835 or 66836 if rendered by a receiving APP (Item is subject to Rule 18)		
66837	Fee: \$39.05 Benefit: 75% = \$29.30 85% = \$33.20		
	Serum vitamin B12 test		
	(Item is subject to Rule 25)		
66838	Fee: \$23.60 Benefit: 75% = \$17.70 85% = \$20.10		
	Quantification of vitamin B12 markers such as holoTranscobalamin or methylmalonic acid, where initial serum vitamin B12 result is low or equivocal		
66839	Fee: \$42.95 Benefit: 75% = \$32.25 85% = \$36.55		
	Serum folate test and, if required, red cell folate test for a patient at risk of folate deficiency, including patients with malabsorption conditions, macrocytic anaemia or coeliac disease		
66840	Fee: \$23.60 Benefit: 75% = \$17.70 85% = \$20.10		
	Quantitation of HbA1c (glycated haemoglobin) performed for the diagnosis of diabetes in asymptomatic patients at high risk. (Item is subject to rule 25)		
66841	Fee: \$16.80 Benefit: 75% = \$12.60 85% = \$14.30		
	CARBON-LABELLED UREA BREATH TEST using oral C-13 or C-14 urea, including the measurement of exhaled 13CO2 or 14CO2 (except if item 12533 applies) for either:-		
	(a) the confirmation of <i>Helicobacter pylori</i> colonisation OR		
	(b) the monitoring of the success of eradication of <i>Helicobacter pylori</i> .		
66900	Fee: \$77.65 Benefit: 75% = \$58.25 85% = \$66.05		
P3. MIC	ROBIOLOGY		
	Group P3. Microbiology		
	Microscopy of wet film material other than blood, from 1 or more sites, obtained directly from a patient (not cultures) including:		
	(a) differential cell count (if performed); or		
	(b) examination for dermatophytes; or		
	(c) dark ground illumination; or		
69300	(d) stained preparation or preparations using any relevant stain or stains;		

P3. MIC	ROBIOLOGY
	1 or more tests
	Fee: \$12.50 Benefit: 75% = \$9.40 85% = \$10.65
	Culture and (if performed) microscopy to detect pathogenic micro-organisms from nasal swabs, throat swabs, eye swabs and ear swabs (excluding swabs taken for epidemiological surveillance), including (if performed):
	(a) pathogen identification and antibiotic susceptibility testing; or
	(b) a service described in item 69300;
	specimens from 1 or more sites
69303	Fee: \$22.00 Benefit: 75% = \$16.50 85% = \$18.70
	Microscopy and culture to detect pathogenic micro-organisms from skin or other superficial sites, including (if performed):
	(a) pathogen identification and antibiotic susceptibility testing; or
	(b) a service described in items 69300, 69303, 69312, 69318;
	1 or more tests on 1 or more specimens
69306	Fee: \$33.75 Benefit: 75% = \$25.35 85% = \$28.70
	Microscopy and culture to detect dermatophytes and other fungi causing cutaneous disease from skin scrapings, skin biopsies, hair and nails (excluding swab specimens) and including (if performed):
	(a) the detection of antigens not elsewhere specified in this Table; or
	(b) a service described in items 69300, 69303, 69306, 69312, 69318;
	1 or more tests on 1 or more specimens
69309	Fee: \$48.15 Benefit: 75% = \$36.15 85% = \$40.95
	Microscopy and culture to detect pathogenic micro-organisms from urethra, vagina, cervix or rectum (except for faecal pathogens), including (if performed):
	(a) pathogen identification and antibiotic susceptibility testing; or
	(b) a service described in items 69300, 69303, 69306 and 69318;
	1 or more tests on 1 or more specimens
69312	Fee: \$33.75 Benefit: 75% = \$25.35 85% = \$28.70
	Detection of Chlamydia trachomatis by any method - 1 test (Item is subject to rule 26)
69316	Fee: \$28.65 Benefit: 75% = \$21.50 85% = \$24.40
	1 test described in item 69494 and a test described in 69316. (Item is subject to rule 26)
69317	Fee: \$35.85 Benefit: 75% = \$26.90 85% = \$30.50
69318	Microscopy and culture to detect pathogenic micro-organisms from specimens of sputum (except when part of items 69324, 69327 and 69330), including (if performed):

(a) pathogen identification and antibiotic susceptibility testing; or (b) a service described in items 69300, 69303, 69306 and 69312; 1 or more tests on 1 or more specimens Fee: \$33.75 Benefit: 75% = \$25.35 85% = \$28.70 2 tests described in item 69494 and a test described in 69316. (Item is subject to rule 69319 Fee: \$42.95 Benefit: 75% = \$32.25 85% = \$36.55 Microscopy and culture of post-operative wounds, aspirates of body cavities, synovia operative or biopsy specimens, for the presence of pathogenic micro-organisms involuntaerobic cultures and the use of different culture media, and including (if performed (a) pathogen identification and antibiotic susceptibility testing; or (b) a service described in item 69300, 69303, 69306, 69312 or 69318; specimens from 1 or more sites Fee: \$48.15 Benefit: 75% = \$36.15 85% = \$40.95 Microscopy (with appropriate stains) and culture for mycobacteria - 1 specimen of spother body fluid or 1 operative or biopsy specimen, including (if performed): (a) microscopy and culture of other bacterial pathogens isolated as a result of this performed identification and antibiotic susceptibility testing;	
1 or more tests on 1 or more specimens Fee: \$33.75 Benefit: 75% = \$25.35 85% = \$28.70 2 tests described in item 69494 and a test described in 69316. (Item is subject to rule Fee: \$42.95 Benefit: 75% = \$32.25 85% = \$36.55 Microscopy and culture of post-operative wounds, aspirates of body cavities, synovia operative or biopsy specimens, for the presence of pathogenic micro-organisms involutionanaerobic cultures and the use of different culture media, and including (if performed (a) pathogen identification and antibiotic susceptibility testing; or (b) a service described in item 69300, 69303, 69306, 69312 or 69318; specimens from 1 or more sites Fee: \$48.15 Benefit: 75% = \$36.15 85% = \$40.95 Microscopy (with appropriate stains) and culture for mycobacteria - 1 specimen of specimen body fluid or 1 operative or biopsy specimen, including (if performed): (a) microscopy and culture of other bacterial pathogens isolated as a result of this performed identification and antibiotic susceptibility testing;	
Fee: \$33.75 Benefit: 75% = \$25.35 85% = \$28.70 2 tests described in item 69494 and a test described in 69316. (Item is subject to rule 69319 Fee: \$42.95 Benefit: 75% = \$32.25 85% = \$36.55 Microscopy and culture of post-operative wounds, aspirates of body cavities, synovia operative or biopsy specimens, for the presence of pathogenic micro-organisms involuntation and antibiotic susceptibility testing; or (a) pathogen identification and antibiotic susceptibility testing; or (b) a service described in item 69300, 69303, 69306, 69312 or 69318; specimens from 1 or more sites Fee: \$48.15 Benefit: 75% = \$36.15 85% = \$40.95 Microscopy (with appropriate stains) and culture for mycobacteria - 1 specimen of spother body fluid or 1 operative or biopsy specimen, including (if performed): (a) microscopy and culture of other bacterial pathogens isolated as a result of this put of pathogen identification and antibiotic susceptibility testing;	
2 tests described in item 69494 and a test described in 69316. (Item is subject to rule Fee: \$42.95 Benefit: 75% = \$32.25 Microscopy and culture of post-operative wounds, aspirates of body cavities, synovia operative or biopsy specimens, for the presence of pathogenic micro-organisms involuntation and the use of different culture media, and including (if performed (a) pathogen identification and antibiotic susceptibility testing; or (b) a service described in item 69300, 69303, 69306, 69312 or 69318; specimens from 1 or more sites Fee: \$48.15 Benefit: 75% = \$36.15 85% = \$40.95 Microscopy (with appropriate stains) and culture for mycobacteria - 1 specimen of spother body fluid or 1 operative or biopsy specimen, including (if performed): (a) microscopy and culture of other bacterial pathogens isolated as a result of this puthogen identification and antibiotic susceptibility testing;	
Fee: \$42.95 Benefit: 75% = \$32.25 85% = \$36.55 Microscopy and culture of post-operative wounds, aspirates of body cavities, synovia operative or biopsy specimens, for the presence of pathogenic micro-organisms involunted anaerobic cultures and the use of different culture media, and including (if performed (a) pathogen identification and antibiotic susceptibility testing; or (b) a service described in item 69300, 69303, 69306, 69312 or 69318; specimens from 1 or more sites Fee: \$48.15 Benefit: 75% = \$36.15 85% = \$40.95 Microscopy (with appropriate stains) and culture for mycobacteria - 1 specimen of specimen body fluid or 1 operative or biopsy specimen, including (if performed): (a) microscopy and culture of other bacterial pathogens isolated as a result of this performed identification and antibiotic susceptibility testing;	
Microscopy and culture of post-operative wounds, aspirates of body cavities, synovia operative or biopsy specimens, for the presence of pathogenic micro-organisms involuntation and the use of different culture media, and including (if performed (a) pathogen identification and antibiotic susceptibility testing; or (b) a service described in item 69300, 69303, 69306, 69312 or 69318; specimens from 1 or more sites Fee: \$48.15 Benefit: 75% = \$36.15 85% = \$40.95 Microscopy (with appropriate stains) and culture for mycobacteria - 1 specimen of spother body fluid or 1 operative or biopsy specimen, including (if performed): (a) microscopy and culture of other bacterial pathogens isolated as a result of this post pathogen identification and antibiotic susceptibility testing;	26)
operative or biopsy specimens, for the presence of pathogenic micro-organisms involunted anaerobic cultures and the use of different culture media, and including (if performed (a) pathogen identification and antibiotic susceptibility testing; or (b) a service described in item 69300, 69303, 69306, 69312 or 69318; specimens from 1 or more sites Fee: \$48.15 Benefit: 75% = \$36.15 85% = \$40.95 Microscopy (with appropriate stains) and culture for mycobacteria - 1 specimen of specimen body fluid or 1 operative or biopsy specimen, including (if performed): (a) microscopy and culture of other bacterial pathogens isolated as a result of this performed identification and antibiotic susceptibility testing;	
(b) a service described in item 69300, 69303, 69306, 69312 or 69318; specimens from 1 or more sites Fee: \$48.15 Benefit: 75% = \$36.15 85% = \$40.95 Microscopy (with appropriate stains) and culture for mycobacteria - 1 specimen of spother body fluid or 1 operative or biopsy specimen, including (if performed): (a) microscopy and culture of other bacterial pathogens isolated as a result of this position of the pathogen identification and antibiotic susceptibility testing;	lving aerobic and
specimens from 1 or more sites Fee: \$48.15 Benefit: 75% = \$36.15 85% = \$40.95 Microscopy (with appropriate stains) and culture for mycobacteria - 1 specimen of spother body fluid or 1 operative or biopsy specimen, including (if performed): (a) microscopy and culture of other bacterial pathogens isolated as a result of this position (b) pathogen identification and antibiotic susceptibility testing;	
Fee: \$48.15 Benefit: 75% = \$36.15 85% = \$40.95 Microscopy (with appropriate stains) and culture for mycobacteria - 1 specimen of spother body fluid or 1 operative or biopsy specimen, including (if performed): (a) microscopy and culture of other bacterial pathogens isolated as a result of this position of the pathogen identification and antibiotic susceptibility testing;	
Microscopy (with appropriate stains) and culture for mycobacteria - 1 specimen of spother body fluid or 1 operative or biopsy specimen, including (if performed): (a) microscopy and culture of other bacterial pathogens isolated as a result of this post pathogen identification and antibiotic susceptibility testing;	
other body fluid or 1 operative or biopsy specimen, including (if performed): (a) microscopy and culture of other bacterial pathogens isolated as a result of this p (b) pathogen identification and antibiotic susceptibility testing;	
(b) pathogen identification and antibiotic susceptibility testing;	outum, urine, or
	procedure; or
including a service mentioned in item 69300	
69324 Fee: \$43.00 Benefit: 75% = \$32.25 85% = \$36.55	
A test described in item 69324 if rendered by a receiving APP	
(Item is subject to rule 18)	
69325 Fee: \$43.00 Benefit: 75% = \$32.25 85% = \$36.55	
Microscopy (with appropriate stains) and culture for mycobacteria - 2 specimens of so other body fluid or 2 operative or biopsy specimens, including (if performed):	sputum, urine, or
(a) microscopy and culture of other bacterial pathogens isolated as a result of this p	procedure; or
(b) pathogen identification and antibiotic susceptibility testing;	
including a service mentioned in item 69300	
69327 Fee: \$85.00 Benefit: 75% = \$63.75 85% = \$72.25	
A test described in item 69327 if rendered by a receiving APP	
(Item is subject to rule 18)	
69328 Fee: \$85.00 Benefit: 75% = \$63.75 85% = \$72.25	
Microscopy (with appropriate stains) and culture for mycobacteria - 3 specimens of so other body fluid or 3 operative or biopsy specimens, including (if performed):	mutum urina ar

P3. MICI	P3. MICROBIOLOGY		
	(a) microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or		
	(b) pathogen identification and antibiotic susceptibility testing;		
	including a service mentioned in item 69300		
	Fee: \$128.00 Benefit: 75% = \$96.00 85% = \$108.80		
	A test described in item 69330 if rendered by a receiving APP		
	(Item is subject to rule 18)		
69331	Fee: \$128.00 Benefit: 75% = \$96.00 85% = \$108.80		
	Urine examination (including serial examination) by any means other than simple culture by dip slide, including:		
	(a) cell count; and		
	(b) culture; and		
	(c) colony count; and		
	(d) (if performed) stained preparations; and		
	(e) (if performed) identification of cultured pathogens; and		
	(f) (if performed) antibiotic susceptibility testing; and		
	(g) (if performed) examination for pH, specific gravity, blood, protein, urobilinogen, sugar, acetone or bile salts		
69333	Fee: \$20.55 Benefit: 75% = \$15.45 85% = \$17.50		
	Microscopy of faeces for ova, cysts and parasites that must include a concentration technique, and the use of fixed stains or antigen detection for cryptosporidia and giardia - including (if performed) a service mentioned in item 69300 - 1 of this item in any 7 day period		
69336	Fee: \$33.45 Benefit: 75% = \$25.10 85% = \$28.45		
	Microscopy of faeces for ova, cysts and parasites using concentration techniques examined subsequent to item 69336 on a separately collected and identified specimen collected within 7 days of the examination described in 69336 - 1 examination in any 7 day period		
69339	Fee: \$19.10 Benefit: 75% = \$14.35 85% = \$16.25		
	Culture and (if performed) microscopy without concentration techniques of faeces for faecal pathogens, using at least 2 selective or enrichment media and culture in at least 2 different atmospheres including (if performed):		
	(a) pathogen identification and antibiotic susceptibility testing; and		
	(b) the detection of clostridial toxins; and		
	(c) a service described in item 69300;		
	- 1 examination in any 7 day period		
69345	Fee: \$52.90 Benefit: 75% = \$39.70 85% = \$45.00		

P3. MICROBIOLOGY			
	Blood culture for paperformed):	thogenic micro-organisms (other than viruses), including sub-cultures and (if	
	(a) identification of any cultured pathogen; and		
	piotic susceptibility testing;		
	to a maximum of 3	sets of cultures - 1 set of cultures	
69354	Fee: \$30.75	Benefit: 75% = \$23.10 85% = \$26.15	
	2 sets of cultures de	scribed in item 69354	
69357	Fee: \$61.45	Benefit: 75% = \$46.10 85% = \$52.25	
	3 sets of cultures de	scribed in item 69354	
69360	Fee: \$92.20	Benefit: 75% = \$69.15 85% = \$78.40	
	Detection of <i>Clostridium difficile</i> or <i>Clostridium difficile</i> toxin (except if a service described in it 69345 has been performed) - one or more tests		
69363	Fee: \$28.65	Benefit: 75% = \$21.50 85% = \$24.40	
	Quantitation of HIV viral RNA load in plasma or serum in the monitoring of a HIV sero-ponot on antiretroviral therapy - 1 or more tests		
69378	Fee: \$180.25	Benefit: 75% = \$135.20 85% = \$153.25	
	A test described in i 18)	tem 69378 if rendered by a receiving APP - 1 or more tests (Item is subject to rule	
69379	Fee: \$180.25	Benefit: 75% = \$135.20 85% = \$153.25	
	Genotypic testing for HIV antiretroviral resistance in a patient with confirmed HIV infection if the patient's viral load is greater than 1,000 copies per ml at any of the following times:		
	(a) at presentation; or		
	(b) before antiretroviral therapy: or		
	(c) when treatment with combination antiretroviral agents fails;		
	maximum of 2 tests in a 12 month period		
69380	Fee: \$770.30	Benefit: 75% = \$577.75 85% = \$686.90	
	_	viral RNA load in plasma or serum in the monitoring of antiretroviral therapy in a atient - 1 or more tests on 1 or more specimens	
69381	Fee: \$180.25	Benefit: 75% = \$135.20 85% = \$153.25	
	Quantitation of HIV tests on 1 or more sp	viral RNA load in cerebrospinal fluid in a HIV sero-positive patient - 1 or more pecimens	
69382	Fee: \$180.25	Benefit: 75% = \$135.20 85% = \$153.25	
	A test described in item 69381 if rendered by a receiving APP - 1 or more tests on 1 or more specimens		
	(Item is subject to rule 18)		
69383	Fee: \$180.25	Benefit: 75% = \$135.20 85% = \$153.25	

P3. MIC	P3. MICROBIOLOGY	
	Quantitation of 1 antibody to microbial antigens not elsewhere described in the Schedule - 1 test	
	(This fee applies where a laboratory performs the only antibody test specified on the request form or performs 1 test and refers the rest to the laboratory of a separate APA)	
	(Item is subject to rule 6)	
69384	(See para PN.0.18 of explanatory notes to this Category) Fee: \$15.65 Benefit: 75% = \$11.75 85% = \$13.35	
	2 tests described in item 69384	
	(This fee applies where 1 laboratory, or more than 1 laboratory belonging to the same APA, performs the only 2 estimations specified on the request form or performs 2 of the antibody estimations specified on the request form and refers the remainder to the laboratory of a separate APA)	
	(Item is subject to rule 6)	
69387	(See para PN.0.18 of explanatory notes to this Category) Fee: \$29.00 Benefit: 75% = \$21.75 85% = \$24.65	
	3 tests described in item 69384	
	(This fee applies where 1 laboratory, or more than 1 laboratory belonging to the same APA, performs the only 3 estimations specified on the request form or performs 3 of the antibody estimations specified on the request form and refers the remainder to the laboratory of a separate APA)	
	(Item is subject to rule 6)	
	(See para PN.0.18 of explanatory notes to this Category)	
69390	Fee: \$42.35 Benefit: 75% = \$31.80 85% = \$36.00	
	4 tests described in item 69384	
	(This fee applies where 1 laboratory, or more than 1 laboratory belonging to the same APA, performs the only 4 estimations specified on the request form or performs 4 of the antibody estimations specified on the request form and refers the remainder to the laboratory of a separate APA)	
	(Item is subject to rule 6)	
	(See para PN.0.18 of explanatory notes to this Category)	
69393	Fee: \$55.70 Benefit: 75% = \$41.80 85% = \$47.35	
	5 or more tests described in item 69384	
(020((This fee applies where 1 laboratory, or more than 1 laboratory belonging to the same APA, performs the	
69396	only 5 estimations specified on the request form or performs 5 of the antibody tests specified on the	

P3. MIC	ROBIOLOGY		
	request form and refers the remainder to the laboratory of a separate APA)		
	(Item is subject to rule 6)		
	(See para PN.0.18 of explanatory notes to this Category) Fee: \$69.10 Benefit: 75% = \$51.85 85% = \$58.75		
	A test described in item 69384, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP - 1 test		
	(Item is subject to rules 6 and 18)		
69400	Fee: \$15.65 Benefit: 75% = \$11.75 85% = \$13.35		
	A test described in item 69384, other than that described in 69400, if rendered by a receiving APP - each test to a maximum of 4 tests		
	(Item is subject to rule 6, 18 and 18A)		
69401	Fee: \$13.35 Benefit: 75% = \$10.05 85% = \$11.35		
	Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:		
	(a) the determination of 1 of the following - rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody, HIV antibody and		
	(b) (if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481		
69405	(See para PN.0.18 of explanatory notes to this Category) Fee: \$15.65 Benefit: 75% = \$11.75 85% = \$13.35		
	Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:		
	(a) the determination of 2 of the following - rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody, HIV antibody and		
	(b) (if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481		
69408	(See para PN.0.18 of explanatory notes to this Category) Fee: \$29.00 Benefit: 75% = \$21.75 85% = \$24.65		
	Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:		
	(a) the determination of 3 of the following - rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody, HIV antibody and		
	(b) (if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481		
69411	(See para PN.0.18 of explanatory notes to this Category) Fee: \$42.35 Benefit: 75% = \$31.80 85% = \$36.00		
69413	Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or		

P3. MIC	ROBIOLOGY	
	varicella during that pregnancy) including:	
	(a) the determination of 4 of the following - rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody, HIV antibody and	
	(b) (if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481	
(See para PN.0.18 of explanatory notes to this Category) Fee: \$55.70 Benefit: 75% = \$41.80 85% = \$47.35		
	Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:	
	(a) the determination of all 5 of the following - rubella immune status, specific syphilis serology, carriage of	
	Hepatitis B, Hepatitis C antibody, HIV antibody and	
	(b) (if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481	
69415	(See para PN.0.18 of explanatory notes to this Category) Fee: \$69.10 Benefit: 75% = \$51.85 85% = \$58.75	
	Detection of Hepatitis C viral RNA in a patient undertaking antiviral therapy for chronic HCV hepatitis (including a service described in item 69499) - 1 test. To a maximum of 4 of this item in a 12 month period	
	(Item is subject to rule 25)	
69445	Fee: \$92.20 Benefit: 75% = \$69.15 85% = \$78.40	
	A test described in item 69445 if rendered by a receiving APP - 1 test.	
	(Item is subject to rule 18 and 25)	
69451	Fee: \$92.20 Benefit: 75% = \$69.15 85% = \$78.40	
	Test of cell-mediated immune response in blood for the detection of latent tuberculosis by interferon gamma release assay (IGRA) in the following people:	
	(a) a person who has been exposed to a confirmed case of active tuberculosis;	
	(b) a person who is infected with human immunodeficiency virus;	
	(c) a person who is to commence, or has commenced, tumour necrosis factor (TNF) inhibitor therapy;	
	(d) a person who is to commence, or has commenced, renal dialysis;	
	(e) a person with silicosis;	
	(f) a person who is, or is about to become, immunosuppressed because of a disease, or a medical treatment, not mentioned in paragraphs (a) to (e)	
69471	(See para PN.3.4 of explanatory notes to this Category) Fee: \$34.90 Benefit: 75% = \$26.20 85% = \$29.70	
	Detection of antibodies to Epstein Barr Virus using specific serology - 1 test	
69472	Fee: \$15.65 Benefit: 75% = \$11.75 85% = \$13.35	

P3. MIC	ROBIOLOGY		
	Detection of antibodies to Epstein Barr Virus using specific serology - 2 or more tests		
69474	Fee: \$28.65	Benefit: 75% = \$21.50 85% = \$24.40	
		atitis antigen or antibodies to determine immune status or viral carriage following cination to Hepatitis A, Hepatitis B, Hepatitis C or Hepatitis D	
	(Item subject to	rule 11)	
69475	Fee: \$15.65	Benefit: 75% = \$11.75 85% = \$13.35	
	2 tests described	l in 69475	
	(Item subject to	rule 11)	
69478	Fee: \$29.25	Benefit: 75% = \$21.95 85% = \$24.90	
	Investigation of infectious causes of acute or chronic hepatitis - 3 tests for hepatitis antibodies or antigens,		
	(Item subject to	rule 11)	
69481	(See para PN.0.19 Fee: \$40.55	of explanatory notes to this Category) Benefit: 75% = \$30.45 85% = \$34.50	
	Quantitation of Hepatitis B viral DNA in patients who are Hepatitis B surface antigen positive and have chronic hepatitis B, but are not receiving antiviral therapy - 1 test		
	(Item is subject	to rule 25)	
69482	Fee: \$152.10	Benefit: 75% = \$114.10 85% = \$129.30	
		Hepatitis B viral DNA in patients who are Hepatitis B surface antigen positive and who patitis B and are receiving antiviral therapy - 1 test	
	(Item is subject to rule 25)		
69483	Fee: \$152.10	Benefit: 75% = \$114.10 85% = \$129.30	
	Supplementary testing for Hepatitis B surface antigen or Hepatitis C antibody using a different assay on the specimen which yielded a reactive result on initial testing		
	(Item is subject to rule 18)		
69484	Fee: \$17.10	Benefit: 75% = \$12.85 85% = \$14.55	
	Quantitation of HCV RNA load in plasma or serum in:		
	(a) the pre-treatment evaluation, of a patient with chronic HCV hepatitis, for antiviral therapy; or		
	(b) the assessment of efficacy of antiviral therapy for such a patient		
	(including a service in item 69499 or 69445)		
	(Item is subject to rule 18 and 25)		
69488	Fee: \$180.25	Benefit: 75% = \$135.20 85% = \$153.25	
69489		in item 69488 if rendered by a receiving APP	

P3. MIC	ROBIOLOGY	
	(Item is subject to rule 18 and 25)	
	Fee: \$180.25 Benefit: 75% = \$135.20 85% = \$153.25	
	Nucleic acid amplification and determination of Hepatitis C virus (HCV) genotype if the patient is HCV RNA positive and is being evaluated for antiviral therapy of chronic HCV hepatitis.	
	To a maximum of 1 of this item in a 12 month period	
69491	Fee: \$204.80 Benefit: 75% = \$153.60 85% = \$174.10	
	A test described in item 69491 if rendered by a receiving APP - 1 test (Item is subject to rule 18 and 25)	
69492	Fee: \$204.80 Benefit: 75% = \$153.60 85% = \$174.10	
	Detection of a virus or microbial antigen or microbial nucleic acid (not elsewhere specified)	
	1 test	
	(Item is subject to rule 6 and 26)	
69494	Fee: \$28.65 Benefit: 75% = \$21.50 85% = \$24.40	
	2 tests described in 69494	
	(Item is subject to rule 6 and 26)	
69495	Fee: \$35.85 Benefit: 75% = \$26.90 85% = \$30.50	
	3 or more tests described in 69494	
	(Item is subject to rule 6 and 26)	
69496	Fee: \$43.05 Benefit: 75% = \$32.30 85% = \$36.60	
	A test described in item 69494, if rendered by a receiving APP, where no tests in the item have been	
	rendered by the referring APP - 1 test (Item is subject to rule 6, 18 and 26)	
69497	Fee: \$28.65 Benefit: 75% = \$21.50 85% = \$24.40	
	A test described in item 69494, other than that described in 69497, if rendered by a receiving APP - each test to a maximum of 2 tests (Item is subject to rule 6, 18 and 26)	
69498	Fee: \$7.20 Benefit: 75% = \$5.40 85% = \$6.15	
	Detection of Hepatitis C viral RNA if at least 1 of the following criteria is satisfied:	
	(a) the patient is Hepatitis C seropositive;	
	(b) the patient's serological status is uncertain after testing;	
	(c) the test is performed for the purpose of:	
	(i) determining the Hepatitis C status of an immunosuppressed or immunocompromised patient; or	
69499	(ii) the detection of acute Hepatitis C prior to seroconversion where considered necessary for the	
ロフサブブ	(ii) the detection of acute repairing e prior to seroconversion where considered necessary for the	

P3. MIC	ROBIOLOGY		
	clinical		
	management of the patient;		
	To a maximum of 1 of this item in a 12 month period		
	(Item is subject to rule 19 and 25)		
	Fee: \$92.20 Benefit: 75% = \$69.15 85% = \$78.40		
	A test described in item 69499 if rendered by a receiving APP - 1 test (Item is subject to rule 18,19 and		
	25)		
69500	Fee: \$92.20 Benefit: 75% = \$69.15 85% = \$78.40		
P4. IMN	IUNOLOGY		
	Group P4. Immunology		
	Electrophoresis, quantitative and qualitative, of serum, urine or other body fluid all collected within a 28 day period, to demonstrate:		
	(a) protein classes; or		
	(b) presence and amount of paraprotein;		
	including the preliminary quantitation of total protein, albumin and globulin - 1 specimen type		
71057	Fee: \$32.90 Benefit: 75% = \$24.70 85% = \$28.00		
	Examination as described in item 71057 of 2 or more specimen types		
71058	Fee: \$50.50 Benefit: 75% = \$37.90 85% = \$42.95		
	Immunofixation or immunoelectrophoresis or isoelectric focusing of:		
	(a) urine for detection of Bence Jones proteins; or		
	(b) serum, plasma or other body fluid;		
	and characterisation of a paraprotein or cryoglobulin -		
	examination of 1 specimen type (eg. serum, urine or CSF)		
71059	Fee: \$35.65 Benefit: 75% = \$26.75 85% = \$30.35		
71037	Examination as described in item 71059 of 2 or more specimen types		
71060	Fee: \$44.05 Benefit: 75% = \$33.05 85% = \$37.45		
	Electrophoresis and immunofixation or immunoelectrophoresis or isoelectric focussing of CSF for the detection of oligoclonal bands and including if required electrophoresis of the patient's serum for comparison purposes - 1 or more tests		
71070			
71062	Fee: \$44.05 Benefit: 75% = \$33.05 85% = \$37.45 Detection and quantitation of cryoglobulins or cryofibrinogen - 1 or more tests		
71064			
71064	Fee: \$20.75 Benefit: 75% = \$15.60 85% = \$17.65		

P4. IMN	IUNOLOGY	
	Quantitation of	total immunoglobulin A by any method in serum, urine or other body fluid - 1 test
71066	Fee: \$14.55	Benefit: 75% = \$10.95 85% = \$12.40
	Quantitation of	total immunoglobulin G by any method in serum, urine or other body fluid - 1 test
71068	Fee: \$14.55	Benefit: 75% = \$10.95 85% = \$12.40
	2 tests describe	d in items 71066, 71068, 71072 or 71074
71069	Fee: \$22.75	Benefit: 75% = \$17.10 85% = \$19.35
	3 or more tests	described in items 71066, 71068, 71072 or 71074
71071	Fee: \$30.95	Benefit: 75% = \$23.25 85% = \$26.35
	Quantitation of	total immunoglobulin M by any method in serum, urine or other body fluid - 1 test
71072	Fee: \$14.55	Benefit: 75% = \$10.95 85% = \$12.40
	Quantitation of	all 4 immunoglobulin G subclasses
71073	Fee: \$106.15	Benefit: 75% = \$79.65 85% = \$90.25
	Quantitation of	total immunoglobulin D by any method in serum, urine or other body fluid - 1 test
71074	Fee: \$14.55	Benefit: 75% = \$10.95 85% = \$12.40
	Quantitation of	immunoglobulin E (total), 1 test.
	(Item is subject	to rule 25)
71075	Fee: \$23.00	Benefit: 75% = \$17.25 85% = \$19.55
	A test described	d in item 71073 if rendered by a receiving APP - 1 test
	(Item is subject	to rule 18)
71076	Fee: \$106.15	Benefit: 75% = \$79.65 85% = \$90.25
71070	Quantitation of secreting myelo aspergillosis, 1	immunoglobulin E (total) in the follow up of a patient with proven immunoglobulin-Eoma, proven congenital immunodeficiency or proven allergic bronchopulmonary test.
	(Item is subject	
71077	Fee: \$27.05	Benefit: 75% = \$20.30 85% = \$23.00
	(Item is subject	ecific immunoglobulin E antibodies to single or multiple potential allergens, 1 test to rule 25)
71079	Fee: \$26.80	Benefit: 75% = \$20.10 85% = \$22.80
	Quantitation of	total haemolytic complement
71081	Fee: \$40.55	Benefit: 75% = \$30.45 85% = \$34.50
		complement components C3 and C4 or properdin factor B - 1 test
71083	Fee: \$20.15	Benefit: 75% = \$15.15 85% = \$17.15
71085	2 tests described	
, 1003		

P4. IMN	IUNOLOGY				
	Fee: \$28.95	Benefit: 75% = \$21.75 85% = \$24.65			
	3 or more tests	described in item 71083			
71087	Fee: \$37.70	Benefit: 75% = \$28.30 85% = \$32.05			
		complement components or breakdown products of complement proteins not elsewhere item in this Schedule - 1 test			
	(Item is subject	(Item is subject to rule 6)			
71089	Fee: \$29.15	Benefit: 75% = \$21.90 85% = \$24.80			
	A test described in item 71089, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP - 1 test				
	(Item is subject	to rule 6 and 18)			
71090	Fee: \$29.15	Benefit: 75% = \$21.90 85% = \$24.80			
	2 tests described	d in item 71089			
	(Item is subject to rule 6)				
71091	Fee: \$52.85	Benefit: 75% = \$39.65 85% = \$44.95			
	Tests described in item 71089, other than that described in 71090, if rendered by a receiving APP - each test to a maximum of 2 tests				
	(Item is subject to rule 6 and 18)				
71092	Fee: \$23.70	Benefit: 75% = \$17.80 85% = \$20.15			
	3 or more tests	described in item 71089			
	(Item is subject to rule 6)				
71093	Fee: \$76.45	Benefit: 75% = \$57.35 85% = \$65.00			
		serum or plasma eosinophil cationic protein, or both, to a maximum of 3 assays in 1 oring the response to therapy in corticosteroid treated asthma, in a child aged less than 12			
	(See para PN.0.20	0 of explanatory notes to this Category)			
71095	Fee: \$40.55	Benefit: 75% = \$30.45 85% = \$34.50			
	A test described in item 71095 if rendered by a receiving APP.				
	(Item is subject to rule 18)				
71096	Fee: \$40.55	Benefit: 75% = \$30.45 85% = \$34.50			
	Antinuclear ant	ibodies - detection in serum or other body fluids, including quantitation if required			
71097	Fee: \$24.45	Benefit: 75% = \$18.35 85% = \$20.80			
	Double-strande	d DNA antibodies - quantitation by 1 or more methods other than the Crithidia method			
71099	Fee: \$26.50	Benefit: 75% = \$19.90 85% = \$22.55			
	Antibodies to 1	or more extractable nuclear antigens - detection in serum or other body fluids			
71101	Fee: \$17.40	Benefit: 75% = \$13.05 85% = \$14.80			

P4. IMN	IUNOLOGY		
	Characterisation of an antibody detected in a service described in item 71101 (including that service)		
71103	Fee: \$52.05 Benefit: 75% = \$39.05 85% = \$44.25		
	Rheumatoid factor - detection by any technique in serum or other body fluids, including quantitation if required		
71106	Fee: \$11.30 Benefit: 75% = \$8.50 85% = \$9.65		
	Antibodies to tissue antigens not elsewhere specified in this Table - detection, including quantitation if required, of 1 antibody		
71119	(See para PN.0.33 of explanatory notes to this Category) Fee: \$17.35 Benefit: 75% = \$13.05 85% = \$14.75		
	Detection of 2 antibodies specified in item 71119		
71121	(See para PN.0.33 of explanatory notes to this Category) Fee: $$20.80$ Benefit: $75\% = 15.60 $85\% = 17.70		
	Detection of 3 antibodies specified in item 71119		
71123	(See para PN.0.33 of explanatory notes to this Category) Fee: \$24.25 Benefit: 75% = \$18.20 85% = \$20.65		
	Detection of 4 or more antibodies specified in item 71119		
71125	(See para PN.0.33 of explanatory notes to this Category) Fee: \$27.65 Benefit: 75% = \$20.75 85% = \$23.55		
	Functional tests for lymphocytes - quantitation other than by microscopy of:		
	(a) proliferation induced by 1 or more mitogens; or		
	(b) proliferation induced by 1 or more antigens; or		
	(c) estimation of 1 or more mixed lymphocyte reactions;		
	including a test described in item 65066 or 65070 (if performed), 1 of this item to a maximum of 2 in a 12 month period		
71127	Fee: \$176.35 Benefit: 75% = \$132.30 85% = \$149.90		
	2 tests described in item 71127		
71129	Fee: \$217.85 Benefit: 75% = \$163.40 85% = \$185.20		
	3 or more tests described in item 71127		
71131	Fee: \$259.35 Benefit: 75% = \$194.55 85% = \$220.45		
	Investigation of recurrent infection by qualitative assessment for the presence of defects in oxidative pathways in neutrophils by the nitroblue tetrazolium (NBT) reduction test		
71133	Fee: \$10.40 Benefit: 75% = \$7.80 85% = \$8.85		
	Investigation of recurrent infection by quantitative assessment of oxidative pathways by flow cytometric techniques, including a test described in 71133 (if performed)		
71134	Fee: \$104.05 Benefit: 75% = \$78.05 85% = \$88.45		
71135	Quantitation of neutrophil function, comprising at least 2 of the following:		

P4. IMM	UNOLOGY		
	(a) chemotaxis;		
	(b) phagocytosis;		
	(c) oxidative metabolism;		
	(d) bactericidal activity;		
	including any test described in items 65066, 65070, 71133 or 71134 (if performed), 1 of this item to a maximum of 2 in a 12 month period		
	Fee: \$207.95 Benefit: 75% = \$156.00 85% = \$176.80		
	Quantitation of cell-mediated immunity by multiple antigen delayed type hypersensitivity intradermal skin testing using a minimum of 7 antigens, 1 of this item to a maximum of 2 in a 12 month period		
71137	Fee: \$30.25 Benefit: 75% = \$22.70 85% = \$25.75		
	Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations, including a total lymphocyte count or total leucocyte count by any method, on 1 or more specimens of blood, CSF or serous fluid		
71139	Fee: \$104.05 Benefit: 75% = \$78.05 85% = \$88.45		
	Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations on 1 or more disaggregated tissue specimens		
71141	Fee: \$197.35 Benefit: 75% = \$148.05 85% = \$167.75		
	Characterisation of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations for the diagnosis (but not monitoring) of an immunological or haematological malignancy, including a service described in 1 or both of items 71139 and 71141 (if performed), on a specimen of blood, CSF, serous fluid or disaggregated tissue		
71143	Fee: \$260.00 Benefit: 75% = \$195.00 85% = \$221.00		
	Characterisation of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations for the diagnosis (but not monitoring) of an immunological or haematological malignancy, including a service described in 1 or more of items 71139, 71141 and 71143 (if performed), on 2 or more specimens of disaggregated tissues or 1 specimen of disaggregated tissue and 1 or more specimens of blood, CSF or serous fluid		
71145	Fee: \$424.50 Benefit: 75% = \$318.40 85% = \$360.85		
	Enumeration of CD34+ cells, only for the purposes of autologous or directed allogeneic haemopoietic stem cell transplantation, including a total white cell count on the pherisis collection		
71146	Fee: \$104.05 Benefit: 75% = \$78.05 85% = \$88.45		
	HLA-B27 typing		
	(Item is subject to rule 27)		
71147	Fee: \$40.55 Benefit: 75% = \$30.45 85% = \$34.50		
	A test described in item 71147 if rendered by a receiving APP.		
	(Item is subject to rule 18 and 27)		
71148	Fee: \$40.55 Benefit: 75% = \$30.45 85% = \$34.50		

P4. IMN	MUNOLOGY		
	Complete tissue typing for 4 HLA-A and HLA-B Class I antigens (including any separation of leucocytes), including (if performed) a service described in item 71147		
71149	Fee: \$108.25 Benefit: 75% = \$81.20 85% = \$92.05		
	Tissue typing for HLA-DR, HLA-DP and HLA-DQ Class II antigens (including any separation of leucocytes) - phenotyping or genotyping of 2 or more antigens		
71151	Fee: \$118.85 Benefit: 75% = \$89.15 85% = \$101.05		
	Investigations in the assessment or diagnosis of systemic inflammatory disease or vasculitis - antineutrophil cytoplasmic antibody immunofluorescence (ANCA test), antineutrophil proteinase 3 antibody (PR-3 ANCA test), antimyeloperoxidase antibody (MPO ANCA test) or antiglomerular basement membrane antibody (GBM test) - detection of 1 antibody		
	(Item is subject to rule 6 and 23)		
71153	Fee: \$34.55 Benefit: 75% = \$25.95 85% = \$29.40		
	A test described in item 71153, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP - 1 test.		
	(Item is subject to rule 6, 18 and 23)		
71154	Fee: \$34.55 Benefit: 75% = \$25.95 85% = \$29.40		
	Detection of 2 antibodies described in item 71153		
	(Item is subject to rule 6 and 23)		
71155	Fee: \$47.45 Benefit: 75% = \$35.60 85% = \$40.35		
	Tests described in item 71153, other than that described in 71154, if rendered by a receiving APP - each test to a maximum of 3 tests		
	(Item is subject to rule 6, 18 and 23)		
71156	Fee: \$12.85 Benefit: 75% = \$9.65 85% = \$10.95		
	Detection of 3 antibodies described in item 71153		
	(Item is subject to rule 6 and 23)		
71157	Fee: \$60.30 Benefit: 75% = \$45.25 85% = \$51.30		
, , , , ,	Detection of 4 or more antibodies described in item 71153		
	(Item is subject to rule 6 and 23)		
71159	Fee: \$73.15 Benefit: 75% = \$54.90 85% = \$62.20		
	Detection of one of the following antibodies (of 1 or more class or isotype) in the assessment or diagnosis of coeliac disease or other gluten hypersensitivity syndromes and including a service described in item 71066 (if performed):		
	a) Antibodies to gliadin; or		
	b) Antibodies to endomysium; or		
	c) Antibodies to tissue transglutaminase;		
71163	7 Indoodes to ussue transgrammase,		

P4. IMN	IUNOLOGY			
	- 1 test			
	Fee: \$24.75	Benefit: 75% = \$18.60 85% = \$21.05		
	Two or more te	sts described in 71163 and including a service described in 71066 (if performed)		
71164	Fee: \$39.90	Benefit: 75% = \$29.95 85% = \$33.95		
	receptor, intrins	ssue antigens (acetylcholine receptor, adrenal cortex, heart, histone, insulin, insulin ic factor, islet cell, lymphocyte, neuron, ovary, parathyroid, platelet, salivary gland, skin basement membrane and intercellular substance, thyroglobulin, thyroid microsome lating hormone receptor) - detection, including quantitation if required, of 1 antibody		
	(Item is subject	to rule 6)		
71165	Fee: \$34.55	Benefit: 75% = \$25.95 85% = \$29.40		
	Detection of 2 a	antibodies described in item 71165		
	(Item is subject	to rule 6)		
71166	Fee: \$47.45	Benefit: 75% = \$35.60 85% = \$40.35		
	Detection of 3 a	antibodies described in item 71165		
	(Item is subject to rule 6)			
71167	Fee: \$60.30	Benefit: 75% = \$45.25 85% = \$51.30		
	Detection of 4 or more antibodies described in item 71165			
	(Item is subject to rule 6)			
71168	Fee: \$73.15	Benefit: 75% = \$54.90 85% = \$62.20		
	A test described in item 71165, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP - 1 test			
	(Item is subject to rule 6 and 18)			
71169	Fee: \$34.55	Benefit: 75% = \$25.95 85% = \$29.40		
	Tests described in item 71165, other than that described in 71169, if rendered by a receiving APP - each test to a maximum of 3 tests			
	(Item is subject to rule 6 and 18)			
71170	Fee: \$12.85	Benefit: 75% = \$9.65 85% = \$10.95		
	Antibody to cardiolipin or beta-2 glycoprotein I - detection, including quantitation if required; one antibody specificity (IgG or IgM)			
71180	Fee: \$34.55	Benefit: 75% = \$25.95 85% = \$29.40		
	Detection of tw	o antibodies described in item 71180		
71183	Fee: \$47.45	Benefit: 75% = \$35.60 85% = \$40.35		
	Detection of three or more antibodies described in item 71180			
71186	Fee: \$60.30	Benefit: 75% = \$45.25 85% = \$51.30		

P4. IMN	MUNOLOGY		
	Detection of spe	ecific IgG antibodies to 1 or more respiratory disease allergens not elsewhere specified.	
71189	Fee: \$15.50	Benefit: 75% = \$11.65 85% = \$13.20	
	2 items describe	ed in item 71189.	
71192	Fee: \$28.35	Benefit: 75% = \$21.30 85% = \$24.10	
	3 or more items	described in item 71189.	
71195	Fee: \$40.05	Benefit: 75% = \$30.05 85% = \$34.05	
	Estimation of serum tryptase for the evaluation of unexplained acute hypotension or suspected anaphylactic event, assessment of risk in stinging insect anaphylaxis, exclusion of mastocytosis, monitoring of known mastocytosis.		
71198	Fee: \$40.55	Benefit: 75% = \$30.45 85% = \$34.50	
	Detection and quantitation, if present, of free kappa and lambda light chains in serum for the diagnosis or monitoring of amyloidosis, myeloma or plasma cell dyscrasias.		
71200	Fee: \$59.60	Benefit: 75% = \$44.70 85% = \$50.70	
	Determination of HLAB5701 status by flow cytometry or cytotoxity assay prior to the initiation of Abacavir therapy including item 73323 if performed.		
71203	Fee: \$40.55	Benefit: 75% = \$30.45 85% = \$34.50	
P5. TIS	SUE PATHOLOG	SY	
	Group P5. Tissue Pathology		
	Examination of complexity level 2 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions - 1 or more separately identified specimens		
	(Item is subject to rule 13)		
72813	Fee: \$71.50	Benefit: 75% = \$53.65 85% = \$60.80	
	the programmed non-small cell lu	emical examination by immunoperoxidase or other labelled antibody techniques using d cell death ligand 1 (PD-L1) antibody of tumour material from a patient diagnosed with ung cancer, to determine if the requirements relating to PD-L1 status for access to under the Pharmaceutical Benefits Scheme are fulfilled.	
72814	Fee: \$74.50	Benefit: 75% = \$55.90 85% = \$63.35	
	Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions - 1 separately identified specimen		
	(Item is subject to rule 13)		
72816	Fee: \$86.35	Benefit: 75% = \$64.80 85% = \$73.40	
72817		complexity level 3 biopsy material with 1 or more tissue blocks, including specimen ssue processing, staining, light microscopy and professional opinion or opinions - 2 to 4	

P5. TISS	SUE PATHOLOGY	
	separately identified specimens	
	(Item is subject to rule 13)	
	Fee: \$96.80 Benefit: 75% = \$72.60 85% = \$82.30	
	Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions - 5 or more separately identified specimens	
	(Item is subject to rule 13)	
72818	Fee: \$107.05 Benefit: 75% = \$80.30 85% = \$91.00	
	Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions - 1 separately identified specimen	
	(Item is subject to rule 13)	
72823	Fee: \$97.15 Benefit: 75% = \$72.90 85% = \$82.60	
	Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions - 2 to 4 separately identified specimens	
	(Item is subject to rule 13)	
72824	Fee: \$141.35 Benefit: 75% = \$106.05 85% = \$120.15	
	Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions - 5 to 7 separately identified specimens	
	(Item is subject to rule 13)	
72825	Fee: \$180.25 Benefit: 75% = \$135.20 85% = \$153.25	
	Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions - 8 to 1 separately identified specimens	
	(Item is subject to rule 13)	
72826	Fee: \$194.60 Benefit: 75% = \$145.95 85% = \$165.45	
72827	Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen	

P5. TIS	SUE PATHOLOGY		
	dissection, all tissue processing, staining, light microscopy and professional opinion or opinions - 12 to 17 separately identified specimens		
	(Item is subject to Rule 13)		
	Fee: \$208.95 Benefit: 75% = \$156.75 85% = \$177.65		
	Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions - 18 or more separately identified specimens		
	(Item is subject to Rule 13)		
72828	Fee: \$223.30 Benefit: 75% = \$167.50 85% = \$189.85		
	Examination of complexity level 5 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions - 1 or more separately identified specimens		
	(Itam is subject to rule 12)		
72830	(Item is subject to rule 13) Fee: \$274.15 Benefit: 75% = \$205.65 85% = \$233.05		
	Examination of complexity level 6 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions - 1 or more separately identified specimens		
	(Item is subject to rule 13)		
72836	Fee: \$417.20 Benefit: 75% = \$312.90 85% = \$354.65		
	Examination of complexicity level 7 biopsy material with multiple tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions - 1 or more separately identified specimens.		
	(Item is subject to rule 13)		
72838	Fee: \$466.85 Benefit: 75% = \$350.15 85% = \$396.85		
	Enzyme histochemistry of skeletal muscle for investigation of primary degenerative or metabolic muscle diseases or of muscle abnormalities secondary to disease of the central or peripheral nervous system - 1 or more tests		
72844	Fee: \$30.75 Benefit: 75% = \$23.10 85% = \$26.15		
	Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen - 1 to 3 antibodies except those listed in 72848		
	(Item is subject to rule 13)		
72846	Fee: \$59.60 Benefit: 75% = \$44.70 85% = \$50.70		
72847	Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen - 4-6 antibodies		

P5. TISS	SUE PATHOLOGY		
	(Item is subject to rule 13)		
	Fee: \$89.40 Benefit: 75% = \$67.05 85% = \$76.00		
	Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen - 1 to 3 of the following antibodies - oestrogen, progesterone and c-erb-B2 (HER2)		
	(Item is subject to rule 13)		
72848	Fee: \$74.50 Benefit: 75% = \$55.90 85% = \$63.35		
	Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen - 7-10 antibodies		
	(Item is subject to rule 13)		
72849	Fee: \$104.30 Benefit: 75% = \$78.25 85% = \$88.70		
	Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen - 11 or more antibodies		
	(Item is subject to rule 13)		
72850	Fee: \$119.20 Benefit: 75% = \$89.40 85% = \$101.35		
	Electron microscopic examination of biopsy material - 1 separately identified specimen		
	(Item is subject to rule 13)		
72851	Fee: \$565.00 Benefit: 75% = \$423.75 85% = \$481.60		
	Electron microscopic examination of biopsy material - 2 or more separately identified specimens		
	(Item is subject to rule 13)		
72852	Fee: \$753.00 Benefit: 75% = \$564.75 85% = \$669.60		
	Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear - 1 separately identified specimen		
	(Item is subject to rule 13)		
72855	Fee: \$184.35 Benefit: 75% = \$138.30 85% = \$156.70		
	Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear - 2 to 4 separately identified specimens		
	(Item is subject to rule 13)		
72856	Fee: \$245.80 Benefit: 75% = \$184.35 85% = \$208.95		

P5. TIS	SUE PATHOLOGY		
	Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear - 5 or more separately identified specimens		
	(Item is subject to rule 13)		
72857	Fee: \$286.75 Benefit: 75% = \$215.10 85% = \$243.75		
	A second opinion, provided in a written report, where the opinion and report together require no more than 30 minutes to complete, on a patient specimen, requested by a treating practitioner, where further information is needed for accurate diagnosis and appropriate patient management.		
72858	(See para PN.0.33 of explanatory notes to this Category) Fee: \$180.00 Benefit: 75% = \$135.00 85% = \$153.00		
	A second opinion, provided in a written report, where the opinion and report together require more than 30 minutes to complete, on a patient specimen, requested by a treating practitioner, where further information is needed for accurate diagnosis and appropriate patient management.		
72859	(See para PN.0.33 of explanatory notes to this Category) Fee: \$370.00 Benefit: 75% = \$277.50 85% = \$314.50		
	OLOGY		
	Group P6. Cytology		
	Cytology (including serial examinations) of nipple discharge or smears from skin, lip, mouth, nose or anus for detection of precancerous or cancerous changes 1 or more tests		
73043	Fee: \$22.85 Benefit: 75% = \$17.15 85% = \$19.45		
	Cytology (including serial examinations) for malignancy (other than an examination mentioned in item 73076); and including any Group P5 service, if performed on:		
	(a) specimens resulting from washings or brushings from sites not specified in item 73043; or		
	(b) a single specimen of sputum or urine; or		
	(c) 1 or more specimens of other body fluids;		
	1 or more tests		
73045	Fee: \$48.60 Benefit: 75% = \$36.45 85% = \$41.35		
	Cytology of a series of 3 sputum or urine specimens for malignant cells		
73047	Fee: \$94.70 Benefit: 75% = \$71.05 85% = \$80.50		
	Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue or tissues - 1 identified site		
73049	Fee: \$68.15 Benefit: 75% = \$51.15 85% = \$57.95		
	Cytology of material obtained directly from a patient at one identified site by fine needle aspiration of solid tissue or tissues if a recognized pathologist:		
	(a) performs the aspiration; or		
	(b) attends the aspiration and performs cytological examination during the attendance		
73051	Fee: \$170.35 Benefit: 75% = \$127.80 85% = \$144.80		

P6. CY1	OLOGY		
	73049, 73051, 7 immunofluoresc	mical examination of material obtained by procedures described in items 73045, 73047, 3062, 73063, 73066 and 73067 for the characterisation of a malignancy by ence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specimen - 1 to 3 antibodies except those listed in 73061	
	(Item is subject	to rule 13)	
73059	Fee: \$43.00	Benefit: 75% = \$32.25 85% = \$36.55	
	73049, 73051, 7 immunofluoresc	mical examination of material obtained by procedures described in items 73045, 73047, 3062, 73063, 73066 and 73067 for the characterisation of a malignancy by ence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specimen - 4 to 6 antibodies	
	(Item is subject to	to rule 13)	
73060	Fee: \$57.35	Benefit: 75% = \$43.05 85% = \$48.75	
	Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051, 73062, 73063, 73066 and 73067 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen - 1 to 3 of the following antibodies - oestrogen, progesterone and c-erb-B2 (HER2)		
	(Item is subject to rule 13)		
73061	Fee: \$51.20	Benefit: 75% = \$38.40 85% = \$43.55	
		erial obtained directly from a patient by fine needle aspiration of solid tissue or tissues - ately identified sites.	
73062	Fee: \$89.00	Benefit: 75% = \$66.75 85% = \$75.65	
	solid tissue or tis	rerial obtained directly from a patient at one identified site by fine needle aspiration of ssues if an employee of an approved pathology authority attends the aspiration for sample adequacy	
73063	Fee: \$99.35	Benefit: 75% = \$74.55 85% = \$84.45	
	Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051, 73062, 73063, 73066 and 73067 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen - 7 to 10 antibodies		
	(Item is subject to rule 13)		
73064	Fee: \$71.70	Benefit: 75% = \$53.80 85% = \$60.95	
	73049, 73051, 7 immunofluoresc	mical examination of material obtained by procedures described in items 73045, 73047, 3062, 73063, 73066 and 73067 for the characterisation of a malignancy by ence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specimen - 11 or more antibodies	
73065	(Item is subject	to rule 13)	

P6. CY	TOLOGY		
	Fee: \$86.00 Benefit: 75% = \$64.50 85% = \$73.10		
	Cytology of material obtained directly from a patient at 2 or more separately identified sites by fine needle aspiration of solid tissue or tissues if a recognized pathologist:		
	(a) performs the aspiration; or		
	(b) attends the aspiration and performs cytological examination during the attendance		
73066	Fee: \$221.45 Benefit: 75% = \$166.10 85% = \$188.25		
	Cytology of material obtained directly from a patient at 2 or more separately identified sites by fine needle aspiration of solid tissue or tissues if an employee of an approved pathology authority attends the aspiration for confirmation of sample adequacy		
73067	Fee: \$129.15 Benefit: 75% = \$96.90 85% = \$109.80		
	73070		
	A test, including partial genotyping, for oncogenic human papillomavirus that may be associated with cervical pre-cancer or cancer:		
	(a) performed on a liquid based cervical specimen; and		
	(b) for an asymptomatic patient who is at least 24 years and 9 months of age		
	For any particular patient, once only in a 57 month period		
73070	(See para PN.0.22 of explanatory notes to this Category) Fee: \$35.00 Benefit: 75% = \$26.25 85% = \$29.75		
	73071		
	A test, including partial genotyping, for oncogenic human papillomavirus that may be associated with cervical pre-cancer or cancer:		
	(a) performed on a self-collected vaginal specimen; and		
	(b) for an asymptomatic patient who is at least 30 years of age		
	For any particular patient, once only in a 7 year period		
73071	(See para PN.0.22 of explanatory notes to this Category) Fee: \$35.00 Benefit: 75% = \$26.25 85% = \$29.75		
	A test, including partial genotyping, for oncogenic human papillomavirus, performed on a liquid based cervical specimen:		
	(a) for the investigation of a patient in a specific population that appears to have a higher risk of cervical pre-cancer or cancer; or		
	(b) for the follow-up management of a patient with a previously detected oncogenic human papillomavirus infection or cervical pre-cancer or cancer; or		
	(c) for the investigation of a patient with symptoms suggestive of cervical cancer; or		
73072	(d) for the follow-up management of a patient after treatment of high grade squamous intraepithelial		

P6. CY	TOLOGY		
	lesions or adenocarcinoma in situ of the cervix; or		
	(e) for the follow-up management of a patient with glandular abnormalities; or		
	(f) for the follow-up management of a patient exposed to diethylstilboestrol in utero		
	(See para PN.0.22 of explanatory notes to this Category) Fee: \$35.00 Benefit: 75% = \$26.25 85% = \$29.75		
	A test, including partial genotyping, for oncogenic human papillomavirus:		
	(a) performed on a self-collected vaginal specimen; and		
	(b) for the follow-up management of a patient with oncogenic human papillomavirus infection or cervical pre-cancer or cancer that was detected by a test to which item 73071 applies		
	For any particular patient, once only in a 21 month period		
73073	(See para PN.0.22 of explanatory notes to this Category) Fee: \$35.00 Benefit: 75% = \$26.25 85% = \$29.75		
	A test, including partial genotyping, for oncogenic human papillomavirus:		
	(a) performed on a liquid based vaginal vault specimen; and		
	(b) for the investigation of a patient following a total hysterectomy		
73074	(See para PN.0.22 of explanatory notes to this Category) Fee: \$35.00 Benefit: 75% = \$26.25 85% = \$29.75		
	A test, including partial genotyping, for oncogenic human papillomavirus, if:		
	(a) the test is a repeat of a test to which item 73070, 73071, 73072, 73073, 73074 or this item applies; and		
	(b) the specimen collected for the previous test is unsatisfactory		
73075	(See para PN.0.22 of explanatory notes to this Category) Fee: \$35.00 Benefit: 75% = \$26.25 85% = \$29.75		
	Cytology of a liquid-based cervical or vaginal vault specimen, where the stained cells are examined microscopically or by automated image analysis by or on behalf of a pathologist, if:		
	(a) the cytology is associated with the detection of oncogenic human papillomavirus infection by:		
	(i) a test to which item 73070, 73071, 73073, 73074 or 73075 applies; or		
	(ii) a test to which item 73072 applies for a patient mentioned in paragraph (a) or (b) of that item; or		
	(b) the cytology is associated with a test to which item 73072 applies for a patient mentioned in paragraph (c), (d), (e) or (f) of that item; or		
	(c) the cytology is associated with a test to which item 73074 applies; or		
	(d) the test is a repeat of a test to which this item applies, if the specimen collected for the previous test is unsatisfactory; or		
73076	(e) the cytology is for the follow-up management of a patient treated for endometrial adenocarcinoma		

P6. CY	TOLOGY		
	(See para PN.0.22 of explanatory notes to this Category) Fee: \$46.00 Benefit: 75% = \$34.50 85% = \$39.10		
P7. GEI	NETICS		
	Group P7. Genetics		
	The study of the whole of every chromosome by cytogenetic or other techniques, performed on 1 or more of any tissue or fluid except blood (including a service mentioned in item 73293, if performed) - 1 or more tests		
73287	Fee: \$394.55 Benefit: 75% = \$295.95 85% = \$335.40		
	The study of the whole of every chromosome by cytogenetic or other techniques, performed on blood (including a service mentioned in item 73293, if performed) - 1 or more tests		
73289	Fee: \$358.95 Benefit: 75% = \$269.25 85% = \$305.15		
	The study of the whole of each chromosome by cytogenetic or other techniques, performed on blood or bone marrow, in the diagnosis and monitoring f haematological malignancy (including a service in items 73287 or 73289, if performed) 1 or more tests.		
73290	Fee: \$394.55 Benefit: 75% = \$295.95 85% = \$335.40		
	Analysis of one or more chromosome regions for specific constitutional genetic abnormalities of blood or fresh tissue in a) diagnostic studies of a person with developmental delay, intellectual disability, autism, or at least two congenital abnormalities, in whom cytogenetic studies (item 73287 or 73289) are either normal or have not been performed; or b) studies of a relative for an abnormality previously identified in such an affected person. - 1 or more tests.		
73291	Fee: \$230.95 Benefit: 75% = \$173.25 85% = \$196.35		
	Analysis of chromosomes by genome-wide micro-array including targeted assessment of specific regions for constitutional genetic abnormalities in diagnostic studies of a person with developmental delay, intellectual disability, autism, or at least two congenital abnormalities (including a service in iter 73287, 73289 or 73291, if performed) - 1 or more tests.		
73292	Fee: \$589.90 Benefit: 75% = \$442.45 85% = \$506.50		
	Analysis of one or more regions on all chromosomes for specific constitutional genetic abnormalities of fresh tissue in diagnostic studies of the products of conception, including exclusion of maternal cell contamination.		
	- 1 or more tests.		
73293	Fee: \$230.95 Benefit: 75% = \$173.25 85% = \$196.35		
	Analysis of the PMP22 gene for constitutional genetic abnormalities causing peripheral neuropathy, either as:		
73294	a) diagnostic studies of an affected person; or		

P7. GEN	NETICS
	b) studies of a relative for an abnormality previously identified in an affected person
	- 1 or more tests.
	Fee: \$230.95 Benefit: 75% = \$173.25 85% = \$196.35
	Detection of germline <i>BRCA1</i> or <i>BRCA2</i> gene mutations, in a patient with platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer with high grade serous features or a high grade serous component, and who has responded to subsequent platinum-based chemotherapy, requested by a specialist or consultant physician, to determine whether the eligibility criteria for olaparib under the Pharmaceutical Benefits Scheme (PBS) are fulfilled.
	Maximum one test per lifetime
73295	(See para PN.0.27 of explanatory notes to this Category) Fee: \$1,200.00 Benefit: 75% = \$900.00 85% = \$1116.60
	Characterisation of germline gene mutations, requested by a specialist or consultant physician, including copy number variation in BRCA1 and BRCA2 genes and one or more of the following genes STK11, PTEN, CDH1, PALB2, or TP53 in a patient with breast or ovarian cancer for whom clinical and family history criteria, as assessed by the specialist or consultant physician who requests the service using a quantitative algorithm, place the patient at >10% risk of having a pathogenic mutation identified in one or more of the genes specified above.
73296	(See para PN.0.27 of explanatory notes to this Category) Fee: \$1,200.00 Benefit: 75% = \$900.00 85% = \$1116.60
	Characterisation of germline gene mutations, requested by a specialist or consultant physician, including copy number variation in BRCA1 and BRCA2 genes and one or more of the following genes STK11, PTEN, CDH1, PALB2, or TP53 in a patient who is a biological relative of a patient who has had a pathogenic mutation identified in one or more of the genes specified above, and has not previously received a service under item 73296.
73297	(See para PN.0.23 of explanatory notes to this Category) Fee: \$400.00 Benefit: 75% = \$300.00 85% = \$340.00
	Detection of mutation of the FMR1 gene where:
	(a) the patient exhibits intellectual disability, ataxia, neurodegeneration, or premature ovarian failure consistent with an FMRI mutation; or
	(b) the patient has a relative with a FMR1 mutation
	1 or more tests
73300	(See para PN.0.23 of explanatory notes to this Category) Fee: \$101.30 Benefit: 75% = \$76.00 85% = \$86.15
	Detection of mutation of the FMR1 gene by Southern Blot analysis where the results in item 73300 are inconclusive
73305	(See para PN.0.23 of explanatory notes to this Category) Fee: \$202.65 Benefit: 75% = \$152.00 85% = \$172.30
	Characterisation of the genotype of a patient for Factor V Leiden gene mutation, or detection of the other relevant mutations in the investigation of proven venous thrombosis or pulmonary embolism - 1 or more tests
73308	Fee: \$36.45 Benefit: 75% = \$27.35 85% = \$31.00

P7. GEN	NETICS		
	A test described in item 73308, if rendered by a receiving APP - 1 or more tests		
	(Item is subject to rule 18)		
73309	Fee: \$36.45 Benefit: 75% = \$27.35 85% = \$31.00		
	Characterisation of the genotype of a person who is a first degree relative of a person who has proven to have 1 or more abnormal genotypes under item 73308 - 1 or more tests		
73311	Fee: \$36.45 Benefit: 75% = \$27.35 85% = \$31.00		
	A test described in item 73311, if rendered by a receiving APP - 1 or more tests		
	(Item is subject to rule 18)		
73312	Fee: \$36.45 Benefit: 75% = \$27.35 85% = \$31.00		
	Characterisation of gene rearrangement or the identification of mutations within a known gene rearrangement, in the diagnosis and monitoring of patients with laboratory evidence of:		
	(a) acute myeloid leukaemia; or		
	(b) acute promyelocytic leukaemia; or		
	(c) acute lymphoid leukaemia; or		
	(d) chronic myeloid leukaemia;		
73314	Fee: \$230.95 Benefit: 75% = \$173.25 85% = \$196.35		
	A test described in item 73314, if rendered by a receiving APP - 1 or more tests		
	(Item is subject to rule 18)		
73315	Fee: \$230.95 Benefit: 75% = \$173.25 85% = \$196.35		
	Detection of the C282Y genetic mutation of the HFE gene and, if performed, detection of other mutations for haemochromatosis where:		
	(a) the patient has an elevated transferrin saturation or elevated serum ferritin on testing of repeated specimens; or		
	(b) the patient has a first degree relative with haemochromatosis; or		
	(c) the patient has a first degree relative with homozygosity for the C282Y genetic mutation, or with compound heterozygosity for recognised genetic mutations for haemochromatosis		
	(Item is subject to rule 20)		
73317	Fee: \$36.45 Benefit: 75% = \$27.35 85% = \$31.00		
	A test described in item 73317, if rendered by a receiving APP - 1 or more tests		
	(Item is subject to rule 18 and 20)		
73318	Fee: \$36.45 Benefit: 75% = \$27.35 85% = \$31.00		
	Detection of HLA-B27 by nucleic acid amplification		
73320			

P7. GEN	NETICS		
	includes a service described in 71147 unless the service in item 73320 is rendered as a pathologist determinable service. (Item is subject to rule 27)		
	Fee: \$40.55 Benefit: 75% = \$30.45 85% = \$34.50		
	A test described in item 73320, if rendered by a receiving APP - 1 or more tests.		
	(Item is subject to rule 18 and 27)		
73321	Fee: \$40.55 Benefit: 75% = \$30.45 85% = \$34.50		
	Determination of HLAB5701 status by molecular techniques prior to the initiation of Abacavir therapy including item 71203 if performed.		
73323	Fee: \$40.55 Benefit: 75% = \$30.45 85% = \$34.50		
	A test described in item 73323 if rendered by a receiving APP		
	1 or more tests		
	(Item is subject to Rule 18)		
73324	Fee: \$40.95 Benefit: 75% = \$30.75 85% = \$34.85		
	Characterisation of mutations in:		
	(a) the JAK2 gene; or		
	(b) the MPL gene; or		
	(c) both genes;		
	in the diagnostic work-up, by, or on behalf of, the specialist or consultant physician, of a patient with clinical and laboratory evidence of:		
	a) polycythaemia vera; or		
	b) essential thrombocythaemia;		
	1 or more tests		
73325	Fee: \$74.50 Benefit: 75% = \$55.90 85% = \$63.35		
	Characterisation of the gene rearrangement FIP1L1-PDGFRA in the diagnostic work-up and management of a patient with laboratory evidence of:		
	a) mast cell disease; or		
	b) idiopathic hypereosinophilic syndrome; or		
	c) chronic eosinophilic leukaemia;.		
73326			

P1. GE	NETICS				
	1 or more tests				
	Fee: \$230.95	Benefit: 75% = \$173.25 85% = \$196.35			
		e polymorphisms in the Thiopurine S-methyltransferase gene for the prevention of during treatment with thiopurine drugs; including (if performed) any service 5075.			
	1 or more tests				
73327	Fee: \$51.95	Benefit: 75% = \$39.00 85% = \$44.20			
	the advice of, a specific the requirements	tion (ISH) test of tumour tissue from a patient with breast cancer requested by, or on sialist or consultant physician who manages the treatment of the patient to determine relating to human epidermal growth factor receptor 2 (HER2) gene amplification for ab under the Pharmaceutical Benefits Scheme (PBS) or the Herceptin Program are			
73332	Fee: \$315.40	Benefit: 75% = \$236.55 85% = \$268.10			
	Detection of germlin	ne mutations of the von Hippel-Lindau (VHL) gene:			
	(a) in a patien	(a) in a patient who has a clinical diagnosis of VHL syndrome and:			
	(i) a family history of VHL syndrome and one of the following:				
	(A	A) haemangioblastoma (retinal or central nervous system);			
	(E	B) phaeochromocytoma;			
	(0	c) renal cell carcinoma; or			
	(i) 2 or m	nore haemangioblastomas; or			
	(ii) one h	aemangioblastoma and a tumour or a cyst of:			
	(A	A) the adrenal gland; or			
	(E	3) the kidney; or			
	(0	C) the pancreas; or			
	Ι)	D) the epididymis; or			
	(E	a broad ligament (other than epididymal and single renal cysts, which are common in the general population); or			
	(a) in a patient presenting with one or more of the following clinical features suggestive of VHL syndrome:				
	(i) haeman	gioblastomas of the brain, spinal cord, or retina;			
	(ii) phaeoc	hromocytoma;			
73333	(iii) functional	extra-adrenal paraganglioma			

P7. GEN	NETICS	
	(See para PN.0.27 of explanatory notes to this Category) Fee: \$600.00 Benefit: 75% = \$450.00 85% = \$516.60	
	Detection of germline mutations of the von Hippel-Lindau (VHL) gene in biological relatives of a patient with a known mutation in the VHL gene	
73334	(See para PN.0.23 of explanatory notes to this Category) Fee: \$340.00 Benefit: 75% = \$255.00 85% = \$289.00	
	Detection of somatic mutations of the von Hippel-Lindau (VHL) gene in a patient with:	
	(a) 2 or more tumours comprising:	
	(i) 2 or more haemangioblastomas, or	
	(ii) one haemangioblastoma and a tumour of:	
	(A) the adrenal gland; or	
	(B) the kidney; or	
	(C) the pancreas; or	
	(D) the epididymis; and	
	(b) no germline mutations of the VHL gene identified by genetic testing	
73335	Fee: \$470.00 Benefit: 75% = \$352.50 85% = \$399.50	
	A test of tumour tissue from a patient with unresectable stage III or stage IV metastatic cutaneous melanoma, requested by, or on behalf of, a specialist or consultant physician, to determine if the requirements relating to BRAF V600 mutation status for access to dabrafenib or vemurafenib under the Pharmaceutical Benefits Scheme are fulfilled.	
73336	Fee: \$230.95 Benefit: 75% = \$173.25 85% = \$196.35	
	A test of tumour tissue from a patient diagnosed with non-small cell lung cancer, shown to have non-squamous histology or histology not otherwise specified, requested by, or on behalf of, a specialist or consultant physician, to determine if the requirements relating to epidermal growth factor receptor (EGFR) gene status for access to erlotinib, gefitinib or afatinib under the Pharmaceutical Benefits Scheme (PBS) are fulfilled.	
73337	Fee: \$397.35 Benefit: 75% = \$298.05 85% = \$337.75	
	A test of tumour tissue from a patient with metastatic colorectal cancer (stage IV), requested by a specialist or consultant physician, to determine if the requirements relating to rat sarcoma oncogene (RAS) gene mutation status for access to cetuximab or panitumumab under the Pharmaceutical Benefits Scheme (PBS) are fulfilled, if:	
	(a) the test is conducted for all clinically relevant mutations on KRAS exons 2, 3 and 4 and NRAS exons 2, 3, and 4; or	
	(b) a RAS mutation is found.	
73338	(See para PN.0.26 of explanatory notes to this Category) Fee: \$362.60 Benefit: 75% = \$271.95 85% = \$308.25	
73339	Detection of germline mutations in the RET gene in patients with a suspected clinical diagnosis of multiple endocrine neoplasia type 2 (MEN2) requested by a specialist or consultant physician who	

P7. GENE	ETICS		
	manages the treatment of the patient.		
	One test. (Item is subject to rule 25)		
	(See para PN.0.23 of explanatory notes to this Category) Fee: \$400.00 Benefit: 75% = \$300.00 85% = \$340.00		
	Detection of a known mutation in the RET gene in an asymptomatic relative of a patient with a documented pathogenic germline RET mutation requested by a specialist or consultant physician who manages the treatment of the patient.		
	One test. (Item is subject to rule 25)		
73340	(See para PN.0.23 of explanatory notes to this Category) Fee: \$200.00 Benefit: 75% = \$150.00 85% = \$170.00		
	Fluorescence in situ hybridisation (FISH) test of tumour tissue from a patient with locally advanced or metastatic non-small cell lung cancer, which is of non-squamous histology or histology not otherwise specified, with documented evidence of anaplastic lymphoma kinase (ALK) immunoreactivity by immunohistochemical (IHC) examination giving a staining intensity score > 0, and with documented absence of activating mutations of the epidermal growth factor receptor (EGFR) gene, requested by a specialist or consultant physician to determine if requirements relating to ALK gene rearrangement status for access to crizotinib, ceritinib or alectinib under the Pharmaceutical Benefits Scheme (PBS) are fulfilled		
73341	Fee: \$400.00 Benefit: 75% = \$300.00 85% = \$340.00		
	An in situ hybridisation (ISH) test of tumour tissue from a patient with metastatic adenocarcinoma of the stomach or gastro-oesophageal junction, with documented evidence of human epidermal growth factor receptor 2 (<i>HER2</i>) overexpression by immunohistochemical (IHC) examination giving a staining intensity score of 2+ or 3+ on the same tumour tissue sample, requested by, or on the advice of, a specialist or consultant physician who manages the treatment of the patient to determine if the requirements relating to <i>HER2</i> gene amplification for access to trastuzumab under the Pharmaceutical Benefits Scheme are fulfilled.		
73342	(See para PN.1.2 of explanatory notes to this Category) Fee: \$315.40 Benefit: 75% = \$236.55 85% = \$268.10		
	Detection of 17p chromosomal deletions by fluorescence <i>in situ</i> hybridisation, in a patient with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma, on a peripheral blood or bone marrow sample, requested by a specialist or consultant physician, to determine if the requirements for access to idelalisib, ibrutinib or venetoclax on the Pharmaceutical Benefits Scheme are fulfilled.		
Amend 73343	Fee: \$230.95 Benefit: 75% = \$173.25 85% = \$196.35		
73344	Fluorescence in situ hybridization (FISH) test of tumour tissue from a patient with locally advanced or metastatic non-small-cell lung cancer (NSCLC), which is of non-squamous histology or histology not otherwise specified, with documented evidence of ROS proto-oncogene 1 (ROS1) immunoreactivity by immunohistochemical (IHC) examination giving a staining intensity score of 2+ or 3+; and with documented absence of both activating mutations of the epidermal growth factor receptor (EGFR) gene and anaplastic lymphoma kinase (ALK) immunoreactivity by IHC, requested by a specialist or consultant physician to determine if requirements relating to ROS1 gene rearrangement status for access to crizotinib under the Pharmaceutical Benefits Scheme are fulfilled.		

IETICS
Fee: \$400.00 Benefit: 75% = \$300.00 85% = \$340.00
Testing of a patient for pathogenic cystic fibrosis transmembrane conductance regulator variants for the purpose of investigating, making or excluding a diagnosis of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder when requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73347, 73348, or 73349 applies.
The patient must have clinical or laboratory findings suggesting there is a high probability suggestive of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder.
(See para PN.7.3 of explanatory notes to this Category) Fee: \$500.00 Benefit: 75% = \$375.00 85% = \$425.00
Testing of a pregnant patient whose carrier status for pathogenic cystic fibrosis transmembrane conductance regulator variants, as well as their reproductive partner carrier status is unknown, for the purpose of determining whether pathogenic cystic fibrosis transmembrane conductance regulator variants are present in the fetus, in order to make or exclude a diagnosis of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder in the fetus when requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73350 applies.
The fetus must have ultrasonic findings of echogenic gut, with unknown familial cystic fibrosis transmembrane conductance regulator variants.
(See para PN.7.3 of explanatory notes to this Category) Fee: \$500.00 Benefit: 75% = \$375.00 85% = \$425.00
Testing of a prospective parent for pathogenic cystic fibrosis transmembrane conductance regulator variants for the purpose of determining the risk of their fetus having pathogenic cystic fibrosis transmembrane conductance regulator variants. This is indicated when the fetus has ultrasonic evidence of echogenic gut when requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73345, 73348, or 73349 applies.
(See para PN.7.3 of explanatory notes to this Category) Fee: \$500.00 Benefit: 75% = \$375.00 85% = \$425.00
Testing of a patient with a laboratory-established family history of pathogenic cystic fibrosis transmembrane conductance regulator variants, for the purpose of determining whether the patient is an asymptomatic genetic carrier of the pathogenic cystic fibrosis transmembrane conductance regulator variants that have been laboratory established in the family history when requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73345, 73347, or 73349 applies.
The patient must have a positive family history, confirmed by laboratory findings of pathogenic cystic fibrosis transmembrane conductance regulator variants, with a personal risk of being a heterozygous genetic carrier of at least 6%. (This includes family relatedness of: parents, children, full-siblings, half-siblings, grand-parents, grandchildren, aunts, uncles, first cousins, and first cousins once-removed, but excludes relatedness of second cousins or more distant relationships).
(See para PN.7.3 of explanatory notes to this Category) Fee: \$250.00 Benefit: 75% = \$187.50 85% = \$212.50
Testing of a patient for pathogenic cystic fibrosis transmembrane conductance regulator variants for the purpose of determining the reproductive risk of the patient with their reproductive partner because their reproductive partner is already known to have pathogenic cystic fibrosis transmembrane conductance

P7. GEN	NETICS
	regulator variants requested by a specialist or consultant physician who manages the treatment of the
	patient, not being a service associated with a service to which item 73345, 73347, or 73348 applies.
	(See para PN.7.3 of explanatory notes to this Category) Fee: \$500.00 Benefit: 75% = \$375.00 85% = \$425.00
	Testing of a pregnant patient, where one or both prospective parents are known to be a genetic carrier of pathogenic cystic fibrosis transmembrane conductance regulator variants for the purpose of determining whether pathogenic cystic fibrosis transmembrane conductance regulator variants are present in the fetus in order to make or exclude a diagnosis of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder in the fetus, when requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73346 applies.
	The fetus must be at 25% or more risk of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder because of known familial cystic fibrosis transmembrane conductance regulator variants.
73350	(See para PN.7.3 of explanatory notes to this Category) Fee: \$250.00 Benefit: 75% = \$187.50 85% = \$212.50
	A test of tumour tissue that is derived from a new sample from a patient with locally advanced (Stage IIIb) or metastatic (Stage IV) non-small cell lung cancer (NSCLC), who has progressed on or after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). The test is to be requested by a specialist or consultant physician, to determine if the requirements relating to EGFR T790M gene status for access to osimertinib under the Pharmaceutical Benefits Scheme are fulfilled.
73351	Fee: \$397.35 Benefit: 75% = \$298.05 85% = \$337.75
P8. INFI	ERTILITY AND PREGNANCY TESTS
	Group P8. Infertility And Pregnancy Tests
	Semen examination for presence of spermatozoa or examination of cervical mucus for spermatozoa (Huhner's test)
73521	(See para TN.1.4 of explanatory notes to this Category) Fee: \$9.70 Benefit: 75% = \$7.30 85% = \$8.25
	Semen examination (other than post-vasectomy semen examination), including:
	(a) measurement of volume, sperm count and motility; and
	(b) examination of stained preparations; and
	(c) morphology; and (if performed)
	(d) differential count and 1 or more chemical tests;
	(Item is subject to rule 25)
73523	
13323	Fee: \$41.75 Benefit: 75% = \$31.35 85% = \$35.50
73323	Fee: \$41.75 Benefit: 75% = \$31.35 85% = \$35.50 Sperm antibodies - sperm-penetrating ability - 1 or more tests

P8. INFI	ERTILITY AND P	REGNANCY TESTS		
		c gonadotrophin (HCG) - detection in serum or urine by 1 or more methods for		
	diagnosis of preg	gnancy - 1 or more tests		
73527	Fee: \$10.00	Benefit: 75% = \$7.50 85% = \$8.50		
	membrane, strip	c gonadotrophin (HCG), quantitation in serum by 1 or more methods (except by latex, or other pregnancy test kit) for diagnosis of threatened abortion, or follow up of nosis of ectopic pregnancy, including any services performed in item 73527 - 1 test		
73529	(See para PN.0.33 Fee: \$28.65	of explanatory notes to this Category) Benefit: $75\% = \$21.50$ $85\% = \$24.40$		
P9. SIM	PLE BASIC PAT	HOLOGY TESTS		
	Group P9. Simp	ole Basic Pathology Tests		
	Semen examinat	ion for presence of spermatozoa		
73801	Fee: \$6.90	Benefit: 75% = \$5.20 85% = \$5.90		
		, erythrocyte sedimentation rate, examination of blood film (including differential haemoglobin, haematocrit or erythrocyte count - 1 test		
73802	Fee: \$4.55	Benefit: 75% = \$3.45 85% = \$3.90		
	2 tests described in item 73802			
73803	Fee: \$6.35	Benefit: 75% = \$4.80 85% = \$5.40		
	3 or more tests described in item 73802			
73804	Fee: \$8.15	Benefit: 75% = \$6.15 85% = \$6.95		
	Microscopy of u	rine, excluding dipstick testing.		
73805	Fee: \$4.55	Benefit: 75% = \$3.45 85% = \$3.90		
	Pregnancy test b	y 1 or more immunochemical methods		
73806	Fee: \$10.15	Benefit: 75% = \$7.65 85% = \$8.65		
	Microscopy for wet film other than urine, including any relevant stain			
73807	Fee: \$6.90	Benefit: 75% = \$5.20 85% = \$5.90		
	Microscopy of C	Gram-stained film, including (if performed) a service described in item 73805 or 73807		
73808	Fee: \$8.65	Benefit: 75% = \$6.50 85% = \$7.40		
	Chemical tests for	or occult blood in faeces by reagent stick, strip, tablet or similar method		
73809	Fee: \$2.35	Benefit: 75% = \$1.80 85% = \$2.00		
	Microscopy for fungi in skin, hair or nails - 1 or more sites			
73810	Fee: \$6.90	Benefit: 75% = \$5.20 85% = \$5.90		
	Mantoux test			
73811	Fee: \$11.20	Benefit: 75% = \$8.40 85% = \$9.55		
		ion for presence of spermatozoa by a participating nurse practitioner		
73828	Fee: \$6.90	Benefit: 85% = \$5.90		

P9. SIM	PLE BASIC PAT	THOLOGY TESTS	
		nt, erythrocyte sedimentation rate, examination of blood film (including differential t), haemoglobin, haematocrit or erythrocyte count by a participating nurse practitioner - 1	
73829	Fee: \$4.55	Benefit: 85% = \$3.90	
	2 tests described	d in item 73829 by a participating nurse practitioner	
73830	Fee: \$6.35	Benefit: 85% = \$5.40	
	3 or more tests	described in item 73829 by a participating nurse practitioner	
73831	Fee: \$8.15	Benefit: 85% = \$6.95	
	Microscopy of	urine, whether stained or not, or catalase test by a participating nurse practitioner	
73832	Fee: \$4.55	Benefit: 85% = \$3.90	
	Pregnancy test l	by 1 or more immunochemical methods by a participating nurse practitioner	
73833	Fee: \$10.15	Benefit: 85% = \$8.65	
		wet film other than urine, including any relevant stain by a participating nurse	
73834	Fee: \$6.90	Benefit: 85% = \$5.90	
		Gram-stained film, including (if performed) a service described in item 73832 or 73834 ng nurse practitioner	
73835	Fee: \$8.65	Benefit: 85% = \$7.40	
	Chemical tests in participating nu	for occult blood in faeces by reagent stick, strip, tablet or similar method by a urse practitioner	
73836	Fee: \$2.35	Benefit: 85% = \$2.00	
	Microscopy for	fungi in skin, hair or nails by a participating nurse practitioner - 1 or more sites	
73837	Fee: \$6.90	Benefit: 85% = \$5.90	
		HbA1c (glycated haemoglobin) performed for the diagnosis of diabetes in asymptomatic risk - not more than once in a 12 month period.	
	(Item is subject to restrictions in rule PR.9.1 of explanatory notes to this category)		
73839	(See para PR.9.1 of explanatory notes to this Category)		
	Quantitation of glycosylated haemoglobin performed in the management of established diabetes – each test to a maximum of 4 tests in a 12 month period.		
	(Item is subject to restrictions in rule PR.9.1 of explanatory notes to this category)		
73840	(See para PR.9.1 of explanatory notes to this Category) Fee: \$17.00 Benefit: 75% = \$12.75 85% = \$14.45		
	urine sample or	urinary microalbumin as determined by urine albumin excretion on a timed overnight urine albumin/creatinine ratio as determined on a first morning urine sample in the established diabetes.	
73844	(Item is subject	to restrictions in rule PR.9.1 of explanatory notes to this category)	

P9. SIM	PLE BASIC PAT	THOLOGY TESTS
	(See para PR.9.1 Fee: \$20.35	of explanatory notes to this Category) Benefit: 75% = \$15.30 85% = \$17.30
P10. P	ATIENT EPISOD	E INITIATION
	Group P10. Pa	itient Episode Initiation
		patient episode that consists of a service described in item 72858 or 72859 in other than those mentioned in item 73900
73899	Fee: \$5.95	Benefit: 75% = \$4.50 85% = \$5.10
		patient episode that consists of a service described in item 72858 or 72859 if the service is rescribed laboratory.
73900	Fee: \$2.40	Benefit: 75% = \$1.80 85% = \$2.05
	services describ	patient episode by collection of a specimen for 1 or more services (other than those bed in items 73922, 73924 or 73926) if the specimen is collected in an approved re that the APA operates in the same premises as it operates a category GX or GY ratory
73920	Fee: \$2.40	Benefit: 75% = \$1.80 85% = \$2.05
		patient episode that consists of a service described in item 73070, 73071, 73072, 73073, or 73076 (in circumstances other than those described in item 73923).
73922	Fee: \$8.20	Benefit: 75% = \$6.15 85% = \$7.00
	73074, 73075 c	patient episode that consists of a service described in items 73070, 73071, 73072, 73073, or 73076 if: (a) the person is a private patient in a recognised hospital; or (b) the person vice from a prescribed laboratory
73923	Fee: \$2.40	Benefit: 75% = \$1.80 85% = \$2.05
	72817, 72818,	patient episode that consists of 1 or more services described in items 72813, 72816, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838 (in circumstances e described in item 73925) from a person who is an in-patient of a hospital.
73924	Fee: \$14.65	Benefit: 75% = \$11.00 85% = \$12.50
		patient episode that consists of 1 or more services described in items 72813, 72816, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838 if the person is:
	(a) a private p	patient of a recognised hospital; or
	(b) a private pa	tient of a hospital who receives the service or services from a prescribed laboratory.
73925	Fee: \$2.40	Benefit: 75% = \$1.80 85% = \$2.05
	72817, 72818,	patient episode that consists of 1 or more services described in items 72813, 72816, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838 (in circumstances e described in item 73927) from a person who is not a patient of a hospital.
73926	Fee: \$8.20	Benefit: 75% = \$6.15 85% = \$7.00
	items, 72813, 7	patient episode by a prescribed laboratory that consists of 1 or more services described in 12816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and the services described in 12816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and the services described in 12816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and the services described in 12816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and the services described in 12816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and the services described in 12816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and the services described in 12816, 72817, 72828, 72828, 72830, 72836 and the services described in 12816, 72817, 72828, 72828, 72828, 72830, 72836 and the services described in 12816, 72817, 72828,
73927	Fee: \$2.40	Benefit: 75% = \$1.80 85% = \$2.05

P10. P	ATIENT EPISODE INITIATION
	Initiation of a patient episode by collection of a specimen for 1 or more services (other than those services described in items 73922, 73924 or 73926) if the specimen is collected in an approved collection centre. Unless item 73920 or 73929 applies
73928	Fee: \$5.95 Benefit: 75% = \$4.50 85% = \$5.10
	Initiation of a patient episode by collection of a specimen for 1 or more services (other than those services described in items 73922, 73924 or 73926) if the specimen is collected by an approved pathology practitioner for a prescribed laboratory or by an employee of an approved pathology authority, who conducts a prescribed laboratory, if the specimen is collected in an approved pathology collection centre
73929	Fee: \$2.40 Benefit: 75% = \$1.80 85% = \$2.05
	Initiation of a patient episode by collection of a specimen for a service for 1 or more services (other than those services described in items 73922, 73924 or 73926) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person who is an inpatient of a hospital other than a recognised hospital. Unless item 73931 applies
73930	Fee: \$5.95 Benefit: 75% = \$4.50 85% = \$5.10
	Initiation of a patient episode by collection of a specimen for 1 or more services (other than those services described in items 73922, 73924 or 73926) if:
	() the specimen is collected by an approved pathology practitioner for a prescribed laboratory or by an employee of an approved pathology authority, who conducts a prescribed laboratory, from a person who is a private patient in a hospital or
	() the person is a private patient in a recognised hospital and the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority
73931	Fee: \$2.40 Benefit: 75% = \$1.80 85% = \$2.05
	Initiation of a patient episode by collection of a specimen for 1 or more services (other than those services described in items 73922, 73924 or 73926) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person in the place where the person was residing. Unless item 73933 applies
73932	Fee: \$10.25 Benefit: 75% = \$7.70 85% = \$8.75
	Initiation of a patient episode by collection of a specimen for 1 or more services (other than those services described in items 73922, 73924 or 73926) if the specimen is collected by an approved pathology practitioner for a prescribed laboratory or by an employee of an approved pathology authority, who conducts a prescribed laboratory, from a person in the place where the person is residing
73933	Fee: \$2.40 Benefit: 75% = \$1.80 85% = \$2.05
	Initiation of a patient episode by collection of a specimen for 1 or more services (other than those services described in items 73922, 73924 and 73926) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person in a residential aged care home or institution. Unless 73935 applies
73934	Fee: \$17.60 Benefit: 75% = \$13.20 85% = \$15.00
73935	Initiation of a patient episode by collection of a specimen for 1 or more services (other than those services described in items 73922, 73924 or 73926) if the specimen is collected by an approved pathology practitioner or by an employee of an approved pathology authority, who conducts a prescribed laboratory, from a person in a residential aged care home or institution

	E	Danie C4. 750/ 01.00 050/ 02.05
	Fee: \$2.40	Benefit: 75% = \$1.80 85% = \$2.05
		atient episode by collection of a specimen for 1 or more services (other than those ed in items 73922, 73924 or 73926) if the specimen is collected from the person by the
73936	Fee: \$5.95	Benefit: 75% = \$4.50 85% = \$5.10
		atient episode by collection of a specimen for 1 or more services (other than those ed in items 73922, 73924 or 73926), if the specimen is collected from the person by the
	() the se	rvice is performed in a prescribed laboratory or
	() the pe	erson is a private patient in a recognised hospital
73937	Fee: \$2.40	Benefit: 75% = \$1.80 85% = \$2.05
	services describ	atient episode by collection of a specimen for 1 or more services (other than those ed in items 73922, 73924 or 73926) if the specimen is collected by or on behalf of the oner. Unless item 73939 applies
73938	Fee: \$7.95	Benefit: 75% = \$6.00 85% = \$6.80
	services describ treating practition	atient episode by collection of a specimen for 1 or more services (other than those ed in items 73922, 73924 or 73926), if the specimen is collected by or on behalf of the oner and if: rvice is performed in a prescribed laboratory or
	() the pe	erson is a private patient in a recognised hospital
73939	Fee: \$2.40	Benefit: 75% = \$1.80 85% = \$2.05
P11. SP	ECIMEN REFER	RED
	Group P11. Spe	ecimen Referred
		cimen by an approved pathology practitioner of an approved pathology authority from d pathology practitioner of a different approved pathology authority or another approved rity
	(Item is subject	to rules 14, 15 and 16)
73940	Fee: \$10.25	Benefit: 75% = \$7.70 85% = \$8.75
P12. MA	NAGEMENT OF	BULK-BILLED
	Group P12. Ma	nagement Of Bulk-Billed Services
	A pathology ser	vice to which an item in this table (other than this item or item 74991) applies if:
	(a) the serv	rice is an unreferred service; and
	(a) the serv	ice is an unresorted service, and
	(a) the serv	100 is all almotorrou sorvice, and

P12. MANAGEMENT OF BULK-BILLED SERVICES
card holder; and
(c) the person is not an admitted patient of a hospital; and
(d) the service is bulk-billed in respect of the fees for:
(i) this item; and
(ii) the other item in this table applying to the service
(See para PN.0.24 of explanatory notes to this Category) Fee: \$7.05 Benefit: 85% = \$6.00
A pathology service to which an item in this table (other than this item or item 74990) applies if:
(a) the service is an unreferred service; and
(b) the service is provided to a person who is under the age of 16 or is a Commonwealth concession card holder; and
(c) the person is not an admitted patient of a hospital; and
(d) the service is bulk-billed in respect of the fees for:
(i) this item; and
(ii) the other item in this table applying to the service; and
(e) the service is provided at, or from, a practice location in:
(i) a regional, rural or remote area; or
(ii) Tasmania; or
(iii) A geographical area included in any of the following SSD spatial units:
(A) Beaudesert Shire Part A
(B) Belconnen
(C) Darwin City
(D) Eastern Outer Melbourne
(E) East Metropolitan, Perth
(F) Frankston City
(G) Gosford-Wyong
(H) Greater Geelong City Part A
(I) Gungahlin-Hall
(J) Ipswich City (part in BSD)

P12. MANAGEMENT OF BULK-BILLED **SERVICES** (K) Litchfield Shire (L) Melton-Wyndham (M) Mornington Peninsula Shire (N) Newcastle (O) North Canberra (P) Palmerston-East Arm (Q) Pine Rivers Shire (R) Queanbeyan (S) South Canberra (T) South Eastern Outer Melbourne (U) Southern Adelaide (V) South West Metropolitan, Perth (W) Thuringowa City Part A (X) Townsville City Part A (Y) Tuggeranong (Z) Weston Creek-Stromlo (ZA) Woden Valley (ZB) Yarra Ranges Shire Part A; or (iv) the geographical area included in the SLA spatial unit of Palm Island (AC) (See para PN.0.24 of explanatory notes to this Category) Fee: \$10.65 **Benefit:** 85% = \$9.10 P13. BULK-BILLING INCENTIVE Group P13. Bulk-Billing Incentive A payment when the episode is bulk billed and includes item 73920. 74992 Fee: \$1.60 **Benefit:** $75\% = \$1.20 \quad 85\% = \1.40 A payment when the episode is bulk billed and includes item 73922 or 73926. 74993 **Benefit:** $75\% = \$2.85 \quad 85\% = \3.20 **Fee:** \$3.75 A payment when the episode is bulk billed and includes item 73924.

Benefit: 75% = \$2.45 85% = \$2.80

74994

Fee: \$3.25

P13. BU	JLK-BILLING IN	ENTIVE
	A payment whe	n the episode is bulk billed and includes item 73899, 73900, 73928, 73930 or 73936.
74995	Fee: \$4.00	Benefit: 75% = \$3.00 85% = \$3.40
	A payment whe	n the episode is bulk billed and includes item 73932 or 73940.
74996	Fee: \$3.70	Benefit: 75% = \$2.80 85% = \$3.15
	A payment whe	n the episode is bulk billed and includes item 73934.
74997	Fee: \$3.30	Benefit: 75% = \$2.50 85% = \$2.85
	A payment whe	n the episode is bulk billed and includes item 73938.
74998	Fee: \$2.00	Benefit: 75% = \$1.50 85% = \$1.70
	A payment who 73933, 73935, 7	n the episode is bulk billed and includes item 73923, 73925, 73927, 73929, 73931, 73937 or 73939.
74999	Fee: \$1.60	Benefit: 75% = \$1.20 85% = \$1.40

INDEX

11 - Deoxycortisol DCOR	66695	Antibodies to tissue antigens - gliadin IgG GLIG	71163
Α		Antibodies to tissue antigens - Jo-1 JO1 Antibodies to tissue antigens - keratin KERA	71119
			71119
Abnormal heamoglobins AH	65117	Antibodies to tissue antigens - mitochondria MA	71119
Acetoacetate ACP	66500	Antibodies to tissue antigens - neutrophil cytoplas	sm ANCA 71153
Acid phosphatase ACP	66500	Antibodies to tissue antigens - PM-Sc1 PM1	71119
Actinimycetes - microbial antibody testing ACT	69384	Antibodies to tissue antigens - reticulin RCA	71119
	2, 65171	Antibodies to tissue antigens - Sc1-70 SCL	71119
Adenovirus - microbial antibody testing ADE	69384	Antibodies to tissue antigens - smooth muscle SM	
Adrenocorticotropic hormone (ACTH) ACTH	66695	Antibodies to tissue antigens - tissue transglutamin	
AFB microscopy & culture of sputum - 1 specimen AFB1	69324	Antibodies to tissue antigens - TSH receptor antib	ody test TSHA
AFB microscopy & culture of sputum - 2 specimens AFB2	69327		71165
AFB microscopy & culture of sputum - 3 specimens AFB3	69330	Antibodies to tissue antigens -glomerular basemer	nt membrane
Alanine aminotransferase ALT	66500	GBM	71153
Albumin ALB	66500	Antibody to cardiolipin or beta 2 glycoprotein AC	
Alcohol (ethanol) ETOH 66626	6, 66800		71, 65175-65179
Aldosterone ALDS	66695	Anus - cytology on specimens from SMCY	73043
ALK gene testing	73341	Apolipoprotein B/A1 ratio APO	66536
Alkaline phosphatase - isoenzymes ALPI	66641	Arsenic AS	66825-66828
Alkaline phosphatase ALP	66500	Aspartate aminotransferase AST	66500
Alpha-1-antitrypsin AAT	66635	Aspergillus - microbial antibody testing ASP	69384
Alpha-fetoprotein AFP 66650-66653	3, 66743	Avian precipitins (bird fancier's disease) - microbi	ial antibody
Aluminium - renal dialysis ALR	66671	testing APP	69384
Amikacin	66800		
Amino acids AA	66752	В	
Amiodarone AMIO	66812		
Amitriptyline AMIT	66812	B12 markers vitamin B12M	66839
Ammonia NH3	66500	B12 vitamin B12	66838
Amniotic fluid examination AFE	66749	Barbiturate BARB	66800
Amylase AMS	66500	Beryllium BE	66825-66828
Amylobarbitone AMYL	66812	Beta-2 microglobulin BMIC	66629
Androstenedione ANDR	66695	Beta-hydroxybutrate BHYB	66500
Angiotensin converting exzyme ACE	66758	Bicarbonate HCO3	66500
Anti - Xa activity QAXA	65147	Bilirubin (all fractions) - in urine UBIL	66500
Antibiotic & antimicrobial chemotherapeutic agents - guan	titation	Bilirubin (all fractions) - neonatal BILN	66749
QQA	66812	Bilirubin (all fractions) BILI	66500
Antibiotic & antimicrobial chemotherapeutic agents - quan	titation	Bird fancier's disease (see avian precipitins) APP	69384
QAA	66800	Blastomyces - microbial antibody testing BLM	69384
Antibodies to extractable nuclear antigens - characterisation	n of		99, 65102, 65105
antibodies if p	71103	65108	
Antibodies to extractable nuclear antigens - detection ENA	71101	Blood - culture BC 6935	54, 69357, 69360
Antibodies to nuclear antigens - detection ANA	71097	Blood - faecal occult FOB 6676	64, 66767, 66770
Antibodies to nuclear antigens - quantitation & measureme		Blood - film BF	65066
DNA binding if po	71099	Blood - full examination FBE	65070
Antibodies to tissue antibodies - liver/kidney microsomes I		Blood - gas GAS	66566
	71119	Blood - group & blood group antibodies BGAB	65096
Antibodies to tissue antigens - ANCA - myeloperoxidase N		Blood - group antibodies BGA	65111
	71153	Blood - group systems BGS	65093
Antibodies to tissue antigens - ANCA - PR3 PR3	71153	Blood - grouping - ABO & RH (D antigens) BG	65090
Antibodies to tissue antigens - anti - actin AACT	71119	Blood - viscosity VISC	65060
Antibodies to tissue antigens - anti - endomysial EMA	71163	BNP or NT-proBNP quantitation BNP	66830
Antibodies to tissue antigens - coeliac disease panel CLC	71163-	Body cavities - aspirations of - microscopy & cult	ure of material
71164		from MCOP	69321
Antibodies to tissue antigens - gastric parietal cell PCA	71119	Body fluids - cytology BFCY	73045
Antibodies to tissue antigens - gliadin IgA GLIA	71163	Bone - low mineral densities CBLB	66773

Dana matakalia kana diasasa CDMD	((77(Consulation forter inhibitors by Dothards assess DETH	(5150
Bone - metabolic bone disease CBMB Bone marrow examination - aspirate BMEA	66776 65087	Coagulation factor inhibitors by Bethesda assay BETH Coccidiodes - microbial antibody testing CCC	65159 69384
Bone marrow examination - aspirate BMEA Bone marrow examination - trephine BMET	65084		63-71164
Bordetella pertussis - microbial antibody testing BOR	69384	Cold agglutinins CAG	65114
Borrelia burgdorferi - microbial antibody testing BOB	69384	Collagen - low bone CBLB	66773
Breath hydrogen test BHT	66674	Collagen - metabolic disease CBMB	66776
Bromide BRMD	66812	Combatability testing XMAT 65099, 65102, 6510	
Brucella - microbial antibody testing BRU	69384	Complement, total haemolytic - components C3 C3	71083
Bulk billing incentive	74995	Complement, total haemolytic - components C4 C4	71083
		Complement, total haemolytic - other components COMP	
С		Complement, total haemolytic - properdin factor B PFB	71083
		Complement, total haemolytic COM	71081
C-l esterase inhibitor - functional CEIF	66647	Copper CU	66831
C-l esterase inhibitor - quantitation CEIQ	66644	Cortisol CORT	66695
C-Peptide CPEP	66695	Cortisol in saliva CORS 667	11-66712
C-Reactive protein CRP	66500	Coxsackie B1-6 - microbial antibody testing COX	69384
CA-125 antigen C125	66650	Creatine Kinase - isoenzyme (electrophoresis) CKIE	66518
CA-15.3 antigen CA15	66650	Creatine kinase - isoenzymes CKI	66518
CA-19.9 antigen	66650	Creatine kinase CK	66500
Caeruloplasmin CPLS	66632	Creatinine C	66500
Calcitonin CALT	66695	Cryofibrinogen - detection and quantitation CFID	71064
Calcium (total or corrected for albumin) CA	66500	Cryoglobulins - characterisation by electrophoresis, and	
Calcium - ionised ICA	66584	immunoelectrophoresis o	71059
Calculus analysis CALC	66590	Cryoglobulins - detection and quantitation CGLD	71064
Campylobacter jejuni - microbial testing antibody CAM	69384	Cryptococcus - microbial antibody testing CRY	69384
Candida - microbial antibody testing CAN	69384	Cultural examination of faeces FCS	69345
Carbamazepine (Tegretol) CARB	66800	Cyclic AMP CAMP	66695
Carboxyhaemoglobin COHB	65117	Cyclosporin A CLSA	66812
Carcinoembryonic antigen CEA	66650	Cystine - qualitative UCYS	66752
Cardiac enzymes (see test groups at PQ.4) CE	66506	Cystine - quantitative CYST	66752
Catecholamines CAT	66779	Cytology - fine needle aspiration of solid tissues - aspirati	73051
Cell mediated immunity - delayed type - hypersensitivity t	test CMI	attendance by	
		Cytology fine needle aspiration of solid tissues ENCV	73040
	71137	Cytology - fine needle aspiration of solid tissues FNCY	73049 73047
Cell-mediated immunity in blood CMIB	71137 69471	Cytology - from 3 sputum or urine specimens SPCY	73047
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR	71137 69471 69312	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine,	73047 washings
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR CFS - microscopy & culture of material from MCPO	71137 69471 69312 69321	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine, or brushings B	73047 washings 73045
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR CFS - microscopy & culture of material from MCPO Characterisation of antibodies if positive ENA ENAP	71137 69471 69312 69321 71103	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine,	73047 washings 73045
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR CFS - microscopy & culture of material from MCPO Characterisation of antibodies if positive ENA ENAP Chemicals, toxic (ingested or absorbed) - assays DRGO	71137 69471 69312 69321 71103 66623	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine, or brushings B Cytology - from skin, nipple discharge, lip, mouth, nose o SMCY	73047 washings 73045 r anus 73043
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR CFS - microscopy & culture of material from MCPO Characterisation of antibodies if positive ENA ENAP Chemicals, toxic (ingested or absorbed) - assays DRGO Chlamydia - microbial antibody testing CHL	71137 69471 69312 69321 71103 66623 69384	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine, or brushings B Cytology - from skin, nipple discharge, lip, mouth, nose o SMCY Cytomegalovirus - microbial antibody testing CMV	73047 washings 73045 r anus 73043 69384
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR CFS - microscopy & culture of material from MCPO Characterisation of antibodies if positive ENA ENAP Chemicals, toxic (ingested or absorbed) - assays DRGO Chlamydia - microbial antibody testing CHL Chloral hydrate CHHY	71137 69471 69312 69321 71103 66623 69384 66812	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine, or brushings B Cytology - from skin, nipple discharge, lip, mouth, nose o SMCY	73047 washings 73045 r anus 73043 69384 ody
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR CFS - microscopy & culture of material from MCPO Characterisation of antibodies if positive ENA ENAP Chemicals, toxic (ingested or absorbed) - assays DRGO Chlamydia - microbial antibody testing CHL Chloral hydrate CHHY Chlorazepate CHZP	71137 69471 69312 69321 71103 66623 69384 66812 66812	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine, or brushings B Cytology - from skin, nipple discharge, lip, mouth, nose of SMCY Cytomegalovirus - microbial antibody testing CMV Cytomegalovirus serology in pregnancy - microbial antibody	73047 washings 73045 r anus 73043 69384 ody
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR CFS - microscopy & culture of material from MCPO Characterisation of antibodies if positive ENA ENAP Chemicals, toxic (ingested or absorbed) - assays DRGO Chlamydia - microbial antibody testing CHL Chloral hydrate CHHY Chlorazepate CHZP Chloride CL	71137 69471 69312 69321 71103 66623 69384 66812 66812 66500	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine, or brushings B Cytology - from skin, nipple discharge, lip, mouth, nose of SMCY Cytomegalovirus - microbial antibody testing CMV Cytomegalovirus serology in pregnancy - microbial antibody	73047 washings 73045 r anus 73043 69384 ody
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR CFS - microscopy & culture of material from MCPO Characterisation of antibodies if positive ENA ENAP Chemicals, toxic (ingested or absorbed) - assays DRGO Chlamydia - microbial antibody testing CHL Chloral hydrate CHHY Chlorazepate CHZP Chloride CL Chloroquinine CLOQ	71137 69471 69312 69321 71103 66623 69384 66812 66812 66500 66812	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine, or brushings B Cytology - from skin, nipple discharge, lip, mouth, nose of SMCY Cytomegalovirus - microbial antibody testing CMV Cytomegalovirus serology in pregnancy - microbial antibot testing CMVP 69405, 6940	73047 washings 73045 r anus 73043 69384 ody
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR CFS - microscopy & culture of material from MCPO Characterisation of antibodies if positive ENA ENAP Chemicals, toxic (ingested or absorbed) - assays DRGO Chlamydia - microbial antibody testing CHL Chloral hydrate CHHY Chlorazepate CHZP Chloride CL Chloroquinine CLOQ Chlorpromazine CHLO	71137 69471 69312 69321 71103 66623 69384 66812 66812 66500 66812 66812	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine, or brushings B Cytology - from skin, nipple discharge, lip, mouth, nose of SMCY Cytomegalovirus - microbial antibody testing CMV Cytomegalovirus serology in pregnancy - microbial antibot testing CMVP 69405, 6940	73047 washings 73045 r anus 73043 69384 ody
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR CFS - microscopy & culture of material from MCPO Characterisation of antibodies if positive ENA ENAP Chemicals, toxic (ingested or absorbed) - assays DRGO Chlamydia - microbial antibody testing CHL Chloral hydrate CHHY Chlorazepate CHZP Chloride CL Chloroquinine CLOQ	71137 69471 69312 69321 71103 66623 69384 66812 66812 66500 66812 66812 66536	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine, or brushings B Cytology - from skin, nipple discharge, lip, mouth, nose of SMCY Cytomegalovirus - microbial antibody testing CMV Cytomegalovirus serology in pregnancy - microbial antibot testing CMVP D-dimer test DD	73047 washings 73045 r anus 73043 69384 ody 18, 69411
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR CFS - microscopy & culture of material from MCPO Characterisation of antibodies if positive ENA ENAP Chemicals, toxic (ingested or absorbed) - assays DRGO Chlamydia - microbial antibody testing CHL Chloral hydrate CHHY Chlorazepate CHZP Chloride CL Chloroquinine CLOQ Chlorpromazine CHLO Cholesterol - HDL HDLC	71137 69471 69312 69321 71103 66623 69384 66812 66500 66812 66536 66500	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine, or brushings B Cytology - from skin, nipple discharge, lip, mouth, nose of SMCY Cytomegalovirus - microbial antibody testing CMV Cytomegalovirus serology in pregnancy - microbial antiboty testing CMVP D D-dimer test DD Dehydroepiandrosterone sulphate (DHEAS) DHEA	73047 washings 73045 r anus 73043 69384 ody 18, 69411
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR CFS - microscopy & culture of material from MCPO Characterisation of antibodies if positive ENA ENAP Chemicals, toxic (ingested or absorbed) - assays DRGO Chlamydia - microbial antibody testing CHL Chloral hydrate CHHY Chlorazepate CHZP Chloride CL Chloroquinine CLOQ Chlorpromazine CHLO Cholesterol - HDL HDLC Cholesterol CHOL	71137 69471 69312 69321 71103 66623 69384 66812 66500 66812 66536 66500 66758	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine, or brushings B Cytology - from skin, nipple discharge, lip, mouth, nose of SMCY Cytomegalovirus - microbial antibody testing CMV Cytomegalovirus serology in pregnancy - microbial antibot testing CMVP D-dimer test DD	73047 washings 73045 r anus 73043 69384 ody 18, 69411
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR CFS - microscopy & culture of material from MCPO Characterisation of antibodies if positive ENA ENAP Chemicals, toxic (ingested or absorbed) - assays DRGO Chlamydia - microbial antibody testing CHL Chloral hydrate CHHY Chlorazepate CHZP Chloride CL Chloroquinine CLOQ Chlorpromazine CHLO Cholesterol - HDL HDLC Cholesterol CHOL Cholinesterase CHSE Chorionic gonadotrophin - detection for pregnancy diagno	71137 69471 69312 69321 71103 66623 69384 66812 66500 66812 66536 66500 66758	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine, or brushings B Cytology - from skin, nipple discharge, lip, mouth, nose of SMCY Cytomegalovirus - microbial antibody testing CMV Cytomegalovirus serology in pregnancy - microbial antiboty testing CMVP D D-dimer test DD Dehydroepiandrosterone sulphate (DHEAS) DHEA Dengue - microbial antibody testing DEN	73047 washings 73045 r anus 73043 69384 ody 18, 69411 65120 66695 69384
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR CFS - microscopy & culture of material from MCPO Characterisation of antibodies if positive ENA ENAP Chemicals, toxic (ingested or absorbed) - assays DRGO Chlamydia - microbial antibody testing CHL Chloral hydrate CHHY Chlorazepate CHZP Chloride CL Chloroquinine CLOQ Chlorpromazine CHLO Cholesterol - HDL HDLC Cholesterol CHOL Cholinesterase CHSE Chorionic gonadotrophin - detection for pregnancy diagnor HCGP 7352	71137 69471 69312 69321 71103 66623 69384 66812 66500 66812 66500 66758	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine, or brushings B Cytology - from skin, nipple discharge, lip, mouth, nose of SMCY Cytomegalovirus - microbial antibody testing CMV Cytomegalovirus serology in pregnancy - microbial antiboty testing CMVP D D-dimer test DD Dehydroepiandrosterone sulphate (DHEAS) DHEA Dengue - microbial antibody testing DEN Desipramine DESI	73047 washings 73045 r anus 73043 69384 ody 8, 69411 65120 66695 69384 66812
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR CFS - microscopy & culture of material from MCPO Characterisation of antibodies if positive ENA ENAP Chemicals, toxic (ingested or absorbed) - assays DRGO Chlamydia - microbial antibody testing CHL Chloral hydrate CHHY Chlorazepate CHZP Chloride CL Chloroquinine CLOQ Chlorpromazine CHLO Cholesterol - HDL HDLC Cholesterol CHOL Cholinesterase CHSE Chorionic gonadotrophin - detection for pregnancy diagnoth HCGP 7352	71137 69471 69312 69321 71103 66623 69384 66812 66500 66812 66536 66500 66758 sisis 7, 73529	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine, or brushings B Cytology - from skin, nipple discharge, lip, mouth, nose of SMCY Cytomegalovirus - microbial antibody testing CMV Cytomegalovirus serology in pregnancy - microbial antiboty testing CMVP D D-dimer test DD Dehydroepiandrosterone sulphate (DHEAS) DHEA Dengue - microbial antibody testing DEN Desipramine DESI Dexamethasone - suppression test DEXA	73047 washings 73045 r anus 73043 69384 ody 8, 69411 65120 66695 69384 66812 66686
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR CFS - microscopy & culture of material from MCPO Characterisation of antibodies if positive ENA ENAP Chemicals, toxic (ingested or absorbed) - assays DRGO Chlamydia - microbial antibody testing CHL Chloral hydrate CHHY Chlorazepate CHZP Chloride CL Chloroquinine CLOQ Chlorpromazine CHLO Cholesterol - HDL HDLC Cholesterol CHOL Cholinesterase CHSE Chorionic gonadotrophin - detection for pregnancy diagnoth HCGP 73529 Chromosome identification - studies - blood CSB	71137 69471 69312 69321 71103 66623 69384 66812 66812 66500 66812 66536 66500 66758 sisis 7, 73529 50-66653	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine, or brushings B Cytology - from skin, nipple discharge, lip, mouth, nose of SMCY Cytomegalovirus - microbial antibody testing CMV Cytomegalovirus serology in pregnancy - microbial antiboty testing CMVP D D-dimer test DD Dehydroepiandrosterone sulphate (DHEAS) DHEA Dengue - microbial antibody testing DEN Desipramine DESI Dexamethasone - suppression test DEXA Dexamethasone DXST DHEAS (Dehydroepiandrosterone sulphate) DHEA Diazepam DIAZ	73047 washings 73045 r anus 73043 69384 ody 18, 69411 65120 66695 69384 66812 66686 66686 66695 66812
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR CFS - microscopy & culture of material from MCPO Characterisation of antibodies if positive ENA ENAP Chemicals, toxic (ingested or absorbed) - assays DRGO Chlamydia - microbial antibody testing CHL Chloral hydrate CHHY Chlorazepate CHZP Chloride CL Chloroquinine CLOQ Chlorpromazine CHLO Cholesterol - HDL HDLC Cholesterol CHOL Cholinesterase CHSE Chorionic gonadotrophin - detection for pregnancy diagnoth HCGP 7352 Chorionic gonadotrophin - quantitation HCG 73529 Chromosome identification - studies - blood CSB Chromosome identification - studies - other than blood CSB	71137 69471 69312 69321 71103 66623 69384 66812 66812 66500 66812 66536 66500 66758 sisis 7, 73529 50-66653	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine, or brushings B Cytology - from skin, nipple discharge, lip, mouth, nose of SMCY Cytomegalovirus - microbial antibody testing CMV Cytomegalovirus serology in pregnancy - microbial antiboty testing CMV D D-dimer test DD Dehydroepiandrosterone sulphate (DHEAS) DHEA Dengue - microbial antibody testing DEN Desipramine DESI Dexamethasone - suppression test DEXA Dexamethasone DXST DHEAS (Dehydroepiandrosterone sulphate) DHEA Diazepam DIAZ Differential cell count DIFF	73047 washings 73045 r anus 73043 69384 ody 8, 69411 65120 66695 69384 66812 66686 66695 66812 66812
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR CFS - microscopy & culture of material from MCPO Characterisation of antibodies if positive ENA ENAP Chemicals, toxic (ingested or absorbed) - assays DRGO Chlamydia - microbial antibody testing CHL Chloral hydrate CHHY Chlorazepate CHZP Chloride CL Chloroquinine CLOQ Chlorpromazine CHLO Cholesterol - HDL HDLC Cholesterol CHOL Cholinesterase CHSE Chorionic gonadotrophin - detection for pregnancy diagnoth HCGP 73529 Chromosome identification - studies - blood CSB Chromosome identification - studies - other than blood CSC Chromosome identification and banding	71137 69471 69312 69321 71103 66623 69384 66812 66812 66500 66812 66536 66500 66758 sisis 7, 73529 50-66653	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine, or brushings B Cytology - from skin, nipple discharge, lip, mouth, nose of SMCY Cytomegalovirus - microbial antibody testing CMV Cytomegalovirus serology in pregnancy - microbial antiboty testing CMV Cytomegalovirus serology in pregnancy - microbial antiboty testing CMVP D D-dimer test DD Dehydroepiandrosterone sulphate (DHEAS) DHEA Dengue - microbial antibody testing DEN Desipramine DESI Dexamethasone - suppression test DEXA Dexamethasone DXST DHEAS (Dehydroepiandrosterone sulphate) DHEA Diazepam DIAZ Differential cell count DIFF Digoxin DIG	73047 washings 73045 r anus 73043 69384 ody 8, 69411 65120 66695 69384 66812 66686 66695 66812 66812 66800
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR CFS - microscopy & culture of material from MCPO Characterisation of antibodies if positive ENA ENAP Chemicals, toxic (ingested or absorbed) - assays DRGO Chlamydia - microbial antibody testing CHL Chloral hydrate CHHY Chlorazepate CHZP Chloride CL Chloroquinine CLOQ Chlorpromazine CHLO Cholesterol - HDL HDLC Cholesterol CHOL Cholinesterase CHSE Chorionic gonadotrophin - detection for pregnancy diagnoth HCGP 7352 Chorionic gonadotrophin - quantitation HCG 73529 Chromosome identification - studies - blood CSB Chromosome identification and banding Chromosome identification and banding	71137 69471 69312 69321 71103 66623 69384 66812 66812 66500 66812 66536 66500 66758 sisis 7, 73529 50-66653 73289 73287 73287 73287	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine, or brushings B Cytology - from skin, nipple discharge, lip, mouth, nose of SMCY Cytomegalovirus - microbial antibody testing CMV Cytomegalovirus serology in pregnancy - microbial antiboty testing CMV Cytomegalovirus serology in pregnancy - microbial antiboty testing CMVP D D-dimer test DD Dehydroepiandrosterone sulphate (DHEAS) DHEA Dengue - microbial antibody testing DEN Desipramine DESI Dexamethasone - suppression test DEXA Dexamethasone DXST DHEAS (Dehydroepiandrosterone sulphate) DHEA Diazepam DIAZ Differential cell count DIFF Digoxin DIG Dihydrotestosterone DHTS	73047 washings 73045 r anus 73043 69384 ody 8, 69411 65120 66695 69384 66812 66686 66695 66812 66812 66800 66695
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR CFS - microscopy & culture of material from MCPO Characterisation of antibodies if positive ENA ENAP Chemicals, toxic (ingested or absorbed) - assays DRGO Chlamydia - microbial antibody testing CHL Chloral hydrate CHHY Chlorazepate CHZP Chloride CL Chloroquinine CLOQ Chlorpromazine CHLO Cholesterol - HDL HDLC Cholesterol CHOL Cholinesterase CHSE Chorionic gonadotrophin - detection for pregnancy diagnoth HCGP 7352 Chorionic gonadotrophin - quantitation HCG 73529 Chromosome identification - studies - blood CSB Chromosome identification - studies - other than blood CS Chromosome identification and banding Chromosome identification and banding Chronic eosinophilic leukaemia	71137 69471 69312 69321 71103 66623 69384 66812 66812 66500 66812 66536 66500 66758 siss 7, 73529 50-66653 73289 73287 73287 73287 73289 73326	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine, or brushings B Cytology - from skin, nipple discharge, lip, mouth, nose of SMCY Cytomegalovirus - microbial antibody testing CMV Cytomegalovirus serology in pregnancy - microbial antiboty testing CMV Cytomegalovirus serology in pregnancy - microbial antiboty testing CMVP D-dimer test DD Dehydroepiandrosterone sulphate (DHEAS) DHEA Dengue - microbial antibody testing DEN Desipramine DESI Dexamethasone - suppression test DEXA Dexamethasone DXST DHEAS (Dehydroepiandrosterone sulphate) DHEA Diazepam DIAZ Differential cell count DIFF Digoxin DIG Dihydrotestosterone DHTS Diphenylhydantoin (Dilantin) DIL	73047 washings 73045 r anus 73043 69384 ody 8, 69411 65120 66695 69384 66812 66686 66695 66812 66800 66695 66812
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR CFS - microscopy & culture of material from MCPO Characterisation of antibodies if positive ENA ENAP Chemicals, toxic (ingested or absorbed) - assays DRGO Chlamydia - microbial antibody testing CHL Chloral hydrate CHHY Chlorazepate CHZP Chloride CL Chloroquinine CLOQ Chlorpromazine CHLO Cholesterol - HDL HDLC Cholesterol CHOL Cholinesterase CHSE Chorionic gonadotrophin - detection for pregnancy diagnoth HCGP 7352 Chorionic gonadotrophin - quantitation HCG 6665 73529 Chromosome identification - studies - blood CSB Chromosome identification - studies - other than blood CS Chromosome identification and banding Chronic eosinophilic leukaemia Cimetidine CMTD	71137 69471 69312 69321 71103 66623 69384 66812 66812 66500 66812 66536 66500 66758 sisis 7, 73529 50-66653 73289 73287 73287 73287 73289 73326 66812	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine, or brushings B Cytology - from skin, nipple discharge, lip, mouth, nose of SMCY Cytomegalovirus - microbial antibody testing CMV Cytomegalovirus serology in pregnancy - microbial antiboty testing CMV Cytomegalovirus serology in pregnancy - microbial antiboty testing CMVP D-dimer test DD Dehydroepiandrosterone sulphate (DHEAS) DHEA Dengue - microbial antibody testing DEN Desipramine DESI Dexamethasone - suppression test DEXA Dexamethasone DXST DHEAS (Dehydroepiandrosterone sulphate) DHEA Diazepam DIAZ Differential cell count DIFF Digoxin DIG Dihydrotestosterone DHTS Diphenylhydantoin (Dilantin) DIL Diphtheria - microbial antibody testing DIP	73047 washings 73045 r anus 73043 69384 ody 8, 69411 65120 66695 69384 66812 66686 66695 66812 66800 66695 66812 69384
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR CFS - microscopy & culture of material from MCPO Characterisation of antibodies if positive ENA ENAP Chemicals, toxic (ingested or absorbed) - assays DRGO Chlamydia - microbial antibody testing CHL Chloral hydrate CHHY Chlorazepate CHZP Chloride CL Chloroquinine CLOQ Chlorpromazine CHLO Cholesterol - HDL HDLC Cholesterol CHOL Cholinesterase CHSE Chorionic gonadotrophin - detection for pregnancy diagnoth HCGP 7352 Chorionic gonadotrophin - quantitation HCG 73529 Chromosome identification - studies - blood CSB Chromosome identification - studies - other than blood CS Chromosome identification and banding Chronic eosinophilic leukaemia Cimetidine CMTD Clobazam CLOB	71137 69471 69312 69321 71103 66623 69384 66812 66812 66500 66812 66536 66500 66758 sisis 7, 73529 50-66653 73289 73287 73287 73287 73287 73289 73326 66812 66812	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine, or brushings B Cytology - from skin, nipple discharge, lip, mouth, nose of SMCY Cytomegalovirus - microbial antibody testing CMV Cytomegalovirus serology in pregnancy - microbial antibutesting CMVP D D-dimer test DD Dehydroepiandrosterone sulphate (DHEAS) DHEA Dengue - microbial antibody testing DEN Desipramine DESI Dexamethasone - suppression test DEXA Dexamethasone DXST DHEAS (Dehydroepiandrosterone sulphate) DHEA Diazepam DIAZ Differential cell count DIFF Digoxin DIG Dihydrotestosterone DHTS Diphenylhydantoin (Dilantin) DIL Diphtheria - microbial antibody testing DIP Direct Coombs test CMBS	73047 washings 73045 r anus 73043 69384 ody 8, 69411 65120 66695 69384 66812 66806 66695 66812 66800 66695 66812 69384 65114
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR CFS - microscopy & culture of material from MCPO Characterisation of antibodies if positive ENA ENAP Chemicals, toxic (ingested or absorbed) - assays DRGO Chlamydia - microbial antibody testing CHL Chloral hydrate CHHY Chlorazepate CHZP Chloride CL Chloroquinine CLOQ Chlorpromazine CHLO Cholesterol - HDL HDLC Cholesterol CHOL Cholinesterase CHSE Chorionic gonadotrophin - detection for pregnancy diagnoth HCGP 73529 Chorionic gonadotrophin - quantitation HCG 73529 Chromosome identification - studies - blood CSB Chromosome identification - studies - other than blood CS Chromosome identification and banding Chronic eosinophilic leukaemia Cimetidine CMTD Clobazam CLOB Clomipramine CLOM	71137 69471 69312 69321 71103 66623 69384 66812 66812 66500 66812 66536 66500 66758 siss 7, 73529 50-66653 73289 73287 73287 73287 73287 73287 73289 73326 66812 66812 66812	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine, or brushings B Cytology - from skin, nipple discharge, lip, mouth, nose of SMCY Cytomegalovirus - microbial antibody testing CMV Cytomegalovirus serology in pregnancy - microbial antibot testing CMVP D-dimer test DD Dehydroepiandrosterone sulphate (DHEAS) DHEA Dengue - microbial antibody testing DEN Desipramine DESI Dexamethasone - suppression test DEXA Dexamethasone DXST DHEAS (Dehydroepiandrosterone sulphate) DHEA Diazepam DIAZ Differential cell count DIFF Digoxin DIG Dihydrotestosterone DHTS Diphenylhydantoin (Dilantin) DIL Diphtheria - microbial antibody testing DIP Direct Coombs test CMBS Disopyramide (Rythmodan) DISO	73047 washings 73045 r anus 73043 69384 ody 8, 69411 65120 66695 69384 66812 66806 66695 66812 66800 66695 66812 69384 65114 66800
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR CFS - microscopy & culture of material from MCPO Characterisation of antibodies if positive ENA ENAP Chemicals, toxic (ingested or absorbed) - assays DRGO Chlamydia - microbial antibody testing CHL Chloral hydrate CHHY Chlorazepate CHZP Chloride CL Chloroquinine CLOQ Chlorpromazine CHLO Cholesterol - HDL HDLC Cholesterol CHOL Cholinesterase CHSE Chorionic gonadotrophin - detection for pregnancy diagnoth HCGP 7352 Chorionic gonadotrophin - quantitation HCG 6665 73529 Chromosome identification - studies - blood CSB Chromosome identification - studies - other than blood CS Chromosome identification and banding Chronic eosinophilic leukaemia Cimetidine CMTD Clobazam CLOB Clomipramine CLOM Clonazepam (Rivotril) CLON	71137 69471 69312 69321 71103 66623 69384 66812 66812 66500 66812 66536 66500 66758 sisis 7, 73529 50-66653 73289 73287 73287 73287 73287 73287 73287 73287 73287 73289 66812 66812 66812 66812	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine, or brushings B Cytology - from skin, nipple discharge, lip, mouth, nose of SMCY Cytomegalovirus - microbial antibody testing CMV Cytomegalovirus serology in pregnancy - microbial antibot testing CMVP D-dimer test DD D-dimer test DD Dehydroepiandrosterone sulphate (DHEAS) DHEA Dengue - microbial antibody testing DEN Desipramine DESI Dexamethasone - suppression test DEXA Dexamethasone DXST DHEAS (Dehydroepiandrosterone sulphate) DHEA Diazepam DIAZ Differential cell count DIFF Digoxin DIG Dihydrotestosterone DHTS Diphenylhydantoin (Dilantin) DIL Diphtheria - microbial antibody testing DIP Direct Coombs test CMBS Disopyramide (Rythmodan) DISO DNA binding - quantitation & measurement if positive Al	73047 washings 73045 r anus 73043 69384 ody 8, 69411 65120 66695 69384 66812 66686 66695 66812 66800 66695 66812 69384 65114 66800 NA
Cell-mediated immunity in blood CMIB Cervix - microscopy & culture of material from MCGR CFS - microscopy & culture of material from MCPO Characterisation of antibodies if positive ENA ENAP Chemicals, toxic (ingested or absorbed) - assays DRGO Chlamydia - microbial antibody testing CHL Chloral hydrate CHHY Chlorazepate CHZP Chloride CL Chloroquinine CLOQ Chlorpromazine CHLO Cholesterol - HDL HDLC Cholesterol CHOL Cholinesterase CHSE Chorionic gonadotrophin - detection for pregnancy diagnoth HCGP 73529 Chorionic gonadotrophin - quantitation HCG 73529 Chromosome identification - studies - blood CSB Chromosome identification - studies - other than blood CS Chromosome identification and banding Chronic eosinophilic leukaemia Cimetidine CMTD Clobazam CLOB Clomipramine CLOM	71137 69471 69312 69321 71103 66623 69384 66812 66812 66500 66812 66536 66500 66758 sisis 7, 73529 50-66653 73289 73287 73287 73287 73287 73287 73287 73287 73289 66812 66812 66812 66812 66812 66812 66812 66812 66812 66812	Cytology - from 3 sputum or urine specimens SPCY Cytology - from body fluids, sputum (1 specimen), urine, or brushings B Cytology - from skin, nipple discharge, lip, mouth, nose of SMCY Cytomegalovirus - microbial antibody testing CMV Cytomegalovirus serology in pregnancy - microbial antibot testing CMVP D-dimer test DD Dehydroepiandrosterone sulphate (DHEAS) DHEA Dengue - microbial antibody testing DEN Desipramine DESI Dexamethasone - suppression test DEXA Dexamethasone DXST DHEAS (Dehydroepiandrosterone sulphate) DHEA Diazepam DIAZ Differential cell count DIFF Digoxin DIG Dihydrotestosterone DHTS Diphenylhydantoin (Dilantin) DIL Diphtheria - microbial antibody testing DIP Direct Coombs test CMBS Disopyramide (Rythmodan) DISO	73047 washings 73045 r anus 73043 69384 ody 8, 69411 65120 66695 69384 66812 66806 66695 66812 66800 66695 66812 69384 65114 66800

Donath Landsteiner antibody test DLAT	65075	Ferritin (see also Iron Studies) FERR	66593
Doxepin hydrochloride DOXE	66812	Fibrin monomer FM	65120
Drugs - abuse treatment programme - assay DATP	66626	Fibrinogen - degradation products FDP	65120
Drugs - inappropriate dosage - assay DRGO	66623	Fibrinogen FIB	65120
Drugs - therapeutic - assay (See individual drugs)	66800	Fitzgerald factor FGF	65150
66812		Flecainide FLEC	66812
Dynamic function tests GHSE	66686	Fletcher factor FF	65150
		Fluorescent treponemal antibody - absorption test (F	TA-ABS) -
E		microbial antibody	69384
		Fluoxetine FLUX	66812
Ear - microscopy & culture of material from MCSW	69303	Foetal red blood cells - Kliehauer KLEI	65162
Echinococcus - microbial antibody testing ECC	69384	Folate - serum SF	66840
Echis test ECHI	65120	Follicle stimulating hormone FSH	66695
ECHO-Coxsackie group - microbial antibody testing ECH		Fragile X FXS	73300, 73305
Electrolytes (see test groups at para PQ.4) E	66509	Frozen section diagnosis of biopsy material FS	72855-72856
	1-72852	Fructosamine FRUC	66557
Electrophoresis - quantitation of paraprotein classes or para		Full blood examination FBE	65070
	7-71058		
Electrophoresis, and immunofixation or immunoelectropho		G	
isoelectric focu	71059		
Electrophoresis, to demonstrate - creatine kinase isoenzym		Gamma glutamyl transpeptidase GGT	66500
Electrophoresis, to demonstrate - creatine kinase isoenzym	66518	Gastric parietal cell - triple antigens - antibodies PCA	
Electrophoresis, to demonstrate - lactate dehydrogenase	00310	Gastrie Gastri Gastri	66695
isoenzymes LDI	66641	Gentamicin	66800
Electrophoresis, to demonstrate - lipoprotein subclasses LE		Gliadin antibodies GLIA	71163
Electrophoresis, to demonstrate - inpoprotein subclasses El	66539	Globulin GLOB	66500
Endomysium antibodies EMA	71163	Glucagon GLGO	66695
	69384		00093
Entamoeba histolytica - microbial antibody testing AMO		Glucose - tolerance test GTT	((51)
Enzyme assays of solid tissue or tissues ENZS	66683	Channa CLUC	66542
Enzyme histochemistry of skeletal muscle EHSK	72844	Glucose GLUC	66500
Eosinophil cationic protein ECP	71095	Glycosylated haemoglobin (Hb Alc) GHB	66551
Epstein Barr virus - microbial antibody testing - EBV 69474	69472	Group P9 - simple basic pathology tests 73806-73811	73802-73804
	65075		73801
Erythrocyte - assessment of haemolysis ERYH		Group P9 - simple basic pathology tests	
Erythrocyte - assessment of metabolic enzymes ERYM	65075	Growth hormone - stimulation by exercise or L-dopa	
Erythrocyte - count RCC	65070	Growth hormone - suppression by dexamethasone or	-
Erythrocyte - sedimentation rate ERS	65060	GHSG Growth hormone GH	66686
Essential thrombocythaemia	73325	Growth normone GH	66695
	6, 66800	11	
Ethosuximide (Zarontin) ETHO	66800	Н	
Extractable nuclear antigens - detection of antibodies to EN			
Eye - microscopy & culture of material from MCSW	71101	Haematocrit HCT	65070
Eye - microscopy & culture of material from MCS w	69303	Haemoglobin HB	65060
_		Haemoglobinopathy tests - HMGP	65081
F		Haemophilus influenzae - microbial antibody testing	
D	<-1-0	Haloperidol HALO	66812
Factor II FII	65150	Haptoglobins HGLB	66632
Factor IX FIX	65150	HDL Cholesterol HDLC	66536
Factor V FV	65150	Heparin - test HEPR	65144
Factor VII FVII	65150	Hepatitis B or C confirmatory test HSVP	69484
Factor VIII VIII	65150	Hepatitis investigation - 3 markers HEP3	69481
Factor X FX	65150	1 65 1 6 7	69408, 69411
Factor XI FXI	65150	69413	
Factor XII FXII	65150	Hepatitis status or carriage - 1 marker HEP1	69475
Factor XIII deficiency test F13D	65150	Hepatitis status or carriage - 2 markers HEP2	69478
Factor XIII XIII	65150	Herpes simplex virus - microbial antibody testing HI	
Faecal blood FOB 66764, 66767	*	Heterophil antibodies IM	65114
faecal fat - haemoglobin FFH	66764	HIAA (hydroxyindoleacetic acid) HIAA	66779
Faecal fat - reducing substances FRS	66761	Histamine HIAM	66779
Faecal fat FFAT	66674		, 72816-72818
Faeces - culture FCS	69345	72823-72828, 72830, 72836	
Faeces - microscopy for parasites OCP 69336	6, 69339	Histoplasma - microbial antibody testing HIP	69384

THE STATE OF THE S	60201	W. L. C. C. W.	52.52.1
HIV - antiretroviral therapy TVLT	69381	Huhner's test HT	73521
HIV - cerebrospinal fluid CVLT HIV - genotypic testing for HIV	69382 69380	Human chorionic gonadatrophin - detection for diagnosis of pregnancy HCGP 7352	7, 73529
HIV - monitoring MVLT	69378	Human chorionic gonadatrophin - quantitation HCG 6665	
HLA typing - HLA class 2 HLA2	71151	73529	10-00033
HLA typing - HLA-B27 HLAB	71147	HVA (homovanillic acid) HVA	66779
HLAB5701 - status by flow cytometry or cytotoxity assa		Hydatid - microbial antibody testing HYD	69384
	71203	Hydroxy methoxy phenylethylene glycol HMPG	66779
HLAB5701 - status by molecular techniques or cytotoxit	y assay	Hydroxy-3-methoxymandelic acid, (previously known as	VMA)
HLAM	73323	HMMA	66779
HLT typing - HLA class 1 HLA1	71149	Hydroxychloroquinine HOCQ	66812
HMMA (hydroxy-3-methoxymandelic acid, previously k		Hydroxyindoleacetic acid HIAA	66779
VMA) HMMA	66779	Hydroxyprogesterone OHP	66695
HMPG (hydroxy-methoxy phenylethylene glycol) HMPG		Hydroxyproline HYDP	66752
Homovanillic acid HVA	66779 66662		
Hormone receptor assay - breast HRA Hormone receptor assay - ovary HRO	66662		
Hormones & hormone binding proteins (see individual hormones who hormone binding proteins)		Idianahia hamanaain ankilia aan daana	72226
and proteins)	66695	Idiopathic hypereosinophilic syndrome Imipramine IMIP	73326 66812
Hormones - 11 deoxycortisol DCOR	66695	Immediate frozen section diagnosis of biopsy material FS	
Hormones - adrenocorticotrophic hormone ACTH	66695	72856	12033-
Hormones - aldosterone ALDS	66695		9, 73061
Hormones - androstenedione ANDR	66695	Immunocyto. 4 + antibodies ICC1	73060
Hormones - C-Peptide CPEP	66695	Immunoelectrophoresis and electrophoresis - characterisat	ion of
Hormones - Calcitonin CALT	66695	cryoglobulins RY	71059
Hormones - cortisol CORT	66695	Immunoelectrophoresis and electrophoresis - characterisat	ion of
Hormones - cyclic AMP CAMP	66695	paraprotein PPRO	71059
Hormones - dehydroepiandrosterone sulphate (DHEAS)		Immunoglobulins - A IGA	71066
Hormones - dihydrotestosterone DHTS	66695 66695	Immunoglobulins - D IGD	71074
Hormones - follicle stimulating hormone FSH	66695	Immunoglobulins - E (total) IGE 71075-7107	
Hormones - gastrin GAST	66695	Immunoglobulins - G IGG	71068 71072
Hormones - glucagon GLGO	66695	Immunoglobulins - M IGM Immunoglobulins -G, 4 subclasses SIGG	71072
Hormones - growth hormone - stimulation by exercise or		Immunohistochemical investigation of biopsy material HI	
GHSE	66686	72848	3 /2040-
Hormones - growth hormone - suppression by dexametha	asone or	Infectious mononucleosis IM	69384
glucose GHSG	66686	Influenza A - microbial antibody testing FLA	69384
Hormones - growth hormone GH	66695	Influenza B - microbial antibody testing FLB	69384
Hormones - hormone receptor assay - breast HRA	66662	Insulin INS	66695
Hormones - hormones receptor assay - ovary HRO	66662	Intestinal disaccharidases INTD	66680
Hormones - human chorionic gonadotrophin - detection in pregnancy diagnosis HCG 735	or 27, 73529	Iron studies (iron, transferrin & ferritin) IS	66596
Hormones - human chorionic gonadotrophin - quantitation		Isoelectric focussing and electrophoresis - characterisation	
66650-666		cryoglobulins RY	71059
Hormones - hydroxyprogesterone OHP	66695	Isoelectric focussing and electrophoresis - characterisation	71059
Hormones - insulin INS	66695	paraprotein PPRO	/1039
Hormones - luteinizing hormone LH	66695	J	
Hormones - oestradiol E2	66695	ŭ	
Hormones - oestrone - E1	66695	Jo-1 - tissue antigens - antibodies JO1	71119
Hormones - parathyroid hormone PTH	66695	Jo 1 tissue untigens untitodates Jo 1	/111/
Hormones - progesterone PROG	66695	K	
Hormones - prolactin PROL	66695	•	
Hormones - renin	66695	Keratin - tissue antigens - antibodies KERA	71119
Hormones - sex hormone binding globulin SHBG Hormones - somatomedin SOMA	66695 66695	Kleihauer test KLEI	65162
Hormones - stimulation by exercise or L-dopa GHSE	66686	KRAS gene mutation status	73338
Hormones - summation by exercise of E-dopa GHSE Hormones - suppression by dexamethasone or glucose G		-	
suppression of denumentations of glucose of	66686	L	
Hormones - testosterone TES	66695		
Hormones - urine steroid fraction or fractions USF	66695	Lactate - dehydrogenase isoenzymes LDI	66641
Hormones - vasoactive intestinal peptide VIP	66695	Lactate - dehydrogenase LDH	66500
Hormones - vasopressin ADH	66695	Lactate LACT	66500

* # 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			
Lamellar body phospholipid LBPH	66749	Microbial antibody testing - Campylobacter jejuni CAM	69384
Lead PB	66665	Microbial antibody testing - Candida CAN	69384
Lecithin/sphingomyelin ratio (amniotic fluid) LS	66749	Microbial antibody testing - Chlamydia CHL	69384
Legionella pneumophila - serogroup 1 - microbial antibod		Microbial antibody testing - Coccidiodes CCC	69384
LP1	69384	Microbial antibody testing - Coxsackie B1-6 COX	69384
Legionella pneumophila - serogroup 2 - microbial antibod		Microbial antibody testing - cryptococcus CRY	69384
LP2	69384	Microbial antibody testing - cytomegalovirus CMV	69384
Leishmaniasis - microbial antibody testing LEI	69384	Microbial antibody testing - cytomegalovirus serology in	
Leptospira - microbial antibody testing LEP	69384	pregnancy CMVP	69384
Leucocyte count - 3 surface markers - blood, CSF, serous		Microbial antibody testing - dengue DEN	69384
LMH3	71139	Microbial antibody testing - diphtheria DIP	69384
Leucocyte count - 3 surface markers - tissue LMT3	71141	Microbial antibody testing - echinococcus ECC	69384
Leucocyte count - 6 surface markers - blood, CSF, serous		Microbial antibody testing - echo-coxsackie group ECH	69384
tissue(s) LMHT	71145	Microbial antibody testing - Entamoeba histolytica AMO	69384
Leucocyte count - 6 surface markers - blood, CSF, serous		Microbial antibody testing - Epstein Barr virus EBV	69474
tissue LM6	71143	Microbial antibody testing - Eptein Barr virus EBV	69472
Leucocyte count - CD34 surface marker only - blood LM0	CD34	Microbial antibody testing - fluorescent treponemal antibody	
	71146	absorption test (69384
Leucocyte count WCC	65070	Microbial antibody testing - Haemophilus influenzae HUS	69384
Light chains - free kappa or lambda LCHS	71200	Microbial antibody testing - herpes simplex virus HPA	69384
Lignocaine LIGN	66800	Microbial antibody testing - Histoplasma HIP	69384
Lip - cytology on specimens from SMCY	73043	Microbial antibody testing - Human Immunodeficiency Vin	us
Lipase LIP	66500		69384
Lipid studies (see test groups at para PQ.4)	66500	Microbial antibody testing - hydatid HYD	69384
Lipoprotein subclasses - electrophoresis LEPG	66539	Microbial antibody testing - infectious mononucleosis IM	69384
Listeria - microbial antibody testing LIS	69384	Microbial antibody testing - influenza A FLA	69384
Lithium LI	66800	Microbial antibody testing - influenza B FLB	69384
Liver/kidney microsomes - tissue antigens - antibodies LK	A71119	Microbial antibody testing - Legionella pneumophila - sero	group 1
Lupus anticoagulant LUPA 6513	7, 65142	LP1	69384
Luteinizing hormone LH	66695	Microbial antibody testing - Legionella pneumophila - sero	group 2
Lymphocytes - functional tests - 1 test LF1	71127	LP2	69384
Lymphocytes - functional tests - 2 test LF2	71129	Microbial antibody testing - leishmaniasis LEI	69384
Lymphocytes - functional tests - 2 test LF2 Lymphocytes - functional tests - 3 tests LF3	71129 71131	Microbial antibody testing - leishmaniasis LEI Microbial antibody testing - Leptospira LEP	69384 69384
		Microbial antibody testing - Leptospira LEP	69384
Lymphocytes - functional tests - 3 tests LF3		Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS	69384 69384
Lymphocytes - functional tests - 3 tests LF3	71131	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA	69384 69384 69384
Lymphocytes - functional tests - 3 tests LF3 M Magnesium MG	71131 66500	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA Microbial antibody testing - Micropolyspora faeni MIC	69384 69384 69384 69384 69384
Lymphocytes - functional tests - 3 tests LF3 M Magnesium MG Mammary serum antigen MSA	71131 66500 66650	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA Microbial antibody testing - Micropolyspora faeni MIC Microbial antibody testing - mumps MUM Microbial antibody testing - Murray Valley encephalitis M	69384 69384 69384 69384 VE 69384
Lymphocytes - functional tests - 3 tests LF3 M Magnesium MG Mammary serum antigen MSA Mantoux test MANT	71131 66500 66650 73811	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA Microbial antibody testing - Micropolyspora faeni MIC Microbial antibody testing - mumps MUM	69384 69384 69384 69384 VE 69384
Lymphocytes - functional tests - 3 tests LF3 M Magnesium MG Mammary serum antigen MSA Mantoux test MANT Mast cell disease	71131 66500 66650 73811 73326	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA Microbial antibody testing - Micropolyspora faeni MIC Microbial antibody testing - mumps MUM Microbial antibody testing - Murray Valley encephalitis M	69384 69384 69384 69384 VE 69384
Lymphocytes - functional tests - 3 tests LF3 M Magnesium MG Mammary serum antigen MSA Mantoux test MANT Mast cell disease Measles - microbial antigen testing MEA	71131 66500 66650 73811 73326 69384	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA Microbial antibody testing - Micropolyspora faeni MIC Microbial antibody testing - mumps MUM Microbial antibody testing - Murray Valley encephalitis M Microbial antibody testing - Mycoplasma pneumoniae MY	69384 69384 69384 69384 69384 VE 69384 C69384
Lymphocytes - functional tests - 3 tests LF3 M Magnesium MG Mammary serum antigen MSA Mantoux test MANT Mast cell disease Measles - microbial antigen testing MEA Metabolic bone disease CBMB	71131 66500 66650 73811 73326 69384 66776	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA Microbial antibody testing - Micropolyspora faeni MIC Microbial antibody testing - mumps MUM Microbial antibody testing - Murray Valley encephalitis M Microbial antibody testing - Mycoplasma pneumoniae MY Microbial antibody testing - Neisseria meningitidis MEN Microbial antibody testing - Newcastle disease NCD	69384 69384 69384 69384 VE 69384 C69384 69384
Lymphocytes - functional tests - 3 tests LF3 M Magnesium MG Mammary serum antigen MSA Mantoux test MANT Mast cell disease Measles - microbial antigen testing MEA Metabolic bone disease CBMB Metanephrines MNEP	71131 66500 66650 73811 73326 69384 66776 66779	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA Microbial antibody testing - Micropolyspora faeni MIC Microbial antibody testing - mumps MUM Microbial antibody testing - Murray Valley encephalitis M Microbial antibody testing - Mycoplasma pneumoniae MY Microbial antibody testing - Neisseria meningitidis MEN	69384 69384 69384 69384 VE 69384 C69384 69384 69384
Magnesium MG Magnesium MG Mammary serum antigen MSA Mantoux test MANT Mast cell disease Measles - microbial antigen testing MEA Metabolic bone disease CBMB Metanephrines MNEP Methadone MTDN	71131 66500 66650 73811 73326 69384 66776 66779 66812	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA Microbial antibody testing - Micropolyspora faeni MIC Microbial antibody testing - mumps MUM Microbial antibody testing - Murray Valley encephalitis M Microbial antibody testing - Mycoplasma pneumoniae MY Microbial antibody testing - Neisseria meningitidis MEN Microbial antibody testing - Newcastle disease NCD Microbial antibody testing - parainfluenza 1 PF1	69384 69384 69384 69384 VE 69384 C69384 69384 69384 69384
M Magnesium MG Mammary serum antigen MSA Mantoux test MANT Mast cell disease Measles - microbial antigen testing MEA Metabolic bone disease CBMB Metanephrines MNEP Methadone MTDN Methaemalbumin detection (Schumm's test) SCHM	71131 66500 66650 73811 73326 69384 66776 66779 66812 65117	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA Microbial antibody testing - Micropolyspora faeni MIC Microbial antibody testing - mumps MUM Microbial antibody testing - Murray Valley encephalitis M Microbial antibody testing - Mycoplasma pneumoniae MY Microbial antibody testing - Neisseria meningitidis MEN Microbial antibody testing - Newcastle disease NCD Microbial antibody testing - parainfluenza 1 PF1 Microbial antibody testing - parainfluenza 2 PF2 Microbial antibody testing - parainfluenza 3 PF3	69384 69384 69384 69384 VE 69384 C69384 69384 69384 69384
M Magnesium MG Mammary serum antigen MSA Mantoux test MANT Mast cell disease Measles - microbial antigen testing MEA Metabolic bone disease CBMB Metanephrines MNEP Methadone MTDN Methaemalbumin detection (Schumm's test) SCHM Methotrextate MTTA	71131 66500 66650 73811 73326 69384 66776 66779 66812 65117 66812	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA Microbial antibody testing - Micropolyspora faeni MIC Microbial antibody testing - mumps MUM Microbial antibody testing - Murray Valley encephalitis M Microbial antibody testing - Mycoplasma pneumoniae MY Microbial antibody testing - Neisseria meningitidis MEN Microbial antibody testing - Newcastle disease NCD Microbial antibody testing - parainfluenza 1 PF1 Microbial antibody testing - parainfluenza 2 PF2	69384 69384 69384 69384 VE 69384 C69384 69384 69384 69384 69384 69384
M Magnesium MG Mammary serum antigen MSA Mantoux test MANT Mast cell disease Measles - microbial antigen testing MEA Metabolic bone disease CBMB Metanephrines MNEP Methadone MTDN Methaemalbumin detection (Schumm's test) SCHM Methotrextate MTTA Methsuximide MSUX	71131 66500 66650 73811 73326 69384 66776 66779 66812 65117 66812 66812	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA Microbial antibody testing - Micropolyspora faeni MIC Microbial antibody testing - mumps MUM Microbial antibody testing - Murray Valley encephalitis M Microbial antibody testing - Mycoplasma pneumoniae MY Microbial antibody testing - Neisseria meningitidis MEN Microbial antibody testing - Newcastle disease NCD Microbial antibody testing - parainfluenza 1 PF1 Microbial antibody testing - parainfluenza 2 PF2 Microbial antibody testing - parainfluenza 3 PF3 Microbial antibody testing - paratyphi PTY	69384 69384 69384 69384 VE 69384 C69384 69384 69384 69384 69384 69384
M Magnesium MG Mammary serum antigen MSA Mantoux test MANT Mast cell disease Measles - microbial antigen testing MEA Metabolic bone disease CBMB Metanephrines MNEP Methadone MTDN Methaemalbumin detection (Schumm's test) SCHM Methotrextate MTTA Methsuximide MSUX Methylphenobarbitone MPBT	71131 66500 66650 73811 73326 69384 66776 66779 66812 65117 66812 66812 66812	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA Microbial antibody testing - Micropolyspora faeni MIC Microbial antibody testing - mumps MUM Microbial antibody testing - Murray Valley encephalitis M Microbial antibody testing - Mycoplasma pneumoniae MY Microbial antibody testing - Neisseria meningitidis MEN Microbial antibody testing - Newcastle disease NCD Microbial antibody testing - parainfluenza 1 PF1 Microbial antibody testing - parainfluenza 2 PF2 Microbial antibody testing - parainfluenza 3 PF3 Microbial antibody testing - paratyphi PTY Microbial antibody testing - pertussis PER	69384 69384 69384 69384 VE 69384 C69384 69384 69384 69384 69384 69384 69384
M Magnesium MG Mammary serum antigen MSA Mantoux test MANT Mast cell disease Measles - microbial antigen testing MEA Metabolic bone disease CBMB Metanephrines MNEP Methadone MTDN Methaemalbumin detection (Schumm's test) SCHM Methotrextate MTTA Methsuximide MSUX Methylphenobarbitone MPBT Metronidazole MRDZ	71131 66500 66650 73811 73326 69384 66776 66779 66812 66812 66812 66812 66812	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA Microbial antibody testing - Micropolyspora faeni MIC Microbial antibody testing - mumps MUM Microbial antibody testing - Murray Valley encephalitis M Microbial antibody testing - Mycoplasma pneumoniae MY Microbial antibody testing - Neisseria meningitidis MEN Microbial antibody testing - Newcastle disease NCD Microbial antibody testing - parainfluenza 1 PF1 Microbial antibody testing - parainfluenza 2 PF2 Microbial antibody testing - parainfluenza 3 PF3 Microbial antibody testing - paratyphi PTY Microbial antibody testing - pertussis PER Microbial antibody testing - poliomyelitis PLO	69384 69384 69384 69384 69384 VE 69384 69384 69384 69384 69384 69384 69384 69384
M Magnesium MG Mammary serum antigen MSA Mantoux test MANT Mast cell disease Measles - microbial antigen testing MEA Metabolic bone disease CBMB Metanephrines MNEP Methadone MTDN Methaemalbumin detection (Schumm's test) SCHM Methotrextate MTTA Methsuximide MSUX Methylphenobarbitone MPBT Metronidazole MRDZ Mexiletine (Mexitil) MEX	71131 66500 66650 73811 73326 69384 66776 66779 66812 66812 66812 66812 66812 66812	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA Microbial antibody testing - Micropolyspora faeni MIC Microbial antibody testing - mumps MUM Microbial antibody testing - Murray Valley encephalitis M Microbial antibody testing - Mycoplasma pneumoniae MY Microbial antibody testing - Neisseria meningitidis MEN Microbial antibody testing - Newcastle disease NCD Microbial antibody testing - parainfluenza 1 PF1 Microbial antibody testing - parainfluenza 2 PF2 Microbial antibody testing - parainfluenza 3 PF3 Microbial antibody testing - paratyphi PTY Microbial antibody testing - pertussis PER Microbial antibody testing - poliomyelitis PLO Microbial antibody testing - Proteus OX 19 POX Microbial antibody testing - Proteus OXK POK	69384 69384 69384 69384 VE 69384 C69384 69384 69384 69384 69384 69384 69384 69384 69384
M Magnesium MG Mammary serum antigen MSA Mantoux test MANT Mast cell disease Measles - microbial antigen testing MEA Metabolic bone disease CBMB Metanephrines MNEP Methadone MTDN Methaemalbumin detection (Schumm's test) SCHM Methotrextate MTTA Methsuximide MSUX Methylphenobarbitone MPBT Metronidazole MRDZ Mexiletine (Mexitil) MEX Mianserin MIAS	71131 66500 66650 73811 73326 69384 66776 66779 66812 65117 66812 66812 66812 66812 66812 66812	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA Microbial antibody testing - Micropolyspora faeni MIC Microbial antibody testing - mumps MUM Microbial antibody testing - Murray Valley encephalitis M Microbial antibody testing - Mycoplasma pneumoniae MY Microbial antibody testing - Neisseria meningitidis MEN Microbial antibody testing - Newcastle disease NCD Microbial antibody testing - parainfluenza 1 PF1 Microbial antibody testing - parainfluenza 2 PF2 Microbial antibody testing - parainfluenza 3 PF3 Microbial antibody testing - paratyphi PTY Microbial antibody testing - pertussis PER Microbial antibody testing - poliomyelitis PLO Microbial antibody testing - Proteus OX 19 POX	69384 69384 69384 69384 VE 69384 C69384 69384 69384 69384 69384 69384 69384 69384 69384 69384
M Magnesium MG Mammary serum antigen MSA Mantoux test MANT Mast cell disease Measles - microbial antigen testing MEA Metabolic bone disease CBMB Metanephrines MNEP Methadone MTDN Methaemalbumin detection (Schumm's test) SCHM Methotrextate MTTA Methsuximide MSUX Methylphenobarbitone MPBT Metronidazole MRDZ Mexiletine (Mexitil) MEX Mianserin MIAS Microalbumin MALB	71131 66500 66650 73811 73326 69384 66776 66779 66812 65117 66812 66812 66812 66812 66812 66812 66812 66812	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA Microbial antibody testing - Micropolyspora faeni MIC Microbial antibody testing - mumps MUM Microbial antibody testing - Murray Valley encephalitis M Microbial antibody testing - Mycoplasma pneumoniae MY Microbial antibody testing - Neisseria meningitidis MEN Microbial antibody testing - Newcastle disease NCD Microbial antibody testing - parainfluenza 1 PF1 Microbial antibody testing - parainfluenza 2 PF2 Microbial antibody testing - parainfluenza 3 PF3 Microbial antibody testing - paratyphi PTY Microbial antibody testing - pertussis PER Microbial antibody testing - poliomyelitis PLO Microbial antibody testing - Proteus OX 19 POX Microbial antibody testing - Proteus OXK POK Microbial antibody testing - Q fever QFF	69384 69384 69384 69384 VE 69384 C69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384
M Magnesium MG Mammary serum antigen MSA Mantoux test MANT Mast cell disease Measles - microbial antigen testing MEA Metabolic bone disease CBMB Metanephrines MNEP Methadone MTDN Methaemalbumin detection (Schumm's test) SCHM Methotrextate MTTA Methsuximide MSUX Methylphenobarbitone MPBT Metronidazole MRDZ Mexiletine (Mexitil) MEX Mianserin MIAS Microalbumin MALB Microbial antibody testing - Varicella zoster VCZ	71131 66500 66650 73811 73326 69384 66776 66779 66812 65117 66812 66812 66812 66812 66812 66812 66812 66812 66812 66812	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA Microbial antibody testing - Micropolyspora faeni MIC Microbial antibody testing - mumps MUM Microbial antibody testing - Murray Valley encephalitis M Microbial antibody testing - Mycoplasma pneumoniae MY Microbial antibody testing - Neisseria meningitidis MEN Microbial antibody testing - Newcastle disease NCD Microbial antibody testing - parainfluenza 1 PF1 Microbial antibody testing - parainfluenza 2 PF2 Microbial antibody testing - parainfluenza 3 PF3 Microbial antibody testing - paratyphi PTY Microbial antibody testing - pertussis PER Microbial antibody testing - poliomyelitis PLO Microbial antibody testing - Proteus OX 19 POX Microbial antibody testing - Proteus OXK POK Microbial antibody testing - Proteus OXK POK Microbial antibody testing - rapid plasma reagin test RPR Microbial antibody testing - respiratory syncytial virus RSN	69384 69384 69384 69384 VE 69384 C69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384
M Magnesium MG Mammary serum antigen MSA Mantoux test MANT Mast cell disease Measles - microbial antigen testing MEA Metabolic bone disease CBMB Metanephrines MNEP Methadone MTDN Methaemalbumin detection (Schumm's test) SCHM Methotrextate MTTA Methsuximide MSUX Methylphenobarbitone MPBT Metronidazole MRDZ Mexiletine (Mexitil) MEX Mianserin MIAS Microalbumin MALB Microbial antibody testing - Varicella zoster VCZ Microbial antibody testing - actinomyetes ACT	71131 66500 66650 73811 73326 69384 66776 66779 66812 65117 66812 66812 66812 66812 66812 66812 66812 66812 66814 66816 69384 69384	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA Microbial antibody testing - Micropolyspora faeni MIC Microbial antibody testing - mumps MUM Microbial antibody testing - Murray Valley encephalitis M Microbial antibody testing - Mycoplasma pneumoniae MY Microbial antibody testing - Neisseria meningitidis MEN Microbial antibody testing - Newcastle disease NCD Microbial antibody testing - parainfluenza 1 PF1 Microbial antibody testing - parainfluenza 2 PF2 Microbial antibody testing - parainfluenza 3 PF3 Microbial antibody testing - paratyphi PTY Microbial antibody testing - pertussis PER Microbial antibody testing - poliomyelitis PLO Microbial antibody testing - Proteus OX 19 POX Microbial antibody testing - Proteus OXK POK Microbial antibody testing - Proteus OXK POK Microbial antibody testing - rapid plasma reagin test RPR Microbial antibody testing - respiratory syncytial virus RSV Microbial antibody testing - Ross River virus RRV	69384 69384 69384 69384 VE 69384 C69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384
M Magnesium MG Mammary serum antigen MSA Mantoux test MANT Mast cell disease Measles - microbial antigen testing MEA Metabolic bone disease CBMB Metanephrines MNEP Methadone MTDN Methaemalbumin detection (Schumm's test) SCHM Methotrextate MTTA Methsuximide MSUX Methylphenobarbitone MPBT Metronidazole MRDZ Mexiletine (Mexitil) MEX Mianserin MIAS Microalbumin MALB Microbial antibody testing - Varicella zoster VCZ Microbial antibody testing - adenovirus ADE	71131 66500 66650 73811 73326 69384 66776 66779 66812 65117 66812 66812 66812 66812 66812 66812 66812 66812 66814 669384 69384 69384	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA Microbial antibody testing - Micropolyspora faeni MIC Microbial antibody testing - mumps MUM Microbial antibody testing - Murray Valley encephalitis M Microbial antibody testing - Mycoplasma pneumoniae MY Microbial antibody testing - Neisseria meningitidis MEN Microbial antibody testing - Newcastle disease NCD Microbial antibody testing - parainfluenza 1 PF1 Microbial antibody testing - parainfluenza 2 PF2 Microbial antibody testing - parainfluenza 3 PF3 Microbial antibody testing - paratyphi PTY Microbial antibody testing - pertussis PER Microbial antibody testing - poliomyelitis PLO Microbial antibody testing - Proteus OX 19 POX Microbial antibody testing - Proteus OXK POK Microbial antibody testing - Proteus OXK POK Microbial antibody testing - rapid plasma reagin test RPR Microbial antibody testing - respiratory syncytial virus RSV Microbial antibody testing - Ross River virus RRV Microbial antibody testing - rubella RUB	69384 69384 69384 69384 VE 69384 C69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384
M Magnesium MG Mammary serum antigen MSA Mantoux test MANT Mast cell disease Measles - microbial antigen testing MEA Metabolic bone disease CBMB Metanephrines MNEP Methadone MTDN Methaemalbumin detection (Schumm's test) SCHM Methotrextate MTTA Methsuximide MSUX Methylphenobarbitone MPBT Metronidazole MRDZ Mexiletine (Mexitil) MEX Mianserin MIAS Microalbumin MALB Microbial antibody testing - Varicella zoster VCZ Microbial antibody testing - adenovirus ADE Microbial antibody testing - aspergillus ASP	71131 66500 66650 73811 73326 69384 66776 66779 66812 65117 66812 66812 66812 66812 66812 66812 66812 66814 69384 69384 69384	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA Microbial antibody testing - Micropolyspora faeni MIC Microbial antibody testing - mumps MUM Microbial antibody testing - Murray Valley encephalitis M Microbial antibody testing - Mycoplasma pneumoniae MY Microbial antibody testing - Neisseria meningitidis MEN Microbial antibody testing - Newcastle disease NCD Microbial antibody testing - parainfluenza 1 PF1 Microbial antibody testing - parainfluenza 2 PF2 Microbial antibody testing - parainfluenza 3 PF3 Microbial antibody testing - paratyphi PTY Microbial antibody testing - pertussis PER Microbial antibody testing - poliomyelitis PLO Microbial antibody testing - Proteus OX 19 POX Microbial antibody testing - Proteus OXK POK Microbial antibody testing - Proteus OXK POK Microbial antibody testing - rapid plasma reagin test RPR Microbial antibody testing - respiratory syncytial virus RSV Microbial antibody testing - Ross River virus RRV Microbial antibody testing - rubella RUB Microbial antibody testing - Salmonella typhi (H) SAH	69384 69384 69384 69384 VE 69384 C69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384
M Magnesium MG Mammary serum antigen MSA Mantoux test MANT Mast cell disease Measles - microbial antigen testing MEA Metabolic bone disease CBMB Metanephrines MNEP Methadone MTDN Methaemalbumin detection (Schumm's test) SCHM Methotrextate MTTA Methsuximide MSUX Methylphenobarbitone MPBT Metronidazole MRDZ Mexiletine (Mexitil) MEX Mianserin MIAS Microalbumin MALB Microbial antibody testing - actinomyetes ACT Microbial antibody testing - aspergillus ASP Microbial antibody testing - avian precipitins (bird fancier	71131 66500 66650 73811 73326 69384 66776 66779 66812 65117 66812 66812 66812 66812 66812 66812 66812 66814 69384 69384 69384 69384	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA Microbial antibody testing - Micropolyspora faeni MIC Microbial antibody testing - mumps MUM Microbial antibody testing - Murray Valley encephalitis M Microbial antibody testing - Mycoplasma pneumoniae MY Microbial antibody testing - Neisseria meningitidis MEN Microbial antibody testing - Newcastle disease NCD Microbial antibody testing - parainfluenza 1 PF1 Microbial antibody testing - parainfluenza 2 PF2 Microbial antibody testing - parainfluenza 3 PF3 Microbial antibody testing - paratyphi PTY Microbial antibody testing - pertussis PER Microbial antibody testing - proteus OX 19 POX Microbial antibody testing - Proteus OXK POK Microbial antibody testing - Proteus OXK POK Microbial antibody testing - rapid plasma reagin test RPR Microbial antibody testing - respiratory syncytial virus RSV Microbial antibody testing - Ross River virus RRV Microbial antibody testing - Ross River virus RRV Microbial antibody testing - Salmonella typhi (H) SAH Microbial antibody testing - Salmonella typhi (O) SAO	69384 69384 69384 69384 VE 69384 C69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384
M Magnesium MG Mammary serum antigen MSA Mantoux test MANT Mast cell disease Measles - microbial antigen testing MEA Metabolic bone disease CBMB Metanephrines MNEP Methadone MTDN Methaemalbumin detection (Schumm's test) SCHM Methotrextate MTTA Methsuximide MSUX Methylphenobarbitone MPBT Metronidazole MRDZ Mexiletine (Mexitil) MEX Mianserin MIAS Microalbumin MALB Microbial antibody testing - actinomyetes ACT Microbial antibody testing - aspergillus ASP Microbial antibody testing - avian precipitins (bird fancier disease) APP	71131 66500 66650 73811 73326 69384 66776 66779 66812 65117 66812 66812 66812 66812 66812 66812 66812 66814 69384 69384 69384 69384 69384	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA Microbial antibody testing - Micropolyspora faeni MIC Microbial antibody testing - mumps MUM Microbial antibody testing - Murray Valley encephalitis M Microbial antibody testing - Mycoplasma pneumoniae MY Microbial antibody testing - Neisseria meningitidis MEN Microbial antibody testing - Newcastle disease NCD Microbial antibody testing - parainfluenza 1 PF1 Microbial antibody testing - parainfluenza 2 PF2 Microbial antibody testing - parainfluenza 3 PF3 Microbial antibody testing - paratyphi PTY Microbial antibody testing - pertussis PER Microbial antibody testing - poliomyelitis PLO Microbial antibody testing - Proteus OX 19 POX Microbial antibody testing - Proteus OXK POK Microbial antibody testing - Proteus OXK POK Microbial antibody testing - rapid plasma reagin test RPR Microbial antibody testing - respiratory syncytial virus RSV Microbial antibody testing - Ross River virus RRV Microbial antibody testing - Ross River virus RRV Microbial antibody testing - Salmonella typhi (H) SAH Microbial antibody testing - Salmonella typhi (O) SAO Microbial antibody testing - Schistosoma STO	69384 69384 69384 69384 VE 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384
M Magnesium MG Mammary serum antigen MSA Mantoux test MANT Mast cell disease Measles - microbial antigen testing MEA Metabolic bone disease CBMB Metanephrines MNEP Methadone MTDN Methaemalbumin detection (Schumm's test) SCHM Methotrextate MTTA Methsuximide MSUX Methylphenobarbitone MPBT Metronidazole MRDZ Mexiletine (Mexitil) MEX Mianserin MIAS Microalbumin MALB Microbial antibody testing - actinomyetes ACT Microbial antibody testing - aspergillus ASP Microbial antibody testing - avian precipitins (bird fancier disease) APP Microbial antibody testing - Blastomyces BLM	71131 66500 66650 73811 73326 69384 66776 66779 66812 65117 66812 66812 66812 66812 66812 66812 66812 66818 66818 66818 66818 66818 69384 69384 69384 69384	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA Microbial antibody testing - Micropolyspora faeni MIC Microbial antibody testing - mumps MUM Microbial antibody testing - Murray Valley encephalitis M Microbial antibody testing - Mycoplasma pneumoniae MY Microbial antibody testing - Neisseria meningitidis MEN Microbial antibody testing - Newcastle disease NCD Microbial antibody testing - parainfluenza 1 PF1 Microbial antibody testing - parainfluenza 2 PF2 Microbial antibody testing - parainfluenza 3 PF3 Microbial antibody testing - paratyphi PTY Microbial antibody testing - pertussis PER Microbial antibody testing - proteus OX 19 POX Microbial antibody testing - Proteus OXK POK Microbial antibody testing - Proteus OXK POK Microbial antibody testing - rapid plasma reagin test RPR Microbial antibody testing - respiratory syncytial virus RSV Microbial antibody testing - Ross River virus RRV Microbial antibody testing - Ross River virus RRV Microbial antibody testing - Salmonella typhi (H) SAH Microbial antibody testing - Salmonella typhi (O) SAO	69384 69384 69384 69384 VE 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384
M Magnesium MG Mammary serum antigen MSA Mantoux test MANT Mast cell disease Measles - microbial antigen testing MEA Metabolic bone disease CBMB Metanephrines MNEP Methadone MTDN Methaemalbumin detection (Schumm's test) SCHM Methotrextate MTTA Methsuximide MSUX Methylphenobarbitone MPBT Metronidazole MRDZ Mexiletine (Mexitil) MEX Mianserin MIAS Microalbumin MALB Microbial antibody testing - actinomyetes ACT Microbial antibody testing - adenovirus ADE Microbial antibody testing - avian precipitins (bird fancier disease) APP Microbial antibody testing - Blastomyces BLM Microbial antibody testing - Bordetella pertussis BOR	71131 66500 66650 73811 73326 69384 66776 66779 66812 65117 66812 66812 66812 66812 66812 66812 66812 66814 69384 69384 69384 69384 69384 69384	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA Microbial antibody testing - Micropolyspora faeni MIC Microbial antibody testing - mumps MUM Microbial antibody testing - Murray Valley encephalitis M Microbial antibody testing - Mycoplasma pneumoniae MY Microbial antibody testing - Neisseria meningitidis MEN Microbial antibody testing - Newcastle disease NCD Microbial antibody testing - parainfluenza 1 PF1 Microbial antibody testing - parainfluenza 2 PF2 Microbial antibody testing - parainfluenza 3 PF3 Microbial antibody testing - paratyphi PTY Microbial antibody testing - pertussis PER Microbial antibody testing - proteus OX 19 POX Microbial antibody testing - Proteus OXK POK Microbial antibody testing - Proteus OXK POK Microbial antibody testing - rapid plasma reagin test RPR Microbial antibody testing - respiratory syncytial virus RSV Microbial antibody testing - Ross River virus RRV Microbial antibody testing - Ross River virus RRV Microbial antibody testing - Salmonella typhi (H) SAH Microbial antibody testing - Salmonella typhi (O) SAO Microbial antibody testing - Schistosoma STO Microbial antibody testing - streptococcal serology - anti D B titre ADNB	69384 69384 69384 69384 VE 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 89384 89384 89384 89384 89384 89384 89384
M Magnesium MG Mammary serum antigen MSA Mantoux test MANT Mast cell disease Measles - microbial antigen testing MEA Metabolic bone disease CBMB Metanephrines MNEP Methadone MTDN Methaemalbumin detection (Schumm's test) SCHM Methotrextate MTTA Methsuximide MSUX Methylphenobarbitone MPBT Metronidazole MRDZ Mexiletine (Mexitil) MEX Mianserin MIAS Microalbumin MALB Microbial antibody testing - actinomyetes ACT Microbial antibody testing - aspergillus ASP Microbial antibody testing - avian precipitins (bird fancier disease) APP Microbial antibody testing - Blastomyces BLM	71131 66500 66650 73811 73326 69384 66776 66779 66812 65117 66812 66812 66812 66812 66812 66812 66812 66818 66818 66818 66818 66818 69384 69384 69384 69384	Microbial antibody testing - Leptospira LEP Microbial antibody testing - Listeria LIS Microbial antibody testing - measles MEA Microbial antibody testing - Micropolyspora faeni MIC Microbial antibody testing - mumps MUM Microbial antibody testing - Murray Valley encephalitis M Microbial antibody testing - Mycoplasma pneumoniae MY Microbial antibody testing - Neisseria meningitidis MEN Microbial antibody testing - Newcastle disease NCD Microbial antibody testing - parainfluenza 1 PF1 Microbial antibody testing - parainfluenza 2 PF2 Microbial antibody testing - parainfluenza 3 PF3 Microbial antibody testing - paratyphi PTY Microbial antibody testing - pertussis PER Microbial antibody testing - poliomyelitis PLO Microbial antibody testing - Proteus OX 19 POX Microbial antibody testing - Proteus OXK POK Microbial antibody testing - Proteus OXK POK Microbial antibody testing - rapid plasma reagin test RPR Microbial antibody testing - respiratory syncytial virus RSV Microbial antibody testing - Ross River virus RRV Microbial antibody testing - Ross River virus RRV Microbial antibody testing - Salmonella typhi (H) SAH Microbial antibody testing - Salmonella typhi (O) SAO Microbial antibody testing - Schistosoma STO Microbial antibody testing - streptococcal serology - anti D	69384 69384 69384 69384 VE 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 69384 89384 89384 89384 89384 89384 89384 89384

Microbial antibody testing - tetanus TET 69384 Microbial antibody testing - Thermoactinomyces vulgaris THE Microbial antibody testing - Thermoactinomyces vulgaris THE Microbial antibody testing - thermopolyspora TPS 69384 Microbial antibody testing - Toxocara TOC 69384 Microbial antibody testing - Toxocara TOX 69384 Microbial antibody testing - Toxoplasma TOX 69384 Microbial antibody testing - TPHA (Treponema pallidum haemagglutination test) TP 69384 Microbial antibody testing - Treponema pallidum haemagglutination test TPHA 69384 Microbial antibody testing - Trichinosis TOS 69384 Microbial antibody testing - trichinosis TOS 69384 Microbial antibody testing - typhus, Weil-Felix TYP 69384 Microbial antibody testing - VDRL (Venereal Disease Research Laboratory) VDRL Microbial antibody testing - Clostridium difficil CLDT 69363 Microscopic examination of - faeces for parasites OCP 69336 Microscopy & culture of - material from nose, throat, eye or ear MCSW Microscopy & culture of - material from skin MCSK 69309 Microscopy & culture of - postoperative wounds, aspirates of body cavities MCPO Microscopy & culture of - specimens of sputum MCSP 69318 Microscopy & culture of - specimens of sputum MCSP 69318 Microscopy & culture of - specimens of sputum, urine or other Microbial antibody testing - Clostridium difficil CLDT 69363 Microscopy & culture of - specimens of sputum MCSP 69318 Microscopy & culture of - specimens of sputum, urine or other Microbial antibody testing - Clostridium difficil CLDT 69363 Microscopy & culture of - specimens of sputum MCSP 69318 Microscopy & culture of - specimens of sputum, urine or other Microbial antibody testing - Clostridium difficil CLDT 69363 Microscopy & culture of - specimens of sputum MCSP 69318 Microscopy & culture of - specimens or sputum MCSP 69318 Microscopy & culture of - specimens or sputum MCSP 69318 Microscopy & culture of - specimens or sputum MCSP 69318 Microscopy & culture of - specimens or sputum MCSP 69318 Microscopy & culture of - specimens or sputum MCSP 69318 Mic
Microbial antibody testing - Thermoactinomyces vulgaris THE 69384 Microbial antibody testing - thermopolyspora TPS 69384 Microbial antibody testing - Toxocara TOC 69384 Microbial antibody testing - toxoplasma TOX 69384 Microbial antibody testing - TPHA (Treponema pallidum haemagglutination test TPH 69384 Microbial antibody testing - Treponema pallidum haemagglutination test TPHA (Treponema pallidum haemagglutination test TPHA (Spane Paramination of Facces for parasites OCP 69363 Microscopic examination of - facces for parasites OCP 69303 Microscopy & culture of - material from skin MCSK 69309 Microscopy & culture of - material from skin MCSK 69309 Microscopy & culture of - postoperative wounds, aspirates of body cavities MCPO 69321 Microscopy & culture of - specimens of sputum MCSP 69318 Microscopy & culture of - specimens of sputum, urine or other 1000 Microscopy & culture of - specimens of sputum, urine or other 1000 Microscopy & culture of - specimens of sputum, urine or other 1000 MCPO 1
Microbial antibody testing - Toxocara TOC 69384 Microbial antibody testing - Toxocara TOC 69384 Microbial antibody testing - Toxocara TOC 69384 Microbial antibody testing - TPHA (Treponema pallidum haemagglutination test) TP 69384 Microbial antibody testing - Treponema pallidum haemagglutination test) TP 69384 Microbial antibody testing - Treponema pallidum haemagglutination test TPHA 69384 Microbial antibody testing - trichinosis TOS 69384 Microbial antibody testing - trichinosis TOS 69384 Microbial antibody testing - typhus, Weil-Felix TYP 69384 Microbial antibody testing - VDRL (Venereal Disease Research Laboratory) VDRL 69384 Microscopic examination of - faeces for parasites OCP 69366 Microscopy & culture of - material from nose, throat, eye or ear MCSW 69309 Microscopy & culture of - material from skin MCSK 69309 Microscopy & culture of - material from skin MCSK 69309 Microscopy & culture of - postoperative wounds, aspirates of body cavities MCPO Microscopy & culture of - specimens of sputum MCSP 69318 Microscopy & culture of - specimens of sputum MCSP 69318 Microscopy & culture of - specimens of sputum, urine or other
Microbial antibody testing - Toxocara TOC 69384 Microbial antibody testing - toxoplasma TOX 69384 Microbial antibody testing - TPHA (Treponema pallidum haemagglutination test) TP 69384 Microbial antibody testing - Treponema pallidum haemagglutination test TPHA 69384 Microbial antibody testing - trichinosis TOS 69384 Microbial antibody testing - trichinosis TOS 69384 Microbial antibody testing - typhus, Weil-Felix TYP 69384 Microbial antibody testing - VDRL (Venereal Disease Research Laboratory) VDRL 69384 Microbial antibody testing - Clostridium difficile CLDT 69363 Microscopic examination of - faeces for parasites OCP 69384 Microscopy & culture of - material from nose, throat, eye or ear MCSW 69303 Microscopy & culture of - material from skin MCSK 69309 Microscopy & culture of - postoperative wounds, aspirates of body cavities MCPO Microscopy & culture of - specimens of sputum MCSP 69318 Microscopy & culture of - specimens of sputum, urine or other MCPO Op/biopsy specimens - microscopy & culture of material from MCPO Oral glucose tolerance test - gestational diabetes GTTP 66542 Osmolality, serum or urine OSML Oxalate OXAL Oxazepam OXAZ PAA (phenyl acetic acid) PAA Parainfluenza 1 - microbial antibody testing PF1 PAA (phenyl acetic acid) PAA Parainfluenza 2 - microbial antibody testing PF2 Parainfluenza 2 - microbial antibody testing PF2 Parainfluenza 3 - microbial antibody testing PF2 Parainfluenza 3 - microbial antibody testing PF3 Paraprotein characterisation - by electrophoresis, and immunoelectrophoresis or Paraprotein characterisation - on concurrently collected serum or urine OSML Oxalate OXAL Oxazepam OXAZ PAA (phenyl acetic acid) PAA Parainfluenza 1 - microbial antibody testing PF2 Parainfluenza 2 - microbial antibody testing PF3 Paraprotein characterisation - by electrophoresis, and immunoelectrophoresis or Paraprotein characterisation - on concurrently collected serum or urine PSEU
Microbial antibody testing - toxoplasma TOX 69384 Microbial antibody testing - TPHA (Treponema pallidum haemagglutination test) TP 69384 Microbial antibody testing - Treponema pallidum haemagglutination test TPHA 69384 Microbial antibody testing - trichinosis TOS 69384 Microbial antibody testing - trichinosis TOS 69384 Microbial antibody testing - typhus, Weil-Felix TYP 69384 Microbial antibody testing - VDRL (Venereal Disease Research Laboratory) VDRL 69384 Microbial antibody testing - Yersinia entercolitica YER 69384 Microbial antibody testing - Clostridium difficile CLDT 69363 Microscopic examination of - faeces for parasites OCP 69336 Microscopy & culture of - material from nose, throat, eye or ear MCSW 69303 Microscopy & culture of - material from skin MCSK 69309 Microscopy & culture of - postoperative wounds, aspirates of body cavities MCPO 69318 Microscopy & culture of - specimens of sputum MCSP 69318 Microscopy & culture of - specimens of sputum, urine or other 71060
Microbial antibody testing - TPHA (Treponema pallidum haemagglutination test) TP 69384 Microbial antibody testing - Treponema pallidum haemagglutination test TPHA 69384 Microbial antibody testing - trichinosis TOS 69384 Microbial antibody testing - trichinosis TOS 69384 Microbial antibody testing - typhus, Weil-Felix TYP 69384 Microbial antibody testing - VDRL (Venereal Disease Research Laboratory) VDRL 69384 Microbial antibody testing - VPRL (Venereal Disease Research Laboratory) VDRL 69384 Microbial antibody testing - Clostridium difficile CLDT 69363 Microscopic examination of - faeces for parasites OCP 69336 Microscopy & culture of - material from nose, throat, eye or ear MCSW 69303 Microscopy & culture of - material from skin MCSK 69309 Microscopy & culture of - material from skin MCSK 69309 Microscopy & culture of - postoperative wounds, aspirates of body cavities MCPO 69318 Microscopy & culture of - specimens of sputum MCSP 69318 Microscopy & culture of - specimens of sputum, urine or other 69321 Microscopy & culture of - specimens of sputum, urine or other 69321 MCPO 69384 Oral glucose challenge test - gestational diabetes OGCT 66545 Oral glucose tolerance test - gestational diabetes OGCT 66545 Oral glucose tolerance test - gestational diabetes OGCT 66542 Osmolality, serum or urine OSML 66563 Oxalate OXAL Oxazepam OXAZ PAA (phenyl acetic acid) PAA Palmitic acid in amniotic fluid PALM 66749 Parainfluenza 1 - microbial antibody testing PF1 69384 Parainfluenza 2 - microbial antibody testing PF2 69384 Parainfluenza 3 - microbial antibody testing PF3 69384 Parainfluenza 3 - microbial antibody testing PF3 69384 Paraprotein characterisation - by electrophoresis, and immunoelectrophoresis or 71059 Paraprotein characterisation - on concurrently collected serum or rother research coral glucose tolerance test - gestational diabetes OGCT Oral glucose
haemagglutination test) TP Microbial antibody testing - Treponema pallidum haemagglutination test TPHA Microbial antibody testing - trichinosis TOS Microbial antibody testing - trichinosis TOS Microbial antibody testing - tryphus, Weil-Felix TYP Microbial antibody testing - VDRL (Venereal Disease Research Laboratory) VDRL Microbial antibody testing - VPRL (Venereal Disease Research Laboratory) VDRL Microbial antibody testing - Vorsinia entercolitica YER Microbial antibody testing - Vorsinia entercolitica YER Microscopic examination of - faeces for parasites OCP 69339 Microscopy & culture of - material from nose, throat, eye or ear MCSW Microscopy & culture of - material from skin MCSK 69303 Microscopy & culture of - postoperative wounds, aspirates of body cavities MCPO Microscopy & culture of - specimens of sputum MCSP Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other
Microbial antibody testing - Treponema pallidum haemagglutination test TPHA 69384 Microbial antibody testing - trichinosis TOS 69384 Microbial antibody testing - tryphus, Weil-Felix TYP 69384 Microbial antibody testing - VDRL (Venereal Disease Research Laboratory) VDRL Microbial antibody testing - Versinia entercolitica YER Microbial antibody testing - Clostridium difficile CLDT 69384 Microscopic examination of - faeces for parasites OCP 69339 Microscopy & culture of - material from nose, throat, eye or ear MCSW 69303 Microscopy & culture of - material from skin MCSK 69304 Microscopy & culture of - material from skin MCSK 69305 Microscopy & culture of - postoperative wounds, aspirates of body cavities MCPO 69318 Microscopy & culture of - specimens of sputum MCSP Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum or urine OSML Oxalate OXAL Oxalate OXAL Oxalet OXAL Oxalet OXAL Oxalet OXAL Oxalet OXAL Palmitic acid in
haemagglutination test TPHA 69384 Microbial antibody testing - trichinosis TOS 69384 Microbial antibody testing - typhus, Weil-Felix TYP 69384 Microbial antibody testing - VDRL (Venereal Disease Research Laboratory) VDRL 69384 Microbial antibody testing - Yersinia entercolitica YER 69384 Microbial antigen testing - Clostridium difficile CLDT 69363 Microscopic examination of - faeces for parasites OCP 69336 69339 Microscopy & culture of - material from nose, throat, eye or ear MCSW 69303 Microscopy & culture of - material from skin MCSK 69309 Microscopy & culture of - postoperative wounds, aspirates of body cavities MCPO 69321 Microscopy & culture of - specimens of sputum MCSP 69318 Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other
Microbial antibody testing - trichinosis TOS 69384 Microbial antibody testing - typhus, Weil-Felix TYP 69384 Microbial antibody testing - VDRL (Venereal Disease Research Laboratory) VDRL 69384 Microbial antibody testing - Yersinia entercolitica YER 69384 Microbial antigen testing - Clostridium difficile CLDT 69363 Microscopic examination of - faeces for parasites OCP 69336 Microscopy & culture of - material from nose, throat, eye or ear MCSW 69303 Microscopy & culture of - material from skin MCSK 69309 Microscopy & culture of - postoperative wounds, aspirates of body cavities MCPO 69321 Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other
Microbial antibody testing - typhus, Weil-Felix TYP 69384 Microbial antibody testing - VDRL (Venereal Disease Research Laboratory) VDRL 69384 Microbial antibody testing - Yersinia entercolitica YER 69384 Microbial antigen testing - Clostridium difficile CLDT 69363 Microscopic examination of - faeces for parasites OCP 69336 69339 Microscopy & culture of - material from nose, throat, eye or ear MCSW 69303 Microscopy & culture of - material from skin MCSK 69309 Microscopy & culture of - postoperative wounds, aspirates of body cavities MCPO 69321 Microscopy & culture of - specimens of sputum MCSP 69318 Microscopy & culture of - specimens of sputum, urine or other 66812 Oxazepam OXAZ FAA (phenyl acetic acid) PAA Parainfluenza 1 - microbial antibody testing PF1 Parainfluenza 2 - microbial antibody testing PF2 Parainfluenza 3 - microbial antibody testing PF3 Paraprotein characterisation - by electrophoresis, and immunoelectrophoresis or Paraprotein characterisation - on concurrently collected serum or urine PPSU Microscopy & culture of - specimens of sputum, urine or other 71060
Microbial antibody testing - VDRL (Venereal Disease Research Laboratory) VDRL 69384 Microbial antibody testing - Yersinia entercolitica YER 69384 Microbial antigen testing - Clostridium difficile CLDT 69363 Microscopic examination of - faeces for parasites OCP 69339 Microscopy & culture of - material from nose, throat, eye or ear MCSW 69303 Microscopy & culture of - material from skin MCSK 69309 Microscopy & culture of - postoperative wounds, aspirates of body cavities MCPO 69321 Microscopy & culture of - specimens of sputum MCSP Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other
Microbial antibody testing - Yersinia entercolitica YER 69384 Microbial antigen testing - Clostridium difficile CLDT 69363 Microscopic examination of - faeces for parasites OCP 69336 69339 Microscopy & culture of - material from nose, throat, eye or ear MCSW 69303 Microscopy & culture of - material from skin MCSK 69309 Microscopy & culture of - postoperative wounds, aspirates of body cavities MCPO 69321 Microscopy & culture of - specimens of sputum MCSP 69318 Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other
Microscopic examination of - faeces for parasites OCP 69366 Microscopy & culture of - material from nose, throat, eye or ear MCSW 69309 Microscopy & culture of - material from skin MCSK 69309 Microscopy & culture of - material from skin MCSK 69309 Microscopy & culture of - postoperative wounds, aspirates of body cavities MCPO 69321 Microscopy & culture of - specimens of sputum MCSP 69318 Microscopy & culture of - specimens of sputum, urine or other 69318 Microscopy & culture of - specimens of sputum, urine or other 69318 Microscopy & culture of - specimens of sputum, urine or other 69318 Microscopy & culture of - specimens of sputum, urine or other 69318 Microscopy & culture of - specimens of sputum, urine or other 71060
Microscopy & culture of - material from nose, throat, eye or ear MCSW Microscopy & culture of - material from skin MCSK Microscopy & culture of - material from skin MCSK Microscopy & culture of - postoperative wounds, aspirates of body cavities MCPO Microscopy & culture of - specimens of sputum MCSP Microscopy & culture of - specimens of sputum, urine or other PAR (phenyl acetic acid) PAR Paraictic acid in amniotic fluid PALM Paracetamol PARA Parainfluenza 1 - microbial antibody testing PF1 Parainfluenza 2 - microbial antibody testing PF2 Parainfluenza 3 - microbial antibody testing PF3 Paraprotein characterisation - by electrophoresis, and immunoelectrophoresis or PAR (phenyl acetic acid) PAR Palmitic acid in amniotic fluid PALM Paracetamol PARA Parainfluenza 1 - microbial antibody testing PF1 Parainfluenza 3 - microbial antibody testing PF2 Paraprotein characterisation - by electrophoresis, and immunoelectrophoresis or Paraprotein characterisation - on concurrently collected serum or urine PPSII
Microscopy & culture of - material from nose, throat, eye or ear MCSW Microscopy & culture of - material from skin MCSK Microscopy & culture of - material from skin MCSK Microscopy & culture of - postoperative wounds, aspirates of body cavities MCPO Microscopy & culture of - specimens of sputum MCSP Microscopy & culture of - specimens of sputum, urine or other Familite actul in animote fluid FALM Paracetamol PARA 66800 Parainfluenza 1 - microbial antibody testing PF1 Parainfluenza 2 - microbial antibody testing PF2 Parainfluenza 3 - microbial antibody testing PF3 Paraprotein characterisation - by electrophoresis, and immunoelectrophoresis or Paraprotein characterisation - on concurrently collected serum or Paracetamol PARA Paracetamol PARA 66800 Parainfluenza 1 - microbial antibody testing PF2 Paraprotein characterisation - by electrophoresis or Paraprotein characterisation - on concurrently collected serum or Paracetamol PARA
Microscopy & culture of - material from nose, throat, eye or ear MCSW Microscopy & culture of - material from skin MCSK Microscopy & culture of - material from skin MCSK Microscopy & culture of - postoperative wounds, aspirates of body cavities MCPO Microscopy & culture of - specimens of sputum MCSP Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - material from nose, throat, eye or ear MaxA Parainfluenza 1 - microbial antibody testing PF1 Parainfluenza 2 - microbial antibody testing PF3 Parainfluenza 3 - microbial antibody testing PF3 Parainfluenza 3 - microbial antibody testing PF3 Parainfluenza 3 - microbial antibody testing PF3 Parainfluenza 3 - microbial antibody testing PF3 Parainfluenza 3 - microbial antibody testing PF3 Parainfluenza 3 - microbial antibody testing PF3 Parainfluenza 3 - microbial antibody testing PF3 Parainfluenza 3 - microbial antibody testing PF3 Parainfluenza 3 - microbial antibody testing PF3 Parainfluenza 3 - microbial antibody testing PF3 Parainfluenza 3 - microbial antibody testing PF3 Parainfluenza 3 - microbial antibody testing PF3 Parainfluenza 3 - microbial antibody testing PF3 Parainfluenza 3 - microbial antibody testing PF3 Parainfluenza 3 - microbial antibody testing PF3 Parainfluenza 3 - microbial antibody testing PF3 Parainfluenza 3 - microbial antibody testing PF3 Parainfluenza 5 - microbial antibody testing PF3 Parainfluenza 7 - microbial antibody testing PF3 Parainfluenza 7 - microbial antibody testing PF3 Parainfluenza 7 - microbial antibody testing PF3 Parainfluenza 7 - microbial antibody testing PF3 Parainfluenza 7 - microbial
MCSW 69303 Microscopy & culture of - material from skin MCSK 69309 Microscopy & culture of - postoperative wounds, aspirates of body cavities MCPO 69321 Microscopy & culture of - specimens of sputum MCSP 69318 Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other 71060
Microscopy & culture of - material from skin MCSK 69309 Microscopy & culture of - postoperative wounds, aspirates of body cavities MCPO 69321 Microscopy & culture of - specimens of sputum MCSP 69318 Microscopy & culture of - specimens of sputum, urine or other 71060
Cavities MCPO Microscopy & culture of - postoperative wounds, aspirates of body cavities MCPO Microscopy & culture of - specimens of sputum MCSP Microscopy & culture of - specimens of sputum MCSP Microscopy & culture of - specimens of sputum, urine or other Paraprotein characterisation - by electrophoresis, and immunoelectrophoresis or Paraprotein characterisation - on concurrently collected serum or Paraprotein characterisation - on concurrently collected serum or Paraprotein characterisation - on concurrently collected serum or Paraprotein characterisation - by electrophoresis, and immunoelectrophoresis or Paraprotein characterisation - by electrophoresis, and immunoelectrophoresis or Paraprotein characterisation - by electrophoresis, and immunoelectrophoresis or Paraprotein characterisation - by electrophoresis, and immunoelectrophoresis or Paraprotein characterisation - by electrophoresis, and immunoelectrophoresis or Paraprotein characterisation - by electrophoresis, and immunoelectrophoresis or Paraprotein characterisation - by electrophoresis, and immunoelectrophoresis or Paraprotein characterisation - by electrophoresis, and immunoelectrophoresis or Paraprotein characterisation - by electrophoresis, and immunoelectrophoresis or Paraprotein characterisation - by electrophoresis, and immunoelectrophoresis or Paraprotein characterisation - by electrophoresis, and immunoelectrophoresis or Paraprotein characterisation - by electrophoresis, and immunoelectrophoresis or Paraprotein characterisation - by electrophoresis, and immunoelectrophoresis or Paraprotein characterisation - by electrophoresis, and immunoelectrophoresis or Paraprotein characterisation - by electrophoresis, and immunoelectrophoresis or Paraprotein characterisation - by electrophoresis, and immunoelectrophoresis or Paraprotein characterisation - by electrophoresis, and immunoelectrophoresis or Paraprotein characterisation - by electrophoresis or Paraprotein characterisation - by electrophoresis or Paraprotein char
Cavities MCPO Microscopy & culture of - specimens of sputum MCSP Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other Microscopy & culture of - specimens of sputum, urine or other 71060
Microscopy & culture of - specimens of sputum MCSP 69318 Microscopy & culture of - specimens of sputum, urine or other Paraprotein characterisation - on concurrently collected serum or 71060
Microscopy & culture of - specimens of sputum, urine or other urine PPSI 71060
body fluids for my 69324, 69327, 69330 Microscopy & culture of - superficial sites MCSS 69306 Microscopy 69306
Migraceony & gulture of prother vegine corries or rootum
MCCP Farasites - inicroscopic examination of facees OCF 09330
Migrogopy of wat film material other than blood MWEM 60200
Microscopy, culture, identification & sensitivity of urine UMCS Microscopy, culture, identification & sensitivity of urine UMCS Parathyroid hormone (PTH) PTH 66695 Parathyroid hormone (PTH) PTH 66384
65120. Partial thromboplastin time PTT 65120.
Mitachondria - tissue antigens - antibodies MA /1119 Patient Episode Initiation private 73800
Mouth - cytology on specimens from SMCY /3043 Patient Episode Initiation public 73000
Mumps - microbial antibody testing MUM 69384 Murray Valley encephalitis - microbial antibody testing MVE Pentobarbitone PENT 66812 Merray Valley encephalitis - microbial antibody testing MVE Pentobarbitone PENT 66812
60394 Femerinic Fried
Mysobacteria microscopy & culture of sputum 1 specimen AED1
60324 Fileliobal ottolle FTIBA 00800
Mycobacteria microscopy & culture of sputum - 2 specimens Phensuximide PHEN Phenylacetic acid PAA 66812 Phenylacetic acid PAA
AFB2 69327 Phenytoin PHEV 66800
Mycobacteria microscopy & culture of sputum - 3 specimens Phosphate PHOS 66500
AFB3 69330 Phosphotidylglygeral PTGI 66740
Mycoplasma pneumoniae - microbial antibody testing MYC 69384 Myoglobin MYOG Myoglobin MYOG Mycoplasma pneumoniae - microbial antibody testing MYC 69384 Platelet - aggregation PLTG Mycoplasma pneumoniae - microbial antibody testing MYC 69384 Platelet - aggregation PLTG Mycoplasma pneumoniae - microbial antibody testing MYC 69384 Myoglobin MYOG Mycoplasma pneumoniae - microbial antibody testing MYC 69384 Myoglobin MYOG Mycoplasma pneumoniae - microbial antibody testing MYC 69384 Myoglobin MYOG Mycoplasma pneumoniae - microbial antibody testing MYC 69384 Myoglobin MYOG Mycoplasma pneumoniae - microbial antibody testing MYC 69384 Myoglobin MYOG Mycoplasma pneumoniae - microbial antibody testing MYC 69384 Myoglobin MYOG Mycoplasma pneumoniae - microbial antibody testing MYC 69384
Platefet count PLTC 050/0
PM-Sc1 - tissue antigens - antibodies PM1 71119 Poliomyelitis microbial antibody testing PLO 60384
1 onomychus - microbiai antibody testing 1 LO 05364
N-acetyl procainamide NAPC Polycythaemia vera 73325 Porphobilinogen in urine UPG 66782
Neisseria menigitidis antibody testing MEN 69384 Porphyrins - quantitative test, 1 or more fractions PR 66785
Netilmicin 66800 Porphyrins in urine - qualitative test, 1 of more fluctions 11 66782
Neutrophil functions NFT 71135 Potassium K 66500
Newcastle disease - microbial antibody testing NCD 69384 Prealbumin PALB 66632
Nipple discharge - cytology on specimens from SMCY 73043 Prednisolone PRED 66812
Nitrazepam NITR 66812 Pregnancy serology - 1 test MSP1 69405
Nordothiepin NDIP 66812 Pregnancy serology - 2 tests MSP2 69408 Norfluoxetine NFLE 66812 Pregnancy serology - 3 tests MSP3 69411
Norfilioxetine NFLE 66812 Pregnancy serology - 3 tests MSP3 69411 Nortriptyline NORT 66812 Pregnancy serology - 4 tests MSP4 69413
Nose - cytology on specimens from SMCY 73043 Pregnancy seroiogy - 4 tests WSF4 Pregnancy testing 73806
Nose - microscopy & culture of material from MCSW 69303 Pregnancy testing - bile acids in blood BABP 66517
Nuclear antigens - detection of antibodies to ANA 71097 Pregnancy testing - HCG detection HCGP 73527, 73529

Pregnancy testing - HCG quantitation HCG	73529	Second, expert, opinion morphology, non-complex - SEON	J 72858
Primidone PRIM	66800	Semen examination - for spermatozoa (post vasectomy) SE	
Procainamide PCAM	66800	Semen examination SEE	73523
Progesterone PROG	66695	Serotonin 5HT	66779
Prolactin PROL	66695	Serum - B12 B12	66838
Propranolol PPNO	66812	Serum Folate & Red cell folate if required	66840
Prostate specific antigen PSA 66655-66656		Serum Folate SF	66840
· -	2, 65171	Sex hormone binding globulin SHBG	66695
	2, 65171	SF	66840
	0-66653	Skin - microscopy & culture of material from MCSS	69306
66743	0 00033	Skin - microscopy, culture & Chlamydia of material from I	
Protein, quantitation of - alpha-l-antitrypsin AAT	66635	5km - microscopy, culture & chiamydia of material from f	69309
Protein, quantitation of - beta-2-microglobulin BMIC	66629	Skin cytology SMCY	73043
Protein, quantitation of - C-1 esterase inhibitor CEI	66644	Smooth muscle - tissue antigens - antibodies SMA	71119
Protein, quantitation of - caeruloplasmin CPLS	66632	Snake venom HISS	66623
Protein, quantitation of - classes or presence and amount of		Sodium NA	66500
	7-71058	Solid tissue or tissues - chemical assays ENZS	66683
Protein, quantitation of - ferritin (see also Iron studies) FE		Solid tissue or tissues - cytology of fine needle aspiration F	
1 Totom, quantitation of Territin (see also from stadies) 1 E.	66593	Sond dissue of dissues eyeology of fine needle dispitation i	73049
Protein, quantitation of - haptoglobins HGLB	66632	Solid tissue or tissues - cytology of fine needle aspitation b	
Protein, quantitation of - microalbumin MALB	66560	presence	73051
Protein, total - quantitation of PROT	66500	Somatomedin SOMA	66695
Proteus OX 19 - microbial antibody testing POX	69384	Sotalol SALL	66812
Proteus OXK - microbial antibody testing POK	69384	Specific IgC antibodies - respiratory disease allergens RDA	
Prothrombin time PT	65120	Specific IgG or IgE antibodies RAST	71079
Pyruvate PVTE	66500	Specimen dissection - level 7 SPE7	72838
1 yluvute 1 v 1D	00300	Sperm antibodies - penetrating ability SPA	73525
Q		Sperm antibodies SAB	73525
u		Sputum - cytology (1 specimen) BFCY	73045
O Favor migrapial antibody testing OFF	69384	Sputum - cytology (3 specimens) SPCY	73047
Q Fever - microbial antibody testing QFF Quinalbarbitone QUIB	66812	Sputum - for mycobacteria - 1 specimen AFB1	69324
		Sputum - for mycobacteria - 2 specimens AFB2	69327
Quinidine QUIN	66800		
Quinine QNN	66812	Sputum - for mycobacteria - 3 specimens AFB3	69330
Quinine QNN		Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP	69330 69318
		Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL	69330 69318 66812
Quinine QNN R	66812	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF	69330 69318 66812 66695
Quinine QNN R Rapid plasma reagin test - microbial antibody testing RPR	66812 69384	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF Streptococcal serology - anti-DNASE B titre - microbial ar	69330 69318 66812 66695 ntibody
Quinine QNN R Rapid plasma reagin test - microbial antibody testing RPR RAST RAST	69384 71079	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF Streptococcal serology - anti-DNASE B titre - microbial ar testing ADNB	69330 69318 66812 66695 atibody 69384
Rapid plasma reagin test - microbial antibody testing RPR RAST RAST Rectum - microscopy & culture of material from MCGR	69384 71079 69312	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF Streptococcal serology - anti-DNASE B titre - microbial ar testing ADNB Streptococcal serology - anti-streptolysin O titre - microbia	69330 69318 66812 66695 atibody 69384
Rapid plasma reagin test - microbial antibody testing RPR RAST RAST Rectum - microscopy & culture of material from MCGR Red blood cells - Kleihauer KLEI	69384 71079 69312 65162	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF Streptococcal serology - anti-DNASE B titre - microbial ar testing ADNB Streptococcal serology - anti-streptolysin O titre - microbia antibody testing	69330 69318 66812 66695 httibody 69384
Rapid plasma reagin test - microbial antibody testing RPR RAST RAST Rectum - microscopy & culture of material from MCGR Red blood cells - Kleihauer KLEI Red cell porphyrins - qualitative test RCP	69384 71079 69312 65162 66782	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF Streptococcal serology - anti-DNASE B titre - microbial ar testing ADNB Streptococcal serology - anti-streptolysin O titre - microbia	69330 69318 66812 66695 httibody 69384
Rapid plasma reagin test - microbial antibody testing RPR RAST RAST Rectum - microscopy & culture of material from MCGR Red blood cells - Kleihauer KLEI Red cell porphyrins - qualitative test RCP Renin REN	69384 71079 69312 65162 66782 66695	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF Streptococcal serology - anti-DNASE B titre - microbial ar testing ADNB Streptococcal serology - anti-streptolysin O titre - microbia antibody testing Streptococcus pneumoniae - microbial antibody testing PO	69330 69318 66812 66695 httibody 69384 dl 69384
Rapid plasma reagin test - microbial antibody testing RPR RAST RAST Rectum - microscopy & culture of material from MCGR Red blood cells - Kleihauer KLEI Red cell porphyrins - qualitative test RCP Renin REN Reptilase test REPT	69384 71079 69312 65162 66782 66695 65120	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF Streptococcal serology - anti-DNASE B titre - microbial ar testing ADNB Streptococcal serology - anti-streptolysin O titre - microbia antibody testing Streptococcus pneumoniae - microbial antibody testing PC Stypven test STYP	69330 69318 66812 66695 htibody 69384 dl 69384 CC 69384 65120
Rapid plasma reagin test - microbial antibody testing RPR RAST RAST Rectum - microscopy & culture of material from MCGR Red blood cells - Kleihauer KLEI Red cell porphyrins - qualitative test RCP Renin REN Reptilase test REPT Respiratory syncytial virus - microbial antibody testing RS	66812 69384 71079 69312 65162 66782 66695 65120 V69384	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF Streptococcal serology - anti-DNASE B titre - microbial ar testing ADNB Streptococcal serology - anti-streptolysin O titre - microbia antibody testing Streptococcus pneumoniae - microbial antibody testing PC Stypven test STYP Sugar water test SWT	69330 69318 66812 66695 htibody 69384 dl 69384 CC 69384
Rapid plasma reagin test - microbial antibody testing RPR RAST RAST Rectum - microscopy & culture of material from MCGR Red blood cells - Kleihauer KLEI Red cell porphyrins - qualitative test RCP Renin REN Reptilase test REPT Respiratory syncytial virus - microbial antibody testing RS Reticulin - tissue antigens - antibodies RCA	66812 69384 71079 69312 65162 66782 66695 65120 V69384 71119	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF Streptococcal serology - anti-DNASE B titre - microbial ar testing ADNB Streptococcal serology - anti-streptolysin O titre - microbia antibody testing Streptococcus pneumoniae - microbial antibody testing PC Stypven test STYP Sugar water test SWT Sulthiame (Ospolot) SUL	69330 69318 66812 66695 htibody 69384 dl 69384 CC 69384 65120 65075
Rapid plasma reagin test - microbial antibody testing RPR RAST RAST Rectum - microscopy & culture of material from MCGR Red blood cells - Kleihauer KLEI Red cell porphyrins - qualitative test RCP Renin REN Reptilase test REPT Respiratory syncytial virus - microbial antibody testing RS Reticulin - tissue antigens - antibodies RCA Reticulocyte count RETC	66812 69384 71079 69312 65162 66782 66695 65120 V69384 71119 65072	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF Streptococcal serology - anti-DNASE B titre - microbial ar testing ADNB Streptococcal serology - anti-streptolysin O titre - microbia antibody testing Streptococcus pneumoniae - microbial antibody testing PC Stypven test STYP Sugar water test SWT	69330 69318 66812 66695 htibody 69384 il 69384 CC 69384 65120 65075 66812
Rapid plasma reagin test - microbial antibody testing RPR RAST RAST Rectum - microscopy & culture of material from MCGR Red blood cells - Kleihauer KLEI Red cell porphyrins - qualitative test RCP Renin REN Reptilase test REPT Respiratory syncytial virus - microbial antibody testing RS Reticulin - tissue antigens - antibodies RCA Reticulocyte count RETC Rheumatoid factor - quantitation RFQ	66812 69384 71079 69312 65162 66782 66695 65120 V69384 71119 65072 71106	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF Streptococcal serology - anti-DNASE B titre - microbial ar testing ADNB Streptococcal serology - anti-streptolysin O titre - microbia antibody testing Streptococcus pneumoniae - microbial antibody testing Stypven test STYP Sugar water test SWT Sulthiame (Ospolot) SUL Syphilis serology (see test groups at para PQ.4) STS	69330 69318 66812 66695 htibody 69384 il 69384 CC 69384 65120 65075 66812
Rapid plasma reagin test - microbial antibody testing RPR RAST RAST Rectum - microscopy & culture of material from MCGR Red blood cells - Kleihauer KLEI Red cell porphyrins - qualitative test RCP Renin REN Reptilase test REPT Respiratory syncytial virus - microbial antibody testing RS Reticulin - tissue antigens - antibodies RCA Reticulocyte count RETC Rheumatoid factor - quantitation RFQ Rheumatoid factor RF	66812 69384 71079 69312 65162 66782 66695 65120 V69384 71119 65072 71106 71106	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF Streptococcal serology - anti-DNASE B titre - microbial ar testing ADNB Streptococcal serology - anti-streptolysin O titre - microbia antibody testing Streptococcus pneumoniae - microbial antibody testing PC Stypven test STYP Sugar water test SWT Sulthiame (Ospolot) SUL	69330 69318 66812 66695 htibody 69384 il 69384 CC 69384 65120 65075 66812
Rapid plasma reagin test - microbial antibody testing RPR RAST RAST Rectum - microscopy & culture of material from MCGR Red blood cells - Kleihauer KLEI Red cell porphyrins - qualitative test RCP Renin REN Reptilase test REPT Respiratory syncytial virus - microbial antibody testing RS Reticulin - tissue antigens - antibodies RCA Reticulocyte count RETC Rheumatoid factor - quantitation RFQ Rheumatoid factor RF Ross River virus - microbial antibody testing RRV	66812 69384 71079 69312 65162 66782 66695 65120 V69384 71119 65072 71106 71106 69384	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF Streptococcal serology - anti-DNASE B titre - microbial ar testing ADNB Streptococcal serology - anti-streptolysin O titre - microbia antibody testing Streptococcus pneumoniae - microbial antibody testing PC Stypven test STYP Sugar water test SWT Sulthiame (Ospolot) SUL Syphilis serology (see test groups at para PQ.4) STS	69330 69318 66812 66695 htibody 69384 dl 69384 CC 69384 65120 65075 66812 69387
Rapid plasma reagin test - microbial antibody testing RPR RAST RAST Rectum - microscopy & culture of material from MCGR Red blood cells - Kleihauer KLEI Red cell porphyrins - qualitative test RCP Renin REN Reptilase test REPT Respiratory syncytial virus - microbial antibody testing RS Reticulin - tissue antigens - antibodies RCA Reticulocyte count RETC Rheumatoid factor - quantitation RFQ Rheumatoid factor RF	66812 69384 71079 69312 65162 66782 66695 65120 V69384 71119 65072 71106 71106 69384 ng RSV	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF Streptococcal serology - anti-DNASE B titre - microbial ar testing ADNB Streptococcal serology - anti-streptolysin O titre - microbia antibody testing Streptococcus pneumoniae - microbial antibody testing PC Stypven test STYP Sugar water test SWT Sulthiame (Ospolot) SUL Syphilis serology (see test groups at para PQ.4) STS T Testosterone TES	69330 69318 66812 66695 htibody 69384 dl 69384 65075 66812 69387
Rapid plasma reagin test - microbial antibody testing RPR RAST RAST Rectum - microscopy & culture of material from MCGR Red blood cells - Kleihauer KLEI Red cell porphyrins - qualitative test RCP Renin REN Reptilase test REPT Respiratory syncytial virus - microbial antibody testing RS Reticulin - tissue antigens - antibodies RCA Reticulocyte count RETC Rheumatoid factor - quantitation RFQ Rheumatoid factor RF Ross River virus - microbial antibody testing RRV RSV (respiratory syncytial virus) - microbial antibody testing	66812 69384 71079 69312 65162 66782 66695 65120 V69384 71119 65072 71106 71106 69384 ng RSV 69384	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF Streptococcal serology - anti-DNASE B titre - microbial ar testing ADNB Streptococcal serology - anti-streptolysin O titre - microbia antibody testing Streptococcus pneumoniae - microbial antibody testing PC Stypven test STYP Sugar water test SWT Sulthiame (Ospolot) SUL Syphilis serology (see test groups at para PQ.4) STS T Testosterone TES Tetanus - microbial antibody testing TET	69330 69318 66812 66695 httbody 69384 dl 69384 65120 65075 66812 69387
Rapid plasma reagin test - microbial antibody testing RPR RAST RAST Rectum - microscopy & culture of material from MCGR Red blood cells - Kleihauer KLEI Red cell porphyrins - qualitative test RCP Renin REN Reptilase test REPT Respiratory syncytial virus - microbial antibody testing RS Reticulin - tissue antigens - antibodies RCA Reticulocyte count RETC Rheumatoid factor - quantitation RFQ Rheumatoid factor RF Ross River virus - microbial antibody testing RRV	66812 69384 71079 69312 65162 66782 66695 65120 V69384 71119 65072 71106 71106 69384 ng RSV	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF Streptococcal serology - anti-DNASE B titre - microbial ar testing ADNB Streptococcal serology - anti-streptolysin O titre - microbia antibody testing Streptococcus pneumoniae - microbial antibody testing PC Stypven test STYP Sugar water test SWT Sulthiame (Ospolot) SUL Syphilis serology (see test groups at para PQ.4) STS T Testosterone TES Tetanus - microbial antibody testing TET Thalassaemia studies TS	69330 69318 66812 66695 httbody 69384 dl 69384 65120 65075 66812 69387
Rapid plasma reagin test - microbial antibody testing RPR RAST RAST Rectum - microscopy & culture of material from MCGR Red blood cells - Kleihauer KLEI Red cell porphyrins - qualitative test RCP Renin REN Reptilase test REPT Respiratory syncytial virus - microbial antibody testing RS Reticulin - tissue antigens - antibodies RCA Reticulocyte count RETC Rheumatoid factor - quantitation RFQ Rheumatoid factor RF Ross River virus - microbial antibody testing RRV RSV (respiratory syncytial virus) - microbial antibody testing Rubella - serology RUB	66812 69384 71079 69312 65162 66782 66695 65120 V69384 71119 65072 71106 71106 69384 ng RSV 69384	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF Streptococcal serology - anti-DNASE B titre - microbial ar testing ADNB Streptococcal serology - anti-streptolysin O titre - microbia antibody testing Streptococcus pneumoniae - microbial antibody testing PC Stypven test STYP Sugar water test SWT Sulthiame (Ospolot) SUL Syphilis serology (see test groups at para PQ.4) STS T Testosterone TES Tetanus - microbial antibody testing TET Thalassaemia studies TS Theophylline THEO	69330 69318 66812 66695 httbody 69384 dl 69384 65120 65075 66812 69387
Rapid plasma reagin test - microbial antibody testing RPR RAST RAST Rectum - microscopy & culture of material from MCGR Red blood cells - Kleihauer KLEI Red cell porphyrins - qualitative test RCP Renin REN Reptilase test REPT Respiratory syncytial virus - microbial antibody testing RS Reticulin - tissue antigens - antibodies RCA Reticulocyte count RETC Rheumatoid factor - quantitation RFQ Rheumatoid factor RF Ross River virus - microbial antibody testing RRV RSV (respiratory syncytial virus) - microbial antibody testing	66812 69384 71079 69312 65162 66782 66695 65120 V69384 71119 65072 71106 71106 69384 ng RSV 69384	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF Streptococcal serology - anti-DNASE B titre - microbial ar testing ADNB Streptococcal serology - anti-streptolysin O titre - microbia antibody testing Streptococcus pneumoniae - microbial antibody testing PC Stypven test STYP Sugar water test SWT Sulthiame (Ospolot) SUL Syphilis serology (see test groups at para PQ.4) STS T Testosterone TES Tetanus - microbial antibody testing TET Thalassaemia studies TS	69330 69318 66812 66695 httbody 69384 dl 69384 65120 65075 66812 69387
Rapid plasma reagin test - microbial antibody testing RPR RAST RAST Rectum - microscopy & culture of material from MCGR Red blood cells - Kleihauer KLEI Red cell porphyrins - qualitative test RCP Renin REN Reptilase test REPT Respiratory syncytial virus - microbial antibody testing RS Reticulin - tissue antigens - antibodies RCA Reticulocyte count RETC Rheumatoid factor - quantitation RFQ Rheumatoid factor RF Ross River virus - microbial antibody testing RRV RSV (respiratory syncytial virus) - microbial antibody testi Rubella - serology RUB	69384 71079 69312 65162 66782 66695 65120 V69384 71119 65072 71106 71106 69384 ng RSV 69384 69384	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF Streptococcal serology - anti-DNASE B titre - microbial ar testing ADNB Streptococcal serology - anti-streptolysin O titre - microbia antibody testing Streptococcus pneumoniae - microbial antibody testing PC Stypven test STYP Sugar water test SWT Sulthiame (Ospolot) SUL Syphilis serology (see test groups at para PQ.4) STS T Testosterone TES Tetanus - microbial antibody testing TET Thalassaemia studies TS Theophylline THEO Thermaactinomyces vulgaris - microbial antibody testing T	69330 69318 66812 66695 httbody 69384 dl 69384 65120 65075 66812 69387 66695 69384 65078 66800 CHE 69384
Rapid plasma reagin test - microbial antibody testing RPR RAST RAST Rectum - microscopy & culture of material from MCGR Red blood cells - Kleihauer KLEI Red cell porphyrins - qualitative test RCP Renin REN Reptilase test REPT Respiratory syncytial virus - microbial antibody testing RS Reticulin - tissue antigens - antibodies RCA Reticulocyte count RETC Rheumatoid factor - quantitation RFQ Rheumatoid factor RF Ross River virus - microbial antibody testing RRV RSV (respiratory syncytial virus) - microbial antibody testi Rubella - serology RUB Salicylate (aspirin) SALI	66812 69384 71079 69312 65162 66782 66695 65120 V69384 71119 65072 71106 71106 69384 ng RSV 69384 69384	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF Streptococcal serology - anti-DNASE B titre - microbial ar testing ADNB Streptococcal serology - anti-streptolysin O titre - microbia antibody testing Streptococcus pneumoniae - microbial antibody testing PC Stypven test STYP Sugar water test SWT Sulthiame (Ospolot) SUL Syphilis serology (see test groups at para PQ.4) STS T Testosterone TES Tetanus - microbial antibody testing TET Thalassaemia studies TS Theophylline THEO Thermactinomyces vulgaris - microbial antibody testing TPS	69330 69318 66812 66695 httibody 69384 dl 69384 65120 65075 66812 69387 66695 69384 65078 66800 CHE 69384
Rapid plasma reagin test - microbial antibody testing RPR RAST RAST Rectum - microscopy & culture of material from MCGR Red blood cells - Kleihauer KLEI Red cell porphyrins - qualitative test RCP Renin REN Reptilase test REPT Respiratory syncytial virus - microbial antibody testing RS Reticulin - tissue antigens - antibodies RCA Reticulocyte count RETC Rheumatoid factor - quantitation RFQ Rheumatoid factor RF Ross River virus - microbial antibody testing RRV RSV (respiratory syncytial virus) - microbial antibody testi Rubella - serology RUB Salicylate (aspirin) SALI Salmonella typhi (H) - microbial antibody testing SAH	66812 69384 71079 69312 65162 66782 66695 65120 V69384 71119 65072 71106 71106 69384 ng RSV 69384 69384	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF Streptococcal serology - anti-DNASE B titre - microbial ar testing ADNB Streptococcal serology - anti-streptolysin O titre - microbia antibody testing Streptococcus pneumoniae - microbial antibody testing PC Stypven test STYP Sugar water test SWT Sulthiame (Ospolot) SUL Syphilis serology (see test groups at para PQ.4) STS T Testosterone TES Tetanus - microbial antibody testing TET Thalassaemia studies TS Theophylline THEO Thermactinomyces vulgaris - microbial antibody testing TPS Thiopentone TOPO	69330 69318 66812 66695 httibody 69384 dl 69384 65120 65075 66812 69387 66695 69384 65078 66800 CHE 69384 69384 69384
Rapid plasma reagin test - microbial antibody testing RPR RAST RAST Rectum - microscopy & culture of material from MCGR Red blood cells - Kleihauer KLEI Red cell porphyrins - qualitative test RCP Renin REN Reptilase test REPT Respiratory syncytial virus - microbial antibody testing RS Reticulin - tissue antigens - antibodies RCA Reticulocyte count RETC Rheumatoid factor - quantitation RFQ Rheumatoid factor RF Ross River virus - microbial antibody testing RRV RSV (respiratory syncytial virus) - microbial antibody testi Rubella - serology RUB S Salicylate (aspirin) SALI Salmonella typhi (H) - microbial antibody testing SAH Salmonella typhi (O) - microbial antibody testing SAO	66812 69384 71079 69312 65162 66782 66695 65120 V69384 71119 65072 71106 71106 69384 ng RSV 69384 69384	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF Streptococcal serology - anti-DNASE B titre - microbial ar testing ADNB Streptococcal serology - anti-streptolysin O titre - microbia antibody testing Streptococcus pneumoniae - microbial antibody testing PC Stypven test STYP Sugar water test SWT Sulthiame (Ospolot) SUL Syphilis serology (see test groups at para PQ.4) STS T Testosterone TES Tetanus - microbial antibody testing TET Thalassaemia studies TS Theophylline THEO Thermactinomyces vulgaris - microbial antibody testing TPS Thiopentone TOPO Thiopurine S-methyltransferase	69330 69318 66812 66695 httbody 69384 dl 69384 65120 65075 66812 69387 66695 69384 65078 66800 CHE 69384 69384 69384 69384 69384
Rapid plasma reagin test - microbial antibody testing RPR RAST RAST Rectum - microscopy & culture of material from MCGR Red blood cells - Kleihauer KLEI Red cell porphyrins - qualitative test RCP Renin REN Reptilase test REPT Respiratory syncytial virus - microbial antibody testing RS Reticulin - tissue antigens - antibodies RCA Reticulocyte count RETC Rheumatoid factor - quantitation RFQ Rheumatoid factor RF Ross River virus - microbial antibody testing RRV RSV (respiratory syncytial virus) - microbial antibody testi Rubella - serology RUB S Salicylate (aspirin) SALI Salmonella typhi (H) - microbial antibody testing SAH Salmonella typhi (O) - microbial antibody testing SAO Schistosoma - microbial antibody testing STO	69384 71079 69312 65162 66782 66695 65120 V69384 71119 65072 71106 71106 69384 ng RSV 69384 69384	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF Streptococcal serology - anti-DNASE B titre - microbial ar testing ADNB Streptococcal serology - anti-streptolysin O titre - microbia antibody testing Streptococcus pneumoniae - microbial antibody testing PC Stypven test STYP Sugar water test SWT Sulthiame (Ospolot) SUL Syphilis serology (see test groups at para PQ.4) STS T Testosterone TES Tetanus - microbial antibody testing TET Thalassaemia studies TS Theophylline THEO Thermactinomyces vulgaris - microbial antibody testing TPS Thiopentone TOPO Thiopurine S-methyltransferase Thioridazine THIO	69330 69318 66812 66695 httibody 69384 dl 69384 65120 65075 66812 69387 66695 69384 65078 66800 CHE 69384 69384 69384
Rapid plasma reagin test - microbial antibody testing RPR RAST RAST Rectum - microscopy & culture of material from MCGR Red blood cells - Kleihauer KLEI Red cell porphyrins - qualitative test RCP Renin REN Reptilase test REPT Respiratory syncytial virus - microbial antibody testing RS Reticulin - tissue antigens - antibodies RCA Reticulocyte count RETC Rheumatoid factor - quantitation RFQ Rheumatoid factor RF Ross River virus - microbial antibody testing RRV RSV (respiratory syncytial virus) - microbial antibody testi Rubella - serology RUB S Salicylate (aspirin) SALI Salmonella typhi (H) - microbial antibody testing SAH Salmonella typhi (O) - microbial antibody testing SAO Schistosoma - microbial antibody testing STO Scl-70 - tissue antigens - antibodies SCL	69384 71079 69312 65162 66782 66695 65120 V69384 71119 65072 71106 71106 69384 ng RSV 69384 69384 69384 69384 69384 69384 69384 71119	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF Streptococcal serology - anti-DNASE B titre - microbial ar testing ADNB Streptococcal serology - anti-streptolysin O titre - microbia antibody testing Streptococcus pneumoniae - microbial antibody testing PC Stypven test STYP Sugar water test SWT Sulthiame (Ospolot) SUL Syphilis serology (see test groups at para PQ.4) STS T Testosterone TES Tetanus - microbial antibody testing TET Thalassaemia studies TS Theophylline THEO Thermactinomyces vulgaris - microbial antibody testing TPS Thiopentone TOPO Thiopurine S-methyltransferase Thioridazine THIO Throat - microscopy & culture of material from MCSW	69330 69318 66812 66695 httbody 69384 dl 69384 65120 65075 66812 69387 66695 69384 65078 66800 CHE 69384 69384 66812 73327 66812
Rapid plasma reagin test - microbial antibody testing RPR RAST RAST Rectum - microscopy & culture of material from MCGR Red blood cells - Kleihauer KLEI Red cell porphyrins - qualitative test RCP Renin REN Reptilase test REPT Respiratory syncytial virus - microbial antibody testing RS Reticulin - tissue antigens - antibodies RCA Reticulocyte count RETC Rheumatoid factor - quantitation RFQ Rheumatoid factor RF Ross River virus - microbial antibody testing RRV RSV (respiratory syncytial virus) - microbial antibody testi Rubella - serology RUB S Salicylate (aspirin) SALI Salmonella typhi (H) - microbial antibody testing SAH Salmonella typhi (O) - microbial antibody testing SAO Schistosoma - microbial antibody testing STO	69384 71079 69312 65162 66782 66695 65120 V69384 71119 65072 71106 71106 69384 ng RSV 69384 69384	Sputum - for mycobacteria - 3 specimens AFB3 Sputum - microscopy & culture of specimens MCSP Stelazine STEL Steroid fraction or fractions in urine USF Streptococcal serology - anti-DNASE B titre - microbial ar testing ADNB Streptococcal serology - anti-streptolysin O titre - microbia antibody testing Streptococcus pneumoniae - microbial antibody testing PC Stypven test STYP Sugar water test SWT Sulthiame (Ospolot) SUL Syphilis serology (see test groups at para PQ.4) STS T Testosterone TES Tetanus - microbial antibody testing TET Thalassaemia studies TS Theophylline THEO Thermactinomyces vulgaris - microbial antibody testing TPS Thiopentone TOPO Thiopurine S-methyltransferase Thioridazine THIO	69330 69318 66812 66695 httibody 69384 dl 69384 65120 65075 66812 69387 66695 69384 65078 66800 CHE 69384 69384 66812 73327 66812 69303

	((710	V D10 1 D1014	((020
Thyroid function tests (including TSH) TFT	66719	Vitamins - B12 markers B12M	66839
Thyroid stimulating hormone	66734	Vitamins - D VITD 66833, 668	
Thyroid stimulating hormone (if requested on its own, or		Vitamins - quantitation of A or E	66607
preliminary test	66716	Vitamins - quantitation of B1, B2, B3, B6 or C	66605
Thyroid stimulating hormone (if requested with other hor		Von Hippel-Lindau - Diagnostics (germline)	73333
referred to in ite 66722-66725, 6672		Von Hippel-Lindau - Predictive (relatives)	73334
Tissue transglutaminase antibodies TTG	71163	Von Hippel-Lindau - Somatic	73335
Tobramicin	66800	Von Willebrand's factor antigen VWA	65150
Total protein PROT	66500	Von Willebrand's factor VWF	65150
Toxocara - microbial antibody testing TOC	69384		
Toxoplasma - microbial antibody testing TOX	69384	W	
TPHA (Treponema pallidum haemagglutination test)	69384		
Treponema pallidum haemagglutination test	69384	Warfarin WFR	66812
Trichinosis - microbial antibody testing TOS	69384		
Triglycerides TRIG	66500	Υ	
Trimipramine TRIM	66812		
Troponin TROP	66518	Yersinia entercolitica - microbial antibody testing YER	69384
Tryptase - serum TRYP	71198		
Tryptic activity in faeces TAF	66677	Z	
Tuberculosis MANT	73811	-	
Tumour markers - CA-125 antigen C125	66650	Zinc ZN	66667
Tumour markers - CA-15.3 anitgen CA15	66650	ZIIIC ZIV	00007
Tumour markers - CA-19.9 antigen CA19	66650		
Tumour markers - carcinoembryonic antigen CEA	66650		
Tumour markers - mammary serum antigen MSA	66650		
Tumour markers - prostate specific antigen PSA	66656		
Tumour markers - prostatic acid phosphatase - 1 or more			
ACP	66656		
Tumour markers - thryroglobulin TGL	66650		
Typhus, Weil-Felix - microbial antibody testing TYP	69384		
U			
ŭ			
Urate URAT	66500		
Urea U	66500		
Urethra - microscopy & culture of material from MCGR	69312		
Urine - acidification test UAT	66587		
Urine - cystine (cysteine) UCYS	66782		
Urine - cytology - on 1 specimen BFCY	73045		
Urine - cytology - on 3 specimens SPCY	73047		
Urine - haemoglobin UHB	66782		
Urine - microscopy, culture, identification & sensitivity U	JMCS		
137	69333		
Urine - porphyrins - qualitative test UPR	66782		
Urine - prophobilinogen UPG	66782		
Urine - steroid fraction or fractions USF	66695		
Urine - urobilinogen UUB	66782		
-			
V			
Vagina - microscopy & culture of material from MCGR	69312		
Valproate (Epilim) VALP	66800		
Vancomycin VAN	66800		
Varicella zoster - microbial antibody testing VCZ	69384		
Vasoactive intestinal peptide VIP	66695		
Vasopressin ADH	66695		
VDRL (Venereal Disease Researce Laboratory) - microbi			
antibody testing VDRL	69384		
Viscosity of blood or plasma VISC	65060		
	35-66836		
Vitamins - 25-hydroxyvitamin D	66833		
Vitamins - B12 B12	66838		

COMPLEXITY LEVELS FOR HISTOPATHOLOGY ITEMS

Adrenal resection, not neoplasm Anus, all specimens not otherwise specified 3 Anus, neoplasm, biopsy 4 Anus, neoplasm, radical resection 6 Anus, submucosal resection – neoplasm 5 Appendix 3 Artery, all specimens not otherwise specified 3 Artery, biopsy 4 Bartholin's gland - cyst Bile duct, resection - all specimens Bone, biopsy, curettings or fragments - lesion Bone, biopsy or curettings quantitation - metabolic disease Bone, femoral head Bone, resection, neoplasm - all sites and types Bone - all specimens not otherwise specified 4 Bone resection, neoplasm - all sites and types Bone - all specimens not otherwise specified 4 Brain nor meninges, not neoplasm - temporal lobe Brain or meninges, not neoplasm - temporal lobe Brain or meninges, resection - not neoplasm Branchial cleft, cyst Breast, excision biopsy, guidewire localisation - non-palpable lesion Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease - all specimen types Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast, orientated wide local excision for carcinoma, with margin assessment Breast tissue - all specimens not otherwise specified Bronchus, biopsy Carotid body - neoplasm 5 Cholesteatoma 3 Digits, amputation - not traumatic 4 Endocrine neoplasm - not otherwise specified 5 Endocrine neoplasm - not otherwise specified 5 Endocrine neoplasm - not otherwise specified 5 Endocrine neoplasm - not otherwise specified 5	Specimen Type	Complexity level
Anus, all specimens not otherwise specified Anus, neoplasm, biopsy 4 Anus, neoplasm, radical resection 6 Anus, submucosal resection – neoplasm 5 Appendix 3 Artery, all specimens not otherwise specified 3 Artery, biopsy 4 Bartholin's gland - cyst Bile duct, resection - all specimens 6 Bone, biopsy, curettings or fragments - lesion Bone, biopsy, curettings quantitation - metabolic disease 6 Bone, femoral head Bone, resection, neoplasm - all sites and types Bone - all specimens not otherwise specified 4 Brain neoplasm, resection - cerebello-pontine angle Brain or meninges, not neoplasm - temporal lobe Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm 4 Brack, excision biopsy, guidewire localisation - non-palpable lesion Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease - all specimen types Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast, nicision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast, orientated wide local excision for carcinoma, with margin assessment Breast rissue - all specimens not otherwise specified 4 Bronchus, biopsy 4 Bronchus, biopsy 5 Cholesteatoma 5 Cholesteatoma 6 Digits, amputation - rot traumatic 7 Ear, middle and inner - not cholesteatoma Endocrine neoplasm - not otherwise specified 5 Bread, orientated wide local excision for carcinoma, with margin assessment 7 Breast, microdochectomy 8 Breast, microdochectomy 9 Breast, orientated wide local excision for carcinoma, with margin assessment 7 Breast microdochectomy 8 Breast, amputation - not traumatic 2 Carotid body - neoplasm - not otherwise specified 5 Bronchus, amputation - rot cholesteatoma Endocrine neoplasm - not otherwise specified	Adrenal resection, neoplasm	5
Anus, neoplasm, biopsy Anus, neoplasm, radical resection Anus, submucosal resection – neoplasm 5 Appendix 3 Artery, all specimens not otherwise specified Artery, biopsy Bartholin's gland - cyst Bile duct, resection - all specimens Bone, biopsy or curettings or fragments - lesion Bone, biopsy or curettings quantitation - metabolic disease Bone, femoral head Bone, resection, neoplasm - all sites and types Bone - all specimens not otherwise specified Brain neoplasm, resection - cerebello-pontine angle Brain or meninges, biopsy - all lesions Brain or meninges, not neoplasm - temporal lobe Brain or meninges, resection - neoplasm (intracranial) Brain or meninges, resection - not neoplasm Branchial cleft, cyst Breast, excision biopsy, guidewire localisation - non-palpable lesion Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease - all specimen types Breast, excision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast - microdochectomy Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast - microdochectomy Breast, excision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast - microdochectomy Breast issue - all specimens not otherwise specified Bronchus, biopsy Carotid body - neoplasm 5 Cholesteatoma Digits, amputation - not traumatic 2 Digits, amputation - traumatic Ear, middle and inner - not cholesteatoma Endocrine neoplasm - not otherwise specified 5	Adrenal resection, not neoplasm	4
Anus, neoplasm, radical resection Anus, submucosal resection – neoplasm Appendix Artery, all specimens not otherwise specified Artery, biopsy Bartholin's gland - cyst Bile duct, resection - all specimens Bone, biopsy, curettings or fragments - lesion Bone, biopsy or curettings quantitation - metabolic disease Bone, femoral head Bone, resection, neoplasm - all sites and types Bone all specimens not otherwise specified Brain neoplasm, resection - cerebello-pontine angle Brain or meninges, biopsy - all lesions Brain or meninges, not neoplasm - temporal lobe Brain or meninges, resection - neoplasm (intracranial) Brain or meninges, resection - not neoplasm Breast, excision biopsy, guidewire localisation - non-palpable lesion Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease - all specimen types Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast, orientated wide local excision for carcinoma, with margin Breast issue - all specimens not otherwise specified Bronchus, biopsy Carotid body - neoplasm Cholesteatoma Digits, amputation - tot traumatic Digits, amputation - traumatic Ear, middle and inner - not cholesteatoma Endocrine neoplasm - not otherwise specified	Anus, all specimens not otherwise specified	3
Anus, submucosal resection – neoplasm Appendix Artery, all specimens not otherwise specified Artery, biopsy Bartholin's gland - cyst Bile duct, resection - all specimens Bone, biopsy, curettings or fragments - lesion Bone, biopsy or curettings quantitation - metabolic disease Bone, femoral head Bone, resection, neoplasm - all sites and types Bone - all specimens not otherwise specified Brain or meninges, biopsy - all lesions Brain or meninges, not neoplasm - temporal lobe Brain or meninges, resection - not neoplasm Brack, excision biopsy, guidewire localisation - non-palpable lesion Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease - all specimen types Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast, orientated wide local excision for carcinoma, with margin assessment Breast microdochectomy Breast, orientated wide local excision for carcinoma, with margin assessment Breast incision biopsy Carotid body - neoplasm Cholesteatoma Digits, amputation - not traumatic Digits, amputation - traumatic Ear, middle and inner - not cholesteatoma Endocrine neoplasm - not otherwise specified Ear, middle and inner - not cholesteatoma Endocrine neoplasm - not otherwise specified	Anus, neoplasm, biopsy	4
Appendix Artery, all specimens not otherwise specified Artery, biopsy Bartholin's gland - cyst Bile duct, resection - all specimens Bone, biopsy, curettings or fragments - lesion Bone, biopsy or curettings quantitation - metabolic disease Bone, femoral head Bone, resection, neoplasm - all sites and types Bone - all specimens not otherwise specified Brain neoplasm, resection - cerebello-pontine angle Brain or meninges, biopsy - all lesions Brain or meninges, not neoplasm - temporal lobe Brain or meninges, resection - neoplasm (intracranial) Brain or meninges, resection - not neoplasm Branchial cleft, cyst Breast, excision biopsy, guidewire localisation - non-palpable lesion Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease - all specimen types Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast, orientated wide local excision for carcinoma, with margin assessment Breast insue - all specimens not otherwise specified Breast, orientated wide local excision for carcinoma, with margin assessment Breast - microdochectomy Breast, orientated wide local excision for carcinoma, with margin assessment Breast - microdochectomy Breast, orientated wide local excision for carcinoma, with margin assessment Breast issue - all specimens not otherwise specified 4 Bronchus, biopsy Carotid body - neoplasm Cholesteatoma 5 Cholesteatoma 5 Digits, amputation - not traumatic 6 Digits, amputation - traumatic 7 Ear, middle and inner - not cholesteatoma 8 Endocrine neoplasm - not otherwise specified 8 Endocrine neoplasm - not otherwise specified	Anus, neoplasm, radical resection	6
Artery, all specimens not otherwise specified Artery, biopsy Bartholin's gland - cyst Bille duct, resection - all specimens Bone, biopsy, curettings or fragments - lesion Bone, biopsy or curettings quantitation - metabolic disease Bone, biopsy or curettings quantitation - metabolic disease Bone, femoral head Bone, resection, neoplasm - all sites and types Bone all specimens not otherwise specified Brain neoplasm, resection - cerebello-pontine angle Brain or meninges, biopsy - all lesions Brain or meninges, not neoplasm - temporal lobe Brain or meninges, resection - neoplasm (intracranial) Brain or meninges, resection - not neoplasm Branchial cleft, cyst Breast, excision biopsy, guidewire localisation - non-palpable lesion Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease - all specimen types Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast, orientated wide local excision for carcinoma, with margin assessment Breast issue - all specimens not otherwise specified 4 Bronchus, biopsy Carotid body - neoplasm Cholesteatoma Digits, amputation - not traumatic Digits, amputation - not traumatic Ear, middle and inner - not cholesteatoma Endocrine neoplasm - not otherwise specified	Anus, submucosal resection – neoplasm	5
Artery, biopsy Bartholin's gland - cyst Bile duct, resection - all specimens Bone, biopsy, curettings or fragments - lesion Bone, biopsy or curettings quantitation - metabolic disease Bone, biopsy or curettings quantitation - metabolic disease Bone, femoral head Bone, resection, neoplasm - all sites and types Bone - all specimens not otherwise specified Brain neoplasm, resection - cerebello-pontine angle Brain or meninges, biopsy - all lesions Brain or meninges, not neoplasm - temporal lobe Brain or meninges, resection - neoplasm (intracranial) Brain or meninges, resection - not neoplasm Branchial cleft, cyst Breast, excision biopsy, guidewire localisation - non-palpable lesion Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease - all specimen types Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast - microdochectomy Breast, orientated wide local excision for carcinoma, with margin assessment Breast issue - all specimens not otherwise specified Bronchus, biopsy Carotid body - neoplasm Cholesteatoma Digits, amputation - not traumatic Digits, amputation - not traumatic Ear, middle and inner - not cholesteatoma Endocrine neoplasm - not otherwise specified Ear, middle and inner - not cholesteatoma Endocrine neoplasm - not otherwise specified	Appendix	3
Bartholin's gland - cyst Bile duct, resection - all specimens Bone, biopsy, curettings or fragments - lesion Bone, biopsy or curettings quantitation - metabolic disease Bone, femoral head Bone, resection, neoplasm - all sites and types Bone marrow, biopsy 4 Bone - all specimens not otherwise specified Brain neoplasm, resection - cerebello-pontine angle Brain or meninges, biopsy - all lesions Brain or meninges, not neoplasm - temporal lobe Brain or meninges, resection - neoplasm (intracranial) Brain or meninges, resection - not neoplasm Branchial cleft, cyst Breast, excision biopsy, guidewire localisation - non-palpable lesion Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease - all specimen types Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast, orientated wide local excision for carcinoma, with margin assessment Breast insue - all specimens not otherwise specified Breast issue - all specimens not otherwise specified Bronchus, biopsy Carotid body - neoplasm Cholesteatoma Digits, amputation - not traumatic Ear, middle and inner - not cholesteatoma Endocrine neoplasm - not otherwise specified Endocrine neoplasm - not otherwise specified	Artery, all specimens not otherwise specified	3
Bile duct, resection - all specimens Bone, biopsy, curettings or fragments - lesion Bone, biopsy or curettings quantitation - metabolic disease Bone, femoral head Bone, resection, neoplasm - all sites and types Bone - all specimens not otherwise specified Brain neoplasm, resection - cerebello-pontine angle Brain or meninges, biopsy - all lesions Brain or meninges, not neoplasm - temporal lobe Brain or meninges, resection - neoplasm (intracranial) Brain or meninges, resection - not neoplasm Branchial cleft, cyst Breast, excision biopsy, guidewire localisation - non-palpable lesion Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease - all specimen types Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast, orientated wide local excision for carcinoma, with margin assessment Breast tissue - all specimens not otherwise specified Bronchus, biopsy Carotid body - neoplasm Cholesteatoma Digits, amputation - not traumatic Ear, middle and inner - not cholesteatoma Endocrine neoplasm - not otherwise specified Endocrine neoplasm - not otherwise specified Endocrine neoplasm - not otherwise specified	Artery, biopsy	4
Bone, biopsy, curettings or fragments - lesion Bone, biopsy or curettings quantitation - metabolic disease Bone, femoral head Bone, resection, neoplasm - all sites and types Bone all specimens not otherwise specified Brain neoplasm, resection - cerebello-pontine angle Brain or meninges, biopsy - all lesions Brain or meninges, not neoplasm - temporal lobe Brain or meninges, resection - neoplasm (intracranial) Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Branchial cleft, cyst Breast, excision biopsy, guidewire localisation - non-palpable lesion Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease - all specimen types Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast - microdochectomy Breast, orientated wide local excision for carcinoma, with margin assessment Breast issue - all specimens not otherwise specified Bronchus, biopsy Carotid body - neoplasm Cholesteatoma Digits, amputation - not traumatic Ear, middle and inner - not cholesteatoma Endocrine neoplasm - not otherwise specified Endocrine neoplasm - not otherwise specified	Bartholin's gland - cyst	3
Bone, biopsy or curettings quantitation - metabolic disease Bone, femoral head Bone, resection, neoplasm - all sites and types Bone marrow, biopsy Bone - all specimens not otherwise specified Brain neoplasm, resection - cerebello-pontine angle Brain or meninges, biopsy - all lesions Brain or meninges, not neoplasm - temporal lobe Brain or meninges, resection - neoplasm (intracranial) Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection, malignant neoplasm or atypical proliferative disease - all specimen types Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease - all specimen types Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast, orientated wide local excision for carcinoma, with margin assessment Breast tissue - all specimens not otherwise specified Bronchus, biopsy Acarotid body - neoplasm Cholesteatoma Digits, amputation - not traumatic Digits, amputation - not cholesteatoma Endocrine neoplasm - not otherwise specified Ear, middle and inner - not cholesteatoma Endocrine neoplasm - not otherwise specified	Bile duct, resection - all specimens	6
Bone, femoral head Bone, resection, neoplasm - all sites and types Bone marrow, biopsy Bone - all specimens not otherwise specified Brain neoplasm, resection - cerebello-pontine angle Brain or meninges, biopsy - all lesions Brain or meninges, not neoplasm - temporal lobe Brain or meninges, resection - neoplasm (intracranial) Brain or meninges, resection - neoplasm (intracranial) Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm or not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm - not otherwise specified Brain or meninges, resection - not otherwise specified Brain or meninges, resection - not otherwise specified Brain or meninges, resection - not otherwise specified Brain or meninges, resection - not otherwise specified Brain or meninges, resection - not otherwise specified Brain or meninges, resection - notherwise specified Brain or meninges, resection - not neoplasm - not otherwise specified Brain or meninges, resection - notherwise specified Brain or meninges, resection - neoplasm - not otherwise specified Brain or meninges, resection - neoplasm - not other	Bone, biopsy, curettings or fragments - lesion	5
Bone, resection, neoplasm - all sites and types Bone marrow, biopsy Bone - all specimens not otherwise specified Brain neoplasm, resection - cerebello-pontine angle Brain or meninges, biopsy - all lesions Brain or meninges, not neoplasm - temporal lobe Brain or meninges, resection - neoplasm (intracranial) Brain or meninges, resection - not neoplasm Brain or meninges, resection - neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - not neoplasm - not otherwise specified Brain or meninges, resection - not neoplasm - not otherwise specified Brain or meninges Brain or meninges, resection - not neoplasm - not otherwise specified Brain or meninges Brain or m	Bone, biopsy or curettings quantitation - metabolic disease	6
Bone marrow, biopsy Bone - all specimens not otherwise specified Brain neoplasm, resection - cerebello-pontine angle Brain or meninges, biopsy - all lesions Brain or meninges, not neoplasm - temporal lobe Brain or meninges, resection - neoplasm (intracranial) Brain or meninges, resection - neoplasm (intracranial) Brain or meninges, resection - not neoplasm Brain or meninges, resection - neoplasm Brain or meninges, resection - neoplasm Brain or meninges, resection - neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - neoplasm Brain or meninges, resection - neoplasm Brain or meninges, resection - not neoplasm Brain or meninges, resection - neoplasm Brain or meninges, resection - neoplasm Brain or meninges, resection - neoplasm Brain or meninges, resection - neoplasm - not otherwise specified 4 Brain or meninges, resection - neoplasm - not otherwise specified 5 Brain or meninges, resection - neoplasm - not otherwise specified 5 Brain or meninges, resection - neoplasm - not otherwise specified 6 Brain or meninges, resection - neoplasm - not otherwise specified 6 Brain or meninges, resection - neoplasm - non neoplasm - neoplasm 6 Brain or meninges, res	Bone, femoral head	4
Bone - all specimens not otherwise specified Brain neoplasm, resection - cerebello-pontine angle Brain or meninges, biopsy - all lesions Brain or meninges, not neoplasm - temporal lobe Brain or meninges, resection - neoplasm (intracranial) Brain or meninges, resection - not neoplasm (intracranial) Brain or meninges, resection - not neoplasm 6 Brain or meninges, pionges (intracranial) 5 Brain or meninges, pionges (intracranial) 6 Brain or meninges, resection - neoplasm - not otherwise specified 4 Brain or meninges, resection - neoplasm - not otherwise specified 5 Brain or meninges, resection - neoplasm - not otherwise specified 6 Brain or meninges, resection - neoplasm - not otherwise specified 6 Brain or meninges, resection - neoplasm - not otherwise specified	Bone, resection, neoplasm - all sites and types	6
Brain neoplasm, resection - cerebello-pontine angle Brain or meninges, biopsy - all lesions Brain or meninges, not neoplasm - temporal lobe Brain or meninges, resection - neoplasm (intracranial) Brain or meninges, resection - neoplasm (intracranial) Brain or meninges, resection - not neoplasm 4 Branchial cleft, cyst 4 Breast, excision biopsy, guidewire localisation - non-palpable lesion Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease - all specimen types Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast - microdochectomy Breast, orientated wide local excision for carcinoma, with margin assessment Breast tissue - all specimens not otherwise specified 4 Bronchus, biopsy Carotid body - neoplasm Cholesteatoma Digits, amputation - not traumatic Digits, amputation - traumatic Ear, middle and inner - not cholesteatoma Endocrine neoplasm - not otherwise specified 5	Bone marrow, biopsy	4
Brain neoplasm, resection - cerebello-pontine angle Brain or meninges, biopsy - all lesions Brain or meninges, not neoplasm - temporal lobe Brain or meninges, resection - neoplasm (intracranial) Brain or meninges, resection - neoplasm (intracranial) Brain or meninges, resection - not neoplasm 4 Branchial cleft, cyst 4 Breast, excision biopsy, guidewire localisation - non-palpable lesion Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease - all specimen types Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast - microdochectomy Breast, orientated wide local excision for carcinoma, with margin assessment Breast tissue - all specimens not otherwise specified 4 Bronchus, biopsy Carotid body - neoplasm Cholesteatoma Digits, amputation - not traumatic Digits, amputation - traumatic Ear, middle and inner - not cholesteatoma Endocrine neoplasm - not otherwise specified 5	Bone - all specimens not otherwise specified	4
Brain or meninges, biopsy - all lesions Brain or meninges, not neoplasm - temporal lobe Brain or meninges, resection - neoplasm (intracranial) Brain or meninges, resection - not neoplasm 4 Brain or meninges, resection - neoplasm (intracranial) 5 Brain or meninges, not neoplasm (intracranial) 5 Brain or meninges, not neoplasm (intracranial) 5 Brain or meninges, not neoplasm 4 Breast, excision biopsy, resection - not neoplasm - non-palpable lesion 6 Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease - all specimen types Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast - microdochectomy Breast, orientated wide local excision for carcinoma, with margin assessment Breast tissue - all specimens not otherwise specified 4 Bronchus, biopsy Carotid body - neoplasm 5 Cholesteatoma 5 Cholesteatoma 3 Digits, amputation - not traumatic 9 Digits, amputation - traumatic 10 Ear, middle and inner - not cholesteatoma 4 Endocrine neoplasm - not otherwise specified 5	Brain neoplasm, resection - cerebello-pontine angle	4
Brain or meninges, resection - neoplasm (intracranial) Brain or meninges, resection - not neoplasm Branchial cleft, cyst Breast, excision biopsy, guidewire localisation - non-palpable lesion Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease - all specimen types Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast - microdochectomy Breast, orientated wide local excision for carcinoma, with margin assessment Breast tissue - all specimens not otherwise specified Bronchus, biopsy Carotid body - neoplasm Cholesteatoma Digits, amputation - not traumatic Digits, amputation - traumatic Ear, middle and inner - not cholesteatoma Endocrine neoplasm - not otherwise specified 5	Brain or meninges, biopsy - all lesions	5
Brain or meninges, resection - neoplasm (intracranial) Brain or meninges, resection - not neoplasm Branchial cleft, cyst Breast, excision biopsy, guidewire localisation - non-palpable lesion Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease - all specimen types Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast - microdochectomy Breast, orientated wide local excision for carcinoma, with margin assessment Breast tissue - all specimens not otherwise specified Bronchus, biopsy Carotid body - neoplasm Cholesteatoma Digits, amputation - not traumatic Digits, amputation - traumatic Ear, middle and inner - not cholesteatoma Endocrine neoplasm - not otherwise specified 5	Brain or meninges, not neoplasm - temporal lobe	6
Brain or meninges, resection - not neoplasm Branchial cleft, cyst Breast, excision biopsy, guidewire localisation - non-palpable lesion Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease - all specimen types Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast - microdochectomy Breast, orientated wide local excision for carcinoma, with margin assessment Breast tissue - all specimens not otherwise specified Bronchus, biopsy Carotid body - neoplasm Cholesteatoma Digits, amputation - not traumatic Ear, middle and inner - not cholesteatoma Endocrine neoplasm - not otherwise specified 5	Brain or meninges, resection - neoplasm (intracranial)	5
Branchial cleft, cyst Breast, excision biopsy, guidewire localisation - non-palpable lesion Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease - all specimen types Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast – microdochectomy Breast, orientated wide local excision for carcinoma, with margin assessment Breast tissue - all specimens not otherwise specified Bronchus, biopsy Carotid body - neoplasm Cholesteatoma Digits, amputation - not traumatic Digits, amputation - traumatic Ear, middle and inner - not cholesteatoma Endocrine neoplasm - not otherwise specified 5		4
Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease - all specimen types Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast - microdochectomy Breast, orientated wide local excision for carcinoma, with margin assessment Breast tissue - all specimens not otherwise specified Bronchus, biopsy Carotid body - neoplasm Cholesteatoma Digits, amputation - not traumatic Digits, amputation - traumatic Ear, middle and inner - not otherwise specified Endocrine neoplasm - not otherwise specified 5	Branchial cleft, cyst	4
Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease - all specimen types Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast - microdochectomy Breast, orientated wide local excision for carcinoma, with margin assessment Breast tissue - all specimens not otherwise specified Bronchus, biopsy Carotid body - neoplasm Cholesteatoma Digits, amputation - not traumatic Digits, amputation - traumatic Ear, middle and inner - not otherwise specified Endocrine neoplasm - not otherwise specified 5	Breast, excision biopsy, guidewire localisation - non-palpable lesion	6
Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types Breast – microdochectomy Breast, orientated wide local excision for carcinoma, with margin assessment Breast tissue - all specimens not otherwise specified Bronchus, biopsy Carotid body - neoplasm Cholesteatoma Digits, amputation - not traumatic Digits, amputation - traumatic Ear, middle and inner - not cholesteatoma Endocrine neoplasm - not otherwise specified 5	Breast, excision biopsy, or radical resection, malignant neoplasm or	6
Breast, orientated wide local excision for carcinoma, with margin assessment Breast tissue - all specimens not otherwise specified Bronchus, biopsy 4 Carotid body - neoplasm 5 Cholesteatoma 3 Digits, amputation - not traumatic 4 Digits, amputation - traumatic Ear, middle and inner - not cholesteatoma Endocrine neoplasm - not otherwise specified 5	Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types	4
Breast tissue - all specimens not otherwise specified Bronchus, biopsy Carotid body - neoplasm Cholesteatoma Digits, amputation - not traumatic Ear, middle and inner - not cholesteatoma Endocrine neoplasm - not otherwise specified	Breast – microdochectomy	6
Bronchus, biopsy 4 Carotid body - neoplasm 5 Cholesteatoma 3 Digits, amputation - not traumatic 4 Digits, amputation - traumatic 2 Ear, middle and inner - not cholesteatoma 4 Endocrine neoplasm - not otherwise specified 5	Breast, orientated wide local excision for carcinoma, with margin assessment	7
Carotid body - neoplasm 5 Cholesteatoma 3 Digits, amputation - not traumatic 4 Digits, amputation - traumatic 2 Ear, middle and inner - not cholesteatoma 4 Endocrine neoplasm - not otherwise specified 5	Breast tissue - all specimens not otherwise specified	4
Carotid body - neoplasm 5 Cholesteatoma 3 Digits, amputation - not traumatic 4 Digits, amputation - traumatic 2 Ear, middle and inner - not cholesteatoma 4 Endocrine neoplasm - not otherwise specified 5	Bronchus, biopsy	4
Cholesteatoma 3 Digits, amputation - not traumatic 4 Digits, amputation - traumatic 2 Ear, middle and inner - not cholesteatoma 4 Endocrine neoplasm - not otherwise specified 5	Carotid body - neoplasm	5
Digits, amputation - traumatic 2 Ear, middle and inner - not cholesteatoma 4 Endocrine neoplasm - not otherwise specified 5	Cholesteatoma	3
Digits, amputation - traumatic 2 Ear, middle and inner - not cholesteatoma 4 Endocrine neoplasm - not otherwise specified 5	Digits, amputation - not traumatic	4
Ear, middle and inner - not cholesteatoma 4 Endocrine neoplasm - not otherwise specified 5		<u> </u>
Endocrine neoplasm - not otherwise specified 5		<u> </u>
	Extremity, amputation or disarticulation – neoplasm	6

Specimen Type	Complexity level
Extremity, amputation - not otherwise specified	4
Eye, conjunctiva - biopsy or pterygium	3
Eye, cornea	4
Eye, enucleation or exenteration - all lesions	6
Eye - not otherwise specified	4
Fallopian tube, biopsy	4
Fallopian tube, ectopic pregnancy	4
Fallopian tube, sterilization	2
Fetus with dissection	6
Foreskin - new born	2
Foreskin - not new born	3
Gallbladder	3
Gallbladder and porta hepatis-radical resection	6
Ganglion cyst, all sites	3
Gum or oral mucosa, biopsy	4
Heart valve	4
Heart - not otherwise specified	5
Hernia sac	2
Hydrocele sac	2
Jaw, upper or lower, including bone, radical resection for neoplasm	6
Joint and periarticular tissue, without bone - all specimens	3
Joint tissue, including bone - all specimens	4
Kidney, biopsy including transplant	5
Kidney, nephrectomy transplant	5
Kidney, partial or total nephrectomy or nephroureterectomy - neoplasm	6
Kidney, partial or total nephrectomy - not neoplasm	4
Large bowel (including rectum), biopsy - all sites	4
Large bowel, colostomy - stoma	3
Large bowel (including rectum), biopsy, for confirmation or exclusion of Hirschsprung's Disease	5
Large bowel (including rectum), polyp	4
Large bowel, segmental resection - colon, not neoplasm	5
Large bowel (including rectum), segmental resection, neoplasm	6
Large bowel (including rectum), submucosal resection – neoplasm	5
Larynx, biopsy	4
Larynx, partial or total resection	5
Larynx, resection with nodes or pharynx or both	6
Lip, biopsy - all specimens not otherwise specified	3
Lip, wedge resection or local excision with orientation	4
Liver, hydatid cyst or resection for trauma	4
Liver, total or subtotal hepatectomy - neoplasm	6
Liver - all specimens not otherwise specified	5

Specimen Type	Complexity level
Lung, needle or transbronchial biopsy	4
Lung, resection - neoplasm	6
Lung, wedge biopsy	5
Lung segment, lobar or total resection	6
Lymph node, biopsy - all sites	4
Lymph node, biopsy – for lymphoma or lymphoproliferative disorder	5
Lymph nodes, regional resection - all sites	5
Mediastinum mass	5
Muscle, biopsy	6
Nasopharynx or oropharynx, biopsy	4
Nerve, biopsy neuropathy	5
Nerve, neurectomy or removal of neoplasm	4
Nerve - not otherwise specified	3
Nose, mucosal biopsy	4
Nose or sinuses, polyps	3
Odontogenic neoplasm	5
Odontogenic or dental cyst	4
Oesophagus, biopsy	4
Oesophagus, diverticulum	3
Oesophagus, partial or total resection	6
Oesophagus, submucosal resection – neoplasm	5
Omentum, biopsy	4
Ovary with or without tube - neoplasm	5
Ovary with or without tube - not neoplasm	4
Pancreas, biopsy	5
Pancreas, cyst	4
Pancreas, subtotal or total with or without splenectomy	6
Parathyroid gland(s)	4
Penisectomy with node dissection	5
Penisectomy - simple	4
Peritoneum, biopsy	4
Pituitary neoplasm	4
Placenta - not third trimester	4
Placenta - third trimester, abnormal pregnancy or delivery	4
Pleura or pericardium, biopsy or tissue	4
Products of conception, spontaneous or missed abortion	4
Products of conception, termination of pregnancy	3
Prostate, radical prostatectomy or cystoprostatectomy for carcinoma	7
Prostate, radical resection	6
Prostate - all types of specimen not otherwise specified	4
Retroperitoneum, neoplasm	5
Salivary gland, Mucocele	3
Salivary gland, neoplasm - all sites	5

Specimen Type	Complexity level
Salivary gland - all specimens not otherwise specified	4
Sinus, paranasal, biopsy	4
Sinus, paranasal, resection - neoplasm	6
Skin, biopsy - blistering skin diseases	4
Skin biopsy - for investigation of alopecia other than for male pattern baldness, where serial horizontal sections are taken	5
Skin, biopsy - for investigation of lymphoproliferative disorder	5
Skin, biopsy - inflammatory dermatosis	4
Skin,eyelid, wedge resection	4
Skin, local resection - orientation	4
Skin, resection of malignant melanoma or melanoma in-situ	5
Skin - all specimens not otherwise specified including all neoplasms and cysts	3
Small bowel - biopsy, all sites	4
Small bowel, diverticulum	3
Small bowel, resection - neoplasm	6
Small bowel – resection, all specimens	5
Small bowel, submucosal resection – neoplasm	5
Soft tissue, infiltrative lesion, extensive resections at least 5cm in maximal dimension	6
Soft tissue, lipoma and variants	3
Soft tissue, neoplasm, not lipoma - all specimens	5
Soft tissue - not otherwise specified	4
Spleen	5
Stomach, endoscopic biopsy or endoscopic polypectomy	4
Stomach, resection, neoplasm - all specimens	6
Stomach, submucosal resection – neoplasm	5
Stomach - all specimens not otherwise specified	4
Tendon or tendon sheath, giant cell neoplasm	4
Tendon or tendon sheath - not otherwise specified	3
Testis, biopsy	5
Testis and adjacent structures, castration	2
Testis and adjacent structures, neoplasm with or without nodes	5
Testis and adjacent structures, vas deferens sterilization	2
Testis and adjacent structures - not otherwise specified	3
Thymus - not otherwise specified	5
Thyroglossal duct - all lesions	4
Thyroid - all specimens	5
Tissue or organ not otherwise specified, abscess	3
Tissue or organ not otherwise specified, haematoma	3
Tissue or organ not otherwise specified, malignant neoplasm with regional nodes	6
Tissue or organ not otherwise specified, neoplasm local	4

Specimen Type	Complexity level
Tissue or organ not otherwise specified, pilonidal cyst or sinus	3
Tissue or organ not otherwise specified, thrombus or embolus	3
Tissue or organ not otherwise specified, veins varicosity	3
Tissue or organ - all specimens not otherwise specified	3
Tongue, biopsy	4
Tongue or tonsil, neoplasm local	5
Tongue or tonsil, neoplasm with nodes	6
Tonsil, biopsy - excluding resection of whole organ	4
Tonsil or adenoids or both	2
Trachea, biopsy	4
reter, biopsy	4
Ureter, resection	5
Urethra, biopsy	4
Urethra, resection	5
Urinary bladder, partial or total with or without prostatectomy	6
Urinary bladder, transurethral resection of neoplasm	5
Urinary bladder - all specimens not otherwise specified	4
Uterus, cervix, curettings or biopsy	4
Uterus, cervix cone, biopsy (including LLETZ or LEEP biopsy)	5
Uterus, endocervix, polyp	3
Uterus, endometrium, polyp	3
Uterus with or without adnexa, malignant neoplasm - all specimen types not otherwise specified	6
Uterus with or without adnexa, neoplasm, Wertheim's or pelvic clearance	6
Uterus and/or cervix - all specimens not otherwise specified	4
Vagina, biopsy	4
Vagina, radical resection	6
Vaginal mucosa, incidental	3
Vulva or labia, biopsy	4
Vulval, subtotal or total with or without nodes	6

CATEGORY 7: CLEFT LIP AND CLEFT PALATE SERVICES

SUMMARY OF CHANGES FROM 01/03/2019

The 01/03/2019 changes to the MBS are summarised below and are identified in the Schedule pages by one or more of the following words appearing above the item number:

(a) new item	New
(b) amended description	Amend
(c) fee amended	Fee
(d) item number changed	Renum
(e) EMSN changed	EMSN

There are no changes to this Category for 01/03/2019.

CLEFT LIP AND CLEFT PALATE SERVICES NOTES

CN.0.1 Schedule Fees and Medicare Benefits

Medicare benefits are based on fees determined for each Schedule service. The fee is referred to in these notes as the "Schedule fee". The fee for any item listed in the Schedule is that which is regarded as being reasonable on average for that service having regard to usual and reasonable variations in the time involved in performing the service on different occasions and to reasonable ranges of complexity and technical difficulty encountered.

The Schedule fee and Medicare benefit levels for the medical services contained in the Schedule are located with the item descriptions. Where appropriate, the calculated benefit has been rounded to the nearest higher 5 cents. However, in no circumstances will the Medicare benefit payable exceed the fee actually charged.

There are presently two levels of Medicare benefit payable for cleft lip and cleft palate services:

(a) 75% of the Schedule fee:

for professional services rendered to a patient as part of an episode of hospital treatment (other than public patients). Medical practitioners must indicate on their accounts if a medical service is rendered in these circumstances by placing an asterisk '*' or the letter 'H' directly after an item number where used; or a description of the professional service and an indication the service was rendered as an episode of hospital treatment (for example, 'in hospital', 'admitted' or 'in patient');

for professional services rendered as part of an episode of hospital-substitute treatment, and the patient who receives the treatment chooses to receive a benefit from a private health insurer. Medical practitioners must indicate on their accounts if a medical service is rendered in these circumstances by placing the words 'hospital-substitute treatment' directly after an item number where used; or a description of the professional service, preceded by the words 'hospital-substitute treatment'.

(b) **85% of the Schedule fee,** or the Schedule fee less \$83.40 (indexed annually), whichever is the greater, for all other professional services.

It should be noted that the Health Insurance Act makes provision for private medical insurance to cover the "patient gap" (ie, the difference between the Medicare benefit and the Schedule fee) for services attracting benefit at the 75% level. Patients may insure with private health insurance organisations for the gap between the 75% Medicare benefit and the Schedule fee or for amounts in excess of the Schedule fee where the patient has an agreement with their health fund.

CN.0.2 Where Medicare Benefits are not Payable

Medicare benefits are not payable in respect of a professional service where the medical expenses for the service:-

- (a) are paid/payable to a public hospital;
- (b) are for a compensable injury or illness for which the patient's insurer or compensation agency has accepted liability. (Please note that if the medical expenses relate to a compensable injury/illness for which the insurer/compensation agency is disputing liability, then Medicare benefits are payable until the liability is accepted);
- (c) are for a medical examination for the purposes of life insurance, superannuation, a provident account scheme, or admission to membership of a friendly society; or
- (d) are incurred in mass immunisation.

Unless the Minister otherwise directs, Medicare benefits are not payable where:

- (a) the service is rendered by or on behalf of, or under an arrangement with the Australian Government, a State or Territory, a local government body or an authority established under Commonwealth, State or Territory law;
- (b) the medical expenses are incurred by the employer of the person to whom the service is rendered;

- (c) the person to whom the service is rendered is employed in an industrial undertaking and that service is rendered for the purposes related to the operation of the undertaking; or
- (d) the services is a health screening service.

Benefits are not payable for items 75150 to 75621 unless the patient was referred by letter of Referral by an eligible orthodontist.

CN.0.3 Limiting Rule

In no circumstances will the benefit payable for a professional service exceed the fee charged for the service.

CN.0.4 Penalties

Penalties of up to \$10,000 or imprisonment for up to five years, or both, may be imposed on any person who makes a statement (oral or written) or who issues or presents a document that is false or misleading in a material particular and which is capable of being used with a claim for benefits. In addition, any practitioner who is found guilty of such offences by a court shall be subject to examination by a Medicare Participation Review Committee and may be counselled or reprimanded or may have services wholly or partially disqualified from the Medicare benefit arrangements.

A penalty of up to \$1,000 or imprisonment for up to three months, or both, may be imposed on any person who obtains a patient's signature on a direct-billing form without the obligatory details having been entered on the form before the person signs, or who fails to cause a patient to be given a copy of the completed form.

CN.0.5 Billing of the Patient

Where the practitioner bills the patient for medical services rendered, the patient needs a properly itemised account/receipt to enable a claim to be made for Medicare benefits.

Under the provisions of the Health Insurance Act and Regulations, Medicare benefits are not payable in respect of a professional service unless there is recorded on the account setting out the fee for the service or on the receipt for the fee in respect of the service, the following particulars:-

- (a) Patient's name;
- (b) The date on which the professional service was rendered;
- (c) A description of the professional service sufficient to identify the item that relates to that service, including an indication where the service is rendered to a person while hospital treatment is provided in a hospital or day-hospital facility (other than a Medicare hospital patient), that is, the words (ie, accommodation and nursing care) "admitted patient" immediately preceding the description of the service or an asterisk "*" directly after an item number where used;
- (d) The name and practice address or name and provider number of the practitioner who actually rendered the service; (Where the practitioner has more than one practice location recorded with the Department of Human Services, the provider number used should be that which is applicable to the practice location at or from which the service was given).

A medical or dental practitioner must notate 'certified dental patient' on the patient's account or include 'certified dental patient' in the text field when submitting a Medicare claim for benefits.

Where a practitioner wishes to apportion the total fee between the appropriate professional fee for the particular service and any balance outstanding in respect of services rendered previously, the practitioner should ensure that the balance is described in such a way (eg balance of account) that it cannot be mistaken as being a separate service. In particular no item number should be shown against the balance.

Only one original itemised account should be issued in respect of any one medical service and any duplicates of accounts or receipts should be clearly marked "duplicate" and should be issued only where the original has been lost. Duplicates should not be issued as a routine system for "accounts rendered".

CN.0.6 Claiming of Benefits Claiming Benefits

The patient, upon receipt of a practitioner's account, has three courses open for paying the account and receiving benefits as outlined below.

Paid Accounts

The patient may pay the account and subsequently present the receipt at a Medicare customer service centre for assessment and payment of the Medicare benefit in cash. In these circumstances, where a claimant personally attends a customer service centre, the claimant is not required to complete a Medicare Patient Claim Form (PC1).

In circumstances where the claimant is seeking a cheque payment of the Medicare benefit or is arranging for an agent to receive the Medicare benefit on the claimant's behalf, completion of a Medicare Patient Claim Form (PC1) is still required.

Unpaid and Partially Paid Accounts

Where the patient has not paid the account, the unpaid account may be presented to Medicare with a Medicare claim form. In this case Medicare will forward to the claimant a benefit cheque made payable to the practitioner.

It will be the patient's responsibility to forward the cheque to the practitioner and make arrangements for payment of the balance of the account if any. "Pay doctor" cheques involving Medicare benefits cannot be sent direct to practitioners or to patients at a practitioner's address (even if requested by the patient to do so). "Pay doctor" cheques will be forwarded to the claimant's last known address.

When issuing a receipt to a patient in respect of an account that is being paid wholly or in part by a Medicare "pay doctor" cheque the practitioner should indicate on the receipt that a "Medicare" cheque for \$.......was involved in the payment of the account.

Assignment of Benefits (Direct-Billing) Arrangements

Under the Health Insurance Act the Assignment of Benefit (direct-billing) facility for professional services is available to all persons in Australia who are eligible for benefit under the Medicare program. This facility is NOT confined to pensioners or people in special need. If a practitioner direct-bills, the practitioner undertakes to accept the relevant Medicare benefit as full payment for the service. Additional charges for that service (irrespective of the purpose or title of the charge) cannot be raised against the patient. Under these arrangements:-

- The patient's Medicare card number must be quoted on all direct-bill forms for that patient.
- The basic forms provided are loose leaf to enable the patient details to be imprinted from the Medicare card.
- The forms include information required by Regulations under Subsection 19(6) of the Health Insurance Act.
- · The practitioner must cause the particulars relating to the professional service to be set out on the assignment form before the patient signs the form and cause the patient to receive a copy of the form as soon as practicable after the patient signs it.

Where a patient is unable to sign the assignment form:

• the signature of the patient's parent, guardian or other responsible person (other than the doctor, doctor's staff, hospital proprietor, hospital staff, residential aged care facility proprietor or residential aged care facility staff) is acceptable; or

• In the absence of a "responsible person" the patient signature section should be left blank.

Where the signature space is either left blank or another person signs on the patient's behalf, the form <u>must</u> include:

- the notation "Patient unable to sign" and
- in the section headed 'Practitioner's Use', an explanation should be given as to why the patient was unable to sign (e.g. unconscious, injured hand etc.) and this note should be signed or initialled by the doctor. If in the opinion of the practitioner the reason is of such a "sensitive" nature that revealing it would constitute an unacceptable breach of patient confidentiality or unduly embarrass or distress the recipient of the patient's copy of the assignment of benefits form, a concessional reason "due to medical condition" to signify that such a situation exists may be substituted for the actual reason. However, this should not be used routinely and in most cases it is expected that the reason given will be more specific.

The administration of the direct-billing arrangements under Medicare as well as the payment of Medicare benefits on patient claims is the responsibility of **the Department of Human Services**. Any enquiries in regard to these matters should therefore be directed to Medicare offices or enquiry points.

Under Medicare any eligible dental practitioner can accept assignment of benefit and direct-bill for any eligible person.

Use of Medicare Cards in Direct Billing

An eligible person who applies to enrol for Medicare benefits (using a Medicare Enrolment/Amendment Application) will be issued with a uniquely numbered Medicare card which shows the Medicare card number, the patient identification number (reference number), the applicant's first given name, initial of second given name, surname and an effective "valid to" date. These cards may be issued on an individual or family basis. Up to 5 persons may be listed on the one Medicare card, and up to 9 persons may be listed under the one Medicare card number.

The Medicare card plays an important part in direct billing as it can be used to imprint the patient details (including Medicare number) on the basic direct-billing forms. A special Medicare imprinter has been developed for this purpose and is available free of charge, on request, from Medicare.

The patient details can of course be entered on the direct-bill forms by hand, but the use of a card to imprint patient details assists practitioners and ensures accuracy of information. The latter is essential to ensure that the processing of a claim by Medicare is expedited.

The Medicare card number must be quoted on direct-bill forms. If the number is not available, then the assignment of benefit facility should not be used. To do so would incur a risk that the patient is not eligible and Medicare benefits not payable.

Where a patient presents without a Medicare card and indicates that he/she has been issued with a card but does not know the details, the practitioner may contact a Medicare telephone enquiry number to obtain the number.

Assignment of Benefit Forms

To meet varying requirements the following types of stationery are available from Medicare. Note that these forms are approved forms under the Health Insurance Act, and no other forms can be used to assign benefits without the approval of the Department of Human Services.

- (a) Form DB2. This form is used to assign benefits for services other than requested pathology. It is loose leaf for imprinting and comprises a throw away cover sheet (after imprinting), a Medicare copy, a Patient copy and a Practitioner copy.
- (b) Form DB4. Is a continuous stationery version of Form DB2, and has been designed for use on most office accounting machines.

The Claim for Assigned Benefits (Form DB1N, DB1H)

Practitioners who accept assigned benefits must claim from Medicare using either Claim for Assigned Benefits form DB1N or DB1H. The DB1N form should be used where services are rendered to persons for treatment provided out of hospital or day hospital treatment. The DB1H form should be used where services are rendered to persons while hospital treatment is provided in a hospital or day hospital facility (other than public patients). Both forms have been designed to enable benefit for a claim to be directed to a practitioner other than the one who rendered the services. The facility is intended for use in situations such as where a short term locum is acting on behalf of the principal doctor and setting the locum up with a provider number and pay-group link for the principal doctor's practice is impractical. Practitioners should note that this facility cannot be used to generate payments to or through a person who does not have a provider number.

The DB1N and DB1H are also loose leaf to enable imprinting of practitioner details using the special Medicare imprinter. For this purpose, practitioner cards, showing the practitioner's name, practice address and provider numbers are available from Medicare on request.

Direct-Bill Stationery

Medical practitioners and eligible dental practitioners wishing to direct-bill may obtain information on direct-bill stationery by telephoning **132150**. Information on the completion of the forms and direct-bill procedures are provided with the forms. Information on direct-billing is available from any Medicare office.

Time Limits Applicable to Lodgement of Claims for Assigned Benefits

A time limit of two years applies to the lodgement of claims with Medicare under the direct-billing (assignment of benefit) arrangements. This means that Medicare benefits are not payable for any service where the service was rendered more than two years earlier than the date the claim was lodged with Medicare.

Provision exists whereby in certain circumstances (eg hardship cases), the Minister may waive the time limits. Special forms for this purpose are available, if required, from the processing centre to which assigned claims are directed.

CN.0.7 Interpretation of the Cleft Lip and Cleft Palate Scheme

The prescribed services in this section have been grouped according to the general nature of the services: orthodontic, oral surgical and general and prosthodontic.

Each professional service listed in the Schedule is a complete medical service in itself. Where a service is rendered partly by one practitioner and partly by another, only the one amount of benefit is payable.

CN.0.8 Multiple Operation Rule

The Schedule fee for two or more operations performed on a patient on the one occasion is calculated by the following rule:-

- \cdot 100% for the item with the greatest Schedule fee, plus 50% for the item with the next greatest Schedule fee, plus 25% for each other item.
- **NOTE:** 1. Fees so calculated which result in a sum which is not a multiple of 5 cents are taken to the next higher multiple of 5 cents.
- 2. Where two or more operations performed on the one occasion have fees which are equal, one of these amounts shall be treated as being greater than the other or others of those amounts.
- 3. The Schedule fee for benefits purposes is the aggregate of the fees calculated in accordance with the above formula.

The above rule does not apply to an operation which is one of two or more operations performed under the one anaesthetic on the same patient by different dental practitioners unless either practitioner assists the other. In this case, the fees and benefits specified in the Schedule apply. For these purposes the term "operation" includes items 75200-75615.

If the operation comprises a combination of procedures which are commonly performed together and for which a specific combined item is provided in the Schedule, it is regarded as the one item and service in applying the multiple operation rule.

CN.0.9 Administration of Anaesthetics

When a medical practitioner administers an anaesthetic in connection with a dental procedure prescribed for the payment of Medicare benefits (and the procedure has been performed by an eligible dental practitioner), Medicare benefits are payable for the administration of the anaesthetic on the same basis as if the procedure had been rendered by a medical practitioner.

To ascertain the Schedule fee for the anaesthetic, medical practitioners should refer to Group T10 - Relative Value Guide for Anaesthesia - of the Medicare Benefits Schedule Book.

CN.0.10 Definitions

Orthodontic treatment planning

Orthodontic treatment planning is defined as the measurement and analysis of the face and jaws and occlusion providing a diagnosis and planned prescription of appliances and treatment required.

Study models

Study models are defined as orthodontic plaster casts of the upper and lower teeth and alveolar processes.

CN.0.11 Referral of Oral and Maxillofacial Surgical Services - (Items 75150 to 75621)

Benefits are payable for items 75150 to 75621 only where the service has been rendered to a patient who has been referred by letter of Referral by an eligible orthodontist.

Item 75621 may be claimed in association with items 45720 to 45754 where the service is performed by a practitioner holding a FRACDS (OMS) qualification with access to Category 3 of the MBS.

CN.0.12 General and Prosthodontic Services - (Item 75800)

Item number 75800 refers to a consultation by a dentist for prevention and prophylaxis and includes such services as dietary advice, oral hygiene and fluoride treatment.

CN.0.13 Over-servicing

Over-servicing must be avoided. In the case of denture services, examples of over-servicing might be:-

- · Unjustifiably frequent replacement of dentures;
- · Provision of new dentures when relining or re-modelling of an existing prosthesis would meet the clinical need;
- · Provision of metal dentures where an acrylic denture would meet the clinical need.

The Schedule includes an item for metal dentures to allow for the provision of a precise, long-term prosthesis. The item is not intended for use during the period of growth, where prostheses must be replaced or altered frequently, unless there is some definite and extraordinary clinical requirement.

CN.0.14 Commonwealth Department of Health Addresses

Postal: GPO Box 9848 in each Capital City

NEW SOUTH WALES

Level 7 1 Oxford Street SYDNEY 2000 Tel (02) 9263 3555

VICTORIA

Casselden Place 2 Lonsdale Street MELBOURNE 3000 Tel (03) 9665 8888

QUEENSLAND

5th Floor Samuel Griffith Building 340 Adelaide Street BRISBANE 4000 Tel (07) 3360 2555

SOUTH AUSTRALIA

Commonwealth Centre 55 Currie Street ADELAIDE 5000 Tel (08) 8237 8111

WESTERN AUSTRALIA

152-158 St George's Terrace PERTH 6000 Tel (08) 9346 5111

TASMANIA

Montpelier Building 21 Kirksway Place BATTERY POINT 7004 Tel (03) 6221 1411

AUSTRALIAN CAPITAL TERRITORY

Alexander Building Furzer Street PHILLIP 2606 Tel (02) 6289 1555

NORTHERN TERRITORY

Cascom Centre 13 Scaturchio Street CASUARINA 0800 Tel (08) 8946 3444

CN.1.1 Introduction - Medicare Benefits

The Medicare Benefits Schedule includes certain professional services in respect of the treatment of cleft lip and cleft palate conditions for which Medicare benefits are payable. These services are normally described as dental services. However, for the purposes of these Notes the word "medical" is to be interpreted to include "dental". The definition of professional service as contained in the Health Insurance Act provides that such a service must be "clinically relevant". A clinically relevant service means a service rendered by a medical or dental practitioner or

optometrist that is generally accepted in the medical, dental or optometrical profession (as the case may be) as being necessary for the appropriate treatment of the patient to whom it is rendered.

Medicare benefits are payable in respect of services listed in the Schedule, when the services are rendered by eligible dental practitioners to prescribed dental patients.

The Schedule lists three categories of professional services:

- · (Group C1) Orthodontic Services
- · (Group C2) Oral and Maxillofacial Surgical Services
- · (Group C3) General and Prosthodontic Services

CN.2.1 Dental Practitioner Eligibility

In order to attract Medicare benefits, all treatment must be carried out by eligible dental practitioners who are resident in Australia.

All registered dental practitioners are entitled to perform simple extraction services covered by Items 75200-75206 listed in Group C2 of the Schedule and the general and prosthodontic services listed in Group C3 of the Schedule.

Dental practitioners who wish to perform those orthodontic services listed in Group C1 of the Schedule must be registered in the specialty of orthodontics.

Dental practitioners who were previously accredited to provide Cleft Lip and Cleft Palate services who do not meet the registration requirements as a dental specialist will be grandfathered under legislative arrangements that came into force on 1 November 2012.

Oral and maxillofacial services listed in Group C2 may be performed by:

- Medical practitioners who are specialists in the practice of their specialty of oral and maxillofacial surgery; and
- · Dental practitioners who were approved by the Minister prior to 1 November 2004 for the purposes of Subsection 3 (1) of the Act to carry out prescribed medical services (oral and maxillofacial surgery) contained in the Medicare Benefits Schedule.
 - Following a referral from an eligible orthodontist.

CN.3.1 Patient Eligibility

To be eligible to claim benefits for Schedule services performed by eligible dental practitioners, a patient must satisfy the following criteria:

- a. The patient must be an Australian resident or any other person or class of persons whom the Minister declares to be eligible. All eligible persons will be issued with a Medicare card on application as evidence of their eligibility.
- b. Under the provisions of Section 3BA of the Health Insurance Act a patient must be a prescribed dental patient, ie
 - a person aged up to 22 years, in respect of whom, has been certified as a prescribed dental patient by a medical practitioner or dental practitioner approved by the Minister, that the person is suffering from a cleft lip or cleft palate condition*;
 - a person aged up to 28 years, in respect of whom, prior to turning 22 years,
 - has been certified as a prescribed dental patient by a medical practitioner or dental practitioner approved by the Minister, that the person is suffering from a cleft lip or cleft palate condition*, and
 - that person commenced treatment for a cleft lip or cleft palate condition;

- a person aged 28 and over requiring a specific course of treatment for the repair of previous reconstructive surgery, provided that:
 - prior to turning 22 years, in respect of whom, has been certified as a prescribed dental patient by a medical practitioner or dental practitioner approved by the Minister, that the person is suffering from a cleft lip or cleft palate condition*, and
 - the person received treatment for a cleft lip or cleft palate condition prior to turning 28 years, and
 - if the Minister has declared in writing that he or she is satisfied that:
 - i. because of exceptional circumstances, the person required repair of previous reconstructive surgery in connection with the condition, and
 - ii. the person therefore needs to undergo that course of treatment; and
- a person aged up to 22 years who has been certified as a prescribed dental patient by a medical practitioner or dental practitioner approved by the Minister, that the person is suffering from a condition determined by the Minister to be a condition to which the definition of a prescribed dental patient under Section 3BA of the Act applies.

In consultation with the professions, the Department of Health has completed a review of the conditions described as 'other' underpinning the Cleft Lip and Cleft Palate Scheme. A Ministerial Determination is now in place for these 'other' conditions, enabling the payment of Medicare benefits for the conditions listed below:

1. Oral a	1. Oral and/or facial clefting		
Limited to	Cleft lip, alveolus and/or palate		
	Tessier facial cleft		
2. Conge	enital or hereditary craniofacial malformation, deformation or disruption		
Limited to	Achondroplasia		
	Branchial arch disorders including: Hemifacial/craniofacial microsomia, Goldenhar syndrome, DiGeorge syndrome, Velocardiofacial syndrome		
	CHARGE syndrome		
	Congenital hemifacial hyperplasia		
	Congenital lymphatic and/or vascular malformations of the head & neck, cystic hygroma, Sturge-Weber syndrome, excluding haemangiomas, birth marks and naevi.		
	Craniofacial Neurofibromatosis Type 1		
	Craniometaphyseal dysplasia		
	Ectodermal dysplasia		
	Hemifacial atrophy (Parry Romberg syndrome)		
	Mandibulofacial dysostosis (Treacher Collins syndrome)		
	Maxillonasal dysplasia (Binder syndrome)		
	Oral-facial digital syndrome Type 1		
	Pierre Robin sequence		
	Rubinstein-Taybi syndrome		
	Sphrintzen-Goldberg syndrome		
	Solitary median maxillary central incisor syndrome		
	Stickler syndrome		
	Syndromic craniosynostoses including: Apert, Crouzon, Pfeiffer, Saethre Chotzen, and Muenke syndromes		

	Trichorhinophalangeal syndrome Type 1
3. Hered molars	itary conditions presenting with the absence of 6 (six) or more permanent teeth, excluding 3 rd
4. Hered	itary conditions where the presence of supernumerary teeth is a major feature
5. Hered	itary conditions affecting the formation of enamel and/or dentine of all teeth
Limited to	Amelogenesis imperfecta
	Dentinogenesis imperfecta
	Regional odontodysplasia

^{*}Note: The above conditions have been listed in the terminology that they are generally known under. Some conditions are similar to, or otherwise known as, other conditions on the list.

Please contact the Department of Human Services on 132 150 if the condition is not listed here.

Application for special consideration of a condition not listed above:

Applications for special consideration of a condition not approved by the Minister should include the following:

- a clinical report from the treating professional, describing the nature of the condition and an outline of the treatment to be undertaken;
- a treatment plan devised by the treating professional, including:
 - an indicative time period for which the patient requires treatment
 - date/s the treatment is expected to commence and
 - date/s the treatment is expected to be completed.
- Imaging reports should also be provided, where available.

This information can be forwarded to the Department of Human Services (DHS) for special consideration of a condition by the Department of Health.

CN.3.2 Application for approval for repairs to previous reconstructive work

Applicants aged 28 and over seeking approval for repairs to previous reconstructive work under the Cleft Lip and Cleft Palate Scheme will be required to provide clinical details outlining the need for the repair of previous reconstructive surgery.

NOTE: Patients aged over 28 years of age are not eligible to receive Medicare payments for treatment until approval from the Minister's delegate has been obtained.

Applications should include the following:

- · proof that the patient has been certified as a prescribed dental patient;
- \cdot a treatment plan devised by the treating professional, for the repair of the reconstructive surgery to be performed, including:
- o an indicative time period for which patient eligibility for claiming related treatments should be reinstated
- o date/s the treatment is expected to commence and
- o date/s the treatment is expected to be completed.
- · proof of previous eligibility and treatment under the Cleft Lip and Cleft Palate Scheme. This should take the form of a letter from the treating practitioner, which lists the patient details as follows:

- o full name
- o date of birth
- o address
- o condition
- o date (or approximate) of original surgery
- · a clinical report from the treating professional, describing the nature of the repair, information detailing the previous reconstructive surgery provided and an outline of the work to be undertaken.

This information will be forwarded to the Department of Human Services (DHS) for confirmation of eligibility.

Further information about the Scheme is available on the DHS' website at:

http://www.humanservices.gov.au/customer/services/medicare/cleft-lip-and-cleft-palate-scheme

Assessment of Applications

Assessment will take into account the information provided by the applicant and consider the circumstances surrounding each individual application. In the assessment, "previous reconstructive surgery" means surgery undertaken to repair structural defects in connection with a cleft lip or cleft palate condition. Repairs to this surgery must be in relation to the failure or deterioration of this surgery and due to that failure or deterioration, the patient requires further surgical intervention to restore optimal function.

Repair to previous reconstructive surgery may involve items in both the main Medicare Benefits Schedule, and items in the Cleft Lip and Cleft Palate Schedule. Under Section 3BA (2A), upon gaining the Minister's approval, applicants will have full access to items in the Cleft Lip and Cleft Palate Schedule that are necessary for the restoration of optimal function (provided the items are rendered by suitably qualified / approved practitioners).

Patients are eligible for Medicare benefits for treatment under the scheme once they are certified by a medical or dental practitioner as a prescribed dental patient.

CN.3.3 Visitors to Australia

Medicare benefits for the Cleft Lip and Cleft Palate Scheme are generally not payable to visitors to Australia or temporary residents.

CN.3.4 Health Care Expenses Incurred Overseas

Medicare does not cover medical or hospital expenses incurred outside Australia.

CLEFT LIP AND CLEFT PALATE SERVICES ITEMS

	Crown C4 Outh adoutin Comings	
	Group C1. Orthodontic Services	
	Note: In this Group, benefit is only payable where the service has been rendered to a patient by a dente practitioner who is registered in the specialty of orthodontics, except for the services covered by Items 75009-75023 which may also be rendered by a medical practitioner who is a specialist in the practice his or her specialty of oral and maxillofacial surgery.	
	CONSULTATIONS	
	INITIAL PROFESSIONAL ATTENDANCE in a single course of treatment by an eligible orthodontis (AO)	
75001	Fee: \$85.55 Benefit: 75% = \$64.20 85% = \$72.75	
	PROFESSIONAL ATTENDANCE by an eligible orthodontist subsequent to the first professional attendance by the orthodontist in a single course of treatment (AO)	
75004	Fee: \$43.00 Benefit: 75% = \$32.25 85% = \$36.55	
	PRODUCTION OF DENTAL STUDY MODELS (not being a service associated with a service to which item 75004 applies) prior to provision of a service to which:	
	(a) item 75030, 75033, 75034, 75036, 75037, 75039, 75045 or 75051 applies; or	
	(b) an item in Group T8 or Groups 03 to 09 applies;	
	in a single course of treatment	
75006	Fee: \$76.25 Benefit: 75% = \$57.20 85% = \$64.85	
	RADIOGRAPHY	
	ORTHODONTIC RADIOGRAPHY orthopantomography (panoramic radiography), including any consultation on the same occasion	
75009	Fee: \$68.15 Benefit: 75% = \$51.15 85% = \$57.95	
	ORTHODONTIC RADIOGRAPHY ANTEROPOSTERIOR CEPHALOMETRIC RADIOGRAPHY with cephalometric tracings OR LATERAL CEPHALOMETRIC RADIOGRAPHY with cephalometric tracings including any consultation on the same occasion	
75012	Fee: \$108.05 Benefit: 75% = \$81.05 85% = \$91.85	
	ORTHODONTIC RADIOGRAPHY ANTEROPOSTERIOR AND LATERAL CEPHALOMETRIC RADIOGRAPHY, with cephalometric tracings including any consultation on the same occasion	
75015	Fee: \$148.55 Benefit: 75% = \$111.45 85% = \$126.30	
75018	ORTHODONTIC RADIOGRAPHY ANTEROPOSTERIOR AND LATERAL CEPHALOMETRIC RADIOGRAPHY, with cephalometric tracings and orthopantomography including any consultation or	

C1. OR	THODONTIC SERVICES
	the same occasion
	Fee: \$189.25 Benefit: 75% = \$141.95 85% = \$160.90
	ORTHODONTIC RADIOGRAPHY hand-wrist studies (including growth prediction) including any consultation on the same occasion
75021	Fee: \$232.05 Benefit: 75% = \$174.05 85% = \$197.25
	INTRAORAL RADIOGRAPHY - single area, periapical or bitewing film
75023	Fee: \$46.45 Benefit: 75% = \$34.85 85% = \$39.50
	PRESURGICAL INFANT MAXILLARY ARCH REPOSITIONING
	PRESURGICAL INFANT MAXILLARY ARCH REPOSITIONING including supply of appliances and all adjustments of appliances and supervision - WHERE 1 APPLIANCE IS USED
75024	Fee: \$600.10 Benefit: 75% = \$450.10 85% = \$516.70
	PRESURGICAL INFANT MAXILLARY ARCH REPOSITIONING including supply of appliances and all adjustments of appliances and supervision WHERE 2 APPLIANCES ARE USED
75027	Fee: \$822.90 Benefit: 75% = \$617.20 85% = \$739.50
	DENTITION TREATMENT
75030	MAXILLARY ARCH EXPANSION not being a service associated with a service to which item 75039, 75042, 75045 or 75048 applies, including supply of appliances, all adjustments of the appliances, removal of the appliances and retention Fee: \$732.70 Benefit: 75% = \$549.55 85% = \$649.30
73030	MIXED DENTITION TREATMENT - incisor alignment using fixed appliances in maxillary arch,
	including supply of appliances, all adjustments of appliances, removal of the appliances and retention
75033	Fee: \$1,200.95 Benefit: 75% = \$900.75 85% = \$1117.55
	MIXED DENTITION TREATMENT - incisor alignment with or without lateral arch expansion using a removable appliance in the maxillary arch, including supply of appliances, associated adjustments and retention
75034	Fee: \$611.25 Benefit: 75% = \$458.45 85% = \$527.85
	MIXED DENTITION TREATMENT - lateral arch expansion and incisor alignment using fixed appliances in maxillary arch, including supply of appliances, all adjustments of appliances, removal of appliances and retention
75036	Fee: \$1,658.75 Benefit: 75% = \$1244.10 85% = \$1575.35
	MIXED DENTITION TREATMENT - lateral arch expansion and incisor correction - 2 arch (maxillary and mandibular) using fixed appliances in both maxillary and mandibular arches, including supply of appliances, all adjustments of appliances, removal of appliances and retention
75037	Fee: \$2,089.15 Benefit: 75% = \$1566.90 85% = \$2005.75

C1. OR	THODONTIC SERVIC	EES		
	(correction and alignment) using fixed appliances, including supply of appliances - initial 3 months of active treatment			
	Fee: \$555.25	Benefit: 75% = \$416.45 85% = \$472.00		
	TREATMENT (corr. 3 months of active tr	TITION TREATMENT - SINGLE ARCH (mandibular or maxillary) ection and alignment) using fixed appliances, including supply of appliances - each eatment (including all adjustments and maintenance and removal of the appliances) aximum of a further 33 months		
75042	Fee: \$207.55	Benefit: 75% = \$155.70 85% = \$176.45		
		TITION TREATMENT 2 ARCH (mandibular and maxillary) TREATMENT ment) using fixed appliances, including supply of appliances - initial 3 months of		
75045	Fee: \$1,111.55	Benefit: 75% = \$833.70 85% = \$1028.15		
	(correction and align months of active trea	TITION TREATMENT - 2 ARCH (mandibular and maxillary) TREATMENT ment) using fixed appliances, including supply of appliances - each subsequent 3 tment (including all adjustments and maintenance, and removal of the appliances) aximum of a further 33 months		
75048	Fee: \$285.05	Benefit: 75% = \$213.80 85% = \$242.30		
	RETENTION, FIXE and supervision of re	D OR REMOVABLE, single arch (mandibular or maxillary) - supply of retainer tention		
75049	Fee: \$333.60	Benefit: 75% = \$250.20 85% = \$283.60		
	RETENTION, FIXE supervision of retent	D OR REMOVABLE, 2-arch (mandibular and maxillary) - supply of retainers and ion		
75050	Fee: \$644.05	Benefit: 75% = \$483.05 85% = \$560.65		
		JAW GROWTH GUIDANCE		
	JAW GROWTH guid all adjustments to app	dance using removable or functional appliances, including supply of appliances and pliances		
75051	Fee: \$988.65	Benefit: 75% = \$741.50 85% = \$905.25		
C2. OR	AL AND MAXILLOFA	CIAL SERVICES		
	Group C2. Oral And Maxillofacial Services			
	Note: (i) In this Group, benefit is only payable where the service has been rendered to a patient has been referred by an eligible orthodontist.			
	is only payable for st	ayable for simple extractions performed by a registered dental practitioner, benefit urgical extractions and other surgical procedures where the service is rendered by er who is a specialist in the practice of his or her speciality of oral and?		
75150		CONSULTATIONS		

C2. OR	AL AND MAXILLOFACIAL SERVICES			
	INITIAL PROFESSIONAL attendance in a single course of treatment by an eligible oral and maxillofacial surgeon where the patient is referred to the surgeon by an eligible orthodontist (AOS)			
	Fee: \$85.55 Benefit: 75% = \$64.20 85% = \$72.75			
	PROFESSIONAL ATTENDANCE by an eligible oral and maxillofacial surgeon subsequent to the fir professional attendance by the surgeon in a single course of treatment where the patient is referred to t surgeon by an eligible orthodontist			
75153	Fee: \$43.00 Benefit: 75% = \$32.25 85% = \$36.55			
	PRODUCTION OF DENTAL STUDY MODELS (not being a service associated with a service to which item 75153 applies) prior to provision of a service:			
Ì	(a) to which item 52321, 53212 or 75618 applies; or			
	(b) to which an item in the series 52330 to 52382, 52600 to 52630, 53400 to 53409 or 53415 to 53429 applies;			
	in a single course of treatment if the patient is referred by an eligible orthodontist (AOS)			
75156	Fee: \$76.25 Benefit: 75% = \$57.20 85% = \$64.85			
	SIMPLE EXTRACTIONS			
	Removal of tooth or tooth fragment (other than treatment to which item 75400, 75403, 75406, 75409, 75412 or 75415 applies), if the patient is referred by an eligible orthodontist (AD)			
75200	Fee: \$54.90 Benefit: 75% = \$41.20 85% = \$46.70 PEMOVAL OF TOOTH OR TOOTH FRACMENT under general engesthesis, if the nation is referred.	ad		
	REMOVAL OF TOOTH OR TOOTH FRAGMENT under general anaesthesia, if the patient is referred by an eligible orthodontist (AD)			
75203	Fee: \$82.45 Benefit: 75% = \$61.85 85% = \$70.10			
	Removal of each additional tooth or tooth fragment at the same attendance at which a service to which item 75200 or 75203 applies is rendered, if the patient is referred by an eligible orthodontist (AD)	h		
75206	Fee: \$27.35 Benefit: 75% = \$20.55 85% = \$23.25			
	SURGICAL EXTRACTIONS			
	Surgical removal of erupted tooth, if the patient is referred by an eligible orthodontist (AOS)			
75400	Fee: \$164.75 Benefit: 75% = \$123.60 85% = \$140.05			
	Surgical removal of tooth with soft tissue impaction, if the patient is referred by an eligible orthodonti (AOS)	ist		
75403	Fee: \$189.25 Benefit: 75% = \$141.95 85% = \$160.90			
	Surgical removal of tooth with partial bone impaction, if the patient is referred by an eligible orthodontist (AOS)			
75406				

	E	D P. 1. 750/ 01/1.75 050/ 0103.25		
	Fee: \$215.65	Benefit: 75% = \$161.75 85% = \$183.35		
	orthodontist (AO	of tooth with complete bone impaction, if the patient is referred by an eligible S)		
75409	Fee: \$244.25	Benefit: 75% = \$183.20 85% = \$207.65		
	Surgical removal eligible orthodon	of tooth fragment requiring incision of soft tissue only, if the patient is referred by an tist (AOS)		
75412	Fee: \$136.40	Benefit: 75% = \$102.30 85% = \$115.95		
	Surgical removal orthodontist (AO	of tooth fragment requiring removal of bone, if the patient is referred by an eligible S)		
75415	Fee: \$164.75	Benefit: 75% = \$123.60 85% = \$140.05		
		OTHER SURGICAL PROCEDURES		
	Surgical exposur orthodontist (AO	e, stimulation and packing of unerupted tooth, if the patient is referred by an eligible S)		
75600	Fee: \$232.05	Benefit: 75% = \$174.05 85% = \$197.25		
	Surgical exposur by an eligible ort	e of unerupted tooth for the purpose of fitting a traction device, if the patient is referred hodontist (AOS)		
75603	Fee: \$272.75	Benefit: 75% = \$204.60 85% = \$231.85		
	Surgical reposition	oning of unerupted tooth, if the patient is referred by an eligible orthodontist (AOS)		
75606	Fee: \$272.75	Benefit: 75% = \$204.60 85% = \$231.85		
	Transplantation of tooth bud, if the patient is referred by an eligible orthodontist (AOS)			
75609	Fee: \$407.15	Benefit: 75% = \$305.40 85% = \$346.10		
73009	ree: \$407.13	Denent: 73% - \$303.40 83% - \$340.10		
	Surgical procedure for intra oral implantation of osseointegrated fixture (first stage), if the patient is referred by an eligible orthodontist (AOS)			
75612	Fee: \$503.85	Benefit: 75% = \$377.90 85% = \$428.30		
	Surgical procedure for fixation of trans mucosal abutment (second stage of osseointegrated implant), if the patient is referred by an eligible orthodontist (AOS)			
75615	Fee: \$186.50	Benefit: 75% = \$139.90 85% = \$158.55		
	Provision and fitting of a bite rising appliance or dental splint for the management of temporomandibular joint dysfunction syndrome, if the patient is referred by an eligible orthodontist (AOS)			
75618	Fee: \$231.60	Benefit: 75% = \$173.70 85% = \$196.90		
	The provision an association with:	d fitting of surgical template in conjunction with orthognathic surgical procedures in		
	(a) an item in	n the series:		
75621	(i) 45720 to	43 / 34, 01		

C2. ORAL AND MAXILLOFACIAL SERVICES

(ii) 52342 to 52375; or

(b) item 52380 or 52382;

if the patient is referred by an eligible orthodontist (AOS)

Fee: \$231.60 **Benefit:** 75% = \$173.70 85% = \$196.90

C3. GE SERVIC	NERAL AND PROSTHODONTIC CES			
	Group C3. General And Prosthodontic Services			
	Note: Benefit is payable for services listed in this Group where they are rendered by a registered dental practitioner			
	CONSULTATIONS			
	ATTENDANCE BY AN ELIGIBLE DENTAL PRACTITIONER involving consultation, preventive treatment and prophylaxis, of not less than 30 minutes' duration each attendance to a maximum of 3 attendances in any period of 12 months			
75800	(See para CN.0.12 of explanatory notes to this Category) Fee: \$82.45 Benefit: 75% = \$61.85 85% = \$70.10			
	PROSTHODONTIC			
	PROVISION AND FITTING OF ACRYLIC BASE PARTIAL DENTURE, including retainers 1 TOOTH			
75803	Fee: \$329.75 Benefit: 75% = \$247.35 85% = \$280.30			
	PROVISION AND FITTING OF ACRYLIC BASE PARTIAL DENTURE, including retainers 2 TEETH			
75806	Fee: \$386.75 Benefit: 75% = \$290.10 85% = \$328.75			
	PROVISION AND FITTING OF ACRYLIC BASE PARTIAL DENTURE. including retainers 3 TEETH			
75809	Fee: \$457.95 Benefit: 75% = \$343.50 85% = \$389.30			
	PROVISION AND FITTING OF ACRYLIC BASE PARTIAL DENTURE, including retainers 4 TEETH			
75812	Fee: \$508.85 Benefit: 75% = \$381.65 85% = \$432.55			
	PROVISION AND FITTING OF ACRYLIC BASE PARTIAL DENTURE, including retainers 5 TO 9 TEETH			
75815	Fee: \$620.90 Benefit: 75% = \$465.70 85% = \$537.50			
	PROVISION AND FITTING OF ACRYLIC BASE PARTIAL DENTURE, including retainers			
	10 TO 12 TEETH			
75818	Fee: \$732.70 Benefit: 75% = \$549.55 85% = \$649.30			
	PROVISION AND FITTING OF CAST METAL BASE (cobalt chromium alloy) PARTIAL DENTURE including casting and retainers			
	1 TOOTH			
75821	Fee: \$590.15 Benefit: 75% = \$442.65 85% = \$506.75			

	STHODONTIC		
PROVISION AN	D FITTING OF CAST METAL BASE (cobalt chromium alloy) PARTIAL ding casting and retainers 2 TEETH		
Fee: \$681.80	Benefit: 75% = \$511.35 85% = \$598.40		
	D FITTING OF CAST METAL BASE (cobalt chromium alloy) PARTIAL ding casting and retainers 3 TEETH		
Fee: \$783.75	Benefit: 75% = \$587.85 85% = \$700.35		
PROVISION AND FITTING OF CAST METAL BASE (cobalt chromium alloy) PARTIAL DENTURE including casting and retainers 4 TEETH			
Fee: \$865.10	Benefit: 75% = \$648.85 85% = \$781.70		
	D FITTING OF CAST METAL BASE (cobalt chromium alloy) PARTIAL ding casting and retainers 5 TO 9 TEETH		
Fee: \$1,058.35	Benefit: 75% = \$793.80 85% = \$974.95		
	D FITTING OF CAST METAL BASE (cobalt chromium alloy) PARTIAL ding casting and retainers 10 TO 12 TEETH		
Fee: \$1,211.05	Benefit: 75% = \$908.30 85% = \$1127.65		
item 75803, 7580	D FITTING OF RETAINERS not being a service associated with a service to which 6, 75809, 75812, 75815, 75818, 75821, 75824, 75827, 75830, 75833 or 75836 ner		
Fee: \$27.35	Benefit: 75% = \$20.55 85% = \$23.25		
	DF PARTIAL DENTURE not being a service associated with a service to which item 809, 75812, 75815, 75818, 75821, 75824, 75827, 75830, 75833 or 75836 applies		
Fee: \$40.75	Benefit: 75% = \$30.60 85% = \$34.65		
RELINING OF PARTIAL DENTURE by laboratory process and associated fitting			
Fee: \$203.65	Benefit: 75% = \$152.75 85% = \$173.15		
REMODELLING	AND FITTING OF PARTIAL DENTURE of more than 4 teeth		
Fee: \$244 25	Benefit: 75% = \$183.20 85% = \$207.65		
	ST METAL BASE OF PARTIAL DENTURE 1 or more points		
	Benefit: 75% = \$91.65 85% = \$103.85		
ADDITION OF A	A TOOTH OR TEETH to a partial denture to replace extracted tooth or teeth including		
Fee: \$122.15	Benefit: 75% = \$91.65 85% = \$103.85		
	PROVISION AND DENTURE include Fee: \$783.75 PROVISION AND DENTURE include Fee: \$783.75 PROVISION AND DENTURE include Fee: \$865.10 PROVISION AND DENTURE include Fee: \$1,058.35 PROVISION AND DENTURE include Fee: \$1,211.05 PROVISION AND DENTURE include Fee: \$1,211.05 PROVISION AND DENTURE include Fee: \$1,211.05 PROVISION AND Item 75803, 75806 applies each retain Fee: \$27.35 ADJUSTMENT OF 75803, 75806, 755 Fee: \$40.75 RELINING OF PEE: \$203.65 REMODELLING Fee: \$244.25 REPAIR TO CASE Fee: \$122.15 ADDITION OF A taking of necessar		

CATEGORY 8: MISCELLANEOUS SERVICES

SUMMARY OF CHANGES FROM 01/03/2019

The 01/03/2019 changes to the MBS are summarised below and are identified in the Schedule pages by one or more of the following words appearing above the item number:

(a) new item	New
(b) amended description	Amend
(c) fee amended	Fee
(d) item number changed	Renum
(e) EMSN changed	EMSN

There are no changes to this Category for 01/03/2019.

MISCELLANEOUS SERVICES NOTES

MN.1.1 Additional Bulk Billing Payment for General Medical Services - (Items 10990 and 10991) Item 10990 can only be claimed where all of the conditions set out in paragraphs (a) to (d) of item 10990 have been met.

Item 10991 can only be claimed where all of the conditions set out in paragraphs (a) to (e) of item 10991 have been met

- Item 10991 can only be used where the service is provided at, or from, a practice location that is listed in item 10991. This includes all regional, rural and remote areas (RRMA 3 to 7 under the Rural Remote Metropolitan Areas classification system), all of Tasmania and those areas covered by a Statistical Subdivision (SSD) or Statistical Local Areas (SLA) listed in item 10991 (SSDs and SLAs are specified in the Australian Standard Geographical Classification (ASGC) 2002). If you are not sure whether your practice location is in an eligible area, you can call the Department of Human Services on 132 150.
- Practice location is the place associated with the medical practitioner's provider number from which the service has been provided. This includes services performed either at the medical practitioner's surgery, or those services performed away from the surgery using the provider number for that surgery (eg home visits or visits to aged care facilities).
- Where a medical practitioner has a practice location in both an eligible and ineligible area, item 10991 can only be claimed in respect of those services provided at, or from, the eligible practice location.

Item 10990 and item 10991 can only be used in conjunction with items in the General Medical Services Table of the MBS. There are similar items to be used in conjunction with diagnostic imaging services (item 64990 or 64991) or pathology services (item 74990 or 74991).

Item 10990 or item 10991 can be claimed for each item of service claimable under the MBS (other than diagnostic imaging services and pathology services), provided the conditions of the relevant item, 10990 or 10991, are satisfied. For example, item 10990 or 10991 can be claimed in conjunction with attendance items, procedural items (other than diagnostic imaging or pathology items) or services provided by a practice nurse on behalf of a medical practitioner (items 10983, 10984, 10986, 10987 and 10997). In some cases, this will mean that item 10990 or 10991 can be claimed more than once in respect of a patient visit.

Item 10990 or 10991 can not be claimed in conjunction with each other.

Where a Medicare benefit is not payable for a particular service (eg because the patient has exceeded the number of allowable services in a period of time), the additional bulk billing payment will not be paid for that service.

All GPs whether vocationally registered or not are eligible to claim the additional bulk billing payment.

Commonwealth concession card holder means a person listed on a Pensioner Concession Card, Health Care Card or Commonwealth Seniors Health Card issued by either Centrelink or the Department of Veterans' Affairs. Gold or White Cards issued by the Department of Veterans' Affairs do not attract the additional bulk billing payment. However, if a Gold or White Card holder also holds a recognised Commonwealth concession card and chooses to be treated under the Medicare arrangements, then that patient is an eligible concession card holder.

Unreferred service means a medical service provided to a patient by, or on behalf of, a medical practitioner, being a service that has not been referred to that practitioner by another medical practitioner or person with referring rights.

The Department of Human Services will undertake regular post payment auditing to ensure that the additional bulk billing payment is being claimed correctly. Centrelink data will be used to verify concessional status and Medicare records will be used to confirm patient age.

MN.1.2 After-hours services provided in areas eligible for the higher bulk billing payment - (Item 10992)

After-hours services provided in areas eligible for the higher bulk billing payment - (Item 10992)

Item 10992 can only be claimed where all of the conditions set out in paragraphs (a) to (g) of item 10992 have been met:

- Item 10992 must be claimed in conjunction with one of the items 585, 588, 591, 594, 599, 600, 761, 763, 766, 769, 772, 776, 788, 789, 5003, 5010, 5023, 5028, 5043, 5049, 5063, 5067, 5220, 5223, 5227, 5228, 5260, 5263, 5265, or 5267. These items are for services provided after-hours outside of consulting rooms or hospital.
- · Item 10992 can only be used where the service is provided in one of the eligible areas listed in item 10992 by a medical practitioner whose practice location (i.e. the location associated with the medical practitioner's provider number) is not in one of these areas.

Medical practitioners whose practice location is inside one of these listed locations should claim item 10991 for eligible services.

Item 10992 cannot be claimed in conjunction with item 10990 or 10991.

Where a Medicare benefit is not payable for a particular service the payment for item 10992 will not be paid for that service.

All GPs, whether vocationally recognised or not, are eligible to claim the additional bulk billing payment.

Commonwealth concession card holder means a person listed on a Pensioner Concession Card, Health Care Card or Commonwealth Seniors Health Card issued by either Centrelink or the Department of Veterans' Affairs. Gold or White Cards issued by the Department of Veterans' Affairs do not attract the additional bulk billing payment. However, if a Gold or White Card holder also holds a recognised Commonwealth concession card and chooses to be treated under the Medicare arrangements, then that patient is an eligible concession card holder.

Unreferred service means a medical service provided to a patient by, or on behalf of, a medical practitioner, being a service that has not been referred to that practitioner by another medical practitioner or person with referring rights.

The Department of Human Services will undertake regular post payment auditing to ensure that the additional bulk billing payment is being claimed correctly. Centrelink data will be used to verify concessional status and Medicare records will be used to confirm patient age.

MN.3.1 Individual Allied Health Services (Items 10950 to 10970) for Chronic Disease Management - Eligible Patients ELIGIBLE PATIENTS

Medicare benefits are available for certain services provided by eligible allied health professionals to people with chronic conditions and complex care needs who are being managed by a GP or medical practitioner using certain Chronic Disease Management (CDM) Medicare items or are enrolled in a Health Care Home. The allied health services must be recommended in the patient's plan as part of the management of their chronic condition.

Chronic medical conditions and complex care needs

A chronic medical condition is one that has been or is likely to be present for at least six months, e.g. asthma, cancer, cardiovascular illness, diabetes mellitus, musculoskeletal conditions.and stroke. A patient is considered to have complex care needs if they require ongoing care from a multidisciplinary team consisting of their GP or medical practitioner and at least two other health or care providers.

Prerequisite CDM services

Patients must have received the following MBS CDM services:

- · GP Management Plan MBS GP item 721 or medical practitioner item 229 (or GP review item 732 or medical practitioner review item 233 for a review of a GPMP); and
- · Team Care Arrangements MBS GP item 723 or medical practitioner item 230 (or GP review items 732 or medical practitioner review item 233 for a review of TCAs)

Alternatively, for patients who are permanent residents of an aged care facility, their GP or medical practitioner must have contributed to, or contributed to a review of, a multidisciplinary care plan prepared for them by the aged care facility (MBS GP item 731 or medical practitioner item 232).

Alternatively, for patients who are enrolled with a Health Care Home, a shared care plan must have been prepared by the medical practitioner who is leading the patient's care.

For more information on the CDM planning items, refer to the explanatory notes for these items.

Allied health membership of a TCAs team

The allied health professional providing the service may be a member of the TCAs team convened by the GP or medical practitioner to manage a patient's chronic condition and complex care needs. However, the service may also be provided by an allied health professional who is not a member of the TCAs team, provided that the service has been identified as necessary by the patient's GP or medical practitioner and recommended in the patient's care plan/s.

Group services

In addition to individual services, patients who have type 2 diabetes may also access MBS items 81100 to 81125 which provide group allied health services. Patients only need to have MBS GP items 721 or 723 or medical practitioner items 229 or 230 or a Health Care Home shared care plan in place to be eligible for the group services.

MN.3.2 Individual Allied Health Services (Items 10950 to 10970) for Chronic Disease Management - Referral Requirements Referral form

For Medicare benefits to be payable, the patient must be referred to an eligible allied health professional by their GP or medical practitioner using a referral form that has been issued by the Australian Government Department of Health or a form that contains all the components of this form.

The form issued by the department is available at www.health.gov.au/mbsprimarycareitems (click on the link for allied health individual services).

GPs and medical practitioners are encouraged to attach a copy of the relevant part of the patient's care plan to the referral form.

GPs and medical practitioners may use one referral form to refer patients for single or multiple services of the same service type (e.g. five chiropractic services). If referring a patient for single or multiple services of different service types (e.g. two dietetic services and three podiatry services), a separate referral form will be needed for each service type.

The patient will need to present the referral form to the allied health professional at the first consultation, unless the GP or medical practitioner has previously provided it directly to the allied health professional.

It is required that allied health professionals retain the referral form for 2 years from the date the service was rendered (for the Department of Human Services auditing purposes).

A copy of the referral form is not required to accompany Medicare claims, and allied health professionals do not need to attach a signed copy of the form to patients' itemised accounts/receipts or assignment of benefit forms.

Completed forms do not have to be sent to the Department of Health.

Health Care Home shared care plan

A Health Care Home shared care plan means a written plan that is prepared for a patient enrolled at a Health Care Home trial site; is prepared by a medical practitioner (including a general practitioner but not including a specialist or consultant physician) who is leading the patient's care at the Health Care Home trial site; and includes: an outline of the patient's agreed current and long-term goals; the person or people responsible for each activity; arrangements to review the plan by a day mentioned in the plan; and if authorised by the patient, arrangements for the transfer of information between the medical practitioner and other health care providers supporting patient care about the patient's condition or conditions and treatment. A Health Care Home Shared care plan must be kept for 2 years after the date it was created.

Referral validity

Medicare benefits are available for up to five allied health services per patient per calendar year. Where a patient receives more than the limit of five services in a calendar year, the additional service/s will not attract a Medicare benefit and the MBS Safety Net arrangements will not apply to costs incurred by the patient for the service/s.

If a patient has not used all of their allied health services under a referral in a calendar year, it is not necessary to obtain a new referral for the "unused" services. However, any "unused" services received from 1 January in the following year under that referral will count as part of the total of five services for which the patient is eligible in that calendar year.

When patients have used all of their referred services, or require a referral for a different type of allied health service recommended in their CDM plan/s or Health Care Home shared care plan, they will need to obtain a new referral from their GP or medical practitioner. GPs and medical practitioners may choose to use this visit to undertake a review of the patient's CDM plan/s or, where appropriate, to manage the process using a GP/medical practitioner consultation item.

It is not necessary to have a new CDM plan/s prepared each calendar year in order to access a new referral/s for eligible allied health services. Patients continue to be eligible for rebates for allied health services while they are being managed under the prerequisite CDM items or Health Care Home shared care plan as long as the need for eligible services continues to be recommended in their plan. However, regular reviews using MBS GP item 732 or medical practitioner item 233 are encouraged.

MN.3.3 Individual Allied Health Services - (Items 10950 to 10970) for Chronic Disease Management - Eligible Providers and Services Eligible allied health providers

The following allied health professionals are eligible to provide services under Medicare for patients with a chronic or terminal medical condition and complex care needs when they meet the provider eligibility requirements set out the next section and are registered with the Department of Human Services.

- Aboriginal and Torres Strait Islander health practitioners
- Aboriginal health workers
- Audiologists
- Chiropractors
- Diabetes educators
- Dietitians
- Exercise physiologists

- Mental health workers
- Occupational therapists
- Osteopaths
- Physiotherapists
- Podiatrists
- Psychologists
- Speech pathologists

Number of services per year

Medicare benefits are available for up to five allied health services per eligible patient, per calendar year. The five allied health services can be made up of one type of service (e.g. five physiotherapy services) or a combination of different types of services (e.g. one dietetic and four podiatry services). Five services per calendar year are the legal maximum per patient and exemptions to this are not possible.

Checking patient eligibility for allied health services

Patients seeking Medicare rebates for allied health services will need to have a valid referral form. If there is any doubt about a patient's eligibility, the Department of Human Services will be able to confirm the number of allied health services already claimed by the patient during the calendar year. The allied health professional or the patient can call the Department of Human Services to check this information (132 150 for provider enquiries; 132 011 for public enquiries).

Service length and type

Individual allied health services under Medicare for patients with a chronic medical condition and complex care needs (items 10950 to 10970) must be of at least 20 minutes duration and provided to an individual patient, not to a group. The allied health professional must personally attend the patient.

Reporting back to the Practitioner

Where an allied health professional provides a single service to the patient under a referral, they must provide a written report back to the referring GP or medical practitioner after each service.

Where an allied health professional provides multiple services to the same patient under the one referral, they must provide a written report back to the referring GP or medical practitioner after the first and last service only, or more often if clinically necessary. Written reports should include:

- any investigations, tests, and/or assessments carried out on the patient;
- any treatment provided; and
- future management of the patient's condition or problem.

The report to the Practitioner must be kept for 2 years from the date of service.

Out-of-pocket expenses and Medicare Safety Net

Allied health professionals can determine their own fees for the professional service. Charges in excess of the Medicare benefit are the responsibility of the patient. However, out-of-pocket costs will count toward the Medicare Safety Net for that patient. Allied health services in excess of five in a calendar year will not attract a Medicare benefit and the Safety Net arrangements will not apply to costs incurred by the patient for such services.

Publicly funded services

Items 10950 to 10970 do not apply for services that are provided by any Commonwealth or state funded services or provided to an admitted patient of a hospital. However, where an exemption under subsection 19(2) of the Health Insurance Act 1973 has been granted to an Aboriginal Community Controlled Health Service or state/territory government health clinic, items 10950 to 10970 can be claimed for services provided by eligible allied health professionals salaried by, or contracted to, the service or health clinic. All requirements of the relevant item must be met, including registration of the allied health professional with the Department of Human Services. Medicare services provided under a subsection 19(2) exemption must be bulk billed (i.e. the Medicare rebate is accepted as full payment for services).

Private health insurance

Patients need to decide if they will use Medicare or their private health insurance ancillary cover to pay for these services. Patients cannot use their private health insurance ancillary cover to 'top up' the Medicare rebate paid for the services.

MN.3.4 Individual Allied Health Services - (Items 10950 to 10970) for Chronic Disease Management - Professional Eligibility

The individual allied health items (10950 to 10970) can only be claimed for services provided by eligible allied health professionals who are registered with the Department of Human Services. To be eligible to register with the Department of Human Services to provide these services, allied health professionals must meet the specific eligibility requirements detailed below.

Aboriginal and Torres Strait Islander health practitioners must be registered with the Aboriginal and Torres Strait Islander Health Practice Board of Australia. Aboriginal and Torres Strait Islander health practitioners may use any of the titles authorised by the Aboriginal and Torres Strait Islander Health Practice Board: Aboriginal health practitioners; Aboriginal and Torres Strait Islander health practitioners or Torres Strait Islander health practitioners.

Aboriginal health workers in a State or Territory other than the Northern Territory must have been awarded either:

- a. a Certificate III in Aboriginal and/or Torres Strait Islander Primary Health Care (or an equivalent or higher qualification) by a registered training organisation; or
- b. a Certificate III in Aboriginal and Torres Strait Islander Health (or an equivalent or higher qualification) by a registered training organisation before 1 July 2012.

Note: Where individuals consider their qualification to be equivalent to or higher than the qualifications listed above, they will need to contact a registered training organisation in their State or Territory to have the qualification assessed as such before they can register with the Department of Human Services. In the Northern Territory, a practitioner must be registered with the Aboriginal and Torres Strait Islander Health Practice Board of Australia.

Audiologists must be either a 'Full Member' of the Audiological Society of Australia Inc (ASA), who holds a 'Certificate of Clinical Practice' issued by the ASA; or an 'Ordinary Member - Audiologist' or 'Fellow Audiologist' of the Australian College of Audiology (ACAud).

Diabetes educators must be a Credentialled Diabetes Educator (CDE) as credentialled by the Australian Diabetes Educators Association (ADEA).

Chiropractors must be registered with the Chiropractic Board of Australia.

Dietitians must be an 'Accredited Practising Dietitian' as recognised by the Dietitians Association of Australia (DAA).

Exercise physiologists must be an 'Accredited Exercise Physiologist' as accredited by Exercise and Sports Science Australia (ESSA).

Mental health workers

'Mental health' can include services provided by members of five different allied health professional groups. 'Mental health workers' are drawn from the following:

- psychologists;
- mental health nurses;
- occupational therapists;
- social workers;
- Aboriginal and Torres Strait Islander health practitioners; and
- Aboriginal health workers.

Psychologists, occupational therapists, Aboriginal and Torres Strait Islander health practitioners and Aboriginal health workers are eligible in separate categories for these items.

Mental health nurses must be a credentialled mental health nurse, as certified by the Australian College of Mental Health Nurses.

Mental health nurses who were registered in the ACT or Tasmania prior to the introduction of the National Registration and Accreditation Scheme (NRAS) on 1 July 2010, will have until 31 December 2010 to be certified by the Australian College of Mental Health Nurses.

Social workers must be a 'Member' of the Australian Association of Social Workers (AASW) and be certified by AASW as meeting the standards for mental health set out in the document published by AASW titled 'Practice Standards for Mental Health Social Workers' as in force on 8 November 2008.

Occupational therapists must be registered with the Occupational Therapy Board of Australia.

Osteopaths must be registered with the Osteopathy Board of Australia.

Physiotherapists must be registered with the Physiotherapy Board of Australia.

Podiatrists must be registered with the Podiatry Board of Australia.

Psychologists must hold general registration in the health profession of psychology under the applicable law in force in the State or Territory in which the service is provided.

Speech pathologists must be a 'Practising Member' of Speech Pathology Australia.

Registering with the Department of Human Services

Provider registration forms may be obtained from the <u>Department of Human Services</u> on 132 150 or at the Department of Human Services website.

Chiropractors, osteopaths, physiotherapists and podiatrists who were already registered with the Department of Human Services on 1 July 2004 to order diagnostic imaging under Medicare, do not need to re-register to provide services under this initiative. Allied health professionals registering with the Department of Human Services for the first time only need to fill in one application form which will give them rights to provide services under this initiative and order diagnostic imaging tests etc., where appropriate, under Medicare.

Changes to provider details

Allied health providers must notify the Department of Human Services in writing of all changes to mailing details to ensure that they continue to receive information about Medicare rebateable allied health services.

The individual allied health items (10950 to 10970) can only be claimed for services provided by eligible allied health professionals who are registered with the Department of Human Services. To be eligible to register with the Department of Human Services to provide these services, allied health professionals must meet the specific eligibility requirements detailed below.

MN.3.5 Individual Allied Health Services (10950 to 10970) for Chronic Disease Management - Further Information

Further information about Medicare Benefits Schedule items is available on the Department of Health's website at www.health.gov.au/mbsprimarycareitems

MN.6.1 Provision of Psychological Therapy Services by Clinical Psychologists - (Items 80000 TO 80021)

OVERVIEW

The Better Access to Psychiatrists, Psychologists and General Practitioners through the Medicare Benefits Schedule initiative commenced on 1 November 2006. Under the Better Access initiative MBS items provide Medicare benefits for the following allied mental health services:

- psychological therapy (items 80000 to 80021) provided by eligible clinical psychologists; and
- focussed psychological strategies allied mental health (items 80100 to 80171) provided by eligible psychologists, occupational therapists and social workers.

MN.6.2 Psychological Therapy Services Attracting Medicare Rebates Eligible psychological therapy services

There are eight MBS items for the provision of psychological therapy services to eligible patients by a clinical psychologist, including five items for face-to-face consultations and three items for video conference consultations. Clinical psychologists must meet the provider eligibility requirements set out below and be registered with the Department of Human Services.

In these notes, 'GP' means a medical practitioner, including a general practitioner, but not including a specialist or consultant physician.

Referrals and Referral Validity

Services provided under the Psychological Therapy items will not attract a Medicare rebate unless:

- a referral has been made by a GP or medical practitioner who is managing the patient under a GP Mental Health Treatment Plan (GP items 2700, 2701, 2715, 2717 or medical practitioner items 272, 276, 281, 282):
- a referral has been made by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan (item 291);
- a referral has been made by a psychiatrist or paediatrician from an eligible psychiatric or paediatric service (see Referral Requirements for further details regarding psychiatrist and paediatrician referrals); or
- a referral has been made by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) under a Health Care Home shared care plan.

Health Care Home shared care plan

A Health Care Home shared care plan means a written plan that is prepared for a patient enrolled at a Health Care Home trial site; is prepared by a medical practitioner (including a general practitioner but not including a specialist or consultant physician) who is leading the patient's care at the Health Care Home trial site; and includes: an outline of the patient's agreed current and long-term goals; the person or people responsible for each activity; arrangements

to review the plan by a day mentioned in the plan; and if authorised by the patient, arrangements for the transfer of information between the medical practitioner and other health care providers supporting patient care about the patient's condition or conditions and treatment.

Number of services per year

Medicare rebates are available for up to 10 individual allied mental health services in a calendar year. The 10 services may consist of: GP/medical practitioner focussed psychological strategies services (GP items 2721 to 2727 or medical practitioner items 283 to 287); and/or psychological therapy services (items 80000 to 80015); and/or focussed psychological strategies - allied mental health services (items 80100 to 80115; 80125 to 80140; 80150 to 80165).

Referrals should be provided, as required, for an initial course of treatment (a maximum of six services but may be less depending on the referral and patient need) to a maximum of 10 services per calendar year. For the purposes of these services, a course of treatment will consist of the number of services stated in the patient's referral (up to a maximum of six in any one referral).

Patients will also be eligible to claim up to 10 separate services within a calendar year for group therapy services involving 6-10 patients to which items 80020 (psychological therapy - clinical psychologist), 80021 (psychological therapy by video conference - clinical psychologist), 80120 (focussed psychological strategies - psychological strategies by video conference - psychologist), 80145 (focussed psychological strategies - occupational therapist), 80146 (focussed psychological strategies by video conference - occupational therapist), 80170 (focussed psychological strategies - social worker) and 80171 (focussed psychological strategies by video conference - social worker) apply. These group services are separate from the individual services and do not count towards the 10 individual services per calendar year maximum associated with those items.

In the instance where a patient has received the 10 psychological therapy services (items 80000 to 80021), focussed psychological services -allied mental health services (items 80100 to 80171) or GP/medical practitioner focussed psychological strategies services (GP items 2721 to 2727 or medical practitioner items 283 to 287) available under the Better Access to Psychiatrists, Psychologists and General Practitioners through the Medicare Benefits Schedule initiative per calendar year and is considered to clinically benefit from some additional services, the patient may be eligible for Primary Health Networks (PHNs) funded psychological therapies if they meet relevant eligibility criteria for the PHN commissioned services. It is recommended that providers refer to their PHN for further guidance.

Service length and type

Services provided by eligible clinical psychologists under these items must be within the specified time period within the item descriptor. The clinical psychologist must personally attend the patient face-to-face, or by video conference for items 80001, 80011, 80021, 80101, 80111, 80121, 80126, 80136, 80146, 80151, 80161 and 80171.

It is expected that professional attendances at places other than consulting rooms would be provided where treatment in other environments is necessary to achieve therapeutic outcomes.

In addition to psycho-education, it is recommended that cognitive-behaviour therapy be provided. However, other evidence-based therapies — such as interpersonal therapy — may be used if considered clinically relevant.

Course of treatment and reporting back to the referring medical practitioner

Patients are eligible to receive up to 10 individual services and up to 10 group sessions in a calendar year.

Within this maximum service allocation, the clinical psychologist can provide one or more courses of treatment. For the purposes of these services, a course of treatment consists of the number of services stated in the patient's referral (up to a maximum of six in any one referral). This enables the referring medical practitioner to consider a report from the clinical psychologist on the services provided to the patient, and the need for further treatment.

On completion of the initial course of treatment, the clinical psychologist must provide a written report to the referring GP or medical practitioner, which includes information on:

- assessments carried out on the patient;
- treatment provided; and
- recommendations on future management of the patient's disorder.

A written report must also be provided to the referring GP or medical practitioner at the completion of any subsequent course(s) of treatment provided to the patient.

Out of pocket expenses and Medicare safety net

Charges in excess of the Medicare benefit for these items are the responsibility of the patient. However, if a service was provided out-of-hospital, any out-of-pocket costs will count towards the Medicare safety net for that patient. The out-of-pocket costs for mental health services which are not Medicare eligible do not count towards the Medicare safety net.

Eligible patients

Items 80000 to 80021 (inclusive) apply to people with an assessed mental disorder and where the patient is referred by a GP or medical practitioner who is managing the patient under a GP Mental Health Treatment Plan (GP items 2700, 2701, 2715, 2717 or medical practitioner items 272, 276, 281, 282), under a Health Care Home shared care plan, under a referred psychiatrist assessment and management plan (item 291), or on referral from an eligible psychiatrist or paediatrician.

The conditions classified as mental disorders for the purposes of these services are informed by the World Health Organisation, 1996, Diagnostic and Management Guidelines for Mental Disorders in Primary Care: ICD-10 Chapter V Primary Care Version. For the purposes of these items, dementia, delirium, tobacco use disorder and mental retardation are not regarded as a mental disorder.

Checking patient eligibility for psychological therapy services

Patients seeking Medicare rebates for psychological therapy services will need to have a referral from a GP, medical practitioner, psychiatrist or paediatrician. If there is any doubt about a patient's eligibility, the Department of Human Services will be able to confirm whether a GP Mental Health Treatment Plan; shared care plan and/or a psychiatrist assessment and management plan is in place and claimed; or an eligible psychiatric or paediatric service has been claimed, as well as the number of allied mental health services already claimed by the patient during the calendar year.

Clinical psychologists can call the Department of Human Services on 132 150 to check this information, while unsure patients can seek clarification by calling 132 011.

The patient will not be eligible if they have not been appropriately referred and a relevant Medicare service provided to them. If the referring service has not yet been claimed, the Department of Human Services will not be aware of the patient's eligibility. In this case the clinical psychologist should, with the patient's permission, contact the referring practitioner to ensure the relevant service has been provided to the patient.

Publicly funded services

Psychological therapy items 80000 to 80021 do not apply for services that are provided by any other Commonwealth or State funded services or provided to an admitted patient of a hospital. However, where an exemption under subsection 19(2) of the *Health Insurance Act 1973* has been granted to an Aboriginal Community Controlled Health Service or state/territory clinic, the items apply for services that are provided by eligible clinical psychologists salaried by, or contracted to, the service as long as all requirements of the items are met, including registration with the Department of Human Services. These services must be direct billed (that is, the Medicare rebate is accepted as full payment for services).

Private health insurance

Patients need to decide if they will use Medicare or their private health insurance ancillary cover to pay for these services. Patients cannot use their private health insurance ancillary cover to 'top up' the Medicare rebate paid for the services.

MN.6.3 Referral Requirements (GPs, Medical Practitioners, Psychiatrists or Paediatricians to Clinical Psychologists for Psychological Therapy) Referrals

Patients must be referred for psychological therapy services by a GP or medical practitioner managing the patient under a GP Mental Health Treatment Plan (GP items 2700, 2701, 2715, 2717 or medical practitioner items 272, 276, 281, 282), or a referred psychiatrist assessment and management plan (item 291); on referral from a psychiatrist or a paediatrician; or a Health Care Home shared care plan.

Referrals from psychiatrists and paediatricians must be made from eligible Medicare services. For specialist psychiatrists and paediatricians these services include any of the specialist attendance items 104 through 109. For consultant physician psychiatrists the relevant eligible Medicare services cover any of the consultant psychiatrist items 293 through 370; while for consultant physician paediatricians the eligible services are consultant physician attendance items 110 through 133.

Referring practitioners are not required to use a specific form to refer patients for these services. The referral may be a letter or note to an eligible clinical psychologist signed and dated by the referring practitioner.

The clinical psychologist must be in receipt of the referral at the first allied mental health consultation. It is recommended that the clinical psychologist retain the referral for 24 months from the date the service was rendered (for the Department of Human Services auditing purposes).

Health Care Home shared care plan

A Health Care Home shared care plan means a written plan that is prepared for a patient enrolled at a Health Care Home trial site; is prepared by a medical practitioner (including a general practitioner but not including a specialist or consultant physician) who is leading the patient's care at the Health Care Home trial site; and includes: an outline of the patient's agreed current and long-term goals; the person or people responsible for each activity; arrangements to review the plan by a day mentioned in the plan; and if authorised by the patient, arrangements for the transfer of information between the medical practitioner and other health care providers supporting patient care about the patient's condition or conditions and treatment.

The Health Care Home shared care plan should also include a record of the patient's agreement to mental health services; an outline of assessment of the patient's mental disorder, including the mental health formulation and diagnosis or provisional diagnosis; and if appropriate, a plan for one or more of crisis intervention and relapse prevention.

Referral validity

Medicare benefits are available for up to 10 individual and/or 10 group psychological therapy services and/or focussed psychological strategies services per patient per calendar year.

Referrals should be provided, as required, for an initial course of treatment (a maximum of six services but may be less depending on the referral and the patient's clinical need) to a maximum of 10 services per calendar year. For the purposes of these services, a course of treatment will consist of the number of services stated in the patient's referral (up to a maximum of six in any one referral).

If a patient has not used all of their psychological therapy services and/or focussed psychological strategies services under a referral in a calendar year, it is not necessary to obtain a new referral for the "unused" services. However, any "unused" services received from 1 January in the following year under that referral will count as part of the total of 10 services for which the patient is eligible in that calendar year.

When patients have used all of their referred services they will need to obtain a new referral from the referring practitioner if they are eligible for further services. Where the patient's care is being managed by a GP or medical practitioner, the GP/medical practitioner may choose to use this visit to undertake a review of the patient's GP Mental Health Treatment Plan, Health Care Home shared care plan, and/or psychiatrist assessment and management plan.

It is not necessary to have a new GP Mental Health Treatment Plan, Health Care Home shared care plan, and/or psychiatrist assessment and management plan prepared each calendar year in order to access a new referral(s) for eligible psychological therapy services and/or focussed psychological strategies services. Patients continue to be eligible for rebates for psychological therapy services and/or focussed psychological strategies services while they are being managed under a GP Mental Health Treatment Plan, Health Care Home shared care plan, and/or a psychiatrist assessment and management plan as long as the need for eligible services continues to be recommended in their plan.

MN.6.4 Clinical Psychologist Professional Eligibility Eligible clinical psychologists

A person is an allied health professional in relation to the provision of a psychological therapy health service if the person:

- a. holds general registration in the health profession of psychology under the applicable law in force in the state or territory in which the service is provided; and
- b. is endorsed by the Psychology Board of Australia to practice in clinical psychology.

Until 31 October 2015, a person was also an allied health professional in relation to the provision of a psychological therapy health service if the person:

- a. holds general registration in the health profession of psychology under the applicable law in force in the state or territory in which the service is provided; and
- b. on 31 October 2015 was an allied health professional in relation to the provision of a psychological therapy health service because the person:
 - i. was a member of the College of Clinical Psychologists of the Australian Psychological Society; or
 - ii. had been assessed by the College of Clinical Psychologists of the Australian Psychological Society as meeting the requirements for membership of that College.

The clinical psychologist must be registered with the Department of Human Services.

Registering with the Department of Human Services

Advice about registering with the Department of Human Services to provide psychological therapy services using items 80000-80021 inclusive is available from the Department of Human Services provider inquiry line on 132 150.

Further information

For further information about Medicare Benefits Schedule items, please go to the Department of Health's website at www.health.gov.au/mbsonline.

For providers, further information is also available for providers from the Department of Human Services provider inquiry line on 132 150.

MN.6.5 Telehealth Psychological Therapy Services

These notes provide information on the telehealth psychological therapy MBS video consultation items by clinical psychologists. A video consultation involves a single clinical psychologist attending a patient, or a group of 6 to 10 patients.

MBS item numbers 80001 and 80011 provide for attendance via videoconferencing by a clinical psychologist to an individual patient. MBS item number 80021 provide for attendance via videoconferencing by a clinical psychologist to a group of 6 to 10 patients. The items are stand-alone items and do not have a derived fee.

These therapies are time limited, being deliverable in up to 10 planned sessions in a calendar year (including services to which items 80001, 80011, 80101, 80111, 80126, 80136, 80151 and 80161 apply).

Patients will also be eligible to claim up to 10 separate services within a calendar year for group therapy services involving 6-10 patients to which items 80021 (psychological therapy via video conference – clinical psychologist), 80121 (focussed psychological strategies via video conference – psychologist), 80146 (focussed psychological strategies via video conference – occupational therapist) and 80171 (focussed psychological strategies via video conference – social worker) apply. These group services are separate from the individual services and do not count towards the 10 individual services per calendar year maximum associated with those items.

Clinical indications

The clinical psychologist must be satisfied that it is clinically appropriate to provide a video consultation to a patient, or a group of 6 to 10 patients.

Restrictions

The MBS telehealth attendance items are not payable for services to an admitted hospital patient (this includes hospital in the home patients). Benefits are not payable for telephone or email consultations. In order to fulfil the item descriptor there must be a visual and audio link between the patient and the remote clinical psychologist. If the remote clinical psychologist is unable to establish both a video and audio link with the patient, a MBS rebate for a telehealth attendance is not payable.

Billing Requirements

All video consultations provided by clinical psychologists must be separately billed. That is, only the relevant telehealth MBS consultation item is to be itemised on the account/bill/voucher. Any other service/item billed should be itemised on a separate account/bill/voucher. This will ensure the claim is accurately assessed as being a video consultation and paid accordingly.

Clinical psychologists should not use the notation 'telehealth', 'verbal consent' or 'Patient unable to sign' to overcome administrative difficulties to obtaining a patient signature for bulk-billed claims (for further information see mbsonline.gov.au/telehealth).

Eligible Geographical Areas

Geographic eligibility for psychological telehealth services funded under Medicare (in Groups M6 and M7) is determined according to the Modified Monash Model (MMM) classifications. Telehealth Eligible Areas are those areas that are within MMM classifications 4 to 7. Patients and providers are able to check their eligibility using the Modified Monash Model locator on the Department of Health's website (http://www.health.gov.au/internet/otd/publishing.nsf/Content/MMM locator).

There is a requirement for the patient and clinical psychologist to be located a minimum of 15 kilometres apart at the time of the consultation. Minimum distance between clinical psychologist and patient video consultations are measured by the most direct (ie least distance) route by road. The patient or the clinical psychologist is not permitted to travel to an area outside the minimum 15 kilometres distance in order to claim a video consultation.

Record Keeping

Participating telehealth clinical psychologists must keep contemporaneous notes of the consultation including documenting that the service was performed by video conference, the date, time and the people who participated.

Only clinical details recorded at the time of the attendance count towards the time of the consultation. It does not include information added at a later time, such as reports of investigations.

Extended Medicare Safety Net (EMSN)

All telehealth consultations (with the exception of the participating optometrist telehealth items) are subject to EMSN caps. The EMSN caps for telehealth consultation items in Groups M6 and M7 are equal to 300% of the schedule fee (to a maximum of \$500).

Aftercare Rule

Video consultations are subject to the same aftercare rules as clinical psychologists providing face-to-face consultations.

Multiple attendances on the same day

In some situations a patient may receive a consultation via video conference and a face-to-face consultation by the same or different clinical psychologist on the same day.

Medicare benefits may be paid for more than one video consultation on a patient on the same day by the same clinical psychologist, provided the second (and any following) video consultations are not a continuation of the initial or earlier video consultations. Clinical psychologists will need to provide the times of each consultation on the patient's account or bulk-billing voucher.

Referrals

The referral procedure for a video consultation is the same as for conventional face-to-face consultations.

Technical requirements

In order to fulfil the item descriptor there must be a visual and audio link between the patient and the remote clinical psychologist. If the remote clinical psychologist is unable to establish both a video and audio link with the patient, a MBS rebate for a telehealth attendance is not payable.

Individual clinicians must be confident that the technology used is able to satisfy the item descriptor and that software and hardware used to deliver a videoconference meets the applicable laws for security and privacy.

MN.7.1 Provision of Focussed Psychological Strategies Services by Allied Health Providers - (Items 80100 to 80170) OVERVIEW

The Better Access to Psychiatrists, Psychologists and General Practitioners through the Medicare Benefits Schedule initiative commenced on 1 November 2006. Under the Better Access initiative MBS items provide Medicare benefits for the following allied mental health services:

- psychological therapy (items 80000 to 80021) provided by eligible clinical psychologists; and
- focussed psychological strategies allied mental health (items 80100 to 80171) provided by eligible psychologists, occupational therapists and social workers.

FOCUSSED PSYCHOLOGICAL STRATEGIES – ALLIED MENTAL HEALTH SERVICES ATTRACTING MEDICARE REBATES

Eligible focussed psychological strategies services

There are 24 MBS items for the provision of focused psychological strategies (FPS) - allied mental health services to eligible patients by allied health professionals:

- 80100, 80105, 80110, 80115 and 80120 for provision of FPS services by a psychologist;
- 80101, 80111 and 80121 for provision of video conference FPS services by a psychologist;
- 80125, 80130, 80135, 80140 and 80145 for provision of FPS services by an occupational therapist;

- 80126, 80136 and 80146 for provision of video conference FPS services by an occupational therapist;
- 80150, 80155, 80160, 80165 and 80170 for provision of FPS services by a social worker; and
- 80151, 80161 and 80171 for provision of video conference FPS services by a social worker.

The allied health professional must meet the provider eligibility requirements set out below and be registered with the Department of Human Services.

In these notes, 'GP' means a medical practitioner, including a general practitioner, but not including a specialist or consultant physician.

Referrals and Referral Validity

Services provided under the focussed psychological strategies – allied mental health items will not attract a Medicare rebate unless:

- a referral has been made by a GP or medical practitioner who is managing the patient under a GP Mental Health Treatment Plan (GP items 2700, 2701, 2715, 2717 or medical practitioner items 272, 276, 281, 282);
- a referral has been made by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) under a shared care plan;
- a referral has been made by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan (item 291); or
- a referral has been made by a psychiatrist or paediatrician from an eligible psychiatric or paediatric service (see Referral Requirements for further details regarding psychiatrist and paediatrician referrals).

Number of services per year

Medicare rebates are available for up to 10 individual allied mental health services in a calendar year. The 10 services may consist of: GP or medical practitioner focussed psychological strategies services (GP items 2721 to 2727 or medical practitioner items 283 to 287); and/or psychological therapy services (items 80000 to 80015); and/or focussed psychological strategies - allied mental health services (items 80100 to 80115; 80125 to 80140; 80150 to 80165.

Referrals should be provided, as required, for an initial course of treatment (a maximum of six services but may be less depending on the referral and patient need) to a maximum of 10 services per calendar year. For the purposes of these services, a course of treatment will consist of the number of services stated in the patient's referral (up to a maximum of six in any one referral).

Patients will also be eligible to claim up to 10 separate services within a calendar year for group therapy services involving 6-10 patients to which items 80020 (psychological therapy – clinical psychologist), 80021 (psychological therapy via video conference – clinical psychologist), 80120 (focussed psychological strategies – psychologist), 80121 (focussed psychological strategies via video conference – psychologist), 80145 (focussed psychological strategies – occupational therapist), 80146 (focussed psychological strategies via video conference – occupational therapist), 80170 (focussed psychological strategies - social worker) and 80171 (focussed psychological strategies via video conference – social worker) apply. These group services are separate from the individual services and do not count towards the 10 individual services per calendar year maximum associated with those items.

In the instance where a patient has received the 10 psychological therapy services (items 80000 to 80021), focussed psychological services-allied mental health services (items 80100 to 80171) or GP or medical practitioner focussed psychological strategies services (GP items 2721 to 2727 or medical practitioner items 283 to 287) available under the Better Access to Psychiatrists, Psychologists and General Practitioners through the Medicare Benefits Schedule initiative per calendar year and is considered to clinically benefit from some additional services, the patient may be eligible for Primary Health Networks (PHNs) funded psychological therapies if they meet relevant eligibility criteria for the PHN commissioned services. It is recommended that providers refer to their PHN for further guidance.

Service length and type

Services provided by eligible allied health professionals under these items must be within the specified time period within the item descriptor. The allied mental health professional must personally attend the patient the patient face to face, or via video conference for items 80001, 80011, 80021, 80101, 80111, 80121, 80126, 80136, 80146, 80151, 80161 and 80171.

It is expected that professional attendances at places other than consulting rooms would be provided where treatment in other environments is necessary to achieve therapeutic outcomes.

A range of acceptable strategies has been approved for use by allied mental health professionals utilising the FPS items.

These are:

1. Psycho-education

(including motivational interviewing)

2. Cognitive-behavioural therapy including:

- Behavioural interventions
- Behaviour modification
- Exposure techniques
- Activity scheduling
- · Cognitive interventions
- Cognitive therapy

3. Relaxation strategies

- Progressive muscle relaxation
- Controlled breathing

4. Skills training

- Problem solving skills and training
- Anger management
- Social skills training
- Communication training
- Stress management
- Parent management training
- **5. Interpersonal therapy** (especially for depression)
- **6. Narrative therapy** (for Aboriginal and Torres Strait Islander people).

Course of treatment and reporting back to the referring medical practitioner

Patients are eligible to receive up to 10 individual services and up to 10 group sessions in a calendar year.

Within this maximum service allocation, the allied mental health professional can provide one or more courses of treatment. For the purposes of these services, a course of treatment consists of the number of services stated in the patient's referral (up to a maximum of six services in any one referral). This enables the referring medical practitioner to consider a report from the allied mental health professional on the services provided to the patient, and the need for further treatment.

On completion of the initial course of treatment, the allied mental health professional must provide a written report to the referring medical practitioner, which includes information on:

- assessments carried out on the patient;
- treatment provided; and
- recommendations on future management of the patient's disorder.

A written report must also be provided to the referring medical practitioner at the completion of any subsequent course(s) of treatment provided to the patient.

Out-of-pocket expenses and Medicare safety net

Charges in excess of the Medicare benefit for these items are the responsibility of the patient. However, if a service was provided out of hospital, any out-of-pocket costs will count towards the Medicare safety net for that patient. The out-of-pocket costs for mental health services which are not Medicare eligible do not count towards the Medicare safety net.

Eligible patients

Items 80100 to 80171 (inclusive) apply to people with an assessed mental disorder and where the patient is referred by a GP or medical practitioner who is managing the patient under a GP Mental Health Treatment Plan (GP items 2700, 2701, 2715, 2717 or medical practitioner items 272, 276, 281, 282) under a referred psychiatrist assessment and management plan (item 291) or Health Care Home shared care plan; or from an eligible psychiatrist or paediatrician.

The conditions classified as mental disorders for the purposes of these services are informed by the World Health Organisation, 1996, Diagnostic and Management Guidelines for Mental Disorders in Primary Care: ICD-10 Chapter V Primary Care Version. For the purposes of these items, dementia, delirium, tobacco use disorder and mental retardation are not regarded as a mental disorder.

Checking patient eligibility for focussed psychological strategies – allied mental health services

Patients seeking Medicare rebates for focussed psychological strategies – allied mental health services will need to have a referral from a GP, medical practitioner, psychiatrist or paediatrician. If there is any doubt about a patient's eligibility, the Department of Human Services will be able to confirm whether a GP Mental Health Treatment Plan, Health Care Home shared care plan and/or a psychiatrist assessment and management plan is in place and claimed; or an eligible psychiatric or paediatric service has been claimed, as well as the number of allied mental health services already claimed by the patient during the calendar year.

Allied mental health professionals can call the Department of Human Services on 132 150 to check this information, while unsure patients can seek clarification by calling 132 011.

The patient will not be eligible if they have not been appropriately referred and a relevant Medicare service provided to them. If the referring service has not yet been claimed, the Department of Human Services will not be aware of the patient's eligibility. In this case the allied mental health professional should, with the patient's permission, contact the referring practitioner to ensure the relevant service has been provided to the patient.

Publicly funded services

Focussed psychological strategies (FPS) services items 80100 to 80171 do not apply for services that are provided by any other Commonwealth or state funded services or provided to an admitted patient of a hospital. However, where an exemption under subsection 19(2) of the *Health Insurance Act 1973* has been granted to an Aboriginal Community Controlled Health Service or state/territory clinic, the FPS services items apply for services that are provided by eligible allied mental health professionals salaried by, or contracted to, the service as long as all requirements of the items are met, including registration with the Department of Human Services. These services must be direct billed (that is, the Medicare rebate is accepted as full payment for services).

Private health insurance

Patients need to decide if they will use Medicare or their private health insurance ancillary cover to pay for these services. Patients cannot use their private health insurance ancillary cover to 'top up' the Medicare rebate paid for the services.

REFERRAL REQUIREMENTS (GPs, MEDICAL PRACTITIONERS, PSYCHIATRISTS OR PAEDIATRICIANS TO ALLIED MENTAL HEALTH PROFESSIONALS)

Referrals

Patients must be referred for focussed psychological strategies – allied mental health services by either a GP or medical practitioner managing the patient under a GP Mental Health Treatment Plan (GP items 2700, 2701, 2715, 2717 or medical practitioner items 272, 276, 281, 282), a Health Care Home shared care plan or referred by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan (item 291); or on referral from a psychiatrist or a paediatrician.

Referrals from psychiatrists and paediatricians must be made from eligible Medicare services. For specialist psychiatrists and paediatricians these services include any of the specialist attendance items 104 through 109. For consultant physician psychiatrists the relevant eligible Medicare services cover any of the consultant psychiatrist items 293 through 370; while for consultant physician paediatricians the eligible services are consultant physician attendance items 110 through 133.

Referring practitioners are not required to use a specific form to refer patients for these services. The referral may be a letter or note to an eligible allied mental health professional signed and dated by the referring practitioner.

The allied mental health professional must be in receipt of the referral at the first allied mental health consultation. It is required that the allied health professional retain the referral for 24 months from the date the service was rendered (for the Department of Human Services auditing purposes).

Referral validity

Medicare benefits are available for up to 10 individual and/or 10 group psychological therapy services and/or focussed psychological strategies services per patient per calendar year.

Referrals should be provided, as required, for an initial course of treatment (a maximum of six services but may be less depending on the referral and the patient's clinical need) to a maximum of 10 services per calendar year. For the purposes of these services, a course of treatment will consist of the number of services stated in the patient's referral (up to a maximum of six in any one referral).

If a patient has not used all of their psychological therapy services and/or focussed psychological strategies services under a referral in a calendar year, it is not necessary to obtain a new referral for the "unused" services. However, any "unused" services received from 1 January in the following year under that referral will count as part of the total of 10 services for which the patient is eligible in that calendar year.

When patients have used all of their referred services they will need to obtain a new referral from the referring practitioner if they are eligible for further services. Where the patient's care is being managed by a GP or medical practitioner, the GP/medical practitioner may choose to use this visit to undertake a review of the patient's GP Mental Health Treatment Plan, Home Health Care shared care plan and/or psychiatrist assessment and management plan.

It is not necessary to have a new GP Mental Health Treatment Plan, Home Health Care shared care plan and/or psychiatrist assessment and management plan prepared each calendar year in order to access a new referral(s) for eligible psychological therapy services and/or focussed psychological strategies services. Patients continue to be eligible for rebates for psychological therapy services and/or focussed psychological strategies services while they are being managed under a GP Mental Health Treatment Plan, Home Health Care shared care plan and/or a psychiatrist assessment and management plan as long as the need for eligible services continues to be recommended in their plan.

Health Care Home shared care plan

A Health Care Home shared care plan means a written plan that is prepared for a patient enrolled at a Health Care Home trial site; is prepared by a medical practitioner (including a general practitioner but not including a specialist

or consultant physician) who is leading the patient's care at the Health Care Home trial site; and includes: an outline of the patient's agreed current and long-term goals; the person or people responsible for each activity; arrangements to review the plan by a day mentioned in the plan; and if authorised by the patient, arrangements for the transfer of information between the medical practitioner and other health care providers supporting patient care about the patient's condition or conditions and treatment. Additionally, a Health Care Home shared care plan must include a record of the patient's agreement to mental health services; an outline of assessment of the patient's mental disorder, including the mental health formulation and diagnosis or provisional diagnosis; and if appropriate, a plan for one or more of crisis intervention and relapse prevention.

ALLIED MENTAL HEALTH PROFESSIONAL ELIGIBILITY

Eligible allied health professionals

A person is an allied health professional in relation to the provision of a FPS service if the person meets one of the following requirements:

- a. the person is a psychologist who holds general registration in the health profession of psychology under the applicable law in force in the State or Territory in which the service is provided;
- b. the person is a member of the Australian Association of Social Workers (AASW) and certified by AASW as the meeting the standards for mental health set out in the document published by AASW titled 'Practice Standards for Mental Health Social Workers 2014' as in force on 25 September 2014;
- c. the person:
 - i. is an occupational therapist who is registered as a person who may provide that kind of service under the applicable law in force in the State or Territory in which the service is provided; and
 - ii. is accredited by Occupational Therapy Australia as:
 - having a minimum of two years experience in mental health; and
 - having undertaken to observe the standards set out in the document published by Occupational Therapy Australia's 'Australian Competency Standards for Occupational Therapists in Mental Health' as in force on 1 November 2006.

Continuing professional development (CPD) for Occupational Therapists and Social Workers providing focussed psychological strategies (FPS) services

Occupational Therapists and Social Workers providing FPS services are required to have completed 10hours FPS CPD.

A CPD year for the purposes of these items is from 1 July to 30 June annually.

Part-time allied mental health professionals are required to have 10 hours of FPS related CPD, the same as full-time allied mental health professionals.

Occupational Therapists and Social Workers who are registered during the course of the CPD year, their obligation to undertake CPD will be on a pro-rata basis. The amount of units will be calculated from the 1st of the month immediately succeeding the month they obtained initial registration. The obligation will be one-twelfth of the yearly requirement for each month.

CPD activities must be relevant to delivering FPS services. Acceptable CPD activities where the content is related to FPS can include formal postgraduate education, workshops, seminars, lectures, journal reading, writing papers, receipt of supervision and peer consultation, and online training.

There is flexibility in the CPD activities that can be undertaken to meet individual professional needs and their practice/client base and client needs. For example, activities could also include assessment and treatment of specific disorders and client types such as youth, or different modalities and delivery such as working with groups.

Registering with the Department of Human Services

Advice about registering with the Department of Human Services to provide focussed psychological strategies - allied mental health services using items 80100-80171 inclusive is available from the Department of Human Services provider inquiry line on 132 150.

Further information

For further information about Medicare Benefits Schedule items, please go to the Department of Health's website at www.health.gov.au/mbsonline

For providers, further information is also available for providers from the Department of Human Services provider inquiry line on 132 150.

The Department of Human Services (DHS) has developed a Health Practitioner Guideline to substantiate that a valid Allied Mental Health service has been provided (for allied health professionals) which is located on the DHS website.

MN.7.2 Telehealth Focussed Psychological Strategies Services

These notes provide information on the telehealth focussed psychological strategies MBS video consultation items by psychologists, occupational therapists and social workers. A video consultation involves a single psychologist, occupational therapist or social worker attending a patient, or a group of 6 to 10 patients.

MBS item numbers 80101, 80111, 80126, 80136, 80151 and 80161 provide for attendance via videoconferencing by a psychologist, occupational therapist or social worker to an individual patient. MBS item numbers 80121, 80146 and 80171 provide for attendance via videoconferencing by a psychologist, occupational therapist or social worker to a group of 6 to 10 patients. The items are stand-alone items and do not have a derived fee.

These therapies are time limited, being deliverable in up to 10 planned sessions in a calendar year (including services to which items 80001, 80011, 80101, 80111, 80126, 80136, 80151 and 80161 apply).

Patients will also be eligible to claim up to 10 separate services within a calendar year for group therapy services involving 6-10 patients to which items 80021 (psychological therapy via video conference – clinical psychologist), 80121 (focussed psychological strategies via video conference – psychologist), 80146 (focussed psychological strategies via video conference – occupational therapist) and 80171 (focussed psychological strategies via video conference – social worker) apply. These group services are separate from the individual services and do not count towards the 10 individual services per calendar year maximum associated with those items.

Clinical indications

The psychologist, occupational therapist or social worker must be satisfied that it is clinically appropriate to provide a video consultation to a patient, or a group of 6 to 10 patients.

Restrictions

The MBS telehealth attendance items are not payable for services to an admitted hospital patient (this includes hospital in the home patients). Benefits are not payable for telephone or email consultations. In order to fulfil the item descriptor there must be a visual and audio link between the patient and the remote psychologist, occupational therapist or social worker. If the remote psychologist, occupational therapist or social worker is unable to establish both a video and audio link with the patient, a MBS rebate for a telehealth attendance is not payable.

Billing Requirements

All video consultations provided by psychologists, occupational therapists or social workers must be separately billed. That is, only the relevant telehealth MBS consultation item is to be itemised on the account/bill/voucher. Any other service/item billed should be itemised on a separate account/bill/voucher. This will ensure the claim is accurately assessed as being a video consultation and paid accordingly.

Psychologists, occupational therapists or social workers should not use the notation 'telehealth', 'verbal consent' or 'Patient unable to sign' to overcome administrative difficulties to obtaining a patient signature for bulk-billed claims (for further information see mbsonline.gov.au/telehealth).

Eligible Geographical Areas

Geographic eligibility for psychological telehealth services funded under Medicare (in Groups M6 and M7) is determined according to the Modified Monash Model (MMM) classifications. Telehealth Eligible Areas are those areas that are within MMM classifications 4 to 7. Patients and providers are able to check their eligibility using the Modified Monash Model locator on the Department of Health's website (http://www.health.gov.au/internet/otd/publishing.nsf/Content/MMM_locator).

There is a requirement for the patient and psychologist, occupational therapist or social worker to be located a minimum of 15 kilometres apart at the time of the consultation. Minimum distance between psychologist, occupational therapist or social worker and patient video consultations are measured by the most direct (ie least distance) route by road. The patient or the psychologist, occupational therapist or social worker is not permitted to travel to an area outside the minimum 15 kilometres distance in order to claim a video consultation.

Record Keeping

Participating telehealth psychologists, occupational therapists and social workers must keep contemporaneous notes of the consultation including documenting that the service was performed by video conference, the date, time and the people who participated.

Only clinical details recorded at the time of the attendance count towards the time of the consultation. It does not include information added at a later time, such as reports of investigations.

Extended Medicare Safety Net (EMSN)

All telehealth consultations (with the exception of the participating optometrist telehealth items) are subject to EMSN caps. The EMSN caps for telehealth consultation items in Groups M6 and M7 are equal to 300% of the schedule fee (to a maximum of \$500).

Aftercare Rule

Video consultations are subject to the same aftercare rules as psychologists, occupational therapists and social workers providing face-to-face consultations.

Multiple attendances on the same day

In some situations a patient may receive a consultation via video conference and a face-to-face consultation by the same or different psychologist, occupational therapist or social worker on the same day.

Medicare benefits may be paid for more than one video consultation on a patient on the same day by the same psychologist, occupational therapist or social worker, provided the second (and any following) video consultations are not a continuation of the initial or earlier video consultations. Psychologists, occupational therapists and social workers will need to provide the times of each consultation on the patient's account or bulk-billing voucher.

Referrals

The referral procedure for a video consultation is the same as for conventional face-to-face consultations.

Technical requirements

In order to fulfil the item descriptor there must be a visual and audio link between the patient and the remote psychologist, occupational therapist or social worker. If the remote clinical psychologist is unable to establish both a video and audio link with the patient, a MBS rebate for a telehealth attendance is not payable.

Individual clinicians must be confident that the technology used is able to satisfy the item descriptor and that software and hardware used to deliver a videoconference meets the applicable laws for security and privacy.

MN.8.1 Pregnancy Support Counselling - Eligible Patients - (Items 81000 to 81010)

Medicare benefits are available for non-directive pregnancy support counselling services provided to a person who is pregnant or who has been pregnant in the 12 months preceding the first service to which item 81000, 81005 or 81010 applies in relation to that pregnancy. Services can be provided either by an eligible GP or by an eligible psychologist, social worker or mental health nurse on referral from a GP.

The term 'GP' is used hereafter as a generic reference to medical practitioners (including a general practitioner, but not including a specialist or consultant physician).

The items may be used to address any pregnancy related issues for which non-directive counselling is appropriate.

MN.8.2 Pregnancy Support Counselling - Eligible Services - (Items 81000 to 81010)

There are four MBS items for the provision of non-directive pregnancy support counselling services:

Item 4001 - services provided by an eligible GP;

Item 81000 - services provided by an eligible psychologist;

Item 81005 - services provided by an eligible social worker; and

Item 81010 - services provided by an eligible mental health nurse.

These notes relate to items 81000-81010. Each individual allied health professional must meet the provider eligibility requirements set out below and be registered with the Department of Human Services.

Service length and type

Non-directive pregnancy support counselling services provided by eligible psychologists, social workers and mental health nurses using items 81000-81010 inclusive must be of at least 30 minutes duration and provided to an individual patient. The allied health professional must personally attend the patient.

The service involves the psychologist, social worker or mental health nurse undertaking a safe, confidential process that helps the patient explore concerns they have about a current pregnancy or a pregnancy that occurred in the preceding 12 months. This includes providing, on request, unbiased, evidence-based information about all options and services available to the patient.

Non-directive counselling is a form of counselling that is based on the understanding that, in many situations, people can resolve their own problems without being provided with a solution by the counsellor. The counsellor's role is to encourage the person to express their feelings but not suggest what decision the person should make. By listening and reflecting back what the person reveals to them, the counsellor helps them to explore and understand their feelings. With this understanding, the person is able to make the decision that is best for them.

Number of services per year

Medicare benefits are available for up to three (3) eligible non-directive pregnancy support counselling services per patient, per pregnancy, provided using items 81000, 81005, 81010 and 4001.

Partners of eligible patients may attend each or any counselling session, however, only one fee applies to each service.

Out-of-pocket expenses and Medicare Safety Net

Charges in excess of the Medicare benefit for these items are the responsibility of the patient. However, such outof-pocket costs will count toward the Medicare safety net for that patient. Non-directive pregnancy support counselling services in excess of three (3) per pregnancy will not attract a Medicare benefit and the safety net arrangements will not apply to costs incurred by the patient for such services.

Publicly funded services

Items 81000, 81005 and 81010 do not apply for services that are provided by any other Commonwealth or State funded services or provided to an admitted patient of a hospital.

However, where an exemption under subsection 19(2) of the *Health Insurance Act 1973* has been granted to an Aboriginal Community Controlled Health Service or State/Territory clinic, items 81000, 81005 and 81010 can be claimed for services provided by an eligible psychologist, social worker or mental health nurse salaried by or contracted to the service, where all requirements of the relevant item are met, including registration with the Department of Human Services. These services must be direct billed (that is, the Medicare rebate is accepted as full payment for services).

Private health insurance

Patients need to decide if they will use Medicare or their private health insurance ancillary cover to pay for these services. Patients cannot use their private health insurance ancillary cover to 'top up' the Medicare rebate paid for the services

MN.8.3 Pregnancy Support Counselling - Referral Requirements - (Items 81000 to 81010)

Patients must be referred for non-directive pregnancy support counselling services by a GP or medical practitioner. GPs/medical practitioners are not required to use a specific form to refer patients for these services. The referral may be a letter or note to an eligible allied health professional signed and dated by the referring GP/medical practitioner.

Patients may be referred by a GP or medical practitioner to more than one eligible allied health professional for eligible non-directive pregnancy support counselling services (for example, where a patient does not wish to continue receiving services from the provider they were referred to in the first instance). However, Medicare benefits are only available for a maximum of three (3) non-directive pregnancy support counselling services to which items 792, 4001, 81000, 81005 and 81010 apply, per patient, per pregnancy.

Where the patient is unsure of the number of Medicare rebated non-directive pregnancy support counselling services they have already accessed, the patient may check with the Department of Human Services on 132 011. Alternatively, the psychologist, social worker or mental health nurse may check with the Department of Human Services.

The relevant allied health professional must be in receipt of the referral at the first non-directive pregnancy support counselling service and must retain the referral for 2 years from the date the service was rendered, for the Department of Human Services auditing purposes.

A copy of the referral is not required to accompany Medicare claims. However, referral details are required to be included on patients' itemised accounts/receipts or Medicare assignment of benefit forms.

Referral validity

The referral is valid for up to three (3) non-directive pregnancy support counselling services, per patient, per pregnancy.

Subsequent Referrals

A new referral is required where the patient seeks to access non-directive pregnancy support counselling in relation to a different pregnancy or where the patient wishes to be referred to a different allied health professional than the one they were referred to in the first instance.

MN.8.4 Pregnancy Support Counselling - Allied Health Professional Eligibility -(Items 81000 to 81010)

Eligible allied health professionals

Items 81000, 81005 and 81010 can only be claimed for services provided by psychologists, social workers and mental health nurses who meet the following specific eligibility requirements, and are registered with the Department of Human Services.

To be eligible to provide services using MBS Item 81000, a psychologist must hold general registration in the health profession of psychology under the applicable law in force in the State or Territory in which the service is provided and be certified by the Australian Psychological Society as appropriately trained in non-directive pregnancy counselling.

To be eligible to provide services using MBS Item 81005, a social worker must be a 'Member' of the Australian Association of Social Workers (AASW), be certified by AASW either as meeting the standards for mental health set out in the document published by AASW titled 'Practice Standards for Mental Health Social Workers 2014' as in force on 25 September 2014 or as an Accredited Social Worker, and have completed appropriate non-directive pregnancy counselling training;

To be eligible to provide services using MBS Item 81010, a mental health nurse must be a 'Credentialled Mental Health Nurse' as certified by the Australian College of Mental Health Nurses, and have completed appropriate non-directive pregnancy counselling training.

Registering with the Department of Human Services

Advice about registering with the Department of Human Services to provide non-directive pregnancy support counselling services using items 81000-81010 inclusive is available from the Department of Human Services provider inquiry line on 132 150.

Further information

A copy of the Medicare Allied Health Supplement can be accessed from www.health.gov.au/mbsonline. The Supplement includes more information about Medicare, including how to make a claim from Medicare.

Further information is also available for providers from the Department of Human Services provider inquiry line on 132 150.

MN.9.1 Group Allied Health Services (Items 81100 to 81125) for People with Type 2 Diabetes - Eligible Patients

MBS items (81100 to 81125) are available for group allied health services for patients with type 2 diabetes. These items apply to services provided by eligible diabetes educators, exercise physiologists and dietitians, on referral from a GP or medical practitioner.

Services available under these items are in addition to the five individual allied health services available to patients each calendar year (refer to items 10950 to 10970).

To be eligible for these services, the patient must have in place one of the following:

• a GP Management Plan (GPMP) (GP item 721 or medical practitioner item 229); OR

- for a resident of a residential aged care facility, the GP or medical practitioner must have contributed to, or contributed to a review of, a care plan prepared for them by the facility (GP item 731 or medical practitioner item 232). [Note: Generally, residents of an aged care facility rely on the facility for assistance to manage their type 2 diabetes. Therefore, the resident may not need to be referred for group allied health services under these items, as the self-management approach offered in group services may not be appropriate.]; OR
- a Health Care Home shared care plan.

Unlike the individual allied health services under items 10950 to 10970, there is no additional requirement for a Team Care Arrangement (GP item 723 or medical practitioner item 230) in order for the patient to be referred for group allied health services.

Once the patient has been referred by their GP or medical practitioner, a diabetes educator, exercise physiologist or dietitian will conduct an individual assessment (under items 81100, 81110 or 81120). A maximum of one (1) assessment service is available per calendar year. After assessment, the patient may receive up to eight (8) group services per calendar year from an eligible diabetes educator, exercise physiologist and/or dietitian (under items 81105, 81115 and 81125). A collaborative approach, where diabetes educators, exercise physiologists and dietitians work together to develop group service programs in their local area, is encouraged.

MN.9.2 Group Allied Health Services (Items 81100 to 81125) for People with Type 2 Diabetes - GP Referral Requirements

Patients must be referred by their GP to an eligible allied health professional (diabetes educator, exercise physiologist or dietitian) who will undertake an individual assessment of their suitability for a group services program (under item 81100, 81110 or 81120).

When referring patients, **GPs** must use a referral form that has been issued by the Australian Government Department of Health or a Health Care Home shared care plan or a form that contains all the components of this form. The form issued by the department is available at http://www.health.gov.au/mbsprimarycareitems (click on the link for group allied health services).

GPs are also encouraged to provide a copy of the relevant part of the patient's care plan to the allied health professional.

Health Care Home shared care plan

A Health Care Home shared care plan means a written plan that is prepared for a patient enrolled at a Health Care Home trial site; is prepared by a medical practitioner (including a general practitioner but not including a specialist or consultant physician) who is leading the patient's care at the Health Care Home trial site; and includes: an outline of the patient's agreed current and long-term goals; the person or people responsible for each activity; arrangements to review the plan by a day mentioned in the plan; and if authorised by the patient, arrangements for the transfer of information between the medical practitioner and other health care providers supporting patient care about the patient's condition or conditions and treatment.

MN.9.3 Group Allied Health Services (Items 81100 to 81125) for People with Type 2 Diabetes - Eligible Allied Health Professionals

Items 81100 to 81125 only apply to services provided by eligible diabetes educators, exercise physiologists and dietitians who are registered with the Department of Human Services. If providers are already registered with the Department of Human Services to use item 10951, 10953 or 10954, they do not need to register separately for items 81100 to 81125. Eligibility criteria are as follows:

Diabetes educator: must be a 'credentialed diabetes educator' (CDE) as credentialed by the Australian Diabetes Educators Association (ADEA).

Exercise physiologist: must be an 'accredited exercise physiologist' as accredited by Exercise and Sports Science Australia (ESSA).

Dietitian: must be an 'accredited practising dietitian' as recognised by the Dietitians Association of Australia (DAA).

The Department of Human Services registration forms may be obtained from the Department of Human Services on 132 150 or at the Department of Human Services' website.

MN.9.4 Assessment for Group Allied Health Services (Items 81100, 81110 and 81120) for People with Type 2 Diabetes

An assessment service is provided by a diabetes educator (item 81100), an exercise physiologist (item 81110) or a dietitian (item 81120), on referral from a GP.

The purpose of this service is to undertake an individual assessment and determine the patient's suitability for a group services program. It involves taking a comprehensive patient history and identification of individual goals. This may also provide an opportunity to identify any patient who is likely to be unsuitable for group services.

Number of services per year

Patients are eligible for a maximum of <u>one</u> assessment for group services (item 81100 **or** 81110 **or** 81120) per calendar year. If more than one assessment service is provided in a calendar year, the subsequent service/s will not attract a Medicare rebate and the MBS Safety Net arrangements will not apply to costs incurred by the patient for the service/s.

If there is any doubt about a patient's eligibility for items 81100, 81110 or 81120, the allied health professional should contact the Department of Human Services to confirm the number of assessment services already claimed by the patient in the calendar year. Allied health professionals can call the Department of Human Services on 132 150 to check this information.

Referral form

The GP must refer the patient using the *Referral form for group allied health services under Medicare for patients with type 2 diabetes* or a Health Care Home shared care plan or a form that contains all the components of this form. The form issued by the department is available at http://www.health.gov.au/mbsprimarycareitems (click on the link for group allied health services).

The allied health professional undertaking the assessment service will need to complete Part B of this form, and the patient will then need to present this form to the provider/s of group services.

Health Care Home shared care plan

A Health Care Home shared care plan means a written plan that is prepared for a patient enrolled at a Health Care Home trial site; is prepared by a medical practitioner (including a general practitioner but not including a specialist or consultant physician) who is leading the patient's care at the Health Care Home trial site; and includes: an outline of the patient's agreed current and long-term goals; the person or people responsible for each activity; arrangements to review the plan by a day mentioned in the plan; and if authorised by the patient, arrangements for the transfer of information between the medical practitioner and other health care providers supporting patient care about the patient's condition or conditions and treatment.

Length of service

This service must be of at least 45 minutes duration and provided to an individual patient. The allied health professional must personally attend the patient.

Reporting requirements

On completion of the assessment service, the allied health professional must provide a written report back to the referring GP outlining the assessment undertaken, whether the patient is suitable for group services and, if so, the nature of the group services to be delivered.

MN.9.5 Group Allied Health Services (Items 81105, 81115 and 81125) for People with Type 2 Diabetes - Service Requirements and Referral Forms

These services are provided in a group setting to assist with the management of type 2 diabetes.

Number of services per year

Patients are eligible for up to eight group allied health services in total (items 81105, 81115 and 81125 inclusive) per calendar year. Each separate group service must be provided to the patient by only one type of allied health professional (i.e. by a diabetes educator, or by an exercise physiologist or by a dietitian). However, the overall group services program provided for the patient could be comprised of one type of service only (e.g. eight diabetes education services) or a combination of services (e.g. three diabetes education services, three dietitian services and two exercise physiology services). An eligible allied health professional with more than one Medicare provider number (e.g. for the provision of diabetes education and dietetics) may provide separate services under each of these provider numbers.

Group allied health service providers are strongly encouraged to deliver multidisciplinary group services programs that allow patients to benefit from a range of interventions designed to assist in the management of their type 2 diabetes.

Where a patient receives more than the limit of eight group services in a calendar year, the additional service/s will not attract a Medicare benefit and the MBS Safety Net arrangements will not apply to costs incurred by the patient for the service/s.

If there is any doubt about a patient's eligibility for group services, the allied health professional should contact the Department of Human Services to confirm the number of group services already claimed by the patient in the calendar year. Allied health professionals can call the Department of Human Services on 132 150 to check this information.

Multiple services on the same day

Where clinically relevant, up to two group services may be provided consecutively on the same day by the same allied health professional.

Referral form

The allied health professional/s undertaking the group services will need to receive the *Referral form for group allied health services under Medicare for patients with type 2 diabetes issued by the Department of Health* or the Health Care Home shared care plan or a form that contains all the components of this form, with Part B completed by the provider who has undertaken the assessment service. The form issued by the department is available at http://www.health.gov.au/mbsprimarycareitems (click on the link for group allied health services).

Health Care Home shared care plan

A Health Care Home shared care plan means a written plan that is prepared for a patient enrolled at a Health Care Home trial site; is prepared by a medical practitioner (including a general practitioner but not including a specialist or consultant physician) who is leading the patient's care at the Health Care Home trial site; and includes: an outline of the patient's agreed current and long-term goals; the person or people responsible for each activity; arrangements to review the plan by a day mentioned in the plan; and if authorised by the patient, arrangements for the transfer of information between the medical practitioner and other health care providers supporting patient care about the patient's condition or conditions and treatment.

Group size

The service must be provided to a person who is part of a group of between two and 12 persons.

Length of service

Each group service must be of at least 60 minutes duration.

Reporting requirements

On completion of the group services program, each allied health professional must provide, or contribute to, a written report back to the referring GP in respect of each patient. The report should describe the group services provided for the patient and indicate the outcomes achieved. While each allied health professional is required to provide feedback to the GP in relation to the group services that they provide to the patient, allied health professionals involved in the provision of a multidisciplinary program are encouraged to combine feedback into a single report to the referring GP.

MN.9.6 Group Allied Health Services (Items 81100 to 81125) for People with Type 2 Diabetes - Additional Requirements

Retention of Referral Form for the Department of Human Services Audit Purposes

It is recommended that Allied health professionals retain a copy of the referral form for 24 months from the date the service was rendered (for the Department of Human Services auditing purposes).

Publicly funded services

Items 81100 - 81125 do not apply for services that are provided by any other Commonwealth or state-funded services or provided to an admitted patient of a hospital. However, where an exemption under subsection 19(2) of the *Health Insurance Act 1973* has been granted to an Aboriginal Community Controlled Health Service or a state/territory government health clinic, items 81100-81125 can be claimed for services provided by eligible allied health professionals salaried by, or contracted to, service or health clinic. All requirements of the relevant item must be met, including registration of the allied health professional with the Department of Human Services. These services must also be bulk billed.

Private health insurance

Patients need to decide if they will use Medicare or their private health insurance ancillary cover to pay for these services. Patients cannot use their private health insurance ancillary cover to 'top up' the Medicare rebate paid.

Out-of-pocket expenses and Medicare Safety Net

Allied health professionals are free to determine their own fees for the professional service. Charges in excess of the Medicare benefit for the allied health items are the responsibility of the patient. However, such out of pocket costs will count toward the Medicare Safety Net for that patient.

MN.9.7 Group Allied Health Services (Items 81100 to 81125) for People with Type 2 Diabetes - Further Information

Further information about these items is available on the Department of Health's website at www.health.gov.au/mbsprimarycareitems

MN.10.1 Provision of Autism, Pervasive Developmental Disorder or Disability Services by Allied Health Professionals - (Items 82000 to 82035) Eligible patients

MBS items 82000 to 82035 provide Medicare-rebateable allied health services to children with autism or any other pervasive developmental disorder (PDD) through the Helping Children with Autism program, and to children with an eligible disability through the Better Start for Children with Disability program. Children with both autism/PDD and an eligible disability can access either program, but not both.

The conditions classified as PDD in 2008 for the purposes of these services were informed by the American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV-TR), Washington, DC, American Psychiatric Association, 2000.

'Eligible disabilities' for the purpose of these services means any of the following conditions:

- (a) sight impairment that results in vision of less than or equal to 6/18 vision or equivalent field loss in the better eye, with correction.
- (b) hearing impairment that results in:
- (iii) a hearing loss of 40 decibels or greater in the better ear, across 4 frequencies; or
- (iv) permanent conductive hearing loss and auditory neuropathy.
- (c) deafblindness
- (d) cerebral palsy
- (e) Down syndrome
- (f) Fragile X syndrome
- (g) Prader-Willi syndrome
- (h) Williams syndrome
- (i) Angelman syndrome
- (j) Kabuki syndrome
- (k) Smith-Magenis syndrome
- (1) CHARGE syndrome
- (m) Cri du Chat syndrome
- (n) Cornelia de Lange syndrome
- (o) microcephaly if a child has:
- (iii) a head circumference less than the third percentile for age and sex; and
- (iv) a functional level at or below 2 standard deviations below the mean for age on a standard developmental test, or an IQ score of less than 70 on a standardised test of intelligence.
- (p) Rett's disorder

[&]quot;standard developmental test" refers to the Bayley Scales of Infant Development or the Griffiths Mental Development Scales; "standardised test of intelligence" means the Wechsler Intelligence Scale for Children (WISC)

or the Wechsler Preschool and Primary Scale of Intelligence (WPPSI). It is up to the clinical judgement of the diagnosing practitioner if other tests are appropriate to be used.

Allied health services available under Medicare

Items are available for **assessment/diagnosis** services, the results of which can contribute to development of a treatment and management plan by the referring medical practitioner, and for **treatment** services.

The assessment/diagnosis items (82000, 82005, 82010, 82030) can be accessed when:

- a child with autism/PDD is aged under 13 years and referred by an eligible consultant psychiatrist or paediatrician; or
- a child with an eligible disability is aged under 13 years and referred by a specialist, consultant physician or GP.

The **treatment** items (82015, 82020, 82025 and 82035) can be accessed when:

- A child with autism/PDD is aged under 15 years and a treatment and management plan has been put in place for them before their 13th birthday, and they have been referred by an eligible consultant psychiatrist or paediatrician.
- A child with an eligible disability is aged under 15 years and a treatment and management plan has been put in place for them before their 13th birthday, and they have been referred by a specialist, consultant physician or GP.

The allied health assessment and treatment services can be provided by eligible audiologists, occupational therapists, optometrists, orthoptists, physiotherapists, psychologists and speech pathologists.

Number of assessment services

Medicare rebates are available for up to four services in total per eligible child, to assist with assessment and diagnosis and development of a treatment plan. The four services may consist of any combination of items 82000, 82005, 82010 and 82030. It is the responsibility of the referring practitioner to allocate these services in keeping with the child's individual needs and to refer the child to appropriate allied health professional(s) accordingly.

These services will not attract a Medicare rebate unless a referral has been made by a consultant psychiatrist (using items 296-370) or paediatrician (using items 110-131) for a child with autism/PDD, or by a specialist or consultant physician (using items 104-131 or 296-370 excluding item 359) or GP (using items 3-51) for a child with a disability.

Number of treatment services

Medicare rebates are available for up to twenty allied health treatment services in total per eligible child. The twenty services may consist of any combination of items 82015, 82020, 82025 and 82035. It is the responsibility of the referring practitioner to allocate these services in keeping with the child's individual treatment needs and to refer the child to appropriate allied health professional(s) accordingly.

These services will not attract a Medicare rebate unless referral has been made by a consultant psychiatrist (using item 289) or paediatrician (using item 135) for children with autism/PDD, or by a specialist or consultant physician (using item 137) or a GP for disability (using item 139) for children with disability.

Service length and type

Services under these items must be for the time period specified within the item descriptor. The allied health professional must personally attend the child.

A child may receive up to four Medicare eligible services from an allied health professional on the same day.

It is anticipated that professional attendances at places other than consulting rooms would be provided where treatment in other environments is necessary to achieve therapeutic outcomes.

It is also expected that participating allied health providers will deliver treatment under these items that is consistent with the autism/PDD or disability treatment plan prepared by the medical practitioner, and is in keeping with commonly established autism/PDD or disability interventions as practised by their profession and appropriate for the age and particular needs of the child being treated.

Eligible allied health professionals

Allied health professionals providing services under these items must be registered with the Department of Human Services. To register with the Department of Human Services to provide these services, an allied health professional must meet the specific eligibility requirements detailed below:

- **Audiologist** must be either a 'Full Member' of the Audiological Society of Australia Inc (ASA), who holds a 'Certificate of Clinical Practice' issued by the ASA; or an 'Ordinary Member Audiologist' or 'Fellow Audiologist' of the Australian College of Audiology (ACAud).
- Occupational Therapist must be registered with the Occupational Therapy Board of Australia.
- **Optometrist** must be registered as an optometrist or optician under a law of a State or an internal Territory that provides for the registration of optometrists or opticians, and be a participating optometrist.
- **Orthoptist** must be registered with the Australian Orthoptic Board and have a Certificate of Currency; and be a member of Orthoptics Australia.
- **Physiotherapis**t must be registered with the Physiotherapy Board of Australia.
- **Psychologist** must hold General Registration with the Psychology Board of Australia.
- **Speech Pathologist** must be a 'Practising Member' of Speech Pathology Australia.

In addition to meeting the above mentioned credentialing requirements, it is expected that eligible providers will "self-select" for the autism/PDD and disability items (i.e. possess the skills and experience appropriate for provision of these services and be oriented to work with children with autism/PDD or disability).

Referral requirements

An allied health professional wanting to provide any of the items 82000-82035 must be in receipt of a current referral provided by an eligible medical practitioner. Referrals are only valid when prerequisite MBS services have been provided.

An eligible allied health professional can provide assessment items (82000, 82005, 82010 and 82030) to a child under the Helping Children with Autism program when:

- the child has previously been provided with any MBS service covering items 110 through 131 inclusive by a consultant paediatrician; or
- the child has previously been provided with any MBS service covering items 296 through 370 (excluding item 359) inclusive by a consultant psychiatrist.

An eligible allied health professional can provide assessment items (82000, 82005, 82010 and 82030) to a child under the Better Start for Children with Disability program when:

- the child has previously been provided with any MBS service covering items 104 through 131 inclusive, or items 296 through 370 (excluding item 359) inclusive by a specialist or consultant physician; or
- the child has previously been provided with any MBS service covering items 3 through 51 by a GP.

An eligible allied health professional can provide treatment items (82015-82025 and 82035) to a child under the Helping Children with Autism program when:

- the child has previously been provided with a treatment plan (item 135) by a consultant paediatrician; or
- the child has previously been provided with a treatment plan (item 289) by a consultant psychiatrist.

An eligible allied health professional can provide treatment items (82015-82025 and 82035) to a child under the Better Start for Children with Disability program when:

- the child has previously been provided with a treatment plan (MBS item 137) by a specialist or consultant physician; or
- the child has previously been provided with a treatment plan (MBS item 139) by a GP.

If the referring service has not yet been claimed, the Department of Human Services (DHS) will not be aware of the child's eligibility and Medicare benefits cannot be paid. DHS will be able to confirm whether a relevant MBS service has been claimed and/or the number of allied health services already claimed by the child. Allied health professionals can call the DHS provider line on 132 150. Parents and carers can call the patient information line on 132 011.

It is recommended that allied health professionals retain the referral for 24 months from the date the service was rendered for Medicare auditing purposes.

Referring medical practitioners are not required to use a specific form to refer patients for these services. The referral may be a letter or note to an eligible allied health professional signed and dated by the referring practitioner.

Referral validity

Medicare benefits are available for up to four allied health assessment and diagnosis services and up to twenty allied health treatment services per patient in total.

Patients will require a separate referral for each allied health professional they are referred to and they will also need new referrals for each new course of treatment.

A course of treatment for the allied health treatment services consists of the number of allied health services stated on the child's referral. This enables the referring practitioner to consider a report from the allied health professional(s) about the services provided to the child, and the need for further treatment.

Within the maximum service allocation of twenty services for the treatment items, the allied health professional(s) can provide one or more courses of treatment. Up to 4 services may be provided to the same child on the same day.

Reporting requirements

A written report must be provided to the referring medical practitioner by the allied health professional(s) after having provided the assessment and diagnosis and development of a treatment plan service(s) to the child.

On completion of a course of treatment, the eligible audiologist, occupational therapist, optometrist, orthoptist, physiotherapist, psychologist and speech pathologist must provide a written report to the referring medical practitioner which includes information on:

- treatment provided;
- recommendations on future management of the child's disorder; and
- any advice provided to third parties (e.g. parents, schools).

A written report must also be provided to the referring medical practitioner at the completion of any subsequent course(s) of treatment provided to the child.

Further information

For more information refer to the <u>MBS online website</u> or the <u>MBS Primary Care Items</u> information page. information page.

MN.11.1 Follow-up Allied Health Services for people of Aboriginal or Torres Strait Islander descent (Items 81300 to 81360) Eligible Patients

A person who is of Aboriginal or Torres Strait Islander descent may be referred by their GP for follow-up allied health services under items 81300 to 81360 when the GP has undertaken a health assessment or a Health Care Home shared care plan and identified a need for follow-up allied health services.

These items are similar to the individual allied health items (items 10950 to 10970) available to patients who have a chronic or terminal medical condition and complex care needs and have a GP Management Plan and Team Care Arrangements or a Health Care Home shared care plan prepared by their GP. However items 81300 to 81360 provide an alternative referral pathway for Aboriginal or Torres Strait Islander people to access allied health services. If a patient meets the eligibility criteria for individual allied health services under the Chronic Disease Management items or the Health Care Home shared care plan and for follow-up allied health services, they can access both sets of services and are eligible for up to ten allied health services under Medicare per calendar year.

A practice nurse/Aboriginal and Torres Strait Islander health practitioner item (10987) is also available for Indigenous Australians who have received a health check. This item enables Aboriginal or Torres Strait Islander people to receive follow-up services from a practice nurse or Aboriginal and Torres Strait Islander health practitioner on behalf of a GP. More detail on this item is provided at explanatory note M.12.4 of the Medicare Benefits Schedule.

Eligible Allied Health Services

The following allied health professionals are eligible to provide services under these items:

- Aboriginal and Torres Strait Islander health practitioners
- Aboriginal Health Workers
- Audiologists
- Chiropractors
- Diabetes Educators
- Dietitians
- Exercise Physiologists
- Mental Health Workers
- Occupational Therapists
- Osteopaths
- Physiotherapists
- Podiatrists

- Psychologists
- Speech Pathologists

Publicly funded services

Items 81300 to 81360 do not apply for services that are provided by any Commonwealth or state or territory government funded services or provided to an admitted patient of a hospital. However, where an exemption under subsection 19(2) of the Health Insurance Act 1973 has been granted to an Aboriginal Community Controlled Health Service or state/territory government health clinic, items 81300 to 81360 can be claimed for services provided by eligible allied health professionals salaried by, or contracted to, the service or health clinic. All requirements of the relevant item must be met, including registration of the allied health professional with the Department of Human Services. Medicare services provided under a subsection 19(2) exemption must be bulk billed (i.e. the Medicare rebate is accepted as full payment for services).

Number of services per year

Medicare benefits are available for up to five follow-up allied health services per eligible patient, per calendar year. The five allied health services can be made up of one type of service (e.g. five physiotherapy services) or a combination of different types of services (e.g. one dietetic, two podiatry and two physiotherapy services).

The annual limit of five allied health services per patient under items 81300 to 81360 is in addition to the individual allied health services for patients with a chronic or terminal medical condition and complex care needs (items 10950 to 10970).

Checking patient eligibility for items 81300 to 81360

If there is any doubt about a patient's eligibility, the Department of Human Services will be able to confirm the number of allied health services already claimed by the patient during the calendar year. Allied health professionals can call the Department of Human Services on 132 150 and patients can call the Department of Human Services on 132 011 or alternatively the Indigenous Access Line for the Department of Human Services on 1800 556 955.

Service length and type

Services provided by eligible allied health professionals under these items must meet the specific requirements set out in the item descriptors. These requirements include that:

- the service is of at least 20 minutes duration;
- the service is provided to the person individually (i.e. not as part of a group service) and in person (i.e. the allied health professional must personally attend the patient);
- the person is not an admitted patient of a hospital;
- the allied health professional must provide a written report to the GP; and
- if the patient has private health insurance, he/she cannot use their private health insurance ancillary cover to 'top up' the Medicare rebate paid for these services.

Private health insurance

Patients need to decide if they will use Medicare or their private health insurance ancillary cover to pay for these services. Patients cannot use their private health insurance ancillary cover to 'top up' the Medicare rebate paid for the services.

Reporting back to the GP

Where an allied health professional provides a single service to the patient under a referral, the allied health professional must provide a written report back to the referring GP after that service.

Where an allied health professional provides multiple services to the same patient under a referral, the allied health professional must provide a written report back to the referring GP after the first and last service, or more often if clinically necessary. Written reports should include:

- any investigations, tests, and/or assessments carried out on the patient;
- any treatment provided; and
- future management of the patient's condition or problem.

Allied health professionals are required to retain the referral form 24 months.

Out-of-pocket expenses and Medicare safety net

Allied health professionals can determine their own fees for the professional service, except where the service is provided under a subsection 19(2) exemption. Charges in excess of the Medicare benefit for the allied health items are the responsibility of the patient. However, such out-of-pocket costs will count toward the Medicare safety net for that patient. Allied health services in excess of five in a calendar year will not attract a Medicare benefit and the safety net arrangements will not apply to costs incurred by the patient for such services.

Referral Requirements

Referral form

For Medicare benefits to be payable, the patient must be referred to an eligible allied health professional by their GP using a referral form that has been issued by the Australian Government Department of Health or a form that contains all the components of this form.

The form issued by the department is available at the <u>MBS Primary Care Items</u> information page (click on the link for follow-up allied health services).

GPs are encouraged to attach a copy of the relevant part of the patient's care plan to the referral form.

GPs may use one referral form to refer patients for single or multiple services of the same service type (e.g. five dietetic services). If referring a patient for single or multiple services of different service types (e.g. two dietetic services and three podiatry services), a separate referral form will be needed for each service type.

The patient will need to present the referral form to the allied health professional at the first consultation, unless the GP has previously provided it directly to the allied health professional.

Allied health professionals are required to retain the referral form for 2 years from the date the service was rendered (for the Department of Human Services auditing purposes). A copy of the referral form is not required to accompany Medicare claims, and allied health professionals do not need to attach a signed copy of the form to patients' itemised accounts/receipts or assignment of benefit forms.

Completed forms do not have to be sent to the Department of Health.

Health Care Home shared care plan

A Health Care Home shared care plan means a written plan that is prepared for a patient enrolled at a Health Care Home trial site; is prepared by a medical practitioner (including a general practitioner but not including a specialist or consultant physician) who is leading the patient's care at the Health Care Home trial site; and includes: an outline of the patient's agreed current and long-term goals; the person or people responsible for each activity; arrangements

to review the plan by a day mentioned in the plan; and if authorised by the patient, arrangements for the transfer of information between the medical practitioner and other health care providers supporting patient care about the patient's condition or conditions and treatment.

Referral validity

A referral is valid for the stated number of services. If all services are not used during the calendar year in which the patient was referred, the unused services can be used in the next calendar year. However, those services will be counted as part of the five rebates for allied health services available to the patient during that calendar year.

When patients have used all of their referred services they will need to obtain a new referral from their GP.

Allied health Professional Eligibility

Items 81300 to 81360 can only be claimed for services provided by eligible allied health professionals who are registered with the Department of Human Services. Allied health professionals already registered with Medicare (e.g. for items 10950 to 10970) do not need to register again to claim these items.

Specific eligibility requirements for allied health professionals providing services under these items are:

Aboriginal and Torres Strait Islander health practitioners must be registered with the Aboriginal and Torres Strait Islander Health Practice Board of Australia. Aboriginal and Torres Strait Islander health practitioners may use any of the titles authorised by the Aboriginal and Torres Strait Islander Health Practice Board: Aboriginal health practitioners; Aboriginal and Torres Strait Islander health practitioners: or Torres Strait Islander health practitioners.

Aboriginal health workers in a State or Territory other than the Northern Territory must have been awarded either:

- a. a Certificate III in Aboriginal and/or Torres Strait Islander Primary Health Care (or an equivalent or higher qualification) by a registered training organisation; or
- b. a Certificate III in Aboriginal and Torres Strait Islander Health (or an equivalent or higher qualification) by a registered training organisation before 1 July 2012.

Note: Where individuals consider their qualification to be equivalent to or higher than the qualifications listed above, they will need to contact a registered training organisation in their State or Territory to have the qualification assessed as such before they can register with the Department of Human Services. In the Northern Territory, a practitioner must be registered with the Aboriginal and Torres Strait Islander Health Practice Board of Australia.

Audiologists must be either a 'Full Member' of the Audiological Society of Australia Inc (ASA), who holds a 'Certificate of Clinical Practice' issued by the ASA; or an 'Ordinary Member - Audiologist' or 'Fellow Audiologist' of the Australian College of Audiology (ACAud).

Chiropractors must be registered with the Chiropractic Board of Australia.

Diabetes educators must be a Credentialled Diabetes Educator (CDE) as credentialled by the Australian Diabetes Educators Association (ADEA).

Dietitians must be an 'Accredited Practising Dietitian' as recognised by the Dietitians Association of Australia (DAA).

Exercise physiologists must be an 'Accredited Exercise Physiologist' as accredited by Exercise and Sports Science Australia (ESSA).

Mental health workers can include services provided by members of five different allied health professional groups. 'Mental health workers' are drawn from the following:

psychologists;

- mental health nurses;
- occupational therapists;
- social workers;
- Aboriginal and Torres Strait Islander health practitioners; and
- Aboriginal health workers.

Psychologists, occupational therapists, Aboriginal and Torres Strait Islander health practitioners and Aboriginal health workers are eligible in separate categories for these items.

Mental health nurses must be a credentialled mental health nurse, as certified by the Australian College of Mental Health Nurses.

Mental health nurses who were registered in the ACT or Tasmania prior to the introduction of the National Registration and Accreditation Scheme (NRAS) on 1 July 2010, will have until 31 December 2010 to be certified by the Australian College of Mental Health Nurses.

Social workers must be a 'Member' of the Australian Association of Social Workers (AASW); and be certified by AASW as meeting the standards for mental health set out in the document published by AASW titled 'Practice Standards for Mental Health Social Workers' as in force on 8 November 2008.

Occupational therapists must be registered with the Occupational Therapy Board of Australia.

Osteopaths must be registered with the Osteopathy Board of Australia.

Physiotherapists must be registered with the Physiotherapy Board of Australia.

Podiatrists must be registered with the Podiatry Board of Australia.

Psychologists must hold general registration in the health profession of psychology under the applicable law in force in the State or Territory in which the service is provided.

Speech pathologists must be a 'Practising Member' of Speech Pathology Australia.

Registering with the Department of Human Services

Provider registration forms may be obtained from the Department of Human Services on 132 150 or by visiting the Department of Human Services website and then searching for "allied health application".

Further information

Further information about these items, including a fact sheet and the referral form, is available on the Department of Health's <u>MBS Primary Care Items</u> information page. For providers, information is also available from the Department of Human Services provider inquiry line on 132 150. The Indigenous Access Line for the Department of Human Services on 1800 556 955 is also a useful source of information.

MN.12.1 Immunisation services provided by an Aboriginal and Torres Strait Islander health practitioner - (Item 10988)

Item 10988 can only be claimed by a medical practitioner where an immunisation is provided to a patient by an Aboriginal and Torres Strait Islander health practitioner on behalf of the medical practitioner.

Item 10988 can be claimed only once per patient visit, even if more than one vaccine is administered during the same patient visit.

An Aboriginal and Torres Strait Islander health practitioner means a person who has been registered as an Aboriginal and Torres Strait Islander health practitioner by the Aboriginal and Torres Strait Islander Health Practice Board of Australia and meets the Board's registration standards. The Aboriginal and Torres Strait Islander health practitioner must be employed or retained by a general practice, or by a health service that has an exemption to claim Medicare benefits under subsection 19(2) of the Health Insurance Act 1973.

An Aboriginal and Torres Strait Islander health practitioner may use any of the titles authorised by the Aboriginal and Torres Strait Islander Health Practice Board: Aboriginal health practitioner; Aboriginal and Torres Strait Islander health practitioner; or Torres Strait Islander health practitioner.

The Aboriginal and Torres Strait Islander health practitioner must be appropriately qualified and trained to provide immunisations. This includes compliance with any territory requirements.

The medical practitioner under whose supervision the immunisation is provided retains responsibility for the health, safety and clinical outcomes of the patient.

Supervision may include distance supervision where the medical practitioner does not have to be physically present at the time that the service is provided by the Aboriginal and Torres Strait Islander health practitioner, but should be able to be contacted for advice if required.

The immunisation must be performed by the Aboriginal and Torres Strait Islander health practitioner in accordance with the current edition of the Australian Immunisation Handbook and the Central Australian Rural Practitioners Association (CARPA) Standard Treatment Manual.

Immunisation means the administration of a registered vaccine to a patient for any purpose other than as part of a mass immunisation of persons.

A registered vaccine means a vaccine that is included on the Australian Register of Therapeutic Goods. This includes all vaccines on the Australian Standard Vaccination Schedule and vaccines covered in the current edition of the Australian Immunisation Handbook. The following substances cannot be claimed under this item: vaccines used experimentally; homeopathic substances; immunotherapy for allergies (eg de-sensitisation preparations); and other substances that are not vaccines. There may also be territory limitations on the administration of some vaccines, such as those for tuberculosis, yellow fever and Q-fever.

All GPs whether vocationally registered or not are eligible to claim this item. District Medical Officers (DMOs) employed by the Northern Territory Department of Health and Community Services are also eligible to claim this item.

Where the medical practitioner provides a professional attendance to the patient (in addition to the immunisation service provided by the Aboriginal and Torres Strait Islander health practitioner), the medical practitioner may also claim for the professional attendance they provide to the patient.

Item 10991 can also be claimed in conjunction with item 10988 provided the conditions of both items are satisfied.

Related Items: 10988

MN.12.2 Wound management services provided by an Aboriginal and Torres Strait Islander health practitioner (item 10989)

Item 10989 can only be claimed by a medical practitioner where wound management (other than normal aftercare) is provided to a patient by an Aboriginal and Torres Strait Islander health practitioner on behalf of the medical practitioner.

Item 10989 can be claimed only once per patient visit, even if more than one wound is treated during the same patient visit.

An Aboriginal and Torres Strait Islander health practitioner means a person who has been registered as an Aboriginal and Torres Strait Islander health practitioner by the Aboriginal and Torres Strait Islander Health Practice

Board of Australia and meets the Board's registration standards. The Aboriginal and Torres Strait Islander health practitioner must be employed or 806 retained by a general practice, or by a health service that has an exemption to claim Medicare benefits under subsection 19(2) of the Health Insurance Act 1973.

An Aboriginal and Torres Strait Islander health practitioner may use any of the titles authorised by the Aboriginal and Torres Strait Islander Health Practice Board: Aboriginal health practitioner; Aboriginal and Torres Strait Islander health practitioner; or Torres Strait Islander health practitioner.

The Aboriginal and Torres Strait Islander health practitioner must be appropriately qualified and trained to treat wounds. This includes compliance with any territory requirements.

The medical practitioner under whose supervision the treatment is provided retains responsibility for the health, safety and clinical outcomes of the patient.

Supervision may include distance supervision where the medical practitioner does not have to be physically present at the time that the service is provided by the Aboriginal and Torres Strait Islander health practitioner, but should be able to be contacted for advice if required.

The medical practitioner must conduct an initial assessment of the patient (including under a distance supervision arrangement if the medical practitioner is not physically present) in order to give instruction in relation to the treatment of the wound.

Where an Aboriginal and Torres Strait Islander health practitioner provides ongoing wound management, the medical practitioner is not required to give instruction or see the patient during each subsequent visit.

MN.12.3 Follow up service provided by a practice nurse or Aboriginal and Torres Strait Islander health practitioner, on behalf of a Medical Practitioner, for an Indigenous person who has received a health assessment (Item 10987)

Item 10987 may be claimed by a medical practitioner, where a follow up service is provided by a practice nurse or Aboriginal and Torres Strait Islander health practitioner on behalf of that medical practitioner for an Indigenous person who has received a health check.

All GPs whether vocationally registered or not are eligible to claim this item. District Medical Officers (DMOs) employed by state/territory health Departments are also eligible to claim this item. The term 'GP' is used in these notes as a generic reference to medical practitioners able to claim this item.

Item 10987 does not apply for services that are provided by any other Commonwealth or State funded services. However, where an exemption under subsection 19(2) of the *Health Insurance Act 1973* has been granted to an Aboriginal Community Controlled Health Service or State/Territory Government Health clinic, item 10987 can be claimed for services provided by practice nurses or Aboriginal and Torres Strait Islander health practitioner salaried or contracted to, the Service or Health clinic. All requirements of the item must be met.

Item 10987 will assist Indigenous patients who have received a health check which has identified a need for follow up services which can be provided by a practice nurse or Aboriginal and Torres Strait Islander health practitioner between further consultations with the patient's GP.

Item 10987 may be used to provide:

- Examinations/interventions as indicated by the health check;
- Education regarding medication compliance and associated monitoring;
- Checks on clinical progress and service access;
- Education, monitoring and counselling activities and lifestyle advice;
- Taking a medical history; and
- Prevention advice for chronic conditions, and associated follow up.

Item 10987 may be claimed up to a maximum of 10 times per patient per calendar year.

Item 10987 may be accessed by an Indigenous patient who has received the Aboriginal and Torres Strait Islander Peoples Health Assessment (item 715), which is available to:

- a) children between the ages of 0 and 14 years;
- b) adults between the ages of 15 and 54 years; and
- c) older people over the age of 55 years.

The item can also be accessed by a child who has received a health check as part of the Northern Territory Emergency Response (NTER).

Patients whose condition is unstable/deteriorating should be referred to their GP for further treatment.

A practice nurse means a registered or enrolled nurse who is employed by, or whose services are otherwise retained by a general practice or by a health service that has an exemption to claim Medicare benefits under sub-section 19(2) of the *Health Insurance Act 1973*.

An Aboriginal and Torres Strait Islander health practitioner means a person who has been registered as an Aboriginal and Torres Strait Islander health practitioner by the Aboriginal and Torres Strait Islander Health Practice Board of Australia and meets the Board's registration standards. The Aboriginal and Torres Strait Islander health practitioner must be employed or retained by a general practice, or by a health service that has an exemption to claim Medicare benefits under subsection 19(2) of the Health Insurance Act 1973.

An Aboriginal and Torres Strait Islander health practitioner may use any of the titles authorised by the Aboriginal and Torres Strait Islander Health Practice Board: Aboriginal health practitioner; Aboriginal and Torres Strait Islander health practitioner; or Torres Strait Islander health practitioner.

In all cases, the GP under whose supervision the health check follow-up is being provided retains responsibility for the health, safety and clinical outcomes of the patient. The GP must be satisfied that the practice nurse or Aboriginal and Torres Strait Islander health practitioner is appropriately qualified and trained to provide the relevant follow up for the patient. GPs are advised to consult their insurer concerning indemnity coverage for services provided on their behalf.

General practices where nurses or Aboriginal and Torres Strait Islander health practitioners provide follow up for Indigenous people who have received a health check, should also have a written clinical risk management strategy covering issues like clinical roles, patient follow up and patient consent.

Continuing professional development is recommended for all nurses and an Aboriginal and Torres Strait Islander health practitioners providing follow up services for Indigenous people who have received a health check.

Supervision of the practice nurse/Aboriginal and Torres Strait Islander health practitioner by the GP at a distance is recognised as an acceptable form of supervision. This means that the claiming GP does not have to be physically present at the time the service is provided. However the GP should be able to be contacted if required.

Where the GP and practice nurse/Aboriginal and Torres Strait Islander health practitioner are at the same location, the GP is not required to be present while the health check follow up is undertaken. It is up to the GP to decide whether they need to see the patient. Where the GP has a consultation with the patient, then the GP is entitled to claim a Medicare item for the time and complexity of their personal attendance on the patient. The time the patient spends receiving a service from the practice nurse or Aboriginal and Torres Strait Islander health practitioner is itemised separately under item 10987 and should not be counted as part of the Medicare items claimed for time spent with the GP. Where the practice nurse or Aboriginal and Torres Strait Islander health practitioner provides another service (eg immunisation, cervical screening) on the same day, the GP is able to claim for all practice nurse/Aboriginal and Torres Strait Islander health practitioner services provided.

Item 10990 or 10991 (bulk billing incentives) can be claimed in conjunction with item 10987 provided the conditions of item 10990 or 10991 are satisfied.

MN.12.4 Provision of monitoring and support for a person with a chronic disease by a practice nurse or Aboriginal and Torres Strait Islander health practitioner (item 10997)

Item 10997 may be claimed by a medical practitioner, where a monitoring and support service for a person with a chronic disease care plan is provided by a practice nurse or Aboriginal and Torres Strait Islander health practitioner on behalf of that medical practitioner.

All GPs whether vocationally registered or not are eligible to claim this item. The term 'GP' is used in these notes as a generic reference to medical practitioners able to claim this item.

Item 10997 does not apply for services that are provided by any other Commonwealth or State funded services. However, where an exemption under subsection 19(2) of the Health Insurance Act 1973 has been granted to an Aboriginal Community Controlled Health Service or State/Territory Government health clinic, item 10997 can be claimed for services provided by practice nurses or Aboriginal and Torres Strait Islander health practitioners salaried by or contracted to, the Service or health clinic. All requirements of the item must be met.

Item 10997 will assist patients who require access to ongoing care, routine treatment and ongoing monitoring and support between the more structured reviews of the care plan by the patient's usual GP.

Item 10997 may be used to provide:

- checks on clinical progress;
- monitoring medication compliance;
- self management advice, and;
- collection of information to support GP/medical practitioner reviews of Care Plans.

The services provided by the practice nurse or Aboriginal and Torres Strait Islander health practitioner should be consistent with the scope of the GP Management Plan, Team Care Arrangements, or Multidisciplinary Care Plan.

Item 10997 may be claimed up to a maximum of 5 times per patient per calendar year.

Item 10997 may only be accessed by a patient with a GP Management Plan, Team Care Arrangements or Multidisciplinary Care Plan (GP items 721, 723, 729, 731, 732 or medical practitioner items 229, 230, 231, 232, 233).

Patients whose condition is unstable/deteriorating should be referred to their GP or medical practitioner for further treatment.

A practice nurse means a registered or enrolled nurse or Nurse Practitioner who is employed by, or whose services are otherwise retained by a general practice.

An Aboriginal and Torres Strait Islander health practitioner means a person who has been registered as an Aboriginal and Torres Strait Islander health practitioner by the Aboriginal and Torres Strait Islander Health Practice Board of Australia and meets the Board's registration standards. The Aboriginal and Torres Strait Islander health practitioner must be employed or retained by a general practice, or by a health service that has an exemption to claim Medicare benefits under subsection 19(2) of the Health Insurance Act 1973.

An Aboriginal and Torres Strait Islander health practitioner may use any of the titles authorised by the Aboriginal and Torres Strait Islander Health Practice Board: Aboriginal health practitioner; Aboriginal and Torres Strait Islander health practitioner; or Torres Strait Islander health practitioner.

In all cases, the GP or medical practitioner under whose supervision the chronic disease monitoring and support is being provided retains responsibility for the health, safety and clinical outcomes of the patient. The GP or medical practitioner must be satisfied that the practice nurse is appropriately qualified and trained to provide chronic disease support and monitoring. GPs and medical practitioners are advised to consult their insurer concerning indemnity coverage for services performed on their behalf.

General practices where nurses or Aboriginal and Torres Strait Islander health practitioner provide chronic disease support and monitoring, should also have a written clinical risk management strategy covering issues like clinical roles, patient follow up and patient consent.

Continuing professional development is recommended for all nurses and Aboriginal and Torres Strait Islander health practitioners providing chronic disease monitoring and support.

Supervision by the GP or medical practitioner at a distance is recognised as an acceptable form of supervision. This means that the claiming GP or medical practitioner does not have to be physically present at the time the service is provided. However, the GP/medical practitioner should be able to be contacted if required.

Where the GP/medical practitioner and the practice nurse/ Aboriginal and Torres Strait Islander health practitioner are at the same location, the GP/medical practitioner is not required to be present while the chronic disease monitoring and support is undertaken. It is up to the GP/medical practitioner to decide whether they need to see the patient. Where the GP/medical practitioner has a consultation with the patient, then the GP/medical practitioner is entitled to claim a Medicare item for the time and complexity of their personal attendance on the patient. The time the patient spends receiving a service from the practice nurse or Aboriginal and Torres Strait Islander health practitioner is itemised separately under item 10997 and should not be counted as part of the Medicare item claimed for time spent with the GP/medical practitioner. Where the practice nurse or Aboriginal and Torres Strait Islander health practitioner provides another service (eg immunisation) on the same day, the GP/medical practitioner is able to claim for both practice nurse/ Aboriginal and Torres Strait Islander health practitioner items.

Item 10990 or 10991 (bulk billing incentives) can be claimed in conjunction with item 10997 provided the conditions of item 10990 or 10991 are satisfied (see explanatory note M.1).

MN.12.5 Telehealth Support Services by Health Professionals

These notes provide information on the telehealth MBS attendance items for health professionals to provide clinical support to their patients during video consultations with a specialist, consultant physicians and psychiatrists under items 10945 to 10948 in Group A10 which are available for participating optometrists, items 82150, 82151 and 82152 in Group M13 which are available for participating midwives, items 82220 to 82225 in Group M14 for participating nurse practitioners and items 10983 and 10984 in Group M12 for practice nurses, Aboriginal and Torres Strait Islander health practitioners or Aboriginal health workers for services provided for and on behalf of a medical practitioner.

Telehealth patient-end support services can only be claimed where:

- a Medicare eligible specialist service is claimed;
- the service is rendered in Australia; and
- where this is necessary for the provision of the specialist service.

The above patient-end support services provide for attendances in various settings including eligible residential aged care services, eligible Aboriginal Medical Service or Aboriginal Community Controlled Health Service to which a 19(2) direction under the Health Insurance Act 1973 applies.

Clinical indications

The specialist, consultant physician or psychiatrist must be satisfied that it is clinically appropriate to provide a video consultation to a patient. The decision to provide clinically relevant support to the patient is the responsibility of the specialist, consultant physician or psychiatrist.

Telehealth specialist services can be provided to patients when there is no patient-end support service provided.

Collaborative Consultation

The practitioner, who provides assistance to the patient where this is necessary for the provision of the specialist service, may seek assistance from a health professional (e.g. a practice nurse, Aboriginal and Torres Strait Islander health practitioner or Aboriginal health worker) but only one item is billable for the patient-end support service. The practitioner must be present during part or all of the consultation in order to bill an appropriate time-tiered MBS item. Any time spent by another health professional called to assist with the consultation may not be counted against the overall time taken to complete the video consultation.

Restrictions

The MBS telehealth attendance items are not payable for services to an admitted hospital patient (this includes hospital in the home patients). Benefits are not payable for telephone or email consultations. In order to fulfill the item descriptor there must be a visual and audio link between the patient and the remote practitioner. If the remote practitioner is unable to establish both a video and audio link with the patient, a MBS rebate for a telehealth attendance is not payable.

Eligible Geographical Areas

Geographic eligibility for telehealth services funded under Medicare are determined according to the Australian Standard Geographical Classification Remoteness Area (ASGC-RA) classifications. Telehealth Eligible Areas are areas that are outside a Major City (RA1) according to ASGC-RA (RA2-5). Patients and providers are able to check their eligibility by following the links on the MBS Online website.

There is a requirement for the patient and specialist to be located a minimum of 15km apart at the time of the consultation. Minimum distance between specialist and patient video consultations are measured by the most direct (ie least distance) route by road. The patient or the specialist is not permitted to travel to an area outside the minimum 15 km distance in order to claim a video conference.

This rule will not apply to specialist video consultation with patients who are a care recipient in a residential care service; or at an Aboriginal Medical Service or an Aboriginal Community Controlled Health Service for which a direction, made under subsection 19(2) of the Health Insurance Act 1973, as these patients are to receive telehealth services anywhere in Australia.

Telehealth Eligible Service Areas are defined at the MBS Online website.

Record Keeping

Participating telehealth practitioners must keep contemporaneous notes of the consultation including documenting that the service was performed by video conference, the date, time and the people who participated.

Only clinical details recorded at the time of the attendance count towards the time of the consultation. It does not include information added at a later time, such as reports of investigations.

Multiple attendances on the same day

In some situations a patient may receive a telehealth consultation and a face to face consultation by the same or different practitioner on the same day.

Medicare benefits may be paid for more than one video consultation on a patient on the same day by the same practitioner, provided the second (and any following) video consultations are not a continuation of the initial or earlier video consultations. Practitioners will need to provide the times of each consultation on the patient's account or bulk billing voucher.

Aftercare Rule

Video consultations are subject to the same aftercare rules as face to face consultations.

Referrals

The referral procedure for a video consultation is the same as for conventional face-to-face consultations.

Technical requirements

In order to fulfill the item descriptor there must be a visual and audio link between the patient and the remote practitioner. If the remote practitioner is unable to establish both a video and audio link with the patient, a MBS rebate for a telehealth attendance is not payable.

Individual clinicians must be confident that the technology used is able to satisfy the item descriptor and that software and hardware used to deliver a video conference meets the applicable laws for security and privacy.

Bulk billing

Bulk bill incentive items 10990 or 10991 may be billed in conjunction with the MBS medical practitioner telehealth items 812, 827, 829, 867, 868, 869, 873, 876, 881, 885, 892 or GP items 2100, 2122, 2125, 2126, 2137, 2138, 2143, 2147, 2179, 2195, 2199 and 2220.

Duration of attendance

The practitioner attending at the patient end of the video consultation does not need to be present for the entire consultation, only as long as is clinically relevant - this can be established in consultation with the specialist. The MBS fee payable for the supporting practitioner will be determined by the total time spent assisting the patient. This time does not need to be continuous.

Aboriginal health workers

For the purpose of items 10983 and 10984 an Aboriginal health worker means a person who:

- a) holds a Certificate III in Aboriginal or Torres Strait Islander Health Worker Primary Health Care (Clinical) or other appropriate qualifications; or
- b) is registered, and holds a current registration issued by a State or Territory regulatory authority, as an Aboriginal health worker; and
- c) is employed by, or whose services are otherwise retained by a medical practitioner or their practice. This includes health service in relation to which a direction made under subsection 19(2) of the Act applies.

Aboriginal and Torres Strait Islander health practitioners

For the purpose of items 10983 and 10984 an Aboriginal and Torres Strait Islander health practitioner means a person who has been registered as an Aboriginal and Torres Strait Islander health practitioner by the Aboriginal and Torres Strait Islander Health Practice Board of Australia and meets the Board's registration standards. The Aboriginal and Torres Strait Islander health practitioner must be employed or retained by a general practice, or by a health service that has an exemption to claim Medicare benefits under subsection 19(2) of the Health Insurance Act 1973.

An Aboriginal and Torres Strait Islander health practitioner may use any of the titles authorised by the Aboriginal and Torres Strait Islander Health Practice Board: Aboriginal health practitioner; Aboriginal and Torres Strait Islander health practitioner; or Torres Strait Islander health practitioner.

Practice Nurse

For the purpose of items 10983 and 10984 a practice nurse means a registered or enrolled nurse who is employed by, or whose services are otherwise retained by a medical practitioner or their practice. This includes a health service in relation to which a direction made under subsection 19(2) of the Health Insurance Act 1973 applies.

MN.13.1 Maternity Services by Participating Midwives - Overview

As at 1 November 2010, Medicare benefits are payable for antenatal, intrapartum and postnatal care for the first 6 weeks after the delivery, provided by eligible privately practising midwives. Eligible midwives can also request certain pathology and diagnostic imaging services for their patients and refer patients to obstetricians and paediatricians, as the clinical need arises. Each service that attracts a Medicare benefit is identified in the Medicare Benefits Schedule (MBS) by an item number. Each item describes the service that the item covers.

MN.13.2 Participating Midwives

To provide services under Medicare, the legislation requires that a midwife be a participating midwife. A participating midwife is an eligible midwife who provides services in a collaborative arrangement or collaborative arrangements with one or more medical practitioners, of a kind or kinds specified in the regulations.

For more details on collaborative arrangements required under the regulations see Point M.13.5.

MN.13.3 Eligible Midwives

Under the legislation, to be an eligible midwife the midwife must be registered or authorised (however described) under State and Territory law to practice midwifery. The midwife must also demonstrate that he or she has the appropriate qualifications and experience to meet the registration standard developed by the Nursing and Midwifery Board of Australia.

Information regarding eligibility can be found on the Nursing and Midwifery Board of Australia (NMBA) site of the Australian Health Practitioner Regulatory Agency (AHPRA) website at:

http://www.nursingmidwiferyboard.gov.au/.

MN.13.4 Midwife Professional Indemnity Insurance

Under National Law, which governs the National Registration and Accreditation Scheme (NRAS), it is a requirement for midwives to have appropriate professional indemnity insurance. All privately practising midwives who wish to provide private midwifery services in must have appropriate professional indemnity insurance from the date the State or Territory in which they were registered enacted National Law.

Further information about professional indemnity insurance for midwives can be found at:

http://www.health.gov.au/internet/main/publishing.nsf/Content/Maternity+Services+Review-Q&A-PIMI

MN.13.5 Collaborative Arrangements

To provide Medicare rebate-able services an eligible midwife must have a collaborative arrangement in place that must provide for consultation, referral or transfer of care as clinical needs dictate, to ensure safe, high quality maternity care.

Under the legislation a collaborative arrangement can be with the following "specified" medical practitioners:

- 1. an obstetrician;
- 2. a medical practitioner who provides obstetric services; or
- 3. a medical practitioner employed or engaged by a hospital authority and authorised by the hospital authority to participate in a collaborative arrangement.

The types of practitioners listed 1) and 2) are defined in the Regulations as "obstetric specified medical practitioners".

Collaborative arrangement can be established in the following ways:

a. where the midwife:

- i. is employed or engaged by 1 or more obstetric specified medical practitioners or by an entity that employs or engages 1 or more obstetric specified medical practitioners; or
- ii. has an agreement, in writing, with an entity, other than a hospital, that employs or engages one or more obstetric specified medical practitioners, OR
- b. receiving patients by referral in writing to the midwife for midwifery treatment from a specified medical practitioner, OR
- c. having a signed written agreement with one or more specified medical practitioners, OR
- d. having an arrangement with and acknowledged by at least one specified medical practitioner
 - an arrangement requires that the eligible midwife must record the following in the midwife's written records:
 - i. The name of at least one specified medical practitioner who is, or will be, collaborating with the midwife in the patient's care (a named medical practitioner);
 - ii. That the midwife has told the patient that the midwife will be providing midwifery services to the patient in collaboration with one or more specified medical practitioners;
 - iii. Acknowledgement by a named medical practitioner that the practitioner will be collaborating in the patient's care;
 - iv. Plans for the circumstances in which the midwife will do any of the following:
 - i. consult with an obstetric specified medical practitioner;
 - ii. refer the patient to a specified medical practitioner;
 - iii. transfer the patient's care to an obstetric specified medical practitioner.
 - ii. The midwife must also record the following in the midwife's written records:
 - i. Any consultation or other communication between the midwife and an obstetric specified medical practitioner about the patient's care;
 - ii. Any referral of the patient by the midwife to a specified medical practitioner;
 - iii. Any transfer by the midwife of the patient's care to an obstetric specified medical practitioner;
 - iv. When the midwife gives a copy of the hospital booking letter for the patient to a named medical practitioner acknowledgement that the named medical practitioner has received the copy;
 - v. When the midwife gives a copy of the patient's maternity care plan prepared by the midwife to a named medical practitioner acknowledgement that the named medical practitioner has received the copy;
 - vi. If the midwife requests diagnostic imaging or pathology services for the patient when the midwife gives the results of the services to a named medical practitioner
 - vii. That the midwife has given a discharge summary at the end of the midwife's care for the patient to:
 - i. a named medical practitioner; and
 - ii. the patient's usual general practitioner, OR
- e. In relation to a hospital, the midwife is:
 - i. credentialed to provide midwifery services after successfully completing a formal process to assess the midwife's competence, performance and professional suitability; and
 - ii. given clinical privileges for a defined scope of clinical practice for the hospital; and
 - iii. permitted to provide midwifery care to his or her own patients at the hospital.

The legislation requires that collaborative arrangements must be in place at the time the participating midwife provides the service.

a. Being employed or engaged by a medical practice or an entity or having a written agreement with an entity An entity may refer to, for example, a community health centre or a medical practice. For a midwife to have a collaborative arrangement in these circumstances, that midwife must be employed or engaged by or have a written agreement with an entity that also employs or engages 1 or more obstetric specified medical practitioners.

The terms employ or engage covers both employees and contractors. This will cover an eligible midwife who is employed or engaged by a medical practice so long as that medical practice employs or engages at least one obstetrician or medical practitioner that provides obstetric services.

There must be at least one obstetric specified medical practitioner employed or engaged by the entity each

time the midwife renders a service/performs treatment. However, there is no requirement that the consultation, referral or transfer of care must always be to the medical practitioner(s) employed/engaged by the entity.

- b. Referral from a medical practitioner
 - A participating midwife's patient will be able to access the MBS and PBS if a patient has been referred in writing to the midwife by a specified medical practitioner. The arrangement must provide for consultation, referral and transfer of care should the clinical need arise.
- c. Written agreement with a medical practitioner A participating midwife's patient will be able to access the MBS and PBS if the nurse practitioner has a written agreement in place with one or more specified medical practitioners. The agreement must be signed by the nurse practitioner and doctor. The arrangement must provide for consultation, referral and transfer of
- d. Arrangement with, acknowledged by a medical practitioner
 Evidence of 'acknowledgement' by an obstetrician/GP obstetrician for each woman for whom the midwife
 provides care is a requirement to ensure that the medical practitioner being named understands and accepts
 the collaborative arrangement.
 - The acknowledgement does not have to be obtained on an individual patient basis. This means that, for example, a midwife could obtain an acknowledgement from a specified medical practitioner that he or she will be the collaborating medical practitioner for some or all of the midwife's patients. Arrangements to collaborate could be obtained in a number of ways including signing of documents, email or fax confirmation, or verbal acknowledgement which the midwife documents in their written records. The midwife is required to record in written records communications in regard to consultations, referral and transfer of the woman's care with the medical practitioner, including information that has been forwarded to the medical practitioner. The midwife is also required to send a copy of all pathology and diagnostic imaging results to a named medical practitioner and to record in the midwife's written records when this occurs (however, there is no requirement that the midwife consult with a medical practitioner in relation to every test result). The purpose of sharing records with the collaborating medical practitioner is to prevent duplication of services and to ensure continuity of care.
- e. Collaborative arrangement with a hospital
 This type of collaborative arrangement applies where an eligible midwife is credentialed for a hospital,
 having successfully completed a formal assessment of his or her qualifications, skills, experience and
 professional standing. It is expected that the assessment would involve an appropriately qualified medical
 practitioner/s. The midwife is also required to have a defined scope of clinical practice at the hospital and
 be eligible to treat his or her own patients at the hospital. The hospital must employ or engage at least one
 obstetric specified medical practitioner. It is expected that the hospital will have a formal written agreement
 with such midwives, addressing consultation, referral and transfer of care, relevant clinical guidelines and
 locally determined policies.

MN.13.6 Provider Numbers

To access the Medicare arrangements, eligible midwives will need to apply to the Department of Human Services for a provider number. A separate provider number is required for each location at which a midwife practices.

Advice about registering with the Department of Human Services to provide midwifery services using items 82100 to 82140 inclusive, is available from the Department of Human Services provider inquiry line on 132 150.

Medicare provider application forms for midwives can be downloaded from the following site:

www.medicareaustralia.gov.au

MN.13.7 Schedule Fees and Medicare Benefits

Each midwifery service is identified in the MBS by an item number. The fee set for any item in the MBS is known as the "Schedule fee". The Schedule fee and Medicare benefit for each service is listed in the item description.

There are two levels of benefit payable for midwifery services:

75% of the Schedule fee for midwifery services rendered to privately insured patients as part of an episode of hospital treatment (other than for public patients); or

85% of the Schedule fee for antenatal and postnatal services rendered to non-admitted patients.

MN.13.8 Safety Nets

Where practitioners charge more than the Medicare benefit, the resultant out-of-pocket costs are the responsibility of the patient.

Assistance is provided to families and singles for out-of-pocket costs for out-of-hospital services through the "original" and "extended" Medicare safety nets:

- the original safety net provides that once the threshold is met, the Medicare benefit increases to 100 per cent of the Schedule fee. The threshold in 2019 is \$470.00; and
- under the Extended Medicare Safety Net (EMSN), once certain thresholds are met, Medicare reimburses 80 per cent of the out-of-pocket costs. However, where the item has an EMSN benefit cap, there is a maximum limit on the EMSN benefit that will be paid for that item.

In 2019, the annual EMSN threshold for concession cardholders and people who receive Family Tax Benefits (Part A) is \$680.70. For all other singles and families the annual threshold is \$2,133.00. These amounts are indexed by Consumer Price Index on 1 January each year.

MN.13.9 Safety Net Capping for Midwifery Items

Midwifery services will be subject to a benefit limit or cap under the EMSN. This is in line with obstetric services which are also subject to a safety net cap. The caps that apply to midwifery services are outlined below:

Item	Maximum increase (\$)
82100	21.70
82105	16.30
82110	21.70
82115	54.10
82130	16.30
82135	21.70
82140	16.30

MN.13.10 Where Medicare Benefits are not payable

Medicare benefits are not available:

- a. for services listed in the MBS, where the service rendered does *not* meet the item description and associated requirements;
- b. where the midwifery service is *not* personally performed by the participating midwife;
- c. for MBS services that are time based, the inclusion of any time period in the consultation periods when the patient is *not* receiving active attention e.g. the time the provider may take to travel to the patient's home or where the patient is resting between blood pressure readings; and
- d. services provided where the patient is not in attendance, such as the issuing of repeat prescriptions;
- e. for telephone attendances;

f. group sessions; and

g. The issuing of repeat prescriptions, updating patient notes or telephone consultations.

The fee charged under Medicare must not include the cost of services that are not part of the MBS service being claimed. Medicare benefits are not payable for good or appliances associated with the service, such as bandages or other skin dressings

Unless the Minister otherwise directs, Medicare benefits are not payable where funding has already been provided under an arrangement with the Commonwealth, state or a local governing body.

MN.13.11 Billing of Patient

Where the practitioner bills the patient for medical services rendered, the patient needs a properly itemised account/receipt to enable a claim to be made for Medicare benefits.

Under the provisions of the Health Insurance Act and Regulations, Medicare benefits are not payable in respect of a professional service unless there is recorded on the account setting out the fee for the service or on the receipt for the fee in respect of the service, the following particulars:-

- (a) Patient's name;
- (b) The date on which the professional service was rendered;
- (c) An item number or a description of the professional service sufficient to identify the item that relates to that service, including an indication where the service is rendered to a person while hospital treatment is provided in a hospital "admitted patient" immediately preceding the description of the service or an asterisk "*" directly after an item number where used;
- (d) The name and practice address and provider number of the participating midwife who actually rendered the service; (where the participating midwife has more than one practice location recorded with the Department of Human Services, the provider number used should be that which is applicable to the practice location at or from which the service was given).

Only one original itemised account should be issued in respect of any one service and any duplicates of accounts or receipts should be clearly marked "duplicate" and should be issued only where the original has been lost. Duplicates should not be issued as a routine system for "accounts rendered".

MN.13.12 Assignment of Benefits (Direct-Billing) Arrangements

Under the Health Insurance Act the Assignment of Benefit (direct-billing) facility for professional services is available to all persons in Australia who are eligible for benefit under the Medicare program. This facility is NOT confined to pensioners or people in special need.

If a participating midwife direct-bills, the participating midwife undertakes to accept the relevant Medicare benefit as full payment for the service. Additional charges for that service (irrespective of the purpose or title of the charge) cannot be raised against the patient. Under these arrangements:-

- The patient's Medicare card number must be quoted on all direct-bill forms for that patient.
- · The basic forms provided are loose leaf to enable the patient details to be imprinted from the Medicare card.
- · The forms include information required by Regulations under Subsection 19(6) of the Health Insurance Act.
- · The practitioner must include the particulars relating to the professional service out on the assignment form before the patient signs the form and ensure that the patient to receive a copy of the form as soon as practicable after the patient signs it.

· Where a patient is unable to sign the assignment form the signature of the patient's parent, guardian or other responsible person (other than the practitioner, practitioner's staff, hospital proprietor, hospital staff, residential aged care facility proprietor or residential aged care facility staff) is acceptable. The reason the patient is unable to sign should also be stated.

The administration of the direct-billing arrangements under Medicare as well as the payment of Medicare benefits on patient claims is the responsibility of **the Department of Human Services**. Any enquiries in regard to these matters should therefore be directed to Medicare offices or enquiry points.

MN.13.13 Assignment of Benefit Forms

Participating midwives wishing to direct-bill are required to use a specific form available from the Department of Human Services. This stationary is available from the Department of Human Services. Note that these forms are approved forms under the Health Insurance Act, and no other forms can be used to assign benefits without the approval of the Department of Human Services. Further information about direct-billing stationary can be obtained by telephoning **132150**.

MN.13.14 Time Limits Applicable to Lodgement of Claims for Assigned Benefits

A time limit of two years applies to the lodgement of claims with Medicare under the direct-billing (assignment of benefit) arrangements. This means that Medicare benefits are not payable for any service where the service was rendered more than two years earlier than the date the claim was lodged with Medicare.

Provision exists whereby in certain circumstances (e.g. hardship cases), the Minister may waive the time limits. Special forms for this purpose are available, if required, from the processing centre to which assigned claims are directed.

MN.13.15 Overview of the Maternity Items

Antenatal, intrapartum and postnatal care provided by participating midwives are covered by MBS items 82100, 82105, 82110, 82115, 82120, 82125, 82130, 82135, 82140. These items cover nine specific types of service that allow the participating midwife to:

- · undertake an initial antenatal attendance of more than 40 minutes duration (item 82100)
- · provide a short antenatal attendance of up to 40 minutes duration (item 82105)
- · provide a long antenatal attendance of more than 40 minutes duration (item 82110);
- · make an assessment of and prepare a maternity care plan for a woman across a pregnancy that has progressed beyond 20 weeks (item 82115);
- · undertake management of a confinement for up to 12 hours, including delivery (item 82120);
- · undertake management of a confinement in excess of 12 hours including delivery (item 82125);
- · provide a short postnatal attendance of up to 40 minutes duration (item 82130);
- provide long postnatal attendance of at least 40 minutes duration (item 82135); and
- provide a comprehensive postnatal check to a woman six weeks after the birth of her baby (item 82140).

MN.13.16 Maternity Services Attracting Medicare Rebates

Medicare Benefits are only payable for clinically relevant services. *Clinically relevant* in relation to midwifery care means a service generally accepted by the midwifery profession as necessary to the appropriate treatment of the patient's clinical condition.

Medicare benefits are only payable where the participating midwife provides care to not more than one patient on the one occasion.

Antenatal Care

Eligible maternity care plan service

There is one MBS item available for eligible midwife practitioners to undertake a comprehensive assessment of and prepare a written maternity care plan for a woman, who is not an admitted patient of a hospital, across a pregnancy that has progressed beyond 20 weeks. It is expected that the care plan would be agreed with the woman and detail such things as agreed expectation, health problems and care needs and appropriate referrals, medication and diagnostic tests.

Number of services

Only one (1) midwifery care plan is payable in any pregnancy.

Antenatal Attendances

Medicare benefits are payable for an antenatal service where a midwife provides a clinically relevant service in respect of a miscarriage. Medicare benefits are not payable for an antenatal attendance associated with the confinement. The confinement items 82120 and 82125 include all associated attendances.

Any clinically relevant indication that requires an antenatal attendance by a midwife on an admitted patient in hospital, but that is not associated with the confinement, will attract a Medicare benefit.

Number of services

Only one (1) initial antenatal attendance under item 82100 is payable in any pregnancy.

There is no limit attached to long and short antenatal attendances by a participating midwife. However, only clinically relevant attendances should be itemised under Medicare and services provided by participating midwives will be subject to Medicare Audit and Professional Review Processes.

Management of Confinement

The MBS includes two items for management of confinement by a participating midwife; 82120 for a confinement of up to 12 hours, and 82125 for a confinement where labour is in excess of 12 hours, and the woman's care has been transferred to another participating midwife.

Medicare benefits are payable under items 82120 and 82125 whether or not the participating midwife undertakes the delivery i.e. including where the woman's care is escalated to an obstetrician during labour or for the delivery.

Medicare benefits are only payable where the service is provided to a woman who is an admitted patient of a hospital, including a hospital birthing centre. For Medicare benefit purposes a confinement is taken to commence when the participating midwife attends a patient that is in labour and who has been admitted to the hospital for confinement and delivery The time period for these items is the period for which the midwife is in exclusive and continuous attendance on the woman for labour, and delivery where performed.

Medicare benefits are only payable for management of confinement where the participating midwife undertaking the service has provided the patient's antenatal care or who is a member of a practice that provided the patient's antenatal care.

It is not intended that these items be claimed routinely by midwives who do not intend to undertake the delivery i.e where the midwife has arranged beforehand for a medical practitioner to undertake the delivery. Where the midwife does not undertake the delivery it is because:

care was transferred to a second midwife for management of labour which had exceeded 12 hours; or

- · there was a clinical need to escalate care to an obstetrician or medical practitioner who provides obstetric services; or
- · the patient's care was transferred from the first midwife to another participating midwife in exceptional circumstances.

Number of services

Only one (1) confinement item 82120 is payable in any pregnancy, except where exceptional circumstances have required the patient's care to be transferred from the first midwife to another participating midwife. In these circumstances, both midwives may bill an item 82120 service.

Medicare rebates are only payable for (1) confinement item 82125.

Postnatal Care

In addition to the long and short antenatal attendance items for postnatal care in the first 6 weeks post delivery the MBS provides for a 6 week postnatal check, after which the woman would be referred back to her usual GP.

Number of services

Only one (1) postnatal check by a participating midwife is payable in any pregnancy.

There is no limit attached to long and short postnatal attendances by a participating midwife. However, only clinically relevant attendances should be itemised under Medicare and services provided by participating midwives will be subject to Medicare Audit and Professional Review Processes.

MN.13.17 Conditions Governing the Provision and Claiming of Items Service length and type

Services under these items must be for the time period specified within the item descriptor.

Professional attendance for MBS items 82100, 82105, 82110, 82115, 82130, 82135, 82140 may be provided in an appropriate setting that includes but is not limited to: the woman's home, a midwifery group practice, a midwife practitioner's rooms or a medical practice.

MN.13.18 Referral Requirements

A participating midwife will be able to refer women to specialist obstetricians and paediatricians as clinical services dictate.

This measure does not include referral by a midwife for allied health care. If a participating midwife refers a patient to an allied health practitioner, no benefits would be payable for that service.

Medicare benefits are not payable specifically for services provided by a lactation consultant at this time. Medicare benefits would be payable for breast feeding support provide as part of the postnatal care by the participating midwife.

A referral is valid for 12 months to cover the confinement (antenatal, birthing and postnatal care for 6 weeks post delivery). Should there be a new pregnancy in that period, a new referral will be required.

A new pregnancy represents a new episode of care.

A referral to a specialist must be in writing in the form of a letter or a note to the specialist and must be signed and dated by the referring midwife. The referral must contain any information relevant to the patient and the specialist must have received the referral on or prior to providing a specialist consultation.

If a specialist provides a consultation without a referral, the specialist's consultation would not attract Medicare benefits at the specialist rate.

There are exemptions from this requirement in an emergency if the specialist considers the patient's condition requires immediate attention without a referral. In that situation, the specialist is taken to be the referring practitioner.

If a referral is lost, stolen or destroyed, the midwife would need to provide a replacement referral as soon as is practicable after the service is provided.

If the woman is a privately admitted patient of a hospital a letter or note is not required. The referring midwife would make a notation in the woman's hospital, which he or she would sign, approving the referral.

A referral is not required to transfer a woman's care during the intra-partum period under items 16527 and 16528. The midwife would make a signed notation in the woman's clinical record approving the transfer of care.

A referral is not required to refer the woman back to her GP after the 6 week postnatal period. The midwife would provide a discharge summary to the GP outlining her maternity history and any relevant clinical issues, which would also be recorded on the patient's notes.

MN.13.19 Requesting Requirements Pathology Services

Determination of Necessity of Service

The participating midwife requesting a pathology service for a woman must determine that the pathology service is necessary.

Request for Service

The service may only be provided in response to a request from the treating practitioner and the request must be in writing (or, if oral, confirmed in writing within fourteen days).

Pathology Services approved for participating midwives

FBC (item 65070)	vaginal /anal swab/GBS (69312)* varicella 69384 - 69401 (antibody test) parvo virus 69384 - 69401
Hb (item 65060)	rubella titre syphilis Hep B/C - items 69405, 69408, 69411, 69413 or 69415 HIV
Group and antibodies (items 65090, 65093, 65096) glucose load (items 66545, 66548)	Serum Bilirubin (SBR); 66500
Downs Syndrome/ Spina Bifida (items 66743, 66750, 66751)	Direct Coombs; 65114
eye swab (69303)	Blood glucose level (item 66500)
skin swab (69306)	Cord PH and gases cord (O2 and CO2) (Item 66566)
skin scrapings (69309)	Group and Hold (item 65099)
Chlamydia (item 69316)	Coagulation Studies (items 65129, 65070)
Gonorrhea (item 69317)	Mid stream urine (item 69324)

[Cervical Screening (Items 75070, 75071, 75075, 75070) [FICO (Item 75525)	Cervical screening (items 73070, 73071, 73075, 73076)	HCG (item 73529)
---	---	------------------

Diagnostic Imaging Services

Determination of Necessity of Service

The participating midwife requesting a diagnostic imaging service for a woman must determine that the diagnostic imaging service is necessary for the appropriate professional care of the patient.

Request for Service

The service may only be provided in response to a request from the treating practitioner, and the request must be in writing, signed and dated.

The request does not have to be in a particular form. However, legislation provides that a request must be in writing and contain sufficient information, in terms that are generally understood by the profession, to clearly identify the item/s of service requested. This includes, where relevant, noting on the request the clinical indication(s) for the requested service. The provision of additional relevant clinical information can often assist the service provider, and enhance the overall service provided to the patient.

It is not necessary that a written request for a diagnostic imaging service be addressed to a particular provider or that, if the request is addressed to a particular provider, the service must be rendered by that provider.

A single request may be used to order a number of diagnostic imaging services. However, all services provided under this request must be rendered within seven days after rendering the first service.

Ultrasound:

Routine morphology scan (item 55706)	Nuchal Translucency (item 55707)
Early dating scan (item 55700)	Post 22 weeks scan (item 55718)
Scan at 12-16 weeks (item 55704)	

MN.14.1 Participating Nurse Practitioners Services - Overview

As at 1 November 2010, Medicare benefits are payable for services provided by privately practising participating nurse practitioners in collaboration with other health care providers. Participating nurse practitioners can also request certain pathology and diagnostic imaging services for their patients and refer patients to specialist, as the clinical need arises. The nurse practitioner services that attract a Medicare benefit are identified in the Medicare Benefits Schedule (MBS) by an item number and the each item describes the service requirements and schedule fee.

MN.14.2 Eligible Nurse Practitioners

Under the legislation, to be an eligible nurse practitioner the nurse practitioner must be registered or authorised (however described) under State and Territory law. The nurse practitioner must also demonstrate that he or she has the appropriate qualifications and experience to meet the registration standard developed by the Nursing and Midwifery Board of Australia (NMBA).

This standard was developed for the purposes of the National Registration and Accreditation Scheme (NRAS), a single regulation and accreditation scheme for health professionals, including nurse practitioners. Additional information is available at the Australian Health Practitioners Regulation Agency (AHPRA) website at: http://www.ahpra.gov.au/index.php

MN.14.3 Provider Numbers

To access the Medicare arrangements, eligible nurse practitioners will need to apply to the Department of Human Services for a provider number. A separate provider number is required for each location at which a nurse practitioner practices.

Advice about registering with the Department of Human Services to provide nurse practitioner services using items 82200 to 82215 inclusive, is available from the Department of Human Services provider inquiry line on 132 150.

Medicare provider application forms for nurse practitioners can be downloaded from the Department of Human Services' website.

MN.14.4 Participating Nurse Practitioners

To provide services under Medicare, the legislation requires that a nurse practitioner be a participating nurse practitioner. A participating nurse practitioner is an eligible nurse practitioner who has a Medicare provider number and who provides Medicare services in a collaborative arrangement or collaborative arrangements with one or more medical practitioners, of a kind or kinds specified in the regulations.

MN.14.5 Collaborative Arrangements

Under the Medicare program collaboration is having arrangements in place with a medical practitioner/s to consult, refer or transfer care as clinical needs dictate, to ensure safe, high quality maternity care. Under Medicare a collaborative arrangement can be with any medical practitioner.

Collaborative arrangement can be established in the following ways:

- a) being employed or engaged by 1 or more specified medical practitioners or by an entity that employs or engages 1 or more specified medical practitioners; OR
- b) receiving patients by referral in writing to the nurse practitioner for treatment from a specified medical practitioner, OR
- c) having a signed written agreement with one or more specified medical practitioners, OR
- d) having an arrangement with and acknowledged by at least one specified medical practitioners. This includes keeping comprehensive notes on all instances of consultation, referral and transfer of care, diagnostic tests requested and the test results and providing the collaborating practitioner/s with those results.

The legislation requires that collaborative arrangements must be in place at the time the participating nurse practitioner provides the service. The legislation requires that for each kind of collaborative arrangement, at least one medical practitioner is needed; it is not possible for the nurse practitioner to have a collaborative arrangement with an entity such as a health service.

a) Being employed or engaged by a medical practice or an entity

An entity may refer to a hospital or community health centre. For a nurse practitioner to have a collaborative arrangement in these circumstances, that nurse practitioner must be employed or engaged by an entity that also employs or engages 1 or more specified medical practitioners.

The terms employ or engage covers both employees and contractors. This will cover an eligible nurse practitioner who is employed or engaged by a medical practice so long as that medical practice employs or engages at least one medical practitioner.

There must be at least one specified medical practitioner employed or engaged by the entity each time the nurse practitioner renders a service/performs treatment. However, there is no requirement that the consultation, referral or transfer of care must always be to the medical practitioner(s) employed/engaged by the entity.

b) Referral from a medical practitioner

A participating nurse practitioner's patient will be able to access the MBS and PBS if a patient has been referred in writing to the nurse practitioner by a specified medical practitioner. The arrangement must provide for consultation, referral and transfer of care should the clinical need arise.

c) Written agreement with a medical practitioner

A nurse practitioner's patient will be able to access the MBS and PBS if the nurse practitioner has a written agreement in place with one or more doctors. The agreement must be signed by the nurse practitioner and a doctor. The arrangement must deal with consultation, referral and transfer to a doctor.

d) Arrangement with, acknowledged by a medical practitioner.

Evidence of 'acknowledgement' by a medical practitioner for each patient for whom the nurse practitioner provides care is a requirement to ensure that the medical practitioner being named understands and accepts the collaborative arrangement.

The acknowledgement does not have to be obtained on an individual patient basis. This means that, for example, a nurse practitioner could obtain an acknowledgement from a specified medical practitioner that he or she will be the collaborating medical practitioner for some or all of the nurse practitioner's patients. Arrangements to collaborate could be obtained in a number of ways including signing of documents, email or fax confirmation, or verbal acknowledgement which the nurse practitioner documents in their written records.

The nurse practitioner is required to record in written records any communications in regard to consultations, referral and transfer of the patient's care with the medical practitioner, including information that has been forwarded to the medical practitioner. The nurse practitioner is also required to send a copy of all pathology and diagnostic imaging results to a named medical practitioner and to record in the nurse practitioner's written records when this occurs (however, there is no requirement that the nurse practitioner consult with a medical practitioner in relation to every test result). The purpose of sharing records with the collaborating medical practitioner is to prevent duplication of services and to ensure continuity of care.

Arrangements to collaborate could be obtained in a number of ways including signing of documents, email or fax confirmation, or verbal acknowledgement which the nurse practitioner documents in their written records.

MN.14.6 Schedule Fees and Medicare Benefits

Each nurse practitioner service is identified in the MBS by an item number. The fee set for any item in the MBS is known as the "Schedule fee". The Schedule fee and Medicare benefit for each service is listed in the item description. The Medicare benefit for nurse practitioner services rendered to non-admitted patients is 85% of the Schedule fee.

MN.14.7 Where Medicare Benefits are not payable

Medicare benefits are not available:

- a. where the service rendered does not meet the item description and associated requirements;
- b. where the nurse practitioner service is not personally performed by the participating nurse practitioner;
- c. for any time period in the consultation periods when the patient is not receiving active attention e.g. the time the provider may take to travel to the patient's home or where the patient is resting between blood pressure readings;
- d. services provided where the patient is not in attendance, such as the issuing of repeat prescriptions;
- e. for telephone attendances; and
- f. group sessions.

The fee charged under Medicare must not include the cost of services that are not part of the MBS service being claimed. Medicare benefits are not payable for good or appliances associated with the service, such as bandages or other skin dressings.

Unless the Minister otherwise directs, Medicare benefits are not payable where funding has already been provided under an arrangement with the Commonwealth, state or a local governing body.

MN.14.8 Billing of the Patient

Where the nurse practitioner bills the patient for medical services rendered, the patient needs a properly itemised account/receipt to enable a claim to be made for Medicare benefits.

Under the provisions of the Health Insurance Act and Regulations, Medicare benefits are not payable in respect of a professional service unless there is recorded on the account setting out the fee for the service or on the receipt for the fee in respect of the service, the following particulars:

- (a) Patient's name;
- (b) The date on which the professional service was rendered;
- (c) An item number or a description of the professional service sufficient to identify the item that relates to that service, including an indication where the service is rendered to a person while hospital treatment is provided in a hospital "admitted patient" immediately preceding the description of the service or an asterisk "*" directly after an item number where used:
- (d) The name and practice address and provider number of the participating nurse practitioner who actually rendered the service; (where the participating nurse practitioner has more than one practice location recorded with the Department of Human Services, the provider number used should be that which is applicable to the practice location at or from which the service was given).

Only one original itemised account should be issued in respect of any one service and any duplicates of accounts or receipts should be clearly marked "duplicate" and should be issued only where the original has been lost. Duplicates should not be issued as a routine system for "accounts rendered".

MN.14.9 Assignment of Benefits (Direct-Billing Arrangements

Under the Health Insurance Act the Assignment of Benefit (direct billing) facility for professional services is available to all persons in Australia who are eligible for benefit under the Medicare program. This facility is NOT confined to pensioners or people in special need.

If a participating nurse practitioner direct-bills, the participating nurse practitioner undertakes to accept the relevant Medicare benefit as full payment for the service. Additional charges for that service (irrespective of the purpose or title of the charge) cannot be raised against the patient.

Under these arrangements:

The patient's Medicare card number must be quoted on all direct bill forms for that patient.

The basic forms provided are loose leaf to enable the patient details to be imprinted from the Medicare card.

The forms include information required by Regulations under Subsection 19(6) of the Health Insurance Act.

The nurse practitioner must include the particulars relating to the professional service out on the assignment form before the patient signs the form and ensure that the patient to receive a copy of the form as soon as practicable after the patient signs it.

Where a patient is unable to sign the assignment form the signature of the patient's parent, guardian or other responsible person (other than the nurse practitioner, nurse practitioner's staff, hospital proprietor, hospital staff,

residential aged care facility proprietor or residential aged care facility staff) is acceptable. The reason the patient is unable to sign should also be stated.

The administration of the direct billing arrangements under Medicare as well as the payment of Medicare benefits on patient claims is the responsibility of the Department of Human Services. Any enquiries in regard to these matters should therefore be directed to Medicare offices or enquiry points.

MN.14.10 Assignment of Benefit Forms

Participating nurse practitioners wishing to direct-bill are required to use a specific form available from the Department of Human Services. This stationary is available from the Department of Human Services. Note that these forms are approved forms under the Health Insurance Act, and no other forms can be used to assign benefits without the approval of the Department of Human Services. Further information about direct-billing stationary can be obtained by telephoning 132150.

MN.14.11 Time Limits applicable to lodgement of claims for assigned benefits

A time limit of two years applies to the lodgement of claims with Medicare under the direct billing (assignment of benefit) arrangements. This means that Medicare benefits are not payable for any service where the service was rendered more than two years earlier than the date the claim was lodged with Medicare.

Provision exists whereby in certain circumstances (e.g. hardship cases), the Minister may waive the time limits. Special forms for this purpose are available, if required, from the processing centre to which assigned claims are directed.

MN.14.12 Overview of the Nurse Practitioner items

Services provided by participating nurse practitioners are covered by MBS items 82200, 82205, 82210, 82215. These items cover four time-tiered specific types of service that allow the participating nurse practitioner to perform a:

professional attendance for an obvious problem, straight forward in nature, with limited examination and management required (82200)

professional attendance for a patient presenting with clinical signs and symptoms with an easily identifiable underlying cause following a short consultation lasting less than 20 minutes duration (item 82205)

professional attendance for a patient presenting with clinical signs and symptoms with no obvious underlying cause requiring a more detailed consultation lasting at least than 20 minutes duration (item 82210);

professional attendance for a patient presenting with multiple clinical signs and symptoms with the possibility of multiple causes and outcomes requiring an extensive consultation of at least 40 minutes (item 82215);

MN.14.13 Nurse Practitioner services attracting Medicare rebates

Medicare Benefits are only payable for clinically relevant services. Clinically relevant in relation to nurse practitioner care means a service generally accepted by the nursing profession as necessary to the appropriate treatment of the patient's clinical condition.

Medicare benefits are only payable where the participating nurse practitioner provides care to not more than one patient on one occasion.

MN.14.14 Conditions governing the provision and claiming of items

Service length and type

Services under these items must be for the time period specified within the item descriptor.

Professional attendance for MBS items 82200, 82205, 82210, 82215, may be provided in an appropriate setting that includes but is not limited to: the patient's home, a nurse practitioner group practice, a nurse practitioner's rooms or a medical practice.

MN.14.15 Referral requirements

A participating nurse practitioner will be able to refer private patients to a specialist and consultant physician as clinical services dictate.

This measure does not include referral by a nurse practitioner for allied health care. If a participating nurse practitioner refers a patient to an allied health practitioner, no benefits would be payable for that service provided by the allied health professional.

A referral given by a participating nurse practitioner is valid until 12 months after the first service given in accordance with the referral.

If the referral is lost, stolen or destroyed, the nurse practitioner would need to provide a replacement referral as soon as is practicable after the service is provided.

A referral to a specialist must be in writing in the form of a letter or a note to the specialist and must be signed and dated by the referring nurse practitioner. The referral must contain any information relevant to the patient and the specialist must have received the referral on or prior to providing a specialist consultation.

There are exemptions from this requirement in an emergency if the specialist considers the patient's condition requires immediate attention without a referral. In that situation, the specialist is taken to be the referring practitioner.

MN.14.16 Requesting requirements Pathology Services

Determination of Necessity of Service

The participating nurse practitioner requesting a pathology service for a patient must determine that the pathology service is necessary.

Request for Service

The service may only be provided in response to a request from the treating practitioner and the request must be in writing (or, if oral, confirmed in writing within fourteen days).

Pathology Services approved for participating nurse practitioners

Nurse practitioners may request MBS pathology items 65060 - 73810 (inclusive). Requesting pathology services must be within the nurse practitioner's scope of practice.

Further information

For further information about Medicare Benefits Schedule items, please go to the Department of Health's website at www.health.gov.au/mbsonline.

Diagnostic Imaging Services

Determination of Necessity of Service

The participating nurse practitioner requesting a diagnostic imaging service for a patient must determine that the diagnostic imaging service is necessary for the appropriate professional care of the patient.

Request for Service

The service may only be provided in response to a request from the treating nurse practitioner, and the request must be in writing, signed and dated. The legislation provides that a request must be in writing and contain sufficient information, in terms that are generally understood by the profession, to clearly identify the item/s of service requested. This includes, where relevant, noting on the request the clinical indication(s) for the requested service. The provision of additional relevant clinical information can often assist the service provider, and enhance the overall service provided to the patient.

It is not necessary that a written request for a diagnostic imaging service be addressed to a particular provider or that, if the request is addressed to a particular provider, the service must be rendered by that provider.

A single request may be used to order a number of diagnostic imaging services. However, all services provided under this request must be rendered within seven days after rendering the first service.

Ultrasound:

Subgroup 1: General Ultrasound

MBS item: 55036 (abdomen)

MBS items: 55070, 55076 (breast)

Subgroup 4: Urological

MBS item: 55600 (prostate)

Subgroup 5: Obstetric and Gynaecological

MBS item: 55768

Subgroup 6: Musculoskeletal

MBS items: 55800, 55804, 55808, 55812, 55816, 55820, 55824, 55828, 55832, 55836, 55840, 55844,

55848, 55850, 55852

X-ray:

Subgroup 1: Radiographic examination of the extremities

MBS items: 57509, 57515, 57521

subgroup 6: Radiographic examination of the thoracic region

MBS items: 58503 - 58527 (inclusive)

MN.15.1 Brain Stem Evoked Response Audiometry - (Item 82300)

Item 82300 can be claimed for the programming of a cochlear speech processor.

MN.15.2 Non-Determinate Audiometry - (Item 82306)

This refers to audiometry covering those services, one or more, referred to in Items 82309-82318 when not performed under the conditions set out in paragraph M15.3.

MN.15.3 Conditions for Audiology Services - (Items 82309 to 82318)

A service specified in Items 82309 to 82318 shall be taken to be a service for the purposes of payment of benefits if, and only if, it is rendered:

- (a) in conditions that allow the establishment of determinate thresholds;
- (b) in a sound attenuated environment with background noise conditions that comply with Australian Standard AS/NZS 1269.3-2005; and
- (c) using calibrated equipment that complies with Australian Standard AS IEC 60645.1-22002, ASIEC60645.2-2002 and AS IEC 60645.3-2002.

MN.15.4 Oto-Acoustic Emission Audiometry - (Item 82332)

Medicare benefits are not payable under Item 82332 for routine screening of infants. The equipment used to provide this service must be capable of displaying the recorded emission and not just a pass/fail indicator.

MN.15.5 Provision of Diagnostic Audiology Services by Audiologists - (Items 82300 to 82332) OVERVIEW

The diagnostic audiology services available through MBS items 82300 to 82332 enable an eligible audiologist to perform diagnostic tests upon written request from an Ear, Nose and Throat (ENT) specialist (a specialist in the specialty of otolaryngology head and neck surgery); or for some services, a written request from a neurologist (a specialist or consultant physician in the specialty of neurology).

These diagnostic audiology services assist ENT specialists and neurologists in their medical diagnosis and/or treatment and/or management of ear disease or related disorders. The new diagnostic audiology items supplement the existing Otolaryngology items for services delivered by, or on behalf of medical practitioners (MBS items 11300 to 11339, excluding 11304).

Requesting arrangements

Medicare benefits are payable only under the following circumstances:

- · For items 82300 and 82306, the written request must be made by an eligible practitioner who is a specialist in the specialty of otolaryngology head and neck surgery;
- · For items 82309 to 82332, the written request must be made by an eligible practitioner who is a specialist in the specialty of otolaryngology head and neck surgery or a specialist or consultant physician in the specialty of neurology.

The written request must be in writing and must contain:

- (a) the date of the request; and
- (b) the name of the eligible practitioner who requested the service and either the address of his or her place of practice or the provider number in respect of his or her place of practice; and
- (c) a description of the service which provides sufficient information to identify the service as relating to a particular item (but need not specify the item number).

Written requests should, where possible, note the clinical indication/s for the requested service/s.

A request may be for the performance of more than one diagnostic audiology service making up a single audiological assessment, but cannot be for more than one audiological assessment. This means that for Medicare benefits to be payable, any re-evaluation of the patient should be made at the discretion of the ENT specialist or neurologist through a separate request.

Audiologists do not have the discretion to self-determine diagnostic tests under items 82300 to 82332. If a written request is incomplete or requires clarification, the audiologist should contact the requesting ENT specialist or

neurologist for further information. If an audiologist considers that additional tests may be necessary, the audiologist should contact the requesting ENTspecialist or neurologist to discuss the need and if the requesting practitioner determines that additional tests are necessary, an amended or separate written request must be arranged.

It is recommended that audiologists retain the written request for 24 months from the date the service was rendered (for Medicare auditing purposes). A copy of the written request is <u>not</u> required to accompany Medicare claims or be attached to patients' itemised accounts/receipts or assignment of benefit forms.

Eligibility requirements for audiologists

The diagnostic audiology items (82300 to 82332) can only be claimed by audiologists who are registered with the Department of Human Services. To be eligible to register with the Department of Human Services to provide these services, audiologists must meet the following requirements:

Audiologists must be either:

- · a 'Full Member' of the Audiological Society of Australia Inc (ASA), who holds a 'Certificate of Clinical Practice' issued by the ASA; or
- · an 'Ordinary Member Audiologist' or 'Fellow Audiologist' of the Australian College of Audiology (ACAud).

Registering with the Department of Human Services

Provider registration forms may be obtained from Medicare on 132 150 or at www.humanservices.gov.au.

Changes to provider details

Audiologists must notify the Department of Human Services in writing of all changes to mailing details to ensure that they continue to receive information about Medicare services.

Reporting requirements

Where an audiologist provides diagnostic audiology service/s to the patient under a written request, they must provide a copy of the results of the service/s performed together with relevant written comments on those results to the requesting ENT specialist or neurologist. It is recommended that these be provided within 7 days of the date the service was performed.

Out-of-pocket expenses and Medicare Safety Net

Audiologists can determine their own fees for the professional service. Charges in excess of the Medicare benefit are the responsibility of the patient. However, out-of-pocket costs will count toward the Medicare Safety Net for that patient.

Publicly funded services

Items 82300 to 82332 do not apply for services that are provided by any Commonwealth or state funded services or provided to an admitted patient of a hospital. However, where an exemption under subsection 19(2) of the Health Insurance Act 1973 has been granted to an Aboriginal Community Controlled Health Service or state/territory government health clinic, items 82300 to 82332 can be claimed for services provided by audiologists salaried by, or contracted to, the service or health clinic. All requirements of the relevant item must be met, including registration of the audiologist with the Department of Human Services. Medicare services provided under a subsection 19(2) exemption must be bulk billed (i.e. the Medicare rebate is accepted as full payment for services).

Private health insurance

Patients need to decide if they will use Medicare or their private health insurance ancillary cover to pay for these services. Patients cannot use their private health insurance ancillary cover to 'top up' the Medicare rebate paid for the services.

MISCELLANEOUS SERVICES ITEMS

M1. MA	NAGEMENT OF BULK-BILLED SERVICES
	Group M1. Management Of Bulk-Billed Services
	A medical service to which an item in this table (other than this item or item 10991) applies if:
	(a) the service is an unreferred service; and
	(b) the service is provided to a person who is under the age of 16 or is a Commonwealth concession card holder; and
	(c) the person is not an admitted patient of a hospital; and
	(d) the service is bulk-billed in respect of the fees for:
	(i) this item; and
	(ii) the other item in this table applying to the service
10990	(See para MN.1.1 of explanatory notes to this Category) Fee: \$7.40 Benefit: 85% = \$6.30
	A medical service to which an item in this table (other than this item or item 10990) applies if:
	(a) the service is an unreferred service; and
	(b) the service is provided to a person who is under the age of 16 or is a Commonwealth concession card holder; and
	(c) the person is not an admitted patient of a hospital; and
	(d) the service is bulk-billed in respect of the fees for:
	(i) this item; and
	(ii) the other item in this table applying to the service: and
	(e) the service is provided at, or from, a practice location in:
	(i) a regional, rural or remote area; or
	(ii) Tasmania; or
	(iii) A geographical area included in any of the following SSD spatial units:
	(A) Beaudesert Shire Part A
	(B) Belconnen
	(C) Darwin City
	(D) Eastern Outer Melbourne
	(E) East Metropolitan, Perth
10991	(F) Frankston City

M1. MANAG	SEMENT OF BULK-BILLED SERVICES
	(G) Gosford-Wyong
	(H) Greater Geelong City Part A
	(I) Gungahlin-Hall
	(J) Ipswich City (part in BSD)
	(K) Litchfield Shire
	(L) Melton-Wyndham
	(M) Mornington Peninsula Shire
	(N) Newcastle
	(O) North Canberra
	(P) Palmerston-East Arm
	(Q) Pine Rivers Shire
	(R) Queanbeyan
	(S) South Canberra
	(T) South Eastern Outer Melbourne
	(U) Southern Adelaide
	(V) South West Metropolitan, Perth
	(W) Thuringowa City Part A
	(X) Townsville City Part A
	(Y) Tuggeranong
	(Z) Weston Creek-Stromlo
	(ZA) Woden Valley
	(ZB) Yarra Ranges Shire Part A; or
	(iv) the geographical area included in the SLA spatial unit of Palm Island (AC)
	ee: \$11.15 Benefit: 85% = \$9.50
50	medical service to which item 585, 588, 591, 594, 599, 600, 761, 763, 766, 769, 772, 776, 788, 789, 003, 5010, 5023, 5028, 5043, 5049, 5063, 5067, 5220, 5223, 5227, 5228, 5260, 5263, 5265 or 5267 oplies if:
(a) the service is an unreferred service; and
(b ca	the service is provided to a person who is under the age of 16 or is a Commonwealth concession and holder; and

M1. MANAGEMENT OF BULK-BILLED SERVICES

- (c) the person is not an admitted patient of a hospital; and
- (d) the service is not provided in consulting rooms; and
- (e) the service is provided in one of the following eligible areas:
 - (i) a regional, rural or remote area; or
 - (ii) Tasmania; or
 - (iii) A geographical area included in any of the following SSD spatial units:
 - (A) Beaudesert Shire Part A
 - (B) Belconnen
 - (C) Darwin City
 - (D) Eastern Outer Melbourne
 - (E) East Metropolitan, Perth
 - (F) Frankston City
 - (G) Gosford-Wyong
 - (H) Greater Geelong City Part A
 - (I) Gungahlin-Hall
 - (J) Ipswich City (part in BSD)
 - (K) Litchfield Shire
 - (L) Melton-Wyndham
 - (M) Mornington Peninsula Shire
 - (N) Newcastle
 - (O) North Canberra
 - (P) Palmerston-East Arm
 - (Q) Pine Rivers Shire
 - (R) Queanbeyan
 - (S) South Canberra
 - (T) South Eastern Outer Melbourne
 - (U) Southern Adelaide
 - (V) South West Metropolitan, Perth

M1. MANAGEMENT OF BULK-BILLED SERVICES

- (W) Thuringowa City Part A
- (X) Townsville City Part A
- (Y) Tuggeranong
- (Z) Weston Creek-Stromlo
- (ZA) Woden Valley
- (ZB) Yarra Ranges Shire Part A; or
- (iv) the geographical area included in the SLA spatial unit of Palm Island (AC)
- (f) the service is provided by, or on behalf of, a medical practitioner whose practice location is not in an eligible area; and
- (g) the service is bulk billed in respect of the fees for:
 - (i) this item; and
 - (ii) the other item in this table applying to the service.

(See para MN.1.2 of explanatory notes to this Category)

Fee: \$11.15 **Benefit:** 85% = \$9.50

M3. ALLIED HEALTH SERVICES

Group M3. Allied Health Services

ABORIGINAL AND TORRES STRAIT ISLANDER HEALTH SERVICE

Aboriginal or Torres Strait Islander health service provided to a person by an eligible Aboriginal health worker or eligible Aboriginal and Torres Strait Islander health practitioner if:

- (a) the service is provided to a person who has:
 - i. a chronic condition; and
 - ii. complex care needs being managed by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) under a shared care plan or under both a GP Management Plan and Team Care Arrangements or, if the person is a resident of an aged care facility, the person's medical practitioner has contributed to a multidisciplinary care plan; and
- (b) the service is recommended in the person's Team Care Arrangements, multidisciplinary care plan or shared care plan as part of the management of the person's chronic condition and complex care needs; and
- (c) the person is referred to the eligible Aboriginal health worker or eligible Aboriginal and Torres Strait Islander health practitioner by the medical practitioner using a referral form that has been issued by the Department or a referral form that contains all the components of the form issued by the Department; and
- (d) the person is not an admitted patient of a hospital; and
- (e) the service is provided to the person individually and in person; and

- (f) the service is of at least 20 minutes duration; and
- (g) after the service, the eligible Aboriginal health worker or eligible Aboriginal and Torres Strait Islander health practitioner gives a written report to the referring medical practitioner mentioned in paragraph (c):
 - (i) if the service is the only service under the referral in relation to that service; or
 - (ii) if the service is the first or the last service under the referral in relation to that service; or
- (iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring medical practitioner would reasonably expect to be informed of in relation to those matters; and
- (h) for a service for which a private health insurance benefit is payable the person who incurred the medical expenses for the service has elected to claim the Medicare benefit for the service, and not the private health insurance benefit;
- to a maximum of five services (including any services to which items 10950 to 10970 apply) in a calendar year

(See para MN.3.4, MN.3.3, MN.3.2, MN.3.5, MN.3.1 of explanatory notes to this Category)

Fee: \$62.25 **Benefit:** 85% = \$52.95 **Extended Medicare Safety Net Cap:** \$186.75

DIABETES EDUCATION SERVICE

Diabetes education health service provided to a person by an eligible diabetes educator if:

- (a) the service is provided to a person who has:
 - i. a chronic condition; and
 - ii. complex care needs being managed by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) under a shared care plan or under both a GP Management Plan and Team Care Arrangements or, if the person is a resident of an aged care facility, the person's medical practitioner has contributed to a multidisciplinary care plan; and
- (b) the service is recommended in the person's Team Care Arrangements, multidisciplinary care plan or shared care plan as part of the management of the person's chronic condition and complex care needs; and
- (c) the person is referred to the eligible diabetes educator by the medical practitioner using a referral form that has been issued by the Department or a referral form that contains all the components of the form issued by the Department; and
- (d) the person is not an admitted patient of a hospital; and
- (e) the service is provided to the person individually and in person; and
- (f) the service is of at least 20 minutes duration; and
- (g) after the service, the eligible diabetes educator gives a written report to the referring medical practitioner mentioned in paragraph (c):
 - (i) if the service is the only service under the referral in relation to that service; or
 - (ii) if the service is the first or the last service under the referral in relation to that service; or

- (iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring medical practitioner would reasonably expect to be informed of in relation to those matters; and
- (h) for a service for which a private health insurance benefit is payable the person who incurred the medical expenses for the service has elected to claim the Medicare benefit for the service, and not the private health insurance benefit;
- to a maximum of five services (including any services to which items 10950 to 10970 apply) in a calendar year

(See para MN.3.4, MN.3.3, MN.3.2, MN.3.5, MN.3.1 of explanatory notes to this Category)

Fee: \$62.25 **Benefit:** 85% = \$52.95 **Extended Medicare Safety Net Cap:** \$186.75

AUDIOLOGY

Audiology health service provided to a person by an eligible audiologist if:

- (a) the service is provided to a person who has:
 - i. a chronic condition; and
 - ii. complex care needs being managed by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) under a shared care plan or under both a GP Management Plan and Team Care Arrangements or, if the person is a resident of an aged care facility, the person's medical practitioner has contributed to a multidisciplinary care plan; and
- (b) the service is recommended in the person's Team Care Arrangements, multidisciplinary care plan or shared can plan as part of the management of the person's chronic condition and complex care needs; and
- (c) the person is referred to the eligible audiologist by the medical practitioner using a referral form that has been issued by the Department or a referral form that contains all the components of the form issued by the Department; and
- (d) the person is not an admitted patient of a hospital; and
- (e) the service is provided to the person individually and in person; and
- (f) the service is of at least 20 minutes duration; and
- (g) after the service, the eligible audiologist gives a written report to the referring medical practitioner mentioned in paragraph (c):
 - (i) if the service is the only service under the referral in relation to that service; or
 - (ii) if the service is the first or the last service under the referral in relation to that service; or
- (iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring medical practitioner would reasonably expect to be informed of in relation to those matters; and
- (h) for a service for which a private health insurance benefit is payable the person who incurred the medical expenses for the service has elected to claim the Medicare benefit for the service, and not the private health insurance benefit;
- to a maximum of five services (including any services to which items 10950 to 10970 apply) in a calendar year

M3. ALLI	ED HEALTH SERVICES
	(See para MN.3.4, MN.3.3, MN.3.2, MN.3.5, MN.3.1 of explanatory notes to this Category) Fee: \$62.25 Benefit: 85% = \$52.95 Extended Medicare Safety Net Cap: \$186.75
	EXERCISE PHYSIOLOGY
	Exercise physiology service provided to a person by an eligible exercise physiologist if:
	(a) the service is provided to a person who has:
	 i. a chronic condition; and ii. complex care needs being managed by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) under a shared care plan or under both a GP Management Plan and Team Care Arrangements or, if the person is a resident of an aged care facility, the person's medical practitioner has contributed to a multidisciplinary care plan; and
	(b) the service is recommended in the person's Team Care Arrangements, multidisciplinary care plan or shared care plan as part of the management of the person's chronic condition and complex care needs; and
	(c) the person is referred to the eligible exercise physiologist by the medical practitioner using a referral form that has been issued by the Department or a referral form that contains all the components of the form issued by the Department; and
	(d) the person is not an admitted patient of a hospital; and
	(e) the service is provided to the person individually and in person; and
	(f) the service is of at least 20 minutes duration; and
	(g) after the service, the eligible exercise physiologist gives a written report to the referring medical practitioner mentioned in paragraph (c):
	(i) if the service is the only service under the referral - in relation to that service; or
	(ii) if the service is the first or the last service under the referral - in relation to that service; or
	(iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring medical practitioner would reasonably expect to be informed of - in relation to those matters; and
	(h) for a service for which a private health insurance benefit is payable - the person who incurred the medical expenses for the service has elected to claim the Medicare benefit for the service, and not the private health insurance benefit;
	- to a maximum of five services (including any services to which items 10950 to 10970 apply) in a calendar year
10953	(See para MN.3.4, MN.3.3, MN.3.2, MN.3.5, MN.3.1 of explanatory notes to this Category) Fee: \$62.25 Benefit: 85% = \$52.95 Extended Medicare Safety Net Cap: \$186.75
	DIETETICS SERVICES
	Dietetics health service provided to a person by an eligible dietician if:
10954	(a) the service is provided to a person who has:

- i. a chronic condition; and
- ii. complex care needs being managed by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) under a shared care plan or under both a GP
 Management Plan and Team Care Arrangements or, if the person is a resident of an aged care facility, the person's medical practitioner has contributed to a multidisciplinary care plan; and
- (b) the service is recommended in the person's Team Care Arrangements, multidisciplinary care plan or shared care plan as part of the management of the person's chronic condition and complex care needs; and
- (c) the person is referred to the eligible dietician by the medical practitioner using a referral form that has been issued by the Department or a referral form that contains all the components of the form issued by the Department; and
- (d) the person is not an admitted patient of a hospital; and
- (e) the service is provided to the person individually and in person; and
- (f) the service is of at least 20 minutes duration; and
- (g) after the service, the eligible dietician gives a written report to the referring medical practitioner mentioned in paragraph (c):
 - (i) if the service is the only service under the referral in relation to that service; or
 - (ii) if the service is the first or the last service under the referral in relation to that service; or
- (iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring medical practitioner would reasonably expect to be informed of in relation to those matters; and
- (h) for a service for which a private health insurance benefit is payable the person who incurred the medical expenses for the service has elected to claim the Medicare benefit for the service, and not the private health insurance benefit;
- to a maximum of five services (including any services to which items 10950 to 10970 apply) in a calendar year

(See para MN.3.4, MN.3.3, MN.3.2, MN.3.5, MN.3.1 of explanatory notes to this Category)

Fee: \$62.25 **Benefit:** 85% = \$52.95 **Extended Medicare Safety Net Cap:** \$186.75

MENTAL HEALTH SERVICE

Mental health service provided to a person by an eligible mental health worker if:

- (a) the service is provided to a person who has:
 - i. a chronic condition; and
 - ii. complex care needs being managed by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) under a shared care plan or under both a GP Management Plan and Team Care Arrangements or, if the person is a resident of an aged care facility, the person's medical practitioner has contributed to a multidisciplinary care plan; and
- (b) the service is recommended in the person's Team Care Arrangements, multidisciplinary care plan or shared care plan as part of the management of the person's chronic condition and complex care needs; and

- (c) the person is referred to the eligible mental health worker by the medical practitioner using a referral form that has been issued by the Department or a referral form that contains all the components of the form issued by the Department; and
- (d) the person is not an admitted patient of a hospital; and
- (e) the service is provided to the person individually and in person; and
- (f) the service is of at least 20 minutes duration; and
- (g) after the service, the eligible mental health worker gives a written report to the referring medical practitioner mentioned in paragraph (c):
 - (i) if the service is the only service under the referral in relation to that service; or
 - (ii) if the service is the first or the last service under the referral in relation to that service; or
- (iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring medical practitioner would reasonably expect to be informed of in relation to those matters; and
- (h) for a service for which a private health insurance benefit is payable the person who incurred the medical expenses for the service has elected to claim the Medicare benefit for the service, and not the private health insurance benefit;
- to a maximum of five services (including any services to which items 10950 to 10970 apply) in a calendar year

(See para MN.3.4, MN.3.3, MN.3.2, MN.3.5, MN.3.1 of explanatory notes to this Category)

Fee: \$62.25 **Benefit:** 85% = \$52.95 **Extended Medicare Safety Net Cap:** \$186.75

OCCUPATIONAL THERAPY

Occupational therapy health service provided to a person by an eligible occupational therapist if:

- (a) the service is provided to a person who has:
 - i. a chronic condition; and
 - ii. complex care needs being managed by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) under a shared care plan or under both a GP Management Plan and Team Care Arrangements or, if the person is a resident of an aged care facility, the person's medical practitioner has contributed to a multidisciplinary care plan; and
- (b) the service is recommended in the person's Team Care Arrangements, multidisciplinary care plan or shared care plan as part of the management of the person's chronic condition and complex care needs; and
- (c) the person is referred to the eligible occupational therapist by the medical practitioner using a referral form that has been issued by the Department or a referral form that contains all the components of the form issued by the Department; and
- (d) the person is not an admitted patient of a hospital; and
- (e) the service is provided to the person individually and in person; and
- (f) the service is of at least 20 minutes duration; and

- (g) after the service, the eligible occupational therapist gives a written report to the referring medical practitioner mentioned in paragraph (c):
 - (i) if the service is the only service under the referral in relation to that service; or
 - (ii) if the service is the first or the last service under the referral in relation to that service; or
- (iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring medical practitioner would reasonably expect to be informed of in relation to those matters; and
- (h) for a service for which a private health insurance benefit is payable the person who incurred the medical expenses for the service has elected to claim the Medicare benefit for the service, and not the private health insurance benefit;
- to a maximum of five services (including any services to which items 10950 to 10970 apply) in a calendar year

(See para MN.3.4, MN.3.3, MN.3.2, MN.3.5, MN.3.1 of explanatory notes to this Category)

Fee: \$62.25 **Benefit:** 85% = \$52.95 **Extended Medicare Safety Net Cap:** \$186.75

PHYSIOTHERAPY

Physiotherapy health service provided to a person by an eligible physiotherapist if:

- (a) the service is provided to a person who has:
 - i. a chronic condition; and
 - ii. complex care needs being managed by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) under a shared care plan or under both a GP Management Plan and Team Care Arrangements or, if the person is a resident of an aged care facility, the person's medical practitioner has contributed to a multidisciplinary care plan; and
- (b) the service is recommended in the person's Team Care Arrangements, multidisciplinary care plan or shared care plan as part of the management of the person's chronic condition and complex care needs; and
- (c) the person is referred to the eligible physiotherapist by the medical practitioner using a referral form that has been issued by the Department or a referral form that contains all the components of the form issued by the Department; and
- (d) the person is not an admitted patient of a hospital; and
- (e) the service is provided to the person individually and in person; and
- (f) the service is of at least 20 minutes duration; and
- (g) after the service, the eligible physiotherapist gives a written report to the referring medical practitioner mentioned in paragraph (c):
 - (i) if the service is the only service under the referral in relation to that service; or
 - (ii) if the service is the first or the last service under the referral in relation to that service; or
- (iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring medical practitioner would reasonably expect to be informed of in relation to those matters; and

- (h) for a service for which a private health insurance benefit is payable the person who incurred the medical expenses for the service has elected to claim the Medicare benefit for the service, and not the private health insurance benefit;
- to a maximum of five services (including any services to which items 10950 to 10970 apply) in a calendar year

(See para MN.3.4, MN.3.3, MN.3.2, MN.3.5, MN.3.1 of explanatory notes to this Category)

Fee: \$62.25 **Benefit:** 85% = \$52.95 **Extended Medicare Safety Net Cap:** \$186.75

PODIATRY

Podiatry health service provided to a person by an eligible podiatrist if:

- (a) the service is provided to a person who has:
 - i. a chronic condition; and
 - ii. complex care needs being managed by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) under a shared care plan or under both a GP Management Plan and Team Care Arrangements or, if the person is a resident of an aged care facility, the person's medical practitioner has contributed to a multidisciplinary care plan; and
- (b) the service is recommended in the person's Team Care Arrangements, multidisciplinary care plan or shared care plan as part of the management of the person's chronic condition and complex care needs; and
- (c) the person is referred to the eligible podiatrist by the medical practitioner using a referral form that has been issued by the Department or a referral form that contains all the components of the form issued by the Department; and
- (d) the person is not an admitted patient of a hospital; and
- (e) the service is provided to the person individually and in person; and
- (f) the service is of at least 20 minutes duration; and
- (g) after the service, the eligible podiatrist gives a written report to the referring medical practitioner mentioned in paragraph (c):
 - (i) if the service is the only service under the referral in relation to that service; or
 - (ii) if the service is the first or the last service under the referral in relation to that service; or
- (iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring medical practitioner would reasonably expect to be informed of in relation to those matters; and
- (h) for a service for which a private health insurance benefit is payable the person who incurred the medical expenses for the service has elected to claim the Medicare benefit for the service, and not the private health insurance benefit;
- to a maximum of five services (including any services to which items 10950 to 10970 apply) in a calendar year

(See para MN.3.4, MN.3.3, MN.3.2, MN.3.5, MN.3.1 of explanatory notes to this Category)

Fee: \$62.25 Benefit: 85% = \$52.95 Extended Medicare Safety Net Cap: \$186.75

CHIROPRACTIC SERVICE

Chiropractic health service provided to a person by an eligible chiropractor if:

- (a) the service is provided to a person who has:
 - i. a chronic condition; and
 - ii. complex care needs being managed by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) under a shared care plan or under both a GP Management Plan and Team Care Arrangements or, if the person is a resident of an aged care facility, the person's medical practitioner has contributed to a multidisciplinary care plan; and
- (b) the service is recommended in the person's Team Care Arrangements, multidisciplinary care plan or shared care plan as part of the management of the person's chronic condition and complex care needs; and
- (c) the person is referred to the eligible chiropractor by the medical practitioner using a referral form that has been issued by the Department or a referral form that contains all the components of the form issued by the Department; and
- (d) the person is not an admitted patient of a hospital; and
- (e) the service is provided to the person individually and in person; and
- (f) the service is of at least 20 minutes duration; and
- (g) after the service, the eligible chiropractor gives a written report to the referring medical practitioner mentioned in paragraph (c):
 - (i) if the service is the only service under the referral in relation to that service; or
 - (ii) if the service is the first or the last service under the referral in relation to that service; or
- (iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring medical practitioner would reasonably expect to be informed of in relation to those matters; and
- (h) for a service for which a private health insurance benefit is payable the person who incurred the medical expenses for the service has elected to claim the Medicare benefit for the service, and not the private health insurance benefit;
- to a maximum of five services (including any services to which items 10950 to 10970 apply) in a calendar year

(See para MN.3.4, MN.3.3, MN.3.2, MN.3.5, MN.3.1 of explanatory notes to this Category)

Fee: \$62.25 **Benefit:** 85% = \$52.95

Extended Medicare Safety Net Cap: \$186.75

OSTEOPATHY

Osteopathy health service provided to a person by an eligible osteopath if:

- (a) the service is provided to a person who has:
 - i. a chronic condition; and
 - ii. complex care needs being managed by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) under a shared care plan or under both a GP Management Plan and Team Care Arrangements or, if the person is a resident of an aged care

10966

facility, the person's medical practitioner has contributed to a multidisciplinary care plan; and

- (b) the service is recommended in the person's Team Care Arrangements, multidisciplinary care plan or shared care plan as part of the management of the person's chronic condition and complex care needs; and
- (c) the person is referred to the eligible osteopath by the medical practitioner using a referral form that has been issued by the Department or a referral form that contains all the components of the form issued by the Department; and
- (d) the person is not an admitted patient of a hospital; and
- (e) the service is provided to the person individually and in person; and
- (f) the service is of at least 20 minutes duration; and
- (g) after the service, the eligible osteopath gives a written report to the referring medical practitioner mentioned in paragraph (c):
 - (i) if the service is the only service under the referral in relation to that service; or
 - (ii) if the service is the first or the last service under the referral in relation to that service; or
- (iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring medical practitioner would reasonably expect to be informed of in relation to those matters; and
- (h) for a service for which a private health insurance benefit is payable the person who incurred the medical expenses for the service has elected to claim the Medicare benefit for the service, and not the private health insurance benefit;
- to a maximum of five services (including any services to which items 10950 to 10970 apply) in a calendar year

(See para MN.3.4, MN.3.3, MN.3.2, MN.3.5, MN.3.1 of explanatory notes to this Category)

Fee: \$62.25 **Benefit:** 85% = \$52.95 **Extended Medicare Safety Net Cap:** \$186.75

PSYCHOLOGY

Psychology health service provided to a person by an eligible psychologist if:

- (a) the service is provided to a person who has:
 - i. a chronic condition; and
 - ii. complex care needs being managed by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) under a shared care plan or under both a GP Management Plan and Team Care Arrangements or, if the person is a resident of an aged care facility, the person's medical practitioner has contributed to a multidisciplinary care plan; and
- (b) the service is recommended in the person's Team Care Arrangements, multidisciplinary care plan or shared care plan as part of the management of the person's chronic condition and complex care needs; and
- (c) the person is referred to the eligible psychologist by the medical practitioner using a referral form that has been issued by the Department or a referral form that contains all the components of the form issued by the Department; and

- (d) the person is not an admitted patient of a hospital; and
- (e) the service is provided to the person individually and in person; and
- (f) the service is of at least 20 minutes duration; and
- (g) after the service, the eligible psychologist gives a written report to the referring medical practitioner mentioned in paragraph (c):
 - (i) if the service is the only service under the referral in relation to that service; or
 - (ii) if the service is the first or the last service under the referral in relation to that service; or
- (iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring medical practitioner would reasonably expect to be informed of in relation to those matters; and
- (h) for a service for which a private health insurance benefit is payable the person who incurred the medical expenses for the service has elected to claim the Medicare benefit for the service, and not the private health insurance benefit;
- to a maximum of five services (including any services to which items 10950 to 10970 apply) in a calendar year

(See para MN.3.4, MN.3.3, MN.3.2, MN.3.5, MN.3.1 of explanatory notes to this Category)

Fee: \$62.25 **Benefit:** 85% = \$52.95 **Extended Medicare Safety Net Cap:** \$186.75

SPEECH PATHOLOGY

Speech pathology health service provided to a person by an eligible speech pathologist if:

- (a) the service is provided to a person who has:
 - i. a chronic condition; and
 - ii. complex care needs being managed by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) under a shared care plan or under both a GP Management Plan and Team Care Arrangements or, if the person is a resident of an aged care facility, the person's medical practitioner has contributed to a multidisciplinary care plan; and
- (b) the service is recommended in the person's Team Care Arrangements, multidisciplinary care plan or shared care plan as part of the management of the person's chronic condition and complex care needs; and
- (c) the person is referred to the eligible speech pathologist by the medical practitioner using a referral form that has been issued by the Department or a referral form that contains all the components of the form issued by the Department; and
- (d) the person is not an admitted patient of a hospital; and
- (e) the service is provided to the person individually and in person; and
- (f) the service is of at least 20 minutes duration; and
- (g) after the service, the eligible speech pathologist gives a written report to the referring medical practitioner mentioned in paragraph (c):

- (i) if the service is the only service under the referral in relation to that service; or
- (ii) if the service is the first or the last service under the referral in relation to that service; or
- (iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring medical practitioner would reasonably expect to be informed of in relation to those matters; and
- (h) for a service for which a private health insurance benefit is payable the person who incurred the medical expenses for the service has elected to claim the Medicare benefit for the service, and not the private health insurance benefit;
- to a maximum of five services (including any services to which items 10950 to 10970 apply) in a calendar year

(See para MN.3.4, MN.3.3, MN.3.2, MN.3.5, MN.3.1 of explanatory notes to this Category)

Fee: \$62.25 **Benefit:** 85% = \$52.95 **Extended Medicare Safety Net Cap:** \$186.75

M6. PSYCHOLOGICAL THERAPY SERVICES

Group M6. Psychological Therapy Services

Professional attendance for the purpose of providing psychological assessment and therapy for a mental disorder by a **clinical psychologist** registered with Medicare Australia as meeting the credentialing requirements for provision of this service, lasting more than 30 minutes but less than 50 minutes, where the patient is referred by a medical practitioner, as part of a GP Mental Health Treatment Plan or as part of a shared care plan; or referred by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan; or referred by a specialist or consultant physician in the practice of his or her field of psychiatry or paediatrics.

These therapies are time limited, being deliverable in up to ten planned sessions in a calendar year (including services to which items 283 to 287; 2721 to 2727; 80000 to 80015; 80100 to 80115; 80125 to 80140; 80150 to 80165 apply).

(Professional attendance at consulting rooms)

(See para MN.6.1 of explanatory notes to this Category) **Fee:** \$99.75 **Benefit:** 85% = \$84.80

80000 **E**

Extended Medicare Safety Net Cap: \$299.25

Professional attendance for the purpose of providing psychological assessment and therapy for a mental disorder by a **clinical psychologist** registered with Medicare Australia as meeting the credentialing requirements for provision of this service, lasting more than 30 minutes but less than 50 minutes, where the patient is referred by a medical practitioner, as part of a GP Mental Health Treatment Plan or as part of a shared care plan; or referred by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan; or referred by a specialist or consultant physician in the practice of his or her field of psychiatry or paediatrics if:

- the attendance is by video conference; and
- the patient is not an admitted patient; and
- the patient is located within a telehealth eligible area; and
- the patient is, at the time of the attendance, at least 15 kilometres by road from the clinical psychologist.

M6. PSYCHOLOGICAL THERAPY SERVICES

Psychological therapy services delivered by video conference are time limited, being deliverable in up to ten planned sessions in a calendar year (including services to which items 80001, 80011, 80101, 80111, 80126, 80136, 80151 and 80161 apply).

Psychological therapy services delivered by video conference time limits include the maximum ten planned sessions in a calendar year services to which items 283 to 287; 2721 to 2727; 80000 to 80015; 80100 to 80115; 80125 to 80140; 80150 to 80165 apply.

(See para MN.6.5 of explanatory notes to this Category)

Fee: \$99.75 Benefit: 85% = \$84.80 Extended Medicare Safety Net Cap: \$299.25

Professional attendance at a place other than consulting rooms.

As per the service requirements outlined for item 80000.

(See para MN.6.1 of explanatory notes to this Category) **Fee:** \$124.65 **Benefit:** 85% = \$106.00

80005 Extended Medicare Safety Net Cap: \$373.95

Professional attendance for the purpose of providing psychological assessment and therapy for a mental disorder by a **clinical psychologist** registered with Medicare Australia as meeting the credentialing requirements for provision of this service, lasting at least 50 minutes, where the patient is referred by a medical practitioner, as part of a GP Mental Health Treatment Plan or as part of a shared care plan; or referred by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan; or referred by a specialist or consultant physician in the practice of his or her field of psychiatry or paediatrics.

These therapies are time limited, being deliverable in up to ten planned sessions in a calendar year (including services to which items 283 to 287; 2721 to 2727; 80000 to 80015; 80100 to 80115; 80125 to 80140; 80150 to 80165 apply).

(Professional attendance at consulting rooms)

(See para MN.6.1 of explanatory notes to this Category) **Fee:** \$146.45 **Benefit:** 85% = \$124.50

Extended Medicare Safety Net Cap: \$439.35

80010

Professional attendance for the purpose of providing psychological assessment and therapy for a mental disorder by a **clinical psychologist** registered with Medicare Australia as meeting the credentialing requirements for provision of this service, lasting at least 50 minutes, where the patient is referred by a medical practitioner, as part of a GP Mental Health Treatment Plan or as part of a shared care plan; or referred by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan; or referred by a specialist or consultant physician in the practice of his or her field of psychiatry or paediatrics if:

- the attendance is by video conference; and
- the patient is not an admitted patient; and
- the patient is located within a telehealth eligible area; and
- the patient is, at the time of the attendance, at least 15 kilometres by road from the clinical psychologist.

80011 Psychological therapy services delivered by video conference are time limited, being deliverable in up

M6. PSYCHOLOGICAL THERAPY SERVICES

to ten planned sessions in a calendar year (including services to which items 80001, 80011, 80101, 80111, 80126, 80136, 80151 and 80161 apply).

Psychological therapy services delivered by video conference time limits include the maximum ten planned sessions in a calendar year services to which items 283 to 287; 2721 to 2727; 80000 to 80015; 80100 to 80115; 80125 to 80140; 80150 to 80165 apply.

(See para MN.6.5 of explanatory notes to this Category)

Fee: \$146.45

Benefit: 85% = \$124.50

Extended Medicare Safety Net Cap: \$439.35

Professional attendance at a place other than consulting rooms

As per the service requirements outlined for item 80010.

(See para MN.6.1 of explanatory notes to this Category)

Fee: \$171.35

Benefit: 85% = \$145.65

Extended Medicare Safety Net Cap: \$500.00

80015

Professional attendance for the purpose of providing psychological therapy for a mental disorder by a **clinical psychologist** registered with Medicare Australia as meeting the credentialing requirements for provision of this service, lasting for at least 60 minutes duration where the patients are referred by a medical practitioner, as part of a GP Mental Health Treatment Plan or as part of a shared care plan; or referred by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan; or referred by a specialist or consultant physician in the practice of his or her field of psychiatry or paediatrics.

These therapies are time limited, being deliverable in up to ten planned sessions in a calendar year (including services to which items 80020, 80021, 80120, 80121, 80145, 80146, 80170 and 80171 apply).

GROUP THERAPY with a group of 6 to 10 patients, EACH PATIENT

(See para MN.6.1 of explanatory notes to this Category) **Fee:** \$37.20 **Benefit:** 85% = \$31.65 **Extended Medicare Safety Net Cap:** \$111.60

80020

Professional attendance for the purpose of providing psychological therapy for a mental disorder by a **clinical psychologist** registered with Medicare Australia as meeting the credentialing requirements for provision of this service, lasting for at least 60 minutes duration where the patients are referred by a medical practitioner, as part of a GP Mental Health Treatment Plan or as part of a shared care plan; or referred by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan; or referred by a specialist or consultant physician in the practice of his or her field of psychiatry or paediatrics if:

- the attendance is by video conference; and
- the patient is not an admitted patient; and
- the patient is located within a telehealth eligible area; and
- the patient is, at the time of the attendance, at least 15 kilometres by road from the clinical psychologist.

80021

Group psychological therapy services delivered by video conference are time limited, being deliverable in up to ten planned sessions in a calendar year (including services to which items 80021, 80121, 80146

M6. PSYCHOLOGICAL THERAPY SERVICES

and 80171 apply).

Group psychological therapy services delivered by video conference time limits include the maximum ten planned sessions in a calendar year services to which items 80020, 80120, 80145 and 80170 apply.

- GROUP THERAPY with a group of 6 to 10 patients, EACH PATIENT

(See para MN.6.5 of explanatory notes to this Category) **Fee:** \$37.20 **Benefit:** 85% = \$31.65 **Extended Medicare Safety Net Cap:** \$111.60

M7. FOCUSSED PSYCHOLOGICAL STRATEGIES (ALLIED MENTAL HEALTH)

Group M7. Focussed Psychological Strategies (Allied Mental Health)

Professional attendance for the purpose of providing focussed psychological strategies services for an assessed mental disorder by a **psychologist** registered with Medicare Australia as meeting the credentialing requirements for provision of this service - lasting more than 20 minutes, but not more than 50 minutes - where the patient is referred by a medical practitioner, as part of a GP Mental Health Treatment Plan or as part of a shared care plan; or referred by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan; or referred by a specialist or consultant physician in the practice of his or her field of psychiatry or paediatrics.

These therapies are time limited, being deliverable in up to ten planned sessions in a calendar year (including services to which items 283 to 287; 2721 to 2727; 80000 to 80015; 80100 to 80115; 80125 to 80140; 80150 to 80165 apply).

(Professional attendance at consulting rooms)

(See para MN.7.1 of explanatory notes to this Category)

Fee: \$70.65 Benefit: 85% = \$60.10 Extended Medicare Safety Net Cap: \$211.95

Professional attendance for the purpose of providing focussed psychological strategies services for an assessed mental disorder by a **psychologist** registered with Medicare Australia as meeting the credentialing requirements for provision of this service - lasting more than 20 minutes, but not more than 50 minutes - where the patient is referred by a medical practitioner, as part of GP Mental Health Treatment Plan or as part of a shared care plan; or referred by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan; or referred by a specialist or consultant physician in the practice of his or her field of psychiatry or paediatrics if:

- the attendance is by video conference; and
- the patient is not an admitted patient; and
- the patient is located within a telehealth eligible area; and
- the patient is, at the time of the attendance, at least 15 kilometres by road from the psychologist.

Focussed psychological strategies delivered by video conference are time limited, being deliverable in up to ten planned sessions in a calendar year (including services to which items 80001, 80011, 80101, 80111, 80126, 80136, 80151 and 80161 apply).

Focussed psychological strategies delivered by video conference time limits include the maximum ten planned sessions in a calendar year services to which items 283 to 287; 2721 to 2727; 80000 to 80015;

80101

M7. FOCUSSED PSYCHOLOGICAL STRATEGIES (ALLIED MENTAL HEALTH) 80100 to 80115; 80125 to 80140; 80150 to 80165 apply. (See para MN.7.2 of explanatory notes to this Category) Fee: \$70.65 **Benefit:** 85% = \$60.10 Extended Medicare Safety Net Cap: \$211.95 Professional attendance at a place other than consulting rooms. As per the psychologist service requirements outlined for item 80100. (See para MN.7.1 of explanatory notes to this Category) **Benefit:** 85% = \$81.75 Fee: \$96.15 80105 Extended Medicare Safety Net Cap: \$288.45 Professional attendance for the purpose of providing focussed psychological strategies services for an assessed mental disorder by a psychologist registered with Medicare Australia as meeting the credentialing requirements for provision of this service - lasting more than 50 minutes - where the patient is referred by a medical practitioner, as part of a GP Mental Health Treatment Plan or as part of a shared care plan; or referred by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan; or referred by a specialist or consultant physician in the practice of his or her field of psychiatry or paediatrics. These therapies are time limited, being deliverable in up to ten planned sessions in a calendar year (including services to which items 283 to 287; 2721 to 2727; 80000 to 80015; 80100 to 80115; 80125 to 80140; 80150 to 80165 apply). (Professional attendance at consulting rooms) (See para MN.7.1 of explanatory notes to this Category) Fee: \$99.75 **Benefit:** 85% = \$84.80 80110 Extended Medicare Safety Net Cap: \$299.25 Professional attendance for the purpose of providing focussed psychological strategies services for an assessed mental disorder by a psychologist registered with Medicare Australia as meeting the credentialing requirements for provision of this service - lasting more than 50 minutes - where the patient is referred by a medical practitioner, as part of a GP Mental Health Treatment Plan or as part of a shared care plan; or referred by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan; or referred by a specialist or consultant physician in the practice of his or her field of psychiatry or paediatrics if: • the attendance is by video conference; and • the patient is not an admitted patient; and • the patient is located within a telehealth eligible area; and • the patient is, at the time of the attendance, at least 15 kilometres by road from the psychologist. Focussed psychological strategies delivered by video conference are time limited, being deliverable in up to ten planned sessions in a calendar year (including services to which items 80001, 80011, 80101, 80111, 80126, 80136, 80151 and 80161 apply). Focussed psychological strategies delivered by video conference time limits include the maximum ten

80111

planned sessions in a calendar year services to which items 283 to 287; 2721 to 2727; 80000 to 80015;

	. FOCUSSED PSYCHOLOGICAL STRATEGIES LLIED MENTAL HEALTH)		
	80100 to 80115; 80125 to 80140; 80150 to 80165 apply.		
	(See para MN.7.2 of explanatory notes to this Category) Fee: \$99.75 Benefit: 85% = \$84.80 Extended Medicare Safety Net Cap: \$299.25		
	Professional attendance at a place other than consulting rooms.		
	As per the psychologist service requirements outlined for item 80110.		
80115	(See para MN.7.1 of explanatory notes to this Category) Fee: \$125.30 Benefit: 85% = \$106.55 Extended Medicare Safety Net Cap: \$375.90		
	Professional attendance for the purpose of providing focussed psychological strategies services for an assessed mental disorder by a psychologist registered with Medicare Australia as meeting the credentialing requirements for provision of this service, lasting for at least 60 minutes duration where the patients are referred by a medical practitioner, as part of a GP Mental Health Treatment Plan or as part of a shared care plan; or referred by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan; or referred by a specialist or consultant physician in the practice of his or her field of psychiatry or paediatrics.		
	These therapies are time limited, being deliverable in up to ten planned sessions in a calendar year (including services to which items 80020, 80021, 80120, 80121, 80145, 80146, 80170 and 80171 apply).		
	GROUP THERAPY with a group of 6 to 10 patients, EACH PATIENT		
	(See para MN.7.1 of explanatory notes to this Category) Fee: \$25.45 Benefit: \$5% = \$21.65		
80120	Fee: \$25.45 Benefit: 85% = \$21.65 Extended Medicare Safety Net Cap: \$76.35		
80121	Professional attendance for the purpose of providing focussed psychological strategies services for an assessed mental disorder by a psychologist registered with Medicare Australia as meeting the credentialing requirements for provision of this service, lasting for at least 60 minutes duration where the patients are referred by a medical practitioner, as part of a GP Mental Health Treatment Plan or as part of a shared care plan; or referred by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan; or referred by a specialist or consultant physician in the practice of his or her field of psychiatry or paediatrics if:		
	 the attendance is by video conference; and the patient is not an admitted patient; and the patient is located within a telehealth eligible area; and the patient is, at the time of the attendance, at least 15 kilometres by road from the psychologist. 		
	Group focussed psychological strategies delivered by video conference are time limited, being deliverable in up to ten planned sessions in a calendar year (including services to which items 80021, 80121, 80146 and 80171 apply).		
	Group focussed psychological strategies delivered by video conference time limits include the maximum ten planned sessions in a calendar year services to which items 80020, 80120, 80145 and 80170 apply.		

M7. FOCUSSED PSYCHOLOGICAL STRATEGIES (ALLIED MENTAL HEALTH)

GROUP THERAPY with a group of 6 to 10 patients, EACH PATIENT

(See para MN.7.2 of explanatory notes to this Category) Fee: \$25.45 **Benefit:** 85% = \$21.65 Extended Medicare Safety Net Cap: \$76.35

Professional attendance for the purpose of providing focussed psychological strategies services for an assessed mental disorder by an **occupational therapist** registered with Medicare Australia as meeting the credentialing requirements for provision of this service - lasting more than 20 minutes, but not more than 50 minutes - where the patient is referred by a medical practitioner, as part of a GP Mental Health Treatment Plan or as part of a shared care plan; or referred by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan; or referred by a specialist or consultant physician in the practice of his or her field of psychiatry or paediatrics.

These therapies are time limited, being deliverable in up to ten planned sessions in a calendar year (including services to which items 283 to 287; 2721 to 2727; 80000 to 80015; 80100 to 80115; 80125 to 80140; 80150 to 80165 apply).

(Professional services at consulting rooms)

(See para MN.7.1 of explanatory notes to this Category)

Fee: \$62.25 **Benefit:** 85% = \$52.95

Extended Medicare Safety Net Cap: \$186.75 80125

> Professional attendance for the purpose of providing focussed psychological strategies services for an assessed mental disorder by an occupational therapist registered with Medicare Australia as meeting the credentialing requirements for provision of this service - lasting more than 20 minutes, but not more than 50 minutes - where the patient is referred by a medical practitioner, as part of a GP Mental Health Treatment Plan or as part of a shared care plan; or referred by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan; or referred by a specialist or consultant physician in the practice of his or her field of psychiatry or paediatrics if:

- the attendance is by video conference; and
- the patient is not an admitted patient; and
- the patient is located within a telehealth eligible area; and
- the patient is, at the time of the attendance, at least 15 kilometres by road from the occupational therapist.

Focussed psychological strategies delivered by video conference are time limited, being deliverable in up to ten planned sessions in a calendar year (including services to which items 80001, 80011, 80101, 80111, 80126, 80136, 80151 and 80161 apply).

Focussed psychological strategies delivered by video conference time limits include the maximum ten planned sessions in a calendar year services to which items 283 to 287; 2721 to 2727; 80000 to 80015; 80100 to 80115; 80125 to 80140; 80150 to 80165 apply.

(See para MN.7.2 of explanatory notes to this Category)

Fee: \$62.25 **Benefit:** 85% = \$52.95 80126 Extended Medicare Safety Net Cap: \$186.75

Professional attendance at a place other than consulting rooms.

M7. FOCUSSED PSYCHOLOGICAL STRATEGIES (ALLIED MENTAL HEALTH)

As per the occupational therapist service requirements outlined for item 80125.

(See para MN.7.1 of explanatory notes to this Category) **Fee:** \$87.70 **Benefit:** 85% = \$74.55 **Extended Medicare Safety Net Cap:** \$263.10

Professional attendance for the purpose of providing focussed psychological strategies services for an assessed mental disorder by an **occupational therapist** registered with Medicare Australia as meeting the credentialing requirements for provision of this service - lasting more than 50 minutes - where the patient is referred by a medical practitioner, as part of a GP Mental Health Treatment Plan or as part of a shared care plan; or referred by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan; or referred by a specialist or consultant physician in the practice of his or her field of psychiatry or paediatrics.

These therapies are time limited, being deliverable in up to ten planned sessions in a calendar year (including services to which items 283 to 287; 2721 to 2727; 80000 to 80015; 80100 to 80115; 80125 to 80140; 80150 to 80165 apply).

(Professional attendance at consulting rooms)

(See para MN.7.1 of explanatory notes to this Category)

Fee: \$87.95 Benefit: 85% = \$74.80 80135 Extended Medicare Safety Net Cap: \$263.85

Professional attendance for the purpose of providing focussed psychological strategies services for an assessed mental disorder by an **occupational therapist** registered with Medicare Australia as meeting the credentialing requirements for provision of this service - lasting more than 50 minutes - where the patient is referred by a medical practitioner, as part of a GP Mental Health Treatment Plan or as part of a shared care plan; or referred by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan; or referred by a specialist or consultant physician in the practice of his or her field of psychiatry or paediatrics if:

- the attendance is by video conference; and
- the patient is not an admitted patient; and
- the patient is located within a telehealth eligible area; and
- the patient is, at the time of the attendance, at least 15 kilometres by road from the occupational therapist.

Focussed psychological strategies delivered by video conference are time limited, being deliverable in up to ten planned sessions in a calendar year (including services to which items 80001, 80011, 80101, 80111, 80126, 80136, 80151 and 80161 apply).

Focussed psychological strategies delivered by video conference time limits include the maximum ten planned sessions in a calendar year services to which items 283 to 287; 2721 to 2727; 80000 to 80015; 80100 to 80115; 80125 to 80140; 80150 to 80165 apply.

(See para MN.7.2 of explanatory notes to this Category)

Fee: \$87.95 Benefit: 85% = \$74.80

80136 Extended Medicare Safety Net Cap: \$263.85

Professional attendance at a place other than consulting rooms.

M7. FOCUSSED PSYCHOLOGICAL STRATEGIES (ALLIED MENTAL HEALTH) As per the occupational therapist service requirements outlined for item 80135. (See para MN.7.1 of explanatory notes to this Category) Fee: \$113.35 **Benefit:** 85% = \$96.35 Extended Medicare Safety Net Cap: \$340.05 Professional attendance for the purpose of providing focussed psychological strategies services for an assessed mental disorder by an occupational therapist registered with Medicare Australia as meeting the credentialing requirements for provision of this service, lasting for at least 60 minutes duration where the patients are referred by a medical practitioner, as part of a GP Mental Health Treatment Plan or as part of a shared care plan; or referred by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan; or referred by a specialist or consultant physician in the practice of his or her field of psychiatry or paediatrics. These therapies are time limited, being deliverable in up to ten planned sessions in a calendar year (including services to which items 80020, 80021, 80120, 80121, 80145, 80146, 80170 and 80171 apply). GROUP THERAPY with a group of 6 to 10 patients, EACH PATIENT (See para MN.7.1 of explanatory notes to this Category) Fee: \$22.35 **Benefit:** 85% = \$19.00 80145 Extended Medicare Safety Net Cap: \$67.05 Professional attendance for the purpose of providing focussed psychological strategies services for an assessed mental disorder by an occupational therapist registered with Medicare Australia as meeting the credentialing requirements for provision of this service, lasting for at least 60 minutes duration where the patients are referred by a medical practitioner, as part of a GP Mental Health Treatment Plan or as part of a shared care plan; or referred by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan; or referred by a specialist or consultant physician in the practice of his or her field of psychiatry or paediatrics if: • the attendance is by video conference; and • the patient is not an admitted patient; and • the patient is located within a telehealth eligible area; and • the patient is, at the time of the attendance, at least 15 kilometres by road from the occupational therapist.

Group focussed psychological strategies delivered by video conference are time limited, being deliverable in up to ten planned sessions in a calendar year (including services to which items 80021, 80121, 80146 and 80171 apply).

Group focussed psychological strategies delivered by video conference time limits include the maximum ten planned sessions in a calendar year services to which items 80020, 80120, 80145 and 80170 apply.

GROUP THERAPY with a group of 6 to 10 patients, EACH PATIENT

(See para MN.7.2 of explanatory notes to this Category) **Fee:** \$22.35 **Benefit:** \$5% = \$19.00

80146 Extended Medicare Safety Net Cap: \$67.05

Professional attendance for the purpose of providing focussed psychological strategies services for an assessed mental disorder by a **social worker** registered with Medicare Australia as meeting the credentialing requirements for provision of this service - lasting more than 20 minutes, but not more than

M7. FOCUSSED PSYCHOLOGICAL STRATEGIES (ALLIED MENTAL HEALTH)

50 minutes - where the patient is referred by a medical practitioner, as part of a GP Mental Health Treatment Plan or as part of a shared care plan; or referred by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan; or referred by a specialist or consultant physician in the practice of his or her field of psychiatry or paediatrics.

These therapies are time limited, being deliverable in up to ten planned sessions in a calendar year (including services to which items 283 to 287; 2721 to 2727; 80000 to 80015; 80100 to 80115; 80125 to 80140; 80150 to 80165 apply).

(Professional attendance at consulting rooms)

(See para MN.7.1 of explanatory notes to this Category) **Fee:** \$62.25 **Benefit:** 85% = \$52.95

Extended Medicare Safety Net Cap: \$186.75

Professional attendance for the purpose of providing focussed psychological strategies services for an assessed mental disorder by a **social worker** registered with Medicare Australia as meeting the credentialing requirements for provision of this service - lasting more than 20 minutes, but not more than 50 minutes - where the patient is referred by a medical practitioner, as part of a GP Mental Health Treatment Plan or as part of a shared care plan; or referred by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan; or referred by a specialist or consultant physician in the practice of his or her field of psychiatry or paediatrics if:

- the attendance is by video conference; and
- the patient is not an admitted patient; and
- the patient is located within a telehealth eligible area; and
- the patient is, at the time of the attendance, at least 15 kilometres by road from the social worker

Focussed psychological strategies delivered by video conference are time limited, being deliverable in up to ten planned sessions in a calendar year (including services to which items 80001, 80011, 80101, 80111, 80126, 80136, 80151 and 80161 apply).

Focussed psychological strategies delivered by video conference time limits include the maximum ten planned sessions in a calendar year services to which items 283 to 287; 2721 to 2727; 80000 to 80015; 80100 to 80115; 80125 to 80140; 80150 to 80165 apply.

(See para MN.7.2 of explanatory notes to this Category)

Fee: \$62.25 Benefit: 85% = \$52.95 Extended Medicare Safety Net Cap: \$186.75

80151

Professional attendance at a place other than consulting rooms.

As per the social worker service requirements outlined for item 80150.

(See para MN.7.1 of explanatory notes to this Category) **Fee:** \$87.70 **Benefit:** 85% = \$74.55

80155 Extended Medicare Safety Net Cap: \$263.10

Professional attendance for the purpose of providing focussed psychological strategies services for an assessed mental disorder by a **social worker** registered with Medicare Australia as meeting the credentialing requirements for provision of this service - lasting more than 50 minutes - where the

M7. FOCUSSED PSYCHOLOGICAL STRATEGIES (ALLIED MENTAL HEALTH)

patient is referred by a medical practitioner, as part of a GP Mental Health Treatment Plan or as part of a shared care plan; or referred by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan; or referred by a specialist or consultant physician in the practice of his or her field of psychiatry or paediatrics.

These therapies are time limited, being deliverable in up to ten planned sessions in a calendar year (including services to which items 283 to 287; 2721 to 2727; 80000 to 80015; 80100 to 80115; 80125 to 80140; 80150 to 80165 apply).

(Professional attendance at consulting rooms)

(See para MN.7.1 of explanatory notes to this Category) **Fee:** \$87.95 **Benefit:** 85% = \$74.80 **Extended Medicare Safety Net Cap:** \$263.85

Professional attendance for the purpose of providing focussed psychological strategies services for an assessed mental disorder by a **social worker** registered with Medicare Australia as meeting the credentialing requirements for provision of this service - lasting more than 50 minutes - where the patient is referred by a medical practitioner, as part of a GP Mental Health Treatment Plan or as part of a shared care plan; or referred by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan; or referred by a specialist or consultant physician in the practice of his or her field of psychiatry or paediatrics if:

- the attendance is by video conference; and
- the patient is not an admitted patient; and
- the patient is located within a telehealth eligible area; and
- the patient is, at the time of the attendance, at least 15 kilometres by road from the social worker

Focussed psychological strategies delivered by video conference are time limited, being deliverable in up to ten planned sessions in a calendar year (including services to which items 80001, 80011, 80101, 80111, 80126, 80136, 80151 and 80161 apply).

Focussed psychological strategies delivered by video conference time limits include the maximum ten planned sessions in a calendar year services to which items 283 to 287; 2721 to 2727; 80000 to 80015; 80100 to 80115; 80125 to 80140; 80150 to 80165 apply.

(See para MN.7.2 of explanatory notes to this Category)

Fee: \$87.95 Benefit: 85% = \$74.80 Extended Medicare Safety Net Cap: \$263.85

80161

Professional attendance at a place other than consulting rooms.

As per the social worker service requirements outlined for item 80160.

(See para MN.7.1 of explanatory notes to this Category) **Fee:** \$113.35 **Benefit:** 85% = \$96.35

80165 Extended Medicare Safety Net Cap: \$340.05

Professional attendance for the purpose of providing focussed psychological strategies services for an assessed mental disorder by a **social worker** registered with Medicare Australia as meeting the credentialing requirements for provision of this service, lasting for at least 60 minutes duration where the

M7. FOCUSSED PSYCHOLOGICAL STRATEGIES (ALLIED MENTAL HEALTH)

patients are referred by a medical practitioner, as part of a GP Mental Health Treatment Plan or as part of a shared care plan; or referred by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan; or referred by a specialist or consultant physician in the practice of his or her field of psychiatry or paediatrics.

These therapies are time limited, being deliverable in up to ten planned sessions in a calendar year (including services to which items 80020, 80021, 80120, 80121, 80145, 80146, 80170 and 80171 apply).

GROUP THERAPY with a group of 6 to 10 patients, EACH PATIENT

(See para MN.7.1 of explanatory notes to this Category) Fee: \$22.35 **Benefit:** 85% = \$19.00 **Extended Medicare Safety Net Cap: \$67.05**

Professional attendance for the purpose of providing focussed psychological strategies services for an assessed mental disorder by a social worker registered with Medicare Australia as meeting the credentialing requirements for provision of this service, lasting for at least 60 minutes duration where the patients are referred by a medical practitioner, as part of a GP Mental Health Treatment Plan or as part of a shared care plan; or referred by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) who is managing the patient under a referred psychiatrist assessment and management plan; or referred by a specialist or consultant physician in the practice of his or her field of psychiatry or paediatrics if:

- the attendance is by video conference; and
- the patient is not an admitted patient; and
- the patient is located within a telehealth eligible area; and
- the patient is, at the time of the attendance, at least 15 kilometres by road from the social worker.

Group focussed psychological strategies delivered by video conference are time limited, being deliverable in up to ten planned sessions in a calendar year (including services to which items 80021, 80121, 80146 and 80171 apply).

Group focussed psychological strategies delivered by video conference time limits include the maximum ten planned sessions in a calendar year services to which items 80020, 80120, 80145 and 80170 apply.

GROUP THERAPY with a group of 6 to 10 patients, EACH PATIENT

(See para MN.7.2 of explanatory notes to this Category) Fee: \$22.35 **Benefit:** 85% = \$19.00

Extended Medicare Safety Net Cap: \$67.05

M8. PREGNANCY SUPPORT COUNSELLING

Group M8. Pregnancy Support Counselling

Provision of a non-directive pregnancy support counselling service to a person who is currently pregnant or who has been pregnant in the preceding 12 months, by an eligible psychologist, where the patient is referred to the psychologist by a medical practitioner (including a general practitioner, but not a specialist or consultant physician), and lasting at least 30 minutes. The service may be used to address any pregnancy related issues for which non-directive counselling is appropriate.

81000

M8. PREGNANCY SUPPORT COUNSELLING

This service may be provided by a psychologist who is registered with Medicare Australia as meeting the credentialling requirements for provision of this service. It may not be provided by a psychologist who has a direct pecuniary interest in a health service that has as its primary purpose the provision of services for pregnancy termination.

To a maximum of three non-directive pregnancy support counselling services per patient, per pregnancy from any of the following items -81000, 81005, 81010 and 4001

(See para MN.8.3, MN.8.2, MN.8.1, MN.8.4 of explanatory notes to this Category)

Fee: \$73 15 **Benefit:** 85% = \$62.20**Extended Medicare Safety Net Cap: \$219.45**

Provision of a non-directive pregnancy support counselling service to a person who is currently pregnant or who has been pregnant in the preceding 12 months, by an eligible social worker, where the patient is referred to the social worker by a medical practitioner (including a general practitioner, but not a specialist or consultant physician), and lasting at least 30 minutes. The service may be used to address any pregnancy related issues for which non-directive counselling is appropriate.

This service may be provided by a social worker who is registered with Medicare Australia as meeting the credentialling requirements for provision of this service. It may not be provided by a social worker who has a direct pecuniary interest in a health service that has as its primary purpose the provision of services for pregnancy termination.

To a maximum of three non-directive pregnancy support counselling services per patient, per pregnancy from any of the following items -81000, 81005, 81010 and 4001

(See para MN.8.3, MN.8.2, MN.8.1, MN.8.4 of explanatory notes to this Category)

Benefit: 85% = \$62.20Fee: \$73.15 81005 Extended Medicare Safety Net Cap: \$219.45

> Provision of a non-directive pregnancy support counselling service to a person who is currently pregnant or who has been pregnant in the preceding 12 months, by an eligible mental health nurse, where the patient is referred to the mental health nurse by a medical practitioner (including a general practitioner.) but not a specialist or consultant physician), and lasting at least 30 minutes. The service may be used to address any pregnancy related issues for which non-directive counselling is appropriate.

> This service may be provided by a mental health nurse who is registered with Medicare Australia as meeting the credentialling requirements for provision of this service. It may not be provided by a mental health nurse who has a direct pecuniary interest in a health service that has as its primary purpose the provision of services for pregnancy termination.

> To a maximum of three non-directive pregnancy support counselling services per patient, per pregnancy from any of the following items - 81000, 81005, 81010 and 4001

81010 (See para MN.8.3, MN.8.2, MN.8.1, MN.8.4 of explanatory notes to this Category)

10.11	PREGNANCY SUPPORT COUNSELLING Production of the production of the				
	Fee: \$73.15 Benefit: 85% = \$62.20 Extended Medicare Safety Net Cap: \$219.45				
M9. AL	M9. ALLIED HEALTH GROUP SERVICES				
	Group M9. Allied Health Group Services				
	DIABETES EDUCATION SERVICE - ASSESSMENT FOR GROUP SERVICES				
	Diabetes education health service provided to a person by an eligible diabetes educator for the purposes of ASSESSING a person's suitability for group services for the management of type 2 diabetes, including taking a comprehensive patient history, identifying an appropriate group services program based on the patient's needs, and preparing the person for the group services, if:				
	(a) the service is provided to a person who has type 2 diabetes; and				
	(b) the person is being managed by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) under a shared care plan or a GP Management Plan [ie item 721 or 732], or if the person is a resident of an aged care facility, their medical practitioner has contributed to a multidisciplinary care plan [ie item 731]; and				
	(c) the person is referred to an eligible diabetes educator by the medical practitioner using a referral form that has been issued by the Department of Health, or a referral form that contains all the components of the form issued by the Department; and				
	(d) the person is not an admitted patient of a hospital; and				
	(e) the service is provided to the person individually and in person; and				
	(f) the service is of at least 45 minutes duration; and				
	(g) after the service, the eligible diabetes educator gives a written report to the referring medical practitioner mentioned in paragraph (c); and				
	(h) in the case of a service in respect of which a private health insurance benefit is payable - the person who incurred the medical expenses in respect of the service has elected to claim the Medicare benefit in respect of the service, and not the private health insurance benefit.				
	Benefits are payable once only in a calendar year for this or any other Assessment for Group Services item (including services to which items 81100, 81110 and 81120 apply).				
81100	(See para MN.9.7, MN.9.6, MN.9.2, MN.9.3, MN.9.4, MN.9.1 of explanatory notes to this Category) Fee: \$79.85 Benefit: 85% = \$67.90 Extended Medicare Safety Net Cap: \$239.55				
31100	DIABETES EDUCATION SERVICE - GROUP SERVICE				
	Diabetes education health service provided to a person by an eligible diabetes educator, as a GROUP SERVICE for the management of type 2 diabetes if:				
81105	(a) the person has been assessed as suitable for a type 2 diabetes group service under assessment item				

M9. ALLIED HEALTH GROUP SERVICES

81100, 81110 or 81120; and

- (b) the service is provided to a person who is part of a group of between 2 and 12 patients inclusive; and
- (c) the person is not an admitted patient of a hospital; and
- (d) the service is provided to a person involving the personal attendance by an eligible diabetes educator; and
- (e) the service is of at least 60 minutes duration; and
- (f) after the last service in the group services program provided to the person under items 81105, 81115 or 81125, the eligible diabetes educator prepares, or contribute to, a written report to be provided to the referring medical practitioner; and
- (g) an attendance record for the group is maintained by the eligible diabetes educator; and
- (h) in the case of a service in respect of which a private health insurance benefit is payable the person who incurred the medical expenses in respect of the service has elected to claim the Medicare benefit in respect of the service, and not the private health insurance benefit;

- to a maximum of eight GROUP SERVICES (including services to which items 81105, 81115 and 81125 apply) in a calendar year.

(See para MN.9.7, MN.9.6, MN.9.2, MN.9.5, MN.9.3, MN.9.1 of explanatory notes to this Category)

Fee: \$19.90 Benefit: 85% = \$16.95 Extended Medicare Safety Net Cap: \$59.70

EXERCISE PHYSIOLOGY SERVICE - ASSESSMENT FOR GROUP SERVICES

Exercise physiology health service provided to a person by an eligible exercise physiologist for the purposes of ASSESSING a person's suitability for group services for the management of type 2 diabetes, including taking a comprehensive patient history, identifying an appropriate group services program based on the patient's needs, and preparing the person for the group services, if:

- (a) the service is provided to a person who has type 2 diabetes; and
- (b) the person is being managed by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) under a shared care plan or a GP Management Plan [ie item 721 or 732, or if the person is a resident of an aged care facility, their medical practitioner has contributed to a multidisciplinary care plan [ie item 731]; and
- (c) the person is referred to an eligible exercise physiologist by the medical practitioner using a referral form that has been issued by the Department of Health, or a referral form that contains all the components of the form issued by the Department; and
- (d) the person is not an admitted patient of a hospital; and
- (e) the service is provided to the person individually and in person; and
- (f) the service is of at least 45 minutes duration; and

M9. ALLIED HEALTH GROUP SERVICES after the service, the eligible exercise physiologist gives a written report to the referring medical practitioner mentioned in paragraph (c); and (h) in the case of a service in respect of which a private health insurance benefit is payable - the person who incurred the medical expenses in respect of the service has elected to claim the Medicare benefit in respect of the service, and not the private health insurance benefit. Benefits are payable once only in a calendar year for this or any other Assessment for Group Services item (including services to which items 81100, 81110 and 81120 apply). (See para MN.9.7, MN.9.6, MN.9.2, MN.9.3, MN.9.4, MN.9.1 of explanatory notes to this Category) **Fee:** \$79.85 **Benefit:** 85% = \$67.90 Extended Medicare Safety Net Cap: \$239.55 EXERCISE PHYSIOLOGY SERVICE - GROUP SERVICE Exercise physiology health service provided to a person by an eligible exercise physiologist, as a GROUP SERVICE for the management of type 2 diabetes if: (a) the person has been assessed as suitable for a type 2 diabetes group service under assessment item 81100, 81110 or 81120; and (b) the service is provided to a person who is part of a group of between 2 and 12 patients inclusive; (c) the person is not an admitted patient of a hospital; and (d) the service is provided to a person involving the personal attendance by an eligible exercise physiologist; and (e) the service is of at least 60 minutes duration; and (f) after the last service in the group services program provided to the person under items 81105, 81115 or 81125, the eligible exercise physiologist prepares, or contribute to, a written report to be provided to the referring medical practitioner; and (g) an attendance record for the group is maintained by the eligible exercise physiologist; and (h) in the case of a service in respect of which a private health insurance benefit is payable - the person who incurred the medical expenses in respect of the service has elected to claim the Medicare benefit in respect of the service, and not the private health insurance benefit; - to a maximum of eight GROUP SERVICES (including services to which items 81105, 81115 and 81125 apply) in a calendar year. (See para MN.9.7, MN.9.6, MN.9.2, MN.9.5, MN.9.3, MN.9.1 of explanatory notes to this Category) Fee: \$19.90 **Benefit:** 85% = \$16.95 Extended Medicare Safety Net Cap: \$59.70 81115 DIETETICS SERVICE - ASSESSMENT FOR GROUP SERVICES 81120

M9. ALLIED HEALTH GROUP SERVICES

Dietetics health service provided to a person by an eligible dietitian for the purposes of ASSESSING a person's suitability for group services for the management of type 2 diabetes, including taking a comprehensive patient history, identifying an appropriate group services program based on the patient's needs, and preparing the person for the group services, if:

- (a) the service is provided to a person who has type 2 diabetes; and
- (b) the person is being managed by a medical practitioner (including a general practitioner, but not a specialist or consultant physician) under a shared care plan or a GP Management Plan [ie item 721 or 732], or if the person is a resident of an aged care facility, their medical practitioner has contributed to a multidisciplinary care plan [ie item 731]; and
- (c) the person is referred to an eligible dietitian by the medical practitioner using a referral form that has been issued by the Department of Health, or a referral form that contains all components of the form issued by the Department; and
- (d) the person is not an admitted patient of a hospital; and
- (e) the service is provided to the person individually and in person; and
- (f) the service is of at least 45 minutes duration; and
- (g) after the service, the eligible dietitian gives a written report to the referring medical practitioner mentioned in paragraph (c); and
- (h) in the case of a service in respect of which a private health insurance benefit is payable the person who incurred the medical expenses in respect of the service has elected to claim the Medicare benefit in respect of the service, and not the private health insurance benefit.

Benefits are payable once only in a calendar year for this or any other Assessment for Group Services item (including services to which items 81100, 81110 and item 81120 apply).

(See para MN.9.7, MN.9.6, MN.9.2, MN.9.3, MN.9.4, MN.9.1 of explanatory notes to this Category)

Fee: \$79.85 **Benefit:** 85% = \$67.90 **Extended Medicare Safety Net Cap:** \$239.55

DIETETICS SERVICE - GROUP SERVICE

Dietetics health service provided to a person by an eligible dietitian, as a GROUP SERVICE for the management of type 2 diabetes if:

- (a) the person has been assessed as suitable for a type 2 diabetes group service under assessment item 81100, 81110 or 81120; and
- (b) the service is provided to a person who is part of a group of between 2 and 12 patients inclusive; and
- (c) the person is not an admitted patient of a hospital; and
- (d) the service is provided to a person involving the personal attendance by an eligible dietitian; and

M9. ALLIED HEALTH GROUP SERVICES

- (e) the service is of at least 60 minutes duration; and
- (f) after the last service in the group services program provided to the person under items 81105, 81115 or 81125, the eligible dietitian prepares, or contribute to, a written report to be provided to the referring medical practitioner; and
- (g) an attendance record for the group is maintained by the eligible dietitian; and
- (h) in the case of a service in respect of which a private health insurance benefit is payable the person who incurred the medical expenses in respect of the service has elected to claim the Medicare benefit in respect of the service, and not the private health insurance benefit;
- to a maximum of eight GROUP SERVICES (including services to which items 81105, 81115 and 81125 apply) in a calendar year.

(See para MN.9.7, MN.9.6, MN.9.2, MN.9.5, MN.9.3, MN.9.1 of explanatory notes to this Category)

Fee: \$19.90 **Benefit:** 85% = \$16.95 **Extended Medicare Safety Net Cap:** \$59.70

M10. AUTISM, PERVASIVE DEVELOPMENTAL DISORDER AND DISABILITY SERVICES

Group M10. Autism, Pervasive Developmental Disorder And Disability Services

PSYCHOLOGY

Psychology health service provided to a child, aged under 13 years, by an eligible psychologist where:

(a) the child is referred by an eligible practitioner for the purpose of assisting the practitioner with their diagnosis of the child;

or

- (b) the child is referred by an eligible practitioner for the purpose of contributing to the child's pervasive developmental disorder
 - (PDD) or disability treatment plan, developed by the practitioner; and
- (c) for a child with PDD, the eligible practitioner is a consultant physician in the practice of his or her field of psychiatry or paediatrics; or for a child with disability, the eligible practitioner is a specialist, consultant physician or general practitioner; and
- (d) the psychologist attending the child is registered with the Department of Human Services as meeting the credentialing requirements for provision of these services; and
- (e) the child is not an admitted patient of a hospital; and
- (f) the service is provided to the child individually and in person; and
- (g) the service lasts at least 50 minutes in duration.

M10. AUTISM, PERVASIVE DEVELOPMENTAL DISORDER AND DISABILITY SERVICES	
	These items are limited to a maximum of four services per patient, consisting of any combination of the following items
	- 82000, 82005, 82010 and 82030
	(See para MN.10.1 of explanatory notes to this Category) Fee: \$99.75 Benefit: 85% = \$84.80 Extended Medicare Safety Net Cap: \$299.25
	SPEECH PATHOLOGY
	Speech pathology health service provided to a child, aged under 13 years, by an eligible speech pathologist where:
	(a) the child is referred by an eligible practitioner for the purpose of assisting the practitioner with their diagnosis of the child;
	or
	(b) the child is referred by an eligible practitioner for the purpose of contributing to the child's pervasive developmental disorder
	(PDD) or disability treatment plan, developed by the practitioner; and
	(c) for a child with PDD, the eligible practitioner is a consultant physician in the practice of his or her field of psychiatry or paediatrics; or for a child with disability, the eligible practitioner is a specialist, consultant physician or general practitioner: and
	(d) the speech pathologist attending the child is registered with the Department of Human Services as meeting the credentialing requirements for provision of these services; and
	(e) the child is not an admitted patient of a hospital; and
	(f) the service is provided to the child individually and in person; and
	(g) the service lasts at least 50 minutes in duration.
	These items are limited to a maximum of four services per patient, consisting of any combination of the following items
	- 82000, 82005, 82010 and 82030
82005	(See para MN.10.1 of explanatory notes to this Category) Fee: \$87.95 Benefit: 85% = \$74.80 Extended Medicare Safety Net Cap: \$263.85
	OCCUPATIONAL THERAPY
82010	Occupational therapy health service provided to a child, aged under 13 years, by an eligible occupational therapist where:

M10. AUTISM, PERVASIVE DEVELOPMENTAL DISORDER AND DISABILITY SERVICES

(a) the child is referred by an eligible practitioner for the purpose of assisting the practitioner with their diagnosis of the child;

or

- (b) the child is referred by an eligible practitioner for the purpose of contributing to the child's pervasive developmental disorder
- (PDD) or disability treatment plan, developed by the practitioner; and
- (c) for a child with PDD, the eligible practitioner is a consultant physician in the practice of his or her field of psychiatry or paediatrics; or for a child with disability, the eligible practitioner is a specialist, consultant physician or general practitioner; and
- (d) the occupational therapist attending the child is registered with the Department of Human Services as meeting the credentialing requirements for provision of these services; and
- (e) the child is not an admitted patient of a hospital; and
- (f) the service is provided to the child individually and in person; and
- (g) the service lasts at least 50 minutes in duration.

These items are limited to a maximum of four services per patient, consisting of any combination of the following items

- 82000, 82005, 82010 and 82030

(See para MN.10.1 of explanatory notes to this Category)

Fee: \$87.95

Benefit: 85% = \$74.80

Extended Medicare Safety Net Cap: \$263.85

PSYCHOLOGY

Psychology health service provided to a child, aged under 15 years, for treatment of a pervasive developmental disorder (PDD) or an eligible disability by an eligible psychologist where:

- (a) the child has been diagnosed with PDD or an eligible disability; and
- (b) the child has received a PDD or disability treatment plan (while aged under 13 years) as prepared by an eligible practitioner; and
- (c) the child has been referred by an eligible practitioner for the provision of services that are consistent with the PDD or disability treatment plan; and
- (d) for a child with PDD, the eligible practitioner is a consultant physician in the practice of his or her field of psychiatry or paediatrics; or for a child with disability, the eligible practitioner is a specialist, consultant physician or general practitioner; and

M10. AUTISM, PERVASIVE DEVELOPMENTAL DISORDER AND DISABILITY SERVICES

- (e) the psychologist attending the child is registered with the Department of Human Services as meeting the credentialing requirements for provision of these services; and
- (f) the child is not an admitted patient of a hospital; and
- (g) the service is provided to the child individually and in person; and
- (h) the service lasts at least 30 minutes in duration.

These items are limited to a maximum of 20 services per patient, consisting of any combination of items

- 82015, 82020, 82025 and 82035

(See para MN.10.1 of explanatory notes to this Category) **Fee:** \$99.75 **Benefit:** 85% = \$84.80

Extended Medicare Safety Net Cap: \$299.25

SPEECH PATHOLOGY

Speech pathology health service provided to a child, aged under 15 years, for treatment of a pervasive developmental disorder (PDD) or an eligible disability by an eligible speech pathologist where:

- (a) the child has been diagnosed with PDD or an eligible disability; and
- (b) the child has received a PDD or disability treatment plan (while aged under 13 years) as prepared by an eligible practitioner; and
- (c) the child has been referred by an eligible practitioner for the provision of services that are consistent with the PDD or disability treatment plan; and
- (d) for a child with PDD, the eligible practitioner is a consultant physician in the practice of his or her field of psychiatry or paediatrics; or for a child with disability, the eligible practitioner is a specialist, consultant physician or general practitioner; and
- (e) the speech pathologist attending the child is registered with the Department of Human Services as meeting the credentialing requirements for provision of these services; and
- (f) the child is not an admitted patient of a hospital; and
- (g) the service is provided to the child individually and in person; and
- (h) the service lasts at least 30 minutes in duration.

These items are limited to a maximum of 20 services per patient, consisting of any combination of items

- 82015, 82020, 82025 and 82035

(See para MN.10.1 of explanatory notes to this Category)

Fee: \$87.95 **Benefit:** 85% = \$74.80

82020 Extended Medicare Safety Net Cap: \$263.85

M10. AUTISM, PERVASIVE DEVELOPMENTAL **DISORDER AND DISABILITY SERVICES**

OCCUPATIONAL THERAPY

Occupational therapy health service provided to a child, aged under 15 years, for treatment of a pervasive developmental disorder (PDD) or an eligible disability by an eligible occupational therapist where:

- (a) the child has been diagnosed with PDD or an eligible disability; and
- (b) the child has received a PDD or disability treatment plan (while aged under 13 years) as prepared by an eligible practitioner; and
- (c) the child has been referred by an eligible practitioner for the provision of services that are consistent with the PDD or disability treatment plan; and
- (d) for a child with PDD, the eligible practitioner is a consultant physician in the practice of his or her field of psychiatry or paediatrics; or for a child with disability, the eligible practitioner is a specialist, consultant physician or general practitioner; and
- (e) the occupational therapist attending the child is registered with the Department of Human Services as meeting the credentialing requirements

for provision of these services; and

- (f) the child is not an admitted patient of a hospital; and
- (g) the service is provided to the child individually and in person; and
- (h) the service lasts at least 30 minutes in duration.

These items are limited to a maximum of 20 services per patient, consisting of any combination of items

- 82015, 82020, 82025 and 82035

(See para MN.10.1 of explanatory notes to this Category)

Fee: \$87.95

Benefit: 85% = \$74.80 Extended Medicare Safety Net Cap: \$263.85

82025

AUDIOLOGY, OPTOMETRY, ORTHOPTIC OR PHYSIOTHERAPY

Audiology, optometry, orthoptic or physiotherapy health service provided to a child, aged under 13 years, by an eligible audiologist, optometrist, orthoptist or physiotherapist where:

(a) the child is referred by an eligible practitioner for the purpose of assisting the practitioner with their diagnosis of the child;

(b) the child is referred by an eligible practitioner for the purpose of contributing to the child's pervasive developmental disorder

M10. AUTISM, PERVASIVE DEVELOPMENTAL DISORDER AND DISABILITY SERVICES

- (PDD) or disability treatment plan, developed by the practitioner; and
- (c) for a child with PDD, the eligible practitioner is a consultant physician in the practice of his or her field of psychiatry or paediatrics; or for a child with disability, the eligible practitioner is a specialist, consultant physician or general practitioner; and
- (d) the audiologist, optometrist, orthoptist or physiotherapist attending the child is registered with the Department of Human Services as meeting the credentialing requirements for provision of these services; and
- (e) the child is not an admitted patient of a hospital; and
- (f) the service is provided to the child individually and in person; and
- (g) the service lasts at least 50 minutes in duration.

These items are limited to a maximum of four services per patient, consisting of any combination of the following items

- 82000, 82005, 82010 and 82030

(See para MN.10.1 of explanatory notes to this Category)

Fee: \$87.95 **Benefit:** 85% = \$74.80 **Extended Medicare Safety Net Cap:** \$263.85

AUDIOLOGY, OPTOMETRY, ORTHOPTIC OR PHYSIOTHERAPY

Audiology, optometry, orthoptic or physiotherapy health service provided to a child, aged under 15 years, for treatment of a pervasive developmental disorder (PDD) or eligible disability by an eligible audiologist, optometrist, orthoptist or physiotherapist where:

- (a) the child has been diagnosed with PDD or eligible disability; and
- (b) the child has received a PDD or disability treatment plan (while aged under 13 years) as prepared by an eligible practitioner; and
- (c) the child has been referred by an eligible practitioner for the provision of services that are consistent with the PDD or disability treatment plan; and
- (d) for a child with PDD, the eligible practitioner is a consultant physician in the practice of his or her field of psychiatry or paediatrics; or for a child with disability, the eligible practitioner is a specialist, consultant physician or general practitioner; and
- (e) the audiologist, optometrist, orthoptist or physiotherapist attending the child is registered with the Department of Human Services as meeting the credentialing requirements for provision of these services; and
- (f) the child is not an admitted patient of a hospital; and
- (g) the service is provided to the child individually and in person; and

M10. AUTISM, PERVASIVE DEVELOPMENTAL DISORDER AND DISABILITY SERVICES

(h) the service lasts at least 30 minutes in duration.

These items are limited to a maximum of 20 services per patient, consisting of any combination of items

- 82015, 82020, 82025 and 82035

(See para MN.10.1 of explanatory notes to this Category)

Fee: \$87.95 Benefit: 85% = \$74.80 Extended Medicare Safety Net Cap: \$263.85

M11. ALLIED HEALTH SERVICES FOR INDIGENOUS AUSTRALIANS WHO HAVE HAD A HEALTH CHECK

Group M11. Allied Health Services For Indigenous Australians Who Have Had A Health Check

ABORIGINAL AND TORRES STRAIT ISLANDER HEALTH SERVICE provided to a person who is of Aboriginal and Torres Strait Islander descent by an eligible Aboriginal health worker or eligible Aboriginal and Torres Strait Islander health practitioner if:

- (a) either:
 - a medical practitioner has undertaken a health assessment and identified a need for follow-up allied health services; or
 - the person's shared care plan identifies the need for follow-up allied health services;
 and
- (b) the person is referred to the eligible Aboriginal health worker or eligible Aboriginal and Torres Strait Islander health practitioner by a medical practitioner using a referral form that has been issued by the Department or a referral form that substantially complies with the form issued by the Department; and
- (c) the person is not an admitted patient of a hospital; and
- (d) the service is provided to the person individually and in person; and
- (e) the service is of at least 20 minutes duration; and
- (f) after the service, the eligible Aboriginal health worker or eligible Aboriginal and Torres Strait Islander health practitioner gives a written report to the referring medical practitioner mentioned in paragraph (b):
 - (i) if the service is the only service under the referral in relation to that service; or
 - (ii) if the service is the first or the last service under the referral in relation to the service; or
 - (iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring medical practitioner would reasonably be expected to be informed of in relation to those matters

81300 - to a maximum of five services (including services to which items 81300 to 81360 inclusive apply) in a

M11. ALLIED HEALTH SERVICES FOR INDIGENOUS AUSTRALIANS WHO HAVE HAD A **HEALTH CHECK** calendar year (See para MN.11.1 of explanatory notes to this Category) Fee: \$62.25 **Benefit:** 85% = \$52.95 **Extended Medicare Safety Net Cap: \$186.75** DIABETES EDUCATION HEALTH SERVICE provided to a person who is of Aboriginal or Torres Strait Islander descent by an eligible diabetes educator if: (a) either: a medical practitioner has identified a need for follow-up allied health services; or i. ii. the person's shared care plan identifies the need for follow-up allied health services; and (b) the person is referred to the eligible diabetes educator by a medical practitioner using a referral form that has been issued by the Department or a referral form that substantially complies with the form issued by the Department; and (c) the person is not an admitted patient of a hospital; and (d) the service is provided to the person individually and in person; and (e) the service is of at least 20 minutes duration; and (f) after the service, the eligible diabetes educator gives a written report to the referring medical practitioner mentioned in paragraph (b): (i) if the service is the only service under the referral - in relation to that service; or (ii) if the service is the first or the last service under the referral - in relation to the service; or (iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring medical practitioner would reasonably be expected to be informed of in relation to those matters: - to a maximum of five services (including services to which items 81300 to 81360 inclusive apply) in a calendar year (See para MN.11.1 of explanatory notes to this Category) Fee: \$62.25 **Benefit:** 85% = \$52.95 81305 Extended Medicare Safety Net Cap: \$186.75 AUDIOLOGY HEALTH SERVICE provided to a person who is of Aboriginal or Torres Strait Islander descent by an eligible audiologist if: (a) either: a medical practitioner has undertaken a health assessment and identified a need for follow-up allied health services; or

ii.

81310

the person's shared care plan identifies the need for follow-up allied health services; and

(b) the person is referred to the eligible audiologist by the medical practitioner using a referral form that has been issued by the Department or a referral form that substantially complies with the form

M11. ALLIED HEALTH SERVICES FOR INDIGENOUS AUSTRALIANS WHO HAVE HAD A HEALTH CHECK

issued by the Department; and

- (c) the person is not an admitted patient of a hospital; and
- (d) the service is provided to the person individually and in person; and
- (e) the service is of at least 20 minutes duration; and
- (f) after the service, the eligible audiologist gives a written report to the referring medical practitioner mentioned in paragraph (b):
 - (i) if the service is the only service under the referral in relation to that service; or
 - (ii) if the service is the first or the last service under the referral in relation to the service; or
- (iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring medical practitioner would reasonably be expected to be informed of in relation to those matters;
- to a maximum of five services (including services to which items 81300 to 81360 inclusive apply) in a calendar year

(See para MN.11.1 of explanatory notes to this Category)

Fee: \$62.25 **Benefit:** 85% = \$52.95 **Extended Medicare Safety Net Cap:** \$186.75

EXERCISE PHYSIOLOGY HEALTH SERVICE provided to a person who is of Aboriginal or Torres Strait Islander descent by an eligible exercise physiologist if:

- (a) either:
 - i. a medical practitioner has undertaken a health assessment and identified a need for follow-up allied health services; or
 - ii. the person's shared care plan identifies the need for follow-up allied health services; and
- (b) the person is referred to the eligible exercise physiologist by a medical practitioner using a referral form that has been issued by the Department or a referral form that substantially complies with the form issued by the Department; and
- (c) the person is not an admitted patient of a hospital; and
- (d) the service is provided to the person individually and in person; and
- (e) the service is of at least 20 minutes duration; and
- (f) after the service, the eligible exercise physiologist gives a written report to the referring medical practitioner mentioned in paragraph (b):
 - (i) if the service is the only service under the referral in relation to that service; or
 - (ii) if the service is the first or the last service under the referral in relation to the service; or
- (iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring medical practitioner would reasonably be expected to be informed of in relation to those

M11. ALLIED HEALTH SERVICES FOR INDIGENOUS AUSTRALIANS WHO HAVE HAD A **HEALTH CHECK** matters: - to a maximum of five services (including services to which items 81300 to 81360 inclusive apply) in a calendar vear (See para MN.11.1 of explanatory notes to this Category) Fee: \$62.25 **Benefit:** 85% = \$52.95 **Extended Medicare Safety Net Cap: \$186.75** DIETETICS HEALTH SERVICE provided to a person who is of Aboriginal or Torres Strait Islander descent by an eligible dietitian if: (a) either: a medical practitioner has undertaken a health assessment and identified a need for follow-up allied health services; or ii. the person's shared care plan identifies the need for follow-up allied health services; and (b) the person is referred to the eligible dietitian by a medical practitioner using a referral form that has been issued by the Department or a referral form that substantially complies with the form issued by the Department; and (c) the person is not an admitted patient of a hospital; and (d) the service is provided to the person individually and in person; and the service is of at least 20 minutes duration; and (f) after the service, the eligible dietitian gives a written report to the referring medical practitioner mentioned in paragraph (b): (i) if the service is the only service under the referral - in relation to that service; or (ii) if the service is the first or the last service under the referral - in relation to the service; or (iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring medical practitioner would reasonably be expected to be informed of - in relation to those matters - to a maximum of five services (including services to which items 81300 to 81360 inclusive apply) in a calendar year (See para MN.11.1 of explanatory notes to this Category) **Benefit:** 85% = \$52.95 Fee: \$62.25 81320 **Extended Medicare Safety Net Cap: \$186.75** MENTAL HEALTH SERVICE provided to a person who is of Aboriginal or Torres Strait Islander descent by an eligible mental health worker if: (a) either: 81325

M11. ALLIED HEALTH SERVICES FOR INDIGENOUS AUSTRALIANS WHO HAVE HAD A HEALTH CHECK

- a medical practitioner has undertaken a health assessment and identified a need for follow-up allied health services: or
- ii. the person's shared care plan identifies the need for follow-up allied health services; and
- (b) the person is referred to the eligible mental health worker by a medical practitioner using a referral form that has been issued by the Department or a referral form that substantially complies with the form issued by the Department; and
- (c) the person is not an admitted patient of a hospital; and
- (d) the service is provided to the person individually and in person; and
- (e) the service is of at least 20 minutes duration; and
- (f) after the service, the eligible mental health worker gives a written report to the referring medical practitioner mentioned in paragraph (b):
 - (i) if the service is the only service under the referral in relation to that service; or
 - (ii) if the service is the first or the last service under the referral in relation to the service; or
- (iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring medical practitioner would reasonably be expected to be informed of in relation to those matters
- to a maximum of five services (including services to which items 81300 to 81360 inclusive apply) in a calendar year

(See para MN.11.1 of explanatory notes to this Category)

Fee: \$62.25 **Benefit:** 85% = \$52.95 **Extended Medicare Safety Net Cap:** \$186.75

OCCUPATIONAL THERAPY HEALTH SERVICE provided to a person who is of Aboriginal or Torres Strait Islander descent by an eligible occupational therapist if

- (a) either:
 - i. a medical practitioner has undertaken a health assessment and identified a need for follow-up allied health services; or
 - the person's shared care plan identifies the need for follow-up allied health services;
 and
- (b) the person is referred to the eligible occupational therapist by a medical practitioner using a referral form that has been issued by the Department or a referral form that substantially complies with the form issued by the Department; and
- (c) the person is not an admitted patient of a hospital; and
- (d) the service is provided to the person individually and in person; and
- (e) the service is of at least 20 minutes duration; and
- 81330 (f) after the service, the eligible occupational therapist gives a written report to the referring medical

M11. ALLIED HEALTH SERVICES FOR INDIGENOUS AUSTRALIANS WHO HAVE HAD A HEALTH CHECK

practitioner mentioned in paragraph (b):

- (i) if the service is the only service under the referral in relation to that service; or
- (ii) if the service is the first or the last service under the referral in relation to the service; or
- (iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring medical practitioner would reasonably be expected to be informed of in relation to those matters
- to a maximum of five services (including services to which items 81300 to 81360 inclusive apply) in a calendar year

(See para MN.11.1 of explanatory notes to this Category)

Fee: \$62.25 Benefit: 85% = \$52.95 Extended Medicare Safety Net Cap: \$186.75

PHYSIOTHERAPY HEALTH SERVICE provided to a person who is of Aboriginal or Torres Strait Islander descent by an eligible physiotherapist if:

- (a) either:
 - i. a medical practitioner has undertaken a health assessment and identified a need for follow-up allied health services; or
 - ii. the person's shared care plan identifies the need for follow-up allied health services; and
- (b) the person is referred to the eligible physiotherapist by a medical practitioner using a referral form that has been issued by the Department or a referral form that substantially complies with the form issued by the Department; and
- (c) the person is not an admitted patient of a hospital; and
- (d) the service is provided to the person individually and in person; and
- (e) the service is of at least 20 minutes duration; and
- (f) after the service, the eligible physiotherapist gives a written report to the referring medical practitioner mentioned in paragraph (b):
 - (i) if the service is the only service under the referral in relation to that service; or
 - (ii) if the service is the first or the last service under the referral in relation to the service; or
 - (iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring medical practitioner would reasonably be expected to be informed of in relation to those matters
- to a maximum of five services (including services to which items 81300 to 81360 inclusive apply) in a calendar year
- (See para MN.11.1 of explanatory notes to this Category)

M11. ALLIED HEALTH SERVICES FOR INDIGENOUS AUSTRALIANS WHO HAVE HAD A **HEALTH CHECK** Fee: \$62.25 **Benefit:** 85% = \$52.95 **Extended Medicare Safety Net Cap: \$186.75** PODIATRY HEALTH SERVICE provided to a person who is of Aboriginal or Torres Strait Islander descent by an eligible podiatrist if: (a) either: a medical practitioner has undertaken a health assessment and identified a need for follow-up allied health services: or ii. the person's shared care plan identifies the need for follow-up allied health services; and the person is referred to the eligible podiatrist by a medical practitioner using a referral form that has been issued by the Department or a referral form that substantially complies with the form issued by the Department; and (c) the person is not an admitted patient of a hospital; and (d) the service is provided to the person individually and in person; and (e) the service is of at least 20 minutes duration; and (f) after the service, the eligible podiatrist gives a written report to the referring medical practitioner mentioned in paragraph (b): (i) if the service is the only service under the referral - in relation to that service; or (ii) if the service is the first or the last service under the referral - in relation to the service; or (iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring medical practitioner would reasonably be expected to be informed of - in relation to those matters - to a maximum of five services (including services to which items 81300 to 81360 inclusive apply) in a calendar year (See para MN.11.1 of explanatory notes to this Category) Fee: \$62.25 **Benefit:** 85% = \$52.95 **Extended Medicare Safety Net Cap: \$186.75** 81340 CHIROPRACTIC HEALTH SERVICE provided to a person who is of Aboriginal or Torres Strait Islander descent by an eligible chiropractor if: (a) either: i. a medical practitioner has undertaken a health assessment and identified a need for follow-up allied health services; or the person's shared care plan identifies the need for follow-up allied health services; and (b) the person is referred to the eligible chiropractor by a medical practitioner using a referral form

81345

that has been issued by the Department or a referral form that substantially complies with the form

M11. ALLIED HEALTH SERVICES FOR INDIGENOUS AUSTRALIANS WHO HAVE HAD A HEALTH CHECK

issued by the Department; and

- (c) the person is not an admitted patient of a hospital; and
- (d) the service is provided to the person individually and in person; and
- (e) the service is of at least 20 minutes duration; and
- (f) after the service, the eligible chiropractor gives a written report to the referring medical practitioner mentioned in paragraph (b):
 - (i) if the service is the only service under the referral in relation to that service; or
 - (ii) if the service is the first or the last service under the referral in relation to the service; or
 - (iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring medical practitioner would reasonably be expected to be informed of in relation to those matters
- to a maximum of five services (including services to which items 81300 to 81360 inclusive apply) in a calendar year

(See para MN.11.1 of explanatory notes to this Category)

Fee: \$62.25 **Benefit:** 85% = \$52.95 **Extended Medicare Safety Net Cap:** \$186.75

OSTEOPATHY HEALTH SERVICE provided to a person who is of Aboriginal or Torres Strait Islander descent by an eligible osteopath if:

- (a) either:
 - i. a medical practitioner has undertaken a health assessment and identified a need for follow-up allied health services; or
 - ii. the person's shared care plan identifies the need for follow-up allied health services; and
- (b) the person is referred to the eligible osteopath by a medical practitioner using a referral form that has been issued by the Department or a referral form that substantially complies with the form issued by the Department; and
- (c) the person is not an admitted patient of a hospital; and
- (d) the service is provided to the person individually and in person; and
- (e) the service is of at least 20 minutes duration; and
- (f) after the service, the eligible osteopath gives a written report to the referring medical practitioner mentioned in paragraph (b):
 - (i) if the service is the only service under the referral in relation to that service; or
 - (ii) if the service is the first or the last service under the referral in relation to the service; or

M11. ALLIED HEALTH SERVICES FOR INDIGENOUS AUSTRALIANS WHO HAVE HAD A **HEALTH CHECK** (iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring practitioner would reasonably be expected to be informed of - in relation to those matters to a maximum of five services (including services to which items 81300 to 81360 inclusive apply) in a calendar year (See para MN.11.1 of explanatory notes to this Category) **Benefit:** 85% = \$52.95 Fee: \$62.25 Extended Medicare Safety Net Cap: \$186.75 PSYCHOLOGY HEALTH SERVICE provided to a person who is of Aboriginal or Torres Strait Islander descent by an eligible psychologist if: (a) either: a medical practitioner has undertaken a health assessment and identified a need for follow-up allied health services; or the person's shared care plan identifies the need for follow-up allied health services; and ii. (b) the person is referred to the eligible psychologist by a medical practitioner using a referral form that has been issued by the Department or a referral form that substantially complies with the form issued by the Department; and the person is not an admitted patient of a hospital; and the service is provided to the person individually and in person; and (e) the service is of at least 20 minutes duration; and after the service, the eligible psychologist gives a written report to the referring medical practitioner mentioned in paragraph (b): (i) if the service is the only service under the referral - in relation to that service; or (ii) if the service is the first or the last service under the referral - in relation to the service; or (iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring medical practitioner would reasonably be expected to be informed of - in relation to those matters - to a maximum of five services (including services to which items 81300 to 81360 inclusive apply) in a calendar year (See para MN.11.1 of explanatory notes to this Category) Fee: \$62.25 **Benefit:** 85% = \$52.95 81355 Extended Medicare Safety Net Cap: \$186.75 SPEECH PATHOLOGY HEALTH SERVICE provided to a person who is of Aboriginal or Torres 81360

M11. ALLIED HEALTH SERVICES FOR INDIGENOUS AUSTRALIANS WHO HAVE HAD A HEALTH CHECK

Strait Islander descent by an eligible speech pathologist if:

- (a) either:
 - i. a medical practitioner has undertaken a health assessment and identified a need for follow-up allied health services; or
 - ii. the person's shared care plan identifies the need for follow-up allied health services; and
- (b) the person is referred to the eligible speech pathologist by a medical practitioner using a referral form that has been issued by the Department or a referral form that substantially complies with the form issued by the Department; and
- (c) the person is not an admitted patient of a hospital; and
- (d) the service is provided to the person individually and in person; and
- (e) the service is of at least 20 minutes duration; and
- (f) after the service, the eligible speech pathologist gives a written report to the referring medical practitioner mentioned in paragraph (b):
 - (i) if the service is the only service under the referral in relation to that service; or
 - (ii) if the service is the first or the last service under the referral in relation to the service; or
 - (iii) if neither subparagraph (i) nor (ii) applies but the service involves matters that the referring medical practitioner would reasonably be expected to be informed of in relation to those matters
- to a maximum of five services (including services to which items 81300 to 81360 inclusive apply) in a calendar year

(See para MN.11.1 of explanatory notes to this Category) **Fee:** \$62.25 **Benefit:** 85% = \$52.95

Extended Medicare Safety Net Cap: \$186.75

M12. SERVICES PROVIDED BY A PRACTICE NURSE OR ABORIGINAL AND TORRES STRAIT ISLANDER HEALTH PRACTITIONER ON BEHALF OF A MEDICAL PRACTITIONER

1. TELEHEALTH SUPPORT SERVICE ON BEHALF OF A MEDICAL PRACTITIONER

	Group M12. Services Provided By A Practice Nurse Or Aboriginal And Torres Strait Islander Health Practitioner On Behalf Of A Medical Practitioner Subgroup 1. Telehealth Support Service On Behalf Of A Medical Practitioner	
	Attendance by a practice nurse, an Aboriginal health worker or an Aboriginal and Torres Strait Islander health practitioner on behalf of, and under the supervision of, a medical practitioner, to provide clinical support to a patient who:	
10983	(a) is participating in a video conferencing consultation with a specialist, consultant physician or	

M12. SERVICES PROVIDED BY A PRACTICE **NURSE OR ABORIGINAL AND TORRES STRAIT ISLANDER HEALTH PRACTITIONER ON BEHALF** OF A MEDICAL PRACTITIONER

1. TELEHEALTH SUPPORT SERVICE ON **BEHALF OF A MEDICAL PRACTITIONER**

psychiatrist; and

- is not an admitted patient; and
- (c) either:
 - (i) is located both:
 - (A) within a telehealth eligible area; and
 - (B) at the time of the attendance-at least 15 kms by road from the specialist, physician or psychiatrist mentioned in paragraph (a); or
 - (ii) is a patient of:
 - (A) an Aboriginal Medical Service; or
 - (B) an Aboriginal Community Controlled Health Service for which a direction made under subsection 19 (2) of the Act applies

(See para MN.12.5 of explanatory notes to this Category)

Fee: \$32.40 **Benefit:** 100% = \$32.40**Extended Medicare Safety Net Cap: \$97.20**

M12. SERVICES PROVIDED BY A PRACTICE NURSE OR ABORIGINAL AND TORRES STRAIT ISLANDER HEALTH PRACTITIONER ON BEHALF OF A MEDICAL PRACTITIONER

2. TELEHEALTH SUPPORT SERVICE ON BEHALF OF A MEDICAL PRACTITIONER AT A RESIDENTIAL AGED CARE FACILITY

Group M12. Services Provided By A Practice Nurse Or Aboriginal And Torres Strait Islander Health Practitioner On Behalf Of A Medical Practitioner

Subgroup 2. Telehealth Support Service On Behalf Of A Medical Practitioner At A Residential Aged Care Facility

Service by a practice nurse or Aboriginal health worker or Aboriginal and Torres Strait Islander health practitioner provided on behalf of, and under the supervision of, a medical practitioner that requires the provision of clinical support to a patient who is:

- a care recipient receiving care in a residential aged care service (other than a self-contained unit); or
- at consulting rooms situated within such a complex if the patient is a care recipient receiving care in a residential aged care service (excluding accommodation in a self-contained unit);

and who is participating in a video consultation with a specialist or consultant physician.

(See para MN.12.5 of explanatory notes to this Category) Fee: \$32.40 **Benefit:** 100% = \$32.40

10984

Extended Medicare Safety Net Cap: \$97.20

M12. SERVICES PROVIDED BY A PRACTICE 3. SERVICES PROVIDED BY A PRACTICE NURSE OR ABORIGINAL AND TORRES STRAIT NURSE OR ABORIGINAL AND TORRES STRAIT ISLANDER HEALTH PRACTITIONER ON BEHALF ISLANDER HEALTH PRACTITIONER ON BEHALF OF A MEDICAL PRACTITIONER OF A MEDICAL PRACTITIONER

M12. SERVICES PROVIDED BY A PRACTICE NURSE OR ABORIGINAL AND TORRES STRAIT ISLANDER HEALTH PRACTITIONER ON BEHALF ISLANDER HEALTH PRACTITIONER ON BEHALF OF A MEDICAL PRACTITIONER OF A MEDICAL PRACTITIONER				
	Group M12. Services Provided By A Practice Nurse Or Aboriginal And Torres Strait Islander Health Practitioner On Behalf Of A Medical Practitioner			
	Subgroup 3. Services Provided By A Practice Nurse Or Aboriginal And Torres Strait Islander Health Practitioner On Behalf Of A Medical Practitioner			
	Follow up service provided by a practice nurse or Aboriginal and Torres Strait Islander health practitioner, on behalf of a medical practitioner, for an Indigenous person who has received a health assessment if:			
	a) The service is provided on behalf of and under the supervision of a			
	medical practitioner; and			
	b) the person is not an admitted patient of a hospital; and			
	c) the service is consistent with the needs identified through the health assessment;			
	- to a maximum of 10 services per patient in a calendar year			
10987	(See para MN.12.3 of explanatory notes to this Category) Fee: \$24.00 Benefit: 100% = \$24.00 Extended Medicare Safety Net Cap: \$72.00			
	Immunisation provided to a person by an Aboriginal and Torres Strait Islander health practitioner if:			
	(a) the immunisation is provided on behalf of, and under the supervision of, a medical practitioner; and			
	(b) the person is not an admitted patient of a hospital.			
10988	(See para MN.12.1 of explanatory notes to this Category) Fee: \$12.00 Benefit: 100% = \$12.00 Extended Medicare Safety Net Cap: \$36.00			
	Treatment of a person's wound (other than normal aftercare) provided by an Aboriginal and Torres Strait Islander health practitioner if:			
	(a) the treatment is provided on behalf of, and under the supervision of, a medical practitioner; and			
	(b) the person is not an admitted patient of a hospital.			
10989	(See para MN.12.2 of explanatory notes to this Category) Fee: \$12.00 Benefit: 100% = \$12.00 Extended Medicare Safety Net Cap: \$36.00			
	Service provided to a person with a chronic disease by a practice nurse or an Aboriginal and Torres Strait Islander health practitioner if:			
	(a) the service is provided on behalf of and under the supervision of a medical practitioner; and			
	(b) the person is not an admitted patient of a hospital; and			
10997	(c) the person has a GP Management Plan, Team Care Arrangements or Multidisciplinary Care Plan in place; and			

M12. SERVICES PROVIDED BY A PRACTICE 3. SERVICES PROVIDED BY A PRACTICE NURSE OR ABORIGINAL AND TORRES STRAIT **NURSE OR ABORIGINAL AND TORRES STRAIT** ISLANDER HEALTH PRACTITIONER ON BEHALF ISLANDER HEALTH PRACTITIONER ON BEHALF OF A MEDICAL PRACTITIONER OF A MEDICAL PRACTITIONER (d) the service is consistent with the GP Management Plan, Team Care Arrangements or Multidisciplinary Care Plan to a maximum of 5 services per patient in a calendar year (See para MN.12.4 of explanatory notes to this Category) **Benefit:** 100% = \$12.00Fee: \$12.00 **Extended Medicare Safety Net Cap: \$36.00** M13. MIDWIFERY SERVICES 1. MBS ITEMS FOR PARTICIPATING MIDWIVES **Group M13. Midwifery Services** Subgroup 1. MBS Items For Participating Midwives Initial antenatal professional attendance by a participating midwife, lasting at least 40 minutes, including all of the following: taking a detailed patient history; (a) performing a comprehensive examination; (b) performing a risk assessment; (d) based on the risk assessment - arranging referral or transfer of the patient's care to an obstetrician; (e) requesting pathology and diagnostic imaging services, when necessary; (f) discussing with the patient the collaborative arrangements for her maternity care and recording the arrangements in the midwife's written records in accordance with section 6 of the Health Insurance Regulations 2018. Payable once only for any pregnancy.

	a yable once only for any pregnancy.	
	(See para MN.13.16 of explanatory notes to this Category) Fee: \$53.40 Benefit: 85% = \$45.40	
82100	Extended Medicare Safety Net Cap: \$21.70	
	Short antenatal professional attendance by a participating midwife, lasting up to 40 minutes.	
	(See para MN.13.16 of explanatory notes to this Category)	
	Fee: \$32.30 Benefit: 75% = \$24.25 85% = \$27.50	
82105	Extended Medicare Safety Net Cap: \$16.30	
	Long antenatal professional attendance by a participating midwife, lasting at least 40 minutes.	
	(See para MN.13.16 of explanatory notes to this Category)	
	Fee: \$53.40 Benefit: 75% = \$40.05 85% = \$45.40	
82110	Extended Medicare Safety Net Cap: \$21.70	
82115	Professional attendance by a participating midwife, lasting at least 90 minutes, for assessment an	

M13. MIDWIFERY SERVICES

1. MBS ITEMS FOR PARTICIPATING MIDWIVES

preparation of a maternity care plan for a patient whose pregnancy has progressed beyond 20 weeks, if:

- (a) the patient is not an admitted patient of a hospital; and
- (b) the participating midwife undertakes a comprehensive assessment of the patient; and
- (c) the participating midwife develops a written maternity care plan that contains:
- · outcomes of the assessment; and
- · details of agreed expectations for care during pregnancy, labour and delivery; and
- · details of any health problems or care needs; and
- · details of collaborative arrangements that apply for the patient; and
- · details of any medication taken by the patient during the pregnancy, and any additional medication that may be required by the patient; and
- · details of any referrals or requests for pathology services or diagnostic imaging services for the patient during the pregnancy, and any additional referrals or requests that may be required for the patient; and
- (d) the maternity care plan is explained and agreed with the patient; and
- (e) the fee does not include any amount for the management of the labour and delivery.

(Includes any antenatal attendance provided on the same occasion).

Payable once only for any pregnancy.

(See para MN.13.16 of explanatory notes to this Category)

Fee: \$319.00 Benefit: 85% = \$271.15 Extended Medicare Safety Net Cap: \$54.10

Management of confinement for up to 12 hours, including delivery (if undertaken), if:

- (a) the patient is an admitted patient of a hospital; and
- (b) the attendance is by a participating midwife who:
 - (i) provided the patient's antenatal care; or
 - (ii) is a member of a practice that provided the patient's antenatal care.

(Includes all attendances related to the confinement by the participating midwife)

M13. MIDWIFERY SERVICES		1. MBS ITEMS FOR PARTICIPATING MIDWIVES		
	Payable once only for any pregnancy			
	(See para MN.13.16 of explanatory notes to this Cate Fee: \$753.30 Benefit: 75% = \$565.00 Extended Medicare Safety Net Cap: \$500.00	gory)		
	Management of confinement for in excess of 12 hours, including delivery where performed.			
	Management of confinement, including delivery (if undertaken) when care is transferred from 1 participating midwife to another participating midwife (the second participating midwife), if:			
	(a) the patient is an admitted patient of a hospital; and			
	(b) the patient's confinement is for longer than 12 hours;			
	(c) the second participating midwife:			
	(i) has provided the patient's antenatal care; or			
	(ii) is a member of a practice that has provided the patient's antenatal care.			
	(Includes all attendances related to the confiner	nent by the second participating midwife)		
	Payable one only for any pregnancy.			
82125	(See para MN.13.16 of explanatory notes to this Cate Fee: \$753.30 Benefit: 75% = \$565.00 Extended Medicare Safety Net Cap: \$500.00	gory)		
82123	Short Postnatal Attendance			
	Short postnatal professional attendance by a par weeks after delivery.	ticipating midwife, lasting up to 40 minutes, within 6		
82130	(See para MN.13.16 of explanatory notes to this Cate Fee: \$53.40 Benefit: 75% = \$40.05 85% Extended Medicare Safety Net Cap: \$16.30			
	Long Postnatal Attendance			
	Long postnatal professional attendance by a par- weeks after delivery.	ticipating midwife, lasting at least 40 minutes, within 6		
82135	(See para MN.13.16 of explanatory notes to this Cate Fee: \$78.50 Benefit: 75% = \$58.90 85% Extended Medicare Safety Net Cap: \$21.70			
32.33	Six Week Postnatal Attendance			
	Postnatal professional attendance by a participal more than 7 weeks after delivery of a baby, included	ring midwife on a patient not less than 6 weeks but not uding:		
82140	(a) a comprehensive examination of patient an	d baby to ensure normal postnatal recovery; and		

M13. MI	DWIFERY SERVICES	1. MBS ITEMS FOR PARTICIPATING MIDWIVES
	(b) referral of the patient to a gener	al practitioner for the ongoing care of the patient and baby
	Payable once only for any pregnancy	:
	(See para MN.13.16 of explanatory notes Fee: \$53.40 Benefit: 85% = Extended Medicare Safety Net Cap	\$45.40
M13. MI	DWIFERY SERVICES	2. TELEHEALTH ATTENDANCES
	Group M13. Midwifery Services	
	S	subgroup 2. Telehealth Attendances
	A professional attendance lasting less midwife that requires the provision o	s than 20 minutes (whether or not continuous) by a participating f clinical support to a patient who:
		onsultation with a specialist practising in his or her speciality of or consultant physician practising in his or her speciality of
	b) is not an admitted patient; a	nd
	c) is located:	
	(i) both:	
	(A) within a teleh	ealth eligible area; and
		the attendance - at least 15 kms by road from the specialist or ohysician mentioned in paragraph (a); or
	(ii) in Australia if the pa	tient is a patient of:
	(A) an Aboriginal	Medical Service; or
		Community Controlled Health Service for which a direction made action 19(2) of the Act applies.
82150	(See para MN.12.5 of explanatory notes t Fee: \$28.30 Benefit: 85% = Extended Medicare Safety Net Cap	\$24.10
	A professional attendance lasting at l midwife that requires the provision o	east 20 minutes (whether or not continuous) by a participating f clinical support to a patient who:
	, 1 1 0	onsultation with a specialist practising in his or her speciality of or consultant physician practising in his or her speciality of
	b) is not an admitted patient; a	nd
82151	c) is located:	

M13. MI	IIDWIFERY SERVICES 2	. TELEHEALTH ATTENDANCES
	(i) both:	
	(A) within a telehealth eligible area; and	
	(B) at the time of the attendance - at least 15 kms by ro physician mentioned in paragraph (a); or	and from the specialist or consultant
	(ii) in Australia if the patient is a patient of:	
	(A) an Aboriginal Medical Service; or	
	(B) an Aboriginal Community Controlled Health under subsection 19(2) of the Act applies.	
	(See para MN.12.5 of explanatory notes to this Category) Fee: \$53.70 Benefit: 85% = \$45.65 Extended Medicare Safety Net Cap: \$161.10	
	A professional attendance lasting at least 40 minutes (whether or no midwife that requires the provision of clinical support to a patient w	
	 a) is participating in a video consultation with a specialist pra obstetrics or a specialist or consultant physician practis paediatrics; and 	
	b) is not an admitted patient; and	
	c) is located:	
	(i) both:	
	(A) within a telehealth eligible area; and	
	(B) at the time of the attendance - at least 15 kms consultant physician mentioned in paragra	
	(ii) in Australia if the patient is a patient of:	
	(A) an Aboriginal Medical Service; or	
	(B) an Aboriginal Community Controlled Health under subsection 19(2) of the Act applies.	
22152	(See para MN.12.5 of explanatory notes to this Category) Fee: \$78.95 Benefit: \$5% = \$67.15	
82152	Extended Medicare Safety Net Cap: \$236.85	4 NUIDEE DE ACTITIONEDE
W14. NU	URSE PRACTITIONERS	1. NURSE PRACTITIONERS
	Group M14. Nurse Practitioners	
	Subgroup 1. Nurse Practitione	ers
	Professional attendance by a participating nurse practitioner for an ostraightforward nature of the task that requires a short patient history examination and management.	
82200	(See para MN.14.12 of explanatory notes to this Category)	

M14. N	IURSE PRACTITIONERS	1. NURSE PRACTITIONERS
	Fee: \$9.60 Benefit: 85% = \$8.20 Extended Medicare Safety Net Cap: \$28.80	
	Professional attendance by a participating nurse practitioner lasting les any of the following:	s than 20 minutes and including
	a) taking a history;	
	b) undertaking clinical examination;	
	c) arranging any necessary investigation;	
	d) implementing a management plan;	
	e) providing appropriate preventive health care,	
	for 1 or more health related issues, with appropriate documentation.	
	(See para MN.14.12 of explanatory notes to this Category) Fee: \$20.95 Benefit: 85% = \$17.85	
82205	Extended Medicare Safety Net Cap: \$62.85	
	Professional attendance by a participating nurse practitioner lasting at of the following:	least 20 minutes and including any
	a) taking a detailed history;	
	b) undertaking clinical examination;	
	c) arranging any necessary investigation;	
	d) implementing a management plan;	
	e) providing appropriate preventive health care,	
	for 1 or more health related issues, with appropriate documentation.	
82210	(See para MN.14.12 of explanatory notes to this Category) Fee: \$39.75 Benefit: 85% = \$33.80 Extended Medicare Safety Net Cap: \$119.25	
82210	Professional attendance by a participating nurse practitioner lasting at	least 40 minutes and including any
	of the following:	to influence and including any
	a) taking an extensive history;	
	b) undertaking clinical examination;	
	c) arranging any necessary investigation;	
	d) implementing a management plan;	
82215	e) providing appropriate preventive health care,	

M14. N	URSE PRACTITIONERS 1. NURSE PRACTITIONE	RS
	for 1 or more health related issues, with appropriate documentation.	
	(See para MN.14.12 of explanatory notes to this Category) Fee: \$58.55 Benefit: 85% = \$49.80 Extended Medicare Safety Net Cap: \$175.65	
M14. N	URSE PRACTITIONERS 2. TELEHEALTH ATTENDAN	CE
	Group M14. Nurse Practitioners	
	Subgroup 2. Telehealth Attendance	
	A professional attendance lasting less than 20 minutes (whether or not continuous) by a participating nurse practitioner that requires the provision of clinical support to a patient who:	
	a) is participating in a video consultation with a specialist or consultant physician; and	
	b) is not an admitted patient; and	
	c) is located:	
	(i) both:	
	(A) within a telehealth eligible area; and	
	(B) at the time of the attendance - at least 15 kms by road from the specialist or consultant physician mentioned in paragraph (a); or	
	(ii) in Australia if the patient is a patient of:	
	(A) an Aboriginal Medical Service; or	
	(B) an Aboriginal Community Controlled Health Service for which a direction made under subsection 19(2) of the Act applies.	de
82220	(See para MN.12.5 of explanatory notes to this Category) Fee: \$28.30 Benefit: 85% = \$24.10 Extended Medicare Safety Net Cap: \$84.90	
	A professional attendance lasting at least 20 minutes (whether or not continuous) by a participating nu practitioner that requires the provision of clinical support to a patient who:	ırse
	a) is participating in a video consultation with a specialist or consultant physician; and	
	b) is not an admitted patient; and	
	c) is located:	
	(i) both:	
	(A) within a telehealth eligible area; and	
	(B) at the time of the attendance - at least 15 kms by road from the specialist or	
82221	consultant physician mentioned in paragraph (a); or	

M14. NURSE PRACTITIONERS		2. TELEHEALTH ATTENDANCE
	(ii) in Australia if the patient is a patient of:	
	(A) an Aboriginal Medical Service; or	
	(B) an Aboriginal Community Controlled under subsection 19(2) of the Act a	Health Service for which a direction made applies.
	(See para MN.12.5 of explanatory notes to this Category) Fee: \$53.70 Benefit: 85% = \$45.65 Extended Medicare Safety Net Cap: \$161.10	
	A professional attendance lasting at least 40 minutes (whether practitioner that requires the provision of clinical support to	
	a) is participating in a video consultation with a specia	alist or consultant physician; and
	b) is not an admitted patient; and	
	c) is located:	
	(i) both:	
	(A) within a telehealth eligible area; and	
	(B) at the time of the attendance - at least consultant physician mentioned in	
	(ii) in Australia if the patient is a patient of:	
	(A) an Aboriginal Medical Service; or	
	(B) an Aboriginal Community Controlled under subsection 19(2) of the Act a	Health Service for which a direction made applies.
82222	(See para MN.12.5 of explanatory notes to this Category) Fee: \$78.95 Benefit: 85% = \$67.15 Extended Medicare Safety Net Cap: \$236.85	
M14. NU	JRSE PRACTITIONERS	3. TELEHEALTH ATTENDANCE AT A RESIDENTIAL AGED CARE FACILITY
	Group M14. Nurse Practitioners	
	Subgroup 3. Telehealth Attendance At A R	Residential Aged Care Facility
	A professional attendance lasting less than 20 minutes (whet nurse practitioner that requires the provision of clinical supp	
	a) is participating in a video consultation with a specialist	or consultant physician; and
	b) either:	

(ii) is at consulting rooms situated within such a complex if the patient is a care recipient

(i) is a care recipient receiving care in a residential care service; or

receiving care in a residential aged care service; and

M14. NU	3. TELEHEALTH ATTENDANCE AT A RSE PRACTITIONERS RESIDENTIAL AGED CARE FACILITY
	c) the professional attendance is not provided at a self-contained unit.
	(See para MN.12.5 of explanatory notes to this Category) Fee: \$28.30 Benefit: 85% = \$24.10 Example 1 Marking as Soft a Not Compared to the Category)
	Extended Medicare Safety Net Cap: \$84.90
	A professional attendance lasting at least 20 minutes (whether or not continuous) by a participating nurse practitioner that requires the provision of clinical support to a patient who:
	a) is participating in a video consultation with a specialist or consultant physician; and
	b) either:
	(i) is a care recipient receiving care in a residential care service; or
	(ii) is at consulting rooms situated within such a complex if the patient is a care recipient receiving care in a residential aged care service; and
	c) the professional attendance is not provided at a self-contained unit
	(See para MN.12.5 of explanatory notes to this Category) Fee: \$53.70 Benefit: \$5% = \$45.65
82224	Extended Medicare Safety Net Cap: \$161.10
	A professional attendance lasting at least 40 minutes (whether or not continuous) by a participating nurse practitioner that requires the provision of clinical support to a patient who:
	a) is participating in a video consultation with a specialist or consultant physician; and
	b) either:
	(i) is a care recipient receiving care in a residential care service; or
	(ii) is at consulting rooms situated within such a complex if the patient is a care recipient receiving care in a residential aged care service; and
	c) the professional attendance is not provided at a self-contained unit
	(See para MN.12.5 of explanatory notes to this Category) Fee: \$78.95 Benefit: 85% = \$67.15
82225	Extended Medicare Safety Net Cap: \$236.85
M15. DIA	AGNOSTIC AUDIOLOGY SERVICES
	Group M15. Diagnostic Audiology Services
	Audiology health service, consisting of BRAIN STEM EVOKED RESPONSE AUDIOMETRY, performed on a person by an eligible audiologist if:
	(a) the service is performed pursuant to a written request made by an eligible practitioner to assist the eligible practitioner in the diagnosis and/or treatment and/or management of ear disease or a related disorder in the person; and
	(b) the eligible practitioner is a specialist in the specialty of otolaryngology head and neck surgery; and
82300	(c) the service is not performed for the purpose of a hearing screening; and

M15. DI	AGNOSTIC AUDIOLOGY SERVICES
	(d) the person is not an admitted patient of a hospital; and
	(e) the service is performed on the person individually and in person; and
	(f) after the service, the eligible audiologist provides a copy of the results of the service performed, together with relevant comments in writing that the eligible audiologist has on those results, to the eligible practitioner who requested the service; and
	(g) a service to which item 11300 applies has not been performed on the person on the same day.
	(See para MN.15.1, MN.15.5 of explanatory notes to this Category) Fee: \$153.95 Benefit: 85% = \$130.90
	Extended Medicare Safety Net Cap: \$461.85
	Audiology health service, consisting of NON-DETERMINATE AUDIOMETRY performed on a person by an eligible audiologist if:
	(a) the service is performed pursuant to a written request made by an eligible practitioner to assist the eligible practitioner in the diagnosis and/or treatment and/or management of ear disease or a related disorder in the person; and
	(b) the eligible practitioner is a specialist in the specialty of otolaryngology head and neck surgery; and
	(c) the service is not performed for the purpose of a hearing screening; and
	(d) the person is not an admitted patient of a hospital; and
	(e) the service is performed on the person individually and in person; and
	(f) after the service, the eligible audiologist provides a copy of the results of the service performed, together with relevant comments in writing that the eligible audiologist has on those results, to the eligible practitioner who requested the service; and
	(g) a service to which item 11306 applies has not been performed on the person on the same day.
82306	(See para MN.15.5, MN.15.2 of explanatory notes to this Category) Fee: \$17.50 Benefit: 85% = \$14.90 Extended Medicare Safety Net Cap: \$52.50
	Audiology health service, consisting of an AIR CONDUCTION AUDIOGRAM performed on a person by an eligible audiologist if:
	(a) the service is performed pursuant to a written request made by an eligible practitioner to assist the eligible practitioner in the diagnosis and/or treatment and/or management of ear disease or a related disorder in the person; and
	(b) the eligible practitioner is:
	(i) a specialist in the specialty of otolaryngology head and neck surgery; or
	(ii) a specialist or consultant physician in the specialty of neurology; and
	(c) the service is not performed for the purpose of a hearing screening; and
	(d) the person is not an admitted patient of a hospital; and
82309	(e) the service is performed on the person individually and in person; and

M15. DIAGNOSTIC AUDIOLOGY SERVICES (f) after the service, the eligible audiologist provides a copy of the results of the service performed, together with relevant comments in writing that the eligible audiologist has on those results, to the eligible practitioner who requested the service; and (g) a service to which item 11309 applies has not been performed on the person on the same day. (See para MN.15.3, MN.15.5 of explanatory notes to this Category) **Benefit:** 85% = \$17.90 Fee: \$21.05 Extended Medicare Safety Net Cap: \$63.15 Audiology health service, consisting of an AIR AND BONE CONDUCTION AUDIOGRAM OR AIR CONDUCTION AND SPEECH DISCRIMINATION AUDIOGRAM performed on a person by an eligible audiologist if: (a) the service is performed pursuant to a written request made by an eligible practitioner to assist the eligible practitioner in the diagnosis and/or treatment and/or management of ear disease or a related disorder in the person; and (b) the eligible practitioner is: (i) a specialist in the specialty of otolaryngology head and neck surgery; or (ii) a specialist or consultant physician in the specialty of neurology; and (c) the service is not performed for the purpose of a hearing screening; and (d) the person is not an admitted patient of a hospital; and (e) the service is performed on the person individually and in person; and (f) after the service, the eligible audiologist provides a copy of the results of the service performed, together with relevant comments in writing that the eligible audiologist has on those results, to the eligible practitioner who requested the service; and (g) a service to which item 11312 applies has not been performed on the person on the same day. (See para MN.15.3, MN.15.5 of explanatory notes to this Category) Fee: \$29.70 **Benefit:** 85% = \$25.25 82312 **Extended Medicare Safety Net Cap: \$89.10** Audiology health service, consisting of an AIR AND BONE CONDUCTION AND SPEECH DISCRIMINATION AUDIOGRAM performed on a person by an eligible audiologist if: (a) the service is performed pursuant to a written request made by an eligible practitioner to assist the eligible practitioner in the diagnosis and/or treatment and/or management of ear disease or a related disorder in the person; and (b) the eligible practitioner is: (i) a specialist in the specialty of otolaryngology head and neck surgery; or (ii) a specialist or consultant physician in the specialty of neurology; and (c) the service is not performed for the purpose of a hearing screening; and

(d) the person is not an admitted patient of a hospital; and

M15. DIAGNOSTIC AUDIOLOGY SERVICES

- (e) the service is performed on the person individually and in person; and
- (f) after the service, the eligible audiologist provides a copy of the results of the service performed, together with relevant comments in writing that the eligible audiologist has on those results, to the eligible practitioner who requested the service; and
- (g) a service to which item 11315 applies has not been performed on the person on the same day.

(See para MN.15.3, MN.15.5 of explanatory notes to this Category)

Fee: \$39.35 **Benefit:** 85% = \$33.45Extended Medicare Safety Net Cap: \$118.05

Audiology health service, consisting of an AIR AND BONE CONDUCTION AND SPEECH DISCRIMINATION AUDIOGRAM WITH OTHER COCHLEAR TESTS performed on a person by an eligible audiologist if:

- (a) the service is performed pursuant to a written request made by an eligible practitioner to assist the eligible practitioner in the diagnosis and/or treatment and/or management of ear disease or a related disorder in the person; and
- (b) the eligible practitioner is:
 - (i) a specialist in the specialty of otolaryngology head and neck surgery; or
 - (ii) a specialist or consultant physician in the specialty of neurology; and
- (c) the service is not performed for the purpose of a hearing screening; and
- (d) the person is not an admitted patient of a hospital; and
- (e) the service is performed on the person individually and in person; and
- (f) after the service, the eligible audiologist provides a copy of the results of the service performed, together with relevant comments in writing that the eligible audiologist has on those results, to the eligible practitioner who requested the service; and
- (g) a service to which item 11318 applies has not been performed on the person on the same day.

(See para MN.15.3, MN.15.5 of explanatory notes to this Category)

Benefit: 85% = \$41.35 Fee: \$48.60

82318 **Extended Medicare Safety Net Cap: \$145.80**

> Audiology health service, consisting of an IMPEDANCE AUDIOGRAM involving tympanometry and measurement of static compliance and acoustic reflex performed on a person by an eligible audiologist (not being a service associated with a service to which item 82309, 82312, 82315 or 82318 applies) if:

- (a) the service is performed pursuant to a written request made by an eligible practitioner to assist the eligible practitioner in the diagnosis and/or treatment and/or management of ear disease or a related disorder in the person; and
- (b) the eligible practitioner is:
 - (i) a specialist in the specialty of otolaryngology head and neck surgery; or
 - (ii) a specialist or consultant physician in the specialty of neurology; and
- (c) the service is not performed for the purpose of a hearing screening; and

M15. DIAGNOSTIC AUDIOLOGY SERVICES (d) the person is not an admitted patient of a hospital; and (e) the service is performed on the person individually and in person; and (f) after the service, the eligible audiologist provides a copy of the results of the service performed, together with relevant comments in writing that the eligible audiologist has on those results, to the eligible practitioner who requested the service; and (g) a service to which item 11324 applies has not been performed on the person on the same day. (See para MN.15.3, MN.15.5 of explanatory notes to this Category) Fee: \$26.30 **Benefit:** 85% = \$22.40 **Extended Medicare Safety Net Cap: \$78.90** Audiology health service, consisting of an IMPEDANCE AUDIOGRAM involving tympanometry and measurement of static compliance and acoustic reflex performed on a person by an eligible audiologist (being a service associated with a service to which item 82309, 82312, 82315 or 82318 applies) if: (a) the service is performed pursuant to a written request made by an eligible practitioner to assist the eligible practitioner in the diagnosis and/or treatment and/or management of ear disease or a related disorder in the person; and (b) the eligible practitioner is: (i) a specialist in the specialty of otolaryngology head and neck surgery; or (ii) a specialist or consultant physician in the specialty of neurology; and (c) the service is not performed for the purpose of a hearing screening; and (d) the person is not an admitted patient of a hospital; and (e) the service is performed on the person individually and in person; and (f) after the service, the eligible audiologist provides a copy of the results of the service performed, together with relevant comments in writing that the eligible audiologist has on those results, to the eligible practitioner who requested the service; and (g) a service to which item 11327 applies has not been performed on the person on the same day. (See para MN.15.3, MN.15.5 of explanatory notes to this Category) Fee: \$15.80 **Benefit:** 85% = \$13.45**Extended Medicare Safety Net Cap: \$47.40** 82327 Audiology health service, consisting of an OTO-ACOUSTIC EMISSION AUDIOMETRY for the detection of permanent congenital hearing impairment, performed by an eligible audiologist on an infant or child in circumstances in which: (a) the service is performed pursuant to a written request made by an eligible practitioner who is: (i) a specialist in the specialty of otolaryngology head and neck surgery; or (ii) a specialist or consultant physician in the specialty of neurology; and (b) the infant or child is at risk due to 1 or more of the following factors: (i) admission to a neonatal intensive care unit;

M15. DIAGNOSTIC AUDIOLOGY SERVICES

- (ii) family history of hearing impairment;
- (iii) intra-uterine or perinatal infection (either suspected or confirmed);
- (iv) birthweight less than 1.5kg;
- (v) craniofacial deformity;
- (vi) birth asphyxia;
- (vii) chromosomal abnormality, including Down Syndrome;
- (viii) exchange transfusion; and
- (c) middle ear pathology has been excluded by specialist opinion; and
- (d) the infant or child is not an admitted patient of a hospital; and
- (e) the service is performed on the infant or child individually and in person; and
- (f) after the service, the eligible audiologist provides a copy of the results of the service performed, together with relevant comments in writing that the eligible audiologist has on those results, to the eligible practitioner who requested the service; and
- (g) a service to which item 11332 applies has not been performed on the infant or child on the same day.

(See para MN.15.4, MN.15.5 of explanatory notes to this Category)

Fee: \$46.85 **Benefit:** 85% = \$39.85 **Extended Medicare Safety Net Cap:** \$140.55

INDEX

Α

allied health services 82000, 82005, 82010, 82015, 82020 82025

Allied health services for indigenous Australians 81300 81305, 81310, 81315, 81320, 81325, 81330, 81335, 81340 81345, 81350, 81355, 81360

В

 Bulk-billing
 10990-10992

 Focussed psychological strategies
 80100, 80105, 80110

 80115, 80120, 80125, 80130, 80135, 80140, 80145, 80150

 80155, 80160, 80165, 80170

 Pregnancy support counselling
 81000, 81005, 81010

Р

Psychological therapy services 80000, 80005, 80010, 80015 80020